,nctId,phase,recruitment,therapies,title,Drug_id
0,NCT01789281,Phase III,Recruiting,"[{'id': 1333, 'therapyName': 'Everolimus + Sandostatin LAR Depot'}]",Everolimus Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Everolimus Study.,7240
0,NCT02035137,,Recruiting,"[{'id': 1425, 'therapyName': '131I-MIBG'}, {'id': 1426, 'therapyName': '131I-MIBG + Irinotecan + Vincristine'}, {'id': 1427, 'therapyName': '131I-MIBG + Vorinostat'}]",131I-MIBG Alone VS. 131I-MIBG With Vincristine and Irinotecan VS131I-MIBG With Vorinistat,7257
1,NCT01175356,Phase I,Completed,"[{'id': 2558, 'therapyName': 'Busulfan + Melphalan'}, {'id': 2590, 'therapyName': 'Cyclophosphamide + Topotecan'}, {'id': 1425, 'therapyName': '131I-MIBG'}, {'id': 2353, 'therapyName': 'Cyclophosphamide + Doxorubicin + Vincristine '}, {'id': 2585, 'therapyName': 'Cisplatin + Etoposide'}]","Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin",7257
2,NCT03126916,Phase III,Not yet recruiting,"[{'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1425, 'therapyName': '131I-MIBG'}, {'id': 1873, 'therapyName': 'Sargramostim'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 5595, 'therapyName': 'Isotretinoin'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 5153, 'therapyName': 'dexrazoxane'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1167, 'therapyName': 'Aldesleukin'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 2286, 'therapyName': 'Dinutuximab  '}]",Iobenguane I-131 or Crizotinib and Standard Therapy in Treating Younger Patients With Newly-Diagnosed High-Risk Neuroblastoma or Ganglioneuroblastoma,7257
0,NCT03030885,Phase I,Recruiting,"[{'id': 5804, 'therapyName': '131I-MIP-1095'}]",Use of an Experimental Radiopharmaceutical (131I-MIP-1095) in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC),8802
0,NCT01384253,Phase I,Completed,"[{'id': 1540, 'therapyName': '212Pb-TCMC-Trastuzumab + Trastuzumab '}]",Safety Study of ²¹²Pb-TCMC-Trastuzumab Radio Immunotherapy,7188
0,NCT01534598,Phase I,Recruiting,"[{'id': 3789, 'therapyName': 'FdCyd + THU'}]",FdCyd and THU for Advanced Solid Tumors,8240
1,NCT00978250,Phase II,Recruiting,"[{'id': 3789, 'therapyName': 'FdCyd + THU'}]",A Multi-Histology Phase II Study of 5-Fluoro-2-Deoxycytidine With Tetrahydrouridine (FdCyd + THU),8240
0,NCT02425306,Phase Ib/II,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 2620, 'therapyName': '6MHP vaccine'}, {'id': 2595, 'therapyName': 'poly ICLC  '}]",Safety Study of a Helper Peptide Vaccine Plus Adjuvant Combinations for the Treatment of Melanoma,7614
1,NCT02382549,Phase Ib/II,Recruiting,"[{'id': 342, 'therapyName': 'Vemurafenib'}, {'id': 2620, 'therapyName': '6MHP vaccine'}]",A Clinical Trial to Evaluate a Helper Peptide Vaccine Plus Vemurafenib in Melanoma,7614
2,NCT02385669,Phase Ib/II,Recruiting,"[{'id': 2620, 'therapyName': '6MHP vaccine'}, {'id': 779, 'therapyName': 'Ipilimumab'}]",A Phase I/II Trial to Evaluate a Peptide Vaccine Plus Ipilimumab in Patients With Melanoma,7614
0,NCT00906516,Phase II,Unknown status,"[{'id': 2146, 'therapyName': 'Neuradiab + Bevacizumab'}]",Neuradiab Combined With Bevacizumab (Avastin) Therapy in Patients With Recurrent Glioblastoma Multiforme,7431
0,NCT02342782,Phase I,Recruiting,"[{'id': 2485, 'therapyName': '90Y basiliximab'}, {'id': 1811, 'therapyName': 'Carmustine'}, {'id': 2392, 'therapyName': 'Cytarabine + Etoposide'}, {'id': 1207, 'therapyName': 'Melphalan'}]",Yttrium Y 90 Basiliximab and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Mature T-cell Non-Hodgkin Lymphoma,7540
1,NCT01476839,Phase I,Recruiting,"[{'id': 6258, 'therapyName': 'Basiliximab + 90Y basiliximab + Carmustine + Cytarbine + Etoposide + Melphalan'}]",Radiolabeled Monoclonal Antibody Therapy and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Primary Refractory or Relapsed Hodgkin Lymphoma,7540
0,NCT02990416,Phase Ib/II,Not yet recruiting,"[{'id': 5137, 'therapyName': 'A-dmDT390-bisFv(UCHT1) + Pembrolizumab'}]",A-dmDT390-bisFv(UCHT1) Fusion Protein With Ionizing Radiation and Pembrolizumab for the Treatment of Stage IV Melanoma,8618
0,NCT02412462,Phase I,Completed,"[{'id': 4317, 'therapyName': 'AB-16B5'}]",Phase I Dose Escalation Study of AB-16B5 in Subjects With an Advanced Solid Malignancy,8408
0,NCT02391480,Phase I,Recruiting,"[{'id': 4028, 'therapyName': 'ABBV-075'}]",A Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Cancer,8328
0,NCT02565758,Phase I,Recruiting,"[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 619, 'therapyName': 'Abraxane'}, {'id': 3846, 'therapyName': 'ABBV-085'}]","ABBV-085, an Antibody Drug Conjugate, in Subjects With Advanced Solid Cancer Tumors",8266
0,NCT03000257,Phase I,Recruiting,"[{'id': 5766, 'therapyName': 'ABBV-181'}]",A Study of ABBV-181 in Participants With Advanced Solid Tumors,8786
0,NCT02365662,Phase I,Recruiting,"[{'id': 2914, 'therapyName': 'ABBV-221'}]",A Study Evaluating Safety and Pharmacokinetics of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor,7837
0,NCT03071757,Phase I,Recruiting,"[{'id': 5446, 'therapyName': 'ABBV-368'}, {'id': 5447, 'therapyName': 'ABBV-368 + Nivolumab'}]","A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors",8693
0,NCT02099058,Phase I,Recruiting,"[{'id': 1743, 'therapyName': 'ABBV-399 + Carboplatin'}, {'id': 1364, 'therapyName': 'ABBV-399 + Erlotinib'}, {'id': 1363, 'therapyName': 'ABBV-399'}, {'id': 1366, 'therapyName': 'ABBV-399 + Bevacizumab'}, {'id': 1365, 'therapyName': 'ABBV-399 + Cetuximab'}]","A Phase 1/1b Study With ABBV-399, an Antibody Drug Conjugate, in Subjects With Advanced Solid Cancer Tumors",7247
0,NCT02955251,Phase I,Recruiting,"[{'id': 5051, 'therapyName': 'ABBV-428 + Nivolumab'}, {'id': 5050, 'therapyName': 'ABBV-428'}]","A Study Evaluating Safety and Pharmacokinetics, and the Recommended Phase 2 Dose (RPTD) of ABBV-428 in Participants With Advanced Solid Tumors",8601
0,NCT03082209,Phase I,Recruiting,"[{'id': 5756, 'therapyName': 'ABBV-621'}]",A Study of the Safety and Tolerability of ABBV-621 in Participants With Previously Treated Solid Tumors and Hematologic Malignancies,8777
0,NCT02988960,Phase I,Recruiting,"[{'id': 5143, 'therapyName': 'ABBV-927 + Nivolumab'}, {'id': 5142, 'therapyName': 'ABBV-927'}]","A Study of ABBV-927, an Immunotherapy, in Participants With Advanced Solid Tumors",8619
0,NCT02939807,Phase II,Recruiting,"[{'id': 3301, 'therapyName': 'ABC294640'}]",A Phase II Study of ABC294640 as Second-Line Monotherapy in Patients With Advanced Hepatocellular Carcinoma,8021
1,NCT02229981,Phase Ib/II,Recruiting,"[{'id': 3301, 'therapyName': 'ABC294640'}]",An Early-Phase Clinical Trial Evaluating ABC294640 in Patients With Refractory/Relapsed Diffuse Large B-cell Lymphoma,8021
2,NCT02757326,Phase Ib/II,Recruiting,"[{'id': 3301, 'therapyName': 'ABC294640'}]",ABC294640 in Refractory / Relapsed Multiple Myeloma,8021
0,NCT02450539,Phase II,"Active, not recruiting","[{'id': 802, 'therapyName': 'Abemaciclib'}, {'id': 720, 'therapyName': 'Docetaxel'}]",A Study of Abemaciclib (LY2835219) in Participants With Stage IV Squamous Non-small Cell Lung Cancer,6942
1,NCT02688088,Phase I,Recruiting,"[{'id': 802, 'therapyName': 'Abemaciclib'}, {'id': 3729, 'therapyName': 'Caffeine + Dextromethorphan + Midazolam + Warfarin'}]",A Study of Abemaciclib in Participants With Cancer That is Advanced or Has Spread to Another Part(s) of the Body,6942
2,NCT02981342,Phase II,Recruiting,"[{'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 802, 'therapyName': 'Abemaciclib'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 5175, 'therapyName': 'Abemaciclib + LY3023414'}, {'id': 5176, 'therapyName': 'Abemaciclib + Galunisertib'}]",A Study of Abemaciclib (LY2835219) Alone or in Combination With Other Agents in Participants With Previously Treated Pancreatic Ductal Adenocarcinoma,6942
3,NCT02644460,Phase I,Recruiting,"[{'id': 802, 'therapyName': 'Abemaciclib'}]",Abemaciclib in Children With DIPG or Recurrent/Refractory Solid Tumors,6942
4,NCT02675231,Phase II,Recruiting,"[{'id': 802, 'therapyName': 'Abemaciclib'}, {'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 744, 'therapyName': 'Fulvestrant'}]","A Study of Abemaciclib (LY2835219) in Women With HR+, HER2+ Locally Advanced or Metastatic Breast Cancer",6942
5,NCT03130439,Phase II,Recruiting,"[{'id': 802, 'therapyName': 'Abemaciclib'}]","Abemaciclib for Patients With Retinoblastoma-Positive, Triple Negative Metastatic Breast Cancer",6942
6,NCT02152631,Phase III,"Active, not recruiting","[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 802, 'therapyName': 'Abemaciclib'}]",A Study of LY2835219 in Participants With Previously Treated Lung Cancer,6942
7,NCT03155997,Phase III,Recruiting,"[{'id': 802, 'therapyName': 'Abemaciclib'}]",A Study to Compare Treatment After Surgery of Abemaciclib (LY2835219) Combined With Standard Endocrine Therapy Versus Endocrine Therapy Alone in Participants With Breast Cancer,6942
8,NCT02117648,,Completed,"[{'id': 1690, 'therapyName': 'Abemaciclib + Clarithromycin'}, {'id': 802, 'therapyName': 'Abemaciclib'}]", A Study of LY2835219 in Participants With Cancer,6942
9,NCT02747004,Phase II,Recruiting,"[{'id': 4387, 'therapyName': 'Abemaciclib + Loperamide'}, {'id': 802, 'therapyName': 'Abemaciclib'}, {'id': 2256, 'therapyName': 'Abemaciclib + Tamoxifen'}]",A Study of Abemaciclib (LY2835219) Plus Tamoxifen or Abemaciclib Alone in Women With Metastatic Breast Cancer (nextMONARCH 1),6942
10,NCT03220646,Phase II,Recruiting,"[{'id': 802, 'therapyName': 'Abemaciclib'}]",The Purpose of This Study is to Test Any Good and Bad Effects of a Study Drug Called Abemaciclib (LY2835219) in Patients With Recurrent Brain Tumors.,6942
11,NCT02107703,Phase III,"Active, not recruiting","[{'id': 802, 'therapyName': 'Abemaciclib'}, {'id': 744, 'therapyName': 'Fulvestrant'}]",A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer,6942
12,NCT02846987,Phase II,Recruiting,"[{'id': 802, 'therapyName': 'Abemaciclib'}]",Study of Abemaciclib in Dedifferentiated Liposarcoma,6942
13,NCT02308020,Phase II,Recruiting,"[{'id': 802, 'therapyName': 'Abemaciclib'}]",A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer That Has Spread to the Brain,6942
14,NCT02981940,Phase II,Recruiting,"[{'id': 802, 'therapyName': 'Abemaciclib'}]",A Study of Abemaciclib in Recurrent Glioblastoma,6942
15,NCT02441946,Phase II,Completed,"[{'id': 802, 'therapyName': 'Abemaciclib'}, {'id': 2700, 'therapyName': 'Loperamide'}, {'id': 633, 'therapyName': 'Anastrozole'}]","A Phase 2 Neoadjuvant Study of Abemaciclib (LY2835219) in Postmenopausal Women With Hormone Receptor Positive, HER2 Negative Breast Cancer",6942
16,NCT02079636,Phase I,Recruiting,"[{'id': 1069, 'therapyName': 'LY3023414'}, {'id': 802, 'therapyName': 'Abemaciclib'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 886, 'therapyName': 'Ramucirumab'}]",A Study of LY2835219 in Combination With Another Anti-cancer Drug in Participants With Lung Cancer (NSCLC),6942
17,NCT02792725,Expanded access,Available,"[{'id': 802, 'therapyName': 'Abemaciclib'}]",Expanded Access Program to Provide Abemaciclib (LY2835219) for the Treatment of Metastatic Breast Cancer,6942
18,NCT02057133,Phase I,Recruiting,"[{'id': 2254, 'therapyName': 'Abemaciclib + Letrozole'}, {'id': 2257, 'therapyName': 'Abemaciclib + Exemestane'}, {'id': 2258, 'therapyName': 'Everolimus + Exemestane + LY2835219'}, {'id': 2255, 'therapyName': 'Abemaciclib + Anastrozole'}, {'id': 2256, 'therapyName': 'Abemaciclib + Tamoxifen'}, {'id': 2259, 'therapyName': 'Abemaciclib + Trastuzumab'}]",A Study of LY2835219 in Combination With Hormone Therapies for Breast Cancer That Has Spread,6942
19,NCT02246621,Phase III,"Active, not recruiting","[{'id': 1854, 'therapyName': 'Abemaciclib + Anastrozole + Letrozole'}, {'id': 1853, 'therapyName': 'Anastrozole + Letrozole'}]",A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast Cancer,6942
20,NCT03099174,Phase I,Recruiting,"[{'id': 5514, 'therapyName': 'Abemaciclib + Xentuzumab'}, {'id': 5515, 'therapyName': 'Abemaciclib + Letrozole + Xentuzumab'}, {'id': 5516, 'therapyName': 'Abemaciclib + Anastrozole + Xentuzumab'}, {'id': 5517, 'therapyName': 'Abemaciclib + Fulvestrant + Xentuzumab'}]",This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast Cancer.,6942
21,NCT02784795,Phase I,Recruiting,"[{'id': 4374, 'therapyName': 'Cisplatin + Gemcitabine + LY3039478'}, {'id': 4375, 'therapyName': 'Carboplatin + Gemcitabine + LY3039478'}, {'id': 4372, 'therapyName': 'LY3039478 + LY3023414'}, {'id': 4373, 'therapyName': 'Abemaciclib + LY3039478'}, {'id': 4371, 'therapyName': 'LY3039478 + Taladegib'}, {'id': 2958, 'therapyName': 'LY3039478'}, {'id': 1069, 'therapyName': 'LY3023414'}]",A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors,6942
22,NCT02779751,Phase II,Recruiting,"[{'id': 4242, 'therapyName': 'Abemaciclib + Pembrolizumab'}]",A Study of Abemaciclib (LY2835219) in Participants With Non-Small Cell Lung Cancer or Breast Cancer,6942
23,NCT02745769,Phase I,Recruiting,"[{'id': 4208, 'therapyName': 'LY2801653 + Ramucirumab'}, {'id': 4209, 'therapyName': 'Abemaciclib + Ramucirumab'}]",A Study in Advanced Cancers Using Ramucirumab (LY3009806) and Other Targeted Agents,6942
24,NCT02977780,Phase II,Recruiting,"[{'id': 1000, 'therapyName': 'CC-115'}, {'id': 5028, 'therapyName': 'Abemaciclib + Temozolomide'}, {'id': 1141, 'therapyName': 'Temozolomide'}, {'id': 5029, 'therapyName': 'Neratinib + Temozolomide'}]",INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT),6942
25,NCT02857270,Phase I,Recruiting,"[{'id': 4588, 'therapyName': 'LY3214996'}, {'id': 4590, 'therapyName': 'LY3214996 + nab-paclitaxel + Gemcitabine'}, {'id': 4589, 'therapyName': 'LY3214996 + Midazolam'}, {'id': 4591, 'therapyName': 'LY3214996 + Abemaciclib'}]",A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer,6942
0,NCT02254785,Phase II,Recruiting,"[{'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 1571, 'therapyName': 'Cabazitaxel'}]",Cabazitaxel vs Abiraterone or Enzalutamide in Patients With Poor Prognosis Metastatic Castration-resistant Prostate Cancer,4697
1,NCT01685125,Phase II,"Active, not recruiting","[{'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1805, 'therapyName': 'Abiraterone'}]",Abiraterone Acetate and Prednisone With or Without Dasatinib in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer,4697
2,NCT02257736,Phase III,"Active, not recruiting","[{'id': 1948, 'therapyName': 'ARN-509 + Abiraterone'}, {'id': 1805, 'therapyName': 'Abiraterone'}]",An Efficacy and Safety Study of JNJ56021927 in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC),4697
3,NCT02987543,Phase III,Recruiting,"[{'id': 837, 'therapyName': 'Olaparib'}, {'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 1805, 'therapyName': 'Abiraterone'}]",Study of Olaparib (Lynparza) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer (PROfound Study),4697
4,NCT02034552,Phase II,"Active, not recruiting","[{'id': 2188, 'therapyName': 'Prednisone'}, {'id': 2001, 'therapyName': 'radium Ra 223 dichloride'}, {'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 1805, 'therapyName': 'Abiraterone'}]",A Randomized Phase IIa Efficacy and Safety Study of Radium-223 Dichloride With Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (CRPC),4697
5,NCT01576172,Phase II,"Active, not recruiting","[{'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 954, 'therapyName': 'Veliparib'}]",Abiraterone Acetate and Prednisone With or Without Veliparib in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer,4697
6,NCT01949337,Phase III,"Active, not recruiting","[{'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 1262, 'therapyName': 'Enzalutamide'}]",Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer,4697
7,NCT02268175,Phase II,"Active, not recruiting","[{'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 795, 'therapyName': 'Leuprolide'}]",Enzalutamide/Leuprolide +/- Abiraterone/Pred in Prostate,4697
8,NCT01848067,Phase Ib/II,"Active, not recruiting","[{'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 626, 'therapyName': 'Alisertib'}]","Alisertib, Abiraterone Acetate and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer",4697
9,NCT01717053,Phase II,"Active, not recruiting","[{'id': 795, 'therapyName': 'Leuprolide'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 759, 'therapyName': 'Goserelin'}]","Abiraterone, Radiotherapy and Short-Term Androgen Deprivation in Unfavorable Localized Prostate Cancer",4697
10,NCT01485861,Phase II,"Active, not recruiting","[{'id': 750, 'therapyName': 'GDC-0980'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 747, 'therapyName': 'Ipatasertib'}]",Study of GDC-0068 Or GDC-0980 With Abiraterone Acetate Versus Abiraterone Acetate in Patients With Castration-Resistant Prostate Cancer Previously Treated With Docetaxel Chemotherapy,4697
11,NCT01681433,Phase II,Terminated,"[{'id': 2188, 'therapyName': 'Prednisone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 1807, 'therapyName': 'OGX-427'}]",OGX-427 in Metastatic Castrate-Resistant Prostate Cancer With Prostate-Specific Antigen Progression While Receiving Abiraterone,4697
12,NCT01751451,Phase II,"Active, not recruiting","[{'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 1814, 'therapyName': 'Degarelix'}]","3-arm Study of Abiraterone Acetate Alone, Abiraterone Acetate Plus Degarelix, a GnRH Antagonist, and Degarelix Alone for Patients With Prostate Cancer With a Rising PSA or a Rising PSA and Nodal Disease Following Definitive Radical Prostatectomy",4697
13,NCT02217566,Phase II,"Active, not recruiting","[{'id': 1805, 'therapyName': 'Abiraterone'}]","Study of Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC), Chemo-Naive, Who Received a Prior Diethylstilbestrol Therapy",4697
14,NCT01972217,Phase II,"Active, not recruiting","[{'id': 2188, 'therapyName': 'Prednisone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 837, 'therapyName': 'Olaparib'}]",Ph II Study to Evaluate Olaparib With Abiraterone in Treating Metastatic Castration Resistant Prostate Cancer,4697
15,NCT03072238,Phase III,Recruiting,"[{'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 5438, 'therapyName': 'Abiraterone + Ipatasertib'}]","Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer",4697
16,NCT02403505,Phase II,"Active, not recruiting","[{'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 1814, 'therapyName': 'Degarelix'}]",Discovery Stage Clinical Study About Oncology Drugs and Single Nucleotide Polymorphisms,4697
17,NCT01517802,Phase III,Recruiting,"[{'id': 1805, 'therapyName': 'Abiraterone'}]",A Study That Provides Long-term Safety Follow-up and Examines Long-term Exposure to Abiraterone Acetate,4697
18,NCT02043678,Phase III,"Active, not recruiting","[{'id': 2188, 'therapyName': 'Prednisone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 2001, 'therapyName': 'radium Ra 223 dichloride'}]","Radium-223 Dichloride and Abiraterone Acetate Compared to Placebo and Abiraterone Acetate for Men With Cancer of the Prostate When Medical or Surgical Castration Does Not Work and When the Cancer Has Spread to the Bone, Has Not Been Treated With Chemotherapy and is Causing no or Only Mild Symptoms",4697
19,NCT01786265,Phase II,"Active, not recruiting","[{'id': 759, 'therapyName': 'Goserelin'}, {'id': 1814, 'therapyName': 'Degarelix'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 795, 'therapyName': 'Leuprolide'}]",Finite Androgen Ablation vs. Finite Androgen Ablation in Combination With Abiraterone Acetate and Prednisone,4697
20,NCT02788201,Phase II,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1133, 'therapyName': 'Mitomycin C'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1013, 'therapyName': 'epirubicin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1137, 'therapyName': 'Bleomycin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 781, 'therapyName': 'Ixabepilone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 2950, 'therapyName': 'Estramustine'}, {'id': 1941, 'therapyName': 'Floxuridine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 1811, 'therapyName': 'Carmustine'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 953, 'therapyName': 'Vandetanib'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 4419, 'therapyName': 'Toremifine'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 2601, 'therapyName': 'Dactinomycin'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 3035, 'therapyName': 'Chlorambucil'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 342, 'therapyName': 'Vemurafenib'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 2635, 'therapyName': 'Vinblastine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 4305, 'therapyName': 'Teniposide'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 4304, 'therapyName': 'Streptozocin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1231, 'therapyName': 'Bendamustine'}, {'id': 4303, 'therapyName': 'Mechlorethamine'}, {'id': 4302, 'therapyName': 'Mitotane'}]",Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma,4697
21,NCT01503229,Phase II,"Active, not recruiting","[{'id': 2188, 'therapyName': 'Prednisone'}, {'id': 1805, 'therapyName': 'Abiraterone'}]",Abiraterone Acetate in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer,4697
22,NCT02353715,Phase I,Recruiting,"[{'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 2648, 'therapyName': 'Sipuleucel-T'}]","Men With Metastatic Castrate-Resistant Prostate Cancer Treated With Either Sipuleucel-T (Provenge), Abiraterone Acetate (Zytiga) or Enzalutamide (Xtandi) Undergoing Cardiopulmonary EXercise Testing",4697
23,NCT01543776,Phase II,"Active, not recruiting","[{'id': 1805, 'therapyName': 'Abiraterone'}]",Food Effect Study of Abiraterone Acetate for Treatment of Patients With Castration-Resistant Prostate Cancer,4697
24,NCT02025010,Phase II,"Active, not recruiting","[{'id': 1805, 'therapyName': 'Abiraterone'}]",Phase II Clinical Trial of Abiraterone Acetate Without Exogenous Glucocorticoids in Men With Castration-resistant Prostate Cancer With Correlative Assessment of Hormone Intermediates.,4697
25,NCT01553188,Phase II,"Active, not recruiting","[{'id': 2188, 'therapyName': 'Prednisone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 1218, 'therapyName': 'Trebananib'}]",AMG 386 and Abiraterone for Advanced Prostate Cancer,4697
26,NCT02379390,Phase II,Terminated,"[{'id': 2188, 'therapyName': 'Prednisone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 1571, 'therapyName': 'Cabazitaxel'}]",Cabazitaxel Versus the Switch to Alternative AR Targeted Therapy Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Primary Resistant Patients to Abiraterone or Enz (PRIMCAB),4697
27,NCT01845792,Phase II,Completed,"[{'id': 1571, 'therapyName': 'Cabazitaxel'}, {'id': 1805, 'therapyName': 'Abiraterone'}]",Study of Abiraterone Acetate and Prednisone in Combination With Cabazitaxel in Patients With Prostate Cancer,4697
28,NCT01961843,Phase I,"Active, not recruiting","[{'id': 2188, 'therapyName': 'Prednisone'}, {'id': 1805, 'therapyName': 'Abiraterone'}]",Abiraterone Acetate for Castrate Resistant Prostate Cancer,4697
29,NCT02415621,Phase I,Recruiting,"[{'id': 1805, 'therapyName': 'Abiraterone'}]",Adaptive Abiraterone Therapy for Metastatic Castration Resistant Prostate Cancer,4697
30,NCT02125357,Phase II,"Active, not recruiting","[{'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 1805, 'therapyName': 'Abiraterone'}]",Sequencing Abiraterone and Enzalutamide in mCRPC,4697
31,NCT02090114,Phase II,Recruiting,"[{'id': 2591, 'therapyName': 'Andriol'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 1262, 'therapyName': 'Enzalutamide'}]",RE-sensitizing With Supraphysiologic Testosterone to Overcome REsistant (The RESTORE Study),4697
32,NCT02849990,Phase II,Recruiting,"[{'id': 4510, 'therapyName': 'Abiraterone + ARN-509 + Degarelix + Indomethacin + Prednisone'}]","Androgen Receptor Antagonist ARN-509, Abiraterone Acetate, Prednisone, Degarelix, and Indomethacin in Treating Patients With Localized Prostate Cancer Before Surgery",4697
33,NCT03009981,Phase III,Recruiting,"[{'id': 5523, 'therapyName': 'Abiraterone + ARN-509 + Degarelix + Prednisone'}, {'id': 5524, 'therapyName': 'ARN-509 + Degarelix'}, {'id': 1814, 'therapyName': 'Degarelix'}]",A Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer,4697
34,NCT02913196,Phase I,Recruiting,"[{'id': 4767, 'therapyName': 'Abiraterone + ARN-509 + Docetaxel + Prednisone'}]","Phase I Trial of Apalutamide Plus Abiraterone Acetate, Docetaxel, and Prednisone in Patients With mCRPC",4697
35,NCT03141671,Phase II,Not yet recruiting,"[{'id': 5742, 'therapyName': 'Bicalutamide + Gonadorelin'}, {'id': 5743, 'therapyName': 'Abiraterone + ARN-509 + Gonadorelin + Prednisone'}]",Randomized Phase II Study of Salvage XRT + ADT +/- Abiraterone and Apalutamide for Rising PSA After RP (FORMULA-509),4697
36,NCT02772588,Phase II,Recruiting,"[{'id': 4206, 'therapyName': 'Abiraterone + ARN-509 + Leuprolide'}]",AASUR in High Risk Prostate Cancer,4697
37,NCT03298087,Phase II,Not yet recruiting,"[{'id': 4206, 'therapyName': 'Abiraterone + ARN-509 + Leuprolide'}]",Systemic and Tumor-Directed Therapy for Oligometastatic Prostate Cancer,4697
38,NCT02903368,Phase II,Recruiting,"[{'id': 3079, 'therapyName': 'Abiraterone + Leuprolide + Prednisone'}, {'id': 4758, 'therapyName': 'Abiraterone + ARN-509 + Leuprolide + Prednisone'}]",Neoadjuvant And Adjuvant Abiraterone Acetate + Aptilutamide Prostate Cancer Undergoing Prostatectomy,4697
39,NCT02703623,Phase II,Recruiting,"[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 2649, 'therapyName': 'Abiraterone + ARN-509 + Prednisone'}, {'id': 3844, 'therapyName': 'Cabazitaxel + Carboplatin'}]",A Dynamic Allocation Modular Sequential Trial of Approved and Promising Therapies in Men With Metastatic Castrate Resistant Prostate Cancer (DynaMO),4697
40,NCT02123758,Phase I,"Active, not recruiting","[{'id': 2649, 'therapyName': 'Abiraterone + ARN-509 + Prednisone'}]",A Study of JNJ-56021927 (ARN-509) and Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer,4697
41,NCT02531516,Phase III,Recruiting,"[{'id': 2649, 'therapyName': 'Abiraterone + ARN-509 + Prednisone'}, {'id': 1507, 'therapyName': 'Bicalutamide'}]",An Efficacy and Safety Study of JNJ-56021927 (ARN-509) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy,4697
42,NCT03098836,Phase II,Recruiting,"[{'id': 2649, 'therapyName': 'Abiraterone + ARN-509 + Prednisone'}]",Apalutamide and Abiraterone Acetate in African American and Caucasian Men With Metastatic Castrate Resistant Prostate Cancer,4697
43,NCT03279250,Phase II,Not yet recruiting,"[{'id': 759, 'therapyName': 'Goserelin'}, {'id': 2050, 'therapyName': 'Triptorelin'}, {'id': 2649, 'therapyName': 'Abiraterone + ARN-509 + Prednisone'}, {'id': 795, 'therapyName': 'Leuprolide'}, {'id': 1947, 'therapyName': 'ARN-509'}]",Effects of Apalutamide Plus LHRH Agonist or Apalutamide Plus Abiraterone Acetate Plus LHRH Agonist for Six Months for Prostate Cancer Patients at High Risk for Recurrence,4697
44,NCT02949284,Phase II,Recruiting,"[{'id': 1947, 'therapyName': 'ARN-509'}, {'id': 2649, 'therapyName': 'Abiraterone + ARN-509 + Prednisone'}]","Androgen Receptor Antagonist ARN-509 With or Without Abiraterone Acetate, Gonadotropin-Releasing Hormone Analog, and Prednisone in Treating Patients With High-Risk Prostate Cancer Undergoing Surgery",4697
45,NCT01741753,Phase I,Terminated,"[{'id': 2499, 'therapyName': 'Abiraterone + BKM120 + Prednisone'}]",BKM120+Abiraterone Acetate for Metastatic CRPC,4697
46,NCT02903160,Phase II,Recruiting,"[{'id': 4759, 'therapyName': 'Abiraterone + Cabazitaxel + Carboplatin + Enzalutamide + Prednisone'}]","Prostate Cancer Intensive, Non-Cross Reactive Therapy (PRINT) for Castration Resistant Prostate Cancer (CRPC)",4697
47,NCT01254864,Phase II,"Active, not recruiting","[{'id': 1817, 'therapyName': 'Abiraterone + Sunitinib'}, {'id': 1818, 'therapyName': 'Abiraterone + Dasatinib\t'}]",Maximum Androgen Depletion,4697
48,NCT02758132,Phase I,Terminated,"[{'id': 4182, 'therapyName': 'Abiraterone + Denosumab + Enzalutamide + Prednisone'}, {'id': 4183, 'therapyName': 'Denosumab + Enzalutamide'}]","Denosumab Plus Enzalutamide, Abiraterone and Prednisone Compared to Denosumab Plus Enzalutamide Alone for Men With Castrate Resistant Prostate Cancer (CRPC) With Bone Metastases",4697
49,NCT03150056,Phase I,Recruiting,"[{'id': 6034, 'therapyName': 'Abiraterone + GSK525762'}, {'id': 6035, 'therapyName': 'Enzalutamide + GSK525762'}, {'id': 2188, 'therapyName': 'Prednisone'}]",Dose Escalation and Dose Expansion Study of GSK525762 in Combination With Androgen Deprivation Therapy and Other Agents in Subjects With Castrate-resistant Prostate Cancer,4697
50,NCT02543255,Phase II,Recruiting,"[{'id': 1571, 'therapyName': 'Cabazitaxel'}, {'id': 3079, 'therapyName': 'Abiraterone + Leuprolide + Prednisone'}, {'id': 1476, 'therapyName': 'Pegfilgrastim'}]",Anti-Androgens and Cabazitaxel in Defining Complete Response in Prostatectomy (ACDC Trial),4697
51,NCT02887976,Phase III,Not yet recruiting,"[{'id': 4678, 'therapyName': 'Abiraterone + Methylprednisolone'}]",Extension of SoluMatrix TM Abiraterone Acetate in Patients Who Completed Study Number CHL-AA-201,4697
52,NCT01828476,Phase II,Terminated,"[{'id': 1316, 'therapyName': 'Hydroxychloroquine'}, {'id': 2597, 'therapyName': 'Abiraterone + Navitoclax'}]",Navitoclax and Abiraterone Acetate With or Without Hydroxychloroquine in Treating Patients With Progressive Metastatic Castrate Refractory Prostate Cancer,4697
53,NCT02807805,Phase II,Recruiting,"[{'id': 4377, 'therapyName': 'Abiraterone + Niclosamide + Prednisone'}]","Abiraterone Acetate, Niclosamide, and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer",4697
54,NCT03012321,Phase II,Recruiting,"[{'id': 5226, 'therapyName': 'Abiraterone + Prednisone + Olaparib'}, {'id': 2748, 'therapyName': 'Abiraterone + Prednisone'}, {'id': 837, 'therapyName': 'Olaparib'}]","Abiraterone Acetate, Olaparib, and Prednisone in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer With DNA Repair Defects",4697
55,NCT01715285,Phase III,"Active, not recruiting","[{'id': 2748, 'therapyName': 'Abiraterone + Prednisone'}]","A Study of Abiraterone Acetate Plus Low-Dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Participants With High-Risk, Metastatic Hormone-Naive Prostate Cancer (mHNPC)",4697
56,NCT01688492,Phase Ib/II,"Active, not recruiting","[{'id': 2748, 'therapyName': 'Abiraterone + Prednisone'}, {'id': 779, 'therapyName': 'Ipilimumab'}]",Combining Ipilimumab With Abiraterone Acetate Plus Prednisone in Chemotherapy and Immunotherapy-na&#239;ve Patients With Progressive Metastatic Castration-resistant Prostate Cancer,4697
57,NCT01940276,Phase II,"Active, not recruiting","[{'id': 2748, 'therapyName': 'Abiraterone + Prednisone'}]",Abiraterone Race in Metastatic Castrate-resistant Prostate Cancer,4697
58,NCT02218606,Phase II,Recruiting,"[{'id': 1571, 'therapyName': 'Cabazitaxel'}, {'id': 2748, 'therapyName': 'Abiraterone + Prednisone'}]",Multicenter Trial of Abiraterone Acetate With or Without Cabazitaxel in Treatment of Metastatic Castration Resistant Prostate Cancer,4697
59,NCT02429193,Phase II,Recruiting,"[{'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 2748, 'therapyName': 'Abiraterone + Prednisone'}]",Biomarkers of Androgen Response and Resistance In Evolution During a Rising PSA (BARRIER-P),4697
60,NCT03016741,FDA approved,Recruiting,"[{'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 2748, 'therapyName': 'Abiraterone + Prednisone'}]",Cognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate Cancer,4697
61,NCT02960022,Phase II,Recruiting,"[{'id': 5371, 'therapyName': 'Enzalutamide + Abiraterone + Prednisone'}, {'id': 1262, 'therapyName': 'Enzalutamide'}]",A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study,4697
0,NCT02540876,Phase I,Recruiting,"[{'id': 975, 'therapyName': 'ABT-348'}]",Ilorasertib in Treating Patients With CDKN2A-deficient Advanced or Metastatic Solid Cancers That Cannot Be Removed by Surgery,7082
1,NCT02478320,Phase II,Recruiting,"[{'id': 975, 'therapyName': 'ABT-348'}]",Phase II Study of Ilorasertib (ABT348) in Patients With CDKN2A Deficient Solid Tumors,7082
0,NCT02573324,Phase II,Recruiting,"[{'id': 976, 'therapyName': 'ABT-414'}, {'id': 1141, 'therapyName': 'Temozolomide'}]",A Study of ABT-414 in Subjects With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification,7085
1,NCT02343406,Phase II,Recruiting,"[{'id': 2075, 'therapyName': 'Lomustine'}, {'id': 976, 'therapyName': 'ABT-414'}, {'id': 1141, 'therapyName': 'Temozolomide'}]",ABT-414 Alone or ABT-414 Plus Temozolomide vs. Lomustine or Temozolomide for Recurrent Glioblastoma,7085
2,NCT01741727,Phase II,Completed,"[{'id': 976, 'therapyName': 'ABT-414'}]",A Study of ABT-414 in Subjects With Solid Tumors,7085
3,NCT01800695,Phase I,Completed,"[{'id': 1141, 'therapyName': 'Temozolomide'}, {'id': 976, 'therapyName': 'ABT-414'}]",Evaluating the Safety and Pharmacokinetics of ABT-414 for Subjects With Glioblastoma Multiforme,7085
0,NCT01472016,Phase I,Completed,"[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1063, 'therapyName': 'ABT-700'}, {'id': 694, 'therapyName': 'Cetuximab'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 1315, 'therapyName': 'FOLFIRI'}]",Study of ABT-700 in Subjects With Advanced Solid Tumors,7182
0,NCT02448251,Phase Ib/II,Recruiting,"[{'id': 2909, 'therapyName': 'AC0010MA'}]","Safety, Pharmacokinetic and Preliminary Efficacy Study of AC0010MA in Advanced Non Small Cell Lung Cancer",7832
0,NCT02448303,Phase II,"Active, not recruiting","[{'id': 1605, 'therapyName': 'Acalabrutinib'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab Alone and In Combination With ACP-196 in Subjects With Advanced Non-small Cell Lung Cancer,7296
1,NCT02351739,Phase II,"Active, not recruiting","[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1605, 'therapyName': 'Acalabrutinib'}]",Study of the Combination of ACP-196 and Pembrolizumab in Subjects With Platinum-refractory Metastatic Bladder Cancer,7296
2,NCT02570711,Phase II,Terminated,"[{'id': 1605, 'therapyName': 'Acalabrutinib'}, {'id': 1779, 'therapyName': 'Nab-paclitaxel + Gemcitabine'}]",Study of Nab Paclitaxel/Gemcitabine Alone and in Combination With ACP-196 in Subjects With Previously Untreated Metastatic Pancreatic Cancer,7296
3,NCT02586857,Phase Ib/II,Recruiting,"[{'id': 1605, 'therapyName': 'Acalabrutinib'}]","A Phase 1b/2, Multicenter, Open-label Study of ACP-196 in Subjects With Recurrent Glioblastoma Multiforme (GBM)",7296
4,NCT02328014,Phase Ib/II,Recruiting,"[{'id': 3265, 'therapyName': 'ACP-319'}, {'id': 1605, 'therapyName': 'Acalabrutinib'}]","ACP-196 in Combination With ACP-319, for Treatment of B-Cell Malignancies",7296
5,NCT02029443,Phase Ib/II,"Active, not recruiting","[{'id': 1605, 'therapyName': 'Acalabrutinib'}]","ACP-196, a Novel Bruton Tyrosine Kinase (Btk) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia",7296
6,NCT02180711,Phase I,"Active, not recruiting","[{'id': 1605, 'therapyName': 'Acalabrutinib'}]","An Open-label, Phase 1b Study of ACP 196 in Subjects With Follicular Lymphoma",7296
7,NCT02537444,Phase II,"Active, not recruiting","[{'id': 1605, 'therapyName': 'Acalabrutinib'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",ACP-196 Alone and in Combination With Pembrolizumab in Subjects With Recurrent Ovarian Cancer (KEYNOTE191),7296
8,NCT02362035,Phase Ib/II,"Active, not recruiting","[{'id': 1605, 'therapyName': 'Acalabrutinib'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]","ACP-196 in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies (KEYNOTE145)",7296
9,NCT02213926,Phase II,"Active, not recruiting","[{'id': 1605, 'therapyName': 'Acalabrutinib'}]","An Open-label, Phase 2 Study of ACP 196 in Subjects With Mantle Cell Lymphoma",7296
10,NCT02970318,Phase III,Recruiting,"[{'id': 2324, 'therapyName': 'Bendamustine + Idelalisib + Rituximab'}, {'id': 1605, 'therapyName': 'Acalabrutinib'}]",A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL,7296
11,NCT02211014,Phase I,"Active, not recruiting","[{'id': 1605, 'therapyName': 'Acalabrutinib'}, {'id': 1390, 'therapyName': 'Dexamethasone'}]","An Open-Label, Phase 1b Study of ACP-196 With and Without Dexamethasone in Subjects With Multiple Myeloma",7296
12,NCT02337829,Phase II,Recruiting,"[{'id': 1605, 'therapyName': 'Acalabrutinib'}]",ACP-196 in Patients With Relapsed/Refractory and Treatment naïve Deletion 17p CLL/SLL,7296
13,NCT02717611,Phase II,"Active, not recruiting","[{'id': 1605, 'therapyName': 'Acalabrutinib'}]",A Study of ACP-196 (Acalabrutinib) in Subjects With Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy,7296
14,NCT02475681,Phase III,"Active, not recruiting","[{'id': 1605, 'therapyName': 'Acalabrutinib'}, {'id': 3035, 'therapyName': 'Chlorambucil'}, {'id': 1646, 'therapyName': 'Obinutuzumab'}]","Elevate CLL TN: Study of Obinutuzumab + Chlorambucil, ACP-196 + Obinutuzumab, and ACP-196 in Subjects With Previously Untreated CLL",7296
15,NCT02477696,Phase III,Recruiting,"[{'id': 1605, 'therapyName': 'Acalabrutinib'}, {'id': 768, 'therapyName': 'Ibrutinib'}]",Elevate CLL R/R: Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects With High Risk Chronic Lymphocytic Leukemia,7296
16,NCT02180724,Phase I,"Active, not recruiting","[{'id': 1605, 'therapyName': 'Acalabrutinib'}]","An Open-label, Phase 1b Study of ACP 196 in Subjects With Waldenström Macroglobulinemia",7296
17,NCT02362048,Phase II,"Active, not recruiting","[{'id': 1605, 'therapyName': 'Acalabrutinib'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",ACP-196 Alone and in Combination With Pembrolizumab in Subjects With Advanced or Metastatic Pancreatic Cancer,7296
18,NCT02454179,Phase II,"Active, not recruiting","[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1605, 'therapyName': 'Acalabrutinib'}]",Study of the Combination of ACP-196 and Pembrolizumab in Subjects With Advanced Head and Neck Squamous Cell Carcinoma,7296
19,NCT02717624,Phase I,"Active, not recruiting","[{'id': 3996, 'therapyName': 'Acalabrutinib + Bendamustine + Rituximab'}]",A Study of ACP-196 in Combination With Bendamustine and Rituximab in Subjects With Mantle Cell Lymphoma,7296
20,NCT02972840,Phase III,Recruiting,"[{'id': 2323, 'therapyName': 'Bendamustine + Rituximab'}, {'id': 3996, 'therapyName': 'Acalabrutinib + Bendamustine + Rituximab'}]",A Study of Bendamustine and Rituximab Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated Mantle Cell Lymphoma,7296
21,NCT02296918,Phase I,"Active, not recruiting","[{'id': 3477, 'therapyName': 'Acalabrutinib + Obinutuzumab'}]",ACP-196 in Combination With Obinutuzumab in Relapsed/Refractory or Untreated CLL/SLL/PLL,7296
22,NCT03205046,Phase Ib/II,Recruiting,"[{'id': 6188, 'therapyName': 'Acalabrutinib + Vistusertib'}]",A Study of Acalabrutinib and Vistusertib in Subjects With Relapsed/Refractory B-cell Malignancies,7296
0,NCT02328014,Phase Ib/II,Recruiting,"[{'id': 3265, 'therapyName': 'ACP-319'}, {'id': 1605, 'therapyName': 'Acalabrutinib'}]","ACP-196 in Combination With ACP-319, for Treatment of B-Cell Malignancies",7997
0,NCT03050814,Phase II,Suspended,"[{'id': 1524, 'therapyName': 'Fluorouracil + Bevacizumab + Capecitabine + Leucovorin + Oxaliplatin'}, {'id': 5336, 'therapyName': 'Ad-CEA + Bevacizumab + FOLFOX'}]",Standard of Care Alone or in Combination With Ad-CEA Vaccine and Avelumab in People With Previously Untreated Metastatic Colorectal Cancer,8666
0,NCT02423902,Phase Ib/II,"Active, not recruiting","[{'id': 4250, 'therapyName': 'Ad-RTS-IL-12 plus AL'}]",A Study of Ad-RTS-hIL-12 With Veledimex in Subjects With Breast Cancer,8388
0,NCT03281382,Phase I,Recruiting,"[{'id': 6283, 'therapyName': 'Ad5-yCD/mutTKSR39rep-hIL12 '}]",Phase 1 Trial of Interleukin 12 Gene Therapy for Metastatic Pancreatic Cancer,8963
0,NCT02842125,Phase I,Recruiting,"[{'id': 5879, 'therapyName': 'Ad5CMV-p53 gene + Capecitabine'}]",Safety and Efficacy of Intra-Arterial Ad-p53 in Liver Metastases of Solid Tumors,7088
0,NCT03125200,Phase I,Recruiting,"[{'id': 5689, 'therapyName': 'ADCT-502'}]",Study of ADCT-502 in Patients With Advanced Solid Tumors With HER2 Expression,8744
0,NCT01825603,Phase I,Recruiting,"[{'id': 4952, 'therapyName': 'ADH-1 + Cisplatin + Gemcitabine'}]","ADH-1, Gemcitabine Hydrochloride and Cisplatin in Treating Patients With Metastatic Pancreatic or Biliary Tract Cancer That Cannot Be Removed By Surgery",8580
0,NCT02101593,Phase I,Completed,"[{'id': 2424, 'therapyName': 'ADI-PEG 20'}]",Ph 1 Trial of ADI PEG 20 Plus Sorafenib to Treat Patients With Liver Cancer,7526
0,NCT02831933,Phase II,Recruiting,"[{'id': 4462, 'therapyName': 'AdV-tk + Nivolumab'}]",Trial of Stereotactic Body Radiation and Gene Therapy Before Nivolumab for Metastatic Non-Small Cell Lung Carcinoma (ENSIGN),8460
1,NCT02768363,Phase II,Recruiting,"[{'id': 5172, 'therapyName': 'AdV-tk + Valacyclovir'}, {'id': 5171, 'therapyName': 'Valacyclovir'}]",Randomized Controlled Trial of ProstAtak Immunotherapy During Active Surveillance for Prostate Cancer (ULYSSES),8460
2,NCT03131037,Phase I,Recruiting,"[{'id': 5172, 'therapyName': 'AdV-tk + Valacyclovir'}]",Intratumoral Gene Mediated Cytotoxic Immunotherapy in Patients With Resectable Non-Small Cell Lung Cancer,8460
3,NCT03004183,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 5172, 'therapyName': 'AdV-tk + Valacyclovir'}]",SBRT and Oncolytic Virus Therapy Before Pembrolizumab for Metastatic TNBC and NSCLC,8460
4,NCT01436968,Phase III,Recruiting,"[{'id': 5171, 'therapyName': 'Valacyclovir'}, {'id': 5172, 'therapyName': 'AdV-tk + Valacyclovir'}]",Phase 3 Study of ProstAtak Immunotherapy With Standard Radiation Therapy for Localized Prostate Cancer,8460
0,NCT02002182,Phase II,Recruiting,"[{'id': 3090, 'therapyName': 'ADXS11-001'}]","ADXS 11-001 Vaccination Prior to Robotic Surgery, HPV-Positive Oropharyngeal Cancer",7935
1,NCT02399813,Phase Ib/II,"Active, not recruiting","[{'id': 3090, 'therapyName': 'ADXS11-001'}]",Phase 2 Study of ADXS11-001 in Subjects With Anal Cancer or Cancer of the Rectum,7935
2,NCT02291055,Phase Ib/II,Recruiting,"[{'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 3090, 'therapyName': 'ADXS11-001'}]",Phase 1-2 Study of ADXS11-001 or MEDI4736 Alone or Combo In Cervical or HPV+ Head &amp; Neck Cancer,7935
3,NCT02853604,Phase III,Recruiting,"[{'id': 3090, 'therapyName': 'ADXS11-001'}]",Study of ADXS11-001 in Subjects With High Risk Locally Advanced Cervical Cancer (AIM2CERV),7935
4,NCT02164461,Phase Ib/II,"Active, not recruiting","[{'id': 3090, 'therapyName': 'ADXS11-001'}]",ADXS11-001 High Dose HPV+ Cervical Cancer,7935
0,NCT02325557,Phase Ib/II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 3050, 'therapyName': 'ADXS31-142 '}]",ADXS31-142 Alone and in Combination With Pembrolizumab (MK-3475) in Patients With Prostate Cancer - KEYNOTE-046,7919
0,NCT02386501,,Recruiting,"[{'id': 4654, 'therapyName': 'ADXS31-164'}]",Dose Escalation Study of ADXS31-164 in Subjects With HER2 Expressing Solid Tumors,8504
0,NCT01430416,Phase I,"Active, not recruiting","[{'id': 621, 'therapyName': 'AEB071'}]",Safety and Efficacy of AEB071 in Metastatic Uveal Melanoma Patients,6829
1,NCT02285244,Phase II,Withdrawn,"[{'id': 621, 'therapyName': 'AEB071'}]","Sotrastaurin Acetate in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, Prolymphocytic Leukemia, or Richter's Transformation",6829
2,NCT02273219,Phase I,Recruiting,"[{'id': 1861, 'therapyName': 'AEB071 + BYL719'}]",Trial of AEB071 in Combination With BYL719 in Patients With Melanoma,6829
3,NCT01854606,Phase Ib/II,Completed,"[{'id': 1951, 'therapyName': 'AEB071 + Everolimus'}]",Safety and Efficacy of AEB071 and EVEROLIMUS in Patients With CD79-mutant or ABC Subtype Diffuse Large B-Cell Lymphoma,6829
4,NCT01801358,Phase Ib/II,Terminated,"[{'id': 807, 'therapyName': 'Binimetinib'}, {'id': 1114, 'therapyName': 'MEK162 + AEB071'}]", A Phase Ib/II Study of AEB071 and MEK162 in Adult Patients With Metastatic Uveal Melanoma,6829
0,NCT02514174,FDA approved,Recruiting,"[{'id': 623, 'therapyName': 'Afatinib'}]",Afatinib Treatment for Patients With EGFR Mutation Positive NSCLC Who Are Age 70 or Older,6823
1,NCT02122172,Phase II,Recruiting,"[{'id': 623, 'therapyName': 'Afatinib'}]",Afatinib in Advanced Refractory Urothelial Cancer,6823
2,NCT01746251,Phase II,"Active, not recruiting","[{'id': 623, 'therapyName': 'Afatinib'}]",Adjuvant Afatinib in Stage I-III NSCLC With EGFR Mutation,6823
3,NCT01824823,Phase II,Terminated,"[{'id': 623, 'therapyName': 'Afatinib'}]",Afatinib After Chemoradiation and Surgery in Treating Patients With Stage III-IV Squamous Cell Carcinoma of the Head and Neck at High-Risk of Recurrence,6823
4,NCT02423525,Phase I,Recruiting,"[{'id': 623, 'therapyName': 'Afatinib'}]",Safety Study of Afatinib for Brain Cancer,6823
5,NCT02491099,Phase II,Recruiting,"[{'id': 623, 'therapyName': 'Afatinib'}]",A Phase II Evaluation of Afatinib,6823
6,NCT01649284,Phase I,Approved for marketing,"[{'id': 623, 'therapyName': 'Afatinib'}]",Afatinib Expanded Access Program,6823
7,NCT01553942,Phase II,Recruiting,"[{'id': 623, 'therapyName': 'Afatinib'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 854, 'therapyName': 'Pemetrexed'}]",Afatinib With CT and RT for EGFR-Mutant NSCLC,6823
8,NCT02451553,Phase I,Recruiting,"[{'id': 623, 'therapyName': 'Afatinib'}, {'id': 1105, 'therapyName': 'Capecitabine'}]","Afatinib Dimaleate and Capecitabine in Treating Patients With Advanced Refractory Solid Tumors, Pancreatic Cancer or Biliary Cancer",6823
9,NCT02438722,Phase II,Recruiting,"[{'id': 623, 'therapyName': 'Afatinib'}, {'id': 694, 'therapyName': 'Cetuximab'}]","S1403, Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer",6823
10,NCT02795156,Phase II,Recruiting,"[{'id': 623, 'therapyName': 'Afatinib'}, {'id': 890, 'therapyName': 'Regorafenib'}]",Study to Assess the Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations,6823
11,NCT02115048,Phase II,"Active, not recruiting","[{'id': 623, 'therapyName': 'Afatinib'}, {'id': 794, 'therapyName': 'Letrozole'}]",Clinical Study for the Treatment of Breast Cancer the Patient Will Receive Afatinib Plus Letrozole or Letrozole Alone,6823
12,NCT02541903,Phase II,Recruiting,"[{'id': 623, 'therapyName': 'Afatinib'}]",Trial Using Gilotrif for Advanced Penile Squamous Cell Carcinoma,6823
13,NCT01647711,Phase I,Completed,"[{'id': 623, 'therapyName': 'Afatinib'}]","A Study of Intermittent, High-dose Afatinib to Determine the Maximal Tolerated Dose and Assess Activity of This Dose Against Non-small Cell Lung Cancer With T790M Mutations",6823
14,NCT02271906,Phase II,Terminated,"[{'id': 623, 'therapyName': 'Afatinib'}]",The ATTAIN Study: A Therapeutic Trial of Afatinib In the Neoadjuvant Setting,6823
15,NCT02465060,Phase II,Recruiting,"[{'id': 660, 'therapyName': 'AZD9291'}, {'id': 3, 'therapyName': 'Dabrafenib'}, {'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 2, 'therapyName': 'Trametinib'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 623, 'therapyName': 'Afatinib'}, {'id': 654, 'therapyName': 'AZD4547'}, {'id': 958, 'therapyName': 'VS-6063'}, {'id': 765, 'therapyName': 'GSK2636771'}]",NCI-MATCH Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas,6823
16,NCT02506517,Phase II,Recruiting,"[{'id': 623, 'therapyName': 'Afatinib'}]",A Study of Afatinib in Patients With Advanced Cancer With Changes in the HER Gene,6823
17,NCT02695290,Phase III,Terminated,"[{'id': 623, 'therapyName': 'Afatinib'}]",Afatinib in EGFR+NSCLC (Recurrent or Stage IV) - Patients With Poor Performance Status (ECOG 2 or 3),6823
18,NCT01345669,Phase III,Terminated,"[{'id': 623, 'therapyName': 'Afatinib'}]",LUX-Head&Neck 2: A Phase III Trial of Afatinib (BIBW 2992) Versus Placebo for the Treatment of Head and Neck Squamous Cell Cancer After Treatment With Chemo-radiotherapy,6823
19,NCT01783587,Phase I,Recruiting,"[{'id': 623, 'therapyName': 'Afatinib'}, {'id': 720, 'therapyName': 'Docetaxel'}]",Safety Study of Afatinib and Postoperative Radiation Therapy to Treat Head and Neck Cancer,6823
20,NCT02372006,Phase I,Recruiting,"[{'id': 623, 'therapyName': 'Afatinib'}]",Phase I Trial of Afatinib in Pediatric Tumours,6823
21,NCT02551718,Phase I,Recruiting,"[{'id': 690, 'therapyName': 'Bosutinib'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 3160, 'therapyName': 'Nelarabine'}, {'id': 3159, 'therapyName': 'Bexarotene'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 998, 'therapyName': 'cabozantinib'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 877, 'therapyName': 'Ponatinib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 623, 'therapyName': 'Afatinib'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 890, 'therapyName': 'Regorafenib'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 2, 'therapyName': 'Trametinib'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 3, 'therapyName': 'Dabrafenib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 789, 'therapyName': 'Ceritinib'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1571, 'therapyName': 'Cabazitaxel'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1327, 'therapyName': 'Pralatrexate'}]",High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia,6823
22,NCT01732640,Phase Ib/II,Completed,"[{'id': 2442, 'therapyName': 'Afatinib + Carboplatin + Paclitaxel'}, {'id': 700, 'therapyName': 'Cisplatin'}]",A Phase I/II Study Afatinib/Carboplatin/Paclitaxel Induction Chemotherapy In HPV-Negative HNSCC.,6823
23,NCT02979977,Phase II,Recruiting,"[{'id': 4190, 'therapyName': 'Afatinib + Cetuximab'}]",Dual Inhibition of EGFR With Afatinib and Cetuximab in the Treatment of Recurrent or Metastatic Squamous Cell Cancers of the Head and Neck,6823
24,NCT01814553,Phase III,Completed,"[{'id': 1374, 'therapyName': 'Afatinib + Loperamide'}]", ADAM-Afatinib Diarrhea Assessment and Management,6823
25,NCT03054038,Phase I,Recruiting,"[{'id': 5363, 'therapyName': 'Afatinib + Necitumumab'}]",Afatinib and Necitumumab in Patients With EGFR Mutation Positive Advanced or Metastatic Non-small Cell Lung Cancer,6823
26,NCT02274012,Phase II,Withdrawn,"[{'id': 2441, 'therapyName': 'Afatinib + Paclitaxel'}]","Trial of Afatinib in Combination With Weekly Paclitaxel in the Second Line Treatment of HER2 Amplified Advanced Gastric, Gastroesophageal Junction and Esophageal Cancer",6823
27,NCT02364609,Phase I,Recruiting,"[{'id': 2435, 'therapyName': 'Afatinib + Pembrolizumab'}]",Pembrolizumab and Afatinib in Patients With Non-small Cell Lung Cancer With Resistance to Erlotinib,6823
28,NCT03157089,Phase II,Not yet recruiting,"[{'id': 2435, 'therapyName': 'Afatinib + Pembrolizumab'}]",Testing Afatinib in Combination With Pembrolizumab in Patients With Squamous Cell Carcinoma of the Lung (LUX-Lung IO),6823
29,NCT01522768,Phase II,Recruiting,"[{'id': 1106, 'therapyName': 'Afatinib + Trastuzumab'}]", Afatinib (BIBW 2992) and Trastuzumab in Patients With Advanced HER2-Positive Trastuzumab-Refractory Advanced Esophagogastric Cancer,6823
30,NCT01999985,Phase I,"Active, not recruiting","[{'id': 1351, 'therapyName': 'Dasatinib + Afatinib'}]",Phase I Trial of Afatinib (BIBW 2992) and Dasatinib in Non-small Cell Lung Cancer (NSCLC),6823
0,NCT02993159,Phase II,Recruiting,"[{'id': 5132, 'therapyName': 'Afimoxifene'}, {'id': 1456, 'therapyName': 'Tamoxifen'}]",Tamoxifen Citrate or Afimoxifene in Treating Patients With Estrogen Receptor Positive Breast Cancer,8616
0,NCT02101918,Phase II,"Active, not recruiting","[{'id': 624, 'therapyName': 'Aflibercept'}]",Ziv-Aflibercept in Treating and Computed Tomography Perfusion Imaging in Predicting Response in Patients With Pancreatic Neuroendocrine Tumors That Are Metastatic or Cannot Be Removed by Surgery,6795
1,NCT02235324,Phase II,Withdrawn,"[{'id': 1841, 'therapyName': 'Aflibercept + Leucovorin + Fluorouracil'}, {'id': 624, 'therapyName': 'Aflibercept'}]","Ziv-Aflibercept Followed by Ziv-Aflibercept, Fluorouracil, and Leucovorin Calcium in Treating Patients With Stage IV Colorectal Cancer",6795
2,NCT01747551,Phase II,"Active, not recruiting","[{'id': 624, 'therapyName': 'Aflibercept'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}]",FOLFOX +/- Ziv-Aflibercept for Esophageal and Gastric Cancer,6795
3,NCT01669720,Phase II,Terminated,"[{'id': 624, 'therapyName': 'Aflibercept'}]",Adjuvant Aflibercept for Metastatic Colorectal Cancer,6795
4,NCT02046538,Phase II,Withdrawn,"[{'id': 1315, 'therapyName': 'FOLFIRI'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 624, 'therapyName': 'Aflibercept'}]",Phase II Study of Zaltrap and Chemotherapy for Advanced Resectable Colorectal Cancer,6795
5,NCT01258855,Phase II,"Active, not recruiting","[{'id': 1167, 'therapyName': 'Aldesleukin'}, {'id': 624, 'therapyName': 'Aflibercept'}]",Aldesleukin With or Without Ziv-Aflibercept in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery,6795
6,NCT01661972,Phase Ib/II,Completed,"[{'id': 2368, 'therapyName': 'Aflibercept + Capecitabine'}]",Phase I/II Study of Capecitabine Plus Aflibercept to Treat Metastatic Colorectal Cancer,6795
7,NCT01571284,Phase III,Completed,"[{'id': 2095, 'therapyName': 'Aflibercept + FOLFIRI'}]",Safety and Quality of Life Study of Aflibercept in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen,6795
8,NCT02045030,Phase II,Terminated,"[{'id': 2095, 'therapyName': 'Aflibercept + FOLFIRI'}]",Study to Identify Biomarkers of Clinical Response to Aflibercept in Patients With Metastatic Colorectal Cancer,6795
9,NCT01652196,Phase II,"Active, not recruiting","[{'id': 2367, 'therapyName': 'Aflibercept + mFOLFOX-6'}]",Aflibercept and FOLFOX6 Treatment for Previously Untreated Stage IV Colorectal Cancer,6795
10,NCT02159989,Phase I,Recruiting,"[{'id': 1595, 'therapyName': 'Aflibercept + MLN0128'}]",MLN0128 and Ziv-Aflibercept in Treating Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed By Surgery,6795
11,NCT02298959,Phase I,Recruiting,"[{'id': 2369, 'therapyName': 'Aflibercept + Pembrolizumab'}]",Pembrolizumab and Ziv-aflibercept in Treating Patients With Advanced Solid Tumors,6795
12,NCT02192541,Phase I,Completed,"[{'id': 1665, 'therapyName': 'Ganetespib + Aflibercept'}]","Ganetespib and Ziv-Aflibercept in Refractory Gastrointestinal Carcinomas, Non-Squamous Non-Small Cell Lung Carcinomas, Urothelial Carcinomas, and Sarcomas",6795
0,NCT03192202,Phase Ib/II,Recruiting,"[{'id': 4389, 'therapyName': 'AFM13'}]",AFM13 in Relapsed/Refractory Cutaneous Lymphomas,8438
1,NCT02665650,Phase I,Recruiting,"[{'id': 4390, 'therapyName': 'AFM13 + Pembrolizumab'}]",Study of the Combination of AFM13 and Pembrolizumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma,8438
0,NCT01531894,Phase II,"Active, not recruiting","[{'id': 625, 'therapyName': 'Afuresertib'}]",Continuation Study of the Oral AKT Inhibitor GSK2110183,6831
1,NCT01428492,Phase I,Completed,"[{'id': 625, 'therapyName': 'Afuresertib'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1390, 'therapyName': 'Dexamethasone'}]",Ph 1b Study to Evaluate GSK2110183 in Combination With Bortezomib and Dexamethasone in Subjects With Multiple Myeloma,6831
2,NCT02235740,Phase I,Terminated,"[{'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 1839, 'therapyName': 'Afuresertib + Carfilzomib'}]","A Study Conducted in Subjects With Relapsed/Refractory Multiple Myeloma (MM); to Determine Dose of Afuresertib in Combination With Carfilzomib (Part 1) and to Investigate the Safety, Pharmacokinetic and Clinical Activity of the Combination Compared With Carfilzomib Alone (Part 2)",6831
3,NCT01532700,Phase II,"Active, not recruiting","[{'id': 1091, 'therapyName': 'Ofatumumab + GSK2110183'}]", An Open-Label Phase 2 Study of Ofatumumab (Arzerra) in Combination With Oral GSK2110183 in the Treatment of Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL),6831
0,NCT02074839,Phase I,"Active, not recruiting","[{'id': 1491, 'therapyName': 'AG-120'}]",Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation,7273
1,NCT02989857,Phase III,Recruiting,"[{'id': 1491, 'therapyName': 'AG-120'}]",Study of AG-120 in Previously Treated Advanced Cholangiocarcinoma With IDH1 Mutations (ClarIDHy),7273
2,NCT02632708,Phase I,Recruiting,"[{'id': 1491, 'therapyName': 'AG-120'}, {'id': 2982, 'therapyName': 'Enasidenib'}, {'id': 3431, 'therapyName': 'Cytarabine + Daunorubicin + Etoposide + Mitoxantrone'}]",Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia With an IDH1 and/or IDH2 Mutation,7273
3,NCT02073994,Phase I,"Active, not recruiting","[{'id': 1491, 'therapyName': 'AG-120'}]","Study of Orally Administered AG-120 in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 Mutation",7273
4,NCT03173248,Phase III,Recruiting,"[{'id': 4002, 'therapyName': 'AG-120 + Azacitidine'}, {'id': 1491, 'therapyName': 'AG-120'}]",Study of AG-120 (Ivosidenib) vs. Placebo in Combination With Azacitidine in Patients With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation (AGILE),7273
5,NCT02677922,Phase Ib/II,Recruiting,"[{'id': 4002, 'therapyName': 'AG-120 + Azacitidine'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 4003, 'therapyName': 'Azacitidine + Enasidenib'}]",A Safety and Efficacy Study of Oral AG-120 Plus Subcutaneous Azacitidine and Oral AG-221 Plus Subcutaneous Azacitidine in Subjects With Newly Diagnosed Acute Myeloid Leukemia (AML),7273
0,NCT02492737,Phase I,"Active, not recruiting","[{'id': 2995, 'therapyName': 'AG-881'}]",Study of Orally Administered AG-881 in Patients With Advanced Hematologic Malignancies With an IDH1 and/or IDH2 Mutation,7894
1,NCT02481154,Phase I,Recruiting,"[{'id': 2995, 'therapyName': 'AG-881'}]","Study of Orally Administered AG-881 in Patients With Advanced Solid Tumors, Including Gliomas, With an IDH1 and/or IDH2 Mutation",7894
0,NCT02694822,Phase I,Recruiting,"[{'id': 5695, 'therapyName': 'AGEN1884'}]","AGEN-1884, an Anti-CTLA-4 Antibody, in Advanced Solid Cancers",8750
0,NCT03104699,Phase Ib/II,Recruiting,"[{'id': 5693, 'therapyName': 'AGEN2034'}]",Phase 1 / 2 Study of AGEN2034 in Advanced Tumors and Cervical Cancer,8748
0,NCT02170389,Phase I,Withdrawn,"[{'id': 4075, 'therapyName': 'AGS-003'}]",Vaccine Therapy Before Surgery in Treating Patients With Localized Kidney Cancer,8337
0,NCT02639182,Phase II,Recruiting,"[{'id': 4220, 'therapyName': 'AGS-16C3F'}, {'id': 649, 'therapyName': 'Axitinib'}]",A Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma,8380
0,NCT03092934,Phase Ib/II,Recruiting,"[{'id': 5753, 'therapyName': 'AK-01'}]",A Study of AK-01 in Solid Tumors,8774
0,NCT02049905,Phase III,Completed,"[{'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1440, 'therapyName': 'Aldoxorubicin'}, {'id': 1439, 'therapyName': 'Gemcitabine + Docetaxel'}]",Phase 3 Study to Treat Patients With Soft Tissue Sarcomas,7260
1,NCT02200757,Phase II,Recruiting,"[{'id': 1440, 'therapyName': 'Aldoxorubicin'}, {'id': 942, 'therapyName': 'Topotecan'}]",Efficacy and Safety of Aldoxorubicin Compared to Topotecan in Subjects With Metastatic Small Cell Lung Cancer,7260
2,NCT01849783,Phase II,Recruiting,"[{'id': 1852, 'therapyName': 'Melphalan + Bortezomib + Thalidomide + Dexamethasone'}, {'id': 3435, 'therapyName': 'Aldoxorubicin + Cisplatin + Cyclophosphamide + Dexamethasone + Etoposide'}]",Autologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple Myeloma,7260
3,NCT02177695,Phase II,Recruiting,"[{'id': 1467, 'therapyName': 'Gemcitabine + Cisplatin'}, {'id': 2564, 'therapyName': 'Aldoxorubicin + Cisplatin + Filgrastim + Methotrexate + Vinblastine'}]","S1314, Co-expression Extrapolation (COXEN) Program to Predict Chemotherapy Response in Patients With Bladder Cancer",7260
4,NCT02412670,Phase II,Recruiting,"[{'id': 2667, 'therapyName': 'Carboplatin + Gemcitabine'}, {'id': 2668, 'therapyName': 'Aldoxorubicin + Cisplatin + Methotrexate + Vincristine'}]",Chemotherapy Before Surgery in Treating Patients With High Grade Upper Urinary Tract Cancer,7260
5,NCT00740805,Phase I,"Active, not recruiting","[{'id': 2989, 'therapyName': 'Aldoxorubicin + Cyclophosphamide + Veliparib'}]","Veliparib, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Non-Hodgkin Lymphoma",7260
6,NCT02560051,Phase II,Recruiting,"[{'id': 1814, 'therapyName': 'Degarelix'}, {'id': 3087, 'therapyName': 'Aldoxorubicin + Docetaxel + Estramustine + Ketoconazole'}]",Hormone Therapy Plus Chemotherapy as Initial Treatment for Local Failures or Advanced Prostate Cancer,7260
7,NCT02261805,Phase Ib/II,Terminated,"[{'id': 3052, 'therapyName': 'Aldoxorubicin + Ganetespib'}]",A Phase I/II Study of Ganetespib in Combination With Doxorubicin,7260
8,NCT02431559,Phase Ib/II,Recruiting,"[{'id': 3101, 'therapyName': 'Aldoxorubicin + MEDI4736 + Motolimod'}]","A Phase 1/2 Study of Motolimod (VTX-2337) and MEDI4736 in Subjects With Recurrent, Platinum-Resistant Ovarian Cancer for Whom Pegylated Liposomal Doxorubicin (PLD) is Indicated",7260
9,NCT02626455,Phase III,Recruiting,"[{'id': 1631, 'therapyName': 'Vincristine'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 3388, 'therapyName': 'Aldoxorubicin +Cyclophosphamide + Prednisone + Rituximab + Vincristine'}, {'id': 995, 'therapyName': 'Copanlisib'}, {'id': 2323, 'therapyName': 'Bendamustine + Rituximab'}, {'id': 897, 'therapyName': 'Rituximab'}]",Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL),7260
0,NCT02075840,Phase III,"Active, not recruiting","[{'id': 698, 'therapyName': 'Alectinib'}, {'id': 706, 'therapyName': 'Crizotinib'}]","ALEX Study: A Randomized, Phase III Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) Patients",6885
1,NCT02521051,Phase Ib/II,Recruiting,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 698, 'therapyName': 'Alectinib'}]","Phase I/II Trial of Alectinib and Bevacizumab in Patients With Advanced, Anaplastic Lymphoma Kinase (ALK)-Positive, Non-Small Cell Lung Cancer",6885
2,NCT01871805,Phase Ib/II,"Active, not recruiting","[{'id': 698, 'therapyName': 'Alectinib'}]",A Study of CH5424802/RO5424802 in Patients With ALK-Rearranged Non-Small Cell Lung Cancer,6885
3,NCT02091141,Phase II,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 698, 'therapyName': 'Alectinib'}, {'id': 1657, 'therapyName': 'Vemurafenib + Cobimetinib'}, {'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 1201, 'therapyName': 'Atezolizumab'}]","My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors",6885
4,NCT02271139,Phase III,No longer available,"[{'id': 698, 'therapyName': 'Alectinib'}]",Expanded Access Study of Alectinib for Patients With ALK-Rearranged Non-Small Cell Lung Cancer Previously Treated With Crizotinib,6885
5,NCT03194893,Phase III,Recruiting,"[{'id': 706, 'therapyName': 'Crizotinib'}, {'id': 698, 'therapyName': 'Alectinib'}]",A Roll Over Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive or Rearranged During Transfection (RET)-Positive Cancer,6885
6,NCT01801111,Phase II,"Active, not recruiting","[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 698, 'therapyName': 'Alectinib'}]",A Study of RO5424802 in Patients With Non-Small Cell Lung Cancer Who Have ALK Mutation and Failed Crizotinib Treatment,6885
7,NCT03131206,Phase Ib/II,Recruiting,"[{'id': 698, 'therapyName': 'Alectinib'}]",A Study of Alectinib in RET-rearranged Non-small Cell Lung Cancer or RET-mutated Thyroid Cancer,6885
8,NCT03178552,Phase II,Recruiting,"[{'id': 4686, 'therapyName': 'Carboplatin + Cisplatin + Gemcitabine'}, {'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 4616, 'therapyName': 'Carboplatin + Cisplatin + Pemetrexed'}, {'id': 698, 'therapyName': 'Alectinib'}]",A Study to Evaluate Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC) (B-FAST),6885
9,NCT02013219,Phase I,"Active, not recruiting","[{'id': 3490, 'therapyName': 'Alectinib + Atezolizumab'}, {'id': 1352, 'therapyName': 'Atezolizumab + Erlotinib'}]",A Phase 1b Study of Atezolizumab in Combination With Erlotinib or Alectinib in Participants With Non-Small Cell Lung Cancer,6885
10,NCT03202940,Phase Ib/II,Recruiting,"[{'id': 5971, 'therapyName': 'Alectinib + Cobimetinib'}]",A Phase IB/II Study of Alectinib Combined With Cobimetinib in Advanced ALK-Rearranged (ALK+) NSCLC,6885
0,NCT02653196,Phase II,Terminated,"[{'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1205, 'therapyName': 'Alemtuzumab'}, {'id': 2373, 'therapyName': 'Palifermin'}, {'id': 2237, 'therapyName': 'Fludarabine + Melphalan'}, {'id': 3948, 'therapyName': 'Cyclosporine + Mycophenolate mofetil + Tacrolimus'}]",A Multi-Institutional Phase II Feasibility Study of Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Malignant Neuro-Epithelial and Other Solid Tumors,83
1,NCT01256398,Phase II,"Active, not recruiting","[{'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 2291, 'therapyName': 'Cyclophosphamide + Fludarabine'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1824, 'therapyName': 'Vincristine + Methotrexate + Mercaptopurine'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 2391, 'therapyName': 'Cytarabine + Daunorubicin + Etoposide'}, {'id': 1476, 'therapyName': 'Pegfilgrastim'}, {'id': 1205, 'therapyName': 'Alemtuzumab'}, {'id': 1642, 'therapyName': 'Leucovorin'}]",Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,83
2,NCT01625351,Phase I,"Active, not recruiting","[{'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1205, 'therapyName': 'Alemtuzumab'}]",A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas,83
3,NCT00520130,Phase Ib/II,"Active, not recruiting","[{'id': 2294, 'therapyName': 'Cytarabine + Fludarabine'}, {'id': 2305, 'therapyName': 'Alemtuzumab + Cyclosporine'}, {'id': 2306, 'therapyName': 'Rituximab + Fludarabine + EPOCH'}, {'id': 2307, 'therapyName': 'Fludarabine + EPOCH'}, {'id': 2238, 'therapyName': 'Sirolimus + Tacrolimus + Methotrexate'}, {'id': 1632, 'therapyName': 'Filgrastim'}]",Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,83
0,NCT01898078,Phase I,"Active, not recruiting","[{'id': 626, 'therapyName': 'Alisertib'}]", Food Effect Study of Alisertib (MLN8237) in Patients With Advanced Solid Tumors or Lymphomas,6832
1,NCT02530619,Phase I,Recruiting,"[{'id': 626, 'therapyName': 'Alisertib'}]",Alisertib in Treating Patients With Myelofibrosis or Relapsed or Refractory Acute Megakaryoblastic Leukemia,6832
2,NCT02560025,Phase II,"Active, not recruiting","[{'id': 626, 'therapyName': 'Alisertib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 712, 'therapyName': 'Cytarabine'}]",Phase II Trial of Alisertib With Induction Chemotherapy in High-risk AML,6832
3,NCT01471964,Phase Ib/II,Suspended,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 626, 'therapyName': 'Alisertib'}]","Study to Assess Safety and Tolerability of MLN8237, In Combination With Erlotinib to Treat Non-Small Cell Lung Cancer",6832
4,NCT02551055,Phase I,Terminated,"[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 626, 'therapyName': 'Alisertib'}, {'id': 3146, 'therapyName': 'TAK-659'}, {'id': 1033, 'therapyName': 'MLN1117'}]","MLN1117 in Combination With Docetaxel, Paclitaxel, and Other Investigational Anticancer Agents to Treat Participants With Gastric and Gastroesophageal Adenocarcinoma",6832
5,NCT02038647,Phase II,"Active, not recruiting","[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 626, 'therapyName': 'Alisertib'}]",Phase 2 Study of Alisertib (MLN8237) in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel as Second Line Therapy for Small Cell Lung Cancer (SCLC),6832
6,NCT02114229,Phase II,Recruiting,"[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 2449, 'therapyName': 'Methotrexate + Cisplatin + Cyclophosphamide + Vincristine'}, {'id': 626, 'therapyName': 'Alisertib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 942, 'therapyName': 'Topotecan'}]",Phase 2 Study of Alisertib Therapy for Rhabdoid Tumors,6832
7,NCT02259010,Phase I,"Active, not recruiting","[{'id': 626, 'therapyName': 'Alisertib'}, {'id': 1026, 'therapyName': 'Itraconazole'}]",A Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics of Alisertib in Patients With Advanced Solid Tumors or Relapsed/Refractory Lymphoma,6832
8,NCT02186509,Phase I,Recruiting,"[{'id': 626, 'therapyName': 'Alisertib'}]",Alisertib and Fractionated Stereotactic Radiosurgery in Treating Patients With Recurrent High Grade Gliomas,6832
9,NCT01848067,Phase Ib/II,"Active, not recruiting","[{'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 626, 'therapyName': 'Alisertib'}]","Alisertib, Abiraterone Acetate and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer",6832
10,NCT01897012,Phase I,Recruiting,"[{'id': 1075, 'therapyName': 'romidepsin'}, {'id': 626, 'therapyName': 'Alisertib'}]",Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas,6832
11,NCT01799278,Phase II,"Active, not recruiting","[{'id': 626, 'therapyName': 'Alisertib'}]",A Phase II Trial of MLN8237 in Patients With Metastatic Castrate Resistant and Neuroendocrine Prostate Cancer,6832
12,NCT02219789,Phase I,"Active, not recruiting","[{'id': 744, 'therapyName': 'Fulvestrant'}, {'id': 626, 'therapyName': 'Alisertib'}]",Alisertib and Fulvestrant in Treating Patients With Hormone Receptor Positive Breast Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery,6832
13,NCT02187991,Phase II,Recruiting,"[{'id': 626, 'therapyName': 'Alisertib'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]",Study to Compare Alisertib With Paclitaxel vs. Paclitaxel Alone in Metastatic or Locally Recurrent Breast Cancer,6832
14,NCT02860000,Phase II,Recruiting,"[{'id': 4561, 'therapyName': 'Alisertib + Fulvestrant'}, {'id': 626, 'therapyName': 'Alisertib'}]","Alisertib With or Without Fulvestrant in Treating Patients With Locally Advanced or Metastatic, Endocrine-Resistant Breast Cancer",6832
15,NCT02293005,Phase II,"Active, not recruiting","[{'id': 626, 'therapyName': 'Alisertib'}]",Alisertib in Malignant Mesothelioma,6832
16,NCT02700022,Phase I,"Active, not recruiting","[{'id': 626, 'therapyName': 'Alisertib'}, {'id': 3395, 'therapyName': 'R-EPOCH'}]",A Phase I Study of Alisertib + R-EPOCH for Treatment of Myc-Positive Aggressive B-cell Lymphomas,6832
17,NCT02214147,Phase I,Completed,"[{'id': 626, 'therapyName': 'Alisertib'}]",Pharmacokinetics of Alisertib in Adults With Advanced Solid Tumors or Relapsed/Refractory Lymphoma With Varying Degrees of Hepatic Function,6832
18,NCT02319018,Phase I,"Active, not recruiting","[{'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 626, 'therapyName': 'Alisertib'}]",Alisertib and Combination Chemotherapy in Treating Patients With Gastrointestinal Tumors,6832
19,NCT01844583,Phase I,Completed,"[{'id': 1239, 'therapyName': 'Alisertib  + Esomeprazole'}, {'id': 1240, 'therapyName': 'Alisertib + Rifampin'}, {'id': 626, 'therapyName': 'Alisertib'}]","Safety, Tolerability and PK of Concomitant Esomeprazole and Rifampin, and QT Study on Single and Multiple-doses of Alisertib",6832
20,NCT01677559,Phase I,"Active, not recruiting","[{'id': 1226, 'therapyName': 'Alisertib + Abraxane'}]",Combining MLN8237 With Nab-Paclitaxel in Patients With Advanced Solid Malignancies,6832
21,NCT01695941,Phase I,Recruiting,"[{'id': 3581, 'therapyName': 'Alisertib + Bortezomib + Rituximab'}]","Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin Lymphoma",6832
22,NCT02780011,Phase I,Not yet recruiting,"[{'id': 4301, 'therapyName': 'Alisertib + Brentuximab vedotin'}]",Alsertib (MLN8237) and Brentuximab Vedotin for Relapsed/Refractory CD30-Positive Lymphomas and Solid Malignancies,6832
23,NCT01924260,Phase I,"Active, not recruiting","[{'id': 1289, 'therapyName': 'Alisertib + Gemcitabine'}]",Alisertib and Gemcitabine Hydrochloride in Treating Patients With Solid Tumors or Pancreatic Cancer,6832
24,NCT01601535,Phase Ib/II,"Active, not recruiting","[{'id': 2628, 'therapyName': 'Alisertib + Irinotecan + Temozolomide'}]",Study of MLN8237 in Combination With Irinotecan and Temozolomide,6832
25,NCT02719691,Phase I,Recruiting,"[{'id': 4214, 'therapyName': 'Alisertib + MLN0128'}]",Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer,6832
26,NCT02812056,Phase I,Withdrawn,"[{'id': 4214, 'therapyName': 'Alisertib + MLN0128'}]",Alisertib and TAK-228 in Participants With Human Papilloma Virus (HPV) Associated Malignancies,6832
27,NCT01639911,Phase I,Completed,"[{'id': 1212, 'therapyName': 'Alisertib + Pazopanib'}]",MLN8237 and Pazopanib in Combination for Solid Tumors,6832
28,NCT01923337,Phase I,"Active, not recruiting","[{'id': 1288, 'therapyName': 'Irinotecan + Alisertib'}]",Irinotecan and Alisertib in Treating Patients With Advanced Solid Tumors or Colorectal Cancer,6832
29,NCT02327169,Phase I,Recruiting,"[{'id': 2175, 'therapyName': 'MLN0128 + MLN2480'}, {'id': 2176, 'therapyName': 'MLN2480 + Alisertib'}, {'id': 2177, 'therapyName': 'MLN2480 + Paclitaxel'}]",A Phase 1B Study of MLN2480 in Combination With MLN0128 or Alisertib or Paclitaxel in Adult Patients With Advanced Nonhematologic Malignancies,6832
0,NCT02799095,Phase I,Recruiting,"[{'id': 4298, 'therapyName': 'ALKS 4230'}]",A Study of the Effects of ALKS 4230 on Subjects With Solid Tumors,8403
0,NCT02273219,Phase I,Recruiting,"[{'id': 1861, 'therapyName': 'AEB071 + BYL719'}]",Trial of AEB071 in Combination With BYL719 in Patients With Melanoma,6882
1,NCT02620839,Phase I,Recruiting,"[{'id': 5627, 'therapyName': 'Alpelisib + Cisplatin'}]",Phase Ib Study of Alpelisib With Cisplatin in Patients With HPV+ Solid Tumor Malignancies,6882
2,NCT03056755,Phase II,Recruiting,"[{'id': 5929, 'therapyName': 'Alpelisib + Fulvestrant'}, {'id': 1553, 'therapyName': 'Letrozole + BYL719'}]","Efficacy and Safety of Treatment With Alpelisib Plus Endocrine Therapy in Patients With HR+, HER2-negative aBC, With PIK3CA Mutations, Whose Disease Has Progressed on or After CDK 4/6 Treatment With an Aromatase Inhibitor (AI) or Fulvestrant",6882
3,NCT02734615,Phase I,Recruiting,"[{'id': 4441, 'therapyName': 'Alpelisib + LSZ 102'}, {'id': 4440, 'therapyName': 'LSZ 102 + Ribociclib'}, {'id': 4439, 'therapyName': 'LSZ 102'}]",Phase I/Ib Trial of LSZ102 Single Agent or LSZ102 + LEE011 or LSZ102 + BYL719 in ER+ Breast Cancers,6882
4,NCT01928459,Phase I,Completed,"[{'id': 1293, 'therapyName': 'BGJ398 + BYL719'}]",Phase 1b Trial of BGJ398/BYL719 in Solid Tumors,6882
5,NCT02537223,Phase I,Recruiting,"[{'id': 691, 'therapyName': 'BYL719'}, {'id': 700, 'therapyName': 'Cisplatin'}]",Phase I Study of BYL719 in Combination With Cisplatin and Radiotherapy in Patients With Squamous Cell Head and Neck Cancer,6882
6,NCT02437318,Phase III,Recruiting,"[{'id': 691, 'therapyName': 'BYL719'}, {'id': 744, 'therapyName': 'Fulvestrant'}]",Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant in Men and Postmenopausal Women With Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment.,6882
7,NCT01219699,Phase I,"Active, not recruiting","[{'id': 691, 'therapyName': 'BYL719'}, {'id': 744, 'therapyName': 'Fulvestrant'}]"," A Study of BYL719 in Adult Patients With Advanced Solid Malignancies, Whose Tumors Have an Alteration of the PIK3CA Gene",6882
8,NCT01708161,Phase I,Completed,"[{'id': 1109, 'therapyName': 'BYL719 + AMG 479'}]",A Phase Ib/II Study of the Combination of BYL719 Plus AMG 479 in Adult Patients With Selected Solid Tumors,6882
9,NCT01300962,Phase I,"Active, not recruiting","[{'id': 1538, 'therapyName': 'BKM120 + Capecitabine + Lapatinib'}, {'id': 1537, 'therapyName': 'BKM120 + Capecitabine + Trastuzumab'}, {'id': 1536, 'therapyName': 'BKM120 + Capecitabine'}, {'id': 1535, 'therapyName': 'BYL719 + Capecitabine'}]",Study of BKM120 or BYL719 and Capecitabine in Patients With Metastatic Breast Cancer,6882
10,NCT02550743,Phase I,Recruiting,"[{'id': 1535, 'therapyName': 'BYL719 + Capecitabine'}]","BrUOG 302:BYL719, Capecitabine and Radiation for Rectal Cancer: A Brown University Oncology Research Group Study",6882
11,NCT02282371,Phase I,Recruiting,"[{'id': 1837, 'therapyName': 'BYL719 + Cetuximab'}]",Cetuximab + BYL719 + IMRT (Intensity-Modulated Radiation Therapy) in Stage III/IVB Head and Neck Squamous Cell Cancer (HNSCC),6882
12,NCT01602315,Phase Ib/II,Terminated,"[{'id': 1837, 'therapyName': 'BYL719 + Cetuximab'}]",A Phase Ib/II Study of BYL719 and Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma,6882
13,NCT03207529,Phase I,Not yet recruiting,"[{'id': 3751, 'therapyName': 'BYL719 + Enzalutamide'}]",Study of BYL719 (Alpelisib) in Combination With Androgen Receptor Inhibitor (Enzalutamide) in Patients With Androgen Receptor (AR)-Positive and PTEN Positive Metastatic Breast Cancer,6882
14,NCT02077933,Phase I,"Active, not recruiting","[{'id': 1384, 'therapyName': 'BYL719 + Everolimus'}, {'id': 1385, 'therapyName': 'BYL719 + Everolimus + Exemestane'}]","Study of Safety and Efficacy of BYL719 With Everolimus or BYL719 With Everolimus and Exemestane in Advanced Breast Cancer Patients, Renal Cell Cancer and Pancreatic Tumors",6882
15,NCT01870505,Phase I,"Active, not recruiting","[{'id': 2318, 'therapyName': 'BYL719 + Exemestane'}, {'id': 1553, 'therapyName': 'Letrozole + BYL719'}]",BYL719 Plus Letrozole or Exemestane for Patients With Hormone-Receptor Positive Locally-Advanced Unresectable or Metastatic Breast Cancer,6882
16,NCT02088684,Phase Ib/II,"Active, not recruiting","[{'id': 2315, 'therapyName': 'BKM120 + Fulvestrant + LEE011'}, {'id': 2316, 'therapyName': 'Fulvestrant + LEE011'}, {'id': 2317, 'therapyName': 'BYL719 + Fulvestrant + LEE011'}]",Study of LEE011 With Fulvestrant and BYL719 or BKM120 in Advanced Breast Cancer,6882
17,NCT02155088,Phase I,"Active, not recruiting","[{'id': 1870, 'therapyName': 'BYL719 + Gemcitabine + Abraxane'}]",BYL719 in Combination With Gemcitabine and (Nab)-Paclitaxel in Locally Advanced and Metastatic Pancreatic Cancer,6882
18,NCT02144038,Phase Ib/II,Completed,"[{'id': 2419, 'therapyName': 'BYL719 + LGH447'}, {'id': 2402, 'therapyName': 'LGH447 '}]",Study of the Safety and Effectiveness of LGH447 and BYL719 in Patients With Relapsed and Refractory Multiple Myeloma,6882
19,NCT01822613,Phase Ib/II,Completed,"[{'id': 2282, 'therapyName': 'Docetaxel + Irinotecan + Paclitaxel'}, {'id': 2283, 'therapyName': 'BYL719 + LJM716'}]",Study of Safety and Efficacy of the Combination of LJM716 and BYL719 in Patients With Previously Treated Esophageal Squamous Cell Carcinoma (ESCC),6882
20,NCT02167854,Phase I,Recruiting,"[{'id': 2059, 'therapyName': 'BYL719 + LJM716 + Trastuzumab'}]","Open-Label Study Evaluating the Safety and Tolerability of LJM716, BYL719 and Trastuzumab in Patients With Metastatic HER2+ Breast Cancer",6882
21,NCT01449058,Phase Ib/II,Completed,"[{'id': 1311, 'therapyName': 'BYL719 + MEK162'}]",A Phase Ib Study of MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors,6882
22,NCT02379247,Phase Ib/II,Recruiting,"[{'id': 2503, 'therapyName': 'BYL719 + nab-paclitaxel'}]",BYL719 and Nab-Paclitaxel in Locally Recurrent or Metastatic HER-2 Negative Breast Cancer,6882
23,NCT01623349,Phase I,"Active, not recruiting","[{'id': 2171, 'therapyName': 'BYL719 + Olaparib'}, {'id': 2170, 'therapyName': 'BKM120 + Olaparib'}]",Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer,6882
24,NCT02051751,Phase I,Completed,"[{'id': 1379, 'therapyName': 'BYL719 + Paclitaxel'}]",A Study to Evaluate the Potential Benefit of the Addition of BYL719 to Paclitaxel in the Treatment of Breast Cancer and Head-and-neck Cancer,6882
25,NCT02038010,Phase I,"Active, not recruiting","[{'id': 1575, 'therapyName': 'BYL719 + Trastuzumab emtansine'}]",BYL719 + T-DM1 in HER2(+) Metastatic Breast Cancer Pts Who Progress on Prior Trastuzumab & Taxane Tx,6882
26,NCT01872260,Phase Ib/II,Recruiting,"[{'id': 1553, 'therapyName': 'Letrozole + BYL719'}, {'id': 1569, 'therapyName': 'LEE011 + BYL719 + Letrozole'}, {'id': 1568, 'therapyName': 'LEE011 + Letrozole'}]","Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer",6882
27,NCT01791478,Phase I,"Active, not recruiting","[{'id': 1553, 'therapyName': 'Letrozole + BYL719'}]",BYL719 and Letrozole in Post-Menopausal Patients With Hormone Receptor-Positive Metastatic Breast Cancer,6882
28,NCT01923168,Phase II,Completed,"[{'id': 1570, 'therapyName': 'BKM120 + Letrozole'}, {'id': 794, 'therapyName': 'Letrozole'}, {'id': 1553, 'therapyName': 'Letrozole + BYL719'}]","Study of Letrozole With or Without BYL719 or Buparlisib, for the Neoadjuvant Treatment of Postmenopausal Women",6882
29,NCT01719380,Phase Ib/II,"Active, not recruiting","[{'id': 1916, 'therapyName': 'Cetuximab + Encorafenib'}, {'id': 1917, 'therapyName': 'LGX818 + Cetuximab + BYL719'}]","Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in BRAF Mutant Metastatic Colorectal Cancer",6882
0,NCT01603212,Phase Ib/II,Completed,"[{'id': 1188, 'therapyName': 'Aldesleukin + Vemurafenib + IFN A2b'}]"," Systemic Therapy With Interferon, Interleukin-2 and BRAF Inhibitor",7217
1,NCT00092222,Phase II,Recruiting,"[{'id': 917, 'therapyName': 'Sirolimus'}, {'id': 1187, 'therapyName': 'Alpha 2 Interferon'}, {'id': 2211, 'therapyName': 'EPOCH'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1008, 'therapyName': 'Doxil'}]",Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity,7217
0,NCT02264613,Phase Ib/II,Recruiting,"[{'id': 2273, 'therapyName': 'ALRN-6924'}]",Safety Study of ALRN-6924 in Patients With Advanced Solid Tumors,7477
1,NCT02909972,Phase I,Recruiting,"[{'id': 4755, 'therapyName': 'ALRN-6924 + Cytarabine'}, {'id': 2273, 'therapyName': 'ALRN-6924'}]",Safety Study of ALRN-6924 in Patients With Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome,7477
0,NCT01625260,Phase Ib/II,"Active, not recruiting","[{'id': 2187, 'therapyName': 'ALT-801'}, {'id': 2191, 'therapyName': 'ALT-801 + Gemcitabine'}]",A Study of ALT-801 in Patients With Bacillus Calmette-Guerin (BCG) Failure Non-Muscle Invasive Bladder Cancer,7458
1,NCT01326871,Phase Ib/II,"Active, not recruiting","[{'id': 2187, 'therapyName': 'ALT-801'}]",A Study of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer,7458
0,NCT02099539,Phase Ib/II,Recruiting,"[{'id': 3060, 'therapyName': 'ALT-803'}]",A Study of ALT-803 in Patients With Relapsed or Refractory Multiple Myeloma,7921
1,NCT01885897,Phase Ib/II,Recruiting,"[{'id': 3060, 'therapyName': 'ALT-803'}]",IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic SCT,7921
2,NCT02989844,Phase II,Recruiting,"[{'id': 3060, 'therapyName': 'ALT-803'}]",QUILT-3.035: Relapse Prophylaxis With ALT-803 for AML and MDS Pts Following Allo HSCT,7921
3,NCT01946789,Phase I,Recruiting,"[{'id': 3060, 'therapyName': 'ALT-803'}]",A Phase 1 Study of the Clinical and Immunologic Effects of ALT-803 in Patients With Advanced Solid Tumors,7921
4,NCT03054909,Phase I,Not yet recruiting,"[{'id': 3060, 'therapyName': 'ALT-803'}]",QUILT-2.021: Phase I of IP Followed by SQ ALT-803 for Ovarian Cancer,7921
5,NCT03136406,Phase Ib/II,Recruiting,"[{'id': 1018, 'therapyName': 'GI-4000'}, {'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 3144, 'therapyName': 'Avelumab'}, {'id': 619, 'therapyName': 'Abraxane'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 6163, 'therapyName': 'ETBX-011'}, {'id': 3060, 'therapyName': 'ALT-803'}]",QUILT-3.039: NANT Pancreatic Cancer Vaccine: Combination Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy,7921
6,NCT03022825,Phase II,Recruiting,"[{'id': 5238, 'therapyName': 'ALT-803 + BCG solution'}]",QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer,7921
7,NCT03050216,Phase II,Recruiting,"[{'id': 5300, 'therapyName': 'ALT-803 + Cyclophosphamide + Fludarabine phosphate'}]",Haplo NK With SQ ALT-803 for Adults With Relapsed or Refractory AML,7921
8,NCT01898793,Phase Ib/II,Recruiting,"[{'id': 3409, 'therapyName': 'Aldesleukin + Cyclophosphamide + Fludarabine '}, {'id': 5300, 'therapyName': 'ALT-803 + Cyclophosphamide + Fludarabine phosphate'}]",Cytokine-induced Memory-like NK Cells in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS),7921
9,NCT03127098,Phase Ib/II,"Active, not recruiting","[{'id': 6239, 'therapyName': 'ALT-803 + ETBX-011'}]","QUILT-3.040: ETBX-011 (Ad5 [E1-, E2b-]-CEA(6D)) Vaccine in Combination With ALT-803 (Super-agonist IL-15) in Subjects Having CEA-Expressing Cancer",7921
10,NCT02559674,Phase Ib/II,Recruiting,"[{'id': 3095, 'therapyName': 'ALT-803 + Gemcitabine + nab-paclitaxel'}]",ALT-803 in Patients With Advanced Pancreatic Cancer Conjunction With Gemcitabine and Nab-Paclitaxel,7921
11,NCT03228667,Phase II,Not yet recruiting,"[{'id': 3061, 'therapyName': 'ALT-803 + Nivolumab'}, {'id': 6037, 'therapyName': 'ALT-803 + Pembrolizumab'}]","QUILT-3.055: A Phase IIb, Single-Arm, Open-Label Study of ALT-803 in Combination With Pembrolizumab or Nivolumab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Disease Progression Following an Initial Response to Treatment With PD-1 Checkpoint Inhibitor Therapy",7921
12,NCT02523469,Phase Ib/II,Recruiting,"[{'id': 3061, 'therapyName': 'ALT-803 + Nivolumab'}]","ALT-803 Plus Nivolumab in Patients With Pretreated, Advanced or Metastatic Non-Small Cell Lung Cancer",7921
13,NCT02384954,Phase Ib/II,Recruiting,"[{'id': 3936, 'therapyName': 'ALT-803 + Rituximab'}]",ALT-803 in Patients With Relapse/Refractory Indolent B Cell Non-Hodgkin Lymphoma (iNHL) in Conjunction With Rituximab,7921
0,NCT02228811,Phase I,"Active, not recruiting","[{'id': 1656, 'therapyName': 'Altiratinib'}]",A Study of DCC-2701 in Participants With Advanced Solid Tumors,7310
0,NCT02520011,Phase II,Recruiting,"[{'id': 628, 'therapyName': 'Alvocidib'}, {'id': 2393, 'therapyName': 'Cytarabine + Mitoxantrone'}]",Alvocidib Biomarker-driven Phase 2 AML Study,6834
1,NCT03298984,Phase I,Not yet recruiting,"[{'id': 6300, 'therapyName': 'Alvocidib + Cytarabine + Daunorubicin'}]",Ph I Study of Alvocidib and Cytarabine/Duanorubicin (7+3) in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML).,6834
0,NCT03013218,Phase I,Recruiting,"[{'id': 5211, 'therapyName': 'ALX148'}, {'id': 5212, 'therapyName': 'ALX148 + Atezolizumab'}, {'id': 5213, 'therapyName': 'ALX148 + Trastuzumab'}]",A Study of ALX148 in Patients With Advanced Solid Tumors and Lymphoma,8635
0,NCT02009449,Phase I,"Active, not recruiting","[{'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 2621, 'therapyName': 'AM0010 '}, {'id': 619, 'therapyName': 'Abraxane'}]",A Phase 1 Study of AM0010 in Patients With Advanced Solid Tumors,7615
1,NCT02923921,Phase III,Recruiting,"[{'id': 5849, 'therapyName': 'AM0010 + mFOLFOX-6'}, {'id': 5850, 'therapyName': 'mFOLFOX-6'}]",Study of AM0010 With FOLFOX Compared to FOLFOX Alone Second-line Tx in Pts With Metastatic Pancreatic Cancer,7615
0,NCT02357147,Phase II,"Active, not recruiting","[{'id': 1857, 'therapyName': 'Cisplatin + Pemetrexed'}, {'id': 3513, 'therapyName': 'Amatuximab'}]",Study of the Safety and Efficacy of Amatuximab in Combination With Pemetrexed and Cisplatin in Subjects With Unresectable Malignant Pleural Mesothelioma (MPM). (ARTEMIS),8111
0,NCT01723020,Phase I,Completed,"[{'id': 1452, 'therapyName': 'AMG 232'}]",A Phase 1 Study Evaluating AMG 232 in Advanced Solid Tumors or Multiple Myeloma,7263
1,NCT03107780,Phase I,Not yet recruiting,"[{'id': 1452, 'therapyName': 'AMG 232'}]",MDM2 Inhibitor AMG-232 in Treating Patients With Recurrent or Newly Diagnosed Glioblastoma,7263
2,NCT02016729,Phase I,Completed,"[{'id': 2, 'therapyName': 'Trametinib'}, {'id': 1452, 'therapyName': 'AMG 232'}]",A Phase 1b Study Evaluating AMG 232 Alone and in Combination With Trametinib in Acute Myeloid Leukemia,7263
3,NCT03217266,Phase I,Not yet recruiting,"[{'id': 1452, 'therapyName': 'AMG 232'}]",MDM2 Inhibitor AMG-232 and Radiation Therapy in Treating Patients With Soft Tissue Sarcoma,7263
4,NCT03041688,Phase I,Not yet recruiting,"[{'id': 6185, 'therapyName': 'AMG 232 + Decitabine'}]","MDM2 Inhibitor AMG-232 and Decitabine in Treating Patients With Relapsed, Refractory, or Newly-Diagnosed Acute Myeloid Leukemia",7263
5,NCT02110355,Phase Ib/II,Recruiting,"[{'id': 1454, 'therapyName': 'AMG 232 + Trametinib'}, {'id': 1453, 'therapyName': 'AMG 232 + Trametinib + Dabrafenib'}, {'id': 1066, 'therapyName': 'Trametinib + Dabrafenib'}]",A Phase 1b/2a Study Evaluating AMG 232 in Metastatic Melanoma,7263
0,NCT01253707,Phase I,Completed,"[{'id': 1064, 'therapyName': 'AMG 337'}]",A Study of AMG 337 in Subjects With Advanced Solid Tumors,7183
1,NCT02016534,Phase II,Terminated,"[{'id': 1064, 'therapyName': 'AMG 337'}]",Phase 2 Study of AMG 337 in MET Amplified Gastric/Esophageal Adenocarcinoma or Other Solid Tumors,7183
2,NCT02344810,Phase Ib/II,Unknown status,"[{'id': 1064, 'therapyName': 'AMG 337'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}]","C-Met Inhibitor AMG 337, Oxaliplatin, Leucovorin Calcium, and Fluorouracil in Treating Patients With Advanced Stomach or Esophageal Cancer",7183
0,NCT03296696,Phase I,Not yet recruiting,"[{'id': 6261, 'therapyName': 'AMG 596'}]",Study of AMG 596 in Patients With EGFRvIII Positive Glioblastoma,8957
0,NCT00858377,Phase I,"Active, not recruiting","[{'id': 983, 'therapyName': 'AMG 900'}]",A Phase 1 First-in-Human Study Evaluating AMG 900 in Advanced Solid Tumors,7092
0,NCT02713529,Phase Ib/II,Recruiting,"[{'id': 4170, 'therapyName': 'AMG820 + Pembrolizumab'}]",Safety Study of AMG 820 and Pembrolizumab Combination in Select Advanced Solid Tumor Cancer,7779
0,NCT02481830,Phase III,"Active, not recruiting","[{'id': 2951, 'therapyName': 'Amrubicin'}, {'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 942, 'therapyName': 'Topotecan'}]",Efficacy Study of Nivolumab or Chemotherapy in Subjects With Relapsed Small-cell Lung Cancer,7866
0,NCT03144245,Phase I,Recruiting,"[{'id': 5711, 'therapyName': 'AMV-564'}]",Study of AMV564 in Patients With AML,8761
0,NCT02057133,Phase I,Recruiting,"[{'id': 2254, 'therapyName': 'Abemaciclib + Letrozole'}, {'id': 2257, 'therapyName': 'Abemaciclib + Exemestane'}, {'id': 2258, 'therapyName': 'Everolimus + Exemestane + LY2835219'}, {'id': 2255, 'therapyName': 'Abemaciclib + Anastrozole'}, {'id': 2256, 'therapyName': 'Abemaciclib + Tamoxifen'}, {'id': 2259, 'therapyName': 'Abemaciclib + Trastuzumab'}]",A Study of LY2835219 in Combination With Hormone Therapies for Breast Cancer That Has Spread,1204
1,NCT02246621,Phase III,"Active, not recruiting","[{'id': 1854, 'therapyName': 'Abemaciclib + Anastrozole + Letrozole'}, {'id': 1853, 'therapyName': 'Anastrozole + Letrozole'}]",A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast Cancer,1204
2,NCT03099174,Phase I,Recruiting,"[{'id': 5514, 'therapyName': 'Abemaciclib + Xentuzumab'}, {'id': 5515, 'therapyName': 'Abemaciclib + Letrozole + Xentuzumab'}, {'id': 5516, 'therapyName': 'Abemaciclib + Anastrozole + Xentuzumab'}, {'id': 5517, 'therapyName': 'Abemaciclib + Fulvestrant + Xentuzumab'}]",This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast Cancer.,1204
3,NCT01216176,Phase Ib/II,"Active, not recruiting","[{'id': 633, 'therapyName': 'Anastrozole'}, {'id': 912, 'therapyName': 'Saracatinib'}]",A Pharmacokinetic and Randomized Trial of Neoadjuvant Treatment With Anastrozole Plus AZDO530 in Postmenopausal Patients With Hormone Receptor Positive Breast Cancer,1204
4,NCT02689921,Phase II,Recruiting,"[{'id': 633, 'therapyName': 'Anastrozole'}, {'id': 794, 'therapyName': 'Letrozole'}, {'id': 795, 'therapyName': 'Leuprolide'}, {'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}, {'id': 738, 'therapyName': 'Exemestane'}]",NEOADjuvant Aromatase Inhibitor and Pertuzumab/Trastuzumab for Women With Breast Cancer (NEOADAPT),1204
5,NCT01160211,Phase III,"Active, not recruiting","[{'id': 1414, 'therapyName': 'Trastuzumab + Lapatinib'}, {'id': 794, 'therapyName': 'Letrozole'}, {'id': 633, 'therapyName': 'Anastrozole'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 738, 'therapyName': 'Exemestane'}]","A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer",1204
6,NCT02648477,Phase II,Recruiting,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 794, 'therapyName': 'Letrozole'}, {'id': 633, 'therapyName': 'Anastrozole'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 1009, 'therapyName': 'Doxorubicin'}]",Pembrolizumab and Doxorubicin Hydrochloride or Anti-Estrogen Therapy in Treating Patients With Triple-Negative or Hormone Receptor-Positive Metastatic Breast Cancer,1204
7,NCT02753686,Phase I,Recruiting,"[{'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 744, 'therapyName': 'Fulvestrant'}, {'id': 794, 'therapyName': 'Letrozole'}, {'id': 633, 'therapyName': 'Anastrozole'}, {'id': 1966, 'therapyName': 'Exemestane + Everolimus'}]",Treatment of Canadian Postmenopausal Women With ER+ Advanced Breast Cancer in the Real-World Setting With Hormone Therapy ± Targeted Therapy (Treat ER+ight),1204
8,NCT00921115,Phase II,"Active, not recruiting","[{'id': 633, 'therapyName': 'Anastrozole'}, {'id': 744, 'therapyName': 'Fulvestrant'}]",Anti-Hormone Therapy (With Anastrazole and Fulvestrant) Before Surgery to Treat Postmenopausal Women With Breast Cancer.,1204
9,NCT02441946,Phase II,Completed,"[{'id': 802, 'therapyName': 'Abemaciclib'}, {'id': 2700, 'therapyName': 'Loperamide'}, {'id': 633, 'therapyName': 'Anastrozole'}]","A Phase 2 Neoadjuvant Study of Abemaciclib (LY2835219) in Postmenopausal Women With Hormone Receptor Positive, HER2 Negative Breast Cancer",1204
10,NCT00570323,Phase II,"Active, not recruiting","[{'id': 1911, 'therapyName': 'Anastrozole  + Fulvestrant'}, {'id': 633, 'therapyName': 'Anastrozole'}]",Arimidex With or Without Faslodex In Postmenopausal Women With HR Positive Breast Cancer,1204
11,NCT02269670,Phase II,"Active, not recruiting","[{'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 1869, 'therapyName': 'Megestrol'}, {'id': 794, 'therapyName': 'Letrozole'}, {'id': 744, 'therapyName': 'Fulvestrant'}, {'id': 633, 'therapyName': 'Anastrozole'}]",Everolimus and Hormone Therapy in Treating Patients With Advanced Hormone Receptor Positive Breast Cancer That Has Progressed or Recurred on Everolimus and Exemestane Therapy,1204
12,NCT02947685,Phase III,Recruiting,"[{'id': 744, 'therapyName': 'Fulvestrant'}, {'id': 856, 'therapyName': 'Pertuzumab'}, {'id': 794, 'therapyName': 'Letrozole'}, {'id': 633, 'therapyName': 'Anastrozole'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 947, 'therapyName': 'Trastuzumab'}]","Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer (PATINA)",1204
13,NCT02476786,Phase II,Recruiting,"[{'id': 633, 'therapyName': 'Anastrozole'}, {'id': 744, 'therapyName': 'Fulvestrant'}, {'id': 759, 'therapyName': 'Goserelin'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 738, 'therapyName': 'Exemestane'}]",Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score,1204
14,NCT02040857,Phase II,"Active, not recruiting","[{'id': 738, 'therapyName': 'Exemestane'}, {'id': 850, 'therapyName': 'Palbociclib'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 794, 'therapyName': 'Letrozole'}, {'id': 633, 'therapyName': 'Anastrozole'}]",Palbociclib + Endocrine Therapy for HR + BrCa,1204
15,NCT03238703,FDA approved,Not yet recruiting,"[{'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 4419, 'therapyName': 'Toremifine'}, {'id': 633, 'therapyName': 'Anastrozole'}, {'id': 794, 'therapyName': 'Letrozole'}]","Endocrine Therapy in Treating Patients With HER2 Negative, Low Risk Breast Cancer",1204
16,NCT01824836,Phase I,Recruiting,"[{'id': 633, 'therapyName': 'Anastrozole'}]",Anastrozole in Treating Aromatase Inhibitor Musculoskeletal Symptoms in Female Patients With Stage I-III Breast Cancer,1204
17,NCT03304080,,Not yet recruiting,"[{'id': 633, 'therapyName': 'Anastrozole'}, {'id': 856, 'therapyName': 'Pertuzumab'}, {'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 850, 'therapyName': 'Palbociclib'}]","Anastrozole, Palbociclib, Trastuzumab and Pertuzumab in Her-positive, Her2-positive Metastatic Breast",1204
18,NCT01674140,Phase III,Recruiting,"[{'id': 759, 'therapyName': 'Goserelin'}, {'id': 633, 'therapyName': 'Anastrozole'}, {'id': 794, 'therapyName': 'Letrozole'}, {'id': 795, 'therapyName': 'Leuprolide'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 738, 'therapyName': 'Exemestane'}]",S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer,1204
19,NCT02206984,Phase I,Recruiting,"[{'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 633, 'therapyName': 'Anastrozole'}, {'id': 744, 'therapyName': 'Fulvestrant'}]",Endocrine Response in Women With Invasive Lobular Breast Cancer,1204
20,NCT01723774,Phase II,Recruiting,"[{'id': 850, 'therapyName': 'Palbociclib'}, {'id': 633, 'therapyName': 'Anastrozole'}, {'id': 759, 'therapyName': 'Goserelin'}]",PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer,1204
21,NCT02188745,Phase II,Recruiting,"[{'id': 738, 'therapyName': 'Exemestane'}, {'id': 1643, 'therapyName': 'Estradiol'}, {'id': 633, 'therapyName': 'Anastrozole'}, {'id': 794, 'therapyName': 'Letrozole'}]",ER Reactivation Therapy for Breast Cancer,1204
22,NCT02278120,Phase III,"Active, not recruiting","[{'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 794, 'therapyName': 'Letrozole'}, {'id': 790, 'therapyName': 'Ribociclib'}, {'id': 759, 'therapyName': 'Goserelin'}, {'id': 633, 'therapyName': 'Anastrozole'}]","Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer",1204
23,NCT01491737,Phase II,"Active, not recruiting","[{'id': 633, 'therapyName': 'Anastrozole'}, {'id': 794, 'therapyName': 'Letrozole'}, {'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}]","A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Patients With Hormone Receptor-Positive, Metastatic HER2-positive Breast Cancer",1204
24,NCT01953588,Phase III,Recruiting,"[{'id': 633, 'therapyName': 'Anastrozole'}, {'id': 744, 'therapyName': 'Fulvestrant'}]",Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery,1204
25,NCT02204098,Phase I,Recruiting,"[{'id': 794, 'therapyName': 'Letrozole'}, {'id': 633, 'therapyName': 'Anastrozole'}, {'id': 759, 'therapyName': 'Goserelin'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 1456, 'therapyName': 'Tamoxifen'}]",Safety and Immune Response to a Mammaglobin-A DNA Vaccine In Breast Cancer Patients Undergoing Neoadjuvant Endocrine Therapy,1204
26,NCT01272037,Phase III,Recruiting,"[{'id': 633, 'therapyName': 'Anastrozole'}, {'id': 794, 'therapyName': 'Letrozole'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 738, 'therapyName': 'Exemestane'}]","Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer",1204
27,NCT02095184,Phase I,Recruiting,"[{'id': 633, 'therapyName': 'Anastrozole'}, {'id': 794, 'therapyName': 'Letrozole'}]",GCC 1366 Anti-Proliferative Response to NeoAdjuvant AIs in Overweight and Obese Patients,1204
28,NCT01197170,Phase I,"Active, not recruiting","[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 633, 'therapyName': 'Anastrozole'}, {'id': 667, 'therapyName': 'Bevacizumab'}]",Hormone Blockade in Combination With Targeted Agents,1204
29,NCT02000596,Phase II,Terminated,"[{'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}, {'id': 1911, 'therapyName': 'Anastrozole  + Fulvestrant'}]",Trastuzmab and Pertuzumab Alone or in Combination With Hormonal Therapy or Chemotherapy With Eribulin in Women Aged 60 and Over With HER2/Neu Overexpressed Locally Advanced or MBC,1204
30,NCT02291913,Phase II,"Active, not recruiting","[{'id': 2267, 'therapyName': 'Everolimus + Tamoxifen'}, {'id': 2268, 'therapyName': 'Anastrozole + Everolimus'}, {'id': 1589, 'therapyName': 'Fulvestrant + Everolimus'}, {'id': 1621, 'therapyName': 'Everolimus + Letrozole'}, {'id': 2269, 'therapyName': 'Everolimus + Toremifene'}, {'id': 1966, 'therapyName': 'Exemestane + Everolimus'}]",Everolimus Combined With Anti-estrogen Therapy in Hormone-Receptor-Positive HER-2 Negative Advanced Breast Cancer,1204
31,NCT02942355,Phase II,Recruiting,"[{'id': 4974, 'therapyName': 'Anastrozole + Palbociclib'}]",Trial of Anastrozole and Palbociclib in Metastatic HER2-Negative Breast Cancer,1204
32,NCT02137837,Phase III,"Active, not recruiting","[{'id': 1589, 'therapyName': 'Fulvestrant + Everolimus'}, {'id': 1590, 'therapyName': 'Fulvestrant + Everolimus + Anastrozole'}, {'id': 744, 'therapyName': 'Fulvestrant'}]","S1222 Trial (Everolimus, Anastrozole and Fulvestrant) in Post-Menopausal Stage IV Breast Cancer",1204
0,NCT02839681,Phase II,Recruiting,"[{'id': 4593, 'therapyName': 'Anetumab ravtansine'}]",Anti-Mesothelin Antibody Drug Conjugate Anetumab Ravtansine for Mesothelin Expressing Lung Adenocarcinoma,8492
1,NCT02824042,Phase I,Recruiting,"[{'id': 4594, 'therapyName': 'Anetumab ravtansine + Itraconazole'}, {'id': 4593, 'therapyName': 'Anetumab ravtansine'}]",Thorough ECG (Electrocardiogram) and Drug Interaction Study With Anetumab Ravtansine and Itraconazole,8492
2,NCT03023722,Phase II,Recruiting,"[{'id': 4593, 'therapyName': 'Anetumab ravtansine'}]",Phase II Anetumab Ravtansine as 2nd Line Treatment for Pancreatic Cancer,8492
3,NCT02639091,Phase I,Recruiting,"[{'id': 4617, 'therapyName': 'Anetumab ravtansine + Cisplatin + Pemetrexed'}]",Phase Ib Study of Anetumab Ravtansine in Combination With Pemetrexed and Cisplatin in Mesothelin-expressing Solid Tumors,8492
4,NCT03126630,Phase Ib/II,Not yet recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 5596, 'therapyName': 'Pembrolizumab + Anetumab ravtansine'}]",Pembrolizumab With or Without Anetumab Ravtansine in Treating Patients With Mesothelin-Positive Pleural Mesothelioma,8492
0,NCT03016377,Phase I,Not yet recruiting,"[{'id': 3585, 'therapyName': 'Anti-CD19 CAR T'}]",Administration of Autologous CAR-T CD19 Antigen With Inducible Safety Switch in Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia,8150
0,NCT03190941,Phase I,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 6061, 'therapyName': 'anti-KRAS G12V mTCR cells'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1167, 'therapyName': 'Aldesleukin'}]",Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*1101 Patients,8905
0,NCT02083250,Phase I,Recruiting,"[{'id': 1844, 'therapyName': 'anti-thymocyte globulin'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 3201, 'therapyName': 'Busulfan + Clofarabine + Fludarabine'}]",Fludarabine/Clofarabine/Busulfan Combined With SAHA in Acute Leukemia,7347
1,NCT00305682,Phase II,Recruiting,"[{'id': 917, 'therapyName': 'Sirolimus'}, {'id': 1845, 'therapyName': 'Mycophenolate mofetil'}, {'id': 1844, 'therapyName': 'anti-thymocyte globulin'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1166, 'therapyName': 'Fludarabine'}]",Non-Myeloablative Conditioning for Unrelated Donor Umbilical Cord Blood Transplant,7347
2,NCT02790515,Phase II,Recruiting,"[{'id': 917, 'therapyName': 'Sirolimus'}, {'id': 1844, 'therapyName': 'anti-thymocyte globulin'}, {'id': 1876, 'therapyName': 'Blinatumomab '}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 5682, 'therapyName': 'Mesna'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1632, 'therapyName': 'Filgrastim'}]",Provision of TCR?? T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation,7347
3,NCT00550992,Phase I,Unknown status,"[{'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1752, 'therapyName': 'Mitoxantrone + Etoposide + Cytarabine'}, {'id': 1848, 'therapyName': 'Cyclophosphamide + Methotrexate + Vincristine + Pegaspargase '}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1650, 'therapyName': 'Cyclosporine'}, {'id': 1844, 'therapyName': 'anti-thymocyte globulin'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1642, 'therapyName': 'Leucovorin'}]",Different Therapies in Treating Infants With Newly Diagnosed Acute Leukemia,7347
4,NCT00084695,Phase II,Unknown status,"[{'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 2558, 'therapyName': 'Busulfan + Melphalan'}, {'id': 1844, 'therapyName': 'anti-thymocyte globulin'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 2188, 'therapyName': 'Prednisone'}]",Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases,7347
5,NCT01701986,Phase Ib/II,Recruiting,"[{'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1845, 'therapyName': 'Mycophenolate mofetil'}, {'id': 1844, 'therapyName': 'anti-thymocyte globulin'}, {'id': 3992, 'therapyName': 'Busulfan + Clofarabine + Gemcitabine'}]",Gemcitabine/Clofarabine/Busulfan and Allogeneic Transplantation for Aggressive Lymphomas,7347
6,NCT02722668,Phase II,Recruiting,"[{'id': 2281, 'therapyName': 'Cyclophosphamide + Fludarabine + Mycophenolate mofetil'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 1844, 'therapyName': 'anti-thymocyte globulin'}]",UCB Transplant for Hematological DIseases Using a Non Myeloablative Prep,7347
7,NCT02472392,Phase I,Completed,"[{'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1844, 'therapyName': 'anti-thymocyte globulin'}]",Study To Examine Toxicity Of Allogeneic Stem Cell Transplantation For Relapsed Or Therapy Refractory Ewings Sarcoma,7347
8,NCT02508038,Phase I,Recruiting,"[{'id': 2971, 'therapyName': 'Zoledronic acid'}, {'id': 2237, 'therapyName': 'Fludarabine + Melphalan'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 1844, 'therapyName': 'anti-thymocyte globulin'}, {'id': 1845, 'therapyName': 'Mycophenolate mofetil'}]", Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa,7347
9,NCT02462252,Phase II,Recruiting,"[{'id': 4411, 'therapyName': 'anti-thymocyte globulin + BKT140 + Cyclosporine + Methylprednisolone'}]","Phase IIA Open Label Study to Evaluate Efficacy and Safety of BL-8040 Followed by (hATG), Cyclosporine and Methyprednisolone in Adult Subjects With Aplastic Anemia or Hypoplastic Myelodysplastic Syndrome",7347
10,NCT01621477,Phase II,Terminated,"[{'id': 1756, 'therapyName': 'Plerixafor'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 1845, 'therapyName': 'Mycophenolate mofetil'}, {'id': 2469, 'therapyName': 'Busulfan + Clofarabine + Thymoglobulin'}, {'id': 1783, 'therapyName': 'Cyclophosphamide + Cytarabine'}]",T-Cell Replete Haploidentical Donor Hematopoietic Stem Cell Plus Natural Killer (NK) Cell Transplantation in Patients With Hematologic Malignancies Relapsed or Refractory Despite Previous Allogeneic Transplant,7347
11,NCT00857389,Phase II,"Active, not recruiting","[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 2469, 'therapyName': 'Busulfan + Clofarabine + Thymoglobulin'}, {'id': 1639, 'therapyName': 'Methotrexate'}]",Thiotepa-Clofarabine-Busulfan With Allogeneic Stem Cell Transplant for High Risk Malignancies,7347
12,NCT00990249,Phase II,Completed,"[{'id': 2469, 'therapyName': 'Busulfan + Clofarabine + Thymoglobulin'}]",Busulfan Plus Clofarabine Followed by Allogeneic Hematopoietic Stem Cell Transplantation,7347
13,NCT00679536,Phase Ib/II,Unknown status,"[{'id': 1846, 'therapyName': 'Busulfan + Fludarabine + anti-thymocyte globulin'}]",Allogeneic Transplantation for Pediatric Leukemias With Unrelated Donors,7347
14,NCT01823198,Phase Ib/II,Recruiting,"[{'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1846, 'therapyName': 'Busulfan + Fludarabine + anti-thymocyte globulin'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 1632, 'therapyName': 'Filgrastim'}]",Natural Killer (NK) Cells With HLA Compatible Hematopoietic Transplantation for High Risk Myeloid Malignancies,7347
0,NCT01218867,Phase Ib/II,Completed,"[{'id': 984, 'therapyName': 'Anti-VEGFR2 CAR CD8 lymphocytes'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1167, 'therapyName': 'Aldesleukin'}]",Treating Metastatic Cancer With Anti-VEGFR2 Gene Engineered CD8+ Lymphocytes,7096
0,NCT02047344,Phase II,Recruiting,"[{'id': 985, 'therapyName': 'Antroquinonol'}]","Efficacy, Safety and Pharmacokinetics Study of Antroquinonol to Treat NSCLC",7098
0,NCT02716116,Phase Ib/II,Recruiting,"[{'id': 3981, 'therapyName': 'AP32788'}]",A Trial of AP32788 in Non-Small Cell Lung Cancer,8315
0,NCT02849990,Phase II,Recruiting,"[{'id': 4510, 'therapyName': 'Abiraterone + ARN-509 + Degarelix + Indomethacin + Prednisone'}]","Androgen Receptor Antagonist ARN-509, Abiraterone Acetate, Prednisone, Degarelix, and Indomethacin in Treating Patients With Localized Prostate Cancer Before Surgery",7369
1,NCT03009981,Phase III,Recruiting,"[{'id': 5523, 'therapyName': 'Abiraterone + ARN-509 + Degarelix + Prednisone'}, {'id': 5524, 'therapyName': 'ARN-509 + Degarelix'}, {'id': 1814, 'therapyName': 'Degarelix'}]",A Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer,7369
2,NCT02913196,Phase I,Recruiting,"[{'id': 4767, 'therapyName': 'Abiraterone + ARN-509 + Docetaxel + Prednisone'}]","Phase I Trial of Apalutamide Plus Abiraterone Acetate, Docetaxel, and Prednisone in Patients With mCRPC",7369
3,NCT03141671,Phase II,Not yet recruiting,"[{'id': 5742, 'therapyName': 'Bicalutamide + Gonadorelin'}, {'id': 5743, 'therapyName': 'Abiraterone + ARN-509 + Gonadorelin + Prednisone'}]",Randomized Phase II Study of Salvage XRT + ADT +/- Abiraterone and Apalutamide for Rising PSA After RP (FORMULA-509),7369
4,NCT02772588,Phase II,Recruiting,"[{'id': 4206, 'therapyName': 'Abiraterone + ARN-509 + Leuprolide'}]",AASUR in High Risk Prostate Cancer,7369
5,NCT03298087,Phase II,Not yet recruiting,"[{'id': 4206, 'therapyName': 'Abiraterone + ARN-509 + Leuprolide'}]",Systemic and Tumor-Directed Therapy for Oligometastatic Prostate Cancer,7369
6,NCT02903368,Phase II,Recruiting,"[{'id': 3079, 'therapyName': 'Abiraterone + Leuprolide + Prednisone'}, {'id': 4758, 'therapyName': 'Abiraterone + ARN-509 + Leuprolide + Prednisone'}]",Neoadjuvant And Adjuvant Abiraterone Acetate + Aptilutamide Prostate Cancer Undergoing Prostatectomy,7369
7,NCT02703623,Phase II,Recruiting,"[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 2649, 'therapyName': 'Abiraterone + ARN-509 + Prednisone'}, {'id': 3844, 'therapyName': 'Cabazitaxel + Carboplatin'}]",A Dynamic Allocation Modular Sequential Trial of Approved and Promising Therapies in Men With Metastatic Castrate Resistant Prostate Cancer (DynaMO),7369
8,NCT02123758,Phase I,"Active, not recruiting","[{'id': 2649, 'therapyName': 'Abiraterone + ARN-509 + Prednisone'}]",A Study of JNJ-56021927 (ARN-509) and Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer,7369
9,NCT02531516,Phase III,Recruiting,"[{'id': 2649, 'therapyName': 'Abiraterone + ARN-509 + Prednisone'}, {'id': 1507, 'therapyName': 'Bicalutamide'}]",An Efficacy and Safety Study of JNJ-56021927 (ARN-509) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy,7369
10,NCT03098836,Phase II,Recruiting,"[{'id': 2649, 'therapyName': 'Abiraterone + ARN-509 + Prednisone'}]",Apalutamide and Abiraterone Acetate in African American and Caucasian Men With Metastatic Castrate Resistant Prostate Cancer,7369
11,NCT03279250,Phase II,Not yet recruiting,"[{'id': 759, 'therapyName': 'Goserelin'}, {'id': 2050, 'therapyName': 'Triptorelin'}, {'id': 2649, 'therapyName': 'Abiraterone + ARN-509 + Prednisone'}, {'id': 795, 'therapyName': 'Leuprolide'}, {'id': 1947, 'therapyName': 'ARN-509'}]",Effects of Apalutamide Plus LHRH Agonist or Apalutamide Plus Abiraterone Acetate Plus LHRH Agonist for Six Months for Prostate Cancer Patients at High Risk for Recurrence,7369
12,NCT02949284,Phase II,Recruiting,"[{'id': 1947, 'therapyName': 'ARN-509'}, {'id': 2649, 'therapyName': 'Abiraterone + ARN-509 + Prednisone'}]","Androgen Receptor Antagonist ARN-509 With or Without Abiraterone Acetate, Gonadotropin-Releasing Hormone Analog, and Prednisone in Treating Patients With High-Risk Prostate Cancer Undergoing Surgery",7369
13,NCT01790126,Phase II,"Active, not recruiting","[{'id': 1947, 'therapyName': 'ARN-509'}]",The Role of Highly Selective Androgen Receptor (AR) Targeted Therapy in Men With Biochemically Relapsed Hormone Sensitive Prostate Cancer,7369
14,NCT02906605,Phase II,Withdrawn,"[{'id': 1947, 'therapyName': 'ARN-509'}, {'id': 4890, 'therapyName': 'ARN-509 + JNJ-64041809'}]","A Study of the Clinical Activity and Safety of JNJ-64041809, a Live Attenuated Listeria Monocytogenes Immunotherapy, in Combination With Apalutamide Versus Apalutamide in Subjects With Metastatic Castration-resistant Prostate Cancer",7369
15,NCT01946204,Phase III,"Active, not recruiting","[{'id': 1947, 'therapyName': 'ARN-509'}]",A Study of ARN-509 in Men With Non-Metastatic Castration-Resistant Prostate Cancer,7369
16,NCT02489318,Phase III,"Active, not recruiting","[{'id': 1947, 'therapyName': 'ARN-509'}]",A Phase 3 Study of JNJ-56021927 Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With Low-Volume mHSPC,7369
17,NCT02578797,Phase I,"Active, not recruiting","[{'id': 1947, 'therapyName': 'ARN-509'}]",A JNJ-56021927 (ARN-509) QT/QTc Study,7369
18,NCT02721979,Phase II,Not yet recruiting,"[{'id': 1947, 'therapyName': 'ARN-509'}]",ARN-509 in Treating Patients With Prostate Cancer Who Are in Active Surveillance,7369
19,NCT02257736,Phase III,"Active, not recruiting","[{'id': 1948, 'therapyName': 'ARN-509 + Abiraterone'}, {'id': 1805, 'therapyName': 'Abiraterone'}]",An Efficacy and Safety Study of JNJ56021927 in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC),7369
20,NCT03093272,Phase II,Recruiting,"[{'id': 795, 'therapyName': 'Leuprolide'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 5521, 'therapyName': 'ARN-509 + Docetaxel'}]",A Study of Docetaxel + ARN-509 in Castration-Resistant Prostate Cancer,7369
21,NCT02106507,Phase I,"Active, not recruiting","[{'id': 2303, 'therapyName': 'ARN-509 + Everolimus'}]",ARN 509 Plus Everolimus in Men With Progressive Metastatic Castration-Resistant Prostate Cancer After Treatment With Abiraterone Acetate,7369
22,NCT02770391,Phase II,Recruiting,"[{'id': 4207, 'therapyName': 'ARN-509 + Leuprolide'}]",ARN-509 and Leuprolide in Intermediate and High-risk Prostate Cancer,7369
23,NCT02811809,Phase II,Not yet recruiting,"[{'id': 795, 'therapyName': 'Leuprolide'}, {'id': 4207, 'therapyName': 'ARN-509 + Leuprolide'}]",Apalutamide Plus Intermittent Hormone Therapy Versus Intermittent Hormone Therapy Alone in Prostate Cancer,7369
24,NCT02924766,Phase I,Recruiting,"[{'id': 4832, 'therapyName': 'ARN-509 + Niraparib'}]",A Safety and Pharmacokinetics Study of Niraparib Plus Apalutamide in Men With Metastatic Castration-Resistant Prostate Cancer (BEDIVERE),7369
0,NCT01497704,Phase Ib/II,Completed,"[{'id': 986, 'therapyName': 'Apatinib'}]",Dose-Escalation and Safety Trial of YN968D1,7099
1,NCT03042611,Phase III,Recruiting,"[{'id': 986, 'therapyName': 'Apatinib'}]",Efficacy and Safety Trial of Apatinib Plus Best Supportive Care Compared to Placebo Plus Best Supportive Care in Patients With Gastric Cancer,7099
0,NCT02935907,Phase I,Recruiting,"[{'id': 5826, 'therapyName': 'APG-115'}]",APG-115 in Patients With Advanced Solid Tumors or Lymphomas,8819
0,NCT03080311,Phase I,Recruiting,"[{'id': 5757, 'therapyName': 'APG-1252'}]",A Study of APG-1252 in Patients With SCLC or Other Solid Tumors,8778
0,NCT03087591,Phase I,Recruiting,"[{'id': 5751, 'therapyName': 'APN401'}]","APN401 in Treating Patients With Recurrent or Metastatic Pancreatic Cancer, Colorectal Cancer, or Other Solid Tumors That Cannot Be Removed by Surgery",8772
0,NCT03072043,Phase Ib/II,Recruiting,"[{'id': 5445, 'therapyName': 'APR-246 + Azacitidine'}]",Phase 1b/2 Safety and Efficacy of APR-246 w/Azacitidine for tx of TP53 Mutant Myeloid Neoplasms,7368
1,NCT02098343,Phase Ib/II,Recruiting,"[{'id': 1953, 'therapyName': 'Carboplatin + Doxorubicin'}, {'id': 1952, 'therapyName': 'APR-246 + Carboplatin + Doxorubicin'}]","p53 Suppressor Activation in Recurrent High Grade Serous Ovarian Cancer, a Phase Ib/II Study of Systemic Carboplatin Combination Chemotherapy With or Without APR-246",7368
0,NCT02482168,Phase I,Recruiting,"[{'id': 3835, 'therapyName': 'APX005M'}]",Study of the CD40 Agonistic Monoclonal Antibody APX005M,8262
1,NCT03214250,Phase Ib/II,Recruiting,"[{'id': 6047, 'therapyName': 'Gemcitabine + nab-paclitaxel + Nivolumab'}, {'id': 6048, 'therapyName': 'APX005M + Gemcitabine + nab-paclitaxel'}, {'id': 6049, 'therapyName': 'APX005M + Gemcitabine + nab-paclitaxel + Nivolumab'}]",Safety and Efficacy of APX005M With Gemcitabine and Nab-Paclitaxel With or Without Nivolumab in Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma,8262
2,NCT03123783,Phase Ib/II,Recruiting,"[{'id': 5608, 'therapyName': 'APX005M + Nivolumab'}]",CD40 Agonistic Antibody APX005M in Combination With Nivolumab,8262
3,NCT03165994,Phase II,Not yet recruiting,"[{'id': 5797, 'therapyName': 'APX005M + Paclitaxel + Carboplatin'}]",APX005M With Concurrent Chemoradiation for Resectable Esophageal and Gastroesophageal Junction Cancers,8262
4,NCT02706353,Phase Ib/II,Recruiting,"[{'id': 3836, 'therapyName': 'APX005M + Pembrolizumab'}]",APX005M in Combination With Systemic Pembrolizumab in Patients With Metastatic Melanoma,8262
0,NCT02282917,Phase I,Recruiting,"[{'id': 987, 'therapyName': 'AR-42'}]",Exploratory Evaluation of AR-42 Histone Deacetylase Inhibitor in the Treatment of Vestibular Schwannoma and Meningioma,7101
1,NCT01798901,Phase I,"Active, not recruiting","[{'id': 1751, 'therapyName': 'AR-42 + Decitabine'}]",AR-42 and Decitabine in Treating Patients With Acute Myeloid Leukemia,7101
2,NCT02569320,Phase I,Suspended,"[{'id': 4299, 'therapyName': 'AR-42 + Dexamethasone + Pomalidomide'}]",HDAC Inhibitor AR-42 and Pomalidomide in Treating Patients With Relapsed Multiple Myeloma,7101
3,NCT02795819,Phase I,Suspended,"[{'id': 4267, 'therapyName': 'AR-42 + Pazopanib'}]",Study of the Pan-DAC Inhibitor AR-42 and Pazopanib in Advanced Sarcoma and Kidney Cancer,7101
0,NCT03230318,Phase III,Recruiting,"[{'id': 2900, 'therapyName': 'ARQ 087'}]",ARQ 087 in Subjects With FGFR2 Gene Fusion Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma,7823
1,NCT01752920,Phase I,"Active, not recruiting","[{'id': 2900, 'therapyName': 'ARQ 087'}]",Phase 1 Dose Escalation Study of ARQ 087 in Adult Subjects With Advanced Solid Tumors,7823
0,NCT03162536,Phase I,Recruiting,"[{'id': 5224, 'therapyName': 'ARQ 531'}]","Safety, PK, PD, and Antitumor Activity of ARQ 531 in Hematologic Malignancies",8641
0,NCT02761694,Phase I,Recruiting,"[{'id': 4331, 'therapyName': 'ARQ 751'}]","Phase 1 Study of ARQ 751 in Solid Tumors With AKT1, 2, 3 Genetic Alterations, Activating PI3K Mutations or PTEN-null",8420
0,NCT02476955,Phase I,Recruiting,"[{'id': 635, 'therapyName': 'ARQ092'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]",Open-label Phase 1b Study of ARQ 092 in Combination With Carboplatin Plus Paclitaxel,6841
1,NCT01473095,Phase I,"Active, not recruiting","[{'id': 635, 'therapyName': 'ARQ092'}]",Phase 1 Dose Escalation Study of ARQ 092 in Adult Subjects With Advanced Solid Tumors and Recurrent Malignant Lymphoma,6841
0,NCT02880371,Phase Ib/II,Recruiting,"[{'id': 4608, 'therapyName': 'ARRY-382 + Pembrolizumab'}]",A Study of ARRY-382 in Combination With Pembrolizumab for the Treatment of Patients With Advanced Solid Tumors,7778
0,NCT01397734,Phase I,"Active, not recruiting","[{'id': 640, 'therapyName': 'Arsenic trioxide'}]",Arsenic Trioxide and Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia (CML),1156
1,NCT01835288,Phase II,Withdrawn,"[{'id': 640, 'therapyName': 'Arsenic trioxide'}]",Arsenic Trioxide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia,1156
2,NCT02788201,Phase II,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1133, 'therapyName': 'Mitomycin C'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1013, 'therapyName': 'epirubicin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1137, 'therapyName': 'Bleomycin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 781, 'therapyName': 'Ixabepilone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 2950, 'therapyName': 'Estramustine'}, {'id': 1941, 'therapyName': 'Floxuridine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 1811, 'therapyName': 'Carmustine'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 953, 'therapyName': 'Vandetanib'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 4419, 'therapyName': 'Toremifine'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 2601, 'therapyName': 'Dactinomycin'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 3035, 'therapyName': 'Chlorambucil'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 342, 'therapyName': 'Vemurafenib'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 2635, 'therapyName': 'Vinblastine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 4305, 'therapyName': 'Teniposide'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 4304, 'therapyName': 'Streptozocin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1231, 'therapyName': 'Bendamustine'}, {'id': 4303, 'therapyName': 'Mechlorethamine'}, {'id': 4302, 'therapyName': 'Mitotane'}]",Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma,1156
3,NCT02551718,Phase I,Recruiting,"[{'id': 690, 'therapyName': 'Bosutinib'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 3160, 'therapyName': 'Nelarabine'}, {'id': 3159, 'therapyName': 'Bexarotene'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 998, 'therapyName': 'cabozantinib'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 877, 'therapyName': 'Ponatinib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 623, 'therapyName': 'Afatinib'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 890, 'therapyName': 'Regorafenib'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 2, 'therapyName': 'Trametinib'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 3, 'therapyName': 'Dabrafenib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 789, 'therapyName': 'Ceritinib'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1571, 'therapyName': 'Cabazitaxel'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1327, 'therapyName': 'Pralatrexate'}]",High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia,1156
4,NCT01409161,Phase II,Recruiting,"[{'id': 3685, 'therapyName': 'Arsenic trioxide + Gemtuzumab ozogamicin + Tretinoin'}]","Acute Promyelocytic Leukemia (APL) Treated With ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin",1156
5,NCT02339740,Phase III,Recruiting,"[{'id': 3686, 'therapyName': 'Cytarabine + Dexamethasone + Idarubicin + Mitoxantrone'}, {'id': 3685, 'therapyName': 'Arsenic trioxide + Gemtuzumab ozogamicin + Tretinoin'}]",Tretinoin and Arsenic Trioxide in Treating Patients With Untreated Acute Promyelocytic Leukemia,1156
6,NCT02699723,Phase I,Not yet recruiting,"[{'id': 3791, 'therapyName': 'Arsenic trioxide + Itraconazole'}]",Arsenic Trioxide and Itraconazole in Treating Patients With Advanced Basal Cell Cancer,1156
7,NCT02190695,Phase II,Recruiting,"[{'id': 1608, 'therapyName': 'Decitabine + Carboplatin'}, {'id': 1609, 'therapyName': 'Decitabine + Arsenic trioxide '}]","A Safety and Efficacy Study Using Decitabine, Decitabine/Carboplatin, Decitabine/Arsenic for the Treatment of Relapsed, Refractory, and Elderly Acute Myeloid Leukemia , Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia",1156
8,NCT02188706,Phase II,"Active, not recruiting","[{'id': 650, 'therapyName': 'Decitabine'}, {'id': 1608, 'therapyName': 'Decitabine + Carboplatin'}, {'id': 1609, 'therapyName': 'Decitabine + Arsenic trioxide '}]","A Leukemia SPORE Phase II Clinical Trial Comparing Decitabine Versus Decitabine/Carboplatin and Decitabine/Arsenic for the Treatment of Relapsed, Refractory, and Elderly Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)",1156
0,NCT02081378,Phase I,Recruiting,"[{'id': 2484, 'therapyName': 'ABL001'}, {'id': 829, 'therapyName': 'Nilotinib'}]","A Phase I, Multicenter, Open-label Study of Oral ABL001 in Patients With Chronic Myelogenous Leukemia (CML) or Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia (Ph+ ALL)",7539
1,NCT03106779,Phase III,Recruiting,"[{'id': 690, 'therapyName': 'Bosutinib'}, {'id': 2484, 'therapyName': 'ABL001'}]","Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs",7539
0,NCT02349139,Phase Ib/II,"Active, not recruiting","[{'id': 2528, 'therapyName': 'CYP17 lyase inhibitor ASN001'}]","Safety, Preliminary Efficacy and Pharmacokinetics of ASN001 in Metastatic Castrate Resistant Prostate Cancer",7559
0,NCT02961283,Phase I,Recruiting,"[{'id': 5827, 'therapyName': 'ASN003'}]",Study of ASN003 in Subjects With Advanced Solid Tumors,8820
0,NCT02038673,Phase I,Completed,"[{'id': 3584, 'therapyName': 'ASP5878'}]",An Open-label Phase I Study of Oral ASP5878 at Single and Multiple Doses in Patients With Solid Tumors,8149
0,NCT02588261,Phase III,"Active, not recruiting","[{'id': 1082, 'therapyName': 'ASP8273'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 4, 'therapyName': 'Erlotinib'}]",A Study of ASP8273 vs. Erlotinib or Gefitinib in First-line Treatment of Patients With Stage IIIB/IV Non-small Cell Lung Cancer Tumors With EGFR Activating Mutations,7198
1,NCT03082300,Phase I,Terminated,"[{'id': 1082, 'therapyName': 'ASP8273'}]",A Study of ASP8273 in Subjects With Non-small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Mutations,7198
2,NCT02674555,Phase I,Withdrawn,"[{'id': 1082, 'therapyName': 'ASP8273'}]","A Study to Investigate the Absorption, Metabolism and Excretion of [14C]ASP8273 in Subjects With Solid Tumors",7198
3,NCT03042013,Phase II,Withdrawn,"[{'id': 1082, 'therapyName': 'ASP8273'}]",A Study for Subjects Who Are Participating in an Astellas-sponsored ASP8273 Study,7198
4,NCT02113813,Phase I,"Active, not recruiting","[{'id': 1082, 'therapyName': 'ASP8273'}]",A Dose Escalation Study of ASP8273 in Subjects With Non-Small-Cell Lung Cancer (NSCLC) Who Have Epidermal Growth Factor Receptor (EGFR) Mutations,7198
0,NCT03164057,Phase II,Recruiting,"[{'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 5153, 'therapyName': 'dexrazoxane'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 651, 'therapyName': 'Azacitidine'}]",A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia,23
1,NCT03020030,Phase III,Recruiting,"[{'id': 3160, 'therapyName': 'Nelarabine'}, {'id': 5153, 'therapyName': 'dexrazoxane'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1642, 'therapyName': 'Leucovorin'}]",Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents,23
2,NCT02521493,Phase III,Recruiting,"[{'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 5912, 'therapyName': 'Asparaginase Erwinia chrysanthemi'}, {'id': 5215, 'therapyName': 'mitoxantrone hydrochloride'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 2206, 'therapyName': 'Asparaginase'}]",Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome,23
3,NCT02538926,Phase II,Not yet recruiting,"[{'id': 770, 'therapyName': 'Imatinib'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 3212, 'therapyName': 'Doxorubicin + Etoposide + Vincristine '}, {'id': 2206, 'therapyName': 'Asparaginase'}]","Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride With Asparaginase in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma",23
4,NCT02788201,Phase II,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1133, 'therapyName': 'Mitomycin C'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1013, 'therapyName': 'epirubicin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1137, 'therapyName': 'Bleomycin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 781, 'therapyName': 'Ixabepilone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 2950, 'therapyName': 'Estramustine'}, {'id': 1941, 'therapyName': 'Floxuridine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 1811, 'therapyName': 'Carmustine'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 953, 'therapyName': 'Vandetanib'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 4419, 'therapyName': 'Toremifine'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 2601, 'therapyName': 'Dactinomycin'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 3035, 'therapyName': 'Chlorambucil'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 342, 'therapyName': 'Vemurafenib'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 2635, 'therapyName': 'Vinblastine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 4305, 'therapyName': 'Teniposide'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 4304, 'therapyName': 'Streptozocin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1231, 'therapyName': 'Bendamustine'}, {'id': 4303, 'therapyName': 'Mechlorethamine'}, {'id': 4302, 'therapyName': 'Mitotane'}]",Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma,23
5,NCT02101853,Phase III,Recruiting,"[{'id': 1876, 'therapyName': 'Blinatumomab '}, {'id': 2347, 'therapyName': 'Leucovorin + Pegaspargase  + Vincristine'}, {'id': 2346, 'therapyName': 'Mercaptopurine + Thioguanine'}, {'id': 2348, 'therapyName': 'Asparaginase + Cyclophosphamide + Etoposide'}, {'id': 2345, 'therapyName': 'Cytarabine + Dexamethasone+ Methotrexate '}]",Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia,23
6,NCT01371981,Phase III,"Active, not recruiting","[{'id': 2391, 'therapyName': 'Cytarabine + Daunorubicin + Etoposide'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 2392, 'therapyName': 'Cytarabine + Etoposide'}, {'id': 2393, 'therapyName': 'Cytarabine + Mitoxantrone'}, {'id': 2394, 'therapyName': 'Asparaginase + Cytarabine'}, {'id': 688, 'therapyName': 'Bortezomib'}]",Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,23
7,NCT02723994,Phase II,Recruiting,"[{'id': 2188, 'therapyName': 'Prednisone'}, {'id': 4685, 'therapyName': 'Dexamethasone + Doxorubicin'}, {'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 2346, 'therapyName': 'Mercaptopurine + Thioguanine'}, {'id': 2394, 'therapyName': 'Asparaginase + Cytarabine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 1848, 'therapyName': 'Cyclophosphamide + Methotrexate + Vincristine + Pegaspargase '}]",A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia,23
0,NCT02521493,Phase III,Recruiting,"[{'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 5912, 'therapyName': 'Asparaginase Erwinia chrysanthemi'}, {'id': 5215, 'therapyName': 'mitoxantrone hydrochloride'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 2206, 'therapyName': 'Asparaginase'}]",Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome,8857
0,NCT02103478,Phase Ib/II,"Active, not recruiting","[{'id': 1759, 'therapyName': 'ASTX727'}]",Pharmacokinetic Guided Dose Escalation and Dose Confirmation With Oral Decitabine and Oral CDAi in Patients With MDS,7333
0,NCT01633541,Phase II,Recruiting,"[{'id': 644, 'therapyName': 'AT-101'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 720, 'therapyName': 'Docetaxel'}]",Chemotherapy AND Bcl-xL Inhibitor (AT-101) For Organ Preservation In Adults With Advanced Laryngeal Cancer,6850
0,NCT03270176,Phase I,Recruiting,"[{'id': 6178, 'therapyName': 'AT-406 + Avelumab'}]",A Dose-Finding Study of the Second Mitochondrial Activator of Caspases (SMAC) Mimetic Debio 1143 When Given in Combination With Avelumab to Participants With Advanced Solid Malignancies and to Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) After Platinum-Based Therapy,8186
0,NCT02503709,Phase I,Recruiting,"[{'id': 2727, 'therapyName': 'AT7519'}, {'id': 645, 'therapyName': 'AT13387'}]",Hsp90 Inhibitor AT13387 and CDKI AT7519 in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery,7683
0,NCT02013219,Phase I,"Active, not recruiting","[{'id': 3490, 'therapyName': 'Alectinib + Atezolizumab'}, {'id': 1352, 'therapyName': 'Atezolizumab + Erlotinib'}]",A Phase 1b Study of Atezolizumab in Combination With Erlotinib or Alectinib in Participants With Non-Small Cell Lung Cancer,7221
1,NCT03013218,Phase I,Recruiting,"[{'id': 5211, 'therapyName': 'ALX148'}, {'id': 5212, 'therapyName': 'ALX148 + Atezolizumab'}, {'id': 5213, 'therapyName': 'ALX148 + Trastuzumab'}]",A Study of ALX148 in Patients With Advanced Solid Tumors and Lymphoma,7221
2,NCT02655822,Phase I,Recruiting,"[{'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 3571, 'therapyName': 'CPI-444 '}]",Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers,7221
3,NCT03023423,Phase Ib/II,Recruiting,"[{'id': 5236, 'therapyName': 'Atezolizumab + Daratumumab'}, {'id': 1201, 'therapyName': 'Atezolizumab'}]",A Study of Daratumumab in Combination With Atezolizumab Compared With Atezolizumab Alone in Participants With Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer (DARZALEX),7221
4,NCT03014648,Phase II,Recruiting,"[{'id': 1201, 'therapyName': 'Atezolizumab'}]",Evaluating the Efficacy of Atezolizumab in Advanced Non-small Cell Lung Cancer (NSCLC),7221
5,NCT02589717,FDA approved,Approved for marketing,"[{'id': 1201, 'therapyName': 'Atezolizumab'}]",An Expanded Access Study of MPDL3280A in Patients With PD-L1-Positive Locally Advanced or Metastatic Urothelial Bladder Cancer After Failure With Platinum-Containing Chemotherapy,7221
6,NCT03133390,Phase II,Recruiting,"[{'id': 4595, 'therapyName': 'Atezolizumab + Bevacizumab'}, {'id': 1201, 'therapyName': 'Atezolizumab'}]",Atezolizumab With or Without Bevacizumab in Cisplatin-ineligible Patients,7221
7,NCT03197935,Phase III,Recruiting,"[{'id': 1476, 'therapyName': 'Pegfilgrastim'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 619, 'therapyName': 'Abraxane'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}]",A Study to Investigate Atezolizumab and Chemotherapy Compared With Placebo and Chemotherapy in the Neoadjuvant Setting in Participants With Early Stage Triple Negative Breast Cancer (IMpassion031),7221
8,NCT03141684,Phase II,Recruiting,"[{'id': 1201, 'therapyName': 'Atezolizumab'}]",Atezolizumab in Treating Patients With Newly Diagnosed and Metastatic Alveolar Soft Part Sarcoma That Cannot Be Removed by Surgery,7221
9,NCT02420821,Phase III,"Active, not recruiting","[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1201, 'therapyName': 'Atezolizumab'}]",A Study of MPDL3280A (Anti-Programmed Death Ligand 1 [PD-L1] Antibody) in Combination With Bevacizumab Versus Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma,7221
10,NCT02844816,Phase II,Recruiting,"[{'id': 1201, 'therapyName': 'Atezolizumab'}]",Atezolizumab in Treating Patients With Recurrent BCG-Unresponsive Non-muscle Invasive Bladder Cancer,7221
11,NCT02431208,Phase I,Suspended,"[{'id': 1164, 'therapyName': 'lenalidomide'}, {'id': 1201, 'therapyName': 'Atezolizumab'}]",A Study of Atezolizumab (Anti-Programmed Death Ligand 1 [PD-L1] Antibody) Administered With or Without Lenalidomide in Participants With Multiple Myeloma (MM),7221
12,NCT03120676,Phase II,Recruiting,"[{'id': 1201, 'therapyName': 'Atezolizumab'}]",Study of Atezolizumab in Relapsed or Refractory Hodgkin Lymphoma,7221
13,NCT02409342,Phase III,Recruiting,"[{'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 700, 'therapyName': 'Cisplatin'}]",A Comparative Study of MPDL3280A (Anti-PDL1 Antibody) With Cisplatin or Carboplatin + Pemetrexed in Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC),7221
14,NCT02541604,Phase I,Recruiting,"[{'id': 1201, 'therapyName': 'Atezolizumab'}]","A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of MPDL3280A (Anti-PD-L1 Antibody) in Pediatric and Young Adult Participants With Solid Tumors",7221
15,NCT03206047,Phase Ib/II,Recruiting,"[{'id': 4693, 'therapyName': 'Atezolizumab + SGI-110'}, {'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 5982, 'therapyName': 'Atezolizumab + SGI-110 + DEC-205-NY-ESO-1 fusion protein vaccine'}]","Atezolizumab, Guadecitabine, and CDX-1401 Vaccine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",7221
16,NCT01903993,Phase II,"Active, not recruiting","[{'id': 1201, 'therapyName': 'Atezolizumab'}]",A Randomized Phase 2 Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) Compared With Docetaxel in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum Therapy - &quot;POPLAR&quot;,7221
17,NCT02657434,Phase III,Recruiting,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 854, 'therapyName': 'Pemetrexed'}]",A Study of Atezolizumab in Combination With Carboplatin or Cisplatin + Pemetrexed Compared With Carboplatin or Cisplatin + Pemetrexed in Participants Who Are Chemotherapy-Naive and Have Stage IV Non-Squamous Non-Small Cell Lung Cancer,7221
18,NCT02927301,Phase II,Recruiting,"[{'id': 1201, 'therapyName': 'Atezolizumab'}]","A Study of Atezolizumab as Neoadjuvant and Adjuvant Therapy in Stage IB, II, or IIIA Resectable and Untreated Non-Small Cell Lung Cancer (NSCLC)",7221
19,NCT01375842,Phase I,"Active, not recruiting","[{'id': 1201, 'therapyName': 'Atezolizumab'}]",A Phase 1 Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) in Patients With Locally Advanced or Metastatic Solid Tumors,7221
20,NCT02792192,Phase Ib/II,Recruiting,"[{'id': 4456, 'therapyName': 'Atezolizumab + BCG solution'}, {'id': 1201, 'therapyName': 'Atezolizumab'}]",Safety and Pharmacology Study of Atezolizumab Alone and in Combination With Bacille Calmette-Guérin (BCG) in High-risk Non-muscle-invasive Bladder Cancer (NMIBC) Participants,7221
21,NCT02108652,Phase II,"Active, not recruiting","[{'id': 1201, 'therapyName': 'Atezolizumab'}]",A Study of MPDL3280A in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer,7221
22,NCT02784483,Phase I,Recruiting,"[{'id': 1201, 'therapyName': 'Atezolizumab'}]","Pilot Study Of Anti-Programmed Death Ligand-1 (Anti-PD-L1, Atezolizumab) In Asymptomatic Myeloma",7221
23,NCT02912559,Phase III,Recruiting,"[{'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}]",Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair or Microsatellite Instability,7221
24,NCT02463994,Phase I,"Active, not recruiting","[{'id': 1201, 'therapyName': 'Atezolizumab'}]",A Pilot Study of MPDL3280A and HIGRT in Metastatic NSCLC,7221
25,NCT02708680,Phase Ib/II,Recruiting,"[{'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 5129, 'therapyName': 'Entinostat + Atezolizumab'}]",Randomized Phase 2 Study of Atezolizumab and Entinostat in Patients With aTN Breast Cancer With Phase 1b Lead In,7221
26,NCT02410512,Phase I,Recruiting,"[{'id': 2729, 'therapyName': 'MOXR0916'}, {'id': 1201, 'therapyName': 'Atezolizumab'}]",A Dose-Escalation Study of the Safety and Pharmacokinetics of MOXR0916 and MPDL3280A in Patients With Locally Advanced or Metastatic Solid Tumors,7221
27,NCT02471846,Phase I,"Active, not recruiting","[{'id': 2888, 'therapyName': 'GDC-0919'}, {'id': 1201, 'therapyName': 'Atezolizumab'}]",A Study of GDC-0919 and MPDL3280A Combination Treatment in Participants With Locally Advanced or Metastatic Solid Tumors,7221
28,NCT02031458,Phase II,"Active, not recruiting","[{'id': 1201, 'therapyName': 'Atezolizumab'}]",A Phase 2 Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) in Patients With PD-L1 Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer - BIRCH,7221
29,NCT02304393,Phase I,Recruiting,"[{'id': 2672, 'therapyName': 'RO7009789'}, {'id': 1201, 'therapyName': 'Atezolizumab'}]",A Study of RO7009789 in Combination With MPDL3280A in Patients With Locally Advanced and Metastatic Solid Tumors,7221
30,NCT02323191,Phase I,Recruiting,"[{'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 2004, 'therapyName': 'LY3022855'}]",A Study of RO5509554 and MPDL3280A Administered in Combination in Patients With Advanced Solid Tumors,7221
31,NCT03024996,Phase III,Recruiting,"[{'id': 1201, 'therapyName': 'Atezolizumab'}]",A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy (IMmotion010),7221
32,NCT02425891,Phase III,"Active, not recruiting","[{'id': 619, 'therapyName': 'Abraxane'}, {'id': 1201, 'therapyName': 'Atezolizumab'}]",A Study of MPDL3280A in Combination With Nab-Paclitaxel Compared With Placebo With Nab-Paclitaxel for Patients With Previously Untreated Metastatic Triple Negative Breast Cancer,7221
33,NCT02350673,Phase I,Recruiting,"[{'id': 2886, 'therapyName': 'RO6895882'}, {'id': 1201, 'therapyName': 'Atezolizumab'}]",A Study of Intravenous RO6895882 and MPDL3280A Combination in Patients With Locally Advanced and/or Metastatic Solid Tumors,7221
34,NCT02848651,Phase II,Recruiting,"[{'id': 1201, 'therapyName': 'Atezolizumab'}]",A Study of Atezolizumab (MPDL3280A) as First-line Monotherapy for Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC): Clinical Evaluation of Novel Blood-Based Diagnostics [B-F1RST],7221
35,NCT02409355,Phase III,"Active, not recruiting","[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1201, 'therapyName': 'Atezolizumab'}]",A Study of MPDL3280A Compared With Gemcitabine + Cisplatin or Carboplatin in Patients With Stage IV Squamous Non-Small Cell Lung Cancer,7221
36,NCT02599454,Phase I,Recruiting,"[{'id': 1201, 'therapyName': 'Atezolizumab'}]",Atezolizumab and Stereotactic Body Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer,7221
37,NCT02928406,Phase III,Recruiting,"[{'id': 1201, 'therapyName': 'Atezolizumab'}]",A Study of Atezolizumab in Locally Advanced or Metastatic Urothelial or Non-Urothelial Carcinoma of the Urinary Tract,7221
38,NCT03191786,Phase III,Recruiting,"[{'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1685, 'therapyName': 'Vinorelbine'}]",A Study of Atezolizumab Compared With Chemotherapy in Treatment Naïve Participants With Locally Advanced or Recurrent or Metastatic Non-Small Cell Lung Cancer Who Are Deemed Unsuitable For Platinum-Containing Therapy,7221
39,NCT02367781,Phase III,"Active, not recruiting","[{'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 2634, 'therapyName': 'Carboplatin + nab-paclitaxel'}]",A Phase III Study of MPDL3280A (Anti-PD-L1 Antibody) in Combination With Carboplatin + Nab-Paclitaxel in Patients With Non-Squamous Non-Small Cell Lung Cancer,7221
40,NCT02451423,Phase II,Recruiting,"[{'id': 1201, 'therapyName': 'Atezolizumab'}]",Study of MPDL3280A in Bladder Cancer,7221
41,NCT02788279,Phase III,"Active, not recruiting","[{'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 1343, 'therapyName': 'Atezolizumab + Cobimetinib'}, {'id': 890, 'therapyName': 'Regorafenib'}]",A Study to Investigate Efficacy and Safety of Cobimetinib Plus Atezolizumab and Atezolizumab Monotherapy Versus Regorafenib in Participants With Metastatic Colorectal Adenocarcinoma,7221
42,NCT02862275,Phase 0,Recruiting,"[{'id': 1201, 'therapyName': 'Atezolizumab'}]",Atezolizumab in Treating Patients With Cancer Following Adoptive Cell Transfer,7221
43,NCT02508870,Phase I,Recruiting,"[{'id': 651, 'therapyName': 'Azacitidine'}, {'id': 1201, 'therapyName': 'Atezolizumab'}]","A Safety and Pharmacology Study of Atezolizumab (MPDL3280A, Anti-PD-L1 Antibody) Administered Alone or in Combination With Azacitidine in Patients With Myelodysplastic Syndromes",7221
44,NCT02302807,Phase III,"Active, not recruiting","[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1685, 'therapyName': 'Vinorelbine'}, {'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 720, 'therapyName': 'Docetaxel'}]",A Study of MPDL3280A Compared With Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer,7221
45,NCT02008227,Phase III,"Active, not recruiting","[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1201, 'therapyName': 'Atezolizumab'}]",A Randomized Phase 3 Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) Compared to Docetaxel in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum Therapy - OAK,7221
46,NCT02091141,Phase II,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 698, 'therapyName': 'Alectinib'}, {'id': 1657, 'therapyName': 'Vemurafenib + Cobimetinib'}, {'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 1201, 'therapyName': 'Atezolizumab'}]","My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors",7221
47,NCT03024437,Phase Ib/II,"Active, not recruiting","[{'id': 5129, 'therapyName': 'Entinostat + Atezolizumab'}, {'id': 5235, 'therapyName': 'Atezolizumab + Entinostat + Bevacizumab'}, {'id': 1201, 'therapyName': 'Atezolizumab'}]",Atezolizumab in Combination With Entinostat and Bevacizumab in Patients With Advanced Renal Cell Carcinoma,7221
48,NCT02609984,Phase II,"Active, not recruiting","[{'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 3273, 'therapyName': 'G305 + ID-LV305'}]",Trial of CMB305 and Atezolizumab in Patients With Sarcoma,7221
49,NCT01984242,Phase II,"Active, not recruiting","[{'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1202, 'therapyName': 'Atezolizumab + Bevacizumab + Capecitabine'}]",A Phase 2 Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) as Monotherapy or in Combination With Avastin (Bevacizumab) Compared to Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma,7221
50,NCT02486718,Phase III,Recruiting,"[{'id': 1201, 'therapyName': 'Atezolizumab'}]",Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer,7221
51,NCT03201458,Phase II,Not yet recruiting,"[{'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 1343, 'therapyName': 'Atezolizumab + Cobimetinib'}]",Atezolizumab With or Without Cobimetinib in Treating Patients With Metastatic Bile Duct Cancer That Cannot Be Removed by Surgery,7221
52,NCT02458638,Phase II,Recruiting,"[{'id': 1201, 'therapyName': 'Atezolizumab'}]",An Open Label Study of MPDL3280A in Advanced Solid Tumors,7221
53,NCT03115801,Phase II,Recruiting,"[{'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 1312, 'therapyName': 'Nivolumab'}]",A Phase II Randomized Trial of Immunotherapy Plus Radiotherapy in Metastatic Genitourinary Cancers,7221
54,NCT02450331,Phase III,Recruiting,"[{'id': 1201, 'therapyName': 'Atezolizumab'}]","IMvigor 010 Study: Anti-Programmed Death-Ligand 1 (PD-L1) Antibody MPDL3280A Treatment Versus Observation as Adjuvant Therapy in Patients With PD-L1 Positive, High Risk Muscle Invasive Bladder Cancer After Cystectomy",7221
55,NCT02849496,Phase II,Recruiting,"[{'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 4511, 'therapyName': 'Atezolizumab + Veliparib'}, {'id': 954, 'therapyName': 'Veliparib'}]",Veliparib and Atezolizumab Either Alone or in Combination in Treating Patients With Stage III-IV Triple Negative Breast Cancer,7221
56,NCT03029832,Phase II,"Active, not recruiting","[{'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 5451, 'therapyName': 'Atezolizumab + MOXR0916'}]",A Study of MOXR0916 in Combination With Atezolizumab Versus Atezolizumab Alone in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma Who Are Ineligible for Cisplatin-Based Therapy,7221
57,NCT03178552,Phase II,Recruiting,"[{'id': 4686, 'therapyName': 'Carboplatin + Cisplatin + Gemcitabine'}, {'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 4616, 'therapyName': 'Carboplatin + Cisplatin + Pemetrexed'}, {'id': 698, 'therapyName': 'Alectinib'}]",A Study to Evaluate Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC) (B-FAST),7221
58,NCT03148418,Phase II,Not yet recruiting,"[{'id': 1201, 'therapyName': 'Atezolizumab'}]",A Study in Participants Previously Enrolled in a Genentech? and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study,7221
59,NCT02525757,Phase II,Recruiting,"[{'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]",MPDL3280A With Chemoradiation for Lung Cancer,7221
60,NCT03237780,Phase II,Not yet recruiting,"[{'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 6098, 'therapyName': 'Atezolizumab + Eribulin'}]",Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer,7221
61,NCT02997228,Phase III,Not yet recruiting,"[{'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 1484, 'therapyName': 'Bevacizumab + Oxaliplatin + Leucovorin + Fluorouracil'}, {'id': 5126, 'therapyName': 'Bevacizumab + Atezolizumab + Fluorouracil + Leucovorin + Oxaliplatin'}]","Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Microsatellite Instability-High Metastatic Colorectal Cancer",7221
62,NCT02367794,Phase III,"Active, not recruiting","[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 619, 'therapyName': 'Abraxane'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1201, 'therapyName': 'Atezolizumab'}]",A Phase III Study of MPDL3280A (Anti-PD-L1) in Combination With Carboplatin + Paclitaxel or Carboplatin + Nab-paclitaxel Compared With Carboplatin + Nab-paclitaxel in Patients With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC),7221
63,NCT02400814,Phase I,Recruiting,"[{'id': 1201, 'therapyName': 'Atezolizumab'}]",MPDL3280A and Stereotactic Ablative Radiotherapy in Patients With Non-small Cell Lung Cancer,7221
64,NCT03074513,Phase II,Recruiting,"[{'id': 4595, 'therapyName': 'Atezolizumab + Bevacizumab'}]",Atezolizumab and Bevacizumab in Rare Solid Tumors,7221
65,NCT03175432,Phase II,Recruiting,"[{'id': 4595, 'therapyName': 'Atezolizumab + Bevacizumab'}]",Study of BEvacizumab in Combination With ATezolizumab in Patients With Untreated Melanoma Brain Metastases  (BEAT-MBM),7221
66,NCT03181100,Phase II,Recruiting,"[{'id': 619, 'therapyName': 'Abraxane'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1343, 'therapyName': 'Atezolizumab + Cobimetinib'}, {'id': 4595, 'therapyName': 'Atezolizumab + Bevacizumab'}, {'id': 3049, 'therapyName': 'Atezolizumab + nab-paclitaxel'}, {'id': 4825, 'therapyName': 'Atezolizumab + Vemurafenib + Cobimetinib'}, {'id': 5606, 'therapyName': 'Atezolizumab + Paclitaxel'}]",Atezolizumab Combinations With Chemotherapy for Anaplastic and Poorly Differentiated Thyroid Carcinomas,7221
67,NCT02921269,Phase II,Suspended,"[{'id': 4595, 'therapyName': 'Atezolizumab + Bevacizumab'}]","Atezolizumab and Bevacizumab in Treating Patients With Recurrent, Persistent, or Metastatic Cervical Cancer",7221
68,NCT02873195,Phase II,Not yet recruiting,"[{'id': 2097, 'therapyName': 'Bevacizumab + Capecitabine'}, {'id': 1202, 'therapyName': 'Atezolizumab + Bevacizumab + Capecitabine'}]",Capecitabine and Bevacizumab With or Without Atezolizumab in Treating Patients With Refractory Metastatic Colorectal Cancer,7221
69,NCT01633970,Phase I,"Active, not recruiting","[{'id': 1203, 'therapyName': 'Atezolizumab + Carboplatin + Paclitaxel'}, {'id': 1204, 'therapyName': 'Atezolizumab + Carboplatin + Pemetrexed'}, {'id': 1202, 'therapyName': 'Atezolizumab + Bevacizumab + Capecitabine'}]",A Phase 1b Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) in Combination With Avastin (Bevacizumab) and/or With Chemotherapy in Patients With Locally Advanced or Metastatic Solid Tumors,7221
70,NCT02715531,Phase I,Recruiting,"[{'id': 3947, 'therapyName': 'Atezolizumab + Gemcitabine + nab-paclitaxel'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 1202, 'therapyName': 'Atezolizumab + Bevacizumab + Capecitabine'}]",A Study of the Safety and Tolerability of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors,7221
71,NCT02724878,Phase II,Recruiting,"[{'id': 1202, 'therapyName': 'Atezolizumab + Bevacizumab + Capecitabine'}]",Study of Atezolizumab + Bevacizumab in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma,7221
72,NCT02366143,Phase III,"Active, not recruiting","[{'id': 2370, 'therapyName': 'Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel'}, {'id': 1489, 'therapyName': 'Nab-paclitaxel + Carboplatin + Bevacizumab'}, {'id': 1203, 'therapyName': 'Atezolizumab + Carboplatin + Paclitaxel'}]",TBAA Phase III Study of MPDL3280A (Anti-PD-L1 Antibody) in Combination With Carboplatin + Paclitaxel With or Without Bevacizumab in Patients With Stage IV Non-squamous Non-small Cell Lung Cancer,7221
73,NCT03038100,Phase III,Recruiting,"[{'id': 2370, 'therapyName': 'Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel'}, {'id': 1152, 'therapyName': 'Bevacizumab + Carboplatin + Paclitaxel'}]","A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (IMagyn050)",7221
74,NCT02839707,Phase II,Recruiting,"[{'id': 4496, 'therapyName': 'Atezolizumab + Bevacizumab + Doxil'}, {'id': 4495, 'therapyName': 'Atezolizumab + Doxil'}, {'id': 1673, 'therapyName': 'Doxil + Bevacizamub'}]","Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",7221
75,NCT03280563,Phase Ib/II,Not yet recruiting,"[{'id': 6269, 'therapyName': 'Atezolizumab + Ipatasertib'}, {'id': 6270, 'therapyName': 'Atezolizumab + Bevacizumab + Exemestane'}, {'id': 1343, 'therapyName': 'Atezolizumab + Cobimetinib'}, {'id': 6271, 'therapyName': 'Atezolizumab + Bevacizumab + Fulvestrant'}, {'id': 6272, 'therapyName': 'Atezolizumab + Bevacizumab + Tamoxifen'}, {'id': 6273, 'therapyName': 'Atezolizumab + Ipatasertib + Fulvestrant'}, {'id': 744, 'therapyName': 'Fulvestrant'}, {'id': 6268, 'therapyName': 'Atezolizumab + Fulvestrant'}]",A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer,7221
76,NCT02174172,Phase I,Recruiting,"[{'id': 6252, 'therapyName': 'Atezolizumab + Bevacizumab +Peg-interferon alfa-2a'}, {'id': 6253, 'therapyName': 'Atezolizumab + Interferon alfa-2b'}, {'id': 6250, 'therapyName': 'Atezolizumab + Peg-interferon alfa-2a'}, {'id': 6249, 'therapyName': 'Atezolizumab + Ipilimumab'}, {'id': 1975, 'therapyName': 'Atezolizumab + Obinutuzumab'}]",A Study to Assess the Safety and Tolerability of MPDL3280A in Combination With Other Immune-modulating Therapies in Patients With Locally Advanced or Metastatic Solid Tumors,7221
77,NCT03193190,Phase Ib/II,Recruiting,"[{'id': 5942, 'therapyName': 'Atezolizumab + BKT140'}, {'id': 5940, 'therapyName': 'Gemcitabine + Nab-Paclitaxel + mFOLFOX-6'}, {'id': 5941, 'therapyName': 'Atezolizumab + PEGPH20'}, {'id': 1343, 'therapyName': 'Atezolizumab + Cobimetinib'}]",A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (PDAC),7221
78,NCT03281369,Phase Ib/II,Not yet recruiting,"[{'id': 1343, 'therapyName': 'Atezolizumab + Cobimetinib'}, {'id': 6274, 'therapyName': 'mFOLFOX-6 + Atezolizumab + Cobimetinib'}, {'id': 6275, 'therapyName': 'mFOLFOX-6 + Atezolizumab'}, {'id': 6276, 'therapyName': 'Atezolizumab + Linagliptin'}, {'id': 5941, 'therapyName': 'Atezolizumab + PEGPH20'}, {'id': 5942, 'therapyName': 'Atezolizumab + BKT140'}, {'id': 1721, 'therapyName': 'Ramucirumab + Paclitaxel'}, {'id': 5850, 'therapyName': 'mFOLFOX-6'}]",A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) (UMBRELLA),7221
79,NCT02500407,Phase I,Recruiting,"[{'id': 6305, 'therapyName': 'Atezolizumab + BTCT4465A'}]",A Safety and Pharmacokinetic Study of BTCT4465A as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL),7221
80,NCT03170960,Phase Ib/II,Recruiting,"[{'id': 6094, 'therapyName': 'Atezolizumab + Cabozantinib'}]",Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors,7221
81,NCT03264066,Phase II,Not yet recruiting,"[{'id': 6094, 'therapyName': 'Atezolizumab + Cabozantinib'}]",A Study to Investigate the Efficacy and Safety of Cobimetinib Plus Atezolizumab in Participants With Solid Tumors,7221
82,NCT03206203,Phase II,Recruiting,"[{'id': 5983, 'therapyName': 'Atezolizumab + Carboplatin'}, {'id': 1092, 'therapyName': 'Carboplatin'}]",Carboplatin With or Without Atezolizumab in Treating Patients With Stage IV Triple Negative Breast Cancer,7221
83,NCT02763579,Phase III,Recruiting,"[{'id': 4164, 'therapyName': 'Atezolizumab + Carboplatin + Etoposide'}, {'id': 1791, 'therapyName': 'Carboplatin + Etoposide'}]",A Study of Carboplatin Plus Etoposide With or Without Atezolizumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer (IMpower133),7221
84,NCT02748889,Phase Ib/II,Terminated,"[{'id': 1791, 'therapyName': 'Carboplatin + Etoposide'}, {'id': 4164, 'therapyName': 'Atezolizumab + Carboplatin + Etoposide'}]",Carboplatin Plus Etoposide With or Without MPDL3280A in Untreated Extensive Stage Small Cell Lung Cancer,7221
85,NCT03041311,Phase II,Recruiting,"[{'id': 5541, 'therapyName': 'Atezolizumab + Carboplatin + Etoposide + Trilaciclib'}, {'id': 4164, 'therapyName': 'Atezolizumab + Carboplatin + Etoposide'}]","Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Extensive Stage Small Cell Lung Cancer (SCLC)",7221
86,NCT02807636,Phase III,Recruiting,"[{'id': 4450, 'therapyName': 'Atezolizumab + Carboplatin + Gemcitabine'}, {'id': 2667, 'therapyName': 'Carboplatin + Gemcitabine'}]",The Effect of Atezolizumab in Combination With Gemcitabine/Carboplatin and Gemcitabine/Carboplatin Alone in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma Who Are Ineligible for Cisplatin-based Therapy,7221
87,NCT02716038,Phase II,Recruiting,"[{'id': 3946, 'therapyName': 'Atezolizumab + Carboplatin + nab-Paclitaxel'}]","Neoadjuvant MPDL3280A, Nab-paclitaxel and Carboplatin (MAC) in NSCLC",7221
88,NCT02883062,Phase II,Not yet recruiting,"[{'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 1203, 'therapyName': 'Atezolizumab + Carboplatin + Paclitaxel'}]","Carboplatin and Paclitaxel With or Without Atezolizumab Before Surgery in Treating Patients With Newly Diagnosed, Stage II-III Triple-Negative Breast Cancer",7221
89,NCT02989584,Phase Ib/II,Recruiting,"[{'id': 5140, 'therapyName': 'Atezolizumab + Cisplatin + Gemcitabine'}]",A Pilot Safety Study of Atezolizumab Combination With Cisplatin + Gemcitabine in Pts With Metastatic Bladder Cancer,7221
90,NCT03093922,Phase II,Recruiting,"[{'id': 5140, 'therapyName': 'Atezolizumab + Cisplatin + Gemcitabine'}]",A Study of Two Dosing Schedules of Atezolizumab in Combination With Gemcitabine and Cisplatin as First-Line Treatment for Metastatic Bladder Cancer,7221
91,NCT03228537,Phase I,Not yet recruiting,"[{'id': 6036, 'therapyName': 'Atezolizumab + Cisplatin + Pemetrexed'}]","Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma",7221
92,NCT02630186,Phase Ib/II,"Active, not recruiting","[{'id': 3575, 'therapyName': 'Atezolizumab + CO1686'}]",A Phase 1b/2 Study of Safety and Efficacy of Rociletinib in Combination With MPDL3280A in Patients With Advanced or Metastatic EGFR-mutant NSCLC,7221
93,NCT03273153,Phase III,Not yet recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1343, 'therapyName': 'Atezolizumab + Cobimetinib'}]",A Study of Cobimetinib Plus Atezolizumab Versus Pembrolizumab in Participants With Previously Untreated Advanced BRAFv600 Wild-Type Melanoma,7221
94,NCT01988896,Phase I,"Active, not recruiting","[{'id': 1343, 'therapyName': 'Atezolizumab + Cobimetinib'}]",A Phase 1b Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) in Combination With Cobimetinib in Patients With Locally Advanced or Metastatic Solid Tumors,7221
95,NCT03108131,Phase II,Recruiting,"[{'id': 1343, 'therapyName': 'Atezolizumab + Cobimetinib'}]",Cobimetinib and Atezolizumab in Advanced Rare Tumors,7221
96,NCT03178851,Phase I,Recruiting,"[{'id': 1343, 'therapyName': 'Atezolizumab + Cobimetinib'}]",A Study Evaluating Cobimetinib (Targeted Therapy) Plus Atezolizumab (Immunotherapy) in Participants With Advanced Melanoma Whose Cancer Has Worsened During or After Treatment With Previous Immunotherapy,7221
97,NCT03202316,Phase II,Recruiting,"[{'id': 5970, 'therapyName': 'Atezolizumab + Cobimetinib + Eribulin'}]",Study of Triple Combination of Atezolizumab + Cobimetinib + Eribulin (ACE) in Patients With Chemotherapy Resistant Metastatic Inflammatory Breast Cancer,7221
98,NCT02495636,Phase II,Withdrawn,"[{'id': 4204, 'therapyName': 'Atezolizumab + DEC-205-NY-ESO-1 fusion protein vaccine'}]","Phase 2 Study of MPDL3280A Combined With CDX-1401 in NY-ESO 1 (+) IIIB, IV or Recurrent Non-Small Cell Lung Cancer",7221
99,NCT03016312,Phase III,Recruiting,"[{'id': 5204, 'therapyName': 'Atezolizumab + Enzalutamide'}, {'id': 1262, 'therapyName': 'Enzalutamide'}]","IMbassador250: A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen",7221
100,NCT02298153,Phase I,"Active, not recruiting","[{'id': 2636, 'therapyName': 'Atezolizumab + Epacadostat'}]",A Study of MPDL3280A in Combination With INCB024360 in Subjects With Previously Treated Stage IIIB or Stage IV Non-Small Cell Lung Cancer,7221
101,NCT03073525,Phase II,Recruiting,"[{'id': 5558, 'therapyName': 'Atezolizumab + FANG vaccine'}]",Trial of Atezolizumab and Vigil for Advanced Gynecological Cancers (A Companion Study to CL-PTL-119),7221
102,NCT02926833,Phase Ib/II,Recruiting,"[{'id': 4830, 'therapyName': 'Atezolizumab + KTE-C19'}]",A Study Evaluating KTE-C19 in Combination With Atezolizumab in Subjects With Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (ZUMA-6),7221
103,NCT02631577,Phase I,Suspended,"[{'id': 3387, 'therapyName': 'Atezolizumab + lenalidomide + Obinutuzumab'}]",A Study Evaluating the Safety and Efficacy of Atezolizumab in Combination With Obinutuzumab Plus Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma,7221
104,NCT02794571,Phase I,Recruiting,"[{'id': 4269, 'therapyName': 'Atezolizumab + MTIG7192A '}, {'id': 4268, 'therapyName': 'MTIG7192A '}]",Safety and Pharmacokinetics (PK) of Escalating Doses of MTIG7192A as a Single Agent and in Combination With Atezolizumab in Locally Advanced or Metastatic Tumors,7221
105,NCT02530489,Phase II,Recruiting,"[{'id': 3049, 'therapyName': 'Atezolizumab + nab-paclitaxel'}]",Neoadjuvant Trial of Nab-Paclitaxel and MPDL3280A,7221
106,NCT02846623,Phase II,Recruiting,"[{'id': 1975, 'therapyName': 'Atezolizumab + Obinutuzumab'}]",Atezolizumab (PD-L1 mAb) in Combination With Obinutuzumab and Ibrutinib in Patients With Relapsed Refractory or High-risk Untreated Chronic Lymphocytic Leukemia (CLL),7221
107,NCT02596971,Phase I,Recruiting,"[{'id': 1975, 'therapyName': 'Atezolizumab + Obinutuzumab'}, {'id': 3266, 'therapyName': 'Cyclophosphamide + Doxorubicin + Prednisone + Vincristine '}, {'id': 1231, 'therapyName': 'Bendamustine'}]",Safety and Efficacy of MPDL3280A in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus CHOP in Patients With Follicular Lymphoma or Diffuse Large B-Cell Lymphoma,7221
108,NCT02220842,Phase I,Recruiting,"[{'id': 1975, 'therapyName': 'Atezolizumab + Obinutuzumab'}]",A Safety and Pharmacology Study of MPDL3280A Administered With Obinutuzumab in Patients With Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma,7221
109,NCT02729896,Phase Ib/II,Recruiting,"[{'id': 4362, 'therapyName': 'Atezolizumab + Obinutuzumab + Polatuzumab Vedotin'}]","A Study of Obinutuzumab, Polatuzumab Vedotin, and Atezolizumab in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)",7221
110,NCT03125902,Phase III,Recruiting,"[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 5606, 'therapyName': 'Atezolizumab + Paclitaxel'}]",A Study of Atezolizumab and Paclitaxel Versus Placebo and Paclitaxel in Participants With Previously Untreated Locally Advanced or Metastatic Triple Negative Breast Cancer (TNBC) (IMpassion131),7221
111,NCT03125928,Phase II,Recruiting,"[{'id': 5600, 'therapyName': 'Atezolizumab + Paclitaxel + Trastuzumab + Pertuzumab'}]","Clinical Trial of Atezolizumab With Paclitaxel, Trastuzumab, and Pertuzumab in Patients With Metastatic HER-2 Positive Breast Cancer",7221
112,NCT02814669,Phase I,Recruiting,"[{'id': 4881, 'therapyName': 'Atezolizumab + Ra 223'}]",Safety and Tolerability of Atezolizumab (ATZ) in Combination With Radium-223 Dichloride (R-223-D) in Metastatic Castrate-Resistant Prostate Cancer (CRPC) Progressed Following Treatment With an Androgen Pathway Inhibitor,7221
113,NCT03208712,Phase I,Not yet recruiting,"[{'id': 4881, 'therapyName': 'Atezolizumab + Ra 223'}]",Radium-223 and Atezolizumab in Patients With Urothelial Carcinoma With Bone Metastases Who Have Had Disease Progression After Platinum-Based Chemotherapy,7221
114,NCT02650713,Phase I,Recruiting,"[{'id': 3412, 'therapyName': 'Atezolizumab + RO6958688 '}]","A Study of the Safety, Pharmacokinetics, and Therapeutic Activity of RO6958688 in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen (CEA)-Positive Solid Tumors",7221
115,NCT03289962,Phase I,Not yet recruiting,"[{'id': 6234, 'therapyName': 'RO7198457'}, {'id': 6235, 'therapyName': 'Atezolizumab + RO7198457'}]",A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors,7221
116,NCT02892318,Phase I,Recruiting,"[{'id': 4693, 'therapyName': 'Atezolizumab + SGI-110'}]",A Study Evaluating the Safety and Pharmacology of Atezolizumab Administered in Combination With Immunomodulatory Agents in Participants With Acute Myeloid Leukemia (AML),7221
117,NCT02935361,Phase Ib/II,Recruiting,"[{'id': 4693, 'therapyName': 'Atezolizumab + SGI-110'}]",Guadecitabine and Atezolizumab in Treating Patients With Advanced Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia That Is Refractory or Relapsed,7221
118,NCT03024216,Phase I,Recruiting,"[{'id': 5642, 'therapyName': 'Atezolizumab + Sipuleucel-T'}]",Clinical Study of Atezolizumab (Anti-PD-L1) and Sipuleucel-T in Patients Who Have Asymptomatic or Minimally Symptomatic Metastatic Castrate Resistant Prostate Cancer,7221
119,NCT03174197,Phase Ib/II,Recruiting,"[{'id': 5872, 'therapyName': 'Atezolizumab + Temozolomide'}]",Atezolizumab (aPDL1) + Temozolomide and Radiation for Newly Diagnosed Glioblastoma (GBM),7221
120,NCT03292172,Phase I,Not yet recruiting,"[{'id': 6286, 'therapyName': 'Atezolizumab + TEN-010'}]","A Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RO6870810 and Atezolizumab (PD-L1 Antibody) in Participants With Advanced Ovarian Cancer or Triple Negative Breast Cancer",7221
121,NCT02605915,Phase I,Recruiting,"[{'id': 3250, 'therapyName': 'Atezolizumab + Trastuzumab'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 856, 'therapyName': 'Pertuzumab'}]",Safety and Pharmacokinetics of Atezolizumab in Combination With Trastuzumab Emtansine or With Trastuzumab and Pertuzumab in Participants With HER2-Positive Breast Cancer,7221
122,NCT02924883,Phase II,"Active, not recruiting","[{'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 3250, 'therapyName': 'Atezolizumab + Trastuzumab'}]",A Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine in Combination With Atezolizumab or Atezolizumab-Placebo in Participants With Human Epidermal Growth Factor-2 (HER2) Positive Locally Advanced or Metastatic Breast Cancer Who Have Received Prior Trastuzumab and Taxane Based Therapy,7221
123,NCT02543645,Phase Ib/II,Terminated,"[{'id': 3086, 'therapyName': 'Atezolizumab + Varlilumab'}]",A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer,7221
124,NCT01656642,Phase I,"Active, not recruiting","[{'id': 1216, 'therapyName': 'Atezolizumab + vemurafenib'}]", A Phase 1b Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) in Combination With Vemurafinib (Zelboraf&#174;) in Patients With Previously Untreated BRAFV600-Mutation Positive Metastatic Melanoma,7221
125,NCT02908672,Phase III,Recruiting,"[{'id': 1657, 'therapyName': 'Vemurafenib + Cobimetinib'}, {'id': 4825, 'therapyName': 'Atezolizumab + Vemurafenib + Cobimetinib'}]",A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Participants With Metastatic or Unresectable Locally Advanced Melanoma,7221
126,NCT03123055,Phase I,Recruiting,"[{'id': 5615, 'therapyName': 'B-701 + Atezolizumab'}]",A Study of B-701 in Combination With Atezolizumab in Treatment of Locally Advanced or Metastatic Urothelial Cell Carcinoma (U22),7221
127,NCT02876224,Phase I,Recruiting,"[{'id': 4609, 'therapyName': 'Cobimetinib + Bevacizumab + Atezolizumab'}]",Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors,7221
128,NCT02919449,Phase I,Recruiting,"[{'id': 6127, 'therapyName': 'MV-NIS + Atezolizumab'}]",Trial of Measles Virotherapy in Combination With Atezolizumab in Patients With Metastatic Non-Small Cell Lung Cancer,7221
129,NCT03063762,Phase I,Recruiting,"[{'id': 5365, 'therapyName': 'RO6874281 + Obinutuzumab + Atezolizumab'}, {'id': 5366, 'therapyName': 'RO6874281 + Obinutuzumab + Atezolizumab + Bevacizumab'}]","Study to Evaluate Safety, Pharmacokinetics and Therapeutic Activity of RO6874281 as a Combination Therapy in Participants With Unresectable Advanced and/or Metastatic Renal Cell Carcinoma (RCC)",7221
0,NCT01980823,Phase I,Recruiting,"[{'id': 1576, 'therapyName': 'Atorvastatin + Metformin'}]",Pre-Surgical Trial of the Combination of Metformin and Atorvastatin in Newly Diagnosed Operable Breast Cancer,1063
1,NCT02497638,Phase II,Recruiting,"[{'id': 1576, 'therapyName': 'Atorvastatin + Metformin'}]",LIpitor and biGuanide to Androgen Delay Trial,1063
0,NCT01898715,Phase I,Recruiting,"[{'id': 4296, 'therapyName': 'ATR-101'}]",Phase 1 Study of ATR-101 in Subjects With Advanced Adrenocortical Carcinoma,8401
0,NCT03052127,Phase I,Recruiting,"[{'id': 5828, 'therapyName': 'AU-011'}]",Phase 1B Study in Subjects With Small to Medium Primary Choroidal Melanoma,8821
0,NCT00889954,Phase I,"Active, not recruiting","[{'id': 1403, 'therapyName': 'Autologous TGF beta resistant HER2 EBV CTLs'}]",Her2 and TGFBeta CTLs in Treatment of Her2 Positive Malignancy,7253
0,NCT01752400,Phase II,"Active, not recruiting","[{'id': 647, 'therapyName': 'AUY922'}]",AUY922 for Advanced ALK-positive NSCLC,6853
1,NCT01854034,Phase II,Completed,"[{'id': 647, 'therapyName': 'AUY922'}]",Phase 2 Study of AUY922 in NSCLC Patients With Exon 20 Insertion Mutations in EGFR,6853
2,NCT01646125,,Terminated,"[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 647, 'therapyName': 'AUY922'}, {'id': 854, 'therapyName': 'Pemetrexed'}]"," An Open-label, Randomized Phase II Study to Evaluate the Efficacy of AUY922 vs Pemetrexed or Docetaxel in NSCLC Patients With EGFR Mutations",6853
3,NCT01772797,Phase I,Completed,"[{'id': 789, 'therapyName': 'Ceritinib'}, {'id': 647, 'therapyName': 'AUY922'}]",Phase Ib Study of LDK378 and AUY922 in ALK-rearranged Non-small Cell Lung Cancer,6853
4,NCT01294826,Phase I,Completed,"[{'id': 1996, 'therapyName': 'AUY922 + Cetuximab'}]",Study of AUY922 and Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer,6853
5,NCT01784640,Phase I,"Active, not recruiting","[{'id': 1270, 'therapyName': 'AUY922 + Pemetrexed'}]",Pemetrexed Disodium and Hsp90 Inhibitor AUY922 in Treating Patients With Previously Treated Stage IV Non-Small Cell Lung Cancer,6853
0,NCT03050814,Phase II,Suspended,"[{'id': 1524, 'therapyName': 'Fluorouracil + Bevacizumab + Capecitabine + Leucovorin + Oxaliplatin'}, {'id': 5336, 'therapyName': 'Ad-CEA + Bevacizumab + FOLFOX'}]",Standard of Care Alone or in Combination With Ad-CEA Vaccine and Avelumab in People With Previously Untreated Metastatic Colorectal Cancer,7952
1,NCT03270176,Phase I,Recruiting,"[{'id': 6178, 'therapyName': 'AT-406 + Avelumab'}]",A Dose-Finding Study of the Second Mitochondrial Activator of Caspases (SMAC) Mimetic Debio 1143 When Given in Combination With Avelumab to Participants With Advanced Solid Malignancies and to Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) After Platinum-Based Therapy,7952
2,NCT03278379,Phase II,Not yet recruiting,"[{'id': 3144, 'therapyName': 'Avelumab'}]",Avelumab in G2-3 NET (NET-002),7952
3,NCT03136406,Phase Ib/II,Recruiting,"[{'id': 1018, 'therapyName': 'GI-4000'}, {'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 3144, 'therapyName': 'Avelumab'}, {'id': 619, 'therapyName': 'Abraxane'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 6163, 'therapyName': 'ETBX-011'}, {'id': 3060, 'therapyName': 'ALT-803'}]",QUILT-3.039: NANT Pancreatic Cancer Vaccine: Combination Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy,7952
4,NCT03158883,Phase I,Recruiting,"[{'id': 3144, 'therapyName': 'Avelumab'}]",Avelumab and Stereotactic Ablative Radiotherapy in Non-responding and Progressing NSCLC Patients,7952
5,NCT02155647,Phase II,Recruiting,"[{'id': 3144, 'therapyName': 'Avelumab'}]",Avelumab in Subjects With Merkel Cell Carcinoma (JAVELIN Merkel 200),7952
6,NCT02625610,Phase III,Recruiting,"[{'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 3144, 'therapyName': 'Avelumab'}, {'id': 1597, 'therapyName': 'Capecitabine + Oxaliplatin'}]",Avelumab in First-Line Gastric Cancer (JAVELIN Gastric 100),7952
7,NCT02603419,Phase I,Recruiting,"[{'id': 3144, 'therapyName': 'Avelumab'}]",Avelumab In Patients With Previously Treated Advanced Stage Classical Hodgkin's Lymphoma (JAVELIN HODGKINS),7952
8,NCT02718417,Phase III,Recruiting,"[{'id': 3144, 'therapyName': 'Avelumab'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]",Avelumab in Previously Untreated Patients With Epithelial Ovarian Cancer (JAVELIN OVARIAN 100),7952
9,NCT02968940,Phase III,Recruiting,"[{'id': 3144, 'therapyName': 'Avelumab'}]",Avelumab With Hypofractionated Radiation Therapy in Adults With Isocitrate Dehydrogenase (IDH) Mutant Glioblastoma,7952
10,NCT02912572,Phase II,Recruiting,"[{'id': 3144, 'therapyName': 'Avelumab'}]","Study of Avelumab in Patients With MSS, MSI-H and POLE-mutated Recurrent or Persistent Endometrial Cancer",7952
11,NCT03000179,Phase II,Recruiting,"[{'id': 3144, 'therapyName': 'Avelumab'}]",Safety and Efficacy of Avelumab in Small Intestinal Adenocarcinoma,7952
12,NCT02875613,Phase II,Recruiting,"[{'id': 3144, 'therapyName': 'Avelumab'}]",Avelumab for Recurrent/Metastatic Nasopharyngeal Cancer,7952
13,NCT03006848,Phase II,Recruiting,"[{'id': 3144, 'therapyName': 'Avelumab'}]",A Phase II Trial of Avelumab in Patients With Recurrent or Progressive Osteosarcoma,7952
14,NCT02395172,Phase III,"Active, not recruiting","[{'id': 3144, 'therapyName': 'Avelumab'}, {'id': 720, 'therapyName': 'Docetaxel'}]",Avelumab in Non-Small Cell Lung Cancer (JAVELIN Lung 200),7952
15,NCT02625623,Phase III,"Active, not recruiting","[{'id': 3144, 'therapyName': 'Avelumab'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1074, 'therapyName': 'Irinotecan'}]",Avelumab in Third-Line Gastric Cancer (JAVELIN Gastric 300),7952
16,NCT03035630,Phase II,Recruiting,"[{'id': 3144, 'therapyName': 'Avelumab'}, {'id': 930, 'therapyName': 'Sunitinib'}]",Sunitinib Followed by Avelumab or the Reverse for Metastatic Renal Cell Carcinoma,7952
17,NCT03076554,Phase II,Recruiting,"[{'id': 3144, 'therapyName': 'Avelumab'}]",A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma After Progression on Platinum-Based Chemotherapy,7952
18,NCT03288350,Phase II,Not yet recruiting,"[{'id': 1930, 'therapyName': 'Cisplatin + Docetaxel + Fluorouracil'}, {'id': 3144, 'therapyName': 'Avelumab'}]",mDCF + Avelumab in Resectable Esophago-gastric Adenocarcinoma (EGA),7952
19,NCT02576574,Phase III,Recruiting,"[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 3144, 'therapyName': 'Avelumab'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 1092, 'therapyName': 'Carboplatin'}]",Avelumab in First-line Non-Small Cell Lung Cancer (JAVELIN Lung 100),7952
20,NCT03271372,Phase III,Not yet recruiting,"[{'id': 3144, 'therapyName': 'Avelumab'}]",Adjuvant Avelumab in Merkel Cell Cancer (ADAM),7952
21,NCT02584829,Phase Ib/II,Suspended,"[{'id': 3156, 'therapyName': 'IFN-B'}, {'id': 3144, 'therapyName': 'Avelumab'}]",Localized Radiation Therapy or Recombinant Interferon Beta and MSB0010718C With or Without Cellular Adoptive Immunotherapy in Treating Patients With Metastatic Merkel Cell Carcinoma,7952
22,NCT02603432,Phase III,Recruiting,"[{'id': 3144, 'therapyName': 'Avelumab'}]",A Study Of Avelumab In Patients With Locally Advanced Or Metastatic Urothelial Cancer (JAVELIN Bladder 100),7952
23,NCT03050554,Phase Ib/II,Recruiting,"[{'id': 3144, 'therapyName': 'Avelumab'}]",Stereotactic Body Radiation Therapy (SBRT) Combined With Avelumab (Anti-PD-L1) for Management of Early Stage Non-Small Cell Lung Cancer (NSCLC),7952
24,NCT03267836,Phase I,Not yet recruiting,"[{'id': 3144, 'therapyName': 'Avelumab'}]",Neoadjuvant Avelumab and Hypofractionated Proton Radiation Therapy Followed by Surgery for Recurrent Radiation-refractory Meningioma,7952
25,NCT02915523,Phase Ib/II,Recruiting,"[{'id': 3144, 'therapyName': 'Avelumab'}, {'id': 5559, 'therapyName': 'Avelumab + Entinostat'}]",Phase 1b/2 Study of Avelumab With or Without Entinostat in Patients With Advanced Epithelial Ovarian Cancer,7952
26,NCT02859454,Phase II,Recruiting,"[{'id': 3144, 'therapyName': 'Avelumab'}]",Avelumab for People With Recurrent Respiratory Papillomatosis,7952
27,NCT01772004,Phase I,Recruiting,"[{'id': 3144, 'therapyName': 'Avelumab'}]",Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor),7952
28,NCT02584634,Phase I,Recruiting,"[{'id': 706, 'therapyName': 'Crizotinib'}, {'id': 3144, 'therapyName': 'Avelumab'}, {'id': 869, 'therapyName': 'PF-06463922'}]","Study to Evaluate Safety, Efficacy, Pharmacokinetics And Pharmacodynamics Of Avelumab In Combination With Either Crizotinib Or PF-06463922 In Patients With NSCLC. (Javelin Lung 101)",7952
29,NCT02580058,Phase III,"Active, not recruiting","[{'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 3144, 'therapyName': 'Avelumab'}]",A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer,7952
30,NCT03047473,Phase II,Recruiting,"[{'id': 3144, 'therapyName': 'Avelumab'}]",Avelumab in Patients With Newly Diagnosed Glioblastoma Multiforme (SEJ),7952
31,NCT03278405,Phase Ib/II,Not yet recruiting,"[{'id': 3144, 'therapyName': 'Avelumab'}]",Avelumab in G3 NEC (NET-001),7952
32,NCT02943317,Phase I,Recruiting,"[{'id': 958, 'therapyName': 'VS-6063'}, {'id': 3144, 'therapyName': 'Avelumab'}]","Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of Defactinib in Combination With Avelumab in Epithelial Ovarian Cancer",7952
33,NCT02684006,Phase III,Recruiting,"[{'id': 3145, 'therapyName': 'Avelumab + Axitinib'}, {'id': 930, 'therapyName': 'Sunitinib'}]",A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer (JAVELIN Renal 101),7952
34,NCT02493751,Phase I,"Active, not recruiting","[{'id': 3145, 'therapyName': 'Avelumab + Axitinib'}]",A Study Of Avelumab In Combination With Axitinib In Advanced Renal Cell Cancer,7952
35,NCT02953561,Phase Ib/II,Recruiting,"[{'id': 5372, 'therapyName': 'Avelumab + Azacitidine'}]",Avelumab (antiPDL1) and Azacytidine in Acute Myeloid Leukemia (AML),7952
36,NCT02951156,Phase III,Recruiting,"[{'id': 5088, 'therapyName': 'Avelumab + Azacitidine + Utomilumab'}, {'id': 5087, 'therapyName': 'Avelumab + Rituximab + Utomilumab'}, {'id': 2323, 'therapyName': 'Bendamustine + Rituximab'}, {'id': 5090, 'therapyName': 'Gemcitabine + Oxaliplatin + Rituximab'}, {'id': 5089, 'therapyName': 'Avelumab + Bendamustine + Rituximab'}]","Avelumab In Combination Regimens That Include An Immune Agonist, Epigenetic Modulator, CD20 Antagonist and/or Conventional Chemotherapy in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)",7952
37,NCT03217747,Phase Ib/II,Recruiting,"[{'id': 5052, 'therapyName': 'Avelumab + Cisplatin'}, {'id': 6044, 'therapyName': 'Avelumab + PF-04518600 + Utomilumab'}, {'id': 6043, 'therapyName': 'Avelumab + Utomilumab'}, {'id': 6045, 'therapyName': 'Avelumab + PF-04518600'}]",Study to Evaluate the Safety and Tolerability of Avelumab in Combination With Other Anti-Cancer Therapies in Patients With Advanced Malignancies,7952
38,NCT02952586,Phase III,Recruiting,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 5052, 'therapyName': 'Avelumab + Cisplatin'}]",Study To Compare Avelumab In Combination With Standard of Care Chemoradiotherapy (SoC CRT) Versus SoC CRT for Definitive Treatment In Patients With Locally Advanced Squamous Cell Carcinoma Of The Head And Neck (JAVELIN HEAD AND NECK 100),7952
39,NCT03258398,Phase II,Recruiting,"[{'id': 6238, 'therapyName': 'Avelumab + eFT508'}, {'id': 4005, 'therapyName': 'eFT508'}]",A Study to Evaluate eFT508 Alone and in Combination With Avelumab in Subjects With MSS Colorectal Cancer,7952
40,NCT02994953,Phase I,Recruiting,"[{'id': 5131, 'therapyName': 'Avelumab + NHS-IL12'}]","A Phase Ib Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Avelumab in Combination With M9241(NHS-IL12)",7952
41,NCT03074318,Phase Ib/II,Recruiting,"[{'id': 5444, 'therapyName': 'Avelumab + trabectedin'}]",Avelumab and Trabectedin in Treating Patients With Liposarcoma or Leiomyosarcoma That is Metastatic or Cannot Be Removed by Surgery,7952
42,NCT02554812,Phase I,Recruiting,"[{'id': 6043, 'therapyName': 'Avelumab + Utomilumab'}]",A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley),7952
43,NCT03268057,Phase Ib/II,Recruiting,"[{'id': 6153, 'therapyName': 'Avelumab + VX15/2503'}]",VX15/2503 in Combination With Avelumab in Advanced Non-small Cell Lung Cancer,7952
44,NCT03147287,Phase II,Recruiting,"[{'id': 850, 'therapyName': 'Palbociclib'}, {'id': 3205, 'therapyName': 'Fulvestrant + Palbociclib'}, {'id': 5684, 'therapyName': 'Fulvestrant + Palbociclib + Avelumab'}, {'id': 744, 'therapyName': 'Fulvestrant'}]",Palbociclib After CDK and Endocrine Therapy (PACE),7952
0,NCT03094169,Phase I,Recruiting,"[{'id': 5755, 'therapyName': 'AVID100'}]",AVID100 in Advanced Epithelial Carcinomas,8776
0,NCT01526473,Phase I,"Active, not recruiting","[{'id': 1068, 'therapyName': 'AVX901'}]",A Phase I Study To Evaluate The Antitumor Activity And Safety Of AVX901,7185
0,NCT02684006,Phase III,Recruiting,"[{'id': 3145, 'therapyName': 'Avelumab + Axitinib'}, {'id': 930, 'therapyName': 'Sunitinib'}]",A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer (JAVELIN Renal 101),4739
1,NCT02493751,Phase I,"Active, not recruiting","[{'id': 3145, 'therapyName': 'Avelumab + Axitinib'}]",A Study Of Avelumab In Combination With Axitinib In Advanced Renal Cell Cancer,4739
2,NCT01649180,Phase II,Terminated,"[{'id': 649, 'therapyName': 'Axitinib'}]",NEXT: Subsequent Exposure to Tyrosine Kinase Inhibition at Recurrence After Adjuvant Therapy in Renal Cell Carcinoma (PrE0801),4739
3,NCT01967576,Phase II,"Active, not recruiting","[{'id': 649, 'therapyName': 'Axitinib'}]","Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Metastatic, Recurrent or Primary Unresectable Pheochromocytoma/Paraganglioma",4739
4,NCT02667886,Phase Ib/II,Recruiting,"[{'id': 649, 'therapyName': 'Axitinib'}, {'id': 3570, 'therapyName': 'X4P-001'}]",Trial of X4P-001 in Patients With Advanced Renal Cell Carcinoma,4739
5,NCT02129647,Phase II,Recruiting,"[{'id': 649, 'therapyName': 'Axitinib'}]",Study of Axitinib in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas,4739
6,NCT03092856,Phase II,Recruiting,"[{'id': 649, 'therapyName': 'Axitinib'}, {'id': 5522, 'therapyName': 'Axitinib + PF-04518600'}]",Axitinib With or Without Anti-OX40 Antibody PF-04518600 in Treating Patients With Metastatic Kidney Cancer,4739
7,NCT00828919,Phase I,"Active, not recruiting","[{'id': 649, 'therapyName': 'Axitinib'}]",Continuing Access To AG- 013736 (A406) For Patients Previously Receiving AG 013736 In Clinical Trials,4739
8,NCT01540526,Phase I,Completed,"[{'id': 649, 'therapyName': 'Axitinib'}]",Pharmacodynamic Study With FLT-PET/CT in Patients With Prostate/Other Solid Malignancies Treated With High Dose Axitinib,4739
9,NCT01321437,Phase II,"Active, not recruiting","[{'id': 649, 'therapyName': 'Axitinib'}]",Study of the Anti-Angiogenesis Agent Axitinib in Patients With Stage III Malignant Melanoma,4739
10,NCT02579811,Phase II,Recruiting,"[{'id': 649, 'therapyName': 'Axitinib'}]",Axitinib Given on an Individualized Schedule for Metastatic Renal Cell Cancer,4739
11,NCT01508117,Phase II,Terminated,"[{'id': 649, 'therapyName': 'Axitinib'}]",Phase II Axitinib (AG-013736) in Elderly Glioblastoma Multiforme (GBM) Patients,4739
12,NCT02762513,Phase II,Recruiting,"[{'id': 649, 'therapyName': 'Axitinib'}]",Expansion Trial for Axitinib In Head And Neck Cancer,4739
13,NCT02164838,Phase I,"Active, not recruiting","[{'id': 649, 'therapyName': 'Axitinib'}]",VEGF Receptor Tyrosine Kinase Inhibitor Axitinib in Children With Recurrent or Refractory Solid Tumors,4739
14,NCT01533948,Phase II,Terminated,"[{'id': 649, 'therapyName': 'Axitinib'}]",Axitinib in Treating Patients With Melanoma That is Metastatic or Cannot Be Removed By Surgery,4739
15,NCT01599754,Phase III,"Active, not recruiting","[{'id': 649, 'therapyName': 'Axitinib'}]",Adjuvant Axitinib Therapy of Renal Cell Cancer in High Risk Patients,4739
16,NCT02693535,Phase II,Recruiting,"[{'id': 1657, 'therapyName': 'Vemurafenib + Cobimetinib'}, {'id': 890, 'therapyName': 'Regorafenib'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 690, 'therapyName': 'Bosutinib'}, {'id': 850, 'therapyName': 'Palbociclib'}, {'id': 694, 'therapyName': 'Cetuximab'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 837, 'therapyName': 'Olaparib'}, {'id': 4, 'therapyName': 'Erlotinib'}]",TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer,4739
17,NCT02788201,Phase II,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1133, 'therapyName': 'Mitomycin C'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1013, 'therapyName': 'epirubicin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1137, 'therapyName': 'Bleomycin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 781, 'therapyName': 'Ixabepilone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 2950, 'therapyName': 'Estramustine'}, {'id': 1941, 'therapyName': 'Floxuridine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 1811, 'therapyName': 'Carmustine'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 953, 'therapyName': 'Vandetanib'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 4419, 'therapyName': 'Toremifine'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 2601, 'therapyName': 'Dactinomycin'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 3035, 'therapyName': 'Chlorambucil'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 342, 'therapyName': 'Vemurafenib'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 2635, 'therapyName': 'Vinblastine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 4305, 'therapyName': 'Teniposide'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 4304, 'therapyName': 'Streptozocin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1231, 'therapyName': 'Bendamustine'}, {'id': 4303, 'therapyName': 'Mechlorethamine'}, {'id': 4302, 'therapyName': 'Mitotane'}]",Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma,4739
18,NCT01409200,Phase II,Recruiting,"[{'id': 649, 'therapyName': 'Axitinib'}]",Neoadjuvant Axitinib in Prostate Cancer,4739
19,NCT02560012,Phase II,Terminated,"[{'id': 735, 'therapyName': 'Everolimus'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 848, 'therapyName': 'Pazopanib'}]",Personalized Targeted Inhibitors Treatment in Renal Cell Cancer,4739
20,NCT02639182,Phase II,Recruiting,"[{'id': 4220, 'therapyName': 'AGS-16C3F'}, {'id': 649, 'therapyName': 'Axitinib'}]",A Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma,4739
21,NCT02551718,Phase I,Recruiting,"[{'id': 690, 'therapyName': 'Bosutinib'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 3160, 'therapyName': 'Nelarabine'}, {'id': 3159, 'therapyName': 'Bexarotene'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 998, 'therapyName': 'cabozantinib'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 877, 'therapyName': 'Ponatinib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 623, 'therapyName': 'Afatinib'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 890, 'therapyName': 'Regorafenib'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 2, 'therapyName': 'Trametinib'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 3, 'therapyName': 'Dabrafenib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 789, 'therapyName': 'Ceritinib'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1571, 'therapyName': 'Cabazitaxel'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1327, 'therapyName': 'Pralatrexate'}]",High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia,4739
22,NCT01727336,Phase II,"Active, not recruiting","[{'id': 1245, 'therapyName': 'Dalantercept + Axitinib'}, {'id': 649, 'therapyName': 'Axitinib'}]", Study of Dalantercept in Patients With Advanced Renal Cell Carcinoma,4739
23,NCT02782403,Phase Ib/II,Recruiting,"[{'id': 4241, 'therapyName': 'Axitinib + Bosutinib'}]","Axitinib and Bosutinib for Patients With Chronic Myeloid Leukemia in Chronic, Accelerated or Blastic Phases",4739
24,NCT01999972,Phase I,"Active, not recruiting","[{'id': 1350, 'therapyName': 'Axitinib + Crizotinib'}]",A Phase 1b Study Of Axitinib In Combination With Crizotinib In Patients With Advanced Solid Tumors,4739
25,NCT03172754,Phase Ib/II,Recruiting,"[{'id': 5837, 'therapyName': 'Axitinib + Nivolumab'}]",Study of Nivolumab and Axitinib in Patients With Advanced Renal Cell Carcinoma,4739
26,NCT02133742,Phase I,"Active, not recruiting","[{'id': 2494, 'therapyName': 'Axitinib + Pembrolizumab'}]","A Dose Finding Study To Evaluate Safety, Drug Interaction, Tumor Markers Of Axitinib In Combination With MK-3475 In Adult Patients With Previously Untreated Advanced Renal Cell Cancer",4739
27,NCT02636725,Phase II,Recruiting,"[{'id': 2494, 'therapyName': 'Axitinib + Pembrolizumab'}]",Axitinib and Pembrolizumab in Subjects With Advanced Alveolar Soft Part Sarcoma and Other Soft Tissue Sarcomas,4739
28,NCT02853331,Phase III,Recruiting,"[{'id': 2494, 'therapyName': 'Axitinib + Pembrolizumab'}, {'id': 930, 'therapyName': 'Sunitinib'}]",Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Axitinib Versus Sunitinib Monotherapy in Participants With Renal Cell Carcinoma (MK-3475-426/KEYNOTE-426),4739
29,NCT02535533,Phase I,Recruiting,"[{'id': 3474, 'therapyName': 'Axitinib + Selenomethionine'}]",SLM + Axitinib for Clear Cell RCC,4739
0,NCT01721577,Phase Ib/II,Unknown status,"[{'id': 2745, 'therapyName': 'AXL1717'}]",Phase I/II Trial of Safety and Anti-tumor Efficacy of AXL1717(Picropodophyllin) in the Treatment of Recurrent Malignant Astrocytomas,7697
0,NCT02250326,Phase II,"Active, not recruiting","[{'id': 1950, 'therapyName': 'Abraxane + Azacitidine'}, {'id': 619, 'therapyName': 'Abraxane'}]",Safety and Efficacy Study of Nab-Paclitaxel With CC-486 and Nab-Paclitaxel Monotherapy as Second Line Treatment for Advanced Nonsquamous Non-small Cell Lung Cancer,917
1,NCT02677922,Phase Ib/II,Recruiting,"[{'id': 4002, 'therapyName': 'AG-120 + Azacitidine'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 4003, 'therapyName': 'Azacitidine + Enasidenib'}]",A Safety and Efficacy Study of Oral AG-120 Plus Subcutaneous Azacitidine and Oral AG-221 Plus Subcutaneous Azacitidine in Subjects With Newly Diagnosed Acute Myeloid Leukemia (AML),917
2,NCT03173248,Phase III,Recruiting,"[{'id': 4002, 'therapyName': 'AG-120 + Azacitidine'}, {'id': 1491, 'therapyName': 'AG-120'}]",Study of AG-120 (Ivosidenib) vs. Placebo in Combination With Azacitidine in Patients With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation (AGILE),917
3,NCT03072043,Phase Ib/II,Recruiting,"[{'id': 5445, 'therapyName': 'APR-246 + Azacitidine'}]",Phase 1b/2 Safety and Efficacy of APR-246 w/Azacitidine for tx of TP53 Mutant Myeloid Neoplasms,917
4,NCT02953561,Phase Ib/II,Recruiting,"[{'id': 5372, 'therapyName': 'Avelumab + Azacitidine'}]",Avelumab (antiPDL1) and Azacytidine in Acute Myeloid Leukemia (AML),917
5,NCT02951156,Phase III,Recruiting,"[{'id': 5088, 'therapyName': 'Avelumab + Azacitidine + Utomilumab'}, {'id': 5087, 'therapyName': 'Avelumab + Rituximab + Utomilumab'}, {'id': 2323, 'therapyName': 'Bendamustine + Rituximab'}, {'id': 5090, 'therapyName': 'Gemcitabine + Oxaliplatin + Rituximab'}, {'id': 5089, 'therapyName': 'Avelumab + Bendamustine + Rituximab'}]","Avelumab In Combination Regimens That Include An Immune Agonist, Epigenetic Modulator, CD20 Antagonist and/or Conventional Chemotherapy in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)",917
6,NCT02269943,Phase II,"Active, not recruiting","[{'id': 651, 'therapyName': 'Azacitidine'}]",Safety and Efficacy of Oral Azacitidine in Previously Treated Subjects With Locally Advanced or Metastatic Nasopharyngeal Carcinoma,917
7,NCT02942290,Phase II,Recruiting,"[{'id': 651, 'therapyName': 'Azacitidine'}, {'id': 1637, 'therapyName': 'GDC-0199 + Azacitidine'}]",A Study Evaluating Venetoclax in Combination With Azacitidine Compared With Azacitidine Alone in Participants With Previously Untreated Higher-Risk Myelodysplastic Syndromes (MDS),917
8,NCT02088541,Phase II,"Active, not recruiting","[{'id': 712, 'therapyName': 'Cytarabine'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 1749, 'therapyName': 'Selinexor'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}]",Selinexor (KPT-330) in Older Patients With Relapsed AML,917
9,NCT02701673,Phase Ib/II,Withdrawn,"[{'id': 651, 'therapyName': 'Azacitidine'}, {'id': 3277, 'therapyName': 'Pyridoxine'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1078, 'therapyName': 'Belinostat'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1207, 'therapyName': 'Melphalan'}]",Belinostat Combined With Azacitidine/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Refractory or Relapsed Lymphoma,917
10,NCT02775903,Phase II,Recruiting,"[{'id': 651, 'therapyName': 'Azacitidine'}, {'id': 4178, 'therapyName': 'Azacitidine + MEDI4736'}]",An Efficacy and Safety Study of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects With Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly Subjects With Acute Myeloid Leukemia (AML),917
11,NCT02920008,Phase III,Recruiting,"[{'id': 650, 'therapyName': 'Decitabine'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1949, 'therapyName': 'SGI-110'}]","Phase 3 Randomized, Open-Label Study of Guadecitabine vs Treatment Choice in Previously Treated Acute Myeloid Leukemia",917
12,NCT01787487,Phase III,Recruiting,"[{'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}]",Evaluation of RUX and AZA Combination as a Therapy For Patients With Myelofibrosis And Myelodysplastic Syndrome/ Myeloproliferative Neoplasm,917
13,NCT01720225,Phase II,"Active, not recruiting","[{'id': 650, 'therapyName': 'Decitabine'}, {'id': 651, 'therapyName': 'Azacitidine'}]",Decitabine Versus Azacitidine in Myelodysplastic Syndrome Patients With Low and Intermediate-1 Risk,917
14,NCT02343536,Phase I,Recruiting,"[{'id': 2488, 'therapyName': 'Cyclophosphamide + Prednisone + Rituximab + Vincristine'}, {'id': 651, 'therapyName': 'Azacitidine'}]","A Phase 1, Open-label,Trial of Oral Azacitidine (CC-486) Plus R-CHOP in Subjects With Large B-Cell Lymphoma or Follicular Lymphoma",917
15,NCT02530463,Phase II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 779, 'therapyName': 'Ipilimumab'}]",Nivolumab and Ipilimumab With 5-azacitidine in Patients With Myelodysplastic Syndromes (MDS),917
16,NCT03151304,Phase II,Recruiting,"[{'id': 5987, 'therapyName': 'Azacitidine + Pracinostat'}, {'id': 651, 'therapyName': 'Azacitidine'}]",A Safety and Efficacy Study of Pracinostat and Azacitidine in Patients With High Risk Myelodysplastic Syndromes,917
17,NCT02348489,Phase III,"Active, not recruiting","[{'id': 1949, 'therapyName': 'SGI-110'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 650, 'therapyName': 'Decitabine'}]","SGI-110 in Adults With Untreated Acute Myeloid Leukemia (AML), Not Considered Candidates for Intensive Remission Induction",917
18,NCT03151408,Phase III,Recruiting,"[{'id': 651, 'therapyName': 'Azacitidine'}, {'id': 5987, 'therapyName': 'Azacitidine + Pracinostat'}]",An Efficacy and Safety Study Of Pracinostat In Combination With Azacitidine In Adults With Acute Myeloid Leukemia,917
19,NCT02469415,Phase II,Terminated,"[{'id': 650, 'therapyName': 'Decitabine'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 2006, 'therapyName': 'Pacritinib'}]",Pacritinib for Patients With Lower-Risk Myelodysplastic Syndromes (MDS),917
20,NCT02508870,Phase I,Recruiting,"[{'id': 651, 'therapyName': 'Azacitidine'}, {'id': 1201, 'therapyName': 'Atezolizumab'}]","A Safety and Pharmacology Study of Atezolizumab (MPDL3280A, Anti-PD-L1 Antibody) Administered Alone or in Combination With Azacitidine in Patients With Myelodysplastic Syndromes",917
21,NCT02721875,Phase I,Terminated,"[{'id': 651, 'therapyName': 'Azacitidine'}, {'id': 957, 'therapyName': 'Volasertib'}]",Trial of Volasertib With or Without Azacitidine in Patients With Myelodysplastic Syndromes,917
22,NCT02400281,Phase Ib/II,Recruiting,"[{'id': 651, 'therapyName': 'Azacitidine'}, {'id': 705, 'therapyName': 'Crenolanib'}, {'id': 1606, 'therapyName': 'Cytarabine + Idarubicin'}]",Study of Crenolanib Combined With Chemotherapy in FLT3-mutated Acute Myeloid Leukemia Patients,917
23,NCT02421939,Phase III,Recruiting,"[{'id': 712, 'therapyName': 'Cytarabine'}, {'id': 3193, 'therapyName': 'Cytarabine + Fludarabine + Idarubicin'}, {'id': 1752, 'therapyName': 'Mitoxantrone + Etoposide + Cytarabine'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 2865, 'therapyName': 'Gilteritinib'}, {'id': 1632, 'therapyName': 'Filgrastim'}]",A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,917
24,NCT01892371,Phase Ib/II,Recruiting,"[{'id': 712, 'therapyName': 'Cytarabine'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 882, 'therapyName': 'Quizartinib'}]",AC220 With 5-Aza or Low Dose Cytarabine,917
25,NCT02599649,Phase II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 2583, 'therapyName': 'Lirilumab '}]",Lirilumab and Nivolumab With 5-Azacitidine in Patients With Myelodysplastic Syndromes (MDS),917
26,NCT02752035,Phase II,Recruiting,"[{'id': 2865, 'therapyName': 'Gilteritinib'}, {'id': 651, 'therapyName': 'Azacitidine'}]","A Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the Treatment of Newly Diagnosed Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation in Patients Not Eligible for Intensive Induction Chemotherapy",917
27,NCT02551718,Phase I,Recruiting,"[{'id': 690, 'therapyName': 'Bosutinib'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 3160, 'therapyName': 'Nelarabine'}, {'id': 3159, 'therapyName': 'Bexarotene'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 998, 'therapyName': 'cabozantinib'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 877, 'therapyName': 'Ponatinib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 623, 'therapyName': 'Afatinib'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 890, 'therapyName': 'Regorafenib'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 2, 'therapyName': 'Trametinib'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 3, 'therapyName': 'Dabrafenib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 789, 'therapyName': 'Ceritinib'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1571, 'therapyName': 'Cabazitaxel'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1327, 'therapyName': 'Pralatrexate'}]",High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia,917
28,NCT02993523,Phase III,Recruiting,"[{'id': 1637, 'therapyName': 'GDC-0199 + Azacitidine'}, {'id': 651, 'therapyName': 'Azacitidine'}]",A Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Treatment Naïve Elderly Subjects With Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy,917
29,NCT03092674,Phase II,Not yet recruiting,"[{'id': 1736, 'therapyName': 'Decitabine + Cytarabine'}, {'id': 2471, 'therapyName': 'Azacitidine + Midostaurin'}, {'id': 3196, 'therapyName': 'Azacitidine + Nivolumab'}, {'id': 651, 'therapyName': 'Azacitidine'}]","Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome",917
30,NCT03164057,Phase II,Recruiting,"[{'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 5153, 'therapyName': 'dexrazoxane'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 651, 'therapyName': 'Azacitidine'}]",A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia,917
31,NCT02129101,Phase I,"Active, not recruiting","[{'id': 651, 'therapyName': 'Azacitidine'}, {'id': 1428, 'therapyName': 'Sonidegib'}]",Azacitidine and Sonidegib in Treating Patients With Myeloid Malignancies,917
32,NCT02374099,Phase II,"Active, not recruiting","[{'id': 651, 'therapyName': 'Azacitidine'}, {'id': 744, 'therapyName': 'Fulvestrant'}]",Study to Assess the Efficacy and Safety of the Epigenetic Modifying Effects of CC-486 (Oral Azacitidine) in Combination With Fulvestrant,917
33,NCT02577406,Phase III,Recruiting,"[{'id': 651, 'therapyName': 'Azacitidine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 2982, 'therapyName': 'Enasidenib'}]",An Efficacy and Safety Study of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects With Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 Mutation (IDHENTIFY),917
34,NCT02204020,Phase II,Withdrawn,"[{'id': 651, 'therapyName': 'Azacitidine'}]",Phase II Study of 5-azacytidine Maintenance After Transplant for AML or MDS,917
35,NCT01814826,Phase I,"Active, not recruiting","[{'id': 1688, 'therapyName': 'MLN4924'}, {'id': 651, 'therapyName': 'Azacitidine'}]",Study of MLN4924 Plus Azacitidine in Treatment-Naïve Patients With Acute Myelogenous Leukemia (AML) Who Are 60 Years or Older,917
36,NCT02265510,Phase I,Recruiting,"[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 1164, 'therapyName': 'lenalidomide'}, {'id': 619, 'therapyName': 'Abraxane'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 2747, 'therapyName': 'INCB052793'}, {'id': 688, 'therapyName': 'Bortezomib'}]","An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies",917
37,NCT00887068,Phase III,"Active, not recruiting","[{'id': 651, 'therapyName': 'Azacitidine'}]",Randomized Allogeneic Azacitidine Study,917
38,NCT02610777,Phase II,"Active, not recruiting","[{'id': 651, 'therapyName': 'Azacitidine'}, {'id': 1688, 'therapyName': 'MLN4924'}]","An Efficacy and Safety Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine in Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML) and Low-Blast Acute Myelogenous Leukemia (AML)",917
39,NCT00946647,Phase II,"Active, not recruiting","[{'id': 1080, 'therapyName': 'Panobinostat'}, {'id': 651, 'therapyName': 'Azacitidine'}]","A Phase Ib/IIb, Open-label, Multi-center, Study of Oral Panobinostat Administered With 5-Azacitidine (in Adult Patients With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML).",917
40,NCT02178072,Phase II,Recruiting,"[{'id': 651, 'therapyName': 'Azacitidine'}]","Window Trial 5-aza in HNSCC, T-tare",917
41,NCT02281084,Phase II,Recruiting,"[{'id': 651, 'therapyName': 'Azacitidine'}, {'id': 4178, 'therapyName': 'Azacitidine + MEDI4736'}]",Safety and Efficacy Study of CC-486 and Durvalumab in Subjects With Myelodysplastic Syndromes,917
42,NCT02788201,Phase II,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1133, 'therapyName': 'Mitomycin C'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1013, 'therapyName': 'epirubicin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1137, 'therapyName': 'Bleomycin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 781, 'therapyName': 'Ixabepilone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 2950, 'therapyName': 'Estramustine'}, {'id': 1941, 'therapyName': 'Floxuridine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 1811, 'therapyName': 'Carmustine'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 953, 'therapyName': 'Vandetanib'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 4419, 'therapyName': 'Toremifine'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 2601, 'therapyName': 'Dactinomycin'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 3035, 'therapyName': 'Chlorambucil'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 342, 'therapyName': 'Vemurafenib'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 2635, 'therapyName': 'Vinblastine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 4305, 'therapyName': 'Teniposide'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 4304, 'therapyName': 'Streptozocin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1231, 'therapyName': 'Bendamustine'}, {'id': 4303, 'therapyName': 'Mechlorethamine'}, {'id': 4302, 'therapyName': 'Mitotane'}]",Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma,917
43,NCT02546986,Phase II,"Active, not recruiting","[{'id': 651, 'therapyName': 'Azacitidine'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Safety and Efficacy Study of CC-486 With MK-3475 to Treat Locally Advanced or Metastatic Non-small Cell Lung Cancer,917
44,NCT01993641,Phase II,Completed,"[{'id': 1758, 'therapyName': 'Pracinostat'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 650, 'therapyName': 'Decitabine'}]",Phase 2 Study Adding Pracinostat to a Hypomethylating Agent (HMA) in Patients With MDS Who Failed to Respond to Single Agent HMA,917
45,NCT01928576,Phase II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 1541, 'therapyName': 'Entinostat'}, {'id': 651, 'therapyName': 'Azacitidine'}]",Phase II Anti-PD1 Epigenetic Priming Study in NSCLC.,917
46,NCT03013998,Phase Ib/II,Recruiting,"[{'id': 4003, 'therapyName': 'Azacitidine + Enasidenib'}, {'id': 5539, 'therapyName': 'Azacitidine + Entospletinib'}, {'id': 5536, 'therapyName': 'Cytarabine + Daunorubicin + Samalizumab'}, {'id': 5538, 'therapyName': 'Azacitidine + BI 836858'}]",Study of Biomarker-Based Treatment of Acute Myeloid Leukemia,917
47,NCT01545947,Phase I,Completed,"[{'id': 1149, 'therapyName': 'Azacitidine + CC-223'}, {'id': 1147, 'therapyName': 'Erlotinib + CC-223'}]"," Study Assessing Safety, Pharmacokinetics and Efficacy of CC-223 With Either Erlotinib or Oral Azacitidine in Advanced Non-Small Cell Lung Cancer",917
48,NCT02954653,Phase I,Recruiting,"[{'id': 6087, 'therapyName': 'PF-06747143'}, {'id': 6092, 'therapyName': 'Cytarabine + Daunorubicin + PF-06747143'}, {'id': 6093, 'therapyName': 'Azacitidine + Decitabine + PF-06747143'}]","A Study Of PF-06747143, As Single Agent Or In Combination With Standard Chemotherapy In Adult Patients With Acute Myeloid Leukemia",917
49,NCT03161223,Phase Ib/II,Not yet recruiting,"[{'id': 5882, 'therapyName': 'Durvalumab + Romidepsin'}, {'id': 4178, 'therapyName': 'Azacitidine + MEDI4736'}, {'id': 5881, 'therapyName': 'Azacitidine + Durvalumab + Romidepsin'}, {'id': 5880, 'therapyName': 'Durvalumab + Pralatrexate + Romidepsin'}]","Durvalumab in Different Combinations With Pralatrexate, Romidepsin and Oral 5-Azacitidine for Lymphoma",917
50,NCT01935947,Phase II,Terminated,"[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 2645, 'therapyName': 'Azacitidine + Entinostat'}, {'id': 2646, 'therapyName': 'Docetaxel + Irinotecan + Pemetrexed '}]",Azacitidine and Entinostat Before Chemotherapy in Treating Patients With Advanced Non-small Cell Lung Cancer,917
51,NCT01305499,Phase II,Recruiting,"[{'id': 2645, 'therapyName': 'Azacitidine + Entinostat'}]",A Trial to Evaluate Two Schedules of MS275 in Combination With 5AC in Elderly Patients With Acute Myeloid Leukemia (AML),917
52,NCT01983969,Phase Ib/II,"Active, not recruiting","[{'id': 897, 'therapyName': 'Rituximab'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 2558, 'therapyName': 'Busulfan + Melphalan'}, {'id': 2557, 'therapyName': 'Azacitidine + Gemcitabine + vorinostat'}]",Aza-SAHA-GBM With AutoSCT for Refractory Lymphoma,917
53,NCT03248479,Phase I,Not yet recruiting,"[{'id': 6133, 'therapyName': 'Azacitidine + Hu5F9-G4'}, {'id': 4947, 'therapyName': 'Hu5F9-G4'}]",Hu5F9-G4 Monotherapy or Hu5F9-G4 in Combination With Azacitidine in Patients With Hematological Malignancies,917
54,NCT02553941,Phase I,Recruiting,"[{'id': 3632, 'therapyName': 'Azacitidine + Ibrutinib'}]",Ibrutinib and Azacitidine for Treatment of Higher Risk Myelodysplastic Syndrome,917
55,NCT02959437,Phase Ib/II,Recruiting,"[{'id': 5477, 'therapyName': 'Azacitidine + INCB024360 + Pembrolizumab'}]",Azacitidine Combined With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors (ECHO-206),917
56,NCT02811497,Phase II,Recruiting,"[{'id': 4178, 'therapyName': 'Azacitidine + MEDI4736'}]",Study of Azacitidine and Durvalumab in Advanced Solid Tumors (METADUR),917
57,NCT02117219,Phase I,Recruiting,"[{'id': 4178, 'therapyName': 'Azacitidine + MEDI4736'}]",Phase 1 Study to Evaluate MEDI4736 in MDS,917
58,NCT01093573,Phase Ib/II,"Active, not recruiting","[{'id': 2471, 'therapyName': 'Azacitidine + Midostaurin'}]",Midostaurin and Azacitidine in Treating Elderly Patients With Acute Myelogenous Leukemia,917
59,NCT03238248,Phase II,Recruiting,"[{'id': 6164, 'therapyName': 'Azacitidine + MLN4924'}]",Pevonedistat and Azacitidine in MDS or MDS/MPN Patients Who Fail Primary Therapy With DNA Methyl Transferase Inhibitors,917
60,NCT02397720,Phase II,Recruiting,"[{'id': 3196, 'therapyName': 'Azacitidine + Nivolumab'}]",A Study of Nivolumab (BMS-936558) in Combination With 5-azacytidine (Vidaza) for the Treatment of Patients With Refractory/ Relapsed Acute Myeloid Leukemia,917
61,NCT03094637,Phase II,Not yet recruiting,"[{'id': 2496, 'therapyName': 'Azacitidine + Pembrolizumab'}]",Azacitidine and Pembrolizumab for Patients With Myelodysplastic Syndrome (MDS),917
62,NCT02900560,Phase II,Recruiting,"[{'id': 2496, 'therapyName': 'Azacitidine + Pembrolizumab'}]",Study of Pembrolizumab With or Without CC-486 in Patients With Platinum-resistant Ovarian Cancer,917
63,NCT02845297,Phase II,Recruiting,"[{'id': 2496, 'therapyName': 'Azacitidine + Pembrolizumab'}]",Phase 2 Study of Azacitidine in Combination With Pembrolizumab in Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients and in Newly Diagnosed Older (?65 Years) AML Patients,917
64,NCT03264404,Phase II,Recruiting,"[{'id': 2496, 'therapyName': 'Azacitidine + Pembrolizumab'}]",Azacitidine and Pembrolizumab in Pancreatic Cancer,917
65,NCT02512172,Phase I,Recruiting,"[{'id': 2496, 'therapyName': 'Azacitidine + Pembrolizumab'}, {'id': 5728, 'therapyName': 'Romidepsin + Pembrolizumab'}, {'id': 5782, 'therapyName': 'Azacitidine + Pembrolizumab + Romidepsin'}]",A Study of Enhancing Response to MK-3475 in Advanced Colorectal Cancer,917
66,NCT02260440,Phase II,"Active, not recruiting","[{'id': 2496, 'therapyName': 'Azacitidine + Pembrolizumab'}]",A Phase 2 Study of MK-3475 in Combination With Azacitidine in Subjects With Chemo-refractory Metastatic Colorectal Cancer,917
67,NCT02816021,Phase II,Recruiting,"[{'id': 2496, 'therapyName': 'Azacitidine + Pembrolizumab'}]",Study of Oral Azacitidine (CC-486) in Combination With Pembrolizumab (MK-3475) in Patients With Metastatic Melanoma,917
68,NCT02367456,Phase Ib/II,Recruiting,"[{'id': 4177, 'therapyName': 'Azacitidine + PF-04449913'}]","A Combination Study of PF-04449913 (Glasdegib) and Azacitidine In 1st Line MDS, AML and CMML Patients",917
69,NCT02829840,Phase Ib/II,Withdrawn,"[{'id': 4464, 'therapyName': 'Azacitidine + Ponatinib'}]","Dose-Escalation Study of Ponatinib, a FLT3 Inhibitor, With and Without Combination of 5-Azacytidine, in Patients With FLT3-Mutated Acute Myeloid Leukemia (AML)",917
70,NCT01926587,Phase Ib/II,Recruiting,"[{'id': 2320, 'therapyName': 'Azacitidine + Regorafenib'}]",Oral Rigosertib in Combination With Azacitidine,917
71,NCT01537744,Phase I,Completed,"[{'id': 1396, 'therapyName': 'Azacitidine + Romidepsin'}]","A Trial of Oral 5-azacitidine in Combination With Romidepsin in Advanced Solid Tumors, With an Expansion Cohort in Non-small Cell Lung Cancer",917
72,NCT01869114,Phase II,Recruiting,"[{'id': 2233, 'therapyName': 'Azacitidine + Sirolimus'}]",Sirolimus and Azacitidine in Treating Patients With High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia That is Recurrent or Not Eligible for Intensive Chemotherapy,917
73,NCT01812252,Phase II,Recruiting,"[{'id': 1606, 'therapyName': 'Cytarabine + Idarubicin'}, {'id': 1798, 'therapyName': 'Decitabine + Azacitidine'}]",Chemotherapy in Treating Patients With Myelodysplastic Syndrome Before Donor Stem Cell Transplant,917
74,NCT02719574,Phase I,Recruiting,"[{'id': 4336, 'therapyName': 'FT-2102'}, {'id': 4449, 'therapyName': 'FT-2102 + Azacitidine'}]",Dose-Escalation Study of FT-2102 as a Single Agent and in Combination With Azacitidine in Patients With AML or MDS With an IDH1 Mutation,917
75,NCT02203773,Phase I,"Active, not recruiting","[{'id': 1636, 'therapyName': 'GDC-0199 + Decitabine'}, {'id': 1637, 'therapyName': 'GDC-0199 + Azacitidine'}]",Phase 1b Acute Myelogenous Leukemia (AML) Study With ABT-199 + Decitabine or Azacitidine (Chemo Combo),917
76,NCT02966782,Phase I,Recruiting,"[{'id': 1637, 'therapyName': 'GDC-0199 + Azacitidine'}, {'id': 1562, 'therapyName': 'Venetoclax'}]",A Study Evaluating Venetoclax Alone and in Combination With Azacitidine in Subjects With Higher-Risk Myelodysplastic Syndromes (MDS) After Hypomethylating Agent-Failure,917
77,NCT03019003,Phase Ib/II,Recruiting,"[{'id': 5199, 'therapyName': 'MEDI4736 + Azacitidine + Tremelimumab'}]","A Phase IB/II Study With Azacitidine, Durvalumab, and Tremelimumab in Recurrent and/or Metastatic Head and Neck Cancer Patients",917
78,NCT02196857,Phase II,Recruiting,"[{'id': 1633, 'therapyName': 'Sorafenib + Azacitidine'}]",Sorafenib Plus 5-Azacitidine Initial Therapy of Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MS) With FLT3-ITD Mutation,917
0,NCT02588105,Phase I,Recruiting,"[{'id': 837, 'therapyName': 'Olaparib'}, {'id': 3557, 'therapyName': 'AZD0156'}]",Study to Assess the Safety and Preliminary Efficacy of AZD0156 at Increasing Doses Alone or in Combination With Other Anti-cancer Treatment in Patients With Advanced Cancer,8135
0,NCT03217838,Phase Ib/II,Recruiting,"[{'id': 3547, 'therapyName': 'AZD2811'}]","Safety, Tolerability, and Efficacy of AZD2811 Nanoparticles in Patients With Relapsed AML/High-Risk Myelodysplastic Syndrome or Treatment-Naïve Patients.",8130
1,NCT02579226,Phase I,Recruiting,"[{'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 3547, 'therapyName': 'AZD2811'}]","A Phase I Study of Safety, Tolerability, and PK of AZD2811 in Patients With Advanced Solid Tumors",8130
0,NCT02228369,Phase I,"Active, not recruiting","[{'id': 660, 'therapyName': 'AZD9291'}, {'id': 2912, 'therapyName': 'AZD3759'}]","Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors, AZD3759 or AZD9291, in Patients Who Have Advanced Non-Small Cell Lung Cancer",7835
0,NCT02546661,Phase I,Recruiting,"[{'id': 654, 'therapyName': 'AZD4547'}, {'id': 1356, 'therapyName': 'Durvalumab'}]","Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer",6857
1,NCT02154490,Phase II,Recruiting,"[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 850, 'therapyName': 'Palbociclib'}, {'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 654, 'therapyName': 'AZD4547'}, {'id': 1016, 'therapyName': 'GDC-0032'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 629, 'therapyName': 'AMG102'}]",Lung-MAP: S1400 Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IIIB-IV Squamous Cell Lung Cancer,6857
2,NCT02465060,Phase II,Recruiting,"[{'id': 660, 'therapyName': 'AZD9291'}, {'id': 3, 'therapyName': 'Dabrafenib'}, {'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 2, 'therapyName': 'Trametinib'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 623, 'therapyName': 'Afatinib'}, {'id': 654, 'therapyName': 'AZD4547'}, {'id': 958, 'therapyName': 'VS-6063'}, {'id': 765, 'therapyName': 'GSK2636771'}]",NCI-MATCH Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas,6857
0,NCT02740985,Phase I,Recruiting,"[{'id': 4223, 'therapyName': 'AZD4635'}, {'id': 4349, 'therapyName': 'AZD4635 + MEDI4736'}]",A Phase 1 Clinical Study of AZD4635 and Durvalumab in Patients With Advanced Solid Malignancies,8381
0,NCT03101839,Phase I,Recruiting,"[{'id': 5914, 'therapyName': 'AZD4785'}]",Phase I Dose-Escalation Study of AZD4785 in Patients With Advanced Solid Tumours,8858
0,NCT02583477,Phase Ib/II,Recruiting,"[{'id': 3099, 'therapyName': 'AZD5069 + MEDI4736'}, {'id': 3163, 'therapyName': 'Gemcitabine + MEDI4736 + nab-paclitaxel'}]",Phase Ib/II Study of MEDI4736 Evaluated in Different Combinations in Metastatic Pancreatic Ductal Carcinoma,7937
1,NCT02499328,Phase Ib/II,Recruiting,"[{'id': 3098, 'therapyName': 'AZD9150 + MEDI4736'}, {'id': 3099, 'therapyName': 'AZD5069 + MEDI4736'}, {'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 2782, 'therapyName': 'AZD9150 '}]",Study to Assess Combination of MEDI4736 With Either AZD9150 or AZD5069 in Patients With Metastatic Squamous Cell Carcinoma of Head and Neck,7937
0,NCT03205176,Phase I,Recruiting,"[{'id': 4910, 'therapyName': 'AZD5153'}]",Phase I Study of AZD5153 in Patients With Relapsed or Refractory Solid Tumors and Lymphomas,8576
0,NCT01226316,Phase I,Recruiting,"[{'id': 655, 'therapyName': 'AZD5363'}]","Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules",6858
1,NCT02208375,Phase Ib/II,Recruiting,"[{'id': 837, 'therapyName': 'Olaparib'}, {'id': 655, 'therapyName': 'AZD5363'}, {'id': 991, 'therapyName': 'Vistusertib'}]",mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian Cancer,6858
2,NCT02576444,Phase II,Recruiting,"[{'id': 3140, 'therapyName': 'MK-1775 + Olaparib'}, {'id': 837, 'therapyName': 'Olaparib'}, {'id': 3141, 'therapyName': 'Olaparib + Vistusertib'}, {'id': 3139, 'therapyName': 'AZD5363 + Olaparib'}]",OLAParib COmbinations,6858
3,NCT01625286,Phase Ib/II,"Active, not recruiting","[{'id': 2192, 'therapyName': 'AZD5363 + Paclitaxel'}]","Investigating Safety, Tolerability and Efficacy of AZD5363 When Combined With Paclitaxel in Breast Cancer Patients",6858
0,NCT02264678,Phase Ib/II,Recruiting,"[{'id': 2881, 'therapyName': 'AZD6738'}, {'id': 4737, 'therapyName': 'AZD6738 + Carboplatin'}, {'id': 4738, 'therapyName': 'AZD6738 + MEDI4736'}, {'id': 4739, 'therapyName': 'AZD6738 + Olaparib'}]",Ascending Doses of AZD6738 in Combination With Chemotherapy and/or Novel Anti Cancer Agents,7813
1,NCT03022409,Phase I,Not yet recruiting,"[{'id': 837, 'therapyName': 'Olaparib'}, {'id': 2881, 'therapyName': 'AZD6738'}]",A Study to Investigate Biomarker Effects of Pre-Surgical Treatment With DNA Damage Repair (DDR) Agents in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC),7813
0,NCT01884285,Phase I,Recruiting,"[{'id': 992, 'therapyName': 'AZD8186'}]",AZD8186 First Time In Patient Ascending Dose Study,7108
1,NCT03218826,Phase I,Not yet recruiting,"[{'id': 6046, 'therapyName': 'AZD8186 + Docetaxel'}]",PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery,7108
0,NCT02260661,Phase I,Completed,"[{'id': 744, 'therapyName': 'Fulvestrant'}, {'id': 2013, 'therapyName': 'AZD8835'}]","Phase I, Dose Study to Look at the Safety and Pharmacokinetics of AZD8835 in Patients With Advanced Solid Tumours",7382
0,NCT02499328,Phase Ib/II,Recruiting,"[{'id': 3098, 'therapyName': 'AZD9150 + MEDI4736'}, {'id': 3099, 'therapyName': 'AZD5069 + MEDI4736'}, {'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 2782, 'therapyName': 'AZD9150 '}]",Study to Assess Combination of MEDI4736 With Either AZD9150 or AZD5069 in Patients With Metastatic Squamous Cell Carcinoma of Head and Neck,7733
1,NCT02417753,Phase II,Terminated,"[{'id': 2782, 'therapyName': 'AZD9150 '}]","AZD9150, a STAT3 Antisense Oligonucleotide, in People With Malignant Ascites",7733
2,NCT02983578,Phase II,Recruiting,"[{'id': 3098, 'therapyName': 'AZD9150 + MEDI4736'}]","AZD9150 With MEDI4736 in Patients With Advanced Pancreatic, Non-Small Lung and Colorectal Cancer",7733
3,NCT02549651,Phase I,Recruiting,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}, {'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 3098, 'therapyName': 'AZD9150 + MEDI4736'}]",MEDI4736 Alone and in Combination With Tremelimumab or AZD9150 in Adult Subjects With Diffuse Large B-cell Lymphoma (D4190C00023),7733
0,NCT02780713,Phase I,Completed,"[{'id': 2997, 'therapyName': 'AZD9496'}]",A Study to Assess the Pharmacokinetics and Safety of Different Forms and Formulations of AZD9496 in Healthy Subjects (PK),7896
1,NCT02248090,Phase I,"Active, not recruiting","[{'id': 2997, 'therapyName': 'AZD9496'}]",AZD9496 First Time in Patients Ascending Dose Study,7896
0,NCT02401542,Phase II,Recruiting,"[{'id': 2934, 'therapyName': 'B-701'}, {'id': 720, 'therapyName': 'Docetaxel'}]",A Phase 2 Study of B-701 in Treatment of Locally Advanced or Metastatic Urothelial Cell Carcinoma,7852
1,NCT03123055,Phase I,Recruiting,"[{'id': 5615, 'therapyName': 'B-701 + Atezolizumab'}]",A Study of B-701 in Combination With Atezolizumab in Treatment of Locally Advanced or Metastatic Urothelial Cell Carcinoma (U22),7852
2,NCT02925533,Phase I,Terminated,"[{'id': 4831, 'therapyName': 'B-701 + Pembrolizumab'}]",Ph 1B B-701 in Combination With Pembrolizumab in Metastatic Transitional Cell Carcinoma of the Urothelial Tract,7852
0,NCT03250299,Phase I,Recruiting,"[{'id': 4908, 'therapyName': 'BAL101553'}]",Microtubule-Targeted Agent BAL101553 and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma,8575
0,NCT01526096,Phase I,Recruiting,"[{'id': 5985, 'therapyName': 'Basiliximab'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1756, 'therapyName': 'Plerixafor'}, {'id': 1207, 'therapyName': 'Melphalan'}]",Stem Cell Transplantation for Patients With Multiple Myeloma,8880
1,NCT02366728,,Recruiting,"[{'id': 5985, 'therapyName': 'Basiliximab'}, {'id': 1141, 'therapyName': 'Temozolomide'}]",DC Migration Study for Newly-Diagnosed GBM,8880
2,NCT01476839,Phase I,Recruiting,"[{'id': 6258, 'therapyName': 'Basiliximab + 90Y basiliximab + Carmustine + Cytarbine + Etoposide + Melphalan'}]",Radiolabeled Monoclonal Antibody Therapy and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Primary Refractory or Relapsed Hodgkin Lymphoma,8880
0,NCT02651610,Phase II,Withdrawn,"[{'id': 3545, 'therapyName': 'Bavituximab'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]",Taxane Therapy With or Without Bavituximab for the Treatment of HER2-Negative Metastatic Breast Cancer,8128
1,NCT01634685,Phase I,"Active, not recruiting","[{'id': 3684, 'therapyName': 'Bavituximab + Capecitabine'}]","A Phase I Study of Bavituximab, Capecitabine, and Radiation for the Treatment of Rectal Adenocarcinoma",8128
2,NCT02989870,Phase I,Recruiting,"[{'id': 5138, 'therapyName': 'Bavituximab + Sorafenib'}]",Sorafenib and Bavituximab Plus SBRT in Unresectable Hepatocellular Carcinoma,8128
3,NCT03139916,Phase II,Recruiting,"[{'id': 5634, 'therapyName': 'Bavituximab + Temozolomide'}]",Phase II Clinical Trial of Bavituximab With Radiation and Temozolomide for Patients With Newly Diagnosed Glioblastoma,8128
0,NCT02369029,Phase I,Terminated,"[{'id': 2598, 'therapyName': 'BAY 1238097 '}]","BAY1238097, First in Man",7598
0,NCT02746081,Phase I,Recruiting,"[{'id': 3987, 'therapyName': 'BAY 1436032'}]",Phase I Study of BAY1436032 in Isocitrate Dehydrogenase-1 (IDH1)-Mutant Advanced Solid Tumors,8317
0,NCT01728311,Phase I,Completed,"[{'id': 666, 'therapyName': 'BAY1082439'}]",Open Label Study of BAY1082439 in Patients With Advanced Cancer,7060
0,NCT01915576,Phase I,Completed,"[{'id': 994, 'therapyName': 'BAY1125976'}]",Phase I Dose Escalation Study With an Allosteric AKT 1/2 Inhibitor in Patients,7111
0,NCT02345382,Phase I,Completed,"[{'id': 4027, 'therapyName': 'BAY1143572'}]",Phase I Dose Escalation of BAY1143572 in Subjects With Acute Leukemia,8327
1,NCT01938638,Phase I,Completed,"[{'id': 4027, 'therapyName': 'BAY1143572'}]",Open Label Phase I Dose Escalation Study With BAY1143572 in Patients With Advanced Cancer,8327
0,NCT02138812,Phase I,"Active, not recruiting","[{'id': 3448, 'therapyName': 'BAY1161909 + Paclitaxel'}]",Phase I Dose Escalation of Oral BAY1161909 in Combination With Intravenous Paclitaxel,8076
0,NCT02368951,Phase I,Terminated,"[{'id': 2931, 'therapyName': 'BAY1187982'}]","Phase I, Dose-escalation Trial of BAY1187982 in Subjects With Advanced Solid Tumors Known to Express Fibroblast Growth Factor Receptor 2 (FGFR2)",7849
0,NCT02366949,Phase I,Recruiting,"[{'id': 3447, 'therapyName': 'BAY1217389 + Paclitaxel'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]",Phase I Study of Oral BAY 1217389 in Combination With Intravenous Paclitaxel,8077
0,NCT03127735,Phase I,Recruiting,"[{'id': 5698, 'therapyName': 'BAY1436032'}]",BAY1436032 in Patients With Mutant IDH1(mIDH1) Advanced Acute Myeloid Leukemia (AML),8752
0,NCT03188965,Phase I,Recruiting,"[{'id': 5962, 'therapyName': 'BAY1895344'}]",First-in-human Study of ATR Inhibitor BAY1895344 in Patients With Advanced Solid Tumors and Lymphomas,8872
0,NCT02448771,Phase Ib/II,Recruiting,"[{'id': 2738, 'therapyName': 'Bazedoxifene + Palbociclib'}]",A Study of Palbociclib in Combination With Bazedoxifene in Hormone Receptor Positive Breast Cancer,7691
0,NCT02658929,Phase I,Recruiting,"[{'id': 5278, 'therapyName': 'bb2121'}]",Study of bb2121 in Multiple Myeloma,8653
0,NCT02232620,Phase II,Recruiting,"[{'id': 1945, 'therapyName': 'BBI503'}]",A Study of BBI503 in Adult Patients With Advanced Gastrointestinal Stromal Tumors,7367
1,NCT02432326,Phase I,Recruiting,"[{'id': 1945, 'therapyName': 'BBI503'}, {'id': 2057, 'therapyName': 'BBI608'}]",A Study of BBI608 and BBI503 Administered in Combination to Adult Patients With Advanced Solid Tumors,7367
2,NCT02432690,Phase II,"Active, not recruiting","[{'id': 1945, 'therapyName': 'BBI503'}]",A Study of BBI503 in Asymptomatic Recurrent Ovarian Cancer Patients With CA-125 Elevation,7367
3,NCT02232633,Phase II,Recruiting,"[{'id': 1945, 'therapyName': 'BBI503'}]",A Study of BBI503 in Adult Patients With Advanced Hepatobiliary Cancer,7367
4,NCT01781455,Phase Ib/II,Recruiting,"[{'id': 1945, 'therapyName': 'BBI503'}]",A Study of BBI503 in Adult Patients With Advanced Solid Tumors,7367
5,NCT02483247,Phase Ib/II,Recruiting,"[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1945, 'therapyName': 'BBI503'}]",A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer,7367
6,NCT02279719,Phase Ib/II,Recruiting,"[{'id': 920, 'therapyName': 'Sorafenib'}, {'id': 2361, 'therapyName': 'BBI503 + Sorafenib'}, {'id': 2362, 'therapyName': 'BBI608 + Sorafenib'}]","A Study of BBI608 in Combination With Sorafenib, or BBI503 in Combination With Sorafenib in Adult Patients With Hepatocellular Carcinoma",7367
0,NCT02178956,Phase III,"Active, not recruiting","[{'id': 2057, 'therapyName': 'BBI608'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]",A Study of BBI608 Plus Weekly Paclitaxel to Treat Gastric and Gastro-Esophageal Junction Cancer,7413
1,NCT02432326,Phase I,Recruiting,"[{'id': 1945, 'therapyName': 'BBI503'}, {'id': 2057, 'therapyName': 'BBI608'}]",A Study of BBI608 and BBI503 Administered in Combination to Adult Patients With Advanced Solid Tumors,7413
2,NCT02315534,Phase Ib/II,Recruiting,"[{'id': 2057, 'therapyName': 'BBI608'}, {'id': 1141, 'therapyName': 'Temozolomide'}]",A Study of BBI608 in Combination With Temozolomide in Adult Patients With Recurrent or Progressed Glioblastoma,7413
3,NCT02352558,Phase I,"Active, not recruiting","[{'id': 770, 'therapyName': 'Imatinib'}, {'id': 2057, 'therapyName': 'BBI608'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 768, 'therapyName': 'Ibrutinib'}, {'id': 1390, 'therapyName': 'Dexamethasone'}]","A Study of BBI608 in Adult Patients With Advanced, Refractory Hematologic Malignancies",7413
4,NCT01775423,Phase Ib/II,Unknown status,"[{'id': 2057, 'therapyName': 'BBI608'}]",A Study of BBI608 in Adult Patients With Advanced Malignancies,7413
5,NCT02024607,Phase Ib/II,"Active, not recruiting","[{'id': 1597, 'therapyName': 'Capecitabine + Oxaliplatin'}, {'id': 2093, 'therapyName': 'BBI608 + Bevacizumab'}, {'id': 2094, 'therapyName': 'BBI608 + Regorafenib'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 2057, 'therapyName': 'BBI608'}, {'id': 1315, 'therapyName': 'FOLFIRI'}]",A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer,7413
6,NCT02753127,Phase III,Recruiting,"[{'id': 1315, 'therapyName': 'FOLFIRI'}, {'id': 2057, 'therapyName': 'BBI608'}]",A Study of Napabucasin (BBI-608) in Combination With FOLFIRI in Adult Patients With Previously Treated Metastatic Colorectal Cancer (CanStem303C),7413
7,NCT02467361,Phase Ib/II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 2057, 'therapyName': 'BBI608'}]",A Study of BBI608 Administered in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Cancers,7413
8,NCT01776307,Phase II,Recruiting,"[{'id': 2090, 'therapyName': 'BBI608 + Cetuximab'}, {'id': 2091, 'therapyName': 'BBI608 + Capecitabine'}, {'id': 2092, 'therapyName': 'BBI608 + Panitumumab'}]",A Study of BBI608 in Adult Patients With Advanced Colorectal Cancer,7413
9,NCT02231723,Phase I,"Active, not recruiting","[{'id': 2630, 'therapyName': 'BBI608 + Gemcitabine + nab-paclitaxel'}]",A Study of BBI608 in Combination With Gemcitabine and Nab-Paclitaxel in Adult Patients With Metastatic Pancreatic Adenocarcinoma,7413
10,NCT02993731,Phase III,Recruiting,"[{'id': 2630, 'therapyName': 'BBI608 + Gemcitabine + nab-paclitaxel'}, {'id': 1779, 'therapyName': 'Nab-paclitaxel + Gemcitabine'}]",A Study of Napabucasin Plus Nab-Paclitaxel With Gemcitabine in Adult Patients With Metastatic Pancreatic Adenocarcinoma (CanStem111P),7413
11,NCT01325441,Phase Ib/II,Recruiting,"[{'id': 2586, 'therapyName': 'BBI608 + Paclitaxel'}]",A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies,7413
12,NCT02826161,Phase III,Terminated,"[{'id': 2586, 'therapyName': 'BBI608 + Paclitaxel'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]","A Study of Napabucasin (BBI-608) Plus Weekly Paclitaxel Versus Weekly Paclitaxel Alone in Patients With Advanced, Previously Treated, Non-Squamous Non-Small Cell Lung Cancer (CanStem43L)",7413
13,NCT02279719,Phase Ib/II,Recruiting,"[{'id': 920, 'therapyName': 'Sorafenib'}, {'id': 2361, 'therapyName': 'BBI503 + Sorafenib'}, {'id': 2362, 'therapyName': 'BBI608 + Sorafenib'}]","A Study of BBI608 in Combination With Sorafenib, or BBI503 in Combination With Sorafenib in Adult Patients With Hepatocellular Carcinoma",7413
0,NCT03022825,Phase II,Recruiting,"[{'id': 5238, 'therapyName': 'ALT-803 + BCG solution'}]",QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer,8459
1,NCT02792192,Phase Ib/II,Recruiting,"[{'id': 4456, 'therapyName': 'Atezolizumab + BCG solution'}, {'id': 1201, 'therapyName': 'Atezolizumab'}]",Safety and Pharmacology Study of Atezolizumab Alone and in Combination With Bacille Calmette-Guérin (BCG) in High-risk Non-muscle-invasive Bladder Cancer (NMIBC) Participants,8459
2,NCT03091660,Phase III,Recruiting,"[{'id': 5478, 'therapyName': 'BCG Tokyo-172 Strain Solution'}, {'id': 4455, 'therapyName': 'BCG solution'}]",Different Strains of BCG With or Without Vaccine in High Grade Non- Muscle Invasive Bladder Cancer,8459
3,NCT02808143,Phase I,Recruiting,"[{'id': 4457, 'therapyName': 'BCG solution + Pembrolizumab'}]",Pembrolizumab and BCG Solution in Treating Patients With Recurrent Non-Muscle-Invasive Bladder Cancer,8459
0,NCT03091660,Phase III,Recruiting,"[{'id': 5478, 'therapyName': 'BCG Tokyo-172 Strain Solution'}, {'id': 4455, 'therapyName': 'BCG solution'}]",Different Strains of BCG With or Without Vaccine in High Grade Non- Muscle Invasive Bladder Cancer,8704
0,NCT01686165,Phase II,"Active, not recruiting","[{'id': 1078, 'therapyName': 'Belinostat'}, {'id': 897, 'therapyName': 'Rituximab'}]",Belinostat and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed Aggressive B-Cell Non-Hodgkin Lymphoma,7194
1,NCT02142530,Phase I,Recruiting,"[{'id': 1078, 'therapyName': 'Belinostat'}, {'id': 1624, 'therapyName': 'Carfilzomib'}]",Carfilzomib Plus Belinostat in Relapsed/Refractory NHL,7194
2,NCT01273155,Phase I,Recruiting,"[{'id': 1078, 'therapyName': 'Belinostat'}]",Belinostat for Solid Tumors and Lymphomas in Patients With Varying Degrees of Hepatic Dysfunction,7194
3,NCT02679131,Phase I,Recruiting,"[{'id': 1078, 'therapyName': 'Belinostat'}]","To Evaluate Safety and Pharmacokinetics of Belinostat in Patients Who Have Mild, Moderate and Severe Renal Impairment.",7194
4,NCT02680795,Phase I,Recruiting,"[{'id': 1078, 'therapyName': 'Belinostat'}]","To Evaluate the Safety and Pharmacokinetics of Belinostat in Patients Who Have Wild-type, Heterozygous, and Homozygous UGT1A1*28 Genotypes",7194
5,NCT02532192,Phase I,Withdrawn,"[{'id': 897, 'therapyName': 'Rituximab'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1689, 'therapyName': 'Fluconazole'}, {'id': 1078, 'therapyName': 'Belinostat'}]","A Phase Ib Study of Belinostat With RDHAP Chemotherapy (Dexamethasone, Cytarabine, Cisplatinum) in Adults With Relapsed or Refractory Diffuse Large B-cell Lymphoma",7194
6,NCT02701673,Phase Ib/II,Withdrawn,"[{'id': 651, 'therapyName': 'Azacitidine'}, {'id': 3277, 'therapyName': 'Pyridoxine'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1078, 'therapyName': 'Belinostat'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1207, 'therapyName': 'Melphalan'}]",Belinostat Combined With Azacitidine/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Refractory or Relapsed Lymphoma,7194
7,NCT00926640,Phase I,Completed,"[{'id': 1123, 'therapyName': 'Belinostat + Cisplatin + Etoposide'}]",A Phase I Study of Belinostat in Combination With Cisplatin and Etoposide in Adults With Small Cell Lung Carcinoma and Other Advanced Cancers,7194
8,NCT02381548,Phase I,"Active, not recruiting","[{'id': 3197, 'therapyName': 'Belinostat + MK-1775'}]",Phase I Trial of AZD1775 and Belinostat in Treating Patients With Relapsed or Refractory Myeloid Malignancies or Untreated Acute Myeloid Leukemia,7194
9,NCT02875002,Phase I,Not yet recruiting,"[{'id': 4826, 'therapyName': 'Belinostat + Volasertib'}]",Study of Volasertib and Belinostat in Patients With Relapsed and Refractory Aggressive B-cell and T-cell Lymphomas,7194
10,NCT02737046,Phase II,Recruiting,"[{'id': 1299, 'therapyName': 'Interferon alfa-2b '}, {'id': 2624, 'therapyName': 'peginterferon alfa-2b'}, {'id': 4361, 'therapyName': 'Belinostat + Zidovudine'}]",Belinostat Therapy With Zidovudine for Adult T-Cell Leukemia-Lymphoma,7194
0,NCT02048488,Phase Ib/II,"Active, not recruiting","[{'id': 949, 'therapyName': 'TSR-011'}]","A Phase I/IIa Open-Label, Dose Escalation and Cohort Expansion Trial of Oral TSR-011 in Patients With Advanced Solid Tumors and Lymphomas",7038
0,NCT02717624,Phase I,"Active, not recruiting","[{'id': 3996, 'therapyName': 'Acalabrutinib + Bendamustine + Rituximab'}]",A Study of ACP-196 in Combination With Bendamustine and Rituximab in Subjects With Mantle Cell Lymphoma,7225
1,NCT02972840,Phase III,Recruiting,"[{'id': 2323, 'therapyName': 'Bendamustine + Rituximab'}, {'id': 3996, 'therapyName': 'Acalabrutinib + Bendamustine + Rituximab'}]",A Study of Bendamustine and Rituximab Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated Mantle Cell Lymphoma,7225
2,NCT02951156,Phase III,Recruiting,"[{'id': 5088, 'therapyName': 'Avelumab + Azacitidine + Utomilumab'}, {'id': 5087, 'therapyName': 'Avelumab + Rituximab + Utomilumab'}, {'id': 2323, 'therapyName': 'Bendamustine + Rituximab'}, {'id': 5090, 'therapyName': 'Gemcitabine + Oxaliplatin + Rituximab'}, {'id': 5089, 'therapyName': 'Avelumab + Bendamustine + Rituximab'}]","Avelumab In Combination Regimens That Include An Immune Agonist, Epigenetic Modulator, CD20 Antagonist and/or Conventional Chemotherapy in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)",7225
3,NCT01415752,Phase II,Recruiting,"[{'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1231, 'therapyName': 'Bendamustine'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1164, 'therapyName': 'lenalidomide'}]","Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma",7225
4,NCT01871675,Phase I,Completed,"[{'id': 897, 'therapyName': 'Rituximab'}, {'id': 1024, 'therapyName': 'Duvelisib'}, {'id': 1231, 'therapyName': 'Bendamustine'}]","Phase Ib Study of IPI-145 in Combination With Bendamustine, Rituximab or Bendamustine/Rituximab in Hematologic Malignancies",7225
5,NCT02153580,Phase I,"Active, not recruiting","[{'id': 1136, 'therapyName': 'Etoposide'}, {'id': 2291, 'therapyName': 'Cyclophosphamide + Fludarabine'}, {'id': 1231, 'therapyName': 'Bendamustine'}]","Cellular Immunotherapy Following Cyclophosphamide in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia or B-Cell Prolymphocytic Leukemia",7225
6,NCT02018861,Phase I,"Active, not recruiting","[{'id': 2406, 'therapyName': 'INCB039110'}, {'id': 3097, 'therapyName': 'INCB039110 + INCB050465'}, {'id': 1231, 'therapyName': 'Bendamustine'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 2352, 'therapyName': 'Carboplatin + Etoposide + Ifosfamide '}, {'id': 3088, 'therapyName': 'INCB050465 '}]","A Phase 1, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 Monotherapy and in Combination With INCB039110 in Subjects With Previously Treated B-Cell Malignancies",7225
7,NCT02005471,Phase III,"Active, not recruiting","[{'id': 1562, 'therapyName': 'Venetoclax'}, {'id': 1231, 'therapyName': 'Bendamustine'}, {'id': 897, 'therapyName': 'Rituximab'}]",A Study of GDC-0199 (ABT-199) Plus MabThera/Rituxan (Rituximab) Compared With Bendamustine Plus MabThera/Rituxan (Rituximab) in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia,7225
8,NCT02162888,Phase I,Completed,"[{'id': 1231, 'therapyName': 'Bendamustine'}]","A Phase I, Bioequivalence Study to Evaluate Two Formulations of Bendamustine (BDM) Hydrochloride (HCl) Administered to Cancer Patients",7225
9,NCT01326702,Phase Ib/II,Completed,"[{'id': 954, 'therapyName': 'Veliparib'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1231, 'therapyName': 'Bendamustine'}]"," Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors",7225
10,NCT02596971,Phase I,Recruiting,"[{'id': 1975, 'therapyName': 'Atezolizumab + Obinutuzumab'}, {'id': 3266, 'therapyName': 'Cyclophosphamide + Doxorubicin + Prednisone + Vincristine '}, {'id': 1231, 'therapyName': 'Bendamustine'}]",Safety and Efficacy of MPDL3280A in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus CHOP in Patients With Follicular Lymphoma or Diffuse Large B-Cell Lymphoma,7225
11,NCT02788201,Phase II,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1133, 'therapyName': 'Mitomycin C'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1013, 'therapyName': 'epirubicin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1137, 'therapyName': 'Bleomycin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 781, 'therapyName': 'Ixabepilone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 2950, 'therapyName': 'Estramustine'}, {'id': 1941, 'therapyName': 'Floxuridine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 1811, 'therapyName': 'Carmustine'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 953, 'therapyName': 'Vandetanib'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 4419, 'therapyName': 'Toremifine'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 2601, 'therapyName': 'Dactinomycin'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 3035, 'therapyName': 'Chlorambucil'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 342, 'therapyName': 'Vemurafenib'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 2635, 'therapyName': 'Vinblastine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 4305, 'therapyName': 'Teniposide'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 4304, 'therapyName': 'Streptozocin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1231, 'therapyName': 'Bendamustine'}, {'id': 4303, 'therapyName': 'Mechlorethamine'}, {'id': 4302, 'therapyName': 'Mitotane'}]",Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma,7225
12,NCT01286272,Phase II,"Active, not recruiting","[{'id': 3909, 'therapyName': 'Bendamustine + Ofatumumab'}, {'id': 3910, 'therapyName': 'Bendamustine + Bortezomib + Ofatumumab'}]",Ofatumumab and Bendamustine Hydrochloride With or Without Bortezomib in Treating Patients With Untreated Follicular Non-Hodgkin Lymphoma,7225
13,NCT01177683,Phase Ib/II,"Active, not recruiting","[{'id': 3349, 'therapyName': 'Bendamustine + Bortezomib + pegylated liposomal-doxorubicin'}, {'id': 1632, 'therapyName': 'Filgrastim'}]",Bendamustine in Combination With Bortezomib and Pegylated Liposomal Doxorubicin for Multiple Myeloma,7225
14,NCT02130869,Phase I,Recruiting,"[{'id': 2378, 'therapyName': 'Bendamustine + Cytarabine + Etoposide'}, {'id': 2460, 'therapyName': 'Busulfan + Hu14.18K322A'}, {'id': 2459, 'therapyName': 'Aldesleukin + Melphalan + Sargramostim'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1791, 'therapyName': 'Carboplatin + Etoposide'}]",A Pilot Study of Immunotherapy Including Haploidentical NK Cell Infusion Following CD133+ Positively-Selected Autologous Hematopoietic Stem Cells in Children With High Risk Solid Tumors or Lymphomas,7225
15,NCT02240719,Phase I,Recruiting,"[{'id': 2336, 'therapyName': 'Bendamustine + Everolimus'}]",Everolimus and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Hematologic Cancer,7225
16,NCT01671904,Phase I,"Active, not recruiting","[{'id': 3638, 'therapyName': 'Bendamustine + GDC-0199 + Obinutuzumab'}, {'id': 3637, 'therapyName': 'Bendamustine + GDC-0199 + Rituximab'}]","A Study of Venetoclax (GDC-0199, ABT-199) in Combination With Bendamustine And MabThera/Rituxan in Participants With Chronic Lymphocytic Leukemia",7225
17,NCT02187861,Phase II,"Active, not recruiting","[{'id': 2323, 'therapyName': 'Bendamustine + Rituximab'}, {'id': 3637, 'therapyName': 'Bendamustine + GDC-0199 + Rituximab'}, {'id': 3937, 'therapyName': 'GDC-0199 + Rituximab'}]",A Study Evaluating the Safety and Efficacy of GDC-0199 (ABT-199) Plus Bendamustine + Rituximab (BR) in Comparison With BR or GDC-0199 Plus Rituximab in Patients With Relapsed and Refractory Follicular Non-Hodgkin's Lymphoma,7225
18,NCT01980888,Phase III,Terminated,"[{'id': 2324, 'therapyName': 'Bendamustine + Idelalisib + Rituximab'}]",Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab in Subjects With Previously Untreated Chronic Lymphocytic Leukemia,7225
19,NCT02970318,Phase III,Recruiting,"[{'id': 2324, 'therapyName': 'Bendamustine + Idelalisib + Rituximab'}, {'id': 1605, 'therapyName': 'Acalabrutinib'}]",A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL,7225
20,NCT03039114,Phase I,Recruiting,"[{'id': 6260, 'therapyName': 'Bendamustine + INCB050465 + Obinutuzumab'}]",Study Evaluating Safety and Efficacy of INCB050465 Combined With Bendamustine and Obinutuzumab in Relapsed or Refractory Follicular Lymphoma (CITADEL-102),7225
21,NCT02733042,Phase Ib/II,Recruiting,"[{'id': 897, 'therapyName': 'Rituximab'}, {'id': 4278, 'therapyName': 'lenalidomide + MEDI4736 + Rituximab'}, {'id': 4279, 'therapyName': 'Bendamustine + MEDI4736 + Rituximab'}, {'id': 2573, 'therapyName': 'Ibrutinib + MEDI4736'}, {'id': 1356, 'therapyName': 'Durvalumab'}]","A Study to Determine Dose, Safety, and Efficacy of Durvalumab as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocytic Leukemia (FUSION NHL 001)",7225
22,NCT01216683,Phase II,Unknown status,"[{'id': 2323, 'therapyName': 'Bendamustine + Rituximab'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1164, 'therapyName': 'lenalidomide'}]","Bendamustine Hydrochloride and Rituximab With or Without Bortezomib Followed by Rituximab With or Without Lenalidomide in Treating Patients With High-Risk Stage II, Stage III, or Stage IV Follicular Lymphoma",7225
23,NCT02257567,Phase Ib/II,"Active, not recruiting","[{'id': 2323, 'therapyName': 'Bendamustine + Rituximab'}, {'id': 4226, 'therapyName': 'Polatuzumab Vedotin'}, {'id': 1646, 'therapyName': 'Obinutuzumab'}]",A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma,7225
24,NCT01974440,Phase III,"Active, not recruiting","[{'id': 768, 'therapyName': 'Ibrutinib'}, {'id': 2323, 'therapyName': 'Bendamustine + Rituximab'}, {'id': 3266, 'therapyName': 'Cyclophosphamide + Doxorubicin + Prednisone + Vincristine '}]","A Study of PCI-32765 (Ibrutinib) in Combination With Either Bendamustine and Rituximab or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Participants With Previously Treated Indolent Non-Hodgkin Lymphoma",7225
25,NCT02576275,Phase III,Withdrawn,"[{'id': 2323, 'therapyName': 'Bendamustine + Rituximab'}, {'id': 1024, 'therapyName': 'Duvelisib'}]",A Study of Duvelisib in Combination With Rituximab and Bendamustine vs Placebo in Combination With Rituximab and Bendamustine in Subjects With Previously-Treated Indolent Non-Hodgkin Lymphoma (BRAVURA),7225
26,NCT02626455,Phase III,Recruiting,"[{'id': 1631, 'therapyName': 'Vincristine'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 3388, 'therapyName': 'Aldoxorubicin +Cyclophosphamide + Prednisone + Rituximab + Vincristine'}, {'id': 995, 'therapyName': 'Copanlisib'}, {'id': 2323, 'therapyName': 'Bendamustine + Rituximab'}, {'id': 897, 'therapyName': 'Rituximab'}]",Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL),7225
27,NCT01732926,Phase III,Terminated,"[{'id': 1023, 'therapyName': 'Idelalisib'}, {'id': 2323, 'therapyName': 'Bendamustine + Rituximab'}]",Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas,7225
28,NCT02954406,Phase I,Recruiting,"[{'id': 5150, 'therapyName': 'Lenalidomide + TAK-659'}, {'id': 5149, 'therapyName': 'Ibrutinib + TAK-659'}, {'id': 5148, 'therapyName': 'Gemcitabine + TAK-659'}, {'id': 5147, 'therapyName': 'Bendamustine + Rituximab + TAK-659'}, {'id': 5146, 'therapyName': 'Bendamustine + TAK-659'}]","A Study of TAK-659 in Combination With Bendamustine (+/-Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Participants With Advanced Non-Hodgkin Lymphoma",7225
29,NCT01716806,Phase II,Recruiting,"[{'id': 3263, 'therapyName': 'Brentuximab vedotin + Nivolumab'}, {'id': 5055, 'therapyName': 'Brentuximab vedotin + Bendamustine'}, {'id': 5056, 'therapyName': 'Brentuximab vedotin + Dacarbazine'}, {'id': 2486, 'therapyName': 'Brentuximab vedotin'}]",A Study of Brentuximab Vedotin in Adults Age 60 and Above With Newly Diagnosed Hodgkin Lymphoma (HL),7225
30,NCT02927769,Phase II,Recruiting,"[{'id': 3263, 'therapyName': 'Brentuximab vedotin + Nivolumab'}, {'id': 5055, 'therapyName': 'Brentuximab vedotin + Bendamustine'}]","A Study of Nivolumab + Brentuximab Vedotin in Children, Adolescents, and Young Adults With Classic Hodgkin Lymphoma (cHL) After Failure of First Line Therapy, Followed by Brentuximab Vedotin + Bendamustine for Participants With a Suboptimal Response (CheckMate 744)",7225
0,NCT02099058,Phase I,Recruiting,"[{'id': 1743, 'therapyName': 'ABBV-399 + Carboplatin'}, {'id': 1364, 'therapyName': 'ABBV-399 + Erlotinib'}, {'id': 1363, 'therapyName': 'ABBV-399'}, {'id': 1366, 'therapyName': 'ABBV-399 + Bevacizumab'}, {'id': 1365, 'therapyName': 'ABBV-399 + Cetuximab'}]","A Phase 1/1b Study With ABBV-399, an Antibody Drug Conjugate, in Subjects With Advanced Solid Cancer Tumors",107
1,NCT01113476,Phase I,Recruiting,"[{'id': 1144, 'therapyName': 'Abraxane + Avastin + Gemcitabine'}]","Nab-paclitaxel, Gemcitabine, and Bevacizumab in Advanced Malignancies",107
2,NCT00733408,Phase II,"Active, not recruiting","[{'id': 1496, 'therapyName': 'Abraxane + Bevacizumab + Erlotinib'}]",Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab Followed By Bevacizumab and Erlotinib Hydrochloride in Treating Patients With Metastatic Breast Cancer,107
3,NCT02065466,Phase Ib/II,Withdrawn,"[{'id': 1380, 'therapyName': 'Abraxane + Temozolomide + Bevacizumab'}]","Combo of Abraxane, TMZ, Bevacizumab in Metastatic Melanoma With Brain Metastases",107
4,NCT03050814,Phase II,Suspended,"[{'id': 1524, 'therapyName': 'Fluorouracil + Bevacizumab + Capecitabine + Leucovorin + Oxaliplatin'}, {'id': 5336, 'therapyName': 'Ad-CEA + Bevacizumab + FOLFOX'}]",Standard of Care Alone or in Combination With Ad-CEA Vaccine and Avelumab in People With Previously Untreated Metastatic Colorectal Cancer,107
5,NCT00301990,Phase II,Unknown status,"[{'id': 2098, 'therapyName': 'Aldesleukin + Bevacizumab'}]",Bevacizumab and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer,107
6,NCT03074513,Phase II,Recruiting,"[{'id': 4595, 'therapyName': 'Atezolizumab + Bevacizumab'}]",Atezolizumab and Bevacizumab in Rare Solid Tumors,107
7,NCT03133390,Phase II,Recruiting,"[{'id': 4595, 'therapyName': 'Atezolizumab + Bevacizumab'}, {'id': 1201, 'therapyName': 'Atezolizumab'}]",Atezolizumab With or Without Bevacizumab in Cisplatin-ineligible Patients,107
8,NCT03175432,Phase II,Recruiting,"[{'id': 4595, 'therapyName': 'Atezolizumab + Bevacizumab'}]",Study of BEvacizumab in Combination With ATezolizumab in Patients With Untreated Melanoma Brain Metastases  (BEAT-MBM),107
9,NCT03181100,Phase II,Recruiting,"[{'id': 619, 'therapyName': 'Abraxane'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1343, 'therapyName': 'Atezolizumab + Cobimetinib'}, {'id': 4595, 'therapyName': 'Atezolizumab + Bevacizumab'}, {'id': 3049, 'therapyName': 'Atezolizumab + nab-paclitaxel'}, {'id': 4825, 'therapyName': 'Atezolizumab + Vemurafenib + Cobimetinib'}, {'id': 5606, 'therapyName': 'Atezolizumab + Paclitaxel'}]",Atezolizumab Combinations With Chemotherapy for Anaplastic and Poorly Differentiated Thyroid Carcinomas,107
10,NCT02921269,Phase II,Suspended,"[{'id': 4595, 'therapyName': 'Atezolizumab + Bevacizumab'}]","Atezolizumab and Bevacizumab in Treating Patients With Recurrent, Persistent, or Metastatic Cervical Cancer",107
11,NCT02873195,Phase II,Not yet recruiting,"[{'id': 2097, 'therapyName': 'Bevacizumab + Capecitabine'}, {'id': 1202, 'therapyName': 'Atezolizumab + Bevacizumab + Capecitabine'}]",Capecitabine and Bevacizumab With or Without Atezolizumab in Treating Patients With Refractory Metastatic Colorectal Cancer,107
12,NCT01984242,Phase II,"Active, not recruiting","[{'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1202, 'therapyName': 'Atezolizumab + Bevacizumab + Capecitabine'}]",A Phase 2 Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) as Monotherapy or in Combination With Avastin (Bevacizumab) Compared to Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma,107
13,NCT01633970,Phase I,"Active, not recruiting","[{'id': 1203, 'therapyName': 'Atezolizumab + Carboplatin + Paclitaxel'}, {'id': 1204, 'therapyName': 'Atezolizumab + Carboplatin + Pemetrexed'}, {'id': 1202, 'therapyName': 'Atezolizumab + Bevacizumab + Capecitabine'}]",A Phase 1b Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) in Combination With Avastin (Bevacizumab) and/or With Chemotherapy in Patients With Locally Advanced or Metastatic Solid Tumors,107
14,NCT02715531,Phase I,Recruiting,"[{'id': 3947, 'therapyName': 'Atezolizumab + Gemcitabine + nab-paclitaxel'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 1202, 'therapyName': 'Atezolizumab + Bevacizumab + Capecitabine'}]",A Study of the Safety and Tolerability of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors,107
15,NCT02724878,Phase II,Recruiting,"[{'id': 1202, 'therapyName': 'Atezolizumab + Bevacizumab + Capecitabine'}]",Study of Atezolizumab + Bevacizumab in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma,107
16,NCT02366143,Phase III,"Active, not recruiting","[{'id': 2370, 'therapyName': 'Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel'}, {'id': 1489, 'therapyName': 'Nab-paclitaxel + Carboplatin + Bevacizumab'}, {'id': 1203, 'therapyName': 'Atezolizumab + Carboplatin + Paclitaxel'}]",TBAA Phase III Study of MPDL3280A (Anti-PD-L1 Antibody) in Combination With Carboplatin + Paclitaxel With or Without Bevacizumab in Patients With Stage IV Non-squamous Non-small Cell Lung Cancer,107
17,NCT03038100,Phase III,Recruiting,"[{'id': 2370, 'therapyName': 'Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel'}, {'id': 1152, 'therapyName': 'Bevacizumab + Carboplatin + Paclitaxel'}]","A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (IMagyn050)",107
18,NCT02839707,Phase II,Recruiting,"[{'id': 4496, 'therapyName': 'Atezolizumab + Bevacizumab + Doxil'}, {'id': 4495, 'therapyName': 'Atezolizumab + Doxil'}, {'id': 1673, 'therapyName': 'Doxil + Bevacizamub'}]","Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",107
19,NCT03280563,Phase Ib/II,Not yet recruiting,"[{'id': 6269, 'therapyName': 'Atezolizumab + Ipatasertib'}, {'id': 6270, 'therapyName': 'Atezolizumab + Bevacizumab + Exemestane'}, {'id': 1343, 'therapyName': 'Atezolizumab + Cobimetinib'}, {'id': 6271, 'therapyName': 'Atezolizumab + Bevacizumab + Fulvestrant'}, {'id': 6272, 'therapyName': 'Atezolizumab + Bevacizumab + Tamoxifen'}, {'id': 6273, 'therapyName': 'Atezolizumab + Ipatasertib + Fulvestrant'}, {'id': 744, 'therapyName': 'Fulvestrant'}, {'id': 6268, 'therapyName': 'Atezolizumab + Fulvestrant'}]",A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer,107
20,NCT02174172,Phase I,Recruiting,"[{'id': 6252, 'therapyName': 'Atezolizumab + Bevacizumab +Peg-interferon alfa-2a'}, {'id': 6253, 'therapyName': 'Atezolizumab + Interferon alfa-2b'}, {'id': 6250, 'therapyName': 'Atezolizumab + Peg-interferon alfa-2a'}, {'id': 6249, 'therapyName': 'Atezolizumab + Ipilimumab'}, {'id': 1975, 'therapyName': 'Atezolizumab + Obinutuzumab'}]",A Study to Assess the Safety and Tolerability of MPDL3280A in Combination With Other Immune-modulating Therapies in Patients With Locally Advanced or Metastatic Solid Tumors,107
21,NCT03024437,Phase Ib/II,"Active, not recruiting","[{'id': 5129, 'therapyName': 'Entinostat + Atezolizumab'}, {'id': 5235, 'therapyName': 'Atezolizumab + Entinostat + Bevacizumab'}, {'id': 1201, 'therapyName': 'Atezolizumab'}]",Atezolizumab in Combination With Entinostat and Bevacizumab in Patients With Advanced Renal Cell Carcinoma,107
22,NCT01884740,Phase Ib/II,Recruiting,"[{'id': 1654, 'therapyName': 'Avastin + Cetuximab'}]",Phase I/II Trial Of Super-Selective Intraarterial Infusion Of Erbitux and Bevacizumab For Treatment Of Relapsed/Refractory Intracranial Glioma In Patients Under 22 Years Of Age,107
23,NCT02024607,Phase Ib/II,"Active, not recruiting","[{'id': 1597, 'therapyName': 'Capecitabine + Oxaliplatin'}, {'id': 2093, 'therapyName': 'BBI608 + Bevacizumab'}, {'id': 2094, 'therapyName': 'BBI608 + Regorafenib'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 2057, 'therapyName': 'BBI608'}, {'id': 1315, 'therapyName': 'FOLFIRI'}]",A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer,107
24,NCT01532089,Phase II,"Active, not recruiting","[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 4, 'therapyName': 'Erlotinib'}]",Erlotinib With or Without Bevacizumab in Treating Patients With Stage IV Non-Small Cell Lung Cancer With EGFR Mutations,107
25,NCT01937715,Phase II,Terminated,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1040, 'therapyName': 'PF-05212384'}, {'id': 1315, 'therapyName': 'FOLFIRI'}]",A Study Of PF-05212384 Plus FOLFIRI Versus Bevacizumab Plus FOLFIRI In Metastatic Colorectal Cancer,107
26,NCT01327612,Phase II,"Active, not recruiting","[{'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 746, 'therapyName': 'Ganitumab'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1458, 'therapyName': 'Conatumumab'}]",Open Label Extension Study of Conatumumab and AMG 479,107
27,NCT01967810,Phase II,Completed,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 2053, 'therapyName': 'GRN1005'}]",ANG1005 in Patients With Recurrent High-Grade Glioma,107
28,NCT01700400,Phase I,Completed,"[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 854, 'therapyName': 'Pemetrexed'}]"," Study of Everolimus, Pemetrexed, Carboplatin, and Bevacizumab to Treat Stage IV Lung Cancer",107
29,NCT01765582,Phase II,Terminated,"[{'id': 1523, 'therapyName': 'Fluorouracil + Capecitabine + Irinotecan + Leucovorin + Oxaliplatin'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1484, 'therapyName': 'Bevacizumab + Oxaliplatin + Leucovorin + Fluorouracil'}]",STEAM: A Study of Sequential and Concurrent FOLFOXIRI/Avastin (Bevacizumab) Regimens Versus FOLFOX/Avastin in First-Line in Patients With Metastatic Colorectal Cancer,107
30,NCT01217931,Phase II,"Active, not recruiting","[{'id': 735, 'therapyName': 'Everolimus'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 667, 'therapyName': 'Bevacizumab'}]",Sequential Two-agent Assessment in Renal Cell Carcinoma Therapy,107
31,NCT02606305,Phase I,Recruiting,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 3232, 'therapyName': 'IMGN853'}]","Study of IMGN853 in Comb. With Bevacizumab, Carboplatin or PLD in Adults With FRa + Adv. EOC, Primary Peritoneal, Fallopian Tube, or Endometrial Cancer",107
32,NCT00184015,,"Active, not recruiting","[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 688, 'therapyName': 'Bortezomib'}]","Bortezomib and Bevacizumab (""BB-mib-mab"") in Patients With Advanced or Recurrent Renal Cell Cancer (RCC)",107
33,NCT00828009,Phase II,Unknown status,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 2142, 'therapyName': 'Emepepimut-S  '}, {'id': 1092, 'therapyName': 'Carboplatin'}]",BLP25 Liposome Vaccine and Bevacizumab After Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery,107
34,NCT01305213,Phase Ib/II,Completed,"[{'id': 1186, 'therapyName': 'Fosbretabulin'}, {'id': 667, 'therapyName': 'Bevacizumab'}]","Bevacizumab With or Without Fosbretabulin Tromethamine in Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer",107
35,NCT01648348,Phase Ib/II,"Active, not recruiting","[{'id': 1242, 'therapyName': 'TRC105'}, {'id': 667, 'therapyName': 'Bevacizumab'}]",Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme,107
36,NCT01588431,Phase II,"Active, not recruiting","[{'id': 1987, 'therapyName': 'Cisplatin + Docetaxel + Cetuximab'}, {'id': 667, 'therapyName': 'Bevacizumab'}]",Bevacizumab/Ph 2 for Locally Advanced Head and Neck Cancer,107
37,NCT01083966,Phase I,Suspended,"[{'id': 667, 'therapyName': 'Bevacizumab'}]",Intraarterial Cerebral Infusion of Avastin for Vestibular Schwannoma (Acoustic Neuroma),107
38,NCT01925573,Phase I,Recruiting,"[{'id': 667, 'therapyName': 'Bevacizumab'}]",NOVOTTF-100A+ Bevacizumab+ Hypofractionated Stereotactic Irradiation Bevacizumab-Naive Recurrent Glioblastoma (GCC 1344),107
39,NCT01356290,Phase II,Recruiting,"[{'id': 1475, 'therapyName': 'Thalidomide'}, {'id': 4418, 'therapyName': 'Fenofibrate'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 2124, 'therapyName': 'Celecoxib'}, {'id': 1783, 'therapyName': 'Cyclophosphamide + Cytarabine'}]",Metronomic and Targeted Anti-angiogenesis Therapy for Children With Recurrent/Progressive Medulloblastoma (MEMMAT),107
40,NCT01392209,Phase I,"Active, not recruiting","[{'id': 667, 'therapyName': 'Bevacizumab'}]",Hypofractionated Stereotactic Radiotherapy With Bevacizumab in the Treatment of Recurrent Malignant Glioma,107
41,NCT00461773,Phase II,Unknown status,"[{'id': 794, 'therapyName': 'Letrozole'}, {'id': 667, 'therapyName': 'Bevacizumab'}]",Randomized Phase II Study of Preoperative Letrozole (Femara) in Combination With Avastin in Hormone Receptor Positive Breast Cancer,107
42,NCT01803282,Phase I,Recruiting,"[{'id': 3320, 'therapyName': 'GS-5745'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 1602, 'therapyName': 'Carboplatin + Pemetrexed'}, {'id': 1315, 'therapyName': 'FOLFIRI'}, {'id': 1779, 'therapyName': 'Nab-paclitaxel + Gemcitabine'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 667, 'therapyName': 'Bevacizumab'}]",Safety and Tolerability Study in Solid Tumors,107
43,NCT01588184,Phase III,Recruiting,"[{'id': 667, 'therapyName': 'Bevacizumab'}]",An Extension Study to Provide Continued Avastin Therapy to Patients With Solid Tumours Who Were Previously Enrolled in a Roche/Genentech Sponsored Study,107
44,NCT03136406,Phase Ib/II,Recruiting,"[{'id': 1018, 'therapyName': 'GI-4000'}, {'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 3144, 'therapyName': 'Avelumab'}, {'id': 619, 'therapyName': 'Abraxane'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 6163, 'therapyName': 'ETBX-011'}, {'id': 3060, 'therapyName': 'ALT-803'}]",QUILT-3.039: NANT Pancreatic Cancer Vaccine: Combination Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy,107
45,NCT01213238,Phase I,"Active, not recruiting","[{'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 667, 'therapyName': 'Bevacizumab'}]","Hepatic Arterial Infusion Oxaliplatin, Capecitabine With or Without Bevacizumab",107
46,NCT00565851,Phase III,"Active, not recruiting","[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 3045, 'therapyName': 'Docetaxel + Paclitaxel'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 667, 'therapyName': 'Bevacizumab'}]","Carboplatin, Paclitaxel and Gemcitabine With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer",107
47,NCT02521051,Phase Ib/II,Recruiting,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 698, 'therapyName': 'Alectinib'}]","Phase I/II Trial of Alectinib and Bevacizumab in Patients With Advanced, Anaplastic Lymphoma Kinase (ALK)-Positive, Non-Small Cell Lung Cancer",107
48,NCT02563002,Phase III,Recruiting,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1315, 'therapyName': 'FOLFIRI'}, {'id': 694, 'therapyName': 'Cetuximab'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}]",Study of Pembrolizumab (MK-3475) vs Standard Therapy in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (MK-3475-177/KEYNOTE-177),107
49,NCT01933815,Phase Ib/II,Recruiting,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 2274, 'therapyName': 'TPI 287'}]",Dose-Escalation Study of TPI 287 + Avastin Followed by Randomized Study of the Same Versus Avastin for Glioblastoma,107
50,NCT01139723,Phase I,Completed,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1616, 'therapyName': 'MINT1526A'}]","A Study of the Safety and Pharmacokinetics of MINT1526A, Administered Intravenously As a Single Agent and in Combination With Bevacizumab to Patients With Advanced Solid Tumors",107
51,NCT01578551,Phase II,"Active, not recruiting","[{'id': 1031, 'therapyName': 'Metformin'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 667, 'therapyName': 'Bevacizumab'}]",A Randomized Phase II Study of Metformin Plus Paclitaxel/Carboplatin/Bevacizumab in Patients With Adenocarcinoma.,107
52,NCT01471054,Phase II,Terminated,"[{'id': 1480, 'therapyName': 'Dexamethasone intravitreal implant'}, {'id': 667, 'therapyName': 'Bevacizumab'}]",Dexamethasone Intravitreal Implant for Treatment of Macular Edema After Plaque Radiotherapy of Uveal Melanoma,107
53,NCT01263782,Phase II,Completed,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1602, 'therapyName': 'Carboplatin + Pemetrexed'}, {'id': 701, 'therapyName': 'Cixutumumab'}]",BATTLE-FL: Front-Line Biomarker-Integrated Treatment Study in Non Small Cell Lung Cancer,107
54,NCT01916447,Phase I,Completed,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 2426, 'therapyName': 'trifluridine/tipiracil hydrochloride'}, {'id': 1074, 'therapyName': 'Irinotecan'}]",A Phase I Study of TAS-102 in Patients With Advanced Gastrointestinal Tumors.,107
55,NCT02768389,Phase I,Recruiting,"[{'id': 667, 'therapyName': 'Bevacizumab'}]",Feasibility Trial of the Modified Atkins Diet and Bevacizumab for Recurrent Glioblastoma,107
56,NCT02120287,Phase II,Recruiting,"[{'id': 667, 'therapyName': 'Bevacizumab'}]",Border Zone Stereotactic Radiosurgery With Bevacizumab in Patients With Glioblastoma Multiforme,107
57,NCT02285959,Phase I,Recruiting,"[{'id': 667, 'therapyName': 'Bevacizumab'}]",Super-Selective Intraarterial Intracranial Infusion of Bevacizumab (Avastin) for Glioblastoma Multiforme,107
58,NCT01954030,Phase Ib/II,Terminated,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 999, 'therapyName': 'Carboxyamidotriazole Orotate'}]",Phase 1/2 CTO + Bevacizumab for Recurrent Glioma Post-Bevacizumab Failure,107
59,NCT02305758,Phase II,Completed,"[{'id': 1315, 'therapyName': 'FOLFIRI'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 954, 'therapyName': 'Veliparib'}]",Study Comparing Veliparib Plus FOLFIRI Versus Placebo Plus FOLFIRI With or Without Bevacizumab in Previously Untreated Metastatic Colorectal Cancer,107
60,NCT01985763,Phase Ib/II,Completed,"[{'id': 757, 'therapyName': 'Genistein'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}]",Genistein in Treatment of Metastatic Colorectal Cancer,107
61,NCT01197170,Phase I,"Active, not recruiting","[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 633, 'therapyName': 'Anastrozole'}, {'id': 667, 'therapyName': 'Bevacizumab'}]",Hormone Blockade in Combination With Targeted Agents,107
62,NCT03032484,Phase II,Recruiting,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 5260, 'therapyName': 'Bevacizumab + TVB-2640'}]",TVB- 2640 in Combination With Bevacizumab in Patients With First Relapse of High Grade Astrocytoma,107
63,NCT01445509,Phase I,"Active, not recruiting","[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 717, 'therapyName': 'Dasatinib'}]",Dasatinib in Combination With Bevacizumab to Treat Advanced Solid Tumors,107
64,NCT02511405,Phase III,"Active, not recruiting","[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 2276, 'therapyName': 'VB-111'}]","A Phase 3, Pivotal Trial of VB-111 Plus Bevacizumab vs. Bevacizumab in Patients With Recurrent Glioblastoma (GLOBE)",107
65,NCT02574663,Phase I,"Active, not recruiting","[{'id': 1779, 'therapyName': 'Nab-paclitaxel + Gemcitabine'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 2022, 'therapyName': 'TGR-1202'}]",TGR-1202 Alone and in Combination With Either Nab-paclitaxel + Gemcitabine or With FOLFOX in Patients With Select Relapsed or Refractory Solid Tumors,107
66,NCT01727089,Phase II,Completed,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1243, 'therapyName': 'Bevacizumab + TRC105'}]", Bevacizumab With or Without Monoclonal Antibody Therapy in Treating Patients With Metastatic Kidney Cancer,107
67,NCT01107626,Phase III,"Active, not recruiting","[{'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 667, 'therapyName': 'Bevacizumab'}]",Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer,107
68,NCT01860638,Phase III,Completed,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 2075, 'therapyName': 'Lomustine'}]",A Comparison of Continuous Avastin (Bevacizumab) Treatment or Placebo in Addition to Lomustine Followed by Standard of Care After Disease Progression in Patients With Glioblastoma,107
69,NCT02456857,Phase II,Recruiting,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 936, 'therapyName': 'Temsirolimus'}]","Liposomal Doxorubicin, Bevacizumab and Temsirolimus (DAT) in Triple-Negative Breast Cancer (TNBC) Insensitive to Standard Neoadjuvant Chemotherapy",107
70,NCT01206530,Phase Ib/II,"Active, not recruiting","[{'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1316, 'therapyName': 'Hydroxychloroquine'}]",FOLFOX/Bevacizumab/Hydroxychloroquine (HCQ) in Colorectal Cancer,107
71,NCT01331616,Phase I,Unknown status,"[{'id': 667, 'therapyName': 'Bevacizumab'}]",Optic Neuropathy in 10 Patients With Glioblastoma Receiving Bevacizumab,107
72,NCT01344824,Phase II,Completed,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 854, 'therapyName': 'Pemetrexed'}]","Carboplatin, Pemetrexed Disodium, and Bevacizumab in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Who Are Light or Never Smokers",107
73,NCT02490878,Phase II,Recruiting,"[{'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 667, 'therapyName': 'Bevacizumab'}]",Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases,107
74,NCT02754362,Phase II,Enrolling by invitation,"[{'id': 2595, 'therapyName': 'poly ICLC  '}, {'id': 667, 'therapyName': 'Bevacizumab'}]",A Toll-like Receptor Agonist as an Adjuvant to Tumor Associated Antigens (TAA) Mixed With Montanide ISA-51 VG With Bevacizumab for Patients With Recurrent Glioblastoma,107
75,NCT01526837,Phase I,Terminated,"[{'id': 667, 'therapyName': 'Bevacizumab'}]",Bevacizumab (Avastin) Into the Tumor Resection Cavity in Subjects With Glioblastoma Multiforme at First Recurrence,107
76,NCT01351415,Phase III,Completed,"[{'id': 667, 'therapyName': 'Bevacizumab'}]",A Study of Avastin (Bevacizumab) in Combination With Standard of Care Treatment in Patients With Lung Cancer,107
77,NCT02743078,Phase II,Recruiting,"[{'id': 667, 'therapyName': 'Bevacizumab'}]",Optune Plus Bevacizumab in Bevacizumab-Refractory Recurrent Glioblastoma,107
78,NCT01814813,Phase II,"Active, not recruiting","[{'id': 667, 'therapyName': 'Bevacizumab'}]",Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery,107
79,NCT01894451,Phase I,Recruiting,"[{'id': 667, 'therapyName': 'Bevacizumab'}]",Pilot Study of Zirconium-89 Bevacizumab Positron Emission Tomography for Imaging Angiogenesis in Patients With Inflammatory Breast Carcinoma Receiving Preoperative Chemotherapy,107
80,NCT02138617,Phase II,Recruiting,"[{'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 1715, 'therapyName': 'Fluorouracil'}]",Genotype-Directed Study Of Irinotecan Dosing In FOLFIRI + BevacizumabTreated Metastatic Colorectal Cancer,107
81,NCT02446431,Phase I,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1076, 'therapyName': 'Valproic acid'}]",Metronomic Therapy for Pediatric Patients With Solid Tumors at High Risk of Recurrence,107
82,NCT01767792,Phase II,"Active, not recruiting","[{'id': 667, 'therapyName': 'Bevacizumab'}]",Phase 2 Study of Bevacizumab in Children and Young Adults With NF 2 and Progressive Vestibular Schwannomas,107
83,NCT02010606,Phase I,"Active, not recruiting","[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1141, 'therapyName': 'Temozolomide'}]",Phase I Study of a Dendritic Cell Vaccine for Patients With Either Newly Diagnosed or Recurrent Glioblastoma,107
84,NCT02420821,Phase III,"Active, not recruiting","[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1201, 'therapyName': 'Atezolizumab'}]",A Study of MPDL3280A (Anti-Programmed Death Ligand 1 [PD-L1] Antibody) in Combination With Bevacizumab Versus Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma,107
85,NCT01132014,Phase I,"Active, not recruiting","[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1154, 'therapyName': 'Dacarbazine'}]",Autologous OC-DC Vaccine in Ovarian Cancer,107
86,NCT02436993,Phase II,Recruiting,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]",Breast Cancer Treatment Using Weekly Carboplatin + Paclitaxel With Pertuzumab + Trastuzumab (HER2+) or Bevacizumab (HER2-) in the Neoadjuvant Setting,107
87,NCT00378638,Phase II,Unknown status,"[{'id': 667, 'therapyName': 'Bevacizumab'}]",Dose-Dense Chemotherapy Plus Bevacizumab in High Risk Lymph Node Positive Breast Cancer,107
88,NCT01061515,Phase I,Recruiting,"[{'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}]",Biweekly Intraperitoneal Oxaliplatin With Systemic Capecitabine and Bevacizumab for Patients With Peritoneal Carcinomatosis From Appendiceal or Colorectal Cancer,107
89,NCT02847559,Phase II,Recruiting,"[{'id': 667, 'therapyName': 'Bevacizumab'}]",Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma,107
90,NCT02157103,Phase II,"Active, not recruiting","[{'id': 667, 'therapyName': 'Bevacizumab'}]",A Study of Subcutaneous Bevacizumab in Relapsed / Progressive Glioblastoma,107
91,NCT01459380,Phase I,Completed,"[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 954, 'therapyName': 'Veliparib'}, {'id': 667, 'therapyName': 'Bevacizumab'}]","Veliparib, Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer",107
92,NCT00879437,Phase II,"Active, not recruiting","[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1076, 'therapyName': 'Valproic acid'}]",Valproic Acid and Radiation Followed by Maintenance Valproic Acid and Bevacizumab in Children With High Grade Gliomas,107
93,NCT01187199,Phase I,"Active, not recruiting","[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 936, 'therapyName': 'Temsirolimus'}]","Phase I Trial of Bevacizumab and Temsirolimus in Combination With 1) Carboplatin, 2) Paclitaxel, 3) Sorafenib for the Treatment of Advanced Cancer",107
94,NCT01894061,Phase II,Recruiting,"[{'id': 667, 'therapyName': 'Bevacizumab'}]",NovoTTF-100A With Bevacizumab (Avastin) in Patients With Recurrent Glioblastoma,107
95,NCT01201850,Phase I,Completed,"[{'id': 667, 'therapyName': 'Bevacizumab'}]",The Role of Bevacizumab in the Treatment of Radiation Necrosis in Children With Central Nervous System Tumors,107
96,NCT01390948,Phase II,"Active, not recruiting","[{'id': 1141, 'therapyName': 'Temozolomide'}, {'id': 667, 'therapyName': 'Bevacizumab'}]",A Study of Avastin (Bevacizumab) in Combination With Temolozomide (TMZ) and Radiotherapy in Paediatric and Adolescent Patients With High-Grade Glioma,107
97,NCT01182350,Phase II,"Active, not recruiting","[{'id': 2115, 'therapyName': 'Bevacizumab + Temozolomide'}, {'id': 2116, 'therapyName': 'Bevacizumab + Erlotinib + Temozolomide'}, {'id': 1146, 'therapyName': 'Bevacizumab + Erlotinib'}, {'id': 667, 'therapyName': 'Bevacizumab'}]",Molecularly Determined Treatment of Diffuse Intrinsic Pontine Gliomas (DIPG),107
98,NCT01898130,Phase II,"Active, not recruiting","[{'id': 667, 'therapyName': 'Bevacizumab'}]",Bevacizumab in Pats w/ Recurrent ST Brain Metas Who Have Failed Whole Brain Radiation Therapy,107
99,NCT02663271,Phase II,Recruiting,"[{'id': 667, 'therapyName': 'Bevacizumab'}]",TTFields and Pulsed Bevacizumab for Recurrent Glioblastoma,107
100,NCT03149003,Phase II,Recruiting,"[{'id': 5986, 'therapyName': 'Bevicizumab + DSP-7888'}, {'id': 667, 'therapyName': 'Bevacizumab'}]",A Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy (WIZARD201G),107
101,NCT02078648,Phase Ib/II,"Active, not recruiting","[{'id': 3010, 'therapyName': 'SL-701'}, {'id': 2595, 'therapyName': 'poly ICLC  '}, {'id': 667, 'therapyName': 'Bevacizumab'}]","Safety and Efficacy Study of SL-701, a Glioma-Associated Antigen Vaccine To Treat Recurrent Glioblastoma Multiforme",107
102,NCT02661815,Phase I,"Active, not recruiting","[{'id': 3469, 'therapyName': 'ACY-1215 + Paclitaxel'}, {'id': 667, 'therapyName': 'Bevacizumab'}]","A Phase 1b Study of Weekly Paclitaxel And Oral Ricolinostat For The Treatment Of Recurrent Platinum Resistant Ovarian, Primary Peritoneal, Or Fallopian Tube Cancer",107
103,NCT02272413,Phase III,"Active, not recruiting","[{'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 667, 'therapyName': 'Bevacizumab'}]",Phase III Trial BI 695502 Plus Chemotherapy vs. Avastin Plus Chemotherapy in Patients With Lung Cancer,107
104,NCT01495988,Phase II,Terminated,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 342, 'therapyName': 'Vemurafenib'}]",Trial of Vemurafenib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma,107
105,NCT01516216,Phase II,"Active, not recruiting","[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}]",Study of Vitamin D in Untreated Metastatic Colorectal Cancer,107
106,NCT02413853,Phase II,Withdrawn,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1083, 'therapyName': 'Pri-724'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}]",Combination Chemotherapy and Bevacizumab With or Without PRI-724 in Treating Patients With Newly Diagnosed Metastatic Colorectal Cancer,107
107,NCT02974621,Phase II,Recruiting,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1971, 'therapyName': 'Cediranib + Olaparib'}]",Cediranib Maleate and Olaparib Compared to Bevacizumab in Treating Patients With Recurrent Glioblastoma,107
108,NCT01266031,Phase Ib/II,Completed,"[{'id': 2110, 'therapyName': 'Bevacizumab + Vorinostat'}, {'id': 667, 'therapyName': 'Bevacizumab'}]",Bevacizumab Versus Bevacizumab Plus Vorinostat in Adults With Recurrent Glioblastoma,107
109,NCT00976573,,Completed,"[{'id': 735, 'therapyName': 'Everolimus'}, {'id': 667, 'therapyName': 'Bevacizumab'}]","Carboplatin, Paclitaxel, and Bevacizumab With or Without Everolimus in Treating Patients With Metastatic Malignant Melanoma",107
110,NCT02017717,Phase III,"Active, not recruiting","[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",A Randomized Study of Nivolumab Versus Bevacizumab and a Safety Study of Nivolumab in Adult Subjects With Recurrent Glioblastoma (GBM) (CheckMate 143),107
111,NCT02429843,Phase I,Recruiting,"[{'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1242, 'therapyName': 'TRC105'}]",A Study of TRC105 in Combination With Paclitaxel/Carboplatin and Bevacizumab in Non-Squamous Cell Lung Cancer,107
112,NCT02884648,Phase II,Recruiting,"[{'id': 667, 'therapyName': 'Bevacizumab'}]",Bevacizumab in Ovarian Cancer Patients With Disease at Second-look Surgery,107
113,NCT01015222,Phase I,"Active, not recruiting","[{'id': 1032, 'therapyName': 'methylnaltrexone'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 667, 'therapyName': 'Bevacizumab'}]","Dasatinib, Bevacizumab, Paclitaxel in Patients With Advanced Malignancies",107
114,NCT01743950,Phase II,Recruiting,"[{'id': 667, 'therapyName': 'Bevacizumab'}]",A Phase II Study of Pulse Reduced Dose Rate Radiation Therapy With Bevacizumab,107
115,NCT02414165,Phase II,"Active, not recruiting","[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 3211, 'therapyName': 'Toca 511 + Toca FC'}, {'id': 1141, 'therapyName': 'Temozolomide'}]",P2/3 Randomized Study of Toca 511 & Toca FC Versus SOC in Subjects Undergoing Surgery for Recurrent GBM/AA (Toca5),107
116,NCT01454102,Phase I,"Active, not recruiting","[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1312, 'therapyName': 'Nivolumab'}]","Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012)",107
117,NCT01269853,Phase Ib/II,Recruiting,"[{'id': 667, 'therapyName': 'Bevacizumab'}]",Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA,107
118,NCT01580969,Phase Ib/II,Recruiting,"[{'id': 667, 'therapyName': 'Bevacizumab'}]","Repeat Radiation, Minocycline and Bevacizumab in Patients With Recurrent Glioma",107
119,NCT02648711,Phase I,"Active, not recruiting","[{'id': 708, 'therapyName': 'CRLX101'}, {'id': 667, 'therapyName': 'Bevacizumab'}]",Alternative Dosing for CRLX101 Alone and With Avastin in Advanced Solid Tumors,107
120,NCT01756352,Phase II,"Active, not recruiting","[{'id': 667, 'therapyName': 'Bevacizumab'}]",FET-PET for Evaluation of Response of Recurrent GBM to Avastin,107
121,NCT01903330,Phase II,Recruiting,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1873, 'therapyName': 'Sargramostim'}]",ERC1671/GM-CSF/Cyclophosphamide for the Treatment of Glioblastoma Multiforme,107
122,NCT01248949,Phase I,Completed,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1176, 'therapyName': 'MEDI3617'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]",A Study to Evaluate the Safety and Antitumor Activity in Subjects With Advanced Solid Tumors,107
123,NCT01788280,Phase I,Not yet recruiting,"[{'id': 667, 'therapyName': 'Bevacizumab'}]",Preliminary Assessment of [18F] Fluciclatide (GE [18F]AH111585) in Glioblastoma Multiforme Treated With Bevacizumab,107
124,NCT01730950,Phase II,"Active, not recruiting","[{'id': 667, 'therapyName': 'Bevacizumab'}]",Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma,107
125,NCT00602329,Phase II,Unknown status,"[{'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 667, 'therapyName': 'Bevacizumab'}]",MRI in Predicting Response in Patients Receiving Combination Chemotherapy and Bevacizumab For Advanced or Metastatic Colorectal Cancer,107
126,NCT01569984,Phase II,Completed,"[{'id': 667, 'therapyName': 'Bevacizumab'}]",Radiosensitization of AVASTIN; (Bevacizumab) With Stereotactic Body Radiotherapy for Colorectal Liver Metastasis,107
127,NCT00588770,Phase III,"Active, not recruiting","[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1835, 'therapyName': 'Docetaxel + Cisplatin'}, {'id': 1833, 'therapyName': 'Cisplatin + Fluorouracil'}, {'id': 1834, 'therapyName': 'Docetaxel + Carboplatin'}, {'id': 1832, 'therapyName': 'Carboplatin + Fluorouracil\t'}]",Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer,107
128,NCT00968240,Phase I,Completed,"[{'id': 667, 'therapyName': 'Bevacizumab'}]",Super-Selective Intraarterial Intracranial Infusion of Avastin (Bevacizumab),107
129,NCT02648477,Phase II,Recruiting,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 794, 'therapyName': 'Letrozole'}, {'id': 633, 'therapyName': 'Anastrozole'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 1009, 'therapyName': 'Doxorubicin'}]",Pembrolizumab and Doxorubicin Hydrochloride or Anti-Estrogen Therapy in Treating Patients With Triple-Negative or Hormone Receptor-Positive Metastatic Breast Cancer,107
130,NCT01312376,Phase I,"Active, not recruiting","[{'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1227, 'therapyName': 'CD3/CD28 costimulated vaccine-primed autologous T-cells'}, {'id': 1222, 'therapyName': 'OC-DC vaccine'}]",Autologous T-Cells Combined With Autologous OC-DC Vaccine in Ovarian Cancer,107
131,NCT01966003,Phase III,Completed,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 2141, 'therapyName': 'Bevacizumab-awwb'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]",Efficacy and Safety Study of ABP 215 Compared With Bevacizumab in Subjects With Advanced Non-Small Cell Lung Cancer,107
132,NCT01493843,Phase II,Completed,"[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 749, 'therapyName': 'GDC-0941'}, {'id': 667, 'therapyName': 'Bevacizumab'}]",Study Evaluating the Safety and Efficacy of Carboplatin/Paclitaxel and Carboplatin/Paclitaxel/Bevacizumab With and Without GDC-0941 in Patients With Previously Untreated Advanced or Recurrent Non-small Cell Lung Cancer,107
133,NCT02833701,Phase I,Recruiting,"[{'id': 667, 'therapyName': 'Bevacizumab'}]",Bevacizumab and Ascorbic Acid in Patients Treating With Recurrent High Grade Glioma,107
134,NCT01067469,Phase II,Completed,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 2118, 'therapyName': 'Bevacizumab + Lomustine'}]",Standard Dose Bevacizumab Versus Low Dose Bevacizumab Plus Lomustine (CCNU) for Recurrent Glioblastoma Multiforme (GBM),107
135,NCT01625936,Phase I,Unknown status,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 708, 'therapyName': 'CRLX101'}]",CRLX101 Plus Bevacizumab in Advanced RCC,107
136,NCT01811498,Phase Ib/II,Recruiting,"[{'id': 667, 'therapyName': 'Bevacizumab'}]",Repeated Super-Selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Newly Diagnosed GBM,107
137,NCT00356031,Phase II,Completed,"[{'id': 667, 'therapyName': 'Bevacizumab'}]",Bevacizumab and Radiation Therapy for Sarcomas,107
138,NCT02158520,Phase II,"Active, not recruiting","[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 1261, 'therapyName': 'Bevacizumab + Abraxane'}]",Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery,107
139,NCT02997228,Phase III,Not yet recruiting,"[{'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 1484, 'therapyName': 'Bevacizumab + Oxaliplatin + Leucovorin + Fluorouracil'}, {'id': 5126, 'therapyName': 'Bevacizumab + Atezolizumab + Fluorouracil + Leucovorin + Oxaliplatin'}]","Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Microsatellite Instability-High Metastatic Colorectal Cancer",107
140,NCT01435395,Phase I,Completed,"[{'id': 2122, 'therapyName': 'Bevacizumab + Bortezomib + Temozolomide'}]","Trial of Temozolomide, Bevacizumab Plus Bortezomib for Recurrent Glioblastoma Multiforme",107
141,NCT02988843,Phase II,Recruiting,"[{'id': 5144, 'therapyName': 'Bevacizumab + Brentuximab vedotin'}]",Study of Brentuximab Vedotin And Bevacizumab In Refractory CD-30 Positive Germ Cell Tumors,107
142,NCT02669173,Phase I,Recruiting,"[{'id': 2097, 'therapyName': 'Bevacizumab + Capecitabine'}]",Capecitabine + Bevacizumab in Patients With Recurrent Glioblastoma,107
143,NCT01722162,Phase II,Completed,"[{'id': 2097, 'therapyName': 'Bevacizumab + Capecitabine'}]",Levocetirizine + Capecitabine + Bevacizumab for Patients With Refractory Colorectal Cancer,107
144,NCT00780494,Phase II,Unknown status,"[{'id': 2096, 'therapyName': 'Bevacizumab + Capecitabine + Carboplatin'}]","Ph II of Capecitabine, Carboplatin and Bevacizumab for Gastroesophageal Junction and Gastric Carcinoma",107
145,NCT01525082,Phase II,"Active, not recruiting","[{'id': 2073, 'therapyName': 'Bevacizumab + Capecitabine + Temozolomide'}]","Capecitabine, Temozolomide and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors",107
146,NCT01295944,Phase II,Recruiting,"[{'id': 2074, 'therapyName': 'Bevacizumab + Carboplatin'}]",Carboplatin and Bevacizumab for Recurrent Ependymoma,107
147,NCT01386710,Phase Ib/II,Suspended,"[{'id': 2074, 'therapyName': 'Bevacizumab + Carboplatin'}]",Repeated Super-selective Intraarterial Cerebral Infusion Of Bevacizumab Plus Carboplatin For Treatment Of Relapsed/Refractory GBM And Anaplastic Astrocytoma,107
148,NCT00936936,Phase II,Recruiting,"[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 2101, 'therapyName': 'Etoposide + Ifosfamide'}, {'id': 2100, 'therapyName': 'Docetaxel + Gemcitabine + Melphalan'}, {'id': 2074, 'therapyName': 'Bevacizumab + Carboplatin'}]",High-dose Chemotherapy for Poor-prognosis Relapsed Germ-Cell Tumors,107
149,NCT01146795,Phase II,Terminated,"[{'id': 1152, 'therapyName': 'Bevacizumab + Carboplatin + Paclitaxel'}]",Neoadjuvant Therapy for Ovarian Cancer,107
150,NCT02364999,Phase III,"Active, not recruiting","[{'id': 1152, 'therapyName': 'Bevacizumab + Carboplatin + Paclitaxel'}]",A Comparative Study Of PF-06439535 Plus Paclitaxel-Carboplatin And Bevacizumab Plus Paclitaxel-Carboplatin Patients With Advanced Non-Squamous NSCLC,107
151,NCT02810457,Phase III,Recruiting,"[{'id': 1152, 'therapyName': 'Bevacizumab + Carboplatin + Paclitaxel'}]",Evaluation of FKB238 and Avastin in Patients With Advanced/Recurrent Non-squamous Non-small Cell Lung Cancer (AVANA),107
152,NCT01239732,Phase III,Completed,"[{'id': 1152, 'therapyName': 'Bevacizumab + Carboplatin + Paclitaxel'}]",A Study of the Addition of Avastin (Bevacizumab) to Carboplatin and Paclitaxel Therapy in Patients With Ovarian Cancer,107
153,NCT01649947,Phase II,Completed,"[{'id': 1487, 'therapyName': 'Bevacizumab + Carboplatin + Paclitaxel + Hydroxychloroquine'}, {'id': 1488, 'therapyName': 'Paclitaxel + Carboplatin + Hydroxychloroquine'}]",Modulation of Autophagy in Patients With Advanced/Recurrent Non-small Cell Lung Cancer - Phase II,107
154,NCT02039674,Phase Ib/II,"Active, not recruiting","[{'id': 2103, 'therapyName': 'Carboplatin + Paclitaxel + Pembrolizumab'}, {'id': 2104, 'therapyName': 'Bevacizumab + Carboplatin + Paclitaxel + Pembrolizumab'}, {'id': 1602, 'therapyName': 'Carboplatin + Pemetrexed'}, {'id': 2106, 'therapyName': 'Ipilimumab + Pembrolizumab '}, {'id': 2107, 'therapyName': 'Erlotinib + Pembrolizumab '}, {'id': 2108, 'therapyName': 'Gefitinib + Pembrolizumab '}]",A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Lung Cancer (MK-3475-021/KEYNOTE-021),107
155,NCT02348255,Phase II,Withdrawn,"[{'id': 2371, 'therapyName': 'Bevacizumab + Carmustine'}]",NovoTTF-100A in Combination With Bevacizumab and Carmustine in Treating Patients With Glioblastoma Multiforme in First Relapse,107
156,NCT02292758,Phase II,Recruiting,"[{'id': 1923, 'therapyName': 'Bevacizumab + Cetuximab + Irinotecan'}, {'id': 1874, 'therapyName': 'Cetuximab + Irinotecan'}]","Phase II Trial of Irinotecan, Cetuximab, and Bevacizumab Compared With Irinotecan, Cetuximab, and Placebo in KRAS-Wildtype, Irinotecan-Refractory, Metastatic Colorectal Cancer",107
157,NCT02853318,Phase II,Recruiting,"[{'id': 4528, 'therapyName': 'Bevacizumab + Cyclophosphamide + Pembrolizumab'}]","Pembrolizumab, Bevacizumab, and Cyclophosphamide in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",107
158,NCT00885326,Phase I,"Active, not recruiting","[{'id': 2072, 'therapyName': 'Bevacizumab + Cyclophosphamide + Zoledronic acid'}]","N2007-02:Bevacizumab,Cyclophosphamide,and Zoledronic Acid in Patients W/ Recurrent or Refractory High-Risk Neuroblastoma",107
159,NCT01959490,Phase II,Completed,"[{'id': 1486, 'therapyName': 'Bevacizumab + Doxorubicin + Cyclophosphamide + Paclitaxel '}, {'id': 1485, 'therapyName': 'Trastuzumab + Docetaxel + Carboplatin'}]",Trastuzumab or Bevacizumab With Combination Chemotherapy in Treating Patients With Stage II-III Breast Cancer,107
160,NCT02923739,Phase II,Recruiting,"[{'id': 4836, 'therapyName': 'Bevacizumab + Emactuzumab + Paclitaxel'}, {'id': 2123, 'therapyName': 'Bevacizumab + Paclitaxel'}]","Induction Discontinuation Trial of Emactuzumab Following Paclitaxel and Bevacizumab in Patients With Platinum-Resistant, Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer - REDIRECT",107
161,NCT01130519,Phase II,Recruiting,"[{'id': 1146, 'therapyName': 'Bevacizumab + Erlotinib'}]",A Phase II Study of Bevacizumab and Erlotinib in Subjects With Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) or Sporadic Papillary Renal Cell Cancer,107
162,NCT02045446,Phase II,"Active, not recruiting","[{'id': 1146, 'therapyName': 'Bevacizumab + Erlotinib'}, {'id': 1439, 'therapyName': 'Gemcitabine + Docetaxel'}]",Maintenance Chemotherapy Versus Consolidative Stereotactic Body Radiation Therapy (SBRT) Plus Maintenance Chemotherapy for Stage IV Non-Small Cell Lung Cancer (NSCLC),107
163,NCT02342379,Phase II,"Active, not recruiting","[{'id': 2144, 'therapyName': 'Bevacizumab + Evofosfamide'}]",TH-302 in Combination With Bevacizumab for Glioblastoma,107
164,NCT01403610,Phase II,Completed,"[{'id': 2144, 'therapyName': 'Bevacizumab + Evofosfamide'}, {'id': 1317, 'therapyName': 'Evofosfamide'}]",Safety and Efficacy Study of TH-302 CNS Penetration in Recurrent High Grade Astrocytoma Following Bevacizumab,107
165,NCT02141295,Phase II,Completed,"[{'id': 1484, 'therapyName': 'Bevacizumab + Oxaliplatin + Leucovorin + Fluorouracil'}, {'id': 1598, 'therapyName': 'RO5520985'}, {'id': 1599, 'therapyName': 'Bevacizumab + Fluorouracil + Leucovorin'}, {'id': 1600, 'therapyName': 'RO5520985 + Leucovorin + Fluorouracil'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}]",A Study Comparing the Efficacy and Safety of RO5520985 and FOLFOX With Bevacizumab and FOLFOX in Patients With Untreated Metastatic Colorectal Cancer (McCAVE),107
166,NCT00602602,Phase II,"Active, not recruiting","[{'id': 2102, 'therapyName': 'Bevacizumab + Fluorouracil + Oxaliplatin'}, {'id': 1296, 'therapyName': 'Gemcitabine + Bevacizumab + Oxaliplatin'}, {'id': 1297, 'therapyName': 'Gemcitabine + Bevacizumab'}]","Bevacizumab, Combination Chemotherapy, and Radiation Therapy in Treating Patients Undergoing Surgery For Locally Advanced Pancreatic Cancer",107
167,NCT01442935,Phase II,"Active, not recruiting","[{'id': 1484, 'therapyName': 'Bevacizumab + Oxaliplatin + Leucovorin + Fluorouracil'}, {'id': 2180, 'therapyName': 'Cetuximab + FOLFIRI'}, {'id': 2181, 'therapyName': 'Bevacizumab + FOLFIRI'}, {'id': 2182, 'therapyName': 'Cetuximab + FOLFOX'}, {'id': 2183, 'therapyName': 'Bevacizumab + FOLFIRINOX'}, {'id': 2184, 'therapyName': 'Cetuximab + FOLFIRINOX'}]",Chemotherapies Associated With Targeted Therapies on the Resection Rate of Hepatic Metastases,107
168,NCT01052363,Phase I,Withdrawn,"[{'id': 2109, 'therapyName': 'Bevacizumab + Fosbretabulin'}]",OXC401-PO1s/WVU 1309 - A Pilot Study of Fosbretabulin With Bevacizumab in Recurrent High-Grade Gliomas,107
169,NCT01106872,Phase Ib/II,Completed,"[{'id': 1466, 'therapyName': 'Bevacizumab + Gemcitabine + Docetaxel + Valproic Acid '}]","Bevacizumab, Chemotherapy and Valproic Acid in Advanced Sarcomas",107
170,NCT02386826,Phase I,Recruiting,"[{'id': 2600, 'therapyName': 'Bevacizumab + INC280'}]","INC280 Combined With Bevacizumab to Evaluate Glioblastoma Multiforme, Metastatic Colorectal Cancer, and Metastatic Renal Cell Carcinoma Patients",107
171,NCT01999270,Phase I,Completed,"[{'id': 2112, 'therapyName': 'Bevacizumab + Irinotecan'}]",Evaluation of FDOPA-PET/MRI in Pediatric Patients With CNS Tumors,107
172,NCT03093155,Phase II,Recruiting,"[{'id': 1122, 'therapyName': 'Bevacizumab + Ixabepilone'}, {'id': 781, 'therapyName': 'Ixabepilone'}]",Evaluation of Weekly Ixabepilone With or Without Biweekly Bevacizumab,107
173,NCT00923130,Phase II,Completed,"[{'id': 1122, 'therapyName': 'Bevacizumab + Ixabepilone'}]",Bevacizumab Plus Ixabepilone to Treat Patients With Advanced Kidney Cancer,107
174,NCT02330562,Phase I,Recruiting,"[{'id': 2166, 'therapyName': 'Bevacizumab + Marizomib'}]",Study of Marizomib With Bevacizumab in Bevacizumab-Na&#239;ve Subjects With WHO Grade IV Malignant Glioma,107
175,NCT02336165,Phase II,"Active, not recruiting","[{'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 2117, 'therapyName': 'Bevacizumab + MEDI4736'}]",Phase 2 Study of MEDI4736 in Patients With Glioblastoma,107
176,NCT02754856,Phase I,Recruiting,"[{'id': 4097, 'therapyName': 'Bevacizumab + MEDI4736 + Tremelimumab + FOLFOX'}]",Tremelimumab (Anti-CTLA-4) Plus MEDI4736 (Anti-PD-L1) in Resectable Colorectal Cancer Liver Metastases.,107
177,NCT02835833,Phase I,Recruiting,"[{'id': 4498, 'therapyName': 'Bevacizumab + Nintedanib'}]",Study of Nintedanib Plus Bevacizumab in Advanced Solid Tumors,107
178,NCT02354131,Phase Ib/II,Recruiting,"[{'id': 832, 'therapyName': 'Niraparib'}, {'id': 4254, 'therapyName': 'Bevacizumab + Niraparib'}]",Niraparib Versus Niraparib-bevacizumab Combination in Women With Platinum-sensitive Epithelial Ovarian Cancer (AVANOVA),107
179,NCT02873962,Phase II,Recruiting,"[{'id': 2111, 'therapyName': 'Bevacizumab + Nivolumab'}]",A Phase II Study Of Nivolumab/ Bevacizumab,107
180,NCT02210117,Phase II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 2111, 'therapyName': 'Bevacizumab + Nivolumab'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Nivolumab vs Nivolumab + Bevacizumab vs Nivolumab + Ipilimumab in Metastatic Renal Cell Carcinoma (mRCC),107
181,NCT02803203,Phase Ib/II,Recruiting,"[{'id': 4366, 'therapyName': 'Bevacizumab + Osimertinib'}]",Osimertinib and Bevacizumab as Treatment for EGFR-mutant Lung Cancers,107
182,NCT02971501,Phase II,Recruiting,"[{'id': 660, 'therapyName': 'AZD9291'}, {'id': 4366, 'therapyName': 'Bevacizumab + Osimertinib'}]",Osimertinib With or Without Bevacizumab in Treating Patients With EGFR Positive Non-small Cell Lung Cancer and Brain Metastases,107
183,NCT01871571,Phase II,Recruiting,"[{'id': 1484, 'therapyName': 'Bevacizumab + Oxaliplatin + Leucovorin + Fluorouracil'}]","Bevacizumab, Fluorouracil, Leucovorin Calcium, and Oxaliplatin Before Surgery in Treating Patients With Stage II-III Rectal Cancer",107
184,NCT01212822,Phase II,"Active, not recruiting","[{'id': 1484, 'therapyName': 'Bevacizumab + Oxaliplatin + Leucovorin + Fluorouracil'}]",Bevacizumab and Combination Chemotherapy Before Surgery in Treating Patients With Locally Advanced Esophageal or Stomach Cancer,107
185,NCT01006369,Phase II,Completed,"[{'id': 1316, 'therapyName': 'Hydroxychloroquine'}, {'id': 1601, 'therapyName': 'Capecitabine + Oxaliplatin + Bevacizumab'}, {'id': 1484, 'therapyName': 'Bevacizumab + Oxaliplatin + Leucovorin + Fluorouracil'}]","Hydroxychloroquine, Capecitabine, Oxaliplatin, and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer",107
186,NCT01622543,Phase II,"Active, not recruiting","[{'id': 1484, 'therapyName': 'Bevacizumab + Oxaliplatin + Leucovorin + Fluorouracil'}, {'id': 893, 'therapyName': 'Reolysin'}]",Reolysin in Combination With FOLFOX6 and Bevacizumab or FOLFOX6 and Bevacizumab Alone in Metastatic Colorectal Cancer,107
187,NCT02047214,Phase II,Terminated,"[{'id': 2123, 'therapyName': 'Bevacizumab + Paclitaxel'}]",Safety and Efficacy Study of TPI 287 + Avastin in Adults With Glioblastoma That Progressed Following Prior Avastin Therapy,107
188,NCT02681549,Phase II,Recruiting,"[{'id': 2119, 'therapyName': 'Bevacizumab + Pembrolizumab'}]",Pembrolizumab Plus Bevacizumab for Treatment of Brain Metastases in Metastatic Melanoma or Non-small Cell Lung Cancer,107
189,NCT02337491,Phase II,"Active, not recruiting","[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 2119, 'therapyName': 'Bevacizumab + Pembrolizumab'}]",Pembrolizumab +/- Bevacizumab for Recurrent GBM,107
190,NCT02313272,Phase I,Recruiting,"[{'id': 2119, 'therapyName': 'Bevacizumab + Pembrolizumab'}]",Phase I Trial of HFSRT With Pembrolizumab and Bevacizumab for Recurrent High Grade Gliomas,107
191,NCT02348008,Phase Ib/II,"Active, not recruiting","[{'id': 2119, 'therapyName': 'Bevacizumab + Pembrolizumab'}]",Phase Ib and Phase II Studies of MK-3475 in Combination + for Renal Cell Carcinoma,107
192,NCT00254319,Phase II,Unknown status,"[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 2114, 'therapyName': 'Bevacizumab + Pemetrexed'}]",Previously Untreated Advanced Non-Small Cell Lung Cancer (NSCLC),107
193,NCT02574078,Phase I,Recruiting,"[{'id': 619, 'therapyName': 'Abraxane'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 2114, 'therapyName': 'Bevacizumab + Pemetrexed'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 1092, 'therapyName': 'Carboplatin'}]",A Master Protocol Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC) (CheckMate 370),107
194,NCT01339039,Phase I,Terminated,"[{'id': 2120, 'therapyName': 'Bevacizumab + Plerixafor'}]",Plerixafor (AMD3100) and Bevacizumab for Recurrent High-Grade Glioma,107
195,NCT01274624,Phase I,"Active, not recruiting","[{'id': 1315, 'therapyName': 'FOLFIRI'}, {'id': 2099, 'therapyName': 'Bevacizumab + Reolysin'}]",Study of REOLYSIN; in Combination With FOLFIRI and Bevacizumab in FOLFIRI Naive Patients With KRAS Mutant Metastatic Colorectal Cancer,107
196,NCT01478321,Phase II,"Active, not recruiting","[{'id': 2115, 'therapyName': 'Bevacizumab + Temozolomide'}]",Efficacy of Hypofractionated XRT w/Bev. + Temozolomide for Recurrent Gliomas,107
197,NCT03128047,Phase I,Recruiting,"[{'id': 2115, 'therapyName': 'Bevacizumab + Temozolomide'}]",HUMC 1612: Optune NovoTTF-200A System,107
198,NCT01891747,Phase Ib/II,"Active, not recruiting","[{'id': 2115, 'therapyName': 'Bevacizumab + Temozolomide'}]", A Phase I/II Study of High-dose L-methylfolate in Combination With Temozolomide and Bevacizumab in Recurrent High Grade Glioma,107
199,NCT01149850,Phase II,"Active, not recruiting","[{'id': 2115, 'therapyName': 'Bevacizumab + Temozolomide'}]",Bevacizumab and Temozolomide in Treating Older Patients With Newly-Diagnosed Glioblastoma Multiforme or Gliosarcoma,107
200,NCT02343549,Phase II,Recruiting,"[{'id': 2115, 'therapyName': 'Bevacizumab + Temozolomide'}]",LCI-NEU-NOV-001 Study of a Device Worn on the Head in Combination With Chemo to Treat Brain Cancer,107
201,NCT00660621,Phase II,Unknown status,"[{'id': 2115, 'therapyName': 'Bevacizumab + Temozolomide'}]","A Phase II Study Of Gliadel, Concomitant Temozolomide And Radiation, Followed By Dose Dense Therapy With Temozolomide Plus Bevacizumab For Newly Diagnosed Malignant High Grade Glioma",107
202,NCT00761644,Phase I,"Active, not recruiting","[{'id': 1121, 'therapyName': 'Bevacizumab + Temsirolimus + Doxil'}]","Doxil, Bevacizumab and Temsirolimus Trial",107
203,NCT01749384,Phase I,Completed,"[{'id': 1254, 'therapyName': 'Bevacizumab + Tivantinib'}]",Tivantinib and Bevacizumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed By Surgery,107
204,NCT01806064,Phase I,"Active, not recruiting","[{'id': 1243, 'therapyName': 'Bevacizumab + TRC105'}]", A Phase 1B Dose-escalation Study of TRC105 in Combination With Axitinib in Patients With Advanced Renal Cell Carcinoma,107
205,NCT02664961,Phase II,Recruiting,"[{'id': 1243, 'therapyName': 'Bevacizumab + TRC105'}]",Study of TRC105 and Bevacizumab in Patients With Refractory Gestational Trophoblastic Neoplasia (GTN),107
206,NCT02654639,Phase II,"Active, not recruiting","[{'id': 3682, 'therapyName': 'Bevacizumab + trifluridine/tipiracil hydrochloride'}]",Ph 2 Study of TAS-102 / Bevacizumab Maintenance Therapy Post Induction Chemotherapy in Metastatic Colorectal Cancer,107
207,NCT01260506,Phase Ib/II,Unknown status,"[{'id': 2277, 'therapyName': 'Bevacizumab + VB-111'}]",Single-Arm Open-Label Multicenter Study of VB-111 in Patients With Recurrent Glioblastoma Multiforme,107
208,NCT00989651,Phase I,"Active, not recruiting","[{'id': 3047, 'therapyName': 'Bevacizumab + Veliparib'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 700, 'therapyName': 'Cisplatin'}]","Carboplatin, Paclitaxel, Bevacizumab, and ABT-888 in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer",107
209,NCT02840409,Phase II,Recruiting,"[{'id': 2635, 'therapyName': 'Vinblastine'}, {'id': 5178, 'therapyName': 'Bevacizumab + Vinblastine'}]",Vinblastine +/- Bevacizumab in Children With Unresectable or Progressive Low Grade Glioma (LGG),107
210,NCT01349660,Phase Ib/II,"Active, not recruiting","[{'id': 1178, 'therapyName': 'BKM120 + Bevacizumab'}]",Combination of BKM120 and Bevacizumab in Refractory Solid Tumors and Relapsed/Refractory Glioblastoma Multiforme,107
211,NCT01283048,Phase I,Completed,"[{'id': 1178, 'therapyName': 'BKM120 + Bevacizumab'}]",Bevacizumab and BKM-120 in Patients With Metastatic Renal Cell Carcinoma,107
212,NCT00408772,Phase II,Withdrawn,"[{'id': 1601, 'therapyName': 'Capecitabine + Oxaliplatin + Bevacizumab'}]","Oxaliplatin, Capecitabine, and Bevacizumab Followed By Surgery and/or Radiofrequency Ablation in Treating Patients With Colorectal Cancer That Has Spread to the Liver and Cannot Be Removed By Surgery",107
213,NCT01208103,Phase II,"Active, not recruiting","[{'id': 1601, 'therapyName': 'Capecitabine + Oxaliplatin + Bevacizumab'}]",Bevacizumab With Capecitabine and Oxaliplatin in Advanced Adenocarcinoma of the Small Bowel or Ampulla of Vater,107
214,NCT02121990,Phase I,"Active, not recruiting","[{'id': 1451, 'therapyName': 'Cisplatin + Paclitaxel + Bevacizumab + Olaparib '}]","Dose-Escalation Study of Intraperitoneal (IP) Cisplatin, IV/IP Paclitaxel, IV Bevacizumab, and Oral Olaparib for Newly Diagnosed Ovarian, Primary Peritoneal, and Fallopian Tube Cancer",107
215,NCT02876224,Phase I,Recruiting,"[{'id': 4609, 'therapyName': 'Cobimetinib + Bevacizumab + Atezolizumab'}]",Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors,107
216,NCT02187302,Phase II,Completed,"[{'id': 1213, 'therapyName': 'CRLX101 + Bevacizumab'}]",CRLX101 in Combination With Bevacizumab for Metastatic Renal Cell Carcinoma (mRCC) Versus Standard of Care (SOC),107
217,NCT01652079,Phase II,"Active, not recruiting","[{'id': 1213, 'therapyName': 'CRLX101 + Bevacizumab'}]",CRLX101 in Combination With Bevacizumab for Recurrent Ovarian/Tubal/Peritoneal Cancer,107
218,NCT01492673,Phase II,"Active, not recruiting","[{'id': 1479, 'therapyName': 'Cyclophosphamide + Topotecan + Bevacizumab'}]","Cyclophosphamide, Topotecan, and Bevacizumab (CTB) in Patients With Relapsed/Refractory Ewing's Sarcoma and Neuroblastoma",107
219,NCT01995188,Phase I,Completed,"[{'id': 1347, 'therapyName': 'DNIB0600A + Carboplatin + Bevacizumab'}, {'id': 1346, 'therapyName': 'DNIB0600A + Carboplatin'}]",A Study to Evaluate the Safety and Pharmacology of DNIB0600A in Patients With Ovarian Cancer,107
220,NCT00923936,Phase II,"Active, not recruiting","[{'id': 1673, 'therapyName': 'Doxil + Bevacizamub'}]",Pilot Study of Liposomal Doxorubicin Combined With Bevacizumab Followed by Bevacizumab Monotherapy in Adults With Advanced Kaposi s Sarcoma,107
221,NCT01746238,Phase I,"Active, not recruiting","[{'id': 1473, 'therapyName': 'Doxorubicin + Bevacizumab'}]",Bevacizumab/Doxorubicin/Radiation for Sarcoma,107
222,NCT01661283,Phase II,"Active, not recruiting","[{'id': 1120, 'therapyName': 'Everolimus + Bevacizumab'}]",Study of Everolimus With Bevacizumab to Treat Refractory Malignant Peripheral Nerve Sheath Tumors,107
223,NCT01031381,Phase II,Completed,"[{'id': 1120, 'therapyName': 'Everolimus + Bevacizumab'}]","Study of RAD001 and Bevacizumab in Recurrent Ovarian, Peritoneal, and Fallopian Tube Cancer",107
224,NCT00756340,Phase I,Completed,"[{'id': 1120, 'therapyName': 'Everolimus + Bevacizumab'}]",A Trial of Everolimus and Bevacizumab in Children With Recurrent Solid Tumors,107
225,NCT01399918,Phase II,"Active, not recruiting","[{'id': 1120, 'therapyName': 'Everolimus + Bevacizumab'}]",Everolimus and Bevacizumab in Advanced Non-Clear Cell Renal Cell Carcinoma (RCC),107
226,NCT02620800,Phase Ib/II,Recruiting,"[{'id': 3621, 'therapyName': 'FABLOx'}]","Study of 5-fluorouracil (5-FU), Nab-paclitaxel, Bevacizumab, Leucovorin, and Oxaliplatin in Patients With Metastatic Pancreatic Cancer",107
227,NCT01551745,Phase II,Completed,"[{'id': 1158, 'therapyName': 'FANG vaccine + Bevacizumab'}]", Salvage Ovarian FANG Vaccine + Bevacizumab,107
228,NCT01936974,Phase II,Terminated,"[{'id': 1295, 'therapyName': 'Gemcitabine + Bevacizumab + Cisplatin'}, {'id': 1296, 'therapyName': 'Gemcitabine + Bevacizumab + Oxaliplatin'}, {'id': 1294, 'therapyName': 'Gemcitabine + Bevacizumab + Carboplatin'}, {'id': 1297, 'therapyName': 'Gemcitabine + Bevacizumab'}]","(PGA) for Platinum-resistant/Refractory, Paclitaxel-Pretreated Recurrent Ovarian and Peritoneal Carcinoma",107
229,NCT00150657,Phase II,Unknown status,"[{'id': 1294, 'therapyName': 'Gemcitabine + Bevacizumab + Carboplatin'}]",Study of Carboplatin/Gemcitabine Plus Bevacizumab in Advanced Lung Cancer,107
230,NCT00942331,Phase III,"Active, not recruiting","[{'id': 1295, 'therapyName': 'Gemcitabine + Bevacizumab + Cisplatin'}, {'id': 1467, 'therapyName': 'Gemcitabine + Cisplatin'}]",Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer,107
231,NCT01950390,Phase II,"Active, not recruiting","[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 1301, 'therapyName': 'Ipilimumab + Bevacizumab'}]",Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot be Removed by Surgery,107
232,NCT01831089,Phase I,Completed,"[{'id': 1196, 'therapyName': 'Lurbinectedin + Paclitaxel + Bevacizumab'}, {'id': 1197, 'therapyName': 'Lurbinectedin + Paclitaxel'}]","Phase I Study of Lurbinectedin (PM01183) in Combination With Paclitaxel, With or Without Bevacizumab, in Selected Advanced Solid Tumors",107
233,NCT01837862,Phase Ib/II,Recruiting,"[{'id': 2134, 'therapyName': 'Mebendazole + Vincristine + Carboplatin + Temozolomide'}, {'id': 2133, 'therapyName': 'Mebendazole + Bevacizumab + Irinotecan'}]",A Phase I/II Study of Mebendazole for the Treatment of Pediatric Gliomas,107
234,NCT02142803,Phase I,Recruiting,"[{'id': 1444, 'therapyName': 'MLN0128 + Bevacizumab'}]",MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors,107
235,NCT00618657,Phase II,"Active, not recruiting","[{'id': 1490, 'therapyName': 'Nab-paclitaxel + Carboplatin + Trastuzumab'}, {'id': 1489, 'therapyName': 'Nab-paclitaxel + Carboplatin + Bevacizumab'}]","Carboplatin+Nab-paclitaxel, Plus Trastuzumab (HER2+) or Bevacizumab (HER2-) in the Neoadjuvant Setting",107
236,NCT00906516,Phase II,Unknown status,"[{'id': 2146, 'therapyName': 'Neuradiab + Bevacizumab'}]",Neuradiab Combined With Bevacizumab (Avastin) Therapy in Patients With Recurrent Glioblastoma Multiforme,107
237,NCT01684397,Phase Ib/II,Recruiting,"[{'id': 1230, 'therapyName': 'Pazopanib + Bevacizumab'}]",Pazopanib Hydrochloride and Bevacizumab in Treating Patients With Previously Untreated Metastatic Kidney Cancer,107
238,NCT03063762,Phase I,Recruiting,"[{'id': 5365, 'therapyName': 'RO6874281 + Obinutuzumab + Atezolizumab'}, {'id': 5366, 'therapyName': 'RO6874281 + Obinutuzumab + Atezolizumab + Bevacizumab'}]","Study to Evaluate Safety, Pharmacokinetics and Therapeutic Activity of RO6874281 as a Combination Therapy in Participants With Unresectable Advanced and/or Metastatic Renal Cell Carcinoma (RCC)",107
239,NCT01871766,Phase II,Recruiting,"[{'id': 1119, 'therapyName': 'Sorafenib + Avastin + Cyclophosphamide'}, {'id': 1436, 'therapyName': 'Vincristine + Dactinomycin'}, {'id': 1435, 'therapyName': 'Vincristine + Dactinomycin + Cyclophosphamide'}]","Treatment of Localized Rhabdomyosarcoma With Chemotherapy, Radiotherapy, and Surgery",107
240,NCT00665990,Phase I,Completed,"[{'id': 1119, 'therapyName': 'Sorafenib + Avastin + Cyclophosphamide'}]",Phase I Study of Bevacizumab and Sorafenib Combined With Low Dose Cyclophosphamide in Patients With Refractory Solid Tumors and Leukemia,107
241,NCT00538005,Phase Ib/II,Unknown status,"[{'id': 2132, 'therapyName': 'Sorafenib + Bevacizumab + Oxaliplatin'}]","Sorafenib, Bevacizumab, and Oxaliplatin in Treating Patients With Metastatic Malignant Melanoma",107
242,NCT01189643,Phase I,"Active, not recruiting","[{'id': 1463, 'therapyName': 'Temozolomide + Irinotecan + Bevacizumab'}]","Irinotecan, Temozolomide and Bevacizumab in Combination With Existing High Dose Alkylator Based Chemotherapy for Treatment of Newly Diagnosed Patients With Desmoplastic Small Round Cell Tumor",107
243,NCT00876993,Phase I,Completed,"[{'id': 1463, 'therapyName': 'Temozolomide + Irinotecan + Bevacizumab'}]",Study of Irinotecan and Bevacizumab With Temozolomide in Refractory/Relapsed Central Nervous System (CNS) Tumors,107
244,NCT01217437,Phase II,"Active, not recruiting","[{'id': 1462, 'therapyName': 'Temozolomide + Irinotecan'}, {'id': 1463, 'therapyName': 'Temozolomide + Irinotecan + Bevacizumab'}]",Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors,107
245,NCT01552434,Phase I,Recruiting,"[{'id': 1376, 'therapyName': 'Temsirolimus + Bevacizumab + Valproic Acid + Cetuximab'}]","Bevacizumab, Temsirolimus, Valproic Acid, Cetuximab",107
246,NCT01191697,Phase II,"Active, not recruiting","[{'id': 1596, 'therapyName': 'Trastuzumab + Bevacizumab'}, {'id': 1597, 'therapyName': 'Capecitabine + Oxaliplatin'}]","CAPOX, Bevacizumab and Trastuzumab for Patients With HER2-Positive Metastatic Esophagogastric Cancer",107
247,NCT01290263,Phase Ib/II,Completed,"[{'id': 1219, 'therapyName': 'Trebananib + Bevacizumab'}, {'id': 1218, 'therapyName': 'Trebananib'}]",Amgen 386 for Recurrent Glioblastoma,107
248,NCT01664182,Phase II,"Active, not recruiting","[{'id': 1223, 'therapyName': 'Trebananib + Sunitinib'}, {'id': 1220, 'therapyName': 'Trebananib + Pazopanib'}, {'id': 1221, 'therapyName': 'Trebananib + Sorafenib'}, {'id': 1218, 'therapyName': 'Trebananib'}, {'id': 1219, 'therapyName': 'Trebananib + Bevacizumab'}]","Trebananib With or Without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Treating Patients With Advanced Kidney Cancer",107
249,NCT01946529,Phase II,"Active, not recruiting","[{'id': 1433, 'therapyName': 'Vincristine + Doxorubicin + Cyclophosphamide + Ifosfamide + Etoposide'}, {'id': 1434, 'therapyName': 'Vincristine + Doxorubicin + Cyclophosphamide + Ifosfamide + Etoposide + others'}]",Therapeutic Trial for Patients With Ewing Sarcoma Family of Tumor and Desmoplastic Small Round Cell Tumors,107
0,NCT01966003,Phase III,Completed,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 2141, 'therapyName': 'Bevacizumab-awwb'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]",Efficacy and Safety Study of ABP 215 Compared With Bevacizumab in Subjects With Advanced Non-Small Cell Lung Cancer,7438
0,NCT01508104,Phase Ib/II,Terminated,"[{'id': 1321, 'therapyName': 'BEZ235 + Everolimus'}, {'id': 735, 'therapyName': 'Everolimus'}]",Safety Study of BEZ235 With Everolimus in Subjects With Advanced Solid Tumors,6868
0,NCT02610361,Phase I,"Active, not recruiting","[{'id': 4025, 'therapyName': 'BGB-283'}]",Study of the Safety and Pharmacokinetics of BGB-283 in Patients With Solid Tumors,8325
0,NCT03150862,Phase Ib/II,Recruiting,"[{'id': 2947, 'therapyName': 'BGB-290'}, {'id': 6124, 'therapyName': 'BGB-290 + Temozolomide'}]",A Study Assessing BGB-290 With Radiation and/or Temozolomide (TMZ) in Subjects With Newly Diagnosed or Recurrent Glioblastoma,7863
1,NCT03150810,Phase Ib/II,Recruiting,"[{'id': 6124, 'therapyName': 'BGB-290 + Temozolomide'}]","Study to Assess Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Subjects With Locally Advanced or Metastatic Solid Tumors",7863
0,NCT02343120,Phase I,Recruiting,"[{'id': 2544, 'therapyName': 'BGB-3111'}]",Study of the Safety and Pharmacokinetics of BGB-3111 in Subjects With B-Cell Lymphoid Malignancies,7573
1,NCT03053440,Phase III,Recruiting,"[{'id': 768, 'therapyName': 'Ibrutinib'}, {'id': 2544, 'therapyName': 'BGB-3111'}]",A Study Comparing BGB-3111 and Ibrutinib in Subjects With Waldenström's Macroglobulinemia (WM),7573
2,NCT02569476,Phase I,Recruiting,"[{'id': 4682, 'therapyName': 'BGB-3111 + Obinutuzumab'}]",BGB 3111 in Combination With Obinutuzumab in Subjects With B-Cell Lymphoid Malignancies,7573
0,NCT02488408,Phase I,Recruiting,"[{'id': 712, 'therapyName': 'Cytarabine'}, {'id': 2660, 'therapyName': 'BGB-324'}]",Multicenter Open-label Study of BGB324 as a Single Agent and in Combination With Cytarabine in Patients With AML,7635
1,NCT02922777,Phase I,Recruiting,"[{'id': 5973, 'therapyName': 'BGB-324 + Docetaxel'}]",Trial of Dose Escalated BGB324 in Previously Treated Non-small Cell Lung Cancer.,7635
2,NCT02424617,Phase Ib/II,Recruiting,"[{'id': 2684, 'therapyName': 'BGB-324 + Erlotinib'}]",A Study of BGB324 in Combination With Erlotinib in Patients With Non-Small Cell Lung Cancer,7635
3,NCT03184571,Phase II,Recruiting,"[{'id': 5964, 'therapyName': 'BGB-324 + Pembrolizumab'}]",BGB324 in Combination With Pembrolizumab in Patients With Advanced NSCLC,7635
4,NCT03184558,Phase II,Recruiting,"[{'id': 5964, 'therapyName': 'BGB-324 + Pembrolizumab'}]",BGB324 in Combination With Pembrolizumab in Patients With TNBC,7635
0,NCT02407990,Phase I,Recruiting,"[{'id': 5871, 'therapyName': 'BGB-A317'}]","Study of the Safety, Pharmacokinetics and Antitumor Activities of BGB-A317 in Subjects With Advanced Tumors",8841
0,NCT01004224,Phase I,"Active, not recruiting","[{'id': 674, 'therapyName': 'BGJ398'}]",A Dose Escalation Study in Adult Patients With Advanced Solid Malignancies,6869
1,NCT02150967,Phase II,Recruiting,"[{'id': 674, 'therapyName': 'BGJ398'}]","A Phase II, Single Arm Study of BGJ398 in Patients With Advanced Cholangiocarcinoma",6869
2,NCT02160041,Phase II,Recruiting,"[{'id': 674, 'therapyName': 'BGJ398'}]",BGJ398 for Patients With Tumors With FGFR Genetic Alterations,6869
3,NCT02706691,Phase II,Not yet recruiting,"[{'id': 674, 'therapyName': 'BGJ398'}]","Pan FGFR Kinase Inhibitor BGJ398 in Treating Patients With FGFR1-3 Translocated, Mutated, or Amplified Recurrent Head and Neck Cancer",6869
4,NCT02657486,Phase I,Recruiting,"[{'id': 674, 'therapyName': 'BGJ398'}]",BGJ398 in Non-Muscle-Invasive Urothelial Carcinoma of the Bladder,6869
5,NCT01975701,Phase II,"Active, not recruiting","[{'id': 674, 'therapyName': 'BGJ398'}]",A Phase 2 Study of BGJ398 in Patients With Recurrent GBM,6869
6,NCT02312804,Phase I,Withdrawn,"[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 674, 'therapyName': 'BGJ398'}]",Ph Ib/BGJ398/Cervix and Other Solid Tumors,6869
7,NCT01928459,Phase I,Completed,"[{'id': 1293, 'therapyName': 'BGJ398 + BYL719'}]",Phase 1b Trial of BGJ398/BYL719 in Solid Tumors,6869
8,NCT01820364,Phase II,Terminated,"[{'id': 1100, 'therapyName': 'Binimetinib + Encorafenib'}, {'id': 1260, 'therapyName': 'Encorafenib + Ribociclib'}, {'id': 1337, 'therapyName': 'Encorafenib + BKM120'}, {'id': 1336, 'therapyName': 'BGJ398 + Encorafenib'}, {'id': 1338, 'therapyName': 'Capmatinib + Encorafenib'}]", LGX818 in Combination With Agents (MEK162; BKM120; LEE011; BGJ398; INC280) in Advanced BRAF Melanoma,6869
9,NCT02575508,Phase Ib/II,Withdrawn,"[{'id': 3142, 'therapyName': 'BGJ398 + Fluorouracil + Irinotecan + Oxaliplatin'}]",Pan FGFR Kinase Inhibitor BGJ398 and Combination Chemotherapy in Treating Patients With Untreated Metastatic Pancreatic Cancer,6869
10,NCT02257541,Phase Ib/II,"Active, not recruiting","[{'id': 2284, 'therapyName': 'BGJ398 + Imatinib'}]",BGJ398 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST),6869
11,NCT02159066,Phase II,"Active, not recruiting","[{'id': 1101, 'therapyName': 'Binimetinib + Encorafenib + Ribociclib'}, {'id': 1100, 'therapyName': 'Binimetinib + Encorafenib'}, {'id': 2216, 'therapyName': 'LGX818 + MEK162 + INC280'}, {'id': 2215, 'therapyName': 'LGX818 + MEK162 + BKM120'}, {'id': 2214, 'therapyName': 'LGX818 + MEK162 + BGJ398'}]","LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma",6869
0,NCT03164772,Phase Ib/II,Not yet recruiting,"[{'id': 5818, 'therapyName': 'BI 1361849 + Durvalumab + Tremelimumab'}]",Phase 1/2 Study of Combination Immunotherapy and mRNA Vaccine in Subjects With NSCLC,8812
0,NCT03156114,Phase I,Recruiting,"[{'id': 5692, 'therapyName': 'BI 754091'}, {'id': 5690, 'therapyName': 'BI 754111'}]",This Study Tests the New Medicine BI 754111 Alone or in Combination With Another New Substance BI 754091 in Patients With Advanced Cancer. The Study Tests Different Doses to Find the Best Dose for Continuous Treatment.,8747
1,NCT02952248,Phase I,Recruiting,"[{'id': 5692, 'therapyName': 'BI 754091'}]",A Trial to Find and Investigate a Safe Dose of a New Substance (BI 754091) for Patients With Solid Tumours,8747
2,NCT03166631,Phase I,Recruiting,"[{'id': 6263, 'therapyName': 'BI 754091 + BI 891065'}, {'id': 6262, 'therapyName': 'BI 891065'}]",A Trial to Find the Safe Dose for BI 891065 Alone and in Combination With BI 754091 in Patients With Incurable Tumours or Tumours That Have Spread,8747
0,NCT03156114,Phase I,Recruiting,"[{'id': 5692, 'therapyName': 'BI 754091'}, {'id': 5690, 'therapyName': 'BI 754111'}]",This Study Tests the New Medicine BI 754111 Alone or in Combination With Another New Substance BI 754091 in Patients With Advanced Cancer. The Study Tests Different Doses to Find the Best Dose for Continuous Treatment.,8745
0,NCT01296932,Phase I,Completed,"[{'id': 4276, 'therapyName': 'BI 836826'}]",BI836826 Dose Escalation in Relapsed Chronic Lymphocytic Leukaemia (CLL),8395
1,NCT02759016,Phase I,Recruiting,"[{'id': 4277, 'therapyName': 'BI 836826 + Ibrutinib'}]","Intravenous BI 836826 in Combination With Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) Patients Who Have Received at Least One Prior Systemic Therapy, and Who Are Eligible for Treatment With Ibrutinib",8395
2,NCT02538614,Phase Ib/II,Terminated,"[{'id': 4396, 'therapyName': 'BI 836826 + Idelalisib '}]",Study of Idelalisib in Combination With BI 836826 in Participants With Chronic Lymphocytic Leukemia,8395
0,NCT03013998,Phase Ib/II,Recruiting,"[{'id': 4003, 'therapyName': 'Azacitidine + Enasidenib'}, {'id': 5539, 'therapyName': 'Azacitidine + Entospletinib'}, {'id': 5536, 'therapyName': 'Cytarabine + Daunorubicin + Samalizumab'}, {'id': 5538, 'therapyName': 'Azacitidine + BI 836858'}]",Study of Biomarker-Based Treatment of Acute Myeloid Leukemia,8715
1,NCT01690624,,Recruiting,"[{'id': 5537, 'therapyName': 'BI 836858'}]",BI 836858 Dose Escalation in Patients With Refractory or Relapsed Acute Myeloid Leukemia and in Patients in Complete Remission With High Risk to Relapse,8715
2,NCT02240706,Phase II,Recruiting,"[{'id': 5537, 'therapyName': 'BI 836858'}]",Phase I/II Trial to Investigate BI 836858 in Myelodysplastic Syndromes,8715
3,NCT02632721,Phase II,Recruiting,"[{'id': 5540, 'therapyName': 'BI 836858 + Decitabine'}, {'id': 650, 'therapyName': 'Decitabine'}]",A Study to Find and Investigate a Safe Dose of BI 836858 in Combination With Decitabine for Patients With Acute Myeloid Leukemia (AML),8715
0,NCT03166631,Phase I,Recruiting,"[{'id': 6263, 'therapyName': 'BI 754091 + BI 891065'}, {'id': 6262, 'therapyName': 'BI 891065'}]",A Trial to Find the Safe Dose for BI 891065 Alone and in Combination With BI 754091 in Patients With Incurable Tumours or Tumours That Have Spread,8958
0,NCT00002651,Phase III,Completed,"[{'id': 1507, 'therapyName': 'Bicalutamide'}, {'id': 759, 'therapyName': 'Goserelin'}]",Hormone Therapy in Treating Men With Stage IV Prostate Cancer,1115
1,NCT01342367,Phase I,Recruiting,"[{'id': 1507, 'therapyName': 'Bicalutamide'}, {'id': 2643, 'therapyName': 'Dutasteride'}, {'id': 2644, 'therapyName': 'Finasteride'}]",Feasibility of Hormones and Radiation for Intermediate or High Risk Prostate Cancer,1115
2,NCT02064036,Phase I,Recruiting,"[{'id': 1507, 'therapyName': 'Bicalutamide'}, {'id': 759, 'therapyName': 'Goserelin'}, {'id': 795, 'therapyName': 'Leuprolide'}]",Stereotactic Boost and Long-Term Androgen Deprivation for Adenocarcinoma of the Prostate,1115
3,NCT01674270,Phase II,Completed,"[{'id': 1507, 'therapyName': 'Bicalutamide'}, {'id': 1814, 'therapyName': 'Degarelix'}]",Degarelix Neo-Adjuvant Radical Prostatectomy Trial,1115
4,NCT02058706,Phase II,Recruiting,"[{'id': 759, 'therapyName': 'Goserelin'}, {'id': 1507, 'therapyName': 'Bicalutamide'}, {'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 795, 'therapyName': 'Leuprolide'}]",LHRH Analogue Therapy With Enzalutamide or Bicalutamide in Treating Patients With Metastatic Hormone Sensitive Prostate Cancer,1115
5,NCT02059213,Phase II,"Active, not recruiting","[{'id': 759, 'therapyName': 'Goserelin'}, {'id': 850, 'therapyName': 'Palbociclib'}, {'id': 1507, 'therapyName': 'Bicalutamide'}, {'id': 795, 'therapyName': 'Leuprolide'}]", A Phase II Study of Androgen Deprivation Therapy With or Without PD 0332991 in RB-Positive Metastatic Prostate Cancer,1115
6,NCT00541047,Phase III,"Active, not recruiting","[{'id': 795, 'therapyName': 'Leuprolide'}, {'id': 759, 'therapyName': 'Goserelin'}, {'id': 1507, 'therapyName': 'Bicalutamide'}]",Radiation Therapy and Androgen Deprivation Therapy in Treating Patients Who Have Undergone Surgery for Prostate Cancer (RADICALS),1115
7,NCT02366494,Phase I,Recruiting,"[{'id': 795, 'therapyName': 'Leuprolide'}, {'id': 759, 'therapyName': 'Goserelin'}, {'id': 2050, 'therapyName': 'Triptorelin'}, {'id': 1507, 'therapyName': 'Bicalutamide'}, {'id': 720, 'therapyName': 'Docetaxel'}]",Micro RNAs to Predict Response to Androgen Deprivation Therapy,1115
8,NCT03147196,Phase II,Recruiting,"[{'id': 5686, 'therapyName': 'Raloxifene + Bicalutamide'}, {'id': 5685, 'therapyName': 'Raloxifene'}, {'id': 1507, 'therapyName': 'Bicalutamide'}]",Bicalutamide and Raloxifene Hydrochloride in Treating Patients With Prostate Cancer Undergoing Surgery,1115
9,NCT00936390,Phase III,"Active, not recruiting","[{'id': 742, 'therapyName': 'Flutamide'}, {'id': 759, 'therapyName': 'Goserelin'}, {'id': 795, 'therapyName': 'Leuprolide'}, {'id': 2050, 'therapyName': 'Triptorelin'}, {'id': 1507, 'therapyName': 'Bicalutamide'}]",Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer,1115
10,NCT02614859,Phase II,Recruiting,"[{'id': 1507, 'therapyName': 'Bicalutamide'}, {'id': 1031, 'therapyName': 'Metformin'}]",Bicalutamide With or Without Metformin for Biochemical Recurrence in Overweight or Obese Prostate Cancer Patients,1115
11,NCT01420250,Phase I,"Active, not recruiting","[{'id': 1507, 'therapyName': 'Bicalutamide'}, {'id': 1571, 'therapyName': 'Cabazitaxel'}]",Cabazitaxel With Radiation and Hormone Therapy for Prostate Cancer,1115
12,NCT01809691,Phase III,"Active, not recruiting","[{'id': 2671, 'therapyName': 'Orteronel '}, {'id': 1507, 'therapyName': 'Bicalutamide'}]","S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer",1115
13,NCT02531516,Phase III,Recruiting,"[{'id': 2649, 'therapyName': 'Abiraterone + ARN-509 + Prednisone'}, {'id': 1507, 'therapyName': 'Bicalutamide'}]",An Efficacy and Safety Study of JNJ-56021927 (ARN-509) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy,1115
14,NCT02346253,Phase Ib/II,Recruiting,"[{'id': 795, 'therapyName': 'Leuprolide'}, {'id': 2050, 'therapyName': 'Triptorelin'}, {'id': 1814, 'therapyName': 'Degarelix'}, {'id': 1507, 'therapyName': 'Bicalutamide'}, {'id': 759, 'therapyName': 'Goserelin'}]",High-Dose Brachytherapy in Treating Patients With Prostate Cancer,1115
15,NCT02582749,Phase II,Recruiting,"[{'id': 4618, 'therapyName': 'Bicalutamide + Ra 223'}, {'id': 1507, 'therapyName': 'Bicalutamide'}]",Androgen Deprivation Therapy +/- Radium-223 Dichloride in Metastatic Prostate Cancer With Bone Metastases,1115
16,NCT03070886,Phase III,Recruiting,"[{'id': 5450, 'therapyName': 'Bicalutamide + Docetaxel + Flutamide + Goserelin + Leuprolide + Nilutamide'}, {'id': 5449, 'therapyName': 'Bicalutamide + Flutamide + Goserelin + Leuprolide + Nilutamide'}]",Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery,1115
17,NCT03043807,Phase II,Recruiting,"[{'id': 3945, 'therapyName': 'Bicalutamide + Docetaxel + Leuprolide'}]",A Study of Definitive Therapy to Treat Prostate Cancer After Prostatectomy,1115
18,NCT02716974,Phase I,Recruiting,"[{'id': 3945, 'therapyName': 'Bicalutamide + Docetaxel + Leuprolide'}]",A Study of Definitive Therapy to Treat Prostate Cancer,1115
19,NCT03141671,Phase II,Not yet recruiting,"[{'id': 5742, 'therapyName': 'Bicalutamide + Gonadorelin'}, {'id': 5743, 'therapyName': 'Abiraterone + ARN-509 + Gonadorelin + Prednisone'}]",Randomized Phase II Study of Salvage XRT + ADT +/- Abiraterone and Apalutamide for Rising PSA After RP (FORMULA-509),1115
20,NCT02605486,Phase Ib/II,Recruiting,"[{'id': 3252, 'therapyName': 'Bicalutamide + Palbociclib'}]",Palbociclib in Combination With Bicalutamide for the Treatment of AR(+) Metastatic Breast Cancer (MBC),1115
21,NCT03090165,Phase Ib/II,Recruiting,"[{'id': 5479, 'therapyName': 'Ribociclib + Bicalutamide'}]",Ribociclib and Bicalutamide in AR+ TNBC,1115
0,NCT02479178,Phase II,Terminated,"[{'id': 3640, 'therapyName': 'BIND-014'}]","A Study of BIND-014 in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical Cancer and Squamous Cell Carcinoma of the Head and Neck  (iNSITE2)",8183
0,NCT03271047,,Recruiting,"[{'id': 807, 'therapyName': 'Binimetinib'}, {'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 779, 'therapyName': 'Ipilimumab'}]",Study of Binimetinib + Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Microsatellite-stable (MSS) Metastatic Colorectal Cancer With RAS Mutation,6827
1,NCT01801358,Phase Ib/II,Terminated,"[{'id': 807, 'therapyName': 'Binimetinib'}, {'id': 1114, 'therapyName': 'MEK162 + AEB071'}]", A Phase Ib/II Study of AEB071 and MEK162 in Adult Patients With Metastatic Uveal Melanoma,6827
2,NCT01927341,Phase Ib/II,Completed,"[{'id': 807, 'therapyName': 'Binimetinib'}, {'id': 845, 'therapyName': 'Panitumumab'}]","Phase Ib/II Study of Efficacy and Safety of MEK162 and Panitumumab, in Adult mCRC Patients With Mutant or Wild-type RAS Tumors",6827
3,NCT01885195,Phase II,Completed,"[{'id': 807, 'therapyName': 'Binimetinib'}]",MEK162 for Patients With RAS/RAF/MEK Activated Tumors,6827
4,NCT02285439,Phase Ib/II,Recruiting,"[{'id': 807, 'therapyName': 'Binimetinib'}]",MEK 162 for Children w/Progressive/Recurrent Cancer/Study for Children w/Low-Grade Gliomas/Other Ras/Raf/MAP Pathway Activated Tumors,6827
5,NCT03170206,Phase Ib/II,Recruiting,"[{'id': 850, 'therapyName': 'Palbociclib'}, {'id': 807, 'therapyName': 'Binimetinib'}, {'id': 5838, 'therapyName': 'Binimetinib + Palbociclib'}]",Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the MEK Inhibitor Binimetinib (MEK162) for Patients With Advanced KRAS Mutant Non-Small Cell Lung Cancer,6827
6,NCT01849874,Phase III,"Active, not recruiting","[{'id': 807, 'therapyName': 'Binimetinib'}]","A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer",6827
7,NCT02089230,Phase Ib/II,Recruiting,"[{'id': 807, 'therapyName': 'Binimetinib'}]","Phase I/II MEK162 Relapsed and/or Refractory Acute Myeloid Leukemia (AML) and Poor Prognosis, Not Suitable for or Unwilling to Receive Standard Therapy",6827
8,NCT01763164,Phase III,"Active, not recruiting","[{'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 807, 'therapyName': 'Binimetinib'}]",Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma,6827
9,NCT03231306,Phase II,Not yet recruiting,"[{'id': 807, 'therapyName': 'Binimetinib'}]",Phase II Study of Binimetinib in Children and Adults With NF1 Plexiform Neurofibromas (NF108-BINI),6827
10,NCT02928224,Phase III,Recruiting,"[{'id': 1916, 'therapyName': 'Cetuximab + Encorafenib'}, {'id': 4886, 'therapyName': 'Binimetinib + Cetuximab + LGX818'}, {'id': 1874, 'therapyName': 'Cetuximab + Irinotecan'}, {'id': 2180, 'therapyName': 'Cetuximab + FOLFIRI'}]",Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer (BEACON CRC),6827
11,NCT02451865,Phase I,Withdrawn,"[{'id': 2740, 'therapyName': 'Binimetinib + Docetaxel'}]","Binimetinib With Docetaxel in Treating Patients With Previously Treated, Stage IV Non-small Cell Lung Cancer",6827
12,NCT02263898,Phase II,Withdrawn,"[{'id': 1100, 'therapyName': 'Binimetinib + Encorafenib'}]",Intermittent LGX818 and MEK162 in Treating Patients With Metastatic Melanoma Who Have BRAFV600 Mutations,6827
13,NCT02159066,Phase II,"Active, not recruiting","[{'id': 1101, 'therapyName': 'Binimetinib + Encorafenib + Ribociclib'}, {'id': 1100, 'therapyName': 'Binimetinib + Encorafenib'}, {'id': 2216, 'therapyName': 'LGX818 + MEK162 + INC280'}, {'id': 2215, 'therapyName': 'LGX818 + MEK162 + BKM120'}, {'id': 2214, 'therapyName': 'LGX818 + MEK162 + BGJ398'}]","LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma",6827
14,NCT01543698,Phase Ib/II,"Active, not recruiting","[{'id': 1100, 'therapyName': 'Binimetinib + Encorafenib'}, {'id': 1101, 'therapyName': 'Binimetinib + Encorafenib + Ribociclib'}]",A Phase Ib/II Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF Dependent Advanced Solid Tumors,6827
15,NCT01820364,Phase II,Terminated,"[{'id': 1100, 'therapyName': 'Binimetinib + Encorafenib'}, {'id': 1260, 'therapyName': 'Encorafenib + Ribociclib'}, {'id': 1337, 'therapyName': 'Encorafenib + BKM120'}, {'id': 1336, 'therapyName': 'BGJ398 + Encorafenib'}, {'id': 1338, 'therapyName': 'Capmatinib + Encorafenib'}]", LGX818 in Combination With Agents (MEK162; BKM120; LEE011; BGJ398; INC280) in Advanced BRAF Melanoma,6827
16,NCT01909453,Phase III,"Active, not recruiting","[{'id': 342, 'therapyName': 'Vemurafenib'}, {'id': 796, 'therapyName': 'Encorafenib'}, {'id': 1100, 'therapyName': 'Binimetinib + Encorafenib'}]",Study Comparing Combination of LGX818 Plus MEK162 and LGX818 Monotherapy Versus Vemurafenib in BRAF Mutant Melanoma,6827
17,NCT02613650,Phase I,Recruiting,"[{'id': 3247, 'therapyName': 'Binimetinib + FOLFIRI'}]",A Trial of FOLFIRI With MEK162 in Patients With Advanced KRAS Positive Metastatic Colorectal Cancers,6827
18,NCT03106415,Phase Ib/II,Recruiting,"[{'id': 5568, 'therapyName': 'Binimetinib + Pembrolizumab'}]",Pembrolizumab and Binimetinib in Treating Patients With Locally Advanced or Metastatic Triple Negative Breast Cancer,6827
19,NCT03158103,Phase I,Recruiting,"[{'id': 5730, 'therapyName': 'Binimetinib + PLX3397'}]",A Study of MEK162 (Binimetinib) in Combination With Pexidartinib in Patients With Advanced Gastrointestinal Stromal Tumor (GIST),6827
20,NCT01781572,Phase Ib/II,"Active, not recruiting","[{'id': 5, 'therapyName': 'Binimetinib + Ribociclib'}]",A Phase Ib/II Study of LEE011 in Combination With MEK162 in Patients With NRAS Mutant Melanoma,6827
21,NCT01449058,Phase Ib/II,Completed,"[{'id': 1311, 'therapyName': 'BYL719 + MEK162'}]",A Phase Ib Study of MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors,6827
22,NCT02105350,Phase I,Suspended,"[{'id': 2210, 'therapyName': 'Gemcitabine + MEK162 + Oxaliplatin'}]",A Study of MEK162 With Gemcitabine and Oxaliplatin in Biliary Cancer,6827
23,NCT02185690,Phase I,Not yet recruiting,"[{'id': 2213, 'therapyName': 'MEK162 + Carboplatin + Pemetrexed'}]","A Phase I/Ib Study of MEK162, a MEK Inhibitor, in Combination With Carboplatin and Pemetrexed in Patients With Non-squamous Carcinoma of the Lung",6827
24,NCT01859026,Phase I,Recruiting,"[{'id': 1253, 'therapyName': 'MEK162 + Erlotinib'}]",A Phase I/IB Trial of MEK162 in Combination With Erlotinib in NSCLC Harboring KRAS or EGFR Mutation,6827
25,NCT02041481,Phase I,"Active, not recruiting","[{'id': 2217, 'therapyName': 'MEK162 + FOLFOX'}]","MEK Inhibitor MEK162 in Combination With Leucovorin Calcium, Fluorouracil, and Oxaliplatin in Treating Patients With Advanced Metastatic Colorectal Cancer",6827
26,NCT01828034,Phase Ib/II,"Active, not recruiting","[{'id': 2218, 'therapyName': 'MEK162 + Gemcitabine + Cisplatin'}]","First Line Gemcitabine, Cisplatin and MEK162 in Advanced Biliary Tract Carcinoma",6827
27,NCT02049801,Phase I,"Active, not recruiting","[{'id': 2220, 'therapyName': 'MEK162 + Idarubicin + Cytarabine'}]","MEK Inhibitor MEK162, Idarubicin, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia",6827
28,NCT01991379,Phase Ib/II,Recruiting,"[{'id': 1430, 'therapyName': 'MEK162 + Imatinib mesylate'}]",MEK162 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST),6827
29,NCT02225574,Phase Ib/II,Completed,"[{'id': 2219, 'therapyName': 'MEK162 + Nilotinib'}]","An Open-Label, Phase I/II Study of Nilotinib (Tasigna) and MEK-162 (ARRY-162) Used in Combination for Patients With Refractory or Advanced Chronic Myeloid Leukemia and Philadelphia Positive Acute Leukemia (Protocol CAMN107AUS41T)",6827
30,NCT01649336,Phase I,Completed,"[{'id': 2010, 'therapyName': 'MEK162 + Paclitaxel'}]","A Study of MEK162 and Paclitaxel in Patients With Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer",6827
0,NCT01940172,Phase I,Completed,"[{'id': 1458, 'therapyName': 'Conatumumab'}, {'id': 2647, 'therapyName': 'Birinapant  '}]",Study of Birinapant in Combination With Conatumumab in Subjects With Relapsed Ovarian Cancer,7623
1,NCT02587962,Phase Ib/II,Recruiting,"[{'id': 6160, 'therapyName': 'Birinapant  + Pembrolizumab'}]",Dose-escalation Study of Birinapant and Pembrolizumab in Solid Tumors,7623
0,NCT01741753,Phase I,Terminated,"[{'id': 2499, 'therapyName': 'Abiraterone + BKM120 + Prednisone'}]",BKM120+Abiraterone Acetate for Metastatic CRPC,6875
1,NCT01695473,Phase II,"Active, not recruiting","[{'id': 680, 'therapyName': 'BKM120'}]",Neoadjuvant BKM120 in High-risk Prostate Cancer,6875
2,NCT01911325,Phase Ib/II,Terminated,"[{'id': 680, 'therapyName': 'BKM120'}, {'id': 720, 'therapyName': 'Docetaxel'}]",Phase II Study of Buparlisib + Docetaxel in Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) Patients,6875
3,NCT01820325,Phase II,Terminated,"[{'id': 680, 'therapyName': 'BKM120'}]", Safety and Efficacy of Buparlisib (BKM120) in Patients With Untreated Squamous Non-small Cell Lung Cancer,6875
4,NCT02220855,Phase II,Recruiting,"[{'id': 680, 'therapyName': 'BKM120'}]",A Study of BKM120 (Buparlisib) in Relapsed or Refractory Thymomas,6875
5,NCT02340780,Phase II,"Active, not recruiting","[{'id': 680, 'therapyName': 'BKM120'}]",Buparlisib in Patients With Relapsed and Refractory Chronic Lymphocytic Leukemia,6875
6,NCT01719250,Phase I,Completed,"[{'id': 680, 'therapyName': 'BKM120'}]",Buparlisib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma,6875
7,NCT01396499,Phase I,Completed,"[{'id': 680, 'therapyName': 'BKM120'}]","Study to Assess Safety, Tolerability and Preliminary Efficacy of BKM120, PI3K Kinase Inhibitor, With Advanced Leukemias",6875
8,NCT01571024,Phase I,Completed,"[{'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 680, 'therapyName': 'BKM120'}]", BKM120 + mFOLFOX6 in Advanced Solid Tumors With Expansion Cohort Pancreatic Cancer,6875
9,NCT01816984,Phase Ib/II,"Active, not recruiting","[{'id': 694, 'therapyName': 'Cetuximab'}, {'id': 680, 'therapyName': 'BKM120'}]",PI3K Inhibitor BKM120 and Cetuximab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer,6875
10,NCT01833169,Phase II,Completed,"[{'id': 680, 'therapyName': 'BKM120'}]",BKM120 for Patients With PI3K-activated Tumors,6875
11,NCT02301364,Phase II,Completed,"[{'id': 680, 'therapyName': 'BKM120'}]",Buparlisib (BKM120) In Patients With Recurrent/Refractory Primary Central Nervous System Lymphoma (PCNSL) and Recurrent/Refractory Secondary Central Nervous System Lymphoma (SCNSL),6875
12,NCT02117817,Phase I,Withdrawn,"[{'id': 1367, 'therapyName': 'BKM120 + Abraxane'}]","Phase I BKM120/Abraxane in Solid Tumors, Expansion Phase Recurrent Endometrial or Ovarian Cancer",6875
13,NCT01349660,Phase Ib/II,"Active, not recruiting","[{'id': 1178, 'therapyName': 'BKM120 + Bevacizumab'}]",Combination of BKM120 and Bevacizumab in Refractory Solid Tumors and Relapsed/Refractory Glioblastoma Multiforme,6875
14,NCT01283048,Phase I,Completed,"[{'id': 1178, 'therapyName': 'BKM120 + Bevacizumab'}]",Bevacizumab and BKM-120 in Patients With Metastatic Renal Cell Carcinoma,6875
15,NCT01300962,Phase I,"Active, not recruiting","[{'id': 1538, 'therapyName': 'BKM120 + Capecitabine + Lapatinib'}, {'id': 1537, 'therapyName': 'BKM120 + Capecitabine + Trastuzumab'}, {'id': 1536, 'therapyName': 'BKM120 + Capecitabine'}, {'id': 1535, 'therapyName': 'BYL719 + Capecitabine'}]",Study of BKM120 or BYL719 and Capecitabine in Patients With Metastatic Breast Cancer,6875
16,NCT02000882,Phase II,"Active, not recruiting","[{'id': 1536, 'therapyName': 'BKM120 + Capecitabine'}]",Capecitabine + BKM120 TNBC BC Brain Met,6875
17,NCT01934361,Phase Ib/II,Completed,"[{'id': 2500, 'therapyName': 'BKM120 + Lomustine'}, {'id': 2501, 'therapyName': 'BKM120 + Carboplatin'}]",Phase Ib/II Study of Buparlisib Plus Carboplatin or Lomustine in Patients With Recurrent Glioblastoma Multiforme,6875
18,NCT01297452,Phase I,Completed,"[{'id': 1183, 'therapyName': 'BKM120 + Carboplatin + Paclitaxel'}]",BKM120 + Carboplatin + Paclitaxel for Patients With Advanced Solid Tumors,6875
19,NCT02113878,Phase I,Recruiting,"[{'id': 1691, 'therapyName': 'BKM120 + Cisplatin'}]",Phase Ib Study of BKM120 With Cisplatin and XRT in High Risk Locally Advanced Squamous Cell Cancer of Head and Neck,6875
20,NCT01540253,Phase I,Completed,"[{'id': 1330, 'therapyName': 'BKM120 + Docetaxel'}]","PI3K Inhibitor BKM120 and Docetaxel in Treating Patients With Advanced Solid Tumor That is Locally Advanced, Cannot Be Removed By Surgery, or Metastatic",6875
21,NCT01487265,Phase II,"Active, not recruiting","[{'id': 1319, 'therapyName': 'BKM120 + Erlotinib'}]",Trial of Erlotinib and BKM120 in Patients With Advanced Non Small Cell Lung Cancer Previously Sensitive to Erlotinib,6875
22,NCT02194049,Phase I,Completed,"[{'id': 1626, 'therapyName': 'BKM120 + Etoposide + Cisplatin'}]","Cisplatin, Etoposide and PI3K Inhibitor BKM120 in Treating Patients With Advanced Solid Tumors or Small Cell Lung Cancer",6875
23,NCT01470209,Phase I,"Active, not recruiting","[{'id': 1314, 'therapyName': 'BKM120 + Everolimus'}]",A Phase I Study of BKM120 and Everolimus in Advanced Solid Malignancies,6875
24,NCT02088684,Phase Ib/II,"Active, not recruiting","[{'id': 2315, 'therapyName': 'BKM120 + Fulvestrant + LEE011'}, {'id': 2316, 'therapyName': 'Fulvestrant + LEE011'}, {'id': 2317, 'therapyName': 'BYL719 + Fulvestrant + LEE011'}]",Study of LEE011 With Fulvestrant and BYL719 or BKM120 in Advanced Breast Cancer,6875
25,NCT01971489,Phase I,Withdrawn,"[{'id': 1304, 'therapyName': 'BKM120 + Gemcitabine + Cisplatin'}]","PI3K Inhibitor BKM120, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Advanced Solid Tumors",6875
26,NCT02614508,Phase I,"Active, not recruiting","[{'id': 3630, 'therapyName': 'BKM120 + Ibrutinib'}, {'id': 3629, 'therapyName': 'BKM120 + Ofatumumab'}]",Buparlisib and Ofatumumab or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia,6875
27,NCT02756247,Phase I,Recruiting,"[{'id': 3630, 'therapyName': 'BKM120 + Ibrutinib'}]",A Clinical Trial of Buparlisib and Ibrutinib in Lymphoma,6875
28,NCT01870726,Phase Ib/II,Completed,"[{'id': 2461, 'therapyName': 'BKM120 + INC280'}]",Safety and Efficacy of INC280 and Buparlisib (BKM120) in Patients With Recurrent Gliobastoma,6875
29,NCT01923168,Phase II,Completed,"[{'id': 1570, 'therapyName': 'BKM120 + Letrozole'}, {'id': 794, 'therapyName': 'Letrozole'}, {'id': 1553, 'therapyName': 'Letrozole + BYL719'}]","Study of Letrozole With or Without BYL719 or Buparlisib, for the Neoadjuvant Treatment of Postmenopausal Women",6875
30,NCT01623349,Phase I,"Active, not recruiting","[{'id': 2171, 'therapyName': 'BYL719 + Olaparib'}, {'id': 2170, 'therapyName': 'BKM120 + Olaparib'}]",Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer,6875
31,NCT01572727,Phase II,Completed,"[{'id': 1545, 'therapyName': 'BKM120 + Paclitaxel'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]","A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation",6875
32,NCT01852292,Phase II,Completed,"[{'id': 1545, 'therapyName': 'BKM120 + Paclitaxel'}]",Study of Efficacy and Safety of Buparlisib (BKM120) Plus Paclitaxel Versus Placebo Plus Paclitaxel in Recurrent or Metastatic Head and Neck Cancer Previously Pre-treated With a Platinum Therapy,6875
33,NCT01591421,Phase Ib/II,"Active, not recruiting","[{'id': 1990, 'therapyName': 'BKM120 + Panitumumab'}]",P13Kinase Inhibitor BKM120 in Combination With Panitumumab in Patients With Metastatic or Advanced RAS-Wild Type Colorectal Cancer.,6875
34,NCT01723800,Phase I,Completed,"[{'id': 1112, 'therapyName': 'BKM120 + Pemetrexed + Carboplatin'}]"," PI3K Inhibitor BKM120, Carboplatin, and Pemetrexed Disodium in Treating Patients With Stage IV Non-Small Cell Lung Cancer",6875
35,NCT02049541,Phase I,"Active, not recruiting","[{'id': 2502, 'therapyName': 'BKM120 + Rituximab'}]",Study of BKM120; Rituximab in Patients With Relapsed or Refractory Indolent B-Cell Lymphoma,6875
36,NCT02303041,Phase I,"Active, not recruiting","[{'id': 1547, 'therapyName': 'BKM120 + Sonidegib'}]",Erismodegib and Buparlisib in Treating Patients With Advanced or Metastatic Basal Cell Carcinoma,6875
37,NCT01576666,Phase Ib/II,Completed,"[{'id': 1547, 'therapyName': 'BKM120 + Sonidegib'}]","Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors",6875
38,NCT01473901,Phase I,Completed,"[{'id': 4474, 'therapyName': 'BKM120 + Temozolomide'}]",A Phase I Dose Escalation Study of BKM120 With Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma,6875
39,NCT01512251,Phase Ib/II,Completed,"[{'id': 1322, 'therapyName': 'BKM120 + Vemurafenib'}]",BKM120 Combined With Vemurafenib (PLX4032) in BRAFV600E/K Mutant Advanced Melanoma,6875
40,NCT01820364,Phase II,Terminated,"[{'id': 1100, 'therapyName': 'Binimetinib + Encorafenib'}, {'id': 1260, 'therapyName': 'Encorafenib + Ribociclib'}, {'id': 1337, 'therapyName': 'Encorafenib + BKM120'}, {'id': 1336, 'therapyName': 'BGJ398 + Encorafenib'}, {'id': 1338, 'therapyName': 'Capmatinib + Encorafenib'}]", LGX818 in Combination With Agents (MEK162; BKM120; LEE011; BGJ398; INC280) in Advanced BRAF Melanoma,6875
41,NCT01610284,Phase III,"Active, not recruiting","[{'id': 1546, 'therapyName': 'Fulvestrant + BKM120'}, {'id': 744, 'therapyName': 'Fulvestrant'}]",Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor,6875
42,NCT01633060,Phase III,"Active, not recruiting","[{'id': 744, 'therapyName': 'Fulvestrant'}, {'id': 1546, 'therapyName': 'Fulvestrant + BKM120'}]","A Phase III Study of BKM120 With Fulvestrant in Patients With HR+, HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi",6875
43,NCT02154776,Phase I,Completed,"[{'id': 1594, 'therapyName': 'LEE011 + BKM120 + Letrozole'}]","Dose Escalation Study of LEE011 in Combination With Buparlisib and Letrozole in HR+, HER2-negative Post-menopausal Women With Advanced Breast Cancer. (LeeBLet)",6875
44,NCT02159066,Phase II,"Active, not recruiting","[{'id': 1101, 'therapyName': 'Binimetinib + Encorafenib + Ribociclib'}, {'id': 1100, 'therapyName': 'Binimetinib + Encorafenib'}, {'id': 2216, 'therapyName': 'LGX818 + MEK162 + INC280'}, {'id': 2215, 'therapyName': 'LGX818 + MEK162 + BKM120'}, {'id': 2214, 'therapyName': 'LGX818 + MEK162 + BGJ398'}]","LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma",6875
0,NCT02462252,Phase II,Recruiting,"[{'id': 4411, 'therapyName': 'anti-thymocyte globulin + BKT140 + Cyclosporine + Methylprednisolone'}]","Phase IIA Open Label Study to Evaluate Efficacy and Safety of BL-8040 Followed by (hATG), Cyclosporine and Methyprednisolone in Adult Subjects With Aplastic Anemia or Hypoplastic Myelodysplastic Syndrome",7786
1,NCT03193190,Phase Ib/II,Recruiting,"[{'id': 5942, 'therapyName': 'Atezolizumab + BKT140'}, {'id': 5940, 'therapyName': 'Gemcitabine + Nab-Paclitaxel + mFOLFOX-6'}, {'id': 5941, 'therapyName': 'Atezolizumab + PEGPH20'}, {'id': 1343, 'therapyName': 'Atezolizumab + Cobimetinib'}]",A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (PDAC),7786
2,NCT03281369,Phase Ib/II,Not yet recruiting,"[{'id': 1343, 'therapyName': 'Atezolizumab + Cobimetinib'}, {'id': 6274, 'therapyName': 'mFOLFOX-6 + Atezolizumab + Cobimetinib'}, {'id': 6275, 'therapyName': 'mFOLFOX-6 + Atezolizumab'}, {'id': 6276, 'therapyName': 'Atezolizumab + Linagliptin'}, {'id': 5941, 'therapyName': 'Atezolizumab + PEGPH20'}, {'id': 5942, 'therapyName': 'Atezolizumab + BKT140'}, {'id': 1721, 'therapyName': 'Ramucirumab + Paclitaxel'}, {'id': 5850, 'therapyName': 'mFOLFOX-6'}]",A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) (UMBRELLA),7786
3,NCT02639559,Phase II,Recruiting,"[{'id': 2849, 'therapyName': 'BKT140'}]",Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem Cells and Allogeneic Transplantation in Patients With Advanced Hematological Malignancies,7786
4,NCT02826486,Phase II,Recruiting,"[{'id': 4757, 'therapyName': 'BKT140 + Pembrolizumab'}, {'id': 2849, 'therapyName': 'BKT140'}]",Study Assessing Safety and Efficacy of Combination of BL-8040 and Pembrolizumab in Metastatic Pancreatic Cancer Patients (COMBAT/KEYNOTE-202) (COMBAT),7786
5,NCT01838395,Phase II,Completed,"[{'id': 3168, 'therapyName': 'BKT140 + Cytarabine'}]",Phase IIa Study Evaluating Safety and Efficacy of BL-8040 in Relapsed/Refractory AML Patients,7786
6,NCT02763384,Phase II,Recruiting,"[{'id': 4275, 'therapyName': 'BKT140 + Nelarabine'}]",BL-8040 and Nelarabine for Relapsed or Refractory T-Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma,7786
7,NCT02907099,Phase II,Recruiting,"[{'id': 4757, 'therapyName': 'BKT140 + Pembrolizumab'}]",Pembrolizumab and BL-8040 in Metastatic Pancreatic Cancer,7786
0,NCT02790515,Phase II,Recruiting,"[{'id': 917, 'therapyName': 'Sirolimus'}, {'id': 1844, 'therapyName': 'anti-thymocyte globulin'}, {'id': 1876, 'therapyName': 'Blinatumomab '}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 5682, 'therapyName': 'Mesna'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1632, 'therapyName': 'Filgrastim'}]",Provision of TCR?? T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation,7355
1,NCT02101853,Phase III,Recruiting,"[{'id': 1876, 'therapyName': 'Blinatumomab '}, {'id': 2347, 'therapyName': 'Leucovorin + Pegaspargase  + Vincristine'}, {'id': 2346, 'therapyName': 'Mercaptopurine + Thioguanine'}, {'id': 2348, 'therapyName': 'Asparaginase + Cyclophosphamide + Etoposide'}, {'id': 2345, 'therapyName': 'Cytarabine + Dexamethasone+ Methotrexate '}]",Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia,7355
2,NCT03117751,Phase II,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1876, 'therapyName': 'Blinatumomab '}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1638, 'therapyName': 'Pegaspargase'}]",Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma,7355
3,NCT03263572,Phase II,Not yet recruiting,"[{'id': 6155, 'therapyName': 'Blinatumomab + Cytarabine + Dexamethasone + Methotrexate + Ponatinib'}, {'id': 6156, 'therapyName': 'Blinatumomab + Dexamethasone + Ponatinib'}]",Blinatumomab and Ponatinib in Patients With Philadelphia Chromosome (Ph)-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL),7355
4,NCT02997761,Phase II,Recruiting,"[{'id': 5125, 'therapyName': 'Blinatumomab + Ibrutinib'}]",Ibrutinib and Blinatumomab in Treating Patients With Relapsed or Refractory B Acute Lymphoblastic Leukemia,7355
5,NCT02879695,Phase I,Recruiting,"[{'id': 4613, 'therapyName': 'Blinatumomab + Ipilimumab + Nivolumab'}]",Blinatumomab and Nivolumab With or Without Ipilimumab in Treating Patients With Poor-Risk Relapsed or Refractory CD19+ Precursor B-Lymphoblastic Leukemia,7355
6,NCT03160079,Phase Ib/II,Recruiting,"[{'id': 5839, 'therapyName': 'Blinatumomab + Pembrolizumab'}]",Blinatumomab and Pembrolizumab for Adults With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia With High Marrow Lymphoblasts,7355
0,NCT02561988,Phase I,Recruiting,"[{'id': 2941, 'therapyName': 'BLU-285'}]",Study of BLU-285 in Patients With Advanced Systemic Mastocytosis (advSM) and Relapsed or Refractory Myeloid Malignancies,7857
1,NCT02508532,Phase I,Recruiting,"[{'id': 2941, 'therapyName': 'BLU-285'}]",Phase 1 Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid Tumors,7857
0,NCT02508467,Phase I,Recruiting,"[{'id': 3165, 'therapyName': 'BLU-554'}]",A Phase 1 Study of BLU-554 in Patients With Hepatocellular Carcinoma and Cholangiocarcinoma,7965
0,NCT03037385,Phase I,Recruiting,"[{'id': 5530, 'therapyName': 'BLU-667'}]","Phase 1 Study of BLU-667 in Patients With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors",8713
0,NCT02829723,Phase Ib/II,Recruiting,"[{'id': 2844, 'therapyName': 'BLZ945'}, {'id': 5071, 'therapyName': 'BLZ945 + PDR001'}]",Phase I/II Study of BLZ945 Single Agent or BLZ945 in Combination With PDR001 in Advanced Solid Tumors,7781
0,NCT03184870,Phase Ib/II,Recruiting,"[{'id': 5905, 'therapyName': 'BMS-813160 + Fluorouracil + Irinotecan + Leucovorin'}, {'id': 5903, 'therapyName': 'BMS-813160 + Nivolumab'}, {'id': 5904, 'therapyName': 'BMS-813160 + Gemcitabine + nab-paclitaxel'}, {'id': 5902, 'therapyName': 'BMS-813160'}]",A Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Patients With Advanced Solid Tumors,8854
0,NCT01292655,Phase I,"Active, not recruiting","[{'id': 2545, 'therapyName': 'BMS-906024'}]",Study to Evaluate the Safety and Tolerability of IV Doses of BMS-906024 in Subjects With Advanced or Metastatic Solid Tumors,7574
1,NCT01653470,Phase I,"Active, not recruiting","[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1315, 'therapyName': 'FOLFIRI'}, {'id': 2545, 'therapyName': 'BMS-906024'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]","Study to Evaluate Safety & Tolerability of BMS-906024 in Combination With Chemotherapy & to Define DLTs & MTD of BMS-906024 in Combination With One of the Following Chemotherapy Regimens; Weekly Paclitaxel, 5FU+Irinotecan or Carboplatin+Paclitaxel in Subjects With Advanced / Metastatic Solid Tumors",7574
2,NCT01363817,Phase I,"Active, not recruiting","[{'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 2545, 'therapyName': 'BMS-906024'}]",Study to Evaluate the Safety and Tolerability of Weekly Intravenous (IV) Doses of BMS-906024 in Subjects With Acute T-cell Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma,7574
0,NCT02247349,Phase Ib/II,"Active, not recruiting","[{'id': 4534, 'therapyName': 'BMS-986012'}, {'id': 4535, 'therapyName': 'BMS-986012 + Nivolumab'}]",BMS-986012 in Relapsed/Refractory SCLC,8476
1,NCT02815592,Phase Ib/II,"Active, not recruiting","[{'id': 1136, 'therapyName': 'Etoposide'}, {'id': 4563, 'therapyName': 'BMS-986012 + Cisplatin + Etoposide'}, {'id': 4564, 'therapyName': 'BMS-986012 + Carboplatin + Etoposide'}]",Trial of BMS-986012 in Combination With Platinum and Etoposide,8476
0,NCT01968109,Phase I,Recruiting,"[{'id': 4197, 'therapyName': 'BMS-986016 + Nivolumab'}, {'id': 4196, 'therapyName': 'BMS-986016'}]",Safety Study of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors,8376
1,NCT02061761,Phase Ib/II,Recruiting,"[{'id': 4197, 'therapyName': 'BMS-986016 + Nivolumab'}, {'id': 4196, 'therapyName': 'BMS-986016'}]",Safety Study of Anti-LAG-3 in Relapsed or Refractory Hematologic Malignancies,8376
2,NCT02996110,Phase II,Recruiting,"[{'id': 4197, 'therapyName': 'BMS-986016 + Nivolumab'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",A Study to Test Combination Treatments in People With Advanced Renal Cell Carcinoma (FRACTION-RCC),8376
3,NCT02935634,Phase II,Recruiting,"[{'id': 4197, 'therapyName': 'BMS-986016 + Nivolumab'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",A Study to Test Combination Treatments in Patients With Advanced Gastric Cancer (FRACTION-GC),8376
4,NCT02750514,Phase II,Recruiting,"[{'id': 1813, 'therapyName': 'Dasatinib + Nivolumab'}, {'id': 4197, 'therapyName': 'BMS-986016 + Nivolumab'}, {'id': 1312, 'therapyName': 'Nivolumab'}]",A Study to Test Combination Treatments in People With Advanced Non-Small Cell Lung Cancer,8376
0,NCT02341625,Phase Ib/II,"Active, not recruiting","[{'id': 4923, 'therapyName': 'BMS-986148'}, {'id': 4924, 'therapyName': 'BMS-986148 + Nivolumab'}]",A Study of BMS-986148 in Patients With Select Advanced Solid Tumors,8581
0,NCT02598960,Phase Ib/II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 3559, 'therapyName': 'BMS-986156'}]",A Study of BMS-986156 Given Alone and in Combination With Nivolumab in Subjects With Advanced Solid Tumors,8136
0,NCT02737475,Phase Ib/II,Recruiting,"[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 4030, 'therapyName': 'BMS-986178'}, {'id': 1312, 'therapyName': 'Nivolumab'}]",Study of BMS-986178 Monotherapy or in Combination With Nivolumab or Ipilimumab in Subjects With Advanced Solid Tumors,8330
0,NCT02754141,Phase Ib/II,Recruiting,"[{'id': 4195, 'therapyName': 'BMS-986179 + Nivolumab'}]",A Study of BMS-986179 Administered in Combination With Nivolumab in Advanced Cancers,8375
0,NCT02828124,Phase Ib/II,"Active, not recruiting","[{'id': 5628, 'therapyName': 'BMS-986183'}, {'id': 5629, 'therapyName': 'BMS-986183 + Nivolumab'}]",A Study of the Safety and Tolerability of BMS-986183 in Patients With Liver Cancer,8729
0,NCT03247283,,Recruiting,"[{'id': 3568, 'therapyName': 'BMS-986205'}]",Pharmacokinetics and Metabolism Study in Healthy Male Participants,8143
1,NCT02658890,Phase Ib/II,Recruiting,"[{'id': 3569, 'therapyName': 'BMS-986205 + Nivolumab'}]","Safety, Tolerability, Pharmacokinetic/Pharmacodynamic and Preliminary Efficacy Study of BMS-986205 Administered in Combination With Nivolumab in Advanced Cancers",8143
0,NCT02913313,Phase Ib/II,Recruiting,"[{'id': 4888, 'therapyName': 'BMS-986207 + Nivolumab'}, {'id': 4887, 'therapyName': 'BMS-986207 '}]",A Study to Evaluate the Safety and Tolerability of Monoclonal Antibody BMS-986207 Alone and in Combination With Nivolumab in Advanced (Solid Tumor) Cancers,8568
0,NCT03110107,Phase Ib/II,Recruiting,"[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 5552, 'therapyName': 'BMS-986218 + Nivolumab'}, {'id': 5551, 'therapyName': 'BMS-986218'}]",First-In-Human Study of Monoclonal Antibody BMS-986218 by Itself and in Combination With Nivolumab in Patients With Advanced Solid Tumors,8716
0,NCT03251924,Phase Ib/II,Recruiting,"[{'id': 6136, 'therapyName': 'BMS-986226 + Nivolumab'}, {'id': 6135, 'therapyName': 'BMS-986226 + Ipilimumab'}, {'id': 6134, 'therapyName': 'BMS-986226'}]",A Dose Escalation and Combination Immunotherapy Study to Evaluate BMS-986226 Alone or in Combination With Nivolumab or Ipilimumab in Patients With Advanced Solid Tumors,8922
0,NCT02419417,Phase Ib/II,Recruiting,"[{'id': 2811, 'therapyName': 'BMS986158'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]",Study of BMS-986158 in Subjects With Select Advanced Solid Tumors,7758
0,NCT02990468,Phase I,Recruiting,"[{'id': 5840, 'therapyName': 'BMX-001 + Cisplatin'}]","A Trial of Concurrent Radiation Therapy, Cisplatin, and BMX-001 in Locally Advanced Head and Neck Cancer (BMX-HN)",8822
1,NCT02655601,Phase Ib/II,Recruiting,"[{'id': 5841, 'therapyName': 'BMX-001 + Temozolomide'}, {'id': 1141, 'therapyName': 'Temozolomide'}]","Trial of Newly Diagnosed High Grade Glioma Treated With Concurrent Radiation Therapy, Temozolomide and BMX-001",8822
0,NCT01695941,Phase I,Recruiting,"[{'id': 3581, 'therapyName': 'Alisertib + Bortezomib + Rituximab'}]","Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin Lymphoma",181
1,NCT01286272,Phase II,"Active, not recruiting","[{'id': 3909, 'therapyName': 'Bendamustine + Ofatumumab'}, {'id': 3910, 'therapyName': 'Bendamustine + Bortezomib + Ofatumumab'}]",Ofatumumab and Bendamustine Hydrochloride With or Without Bortezomib in Treating Patients With Untreated Follicular Non-Hodgkin Lymphoma,181
2,NCT01177683,Phase Ib/II,"Active, not recruiting","[{'id': 3349, 'therapyName': 'Bendamustine + Bortezomib + pegylated liposomal-doxorubicin'}, {'id': 1632, 'therapyName': 'Filgrastim'}]",Bendamustine in Combination With Bortezomib and Pegylated Liposomal Doxorubicin for Multiple Myeloma,181
3,NCT01435395,Phase I,Completed,"[{'id': 2122, 'therapyName': 'Bevacizumab + Bortezomib + Temozolomide'}]","Trial of Temozolomide, Bevacizumab Plus Bortezomib for Recurrent Glioblastoma Multiforme",181
4,NCT02703779,Phase II,Recruiting,"[{'id': 688, 'therapyName': 'Bortezomib'}, {'id': 3933, 'therapyName': 'Filgrastim + Plerixafor'}]",Exploratory Trial to Estimate Proportion of Patients With Tumor Cell Contaminated Leukapheresis Products With and Without Bortezomib With In-vivo Purging - Multiple Myeloma (MM),181
5,NCT01216683,Phase II,Unknown status,"[{'id': 2323, 'therapyName': 'Bendamustine + Rituximab'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1164, 'therapyName': 'lenalidomide'}]","Bendamustine Hydrochloride and Rituximab With or Without Bortezomib Followed by Rituximab With or Without Lenalidomide in Treating Patients With High-Risk Stage II, Stage III, or Stage IV Follicular Lymphoma",181
6,NCT00184015,,"Active, not recruiting","[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 688, 'therapyName': 'Bortezomib'}]","Bortezomib and Bevacizumab (""BB-mib-mab"") in Patients With Advanced or Recurrent Renal Cell Cancer (RCC)",181
7,NCT02440464,Phase II,Recruiting,"[{'id': 3321, 'therapyName': 'Tacrolimus + Methotrexate'}, {'id': 1359, 'therapyName': 'Ixazomib'}, {'id': 2237, 'therapyName': 'Fludarabine + Melphalan'}, {'id': 688, 'therapyName': 'Bortezomib'}]",Allogeneic Hematopoietic Stem Cell Transplantation With Ixazomib for High Risk Multiple Myeloma (BMT CTN 1302),181
8,NCT01695330,Phase II,Terminated,"[{'id': 688, 'therapyName': 'Bortezomib'}]",Subcutaneous (SC) Bortezomib-Regimens for Patients With RR MM Failing Prior IV Bortezomib-Containing Regimens,181
9,NCT01453101,Phase II,"Active, not recruiting","[{'id': 2237, 'therapyName': 'Fludarabine + Melphalan'}, {'id': 688, 'therapyName': 'Bortezomib'}]",Allogeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma,181
10,NCT02605356,Phase Ib/II,Withdrawn,"[{'id': 2001, 'therapyName': 'radium Ra 223 dichloride'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1390, 'therapyName': 'Dexamethasone'}]",Phase 1b/2 Study Testing Radium-223 Dichloride/Bortezomib/Dexamethasone Combination in Relapsed Multiple Myeloma,181
11,NCT01241708,Phase III,Recruiting,"[{'id': 688, 'therapyName': 'Bortezomib'}]",Tandem Auto Stem Cell Transplant With Melphalan Followed by Melphalan and Bortezomib in Patients With Multiple Myeloma ((Mel/MelVel)),181
12,NCT02265510,Phase I,Recruiting,"[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 1164, 'therapyName': 'lenalidomide'}, {'id': 619, 'therapyName': 'Abraxane'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 2747, 'therapyName': 'INCB052793'}, {'id': 688, 'therapyName': 'Bortezomib'}]","An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies",181
13,NCT03117751,Phase II,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1876, 'therapyName': 'Blinatumomab '}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1638, 'therapyName': 'Pegaspargase'}]",Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma,181
14,NCT02308280,Phase II,Recruiting,"[{'id': 688, 'therapyName': 'Bortezomib'}]",Nonmyeloablative Allogeneic Stem Cell Transplant Followed by Bortezomib in High-risk Multiple Myeloma Patients,181
15,NCT01371981,Phase III,"Active, not recruiting","[{'id': 2391, 'therapyName': 'Cytarabine + Daunorubicin + Etoposide'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 2392, 'therapyName': 'Cytarabine + Etoposide'}, {'id': 2393, 'therapyName': 'Cytarabine + Mitoxantrone'}, {'id': 2394, 'therapyName': 'Asparaginase + Cytarabine'}, {'id': 688, 'therapyName': 'Bortezomib'}]",Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,181
16,NCT01453088,Phase II,Recruiting,"[{'id': 1207, 'therapyName': 'Melphalan'}, {'id': 688, 'therapyName': 'Bortezomib'}]",Auto Transplant High Dose Melphalan vs High Dose Melphalan+Bortezomib in Pts With Multiple Myeloma Age 65 Years or Older,181
17,NCT02112916,Phase III,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1009, 'therapyName': 'Doxorubicin'}]",Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma,181
18,NCT02788201,Phase II,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1133, 'therapyName': 'Mitomycin C'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1013, 'therapyName': 'epirubicin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1137, 'therapyName': 'Bleomycin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 781, 'therapyName': 'Ixabepilone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 2950, 'therapyName': 'Estramustine'}, {'id': 1941, 'therapyName': 'Floxuridine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 1811, 'therapyName': 'Carmustine'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 953, 'therapyName': 'Vandetanib'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 4419, 'therapyName': 'Toremifine'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 2601, 'therapyName': 'Dactinomycin'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 3035, 'therapyName': 'Chlorambucil'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 342, 'therapyName': 'Vemurafenib'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 2635, 'therapyName': 'Vinblastine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 4305, 'therapyName': 'Teniposide'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 4304, 'therapyName': 'Streptozocin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1231, 'therapyName': 'Bendamustine'}, {'id': 4303, 'therapyName': 'Mechlorethamine'}, {'id': 4302, 'therapyName': 'Mitotane'}]",Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma,181
19,NCT01833143,Phase II,"Active, not recruiting","[{'id': 688, 'therapyName': 'Bortezomib'}]",Bortezomib in KRAS-Mutant Non-Small Cell Lung Cancer in Never Smokers or Those With KRAS G12D,181
20,NCT02553460,Phase II,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1642, 'therapyName': 'Leucovorin'}]",Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) I,181
21,NCT02139397,Phase Ib/II,Recruiting,"[{'id': 2629, 'therapyName': 'Eflornithine'}, {'id': 688, 'therapyName': 'Bortezomib'}]",Study of DFMO in Combination With Bortezomib for Relapsed or Refractory Neuroblastoma,181
22,NCT02343042,Phase Ib/II,Recruiting,"[{'id': 688, 'therapyName': 'Bortezomib'}, {'id': 2479, 'therapyName': 'Dexamethasone + Selinexor'}, {'id': 1622, 'therapyName': 'Pomalidomide'}]",Phase 1b/2 Study of Selinexor (KPT-330) in Combination w/ Backbone Treatments for Resistant/Refractory Multiple Myeloma,181
23,NCT03136146,Phase II,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1090, 'therapyName': 'Ofatumumab'}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 1476, 'therapyName': 'Pegfilgrastim'}]","Study of Clofarabine, Etoposide, Cyclophosphamide [CEC], Liposomal Vincristine (VCR), Dexamethasone and Bortezomib in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LL)",181
24,NCT02352558,Phase I,"Active, not recruiting","[{'id': 770, 'therapyName': 'Imatinib'}, {'id': 2057, 'therapyName': 'BBI608'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 768, 'therapyName': 'Ibrutinib'}, {'id': 1390, 'therapyName': 'Dexamethasone'}]","A Study of BBI608 in Adult Patients With Advanced, Refractory Hematologic Malignancies",181
25,NCT03004287,Phase II,Recruiting,"[{'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1164, 'therapyName': 'lenalidomide'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 1630, 'therapyName': 'Daratumumab'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1475, 'therapyName': 'Thalidomide'}]",2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy,181
26,NCT01313897,Phase II,Completed,"[{'id': 688, 'therapyName': 'Bortezomib'}]","UARK 2010-35, A Study of Expanded Natural Killer Cell Therapy for Multiple Myeloma (NK2010-35)",181
27,NCT01863550,Phase III,Recruiting,"[{'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 1164, 'therapyName': 'lenalidomide'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 688, 'therapyName': 'Bortezomib'}]",Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma,181
28,NCT00114738,Phase II,"Active, not recruiting","[{'id': 3395, 'therapyName': 'R-EPOCH'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 688, 'therapyName': 'Bortezomib'}]",EPOCH-R Chemotherapy Plus Bortezomib to Treat Mantle Cell Lymphoma,181
29,NCT01415752,Phase II,Recruiting,"[{'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1231, 'therapyName': 'Bendamustine'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1164, 'therapyName': 'lenalidomide'}]","Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma",181
30,NCT01769209,Phase II,"Active, not recruiting","[{'id': 688, 'therapyName': 'Bortezomib'}, {'id': 3195, 'therapyName': 'Cytarabine + Methotrexate '}, {'id': 1830, 'therapyName': 'Vincristine + Dexamethasone + Pegaspargase + Doxorubicin'}]",Bortezomib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia,181
31,NCT02195479,Phase III,Recruiting,"[{'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1630, 'therapyName': 'Daratumumab'}, {'id': 1207, 'therapyName': 'Melphalan'}]",A Study of Combination of Daratumumanb and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma,181
32,NCT02559778,Phase I,Recruiting,"[{'id': 688, 'therapyName': 'Bortezomib'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 2629, 'therapyName': 'Eflornithine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 717, 'therapyName': 'Dasatinib'}]",Pediatric Precision Laboratory Advanced Neuroblastoma Therapy,181
33,NCT02535806,Phase II,Terminated,"[{'id': 1631, 'therapyName': 'Vincristine'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 2188, 'therapyName': 'Prednisone'}]",Four Drug Reinduction With Bortezomib for Relapsed or Refractory ALL or LL in Children and Young Adults,181
34,NCT00092222,Phase II,Recruiting,"[{'id': 917, 'therapyName': 'Sirolimus'}, {'id': 1187, 'therapyName': 'Alpha 2 Interferon'}, {'id': 2211, 'therapyName': 'EPOCH'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1008, 'therapyName': 'Doxil'}]",Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity,181
35,NCT01428492,Phase I,Completed,"[{'id': 625, 'therapyName': 'Afuresertib'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1390, 'therapyName': 'Dexamethasone'}]",Ph 1b Study to Evaluate GSK2110183 in Combination With Bortezomib and Dexamethasone in Subjects With Multiple Myeloma,181
36,NCT02419755,Phase II,Terminated,"[{'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 2188, 'therapyName': 'Prednisone'}]",Bortezomib and Vorinostat in Younger Patients With Refractory or Relapsed MLL Rearranged Hematologic Malignancies,181
37,NCT03056599,,Recruiting,"[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1299, 'therapyName': 'Interferon alfa-2b '}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1733, 'therapyName': 'interferon gamma '}, {'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 3420, 'therapyName': 'trabectedin'}, {'id': 1167, 'therapyName': 'Aldesleukin'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 720, 'therapyName': 'Docetaxel'}]",Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO™ Device in Soft Tissue Sarcoma,181
38,NCT02551718,Phase I,Recruiting,"[{'id': 690, 'therapyName': 'Bosutinib'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 3160, 'therapyName': 'Nelarabine'}, {'id': 3159, 'therapyName': 'Bexarotene'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 998, 'therapyName': 'cabozantinib'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 877, 'therapyName': 'Ponatinib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 623, 'therapyName': 'Afatinib'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 890, 'therapyName': 'Regorafenib'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 2, 'therapyName': 'Trametinib'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 3, 'therapyName': 'Dabrafenib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 789, 'therapyName': 'Ceritinib'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1571, 'therapyName': 'Cabazitaxel'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1327, 'therapyName': 'Pralatrexate'}]",High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia,181
39,NCT01522872,Phase Ib/II,"Active, not recruiting","[{'id': 1317, 'therapyName': 'Evofosfamide'}, {'id': 688, 'therapyName': 'Bortezomib'}]",Open-label Study of TH-302 and Dexamethasone With or Without Bortezomib in Subjects With Relapsed/Refractory Multiple Myeloma,181
40,NCT02188368,Phase II,Recruiting,"[{'id': 1625, 'therapyName': 'Bortezomib + Carfilzomib + Clarithromycin'}, {'id': 1674, 'therapyName': 'Doxil + Pomalidomide'}, {'id': 1622, 'therapyName': 'Pomalidomide'}]",Pomalidomide for Lenalidomide for Failures,181
41,NCT01439750,Phase Ib/II,"Active, not recruiting","[{'id': 3394, 'therapyName': 'Bortezomib + Cladribine + Rituximab'}]","Bortezomib (VELCADE), Cladribine and Rituximab (VCR) in Mantle Cell Lymphoma (PSHCI 10-011)",181
42,NCT02211755,Phase I,Recruiting,"[{'id': 3063, 'therapyName': 'Bortezomib + Clofarabine'}]",Trial of the Combination of Bortezomib and Clofarabine in Adults With Relapsed Solid Tumors,181
43,NCT01146834,Phase III,Recruiting,"[{'id': 3345, 'therapyName': 'Bortezomib + Filgrastim'}, {'id': 5459, 'therapyName': 'Bortezomib + Cyclophosphamide + G-CSF'}, {'id': 5460, 'therapyName': 'Bortezomib + Cyclophosphamide'}]",Trial of Three Stem Cell Mobilization Regimens for Multiple Myeloma,181
44,NCT02951819,Phase II,Recruiting,"[{'id': 4951, 'therapyName': 'Bortezomib + Cyclophosphamide + Daratumumab + Dexamethasone'}]",A Study to Evaluate Dara-CyBorD in Previously Untreated and Relapsed Subjects With Multiple Myeloma,181
45,NCT01729338,Phase II,Terminated,"[{'id': 3358, 'therapyName': 'Bortezomib + Cyclophosphamide + lenalidomide'}]",Velcade + Cyclophosphamide in Newly Diagnosed Multiple Myeloma,181
46,NCT01954784,Phase I,Terminated,"[{'id': 3434, 'therapyName': 'Bortezomib + Cyclosporine + Mycophenolate'}, {'id': 1164, 'therapyName': 'lenalidomide'}]",Lenalidomide After Donor Stem Cell Transplant and Bortezomib in Treating Patients With High Risk Multiple Myeloma,181
47,NCT01734928,Phase III,"Active, not recruiting","[{'id': 1622, 'therapyName': 'Pomalidomide'}, {'id': 2470, 'therapyName': 'Bortezomib + Dexamethasone'}]","Safety and Efficacy of Pomalidomide, Bortezomib and Low-dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma",181
48,NCT01998971,Phase I,Recruiting,"[{'id': 1622, 'therapyName': 'Pomalidomide'}, {'id': 2470, 'therapyName': 'Bortezomib + Dexamethasone'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1475, 'therapyName': 'Thalidomide'}, {'id': 1164, 'therapyName': 'lenalidomide'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 1630, 'therapyName': 'Daratumumab'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 1275, 'therapyName': 'Diphenhydramine'}, {'id': 3323, 'therapyName': 'Montelukast'}]",A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma,181
49,NCT01323751,Phase Ib/II,Completed,"[{'id': 2470, 'therapyName': 'Bortezomib + Dexamethasone'}, {'id': 1613, 'therapyName': 'ACY-1215'}]",Study of ACY-1215 Alone and in Combination With Bortezomib and Dexamethasone in Multiple Myeloma,181
50,NCT01919086,Phase II,"Active, not recruiting","[{'id': 1164, 'therapyName': 'lenalidomide'}, {'id': 2470, 'therapyName': 'Bortezomib + Dexamethasone'}]",Response Adapted Therapy With Bortezomib/Dexamethasone Followed by Addition of Lenalidomide in Non Responders as Initial Treatment for Patients With Multiple Myeloma,181
51,NCT02136134,Phase III,"Active, not recruiting","[{'id': 1630, 'therapyName': 'Daratumumab'}, {'id': 2470, 'therapyName': 'Bortezomib + Dexamethasone'}]",Addition of Daratumumab to Combination of Bortezomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma,181
52,NCT02755597,Phase III,Recruiting,"[{'id': 2470, 'therapyName': 'Bortezomib + Dexamethasone'}, {'id': 3436, 'therapyName': 'Bortezomib + Dexamethasone + GDC-0199\t'}]",A Study Evaluating Venetoclax (ABT-199) in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy,181
53,NCT03110562,Phase III,Recruiting,"[{'id': 5639, 'therapyName': 'Selinexor + Bortezomib + Dexamethasone'}, {'id': 2470, 'therapyName': 'Bortezomib + Dexamethasone'}]","Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple Myeloma (BOSTON)",181
54,NCT01470131,Phase III,Unknown status,"[{'id': 804, 'therapyName': 'Masitinib'}, {'id': 2470, 'therapyName': 'Bortezomib + Dexamethasone'}]",A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Patients With Relapse or Refractory Multiple Myeloma,181
55,NCT01711528,Phase I,"Active, not recruiting","[{'id': 3437, 'therapyName': 'Bortezomib + Dexamethasone + Dinaciclib'}]","Dinaciclib, Bortezomib, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma",181
56,NCT02718833,Phase II,Recruiting,"[{'id': 4031, 'therapyName': 'Bortezomib + Dexamethasone + Elotuzumab + Panobinostat'}]","A Study of Elotuzumab With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed Multiple Myeloma",181
57,NCT01794507,Phase I,"Active, not recruiting","[{'id': 3436, 'therapyName': 'Bortezomib + Dexamethasone + GDC-0199\t'}]",A Study Evaluating ABT-199 in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy,181
58,NCT03168100,Phase II,Recruiting,"[{'id': 3342, 'therapyName': 'Bortezomib + Dexamethasone + lenalidomide'}, {'id': 3353, 'therapyName': 'Elotuzumab + Dexamethasone + Lenalidomide'}]","2017-03: A Single-Arm, Open-label Study of Anti-Signaling Lymphocytic Activation Molecule F7 (Anti-SLAMF7) Monoclonal Antibody (mAb) Therapy After Autologous Stem Cell Transplant in Patients With Multiple Myeloma",181
59,NCT01668719,Phase Ib/II,Recruiting,"[{'id': 3343, 'therapyName': 'Elotuzumab'}, {'id': 3342, 'therapyName': 'Bortezomib + Dexamethasone + lenalidomide'}]","S1211, Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma",181
60,NCT01208662,Phase III,Recruiting,"[{'id': 3342, 'therapyName': 'Bortezomib + Dexamethasone + lenalidomide'}]","Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65  (DFCI 10-106)",181
61,NCT02874742,Phase II,Recruiting,"[{'id': 1630, 'therapyName': 'Daratumumab'}, {'id': 3342, 'therapyName': 'Bortezomib + Dexamethasone + lenalidomide'}]","Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Subjects With Newly Diagnosed Multiple Myeloma",181
62,NCT02720510,Phase II,Recruiting,"[{'id': 1080, 'therapyName': 'Panobinostat'}, {'id': 3342, 'therapyName': 'Bortezomib + Dexamethasone + lenalidomide'}]","A Trial Evaluating Efficacy & Safety of RVD +/- Panobinostat in Transplant Eligible, Newly Diagnosed Multiple Myeloma (NDMM)",181
63,NCT02375555,Phase II,"Active, not recruiting","[{'id': 3343, 'therapyName': 'Elotuzumab'}, {'id': 3342, 'therapyName': 'Bortezomib + Dexamethasone + lenalidomide'}]","Study of Bortezomib,Lenalidomide,Dexamethasone & Elotuzumab in Newly Diagnosed MM",181
64,NCT02441686,Phase II,"Active, not recruiting","[{'id': 3342, 'therapyName': 'Bortezomib + Dexamethasone + lenalidomide'}]","Phase II Study of Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone Therapy for Newly Diagnosed Multiple Myeloma",181
65,NCT01440582,Phase I,"Active, not recruiting","[{'id': 3362, 'therapyName': 'Bortezomib + Dexamethasone + lenalidomide + Panobinostat'}]",Combination Therapy of Lenalidomide/Bortezomib/Dexamethasone and Panobinostat in Transplant Eligible New Diagnosed Multiple Myeloma (MM) Patients,181
66,NCT01965353,Phase I,"Active, not recruiting","[{'id': 3362, 'therapyName': 'Bortezomib + Dexamethasone + lenalidomide + Panobinostat'}]",A Phase I Study Of Panobinostat/Lenalidomide/Bortezomib/Dex for Relapsed And Relapsed/Refractory Multiple Myeloma,181
67,NCT01728259,Phase I,Suspended,"[{'id': 4501, 'therapyName': 'Bortezomib + Dexamethasone + Pomalidomide'}]","First-line Pomalidomide, Bortezomib, and Dexamethasone For AL Amyloidosis or LCDD",181
68,NCT02928029,Phase Ib/II,Recruiting,"[{'id': 6161, 'therapyName': 'Bortezomib + Dexamethasone + radium Ra 223 dichloride'}]",Study Testing Radium-223 Dichloride in Relapsed Multiple Myeloma,181
69,NCT02514382,Phase I,Recruiting,"[{'id': 3432, 'therapyName': 'Bortezomib + Dexamethasone + Reolysin'}]","Wild-Type Reovirus, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma",181
70,NCT02666209,Phase I,No longer available,"[{'id': 3556, 'therapyName': 'Bortezomib + Dexamethasone + Ulocuplumab'}, {'id': 3555, 'therapyName': 'Dexamethasone + lenalidomide + Ulocuplumab'}]",Early Patient Access Single Named Patient Program for the Use of Ulocuplumab for the Treatment of Multiple Myeloma,181
71,NCT02783625,Phase I,Recruiting,"[{'id': 4240, 'therapyName': 'Bortezomib + Duvelisib'}, {'id': 4239, 'therapyName': 'Duvelisib + romidepsin '}]",Trial of Duvelisib in Combination With Either Romidepsin or Bortezomib in Relapsed/Refractory T-cell Lymphomas,181
72,NCT02719613,Phase II,Recruiting,"[{'id': 4533, 'therapyName': 'Bortezomib + Elotuzumab + Dexamethasone + lenalidomide'}]",Continuing Treatment for Subjects Who Have Participated in a Prior Protocol Investigating Elotuzumab,181
73,NCT00671112,Phase I,Terminated,"[{'id': 2234, 'therapyName': 'Bortezomib + Everolimus'}]",Everolimus and Bortezomib in Treating Patients With Relapsed or Refractory Lymphoma,181
74,NCT02220608,Phase I,Completed,"[{'id': 3345, 'therapyName': 'Bortezomib + Filgrastim'}]",Phase I Study of Bortezomib With G-CSF for Stem Cell Mobilization in Patients With Multiple Myeloma,181
75,NCT01163357,Phase I,Recruiting,"[{'id': 917, 'therapyName': 'Sirolimus'}, {'id': 2288, 'therapyName': 'Bortezomib + Fludarabine + Melphalan'}]","Bortezomib, Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant For High-Risk Stage I or II Multiple Myeloma",181
76,NCT02658396,Phase I,Withdrawn,"[{'id': 3427, 'therapyName': 'Bortezomib + GO-203-2C'}]",GO-203-2C + Bortezomib For Relapsed Or Refractory MM,181
77,NCT02312102,Phase I,Recruiting,"[{'id': 3220, 'therapyName': 'Bortezomib + lenalidomide'}]",Phase I Study of Velcade and Lenalidomide in Patients With Relapsed AML and MDS After Allogeneic Stem Cell Transplantation,181
78,NCT00996385,Phase II,Unknown status,"[{'id': 3064, 'therapyName': 'Bortezomib + Oxaliplatin'}]",Velcade and Eloxatin for Patients With Malignant Pleural or Peritoneal Mesothelioma,181
79,NCT01736943,Phase II,Recruiting,"[{'id': 3184, 'therapyName': 'Bortezomib + pegylated liposomal-doxorubicin'}]",Bortezomib and Doxil for the Treatment of Patients With Acute Myelogenous Leukemia,181
80,NCT00903968,Phase Ib/II,Completed,"[{'id': 3348, 'therapyName': 'Bortezomib + Plerixafor'}]",Combination Plerixafor (AMD3100)and Bortezomib in Relapsed or Relapsed/Refractory Multiple Myeloma,181
81,NCT02484261,Phase I,Recruiting,"[{'id': 3191, 'therapyName': 'Bortezomib + Pravastatin'}]",Monitoring and Treatment of Relapsed Leukemia Following Allogeneic Hematopoietic Stem Cell Transplantation in Children,181
82,NCT02613598,Phase I,Recruiting,"[{'id': 3262, 'therapyName': 'Bortezomib + Ruxolitinib'}]",Dose Escalation Study to Determine the Maximum Tolerated Dose of the Combination of Ruxolitinib and Bortezomib in Patients With Relapsed or Refractory Lymphoma,181
83,NCT02254551,Phase II,Terminated,"[{'id': 1954, 'therapyName': 'Bortezomib + Sonidegib'}]",Safety/Efficacy Study of LDE225 (Sonidegib) Plus Bortezomib in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma,181
84,NCT01861314,Phase I,"Active, not recruiting","[{'id': 1793, 'therapyName': 'Bortezomib + Sorafenib + Decitabine   '}]","Bortezomib, Sorafenib Tosylate, and Decitabine in Treating Patients With Acute Myeloid Leukemia",181
85,NCT01534260,Phase Ib/II,Recruiting,"[{'id': 2366, 'therapyName': 'Bortezomib + Sorafenib + vorinostat'}]","Phase I/II Study of Combination of Sorafenib, Vorinostat, and Bortezomib for the Treatment of Acute Myeloid Leukemia With Complex- or Poor-risk (Monosomy 5/7) Cytogenetics or FLT3-ITD Positive Genotype",181
86,NCT00998010,Phase II,"Active, not recruiting","[{'id': 3055, 'therapyName': 'Bortezomib + Temozolomide'}]","Bortezomib, Temozolomide, and Regional Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma",181
87,NCT01497626,Phase I,Terminated,"[{'id': 1394, 'therapyName': 'Lapatinib + bortezomib'}]",Lapatinib and Bortezomib in Patients With Advanced Malignancies,181
88,NCT01672736,Phase Ib/II,"Active, not recruiting","[{'id': 1831, 'therapyName': 'Linsitinib + Bortezomib + Dexamethasone'}]",A Trial of ASP7487 (OSI-906) in Combination With Bortezomib for the Treatment of Relapsed Multiple Myeloma,181
89,NCT00734877,Phase III,Recruiting,"[{'id': 1851, 'therapyName': 'Cisplatin + Doxorubicin + Cyclophosphamide + Etoposide'}, {'id': 1852, 'therapyName': 'Melphalan + Bortezomib + Thalidomide + Dexamethasone'}]","UARK 2008-01, Total Therapy 4 - A Phase III Trial for Low Risk Myeloma",181
90,NCT01849783,Phase II,Recruiting,"[{'id': 1852, 'therapyName': 'Melphalan + Bortezomib + Thalidomide + Dexamethasone'}, {'id': 3435, 'therapyName': 'Aldoxorubicin + Cisplatin + Cyclophosphamide + Dexamethasone + Etoposide'}]",Autologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple Myeloma,181
91,NCT01111188,,"Active, not recruiting","[{'id': 1730, 'therapyName': 'Palbociclib + Velcade'}]", Trial of PD 0332991 Plus Bortezomib in Patients With Relapsed Mantle Cell Lymphoma,181
92,NCT02518750,Phase II,Recruiting,"[{'id': 1604, 'therapyName': 'Panobinostat + Bortezomib + Dexamethasone'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 3160, 'therapyName': 'Nelarabine'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 3217, 'therapyName': 'Cyclophosphamide + Etoposide'}, {'id': 3216, 'therapyName': 'Cytarabine + Methotrexate + Prednisone'}, {'id': 1746, 'therapyName': 'Clofarabine'}]",Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoma,181
93,NCT02654990,Phase II,Recruiting,"[{'id': 1604, 'therapyName': 'Panobinostat + Bortezomib + Dexamethasone'}]",Panobinostat/Bortezomib/Dexamethasone in Relapsed or Relapsed-and-refractory Multiple Myeloma,181
94,NCT02568943,Phase I,Available,"[{'id': 1604, 'therapyName': 'Panobinostat + Bortezomib + Dexamethasone'}]","An Expanded Treatment Protocol of Panobinostat in Combination Therapy for Relapsed, and Relapsed and Refractory Multiple Myeloma",181
95,NCT02204553,Phase I,No longer available,"[{'id': 1604, 'therapyName': 'Panobinostat + Bortezomib + Dexamethasone'}]",Expanded Treatment Prot of Panobinostat in Combo w/ Bortez and Dex in Pts w/ Relapsed and/or Refractory Multiple Myeloma,181
96,NCT01267812,Phase II,"Active, not recruiting","[{'id': 1649, 'therapyName': 'Rituximab + Bortezomib'}]",Bortezomib and Rituximab in Treating Patients With Mantle Cell Lymphoma Who Have Previously Undergone Stem Cell Transplantation,181
97,NCT01058239,Phase II,"Active, not recruiting","[{'id': 1649, 'therapyName': 'Rituximab + Bortezomib'}]",Bortezomib Plus Rituximab for EBV+ PTLD,181
0,NCT02782403,Phase Ib/II,Recruiting,"[{'id': 4241, 'therapyName': 'Axitinib + Bosutinib'}]","Axitinib and Bosutinib for Patients With Chronic Myeloid Leukemia in Chronic, Accelerated or Blastic Phases",4738
1,NCT02551718,Phase I,Recruiting,"[{'id': 690, 'therapyName': 'Bosutinib'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 3160, 'therapyName': 'Nelarabine'}, {'id': 3159, 'therapyName': 'Bexarotene'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 998, 'therapyName': 'cabozantinib'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 877, 'therapyName': 'Ponatinib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 623, 'therapyName': 'Afatinib'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 890, 'therapyName': 'Regorafenib'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 2, 'therapyName': 'Trametinib'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 3, 'therapyName': 'Dabrafenib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 789, 'therapyName': 'Ceritinib'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1571, 'therapyName': 'Cabazitaxel'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1327, 'therapyName': 'Pralatrexate'}]",High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia,4738
2,NCT03106779,Phase III,Recruiting,"[{'id': 690, 'therapyName': 'Bosutinib'}, {'id': 2484, 'therapyName': 'ABL001'}]","Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs",4738
3,NCT02130557,Phase III,"Active, not recruiting","[{'id': 690, 'therapyName': 'Bosutinib'}, {'id': 770, 'therapyName': 'Imatinib'}]","A Multicenter Phase 3, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia",4738
4,NCT01331291,Phase II,Completed,"[{'id': 690, 'therapyName': 'Bosutinib'}]",Bosutinib in Adult Patients With Recurrent Glioblastoma,4738
5,NCT02228382,FDA approved,"Active, not recruiting","[{'id': 690, 'therapyName': 'Bosutinib'}]",Safety And Efficacy Study Of Bosutinib In Patients With Philadelphia Chromosome Positive Chronic Myeloid Leukemia Previously Treated With One Or More Tyrosine Kinase Inhibitors,4738
6,NCT02906696,Phase II,Recruiting,"[{'id': 690, 'therapyName': 'Bosutinib'}]",Bosutinib Dose-Optimization Study in Chronic Myeloid Leukemia (CML),4738
7,NCT01903733,Phase I,Recruiting,"[{'id': 690, 'therapyName': 'Bosutinib'}]",Bosutinib Treatment Extension Study Only For Subjects With Chronic Myeloid Leukemia (CML) Who Have Previously Participated In Bosutinib Studies B1871006 Or B1871008,4738
8,NCT02693535,Phase II,Recruiting,"[{'id': 1657, 'therapyName': 'Vemurafenib + Cobimetinib'}, {'id': 890, 'therapyName': 'Regorafenib'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 690, 'therapyName': 'Bosutinib'}, {'id': 850, 'therapyName': 'Palbociclib'}, {'id': 694, 'therapyName': 'Cetuximab'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 837, 'therapyName': 'Olaparib'}, {'id': 4, 'therapyName': 'Erlotinib'}]",TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer,4738
9,NCT02311998,Phase Ib/II,Recruiting,"[{'id': 3200, 'therapyName': 'Bosutinib + inotuzumab ozogamicin'}]",Phase I/II Study of Bosutinib in Combination With Inotuzumab Ozogamicin in CD22-positive Philadelphia-Chromosome (PC) Positive Acute Lymphoblastic Leukemia (ALL) and Chronic Myeloid Leukemia (CML),4738
10,NCT03023319,Phase I,Recruiting,"[{'id': 5237, 'therapyName': 'Bosutinib + Pemetrexed'}]",Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors,4738
0,NCT02650804,Phase II,Recruiting,"[{'id': 5759, 'therapyName': 'BPM 31510'}, {'id': 5842, 'therapyName': 'BPM 31510 + Gemcitabine'}]",BPM31510 Administered Intravenously With or Without Gemcitabine in Advanced Pancreatic Cancer Patients,8780
0,NCT02065869,Phase Ib/II,Recruiting,"[{'id': 6053, 'therapyName': 'BPX-501'}, {'id': 5992, 'therapyName': 'Rimiducid'}]",Safety Study of Gene Modified Donor T-cells Following TCR Alpha Beta Depleted Stem Cell Transplant,8899
1,NCT02487459,Phase I,Not yet recruiting,"[{'id': 6053, 'therapyName': 'BPX-501'}, {'id': 5992, 'therapyName': 'Rimiducid'}]",Safety Study of Gene Modified Donor T-Cells in Adults With Advanced Hematologic Malignancies,8899
2,NCT02786485,Phase I,Not yet recruiting,"[{'id': 5992, 'therapyName': 'Rimiducid'}, {'id': 6053, 'therapyName': 'BPX-501'}]",Study of Matched Unrelated Donor T Cell Infusion for Hematologic Malignancies After Allo-HSCT,8899
3,NCT01744223,Phase Ib/II,Recruiting,"[{'id': 5992, 'therapyName': 'Rimiducid'}, {'id': 6053, 'therapyName': 'BPX-501'}]",Safety Study of Gene Modified Donor T-cells Following Partially Mismatched Stem Cell Transplant,8899
0,NCT02477878,Phase I,Recruiting,"[{'id': 5995, 'therapyName': 'BPX-601'}, {'id': 5992, 'therapyName': 'Rimiducid'}]",Study of Gene Modified Donor T Cell Infusion in Patients With Recurrent Disease After Allogeneic Transplant,8884
0,NCT02743611,Phase I,Recruiting,"[{'id': 5992, 'therapyName': 'Rimiducid'}, {'id': 5991, 'therapyName': 'BPX-701'}]",Dose Finding Study Evaluating Safety and Feasibility in Patients With Relapsed or Refractory Myeloid Neoplasms,8881
0,NCT02780011,Phase I,Not yet recruiting,"[{'id': 4301, 'therapyName': 'Alisertib + Brentuximab vedotin'}]",Alsertib (MLN8237) and Brentuximab Vedotin for Relapsed/Refractory CD30-Positive Lymphomas and Solid Malignancies,7541
1,NCT02988843,Phase II,Recruiting,"[{'id': 5144, 'therapyName': 'Bevacizumab + Brentuximab vedotin'}]",Study of Brentuximab Vedotin And Bevacizumab In Refractory CD-30 Positive Germ Cell Tumors,7541
2,NCT02684292,Phase III,Recruiting,"[{'id': 2486, 'therapyName': 'Brentuximab vedotin'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Study of Pembrolizumab (MK-3475) vs. Brentuximab Vedotin in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-204/KEYNOTE-204),7541
3,NCT03138499,Phase III,Recruiting,"[{'id': 2486, 'therapyName': 'Brentuximab vedotin'}, {'id': 3263, 'therapyName': 'Brentuximab vedotin + Nivolumab'}]","Phase III Trial of Nivolumab Plus Brentuximab Vedotin Versus Brentuximab Vedotin Alone in Patients With Advanced Stage Classical Hodgkin Lymphoma, Who Are Relapsed/ Refractory or Who Are Not Eligible for Autologous Stem Cell Transplant,",7541
4,NCT03233347,,Not yet recruiting,"[{'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 2486, 'therapyName': 'Brentuximab vedotin'}, {'id': 2635, 'therapyName': 'Vinblastine'}, {'id': 1312, 'therapyName': 'Nivolumab'}]","Doxorubicin Hydrochloride, Vinblastine, Dacarbazine, Brentuximab Vedotin, and Nivolumab in Treating Patients With Stage I-II Hodgkin Lymphoma",7541
5,NCT01716806,Phase II,Recruiting,"[{'id': 3263, 'therapyName': 'Brentuximab vedotin + Nivolumab'}, {'id': 5055, 'therapyName': 'Brentuximab vedotin + Bendamustine'}, {'id': 5056, 'therapyName': 'Brentuximab vedotin + Dacarbazine'}, {'id': 2486, 'therapyName': 'Brentuximab vedotin'}]",A Study of Brentuximab Vedotin in Adults Age 60 and Above With Newly Diagnosed Hodgkin Lymphoma (HL),7541
6,NCT02408042,Phase Ib/II,Withdrawn,"[{'id': 897, 'therapyName': 'Rituximab'}, {'id': 2352, 'therapyName': 'Carboplatin + Etoposide + Ifosfamide '}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 2486, 'therapyName': 'Brentuximab vedotin'}]",Study of Pembrolizumab With Chemotherapy in Patients With Advanced Lymphoma (PembroHeme),7541
7,NCT02927769,Phase II,Recruiting,"[{'id': 3263, 'therapyName': 'Brentuximab vedotin + Nivolumab'}, {'id': 5055, 'therapyName': 'Brentuximab vedotin + Bendamustine'}]","A Study of Nivolumab + Brentuximab Vedotin in Children, Adolescents, and Young Adults With Classic Hodgkin Lymphoma (cHL) After Failure of First Line Therapy, Followed by Brentuximab Vedotin + Bendamustine for Participants With a Suboptimal Response (CheckMate 744)",7541
8,NCT02729961,Phase Ib/II,Not yet recruiting,"[{'id': 4169, 'therapyName': 'Brentuximab vedotin + Ceritinib'}]",Ceritinib With Brentuximab Vedotin in Treating Patients With ALK-Positive Anaplastic Large Cell Lymphoma,7541
9,NCT02744612,Phase II,Recruiting,"[{'id': 4300, 'therapyName': 'Brentuximab vedotin + Ibrutinib'}]",Ibrutinib and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma,7541
10,NCT01896999,Phase I,Recruiting,"[{'id': 2487, 'therapyName': 'Brentuximab vedotin + Ipilimumab'}]",Ipilimumab and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma,7541
11,NCT02429375,Phase Ib/II,"Active, not recruiting","[{'id': 3264, 'therapyName': 'Brentuximab vedotin + Mocetinostat'}]",Mocetinostat (MGCD0103) Plus Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Hodgkin Lymphoma,7541
12,NCT02758717,Phase II,Recruiting,"[{'id': 3263, 'therapyName': 'Brentuximab vedotin + Nivolumab'}]",Nivolumab and Brentuximab Vedotin in Treating Older Patients With Untreated Hodgkin Lymphoma,7541
13,NCT02572167,Phase Ib/II,"Active, not recruiting","[{'id': 3263, 'therapyName': 'Brentuximab vedotin + Nivolumab'}]",A Study of Brentuximab Vedotin Combined With Nivolumab for Relapsed or Refractory Hodgkin Lymphoma,7541
14,NCT02581631,Phase Ib/II,Recruiting,"[{'id': 3263, 'therapyName': 'Brentuximab vedotin + Nivolumab'}]",A Safety and Efficacy Study of Nivolumab in Combination With Brentuximab Vedotin to Treat Non-Hodgkin Lymphomas (CheckMate 436),7541
15,NCT03057795,Phase II,Recruiting,"[{'id': 3263, 'therapyName': 'Brentuximab vedotin + Nivolumab'}]",Nivolumab and Brentuximab Vedotin After Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Classical Hodgkin Lymphoma,7541
0,NCT02094573,Phase II,"Active, not recruiting","[{'id': 634, 'therapyName': 'AP26113'}]","A Phase 2, Multicenter, Randomized Study of AP26113",6840
1,NCT01449461,Phase Ib/II,"Active, not recruiting","[{'id': 634, 'therapyName': 'AP26113'}]",A Phase 1/2 Study of the Oral ALK/EGFR Inhibitor AP26113,6840
2,NCT02706626,Phase II,Recruiting,"[{'id': 634, 'therapyName': 'AP26113'}]",Trial of Brigatinib After Treatment With Second-Generation ALK Inhibitors,6840
3,NCT02737501,Phase III,"Active, not recruiting","[{'id': 634, 'therapyName': 'AP26113'}, {'id': 706, 'therapyName': 'Crizotinib'}]",ALTA-1L Study: A Phase 3 Study of Brigatinib Versus Crizotinib in ALK-positive Advanced Non-Small Cell Lung Cancer Patients,6840
4,NCT02784158,Phase I,No longer available,"[{'id': 634, 'therapyName': 'AP26113'}]",An Expanded Access Study of Brigatinib for Patients With ALK-positive Advanced Non-Small Cell Lung Cancer,6840
0,NCT01778439,Phase I,Completed,"[{'id': 839, 'therapyName': 'Brontictuzumab'}]",A Dose Escalation Study of OMP-52M51 in Subjects With Solid Tumors,7069
1,NCT01703572,Phase I,Completed,"[{'id': 839, 'therapyName': 'Brontictuzumab'}]",A Dose Escalation Study of OMP-52M51 in Subjects With Lymphoid Malignancies,7069
2,NCT03031691,Phase I,"Active, not recruiting","[{'id': 5261, 'therapyName': 'Brontictuzumab + Trifluridine'}]",A Study of Brontictuzumab With Chemotherapy for Subjects With Previously Treated Metastatic Colorectal Cancer,7069
0,NCT02500407,Phase I,Recruiting,"[{'id': 6305, 'therapyName': 'Atezolizumab + BTCT4465A'}]",A Safety and Pharmacokinetic Study of BTCT4465A as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL),8967
0,NCT00550992,Phase I,Unknown status,"[{'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1752, 'therapyName': 'Mitoxantrone + Etoposide + Cytarabine'}, {'id': 1848, 'therapyName': 'Cyclophosphamide + Methotrexate + Vincristine + Pegaspargase '}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1650, 'therapyName': 'Cyclosporine'}, {'id': 1844, 'therapyName': 'anti-thymocyte globulin'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1642, 'therapyName': 'Leucovorin'}]",Different Therapies in Treating Infants With Newly Diagnosed Acute Leukemia,997
1,NCT03259503,Phase Ib/II,Not yet recruiting,"[{'id': 1206, 'therapyName': 'Busulfan'}, {'id': 837, 'therapyName': 'Olaparib'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 2373, 'therapyName': 'Palifermin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 3277, 'therapyName': 'Pyridoxine'}, {'id': 897, 'therapyName': 'Rituximab'}]",Olaparib Combined With High-Dose Chemotherapy for Refractory Lymphomas,997
2,NCT02551718,Phase I,Recruiting,"[{'id': 690, 'therapyName': 'Bosutinib'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 3160, 'therapyName': 'Nelarabine'}, {'id': 3159, 'therapyName': 'Bexarotene'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 998, 'therapyName': 'cabozantinib'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 877, 'therapyName': 'Ponatinib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 623, 'therapyName': 'Afatinib'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 890, 'therapyName': 'Regorafenib'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 2, 'therapyName': 'Trametinib'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 3, 'therapyName': 'Dabrafenib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 789, 'therapyName': 'Ceritinib'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1571, 'therapyName': 'Cabazitaxel'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1327, 'therapyName': 'Pralatrexate'}]",High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia,997
3,NCT03126916,Phase III,Not yet recruiting,"[{'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1425, 'therapyName': '131I-MIBG'}, {'id': 1873, 'therapyName': 'Sargramostim'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 5595, 'therapyName': 'Isotretinoin'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 5153, 'therapyName': 'dexrazoxane'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1167, 'therapyName': 'Aldesleukin'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 2286, 'therapyName': 'Dinutuximab  '}]",Iobenguane I-131 or Crizotinib and Standard Therapy in Treating Younger Patients With Newly-Diagnosed High-Risk Neuroblastoma or Ganglioneuroblastoma,997
4,NCT02793544,Phase II,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 1845, 'therapyName': 'Mycophenolate mofetil'}, {'id': 5682, 'therapyName': 'Mesna'}, {'id': 1166, 'therapyName': 'Fludarabine'}]",HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide,997
5,NCT02788201,Phase II,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1133, 'therapyName': 'Mitomycin C'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1013, 'therapyName': 'epirubicin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1137, 'therapyName': 'Bleomycin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 781, 'therapyName': 'Ixabepilone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 2950, 'therapyName': 'Estramustine'}, {'id': 1941, 'therapyName': 'Floxuridine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 1811, 'therapyName': 'Carmustine'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 953, 'therapyName': 'Vandetanib'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 4419, 'therapyName': 'Toremifine'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 2601, 'therapyName': 'Dactinomycin'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 3035, 'therapyName': 'Chlorambucil'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 342, 'therapyName': 'Vemurafenib'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 2635, 'therapyName': 'Vinblastine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 4305, 'therapyName': 'Teniposide'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 4304, 'therapyName': 'Streptozocin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1231, 'therapyName': 'Bendamustine'}, {'id': 4303, 'therapyName': 'Mechlorethamine'}, {'id': 4302, 'therapyName': 'Mitotane'}]",Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma,997
6,NCT02251821,Phase II,Recruiting,"[{'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 1845, 'therapyName': 'Mycophenolate mofetil'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 2006, 'therapyName': 'Pacritinib'}, {'id': 823, 'therapyName': 'Momelotinib'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}]",JAK-2 Inhibitor Before Donor Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis,997
7,NCT02472392,Phase I,Completed,"[{'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1844, 'therapyName': 'anti-thymocyte globulin'}]",Study To Examine Toxicity Of Allogeneic Stem Cell Transplantation For Relapsed Or Therapy Refractory Ewings Sarcoma,997
8,NCT01625351,Phase I,"Active, not recruiting","[{'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1205, 'therapyName': 'Alemtuzumab'}]",A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas,997
9,NCT01707004,Phase I,"Active, not recruiting","[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1206, 'therapyName': 'Busulfan'}]",Decitabine and Total-Body Irradiation Followed By Donor Bone Marrow Transplant and Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia,997
10,NCT02701673,Phase Ib/II,Withdrawn,"[{'id': 651, 'therapyName': 'Azacitidine'}, {'id': 3277, 'therapyName': 'Pyridoxine'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1078, 'therapyName': 'Belinostat'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1207, 'therapyName': 'Melphalan'}]",Belinostat Combined With Azacitidine/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Refractory or Relapsed Lymphoma,997
11,NCT02083250,Phase I,Recruiting,"[{'id': 1844, 'therapyName': 'anti-thymocyte globulin'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 3201, 'therapyName': 'Busulfan + Clofarabine + Fludarabine'}]",Fludarabine/Clofarabine/Busulfan Combined With SAHA in Acute Leukemia,997
12,NCT01701986,Phase Ib/II,Recruiting,"[{'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1845, 'therapyName': 'Mycophenolate mofetil'}, {'id': 1844, 'therapyName': 'anti-thymocyte globulin'}, {'id': 3992, 'therapyName': 'Busulfan + Clofarabine + Gemcitabine'}]",Gemcitabine/Clofarabine/Busulfan and Allogeneic Transplantation for Aggressive Lymphomas,997
13,NCT01621477,Phase II,Terminated,"[{'id': 1756, 'therapyName': 'Plerixafor'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 1845, 'therapyName': 'Mycophenolate mofetil'}, {'id': 2469, 'therapyName': 'Busulfan + Clofarabine + Thymoglobulin'}, {'id': 1783, 'therapyName': 'Cyclophosphamide + Cytarabine'}]",T-Cell Replete Haploidentical Donor Hematopoietic Stem Cell Plus Natural Killer (NK) Cell Transplantation in Patients With Hematologic Malignancies Relapsed or Refractory Despite Previous Allogeneic Transplant,997
14,NCT00857389,Phase II,"Active, not recruiting","[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 2469, 'therapyName': 'Busulfan + Clofarabine + Thymoglobulin'}, {'id': 1639, 'therapyName': 'Methotrexate'}]",Thiotepa-Clofarabine-Busulfan With Allogeneic Stem Cell Transplant for High Risk Malignancies,997
15,NCT00990249,Phase II,Completed,"[{'id': 2469, 'therapyName': 'Busulfan + Clofarabine + Thymoglobulin'}]",Busulfan Plus Clofarabine Followed by Allogeneic Hematopoietic Stem Cell Transplantation,997
16,NCT00513474,Phase I,Completed,"[{'id': 2313, 'therapyName': 'Rasburicase'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 1650, 'therapyName': 'Cyclosporine'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 2314, 'therapyName': 'Busulfan + Cyclophosphamide + Etoposide'}]",Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant,997
17,NCT02221310,Phase II,Recruiting,"[{'id': 3932, 'therapyName': 'Busulfan + Cyclophosphamide + Gemtuzumab ozogamicin'}]",Immunochemotherapy and AlloSCT in Patients With High Risk CD33+ AML/MDS,997
18,NCT03240861,Phase I,Not yet recruiting,"[{'id': 6116, 'therapyName': 'Busulfan + Fludarabine'}, {'id': 3933, 'therapyName': 'Filgrastim + Plerixafor'}, {'id': 1167, 'therapyName': 'Aldesleukin'}]",Genetically Engineered PBMC and PBSC Expressing NY-ESO-1 TCR After a Myeloablative Conditioning Regimen to Treat Patients With Advanced Cancer (NYESO SCT),997
19,NCT00679536,Phase Ib/II,Unknown status,"[{'id': 1846, 'therapyName': 'Busulfan + Fludarabine + anti-thymocyte globulin'}]",Allogeneic Transplantation for Pediatric Leukemias With Unrelated Donors,997
20,NCT01823198,Phase Ib/II,Recruiting,"[{'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1846, 'therapyName': 'Busulfan + Fludarabine + anti-thymocyte globulin'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 1632, 'therapyName': 'Filgrastim'}]",Natural Killer (NK) Cells With HLA Compatible Hematopoietic Transplantation for High Risk Myeloid Malignancies,997
21,NCT02057770,Phase I,Recruiting,"[{'id': 5724, 'therapyName': 'Busulfan + Fludarabine phosphate + Cyclophosphamide'}, {'id': 5647, 'therapyName': 'Tocilizumab'}]",Allogeneic or Haploidentical Stem Cell Transplant Followed By High-Dose Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia,997
22,NCT02961816,Phase II,Withdrawn,"[{'id': 3277, 'therapyName': 'Pyridoxine'}, {'id': 4976, 'therapyName': 'Busulfan + Gemcitabine + Melphalan + Panobinostat'}, {'id': 4977, 'therapyName': 'Dexamethasone + Filgrastim + Palifermin + Rituximab'}]",Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Lymphoma,997
23,NCT02130869,Phase I,Recruiting,"[{'id': 2378, 'therapyName': 'Bendamustine + Cytarabine + Etoposide'}, {'id': 2460, 'therapyName': 'Busulfan + Hu14.18K322A'}, {'id': 2459, 'therapyName': 'Aldesleukin + Melphalan + Sargramostim'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1791, 'therapyName': 'Carboplatin + Etoposide'}]",A Pilot Study of Immunotherapy Including Haploidentical NK Cell Infusion Following CD133+ Positively-Selected Autologous Hematopoietic Stem Cells in Children With High Risk Solid Tumors or Lymphomas,997
24,NCT00020566,Phase III,Unknown status,"[{'id': 2558, 'therapyName': 'Busulfan + Melphalan'}, {'id': 2670, 'therapyName': 'Vincristine + Doxorubicin + Dactinomycin + Ifosfamide + Etoposide'}]","Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation, Radiation Therapy, and/or Surgery in Treating Patients With Ewing's Sarcoma",997
25,NCT00084695,Phase II,Unknown status,"[{'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 2558, 'therapyName': 'Busulfan + Melphalan'}, {'id': 1844, 'therapyName': 'anti-thymocyte globulin'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 2188, 'therapyName': 'Prednisone'}]",Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases,997
26,NCT01175356,Phase I,Completed,"[{'id': 2558, 'therapyName': 'Busulfan + Melphalan'}, {'id': 2590, 'therapyName': 'Cyclophosphamide + Topotecan'}, {'id': 1425, 'therapyName': '131I-MIBG'}, {'id': 2353, 'therapyName': 'Cyclophosphamide + Doxorubicin + Vincristine '}, {'id': 2585, 'therapyName': 'Cisplatin + Etoposide'}]","Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin",997
27,NCT02506959,Phase II,Recruiting,"[{'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 2558, 'therapyName': 'Busulfan + Melphalan'}, {'id': 3277, 'therapyName': 'Pyridoxine'}, {'id': 1080, 'therapyName': 'Panobinostat'}, {'id': 2373, 'therapyName': 'Palifermin'}, {'id': 755, 'therapyName': 'Gemcitabine'}]",Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Myeloma,997
28,NCT01505569,Phase I,Recruiting,"[{'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 2558, 'therapyName': 'Busulfan + Melphalan'}, {'id': 2101, 'therapyName': 'Etoposide + Ifosfamide'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 1092, 'therapyName': 'Carboplatin'}]",Auto Transplant for High Risk or Relapsed Solid or CNS Tumors,997
29,NCT01983969,Phase Ib/II,"Active, not recruiting","[{'id': 897, 'therapyName': 'Rituximab'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 2558, 'therapyName': 'Busulfan + Melphalan'}, {'id': 2557, 'therapyName': 'Azacitidine + Gemcitabine + vorinostat'}]",Aza-SAHA-GBM With AutoSCT for Refractory Lymphoma,997
30,NCT02589145,Phase Ib/II,Recruiting,"[{'id': 1164, 'therapyName': 'lenalidomide'}, {'id': 3277, 'therapyName': 'Pyridoxine'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 2558, 'therapyName': 'Busulfan + Melphalan'}, {'id': 3278, 'therapyName': 'Enoxaparin'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 2373, 'therapyName': 'Palifermin'}]",Lenalidomide Combined With Vorinostat/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Diffuse Large B-Cell Lymphoma of the ABC Subtype,997
31,NCT01857934,Phase II,Recruiting,"[{'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1873, 'therapyName': 'Sargramostim'}, {'id': 1167, 'therapyName': 'Aldesleukin'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 2627, 'therapyName': 'Levetiracetam'}, {'id': 2585, 'therapyName': 'Cisplatin + Etoposide'}, {'id': 2458, 'therapyName': 'Hu14.18K322A'}, {'id': 2558, 'therapyName': 'Busulfan + Melphalan'}, {'id': 2590, 'therapyName': 'Cyclophosphamide + Topotecan'}]",Therapy for Children With Advanced Stage Neuroblastoma,997
32,NCT03247088,Phase Ib/II,Recruiting,"[{'id': 6122, 'therapyName': 'Busulfan + Sorafenib + Fludarabine'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 1632, 'therapyName': 'Filgrastim'}]",Study Of Sorafenib Added To Busulfan And Fludarabine Conditioning Regimen In Patients With Relapsed/Refractory AML Undergoing Stem Cell Transplantation,997
0,NCT02296242,Phase Ib/II,Completed,"[{'id': 997, 'therapyName': 'BVD-523'}]",Phase 1/2 Study of the ERK1/2 Inhibitor BVD-523 in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndromes,7114
1,NCT01781429,Phase Ib/II,"Active, not recruiting","[{'id': 997, 'therapyName': 'BVD-523'}]","Phase I Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of BVD-523 in Patients With Advanced Malignancies",7114
2,NCT02608229,Phase I,Recruiting,"[{'id': 3249, 'therapyName': 'BVD-523 + Gemcitabine + nab-paclitaxel'}]",BVD-523 Plus Nab-paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Cancer,7114
0,NCT03195699,Phase I,Not yet recruiting,"[{'id': 5961, 'therapyName': 'C188-9'}]","Phase I Study of Oral STAT3 Inhibitor, C188-9, in Patients With Advanced Cancers",8871
0,NCT02812875,Phase I,Recruiting,"[{'id': 5885, 'therapyName': 'CA-170'}]","A Study of CA-170 (Oral PD-L1, PD-L2 and VISTA Checkpoint Antagonist) in Patients With Advanced Tumors and Lymphomas",8844
0,NCT02903160,Phase II,Recruiting,"[{'id': 4759, 'therapyName': 'Abiraterone + Cabazitaxel + Carboplatin + Enzalutamide + Prednisone'}]","Prostate Cancer Intensive, Non-Cross Reactive Therapy (PRINT) for Castration Resistant Prostate Cancer (CRPC)",7288
1,NCT01845792,Phase II,Completed,"[{'id': 1571, 'therapyName': 'Cabazitaxel'}, {'id': 1805, 'therapyName': 'Abiraterone'}]",Study of Abiraterone Acetate and Prednisone in Combination With Cabazitaxel in Patients With Prostate Cancer,7288
2,NCT02543255,Phase II,Recruiting,"[{'id': 1571, 'therapyName': 'Cabazitaxel'}, {'id': 3079, 'therapyName': 'Abiraterone + Leuprolide + Prednisone'}, {'id': 1476, 'therapyName': 'Pegfilgrastim'}]",Anti-Androgens and Cabazitaxel in Defining Complete Response in Prostatectomy (ACDC Trial),7288
3,NCT02551718,Phase I,Recruiting,"[{'id': 690, 'therapyName': 'Bosutinib'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 3160, 'therapyName': 'Nelarabine'}, {'id': 3159, 'therapyName': 'Bexarotene'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 998, 'therapyName': 'cabozantinib'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 877, 'therapyName': 'Ponatinib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 623, 'therapyName': 'Afatinib'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 890, 'therapyName': 'Regorafenib'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 2, 'therapyName': 'Trametinib'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 3, 'therapyName': 'Dabrafenib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 789, 'therapyName': 'Ceritinib'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1571, 'therapyName': 'Cabazitaxel'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1327, 'therapyName': 'Pralatrexate'}]",High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia,7288
4,NCT01420250,Phase I,"Active, not recruiting","[{'id': 1507, 'therapyName': 'Bicalutamide'}, {'id': 1571, 'therapyName': 'Cabazitaxel'}]",Cabazitaxel With Radiation and Hormone Therapy for Prostate Cancer,7288
5,NCT02218606,Phase II,Recruiting,"[{'id': 1571, 'therapyName': 'Cabazitaxel'}, {'id': 2748, 'therapyName': 'Abiraterone + Prednisone'}]",Multicenter Trial of Abiraterone Acetate With or Without Cabazitaxel in Treatment of Metastatic Castration Resistant Prostate Cancer,7288
6,NCT02379390,Phase II,Terminated,"[{'id': 2188, 'therapyName': 'Prednisone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 1571, 'therapyName': 'Cabazitaxel'}]",Cabazitaxel Versus the Switch to Alternative AR Targeted Therapy Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Primary Resistant Patients to Abiraterone or Enz (PRIMCAB),7288
7,NCT01513733,Phase I,Completed,"[{'id': 2699, 'therapyName': 'Tasquinimod'}, {'id': 1571, 'therapyName': 'Cabazitaxel'}]",The CATCH Prostate Cancer Trial Cabazitaxel And Tasquinimod in Men With Prostate Cancer,7288
8,NCT02254785,Phase II,Recruiting,"[{'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 1571, 'therapyName': 'Cabazitaxel'}]",Cabazitaxel vs Abiraterone or Enzalutamide in Patients With Poor Prognosis Metastatic Castration-resistant Prostate Cancer,7288
9,NCT02703623,Phase II,Recruiting,"[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 2649, 'therapyName': 'Abiraterone + ARN-509 + Prednisone'}, {'id': 3844, 'therapyName': 'Cabazitaxel + Carboplatin'}]",A Dynamic Allocation Modular Sequential Trial of Approved and Promising Therapies in Men With Metastatic Castrate Resistant Prostate Cancer (DynaMO),7288
10,NCT03263650,Phase II,Recruiting,"[{'id': 3844, 'therapyName': 'Cabazitaxel + Carboplatin'}, {'id': 837, 'therapyName': 'Olaparib'}]",Randomized Phase II Study of Olaparib Maintenance Following Cabazitaxel-Carbo in Men With AVPC,7288
11,NCT02522715,Phase Ib/II,Recruiting,"[{'id': 3056, 'therapyName': 'Cabazitaxel + Enzalutamide'}, {'id': 2188, 'therapyName': 'Prednisone'}]","Enzalutamide and Cabazitaxel in Treating Patients With Metastatic, Hormone-Resistant Prostate Cancer",7288
12,NCT01934894,Phase II,Terminated,"[{'id': 1572, 'therapyName': 'Cabazitaxel + Lapatinib'}]",Cabazitaxel Plus Lapatinib as Therapy for HER2-Positive Metastatic Breast Cancer Patients With Intracranial Metastases,7288
0,NCT03170960,Phase Ib/II,Recruiting,"[{'id': 6094, 'therapyName': 'Atezolizumab + Cabozantinib'}]",Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors,7115
1,NCT03264066,Phase II,Not yet recruiting,"[{'id': 6094, 'therapyName': 'Atezolizumab + Cabozantinib'}]",A Study to Investigate the Efficacy and Safety of Cobimetinib Plus Atezolizumab in Participants With Solid Tumors,7115
2,NCT01639508,Phase II,Recruiting,"[{'id': 998, 'therapyName': 'cabozantinib'}]",Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes,7115
3,NCT02036476,Phase II,"Active, not recruiting","[{'id': 998, 'therapyName': 'cabozantinib'}]",Cabozantinib in Recurrent/Metastatic Merkel Cell Carcinoma,7115
4,NCT02867592,Phase II,Recruiting,"[{'id': 998, 'therapyName': 'cabozantinib'}]","Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors",7115
5,NCT01703065,Phase I,"Active, not recruiting","[{'id': 998, 'therapyName': 'cabozantinib'}]",Cabozantinib in Treating Men With Castration-Resistant Prostate Cancer,7115
6,NCT01961765,Phase I,Completed,"[{'id': 998, 'therapyName': 'cabozantinib'}]",Phase I Trial of Cabozantinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia,7115
7,NCT01866293,Phase Ib/II,Completed,"[{'id': 998, 'therapyName': 'cabozantinib'}]",Cabozantinib (XL184) in Patients With Relapsed or Refractory Myeloma,7115
8,NCT01582295,Phase I,Completed,"[{'id': 998, 'therapyName': 'cabozantinib'}]",XL184 For Relapsed/Refractory Multiple Myeloma (MM) With Bone Disease,7115
9,NCT01630590,Phase II,"Active, not recruiting","[{'id': 998, 'therapyName': 'cabozantinib'}]",Cabozantinib and Androgen Ablation in Patients With Androgen-Dependent Metastatic Prostate Cancer,7115
10,NCT01835145,Phase II,"Active, not recruiting","[{'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 1141, 'therapyName': 'Temozolomide'}, {'id': 998, 'therapyName': 'cabozantinib'}]",Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Melanoma of the Eye,7115
11,NCT03201250,,Not yet recruiting,"[{'id': 998, 'therapyName': 'cabozantinib'}]",Cabozantinib as a Targeted Strategy to Reverse Carfilzomib Resistance in Refractory Multiple Myeloma,7115
12,NCT02260531,Phase II,Recruiting,"[{'id': 998, 'therapyName': 'cabozantinib'}, {'id': 947, 'therapyName': 'Trastuzumab'}]",Cabozantinib + / - Trastuzumab In Breast Cancer Patients w/ Brain Metastases,7115
13,NCT02761057,Phase II,Recruiting,"[{'id': 2161, 'therapyName': 'Savolitinib'}, {'id': 998, 'therapyName': 'cabozantinib'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 930, 'therapyName': 'Sunitinib'}]","Cabozantinib-S-Malate, Crizotinib, Volitinib, or Sunitinib Malate in Treating Patients With Locally Advanced or Metastatic Kidney Cancer",7115
14,NCT02885324,Phase II,Recruiting,"[{'id': 998, 'therapyName': 'cabozantinib'}]",Pilot Study of Cabozantinib for Recurrent or Progressive High-Grade Glioma in Children,7115
15,NCT02315430,Phase II,"Active, not recruiting","[{'id': 998, 'therapyName': 'cabozantinib'}]","Cabozantinib-S-Malate in Treating Patients With Recurrent or Progressive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",7115
16,NCT01835158,Phase II,"Active, not recruiting","[{'id': 998, 'therapyName': 'cabozantinib'}, {'id': 1236, 'therapyName': 'Cabozantinib + Sunitinib'}]",Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer,7115
17,NCT01812668,Phase I,"Active, not recruiting","[{'id': 998, 'therapyName': 'cabozantinib'}]",Cabozantinib-S-Malate in Treating Patients With Hormone-Resistant Metastatic Prostate Cancer,7115
18,NCT01709435,Phase I,"Active, not recruiting","[{'id': 998, 'therapyName': 'cabozantinib'}]", Cabozantinib in Treating Younger Patients With Recurrent or Refractory Solid Tumors,7115
19,NCT01811212,Phase II,"Active, not recruiting","[{'id': 998, 'therapyName': 'cabozantinib'}]",Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer,7115
20,NCT02041260,Phase II,Recruiting,"[{'id': 998, 'therapyName': 'cabozantinib'}]",A Phase II Trial of Cabozantinib for the Treatment of Radioiodine (RAI)-Refractory Differentiated Thyroid Carcinoma (DTC) in the First-line Setting,7115
21,NCT01688999,Phase II,"Active, not recruiting","[{'id': 998, 'therapyName': 'cabozantinib'}]",Cabozantinib for Advanced Urothelial Cancer,7115
22,NCT01834651,Phase II,Completed,"[{'id': 998, 'therapyName': 'cabozantinib'}]",A Phase II Study of Cabozantinib (XL184) Therapy in Castrate Resistant Prostate Cancer (CRPC) With Visceral Metastases,7115
23,NCT01865747,Phase III,"Active, not recruiting","[{'id': 735, 'therapyName': 'Everolimus'}, {'id': 998, 'therapyName': 'cabozantinib'}]",A Study of Cabozantinib (XL184) vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma,7115
24,NCT01908426,Phase III,Recruiting,"[{'id': 998, 'therapyName': 'cabozantinib'}]",Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib,7115
25,NCT01935934,Phase II,Suspended,"[{'id': 998, 'therapyName': 'cabozantinib'}]",Cabozantinib-S-Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer,7115
26,NCT01588821,Phase II,"Active, not recruiting","[{'id': 998, 'therapyName': 'cabozantinib'}]",Cabozantinib in Advanced Solid Malignancies,7115
27,NCT02551718,Phase I,Recruiting,"[{'id': 690, 'therapyName': 'Bosutinib'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 3160, 'therapyName': 'Nelarabine'}, {'id': 3159, 'therapyName': 'Bexarotene'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 998, 'therapyName': 'cabozantinib'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 877, 'therapyName': 'Ponatinib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 623, 'therapyName': 'Afatinib'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 890, 'therapyName': 'Regorafenib'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 2, 'therapyName': 'Trametinib'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 3, 'therapyName': 'Dabrafenib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 789, 'therapyName': 'Ceritinib'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1571, 'therapyName': 'Cabazitaxel'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1327, 'therapyName': 'Pralatrexate'}]",High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia,7115
28,NCT01822522,Phase I,Recruiting,"[{'id': 998, 'therapyName': 'cabozantinib'}]",Cabozantinib-S-Malate in Treating Patients With Advanced Solid Tumors and Human Immunodeficiency Virus,7115
29,NCT02101736,Phase II,"Active, not recruiting","[{'id': 998, 'therapyName': 'cabozantinib'}]",Cabozantinib for Plexiform Neurofibromas (PN) in Subjects With NF1 (16 Years +),7115
30,NCT02132598,Phase II,Recruiting,"[{'id': 998, 'therapyName': 'cabozantinib'}]",Trial of Cabozantinib (XL184) in Non-Small Cell Lung Cancer With Brain Metastases,7115
31,NCT01466036,Phase II,"Active, not recruiting","[{'id': 998, 'therapyName': 'cabozantinib'}]",Cabozantinib in Advanced Pancreatic Neuroendocrine and Carcinoid Tumors,7115
32,NCT01755195,Phase II,Recruiting,"[{'id': 998, 'therapyName': 'cabozantinib'}]",Cabozantinib for Adults With Advanced Soft Tissue Sarcoma,7115
33,NCT02302833,Phase I,Recruiting,"[{'id': 998, 'therapyName': 'cabozantinib'}]",Cabozantinib for Malignant Pheochromocytoma,7115
34,NCT01683994,Phase I,"Active, not recruiting","[{'id': 2069, 'therapyName': 'cabozantinib + Docetaxel'}]",Cabozantinib Plus Docetaxel and Prednisone for Advanced Prostate Cancer,7115
35,NCT03213626,Phase II,Not yet recruiting,"[{'id': 1255, 'therapyName': 'Cabozantinib + Erlotinib'}]",Cabozantinib and Erlotinib for Patients With EGFR and c-Met Co-expressing Metastatic Pancreatic Adenocarcinoma,7115
36,NCT01866410,Phase II,"Active, not recruiting","[{'id': 1255, 'therapyName': 'Cabozantinib + Erlotinib'}]",Cabozantinib-S-Malate and Erlotinib Hydrochloride in Treating Patients With Previously Treated Metastatic Non-Small Cell Lung Cancer,7115
37,NCT01441947,Phase II,"Active, not recruiting","[{'id': 1965, 'therapyName': 'cabozantinib + Fulvestrant'}]",Cabozantinib in Women With Metastatic Hormone-Receptor-Positive Breast Cancer,7115
38,NCT01663272,Phase I,"Active, not recruiting","[{'id': 2070, 'therapyName': 'Cabozantinib + Gemcitabine'}]",A Trial of Cabozantinib (XL184) and Gemcitabine in Advanced Pancreatic Cancer,7115
39,NCT03141177,Phase III,Recruiting,"[{'id': 2068, 'therapyName': 'Cabozantinib + Ipilimumab + Nivolumab'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 2067, 'therapyName': 'Cabozantinib + Nivolumab'}]",A Study of Nivolumab Combined With Cabozantinib or Nivolumab and Ipilimumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 9ER),7115
40,NCT03299946,Phase I,Not yet recruiting,"[{'id': 2067, 'therapyName': 'Cabozantinib + Nivolumab'}]",Feasibility and Efficacy of Neoadjuvant Cabozantinib Plus Nivolumab (CaboNivo) Followed by Definitive Resection for Patients With Locally Advanced Hepatocellular Carcinoma (HCC),7115
41,NCT02496208,Phase I,Recruiting,"[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 2067, 'therapyName': 'Cabozantinib + Nivolumab'}]",Cabozantinib Plus Nivolumab (CaboNivo) Alone or in Combination With Ipilimumab (CaboNivoIpi) in Patients With Advanced/Metastatic Urothelial Carcinoma and Other Genitourinary Tumors,7115
42,NCT01835184,Phase I,Terminated,"[{'id': 1235, 'therapyName': 'Cabozantinib + Vemurafenib'}]",Cabozantinib-S-Malate and Vemurafenib in Treating Patients With Solid Tumors or Melanoma That is Metastatic or That Cannot Be Removed By Surgery,7115
43,NCT02008383,Phase I,Recruiting,"[{'id': 1985, 'therapyName': 'Panitumumab + cabozantinib'}]",Cabozantinib and Panitumumab to Treat KRAS Wild-Type Metastatic Colorectal Cancer,7115
44,NCT03149822,Phase Ib/II,Not yet recruiting,"[{'id': 5680, 'therapyName': 'Pembrolizumab + Cabozantinib'}]",Study of Pembrolizumab and Cabozantinib in Patients With Metastatic Renal Cell Carcinoma,7115
0,NCT00536991,Phase Ib/II,Terminated,"[{'id': 2188, 'therapyName': 'Prednisone'}, {'id': 2889, 'therapyName': 'calcitriol'}, {'id': 2858, 'therapyName': 'Ketoconazole'}]","Calcitriol, Ketoconazole, and Hydrocortisone in Treating Patients With Advanced or Recurrent Prostate Cancer",7817
0,NCT02332655,Phase Ib/II,"Active, not recruiting","[{'id': 2632, 'therapyName': 'Cannabidiol'}]",Cannabidiol Expanded Access Study in Medically Refractory Sturge-Weber Syndrome,7620
0,NCT03050814,Phase II,Suspended,"[{'id': 1524, 'therapyName': 'Fluorouracil + Bevacizumab + Capecitabine + Leucovorin + Oxaliplatin'}, {'id': 5336, 'therapyName': 'Ad-CEA + Bevacizumab + FOLFOX'}]",Standard of Care Alone or in Combination With Ad-CEA Vaccine and Avelumab in People With Previously Untreated Metastatic Colorectal Cancer,1088
1,NCT02842125,Phase I,Recruiting,"[{'id': 5879, 'therapyName': 'Ad5CMV-p53 gene + Capecitabine'}]",Safety and Efficacy of Intra-Arterial Ad-p53 in Liver Metastases of Solid Tumors,1088
2,NCT01661972,Phase Ib/II,Completed,"[{'id': 2368, 'therapyName': 'Aflibercept + Capecitabine'}]",Phase I/II Study of Capecitabine Plus Aflibercept to Treat Metastatic Colorectal Cancer,1088
3,NCT02025192,Phase I,"Active, not recruiting","[{'id': 1560, 'therapyName': 'ARRY-380 + Trastuzumab'}, {'id': 1577, 'therapyName': 'ARRY-380 + Capecitabine'}]",A Phase 1b Study of ONT-380 Combined With Capecitabine and/or Trastuzumab in Patients With HER2+ Metastatic Breast Cancer,1088
4,NCT02614794,Phase II,Recruiting,"[{'id': 3340, 'therapyName': 'ARRY-380 + Capecitabine + Trastuzumab'}, {'id': 1409, 'therapyName': 'Capecitabine + Trastuzumab'}]",Study of ONT-380 vs Placebo in Combo w/ Capecitabine & Trastuzumab in Patients w/ Metastatic HER2+ Breast Cancer,1088
5,NCT02873195,Phase II,Not yet recruiting,"[{'id': 2097, 'therapyName': 'Bevacizumab + Capecitabine'}, {'id': 1202, 'therapyName': 'Atezolizumab + Bevacizumab + Capecitabine'}]",Capecitabine and Bevacizumab With or Without Atezolizumab in Treating Patients With Refractory Metastatic Colorectal Cancer,1088
6,NCT01984242,Phase II,"Active, not recruiting","[{'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1202, 'therapyName': 'Atezolizumab + Bevacizumab + Capecitabine'}]",A Phase 2 Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) as Monotherapy or in Combination With Avastin (Bevacizumab) Compared to Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma,1088
7,NCT01633970,Phase I,"Active, not recruiting","[{'id': 1203, 'therapyName': 'Atezolizumab + Carboplatin + Paclitaxel'}, {'id': 1204, 'therapyName': 'Atezolizumab + Carboplatin + Pemetrexed'}, {'id': 1202, 'therapyName': 'Atezolizumab + Bevacizumab + Capecitabine'}]",A Phase 1b Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) in Combination With Avastin (Bevacizumab) and/or With Chemotherapy in Patients With Locally Advanced or Metastatic Solid Tumors,1088
8,NCT02715531,Phase I,Recruiting,"[{'id': 3947, 'therapyName': 'Atezolizumab + Gemcitabine + nab-paclitaxel'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 1202, 'therapyName': 'Atezolizumab + Bevacizumab + Capecitabine'}]",A Study of the Safety and Tolerability of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors,1088
9,NCT02724878,Phase II,Recruiting,"[{'id': 1202, 'therapyName': 'Atezolizumab + Bevacizumab + Capecitabine'}]",Study of Atezolizumab + Bevacizumab in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma,1088
10,NCT01634685,Phase I,"Active, not recruiting","[{'id': 3684, 'therapyName': 'Bavituximab + Capecitabine'}]","A Phase I Study of Bavituximab, Capecitabine, and Radiation for the Treatment of Rectal Adenocarcinoma",1088
11,NCT01776307,Phase II,Recruiting,"[{'id': 2090, 'therapyName': 'BBI608 + Cetuximab'}, {'id': 2091, 'therapyName': 'BBI608 + Capecitabine'}, {'id': 2092, 'therapyName': 'BBI608 + Panitumumab'}]",A Study of BBI608 in Adult Patients With Advanced Colorectal Cancer,1088
12,NCT02669173,Phase I,Recruiting,"[{'id': 2097, 'therapyName': 'Bevacizumab + Capecitabine'}]",Capecitabine + Bevacizumab in Patients With Recurrent Glioblastoma,1088
13,NCT01722162,Phase II,Completed,"[{'id': 2097, 'therapyName': 'Bevacizumab + Capecitabine'}]",Levocetirizine + Capecitabine + Bevacizumab for Patients With Refractory Colorectal Cancer,1088
14,NCT00780494,Phase II,Unknown status,"[{'id': 2096, 'therapyName': 'Bevacizumab + Capecitabine + Carboplatin'}]","Ph II of Capecitabine, Carboplatin and Bevacizumab for Gastroesophageal Junction and Gastric Carcinoma",1088
15,NCT01525082,Phase II,"Active, not recruiting","[{'id': 2073, 'therapyName': 'Bevacizumab + Capecitabine + Temozolomide'}]","Capecitabine, Temozolomide and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors",1088
16,NCT01300962,Phase I,"Active, not recruiting","[{'id': 1538, 'therapyName': 'BKM120 + Capecitabine + Lapatinib'}, {'id': 1537, 'therapyName': 'BKM120 + Capecitabine + Trastuzumab'}, {'id': 1536, 'therapyName': 'BKM120 + Capecitabine'}, {'id': 1535, 'therapyName': 'BYL719 + Capecitabine'}]",Study of BKM120 or BYL719 and Capecitabine in Patients With Metastatic Breast Cancer,1088
17,NCT02000882,Phase II,"Active, not recruiting","[{'id': 1536, 'therapyName': 'BKM120 + Capecitabine'}]",Capecitabine + BKM120 TNBC BC Brain Met,1088
18,NCT02550743,Phase I,Recruiting,"[{'id': 1535, 'therapyName': 'BYL719 + Capecitabine'}]","BrUOG 302:BYL719, Capecitabine and Radiation for Rectal Cancer: A Brown University Oncology Research Group Study",1088
19,NCT02314117,Phase III,"Active, not recruiting","[{'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 886, 'therapyName': 'Ramucirumab'}]",A Study of Ramucirumab (LY3009806) in Combination With Capecitabine and Cisplatin in Participants With Stomach Cancer,1088
20,NCT01497392,Phase I,Completed,"[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 721, 'therapyName': 'Dovitinib'}, {'id': 1105, 'therapyName': 'Capecitabine'}]"," Dovitinib Lactate, Gemcitabine Hydrochloride, and Capecitabine in Treating Patients With Advanced or Metastatic Solid Tumors, Pancreatic Cancer and Biliary Cancers",1088
21,NCT02483247,Phase Ib/II,Recruiting,"[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1945, 'therapyName': 'BBI503'}]",A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer,1088
22,NCT01729923,Phase II,Terminated,"[{'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 2124, 'therapyName': 'Celecoxib'}]",A Trial of Maintenance ADAPT Therapy With Capecitabine and Celecoxib in Patients With Metastatic Colorectal Cancer,1088
23,NCT01921751,Phase II,Terminated,"[{'id': 1779, 'therapyName': 'Nab-paclitaxel + Gemcitabine'}, {'id': 1105, 'therapyName': 'Capecitabine'}]",High or Standard Intensity Radiation Therapy After Gemcitabine Hydrochloride and Nab-paclitaxel in Treating Patients With Pancreatic Cancer That Cannot Be Removed by Surgery,1088
24,NCT02042443,Phase II,Completed,"[{'id': 2278, 'therapyName': 'Fluorouracil + Leucovorin'}, {'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 2, 'therapyName': 'Trametinib'}]",Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery,1088
25,NCT01061515,Phase I,Recruiting,"[{'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}]",Biweekly Intraperitoneal Oxaliplatin With Systemic Capecitabine and Bevacizumab for Patients With Peritoneal Carcinomatosis From Appendiceal or Colorectal Cancer,1088
26,NCT02981342,Phase II,Recruiting,"[{'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 802, 'therapyName': 'Abemaciclib'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 5175, 'therapyName': 'Abemaciclib + LY3023414'}, {'id': 5176, 'therapyName': 'Abemaciclib + Galunisertib'}]",A Study of Abemaciclib (LY2835219) Alone or in Combination With Other Agents in Participants With Previously Treated Pancreatic Ductal Adenocarcinoma,1088
27,NCT02451553,Phase I,Recruiting,"[{'id': 623, 'therapyName': 'Afatinib'}, {'id': 1105, 'therapyName': 'Capecitabine'}]","Afatinib Dimaleate and Capecitabine in Treating Patients With Advanced Refractory Solid Tumors, Pancreatic Cancer or Biliary Cancer",1088
28,NCT01828554,Phase III,Recruiting,"[{'id': 1105, 'therapyName': 'Capecitabine'}]",Capecitabine Pharmacokinetics(PK)-Actual Versus Ideal Body Weight,1088
29,NCT02119663,Phase III,Terminated,"[{'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 1615, 'therapyName': 'Ruxolitinib + Capecitabine'}]",A Study of Ruxolitinib in Pancreatic Cancer Patients,1088
30,NCT01997333,Phase II,"Active, not recruiting","[{'id': 3597, 'therapyName': 'Glembatumumab vedotin'}, {'id': 1105, 'therapyName': 'Capecitabine'}]","Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer",1088
31,NCT03093870,Phase II,Not yet recruiting,"[{'id': 5543, 'therapyName': 'Capecitabine + Varlitinib'}, {'id': 1105, 'therapyName': 'Capecitabine'}]",Varlitinib in Combination With Capecitabine for Advanced or Metastatic Biliary Tract Cancer,1088
32,NCT02009449,Phase I,"Active, not recruiting","[{'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 2621, 'therapyName': 'AM0010 '}, {'id': 619, 'therapyName': 'Abraxane'}]",A Phase 1 Study of AM0010 in Patients With Advanced Solid Tumors,1088
33,NCT02305186,Phase Ib/II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1105, 'therapyName': 'Capecitabine'}]",Safety and Immunological Effect of Pembrolizumab in Resectable or Borderline Resectable Pancreatic Cancer,1088
34,NCT02083653,Phase II,"Active, not recruiting","[{'id': 931, 'therapyName': 'SYM004'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1105, 'therapyName': 'Capecitabine'}]",Sym004 vs Standard of Care in Subjects With Metastatic Colorectal Cancer,1088
35,NCT01213238,Phase I,"Active, not recruiting","[{'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 667, 'therapyName': 'Bevacizumab'}]","Hepatic Arterial Infusion Oxaliplatin, Capecitabine With or Without Bevacizumab",1088
36,NCT01945775,Phase III,"Active, not recruiting","[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 1685, 'therapyName': 'Vinorelbine'}, {'id': 682, 'therapyName': 'Talazoparib'}, {'id': 728, 'therapyName': 'Eribulin'}]","A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study)",1088
37,NCT02297230,Phase Ib/II,Completed,"[{'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1551, 'therapyName': 'Trastuzumab + Paclitaxel'}]",Locally Advanced Breast Cancer: Individualized Treatment Based On Tumor Molecular Characteristics,1088
38,NCT02492711,Phase III,Recruiting,"[{'id': 1685, 'therapyName': 'Vinorelbine'}, {'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 808, 'therapyName': 'MGAH22'}]",Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer,1088
39,NCT02921256,Phase II,Recruiting,"[{'id': 954, 'therapyName': 'Veliparib'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 4838, 'therapyName': 'Capecitabine + Veliparib'}, {'id': 1105, 'therapyName': 'Capecitabine'}]",Veliparib and Combination Chemotherapy in Treating Patient With Locally Advanced Rectal Cancer,1088
40,NCT02423954,Phase Ib/II,"Active, not recruiting","[{'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 1074, 'therapyName': 'Irinotecan'}]",Study of Nivolumab Plus Chemotherapy in Patients With Advanced Cancer (NivoPlus),1088
41,NCT02555657,Phase III,"Active, not recruiting","[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1685, 'therapyName': 'Vinorelbine'}, {'id': 1105, 'therapyName': 'Capecitabine'}]",Study of Single Agent Pembrolizumab (MK-3475) Versus Single Agent Chemotherapy for Metastatic Triple Negative Breast Cancer (MK-3475-119/KEYNOTE-119),1088
42,NCT02117479,Phase III,Terminated,"[{'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 1105, 'therapyName': 'Capecitabine'}]",Study of Ruxolitinib in Pancreatic Cancer Patients (Janus 1),1088
43,NCT02000622,Phase III,"Active, not recruiting","[{'id': 837, 'therapyName': 'Olaparib'}, {'id': 1685, 'therapyName': 'Vinorelbine'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1105, 'therapyName': 'Capecitabine'}]",Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations.,1088
44,NCT02229149,Phase II,"Active, not recruiting","[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}, {'id': 619, 'therapyName': 'Abraxane'}, {'id': 1685, 'therapyName': 'Vinorelbine'}, {'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 1105, 'therapyName': 'Capecitabine'}]","Phase 2 Study of Standard Chemotherapy With Trastuzumab, Plus or Minus Pertuzumab, for Pre-treated Metastatic Breast Cancer",1088
45,NCT02178644,Phase I,Recruiting,"[{'id': 1699, 'therapyName': 'KD018'}, {'id': 1105, 'therapyName': 'Capecitabine'}]",Pilot Trial of KD018 With Neo-Adjuvant Concurrent Chemo-Radiation Therapy in Patients With Locally Advanced Rectal Cancer,1088
46,NCT02244489,Phase I,Terminated,"[{'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 823, 'therapyName': 'Momelotinib'}]",Momelotinib Combined With Capecitabine and Oxaliplatin in Adults With Relapsed/Refractory Metastatic Pancreatic Ductal Adenocarcinoma,1088
47,NCT02494583,Phase III,"Active, not recruiting","[{'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 1833, 'therapyName': 'Cisplatin + Fluorouracil'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Study of Pembrolizumab (MK-3475) as First-Line Monotherapy and Combination Therapy for Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-062/KEYNOTE-062),1088
48,NCT02120417,Phase II,Terminated,"[{'id': 1615, 'therapyName': 'Ruxolitinib + Capecitabine'}, {'id': 1105, 'therapyName': 'Capecitabine'}]",A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer,1088
49,NCT03136406,Phase Ib/II,Recruiting,"[{'id': 1018, 'therapyName': 'GI-4000'}, {'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 3144, 'therapyName': 'Avelumab'}, {'id': 619, 'therapyName': 'Abraxane'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 6163, 'therapyName': 'ETBX-011'}, {'id': 3060, 'therapyName': 'ALT-803'}]",QUILT-3.039: NANT Pancreatic Cancer Vaccine: Combination Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy,1088
50,NCT02688712,Phase II,Recruiting,"[{'id': 5788, 'therapyName': 'Capecitabine + Galunisertib'}, {'id': 5789, 'therapyName': 'Fluorouracil + Galunisertib'}, {'id': 2409, 'therapyName': 'Galunisertib'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1105, 'therapyName': 'Capecitabine'}]",ExIST Study of LY2157299 (Galunisertib) in Rectal Cancer,1088
51,NCT03221426,Phase III,Recruiting,"[{'id': 3999, 'therapyName': 'Capecitabine + Cisplatin'}, {'id': 6050, 'therapyName': 'Capecitabine + Cisplatin + Pembrolizumab'}, {'id': 6051, 'therapyName': 'Cisplatin + Fluorouracil + Pembrolizumab'}, {'id': 1833, 'therapyName': 'Cisplatin + Fluorouracil'}]",Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585),1088
52,NCT02726399,Phase II,Recruiting,"[{'id': 3999, 'therapyName': 'Capecitabine + Cisplatin'}, {'id': 3998, 'therapyName': 'Ramucirumab + Trastuzumab'}]",Ramucirumab With Trastuzumab and Capecitabine/Cisplatin in Patients With Metastatic HER2-Positive Gastroesophageal Junction and Gastric Cancer,1088
53,NCT02954536,Phase II,Recruiting,"[{'id': 4945, 'therapyName': 'Capecitabine + Cisplatin + Pembrolizumab + Trastuzumab'}]",Phase II Trial of Pembrolizumab With Trastuzumab and Chemotherapy in Advanced HER2 Positive Esophagogastric (EG) Cancer,1088
54,NCT01450696,Phase III,Terminated,"[{'id': 1899, 'therapyName': 'Capecitabine + Cisplatin + Trastuzumab'}]",HELOISE Study: A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer,1088
55,NCT01873833,Phase II,Recruiting,"[{'id': 1559, 'therapyName': 'Capecitabine + Cyclophosphamide + Lapatinib + Trastuzumab'}]","Capecitabine, Cyclophosphamide, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With HER2-Positive Metastatic Breast Cancer",1088
56,NCT02358863,Phase I,Terminated,"[{'id': 4311, 'therapyName': 'Docetaxel + Irinotecan'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 1835, 'therapyName': 'Docetaxel + Cisplatin'}, {'id': 1406, 'therapyName': 'Camptosar + Cisplatin'}, {'id': 4310, 'therapyName': 'Epirubicin + Docetaxel'}, {'id': 4309, 'therapyName': 'Capecitabine + Docetaxel'}]",Molecularly Tailored Therapy for Patients With Metastatic Cancer of the Esophagus and Stomach (mEGA),1088
57,NCT02611960,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 4203, 'therapyName': 'Capecitabine + Docetaxel + Gemcitabine'}]","Study of Pembrolizumab (MK-3475) in Platinum Pre-treated Recurrent/Metastatic Nasopharyngeal Cancer (MK-3475-122, KEYNOTE-122)",1088
58,NCT03152370,Phase I,Recruiting,"[{'id': 5798, 'therapyName': 'E7046 + mFOLFOX-6'}, {'id': 5805, 'therapyName': 'Capecitabine + E7046'}]",Preoperative Radiotherapy and E7046 in Rectum Cancer (PRAER 1),1088
59,NCT02918162,Phase II,Recruiting,"[{'id': 4776, 'therapyName': 'Capecitabine + Epirubicin + Oxaliplatin + Pembrolizumab'}]",Perioperative Chemo and Pembrolizumab in Gastric Cancer,1088
60,NCT02199236,Phase I,Recruiting,"[{'id': 1619, 'therapyName': 'Capecitabine + Fluorouracil'}]",Dose Escalation Trial of Endoluminal High-Dose-Rate Brachytherapy With Concurrent Chemotherapy for Rectal or Anal Cancer in Patients With Recurrent Disease or Undergoing Non-Operative Management,1088
61,NCT01774786,Phase III,"Active, not recruiting","[{'id': 856, 'therapyName': 'Pertuzumab'}, {'id': 1894, 'therapyName': 'Capecitabine + Fluorouracil + Cisplatin + Trastuzumab'}]",A Study of Perjeta (Pertuzumab) in Combination With Herceptin (Trastuzumab) and Chemotherapy in Patients With HER2-Positive Metastatic Gastroesophageal Junction or Gastric Cancer,1088
62,NCT02004262,Phase II,Completed,"[{'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 2383, 'therapyName': 'Capecitabine + Fluorouracil + Gemcitabine '}]",Safety and Efficacy of Combination Listeria/GVAX Pancreas Vaccine in the Pancreatic Cancer Setting,1088
63,NCT02935309,Phase I,Recruiting,"[{'id': 4779, 'therapyName': 'Capecitabine + Lenvatinib'}]",Phase I Study of Capecitabine and Lenvatinib With External Radiation in Rectal Adenocarcinoma,1088
64,NCT02915172,Phase I,Withdrawn,"[{'id': 4779, 'therapyName': 'Capecitabine + Lenvatinib'}]",Lenvatinib and Capecitabine in Patients With Advanced Malignancies,1088
65,NCT01494662,Phase II,"Active, not recruiting","[{'id': 1543, 'therapyName': 'Capecitabine + Neratinib'}, {'id': 828, 'therapyName': 'Neratinib'}]",HKI-272 for HER2-Positive Breast Cancer and Brain Metastases,1088
66,NCT01808573,Phase III,"Active, not recruiting","[{'id': 1399, 'therapyName': 'Lapatinib + Capecitabine'}, {'id': 1543, 'therapyName': 'Capecitabine + Neratinib'}]",A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic Setting,1088
67,NCT02780700,Phase II,Terminated,"[{'id': 2589, 'therapyName': 'Capecitabine + Nintedanib'}, {'id': 831, 'therapyName': 'Nintedanib'}]",Nintedanib Alone or in Combination With Capecitabine in Refractory Metastatic Colorectal Cancer [LUME-Colon 2],1088
68,NCT02393755,Phase Ib/II,"Active, not recruiting","[{'id': 2589, 'therapyName': 'Capecitabine + Nintedanib'}]",Nintedanib and Capecitabine in Treating Patients With Refractory Metastatic Colorectal Cancer,1088
69,NCT02872116,Phase III,Recruiting,"[{'id': 1597, 'therapyName': 'Capecitabine + Oxaliplatin'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}]",Efficacy Study of Nivolumab Plus Ipilimumab Against Chemotherapy Standard of Care in Stomach Cancer or Stomach/Esophagus Junction Cancer (CheckMate649),1088
70,NCT02024607,Phase Ib/II,"Active, not recruiting","[{'id': 1597, 'therapyName': 'Capecitabine + Oxaliplatin'}, {'id': 2093, 'therapyName': 'BBI608 + Bevacizumab'}, {'id': 2094, 'therapyName': 'BBI608 + Regorafenib'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 2057, 'therapyName': 'BBI608'}, {'id': 1315, 'therapyName': 'FOLFIRI'}]",A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer,1088
71,NCT02625610,Phase III,Recruiting,"[{'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 3144, 'therapyName': 'Avelumab'}, {'id': 1597, 'therapyName': 'Capecitabine + Oxaliplatin'}]",Avelumab in First-Line Gastric Cancer (JAVELIN Gastric 100),1088
72,NCT01191697,Phase II,"Active, not recruiting","[{'id': 1596, 'therapyName': 'Trastuzumab + Bevacizumab'}, {'id': 1597, 'therapyName': 'Capecitabine + Oxaliplatin'}]","CAPOX, Bevacizumab and Trastuzumab for Patients With HER2-Positive Metastatic Esophagogastric Cancer",1088
73,NCT00408772,Phase II,Withdrawn,"[{'id': 1601, 'therapyName': 'Capecitabine + Oxaliplatin + Bevacizumab'}]","Oxaliplatin, Capecitabine, and Bevacizumab Followed By Surgery and/or Radiofrequency Ablation in Treating Patients With Colorectal Cancer That Has Spread to the Liver and Cannot Be Removed By Surgery",1088
74,NCT01006369,Phase II,Completed,"[{'id': 1316, 'therapyName': 'Hydroxychloroquine'}, {'id': 1601, 'therapyName': 'Capecitabine + Oxaliplatin + Bevacizumab'}, {'id': 1484, 'therapyName': 'Bevacizumab + Oxaliplatin + Leucovorin + Fluorouracil'}]","Hydroxychloroquine, Capecitabine, Oxaliplatin, and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer",1088
75,NCT01208103,Phase II,"Active, not recruiting","[{'id': 1601, 'therapyName': 'Capecitabine + Oxaliplatin + Bevacizumab'}]",Bevacizumab With Capecitabine and Oxaliplatin in Advanced Adenocarcinoma of the Small Bowel or Ampulla of Vater,1088
76,NCT03111732,Phase II,Recruiting,"[{'id': 5549, 'therapyName': 'Capecitabine + Oxaliplatin + Pembrolizumab'}]","Pembrolizumab, a Monoclonal Antibody Against PD-1, in Combination With Capecitabine and Oxaliplatin (CAPOX) in People With Advanced Biliary Tract Carcinoma (BTC)",1088
77,NCT00967655,Phase II,Unknown status,"[{'id': 1960, 'therapyName': 'Capecitabine + Panitumumab'}, {'id': 1074, 'therapyName': 'Irinotecan'}]","Capecitabine, Panitumumab, and Radiation Therapy With or Without Irinotecan Hydrochloride in Treating Patients Undergoing Surgery for Localized Rectal Cancer",1088
78,NCT03257163,Phase II,Recruiting,"[{'id': 4022, 'therapyName': 'Capecitabine + Pembrolizumab'}]","Pembrolizumab, Capecitabine, and Radiation Therapy in Treating Patients With Mismatch-Repair Deficient and Epstein-Barr Virus Positive Gastric Cancer",1088
79,NCT02734290,Phase Ib/II,Recruiting,"[{'id': 4022, 'therapyName': 'Capecitabine + Pembrolizumab'}, {'id': 4021, 'therapyName': 'Paclitaxel + Pembrolizumab'}]",Standard of Care Chemotherapy Plus Pembrolizumab for Breast Cancer,1088
80,NCT03044730,Phase II,Recruiting,"[{'id': 4022, 'therapyName': 'Capecitabine + Pembrolizumab'}]",Pembrolizumab and Capecitabine in Treating Patients With Locally Advanced or Metastatic Triple Negative or Hormone-Refractory Breast Cancer That Cannot Be Removed by Surgery,1088
81,NCT02025803,Phase I,"Active, not recruiting","[{'id': 4335, 'therapyName': 'Capecitabine + TAS-114'}]","A Safety, Tolerability and Pharmacokinetic Study of TAS-114 in Combination With Capecitabine in Patients With Advanced Solid Tumors",1088
82,NCT02213744,Phase II,Terminated,"[{'id': 1890, 'therapyName': 'Vinorelbine + Trastuzumab'}, {'id': 1409, 'therapyName': 'Capecitabine + Trastuzumab'}, {'id': 1889, 'therapyName': 'Gemcitabine + Trastuzumab'}, {'id': 1888, 'therapyName': 'MM-302 + Trastuzumab'}]",MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in HER2-Positive Locally Advanced/Metastatic Breast Cancer Patients,1088
83,NCT02831179,Phase I,Withdrawn,"[{'id': 4463, 'therapyName': 'Capecitabine + Veliparib + Temozolomide'}]","Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor",1088
84,NCT01683422,Phase II,Recruiting,"[{'id': 2473, 'therapyName': 'Erlotinib + Capecitabine + Gemcitabine'}]",Chemotherapy Plus Proton-chemotherapy for Locally Advanced Pancreatic Cancer,1088
85,NCT01765582,Phase II,Terminated,"[{'id': 1523, 'therapyName': 'Fluorouracil + Capecitabine + Irinotecan + Leucovorin + Oxaliplatin'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1484, 'therapyName': 'Bevacizumab + Oxaliplatin + Leucovorin + Fluorouracil'}]",STEAM: A Study of Sequential and Concurrent FOLFOXIRI/Avastin (Bevacizumab) Regimens Versus FOLFOX/Avastin in First-Line in Patients With Metastatic Colorectal Cancer,1088
86,NCT00790816,Phase I,Completed,"[{'id': 1410, 'therapyName': 'Lapatinib + Paclitaxel'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 1414, 'therapyName': 'Trastuzumab + Lapatinib'}, {'id': 1399, 'therapyName': 'Lapatinib + Capecitabine'}, {'id': 1497, 'therapyName': 'Lapatinib + Letrozole'}, {'id': 1498, 'therapyName': 'Lapatinib + Oxaliplatin + Capecitabine'}, {'id': 1499, 'therapyName': 'Lapatinib + Gemcitabine'}, {'id': 1500, 'therapyName': 'Lapatinib + Docetaxel'}, {'id': 1501, 'therapyName': 'Lapatinib + Oxaliplatin + Leucovorin + Fluorouracil'}, {'id': 1502, 'therapyName': 'Lapatinib + Irinotecan + Leucovorin + Fluorouracil'}]",Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents,1088
87,NCT02650752,Phase I,Recruiting,"[{'id': 1399, 'therapyName': 'Lapatinib + Capecitabine'}]",Intermittent High-Dose Lapatinib in Tandem With Capecitabine for HER2 Overexpressed/Amplified Metastatic Breast Cancer With Central Nervous System (CNS) Metastases,1088
88,NCT01783756,Phase Ib/II,"Active, not recruiting","[{'id': 1552, 'therapyName': 'Lapatinib + Capecitabine + Everolimus'}]","Phase 1b/2 Trial Using Lapatinib, Everolimus and Capecitabine for Treatment of HER-2 Positive Breast Cancer With CNS Metastasis",1088
89,NCT01640665,Phase I,Completed,"[{'id': 2428, 'therapyName': 'Sorafenib + Capecitabine'}]",Pilot Study of Sorafenib and Bi-weekly Capecitabine in Patients With Advanced Breast and Gastrointestinal Tumors,1088
90,NCT01471353,Phase II,"Active, not recruiting","[{'id': 2428, 'therapyName': 'Sorafenib + Capecitabine'}]",Sorafenib Plus Capecitabine (SorCape) in Previously Treated Metastatic Colorectal Cancer,1088
91,NCT00781612,Phase II,Recruiting,"[{'id': 5471, 'therapyName': 'Trastuzumab + trastuzumab emtansine'}, {'id': 5470, 'therapyName': 'Paclitaxel + trastuzumab emtansine'}, {'id': 1402, 'therapyName': 'trastuzumab emtansine'}, {'id': 3930, 'therapyName': 'Docetaxel + T-DM1'}, {'id': 1976, 'therapyName': 'trastuzumab emtansine + Capecitabine'}, {'id': 1492, 'therapyName': 'T-DM1 + Pertuzumab'}]",A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies,1088
92,NCT01702558,Phase II,Completed,"[{'id': 1402, 'therapyName': 'trastuzumab emtansine'}, {'id': 1976, 'therapyName': 'trastuzumab emtansine + Capecitabine'}]",A Combination Study of Kadcyla (Trastuzumab Emtansine) and Capecitabine in Patients With HER2-Positive Metastatic Breast Cancer and Patients With HER2-Positive Locally Advanced / Metastatic Gastric Cancer,1088
0,NCT02386826,Phase I,Recruiting,"[{'id': 2600, 'therapyName': 'Bevacizumab + INC280'}]","INC280 Combined With Bevacizumab to Evaluate Glioblastoma Multiforme, Metastatic Colorectal Cancer, and Metastatic Renal Cell Carcinoma Patients",7184
1,NCT01870726,Phase Ib/II,Completed,"[{'id': 2461, 'therapyName': 'BKM120 + INC280'}]",Safety and Efficacy of INC280 and Buparlisib (BKM120) in Patients With Recurrent Gliobastoma,7184
2,NCT02414139,Phase II,Recruiting,"[{'id': 1065, 'therapyName': 'Capmatinib'}]",Clinical Study of Oral cMET Inhibitor INC280 in Adult Patients With Advanced Non-small Cell Lung Cancer Who Have Received One or Two Prior Lines of Therapy,7184
3,NCT02468661,Phase Ib/II,Recruiting,"[{'id': 1065, 'therapyName': 'Capmatinib'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 1857, 'therapyName': 'Cisplatin + Pemetrexed'}, {'id': 1602, 'therapyName': 'Carboplatin + Pemetrexed'}]","A Safety and Efficacy Study of INC280 Alone, and in Combination With Erlotinib, Compared to Chemotherapy, in Advanced/Metastatic Non-small Cell Lung Cancer Patients With EGFR Mutation and cMET Amplification",7184
4,NCT02925104,Phase I,Recruiting,"[{'id': 1065, 'therapyName': 'Capmatinib'}]","A Dose Escalation Study to Assess PK, Safety and Tolerability of INC280 When Taken With Food in cMET Dysregulated Advanced Solid Tumors.",7184
5,NCT03040973,FDA approved,Recruiting,"[{'id': 1065, 'therapyName': 'Capmatinib'}]",Roll-over Study for Patients With cMET-dependent Malignancies Who Previously Completed a Novartis Capmatinib Study,7184
6,NCT02520752,Phase I,"Active, not recruiting","[{'id': 2685, 'therapyName': 'Midazolam'}, {'id': 1065, 'therapyName': 'Capmatinib'}]",A DDI Study to Assess the Effect of INC280 on the PK of Midazolam and Caffeine in Patients With cMET-dysregulated Advanced Solid Tumors,7184
7,NCT02626234,Phase I,Completed,"[{'id': 1065, 'therapyName': 'Capmatinib'}]",A Drug-drug Interaction (DDI) Study to Assess the Effect of INC280 on the Pharmacokinetics of Digoxin and Rosuvastatin in Patients With cMET-dysregulated Advanced Solid Tumors,7184
8,NCT02019693,Phase II,Recruiting,"[{'id': 1065, 'therapyName': 'Capmatinib'}]",A Phase 2 Study of the MET Kinase Inhibitor INC280 in Papillary Renal Cell Cancer,7184
9,NCT01324479,Phase I,Completed,"[{'id': 1065, 'therapyName': 'Capmatinib'}]",Study of INC280 in Patients With c-MET Dependent Advanced Solid Tumors,7184
10,NCT02750215,Phase II,"Active, not recruiting","[{'id': 1065, 'therapyName': 'Capmatinib'}]",A Study of Capmatinib (INC280) in NSCLC Patients With MET Exon 14 Alterations Who Have Received Prior MET Inhibitor,7184
11,NCT01820364,Phase II,Terminated,"[{'id': 1100, 'therapyName': 'Binimetinib + Encorafenib'}, {'id': 1260, 'therapyName': 'Encorafenib + Ribociclib'}, {'id': 1337, 'therapyName': 'Encorafenib + BKM120'}, {'id': 1336, 'therapyName': 'BGJ398 + Encorafenib'}, {'id': 1338, 'therapyName': 'Capmatinib + Encorafenib'}]", LGX818 in Combination With Agents (MEK162; BKM120; LEE011; BGJ398; INC280) in Advanced BRAF Melanoma,7184
12,NCT02335944,Phase Ib/II,Recruiting,"[{'id': 2445, 'therapyName': 'EGF816 + INC280'}]",Study of Safety and Efficacy of EGF816 in Combination With INC280 in Non-small Cell Lung Cancer Patients With EGFR Mutation.,7184
13,NCT02205398,Phase Ib/II,Terminated,"[{'id': 1618, 'therapyName': 'INC280 + Cetuximab '}]","Study of Safety and Efficacy of INC280 and Cetuximab, in Adult c-MET Positive mCRC and HNSCC Patients After Progression on Cetuximab or Panitumumab Therapy",7184
14,NCT02323126,Phase II,Recruiting,"[{'id': 2443, 'therapyName': 'EGF816 + Nivolumab'}, {'id': 2444, 'therapyName': 'INC280 + Nivolumab'}]",Study of Efficacy and Safety of Nivolumab in Combination With EGF816 and of Nivolumab in Combination With INC280 in Patients With Previously Treated Non-small Cell Lung Cancer,7184
15,NCT02795429,Phase Ib/II,Recruiting,"[{'id': 2659, 'therapyName': 'PDR001'}, {'id': 4492, 'therapyName': 'INC280 + PDR001'}]",Phase Ib/II Study of INC280 + PDR001 or PDR001 Single Agent in Advanced HCC,7184
16,NCT02159066,Phase II,"Active, not recruiting","[{'id': 1101, 'therapyName': 'Binimetinib + Encorafenib + Ribociclib'}, {'id': 1100, 'therapyName': 'Binimetinib + Encorafenib'}, {'id': 2216, 'therapyName': 'LGX818 + MEK162 + INC280'}, {'id': 2215, 'therapyName': 'LGX818 + MEK162 + BKM120'}, {'id': 2214, 'therapyName': 'LGX818 + MEK162 + BGJ398'}]","LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma",7184
0,NCT02099058,Phase I,Recruiting,"[{'id': 1743, 'therapyName': 'ABBV-399 + Carboplatin'}, {'id': 1364, 'therapyName': 'ABBV-399 + Erlotinib'}, {'id': 1363, 'therapyName': 'ABBV-399'}, {'id': 1366, 'therapyName': 'ABBV-399 + Bevacizumab'}, {'id': 1365, 'therapyName': 'ABBV-399 + Cetuximab'}]","A Phase 1/1b Study With ABBV-399, an Antibody Drug Conjugate, in Subjects With Advanced Solid Cancer Tumors",947
1,NCT02903160,Phase II,Recruiting,"[{'id': 4759, 'therapyName': 'Abiraterone + Cabazitaxel + Carboplatin + Enzalutamide + Prednisone'}]","Prostate Cancer Intensive, Non-Cross Reactive Therapy (PRINT) for Castration Resistant Prostate Cancer (CRPC)",947
2,NCT01412229,Phase II,"Active, not recruiting","[{'id': 1957, 'therapyName': 'Abraxane + Carboplatin + Cetuximab'}]",Induction Chemotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck,947
3,NCT02270814,Phase II,Recruiting,"[{'id': 1957, 'therapyName': 'Abraxane + Carboplatin + Cetuximab'}, {'id': 1956, 'therapyName': 'Abraxane + Cisplatin + Cetuximab'}]","Cisplatin, Nab-Paclitaxel, and Cetuximab (CACTUX) in Patients With Incurable Head and Neck Squamous Cell Carcinoma",947
4,NCT01732640,Phase Ib/II,Completed,"[{'id': 2442, 'therapyName': 'Afatinib + Carboplatin + Paclitaxel'}, {'id': 700, 'therapyName': 'Cisplatin'}]",A Phase I/II Study Afatinib/Carboplatin/Paclitaxel Induction Chemotherapy In HPV-Negative HNSCC.,947
5,NCT02098343,Phase Ib/II,Recruiting,"[{'id': 1953, 'therapyName': 'Carboplatin + Doxorubicin'}, {'id': 1952, 'therapyName': 'APR-246 + Carboplatin + Doxorubicin'}]","p53 Suppressor Activation in Recurrent High Grade Serous Ovarian Cancer, a Phase Ib/II Study of Systemic Carboplatin Combination Chemotherapy With or Without APR-246",947
6,NCT03165994,Phase II,Not yet recruiting,"[{'id': 5797, 'therapyName': 'APX005M + Paclitaxel + Carboplatin'}]",APX005M With Concurrent Chemoradiation for Resectable Esophageal and Gastroesophageal Junction Cancers,947
7,NCT02366143,Phase III,"Active, not recruiting","[{'id': 2370, 'therapyName': 'Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel'}, {'id': 1489, 'therapyName': 'Nab-paclitaxel + Carboplatin + Bevacizumab'}, {'id': 1203, 'therapyName': 'Atezolizumab + Carboplatin + Paclitaxel'}]",TBAA Phase III Study of MPDL3280A (Anti-PD-L1 Antibody) in Combination With Carboplatin + Paclitaxel With or Without Bevacizumab in Patients With Stage IV Non-squamous Non-small Cell Lung Cancer,947
8,NCT03038100,Phase III,Recruiting,"[{'id': 2370, 'therapyName': 'Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel'}, {'id': 1152, 'therapyName': 'Bevacizumab + Carboplatin + Paclitaxel'}]","A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (IMagyn050)",947
9,NCT03206203,Phase II,Recruiting,"[{'id': 5983, 'therapyName': 'Atezolizumab + Carboplatin'}, {'id': 1092, 'therapyName': 'Carboplatin'}]",Carboplatin With or Without Atezolizumab in Treating Patients With Stage IV Triple Negative Breast Cancer,947
10,NCT02763579,Phase III,Recruiting,"[{'id': 4164, 'therapyName': 'Atezolizumab + Carboplatin + Etoposide'}, {'id': 1791, 'therapyName': 'Carboplatin + Etoposide'}]",A Study of Carboplatin Plus Etoposide With or Without Atezolizumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer (IMpower133),947
11,NCT02748889,Phase Ib/II,Terminated,"[{'id': 1791, 'therapyName': 'Carboplatin + Etoposide'}, {'id': 4164, 'therapyName': 'Atezolizumab + Carboplatin + Etoposide'}]",Carboplatin Plus Etoposide With or Without MPDL3280A in Untreated Extensive Stage Small Cell Lung Cancer,947
12,NCT03041311,Phase II,Recruiting,"[{'id': 5541, 'therapyName': 'Atezolizumab + Carboplatin + Etoposide + Trilaciclib'}, {'id': 4164, 'therapyName': 'Atezolizumab + Carboplatin + Etoposide'}]","Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Extensive Stage Small Cell Lung Cancer (SCLC)",947
13,NCT02807636,Phase III,Recruiting,"[{'id': 4450, 'therapyName': 'Atezolizumab + Carboplatin + Gemcitabine'}, {'id': 2667, 'therapyName': 'Carboplatin + Gemcitabine'}]",The Effect of Atezolizumab in Combination With Gemcitabine/Carboplatin and Gemcitabine/Carboplatin Alone in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma Who Are Ineligible for Cisplatin-based Therapy,947
14,NCT02716038,Phase II,Recruiting,"[{'id': 3946, 'therapyName': 'Atezolizumab + Carboplatin + nab-Paclitaxel'}]","Neoadjuvant MPDL3280A, Nab-paclitaxel and Carboplatin (MAC) in NSCLC",947
15,NCT01633970,Phase I,"Active, not recruiting","[{'id': 1203, 'therapyName': 'Atezolizumab + Carboplatin + Paclitaxel'}, {'id': 1204, 'therapyName': 'Atezolizumab + Carboplatin + Pemetrexed'}, {'id': 1202, 'therapyName': 'Atezolizumab + Bevacizumab + Capecitabine'}]",A Phase 1b Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) in Combination With Avastin (Bevacizumab) and/or With Chemotherapy in Patients With Locally Advanced or Metastatic Solid Tumors,947
16,NCT02883062,Phase II,Not yet recruiting,"[{'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 1203, 'therapyName': 'Atezolizumab + Carboplatin + Paclitaxel'}]","Carboplatin and Paclitaxel With or Without Atezolizumab Before Surgery in Treating Patients With Newly Diagnosed, Stage II-III Triple-Negative Breast Cancer",947
17,NCT02264678,Phase Ib/II,Recruiting,"[{'id': 2881, 'therapyName': 'AZD6738'}, {'id': 4737, 'therapyName': 'AZD6738 + Carboplatin'}, {'id': 4738, 'therapyName': 'AZD6738 + MEDI4736'}, {'id': 4739, 'therapyName': 'AZD6738 + Olaparib'}]",Ascending Doses of AZD6738 in Combination With Chemotherapy and/or Novel Anti Cancer Agents,947
18,NCT00780494,Phase II,Unknown status,"[{'id': 2096, 'therapyName': 'Bevacizumab + Capecitabine + Carboplatin'}]","Ph II of Capecitabine, Carboplatin and Bevacizumab for Gastroesophageal Junction and Gastric Carcinoma",947
19,NCT01295944,Phase II,Recruiting,"[{'id': 2074, 'therapyName': 'Bevacizumab + Carboplatin'}]",Carboplatin and Bevacizumab for Recurrent Ependymoma,947
20,NCT01386710,Phase Ib/II,Suspended,"[{'id': 2074, 'therapyName': 'Bevacizumab + Carboplatin'}]",Repeated Super-selective Intraarterial Cerebral Infusion Of Bevacizumab Plus Carboplatin For Treatment Of Relapsed/Refractory GBM And Anaplastic Astrocytoma,947
21,NCT00936936,Phase II,Recruiting,"[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 2101, 'therapyName': 'Etoposide + Ifosfamide'}, {'id': 2100, 'therapyName': 'Docetaxel + Gemcitabine + Melphalan'}, {'id': 2074, 'therapyName': 'Bevacizumab + Carboplatin'}]",High-dose Chemotherapy for Poor-prognosis Relapsed Germ-Cell Tumors,947
22,NCT01146795,Phase II,Terminated,"[{'id': 1152, 'therapyName': 'Bevacizumab + Carboplatin + Paclitaxel'}]",Neoadjuvant Therapy for Ovarian Cancer,947
23,NCT02364999,Phase III,"Active, not recruiting","[{'id': 1152, 'therapyName': 'Bevacizumab + Carboplatin + Paclitaxel'}]",A Comparative Study Of PF-06439535 Plus Paclitaxel-Carboplatin And Bevacizumab Plus Paclitaxel-Carboplatin Patients With Advanced Non-Squamous NSCLC,947
24,NCT02810457,Phase III,Recruiting,"[{'id': 1152, 'therapyName': 'Bevacizumab + Carboplatin + Paclitaxel'}]",Evaluation of FKB238 and Avastin in Patients With Advanced/Recurrent Non-squamous Non-small Cell Lung Cancer (AVANA),947
25,NCT01239732,Phase III,Completed,"[{'id': 1152, 'therapyName': 'Bevacizumab + Carboplatin + Paclitaxel'}]",A Study of the Addition of Avastin (Bevacizumab) to Carboplatin and Paclitaxel Therapy in Patients With Ovarian Cancer,947
26,NCT01649947,Phase II,Completed,"[{'id': 1487, 'therapyName': 'Bevacizumab + Carboplatin + Paclitaxel + Hydroxychloroquine'}, {'id': 1488, 'therapyName': 'Paclitaxel + Carboplatin + Hydroxychloroquine'}]",Modulation of Autophagy in Patients With Advanced/Recurrent Non-small Cell Lung Cancer - Phase II,947
27,NCT02039674,Phase Ib/II,"Active, not recruiting","[{'id': 2103, 'therapyName': 'Carboplatin + Paclitaxel + Pembrolizumab'}, {'id': 2104, 'therapyName': 'Bevacizumab + Carboplatin + Paclitaxel + Pembrolizumab'}, {'id': 1602, 'therapyName': 'Carboplatin + Pemetrexed'}, {'id': 2106, 'therapyName': 'Ipilimumab + Pembrolizumab '}, {'id': 2107, 'therapyName': 'Erlotinib + Pembrolizumab '}, {'id': 2108, 'therapyName': 'Gefitinib + Pembrolizumab '}]",A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Lung Cancer (MK-3475-021/KEYNOTE-021),947
28,NCT01934361,Phase Ib/II,Completed,"[{'id': 2500, 'therapyName': 'BKM120 + Lomustine'}, {'id': 2501, 'therapyName': 'BKM120 + Carboplatin'}]",Phase Ib/II Study of Buparlisib Plus Carboplatin or Lomustine in Patients With Recurrent Glioblastoma Multiforme,947
29,NCT01297452,Phase I,Completed,"[{'id': 1183, 'therapyName': 'BKM120 + Carboplatin + Paclitaxel'}]",BKM120 + Carboplatin + Paclitaxel for Patients With Advanced Solid Tumors,947
30,NCT01723800,Phase I,Completed,"[{'id': 1112, 'therapyName': 'BKM120 + Pemetrexed + Carboplatin'}]"," PI3K Inhibitor BKM120, Carboplatin, and Pemetrexed Disodium in Treating Patients With Stage IV Non-Small Cell Lung Cancer",947
31,NCT02815592,Phase Ib/II,"Active, not recruiting","[{'id': 1136, 'therapyName': 'Etoposide'}, {'id': 4563, 'therapyName': 'BMS-986012 + Cisplatin + Etoposide'}, {'id': 4564, 'therapyName': 'BMS-986012 + Carboplatin + Etoposide'}]",Trial of BMS-986012 in Combination With Platinum and Etoposide,947
32,NCT02703623,Phase II,Recruiting,"[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 2649, 'therapyName': 'Abiraterone + ARN-509 + Prednisone'}, {'id': 3844, 'therapyName': 'Cabazitaxel + Carboplatin'}]",A Dynamic Allocation Modular Sequential Trial of Approved and Promising Therapies in Men With Metastatic Castrate Resistant Prostate Cancer (DynaMO),947
33,NCT03263650,Phase II,Recruiting,"[{'id': 3844, 'therapyName': 'Cabazitaxel + Carboplatin'}, {'id': 837, 'therapyName': 'Olaparib'}]",Randomized Phase II Study of Olaparib Maintenance Following Cabazitaxel-Carbo in Men With AVPC,947
34,NCT01445418,Phase I,"Active, not recruiting","[{'id': 837, 'therapyName': 'Olaparib'}, {'id': 1092, 'therapyName': 'Carboplatin'}]",AZD2281 Plus Carboplatin to Treat Breast and Ovarian Cancer,947
35,NCT01493843,Phase II,Completed,"[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 749, 'therapyName': 'GDC-0941'}, {'id': 667, 'therapyName': 'Bevacizumab'}]",Study Evaluating the Safety and Efficacy of Carboplatin/Paclitaxel and Carboplatin/Paclitaxel/Bevacizumab With and Without GDC-0941 in Patients With Previously Untreated Advanced or Recurrent Non-small Cell Lung Cancer,947
36,NCT01892046,Phase I,Completed,"[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 866, 'therapyName': 'SNX-5422'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]",Safety and Pharmacology of SNX-5422 Plus Carboplatin and Paclitaxel in Subjects With Solid Tumors,947
37,NCT02409342,Phase III,Recruiting,"[{'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 700, 'therapyName': 'Cisplatin'}]",A Comparative Study of MPDL3280A (Anti-PDL1 Antibody) With Cisplatin or Carboplatin + Pemetrexed in Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC),947
38,NCT02437812,Phase II,Recruiting,"[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1031, 'therapyName': 'Metformin'}]","Study of Paclitaxel, Carboplatin and Oral Metformin in the Treatment of Advanced Stage Ovarian Carcinoma",947
39,NCT02199171,Phase I,Unknown status,"[{'id': 1092, 'therapyName': 'Carboplatin'}]","Heated Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Peritoneal Cancer",947
40,NCT02477826,Phase III,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 755, 'therapyName': 'Gemcitabine'}]","An Open-Label, Trial of Nivolumab and Nivolumab Plus Ipilimumab Versus Platinum Doublet Chemotherapy in Subjects With Stage IV Non-Small Cell Lung Cancer (NSCLC)",947
41,NCT01344824,Phase II,Completed,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 854, 'therapyName': 'Pemetrexed'}]","Carboplatin, Pemetrexed Disodium, and Bevacizumab in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Who Are Light or Never Smokers",947
42,NCT01281176,,"Active, not recruiting","[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1092, 'therapyName': 'Carboplatin'}]",High-Dose or Low-Dose Vorinostat in Combination With Carboplatin or Paclitaxel in Treating Patients With Advanced Solid Tumors,947
43,NCT02389751,Phase I,"Active, not recruiting","[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 745, 'therapyName': 'Ganetespib'}]",A Study of Ganetespib in Combination With Chemoradiation,947
44,NCT01633541,Phase II,Recruiting,"[{'id': 644, 'therapyName': 'AT-101'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 720, 'therapyName': 'Docetaxel'}]",Chemotherapy AND Bcl-xL Inhibitor (AT-101) For Organ Preservation In Adults With Advanced Laryngeal Cancer,947
45,NCT02409355,Phase III,"Active, not recruiting","[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1201, 'therapyName': 'Atezolizumab'}]",A Study of MPDL3280A Compared With Gemcitabine + Cisplatin or Carboplatin in Patients With Stage IV Squamous Non-Small Cell Lung Cancer,947
46,NCT02009449,Phase I,"Active, not recruiting","[{'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 2621, 'therapyName': 'AM0010 '}, {'id': 619, 'therapyName': 'Abraxane'}]",A Phase 1 Study of AM0010 in Patients With Advanced Solid Tumors,947
47,NCT02309177,Phase I,Recruiting,"[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 2489, 'therapyName': 'Abraxane + Nivolumab'}]","Safety Study of Nivolumab With Nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, Nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or Nab-Paclitaxel in Recurrent Metastatic Breast Cancer",947
48,NCT02470585,Phase III,"Active, not recruiting","[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 954, 'therapyName': 'Veliparib'}]","Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Subjects With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",947
49,NCT02114229,Phase II,Recruiting,"[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 2449, 'therapyName': 'Methotrexate + Cisplatin + Cyclophosphamide + Vincristine'}, {'id': 626, 'therapyName': 'Alisertib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 942, 'therapyName': 'Topotecan'}]",Phase 2 Study of Alisertib Therapy for Rhabdoid Tumors,947
50,NCT01187199,Phase I,"Active, not recruiting","[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 936, 'therapyName': 'Temsirolimus'}]","Phase I Trial of Bevacizumab and Temsirolimus in Combination With 1) Carboplatin, 2) Paclitaxel, 3) Sorafenib for the Treatment of Advanced Cancer",947
51,NCT02581943,Phase II,Suspended,"[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1092, 'therapyName': 'Carboplatin'}]",Effect of Pembrolizumab With or Without Carboplatin and Paclitaxel on Immune Response in Patients With Recurrent or Stage IIIB-IV Non-small Cell Lung Cancer,947
52,NCT00993655,Phase III,Completed,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1092, 'therapyName': 'Carboplatin'}]"," Comparing Combination Chemotherapy Regimens in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer",947
53,NCT00254319,Phase II,Unknown status,"[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 2114, 'therapyName': 'Bevacizumab + Pemetrexed'}]",Previously Untreated Advanced Non-Small Cell Lung Cancer (NSCLC),947
54,NCT01042522,Phase II,Recruiting,"[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1137, 'therapyName': 'Bleomycin'}]","Paclitaxel and Carboplatin or Bleomycin Sulfate, Etoposide Phosphate, and Cisplatin in Treating Patients With Advanced or Recurrent Sex Cord-Ovarian Stromal Tumors",947
55,NCT00989651,Phase I,"Active, not recruiting","[{'id': 3047, 'therapyName': 'Bevacizumab + Veliparib'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 700, 'therapyName': 'Cisplatin'}]","Carboplatin, Paclitaxel, Bevacizumab, and ABT-888 in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer",947
56,NCT02264990,Phase III,"Active, not recruiting","[{'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 954, 'therapyName': 'Veliparib'}, {'id': 700, 'therapyName': 'Cisplatin'}]",Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Subjects Receiving First Cytotoxic Chemotherapy for Metastatic or Advanced Non-Squamous Non-Small Cell Lung Cancer Who Are Current or Former Smokers,947
57,NCT02605915,Phase I,Recruiting,"[{'id': 3250, 'therapyName': 'Atezolizumab + Trastuzumab'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 856, 'therapyName': 'Pertuzumab'}]",Safety and Pharmacokinetics of Atezolizumab in Combination With Trastuzumab Emtansine or With Trastuzumab and Pertuzumab in Participants With HER2-Positive Breast Cancer,947
58,NCT03057106,Phase II,Recruiting,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}, {'id': 854, 'therapyName': 'Pemetrexed'}]",Durvalumab and Tremelimumab ± Platinum-Based Chemotherapy in Patients With Metastatic Squamous or Non-Squamous NSCLC,947
59,NCT00303849,Phase Ib/II,Recruiting,"[{'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 2562, 'therapyName': 'Etoposide + Melphalan'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1476, 'therapyName': 'Pegfilgrastim'}]",Combination Chemotherapy With BBBD Followed By Sodium Thiosulfate in Treating Patients With Anaplastic Oligodendroglioma or Oligoastrocytoma,947
60,NCT01248949,Phase I,Completed,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1176, 'therapyName': 'MEDI3617'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]",A Study to Evaluate the Safety and Antitumor Activity in Subjects With Advanced Solid Tumors,947
61,NCT02419495,Phase I,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1749, 'therapyName': 'Selinexor'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 1009, 'therapyName': 'Doxorubicin'}]",Selinexor in Combination With Standard Chemotherapy,947
62,NCT02657434,Phase III,Recruiting,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 854, 'therapyName': 'Pemetrexed'}]",A Study of Atezolizumab in Combination With Carboplatin or Cisplatin + Pemetrexed Compared With Carboplatin or Cisplatin + Pemetrexed in Participants Who Are Chemotherapy-Naive and Have Stage IV Non-Squamous Non-Small Cell Lung Cancer,947
63,NCT02032277,Phase III,"Active, not recruiting","[{'id': 1977, 'therapyName': 'Doxorubicin + Cyclophosphamide'}, {'id': 954, 'therapyName': 'Veliparib'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]",A Study Evaluating Safety and Efficacy of the Addition of ABT-888 Plus Carboplatin Versus the Addition of Carboplatin to Standard Chemotherapy Versus Standard Chemotherapy in Subjects With Early Stage Triple Negative Breast Cancer,947
64,NCT01459380,Phase I,Completed,"[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 954, 'therapyName': 'Veliparib'}, {'id': 667, 'therapyName': 'Bevacizumab'}]","Veliparib, Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer",947
65,NCT01064479,Phase II,"Active, not recruiting","[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 700, 'therapyName': 'Cisplatin'}]",Docetaxel And Cisplatin With or Without Erlotinib For Metastatic Or Recurrent Squamous Cell Carcinoma Of Head And Neck,947
66,NCT01249443,Phase I,Terminated,"[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]",Vorinostat in Combination With Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors and HIV Infection,947
67,NCT01248962,Phase II,"Active, not recruiting","[{'id': 1092, 'therapyName': 'Carboplatin'}]","Standard Infusion Carboplatin Versus Prophylactic Extended Infusion Carboplatin in Patients With Patients With Recurrent, Ovary, Fallopian Tube, and Primary Peritoneal Cancer",947
68,NCT01928160,Phase II,Withdrawn,"[{'id': 1290, 'therapyName': 'Erlotinib + Pemetrexed'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1291, 'therapyName': 'Erlotinib + Carboplatin'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1292, 'therapyName': 'Erlotinib + Cisplatin'}]",Pemetrexed Disodium and Carboplatin or Cisplatin With or Without Erlotinib Hydrochloride in Treating Patient With Stage IV Non-Small Cell Lung Cancer Resistant to First-Line Therapy With Erlotinib Hydrochloride or Gefitinib,947
69,NCT03126916,Phase III,Not yet recruiting,"[{'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1425, 'therapyName': '131I-MIBG'}, {'id': 1873, 'therapyName': 'Sargramostim'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 5595, 'therapyName': 'Isotretinoin'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 5153, 'therapyName': 'dexrazoxane'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1167, 'therapyName': 'Aldesleukin'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 2286, 'therapyName': 'Dinutuximab  '}]",Iobenguane I-131 or Crizotinib and Standard Therapy in Treating Younger Patients With Newly-Diagnosed High-Risk Neuroblastoma or Ganglioneuroblastoma,947
70,NCT02855944,Phase III,Recruiting,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 906, 'therapyName': 'Rucaparib'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]","ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients",947
71,NCT02606305,Phase I,Recruiting,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 3232, 'therapyName': 'IMGN853'}]","Study of IMGN853 in Comb. With Bevacizumab, Carboplatin or PLD in Adults With FRa + Adv. EOC, Primary Peritoneal, Fallopian Tube, or Endometrial Cancer",947
72,NCT01820754,Phase II,"Active, not recruiting","[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]",Evaluation of Circulating T Cells and Tumor Infiltrating Lymphocytes (TILs) During / After Pre-Surgery Chemotherapy in Non-Small Cell Lung Cancer (NSCLC),947
73,NCT02446600,Phase III,Recruiting,"[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 837, 'therapyName': 'Olaparib'}, {'id': 1001, 'therapyName': 'Cediranib'}]","Olaparib or Cediranib Maleate and Olaparib Compared With Standard Platinum-Based Chemotherapy in Treating Patients With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",947
74,NCT01836029,Phase II,"Active, not recruiting","[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 2000, 'therapyName': 'Fluorouracil + Cetuximab'}, {'id': 1092, 'therapyName': 'Carboplatin'}]",Chemotherapy Plus Cetuximab in Combination With VTX-2337 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck,947
75,NCT02041533,Phase III,"Active, not recruiting","[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 755, 'therapyName': 'Gemcitabine'}]","An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026)",947
76,NCT02312804,Phase I,Withdrawn,"[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 674, 'therapyName': 'BGJ398'}]",Ph Ib/BGJ398/Cervix and Other Solid Tumors,947
77,NCT02561832,Phase I,Completed,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 837, 'therapyName': 'Olaparib'}, {'id': 1092, 'therapyName': 'Carboplatin'}]","A Study to Assess the Safety, Tolerability and Efficacy of Olaparib in Combination With Carboplatin in Patients With HER-2 Negative Breast Cancer",947
78,NCT01526603,Phase I,Recruiting,"[{'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1092, 'therapyName': 'Carboplatin'}]",High Dose Chemotherapy and Autologous Transplant for Neuroblastoma,947
79,NCT02367794,Phase III,"Active, not recruiting","[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 619, 'therapyName': 'Abraxane'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1201, 'therapyName': 'Atezolizumab'}]",A Phase III Study of MPDL3280A (Anti-PD-L1) in Combination With Carboplatin + Paclitaxel or Carboplatin + Nab-paclitaxel Compared With Carboplatin + Nab-paclitaxel in Patients With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC),947
80,NCT02035345,FDA approved,Terminated,"[{'id': 1092, 'therapyName': 'Carboplatin'}]",Slowed Carboplatin Infusion for Ovarian Cancer Patients Receiving Carboplatin Re-Treatment,947
81,NCT02578680,Phase III,"Active, not recruiting","[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 700, 'therapyName': 'Cisplatin'}]",Study of Platinum+Pemetrexed Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Non-squamous Non-small Cell Lung Cancer (MK-3475-189/KEYNOTE-189),947
82,NCT02341456,Phase I,"Active, not recruiting","[{'id': 822, 'therapyName': 'MK-1775'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]",Phase Ib Study AZD1775 in Combination With Carboplatin and Paclitaxel in Adult Asian Patients With Solid Tumours,947
83,NCT02531932,Phase II,Recruiting,"[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 735, 'therapyName': 'Everolimus'}]",Comparison of Single-Agent Carboplatin vs the Combination of Carboplatin and Everolimus for the Treatment of Advanced Triple-Negative Breast Cancer,947
84,NCT02122770,Phase I,"Active, not recruiting","[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1026, 'therapyName': 'Itraconazole'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1688, 'therapyName': 'MLN4924'}, {'id': 1689, 'therapyName': 'Fluconazole'}]","Effects of Fluconazole and Itraconazole CYP3A-Mediated Inhibition on the Pharmacokinetics, Safety, and Tolerability of MLN4924 in Patients With Advanced Solid Tumors",947
85,NCT02358031,Phase III,"Active, not recruiting","[{'id': 694, 'therapyName': 'Cetuximab'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 700, 'therapyName': 'Cisplatin'}]",A Study of Pembrolizumab (MK-3475) for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (MK-3475-048/KEYNOTE-048),947
86,NCT02142738,Phase III,"Active, not recruiting","[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 854, 'therapyName': 'Pemetrexed'}]",Study of Pembrolizumab (MK-3475) Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (MK-3475-024/KEYNOTE-024),947
87,NCT02788201,Phase II,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1133, 'therapyName': 'Mitomycin C'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1013, 'therapyName': 'epirubicin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1137, 'therapyName': 'Bleomycin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 781, 'therapyName': 'Ixabepilone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 2950, 'therapyName': 'Estramustine'}, {'id': 1941, 'therapyName': 'Floxuridine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 1811, 'therapyName': 'Carmustine'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 953, 'therapyName': 'Vandetanib'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 4419, 'therapyName': 'Toremifine'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 2601, 'therapyName': 'Dactinomycin'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 3035, 'therapyName': 'Chlorambucil'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 342, 'therapyName': 'Vemurafenib'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 2635, 'therapyName': 'Vinblastine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 4305, 'therapyName': 'Teniposide'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 4304, 'therapyName': 'Streptozocin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1231, 'therapyName': 'Bendamustine'}, {'id': 4303, 'therapyName': 'Mechlorethamine'}, {'id': 4302, 'therapyName': 'Mitotane'}]",Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma,947
88,NCT01366144,Phase I,Recruiting,"[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 954, 'therapyName': 'Veliparib'}, {'id': 1092, 'therapyName': 'Carboplatin'}]","Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction",947
89,NCT01664754,Phase I,"Active, not recruiting","[{'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 738, 'therapyName': 'Exemestane'}]","Exemestane, Pemetrexed Disodium, and Carboplatin in Treating Post-Menopausal Women With Stage IV Non-Small Cell Lung Cancer",947
90,NCT01859741,Phase Ib/II,"Active, not recruiting","[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 2547, 'therapyName': 'Tarextumab'}]",A Phase 1b/2 Study of OMP-59R5 in Combination With Etoposide and Platinum Therapy in Subjects With Untreated Extensive Stage Small Cell Lung Cancer (PINNACLE),947
91,NCT01493505,Phase III,Terminated,"[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1218, 'therapyName': 'Trebananib'}]", TRINOVA-3,947
92,NCT01653470,Phase I,"Active, not recruiting","[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1315, 'therapyName': 'FOLFIRI'}, {'id': 2545, 'therapyName': 'BMS-906024'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]","Study to Evaluate Safety & Tolerability of BMS-906024 in Combination With Chemotherapy & to Define DLTs & MTD of BMS-906024 in Combination With One of the Following Chemotherapy Regimens; Weekly Paclitaxel, 5FU+Irinotecan or Carboplatin+Paclitaxel in Subjects With Advanced / Metastatic Solid Tumors",947
93,NCT01407562,Phase I,"Active, not recruiting","[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}]","Study of Pazopanib, Paclitaxel, and Carboplatin in Patients With Advanced Solid Tumors",947
94,NCT01437449,Phase II,"Active, not recruiting","[{'id': 1987, 'therapyName': 'Cisplatin + Docetaxel + Cetuximab'}, {'id': 1092, 'therapyName': 'Carboplatin'}]","Weekly Docetaxel, Cisplatin, and Cetuximab (TPC) in Palliative Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck (SCCHN)",947
95,NCT01450761,Phase III,Completed,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1136, 'therapyName': 'Etoposide'}]",Trial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab Plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy Alone,947
96,NCT01898494,Phase II,"Active, not recruiting","[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1092, 'therapyName': 'Carboplatin'}]",Transoral Surgery Followed By Low-Dose or Standard-Dose Radiation Therapy With or Without Chemotherapy in Treating Patients With HPV Positive Stage III-IVA Oropharyngeal Cancer,947
97,NCT01700400,Phase I,Completed,"[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 854, 'therapyName': 'Pemetrexed'}]"," Study of Everolimus, Pemetrexed, Carboplatin, and Bevacizumab to Treat Stage IV Lung Cancer",947
98,NCT00565851,Phase III,"Active, not recruiting","[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 3045, 'therapyName': 'Docetaxel + Paclitaxel'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 667, 'therapyName': 'Bevacizumab'}]","Carboplatin, Paclitaxel and Gemcitabine With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer",947
99,NCT01218048,Phase II,"Active, not recruiting","[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 694, 'therapyName': 'Cetuximab'}]",ERBITUX; Followed by Adjuvant Treatment With Chemoradiation and ERBITUX; for Locally Advanced Head and Neck Squamous Cell Carcinoma,947
100,NCT01454102,Phase I,"Active, not recruiting","[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1312, 'therapyName': 'Nivolumab'}]","Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012)",947
101,NCT02281955,Phase II,Recruiting,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 694, 'therapyName': 'Cetuximab'}]",De-intensification of Radiation and Chemotherapy for Low-Risk HPV-related Oropharyngeal SCC,947
102,NCT01505569,Phase I,Recruiting,"[{'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 2558, 'therapyName': 'Busulfan + Melphalan'}, {'id': 2101, 'therapyName': 'Etoposide + Ifosfamide'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 1092, 'therapyName': 'Carboplatin'}]",Auto Transplant for High Risk or Relapsed Solid or CNS Tumors,947
103,NCT02574078,Phase I,Recruiting,"[{'id': 619, 'therapyName': 'Abraxane'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 2114, 'therapyName': 'Bevacizumab + Pemetrexed'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 1092, 'therapyName': 'Carboplatin'}]",A Master Protocol Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC) (CheckMate 370),947
104,NCT02576574,Phase III,Recruiting,"[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 3144, 'therapyName': 'Avelumab'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 1092, 'therapyName': 'Carboplatin'}]",Avelumab in First-line Non-Small Cell Lung Cancer (JAVELIN Lung 100),947
105,NCT02489903,Phase II,Recruiting,"[{'id': 1136, 'therapyName': 'Etoposide'}, {'id': 3680, 'therapyName': 'RRx-001'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 619, 'therapyName': 'Abraxane'}]","RRx-001 in Small, Non-small Cell Lung Cancer, and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens",947
106,NCT01357161,Phase II,Completed,"[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 822, 'therapyName': 'MK-1775'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]", A Study of MK-1775 in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone for Participants With Platinum-Sensitive Ovarian Tumors With the P53 Gene Mutation (MK-1775-004),947
107,NCT00492687,Phase II,Unknown status,"[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1141, 'therapyName': 'Temozolomide'}, {'id': 1456, 'therapyName': 'Tamoxifen'}]","Radiation Therapy, Temozolomide, Tamoxifen, and Carboplatin in Treating Patients With Malignant Gliomas",947
108,NCT01927744,Phase II,Recruiting,"[{'id': 2474, 'therapyName': 'Erlotinib + Docetaxel'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1092, 'therapyName': 'Carboplatin'}]","Study of Chemotherapy With Cisplatin/CarboplatinAstellas Pharma Inc, OSI Pharmaceuticals, Kadoorie Foundation, and Docetaxel With or Without Erlotinib in Patients With Head and Neck Squamous Cell Carcinomas Amenable for Surgical Resection",947
109,NCT01281150,Phase I,Completed,"[{'id': 954, 'therapyName': 'Veliparib'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1092, 'therapyName': 'Carboplatin'}]",Veliparib in Combination With Carboplatin and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors,947
110,NCT00828009,Phase II,Unknown status,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 2142, 'therapyName': 'Emepepimut-S  '}, {'id': 1092, 'therapyName': 'Carboplatin'}]",BLP25 Liposome Vaccine and Bevacizumab After Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery,947
111,NCT03242915,Phase II,Not yet recruiting,"[{'id': 2105, 'therapyName': 'Carboplatin +  Pembrolizumab + Pemetrexed '}]",Pembrolizumab in Combination With Platinum-based Doublet Chemotherapy in Patients With EGFR Mutation and ALK Positive NSCLC (Non-Small Cell Lung Cancer) With Progressive Disease Following Prior Tyrosine Kinase Inhibitors (TKIs),947
112,NCT02741570,Phase III,Recruiting,"[{'id': 4168, 'therapyName': 'Carboplatin + Cetuximab + Cisplatin + Fluorouracil'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care (Extreme Study Regimen) as First Line Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck,947
113,NCT02124707,Phase II,Recruiting,"[{'id': 1989, 'therapyName': 'Carboplatin + Cetuximab + Paclitaxel'}]","Weekly Carboplatin, Paclitaxel and Cetuximab Treatment for Patients With Recurrent or Metastatic SCCHN",947
114,NCT03174275,Phase II,Not yet recruiting,"[{'id': 5873, 'therapyName': 'Carboplatin + Cisplatin + Durvalumab + Paclitaxel'}, {'id': 3997, 'therapyName': 'Carboplatin + Durvalumab + Paclitaxel'}]","Carboplatin, Nab-Paclitaxel, Durvalumab Before Surgery and Adjuvant Therapy in Head and Neck Squamous Cell Carcinoma",947
115,NCT02899728,Phase II,Suspended,"[{'id': 4728, 'therapyName': 'Carboplatin + Cisplatin + Etoposide'}, {'id': 1971, 'therapyName': 'Cediranib + Olaparib'}]","Olaparib, Cediranib Maleate, and Standard Chemotherapy in Treating Patients With Small Cell Lung Cancer",947
116,NCT03043872,Phase III,Recruiting,"[{'id': 5305, 'therapyName': 'MEDI4736 + Tremelimumab + Carboplatin + Cisplatin + Etoposide'}, {'id': 5306, 'therapyName': 'MEDI4736 + Carboplatin + Cisplatin + Etoposide'}, {'id': 4728, 'therapyName': 'Carboplatin + Cisplatin + Etoposide'}]",Durvalumab+/- Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer (Caspian),947
117,NCT02934503,Phase II,Recruiting,"[{'id': 6184, 'therapyName': 'Carboplatin + Cisplatin + Etoposide + Pembrolizumab'}]",Study of Pembrolizumab and Chemotherapy With or Without Radiation in Small Cell Lung Cancer (SCLC),947
118,NCT03178552,Phase II,Recruiting,"[{'id': 4686, 'therapyName': 'Carboplatin + Cisplatin + Gemcitabine'}, {'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 4616, 'therapyName': 'Carboplatin + Cisplatin + Pemetrexed'}, {'id': 698, 'therapyName': 'Alectinib'}]",A Study to Evaluate Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC) (B-FAST),947
119,NCT02516241,Phase III,Recruiting,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}, {'id': 4686, 'therapyName': 'Carboplatin + Cisplatin + Gemcitabine'}, {'id': 1356, 'therapyName': 'Durvalumab'}]",Study of MEDI4736 With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer,947
120,NCT02853305,Phase III,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 4686, 'therapyName': 'Carboplatin + Cisplatin + Gemcitabine'}]",Study of Pembrolizumab With or Without Platinum-based Combination Chemotherapy Versus Chemotherapy Alone in Urothelial Carcinoma (MK-3475-361/KEYNOTE-361),947
121,NCT03215706,Phase III,Recruiting,"[{'id': 6132, 'therapyName': 'Carboplatin + Cisplatin + Paclitaxel + Pemetrexed'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",A Study of Nivolumab and Ipilimumab Combined With Chemotherapy Compared to Chemotherapy by Itself as the First Treatment Given for Stage IV Non-Small Cell Lung Cancer (NSCLC) (CheckMate 9LA),947
122,NCT02864251,Phase III,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}, {'id': 4616, 'therapyName': 'Carboplatin + Cisplatin + Pemetrexed'}]","A Study of Nivolumab + Chemotherapy or Nivolumab + Ipilimumab Versus Chemotherapy in Patients With EGFR Mutation, T790M Negative NSCLC Who Have Failed 1L EGFR TKI Therapy (CheckMate722)",947
123,NCT02899299,Phase III,Recruiting,"[{'id': 4616, 'therapyName': 'Carboplatin + Cisplatin + Pemetrexed'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients (CheckMate743),947
124,NCT02703272,Phase III,Recruiting,"[{'id': 768, 'therapyName': 'Ibrutinib'}, {'id': 4307, 'therapyName': 'Carboplatin + Dexamethasone + Etoposide + Ifosfamide + Rituximab'}, {'id': 4308, 'therapyName': 'Carboplatin + Dexamethasone + Idarubicin + Ifosfamide + Rituximab + Vincristine'}]",A Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Participants With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma,947
125,NCT02565901,Phase Ib/II,Recruiting,"[{'id': 3111, 'therapyName': 'Carboplatin + Docetaxel + Sirolimus '}]","Sirolimus, Docetaxel, and Carboplatin in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer",947
126,NCT01281514,Phase I,Recruiting,"[{'id': 2168, 'therapyName': 'Carboplatin + Doxil + Everolimus'}]","Carboplatin, Pegylated Liposomal Doxorubicin Hydrochloride, and Everolimus in Treating Patients With Relapsed Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer",947
127,NCT02726997,Phase Ib/II,Recruiting,"[{'id': 3997, 'therapyName': 'Carboplatin + Durvalumab + Paclitaxel'}]",Matched Paired Pharmacodynamics and Feasibility Study of Durvalumab in Combination With Chemotherapy in Frontline Ovarian Cancer,947
128,NCT02962063,Phase Ib/II,Recruiting,"[{'id': 3997, 'therapyName': 'Carboplatin + Durvalumab + Paclitaxel'}]","Durvalumab, an Anti-PD-L1 Antibody, and Chemoradiation Before Surgery for Esophageal Cancer",947
129,NCT02684227,Phase II,Recruiting,"[{'id': 3681, 'therapyName': 'Carboplatin + Enzalutamide + Paclitaxel'}]",Enzalutamide in Combination With Carboplatin and Paclitaxel in Endometrial Cancer,947
130,NCT02017964,Phase II,Completed,"[{'id': 1791, 'therapyName': 'Carboplatin + Etoposide'}, {'id': 2673, 'therapyName': 'Cyclophosphamide + Methotrexate + Vincristine  '}]","Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed, Non-Metastatic Desmoplastic Medulloblastoma",947
131,NCT02499770,Phase Ib/II,"Active, not recruiting","[{'id': 1791, 'therapyName': 'Carboplatin + Etoposide'}, {'id': 3074, 'therapyName': 'Trilaciclib'}]",G1T28 (CDK 4/6 Inhibitor) in Combination With Etoposide and Carboplatin in Extensive Stage Small Cell Lung Cancer (SCLC),947
132,NCT02658214,Phase I,Recruiting,"[{'id': 2667, 'therapyName': 'Carboplatin + Gemcitabine'}, {'id': 2634, 'therapyName': 'Carboplatin + nab-paclitaxel'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 1791, 'therapyName': 'Carboplatin + Etoposide'}]",Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors,947
133,NCT01722292,Phase Ib/II,Terminated,"[{'id': 1587, 'therapyName': 'Taladegib'}, {'id': 1791, 'therapyName': 'Carboplatin + Etoposide'}]",A Study of LY2940680 in Small Cell Lung Cancer,947
134,NCT02130869,Phase I,Recruiting,"[{'id': 2378, 'therapyName': 'Bendamustine + Cytarabine + Etoposide'}, {'id': 2460, 'therapyName': 'Busulfan + Hu14.18K322A'}, {'id': 2459, 'therapyName': 'Aldesleukin + Melphalan + Sargramostim'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1791, 'therapyName': 'Carboplatin + Etoposide'}]",A Pilot Study of Immunotherapy Including Haploidentical NK Cell Infusion Following CD133+ Positively-Selected Autologous Hematopoietic Stem Cells in Children With High Risk Solid Tumors or Lymphomas,947
135,NCT03066778,Phase III,Recruiting,"[{'id': 2585, 'therapyName': 'Cisplatin + Etoposide'}, {'id': 5145, 'therapyName': 'Cisplatin + Etoposide + Pembrolizumab'}, {'id': 2604, 'therapyName': 'Carboplatin + Etoposide + Pembrolizumab'}, {'id': 1791, 'therapyName': 'Carboplatin + Etoposide'}]",A Study of Pembrolizumab (MK-3475) in Combination With Etoposide/Platinum (Cisplatin or Carboplatin) for Participants With Extensive Stage Small Cell Lung Cancer (MK-3475-604/KEYNOTE-604),947
136,NCT01453205,Phase II,Completed,"[{'id': 2354, 'therapyName': 'Cisplatin + Cytarabine + Dexamethasone'}, {'id': 2352, 'therapyName': 'Carboplatin + Etoposide + Ifosfamide '}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 2407, 'therapyName': 'MEDI-551'}]","A Phase 2, Multicenter, Randomized, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)",947
137,NCT02408042,Phase Ib/II,Withdrawn,"[{'id': 897, 'therapyName': 'Rituximab'}, {'id': 2352, 'therapyName': 'Carboplatin + Etoposide + Ifosfamide '}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 2486, 'therapyName': 'Brentuximab vedotin'}]",Study of Pembrolizumab With Chemotherapy in Patients With Advanced Lymphoma (PembroHeme),947
138,NCT02018861,Phase I,"Active, not recruiting","[{'id': 2406, 'therapyName': 'INCB039110'}, {'id': 3097, 'therapyName': 'INCB039110 + INCB050465'}, {'id': 1231, 'therapyName': 'Bendamustine'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 2352, 'therapyName': 'Carboplatin + Etoposide + Ifosfamide '}, {'id': 3088, 'therapyName': 'INCB050465 '}]","A Phase 1, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 Monotherapy and in Combination With INCB039110 in Subjects With Previously Treated B-Cell Malignancies",947
139,NCT01169636,Phase Ib/II,Completed,"[{'id': 1080, 'therapyName': 'Panobinostat'}, {'id': 1476, 'therapyName': 'Pegfilgrastim'}, {'id': 2352, 'therapyName': 'Carboplatin + Etoposide + Ifosfamide '}]","Panobinostat Plus Ifosfamide, Carboplatin, and Etoposide (ICE) Compared With ICE For Relapsed Hodgkin Lymphoma",947
140,NCT01959698,Phase Ib/II,Recruiting,"[{'id': 2351, 'therapyName': 'Carfilzomib + Rituximab'}, {'id': 2352, 'therapyName': 'Carboplatin + Etoposide + Ifosfamide '}]","Carfilzomib, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma",947
141,NCT02471911,Phase I,Recruiting,"[{'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 3360, 'therapyName': 'Carboplatin + Etoposide + Ifosfamide + Rituximab'}, {'id': 1749, 'therapyName': 'Selinexor'}]",KPT-330 Plus RICE for Relapsed/Refractory Aggressive B-Cell Lymphoma,947
142,NCT02219737,Phase I,"Active, not recruiting","[{'id': 768, 'therapyName': 'Ibrutinib'}, {'id': 3360, 'therapyName': 'Carboplatin + Etoposide + Ifosfamide + Rituximab'}]",Ibrutinib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma,947
143,NCT02116959,Phase I,Unknown status,"[{'id': 2559, 'therapyName': 'Carboplatin + Etoposide + Melphalan + Vincristine'}]",Alternating Systemic Chemotherapy and Intra-Arterial Melphalan Chemotherapy in Children With Intra-Ocular Retinoblastoma,947
144,NCT02402920,Phase I,Recruiting,"[{'id': 2604, 'therapyName': 'Carboplatin + Etoposide + Pembrolizumab'}, {'id': 700, 'therapyName': 'Cisplatin'}]",Phase I Trial of MK-3475 and Concurrent Chemo/Radiation for the Elimination of Small Cell Lung Cancer,947
145,NCT02289690,Phase I,Recruiting,"[{'id': 1544, 'therapyName': 'Carboplatin + Etoposide + Veliparib'}]",Dose Escalation and Double-blind Study of Veliparib in Combination With Carboplatin and Etoposide in Treatment-naive Extensive Stage Disease Small Cell Lung Cancer,947
146,NCT01711541,Phase Ib/II,Suspended,"[{'id': 1544, 'therapyName': 'Carboplatin + Etoposide + Veliparib'}, {'id': 1849, 'therapyName': 'Cisplatin + Fluorouracil + Hydroxyurea'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]",Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IV Head and Neck Cancer,947
147,NCT01506609,Phase II,"Active, not recruiting","[{'id': 1193, 'therapyName': 'Veliparib + Temozolomide'}, {'id': 1544, 'therapyName': 'Carboplatin + Etoposide + Veliparib'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]",The Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide or In Combination With Carboplatin and Paclitaxel Versus Placebo in Subjects With BRCA1 and BRCA2 Mutation and Metastatic Breast Cancer,947
148,NCT01386385,Phase Ib/II,Recruiting,"[{'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 1544, 'therapyName': 'Carboplatin + Etoposide + Veliparib'}]","Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery",947
149,NCT00588770,Phase III,"Active, not recruiting","[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1835, 'therapyName': 'Docetaxel + Cisplatin'}, {'id': 1833, 'therapyName': 'Cisplatin + Fluorouracil'}, {'id': 1834, 'therapyName': 'Docetaxel + Carboplatin'}, {'id': 1832, 'therapyName': 'Carboplatin + Fluorouracil\t'}]",Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer,947
150,NCT01183559,Phase I,Unknown status,"[{'id': 2071, 'therapyName': 'Carboplatin + Fluorouracil + Paclitaxel + Vandetanib'}]","A Trial of ZD6474 (Zactima), Paclitaxel, Carboplatin, 5-Fluorouracil, and XRT Followed by Surgery",947
151,NCT03206177,Phase I,Recruiting,"[{'id': 6265, 'therapyName': 'Carboplatin + Galunisertib + Paclitaxel'}]",Paclitaxel/Carboplatin + Galunisertib for Patients With Carcinosarcoma of the Uterus or Ovary,947
152,NCT02046421,Phase I,"Active, not recruiting","[{'id': 2603, 'therapyName': 'Mifepristone'}, {'id': 2667, 'therapyName': 'Carboplatin + Gemcitabine'}]","Carboplatin, Gemcitabine Hydrochloride, and Mifepristone in Treating Patients With Advanced Breast Cancer or Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer",947
153,NCT03164616,Phase III,Recruiting,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}, {'id': 1857, 'therapyName': 'Cisplatin + Pemetrexed'}, {'id': 1602, 'therapyName': 'Carboplatin + Pemetrexed'}, {'id': 1467, 'therapyName': 'Gemcitabine + Cisplatin'}, {'id': 2667, 'therapyName': 'Carboplatin + Gemcitabine'}, {'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 2634, 'therapyName': 'Carboplatin + nab-paclitaxel'}]",Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON). (POSEIDON),947
154,NCT02819518,Phase III,Recruiting,"[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 619, 'therapyName': 'Abraxane'}, {'id': 2667, 'therapyName': 'Carboplatin + Gemcitabine'}]",Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs. Placebo Plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (MK-3475-355/KEYNOTE-355),947
155,NCT02755272,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 2667, 'therapyName': 'Carboplatin + Gemcitabine'}]",A Study of Pembrolizumab With Carboplatin and Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer,947
156,NCT02542293,Phase III,Recruiting,"[{'id': 1467, 'therapyName': 'Gemcitabine + Cisplatin'}, {'id': 2667, 'therapyName': 'Carboplatin + Gemcitabine'}, {'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 1857, 'therapyName': 'Cisplatin + Pemetrexed'}, {'id': 1602, 'therapyName': 'Carboplatin + Pemetrexed'}]",Study of 1st Line Therapy Study of MEDI4736 With Tremelimumab Versus SoC in Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE).,947
157,NCT02412670,Phase II,Recruiting,"[{'id': 2667, 'therapyName': 'Carboplatin + Gemcitabine'}, {'id': 2668, 'therapyName': 'Aldoxorubicin + Cisplatin + Methotrexate + Vincristine'}]",Chemotherapy Before Surgery in Treating Patients With High Grade Upper Urinary Tract Cancer,947
158,NCT02978716,Phase II,Recruiting,"[{'id': 2667, 'therapyName': 'Carboplatin + Gemcitabine'}, {'id': 5737, 'therapyName': 'Carboplatin + Gemcitabine + Trilaciclib'}]","Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC)",947
159,NCT02627443,Phase II,Recruiting,"[{'id': 2667, 'therapyName': 'Carboplatin + Gemcitabine'}, {'id': 2879, 'therapyName': 'VX-970'}]","Carboplatin and Gemcitabine Hydrochloride With or Without ATR Kinase Inhibitor VX-970 in Treating Patients With Recurrent and Metastatic Ovarian, Primary Peritoneal, or Fallopian Tube Cancer",947
160,NCT01663857,Phase Ib/II,"Active, not recruiting","[{'id': 3296, 'therapyName': 'Ralimetinib'}, {'id': 2667, 'therapyName': 'Carboplatin + Gemcitabine'}]",A Study of LY2228820 for Recurrent Ovarian Cancer,947
161,NCT02435680,Phase II,"Active, not recruiting","[{'id': 2838, 'therapyName': 'MCS110'}, {'id': 2667, 'therapyName': 'Carboplatin + Gemcitabine'}]",Efficacy Study of MCS110 Given With Carboplatin and Gemcitabine in Advanced Triple Negative Breast Cancer (TNBC),947
162,NCT03036098,Phase III,Recruiting,"[{'id': 1467, 'therapyName': 'Gemcitabine + Cisplatin'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}, {'id': 2667, 'therapyName': 'Carboplatin + Gemcitabine'}]",Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care Chemotherapy in Treatment of Patients With Untreated Inoperable or Metastatic Urothelial Cancer,947
163,NCT02784795,Phase I,Recruiting,"[{'id': 4374, 'therapyName': 'Cisplatin + Gemcitabine + LY3039478'}, {'id': 4375, 'therapyName': 'Carboplatin + Gemcitabine + LY3039478'}, {'id': 4372, 'therapyName': 'LY3039478 + LY3023414'}, {'id': 4373, 'therapyName': 'Abemaciclib + LY3039478'}, {'id': 4371, 'therapyName': 'LY3039478 + Taladegib'}, {'id': 2958, 'therapyName': 'LY3039478'}, {'id': 1069, 'therapyName': 'LY3023414'}]",A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors,947
164,NCT01376310,Phase II,"Active, not recruiting","[{'id': 1264, 'therapyName': 'Docetaxel + Trametinib'}, {'id': 1265, 'therapyName': 'Erlotinib + Trametinib'}, {'id': 2, 'therapyName': 'Trametinib'}, {'id': 1266, 'therapyName': 'Pemetrexed + GSK1120212'}, {'id': 1267, 'therapyName': 'Carboplatin + GSK1120212'}, {'id': 1268, 'therapyName': 'nab-paclitaxel + GSK1120212'}, {'id': 1269, 'therapyName': 'Gemcitabine + GSK1120212'}, {'id': 1271, 'therapyName': 'Everolimus + GSK1120212'}]",GSK1120212 Rollover Study,947
165,NCT00983398,Phase Ib/II,Recruiting,"[{'id': 1476, 'therapyName': 'Pegfilgrastim'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 2587, 'therapyName': 'Carboplatin + Melphalan'}]","Melphalan, Carboplatin, and Sodium Thiosulfate for Patients With Central Nervous System (CNS) Embryonal or Germ Cell Tumors",947
166,NCT00293475,Phase Ib/II,Recruiting,"[{'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1476, 'therapyName': 'Pegfilgrastim'}, {'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 2669, 'therapyName': 'Carboplatin + Methotrexate + Rituximab'}]",Rituximab and Methotrexate Chemotherapy w/Blood-Brain Barrier Disruption (BBBD) &amp; Sodium Thiosulfate Chemoprotection for Patients With Newly Diagnosed PCNSL,947
167,NCT02775435,Phase III,Recruiting,"[{'id': 2634, 'therapyName': 'Carboplatin + nab-paclitaxel'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]",A Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With First Line Metastatic Squamous Non-small Cell Lung Cancer (MK-3475-407/KEYNOTE-407),947
168,NCT02367781,Phase III,"Active, not recruiting","[{'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 2634, 'therapyName': 'Carboplatin + nab-paclitaxel'}]",A Phase III Study of MPDL3280A (Anti-PD-L1 Antibody) in Combination With Carboplatin + Nab-Paclitaxel in Patients With Non-Squamous Non-Small Cell Lung Cancer,947
169,NCT02382406,Phase Ib/II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 2634, 'therapyName': 'Carboplatin + nab-paclitaxel'}]",Carboplatin/Nab-Paclitaxel and MK-3475 in NSCLC,947
170,NCT02392507,Phase II,Recruiting,"[{'id': 2599, 'therapyName': 'Carboplatin + nab-paclitaxel + Necitumumab'}]",A Study of Nab-Paclitaxel and Carboplatin Plus Necitumumab (LY3012211) in Participants With Stage IV Squamous NSCLC,947
171,NCT03121352,Phase I,Recruiting,"[{'id': 5591, 'therapyName': 'Carboplatin + nab-paclitaxel + Pembrolizumab'}]","Pilot Study of Carboplatin, Nab-Paclitaxel and Pembrolizumab for Metastatic Triple-Negative Breast Cancer",947
172,NCT03209401,Phase I,Not yet recruiting,"[{'id': 5984, 'therapyName': 'Carboplatin + Niraparib'}]",Niraparib Plus Carboplatin in Patients With Homologous Recombination Deficient Advanced Solid Tumor Malignancies,947
173,NCT03256136,Phase II,Not yet recruiting,"[{'id': 6159, 'therapyName': 'Carboplatin + Nivolumab + Pemetrexed'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]","A Phase II Study of Nivolumab in Combination With Carboplatin and Pemetrexed, or Nivolumab in Combination With Ipilimumab, in Patients With Advanced, EGFR-mutant or ALK-rearranged, Non-Small Cell Lung Cancer",947
174,NCT02876107,Phase II,Recruiting,"[{'id': 1977, 'therapyName': 'Doxorubicin + Cyclophosphamide'}, {'id': 3386, 'therapyName': 'Carboplatin + Paclitaxel + Panitumumab'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]",A Phase II Study of Using Panitumumab/Carboplatin/Paclitaxel (PaCT) Followed by Anthracycline-Containing Regimen (AC) for New Triple-Negative Inflammatory Breast Cancer (TN-IBC),947
175,NCT02593175,Phase II,Recruiting,"[{'id': 3386, 'therapyName': 'Carboplatin + Paclitaxel + Panitumumab'}]","Women's Triple-Negative First-Line Study: A Phase II Trial of Panitumumab, Carboplatin and Paclitaxel (PaCT) in Patients With Localized Triple-Negative Breast Cancer (TNBC) With Tumors Predicted Insensitive to Standard Neoadjuvant Chemotherapy",947
176,NCT03064854,Phase I,Recruiting,"[{'id': 6027, 'therapyName': 'Carboplatin + Paclitaxel + PDR001'}, {'id': 6026, 'therapyName': 'Cisplatin + Pemetrexed + PDR001'}, {'id': 6025, 'therapyName': 'Cisplatin + Gemcitabine + PDR001'}, {'id': 6024, 'therapyName': 'Pemetrexed + PDR001 + Cisplatin + Carboplatin'}]","PDR001 in Combination With Platinum-doublet Chemotherapy in PD-L1 Unselected, Metastatic NSCLC Patients (ElevatION:NSCLC-101 Trial)",947
177,NCT02621398,Phase I,Suspended,"[{'id': 2103, 'therapyName': 'Carboplatin + Paclitaxel + Pembrolizumab'}]","Pembrolizumab, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Stage II-IIIB Non-Small Cell Lung Cancer",947
178,NCT02549209,Phase II,Recruiting,"[{'id': 2103, 'therapyName': 'Carboplatin + Paclitaxel + Pembrolizumab'}]",Pembro/Carbo/Taxol in Endometrial Cancer,947
179,NCT02630823,Phase I,Recruiting,"[{'id': 2103, 'therapyName': 'Carboplatin + Paclitaxel + Pembrolizumab'}]",MK-3475 Immunotherapy in Endometrial Carcinoma,947
180,NCT02834975,Phase II,Recruiting,"[{'id': 2103, 'therapyName': 'Carboplatin + Paclitaxel + Pembrolizumab'}]","Pembrolizumab, Paclitaxel, and Carboplatin in Patients With Advanced Stage Epithelial Ovarian Cancer (EOC).",947
181,NCT02766582,Phase II,Recruiting,"[{'id': 2103, 'therapyName': 'Carboplatin + Paclitaxel + Pembrolizumab'}]",Phase II: Pembrolizumab/Carboplatin/Taxol in Epithelial Ovary Cancer,947
182,NCT03064490,Phase II,Recruiting,"[{'id': 2103, 'therapyName': 'Carboplatin + Paclitaxel + Pembrolizumab'}]","Pembrolizumab, Radiotherapy, and Chemotherapy in Neoadjuvant Treatment of Malignant Esophago-gastric Diseases (PROCEED)",947
183,NCT02617849,Phase II,Recruiting,"[{'id': 2103, 'therapyName': 'Carboplatin + Paclitaxel + Pembrolizumab'}]",Pembrolizumab With Carboplatin/Paclitaxel in Patients With Metastatic Melanoma,947
184,NCT02944396,Phase II,Recruiting,"[{'id': 5054, 'therapyName': 'Carboplatin + Paclitaxel + Pemetrexed + Veliparib'}, {'id': 5053, 'therapyName': 'Carboplatin + Paclitaxel + Pemetrexed + Nivolumab + Veliparib'}]",Study of Veliparib in Combination With Nivolumab and Platinum Doublet Chemotherapy in Participants With Metastatic or Advanced Non-Small Cell Lung Cancer (NSCLC),947
185,NCT03206645,Phase I,Recruiting,"[{'id': 6266, 'therapyName': 'Carboplatin + Paclitaxel + PTC596'}]",PTC-596 in Women With Ovarian Cancer Receiving Neoadjuvant Chemotherapy,947
186,NCT02269293,Phase I,Recruiting,"[{'id': 2640, 'therapyName': 'Carboplatin + Paclitaxel + Selinexor'}]","Selective Inhibitor of Nuclear Export, Selinexor (KPT-330) in Combination With Paclitaxel and Carboplatin in Patients With Advanced Ovarian or Endometrial Cancers",947
187,NCT01912625,Phase I,Recruiting,"[{'id': 2196, 'therapyName': 'Carboplatin + Paclitaxel + Trametinib'}]","Trametinib, Combination Chemotherapy, and Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery",947
188,NCT03194373,Phase II,Recruiting,"[{'id': 4735, 'therapyName': 'Carboplatin + Palbociclib'}]",Phase II Trial Evaluating the Efficacy of Palbociclib in Combination With Carboplatin for the Treatment of Unresectable Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma,947
189,NCT02897375,Phase I,Recruiting,"[{'id': 4734, 'therapyName': 'Cisplatin + Palbociclib'}, {'id': 4735, 'therapyName': 'Carboplatin + Palbociclib'}]",Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors,947
190,NCT03029598,Phase Ib/II,Recruiting,"[{'id': 5265, 'therapyName': 'Carboplatin + Pembrolizumab'}]","Pembrolizumab and Carboplatin in Treating Patients With Relapsed or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",947
191,NCT03095352,Phase II,Recruiting,"[{'id': 5265, 'therapyName': 'Carboplatin + Pembrolizumab'}]","A Randomized Phase II Study of Pembrolizumab, an Anti-PD (Programmed Cell Death)-1 Antibody, in Combination With Carboplatin Compared to Carboplatin Alone in Breast Cancer Patients With Chest Wall Disease",947
192,NCT03213041,Phase II,Recruiting,"[{'id': 5265, 'therapyName': 'Carboplatin + Pembrolizumab'}]",Pembrolizumab and Carboplatin in Treating Patients With Circulating Tumor Cells Positive Metastatic Breast Cancer,947
193,NCT02259582,Phase II,"Active, not recruiting","[{'id': 1602, 'therapyName': 'Carboplatin + Pemetrexed'}, {'id': 2007, 'therapyName': 'Demcizumab'}]","A Study of Carboplatin, Pemetrexed Plus Placebo vs Carboplatin, Pemetrexed Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With Non-Squamous Non-Small Cell Lung Cancer",947
194,NCT01803282,Phase I,Recruiting,"[{'id': 3320, 'therapyName': 'GS-5745'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 1602, 'therapyName': 'Carboplatin + Pemetrexed'}, {'id': 1315, 'therapyName': 'FOLFIRI'}, {'id': 1779, 'therapyName': 'Nab-paclitaxel + Gemcitabine'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 667, 'therapyName': 'Bevacizumab'}]",Safety and Tolerability Study in Solid Tumors,947
195,NCT02591615,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 1602, 'therapyName': 'Carboplatin + Pemetrexed'}]",Optimal Sequencing of Pembrolizumab (MK-3475) and Standard Platinum-based Chemotherapy in First-Line NSCLC,947
196,NCT01263782,Phase II,Completed,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1602, 'therapyName': 'Carboplatin + Pemetrexed'}, {'id': 701, 'therapyName': 'Cixutumumab'}]",BATTLE-FL: Front-Line Biomarker-Integrated Treatment Study in Non Small Cell Lung Cancer,947
197,NCT02468661,Phase Ib/II,Recruiting,"[{'id': 1065, 'therapyName': 'Capmatinib'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 1857, 'therapyName': 'Cisplatin + Pemetrexed'}, {'id': 1602, 'therapyName': 'Carboplatin + Pemetrexed'}]","A Safety and Efficacy Study of INC280 Alone, and in Combination With Erlotinib, Compared to Chemotherapy, in Advanced/Metastatic Non-small Cell Lung Cancer Patients With EGFR Mutation and cMET Amplification",947
198,NCT02087241,Phase II,Terminated,"[{'id': 822, 'therapyName': 'MK-1775'}, {'id': 1602, 'therapyName': 'Carboplatin + Pemetrexed'}]",Ph II Trial of Carboplatin and Pemetrexed With or Without AZD1775 for Untreated Lung Cancer,947
199,NCT02789657,Phase II,Recruiting,"[{'id': 4235, 'therapyName': 'Carboplatin + Pertuzumab + Trastuzumab + Paclitaxel'}, {'id': 1977, 'therapyName': 'Doxorubicin + Cyclophosphamide'}]",BrUOG 308: Efficacy of wPCbTP and Switching to an AC in Non-responding Patients as Neoadjuvant Therapy in Clinical Stage I-III HER2-positive Breast Cancer.,947
200,NCT01690468,Phase Ib/II,Recruiting,"[{'id': 4566, 'therapyName': 'Carboplatin + Triciribine'}]",PTX-200 and Carboplatin in Ovarian Cancer,947
201,NCT02551159,Phase III,"Active, not recruiting","[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 1914, 'therapyName': 'Cetuximab + Carboplatin + Fluorouracil'}, {'id': 1652, 'therapyName': 'Tremelimumab'}]",Phase III Open Label First Line Therapy Study of MEDI 4736 With or Without Tremelimumab Versus Standard of Care (SOC) in SCCHN,947
202,NCT01063075,Phase II,Completed,"[{'id': 1914, 'therapyName': 'Cetuximab + Carboplatin + Fluorouracil'}]",A Study in Advanced Solid Tumors,947
203,NCT01316757,Phase II,"Active, not recruiting","[{'id': 1921, 'therapyName': 'Cetuximab + Paclitaxel + Carboplatin + Erlotinib'}]","Carboplatin, Paclitaxel, Cetuximab, and Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Head and Neck Squamous Cell Cancer",947
204,NCT01822496,Phase II,Recruiting,"[{'id': 1375, 'therapyName': 'Cisplatin + Etoposide + Paclitaxel + Carboplatin + Erlotinib'}]",Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer,947
205,NCT02998528,Phase III,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}, {'id': 5241, 'therapyName': 'Cisplatin + Vinorelbine + Gemcitabine + Docetaxel + Pemetrexed + Carboplatin'}]",A Neoadjuvant Study of Nivolumab and Ipilimumab Compared to Chemotherapy Doublet in Early Stage Non-Small Cell Lung Cancer (NSCLC) (CheckMate 816),947
206,NCT01440998,Phase I,"Active, not recruiting","[{'id': 1819, 'therapyName': 'Dasatinib + Paclitaxel + Carboplatin'}]","Dasatinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer",947
207,NCT02190695,Phase II,Recruiting,"[{'id': 1608, 'therapyName': 'Decitabine + Carboplatin'}, {'id': 1609, 'therapyName': 'Decitabine + Arsenic trioxide '}]","A Safety and Efficacy Study Using Decitabine, Decitabine/Carboplatin, Decitabine/Arsenic for the Treatment of Relapsed, Refractory, and Elderly Acute Myeloid Leukemia , Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia",947
208,NCT02188706,Phase II,"Active, not recruiting","[{'id': 650, 'therapyName': 'Decitabine'}, {'id': 1608, 'therapyName': 'Decitabine + Carboplatin'}, {'id': 1609, 'therapyName': 'Decitabine + Arsenic trioxide '}]","A Leukemia SPORE Phase II Clinical Trial Comparing Decitabine Versus Decitabine/Carboplatin and Decitabine/Arsenic for the Treatment of Relapsed, Refractory, and Elderly Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)",947
209,NCT01995188,Phase I,Completed,"[{'id': 1347, 'therapyName': 'DNIB0600A + Carboplatin + Bevacizumab'}, {'id': 1346, 'therapyName': 'DNIB0600A + Carboplatin'}]",A Study to Evaluate the Safety and Pharmacology of DNIB0600A in Patients With Ovarian Cancer,947
210,NCT01779050,Phase II,"Active, not recruiting","[{'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1087, 'therapyName': 'Epirubicin + Cyclophosphamide'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1982, 'therapyName': 'Fluorouracil + Epirubicin + Cyclophosphamide'}, {'id': 1834, 'therapyName': 'Docetaxel + Carboplatin'}, {'id': 1881, 'therapyName': 'Docetaxel + Cyclophosphamide'}]",Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer Patients With ERBB2 Expressing Disseminated Tumor Cells,947
211,NCT02957968,Phase II,Recruiting,"[{'id': 1495, 'therapyName': 'Paclitaxel + Doxorubicin + Cyclophosphamide'}, {'id': 5729, 'therapyName': 'Doxorubicin + Cyclophosphamide + Paclitaxel + Carboplatin'}]",Neoadj Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca,947
212,NCT01490749,Phase I,"Active, not recruiting","[{'id': 1924, 'therapyName': 'Everolimus + Paclitaxel + Carboplatin + Cetuximab'}]",Trial of XELOX Followed by Radiation Combined With Carboplatin and RAD001 for Esophageal Cancer,947
213,NCT02920450,Phase Ib/II,Recruiting,"[{'id': 4785, 'therapyName': 'Gedatolisib + Paclitaxel + Carboplatin'}]","Study of Paclitaxel, Carboplatin, and PF-05212384 in Advanced or Metastatic NSCLC",947
214,NCT01936974,Phase II,Terminated,"[{'id': 1295, 'therapyName': 'Gemcitabine + Bevacizumab + Cisplatin'}, {'id': 1296, 'therapyName': 'Gemcitabine + Bevacizumab + Oxaliplatin'}, {'id': 1294, 'therapyName': 'Gemcitabine + Bevacizumab + Carboplatin'}, {'id': 1297, 'therapyName': 'Gemcitabine + Bevacizumab'}]","(PGA) for Platinum-resistant/Refractory, Paclitaxel-Pretreated Recurrent Ovarian and Peritoneal Carcinoma",947
215,NCT00150657,Phase II,Unknown status,"[{'id': 1294, 'therapyName': 'Gemcitabine + Bevacizumab + Carboplatin'}]",Study of Carboplatin/Gemcitabine Plus Bevacizumab in Advanced Lung Cancer,947
216,NCT01916109,Phase II,Terminated,"[{'id': 1943, 'therapyName': 'Gemcitabine + Carboplatin + Panitumumab'}]","Study of Gemcitabine, Carboplatin, and Panitumumab (GCaP) as Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer",947
217,NCT03085914,Phase Ib/II,Recruiting,"[{'id': 5483, 'therapyName': 'INCB024360 + Nivolumab + mFOLFOX6'}, {'id': 5484, 'therapyName': 'INCB024360 + Nivolumab + Gemcitabine + nab-paclitaxel'}, {'id': 5485, 'therapyName': 'INCB024360 + Pembrolizumab + Carboplatin + Paclitaxel'}, {'id': 5486, 'therapyName': 'INCB024360 + Pembrolizumab + Carboplatin + Pemetrexed'}, {'id': 5487, 'therapyName': 'INCB024360 + Pembrolizumab + Cyclophosphamide'}]",A Study of Epacadostat in Combination With a PD-1 Inhibitor and Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors (ECHO-207),947
218,NCT01593228,Phase III,Completed,"[{'id': 1173, 'therapyName': 'Iniparib + doxorubicin + carboplatin'}, {'id': 1172, 'therapyName': 'Iniparib + Paclitaxel'}, {'id': 1171, 'therapyName': 'Iniparib + Irinotecan'}, {'id': 1170, 'therapyName': 'Iniparib + Topotecan'}, {'id': 1169, 'therapyName': 'Iniparib + Gemcitabine + Carboplatin'}, {'id': 1168, 'therapyName': 'Iniparib'}]", Treatment Extension Study for Patients Who Have Previously Participated and Have Benefited From Iniparib in a Clinical Trial,947
219,NCT01612351,Phase II,"Active, not recruiting","[{'id': 2477, 'therapyName': 'Lapatinib + Carboplatin + Cisplatin + Paclitaxel'}, {'id': 2476, 'therapyName': 'Lapatinib + Carboplatin + Paclitaxel'}]",Multimodality Risk Adapted Tx Including Induction Chemo for SCCHN Amenable to Transoral Surgery,947
220,NCT03056833,Phase I,Recruiting,"[{'id': 5333, 'therapyName': 'LEE011 + Carboplatin + Paclitaxel'}]",Ribociclib (Ribociclib (LEE-011)) With Platinum-based Chemotherapy in Recurrent Platinum Sensitive Ovarian Cancer,947
221,NCT01837862,Phase Ib/II,Recruiting,"[{'id': 2134, 'therapyName': 'Mebendazole + Vincristine + Carboplatin + Temozolomide'}, {'id': 2133, 'therapyName': 'Mebendazole + Bevacizumab + Irinotecan'}]",A Phase I/II Study of Mebendazole for the Treatment of Pediatric Gliomas,947
222,NCT02185690,Phase I,Not yet recruiting,"[{'id': 2213, 'therapyName': 'MEK162 + Carboplatin + Pemetrexed'}]","A Phase I/Ib Study of MEK162, a MEK Inhibitor, in Combination With Carboplatin and Pemetrexed in Patients With Non-squamous Carcinoma of the Lung",947
223,NCT03238495,Phase II,Recruiting,"[{'id': 1879, 'therapyName': 'Pertuzumab + Trastuzumab + Carboplatin + Docetaxel'}, {'id': 6101, 'therapyName': 'Metformin + Pertuzumab + Trastuzumab + Carboplatin + Docetaxel'}]",Randomized Trial of Neo-adjuvant Chemotherapy With or Without Metformin for HER2 Positive Operable Breast Cancer,947
224,NCT01827384,Phase II,Recruiting,"[{'id': 1194, 'therapyName': 'MK-1775 + Carboplatin '}, {'id': 1193, 'therapyName': 'Veliparib + Temozolomide'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 2, 'therapyName': 'Trametinib'}]",Molecular Profiling-Based Targeted Therapy in Treating Patients With Advanced Solid Tumors,947
225,NCT02272790,Phase II,Recruiting,"[{'id': 1194, 'therapyName': 'MK-1775 + Carboplatin '}, {'id': 1279, 'therapyName': 'MK-1775 + Gemcitabine'}, {'id': 1567, 'therapyName': 'MK-1775 + Paclitaxel'}]","A Phase II Study Comparing AZD1775 + Chemotherapy Versus Chemotherapy Alone in Patients to Treat Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.",947
226,NCT00618657,Phase II,"Active, not recruiting","[{'id': 1490, 'therapyName': 'Nab-paclitaxel + Carboplatin + Trastuzumab'}, {'id': 1489, 'therapyName': 'Nab-paclitaxel + Carboplatin + Bevacizumab'}]","Carboplatin+Nab-paclitaxel, Plus Trastuzumab (HER2+) or Bevacizumab (HER2-) in the Neoadjuvant Setting",947
227,NCT02941601,Phase II,Withdrawn,"[{'id': 4973, 'therapyName': 'Necitumumab + Gemcitabine + Carboplatin'}]",A Study of Gemcitabine-Carboplatin Plus Necitumumab (LY3012211) in Chemotherapy-Naïve Participants With Locally Advanced or Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC),947
228,NCT03107182,Phase II,Recruiting,"[{'id': 5581, 'therapyName': 'Dexamethasone + Diphenhydramine + Famotidine + 5FU + Hydroxyurea + Paclitaxel'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 5303, 'therapyName': 'Nivolumab + Carboplatin + Paclitaxel'}]",Oropharyngeal Tumor Induction Chemotherapy and Response-stratified Locoregional Therapy Trial in Order to Minimize Long-term Adverse Events,947
229,NCT03245892,Phase I,Recruiting,"[{'id': 5303, 'therapyName': 'Nivolumab + Carboplatin + Paclitaxel'}]",A Study of Carboplatin and Paclitaxel Chemotherapy With Nivolumab in Patients With Ovarian Cancer,947
230,NCT03044613,Phase I,Recruiting,"[{'id': 5304, 'therapyName': 'Nivolumab + Ipilimumab + Carboplatin + Paclitaxel'}, {'id': 5303, 'therapyName': 'Nivolumab + Carboplatin + Paclitaxel'}]",Nivolumab or Nivolumab/Ipilimumab Prior to Chemoradiation Plus Nivolumab With II/III Gastro/Esophageal Cancer,947
231,NCT03016871,Phase II,Recruiting,"[{'id': 5198, 'therapyName': 'Nivolumab + Etoposide + Ifosfamide + Carboplatin'}]","Nivolumab, Ifosfamide, Carboplatin, and Etoposide as Second-Line Therapy in Treating Patients With Refractory or Relapsed Hodgkin Lymphoma",947
232,NCT02044601,Phase Ib/II,Withdrawn,"[{'id': 1370, 'therapyName': 'Onartuzumab + Paclitaxel + Carboplatin'}, {'id': 1371, 'therapyName': 'Onartuzumab + Erlotinib + Paclitaxel + Carboplatin'}]",Biomarker-Integrated Approach of Targeted Therapy for Lung Cancer Elimination Plus External Beam Radiation Therapy (BATTLE-XRT),947
233,NCT01616303,Phase II,"Active, not recruiting","[{'id': 1190, 'therapyName': 'Oregovomab + Carboplatin + Paclitaxel'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]", A Controlled Study of the Effectiveness of Oregovomab (Antibody) Plus Chemotherapy in Advanced Ovarian Cancer,947
234,NCT02317874,Phase I,Recruiting,"[{'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 682, 'therapyName': 'Talazoparib'}]","PARP Inhibitor BMN-673, Carboplatin, and Paclitaxel in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery",947
235,NCT02513563,Phase II,Recruiting,"[{'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 822, 'therapyName': 'MK-1775'}]",AZD1775 Plus Carboplatin-Paclitaxel in Squamous Cell Lung Cancer,947
236,NCT00954174,Phase III,"Active, not recruiting","[{'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 1125, 'therapyName': 'Paclitaxel + Ifosfamide'}]","Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritorium Cavity Cancer",947
237,NCT02713386,Phase Ib/II,Recruiting,"[{'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]","Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",947
238,NCT02718417,Phase III,Recruiting,"[{'id': 3144, 'therapyName': 'Avelumab'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]",Avelumab in Previously Untreated Patients With Epithelial Ovarian Cancer (JAVELIN OVARIAN 100),947
239,NCT02051868,Phase II,Recruiting,"[{'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 1833, 'therapyName': 'Cisplatin + Fluorouracil'}]",International Multicentre Study in Advanced Anal Cancer Comparing Cisplatin Plus 5 FU vs Carboplatin Plus Weekly Paclitaxel (InterAACT),947
240,NCT02453282,Phase III,"Active, not recruiting","[{'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 1467, 'therapyName': 'Gemcitabine + Cisplatin'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 1652, 'therapyName': 'Tremelimumab'}]",Phase III Open Label First Line Therapy Study of MEDI 4736 With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC).,947
241,NCT02106546,Phase III,"Active, not recruiting","[{'id': 954, 'therapyName': 'Veliparib'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]","Randomized, Double-Blind, Multicenter, Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Previously Untreated Advanced or Metastatic Squamous Non-Small Cell Lung Cancer",947
242,NCT02530437,Phase Ib/II,Recruiting,"[{'id': 1587, 'therapyName': 'Taladegib'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]","A Phase 1B/2 Study of LY2940680 in Combination With Weekly Paclitaxel, Carboplatin, and Radiation in Localized Adenocarcinoma of the Esophagus or Gastroesophageal Junction",947
243,NCT01769391,Phase II,"Active, not recruiting","[{'id': 826, 'therapyName': 'Necitumumab'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]",A Study of Necitumumab and Chemotherapy in Participants With Stage IV Squamous Non-Small Cell Lung Cancer,947
244,NCT02520154,Phase II,Recruiting,"[{'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab in Combination With Chemotherapy in Frontline Ovarian Cancer,947
245,NCT02358200,Phase I,"Active, not recruiting","[{'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 682, 'therapyName': 'Talazoparib'}]",Study of BMN-673 With Carboplatin and Paclitaxel in Patients With Advanced BRCA-mutated Solid Tumor or Triple Negative Metastatic Breast Cancer,947
246,NCT01578551,Phase II,"Active, not recruiting","[{'id': 1031, 'therapyName': 'Metformin'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 667, 'therapyName': 'Bevacizumab'}]",A Randomized Phase II Study of Metformin Plus Paclitaxel/Carboplatin/Bevacizumab in Patients With Adenocarcinoma.,947
247,NCT02998268,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]",Study of Pembrolizumab in Locally Advanced Esophageal Adenocarcinoma,947
248,NCT02124421,Phase II,Recruiting,"[{'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 1812, 'therapyName': 'Cisplatin + Paclitaxel'}]","Outcomes in CRS/HIPEC as Initial Treatment of Ovarian, Fallopian Tube and Primary Peritoneal Cancer",947
249,NCT01196390,Phase III,"Active, not recruiting","[{'id': 1887, 'therapyName': 'Paclitaxel + Carboplatin + Trastuzumab'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]","Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer",947
250,NCT01367002,Phase II,"Active, not recruiting","[{'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]",Evaluation of Carboplatin/Paclitaxel With and Without Trastuzumab (Herceptin) in Uterine Serous Cancer,947
251,NCT02436993,Phase II,Recruiting,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]",Breast Cancer Treatment Using Weekly Carboplatin + Paclitaxel With Pertuzumab + Trastuzumab (HER2+) or Bevacizumab (HER2-) in the Neoadjuvant Setting,947
252,NCT02163694,Phase III,Recruiting,"[{'id': 954, 'therapyName': 'Veliparib'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]","A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Cancer",947
253,NCT02525757,Phase II,Recruiting,"[{'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]",MPDL3280A With Chemoradiation for Lung Cancer,947
254,NCT02730546,Phase Ib/II,Suspended,"[{'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]","Pembrolizumab, Combination Chemotherapy, and Radiation Therapy Before Surgery in Treating Adult Patients With Locally Advanced Gastroesophageal Junction or Gastric Cardia Cancer That Can Be Removed by Surgery",947
255,NCT00980954,Phase III,Recruiting,"[{'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 700, 'therapyName': 'Cisplatin'}]",Chemotherapy and Pelvic Radiation Therapy With or Without Additional Chemotherapy in Treating Patients With High-Risk Early-Stage Cervical Cancer After Radical Hysterectomy,947
256,NCT02272413,Phase III,"Active, not recruiting","[{'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 667, 'therapyName': 'Bevacizumab'}]",Phase III Trial BI 695502 Plus Chemotherapy vs. Avastin Plus Chemotherapy in Patients With Lung Cancer,947
257,NCT02220894,Phase III,Recruiting,"[{'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Study of MK-3475 (Pembrolizumab) Versus Platinum-based Chemotherapy for Participants With PD-L1-positive Advanced or Metastatic Non-small Cell Lung Cancer (MK-3475-042/KEYNOTE-042),947
258,NCT02186847,Phase II,"Active, not recruiting","[{'id': 1031, 'therapyName': 'Metformin'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]",Chemotherapy and Radiation Therapy With or Without Metformin Hydrochloride in Treating Patients With Stage III Non-small Cell Lung Cancer,947
259,NCT03036488,Phase III,Recruiting,"[{'id': 1087, 'therapyName': 'Epirubicin + Cyclophosphamide'}, {'id': 1977, 'therapyName': 'Doxorubicin + Cyclophosphamide'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]",Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522),947
260,NCT02065687,Phase III,Recruiting,"[{'id': 1381, 'therapyName': 'Paclitaxel + Carboplatin + Metformin'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]","Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer",947
261,NCT02412371,Phase II,Recruiting,"[{'id': 954, 'therapyName': 'Veliparib'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]",A Study Evaluating the Efficacy and Tolerability of Veliparib in Combination With Paclitaxel/Carboplatin-Based Chemoradiotherapy Followed by Veliparib and Paclitaxel/Carboplatin Consolidation in Subjects With Stage III Non-Small Cell Lung Cancer,947
262,NCT01966003,Phase III,Completed,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 2141, 'therapyName': 'Bevacizumab-awwb'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]",Efficacy and Safety Study of ABP 215 Compared With Bevacizumab in Subjects With Advanced Non-Small Cell Lung Cancer,947
263,NCT02476955,Phase I,Recruiting,"[{'id': 635, 'therapyName': 'ARQ092'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]",Open-label Phase 1b Study of ARQ 092 in Combination With Carboplatin Plus Paclitaxel,947
264,NCT02429843,Phase I,Recruiting,"[{'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1242, 'therapyName': 'TRC105'}]",A Study of TRC105 in Combination With Paclitaxel/Carboplatin and Bevacizumab in Non-Squamous Cell Lung Cancer,947
265,NCT00979212,Phase II,"Active, not recruiting","[{'id': 845, 'therapyName': 'Panitumumab'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]",Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer (Cetuximab Closed as of 05/14/10),947
266,NCT01868022,Phase I,"Active, not recruiting","[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1857, 'therapyName': 'Cisplatin + Pemetrexed'}, {'id': 2899, 'therapyName': 'GSK3052230'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]","Study to Evaluate GSK3052230 in Combination With Paclitaxel and Carboplatin, or Docetaxel or as Single Agent in Subjects With Solid Malignancies and Deregulated Fibroblast Growth Factor (FGF) Pathway Signaling",947
267,NCT02122185,Phase II,Recruiting,"[{'id': 1031, 'therapyName': 'Metformin'}, {'id': 1827, 'therapyName': 'Paclitaxel + Carboplatin + Docetaxel'}]","Metformin Hydrochloride and Combination Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",947
268,NCT02050009,Phase I,Withdrawn,"[{'id': 1381, 'therapyName': 'Paclitaxel + Carboplatin + Metformin'}]","Metformin Hydrochloride, Carboplatin, and Paclitaxel in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",947
269,NCT01036087,Phase II,"Active, not recruiting","[{'id': 1984, 'therapyName': 'Panitumumab + Abraxane + Carboplatin'}, {'id': 1982, 'therapyName': 'Fluorouracil + Epirubicin + Cyclophosphamide'}]","Panitumumab, Nab-paclitaxel and Carboplatin for HER2 Negative Inflammatory Breast Cancer",947
270,NCT03077828,Phase II,Recruiting,"[{'id': 5435, 'therapyName': 'Pembrolizumab + Etoposide + Carboplatin + Ifosfamide'}]",Pembrolizumab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma,947
271,NCT02003209,Phase III,"Active, not recruiting","[{'id': 759, 'therapyName': 'Goserelin'}, {'id': 1879, 'therapyName': 'Pertuzumab + Trastuzumab + Carboplatin + Docetaxel'}]","Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer",947
272,NCT02131064,Phase III,"Active, not recruiting","[{'id': 1492, 'therapyName': 'T-DM1 + Pertuzumab'}, {'id': 1879, 'therapyName': 'Pertuzumab + Trastuzumab + Carboplatin + Docetaxel'}]",A Study Comparing Kadcyla Plus Perjeta Treatment to Chemotherapy Combined With Herceptin Plus Perjeta in Patients With HER2-Positive Breast Cancer,947
273,NCT02383212,Phase I,"Active, not recruiting","[{'id': 5722, 'therapyName': 'REGN2810 + Carboplatin + Docetaxel'}, {'id': 5721, 'therapyName': 'REGN2810 + Carboplatin + Pemetrexed'}, {'id': 5723, 'therapyName': 'REGN2810 + GM-CSF + Cyclophosphamide'}, {'id': 5718, 'therapyName': 'REGN2810 + Cyclophosphamide'}, {'id': 5656, 'therapyName': 'REGN2810'}, {'id': 5720, 'therapyName': 'REGN2810 + Carboplatin + Paclitaxel'}, {'id': 5719, 'therapyName': 'REGN2810 + Docetaxel'}]",Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies,947
274,NCT01959490,Phase II,Completed,"[{'id': 1486, 'therapyName': 'Bevacizumab + Doxorubicin + Cyclophosphamide + Paclitaxel '}, {'id': 1485, 'therapyName': 'Trastuzumab + Docetaxel + Carboplatin'}]",Trastuzumab or Bevacizumab With Combination Chemotherapy in Treating Patients With Stage II-III Breast Cancer,947
275,NCT02187744,Phase III,Completed,"[{'id': 1485, 'therapyName': 'Trastuzumab + Docetaxel + Carboplatin'}]",A Study Of PF-05280014 Or Trastuzumab Plus Taxotere&#174; And Carboplatin In HER2 Positive Breast Cancer In The Neoadjuvant Setting (REFLECTIONS B327-04),947
276,NCT01501487,FDA approved,"Active, not recruiting","[{'id': 1902, 'therapyName': 'Docetaxel + Doxorubicin + Cyclophosphamide'}, {'id': 1982, 'therapyName': 'Fluorouracil + Epirubicin + Cyclophosphamide'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1476, 'therapyName': 'Pegfilgrastim'}, {'id': 1881, 'therapyName': 'Docetaxel + Cyclophosphamide'}, {'id': 1977, 'therapyName': 'Doxorubicin + Cyclophosphamide'}, {'id': 1485, 'therapyName': 'Trastuzumab + Docetaxel + Carboplatin'}, {'id': 1978, 'therapyName': 'Pertuzumab + Trastuzumab + Docetaxel'}]",MINT I Multi- Institutional Neo-adjuvant Therapy MammaPrint Project I,947
277,NCT01434316,Phase I,Recruiting,"[{'id': 1277, 'therapyName': 'Veliparib + Dinaciclib'}, {'id': 1278, 'therapyName': 'Veliparib + Dinaciclib + carboplatin'}]",Veliparib and Dinaciclib With or Without Carboplatin in Treating Patients With Advanced Solid Tumors,947
278,NCT01636622,Phase I,"Active, not recruiting","[{'id': 1209, 'therapyName': 'Vemurafenib + Carboplatin + Paclitaxel '}]"," Study of Vemurafenib, Carboplatin, and Paclitaxel",947
279,NCT03064867,Phase I,Recruiting,"[{'id': 5404, 'therapyName': 'Venetoclax + Rituximab + Ifosfamide + Carboplatin + Etoposide'}]",Venetoclax Plus R-ICE Chemotherapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma,947
0,NCT01107522,Phase I,"Active, not recruiting","[{'id': 1142, 'therapyName': 'CTO + Temozolomide'}, {'id': 999, 'therapyName': 'Carboxyamidotriazole Orotate'}]",Safety and Tolerability of Carboxyamidotriazole Orotate (CTO) in Solid Tumors or With Temodar&#174; in Glioblastoma or Other Recurrent Malignant Gliomas or in Combination With Temodar&#174; and Radiation Therapy for Patients With Newly Diagnosed Glioblastoma and Malignant Gliomas,7118
1,NCT01989052,Phase Ib/II,Terminated,"[{'id': 2075, 'therapyName': 'Lomustine'}, {'id': 999, 'therapyName': 'Carboxyamidotriazole Orotate'}]",Ph 1/2 CTO With Lomustine for Bevacizumab-Naive Recurrent Glioma,7118
2,NCT01954030,Phase Ib/II,Terminated,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 999, 'therapyName': 'Carboxyamidotriazole Orotate'}]",Phase 1/2 CTO + Bevacizumab for Recurrent Glioma Post-Bevacizumab Failure,7118
0,NCT02235740,Phase I,Terminated,"[{'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 1839, 'therapyName': 'Afuresertib + Carfilzomib'}]","A Study Conducted in Subjects With Relapsed/Refractory Multiple Myeloma (MM); to Determine Dose of Afuresertib in Combination With Carfilzomib (Part 1) and to Investigate the Safety, Pharmacokinetic and Clinical Activity of the Combination Compared With Carfilzomib Alone (Part 2)",7299
1,NCT02188368,Phase II,Recruiting,"[{'id': 1625, 'therapyName': 'Bortezomib + Carfilzomib + Clarithromycin'}, {'id': 1674, 'therapyName': 'Doxil + Pomalidomide'}, {'id': 1622, 'therapyName': 'Pomalidomide'}]",Pomalidomide for Lenalidomide for Failures,7299
2,NCT02512926,Phase I,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 1136, 'therapyName': 'Etoposide'}]",Carfilzomib in Combination With Cyclophosphamide and Etoposide for Children,7299
3,NCT03004287,Phase II,Recruiting,"[{'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1164, 'therapyName': 'lenalidomide'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 1630, 'therapyName': 'Daratumumab'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1475, 'therapyName': 'Thalidomide'}]",2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy,7299
4,NCT02788201,Phase II,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1133, 'therapyName': 'Mitomycin C'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1013, 'therapyName': 'epirubicin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1137, 'therapyName': 'Bleomycin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 781, 'therapyName': 'Ixabepilone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 2950, 'therapyName': 'Estramustine'}, {'id': 1941, 'therapyName': 'Floxuridine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 1811, 'therapyName': 'Carmustine'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 953, 'therapyName': 'Vandetanib'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 4419, 'therapyName': 'Toremifine'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 2601, 'therapyName': 'Dactinomycin'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 3035, 'therapyName': 'Chlorambucil'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 342, 'therapyName': 'Vemurafenib'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 2635, 'therapyName': 'Vinblastine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 4305, 'therapyName': 'Teniposide'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 4304, 'therapyName': 'Streptozocin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1231, 'therapyName': 'Bendamustine'}, {'id': 4303, 'therapyName': 'Mechlorethamine'}, {'id': 4302, 'therapyName': 'Mitotane'}]",Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma,7299
5,NCT01863550,Phase III,Recruiting,"[{'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 1164, 'therapyName': 'lenalidomide'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 688, 'therapyName': 'Bortezomib'}]",Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma,7299
6,NCT02265510,Phase I,Recruiting,"[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 1164, 'therapyName': 'lenalidomide'}, {'id': 619, 'therapyName': 'Abraxane'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 2747, 'therapyName': 'INCB052793'}, {'id': 688, 'therapyName': 'Bortezomib'}]","An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies",7299
7,NCT02551718,Phase I,Recruiting,"[{'id': 690, 'therapyName': 'Bosutinib'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 3160, 'therapyName': 'Nelarabine'}, {'id': 3159, 'therapyName': 'Bexarotene'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 998, 'therapyName': 'cabozantinib'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 877, 'therapyName': 'Ponatinib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 623, 'therapyName': 'Afatinib'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 890, 'therapyName': 'Regorafenib'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 2, 'therapyName': 'Trametinib'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 3, 'therapyName': 'Dabrafenib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 789, 'therapyName': 'Ceritinib'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1571, 'therapyName': 'Cabazitaxel'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1327, 'therapyName': 'Pralatrexate'}]",High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia,7299
8,NCT01998971,Phase I,Recruiting,"[{'id': 1622, 'therapyName': 'Pomalidomide'}, {'id': 2470, 'therapyName': 'Bortezomib + Dexamethasone'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1475, 'therapyName': 'Thalidomide'}, {'id': 1164, 'therapyName': 'lenalidomide'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 1630, 'therapyName': 'Daratumumab'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 1275, 'therapyName': 'Diphenhydramine'}, {'id': 3323, 'therapyName': 'Montelukast'}]",A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma,7299
9,NCT02142530,Phase I,Recruiting,"[{'id': 1078, 'therapyName': 'Belinostat'}, {'id': 1624, 'therapyName': 'Carfilzomib'}]",Carfilzomib Plus Belinostat in Relapsed/Refractory NHL,7299
10,NCT02802163,Phase Ib/II,Withdrawn,"[{'id': 4367, 'therapyName': 'Carfilzomib + Dexamethasone + lenalidomide + Panobinostat'}]","Induction Therapy for Multiple Myeloma With Carfilzomib, Lenalidomide,Dexamethasone,Panobinostat",7299
11,NCT03256045,Phase II,Not yet recruiting,"[{'id': 6289, 'therapyName': 'Carfilzomib + Dexamethasone + Panobinostat'}]","Panobinostat, Carfilzomib and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma",7299
12,NCT02101944,Phase I,Recruiting,"[{'id': 2463, 'therapyName': 'Carfilzomib + Dexamethasone + Reolysin'}]","Viral Protein Production After Dexamethasone, Wild-Type Reovirus, and Carfilzomib in Treating Patients With Multiple Myeloma",7299
13,NCT02199665,Phase I,"Active, not recruiting","[{'id': 2985, 'therapyName': 'Carfilzomib + Dexamethasone + Selinexor'}]","Selinexor, Carfilzomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma",7299
14,NCT02628704,Phase II,Withdrawn,"[{'id': 2985, 'therapyName': 'Carfilzomib + Dexamethasone + Selinexor'}]","Selinexor, Carfilzomib, and Dexamethasone Versus Placebo, Carfilzomib, and Dexamethasone in Multiple Myeloma",7299
15,NCT02899052,Phase II,Recruiting,"[{'id': 5268, 'therapyName': 'Carfilzomib + Dexamethasone + Venetoclax'}]",Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma (MM),7299
16,NCT02969837,Phase II,Recruiting,"[{'id': 5033, 'therapyName': 'Carfilzomib + Elotuzumab + Dexamethasone + lenalidomide'}]","Study of Initial Treatment With Elotuzumab, Carfilzomib, Lenalidomide and Dexamethasone in Multiple Myeloma",7299
17,NCT03104270,Phase II,Recruiting,"[{'id': 5555, 'therapyName': 'Carfilzomib + Elotuzumab + Dexamethasone + Pomalidomide'}]",Combination Study for High Risk Multiple Myeloma Patients,7299
18,NCT01962792,Phase Ib/II,Recruiting,"[{'id': 3282, 'therapyName': 'Carfilzomib + Ibrutinib'}, {'id': 1390, 'therapyName': 'Dexamethasone'}]","Study of the Bruton's Tyrosine Kinase Inhibitor in Combination With Carfilzomib (Kyprolis), in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma",7299
19,NCT02269085,Phase Ib/II,"Active, not recruiting","[{'id': 3282, 'therapyName': 'Carfilzomib + Ibrutinib'}]",A Phase I/II Trial of PCI-32765 (BTK Inhibitor) in Combination With Carfilzomib in Relapse/Refractory Mantle Cell Lymphoma,7299
20,NCT01301807,Phase I,"Active, not recruiting","[{'id': 3438, 'therapyName': 'Carfilzomib + Panobinostat'}]",Carfilzomib Plus Panobinostat in Relapsed/Refractory Multiple Myeloma (MM),7299
21,NCT02073097,Phase Ib/II,Recruiting,"[{'id': 2351, 'therapyName': 'Carfilzomib + Rituximab'}, {'id': 2353, 'therapyName': 'Cyclophosphamide + Doxorubicin + Vincristine '}]","Carfilzomib, Rituximab, and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Lymphoma",7299
22,NCT01959698,Phase Ib/II,Recruiting,"[{'id': 2351, 'therapyName': 'Carfilzomib + Rituximab'}, {'id': 2352, 'therapyName': 'Carboplatin + Etoposide + Ifosfamide '}]","Carfilzomib, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma",7299
23,NCT02867618,Phase Ib/II,Recruiting,"[{'id': 4598, 'therapyName': 'Carfilzomib + TGR-1202'}]",Carfilzomib and TGR-1202 in Treatment of R/R Lymphoma,7299
0,NCT01476839,Phase I,Recruiting,"[{'id': 6258, 'therapyName': 'Basiliximab + 90Y basiliximab + Carmustine + Cytarbine + Etoposide + Melphalan'}]",Radiolabeled Monoclonal Antibody Therapy and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Primary Refractory or Relapsed Hodgkin Lymphoma,255
1,NCT02348255,Phase II,Withdrawn,"[{'id': 2371, 'therapyName': 'Bevacizumab + Carmustine'}]",NovoTTF-100A in Combination With Bevacizumab and Carmustine in Treating Patients With Glioblastoma Multiforme in First Relapse,255
2,NCT02342782,Phase I,Recruiting,"[{'id': 2485, 'therapyName': '90Y basiliximab'}, {'id': 1811, 'therapyName': 'Carmustine'}, {'id': 2392, 'therapyName': 'Cytarabine + Etoposide'}, {'id': 1207, 'therapyName': 'Melphalan'}]",Yttrium Y 90 Basiliximab and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Mature T-cell Non-Hodgkin Lymphoma,255
3,NCT02343666,Phase I,Recruiting,"[{'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1811, 'therapyName': 'Carmustine'}, {'id': 1756, 'therapyName': 'Plerixafor'}, {'id': 2556, 'therapyName': 'O6-benzylguanine'}]",HIV-Resistant Gene Modified Stem Cells and Chemotherapy in Treating Patients With Lymphoma With HIV Infection,255
4,NCT02788201,Phase II,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1133, 'therapyName': 'Mitomycin C'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1013, 'therapyName': 'epirubicin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1137, 'therapyName': 'Bleomycin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 781, 'therapyName': 'Ixabepilone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 2950, 'therapyName': 'Estramustine'}, {'id': 1941, 'therapyName': 'Floxuridine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 1811, 'therapyName': 'Carmustine'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 953, 'therapyName': 'Vandetanib'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 4419, 'therapyName': 'Toremifine'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 2601, 'therapyName': 'Dactinomycin'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 3035, 'therapyName': 'Chlorambucil'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 342, 'therapyName': 'Vemurafenib'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 2635, 'therapyName': 'Vinblastine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 4305, 'therapyName': 'Teniposide'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 4304, 'therapyName': 'Streptozocin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1231, 'therapyName': 'Bendamustine'}, {'id': 4303, 'therapyName': 'Mechlorethamine'}, {'id': 4302, 'therapyName': 'Mitotane'}]",Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma,255
5,NCT02570542,Phase II,Recruiting,"[{'id': 1756, 'therapyName': 'Plerixafor'}, {'id': 3359, 'therapyName': 'Carmustine + Cytarabine + Etoposide + Melphalan'}]",Impact of CD34+ Cell Dose on Progression-free Survival Following High-Dose Therapy and Autologous Stem Cell Transplantation for Relapsed and Refractory Diffuse Large B-cell Lymphoma (DLBCL),255
6,NCT02443077,Phase III,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 3359, 'therapyName': 'Carmustine + Cytarabine + Etoposide + Melphalan'}, {'id': 768, 'therapyName': 'Ibrutinib'}]",Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma,255
7,NCT00669669,Phase Ib/II,"Active, not recruiting","[{'id': 2556, 'therapyName': 'O6-benzylguanine'}, {'id': 2555, 'therapyName': 'Carmustine + Filgrastim + Plerixafor + Temozolomide'}]",Dose-Intensive Chemotherapy in Combination With Chemoprotected Autologous Stem Cells in Treating Patients With Malignant Gliomas,255
0,NCT02935543,Phase II,Recruiting,"[{'id': 5999, 'therapyName': 'CART19 cells'}]",CART19 in Patient With ALL,8887
1,NCT02640209,Phase I,Recruiting,"[{'id': 5999, 'therapyName': 'CART19 cells'}]",Pilot Trial Of Autologous T Cells Engineered To Express Anti-CD19 Chimeric Antigen Receptor (CART19)In Combination With Ibrutinib In Patients With Relapsed Or Refractory CD19+ Chronic Lymphocytic Leukemia (CLL)Or Small Lymphocytic Lymphoma (SLL),8887
0,NCT02903914,Phase I,Recruiting,"[{'id': 4722, 'therapyName': 'CB-1158 + Nivolumab'}, {'id': 4721, 'therapyName': 'CB-1158'}]",Arginase Inhibitor CB-1158 in Patients With Solid Tumors,8531
0,NCT02223598,Phase I,Terminated,"[{'id': 1944, 'therapyName': 'CB-5083'}, {'id': 4513, 'therapyName': 'CB-5083 + Dexamethasone'}]",A Phase 1 Study Evaluating CB-5083 in Subjects With Lymphoid Hematological Malignancies  (CLC-102),7366
1,NCT02243917,Phase I,"Active, not recruiting","[{'id': 1944, 'therapyName': 'CB-5083'}]",A Phase 1 Study Evaluating CB-5083 in Patients With Advanced Solid Tumors,7366
0,NCT02071927,Phase I,Completed,"[{'id': 1667, 'therapyName': 'CB-839'}]",Study of the Glutaminase Inhibitor CB-839 in Leukemia,7312
1,NCT02071862,Phase I,Recruiting,"[{'id': 1667, 'therapyName': 'CB-839'}]",Study of the Glutaminase Inhibitor CB-839 in Solid Tumors,7312
2,NCT03263429,Phase Ib/II,Recruiting,"[{'id': 6158, 'therapyName': 'CB-839 + Irinotecan + Panitumumab'}]",Novel PET/CT Imaging Biomarkers of CB-839 in Combination With Panitumumab and Irinotecan in Patients With Metastatic and Refractory RAS Wildtype Colorectal Cancer,7312
3,NCT02771626,Phase Ib/II,Recruiting,"[{'id': 4274, 'therapyName': 'CB-839 + Nivolumab'}]",Study CB-839 in Combination With Nivolumab in Patients With ccRCC and Other Solid Tumors,7312
0,NCT01905228,Phase I,Recruiting,"[{'id': 3940, 'therapyName': 'CBL0137 '}]",A Phase 1 Trial of CBL0137 in Patients With Metastatic or Unresectable Advanced Solid Neoplasm or Refractory Lymphomas,8304
0,NCT03113188,Phase I,Recruiting,"[{'id': 6186, 'therapyName': 'CBP501 + Cisplatin + Nivolumab'}]","CBP501, Cisplatin and Nivolumab in Advanced Refractory Tumors",8480
0,NCT03175224,Phase I,Recruiting,"[{'id': 5963, 'therapyName': 'CBT-101'}]",CBT-101 Study for Advanced Solid Tumors and c-Met Dysregulation,8873
0,NCT02977780,Phase II,Recruiting,"[{'id': 1000, 'therapyName': 'CC-115'}, {'id': 5028, 'therapyName': 'Abemaciclib + Temozolomide'}, {'id': 1141, 'therapyName': 'Temozolomide'}, {'id': 5029, 'therapyName': 'Neratinib + Temozolomide'}]",INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT),7119
1,NCT01353625,Phase I,"Active, not recruiting","[{'id': 1000, 'therapyName': 'CC-115'}]","Study to Assess Safety and Tolerability of Oral CC-115 for Patients With Advanced Solid Tumors, and Hematologic Malignancies.",7119
2,NCT02833883,Phase I,Recruiting,"[{'id': 4459, 'therapyName': 'CC-115 + Enzalutamide'}]","Use of an Experimental Drug, CC-115, With Enzalutamide in Men With Castration-Resistant Prostate Cancer",7119
0,NCT02406742,Phase Ib/II,Recruiting,"[{'id': 1646, 'therapyName': 'Obinutuzumab'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 768, 'therapyName': 'Ibrutinib'}, {'id': 2358, 'therapyName': 'CC-122'}]","A Phase 1/2, Open-label, Dose Finding Study to Evaluate CC-122 in Combination With Rituximab, Ibrutinib and Obinutuzumab in Subjects With Relapsed/Refractory CLL/SLL (ENHANCE)",7500
1,NCT01421524,Phase I,Recruiting,"[{'id': 2358, 'therapyName': 'CC-122'}]","Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma",7500
2,NCT02031419,Phase I,Recruiting,"[{'id': 2376, 'therapyName': 'CC-122 + CC-292'}, {'id': 2377, 'therapyName': 'CC-223 + CC-292'}, {'id': 2375, 'therapyName': 'CC-122 + CC-223'}, {'id': 897, 'therapyName': 'Rituximab'}]","Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-cell Lymphoma",7500
3,NCT02859324,Phase Ib/II,Recruiting,"[{'id': 4611, 'therapyName': 'CC-122 + Nivolumab'}]",A Safety and Efficacy Study of CC-122 in Combination With Nivolumab in Subjects With Unresectable Hepatocellular Carcinoma (HCC),7500
4,NCT02323906,Phase Ib/II,Terminated,"[{'id': 2430, 'therapyName': 'Sorafenib + CC-122'}]",Safety and Efficacy Study of CC-122 Combined With Sorafenib for Primary Liver Cancer,7500
0,NCT01545947,Phase I,Completed,"[{'id': 1149, 'therapyName': 'Azacitidine + CC-223'}, {'id': 1147, 'therapyName': 'Erlotinib + CC-223'}]"," Study Assessing Safety, Pharmacokinetics and Efficacy of CC-223 With Either Erlotinib or Oral Azacitidine in Advanced Non-Small Cell Lung Cancer",6884
1,NCT02031419,Phase I,Recruiting,"[{'id': 2376, 'therapyName': 'CC-122 + CC-292'}, {'id': 2377, 'therapyName': 'CC-223 + CC-292'}, {'id': 2375, 'therapyName': 'CC-122 + CC-223'}, {'id': 897, 'therapyName': 'Rituximab'}]","Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-cell Lymphoma",6884
2,NCT01177397,Phase Ib/II,Completed,"[{'id': 693, 'therapyName': 'CC-223'}]","Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma",6884
0,NCT02031419,Phase I,Recruiting,"[{'id': 2376, 'therapyName': 'CC-122 + CC-292'}, {'id': 2377, 'therapyName': 'CC-223 + CC-292'}, {'id': 2375, 'therapyName': 'CC-122 + CC-223'}, {'id': 897, 'therapyName': 'Rituximab'}]","Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-cell Lymphoma",7501
0,NCT02313012,Phase I,Terminated,"[{'id': 2874, 'therapyName': 'CC-90003'}]",Safety and PK Study of CC-90003 in Relapsed/Refractory Solid Tumors,7807
0,NCT01312376,Phase I,"Active, not recruiting","[{'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1227, 'therapyName': 'CD3/CD28 costimulated vaccine-primed autologous T-cells'}, {'id': 1222, 'therapyName': 'OC-DC vaccine'}]",Autologous T-Cells Combined With Autologous OC-DC Vaccine in Ovarian Cancer,7224
0,NCT02837991,Phase Ib/II,Recruiting,"[{'id': 5774, 'therapyName': 'CDX-014'}]","A Dose Escalation, Safety and Activity Study of CDX-014 in Patients With Advanced or Metastatic Renal Cell Carcinoma",8793
0,NCT02642016,Phase I,Recruiting,"[{'id': 4037, 'therapyName': 'CDX-0158'}]",A Study to Evaluate the Safety and Pharmacokinetics of KTN0158 in Adult Patients With Advanced Solid Tumors,8332
0,NCT02129075,Phase II,"Active, not recruiting","[{'id': 3006, 'therapyName': 'NeoVax melanoma vaccine'}, {'id': 3007, 'therapyName': 'CDX-301'}, {'id': 1324, 'therapyName': 'DEC-205-NY-ESO-1 fusion protein vaccine'}]",CDX-1401 and Poly-ICLC Vaccine Therapy With or Without CDX-301in Treating Patients With Stage IIB-IV Melanoma,7904
1,NCT02200380,Phase II,Terminated,"[{'id': 1756, 'therapyName': 'Plerixafor'}, {'id': 3007, 'therapyName': 'CDX-301'}]",A Safety and Tolerability Study of CDX-301 With or Without Plerixafor for Stem Cell Mobilization in Matched Related Allogeneic Donor/Recipient Sibling Transplant Pairs,7904
2,NCT01976585,Phase Ib/II,Recruiting,"[{'id': 4337, 'therapyName': 'CDX-301 + poly ICLC '}]",In Situ Vaccine for Low-Grade Lymphoma: Combination of Intratumoral Flt3L and Poly-ICLC With Low-Dose Radiotherapy,7904
0,NCT02014909,Phase I,Completed,"[{'id': 2054, 'therapyName': 'CDX-3379'}, {'id': 2063, 'therapyName': 'CDX-3379 + Vemurafenib'}, {'id': 2064, 'therapyName': 'CDX-3379 + Trastuzumab'}, {'id': 2061, 'therapyName': 'Cetuximab + CDX-3379'}, {'id': 2062, 'therapyName': 'CDX-3379 + Erlotinib'}]",A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of KTN3379 in Adult Subjects With Advanced Tumors,7410
1,NCT02473731,Phase I,Completed,"[{'id': 2054, 'therapyName': 'CDX-3379'}]",A Window of Opportunity Study of KTN3379 in Surgically Resectable Head and Neck Cancer Patients,7410
2,NCT02456701,Phase I,Completed,"[{'id': 2063, 'therapyName': 'CDX-3379 + Vemurafenib'}]",Enhancing Radioiodine Incorporation Into BRAF Mutant Thyroid Cancers With the Combination of Vemurafenib and KTN3379,7410
3,NCT03254927,Phase II,Not yet recruiting,"[{'id': 2061, 'therapyName': 'Cetuximab + CDX-3379'}]",A Study of CDX-3379 and Cetuximab and in Patients With Advanced Head and Neck Squamous Cell Carcinoma,7410
0,NCT00942877,Phase II,"Active, not recruiting","[{'id': 1001, 'therapyName': 'Cediranib'}]",Phase II Study of Cediranib (AZD2171) in Patients With Alveolar Soft Part Sarcoma,7120
1,NCT01391962,Phase II,Recruiting,"[{'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1001, 'therapyName': 'Cediranib'}]",Sunitinib or Cediranib for Alveolar Soft Part Sarcoma,7120
2,NCT02502266,Phase II,Suspended,"[{'id': 942, 'therapyName': 'Topotecan'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 837, 'therapyName': 'Olaparib'}, {'id': 1001, 'therapyName': 'Cediranib'}]","Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",7120
3,NCT01208051,Phase Ib/II,"Active, not recruiting","[{'id': 2437, 'therapyName': 'Cediranib + Lenalidomide'}, {'id': 1001, 'therapyName': 'Cediranib'}]",Cediranib Maleate With or Without Lenalidomide in Treating Patients With Thyroid Cancer,7120
4,NCT02446600,Phase III,Recruiting,"[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 837, 'therapyName': 'Olaparib'}, {'id': 1001, 'therapyName': 'Cediranib'}]","Olaparib or Cediranib Maleate and Olaparib Compared With Standard Platinum-Based Chemotherapy in Treating Patients With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",7120
5,NCT01064648,Phase Ib/II,"Active, not recruiting","[{'id': 2432, 'therapyName': 'Cediranib + Cisplatin + Pemetrexed'}]",Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma,7120
6,NCT02484404,Phase Ib/II,Recruiting,"[{'id': 2895, 'therapyName': 'Cediranib + Durvalumab'}, {'id': 2894, 'therapyName': 'Durvalumab + Olaparib'}]",Phase 1 and 2 Study of MEDI4736 in Combination With Olaparib or Cediranib for Advanced Solid Tumors and Recurrent Ovarian Cancer,7120
7,NCT02345265,Phase II,"Active, not recruiting","[{'id': 1971, 'therapyName': 'Cediranib + Olaparib'}]","Olaparib and Cediranib Maleate in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer",7120
8,NCT02893917,Phase II,Recruiting,"[{'id': 1971, 'therapyName': 'Cediranib + Olaparib'}, {'id': 837, 'therapyName': 'Olaparib'}]",Olaparib With or Without Cediranib in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer,7120
9,NCT02498613,Phase II,Recruiting,"[{'id': 1971, 'therapyName': 'Cediranib + Olaparib'}]",Cediranib Maleate and Olaparib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery,7120
10,NCT02340611,Phase II,Recruiting,"[{'id': 1971, 'therapyName': 'Cediranib + Olaparib'}]",A Study of Cediranib and Olaparib at the Time Ovarian Cancer Worsens on Olaparib,7120
11,NCT02681237,Phase I,Recruiting,"[{'id': 1971, 'therapyName': 'Cediranib + Olaparib'}]",A Study of Cediranib and Olaparib at Disease Worsening in Ovarian Cancer,7120
12,NCT01116648,Phase Ib/II,"Active, not recruiting","[{'id': 837, 'therapyName': 'Olaparib'}, {'id': 1971, 'therapyName': 'Cediranib + Olaparib'}]","Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer",7120
13,NCT02899728,Phase II,Suspended,"[{'id': 4728, 'therapyName': 'Carboplatin + Cisplatin + Etoposide'}, {'id': 1971, 'therapyName': 'Cediranib + Olaparib'}]","Olaparib, Cediranib Maleate, and Standard Chemotherapy in Treating Patients With Small Cell Lung Cancer",7120
14,NCT02889900,Phase II,Recruiting,"[{'id': 1971, 'therapyName': 'Cediranib + Olaparib'}]",Efficacy and Safety Study of Cediranib in Combination With Olaparib in Patients With Recurrent Platinum-Resistant Ovarian Cancer (CONCERTO),7120
15,NCT02974621,Phase II,Recruiting,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1971, 'therapyName': 'Cediranib + Olaparib'}]",Cediranib Maleate and Olaparib Compared to Bevacizumab in Treating Patients With Recurrent Glioblastoma,7120
0,NCT02030964,Phase I,"Active, not recruiting","[{'id': 2590, 'therapyName': 'Cyclophosphamide + Topotecan'}, {'id': 2124, 'therapyName': 'Celecoxib'}]",N2012-01 Phase 1 Study of Difluoromethylornithine (DFMO) and Celecoxib With Cyclophosphamide/Topotecan,474
1,NCT01356290,Phase II,Recruiting,"[{'id': 1475, 'therapyName': 'Thalidomide'}, {'id': 4418, 'therapyName': 'Fenofibrate'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 2124, 'therapyName': 'Celecoxib'}, {'id': 1783, 'therapyName': 'Cyclophosphamide + Cytarabine'}]",Metronomic and Targeted Anti-angiogenesis Therapy for Children With Recurrent/Progressive Medulloblastoma (MEMMAT),474
2,NCT01729923,Phase II,Terminated,"[{'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 2124, 'therapyName': 'Celecoxib'}]",A Trial of Maintenance ADAPT Therapy With Capecitabine and Celecoxib in Patients With Metastatic Colorectal Cancer,474
3,NCT02574728,Phase II,Recruiting,"[{'id': 3143, 'therapyName': 'Celecoxib + Cyclophosphamide + Etoposide + Sirolimus'}]",Sirolimus in Combination With Metronomic Chemotherapy in Children With Recurrent and/or Refractory Solid and CNS Tumors,474
4,NCT00970502,Phase Ib/II,Completed,"[{'id': 2125, 'therapyName': 'Celecoxib + Erlotinib'}]","Erlotinib, Celecoxib and Reirradiation for Recurrent Head and Neck Cancer",474
5,NCT02401295,Phase I,Completed,"[{'id': 3433, 'therapyName': 'Celecoxib + Itraconazole + Tretinoin '}]","ATRA, Celecoxib, and Itraconazole as Maintenance",474
6,NCT02839694,Phase I,Withdrawn,"[{'id': 3567, 'therapyName': 'Decitabine + Tetrahydrouridine'}, {'id': 4592, 'therapyName': 'Decitabine + Tetrahydrouridine + Celecoxib'}]",Adjuvant Oral Decitabine and Tetrahydrouridine With or Without Celecoxib in People Undergoing Pulmonary Metastasectomy,474
0,NCT01922752,Phase I,Completed,"[{'id': 2147, 'therapyName': 'CEP-37440'}]",To Determine the Maximum Tolerated Dose of Oral CEP-37440 in Patients With Advanced or Metastatic Solid Tumors,7441
0,NCT01994382,Phase I,Recruiting,"[{'id': 2531, 'therapyName': 'Cerdulatinib'}]",Phase 1 Dose Escalation Study in Chronic Lymphocytic Leukemia and Non-hodgkin Lymphoma,7561
0,NCT02729961,Phase Ib/II,Not yet recruiting,"[{'id': 4169, 'therapyName': 'Brentuximab vedotin + Ceritinib'}]",Ceritinib With Brentuximab Vedotin in Treating Patients With ALK-Positive Anaplastic Large Cell Lymphoma,6932
1,NCT02605746,Phase I,Recruiting,"[{'id': 789, 'therapyName': 'Ceritinib'}]",Preoperative Ceritinib (LDK378) in Glioblastoma Multiforme and CNS Metastasis,6932
2,NCT01742286,Phase I,Recruiting,"[{'id': 789, 'therapyName': 'Ceritinib'}]","Phase I Study of LDK378 in Pediatric, Malignancies With a Genetic Alteration in Anaplastic Lymphoma Kinase (ALK)",6932
3,NCT02551718,Phase I,Recruiting,"[{'id': 690, 'therapyName': 'Bosutinib'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 3160, 'therapyName': 'Nelarabine'}, {'id': 3159, 'therapyName': 'Bexarotene'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 998, 'therapyName': 'cabozantinib'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 877, 'therapyName': 'Ponatinib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 623, 'therapyName': 'Afatinib'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 890, 'therapyName': 'Regorafenib'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 2, 'therapyName': 'Trametinib'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 3, 'therapyName': 'Dabrafenib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 789, 'therapyName': 'Ceritinib'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1571, 'therapyName': 'Cabazitaxel'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1327, 'therapyName': 'Pralatrexate'}]",High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia,6932
4,NCT01772797,Phase I,Completed,"[{'id': 789, 'therapyName': 'Ceritinib'}, {'id': 647, 'therapyName': 'AUY922'}]",Phase Ib Study of LDK378 and AUY922 in ALK-rearranged Non-small Cell Lung Cancer,6932
5,NCT02299505,Phase I,Recruiting,"[{'id': 789, 'therapyName': 'Ceritinib'}]",Pharmacokinetic and Safety Study of Lower Doses of Ceritinib Taken With a Low-fat Meal Versus 750 mg of Ceritinib in the Fasted State in Adult Patients With (ALK-positive) Metastatic Non-small Cell Lung Cancer (NSCLC),6932
6,NCT02321501,Phase I,Recruiting,"[{'id': 2295, 'therapyName': 'Ceritinib + Everolimus'}, {'id': 789, 'therapyName': 'Ceritinib'}]",Phase I/Ib Dose Escalation and Biomarker Study of Ceritinib (LDK378) + Everolimus for Locally Advanced or Metastatic Solid Tumors With an Expansion in Non-Small Cell Lung Cancer (NSCLC) Characterized by Abnormalities in Anaplastic Lymphoma Kinase (ALK) Expression,6932
7,NCT01947608,Phase I,Available,"[{'id': 789, 'therapyName': 'Ceritinib'}]",Expanded Treatment Protocol With LDK378 in ALK(+) NSCLC,6932
8,NCT02638909,Phase II,Recruiting,"[{'id': 789, 'therapyName': 'Ceritinib'}]",Study of Oral Ceritinib in Patients With ALK-Activated Gastrointestinal Malignancies,6932
9,NCT02186821,Phase II,Completed,"[{'id': 789, 'therapyName': 'Ceritinib'}]",Ceritinib (LDK378) for Patients Whose Tumors Have Aberrations in ALK or ROS1 (SIGNATURE),6932
10,NCT02289144,Phase II,Recruiting,"[{'id': 789, 'therapyName': 'Ceritinib'}]",Ceritinib (LDK378) in Mutation and Oncogene Directed Therapy in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer,6932
11,NCT02343679,Phase II,Withdrawn,"[{'id': 789, 'therapyName': 'Ceritinib'}]",Novartis PhII Ceritinib (LDK378) in R/R ALK+ Hem Malignancies,6932
12,NCT01828112,Phase III,"Active, not recruiting","[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 789, 'therapyName': 'Ceritinib'}]",LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib,6932
13,NCT02584933,FDA approved,Recruiting,"[{'id': 789, 'therapyName': 'Ceritinib'}]",Roll-over Study to Allow Access to Certinib (LDK378) for Patients Who Are on Ceritinib Treatment in a Novartis-sponsored Study,6932
14,NCT02422589,Phase I,Recruiting,"[{'id': 2505, 'therapyName': 'Warfarin'}, {'id': 2685, 'therapyName': 'Midazolam'}, {'id': 789, 'therapyName': 'Ceritinib'}]","A Phase I, Multi-center, Open Label, Drug-drug Interaction Study to Assess the Effect of Ceritinib on the Pharmacokinetics of Warfarin and Midazolam in Patients With ALK-positive Advanced Tumors",6932
15,NCT02336451,Phase II,Recruiting,"[{'id': 789, 'therapyName': 'Ceritinib'}]",A Phase II Study to Evaluate the Efficacy and Safety of Oral Ceritinib in Patients With ALK-positive NSCLC Metastatic to the Brain and/or to Leptomeninges,6932
16,NCT02513667,Phase II,Recruiting,"[{'id': 789, 'therapyName': 'Ceritinib'}]",Ceritinib in Combination With Stereotactic Ablative Radiation Metastatic Lung Adenocarcinoma,6932
17,NCT02227940,Phase I,Recruiting,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 619, 'therapyName': 'Abraxane'}, {'id': 2554, 'therapyName': 'Ceritinib + Gemcitabine'}]",Ceritinib and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors or Locally Advanced or Metastatic Pancreatic Cancer,6932
18,NCT02780128,Phase I,Recruiting,"[{'id': 2186, 'therapyName': 'HDM201'}, {'id': 2638, 'therapyName': 'Ceritinib + LEE011'}, {'id': 2, 'therapyName': 'Trametinib'}]",Next Generation Personalized Neuroblastoma Therapy,6932
19,NCT02292550,Phase Ib/II,"Active, not recruiting","[{'id': 2638, 'therapyName': 'Ceritinib + LEE011'}]",Study of Safety and Efficacy of LEE011 and Ceritinib in Patients With ALK-positive Non-small Cell Lung Cancer.,6932
20,NCT02393625,Phase I,Recruiting,"[{'id': 2565, 'therapyName': 'Ceritinib + Nivolumab'}]",Study of Safety and Efficacy of Ceritinib in Combination With Nivolumab in Patients With ALK-positive Non-small Cell Lung Cancer,6932
21,NCT03087448,Phase Ib/II,Recruiting,"[{'id': 6303, 'therapyName': 'Ceritinib + Trametinib'}]",Ceritinib + Trametinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer (NSCLC),6932
0,NCT02099058,Phase I,Recruiting,"[{'id': 1743, 'therapyName': 'ABBV-399 + Carboplatin'}, {'id': 1364, 'therapyName': 'ABBV-399 + Erlotinib'}, {'id': 1363, 'therapyName': 'ABBV-399'}, {'id': 1366, 'therapyName': 'ABBV-399 + Bevacizumab'}, {'id': 1365, 'therapyName': 'ABBV-399 + Cetuximab'}]","A Phase 1/1b Study With ABBV-399, an Antibody Drug Conjugate, in Subjects With Advanced Solid Cancer Tumors",2
1,NCT01412229,Phase II,"Active, not recruiting","[{'id': 1957, 'therapyName': 'Abraxane + Carboplatin + Cetuximab'}]",Induction Chemotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck,2
2,NCT02270814,Phase II,Recruiting,"[{'id': 1957, 'therapyName': 'Abraxane + Carboplatin + Cetuximab'}, {'id': 1956, 'therapyName': 'Abraxane + Cisplatin + Cetuximab'}]","Cisplatin, Nab-Paclitaxel, and Cetuximab (CACTUX) in Patients With Incurable Head and Neck Squamous Cell Carcinoma",2
3,NCT02979977,Phase II,Recruiting,"[{'id': 4190, 'therapyName': 'Afatinib + Cetuximab'}]",Dual Inhibition of EGFR With Afatinib and Cetuximab in the Treatment of Recurrent or Metastatic Squamous Cell Cancers of the Head and Neck,2
4,NCT01294826,Phase I,Completed,"[{'id': 1996, 'therapyName': 'AUY922 + Cetuximab'}]",Study of AUY922 and Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer,2
5,NCT01884740,Phase Ib/II,Recruiting,"[{'id': 1654, 'therapyName': 'Avastin + Cetuximab'}]",Phase I/II Trial Of Super-Selective Intraarterial Infusion Of Erbitux and Bevacizumab For Treatment Of Relapsed/Refractory Intracranial Glioma In Patients Under 22 Years Of Age,2
6,NCT01776307,Phase II,Recruiting,"[{'id': 2090, 'therapyName': 'BBI608 + Cetuximab'}, {'id': 2091, 'therapyName': 'BBI608 + Capecitabine'}, {'id': 2092, 'therapyName': 'BBI608 + Panitumumab'}]",A Study of BBI608 in Adult Patients With Advanced Colorectal Cancer,2
7,NCT02292758,Phase II,Recruiting,"[{'id': 1923, 'therapyName': 'Bevacizumab + Cetuximab + Irinotecan'}, {'id': 1874, 'therapyName': 'Cetuximab + Irinotecan'}]","Phase II Trial of Irinotecan, Cetuximab, and Bevacizumab Compared With Irinotecan, Cetuximab, and Placebo in KRAS-Wildtype, Irinotecan-Refractory, Metastatic Colorectal Cancer",2
8,NCT02928224,Phase III,Recruiting,"[{'id': 1916, 'therapyName': 'Cetuximab + Encorafenib'}, {'id': 4886, 'therapyName': 'Binimetinib + Cetuximab + LGX818'}, {'id': 1874, 'therapyName': 'Cetuximab + Irinotecan'}, {'id': 2180, 'therapyName': 'Cetuximab + FOLFIRI'}]",Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer (BEACON CRC),2
9,NCT02282371,Phase I,Recruiting,"[{'id': 1837, 'therapyName': 'BYL719 + Cetuximab'}]",Cetuximab + BYL719 + IMRT (Intensity-Modulated Radiation Therapy) in Stage III/IVB Head and Neck Squamous Cell Cancer (HNSCC),2
10,NCT01602315,Phase Ib/II,Terminated,"[{'id': 1837, 'therapyName': 'BYL719 + Cetuximab'}]",A Phase Ib/II Study of BYL719 and Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma,2
11,NCT02741570,Phase III,Recruiting,"[{'id': 4168, 'therapyName': 'Carboplatin + Cetuximab + Cisplatin + Fluorouracil'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care (Extreme Study Regimen) as First Line Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck,2
12,NCT02124707,Phase II,Recruiting,"[{'id': 1989, 'therapyName': 'Carboplatin + Cetuximab + Paclitaxel'}]","Weekly Carboplatin, Paclitaxel and Cetuximab Treatment for Patients With Recurrent or Metastatic SCCHN",2
13,NCT00957853,Phase II,"Active, not recruiting","[{'id': 694, 'therapyName': 'Cetuximab'}, {'id': 701, 'therapyName': 'Cixutumumab'}]",Preoperative Treatment With Cetuximab and/or IMC-A12,2
14,NCT01663259,Phase I,"Active, not recruiting","[{'id': 694, 'therapyName': 'Cetuximab'}]",Reduced-intensity Therapy for Oropharyngeal Cancer in Non-smoking HPV-16 Positive Patients,2
15,NCT01652482,Phase II,Completed,"[{'id': 694, 'therapyName': 'Cetuximab'}, {'id': 806, 'therapyName': 'MEHD7945A'}, {'id': 1315, 'therapyName': 'FOLFIRI'}]",A Study of MEHD7945A + FOLFIRI Versus Cetuximab + FOLFIRI in Second Line in Patients With KRAS Wild-Type Metastatic Colorectal Cancer,2
16,NCT01468896,Phase Ib/II,"Active, not recruiting","[{'id': 694, 'therapyName': 'Cetuximab'}]","Cetuximab and Recombinant Interleukin-12 in Treating Patients With Squamous Cell Carcinoma of the Head and Neck That is Recurrent, Metastatic, or Cannot Be Removed by Surgery",2
17,NCT00904345,Phase II,"Active, not recruiting","[{'id': 694, 'therapyName': 'Cetuximab'}]",Study of Radiation (RT) Concurrent With Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (SCC),2
18,NCT02124850,Phase I,Recruiting,"[{'id': 694, 'therapyName': 'Cetuximab'}]",A Phase Ib Study of Neoadjuvant Immune Biomarker Modulation With ERBITUX&#174; (Cetuximab) and VTX-2337,2
19,NCT02800486,Phase II,Recruiting,"[{'id': 694, 'therapyName': 'Cetuximab'}]","Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA",2
20,NCT01309126,Phase III,Terminated,"[{'id': 694, 'therapyName': 'Cetuximab'}, {'id': 2065, 'therapyName': 'Cetuximab + Imprime PGG'}]",Study of Imprime PGG in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer,2
21,NCT02105636,Phase III,"Active, not recruiting","[{'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 694, 'therapyName': 'Cetuximab'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1312, 'therapyName': 'Nivolumab'}]",Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Head and Neck Carcinoma (CheckMate 141),2
22,NCT01025089,Phase II,"Active, not recruiting","[{'id': 694, 'therapyName': 'Cetuximab'}, {'id': 1927, 'therapyName': 'Cisplatin + Doxorubicin + Cyclophosphamide'}]",Chemotherapy Plus Cetuximab Followed by Surgical Resection in Patients With Locally Advanced or Recurrent Thymoma or Thymic Carcinoma,2
23,NCT01524978,Phase II,"Active, not recruiting","[{'id': 342, 'therapyName': 'Vemurafenib'}, {'id': 694, 'therapyName': 'Cetuximab'}]",A Study of Zelboraf (Vemurafenib) in Patients With BRAF V600 Mutation-Positive Cancers,2
24,NCT01467115,Phase II,Completed,"[{'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 1930, 'therapyName': 'Cisplatin + Docetaxel + Fluorouracil'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 694, 'therapyName': 'Cetuximab'}]",INDUCTION CHEMOTHERAPY FOLLOWED BY CETUXIMAB AND RADIATION THERAPY FOR HEAD AND NECK CANCER,2
25,NCT00292955,Phase II,Unknown status,"[{'id': 694, 'therapyName': 'Cetuximab'}, {'id': 700, 'therapyName': 'Cisplatin'}]","Cetuximab, Cisplatin, and Radiotherapy in Women With Locally Advanced Cervical Carcinoma",2
26,NCT01104922,Phase II,"Active, not recruiting","[{'id': 694, 'therapyName': 'Cetuximab'}]",Re-irradiation With Fractionated Stereotactic Radiosurgery Plus Cetuximab in Patients With Recurrent Squamous Cell Carcinoma of the Head and Neck,2
27,NCT02324608,Phase I,Recruiting,"[{'id': 694, 'therapyName': 'Cetuximab'}]",Cetuximab Before Surgery in Treating Patients With Aggressive Locally Advanced Skin Cancer,2
28,NCT01816984,Phase Ib/II,"Active, not recruiting","[{'id': 694, 'therapyName': 'Cetuximab'}, {'id': 680, 'therapyName': 'BKM120'}]",PI3K Inhibitor BKM120 and Cetuximab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer,2
29,NCT01472016,Phase I,Completed,"[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1063, 'therapyName': 'ABT-700'}, {'id': 694, 'therapyName': 'Cetuximab'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 1315, 'therapyName': 'FOLFIRI'}]",Study of ABT-700 in Subjects With Advanced Solid Tumors,2
30,NCT01238237,Phase I,Completed,"[{'id': 694, 'therapyName': 'Cetuximab'}]",Super-Selective Intraarterial Cerebral Infusion of Cetuximab for the Treatment of Recurrent Glioblastoma Multiforme and Anaplastic Astrocytoma,2
31,NCT01979211,Phase II,Recruiting,"[{'id': 694, 'therapyName': 'Cetuximab'}]",Post-operative Radiation With Cetuximab for Locally Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck,2
32,NCT02563002,Phase III,Recruiting,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1315, 'therapyName': 'FOLFIRI'}, {'id': 694, 'therapyName': 'Cetuximab'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}]",Study of Pembrolizumab (MK-3475) vs Standard Therapy in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (MK-3475-177/KEYNOTE-177),2
33,NCT02499120,Phase II,Recruiting,"[{'id': 850, 'therapyName': 'Palbociclib'}, {'id': 694, 'therapyName': 'Cetuximab'}]",Safety And Efficacy Study Of Palbociclib Plus Cetuximab Versus Cetuximab To Treat Head And Neck Cancer,2
34,NCT02555644,Phase I,Recruiting,"[{'id': 1651, 'therapyName': 'Prexasertib'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 694, 'therapyName': 'Cetuximab'}]",A Study of LY2606368 With Chemotherapy and Radiation in Participants With Head and Neck Cancer,2
35,NCT02693535,Phase II,Recruiting,"[{'id': 1657, 'therapyName': 'Vemurafenib + Cobimetinib'}, {'id': 890, 'therapyName': 'Regorafenib'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 690, 'therapyName': 'Bosutinib'}, {'id': 850, 'therapyName': 'Palbociclib'}, {'id': 694, 'therapyName': 'Cetuximab'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 837, 'therapyName': 'Olaparib'}, {'id': 4, 'therapyName': 'Erlotinib'}]",TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer,2
36,NCT02599324,Phase Ib/II,Recruiting,"[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 768, 'therapyName': 'Ibrutinib'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 694, 'therapyName': 'Cetuximab'}]",A Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors,2
37,NCT02057107,Phase II,Recruiting,"[{'id': 694, 'therapyName': 'Cetuximab'}, {'id': 720, 'therapyName': 'Docetaxel'}]","Stereotactic Body Radiation Therapy (SBRT) With Cetuximab +/- Docetaxel Followed by Adjuvant Cetuximab +/- Docetaxel in Recurrent, Previously-Irradiated Squamous Cell Carcinoma of the Head and Neck (SCCHN)",2
38,NCT02358031,Phase III,"Active, not recruiting","[{'id': 694, 'therapyName': 'Cetuximab'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 700, 'therapyName': 'Cisplatin'}]",A Study of Pembrolizumab (MK-3475) for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (MK-3475-048/KEYNOTE-048),2
39,NCT01285037,Phase I,"Active, not recruiting","[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 694, 'therapyName': 'Cetuximab'}, {'id': 1030, 'therapyName': 'LY2801653'}]",A Study of LY2801653 in Advanced Cancer,2
40,NCT03258554,Phase II,Not yet recruiting,"[{'id': 694, 'therapyName': 'Cetuximab'}, {'id': 1356, 'therapyName': 'Durvalumab'}]",Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Stage III-IVB Head and Neck Cancer Who Cannot Take Cisplatin,2
41,NCT01577173,Phase II,Completed,"[{'id': 694, 'therapyName': 'Cetuximab'}, {'id': 806, 'therapyName': 'MEHD7945A'}]",A Study of MEHD7945A Versus Cetuximab in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of The Head And Neck,2
42,NCT00956007,Phase III,Recruiting,"[{'id': 694, 'therapyName': 'Cetuximab'}]",Radiation Therapy With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer,2
43,NCT01540682,,"Active, not recruiting","[{'id': 694, 'therapyName': 'Cetuximab'}]",MLN8237 in Head and Neck Cancer,2
44,NCT01218048,Phase II,"Active, not recruiting","[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 694, 'therapyName': 'Cetuximab'}]",ERBITUX; Followed by Adjuvant Treatment With Chemoradiation and ERBITUX; for Locally Advanced Head and Neck Squamous Cell Carcinoma,2
45,NCT02252042,Phase III,"Active, not recruiting","[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 694, 'therapyName': 'Cetuximab'}, {'id': 720, 'therapyName': 'Docetaxel'}]",Pembrolizumab (MK-3475) Versus Standard Treatment for Recurrent or Metastatic Head and Neck Cancer (MK-3475-040/KEYNOTE-040),2
46,NCT02438722,Phase II,Recruiting,"[{'id': 623, 'therapyName': 'Afatinib'}, {'id': 694, 'therapyName': 'Cetuximab'}]","S1403, Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer",2
47,NCT02281955,Phase II,Recruiting,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 694, 'therapyName': 'Cetuximab'}]",De-intensification of Radiation and Chemotherapy for Low-Risk HPV-related Oropharyngeal SCC,2
48,NCT01744340,Phase Ib/II,Completed,"[{'id': 728, 'therapyName': 'Eribulin'}, {'id': 694, 'therapyName': 'Cetuximab'}]",A Dose Finding Study of Eribulin Mesylate and Cetuximab For Patients With Advanced Head and Neck and Colon Cancer,2
49,NCT02551159,Phase III,"Active, not recruiting","[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 1914, 'therapyName': 'Cetuximab + Carboplatin + Fluorouracil'}, {'id': 1652, 'therapyName': 'Tremelimumab'}]",Phase III Open Label First Line Therapy Study of MEDI 4736 With or Without Tremelimumab Versus Standard of Care (SOC) in SCCHN,2
50,NCT01063075,Phase II,Completed,"[{'id': 1914, 'therapyName': 'Cetuximab + Carboplatin + Fluorouracil'}]",A Study in Advanced Solid Tumors,2
51,NCT03254927,Phase II,Not yet recruiting,"[{'id': 2061, 'therapyName': 'Cetuximab + CDX-3379'}]",A Study of CDX-3379 and Cetuximab and in Patients With Advanced Head and Neck Squamous Cell Carcinoma,2
52,NCT02014909,Phase I,Completed,"[{'id': 2054, 'therapyName': 'CDX-3379'}, {'id': 2063, 'therapyName': 'CDX-3379 + Vemurafenib'}, {'id': 2064, 'therapyName': 'CDX-3379 + Trastuzumab'}, {'id': 2061, 'therapyName': 'Cetuximab + CDX-3379'}, {'id': 2062, 'therapyName': 'CDX-3379 + Erlotinib'}]",A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of KTN3379 in Adult Subjects With Advanced Tumors,2
53,NCT01099358,Phase II,Completed,"[{'id': 1915, 'therapyName': 'Cetuximab + Cisplatin'}, {'id': 1715, 'therapyName': 'Fluorouracil'}]",Study in Advanced Solid Tumors,2
54,NCT02177838,Phase II,Suspended,"[{'id': 1915, 'therapyName': 'Cetuximab + Cisplatin'}]",Cetuximab and Radiation Therapy in Treating Patients With Stage III-IV Head and Neck Cancer,2
55,NCT00316888,Phase II,"Active, not recruiting","[{'id': 1928, 'therapyName': 'Cetuximab + Cisplatin + Fluorouracil + Radiotherapy'}]","Cetuximab, Cisplatin, Fluorouracil, and Radiation Therapy in Treating Patients With Stage I, Stage II, or Stage III Anal Cancer",2
56,NCT01133678,Phase II,"Active, not recruiting","[{'id': 1790, 'therapyName': 'Cetuximab + Cisplatin + Paclitaxel'}, {'id': 735, 'therapyName': 'Everolimus'}]",Study in Locally Advanced Squamous Cell Carcinoma of Head and Neck,2
57,NCT01488318,Phase II,Terminated,"[{'id': 1820, 'therapyName': 'Cetuximab + Dasatinib'}]",Cetuximab and Dasatinib in Recurrent Squamous Cell Carcinoma,2
58,NCT01719380,Phase Ib/II,"Active, not recruiting","[{'id': 1916, 'therapyName': 'Cetuximab + Encorafenib'}, {'id': 1917, 'therapyName': 'LGX818 + Cetuximab + BYL719'}]","Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in BRAF Mutant Metastatic Colorectal Cancer",2
59,NCT03109158,Phase Ib/II,Recruiting,"[{'id': 5578, 'therapyName': 'Cetuximab + Fluorouracil + NC-6004'}]",NC-6004 With 5-FU and Cetuximab for Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck,2
60,NCT01442935,Phase II,"Active, not recruiting","[{'id': 1484, 'therapyName': 'Bevacizumab + Oxaliplatin + Leucovorin + Fluorouracil'}, {'id': 2180, 'therapyName': 'Cetuximab + FOLFIRI'}, {'id': 2181, 'therapyName': 'Bevacizumab + FOLFIRI'}, {'id': 2182, 'therapyName': 'Cetuximab + FOLFOX'}, {'id': 2183, 'therapyName': 'Bevacizumab + FOLFIRINOX'}, {'id': 2184, 'therapyName': 'Cetuximab + FOLFIRINOX'}]",Chemotherapies Associated With Targeted Therapies on the Resection Rate of Hepatic Metastases,2
61,NCT02573220,Phase I,Withdrawn,"[{'id': 2180, 'therapyName': 'Cetuximab + FOLFIRI'}]",Irinotecan Hydrochloride With FOLFIRI and Cetuximab as First-Line Therapy in Treating Patients With RAS Wild-Type Colorectal Cancer,2
62,NCT01703390,Phase II,Unknown status,"[{'id': 2182, 'therapyName': 'Cetuximab + FOLFOX'}, {'id': 2180, 'therapyName': 'Cetuximab + FOLFIRI'}]",Biomarker Directed Treatment in Metastatic Colorectal Cancer,2
63,NCT02953782,Phase Ib/II,Recruiting,"[{'id': 4948, 'therapyName': 'Cetuximab + Hu5F9-G4'}]",Trial of Hu5F9-G4 in Combination With Cetuximab in Patients With Solid Tumors and Advanced Colorectal Cancer,2
64,NCT02643550,Phase Ib/II,Recruiting,"[{'id': 3383, 'therapyName': 'Cetuximab + IPH2201'}]",Study of IPH2201 (Monalizumab) and Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck,2
65,NCT01860430,Phase I,"Active, not recruiting","[{'id': 1926, 'therapyName': 'Cetuximab + Ipilimumab'}]",A Phase Ib Trial of Concurrent Cetuximab (ERBITUX) and Intensity Modulated Radiotherapy (IMRT) With Ipilimumab (YERVOY) in Locally Advanced Head and Neck Cancer,2
66,NCT01935921,Phase I,"Active, not recruiting","[{'id': 1926, 'therapyName': 'Cetuximab + Ipilimumab'}]","Ipilimumab, Cetuximab, and Intensity-Modulated Radiation Therapy in Treating Patients With Previously Untreated Stage III-IVB Head and Neck Cancer",2
67,NCT02164916,Phase II,"Active, not recruiting","[{'id': 1874, 'therapyName': 'Cetuximab + Irinotecan'}, {'id': 1331, 'therapyName': 'Vemurafenib + Cetuximab + Irinotecan '}]",S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer,2
68,NCT01079780,Phase II,Unknown status,"[{'id': 1920, 'therapyName': 'Irinotecan + Cetuximab + Ramucirumab'}, {'id': 1874, 'therapyName': 'Cetuximab + Irinotecan'}]",Irinotecan Hydrochloride and Cetuximab With or Without Ramucirumab in Treating Patients With Advanced Colorectal Cancer With Progressive Disease After Treatment With Bevacizumab-Containing Chemotherapy,2
69,NCT03290937,Phase I,Not yet recruiting,"[{'id': 6288, 'therapyName': 'Cetuximab + Irinotecan + Utomilumab'}]","Clinical Trial Evaluating the Safety and Response With PF-05082566, Cetuximab and Irinotecan in Patients With Advanced Colorectal Cancer",2
70,NCT02861898,Phase Ib/II,Recruiting,"[{'id': 4559, 'therapyName': 'Cetuximab + Mannitol'}]",Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma,2
71,NCT02573493,Phase II,Recruiting,"[{'id': 3126, 'therapyName': 'Cisplatin + nab-paclitaxel'}, {'id': 3127, 'therapyName': 'Cetuximab + nab-paclitaxel'}]",Nab-Paclitaxel and Cisplatin or Nab-paclitaxel as Induction Therapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (HNSCC),2
72,NCT01960023,Phase Ib/II,"Active, not recruiting","[{'id': 1118, 'therapyName': 'Cetuximab + Neratinib'}]",Safety and Efficacy Study of Neratinib and Cetuximab to Treat Patients With Quadruple Wild-Type Metastatic Colorectal Cancer,2
73,NCT02764593,Phase I,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 4760, 'therapyName': 'Cisplatin + Nivolumab'}, {'id': 4761, 'therapyName': 'Cetuximab + Nivolumab'}]",Chemotherapy +/- Nivolumab in Patients With Intermediate and High-Risk Local-Regionally Advanced Head and Neck Squamous Cell Carcinoma,2
74,NCT01316757,Phase II,"Active, not recruiting","[{'id': 1921, 'therapyName': 'Cetuximab + Paclitaxel + Carboplatin + Erlotinib'}]","Carboplatin, Paclitaxel, Cetuximab, and Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Head and Neck Squamous Cell Cancer",2
75,NCT02241187,Phase I,Completed,"[{'id': 2145, 'therapyName': 'Cetuximab + PEGPH20'}]",Two Stage Study Of Single Dose PEGPH20 And Cetuximab In Patients With Pancreatic Adenocarcinoma Prior To Surgical Resection,2
76,NCT02124148,Phase I,Recruiting,"[{'id': 1994, 'therapyName': 'Cisplatin + Prexasertib'}, {'id': 1993, 'therapyName': 'Cetuximab + Prexasertib'}, {'id': 6248, 'therapyName': 'Pemetrexed + Prexasertib'}, {'id': 6247, 'therapyName': 'LY3023414 + Prexasertib'}, {'id': 6246, 'therapyName': 'Fluoruracil + Leucovorin + Prexasertib'}]",A Study of LY2606368 With Cisplatin or Cetuximab in Participants With Advanced Cancer,2
77,NCT02630420,Phase I,Not yet recruiting,"[{'id': 3790, 'therapyName': 'Cetuximab + Savolitinib'}]",Cetuximab and Savolitinib Treatment of Ras Wild-Type Colorectal Cancer,2
78,NCT02110082,Phase I,Completed,"[{'id': 2066, 'therapyName': 'Cetuximab + Urelumab'}]",Combination Study of Urelumab and Cetuximab in Patients With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Head and Neck Cancer,2
79,NCT01588431,Phase II,"Active, not recruiting","[{'id': 1987, 'therapyName': 'Cisplatin + Docetaxel + Cetuximab'}, {'id': 667, 'therapyName': 'Bevacizumab'}]",Bevacizumab/Ph 2 for Locally Advanced Head and Neck Cancer,2
80,NCT01437449,Phase II,"Active, not recruiting","[{'id': 1987, 'therapyName': 'Cisplatin + Docetaxel + Cetuximab'}, {'id': 1092, 'therapyName': 'Carboplatin'}]","Weekly Docetaxel, Cisplatin, and Cetuximab (TPC) in Palliative Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck (SCCHN)",2
81,NCT01581970,Phase II,Completed,"[{'id': 1997, 'therapyName': 'Cyclophosphamide + Cetuximab'}]",Potentiation of Cetuximab by Tregs Depletion With CSA in Advanced Head &amp; Neck Cancer,2
82,NCT02128906,Phase II,Recruiting,"[{'id': 1925, 'therapyName': 'Docetaxel + Cetuximab'}, {'id': 700, 'therapyName': 'Cisplatin'}]",Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC,2
83,NCT01794845,Phase II,Terminated,"[{'id': 1925, 'therapyName': 'Docetaxel + Cetuximab'}]",Phase II Trial Using Erbitux+ Taxotere With Low Dose Fractionated Radiation for Recurrent Unresectable Locally Advanced Head and Neck Carcinoma,2
84,NCT01810913,Phase II,"Active, not recruiting","[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1925, 'therapyName': 'Docetaxel + Cetuximab'}]","Radiation Therapy With Cisplatin, Docetaxel, or Cetuximab After Surgery in Treating Patients With Stage III-IV Squamous Cell Head and Neck Cancer",2
85,NCT01490749,Phase I,"Active, not recruiting","[{'id': 1924, 'therapyName': 'Everolimus + Paclitaxel + Carboplatin + Cetuximab'}]",Trial of XELOX Followed by Radiation Combined With Carboplatin and RAD001 for Esophageal Cancer,2
86,NCT02277197,Phase I,"Active, not recruiting","[{'id': 1959, 'therapyName': 'Ficlatuzumab + Cetuximab'}]",Ficlatuzumab and Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC),2
87,NCT01836029,Phase II,"Active, not recruiting","[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 2000, 'therapyName': 'Fluorouracil + Cetuximab'}, {'id': 1092, 'therapyName': 'Carboplatin'}]",Chemotherapy Plus Cetuximab in Combination With VTX-2337 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck,2
88,NCT02205398,Phase Ib/II,Terminated,"[{'id': 1618, 'therapyName': 'INC280 + Cetuximab '}]","Study of Safety and Efficacy of INC280 and Cetuximab, in Adult c-MET Positive mCRC and HNSCC Patients After Progression on Cetuximab or Panitumumab Therapy",2
89,NCT00871169,Phase II,Completed,"[{'id': 1919, 'therapyName': 'Irinotecan + Oxaliplatin + Cetuximab'}]","Combination of Irinotecan, Oxaliplatin and Cetuximab for Locally Advanced or Metastatic Pancreatic Cancer",2
90,NCT02278133,Phase Ib/II,Completed,"[{'id': 2008, 'therapyName': 'LGK974 + LGX818 + Cetuximab'}]",Study of WNT974 in Combination With LGX818 and Cetuximab in Patients With BRAF-mutant Metastatic Colorectal Cancer (mCRC) and Wnt Pathway Mutations,2
91,NCT01871311,Phase I,Recruiting,"[{'id': 1929, 'therapyName': 'Nilotinib + Cetuximab'}]",A Phase I Study of the BCR-ABL Tyrosine Kinase Inhibitor Nilontinib and Cetuximab in Patients With Solid Tumors That Can be Treated With Cetuximab,2
92,NCT01758731,Phase I,"Active, not recruiting","[{'id': 1999, 'therapyName': 'Olaparib + Cetuximab'}]",Study of Olaparib With Radiation Therapy and Cetuximab in Advanced Head and Neck Cancer With Heavy Smoking History,2
93,NCT00660218,Phase Ib/II,Unknown status,"[{'id': 1988, 'therapyName': 'Paclitaxel + Cetuximab'}]","A Phase I/II Study of Radiation Therapy, Paclitaxel Poliglumex and Cetuximab in Advanced Head and Neck Cancer",2
94,NCT02101034,Phase Ib/II,Recruiting,"[{'id': 1705, 'therapyName': 'Palbociclib + Cetuximab'}]",PD 0332991 and Cetuximab in Patients With Incurable SCCHN,2
95,NCT01716416,Phase I,"Active, not recruiting","[{'id': 1838, 'therapyName': 'Pazopanib + Cetuximab'}]",Pazopanib Plus Cetuximab for Incurable Head and Neck Squamous Cell Carcinoma (HNSCC),2
96,NCT02713373,Phase Ib/II,Recruiting,"[{'id': 1910, 'therapyName': 'Pembrolizumab + Cetuximab'}]",Cetuximab and Pembrolizumab in Treating Patients With Colorectal Cancer That is Metastatic or Cannot Be Removed by Surgery,2
97,NCT03082534,Phase II,Recruiting,"[{'id': 1910, 'therapyName': 'Pembrolizumab + Cetuximab'}]",Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma,2
98,NCT02318901,Phase Ib/II,"Active, not recruiting","[{'id': 1909, 'therapyName': 'Pembrolizumab + trastuzumab emtansine'}, {'id': 1908, 'therapyName': 'Pembrolizumab + Trastuzumab'}, {'id': 1910, 'therapyName': 'Pembrolizumab + Cetuximab'}]",Pembrolizumab and Monoclonal Antibody Therapy in Advanced Cancer,2
99,NCT01727869,Phase I,Completed,"[{'id': 1246, 'therapyName': 'REGN1400 + Erlotinib'}, {'id': 1247, 'therapyName': 'REGN1400 + Cetuximab'}, {'id': 1072, 'therapyName': 'REGN1400'}]", Study of REGN1400 Alone and in Combination With Erlotinib or Cetuximab in Patients With Certain Types of Cancer,2
100,NCT02095054,Phase I,"Active, not recruiting","[{'id': 1305, 'therapyName': 'Regorafenib + Cetuximab'}]",Regorafenib and Cetuximab in Patients With Advanced Malignancy,2
101,NCT01973868,Phase I,"Active, not recruiting","[{'id': 1305, 'therapyName': 'Regorafenib + Cetuximab'}]",Safety and Pharmacokinetics of Regorafenib and Cetuximab in Combination,2
102,NCT01552434,Phase I,Recruiting,"[{'id': 1376, 'therapyName': 'Temsirolimus + Bevacizumab + Valproic Acid + Cetuximab'}]","Bevacizumab, Temsirolimus, Valproic Acid, Cetuximab",2
103,NCT01787500,Phase I,"Active, not recruiting","[{'id': 1331, 'therapyName': 'Vemurafenib + Cetuximab + Irinotecan '}]","Vemurafenib, Cetuximab, and Irinotecan in Advanced Solid Cancers",2
0,NCT03187288,Phase I,Not yet recruiting,"[{'id': 4029, 'therapyName': 'CFI-400945'}]",A Study of CFI-400945 Fumarate in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome,8329
1,NCT01954316,Phase I,Recruiting,"[{'id': 4029, 'therapyName': 'CFI-400945'}]",A Study of CFI-400945 Fumarate in Patients With Advanced Cancer,8329
0,NCT02792465,Phase I,Recruiting,"[{'id': 5853, 'therapyName': 'CFI-402257'}]",A Study of Investigational Drug CFI-402257 in Patients With Advanced Cancers,8831
0,NCT02365818,Phase II,"Active, not recruiting","[{'id': 2523, 'therapyName': 'CG0070'}]",Safety and Efficacy of CG0070 Oncolytic Virus Regimen for High Grade Non-Muscle Invasive Bladder Cancer After BCG Failure,7556
1,NCT01438112,,Terminated,"[{'id': 2524, 'therapyName': 'Gemcitabine + interferon + Mitomycin C + Valrubicin '}, {'id': 2523, 'therapyName': 'CG0070'}]",Efficacy Study of Recombinant Adenovirus for Non Muscle Invasive Bladder Cancer,7556
0,NCT01760525,Phase I,"Active, not recruiting","[{'id': 2077, 'therapyName': 'CGM097'}]",A Phase I Dose Escalation Study of CGM097 in Adult Patients With Selected Advanced Solid Tumors,7415
0,NCT02122809,Phase I,Completed,"[{'id': 1998, 'therapyName': 'Chiauranib'}]",Phase I Study of Chiauranib in Patients With Advanced Solid Tumors,7373
0,NCT02718066,Phase Ib/II,Recruiting,"[{'id': 4689, 'therapyName': 'Chidamide + Nivolumab'}]","Study of HBI-8000 With Nivolumab in Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancer",7900
0,NCT02955290,Phase Ib/II,Recruiting,"[{'id': 4941, 'therapyName': 'CIMAvax-EGF + Nivolumab'}]",CIMAvax Vaccine and Nivolumab in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer,8481
0,NCT02222688,Phase I,Recruiting,"[{'id': 4312, 'therapyName': 'Cirmtuzumab'}]",UC-961 (Cirmtuzumab) in Relapsed or Refractory Chronic Lymphocytic Leukemia,8404
1,NCT02860676,Phase I,Enrolling by invitation,"[{'id': 4312, 'therapyName': 'Cirmtuzumab'}]",Extension Study of UC-961 (Cirmtuzumab) for Patients With Chronic Lymphocytic Leukemia Treated Previously With UC-961,8404
2,NCT03088878,Phase Ib/II,Not yet recruiting,"[{'id': 5480, 'therapyName': 'Cirmtuzumab + Ibrutinib'}, {'id': 768, 'therapyName': 'Ibrutinib'}]",A Study of the Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies,8404
3,NCT02776917,Phase I,Not yet recruiting,"[{'id': 4313, 'therapyName': 'Cirmtuzumab + Paclitaxel'}]","Study of Cirmtuzumab and Paclitaxel for Metastatic or Locally Advanced, Unresectable Breast Cancer",8404
0,NCT02270814,Phase II,Recruiting,"[{'id': 1957, 'therapyName': 'Abraxane + Carboplatin + Cetuximab'}, {'id': 1956, 'therapyName': 'Abraxane + Cisplatin + Cetuximab'}]","Cisplatin, Nab-Paclitaxel, and Cetuximab (CACTUX) in Patients With Incurable Head and Neck Squamous Cell Carcinoma",505
1,NCT02856568,Phase I,Withdrawn,"[{'id': 4526, 'therapyName': 'ACY-1215 + Cisplatin + Gemcitabine'}]","Ricolinostat, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Unresectable or Metastatic Cholangiocarcinoma",505
2,NCT01825603,Phase I,Recruiting,"[{'id': 4952, 'therapyName': 'ADH-1 + Cisplatin + Gemcitabine'}]","ADH-1, Gemcitabine Hydrochloride and Cisplatin in Treating Patients With Metastatic Pancreatic or Biliary Tract Cancer That Cannot Be Removed By Surgery",505
3,NCT01849783,Phase II,Recruiting,"[{'id': 1852, 'therapyName': 'Melphalan + Bortezomib + Thalidomide + Dexamethasone'}, {'id': 3435, 'therapyName': 'Aldoxorubicin + Cisplatin + Cyclophosphamide + Dexamethasone + Etoposide'}]",Autologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple Myeloma,505
4,NCT02177695,Phase II,Recruiting,"[{'id': 1467, 'therapyName': 'Gemcitabine + Cisplatin'}, {'id': 2564, 'therapyName': 'Aldoxorubicin + Cisplatin + Filgrastim + Methotrexate + Vinblastine'}]","S1314, Co-expression Extrapolation (COXEN) Program to Predict Chemotherapy Response in Patients With Bladder Cancer",505
5,NCT02412670,Phase II,Recruiting,"[{'id': 2667, 'therapyName': 'Carboplatin + Gemcitabine'}, {'id': 2668, 'therapyName': 'Aldoxorubicin + Cisplatin + Methotrexate + Vincristine'}]",Chemotherapy Before Surgery in Treating Patients With High Grade Upper Urinary Tract Cancer,505
6,NCT02620839,Phase I,Recruiting,"[{'id': 5627, 'therapyName': 'Alpelisib + Cisplatin'}]",Phase Ib Study of Alpelisib With Cisplatin in Patients With HPV+ Solid Tumor Malignancies,505
7,NCT02639091,Phase I,Recruiting,"[{'id': 4617, 'therapyName': 'Anetumab ravtansine + Cisplatin + Pemetrexed'}]",Phase Ib Study of Anetumab Ravtansine in Combination With Pemetrexed and Cisplatin in Mesothelin-expressing Solid Tumors,505
8,NCT02989584,Phase Ib/II,Recruiting,"[{'id': 5140, 'therapyName': 'Atezolizumab + Cisplatin + Gemcitabine'}]",A Pilot Safety Study of Atezolizumab Combination With Cisplatin + Gemcitabine in Pts With Metastatic Bladder Cancer,505
9,NCT03093922,Phase II,Recruiting,"[{'id': 5140, 'therapyName': 'Atezolizumab + Cisplatin + Gemcitabine'}]",A Study of Two Dosing Schedules of Atezolizumab in Combination With Gemcitabine and Cisplatin as First-Line Treatment for Metastatic Bladder Cancer,505
10,NCT03228537,Phase I,Not yet recruiting,"[{'id': 6036, 'therapyName': 'Atezolizumab + Cisplatin + Pemetrexed'}]","Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma",505
11,NCT03217747,Phase Ib/II,Recruiting,"[{'id': 5052, 'therapyName': 'Avelumab + Cisplatin'}, {'id': 6044, 'therapyName': 'Avelumab + PF-04518600 + Utomilumab'}, {'id': 6043, 'therapyName': 'Avelumab + Utomilumab'}, {'id': 6045, 'therapyName': 'Avelumab + PF-04518600'}]",Study to Evaluate the Safety and Tolerability of Avelumab in Combination With Other Anti-Cancer Therapies in Patients With Advanced Malignancies,505
12,NCT02952586,Phase III,Recruiting,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 5052, 'therapyName': 'Avelumab + Cisplatin'}]",Study To Compare Avelumab In Combination With Standard of Care Chemoradiotherapy (SoC CRT) Versus SoC CRT for Definitive Treatment In Patients With Locally Advanced Squamous Cell Carcinoma Of The Head And Neck (JAVELIN HEAD AND NECK 100),505
13,NCT02631590,Phase II,Recruiting,"[{'id': 3315, 'therapyName': 'BAY80-6946 + Cisplatin + Gemcitabine'}]",Copanlisib (BAY 80-6946) in Combination With Gemcitabine and Cisplatin in Advanced Cholangiocarcinoma,505
14,NCT00926640,Phase I,Completed,"[{'id': 1123, 'therapyName': 'Belinostat + Cisplatin + Etoposide'}]",A Phase I Study of Belinostat in Combination With Cisplatin and Etoposide in Adults With Small Cell Lung Carcinoma and Other Advanced Cancers,505
15,NCT02113878,Phase I,Recruiting,"[{'id': 1691, 'therapyName': 'BKM120 + Cisplatin'}]",Phase Ib Study of BKM120 With Cisplatin and XRT in High Risk Locally Advanced Squamous Cell Cancer of Head and Neck,505
16,NCT02194049,Phase I,Completed,"[{'id': 1626, 'therapyName': 'BKM120 + Etoposide + Cisplatin'}]","Cisplatin, Etoposide and PI3K Inhibitor BKM120 in Treating Patients With Advanced Solid Tumors or Small Cell Lung Cancer",505
17,NCT01971489,Phase I,Withdrawn,"[{'id': 1304, 'therapyName': 'BKM120 + Gemcitabine + Cisplatin'}]","PI3K Inhibitor BKM120, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Advanced Solid Tumors",505
18,NCT02815592,Phase Ib/II,"Active, not recruiting","[{'id': 1136, 'therapyName': 'Etoposide'}, {'id': 4563, 'therapyName': 'BMS-986012 + Cisplatin + Etoposide'}, {'id': 4564, 'therapyName': 'BMS-986012 + Carboplatin + Etoposide'}]",Trial of BMS-986012 in Combination With Platinum and Etoposide,505
19,NCT02990468,Phase I,Recruiting,"[{'id': 5840, 'therapyName': 'BMX-001 + Cisplatin'}]","A Trial of Concurrent Radiation Therapy, Cisplatin, and BMX-001 in Locally Advanced Head and Neck Cancer (BMX-HN)",505
20,NCT02358863,Phase I,Terminated,"[{'id': 4311, 'therapyName': 'Docetaxel + Irinotecan'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 1835, 'therapyName': 'Docetaxel + Cisplatin'}, {'id': 1406, 'therapyName': 'Camptosar + Cisplatin'}, {'id': 4310, 'therapyName': 'Epirubicin + Docetaxel'}, {'id': 4309, 'therapyName': 'Capecitabine + Docetaxel'}]",Molecularly Tailored Therapy for Patients With Metastatic Cancer of the Esophagus and Stomach (mEGA),505
21,NCT03221426,Phase III,Recruiting,"[{'id': 3999, 'therapyName': 'Capecitabine + Cisplatin'}, {'id': 6050, 'therapyName': 'Capecitabine + Cisplatin + Pembrolizumab'}, {'id': 6051, 'therapyName': 'Cisplatin + Fluorouracil + Pembrolizumab'}, {'id': 1833, 'therapyName': 'Cisplatin + Fluorouracil'}]",Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585),505
22,NCT02726399,Phase II,Recruiting,"[{'id': 3999, 'therapyName': 'Capecitabine + Cisplatin'}, {'id': 3998, 'therapyName': 'Ramucirumab + Trastuzumab'}]",Ramucirumab With Trastuzumab and Capecitabine/Cisplatin in Patients With Metastatic HER2-Positive Gastroesophageal Junction and Gastric Cancer,505
23,NCT02954536,Phase II,Recruiting,"[{'id': 4945, 'therapyName': 'Capecitabine + Cisplatin + Pembrolizumab + Trastuzumab'}]",Phase II Trial of Pembrolizumab With Trastuzumab and Chemotherapy in Advanced HER2 Positive Esophagogastric (EG) Cancer,505
24,NCT01450696,Phase III,Terminated,"[{'id': 1899, 'therapyName': 'Capecitabine + Cisplatin + Trastuzumab'}]",HELOISE Study: A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer,505
25,NCT01774786,Phase III,"Active, not recruiting","[{'id': 856, 'therapyName': 'Pertuzumab'}, {'id': 1894, 'therapyName': 'Capecitabine + Fluorouracil + Cisplatin + Trastuzumab'}]",A Study of Perjeta (Pertuzumab) in Combination With Herceptin (Trastuzumab) and Chemotherapy in Patients With HER2-Positive Metastatic Gastroesophageal Junction or Gastric Cancer,505
26,NCT02741570,Phase III,Recruiting,"[{'id': 4168, 'therapyName': 'Carboplatin + Cetuximab + Cisplatin + Fluorouracil'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care (Extreme Study Regimen) as First Line Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck,505
27,NCT03174275,Phase II,Not yet recruiting,"[{'id': 5873, 'therapyName': 'Carboplatin + Cisplatin + Durvalumab + Paclitaxel'}, {'id': 3997, 'therapyName': 'Carboplatin + Durvalumab + Paclitaxel'}]","Carboplatin, Nab-Paclitaxel, Durvalumab Before Surgery and Adjuvant Therapy in Head and Neck Squamous Cell Carcinoma",505
28,NCT02899728,Phase II,Suspended,"[{'id': 4728, 'therapyName': 'Carboplatin + Cisplatin + Etoposide'}, {'id': 1971, 'therapyName': 'Cediranib + Olaparib'}]","Olaparib, Cediranib Maleate, and Standard Chemotherapy in Treating Patients With Small Cell Lung Cancer",505
29,NCT03043872,Phase III,Recruiting,"[{'id': 5305, 'therapyName': 'MEDI4736 + Tremelimumab + Carboplatin + Cisplatin + Etoposide'}, {'id': 5306, 'therapyName': 'MEDI4736 + Carboplatin + Cisplatin + Etoposide'}, {'id': 4728, 'therapyName': 'Carboplatin + Cisplatin + Etoposide'}]",Durvalumab+/- Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer (Caspian),505
30,NCT02934503,Phase II,Recruiting,"[{'id': 6184, 'therapyName': 'Carboplatin + Cisplatin + Etoposide + Pembrolizumab'}]",Study of Pembrolizumab and Chemotherapy With or Without Radiation in Small Cell Lung Cancer (SCLC),505
31,NCT03178552,Phase II,Recruiting,"[{'id': 4686, 'therapyName': 'Carboplatin + Cisplatin + Gemcitabine'}, {'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 4616, 'therapyName': 'Carboplatin + Cisplatin + Pemetrexed'}, {'id': 698, 'therapyName': 'Alectinib'}]",A Study to Evaluate Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC) (B-FAST),505
32,NCT02516241,Phase III,Recruiting,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}, {'id': 4686, 'therapyName': 'Carboplatin + Cisplatin + Gemcitabine'}, {'id': 1356, 'therapyName': 'Durvalumab'}]",Study of MEDI4736 With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer,505
33,NCT02853305,Phase III,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 4686, 'therapyName': 'Carboplatin + Cisplatin + Gemcitabine'}]",Study of Pembrolizumab With or Without Platinum-based Combination Chemotherapy Versus Chemotherapy Alone in Urothelial Carcinoma (MK-3475-361/KEYNOTE-361),505
34,NCT03215706,Phase III,Recruiting,"[{'id': 6132, 'therapyName': 'Carboplatin + Cisplatin + Paclitaxel + Pemetrexed'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",A Study of Nivolumab and Ipilimumab Combined With Chemotherapy Compared to Chemotherapy by Itself as the First Treatment Given for Stage IV Non-Small Cell Lung Cancer (NSCLC) (CheckMate 9LA),505
35,NCT02864251,Phase III,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}, {'id': 4616, 'therapyName': 'Carboplatin + Cisplatin + Pemetrexed'}]","A Study of Nivolumab + Chemotherapy or Nivolumab + Ipilimumab Versus Chemotherapy in Patients With EGFR Mutation, T790M Negative NSCLC Who Have Failed 1L EGFR TKI Therapy (CheckMate722)",505
36,NCT02899299,Phase III,Recruiting,"[{'id': 4616, 'therapyName': 'Carboplatin + Cisplatin + Pemetrexed'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients (CheckMate743),505
37,NCT03113188,Phase I,Recruiting,"[{'id': 6186, 'therapyName': 'CBP501 + Cisplatin + Nivolumab'}]","CBP501, Cisplatin and Nivolumab in Advanced Refractory Tumors",505
38,NCT01064648,Phase Ib/II,"Active, not recruiting","[{'id': 2432, 'therapyName': 'Cediranib + Cisplatin + Pemetrexed'}]",Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma,505
39,NCT01099358,Phase II,Completed,"[{'id': 1915, 'therapyName': 'Cetuximab + Cisplatin'}, {'id': 1715, 'therapyName': 'Fluorouracil'}]",Study in Advanced Solid Tumors,505
40,NCT02177838,Phase II,Suspended,"[{'id': 1915, 'therapyName': 'Cetuximab + Cisplatin'}]",Cetuximab and Radiation Therapy in Treating Patients With Stage III-IV Head and Neck Cancer,505
41,NCT00316888,Phase II,"Active, not recruiting","[{'id': 1928, 'therapyName': 'Cetuximab + Cisplatin + Fluorouracil + Radiotherapy'}]","Cetuximab, Cisplatin, Fluorouracil, and Radiation Therapy in Treating Patients With Stage I, Stage II, or Stage III Anal Cancer",505
42,NCT01133678,Phase II,"Active, not recruiting","[{'id': 1790, 'therapyName': 'Cetuximab + Cisplatin + Paclitaxel'}, {'id': 735, 'therapyName': 'Everolimus'}]",Study in Locally Advanced Squamous Cell Carcinoma of Head and Neck,505
43,NCT02595905,Phase I,Recruiting,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 954, 'therapyName': 'Veliparib'}]",Cisplatin With or Without Veliparib in Treating Patients With Stage IV Triple-Negative and/or BRCA Mutation-Associated Breast Cancer,505
44,NCT02635360,Phase II,Recruiting,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab and Chemoradiation Treatment for Advanced Cervical Cancer,505
45,NCT02477826,Phase III,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 755, 'therapyName': 'Gemcitabine'}]","An Open-Label, Trial of Nivolumab and Nivolumab Plus Ipilimumab Versus Platinum Doublet Chemotherapy in Subjects With Stage IV Non-Small Cell Lung Cancer (NSCLC)",505
46,NCT00993655,Phase III,Completed,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1092, 'therapyName': 'Carboplatin'}]"," Comparing Combination Chemotherapy Regimens in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer",505
47,NCT01128387,Phase Ib/II,Completed,"[{'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 845, 'therapyName': 'Panitumumab'}, {'id': 700, 'therapyName': 'Cisplatin'}]",Trial of Panitumumab/Cisplatin/Fluorouracil With XRT in Esophageal Cancer,505
48,NCT02196168,Phase II,Terminated,"[{'id': 822, 'therapyName': 'MK-1775'}, {'id': 700, 'therapyName': 'Cisplatin'}]",Cisplatin With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer,505
49,NCT02009449,Phase I,"Active, not recruiting","[{'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 2621, 'therapyName': 'AM0010 '}, {'id': 619, 'therapyName': 'Abraxane'}]",A Phase 1 Study of AM0010 in Patients With Advanced Solid Tumors,505
50,NCT00980954,Phase III,Recruiting,"[{'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 700, 'therapyName': 'Cisplatin'}]",Chemotherapy and Pelvic Radiation Therapy With or Without Additional Chemotherapy in Treating Patients With High-Risk Early-Stage Cervical Cancer After Radical Hysterectomy,505
51,NCT01982448,Phase II,Recruiting,"[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 700, 'therapyName': 'Cisplatin'}]",Cisplatin vs Paclitaxel for Triple Neg,505
52,NCT01240590,Phase Ib/II,Completed,"[{'id': 1461, 'therapyName': 'Crolibulin + Cisplatin'}, {'id': 700, 'therapyName': 'Cisplatin'}]",A Phase I/II Trial of Crolibulin (EPC2407) Plus Cisplatin in Adults With Solid Tumors With a Focus on Anaplastic Thyroid Cancer (ATC),505
53,NCT03040999,Phase III,Recruiting,"[{'id': 3256, 'therapyName': 'Cisplatin + Pembrolizumab'}, {'id': 700, 'therapyName': 'Cisplatin'}]",Study of Pembrolizumab (MK-3475) or Placebo With Chemoradiation in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-412/KEYNOTE-412),505
54,NCT01732640,Phase Ib/II,Completed,"[{'id': 2442, 'therapyName': 'Afatinib + Carboplatin + Paclitaxel'}, {'id': 700, 'therapyName': 'Cisplatin'}]",A Phase I/II Study Afatinib/Carboplatin/Paclitaxel Induction Chemotherapy In HPV-Negative HNSCC.,505
55,NCT01064921,Phase I,"Active, not recruiting","[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1077, 'therapyName': 'Vorinostat'}]",Ph I Vorinostat in the Treatment of Advanced Staged Oropharyngeal Squamous Cell Carcinoma,505
56,NCT02394652,Phase II,Recruiting,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1031, 'therapyName': 'Metformin'}]",The Potential for Metformin to Improve Tumor Oxygenation in Locally Advanced Cervix Cancer,505
57,NCT02657434,Phase III,Recruiting,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 854, 'therapyName': 'Pemetrexed'}]",A Study of Atezolizumab in Combination With Carboplatin or Cisplatin + Pemetrexed Compared With Carboplatin or Cisplatin + Pemetrexed in Participants Who Are Chemotherapy-Naive and Have Stage IV Non-Squamous Non-Small Cell Lung Cancer,505
58,NCT02381535,Phase I,"Active, not recruiting","[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 645, 'therapyName': 'AT13387'}]",Hsp90 Inhibitor AT13387 in Treating Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck Receiving Radiation Therapy and Cisplatin,505
59,NCT01711515,Phase I,"Active, not recruiting","[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 700, 'therapyName': 'Cisplatin'}]",Chemoradiation Therapy and Ipilimumab in Treating Patients With Locally Advanced Cervical Cancer,505
60,NCT01633541,Phase II,Recruiting,"[{'id': 644, 'therapyName': 'AT-101'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 720, 'therapyName': 'Docetaxel'}]",Chemotherapy AND Bcl-xL Inhibitor (AT-101) For Organ Preservation In Adults With Advanced Laryngeal Cancer,505
61,NCT02128906,Phase II,Recruiting,"[{'id': 1925, 'therapyName': 'Docetaxel + Cetuximab'}, {'id': 700, 'therapyName': 'Cisplatin'}]",Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC,505
62,NCT02409342,Phase III,Recruiting,"[{'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 700, 'therapyName': 'Cisplatin'}]",A Comparative Study of MPDL3280A (Anti-PDL1 Antibody) With Cisplatin or Carboplatin + Pemetrexed in Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC),505
63,NCT02855944,Phase III,Recruiting,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 906, 'therapyName': 'Rucaparib'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]","ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients",505
64,NCT02429466,Phase I,Recruiting,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1949, 'therapyName': 'SGI-110'}]",Study of the Hypomethylating Drug SGI-110 Plus Cisplatin in Relapsed Refractory Germ Cell Tumors,505
65,NCT02157792,Phase I,Recruiting,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 2879, 'therapyName': 'VX-970'}, {'id': 755, 'therapyName': 'Gemcitabine'}]","An Open-Label, First-in-Human Study of the Safety, Tolerability, and Pharmacokinetics of VX-970 in Combination With Cytotoxic Chemotherapy",505
66,NCT03107182,Phase II,Recruiting,"[{'id': 5581, 'therapyName': 'Dexamethasone + Diphenhydramine + Famotidine + 5FU + Hydroxyurea + Paclitaxel'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 5303, 'therapyName': 'Nivolumab + Carboplatin + Paclitaxel'}]",Oropharyngeal Tumor Induction Chemotherapy and Response-stratified Locoregional Therapy Trial in Order to Minimize Long-term Adverse Events,505
67,NCT01553942,Phase II,Recruiting,"[{'id': 623, 'therapyName': 'Afatinib'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 854, 'therapyName': 'Pemetrexed'}]",Afatinib With CT and RT for EGFR-Mutant NSCLC,505
68,NCT00292955,Phase II,Unknown status,"[{'id': 694, 'therapyName': 'Cetuximab'}, {'id': 700, 'therapyName': 'Cisplatin'}]","Cetuximab, Cisplatin, and Radiotherapy in Women With Locally Advanced Cervical Carcinoma",505
69,NCT01064479,Phase II,"Active, not recruiting","[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 700, 'therapyName': 'Cisplatin'}]",Docetaxel And Cisplatin With or Without Erlotinib For Metastatic Or Recurrent Squamous Cell Carcinoma Of Head And Neck,505
70,NCT02296684,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 700, 'therapyName': 'Cisplatin'}]",Immunotherapy With MK-3475 in Surgically Resectable Head and Neck Squamous Cell Carcinoma,505
71,NCT02641093,Phase II,Recruiting,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Phase II Trial of Adjuvant Cisplatin and Radiation With Pembrolizumab in Resected Head and Neck Squamous Cell Carcinoma,505
72,NCT02409355,Phase III,"Active, not recruiting","[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1201, 'therapyName': 'Atezolizumab'}]",A Study of MPDL3280A Compared With Gemcitabine + Cisplatin or Carboplatin in Patients With Stage IV Squamous Non-Small Cell Lung Cancer,505
73,NCT02555644,Phase I,Recruiting,"[{'id': 1651, 'therapyName': 'Prexasertib'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 694, 'therapyName': 'Cetuximab'}]",A Study of LY2606368 With Chemotherapy and Radiation in Participants With Head and Neck Cancer,505
74,NCT02201355,Phase I,"Active, not recruiting","[{'id': 700, 'therapyName': 'Cisplatin'}]","Reduced-Volume Hypofractionated, PET-directed Intensity Modulated Radiotherapy Concurrent With Weekly Cisplatin Chemotherapy for Squamous Cell Carcinoma of the Head and Neck",505
75,NCT03057106,Phase II,Recruiting,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}, {'id': 854, 'therapyName': 'Pemetrexed'}]",Durvalumab and Tremelimumab ± Platinum-Based Chemotherapy in Patients With Metastatic Squamous or Non-Squamous NSCLC,505
76,NCT01285037,Phase I,"Active, not recruiting","[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 694, 'therapyName': 'Cetuximab'}, {'id': 1030, 'therapyName': 'LY2801653'}]",A Study of LY2801653 in Advanced Cancer,505
77,NCT01820754,Phase II,"Active, not recruiting","[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]",Evaluation of Circulating T Cells and Tumor Infiltrating Lymphocytes (TILs) During / After Pre-Surgery Chemotherapy in Non-Small Cell Lung Cancer (NSCLC),505
78,NCT01336842,Phase I,Completed,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1080, 'therapyName': 'Panobinostat'}, {'id': 854, 'therapyName': 'Pemetrexed'}]",Study of Cisplatin and Pemetrexed in Combination With Panobinostat in Solid Tumors,505
79,NCT01836029,Phase II,"Active, not recruiting","[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 2000, 'therapyName': 'Fluorouracil + Cetuximab'}, {'id': 1092, 'therapyName': 'Carboplatin'}]",Chemotherapy Plus Cetuximab in Combination With VTX-2337 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck,505
80,NCT02041533,Phase III,"Active, not recruiting","[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 755, 'therapyName': 'Gemcitabine'}]","An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026)",505
81,NCT02985658,Phase I,Available,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 954, 'therapyName': 'Veliparib'}, {'id': 1685, 'therapyName': 'Vinorelbine'}]",Expanded Access With ABT-888 (Veliparib) to Treat Metastatic Breast Cancer,505
82,NCT01810913,Phase II,"Active, not recruiting","[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1925, 'therapyName': 'Docetaxel + Cetuximab'}]","Radiation Therapy With Cisplatin, Docetaxel, or Cetuximab After Surgery in Treating Patients With Stage III-IV Squamous Cell Head and Neck Cancer",505
83,NCT01042522,Phase II,Recruiting,"[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1137, 'therapyName': 'Bleomycin'}]","Paclitaxel and Carboplatin or Bleomycin Sulfate, Etoposide Phosphate, and Cisplatin in Treating Patients With Advanced or Recurrent Sex Cord-Ovarian Stromal Tumors",505
84,NCT01737008,Phase I,Completed,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 714, 'therapyName': 'Dacomitinib'}]",Study of Dacomitinib With Radiotherapy With and Without Cisplatin in Patients With Squamous Cell Carcinoma of the Head and Neck,505
85,NCT02537223,Phase I,Recruiting,"[{'id': 691, 'therapyName': 'BYL719'}, {'id': 700, 'therapyName': 'Cisplatin'}]",Phase I Study of BYL719 in Combination With Cisplatin and Radiotherapy in Patients With Squamous Cell Head and Neck Cancer,505
86,NCT02264990,Phase III,"Active, not recruiting","[{'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 954, 'therapyName': 'Veliparib'}, {'id': 700, 'therapyName': 'Cisplatin'}]",Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Subjects Receiving First Cytotoxic Chemotherapy for Metastatic or Advanced Non-Squamous Non-Small Cell Lung Cancer Who Are Current or Former Smokers,505
87,NCT01928160,Phase II,Withdrawn,"[{'id': 1290, 'therapyName': 'Erlotinib + Pemetrexed'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1291, 'therapyName': 'Erlotinib + Carboplatin'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1292, 'therapyName': 'Erlotinib + Cisplatin'}]",Pemetrexed Disodium and Carboplatin or Cisplatin With or Without Erlotinib Hydrochloride in Treating Patient With Stage IV Non-Small Cell Lung Cancer Resistant to First-Line Therapy With Erlotinib Hydrochloride or Gefitinib,505
88,NCT02551159,Phase III,"Active, not recruiting","[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 1914, 'therapyName': 'Cetuximab + Carboplatin + Fluorouracil'}, {'id': 1652, 'therapyName': 'Tremelimumab'}]",Phase III Open Label First Line Therapy Study of MEDI 4736 With or Without Tremelimumab Versus Standard of Care (SOC) in SCCHN,505
89,NCT02227940,Phase I,Recruiting,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 619, 'therapyName': 'Abraxane'}, {'id': 2554, 'therapyName': 'Ceritinib + Gemcitabine'}]",Ceritinib and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors or Locally Advanced or Metastatic Pancreatic Cancer,505
90,NCT02788201,Phase II,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1133, 'therapyName': 'Mitomycin C'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1013, 'therapyName': 'epirubicin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1137, 'therapyName': 'Bleomycin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 781, 'therapyName': 'Ixabepilone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 2950, 'therapyName': 'Estramustine'}, {'id': 1941, 'therapyName': 'Floxuridine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 1811, 'therapyName': 'Carmustine'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 953, 'therapyName': 'Vandetanib'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 4419, 'therapyName': 'Toremifine'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 2601, 'therapyName': 'Dactinomycin'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 3035, 'therapyName': 'Chlorambucil'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 342, 'therapyName': 'Vemurafenib'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 2635, 'therapyName': 'Vinblastine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 4305, 'therapyName': 'Teniposide'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 4304, 'therapyName': 'Streptozocin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1231, 'therapyName': 'Bendamustine'}, {'id': 4303, 'therapyName': 'Mechlorethamine'}, {'id': 4302, 'therapyName': 'Mitotane'}]",Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma,505
91,NCT02365766,Phase Ib/II,Recruiting,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 755, 'therapyName': 'Gemcitabine'}]",Study of Neoadjuvant Pembrolizumab in Combination With Gemcitabine Based Therapy in Cis-eligible or -Ineligible Subjects With Urothelial Cancer,505
92,NCT02349958,Phase II,Recruiting,"[{'id': 1133, 'therapyName': 'Mitomycin C'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1009, 'therapyName': 'Doxorubicin'}]",Clinical Trial of Intraperitoneal Hyperthermic Chemotherapy,505
93,NCT02578680,Phase III,"Active, not recruiting","[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 700, 'therapyName': 'Cisplatin'}]",Study of Platinum+Pemetrexed Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Non-squamous Non-small Cell Lung Cancer (MK-3475-189/KEYNOTE-189),505
94,NCT02358031,Phase III,"Active, not recruiting","[{'id': 694, 'therapyName': 'Cetuximab'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 700, 'therapyName': 'Cisplatin'}]",A Study of Pembrolizumab (MK-3475) for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (MK-3475-048/KEYNOTE-048),505
95,NCT03126916,Phase III,Not yet recruiting,"[{'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1425, 'therapyName': '131I-MIBG'}, {'id': 1873, 'therapyName': 'Sargramostim'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 5595, 'therapyName': 'Isotretinoin'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 5153, 'therapyName': 'dexrazoxane'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1167, 'therapyName': 'Aldesleukin'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 2286, 'therapyName': 'Dinutuximab  '}]",Iobenguane I-131 or Crizotinib and Standard Therapy in Treating Younger Patients With Newly-Diagnosed High-Risk Neuroblastoma or Ganglioneuroblastoma,505
96,NCT02142738,Phase III,"Active, not recruiting","[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 854, 'therapyName': 'Pemetrexed'}]",Study of Pembrolizumab (MK-3475) Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (MK-3475-024/KEYNOTE-024),505
97,NCT01409174,Phase Ib/II,Terminated,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 1167, 'therapyName': 'Aldesleukin'}, {'id': 1141, 'therapyName': 'Temozolomide'}, {'id': 1299, 'therapyName': 'Interferon alfa-2b '}]",IPI Biochemotherapy for Chemonaive Patients With Metastatic Melanoma,505
98,NCT01450761,Phase III,Completed,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1136, 'therapyName': 'Etoposide'}]",Trial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab Plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy Alone,505
99,NCT01711658,Phase II,"Active, not recruiting","[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 2475, 'therapyName': 'Lapatinib + Cisplatin'}]",TRYHARD: Radiation Therapy Plus Cisplatin With or Without Lapatinib in Treating Patients With Head and Neck Cancer,505
100,NCT01918306,Phase Ib/II,Terminated,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1554, 'therapyName': 'GDC-0941 + Cisplatin'}]",GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast Cancer,505
101,NCT02508246,Phase I,Recruiting,"[{'id': 822, 'therapyName': 'MK-1775'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 700, 'therapyName': 'Cisplatin'}]","AZD1775, Docetaxel, and Cisplatin Before Surgery in Treating Patients With Borderline Resectable Stage III-IVB Squamous Cell Carcinoma of the Head and Neck",505
102,NCT03004287,Phase II,Recruiting,"[{'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1164, 'therapyName': 'lenalidomide'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 1630, 'therapyName': 'Daratumumab'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1475, 'therapyName': 'Thalidomide'}]",2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy,505
103,NCT00989651,Phase I,"Active, not recruiting","[{'id': 3047, 'therapyName': 'Bevacizumab + Veliparib'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 700, 'therapyName': 'Cisplatin'}]","Carboplatin, Paclitaxel, Bevacizumab, and ABT-888 in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer",505
104,NCT01454102,Phase I,"Active, not recruiting","[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1312, 'therapyName': 'Nivolumab'}]","Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012)",505
105,NCT01898494,Phase II,"Active, not recruiting","[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1092, 'therapyName': 'Carboplatin'}]",Transoral Surgery Followed By Low-Dose or Standard-Dose Radiation Therapy With or Without Chemotherapy in Treating Patients With HPV Positive Stage III-IVA Oropharyngeal Cancer,505
106,NCT02281955,Phase II,Recruiting,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 694, 'therapyName': 'Cetuximab'}]",De-intensification of Radiation and Chemotherapy for Low-Risk HPV-related Oropharyngeal SCC,505
107,NCT02532192,Phase I,Withdrawn,"[{'id': 897, 'therapyName': 'Rituximab'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1689, 'therapyName': 'Fluconazole'}, {'id': 1078, 'therapyName': 'Belinostat'}]","A Phase Ib Study of Belinostat With RDHAP Chemotherapy (Dexamethasone, Cytarabine, Cisplatinum) in Adults With Relapsed or Refractory Diffuse Large B-cell Lymphoma",505
108,NCT02576574,Phase III,Recruiting,"[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 3144, 'therapyName': 'Avelumab'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 1092, 'therapyName': 'Carboplatin'}]",Avelumab in First-line Non-Small Cell Lung Cancer (JAVELIN Lung 100),505
109,NCT02314117,Phase III,"Active, not recruiting","[{'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 886, 'therapyName': 'Ramucirumab'}]",A Study of Ramucirumab (LY3009806) in Combination With Capecitabine and Cisplatin in Participants With Stomach Cancer,505
110,NCT02489903,Phase II,Recruiting,"[{'id': 1136, 'therapyName': 'Etoposide'}, {'id': 3680, 'therapyName': 'RRx-001'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 619, 'therapyName': 'Abraxane'}]","RRx-001 in Small, Non-small Cell Lung Cancer, and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens",505
111,NCT02402920,Phase I,Recruiting,"[{'id': 2604, 'therapyName': 'Carboplatin + Etoposide + Pembrolizumab'}, {'id': 700, 'therapyName': 'Cisplatin'}]",Phase I Trial of MK-3475 and Concurrent Chemo/Radiation for the Elimination of Small Cell Lung Cancer,505
112,NCT01218048,Phase II,"Active, not recruiting","[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 694, 'therapyName': 'Cetuximab'}]",ERBITUX; Followed by Adjuvant Treatment With Chemoradiation and ERBITUX; for Locally Advanced Head and Neck Squamous Cell Carcinoma,505
113,NCT02107235,Phase I,Completed,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1046, 'therapyName': 'rigosertib'}]",Platinum-based Chemoradiotherapy and Rigosertib in Head and Neck Cancer,505
114,NCT01927744,Phase II,Recruiting,"[{'id': 2474, 'therapyName': 'Erlotinib + Docetaxel'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1092, 'therapyName': 'Carboplatin'}]","Study of Chemotherapy With Cisplatin/CarboplatinAstellas Pharma Inc, OSI Pharmaceuticals, Kadoorie Foundation, and Docetaxel With or Without Erlotinib in Patients With Head and Neck Squamous Cell Carcinomas Amenable for Surgical Resection",505
115,NCT02254278,Phase II,"Active, not recruiting","[{'id': 700, 'therapyName': 'Cisplatin'}]",Reduced-Dose Intensity-Modulated Radiation Therapy With or Without Cisplatin in Treating Patients With Advanced Oropharyngeal Cancer,505
116,NCT01859741,Phase Ib/II,"Active, not recruiting","[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 2547, 'therapyName': 'Tarextumab'}]",A Phase 1b/2 Study of OMP-59R5 in Combination With Etoposide and Platinum Therapy in Subjects With Untreated Extensive Stage Small Cell Lung Cancer (PINNACLE),505
117,NCT01014598,Phase I,"Active, not recruiting","[{'id': 700, 'therapyName': 'Cisplatin'}]",Cisplatin in Treating Patients With Lung Cancer,505
118,NCT01453205,Phase II,Completed,"[{'id': 2354, 'therapyName': 'Cisplatin + Cytarabine + Dexamethasone'}, {'id': 2352, 'therapyName': 'Carboplatin + Etoposide + Ifosfamide '}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 2407, 'therapyName': 'MEDI-551'}]","A Phase 2, Multicenter, Randomized, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)",505
119,NCT02436707,Phase II,Recruiting,"[{'id': 768, 'therapyName': 'Ibrutinib'}, {'id': 3391, 'therapyName': 'Cisplatin + Dexamethasone + Gemcitabine + Rituximab'}]",Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma,505
120,NCT01588431,Phase II,"Active, not recruiting","[{'id': 1987, 'therapyName': 'Cisplatin + Docetaxel + Cetuximab'}, {'id': 667, 'therapyName': 'Bevacizumab'}]",Bevacizumab/Ph 2 for Locally Advanced Head and Neck Cancer,505
121,NCT01437449,Phase II,"Active, not recruiting","[{'id': 1987, 'therapyName': 'Cisplatin + Docetaxel + Cetuximab'}, {'id': 1092, 'therapyName': 'Carboplatin'}]","Weekly Docetaxel, Cisplatin, and Cetuximab (TPC) in Palliative Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck (SCCHN)",505
122,NCT01467115,Phase II,Completed,"[{'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 1930, 'therapyName': 'Cisplatin + Docetaxel + Fluorouracil'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 694, 'therapyName': 'Cetuximab'}]",INDUCTION CHEMOTHERAPY FOLLOWED BY CETUXIMAB AND RADIATION THERAPY FOR HEAD AND NECK CANCER,505
123,NCT01914900,Phase II,Unknown status,"[{'id': 1930, 'therapyName': 'Cisplatin + Docetaxel + Fluorouracil'}]",Preoperative TPF Chemotherapy in a Population of Molecularly Selected Locally Advanced Resectable Oral Cavity Squamous Cell Cancer,505
124,NCT03288350,Phase II,Not yet recruiting,"[{'id': 1930, 'therapyName': 'Cisplatin + Docetaxel + Fluorouracil'}, {'id': 3144, 'therapyName': 'Avelumab'}]",mDCF + Avelumab in Resectable Esophago-gastric Adenocarcinoma (EGA),505
125,NCT02225405,Phase I,Recruiting,"[{'id': 2372, 'therapyName': 'Cisplatin + Docetaxel + Nintedanib'}]","Induction Study of Cisplatin, Docetaxel, and Nintedanib Stage IB-IIIA Non-Small Cell Lung Cancer (NCLC)",505
126,NCT01025089,Phase II,"Active, not recruiting","[{'id': 694, 'therapyName': 'Cetuximab'}, {'id': 1927, 'therapyName': 'Cisplatin + Doxorubicin + Cyclophosphamide'}]",Chemotherapy Plus Cetuximab Followed by Surgical Resection in Patients With Locally Advanced or Recurrent Thymoma or Thymic Carcinoma,505
127,NCT00734877,Phase III,Recruiting,"[{'id': 1851, 'therapyName': 'Cisplatin + Doxorubicin + Cyclophosphamide + Etoposide'}, {'id': 1852, 'therapyName': 'Melphalan + Bortezomib + Thalidomide + Dexamethasone'}]","UARK 2008-01, Total Therapy 4 - A Phase III Trial for Low Risk Myeloma",505
128,NCT02899195,Phase II,Recruiting,"[{'id': 5630, 'therapyName': 'Cisplatin + Durvalumab + Pemetrexed'}, {'id': 1356, 'therapyName': 'Durvalumab'}]",Phase II MEDI4736 in Combination With Chemotherapy for First-Line Treatment of Unresectable Mesothelioma (PrE0505),505
129,NCT02537418,Phase I,"Active, not recruiting","[{'id': 2585, 'therapyName': 'Cisplatin + Etoposide'}, {'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 1652, 'therapyName': 'Tremelimumab'}]",Durvalumab With or Without Tremelimumab in Advanced Incurable Solid Malignancies Receiving Standard Chemotherapy Regimens,505
130,NCT03066778,Phase III,Recruiting,"[{'id': 2585, 'therapyName': 'Cisplatin + Etoposide'}, {'id': 5145, 'therapyName': 'Cisplatin + Etoposide + Pembrolizumab'}, {'id': 2604, 'therapyName': 'Carboplatin + Etoposide + Pembrolizumab'}, {'id': 1791, 'therapyName': 'Carboplatin + Etoposide'}]",A Study of Pembrolizumab (MK-3475) in Combination With Etoposide/Platinum (Cisplatin or Carboplatin) for Participants With Extensive Stage Small Cell Lung Cancer (MK-3475-604/KEYNOTE-604),505
131,NCT02768558,Phase III,Recruiting,"[{'id': 2585, 'therapyName': 'Cisplatin + Etoposide'}, {'id': 4922, 'therapyName': 'Cisplatin + Etoposide + Nivolumab'}]",Cisplatin and Etoposide Plus Radiation Followed By Nivolumab/Placebo For Locally Advanced NSCLC,505
132,NCT01642251,Phase Ib/II,"Active, not recruiting","[{'id': 2585, 'therapyName': 'Cisplatin + Etoposide'}, {'id': 954, 'therapyName': 'Veliparib'}]",Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer or Metastatic Large Cell Neuroendocrine Non-small Cell Lung Cancer,505
133,NCT01857934,Phase II,Recruiting,"[{'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1873, 'therapyName': 'Sargramostim'}, {'id': 1167, 'therapyName': 'Aldesleukin'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 2627, 'therapyName': 'Levetiracetam'}, {'id': 2585, 'therapyName': 'Cisplatin + Etoposide'}, {'id': 2458, 'therapyName': 'Hu14.18K322A'}, {'id': 2558, 'therapyName': 'Busulfan + Melphalan'}, {'id': 2590, 'therapyName': 'Cyclophosphamide + Topotecan'}]",Therapy for Children With Advanced Stage Neuroblastoma,505
134,NCT01175356,Phase I,Completed,"[{'id': 2558, 'therapyName': 'Busulfan + Melphalan'}, {'id': 2590, 'therapyName': 'Cyclophosphamide + Topotecan'}, {'id': 1425, 'therapyName': '131I-MIBG'}, {'id': 2353, 'therapyName': 'Cyclophosphamide + Doxorubicin + Vincristine '}, {'id': 2585, 'therapyName': 'Cisplatin + Etoposide'}]","Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin",505
135,NCT01822496,Phase II,Recruiting,"[{'id': 1375, 'therapyName': 'Cisplatin + Etoposide + Paclitaxel + Carboplatin + Erlotinib'}]",Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer,505
136,NCT02987998,Phase I,Recruiting,"[{'id': 5145, 'therapyName': 'Cisplatin + Etoposide + Pembrolizumab'}]",Neoadjuvant Chemoradiation Plus Pembrolizumab Followed By Consolidation Pembrolizumab in NSCLC,505
137,NCT01579929,Phase I,Completed,"[{'id': 2504, 'therapyName': 'Cisplatin + Etoposide + Sonidegib'}]","Combination of the Hedgehog Inhibitor, LDE225, With Etoposide and Cisplatin in the First-Line Treatment of Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC)",505
138,NCT01182168,Phase I,Completed,"[{'id': 2296, 'therapyName': 'Cisplatin + Everolimus + Gemcitabine'}]",Gemcitabine and Split-Dose Cisplatin Plus Everolimus (RAD001) in Patients With Advanced Solid Tumor Malignancies,505
139,NCT03189719,Phase III,Recruiting,"[{'id': 1833, 'therapyName': 'Cisplatin + Fluorouracil'}, {'id': 6051, 'therapyName': 'Cisplatin + Fluorouracil + Pembrolizumab'}]",First-line Esophageal Carcinoma Study With Chemo vs. Chemo Plus Pembrolizumab (MK-3475-590/KEYNOTE-590),505
140,NCT00588770,Phase III,"Active, not recruiting","[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1835, 'therapyName': 'Docetaxel + Cisplatin'}, {'id': 1833, 'therapyName': 'Cisplatin + Fluorouracil'}, {'id': 1834, 'therapyName': 'Docetaxel + Carboplatin'}, {'id': 1832, 'therapyName': 'Carboplatin + Fluorouracil\t'}]",Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer,505
141,NCT03143153,Phase III,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}, {'id': 1833, 'therapyName': 'Cisplatin + Fluorouracil'}, {'id': 5799, 'therapyName': 'Nivolumab + Cisplatin + Fluorouacil'}]",A Study to Evaluate Efficacy in Subjects With Esophageal Cancer Treated With Nivolumab and Ipilimumab or Nivolumab Combined With Fluorouracil Plus Cisplatin Versus Fluorouracil Plus Cisplatin (CheckMate 648),505
142,NCT02494583,Phase III,"Active, not recruiting","[{'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 1833, 'therapyName': 'Cisplatin + Fluorouracil'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Study of Pembrolizumab (MK-3475) as First-Line Monotherapy and Combination Therapy for Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-062/KEYNOTE-062),505
143,NCT02335411,Phase II,"Active, not recruiting","[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1833, 'therapyName': 'Cisplatin + Fluorouracil'}]",A Study of Pembrolizumab (MK-3475) in Participants With Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-059/KEYNOTE-059),505
144,NCT02051868,Phase II,Recruiting,"[{'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 1833, 'therapyName': 'Cisplatin + Fluorouracil'}]",International Multicentre Study in Advanced Anal Cancer Comparing Cisplatin Plus 5 FU vs Carboplatin Plus Weekly Paclitaxel (InterAACT),505
145,NCT01711541,Phase Ib/II,Suspended,"[{'id': 1544, 'therapyName': 'Carboplatin + Etoposide + Veliparib'}, {'id': 1849, 'therapyName': 'Cisplatin + Fluorouracil + Hydroxyurea'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]",Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IV Head and Neck Cancer,505
146,NCT00980460,Phase III,Recruiting,"[{'id': 2298, 'therapyName': 'Irinotecan + Temsirolimus + Vincristine'}, {'id': 2297, 'therapyName': 'Cisplatin + Fluorouracil + Vincristine'}, {'id': 1009, 'therapyName': 'Doxorubicin'}]",Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer,505
147,NCT02393248,Phase Ib/II,Recruiting,"[{'id': 4176, 'therapyName': 'Cisplatin + Gemcitabine + INCB054828'}, {'id': 4174, 'therapyName': 'Docetaxel + INCB054828'}, {'id': 4088, 'therapyName': 'Epacadostat + Pembrolizumab'}]","Open-Label, Dose-Escalation Study of INCB054828 in Subjects With Advanced Malignancies",505
148,NCT02784795,Phase I,Recruiting,"[{'id': 4374, 'therapyName': 'Cisplatin + Gemcitabine + LY3039478'}, {'id': 4375, 'therapyName': 'Carboplatin + Gemcitabine + LY3039478'}, {'id': 4372, 'therapyName': 'LY3039478 + LY3023414'}, {'id': 4373, 'therapyName': 'Abemaciclib + LY3039478'}, {'id': 4371, 'therapyName': 'LY3039478 + Taladegib'}, {'id': 2958, 'therapyName': 'LY3039478'}, {'id': 1069, 'therapyName': 'LY3023414'}]",A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors,505
149,NCT02754726,Phase II,Recruiting,"[{'id': 4087, 'therapyName': 'Cisplatin + Gemcitabine + nab-paclitaxel + Nivolumab + Paricalcitol'}]",Combination Therapy for Patients With Untreated Metastatic Pancreatic Ductal Adenocarcinoma,505
150,NCT03101566,Phase II,Recruiting,"[{'id': 5511, 'therapyName': 'Cisplatin + Gemcitabine + Nivolumab'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Study of Nivolumab in Combination With Gemcitabine/Cisplatin or Ipilimumab for Patients With Advanced Unresectable Biliary Tract Cancer,505
151,NCT03064854,Phase I,Recruiting,"[{'id': 6027, 'therapyName': 'Carboplatin + Paclitaxel + PDR001'}, {'id': 6026, 'therapyName': 'Cisplatin + Pemetrexed + PDR001'}, {'id': 6025, 'therapyName': 'Cisplatin + Gemcitabine + PDR001'}, {'id': 6024, 'therapyName': 'Pemetrexed + PDR001 + Cisplatin + Carboplatin'}]","PDR001 in Combination With Platinum-doublet Chemotherapy in PD-L1 Unselected, Metastatic NSCLC Patients (ElevatION:NSCLC-101 Trial)",505
152,NCT02608684,Phase II,Recruiting,"[{'id': 3248, 'therapyName': 'Cisplatin + Gemcitabine + Pembrolizumab'}]",A Study of Pembrolizumab With Standard Treatment in Patients With Recurrent Platinum-resistant Ovarian Cancer,505
153,NCT02690558,Phase II,Recruiting,"[{'id': 3248, 'therapyName': 'Cisplatin + Gemcitabine + Pembrolizumab'}]",Phase 2 Study of Pembrolizumab in Combination With Gemcitabine and Cisplatin as Neoadjuvant Therapy,505
154,NCT02128282,Phase Ib/II,Recruiting,"[{'id': 1467, 'therapyName': 'Gemcitabine + Cisplatin'}, {'id': 6091, 'therapyName': 'Cisplatin + Gemcitabine + Silmitasertib'}]",Study of CX-4945 in Combination With Gemcitabine and Cisplatin for Frontline Treatment of Cholangiocarcinoma,505
155,NCT01938573,Phase Ib/II,Completed,"[{'id': 2289, 'therapyName': 'Cisplatin + Gemcitabine + Sirolimus '}]","Sirolimus, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Bladder Cancer",505
156,NCT01888302,Phase I,Completed,"[{'id': 2289, 'therapyName': 'Cisplatin + Gemcitabine + Sirolimus '}]","Sirolimus, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients At High Risk for Cholangiocarcinoma Recurrence After Liver Transplant or Surgery",505
157,NCT02567409,Phase II,Recruiting,"[{'id': 1467, 'therapyName': 'Gemcitabine + Cisplatin'}, {'id': 3110, 'therapyName': 'Cisplatin + Gemcitabine + VX-970'}]",Cisplatin and Gemcitabine Hydrochloride With or Without ATR Kinase Inhibitor VX-970 in Treating Patients With Metastatic Urothelial Cancer,505
158,NCT02949700,Phase Ib/II,Recruiting,"[{'id': 2205, 'therapyName': 'Cisplatin + Metformin'}]",Phase I/II Study OF Metformin in Combination With Cisplatin and Radiation in Head and Neck Squamous Cell Carcinoma,505
159,NCT02325401,Phase I,Recruiting,"[{'id': 2205, 'therapyName': 'Cisplatin + Metformin'}]",Dose-finding Study of Metformin With Chemoradiation in Locally Advanced Head and Neck Squamous Cell Carcinoma,505
160,NCT02573493,Phase II,Recruiting,"[{'id': 3126, 'therapyName': 'Cisplatin + nab-paclitaxel'}, {'id': 3127, 'therapyName': 'Cetuximab + nab-paclitaxel'}]",Nab-Paclitaxel and Cisplatin or Nab-paclitaxel as Induction Therapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (HNSCC),505
161,NCT03193853,Phase II,Recruiting,"[{'id': 3126, 'therapyName': 'Cisplatin + nab-paclitaxel'}, {'id': 1283, 'therapyName': 'MLN1117 + Sapanisertib'}]",TAK-228 and TAK-117 Followed by Cisplatin and Nab Paclitaxel for Metastatic Triple Negative Breast Cancer,505
162,NCT02764593,Phase I,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 4760, 'therapyName': 'Cisplatin + Nivolumab'}, {'id': 4761, 'therapyName': 'Cetuximab + Nivolumab'}]",Chemotherapy +/- Nivolumab in Patients With Intermediate and High-Risk Local-Regionally Advanced Head and Neck Squamous Cell Carcinoma,505
163,NCT02124421,Phase II,Recruiting,"[{'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 1812, 'therapyName': 'Cisplatin + Paclitaxel'}]","Outcomes in CRS/HIPEC as Initial Treatment of Ovarian, Fallopian Tube and Primary Peritoneal Cancer",505
164,NCT02121990,Phase I,"Active, not recruiting","[{'id': 1451, 'therapyName': 'Cisplatin + Paclitaxel + Bevacizumab + Olaparib '}]","Dose-Escalation Study of Intraperitoneal (IP) Cisplatin, IV/IP Paclitaxel, IV Bevacizumab, and Oral Olaparib for Newly Diagnosed Ovarian, Primary Peritoneal, and Fallopian Tube Cancer",505
165,NCT02897375,Phase I,Recruiting,"[{'id': 4734, 'therapyName': 'Cisplatin + Palbociclib'}, {'id': 4735, 'therapyName': 'Carboplatin + Palbociclib'}]",Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors,505
166,NCT02759575,Phase Ib/II,Recruiting,"[{'id': 3256, 'therapyName': 'Cisplatin + Pembrolizumab'}]",A Study of Chemoradiation Plus Pembrolizumab for Locally Advanced Laryngeal Squamous Cell Carcinoma,505
167,NCT02775812,Phase I,Recruiting,"[{'id': 3256, 'therapyName': 'Cisplatin + Pembrolizumab'}]","Cisplatin, Radiation Therapy, and Pembrolizumab in Treating Patients With Stage III-IV Head and Neck Squamous Cell Carcinoma",505
168,NCT02586207,Phase I,Recruiting,"[{'id': 3256, 'therapyName': 'Cisplatin + Pembrolizumab'}]",Pembrolizumab in Combination With CRT for LA-SCCHN,505
169,NCT02777385,Phase II,Recruiting,"[{'id': 3256, 'therapyName': 'Cisplatin + Pembrolizumab'}]",Pembrolizumab in Combination With Cisplatin and Intensity Modulated Radiotherapy (IMRT) in Head and Neck Cancer,505
170,NCT02119650,Phase II,Terminated,"[{'id': 1856, 'therapyName': 'Ruxolitinib + Cisplatin + Pemetrexed'}, {'id': 1857, 'therapyName': 'Cisplatin + Pemetrexed'}]",Ruxolitinib in Combination With Pemetrexed/Cisplatin in Non Small Cell Lung Cancer,505
171,NCT02784171,Phase II,Recruiting,"[{'id': 1857, 'therapyName': 'Cisplatin + Pemetrexed'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma,505
172,NCT01907100,Phase III,Recruiting,"[{'id': 1857, 'therapyName': 'Cisplatin + Pemetrexed'}, {'id': 831, 'therapyName': 'Nintedanib'}]",Nintedanib (BIBF 1120) in Mesothelioma,505
173,NCT02357147,Phase II,"Active, not recruiting","[{'id': 1857, 'therapyName': 'Cisplatin + Pemetrexed'}, {'id': 3513, 'therapyName': 'Amatuximab'}]",Study of the Safety and Efficacy of Amatuximab in Combination With Pemetrexed and Cisplatin in Subjects With Unresectable Malignant Pleural Mesothelioma (MPM). (ARTEMIS),505
174,NCT03164616,Phase III,Recruiting,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}, {'id': 1857, 'therapyName': 'Cisplatin + Pemetrexed'}, {'id': 1602, 'therapyName': 'Carboplatin + Pemetrexed'}, {'id': 1467, 'therapyName': 'Gemcitabine + Cisplatin'}, {'id': 2667, 'therapyName': 'Carboplatin + Gemcitabine'}, {'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 2634, 'therapyName': 'Carboplatin + nab-paclitaxel'}]",Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON). (POSEIDON),505
175,NCT01868022,Phase I,"Active, not recruiting","[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1857, 'therapyName': 'Cisplatin + Pemetrexed'}, {'id': 2899, 'therapyName': 'GSK3052230'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]","Study to Evaluate GSK3052230 in Combination With Paclitaxel and Carboplatin, or Docetaxel or as Single Agent in Subjects With Solid Malignancies and Deregulated Fibroblast Growth Factor (FGF) Pathway Signaling",505
176,NCT02468661,Phase Ib/II,Recruiting,"[{'id': 1065, 'therapyName': 'Capmatinib'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 1857, 'therapyName': 'Cisplatin + Pemetrexed'}, {'id': 1602, 'therapyName': 'Carboplatin + Pemetrexed'}]","A Safety and Efficacy Study of INC280 Alone, and in Combination With Erlotinib, Compared to Chemotherapy, in Advanced/Metastatic Non-small Cell Lung Cancer Patients With EGFR Mutation and cMET Amplification",505
177,NCT02542293,Phase III,Recruiting,"[{'id': 1467, 'therapyName': 'Gemcitabine + Cisplatin'}, {'id': 2667, 'therapyName': 'Carboplatin + Gemcitabine'}, {'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 1857, 'therapyName': 'Cisplatin + Pemetrexed'}, {'id': 1602, 'therapyName': 'Carboplatin + Pemetrexed'}]",Study of 1st Line Therapy Study of MEDI4736 With Tremelimumab Versus SoC in Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE).,505
178,NCT02707666,Phase I,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1857, 'therapyName': 'Cisplatin + Pemetrexed'}]",A Pilot Window-Of-Opportunity Study of the Anti-PD-1 Antibody Pembrolizumab in Patients With Resectable Malignant Pleural Mesothelioma,505
179,NCT02337530,Phase II,"Active, not recruiting","[{'id': 913, 'therapyName': 'Selumetinib'}, {'id': 1857, 'therapyName': 'Cisplatin + Pemetrexed'}]",Selumetinib in Patients Receiving Pemetrexed and Cisplatin in Advanced or Metastatic KRAS Wildtype or Unknown Non-Squamous Non-Small Cell Lung Cancer,505
180,NCT02124148,Phase I,Recruiting,"[{'id': 1994, 'therapyName': 'Cisplatin + Prexasertib'}, {'id': 1993, 'therapyName': 'Cetuximab + Prexasertib'}, {'id': 6248, 'therapyName': 'Pemetrexed + Prexasertib'}, {'id': 6247, 'therapyName': 'LY3023414 + Prexasertib'}, {'id': 6246, 'therapyName': 'Fluoruracil + Leucovorin + Prexasertib'}]",A Study of LY2606368 With Cisplatin or Cetuximab in Participants With Advanced Cancer,505
181,NCT02393794,Phase Ib/II,"Active, not recruiting","[{'id': 2993, 'therapyName': 'Cisplatin + Romidepsin '}]",Romidepsin Plus Cisplatin in Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC),505
182,NCT00492505,Phase II,Unknown status,"[{'id': 2212, 'therapyName': 'Cisplatin + Sorafenib + Tamoxifen'}]","Sorafenib, Tamoxifen, and Cisplatin in Treating Patients With High-Risk Stage III Melanoma",505
183,NCT02723864,Phase I,Recruiting,"[{'id': 3993, 'therapyName': 'Cisplatin + Veliparib + VX-970'}]","Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors",505
184,NCT02998528,Phase III,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}, {'id': 5241, 'therapyName': 'Cisplatin + Vinorelbine + Gemcitabine + Docetaxel + Pemetrexed + Carboplatin'}]",A Neoadjuvant Study of Nivolumab and Ipilimumab Compared to Chemotherapy Doublet in Early Stage Non-Small Cell Lung Cancer (NSCLC) (CheckMate 816),505
185,NCT02567422,Phase I,Recruiting,"[{'id': 3109, 'therapyName': 'Cisplatin + VX-970'}]","VX-970, Cisplatin, and Radiation Therapy in Treating Patients With Locally Advanced HPV-Negative Head and Neck Squamous Cell Carcinoma",505
186,NCT01878617,Phase II,Recruiting,"[{'id': 956, 'therapyName': 'Vismodegib'}, {'id': 1800, 'therapyName': 'Cyclophosphamide + Cisplatin + Vincristine '}, {'id': 1801, 'therapyName': 'Pemetrexed + Gemcitabine'}]",A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma,505
187,NCT02277184,Phase I,Terminated,"[{'id': 1955, 'therapyName': 'Ficlatuzumab + Cisplatin'}]","Ficlatuzumab, Cisplatin and IMRT in Locally Advanced Head and Neck Squamous Cell Carcinoma",505
188,NCT01936974,Phase II,Terminated,"[{'id': 1295, 'therapyName': 'Gemcitabine + Bevacizumab + Cisplatin'}, {'id': 1296, 'therapyName': 'Gemcitabine + Bevacizumab + Oxaliplatin'}, {'id': 1294, 'therapyName': 'Gemcitabine + Bevacizumab + Carboplatin'}, {'id': 1297, 'therapyName': 'Gemcitabine + Bevacizumab'}]","(PGA) for Platinum-resistant/Refractory, Paclitaxel-Pretreated Recurrent Ovarian and Peritoneal Carcinoma",505
189,NCT00942331,Phase III,"Active, not recruiting","[{'id': 1295, 'therapyName': 'Gemcitabine + Bevacizumab + Cisplatin'}, {'id': 1467, 'therapyName': 'Gemcitabine + Cisplatin'}]",Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer,505
190,NCT01585805,Phase II,Recruiting,"[{'id': 954, 'therapyName': 'Veliparib'}, {'id': 1467, 'therapyName': 'Gemcitabine + Cisplatin'}]",Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Patients With Locally Advanced or Metastatic Pancreatic Cancer,505
191,NCT02300610,Phase I,"Active, not recruiting","[{'id': 1467, 'therapyName': 'Gemcitabine + Cisplatin'}, {'id': 1262, 'therapyName': 'Enzalutamide'}]",Enzalutamide in Combination With Gemcitabine and Cisplatin in Bladder Cancer,505
192,NCT02537561,Phase I,Withdrawn,"[{'id': 682, 'therapyName': 'Talazoparib'}, {'id': 1467, 'therapyName': 'Gemcitabine + Cisplatin'}]",Talazoparib in Combination With Gemcitabine and Cisplatin in Patients With Advanced Solid Tumors,505
193,NCT03036098,Phase III,Recruiting,"[{'id': 1467, 'therapyName': 'Gemcitabine + Cisplatin'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}, {'id': 2667, 'therapyName': 'Carboplatin + Gemcitabine'}]",Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care Chemotherapy in Treatment of Patients With Untreated Inoperable or Metastatic Urothelial Cancer,505
194,NCT02711553,Phase II,"Active, not recruiting","[{'id': 886, 'therapyName': 'Ramucirumab'}, {'id': 1030, 'therapyName': 'LY2801653'}, {'id': 1467, 'therapyName': 'Gemcitabine + Cisplatin'}]",A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer,505
195,NCT02453282,Phase III,"Active, not recruiting","[{'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 1467, 'therapyName': 'Gemcitabine + Cisplatin'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 1652, 'therapyName': 'Tremelimumab'}]",Phase III Open Label First Line Therapy Study of MEDI 4736 With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC).,505
196,NCT02452970,Phase II,"Active, not recruiting","[{'id': 3680, 'therapyName': 'RRx-001'}, {'id': 1467, 'therapyName': 'Gemcitabine + Cisplatin'}]",RRx-001 in Second Line Treatment of Advanced Cholangiocarcinoma Prior to Readministration of First-Line Therapy (EPIC),505
197,NCT01612351,Phase II,"Active, not recruiting","[{'id': 2477, 'therapyName': 'Lapatinib + Carboplatin + Cisplatin + Paclitaxel'}, {'id': 2476, 'therapyName': 'Lapatinib + Carboplatin + Paclitaxel'}]",Multimodality Risk Adapted Tx Including Induction Chemo for SCCHN Amenable to Transoral Surgery,505
198,NCT01828034,Phase Ib/II,"Active, not recruiting","[{'id': 2218, 'therapyName': 'MEK162 + Gemcitabine + Cisplatin'}]","First Line Gemcitabine, Cisplatin and MEK162 in Advanced Biliary Tract Carcinoma",505
199,NCT02114229,Phase II,Recruiting,"[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 2449, 'therapyName': 'Methotrexate + Cisplatin + Cyclophosphamide + Vincristine'}, {'id': 626, 'therapyName': 'Alisertib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 942, 'therapyName': 'Topotecan'}]",Phase 2 Study of Alisertib Therapy for Rhabdoid Tumors,505
200,NCT00602667,Phase I,"Active, not recruiting","[{'id': 2449, 'therapyName': 'Methotrexate + Cisplatin + Cyclophosphamide + Vincristine'}, {'id': 2450, 'therapyName': 'Cyclophosphamide + Etoposide + Topotecan'}, {'id': 2451, 'therapyName': 'Erlotinib + Cyclophosphamide + Topotecan'}]","Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma",505
201,NCT02585973,Phase I,Recruiting,"[{'id': 1725, 'therapyName': 'MK-1775 + Cisplatin'}]",Dose-escalating AZD1775 + Concurrent Radiation + Cisplatin for Intermediate/High Risk HNSCC,505
202,NCT01958658,Phase I,Suspended,"[{'id': 1725, 'therapyName': 'MK-1775 + Cisplatin'}]","AZD1775, Cisplatin, and Radiation Therapy in Treating Patients With Cervical Cancer",505
203,NCT03012477,Phase II,Recruiting,"[{'id': 1725, 'therapyName': 'MK-1775 + Cisplatin'}]",CISPLATIN + AZD-1775 In Breast Cancer,505
204,NCT03116971,Phase Ib/II,Recruiting,"[{'id': 5546, 'therapyName': 'MSC2490484A  + Cisplatin + Etoposide'}, {'id': 3616, 'therapyName': 'MSC2490484A '}]",Phase Ib/II Study of M3814 With Etoposide and Cisplatin in Small Cell Lung Cancer (SCLC) Extensive Disease (ED),505
205,NCT01788566,Phase II,Completed,"[{'id': 2882, 'therapyName': 'Necitumumab + Gemcitabine + Cisplatin'}]",A Study of Gemcitabine-Cisplatin Chemotherapy Plus Necitumumab in the First-Line Treatment of Participants With Lung Cancer,505
206,NCT01920061,Phase I,Recruiting,"[{'id': 1287, 'therapyName': 'PF-05212384 + Dacomitinib'}, {'id': 1286, 'therapyName': 'PF-05212384 + Cisplatin'}, {'id': 1285, 'therapyName': 'PF-05212384 + Docetaxel'}]",A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents,505
207,NCT02819999,Phase I,Recruiting,"[{'id': 4827, 'therapyName': 'Rovalpituzumab Tesirine + Cisplatin + Etoposide'}, {'id': 3544, 'therapyName': 'Rovalpituzumab Tesirine'}]",A Study of Rovalpituzumab Tesirine (SC16LD6.5) in the Frontline Treatment of Patients With Delta-Like Protein 3-Expressing Extensive Stage Small Cell Lung Cancer,505
208,NCT02151084,Phase II,Recruiting,"[{'id': 2222, 'therapyName': 'Selumetinib + Cisplatin + Gemcitabine'}]",A Study of Different Dosing Schedules of Selumetinib With Cisplatin/Gemcitabine (CIS/GEM) Versus CIS/GEM Alone in Biliary Cancer,505
209,NCT02035527,Phase Ib/II,"Active, not recruiting","[{'id': 2431, 'therapyName': 'Sorafenib + Cisplatin + Docetaxel'}]","Sorafenib Tosylate, Cisplatin, and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck",505
210,NCT01194869,Phase II,Terminated,"[{'id': 1534, 'therapyName': 'Sorafenib + Cisplatin + Paclitaxel'}]","Preoperative Clinical Trial of Sorafenib in Combination With Cisplatin Followed by Paclitaxel for Triple Negative (ER-, PR-, Her2-)Early Stage Breast Cancer",505
211,NCT00489944,Phase II,Unknown status,"[{'id': 1963, 'therapyName': 'Sunitinib + Tamoxifen + Cisplatin'}]","Sunitinib, Tamoxifen, and Cisplatin in Treating Patients With High-Risk Ocular Melanoma",505
0,NCT02935790,Phase I,Completed,"[{'id': 3312, 'therapyName': 'ACY-241 + Ipilimumab + Nivolumab'}]",Selective HDAC6 Inhibitor ACY-241 in Combination With Ipilimumab and Nivolumab,8030
1,NCT02635061,Phase I,Recruiting,"[{'id': 3312, 'therapyName': 'ACY-241 + Ipilimumab + Nivolumab'}]",Selective HDAC6 Inhibitor ACY 241 in Combination With Nivolumab in Patients With Unresectable Non Small Cell Lung Cancer,8030
2,NCT02551185,Phase I,Recruiting,"[{'id': 3311, 'therapyName': 'Citarinostat'}]",ACY 241 in Combination With Paclitaxel in Patients With Advanced Solid Tumors,8030
3,NCT02400242,Phase I,"Active, not recruiting","[{'id': 3311, 'therapyName': 'Citarinostat'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 1622, 'therapyName': 'Pomalidomide'}]",Study of ACY-241 Alone and in Combination With Pomalidomide and Dexamethasone in Multiple Myeloma,8030
0,NCT01263782,Phase II,Completed,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1602, 'therapyName': 'Carboplatin + Pemetrexed'}, {'id': 701, 'therapyName': 'Cixutumumab'}]",BATTLE-FL: Front-Line Biomarker-Integrated Treatment Study in Non Small Cell Lung Cancer,6887
1,NCT00957853,Phase II,"Active, not recruiting","[{'id': 694, 'therapyName': 'Cetuximab'}, {'id': 701, 'therapyName': 'Cixutumumab'}]",Preoperative Treatment With Cetuximab and/or IMC-A12,6887
0,NCT02900664,Phase I,Recruiting,"[{'id': 5399, 'therapyName': 'PDR001 + EGF816'}, {'id': 5397, 'therapyName': 'PDR001 + CJM112'}, {'id': 5398, 'therapyName': 'PDR001 + Trametinib'}, {'id': 5395, 'therapyName': 'PDR001 + Canakinumab'}]","A Study of PDR001 in Combination With CJM112, EGF816, Ilaris (Canakinumab) or Mekinist (Trametinib)",8677
1,NCT03111992,Phase I,Recruiting,"[{'id': 5311, 'therapyName': 'PDR001 + LCL161'}, {'id': 5397, 'therapyName': 'PDR001 + CJM112'}, {'id': 2659, 'therapyName': 'PDR001'}]","Study of Single Agent CJM112, and PDR001 in Combination With LCL161 or CJM112 in Patients With Multiple Myeloma",8677
0,NCT02926768,Phase Ib/II,Recruiting,"[{'id': 5329, 'therapyName': 'CK-101'}]",Phase I/II Study of CK-101 in NSCLC Patients and Other Advanced Solid Tumors,8663
0,NCT01439750,Phase Ib/II,"Active, not recruiting","[{'id': 3394, 'therapyName': 'Bortezomib + Cladribine + Rituximab'}]","Bortezomib (VELCADE), Cladribine and Rituximab (VCR) in Mantle Cell Lymphoma (PSHCI 10-011)",235
1,NCT01515527,Phase II,Recruiting,"[{'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 650, 'therapyName': 'Decitabine'}]",Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS),235
2,NCT02096055,Phase II,Recruiting,"[{'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1949, 'therapyName': 'SGI-110'}, {'id': 1022, 'therapyName': 'Idarubicin'}]",4-Arm Phase II Study of SGI-110 in Elderly Acute Myeloid Leukemia (AML),235
3,NCT02756572,Phase I,Recruiting,"[{'id': 917, 'therapyName': 'Sirolimus'}, {'id': 1845, 'therapyName': 'Mycophenolate mofetil'}, {'id': 1650, 'therapyName': 'Cyclosporine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 5215, 'therapyName': 'mitoxantrone hydrochloride'}, {'id': 1166, 'therapyName': 'Fludarabine'}]",Early Allogeneic Hematopoietic Cell Transplantation in Treating Patients With Relapsed or Refractory High-Grade Myelodysplastic Syndrome or Acute Myeloid Leukemia,235
4,NCT02788201,Phase II,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1133, 'therapyName': 'Mitomycin C'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1013, 'therapyName': 'epirubicin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1137, 'therapyName': 'Bleomycin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 781, 'therapyName': 'Ixabepilone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 2950, 'therapyName': 'Estramustine'}, {'id': 1941, 'therapyName': 'Floxuridine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 1811, 'therapyName': 'Carmustine'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 953, 'therapyName': 'Vandetanib'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 4419, 'therapyName': 'Toremifine'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 2601, 'therapyName': 'Dactinomycin'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 3035, 'therapyName': 'Chlorambucil'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 342, 'therapyName': 'Vemurafenib'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 2635, 'therapyName': 'Vinblastine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 4305, 'therapyName': 'Teniposide'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 4304, 'therapyName': 'Streptozocin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1231, 'therapyName': 'Bendamustine'}, {'id': 4303, 'therapyName': 'Mechlorethamine'}, {'id': 4302, 'therapyName': 'Mitotane'}]",Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma,235
5,NCT02551718,Phase I,Recruiting,"[{'id': 690, 'therapyName': 'Bosutinib'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 3160, 'therapyName': 'Nelarabine'}, {'id': 3159, 'therapyName': 'Bexarotene'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 998, 'therapyName': 'cabozantinib'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 877, 'therapyName': 'Ponatinib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 623, 'therapyName': 'Afatinib'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 890, 'therapyName': 'Regorafenib'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 2, 'therapyName': 'Trametinib'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 3, 'therapyName': 'Dabrafenib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 789, 'therapyName': 'Ceritinib'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1571, 'therapyName': 'Cabazitaxel'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1327, 'therapyName': 'Pralatrexate'}]",High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia,235
6,NCT02728050,Phase Ib/II,Recruiting,"[{'id': 920, 'therapyName': 'Sorafenib'}, {'id': 4363, 'therapyName': 'Cladribine + Cytarabine + Filgrastim + Mitoxantrone'}]","Filgrastim, Cladribine, Cytarabine and Mitoxantrone With or Without Sorafenib Tosylate in Treating Patients With Newly-Diagnosed, High-Risk Acute Myeloid Leukemia or Myelodysplastic Syndrome",235
7,NCT02416908,Phase Ib/II,Recruiting,"[{'id': 1749, 'therapyName': 'Selinexor'}, {'id': 3178, 'therapyName': 'Cladribine + Cytarabine + Plerixafor'}]",Study of CLAG + Selinexor in Relapsed or Refractory Acute Myeloid Leukemia,235
0,NCT02211755,Phase I,Recruiting,"[{'id': 3063, 'therapyName': 'Bortezomib + Clofarabine'}]",Trial of the Combination of Bortezomib and Clofarabine in Adults With Relapsed Solid Tumors,621
1,NCT02083250,Phase I,Recruiting,"[{'id': 1844, 'therapyName': 'anti-thymocyte globulin'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 3201, 'therapyName': 'Busulfan + Clofarabine + Fludarabine'}]",Fludarabine/Clofarabine/Busulfan Combined With SAHA in Acute Leukemia,621
2,NCT01701986,Phase Ib/II,Recruiting,"[{'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1845, 'therapyName': 'Mycophenolate mofetil'}, {'id': 1844, 'therapyName': 'anti-thymocyte globulin'}, {'id': 3992, 'therapyName': 'Busulfan + Clofarabine + Gemcitabine'}]",Gemcitabine/Clofarabine/Busulfan and Allogeneic Transplantation for Aggressive Lymphomas,621
3,NCT01621477,Phase II,Terminated,"[{'id': 1756, 'therapyName': 'Plerixafor'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 1845, 'therapyName': 'Mycophenolate mofetil'}, {'id': 2469, 'therapyName': 'Busulfan + Clofarabine + Thymoglobulin'}, {'id': 1783, 'therapyName': 'Cyclophosphamide + Cytarabine'}]",T-Cell Replete Haploidentical Donor Hematopoietic Stem Cell Plus Natural Killer (NK) Cell Transplantation in Patients With Hematologic Malignancies Relapsed or Refractory Despite Previous Allogeneic Transplant,621
4,NCT00857389,Phase II,"Active, not recruiting","[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 2469, 'therapyName': 'Busulfan + Clofarabine + Thymoglobulin'}, {'id': 1639, 'therapyName': 'Methotrexate'}]",Thiotepa-Clofarabine-Busulfan With Allogeneic Stem Cell Transplant for High Risk Malignancies,621
5,NCT00990249,Phase II,Completed,"[{'id': 2469, 'therapyName': 'Busulfan + Clofarabine + Thymoglobulin'}]",Busulfan Plus Clofarabine Followed by Allogeneic Hematopoietic Stem Cell Transplantation,621
6,NCT02551718,Phase I,Recruiting,"[{'id': 690, 'therapyName': 'Bosutinib'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 3160, 'therapyName': 'Nelarabine'}, {'id': 3159, 'therapyName': 'Bexarotene'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 998, 'therapyName': 'cabozantinib'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 877, 'therapyName': 'Ponatinib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 623, 'therapyName': 'Afatinib'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 890, 'therapyName': 'Regorafenib'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 2, 'therapyName': 'Trametinib'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 3, 'therapyName': 'Dabrafenib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 789, 'therapyName': 'Ceritinib'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1571, 'therapyName': 'Cabazitaxel'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1327, 'therapyName': 'Pralatrexate'}]",High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia,621
7,NCT01252667,Phase II,Recruiting,"[{'id': 2272, 'therapyName': 'Cyclosporine + Mycophenolate mofetil'}, {'id': 1746, 'therapyName': 'Clofarabine'}]",Clofarabine and Low-Dose Total-Body Irradiation in Treating Patients With Acute Myeloid Leukemia Undergoing Donor Peripheral Blood Stem Cell Transplant,621
8,NCT02085408,Phase III,Recruiting,"[{'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 1738, 'therapyName': 'Daunorubicin + Cytarabine'}]",Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia,621
9,NCT01794702,Phase Ib/II,"Active, not recruiting","[{'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 650, 'therapyName': 'Decitabine'}]","Decitabine Followed by Clofarabine, Idarubicin, and Cytarabine in Acute Leukemia",621
10,NCT03136146,Phase II,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1090, 'therapyName': 'Ofatumumab'}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 1476, 'therapyName': 'Pegfilgrastim'}]","Study of Clofarabine, Etoposide, Cyclophosphamide [CEC], Liposomal Vincristine (VCR), Dexamethasone and Bortezomib in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LL)",621
11,NCT02788201,Phase II,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1133, 'therapyName': 'Mitomycin C'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1013, 'therapyName': 'epirubicin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1137, 'therapyName': 'Bleomycin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 781, 'therapyName': 'Ixabepilone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 2950, 'therapyName': 'Estramustine'}, {'id': 1941, 'therapyName': 'Floxuridine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 1811, 'therapyName': 'Carmustine'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 953, 'therapyName': 'Vandetanib'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 4419, 'therapyName': 'Toremifine'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 2601, 'therapyName': 'Dactinomycin'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 3035, 'therapyName': 'Chlorambucil'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 342, 'therapyName': 'Vemurafenib'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 2635, 'therapyName': 'Vinblastine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 4305, 'therapyName': 'Teniposide'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 4304, 'therapyName': 'Streptozocin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1231, 'therapyName': 'Bendamustine'}, {'id': 4303, 'therapyName': 'Mechlorethamine'}, {'id': 4302, 'therapyName': 'Mitotane'}]",Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma,621
12,NCT03117751,Phase II,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1876, 'therapyName': 'Blinatumomab '}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1638, 'therapyName': 'Pegaspargase'}]",Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma,621
13,NCT02518750,Phase II,Recruiting,"[{'id': 1604, 'therapyName': 'Panobinostat + Bortezomib + Dexamethasone'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 3160, 'therapyName': 'Nelarabine'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 3217, 'therapyName': 'Cyclophosphamide + Etoposide'}, {'id': 3216, 'therapyName': 'Cytarabine + Methotrexate + Prednisone'}, {'id': 1746, 'therapyName': 'Clofarabine'}]",Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoma,621
14,NCT02883049,Phase III,Suspended,"[{'id': 717, 'therapyName': 'Dasatinib'}, {'id': 4685, 'therapyName': 'Dexamethasone + Doxorubicin'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1746, 'therapyName': 'Clofarabine'}]",Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations,621
15,NCT00908167,Phase I,Completed,"[{'id': 2374, 'therapyName': 'Clofarabine + Cytarabine + Sorafenib'}]",Sorafenib in Combination With Cytarabine and Clofarabine in Patients With Refractory or Relapsed Hematologic Malignancies,621
16,NCT00549848,Phase III,"Active, not recruiting","[{'id': 1781, 'therapyName': 'Vincristine + Pegaspargase + Daunorubicin'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1782, 'therapyName': 'Clofarabine + Etoposide + Cyclophosphamide'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}]",Total Therapy Study XVI for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia,621
17,NCT01885689,Phase II,Recruiting,"[{'id': 2236, 'therapyName': 'Clofarabine + Melphalan'}]",Clofarabine and Melphalan Before Donor Stem Cell Transplant in Treating Patients With Myelodysplasia or Acute Leukemia in Remission,621
0,NCT02189174,Phase Ib/II,Terminated,"[{'id': 1464, 'therapyName': 'CLR457'}]",Study of CLR457 Administered Orally in Adult Patients With Advanced Solid Malignancies,7269
0,NCT02346955,Phase I,Terminated,"[{'id': 4246, 'therapyName': 'CM-24'}, {'id': 4247, 'therapyName': 'CM-24 + Pembrolizumab'}]",Study of CM-24 (MK-6018) Alone and In Combination With Pembrolizumab (MK-3475) in Participants With Selected Advanced or Recurrent Malignancies (MK-6018-001),8387
0,NCT02387125,Phase I,Recruiting,"[{'id': 4318, 'therapyName': 'CMB305'}]","A Phase 1b Safety Study of CMB305 (Sequentially Administered LV305 and G305) in Patients With Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1",8409
0,NCT02630186,Phase Ib/II,"Active, not recruiting","[{'id': 3575, 'therapyName': 'Atezolizumab + CO1686'}]",A Phase 1b/2 Study of Safety and Efficacy of Rociletinib in Combination With MPDL3280A in Patients With Advanced or Metastatic EGFR-mutant NSCLC,7122
1,NCT02186301,Phase II,Terminated,"[{'id': 1003, 'therapyName': 'CO1686'}, {'id': 4, 'therapyName': 'Erlotinib'}]",TIGER-1: Safety and Efficacy Study of Rociletinib (CO-1686) or Erlotinib in Patients With EGFR Mutant NSCLC Who Have Not Had Any Previous EGFR Directed Therapy,7122
2,NCT02705339,Phase II,Withdrawn,"[{'id': 1003, 'therapyName': 'CO1686'}]",Rociletinib Genomic Landscape in Non-small Cell Lung Cancer (NSCLC),7122
3,NCT01526928,Phase Ib/II,"Active, not recruiting","[{'id': 1003, 'therapyName': 'CO1686'}]","Study to Evaluate Safety, Pharmacokinetics, and Efficacy of CO-1686 in Previously Treated Mutant Epidermal Growth Factor Receptor (EGFR) in Non-Small Cell Lung Cancer (NSCLC) Patients",7122
4,NCT02147990,Phase II,Unknown status,"[{'id': 1003, 'therapyName': 'CO1686'}]",Open Label Safety and Efficacy Study of Rociletinib (CO-1686) in Patients With T790M Positive NSCLC Who Have Failed One Previous EGFR-Directed TKI,7122
5,NCT02547675,Phase I,No longer available,"[{'id': 1003, 'therapyName': 'CO1686'}]",Rociletinib (CO-1686) USA Expanded Access Program,7122
6,NCT02322281,Phase III,"Active, not recruiting","[{'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1003, 'therapyName': 'CO1686'}]","TIGER-3 Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet Chemotherapy",7122
7,NCT02580708,Phase Ib/II,Completed,"[{'id': 2, 'therapyName': 'Trametinib'}, {'id': 1003, 'therapyName': 'CO1686'}]",A Phase 1/2 Study of the Safety and Efficacy of Rociletinib When Administered in Combination With Trametinib in Patients With Activating EGFR Mutation-positive Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC),7122
0,NCT03202940,Phase Ib/II,Recruiting,"[{'id': 5971, 'therapyName': 'Alectinib + Cobimetinib'}]",A Phase IB/II Study of Alectinib Combined With Cobimetinib in Advanced ALK-Rearranged (ALK+) NSCLC,7123
1,NCT03281369,Phase Ib/II,Not yet recruiting,"[{'id': 1343, 'therapyName': 'Atezolizumab + Cobimetinib'}, {'id': 6274, 'therapyName': 'mFOLFOX-6 + Atezolizumab + Cobimetinib'}, {'id': 6275, 'therapyName': 'mFOLFOX-6 + Atezolizumab'}, {'id': 6276, 'therapyName': 'Atezolizumab + Linagliptin'}, {'id': 5941, 'therapyName': 'Atezolizumab + PEGPH20'}, {'id': 5942, 'therapyName': 'Atezolizumab + BKT140'}, {'id': 1721, 'therapyName': 'Ramucirumab + Paclitaxel'}, {'id': 5850, 'therapyName': 'mFOLFOX-6'}]",A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) (UMBRELLA),7123
2,NCT03280563,Phase Ib/II,Not yet recruiting,"[{'id': 6269, 'therapyName': 'Atezolizumab + Ipatasertib'}, {'id': 6270, 'therapyName': 'Atezolizumab + Bevacizumab + Exemestane'}, {'id': 1343, 'therapyName': 'Atezolizumab + Cobimetinib'}, {'id': 6271, 'therapyName': 'Atezolizumab + Bevacizumab + Fulvestrant'}, {'id': 6272, 'therapyName': 'Atezolizumab + Bevacizumab + Tamoxifen'}, {'id': 6273, 'therapyName': 'Atezolizumab + Ipatasertib + Fulvestrant'}, {'id': 744, 'therapyName': 'Fulvestrant'}, {'id': 6268, 'therapyName': 'Atezolizumab + Fulvestrant'}]",A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer,7123
3,NCT03181100,Phase II,Recruiting,"[{'id': 619, 'therapyName': 'Abraxane'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1343, 'therapyName': 'Atezolizumab + Cobimetinib'}, {'id': 4595, 'therapyName': 'Atezolizumab + Bevacizumab'}, {'id': 3049, 'therapyName': 'Atezolizumab + nab-paclitaxel'}, {'id': 4825, 'therapyName': 'Atezolizumab + Vemurafenib + Cobimetinib'}, {'id': 5606, 'therapyName': 'Atezolizumab + Paclitaxel'}]",Atezolizumab Combinations With Chemotherapy for Anaplastic and Poorly Differentiated Thyroid Carcinomas,7123
4,NCT03273153,Phase III,Not yet recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1343, 'therapyName': 'Atezolizumab + Cobimetinib'}]",A Study of Cobimetinib Plus Atezolizumab Versus Pembrolizumab in Participants With Previously Untreated Advanced BRAFv600 Wild-Type Melanoma,7123
5,NCT02788279,Phase III,"Active, not recruiting","[{'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 1343, 'therapyName': 'Atezolizumab + Cobimetinib'}, {'id': 890, 'therapyName': 'Regorafenib'}]",A Study to Investigate Efficacy and Safety of Cobimetinib Plus Atezolizumab and Atezolizumab Monotherapy Versus Regorafenib in Participants With Metastatic Colorectal Adenocarcinoma,7123
6,NCT03201458,Phase II,Not yet recruiting,"[{'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 1343, 'therapyName': 'Atezolizumab + Cobimetinib'}]",Atezolizumab With or Without Cobimetinib in Treating Patients With Metastatic Bile Duct Cancer That Cannot Be Removed by Surgery,7123
7,NCT03193190,Phase Ib/II,Recruiting,"[{'id': 5942, 'therapyName': 'Atezolizumab + BKT140'}, {'id': 5940, 'therapyName': 'Gemcitabine + Nab-Paclitaxel + mFOLFOX-6'}, {'id': 5941, 'therapyName': 'Atezolizumab + PEGPH20'}, {'id': 1343, 'therapyName': 'Atezolizumab + Cobimetinib'}]",A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (PDAC),7123
8,NCT01988896,Phase I,"Active, not recruiting","[{'id': 1343, 'therapyName': 'Atezolizumab + Cobimetinib'}]",A Phase 1b Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) in Combination With Cobimetinib in Patients With Locally Advanced or Metastatic Solid Tumors,7123
9,NCT03108131,Phase II,Recruiting,"[{'id': 1343, 'therapyName': 'Atezolizumab + Cobimetinib'}]",Cobimetinib and Atezolizumab in Advanced Rare Tumors,7123
10,NCT03178851,Phase I,Recruiting,"[{'id': 1343, 'therapyName': 'Atezolizumab + Cobimetinib'}]",A Study Evaluating Cobimetinib (Targeted Therapy) Plus Atezolizumab (Immunotherapy) in Participants With Advanced Melanoma Whose Cancer Has Worsened During or After Treatment With Previous Immunotherapy,7123
11,NCT03202316,Phase II,Recruiting,"[{'id': 5970, 'therapyName': 'Atezolizumab + Cobimetinib + Eribulin'}]",Study of Triple Combination of Atezolizumab + Cobimetinib + Eribulin (ACE) in Patients With Chemotherapy Resistant Metastatic Inflammatory Breast Cancer,7123
12,NCT02908672,Phase III,Recruiting,"[{'id': 1657, 'therapyName': 'Vemurafenib + Cobimetinib'}, {'id': 4825, 'therapyName': 'Atezolizumab + Vemurafenib + Cobimetinib'}]",A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Participants With Metastatic or Unresectable Locally Advanced Melanoma,7123
13,NCT02427893,Phase III,Withdrawn,"[{'id': 1004, 'therapyName': 'Cobimetinib'}, {'id': 342, 'therapyName': 'Vemurafenib'}]",Trial of Vemurafenib and Cobimetinib in Patients With Advanced BRAFV600 Mutant Melanoma,7123
14,NCT02457793,Phase I,Completed,"[{'id': 1004, 'therapyName': 'Cobimetinib'}, {'id': 2149, 'therapyName': 'GDC-0994'}]","A Study of the Safety, Tolerability, and Effects of Cobimetinib and GDC-0994 in Patients With Locally Advanced or Metastatic Solid Tumors",7123
15,NCT02639546,Phase I,Recruiting,"[{'id': 1004, 'therapyName': 'Cobimetinib'}]",iMATRIXcobi: Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Patients With Previously Treated Solid Tumors,7123
16,NCT02322814,Phase II,Recruiting,"[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1004, 'therapyName': 'Cobimetinib'}]",A Study of Cobimetinib in Combination With Paclitaxel as First-line Treatment for Patients With Metastatic Triple-negative Breast Cancer,7123
17,NCT02876224,Phase I,Recruiting,"[{'id': 4609, 'therapyName': 'Cobimetinib + Bevacizumab + Atezolizumab'}]",Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors,7123
18,NCT01562275,Phase I,Completed,"[{'id': 1160, 'therapyName': 'Cobimetinib + GDC-0068'}]"," A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0973 in Combination With GDC-0068 When Administered in Patients With Locally Advanced or Metastatic Solid Tumors",7123
19,NCT03101254,Phase Ib/II,Recruiting,"[{'id': 5512, 'therapyName': 'Cobimetinib + LY3022855 + Vemurafenib'}]",LY3022855 With BRAF/MEK Inhibition in Patients With Melanoma,7123
20,NCT02670044,Phase Ib/II,Recruiting,"[{'id': 4171, 'therapyName': 'Cobimetinib + Venetoclax'}, {'id': 4172, 'therapyName': 'RO5503781 + Venetoclax'}]",A Study of Venetoclax in Combination With Cobimetinib and Venetoclax in Combination With Idasanutlin in Patients Aged >/= 60 Years With Relapsed or Refractory Acute Myeloid Leukemia Who Are Not Eligible for Cytotoxic Therapy,7123
21,NCT02721459,Phase I,Recruiting,"[{'id': 3995, 'therapyName': 'Cobimetinib + XL888 + Vemurafenib'}]",XL888 + Vemurafenib + Cobimetinib for Unresectable B Rapidly Accelerated Fibrosarcoma (BRAF) Mutated Stage III/IV Melanoma,7123
22,NCT01986166,Phase I,Completed,"[{'id': 1342, 'therapyName': 'MEHD7945A + Cobimetinib'}]",A Study of MEHD7945A and Cobimetinib (GDC-0973) in Patients With Locally Advanced or Metastatic Cancers With Mutant KRAS,7123
23,NCT01974258,Phase I,Withdrawn,"[{'id': 1306, 'therapyName': 'Onartuzumab + Vemurafenib'}, {'id': 1307, 'therapyName': 'Onartuzumab + Cobimetinib'}, {'id': 1308, 'therapyName': 'Onartuzumab + Cobimetinib + Vemurafenib'}]","Safety, Tolerability, and Pharmacokinetics of Onartuzumab Combined With Vemurafenib and/or Cobimetinib in Cancer Patients",7123
24,NCT02036086,Phase II,Recruiting,"[{'id': 1657, 'therapyName': 'Vemurafenib + Cobimetinib'}]",Study of Neo-adjuvant Use of Vemurafenib Plus Cobimetinib for BRAF Mutant Melanoma With Palpable Lymph Node Metastases,7123
25,NCT02693535,Phase II,Recruiting,"[{'id': 1657, 'therapyName': 'Vemurafenib + Cobimetinib'}, {'id': 890, 'therapyName': 'Regorafenib'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 690, 'therapyName': 'Bosutinib'}, {'id': 850, 'therapyName': 'Palbociclib'}, {'id': 694, 'therapyName': 'Cetuximab'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 837, 'therapyName': 'Olaparib'}, {'id': 4, 'therapyName': 'Erlotinib'}]",TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer,7123
26,NCT03005639,Phase II,Recruiting,"[{'id': 1657, 'therapyName': 'Vemurafenib + Cobimetinib'}]",ML29255 Neoadjuvant Vemurafenib and Cobimetinib Melanoma,7123
27,NCT03224767,Phase II,Recruiting,"[{'id': 1657, 'therapyName': 'Vemurafenib + Cobimetinib'}]",Vemurafenib and Cobimetinib in Treating Patients With BRAF V600E Mutation Positive Craniopharyngioma,7123
28,NCT02091141,Phase II,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 698, 'therapyName': 'Alectinib'}, {'id': 1657, 'therapyName': 'Vemurafenib + Cobimetinib'}, {'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 1201, 'therapyName': 'Atezolizumab'}]","My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors",7123
29,NCT02230306,Phase II,Terminated,"[{'id': 1657, 'therapyName': 'Vemurafenib + Cobimetinib'}]",Phase II Study of Cobimetinib in Combination With Vemurafenib in Active Melanoma Brain Metastases,7123
0,NCT01940172,Phase I,Completed,"[{'id': 1458, 'therapyName': 'Conatumumab'}, {'id': 2647, 'therapyName': 'Birinapant  '}]",Study of Birinapant in Combination With Conatumumab in Subjects With Relapsed Ovarian Cancer,7266
1,NCT01327612,Phase II,"Active, not recruiting","[{'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 746, 'therapyName': 'Ganitumab'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1458, 'therapyName': 'Conatumumab'}]",Open Label Extension Study of Conatumumab and AMG 479,7266
0,NCT02729701,Phase II,Recruiting,"[{'id': 5928, 'therapyName': 'Conjugated estrogens/bazedoxifene'}]",Pilot Study of the Effect of Duavee on Benign Breast Tissue Proliferation,8864
1,NCT02694809,Phase II,Recruiting,"[{'id': 5928, 'therapyName': 'Conjugated estrogens/bazedoxifene'}]",Conjugated Estrogens/Bazedoxifene in Treating Patients With Ductal Carcinoma in Situ Undergoing Surgery,8864
0,NCT02631590,Phase II,Recruiting,"[{'id': 3315, 'therapyName': 'BAY80-6946 + Cisplatin + Gemcitabine'}]",Copanlisib (BAY 80-6946) in Combination With Gemcitabine and Cisplatin in Advanced Cholangiocarcinoma,7112
1,NCT02155582,Phase I,Completed,"[{'id': 995, 'therapyName': 'Copanlisib'}]",Copanlisib Pharmacodynamic Study,7112
2,NCT02455297,Phase II,Terminated,"[{'id': 995, 'therapyName': 'Copanlisib'}]",Phase IIa Study of Copanlisib in Relapsed or Refractory Mantle Cell Lymphoma (MCL),7112
3,NCT02391116,Phase II,"Active, not recruiting","[{'id': 995, 'therapyName': 'Copanlisib'}]",Phase II Copanlisib in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL),7112
4,NCT02728258,Phase II,Suspended,"[{'id': 995, 'therapyName': 'Copanlisib'}]",Copanlisib in Treating Patients With Persistent or Recurrent Endometrial Cancer,7112
5,NCT02626455,Phase III,Recruiting,"[{'id': 1631, 'therapyName': 'Vincristine'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 3388, 'therapyName': 'Aldoxorubicin +Cyclophosphamide + Prednisone + Rituximab + Vincristine'}, {'id': 995, 'therapyName': 'Copanlisib'}, {'id': 2323, 'therapyName': 'Bendamustine + Rituximab'}, {'id': 897, 'therapyName': 'Rituximab'}]",Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL),7112
6,NCT01660451,Phase II,"Active, not recruiting","[{'id': 995, 'therapyName': 'Copanlisib'}]","Open-label, Uncontrolled Phase II Trial of Intravenous PI3K Inhibitor BAY80-6946 in Patients With Relapsed, Indolent or Aggressive Non-Hodgkin's Lymphomas",7112
7,NCT02369016,Phase III,"Active, not recruiting","[{'id': 995, 'therapyName': 'Copanlisib'}]",Phase III Copanlisib in Rituximab-refractory iNHL,7112
8,NCT02253420,Phase I,Recruiting,"[{'id': 995, 'therapyName': 'Copanlisib'}, {'id': 1026, 'therapyName': 'Itraconazole'}]",COPANLISIB (BAY80-6946) Drug-drug Interaction Study in Advanced Solid Tumor Patients,7112
9,NCT02367040,Phase III,Recruiting,"[{'id': 897, 'therapyName': 'Rituximab'}, {'id': 995, 'therapyName': 'Copanlisib'}]",Copanlisib and Rituximab in Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (iNHL),7112
10,NCT03128619,Phase Ib/II,Recruiting,"[{'id': 5594, 'therapyName': 'Copanlisib + Palbociclib + Letrozole'}, {'id': 5593, 'therapyName': 'Copanlisib + Letrozole'}]","Copanlisib, Letrozole, and Palbociclib in Treating Patients With Hormone Receptor Positive HER2 Negative Stage I-IV Breast Cancer",7112
11,NCT01411410,Phase I,Completed,"[{'id': 1276, 'therapyName': 'Copanlisib + Paclitaxel'}]",Phase I Study of PI3(Phosphoinositol 3)-Kinase Inhibitor BAY80-6946 With Paclitaxel in Patients With Advanced Cancer,7112
0,NCT02043665,Phase I,Recruiting,"[{'id': 2974, 'therapyName': 'coxsackievirus A21'}]",Systemic Treatment Of Resistant Metastatic Disease Employing CVA21 and Pembrolizumab in Non-small Cell Lung Cancer and Bladder Cancer (STORM/ KEYNOTE-200) (STORM),7882
1,NCT02307149,Phase I,Recruiting,"[{'id': 2974, 'therapyName': 'coxsackievirus A21'}, {'id': 779, 'therapyName': 'Ipilimumab'}]",Study of Intratumoral CAVATAK (Coxsackievirus A21) and Ipilimumab in Patients With Advanced Melanoma,7882
2,NCT02565992,Phase I,Recruiting,"[{'id': 3136, 'therapyName': 'coxsackievirus A21 + Pembrolizumab'}]",Phase I Study of Intratumoral CAVATAK and Pembrolizumab in Subjects With Advanced Melanoma,7882
0,NCT02157636,Phase I,Recruiting,"[{'id': 2033, 'therapyName': 'CPI-0610'}]",A Phase 1 Study Evaluating CPI-0610 in Patients With Previously Treated Multiple Myeloma,7399
1,NCT01949883,Phase I,Recruiting,"[{'id': 2033, 'therapyName': 'CPI-0610'}]",A Phase 1 Study Evaluating CPI-0610 in Patients With Progressive Lymphoma,7399
2,NCT02158858,Phase I,Recruiting,"[{'id': 2033, 'therapyName': 'CPI-0610'}]","A Phase 1 Study Evaluating CPI-0610 in Patients With Acute Leukemia, Myelodysplastic Syndrome, or Myelodysplastic/Myeloproliferative Neoplasms",7399
0,NCT02395601,Phase I,Recruiting,"[{'id': 2733, 'therapyName': 'CPI-1205'}]",A Study Evaluating CPI-1205 in Patients With B-Cell Lymphomas,7688
0,NCT02655822,Phase I,Recruiting,"[{'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 3571, 'therapyName': 'CPI-444 '}]",Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers,8145
0,NCT02019069,Phase II,Recruiting,"[{'id': 4341, 'therapyName': 'CPX-351'}]",CPX-351 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome,8427
1,NCT01804101,Phase I,"Active, not recruiting","[{'id': 4341, 'therapyName': 'CPX-351'}]",Liposomal Cytarabine-Daunorubicin CPX-351 in Treating Patients With Untreated Myelodysplastic Syndrome or Acute Myeloid Leukemia,8427
2,NCT01943682,Phase I,Recruiting,"[{'id': 4341, 'therapyName': 'CPX-351'}]",Safety Study of CPX-351 in Children With Relapsed Leukemia or Lymphoma,8427
3,NCT02269579,Phase II,Recruiting,"[{'id': 4341, 'therapyName': 'CPX-351'}]",Pharmacokinetic and Pharmacodynamic Assessment of Treatment With CPX-351 (Cytarabine: Daunorubicin) Liposome for Injection in Acute Leukemias and MDS Patients With Moderate Hepatic Impairment,8427
4,NCT02286726,Phase II,Recruiting,"[{'id': 4341, 'therapyName': 'CPX-351'}]",Phase II CPX-351 in Acute Myeloid Leukemia (AML),8427
5,NCT02533115,Expanded access,Approved for marketing,"[{'id': 4341, 'therapyName': 'CPX-351'}]",EAP of CPX-351 (VYXEOS) for Patients 60-75 Years of Age With Secondary AML,8427
6,NCT02642965,Phase Ib/II,Recruiting,"[{'id': 4391, 'therapyName': 'CPX-351 + Cytarabine + Filgrastim + Fludarabine '}]","Liposomal Cytarabine-Daunorubicin CPX-351, Fludarabine Phosphate, Cytarabine, and Filgrastim in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia",8427
0,NCT01657682,Phase II,Recruiting,"[{'id': 705, 'therapyName': 'Crenolanib'}]",A Phase II Study of Crenolanib in Relapsed/Refractory Acute Myeloid Leukemia Patients With FLT3 Activating Mutations,6889
1,NCT02626364,Phase II,Recruiting,"[{'id': 705, 'therapyName': 'Crenolanib'}]",Study of Crenolanib in Recurrent/Refractory Glioblastoma With PDGFRA Gene Amplification,6889
2,NCT02400281,Phase Ib/II,Recruiting,"[{'id': 651, 'therapyName': 'Azacitidine'}, {'id': 705, 'therapyName': 'Crenolanib'}, {'id': 1606, 'therapyName': 'Cytarabine + Idarubicin'}]",Study of Crenolanib Combined With Chemotherapy in FLT3-mutated Acute Myeloid Leukemia Patients,6889
3,NCT02847429,Phase III,Recruiting,"[{'id': 705, 'therapyName': 'Crenolanib'}]",Randomized Trial of Crenolanib in Subjects With D842V Mutated GIST,6889
4,NCT02400255,Phase II,Recruiting,"[{'id': 705, 'therapyName': 'Crenolanib'}]",Crenolanib Maintenance Following Allogeneic Stem Cell Transplantation in FLT3-positive Acute Myeloid Leukemia Patients,6889
5,NCT02283177,Phase II,Recruiting,"[{'id': 2637, 'therapyName': 'Crenolanib + Cytarabine + Daunorubicin'}]",A Safety and Tolerability Study of Crenolanib in Combination With Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia Patients With FLT3 Mutations,6889
6,NCT02626338,Phase Ib/II,Recruiting,"[{'id': 4024, 'therapyName': 'Crenolanib + Cytarabine + Mitoxantrone'}]",Pilot Study of Crenolanib Combined With Cytarabine and Mitoxantrone in Subjects With R/R AML,6889
7,NCT03193918,Phase I,Recruiting,"[{'id': 5943, 'therapyName': 'Crenolanib + Paclitaxel + Ramucirumab'}]",Study of Crenolanib With Ramucirumab and Paclitaxel for Advanced Esophagogastric Adenocarcinoma,6889
8,NCT02270788,Phase I,Completed,"[{'id': 1865, 'therapyName': 'Methotrexate + Cytarabine + Leucovorin'}, {'id': 1864, 'therapyName': 'Crenolanib + Sorafenib'}]",Crenolanib in Combination With Sorafenib in Patients With Refractory or Relapsed Hematologic Malignancies,6889
0,NCT01999972,Phase I,"Active, not recruiting","[{'id': 1350, 'therapyName': 'Axitinib + Crizotinib'}]",A Phase 1b Study Of Axitinib In Combination With Crizotinib In Patients With Advanced Solid Tumors,6890
1,NCT03194893,Phase III,Recruiting,"[{'id': 706, 'therapyName': 'Crizotinib'}, {'id': 698, 'therapyName': 'Alectinib'}]",A Roll Over Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive or Rearranged During Transfection (RET)-Positive Cancer,6890
2,NCT01712217,Phase Ib/II,"Active, not recruiting","[{'id': 706, 'therapyName': 'Crizotinib'}, {'id': 645, 'therapyName': 'AT13387'}]",A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib,6890
3,NCT02201992,Phase III,Recruiting,"[{'id': 706, 'therapyName': 'Crizotinib'}]",Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial),6890
4,NCT02559778,Phase I,Recruiting,"[{'id': 688, 'therapyName': 'Bortezomib'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 2629, 'therapyName': 'Eflornithine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 717, 'therapyName': 'Dasatinib'}]",Pediatric Precision Laboratory Advanced Neuroblastoma Therapy,6890
5,NCT02465060,Phase II,Recruiting,"[{'id': 660, 'therapyName': 'AZD9291'}, {'id': 3, 'therapyName': 'Dabrafenib'}, {'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 2, 'therapyName': 'Trametinib'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 623, 'therapyName': 'Afatinib'}, {'id': 654, 'therapyName': 'AZD4547'}, {'id': 958, 'therapyName': 'VS-6063'}, {'id': 765, 'therapyName': 'GSK2636771'}]",NCI-MATCH Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas,6890
6,NCT01576406,Phase I,Completed,"[{'id': 706, 'therapyName': 'Crizotinib'}]",Hepatic Impairment Study For Crizotinib In Advanced Cancer Patients,6890
7,NCT02473497,Expanded access,Available,"[{'id': 706, 'therapyName': 'Crizotinib'}]",Crizotinib (Xalkori) Expanded Access Protocol For The Treatment Of Adult Or Pediatric Patients,6890
8,NCT02788201,Phase II,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1133, 'therapyName': 'Mitomycin C'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1013, 'therapyName': 'epirubicin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1137, 'therapyName': 'Bleomycin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 781, 'therapyName': 'Ixabepilone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 2950, 'therapyName': 'Estramustine'}, {'id': 1941, 'therapyName': 'Floxuridine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 1811, 'therapyName': 'Carmustine'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 953, 'therapyName': 'Vandetanib'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 4419, 'therapyName': 'Toremifine'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 2601, 'therapyName': 'Dactinomycin'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 3035, 'therapyName': 'Chlorambucil'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 342, 'therapyName': 'Vemurafenib'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 2635, 'therapyName': 'Vinblastine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 4305, 'therapyName': 'Teniposide'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 4304, 'therapyName': 'Streptozocin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1231, 'therapyName': 'Bendamustine'}, {'id': 4303, 'therapyName': 'Mechlorethamine'}, {'id': 4302, 'therapyName': 'Mitotane'}]",Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma,6890
9,NCT03052608,Phase III,Recruiting,"[{'id': 869, 'therapyName': 'PF-06463922'}, {'id': 706, 'therapyName': 'Crizotinib'}]",A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC,6890
10,NCT00939770,Phase Ib/II,"Active, not recruiting","[{'id': 706, 'therapyName': 'Crizotinib'}]",Crizotinib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma,6890
11,NCT01970865,Phase Ib/II,Recruiting,"[{'id': 869, 'therapyName': 'PF-06463922'}, {'id': 706, 'therapyName': 'Crizotinib'}]",A Study Of PF-06463922 An ALK/ROS1 Inhibitor In Patients With Advanced Non Small Cell Lung Cancer With Specific Molecular Alterations,6890
12,NCT02737501,Phase III,"Active, not recruiting","[{'id': 634, 'therapyName': 'AP26113'}, {'id': 706, 'therapyName': 'Crizotinib'}]",ALTA-1L Study: A Phase 3 Study of Brigatinib Versus Crizotinib in ALK-positive Advanced Non-Small Cell Lung Cancer Patients,6890
13,NCT02551718,Phase I,Recruiting,"[{'id': 690, 'therapyName': 'Bosutinib'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 3160, 'therapyName': 'Nelarabine'}, {'id': 3159, 'therapyName': 'Bexarotene'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 998, 'therapyName': 'cabozantinib'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 877, 'therapyName': 'Ponatinib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 623, 'therapyName': 'Afatinib'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 890, 'therapyName': 'Regorafenib'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 2, 'therapyName': 'Trametinib'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 3, 'therapyName': 'Dabrafenib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 789, 'therapyName': 'Ceritinib'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1571, 'therapyName': 'Cabazitaxel'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1327, 'therapyName': 'Pralatrexate'}]",High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia,6890
14,NCT02767804,Phase III,Recruiting,"[{'id': 706, 'therapyName': 'Crizotinib'}, {'id': 961, 'therapyName': 'X-396'}]",eXalt3: Study Comparing X-396 to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients,6890
15,NCT02612194,Phase II,Recruiting,"[{'id': 706, 'therapyName': 'Crizotinib'}]",LCI-GU-URO-CRI-001: Crizotinib in Patients With c-MET or RON-Positive Metastatic Urothelial Cancer,6890
16,NCT01531361,Phase I,Recruiting,"[{'id': 706, 'therapyName': 'Crizotinib'}, {'id': 1326, 'therapyName': 'Vemurafenib + Sorafenib'}]",Sorafenib or Crizotinib and Vemurafenib in Advanced Cancer,6890
17,NCT03088930,Phase II,Not yet recruiting,"[{'id': 706, 'therapyName': 'Crizotinib'}]",Evaluating Crizotinib in the Neoadjuvant Setting in Patients With Non-small Cell Lung Cancer,6890
18,NCT01606878,Phase I,Recruiting,"[{'id': 2952, 'therapyName': 'Dexamethasone + Doxorubicin + Vincristine'}, {'id': 2590, 'therapyName': 'Cyclophosphamide + Topotecan'}, {'id': 706, 'therapyName': 'Crizotinib'}]",Crizotinib and Combination Chemotherapy in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma,6890
19,NCT02584634,Phase I,Recruiting,"[{'id': 706, 'therapyName': 'Crizotinib'}, {'id': 3144, 'therapyName': 'Avelumab'}, {'id': 869, 'therapyName': 'PF-06463922'}]","Study to Evaluate Safety, Efficacy, Pharmacokinetics And Pharmacodynamics Of Avelumab In Combination With Either Crizotinib Or PF-06463922 In Patients With NSCLC. (Javelin Lung 101)",6890
20,NCT00932451,Phase II,Completed,"[{'id': 706, 'therapyName': 'Crizotinib'}]","An Investigational Drug, PF-02341066, Is Being Studied In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene",6890
21,NCT02075840,Phase III,"Active, not recruiting","[{'id': 698, 'therapyName': 'Alectinib'}, {'id': 706, 'therapyName': 'Crizotinib'}]","ALEX Study: A Randomized, Phase III Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) Patients",6890
22,NCT02277457,Phase I,Withdrawn,"[{'id': 706, 'therapyName': 'Crizotinib'}, {'id': 4, 'therapyName': 'Erlotinib'}]","Personalized Adaptive Radiation Therapy With Individualized Systemic Targeted Therapy (PARTIST) for Locally Advanced, Non-small Cell Lung Cancer With Genomic Driver Mutations",6890
23,NCT02574078,Phase I,Recruiting,"[{'id': 619, 'therapyName': 'Abraxane'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 2114, 'therapyName': 'Bevacizumab + Pemetrexed'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 1092, 'therapyName': 'Carboplatin'}]",A Master Protocol Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC) (CheckMate 370),6890
24,NCT02223819,Phase II,Recruiting,"[{'id': 706, 'therapyName': 'Crizotinib'}]",Adjuvant Crizotinib in High-Risk Uveal Melanoma Following Definitive Therapy,6890
25,NCT02511184,Phase I,Recruiting,"[{'id': 706, 'therapyName': 'Crizotinib'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Crizotinib Plus Pembrolizumab In Alk-positive Advanced Non Small Cell Lung Cancer Patients,6890
26,NCT03126916,Phase III,Not yet recruiting,"[{'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1425, 'therapyName': '131I-MIBG'}, {'id': 1873, 'therapyName': 'Sargramostim'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 5595, 'therapyName': 'Isotretinoin'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 5153, 'therapyName': 'dexrazoxane'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1167, 'therapyName': 'Aldesleukin'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 2286, 'therapyName': 'Dinutuximab  '}]",Iobenguane I-131 or Crizotinib and Standard Therapy in Treating Younger Patients With Newly-Diagnosed High-Risk Neuroblastoma or Ganglioneuroblastoma,6890
27,NCT01121588,,"Active, not recruiting","[{'id': 706, 'therapyName': 'Crizotinib'}]","An Investigational Drug, Crizotinib (PF-02341066), Is Being Studied In Tumors, Except Non-Small Cell Lung Cancer, That Are Positive For Anaplastic Lymphoma Kinase (ALK)",6890
28,NCT02693535,Phase II,Recruiting,"[{'id': 1657, 'therapyName': 'Vemurafenib + Cobimetinib'}, {'id': 890, 'therapyName': 'Regorafenib'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 690, 'therapyName': 'Bosutinib'}, {'id': 850, 'therapyName': 'Palbociclib'}, {'id': 694, 'therapyName': 'Cetuximab'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 837, 'therapyName': 'Olaparib'}, {'id': 4, 'therapyName': 'Erlotinib'}]",TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer,6890
29,NCT01979536,Phase II,Suspended,"[{'id': 706, 'therapyName': 'Crizotinib'}]",Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma,6890
30,NCT02761057,Phase II,Recruiting,"[{'id': 2161, 'therapyName': 'Savolitinib'}, {'id': 998, 'therapyName': 'cabozantinib'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 930, 'therapyName': 'Sunitinib'}]","Cabozantinib-S-Malate, Crizotinib, Volitinib, or Sunitinib Malate in Treating Patients With Locally Advanced or Metastatic Kidney Cancer",6890
31,NCT01744652,Phase I,"Active, not recruiting","[{'id': 1252, 'therapyName': 'Crizotinib + Dasatinib'}]",Dasatinib and Crizotinib in Advanced Cancer,6890
32,NCT01644773,Phase I,Recruiting,"[{'id': 1252, 'therapyName': 'Crizotinib + Dasatinib'}]",Study of the Combination of Crizotinib and Dasatinib in Pediatric Research Participants With Diffuse Pontine Glioma (DIPG) and High-Grade Glioma (HGG),6890
33,NCT02207504,Phase I,"Active, not recruiting","[{'id': 2446, 'therapyName': 'Crizotinib + Enzalutamide'}]",Crizotinib in Combination With Enzalutamide in Metastatic Castration-resistant Prostate Cancer,6890
34,NCT00585195,Phase I,Recruiting,"[{'id': 1526, 'therapyName': 'Crizotinib + Itraconazole\t'}, {'id': 1483, 'therapyName': 'Crizotinib + Rifampin'}]","A Study Of Oral PF-02341066, A c-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer",6890
35,NCT01548144,Phase I,"Active, not recruiting","[{'id': 1153, 'therapyName': 'Crizotinib + Pazopanib'}, {'id': 1151, 'therapyName': 'Crizotinib + Pemetrexed'}, {'id': 1156, 'therapyName': 'Pazopanib + Pemetrexed'}, {'id': 1155, 'therapyName': 'Crizotinib + Pazopanib + Pemetrexed'}]",Pazopanib or Pemetrexed and Crizotinib in Advanced Cancer,6890
36,NCT02134912,Phase II,Recruiting,"[{'id': 1151, 'therapyName': 'Crizotinib + Pemetrexed'}, {'id': 854, 'therapyName': 'Pemetrexed'}]",S1300: Pemetrexed Disodium With or Without Crizotinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer That Has Progressed After Crizotinib,6890
37,NCT01579994,Phase I,"Active, not recruiting","[{'id': 2190, 'therapyName': 'Ganetespib + Crizotinib'}]",Crizotinib and Ganetespib (STA-9090) in ALK Positive Lung Cancers,6890
38,NCT01998126,Phase I,"Active, not recruiting","[{'id': 1348, 'therapyName': 'Ipilimumab + Erlotinib'}, {'id': 1349, 'therapyName': 'Ipilimumab + Crizotinib'}]",Ipilimumab Plus Targeted Inhibitor (Erlotinib or Crizotinib) for EGFR or ALK Mutated Stage IV Non-small Cell Lung Cancer: Phase Ib With Expansion Cohorts,6890
39,NCT02074878,Phase I,Terminated,"[{'id': 1962, 'therapyName': 'Sunitinib + Crizotinib'}]",CRIZENT: Crizotinib and Sunitinib in Metastatic Breast Cancer,6890
0,NCT02648711,Phase I,"Active, not recruiting","[{'id': 708, 'therapyName': 'CRLX101'}, {'id': 667, 'therapyName': 'Bevacizumab'}]",Alternative Dosing for CRLX101 Alone and With Avastin in Advanced Solid Tumors,7055
1,NCT01625936,Phase I,Unknown status,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 708, 'therapyName': 'CRLX101'}]",CRLX101 Plus Bevacizumab in Advanced RCC,7055
2,NCT02187302,Phase II,Completed,"[{'id': 1213, 'therapyName': 'CRLX101 + Bevacizumab'}]",CRLX101 in Combination With Bevacizumab for Metastatic Renal Cell Carcinoma (mRCC) Versus Standard of Care (SOC),7055
3,NCT01652079,Phase II,"Active, not recruiting","[{'id': 1213, 'therapyName': 'CRLX101 + Bevacizumab'}]",CRLX101 in Combination With Bevacizumab for Recurrent Ovarian/Tubal/Peritoneal Cancer,7055
4,NCT02769962,Phase Ib/II,Recruiting,"[{'id': 4348, 'therapyName': 'CRLX101 + Olaparib'}]","Trial of CRLX101, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer",7055
0,NCT01240590,Phase Ib/II,Completed,"[{'id': 1461, 'therapyName': 'Crolibulin + Cisplatin'}, {'id': 700, 'therapyName': 'Cisplatin'}]",A Phase I/II Trial of Crolibulin (EPC2407) Plus Cisplatin in Adults With Solid Tumors With a Focus on Anaplastic Thyroid Cancer (ATC),7268
0,NCT02575807,Phase Ib/II,Recruiting,"[{'id': 2575, 'therapyName': 'Epacadostat'}, {'id': 2641, 'therapyName': 'CRS-207'}]","Safety and Efficacy of CRS-207 With Epacadostat in Platinum Resistant Ovarian, Fallopian, or Peritoneal Cancer",7621
1,NCT02243371,Phase II,"Active, not recruiting","[{'id': 2642, 'therapyName': 'GVAX pancreatic cancer vaccine  '}, {'id': 2641, 'therapyName': 'CRS-207'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}]",GVAX Pancreas Vaccine (With CY) and CRS-207 With or Without Nivolumab,7621
2,NCT03006302,Phase II,Not yet recruiting,"[{'id': 5169, 'therapyName': 'CRS-207 + INCB024360 + Pembrolizumab'}, {'id': 5170, 'therapyName': 'CRS-207 + Cyclophosphamide + GVAX panc vaccine + INCB024360 + Pembrolizumab'}]","Epacadostat, Pembrolizumab, and CRS-207, With or Without CY/GVAX Pancreas in Patients With Metastatic Pancreas Cancer",7621
3,NCT03122548,Phase II,Recruiting,"[{'id': 5716, 'therapyName': 'CRS-207 + Pembrolizumab'}]","Safety and Efficacy of CRS-207 With Pembrolizumab in Gastric, Gastroesophageal Junction or Esophageal Cancers",7621
4,NCT03175172,Phase II,Recruiting,"[{'id': 5716, 'therapyName': 'CRS-207 + Pembrolizumab'}]",Evaluation of CRS-207 With Pembrolizumab in Previously Treated MPM,7621
0,NCT02674750,Phase II,Recruiting,"[{'id': 4447, 'therapyName': 'CUDC-907 + Rituximab'}, {'id': 709, 'therapyName': 'CUDC-907'}]",Study to Evaluate the Efficacy and Safety of CUDC-907 With and Without Rituximab in Patients With RR MYC-Altered DLBCL,7062
1,NCT01742988,Phase I,Recruiting,"[{'id': 709, 'therapyName': 'CUDC-907'}]","Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-907 in Patients With Lymphoma or Multiple Myeloma",7062
2,NCT02307240,Phase I,Recruiting,"[{'id': 709, 'therapyName': 'CUDC-907'}]","Open Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-907 in Subjects With Advanced/Relapsed Solid Tumors",7062
3,NCT03002623,Phase II,Recruiting,"[{'id': 709, 'therapyName': 'CUDC-907'}]",CUDC-907 Treatment in People With Metastatic and Locally Advanced Thyroid Cancer,7062
4,NCT02909777,Phase I,Recruiting,"[{'id': 709, 'therapyName': 'CUDC-907'}]","Trial of CUDC-907 in Children and Young Adults With Relapsed or Refractory Solid Tumors, CNS Tumors, or Lymphoma",7062
0,NCT01630733,Phase III,Recruiting,"[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 3648, 'therapyName': 'Custirsen + Docetaxel'}]","A Multinational, Randomized, Open-Label Study of Custirsen In Patients With Advanced or Metastatic (Stage IV) Non-Small Cell Lung Cancer",8185
0,NCT02840994,Phase Ib/II,Recruiting,"[{'id': 5244, 'therapyName': 'CV301 + Nivolumab'}, {'id': 1312, 'therapyName': 'Nivolumab'}]",A Trial of CV301 in Combination With Nivolumab Versus Nivolumab in Subjects With Previously Treated Non-Small Cell Lung Cancer,8644
0,NCT02426723,Phase I,Recruiting,"[{'id': 3081, 'therapyName': 'CWP232291'}, {'id': 4036, 'therapyName': 'Dexamethasone + lenalidomide'}]",Clinical Study of CWP232291 in Relapsed or Refractory Myeloma Patients,7930
1,NCT01398462,Phase I,Completed,"[{'id': 3081, 'therapyName': 'CWP232291'}]",Phase I Clinical Study of CWP232291 in Acute Myeloid Leukemia Patients,7930
0,NCT03013491,Phase II,Recruiting,"[{'id': 5209, 'therapyName': 'CX-072 + Ipilimumab'}, {'id': 5210, 'therapyName': 'CX-072 + Vemurafenib'}, {'id': 5208, 'therapyName': 'CX-072'}]",A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas,8634
0,NCT03149549,Phase Ib/II,Recruiting,"[{'id': 5709, 'therapyName': 'CX-2009'}]",PROCLAIM-CX-2009: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2009 for Patients With Selected Solid Tumors,8759
0,NCT02070406,Phase I,Recruiting,"[{'id': 3409, 'therapyName': 'Aldesleukin + Cyclophosphamide + Fludarabine '}, {'id': 2696, 'therapyName': 'NY-ESO-1 peptide vaccine'}]","Gene-Modified T Cells, Vaccine Therapy, and Ipilimumab in Treating Patients With Locally Advanced or Metastatic Malignancies",521
1,NCT02775292,Phase I,Recruiting,"[{'id': 3409, 'therapyName': 'Aldesleukin + Cyclophosphamide + Fludarabine '}, {'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 2696, 'therapyName': 'NY-ESO-1 peptide vaccine'}]","Gene-Modified T Cells, Vaccine Therapy, and Nivolumab in Treating Patients With Stage IV or Locally Advanced Solid Tumors Expressing NY-ESO-1",521
2,NCT02652455,Phase I,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 3409, 'therapyName': 'Aldesleukin + Cyclophosphamide + Fludarabine '}, {'id': 2055, 'therapyName': 'Urelumab'}]","Combining PD-1 Blockade, CD137 Agonism and Adoptive Cell Therapy for Metastatic Melanoma",521
3,NCT01898793,Phase Ib/II,Recruiting,"[{'id': 3409, 'therapyName': 'Aldesleukin + Cyclophosphamide + Fludarabine '}, {'id': 5300, 'therapyName': 'ALT-803 + Cyclophosphamide + Fludarabine phosphate'}]",Cytokine-induced Memory-like NK Cells in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS),521
4,NCT02500576,Phase II,Recruiting,"[{'id': 5683, 'therapyName': 'Aldesleukin + Cyclophosphamide + Fludarabine + Mesna + Pembrolizumab'}]","MK-3475 With Lymphodepletion, TIL and High or Low Dose Interleukin-2 (IL-2)",521
5,NCT02858310,Phase I,Recruiting,"[{'id': 4562, 'therapyName': 'Aldesleukin + Cyclophosphamide + Fludarabine + Pembrolizumab'}]",E7 TCR T Cells With or Without PD-1 Blockade for Human Papillomavirus-Associated Cancers,521
6,NCT03068624,Phase I,Recruiting,"[{'id': 5733, 'therapyName': 'Aldesleukin + Cyclophosphamide + Ipilimumab'}]",Study of Cellular Adoptive Immunotherapy Using Autologous CD8+ Antigen-Specific T Cells and Anti-CTLA4 for Patients With Metastatic Uveal Melanoma,521
7,NCT02757391,Phase I,Not yet recruiting,"[{'id': 4193, 'therapyName': 'Aldesleukin + Cyclophosphamide + Pembrolizumab'}]",T Cell Immunotherapy Plus Anti-PD1 Antibody in Advanced Solid Malignancies,521
8,NCT01849783,Phase II,Recruiting,"[{'id': 1852, 'therapyName': 'Melphalan + Bortezomib + Thalidomide + Dexamethasone'}, {'id': 3435, 'therapyName': 'Aldoxorubicin + Cisplatin + Cyclophosphamide + Dexamethasone + Etoposide'}]",Autologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple Myeloma,521
9,NCT00740805,Phase I,"Active, not recruiting","[{'id': 2989, 'therapyName': 'Aldoxorubicin + Cyclophosphamide + Veliparib'}]","Veliparib, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Non-Hodgkin Lymphoma",521
10,NCT02626455,Phase III,Recruiting,"[{'id': 1631, 'therapyName': 'Vincristine'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 3388, 'therapyName': 'Aldoxorubicin +Cyclophosphamide + Prednisone + Rituximab + Vincristine'}, {'id': 995, 'therapyName': 'Copanlisib'}, {'id': 2323, 'therapyName': 'Bendamustine + Rituximab'}, {'id': 897, 'therapyName': 'Rituximab'}]",Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL),521
11,NCT00602693,Phase I,Completed,"[{'id': 917, 'therapyName': 'Sirolimus'}, {'id': 2311, 'therapyName': 'Allopurinol + Cyclophosphamide + Fludarabine'}]",T-Regulatory Cell Infusion Post Umbilical Cord Blood Transplant in Patients With Advanced Hematologic Cancer,521
12,NCT03050216,Phase II,Recruiting,"[{'id': 5300, 'therapyName': 'ALT-803 + Cyclophosphamide + Fludarabine phosphate'}]",Haplo NK With SQ ALT-803 for Adults With Relapsed or Refractory AML,521
13,NCT02101853,Phase III,Recruiting,"[{'id': 1876, 'therapyName': 'Blinatumomab '}, {'id': 2347, 'therapyName': 'Leucovorin + Pegaspargase  + Vincristine'}, {'id': 2346, 'therapyName': 'Mercaptopurine + Thioguanine'}, {'id': 2348, 'therapyName': 'Asparaginase + Cyclophosphamide + Etoposide'}, {'id': 2345, 'therapyName': 'Cytarabine + Dexamethasone+ Methotrexate '}]",Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia,521
14,NCT02853318,Phase II,Recruiting,"[{'id': 4528, 'therapyName': 'Bevacizumab + Cyclophosphamide + Pembrolizumab'}]","Pembrolizumab, Bevacizumab, and Cyclophosphamide in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",521
15,NCT00885326,Phase I,"Active, not recruiting","[{'id': 2072, 'therapyName': 'Bevacizumab + Cyclophosphamide + Zoledronic acid'}]","N2007-02:Bevacizumab,Cyclophosphamide,and Zoledronic Acid in Patients W/ Recurrent or Refractory High-Risk Neuroblastoma",521
16,NCT01959490,Phase II,Completed,"[{'id': 1486, 'therapyName': 'Bevacizumab + Doxorubicin + Cyclophosphamide + Paclitaxel '}, {'id': 1485, 'therapyName': 'Trastuzumab + Docetaxel + Carboplatin'}]",Trastuzumab or Bevacizumab With Combination Chemotherapy in Treating Patients With Stage II-III Breast Cancer,521
17,NCT01146834,Phase III,Recruiting,"[{'id': 3345, 'therapyName': 'Bortezomib + Filgrastim'}, {'id': 5459, 'therapyName': 'Bortezomib + Cyclophosphamide + G-CSF'}, {'id': 5460, 'therapyName': 'Bortezomib + Cyclophosphamide'}]",Trial of Three Stem Cell Mobilization Regimens for Multiple Myeloma,521
18,NCT02951819,Phase II,Recruiting,"[{'id': 4951, 'therapyName': 'Bortezomib + Cyclophosphamide + Daratumumab + Dexamethasone'}]",A Study to Evaluate Dara-CyBorD in Previously Untreated and Relapsed Subjects With Multiple Myeloma,521
19,NCT01729338,Phase II,Terminated,"[{'id': 3358, 'therapyName': 'Bortezomib + Cyclophosphamide + lenalidomide'}]",Velcade + Cyclophosphamide in Newly Diagnosed Multiple Myeloma,521
20,NCT00513474,Phase I,Completed,"[{'id': 2313, 'therapyName': 'Rasburicase'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 1650, 'therapyName': 'Cyclosporine'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 2314, 'therapyName': 'Busulfan + Cyclophosphamide + Etoposide'}]",Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant,521
21,NCT02221310,Phase II,Recruiting,"[{'id': 3932, 'therapyName': 'Busulfan + Cyclophosphamide + Gemtuzumab ozogamicin'}]",Immunochemotherapy and AlloSCT in Patients With High Risk CD33+ AML/MDS,521
22,NCT02057770,Phase I,Recruiting,"[{'id': 5724, 'therapyName': 'Busulfan + Fludarabine phosphate + Cyclophosphamide'}, {'id': 5647, 'therapyName': 'Tocilizumab'}]",Allogeneic or Haploidentical Stem Cell Transplant Followed By High-Dose Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia,521
23,NCT01873833,Phase II,Recruiting,"[{'id': 1559, 'therapyName': 'Capecitabine + Cyclophosphamide + Lapatinib + Trastuzumab'}]","Capecitabine, Cyclophosphamide, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With HER2-Positive Metastatic Breast Cancer",521
24,NCT02574728,Phase II,Recruiting,"[{'id': 3143, 'therapyName': 'Celecoxib + Cyclophosphamide + Etoposide + Sirolimus'}]",Sirolimus in Combination With Metronomic Chemotherapy in Children With Recurrent and/or Refractory Solid and CNS Tumors,521
25,NCT01025089,Phase II,"Active, not recruiting","[{'id': 694, 'therapyName': 'Cetuximab'}, {'id': 1927, 'therapyName': 'Cisplatin + Doxorubicin + Cyclophosphamide'}]",Chemotherapy Plus Cetuximab Followed by Surgical Resection in Patients With Locally Advanced or Recurrent Thymoma or Thymic Carcinoma,521
26,NCT00734877,Phase III,Recruiting,"[{'id': 1851, 'therapyName': 'Cisplatin + Doxorubicin + Cyclophosphamide + Etoposide'}, {'id': 1852, 'therapyName': 'Melphalan + Bortezomib + Thalidomide + Dexamethasone'}]","UARK 2008-01, Total Therapy 4 - A Phase III Trial for Low Risk Myeloma",521
27,NCT00549848,Phase III,"Active, not recruiting","[{'id': 1781, 'therapyName': 'Vincristine + Pegaspargase + Daunorubicin'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1782, 'therapyName': 'Clofarabine + Etoposide + Cyclophosphamide'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}]",Total Therapy Study XVI for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia,521
28,NCT03006302,Phase II,Not yet recruiting,"[{'id': 5169, 'therapyName': 'CRS-207 + INCB024360 + Pembrolizumab'}, {'id': 5170, 'therapyName': 'CRS-207 + Cyclophosphamide + GVAX panc vaccine + INCB024360 + Pembrolizumab'}]","Epacadostat, Pembrolizumab, and CRS-207, With or Without CY/GVAX Pancreas in Patients With Metastatic Pancreas Cancer",521
29,NCT01707004,Phase I,"Active, not recruiting","[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1206, 'therapyName': 'Busulfan'}]",Decitabine and Total-Body Irradiation Followed By Donor Bone Marrow Transplant and Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia,521
30,NCT02512926,Phase I,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 1136, 'therapyName': 'Etoposide'}]",Carfilzomib in Combination With Cyclophosphamide and Etoposide for Children,521
31,NCT03117751,Phase II,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1876, 'therapyName': 'Blinatumomab '}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1638, 'therapyName': 'Pegaspargase'}]",Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma,521
32,NCT00857389,Phase II,"Active, not recruiting","[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 2469, 'therapyName': 'Busulfan + Clofarabine + Thymoglobulin'}, {'id': 1639, 'therapyName': 'Methotrexate'}]",Thiotepa-Clofarabine-Busulfan With Allogeneic Stem Cell Transplant for High Risk Malignancies,521
33,NCT01218867,Phase Ib/II,Completed,"[{'id': 984, 'therapyName': 'Anti-VEGFR2 CAR CD8 lymphocytes'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1167, 'therapyName': 'Aldesleukin'}]",Treating Metastatic Cancer With Anti-VEGFR2 Gene Engineered CD8+ Lymphocytes,521
34,NCT01966289,Phase I,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1949, 'therapyName': 'SGI-110'}, {'id': 2977, 'therapyName': 'GVAX colorectal cancer vaccine'}]",SGI-110 in Combination With an Allogeneic Colon Cancer Cell Vaccine (GVAX) and Cyclophosphamide (CY) in Metastatic Colorectal Cancer (mCRC),521
35,NCT03190941,Phase I,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 6061, 'therapyName': 'anti-KRAS G12V mTCR cells'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1167, 'therapyName': 'Aldesleukin'}]",Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*1101 Patients,521
36,NCT02159495,Phase I,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}]",Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia,521
37,NCT02621021,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1167, 'therapyName': 'Aldesleukin'}]",A Prospective Randomized and Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab,521
38,NCT01253460,Phase II,"Active, not recruiting","[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 3215, 'therapyName': 'Rituximab + sapacitabine'}]","Sapacitabine, Cyclophosphamide, Rituximab for Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma (CLL/SLL) With Deletion (11q22-23)",521
39,NCT01319981,Phase II,Recruiting,"[{'id': 1476, 'therapyName': 'Pegfilgrastim'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}]",Hyper-CVAD With Liposomal Vincristine in Acute Lymphoblastic Leukemia,521
40,NCT01993719,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1167, 'therapyName': 'Aldesleukin'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}]",Immunotherapy Using Tumor Infiltrating Lymphocytes Comparing 2 Different Conditioning Regimens for Patients With Metastatic Melanoma,521
41,NCT02181478,Phase I,Recruiting,"[{'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}]",Intra-Osseous Co-Transplant of UCB and hMSC,521
42,NCT03126916,Phase III,Not yet recruiting,"[{'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1425, 'therapyName': '131I-MIBG'}, {'id': 1873, 'therapyName': 'Sargramostim'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 5595, 'therapyName': 'Isotretinoin'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 5153, 'therapyName': 'dexrazoxane'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1167, 'therapyName': 'Aldesleukin'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 2286, 'therapyName': 'Dinutuximab  '}]",Iobenguane I-131 or Crizotinib and Standard Therapy in Treating Younger Patients With Newly-Diagnosed High-Risk Neuroblastoma or Ganglioneuroblastoma,521
43,NCT00074490,Phase II,Completed,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1650, 'therapyName': 'Cyclosporine'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1166, 'therapyName': 'Fludarabine'}]",Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,521
44,NCT01351909,Phase Ib/II,"Active, not recruiting","[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 954, 'therapyName': 'Veliparib'}]",Cyclophosphamide With or Without Veliparib in Treating Patients With Locally Advanced or Metastatic Breast Cancer,521
45,NCT03136146,Phase II,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1090, 'therapyName': 'Ofatumumab'}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 1476, 'therapyName': 'Pegfilgrastim'}]","Study of Clofarabine, Etoposide, Cyclophosphamide [CEC], Liposomal Vincristine (VCR), Dexamethasone and Bortezomib in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LL)",521
46,NCT02118311,Phase II,Withdrawn,"[{'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}]",T Regulatory Cell for Suppression of Acute Graft-vs-Host-Disease After a Non-Myeloablative Umbilical Cord Blood Transplantation,521
47,NCT01746849,Phase II,Recruiting,"[{'id': 795, 'therapyName': 'Leuprolide'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 2373, 'therapyName': 'Palifermin'}]",Palifermin With Leuprolide Acetate for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation,521
48,NCT03004287,Phase II,Recruiting,"[{'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1164, 'therapyName': 'lenalidomide'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 1630, 'therapyName': 'Daratumumab'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1475, 'therapyName': 'Thalidomide'}]",2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy,521
49,NCT00305682,Phase II,Recruiting,"[{'id': 917, 'therapyName': 'Sirolimus'}, {'id': 1845, 'therapyName': 'Mycophenolate mofetil'}, {'id': 1844, 'therapyName': 'anti-thymocyte globulin'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1166, 'therapyName': 'Fludarabine'}]",Non-Myeloablative Conditioning for Unrelated Donor Umbilical Cord Blood Transplant,521
50,NCT00971737,Phase II,Unknown status,"[{'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}]",Cyclophosphamide and Vaccine Therapy With or Without Trastuzumab in Treating Patients With Metastatic Breast Cancer,521
51,NCT02118285,Phase I,Completed,"[{'id': 1167, 'therapyName': 'Aldesleukin'}, {'id': 2575, 'therapyName': 'Epacadostat'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1166, 'therapyName': 'Fludarabine'}]","Intraperitoneal Natural Killer Cells and INCB024360 for Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer",521
52,NCT01338987,Phase II,"Active, not recruiting","[{'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 795, 'therapyName': 'Leuprolide'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}]",Pilot Study of Lupron to Improve Immune Function After Allogeneic Bone Marrow Transplantation,521
53,NCT03247088,Phase Ib/II,Recruiting,"[{'id': 6122, 'therapyName': 'Busulfan + Sorafenib + Fludarabine'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 1632, 'therapyName': 'Filgrastim'}]",Study Of Sorafenib Added To Busulfan And Fludarabine Conditioning Regimen In Patients With Relapsed/Refractory AML Undergoing Stem Cell Transplantation,521
54,NCT03215810,,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1166, 'therapyName': 'Fludarabine'}]",Nivolumab and Tumor Infiltrating Lymphocytes (TIL) in Advanced Non-Small Cell Lung Cancer,521
55,NCT03007147,Phase III,Recruiting,"[{'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 5153, 'therapyName': 'dexrazoxane'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 5167, 'therapyName': 'Methylprednisolone'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 5168, 'therapyName': 'Prednisolone'}, {'id': 1009, 'therapyName': 'Doxorubicin'}]",Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia,521
56,NCT03147612,Phase II,Not yet recruiting,"[{'id': 5682, 'therapyName': 'Mesna'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 877, 'therapyName': 'Ponatinib'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 712, 'therapyName': 'Cytarabine'}]",Study of the Combination of Low-Intensity Chemotherapy and Ponatinib in Patients With Philadelphia Chromosome (Ph)-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL),521
57,NCT03023046,Phase II,Recruiting,"[{'id': 897, 'therapyName': 'Rituximab'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 1631, 'therapyName': 'Vincristine'}]","Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma",521
58,NCT00084695,Phase II,Unknown status,"[{'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 2558, 'therapyName': 'Busulfan + Melphalan'}, {'id': 1844, 'therapyName': 'anti-thymocyte globulin'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 2188, 'therapyName': 'Prednisone'}]",Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases,521
59,NCT02251821,Phase II,Recruiting,"[{'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 1845, 'therapyName': 'Mycophenolate mofetil'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 2006, 'therapyName': 'Pacritinib'}, {'id': 823, 'therapyName': 'Momelotinib'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}]",JAK-2 Inhibitor Before Donor Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis,521
60,NCT02446431,Phase I,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1076, 'therapyName': 'Valproic acid'}]",Metronomic Therapy for Pediatric Patients With Solid Tumors at High Risk of Recurrence,521
61,NCT02027935,Phase II,Recruiting,"[{'id': 1167, 'therapyName': 'Aldesleukin'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 779, 'therapyName': 'Ipilimumab'}]",Cellular Adoptive Immunotherapy Using Autologous CD8+ Antigen-Specific T Cells and Anti-CTLA4,521
62,NCT00828009,Phase II,Unknown status,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 2142, 'therapyName': 'Emepepimut-S  '}, {'id': 1092, 'therapyName': 'Carboplatin'}]",BLP25 Liposome Vaccine and Bevacizumab After Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery,521
63,NCT01614197,Phase I,Recruiting,"[{'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1639, 'therapyName': 'Methotrexate'}]",A Trial of Temsirolimus With Etoposide and Cyclophosphamide in Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkins Lymphoma,521
64,NCT02790515,Phase II,Recruiting,"[{'id': 917, 'therapyName': 'Sirolimus'}, {'id': 1844, 'therapyName': 'anti-thymocyte globulin'}, {'id': 1876, 'therapyName': 'Blinatumomab '}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 5682, 'therapyName': 'Mesna'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1632, 'therapyName': 'Filgrastim'}]",Provision of TCR?? T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation,521
65,NCT02234921,Phase I,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}]",Pilot Study of DRibble Vaccine for Prostate Cancer Patients,521
66,NCT02004262,Phase II,Completed,"[{'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 2383, 'therapyName': 'Capecitabine + Fluorouracil + Gemcitabine '}]",Safety and Efficacy of Combination Listeria/GVAX Pancreas Vaccine in the Pancreatic Cancer Setting,521
67,NCT02210104,Phase I,Withdrawn,"[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}]",Adoptive Therapy Using Antigen-Specific CD4 T-Cells,521
68,NCT02472392,Phase I,Completed,"[{'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1844, 'therapyName': 'anti-thymocyte globulin'}]",Study To Examine Toxicity Of Allogeneic Stem Cell Transplantation For Relapsed Or Therapy Refractory Ewings Sarcoma,521
69,NCT01312376,Phase I,"Active, not recruiting","[{'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1227, 'therapyName': 'CD3/CD28 costimulated vaccine-primed autologous T-cells'}, {'id': 1222, 'therapyName': 'OC-DC vaccine'}]",Autologous T-Cells Combined With Autologous OC-DC Vaccine in Ovarian Cancer,521
70,NCT02043587,Phase II,Recruiting,"[{'id': 897, 'therapyName': 'Rituximab'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1136, 'therapyName': 'Etoposide'}]",Chemotherapy With Liposomal Cytarabine CNS Prophylaxis for Adult Acute Lymphoblastic Leukemia &amp; Lymphoblastic Lymphoma,521
71,NCT03020030,Phase III,Recruiting,"[{'id': 3160, 'therapyName': 'Nelarabine'}, {'id': 5153, 'therapyName': 'dexrazoxane'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1642, 'therapyName': 'Leucovorin'}]",Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents,521
72,NCT03197935,Phase III,Recruiting,"[{'id': 1476, 'therapyName': 'Pegfilgrastim'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 619, 'therapyName': 'Abraxane'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}]",A Study to Investigate Atezolizumab and Chemotherapy Compared With Placebo and Chemotherapy in the Neoadjuvant Setting in Participants With Early Stage Triple Negative Breast Cancer (IMpassion031),521
73,NCT02432274,Phase Ib/II,Recruiting,"[{'id': 1136, 'therapyName': 'Etoposide'}, {'id': 792, 'therapyName': 'Lenvatinib'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}]",Study of Lenvatinib in Children and Adolescents With Refractory or Relapsed Solid Malignancies,521
74,NCT02793544,Phase II,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 1845, 'therapyName': 'Mycophenolate mofetil'}, {'id': 5682, 'therapyName': 'Mesna'}, {'id': 1166, 'therapyName': 'Fludarabine'}]",HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide,521
75,NCT01661400,Phase I,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1475, 'therapyName': 'Thalidomide'}]",Anti-Angiogenic Therapy Post Transplant (ASCR) for Relapsed and Refractory Pediatric Solid Tumors,521
76,NCT01822652,Phase I,"Active, not recruiting","[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]","3rd Generation GD-2 Chimeric Antigen Receptor and iCaspase Suicide Safety Switch, Neuroblastoma, GRAIN",521
77,NCT00902044,Phase I,Recruiting,"[{'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 2940, 'therapyName': 'HER2 sensitized T-cells'}]",Her2 Chimeric Antigen Receptor Expressing T Cells in Advanced Sarcoma,521
78,NCT03136406,Phase Ib/II,Recruiting,"[{'id': 1018, 'therapyName': 'GI-4000'}, {'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 3144, 'therapyName': 'Avelumab'}, {'id': 619, 'therapyName': 'Abraxane'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 6163, 'therapyName': 'ETBX-011'}, {'id': 3060, 'therapyName': 'ALT-803'}]",QUILT-3.039: NANT Pancreatic Cancer Vaccine: Combination Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy,521
79,NCT02243371,Phase II,"Active, not recruiting","[{'id': 2642, 'therapyName': 'GVAX pancreatic cancer vaccine  '}, {'id': 2641, 'therapyName': 'CRS-207'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}]",GVAX Pancreas Vaccine (With CY) and CRS-207 With or Without Nivolumab,521
80,NCT02792114,Phase I,Recruiting,"[{'id': 5992, 'therapyName': 'Rimiducid'}, {'id': 6029, 'therapyName': 'Mesothelin CAR-T cells'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}]",T-Cell Therapy for Advanced Breast Cancer,521
81,NCT02112916,Phase III,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1009, 'therapyName': 'Doxorubicin'}]",Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma,521
82,NCT02561832,Phase I,Completed,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 837, 'therapyName': 'Olaparib'}, {'id': 1092, 'therapyName': 'Carboplatin'}]","A Study to Assess the Safety, Tolerability and Efficacy of Olaparib in Combination With Carboplatin in Patients With HER-2 Negative Breast Cancer",521
83,NCT01963481,Phase II,"Active, not recruiting","[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 738, 'therapyName': 'Exemestane'}]",Exemestane and Cyclophosphamide for Metastatic Breast Cancer,521
84,NCT02443077,Phase III,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 3359, 'therapyName': 'Carmustine + Cytarabine + Etoposide + Melphalan'}, {'id': 768, 'therapyName': 'Ibrutinib'}]",Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma,521
85,NCT02553460,Phase II,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1642, 'therapyName': 'Leucovorin'}]",Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) I,521
86,NCT01903330,Phase II,Recruiting,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1873, 'therapyName': 'Sargramostim'}]",ERC1671/GM-CSF/Cyclophosphamide for the Treatment of Glioblastoma Multiforme,521
87,NCT02419495,Phase I,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1749, 'therapyName': 'Selinexor'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 1009, 'therapyName': 'Doxorubicin'}]",Selinexor in Combination With Standard Chemotherapy,521
88,NCT02425306,Phase Ib/II,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 2620, 'therapyName': '6MHP vaccine'}, {'id': 2595, 'therapyName': 'poly ICLC  '}]",Safety Study of a Helper Peptide Vaccine Plus Adjuvant Combinations for the Treatment of Melanoma,521
89,NCT02538926,Phase II,Not yet recruiting,"[{'id': 770, 'therapyName': 'Imatinib'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 3212, 'therapyName': 'Doxorubicin + Etoposide + Vincristine '}, {'id': 2206, 'therapyName': 'Asparaginase'}]","Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride With Asparaginase in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma",521
90,NCT01581970,Phase II,Completed,"[{'id': 1997, 'therapyName': 'Cyclophosphamide + Cetuximab'}]",Potentiation of Cetuximab by Tregs Depletion With CSA in Advanced Head &amp; Neck Cancer,521
91,NCT01878617,Phase II,Recruiting,"[{'id': 956, 'therapyName': 'Vismodegib'}, {'id': 1800, 'therapyName': 'Cyclophosphamide + Cisplatin + Vincristine '}, {'id': 1801, 'therapyName': 'Pemetrexed + Gemcitabine'}]",A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma,521
92,NCT03150693,Phase III,Recruiting,"[{'id': 897, 'therapyName': 'Rituximab'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1783, 'therapyName': 'Cyclophosphamide + Cytarabine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 3628, 'therapyName': 'Allopurinol'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 3199, 'therapyName': 'inotuzumab ozogamicin'}]",Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia,521
93,NCT01621477,Phase II,Terminated,"[{'id': 1756, 'therapyName': 'Plerixafor'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 1845, 'therapyName': 'Mycophenolate mofetil'}, {'id': 2469, 'therapyName': 'Busulfan + Clofarabine + Thymoglobulin'}, {'id': 1783, 'therapyName': 'Cyclophosphamide + Cytarabine'}]",T-Cell Replete Haploidentical Donor Hematopoietic Stem Cell Plus Natural Killer (NK) Cell Transplantation in Patients With Hematologic Malignancies Relapsed or Refractory Despite Previous Allogeneic Transplant,521
94,NCT01356290,Phase II,Recruiting,"[{'id': 1475, 'therapyName': 'Thalidomide'}, {'id': 4418, 'therapyName': 'Fenofibrate'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 2124, 'therapyName': 'Celecoxib'}, {'id': 1783, 'therapyName': 'Cyclophosphamide + Cytarabine'}]",Metronomic and Targeted Anti-angiogenesis Therapy for Children With Recurrent/Progressive Medulloblastoma (MEMMAT),521
95,NCT02389309,Phase I,Recruiting,"[{'id': 2697, 'therapyName': 'Cyclophosphamide + Dasatinib + Temsirolimus'}]","A Trial of Dasatinib (PDGFR and SRC Inhibitor), Temsirolimus and Cyclophosphamide in Patients With Advanced Solid Tumors",521
96,NCT02420717,Phase II,Recruiting,"[{'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 3195, 'therapyName': 'Cytarabine + Methotrexate '}, {'id': 2046, 'therapyName': 'Cyclophosphamide + Dexamethasone + Doxorubicin + Vincristine '}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 3194, 'therapyName': 'Mercaptopurine + Methotrexate + Prednisone + Vincristine'}]",Ruxolitinib or Dasatinib With Chemotherapy in Patients With Philadelphia Chromosome (Ph)-Like Acute Lymphoblastic Leukemia (ALL),521
97,NCT01424982,Phase II,Recruiting,"[{'id': 1476, 'therapyName': 'Pegfilgrastim'}, {'id': 2048, 'therapyName': 'Cytarabine + Methotrexate + Ponatinib'}, {'id': 2049, 'therapyName': 'Ponatinib + Vincristine'}, {'id': 2046, 'therapyName': 'Cyclophosphamide + Dexamethasone + Doxorubicin + Vincristine '}, {'id': 1642, 'therapyName': 'Leucovorin'}]",Hyper-CVAD and Ponatinib in Ph-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL),521
98,NCT02636322,Phase II,Recruiting,"[{'id': 2482, 'therapyName': 'Cyclophosphamide + Doxorubicin + Etoposide + Vincristine '}, {'id': 1610, 'therapyName': 'Rituximab + Lenalidomide + Ibrutinib'}, {'id': 2188, 'therapyName': 'Prednisone'}]","A Study of Rituximab, Lenalidomide, and Ibrutinib Combined With Dose Adjusted Chemotherapy For Patients With High Risk Diffuse Large B-Cell Lymphoma",521
99,NCT02337985,Phase I,Recruiting,"[{'id': 897, 'therapyName': 'Rituximab'}, {'id': 2482, 'therapyName': 'Cyclophosphamide + Doxorubicin + Etoposide + Vincristine '}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 2188, 'therapyName': 'Prednisone'}]",Gene Therapy and Combination Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin Lymphoma,521
100,NCT03285607,Phase I,Not yet recruiting,"[{'id': 6236, 'therapyName': 'Cyclophosphamide + Doxorubicin + Paclitaxel + MCS110'}]","MCS110 Combined With Neoadjuvant Doxorubicin, Cyclophosphamide, and Weekly Paclitaxel in Patients With Hormone-Receptor Positive and HER2- Breast Cancer",521
101,NCT02876302,Phase II,Recruiting,"[{'id': 4679, 'therapyName': 'Cyclophosphamide + Doxorubicin + Paclitaxel + Ruxolitinib'}]",Study Of Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative Inflammatory Breast Cancer,521
102,NCT01992653,Phase I,"Active, not recruiting","[{'id': 4248, 'therapyName': 'Cyclophosphamide + Doxorubicin + Prednisone'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 4226, 'therapyName': 'Polatuzumab Vedotin'}, {'id': 1646, 'therapyName': 'Obinutuzumab'}]","A Study of Polatuzumab Vedotin in Combination With Rituximab or Obinutuzumab, Cyclophosphamide, Doxorubicin, and Prednisone in Participants With B-Cell Non-Hodgkin's Lymphoma",521
103,NCT02531308,Phase II,Terminated,"[{'id': 1031, 'therapyName': 'Metformin'}, {'id': 3266, 'therapyName': 'Cyclophosphamide + Doxorubicin + Prednisone + Vincristine '}, {'id': 1476, 'therapyName': 'Pegfilgrastim'}, {'id': 897, 'therapyName': 'Rituximab'}]",Metformin in Combination With Standard Induction Therapy for Large B-cell Lymphoma (DLBCL),521
104,NCT01855750,Phase III,"Active, not recruiting","[{'id': 768, 'therapyName': 'Ibrutinib'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 3266, 'therapyName': 'Cyclophosphamide + Doxorubicin + Prednisone + Vincristine '}]","A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma",521
105,NCT01974440,Phase III,"Active, not recruiting","[{'id': 768, 'therapyName': 'Ibrutinib'}, {'id': 2323, 'therapyName': 'Bendamustine + Rituximab'}, {'id': 3266, 'therapyName': 'Cyclophosphamide + Doxorubicin + Prednisone + Vincristine '}]","A Study of PCI-32765 (Ibrutinib) in Combination With Either Bendamustine and Rituximab or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Participants With Previously Treated Indolent Non-Hodgkin Lymphoma",521
106,NCT02596971,Phase I,Recruiting,"[{'id': 1975, 'therapyName': 'Atezolizumab + Obinutuzumab'}, {'id': 3266, 'therapyName': 'Cyclophosphamide + Doxorubicin + Prednisone + Vincristine '}, {'id': 1231, 'therapyName': 'Bendamustine'}]",Safety and Efficacy of MPDL3280A in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus CHOP in Patients With Follicular Lymphoma or Diffuse Large B-Cell Lymphoma,521
107,NCT02055820,Phase I,"Active, not recruiting","[{'id': 1562, 'therapyName': 'Venetoclax'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 3266, 'therapyName': 'Cyclophosphamide + Doxorubicin + Prednisone + Vincristine '}, {'id': 1646, 'therapyName': 'Obinutuzumab'}]",A Safety and Pharmacokinetics Study of GDC-0199 (ABT-199) in Patients With Non-Hodgkin's Lymphoma,521
108,NCT02541565,Phase I,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 3266, 'therapyName': 'Cyclophosphamide + Doxorubicin + Prednisone + Vincristine '}, {'id': 897, 'therapyName': 'Rituximab'}]",Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Diffuse Large B-cell Lymphoma,521
109,NCT02427620,Phase II,Recruiting,"[{'id': 2353, 'therapyName': 'Cyclophosphamide + Doxorubicin + Vincristine '}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 3195, 'therapyName': 'Cytarabine + Methotrexate '}, {'id': 1642, 'therapyName': 'Leucovorin'}]",A Study of Ibrutinib Plus Rituximab With Hyper-CVAD Consolidation in Newly Diagnosed Young Patients With Mantle Cell Lymphoma,521
110,NCT01175356,Phase I,Completed,"[{'id': 2558, 'therapyName': 'Busulfan + Melphalan'}, {'id': 2590, 'therapyName': 'Cyclophosphamide + Topotecan'}, {'id': 1425, 'therapyName': '131I-MIBG'}, {'id': 2353, 'therapyName': 'Cyclophosphamide + Doxorubicin + Vincristine '}, {'id': 2585, 'therapyName': 'Cisplatin + Etoposide'}]","Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin",521
111,NCT02073097,Phase Ib/II,Recruiting,"[{'id': 2351, 'therapyName': 'Carfilzomib + Rituximab'}, {'id': 2353, 'therapyName': 'Cyclophosphamide + Doxorubicin + Vincristine '}]","Carfilzomib, Rituximab, and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Lymphoma",521
112,NCT02323230,Phase II,"Active, not recruiting","[{'id': 4280, 'therapyName': 'Cyclophosphamide + DPX-Survivac'}]",A Study of DPX-Survivac Vaccine Therapy in Patients With Recurrent Survivin-expressing DLBCL,521
113,NCT02785250,Phase I,Recruiting,"[{'id': 4238, 'therapyName': 'Cyclophosphamide + DPX-Survivac + INCB024360 '}]",Study of DPX-Survivac Vaccine Therapy and Epacadostat in Patients With Recurrent Ovarian Cancer,521
114,NCT02518750,Phase II,Recruiting,"[{'id': 1604, 'therapyName': 'Panobinostat + Bortezomib + Dexamethasone'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 3160, 'therapyName': 'Nelarabine'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 3217, 'therapyName': 'Cyclophosphamide + Etoposide'}, {'id': 3216, 'therapyName': 'Cytarabine + Methotrexate + Prednisone'}, {'id': 1746, 'therapyName': 'Clofarabine'}]",Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoma,521
115,NCT00602667,Phase I,"Active, not recruiting","[{'id': 2449, 'therapyName': 'Methotrexate + Cisplatin + Cyclophosphamide + Vincristine'}, {'id': 2450, 'therapyName': 'Cyclophosphamide + Etoposide + Topotecan'}, {'id': 2451, 'therapyName': 'Erlotinib + Cyclophosphamide + Topotecan'}]","Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma",521
116,NCT00338377,Phase II,Recruiting,"[{'id': 2291, 'therapyName': 'Cyclophosphamide + Fludarabine'}, {'id': 1167, 'therapyName': 'Aldesleukin'}]",Lymphodepletion Plus Adoptive Cell Transfer With or Without Dendritic Cell Immunization,521
117,NCT01701674,Phase I,"Active, not recruiting","[{'id': 2291, 'therapyName': 'Cyclophosphamide + Fludarabine'}, {'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 1167, 'therapyName': 'Aldesleukin'}]",Ipilimumab With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 in Melanoma Mets Pts,521
118,NCT00003553,Phase II,Unknown status,"[{'id': 2291, 'therapyName': 'Cyclophosphamide + Fludarabine'}, {'id': 1650, 'therapyName': 'Cyclosporine'}, {'id': 1845, 'therapyName': 'Mycophenolate mofetil'}, {'id': 1639, 'therapyName': 'Methotrexate'}]",Peripheral Stem Cell Transplant in Treating Patients With Metastatic Kidney Cancer,521
119,NCT02153580,Phase I,"Active, not recruiting","[{'id': 1136, 'therapyName': 'Etoposide'}, {'id': 2291, 'therapyName': 'Cyclophosphamide + Fludarabine'}, {'id': 1231, 'therapyName': 'Bendamustine'}]","Cellular Immunotherapy Following Cyclophosphamide in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia or B-Cell Prolymphocytic Leukemia",521
120,NCT01256398,Phase II,"Active, not recruiting","[{'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 2291, 'therapyName': 'Cyclophosphamide + Fludarabine'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1824, 'therapyName': 'Vincristine + Methotrexate + Mercaptopurine'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 2391, 'therapyName': 'Cytarabine + Daunorubicin + Etoposide'}, {'id': 1476, 'therapyName': 'Pegfilgrastim'}, {'id': 1205, 'therapyName': 'Alemtuzumab'}, {'id': 1642, 'therapyName': 'Leucovorin'}]",Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,521
121,NCT00167180,Phase II,Completed,"[{'id': 2291, 'therapyName': 'Cyclophosphamide + Fludarabine'}]",Post Transplant Donor Lymphocyte Infusion,521
122,NCT01174121,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 2291, 'therapyName': 'Cyclophosphamide + Fludarabine'}, {'id': 1167, 'therapyName': 'Aldesleukin'}]",Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer,521
123,NCT02356159,Phase Ib/II,Recruiting,"[{'id': 2294, 'therapyName': 'Cytarabine + Fludarabine'}, {'id': 2373, 'therapyName': 'Palifermin'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 2238, 'therapyName': 'Sirolimus + Tacrolimus + Methotrexate'}, {'id': 2292, 'therapyName': 'Doxorubicin + Etoposide + Fludarabine + Vincristine '}, {'id': 2291, 'therapyName': 'Cyclophosphamide + Fludarabine'}, {'id': 897, 'therapyName': 'Rituximab'}]",Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation,521
124,NCT01804634,Phase II,Recruiting,"[{'id': 1373, 'therapyName': 'Cyclophosphamide + Fludarabine + Melphalan + Sirolimus'}]",A Phase II Trial of Reduced Intensity Conditioning and Haploidentical BMT for High-risk Solid Tumors,521
125,NCT02556931,Phase II,Recruiting,"[{'id': 4228, 'therapyName': 'Cyclophosphamide + Fludarabine + Melphalan + Tacrolimus'}]","Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies",521
126,NCT02722668,Phase II,Recruiting,"[{'id': 2281, 'therapyName': 'Cyclophosphamide + Fludarabine + Mycophenolate mofetil'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 1844, 'therapyName': 'anti-thymocyte globulin'}]",UCB Transplant for Hematological DIseases Using a Non Myeloablative Prep,521
127,NCT02423915,Phase Ib/II,Recruiting,"[{'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 2281, 'therapyName': 'Cyclophosphamide + Fludarabine + Mycophenolate mofetil'}, {'id': 917, 'therapyName': 'Sirolimus'}]",Fucosylated T Cells for Graft Versus Host Disease (GVHD) Prevention,521
128,NCT01203722,Phase Ib/II,Recruiting,"[{'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 2281, 'therapyName': 'Cyclophosphamide + Fludarabine + Mycophenolate mofetil'}]","Reduced Intensity, Partially HLA Mismatched BMT to Treat Hematologic Malignancies",521
129,NCT02629809,Phase II,Recruiting,"[{'id': 3628, 'therapyName': 'Allopurinol'}, {'id': 3627, 'therapyName': 'Cyclophosphamide + Fludarabine + Obinutuzumab'}, {'id': 768, 'therapyName': 'Ibrutinib'}]","First-line Therapy With Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (GA-101) (iFCG) for Patients With Chronic Lymphocytic Leukemia (CLL)",521
130,NCT02158091,Phase Ib/II,"Active, not recruiting","[{'id': 2339, 'therapyName': 'Cyclophosphamide + Fludarabine + Rituximab '}, {'id': 1024, 'therapyName': 'Duvelisib'}]","A Phase 1b/2 Study of IPI-145 Plus FCR in Previously Untreated, Younger Patients With CLL",521
131,NCT03056339,Phase Ib/II,Recruiting,"[{'id': 6217, 'therapyName': 'Cyclophosphamide + Fludarabine phosphate + iC9/CAR.19/IL15-Transduced CB-NK'}]",Umbilical & Cord Blood (CB)- Derived CAR-Engineered NK Cells for B Lymphoid Malignancies,521
132,NCT02379520,Phase I,Recruiting,"[{'id': 5328, 'therapyName': 'Cyclophosphamide + Fludarabine phosphate + Nivolumab'}]","HPV-16/18 E6/E7-Specific T Lymphocytes, Relapsed HPV-Associated Cancers, HESTIA (HESTIA)",521
133,NCT02132949,Phase II,"Active, not recruiting","[{'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}, {'id': 1495, 'therapyName': 'Paclitaxel + Doxorubicin + Cyclophosphamide'}, {'id': 1895, 'therapyName': 'Cyclophosphamide + Fluorouracil + Docetaxel + Epirubicin  '}]","A Study Evaluating Perjeta (Pertuzumab) Combined With Herceptin (Trastuzumab) and Standard Anthracycline-based Chemotherapy in Patients With HER2-positive Locally Advanced, Inflammatory, or Early-stage Breast Cancer.",521
134,NCT02981524,Phase II,Recruiting,"[{'id': 5079, 'therapyName': 'Cyclophosphamide + GVAX colorectal cancer vaccine + Pembrolizumab'}]",Phase 2 Study of GVAX (With CY) and Pembrolizumab in MMR-p Advanced Colorectal Cancer,521
135,NCT02451982,Phase Ib/II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 3622, 'therapyName': 'Cyclophosphamide + GVAX pancreatic cancer vaccine '}]",Neoadjuvant/Adjuvant GVAX Pancreas Vaccine (With CY) With or Without Nivolumab Trial for Surgically Resectable Pancreatic Cancer,521
136,NCT03153410,Phase I,Not yet recruiting,"[{'id': 5778, 'therapyName': 'Cyclophosphamide + GVAX pancreatic cancer vaccine + LY3022855 + Pembrolizumab'}]","Pilot Study With CY, Pembrolizumab, GVAX, and IMC-CS4 (LY3022855) in Patients With Borderline Resectable Adenocarcinoma of the Pancreas",521
137,NCT02648282,Phase II,Recruiting,"[{'id': 4473, 'therapyName': 'Cyclophosphamide + GVAX pancreatic cancer vaccine + Pembrolizumab'}]","Study With CY, Pembrolizumab, GVAX, and SBRT in Patients With Locally Advanced Pancreatic Cancer",521
138,NCT02706405,Phase I,Recruiting,"[{'id': 4365, 'therapyName': 'Cyclophosphamide + JCAR014 + MEDI4736'}]",JCAR014 and Durvalumab in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma,521
139,NCT01955434,Phase II,Recruiting,"[{'id': 4019, 'therapyName': 'Cyclophosphamide + LCL161'}]",SMAC Mimetic LCL161 Alone or With Cyclophosphamide in Treating Patients With Relapsed or Refractory Multiple Myeloma,521
140,NCT02017964,Phase II,Completed,"[{'id': 1791, 'therapyName': 'Carboplatin + Etoposide'}, {'id': 2673, 'therapyName': 'Cyclophosphamide + Methotrexate + Vincristine  '}]","Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed, Non-Metastatic Desmoplastic Medulloblastoma",521
141,NCT00550992,Phase I,Unknown status,"[{'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1752, 'therapyName': 'Mitoxantrone + Etoposide + Cytarabine'}, {'id': 1848, 'therapyName': 'Cyclophosphamide + Methotrexate + Vincristine + Pegaspargase '}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1650, 'therapyName': 'Cyclosporine'}, {'id': 1844, 'therapyName': 'anti-thymocyte globulin'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1642, 'therapyName': 'Leucovorin'}]",Different Therapies in Treating Infants With Newly Diagnosed Acute Leukemia,521
142,NCT02723994,Phase II,Recruiting,"[{'id': 2188, 'therapyName': 'Prednisone'}, {'id': 4685, 'therapyName': 'Dexamethasone + Doxorubicin'}, {'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 2346, 'therapyName': 'Mercaptopurine + Thioguanine'}, {'id': 2394, 'therapyName': 'Asparaginase + Cytarabine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 1848, 'therapyName': 'Cyclophosphamide + Methotrexate + Vincristine + Pegaspargase '}]",A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia,521
143,NCT03003676,Phase I,Recruiting,"[{'id': 5173, 'therapyName': 'Cyclophosphamide + ONCOS-102 + Pembrolizumab'}]","A Pilot Study of Sequential ONCOS-102, an Engineered Oncolytic Adenovirus Expressing GMCSF, and Pembrolizumab in Patients With Advanced or Unresectable Melanoma Progressing After Programmed Cell Death Protein 1 (PD1) Blockade",521
144,NCT01106898,Phase II,Unknown status,"[{'id': 1980, 'therapyName': 'Cyclophosphamide + Paclitaxel'}, {'id': 947, 'therapyName': 'Trastuzumab'}]",Cyclophosphamide and Paclitaxel With or Without Trastuzumab in Treating Women With Stage I or Stage II Breast Cancer Who Have Undergone Surgery,521
145,NCT01750073,Phase II,Recruiting,"[{'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 1980, 'therapyName': 'Cyclophosphamide + Paclitaxel'}]",Paclitaxel and Cyclophosphamide With or Without Trastuzumab Before Surgery in Treating Patients With Previously Untreated Stage I-III Breast Cancer,521
146,NCT02654119,Phase II,Recruiting,"[{'id': 1898, 'therapyName': 'Cyclophosphamide + Paclitaxel + Trastuzumab '}]","Cyclophosphamide, Paclitaxel, and Trastuzumab in Treating Patients With Stage I-II HER2/Neu Positive Breast Cancer After Surgery",521
147,NCT02948101,Phase II,Not yet recruiting,"[{'id': 5848, 'therapyName': 'Cyclophosphamide + PD 0360324'}]",Pre-Conditioning Effects of Anti-Macrophage Therapy Using PD 0360324 in Recurrent Platinum-Resistant Epithelial Ovarian Cancer,521
148,NCT02650635,Phase I,"Active, not recruiting","[{'id': 3413, 'therapyName': 'Cyclophosphamide + Pegfilgrastim + VTX-2337'}]","TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid Tumors",521
149,NCT02768701,Phase II,Recruiting,"[{'id': 4891, 'therapyName': 'Cyclophosphamide + Pembrolizumab'}]",Study Of Single-dose Cyclophosphamide +Pembrolizumab In Patients With Metastatic Triple Negative Breast Cancer,521
150,NCT03092453,Phase I,Recruiting,"[{'id': 4891, 'therapyName': 'Cyclophosphamide + Pembrolizumab'}]",Dendritic Cell Vaccination in Patients With Advanced Melamona,521
151,NCT00923845,Phase II,Completed,"[{'id': 917, 'therapyName': 'Sirolimus'}, {'id': 2308, 'therapyName': 'Cyclophosphamide + Pentostatin'}]",Low-Intensity Stem Cell Transplantation With Multiple Lymphocyte Infusions to Treat Advanced Kidney Cancer,521
152,NCT02873819,Phase II,Recruiting,"[{'id': 4614, 'therapyName': 'MAGE-A3 vaccine'}, {'id': 4615, 'therapyName': 'Cyclophosphamide + poly ICLC  + Sargramostim'}]",Safety and Efficacy Study of GL-0817 (With Cyclophosphamide) for the Prevention of Recurrence of Squamous Cell Carcinoma of the Oral Cavity,521
153,NCT02343536,Phase I,Recruiting,"[{'id': 2488, 'therapyName': 'Cyclophosphamide + Prednisone + Rituximab + Vincristine'}, {'id': 651, 'therapyName': 'Azacitidine'}]","A Phase 1, Open-label,Trial of Oral Azacitidine (CC-486) Plus R-CHOP in Subjects With Large B-Cell Lymphoma or Follicular Lymphoma",521
154,NCT01925131,Phase I,Recruiting,"[{'id': 3221, 'therapyName': 'Cyclophosphamide + Prednisone + Vincristine'}, {'id': 3199, 'therapyName': 'inotuzumab ozogamicin'}]","S1312, Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Leukemia",521
155,NCT02298348,Phase I,Recruiting,"[{'id': 2360, 'therapyName': 'Cyclophosphamide + Sorafenib + Topotecan'}]",Sorafenib and Cyclophosphamide/Topotecan in Patients With Relapsed and Refractory Neuroblastoma,521
156,NCT02030964,Phase I,"Active, not recruiting","[{'id': 2590, 'therapyName': 'Cyclophosphamide + Topotecan'}, {'id': 2124, 'therapyName': 'Celecoxib'}]",N2012-01 Phase 1 Study of Difluoromethylornithine (DFMO) and Celecoxib With Cyclophosphamide/Topotecan,521
157,NCT01606878,Phase I,Recruiting,"[{'id': 2952, 'therapyName': 'Dexamethasone + Doxorubicin + Vincristine'}, {'id': 2590, 'therapyName': 'Cyclophosphamide + Topotecan'}, {'id': 706, 'therapyName': 'Crizotinib'}]",Crizotinib and Combination Chemotherapy in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma,521
158,NCT01857934,Phase II,Recruiting,"[{'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1873, 'therapyName': 'Sargramostim'}, {'id': 1167, 'therapyName': 'Aldesleukin'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 2627, 'therapyName': 'Levetiracetam'}, {'id': 2585, 'therapyName': 'Cisplatin + Etoposide'}, {'id': 2458, 'therapyName': 'Hu14.18K322A'}, {'id': 2558, 'therapyName': 'Busulfan + Melphalan'}, {'id': 2590, 'therapyName': 'Cyclophosphamide + Topotecan'}]",Therapy for Children With Advanced Stage Neuroblastoma,521
159,NCT01492673,Phase II,"Active, not recruiting","[{'id': 1479, 'therapyName': 'Cyclophosphamide + Topotecan + Bevacizumab'}]","Cyclophosphamide, Topotecan, and Bevacizumab (CTB) in Patients With Relapsed/Refractory Ewing's Sarcoma and Neuroblastoma",521
160,NCT01275677,Phase III,"Active, not recruiting","[{'id': 1503, 'therapyName': 'Paclitaxel + Trastuzumab + Doxorubicin + Cyclophosphamide'}, {'id': 1881, 'therapyName': 'Docetaxel + Cyclophosphamide'}, {'id': 1882, 'therapyName': 'Docetaxel + Cyclophosphamide + Trastuzumab'}, {'id': 1495, 'therapyName': 'Paclitaxel + Doxorubicin + Cyclophosphamide'}]",Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,521
161,NCT01501487,FDA approved,"Active, not recruiting","[{'id': 1902, 'therapyName': 'Docetaxel + Doxorubicin + Cyclophosphamide'}, {'id': 1982, 'therapyName': 'Fluorouracil + Epirubicin + Cyclophosphamide'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1476, 'therapyName': 'Pegfilgrastim'}, {'id': 1881, 'therapyName': 'Docetaxel + Cyclophosphamide'}, {'id': 1977, 'therapyName': 'Doxorubicin + Cyclophosphamide'}, {'id': 1485, 'therapyName': 'Trastuzumab + Docetaxel + Carboplatin'}, {'id': 1978, 'therapyName': 'Pertuzumab + Trastuzumab + Docetaxel'}]",MINT I Multi- Institutional Neo-adjuvant Therapy MammaPrint Project I,521
162,NCT01779050,Phase II,"Active, not recruiting","[{'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1087, 'therapyName': 'Epirubicin + Cyclophosphamide'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1982, 'therapyName': 'Fluorouracil + Epirubicin + Cyclophosphamide'}, {'id': 1834, 'therapyName': 'Docetaxel + Carboplatin'}, {'id': 1881, 'therapyName': 'Docetaxel + Cyclophosphamide'}]",Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer Patients With ERBB2 Expressing Disseminated Tumor Cells,521
163,NCT01796197,Phase II,"Active, not recruiting","[{'id': 1977, 'therapyName': 'Doxorubicin + Cyclophosphamide'}, {'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]",Paclitaxel + Trastuzumab + Pertuzumab as Pre-Op for Inflammatory BrCa,521
164,NCT02876107,Phase II,Recruiting,"[{'id': 1977, 'therapyName': 'Doxorubicin + Cyclophosphamide'}, {'id': 3386, 'therapyName': 'Carboplatin + Paclitaxel + Panitumumab'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]",A Phase II Study of Using Panitumumab/Carboplatin/Paclitaxel (PaCT) Followed by Anthracycline-Containing Regimen (AC) for New Triple-Negative Inflammatory Breast Cancer (TN-IBC),521
165,NCT01897441,Phase I,Recruiting,"[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1551, 'therapyName': 'Trastuzumab + Paclitaxel'}, {'id': 1977, 'therapyName': 'Doxorubicin + Cyclophosphamide'}]",Chemotherapy Before Surgery and Tissue Sample Collection in Patients With Stage IIA-IIIC Breast Cancer,521
166,NCT03036488,Phase III,Recruiting,"[{'id': 1087, 'therapyName': 'Epirubicin + Cyclophosphamide'}, {'id': 1977, 'therapyName': 'Doxorubicin + Cyclophosphamide'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]",Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522),521
167,NCT02489448,Phase Ib/II,Recruiting,"[{'id': 3100, 'therapyName': 'MEDI4736 + nab-paclitaxel'}, {'id': 1977, 'therapyName': 'Doxorubicin + Cyclophosphamide'}]",Neoadjuvant MEDI4736 Concomitant With Weekly Nab-paclitaxel and Dose-dense AC for Stage I-III Triple Negative Breast Cancer,521
168,NCT02032277,Phase III,"Active, not recruiting","[{'id': 1977, 'therapyName': 'Doxorubicin + Cyclophosphamide'}, {'id': 954, 'therapyName': 'Veliparib'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]",A Study Evaluating Safety and Efficacy of the Addition of ABT-888 Plus Carboplatin Versus the Addition of Carboplatin to Standard Chemotherapy Versus Standard Chemotherapy in Subjects With Early Stage Triple Negative Breast Cancer,521
169,NCT01697293,Phase Ib/II,Recruiting,"[{'id': 3054, 'therapyName': 'Paclitaxel + Triciribine'}, {'id': 1977, 'therapyName': 'Doxorubicin + Cyclophosphamide'}]","Triciribine Phosphate, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide in Treating Patients With Stage IIB-IV Breast Cancer",521
170,NCT02789657,Phase II,Recruiting,"[{'id': 4235, 'therapyName': 'Carboplatin + Pertuzumab + Trastuzumab + Paclitaxel'}, {'id': 1977, 'therapyName': 'Doxorubicin + Cyclophosphamide'}]",BrUOG 308: Efficacy of wPCbTP and Switching to an AC in Non-responding Patients as Neoadjuvant Therapy in Clinical Stage I-III HER2-positive Breast Cancer.,521
171,NCT00574587,Phase Ib/II,Unknown status,"[{'id': 1983, 'therapyName': 'vorinostat + Paclitaxel'}, {'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 1977, 'therapyName': 'Doxorubicin + Cyclophosphamide'}]","Trial for Locally Advanced Her2 Positive Breast Cancer Using Paclitaxel, Trastuzumab, Doxorubicin and Cyclophasmide on a Weekly Basis",521
172,NCT02957968,Phase II,Recruiting,"[{'id': 1495, 'therapyName': 'Paclitaxel + Doxorubicin + Cyclophosphamide'}, {'id': 5729, 'therapyName': 'Doxorubicin + Cyclophosphamide + Paclitaxel + Carboplatin'}]",Neoadj Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca,521
173,NCT01901146,Phase III,Completed,"[{'id': 1087, 'therapyName': 'Epirubicin + Cyclophosphamide'}, {'id': 1551, 'therapyName': 'Trastuzumab + Paclitaxel'}]",Efficacy and Safety Study of ABP 980 Compared With Trastuzumab in Subjects With HER2 Positive Early Breast Cancer (Lilac),521
174,NCT00092222,Phase II,Recruiting,"[{'id': 917, 'therapyName': 'Sirolimus'}, {'id': 1187, 'therapyName': 'Alpha 2 Interferon'}, {'id': 2211, 'therapyName': 'EPOCH'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1008, 'therapyName': 'Doxil'}]",Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity,521
175,NCT00520130,Phase Ib/II,"Active, not recruiting","[{'id': 2294, 'therapyName': 'Cytarabine + Fludarabine'}, {'id': 2305, 'therapyName': 'Alemtuzumab + Cyclosporine'}, {'id': 2306, 'therapyName': 'Rituximab + Fludarabine + EPOCH'}, {'id': 2307, 'therapyName': 'Fludarabine + EPOCH'}, {'id': 2238, 'therapyName': 'Sirolimus + Tacrolimus + Methotrexate'}, {'id': 1632, 'therapyName': 'Filgrastim'}]",Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,521
176,NCT01760655,Phase II,Recruiting,"[{'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 1842, 'therapyName': 'Fludarabine + Thiotepa + Cyclophosphamide'}, {'id': 1845, 'therapyName': 'Mycophenolate mofetil'}]",Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies,521
177,NCT01036087,Phase II,"Active, not recruiting","[{'id': 1984, 'therapyName': 'Panitumumab + Abraxane + Carboplatin'}, {'id': 1982, 'therapyName': 'Fluorouracil + Epirubicin + Cyclophosphamide'}]","Panitumumab, Nab-paclitaxel and Carboplatin for HER2 Negative Inflammatory Breast Cancer",521
178,NCT02117024,Phase II,"Active, not recruiting","[{'id': 2472, 'therapyName': 'HS-110 + Cyclophosphamide'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 1685, 'therapyName': 'Vinorelbine'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]",A Phase 2 Study of Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer,521
179,NCT02251548,Phase II,Recruiting,"[{'id': 2185, 'therapyName': 'Ibrutinib + Rituximab + Cyclophosphamide + Fludarabine'}]","A Phase II Study of Ibrutinib Plus FCR in Previously Untreated, Younger Patients With Chronic Lymphocytic Leukemia",521
180,NCT03085914,Phase Ib/II,Recruiting,"[{'id': 5483, 'therapyName': 'INCB024360 + Nivolumab + mFOLFOX6'}, {'id': 5484, 'therapyName': 'INCB024360 + Nivolumab + Gemcitabine + nab-paclitaxel'}, {'id': 5485, 'therapyName': 'INCB024360 + Pembrolizumab + Carboplatin + Paclitaxel'}, {'id': 5486, 'therapyName': 'INCB024360 + Pembrolizumab + Carboplatin + Pemetrexed'}, {'id': 5487, 'therapyName': 'INCB024360 + Pembrolizumab + Cyclophosphamide'}]",A Study of Epacadostat in Combination With a PD-1 Inhibitor and Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors (ECHO-207),521
181,NCT03153462,Expanded access,Available,"[{'id': 5098, 'therapyName': 'KTE-C19 + Fludarabine phosphate + Cyclophosphamide'}]",Axicabtagene Ciloleucel Expanded Access Study,521
182,NCT02601313,Phase II,Recruiting,"[{'id': 5098, 'therapyName': 'KTE-C19 + Fludarabine phosphate + Cyclophosphamide'}]",A Phase 2 Multicenter Study Evaluating Subjects With Relapsed/Refractory Mantle Cell Lymphoma (ZUMA-2),521
183,NCT03003520,Phase II,Recruiting,"[{'id': 5350, 'therapyName': 'MEDI4736 + R2-CHOP'}, {'id': 5349, 'therapyName': 'MEDI4736 + Rituximab + Doxorubicin + Vincristine + Cyclophosphamide + Prednisone'}]",A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma,521
184,NCT02114229,Phase II,Recruiting,"[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 2449, 'therapyName': 'Methotrexate + Cisplatin + Cyclophosphamide + Vincristine'}, {'id': 626, 'therapyName': 'Alisertib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 942, 'therapyName': 'Topotecan'}]",Phase 2 Study of Alisertib Therapy for Rhabdoid Tumors,521
185,NCT03269669,Phase II,Recruiting,"[{'id': 6257, 'therapyName': 'Obinutuzumab + CHOP'}, {'id': 6302, 'therapyName': 'Lenalidomide + Obinutuzumab\t'}, {'id': 6301, 'therapyName': 'Obinutuzumab + TGR-1202'}, {'id': 2188, 'therapyName': 'Prednisone'}]","Obinutuzumab With or Without PI3K-delta Inhibitor TGR-1202, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma",521
186,NCT02379585,Phase Ib/II,Terminated,"[{'id': 1495, 'therapyName': 'Paclitaxel + Doxorubicin + Cyclophosphamide'}, {'id': 1978, 'therapyName': 'Pertuzumab + Trastuzumab + Docetaxel'}]",Study of Short-term Fasting on Neoadjuvant Chemotherapy in Patients With Newly Diagnosed Breast Cancer,521
187,NCT01042379,Phase II,Recruiting,"[{'id': 1218, 'therapyName': 'Trebananib'}, {'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}, {'id': 746, 'therapyName': 'Ganitumab'}, {'id': 1495, 'therapyName': 'Paclitaxel + Doxorubicin + Cyclophosphamide'}, {'id': 1494, 'therapyName': 'MK2206 + Trastuzumab'}, {'id': 1493, 'therapyName': 'Trebananib + Trastuzumab'}, {'id': 1492, 'therapyName': 'T-DM1 + Pertuzumab'}]",I-SPY 2 TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer,521
188,NCT02637375,Phase I,Withdrawn,"[{'id': 1495, 'therapyName': 'Paclitaxel + Doxorubicin + Cyclophosphamide'}, {'id': 745, 'therapyName': 'Ganetespib'}]",A Pilot Preoperative Trial of Ganetespib With Paclitaxel for Triple-Negative Breast Cancer,521
189,NCT01008150,Phase II,Unknown status,"[{'id': 1504, 'therapyName': 'Paclitaxel + Trastuzumab + Neratinib + Doxorubicin + Cyclophosphamide'}, {'id': 1503, 'therapyName': 'Paclitaxel + Trastuzumab + Doxorubicin + Cyclophosphamide'}, {'id': 1505, 'therapyName': 'Paclitaxel + Neratinib + Doxorubicin + Cyclophosphamide'}]",Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer,521
190,NCT03101748,Phase Ib/II,Not yet recruiting,"[{'id': 3187, 'therapyName': 'Neratinib + Paclitaxel + Pertuzumab + Trastuzumab'}, {'id': 1505, 'therapyName': 'Paclitaxel + Neratinib + Doxorubicin + Cyclophosphamide'}]",3HT With Taxol for Metastatic Breast Cancer,521
191,NCT03029403,Phase II,Not yet recruiting,"[{'id': 5266, 'therapyName': 'Pembrolizumab + DPX-Survivac + Cyclophosphamide'}]","Phase 2 Study of Pembrolizumab, DPX-Survivac Vaccine and Cyclophosphamide in Advanced Ovarian, Primary Peritoneal or Fallopian Tube Cancer",521
192,NCT01855828,Phase II,Recruiting,"[{'id': 1549, 'therapyName': 'Pertuzumab + Trastuzumab + Paclitaxel'}, {'id': 1550, 'therapyName': 'Pertuzumab + Trastuzumab + Fluorouracil + Epirubicin + Cyclophosphamide'}]",Phase 2 Trial of Pertuzumab and Trastuzumab With Weekly Paclitaxel and Chemotherapy for HER2 Positive Breast Cancer,521
193,NCT03107988,Phase I,Recruiting,"[{'id': 5580, 'therapyName': 'PF-06463922 + Cyclophosphamide + Topotecan'}, {'id': 869, 'therapyName': 'PF-06463922'}]",Study of Lorlatinib (PF-06463922),521
194,NCT02605694,Phase II,Withdrawn,"[{'id': 3389, 'therapyName': 'Duvelisib + Rituximab'}, {'id': 2195, 'therapyName': 'R-CHOP'}]",Duvelisib With Rituximab vs R-CHOP in Subjects With Relapsed/Refractory Follicular Lymphoma (FRESCO),521
195,NCT01334502,Phase I,Completed,"[{'id': 735, 'therapyName': 'Everolimus'}, {'id': 2195, 'therapyName': 'R-CHOP'}]","Everolimus, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Untreated Diffuse Large B-Cell Lymphoma",521
196,NCT03263026,Phase III,Not yet recruiting,"[{'id': 2195, 'therapyName': 'R-CHOP'}, {'id': 1682, 'therapyName': 'Enzastaurin'}]",Study to Assess Enzastaurin + R-CHOP in Subjects With DLBCL With the Genomic Biomarker DGM1,521
197,NCT03274492,Phase III,Not yet recruiting,"[{'id': 4226, 'therapyName': 'Polatuzumab Vedotin'}, {'id': 6177, 'therapyName': 'R-CHP'}, {'id': 2195, 'therapyName': 'R-CHOP'}]","A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma",521
198,NCT01193842,Phase Ib/II,"Active, not recruiting","[{'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 3395, 'therapyName': 'R-EPOCH'}]",Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas,521
199,NCT02700022,Phase I,"Active, not recruiting","[{'id': 626, 'therapyName': 'Alisertib'}, {'id': 3395, 'therapyName': 'R-EPOCH'}]",A Phase I Study of Alisertib + R-EPOCH for Treatment of Myc-Positive Aggressive B-cell Lymphomas,521
200,NCT00114738,Phase II,"Active, not recruiting","[{'id': 3395, 'therapyName': 'R-EPOCH'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 688, 'therapyName': 'Bortezomib'}]",EPOCH-R Chemotherapy Plus Bortezomib to Treat Mantle Cell Lymphoma,521
201,NCT02383212,Phase I,"Active, not recruiting","[{'id': 5722, 'therapyName': 'REGN2810 + Carboplatin + Docetaxel'}, {'id': 5721, 'therapyName': 'REGN2810 + Carboplatin + Pemetrexed'}, {'id': 5723, 'therapyName': 'REGN2810 + GM-CSF + Cyclophosphamide'}, {'id': 5718, 'therapyName': 'REGN2810 + Cyclophosphamide'}, {'id': 5656, 'therapyName': 'REGN2810'}, {'id': 5720, 'therapyName': 'REGN2810 + Carboplatin + Paclitaxel'}, {'id': 5719, 'therapyName': 'REGN2810 + Docetaxel'}]",Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies,521
202,NCT02354547,Phase I,Recruiting,"[{'id': 3617, 'therapyName': 'SGT-53 + Cyclophosphamide + Topotecan'}]",A Study of SGT-53 in Children With Refractory or Recurrent Solid Tumors,521
203,NCT03099356,Phase II,Recruiting,"[{'id': 5513, 'therapyName': 'Sirolimus + Cyclophosphamide'}]","Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer",521
204,NCT01689987,Phase I,Completed,"[{'id': 2385, 'therapyName': 'Sirolimus + Cyclophosphamide + Dexamethasone + Hydroxychloroquine'}]","Hydroxychloroquine, Cyclophosphamide, Dexamethasone, and Sirolimus in Treating Patients With Relapsed or Refractory Multiple Myeloma",521
205,NCT01670175,Phase I,Completed,"[{'id': 1224, 'therapyName': 'Sirolimus + Cyclophosphamide + Topotecan'}]",Sirolimus With Cyclophosphamide and Topotecan for Pediatric/Adolescent Relapsed and Refractory Solid Tumors,521
206,NCT01871766,Phase II,Recruiting,"[{'id': 1119, 'therapyName': 'Sorafenib + Avastin + Cyclophosphamide'}, {'id': 1436, 'therapyName': 'Vincristine + Dactinomycin'}, {'id': 1435, 'therapyName': 'Vincristine + Dactinomycin + Cyclophosphamide'}]","Treatment of Localized Rhabdomyosarcoma With Chemotherapy, Radiotherapy, and Surgery",521
207,NCT00665990,Phase I,Completed,"[{'id': 1119, 'therapyName': 'Sorafenib + Avastin + Cyclophosphamide'}]",Phase I Study of Bevacizumab and Sorafenib Combined With Low Dose Cyclophosphamide in Patients With Refractory Solid Tumors and Leukemia,521
208,NCT03036904,Phase I,Recruiting,"[{'id': 5294, 'therapyName': 'Venetoclax + DA-EPOCH-R'}]",Study of Venetoclax Plus DA-EPOCH-R for the Treatment of Aggressive B-Cell Lymphomas (V+DA-EPOCH-R),521
209,NCT02567435,Phase III,Suspended,"[{'id': 1435, 'therapyName': 'Vincristine + Dactinomycin + Cyclophosphamide'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1074, 'therapyName': 'Irinotecan'}]",Combination Chemotherapy and Irinotecan Hydrochloride or Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma,521
210,NCT01946529,Phase II,"Active, not recruiting","[{'id': 1433, 'therapyName': 'Vincristine + Doxorubicin + Cyclophosphamide + Ifosfamide + Etoposide'}, {'id': 1434, 'therapyName': 'Vincristine + Doxorubicin + Cyclophosphamide + Ifosfamide + Etoposide + others'}]",Therapeutic Trial for Patients With Ewing Sarcoma Family of Tumor and Desmoplastic Small Round Cell Tumors,521
211,NCT02306161,Phase II,Recruiting,"[{'id': 1433, 'therapyName': 'Vincristine + Doxorubicin + Cyclophosphamide + Ifosfamide + Etoposide'}, {'id': 746, 'therapyName': 'Ganitumab'}]",Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma,521
0,NCT02909972,Phase I,Recruiting,"[{'id': 4755, 'therapyName': 'ALRN-6924 + Cytarabine'}, {'id': 2273, 'therapyName': 'ALRN-6924'}]",Safety Study of ALRN-6924 in Patients With Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome,976
1,NCT03298984,Phase I,Not yet recruiting,"[{'id': 6300, 'therapyName': 'Alvocidib + Cytarabine + Daunorubicin'}]",Ph I Study of Alvocidib and Cytarabine/Duanorubicin (7+3) in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML).,976
2,NCT01371981,Phase III,"Active, not recruiting","[{'id': 2391, 'therapyName': 'Cytarabine + Daunorubicin + Etoposide'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 2392, 'therapyName': 'Cytarabine + Etoposide'}, {'id': 2393, 'therapyName': 'Cytarabine + Mitoxantrone'}, {'id': 2394, 'therapyName': 'Asparaginase + Cytarabine'}, {'id': 688, 'therapyName': 'Bortezomib'}]",Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,976
3,NCT02723994,Phase II,Recruiting,"[{'id': 2188, 'therapyName': 'Prednisone'}, {'id': 4685, 'therapyName': 'Dexamethasone + Doxorubicin'}, {'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 2346, 'therapyName': 'Mercaptopurine + Thioguanine'}, {'id': 2394, 'therapyName': 'Asparaginase + Cytarabine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 1848, 'therapyName': 'Cyclophosphamide + Methotrexate + Vincristine + Pegaspargase '}]",A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia,976
4,NCT01476839,Phase I,Recruiting,"[{'id': 6258, 'therapyName': 'Basiliximab + 90Y basiliximab + Carmustine + Cytarbine + Etoposide + Melphalan'}]",Radiolabeled Monoclonal Antibody Therapy and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Primary Refractory or Relapsed Hodgkin Lymphoma,976
5,NCT02130869,Phase I,Recruiting,"[{'id': 2378, 'therapyName': 'Bendamustine + Cytarabine + Etoposide'}, {'id': 2460, 'therapyName': 'Busulfan + Hu14.18K322A'}, {'id': 2459, 'therapyName': 'Aldesleukin + Melphalan + Sargramostim'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1791, 'therapyName': 'Carboplatin + Etoposide'}]",A Pilot Study of Immunotherapy Including Haploidentical NK Cell Infusion Following CD133+ Positively-Selected Autologous Hematopoietic Stem Cells in Children With High Risk Solid Tumors or Lymphomas,976
6,NCT01838395,Phase II,Completed,"[{'id': 3168, 'therapyName': 'BKT140 + Cytarabine'}]",Phase IIa Study Evaluating Safety and Efficacy of BL-8040 in Relapsed/Refractory AML Patients,976
7,NCT03263572,Phase II,Not yet recruiting,"[{'id': 6155, 'therapyName': 'Blinatumomab + Cytarabine + Dexamethasone + Methotrexate + Ponatinib'}, {'id': 6156, 'therapyName': 'Blinatumomab + Dexamethasone + Ponatinib'}]",Blinatumomab and Ponatinib in Patients With Philadelphia Chromosome (Ph)-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL),976
8,NCT02570542,Phase II,Recruiting,"[{'id': 1756, 'therapyName': 'Plerixafor'}, {'id': 3359, 'therapyName': 'Carmustine + Cytarabine + Etoposide + Melphalan'}]",Impact of CD34+ Cell Dose on Progression-free Survival Following High-Dose Therapy and Autologous Stem Cell Transplantation for Relapsed and Refractory Diffuse Large B-cell Lymphoma (DLBCL),976
9,NCT02443077,Phase III,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 3359, 'therapyName': 'Carmustine + Cytarabine + Etoposide + Melphalan'}, {'id': 768, 'therapyName': 'Ibrutinib'}]",Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma,976
10,NCT01453205,Phase II,Completed,"[{'id': 2354, 'therapyName': 'Cisplatin + Cytarabine + Dexamethasone'}, {'id': 2352, 'therapyName': 'Carboplatin + Etoposide + Ifosfamide '}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 2407, 'therapyName': 'MEDI-551'}]","A Phase 2, Multicenter, Randomized, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)",976
11,NCT02728050,Phase Ib/II,Recruiting,"[{'id': 920, 'therapyName': 'Sorafenib'}, {'id': 4363, 'therapyName': 'Cladribine + Cytarabine + Filgrastim + Mitoxantrone'}]","Filgrastim, Cladribine, Cytarabine and Mitoxantrone With or Without Sorafenib Tosylate in Treating Patients With Newly-Diagnosed, High-Risk Acute Myeloid Leukemia or Myelodysplastic Syndrome",976
12,NCT02416908,Phase Ib/II,Recruiting,"[{'id': 1749, 'therapyName': 'Selinexor'}, {'id': 3178, 'therapyName': 'Cladribine + Cytarabine + Plerixafor'}]",Study of CLAG + Selinexor in Relapsed or Refractory Acute Myeloid Leukemia,976
13,NCT00908167,Phase I,Completed,"[{'id': 2374, 'therapyName': 'Clofarabine + Cytarabine + Sorafenib'}]",Sorafenib in Combination With Cytarabine and Clofarabine in Patients With Refractory or Relapsed Hematologic Malignancies,976
14,NCT02642965,Phase Ib/II,Recruiting,"[{'id': 4391, 'therapyName': 'CPX-351 + Cytarabine + Filgrastim + Fludarabine '}]","Liposomal Cytarabine-Daunorubicin CPX-351, Fludarabine Phosphate, Cytarabine, and Filgrastim in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia",976
15,NCT02283177,Phase II,Recruiting,"[{'id': 2637, 'therapyName': 'Crenolanib + Cytarabine + Daunorubicin'}]",A Safety and Tolerability Study of Crenolanib in Combination With Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia Patients With FLT3 Mutations,976
16,NCT02626338,Phase Ib/II,Recruiting,"[{'id': 4024, 'therapyName': 'Crenolanib + Cytarabine + Mitoxantrone'}]",Pilot Study of Crenolanib Combined With Cytarabine and Mitoxantrone in Subjects With R/R AML,976
17,NCT03150693,Phase III,Recruiting,"[{'id': 897, 'therapyName': 'Rituximab'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1783, 'therapyName': 'Cyclophosphamide + Cytarabine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 3628, 'therapyName': 'Allopurinol'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 3199, 'therapyName': 'inotuzumab ozogamicin'}]",Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia,976
18,NCT01621477,Phase II,Terminated,"[{'id': 1756, 'therapyName': 'Plerixafor'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 1845, 'therapyName': 'Mycophenolate mofetil'}, {'id': 2469, 'therapyName': 'Busulfan + Clofarabine + Thymoglobulin'}, {'id': 1783, 'therapyName': 'Cyclophosphamide + Cytarabine'}]",T-Cell Replete Haploidentical Donor Hematopoietic Stem Cell Plus Natural Killer (NK) Cell Transplantation in Patients With Hematologic Malignancies Relapsed or Refractory Despite Previous Allogeneic Transplant,976
19,NCT01356290,Phase II,Recruiting,"[{'id': 1475, 'therapyName': 'Thalidomide'}, {'id': 4418, 'therapyName': 'Fenofibrate'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 2124, 'therapyName': 'Celecoxib'}, {'id': 1783, 'therapyName': 'Cyclophosphamide + Cytarabine'}]",Metronomic and Targeted Anti-angiogenesis Therapy for Children With Recurrent/Progressive Medulloblastoma (MEMMAT),976
20,NCT02412475,Phase I,"Active, not recruiting","[{'id': 712, 'therapyName': 'Cytarabine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 650, 'therapyName': 'Decitabine'}]",Epigenetic Reprogramming in Relapse AML,976
21,NCT01515527,Phase II,Recruiting,"[{'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 650, 'therapyName': 'Decitabine'}]",Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS),976
22,NCT02088541,Phase II,"Active, not recruiting","[{'id': 712, 'therapyName': 'Cytarabine'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 1749, 'therapyName': 'Selinexor'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}]",Selinexor (KPT-330) in Older Patients With Relapsed AML,976
23,NCT02573363,Phase I,Recruiting,"[{'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 1749, 'therapyName': 'Selinexor'}]",Selinexor With Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia,976
24,NCT02203526,Phase I,Suspended,"[{'id': 1607, 'therapyName': 'Temozolomide + Etoposide + Doxil + Dexamethasone + Ibrutinib'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 897, 'therapyName': 'Rituximab'}]","Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Dose-Adjusted-Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (DA-TEDDI-R) in Primary CNS Lymphoma",976
25,NCT02920008,Phase III,Recruiting,"[{'id': 650, 'therapyName': 'Decitabine'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1949, 'therapyName': 'SGI-110'}]","Phase 3 Randomized, Open-Label Study of Guadecitabine vs Treatment Choice in Previously Treated Acute Myeloid Leukemia",976
26,NCT02043587,Phase II,Recruiting,"[{'id': 897, 'therapyName': 'Rituximab'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1136, 'therapyName': 'Etoposide'}]",Chemotherapy With Liposomal Cytarabine CNS Prophylaxis for Adult Acute Lymphoblastic Leukemia &amp; Lymphoblastic Lymphoma,976
27,NCT02348489,Phase III,"Active, not recruiting","[{'id': 1949, 'therapyName': 'SGI-110'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 650, 'therapyName': 'Decitabine'}]","SGI-110 in Adults With Untreated Acute Myeloid Leukemia (AML), Not Considered Candidates for Intensive Remission Induction",976
28,NCT01794702,Phase Ib/II,"Active, not recruiting","[{'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 650, 'therapyName': 'Decitabine'}]","Decitabine Followed by Clofarabine, Idarubicin, and Cytarabine in Acute Leukemia",976
29,NCT03214562,,Recruiting,"[{'id': 1562, 'therapyName': 'Venetoclax'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 712, 'therapyName': 'Cytarabine'}]",Study of the BCL-2 Inhibitor Venetoclax in Combination With Standard Intensive Acute Myeloid Leukemia (AML) Induction/Consolidation Therapy With FLAG-IDA in Patients With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia (AML),976
30,NCT02421939,Phase III,Recruiting,"[{'id': 712, 'therapyName': 'Cytarabine'}, {'id': 3193, 'therapyName': 'Cytarabine + Fludarabine + Idarubicin'}, {'id': 1752, 'therapyName': 'Mitoxantrone + Etoposide + Cytarabine'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 2865, 'therapyName': 'Gilteritinib'}, {'id': 1632, 'therapyName': 'Filgrastim'}]",A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,976
31,NCT02488408,Phase I,Recruiting,"[{'id': 712, 'therapyName': 'Cytarabine'}, {'id': 2660, 'therapyName': 'BGB-324'}]",Multicenter Open-label Study of BGB324 as a Single Agent and in Combination With Cytarabine in Patients With AML,976
32,NCT03020030,Phase III,Recruiting,"[{'id': 3160, 'therapyName': 'Nelarabine'}, {'id': 5153, 'therapyName': 'dexrazoxane'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1642, 'therapyName': 'Leucovorin'}]",Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents,976
33,NCT01870596,Phase II,Completed,"[{'id': 712, 'therapyName': 'Cytarabine'}, {'id': 2027, 'therapyName': 'MK-8776'}]",Cytarabine With or Without SCH 900776 in Treating Adult Patients With Relapsed Acute Myeloid Leukemia,976
34,NCT02551718,Phase I,Recruiting,"[{'id': 690, 'therapyName': 'Bosutinib'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 3160, 'therapyName': 'Nelarabine'}, {'id': 3159, 'therapyName': 'Bexarotene'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 998, 'therapyName': 'cabozantinib'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 877, 'therapyName': 'Ponatinib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 623, 'therapyName': 'Afatinib'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 890, 'therapyName': 'Regorafenib'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 2, 'therapyName': 'Trametinib'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 3, 'therapyName': 'Dabrafenib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 789, 'therapyName': 'Ceritinib'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1571, 'therapyName': 'Cabazitaxel'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1327, 'therapyName': 'Pralatrexate'}]",High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia,976
35,NCT03263936,Phase I,Recruiting,"[{'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1632, 'therapyName': 'Filgrastim'}]",Epigenetic Reprogramming in Relapse/Refractory AML,976
36,NCT02532192,Phase I,Withdrawn,"[{'id': 897, 'therapyName': 'Rituximab'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1689, 'therapyName': 'Fluconazole'}, {'id': 1078, 'therapyName': 'Belinostat'}]","A Phase Ib Study of Belinostat With RDHAP Chemotherapy (Dexamethasone, Cytarabine, Cisplatinum) in Adults With Relapsed or Refractory Diffuse Large B-cell Lymphoma",976
37,NCT03164057,Phase II,Recruiting,"[{'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 5153, 'therapyName': 'dexrazoxane'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 651, 'therapyName': 'Azacitidine'}]",A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia,976
38,NCT02351037,Phase II,Terminated,"[{'id': 768, 'therapyName': 'Ibrutinib'}, {'id': 712, 'therapyName': 'Cytarabine'}]",A Multicenter Open-Label Phase 2a Study of Ibrutinib With or Without Cytarabine in Subjects With Acute Myeloid Leukemia,976
39,NCT02756962,Phase II,Recruiting,"[{'id': 810, 'therapyName': 'Midostaurin'}, {'id': 712, 'therapyName': 'Cytarabine'}]",Improving Risk Assessment of AML With a Precision Genomic Strategy to Assess Mutation Clearance,976
40,NCT03147612,Phase II,Not yet recruiting,"[{'id': 5682, 'therapyName': 'Mesna'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 877, 'therapyName': 'Ponatinib'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 712, 'therapyName': 'Cytarabine'}]",Study of the Combination of Low-Intensity Chemotherapy and Ponatinib in Patients With Philadelphia Chromosome (Ph)-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL),976
41,NCT02419755,Phase II,Terminated,"[{'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 2188, 'therapyName': 'Prednisone'}]",Bortezomib and Vorinostat in Younger Patients With Refractory or Relapsed MLL Rearranged Hematologic Malignancies,976
42,NCT00549848,Phase III,"Active, not recruiting","[{'id': 1781, 'therapyName': 'Vincristine + Pegaspargase + Daunorubicin'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1782, 'therapyName': 'Clofarabine + Etoposide + Cyclophosphamide'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}]",Total Therapy Study XVI for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia,976
43,NCT01892371,Phase Ib/II,Recruiting,"[{'id': 712, 'therapyName': 'Cytarabine'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 882, 'therapyName': 'Quizartinib'}]",AC220 With 5-Aza or Low Dose Cytarabine,976
44,NCT03194932,Phase I,Recruiting,"[{'id': 712, 'therapyName': 'Cytarabine'}]",Study of Venetoclax in Combination With Chemotherapy in Pediatric Patients With Refractory or Relapsed Acute Myeloid Leukemia,976
45,NCT02883049,Phase III,Suspended,"[{'id': 717, 'therapyName': 'Dasatinib'}, {'id': 4685, 'therapyName': 'Dexamethasone + Doxorubicin'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1746, 'therapyName': 'Clofarabine'}]",Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations,976
46,NCT01546038,Phase Ib/II,"Active, not recruiting","[{'id': 1748, 'therapyName': 'PF-04449913'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 1738, 'therapyName': 'Daunorubicin + Cytarabine'}]",A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,976
47,NCT02212561,Phase Ib/II,Completed,"[{'id': 1749, 'therapyName': 'Selinexor'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 2345, 'therapyName': 'Cytarabine + Dexamethasone+ Methotrexate '}, {'id': 1166, 'therapyName': 'Fludarabine'}]",Selinexor With Fludarabine and Cytarabine for Treatment of Refractory or Relapsed Leukemia or Myelodysplastic Syndrome,976
48,NCT03007147,Phase III,Recruiting,"[{'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 5153, 'therapyName': 'dexrazoxane'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 5167, 'therapyName': 'Methylprednisolone'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 5168, 'therapyName': 'Prednisolone'}, {'id': 1009, 'therapyName': 'Doxorubicin'}]",Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia,976
49,NCT03069352,Phase III,Recruiting,"[{'id': 3182, 'therapyName': 'Cytarabine + GDC-0199'}, {'id': 712, 'therapyName': 'Cytarabine'}]",A Study of Venetoclax in Combination With Low Dose Cytarabine Versus Low Dose Cytarabine Alone in Treatment Naïve Patients With Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy,976
50,NCT02535806,Phase II,Terminated,"[{'id': 1631, 'therapyName': 'Vincristine'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 2188, 'therapyName': 'Prednisone'}]",Four Drug Reinduction With Bortezomib for Relapsed or Refractory ALL or LL in Children and Young Adults,976
51,NCT02907359,Phase III,Recruiting,"[{'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1949, 'therapyName': 'SGI-110'}]",Guadecitabine (SGI-110) vs Treatment Choice in Adults With MDS or CMML Previously Treated With HMAs,976
52,NCT02666950,Phase II,Recruiting,"[{'id': 822, 'therapyName': 'MK-1775'}, {'id': 712, 'therapyName': 'Cytarabine'}]",WEE1 Inhibitor AZD1775 With or Without Cytarabine in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome,976
53,NCT02545283,Phase III,Recruiting,"[{'id': 712, 'therapyName': 'Cytarabine'}, {'id': 4395, 'therapyName': 'Cytarabine + Idasanutlin'}]",A Study of Idasanutlin With Cytarabine Versus Cytarabine Plus Placebo in Patients With Relapsed or Refractory Acute Myeloid Leukemia,976
54,NCT02112916,Phase III,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1009, 'therapyName': 'Doxorubicin'}]",Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma,976
55,NCT01321346,Phase I,Completed,"[{'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1080, 'therapyName': 'Panobinostat'}]",A Study Of Panobinostat In Children With Refractory Hematologic Malignancies,976
56,NCT02756572,Phase I,Recruiting,"[{'id': 917, 'therapyName': 'Sirolimus'}, {'id': 1845, 'therapyName': 'Mycophenolate mofetil'}, {'id': 1650, 'therapyName': 'Cyclosporine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 5215, 'therapyName': 'mitoxantrone hydrochloride'}, {'id': 1166, 'therapyName': 'Fludarabine'}]",Early Allogeneic Hematopoietic Cell Transplantation in Treating Patients With Relapsed or Refractory High-Grade Myelodysplastic Syndrome or Acute Myeloid Leukemia,976
57,NCT02788201,Phase II,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1133, 'therapyName': 'Mitomycin C'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1013, 'therapyName': 'epirubicin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1137, 'therapyName': 'Bleomycin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 781, 'therapyName': 'Ixabepilone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 2950, 'therapyName': 'Estramustine'}, {'id': 1941, 'therapyName': 'Floxuridine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 1811, 'therapyName': 'Carmustine'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 953, 'therapyName': 'Vandetanib'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 4419, 'therapyName': 'Toremifine'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 2601, 'therapyName': 'Dactinomycin'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 3035, 'therapyName': 'Chlorambucil'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 342, 'therapyName': 'Vemurafenib'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 2635, 'therapyName': 'Vinblastine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 4305, 'therapyName': 'Teniposide'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 4304, 'therapyName': 'Streptozocin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1231, 'therapyName': 'Bendamustine'}, {'id': 4303, 'therapyName': 'Mechlorethamine'}, {'id': 4302, 'therapyName': 'Mitotane'}]",Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma,976
58,NCT01614197,Phase I,Recruiting,"[{'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1639, 'therapyName': 'Methotrexate'}]",A Trial of Temsirolimus With Etoposide and Cyclophosphamide in Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkins Lymphoma,976
59,NCT02577406,Phase III,Recruiting,"[{'id': 651, 'therapyName': 'Azacitidine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 2982, 'therapyName': 'Enasidenib'}]",An Efficacy and Safety Study of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects With Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 Mutation (IDHENTIFY),976
60,NCT01187810,Phase I,"Active, not recruiting","[{'id': 2731, 'therapyName': 'Fenretinide'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1639, 'therapyName': 'Methotrexate'}]","Fenretinide in Children With Recurrent/Resistant ALL, AML, and NHL",976
61,NCT02521493,Phase III,Recruiting,"[{'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 5912, 'therapyName': 'Asparaginase Erwinia chrysanthemi'}, {'id': 5215, 'therapyName': 'mitoxantrone hydrochloride'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 2206, 'therapyName': 'Asparaginase'}]",Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome,976
62,NCT02553460,Phase II,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1642, 'therapyName': 'Leucovorin'}]",Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) I,976
63,NCT02560025,Phase II,"Active, not recruiting","[{'id': 626, 'therapyName': 'Alisertib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 712, 'therapyName': 'Cytarabine'}]",Phase II Trial of Alisertib With Induction Chemotherapy in High-risk AML,976
64,NCT03117751,Phase II,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1876, 'therapyName': 'Blinatumomab '}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1638, 'therapyName': 'Pegaspargase'}]",Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma,976
65,NCT02680951,Phase I,Recruiting,"[{'id': 3731, 'therapyName': 'Cytarabine + Dasatinib + Fludarabine  + Idarubicin'}]",Dasatinib in Combination With Chemotherapy for Relapsed or Refractory Core Binding Factor Acute Myeloid Leukemia,976
66,NCT01256398,Phase II,"Active, not recruiting","[{'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 2291, 'therapyName': 'Cyclophosphamide + Fludarabine'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1824, 'therapyName': 'Vincristine + Methotrexate + Mercaptopurine'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 2391, 'therapyName': 'Cytarabine + Daunorubicin + Etoposide'}, {'id': 1476, 'therapyName': 'Pegfilgrastim'}, {'id': 1205, 'therapyName': 'Alemtuzumab'}, {'id': 1642, 'therapyName': 'Leucovorin'}]",Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,976
67,NCT02632708,Phase I,Recruiting,"[{'id': 1491, 'therapyName': 'AG-120'}, {'id': 2982, 'therapyName': 'Enasidenib'}, {'id': 3431, 'therapyName': 'Cytarabine + Daunorubicin + Etoposide + Mitoxantrone'}]",Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia With an IDH1 and/or IDH2 Mutation,976
68,NCT02668653,Phase III,Recruiting,"[{'id': 3543, 'therapyName': 'Cytarabine + Daunorubicin + Idarubicin'}, {'id': 882, 'therapyName': 'Quizartinib'}]",Quizartinib With Standard of Care Chemotherapy and as Maintenance Therapy in Patients With Newly Diagnosed FLT3-ITD (+) AML,976
69,NCT02323607,Phase I,Suspended,"[{'id': 3219, 'therapyName': 'Cytarabine + Daunorubicin + Pacritinib'}, {'id': 3177, 'therapyName': 'Pacritinib + Decitabine'}]",Pacritinib and Chemotherapy in Treating Patients With Acute Myeloid Leukemia and FLT3 Mutations,976
70,NCT01463046,Phase I,"Active, not recruiting","[{'id': 3185, 'therapyName': 'Cytarabine + Daunorubicin + Panobinostat'}]",Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome,976
71,NCT02954653,Phase I,Recruiting,"[{'id': 6087, 'therapyName': 'PF-06747143'}, {'id': 6092, 'therapyName': 'Cytarabine + Daunorubicin + PF-06747143'}, {'id': 6093, 'therapyName': 'Azacitidine + Decitabine + PF-06747143'}]","A Study Of PF-06747143, As Single Agent Or In Combination With Standard Chemotherapy In Adult Patients With Acute Myeloid Leukemia",976
72,NCT03013998,Phase Ib/II,Recruiting,"[{'id': 4003, 'therapyName': 'Azacitidine + Enasidenib'}, {'id': 5539, 'therapyName': 'Azacitidine + Entospletinib'}, {'id': 5536, 'therapyName': 'Cytarabine + Daunorubicin + Samalizumab'}, {'id': 5538, 'therapyName': 'Azacitidine + BI 836858'}]",Study of Biomarker-Based Treatment of Acute Myeloid Leukemia,976
73,NCT02339740,Phase III,Recruiting,"[{'id': 3686, 'therapyName': 'Cytarabine + Dexamethasone + Idarubicin + Mitoxantrone'}, {'id': 3685, 'therapyName': 'Arsenic trioxide + Gemtuzumab ozogamicin + Tretinoin'}]",Tretinoin and Arsenic Trioxide in Treating Patients With Untreated Acute Promyelocytic Leukemia,976
74,NCT02101853,Phase III,Recruiting,"[{'id': 1876, 'therapyName': 'Blinatumomab '}, {'id': 2347, 'therapyName': 'Leucovorin + Pegaspargase  + Vincristine'}, {'id': 2346, 'therapyName': 'Mercaptopurine + Thioguanine'}, {'id': 2348, 'therapyName': 'Asparaginase + Cyclophosphamide + Etoposide'}, {'id': 2345, 'therapyName': 'Cytarabine + Dexamethasone+ Methotrexate '}]",Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia,976
75,NCT02342782,Phase I,Recruiting,"[{'id': 2485, 'therapyName': '90Y basiliximab'}, {'id': 1811, 'therapyName': 'Carmustine'}, {'id': 2392, 'therapyName': 'Cytarabine + Etoposide'}, {'id': 1207, 'therapyName': 'Melphalan'}]",Yttrium Y 90 Basiliximab and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Mature T-cell Non-Hodgkin Lymphoma,976
76,NCT02109627,Phase I,Recruiting,"[{'id': 3183, 'therapyName': 'Cytarabine + Ficlatuzumab'}]",Ficlatuzumab With High Dose Cytarabine in Relapsed and Refractory AML,976
77,NCT02791919,Phase I,Withdrawn,"[{'id': 822, 'therapyName': 'MK-1775'}, {'id': 4271, 'therapyName': 'Cytarabine + Filgrastim + Fludarabine'}]","Wee1 Kinase Inhibitor AZD1775 and Combination Chemotherapy in Treating Children, Adolescents and Young Adults With Relapsed or Refractory Acute Myeloid Leukemia",976
78,NCT02356159,Phase Ib/II,Recruiting,"[{'id': 2294, 'therapyName': 'Cytarabine + Fludarabine'}, {'id': 2373, 'therapyName': 'Palifermin'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 2238, 'therapyName': 'Sirolimus + Tacrolimus + Methotrexate'}, {'id': 2292, 'therapyName': 'Doxorubicin + Etoposide + Fludarabine + Vincristine '}, {'id': 2291, 'therapyName': 'Cyclophosphamide + Fludarabine'}, {'id': 897, 'therapyName': 'Rituximab'}]",Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation,976
79,NCT00520130,Phase Ib/II,"Active, not recruiting","[{'id': 2294, 'therapyName': 'Cytarabine + Fludarabine'}, {'id': 2305, 'therapyName': 'Alemtuzumab + Cyclosporine'}, {'id': 2306, 'therapyName': 'Rituximab + Fludarabine + EPOCH'}, {'id': 2307, 'therapyName': 'Fludarabine + EPOCH'}, {'id': 2238, 'therapyName': 'Sirolimus + Tacrolimus + Methotrexate'}, {'id': 1632, 'therapyName': 'Filgrastim'}]",Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,976
80,NCT02039726,Phase III,"Active, not recruiting","[{'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 3193, 'therapyName': 'Cytarabine + Fludarabine + Idarubicin'}, {'id': 1752, 'therapyName': 'Mitoxantrone + Etoposide + Cytarabine'}, {'id': 882, 'therapyName': 'Quizartinib'}]",An Open-label Study of Quizartinib Monotherapy vs. Salvage Chemotherapy in Acute Myeloid Leukemia (AML) Subjects,976
81,NCT02676323,Phase Ib/II,Recruiting,"[{'id': 3732, 'therapyName': 'Cytarabine + Fludarabine + Leucovorin + Panobinostat'}]",Panobinostat With Fludarabine and Cytarabine for Treatment of Children With Acute Myeloid Leukemia or Myelodysplastic Syndrome,976
82,NCT02649764,Phase I,Recruiting,"[{'id': 3535, 'therapyName': 'Cytarabine + Fludarabine + Prexasertib'}]",LY2606368 in Combination With Cytarabine and Fludarabine in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HRMDS),976
83,NCT02287233,Phase I,"Active, not recruiting","[{'id': 3182, 'therapyName': 'Cytarabine + GDC-0199'}]",A Study Evaluating ABT-199 in Combination With Low-Dose Cytarabine in Treatment-Naïve Subjects With Acute Myelogenous Leukemia (AML),976
84,NCT01812252,Phase II,Recruiting,"[{'id': 1606, 'therapyName': 'Cytarabine + Idarubicin'}, {'id': 1798, 'therapyName': 'Decitabine + Azacitidine'}]",Chemotherapy in Treating Patients With Myelodysplastic Syndrome Before Donor Stem Cell Transplant,976
85,NCT02236013,Phase I,Recruiting,"[{'id': 1606, 'therapyName': 'Cytarabine + Idarubicin'}, {'id': 2865, 'therapyName': 'Gilteritinib'}]",A Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia,976
86,NCT02835729,Phase Ib/II,Recruiting,"[{'id': 1606, 'therapyName': 'Cytarabine + Idarubicin'}, {'id': 4499, 'therapyName': 'Cytarabine + Idarubicin + indoximod'}]",A Study of Indoximod in Combination With (7+3) Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia,976
87,NCT02306291,Phase Ib/II,Recruiting,"[{'id': 1606, 'therapyName': 'Cytarabine + Idarubicin'}, {'id': 1752, 'therapyName': 'Mitoxantrone + Etoposide + Cytarabine'}, {'id': 4402, 'therapyName': 'GMI-1271'}]","Study to Determine Safety, Pharmacokinetics and Efficacy of GMI-1271 in Combination With Chemotherapy in AML",976
88,NCT02665143,Phase Ib/II,Recruiting,"[{'id': 1606, 'therapyName': 'Cytarabine + Idarubicin'}, {'id': 831, 'therapyName': 'Nintedanib'}]",A Randomized Trial of a Combination of Nintedanib/Placebo in Combination With Induction Chemotherapy for Patients With Refractory or First Relapse Acute Myeloid Leukemia,976
89,NCT02779283,Phase I,Recruiting,"[{'id': 717, 'therapyName': 'Dasatinib'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 877, 'therapyName': 'Ponatinib'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 1606, 'therapyName': 'Cytarabine + Idarubicin'}, {'id': 930, 'therapyName': 'Sunitinib'}]",Personalized Kinase Inhibitor Therapy Combined With Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,976
90,NCT02046122,Phase I,Recruiting,"[{'id': 1606, 'therapyName': 'Cytarabine + Idarubicin'}]",Adoptive Transfer of Haplo-identical DLI for AML and MDS,976
91,NCT02400281,Phase Ib/II,Recruiting,"[{'id': 651, 'therapyName': 'Azacitidine'}, {'id': 705, 'therapyName': 'Crenolanib'}, {'id': 1606, 'therapyName': 'Cytarabine + Idarubicin'}]",Study of Crenolanib Combined With Chemotherapy in FLT3-mutated Acute Myeloid Leukemia Patients,976
92,NCT01876953,Phase Ib/II,"Active, not recruiting","[{'id': 1850, 'therapyName': 'Cytarabine + Idarubicin + Dasatinib'}]","Dasatinib, Cytarabine, and Idarubicin in Treating Patients With High-Risk Acute Myeloid Leukemia",976
93,NCT02635074,Phase I,Recruiting,"[{'id': 3573, 'therapyName': 'Cytarabine + Idarubicin + Ibrutinib'}]","Ibrutinib, Idarubicin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia",976
94,NCT02652871,Phase I,Recruiting,"[{'id': 3470, 'therapyName': 'Cytarabine + Idarubicin + LY2510924'}]","A Phase 1b, Open-label Study of LY2510924, Idarubicin and Cytarabine in Patients With Relapsed or Refractory Acute Myeloid Leukemia",976
95,NCT02464657,Phase Ib/II,Recruiting,"[{'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 3192, 'therapyName': 'Cytarabine + Idarubicin + Nivolumab'}]",Nivolumab in Acute Myeloid Leukemia (AML),976
96,NCT01822015,Phase I,"Active, not recruiting","[{'id': 2232, 'therapyName': 'Cytarabine + Idarubicin + Sirolimus'}]","Sirolimus, Idarubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia",976
97,NCT02527174,Phase I,Withdrawn,"[{'id': 3213, 'therapyName': 'Cytarabine + Idarubicin + Volasertib'}]",A Study of Volasertib Plus Induction Chemotherapy for Acute Myeloid Leukemia (VIAC),976
98,NCT02905994,Phase I,Withdrawn,"[{'id': 3213, 'therapyName': 'Cytarabine + Idarubicin + Volasertib'}]",Volasertib Combined With Induction Chemotherapy in Acute Myeloid Leukemia,976
99,NCT02420717,Phase II,Recruiting,"[{'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 3195, 'therapyName': 'Cytarabine + Methotrexate '}, {'id': 2046, 'therapyName': 'Cyclophosphamide + Dexamethasone + Doxorubicin + Vincristine '}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 3194, 'therapyName': 'Mercaptopurine + Methotrexate + Prednisone + Vincristine'}]",Ruxolitinib or Dasatinib With Chemotherapy in Patients With Philadelphia Chromosome (Ph)-Like Acute Lymphoblastic Leukemia (ALL),976
100,NCT02427620,Phase II,Recruiting,"[{'id': 2353, 'therapyName': 'Cyclophosphamide + Doxorubicin + Vincristine '}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 3195, 'therapyName': 'Cytarabine + Methotrexate '}, {'id': 1642, 'therapyName': 'Leucovorin'}]",A Study of Ibrutinib Plus Rituximab With Hyper-CVAD Consolidation in Newly Diagnosed Young Patients With Mantle Cell Lymphoma,976
101,NCT01769209,Phase II,"Active, not recruiting","[{'id': 688, 'therapyName': 'Bortezomib'}, {'id': 3195, 'therapyName': 'Cytarabine + Methotrexate '}, {'id': 1830, 'therapyName': 'Vincristine + Dexamethasone + Pegaspargase + Doxorubicin'}]",Bortezomib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia,976
102,NCT01424982,Phase II,Recruiting,"[{'id': 1476, 'therapyName': 'Pegfilgrastim'}, {'id': 2048, 'therapyName': 'Cytarabine + Methotrexate + Ponatinib'}, {'id': 2049, 'therapyName': 'Ponatinib + Vincristine'}, {'id': 2046, 'therapyName': 'Cyclophosphamide + Dexamethasone + Doxorubicin + Vincristine '}, {'id': 1642, 'therapyName': 'Leucovorin'}]",Hyper-CVAD and Ponatinib in Ph-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL),976
103,NCT02518750,Phase II,Recruiting,"[{'id': 1604, 'therapyName': 'Panobinostat + Bortezomib + Dexamethasone'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 3160, 'therapyName': 'Nelarabine'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 3217, 'therapyName': 'Cyclophosphamide + Etoposide'}, {'id': 3216, 'therapyName': 'Cytarabine + Methotrexate + Prednisone'}, {'id': 1746, 'therapyName': 'Clofarabine'}]",Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoma,976
104,NCT03207334,Phase II,Not yet recruiting,"[{'id': 6095, 'therapyName': 'Cytarabine + Midostaurin'}]",iCare4: Genomic Signatures With Midostaurin in Acute Myeloid Leukemia (UF-BMT-AML-001),976
105,NCT02520011,Phase II,Recruiting,"[{'id': 628, 'therapyName': 'Alvocidib'}, {'id': 2393, 'therapyName': 'Cytarabine + Mitoxantrone'}]",Alvocidib Biomarker-driven Phase 2 AML Study,976
106,NCT02576301,Phase Ib/II,Recruiting,"[{'id': 3524, 'therapyName': 'OXi4503'}, {'id': 3887, 'therapyName': 'Cytarabine + OXi4503'}]",Dose Escalation of OXi4503 as Single Agent and Combination With Cytarabine w/Subsequent Ph 2 Cohorts for AML and MDS,976
107,NCT01606579,Phase Ib/II,Completed,"[{'id': 2466, 'therapyName': 'Cytarabine + Pri-724'}, {'id': 2465, 'therapyName': 'Dasatinib + Pri-724'}, {'id': 1083, 'therapyName': 'Pri-724'}]",Safety and Efficacy Study of PRI-724 in Subjects With Advanced Myeloid Malignancies,976
108,NCT02305563,Phase Ib/II,Recruiting,"[{'id': 6259, 'therapyName': 'Cytarabine + Ulocuplumab'}]",An Investigational Immuno-therapy Study of Ulocuplumab in Combination With Low Dose Cytarabine in Patients With Newly Diagnosed Acute Myeloid Leukemia,976
109,NCT01880437,Phase II,Terminated,"[{'id': 1802, 'therapyName': 'Cytarabine + Vismodegib'}]",A Study of Vismodegib in Patients With Relapsed/Refractory Acute Myelogenous Leukemia and Relapsed Refractory High-Risk Myleodysplastic Syndrome,976
110,NCT01806571,Phase II,Recruiting,"[{'id': 1738, 'therapyName': 'Daunorubicin + Cytarabine'}, {'id': 829, 'therapyName': 'Nilotinib'}]","Daunorubicin Hydrochloride, Cytarabine, and Nilotinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia",976
111,NCT02403310,Phase I,"Active, not recruiting","[{'id': 1738, 'therapyName': 'Daunorubicin + Cytarabine'}, {'id': 1749, 'therapyName': 'Selinexor'}]",A Study of Selinexor in Combination With Daunorubicin and Cytarabine for Untreated AML,976
112,NCT02085408,Phase III,Recruiting,"[{'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 1738, 'therapyName': 'Daunorubicin + Cytarabine'}]",Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia,976
113,NCT02343939,Phase Ib/II,Recruiting,"[{'id': 650, 'therapyName': 'Decitabine'}, {'id': 1738, 'therapyName': 'Daunorubicin + Cytarabine'}, {'id': 2522, 'therapyName': 'Entospletinib  '}]",Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML),976
114,NCT01627041,Phase II,"Active, not recruiting","[{'id': 1739, 'therapyName': 'Daunorubicin + Cytarabine + Decitabine'}, {'id': 1738, 'therapyName': 'Daunorubicin + Cytarabine'}]","Decitabine, Cytarabine, and Daunorubicin Hydrochloride in Treating Patients With Acute Myeloid Leukemia",976
115,NCT01829503,Phase II,"Active, not recruiting","[{'id': 1736, 'therapyName': 'Decitabine + Cytarabine'}]",Phase II Study of Decitabine and Cytarabine for Older Patients With Newly Diagnosed Acute Myeloid Leukemia (AML),976
116,NCT03092674,Phase II,Not yet recruiting,"[{'id': 1736, 'therapyName': 'Decitabine + Cytarabine'}, {'id': 2471, 'therapyName': 'Azacitidine + Midostaurin'}, {'id': 3196, 'therapyName': 'Azacitidine + Nivolumab'}, {'id': 651, 'therapyName': 'Azacitidine'}]","Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome",976
117,NCT02121418,Phase I,"Active, not recruiting","[{'id': 1736, 'therapyName': 'Decitabine + Cytarabine'}]","Decitabine and Cytarabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia, High Risk Myelodysplastic Syndrome, or Myeloproliferative Neoplasm",976
118,NCT02049801,Phase I,"Active, not recruiting","[{'id': 2220, 'therapyName': 'MEK162 + Idarubicin + Cytarabine'}]","MEK Inhibitor MEK162, Idarubicin, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia",976
119,NCT01849276,Phase I,"Active, not recruiting","[{'id': 1792, 'therapyName': 'Metformin + Cytarabine'}]",Metformin+Cytarabine for the Treatment of Relapsed/Refractory AML,976
120,NCT02270788,Phase I,Completed,"[{'id': 1865, 'therapyName': 'Methotrexate + Cytarabine + Leucovorin'}, {'id': 1864, 'therapyName': 'Crenolanib + Sorafenib'}]",Crenolanib in Combination With Sorafenib in Patients With Refractory or Relapsed Hematologic Malignancies,976
121,NCT00550992,Phase I,Unknown status,"[{'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1752, 'therapyName': 'Mitoxantrone + Etoposide + Cytarabine'}, {'id': 1848, 'therapyName': 'Cyclophosphamide + Methotrexate + Vincristine + Pegaspargase '}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1650, 'therapyName': 'Cyclosporine'}, {'id': 1844, 'therapyName': 'anti-thymocyte globulin'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1642, 'therapyName': 'Leucovorin'}]",Different Therapies in Treating Infants With Newly Diagnosed Acute Leukemia,976
122,NCT01729845,Phase Ib/II,"Active, not recruiting","[{'id': 1752, 'therapyName': 'Mitoxantrone + Etoposide + Cytarabine'}, {'id': 650, 'therapyName': 'Decitabine'}]","Decitabine Followed By Mitoxantrone Hydrochloride, Etoposide, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes",976
123,NCT01222143,Phase Ib/II,Terminated,"[{'id': 1752, 'therapyName': 'Mitoxantrone + Etoposide + Cytarabine'}, {'id': 829, 'therapyName': 'Nilotinib'}]","Safety and Efficacy Study of Nilotinib Combined With Mitoxantrone, Etoposide, and High-dose Cytarabine Induction Chemotherapy Followed by Consolidation for Patients With C-kit Positive Acute Myeloid Leukemia",976
124,NCT02299518,Phase I,Recruiting,"[{'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1749, 'therapyName': 'Selinexor'}, {'id': 1752, 'therapyName': 'Mitoxantrone + Etoposide + Cytarabine'}]",Selinexor and Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia,976
125,NCT02583893,Phase II,Recruiting,"[{'id': 917, 'therapyName': 'Sirolimus'}, {'id': 1752, 'therapyName': 'Mitoxantrone + Etoposide + Cytarabine'}]",Biomarkers in Predicting Treatment Response to Sirolimus and Chemotherapy in Patients With High-Risk Acute Myeloid Leukemia,976
126,NCT02029417,Phase II,Terminated,"[{'id': 1794, 'therapyName': 'Omacetaxine + Cytarabine + Decitabine'}]","Omacetaxine Mepesuccinate, Cytarabine, and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia",976
127,NCT02532010,Phase II,"Active, not recruiting","[{'id': 3177, 'therapyName': 'Pacritinib + Decitabine'}, {'id': 3176, 'therapyName': 'Pacritinib + Cytarabine'}]",Pacritinib Combined With Decitabine or Cytarabine in Older Patients With AML,976
128,NCT03071276,Phase II,Recruiting,"[{'id': 5448, 'therapyName': 'Selinexor + Fludarabine phosphate + Cytarabine + Methotrexate + Prednisone'}]",Selinexor in Combination With Fludarabine and Cytarabine in Patients With Refractory or Relapsed Acute Myeloid Leukemia,976
0,NCT02110355,Phase Ib/II,Recruiting,"[{'id': 1454, 'therapyName': 'AMG 232 + Trametinib'}, {'id': 1453, 'therapyName': 'AMG 232 + Trametinib + Dabrafenib'}, {'id': 1066, 'therapyName': 'Trametinib + Dabrafenib'}]",A Phase 1b/2a Study Evaluating AMG 232 in Metastatic Melanoma,6819
1,NCT02097225,Phase I,Recruiting,"[{'id': 1362, 'therapyName': 'AT13387 + Dabrafenib + Trametinib'}]","Hsp90 Inhibitor AT13387, Dabrafenib, and Trametinib in Treating Patients With Recurrent Melanoma That is Metastatic or Cannot be Removed by Surgery",6819
2,NCT02465060,Phase II,Recruiting,"[{'id': 660, 'therapyName': 'AZD9291'}, {'id': 3, 'therapyName': 'Dabrafenib'}, {'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 2, 'therapyName': 'Trametinib'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 623, 'therapyName': 'Afatinib'}, {'id': 654, 'therapyName': 'AZD4547'}, {'id': 958, 'therapyName': 'VS-6063'}, {'id': 765, 'therapyName': 'GSK2636771'}]",NCI-MATCH Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas,6819
3,NCT01336634,Phase II,"Active, not recruiting","[{'id': 3, 'therapyName': 'Dabrafenib'}, {'id': 1066, 'therapyName': 'Trametinib + Dabrafenib'}]",Study of Selective BRAF Kinase Inhibitor Dabrafenib Monotherapy Twice Daily and in Combination With Dabrafenib Twice Daily and Trametinib Once Daily in Combination Therapy in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer.,6819
4,NCT01940809,Phase II,Recruiting,"[{'id': 3, 'therapyName': 'Dabrafenib'}, {'id': 2, 'therapyName': 'Trametinib'}, {'id': 779, 'therapyName': 'Ipilimumab'}]","Ipilimumab With or Without Dabrafenib, and/or Trametinib in Treating Patients With Melanoma That is Metastatic or Cannot Be Removed By Surgery",6819
5,NCT01682213,Phase II,"Active, not recruiting","[{'id': 3, 'therapyName': 'Dabrafenib'}]",Adjuvant Dabrafenib (GSK2118436) in Patients With Surgically Resected AJCC Stage IIIC Melanoma Characterized by a BRAFV600E/K Mutation,6819
6,NCT03091257,Phase I,Recruiting,"[{'id': 1066, 'therapyName': 'Trametinib + Dabrafenib'}, {'id': 3, 'therapyName': 'Dabrafenib'}, {'id': 2, 'therapyName': 'Trametinib'}]",A Study of Dabrafenib and/or Trametinib in Patients With Relapsed and/or Refractory Multiple Myeloma,6819
7,NCT01907802,Phase I,"Active, not recruiting","[{'id': 3, 'therapyName': 'Dabrafenib'}]",Dabrafenib in Treating Patients With Solid Tumors and Kidney or Liver Dysfunction,6819
8,NCT02367859,Phase I,Recruiting,"[{'id': 3, 'therapyName': 'Dabrafenib'}]",Dabrafenib in Treating Patients With BRAF Mutated Ameloblastoma,6819
9,NCT01231594,Phase I,Recruiting,"[{'id': 3, 'therapyName': 'Dabrafenib'}, {'id': 2, 'therapyName': 'Trametinib'}]",A Rollover Study to Provide Continued Treatment With GSK2118436 to Subjects With BRAF Mutation-Positive Tumors,6819
10,NCT01738451,Phase I,Completed,"[{'id': 3, 'therapyName': 'Dabrafenib'}]", A Study to Evaluate the Effect of Repeat Oral Dosing of GSK2118436 on Cardiac Repolarization in Subjects With V600 BRAF Mutation-Positive Tumors,6819
11,NCT02551718,Phase I,Recruiting,"[{'id': 690, 'therapyName': 'Bosutinib'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 3160, 'therapyName': 'Nelarabine'}, {'id': 3159, 'therapyName': 'Bexarotene'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 998, 'therapyName': 'cabozantinib'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 877, 'therapyName': 'Ponatinib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 623, 'therapyName': 'Afatinib'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 890, 'therapyName': 'Regorafenib'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 2, 'therapyName': 'Trametinib'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 3, 'therapyName': 'Dabrafenib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 789, 'therapyName': 'Ceritinib'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1571, 'therapyName': 'Cabazitaxel'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1327, 'therapyName': 'Pralatrexate'}]",High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia,6819
12,NCT01701037,Phase II,Terminated,"[{'id': 1066, 'therapyName': 'Trametinib + Dabrafenib'}, {'id': 3, 'therapyName': 'Dabrafenib'}]", Dabrafenib Alone and in Combination With Trametinib Before Surgery in Treating Patients With Locally or Regionally Advanced Melanoma That Can Be Removed By Surgery,6819
13,NCT01534897,Phase I,Completed,"[{'id': 3, 'therapyName': 'Dabrafenib'}]",Re-differentiation of Radioiodine-Refractory BRAF V600E-mutant Papillary Thyroid Carcinoma With GSK2118436,6819
14,NCT01677741,Phase I,Recruiting,"[{'id': 3, 'therapyName': 'Dabrafenib'}]"," The Study to Determine Safety, Tolerability and Pharmacokinetics of Oral Dabrafenib In Pediatric Subjects",6819
15,NCT01723202,Phase II,"Active, not recruiting","[{'id': 1066, 'therapyName': 'Trametinib + Dabrafenib'}, {'id': 3, 'therapyName': 'Dabrafenib'}]",Dabrafenib With or Without Trametinib in Treating Patients With Recurrent Thyroid Cancer,6819
16,NCT01978236,Phase II,Completed,"[{'id': 1066, 'therapyName': 'Trametinib + Dabrafenib'}, {'id': 3, 'therapyName': 'Dabrafenib'}]","Dabrafenib/Trametinib, BRAF or BRAF AND MEK Pre-op With BRAF and MEK Post-op, Phase IIB, Melanoma With Brain Mets,Biomarkers and Metabolites",6819
17,NCT01721603,Phase II,Completed,"[{'id': 3, 'therapyName': 'Dabrafenib'}]", A Phase 2 Prospective Trial of Dabrafenib With Stereotactic Radiosurgery in BRAFV600E Melanoma Brain Metastases,6819
18,NCT02915666,Phase I,Recruiting,"[{'id': 4778, 'therapyName': 'Dabrafenib + Digoxin + Trametinib'}]",A Clinical Trial of Patients With Melanoma,6819
19,NCT02027961,Phase Ib/II,"Active, not recruiting","[{'id': 1357, 'therapyName': 'Dabrafenib + Durvalumab + Trametinib'}, {'id': 1358, 'therapyName': 'Durvalumab + Trametinib'}]",Phase 1 Safety and Tolerability of MEDI4736 in Combination With Dabrafenib and Trametinib or With Trametinib Alone,6819
20,NCT01902173,Phase Ib/II,Suspended,"[{'id': 2, 'therapyName': 'Trametinib'}, {'id': 2200, 'therapyName': 'Dabrafenib + GSK2141795'}]","GSK2141795, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer",6819
21,NCT03272464,Phase I,Not yet recruiting,"[{'id': 6176, 'therapyName': 'Dabrafenib + INCB039110 + Trametinib'}]",Phase I Study of INCB039110 in Combination With Dabrafenib and Trametinib in Patients With BRAF-mutant Melanoma and Other Solid Tumors.,6819
22,NCT02200562,Phase Ib/II,Terminated,"[{'id': 1257, 'therapyName': 'Dabrafenib + Ipilimumab'}]",Ipilimumab and Dabrafenib in the 1st Line Tx of Unresectable Stage III/IV Melanoma,6819
23,NCT01767454,Phase I,Completed,"[{'id': 1258, 'therapyName': 'Dabrafenib + Ipilimumab + Trametinib'}, {'id': 1257, 'therapyName': 'Dabrafenib + Ipilimumab'}]",Study of Dabrafenib +/- Trametinib in Combination With Ipilimumab for V600E/K Mutation Positive Metastatic or Unresectable Melanoma,6819
24,NCT01947023,Phase I,Recruiting,"[{'id': 2478, 'therapyName': 'Dabrafenib + Lapatinib'}]",Dabrafenib and Lapatinib Ditosylate in Treating Patients With Refractory Thyroid Cancer That Cannot Be Removed by Surgery,6819
25,NCT02910700,Phase II,Recruiting,"[{'id': 4753, 'therapyName': 'Nivolumab + Trametinib'}, {'id': 4754, 'therapyName': 'Dabrafenib + Nivolumab + Trametinib'}]",Study of the Anti-PD-1 Antibody Nivolumab in Combination With Dabrafenib and/or Trametinib in Patients With BRAF or NRAS-mutated Metastatic Melanoma,6819
26,NCT01713972,Phase I,"Active, not recruiting","[{'id': 1233, 'therapyName': 'Dabrafenib + Pazopanib'}]", Dabrafenib and Pazopanib Hydrochloride in Treating Patients With Advanced Malignant Tumors,6819
27,NCT01954043,Phase I,Completed,"[{'id': 1302, 'therapyName': 'Dabrafenib + Rabeprazole + Rifampin'}]",A Pharmacokinetics (PK) Study of the Effects Rabeprazole and Rifampin on Dabrafenib in Subjects With BRAF V600 Mutation Positive Tumors,6819
28,NCT02082665,Phase I,Completed,"[{'id': 1388, 'therapyName': 'Dabrafenib + Rosuvastatin + Midazolam'}]",Effects of Dabrafenib on the Single Dose Pharmacokinetics (PK) of Rosuvastatin and Midazolam,6819
29,NCT02143050,Phase Ib/II,Recruiting,"[{'id': 1443, 'therapyName': 'Dabrafenib + Trametinib + Metformin'}]","Study of Dabrafenib, Trametinib and Metformin for Melanoma Patients",6819
30,NCT02967692,Phase III,Recruiting,"[{'id': 6023, 'therapyName': 'Dabrafenib + Trametinib + PDR001'}, {'id': 1066, 'therapyName': 'Trametinib + Dabrafenib'}]","A Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced Melanoma",6819
31,NCT03026517,Phase I,Recruiting,"[{'id': 5270, 'therapyName': 'Dabrafenib + Trametinib + Phenformin'}]",Clinical Trial of Phenformin in Combination With Dabrafenib and Trametinib for Patients With BRAF-mutated Melanoma,6819
32,NCT01619774,Phase II,Completed,"[{'id': 1191, 'therapyName': 'GSK1120212 + Dabrafenib'}]", An Open-Label Phase II Study of the Combination of GSK2118436 and GSK1120212 in Patients With Metastatic Melanoma Which is Refractory or Resistant to BRAF Inhibitor,6819
33,NCT01750918,Phase II,"Active, not recruiting","[{'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1718, 'therapyName': 'Panitumumab + Dabrafenib'}, {'id': 1992, 'therapyName': 'Panitumumab + Trametinib + Dabrafenib'}, {'id': 1991, 'therapyName': 'Panitumumab + Trametinib'}]",BRAF/MEK/EGFR Inhibitor Combination Study in Colorectal Cancer (CRC),6819
34,NCT02130466,Phase Ib/II,Recruiting,"[{'id': 1450, 'therapyName': 'Pembrolizumab + Trametinib'}, {'id': 1448, 'therapyName': 'Pembrolizumab + Dabrafenib'}, {'id': 1449, 'therapyName': 'Pembrolizumab + Dabrafenib + Trametinib'}]",A Study of the Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With Trametinib and Dabrafenib in Participants With Advanced Melanoma (MK-3475-022),6819
35,NCT03149029,Phase II,Not yet recruiting,"[{'id': 1449, 'therapyName': 'Pembrolizumab + Dabrafenib + Trametinib'}, {'id': 1450, 'therapyName': 'Pembrolizumab + Trametinib'}]",Abbreviated MAPK Targeted Therapy Plus Pembrolizumab in Melanoma,6819
36,NCT03088176,Phase I,Recruiting,"[{'id': 5481, 'therapyName': 'talimogene laherparepvec + Dabrafenib + Trametinib'}]",Combining Talimogene Laherparepvec With BRAF and MEK Inhibitors in BRAF Mutated Advanced Melanoma,6819
37,NCT01726738,Phase II,"Active, not recruiting","[{'id': 1066, 'therapyName': 'Trametinib + Dabrafenib'}]",LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations,6819
38,NCT01989585,Phase Ib/II,Recruiting,"[{'id': 1303, 'therapyName': 'Trametinib + Dabrafenib + Navitoclax'}, {'id': 1066, 'therapyName': 'Trametinib + Dabrafenib'}]","Dabrafenib, Trametinib, and Navitoclax in Treating Patients With Solid Tumors That Are Metastatic or Cannot be Removed by Surgery",6819
39,NCT02974803,Phase II,Not yet recruiting,"[{'id': 1066, 'therapyName': 'Trametinib + Dabrafenib'}]",Concurrent Dabrafenib and Trametinib With Sterotactic Radiation in Patients With BRAF Mutation-Positive Malignant Melanoma and Brain Metastases,6819
40,NCT02224781,Phase III,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}, {'id': 1066, 'therapyName': 'Trametinib + Dabrafenib'}]",Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma,6819
41,NCT02196181,Phase II,Recruiting,"[{'id': 1066, 'therapyName': 'Trametinib + Dabrafenib'}]",Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by Surgery,6819
42,NCT02039947,Phase II,"Active, not recruiting","[{'id': 1066, 'therapyName': 'Trametinib + Dabrafenib'}]",Study to Evaluate Treatment of Dabrafenib Plus Trametinib in Subjects With BRAF Mutation-Positive Melanoma That Has Metastasized to the Brain,6819
43,NCT02231775,Phase II,Recruiting,"[{'id': 1066, 'therapyName': 'Trametinib + Dabrafenib'}]",Combi-Neo Study for Stage IV Melanoma,6819
44,NCT02124772,Phase I,Recruiting,"[{'id': 2, 'therapyName': 'Trametinib'}, {'id': 1066, 'therapyName': 'Trametinib + Dabrafenib'}]","Study to Investigate Safety, Pharmacokinetic (PK), Pharmacodynamic (PD) and Clinical Activity of Trametinib in Subjects With Cancer or Plexiform Neurofibromas and Trametinib in Combination With Dabrafenib in Subjects With Cancers Harboring V600 Mutations",6819
45,NCT01682083,Phase III,"Active, not recruiting","[{'id': 1066, 'therapyName': 'Trametinib + Dabrafenib'}]", A Study of the BRAF Inhibitor Dabrafenib in Combination With the MEK Inhibitor Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma After Surgical Resection.,6819
46,NCT02034110,Phase II,Recruiting,"[{'id': 1066, 'therapyName': 'Trametinib + Dabrafenib'}]",Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers,6819
0,NCT03033914,Phase I,Recruiting,"[{'id': 5296, 'therapyName': 'Dacarbazine + Doxorubicin + Vinblastine + Nivolumab'}, {'id': 5295, 'therapyName': 'Bleomycin + Dacarbazine + Doxorubicin + Vinblastine + Nivolumab'}]",A(B)VD Followed by Nivolumab as Frontline Therapy for Higher Risk Patients With Classical Hodgkin Lymphoma,841
1,NCT01716806,Phase II,Recruiting,"[{'id': 3263, 'therapyName': 'Brentuximab vedotin + Nivolumab'}, {'id': 5055, 'therapyName': 'Brentuximab vedotin + Bendamustine'}, {'id': 5056, 'therapyName': 'Brentuximab vedotin + Dacarbazine'}, {'id': 2486, 'therapyName': 'Brentuximab vedotin'}]",A Study of Brentuximab Vedotin in Adults Age 60 and Above With Newly Diagnosed Hodgkin Lymphoma (HL),841
2,NCT01835145,Phase II,"Active, not recruiting","[{'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 1141, 'therapyName': 'Temozolomide'}, {'id': 998, 'therapyName': 'cabozantinib'}]",Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Melanoma of the Eye,841
3,NCT02678572,Phase III,Recruiting,"[{'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Percutaneous Hepatic Perfusion vs Best Alternative Care in Patients With Hepatic-dominant Ocular Melanoma,841
4,NCT02049905,Phase III,Completed,"[{'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1440, 'therapyName': 'Aldoxorubicin'}, {'id': 1439, 'therapyName': 'Gemcitabine + Docetaxel'}]",Phase 3 Study to Treat Patients With Soft Tissue Sarcomas,841
5,NCT03070392,Phase II,Recruiting,"[{'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 3847, 'therapyName': 'IMCgp100'}]",Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma,841
6,NCT03233347,,Not yet recruiting,"[{'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 2486, 'therapyName': 'Brentuximab vedotin'}, {'id': 2635, 'therapyName': 'Vinblastine'}, {'id': 1312, 'therapyName': 'Nivolumab'}]","Doxorubicin Hydrochloride, Vinblastine, Dacarbazine, Brentuximab Vedotin, and Nivolumab in Treating Patients With Stage I-II Hodgkin Lymphoma",841
7,NCT01693068,Phase II,Completed,"[{'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 871, 'therapyName': 'Pimasertib'}]",Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma,841
8,NCT01763164,Phase III,"Active, not recruiting","[{'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 807, 'therapyName': 'Binimetinib'}]",Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma,841
9,NCT02788201,Phase II,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1133, 'therapyName': 'Mitomycin C'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1013, 'therapyName': 'epirubicin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1137, 'therapyName': 'Bleomycin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 781, 'therapyName': 'Ixabepilone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 2950, 'therapyName': 'Estramustine'}, {'id': 1941, 'therapyName': 'Floxuridine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 1811, 'therapyName': 'Carmustine'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 953, 'therapyName': 'Vandetanib'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 4419, 'therapyName': 'Toremifine'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 2601, 'therapyName': 'Dactinomycin'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 3035, 'therapyName': 'Chlorambucil'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 342, 'therapyName': 'Vemurafenib'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 2635, 'therapyName': 'Vinblastine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 4305, 'therapyName': 'Teniposide'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 4304, 'therapyName': 'Streptozocin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1231, 'therapyName': 'Bendamustine'}, {'id': 4303, 'therapyName': 'Mechlorethamine'}, {'id': 4302, 'therapyName': 'Mitotane'}]",Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma,841
10,NCT01132014,Phase I,"Active, not recruiting","[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1154, 'therapyName': 'Dacarbazine'}]",Autologous OC-DC Vaccine in Ovarian Cancer,841
11,NCT03226249,Phase II,Not yet recruiting,"[{'id': 6157, 'therapyName': 'Dacarbazine + Doxorubicin + Pembrolizumab +Vinblastine'}]",PET-Directed Therapy With Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Classical Hodgkin Lymphoma,841
12,NCT01974752,Phase III,Completed,"[{'id': 1432, 'therapyName': 'Selumetinib + Dacarbazine'}]",Selumetinib (AZD6244: ARRY-142886) (Hyd-Sulfate) in Metastatic Uveal Melanoma (SUMIT),841
0,NCT01465802,Phase II,Completed,"[{'id': 714, 'therapyName': 'Dacomitinib'}, {'id': 1392, 'therapyName': 'Alclometasone'}, {'id': 1391, 'therapyName': 'Doxycycline'}]",Study Of Dacomitinib (PF-00299804) In Advanced NSCLC Patients (Post Chemo Or Select First Line) To Evaluate Prophylactic Intervention On Derm And GI AEs And PRO,6893
1,NCT02047747,Phase II,Terminated,"[{'id': 714, 'therapyName': 'Dacomitinib'}]",A Phase II Study of Dacomitinib in Progressive Brain Metastases,6893
2,NCT01858389,Phase II,Completed,"[{'id': 714, 'therapyName': 'Dacomitinib'}]",A Study Of Dacomitinib (PF-00299804) In Patients With Advanced Non-Small Cell Lung Cancer,6893
3,NCT01737008,Phase I,Completed,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 714, 'therapyName': 'Dacomitinib'}]",Study of Dacomitinib With Radiotherapy With and Without Cisplatin in Patients With Squamous Cell Carcinoma of the Head and Neck,6893
4,NCT01112527,Phase II,"Active, not recruiting","[{'id': 714, 'therapyName': 'Dacomitinib'}]",PF-00299804 in Adult Patients With Relapsed/Recurrent Glioblastoma,6893
5,NCT01920061,Phase I,Recruiting,"[{'id': 1287, 'therapyName': 'PF-05212384 + Dacomitinib'}, {'id': 1286, 'therapyName': 'PF-05212384 + Cisplatin'}, {'id': 1285, 'therapyName': 'PF-05212384 + Docetaxel'}]",A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents,6893
0,NCT01727336,Phase II,"Active, not recruiting","[{'id': 1245, 'therapyName': 'Dalantercept + Axitinib'}, {'id': 649, 'therapyName': 'Axitinib'}]", Study of Dalantercept in Patients With Advanced Renal Cell Carcinoma,7228
1,NCT02024087,Phase Ib/II,"Active, not recruiting","[{'id': 2364, 'therapyName': 'Dalantercept + Sorafenib'}]",Study of Dalantercept and Sorafenib in Patients With Advanced Hepatocellular Carcinoma,7228
0,NCT03023423,Phase Ib/II,Recruiting,"[{'id': 5236, 'therapyName': 'Atezolizumab + Daratumumab'}, {'id': 1201, 'therapyName': 'Atezolizumab'}]",A Study of Daratumumab in Combination With Atezolizumab Compared With Atezolizumab Alone in Participants With Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer (DARZALEX),7302
1,NCT02951819,Phase II,Recruiting,"[{'id': 4951, 'therapyName': 'Bortezomib + Cyclophosphamide + Daratumumab + Dexamethasone'}]",A Study to Evaluate Dara-CyBorD in Previously Untreated and Relapsed Subjects With Multiple Myeloma,7302
2,NCT02136134,Phase III,"Active, not recruiting","[{'id': 1630, 'therapyName': 'Daratumumab'}, {'id': 2470, 'therapyName': 'Bortezomib + Dexamethasone'}]",Addition of Daratumumab to Combination of Bortezomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma,7302
3,NCT02195479,Phase III,Recruiting,"[{'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1630, 'therapyName': 'Daratumumab'}, {'id': 1207, 'therapyName': 'Melphalan'}]",A Study of Combination of Daratumumanb and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma,7302
4,NCT03011034,Phase II,Recruiting,"[{'id': 5809, 'therapyName': 'Talacotuzumab'}, {'id': 1630, 'therapyName': 'Daratumumab'}]",Study to Separately Evaluate the Activity of Talacotuzumab (JNJ-56022473) or Daratumumab in Transfusion-Dependent Participants With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) Who Are Relapsed or Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment,7302
5,NCT01998971,Phase I,Recruiting,"[{'id': 1622, 'therapyName': 'Pomalidomide'}, {'id': 2470, 'therapyName': 'Bortezomib + Dexamethasone'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1475, 'therapyName': 'Thalidomide'}, {'id': 1164, 'therapyName': 'lenalidomide'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 1630, 'therapyName': 'Daratumumab'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 1275, 'therapyName': 'Diphenhydramine'}, {'id': 3323, 'therapyName': 'Montelukast'}]",A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma,7302
6,NCT03004287,Phase II,Recruiting,"[{'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1164, 'therapyName': 'lenalidomide'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 1630, 'therapyName': 'Daratumumab'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1475, 'therapyName': 'Thalidomide'}]",2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy,7302
7,NCT02874742,Phase II,Recruiting,"[{'id': 1630, 'therapyName': 'Daratumumab'}, {'id': 3342, 'therapyName': 'Bortezomib + Dexamethasone + lenalidomide'}]","Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Subjects With Newly Diagnosed Multiple Myeloma",7302
8,NCT02807454,Phase Ib/II,"Active, not recruiting","[{'id': 4531, 'therapyName': 'Daratumumab + Dexamethasone + MEDI4736 + Pomalidomide'}, {'id': 4530, 'therapyName': 'Daratumumab + MEDI4736'}]",A Study to Determine the Safety and Efficacy for the Combination of Durvalumab and Daratumumab in Relapsed and Refractory Multiple Myeloma (FUSIONMM-003),7302
9,NCT03000452,Phase II,"Active, not recruiting","[{'id': 4530, 'therapyName': 'Daratumumab + MEDI4736'}]",A Study to Determine the Efficacy of the Combination of Daratumumab (DARA) Plus Durvalumab (DURVA) (D2) in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) (FUSION-MM-005),7302
10,NCT03098550,Phase Ib/II,Recruiting,"[{'id': 5520, 'therapyName': 'Daratumumab + Nivolumab '}]",A Study to Test the Safety and Effectiveness of Nivolumab Combined With Daratumumab in Patients With Advanced Solid Tumors or Tumors That Have Spread,7302
11,NCT03221634,Phase II,Not yet recruiting,"[{'id': 6115, 'therapyName': 'Daratumumab + Pembrolizumab'}]",Efficacy and Safety Study of Pembrolizumab (MK-3475) in Combination With Daratumumab in Participants With Relapsed Refractory Multiple Myeloma (MK-3475-668/KEYNOTE-668),7302
12,NCT03068351,Phase I,Recruiting,"[{'id': 937, 'therapyName': 'TEN-010'}, {'id': 5957, 'therapyName': 'Daratumumab + TEN-010'}]",Study of Bromodomain and Extra-Terminal Protein (BET) Inhibitor RO6870810 as Mono- and Combination Therapy in Advanced Multiple Myeloma,7302
0,NCT01254864,Phase II,"Active, not recruiting","[{'id': 1817, 'therapyName': 'Abiraterone + Sunitinib'}, {'id': 1818, 'therapyName': 'Abiraterone + Dasatinib\t'}]",Maximum Androgen Depletion,1241
1,NCT01488318,Phase II,Terminated,"[{'id': 1820, 'therapyName': 'Cetuximab + Dasatinib'}]",Cetuximab and Dasatinib in Recurrent Squamous Cell Carcinoma,1241
2,NCT01744652,Phase I,"Active, not recruiting","[{'id': 1252, 'therapyName': 'Crizotinib + Dasatinib'}]",Dasatinib and Crizotinib in Advanced Cancer,1241
3,NCT01644773,Phase I,Recruiting,"[{'id': 1252, 'therapyName': 'Crizotinib + Dasatinib'}]",Study of the Combination of Crizotinib and Dasatinib in Pediatric Research Participants With Diffuse Pontine Glioma (DIPG) and High-Grade Glioma (HGG),1241
4,NCT02389309,Phase I,Recruiting,"[{'id': 2697, 'therapyName': 'Cyclophosphamide + Dasatinib + Temsirolimus'}]","A Trial of Dasatinib (PDGFR and SRC Inhibitor), Temsirolimus and Cyclophosphamide in Patients With Advanced Solid Tumors",1241
5,NCT02680951,Phase I,Recruiting,"[{'id': 3731, 'therapyName': 'Cytarabine + Dasatinib + Fludarabine  + Idarubicin'}]",Dasatinib in Combination With Chemotherapy for Relapsed or Refractory Core Binding Factor Acute Myeloid Leukemia,1241
6,NCT01876953,Phase Ib/II,"Active, not recruiting","[{'id': 1850, 'therapyName': 'Cytarabine + Idarubicin + Dasatinib'}]","Dasatinib, Cytarabine, and Idarubicin in Treating Patients With High-Risk Acute Myeloid Leukemia",1241
7,NCT01685125,Phase II,"Active, not recruiting","[{'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1805, 'therapyName': 'Abiraterone'}]",Abiraterone Acetate and Prednisone With or Without Dasatinib in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer,1241
8,NCT02779283,Phase I,Recruiting,"[{'id': 717, 'therapyName': 'Dasatinib'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 877, 'therapyName': 'Ponatinib'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 1606, 'therapyName': 'Cytarabine + Idarubicin'}, {'id': 930, 'therapyName': 'Sunitinib'}]",Personalized Kinase Inhibitor Therapy Combined With Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,1241
9,NCT00700882,Phase II,Unknown status,"[{'id': 717, 'therapyName': 'Dasatinib'}]","Dasatinib in Treating Patients With Locally Advanced or Metastatic Mucosal Melanoma, Acral Melanoma, or Vulvovaginal Melanoma That Cannot Be Removed By Surgery",1241
10,NCT01471106,Phase II,Recruiting,"[{'id': 717, 'therapyName': 'Dasatinib'}]",Phase II Short-term Adjuvant Therapy and Biomarker Studies With Targeted Agents in Women With Estrogen Receptor Negative Breast Cancer,1241
11,NCT01514864,Phase II,Terminated,"[{'id': 717, 'therapyName': 'Dasatinib'}]",Trial of Dasatinib in Subjects With Advanced Cancers Harboring DDR2 Mutation or Inactivating B-RAF Mutation,1241
12,NCT02268370,Phase II,Recruiting,"[{'id': 717, 'therapyName': 'Dasatinib'}]",Treatment-free Remission Accomplished With Dasatinib in Patients With CML (TRAD),1241
13,NCT02428855,Phase II,"Active, not recruiting","[{'id': 717, 'therapyName': 'Dasatinib'}]",Phase II Trial of Dasatinib in Patients With Isocitrate Dehydrogenase (IDH)-Mutant Advanced Intrahepatic Cholangiocarcinoma,1241
14,NCT02709083,Phase II,Recruiting,"[{'id': 717, 'therapyName': 'Dasatinib'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 770, 'therapyName': 'Imatinib'}]","Dasatinib or Nilotinib Followed by Imatinib in Patients With Newly Diagnosed, Chronic Phase Chronic Myeloid Leukemia",1241
15,NCT01876212,Phase II,Recruiting,"[{'id': 717, 'therapyName': 'Dasatinib'}]",Dendritic Cell Vaccines + Dasatinib for Metastatic Melanoma,1241
16,NCT01850004,Phase II,"Active, not recruiting","[{'id': 717, 'therapyName': 'Dasatinib'}]",Open-Label Study Evaluating Dasatinib Therapy Discontinuation in Patients With Chronic Phase Chronic Myeloid Leukemia With Stable Complete Molecular Response,1241
17,NCT01256398,Phase II,"Active, not recruiting","[{'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 2291, 'therapyName': 'Cyclophosphamide + Fludarabine'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1824, 'therapyName': 'Vincristine + Methotrexate + Mercaptopurine'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 2391, 'therapyName': 'Cytarabine + Daunorubicin + Etoposide'}, {'id': 1476, 'therapyName': 'Pegfilgrastim'}, {'id': 1205, 'therapyName': 'Alemtuzumab'}, {'id': 1642, 'therapyName': 'Leucovorin'}]",Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,1241
18,NCT00918463,Phase II,Completed,"[{'id': 717, 'therapyName': 'Dasatinib'}]",A Study to Evaluate the Safety and Efficacy of Dasatinib (Sprycel) in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL),1241
19,NCT02059265,Phase II,"Active, not recruiting","[{'id': 717, 'therapyName': 'Dasatinib'}]","Dasatinib in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, Endometrial or Peritoneal Cancer",1241
20,NCT01609816,Phase Ib/II,Recruiting,"[{'id': 717, 'therapyName': 'Dasatinib'}]","Dasatinib in Treating Patients With Multiple Myeloma, Non-Hodgkin, or Hodgkin Lymphoma Previously Treated With Autologous Stem Cell Transplant",1241
21,NCT02043587,Phase II,Recruiting,"[{'id': 897, 'therapyName': 'Rituximab'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1136, 'therapyName': 'Etoposide'}]",Chemotherapy With Liposomal Cytarabine CNS Prophylaxis for Adult Acute Lymphoblastic Leukemia &amp; Lymphoblastic Lymphoma,1241
22,NCT03023046,Phase II,Recruiting,"[{'id': 897, 'therapyName': 'Rituximab'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 1631, 'therapyName': 'Vincristine'}]","Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma",1241
23,NCT02551718,Phase I,Recruiting,"[{'id': 690, 'therapyName': 'Bosutinib'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 3160, 'therapyName': 'Nelarabine'}, {'id': 3159, 'therapyName': 'Bexarotene'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 998, 'therapyName': 'cabozantinib'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 877, 'therapyName': 'Ponatinib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 623, 'therapyName': 'Afatinib'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 890, 'therapyName': 'Regorafenib'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 2, 'therapyName': 'Trametinib'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 3, 'therapyName': 'Dabrafenib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 789, 'therapyName': 'Ceritinib'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1571, 'therapyName': 'Cabazitaxel'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1327, 'therapyName': 'Pralatrexate'}]",High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia,1241
24,NCT03020030,Phase III,Recruiting,"[{'id': 3160, 'therapyName': 'Nelarabine'}, {'id': 5153, 'therapyName': 'dexrazoxane'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1642, 'therapyName': 'Leucovorin'}]",Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents,1241
25,NCT02559778,Phase I,Recruiting,"[{'id': 688, 'therapyName': 'Bortezomib'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 2629, 'therapyName': 'Eflornithine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 717, 'therapyName': 'Dasatinib'}]",Pediatric Precision Laboratory Advanced Neuroblastoma Therapy,1241
26,NCT01593254,Phase II,"Active, not recruiting","[{'id': 770, 'therapyName': 'Imatinib'}, {'id': 717, 'therapyName': 'Dasatinib'}]",Phase IIb Study of Dasatinib Versus Imatinib in Patients With CML-CP Who Have Not Achieved an Early Optimal Response to Imatinib,1241
27,NCT01643603,Phase Ib/II,Recruiting,"[{'id': 717, 'therapyName': 'Dasatinib'}]",Dasatinib in Treating Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant,1241
28,NCT02883049,Phase III,Suspended,"[{'id': 717, 'therapyName': 'Dasatinib'}, {'id': 4685, 'therapyName': 'Dexamethasone + Doxorubicin'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1746, 'therapyName': 'Clofarabine'}]",Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations,1241
29,NCT02420717,Phase II,Recruiting,"[{'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 3195, 'therapyName': 'Cytarabine + Methotrexate '}, {'id': 2046, 'therapyName': 'Cyclophosphamide + Dexamethasone + Doxorubicin + Vincristine '}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 3194, 'therapyName': 'Mercaptopurine + Methotrexate + Prednisone + Vincristine'}]",Ruxolitinib or Dasatinib With Chemotherapy in Patients With Philadelphia Chromosome (Ph)-Like Acute Lymphoblastic Leukemia (ALL),1241
30,NCT01482728,Phase I,Completed,"[{'id': 717, 'therapyName': 'Dasatinib'}]",Bristol-Myers Squibb Dasatinib Src Inhibition in Endometrial Cancer,1241
31,NCT02015728,Phase I,"Active, not recruiting","[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1804, 'therapyName': 'Temozolomide + Etoposide'}, {'id': 920, 'therapyName': 'Sorafenib'}]",Selecting Patient-Specific Biologically Targeted Therapy for Pediatric Patients With Refractory Or Recurrent Brain Tumors,1241
32,NCT00549848,Phase III,"Active, not recruiting","[{'id': 1781, 'therapyName': 'Vincristine + Pegaspargase + Daunorubicin'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1782, 'therapyName': 'Clofarabine + Etoposide + Cyclophosphamide'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}]",Total Therapy Study XVI for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia,1241
33,NCT01015222,Phase I,"Active, not recruiting","[{'id': 1032, 'therapyName': 'methylnaltrexone'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 667, 'therapyName': 'Bevacizumab'}]","Dasatinib, Bevacizumab, Paclitaxel in Patients With Advanced Malignancies",1241
34,NCT01620216,Phase II,Recruiting,"[{'id': 930, 'therapyName': 'Sunitinib'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 877, 'therapyName': 'Ponatinib'}, {'id': 920, 'therapyName': 'Sorafenib'}]",Validation of an in Vitro Assay to Predict Targeted Therapies for Acute Leukemia Patients,1241
35,NCT01244750,Phase I,"Active, not recruiting","[{'id': 770, 'therapyName': 'Imatinib'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 829, 'therapyName': 'Nilotinib'}]",Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting,1241
36,NCT02720185,Phase II,Recruiting,"[{'id': 717, 'therapyName': 'Dasatinib'}]",The Window of Opportunity of Dasatinib in Operable Triple Negative Breast Cancers With nEGFR,1241
37,NCT02788201,Phase II,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1133, 'therapyName': 'Mitomycin C'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1013, 'therapyName': 'epirubicin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1137, 'therapyName': 'Bleomycin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 781, 'therapyName': 'Ixabepilone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 2950, 'therapyName': 'Estramustine'}, {'id': 1941, 'therapyName': 'Floxuridine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 1811, 'therapyName': 'Carmustine'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 953, 'therapyName': 'Vandetanib'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 4419, 'therapyName': 'Toremifine'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 2601, 'therapyName': 'Dactinomycin'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 3035, 'therapyName': 'Chlorambucil'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 342, 'therapyName': 'Vemurafenib'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 2635, 'therapyName': 'Vinblastine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 4305, 'therapyName': 'Teniposide'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 4304, 'therapyName': 'Streptozocin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1231, 'therapyName': 'Bendamustine'}, {'id': 4303, 'therapyName': 'Mechlorethamine'}, {'id': 4302, 'therapyName': 'Mitotane'}]",Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma,1241
38,NCT00777036,,"Active, not recruiting","[{'id': 717, 'therapyName': 'Dasatinib'}]",A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolerant to Imatinib,1241
39,NCT01445509,Phase I,"Active, not recruiting","[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 717, 'therapyName': 'Dasatinib'}]",Dasatinib in Combination With Bevacizumab to Treat Advanced Solid Tumors,1241
40,NCT02143414,Phase II,Recruiting,"[{'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1824, 'therapyName': 'Vincristine + Methotrexate + Mercaptopurine'}]","Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia",1241
41,NCT02693535,Phase II,Recruiting,"[{'id': 1657, 'therapyName': 'Vemurafenib + Cobimetinib'}, {'id': 890, 'therapyName': 'Regorafenib'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 690, 'therapyName': 'Bosutinib'}, {'id': 850, 'therapyName': 'Palbociclib'}, {'id': 694, 'therapyName': 'Cetuximab'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 837, 'therapyName': 'Olaparib'}, {'id': 4, 'therapyName': 'Erlotinib'}]",TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer,1241
42,NCT00892190,Phase I,Completed,"[{'id': 717, 'therapyName': 'Dasatinib'}]",Study of Dasatinib and All-Trans Retinoic Acid for Relapsed/Refractory and/or Elderly Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome,1241
43,NCT01441882,Phase II,"Active, not recruiting","[{'id': 717, 'therapyName': 'Dasatinib'}]",A Study of Dasatinib in Chronic Lymphocytic Leukemia in Patients Who Exhibit in Vitro Dasatinib Sensitivity,1241
44,NCT01990196,Phase II,Recruiting,"[{'id': 717, 'therapyName': 'Dasatinib'}, {'id': 2, 'therapyName': 'Trametinib'}, {'id': 1815, 'therapyName': 'Degarelix + Enzalutamide'}]",Neoadjuvant Phase 2 Study Comparing the Effects of AR Inhibition With/Without SRC or MEK Inhibition in Prostate Cancer,1241
45,NCT01660906,Phase III,Completed,"[{'id': 717, 'therapyName': 'Dasatinib'}]","This Study Will be a Phase IV, Open-label, Multicenter Study of Dasatinib in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients With Chronic, Low-grade Non-Hematologic Toxicity to Imatinib",1241
46,NCT03117751,Phase II,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1876, 'therapyName': 'Blinatumomab '}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1638, 'therapyName': 'Pegaspargase'}]",Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma,1241
47,NCT02689440,FDA approved,Recruiting,"[{'id': 717, 'therapyName': 'Dasatinib'}]",Therapy of Early Chronic Phase Chronic Myelogenous Leukemia (CML) With Dasatinib,1241
48,NCT01652976,Phase II,"Active, not recruiting","[{'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 717, 'therapyName': 'Dasatinib'}]","Phase II Study of 5-FU, Oxaliplatin Plus Dasatinib in Metastatic Pancreatic Adenocarcinoma",1241
49,NCT01999985,Phase I,"Active, not recruiting","[{'id': 1351, 'therapyName': 'Dasatinib + Afatinib'}]",Phase I Trial of Afatinib (BIBW 2992) and Dasatinib in Non-small Cell Lung Cancer (NSCLC),1241
50,NCT01498445,Phase Ib/II,Recruiting,"[{'id': 1760, 'therapyName': 'Dasatinib + Decitabine '}]",Phase I/II - Dasatinib and Decitabine,1241
51,NCT02494882,Phase I,Recruiting,"[{'id': 3218, 'therapyName': 'Dasatinib + Dexamethasone + Ruxolitinib'}]",Adding Ruxolitinib to a Combination of Dasatinib Plus Dexamethasone in Remission Induction Therapy in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Patients Aged 40 Years or Older,1241
52,NCT03041701,Phase Ib/II,Recruiting,"[{'id': 5287, 'therapyName': 'Dasatinib + Ganitumab'}]",Insulin-like Growth Factor 1 Receptor (IGF-1R) Antibody AMG479 (Ganitumab) in Combination With the Src Family Kinase (SFK) Inhibitor Dasatinib in People With Embryonal and Alveolar Rhabdomyosarcoma,1241
53,NCT02815059,Phase I,Recruiting,"[{'id': 4438, 'therapyName': 'Dasatinib + Ibrutinib + Prednisone'}]","Study of Pts With Philadelphia Chromosome-Pos ALL With Comb of Ibrutinib, Dasatinib, and Prednisone",1241
54,NCT01643278,Phase I,Completed,"[{'id': 1803, 'therapyName': 'Dasatinib + Ipilimumab'}]",Dasatinib and Ipilimumab in Treating Patients With Gastrointestinal Stromal Tumors or Other Sarcomas That Cannot Be Removed by Surgery or Are Metastatic,1241
55,NCT00829647,Phase Ib/II,Withdrawn,"[{'id': 1825, 'therapyName': 'Dasatinib + lenalidomide'}]",A Study Using Two Oral Chemotherapy Agents for Chronic Lymphocytic Leukemia,1241
56,NCT02819804,Phase I,Recruiting,"[{'id': 1813, 'therapyName': 'Dasatinib + Nivolumab'}]",Nivolumab and Dasatinib in Treating Patients With Relapsed or Refractory Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia,1241
57,NCT02750514,Phase II,Recruiting,"[{'id': 1813, 'therapyName': 'Dasatinib + Nivolumab'}, {'id': 4197, 'therapyName': 'BMS-986016 + Nivolumab'}, {'id': 1312, 'therapyName': 'Nivolumab'}]",A Study to Test Combination Treatments in People With Advanced Non-Small Cell Lung Cancer,1241
58,NCT02011945,Phase I,"Active, not recruiting","[{'id': 1813, 'therapyName': 'Dasatinib + Nivolumab'}]",A Phase 1B Study to Investigate the Safety and Preliminary Efficacy for the Combination of Dasatinib Plus Nivolumab in Patients With Chronic Myeloid Leukemia,1241
59,NCT02954523,Phase Ib/II,Recruiting,"[{'id': 4946, 'therapyName': 'Dasatinib + Osimertinib'}]",Dasatinib and Osimertinib (AZD9291) in Advanced Non-Small Cell Lung Cancer With EGFR Mutations,1241
60,NCT01440998,Phase I,"Active, not recruiting","[{'id': 1819, 'therapyName': 'Dasatinib + Paclitaxel + Carboplatin'}]","Dasatinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer",1241
61,NCT01606579,Phase Ib/II,Completed,"[{'id': 2466, 'therapyName': 'Cytarabine + Pri-724'}, {'id': 2465, 'therapyName': 'Dasatinib + Pri-724'}, {'id': 1083, 'therapyName': 'Pri-724'}]",Safety and Efficacy Study of PRI-724 in Subjects With Advanced Myeloid Malignancies,1241
62,NCT01173679,Phase II,Terminated,"[{'id': 1821, 'therapyName': 'Dasatinib + Rituximab + Fludarabine'}]",Dasatinib With Fludarabine and Rituximab in Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL),1241
63,NCT01660971,Phase I,"Active, not recruiting","[{'id': 1816, 'therapyName': 'Gemcitabine + Dasatinib + Erlotinib'}]","Gemcitabine Hydrochloride, Dasatinib, and Erlotinib Hydrochloride in Treating Patients With Metastatic Pancreatic Cancer That Cannot Be Removed By Surgery",1241
64,NCT02047149,Phase I,Terminated,"[{'id': 1789, 'therapyName': 'Zileuton + Dasatinib'}]",Evaluating the Safety of Zileuton (Zyflo(R)) in Combination With Dasatinib (Sprycel (R) in Chronic Myelogenous Leukemia,1241
0,NCT03298984,Phase I,Not yet recruiting,"[{'id': 6300, 'therapyName': 'Alvocidib + Cytarabine + Daunorubicin'}]",Ph I Study of Alvocidib and Cytarabine/Duanorubicin (7+3) in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML).,684
1,NCT02283177,Phase II,Recruiting,"[{'id': 2637, 'therapyName': 'Crenolanib + Cytarabine + Daunorubicin'}]",A Safety and Tolerability Study of Crenolanib in Combination With Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia Patients With FLT3 Mutations,684
2,NCT01371981,Phase III,"Active, not recruiting","[{'id': 2391, 'therapyName': 'Cytarabine + Daunorubicin + Etoposide'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 2392, 'therapyName': 'Cytarabine + Etoposide'}, {'id': 2393, 'therapyName': 'Cytarabine + Mitoxantrone'}, {'id': 2394, 'therapyName': 'Asparaginase + Cytarabine'}, {'id': 688, 'therapyName': 'Bortezomib'}]",Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,684
3,NCT01256398,Phase II,"Active, not recruiting","[{'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 2291, 'therapyName': 'Cyclophosphamide + Fludarabine'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1824, 'therapyName': 'Vincristine + Methotrexate + Mercaptopurine'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 2391, 'therapyName': 'Cytarabine + Daunorubicin + Etoposide'}, {'id': 1476, 'therapyName': 'Pegfilgrastim'}, {'id': 1205, 'therapyName': 'Alemtuzumab'}, {'id': 1642, 'therapyName': 'Leucovorin'}]",Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,684
4,NCT02632708,Phase I,Recruiting,"[{'id': 1491, 'therapyName': 'AG-120'}, {'id': 2982, 'therapyName': 'Enasidenib'}, {'id': 3431, 'therapyName': 'Cytarabine + Daunorubicin + Etoposide + Mitoxantrone'}]",Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia With an IDH1 and/or IDH2 Mutation,684
5,NCT02668653,Phase III,Recruiting,"[{'id': 3543, 'therapyName': 'Cytarabine + Daunorubicin + Idarubicin'}, {'id': 882, 'therapyName': 'Quizartinib'}]",Quizartinib With Standard of Care Chemotherapy and as Maintenance Therapy in Patients With Newly Diagnosed FLT3-ITD (+) AML,684
6,NCT02323607,Phase I,Suspended,"[{'id': 3219, 'therapyName': 'Cytarabine + Daunorubicin + Pacritinib'}, {'id': 3177, 'therapyName': 'Pacritinib + Decitabine'}]",Pacritinib and Chemotherapy in Treating Patients With Acute Myeloid Leukemia and FLT3 Mutations,684
7,NCT01463046,Phase I,"Active, not recruiting","[{'id': 3185, 'therapyName': 'Cytarabine + Daunorubicin + Panobinostat'}]",Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome,684
8,NCT02954653,Phase I,Recruiting,"[{'id': 6087, 'therapyName': 'PF-06747143'}, {'id': 6092, 'therapyName': 'Cytarabine + Daunorubicin + PF-06747143'}, {'id': 6093, 'therapyName': 'Azacitidine + Decitabine + PF-06747143'}]","A Study Of PF-06747143, As Single Agent Or In Combination With Standard Chemotherapy In Adult Patients With Acute Myeloid Leukemia",684
9,NCT03013998,Phase Ib/II,Recruiting,"[{'id': 4003, 'therapyName': 'Azacitidine + Enasidenib'}, {'id': 5539, 'therapyName': 'Azacitidine + Entospletinib'}, {'id': 5536, 'therapyName': 'Cytarabine + Daunorubicin + Samalizumab'}, {'id': 5538, 'therapyName': 'Azacitidine + BI 836858'}]",Study of Biomarker-Based Treatment of Acute Myeloid Leukemia,684
10,NCT03164057,Phase II,Recruiting,"[{'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 5153, 'therapyName': 'dexrazoxane'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 651, 'therapyName': 'Azacitidine'}]",A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia,684
11,NCT02560025,Phase II,"Active, not recruiting","[{'id': 626, 'therapyName': 'Alisertib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 712, 'therapyName': 'Cytarabine'}]",Phase II Trial of Alisertib With Induction Chemotherapy in High-risk AML,684
12,NCT03117751,Phase II,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1876, 'therapyName': 'Blinatumomab '}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1638, 'therapyName': 'Pegaspargase'}]",Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma,684
13,NCT00550992,Phase I,Unknown status,"[{'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1752, 'therapyName': 'Mitoxantrone + Etoposide + Cytarabine'}, {'id': 1848, 'therapyName': 'Cyclophosphamide + Methotrexate + Vincristine + Pegaspargase '}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1650, 'therapyName': 'Cyclosporine'}, {'id': 1844, 'therapyName': 'anti-thymocyte globulin'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1642, 'therapyName': 'Leucovorin'}]",Different Therapies in Treating Infants With Newly Diagnosed Acute Leukemia,684
14,NCT02112916,Phase III,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1009, 'therapyName': 'Doxorubicin'}]",Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma,684
15,NCT03007147,Phase III,Recruiting,"[{'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 5153, 'therapyName': 'dexrazoxane'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 5167, 'therapyName': 'Methylprednisolone'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 5168, 'therapyName': 'Prednisolone'}, {'id': 1009, 'therapyName': 'Doxorubicin'}]",Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia,684
16,NCT02412475,Phase I,"Active, not recruiting","[{'id': 712, 'therapyName': 'Cytarabine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 650, 'therapyName': 'Decitabine'}]",Epigenetic Reprogramming in Relapse AML,684
17,NCT02551718,Phase I,Recruiting,"[{'id': 690, 'therapyName': 'Bosutinib'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 3160, 'therapyName': 'Nelarabine'}, {'id': 3159, 'therapyName': 'Bexarotene'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 998, 'therapyName': 'cabozantinib'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 877, 'therapyName': 'Ponatinib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 623, 'therapyName': 'Afatinib'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 890, 'therapyName': 'Regorafenib'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 2, 'therapyName': 'Trametinib'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 3, 'therapyName': 'Dabrafenib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 789, 'therapyName': 'Ceritinib'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1571, 'therapyName': 'Cabazitaxel'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1327, 'therapyName': 'Pralatrexate'}]",High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia,684
18,NCT03150693,Phase III,Recruiting,"[{'id': 897, 'therapyName': 'Rituximab'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1783, 'therapyName': 'Cyclophosphamide + Cytarabine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 3628, 'therapyName': 'Allopurinol'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 3199, 'therapyName': 'inotuzumab ozogamicin'}]",Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia,684
19,NCT02043587,Phase II,Recruiting,"[{'id': 897, 'therapyName': 'Rituximab'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1136, 'therapyName': 'Etoposide'}]",Chemotherapy With Liposomal Cytarabine CNS Prophylaxis for Adult Acute Lymphoblastic Leukemia &amp; Lymphoblastic Lymphoma,684
20,NCT02521493,Phase III,Recruiting,"[{'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 5912, 'therapyName': 'Asparaginase Erwinia chrysanthemi'}, {'id': 5215, 'therapyName': 'mitoxantrone hydrochloride'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 2206, 'therapyName': 'Asparaginase'}]",Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome,684
21,NCT02788201,Phase II,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1133, 'therapyName': 'Mitomycin C'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1013, 'therapyName': 'epirubicin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1137, 'therapyName': 'Bleomycin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 781, 'therapyName': 'Ixabepilone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 2950, 'therapyName': 'Estramustine'}, {'id': 1941, 'therapyName': 'Floxuridine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 1811, 'therapyName': 'Carmustine'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 953, 'therapyName': 'Vandetanib'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 4419, 'therapyName': 'Toremifine'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 2601, 'therapyName': 'Dactinomycin'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 3035, 'therapyName': 'Chlorambucil'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 342, 'therapyName': 'Vemurafenib'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 2635, 'therapyName': 'Vinblastine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 4305, 'therapyName': 'Teniposide'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 4304, 'therapyName': 'Streptozocin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1231, 'therapyName': 'Bendamustine'}, {'id': 4303, 'therapyName': 'Mechlorethamine'}, {'id': 4302, 'therapyName': 'Mitotane'}]",Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma,684
22,NCT01806571,Phase II,Recruiting,"[{'id': 1738, 'therapyName': 'Daunorubicin + Cytarabine'}, {'id': 829, 'therapyName': 'Nilotinib'}]","Daunorubicin Hydrochloride, Cytarabine, and Nilotinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia",684
23,NCT02403310,Phase I,"Active, not recruiting","[{'id': 1738, 'therapyName': 'Daunorubicin + Cytarabine'}, {'id': 1749, 'therapyName': 'Selinexor'}]",A Study of Selinexor in Combination With Daunorubicin and Cytarabine for Untreated AML,684
24,NCT01546038,Phase Ib/II,"Active, not recruiting","[{'id': 1748, 'therapyName': 'PF-04449913'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 1738, 'therapyName': 'Daunorubicin + Cytarabine'}]",A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,684
25,NCT02085408,Phase III,Recruiting,"[{'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 1738, 'therapyName': 'Daunorubicin + Cytarabine'}]",Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia,684
26,NCT02343939,Phase Ib/II,Recruiting,"[{'id': 650, 'therapyName': 'Decitabine'}, {'id': 1738, 'therapyName': 'Daunorubicin + Cytarabine'}, {'id': 2522, 'therapyName': 'Entospletinib  '}]",Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML),684
27,NCT01627041,Phase II,"Active, not recruiting","[{'id': 1739, 'therapyName': 'Daunorubicin + Cytarabine + Decitabine'}, {'id': 1738, 'therapyName': 'Daunorubicin + Cytarabine'}]","Decitabine, Cytarabine, and Daunorubicin Hydrochloride in Treating Patients With Acute Myeloid Leukemia",684
28,NCT00549848,Phase III,"Active, not recruiting","[{'id': 1781, 'therapyName': 'Vincristine + Pegaspargase + Daunorubicin'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1782, 'therapyName': 'Clofarabine + Etoposide + Cyclophosphamide'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}]",Total Therapy Study XVI for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia,684
0,NCT03059485,Phase II,Recruiting,"[{'id': 5369, 'therapyName': 'DC/AML Vaccine'}, {'id': 5370, 'therapyName': 'DC/AML Vaccine + MEDI4736'}]",DC/AML Fusion Cell Vaccine vs DC/AML Fusion Cell Vaccine Plus Durvalumab vs Observation in Patients Who Achieve a Chemotherapy-induced Remission,8673
0,NCT02571036,Phase I,Recruiting,"[{'id': 4316, 'therapyName': 'DCC-2618'}]","A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies",8407
0,NCT03069469,Phase I,Recruiting,"[{'id': 5760, 'therapyName': 'DCC-3014'}]",Study of DCC-3014 in Patients With Advanced Malignancies,8781
0,NCT02314052,Phase Ib/II,Terminated,"[{'id': 3122, 'therapyName': 'DCR-MYC'}]","Phase Ib/2, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Hepatocellular Carcinoma",7950
1,NCT02110563,Phase I,Terminated,"[{'id': 3122, 'therapyName': 'DCR-MYC'}]","Phase I, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Solid Tumors, Multiple Myeloma, or Lymphoma",7950
0,NCT03014804,Phase II,Not yet recruiting,"[{'id': 5205, 'therapyName': 'DCVax-L'}, {'id': 5206, 'therapyName': 'DCVax-L + Nivolumab'}]",Dendritic Cell-Autologous Lung Tumor Vaccine and Nivolumab in Treating Patients With Recurrent Glioblastoma,8633
1,NCT02146066,Expanded access,Available,"[{'id': 5205, 'therapyName': 'DCVax-L'}]",Expanded Access Protocol for GBM Patients With Already Manufactured DCVax®-L Who Have Screen-Failed Protocol 020221,8633
0,NCT01948297,Phase I,Recruiting,"[{'id': 1014, 'therapyName': 'FF-284'}]",Debio 1347-101 Phase I Trial in Advanced Solid Tumours With Fibroblast Growth Factor Receptor (FGFR) Alterations,7130
0,NCT02495636,Phase II,Withdrawn,"[{'id': 4204, 'therapyName': 'Atezolizumab + DEC-205-NY-ESO-1 fusion protein vaccine'}]","Phase 2 Study of MPDL3280A Combined With CDX-1401 in NY-ESO 1 (+) IIIB, IV or Recurrent Non-Small Cell Lung Cancer",7238
1,NCT03206047,Phase Ib/II,Recruiting,"[{'id': 4693, 'therapyName': 'Atezolizumab + SGI-110'}, {'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 5982, 'therapyName': 'Atezolizumab + SGI-110 + DEC-205-NY-ESO-1 fusion protein vaccine'}]","Atezolizumab, Guadecitabine, and CDX-1401 Vaccine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",7238
2,NCT01834248,Phase I,Completed,"[{'id': 1795, 'therapyName': 'DEC-205-NY-ESO-1 + Decitabine '}]",DEC-205/NY-ESO-1 Fusion Protein CDX-1401and Decitabine in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia,7238
3,NCT02129075,Phase II,"Active, not recruiting","[{'id': 3006, 'therapyName': 'NeoVax melanoma vaccine'}, {'id': 3007, 'therapyName': 'CDX-301'}, {'id': 1324, 'therapyName': 'DEC-205-NY-ESO-1 fusion protein vaccine'}]",CDX-1401 and Poly-ICLC Vaccine Therapy With or Without CDX-301in Treating Patients With Stage IIB-IV Melanoma,7238
4,NCT02413827,Phase Ib/II,Terminated,"[{'id': 2526, 'therapyName': 'Nivolumab + Varlilumab'}, {'id': 1324, 'therapyName': 'DEC-205-NY-ESO-1 fusion protein vaccine'}, {'id': 2595, 'therapyName': 'poly ICLC  '}]",A Study of Varlilumab (Anti-CD27) and Ipilimumab and CDX-1401 in Patients With Unresectable Stage III or IV Melanoma,7238
5,NCT02166905,Phase Ib/II,Recruiting,"[{'id': 2595, 'therapyName': 'poly ICLC  '}, {'id': 1324, 'therapyName': 'DEC-205-NY-ESO-1 fusion protein vaccine'}, {'id': 2575, 'therapyName': 'Epacadostat'}]","DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, and IDO1 Inhibitor INCB024360 in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission",7238
6,NCT01522820,Phase I,Completed,"[{'id': 1324, 'therapyName': 'DEC-205-NY-ESO-1 fusion protein vaccine'}, {'id': 917, 'therapyName': 'Sirolimus'}]",Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors,7238
0,NCT03041688,Phase I,Not yet recruiting,"[{'id': 6185, 'therapyName': 'AMG 232 + Decitabine'}]","MDM2 Inhibitor AMG-232 and Decitabine in Treating Patients With Relapsed, Refractory, or Newly-Diagnosed Acute Myeloid Leukemia",1249
1,NCT01798901,Phase I,"Active, not recruiting","[{'id': 1751, 'therapyName': 'AR-42 + Decitabine'}]",AR-42 and Decitabine in Treating Patients With Acute Myeloid Leukemia,1249
2,NCT02954653,Phase I,Recruiting,"[{'id': 6087, 'therapyName': 'PF-06747143'}, {'id': 6092, 'therapyName': 'Cytarabine + Daunorubicin + PF-06747143'}, {'id': 6093, 'therapyName': 'Azacitidine + Decitabine + PF-06747143'}]","A Study Of PF-06747143, As Single Agent Or In Combination With Standard Chemotherapy In Adult Patients With Acute Myeloid Leukemia",1249
3,NCT02632721,Phase II,Recruiting,"[{'id': 5540, 'therapyName': 'BI 836858 + Decitabine'}, {'id': 650, 'therapyName': 'Decitabine'}]",A Study to Find and Investigate a Safe Dose of BI 836858 in Combination With Decitabine for Patients With Acute Myeloid Leukemia (AML),1249
4,NCT01861314,Phase I,"Active, not recruiting","[{'id': 1793, 'therapyName': 'Bortezomib + Sorafenib + Decitabine   '}]","Bortezomib, Sorafenib Tosylate, and Decitabine in Treating Patients With Acute Myeloid Leukemia",1249
5,NCT01498445,Phase Ib/II,Recruiting,"[{'id': 1760, 'therapyName': 'Dasatinib + Decitabine '}]",Phase I/II - Dasatinib and Decitabine,1249
6,NCT01627041,Phase II,"Active, not recruiting","[{'id': 1739, 'therapyName': 'Daunorubicin + Cytarabine + Decitabine'}, {'id': 1738, 'therapyName': 'Daunorubicin + Cytarabine'}]","Decitabine, Cytarabine, and Daunorubicin Hydrochloride in Treating Patients With Acute Myeloid Leukemia",1249
7,NCT01834248,Phase I,Completed,"[{'id': 1795, 'therapyName': 'DEC-205-NY-ESO-1 + Decitabine '}]",DEC-205/NY-ESO-1 Fusion Protein CDX-1401and Decitabine in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia,1249
8,NCT02920008,Phase III,Recruiting,"[{'id': 650, 'therapyName': 'Decitabine'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1949, 'therapyName': 'SGI-110'}]","Phase 3 Randomized, Open-Label Study of Guadecitabine vs Treatment Choice in Previously Treated Acute Myeloid Leukemia",1249
9,NCT01720225,Phase II,"Active, not recruiting","[{'id': 650, 'therapyName': 'Decitabine'}, {'id': 651, 'therapyName': 'Azacitidine'}]",Decitabine Versus Azacitidine in Myelodysplastic Syndrome Patients With Low and Intermediate-1 Risk,1249
10,NCT02332889,Phase Ib/II,Terminated,"[{'id': 650, 'therapyName': 'Decitabine'}, {'id': 2595, 'therapyName': 'poly ICLC  '}]",Phase I/II Decitabine/Vaccine Therapy in Relapsed/Refractory Pediatric High Grade Gliomas/Medulloblastomas/CNS PNETs,1249
11,NCT02088541,Phase II,"Active, not recruiting","[{'id': 712, 'therapyName': 'Cytarabine'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 1749, 'therapyName': 'Selinexor'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}]",Selinexor (KPT-330) in Older Patients With Relapsed AML,1249
12,NCT02073838,Phase II,Recruiting,"[{'id': 650, 'therapyName': 'Decitabine'}, {'id': 3179, 'therapyName': 'Vismodegib + Ribavirin'}]",Ribavirin and Hedgehog Inhibitor With or Without Decitabine in AML,1249
13,NCT01786343,Phase II,Recruiting,"[{'id': 650, 'therapyName': 'Decitabine'}]",Decitabine for Older or Unfit Patients With Acute Myeloid Leukemia (AML),1249
14,NCT02348489,Phase III,"Active, not recruiting","[{'id': 1949, 'therapyName': 'SGI-110'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 650, 'therapyName': 'Decitabine'}]","SGI-110 in Adults With Untreated Acute Myeloid Leukemia (AML), Not Considered Candidates for Intensive Remission Induction",1249
15,NCT01241162,Phase I,Completed,"[{'id': 650, 'therapyName': 'Decitabine'}]",Decitabine Followed by a Cancer Antigen Vaccine for Patients With Neuroblastoma and Sarcoma,1249
16,NCT02343939,Phase Ib/II,Recruiting,"[{'id': 650, 'therapyName': 'Decitabine'}, {'id': 1738, 'therapyName': 'Daunorubicin + Cytarabine'}, {'id': 2522, 'therapyName': 'Entospletinib  '}]",Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML),1249
17,NCT02412475,Phase I,"Active, not recruiting","[{'id': 712, 'therapyName': 'Cytarabine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 650, 'therapyName': 'Decitabine'}]",Epigenetic Reprogramming in Relapse AML,1249
18,NCT01515527,Phase II,Recruiting,"[{'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 650, 'therapyName': 'Decitabine'}]",Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS),1249
19,NCT01794702,Phase Ib/II,"Active, not recruiting","[{'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 650, 'therapyName': 'Decitabine'}]","Decitabine Followed by Clofarabine, Idarubicin, and Cytarabine in Acute Leukemia",1249
20,NCT02469415,Phase II,Terminated,"[{'id': 650, 'therapyName': 'Decitabine'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 2006, 'therapyName': 'Pacritinib'}]",Pacritinib for Patients With Lower-Risk Myelodysplastic Syndromes (MDS),1249
21,NCT01593670,Phase II,Terminated,"[{'id': 650, 'therapyName': 'Decitabine'}, {'id': 1167, 'therapyName': 'Aldesleukin'}, {'id': 1077, 'therapyName': 'Vorinostat'}]",Decitabine and Vorinostat Conditioning Followed by CD3-/CD19- NK Cells Infusion for High Risk Myelodysplastic Syndromes,1249
22,NCT03263936,Phase I,Recruiting,"[{'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1632, 'therapyName': 'Filgrastim'}]",Epigenetic Reprogramming in Relapse/Refractory AML,1249
23,NCT01729845,Phase Ib/II,"Active, not recruiting","[{'id': 1752, 'therapyName': 'Mitoxantrone + Etoposide + Cytarabine'}, {'id': 650, 'therapyName': 'Decitabine'}]","Decitabine Followed By Mitoxantrone Hydrochloride, Etoposide, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes",1249
24,NCT02551718,Phase I,Recruiting,"[{'id': 690, 'therapyName': 'Bosutinib'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 3160, 'therapyName': 'Nelarabine'}, {'id': 3159, 'therapyName': 'Bexarotene'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 998, 'therapyName': 'cabozantinib'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 877, 'therapyName': 'Ponatinib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 623, 'therapyName': 'Afatinib'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 890, 'therapyName': 'Regorafenib'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 2, 'therapyName': 'Trametinib'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 3, 'therapyName': 'Dabrafenib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 789, 'therapyName': 'Ceritinib'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1571, 'therapyName': 'Cabazitaxel'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1327, 'therapyName': 'Pralatrexate'}]",High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia,1249
25,NCT03164057,Phase II,Recruiting,"[{'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 5153, 'therapyName': 'dexrazoxane'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 651, 'therapyName': 'Azacitidine'}]",A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia,1249
26,NCT01483274,Phase I,Withdrawn,"[{'id': 650, 'therapyName': 'Decitabine'}]",Decitabine and Vaccine Therapy for Patients With Relapsed AML Following Allogeneic Stem Cell Transplantation,1249
27,NCT01546038,Phase Ib/II,"Active, not recruiting","[{'id': 1748, 'therapyName': 'PF-04449913'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 1738, 'therapyName': 'Daunorubicin + Cytarabine'}]",A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,1249
28,NCT01303796,Phase III,Unknown status,"[{'id': 1747, 'therapyName': 'Decitabine + Sapacitabine'}, {'id': 650, 'therapyName': 'Decitabine'}]",A Study of Oral Sapacitabine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (SEAMLESS),1249
29,NCT01707004,Phase I,"Active, not recruiting","[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1206, 'therapyName': 'Busulfan'}]",Decitabine and Total-Body Irradiation Followed By Donor Bone Marrow Transplant and Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia,1249
30,NCT02188706,Phase II,"Active, not recruiting","[{'id': 650, 'therapyName': 'Decitabine'}, {'id': 1608, 'therapyName': 'Decitabine + Carboplatin'}, {'id': 1609, 'therapyName': 'Decitabine + Arsenic trioxide '}]","A Leukemia SPORE Phase II Clinical Trial Comparing Decitabine Versus Decitabine/Carboplatin and Decitabine/Arsenic for the Treatment of Relapsed, Refractory, and Elderly Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)",1249
31,NCT01687400,Phase II,"Active, not recruiting","[{'id': 650, 'therapyName': 'Decitabine'}]",Genomic Predictors of Decitabine Response in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes,1249
32,NCT02788201,Phase II,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1133, 'therapyName': 'Mitomycin C'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1013, 'therapyName': 'epirubicin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1137, 'therapyName': 'Bleomycin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 781, 'therapyName': 'Ixabepilone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 2950, 'therapyName': 'Estramustine'}, {'id': 1941, 'therapyName': 'Floxuridine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 1811, 'therapyName': 'Carmustine'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 953, 'therapyName': 'Vandetanib'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 4419, 'therapyName': 'Toremifine'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 2601, 'therapyName': 'Dactinomycin'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 3035, 'therapyName': 'Chlorambucil'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 342, 'therapyName': 'Vemurafenib'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 2635, 'therapyName': 'Vinblastine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 4305, 'therapyName': 'Teniposide'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 4304, 'therapyName': 'Streptozocin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1231, 'therapyName': 'Bendamustine'}, {'id': 4303, 'therapyName': 'Mechlorethamine'}, {'id': 4302, 'therapyName': 'Mitotane'}]",Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma,1249
33,NCT02472145,Phase III,"Active, not recruiting","[{'id': 650, 'therapyName': 'Decitabine'}, {'id': 5909, 'therapyName': 'Decitabine + Talacotuzumab'}]",An Efficacy and Safety Study of Decitabine (DACOGEN) Plus Talacotuzumab (JNJ-56022473; Anti CD123) Versus Decitabine (DACOGEN) Alone in Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy,1249
34,NCT01483690,Phase Ib/II,Terminated,"[{'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}]",A Pilot Study of Decitabine and Vorinostat With Chemotherapy for Relapsed ALL,1249
35,NCT01993641,Phase II,Completed,"[{'id': 1758, 'therapyName': 'Pracinostat'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 650, 'therapyName': 'Decitabine'}]",Phase 2 Study Adding Pracinostat to a Hypomethylating Agent (HMA) in Patients With MDS Who Failed to Respond to Single Agent HMA,1249
36,NCT02190695,Phase II,Recruiting,"[{'id': 1608, 'therapyName': 'Decitabine + Carboplatin'}, {'id': 1609, 'therapyName': 'Decitabine + Arsenic trioxide '}]","A Safety and Efficacy Study Using Decitabine, Decitabine/Carboplatin, Decitabine/Arsenic for the Treatment of Relapsed, Refractory, and Elderly Acute Myeloid Leukemia , Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia",1249
37,NCT01812252,Phase II,Recruiting,"[{'id': 1606, 'therapyName': 'Cytarabine + Idarubicin'}, {'id': 1798, 'therapyName': 'Decitabine + Azacitidine'}]",Chemotherapy in Treating Patients With Myelodysplastic Syndrome Before Donor Stem Cell Transplant,1249
38,NCT01829503,Phase II,"Active, not recruiting","[{'id': 1736, 'therapyName': 'Decitabine + Cytarabine'}]",Phase II Study of Decitabine and Cytarabine for Older Patients With Newly Diagnosed Acute Myeloid Leukemia (AML),1249
39,NCT03092674,Phase II,Not yet recruiting,"[{'id': 1736, 'therapyName': 'Decitabine + Cytarabine'}, {'id': 2471, 'therapyName': 'Azacitidine + Midostaurin'}, {'id': 3196, 'therapyName': 'Azacitidine + Nivolumab'}, {'id': 651, 'therapyName': 'Azacitidine'}]","Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome",1249
40,NCT02121418,Phase I,"Active, not recruiting","[{'id': 1736, 'therapyName': 'Decitabine + Cytarabine'}]","Decitabine and Cytarabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia, High Risk Myelodysplastic Syndrome, or Myeloproliferative Neoplasm",1249
41,NCT02890329,Phase I,Recruiting,"[{'id': 5738, 'therapyName': 'Decitabine + Ipilimumab'}]",Ipilimumab and Decitabine in Treating Patients With Relapsed or Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia,1249
42,NCT02634827,Phase II,Recruiting,"[{'id': 1769, 'therapyName': 'Decitabine + Midostaurin'}]",Midostaurin and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia and FLT3 Mutation,1249
43,NCT01846624,Phase II,"Active, not recruiting","[{'id': 1769, 'therapyName': 'Decitabine + Midostaurin'}]",Decitabine and Midostaurin in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia,1249
44,NCT03009240,Phase I,Recruiting,"[{'id': 5214, 'therapyName': 'Decitabine + MLN4924'}]",Pevonedistat and Decitabine in Treating Patients With High Risk Acute Myeloid Leukemia,1249
45,NCT02664181,Phase II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 5910, 'therapyName': 'Decitabine + Nivolumab + Tetrahydrouridine'}]",Pharmacologically Rational EpigenetiC Immunotherapy for SEcond Line Therapy in Patients With Non-Small Cell Lung Cancer (PRECISE),1249
46,NCT03063944,Phase I,"Active, not recruiting","[{'id': 5794, 'therapyName': 'Decitabine + OPB-111077'}]",STAT Inhibitor OPB-111077 and Decitabine in Treating Patients With Acute Myeloid Leukemia That Is Refractory or Newly Diagnosed and Ineligible for Intensive Chemotherapy,1249
47,NCT02109744,Phase Ib/II,Recruiting,"[{'id': 1796, 'therapyName': 'Decitabine + Sirolimus'}, {'id': 1797, 'therapyName': 'Decitabine + Ribavirin'}]",Study of Decitabine in Combination With Sequential Rapamycin or Ribavirin in High Risk AML Patients,1249
48,NCT02093403,Phase I,"Active, not recruiting","[{'id': 1768, 'therapyName': 'Decitabine + Selinexor'}]",Decitabine and Selinexor in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia,1249
49,NCT02878785,Phase Ib/II,Recruiting,"[{'id': 5531, 'therapyName': 'Decitabine + Talazoparib'}]",Decitabine and Talazoparib in Untreated AML and R/R AML (1565GCC) ,1249
50,NCT00925132,Phase Ib/II,Terminated,"[{'id': 1737, 'therapyName': 'Decitabine + Temozolomide + Panobinostat'}]","Treatment of Resistant Metastatic Melanoma Using Decitabine, Temozolomide and Panobinostat",1249
51,NCT02839694,Phase I,Withdrawn,"[{'id': 3567, 'therapyName': 'Decitabine + Tetrahydrouridine'}, {'id': 4592, 'therapyName': 'Decitabine + Tetrahydrouridine + Celecoxib'}]",Adjuvant Oral Decitabine and Tetrahydrouridine With or Without Celecoxib in People Undergoing Pulmonary Metastasectomy,1249
52,NCT02846935,Phase 0,Recruiting,"[{'id': 3567, 'therapyName': 'Decitabine + Tetrahydrouridine'}]",p53/p16-Independent Epigenetic Therapy With Oral Decitabine/Tetrahydrouridine for Refractory/Relapsed Lymphoid Malignancies,1249
53,NCT02847000,Phase 0,Recruiting,"[{'id': 3567, 'therapyName': 'Decitabine + Tetrahydrouridine'}]",p53/p16-Independent Epigenetic Therapy With Oral Decitabine/Tetrahydrouridine for Pancreatic Cancer,1249
54,NCT01893320,Phase Ib/II,"Active, not recruiting","[{'id': 1766, 'therapyName': 'Decitabine + Vosaroxin'}]",Study of Vosaroxin and Decitabine in Older Patients With Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome,1249
55,NCT02010645,Phase II,"Active, not recruiting","[{'id': 1763, 'therapyName': 'Eltrombopag + Decitabine'}]",Eltrombopag With Decitabine in Advanced Myelodysplastic Syndrome (MDS),1249
56,NCT02203773,Phase I,"Active, not recruiting","[{'id': 1636, 'therapyName': 'GDC-0199 + Decitabine'}, {'id': 1637, 'therapyName': 'GDC-0199 + Azacitidine'}]",Phase 1b Acute Myelogenous Leukemia (AML) Study With ABT-199 + Decitabine or Azacitidine (Chemo Combo),1249
57,NCT02499861,Phase Ib/II,Recruiting,"[{'id': 1734, 'therapyName': 'Genistein + Decitabine'}]",Phase I/II a Study of Decitabine in Combination With Genistein in Pediatric Relapsed or Refractory Malignancies,1249
58,NCT01628471,Phase Ib/II,Completed,"[{'id': 1734, 'therapyName': 'Genistein + Decitabine'}]","MTD Determination, Safety and Efficacy of the Decitabine-Genistein Drug Combination in Advanced Solid Tumors and Non-Small Cell Lung Cancer",1249
59,NCT02029417,Phase II,Terminated,"[{'id': 1794, 'therapyName': 'Omacetaxine + Cytarabine + Decitabine'}]","Omacetaxine Mepesuccinate, Cytarabine, and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia",1249
60,NCT02141477,Phase II,Terminated,"[{'id': 1762, 'therapyName': 'Omacetaxine + Decitabine'}]",Omacetaxine and Decitabine in Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndrome (MDS),1249
61,NCT02532010,Phase II,"Active, not recruiting","[{'id': 3177, 'therapyName': 'Pacritinib + Decitabine'}, {'id': 3176, 'therapyName': 'Pacritinib + Cytarabine'}]",Pacritinib Combined With Decitabine or Cytarabine in Older Patients With AML,1249
62,NCT02323607,Phase I,Suspended,"[{'id': 3219, 'therapyName': 'Cytarabine + Daunorubicin + Pacritinib'}, {'id': 3177, 'therapyName': 'Pacritinib + Decitabine'}]",Pacritinib and Chemotherapy in Treating Patients With Acute Myeloid Leukemia and FLT3 Mutations,1249
63,NCT02564536,Phase I,Withdrawn,"[{'id': 3177, 'therapyName': 'Pacritinib + Decitabine'}]",Pacritinib in Combination With Low Dose Decitabine in Intermediate-High Risk Myelofibrosis or Myeloproliferative Neoplasm (MPN)/Myelodysplastic Syndrome (MDS),1249
64,NCT03132454,Phase I,Recruiting,"[{'id': 5637, 'therapyName': 'Palbociclib + Decitabine'}, {'id': 5636, 'therapyName': 'Palbociclib + Dexamethasone'}, {'id': 850, 'therapyName': 'Palbociclib'}, {'id': 5638, 'therapyName': 'Palbociclib + Sorafenib'}]",Study of Palbociclib Alone and in Combination in Patients With Relapsed and Refractory (R/R) Leukemias,1249
65,NCT02996474,Phase Ib/II,Recruiting,"[{'id': 5127, 'therapyName': 'Pembrolizumab + Decitabine'}]",Pembrolizumab and Decitabine for Refractory or Relapsed Acute Myeloid Leukemia,1249
66,NCT01352650,Phase I,"Active, not recruiting","[{'id': 1770, 'therapyName': 'Plerixafor + Decitabine'}]",Decitabine and Plerixafor in Elderly Acute Myeloid Leukemia (AML),1249
67,NCT02076191,Phase Ib/II,Recruiting,"[{'id': 1735, 'therapyName': 'Ruxolitinib + Decitabine'}]",Study of Combination Ruxolitinib and Decitabine Treatment for Accelerated Phase MPN or Post-MPN AML,1249
68,NCT02257138,Phase Ib/II,Recruiting,"[{'id': 1735, 'therapyName': 'Ruxolitinib + Decitabine'}]",Study of Ruxolitinib Plus Decitabine in Patients With Acute Myeloid Leukemia (AML),1249
69,NCT01876641,Phase Ib/II,Recruiting,"[{'id': 1259, 'therapyName': 'Vemurafenib + Decitabine'}]",Treatment of a Resistant Disease Using Decitabine Combined With Vemurafenib,1249
70,NCT02003573,Phase I,Terminated,"[{'id': 1745, 'therapyName': 'Volasertib + Decitabine'}]",Volasertib + Decitabine in Patients With Acute Myeloid Leukemia (AML),1249
0,NCT01952249,Phase Ib/II,Completed,"[{'id': 2007, 'therapyName': 'Demcizumab'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]",A Study of Demcizumab Plus Paclitaxel in Subjects With Platinum Resistant Ovarian,7379
1,NCT02259582,Phase II,"Active, not recruiting","[{'id': 1602, 'therapyName': 'Carboplatin + Pemetrexed'}, {'id': 2007, 'therapyName': 'Demcizumab'}]","A Study of Carboplatin, Pemetrexed Plus Placebo vs Carboplatin, Pemetrexed Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With Non-Squamous Non-Small Cell Lung Cancer",7379
2,NCT02289898,Phase II,"Active, not recruiting","[{'id': 2639, 'therapyName': 'Demcizumab + Gemcitabine + nab-paclitaxel'}]","Study of Gemcitabine, Abraxane Plus Placebo Versus Gemcitabine, Abraxane Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With 1st-Line Metastatic Pancreatic Ductal Adenocarcinoma",7379
3,NCT02722954,Phase I,"Active, not recruiting","[{'id': 3994, 'therapyName': 'Demcizumab + Pembrolizumab'}]",A Study of Demcizumab Plus Pembrolizumab +/- Chemotherapy,7379
0,NCT02758132,Phase I,Terminated,"[{'id': 4182, 'therapyName': 'Abiraterone + Denosumab + Enzalutamide + Prednisone'}, {'id': 4183, 'therapyName': 'Denosumab + Enzalutamide'}]","Denosumab Plus Enzalutamide, Abiraterone and Prednisone Compared to Denosumab Plus Enzalutamide Alone for Men With Castrate Resistant Prostate Cancer (CRPC) With Bone Metastases",7220
1,NCT01345019,Phase III,"Active, not recruiting","[{'id': 1198, 'therapyName': 'Denosumab'}, {'id': 2971, 'therapyName': 'Zoledronic acid'}]",Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma,7220
2,NCT01952054,Phase II,Recruiting,"[{'id': 1198, 'therapyName': 'Denosumab'}]",Denosumab for Breast Cancer With Bone Mets,7220
3,NCT00680992,Phase II,"Active, not recruiting","[{'id': 1198, 'therapyName': 'Denosumab'}]",Study of Denosumab in Subjects With Giant Cell Tumor of Bone,7220
4,NCT02833610,Phase II,Recruiting,"[{'id': 1198, 'therapyName': 'Denosumab'}]",A Study of Denosumab in Multiple Myeloma Patients With Renal Insufficiency,7220
5,NCT02366130,Phase II,Recruiting,"[{'id': 2001, 'therapyName': 'radium Ra 223 dichloride'}, {'id': 1198, 'therapyName': 'Denosumab'}]",Phase II Trial of Ra-223 Dichloride and Hormonal Treatment,7220
6,NCT03070002,Phase II,Recruiting,"[{'id': 1198, 'therapyName': 'Denosumab'}]","Denosumab in Treating Patients With ER and/or PR Positive, HER2 Negative Metastatic Breast Cancer With Bone Metastases and Detectable Circulating Tumor Cells",7220
7,NCT01545648,Phase II,"Active, not recruiting","[{'id': 1198, 'therapyName': 'Denosumab'}]",Pilot Study to Evaluate the Impact of Denosumab on Disseminated Tumor Cells (DTC) in Patients With Early Stage Breast Cancer,7220
8,NCT02470091,Phase II,Recruiting,"[{'id': 1198, 'therapyName': 'Denosumab'}]",Denosumab in Treating Patients With Recurrent or Refractory Osteosarcoma,7220
9,NCT02900469,Phase 0,Recruiting,"[{'id': 1198, 'therapyName': 'Denosumab'}]",Safety Study of Denosumab to Treat Breast Cancer,7220
10,NCT02721433,FDA approved,Recruiting,"[{'id': 4784, 'therapyName': 'Denosumab + pamidronate + Zoledronic acid'}]",4-weekly Versus 12-weekly Administration of Bone-targeted Agents in Patients With Bone Metastases (REaCT-BTA),7220
11,NCT01624766,Phase I,Recruiting,"[{'id': 1199, 'therapyName': 'Everolimus + Denosumab'}, {'id': 1192, 'therapyName': 'Anakinra + Everolimus'}]",Anakinra or Denosumab and Everolimus in Advanced Cancer,7220
0,NCT01471054,Phase II,Terminated,"[{'id': 1480, 'therapyName': 'Dexamethasone intravitreal implant'}, {'id': 667, 'therapyName': 'Bevacizumab'}]",Dexamethasone Intravitreal Implant for Treatment of Macular Edema After Plaque Radiotherapy of Uveal Melanoma,7271
0,NCT01711528,Phase I,"Active, not recruiting","[{'id': 3437, 'therapyName': 'Bortezomib + Dexamethasone + Dinaciclib'}]","Dinaciclib, Bortezomib, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma",6896
1,NCT01783171,Phase I,Completed,"[{'id': 2193, 'therapyName': 'Dinaciclib + MK2206'}]",Dinaciclib and Akt Inhibitor MK2206 in Treating Patients With Pancreatic Cancer That Cannot Be Removed By Surgery,6896
2,NCT02684617,Phase I,Recruiting,"[{'id': 4225, 'therapyName': 'Dinaciclib + Pembrolizumab'}]",Study of Pembrolizumab (MK-3475) in Combination With Dinaciclib (MK-7965) in Hematologic Malignancies  (MK-3475-155) (KEYNOTE-155),6896
3,NCT01676753,Phase Ib/II,Recruiting,"[{'id': 4225, 'therapyName': 'Dinaciclib + Pembrolizumab'}]",Phase 1b Dose De-escalation Trial of Dinaciclib With Pembrolizumab for Advanced Breast Cancer,6896
4,NCT01434316,Phase I,Recruiting,"[{'id': 1277, 'therapyName': 'Veliparib + Dinaciclib'}, {'id': 1278, 'therapyName': 'Veliparib + Dinaciclib + carboplatin'}]",Veliparib and Dinaciclib With or Without Carboplatin in Treating Patients With Advanced Solid Tumors,6896
0,NCT01767194,Phase II,Suspended,"[{'id': 2286, 'therapyName': 'Dinutuximab  '}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1462, 'therapyName': 'Temozolomide + Irinotecan'}]",Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Monoclonal Antibody Ch14.18 in Treating Younger Patients With Refractory or Relapsed Neuroblastoma,7480
1,NCT03126916,Phase III,Not yet recruiting,"[{'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1425, 'therapyName': '131I-MIBG'}, {'id': 1873, 'therapyName': 'Sargramostim'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 5595, 'therapyName': 'Isotretinoin'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 5153, 'therapyName': 'dexrazoxane'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1167, 'therapyName': 'Aldesleukin'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 2286, 'therapyName': 'Dinutuximab  '}]",Iobenguane I-131 or Crizotinib and Standard Therapy in Treating Younger Patients With Newly-Diagnosed High-Risk Neuroblastoma or Ganglioneuroblastoma,7480
0,NCT02013154,Phase I,Recruiting,"[{'id': 6254, 'therapyName': 'DKN-01 + Paclitaxel'}]",A Study of DKN-01 in Combination With Paclitaxel,8953
0,NCT02197169,Phase I,"Active, not recruiting","[{'id': 4407, 'therapyName': 'DNX-2401'}, {'id': 4444, 'therapyName': 'DNX-2401 + interferon gamma '}]",DNX-2401 With Interferon Gamma (IFN-gamma) for Recurrent Glioblastoma or Gliosarcoma Brain Tumors (TARGET-I),8443
1,NCT02798406,Phase II,Recruiting,"[{'id': 4408, 'therapyName': 'DNX-2401 + Pembrolizumab'}]",Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects (CAPTIVE),8443
0,NCT02913196,Phase I,Recruiting,"[{'id': 4767, 'therapyName': 'Abiraterone + ARN-509 + Docetaxel + Prednisone'}]","Phase I Trial of Apalutamide Plus Abiraterone Acetate, Docetaxel, and Prednisone in Patients With mCRPC",1235
1,NCT02560051,Phase II,Recruiting,"[{'id': 1814, 'therapyName': 'Degarelix'}, {'id': 3087, 'therapyName': 'Aldoxorubicin + Docetaxel + Estramustine + Ketoconazole'}]",Hormone Therapy Plus Chemotherapy as Initial Treatment for Local Failures or Advanced Prostate Cancer,1235
2,NCT03093272,Phase II,Recruiting,"[{'id': 795, 'therapyName': 'Leuprolide'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 5521, 'therapyName': 'ARN-509 + Docetaxel'}]",A Study of Docetaxel + ARN-509 in Castration-Resistant Prostate Cancer,1235
3,NCT03218826,Phase I,Not yet recruiting,"[{'id': 6046, 'therapyName': 'AZD8186 + Docetaxel'}]",PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery,1235
4,NCT01106872,Phase Ib/II,Completed,"[{'id': 1466, 'therapyName': 'Bevacizumab + Gemcitabine + Docetaxel + Valproic Acid '}]","Bevacizumab, Chemotherapy and Valproic Acid in Advanced Sarcomas",1235
5,NCT02922777,Phase I,Recruiting,"[{'id': 5973, 'therapyName': 'BGB-324 + Docetaxel'}]",Trial of Dose Escalated BGB324 in Previously Treated Non-small Cell Lung Cancer.,1235
6,NCT03070886,Phase III,Recruiting,"[{'id': 5450, 'therapyName': 'Bicalutamide + Docetaxel + Flutamide + Goserelin + Leuprolide + Nilutamide'}, {'id': 5449, 'therapyName': 'Bicalutamide + Flutamide + Goserelin + Leuprolide + Nilutamide'}]",Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery,1235
7,NCT03043807,Phase II,Recruiting,"[{'id': 3945, 'therapyName': 'Bicalutamide + Docetaxel + Leuprolide'}]",A Study of Definitive Therapy to Treat Prostate Cancer After Prostatectomy,1235
8,NCT02716974,Phase I,Recruiting,"[{'id': 3945, 'therapyName': 'Bicalutamide + Docetaxel + Leuprolide'}]",A Study of Definitive Therapy to Treat Prostate Cancer,1235
9,NCT02451865,Phase I,Withdrawn,"[{'id': 2740, 'therapyName': 'Binimetinib + Docetaxel'}]","Binimetinib With Docetaxel in Treating Patients With Previously Treated, Stage IV Non-small Cell Lung Cancer",1235
10,NCT01540253,Phase I,Completed,"[{'id': 1330, 'therapyName': 'BKM120 + Docetaxel'}]","PI3K Inhibitor BKM120 and Docetaxel in Treating Patients With Advanced Solid Tumor That is Locally Advanced, Cannot Be Removed By Surgery, or Metastatic",1235
11,NCT01683994,Phase I,"Active, not recruiting","[{'id': 2069, 'therapyName': 'cabozantinib + Docetaxel'}]",Cabozantinib Plus Docetaxel and Prednisone for Advanced Prostate Cancer,1235
12,NCT02358863,Phase I,Terminated,"[{'id': 4311, 'therapyName': 'Docetaxel + Irinotecan'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 1835, 'therapyName': 'Docetaxel + Cisplatin'}, {'id': 1406, 'therapyName': 'Camptosar + Cisplatin'}, {'id': 4310, 'therapyName': 'Epirubicin + Docetaxel'}, {'id': 4309, 'therapyName': 'Capecitabine + Docetaxel'}]",Molecularly Tailored Therapy for Patients With Metastatic Cancer of the Esophagus and Stomach (mEGA),1235
13,NCT02611960,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 4203, 'therapyName': 'Capecitabine + Docetaxel + Gemcitabine'}]","Study of Pembrolizumab (MK-3475) in Platinum Pre-treated Recurrent/Metastatic Nasopharyngeal Cancer (MK-3475-122, KEYNOTE-122)",1235
14,NCT02565901,Phase Ib/II,Recruiting,"[{'id': 3111, 'therapyName': 'Carboplatin + Docetaxel + Sirolimus '}]","Sirolimus, Docetaxel, and Carboplatin in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer",1235
15,NCT01588431,Phase II,"Active, not recruiting","[{'id': 1987, 'therapyName': 'Cisplatin + Docetaxel + Cetuximab'}, {'id': 667, 'therapyName': 'Bevacizumab'}]",Bevacizumab/Ph 2 for Locally Advanced Head and Neck Cancer,1235
16,NCT01437449,Phase II,"Active, not recruiting","[{'id': 1987, 'therapyName': 'Cisplatin + Docetaxel + Cetuximab'}, {'id': 1092, 'therapyName': 'Carboplatin'}]","Weekly Docetaxel, Cisplatin, and Cetuximab (TPC) in Palliative Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck (SCCHN)",1235
17,NCT01467115,Phase II,Completed,"[{'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 1930, 'therapyName': 'Cisplatin + Docetaxel + Fluorouracil'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 694, 'therapyName': 'Cetuximab'}]",INDUCTION CHEMOTHERAPY FOLLOWED BY CETUXIMAB AND RADIATION THERAPY FOR HEAD AND NECK CANCER,1235
18,NCT01914900,Phase II,Unknown status,"[{'id': 1930, 'therapyName': 'Cisplatin + Docetaxel + Fluorouracil'}]",Preoperative TPF Chemotherapy in a Population of Molecularly Selected Locally Advanced Resectable Oral Cavity Squamous Cell Cancer,1235
19,NCT03288350,Phase II,Not yet recruiting,"[{'id': 1930, 'therapyName': 'Cisplatin + Docetaxel + Fluorouracil'}, {'id': 3144, 'therapyName': 'Avelumab'}]",mDCF + Avelumab in Resectable Esophago-gastric Adenocarcinoma (EGA),1235
20,NCT02225405,Phase I,Recruiting,"[{'id': 2372, 'therapyName': 'Cisplatin + Docetaxel + Nintedanib'}]","Induction Study of Cisplatin, Docetaxel, and Nintedanib Stage IB-IIIA Non-Small Cell Lung Cancer (NCLC)",1235
21,NCT02998528,Phase III,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}, {'id': 5241, 'therapyName': 'Cisplatin + Vinorelbine + Gemcitabine + Docetaxel + Pemetrexed + Carboplatin'}]",A Neoadjuvant Study of Nivolumab and Ipilimumab Compared to Chemotherapy Doublet in Early Stage Non-Small Cell Lung Cancer (NSCLC) (CheckMate 816),1235
22,NCT01630733,Phase III,Recruiting,"[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 3648, 'therapyName': 'Custirsen + Docetaxel'}]","A Multinational, Randomized, Open-Label Study of Custirsen In Patients With Advanced or Metastatic (Stage IV) Non-Small Cell Lung Cancer",1235
23,NCT02132949,Phase II,"Active, not recruiting","[{'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}, {'id': 1495, 'therapyName': 'Paclitaxel + Doxorubicin + Cyclophosphamide'}, {'id': 1895, 'therapyName': 'Cyclophosphamide + Fluorouracil + Docetaxel + Epirubicin  '}]","A Study Evaluating Perjeta (Pertuzumab) Combined With Herceptin (Trastuzumab) and Standard Anthracycline-based Chemotherapy in Patients With HER2-positive Locally Advanced, Inflammatory, or Early-stage Breast Cancer.",1235
24,NCT02861573,Phase I,Recruiting,"[{'id': 5343, 'therapyName': 'Dexamethasone + Docetaxel + Pembrolizumab + Prednisone'}, {'id': 5342, 'therapyName': 'Olaparib + Pembrolizumab'}, {'id': 2666, 'therapyName': 'Enzalutamide + Pembrolizumab'}]",Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365),1235
25,NCT01472016,Phase I,Completed,"[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1063, 'therapyName': 'ABT-700'}, {'id': 694, 'therapyName': 'Cetuximab'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 1315, 'therapyName': 'FOLFIRI'}]",Study of ABT-700 in Subjects With Advanced Solid Tumors,1235
26,NCT02283320,Phase II,Completed,"[{'id': 720, 'therapyName': 'Docetaxel'}]",A Study of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension) as Second-line Therapy for Patients With KRAS Positive or Squamous Cell Non-Small Cell Lung Cancer,1235
27,NCT01810913,Phase II,"Active, not recruiting","[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1925, 'therapyName': 'Docetaxel + Cetuximab'}]","Radiation Therapy With Cisplatin, Docetaxel, or Cetuximab After Surgery in Treating Patients With Stage III-IV Squamous Cell Head and Neck Cancer",1235
28,NCT03137771,Phase II,Recruiting,"[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 4, 'therapyName': 'Erlotinib'}]",Maintenance Chemotherapy With or Without Stereotactic Body Radiation Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer,1235
29,NCT02494713,Phase II,Recruiting,"[{'id': 1814, 'therapyName': 'Degarelix'}, {'id': 2950, 'therapyName': 'Estramustine'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 2858, 'therapyName': 'Ketoconazole'}]",Hormonal Therapy and Chemotherapy Followed by Prostatectomy in Patients With Prostate Cancer,1235
30,NCT02117024,Phase II,"Active, not recruiting","[{'id': 2472, 'therapyName': 'HS-110 + Cyclophosphamide'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 1685, 'therapyName': 'Vinorelbine'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]",A Phase 2 Study of Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer,1235
31,NCT02387216,Phase II,Recruiting,"[{'id': 820, 'therapyName': 'Seribantumab'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 720, 'therapyName': 'Docetaxel'}]",A Study of MM-121 in Combination With Chemotherapy Versus Chemotherapy Alone in Heregulin Positive NSCLC,1235
32,NCT02605915,Phase I,Recruiting,"[{'id': 3250, 'therapyName': 'Atezolizumab + Trastuzumab'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 856, 'therapyName': 'Pertuzumab'}]",Safety and Pharmacokinetics of Atezolizumab in Combination With Trastuzumab Emtansine or With Trastuzumab and Pertuzumab in Participants With HER2-Positive Breast Cancer,1235
33,NCT01780545,Phase II,Completed,"[{'id': 1807, 'therapyName': 'OGX-427'}, {'id': 720, 'therapyName': 'Docetaxel'}]",Phase 2 Study of Docetaxel +/- OGX-427 in Patients With Relapsed or Refractory Metastatic Bladder Cancer,1235
34,NCT02009449,Phase I,"Active, not recruiting","[{'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 2621, 'therapyName': 'AM0010 '}, {'id': 619, 'therapyName': 'Abraxane'}]",A Phase 1 Study of AM0010 in Patients With Advanced Solid Tumors,1235
35,NCT02426125,Phase III,"Active, not recruiting","[{'id': 886, 'therapyName': 'Ramucirumab'}, {'id': 720, 'therapyName': 'Docetaxel'}]",A Study of Ramucirumab (LY3009806) Plus Docetaxel in Participants With Urothelial Cancer,1235
36,NCT02401542,Phase II,Recruiting,"[{'id': 2934, 'therapyName': 'B-701'}, {'id': 720, 'therapyName': 'Docetaxel'}]",A Phase 2 Study of B-701 in Treatment of Locally Advanced or Metastatic Urothelial Cell Carcinoma,1235
37,NCT02366494,Phase I,Recruiting,"[{'id': 795, 'therapyName': 'Leuprolide'}, {'id': 759, 'therapyName': 'Goserelin'}, {'id': 2050, 'therapyName': 'Triptorelin'}, {'id': 1507, 'therapyName': 'Bicalutamide'}, {'id': 720, 'therapyName': 'Docetaxel'}]",Micro RNAs to Predict Response to Androgen Deprivation Therapy,1235
38,NCT02252042,Phase III,"Active, not recruiting","[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 694, 'therapyName': 'Cetuximab'}, {'id': 720, 'therapyName': 'Docetaxel'}]",Pembrolizumab (MK-3475) Versus Standard Treatment for Recurrent or Metastatic Head and Neck Cancer (MK-3475-040/KEYNOTE-040),1235
39,NCT03056599,,Recruiting,"[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1299, 'therapyName': 'Interferon alfa-2b '}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1733, 'therapyName': 'interferon gamma '}, {'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 3420, 'therapyName': 'trabectedin'}, {'id': 1167, 'therapyName': 'Aldesleukin'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 720, 'therapyName': 'Docetaxel'}]",Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO™ Device in Soft Tissue Sarcoma,1235
40,NCT01641939,Phase III,Terminated,"[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1402, 'therapyName': 'trastuzumab emtansine'}]",A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer,1235
41,NCT02551055,Phase I,Terminated,"[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 626, 'therapyName': 'Alisertib'}, {'id': 3146, 'therapyName': 'TAK-659'}, {'id': 1033, 'therapyName': 'MLN1117'}]","MLN1117 in Combination With Docetaxel, Paclitaxel, and Other Investigational Anticancer Agents to Treat Participants With Gastric and Gastroesophageal Adenocarcinoma",1235
42,NCT01572038,Phase III,"Active, not recruiting","[{'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}, {'id': 619, 'therapyName': 'Abraxane'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]",A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) and A Taxane in First-Line Treatment in Patients With HER2-Positive Advanced Breast Cancer (PERUSE),1235
43,NCT01911325,Phase Ib/II,Terminated,"[{'id': 680, 'therapyName': 'BKM120'}, {'id': 720, 'therapyName': 'Docetaxel'}]",Phase II Study of Buparlisib + Docetaxel in Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) Patients,1235
44,NCT02105636,Phase III,"Active, not recruiting","[{'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 694, 'therapyName': 'Cetuximab'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1312, 'therapyName': 'Nivolumab'}]",Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Head and Neck Carcinoma (CheckMate 141),1235
45,NCT02257619,Phase II,Terminated,"[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 2406, 'therapyName': 'INCB039110'}]",Study of INCB039110 in Combination With Docetaxel in Subjects With Non-Small Cell Lung Cancer,1235
46,NCT02057107,Phase II,Recruiting,"[{'id': 694, 'therapyName': 'Cetuximab'}, {'id': 720, 'therapyName': 'Docetaxel'}]","Stereotactic Body Radiation Therapy (SBRT) With Cetuximab +/- Docetaxel Followed by Adjuvant Cetuximab +/- Docetaxel in Recurrent, Previously-Irradiated Squamous Cell Carcinoma of the Head and Neck (SCCHN)",1235
47,NCT02229149,Phase II,"Active, not recruiting","[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}, {'id': 619, 'therapyName': 'Abraxane'}, {'id': 1685, 'therapyName': 'Vinorelbine'}, {'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 1105, 'therapyName': 'Capecitabine'}]","Phase 2 Study of Standard Chemotherapy With Trastuzumab, Plus or Minus Pertuzumab, for Pre-treated Metastatic Breast Cancer",1235
48,NCT01708993,Phase II,Completed,"[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 1110, 'therapyName': 'Reolysin + Pemetrexed'}, {'id': 1111, 'therapyName': 'Reolysin + Docetaxel'}]"," Reolysin in Patients With Previously Treated Advanced or Metastatic, Non Small Cell Lung Cancer Receiving Standard Salvage Therapy",1235
49,NCT01792050,Phase II,"Active, not recruiting","[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 2976, 'therapyName': 'indoximod'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]",Study of Chemotherapy in Combination With IDO Inhibitor in Metastatic Breast Cancer,1235
50,NCT02182622,Phase I,Unknown status,"[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1428, 'therapyName': 'Sonidegib'}]",LDE225 + Docetaxel/Prednisone for Adv/Met Castrate Resistant Prostate Cancer w/ Disease Progression After Docetaxel,1235
51,NCT01750281,Phase II,"Active, not recruiting","[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1117, 'therapyName': 'Selumetinib + Docetaxel'}]",Assess Efficacy and Safety of AZD6244 in Combination With Docetaxel in Patients Receiving Second Line Non Small Cell Lung Cancer Treatment.,1235
52,NCT01798485,Phase III,Terminated,"[{'id': 745, 'therapyName': 'Ganetespib'}, {'id': 720, 'therapyName': 'Docetaxel'}]",A Phase 3 Study of Ganetespib in Combination With Docetaxel Versus Docetaxel Alone in Patients With Advanced NSCLC,1235
53,NCT01783587,Phase I,Recruiting,"[{'id': 623, 'therapyName': 'Afatinib'}, {'id': 720, 'therapyName': 'Docetaxel'}]",Safety Study of Afatinib and Postoperative Radiation Therapy to Treat Head and Neck Cancer,1235
54,NCT01646125,,Terminated,"[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 647, 'therapyName': 'AUY922'}, {'id': 854, 'therapyName': 'Pemetrexed'}]"," An Open-label, Randomized Phase II Study to Evaluate the Efficacy of AUY922 vs Pemetrexed or Docetaxel in NSCLC Patients With EGFR Mutations",1235
55,NCT02154490,Phase II,Recruiting,"[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 850, 'therapyName': 'Palbociclib'}, {'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 654, 'therapyName': 'AZD4547'}, {'id': 1016, 'therapyName': 'GDC-0032'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 629, 'therapyName': 'AMG102'}]",Lung-MAP: S1400 Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IIIB-IV Squamous Cell Lung Cancer,1235
56,NCT01879085,Phase Ib/II,Recruiting,"[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1476, 'therapyName': 'Pegfilgrastim'}, {'id': 1077, 'therapyName': 'Vorinostat'}]",Phase 1b/2 Study of Vorinostat in Combination With Gemcitabine and Docetaxel in Advanced Sarcoma,1235
57,NCT01779050,Phase II,"Active, not recruiting","[{'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1087, 'therapyName': 'Epirubicin + Cyclophosphamide'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1982, 'therapyName': 'Fluorouracil + Epirubicin + Cyclophosphamide'}, {'id': 1834, 'therapyName': 'Docetaxel + Carboplatin'}, {'id': 1881, 'therapyName': 'Docetaxel + Cyclophosphamide'}]",Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer Patients With ERBB2 Expressing Disseminated Tumor Cells,1235
58,NCT01064479,Phase II,"Active, not recruiting","[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 700, 'therapyName': 'Cisplatin'}]",Docetaxel And Cisplatin With or Without Erlotinib For Metastatic Or Recurrent Squamous Cell Carcinoma Of Head And Neck,1235
59,NCT02437370,Phase I,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 720, 'therapyName': 'Docetaxel'}]",Pembrolizumab and Docetaxel or Gemcitabine Hydrochloride in Treating Patients Urothelial Cancer,1235
60,NCT02122770,Phase I,"Active, not recruiting","[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1026, 'therapyName': 'Itraconazole'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1688, 'therapyName': 'MLN4924'}, {'id': 1689, 'therapyName': 'Fluconazole'}]","Effects of Fluconazole and Itraconazole CYP3A-Mediated Inhibition on the Pharmacokinetics, Safety, and Tolerability of MLN4924 in Patients With Advanced Solid Tumors",1235
61,NCT01362374,Phase I,"Active, not recruiting","[{'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 747, 'therapyName': 'Ipatasertib'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}]","Safety and Pharmacology Of GDC-0068 in Combination With Docetaxel, Fluoropyrimidine Plus Oxaliplatin, Paclitaxel, or Enzalutamide in Patients With Advanced Solid Tumors",1235
62,NCT02231164,Phase III,Terminated,"[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 831, 'therapyName': 'Nintedanib'}]",LUME-Columbus: Nintedanib Plus Docetaxel in Advanced Non-small Cell Lung Cancer With Translational Research,1235
63,NCT01828112,Phase III,"Active, not recruiting","[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 789, 'therapyName': 'Ceritinib'}]",LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib,1235
64,NCT01927744,Phase II,Recruiting,"[{'id': 2474, 'therapyName': 'Erlotinib + Docetaxel'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1092, 'therapyName': 'Carboplatin'}]","Study of Chemotherapy With Cisplatin/CarboplatinAstellas Pharma Inc, OSI Pharmaceuticals, Kadoorie Foundation, and Docetaxel With or Without Erlotinib in Patients With Head and Neck Squamous Cell Carcinomas Amenable for Surgical Resection",1235
65,NCT01868022,Phase I,"Active, not recruiting","[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1857, 'therapyName': 'Cisplatin + Pemetrexed'}, {'id': 2899, 'therapyName': 'GSK3052230'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]","Study to Evaluate GSK3052230 in Combination With Paclitaxel and Carboplatin, or Docetaxel or as Single Agent in Subjects With Solid Malignancies and Deregulated Fibroblast Growth Factor (FGF) Pathway Signaling",1235
66,NCT02504489,Phase III,Recruiting,"[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 3679, 'therapyName': 'Docetaxel + Plinabulin'}]",Plinabulin (P) + Docetaxel (D) vs D as 2nd-Line Chemo in Patients With Advanced NSCLC With at Least 1 Large Lung Lesion,1235
67,NCT02331251,Phase Ib/II,"Active, not recruiting","[{'id': 1685, 'therapyName': 'Vinorelbine'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 619, 'therapyName': 'Abraxane'}]",Study of Pembrolizumab Plus Chemotherapy in Patients With Advanced Cancer (PembroPlus),1235
68,NCT02008227,Phase III,"Active, not recruiting","[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1201, 'therapyName': 'Atezolizumab'}]",A Randomized Phase 3 Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) Compared to Docetaxel in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum Therapy - OAK,1235
69,NCT02302807,Phase III,"Active, not recruiting","[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1685, 'therapyName': 'Vinorelbine'}, {'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 720, 'therapyName': 'Docetaxel'}]",A Study of MPDL3280A Compared With Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer,1235
70,NCT01633541,Phase II,Recruiting,"[{'id': 644, 'therapyName': 'AT-101'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 720, 'therapyName': 'Docetaxel'}]",Chemotherapy AND Bcl-xL Inhibitor (AT-101) For Organ Preservation In Adults With Advanced Laryngeal Cancer,1235
71,NCT02395172,Phase III,"Active, not recruiting","[{'id': 3144, 'therapyName': 'Avelumab'}, {'id': 720, 'therapyName': 'Docetaxel'}]",Avelumab in Non-Small Cell Lung Cancer (JAVELIN Lung 200),1235
72,NCT02508246,Phase I,Recruiting,"[{'id': 822, 'therapyName': 'MK-1775'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 700, 'therapyName': 'Cisplatin'}]","AZD1775, Docetaxel, and Cisplatin Before Surgery in Treating Patients With Borderline Resectable Stage III-IVB Squamous Cell Carcinoma of the Head and Neck",1235
73,NCT02599324,Phase Ib/II,Recruiting,"[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 768, 'therapyName': 'Ibrutinib'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 694, 'therapyName': 'Cetuximab'}]",A Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors,1235
74,NCT02450539,Phase II,"Active, not recruiting","[{'id': 802, 'therapyName': 'Abemaciclib'}, {'id': 720, 'therapyName': 'Docetaxel'}]",A Study of Abemaciclib (LY2835219) in Participants With Stage IV Squamous Non-small Cell Lung Cancer,1235
75,NCT02536495,Phase Ib/II,Withdrawn,"[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1749, 'therapyName': 'Selinexor'}]",Selinexor and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Lung Cancer,1235
76,NCT02322281,Phase III,"Active, not recruiting","[{'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1003, 'therapyName': 'CO1686'}]","TIGER-3 Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet Chemotherapy",1235
77,NCT02574078,Phase I,Recruiting,"[{'id': 619, 'therapyName': 'Abraxane'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 2114, 'therapyName': 'Bevacizumab + Pemetrexed'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 1092, 'therapyName': 'Carboplatin'}]",A Master Protocol Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC) (CheckMate 370),1235
78,NCT02788201,Phase II,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1133, 'therapyName': 'Mitomycin C'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1013, 'therapyName': 'epirubicin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1137, 'therapyName': 'Bleomycin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 781, 'therapyName': 'Ixabepilone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 2950, 'therapyName': 'Estramustine'}, {'id': 1941, 'therapyName': 'Floxuridine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 1811, 'therapyName': 'Carmustine'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 953, 'therapyName': 'Vandetanib'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 4419, 'therapyName': 'Toremifine'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 2601, 'therapyName': 'Dactinomycin'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 3035, 'therapyName': 'Chlorambucil'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 342, 'therapyName': 'Vemurafenib'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 2635, 'therapyName': 'Vinblastine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 4305, 'therapyName': 'Teniposide'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 4304, 'therapyName': 'Streptozocin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1231, 'therapyName': 'Bendamustine'}, {'id': 4303, 'therapyName': 'Mechlorethamine'}, {'id': 4302, 'therapyName': 'Mitotane'}]",Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma,1235
79,NCT03041181,Phase II,Recruiting,"[{'id': 5288, 'therapyName': 'Docetaxel + Nivolumab'}, {'id': 720, 'therapyName': 'Docetaxel'}]",Docetaxel Plus Nivolumab or Docetaxel Alone in Patients With Advanced Non-squamous NSCLC Previously Treated With Nivolumab,1235
80,NCT00588770,Phase III,"Active, not recruiting","[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1835, 'therapyName': 'Docetaxel + Cisplatin'}, {'id': 1833, 'therapyName': 'Cisplatin + Fluorouracil'}, {'id': 1834, 'therapyName': 'Docetaxel + Carboplatin'}, {'id': 1832, 'therapyName': 'Carboplatin + Fluorouracil\t'}]",Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer,1235
81,NCT02128906,Phase II,Recruiting,"[{'id': 1925, 'therapyName': 'Docetaxel + Cetuximab'}, {'id': 700, 'therapyName': 'Cisplatin'}]",Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC,1235
82,NCT01794845,Phase II,Terminated,"[{'id': 1925, 'therapyName': 'Docetaxel + Cetuximab'}]",Phase II Trial Using Erbitux+ Taxotere With Low Dose Fractionated Radiation for Recurrent Unresectable Locally Advanced Head and Neck Carcinoma,1235
83,NCT01275677,Phase III,"Active, not recruiting","[{'id': 1503, 'therapyName': 'Paclitaxel + Trastuzumab + Doxorubicin + Cyclophosphamide'}, {'id': 1881, 'therapyName': 'Docetaxel + Cyclophosphamide'}, {'id': 1882, 'therapyName': 'Docetaxel + Cyclophosphamide + Trastuzumab'}, {'id': 1495, 'therapyName': 'Paclitaxel + Doxorubicin + Cyclophosphamide'}]",Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,1235
84,NCT01501487,FDA approved,"Active, not recruiting","[{'id': 1902, 'therapyName': 'Docetaxel + Doxorubicin + Cyclophosphamide'}, {'id': 1982, 'therapyName': 'Fluorouracil + Epirubicin + Cyclophosphamide'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1476, 'therapyName': 'Pegfilgrastim'}, {'id': 1881, 'therapyName': 'Docetaxel + Cyclophosphamide'}, {'id': 1977, 'therapyName': 'Doxorubicin + Cyclophosphamide'}, {'id': 1485, 'therapyName': 'Trastuzumab + Docetaxel + Carboplatin'}, {'id': 1978, 'therapyName': 'Pertuzumab + Trastuzumab + Docetaxel'}]",MINT I Multi- Institutional Neo-adjuvant Therapy MammaPrint Project I,1235
85,NCT03211117,Phase II,Recruiting,"[{'id': 6040, 'therapyName': 'Docetaxel + Doxorubicin + Pembrolizumab'}]","Pembrolizumab, Chemotherapy, and Radiation Therapy With or Without Surgery in Treating Patients With Anaplastic Thyroid Cancer",1235
86,NCT02685267,Phase II,"Active, not recruiting","[{'id': 4681, 'therapyName': 'Docetaxel + Enzalutamide + Prednisone'}, {'id': 2462, 'therapyName': 'Docetaxel + Prednisone'}]",Docetaxel/Prednisone Versus Docetaxel/Prednisone and Enzalutamide in Castration-Resistant Prostate Cancer (Doce/Enza),1235
87,NCT02494921,Phase Ib/II,Recruiting,"[{'id': 3113, 'therapyName': 'Docetaxel + Filgrastim + Prednisone + Ribociclib'}]",LEE011 (Ribociclib) in Combination With Docetaxel Plus Prednisone in mCRPC,1235
88,NCT01862081,Phase I,Completed,"[{'id': 2321, 'therapyName': 'Docetaxel + GDC-0032 '}, {'id': 2322, 'therapyName': 'GDC-0032 + Paclitaxel'}]","A Dose-Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of GDC-0032 in Combination With Docetaxel or With Paclitaxel in Patients With HER2-negative Locally Recurrent or Metastatic Breast Cancer",1235
89,NCT00936936,Phase II,Recruiting,"[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 2101, 'therapyName': 'Etoposide + Ifosfamide'}, {'id': 2100, 'therapyName': 'Docetaxel + Gemcitabine + Melphalan'}, {'id': 2074, 'therapyName': 'Bevacizumab + Carboplatin'}]",High-dose Chemotherapy for Poor-prognosis Relapsed Germ-Cell Tumors,1235
90,NCT02393248,Phase Ib/II,Recruiting,"[{'id': 4176, 'therapyName': 'Cisplatin + Gemcitabine + INCB054828'}, {'id': 4174, 'therapyName': 'Docetaxel + INCB054828'}, {'id': 4088, 'therapyName': 'Epacadostat + Pembrolizumab'}]","Open-Label, Dose-Escalation Study of INCB054828 in Subjects With Advanced Malignancies",1235
91,NCT02460367,Phase Ib/II,Recruiting,"[{'id': 3578, 'therapyName': 'Docetaxel + Indoximod'}]",Immunotherapy Combination Study in Advanced Previously Treated Non-Small Cell Lung Cancer,1235
92,NCT01822613,Phase Ib/II,Completed,"[{'id': 2282, 'therapyName': 'Docetaxel + Irinotecan + Paclitaxel'}, {'id': 2283, 'therapyName': 'BYL719 + LJM716'}]",Study of Safety and Efficacy of the Combination of LJM716 and BYL719 in Patients With Previously Treated Esophageal Squamous Cell Carcinoma (ESCC),1235
93,NCT02564263,Phase III,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 2282, 'therapyName': 'Docetaxel + Irinotecan + Paclitaxel'}]",Study of Pembrolizumab (MK-3475) Versus Investigator's Choice Standard Therapy for Participants With Advanced Esophageal/Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181),1235
94,NCT01935947,Phase II,Terminated,"[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 2645, 'therapyName': 'Azacitidine + Entinostat'}, {'id': 2646, 'therapyName': 'Docetaxel + Irinotecan + Pemetrexed '}]",Azacitidine and Entinostat Before Chemotherapy in Treating Patients With Advanced Non-small Cell Lung Cancer,1235
95,NCT02834403,Phase Ib/II,Recruiting,"[{'id': 1476, 'therapyName': 'Pegfilgrastim'}, {'id': 6123, 'therapyName': 'Docetaxel + L-NMMA'}, {'id': 6096, 'therapyName': 'L-NMMA'}]",L-NMMA Plus Docetaxel in Refractory Locally Advanced or Metastatic Triple Negative Breast Cancer Patients,1235
96,NCT01837667,Phase I,Completed,"[{'id': 3683, 'therapyName': 'Docetaxel + LB-100'}]",Phase I Study of LB-100 With Docetaxel in Solid Tumors,1235
97,NCT03228186,Phase II,Not yet recruiting,"[{'id': 6033, 'therapyName': 'Docetaxel + MLN4924'}]",Trial of Pevonedistat Plus Docetaxel in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer,1235
98,NCT02799602,Phase III,Recruiting,"[{'id': 836, 'therapyName': 'ODM-201'}, {'id': 4921, 'therapyName': 'Docetaxel + ODM-201'}]",ODM-201 in Addition to Standard ADT and Docetaxel in Metastatic Castration Sensitive Prostate Cancer (ARASENS),1235
99,NCT02569242,Phase III,"Active, not recruiting","[{'id': 3045, 'therapyName': 'Docetaxel + Paclitaxel'}, {'id': 1312, 'therapyName': 'Nivolumab'}]",Study of Nivolumab in Unresectable Advanced or Recurrent Esophageal Cancer,1235
100,NCT00565851,Phase III,"Active, not recruiting","[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 3045, 'therapyName': 'Docetaxel + Paclitaxel'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 667, 'therapyName': 'Bevacizumab'}]","Carboplatin, Paclitaxel and Gemcitabine With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer",1235
101,NCT01385228,Phase I,Completed,"[{'id': 2042, 'therapyName': 'Docetaxel + Pazopanib + Pegfilgrastim'}]","Pazopanib, Docetaxel, Prednisone Prostate",1235
102,NCT03083808,Phase II,Recruiting,"[{'id': 5497, 'therapyName': 'Pembrolizumab + Gemcitabine'}, {'id': 5496, 'therapyName': 'Docetaxel + Pembrolizumab'}, {'id': 5498, 'therapyName': 'Pemetrexed + Pembrolizumab'}, {'id': 854, 'therapyName': 'Pemetrexed'}]",Phase II Trial of Continuation Therapy in Advanced NSCLC,1235
103,NCT02654587,Phase III,"Active, not recruiting","[{'id': 4327, 'therapyName': 'OSE 2101 '}, {'id': 4328, 'therapyName': 'Docetaxel + Pemetrexed'}]",Study of OSE2101 Versus Standard Treatment as 2nd or 3rd Line in HLA-A2 Positive Patients With Advanced NSCLC (ATALANTE 1),1235
104,NCT01619813,Phase II,Completed,"[{'id': 2462, 'therapyName': 'Docetaxel + Prednisone'}, {'id': 893, 'therapyName': 'Reolysin'}]",Reolysin Combined With Docetaxel and Prednisone or Docetaxel and Prednisone Alone in Metastatic Castration Resistant Prostate Cancer,1235
105,NCT03095612,Phase Ib/II,Not yet recruiting,"[{'id': 5534, 'therapyName': 'Docetaxel + Selinexor'}]",Phase 1/2 Trial of Selinexor (KPT-330) With Docetaxel for Non-small Cell Lung Cancer (NSCLC),1235
106,NCT02793219,Phase II,Not yet recruiting,"[{'id': 4270, 'therapyName': 'Docetaxel + Sipuleucel-T'}]",Provenge Followed by Docetaxel in Castration-Resistant Prostate Cancer,1235
107,NCT02793765,Phase II,Not yet recruiting,"[{'id': 4270, 'therapyName': 'Docetaxel + Sipuleucel-T'}]",Docetaxel Followed by Provenge in Metastatic Prostate Cancer,1235
108,NCT00589420,Phase II,Unknown status,"[{'id': 2390, 'therapyName': 'Docetaxel + Sorafenib'}]",Sorafenib and Docetaxel in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Previous Hormone Therapy,1235
109,NCT00781612,Phase II,Recruiting,"[{'id': 5471, 'therapyName': 'Trastuzumab + trastuzumab emtansine'}, {'id': 5470, 'therapyName': 'Paclitaxel + trastuzumab emtansine'}, {'id': 1402, 'therapyName': 'trastuzumab emtansine'}, {'id': 3930, 'therapyName': 'Docetaxel + T-DM1'}, {'id': 1976, 'therapyName': 'trastuzumab emtansine + Capecitabine'}, {'id': 1492, 'therapyName': 'T-DM1 + Pertuzumab'}]",A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies,1235
110,NCT01376310,Phase II,"Active, not recruiting","[{'id': 1264, 'therapyName': 'Docetaxel + Trametinib'}, {'id': 1265, 'therapyName': 'Erlotinib + Trametinib'}, {'id': 2, 'therapyName': 'Trametinib'}, {'id': 1266, 'therapyName': 'Pemetrexed + GSK1120212'}, {'id': 1267, 'therapyName': 'Carboplatin + GSK1120212'}, {'id': 1268, 'therapyName': 'nab-paclitaxel + GSK1120212'}, {'id': 1269, 'therapyName': 'Gemcitabine + GSK1120212'}, {'id': 1271, 'therapyName': 'Everolimus + GSK1120212'}]",GSK1120212 Rollover Study,1235
111,NCT02642042,Phase II,Recruiting,"[{'id': 1264, 'therapyName': 'Docetaxel + Trametinib'}]",Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV Non-small Cell Lung Cancer,1235
112,NCT01957007,Phase I,Completed,"[{'id': 4413, 'therapyName': 'Docetaxel + Vantictumab'}]",A Study of Vantictumab (OMP-18R5) in Combination With Docetaxel in Patients With Previously Treated NSCLC,1235
113,NCT02213289,Phase Ib/II,Recruiting,"[{'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 1913, 'therapyName': 'FOLTAX'}, {'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 1315, 'therapyName': 'FOLFIRI'}, {'id': 629, 'therapyName': 'AMG102'}]",PANGEA-IMBBP: Personalized Antibodies for Gastro-Esophageal Adenocarcinoma - A 1st Pilot Metastatic Trial of Biologics Beyond Progression,1235
114,NCT02049905,Phase III,Completed,"[{'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1440, 'therapyName': 'Aldoxorubicin'}, {'id': 1439, 'therapyName': 'Gemcitabine + Docetaxel'}]",Phase 3 Study to Treat Patients With Soft Tissue Sarcomas,1235
115,NCT01593748,Phase II,"Active, not recruiting","[{'id': 1439, 'therapyName': 'Gemcitabine + Docetaxel'}, {'id': 1478, 'therapyName': 'Gemcitabine + Pazopanib'}]",A Treatment Trial Comparing Gemcitabine and Pazopanib Versus Gemcitabine and Docetaxel for Patients With Advanced Soft Tissue Sarcoma,1235
116,NCT02659020,Phase Ib/II,Recruiting,"[{'id': 3269, 'therapyName': 'Olaratumab'}, {'id': 1439, 'therapyName': 'Gemcitabine + Docetaxel'}]",A Study of Olaratumab (LY3012207) in Participants With Advanced Soft Tissue Sarcoma,1235
117,NCT02511132,Phase II,"Active, not recruiting","[{'id': 1157, 'therapyName': 'FANG vaccine'}, {'id': 1439, 'therapyName': 'Gemcitabine + Docetaxel'}]",Randomized Phase IIb Trial of Vigil Versus Gemcitabine + Docetaxel for Ewing's Sarcoma,1235
118,NCT02045446,Phase II,"Active, not recruiting","[{'id': 1146, 'therapyName': 'Bevacizumab + Erlotinib'}, {'id': 1439, 'therapyName': 'Gemcitabine + Docetaxel'}]",Maintenance Chemotherapy Versus Consolidative Stereotactic Body Radiation Therapy (SBRT) Plus Maintenance Chemotherapy for Stage IV Non-Small Cell Lung Cancer (NSCLC),1235
119,NCT01719302,Phase Ib/II,Completed,"[{'id': 1470, 'therapyName': 'Gemcitabine + Docetaxel + Pazopanib'}]","Docetaxel, Gemcitabine and Pazopanib as Treatment for Soft Tissue Sarcoma",1235
120,NCT01418001,Phase Ib/II,Terminated,"[{'id': 1470, 'therapyName': 'Gemcitabine + Docetaxel + Pazopanib'}]",Gemcitabine and Docetaxel in Combination With Pazopanib (Gem/Doce/Pzb) for the Neoadjuvant Treatment of Soft Tissue Sarcoma (STS),1235
121,NCT00790816,Phase I,Completed,"[{'id': 1410, 'therapyName': 'Lapatinib + Paclitaxel'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 1414, 'therapyName': 'Trastuzumab + Lapatinib'}, {'id': 1399, 'therapyName': 'Lapatinib + Capecitabine'}, {'id': 1497, 'therapyName': 'Lapatinib + Letrozole'}, {'id': 1498, 'therapyName': 'Lapatinib + Oxaliplatin + Capecitabine'}, {'id': 1499, 'therapyName': 'Lapatinib + Gemcitabine'}, {'id': 1500, 'therapyName': 'Lapatinib + Docetaxel'}, {'id': 1501, 'therapyName': 'Lapatinib + Oxaliplatin + Leucovorin + Fluorouracil'}, {'id': 1502, 'therapyName': 'Lapatinib + Irinotecan + Leucovorin + Fluorouracil'}]",Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents,1235
122,NCT03238495,Phase II,Recruiting,"[{'id': 1879, 'therapyName': 'Pertuzumab + Trastuzumab + Carboplatin + Docetaxel'}, {'id': 6101, 'therapyName': 'Metformin + Pertuzumab + Trastuzumab + Carboplatin + Docetaxel'}]",Randomized Trial of Neo-adjuvant Chemotherapy With or Without Metformin for HER2 Positive Operable Breast Cancer,1235
123,NCT00975767,Phase Ib/II,Terminated,"[{'id': 1127, 'therapyName': 'MGCD265 + Docetaxel'}, {'id': 1126, 'therapyName': 'MGCD265 + Erlotinib'}]",A Study of MGCD265 Given With Erlotinib or Docetaxel in Subjects With Advanced Malignancies or Non-Small Cell Lung Cancer,1235
124,NCT02122185,Phase II,Recruiting,"[{'id': 1031, 'therapyName': 'Metformin'}, {'id': 1827, 'therapyName': 'Paclitaxel + Carboplatin + Docetaxel'}]","Metformin Hydrochloride and Combination Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",1235
125,NCT02003209,Phase III,"Active, not recruiting","[{'id': 759, 'therapyName': 'Goserelin'}, {'id': 1879, 'therapyName': 'Pertuzumab + Trastuzumab + Carboplatin + Docetaxel'}]","Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer",1235
126,NCT02131064,Phase III,"Active, not recruiting","[{'id': 1492, 'therapyName': 'T-DM1 + Pertuzumab'}, {'id': 1879, 'therapyName': 'Pertuzumab + Trastuzumab + Carboplatin + Docetaxel'}]",A Study Comparing Kadcyla Plus Perjeta Treatment to Chemotherapy Combined With Herceptin Plus Perjeta in Patients With HER2-Positive Breast Cancer,1235
127,NCT01966471,Phase III,"Active, not recruiting","[{'id': 1492, 'therapyName': 'T-DM1 + Pertuzumab'}, {'id': 1978, 'therapyName': 'Pertuzumab + Trastuzumab + Docetaxel'}, {'id': 1549, 'therapyName': 'Pertuzumab + Trastuzumab + Paclitaxel'}]",A Study of Kadcyla (Trastuzumab Emtansine) Plus Perjeta (Pertuzumab) Following Anthracyclines in Comparison With Herceptin (Trastuzumab) Plus Perjeta and a Taxane Following Anthracyclines as Adjuvant Therapy in Patients With Operable HER2-Positive Primary Breast Cancer,1235
128,NCT02345772,Phase I,Terminated,"[{'id': 744, 'therapyName': 'Fulvestrant'}, {'id': 1978, 'therapyName': 'Pertuzumab + Trastuzumab + Docetaxel'}]","Neoadjuvant Hormonal Therapy Combined With Chemoimmunotherapy (Taxotere, Trastuzumab and Pertuzumab) in Patients With HER2-positive and ER-Positive Breast Cancer",1235
129,NCT02379585,Phase Ib/II,Terminated,"[{'id': 1495, 'therapyName': 'Paclitaxel + Doxorubicin + Cyclophosphamide'}, {'id': 1978, 'therapyName': 'Pertuzumab + Trastuzumab + Docetaxel'}]",Study of Short-term Fasting on Neoadjuvant Chemotherapy in Patients With Newly Diagnosed Breast Cancer,1235
130,NCT02402712,Phase III,"Active, not recruiting","[{'id': 1978, 'therapyName': 'Pertuzumab + Trastuzumab + Docetaxel'}]",Phase IIIb Study to Evaluate the Safety and Tolerability of Herceptin SC With Perjeta and Docetaxel in Patients With HER2-positive Advanced Breast Cancer,1235
131,NCT01876251,,Terminated,"[{'id': 1115, 'therapyName': 'PF-03084014 + Docetaxel'}]", A Study Evaluating The PF-03084014 In Combination With Docetaxel In Patients With Advanced Breast Cancer,1235
132,NCT01920061,Phase I,Recruiting,"[{'id': 1287, 'therapyName': 'PF-05212384 + Dacomitinib'}, {'id': 1286, 'therapyName': 'PF-05212384 + Cisplatin'}, {'id': 1285, 'therapyName': 'PF-05212384 + Docetaxel'}]",A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents,1235
133,NCT02831491,Phase II,Withdrawn,"[{'id': 1423, 'therapyName': 'Ramucirumab + Docetaxel'}]",A Study of Ramucirumab (LY3009806) in Combination With Weekly Docetaxel in Participants With Stage IV Non-Small Cell Lung Cancer,1235
134,NCT02383212,Phase I,"Active, not recruiting","[{'id': 5722, 'therapyName': 'REGN2810 + Carboplatin + Docetaxel'}, {'id': 5721, 'therapyName': 'REGN2810 + Carboplatin + Pemetrexed'}, {'id': 5723, 'therapyName': 'REGN2810 + GM-CSF + Cyclophosphamide'}, {'id': 5718, 'therapyName': 'REGN2810 + Cyclophosphamide'}, {'id': 5656, 'therapyName': 'REGN2810'}, {'id': 5720, 'therapyName': 'REGN2810 + Carboplatin + Paclitaxel'}, {'id': 5719, 'therapyName': 'REGN2810 + Docetaxel'}]",Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies,1235
135,NCT02179671,Phase II,Completed,"[{'id': 1117, 'therapyName': 'Selumetinib + Docetaxel'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 660, 'therapyName': 'AZD9291'}, {'id': 1652, 'therapyName': 'Tremelimumab'}]","Immune-Modulated Study of Selected Small Molecules (Gefitinib, AZD9291, or Selumetinib + Docetaxel) or a 1st Immune-Mediated Therapy (IMT; Tremelimumab) With a Sequential Switch to a 2nd IMT (MEDI4736) in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer",1235
136,NCT01933932,Phase III,"Active, not recruiting","[{'id': 1117, 'therapyName': 'Selumetinib + Docetaxel'}]",Assess Efficacy and Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC,1235
137,NCT02035527,Phase Ib/II,"Active, not recruiting","[{'id': 2431, 'therapyName': 'Sorafenib + Cisplatin + Docetaxel'}]","Sorafenib Tosylate, Cisplatin, and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck",1235
138,NCT01959490,Phase II,Completed,"[{'id': 1486, 'therapyName': 'Bevacizumab + Doxorubicin + Cyclophosphamide + Paclitaxel '}, {'id': 1485, 'therapyName': 'Trastuzumab + Docetaxel + Carboplatin'}]",Trastuzumab or Bevacizumab With Combination Chemotherapy in Treating Patients With Stage II-III Breast Cancer,1235
139,NCT02187744,Phase III,Completed,"[{'id': 1485, 'therapyName': 'Trastuzumab + Docetaxel + Carboplatin'}]",A Study Of PF-05280014 Or Trastuzumab Plus Taxotere&#174; And Carboplatin In HER2 Positive Breast Cancer In The Neoadjuvant Setting (REFLECTIONS B327-04),1235
140,NCT02146222,Phase I,"Active, not recruiting","[{'id': 1442, 'therapyName': 'X-82 + Docetaxel'}]",VEGFR/PDGFR Dual Kinase Inhibitor X-82 and Docetaxel in Treating Patients With Solid Tumors,1235
0,NCT01455389,Phase Ib/II,Recruiting,"[{'id': 1313, 'therapyName': 'DOTAP:chol-Fus1'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 1275, 'therapyName': 'Diphenhydramine'}, {'id': 1390, 'therapyName': 'Dexamethasone'}]",FUS1-nanoparticles and Erlotinib in Stage IV Lung Cancer,7236
0,NCT01769547,Phase II,Terminated,"[{'id': 721, 'therapyName': 'Dovitinib'}]",A Phase II Study of Single-agent DOVitinib in Advanced Malignant PlEural Mesothelioma Which Has Progressed Following Prior Platinum-Antifolate Chemotherapy,6897
1,NCT01831726,Phase II,Completed,"[{'id': 721, 'therapyName': 'Dovitinib'}]",Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib,6897
2,NCT01497392,Phase I,Completed,"[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 721, 'therapyName': 'Dovitinib'}, {'id': 1105, 'therapyName': 'Capecitabine'}]"," Dovitinib Lactate, Gemcitabine Hydrochloride, and Capecitabine in Treating Patients With Advanced or Metastatic Solid Tumors, Pancreatic Cancer and Biliary Cancers",6897
3,NCT01266070,,Terminated,"[{'id': 721, 'therapyName': 'Dovitinib'}]", TKI 258 in Von Hippel-Lindau Syndrome (VHL),6897
4,NCT01484041,Phase Ib/II,Terminated,"[{'id': 721, 'therapyName': 'Dovitinib'}]",Dovitinib Plus an Aromatase Inhibitor for Metastatic Breast Cancer,6897
5,NCT02108782,Phase II,Withdrawn,"[{'id': 721, 'therapyName': 'Dovitinib'}]",Dovitinib Lactate in Treating Patients With Pancreatic Neuroendocrine Tumors,6897
6,NCT01753713,Phase II,"Active, not recruiting","[{'id': 721, 'therapyName': 'Dovitinib'}]",Dovitinib in Treating Patients With Recurrent or Progressive Glioblastoma,6897
7,NCT01888965,Phase II,Terminated,"[{'id': 721, 'therapyName': 'Dovitinib'}]",Maintenance Dovitinib for Colorectal and Pancreas Cancer,6897
8,NCT01994590,Phase II,Terminated,"[{'id': 721, 'therapyName': 'Dovitinib'}]",Dovitinib (TKI258) and Abiraterone Acetate in Metastatic Castrate-Resistant Prostate Cancer (mCRPC),6897
9,NCT02048943,Phase I,Withdrawn,"[{'id': 1372, 'therapyName': 'Dovitinib + Gemcitabine + Abraxane'}, {'id': 619, 'therapyName': 'Abraxane'}, {'id': 721, 'therapyName': 'Dovitinib'}]","Dovitinib Lactate, Gemcitabine Hydrochloride, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Solid Tumors or Pancreatic Cancer",6897
10,NCT01443481,Phase I,Completed,"[{'id': 721, 'therapyName': 'Dovitinib'}]",Pharmacokinetics (PK) of TKI258 in Cancer Patients With Normal and Impaired Hepatic Function,6897
11,NCT01676714,Phase II,Completed,"[{'id': 721, 'therapyName': 'Dovitinib'}]",Study of Dovitinib and Biomarkers in Advanced Non-Small Cell Lung Cancer or Advanced Colorectal Cancer,6897
12,NCT01678105,,Completed,"[{'id': 721, 'therapyName': 'Dovitinib'}]", A Phase II Study of Dovitinib in Recurrent and/or Metastatic Adenoid Cystic Carcinoma of the Salivary Glands,6897
13,NCT01262027,Phase II,"Active, not recruiting","[{'id': 721, 'therapyName': 'Dovitinib'}]", TKI258 for Metastatic Inflammatory Breast Cancer Patients,6897
14,NCT02116803,Phase III,Completed,"[{'id': 721, 'therapyName': 'Dovitinib'}]",An Open Label Multi-center Extension Study to Evaluate Long-term Safety/ Tolerability of Dovitinib in Patients With Solid Tumors Who Continue to Receive Treatment With Dovitinib (TKI258) in Novartis-sponsored Single Agent Dovitinib Studies Which Fulfilled the Requirements for the Primary Objective,6897
15,NCT01700270,Phase I,Completed,"[{'id': 1232, 'therapyName': 'Dovitinib + Fluvoxamine'}]", Pharmacokinetic Drug-drug Interaction Study of Dovitinib (TKI258) in Patients With Advanced Solid Tumors.,6897
16,NCT01528345,Phase II,Terminated,"[{'id': 2189, 'therapyName': 'Fulvestrant + Dovitinib'}, {'id': 744, 'therapyName': 'Fulvestrant'}]","Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer",6897
0,NCT02098343,Phase Ib/II,Recruiting,"[{'id': 1953, 'therapyName': 'Carboplatin + Doxorubicin'}, {'id': 1952, 'therapyName': 'APR-246 + Carboplatin + Doxorubicin'}]","p53 Suppressor Activation in Recurrent High Grade Serous Ovarian Cancer, a Phase Ib/II Study of Systemic Carboplatin Combination Chemotherapy With or Without APR-246",986
1,NCT01959490,Phase II,Completed,"[{'id': 1486, 'therapyName': 'Bevacizumab + Doxorubicin + Cyclophosphamide + Paclitaxel '}, {'id': 1485, 'therapyName': 'Trastuzumab + Docetaxel + Carboplatin'}]",Trastuzumab or Bevacizumab With Combination Chemotherapy in Treating Patients With Stage II-III Breast Cancer,986
2,NCT03033914,Phase I,Recruiting,"[{'id': 5296, 'therapyName': 'Dacarbazine + Doxorubicin + Vinblastine + Nivolumab'}, {'id': 5295, 'therapyName': 'Bleomycin + Dacarbazine + Doxorubicin + Vinblastine + Nivolumab'}]",A(B)VD Followed by Nivolumab as Frontline Therapy for Higher Risk Patients With Classical Hodgkin Lymphoma,986
3,NCT01025089,Phase II,"Active, not recruiting","[{'id': 694, 'therapyName': 'Cetuximab'}, {'id': 1927, 'therapyName': 'Cisplatin + Doxorubicin + Cyclophosphamide'}]",Chemotherapy Plus Cetuximab Followed by Surgical Resection in Patients With Locally Advanced or Recurrent Thymoma or Thymic Carcinoma,986
4,NCT00734877,Phase III,Recruiting,"[{'id': 1851, 'therapyName': 'Cisplatin + Doxorubicin + Cyclophosphamide + Etoposide'}, {'id': 1852, 'therapyName': 'Melphalan + Bortezomib + Thalidomide + Dexamethasone'}]","UARK 2008-01, Total Therapy 4 - A Phase III Trial for Low Risk Myeloma",986
5,NCT02420717,Phase II,Recruiting,"[{'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 3195, 'therapyName': 'Cytarabine + Methotrexate '}, {'id': 2046, 'therapyName': 'Cyclophosphamide + Dexamethasone + Doxorubicin + Vincristine '}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 3194, 'therapyName': 'Mercaptopurine + Methotrexate + Prednisone + Vincristine'}]",Ruxolitinib or Dasatinib With Chemotherapy in Patients With Philadelphia Chromosome (Ph)-Like Acute Lymphoblastic Leukemia (ALL),986
6,NCT01424982,Phase II,Recruiting,"[{'id': 1476, 'therapyName': 'Pegfilgrastim'}, {'id': 2048, 'therapyName': 'Cytarabine + Methotrexate + Ponatinib'}, {'id': 2049, 'therapyName': 'Ponatinib + Vincristine'}, {'id': 2046, 'therapyName': 'Cyclophosphamide + Dexamethasone + Doxorubicin + Vincristine '}, {'id': 1642, 'therapyName': 'Leucovorin'}]",Hyper-CVAD and Ponatinib in Ph-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL),986
7,NCT02636322,Phase II,Recruiting,"[{'id': 2482, 'therapyName': 'Cyclophosphamide + Doxorubicin + Etoposide + Vincristine '}, {'id': 1610, 'therapyName': 'Rituximab + Lenalidomide + Ibrutinib'}, {'id': 2188, 'therapyName': 'Prednisone'}]","A Study of Rituximab, Lenalidomide, and Ibrutinib Combined With Dose Adjusted Chemotherapy For Patients With High Risk Diffuse Large B-Cell Lymphoma",986
8,NCT02337985,Phase I,Recruiting,"[{'id': 897, 'therapyName': 'Rituximab'}, {'id': 2482, 'therapyName': 'Cyclophosphamide + Doxorubicin + Etoposide + Vincristine '}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 2188, 'therapyName': 'Prednisone'}]",Gene Therapy and Combination Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin Lymphoma,986
9,NCT03285607,Phase I,Not yet recruiting,"[{'id': 6236, 'therapyName': 'Cyclophosphamide + Doxorubicin + Paclitaxel + MCS110'}]","MCS110 Combined With Neoadjuvant Doxorubicin, Cyclophosphamide, and Weekly Paclitaxel in Patients With Hormone-Receptor Positive and HER2- Breast Cancer",986
10,NCT02876302,Phase II,Recruiting,"[{'id': 4679, 'therapyName': 'Cyclophosphamide + Doxorubicin + Paclitaxel + Ruxolitinib'}]",Study Of Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative Inflammatory Breast Cancer,986
11,NCT01992653,Phase I,"Active, not recruiting","[{'id': 4248, 'therapyName': 'Cyclophosphamide + Doxorubicin + Prednisone'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 4226, 'therapyName': 'Polatuzumab Vedotin'}, {'id': 1646, 'therapyName': 'Obinutuzumab'}]","A Study of Polatuzumab Vedotin in Combination With Rituximab or Obinutuzumab, Cyclophosphamide, Doxorubicin, and Prednisone in Participants With B-Cell Non-Hodgkin's Lymphoma",986
12,NCT02531308,Phase II,Terminated,"[{'id': 1031, 'therapyName': 'Metformin'}, {'id': 3266, 'therapyName': 'Cyclophosphamide + Doxorubicin + Prednisone + Vincristine '}, {'id': 1476, 'therapyName': 'Pegfilgrastim'}, {'id': 897, 'therapyName': 'Rituximab'}]",Metformin in Combination With Standard Induction Therapy for Large B-cell Lymphoma (DLBCL),986
13,NCT01855750,Phase III,"Active, not recruiting","[{'id': 768, 'therapyName': 'Ibrutinib'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 3266, 'therapyName': 'Cyclophosphamide + Doxorubicin + Prednisone + Vincristine '}]","A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma",986
14,NCT01974440,Phase III,"Active, not recruiting","[{'id': 768, 'therapyName': 'Ibrutinib'}, {'id': 2323, 'therapyName': 'Bendamustine + Rituximab'}, {'id': 3266, 'therapyName': 'Cyclophosphamide + Doxorubicin + Prednisone + Vincristine '}]","A Study of PCI-32765 (Ibrutinib) in Combination With Either Bendamustine and Rituximab or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Participants With Previously Treated Indolent Non-Hodgkin Lymphoma",986
15,NCT02596971,Phase I,Recruiting,"[{'id': 1975, 'therapyName': 'Atezolizumab + Obinutuzumab'}, {'id': 3266, 'therapyName': 'Cyclophosphamide + Doxorubicin + Prednisone + Vincristine '}, {'id': 1231, 'therapyName': 'Bendamustine'}]",Safety and Efficacy of MPDL3280A in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus CHOP in Patients With Follicular Lymphoma or Diffuse Large B-Cell Lymphoma,986
16,NCT02055820,Phase I,"Active, not recruiting","[{'id': 1562, 'therapyName': 'Venetoclax'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 3266, 'therapyName': 'Cyclophosphamide + Doxorubicin + Prednisone + Vincristine '}, {'id': 1646, 'therapyName': 'Obinutuzumab'}]",A Safety and Pharmacokinetics Study of GDC-0199 (ABT-199) in Patients With Non-Hodgkin's Lymphoma,986
17,NCT02541565,Phase I,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 3266, 'therapyName': 'Cyclophosphamide + Doxorubicin + Prednisone + Vincristine '}, {'id': 897, 'therapyName': 'Rituximab'}]",Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Diffuse Large B-cell Lymphoma,986
18,NCT02427620,Phase II,Recruiting,"[{'id': 2353, 'therapyName': 'Cyclophosphamide + Doxorubicin + Vincristine '}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 3195, 'therapyName': 'Cytarabine + Methotrexate '}, {'id': 1642, 'therapyName': 'Leucovorin'}]",A Study of Ibrutinib Plus Rituximab With Hyper-CVAD Consolidation in Newly Diagnosed Young Patients With Mantle Cell Lymphoma,986
19,NCT01175356,Phase I,Completed,"[{'id': 2558, 'therapyName': 'Busulfan + Melphalan'}, {'id': 2590, 'therapyName': 'Cyclophosphamide + Topotecan'}, {'id': 1425, 'therapyName': '131I-MIBG'}, {'id': 2353, 'therapyName': 'Cyclophosphamide + Doxorubicin + Vincristine '}, {'id': 2585, 'therapyName': 'Cisplatin + Etoposide'}]","Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin",986
20,NCT02073097,Phase Ib/II,Recruiting,"[{'id': 2351, 'therapyName': 'Carfilzomib + Rituximab'}, {'id': 2353, 'therapyName': 'Cyclophosphamide + Doxorubicin + Vincristine '}]","Carfilzomib, Rituximab, and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Lymphoma",986
21,NCT03226249,Phase II,Not yet recruiting,"[{'id': 6157, 'therapyName': 'Dacarbazine + Doxorubicin + Pembrolizumab +Vinblastine'}]",PET-Directed Therapy With Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Classical Hodgkin Lymphoma,986
22,NCT02883049,Phase III,Suspended,"[{'id': 717, 'therapyName': 'Dasatinib'}, {'id': 4685, 'therapyName': 'Dexamethasone + Doxorubicin'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1746, 'therapyName': 'Clofarabine'}]",Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations,986
23,NCT02723994,Phase II,Recruiting,"[{'id': 2188, 'therapyName': 'Prednisone'}, {'id': 4685, 'therapyName': 'Dexamethasone + Doxorubicin'}, {'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 2346, 'therapyName': 'Mercaptopurine + Thioguanine'}, {'id': 2394, 'therapyName': 'Asparaginase + Cytarabine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 1848, 'therapyName': 'Cyclophosphamide + Methotrexate + Vincristine + Pegaspargase '}]",A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia,986
24,NCT01606878,Phase I,Recruiting,"[{'id': 2952, 'therapyName': 'Dexamethasone + Doxorubicin + Vincristine'}, {'id': 2590, 'therapyName': 'Cyclophosphamide + Topotecan'}, {'id': 706, 'therapyName': 'Crizotinib'}]",Crizotinib and Combination Chemotherapy in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma,986
25,NCT01501487,FDA approved,"Active, not recruiting","[{'id': 1902, 'therapyName': 'Docetaxel + Doxorubicin + Cyclophosphamide'}, {'id': 1982, 'therapyName': 'Fluorouracil + Epirubicin + Cyclophosphamide'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1476, 'therapyName': 'Pegfilgrastim'}, {'id': 1881, 'therapyName': 'Docetaxel + Cyclophosphamide'}, {'id': 1977, 'therapyName': 'Doxorubicin + Cyclophosphamide'}, {'id': 1485, 'therapyName': 'Trastuzumab + Docetaxel + Carboplatin'}, {'id': 1978, 'therapyName': 'Pertuzumab + Trastuzumab + Docetaxel'}]",MINT I Multi- Institutional Neo-adjuvant Therapy MammaPrint Project I,986
26,NCT03211117,Phase II,Recruiting,"[{'id': 6040, 'therapyName': 'Docetaxel + Doxorubicin + Pembrolizumab'}]","Pembrolizumab, Chemotherapy, and Radiation Therapy With or Without Surgery in Treating Patients With Anaplastic Thyroid Cancer",986
27,NCT03126916,Phase III,Not yet recruiting,"[{'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1425, 'therapyName': '131I-MIBG'}, {'id': 1873, 'therapyName': 'Sargramostim'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 5595, 'therapyName': 'Isotretinoin'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 5153, 'therapyName': 'dexrazoxane'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1167, 'therapyName': 'Aldesleukin'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 2286, 'therapyName': 'Dinutuximab  '}]",Iobenguane I-131 or Crizotinib and Standard Therapy in Treating Younger Patients With Newly-Diagnosed High-Risk Neuroblastoma or Ganglioneuroblastoma,986
28,NCT01459380,Phase I,Completed,"[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 954, 'therapyName': 'Veliparib'}, {'id': 667, 'therapyName': 'Bevacizumab'}]","Veliparib, Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer",986
29,NCT01015833,Phase III,"Active, not recruiting","[{'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 920, 'therapyName': 'Sorafenib'}]",Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,986
30,NCT02502266,Phase II,Suspended,"[{'id': 942, 'therapyName': 'Topotecan'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 837, 'therapyName': 'Olaparib'}, {'id': 1001, 'therapyName': 'Cediranib'}]","Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",986
31,NCT03197935,Phase III,Recruiting,"[{'id': 1476, 'therapyName': 'Pegfilgrastim'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 619, 'therapyName': 'Abraxane'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}]",A Study to Investigate Atezolizumab and Chemotherapy Compared With Placebo and Chemotherapy in the Neoadjuvant Setting in Participants With Early Stage Triple Negative Breast Cancer (IMpassion031),986
32,NCT02349958,Phase II,Recruiting,"[{'id': 1133, 'therapyName': 'Mitomycin C'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1009, 'therapyName': 'Doxorubicin'}]",Clinical Trial of Intraperitoneal Hyperthermic Chemotherapy,986
33,NCT03117751,Phase II,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1876, 'therapyName': 'Blinatumomab '}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1638, 'therapyName': 'Pegaspargase'}]",Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma,986
34,NCT00074490,Phase II,Completed,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1650, 'therapyName': 'Cyclosporine'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1166, 'therapyName': 'Fludarabine'}]",Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,986
35,NCT00549848,Phase III,"Active, not recruiting","[{'id': 1781, 'therapyName': 'Vincristine + Pegaspargase + Daunorubicin'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1782, 'therapyName': 'Clofarabine + Etoposide + Cyclophosphamide'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}]",Total Therapy Study XVI for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia,986
36,NCT02648477,Phase II,Recruiting,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 794, 'therapyName': 'Letrozole'}, {'id': 633, 'therapyName': 'Anastrozole'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 1009, 'therapyName': 'Doxorubicin'}]",Pembrolizumab and Doxorubicin Hydrochloride or Anti-Estrogen Therapy in Treating Patients With Triple-Negative or Hormone Receptor-Positive Metastatic Breast Cancer,986
37,NCT01750073,Phase II,Recruiting,"[{'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 1980, 'therapyName': 'Cyclophosphamide + Paclitaxel'}]",Paclitaxel and Cyclophosphamide With or Without Trastuzumab Before Surgery in Treating Patients With Previously Untreated Stage I-III Breast Cancer,986
38,NCT01815294,Phase I,Completed,"[{'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1008, 'therapyName': 'Doxil'}]", A Pivotal Bioequivalence Study of DOXIL/CAELYX (Doxorubicin HCL) in Patients With Advanced or Refractory Solid Malignancies Including Patients With Ovarian Cancer,986
39,NCT01857934,Phase II,Recruiting,"[{'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1873, 'therapyName': 'Sargramostim'}, {'id': 1167, 'therapyName': 'Aldesleukin'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 2627, 'therapyName': 'Levetiracetam'}, {'id': 2585, 'therapyName': 'Cisplatin + Etoposide'}, {'id': 2458, 'therapyName': 'Hu14.18K322A'}, {'id': 2558, 'therapyName': 'Busulfan + Melphalan'}, {'id': 2590, 'therapyName': 'Cyclophosphamide + Topotecan'}]",Therapy for Children With Advanced Stage Neuroblastoma,986
40,NCT03145558,Phase II,Not yet recruiting,"[{'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 3028, 'therapyName': 'tirapazamine'}]",TATE Versus TACE in Intermediate Stage HCC (TATE),986
41,NCT03150693,Phase III,Recruiting,"[{'id': 897, 'therapyName': 'Rituximab'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1783, 'therapyName': 'Cyclophosphamide + Cytarabine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 3628, 'therapyName': 'Allopurinol'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 3199, 'therapyName': 'inotuzumab ozogamicin'}]",Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia,986
42,NCT02580058,Phase III,"Active, not recruiting","[{'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 3144, 'therapyName': 'Avelumab'}]",A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer,986
43,NCT02331251,Phase Ib/II,"Active, not recruiting","[{'id': 1685, 'therapyName': 'Vinorelbine'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 619, 'therapyName': 'Abraxane'}]",Study of Pembrolizumab Plus Chemotherapy in Patients With Advanced Cancer (PembroPlus),986
44,NCT02446600,Phase III,Recruiting,"[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 837, 'therapyName': 'Olaparib'}, {'id': 1001, 'therapyName': 'Cediranib'}]","Olaparib or Cediranib Maleate and Olaparib Compared With Standard Platinum-Based Chemotherapy in Treating Patients With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",986
45,NCT02451943,Phase III,"Active, not recruiting","[{'id': 3269, 'therapyName': 'Olaratumab'}, {'id': 1009, 'therapyName': 'Doxorubicin'}]",A Study of Doxorubicin Plus Olaratumab (LY3012207) in Participants With Advanced or Metastatic Soft Tissue Sarcoma,986
46,NCT02312245,Phase II,Recruiting,"[{'id': 942, 'therapyName': 'Topotecan'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 755, 'therapyName': 'Gemcitabine'}]","Avatar-Directed Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer",986
47,NCT02460991,Phase I,Terminated,"[{'id': 920, 'therapyName': 'Sorafenib'}, {'id': 1009, 'therapyName': 'Doxorubicin'}]",A Study of ONCO-DOX in Locally Advanced Hepatocellular Carcinoma,986
48,NCT01319981,Phase II,Recruiting,"[{'id': 1476, 'therapyName': 'Pegfilgrastim'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}]",Hyper-CVAD With Liposomal Vincristine in Acute Lymphoblastic Leukemia,986
49,NCT02112916,Phase III,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1009, 'therapyName': 'Doxorubicin'}]",Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma,986
50,NCT01655693,Phase III,"Active, not recruiting","[{'id': 1009, 'therapyName': 'Doxorubicin'}]",Efficacy and Safety Doxorubicin Transdrug Study in Patients Suffering From Advanced Hepatocellular Carcinoma (ReLive),986
51,NCT02788201,Phase II,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1133, 'therapyName': 'Mitomycin C'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1013, 'therapyName': 'epirubicin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1137, 'therapyName': 'Bleomycin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 781, 'therapyName': 'Ixabepilone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 2950, 'therapyName': 'Estramustine'}, {'id': 1941, 'therapyName': 'Floxuridine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 1811, 'therapyName': 'Carmustine'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 953, 'therapyName': 'Vandetanib'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 4419, 'therapyName': 'Toremifine'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 2601, 'therapyName': 'Dactinomycin'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 3035, 'therapyName': 'Chlorambucil'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 342, 'therapyName': 'Vemurafenib'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 2635, 'therapyName': 'Vinblastine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 4305, 'therapyName': 'Teniposide'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 4304, 'therapyName': 'Streptozocin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1231, 'therapyName': 'Bendamustine'}, {'id': 4303, 'therapyName': 'Mechlorethamine'}, {'id': 4302, 'therapyName': 'Mitotane'}]",Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma,986
52,NCT03007147,Phase III,Recruiting,"[{'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 5153, 'therapyName': 'dexrazoxane'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 5167, 'therapyName': 'Methylprednisolone'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 5168, 'therapyName': 'Prednisolone'}, {'id': 1009, 'therapyName': 'Doxorubicin'}]",Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia,986
53,NCT02049905,Phase III,Completed,"[{'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1440, 'therapyName': 'Aldoxorubicin'}, {'id': 1439, 'therapyName': 'Gemcitabine + Docetaxel'}]",Phase 3 Study to Treat Patients With Soft Tissue Sarcomas,986
54,NCT02483247,Phase Ib/II,Recruiting,"[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1945, 'therapyName': 'BBI503'}]",A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer,986
55,NCT02677116,Phase I,Recruiting,"[{'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 3618, 'therapyName': 'Irinotecan + Vincristine'}, {'id': 3269, 'therapyName': 'Olaratumab'}]",A Study of Olaratumab Alone and in Combination With Standard Chemotherapies in Children With Cancer,986
56,NCT02494713,Phase II,Recruiting,"[{'id': 1814, 'therapyName': 'Degarelix'}, {'id': 2950, 'therapyName': 'Estramustine'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 2858, 'therapyName': 'Ketoconazole'}]",Hormonal Therapy and Chemotherapy Followed by Prostatectomy in Patients With Prostate Cancer,986
57,NCT01523977,Phase I,"Active, not recruiting","[{'id': 2188, 'therapyName': 'Prednisone'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1638, 'therapyName': 'Pegaspargase'}]",Everolimus With Multiagent Re-Induction Chemotherapy in Pediatric Patients With ALL,986
58,NCT02456857,Phase II,Recruiting,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 936, 'therapyName': 'Temsirolimus'}]","Liposomal Doxorubicin, Bevacizumab and Temsirolimus (DAT) in Triple-Negative Breast Cancer (TNBC) Insensitive to Standard Neoadjuvant Chemotherapy",986
59,NCT02606305,Phase I,Recruiting,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 3232, 'therapyName': 'IMGN853'}]","Study of IMGN853 in Comb. With Bevacizumab, Carboplatin or PLD in Adults With FRa + Adv. EOC, Primary Peritoneal, Fallopian Tube, or Endometrial Cancer",986
60,NCT00980460,Phase III,Recruiting,"[{'id': 2298, 'therapyName': 'Irinotecan + Temsirolimus + Vincristine'}, {'id': 2297, 'therapyName': 'Cisplatin + Fluorouracil + Vincristine'}, {'id': 1009, 'therapyName': 'Doxorubicin'}]",Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer,986
61,NCT03004287,Phase II,Recruiting,"[{'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1164, 'therapyName': 'lenalidomide'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 1630, 'therapyName': 'Daratumumab'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1475, 'therapyName': 'Thalidomide'}]",2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy,986
62,NCT02094872,Phase II,"Active, not recruiting","[{'id': 1009, 'therapyName': 'Doxorubicin'}]",Molecularly Targeted Therapy in Treating Patients With BRAF Wild-type Melanoma That is Metastatic,986
63,NCT03023046,Phase II,Recruiting,"[{'id': 897, 'therapyName': 'Rituximab'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 1631, 'therapyName': 'Vincristine'}]","Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma",986
64,NCT03056599,,Recruiting,"[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1299, 'therapyName': 'Interferon alfa-2b '}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1733, 'therapyName': 'interferon gamma '}, {'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 3420, 'therapyName': 'trabectedin'}, {'id': 1167, 'therapyName': 'Aldesleukin'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 720, 'therapyName': 'Docetaxel'}]",Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO™ Device in Soft Tissue Sarcoma,986
65,NCT02419755,Phase II,Terminated,"[{'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 2188, 'therapyName': 'Prednisone'}]",Bortezomib and Vorinostat in Younger Patients With Refractory or Relapsed MLL Rearranged Hematologic Malignancies,986
66,NCT03020030,Phase III,Recruiting,"[{'id': 3160, 'therapyName': 'Nelarabine'}, {'id': 5153, 'therapyName': 'dexrazoxane'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1642, 'therapyName': 'Leucovorin'}]",Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents,986
67,NCT01375699,Phase I,"Active, not recruiting","[{'id': 1009, 'therapyName': 'Doxorubicin'}]","Doxorubicin With or Without Sildenafil, With Analysis of Cardiac Markers",986
68,NCT02192021,Phase I,Recruiting,"[{'id': 1009, 'therapyName': 'Doxorubicin'}]",Micro Needle Array-Doxorubicin (MNA-D) in Patients With Cutaneous T-cell Lymphoma (CTCL),986
69,NCT02419495,Phase I,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1749, 'therapyName': 'Selinexor'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 1009, 'therapyName': 'Doxorubicin'}]",Selinexor in Combination With Standard Chemotherapy,986
70,NCT01746238,Phase I,"Active, not recruiting","[{'id': 1473, 'therapyName': 'Doxorubicin + Bevacizumab'}]",Bevacizumab/Doxorubicin/Radiation for Sarcoma,986
71,NCT01796197,Phase II,"Active, not recruiting","[{'id': 1977, 'therapyName': 'Doxorubicin + Cyclophosphamide'}, {'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]",Paclitaxel + Trastuzumab + Pertuzumab as Pre-Op for Inflammatory BrCa,986
72,NCT02876107,Phase II,Recruiting,"[{'id': 1977, 'therapyName': 'Doxorubicin + Cyclophosphamide'}, {'id': 3386, 'therapyName': 'Carboplatin + Paclitaxel + Panitumumab'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]",A Phase II Study of Using Panitumumab/Carboplatin/Paclitaxel (PaCT) Followed by Anthracycline-Containing Regimen (AC) for New Triple-Negative Inflammatory Breast Cancer (TN-IBC),986
73,NCT01897441,Phase I,Recruiting,"[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1551, 'therapyName': 'Trastuzumab + Paclitaxel'}, {'id': 1977, 'therapyName': 'Doxorubicin + Cyclophosphamide'}]",Chemotherapy Before Surgery and Tissue Sample Collection in Patients With Stage IIA-IIIC Breast Cancer,986
74,NCT03036488,Phase III,Recruiting,"[{'id': 1087, 'therapyName': 'Epirubicin + Cyclophosphamide'}, {'id': 1977, 'therapyName': 'Doxorubicin + Cyclophosphamide'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]",Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522),986
75,NCT02489448,Phase Ib/II,Recruiting,"[{'id': 3100, 'therapyName': 'MEDI4736 + nab-paclitaxel'}, {'id': 1977, 'therapyName': 'Doxorubicin + Cyclophosphamide'}]",Neoadjuvant MEDI4736 Concomitant With Weekly Nab-paclitaxel and Dose-dense AC for Stage I-III Triple Negative Breast Cancer,986
76,NCT02032277,Phase III,"Active, not recruiting","[{'id': 1977, 'therapyName': 'Doxorubicin + Cyclophosphamide'}, {'id': 954, 'therapyName': 'Veliparib'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]",A Study Evaluating Safety and Efficacy of the Addition of ABT-888 Plus Carboplatin Versus the Addition of Carboplatin to Standard Chemotherapy Versus Standard Chemotherapy in Subjects With Early Stage Triple Negative Breast Cancer,986
77,NCT01697293,Phase Ib/II,Recruiting,"[{'id': 3054, 'therapyName': 'Paclitaxel + Triciribine'}, {'id': 1977, 'therapyName': 'Doxorubicin + Cyclophosphamide'}]","Triciribine Phosphate, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide in Treating Patients With Stage IIB-IV Breast Cancer",986
78,NCT02789657,Phase II,Recruiting,"[{'id': 4235, 'therapyName': 'Carboplatin + Pertuzumab + Trastuzumab + Paclitaxel'}, {'id': 1977, 'therapyName': 'Doxorubicin + Cyclophosphamide'}]",BrUOG 308: Efficacy of wPCbTP and Switching to an AC in Non-responding Patients as Neoadjuvant Therapy in Clinical Stage I-III HER2-positive Breast Cancer.,986
79,NCT00574587,Phase Ib/II,Unknown status,"[{'id': 1983, 'therapyName': 'vorinostat + Paclitaxel'}, {'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 1977, 'therapyName': 'Doxorubicin + Cyclophosphamide'}]","Trial for Locally Advanced Her2 Positive Breast Cancer Using Paclitaxel, Trastuzumab, Doxorubicin and Cyclophasmide on a Weekly Basis",986
80,NCT02957968,Phase II,Recruiting,"[{'id': 1495, 'therapyName': 'Paclitaxel + Doxorubicin + Cyclophosphamide'}, {'id': 5729, 'therapyName': 'Doxorubicin + Cyclophosphamide + Paclitaxel + Carboplatin'}]",Neoadj Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca,986
81,NCT02356159,Phase Ib/II,Recruiting,"[{'id': 2294, 'therapyName': 'Cytarabine + Fludarabine'}, {'id': 2373, 'therapyName': 'Palifermin'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 2238, 'therapyName': 'Sirolimus + Tacrolimus + Methotrexate'}, {'id': 2292, 'therapyName': 'Doxorubicin + Etoposide + Fludarabine + Vincristine '}, {'id': 2291, 'therapyName': 'Cyclophosphamide + Fludarabine'}, {'id': 897, 'therapyName': 'Rituximab'}]",Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation,986
82,NCT02538926,Phase II,Not yet recruiting,"[{'id': 770, 'therapyName': 'Imatinib'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 3212, 'therapyName': 'Doxorubicin + Etoposide + Vincristine '}, {'id': 2206, 'therapyName': 'Asparaginase'}]","Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride With Asparaginase in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma",986
83,NCT01446809,Phase I,"Active, not recruiting","[{'id': 1472, 'therapyName': 'Doxorubicin + Ifosfamide'}, {'id': 1471, 'therapyName': 'Pazopanib + Doxorubicin + Ifosfamide'}]",Pazopanib Hydrochloride Followed By Chemotherapy and Surgery in Treating Patients With Soft Tissue Sarcoma,986
84,NCT02180867,Phase II,Recruiting,"[{'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1472, 'therapyName': 'Doxorubicin + Ifosfamide'}]",Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Hydrochloride Before Surgery in Treating Patients With Newly Diagnosed Non-Rhabdomyosarcoma Soft Tissue Sarcomas That Can be Removed by Surgery (PAZNTIS),986
85,NCT03283696,Phase I,Not yet recruiting,"[{'id': 6292, 'therapyName': 'Doxorubicin + Ifosfamide + Mesna + Olaratumab'}]","A Study of Olaratumab (LY3012207), Doxorubicin, and Ifosfamide in Participants With Advanced or Metastatic Soft Tissue Sarcoma",986
86,NCT02584309,Phase II,Recruiting,"[{'id': 5153, 'therapyName': 'dexrazoxane'}, {'id': 4140, 'therapyName': 'Doxorubicin + Olaratumab'}]",Doxorubicin With Upfront Dexrazoxane Plus Olaratumab for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma,986
87,NCT02783599,Phase I,Recruiting,"[{'id': 4140, 'therapyName': 'Doxorubicin + Olaratumab'}]",A Study of Olaratumab (LY3012207) in Participants With Soft Tissue Sarcoma,986
88,NCT03056001,Phase II,Recruiting,"[{'id': 4690, 'therapyName': 'Doxorubicin + Pembrolizumab'}]","Safety, Tolerability, and Efficacy of Doxorubicin and Pembrolizumab for Sarcoma",986
89,NCT02888665,Phase Ib/II,Recruiting,"[{'id': 4690, 'therapyName': 'Doxorubicin + Pembrolizumab'}]",Pembrolizumab and Doxorubicin Hydrochloride in Treating Patients With Sarcoma That is Metastatic or Cannot Be Removed by Surgery,986
90,NCT03009201,Phase I,Recruiting,"[{'id': 5179, 'therapyName': 'Doxorubicin + Ribociclib'}]",Ribociclib and Doxorubicin Hydrochloride in Treating Patients Metastatic or Advanced Soft Tissue Sarcomas That Cannot Be Removed by Surgery,986
91,NCT01840592,Phase II,"Active, not recruiting","[{'id': 2363, 'therapyName': 'Doxorubicin + Sorafenib'}]",Sorafenib Plus Doxorubicin in Patients With Advanced Hepatocellular Carcinoma With Disease Progression on Sorafenib,986
92,NCT00092222,Phase II,Recruiting,"[{'id': 917, 'therapyName': 'Sirolimus'}, {'id': 1187, 'therapyName': 'Alpha 2 Interferon'}, {'id': 2211, 'therapyName': 'EPOCH'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1008, 'therapyName': 'Doxil'}]",Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity,986
93,NCT00520130,Phase Ib/II,"Active, not recruiting","[{'id': 2294, 'therapyName': 'Cytarabine + Fludarabine'}, {'id': 2305, 'therapyName': 'Alemtuzumab + Cyclosporine'}, {'id': 2306, 'therapyName': 'Rituximab + Fludarabine + EPOCH'}, {'id': 2307, 'therapyName': 'Fludarabine + EPOCH'}, {'id': 2238, 'therapyName': 'Sirolimus + Tacrolimus + Methotrexate'}, {'id': 1632, 'therapyName': 'Filgrastim'}]",Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,986
94,NCT01593228,Phase III,Completed,"[{'id': 1173, 'therapyName': 'Iniparib + doxorubicin + carboplatin'}, {'id': 1172, 'therapyName': 'Iniparib + Paclitaxel'}, {'id': 1171, 'therapyName': 'Iniparib + Irinotecan'}, {'id': 1170, 'therapyName': 'Iniparib + Topotecan'}, {'id': 1169, 'therapyName': 'Iniparib + Gemcitabine + Carboplatin'}, {'id': 1168, 'therapyName': 'Iniparib'}]", Treatment Extension Study for Patients Who Have Previously Participated and Have Benefited From Iniparib in a Clinical Trial,986
95,NCT03003520,Phase II,Recruiting,"[{'id': 5350, 'therapyName': 'MEDI4736 + R2-CHOP'}, {'id': 5349, 'therapyName': 'MEDI4736 + Rituximab + Doxorubicin + Vincristine + Cyclophosphamide + Prednisone'}]",A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma,986
96,NCT03269669,Phase II,Recruiting,"[{'id': 6257, 'therapyName': 'Obinutuzumab + CHOP'}, {'id': 6302, 'therapyName': 'Lenalidomide + Obinutuzumab\t'}, {'id': 6301, 'therapyName': 'Obinutuzumab + TGR-1202'}, {'id': 2188, 'therapyName': 'Prednisone'}]","Obinutuzumab With or Without PI3K-delta Inhibitor TGR-1202, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma",986
97,NCT02379585,Phase Ib/II,Terminated,"[{'id': 1495, 'therapyName': 'Paclitaxel + Doxorubicin + Cyclophosphamide'}, {'id': 1978, 'therapyName': 'Pertuzumab + Trastuzumab + Docetaxel'}]",Study of Short-term Fasting on Neoadjuvant Chemotherapy in Patients With Newly Diagnosed Breast Cancer,986
98,NCT01275677,Phase III,"Active, not recruiting","[{'id': 1503, 'therapyName': 'Paclitaxel + Trastuzumab + Doxorubicin + Cyclophosphamide'}, {'id': 1881, 'therapyName': 'Docetaxel + Cyclophosphamide'}, {'id': 1882, 'therapyName': 'Docetaxel + Cyclophosphamide + Trastuzumab'}, {'id': 1495, 'therapyName': 'Paclitaxel + Doxorubicin + Cyclophosphamide'}]",Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,986
99,NCT02132949,Phase II,"Active, not recruiting","[{'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}, {'id': 1495, 'therapyName': 'Paclitaxel + Doxorubicin + Cyclophosphamide'}, {'id': 1895, 'therapyName': 'Cyclophosphamide + Fluorouracil + Docetaxel + Epirubicin  '}]","A Study Evaluating Perjeta (Pertuzumab) Combined With Herceptin (Trastuzumab) and Standard Anthracycline-based Chemotherapy in Patients With HER2-positive Locally Advanced, Inflammatory, or Early-stage Breast Cancer.",986
100,NCT01042379,Phase II,Recruiting,"[{'id': 1218, 'therapyName': 'Trebananib'}, {'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}, {'id': 746, 'therapyName': 'Ganitumab'}, {'id': 1495, 'therapyName': 'Paclitaxel + Doxorubicin + Cyclophosphamide'}, {'id': 1494, 'therapyName': 'MK2206 + Trastuzumab'}, {'id': 1493, 'therapyName': 'Trebananib + Trastuzumab'}, {'id': 1492, 'therapyName': 'T-DM1 + Pertuzumab'}]",I-SPY 2 TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer,986
101,NCT02637375,Phase I,Withdrawn,"[{'id': 1495, 'therapyName': 'Paclitaxel + Doxorubicin + Cyclophosphamide'}, {'id': 745, 'therapyName': 'Ganetespib'}]",A Pilot Preoperative Trial of Ganetespib With Paclitaxel for Triple-Negative Breast Cancer,986
102,NCT01008150,Phase II,Unknown status,"[{'id': 1504, 'therapyName': 'Paclitaxel + Trastuzumab + Neratinib + Doxorubicin + Cyclophosphamide'}, {'id': 1503, 'therapyName': 'Paclitaxel + Trastuzumab + Doxorubicin + Cyclophosphamide'}, {'id': 1505, 'therapyName': 'Paclitaxel + Neratinib + Doxorubicin + Cyclophosphamide'}]",Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer,986
103,NCT03101748,Phase Ib/II,Not yet recruiting,"[{'id': 3187, 'therapyName': 'Neratinib + Paclitaxel + Pertuzumab + Trastuzumab'}, {'id': 1505, 'therapyName': 'Paclitaxel + Neratinib + Doxorubicin + Cyclophosphamide'}]",3HT With Taxol for Metastatic Breast Cancer,986
104,NCT02605694,Phase II,Withdrawn,"[{'id': 3389, 'therapyName': 'Duvelisib + Rituximab'}, {'id': 2195, 'therapyName': 'R-CHOP'}]",Duvelisib With Rituximab vs R-CHOP in Subjects With Relapsed/Refractory Follicular Lymphoma (FRESCO),986
105,NCT01334502,Phase I,Completed,"[{'id': 735, 'therapyName': 'Everolimus'}, {'id': 2195, 'therapyName': 'R-CHOP'}]","Everolimus, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Untreated Diffuse Large B-Cell Lymphoma",986
106,NCT03263026,Phase III,Not yet recruiting,"[{'id': 2195, 'therapyName': 'R-CHOP'}, {'id': 1682, 'therapyName': 'Enzastaurin'}]",Study to Assess Enzastaurin + R-CHOP in Subjects With DLBCL With the Genomic Biomarker DGM1,986
107,NCT03274492,Phase III,Not yet recruiting,"[{'id': 4226, 'therapyName': 'Polatuzumab Vedotin'}, {'id': 6177, 'therapyName': 'R-CHP'}, {'id': 2195, 'therapyName': 'R-CHOP'}]","A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma",986
108,NCT01193842,Phase Ib/II,"Active, not recruiting","[{'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 3395, 'therapyName': 'R-EPOCH'}]",Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas,986
109,NCT02700022,Phase I,"Active, not recruiting","[{'id': 626, 'therapyName': 'Alisertib'}, {'id': 3395, 'therapyName': 'R-EPOCH'}]",A Phase I Study of Alisertib + R-EPOCH for Treatment of Myc-Positive Aggressive B-cell Lymphomas,986
110,NCT00114738,Phase II,"Active, not recruiting","[{'id': 3395, 'therapyName': 'R-EPOCH'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 688, 'therapyName': 'Bortezomib'}]",EPOCH-R Chemotherapy Plus Bortezomib to Treat Mantle Cell Lymphoma,986
111,NCT03042819,Phase I,Recruiting,"[{'id': 5286, 'therapyName': 'Selinexor + Doxorubicin'}]",Study of Selinexor and Doxorubicin in Advanced Soft Tissue Sarcomas,986
112,NCT03036904,Phase I,Recruiting,"[{'id': 5294, 'therapyName': 'Venetoclax + DA-EPOCH-R'}]",Study of Venetoclax Plus DA-EPOCH-R for the Treatment of Aggressive B-Cell Lymphomas (V+DA-EPOCH-R),986
113,NCT01324180,Phase I,Completed,"[{'id': 1031, 'therapyName': 'Metformin'}, {'id': 1830, 'therapyName': 'Vincristine + Dexamethasone + Pegaspargase + Doxorubicin'}]","Vincristine, Dexamethasone, Doxorubicin, and PEG-asparaginase (VPLD) and Metformin for Relapsed Childhood Acute Lymphoblastic Leukemia (ALL)",986
114,NCT01769209,Phase II,"Active, not recruiting","[{'id': 688, 'therapyName': 'Bortezomib'}, {'id': 3195, 'therapyName': 'Cytarabine + Methotrexate '}, {'id': 1830, 'therapyName': 'Vincristine + Dexamethasone + Pegaspargase + Doxorubicin'}]",Bortezomib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia,986
115,NCT01946529,Phase II,"Active, not recruiting","[{'id': 1433, 'therapyName': 'Vincristine + Doxorubicin + Cyclophosphamide + Ifosfamide + Etoposide'}, {'id': 1434, 'therapyName': 'Vincristine + Doxorubicin + Cyclophosphamide + Ifosfamide + Etoposide + others'}]",Therapeutic Trial for Patients With Ewing Sarcoma Family of Tumor and Desmoplastic Small Round Cell Tumors,986
116,NCT02306161,Phase II,Recruiting,"[{'id': 1433, 'therapyName': 'Vincristine + Doxorubicin + Cyclophosphamide + Ifosfamide + Etoposide'}, {'id': 746, 'therapyName': 'Ganitumab'}]",Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma,986
117,NCT00020566,Phase III,Unknown status,"[{'id': 2558, 'therapyName': 'Busulfan + Melphalan'}, {'id': 2670, 'therapyName': 'Vincristine + Doxorubicin + Dactinomycin + Ifosfamide + Etoposide'}]","Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation, Radiation Therapy, and/or Surgery in Treating Patients With Ewing's Sarcoma",986
0,NCT02323230,Phase II,"Active, not recruiting","[{'id': 4280, 'therapyName': 'Cyclophosphamide + DPX-Survivac'}]",A Study of DPX-Survivac Vaccine Therapy in Patients With Recurrent Survivin-expressing DLBCL,8385
1,NCT02785250,Phase I,Recruiting,"[{'id': 4238, 'therapyName': 'Cyclophosphamide + DPX-Survivac + INCB024360 '}]",Study of DPX-Survivac Vaccine Therapy and Epacadostat in Patients With Recurrent Ovarian Cancer,8385
2,NCT03029403,Phase II,Not yet recruiting,"[{'id': 5266, 'therapyName': 'Pembrolizumab + DPX-Survivac + Cyclophosphamide'}]","Phase 2 Study of Pembrolizumab, DPX-Survivac Vaccine and Cyclophosphamide in Advanced Ovarian, Primary Peritoneal or Fallopian Tube Cancer",8385
0,NCT01288430,Phase I,Terminated,"[{'id': 1181, 'therapyName': 'DS-2248'}]","A Study of DS-2248, in Subjects With Advanced Solid Tumors",7215
0,NCT02579824,Phase I,Recruiting,"[{'id': 2079, 'therapyName': 'DS-3032b'}]",DS-3032b for Relapsed and/or Refractory (RR) Myeloma,7417
1,NCT01877382,Phase I,Recruiting,"[{'id': 2079, 'therapyName': 'DS-3032b'}]","A Phase 1 Multiple Ascending Dose Study of DS-3032b, an Oral Murine Double Minute 2 (MDM2) Inhibitor, in Subjects With Advanced Solid Tumors or Lymphomas",7417
2,NCT02319369,Phase I,Recruiting,"[{'id': 2079, 'therapyName': 'DS-3032b'}]","Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-3032b in Hematological Malignancies",7417
0,NCT01588678,Phase I,Completed,"[{'id': 1010, 'therapyName': 'DS-3078a'}]"," A Open-Label, Multiple Ascending Dose Study of DS-3078a, an Oral TORC1/2 Kinase Inhibitor, in Subjects With Advanced Solid Tumors or Lymphomas",7127
0,NCT03110354,Phase I,Recruiting,"[{'id': 5691, 'therapyName': 'DS-3201b'}]",DS-3201b for Acute Myelogenous Leukemia (AML) or Acute Lymphocytic Leukemia (ALL),8746
0,NCT02564900,Phase I,Recruiting,"[{'id': 4844, 'therapyName': 'DS-8201a'}]",Study of DS-8201a in Subjects With Advanced Solid Malignant Tumors,8559
1,NCT03248492,Phase II,Recruiting,"[{'id': 4844, 'therapyName': 'DS-8201a'}]",DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer,8559
0,NCT02279433,Phase I,"Active, not recruiting","[{'id': 4343, 'therapyName': 'DS6051b'}]","A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051b",8428
0,NCT03149003,Phase II,Recruiting,"[{'id': 5986, 'therapyName': 'Bevicizumab + DSP-7888'}, {'id': 667, 'therapyName': 'Bevacizumab'}]",A Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy (WIZARD201G),8411
1,NCT02498665,Phase I,Recruiting,"[{'id': 4320, 'therapyName': 'DSP-7888'}]",A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies,8411
0,NCT02431559,Phase Ib/II,Recruiting,"[{'id': 3101, 'therapyName': 'Aldoxorubicin + MEDI4736 + Motolimod'}]","A Phase 1/2 Study of Motolimod (VTX-2337) and MEDI4736 in Subjects With Recurrent, Platinum-Resistant Ovarian Cancer for Whom Pegylated Liposomal Doxorubicin (PLD) is Indicated",7245
1,NCT03161223,Phase Ib/II,Not yet recruiting,"[{'id': 5882, 'therapyName': 'Durvalumab + Romidepsin'}, {'id': 4178, 'therapyName': 'Azacitidine + MEDI4736'}, {'id': 5881, 'therapyName': 'Azacitidine + Durvalumab + Romidepsin'}, {'id': 5880, 'therapyName': 'Durvalumab + Pralatrexate + Romidepsin'}]","Durvalumab in Different Combinations With Pralatrexate, Romidepsin and Oral 5-Azacitidine for Lymphoma",7245
2,NCT02281084,Phase II,Recruiting,"[{'id': 651, 'therapyName': 'Azacitidine'}, {'id': 4178, 'therapyName': 'Azacitidine + MEDI4736'}]",Safety and Efficacy Study of CC-486 and Durvalumab in Subjects With Myelodysplastic Syndromes,7245
3,NCT02811497,Phase II,Recruiting,"[{'id': 4178, 'therapyName': 'Azacitidine + MEDI4736'}]",Study of Azacitidine and Durvalumab in Advanced Solid Tumors (METADUR),7245
4,NCT02775903,Phase II,Recruiting,"[{'id': 651, 'therapyName': 'Azacitidine'}, {'id': 4178, 'therapyName': 'Azacitidine + MEDI4736'}]",An Efficacy and Safety Study of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects With Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly Subjects With Acute Myeloid Leukemia (AML),7245
5,NCT02117219,Phase I,Recruiting,"[{'id': 4178, 'therapyName': 'Azacitidine + MEDI4736'}]",Phase 1 Study to Evaluate MEDI4736 in MDS,7245
6,NCT02740985,Phase I,Recruiting,"[{'id': 4223, 'therapyName': 'AZD4635'}, {'id': 4349, 'therapyName': 'AZD4635 + MEDI4736'}]",A Phase 1 Clinical Study of AZD4635 and Durvalumab in Patients With Advanced Solid Malignancies,7245
7,NCT02583477,Phase Ib/II,Recruiting,"[{'id': 3099, 'therapyName': 'AZD5069 + MEDI4736'}, {'id': 3163, 'therapyName': 'Gemcitabine + MEDI4736 + nab-paclitaxel'}]",Phase Ib/II Study of MEDI4736 Evaluated in Different Combinations in Metastatic Pancreatic Ductal Carcinoma,7245
8,NCT02499328,Phase Ib/II,Recruiting,"[{'id': 3098, 'therapyName': 'AZD9150 + MEDI4736'}, {'id': 3099, 'therapyName': 'AZD5069 + MEDI4736'}, {'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 2782, 'therapyName': 'AZD9150 '}]",Study to Assess Combination of MEDI4736 With Either AZD9150 or AZD5069 in Patients With Metastatic Squamous Cell Carcinoma of Head and Neck,7245
9,NCT02264678,Phase Ib/II,Recruiting,"[{'id': 2881, 'therapyName': 'AZD6738'}, {'id': 4737, 'therapyName': 'AZD6738 + Carboplatin'}, {'id': 4738, 'therapyName': 'AZD6738 + MEDI4736'}, {'id': 4739, 'therapyName': 'AZD6738 + Olaparib'}]",Ascending Doses of AZD6738 in Combination With Chemotherapy and/or Novel Anti Cancer Agents,7245
10,NCT02983578,Phase II,Recruiting,"[{'id': 3098, 'therapyName': 'AZD9150 + MEDI4736'}]","AZD9150 With MEDI4736 in Patients With Advanced Pancreatic, Non-Small Lung and Colorectal Cancer",7245
11,NCT02549651,Phase I,Recruiting,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}, {'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 3098, 'therapyName': 'AZD9150 + MEDI4736'}]",MEDI4736 Alone and in Combination With Tremelimumab or AZD9150 in Adult Subjects With Diffuse Large B-cell Lymphoma (D4190C00023),7245
12,NCT02143466,Phase I,Recruiting,"[{'id': 2224, 'therapyName': 'AZD9291 + Savolitinib'}, {'id': 2225, 'therapyName': 'Osimertinib + Selumetinib'}, {'id': 2223, 'therapyName': 'AZD9291 + MEDI4736'}]",AZD9291 in Combination With Ascending Doses of Novel Therapeutics,7245
13,NCT02733042,Phase Ib/II,Recruiting,"[{'id': 897, 'therapyName': 'Rituximab'}, {'id': 4278, 'therapyName': 'lenalidomide + MEDI4736 + Rituximab'}, {'id': 4279, 'therapyName': 'Bendamustine + MEDI4736 + Rituximab'}, {'id': 2573, 'therapyName': 'Ibrutinib + MEDI4736'}, {'id': 1356, 'therapyName': 'Durvalumab'}]","A Study to Determine Dose, Safety, and Efficacy of Durvalumab as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocytic Leukemia (FUSION NHL 001)",7245
14,NCT02336165,Phase II,"Active, not recruiting","[{'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 2117, 'therapyName': 'Bevacizumab + MEDI4736'}]",Phase 2 Study of MEDI4736 in Patients With Glioblastoma,7245
15,NCT02754856,Phase I,Recruiting,"[{'id': 4097, 'therapyName': 'Bevacizumab + MEDI4736 + Tremelimumab + FOLFOX'}]",Tremelimumab (Anti-CTLA-4) Plus MEDI4736 (Anti-PD-L1) in Resectable Colorectal Cancer Liver Metastases.,7245
16,NCT03164772,Phase Ib/II,Not yet recruiting,"[{'id': 5818, 'therapyName': 'BI 1361849 + Durvalumab + Tremelimumab'}]",Phase 1/2 Study of Combination Immunotherapy and mRNA Vaccine in Subjects With NSCLC,7245
17,NCT03174275,Phase II,Not yet recruiting,"[{'id': 5873, 'therapyName': 'Carboplatin + Cisplatin + Durvalumab + Paclitaxel'}, {'id': 3997, 'therapyName': 'Carboplatin + Durvalumab + Paclitaxel'}]","Carboplatin, Nab-Paclitaxel, Durvalumab Before Surgery and Adjuvant Therapy in Head and Neck Squamous Cell Carcinoma",7245
18,NCT02726997,Phase Ib/II,Recruiting,"[{'id': 3997, 'therapyName': 'Carboplatin + Durvalumab + Paclitaxel'}]",Matched Paired Pharmacodynamics and Feasibility Study of Durvalumab in Combination With Chemotherapy in Frontline Ovarian Cancer,7245
19,NCT02962063,Phase Ib/II,Recruiting,"[{'id': 3997, 'therapyName': 'Carboplatin + Durvalumab + Paclitaxel'}]","Durvalumab, an Anti-PD-L1 Antibody, and Chemoradiation Before Surgery for Esophageal Cancer",7245
20,NCT02484404,Phase Ib/II,Recruiting,"[{'id': 2895, 'therapyName': 'Cediranib + Durvalumab'}, {'id': 2894, 'therapyName': 'Durvalumab + Olaparib'}]",Phase 1 and 2 Study of MEDI4736 in Combination With Olaparib or Cediranib for Advanced Solid Tumors and Recurrent Ovarian Cancer,7245
21,NCT02899195,Phase II,Recruiting,"[{'id': 5630, 'therapyName': 'Cisplatin + Durvalumab + Pemetrexed'}, {'id': 1356, 'therapyName': 'Durvalumab'}]",Phase II MEDI4736 in Combination With Chemotherapy for First-Line Treatment of Unresectable Mesothelioma (PrE0505),7245
22,NCT02706405,Phase I,Recruiting,"[{'id': 4365, 'therapyName': 'Cyclophosphamide + JCAR014 + MEDI4736'}]",JCAR014 and Durvalumab in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma,7245
23,NCT02027961,Phase Ib/II,"Active, not recruiting","[{'id': 1357, 'therapyName': 'Dabrafenib + Durvalumab + Trametinib'}, {'id': 1358, 'therapyName': 'Durvalumab + Trametinib'}]",Phase 1 Safety and Tolerability of MEDI4736 in Combination With Dabrafenib and Trametinib or With Trametinib Alone,7245
24,NCT02807454,Phase Ib/II,"Active, not recruiting","[{'id': 4531, 'therapyName': 'Daratumumab + Dexamethasone + MEDI4736 + Pomalidomide'}, {'id': 4530, 'therapyName': 'Daratumumab + MEDI4736'}]",A Study to Determine the Safety and Efficacy for the Combination of Durvalumab and Daratumumab in Relapsed and Refractory Multiple Myeloma (FUSIONMM-003),7245
25,NCT03000452,Phase II,"Active, not recruiting","[{'id': 4530, 'therapyName': 'Daratumumab + MEDI4736'}]",A Study to Determine the Efficacy of the Combination of Daratumumab (DARA) Plus Durvalumab (DURVA) (D2) in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) (FUSION-MM-005),7245
26,NCT03059485,Phase II,Recruiting,"[{'id': 5369, 'therapyName': 'DC/AML Vaccine'}, {'id': 5370, 'therapyName': 'DC/AML Vaccine + MEDI4736'}]",DC/AML Fusion Cell Vaccine vs DC/AML Fusion Cell Vaccine Plus Durvalumab vs Observation in Patients Who Achieve a Chemotherapy-induced Remission,7245
27,NCT02273375,Phase III,Recruiting,"[{'id': 1356, 'therapyName': 'Durvalumab'}]",Double Blind Placebo Controlled Controlled Study of Adjuvant MEDI4736 In Completely Resected NSCLC,7245
28,NCT02886065,Phase I,Recruiting,"[{'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 5082, 'therapyName': 'PVX-410 + MEDI4736'}, {'id': 5081, 'therapyName': 'PVX-410 + MEDI4736 + lenalidomide'}]","A Phase 1b Study of PVX-410, a Multi-Peptide Cancer Vaccine, and Durvalumab (Anti-PDL1) With and Without Lenalidomide for Patients With Smoldering Multiple Myeloma",7245
29,NCT03015129,Phase II,Recruiting,"[{'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}]",A Study of Durvalumab With or Without Tremelimumab in Endometrial Cancer,7245
30,NCT03038477,Phase II,Recruiting,"[{'id': 1356, 'therapyName': 'Durvalumab'}]",A Study of Durvalumab in Patients With Borderline Resectable Pancreas Adenocarcinoma Following Neoadjuvant Therapy and Successful Surgical Resection,7245
31,NCT02793466,Phase I,Recruiting,"[{'id': 1356, 'therapyName': 'Durvalumab'}]",Durvalumab in Pediatric and Adolescent Patients,7245
32,NCT02527434,Phase II,"Active, not recruiting","[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}, {'id': 1356, 'therapyName': 'Durvalumab'}]",Study of Tremelimumab in Patients With Advanced Solid Tumors,7245
33,NCT03084471,Phase III,Recruiting,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}, {'id': 1356, 'therapyName': 'Durvalumab'}]","An Open-Label, Multi-Centre, Study to Assess the Safety of Fixed-Dose Durvalumab + Tremelimumab Combination Therapy or Durvalumab Monotherapy in Advanced Solid Malignancies. (STRONG)",7245
34,NCT03298451,Phase III,Not yet recruiting,"[{'id': 920, 'therapyName': 'Sorafenib'}, {'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}, {'id': 1356, 'therapyName': 'Durvalumab'}]",Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Unresectable Hepatocellular Carcinoma,7245
35,NCT02516241,Phase III,Recruiting,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}, {'id': 4686, 'therapyName': 'Carboplatin + Cisplatin + Gemcitabine'}, {'id': 1356, 'therapyName': 'Durvalumab'}]",Study of MEDI4736 With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer,7245
36,NCT03196401,Phase I,Suspended,"[{'id': 1356, 'therapyName': 'Durvalumab'}]",A Study of Immunotherapy Plus Radiation Therapy to Stimulate Immunity in Solitary Bone Plasmacytoma,7245
37,NCT02319044,Phase II,"Active, not recruiting","[{'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 1652, 'therapyName': 'Tremelimumab'}]","Phase II Study of MEDI4736, Tremelimumab, and MEDI4736 in Combination w/ Tremelimumab Squamous Cell Carcinoma of the Head and Neck",7245
38,NCT02558894,Phase II,Completed,"[{'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 1652, 'therapyName': 'Tremelimumab'}]",Phase II Study of MEDI4736 Monotherapy or in Combinations With Tremelimumab in Metastatic Pancreatic Ductal Carcinoma,7245
39,NCT02207530,Phase II,"Active, not recruiting","[{'id': 1356, 'therapyName': 'Durvalumab'}]",Phase II Study of MEDI4736 Monotherapy in the Treatment of Patients With Recurrent or Metastatic SCCHN.,7245
40,NCT02788773,Phase II,Recruiting,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}, {'id': 1356, 'therapyName': 'Durvalumab'}]",Durvalumab With or Without Tremelimumab in Metastatic Castration Resistant Prostate Cancer,7245
41,NCT03206073,Phase Ib/II,Recruiting,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}, {'id': 1356, 'therapyName': 'Durvalumab'}]",A Phase I/II Study of Pexa-Vec Oncolytic Virus in Combination With Immune Checkpoint Inhibition in Refractory Colorectal Cancer,7245
42,NCT02369874,Phase III,"Active, not recruiting","[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}, {'id': 1356, 'therapyName': 'Durvalumab'}]",Study of MEDI4736 Monotherapy and in Combination With Tremelimumab Versus Standard of Care Therapy in Patients With Head and Neck Cancer,7245
43,NCT02879617,Phase II,Recruiting,"[{'id': 1356, 'therapyName': 'Durvalumab'}]",A Clinical Trial of Durvalumab (MEDI4736) as 1st Line Therapy in Advanced Non-small Cell Lung Cancer Patients,7245
44,NCT02340975,Phase Ib/II,Recruiting,"[{'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 1652, 'therapyName': 'Tremelimumab'}]","A Phase 1b/2 Study of MEDI4736 With Tremelimumab, MEDI4736 or Tremelimumab Monotherapy in Gastric or GEJ Adenocarcinoma",7245
45,NCT03011814,Phase Ib/II,"Active, not recruiting","[{'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 3934, 'therapyName': 'lenalidomide + MEDI4736'}]",Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma,7245
46,NCT02227667,Phase II,Recruiting,"[{'id': 1356, 'therapyName': 'Durvalumab'}]",Evaluate the Efficacy of MEDI4736 in Immunological Subsets of Advanced Colorectal Cancer,7245
47,NCT02966587,Phase II,Not yet recruiting,"[{'id': 1356, 'therapyName': 'Durvalumab'}]",Durvalumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer,7245
48,NCT02891161,Phase Ib/II,Recruiting,"[{'id': 1356, 'therapyName': 'Durvalumab'}]",Durvalumab And Radiation Therapy Followed by Adjuvant Durvalumab in Patients With Urothelial Cancer (T2-4 N0-2 M0) of the Bladder,7245
49,NCT02901548,Phase II,Recruiting,"[{'id': 1356, 'therapyName': 'Durvalumab'}]",Phase 2 Durvalumab (Medi4736) for Bacillus Calmette-Guérin (BCG) Refactory Urothelial Carcinoma in Situ of the Bladder,7245
50,NCT03235869,Phase I,Not yet recruiting,"[{'id': 1356, 'therapyName': 'Durvalumab'}]",Radiation Therapy Plus Durvalumab for Tumor-Stage Cutaneous T-Cell Lymphoma,7245
51,NCT02205333,Phase Ib/II,Terminated,"[{'id': 897, 'therapyName': 'Rituximab'}, {'id': 1653, 'therapyName': 'MEDI6469'}, {'id': 1652, 'therapyName': 'Tremelimumab'}, {'id': 1356, 'therapyName': 'Durvalumab'}]",A Phase 1b/2 Safety and Tolerability of MEDI6469 in Combination With Therapeutic Immune Agents or Monoclonal Antibodies,7245
52,NCT02551159,Phase III,"Active, not recruiting","[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 1914, 'therapyName': 'Cetuximab + Carboplatin + Fluorouracil'}, {'id': 1652, 'therapyName': 'Tremelimumab'}]",Phase III Open Label First Line Therapy Study of MEDI 4736 With or Without Tremelimumab Versus Standard of Care (SOC) in SCCHN,7245
53,NCT02904954,Phase II,Recruiting,"[{'id': 1356, 'therapyName': 'Durvalumab'}]",Durvalumab (MEDI4736) With or Without SBRT in Clinical Stage IB and II Non-small Cell Lung Cancer,7245
54,NCT02221960,Phase I,"Active, not recruiting","[{'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 3119, 'therapyName': 'MEDI6383'}]",A Phase 1 Study to Evaluate MEDI6383 Alone and in Combination With MEDI4736 in Adult Subjects With Select Advanced Solid Tumors,7245
55,NCT03007407,Phase II,Recruiting,"[{'id': 1652, 'therapyName': 'Tremelimumab'}, {'id': 1356, 'therapyName': 'Durvalumab'}]",Study of Durvalumab and Tremelimumab After Radiation for Microsatellite Stable Metastatic Colorectal Cancer Progressing on Chemotherapy,7245
56,NCT02592551,Phase II,Recruiting,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}, {'id': 1356, 'therapyName': 'Durvalumab'}]",MEDI4736 Or MEDI4736 + Tremelimumab In Surgically Resectable Malignant Pleural Mesothelioma,7245
57,NCT03150836,Phase II,Not yet recruiting,"[{'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}]","Radiation Therapy and Durvalumab, With or Without Tremelimumab, in Patients With Bladder Cancer",7245
58,NCT02291055,Phase Ib/II,Recruiting,"[{'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 3090, 'therapyName': 'ADXS11-001'}]",Phase 1-2 Study of ADXS11-001 or MEDI4736 Alone or Combo In Cervical or HPV+ Head &amp; Neck Cancer,7245
59,NCT02154490,Phase II,Recruiting,"[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 850, 'therapyName': 'Palbociclib'}, {'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 654, 'therapyName': 'AZD4547'}, {'id': 1016, 'therapyName': 'GDC-0032'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 629, 'therapyName': 'AMG102'}]",Lung-MAP: S1400 Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IIIB-IV Squamous Cell Lung Cancer,7245
60,NCT02179671,Phase II,Completed,"[{'id': 1117, 'therapyName': 'Selumetinib + Docetaxel'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 660, 'therapyName': 'AZD9291'}, {'id': 1652, 'therapyName': 'Tremelimumab'}]","Immune-Modulated Study of Selected Small Molecules (Gefitinib, AZD9291, or Selumetinib + Docetaxel) or a 1st Immune-Mediated Therapy (IMT; Tremelimumab) With a Sequential Switch to a 2nd IMT (MEDI4736) in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer",7245
61,NCT02087423,Phase II,"Active, not recruiting","[{'id': 1356, 'therapyName': 'Durvalumab'}]",A Global Study to Assess the Effects of MEDI4736 in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer (ATLANTIC),7245
62,NCT02262741,Phase I,"Active, not recruiting","[{'id': 1652, 'therapyName': 'Tremelimumab'}, {'id': 1356, 'therapyName': 'Durvalumab'}]","A Phase I Study to Evaluate the Safety, Tolerability and Efficacy of MEDI4736 With Tremelimumab or Tremelimumab Alone in Head and Neck Cancer",7245
63,NCT02454933,Phase III,"Active, not recruiting","[{'id': 660, 'therapyName': 'AZD9291'}, {'id': 1356, 'therapyName': 'Durvalumab'}]",Study of AZD9291 Plus MEDI4736 Versus AZD9291 Monotherapy in NSCLC After Previous EGFR TKI Therapy in T790M Mutation Positive Tumours,7245
64,NCT02639065,Phase II,Recruiting,"[{'id': 1356, 'therapyName': 'Durvalumab'}]",A Study of Durvalumab (MEDI4736) in Esophageal Cancer,7245
65,NCT03164616,Phase III,Recruiting,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}, {'id': 1857, 'therapyName': 'Cisplatin + Pemetrexed'}, {'id': 1602, 'therapyName': 'Carboplatin + Pemetrexed'}, {'id': 1467, 'therapyName': 'Gemcitabine + Cisplatin'}, {'id': 2667, 'therapyName': 'Carboplatin + Gemcitabine'}, {'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 2634, 'therapyName': 'Carboplatin + nab-paclitaxel'}]",Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON). (POSEIDON),7245
66,NCT02503774,Phase I,Recruiting,"[{'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 3089, 'therapyName': 'MEDI9447'}]",MEDI9447 Alone and in Combination With MEDI4736 in Adult Subjects With Select Advanced Solid Tumors,7245
67,NCT02301130,Phase I,"Active, not recruiting","[{'id': 2968, 'therapyName': 'Mogamulizumab '}, {'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 1652, 'therapyName': 'Tremelimumab'}]",Study of Mogamulizumab + MEDI4736 and Mogamulizumab + Tremelimumab in Subjects w/ Advanced Solid Tumors,7245
68,NCT02537418,Phase I,"Active, not recruiting","[{'id': 2585, 'therapyName': 'Cisplatin + Etoposide'}, {'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 1652, 'therapyName': 'Tremelimumab'}]",Durvalumab With or Without Tremelimumab in Advanced Incurable Solid Malignancies Receiving Standard Chemotherapy Regimens,7245
69,NCT02352948,Phase III,"Active, not recruiting","[{'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 2438, 'therapyName': 'Erlotinib + Gemcitabine + Vinorelbine'}, {'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}, {'id': 1652, 'therapyName': 'Tremelimumab'}]","A Global Study to Assess the Effects of MEDI4736, Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer",7245
70,NCT02546661,Phase I,Recruiting,"[{'id': 654, 'therapyName': 'AZD4547'}, {'id': 1356, 'therapyName': 'Durvalumab'}]","Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer",7245
71,NCT02088112,Phase I,"Active, not recruiting","[{'id': 751, 'therapyName': 'Gefitinib'}, {'id': 1356, 'therapyName': 'Durvalumab'}]",MEDI4736 (Anti PD-L1) Combined With Gefitinib in Subjects With Non-Small Cell Lung Cancer(NSCLC),7245
72,NCT02519348,Phase II,Recruiting,"[{'id': 1652, 'therapyName': 'Tremelimumab'}, {'id': 1356, 'therapyName': 'Durvalumab'}]","A Study of MEDI4736 With Tremelimumab, MEDI4736 or Tremelimumab Monotherapy in Unresectable Hepatocellular Carcinoma",7245
73,NCT03026062,Phase II,Recruiting,"[{'id': 1652, 'therapyName': 'Tremelimumab'}, {'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}, {'id': 1356, 'therapyName': 'Durvalumab'}]",Durvalumab and Tremelimumab in Combo Versus Sequential,7245
74,NCT01693562,Phase Ib/II,"Active, not recruiting","[{'id': 1356, 'therapyName': 'Durvalumab'}]",A Phase 1/2 Study to Evaluate MEDI4736,7245
75,NCT02616640,Phase I,"Active, not recruiting","[{'id': 1622, 'therapyName': 'Pomalidomide'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 1356, 'therapyName': 'Durvalumab'}]",A Study to Determine Dose and Regimen of Durvalumab as Monotherapy or in Combination With Pomalidomide With or Without Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma,7245
76,NCT03277482,Phase I,Not yet recruiting,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}, {'id': 1356, 'therapyName': 'Durvalumab'}]","Durvalumab, Tremelimumab + Radiotherapy in Gynecologic Cancer",7245
77,NCT02453282,Phase III,"Active, not recruiting","[{'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 1467, 'therapyName': 'Gemcitabine + Cisplatin'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 1652, 'therapyName': 'Tremelimumab'}]",Phase III Open Label First Line Therapy Study of MEDI 4736 With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC).,7245
78,NCT03144778,Phase I,Recruiting,"[{'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}]",Checkpoint Inhibitors Assessment in Oropharynx Carcinoma (CIAO),7245
79,NCT03199040,Phase I,Not yet recruiting,"[{'id': 1356, 'therapyName': 'Durvalumab'}]",Neoantigen DNA Vaccine Alone vs. Neoantigen DNA Vaccine Plus Durvalumab in Triple Negative Breast Cancer Patients Following Standard of Care Therapy,7245
80,NCT02868632,Phase I,Recruiting,"[{'id': 1652, 'therapyName': 'Tremelimumab'}, {'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}, {'id': 1356, 'therapyName': 'Durvalumab'}]","Study of Immune Checkpoint Inhibition With Radiation Therapy in Unresectable, Non-metastatic Pancreatic Cancer",7245
81,NCT03258554,Phase II,Not yet recruiting,"[{'id': 694, 'therapyName': 'Cetuximab'}, {'id': 1356, 'therapyName': 'Durvalumab'}]",Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Stage III-IVB Head and Neck Cancer Who Cannot Take Cisplatin,7245
82,NCT03283943,Phase I,Not yet recruiting,"[{'id': 1356, 'therapyName': 'Durvalumab'}]",PDL-1 Inhibition and Focal Sensitizing Radiotherapy in Recurrent Ovarian/Primary Peritoneal/Fallopian Tube Cancers.,7245
83,NCT03245541,Phase Ib/II,Recruiting,"[{'id': 1356, 'therapyName': 'Durvalumab'}]",Study of Durvalumab and Stereotactive Ablative Body Radiotherapy in Advanced Pancreatic Adenocarcinoma (DurvaRad),7245
84,NCT02827838,Phase I,Recruiting,"[{'id': 1356, 'therapyName': 'Durvalumab'}]",Durvalumab Before Surgery in Treating Patients With Oral Cavity or Oropharynx Cancer,7245
85,NCT02311361,Phase I,Recruiting,"[{'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 1652, 'therapyName': 'Tremelimumab'}]",Immune Checkpoint Inhibition (Tremelimumab and/or MEDI4736) in Combination With Radiation Therapy in Patients With Unresectable Pancreatic Cancer,7245
86,NCT02535078,Phase Ib/II,Recruiting,"[{'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 3847, 'therapyName': 'IMCgp100'}, {'id': 1652, 'therapyName': 'Tremelimumab'}]",Phase 1b/2 Study of the Combination of IMCgp100 With Durvalumab and/or Tremelimumab in Cutaneous Melanoma,7245
87,NCT03215095,Phase I,Recruiting,"[{'id': 1356, 'therapyName': 'Durvalumab'}]",RAI Plus Immunotherapy for Recurrent/Metastatic Thyroid Cancers,7245
88,NCT02125461,Phase III,"Active, not recruiting","[{'id': 1356, 'therapyName': 'Durvalumab'}]",A Global Study to Assess the Effects of MEDI4736 Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer (PACIFIC),7245
89,NCT02669914,Phase II,Recruiting,"[{'id': 1356, 'therapyName': 'Durvalumab'}]",MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors,7245
90,NCT02794883,Phase II,Recruiting,"[{'id': 1652, 'therapyName': 'Tremelimumab'}, {'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}, {'id': 1356, 'therapyName': 'Durvalumab'}]",Tremelimumab and Durvalumab in Combination or Alone in Treating Patients With Recurrent Malignant Glioma,7245
91,NCT03162224,Phase Ib/II,Recruiting,"[{'id': 5791, 'therapyName': 'Durvalumab + MEDI0457'}]",Safety and Efficacy of MEDI0457 and Durvalumab in Patients With HPV Associated Recurrent/Metastatic Head and Neck Cancer,7245
92,NCT02734004,Phase Ib/II,"Active, not recruiting","[{'id': 2894, 'therapyName': 'Durvalumab + Olaparib'}]",A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors. (MEDIOLA),7245
93,NCT03258593,Phase I,Not yet recruiting,"[{'id': 6291, 'therapyName': 'Durvalumab + Oportuzumab monatox'}]",Durvalumab and Vicinium in Subjects With High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated With Bacillus Calmette-Guerin (BCG),7245
94,NCT03257761,Phase I,Not yet recruiting,"[{'id': 6146, 'therapyName': 'Durvalumab + SGI-110'}]","Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer",7245
95,NCT02000947,Phase Ib/II,"Active, not recruiting","[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}]",A Phase 1b Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Non-small Cell Lung Cancer,7245
96,NCT02938793,Phase II,Recruiting,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}]",Durvalumab in Combination With Tremelimumab in Subjects With Advanced Rare Solid Tumors,7245
97,NCT02812420,Phase I,Recruiting,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}]","Pre-Surgical Study Evaluating Anti-PD-L1 Antibody (Durvalumab) Plus Anti-CTLA-4 (Tremelimumab) in Patients With Muscle-Invasive, High-Risk Urothelial Carcinoma Who Are Ineligible for Cisplatin-based Neoadjuvant Chemotherapy",7245
98,NCT03130764,Phase II,Not yet recruiting,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}]",Durvalumab and Tremelimumab for Adjuvant Therapy of Resected NSCLC,7245
99,NCT03005002,Phase I,Recruiting,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}]",Durvalumab and Tremelimumab in Treating Patients With Microsatellite Stable Metastatic Colorectal Cancer to the Liver,7245
100,NCT03158064,Phase II,Recruiting,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}]","Evaluating Immune Therapy, Duravalumab (MEDI4736) With Tremelimumab for Relapsed/Refractory Germ Cell Tumors",7245
101,NCT02542293,Phase III,Recruiting,"[{'id': 1467, 'therapyName': 'Gemcitabine + Cisplatin'}, {'id': 2667, 'therapyName': 'Carboplatin + Gemcitabine'}, {'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 1857, 'therapyName': 'Cisplatin + Pemetrexed'}, {'id': 1602, 'therapyName': 'Carboplatin + Pemetrexed'}]",Study of 1st Line Therapy Study of MEDI4736 With Tremelimumab Versus SoC in Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE).,7245
102,NCT02879162,Phase II,Recruiting,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}]",Durvalumab and Tremelimumab in Patients With Advanced Rare Tumours,7245
103,NCT03122509,Phase II,Recruiting,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}]","A Clinical Trial of Durvalumab and Tremelimumab, Administered With Radiation Therapy or Ablation in Patients With Colorectal Cancer",7245
104,NCT02879318,Phase II,Recruiting,"[{'id': 1779, 'therapyName': 'Nab-paclitaxel + Gemcitabine'}, {'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}]","Gemcitabine and Nab-Paclitaxel vs Gemcitabine, Nab-Paclitaxel, Durvalumab and Tremelimumab as 1st Line Therapy in Pancreatic Adenocarcinoma",7245
105,NCT03122496,Phase I,Recruiting,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}]",Immunotherapy and Stereotactic Body Radiotherapy (SBRT) for Metastatic Anaplastic Thyroid Cancer,7245
106,NCT02815995,Phase II,Recruiting,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}]",Multi-Arm Study to Test the Efficacy of Immunotherapeutic Agents in Multiple Sarcoma Subtypes,7245
107,NCT02639026,Phase I,Recruiting,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}]","Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic Cancers",7245
108,NCT03275597,Phase I,Not yet recruiting,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}]",Phase Ib Study of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Non-small Lung Cancer (NSCLC) With Dual Immune Checkpoint Inhibition,7245
109,NCT02870920,Phase II,"Active, not recruiting","[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}]",Durvalumab and Tremelimumab and Best Supportive Care vs Best Supportive Care Alone in Patients With Advanced Colorectal Adenocarcinoma Refractory to Standard Therapies,7245
110,NCT03132467,Phase I,Recruiting,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}]",Evaluating Anti-PD-L1 Antibody (Durvalumab) Plus Anti-CTLA-4 Antibody (Tremelimumab) in HR+/HER2- Breast Cancer,7245
111,NCT03057106,Phase II,Recruiting,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}, {'id': 854, 'therapyName': 'Pemetrexed'}]",Durvalumab and Tremelimumab ± Platinum-Based Chemotherapy in Patients With Metastatic Squamous or Non-Squamous NSCLC,7245
112,NCT03204812,Phase II,Recruiting,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}]",Tremelimumab + Durvalumab Chemotherapy Naive CRPC,7245
113,NCT02716805,Phase I,"Active, not recruiting","[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}]","Phase 1 Study to Assess Safety & Tolerability of Tremelimumab & Durvalumab, Administered With High Dose Chemotherapy and Autologous Stem Cell Transplant",7245
114,NCT01975831,Phase I,"Active, not recruiting","[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}]",A Phase 1 Study to Evaluate MEDI4736 in Combination With Tremelimumab,7245
115,NCT02536794,Phase II,Suspended,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}]",MEDI4736 and Tremelimumab in Treating Patients With Metastatic HER2 Negative Breast Cancer,7245
116,NCT02658214,Phase I,Recruiting,"[{'id': 2667, 'therapyName': 'Carboplatin + Gemcitabine'}, {'id': 2634, 'therapyName': 'Carboplatin + nab-paclitaxel'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 1791, 'therapyName': 'Carboplatin + Etoposide'}]",Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors,7245
117,NCT02888743,Phase II,Recruiting,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}]",Durvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating Patients With Metastatic Colorectal or Non-small Cell Lung Cancer,7245
118,NCT02261220,Phase I,"Active, not recruiting","[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}]",A Phase 1 Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Solid Tumors,7245
119,NCT02762006,Phase I,Recruiting,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}]",Neoadjuvant MEDI 4736 +/- Tremelimumab in Locally Advanced Renal Cell Carcinoma,7245
120,NCT03075527,Phase II,Recruiting,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}]",A Phase 2 Study of Durvalumab in Combination With Tremelimumab in Malignant Pleural Mesothelioma,7245
121,NCT03283605,Phase Ib/II,Not yet recruiting,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}]",Immunotherapy and SBRT for Metastatic Head and Neck Carcinomas,7245
122,NCT02821754,Phase Ib/II,Recruiting,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}]",A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC),7245
123,NCT02725489,Phase II,Recruiting,"[{'id': 4388, 'therapyName': 'FANG vaccine + MEDI4736'}]",Pilot Study of Durvalumab (MEDI4736) in Combination With Vigil in Advanced Breast Cancer,7245
124,NCT02734160,Phase I,Recruiting,"[{'id': 4211, 'therapyName': 'Galunisertib + MEDI4736'}]",A Study of Galunisertib (LY2157299) and Durvalumab (MEDI4736) in Participants With Metastatic Pancreatic Cancer,7245
125,NCT02403271,Phase Ib/II,Completed,"[{'id': 2573, 'therapyName': 'Ibrutinib + MEDI4736'}]",A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors,7245
126,NCT02401048,Phase Ib/II,"Active, not recruiting","[{'id': 2573, 'therapyName': 'Ibrutinib + MEDI4736'}]",A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Lymphomas,7245
127,NCT02318277,Phase Ib/II,Recruiting,"[{'id': 3015, 'therapyName': 'INCB024360 + MEDI4736'}]",A Study of INCB024360 in Combination With MEDI4736 in Subjects With Selected Advanced Solid Tumors,7245
128,NCT02685826,Phase I,Suspended,"[{'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 3934, 'therapyName': 'lenalidomide + MEDI4736'}]",A Study of Durvalumab in Combination With Lenalidomide With and Without Dexamethasone in Subjects With Newly Diagnosed Multiple Myeloma,7245
129,NCT02737072,Phase I,"Active, not recruiting","[{'id': 4210, 'therapyName': 'LY2510924 + MEDI4736'}]",A Study of LY2510924 and Durvalumab in Participants With Solid Tumors,7245
130,NCT02718911,Phase I,Recruiting,"[{'id': 4216, 'therapyName': 'LY3022855 + Tremelimumab'}, {'id': 4215, 'therapyName': 'LY3022855 + MEDI4736'}]",A Study of LY3022855 in Combination With Durvalumab or Tremelimumab in Participants With Advanced Solid Tumors,7245
131,NCT02705482,Phase I,Recruiting,"[{'id': 3840, 'therapyName': 'MEDI0562 + Tremelimumab'}, {'id': 3839, 'therapyName': 'MEDI0562 + MEDI4736'}]",A Study to Evaluate MEDI0562 in Combination With Immune Therapeutic Agents in Adult Subjects With Advanced Solid Tumors,7245
132,NCT02118337,Phase I,Recruiting,"[{'id': 3121, 'therapyName': 'MEDI0680 + MEDI4736'}]","A Phase 1, Open-label Study to Evaluate the Safety and Tolerability of MEDI0680 (AMP-514) in Combination With MEDI4736 in Subjects With Advanced Malignancies",7245
133,NCT03019003,Phase Ib/II,Recruiting,"[{'id': 5199, 'therapyName': 'MEDI4736 + Azacitidine + Tremelimumab'}]","A Phase IB/II Study With Azacitidine, Durvalumab, and Tremelimumab in Recurrent and/or Metastatic Head and Neck Cancer Patients",7245
134,NCT03043872,Phase III,Recruiting,"[{'id': 5305, 'therapyName': 'MEDI4736 + Tremelimumab + Carboplatin + Cisplatin + Etoposide'}, {'id': 5306, 'therapyName': 'MEDI4736 + Carboplatin + Cisplatin + Etoposide'}, {'id': 4728, 'therapyName': 'Carboplatin + Cisplatin + Etoposide'}]",Durvalumab+/- Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer (Caspian),7245
135,NCT03089645,Phase I,Recruiting,"[{'id': 5588, 'therapyName': 'MEDI5083'}, {'id': 5589, 'therapyName': 'MEDI4736 + MEDI5083'}]",MEDI5083 Alone and in Combination With Durvalumab in Subjects With Select Advanced Solid Tumors,7245
136,NCT02900157,Phase I,"Active, not recruiting","[{'id': 4727, 'therapyName': 'MEDI4736 + MEDI9090'}]",Study to Evaluate the Safety and Pharmacokinetics of MEDI9090 in Subjects With Advanced Solid Tumors,7245
137,NCT02617277,Phase I,Recruiting,"[{'id': 3414, 'therapyName': 'MEDI4736 + MK-1775'}]","Safety, Tolerability and Pharmacokinetics of AZD1775 Plus MEDI4736 in Patients With Advanced Solid Tumours",7245
138,NCT02805660,Phase Ib/II,Recruiting,"[{'id': 4378, 'therapyName': 'MEDI4736 + Mocetinostat'}]",Phase 1/2 Study of Mocetinostat and Durvalumab in Patients With Advanced Solid Tumors and NSCLC,7245
139,NCT02993991,Phase I,Not yet recruiting,"[{'id': 4378, 'therapyName': 'MEDI4736 + Mocetinostat'}]",Pre-operative Mocetinostat (MGCD0103) and Durvalumab (MEDI4736) (PRIMED) for Squamous Cell Carcinoma of the Oral Cavity,7245
140,NCT02489448,Phase Ib/II,Recruiting,"[{'id': 3100, 'therapyName': 'MEDI4736 + nab-paclitaxel'}, {'id': 1977, 'therapyName': 'Doxorubicin + Cyclophosphamide'}]",Neoadjuvant MEDI4736 Concomitant With Weekly Nab-paclitaxel and Dose-dense AC for Stage I-III Triple Negative Breast Cancer,7245
141,NCT02953457,Phase Ib/II,Recruiting,"[{'id': 4949, 'therapyName': 'MEDI4736 + Olaparib + Tremelimumab'}]","Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRAC2 Mutation",7245
142,NCT02643303,Phase Ib/II,Recruiting,"[{'id': 3385, 'therapyName': 'MEDI4736 + poly ICLC '}, {'id': 1652, 'therapyName': 'Tremelimumab'}]","A Phase 1/2 Study of In Situ Vaccination With Tremelimumab and IV Durvalumab Plus PolyICLC in Subjects With Advanced, Measurable, Biopsy-accessible Cancers",7245
143,NCT02826434,Phase I,Recruiting,"[{'id': 4466, 'therapyName': 'MEDI4736 + PVX-410 + poly ICLC '}]",Adjuvant PVX-410 Vaccine and Durvalumab in Stage II/III Triple Negative Breast Cancer,7245
144,NCT03003520,Phase II,Recruiting,"[{'id': 5350, 'therapyName': 'MEDI4736 + R2-CHOP'}, {'id': 5349, 'therapyName': 'MEDI4736 + Rituximab + Doxorubicin + Vincristine + Cyclophosphamide + Prednisone'}]",A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma,7245
145,NCT02572687,Phase I,Recruiting,"[{'id': 3257, 'therapyName': 'MEDI4736 + Ramucirumab'}]",A Study of Ramucirumab (LY3009806) Plus MEDI4736 in Participants With Advanced Gastrointestinal or Thoracic Malignancies,7245
146,NCT03004105,Phase II,Not yet recruiting,"[{'id': 3162, 'therapyName': 'MEDI4736 + Selumetinib'}]",MEDI4736 With Selumetinib for KRAS Mutant Non-Small Cell Lung Cancer (NSCLC),7245
147,NCT02586987,Phase I,Recruiting,"[{'id': 3162, 'therapyName': 'MEDI4736 + Selumetinib'}]","A Study to Assess the Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of Ascending Doses of Selumetinib in Combination With MEDI4736 in Patients With Advanced Solid Tumours",7245
148,NCT02764333,Phase II,Recruiting,"[{'id': 4180, 'therapyName': 'MEDI4736 + TPIV 200'}]",TPIV200/huFR-1 (A Multi-Epitope Anti-Folate Receptor Vaccine) Plus Anti-PD-L1 MEDI4736 (Durvalumab) in Patients With Platinum Resistant Ovarian Cancer,7245
149,NCT02649686,Phase I,"Active, not recruiting","[{'id': 4218, 'therapyName': 'MEDI4736 + Trastuzumab'}]",Durvalumab in Patients With HER-2 Positive Metastatic Breast Cancer Receiving Trastuzumab,7245
150,NCT02898116,Phase Ib/II,Recruiting,"[{'id': 4730, 'therapyName': 'MEDI4736 + X-396'}, {'id': 961, 'therapyName': 'X-396'}]","A Study of ALK Inhibitor, Ensartinib, and Anti-PD-L1, Durvalumab, in Subjects With ALK-rearranged Non-small Cell Lung Cancer",7245
151,NCT02556463,Phase I,Recruiting,"[{'id': 5457, 'therapyName': 'MEDI9197'}, {'id': 5458, 'therapyName': 'MEDI9197 + MEDI4736'}]",A Study of MEDI9197 in Subjects With Solid Tumors or CTCL and in Combination With Durvalumab and Palliative Radiation in Subjects With Solid Tumors,7245
152,NCT02963831,Phase Ib/II,Recruiting,"[{'id': 4978, 'therapyName': 'ONCOS-102 + MEDI4736'}]","A Phase 1/2 Study to Investigate the Safety, Biologic and Anti-tumor Activity of ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies",7245
153,NCT03085849,Phase I,Recruiting,"[{'id': 5488, 'therapyName': 'SGI-110 + MEDI4736 + Tremelimumab'}]",SGI-110 Plus Durvalumab/Tremelimumab in SCLC,7245
0,NCT02783625,Phase I,Recruiting,"[{'id': 4240, 'therapyName': 'Bortezomib + Duvelisib'}, {'id': 4239, 'therapyName': 'Duvelisib + romidepsin '}]",Trial of Duvelisib in Combination With Either Romidepsin or Bortezomib in Relapsed/Refractory T-cell Lymphomas,7141
1,NCT02004522,Phase III,"Active, not recruiting","[{'id': 1024, 'therapyName': 'Duvelisib'}, {'id': 1090, 'therapyName': 'Ofatumumab'}]",A Phase 3 Study of IPI-145 Versus Ofatumumab in Patients With Relapsed or Refractory CLL/SLL (DUO),7141
2,NCT02204982,Phase III,Terminated,"[{'id': 1024, 'therapyName': 'Duvelisib'}, {'id': 897, 'therapyName': 'Rituximab'}]",Study of IPI-145 in Combination With Rituximab vs Rituximab in Subjects With Previously Treated Follicular Lymphoma (DYNAMO + R),7141
3,NCT01871675,Phase I,Completed,"[{'id': 897, 'therapyName': 'Rituximab'}, {'id': 1024, 'therapyName': 'Duvelisib'}, {'id': 1231, 'therapyName': 'Bendamustine'}]","Phase Ib Study of IPI-145 in Combination With Bendamustine, Rituximab or Bendamustine/Rituximab in Hematologic Malignancies",7141
4,NCT01882803,Phase II,"Active, not recruiting","[{'id': 1024, 'therapyName': 'Duvelisib'}]",A Phase 2 Study of IPI-145 in Subjects With Refractory Indolent Non-Hodgkin Lymphoma (DYNAMO),7141
5,NCT02158091,Phase Ib/II,"Active, not recruiting","[{'id': 2339, 'therapyName': 'Cyclophosphamide + Fludarabine + Rituximab '}, {'id': 1024, 'therapyName': 'Duvelisib'}]","A Phase 1b/2 Study of IPI-145 Plus FCR in Previously Untreated, Younger Patients With CLL",7141
6,NCT02049515,Phase III,Enrolling by invitation,"[{'id': 1090, 'therapyName': 'Ofatumumab'}, {'id': 1024, 'therapyName': 'Duvelisib'}]",A Phase 3 Extension Study of IPI-145 and Ofatumumab in Patients With CLL/SLL Previously Enrolled in Study IPI-145-07,7141
7,NCT02576275,Phase III,Withdrawn,"[{'id': 2323, 'therapyName': 'Bendamustine + Rituximab'}, {'id': 1024, 'therapyName': 'Duvelisib'}]",A Study of Duvelisib in Combination With Rituximab and Bendamustine vs Placebo in Combination With Rituximab and Bendamustine in Subjects With Previously-Treated Indolent Non-Hodgkin Lymphoma (BRAVURA),7141
8,NCT02292225,Phase I,Terminated,"[{'id': 2341, 'therapyName': 'Duvelisib + Obinutuzumab'}]",IPI-145 With Obinutuzumab in Patients With CLL/SLL Previously Treated With a BTKi,7141
9,NCT02605694,Phase II,Withdrawn,"[{'id': 3389, 'therapyName': 'Duvelisib + Rituximab'}, {'id': 2195, 'therapyName': 'R-CHOP'}]",Duvelisib With Rituximab vs R-CHOP in Subjects With Relapsed/Refractory Follicular Lymphoma (FRESCO),7141
10,NCT02640833,Phase I,Withdrawn,"[{'id': 3624, 'therapyName': 'GDC-0199 + Duvelisib'}]","A Study of Duvelisib and Venetoclax in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Indolent or Aggressive Non-Hodgkin Lymphoma, Who Have Not Previously Received a Bcl-2 or PI3K Inhibitor",7141
0,NCT02418000,Phase Ib/II,Terminated,"[{'id': 1011, 'therapyName': 'E6201'}]",A Study of E6201 for the Treatment of Advanced Hematologic Malignancies With FLT3 Mutation,7128
0,NCT03152370,Phase I,Recruiting,"[{'id': 5798, 'therapyName': 'E7046 + mFOLFOX-6'}, {'id': 5805, 'therapyName': 'Capecitabine + E7046'}]",Preoperative Radiotherapy and E7046 in Rectum Cancer (PRAER 1),8749
1,NCT02540291,Phase I,Recruiting,"[{'id': 5694, 'therapyName': 'E7046'}]",Study of E7046 in Subjects With Selected Advanced Malignancies,8749
0,NCT01570036,Phase II,Recruiting,"[{'id': 3766, 'therapyName': 'E75'}, {'id': 1873, 'therapyName': 'Sargramostim'}, {'id': 947, 'therapyName': 'Trastuzumab'}]",Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax,8228
1,NCT01479244,Phase III,Completed,"[{'id': 3766, 'therapyName': 'E75'}, {'id': 1873, 'therapyName': 'Sargramostim'}]",Efficacy and Safety Study of NeuVax (Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence,8228
2,NCT02297698,Phase II,Recruiting,"[{'id': 1873, 'therapyName': 'Sargramostim'}, {'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 3766, 'therapyName': 'E75'}]",Phase II Trial of Combination Immunotherapy With NeuVax and Trastuzumab in High-risk HER2+ Breast Cancer Patients,8228
0,NCT01498484,Phase II,"Active, not recruiting","[{'id': 5057, 'therapyName': 'EB-VST cells'}]",Therapeutic Effects of Epstein-Barr Virus Immune T-Lymphocytes Derived From a Normal HLA-Compatible Or Partially-Matched Third-Party Donor in the Treatment of EBV Lymphoproliferative Disorders and EBV-Associated Malignancies,8602
1,NCT02973113,Phase I,Recruiting,"[{'id': 5058, 'therapyName': 'EB-VST cells + Nivolumab'}]","Nivolumab With Epstein Barr Virus Specific T Cells (EB-VSTS), Relapsed/Refractory EBV Positive Lymphoma (PREVALE) (PREVALE)",8602
0,NCT01999738,Phase I,"Active, not recruiting","[{'id': 1603, 'therapyName': 'EC1456'}]",Folic Acid-Tubulysin Conjugate EC1456 In Patients With Advanced Solid Tumors,7295
0,NCT02576496,Phase I,Recruiting,"[{'id': 6104, 'therapyName': 'EDO-S101'}]","Study of EDO-S101, A First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies",8916
0,NCT02139397,Phase Ib/II,Recruiting,"[{'id': 2629, 'therapyName': 'Eflornithine'}, {'id': 688, 'therapyName': 'Bortezomib'}]",Study of DFMO in Combination With Bortezomib for Relapsed or Refractory Neuroblastoma,7618
1,NCT02559778,Phase I,Recruiting,"[{'id': 688, 'therapyName': 'Bortezomib'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 2629, 'therapyName': 'Eflornithine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 717, 'therapyName': 'Dasatinib'}]",Pediatric Precision Laboratory Advanced Neuroblastoma Therapy,7618
0,NCT03258398,Phase II,Recruiting,"[{'id': 6238, 'therapyName': 'Avelumab + eFT508'}, {'id': 4005, 'therapyName': 'eFT508'}]",A Study to Evaluate eFT508 Alone and in Combination With Avelumab in Subjects With MSS Colorectal Cancer,8321
1,NCT02605083,Phase Ib/II,Recruiting,"[{'id': 4005, 'therapyName': 'eFT508'}]",A Dose Escalation and Cohort-Expansion Study of Oral eFT508 in Subjects With Advanced Solid Tumors,8321
2,NCT02937675,Phase Ib/II,Recruiting,"[{'id': 4005, 'therapyName': 'eFT508'}]",A Phase 1-2 Dose-Escalation and Cohort-Expansion Study of Oral eFT508 in Subjects With Hematological Malignancies,8321
0,NCT02108964,Phase Ib/II,Recruiting,"[{'id': 1309, 'therapyName': 'EGF816'}]","A Phase I/II, Multicenter, Open-label Study of EGFRmut-TKI EGF816, Administered Orally in Adult Patients With EGFRmut Solid Malignancies",7234
1,NCT03292133,Phase II,Not yet recruiting,"[{'id': 6287, 'therapyName': 'EGF816 + Gefitinib'}]",A Study of EGF816 and Gefitinib in TKI-naïve EGFR-mutant Non-Small Cell Lung Cancer,7234
2,NCT02335944,Phase Ib/II,Recruiting,"[{'id': 2445, 'therapyName': 'EGF816 + INC280'}]",Study of Safety and Efficacy of EGF816 in Combination With INC280 in Non-small Cell Lung Cancer Patients With EGFR Mutation.,7234
3,NCT02323126,Phase II,Recruiting,"[{'id': 2443, 'therapyName': 'EGF816 + Nivolumab'}, {'id': 2444, 'therapyName': 'INC280 + Nivolumab'}]",Study of Efficacy and Safety of Nivolumab in Combination With EGF816 and of Nivolumab in Combination With INC280 in Patients With Previously Treated Non-small Cell Lung Cancer,7234
4,NCT02900664,Phase I,Recruiting,"[{'id': 5399, 'therapyName': 'PDR001 + EGF816'}, {'id': 5397, 'therapyName': 'PDR001 + CJM112'}, {'id': 5398, 'therapyName': 'PDR001 + Trametinib'}, {'id': 5395, 'therapyName': 'PDR001 + Canakinumab'}]","A Study of PDR001 in Combination With CJM112, EGF816, Ilaris (Canakinumab) or Mekinist (Trametinib)",7234
0,NCT00903461,Phase Ib/II,Terminated,"[{'id': 2130, 'therapyName': 'EGFR Antisense DNA'}]",Safety and Efficacy of Radiation/Cetuximab Plus EGFR Antisense DNA for Head and Neck Squamous Cell Carcinoma,7430
0,NCT02766699,Phase I,Recruiting,"[{'id': 5331, 'therapyName': 'EGFR(V)-EDV-Dox'}]","A Study to Evaluate the Safety, Tolerability and Immunogenicity of EGFR(V)-EDV-Dox in Subjects With Recurrent Glioblastoma Multiforme (GBM) (CerebralEDV)",8665
0,NCT02521090,Phase Ib/II,Withdrawn,"[{'id': 1012, 'therapyName': 'EGFRBi-armed autologous activated T cells'}]",EGFRBi-Armed Autologous T Cells in Treating Patients With Recurrent or Refractory Glioblastoma,7129
1,NCT01081808,Phase I,Terminated,"[{'id': 1012, 'therapyName': 'EGFRBi-armed autologous activated T cells'}]","Laboratory-Treated Autologous Lymphocytes, Aldesleukin, and Sargramostim (GM-CSF) in Treating Advanced Solid Tumors",7129
2,NCT01420874,Phase I,"Active, not recruiting","[{'id': 1012, 'therapyName': 'EGFRBi-armed autologous activated T cells'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}]",Anti-CD3 x Anti-Erbitux Armed Activated T Cells (Phase Ib) for Gastrointestinal (GI Cancer),7129
3,NCT00569296,,Terminated,"[{'id': 1012, 'therapyName': 'EGFRBi-armed autologous activated T cells'}]"," Laboratory-Treated Autologous Lymphocytes, Aldesleukin, and GM-CSF in Treating Patients With Recurrent, Refractory, or Metastatic Non-Small Cell Lung Cancer",7129
0,NCT02718833,Phase II,Recruiting,"[{'id': 4031, 'therapyName': 'Bortezomib + Dexamethasone + Elotuzumab + Panobinostat'}]","A Study of Elotuzumab With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed Multiple Myeloma",8048
1,NCT02719613,Phase II,Recruiting,"[{'id': 4533, 'therapyName': 'Bortezomib + Elotuzumab + Dexamethasone + lenalidomide'}]",Continuing Treatment for Subjects Who Have Participated in a Prior Protocol Investigating Elotuzumab,8048
2,NCT02969837,Phase II,Recruiting,"[{'id': 5033, 'therapyName': 'Carfilzomib + Elotuzumab + Dexamethasone + lenalidomide'}]","Study of Initial Treatment With Elotuzumab, Carfilzomib, Lenalidomide and Dexamethasone in Multiple Myeloma",8048
3,NCT03104270,Phase II,Recruiting,"[{'id': 5555, 'therapyName': 'Carfilzomib + Elotuzumab + Dexamethasone + Pomalidomide'}]",Combination Study for High Risk Multiple Myeloma Patients,8048
4,NCT03227432,Phase II,Not yet recruiting,"[{'id': 6118, 'therapyName': 'Dexamethasone + Elotuzumab + Nivolumab + Pomalidomide'}, {'id': 6117, 'therapyName': 'Elotuzumab + Nivolumab'}]",An Exploratory Study to Evaluate the Combination of Elotuzumab and Nivolumab With and Without Pomalidomide in Relapsed Refractory Multiple Myeloma,8048
5,NCT01729091,Phase Ib/II,Recruiting,"[{'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 3343, 'therapyName': 'Elotuzumab'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1164, 'therapyName': 'lenalidomide'}]",Study of Umbilical Cord Blood-derived Natural Killer Cells in Conjunction With High Dose Chemotherapy and Autologous Stem Cell Transplant for Patients With Multiple Myeloma,8048
6,NCT02726581,Phase III,"Active, not recruiting","[{'id': 3343, 'therapyName': 'Elotuzumab'}, {'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 3792, 'therapyName': 'Dexamethasone + Pomalidomide'}]","Study of Combinations of Nivolumab, Elotuzumab, Pomalidomide and Dexamethasone in Multiple Myeloma",8048
7,NCT01668719,Phase Ib/II,Recruiting,"[{'id': 3343, 'therapyName': 'Elotuzumab'}, {'id': 3342, 'therapyName': 'Bortezomib + Dexamethasone + lenalidomide'}]","S1211, Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma",8048
8,NCT02654132,Phase II,"Active, not recruiting","[{'id': 3792, 'therapyName': 'Dexamethasone + Pomalidomide'}, {'id': 3343, 'therapyName': 'Elotuzumab'}]",Trial of Elotuzumab With or Without Pomalidomide and Low-dose Dexamethasone to Treat Refractory and Relapsed and Refractory Multiple Myeloma,8048
9,NCT02252263,Phase I,"Active, not recruiting","[{'id': 2055, 'therapyName': 'Urelumab'}, {'id': 2583, 'therapyName': 'Lirilumab '}, {'id': 3343, 'therapyName': 'Elotuzumab'}]",A Phase I Open Label Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination With Either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects With Multiple Myeloma,8048
10,NCT02375555,Phase II,"Active, not recruiting","[{'id': 3343, 'therapyName': 'Elotuzumab'}, {'id': 3342, 'therapyName': 'Bortezomib + Dexamethasone + lenalidomide'}]","Study of Bortezomib,Lenalidomide,Dexamethasone & Elotuzumab in Newly Diagnosed MM",8048
11,NCT02159365,Phase II,"Active, not recruiting","[{'id': 3353, 'therapyName': 'Elotuzumab + Dexamethasone + Lenalidomide'}]",Study of Safety of Elotuzumab Administered Over Approximately 60 Minutes in Combination With Lenalidomide and Dexamethasone for Newly Diagnosed or Relapsed/Refractory Multiple Myeloma Patients,8048
12,NCT03168100,Phase II,Recruiting,"[{'id': 3342, 'therapyName': 'Bortezomib + Dexamethasone + lenalidomide'}, {'id': 3353, 'therapyName': 'Elotuzumab + Dexamethasone + Lenalidomide'}]","2017-03: A Single-Arm, Open-label Study of Anti-Signaling Lymphocytic Activation Molecule F7 (Anti-SLAMF7) Monoclonal Antibody (mAb) Therapy After Autologous Stem Cell Transplant in Patients With Multiple Myeloma",8048
13,NCT02368301,Phase I,Approved for marketing,"[{'id': 3353, 'therapyName': 'Elotuzumab + Dexamethasone + Lenalidomide'}]",Expanded Access Treatment Protocol CA204-143,8048
14,NCT02843074,Phase II,Recruiting,"[{'id': 3353, 'therapyName': 'Elotuzumab + Dexamethasone + Lenalidomide'}]","Elotuzumab, Lenalidomide and Dexamethasone (ERd) in the Induction, Consolidation and Maintenance Treatment of Transplant-Eligible, Newly Diagnosed Multiple Myeloma Patients",8048
15,NCT02612779,Phase II,"Active, not recruiting","[{'id': 3355, 'therapyName': 'Elotuzumab + Dexamethasone + Pomalidomide'}]",A Study of Elotuzumab in Combination With Pomalidomide and Low Dose Dexamethasone (EPd) in Patients With Multiple Myeloma Relapsed or Refractory to Prior Treatment With Lenalidomide,8048
16,NCT03030261,Phase II,Not yet recruiting,"[{'id': 1207, 'therapyName': 'Melphalan'}, {'id': 3355, 'therapyName': 'Elotuzumab + Dexamethasone + Pomalidomide'}]","Elotuzumab, Pomalidomide, & Dexamethasone (Elo-Pom-Dex) With Second Autologous Stem Cell Transplantation for Relapsed Multiple Myeloma",8048
17,NCT02420860,Phase II,Recruiting,"[{'id': 5972, 'therapyName': 'Famotidine'}, {'id': 3430, 'therapyName': 'Elotuzumab + lenalidomide'}, {'id': 1275, 'therapyName': 'Diphenhydramine'}, {'id': 1390, 'therapyName': 'Dexamethasone'}]",Study of Elotuzumab With Lenalidomide as Maintenance After Autologous Stem Cell Transplant (ASCT),8048
18,NCT02279394,Phase II,"Active, not recruiting","[{'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 3430, 'therapyName': 'Elotuzumab + lenalidomide'}]",Trial of Combination of Elotuzumab and Lenalidomide +/- Dexamethasone in High-Risk Smoldering Multiple Myeloma,8048
19,NCT02655458,Phase I,Completed,"[{'id': 3430, 'therapyName': 'Elotuzumab + lenalidomide'}]",Elotuzumab in Autologous Stem Cell Transplantation (ASCT) and Lenalidomide Maintenance for Multiple Myeloma,8048
0,NCT02010645,Phase II,"Active, not recruiting","[{'id': 1763, 'therapyName': 'Eltrombopag + Decitabine'}]",Eltrombopag With Decitabine in Advanced Myelodysplastic Syndrome (MDS),4713
0,NCT02923739,Phase II,Recruiting,"[{'id': 4836, 'therapyName': 'Bevacizumab + Emactuzumab + Paclitaxel'}, {'id': 2123, 'therapyName': 'Bevacizumab + Paclitaxel'}]","Induction Discontinuation Trial of Emactuzumab Following Paclitaxel and Bevacizumab in Patients With Platinum-Resistant, Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer - REDIRECT",7780
1,NCT01494688,Phase I,"Active, not recruiting","[{'id': 2843, 'therapyName': 'Emactuzumab'}, {'id': 4249, 'therapyName': 'Emactuzumab + Paclitaxel'}]",A Study of RO5509554 as Monotherapy and in Combination With Paclitaxel in Patients With Advanced Solid Tumors,7780
2,NCT02760797,Phase I,Recruiting,"[{'id': 4181, 'therapyName': 'Emactuzumab + RO7009789'}]",A Study of Emactuzumab and RO7009789 Administered in Combination in Participants With Advanced Solid Tumors,7780
0,NCT01014936,,Completed,"[{'id': 726, 'therapyName': 'EMD 1214063'}]"," First-in-Man, Dose-escalation Trial of C-met Kinase Inhibitor MSC2156119J in Subjects With Advanced Solid Tumors",6902
0,NCT00828009,Phase II,Unknown status,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 2142, 'therapyName': 'Emepepimut-S  '}, {'id': 1092, 'therapyName': 'Carboplatin'}]",BLP25 Liposome Vaccine and Bevacizumab After Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery,7439
0,NCT01900652,Phase II,Completed,"[{'id': 1179, 'therapyName': 'Emibetuzumab + Erlotinib'}, {'id': 803, 'therapyName': 'Emibetuzumab'}]",A Study of LY2875358 in Non Small Cell Lung Cancer (NSCLC) Participants,6943
1,NCT01287546,Phase I,Completed,"[{'id': 1179, 'therapyName': 'Emibetuzumab + Erlotinib'}, {'id': 1180, 'therapyName': 'Emibetuzumab + Trametinib'}, {'id': 803, 'therapyName': 'Emibetuzumab'}]",A Study of LY2875358 in Participants With Advanced Cancer,6943
2,NCT02082210,Phase Ib/II,"Active, not recruiting","[{'id': 1387, 'therapyName': 'Emibetuzumab + Ramucirumab'}]",A Study of LY2875358 in Combination With Ramucirumab (LY3009806) in Participants With Advanced Cancer,6943
0,NCT02636036,Phase I,Recruiting,"[{'id': 3620, 'therapyName': 'Enadenotucirev + Pembrolizumab'}]",Study of Enadenotucirev and Pembrolizumab in Subjects With Metastatic or Advanced Epithelial Tumors,8176
0,NCT03013998,Phase Ib/II,Recruiting,"[{'id': 4003, 'therapyName': 'Azacitidine + Enasidenib'}, {'id': 5539, 'therapyName': 'Azacitidine + Entospletinib'}, {'id': 5536, 'therapyName': 'Cytarabine + Daunorubicin + Samalizumab'}, {'id': 5538, 'therapyName': 'Azacitidine + BI 836858'}]",Study of Biomarker-Based Treatment of Acute Myeloid Leukemia,7889
1,NCT02677922,Phase Ib/II,Recruiting,"[{'id': 4002, 'therapyName': 'AG-120 + Azacitidine'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 4003, 'therapyName': 'Azacitidine + Enasidenib'}]",A Safety and Efficacy Study of Oral AG-120 Plus Subcutaneous Azacitidine and Oral AG-221 Plus Subcutaneous Azacitidine in Subjects With Newly Diagnosed Acute Myeloid Leukemia (AML),7889
2,NCT02273739,Phase Ib/II,Completed,"[{'id': 2982, 'therapyName': 'Enasidenib'}]","Study of Orally Administered AG-221 in Subjects With Advanced Solid Tumors, Including Glioma, and With Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation",7889
3,NCT02632708,Phase I,Recruiting,"[{'id': 1491, 'therapyName': 'AG-120'}, {'id': 2982, 'therapyName': 'Enasidenib'}, {'id': 3431, 'therapyName': 'Cytarabine + Daunorubicin + Etoposide + Mitoxantrone'}]",Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia With an IDH1 and/or IDH2 Mutation,7889
4,NCT01915498,Phase I,"Active, not recruiting","[{'id': 2982, 'therapyName': 'Enasidenib'}]",Phase 1 Study of AG-221 in Subjects With Advanced Hematologic Malignancies With an IDH2 Mutation,7889
5,NCT02577406,Phase III,Recruiting,"[{'id': 651, 'therapyName': 'Azacitidine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 2982, 'therapyName': 'Enasidenib'}]",An Efficacy and Safety Study of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects With Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 Mutation (IDHENTIFY),7889
0,NCT01820364,Phase II,Terminated,"[{'id': 1100, 'therapyName': 'Binimetinib + Encorafenib'}, {'id': 1260, 'therapyName': 'Encorafenib + Ribociclib'}, {'id': 1337, 'therapyName': 'Encorafenib + BKM120'}, {'id': 1336, 'therapyName': 'BGJ398 + Encorafenib'}, {'id': 1338, 'therapyName': 'Capmatinib + Encorafenib'}]", LGX818 in Combination With Agents (MEK162; BKM120; LEE011; BGJ398; INC280) in Advanced BRAF Melanoma,6936
1,NCT02928224,Phase III,Recruiting,"[{'id': 1916, 'therapyName': 'Cetuximab + Encorafenib'}, {'id': 4886, 'therapyName': 'Binimetinib + Cetuximab + LGX818'}, {'id': 1874, 'therapyName': 'Cetuximab + Irinotecan'}, {'id': 2180, 'therapyName': 'Cetuximab + FOLFIRI'}]",Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer (BEACON CRC),6936
2,NCT02263898,Phase II,Withdrawn,"[{'id': 1100, 'therapyName': 'Binimetinib + Encorafenib'}]",Intermittent LGX818 and MEK162 in Treating Patients With Metastatic Melanoma Who Have BRAFV600 Mutations,6936
3,NCT02159066,Phase II,"Active, not recruiting","[{'id': 1101, 'therapyName': 'Binimetinib + Encorafenib + Ribociclib'}, {'id': 1100, 'therapyName': 'Binimetinib + Encorafenib'}, {'id': 2216, 'therapyName': 'LGX818 + MEK162 + INC280'}, {'id': 2215, 'therapyName': 'LGX818 + MEK162 + BKM120'}, {'id': 2214, 'therapyName': 'LGX818 + MEK162 + BGJ398'}]","LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma",6936
4,NCT01543698,Phase Ib/II,"Active, not recruiting","[{'id': 1100, 'therapyName': 'Binimetinib + Encorafenib'}, {'id': 1101, 'therapyName': 'Binimetinib + Encorafenib + Ribociclib'}]",A Phase Ib/II Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF Dependent Advanced Solid Tumors,6936
5,NCT01909453,Phase III,"Active, not recruiting","[{'id': 342, 'therapyName': 'Vemurafenib'}, {'id': 796, 'therapyName': 'Encorafenib'}, {'id': 1100, 'therapyName': 'Binimetinib + Encorafenib'}]",Study Comparing Combination of LGX818 Plus MEK162 and LGX818 Monotherapy Versus Vemurafenib in BRAF Mutant Melanoma,6936
6,NCT01719380,Phase Ib/II,"Active, not recruiting","[{'id': 1916, 'therapyName': 'Cetuximab + Encorafenib'}, {'id': 1917, 'therapyName': 'LGX818 + Cetuximab + BYL719'}]","Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in BRAF Mutant Metastatic Colorectal Cancer",6936
7,NCT01894672,Phase II,Completed,"[{'id': 796, 'therapyName': 'Encorafenib'}]","BRAF Inhibitor, LGX818, Utilizing a Pulsatile Schedule in Patients With Stage IV or Unresectable Stage III Melanoma Characterized by a BRAFV600 Mutation",6936
8,NCT01777776,Phase Ib/II,Terminated,"[{'id': 796, 'therapyName': 'Encorafenib'}, {'id': 1260, 'therapyName': 'Encorafenib + Ribociclib'}]",Safety and Efficacy of LEE011 and LGX818 in Patients With BRAF Mutant Melanoma.,6936
9,NCT01981187,Phase II,Completed,"[{'id': 796, 'therapyName': 'Encorafenib'}]",LGX818 for Patients With BRAFV600 Mutated Tumors,6936
10,NCT01436656,Phase I,"Active, not recruiting","[{'id': 796, 'therapyName': 'Encorafenib'}]",A Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant Melanoma,6936
11,NCT02278133,Phase Ib/II,Completed,"[{'id': 2008, 'therapyName': 'LGK974 + LGX818 + Cetuximab'}]",Study of WNT974 in Combination With LGX818 and Cetuximab in Patients With BRAF-mutant Metastatic Colorectal Cancer (mCRC) and Wnt Pathway Mutations,6936
0,NCT03219333,Phase II,Recruiting,"[{'id': 4125, 'therapyName': 'Enfortumab vedotin'}]",A Study of Enfortumab Vedotin for Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer (EV-201),8356
0,NCT02234986,Phase II,"Active, not recruiting","[{'id': 727, 'therapyName': 'ENMD-2076'}]","A Multi-center, Open-label Study of Oral ENMD-2076 for the Treatment of Patients With Advanced Fibrolamellar Carcinoma",6903
1,NCT01719744,,Completed,"[{'id': 727, 'therapyName': 'ENMD-2076'}]", Study of ENMD-2076 in Patients With Advanced/Metastatic Soft Tissue Sarcoma,6903
2,NCT01914510,Phase II,Recruiting,"[{'id': 727, 'therapyName': 'ENMD-2076'}]",A Study of ENMD-2076 in Ovarian Clear Cell Cancers,6903
3,NCT01639248,,Completed,"[{'id': 727, 'therapyName': 'ENMD-2076'}]", A Phase II Study of the Aurora and Angiogenic Kinase Inhibitor ENMD-2076 in Previously Treated Locally Advanced and Metastatic Triple-Negative Breast Cancer,6903
0,NCT02746328,Phase II,"Active, not recruiting","[{'id': 5026, 'therapyName': 'enobosarm'}]",Add-on Study for Protocol G200802 (NCT02463032): Effect of GTx-024 on Maximal Neuromuscular Function and Lean Body Mass,8594
1,NCT02463032,Phase II,"Active, not recruiting","[{'id': 5026, 'therapyName': 'enobosarm'}]",Efficacy and Safety of GTx-024 in Patients With ER+/AR+ Breast Cancer,8594
2,NCT02368691,Phase II,Terminated,"[{'id': 5026, 'therapyName': 'enobosarm'}]",Efficacy and Safety of GTx-024 in Patients With Androgen Receptor-Positive Triple Negative Breast Cancer (AR+ TNBC),8594
3,NCT02971761,Phase II,Recruiting,"[{'id': 5027, 'therapyName': 'enobosarm + Pembrolizumab'}]",Pembrolizumab and Enobosarm in Treating Patients With Androgen Receptor Positive Metastatic Triple Negative Breast Cancer,8594
0,NCT02898116,Phase Ib/II,Recruiting,"[{'id': 4730, 'therapyName': 'MEDI4736 + X-396'}, {'id': 961, 'therapyName': 'X-396'}]","A Study of ALK Inhibitor, Ensartinib, and Anti-PD-L1, Durvalumab, in Subjects With ALK-rearranged Non-small Cell Lung Cancer",7044
1,NCT02767804,Phase III,Recruiting,"[{'id': 706, 'therapyName': 'Crizotinib'}, {'id': 961, 'therapyName': 'X-396'}]",eXalt3: Study Comparing X-396 to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients,7044
2,NCT03213652,Phase II,Recruiting,"[{'id': 961, 'therapyName': 'X-396'}]","Pediatric MATCH: Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations",7044
3,NCT01625234,Phase Ib/II,Recruiting,"[{'id': 961, 'therapyName': 'X-396'}]","Phase 1/2 Study of X-396, an Oral ALK Inhibitor, in Patients With Advanced Solid Tumors and Non-Small Cell Lung Cancer",7044
4,NCT03155620,Phase II,Recruiting,"[{'id': 2683, 'therapyName': 'Tazemetostat'}, {'id': 2650, 'therapyName': 'LOXO-101'}, {'id': 1069, 'therapyName': 'LY3023414'}, {'id': 342, 'therapyName': 'Vemurafenib'}, {'id': 837, 'therapyName': 'Olaparib'}, {'id': 913, 'therapyName': 'Selumetinib'}, {'id': 961, 'therapyName': 'X-396'}]",Pediatric MATCH: Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Advanced Refractory Solid Tumors or Lymphomas,7044
0,NCT03024437,Phase Ib/II,"Active, not recruiting","[{'id': 5129, 'therapyName': 'Entinostat + Atezolizumab'}, {'id': 5235, 'therapyName': 'Atezolizumab + Entinostat + Bevacizumab'}, {'id': 1201, 'therapyName': 'Atezolizumab'}]",Atezolizumab in Combination With Entinostat and Bevacizumab in Patients With Advanced Renal Cell Carcinoma,7280
1,NCT02915523,Phase Ib/II,Recruiting,"[{'id': 3144, 'therapyName': 'Avelumab'}, {'id': 5559, 'therapyName': 'Avelumab + Entinostat'}]",Phase 1b/2 Study of Avelumab With or Without Entinostat in Patients With Advanced Epithelial Ovarian Cancer,7280
2,NCT01935947,Phase II,Terminated,"[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 2645, 'therapyName': 'Azacitidine + Entinostat'}, {'id': 2646, 'therapyName': 'Docetaxel + Irinotecan + Pemetrexed '}]",Azacitidine and Entinostat Before Chemotherapy in Treating Patients With Advanced Non-small Cell Lung Cancer,7280
3,NCT01305499,Phase II,Recruiting,"[{'id': 2645, 'therapyName': 'Azacitidine + Entinostat'}]",A Trial to Evaluate Two Schedules of MS275 in Combination With 5AC in Elderly Patients With Acute Myeloid Leukemia (AML),7280
4,NCT01038778,Phase Ib/II,"Active, not recruiting","[{'id': 1541, 'therapyName': 'Entinostat'}, {'id': 1167, 'therapyName': 'Aldesleukin'}]",Entinostat in Combination With Aldesleukin in Treating Patients With Metastatic Kidney Cancer,7280
5,NCT02453620,Phase I,Recruiting,"[{'id': 1541, 'therapyName': 'Entinostat'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]","Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer",7280
6,NCT03211988,Phase II,Not yet recruiting,"[{'id': 1541, 'therapyName': 'Entinostat'}]",Entinostat Neuroendocrine (NE) Tumor,7280
7,NCT01928576,Phase II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 1541, 'therapyName': 'Entinostat'}, {'id': 651, 'therapyName': 'Azacitidine'}]",Phase II Anti-PD1 Epigenetic Priming Study in NSCLC.,7280
8,NCT02780804,Phase I,Recruiting,"[{'id': 1541, 'therapyName': 'Entinostat'}]",Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors,7280
9,NCT02897778,Phase I,Completed,"[{'id': 1541, 'therapyName': 'Entinostat'}]",Cardiac Safety Study of Entinostat in Men and Women With Advanced Solid Tumors,7280
10,NCT02115282,Phase III,Recruiting,"[{'id': 759, 'therapyName': 'Goserelin'}, {'id': 1541, 'therapyName': 'Entinostat'}, {'id': 738, 'therapyName': 'Exemestane'}]",Exemestane With or Without Entinostat in Treating Postmenopausal Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic,7280
11,NCT02708680,Phase Ib/II,Recruiting,"[{'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 5129, 'therapyName': 'Entinostat + Atezolizumab'}]",Randomized Phase 2 Study of Atezolizumab and Entinostat in Patients With aTN Breast Cancer With Phase 1b Lead In,7280
12,NCT02820961,Phase I,Recruiting,"[{'id': 4437, 'therapyName': 'Entinostat + Exemestane'}]",Drug-Drug Interaction Study of Entinostat and Exemestane in Postmenopausal Women With ER+ Breast Cancer,7280
13,NCT03215264,Phase Ib/II,Not yet recruiting,"[{'id': 6052, 'therapyName': 'Entinostat + Hydroxychloroquine + Regorafenib'}]","Phase I/II Trial of Regorafenib, Hydroxychloroquine, and Entinostat in Metastatic Colorectal Cancer",7280
14,NCT01434303,Phase I,"Active, not recruiting","[{'id': 1542, 'therapyName': 'Entinostat + Lapatinib + Trastuzumab'}]","Entinostat, Lapatinib Ditosylate and Trastuzumab in Treating Patients With Locally Recurrent or Distant Relapsed Metastatic Breast Cancer Previously Treated With Trastuzumab Only",7280
15,NCT03250273,Phase II,Not yet recruiting,"[{'id': 6114, 'therapyName': 'Entinostat + Nivolumab'}]",A Clinical Trial of Entinostat in Combination With Nivolumab for Patients With Previously Treated Unresectable or Metastatic Cholangiocarcinoma and Pancreatic Adenocarcinoma,7280
16,NCT02936752,Phase I,Recruiting,"[{'id': 3354, 'therapyName': 'Entinostat + Pembrolizumab'}]",Entinostat and Pembrolizumab in Treating Patients With Myelodysplastic Syndrome After DNMTi Therapy Failure,7280
17,NCT02909452,Phase I,Recruiting,"[{'id': 3354, 'therapyName': 'Entinostat + Pembrolizumab'}]",Continuation Study of Entinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumors,7280
18,NCT02437136,Phase Ib/II,Recruiting,"[{'id': 3354, 'therapyName': 'Entinostat + Pembrolizumab'}]",Ph1b/2 Dose-Escalation Study of Entinostat With Pembrolizumab in NSCLC With Expansion Cohorts in NSCLC and Melanoma,7280
19,NCT03179930,Phase II,Recruiting,"[{'id': 3354, 'therapyName': 'Entinostat + Pembrolizumab'}]",Combination Therapy With Entinostat and Pembrolizumab in Relapsed and Refractory Lymphomas,7280
20,NCT03018249,Phase II,Recruiting,"[{'id': 2401, 'therapyName': 'Medroxyprogesterone'}, {'id': 5203, 'therapyName': 'Medroxyprogesterone + Entinostat'}]",Medroxyprogesterone Acetate With or Without Entinostat Before Surgery in Treating Patients With Endometrioid Endometrial Cancer,7280
0,NCT03013998,Phase Ib/II,Recruiting,"[{'id': 4003, 'therapyName': 'Azacitidine + Enasidenib'}, {'id': 5539, 'therapyName': 'Azacitidine + Entospletinib'}, {'id': 5536, 'therapyName': 'Cytarabine + Daunorubicin + Samalizumab'}, {'id': 5538, 'therapyName': 'Azacitidine + BI 836858'}]",Study of Biomarker-Based Treatment of Acute Myeloid Leukemia,7555
1,NCT01799889,Phase II,"Active, not recruiting","[{'id': 2522, 'therapyName': 'Entospletinib  '}]",A Phase 2 of Entospletinib in Subjects With Relapsed or Refractory Hematologic Malignancies,7555
2,NCT02343939,Phase Ib/II,Recruiting,"[{'id': 650, 'therapyName': 'Decitabine'}, {'id': 1738, 'therapyName': 'Daunorubicin + Cytarabine'}, {'id': 2522, 'therapyName': 'Entospletinib  '}]",Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML),7555
0,NCT02097810,Phase Ib/II,Recruiting,"[{'id': 1455, 'therapyName': 'Entrectinib'}]","A Phase 1/2a Study of Oral RXDX-101 in Adult Patients With Locally Advanced or Metastatic Cancer; Study Targeting ALK, ROS1, or TRKA/B/C",7264
1,NCT02650401,Phase I,Recruiting,"[{'id': 1455, 'therapyName': 'Entrectinib'}]",Study of RXDX-101 in Children With Recurrent or Refractory Solid Tumors and Primary CNS Tumors,7264
2,NCT03066661,Expanded access,Available,"[{'id': 1455, 'therapyName': 'Entrectinib'}]","Expanded Access to Entrectinib for Cancers With NTRK1/2/3, ROS1, or ALK Gene Fusions",7264
3,NCT02568267,Phase II,Recruiting,"[{'id': 1455, 'therapyName': 'Entrectinib'}]","Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK1/2/3, ROS1, or ALK Gene Rearrangements  (STARTRK-2)",7264
0,NCT02903160,Phase II,Recruiting,"[{'id': 4759, 'therapyName': 'Abiraterone + Cabazitaxel + Carboplatin + Enzalutamide + Prednisone'}]","Prostate Cancer Intensive, Non-Cross Reactive Therapy (PRINT) for Castration Resistant Prostate Cancer (CRPC)",7230
1,NCT02758132,Phase I,Terminated,"[{'id': 4182, 'therapyName': 'Abiraterone + Denosumab + Enzalutamide + Prednisone'}, {'id': 4183, 'therapyName': 'Denosumab + Enzalutamide'}]","Denosumab Plus Enzalutamide, Abiraterone and Prednisone Compared to Denosumab Plus Enzalutamide Alone for Men With Castrate Resistant Prostate Cancer (CRPC) With Bone Metastases",7230
2,NCT03016312,Phase III,Recruiting,"[{'id': 5204, 'therapyName': 'Atezolizumab + Enzalutamide'}, {'id': 1262, 'therapyName': 'Enzalutamide'}]","IMbassador250: A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen",7230
3,NCT03207529,Phase I,Not yet recruiting,"[{'id': 3751, 'therapyName': 'BYL719 + Enzalutamide'}]",Study of BYL719 (Alpelisib) in Combination With Androgen Receptor Inhibitor (Enzalutamide) in Patients With Androgen Receptor (AR)-Positive and PTEN Positive Metastatic Breast Cancer,7230
4,NCT02522715,Phase Ib/II,Recruiting,"[{'id': 3056, 'therapyName': 'Cabazitaxel + Enzalutamide'}, {'id': 2188, 'therapyName': 'Prednisone'}]","Enzalutamide and Cabazitaxel in Treating Patients With Metastatic, Hormone-Resistant Prostate Cancer",7230
5,NCT02684227,Phase II,Recruiting,"[{'id': 3681, 'therapyName': 'Carboplatin + Enzalutamide + Paclitaxel'}]",Enzalutamide in Combination With Carboplatin and Paclitaxel in Endometrial Cancer,7230
6,NCT02833883,Phase I,Recruiting,"[{'id': 4459, 'therapyName': 'CC-115 + Enzalutamide'}]","Use of an Experimental Drug, CC-115, With Enzalutamide in Men With Castration-Resistant Prostate Cancer",7230
7,NCT02207504,Phase I,"Active, not recruiting","[{'id': 2446, 'therapyName': 'Crizotinib + Enzalutamide'}]",Crizotinib in Combination With Enzalutamide in Metastatic Castration-resistant Prostate Cancer,7230
8,NCT01990196,Phase II,Recruiting,"[{'id': 717, 'therapyName': 'Dasatinib'}, {'id': 2, 'therapyName': 'Trametinib'}, {'id': 1815, 'therapyName': 'Degarelix + Enzalutamide'}]",Neoadjuvant Phase 2 Study Comparing the Effects of AR Inhibition With/Without SRC or MEK Inhibition in Prostate Cancer,7230
9,NCT02685267,Phase II,"Active, not recruiting","[{'id': 4681, 'therapyName': 'Docetaxel + Enzalutamide + Prednisone'}, {'id': 2462, 'therapyName': 'Docetaxel + Prednisone'}]",Docetaxel/Prednisone Versus Docetaxel/Prednisone and Enzalutamide in Castration-Resistant Prostate Cancer (Doce/Enza),7230
10,NCT02213107,Phase II,"Active, not recruiting","[{'id': 3067, 'therapyName': 'Dutasteride + Enzalutamide'}]",Enzalutamide & Dutasteride as 1st Line Treatment for Patients =/&gt; 65 Years Old With Prostate Cancer.,7230
11,NCT02003924,Phase III,"Active, not recruiting","[{'id': 1262, 'therapyName': 'Enzalutamide'}]",Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer,7230
12,NCT02028988,Phase II,"Active, not recruiting","[{'id': 1262, 'therapyName': 'Enzalutamide'}]",Enzalutamide + External Beam Rt For Prostate,7230
13,NCT02457910,Phase Ib/II,Recruiting,"[{'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 1016, 'therapyName': 'GDC-0032'}]",Taselisib and Enzalutamide in Treating Patients With Androgen Receptor Positive Triple-Negative Metastatic Breast Cancer,7230
14,NCT02203695,Phase II,Recruiting,"[{'id': 1262, 'therapyName': 'Enzalutamide'}]",Randomized Salvage Radiation Therapy Plus Enzalutamide Post Prostatectomy,7230
15,NCT02403505,Phase II,"Active, not recruiting","[{'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 1814, 'therapyName': 'Degarelix'}]",Discovery Stage Clinical Study About Oncology Drugs and Single Nucleotide Polymorphisms,7230
16,NCT02023463,Phase I,"Active, not recruiting","[{'id': 759, 'therapyName': 'Goserelin'}, {'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 795, 'therapyName': 'Leuprolide'}]","Enzalutamide, Radiation Therapy and Hormone Therapy in Treating Patients With Intermediate or High-Risk Prostate Cancer",7230
17,NCT02676986,Phase II,Recruiting,"[{'id': 6183, 'therapyName': 'Enzalutamide + Exemestane'}, {'id': 1262, 'therapyName': 'Enzalutamide'}]","Short-term Preoperative Treatment With Enzalutamide, Alone or in Combination With Exemestane in Primary Breast Cancer (ARB)",7230
18,NCT02446405,Phase III,"Active, not recruiting","[{'id': 1262, 'therapyName': 'Enzalutamide'}]",Enzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer,7230
19,NCT02555189,Phase Ib/II,Recruiting,"[{'id': 790, 'therapyName': 'Ribociclib'}, {'id': 1262, 'therapyName': 'Enzalutamide'}]","Enzalutamide With and Without Ribociclib for Metastatic, Castrate-Resistant, Chemotherapy-Naive Prostate Cancer That Retains RB Expression",7230
20,NCT02199197,Phase II,Recruiting,"[{'id': 1262, 'therapyName': 'Enzalutamide'}]",Radium Ra 223 With Enzalutamide in Men With Metastatic Castration Refractory Prostate Cancer,7230
21,NCT02438007,Phase III,Terminated,"[{'id': 1508, 'therapyName': 'galeterone'}, {'id': 1262, 'therapyName': 'Enzalutamide'}]",A Study of Galeterone Compared to Enzalutamide In Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic CRPC,7230
22,NCT02407054,Phase II,Recruiting,"[{'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 1069, 'therapyName': 'LY3023414'}]",A Study of Enzalutamide and LY3023414 in Men With Prostate Cancer,7230
23,NCT02489123,Phase I,Recruiting,"[{'id': 1262, 'therapyName': 'Enzalutamide'}]",Enzalutamide in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma,7230
24,NCT02204072,Phase I,Recruiting,"[{'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 2916, 'therapyName': 'Xentuzumab'}]",BI836845 Plus Enzalutamide in Castrate Resistant Prostate Cancer (CRPC),7230
25,NCT02353715,Phase I,Recruiting,"[{'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 2648, 'therapyName': 'Sipuleucel-T'}]","Men With Metastatic Castrate-Resistant Prostate Cancer Treated With Either Sipuleucel-T (Provenge), Abiraterone Acetate (Zytiga) or Enzalutamide (Xtandi) Undergoing Cardiopulmonary EXercise Testing",7230
26,NCT02125357,Phase II,"Active, not recruiting","[{'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 1805, 'therapyName': 'Abiraterone'}]",Sequencing Abiraterone and Enzalutamide in mCRPC,7230
27,NCT02929576,Phase III,Withdrawn,"[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 3725, 'therapyName': 'Enzalutamide + Paclitaxel'}, {'id': 1262, 'therapyName': 'Enzalutamide'}]","Efficacy and Safety Study of Enzalutamide in Combination With Paclitaxel Chemotherapy or as Monotherapy Versus Placebo With Paclitaxel in Patients With Advanced, Diagnostic-Positive, Triple-Negative Breast Cancer (ENDEAR)",7230
28,NCT02254785,Phase II,Recruiting,"[{'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 1571, 'therapyName': 'Cabazitaxel'}]",Cabazitaxel vs Abiraterone or Enzalutamide in Patients With Poor Prognosis Metastatic Castration-resistant Prostate Cancer,7230
29,NCT02491411,Phase I,Recruiting,"[{'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 1390, 'therapyName': 'Dexamethasone'}]",Dexamethasone Prior to Re-treatment With Enzalutamide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Treated With Enzalutamide and Docetaxel,7230
30,NCT02429193,Phase II,Recruiting,"[{'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 2748, 'therapyName': 'Abiraterone + Prednisone'}]",Biomarkers of Androgen Response and Resistance In Evolution During a Rising PSA (BARRIER-P),7230
31,NCT02012296,Phase Ib/II,Recruiting,"[{'id': 2603, 'therapyName': 'Mifepristone'}, {'id': 1262, 'therapyName': 'Enzalutamide'}]",Enzalutamide and Mifepristone in Treating Patients With Metastatic Hormone Resistant Prostate Cancer,7230
32,NCT02057939,Phase II,"Active, not recruiting","[{'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 795, 'therapyName': 'Leuprolide'}]",Salvage Therapeutic Radiation With Enzalutamide and ADT in Men With Recurrent Prostate Cancer (STREAM),7230
33,NCT02286921,Phase II,Recruiting,"[{'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 2591, 'therapyName': 'Andriol'}]","Testosterone Revival Abolishes Negative Symptoms, Fosters Objective Response and Modulates Enzalutamide Resistance",7230
34,NCT02268175,Phase II,"Active, not recruiting","[{'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 795, 'therapyName': 'Leuprolide'}]",Enzalutamide/Leuprolide +/- Abiraterone/Pred in Prostate,7230
35,NCT02685397,Phase II,Recruiting,"[{'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 2050, 'therapyName': 'Triptorelin'}, {'id': 759, 'therapyName': 'Goserelin'}, {'id': 795, 'therapyName': 'Leuprolide'}]",Management of Castration-Resistant Prostate Cancer With Oligometastases,7230
36,NCT02607228,Phase Ib/II,Recruiting,"[{'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 3561, 'therapyName': 'GS-5829 + Exemestane'}]","Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5829 as a Single Agent and In Combination With Enzalutamide in Participants With Metastatic Castrate-Resistant Prostate Cancer",7230
37,NCT01927627,Phase II,"Active, not recruiting","[{'id': 1262, 'therapyName': 'Enzalutamide'}]",Enzalutamide in Patients With High-risk Prostate Cancer,7230
38,NCT01974765,Phase II,Recruiting,"[{'id': 1262, 'therapyName': 'Enzalutamide'}]","Enzalutamide in Patients With Androgen Receptor Positive (AR+) Ovarian, Primary Peritoneal or Fallopian Tube Cancer and One, Two or Three Prior Therapies",7230
39,NCT02749903,Phase II,Recruiting,"[{'id': 1262, 'therapyName': 'Enzalutamide'}]",Enzalutamide for Patients With Androgen Receptor Positive Salivary Cancers,7230
40,NCT02300610,Phase I,"Active, not recruiting","[{'id': 1467, 'therapyName': 'Gemcitabine + Cisplatin'}, {'id': 1262, 'therapyName': 'Enzalutamide'}]",Enzalutamide in Combination With Gemcitabine and Cisplatin in Bladder Cancer,7230
41,NCT01942837,Phase II,"Active, not recruiting","[{'id': 1262, 'therapyName': 'Enzalutamide'}]",Phase II Trial of Enzalutamide for Castrate-resistant Prostate Cancer With Correlative Assessment of Androgen Receptor Signaling,7230
42,NCT02532114,Phase I,Recruiting,"[{'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 3072, 'therapyName': 'Niclosamide'}]","Niclosamide and Enzalutamide in Treating Patients With Androgen Receptor Splice Variant-Positive, Castration-Resistant, Metastatic Prostate Cancer",7230
43,NCT02605863,Phase II,Recruiting,"[{'id': 1262, 'therapyName': 'Enzalutamide'}]",Enzalutamide for Bladder Cancer Chemoprevention,7230
44,NCT02677896,Phase III,Recruiting,"[{'id': 1262, 'therapyName': 'Enzalutamide'}]",A Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC),7230
45,NCT01977651,FDA approved,"Active, not recruiting","[{'id': 1262, 'therapyName': 'Enzalutamide'}]",A Study to Evaluate the Potential Increased Risk of Seizures Among Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Treated With Enzalutamide,7230
46,NCT02007512,Phase II,"Active, not recruiting","[{'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 738, 'therapyName': 'Exemestane'}]",Safety Study of Enzalutamide in Combination With Exemestane in Patients With Advanced Breast Cancer,7230
47,NCT02452008,Phase II,Recruiting,"[{'id': 2409, 'therapyName': 'Galunisertib'}, {'id': 1262, 'therapyName': 'Enzalutamide'}]",Study of TGF-Beta Receptor Inhibitor LY2157299 and Enzalutamide in Metastatic Castration-resistant Prostate Cancer,7230
48,NCT02384382,Phase II,"Active, not recruiting","[{'id': 1262, 'therapyName': 'Enzalutamide'}]",A Positron Emission Tomography/Computed Tomography (PET/CT) Bone Imaging Study in Patients Receiving Enzalutamide for Castration-Resistant Prostate Cancer (CRPC),7230
49,NCT02446444,Phase III,Recruiting,"[{'id': 1262, 'therapyName': 'Enzalutamide'}]","Enzalutamide in Androgen Deprivation Therapy With Radiation Therapy for High Risk, Clinically Localised, Prostate Cancer",7230
50,NCT02799745,Phase II,Recruiting,"[{'id': 1262, 'therapyName': 'Enzalutamide'}]",A Randomized Study of Enzalutamide in Patients With Localized Prostate Cancer Undergoing Active Surveillance (ENACT) (ENACT),7230
51,NCT02379390,Phase II,Terminated,"[{'id': 2188, 'therapyName': 'Prednisone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 1571, 'therapyName': 'Cabazitaxel'}]",Cabazitaxel Versus the Switch to Alternative AR Targeted Therapy Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Primary Resistant Patients to Abiraterone or Enz (PRIMCAB),7230
52,NCT02500901,Phase I,"Active, not recruiting","[{'id': 832, 'therapyName': 'Niraparib'}, {'id': 1262, 'therapyName': 'Enzalutamide'}]",Enzalutamide and Niraparib in the Treatment of Metastatic Castrate-Resistant Prostate Cancer (CRPC),7230
53,NCT02319837,Phase III,Recruiting,"[{'id': 795, 'therapyName': 'Leuprolide'}, {'id': 1262, 'therapyName': 'Enzalutamide'}]",Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK),7230
54,NCT02215096,Phase I,Recruiting,"[{'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 765, 'therapyName': 'GSK2636771'}]",Dose-finding Study of GSK2636771 When Administered in Combination With Enzalutamide in Male Subjects With Metastatic Castration-Resistant Prostate Cancer,7230
55,NCT02090114,Phase II,Recruiting,"[{'id': 2591, 'therapyName': 'Andriol'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 1262, 'therapyName': 'Enzalutamide'}]",RE-sensitizing With Supraphysiologic Testosterone to Overcome REsistant (The RESTORE Study),7230
56,NCT02278185,Phase II,Recruiting,"[{'id': 759, 'therapyName': 'Goserelin'}, {'id': 1814, 'therapyName': 'Degarelix'}, {'id': 2047, 'therapyName': 'Histrelin acetate'}, {'id': 2050, 'therapyName': 'Triptorelin'}, {'id': 795, 'therapyName': 'Leuprolide'}, {'id': 1262, 'therapyName': 'Enzalutamide'}]",Enzalutamide Versus Standard Androgen Deprivation Therapy for the Treatment Hormone Sensitive Prostate Cancer,7230
57,NCT02507570,Phase II,"Active, not recruiting","[{'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 2001, 'therapyName': 'radium Ra 223 dichloride'}]",Open Label Phase Two Study of Enzalutamide With Concurrent Administration of Radium Ra 223 Dichloride in Castration-Resistant (Hormone-Refractory) Prostate Cancer Subjects With Symptomatic Bone Metastasis,7230
58,NCT02138383,Phase I,"Active, not recruiting","[{'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 619, 'therapyName': 'Abraxane'}, {'id': 755, 'therapyName': 'Gemcitabine'}]",Enzalutamide in Combination With Gemcitabine and Nab-Paclitaxel for the Treatment of Advanced Pancreatic Cancer,7230
59,NCT02528643,Phase II,"Active, not recruiting","[{'id': 1262, 'therapyName': 'Enzalutamide'}]",A Study to Assess the Efficacy and Safety of Enzalutamide in Subjects With Advanced Hepatocellular Carcinoma,7230
60,NCT02750358,Phase II,Recruiting,"[{'id': 1262, 'therapyName': 'Enzalutamide'}]",Feasibility Study of Adjuvant Enzalutamide for the Treatment of Early Stage AR (+) Triple Negative Breast Cancer,7230
61,NCT02987543,Phase III,Recruiting,"[{'id': 837, 'therapyName': 'Olaparib'}, {'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 1805, 'therapyName': 'Abiraterone'}]",Study of Olaparib (Lynparza) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer (PROfound Study),7230
62,NCT02058706,Phase II,Recruiting,"[{'id': 759, 'therapyName': 'Goserelin'}, {'id': 1507, 'therapyName': 'Bicalutamide'}, {'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 795, 'therapyName': 'Leuprolide'}]",LHRH Analogue Therapy With Enzalutamide or Bicalutamide in Treating Patients With Metastatic Hormone Sensitive Prostate Cancer,7230
63,NCT01867333,Phase II,"Active, not recruiting","[{'id': 3069, 'therapyName': 'PROSTVAC-F/TRICOM '}, {'id': 1262, 'therapyName': 'Enzalutamide'}]",Enzalutamide With or Without Vaccine Therapy for Advanced Prostate Cancer,7230
64,NCT02064582,Phase II,Recruiting,"[{'id': 795, 'therapyName': 'Leuprolide'}, {'id': 1262, 'therapyName': 'Enzalutamide'}]","Enzalutamide and Hormone Therapy Before, During, and After Radiation for High Risk Localized Prostate Cancer",7230
65,NCT02034552,Phase II,"Active, not recruiting","[{'id': 2188, 'therapyName': 'Prednisone'}, {'id': 2001, 'therapyName': 'radium Ra 223 dichloride'}, {'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 1805, 'therapyName': 'Abiraterone'}]",A Randomized Phase IIa Efficacy and Safety Study of Radium-223 Dichloride With Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (CRPC),7230
66,NCT02960022,Phase II,Recruiting,"[{'id': 5371, 'therapyName': 'Enzalutamide + Abiraterone + Prednisone'}, {'id': 1262, 'therapyName': 'Enzalutamide'}]",A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study,7230
67,NCT01362374,Phase I,"Active, not recruiting","[{'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 747, 'therapyName': 'Ipatasertib'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}]","Safety and Pharmacology Of GDC-0068 in Combination With Docetaxel, Fluoropyrimidine Plus Oxaliplatin, Paclitaxel, or Enzalutamide in Patients With Advanced Solid Tumors",7230
68,NCT02885649,Phase 0,Not yet recruiting,"[{'id': 1262, 'therapyName': 'Enzalutamide'}]",Enzalutamide Before Surgery in Treating Patients With Kidney Cancer,7230
69,NCT02642913,Phase Ib/II,Recruiting,"[{'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 920, 'therapyName': 'Sorafenib'}]",Study of Enzalutamide With and Without Sorafenib in Advanced Hepatocellular Carcinoma Patients,7230
70,NCT01949337,Phase III,"Active, not recruiting","[{'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 1262, 'therapyName': 'Enzalutamide'}]",Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer,7230
71,NCT03016741,FDA approved,Recruiting,"[{'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 2748, 'therapyName': 'Abiraterone + Prednisone'}]",Cognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate Cancer,7230
72,NCT02256111,Phase II,Recruiting,"[{'id': 1262, 'therapyName': 'Enzalutamide'}]",EXTEND Exercise Trial,7230
73,NCT02441517,FDA approved,Terminated,"[{'id': 1262, 'therapyName': 'Enzalutamide'}]",A Study of Enzalutamide Re-treatment in Metastatic Castration-resistant Prostate Cancer After Docetaxel Treatment in Patients Who Have Previously Received Enzalutamide,7230
74,NCT02125084,Phase I,"Active, not recruiting","[{'id': 2264, 'therapyName': 'Enzalutamide + Everolimus'}]",Enzalutamide Plus Everolimus in Men With Metastatic Castrate-Resistant Prostate Cancer,7230
75,NCT02953860,Phase II,Recruiting,"[{'id': 4940, 'therapyName': 'Enzalutamide + Fulvestrant'}]",Fulvestrant Plus Enzalutamide in ER+/Her2- Advanced Breast Cancer,7230
76,NCT02955394,Phase II,Recruiting,"[{'id': 744, 'therapyName': 'Fulvestrant'}, {'id': 4940, 'therapyName': 'Enzalutamide + Fulvestrant'}]",Preoperative Fulvestrant With or Without Enzalutamide in ER+/Her2- Breast Cancer,7230
77,NCT03150056,Phase I,Recruiting,"[{'id': 6034, 'therapyName': 'Abiraterone + GSK525762'}, {'id': 6035, 'therapyName': 'Enzalutamide + GSK525762'}, {'id': 2188, 'therapyName': 'Prednisone'}]",Dose Escalation and Dose Expansion Study of GSK525762 in Combination With Androgen Deprivation Therapy and Other Agents in Subjects With Castrate-resistant Prostate Cancer,7230
78,NCT02935205,Phase Ib/II,Not yet recruiting,"[{'id': 4876, 'therapyName': 'Enzalutamide + Indomethacin'}]",Enzalutamide and Indomethacin in Treating Patients With Recurrent or Metastatic Hormone-Resistant Prostate Cancer,7230
79,NCT02508636,Phase II,Recruiting,"[{'id': 3180, 'therapyName': 'Enzalutamide + Leuprolide'}]",Trial of Radiotherapy With Leuprolide and Enzalutamide in High Risk Prostate,7230
80,NCT02991911,Phase I,Recruiting,"[{'id': 5217, 'therapyName': 'Enzalutamide + MEDI3726'}, {'id': 5216, 'therapyName': 'MEDI3726'}]",A Phase 1/1b Study of MEDI3726 in Adults Subjects With Metastatic Castration Resistant Prostate Cancer,7230
81,NCT02339168,Phase I,Recruiting,"[{'id': 2202, 'therapyName': 'Enzalutamide + Metformin'}]",Enzalutamide and Metformin Hydrochloride in Treating Patients With Hormone-Resistant Prostate Cancer,7230
82,NCT02689427,Phase II,Recruiting,"[{'id': 3725, 'therapyName': 'Enzalutamide + Paclitaxel'}]",Phase IIB Neoadjuvant Enzalutamide (ZT) Plus Taxol for Androgen Receptor (AR)-Positive Triple-Negative Breast Cancer (AR+ TNBC),7230
83,NCT02312557,Phase II,Recruiting,"[{'id': 2666, 'therapyName': 'Enzalutamide + Pembrolizumab'}]",Pembrolizumab in Treating Patients With Metastatic Castration Resistant Prostate Cancer Previously Treated With Enzalutamide,7230
84,NCT02861573,Phase I,Recruiting,"[{'id': 5343, 'therapyName': 'Dexamethasone + Docetaxel + Pembrolizumab + Prednisone'}, {'id': 5342, 'therapyName': 'Olaparib + Pembrolizumab'}, {'id': 2666, 'therapyName': 'Enzalutamide + Pembrolizumab'}]",Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365),7230
85,NCT01875250,Phase II,"Active, not recruiting","[{'id': 4884, 'therapyName': 'Enzalutamide + PROSTVAC-F/TRICOM + PROSTVAC-V/TRICOM'}]",Enzalutamide in Combination With PSA-TRICOM in Patients With Non-Metastatic Castration Sensitive Prostate Cancer,7230
86,NCT01885949,Phase II,"Active, not recruiting","[{'id': 2395, 'therapyName': 'Enzalutamide + Tivozanib'}]",Tivozanib + Enzalutamide in Adv Prostate Cancer,7230
87,NCT02091960,Phase II,"Active, not recruiting","[{'id': 1878, 'therapyName': 'Enzalutamide + Trastuzumab'}]","A Study to Assess the Efficacy and Safety of Enzalutamide With Trastuzumab in Subjects With Human Epidermal Growth Factor Receptor 2 Positive (HER2+), Androgen Receptor Positive (AR+) and Estrogen Receptor Negative (ER-) Metastatic or Locally Advanced Breast Cancer",7230
88,NCT02711956,Phase I,Recruiting,"[{'id': 4033, 'therapyName': 'Enzalutamide + ZEN003694'}]",A Study of ZEN003694 in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer,7230
89,NCT03123978,Phase I,Recruiting,"[{'id': 5607, 'therapyName': 'Niclosamide + Enzalutamide'}]",Enzalutamide and Niclosamide in Treating Patients With Recurrent or Metastatic Castration-Resistant Prostate Cancer,7230
0,NCT03263026,Phase III,Not yet recruiting,"[{'id': 2195, 'therapyName': 'R-CHOP'}, {'id': 1682, 'therapyName': 'Enzastaurin'}]",Study to Assess Enzastaurin + R-CHOP in Subjects With DLBCL With the Genomic Biomarker DGM1,7316
0,NCT02298153,Phase I,"Active, not recruiting","[{'id': 2636, 'therapyName': 'Atezolizumab + Epacadostat'}]",A Study of MPDL3280A in Combination With INCB024360 in Subjects With Previously Treated Stage IIIB or Stage IV Non-Small Cell Lung Cancer,7587
1,NCT02959437,Phase Ib/II,Recruiting,"[{'id': 5477, 'therapyName': 'Azacitidine + INCB024360 + Pembrolizumab'}]",Azacitidine Combined With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors (ECHO-206),7587
2,NCT03006302,Phase II,Not yet recruiting,"[{'id': 5169, 'therapyName': 'CRS-207 + INCB024360 + Pembrolizumab'}, {'id': 5170, 'therapyName': 'CRS-207 + Cyclophosphamide + GVAX panc vaccine + INCB024360 + Pembrolizumab'}]","Epacadostat, Pembrolizumab, and CRS-207, With or Without CY/GVAX Pancreas in Patients With Metastatic Pancreas Cancer",7587
3,NCT02785250,Phase I,Recruiting,"[{'id': 4238, 'therapyName': 'Cyclophosphamide + DPX-Survivac + INCB024360 '}]",Study of DPX-Survivac Vaccine Therapy and Epacadostat in Patients With Recurrent Ovarian Cancer,7587
4,NCT02118285,Phase I,Completed,"[{'id': 1167, 'therapyName': 'Aldesleukin'}, {'id': 2575, 'therapyName': 'Epacadostat'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1166, 'therapyName': 'Fludarabine'}]","Intraperitoneal Natural Killer Cells and INCB024360 for Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer",7587
5,NCT02575807,Phase Ib/II,Recruiting,"[{'id': 2575, 'therapyName': 'Epacadostat'}, {'id': 2641, 'therapyName': 'CRS-207'}]","Safety and Efficacy of CRS-207 With Epacadostat in Platinum Resistant Ovarian, Fallopian, or Peritoneal Cancer",7587
6,NCT01961115,Phase II,"Active, not recruiting","[{'id': 2575, 'therapyName': 'Epacadostat'}, {'id': 3016, 'therapyName': 'MELITAC 12.1 Peptide Vaccine '}]",INCB024360 and Vaccine Therapy in Treating Patients With Stage III-IV Melanoma,7587
7,NCT02042430,Phase I,"Active, not recruiting","[{'id': 2575, 'therapyName': 'Epacadostat'}]","INCB024360 Before Surgery in Treating Patients With Newly Diagnosed Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",7587
8,NCT02178722,Phase Ib/II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 2575, 'therapyName': 'Epacadostat'}]","A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of MK-3475 in Combination With INCB024360 in Subjects With Selected Solid Tumors and Advanced NSCLC (INCB 24360-202 / MK-3475-037 / KEYNOTE-037)",7587
9,NCT02166905,Phase Ib/II,Recruiting,"[{'id': 2595, 'therapyName': 'poly ICLC  '}, {'id': 1324, 'therapyName': 'DEC-205-NY-ESO-1 fusion protein vaccine'}, {'id': 2575, 'therapyName': 'Epacadostat'}]","DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, and IDO1 Inhibitor INCB024360 in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission",7587
10,NCT03277352,Phase Ib/II,Not yet recruiting,"[{'id': 6277, 'therapyName': 'Epacadostat + INCAGN01876 + Pembrolizumab'}]",INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies,7587
11,NCT02752074,Phase III,"Active, not recruiting","[{'id': 4088, 'therapyName': 'Epacadostat + Pembrolizumab'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",A Phase 3 Study of Pembrolizumab + Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma,7587
12,NCT03196232,Phase II,Recruiting,"[{'id': 4088, 'therapyName': 'Epacadostat + Pembrolizumab'}]",Epacadostat and Pembrolizumab in Treating Patients With Metastatic or Unresectable Gastroesophageal Junction or Gastric Cancer,7587
13,NCT03291054,Phase II,Not yet recruiting,"[{'id': 4088, 'therapyName': 'Epacadostat + Pembrolizumab'}]",Epacadostat and Pembrolizumab in Patients With GIST,7587
14,NCT02393248,Phase Ib/II,Recruiting,"[{'id': 4176, 'therapyName': 'Cisplatin + Gemcitabine + INCB054828'}, {'id': 4174, 'therapyName': 'Docetaxel + INCB054828'}, {'id': 4088, 'therapyName': 'Epacadostat + Pembrolizumab'}]","Open-Label, Dose-Escalation Study of INCB054828 in Subjects With Advanced Malignancies",7587
15,NCT03238638,Phase II,Not yet recruiting,"[{'id': 4088, 'therapyName': 'Epacadostat + Pembrolizumab'}]","A Study of Epacadostat + Pembrolizumab in Head and Neck Cancer Patients, Who Failed Prior PD-1/PD-L1 Therapy",7587
16,NCT02318277,Phase Ib/II,Recruiting,"[{'id': 3015, 'therapyName': 'INCB024360 + MEDI4736'}]",A Study of INCB024360 in Combination With MEDI4736 in Subjects With Selected Advanced Solid Tumors,7587
17,NCT02327078,Phase Ib/II,Recruiting,"[{'id': 3059, 'therapyName': 'INCB024360 + Nivolumab'}]","A Study of the Safety, Tolerability, and Efficacy of INCB24360 Administered in Combination With Nivolumab in Select Advanced Cancers",7587
18,NCT03085914,Phase Ib/II,Recruiting,"[{'id': 5483, 'therapyName': 'INCB024360 + Nivolumab + mFOLFOX6'}, {'id': 5484, 'therapyName': 'INCB024360 + Nivolumab + Gemcitabine + nab-paclitaxel'}, {'id': 5485, 'therapyName': 'INCB024360 + Pembrolizumab + Carboplatin + Paclitaxel'}, {'id': 5486, 'therapyName': 'INCB024360 + Pembrolizumab + Carboplatin + Pemetrexed'}, {'id': 5487, 'therapyName': 'INCB024360 + Pembrolizumab + Cyclophosphamide'}]",A Study of Epacadostat in Combination With a PD-1 Inhibitor and Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors (ECHO-207),7587
19,NCT02559492,Phase I,"Active, not recruiting","[{'id': 3096, 'therapyName': 'INCB039110 + INCB024360'}, {'id': 3097, 'therapyName': 'INCB039110 + INCB050465'}]",INCB039110 Combined With INCB024360 and/or INCB039110 Combined With INCB050465 in Advanced Solid Tumors,7587
0,NCT02606123,Phase Ib/II,"Active, not recruiting","[{'id': 5611, 'therapyName': 'EPI-506'}]",Safety and Anti-Tumor Study of Oral EPI-506 for Patients With Metastatic Castration-Resistant Prostate Cancer,8726
0,NCT02918162,Phase II,Recruiting,"[{'id': 4776, 'therapyName': 'Capecitabine + Epirubicin + Oxaliplatin + Pembrolizumab'}]",Perioperative Chemo and Pembrolizumab in Gastric Cancer,437
1,NCT02132949,Phase II,"Active, not recruiting","[{'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}, {'id': 1495, 'therapyName': 'Paclitaxel + Doxorubicin + Cyclophosphamide'}, {'id': 1895, 'therapyName': 'Cyclophosphamide + Fluorouracil + Docetaxel + Epirubicin  '}]","A Study Evaluating Perjeta (Pertuzumab) Combined With Herceptin (Trastuzumab) and Standard Anthracycline-based Chemotherapy in Patients With HER2-positive Locally Advanced, Inflammatory, or Early-stage Breast Cancer.",437
2,NCT02788201,Phase II,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1133, 'therapyName': 'Mitomycin C'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1013, 'therapyName': 'epirubicin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1137, 'therapyName': 'Bleomycin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 781, 'therapyName': 'Ixabepilone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 2950, 'therapyName': 'Estramustine'}, {'id': 1941, 'therapyName': 'Floxuridine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 1811, 'therapyName': 'Carmustine'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 953, 'therapyName': 'Vandetanib'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 4419, 'therapyName': 'Toremifine'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 2601, 'therapyName': 'Dactinomycin'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 3035, 'therapyName': 'Chlorambucil'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 342, 'therapyName': 'Vemurafenib'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 2635, 'therapyName': 'Vinblastine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 4305, 'therapyName': 'Teniposide'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 4304, 'therapyName': 'Streptozocin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1231, 'therapyName': 'Bendamustine'}, {'id': 4303, 'therapyName': 'Mechlorethamine'}, {'id': 4302, 'therapyName': 'Mitotane'}]",Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma,437
3,NCT01901146,Phase III,Completed,"[{'id': 1087, 'therapyName': 'Epirubicin + Cyclophosphamide'}, {'id': 1551, 'therapyName': 'Trastuzumab + Paclitaxel'}]",Efficacy and Safety Study of ABP 980 Compared With Trastuzumab in Subjects With HER2 Positive Early Breast Cancer (Lilac),437
4,NCT03036488,Phase III,Recruiting,"[{'id': 1087, 'therapyName': 'Epirubicin + Cyclophosphamide'}, {'id': 1977, 'therapyName': 'Doxorubicin + Cyclophosphamide'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]",Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522),437
5,NCT01779050,Phase II,"Active, not recruiting","[{'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1087, 'therapyName': 'Epirubicin + Cyclophosphamide'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1982, 'therapyName': 'Fluorouracil + Epirubicin + Cyclophosphamide'}, {'id': 1834, 'therapyName': 'Docetaxel + Carboplatin'}, {'id': 1881, 'therapyName': 'Docetaxel + Cyclophosphamide'}]",Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer Patients With ERBB2 Expressing Disseminated Tumor Cells,437
6,NCT02358863,Phase I,Terminated,"[{'id': 4311, 'therapyName': 'Docetaxel + Irinotecan'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 1835, 'therapyName': 'Docetaxel + Cisplatin'}, {'id': 1406, 'therapyName': 'Camptosar + Cisplatin'}, {'id': 4310, 'therapyName': 'Epirubicin + Docetaxel'}, {'id': 4309, 'therapyName': 'Capecitabine + Docetaxel'}]",Molecularly Tailored Therapy for Patients With Metastatic Cancer of the Esophagus and Stomach (mEGA),437
7,NCT02050919,Phase II,Recruiting,"[{'id': 2365, 'therapyName': 'Epirubicin + Ifosfamide + Sorafenib'}]","Sorafenib Tosylate, Combination Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With High-Risk Stage IIB-IV Soft Tissue Sarcoma",437
8,NCT01501487,FDA approved,"Active, not recruiting","[{'id': 1902, 'therapyName': 'Docetaxel + Doxorubicin + Cyclophosphamide'}, {'id': 1982, 'therapyName': 'Fluorouracil + Epirubicin + Cyclophosphamide'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1476, 'therapyName': 'Pegfilgrastim'}, {'id': 1881, 'therapyName': 'Docetaxel + Cyclophosphamide'}, {'id': 1977, 'therapyName': 'Doxorubicin + Cyclophosphamide'}, {'id': 1485, 'therapyName': 'Trastuzumab + Docetaxel + Carboplatin'}, {'id': 1978, 'therapyName': 'Pertuzumab + Trastuzumab + Docetaxel'}]",MINT I Multi- Institutional Neo-adjuvant Therapy MammaPrint Project I,437
9,NCT01036087,Phase II,"Active, not recruiting","[{'id': 1984, 'therapyName': 'Panitumumab + Abraxane + Carboplatin'}, {'id': 1982, 'therapyName': 'Fluorouracil + Epirubicin + Cyclophosphamide'}]","Panitumumab, Nab-paclitaxel and Carboplatin for HER2 Negative Inflammatory Breast Cancer",437
10,NCT01855828,Phase II,Recruiting,"[{'id': 1549, 'therapyName': 'Pertuzumab + Trastuzumab + Paclitaxel'}, {'id': 1550, 'therapyName': 'Pertuzumab + Trastuzumab + Fluorouracil + Epirubicin + Cyclophosphamide'}]",Phase 2 Trial of Pertuzumab and Trastuzumab With Weekly Paclitaxel and Chemotherapy for HER2 Positive Breast Cancer,437
0,NCT02141828,Phase I,Completed,"[{'id': 2855, 'therapyName': 'EPZ-5676'}]",A Phase 1 Dose Escalation and Expanded Cohort Study of EPZ-5676 in the Treatment of Pediatric Patients With Relapsed/Refractory Leukemias Bearing a Rearrangement of the MLL Gene,7792
0,NCT02099058,Phase I,Recruiting,"[{'id': 1743, 'therapyName': 'ABBV-399 + Carboplatin'}, {'id': 1364, 'therapyName': 'ABBV-399 + Erlotinib'}, {'id': 1363, 'therapyName': 'ABBV-399'}, {'id': 1366, 'therapyName': 'ABBV-399 + Bevacizumab'}, {'id': 1365, 'therapyName': 'ABBV-399 + Cetuximab'}]","A Phase 1/1b Study With ABBV-399, an Antibody Drug Conjugate, in Subjects With Advanced Solid Cancer Tumors",520
1,NCT00733408,Phase II,"Active, not recruiting","[{'id': 1496, 'therapyName': 'Abraxane + Bevacizumab + Erlotinib'}]",Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab Followed By Bevacizumab and Erlotinib Hydrochloride in Treating Patients With Metastatic Breast Cancer,520
2,NCT02013219,Phase I,"Active, not recruiting","[{'id': 3490, 'therapyName': 'Alectinib + Atezolizumab'}, {'id': 1352, 'therapyName': 'Atezolizumab + Erlotinib'}]",A Phase 1b Study of Atezolizumab in Combination With Erlotinib or Alectinib in Participants With Non-Small Cell Lung Cancer,520
3,NCT01130519,Phase II,Recruiting,"[{'id': 1146, 'therapyName': 'Bevacizumab + Erlotinib'}]",A Phase II Study of Bevacizumab and Erlotinib in Subjects With Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) or Sporadic Papillary Renal Cell Cancer,520
4,NCT02045446,Phase II,"Active, not recruiting","[{'id': 1146, 'therapyName': 'Bevacizumab + Erlotinib'}, {'id': 1439, 'therapyName': 'Gemcitabine + Docetaxel'}]",Maintenance Chemotherapy Versus Consolidative Stereotactic Body Radiation Therapy (SBRT) Plus Maintenance Chemotherapy for Stage IV Non-Small Cell Lung Cancer (NSCLC),520
5,NCT01182350,Phase II,"Active, not recruiting","[{'id': 2115, 'therapyName': 'Bevacizumab + Temozolomide'}, {'id': 2116, 'therapyName': 'Bevacizumab + Erlotinib + Temozolomide'}, {'id': 1146, 'therapyName': 'Bevacizumab + Erlotinib'}, {'id': 667, 'therapyName': 'Bevacizumab'}]",Molecularly Determined Treatment of Diffuse Intrinsic Pontine Gliomas (DIPG),520
6,NCT02424617,Phase Ib/II,Recruiting,"[{'id': 2684, 'therapyName': 'BGB-324 + Erlotinib'}]",A Study of BGB324 in Combination With Erlotinib in Patients With Non-Small Cell Lung Cancer,520
7,NCT01487265,Phase II,"Active, not recruiting","[{'id': 1319, 'therapyName': 'BKM120 + Erlotinib'}]",Trial of Erlotinib and BKM120 in Patients With Advanced Non Small Cell Lung Cancer Previously Sensitive to Erlotinib,520
8,NCT03213626,Phase II,Not yet recruiting,"[{'id': 1255, 'therapyName': 'Cabozantinib + Erlotinib'}]",Cabozantinib and Erlotinib for Patients With EGFR and c-Met Co-expressing Metastatic Pancreatic Adenocarcinoma,520
9,NCT01866410,Phase II,"Active, not recruiting","[{'id': 1255, 'therapyName': 'Cabozantinib + Erlotinib'}]",Cabozantinib-S-Malate and Erlotinib Hydrochloride in Treating Patients With Previously Treated Metastatic Non-Small Cell Lung Cancer,520
10,NCT02014909,Phase I,Completed,"[{'id': 2054, 'therapyName': 'CDX-3379'}, {'id': 2063, 'therapyName': 'CDX-3379 + Vemurafenib'}, {'id': 2064, 'therapyName': 'CDX-3379 + Trastuzumab'}, {'id': 2061, 'therapyName': 'Cetuximab + CDX-3379'}, {'id': 2062, 'therapyName': 'CDX-3379 + Erlotinib'}]",A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of KTN3379 in Adult Subjects With Advanced Tumors,520
11,NCT00970502,Phase Ib/II,Completed,"[{'id': 2125, 'therapyName': 'Celecoxib + Erlotinib'}]","Erlotinib, Celecoxib and Reirradiation for Recurrent Head and Neck Cancer",520
12,NCT01316757,Phase II,"Active, not recruiting","[{'id': 1921, 'therapyName': 'Cetuximab + Paclitaxel + Carboplatin + Erlotinib'}]","Carboplatin, Paclitaxel, Cetuximab, and Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Head and Neck Squamous Cell Cancer",520
13,NCT01822496,Phase II,Recruiting,"[{'id': 1375, 'therapyName': 'Cisplatin + Etoposide + Paclitaxel + Carboplatin + Erlotinib'}]",Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer,520
14,NCT01900652,Phase II,Completed,"[{'id': 1179, 'therapyName': 'Emibetuzumab + Erlotinib'}, {'id': 803, 'therapyName': 'Emibetuzumab'}]",A Study of LY2875358 in Non Small Cell Lung Cancer (NSCLC) Participants,520
15,NCT01287546,Phase I,Completed,"[{'id': 1179, 'therapyName': 'Emibetuzumab + Erlotinib'}, {'id': 1180, 'therapyName': 'Emibetuzumab + Trametinib'}, {'id': 803, 'therapyName': 'Emibetuzumab'}]",A Study of LY2875358 in Participants With Advanced Cancer,520
16,NCT02468661,Phase Ib/II,Recruiting,"[{'id': 1065, 'therapyName': 'Capmatinib'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 1857, 'therapyName': 'Cisplatin + Pemetrexed'}, {'id': 1602, 'therapyName': 'Carboplatin + Pemetrexed'}]","A Safety and Efficacy Study of INC280 Alone, and in Combination With Erlotinib, Compared to Chemotherapy, in Advanced/Metastatic Non-small Cell Lung Cancer Patients With EGFR Mutation and cMET Amplification",520
17,NCT00054496,Phase II,Unknown status,"[{'id': 4, 'therapyName': 'Erlotinib'}]",Erlotinib in Treating Patients With Recurrent or Progressive Glioblastoma Multiforme,520
18,NCT02296125,Phase III,"Active, not recruiting","[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 660, 'therapyName': 'AZD9291'}, {'id': 751, 'therapyName': 'Gefitinib'}]",AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer,520
19,NCT02770014,Phase II,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}]",Rapid Plasma Genotyping For Early Initiation Of Erlotinib In EGFR Mutant Lung Cancer,520
20,NCT02186301,Phase II,Terminated,"[{'id': 1003, 'therapyName': 'CO1686'}, {'id': 4, 'therapyName': 'Erlotinib'}]",TIGER-1: Safety and Efficacy Study of Rociletinib (CO-1686) or Erlotinib in Patients With EGFR Mutant NSCLC Who Have Not Had Any Previous EGFR Directed Therapy,520
21,NCT02788201,Phase II,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1133, 'therapyName': 'Mitomycin C'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1013, 'therapyName': 'epirubicin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1137, 'therapyName': 'Bleomycin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 781, 'therapyName': 'Ixabepilone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 2950, 'therapyName': 'Estramustine'}, {'id': 1941, 'therapyName': 'Floxuridine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 1811, 'therapyName': 'Carmustine'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 953, 'therapyName': 'Vandetanib'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 4419, 'therapyName': 'Toremifine'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 2601, 'therapyName': 'Dactinomycin'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 3035, 'therapyName': 'Chlorambucil'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 342, 'therapyName': 'Vemurafenib'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 2635, 'therapyName': 'Vinblastine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 4305, 'therapyName': 'Teniposide'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 4304, 'therapyName': 'Streptozocin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1231, 'therapyName': 'Bendamustine'}, {'id': 4303, 'therapyName': 'Mechlorethamine'}, {'id': 4302, 'therapyName': 'Mitotane'}]",Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma,520
22,NCT02961374,Phase II,Not yet recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}]",Erlotinib Hydrochloride in Reducing Duodenal Polyp Burden in Patients With Familial Adenomatous Polyposis at Risk of Developing Colon Cancer,520
23,NCT01344824,Phase II,Completed,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 854, 'therapyName': 'Pemetrexed'}]","Carboplatin, Pemetrexed Disodium, and Bevacizumab in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Who Are Light or Never Smokers",520
24,NCT02193282,Phase III,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}]",Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-Small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial),520
25,NCT03137771,Phase II,Recruiting,"[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 4, 'therapyName': 'Erlotinib'}]",Maintenance Chemotherapy With or Without Stereotactic Body Radiation Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer,520
26,NCT02015728,Phase I,"Active, not recruiting","[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1804, 'therapyName': 'Temozolomide + Etoposide'}, {'id': 920, 'therapyName': 'Sorafenib'}]",Selecting Patient-Specific Biologically Targeted Therapy for Pediatric Patients With Refractory Or Recurrent Brain Tumors,520
27,NCT02134886,Phase I,Terminated,"[{'id': 4, 'therapyName': 'Erlotinib'}]",Erlotinib Hydrochloride in Treating Non-Small Cell Lung Cancer That is Metastatic or Cannot be Removed by Surgery in Patients With HIV Infection,520
28,NCT02551718,Phase I,Recruiting,"[{'id': 690, 'therapyName': 'Bosutinib'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 3160, 'therapyName': 'Nelarabine'}, {'id': 3159, 'therapyName': 'Bexarotene'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 998, 'therapyName': 'cabozantinib'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 877, 'therapyName': 'Ponatinib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 623, 'therapyName': 'Afatinib'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 890, 'therapyName': 'Regorafenib'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 2, 'therapyName': 'Trametinib'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 3, 'therapyName': 'Dabrafenib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 789, 'therapyName': 'Ceritinib'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1571, 'therapyName': 'Cabazitaxel'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1327, 'therapyName': 'Pralatrexate'}]",High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia,520
29,NCT02134015,Phase III,Terminated,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 2530, 'therapyName': 'Patritumab + Erlotinib'}]",Study of Patritumab in Combination With Erlotinib in Subjects With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC). (HER3-Lung),520
30,NCT01455389,Phase Ib/II,Recruiting,"[{'id': 1313, 'therapyName': 'DOTAP:chol-Fus1'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 1275, 'therapyName': 'Diphenhydramine'}, {'id': 1390, 'therapyName': 'Dexamethasone'}]",FUS1-nanoparticles and Erlotinib in Stage IV Lung Cancer,520
31,NCT00301418,Phase Ib/II,Completed,"[{'id': 4, 'therapyName': 'Erlotinib'}]",Oral Tarceva Study for Recurrent/Residual Glioblastoma Multiforme and Anaplastic Astrocytoma,520
32,NCT02588261,Phase III,"Active, not recruiting","[{'id': 1082, 'therapyName': 'ASP8273'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 4, 'therapyName': 'Erlotinib'}]",A Study of ASP8273 vs. Erlotinib or Gefitinib in First-line Treatment of Patients With Stage IIIB/IV Non-small Cell Lung Cancer Tumors With EGFR Activating Mutations,520
33,NCT01472016,Phase I,Completed,"[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1063, 'therapyName': 'ABT-700'}, {'id': 694, 'therapyName': 'Cetuximab'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 1315, 'therapyName': 'FOLFIRI'}]",Study of ABT-700 in Subjects With Advanced Solid Tumors,520
34,NCT01197170,Phase I,"Active, not recruiting","[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 633, 'therapyName': 'Anastrozole'}, {'id': 667, 'therapyName': 'Bevacizumab'}]",Hormone Blockade in Combination With Targeted Agents,520
35,NCT01857271,Phase II,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}]",Erlotinib Hydrochloride Before Surgery in Treating Patients With Stage III Non-Small Cell Lung Cancer,520
36,NCT01592383,Phase II,Completed,"[{'id': 4, 'therapyName': 'Erlotinib'}]",Erlotinib Hydrochloride in Treating Patients With Malignant Peritoneal Mesothelioma,520
37,NCT01233687,Phase Ib/II,Completed,"[{'id': 629, 'therapyName': 'AMG102'}, {'id': 4, 'therapyName': 'Erlotinib'}]",AMG 102 and Erlotinib for Advanced Non-Small Cell Lung Cancer,520
38,NCT02091141,Phase II,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 698, 'therapyName': 'Alectinib'}, {'id': 1657, 'therapyName': 'Vemurafenib + Cobimetinib'}, {'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 1201, 'therapyName': 'Atezolizumab'}]","My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors",520
39,NCT02450591,Phase I,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}]",Local Therapies for Oligometastatic Non-Small Cell Lung Cancer Harboring Sensitizing EGFR Mutations,520
40,NCT02004262,Phase II,Completed,"[{'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 2383, 'therapyName': 'Capecitabine + Fluorouracil + Gemcitabine '}]",Safety and Efficacy of Combination Listeria/GVAX Pancreas Vaccine in the Pancreatic Cancer Setting,520
41,NCT01454102,Phase I,"Active, not recruiting","[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1312, 'therapyName': 'Nivolumab'}]","Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012)",520
42,NCT01532089,Phase II,"Active, not recruiting","[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 4, 'therapyName': 'Erlotinib'}]",Erlotinib With or Without Bevacizumab in Treating Patients With Stage IV Non-Small Cell Lung Cancer With EGFR Mutations,520
43,NCT02277457,Phase I,Withdrawn,"[{'id': 706, 'therapyName': 'Crizotinib'}, {'id': 4, 'therapyName': 'Erlotinib'}]","Personalized Adaptive Radiation Therapy With Individualized Systemic Targeted Therapy (PARTIST) for Locally Advanced, Non-small Cell Lung Cancer With Genomic Driver Mutations",520
44,NCT02574078,Phase I,Recruiting,"[{'id': 619, 'therapyName': 'Abraxane'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 2114, 'therapyName': 'Bevacizumab + Pemetrexed'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 1092, 'therapyName': 'Carboplatin'}]",A Master Protocol Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC) (CheckMate 370),520
45,NCT00997334,Phase II,Completed,"[{'id': 4, 'therapyName': 'Erlotinib'}]",Erlotinib Therapy and Subsequent Development of Mechanisms of Secondary Resistance in Patients With NSCLC,520
46,NCT01306045,Phase II,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 816, 'therapyName': 'MK2206'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 913, 'therapyName': 'Selumetinib'}]","Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies",520
47,NCT02411448,Phase III,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 886, 'therapyName': 'Ramucirumab'}]",A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Participants With EGFR Mutation-Positive Metastatic NSCLC,520
48,NCT01064479,Phase II,"Active, not recruiting","[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 700, 'therapyName': 'Cisplatin'}]",Docetaxel And Cisplatin With or Without Erlotinib For Metastatic Or Recurrent Squamous Cell Carcinoma Of Head And Neck,520
49,NCT01471964,Phase Ib/II,Suspended,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 626, 'therapyName': 'Alisertib'}]","Study to Assess Safety and Tolerability of MLN8237, In Combination With Erlotinib to Treat Non-Small Cell Lung Cancer",520
50,NCT02318368,Phase II,Terminated,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 2169, 'therapyName': 'Ficlatuzumab + Erlotinib'}]","A Phase 2, Multicenter, Study of Ficlatuzumab Plus Erlotinib Versus Placebo Plus Erlotinib in Subjects Who Have Previously Untreated Metastatic, EGFR-mutated Non-small Cell Lung Cancer (NSCLC) and BDX004 Positive Label",520
51,NCT02355431,Phase II,Withdrawn,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 2406, 'therapyName': 'INCB039110'}]",INCB039110 in Combination With Erlotinib in Non Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor (EGFR) Activating Mutations,520
52,NCT00547105,Phase II,Unknown status,"[{'id': 4, 'therapyName': 'Erlotinib'}]",Erlotinib and Stereotactic Body Radiation Therapy in Treating Patients With Locally Advanced or Metastatic Non-Small Call Lung Cancer,520
53,NCT01248247,Phase I,"Active, not recruiting","[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 1098, 'therapyName': 'MK2206 + Selumetinib'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 1097, 'therapyName': 'Erlotinib + MK2206'}]",BATTLE-2 Program: A Biomarker-Integrated Targeted Therapy Study,520
54,NCT01116336,Phase I,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}]",Phase I Chemoprevention Trial With Green Tea Polyphenon E and Erlotinib in Patients With Premalignant Lesions of the Head and Neck,520
55,NCT02152631,Phase III,"Active, not recruiting","[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 802, 'therapyName': 'Abemaciclib'}]",A Study of LY2835219 in Participants With Previously Treated Lung Cancer,520
56,NCT01967095,Phase I,"Active, not recruiting","[{'id': 4, 'therapyName': 'Erlotinib'}]",Low Dose Daily Erlotinib in Combination With High Dose Twice Weekly Erlotinib in Patients With EGFR-Mutant Lung Cancer,520
57,NCT02169284,Phase II,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}]",Erlotinib Hydrochloride in Treating Patients With Bladder Cancer Undergoing Surgery,520
58,NCT02117024,Phase II,"Active, not recruiting","[{'id': 2472, 'therapyName': 'HS-110 + Cyclophosphamide'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 1685, 'therapyName': 'Vinorelbine'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]",A Phase 2 Study of Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer,520
59,NCT01801111,Phase II,"Active, not recruiting","[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 698, 'therapyName': 'Alectinib'}]",A Study of RO5424802 in Patients With Non-Small Cell Lung Cancer Who Have ALK Mutation and Failed Crizotinib Treatment,520
60,NCT01573702,Phase II,"Active, not recruiting","[{'id': 4, 'therapyName': 'Erlotinib'}]",Stereotactic Radiosurgery or Other Local Ablation Then Erlotinib in Epidermal Growth Factor Receptor (EGFR),520
61,NCT01456325,Phase III,Completed,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 838, 'therapyName': 'Onartuzumab'}]",A Study of Onartuzumab (MetMAb) in Combination With Tarceva (Erlotinib) in Patients With Met Diagnostic-Positive Non-Small Cell Lung Cancer Who Have Received Chemotherapy For Advanced or Metastatic Disease (MetLung),520
62,NCT02154490,Phase II,Recruiting,"[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 850, 'therapyName': 'Palbociclib'}, {'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 654, 'therapyName': 'AZD4547'}, {'id': 1016, 'therapyName': 'GDC-0032'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 629, 'therapyName': 'AMG102'}]",Lung-MAP: S1400 Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IIIB-IV Squamous Cell Lung Cancer,520
63,NCT02693535,Phase II,Recruiting,"[{'id': 1657, 'therapyName': 'Vemurafenib + Cobimetinib'}, {'id': 890, 'therapyName': 'Regorafenib'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 690, 'therapyName': 'Bosutinib'}, {'id': 850, 'therapyName': 'Palbociclib'}, {'id': 694, 'therapyName': 'Cetuximab'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 837, 'therapyName': 'Olaparib'}, {'id': 4, 'therapyName': 'Erlotinib'}]",TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer,520
64,NCT01683422,Phase II,Recruiting,"[{'id': 2473, 'therapyName': 'Erlotinib + Capecitabine + Gemcitabine'}]",Chemotherapy Plus Proton-chemotherapy for Locally Advanced Pancreatic Cancer,520
65,NCT01928160,Phase II,Withdrawn,"[{'id': 1290, 'therapyName': 'Erlotinib + Pemetrexed'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1291, 'therapyName': 'Erlotinib + Carboplatin'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1292, 'therapyName': 'Erlotinib + Cisplatin'}]",Pemetrexed Disodium and Carboplatin or Cisplatin With or Without Erlotinib Hydrochloride in Treating Patient With Stage IV Non-Small Cell Lung Cancer Resistant to First-Line Therapy With Erlotinib Hydrochloride or Gefitinib,520
66,NCT01545947,Phase I,Completed,"[{'id': 1149, 'therapyName': 'Azacitidine + CC-223'}, {'id': 1147, 'therapyName': 'Erlotinib + CC-223'}]"," Study Assessing Safety, Pharmacokinetics and Efficacy of CC-223 With Either Erlotinib or Oral Azacitidine in Advanced Non-Small Cell Lung Cancer",520
67,NCT00602667,Phase I,"Active, not recruiting","[{'id': 2449, 'therapyName': 'Methotrexate + Cisplatin + Cyclophosphamide + Vincristine'}, {'id': 2450, 'therapyName': 'Cyclophosphamide + Etoposide + Topotecan'}, {'id': 2451, 'therapyName': 'Erlotinib + Cyclophosphamide + Topotecan'}]","Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma",520
68,NCT01927744,Phase II,Recruiting,"[{'id': 2474, 'therapyName': 'Erlotinib + Docetaxel'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1092, 'therapyName': 'Carboplatin'}]","Study of Chemotherapy With Cisplatin/CarboplatinAstellas Pharma Inc, OSI Pharmaceuticals, Kadoorie Foundation, and Docetaxel With or Without Erlotinib in Patients With Head and Neck Squamous Cell Carcinomas Amenable for Surgical Resection",520
69,NCT02321293,Phase I,Unknown status,"[{'id': 2379, 'therapyName': 'Erlotinib + Gefitinib'}]",A Open-label Prospective Cohort Trial of Curcumin Plus Tyrosine Kinase Inhibitors (TKI) for EGFR -Mutant Advanced NSCLC,520
70,NCT02154737,Phase I,Recruiting,"[{'id': 2381, 'therapyName': 'Erlotinib + Gemcitabine'}]",Gemcitabine and Pulse Dose Erlotinib in Second Line Treatment of Advanced Pancreatic Cancer,520
71,NCT01013649,Phase II,Recruiting,"[{'id': 2381, 'therapyName': 'Erlotinib + Gemcitabine'}, {'id': 755, 'therapyName': 'Gemcitabine'}]",Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed By the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed By Surgery,520
72,NCT02352948,Phase III,"Active, not recruiting","[{'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 2438, 'therapyName': 'Erlotinib + Gemcitabine + Vinorelbine'}, {'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}, {'id': 1652, 'therapyName': 'Tremelimumab'}]","A Global Study to Assess the Effects of MEDI4736, Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer",520
73,NCT02991651,Phase I,Recruiting,"[{'id': 5135, 'therapyName': 'Erlotinib + IRX4204'}]",Study of IRX4204 With Erlotinib in Previously Treated Advanced NSCLC,520
74,NCT02942095,Phase I,Recruiting,"[{'id': 4885, 'therapyName': 'Erlotinib + Ixazomib'}]",Phase I Study of Ixazomib and Erlotinib in Solid Tumors,520
75,NCT02206763,Phase I,Terminated,"[{'id': 2380, 'therapyName': 'Erlotinib + Momelotinib'}]",Erlotinib and Momelotinib for the Treatment of Epidermal Growth Factor Receptor (EGFR) Mutated EGFR Tyrosine Kinase Inhibitor (TKI) Naive Metastatic Non-Small Cell Lung Cancer (NSCLC),520
76,NCT02535338,Phase Ib/II,Suspended,"[{'id': 3071, 'therapyName': 'Erlotinib + Onalespib'}]",Erlotinib Hydrochloride and Hsp90 Inhibitor AT13387 in Treating Patients With Recurrent or Metastatic Non-small Cell Lung Cancer,520
77,NCT02342353,Phase Ib/II,Recruiting,"[{'id': 2382, 'therapyName': 'Erlotinib + Pacritinib'}]",Pacritinib in Patients With Endothelial Growth Factor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC) After EGFR Tyrosine Kinase Inhibitor (TKI),520
78,NCT02039674,Phase Ib/II,"Active, not recruiting","[{'id': 2103, 'therapyName': 'Carboplatin + Paclitaxel + Pembrolizumab'}, {'id': 2104, 'therapyName': 'Bevacizumab + Carboplatin + Paclitaxel + Pembrolizumab'}, {'id': 1602, 'therapyName': 'Carboplatin + Pemetrexed'}, {'id': 2106, 'therapyName': 'Ipilimumab + Pembrolizumab '}, {'id': 2107, 'therapyName': 'Erlotinib + Pembrolizumab '}, {'id': 2108, 'therapyName': 'Gefitinib + Pembrolizumab '}]",A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Lung Cancer (MK-3475-021/KEYNOTE-021),520
79,NCT00573989,Phase Ib/II,Terminated,"[{'id': 1290, 'therapyName': 'Erlotinib + Pemetrexed'}]","Intensity-Modulated Radiation Therapy, Pemetrexed, and Erlotinib in Treating Patients With Recurrent or Second Primary Head and Neck Cancer",520
80,NCT00950365,Phase II,Unknown status,"[{'id': 1290, 'therapyName': 'Erlotinib + Pemetrexed'}, {'id': 854, 'therapyName': 'Pemetrexed'}]",Pharmacodynamic Separation of Pemetrexed and Erlotinib as Second-line Therapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC),520
81,NCT01532011,Phase I,Completed,"[{'id': 1328, 'therapyName': 'Erlotinib + Pralatrexate'}]",Erlotinib in Combination With Pralatrexate in Advanced Malignancies,520
82,NCT01839955,Phase Ib/II,Completed,"[{'id': 1237, 'therapyName': 'Erlotinib + Quinacrine'}]",Erlotinib Hydrochloride and Quinacrine Dihydrochloride in Stage IIIB-IV Non-Small Cell Lung Cancer,520
83,NCT01962896,Phase II,Recruiting,"[{'id': 2253, 'therapyName': 'Erlotinib + Sirolimus'}]",A Phase II Study of Sirolimus and Erlotinib in Recurrent/Refractory Germ Cell Tumors,520
84,NCT02689336,Phase II,Recruiting,"[{'id': 3726, 'therapyName': 'Erlotinib + Temozolomide'}]",Erlotinib in Combination With Temozolomide in Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors,520
85,NCT02080078,Phase I,Recruiting,"[{'id': 2436, 'therapyName': 'Erlotinib + Theophylline'}]",A Phase I Dose Escalation Study of Erlotinib in Combination With Theophylline,520
86,NCT01376310,Phase II,"Active, not recruiting","[{'id': 1264, 'therapyName': 'Docetaxel + Trametinib'}, {'id': 1265, 'therapyName': 'Erlotinib + Trametinib'}, {'id': 2, 'therapyName': 'Trametinib'}, {'id': 1266, 'therapyName': 'Pemetrexed + GSK1120212'}, {'id': 1267, 'therapyName': 'Carboplatin + GSK1120212'}, {'id': 1268, 'therapyName': 'nab-paclitaxel + GSK1120212'}, {'id': 1269, 'therapyName': 'Gemcitabine + GSK1120212'}, {'id': 1271, 'therapyName': 'Everolimus + GSK1120212'}]",GSK1120212 Rollover Study,520
87,NCT03076164,Phase Ib/II,Recruiting,"[{'id': 1265, 'therapyName': 'Erlotinib + Trametinib'}]",A Phase 1/2 Trial of Trametinib and Erlotinib in Patients With EGFR-Mutant Lung Adenocarcinomas and Acquired Resistance to Erlotinib,520
88,NCT01660971,Phase I,"Active, not recruiting","[{'id': 1816, 'therapyName': 'Gemcitabine + Dasatinib + Erlotinib'}]","Gemcitabine Hydrochloride, Dasatinib, and Erlotinib Hydrochloride in Treating Patients With Metastatic Pancreatic Cancer That Cannot Be Removed By Surgery",520
89,NCT01911507,Phase I,Recruiting,"[{'id': 1284, 'therapyName': 'INCB028060 + Erlotinib'}]",INC280 and Erlotinib Hydrochloride in Treating Patients With Non-small Cell Lung Cancer,520
90,NCT01998126,Phase I,"Active, not recruiting","[{'id': 1348, 'therapyName': 'Ipilimumab + Erlotinib'}, {'id': 1349, 'therapyName': 'Ipilimumab + Crizotinib'}]",Ipilimumab Plus Targeted Inhibitor (Erlotinib or Crizotinib) for EGFR or ALK Mutated Stage IV Non-small Cell Lung Cancer: Phase Ib With Expansion Cohorts,520
91,NCT01859026,Phase I,Recruiting,"[{'id': 1253, 'therapyName': 'MEK162 + Erlotinib'}]",A Phase I/IB Trial of MEK162 in Combination With Erlotinib in NSCLC Harboring KRAS or EGFR Mutation,520
92,NCT01650506,Phase I,Completed,"[{'id': 1828, 'therapyName': 'Metformin + Erlotinib'}]",Study of Erlotinib and Metformin in Triple Negative Breast Cancer,520
93,NCT00975767,Phase Ib/II,Terminated,"[{'id': 1127, 'therapyName': 'MGCD265 + Docetaxel'}, {'id': 1126, 'therapyName': 'MGCD265 + Erlotinib'}]",A Study of MGCD265 Given With Erlotinib or Docetaxel in Subjects With Advanced Malignancies or Non-Small Cell Lung Cancer,520
94,NCT01887886,Phase III,Completed,"[{'id': 1280, 'therapyName': 'Onartuzumab + Erlotinib'}]",A Study of Onartuzumab in Combination With Erlotinib in Patients With MET-Positive Stage IIIB or IV Non-Small Cell Lung Cancer Carrying an Activating EGFR Mutation,520
95,NCT02044601,Phase Ib/II,Withdrawn,"[{'id': 1370, 'therapyName': 'Onartuzumab + Paclitaxel + Carboplatin'}, {'id': 1371, 'therapyName': 'Onartuzumab + Erlotinib + Paclitaxel + Carboplatin'}]",Biomarker-Integrated Approach of Targeted Therapy for Lung Cancer Elimination Plus External Beam Radiation Therapy (BATTLE-XRT),520
96,NCT00940316,Phase II,"Active, not recruiting","[{'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 1940, 'therapyName': 'Panitumumab + Erlotinib'}]",Dual Epidermal Growth Factor Receptor Inhibition With Erlotinib and Panitumumab With or Without Chemotherapy for Advanced Colorectal Cancer,520
97,NCT01727869,Phase I,Completed,"[{'id': 1246, 'therapyName': 'REGN1400 + Erlotinib'}, {'id': 1247, 'therapyName': 'REGN1400 + Cetuximab'}, {'id': 1072, 'therapyName': 'REGN1400'}]", Study of REGN1400 Alone and in Combination With Erlotinib or Cetuximab in Patients With Certain Types of Cancer,520
98,NCT02155465,Phase Ib/II,"Active, not recruiting","[{'id': 1858, 'therapyName': 'Ruxolitinib + Erlotinib'}]",Trial of Ruxolitinib and Erlotinib in Patients With EGFR-mutant Lung Adenocarcinoma With Acquired Resistance to Erlotinib,520
0,NCT03127098,Phase Ib/II,"Active, not recruiting","[{'id': 6239, 'therapyName': 'ALT-803 + ETBX-011'}]","QUILT-3.040: ETBX-011 (Ad5 [E1-, E2b-]-CEA(6D)) Vaccine in Combination With ALT-803 (Super-agonist IL-15) in Subjects Having CEA-Expressing Cancer",8931
1,NCT03136406,Phase Ib/II,Recruiting,"[{'id': 1018, 'therapyName': 'GI-4000'}, {'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 3144, 'therapyName': 'Avelumab'}, {'id': 619, 'therapyName': 'Abraxane'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 6163, 'therapyName': 'ETBX-011'}, {'id': 3060, 'therapyName': 'ALT-803'}]",QUILT-3.039: NANT Pancreatic Cancer Vaccine: Combination Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy,8931
0,NCT01849783,Phase II,Recruiting,"[{'id': 1852, 'therapyName': 'Melphalan + Bortezomib + Thalidomide + Dexamethasone'}, {'id': 3435, 'therapyName': 'Aldoxorubicin + Cisplatin + Cyclophosphamide + Dexamethasone + Etoposide'}]",Autologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple Myeloma,763
1,NCT02101853,Phase III,Recruiting,"[{'id': 1876, 'therapyName': 'Blinatumomab '}, {'id': 2347, 'therapyName': 'Leucovorin + Pegaspargase  + Vincristine'}, {'id': 2346, 'therapyName': 'Mercaptopurine + Thioguanine'}, {'id': 2348, 'therapyName': 'Asparaginase + Cyclophosphamide + Etoposide'}, {'id': 2345, 'therapyName': 'Cytarabine + Dexamethasone+ Methotrexate '}]",Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia,763
2,NCT02763579,Phase III,Recruiting,"[{'id': 4164, 'therapyName': 'Atezolizumab + Carboplatin + Etoposide'}, {'id': 1791, 'therapyName': 'Carboplatin + Etoposide'}]",A Study of Carboplatin Plus Etoposide With or Without Atezolizumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer (IMpower133),763
3,NCT02748889,Phase Ib/II,Terminated,"[{'id': 1791, 'therapyName': 'Carboplatin + Etoposide'}, {'id': 4164, 'therapyName': 'Atezolizumab + Carboplatin + Etoposide'}]",Carboplatin Plus Etoposide With or Without MPDL3280A in Untreated Extensive Stage Small Cell Lung Cancer,763
4,NCT03041311,Phase II,Recruiting,"[{'id': 5541, 'therapyName': 'Atezolizumab + Carboplatin + Etoposide + Trilaciclib'}, {'id': 4164, 'therapyName': 'Atezolizumab + Carboplatin + Etoposide'}]","Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Extensive Stage Small Cell Lung Cancer (SCLC)",763
5,NCT01476839,Phase I,Recruiting,"[{'id': 6258, 'therapyName': 'Basiliximab + 90Y basiliximab + Carmustine + Cytarbine + Etoposide + Melphalan'}]",Radiolabeled Monoclonal Antibody Therapy and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Primary Refractory or Relapsed Hodgkin Lymphoma,763
6,NCT00926640,Phase I,Completed,"[{'id': 1123, 'therapyName': 'Belinostat + Cisplatin + Etoposide'}]",A Phase I Study of Belinostat in Combination With Cisplatin and Etoposide in Adults With Small Cell Lung Carcinoma and Other Advanced Cancers,763
7,NCT02130869,Phase I,Recruiting,"[{'id': 2378, 'therapyName': 'Bendamustine + Cytarabine + Etoposide'}, {'id': 2460, 'therapyName': 'Busulfan + Hu14.18K322A'}, {'id': 2459, 'therapyName': 'Aldesleukin + Melphalan + Sargramostim'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1791, 'therapyName': 'Carboplatin + Etoposide'}]",A Pilot Study of Immunotherapy Including Haploidentical NK Cell Infusion Following CD133+ Positively-Selected Autologous Hematopoietic Stem Cells in Children With High Risk Solid Tumors or Lymphomas,763
8,NCT02194049,Phase I,Completed,"[{'id': 1626, 'therapyName': 'BKM120 + Etoposide + Cisplatin'}]","Cisplatin, Etoposide and PI3K Inhibitor BKM120 in Treating Patients With Advanced Solid Tumors or Small Cell Lung Cancer",763
9,NCT02815592,Phase Ib/II,"Active, not recruiting","[{'id': 1136, 'therapyName': 'Etoposide'}, {'id': 4563, 'therapyName': 'BMS-986012 + Cisplatin + Etoposide'}, {'id': 4564, 'therapyName': 'BMS-986012 + Carboplatin + Etoposide'}]",Trial of BMS-986012 in Combination With Platinum and Etoposide,763
10,NCT00513474,Phase I,Completed,"[{'id': 2313, 'therapyName': 'Rasburicase'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 1650, 'therapyName': 'Cyclosporine'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 2314, 'therapyName': 'Busulfan + Cyclophosphamide + Etoposide'}]",Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant,763
11,NCT02899728,Phase II,Suspended,"[{'id': 4728, 'therapyName': 'Carboplatin + Cisplatin + Etoposide'}, {'id': 1971, 'therapyName': 'Cediranib + Olaparib'}]","Olaparib, Cediranib Maleate, and Standard Chemotherapy in Treating Patients With Small Cell Lung Cancer",763
12,NCT03043872,Phase III,Recruiting,"[{'id': 5305, 'therapyName': 'MEDI4736 + Tremelimumab + Carboplatin + Cisplatin + Etoposide'}, {'id': 5306, 'therapyName': 'MEDI4736 + Carboplatin + Cisplatin + Etoposide'}, {'id': 4728, 'therapyName': 'Carboplatin + Cisplatin + Etoposide'}]",Durvalumab+/- Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer (Caspian),763
13,NCT02934503,Phase II,Recruiting,"[{'id': 6184, 'therapyName': 'Carboplatin + Cisplatin + Etoposide + Pembrolizumab'}]",Study of Pembrolizumab and Chemotherapy With or Without Radiation in Small Cell Lung Cancer (SCLC),763
14,NCT02703272,Phase III,Recruiting,"[{'id': 768, 'therapyName': 'Ibrutinib'}, {'id': 4307, 'therapyName': 'Carboplatin + Dexamethasone + Etoposide + Ifosfamide + Rituximab'}, {'id': 4308, 'therapyName': 'Carboplatin + Dexamethasone + Idarubicin + Ifosfamide + Rituximab + Vincristine'}]",A Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Participants With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma,763
15,NCT02017964,Phase II,Completed,"[{'id': 1791, 'therapyName': 'Carboplatin + Etoposide'}, {'id': 2673, 'therapyName': 'Cyclophosphamide + Methotrexate + Vincristine  '}]","Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed, Non-Metastatic Desmoplastic Medulloblastoma",763
16,NCT02499770,Phase Ib/II,"Active, not recruiting","[{'id': 1791, 'therapyName': 'Carboplatin + Etoposide'}, {'id': 3074, 'therapyName': 'Trilaciclib'}]",G1T28 (CDK 4/6 Inhibitor) in Combination With Etoposide and Carboplatin in Extensive Stage Small Cell Lung Cancer (SCLC),763
17,NCT02658214,Phase I,Recruiting,"[{'id': 2667, 'therapyName': 'Carboplatin + Gemcitabine'}, {'id': 2634, 'therapyName': 'Carboplatin + nab-paclitaxel'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 1791, 'therapyName': 'Carboplatin + Etoposide'}]",Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors,763
18,NCT01722292,Phase Ib/II,Terminated,"[{'id': 1587, 'therapyName': 'Taladegib'}, {'id': 1791, 'therapyName': 'Carboplatin + Etoposide'}]",A Study of LY2940680 in Small Cell Lung Cancer,763
19,NCT03066778,Phase III,Recruiting,"[{'id': 2585, 'therapyName': 'Cisplatin + Etoposide'}, {'id': 5145, 'therapyName': 'Cisplatin + Etoposide + Pembrolizumab'}, {'id': 2604, 'therapyName': 'Carboplatin + Etoposide + Pembrolizumab'}, {'id': 1791, 'therapyName': 'Carboplatin + Etoposide'}]",A Study of Pembrolizumab (MK-3475) in Combination With Etoposide/Platinum (Cisplatin or Carboplatin) for Participants With Extensive Stage Small Cell Lung Cancer (MK-3475-604/KEYNOTE-604),763
20,NCT01453205,Phase II,Completed,"[{'id': 2354, 'therapyName': 'Cisplatin + Cytarabine + Dexamethasone'}, {'id': 2352, 'therapyName': 'Carboplatin + Etoposide + Ifosfamide '}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 2407, 'therapyName': 'MEDI-551'}]","A Phase 2, Multicenter, Randomized, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)",763
21,NCT02408042,Phase Ib/II,Withdrawn,"[{'id': 897, 'therapyName': 'Rituximab'}, {'id': 2352, 'therapyName': 'Carboplatin + Etoposide + Ifosfamide '}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 2486, 'therapyName': 'Brentuximab vedotin'}]",Study of Pembrolizumab With Chemotherapy in Patients With Advanced Lymphoma (PembroHeme),763
22,NCT02018861,Phase I,"Active, not recruiting","[{'id': 2406, 'therapyName': 'INCB039110'}, {'id': 3097, 'therapyName': 'INCB039110 + INCB050465'}, {'id': 1231, 'therapyName': 'Bendamustine'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 2352, 'therapyName': 'Carboplatin + Etoposide + Ifosfamide '}, {'id': 3088, 'therapyName': 'INCB050465 '}]","A Phase 1, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 Monotherapy and in Combination With INCB039110 in Subjects With Previously Treated B-Cell Malignancies",763
23,NCT01169636,Phase Ib/II,Completed,"[{'id': 1080, 'therapyName': 'Panobinostat'}, {'id': 1476, 'therapyName': 'Pegfilgrastim'}, {'id': 2352, 'therapyName': 'Carboplatin + Etoposide + Ifosfamide '}]","Panobinostat Plus Ifosfamide, Carboplatin, and Etoposide (ICE) Compared With ICE For Relapsed Hodgkin Lymphoma",763
24,NCT01959698,Phase Ib/II,Recruiting,"[{'id': 2351, 'therapyName': 'Carfilzomib + Rituximab'}, {'id': 2352, 'therapyName': 'Carboplatin + Etoposide + Ifosfamide '}]","Carfilzomib, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma",763
25,NCT02471911,Phase I,Recruiting,"[{'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 3360, 'therapyName': 'Carboplatin + Etoposide + Ifosfamide + Rituximab'}, {'id': 1749, 'therapyName': 'Selinexor'}]",KPT-330 Plus RICE for Relapsed/Refractory Aggressive B-Cell Lymphoma,763
26,NCT02219737,Phase I,"Active, not recruiting","[{'id': 768, 'therapyName': 'Ibrutinib'}, {'id': 3360, 'therapyName': 'Carboplatin + Etoposide + Ifosfamide + Rituximab'}]",Ibrutinib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma,763
27,NCT02116959,Phase I,Unknown status,"[{'id': 2559, 'therapyName': 'Carboplatin + Etoposide + Melphalan + Vincristine'}]",Alternating Systemic Chemotherapy and Intra-Arterial Melphalan Chemotherapy in Children With Intra-Ocular Retinoblastoma,763
28,NCT02402920,Phase I,Recruiting,"[{'id': 2604, 'therapyName': 'Carboplatin + Etoposide + Pembrolizumab'}, {'id': 700, 'therapyName': 'Cisplatin'}]",Phase I Trial of MK-3475 and Concurrent Chemo/Radiation for the Elimination of Small Cell Lung Cancer,763
29,NCT02289690,Phase I,Recruiting,"[{'id': 1544, 'therapyName': 'Carboplatin + Etoposide + Veliparib'}]",Dose Escalation and Double-blind Study of Veliparib in Combination With Carboplatin and Etoposide in Treatment-naive Extensive Stage Disease Small Cell Lung Cancer,763
30,NCT01711541,Phase Ib/II,Suspended,"[{'id': 1544, 'therapyName': 'Carboplatin + Etoposide + Veliparib'}, {'id': 1849, 'therapyName': 'Cisplatin + Fluorouracil + Hydroxyurea'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]",Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IV Head and Neck Cancer,763
31,NCT01506609,Phase II,"Active, not recruiting","[{'id': 1193, 'therapyName': 'Veliparib + Temozolomide'}, {'id': 1544, 'therapyName': 'Carboplatin + Etoposide + Veliparib'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]",The Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide or In Combination With Carboplatin and Paclitaxel Versus Placebo in Subjects With BRCA1 and BRCA2 Mutation and Metastatic Breast Cancer,763
32,NCT01386385,Phase Ib/II,Recruiting,"[{'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 1544, 'therapyName': 'Carboplatin + Etoposide + Veliparib'}]","Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery",763
33,NCT02570542,Phase II,Recruiting,"[{'id': 1756, 'therapyName': 'Plerixafor'}, {'id': 3359, 'therapyName': 'Carmustine + Cytarabine + Etoposide + Melphalan'}]",Impact of CD34+ Cell Dose on Progression-free Survival Following High-Dose Therapy and Autologous Stem Cell Transplantation for Relapsed and Refractory Diffuse Large B-cell Lymphoma (DLBCL),763
34,NCT02443077,Phase III,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 3359, 'therapyName': 'Carmustine + Cytarabine + Etoposide + Melphalan'}, {'id': 768, 'therapyName': 'Ibrutinib'}]",Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma,763
35,NCT02574728,Phase II,Recruiting,"[{'id': 3143, 'therapyName': 'Celecoxib + Cyclophosphamide + Etoposide + Sirolimus'}]",Sirolimus in Combination With Metronomic Chemotherapy in Children With Recurrent and/or Refractory Solid and CNS Tumors,763
36,NCT00734877,Phase III,Recruiting,"[{'id': 1851, 'therapyName': 'Cisplatin + Doxorubicin + Cyclophosphamide + Etoposide'}, {'id': 1852, 'therapyName': 'Melphalan + Bortezomib + Thalidomide + Dexamethasone'}]","UARK 2008-01, Total Therapy 4 - A Phase III Trial for Low Risk Myeloma",763
37,NCT02537418,Phase I,"Active, not recruiting","[{'id': 2585, 'therapyName': 'Cisplatin + Etoposide'}, {'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 1652, 'therapyName': 'Tremelimumab'}]",Durvalumab With or Without Tremelimumab in Advanced Incurable Solid Malignancies Receiving Standard Chemotherapy Regimens,763
38,NCT02768558,Phase III,Recruiting,"[{'id': 2585, 'therapyName': 'Cisplatin + Etoposide'}, {'id': 4922, 'therapyName': 'Cisplatin + Etoposide + Nivolumab'}]",Cisplatin and Etoposide Plus Radiation Followed By Nivolumab/Placebo For Locally Advanced NSCLC,763
39,NCT01642251,Phase Ib/II,"Active, not recruiting","[{'id': 2585, 'therapyName': 'Cisplatin + Etoposide'}, {'id': 954, 'therapyName': 'Veliparib'}]",Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer or Metastatic Large Cell Neuroendocrine Non-small Cell Lung Cancer,763
40,NCT01857934,Phase II,Recruiting,"[{'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1873, 'therapyName': 'Sargramostim'}, {'id': 1167, 'therapyName': 'Aldesleukin'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 2627, 'therapyName': 'Levetiracetam'}, {'id': 2585, 'therapyName': 'Cisplatin + Etoposide'}, {'id': 2458, 'therapyName': 'Hu14.18K322A'}, {'id': 2558, 'therapyName': 'Busulfan + Melphalan'}, {'id': 2590, 'therapyName': 'Cyclophosphamide + Topotecan'}]",Therapy for Children With Advanced Stage Neuroblastoma,763
41,NCT01175356,Phase I,Completed,"[{'id': 2558, 'therapyName': 'Busulfan + Melphalan'}, {'id': 2590, 'therapyName': 'Cyclophosphamide + Topotecan'}, {'id': 1425, 'therapyName': '131I-MIBG'}, {'id': 2353, 'therapyName': 'Cyclophosphamide + Doxorubicin + Vincristine '}, {'id': 2585, 'therapyName': 'Cisplatin + Etoposide'}]","Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin",763
42,NCT01822496,Phase II,Recruiting,"[{'id': 1375, 'therapyName': 'Cisplatin + Etoposide + Paclitaxel + Carboplatin + Erlotinib'}]",Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer,763
43,NCT02987998,Phase I,Recruiting,"[{'id': 5145, 'therapyName': 'Cisplatin + Etoposide + Pembrolizumab'}]",Neoadjuvant Chemoradiation Plus Pembrolizumab Followed By Consolidation Pembrolizumab in NSCLC,763
44,NCT01579929,Phase I,Completed,"[{'id': 2504, 'therapyName': 'Cisplatin + Etoposide + Sonidegib'}]","Combination of the Hedgehog Inhibitor, LDE225, With Etoposide and Cisplatin in the First-Line Treatment of Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC)",763
45,NCT00549848,Phase III,"Active, not recruiting","[{'id': 1781, 'therapyName': 'Vincristine + Pegaspargase + Daunorubicin'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1782, 'therapyName': 'Clofarabine + Etoposide + Cyclophosphamide'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}]",Total Therapy Study XVI for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia,763
46,NCT02636322,Phase II,Recruiting,"[{'id': 2482, 'therapyName': 'Cyclophosphamide + Doxorubicin + Etoposide + Vincristine '}, {'id': 1610, 'therapyName': 'Rituximab + Lenalidomide + Ibrutinib'}, {'id': 2188, 'therapyName': 'Prednisone'}]","A Study of Rituximab, Lenalidomide, and Ibrutinib Combined With Dose Adjusted Chemotherapy For Patients With High Risk Diffuse Large B-Cell Lymphoma",763
47,NCT02337985,Phase I,Recruiting,"[{'id': 897, 'therapyName': 'Rituximab'}, {'id': 2482, 'therapyName': 'Cyclophosphamide + Doxorubicin + Etoposide + Vincristine '}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 2188, 'therapyName': 'Prednisone'}]",Gene Therapy and Combination Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin Lymphoma,763
48,NCT02518750,Phase II,Recruiting,"[{'id': 1604, 'therapyName': 'Panobinostat + Bortezomib + Dexamethasone'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 3160, 'therapyName': 'Nelarabine'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 3217, 'therapyName': 'Cyclophosphamide + Etoposide'}, {'id': 3216, 'therapyName': 'Cytarabine + Methotrexate + Prednisone'}, {'id': 1746, 'therapyName': 'Clofarabine'}]",Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoma,763
49,NCT00602667,Phase I,"Active, not recruiting","[{'id': 2449, 'therapyName': 'Methotrexate + Cisplatin + Cyclophosphamide + Vincristine'}, {'id': 2450, 'therapyName': 'Cyclophosphamide + Etoposide + Topotecan'}, {'id': 2451, 'therapyName': 'Erlotinib + Cyclophosphamide + Topotecan'}]","Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma",763
50,NCT01371981,Phase III,"Active, not recruiting","[{'id': 2391, 'therapyName': 'Cytarabine + Daunorubicin + Etoposide'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 2392, 'therapyName': 'Cytarabine + Etoposide'}, {'id': 2393, 'therapyName': 'Cytarabine + Mitoxantrone'}, {'id': 2394, 'therapyName': 'Asparaginase + Cytarabine'}, {'id': 688, 'therapyName': 'Bortezomib'}]",Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,763
51,NCT01256398,Phase II,"Active, not recruiting","[{'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 2291, 'therapyName': 'Cyclophosphamide + Fludarabine'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1824, 'therapyName': 'Vincristine + Methotrexate + Mercaptopurine'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 2391, 'therapyName': 'Cytarabine + Daunorubicin + Etoposide'}, {'id': 1476, 'therapyName': 'Pegfilgrastim'}, {'id': 1205, 'therapyName': 'Alemtuzumab'}, {'id': 1642, 'therapyName': 'Leucovorin'}]",Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,763
52,NCT02632708,Phase I,Recruiting,"[{'id': 1491, 'therapyName': 'AG-120'}, {'id': 2982, 'therapyName': 'Enasidenib'}, {'id': 3431, 'therapyName': 'Cytarabine + Daunorubicin + Etoposide + Mitoxantrone'}]",Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia With an IDH1 and/or IDH2 Mutation,763
53,NCT02342782,Phase I,Recruiting,"[{'id': 2485, 'therapyName': '90Y basiliximab'}, {'id': 1811, 'therapyName': 'Carmustine'}, {'id': 2392, 'therapyName': 'Cytarabine + Etoposide'}, {'id': 1207, 'therapyName': 'Melphalan'}]",Yttrium Y 90 Basiliximab and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Mature T-cell Non-Hodgkin Lymphoma,763
54,NCT02356159,Phase Ib/II,Recruiting,"[{'id': 2294, 'therapyName': 'Cytarabine + Fludarabine'}, {'id': 2373, 'therapyName': 'Palifermin'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 2238, 'therapyName': 'Sirolimus + Tacrolimus + Methotrexate'}, {'id': 2292, 'therapyName': 'Doxorubicin + Etoposide + Fludarabine + Vincristine '}, {'id': 2291, 'therapyName': 'Cyclophosphamide + Fludarabine'}, {'id': 897, 'therapyName': 'Rituximab'}]",Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation,763
55,NCT02538926,Phase II,Not yet recruiting,"[{'id': 770, 'therapyName': 'Imatinib'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 3212, 'therapyName': 'Doxorubicin + Etoposide + Vincristine '}, {'id': 2206, 'therapyName': 'Asparaginase'}]","Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride With Asparaginase in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma",763
56,NCT00092222,Phase II,Recruiting,"[{'id': 917, 'therapyName': 'Sirolimus'}, {'id': 1187, 'therapyName': 'Alpha 2 Interferon'}, {'id': 2211, 'therapyName': 'EPOCH'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1008, 'therapyName': 'Doxil'}]",Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity,763
57,NCT03126916,Phase III,Not yet recruiting,"[{'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1425, 'therapyName': '131I-MIBG'}, {'id': 1873, 'therapyName': 'Sargramostim'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 5595, 'therapyName': 'Isotretinoin'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 5153, 'therapyName': 'dexrazoxane'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1167, 'therapyName': 'Aldesleukin'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 2286, 'therapyName': 'Dinutuximab  '}]",Iobenguane I-131 or Crizotinib and Standard Therapy in Treating Younger Patients With Newly-Diagnosed High-Risk Neuroblastoma or Ganglioneuroblastoma,763
58,NCT01356290,Phase II,Recruiting,"[{'id': 1475, 'therapyName': 'Thalidomide'}, {'id': 4418, 'therapyName': 'Fenofibrate'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 2124, 'therapyName': 'Celecoxib'}, {'id': 1783, 'therapyName': 'Cyclophosphamide + Cytarabine'}]",Metronomic and Targeted Anti-angiogenesis Therapy for Children With Recurrent/Progressive Medulloblastoma (MEMMAT),763
59,NCT01526603,Phase I,Recruiting,"[{'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1092, 'therapyName': 'Carboplatin'}]",High Dose Chemotherapy and Autologous Transplant for Neuroblastoma,763
60,NCT01042522,Phase II,Recruiting,"[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1137, 'therapyName': 'Bleomycin'}]","Paclitaxel and Carboplatin or Bleomycin Sulfate, Etoposide Phosphate, and Cisplatin in Treating Patients With Advanced or Recurrent Sex Cord-Ovarian Stromal Tumors",763
61,NCT02512926,Phase I,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 1136, 'therapyName': 'Etoposide'}]",Carfilzomib in Combination With Cyclophosphamide and Etoposide for Children,763
62,NCT00074490,Phase II,Completed,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1650, 'therapyName': 'Cyclosporine'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1166, 'therapyName': 'Fludarabine'}]",Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,763
63,NCT02883049,Phase III,Suspended,"[{'id': 717, 'therapyName': 'Dasatinib'}, {'id': 4685, 'therapyName': 'Dexamethasone + Doxorubicin'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1746, 'therapyName': 'Clofarabine'}]",Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations,763
64,NCT01450761,Phase III,Completed,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1136, 'therapyName': 'Etoposide'}]",Trial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab Plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy Alone,763
65,NCT02432274,Phase Ib/II,Recruiting,"[{'id': 1136, 'therapyName': 'Etoposide'}, {'id': 792, 'therapyName': 'Lenvatinib'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}]",Study of Lenvatinib in Children and Adolescents With Refractory or Relapsed Solid Malignancies,763
66,NCT03117751,Phase II,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1876, 'therapyName': 'Blinatumomab '}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1638, 'therapyName': 'Pegaspargase'}]",Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma,763
67,NCT02112916,Phase III,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1009, 'therapyName': 'Doxorubicin'}]",Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma,763
68,NCT02788201,Phase II,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1133, 'therapyName': 'Mitomycin C'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1013, 'therapyName': 'epirubicin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1137, 'therapyName': 'Bleomycin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 781, 'therapyName': 'Ixabepilone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 2950, 'therapyName': 'Estramustine'}, {'id': 1941, 'therapyName': 'Floxuridine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 1811, 'therapyName': 'Carmustine'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 953, 'therapyName': 'Vandetanib'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 4419, 'therapyName': 'Toremifine'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 2601, 'therapyName': 'Dactinomycin'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 3035, 'therapyName': 'Chlorambucil'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 342, 'therapyName': 'Vemurafenib'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 2635, 'therapyName': 'Vinblastine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 4305, 'therapyName': 'Teniposide'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 4304, 'therapyName': 'Streptozocin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1231, 'therapyName': 'Bendamustine'}, {'id': 4303, 'therapyName': 'Mechlorethamine'}, {'id': 4302, 'therapyName': 'Mitotane'}]",Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma,763
69,NCT03007147,Phase III,Recruiting,"[{'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 5153, 'therapyName': 'dexrazoxane'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 5167, 'therapyName': 'Methylprednisolone'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 5168, 'therapyName': 'Prednisolone'}, {'id': 1009, 'therapyName': 'Doxorubicin'}]",Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia,763
70,NCT01614197,Phase I,Recruiting,"[{'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1639, 'therapyName': 'Methotrexate'}]",A Trial of Temsirolimus With Etoposide and Cyclophosphamide in Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkins Lymphoma,763
71,NCT02153580,Phase I,"Active, not recruiting","[{'id': 1136, 'therapyName': 'Etoposide'}, {'id': 2291, 'therapyName': 'Cyclophosphamide + Fludarabine'}, {'id': 1231, 'therapyName': 'Bendamustine'}]","Cellular Immunotherapy Following Cyclophosphamide in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia or B-Cell Prolymphocytic Leukemia",763
72,NCT02489903,Phase II,Recruiting,"[{'id': 1136, 'therapyName': 'Etoposide'}, {'id': 3680, 'therapyName': 'RRx-001'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 619, 'therapyName': 'Abraxane'}]","RRx-001 in Small, Non-small Cell Lung Cancer, and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens",763
73,NCT03164057,Phase II,Recruiting,"[{'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 5153, 'therapyName': 'dexrazoxane'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 651, 'therapyName': 'Azacitidine'}]",A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia,763
74,NCT02521493,Phase III,Recruiting,"[{'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 5912, 'therapyName': 'Asparaginase Erwinia chrysanthemi'}, {'id': 5215, 'therapyName': 'mitoxantrone hydrochloride'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 2206, 'therapyName': 'Asparaginase'}]",Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome,763
75,NCT02653196,Phase II,Terminated,"[{'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1205, 'therapyName': 'Alemtuzumab'}, {'id': 2373, 'therapyName': 'Palifermin'}, {'id': 2237, 'therapyName': 'Fludarabine + Melphalan'}, {'id': 3948, 'therapyName': 'Cyclosporine + Mycophenolate mofetil + Tacrolimus'}]",A Multi-Institutional Phase II Feasibility Study of Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Malignant Neuro-Epithelial and Other Solid Tumors,763
76,NCT02553460,Phase II,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1642, 'therapyName': 'Leucovorin'}]",Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) I,763
77,NCT03136146,Phase II,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1090, 'therapyName': 'Ofatumumab'}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 1476, 'therapyName': 'Pegfilgrastim'}]","Study of Clofarabine, Etoposide, Cyclophosphamide [CEC], Liposomal Vincristine (VCR), Dexamethasone and Bortezomib in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LL)",763
78,NCT02114229,Phase II,Recruiting,"[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 2449, 'therapyName': 'Methotrexate + Cisplatin + Cyclophosphamide + Vincristine'}, {'id': 626, 'therapyName': 'Alisertib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 942, 'therapyName': 'Topotecan'}]",Phase 2 Study of Alisertib Therapy for Rhabdoid Tumors,763
79,NCT03004287,Phase II,Recruiting,"[{'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1164, 'therapyName': 'lenalidomide'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 1630, 'therapyName': 'Daratumumab'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1475, 'therapyName': 'Thalidomide'}]",2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy,763
80,NCT03023046,Phase II,Recruiting,"[{'id': 897, 'therapyName': 'Rituximab'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 1631, 'therapyName': 'Vincristine'}]","Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma",763
81,NCT02299518,Phase I,Recruiting,"[{'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1749, 'therapyName': 'Selinexor'}, {'id': 1752, 'therapyName': 'Mitoxantrone + Etoposide + Cytarabine'}]",Selinexor and Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia,763
82,NCT02157792,Phase I,Recruiting,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 2879, 'therapyName': 'VX-970'}, {'id': 755, 'therapyName': 'Gemcitabine'}]","An Open-Label, First-in-Human Study of the Safety, Tolerability, and Pharmacokinetics of VX-970 in Combination With Cytotoxic Chemotherapy",763
83,NCT00936936,Phase II,Recruiting,"[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 2101, 'therapyName': 'Etoposide + Ifosfamide'}, {'id': 2100, 'therapyName': 'Docetaxel + Gemcitabine + Melphalan'}, {'id': 2074, 'therapyName': 'Bevacizumab + Carboplatin'}]",High-dose Chemotherapy for Poor-prognosis Relapsed Germ-Cell Tumors,763
84,NCT03020030,Phase III,Recruiting,"[{'id': 3160, 'therapyName': 'Nelarabine'}, {'id': 5153, 'therapyName': 'dexrazoxane'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1642, 'therapyName': 'Leucovorin'}]",Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents,763
85,NCT01859741,Phase Ib/II,"Active, not recruiting","[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 2547, 'therapyName': 'Tarextumab'}]",A Phase 1b/2 Study of OMP-59R5 in Combination With Etoposide and Platinum Therapy in Subjects With Untreated Extensive Stage Small Cell Lung Cancer (PINNACLE),763
86,NCT02551718,Phase I,Recruiting,"[{'id': 690, 'therapyName': 'Bosutinib'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 3160, 'therapyName': 'Nelarabine'}, {'id': 3159, 'therapyName': 'Bexarotene'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 998, 'therapyName': 'cabozantinib'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 877, 'therapyName': 'Ponatinib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 623, 'therapyName': 'Afatinib'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 890, 'therapyName': 'Regorafenib'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 2, 'therapyName': 'Trametinib'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 3, 'therapyName': 'Dabrafenib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 789, 'therapyName': 'Ceritinib'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1571, 'therapyName': 'Cabazitaxel'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1327, 'therapyName': 'Pralatrexate'}]",High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia,763
87,NCT02043587,Phase II,Recruiting,"[{'id': 897, 'therapyName': 'Rituximab'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1136, 'therapyName': 'Etoposide'}]",Chemotherapy With Liposomal Cytarabine CNS Prophylaxis for Adult Acute Lymphoblastic Leukemia &amp; Lymphoblastic Lymphoma,763
88,NCT01408043,Phase I,Terminated,"[{'id': 3222, 'therapyName': 'Etoposide + Filgrastim + Plerixafor'}]","Etoposide, Filgrastim, and Plerixafor in Improving Stem Cell Mobilization in Treating Patients With Non-Hodgkin Lymphoma",763
89,NCT01505569,Phase I,Recruiting,"[{'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 2558, 'therapyName': 'Busulfan + Melphalan'}, {'id': 2101, 'therapyName': 'Etoposide + Ifosfamide'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 1092, 'therapyName': 'Carboplatin'}]",Auto Transplant for High Risk or Relapsed Solid or CNS Tumors,763
90,NCT00303849,Phase Ib/II,Recruiting,"[{'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 2562, 'therapyName': 'Etoposide + Melphalan'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1476, 'therapyName': 'Pegfilgrastim'}]",Combination Chemotherapy With BBBD Followed By Sodium Thiosulfate in Treating Patients With Anaplastic Oligodendroglioma or Oligoastrocytoma,763
91,NCT00520130,Phase Ib/II,"Active, not recruiting","[{'id': 2294, 'therapyName': 'Cytarabine + Fludarabine'}, {'id': 2305, 'therapyName': 'Alemtuzumab + Cyclosporine'}, {'id': 2306, 'therapyName': 'Rituximab + Fludarabine + EPOCH'}, {'id': 2307, 'therapyName': 'Fludarabine + EPOCH'}, {'id': 2238, 'therapyName': 'Sirolimus + Tacrolimus + Methotrexate'}, {'id': 1632, 'therapyName': 'Filgrastim'}]",Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,763
92,NCT02421939,Phase III,Recruiting,"[{'id': 712, 'therapyName': 'Cytarabine'}, {'id': 3193, 'therapyName': 'Cytarabine + Fludarabine + Idarubicin'}, {'id': 1752, 'therapyName': 'Mitoxantrone + Etoposide + Cytarabine'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 2865, 'therapyName': 'Gilteritinib'}, {'id': 1632, 'therapyName': 'Filgrastim'}]",A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,763
93,NCT00550992,Phase I,Unknown status,"[{'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1752, 'therapyName': 'Mitoxantrone + Etoposide + Cytarabine'}, {'id': 1848, 'therapyName': 'Cyclophosphamide + Methotrexate + Vincristine + Pegaspargase '}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1650, 'therapyName': 'Cyclosporine'}, {'id': 1844, 'therapyName': 'anti-thymocyte globulin'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1642, 'therapyName': 'Leucovorin'}]",Different Therapies in Treating Infants With Newly Diagnosed Acute Leukemia,763
94,NCT01729845,Phase Ib/II,"Active, not recruiting","[{'id': 1752, 'therapyName': 'Mitoxantrone + Etoposide + Cytarabine'}, {'id': 650, 'therapyName': 'Decitabine'}]","Decitabine Followed By Mitoxantrone Hydrochloride, Etoposide, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes",763
95,NCT01222143,Phase Ib/II,Terminated,"[{'id': 1752, 'therapyName': 'Mitoxantrone + Etoposide + Cytarabine'}, {'id': 829, 'therapyName': 'Nilotinib'}]","Safety and Efficacy Study of Nilotinib Combined With Mitoxantrone, Etoposide, and High-dose Cytarabine Induction Chemotherapy Followed by Consolidation for Patients With C-kit Positive Acute Myeloid Leukemia",763
96,NCT02306291,Phase Ib/II,Recruiting,"[{'id': 1606, 'therapyName': 'Cytarabine + Idarubicin'}, {'id': 1752, 'therapyName': 'Mitoxantrone + Etoposide + Cytarabine'}, {'id': 4402, 'therapyName': 'GMI-1271'}]","Study to Determine Safety, Pharmacokinetics and Efficacy of GMI-1271 in Combination With Chemotherapy in AML",763
97,NCT02039726,Phase III,"Active, not recruiting","[{'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 3193, 'therapyName': 'Cytarabine + Fludarabine + Idarubicin'}, {'id': 1752, 'therapyName': 'Mitoxantrone + Etoposide + Cytarabine'}, {'id': 882, 'therapyName': 'Quizartinib'}]",An Open-label Study of Quizartinib Monotherapy vs. Salvage Chemotherapy in Acute Myeloid Leukemia (AML) Subjects,763
98,NCT02583893,Phase II,Recruiting,"[{'id': 917, 'therapyName': 'Sirolimus'}, {'id': 1752, 'therapyName': 'Mitoxantrone + Etoposide + Cytarabine'}]",Biomarkers in Predicting Treatment Response to Sirolimus and Chemotherapy in Patients With High-Risk Acute Myeloid Leukemia,763
99,NCT03116971,Phase Ib/II,Recruiting,"[{'id': 5546, 'therapyName': 'MSC2490484A  + Cisplatin + Etoposide'}, {'id': 3616, 'therapyName': 'MSC2490484A '}]",Phase Ib/II Study of M3814 With Etoposide and Cisplatin in Small Cell Lung Cancer (SCLC) Extensive Disease (ED),763
100,NCT03016871,Phase II,Recruiting,"[{'id': 5198, 'therapyName': 'Nivolumab + Etoposide + Ifosfamide + Carboplatin'}]","Nivolumab, Ifosfamide, Carboplatin, and Etoposide as Second-Line Therapy in Treating Patients With Refractory or Relapsed Hodgkin Lymphoma",763
101,NCT03077828,Phase II,Recruiting,"[{'id': 5435, 'therapyName': 'Pembrolizumab + Etoposide + Carboplatin + Ifosfamide'}]",Pembrolizumab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma,763
102,NCT01193842,Phase Ib/II,"Active, not recruiting","[{'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 3395, 'therapyName': 'R-EPOCH'}]",Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas,763
103,NCT02700022,Phase I,"Active, not recruiting","[{'id': 626, 'therapyName': 'Alisertib'}, {'id': 3395, 'therapyName': 'R-EPOCH'}]",A Phase I Study of Alisertib + R-EPOCH for Treatment of Myc-Positive Aggressive B-cell Lymphomas,763
104,NCT00114738,Phase II,"Active, not recruiting","[{'id': 3395, 'therapyName': 'R-EPOCH'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 688, 'therapyName': 'Bortezomib'}]",EPOCH-R Chemotherapy Plus Bortezomib to Treat Mantle Cell Lymphoma,763
105,NCT02819999,Phase I,Recruiting,"[{'id': 4827, 'therapyName': 'Rovalpituzumab Tesirine + Cisplatin + Etoposide'}, {'id': 3544, 'therapyName': 'Rovalpituzumab Tesirine'}]",A Study of Rovalpituzumab Tesirine (SC16LD6.5) in the Frontline Treatment of Patients With Delta-Like Protein 3-Expressing Extensive Stage Small Cell Lung Cancer,763
106,NCT02015728,Phase I,"Active, not recruiting","[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1804, 'therapyName': 'Temozolomide + Etoposide'}, {'id': 920, 'therapyName': 'Sorafenib'}]",Selecting Patient-Specific Biologically Targeted Therapy for Pediatric Patients With Refractory Or Recurrent Brain Tumors,763
107,NCT02203526,Phase I,Suspended,"[{'id': 1607, 'therapyName': 'Temozolomide + Etoposide + Doxil + Dexamethasone + Ibrutinib'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 897, 'therapyName': 'Rituximab'}]","Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Dose-Adjusted-Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (DA-TEDDI-R) in Primary CNS Lymphoma",763
108,NCT03036904,Phase I,Recruiting,"[{'id': 5294, 'therapyName': 'Venetoclax + DA-EPOCH-R'}]",Study of Venetoclax Plus DA-EPOCH-R for the Treatment of Aggressive B-Cell Lymphomas (V+DA-EPOCH-R),763
109,NCT03064867,Phase I,Recruiting,"[{'id': 5404, 'therapyName': 'Venetoclax + Rituximab + Ifosfamide + Carboplatin + Etoposide'}]",Venetoclax Plus R-ICE Chemotherapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma,763
110,NCT01946529,Phase II,"Active, not recruiting","[{'id': 1433, 'therapyName': 'Vincristine + Doxorubicin + Cyclophosphamide + Ifosfamide + Etoposide'}, {'id': 1434, 'therapyName': 'Vincristine + Doxorubicin + Cyclophosphamide + Ifosfamide + Etoposide + others'}]",Therapeutic Trial for Patients With Ewing Sarcoma Family of Tumor and Desmoplastic Small Round Cell Tumors,763
111,NCT02306161,Phase II,Recruiting,"[{'id': 1433, 'therapyName': 'Vincristine + Doxorubicin + Cyclophosphamide + Ifosfamide + Etoposide'}, {'id': 746, 'therapyName': 'Ganitumab'}]",Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma,763
112,NCT00020566,Phase III,Unknown status,"[{'id': 2558, 'therapyName': 'Busulfan + Melphalan'}, {'id': 2670, 'therapyName': 'Vincristine + Doxorubicin + Dactinomycin + Ifosfamide + Etoposide'}]","Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation, Radiation Therapy, and/or Surgery in Treating Patients With Ewing's Sarcoma",763
113,NCT01294670,Phase Ib/II,"Active, not recruiting","[{'id': 1182, 'therapyName': 'Vorinostat + Etoposide'}]",Clinical Study of Vorinostat in Combination With Etoposide in Pediatric Patients &lt; 21 Years at Diagnosis With Refractory Solid Tumors,763
0,NCT01854606,Phase Ib/II,Completed,"[{'id': 1951, 'therapyName': 'AEB071 + Everolimus'}]",Safety and Efficacy of AEB071 and EVEROLIMUS in Patients With CD79-mutant or ABC Subtype Diffuse Large B-Cell Lymphoma,1530
1,NCT01061788,Phase I,Recruiting,"[{'id': 1138, 'therapyName': 'AMG479 + Everolimus + Panitumumab'}]","A Trial of AMG 479, Everolimus (RAD001) and Panitumumab in Patients With Advanced Cancer",1530
2,NCT01624766,Phase I,Recruiting,"[{'id': 1199, 'therapyName': 'Everolimus + Denosumab'}, {'id': 1192, 'therapyName': 'Anakinra + Everolimus'}]",Anakinra or Denosumab and Everolimus in Advanced Cancer,1530
3,NCT02291913,Phase II,"Active, not recruiting","[{'id': 2267, 'therapyName': 'Everolimus + Tamoxifen'}, {'id': 2268, 'therapyName': 'Anastrozole + Everolimus'}, {'id': 1589, 'therapyName': 'Fulvestrant + Everolimus'}, {'id': 1621, 'therapyName': 'Everolimus + Letrozole'}, {'id': 2269, 'therapyName': 'Everolimus + Toremifene'}, {'id': 1966, 'therapyName': 'Exemestane + Everolimus'}]",Everolimus Combined With Anti-estrogen Therapy in Hormone-Receptor-Positive HER-2 Negative Advanced Breast Cancer,1530
4,NCT02106507,Phase I,"Active, not recruiting","[{'id': 2303, 'therapyName': 'ARN-509 + Everolimus'}]",ARN 509 Plus Everolimus in Men With Progressive Metastatic Castration-Resistant Prostate Cancer After Treatment With Abiraterone Acetate,1530
5,NCT02240719,Phase I,Recruiting,"[{'id': 2336, 'therapyName': 'Bendamustine + Everolimus'}]",Everolimus and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Hematologic Cancer,1530
6,NCT01508104,Phase Ib/II,Terminated,"[{'id': 1321, 'therapyName': 'BEZ235 + Everolimus'}, {'id': 735, 'therapyName': 'Everolimus'}]",Safety Study of BEZ235 With Everolimus in Subjects With Advanced Solid Tumors,1530
7,NCT01470209,Phase I,"Active, not recruiting","[{'id': 1314, 'therapyName': 'BKM120 + Everolimus'}]",A Phase I Study of BKM120 and Everolimus in Advanced Solid Malignancies,1530
8,NCT00671112,Phase I,Terminated,"[{'id': 2234, 'therapyName': 'Bortezomib + Everolimus'}]",Everolimus and Bortezomib in Treating Patients With Relapsed or Refractory Lymphoma,1530
9,NCT02077933,Phase I,"Active, not recruiting","[{'id': 1384, 'therapyName': 'BYL719 + Everolimus'}, {'id': 1385, 'therapyName': 'BYL719 + Everolimus + Exemestane'}]","Study of Safety and Efficacy of BYL719 With Everolimus or BYL719 With Everolimus and Exemestane in Advanced Breast Cancer Patients, Renal Cell Cancer and Pancreatic Tumors",1530
10,NCT01281514,Phase I,Recruiting,"[{'id': 2168, 'therapyName': 'Carboplatin + Doxil + Everolimus'}]","Carboplatin, Pegylated Liposomal Doxorubicin Hydrochloride, and Everolimus in Treating Patients With Relapsed Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer",1530
11,NCT02321501,Phase I,Recruiting,"[{'id': 2295, 'therapyName': 'Ceritinib + Everolimus'}, {'id': 789, 'therapyName': 'Ceritinib'}]",Phase I/Ib Dose Escalation and Biomarker Study of Ceritinib (LDK378) + Everolimus for Locally Advanced or Metastatic Solid Tumors With an Expansion in Non-Small Cell Lung Cancer (NSCLC) Characterized by Abnormalities in Anaplastic Lymphoma Kinase (ALK) Expression,1530
12,NCT01182168,Phase I,Completed,"[{'id': 2296, 'therapyName': 'Cisplatin + Everolimus + Gemcitabine'}]",Gemcitabine and Split-Dose Cisplatin Plus Everolimus (RAD001) in Patients With Advanced Solid Tumor Malignancies,1530
13,NCT02125084,Phase I,"Active, not recruiting","[{'id': 2264, 'therapyName': 'Enzalutamide + Everolimus'}]",Enzalutamide Plus Everolimus in Men With Metastatic Castrate-Resistant Prostate Cancer,1530
14,NCT02120469,Phase I,Recruiting,"[{'id': 2252, 'therapyName': 'Eribulin + Everolimus'}]",Eribulin Mesylate and Everolimus in Treating Patients With Triple-Negative Metastatic Breast Cancer,1530
15,NCT02504892,Phase II,Recruiting,"[{'id': 735, 'therapyName': 'Everolimus'}]",Everolimus Therapy in People With Birt-Hogg-Dube Syndrome (BHD)-Associated Kidney Cancer or Sporadic Chromophobe Renal Cancer,1530
16,NCT02560012,Phase II,Terminated,"[{'id': 735, 'therapyName': 'Everolimus'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 848, 'therapyName': 'Pazopanib'}]",Personalized Targeted Inhibitors Treatment in Renal Cell Cancer,1530
17,NCT02236572,Phase II,"Active, not recruiting","[{'id': 735, 'therapyName': 'Everolimus'}]","Neoadj ph 2 AI Plus Everolimus in Postmenopausal Women w/ ER Pos/HER2 Neg, Low Risk Score",1530
18,NCT01334502,Phase I,Completed,"[{'id': 735, 'therapyName': 'Everolimus'}, {'id': 2195, 'therapyName': 'R-CHOP'}]","Everolimus, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Untreated Diffuse Large B-Cell Lymphoma",1530
19,NCT01827384,Phase II,Recruiting,"[{'id': 1194, 'therapyName': 'MK-1775 + Carboplatin '}, {'id': 1193, 'therapyName': 'Veliparib + Temozolomide'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 2, 'therapyName': 'Trametinib'}]",Molecular Profiling-Based Targeted Therapy in Treating Patients With Advanced Solid Tumors,1530
20,NCT01931163,Phase II,Recruiting,"[{'id': 735, 'therapyName': 'Everolimus'}]",NECTAR Everolimus Plus Cisplatin in Triple (-) Breast Cancer,1530
21,NCT01674140,Phase III,Recruiting,"[{'id': 759, 'therapyName': 'Goserelin'}, {'id': 633, 'therapyName': 'Anastrozole'}, {'id': 794, 'therapyName': 'Letrozole'}, {'id': 795, 'therapyName': 'Leuprolide'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 738, 'therapyName': 'Exemestane'}]",S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer,1530
22,NCT01215136,Phase II,"Active, not recruiting","[{'id': 735, 'therapyName': 'Everolimus'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]",First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma,1530
23,NCT01523977,Phase I,"Active, not recruiting","[{'id': 2188, 'therapyName': 'Prednisone'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1638, 'therapyName': 'Pegaspargase'}]",Everolimus With Multiagent Re-Induction Chemotherapy in Pediatric Patients With ALL,1530
24,NCT01665768,Phase II,"Active, not recruiting","[{'id': 897, 'therapyName': 'Rituximab'}, {'id': 735, 'therapyName': 'Everolimus'}]",Maintenance Rituximab With mTor Inhibition After High-dose Consolidative Therapy in Lymphoma,1530
25,NCT01197170,Phase I,"Active, not recruiting","[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 633, 'therapyName': 'Anastrozole'}, {'id': 667, 'therapyName': 'Bevacizumab'}]",Hormone Blockade in Combination With Targeted Agents,1530
26,NCT01270321,Phase II,"Active, not recruiting","[{'id': 2260, 'therapyName': 'Pasireotide'}, {'id': 735, 'therapyName': 'Everolimus'}]",A Trial of Pasireotide and Everolimus in Adult Patients With Radioiodine-Refractory Differentiated and Medullary Thyroid Cancer,1530
27,NCT02205515,Phase Ib/II,Recruiting,"[{'id': 735, 'therapyName': 'Everolimus'}]","An Open Label, Single-Centre, Phase II Study of Everolimus With EBRT for the Treatment of mNET Liver Metastasis",1530
28,NCT01548807,Phase I,Recruiting,"[{'id': 735, 'therapyName': 'Everolimus'}]",Phase 1 Trial of the Mammalian Target of Rapamycin (mTOR) Inhibitor Everolimus Plus Radiation Therapy (RT) for Salvage Treatment of Biochemical Recurrence in Prostate Cancer Patients Following Prostatectomy,1530
29,NCT02332902,Phase II,Completed,"[{'id': 735, 'therapyName': 'Everolimus'}]",Everolimus for Treatment of Disfiguring Cutaneous Lesions in Neurofibromatosis1 CRAD001CUS232T,1530
30,NCT01797523,Phase II,"Active, not recruiting","[{'id': 794, 'therapyName': 'Letrozole'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 1031, 'therapyName': 'Metformin'}]",RAD/Letrozole/Metformin,1530
31,NCT00610948,Phase I,Completed,"[{'id': 735, 'therapyName': 'Everolimus'}, {'id': 845, 'therapyName': 'Panitumumab'}]","Everolimus, Fluorouracil, Leucovorin, Panitumumab, and Oxaliplatin in Treating Patients With Solid Tumors That Did Not Respond to Treatment",1530
32,NCT02269670,Phase II,"Active, not recruiting","[{'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 1869, 'therapyName': 'Megestrol'}, {'id': 794, 'therapyName': 'Letrozole'}, {'id': 744, 'therapyName': 'Fulvestrant'}, {'id': 633, 'therapyName': 'Anastrozole'}]",Everolimus and Hormone Therapy in Treating Patients With Advanced Hormone Receptor Positive Breast Cancer That Has Progressed or Recurred on Everolimus and Exemestane Therapy,1530
33,NCT02531932,Phase II,Recruiting,"[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 735, 'therapyName': 'Everolimus'}]",Comparison of Single-Agent Carboplatin vs the Combination of Carboplatin and Everolimus for the Treatment of Advanced Triple-Negative Breast Cancer,1530
34,NCT02724020,Phase II,Recruiting,"[{'id': 1283, 'therapyName': 'MLN1117 + Sapanisertib'}, {'id': 1282, 'therapyName': 'Sapanisertib'}, {'id': 735, 'therapyName': 'Everolimus'}]",MLN0128 and MLN0128 + MLN1117 Compared With Everolimus in the Treatment of Adults With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma,1530
35,NCT01120249,Phase III,"Active, not recruiting","[{'id': 735, 'therapyName': 'Everolimus'}]","S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery",1530
36,NCT02089334,Phase Ib/II,Recruiting,"[{'id': 2262, 'therapyName': 'Everolimus + RX-0201'}, {'id': 735, 'therapyName': 'Everolimus'}]","Dose-Finding, Safety and Efficacy Study of RX-0201 Plus Everolimus in Metastatic Renal Cell Cancer",1530
37,NCT02551718,Phase I,Recruiting,"[{'id': 690, 'therapyName': 'Bosutinib'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 3160, 'therapyName': 'Nelarabine'}, {'id': 3159, 'therapyName': 'Bexarotene'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 998, 'therapyName': 'cabozantinib'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 877, 'therapyName': 'Ponatinib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 623, 'therapyName': 'Afatinib'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 890, 'therapyName': 'Regorafenib'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 2, 'therapyName': 'Trametinib'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 3, 'therapyName': 'Dabrafenib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 789, 'therapyName': 'Ceritinib'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1571, 'therapyName': 'Cabazitaxel'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1327, 'therapyName': 'Pralatrexate'}]",High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia,1530
38,NCT01218555,Phase I,"Active, not recruiting","[{'id': 1164, 'therapyName': 'lenalidomide'}, {'id': 735, 'therapyName': 'Everolimus'}]",Study of Everolimus (RAD001)in Combination With Lenalidomide,1530
39,NCT01880749,Phase I,"Active, not recruiting","[{'id': 735, 'therapyName': 'Everolimus'}]",Exploring the Activity of RAD001 in Vestibular Schwannomas and Meningiomas,1530
40,NCT03032406,Phase II,Recruiting,"[{'id': 2231, 'therapyName': 'Everolimus + Hydroxychloroquine'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 1316, 'therapyName': 'Hydroxychloroquine'}]","CLEVER Pilot Trial: A Phase II Pilot Trial of HydroxyChLoroquine, EVErolimus or the Combination for Prevention of Recurrent Breast Cancer",1530
41,NCT01133678,Phase II,"Active, not recruiting","[{'id': 1790, 'therapyName': 'Cetuximab + Cisplatin + Paclitaxel'}, {'id': 735, 'therapyName': 'Everolimus'}]",Study in Locally Advanced Squamous Cell Carcinoma of Head and Neck,1530
42,NCT02520063,Phase Ib/II,Recruiting,"[{'id': 794, 'therapyName': 'Letrozole'}, {'id': 1242, 'therapyName': 'TRC105'}, {'id': 735, 'therapyName': 'Everolimus'}]","Preoperative Combination of Letrozole, Everolimus, and TRC105 in Postmenopausal Hormone-Receptor Positive and Her2 Negative Breast Cancer",1530
43,NCT02273752,Phase II,Terminated,"[{'id': 735, 'therapyName': 'Everolimus'}]","Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer",1530
44,NCT01345136,Phase II,Recruiting,"[{'id': 735, 'therapyName': 'Everolimus'}]",Study of RAD001 for Treatment of NF2-related Vestibular Schwannoma,1530
45,NCT00912340,Phase II,"Active, not recruiting","[{'id': 735, 'therapyName': 'Everolimus'}, {'id': 947, 'therapyName': 'Trastuzumab'}]",Randomized Phase II Trial of Trastuzumab or EVEROLIMUS in Hormone-refractory Metastatic Breast Cancer,1530
46,NCT01700400,Phase I,Completed,"[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 854, 'therapyName': 'Pemetrexed'}]"," Study of Everolimus, Pemetrexed, Carboplatin, and Bevacizumab to Treat Stage IV Lung Cancer",1530
47,NCT02599324,Phase Ib/II,Recruiting,"[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 768, 'therapyName': 'Ibrutinib'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 694, 'therapyName': 'Cetuximab'}]",A Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors,1530
48,NCT00976573,,Completed,"[{'id': 735, 'therapyName': 'Everolimus'}, {'id': 667, 'therapyName': 'Bevacizumab'}]","Carboplatin, Paclitaxel, and Bevacizumab With or Without Everolimus in Treating Patients With Metastatic Malignant Melanoma",1530
49,NCT02450175,Phase I,Unknown status,"[{'id': 794, 'therapyName': 'Letrozole'}, {'id': 735, 'therapyName': 'Everolimus'}]","Etiology of the Platelet-Cancer Metastatic Pathway - A Study of Inflammatory Markers, Platelet Characteristics and Metastatic Surrogates in Cancer Patients and Controls",1530
50,NCT02143726,Phase II,Recruiting,"[{'id': 920, 'therapyName': 'Sorafenib'}, {'id': 735, 'therapyName': 'Everolimus'}]","Sorafenib Tosylate With or Without Everolimus in Treating Patients With Advanced, Radioactive Iodine Refractory Thyroid Cancer",1530
51,NCT02201212,Phase II,Recruiting,"[{'id': 735, 'therapyName': 'Everolimus'}]",Everolimus for Cancer With TSC1 or TSC2 Mutation,1530
52,NCT01087554,Phase I,"Active, not recruiting","[{'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 1077, 'therapyName': 'Vorinostat'}]",Sirolimus or Everolimus or Temsirolimus and Vorinostat in Advanced Cancer,1530
53,NCT02397083,Phase II,Recruiting,"[{'id': 735, 'therapyName': 'Everolimus'}]",Phase II Study of Intrauterine Device (IUD) Alone or in Combination With Everolimus in Endometrial Cancer,1530
54,NCT02254239,Phase I,"Active, not recruiting","[{'id': 735, 'therapyName': 'Everolimus'}]",Everolimus and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma,1530
55,NCT00831480,Phase II,Terminated,"[{'id': 735, 'therapyName': 'Everolimus'}]",Everolimus(RAD001) For Advanced Renal Cell Carcinoma(RCC)Before Kidney Removal,1530
56,NCT00823459,Phase II,Completed,"[{'id': 735, 'therapyName': 'Everolimus'}]",Phase II Trial of RAD001 in Patients With Recurrent Low Grade Glioma,1530
57,NCT01734512,Phase II,Recruiting,"[{'id': 735, 'therapyName': 'Everolimus'}]",PNOC 001: Phase II Study of Everolimus for Recurrent or Progressive Low-grade Gliomas in Children,1530
58,NCT02081755,,Recruiting,"[{'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 735, 'therapyName': 'Everolimus'}]",Safety and Efficacy of Everolimus Treatment in Liver Transplantation for Liver Cancer,1530
59,NCT02315625,Phase II,Recruiting,"[{'id': 735, 'therapyName': 'Everolimus'}, {'id': 930, 'therapyName': 'Sunitinib'}]",Study of Mutation-Targeted Therapy With Sunitinib or Everolimus in People With Advanced Low- or Intermediate-Grade Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas With or Without Cytoreductive Surgery,1530
60,NCT01603004,Phase I,Recruiting,"[{'id': 735, 'therapyName': 'Everolimus'}, {'id': 930, 'therapyName': 'Sunitinib'}]",Potential Imaging and Molecular Predictors of Response to Novel Therapies in Metastatic Pancreatic Neuroendocrine Tumors,1530
61,NCT02031536,Phase II,Terminated,"[{'id': 735, 'therapyName': 'Everolimus'}]",Everolimus in Patients With Pancreatic Neuroendocrine Tumors Metastatic to the Liver Previously Treated With Surgery,1530
62,NCT01637090,Phase II,Terminated,"[{'id': 735, 'therapyName': 'Everolimus'}]",Everolimus in Treating Cutaneous T-cell Lymphoma,1530
63,NCT01865747,Phase III,"Active, not recruiting","[{'id': 735, 'therapyName': 'Everolimus'}, {'id': 998, 'therapyName': 'cabozantinib'}]",A Study of Cabozantinib (XL184) vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma,1530
64,NCT02539459,Phase II,Recruiting,"[{'id': 735, 'therapyName': 'Everolimus'}]",Sporadic Angiomyolipomas (AMLs) Growth Kinetics While on Everolimus,1530
65,NCT01217931,Phase II,"Active, not recruiting","[{'id': 735, 'therapyName': 'Everolimus'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 667, 'therapyName': 'Bevacizumab'}]",Sequential Two-agent Assessment in Renal Cell Carcinoma Therapy,1530
66,NCT02155920,Phase II,Recruiting,"[{'id': 735, 'therapyName': 'Everolimus'}]",Everolimus for Children With Recurrent or Progressive Ependymomaildren With Recurrent or Progressive Ependymoma,1530
67,NCT02015728,Phase I,"Active, not recruiting","[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1804, 'therapyName': 'Temozolomide + Etoposide'}, {'id': 920, 'therapyName': 'Sorafenib'}]",Selecting Patient-Specific Biologically Targeted Therapy for Pediatric Patients With Refractory Or Recurrent Brain Tumors,1530
68,NCT01111058,Phase II,"Active, not recruiting","[{'id': 735, 'therapyName': 'Everolimus'}]",Everolimus Versus Placebo in Head and Neck Cancer,1530
69,NCT02023905,Phase II,Recruiting,"[{'id': 1141, 'therapyName': 'Temozolomide'}, {'id': 735, 'therapyName': 'Everolimus'}]",Everolimus With and Without Temozolomide in Adult Low Grade Glioma,1530
70,NCT02352844,Phase II,"Active, not recruiting","[{'id': 735, 'therapyName': 'Everolimus'}]","Everolimus in Patients With Advanced Solid Malignancies With TSC1, TSC2, NF1, NF2, or STK11 Mutations",1530
71,NCT01122199,Phase I,Completed,"[{'id': 1145, 'therapyName': 'Everolimus + AMG479'}]",Study of RAD001 + AMG479 for Patients With Advanced Solid Tumors,1530
72,NCT01661283,Phase II,"Active, not recruiting","[{'id': 1120, 'therapyName': 'Everolimus + Bevacizumab'}]",Study of Everolimus With Bevacizumab to Treat Refractory Malignant Peripheral Nerve Sheath Tumors,1530
73,NCT01031381,Phase II,Completed,"[{'id': 1120, 'therapyName': 'Everolimus + Bevacizumab'}]","Study of RAD001 and Bevacizumab in Recurrent Ovarian, Peritoneal, and Fallopian Tube Cancer",1530
74,NCT00756340,Phase I,Completed,"[{'id': 1120, 'therapyName': 'Everolimus + Bevacizumab'}]",A Trial of Everolimus and Bevacizumab in Children With Recurrent Solid Tumors,1530
75,NCT01399918,Phase II,"Active, not recruiting","[{'id': 1120, 'therapyName': 'Everolimus + Bevacizumab'}]",Everolimus and Bevacizumab in Advanced Non-Clear Cell Renal Cell Carcinoma (RCC),1530
76,NCT02057133,Phase I,Recruiting,"[{'id': 2254, 'therapyName': 'Abemaciclib + Letrozole'}, {'id': 2257, 'therapyName': 'Abemaciclib + Exemestane'}, {'id': 2258, 'therapyName': 'Everolimus + Exemestane + LY2835219'}, {'id': 2255, 'therapyName': 'Abemaciclib + Anastrozole'}, {'id': 2256, 'therapyName': 'Abemaciclib + Tamoxifen'}, {'id': 2259, 'therapyName': 'Abemaciclib + Trastuzumab'}]",A Study of LY2835219 in Combination With Hormone Therapies for Breast Cancer That Has Spread,1530
77,NCT03014297,Phase I,Recruiting,"[{'id': 5207, 'therapyName': 'Everolimus + Fosbretabulin'}]",Fosbretabulin With Everolimus in Neuroendocrine Tumors With Progression,1530
78,NCT01259063,Phase Ib/II,Completed,"[{'id': 2279, 'therapyName': 'Everolimus + Gemcitabine'}]",RAD001 and Intravesical Gemcitabine in BCG-Refractory Primary or Secondary Carcinoma In Situ of the Bladder,1530
79,NCT01376310,Phase II,"Active, not recruiting","[{'id': 1264, 'therapyName': 'Docetaxel + Trametinib'}, {'id': 1265, 'therapyName': 'Erlotinib + Trametinib'}, {'id': 2, 'therapyName': 'Trametinib'}, {'id': 1266, 'therapyName': 'Pemetrexed + GSK1120212'}, {'id': 1267, 'therapyName': 'Carboplatin + GSK1120212'}, {'id': 1268, 'therapyName': 'nab-paclitaxel + GSK1120212'}, {'id': 1269, 'therapyName': 'Gemcitabine + GSK1120212'}, {'id': 1271, 'therapyName': 'Everolimus + GSK1120212'}]",GSK1120212 Rollover Study,1530
80,NCT01510119,Phase Ib/II,"Active, not recruiting","[{'id': 2231, 'therapyName': 'Everolimus + Hydroxychloroquine'}]",Autophagy Inhibition to Augment mTOR Inhibition: A Phase I/II Trial of RAD001 and Hydroxychloroquine in Patients With Previously Treated Renal Cell Carcinoma,1530
81,NCT01188889,Phase Ib/II,Withdrawn,"[{'id': 2198, 'therapyName': 'Everolimus + Imatinib'}]",RAD001 in Patients With Chronic Phase Chronic Myeloid Leukemia w/ Molecular Disease,1530
82,NCT01283789,Phase II,"Active, not recruiting","[{'id': 1539, 'therapyName': 'Everolimus + Lapatinib'}]",Lapatinib and RAD-001 for HER2 Positive Metastatic Breast Cancer,1530
83,NCT02811861,Phase III,Recruiting,"[{'id': 1713, 'therapyName': 'Everolimus + Lenvatinib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 4782, 'therapyName': 'Lenvatinib + Pembrolizumab'}]",Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma,1530
84,NCT03173560,Phase II,Recruiting,"[{'id': 1713, 'therapyName': 'Everolimus + Lenvatinib'}]",Trial to Assess Safety and Efficacy of Lenvatinib in Combination With Everolimus in Participants With Renal Cell Carcinoma,1530
85,NCT03245151,Phase Ib/II,Not yet recruiting,"[{'id': 1713, 'therapyName': 'Everolimus + Lenvatinib'}]","Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including Central Nervous System Tumors",1530
86,NCT02915783,Phase II,Recruiting,"[{'id': 1713, 'therapyName': 'Everolimus + Lenvatinib'}]",A Phase 2 Trial to Evaluate Efficacy and Safety of Lenvatinib in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Non Clear Cell Renal Cell Carcinoma (nccRCC) Who Have Not Received Any Chemotherapy for Advanced Disease,1530
87,NCT03139747,Phase II,Recruiting,"[{'id': 1713, 'therapyName': 'Everolimus + Lenvatinib'}]",UPCC 36315 A Phase II Study Of Everolimus (RAD001) And Lenvatinib (E7080) In Patients With Metastatic Differentiated Thyroid Cancer Who Have Progressed on Lenvatinib Alone,1530
88,NCT02228681,Phase II,"Active, not recruiting","[{'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 2401, 'therapyName': 'Medroxyprogesterone'}, {'id': 1621, 'therapyName': 'Everolimus + Letrozole'}]",Everolimus and Letrozole or Hormonal Therapy to Treat Endometrial Cancer,1530
89,NCT02188550,Phase II,Unknown status,"[{'id': 1621, 'therapyName': 'Everolimus + Letrozole'}]",Single Arm Trial With Combination of Everolimus and Letrozole in Treatment of Platinum Resistant Relapse or Refractory or Persistent Ovarian Cancer/Endometrial Cancer,1530
90,NCT02283658,Phase II,"Active, not recruiting","[{'id': 1621, 'therapyName': 'Everolimus + Letrozole'}]","Everolimus and Letrozole in Treating Patients With Recurrent Hormone Receptor Positive Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer",1530
91,NCT01698918,Phase II,"Active, not recruiting","[{'id': 1966, 'therapyName': 'Exemestane + Everolimus'}, {'id': 1621, 'therapyName': 'Everolimus + Letrozole'}]","Open-label, Phase II, Study of Everolimus Plus Letrozole in Postmenopausal Women With ER+, HER2- Metastatic or Locally Advanced Breast Cancer",1530
92,NCT02152943,Phase I,Recruiting,"[{'id': 1591, 'therapyName': 'Everolimus + Letrozole + Trastuzumab'}]","Everolimus, Letrozole and Trastuzumab in HR- and HER2/Neu-positive Patients",1530
93,NCT01490749,Phase I,"Active, not recruiting","[{'id': 1924, 'therapyName': 'Everolimus + Paclitaxel + Carboplatin + Cetuximab'}]",Trial of XELOX Followed by Radiation Combined With Carboplatin and RAD001 for Esophageal Cancer,1530
94,NCT01252251,Phase II,Completed,"[{'id': 2261, 'therapyName': 'Everolimus + Pasireotide'}]",RAD001 (Everolimus) and Pasireotide (SOM230) LAR in Patients With Advanced Uveal Melanoma,1530
95,NCT01313559,Phase II,Terminated,"[{'id': 2261, 'therapyName': 'Everolimus + Pasireotide'}, {'id': 2260, 'therapyName': 'Pasireotide'}]","Pasireotide (SOM230) With or Without Everolimus in Treating Patients With Hormone Resistant, Chemotherapy Naive Prostate Cancer",1530
96,NCT01184326,Phase I,Completed,"[{'id': 1806, 'therapyName': 'everolimus + pazopanib'}]",An Expanded Phase I Study of Pazopanib and Everolimus in Patients With Advanced Solid Tumors and Previously Treated Advanced Urothelial Cancer,1530
97,NCT01789281,Phase III,Recruiting,"[{'id': 1333, 'therapyName': 'Everolimus + Sandostatin LAR Depot'}]",Everolimus Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Everolimus Study.,1530
98,NCT02138929,Phase I,"Active, not recruiting","[{'id': 1871, 'therapyName': 'Everolimus + Sonidegib'}]",LDE225 + Everolimus in Advanced Gastroesophageal Adenocarcinoma,1530
99,NCT01434602,Phase Ib/II,Recruiting,"[{'id': 2299, 'therapyName': 'Everolimus + Sorafenib'}]",Phase I-II Everolimus and Sorafenib in Recurrent High-Grade Gliomas,1530
100,NCT01263951,Phase II,"Active, not recruiting","[{'id': 2299, 'therapyName': 'Everolimus + Sorafenib'}]",Study of Everolimus and Sorafenib in Patients With Advanced Thyroid Cancer Who Progressed on Sorafenib Alone,1530
101,NCT02258451,Phase II,Recruiting,"[{'id': 1966, 'therapyName': 'Exemestane + Everolimus'}, {'id': 2001, 'therapyName': 'radium Ra 223 dichloride'}]",Study of Radium-223 Dichloride Versus Placebo and Treatment With Exemestane / Everolimus in Subjects With Bone Predominant HER2 (Human Epidermal Growth Factor Receptor 2) Negative Hormone Receptor Positive Metastatic Breast Cancer,1530
102,NCT01857193,Phase Ib/II,Recruiting,"[{'id': 2265, 'therapyName': 'LEE011 + Everolimus + Exemestane'}, {'id': 1966, 'therapyName': 'Exemestane + Everolimus'}, {'id': 2266, 'therapyName': 'LEE011 + Exemestane'}]",Phase Ib/II Trial of LEE011 With Everolimus (RAD001) and Exemestane in the Treatment of ER+ Her2- Advanced Breast Cancer,1530
103,NCT02753686,Phase I,Recruiting,"[{'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 744, 'therapyName': 'Fulvestrant'}, {'id': 794, 'therapyName': 'Letrozole'}, {'id': 633, 'therapyName': 'Anastrozole'}, {'id': 1966, 'therapyName': 'Exemestane + Everolimus'}]",Treatment of Canadian Postmenopausal Women With ER+ Advanced Breast Cancer in the Real-World Setting With Hormone Therapy ± Targeted Therapy (Treat ER+ight),1530
104,NCT02871791,Phase Ib/II,Recruiting,"[{'id': 4597, 'therapyName': 'Exemestane + Everolimus + Palbociclib'}]",Palbociclib With Everolimus + Exemestane In BC,1530
105,NCT02137837,Phase III,"Active, not recruiting","[{'id': 1589, 'therapyName': 'Fulvestrant + Everolimus'}, {'id': 1590, 'therapyName': 'Fulvestrant + Everolimus + Anastrozole'}, {'id': 744, 'therapyName': 'Fulvestrant'}]","S1222 Trial (Everolimus, Anastrozole and Fulvestrant) in Post-Menopausal Stage IV Breast Cancer",1530
106,NCT01797120,Phase II,Completed,"[{'id': 1589, 'therapyName': 'Fulvestrant + Everolimus'}, {'id': 744, 'therapyName': 'Fulvestrant'}]","Study of Fulvestrant +/- Everolimus in Post-Menopausal, Hormone-Receptor + Metastatic Breast Ca Resistant to AI",1530
107,NCT01783756,Phase Ib/II,"Active, not recruiting","[{'id': 1552, 'therapyName': 'Lapatinib + Capecitabine + Everolimus'}]","Phase 1b/2 Trial Using Lapatinib, Everolimus and Capecitabine for Treatment of HER-2 Positive Breast Cancer With CNS Metastasis",1530
108,NCT02732119,Phase Ib/II,Recruiting,"[{'id': 2265, 'therapyName': 'LEE011 + Everolimus + Exemestane'}]",Study of Ribociclib With Everolimus + Exemestane in HR+ HER2- Locally Advanced/Metastatic Breast Cancer Post Progression on CDK 4/6 Inhibitor. (TRINITI-1),1530
109,NCT01733004,Phase I,Completed,"[{'id': 1248, 'therapyName': 'MM-141 + Everolimus'}, {'id': 1073, 'therapyName': 'MM-141'}, {'id': 1249, 'therapyName': 'MM-141 + Abraxane + Gemcitabine'}]",A Phase 1 Study of MM-141 in Patients With Advanced Solid Tumors,1530
110,NCT03065387,Phase I,Not yet recruiting,"[{'id': 5401, 'therapyName': 'Neratinib + Everolimus'}, {'id': 5402, 'therapyName': 'Neratinib + Palbociclib'}, {'id': 5403, 'therapyName': 'Neratinib + Trametinib'}]","Study of the Pan-ERBB Inhibitor Neratinib Given in Combination With Everolimus, Palbociclib or Trametinib in Advanced Cancer Subjects With EGFR Mutation/Amplification, HER2 Mutation/Amplification or HER3/4 Mutation",1530
111,NCT03154281,Phase I,Not yet recruiting,"[{'id': 5732, 'therapyName': 'Niraparib + Everolimus'}]",Evaluation of the Safety and Tolerability of Niraparib With Everolimus in Ovarian and Breast,1530
112,NCT00918333,Phase Ib/II,"Active, not recruiting","[{'id': 1964, 'therapyName': 'Panobinostat + Everolimus'}]","Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma",1530
113,NCT01582009,Phase Ib/II,Terminated,"[{'id': 1964, 'therapyName': 'Panobinostat + Everolimus'}]",Panobinostat and Everolimus in Treating Patients With Metastatic or Unresectable Renal Cell Cancer That Does Not Respond to Treatment With Sunitinib Malate or Sorafenib Tosylate,1530
114,NCT00978432,Phase II,Terminated,"[{'id': 1964, 'therapyName': 'Panobinostat + Everolimus'}]",Epigenetic Modulation in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL),1530
115,NCT02890069,Phase I,Recruiting,"[{'id': 5311, 'therapyName': 'PDR001 + LCL161'}, {'id': 5312, 'therapyName': 'PDR001 + Everolimus'}, {'id': 5313, 'therapyName': 'PDR001 + Panobinostat'}]","A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat",1530
116,NCT01889420,Phase I,Terminated,"[{'id': 2312, 'therapyName': 'Pomalidomide + Everolimus + Dexamethasone'}]","Phase I Trial of Everolimus, Pomalidomide and Dexamethasone Patients With Relapsed/Refractory Multiple Myeloma",1530
117,NCT03114527,Phase II,Recruiting,"[{'id': 5073, 'therapyName': 'Ribociclib + Everolimus'}]",Phase II Trial of Ribociclib and Everolimus in Advanced Dedifferentiated Liposarcoma (DDL) and Leiomyosarcoma (LMS),1530
118,NCT03070301,Phase II,Recruiting,"[{'id': 5073, 'therapyName': 'Ribociclib + Everolimus'}]",A Study of LEE011 With Everolimus in Patients With Advanced Neuroendocrine Tumors,1530
119,NCT02985125,Phase Ib/II,Recruiting,"[{'id': 5073, 'therapyName': 'Ribociclib + Everolimus'}]",LEE011 Plus Everolimus in Patients With Metastatic Pancreatic Adenocarcinoma Refractory to Chemotherapy,1530
120,NCT03008408,Phase II,Recruiting,"[{'id': 5180, 'therapyName': 'Ribociclib + Everolimus + Letrozole'}]","Phase II Ribociclib, Everolimus and Letrozole in Endometrial Cancer",1530
121,NCT01305941,Phase II,"Active, not recruiting","[{'id': 1411, 'therapyName': 'Trastuzumab + Everolimus + Vinorelbine'}]","A Study Of Everolimus, Trastuzumab And Vinorelbine In HER2-Positive Breast Cancer Brain Metastases",1530
122,NCT01582191,Phase I,Recruiting,"[{'id': 1163, 'therapyName': 'Vandetanib + Everolimus'}]",Vandetanib With Everolimus,1530
123,NCT01596140,Phase I,"Active, not recruiting","[{'id': 1175, 'therapyName': 'Vemurafenib + Temsirolimus'}, {'id': 1174, 'therapyName': 'Vemurafenib + Everolimus'}]",Vemurafenib in Combination With Everolimus or Temsirolimus With Advanced Cancer,1530
124,NCT01784861,Phase Ib/II,"Active, not recruiting","[{'id': 1272, 'therapyName': 'X-82 + Everolimus'}]",VEGFR/PDGFR Dual Kinase Inhibitor X-82 and Everolimus for Treating Patients With Pancreatic Neuroendocrine Tumors,1530
0,NCT02342379,Phase II,"Active, not recruiting","[{'id': 2144, 'therapyName': 'Bevacizumab + Evofosfamide'}]",TH-302 in Combination With Bevacizumab for Glioblastoma,7237
1,NCT01403610,Phase II,Completed,"[{'id': 2144, 'therapyName': 'Bevacizumab + Evofosfamide'}, {'id': 1317, 'therapyName': 'Evofosfamide'}]",Safety and Efficacy Study of TH-302 CNS Penetration in Recurrent High Grade Astrocytoma Following Bevacizumab,7237
2,NCT01522872,Phase Ib/II,"Active, not recruiting","[{'id': 1317, 'therapyName': 'Evofosfamide'}, {'id': 688, 'therapyName': 'Bortezomib'}]",Open-label Study of TH-302 and Dexamethasone With or Without Bortezomib in Subjects With Relapsed/Refractory Multiple Myeloma,7237
3,NCT03098160,Phase I,Recruiting,"[{'id': 5745, 'therapyName': 'Evofosfamide + Ipilimumab'}]",Immunotherapy Study of Evofosfamide in Combination With Ipilimumab,7237
4,NCT01485042,Phase I,Completed,"[{'id': 1318, 'therapyName': 'Evofosfamide + Pazopanib'}]",Dose Escalation Study of Pazopanib Plus TH-302,7237
5,NCT01497444,Phase Ib/II,Suspended,"[{'id': 1320, 'therapyName': 'Evofosfamide + Sorafenib'}]",Sorafenib Tosylate and Hypoxia-Activated Prodrug TH-302 in Treating Patients With Advanced Kidney Cancer or Liver Cancer That Cannot Be Removed By Surgery,7237
0,NCT02057133,Phase I,Recruiting,"[{'id': 2254, 'therapyName': 'Abemaciclib + Letrozole'}, {'id': 2257, 'therapyName': 'Abemaciclib + Exemestane'}, {'id': 2258, 'therapyName': 'Everolimus + Exemestane + LY2835219'}, {'id': 2255, 'therapyName': 'Abemaciclib + Anastrozole'}, {'id': 2256, 'therapyName': 'Abemaciclib + Tamoxifen'}, {'id': 2259, 'therapyName': 'Abemaciclib + Trastuzumab'}]",A Study of LY2835219 in Combination With Hormone Therapies for Breast Cancer That Has Spread,979
1,NCT03280563,Phase Ib/II,Not yet recruiting,"[{'id': 6269, 'therapyName': 'Atezolizumab + Ipatasertib'}, {'id': 6270, 'therapyName': 'Atezolizumab + Bevacizumab + Exemestane'}, {'id': 1343, 'therapyName': 'Atezolizumab + Cobimetinib'}, {'id': 6271, 'therapyName': 'Atezolizumab + Bevacizumab + Fulvestrant'}, {'id': 6272, 'therapyName': 'Atezolizumab + Bevacizumab + Tamoxifen'}, {'id': 6273, 'therapyName': 'Atezolizumab + Ipatasertib + Fulvestrant'}, {'id': 744, 'therapyName': 'Fulvestrant'}, {'id': 6268, 'therapyName': 'Atezolizumab + Fulvestrant'}]",A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer,979
2,NCT02077933,Phase I,"Active, not recruiting","[{'id': 1384, 'therapyName': 'BYL719 + Everolimus'}, {'id': 1385, 'therapyName': 'BYL719 + Everolimus + Exemestane'}]","Study of Safety and Efficacy of BYL719 With Everolimus or BYL719 With Everolimus and Exemestane in Advanced Breast Cancer Patients, Renal Cell Cancer and Pancreatic Tumors",979
3,NCT01870505,Phase I,"Active, not recruiting","[{'id': 2318, 'therapyName': 'BYL719 + Exemestane'}, {'id': 1553, 'therapyName': 'Letrozole + BYL719'}]",BYL719 Plus Letrozole or Exemestane for Patients With Hormone-Receptor Positive Locally-Advanced Unresectable or Metastatic Breast Cancer,979
4,NCT02820961,Phase I,Recruiting,"[{'id': 4437, 'therapyName': 'Entinostat + Exemestane'}]",Drug-Drug Interaction Study of Entinostat and Exemestane in Postmenopausal Women With ER+ Breast Cancer,979
5,NCT02676986,Phase II,Recruiting,"[{'id': 6183, 'therapyName': 'Enzalutamide + Exemestane'}, {'id': 1262, 'therapyName': 'Enzalutamide'}]","Short-term Preoperative Treatment With Enzalutamide, Alone or in Combination With Exemestane in Primary Breast Cancer (ARB)",979
6,NCT02040857,Phase II,"Active, not recruiting","[{'id': 738, 'therapyName': 'Exemestane'}, {'id': 850, 'therapyName': 'Palbociclib'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 794, 'therapyName': 'Letrozole'}, {'id': 633, 'therapyName': 'Anastrozole'}]",Palbociclib + Endocrine Therapy for HR + BrCa,979
7,NCT02753686,Phase I,Recruiting,"[{'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 744, 'therapyName': 'Fulvestrant'}, {'id': 794, 'therapyName': 'Letrozole'}, {'id': 633, 'therapyName': 'Anastrozole'}, {'id': 1966, 'therapyName': 'Exemestane + Everolimus'}]",Treatment of Canadian Postmenopausal Women With ER+ Advanced Breast Cancer in the Real-World Setting With Hormone Therapy ± Targeted Therapy (Treat ER+ight),979
8,NCT02598557,Phase II,Recruiting,"[{'id': 738, 'therapyName': 'Exemestane'}]",Alternative Dosing of Exemestane Before Surgery in Treating Postmenopausal Patients With Stage 0-II Estrogen Positive Breast Cancer,979
9,NCT03238703,FDA approved,Not yet recruiting,"[{'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 4419, 'therapyName': 'Toremifine'}, {'id': 633, 'therapyName': 'Anastrozole'}, {'id': 794, 'therapyName': 'Letrozole'}]","Endocrine Therapy in Treating Patients With HER2 Negative, Low Risk Breast Cancer",979
10,NCT02983604,Phase Ib/II,Recruiting,"[{'id': 738, 'therapyName': 'Exemestane'}, {'id': 5074, 'therapyName': 'GS-5829 + Fulvestrant'}, {'id': 3561, 'therapyName': 'GS-5829 + Exemestane'}, {'id': 744, 'therapyName': 'Fulvestrant'}]",GS-5829 in Combination With Exemestane or Fulvestrant Comparing With Exemestane or Fulvestrant Alone in Women With Advanced Estrogen Receptor Positive HER2- Breast Cancer,979
11,NCT03300557,Phase II,Not yet recruiting,"[{'id': 738, 'therapyName': 'Exemestane'}]",Exemestane in Treating Patients With Complex Atypical Hyperplasia of the Endometrium/Endometrial Intraepithelial Neoplasia or Grade 1 Endometrial Cancer,979
12,NCT02947685,Phase III,Recruiting,"[{'id': 744, 'therapyName': 'Fulvestrant'}, {'id': 856, 'therapyName': 'Pertuzumab'}, {'id': 794, 'therapyName': 'Letrozole'}, {'id': 633, 'therapyName': 'Anastrozole'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 947, 'therapyName': 'Trastuzumab'}]","Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer (PATINA)",979
13,NCT02788201,Phase II,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1133, 'therapyName': 'Mitomycin C'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1013, 'therapyName': 'epirubicin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1137, 'therapyName': 'Bleomycin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 781, 'therapyName': 'Ixabepilone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 2950, 'therapyName': 'Estramustine'}, {'id': 1941, 'therapyName': 'Floxuridine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 1811, 'therapyName': 'Carmustine'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 953, 'therapyName': 'Vandetanib'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 4419, 'therapyName': 'Toremifine'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 2601, 'therapyName': 'Dactinomycin'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 3035, 'therapyName': 'Chlorambucil'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 342, 'therapyName': 'Vemurafenib'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 2635, 'therapyName': 'Vinblastine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 4305, 'therapyName': 'Teniposide'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 4304, 'therapyName': 'Streptozocin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1231, 'therapyName': 'Bendamustine'}, {'id': 4303, 'therapyName': 'Mechlorethamine'}, {'id': 4302, 'therapyName': 'Mitotane'}]",Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma,979
14,NCT02115282,Phase III,Recruiting,"[{'id': 759, 'therapyName': 'Goserelin'}, {'id': 1541, 'therapyName': 'Entinostat'}, {'id': 738, 'therapyName': 'Exemestane'}]",Exemestane With or Without Entinostat in Treating Postmenopausal Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic,979
15,NCT01160211,Phase III,"Active, not recruiting","[{'id': 1414, 'therapyName': 'Trastuzumab + Lapatinib'}, {'id': 794, 'therapyName': 'Letrozole'}, {'id': 633, 'therapyName': 'Anastrozole'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 738, 'therapyName': 'Exemestane'}]","A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer",979
16,NCT01674140,Phase III,Recruiting,"[{'id': 759, 'therapyName': 'Goserelin'}, {'id': 633, 'therapyName': 'Anastrozole'}, {'id': 794, 'therapyName': 'Letrozole'}, {'id': 795, 'therapyName': 'Leuprolide'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 738, 'therapyName': 'Exemestane'}]",S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer,979
17,NCT02007512,Phase II,"Active, not recruiting","[{'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 738, 'therapyName': 'Exemestane'}]",Safety Study of Enzalutamide in Combination With Exemestane in Patients With Advanced Breast Cancer,979
18,NCT02666105,Phase II,Recruiting,"[{'id': 738, 'therapyName': 'Exemestane'}]",Exemestane in Post-Menopausal Women With NSCLC,979
19,NCT01664754,Phase I,"Active, not recruiting","[{'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 738, 'therapyName': 'Exemestane'}]","Exemestane, Pemetrexed Disodium, and Carboplatin in Treating Post-Menopausal Women With Stage IV Non-Small Cell Lung Cancer",979
20,NCT01963481,Phase II,"Active, not recruiting","[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 738, 'therapyName': 'Exemestane'}]",Exemestane and Cyclophosphamide for Metastatic Breast Cancer,979
21,NCT02188745,Phase II,Recruiting,"[{'id': 738, 'therapyName': 'Exemestane'}, {'id': 1643, 'therapyName': 'Estradiol'}, {'id': 633, 'therapyName': 'Anastrozole'}, {'id': 794, 'therapyName': 'Letrozole'}]",ER Reactivation Therapy for Breast Cancer,979
22,NCT02204098,Phase I,Recruiting,"[{'id': 794, 'therapyName': 'Letrozole'}, {'id': 633, 'therapyName': 'Anastrozole'}, {'id': 759, 'therapyName': 'Goserelin'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 1456, 'therapyName': 'Tamoxifen'}]",Safety and Immune Response to a Mammaglobin-A DNA Vaccine In Breast Cancer Patients Undergoing Neoadjuvant Endocrine Therapy,979
23,NCT02648477,Phase II,Recruiting,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 794, 'therapyName': 'Letrozole'}, {'id': 633, 'therapyName': 'Anastrozole'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 1009, 'therapyName': 'Doxorubicin'}]",Pembrolizumab and Doxorubicin Hydrochloride or Anti-Estrogen Therapy in Treating Patients With Triple-Negative or Hormone Receptor-Positive Metastatic Breast Cancer,979
24,NCT02689921,Phase II,Recruiting,"[{'id': 633, 'therapyName': 'Anastrozole'}, {'id': 794, 'therapyName': 'Letrozole'}, {'id': 795, 'therapyName': 'Leuprolide'}, {'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}, {'id': 738, 'therapyName': 'Exemestane'}]",NEOADjuvant Aromatase Inhibitor and Pertuzumab/Trastuzumab for Women With Breast Cancer (NEOADAPT),979
25,NCT01272037,Phase III,Recruiting,"[{'id': 633, 'therapyName': 'Anastrozole'}, {'id': 794, 'therapyName': 'Letrozole'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 738, 'therapyName': 'Exemestane'}]","Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer",979
26,NCT02476786,Phase II,Recruiting,"[{'id': 633, 'therapyName': 'Anastrozole'}, {'id': 744, 'therapyName': 'Fulvestrant'}, {'id': 759, 'therapyName': 'Goserelin'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 738, 'therapyName': 'Exemestane'}]",Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score,979
27,NCT01698918,Phase II,"Active, not recruiting","[{'id': 1966, 'therapyName': 'Exemestane + Everolimus'}, {'id': 1621, 'therapyName': 'Everolimus + Letrozole'}]","Open-label, Phase II, Study of Everolimus Plus Letrozole in Postmenopausal Women With ER+, HER2- Metastatic or Locally Advanced Breast Cancer",979
28,NCT02258451,Phase II,Recruiting,"[{'id': 1966, 'therapyName': 'Exemestane + Everolimus'}, {'id': 2001, 'therapyName': 'radium Ra 223 dichloride'}]",Study of Radium-223 Dichloride Versus Placebo and Treatment With Exemestane / Everolimus in Subjects With Bone Predominant HER2 (Human Epidermal Growth Factor Receptor 2) Negative Hormone Receptor Positive Metastatic Breast Cancer,979
29,NCT01857193,Phase Ib/II,Recruiting,"[{'id': 2265, 'therapyName': 'LEE011 + Everolimus + Exemestane'}, {'id': 1966, 'therapyName': 'Exemestane + Everolimus'}, {'id': 2266, 'therapyName': 'LEE011 + Exemestane'}]",Phase Ib/II Trial of LEE011 With Everolimus (RAD001) and Exemestane in the Treatment of ER+ Her2- Advanced Breast Cancer,979
30,NCT02291913,Phase II,"Active, not recruiting","[{'id': 2267, 'therapyName': 'Everolimus + Tamoxifen'}, {'id': 2268, 'therapyName': 'Anastrozole + Everolimus'}, {'id': 1589, 'therapyName': 'Fulvestrant + Everolimus'}, {'id': 1621, 'therapyName': 'Everolimus + Letrozole'}, {'id': 2269, 'therapyName': 'Everolimus + Toremifene'}, {'id': 1966, 'therapyName': 'Exemestane + Everolimus'}]",Everolimus Combined With Anti-estrogen Therapy in Hormone-Receptor-Positive HER-2 Negative Advanced Breast Cancer,979
31,NCT02871791,Phase Ib/II,Recruiting,"[{'id': 4597, 'therapyName': 'Exemestane + Everolimus + Palbociclib'}]",Palbociclib With Everolimus + Exemestane In BC,979
32,NCT02392611,Phase I,"Active, not recruiting","[{'id': 3561, 'therapyName': 'GS-5829 + Exemestane'}]","Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5829 in Adults With Advanced Solid Tumors and Lymphomas",979
33,NCT02607228,Phase Ib/II,Recruiting,"[{'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 3561, 'therapyName': 'GS-5829 + Exemestane'}]","Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5829 as a Single Agent and In Combination With Enzalutamide in Participants With Metastatic Castrate-Resistant Prostate Cancer",979
34,NCT02732119,Phase Ib/II,Recruiting,"[{'id': 2265, 'therapyName': 'LEE011 + Everolimus + Exemestane'}]",Study of Ribociclib With Everolimus + Exemestane in HR+ HER2- Locally Advanced/Metastatic Breast Cancer Post Progression on CDK 4/6 Inhibitor. (TRINITI-1),979
35,NCT02049957,Phase Ib/II,Recruiting,"[{'id': 1581, 'therapyName': 'MLN0128 + Fulvestrant'}, {'id': 1580, 'therapyName': 'MLN0128 + Exemestane'}]",Safety and Efficacy Study of MLN0128 in Combination With Exemestane or Fulvestrant in Postmenopausal Women With ER/PR+ Metastatic Breast Cancer,979
36,NCT01594216,Phase II,"Active, not recruiting","[{'id': 1108, 'therapyName': 'Ruxolitinib + Exemestane'}]", Ruxolitinib in Estrogen Receptor Positive Breast Cancer,979
0,NCT02564614,Phase I,"Active, not recruiting","[{'id': 3612, 'therapyName': 'EZN-2968'}]","A Study of Hypoxia-inducible Factor 1a (HIF1A) Messenger Ribonucleic Acid (mRNA) Antagonist (RO7070179), to Demonstrate Proof-of-mechanism in Adult Participants With Hepatocellular Carcinoma (HCC)",8171
0,NCT03073525,Phase II,Recruiting,"[{'id': 5558, 'therapyName': 'Atezolizumab + FANG vaccine'}]",Trial of Atezolizumab and Vigil for Advanced Gynecological Cancers (A Companion Study to CL-PTL-119),7210
1,NCT02511132,Phase II,"Active, not recruiting","[{'id': 1157, 'therapyName': 'FANG vaccine'}, {'id': 1439, 'therapyName': 'Gemcitabine + Docetaxel'}]",Randomized Phase IIb Trial of Vigil Versus Gemcitabine + Docetaxel for Ewing's Sarcoma,7210
2,NCT02574533,Phase I,Completed,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1157, 'therapyName': 'FANG vaccine'}]",Pilot Study of Vigil + Pembrolizumab for Advanced Melanoma,7210
3,NCT02346747,Phase II,"Active, not recruiting","[{'id': 1157, 'therapyName': 'FANG vaccine'}]",Phase II/III Trial of Maintenance Vigil for High Risk Stage III/IV Ovarian Cancer (VITAL),7210
4,NCT01551745,Phase II,Completed,"[{'id': 1158, 'therapyName': 'FANG vaccine + Bevacizumab'}]", Salvage Ovarian FANG Vaccine + Bevacizumab,7210
5,NCT02725489,Phase II,Recruiting,"[{'id': 4388, 'therapyName': 'FANG vaccine + MEDI4736'}]",Pilot Study of Durvalumab (MEDI4736) in Combination With Vigil in Advanced Breast Cancer,7210
6,NCT02639234,Phase II,Withdrawn,"[{'id': 3572, 'therapyName': 'FANG vaccine + Nivolumab'}]",Vigil + Nivolumab in Advanced Non-Small Cell Lung Cancer,7210
0,NCT02289950,Phase II,Recruiting,"[{'id': 3230, 'therapyName': 'Farletuzumab'}]",A Study to Assess the Efficacy and Safety of Farletuzumab (MORAb 003) in Combination With Carboplatin Plus Paclitaxel or Carboplatin Plus Pegylated Liposomal Doxorubicin (PLD) in Subjects With Low CA125 Platinum-Sensitive Ovarian Cancer,7975
0,NCT02936102,Phase I,Recruiting,"[{'id': 4971, 'therapyName': 'FAZ053'}, {'id': 4972, 'therapyName': 'FAZ053 + PDR001'}]",A Study of FAZ053 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.,8589
0,NCT02495415,Phase II,Recruiting,"[{'id': 2731, 'therapyName': 'Fenretinide'}]",Trial of Intravenous Fenretinide Emulsion for Patients With Relapsed/Refractory Peripheral T-cell Lymphomas,4681
1,NCT01187810,Phase I,"Active, not recruiting","[{'id': 2731, 'therapyName': 'Fenretinide'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1639, 'therapyName': 'Methotrexate'}]","Fenretinide in Children With Recurrent/Resistant ALL, AML, and NHL",4681
2,NCT01535157,Phase Ib/II,"Active, not recruiting","[{'id': 2858, 'therapyName': 'Ketoconazole'}, {'id': 2731, 'therapyName': 'Fenretinide'}]",Fenretinide/LXS Oral Powder Plus Ketoconazole in Recurrent Ovarian Cancer,4681
3,NCT02163356,Phase I,Recruiting,"[{'id': 1631, 'therapyName': 'Vincristine'}, {'id': 2731, 'therapyName': 'Fenretinide'}, {'id': 2858, 'therapyName': 'Ketoconazole'}]",Fenretinide Lym-X-Sorb + Ketoconazole + Vincristine for Recurrent or Resistant Neuroblastoma,4681
4,NCT02075177,Phase I,Available,"[{'id': 2858, 'therapyName': 'Ketoconazole'}, {'id': 2731, 'therapyName': 'Fenretinide'}]",Expanded Access Study of Fenretinide Lym-X-Sorb Plus Ketoconazole in Neuroblastoma,4681
5,NCT01553071,Phase I,Recruiting,"[{'id': 1049, 'therapyName': 'Safingol'}, {'id': 2731, 'therapyName': 'Fenretinide'}]",Phase I Trial of IV Fenretinide (4-HPR) Plus IV Safingol for Patients With Relapsed Malignancies,4681
0,NCT02454010,Phase I,Recruiting,"[{'id': 3833, 'therapyName': 'FF-21101(90Y)'}]",A Dose Escalation Study of Radio-labeled Antibody for the Treatment of Advanced Cancer,8261
0,NCT02325739,Phase Ib/II,Recruiting,"[{'id': 2031, 'therapyName': 'FGF401'}]",Safety and Efficacy of FGF401 in Patients With Solid Malignancies,7397
0,NCT02109627,Phase I,Recruiting,"[{'id': 3183, 'therapyName': 'Cytarabine + Ficlatuzumab'}]",Ficlatuzumab With High Dose Cytarabine in Relapsed and Refractory AML,6904
1,NCT02090127,Phase I,No longer available,"[{'id': 740, 'therapyName': 'Ficlatuzumab'}]",Protocol to Allow Continued Access of Ficlatuzumab to P05538 Patient,6904
2,NCT02277197,Phase I,"Active, not recruiting","[{'id': 1959, 'therapyName': 'Ficlatuzumab + Cetuximab'}]",Ficlatuzumab and Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC),6904
3,NCT02277184,Phase I,Terminated,"[{'id': 1955, 'therapyName': 'Ficlatuzumab + Cisplatin'}]","Ficlatuzumab, Cisplatin and IMRT in Locally Advanced Head and Neck Squamous Cell Carcinoma",6904
4,NCT02318368,Phase II,Terminated,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 2169, 'therapyName': 'Ficlatuzumab + Erlotinib'}]","A Phase 2, Multicenter, Study of Ficlatuzumab Plus Erlotinib Versus Placebo Plus Erlotinib in Subjects Who Have Previously Untreated Metastatic, EGFR-mutated Non-small Cell Lung Cancer (NSCLC) and BDX004 Positive Label",6904
0,NCT02177695,Phase II,Recruiting,"[{'id': 1467, 'therapyName': 'Gemcitabine + Cisplatin'}, {'id': 2564, 'therapyName': 'Aldoxorubicin + Cisplatin + Filgrastim + Methotrexate + Vinblastine'}]","S1314, Co-expression Extrapolation (COXEN) Program to Predict Chemotherapy Response in Patients With Bladder Cancer",95
1,NCT01146834,Phase III,Recruiting,"[{'id': 3345, 'therapyName': 'Bortezomib + Filgrastim'}, {'id': 5459, 'therapyName': 'Bortezomib + Cyclophosphamide + G-CSF'}, {'id': 5460, 'therapyName': 'Bortezomib + Cyclophosphamide'}]",Trial of Three Stem Cell Mobilization Regimens for Multiple Myeloma,95
2,NCT02220608,Phase I,Completed,"[{'id': 3345, 'therapyName': 'Bortezomib + Filgrastim'}]",Phase I Study of Bortezomib With G-CSF for Stem Cell Mobilization in Patients With Multiple Myeloma,95
3,NCT00669669,Phase Ib/II,"Active, not recruiting","[{'id': 2556, 'therapyName': 'O6-benzylguanine'}, {'id': 2555, 'therapyName': 'Carmustine + Filgrastim + Plerixafor + Temozolomide'}]",Dose-Intensive Chemotherapy in Combination With Chemoprotected Autologous Stem Cells in Treating Patients With Malignant Gliomas,95
4,NCT02728050,Phase Ib/II,Recruiting,"[{'id': 920, 'therapyName': 'Sorafenib'}, {'id': 4363, 'therapyName': 'Cladribine + Cytarabine + Filgrastim + Mitoxantrone'}]","Filgrastim, Cladribine, Cytarabine and Mitoxantrone With or Without Sorafenib Tosylate in Treating Patients With Newly-Diagnosed, High-Risk Acute Myeloid Leukemia or Myelodysplastic Syndrome",95
5,NCT02642965,Phase Ib/II,Recruiting,"[{'id': 4391, 'therapyName': 'CPX-351 + Cytarabine + Filgrastim + Fludarabine '}]","Liposomal Cytarabine-Daunorubicin CPX-351, Fludarabine Phosphate, Cytarabine, and Filgrastim in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia",95
6,NCT02791919,Phase I,Withdrawn,"[{'id': 822, 'therapyName': 'MK-1775'}, {'id': 4271, 'therapyName': 'Cytarabine + Filgrastim + Fludarabine'}]","Wee1 Kinase Inhibitor AZD1775 and Combination Chemotherapy in Treating Children, Adolescents and Young Adults With Relapsed or Refractory Acute Myeloid Leukemia",95
7,NCT02961816,Phase II,Withdrawn,"[{'id': 3277, 'therapyName': 'Pyridoxine'}, {'id': 4976, 'therapyName': 'Busulfan + Gemcitabine + Melphalan + Panobinostat'}, {'id': 4977, 'therapyName': 'Dexamethasone + Filgrastim + Palifermin + Rituximab'}]",Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Lymphoma,95
8,NCT02494921,Phase Ib/II,Recruiting,"[{'id': 3113, 'therapyName': 'Docetaxel + Filgrastim + Prednisone + Ribociclib'}]",LEE011 (Ribociclib) in Combination With Docetaxel Plus Prednisone in mCRPC,95
9,NCT01408043,Phase I,Terminated,"[{'id': 3222, 'therapyName': 'Etoposide + Filgrastim + Plerixafor'}]","Etoposide, Filgrastim, and Plerixafor in Improving Stem Cell Mobilization in Treating Patients With Non-Hodgkin Lymphoma",95
10,NCT01857934,Phase II,Recruiting,"[{'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1873, 'therapyName': 'Sargramostim'}, {'id': 1167, 'therapyName': 'Aldesleukin'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 2627, 'therapyName': 'Levetiracetam'}, {'id': 2585, 'therapyName': 'Cisplatin + Etoposide'}, {'id': 2458, 'therapyName': 'Hu14.18K322A'}, {'id': 2558, 'therapyName': 'Busulfan + Melphalan'}, {'id': 2590, 'therapyName': 'Cyclophosphamide + Topotecan'}]",Therapy for Children With Advanced Stage Neuroblastoma,95
11,NCT02039726,Phase III,"Active, not recruiting","[{'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 3193, 'therapyName': 'Cytarabine + Fludarabine + Idarubicin'}, {'id': 1752, 'therapyName': 'Mitoxantrone + Etoposide + Cytarabine'}, {'id': 882, 'therapyName': 'Quizartinib'}]",An Open-label Study of Quizartinib Monotherapy vs. Salvage Chemotherapy in Acute Myeloid Leukemia (AML) Subjects,95
12,NCT00303849,Phase Ib/II,Recruiting,"[{'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 2562, 'therapyName': 'Etoposide + Melphalan'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1476, 'therapyName': 'Pegfilgrastim'}]",Combination Chemotherapy With BBBD Followed By Sodium Thiosulfate in Treating Patients With Anaplastic Oligodendroglioma or Oligoastrocytoma,95
13,NCT00983398,Phase Ib/II,Recruiting,"[{'id': 1476, 'therapyName': 'Pegfilgrastim'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 2587, 'therapyName': 'Carboplatin + Melphalan'}]","Melphalan, Carboplatin, and Sodium Thiosulfate for Patients With Central Nervous System (CNS) Embryonal or Germ Cell Tumors",95
14,NCT02337985,Phase I,Recruiting,"[{'id': 897, 'therapyName': 'Rituximab'}, {'id': 2482, 'therapyName': 'Cyclophosphamide + Doxorubicin + Etoposide + Vincristine '}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 2188, 'therapyName': 'Prednisone'}]",Gene Therapy and Combination Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin Lymphoma,95
15,NCT00513474,Phase I,Completed,"[{'id': 2313, 'therapyName': 'Rasburicase'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 1650, 'therapyName': 'Cyclosporine'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 2314, 'therapyName': 'Busulfan + Cyclophosphamide + Etoposide'}]",Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant,95
16,NCT01467115,Phase II,Completed,"[{'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 1930, 'therapyName': 'Cisplatin + Docetaxel + Fluorouracil'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 694, 'therapyName': 'Cetuximab'}]",INDUCTION CHEMOTHERAPY FOLLOWED BY CETUXIMAB AND RADIATION THERAPY FOR HEAD AND NECK CANCER,95
17,NCT03247088,Phase Ib/II,Recruiting,"[{'id': 6122, 'therapyName': 'Busulfan + Sorafenib + Fludarabine'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 1632, 'therapyName': 'Filgrastim'}]",Study Of Sorafenib Added To Busulfan And Fludarabine Conditioning Regimen In Patients With Relapsed/Refractory AML Undergoing Stem Cell Transplantation,95
18,NCT02343666,Phase I,Recruiting,"[{'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1811, 'therapyName': 'Carmustine'}, {'id': 1756, 'therapyName': 'Plerixafor'}, {'id': 2556, 'therapyName': 'O6-benzylguanine'}]",HIV-Resistant Gene Modified Stem Cells and Chemotherapy in Treating Patients With Lymphoma With HIV Infection,95
19,NCT00293475,Phase Ib/II,Recruiting,"[{'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1476, 'therapyName': 'Pegfilgrastim'}, {'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 2669, 'therapyName': 'Carboplatin + Methotrexate + Rituximab'}]",Rituximab and Methotrexate Chemotherapy w/Blood-Brain Barrier Disruption (BBBD) &amp; Sodium Thiosulfate Chemoprotection for Patients With Newly Diagnosed PCNSL,95
20,NCT01729091,Phase Ib/II,Recruiting,"[{'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 3343, 'therapyName': 'Elotuzumab'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1164, 'therapyName': 'lenalidomide'}]",Study of Umbilical Cord Blood-derived Natural Killer Cells in Conjunction With High Dose Chemotherapy and Autologous Stem Cell Transplant for Patients With Multiple Myeloma,95
21,NCT02104427,Phase II,Completed,"[{'id': 2853, 'therapyName': 'TG-0054'}, {'id': 1632, 'therapyName': 'Filgrastim'}]","PD and Safety of TG-0054 Combined With G-CSF in Multiple Myeloma, Non-Hodgkin Lymphoma and Hodgkin Disease Patients",95
22,NCT03214562,,Recruiting,"[{'id': 1562, 'therapyName': 'Venetoclax'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 712, 'therapyName': 'Cytarabine'}]",Study of the BCL-2 Inhibitor Venetoclax in Combination With Standard Intensive Acute Myeloid Leukemia (AML) Induction/Consolidation Therapy With FLAG-IDA in Patients With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia (AML),95
23,NCT02356159,Phase Ib/II,Recruiting,"[{'id': 2294, 'therapyName': 'Cytarabine + Fludarabine'}, {'id': 2373, 'therapyName': 'Palifermin'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 2238, 'therapyName': 'Sirolimus + Tacrolimus + Methotrexate'}, {'id': 2292, 'therapyName': 'Doxorubicin + Etoposide + Fludarabine + Vincristine '}, {'id': 2291, 'therapyName': 'Cyclophosphamide + Fludarabine'}, {'id': 897, 'therapyName': 'Rituximab'}]",Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation,95
24,NCT02412475,Phase I,"Active, not recruiting","[{'id': 712, 'therapyName': 'Cytarabine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 650, 'therapyName': 'Decitabine'}]",Epigenetic Reprogramming in Relapse AML,95
25,NCT01526603,Phase I,Recruiting,"[{'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1092, 'therapyName': 'Carboplatin'}]",High Dose Chemotherapy and Autologous Transplant for Neuroblastoma,95
26,NCT01823198,Phase Ib/II,Recruiting,"[{'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1846, 'therapyName': 'Busulfan + Fludarabine + anti-thymocyte globulin'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 1632, 'therapyName': 'Filgrastim'}]",Natural Killer (NK) Cells With HLA Compatible Hematopoietic Transplantation for High Risk Myeloid Malignancies,95
27,NCT02756572,Phase I,Recruiting,"[{'id': 917, 'therapyName': 'Sirolimus'}, {'id': 1845, 'therapyName': 'Mycophenolate mofetil'}, {'id': 1650, 'therapyName': 'Cyclosporine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 5215, 'therapyName': 'mitoxantrone hydrochloride'}, {'id': 1166, 'therapyName': 'Fludarabine'}]",Early Allogeneic Hematopoietic Cell Transplantation in Treating Patients With Relapsed or Refractory High-Grade Myelodysplastic Syndrome or Acute Myeloid Leukemia,95
28,NCT02790515,Phase II,Recruiting,"[{'id': 917, 'therapyName': 'Sirolimus'}, {'id': 1844, 'therapyName': 'anti-thymocyte globulin'}, {'id': 1876, 'therapyName': 'Blinatumomab '}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 5682, 'therapyName': 'Mesna'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1632, 'therapyName': 'Filgrastim'}]",Provision of TCR?? T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation,95
29,NCT01526096,Phase I,Recruiting,"[{'id': 5985, 'therapyName': 'Basiliximab'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1756, 'therapyName': 'Plerixafor'}, {'id': 1207, 'therapyName': 'Melphalan'}]",Stem Cell Transplantation for Patients With Multiple Myeloma,95
30,NCT01707004,Phase I,"Active, not recruiting","[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1206, 'therapyName': 'Busulfan'}]",Decitabine and Total-Body Irradiation Followed By Donor Bone Marrow Transplant and Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia,95
31,NCT01256398,Phase II,"Active, not recruiting","[{'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 2291, 'therapyName': 'Cyclophosphamide + Fludarabine'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1824, 'therapyName': 'Vincristine + Methotrexate + Mercaptopurine'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 2391, 'therapyName': 'Cytarabine + Daunorubicin + Etoposide'}, {'id': 1476, 'therapyName': 'Pegfilgrastim'}, {'id': 1205, 'therapyName': 'Alemtuzumab'}, {'id': 1642, 'therapyName': 'Leucovorin'}]",Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,95
32,NCT00857389,Phase II,"Active, not recruiting","[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 2469, 'therapyName': 'Busulfan + Clofarabine + Thymoglobulin'}, {'id': 1639, 'therapyName': 'Methotrexate'}]",Thiotepa-Clofarabine-Busulfan With Allogeneic Stem Cell Transplant for High Risk Malignancies,95
33,NCT02421939,Phase III,Recruiting,"[{'id': 712, 'therapyName': 'Cytarabine'}, {'id': 3193, 'therapyName': 'Cytarabine + Fludarabine + Idarubicin'}, {'id': 1752, 'therapyName': 'Mitoxantrone + Etoposide + Cytarabine'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 2865, 'therapyName': 'Gilteritinib'}, {'id': 1632, 'therapyName': 'Filgrastim'}]",A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,95
34,NCT03197935,Phase III,Recruiting,"[{'id': 1476, 'therapyName': 'Pegfilgrastim'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 619, 'therapyName': 'Abraxane'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}]",A Study to Investigate Atezolizumab and Chemotherapy Compared With Placebo and Chemotherapy in the Neoadjuvant Setting in Participants With Early Stage Triple Negative Breast Cancer (IMpassion031),95
35,NCT01319981,Phase II,Recruiting,"[{'id': 1476, 'therapyName': 'Pegfilgrastim'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}]",Hyper-CVAD With Liposomal Vincristine in Acute Lymphoblastic Leukemia,95
36,NCT01177683,Phase Ib/II,"Active, not recruiting","[{'id': 3349, 'therapyName': 'Bendamustine + Bortezomib + pegylated liposomal-doxorubicin'}, {'id': 1632, 'therapyName': 'Filgrastim'}]",Bendamustine in Combination With Bortezomib and Pegylated Liposomal Doxorubicin for Multiple Myeloma,95
37,NCT02098109,Phase II,Completed,"[{'id': 1756, 'therapyName': 'Plerixafor'}, {'id': 1632, 'therapyName': 'Filgrastim'}]",Non-inferiority Study of XM02 Filgrastim (Granix) and Filgrastim (Neupogen) in Combination With Plerixafor for Autologous Stem Cell Mobilization in Patients With Multiple Myeloma or Non-Hodgkin Lymphoma,95
38,NCT00520130,Phase Ib/II,"Active, not recruiting","[{'id': 2294, 'therapyName': 'Cytarabine + Fludarabine'}, {'id': 2305, 'therapyName': 'Alemtuzumab + Cyclosporine'}, {'id': 2306, 'therapyName': 'Rituximab + Fludarabine + EPOCH'}, {'id': 2307, 'therapyName': 'Fludarabine + EPOCH'}, {'id': 2238, 'therapyName': 'Sirolimus + Tacrolimus + Methotrexate'}, {'id': 1632, 'therapyName': 'Filgrastim'}]",Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,95
39,NCT03164057,Phase II,Recruiting,"[{'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 5153, 'therapyName': 'dexrazoxane'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 651, 'therapyName': 'Azacitidine'}]",A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia,95
40,NCT01505569,Phase I,Recruiting,"[{'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 2558, 'therapyName': 'Busulfan + Melphalan'}, {'id': 2101, 'therapyName': 'Etoposide + Ifosfamide'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 1092, 'therapyName': 'Carboplatin'}]",Auto Transplant for High Risk or Relapsed Solid or CNS Tumors,95
41,NCT01547806,Phase II,"Active, not recruiting","[{'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1756, 'therapyName': 'Plerixafor'}]",Collection of Transplant Stem Cells for Plasma Cell Myeloma,95
42,NCT02423915,Phase Ib/II,Recruiting,"[{'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 2281, 'therapyName': 'Cyclophosphamide + Fludarabine + Mycophenolate mofetil'}, {'id': 917, 'therapyName': 'Sirolimus'}]",Fucosylated T Cells for Graft Versus Host Disease (GVHD) Prevention,95
43,NCT02427620,Phase II,Recruiting,"[{'id': 2353, 'therapyName': 'Cyclophosphamide + Doxorubicin + Vincristine '}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 3195, 'therapyName': 'Cytarabine + Methotrexate '}, {'id': 1642, 'therapyName': 'Leucovorin'}]",A Study of Ibrutinib Plus Rituximab With Hyper-CVAD Consolidation in Newly Diagnosed Young Patients With Mantle Cell Lymphoma,95
44,NCT01701986,Phase Ib/II,Recruiting,"[{'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1845, 'therapyName': 'Mycophenolate mofetil'}, {'id': 1844, 'therapyName': 'anti-thymocyte globulin'}, {'id': 3992, 'therapyName': 'Busulfan + Clofarabine + Gemcitabine'}]",Gemcitabine/Clofarabine/Busulfan and Allogeneic Transplantation for Aggressive Lymphomas,95
45,NCT03147612,Phase II,Not yet recruiting,"[{'id': 5682, 'therapyName': 'Mesna'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 877, 'therapyName': 'Ponatinib'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 712, 'therapyName': 'Cytarabine'}]",Study of the Combination of Low-Intensity Chemotherapy and Ponatinib in Patients With Philadelphia Chromosome (Ph)-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL),95
46,NCT01858883,Phase I,Completed,"[{'id': 619, 'therapyName': 'Abraxane'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 2406, 'therapyName': 'INCB039110'}, {'id': 755, 'therapyName': 'Gemcitabine'}]",Safety Study of INCB039110 in Combination With Gemcitabine and Nab-Paclitaxel in Subjects With Advanced Solid Tumors,95
47,NCT00074490,Phase II,Completed,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1650, 'therapyName': 'Cyclosporine'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1166, 'therapyName': 'Fludarabine'}]",Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,95
48,NCT02130869,Phase I,Recruiting,"[{'id': 2378, 'therapyName': 'Bendamustine + Cytarabine + Etoposide'}, {'id': 2460, 'therapyName': 'Busulfan + Hu14.18K322A'}, {'id': 2459, 'therapyName': 'Aldesleukin + Melphalan + Sargramostim'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1791, 'therapyName': 'Carboplatin + Etoposide'}]",A Pilot Study of Immunotherapy Including Haploidentical NK Cell Infusion Following CD133+ Positively-Selected Autologous Hematopoietic Stem Cells in Children With High Risk Solid Tumors or Lymphomas,95
49,NCT03263936,Phase I,Recruiting,"[{'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1632, 'therapyName': 'Filgrastim'}]",Epigenetic Reprogramming in Relapse/Refractory AML,95
50,NCT02703779,Phase II,Recruiting,"[{'id': 688, 'therapyName': 'Bortezomib'}, {'id': 3933, 'therapyName': 'Filgrastim + Plerixafor'}]",Exploratory Trial to Estimate Proportion of Patients With Tumor Cell Contaminated Leukapheresis Products With and Without Bortezomib With In-vivo Purging - Multiple Myeloma (MM),95
51,NCT03240861,Phase I,Not yet recruiting,"[{'id': 6116, 'therapyName': 'Busulfan + Fludarabine'}, {'id': 3933, 'therapyName': 'Filgrastim + Plerixafor'}, {'id': 1167, 'therapyName': 'Aldesleukin'}]",Genetically Engineered PBMC and PBSC Expressing NY-ESO-1 TCR After a Myeloablative Conditioning Regimen to Treat Patients With Advanced Cancer (NYESO SCT),95
0,NCT02490930,Phase I,Completed,"[{'id': 3610, 'therapyName': 'Fingolimod'}]",A Safety Study of Fingolimod With Radiation and Temozolomide in Newly Diagnosed High Grade Glioma,6778
0,NCT02070406,Phase I,Recruiting,"[{'id': 3409, 'therapyName': 'Aldesleukin + Cyclophosphamide + Fludarabine '}, {'id': 2696, 'therapyName': 'NY-ESO-1 peptide vaccine'}]","Gene-Modified T Cells, Vaccine Therapy, and Ipilimumab in Treating Patients With Locally Advanced or Metastatic Malignancies",1060
1,NCT02775292,Phase I,Recruiting,"[{'id': 3409, 'therapyName': 'Aldesleukin + Cyclophosphamide + Fludarabine '}, {'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 2696, 'therapyName': 'NY-ESO-1 peptide vaccine'}]","Gene-Modified T Cells, Vaccine Therapy, and Nivolumab in Treating Patients With Stage IV or Locally Advanced Solid Tumors Expressing NY-ESO-1",1060
2,NCT02652455,Phase I,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 3409, 'therapyName': 'Aldesleukin + Cyclophosphamide + Fludarabine '}, {'id': 2055, 'therapyName': 'Urelumab'}]","Combining PD-1 Blockade, CD137 Agonism and Adoptive Cell Therapy for Metastatic Melanoma",1060
3,NCT01898793,Phase Ib/II,Recruiting,"[{'id': 3409, 'therapyName': 'Aldesleukin + Cyclophosphamide + Fludarabine '}, {'id': 5300, 'therapyName': 'ALT-803 + Cyclophosphamide + Fludarabine phosphate'}]",Cytokine-induced Memory-like NK Cells in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS),1060
4,NCT02500576,Phase II,Recruiting,"[{'id': 5683, 'therapyName': 'Aldesleukin + Cyclophosphamide + Fludarabine + Mesna + Pembrolizumab'}]","MK-3475 With Lymphodepletion, TIL and High or Low Dose Interleukin-2 (IL-2)",1060
5,NCT02858310,Phase I,Recruiting,"[{'id': 4562, 'therapyName': 'Aldesleukin + Cyclophosphamide + Fludarabine + Pembrolizumab'}]",E7 TCR T Cells With or Without PD-1 Blockade for Human Papillomavirus-Associated Cancers,1060
6,NCT00602693,Phase I,Completed,"[{'id': 917, 'therapyName': 'Sirolimus'}, {'id': 2311, 'therapyName': 'Allopurinol + Cyclophosphamide + Fludarabine'}]",T-Regulatory Cell Infusion Post Umbilical Cord Blood Transplant in Patients With Advanced Hematologic Cancer,1060
7,NCT03050216,Phase II,Recruiting,"[{'id': 5300, 'therapyName': 'ALT-803 + Cyclophosphamide + Fludarabine phosphate'}]",Haplo NK With SQ ALT-803 for Adults With Relapsed or Refractory AML,1060
8,NCT01163357,Phase I,Recruiting,"[{'id': 917, 'therapyName': 'Sirolimus'}, {'id': 2288, 'therapyName': 'Bortezomib + Fludarabine + Melphalan'}]","Bortezomib, Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant For High-Risk Stage I or II Multiple Myeloma",1060
9,NCT02083250,Phase I,Recruiting,"[{'id': 1844, 'therapyName': 'anti-thymocyte globulin'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 3201, 'therapyName': 'Busulfan + Clofarabine + Fludarabine'}]",Fludarabine/Clofarabine/Busulfan Combined With SAHA in Acute Leukemia,1060
10,NCT03240861,Phase I,Not yet recruiting,"[{'id': 6116, 'therapyName': 'Busulfan + Fludarabine'}, {'id': 3933, 'therapyName': 'Filgrastim + Plerixafor'}, {'id': 1167, 'therapyName': 'Aldesleukin'}]",Genetically Engineered PBMC and PBSC Expressing NY-ESO-1 TCR After a Myeloablative Conditioning Regimen to Treat Patients With Advanced Cancer (NYESO SCT),1060
11,NCT00679536,Phase Ib/II,Unknown status,"[{'id': 1846, 'therapyName': 'Busulfan + Fludarabine + anti-thymocyte globulin'}]",Allogeneic Transplantation for Pediatric Leukemias With Unrelated Donors,1060
12,NCT01823198,Phase Ib/II,Recruiting,"[{'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1846, 'therapyName': 'Busulfan + Fludarabine + anti-thymocyte globulin'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 1632, 'therapyName': 'Filgrastim'}]",Natural Killer (NK) Cells With HLA Compatible Hematopoietic Transplantation for High Risk Myeloid Malignancies,1060
13,NCT02057770,Phase I,Recruiting,"[{'id': 5724, 'therapyName': 'Busulfan + Fludarabine phosphate + Cyclophosphamide'}, {'id': 5647, 'therapyName': 'Tocilizumab'}]",Allogeneic or Haploidentical Stem Cell Transplant Followed By High-Dose Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia,1060
14,NCT03247088,Phase Ib/II,Recruiting,"[{'id': 6122, 'therapyName': 'Busulfan + Sorafenib + Fludarabine'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 1632, 'therapyName': 'Filgrastim'}]",Study Of Sorafenib Added To Busulfan And Fludarabine Conditioning Regimen In Patients With Relapsed/Refractory AML Undergoing Stem Cell Transplantation,1060
15,NCT02642965,Phase Ib/II,Recruiting,"[{'id': 4391, 'therapyName': 'CPX-351 + Cytarabine + Filgrastim + Fludarabine '}]","Liposomal Cytarabine-Daunorubicin CPX-351, Fludarabine Phosphate, Cytarabine, and Filgrastim in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia",1060
16,NCT00338377,Phase II,Recruiting,"[{'id': 2291, 'therapyName': 'Cyclophosphamide + Fludarabine'}, {'id': 1167, 'therapyName': 'Aldesleukin'}]",Lymphodepletion Plus Adoptive Cell Transfer With or Without Dendritic Cell Immunization,1060
17,NCT01701674,Phase I,"Active, not recruiting","[{'id': 2291, 'therapyName': 'Cyclophosphamide + Fludarabine'}, {'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 1167, 'therapyName': 'Aldesleukin'}]",Ipilimumab With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 in Melanoma Mets Pts,1060
18,NCT00003553,Phase II,Unknown status,"[{'id': 2291, 'therapyName': 'Cyclophosphamide + Fludarabine'}, {'id': 1650, 'therapyName': 'Cyclosporine'}, {'id': 1845, 'therapyName': 'Mycophenolate mofetil'}, {'id': 1639, 'therapyName': 'Methotrexate'}]",Peripheral Stem Cell Transplant in Treating Patients With Metastatic Kidney Cancer,1060
19,NCT02153580,Phase I,"Active, not recruiting","[{'id': 1136, 'therapyName': 'Etoposide'}, {'id': 2291, 'therapyName': 'Cyclophosphamide + Fludarabine'}, {'id': 1231, 'therapyName': 'Bendamustine'}]","Cellular Immunotherapy Following Cyclophosphamide in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia or B-Cell Prolymphocytic Leukemia",1060
20,NCT01256398,Phase II,"Active, not recruiting","[{'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 2291, 'therapyName': 'Cyclophosphamide + Fludarabine'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1824, 'therapyName': 'Vincristine + Methotrexate + Mercaptopurine'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 2391, 'therapyName': 'Cytarabine + Daunorubicin + Etoposide'}, {'id': 1476, 'therapyName': 'Pegfilgrastim'}, {'id': 1205, 'therapyName': 'Alemtuzumab'}, {'id': 1642, 'therapyName': 'Leucovorin'}]",Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,1060
21,NCT00167180,Phase II,Completed,"[{'id': 2291, 'therapyName': 'Cyclophosphamide + Fludarabine'}]",Post Transplant Donor Lymphocyte Infusion,1060
22,NCT01174121,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 2291, 'therapyName': 'Cyclophosphamide + Fludarabine'}, {'id': 1167, 'therapyName': 'Aldesleukin'}]",Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer,1060
23,NCT02356159,Phase Ib/II,Recruiting,"[{'id': 2294, 'therapyName': 'Cytarabine + Fludarabine'}, {'id': 2373, 'therapyName': 'Palifermin'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 2238, 'therapyName': 'Sirolimus + Tacrolimus + Methotrexate'}, {'id': 2292, 'therapyName': 'Doxorubicin + Etoposide + Fludarabine + Vincristine '}, {'id': 2291, 'therapyName': 'Cyclophosphamide + Fludarabine'}, {'id': 897, 'therapyName': 'Rituximab'}]",Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation,1060
24,NCT01804634,Phase II,Recruiting,"[{'id': 1373, 'therapyName': 'Cyclophosphamide + Fludarabine + Melphalan + Sirolimus'}]",A Phase II Trial of Reduced Intensity Conditioning and Haploidentical BMT for High-risk Solid Tumors,1060
25,NCT02556931,Phase II,Recruiting,"[{'id': 4228, 'therapyName': 'Cyclophosphamide + Fludarabine + Melphalan + Tacrolimus'}]","Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies",1060
26,NCT02722668,Phase II,Recruiting,"[{'id': 2281, 'therapyName': 'Cyclophosphamide + Fludarabine + Mycophenolate mofetil'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 1844, 'therapyName': 'anti-thymocyte globulin'}]",UCB Transplant for Hematological DIseases Using a Non Myeloablative Prep,1060
27,NCT02423915,Phase Ib/II,Recruiting,"[{'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 2281, 'therapyName': 'Cyclophosphamide + Fludarabine + Mycophenolate mofetil'}, {'id': 917, 'therapyName': 'Sirolimus'}]",Fucosylated T Cells for Graft Versus Host Disease (GVHD) Prevention,1060
28,NCT01203722,Phase Ib/II,Recruiting,"[{'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 2281, 'therapyName': 'Cyclophosphamide + Fludarabine + Mycophenolate mofetil'}]","Reduced Intensity, Partially HLA Mismatched BMT to Treat Hematologic Malignancies",1060
29,NCT02629809,Phase II,Recruiting,"[{'id': 3628, 'therapyName': 'Allopurinol'}, {'id': 3627, 'therapyName': 'Cyclophosphamide + Fludarabine + Obinutuzumab'}, {'id': 768, 'therapyName': 'Ibrutinib'}]","First-line Therapy With Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (GA-101) (iFCG) for Patients With Chronic Lymphocytic Leukemia (CLL)",1060
30,NCT02158091,Phase Ib/II,"Active, not recruiting","[{'id': 2339, 'therapyName': 'Cyclophosphamide + Fludarabine + Rituximab '}, {'id': 1024, 'therapyName': 'Duvelisib'}]","A Phase 1b/2 Study of IPI-145 Plus FCR in Previously Untreated, Younger Patients With CLL",1060
31,NCT03056339,Phase Ib/II,Recruiting,"[{'id': 6217, 'therapyName': 'Cyclophosphamide + Fludarabine phosphate + iC9/CAR.19/IL15-Transduced CB-NK'}]",Umbilical & Cord Blood (CB)- Derived CAR-Engineered NK Cells for B Lymphoid Malignancies,1060
32,NCT02379520,Phase I,Recruiting,"[{'id': 5328, 'therapyName': 'Cyclophosphamide + Fludarabine phosphate + Nivolumab'}]","HPV-16/18 E6/E7-Specific T Lymphocytes, Relapsed HPV-Associated Cancers, HESTIA (HESTIA)",1060
33,NCT03128034,Phase Ib/II,Recruiting,"[{'id': 5714, 'therapyName': 'Cyclosporine + Fludarabine phosphate + Mycophenolate mofetil + Sirolimus'}]","211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome",1060
34,NCT02680951,Phase I,Recruiting,"[{'id': 3731, 'therapyName': 'Cytarabine + Dasatinib + Fludarabine  + Idarubicin'}]",Dasatinib in Combination With Chemotherapy for Relapsed or Refractory Core Binding Factor Acute Myeloid Leukemia,1060
35,NCT02791919,Phase I,Withdrawn,"[{'id': 822, 'therapyName': 'MK-1775'}, {'id': 4271, 'therapyName': 'Cytarabine + Filgrastim + Fludarabine'}]","Wee1 Kinase Inhibitor AZD1775 and Combination Chemotherapy in Treating Children, Adolescents and Young Adults With Relapsed or Refractory Acute Myeloid Leukemia",1060
36,NCT00520130,Phase Ib/II,"Active, not recruiting","[{'id': 2294, 'therapyName': 'Cytarabine + Fludarabine'}, {'id': 2305, 'therapyName': 'Alemtuzumab + Cyclosporine'}, {'id': 2306, 'therapyName': 'Rituximab + Fludarabine + EPOCH'}, {'id': 2307, 'therapyName': 'Fludarabine + EPOCH'}, {'id': 2238, 'therapyName': 'Sirolimus + Tacrolimus + Methotrexate'}, {'id': 1632, 'therapyName': 'Filgrastim'}]",Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,1060
37,NCT02421939,Phase III,Recruiting,"[{'id': 712, 'therapyName': 'Cytarabine'}, {'id': 3193, 'therapyName': 'Cytarabine + Fludarabine + Idarubicin'}, {'id': 1752, 'therapyName': 'Mitoxantrone + Etoposide + Cytarabine'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 2865, 'therapyName': 'Gilteritinib'}, {'id': 1632, 'therapyName': 'Filgrastim'}]",A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,1060
38,NCT02039726,Phase III,"Active, not recruiting","[{'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 3193, 'therapyName': 'Cytarabine + Fludarabine + Idarubicin'}, {'id': 1752, 'therapyName': 'Mitoxantrone + Etoposide + Cytarabine'}, {'id': 882, 'therapyName': 'Quizartinib'}]",An Open-label Study of Quizartinib Monotherapy vs. Salvage Chemotherapy in Acute Myeloid Leukemia (AML) Subjects,1060
39,NCT02676323,Phase Ib/II,Recruiting,"[{'id': 3732, 'therapyName': 'Cytarabine + Fludarabine + Leucovorin + Panobinostat'}]",Panobinostat With Fludarabine and Cytarabine for Treatment of Children With Acute Myeloid Leukemia or Myelodysplastic Syndrome,1060
40,NCT02649764,Phase I,Recruiting,"[{'id': 3535, 'therapyName': 'Cytarabine + Fludarabine + Prexasertib'}]",LY2606368 in Combination With Cytarabine and Fludarabine in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HRMDS),1060
41,NCT01173679,Phase II,Terminated,"[{'id': 1821, 'therapyName': 'Dasatinib + Rituximab + Fludarabine'}]",Dasatinib With Fludarabine and Rituximab in Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL),1060
42,NCT00084695,Phase II,Unknown status,"[{'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 2558, 'therapyName': 'Busulfan + Melphalan'}, {'id': 1844, 'therapyName': 'anti-thymocyte globulin'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 2188, 'therapyName': 'Prednisone'}]",Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases,1060
43,NCT03164057,Phase II,Recruiting,"[{'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 5153, 'therapyName': 'dexrazoxane'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 651, 'therapyName': 'Azacitidine'}]",A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia,1060
44,NCT00902044,Phase I,Recruiting,"[{'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 2940, 'therapyName': 'HER2 sensitized T-cells'}]",Her2 Chimeric Antigen Receptor Expressing T Cells in Advanced Sarcoma,1060
45,NCT03214562,,Recruiting,"[{'id': 1562, 'therapyName': 'Venetoclax'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 712, 'therapyName': 'Cytarabine'}]",Study of the BCL-2 Inhibitor Venetoclax in Combination With Standard Intensive Acute Myeloid Leukemia (AML) Induction/Consolidation Therapy With FLAG-IDA in Patients With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia (AML),1060
46,NCT01625351,Phase I,"Active, not recruiting","[{'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1205, 'therapyName': 'Alemtuzumab'}]",A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas,1060
47,NCT01822652,Phase I,"Active, not recruiting","[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]","3rd Generation GD-2 Chimeric Antigen Receptor and iCaspase Suicide Safety Switch, Neuroblastoma, GRAIN",1060
48,NCT02412475,Phase I,"Active, not recruiting","[{'id': 712, 'therapyName': 'Cytarabine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 650, 'therapyName': 'Decitabine'}]",Epigenetic Reprogramming in Relapse AML,1060
49,NCT01231412,Phase III,"Active, not recruiting","[{'id': 917, 'therapyName': 'Sirolimus'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 2272, 'therapyName': 'Cyclosporine + Mycophenolate mofetil'}]",Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant,1060
50,NCT02251821,Phase II,Recruiting,"[{'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 1845, 'therapyName': 'Mycophenolate mofetil'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 2006, 'therapyName': 'Pacritinib'}, {'id': 823, 'therapyName': 'Momelotinib'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}]",JAK-2 Inhibitor Before Donor Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis,1060
51,NCT01218867,Phase Ib/II,Completed,"[{'id': 984, 'therapyName': 'Anti-VEGFR2 CAR CD8 lymphocytes'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1167, 'therapyName': 'Aldesleukin'}]",Treating Metastatic Cancer With Anti-VEGFR2 Gene Engineered CD8+ Lymphocytes,1060
52,NCT02621021,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1167, 'therapyName': 'Aldesleukin'}]",A Prospective Randomized and Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab,1060
53,NCT03215810,,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1166, 'therapyName': 'Fludarabine'}]",Nivolumab and Tumor Infiltrating Lymphocytes (TIL) in Advanced Non-Small Cell Lung Cancer,1060
54,NCT01993719,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1167, 'therapyName': 'Aldesleukin'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}]",Immunotherapy Using Tumor Infiltrating Lymphocytes Comparing 2 Different Conditioning Regimens for Patients With Metastatic Melanoma,1060
55,NCT02551718,Phase I,Recruiting,"[{'id': 690, 'therapyName': 'Bosutinib'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 3160, 'therapyName': 'Nelarabine'}, {'id': 3159, 'therapyName': 'Bexarotene'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 998, 'therapyName': 'cabozantinib'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 877, 'therapyName': 'Ponatinib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 623, 'therapyName': 'Afatinib'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 890, 'therapyName': 'Regorafenib'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 2, 'therapyName': 'Trametinib'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 3, 'therapyName': 'Dabrafenib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 789, 'therapyName': 'Ceritinib'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1571, 'therapyName': 'Cabazitaxel'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1327, 'therapyName': 'Pralatrexate'}]",High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia,1060
56,NCT02181478,Phase I,Recruiting,"[{'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}]",Intra-Osseous Co-Transplant of UCB and hMSC,1060
57,NCT02118311,Phase II,Withdrawn,"[{'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}]",T Regulatory Cell for Suppression of Acute Graft-vs-Host-Disease After a Non-Myeloablative Umbilical Cord Blood Transplantation,1060
58,NCT02790515,Phase II,Recruiting,"[{'id': 917, 'therapyName': 'Sirolimus'}, {'id': 1844, 'therapyName': 'anti-thymocyte globulin'}, {'id': 1876, 'therapyName': 'Blinatumomab '}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 5682, 'therapyName': 'Mesna'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1632, 'therapyName': 'Filgrastim'}]",Provision of TCR?? T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation,1060
59,NCT03263936,Phase I,Recruiting,"[{'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1632, 'therapyName': 'Filgrastim'}]",Epigenetic Reprogramming in Relapse/Refractory AML,1060
60,NCT00305682,Phase II,Recruiting,"[{'id': 917, 'therapyName': 'Sirolimus'}, {'id': 1845, 'therapyName': 'Mycophenolate mofetil'}, {'id': 1844, 'therapyName': 'anti-thymocyte globulin'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1166, 'therapyName': 'Fludarabine'}]",Non-Myeloablative Conditioning for Unrelated Donor Umbilical Cord Blood Transplant,1060
61,NCT02212561,Phase Ib/II,Completed,"[{'id': 1749, 'therapyName': 'Selinexor'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 2345, 'therapyName': 'Cytarabine + Dexamethasone+ Methotrexate '}, {'id': 1166, 'therapyName': 'Fludarabine'}]",Selinexor With Fludarabine and Cytarabine for Treatment of Refractory or Relapsed Leukemia or Myelodysplastic Syndrome,1060
62,NCT02118285,Phase I,Completed,"[{'id': 1167, 'therapyName': 'Aldesleukin'}, {'id': 2575, 'therapyName': 'Epacadostat'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1166, 'therapyName': 'Fludarabine'}]","Intraperitoneal Natural Killer Cells and INCB024360 for Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer",1060
63,NCT00074490,Phase II,Completed,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1650, 'therapyName': 'Cyclosporine'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1166, 'therapyName': 'Fludarabine'}]",Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,1060
64,NCT02756572,Phase I,Recruiting,"[{'id': 917, 'therapyName': 'Sirolimus'}, {'id': 1845, 'therapyName': 'Mycophenolate mofetil'}, {'id': 1650, 'therapyName': 'Cyclosporine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 5215, 'therapyName': 'mitoxantrone hydrochloride'}, {'id': 1166, 'therapyName': 'Fludarabine'}]",Early Allogeneic Hematopoietic Cell Transplantation in Treating Patients With Relapsed or Refractory High-Grade Myelodysplastic Syndrome or Acute Myeloid Leukemia,1060
65,NCT01312376,Phase I,"Active, not recruiting","[{'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1227, 'therapyName': 'CD3/CD28 costimulated vaccine-primed autologous T-cells'}, {'id': 1222, 'therapyName': 'OC-DC vaccine'}]",Autologous T-Cells Combined With Autologous OC-DC Vaccine in Ovarian Cancer,1060
66,NCT02472392,Phase I,Completed,"[{'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1844, 'therapyName': 'anti-thymocyte globulin'}]",Study To Examine Toxicity Of Allogeneic Stem Cell Transplantation For Relapsed Or Therapy Refractory Ewings Sarcoma,1060
67,NCT01707004,Phase I,"Active, not recruiting","[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1206, 'therapyName': 'Busulfan'}]",Decitabine and Total-Body Irradiation Followed By Donor Bone Marrow Transplant and Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia,1060
68,NCT01659151,Phase II,"Active, not recruiting","[{'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 342, 'therapyName': 'Vemurafenib'}]", Vemurafenib With Lymphodepletion Plus Adoptive Cell Transfer &amp; High Dose IL-2 Metastatic Melanoma,1060
69,NCT03190941,Phase I,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 6061, 'therapyName': 'anti-KRAS G12V mTCR cells'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1167, 'therapyName': 'Aldesleukin'}]",Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*1101 Patients,1060
70,NCT01529827,Phase II,"Active, not recruiting","[{'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 1845, 'therapyName': 'Mycophenolate mofetil'}, {'id': 1166, 'therapyName': 'Fludarabine'}]","Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies",1060
71,NCT02793544,Phase II,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 1845, 'therapyName': 'Mycophenolate mofetil'}, {'id': 5682, 'therapyName': 'Mesna'}, {'id': 1166, 'therapyName': 'Fludarabine'}]",HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide,1060
72,NCT01251575,Phase II,Recruiting,"[{'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 2270, 'therapyName': 'Cyclosporine + Mycophenolate mofetil + Sirolimus'}]","Sirolimus, Cyclosporine, and Mycophenolate Mofetil In Preventing Graft-Versus-Host Disease in Treating Patients With Hematologic Malignancies Undergoing Donor Peripheral Blood Stem Cell Transplant",1060
73,NCT02788201,Phase II,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1133, 'therapyName': 'Mitomycin C'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1013, 'therapyName': 'epirubicin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1137, 'therapyName': 'Bleomycin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 781, 'therapyName': 'Ixabepilone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 2950, 'therapyName': 'Estramustine'}, {'id': 1941, 'therapyName': 'Floxuridine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 1811, 'therapyName': 'Carmustine'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 953, 'therapyName': 'Vandetanib'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 4419, 'therapyName': 'Toremifine'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 2601, 'therapyName': 'Dactinomycin'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 3035, 'therapyName': 'Chlorambucil'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 342, 'therapyName': 'Vemurafenib'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 2635, 'therapyName': 'Vinblastine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 4305, 'therapyName': 'Teniposide'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 4304, 'therapyName': 'Streptozocin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1231, 'therapyName': 'Bendamustine'}, {'id': 4303, 'therapyName': 'Mechlorethamine'}, {'id': 4302, 'therapyName': 'Mitotane'}]",Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma,1060
74,NCT02514083,Phase II,Recruiting,"[{'id': 3633, 'therapyName': 'Fludarabine + Ibrutinib'}]",A Phase II Study Using Ibrutinib and Short-Course Fludarabine in Previously Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL),1060
75,NCT03204188,Phase II,Recruiting,"[{'id': 6154, 'therapyName': 'Fludarabine + Ibrutinib + Pembrolizumab'}]","Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma",1060
76,NCT01453101,Phase II,"Active, not recruiting","[{'id': 2237, 'therapyName': 'Fludarabine + Melphalan'}, {'id': 688, 'therapyName': 'Bortezomib'}]",Allogeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma,1060
77,NCT02771197,Phase II,Recruiting,"[{'id': 2237, 'therapyName': 'Fludarabine + Melphalan'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Lymphodepletion and Anti-PD-1 Blockade to Reduce Relapse in AML Patient Not Eligible for Transplant,1060
78,NCT02440464,Phase II,Recruiting,"[{'id': 3321, 'therapyName': 'Tacrolimus + Methotrexate'}, {'id': 1359, 'therapyName': 'Ixazomib'}, {'id': 2237, 'therapyName': 'Fludarabine + Melphalan'}, {'id': 688, 'therapyName': 'Bortezomib'}]",Allogeneic Hematopoietic Stem Cell Transplantation With Ixazomib for High Risk Multiple Myeloma (BMT CTN 1302),1060
79,NCT02508038,Phase I,Recruiting,"[{'id': 2971, 'therapyName': 'Zoledronic acid'}, {'id': 2237, 'therapyName': 'Fludarabine + Melphalan'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 1844, 'therapyName': 'anti-thymocyte globulin'}, {'id': 1845, 'therapyName': 'Mycophenolate mofetil'}]", Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa,1060
80,NCT02528877,Phase I,Withdrawn,"[{'id': 2237, 'therapyName': 'Fludarabine + Melphalan'}, {'id': 3181, 'therapyName': 'Ruxolitinib + Sirolimus + Tacrolimus'}]","Ruxolitinib Phosphate, Tacrolimus and Sirolimus in Preventing Acute Graft-versus-Host Disease During Reduced Intensity Donor Hematopoietic Cell Transplant in Patients With Myelofibrosis",1060
81,NCT02333162,Phase I,Recruiting,"[{'id': 1845, 'therapyName': 'Mycophenolate mofetil'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 2237, 'therapyName': 'Fludarabine + Melphalan'}]","Intensity Modulated Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients With Relapsed Hematologic Cancers Undergoing a Second Donor Stem Cell Transplant",1060
82,NCT00577278,Phase II,"Active, not recruiting","[{'id': 767, 'therapyName': 'Ibritumomab'}, {'id': 2238, 'therapyName': 'Sirolimus + Tacrolimus + Methotrexate'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 2237, 'therapyName': 'Fludarabine + Melphalan'}]","Yttrium Y 90 Ibritumomab Tiuxetan, Rituximab, Indium In-111 Ibritumomab Tiuxetan, Fludarabine, Melphalan, and Donor Stem Cell Transplant in Treating Patients With B-Cell Non-Hodgkin Lymphoma",1060
83,NCT02653196,Phase II,Terminated,"[{'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1205, 'therapyName': 'Alemtuzumab'}, {'id': 2373, 'therapyName': 'Palifermin'}, {'id': 2237, 'therapyName': 'Fludarabine + Melphalan'}, {'id': 3948, 'therapyName': 'Cyclosporine + Mycophenolate mofetil + Tacrolimus'}]",A Multi-Institutional Phase II Feasibility Study of Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Malignant Neuro-Epithelial and Other Solid Tumors,1060
84,NCT01760655,Phase II,Recruiting,"[{'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 1842, 'therapyName': 'Fludarabine + Thiotepa + Cyclophosphamide'}, {'id': 1845, 'therapyName': 'Mycophenolate mofetil'}]",Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies,1060
85,NCT02251548,Phase II,Recruiting,"[{'id': 2185, 'therapyName': 'Ibrutinib + Rituximab + Cyclophosphamide + Fludarabine'}]","A Phase II Study of Ibrutinib Plus FCR in Previously Untreated, Younger Patients With Chronic Lymphocytic Leukemia",1060
86,NCT03153462,Expanded access,Available,"[{'id': 5098, 'therapyName': 'KTE-C19 + Fludarabine phosphate + Cyclophosphamide'}]",Axicabtagene Ciloleucel Expanded Access Study,1060
87,NCT02601313,Phase II,Recruiting,"[{'id': 5098, 'therapyName': 'KTE-C19 + Fludarabine phosphate + Cyclophosphamide'}]",A Phase 2 Multicenter Study Evaluating Subjects With Relapsed/Refractory Mantle Cell Lymphoma (ZUMA-2),1060
88,NCT01619761,Phase I,Recruiting,"[{'id': 897, 'therapyName': 'Rituximab'}, {'id': 1847, 'therapyName': 'lenalidomide + Fludarabine + Melphalan'}, {'id': 1845, 'therapyName': 'Mycophenolate mofetil'}, {'id': 1843, 'therapyName': 'Tacrolimus'}]",Natural Killer (NK) Cells in Cord Blood Transplantation,1060
89,NCT03071276,Phase II,Recruiting,"[{'id': 5448, 'therapyName': 'Selinexor + Fludarabine phosphate + Cytarabine + Methotrexate + Prednisone'}]",Selinexor in Combination With Fludarabine and Cytarabine in Patients With Refractory or Relapsed Acute Myeloid Leukemia,1060
0,NCT03050814,Phase II,Suspended,"[{'id': 1524, 'therapyName': 'Fluorouracil + Bevacizumab + Capecitabine + Leucovorin + Oxaliplatin'}, {'id': 5336, 'therapyName': 'Ad-CEA + Bevacizumab + FOLFOX'}]",Standard of Care Alone or in Combination With Ad-CEA Vaccine and Avelumab in People With Previously Untreated Metastatic Colorectal Cancer,534
1,NCT01571284,Phase III,Completed,"[{'id': 2095, 'therapyName': 'Aflibercept + FOLFIRI'}]",Safety and Quality of Life Study of Aflibercept in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen,534
2,NCT02045030,Phase II,Terminated,"[{'id': 2095, 'therapyName': 'Aflibercept + FOLFIRI'}]",Study to Identify Biomarkers of Clinical Response to Aflibercept in Patients With Metastatic Colorectal Cancer,534
3,NCT02235324,Phase II,Withdrawn,"[{'id': 1841, 'therapyName': 'Aflibercept + Leucovorin + Fluorouracil'}, {'id': 624, 'therapyName': 'Aflibercept'}]","Ziv-Aflibercept Followed by Ziv-Aflibercept, Fluorouracil, and Leucovorin Calcium in Treating Patients With Stage IV Colorectal Cancer",534
4,NCT01652196,Phase II,"Active, not recruiting","[{'id': 2367, 'therapyName': 'Aflibercept + mFOLFOX-6'}]",Aflibercept and FOLFOX6 Treatment for Previously Untreated Stage IV Colorectal Cancer,534
5,NCT02923921,Phase III,Recruiting,"[{'id': 5849, 'therapyName': 'AM0010 + mFOLFOX-6'}, {'id': 5850, 'therapyName': 'mFOLFOX-6'}]",Study of AM0010 With FOLFOX Compared to FOLFOX Alone Second-line Tx in Pts With Metastatic Pancreatic Cancer,534
6,NCT02997228,Phase III,Not yet recruiting,"[{'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 1484, 'therapyName': 'Bevacizumab + Oxaliplatin + Leucovorin + Fluorouracil'}, {'id': 5126, 'therapyName': 'Bevacizumab + Atezolizumab + Fluorouracil + Leucovorin + Oxaliplatin'}]","Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Microsatellite Instability-High Metastatic Colorectal Cancer",534
7,NCT02141295,Phase II,Completed,"[{'id': 1484, 'therapyName': 'Bevacizumab + Oxaliplatin + Leucovorin + Fluorouracil'}, {'id': 1598, 'therapyName': 'RO5520985'}, {'id': 1599, 'therapyName': 'Bevacizumab + Fluorouracil + Leucovorin'}, {'id': 1600, 'therapyName': 'RO5520985 + Leucovorin + Fluorouracil'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}]",A Study Comparing the Efficacy and Safety of RO5520985 and FOLFOX With Bevacizumab and FOLFOX in Patients With Untreated Metastatic Colorectal Cancer (McCAVE),534
8,NCT00602602,Phase II,"Active, not recruiting","[{'id': 2102, 'therapyName': 'Bevacizumab + Fluorouracil + Oxaliplatin'}, {'id': 1296, 'therapyName': 'Gemcitabine + Bevacizumab + Oxaliplatin'}, {'id': 1297, 'therapyName': 'Gemcitabine + Bevacizumab'}]","Bevacizumab, Combination Chemotherapy, and Radiation Therapy in Treating Patients Undergoing Surgery For Locally Advanced Pancreatic Cancer",534
9,NCT01442935,Phase II,"Active, not recruiting","[{'id': 1484, 'therapyName': 'Bevacizumab + Oxaliplatin + Leucovorin + Fluorouracil'}, {'id': 2180, 'therapyName': 'Cetuximab + FOLFIRI'}, {'id': 2181, 'therapyName': 'Bevacizumab + FOLFIRI'}, {'id': 2182, 'therapyName': 'Cetuximab + FOLFOX'}, {'id': 2183, 'therapyName': 'Bevacizumab + FOLFIRINOX'}, {'id': 2184, 'therapyName': 'Cetuximab + FOLFIRINOX'}]",Chemotherapies Associated With Targeted Therapies on the Resection Rate of Hepatic Metastases,534
10,NCT02754856,Phase I,Recruiting,"[{'id': 4097, 'therapyName': 'Bevacizumab + MEDI4736 + Tremelimumab + FOLFOX'}]",Tremelimumab (Anti-CTLA-4) Plus MEDI4736 (Anti-PD-L1) in Resectable Colorectal Cancer Liver Metastases.,534
11,NCT01871571,Phase II,Recruiting,"[{'id': 1484, 'therapyName': 'Bevacizumab + Oxaliplatin + Leucovorin + Fluorouracil'}]","Bevacizumab, Fluorouracil, Leucovorin Calcium, and Oxaliplatin Before Surgery in Treating Patients With Stage II-III Rectal Cancer",534
12,NCT01212822,Phase II,"Active, not recruiting","[{'id': 1484, 'therapyName': 'Bevacizumab + Oxaliplatin + Leucovorin + Fluorouracil'}]",Bevacizumab and Combination Chemotherapy Before Surgery in Treating Patients With Locally Advanced Esophageal or Stomach Cancer,534
13,NCT01006369,Phase II,Completed,"[{'id': 1316, 'therapyName': 'Hydroxychloroquine'}, {'id': 1601, 'therapyName': 'Capecitabine + Oxaliplatin + Bevacizumab'}, {'id': 1484, 'therapyName': 'Bevacizumab + Oxaliplatin + Leucovorin + Fluorouracil'}]","Hydroxychloroquine, Capecitabine, Oxaliplatin, and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer",534
14,NCT01622543,Phase II,"Active, not recruiting","[{'id': 1484, 'therapyName': 'Bevacizumab + Oxaliplatin + Leucovorin + Fluorouracil'}, {'id': 893, 'therapyName': 'Reolysin'}]",Reolysin in Combination With FOLFOX6 and Bevacizumab or FOLFOX6 and Bevacizumab Alone in Metastatic Colorectal Cancer,534
15,NCT01765582,Phase II,Terminated,"[{'id': 1523, 'therapyName': 'Fluorouracil + Capecitabine + Irinotecan + Leucovorin + Oxaliplatin'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1484, 'therapyName': 'Bevacizumab + Oxaliplatin + Leucovorin + Fluorouracil'}]",STEAM: A Study of Sequential and Concurrent FOLFOXIRI/Avastin (Bevacizumab) Regimens Versus FOLFOX/Avastin in First-Line in Patients With Metastatic Colorectal Cancer,534
16,NCT02575508,Phase Ib/II,Withdrawn,"[{'id': 3142, 'therapyName': 'BGJ398 + Fluorouracil + Irinotecan + Oxaliplatin'}]",Pan FGFR Kinase Inhibitor BGJ398 and Combination Chemotherapy in Treating Patients With Untreated Metastatic Pancreatic Cancer,534
17,NCT02613650,Phase I,Recruiting,"[{'id': 3247, 'therapyName': 'Binimetinib + FOLFIRI'}]",A Trial of FOLFIRI With MEK162 in Patients With Advanced KRAS Positive Metastatic Colorectal Cancers,534
18,NCT03184870,Phase Ib/II,Recruiting,"[{'id': 5905, 'therapyName': 'BMS-813160 + Fluorouracil + Irinotecan + Leucovorin'}, {'id': 5903, 'therapyName': 'BMS-813160 + Nivolumab'}, {'id': 5904, 'therapyName': 'BMS-813160 + Gemcitabine + nab-paclitaxel'}, {'id': 5902, 'therapyName': 'BMS-813160'}]",A Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Patients With Advanced Solid Tumors,534
19,NCT02199236,Phase I,Recruiting,"[{'id': 1619, 'therapyName': 'Capecitabine + Fluorouracil'}]",Dose Escalation Trial of Endoluminal High-Dose-Rate Brachytherapy With Concurrent Chemotherapy for Rectal or Anal Cancer in Patients With Recurrent Disease or Undergoing Non-Operative Management,534
20,NCT01774786,Phase III,"Active, not recruiting","[{'id': 856, 'therapyName': 'Pertuzumab'}, {'id': 1894, 'therapyName': 'Capecitabine + Fluorouracil + Cisplatin + Trastuzumab'}]",A Study of Perjeta (Pertuzumab) in Combination With Herceptin (Trastuzumab) and Chemotherapy in Patients With HER2-Positive Metastatic Gastroesophageal Junction or Gastric Cancer,534
21,NCT02004262,Phase II,Completed,"[{'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 2383, 'therapyName': 'Capecitabine + Fluorouracil + Gemcitabine '}]",Safety and Efficacy of Combination Listeria/GVAX Pancreas Vaccine in the Pancreatic Cancer Setting,534
22,NCT02741570,Phase III,Recruiting,"[{'id': 4168, 'therapyName': 'Carboplatin + Cetuximab + Cisplatin + Fluorouracil'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care (Extreme Study Regimen) as First Line Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck,534
23,NCT00588770,Phase III,"Active, not recruiting","[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1835, 'therapyName': 'Docetaxel + Cisplatin'}, {'id': 1833, 'therapyName': 'Cisplatin + Fluorouracil'}, {'id': 1834, 'therapyName': 'Docetaxel + Carboplatin'}, {'id': 1832, 'therapyName': 'Carboplatin + Fluorouracil\t'}]",Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer,534
24,NCT01183559,Phase I,Unknown status,"[{'id': 2071, 'therapyName': 'Carboplatin + Fluorouracil + Paclitaxel + Vandetanib'}]","A Trial of ZD6474 (Zactima), Paclitaxel, Carboplatin, 5-Fluorouracil, and XRT Followed by Surgery",534
25,NCT02551159,Phase III,"Active, not recruiting","[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 1914, 'therapyName': 'Cetuximab + Carboplatin + Fluorouracil'}, {'id': 1652, 'therapyName': 'Tremelimumab'}]",Phase III Open Label First Line Therapy Study of MEDI 4736 With or Without Tremelimumab Versus Standard of Care (SOC) in SCCHN,534
26,NCT01063075,Phase II,Completed,"[{'id': 1914, 'therapyName': 'Cetuximab + Carboplatin + Fluorouracil'}]",A Study in Advanced Solid Tumors,534
27,NCT00316888,Phase II,"Active, not recruiting","[{'id': 1928, 'therapyName': 'Cetuximab + Cisplatin + Fluorouracil + Radiotherapy'}]","Cetuximab, Cisplatin, Fluorouracil, and Radiation Therapy in Treating Patients With Stage I, Stage II, or Stage III Anal Cancer",534
28,NCT03109158,Phase Ib/II,Recruiting,"[{'id': 5578, 'therapyName': 'Cetuximab + Fluorouracil + NC-6004'}]",NC-6004 With 5-FU and Cetuximab for Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck,534
29,NCT02573220,Phase I,Withdrawn,"[{'id': 2180, 'therapyName': 'Cetuximab + FOLFIRI'}]",Irinotecan Hydrochloride With FOLFIRI and Cetuximab as First-Line Therapy in Treating Patients With RAS Wild-Type Colorectal Cancer,534
30,NCT02928224,Phase III,Recruiting,"[{'id': 1916, 'therapyName': 'Cetuximab + Encorafenib'}, {'id': 4886, 'therapyName': 'Binimetinib + Cetuximab + LGX818'}, {'id': 1874, 'therapyName': 'Cetuximab + Irinotecan'}, {'id': 2180, 'therapyName': 'Cetuximab + FOLFIRI'}]",Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer (BEACON CRC),534
31,NCT01703390,Phase II,Unknown status,"[{'id': 2182, 'therapyName': 'Cetuximab + FOLFOX'}, {'id': 2180, 'therapyName': 'Cetuximab + FOLFIRI'}]",Biomarker Directed Treatment in Metastatic Colorectal Cancer,534
32,NCT01467115,Phase II,Completed,"[{'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 1930, 'therapyName': 'Cisplatin + Docetaxel + Fluorouracil'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 694, 'therapyName': 'Cetuximab'}]",INDUCTION CHEMOTHERAPY FOLLOWED BY CETUXIMAB AND RADIATION THERAPY FOR HEAD AND NECK CANCER,534
33,NCT01914900,Phase II,Unknown status,"[{'id': 1930, 'therapyName': 'Cisplatin + Docetaxel + Fluorouracil'}]",Preoperative TPF Chemotherapy in a Population of Molecularly Selected Locally Advanced Resectable Oral Cavity Squamous Cell Cancer,534
34,NCT03288350,Phase II,Not yet recruiting,"[{'id': 1930, 'therapyName': 'Cisplatin + Docetaxel + Fluorouracil'}, {'id': 3144, 'therapyName': 'Avelumab'}]",mDCF + Avelumab in Resectable Esophago-gastric Adenocarcinoma (EGA),534
35,NCT03189719,Phase III,Recruiting,"[{'id': 1833, 'therapyName': 'Cisplatin + Fluorouracil'}, {'id': 6051, 'therapyName': 'Cisplatin + Fluorouracil + Pembrolizumab'}]",First-line Esophageal Carcinoma Study With Chemo vs. Chemo Plus Pembrolizumab (MK-3475-590/KEYNOTE-590),534
36,NCT03143153,Phase III,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}, {'id': 1833, 'therapyName': 'Cisplatin + Fluorouracil'}, {'id': 5799, 'therapyName': 'Nivolumab + Cisplatin + Fluorouacil'}]",A Study to Evaluate Efficacy in Subjects With Esophageal Cancer Treated With Nivolumab and Ipilimumab or Nivolumab Combined With Fluorouracil Plus Cisplatin Versus Fluorouracil Plus Cisplatin (CheckMate 648),534
37,NCT02494583,Phase III,"Active, not recruiting","[{'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 1833, 'therapyName': 'Cisplatin + Fluorouracil'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Study of Pembrolizumab (MK-3475) as First-Line Monotherapy and Combination Therapy for Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-062/KEYNOTE-062),534
38,NCT02335411,Phase II,"Active, not recruiting","[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1833, 'therapyName': 'Cisplatin + Fluorouracil'}]",A Study of Pembrolizumab (MK-3475) in Participants With Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-059/KEYNOTE-059),534
39,NCT02051868,Phase II,Recruiting,"[{'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 1833, 'therapyName': 'Cisplatin + Fluorouracil'}]",International Multicentre Study in Advanced Anal Cancer Comparing Cisplatin Plus 5 FU vs Carboplatin Plus Weekly Paclitaxel (InterAACT),534
40,NCT03221426,Phase III,Recruiting,"[{'id': 3999, 'therapyName': 'Capecitabine + Cisplatin'}, {'id': 6050, 'therapyName': 'Capecitabine + Cisplatin + Pembrolizumab'}, {'id': 6051, 'therapyName': 'Cisplatin + Fluorouracil + Pembrolizumab'}, {'id': 1833, 'therapyName': 'Cisplatin + Fluorouracil'}]",Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585),534
41,NCT01711541,Phase Ib/II,Suspended,"[{'id': 1544, 'therapyName': 'Carboplatin + Etoposide + Veliparib'}, {'id': 1849, 'therapyName': 'Cisplatin + Fluorouracil + Hydroxyurea'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]",Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IV Head and Neck Cancer,534
42,NCT00980460,Phase III,Recruiting,"[{'id': 2298, 'therapyName': 'Irinotecan + Temsirolimus + Vincristine'}, {'id': 2297, 'therapyName': 'Cisplatin + Fluorouracil + Vincristine'}, {'id': 1009, 'therapyName': 'Doxorubicin'}]",Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer,534
43,NCT02132949,Phase II,"Active, not recruiting","[{'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}, {'id': 1495, 'therapyName': 'Paclitaxel + Doxorubicin + Cyclophosphamide'}, {'id': 1895, 'therapyName': 'Cyclophosphamide + Fluorouracil + Docetaxel + Epirubicin  '}]","A Study Evaluating Perjeta (Pertuzumab) Combined With Herceptin (Trastuzumab) and Standard Anthracycline-based Chemotherapy in Patients With HER2-positive Locally Advanced, Inflammatory, or Early-stage Breast Cancer.",534
44,NCT03107182,Phase II,Recruiting,"[{'id': 5581, 'therapyName': 'Dexamethasone + Diphenhydramine + Famotidine + 5FU + Hydroxyurea + Paclitaxel'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 5303, 'therapyName': 'Nivolumab + Carboplatin + Paclitaxel'}]",Oropharyngeal Tumor Induction Chemotherapy and Response-stratified Locoregional Therapy Trial in Order to Minimize Long-term Adverse Events,534
45,NCT03152370,Phase I,Recruiting,"[{'id': 5798, 'therapyName': 'E7046 + mFOLFOX-6'}, {'id': 5805, 'therapyName': 'Capecitabine + E7046'}]",Preoperative Radiotherapy and E7046 in Rectum Cancer (PRAER 1),534
46,NCT02620800,Phase Ib/II,Recruiting,"[{'id': 3621, 'therapyName': 'FABLOx'}]","Study of 5-fluorouracil (5-FU), Nab-paclitaxel, Bevacizumab, Leucovorin, and Oxaliplatin in Patients With Metastatic Pancreatic Cancer",534
47,NCT03069950,Phase II,Recruiting,"[{'id': 5476, 'therapyName': 'Floxiuridine + Panitumumab + Dexamethasone + FOLFIRI'}]",Study of Chemotherapy With or Without Hepatic Arterial Infusion for Patients With Unresectable Metastatic Colorectal Cancer to the Liver,534
48,NCT02083653,Phase II,"Active, not recruiting","[{'id': 931, 'therapyName': 'SYM004'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1105, 'therapyName': 'Capecitabine'}]",Sym004 vs Standard of Care in Subjects With Metastatic Colorectal Cancer,534
49,NCT02620423,Phase I,"Active, not recruiting","[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 893, 'therapyName': 'Reolysin'}, {'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Study of Pembrolizumab With REOLYSIN and Chemotherapy in Patients With Advanced Pancreatic Adenocarcinoma,534
50,NCT02314117,Phase III,"Active, not recruiting","[{'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 886, 'therapyName': 'Ramucirumab'}]",A Study of Ramucirumab (LY3009806) in Combination With Capecitabine and Cisplatin in Participants With Stomach Cancer,534
51,NCT01750918,Phase II,"Active, not recruiting","[{'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1718, 'therapyName': 'Panitumumab + Dabrafenib'}, {'id': 1992, 'therapyName': 'Panitumumab + Trametinib + Dabrafenib'}, {'id': 1991, 'therapyName': 'Panitumumab + Trametinib'}]",BRAF/MEK/EGFR Inhibitor Combination Study in Colorectal Cancer (CRC),534
52,NCT02358031,Phase III,"Active, not recruiting","[{'id': 694, 'therapyName': 'Cetuximab'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 700, 'therapyName': 'Cisplatin'}]",A Study of Pembrolizumab (MK-3475) for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (MK-3475-048/KEYNOTE-048),534
53,NCT01128387,Phase Ib/II,Completed,"[{'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 845, 'therapyName': 'Panitumumab'}, {'id': 700, 'therapyName': 'Cisplatin'}]",Trial of Panitumumab/Cisplatin/Fluorouracil With XRT in Esophageal Cancer,534
54,NCT01775501,Phase II,Recruiting,"[{'id': 920, 'therapyName': 'Sorafenib'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 1642, 'therapyName': 'Leucovorin'}]",Sorafenib + mFOLFOX for Hepatocellular Carcinoma,534
55,NCT02138617,Phase II,Recruiting,"[{'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 1715, 'therapyName': 'Fluorouracil'}]",Genotype-Directed Study Of Irinotecan Dosing In FOLFIRI + BevacizumabTreated Metastatic Colorectal Cancer,534
56,NCT02788201,Phase II,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1133, 'therapyName': 'Mitomycin C'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1013, 'therapyName': 'epirubicin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1137, 'therapyName': 'Bleomycin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 781, 'therapyName': 'Ixabepilone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 2950, 'therapyName': 'Estramustine'}, {'id': 1941, 'therapyName': 'Floxuridine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 1811, 'therapyName': 'Carmustine'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 953, 'therapyName': 'Vandetanib'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 4419, 'therapyName': 'Toremifine'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 2601, 'therapyName': 'Dactinomycin'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 3035, 'therapyName': 'Chlorambucil'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 342, 'therapyName': 'Vemurafenib'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 2635, 'therapyName': 'Vinblastine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 4305, 'therapyName': 'Teniposide'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 4304, 'therapyName': 'Streptozocin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1231, 'therapyName': 'Bendamustine'}, {'id': 4303, 'therapyName': 'Mechlorethamine'}, {'id': 4302, 'therapyName': 'Mitotane'}]",Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma,534
57,NCT02688712,Phase II,Recruiting,"[{'id': 5788, 'therapyName': 'Capecitabine + Galunisertib'}, {'id': 5789, 'therapyName': 'Fluorouracil + Galunisertib'}, {'id': 2409, 'therapyName': 'Galunisertib'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1105, 'therapyName': 'Capecitabine'}]",ExIST Study of LY2157299 (Galunisertib) in Rectal Cancer,534
58,NCT01099358,Phase II,Completed,"[{'id': 1915, 'therapyName': 'Cetuximab + Cisplatin'}, {'id': 1715, 'therapyName': 'Fluorouracil'}]",Study in Advanced Solid Tumors,534
59,NCT03136406,Phase Ib/II,Recruiting,"[{'id': 1018, 'therapyName': 'GI-4000'}, {'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 3144, 'therapyName': 'Avelumab'}, {'id': 619, 'therapyName': 'Abraxane'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 6163, 'therapyName': 'ETBX-011'}, {'id': 3060, 'therapyName': 'ALT-803'}]",QUILT-3.039: NANT Pancreatic Cancer Vaccine: Combination Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy,534
60,NCT01836029,Phase II,"Active, not recruiting","[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 2000, 'therapyName': 'Fluorouracil + Cetuximab'}, {'id': 1092, 'therapyName': 'Carboplatin'}]",Chemotherapy Plus Cetuximab in Combination With VTX-2337 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck,534
61,NCT01501487,FDA approved,"Active, not recruiting","[{'id': 1902, 'therapyName': 'Docetaxel + Doxorubicin + Cyclophosphamide'}, {'id': 1982, 'therapyName': 'Fluorouracil + Epirubicin + Cyclophosphamide'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1476, 'therapyName': 'Pegfilgrastim'}, {'id': 1881, 'therapyName': 'Docetaxel + Cyclophosphamide'}, {'id': 1977, 'therapyName': 'Doxorubicin + Cyclophosphamide'}, {'id': 1485, 'therapyName': 'Trastuzumab + Docetaxel + Carboplatin'}, {'id': 1978, 'therapyName': 'Pertuzumab + Trastuzumab + Docetaxel'}]",MINT I Multi- Institutional Neo-adjuvant Therapy MammaPrint Project I,534
62,NCT01036087,Phase II,"Active, not recruiting","[{'id': 1984, 'therapyName': 'Panitumumab + Abraxane + Carboplatin'}, {'id': 1982, 'therapyName': 'Fluorouracil + Epirubicin + Cyclophosphamide'}]","Panitumumab, Nab-paclitaxel and Carboplatin for HER2 Negative Inflammatory Breast Cancer",534
63,NCT01779050,Phase II,"Active, not recruiting","[{'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1087, 'therapyName': 'Epirubicin + Cyclophosphamide'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1982, 'therapyName': 'Fluorouracil + Epirubicin + Cyclophosphamide'}, {'id': 1834, 'therapyName': 'Docetaxel + Carboplatin'}, {'id': 1881, 'therapyName': 'Docetaxel + Cyclophosphamide'}]",Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer Patients With ERBB2 Expressing Disseminated Tumor Cells,534
64,NCT02785068,Phase I,Withdrawn,"[{'id': 4532, 'therapyName': 'Fluorouracil + Irinotecan + Leucovorin + MM-151'}]",Evaluation of MM-151 + Nal-IRI + 5-FU + Leucovorin in RAS/RAF Wild-type Metastatic Colorectal Cancer,534
65,NCT02448810,Phase II,Terminated,"[{'id': 2278, 'therapyName': 'Fluorouracil + Leucovorin'}, {'id': 2996, 'therapyName': 'Imalumab'}, {'id': 845, 'therapyName': 'Panitumumab'}]",Phase 2a Study of BAX69 and 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer,534
66,NCT02042443,Phase II,Completed,"[{'id': 2278, 'therapyName': 'Fluorouracil + Leucovorin'}, {'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 2, 'therapyName': 'Trametinib'}]",Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery,534
67,NCT02620865,Phase Ib/II,Suspended,"[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1167, 'therapyName': 'Aldesleukin'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 1873, 'therapyName': 'Sargramostim'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 2278, 'therapyName': 'Fluorouracil + Leucovorin'}]",Bispecific Antibody Armed Activated T-cells With Aldesleukin and Sargramostim in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer,534
68,NCT01959672,Phase II,Recruiting,"[{'id': 827, 'therapyName': 'Nelfinavir'}, {'id': 1189, 'therapyName': 'Oregovomab'}, {'id': 2278, 'therapyName': 'Fluorouracil + Leucovorin'}, {'id': 755, 'therapyName': 'Gemcitabine'}]",Combination Chemotherapy With or Without Oregovomab Followed by Stereotactic Body Radiation Therapy and Nelfinavir Mesylate in Treating Patients With Locally Advanced Pancreatic Cancer,534
69,NCT01383538,Phase I,Completed,"[{'id': 2498, 'therapyName': 'Fluorouracil + Leucovorin + Irinotecan + Oxaliplatin + Saridegib'}]",FOLFIRINOX Plus IPI-926 for Advanced Pancreatic Adenocarcinoma,534
70,NCT02124148,Phase I,Recruiting,"[{'id': 1994, 'therapyName': 'Cisplatin + Prexasertib'}, {'id': 1993, 'therapyName': 'Cetuximab + Prexasertib'}, {'id': 6248, 'therapyName': 'Pemetrexed + Prexasertib'}, {'id': 6247, 'therapyName': 'LY3023414 + Prexasertib'}, {'id': 6246, 'therapyName': 'Fluoruracil + Leucovorin + Prexasertib'}]",A Study of LY2606368 With Cisplatin or Cetuximab in Participants With Advanced Cancer,534
71,NCT01814501,Phase II,Recruiting,"[{'id': 1315, 'therapyName': 'FOLFIRI'}, {'id': 845, 'therapyName': 'Panitumumab'}]",Panitumumab and Chemotherapy in Patients With Advanced Colorectal Cancer After Prior Therapy With Bevacizumab,534
72,NCT02046538,Phase II,Withdrawn,"[{'id': 1315, 'therapyName': 'FOLFIRI'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 624, 'therapyName': 'Aflibercept'}]",Phase II Study of Zaltrap and Chemotherapy for Advanced Resectable Colorectal Cancer,534
73,NCT02482441,Phase I,Recruiting,"[{'id': 4401, 'therapyName': 'Rosmantuzumab'}, {'id': 1315, 'therapyName': 'FOLFIRI'}]","A Phase 1a/b Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of OMP-131R10",534
74,NCT01312857,Phase II,Recruiting,"[{'id': 845, 'therapyName': 'Panitumumab'}, {'id': 1315, 'therapyName': 'FOLFIRI'}, {'id': 1941, 'therapyName': 'Floxuridine'}]","Study of Hepatic Arterial Infusion With Intravenous Irinotecan, 5FU and Leucovorin With or Without Panitumumab, in Patients With Wild Type KRAS Who Have Resected Hepatic Metastases From Colorectal Cancer",534
75,NCT01488552,Phase Ib/II,Completed,"[{'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 1315, 'therapyName': 'FOLFIRI'}, {'id': 1779, 'therapyName': 'Nab-paclitaxel + Gemcitabine'}, {'id': 1031, 'therapyName': 'Metformin'}]",Gemcitabine+Nab-paclitaxel and FOLFIRINOX and Molecular Profiling for Patients With Advanced Pancreatic Cancer,534
76,NCT01274624,Phase I,"Active, not recruiting","[{'id': 1315, 'therapyName': 'FOLFIRI'}, {'id': 2099, 'therapyName': 'Bevacizumab + Reolysin'}]",Study of REOLYSIN; in Combination With FOLFIRI and Bevacizumab in FOLFIRI Naive Patients With KRAS Mutant Metastatic Colorectal Cancer,534
77,NCT02024607,Phase Ib/II,"Active, not recruiting","[{'id': 1597, 'therapyName': 'Capecitabine + Oxaliplatin'}, {'id': 2093, 'therapyName': 'BBI608 + Bevacizumab'}, {'id': 2094, 'therapyName': 'BBI608 + Regorafenib'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 2057, 'therapyName': 'BBI608'}, {'id': 1315, 'therapyName': 'FOLFIRI'}]",A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer,534
78,NCT01260415,Phase II,Completed,"[{'id': 845, 'therapyName': 'Panitumumab'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 1315, 'therapyName': 'FOLFIRI'}]",A Study of Perioperative Chemotherapy Plus Panitumumab in Patients With Colorectal Cancer Liver Metastases,534
79,NCT02605044,Phase III,Recruiting,"[{'id': 804, 'therapyName': 'Masitinib'}, {'id': 1315, 'therapyName': 'FOLFIRI'}]",Study to Compare the Efficacy and Safety of Masitinib in Combination With FOLFIRI to Placebo in Combination With FOLFIRI in Second Line Treatment of Patients With Metastatic Colorectal Cancer,534
80,NCT02753127,Phase III,Recruiting,"[{'id': 1315, 'therapyName': 'FOLFIRI'}, {'id': 2057, 'therapyName': 'BBI608'}]",A Study of Napabucasin (BBI-608) in Combination With FOLFIRI in Adult Patients With Previously Treated Metastatic Colorectal Cancer (CanStem303C),534
81,NCT02305758,Phase II,Completed,"[{'id': 1315, 'therapyName': 'FOLFIRI'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 954, 'therapyName': 'Veliparib'}]",Study Comparing Veliparib Plus FOLFIRI Versus Placebo Plus FOLFIRI With or Without Bevacizumab in Previously Untreated Metastatic Colorectal Cancer,534
82,NCT02508077,Phase II,Terminated,"[{'id': 1315, 'therapyName': 'FOLFIRI'}, {'id': 845, 'therapyName': 'Panitumumab'}]",FOLFIRI and Panitumumab in Treating Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer,534
83,NCT01803282,Phase I,Recruiting,"[{'id': 3320, 'therapyName': 'GS-5745'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 1602, 'therapyName': 'Carboplatin + Pemetrexed'}, {'id': 1315, 'therapyName': 'FOLFIRI'}, {'id': 1779, 'therapyName': 'Nab-paclitaxel + Gemcitabine'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 667, 'therapyName': 'Bevacizumab'}]",Safety and Tolerability Study in Solid Tumors,534
84,NCT01298570,Phase II,"Active, not recruiting","[{'id': 1315, 'therapyName': 'FOLFIRI'}, {'id': 890, 'therapyName': 'Regorafenib'}]",Regorafenib+FOLFIRI Versus Placebo+FOLFIRI as 2nd Line Tx in Metastatic Colorectal Cancer,534
85,NCT01653470,Phase I,"Active, not recruiting","[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1315, 'therapyName': 'FOLFIRI'}, {'id': 2545, 'therapyName': 'BMS-906024'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]","Study to Evaluate Safety & Tolerability of BMS-906024 in Combination With Chemotherapy & to Define DLTs & MTD of BMS-906024 in Combination With One of the Following Chemotherapy Regimens; Weekly Paclitaxel, 5FU+Irinotecan or Carboplatin+Paclitaxel in Subjects With Advanced / Metastatic Solid Tumors",534
86,NCT01937715,Phase II,Terminated,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1040, 'therapyName': 'PF-05212384'}, {'id': 1315, 'therapyName': 'FOLFIRI'}]",A Study Of PF-05212384 Plus FOLFIRI Versus Bevacizumab Plus FOLFIRI In Metastatic Colorectal Cancer,534
87,NCT02890355,,Recruiting,"[{'id': 954, 'therapyName': 'Veliparib'}, {'id': 1315, 'therapyName': 'FOLFIRI'}]",FOLFIRI or Modified FOLFIRI and Veliparib as Second Line Therapy in Treating Patients With Metastatic Pancreatic Cancer,534
88,NCT02563002,Phase III,Recruiting,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1315, 'therapyName': 'FOLFIRI'}, {'id': 694, 'therapyName': 'Cetuximab'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}]",Study of Pembrolizumab (MK-3475) vs Standard Therapy in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (MK-3475-177/KEYNOTE-177),534
89,NCT02213289,Phase Ib/II,Recruiting,"[{'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 1913, 'therapyName': 'FOLTAX'}, {'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 1315, 'therapyName': 'FOLFIRI'}, {'id': 629, 'therapyName': 'AMG102'}]",PANGEA-IMBBP: Personalized Antibodies for Gastro-Esophageal Adenocarcinoma - A 1st Pilot Metastatic Trial of Biologics Beyond Progression,534
90,NCT01472016,Phase I,Completed,"[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1063, 'therapyName': 'ABT-700'}, {'id': 694, 'therapyName': 'Cetuximab'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 1315, 'therapyName': 'FOLFIRI'}]",Study of ABT-700 in Subjects With Advanced Solid Tumors,534
91,NCT01652482,Phase II,Completed,"[{'id': 694, 'therapyName': 'Cetuximab'}, {'id': 806, 'therapyName': 'MEHD7945A'}, {'id': 1315, 'therapyName': 'FOLFIRI'}]",A Study of MEHD7945A + FOLFIRI Versus Cetuximab + FOLFIRI in Second Line in Patients With KRAS Wild-Type Metastatic Colorectal Cancer,534
92,NCT03035253,Phase I,Recruiting,"[{'id': 5297, 'therapyName': 'FOLFIRI + OMP-305B83'}]",A Study of OMP-305B83 in Subjects With Metastatic Colorectal Cancer,534
93,NCT02568046,Phase Ib/II,"Active, not recruiting","[{'id': 3949, 'therapyName': 'FOLFIRI + SYM004'}]",Sym004 in Combination With FOLFIRI in Metastatic Colorectal Cancer Patients,534
94,NCT01485744,Phase I,"Active, not recruiting","[{'id': 1903, 'therapyName': 'FOLFIRINOX'}, {'id': 1428, 'therapyName': 'Sonidegib'}]","LDE225 With Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan for Untreated Advanced Pancreatic Cancer",534
95,NCT01821729,Phase II,Recruiting,"[{'id': 1903, 'therapyName': 'FOLFIRINOX'}, {'id': 2998, 'therapyName': 'Losartan'}]",Proton w/FOLFIRINOX-Losartan for Pancreatic Cancer,534
96,NCT01928290,Phase II,Recruiting,"[{'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 1903, 'therapyName': 'FOLFIRINOX'}]","Combination Chemotherapy in Treating Patients With Advanced Stomach, Gastroesophageal, or Esophageal Cancer",534
97,NCT01896869,Phase II,Suspended,"[{'id': 1903, 'therapyName': 'FOLFIRINOX'}, {'id': 779, 'therapyName': 'Ipilimumab'}]","A Phase 2, Multicenter Study of FOLFIRINOX Followed by Ipilimumab With Allogenic GM-CSF Transfected Pancreatic Tumor Vaccine in the Treatment of Metastatic Pancreatic Cancer",534
98,NCT02581215,Phase II,Recruiting,"[{'id': 886, 'therapyName': 'Ramucirumab'}, {'id': 1903, 'therapyName': 'FOLFIRINOX'}]",Phase II Randomized Trial of FOLFIRINOX +/- Ramucirumab in Advanced Pancreatic Cancer,534
99,NCT03193190,Phase Ib/II,Recruiting,"[{'id': 5942, 'therapyName': 'Atezolizumab + BKT140'}, {'id': 5940, 'therapyName': 'Gemcitabine + Nab-Paclitaxel + mFOLFOX-6'}, {'id': 5941, 'therapyName': 'Atezolizumab + PEGPH20'}, {'id': 1343, 'therapyName': 'Atezolizumab + Cobimetinib'}]",A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (PDAC),534
100,NCT03085914,Phase Ib/II,Recruiting,"[{'id': 5483, 'therapyName': 'INCB024360 + Nivolumab + mFOLFOX6'}, {'id': 5484, 'therapyName': 'INCB024360 + Nivolumab + Gemcitabine + nab-paclitaxel'}, {'id': 5485, 'therapyName': 'INCB024360 + Pembrolizumab + Carboplatin + Paclitaxel'}, {'id': 5486, 'therapyName': 'INCB024360 + Pembrolizumab + Carboplatin + Pemetrexed'}, {'id': 5487, 'therapyName': 'INCB024360 + Pembrolizumab + Cyclophosphamide'}]",A Study of Epacadostat in Combination With a PD-1 Inhibitor and Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors (ECHO-207),534
101,NCT00790816,Phase I,Completed,"[{'id': 1410, 'therapyName': 'Lapatinib + Paclitaxel'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 1414, 'therapyName': 'Trastuzumab + Lapatinib'}, {'id': 1399, 'therapyName': 'Lapatinib + Capecitabine'}, {'id': 1497, 'therapyName': 'Lapatinib + Letrozole'}, {'id': 1498, 'therapyName': 'Lapatinib + Oxaliplatin + Capecitabine'}, {'id': 1499, 'therapyName': 'Lapatinib + Gemcitabine'}, {'id': 1500, 'therapyName': 'Lapatinib + Docetaxel'}, {'id': 1501, 'therapyName': 'Lapatinib + Oxaliplatin + Leucovorin + Fluorouracil'}, {'id': 1502, 'therapyName': 'Lapatinib + Irinotecan + Leucovorin + Fluorouracil'}]",Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents,534
102,NCT02041481,Phase I,"Active, not recruiting","[{'id': 2217, 'therapyName': 'MEK162 + FOLFOX'}]","MEK Inhibitor MEK162 in Combination With Leucovorin Calcium, Fluorouracil, and Oxaliplatin in Treating Patients With Advanced Metastatic Colorectal Cancer",534
103,NCT03281369,Phase Ib/II,Not yet recruiting,"[{'id': 1343, 'therapyName': 'Atezolizumab + Cobimetinib'}, {'id': 6274, 'therapyName': 'mFOLFOX-6 + Atezolizumab + Cobimetinib'}, {'id': 6275, 'therapyName': 'mFOLFOX-6 + Atezolizumab'}, {'id': 6276, 'therapyName': 'Atezolizumab + Linagliptin'}, {'id': 5941, 'therapyName': 'Atezolizumab + PEGPH20'}, {'id': 5942, 'therapyName': 'Atezolizumab + BKT140'}, {'id': 1721, 'therapyName': 'Ramucirumab + Paclitaxel'}, {'id': 5850, 'therapyName': 'mFOLFOX-6'}]",A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) (UMBRELLA),534
104,NCT01206530,Phase Ib/II,"Active, not recruiting","[{'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1316, 'therapyName': 'Hydroxychloroquine'}]",FOLFOX/Bevacizumab/Hydroxychloroquine (HCQ) in Colorectal Cancer,534
105,NCT02730546,Phase Ib/II,Suspended,"[{'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]","Pembrolizumab, Combination Chemotherapy, and Radiation Therapy Before Surgery in Treating Adult Patients With Locally Advanced Gastroesophageal Junction or Gastric Cardia Cancer That Can Be Removed by Surgery",534
106,NCT01662869,Phase III,Completed,"[{'id': 838, 'therapyName': 'Onartuzumab'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}]",A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic HER2-Negative And Met-Positive Gastroesophageal Cancer (MetGastric),534
107,NCT02625610,Phase III,Recruiting,"[{'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 3144, 'therapyName': 'Avelumab'}, {'id': 1597, 'therapyName': 'Capecitabine + Oxaliplatin'}]",Avelumab in First-Line Gastric Cancer (JAVELIN Gastric 100),534
108,NCT02912559,Phase III,Recruiting,"[{'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}]",Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair or Microsatellite Instability,534
109,NCT01586611,Phase III,Unknown status,"[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}]",A Study to See if hENT1 Testing on Tumour Tissue Can Predict Response to Treatment With Gemcitabine Chemotherapy and if a Different Chemotherapy Called FOLFOX is Better Than Gemcitabine in Metastatic Pancreas Cancer,534
110,NCT02268825,Phase Ib/II,"Active, not recruiting","[{'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Phase I/IIA Study MK-3475 With Chemotherapy in Patients With Advanced GI Cancers,534
111,NCT02413853,Phase II,Withdrawn,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1083, 'therapyName': 'Pri-724'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}]",Combination Chemotherapy and Bevacizumab With or Without PRI-724 in Treating Patients With Newly Diagnosed Metastatic Colorectal Cancer,534
112,NCT01985763,Phase Ib/II,Completed,"[{'id': 757, 'therapyName': 'Genistein'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}]",Genistein in Treatment of Metastatic Colorectal Cancer,534
113,NCT02344810,Phase Ib/II,Unknown status,"[{'id': 1064, 'therapyName': 'AMG 337'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}]","C-Met Inhibitor AMG 337, Oxaliplatin, Leucovorin Calcium, and Fluorouracil in Treating Patients With Advanced Stomach or Esophageal Cancer",534
114,NCT01327612,Phase II,"Active, not recruiting","[{'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 746, 'therapyName': 'Ganitumab'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1458, 'therapyName': 'Conatumumab'}]",Open Label Extension Study of Conatumumab and AMG 479,534
115,NCT02009449,Phase I,"Active, not recruiting","[{'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 2621, 'therapyName': 'AM0010 '}, {'id': 619, 'therapyName': 'Abraxane'}]",A Phase 1 Study of AM0010 in Patients With Advanced Solid Tumors,534
116,NCT02921256,Phase II,Recruiting,"[{'id': 954, 'therapyName': 'Veliparib'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 4838, 'therapyName': 'Capecitabine + Veliparib'}, {'id': 1105, 'therapyName': 'Capecitabine'}]",Veliparib and Combination Chemotherapy in Treating Patient With Locally Advanced Rectal Cancer,534
117,NCT01896531,Phase II,"Active, not recruiting","[{'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 747, 'therapyName': 'Ipatasertib'}]",A Study of GDC-0068 in Combination With Fluoropyrimidine Plus Oxaliplatin in Patients With Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer,534
118,NCT02574663,Phase I,"Active, not recruiting","[{'id': 1779, 'therapyName': 'Nab-paclitaxel + Gemcitabine'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 2022, 'therapyName': 'TGR-1202'}]",TGR-1202 Alone and in Combination With Either Nab-paclitaxel + Gemcitabine or With FOLFOX in Patients With Select Relapsed or Refractory Solid Tumors,534
119,NCT02943603,Phase II,Withdrawn,"[{'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}]",A Study of Perioperative mFOLFOX6 Plus Pembrolizumab in Patients With Potentially Resectable Adenocarcinoma of the Gastroesophageal Junction (GEJ) and Stomach,534
120,NCT01362374,Phase I,"Active, not recruiting","[{'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 747, 'therapyName': 'Ipatasertib'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}]","Safety and Pharmacology Of GDC-0068 in Combination With Docetaxel, Fluoropyrimidine Plus Oxaliplatin, Paclitaxel, or Enzalutamide in Patients With Advanced Solid Tumors",534
121,NCT01747551,Phase II,"Active, not recruiting","[{'id': 624, 'therapyName': 'Aflibercept'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}]",FOLFOX +/- Ziv-Aflibercept for Esophageal and Gastric Cancer,534
122,NCT00602329,Phase II,Unknown status,"[{'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 667, 'therapyName': 'Bevacizumab'}]",MRI in Predicting Response in Patients Receiving Combination Chemotherapy and Bevacizumab For Advanced or Metastatic Colorectal Cancer,534
123,NCT02358863,Phase I,Terminated,"[{'id': 4311, 'therapyName': 'Docetaxel + Irinotecan'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 1835, 'therapyName': 'Docetaxel + Cisplatin'}, {'id': 1406, 'therapyName': 'Camptosar + Cisplatin'}, {'id': 4310, 'therapyName': 'Epirubicin + Docetaxel'}, {'id': 4309, 'therapyName': 'Capecitabine + Docetaxel'}]",Molecularly Tailored Therapy for Patients With Metastatic Cancer of the Esophagus and Stomach (mEGA),534
124,NCT01516216,Phase II,"Active, not recruiting","[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}]",Study of Vitamin D in Untreated Metastatic Colorectal Cancer,534
125,NCT01489865,Phase Ib/II,Recruiting,"[{'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 954, 'therapyName': 'Veliparib'}]",ABT-888 With Modified FOLFOX6 in Patients With Metastatic Pancreatic Cancer,534
126,NCT02375672,Phase II,"Active, not recruiting","[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}]",Study of Pembrolizumab in Combination With Chemotherapy for Patients With Advanced Colorectal Cancer,534
127,NCT01571024,Phase I,Completed,"[{'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 680, 'therapyName': 'BKM120'}]", BKM120 + mFOLFOX6 in Advanced Solid Tumors With Expansion Cohort Pancreatic Cancer,534
128,NCT01420874,Phase I,"Active, not recruiting","[{'id': 1012, 'therapyName': 'EGFRBi-armed autologous activated T cells'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}]",Anti-CD3 x Anti-Erbitux Armed Activated T Cells (Phase Ib) for Gastrointestinal (GI Cancer),534
129,NCT02715531,Phase I,Recruiting,"[{'id': 3947, 'therapyName': 'Atezolizumab + Gemcitabine + nab-paclitaxel'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 1202, 'therapyName': 'Atezolizumab + Bevacizumab + Capecitabine'}]",A Study of the Safety and Tolerability of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors,534
130,NCT02872116,Phase III,Recruiting,"[{'id': 1597, 'therapyName': 'Capecitabine + Oxaliplatin'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}]",Efficacy Study of Nivolumab Plus Ipilimumab Against Chemotherapy Standard of Care in Stomach Cancer or Stomach/Esophagus Junction Cancer (CheckMate649),534
131,NCT01666730,Phase II,Recruiting,"[{'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 1031, 'therapyName': 'Metformin'}]",Metformin Plus Modified FOLFOX 6 in Metastatic Pancreatic Cancer,534
132,NCT02319018,Phase I,"Active, not recruiting","[{'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 626, 'therapyName': 'Alisertib'}]",Alisertib and Combination Chemotherapy in Treating Patients With Gastrointestinal Tumors,534
133,NCT02658214,Phase I,Recruiting,"[{'id': 2667, 'therapyName': 'Carboplatin + Gemcitabine'}, {'id': 2634, 'therapyName': 'Carboplatin + nab-paclitaxel'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 1791, 'therapyName': 'Carboplatin + Etoposide'}]",Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors,534
134,NCT01652976,Phase II,"Active, not recruiting","[{'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 717, 'therapyName': 'Dasatinib'}]","Phase II Study of 5-FU, Oxaliplatin Plus Dasatinib in Metastatic Pancreatic Adenocarcinoma",534
135,NCT02545504,Phase III,"Active, not recruiting","[{'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 3320, 'therapyName': 'GS-5745'}]",GS-5745 With mFOLFOX6 as First Line Treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma,534
136,NCT01522989,Phase I,"Active, not recruiting","[{'id': 1703, 'therapyName': 'Palbociclib + Fluorouracil + Oxaliplatin'}]","PD-0332991, 5-FU, and Oxaliplatin for Advanced Solid Tumor Malignancies",534
137,NCT01307956,Phase II,Unknown status,"[{'id': 1986, 'therapyName': 'Panitumumab + FOLFOX'}]","Panitumumab, Combination Chemotherapy, and Radiation Therapy Before Surgery in Treating Patients With Advanced Esophageal or Gastroesophageal Junction Cancer",534
138,NCT01855828,Phase II,Recruiting,"[{'id': 1549, 'therapyName': 'Pertuzumab + Trastuzumab + Paclitaxel'}, {'id': 1550, 'therapyName': 'Pertuzumab + Trastuzumab + Fluorouracil + Epirubicin + Cyclophosphamide'}]",Phase 2 Trial of Pertuzumab and Trastuzumab With Weekly Paclitaxel and Chemotherapy for HER2 Positive Breast Cancer,534
139,NCT01913639,Phase II,"Active, not recruiting","[{'id': 2014, 'therapyName': 'Regorafenib + FOLFOX'}]",FOLFOX Plus Regorafenib in Patients With Unresectable or Metastatic Esophagogastric Cancer,534
140,NCT01740648,Phase I,"Active, not recruiting","[{'id': 1113, 'therapyName': 'Trametinib + Fluorouracil'}]","Trametinib, Fluorouracil, and Radiation Therapy Before Surgery in Treating Patients With Stage II-III Rectal Cancer",534
0,NCT03070886,Phase III,Recruiting,"[{'id': 5450, 'therapyName': 'Bicalutamide + Docetaxel + Flutamide + Goserelin + Leuprolide + Nilutamide'}, {'id': 5449, 'therapyName': 'Bicalutamide + Flutamide + Goserelin + Leuprolide + Nilutamide'}]",Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery,491
1,NCT00936390,Phase III,"Active, not recruiting","[{'id': 742, 'therapyName': 'Flutamide'}, {'id': 759, 'therapyName': 'Goserelin'}, {'id': 795, 'therapyName': 'Leuprolide'}, {'id': 2050, 'therapyName': 'Triptorelin'}, {'id': 1507, 'therapyName': 'Bicalutamide'}]",Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer,491
2,NCT00223665,Phase II,Unknown status,"[{'id': 795, 'therapyName': 'Leuprolide'}, {'id': 742, 'therapyName': 'Flutamide'}]",Intermittent Hormone Therapy in Men With Localized Prostate Cancer After Radiation Therapy or Radical Prostatectomy,491
0,NCT02335814,Phase I,Terminated,"[{'id': 2529, 'therapyName': 'FLX925  '}]",First-in-Human Study of FLX925 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia,7560
0,NCT01052363,Phase I,Withdrawn,"[{'id': 2109, 'therapyName': 'Bevacizumab + Fosbretabulin'}]",OXC401-PO1s/WVU 1309 - A Pilot Study of Fosbretabulin With Bevacizumab in Recurrent High-Grade Gliomas,7216
1,NCT03014297,Phase I,Recruiting,"[{'id': 5207, 'therapyName': 'Everolimus + Fosbretabulin'}]",Fosbretabulin With Everolimus in Neuroendocrine Tumors With Progression,7216
2,NCT01305213,Phase Ib/II,Completed,"[{'id': 1186, 'therapyName': 'Fosbretabulin'}, {'id': 667, 'therapyName': 'Bevacizumab'}]","Bevacizumab With or Without Fosbretabulin Tromethamine in Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer",7216
0,NCT02611063,Phase I,Recruiting,"[{'id': 1528, 'therapyName': 'Fostamatinib'}]",Evaluation of Fostamatinib in Patients With cGVHD After Allogeneic Stem Cell Transplant,7277
0,NCT02526017,Phase I,Recruiting,"[{'id': 2840, 'therapyName': 'FPA008'}, {'id': 1312, 'therapyName': 'Nivolumab'}]",Study of FPA008 in Combination With Nivolumab in Patients With Selected Advance Cancers,7777
1,NCT02471716,Phase Ib/II,Recruiting,"[{'id': 2840, 'therapyName': 'FPA008'}]",Study of FPA008 in Patients With Pigmented Villonodular Synovitis / Diffuse Type Tenosynovial Giant Cell Tumor,7777
0,NCT02318329,Phase I,Recruiting,"[{'id': 2933, 'therapyName': 'FPA144'}]","Open-Label, Dose-Finding Study Evaluating Safety and PK of FPA144 in Patients With Advanced Solid Tumors",7851
0,NCT02581787,Phase Ib/II,Recruiting,"[{'id': 2707, 'therapyName': 'fresolimumab'}]",SABR-ATAC: A Trial of TGF-beta Inhibition and Stereotactic Ablative Radiotherapy for Early Stage Non-small Cell Lung Cancer,7668
0,NCT02719574,Phase I,Recruiting,"[{'id': 4336, 'therapyName': 'FT-2102'}, {'id': 4449, 'therapyName': 'FT-2102 + Azacitidine'}]",Dose-Escalation Study of FT-2102 as a Single Agent and in Combination With Azacitidine in Patients With AML or MDS With an IDH1 Mutation,8424
0,NCT03099174,Phase I,Recruiting,"[{'id': 5514, 'therapyName': 'Abemaciclib + Xentuzumab'}, {'id': 5515, 'therapyName': 'Abemaciclib + Letrozole + Xentuzumab'}, {'id': 5516, 'therapyName': 'Abemaciclib + Anastrozole + Xentuzumab'}, {'id': 5517, 'therapyName': 'Abemaciclib + Fulvestrant + Xentuzumab'}]",This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast Cancer.,936
1,NCT02860000,Phase II,Recruiting,"[{'id': 4561, 'therapyName': 'Alisertib + Fulvestrant'}, {'id': 626, 'therapyName': 'Alisertib'}]","Alisertib With or Without Fulvestrant in Treating Patients With Locally Advanced or Metastatic, Endocrine-Resistant Breast Cancer",936
2,NCT03056755,Phase II,Recruiting,"[{'id': 5929, 'therapyName': 'Alpelisib + Fulvestrant'}, {'id': 1553, 'therapyName': 'Letrozole + BYL719'}]","Efficacy and Safety of Treatment With Alpelisib Plus Endocrine Therapy in Patients With HR+, HER2-negative aBC, With PIK3CA Mutations, Whose Disease Has Progressed on or After CDK 4/6 Treatment With an Aromatase Inhibitor (AI) or Fulvestrant",936
3,NCT00570323,Phase II,"Active, not recruiting","[{'id': 1911, 'therapyName': 'Anastrozole  + Fulvestrant'}, {'id': 633, 'therapyName': 'Anastrozole'}]",Arimidex With or Without Faslodex In Postmenopausal Women With HR Positive Breast Cancer,936
4,NCT02000596,Phase II,Terminated,"[{'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}, {'id': 1911, 'therapyName': 'Anastrozole  + Fulvestrant'}]",Trastuzmab and Pertuzumab Alone or in Combination With Hormonal Therapy or Chemotherapy With Eribulin in Women Aged 60 and Over With HER2/Neu Overexpressed Locally Advanced or MBC,936
5,NCT03280563,Phase Ib/II,Not yet recruiting,"[{'id': 6269, 'therapyName': 'Atezolizumab + Ipatasertib'}, {'id': 6270, 'therapyName': 'Atezolizumab + Bevacizumab + Exemestane'}, {'id': 1343, 'therapyName': 'Atezolizumab + Cobimetinib'}, {'id': 6271, 'therapyName': 'Atezolizumab + Bevacizumab + Fulvestrant'}, {'id': 6272, 'therapyName': 'Atezolizumab + Bevacizumab + Tamoxifen'}, {'id': 6273, 'therapyName': 'Atezolizumab + Ipatasertib + Fulvestrant'}, {'id': 744, 'therapyName': 'Fulvestrant'}, {'id': 6268, 'therapyName': 'Atezolizumab + Fulvestrant'}]",A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer,936
6,NCT02088684,Phase Ib/II,"Active, not recruiting","[{'id': 2315, 'therapyName': 'BKM120 + Fulvestrant + LEE011'}, {'id': 2316, 'therapyName': 'Fulvestrant + LEE011'}, {'id': 2317, 'therapyName': 'BYL719 + Fulvestrant + LEE011'}]",Study of LEE011 With Fulvestrant and BYL719 or BKM120 in Advanced Breast Cancer,936
7,NCT01441947,Phase II,"Active, not recruiting","[{'id': 1965, 'therapyName': 'cabozantinib + Fulvestrant'}]",Cabozantinib in Women With Metastatic Hormone-Receptor-Positive Breast Cancer,936
8,NCT02953860,Phase II,Recruiting,"[{'id': 4940, 'therapyName': 'Enzalutamide + Fulvestrant'}]",Fulvestrant Plus Enzalutamide in ER+/Her2- Advanced Breast Cancer,936
9,NCT02955394,Phase II,Recruiting,"[{'id': 744, 'therapyName': 'Fulvestrant'}, {'id': 4940, 'therapyName': 'Enzalutamide + Fulvestrant'}]",Preoperative Fulvestrant With or Without Enzalutamide in ER+/Her2- Breast Cancer,936
10,NCT02947685,Phase III,Recruiting,"[{'id': 744, 'therapyName': 'Fulvestrant'}, {'id': 856, 'therapyName': 'Pertuzumab'}, {'id': 794, 'therapyName': 'Letrozole'}, {'id': 633, 'therapyName': 'Anastrozole'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 947, 'therapyName': 'Trastuzumab'}]","Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer (PATINA)",936
11,NCT02384239,Phase II,Recruiting,"[{'id': 744, 'therapyName': 'Fulvestrant'}, {'id': 850, 'therapyName': 'Palbociclib'}, {'id': 1456, 'therapyName': 'Tamoxifen'}]",A Study of Palbociclib in Combination With Fulvestrant or Tamoxifen as Treatment for Metastatic Breast Cancer,936
12,NCT02476786,Phase II,Recruiting,"[{'id': 633, 'therapyName': 'Anastrozole'}, {'id': 744, 'therapyName': 'Fulvestrant'}, {'id': 759, 'therapyName': 'Goserelin'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 738, 'therapyName': 'Exemestane'}]",Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score,936
13,NCT01296555,Phase I,Recruiting,"[{'id': 744, 'therapyName': 'Fulvestrant'}, {'id': 1016, 'therapyName': 'GDC-0032'}, {'id': 794, 'therapyName': 'Letrozole'}]",A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Patients With Locally Advanced or Metastatic Solid Tumors And in Combination With Endocrine Therapy in Patients With Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer,936
14,NCT02964507,Phase II,Recruiting,"[{'id': 744, 'therapyName': 'Fulvestrant'}, {'id': 5242, 'therapyName': 'GSK525762 + Fulvestrant'}]",Dose Escalation and Expansion Study of GSK525762 in Combination With Fulvestrant in Subjects With Estrogen Receptor Positive (ER+) Breast Cancer,936
15,NCT02684032,Phase I,Recruiting,"[{'id': 794, 'therapyName': 'Letrozole'}, {'id': 744, 'therapyName': 'Fulvestrant'}, {'id': 4034, 'therapyName': 'Gedatolisib + Palbociclib'}]",A Study To Assess The Tolerability And Clinical Activity Of Gedatolisib In Combination With Palbociclib/Letrozole Or Palbociclib/Fulvestrant In Women With Metastatic Breast Cancer,936
16,NCT02756364,Phase II,Recruiting,"[{'id': 1581, 'therapyName': 'MLN0128 + Fulvestrant'}, {'id': 744, 'therapyName': 'Fulvestrant'}]",MLN0128 in Combination With Fulvestrant in Women With Advanced or Metastatic Breast Cancer After Aromatase Inhibitor Therapy,936
17,NCT02374099,Phase II,"Active, not recruiting","[{'id': 651, 'therapyName': 'Azacitidine'}, {'id': 744, 'therapyName': 'Fulvestrant'}]",Study to Assess the Efficacy and Safety of the Epigenetic Modifying Effects of CC-486 (Oral Azacitidine) in Combination With Fulvestrant,936
18,NCT02569801,Phase II,"Active, not recruiting","[{'id': 2150, 'therapyName': 'GDC-0810'}, {'id': 744, 'therapyName': 'Fulvestrant'}]",A Study of GDC-0810 Versus Fulvestrant in Women With Advanced or Metastatic Breast Cancer Resistant to Aromatase Inhibitor Therapy,936
19,NCT01219699,Phase I,"Active, not recruiting","[{'id': 691, 'therapyName': 'BYL719'}, {'id': 744, 'therapyName': 'Fulvestrant'}]"," A Study of BYL719 in Adult Patients With Advanced Solid Malignancies, Whose Tumors Have an Alteration of the PIK3CA Gene",936
20,NCT02936206,Phase I,Recruiting,"[{'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 744, 'therapyName': 'Fulvestrant'}]",Examination of Breast Cancer Cells of Pre-menopausal Women Before and After Exposure to Tamoxifen or Fulvestrant.,936
21,NCT03241810,,Recruiting,"[{'id': 744, 'therapyName': 'Fulvestrant'}, {'id': 820, 'therapyName': 'Seribantumab'}]",Phase 2 Trial of Seribantumab Plus Fulvestrant in Postmenopausal Women With Metastatic Breast Cancer,936
22,NCT02675231,Phase II,Recruiting,"[{'id': 802, 'therapyName': 'Abemaciclib'}, {'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 744, 'therapyName': 'Fulvestrant'}]","A Study of Abemaciclib (LY2835219) in Women With HR+, HER2+ Locally Advanced or Metastatic Breast Cancer",936
23,NCT02626507,Phase I,Recruiting,"[{'id': 850, 'therapyName': 'Palbociclib'}, {'id': 1040, 'therapyName': 'PF-05212384'}, {'id': 759, 'therapyName': 'Goserelin'}, {'id': 744, 'therapyName': 'Fulvestrant'}]",Phase I Study of Combination of Gedatolisib With Palbociclib and Faslodex in Patients With ER+/HER2- Breast Cancer,936
24,NCT01633060,Phase III,"Active, not recruiting","[{'id': 744, 'therapyName': 'Fulvestrant'}, {'id': 1546, 'therapyName': 'Fulvestrant + BKM120'}]","A Phase III Study of BKM120 With Fulvestrant in Patients With HR+, HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi",936
25,NCT02137837,Phase III,"Active, not recruiting","[{'id': 1589, 'therapyName': 'Fulvestrant + Everolimus'}, {'id': 1590, 'therapyName': 'Fulvestrant + Everolimus + Anastrozole'}, {'id': 744, 'therapyName': 'Fulvestrant'}]","S1222 Trial (Everolimus, Anastrozole and Fulvestrant) in Post-Menopausal Stage IV Breast Cancer",936
26,NCT02983604,Phase Ib/II,Recruiting,"[{'id': 738, 'therapyName': 'Exemestane'}, {'id': 5074, 'therapyName': 'GS-5829 + Fulvestrant'}, {'id': 3561, 'therapyName': 'GS-5829 + Exemestane'}, {'id': 744, 'therapyName': 'Fulvestrant'}]",GS-5829 in Combination With Exemestane or Fulvestrant Comparing With Exemestane or Fulvestrant Alone in Women With Advanced Estrogen Receptor Positive HER2- Breast Cancer,936
27,NCT02260661,Phase I,Completed,"[{'id': 744, 'therapyName': 'Fulvestrant'}, {'id': 2013, 'therapyName': 'AZD8835'}]","Phase I, Dose Study to Look at the Safety and Pharmacokinetics of AZD8835 in Patients With Advanced Solid Tumours",936
28,NCT02422615,Phase III,"Active, not recruiting","[{'id': 790, 'therapyName': 'Ribociclib'}, {'id': 744, 'therapyName': 'Fulvestrant'}]",Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer.,936
29,NCT02630693,Phase II,"Active, not recruiting","[{'id': 850, 'therapyName': 'Palbociclib'}, {'id': 744, 'therapyName': 'Fulvestrant'}, {'id': 1456, 'therapyName': 'Tamoxifen'}]","Study Comparing Two Different Schedules of Palbociclib Plus Second Line Endocrine Therapy in Women With Estrogen Receptor Positive, HER2 Negative Advanced/Metastatic Breast Cancer",936
30,NCT01437566,Phase II,Completed,"[{'id': 750, 'therapyName': 'GDC-0980'}, {'id': 744, 'therapyName': 'Fulvestrant'}, {'id': 749, 'therapyName': 'GDC-0941'}]",Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Patients Resistant to Aromatase Inhibitor Therapy,936
31,NCT02107703,Phase III,"Active, not recruiting","[{'id': 802, 'therapyName': 'Abemaciclib'}, {'id': 744, 'therapyName': 'Fulvestrant'}]",A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer,936
32,NCT01610284,Phase III,"Active, not recruiting","[{'id': 1546, 'therapyName': 'Fulvestrant + BKM120'}, {'id': 744, 'therapyName': 'Fulvestrant'}]",Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor,936
33,NCT02913430,Phase II,Recruiting,"[{'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 744, 'therapyName': 'Fulvestrant'}]",Phase II Treatment of Metastatic Breast Cancer With Fulvestrant or Tamoxifen,936
34,NCT02437318,Phase III,Recruiting,"[{'id': 691, 'therapyName': 'BYL719'}, {'id': 744, 'therapyName': 'Fulvestrant'}]",Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant in Men and Postmenopausal Women With Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment.,936
35,NCT01953588,Phase III,Recruiting,"[{'id': 633, 'therapyName': 'Anastrozole'}, {'id': 744, 'therapyName': 'Fulvestrant'}]",Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery,936
36,NCT01560416,Phase II,"Active, not recruiting","[{'id': 744, 'therapyName': 'Fulvestrant'}, {'id': 745, 'therapyName': 'Ganetespib'}]",Fulvestrant With or Without Ganetespib in HR+ Breast Cancer,936
37,NCT02219789,Phase I,"Active, not recruiting","[{'id': 744, 'therapyName': 'Fulvestrant'}, {'id': 626, 'therapyName': 'Alisertib'}]",Alisertib and Fulvestrant in Treating Patients With Hormone Receptor Positive Breast Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery,936
38,NCT02540330,Phase II,Recruiting,"[{'id': 744, 'therapyName': 'Fulvestrant'}]",PK Study of Pre-Surgical Intramuscular and Intraductal Fulvestrant in Women With Invasive Breast Cancer or DCIS Undergoing Mastectomy,936
39,NCT02345772,Phase I,Terminated,"[{'id': 744, 'therapyName': 'Fulvestrant'}, {'id': 1978, 'therapyName': 'Pertuzumab + Trastuzumab + Docetaxel'}]","Neoadjuvant Hormonal Therapy Combined With Chemoimmunotherapy (Taxotere, Trastuzumab and Pertuzumab) in Patients With HER2-positive and ER-Positive Breast Cancer",936
40,NCT02753686,Phase I,Recruiting,"[{'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 744, 'therapyName': 'Fulvestrant'}, {'id': 794, 'therapyName': 'Letrozole'}, {'id': 633, 'therapyName': 'Anastrozole'}, {'id': 1966, 'therapyName': 'Exemestane + Everolimus'}]",Treatment of Canadian Postmenopausal Women With ER+ Advanced Breast Cancer in the Real-World Setting With Hormone Therapy ± Targeted Therapy (Treat ER+ight),936
41,NCT02206984,Phase I,Recruiting,"[{'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 633, 'therapyName': 'Anastrozole'}, {'id': 744, 'therapyName': 'Fulvestrant'}]",Endocrine Response in Women With Invasive Lobular Breast Cancer,936
42,NCT01797120,Phase II,Completed,"[{'id': 1589, 'therapyName': 'Fulvestrant + Everolimus'}, {'id': 744, 'therapyName': 'Fulvestrant'}]","Study of Fulvestrant +/- Everolimus in Post-Menopausal, Hormone-Receptor + Metastatic Breast Ca Resistant to AI",936
43,NCT01528345,Phase II,Terminated,"[{'id': 2189, 'therapyName': 'Fulvestrant + Dovitinib'}, {'id': 744, 'therapyName': 'Fulvestrant'}]","Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer",936
44,NCT02632045,Phase II,Recruiting,"[{'id': 744, 'therapyName': 'Fulvestrant'}, {'id': 790, 'therapyName': 'Ribociclib'}]",Study of Efficacy of Ribociclib After Progression on CDK4/6 Inhibition in Patients With HR+ H2N- Advanced Breast Cancer,936
45,NCT02340221,Phase III,Recruiting,"[{'id': 744, 'therapyName': 'Fulvestrant'}, {'id': 1016, 'therapyName': 'GDC-0032'}]",SANDPIPER Study: A Study Of Taselisib + Fulvestrant Versus Placebo + Fulvestrant In Patients With Advanced or Metastatic Breast Cancer Who Have Disease Recurrence or Progression During or After Aromatase Inhibitor Therapy,936
46,NCT02269670,Phase II,"Active, not recruiting","[{'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 1869, 'therapyName': 'Megestrol'}, {'id': 794, 'therapyName': 'Letrozole'}, {'id': 744, 'therapyName': 'Fulvestrant'}, {'id': 633, 'therapyName': 'Anastrozole'}]",Everolimus and Hormone Therapy in Treating Patients With Advanced Hormone Receptor Positive Breast Cancer That Has Progressed or Recurred on Everolimus and Exemestane Therapy,936
47,NCT00921115,Phase II,"Active, not recruiting","[{'id': 633, 'therapyName': 'Anastrozole'}, {'id': 744, 'therapyName': 'Fulvestrant'}]",Anti-Hormone Therapy (With Anastrazole and Fulvestrant) Before Surgery to Treat Postmenopausal Women With Breast Cancer.,936
48,NCT03147287,Phase II,Recruiting,"[{'id': 850, 'therapyName': 'Palbociclib'}, {'id': 3205, 'therapyName': 'Fulvestrant + Palbociclib'}, {'id': 5684, 'therapyName': 'Fulvestrant + Palbociclib + Avelumab'}, {'id': 744, 'therapyName': 'Fulvestrant'}]",Palbociclib After CDK and Endocrine Therapy (PACE),936
49,NCT02291913,Phase II,"Active, not recruiting","[{'id': 2267, 'therapyName': 'Everolimus + Tamoxifen'}, {'id': 2268, 'therapyName': 'Anastrozole + Everolimus'}, {'id': 1589, 'therapyName': 'Fulvestrant + Everolimus'}, {'id': 1621, 'therapyName': 'Everolimus + Letrozole'}, {'id': 2269, 'therapyName': 'Everolimus + Toremifene'}, {'id': 1966, 'therapyName': 'Exemestane + Everolimus'}]",Everolimus Combined With Anti-estrogen Therapy in Hormone-Receptor-Positive HER-2 Negative Advanced Breast Cancer,936
50,NCT02384746,Phase I,Recruiting,"[{'id': 2568, 'therapyName': 'Fulvestrant + Ixazomib'}]",Phase I Study of the Combination of MLN9708 and Fulvestrant,936
51,NCT03289039,,Not yet recruiting,"[{'id': 828, 'therapyName': 'Neratinib'}, {'id': 5705, 'therapyName': 'Fulvestrant + Neratinib'}]","A Phase 2 Study of Neratinib With or Without Fulvestrant in HER2-Positive, ER-Positive Metastatic Breast Cancer",936
52,NCT02599714,Phase Ib/II,Recruiting,"[{'id': 3205, 'therapyName': 'Fulvestrant + Palbociclib'}, {'id': 991, 'therapyName': 'Vistusertib'}]",Study of AZD2014 and Palbociclib in Patients With Estrogen Receptor Positive (ER+) Metastatic Breast Cancer (PASTOR),936
53,NCT03007979,Phase II,Recruiting,"[{'id': 759, 'therapyName': 'Goserelin'}, {'id': 3205, 'therapyName': 'Fulvestrant + Palbociclib'}, {'id': 2922, 'therapyName': 'Palbociclib + Letrozole'}]",Alternative Dosing Schedule of Palbociclib in Metastatic Hormone Receptor Positive Breast Cancer,936
54,NCT02760030,Phase II,Recruiting,"[{'id': 3205, 'therapyName': 'Fulvestrant + Palbociclib'}]",Fulvestrant and Palbociclib in Treating Older Patients With Hormone Responsive Breast Cancer That Cannot Be Removed by Surgery,936
55,NCT02738866,Phase II,Recruiting,"[{'id': 3205, 'therapyName': 'Fulvestrant + Palbociclib'}]",Palbociclib With Fulvestrant for Metastatic Breast Cancer After Treatment With Palbociclib and an Aromatase Inhibitor,936
56,NCT03294694,Phase I,Not yet recruiting,"[{'id': 6285, 'therapyName': 'Fulvestrant + PDR001 + Ribociclib'}, {'id': 6284, 'therapyName': 'PDR001 + Ribociclib'}]",Ribociclib + PDR001 in Breast Cancer and Ovarian Cancer,936
57,NCT03006172,Phase I,Recruiting,"[{'id': 5182, 'therapyName': 'GDC-0077 + Letrozole + Palbociclib'}, {'id': 5181, 'therapyName': 'GDC-0077'}, {'id': 5184, 'therapyName': 'GDC-0077 + Fulvestrant'}, {'id': 5183, 'therapyName': 'GDC-0077 + Letrozole'}]","To Evaluate the Safety, Tolerability, and Pharmacokinetics of GDC-0077 Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer",936
58,NCT03238196,Phase I,Recruiting,"[{'id': 6099, 'therapyName': 'JNJ-42756493 + Fulvestrant + Palbociclib'}]","Fulvestrant, Palbociclib and Erdafitinib in ER+/HER2-/FGFR-amplified Metastatic Breast Cancer",936
59,NCT02049957,Phase Ib/II,Recruiting,"[{'id': 1581, 'therapyName': 'MLN0128 + Fulvestrant'}, {'id': 1580, 'therapyName': 'MLN0128 + Exemestane'}]",Safety and Efficacy Study of MLN0128 in Combination With Exemestane or Fulvestrant in Postmenopausal Women With ER/PR+ Metastatic Breast Cancer,936
60,NCT01597388,Phase I,"Active, not recruiting","[{'id': 2199, 'therapyName': 'Vistusertib + Fulvestrant'}]",AZD2014 and Fulvestrant in Patients With ER+ Advanced Metastatic Breast Cancer,936
0,NCT02609984,Phase II,"Active, not recruiting","[{'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 3273, 'therapyName': 'G305 + ID-LV305'}]",Trial of CMB305 and Atezolizumab in Patients With Sarcoma,8003
0,NCT02438007,Phase III,Terminated,"[{'id': 1508, 'therapyName': 'galeterone'}, {'id': 1262, 'therapyName': 'Enzalutamide'}]",A Study of Galeterone Compared to Enzalutamide In Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic CRPC,7274
1,NCT01709734,Phase II,"Active, not recruiting","[{'id': 1508, 'therapyName': 'galeterone'}]","A 2 Part, Phase 2 Trial of Galeterone in the Treatment of Castration Resistant Prostate Cancer",7274
0,NCT02981342,Phase II,Recruiting,"[{'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 802, 'therapyName': 'Abemaciclib'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 5175, 'therapyName': 'Abemaciclib + LY3023414'}, {'id': 5176, 'therapyName': 'Abemaciclib + Galunisertib'}]",A Study of Abemaciclib (LY2835219) Alone or in Combination With Other Agents in Participants With Previously Treated Pancreatic Ductal Adenocarcinoma,7515
1,NCT02688712,Phase II,Recruiting,"[{'id': 5788, 'therapyName': 'Capecitabine + Galunisertib'}, {'id': 5789, 'therapyName': 'Fluorouracil + Galunisertib'}, {'id': 2409, 'therapyName': 'Galunisertib'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1105, 'therapyName': 'Capecitabine'}]",ExIST Study of LY2157299 (Galunisertib) in Rectal Cancer,7515
2,NCT03206177,Phase I,Recruiting,"[{'id': 6265, 'therapyName': 'Carboplatin + Galunisertib + Paclitaxel'}]",Paclitaxel/Carboplatin + Galunisertib for Patients With Carcinosarcoma of the Uterus or Ovary,7515
3,NCT02906397,Phase I,Recruiting,"[{'id': 2409, 'therapyName': 'Galunisertib'}]",A Phase I Study of Galunisertib (LY2157299) Plus Stereotactic Body Radiotherapy (SBRT) in Patients With Advanced Hepatocellular Carcinoma (HCC),7515
4,NCT02452008,Phase II,Recruiting,"[{'id': 2409, 'therapyName': 'Galunisertib'}, {'id': 1262, 'therapyName': 'Enzalutamide'}]",Study of TGF-Beta Receptor Inhibitor LY2157299 and Enzalutamide in Metastatic Castration-resistant Prostate Cancer,7515
5,NCT02423343,Phase Ib/II,Recruiting,"[{'id': 2409, 'therapyName': 'Galunisertib'}, {'id': 1312, 'therapyName': 'Nivolumab'}]","A Study of Galunisertib (LY2157299) in Combination With Nivolumab in Advanced Refractory Solid Tumors and in Recurrent or Refractory NSCLC, Hepatocellular Carcinoma, or Glioma",7515
6,NCT02304419,Phase I,Completed,"[{'id': 2409, 'therapyName': 'Galunisertib'}]",A Study of Galunisertib on the Immune System in Participants With Cancer,7515
7,NCT01246986,Phase II,"Active, not recruiting","[{'id': 2421, 'therapyName': 'Galunisertib + Sorafenib'}, {'id': 2409, 'therapyName': 'Galunisertib'}]",A Study of LY2157299 in Participants With Hepatocellular Carcinoma,7515
8,NCT02734160,Phase I,Recruiting,"[{'id': 4211, 'therapyName': 'Galunisertib + MEDI4736'}]",A Study of Galunisertib (LY2157299) and Durvalumab (MEDI4736) in Participants With Metastatic Pancreatic Cancer,7515
9,NCT02672475,Phase I,Recruiting,"[{'id': 3541, 'therapyName': 'Galunisertib + Paclitaxel'}]",Galunisertib and Paclitaxel in Treating Patients With Metastatic Androgen Receptor Negative (AR-) Triple Negative Breast Cancer,7515
0,NCT02261805,Phase Ib/II,Terminated,"[{'id': 3052, 'therapyName': 'Aldoxorubicin + Ganetespib'}]",A Phase I/II Study of Ganetespib in Combination With Doxorubicin,6907
1,NCT01798485,Phase III,Terminated,"[{'id': 745, 'therapyName': 'Ganetespib'}, {'id': 720, 'therapyName': 'Docetaxel'}]",A Phase 3 Study of Ganetespib in Combination With Docetaxel Versus Docetaxel Alone in Patients With Advanced NSCLC,6907
2,NCT02334319,Phase I,Terminated,"[{'id': 745, 'therapyName': 'Ganetespib'}]",Ganetespib Window of Opportunity Study in Head and Neck Cancers,6907
3,NCT01200238,Phase II,"Active, not recruiting","[{'id': 745, 'therapyName': 'Ganetespib'}]",STA-9090(Ganetespib) in Metastatic Ocular Melanoma,6907
4,NCT01560416,Phase II,"Active, not recruiting","[{'id': 744, 'therapyName': 'Fulvestrant'}, {'id': 745, 'therapyName': 'Ganetespib'}]",Fulvestrant With or Without Ganetespib in HR+ Breast Cancer,6907
5,NCT01962948,Phase II,"Active, not recruiting","[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 745, 'therapyName': 'Ganetespib'}]","Paclitaxel and Ganetespib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",6907
6,NCT02637375,Phase I,Withdrawn,"[{'id': 1495, 'therapyName': 'Paclitaxel + Doxorubicin + Cyclophosphamide'}, {'id': 745, 'therapyName': 'Ganetespib'}]",A Pilot Preoperative Trial of Ganetespib With Paclitaxel for Triple-Negative Breast Cancer,6907
7,NCT02389751,Phase I,"Active, not recruiting","[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 745, 'therapyName': 'Ganetespib'}]",A Study of Ganetespib in Combination With Chemoradiation,6907
8,NCT02192541,Phase I,Completed,"[{'id': 1665, 'therapyName': 'Ganetespib + Aflibercept'}]","Ganetespib and Ziv-Aflibercept in Refractory Gastrointestinal Carcinomas, Non-Squamous Non-Small Cell Lung Carcinomas, Urothelial Carcinomas, and Sarcomas",6907
9,NCT01579994,Phase I,"Active, not recruiting","[{'id': 2190, 'therapyName': 'Ganetespib + Crizotinib'}]",Crizotinib and Ganetespib (STA-9090) in ALK Positive Lung Cancers,6907
10,NCT02060253,Phase I,"Active, not recruiting","[{'id': 1579, 'therapyName': 'Ganetespib + Paclitaxel + Trastuzumab'}]","Ganetespib, Paclitaxel and Trastuzumab for Advanced or Metastatic Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Breast Cancer",6907
11,NCT02008877,Phase Ib/II,"Active, not recruiting","[{'id': 2271, 'therapyName': 'Ganetespib + Sirolimus'}]",A Trial of Ganetespib Plus Sirolimus: Phase 1 Includes Multiple Sarcoma Subtypes and Phase 2 MPNST,6907
0,NCT01061788,Phase I,Recruiting,"[{'id': 1138, 'therapyName': 'AMG479 + Everolimus + Panitumumab'}]","A Trial of AMG 479, Everolimus (RAD001) and Panitumumab in Patients With Advanced Cancer",6908
1,NCT01708161,Phase I,Completed,"[{'id': 1109, 'therapyName': 'BYL719 + AMG 479'}]",A Phase Ib/II Study of the Combination of BYL719 Plus AMG 479 in Adult Patients With Selected Solid Tumors,6908
2,NCT03041701,Phase Ib/II,Recruiting,"[{'id': 5287, 'therapyName': 'Dasatinib + Ganitumab'}]",Insulin-like Growth Factor 1 Receptor (IGF-1R) Antibody AMG479 (Ganitumab) in Combination With the Src Family Kinase (SFK) Inhibitor Dasatinib in People With Embryonal and Alveolar Rhabdomyosarcoma,6908
3,NCT01122199,Phase I,Completed,"[{'id': 1145, 'therapyName': 'Everolimus + AMG479'}]",Study of RAD001 + AMG479 for Patients With Advanced Solid Tumors,6908
4,NCT01327612,Phase II,"Active, not recruiting","[{'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 746, 'therapyName': 'Ganitumab'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1458, 'therapyName': 'Conatumumab'}]",Open Label Extension Study of Conatumumab and AMG 479,6908
5,NCT01042379,Phase II,Recruiting,"[{'id': 1218, 'therapyName': 'Trebananib'}, {'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}, {'id': 746, 'therapyName': 'Ganitumab'}, {'id': 1495, 'therapyName': 'Paclitaxel + Doxorubicin + Cyclophosphamide'}, {'id': 1494, 'therapyName': 'MK2206 + Trastuzumab'}, {'id': 1493, 'therapyName': 'Trebananib + Trastuzumab'}, {'id': 1492, 'therapyName': 'T-DM1 + Pertuzumab'}]",I-SPY 2 TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer,6908
6,NCT02306161,Phase II,Recruiting,"[{'id': 1433, 'therapyName': 'Vincristine + Doxorubicin + Cyclophosphamide + Ifosfamide + Etoposide'}, {'id': 746, 'therapyName': 'Ganitumab'}]",Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma,6908
0,NCT02173093,Phase Ib/II,Recruiting,"[{'id': 2058, 'therapyName': 'Aldesleukin + GD2Bi-a ATC + Sargramostim '}]",Activated T Cells Armed With GD2 Bispecific Antibody in Children and Young Adults With Neuroblastoma and Osteosarcoma,7407
0,NCT01862081,Phase I,Completed,"[{'id': 2321, 'therapyName': 'Docetaxel + GDC-0032 '}, {'id': 2322, 'therapyName': 'GDC-0032 + Paclitaxel'}]","A Dose-Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of GDC-0032 in Combination With Docetaxel or With Paclitaxel in Patients With HER2-negative Locally Recurrent or Metastatic Breast Cancer",7133
1,NCT02785913,Phase II,"Active, not recruiting","[{'id': 1016, 'therapyName': 'GDC-0032'}]",Lung-MAP: Taselisib as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches,7133
2,NCT02273973,Phase II,Completed,"[{'id': 1016, 'therapyName': 'GDC-0032'}]",Study of Neoadjuvant Letrozole + GDC-0032 Versus Letrozole + Placebo in Post-Menopausal Women With Breast Cancer (LORELEI),7133
3,NCT02457910,Phase Ib/II,Recruiting,"[{'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 1016, 'therapyName': 'GDC-0032'}]",Taselisib and Enzalutamide in Treating Patients With Androgen Receptor Positive Triple-Negative Metastatic Breast Cancer,7133
4,NCT01296555,Phase I,Recruiting,"[{'id': 744, 'therapyName': 'Fulvestrant'}, {'id': 1016, 'therapyName': 'GDC-0032'}, {'id': 794, 'therapyName': 'Letrozole'}]",A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Patients With Locally Advanced or Metastatic Solid Tumors And in Combination With Endocrine Therapy in Patients With Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer,7133
5,NCT02154490,Phase II,Recruiting,"[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 850, 'therapyName': 'Palbociclib'}, {'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 654, 'therapyName': 'AZD4547'}, {'id': 1016, 'therapyName': 'GDC-0032'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 629, 'therapyName': 'AMG102'}]",Lung-MAP: S1400 Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IIIB-IV Squamous Cell Lung Cancer,7133
6,NCT02390427,Phase I,Recruiting,"[{'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 856, 'therapyName': 'Pertuzumab'}, {'id': 1016, 'therapyName': 'GDC-0032'}]",Phase Ib Dose-escalation Trial of Taselisib (GDC-0032) in Combination With Anti-HER2 Therapies in Participants With Advanced HER2+ Breast Cancer,7133
7,NCT02340221,Phase III,Recruiting,"[{'id': 744, 'therapyName': 'Fulvestrant'}, {'id': 1016, 'therapyName': 'GDC-0032'}]",SANDPIPER Study: A Study Of Taselisib + Fulvestrant Versus Placebo + Fulvestrant In Patients With Advanced or Metastatic Breast Cancer Who Have Disease Recurrence or Progression During or After Aromatase Inhibitor Therapy,7133
0,NCT03006172,Phase I,Recruiting,"[{'id': 5182, 'therapyName': 'GDC-0077 + Letrozole + Palbociclib'}, {'id': 5181, 'therapyName': 'GDC-0077'}, {'id': 5184, 'therapyName': 'GDC-0077 + Fulvestrant'}, {'id': 5183, 'therapyName': 'GDC-0077 + Letrozole'}]","To Evaluate the Safety, Tolerability, and Pharmacokinetics of GDC-0077 Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer",8627
0,NCT01547546,Phase I,Completed,"[{'id': 2018, 'therapyName': 'GDC-0084'}]",A Study of GDC-0084 in Patients With Progressive or Recurrent High-Grade Glioma,7384
0,NCT01564251,Phase I,"Active, not recruiting","[{'id': 2113, 'therapyName': 'GDC-0575 + Gemcitabine'}, {'id': 2024, 'therapyName': 'GDC-0575'}]",A Study of GDC-0575 Alone And in Combination With Gemcitabine in Patients With Refractory Solid Tumors or Lymphoma,7390
0,NCT01106599,Phase I,Completed,"[{'id': 748, 'therapyName': 'GDC-0623'}]","A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0623 in Patients With Locally Advanced or Metastatic Solid Tumors",6910
0,NCT02569801,Phase II,"Active, not recruiting","[{'id': 2150, 'therapyName': 'GDC-0810'}, {'id': 744, 'therapyName': 'Fulvestrant'}]",A Study of GDC-0810 Versus Fulvestrant in Women With Advanced or Metastatic Breast Cancer Resistant to Aromatase Inhibitor Therapy,7443
1,NCT01823835,Phase II,"Active, not recruiting","[{'id': 2150, 'therapyName': 'GDC-0810'}]",A Study of ARN-810 (GDC-0810) in Postmenopausal Women With Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer,7443
0,NCT01908413,Phase I,Terminated,"[{'id': 3639, 'therapyName': 'GDC-0917'}]","Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-427 When Given to Patients With Advanced and Refractory Solid Tumors or Lymphoma",8182
0,NCT02471846,Phase I,"Active, not recruiting","[{'id': 2888, 'therapyName': 'GDC-0919'}, {'id': 1201, 'therapyName': 'Atezolizumab'}]",A Study of GDC-0919 and MPDL3280A Combination Treatment in Participants With Locally Advanced or Metastatic Solid Tumors,7816
1,NCT02048709,Phase I,Completed,"[{'id': 2888, 'therapyName': 'GDC-0919'}]",IDO Inhibitor in Advanced Solid Tumors,7816
0,NCT01493843,Phase II,Completed,"[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 749, 'therapyName': 'GDC-0941'}, {'id': 667, 'therapyName': 'Bevacizumab'}]",Study Evaluating the Safety and Efficacy of Carboplatin/Paclitaxel and Carboplatin/Paclitaxel/Bevacizumab With and Without GDC-0941 in Patients With Previously Untreated Advanced or Recurrent Non-small Cell Lung Cancer,6911
1,NCT01437566,Phase II,Completed,"[{'id': 750, 'therapyName': 'GDC-0980'}, {'id': 744, 'therapyName': 'Fulvestrant'}, {'id': 749, 'therapyName': 'GDC-0941'}]",Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Patients Resistant to Aromatase Inhibitor Therapy,6911
2,NCT01918306,Phase Ib/II,Terminated,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1554, 'therapyName': 'GDC-0941 + Cisplatin'}]",GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast Cancer,6911
0,NCT01437566,Phase II,Completed,"[{'id': 750, 'therapyName': 'GDC-0980'}, {'id': 744, 'therapyName': 'Fulvestrant'}, {'id': 749, 'therapyName': 'GDC-0941'}]",Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Patients Resistant to Aromatase Inhibitor Therapy,6913
1,NCT01485861,Phase II,"Active, not recruiting","[{'id': 750, 'therapyName': 'GDC-0980'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 747, 'therapyName': 'Ipatasertib'}]",Study of GDC-0068 Or GDC-0980 With Abiraterone Acetate Versus Abiraterone Acetate in Patients With Castration-Resistant Prostate Cancer Previously Treated With Docetaxel Chemotherapy,6913
2,NCT00854152,,Completed,"[{'id': 750, 'therapyName': 'GDC-0980'}]", A Study Evaluating GDC-0980 Administered Once Daily in Patients With Refractory Solid Tumors or Non-Hodgkin's Lymphoma,6913
0,NCT01875705,Phase I,Completed,"[{'id': 2149, 'therapyName': 'GDC-0994'}]",A Dose-Escalation Study of GDC-0994 in Patients With Locally Advanced or Metastatic Solid Tumors,7442
1,NCT02457793,Phase I,Completed,"[{'id': 1004, 'therapyName': 'Cobimetinib'}, {'id': 2149, 'therapyName': 'GDC-0994'}]","A Study of the Safety, Tolerability, and Effects of Cobimetinib and GDC-0994 in Patients With Locally Advanced or Metastatic Solid Tumors",7442
0,NCT02920450,Phase Ib/II,Recruiting,"[{'id': 4785, 'therapyName': 'Gedatolisib + Paclitaxel + Carboplatin'}]","Study of Paclitaxel, Carboplatin, and PF-05212384 in Advanced or Metastatic NSCLC",7159
1,NCT03065062,Phase I,Recruiting,"[{'id': 4034, 'therapyName': 'Gedatolisib + Palbociclib'}]","Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors",7159
2,NCT02684032,Phase I,Recruiting,"[{'id': 794, 'therapyName': 'Letrozole'}, {'id': 744, 'therapyName': 'Fulvestrant'}, {'id': 4034, 'therapyName': 'Gedatolisib + Palbociclib'}]",A Study To Assess The Tolerability And Clinical Activity Of Gedatolisib In Combination With Palbociclib/Letrozole Or Palbociclib/Fulvestrant In Women With Metastatic Breast Cancer,7159
3,NCT03243331,Phase I,Not yet recruiting,"[{'id': 6110, 'therapyName': 'Gedatolisib + PF-06647020'}]",An Initial Safety Study of Gedatolisib Plus PTK7-ADC for Metastatic Triple-negative Breast Cancer,7159
4,NCT01347866,Phase I,Terminated,"[{'id': 1040, 'therapyName': 'PF-05212384'}, {'id': 849, 'therapyName': 'PD-0325901'}, {'id': 1074, 'therapyName': 'Irinotecan'}]",Clinical Study Of PI3K/mTOR Inhibitors In Combination With An Oral MEK Inhibitor Or Irinotecan In Patients With Advanced Cancer,7159
5,NCT02626507,Phase I,Recruiting,"[{'id': 850, 'therapyName': 'Palbociclib'}, {'id': 1040, 'therapyName': 'PF-05212384'}, {'id': 759, 'therapyName': 'Goserelin'}, {'id': 744, 'therapyName': 'Fulvestrant'}]",Phase I Study of Combination of Gedatolisib With Palbociclib and Faslodex in Patients With ER+/HER2- Breast Cancer,7159
6,NCT01937715,Phase II,Terminated,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1040, 'therapyName': 'PF-05212384'}, {'id': 1315, 'therapyName': 'FOLFIRI'}]",A Study Of PF-05212384 Plus FOLFIRI Versus Bevacizumab Plus FOLFIRI In Metastatic Colorectal Cancer,7159
7,NCT01920061,Phase I,Recruiting,"[{'id': 1287, 'therapyName': 'PF-05212384 + Dacomitinib'}, {'id': 1286, 'therapyName': 'PF-05212384 + Cisplatin'}, {'id': 1285, 'therapyName': 'PF-05212384 + Docetaxel'}]",A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents,7159
0,NCT03292133,Phase II,Not yet recruiting,"[{'id': 6287, 'therapyName': 'EGF816 + Gefitinib'}]",A Study of EGF816 and Gefitinib in TKI-naïve EGFR-mutant Non-Small Cell Lung Cancer,310
1,NCT02321293,Phase I,Unknown status,"[{'id': 2379, 'therapyName': 'Erlotinib + Gefitinib'}]",A Open-label Prospective Cohort Trial of Curcumin Plus Tyrosine Kinase Inhibitors (TKI) for EGFR -Mutant Advanced NSCLC,310
2,NCT02179671,Phase II,Completed,"[{'id': 1117, 'therapyName': 'Selumetinib + Docetaxel'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 660, 'therapyName': 'AZD9291'}, {'id': 1652, 'therapyName': 'Tremelimumab'}]","Immune-Modulated Study of Selected Small Molecules (Gefitinib, AZD9291, or Selumetinib + Docetaxel) or a 1st Immune-Mediated Therapy (IMT; Tremelimumab) With a Sequential Switch to a 2nd IMT (MEDI4736) in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer",310
3,NCT02588261,Phase III,"Active, not recruiting","[{'id': 1082, 'therapyName': 'ASP8273'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 4, 'therapyName': 'Erlotinib'}]",A Study of ASP8273 vs. Erlotinib or Gefitinib in First-line Treatment of Patients With Stage IIIB/IV Non-small Cell Lung Cancer Tumors With EGFR Activating Mutations,310
4,NCT02088112,Phase I,"Active, not recruiting","[{'id': 751, 'therapyName': 'Gefitinib'}, {'id': 1356, 'therapyName': 'Durvalumab'}]",MEDI4736 (Anti PD-L1) Combined With Gefitinib in Subjects With Non-Small Cell Lung Cancer(NSCLC),310
5,NCT02296125,Phase III,"Active, not recruiting","[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 660, 'therapyName': 'AZD9291'}, {'id': 751, 'therapyName': 'Gefitinib'}]",AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer,310
6,NCT02788201,Phase II,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1133, 'therapyName': 'Mitomycin C'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1013, 'therapyName': 'epirubicin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1137, 'therapyName': 'Bleomycin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 781, 'therapyName': 'Ixabepilone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 2950, 'therapyName': 'Estramustine'}, {'id': 1941, 'therapyName': 'Floxuridine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 1811, 'therapyName': 'Carmustine'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 953, 'therapyName': 'Vandetanib'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 4419, 'therapyName': 'Toremifine'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 2601, 'therapyName': 'Dactinomycin'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 3035, 'therapyName': 'Chlorambucil'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 342, 'therapyName': 'Vemurafenib'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 2635, 'therapyName': 'Vinblastine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 4305, 'therapyName': 'Teniposide'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 4304, 'therapyName': 'Streptozocin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1231, 'therapyName': 'Bendamustine'}, {'id': 4303, 'therapyName': 'Mechlorethamine'}, {'id': 4302, 'therapyName': 'Mitotane'}]",Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma,310
7,NCT02551718,Phase I,Recruiting,"[{'id': 690, 'therapyName': 'Bosutinib'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 3160, 'therapyName': 'Nelarabine'}, {'id': 3159, 'therapyName': 'Bexarotene'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 998, 'therapyName': 'cabozantinib'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 877, 'therapyName': 'Ponatinib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 623, 'therapyName': 'Afatinib'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 890, 'therapyName': 'Regorafenib'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 2, 'therapyName': 'Trametinib'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 3, 'therapyName': 'Dabrafenib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 789, 'therapyName': 'Ceritinib'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1571, 'therapyName': 'Cabazitaxel'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1327, 'therapyName': 'Pralatrexate'}]",High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia,310
8,NCT03122717,Phase I,Recruiting,"[{'id': 5616, 'therapyName': 'Gefitinib + Osimertinib'}]",Osimertinib and Gefitinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer,310
9,NCT02039674,Phase Ib/II,"Active, not recruiting","[{'id': 2103, 'therapyName': 'Carboplatin + Paclitaxel + Pembrolizumab'}, {'id': 2104, 'therapyName': 'Bevacizumab + Carboplatin + Paclitaxel + Pembrolizumab'}, {'id': 1602, 'therapyName': 'Carboplatin + Pemetrexed'}, {'id': 2106, 'therapyName': 'Ipilimumab + Pembrolizumab '}, {'id': 2107, 'therapyName': 'Erlotinib + Pembrolizumab '}, {'id': 2108, 'therapyName': 'Gefitinib + Pembrolizumab '}]",A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Lung Cancer (MK-3475-021/KEYNOTE-021),310
0,NCT01113476,Phase I,Recruiting,"[{'id': 1144, 'therapyName': 'Abraxane + Avastin + Gemcitabine'}]","Nab-paclitaxel, Gemcitabine, and Bevacizumab in Advanced Malignancies",433
1,NCT02336087,Phase I,Recruiting,"[{'id': 2204, 'therapyName': 'Abraxane + Gemcitabine + Metformin'}]","Gemcitabine Hydrochloride, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Metformin Hydrochloride, and a Standardized Dietary Supplement in Treating Patients With Metastatic Pancreatic Cancer",433
2,NCT02349867,Phase I,Recruiting,"[{'id': 2429, 'therapyName': 'Abraxane + Gemcitabine + Sorafenib + Vorinostat'}]","Gemcitabine Hydrochloride, Nab-Paclitaxel, Radiation Therapy, Sorafenib Tosylate,Vorinostat in Treating Previously Untreated Pancreatic Cancer Patients",433
3,NCT02856568,Phase I,Withdrawn,"[{'id': 4526, 'therapyName': 'ACY-1215 + Cisplatin + Gemcitabine'}]","Ricolinostat, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Unresectable or Metastatic Cholangiocarcinoma",433
4,NCT01825603,Phase I,Recruiting,"[{'id': 4952, 'therapyName': 'ADH-1 + Cisplatin + Gemcitabine'}]","ADH-1, Gemcitabine Hydrochloride and Cisplatin in Treating Patients With Metastatic Pancreatic or Biliary Tract Cancer That Cannot Be Removed By Surgery",433
5,NCT01924260,Phase I,"Active, not recruiting","[{'id': 1289, 'therapyName': 'Alisertib + Gemcitabine'}]",Alisertib and Gemcitabine Hydrochloride in Treating Patients With Solid Tumors or Pancreatic Cancer,433
6,NCT01625260,Phase Ib/II,"Active, not recruiting","[{'id': 2187, 'therapyName': 'ALT-801'}, {'id': 2191, 'therapyName': 'ALT-801 + Gemcitabine'}]",A Study of ALT-801 in Patients With Bacillus Calmette-Guerin (BCG) Failure Non-Muscle Invasive Bladder Cancer,433
7,NCT02559674,Phase Ib/II,Recruiting,"[{'id': 3095, 'therapyName': 'ALT-803 + Gemcitabine + nab-paclitaxel'}]",ALT-803 in Patients With Advanced Pancreatic Cancer Conjunction With Gemcitabine and Nab-Paclitaxel,433
8,NCT03214250,Phase Ib/II,Recruiting,"[{'id': 6047, 'therapyName': 'Gemcitabine + nab-paclitaxel + Nivolumab'}, {'id': 6048, 'therapyName': 'APX005M + Gemcitabine + nab-paclitaxel'}, {'id': 6049, 'therapyName': 'APX005M + Gemcitabine + nab-paclitaxel + Nivolumab'}]",Safety and Efficacy of APX005M With Gemcitabine and Nab-Paclitaxel With or Without Nivolumab in Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma,433
9,NCT02807636,Phase III,Recruiting,"[{'id': 4450, 'therapyName': 'Atezolizumab + Carboplatin + Gemcitabine'}, {'id': 2667, 'therapyName': 'Carboplatin + Gemcitabine'}]",The Effect of Atezolizumab in Combination With Gemcitabine/Carboplatin and Gemcitabine/Carboplatin Alone in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma Who Are Ineligible for Cisplatin-based Therapy,433
10,NCT02989584,Phase Ib/II,Recruiting,"[{'id': 5140, 'therapyName': 'Atezolizumab + Cisplatin + Gemcitabine'}]",A Pilot Safety Study of Atezolizumab Combination With Cisplatin + Gemcitabine in Pts With Metastatic Bladder Cancer,433
11,NCT03093922,Phase II,Recruiting,"[{'id': 5140, 'therapyName': 'Atezolizumab + Cisplatin + Gemcitabine'}]",A Study of Two Dosing Schedules of Atezolizumab in Combination With Gemcitabine and Cisplatin as First-Line Treatment for Metastatic Bladder Cancer,433
12,NCT02715531,Phase I,Recruiting,"[{'id': 3947, 'therapyName': 'Atezolizumab + Gemcitabine + nab-paclitaxel'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 1202, 'therapyName': 'Atezolizumab + Bevacizumab + Capecitabine'}]",A Study of the Safety and Tolerability of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors,433
13,NCT01983969,Phase Ib/II,"Active, not recruiting","[{'id': 897, 'therapyName': 'Rituximab'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 2558, 'therapyName': 'Busulfan + Melphalan'}, {'id': 2557, 'therapyName': 'Azacitidine + Gemcitabine + vorinostat'}]",Aza-SAHA-GBM With AutoSCT for Refractory Lymphoma,433
14,NCT02631590,Phase II,Recruiting,"[{'id': 3315, 'therapyName': 'BAY80-6946 + Cisplatin + Gemcitabine'}]",Copanlisib (BAY 80-6946) in Combination With Gemcitabine and Cisplatin in Advanced Cholangiocarcinoma,433
15,NCT02231723,Phase I,"Active, not recruiting","[{'id': 2630, 'therapyName': 'BBI608 + Gemcitabine + nab-paclitaxel'}]",A Study of BBI608 in Combination With Gemcitabine and Nab-Paclitaxel in Adult Patients With Metastatic Pancreatic Adenocarcinoma,433
16,NCT02993731,Phase III,Recruiting,"[{'id': 2630, 'therapyName': 'BBI608 + Gemcitabine + nab-paclitaxel'}, {'id': 1779, 'therapyName': 'Nab-paclitaxel + Gemcitabine'}]",A Study of Napabucasin Plus Nab-Paclitaxel With Gemcitabine in Adult Patients With Metastatic Pancreatic Adenocarcinoma (CanStem111P),433
17,NCT01106872,Phase Ib/II,Completed,"[{'id': 1466, 'therapyName': 'Bevacizumab + Gemcitabine + Docetaxel + Valproic Acid '}]","Bevacizumab, Chemotherapy and Valproic Acid in Advanced Sarcomas",433
18,NCT01971489,Phase I,Withdrawn,"[{'id': 1304, 'therapyName': 'BKM120 + Gemcitabine + Cisplatin'}]","PI3K Inhibitor BKM120, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Advanced Solid Tumors",433
19,NCT03184870,Phase Ib/II,Recruiting,"[{'id': 5905, 'therapyName': 'BMS-813160 + Fluorouracil + Irinotecan + Leucovorin'}, {'id': 5903, 'therapyName': 'BMS-813160 + Nivolumab'}, {'id': 5904, 'therapyName': 'BMS-813160 + Gemcitabine + nab-paclitaxel'}, {'id': 5902, 'therapyName': 'BMS-813160'}]",A Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Patients With Advanced Solid Tumors,433
20,NCT02650804,Phase II,Recruiting,"[{'id': 5759, 'therapyName': 'BPM 31510'}, {'id': 5842, 'therapyName': 'BPM 31510 + Gemcitabine'}]",BPM31510 Administered Intravenously With or Without Gemcitabine in Advanced Pancreatic Cancer Patients,433
21,NCT01701986,Phase Ib/II,Recruiting,"[{'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1845, 'therapyName': 'Mycophenolate mofetil'}, {'id': 1844, 'therapyName': 'anti-thymocyte globulin'}, {'id': 3992, 'therapyName': 'Busulfan + Clofarabine + Gemcitabine'}]",Gemcitabine/Clofarabine/Busulfan and Allogeneic Transplantation for Aggressive Lymphomas,433
22,NCT02961816,Phase II,Withdrawn,"[{'id': 3277, 'therapyName': 'Pyridoxine'}, {'id': 4976, 'therapyName': 'Busulfan + Gemcitabine + Melphalan + Panobinostat'}, {'id': 4977, 'therapyName': 'Dexamethasone + Filgrastim + Palifermin + Rituximab'}]",Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Lymphoma,433
23,NCT02608229,Phase I,Recruiting,"[{'id': 3249, 'therapyName': 'BVD-523 + Gemcitabine + nab-paclitaxel'}]",BVD-523 Plus Nab-paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Cancer,433
24,NCT02155088,Phase I,"Active, not recruiting","[{'id': 1870, 'therapyName': 'BYL719 + Gemcitabine + Abraxane'}]",BYL719 in Combination With Gemcitabine and (Nab)-Paclitaxel in Locally Advanced and Metastatic Pancreatic Cancer,433
25,NCT01663272,Phase I,"Active, not recruiting","[{'id': 2070, 'therapyName': 'Cabozantinib + Gemcitabine'}]",A Trial of Cabozantinib (XL184) and Gemcitabine in Advanced Pancreatic Cancer,433
26,NCT02611960,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 4203, 'therapyName': 'Capecitabine + Docetaxel + Gemcitabine'}]","Study of Pembrolizumab (MK-3475) in Platinum Pre-treated Recurrent/Metastatic Nasopharyngeal Cancer (MK-3475-122, KEYNOTE-122)",433
27,NCT02004262,Phase II,Completed,"[{'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 2383, 'therapyName': 'Capecitabine + Fluorouracil + Gemcitabine '}]",Safety and Efficacy of Combination Listeria/GVAX Pancreas Vaccine in the Pancreatic Cancer Setting,433
28,NCT03178552,Phase II,Recruiting,"[{'id': 4686, 'therapyName': 'Carboplatin + Cisplatin + Gemcitabine'}, {'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 4616, 'therapyName': 'Carboplatin + Cisplatin + Pemetrexed'}, {'id': 698, 'therapyName': 'Alectinib'}]",A Study to Evaluate Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC) (B-FAST),433
29,NCT02516241,Phase III,Recruiting,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}, {'id': 4686, 'therapyName': 'Carboplatin + Cisplatin + Gemcitabine'}, {'id': 1356, 'therapyName': 'Durvalumab'}]",Study of MEDI4736 With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer,433
30,NCT02853305,Phase III,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 4686, 'therapyName': 'Carboplatin + Cisplatin + Gemcitabine'}]",Study of Pembrolizumab With or Without Platinum-based Combination Chemotherapy Versus Chemotherapy Alone in Urothelial Carcinoma (MK-3475-361/KEYNOTE-361),433
31,NCT02046421,Phase I,"Active, not recruiting","[{'id': 2603, 'therapyName': 'Mifepristone'}, {'id': 2667, 'therapyName': 'Carboplatin + Gemcitabine'}]","Carboplatin, Gemcitabine Hydrochloride, and Mifepristone in Treating Patients With Advanced Breast Cancer or Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer",433
32,NCT03164616,Phase III,Recruiting,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}, {'id': 1857, 'therapyName': 'Cisplatin + Pemetrexed'}, {'id': 1602, 'therapyName': 'Carboplatin + Pemetrexed'}, {'id': 1467, 'therapyName': 'Gemcitabine + Cisplatin'}, {'id': 2667, 'therapyName': 'Carboplatin + Gemcitabine'}, {'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 2634, 'therapyName': 'Carboplatin + nab-paclitaxel'}]",Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON). (POSEIDON),433
33,NCT02819518,Phase III,Recruiting,"[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 619, 'therapyName': 'Abraxane'}, {'id': 2667, 'therapyName': 'Carboplatin + Gemcitabine'}]",Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs. Placebo Plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (MK-3475-355/KEYNOTE-355),433
34,NCT02755272,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 2667, 'therapyName': 'Carboplatin + Gemcitabine'}]",A Study of Pembrolizumab With Carboplatin and Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer,433
35,NCT02542293,Phase III,Recruiting,"[{'id': 1467, 'therapyName': 'Gemcitabine + Cisplatin'}, {'id': 2667, 'therapyName': 'Carboplatin + Gemcitabine'}, {'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 1857, 'therapyName': 'Cisplatin + Pemetrexed'}, {'id': 1602, 'therapyName': 'Carboplatin + Pemetrexed'}]",Study of 1st Line Therapy Study of MEDI4736 With Tremelimumab Versus SoC in Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE).,433
36,NCT02658214,Phase I,Recruiting,"[{'id': 2667, 'therapyName': 'Carboplatin + Gemcitabine'}, {'id': 2634, 'therapyName': 'Carboplatin + nab-paclitaxel'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 1791, 'therapyName': 'Carboplatin + Etoposide'}]",Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors,433
37,NCT02412670,Phase II,Recruiting,"[{'id': 2667, 'therapyName': 'Carboplatin + Gemcitabine'}, {'id': 2668, 'therapyName': 'Aldoxorubicin + Cisplatin + Methotrexate + Vincristine'}]",Chemotherapy Before Surgery in Treating Patients With High Grade Upper Urinary Tract Cancer,433
38,NCT02978716,Phase II,Recruiting,"[{'id': 2667, 'therapyName': 'Carboplatin + Gemcitabine'}, {'id': 5737, 'therapyName': 'Carboplatin + Gemcitabine + Trilaciclib'}]","Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC)",433
39,NCT02627443,Phase II,Recruiting,"[{'id': 2667, 'therapyName': 'Carboplatin + Gemcitabine'}, {'id': 2879, 'therapyName': 'VX-970'}]","Carboplatin and Gemcitabine Hydrochloride With or Without ATR Kinase Inhibitor VX-970 in Treating Patients With Recurrent and Metastatic Ovarian, Primary Peritoneal, or Fallopian Tube Cancer",433
40,NCT01663857,Phase Ib/II,"Active, not recruiting","[{'id': 3296, 'therapyName': 'Ralimetinib'}, {'id': 2667, 'therapyName': 'Carboplatin + Gemcitabine'}]",A Study of LY2228820 for Recurrent Ovarian Cancer,433
41,NCT02435680,Phase II,"Active, not recruiting","[{'id': 2838, 'therapyName': 'MCS110'}, {'id': 2667, 'therapyName': 'Carboplatin + Gemcitabine'}]",Efficacy Study of MCS110 Given With Carboplatin and Gemcitabine in Advanced Triple Negative Breast Cancer (TNBC),433
42,NCT03036098,Phase III,Recruiting,"[{'id': 1467, 'therapyName': 'Gemcitabine + Cisplatin'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}, {'id': 2667, 'therapyName': 'Carboplatin + Gemcitabine'}]",Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care Chemotherapy in Treatment of Patients With Untreated Inoperable or Metastatic Urothelial Cancer,433
43,NCT02784795,Phase I,Recruiting,"[{'id': 4374, 'therapyName': 'Cisplatin + Gemcitabine + LY3039478'}, {'id': 4375, 'therapyName': 'Carboplatin + Gemcitabine + LY3039478'}, {'id': 4372, 'therapyName': 'LY3039478 + LY3023414'}, {'id': 4373, 'therapyName': 'Abemaciclib + LY3039478'}, {'id': 4371, 'therapyName': 'LY3039478 + Taladegib'}, {'id': 2958, 'therapyName': 'LY3039478'}, {'id': 1069, 'therapyName': 'LY3023414'}]",A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors,433
44,NCT02227940,Phase I,Recruiting,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 619, 'therapyName': 'Abraxane'}, {'id': 2554, 'therapyName': 'Ceritinib + Gemcitabine'}]",Ceritinib and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors or Locally Advanced or Metastatic Pancreatic Cancer,433
45,NCT02436707,Phase II,Recruiting,"[{'id': 768, 'therapyName': 'Ibrutinib'}, {'id': 3391, 'therapyName': 'Cisplatin + Dexamethasone + Gemcitabine + Rituximab'}]",Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma,433
46,NCT01182168,Phase I,Completed,"[{'id': 2296, 'therapyName': 'Cisplatin + Everolimus + Gemcitabine'}]",Gemcitabine and Split-Dose Cisplatin Plus Everolimus (RAD001) in Patients With Advanced Solid Tumor Malignancies,433
47,NCT02393248,Phase Ib/II,Recruiting,"[{'id': 4176, 'therapyName': 'Cisplatin + Gemcitabine + INCB054828'}, {'id': 4174, 'therapyName': 'Docetaxel + INCB054828'}, {'id': 4088, 'therapyName': 'Epacadostat + Pembrolizumab'}]","Open-Label, Dose-Escalation Study of INCB054828 in Subjects With Advanced Malignancies",433
48,NCT02754726,Phase II,Recruiting,"[{'id': 4087, 'therapyName': 'Cisplatin + Gemcitabine + nab-paclitaxel + Nivolumab + Paricalcitol'}]",Combination Therapy for Patients With Untreated Metastatic Pancreatic Ductal Adenocarcinoma,433
49,NCT03101566,Phase II,Recruiting,"[{'id': 5511, 'therapyName': 'Cisplatin + Gemcitabine + Nivolumab'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Study of Nivolumab in Combination With Gemcitabine/Cisplatin or Ipilimumab for Patients With Advanced Unresectable Biliary Tract Cancer,433
50,NCT03064854,Phase I,Recruiting,"[{'id': 6027, 'therapyName': 'Carboplatin + Paclitaxel + PDR001'}, {'id': 6026, 'therapyName': 'Cisplatin + Pemetrexed + PDR001'}, {'id': 6025, 'therapyName': 'Cisplatin + Gemcitabine + PDR001'}, {'id': 6024, 'therapyName': 'Pemetrexed + PDR001 + Cisplatin + Carboplatin'}]","PDR001 in Combination With Platinum-doublet Chemotherapy in PD-L1 Unselected, Metastatic NSCLC Patients (ElevatION:NSCLC-101 Trial)",433
51,NCT02608684,Phase II,Recruiting,"[{'id': 3248, 'therapyName': 'Cisplatin + Gemcitabine + Pembrolizumab'}]",A Study of Pembrolizumab With Standard Treatment in Patients With Recurrent Platinum-resistant Ovarian Cancer,433
52,NCT02690558,Phase II,Recruiting,"[{'id': 3248, 'therapyName': 'Cisplatin + Gemcitabine + Pembrolizumab'}]",Phase 2 Study of Pembrolizumab in Combination With Gemcitabine and Cisplatin as Neoadjuvant Therapy,433
53,NCT02128282,Phase Ib/II,Recruiting,"[{'id': 1467, 'therapyName': 'Gemcitabine + Cisplatin'}, {'id': 6091, 'therapyName': 'Cisplatin + Gemcitabine + Silmitasertib'}]",Study of CX-4945 in Combination With Gemcitabine and Cisplatin for Frontline Treatment of Cholangiocarcinoma,433
54,NCT01938573,Phase Ib/II,Completed,"[{'id': 2289, 'therapyName': 'Cisplatin + Gemcitabine + Sirolimus '}]","Sirolimus, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Bladder Cancer",433
55,NCT01888302,Phase I,Completed,"[{'id': 2289, 'therapyName': 'Cisplatin + Gemcitabine + Sirolimus '}]","Sirolimus, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients At High Risk for Cholangiocarcinoma Recurrence After Liver Transplant or Surgery",433
56,NCT02567409,Phase II,Recruiting,"[{'id': 1467, 'therapyName': 'Gemcitabine + Cisplatin'}, {'id': 3110, 'therapyName': 'Cisplatin + Gemcitabine + VX-970'}]",Cisplatin and Gemcitabine Hydrochloride With or Without ATR Kinase Inhibitor VX-970 in Treating Patients With Metastatic Urothelial Cancer,433
57,NCT02998528,Phase III,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}, {'id': 5241, 'therapyName': 'Cisplatin + Vinorelbine + Gemcitabine + Docetaxel + Pemetrexed + Carboplatin'}]",A Neoadjuvant Study of Nivolumab and Ipilimumab Compared to Chemotherapy Doublet in Early Stage Non-Small Cell Lung Cancer (NSCLC) (CheckMate 816),433
58,NCT02546531,Phase I,Recruiting,"[{'id': 3083, 'therapyName': 'Defactinib + Gemcitabine + Pembrolizumab'}]",Defactinib Combined With Pembrolizumab and Gemcitabine in Patients With Advanced Cancer,433
59,NCT02289898,Phase II,"Active, not recruiting","[{'id': 2639, 'therapyName': 'Demcizumab + Gemcitabine + nab-paclitaxel'}]","Study of Gemcitabine, Abraxane Plus Placebo Versus Gemcitabine, Abraxane Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With 1st-Line Metastatic Pancreatic Ductal Adenocarcinoma",433
60,NCT00936936,Phase II,Recruiting,"[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 2101, 'therapyName': 'Etoposide + Ifosfamide'}, {'id': 2100, 'therapyName': 'Docetaxel + Gemcitabine + Melphalan'}, {'id': 2074, 'therapyName': 'Bevacizumab + Carboplatin'}]",High-dose Chemotherapy for Poor-prognosis Relapsed Germ-Cell Tumors,433
61,NCT02048943,Phase I,Withdrawn,"[{'id': 1372, 'therapyName': 'Dovitinib + Gemcitabine + Abraxane'}, {'id': 619, 'therapyName': 'Abraxane'}, {'id': 721, 'therapyName': 'Dovitinib'}]","Dovitinib Lactate, Gemcitabine Hydrochloride, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Solid Tumors or Pancreatic Cancer",433
62,NCT01683422,Phase II,Recruiting,"[{'id': 2473, 'therapyName': 'Erlotinib + Capecitabine + Gemcitabine'}]",Chemotherapy Plus Proton-chemotherapy for Locally Advanced Pancreatic Cancer,433
63,NCT02154737,Phase I,Recruiting,"[{'id': 2381, 'therapyName': 'Erlotinib + Gemcitabine'}]",Gemcitabine and Pulse Dose Erlotinib in Second Line Treatment of Advanced Pancreatic Cancer,433
64,NCT01013649,Phase II,Recruiting,"[{'id': 2381, 'therapyName': 'Erlotinib + Gemcitabine'}, {'id': 755, 'therapyName': 'Gemcitabine'}]",Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed By the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed By Surgery,433
65,NCT02352948,Phase III,"Active, not recruiting","[{'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 2438, 'therapyName': 'Erlotinib + Gemcitabine + Vinorelbine'}, {'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}, {'id': 1652, 'therapyName': 'Tremelimumab'}]","A Global Study to Assess the Effects of MEDI4736, Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer",433
66,NCT01259063,Phase Ib/II,Completed,"[{'id': 2279, 'therapyName': 'Everolimus + Gemcitabine'}]",RAD001 and Intravesical Gemcitabine in BCG-Refractory Primary or Secondary Carcinoma In Situ of the Bladder,433
67,NCT01564251,Phase I,"Active, not recruiting","[{'id': 2113, 'therapyName': 'GDC-0575 + Gemcitabine'}, {'id': 2024, 'therapyName': 'GDC-0575'}]",A Study of GDC-0575 Alone And in Combination With Gemcitabine in Patients With Refractory Solid Tumors or Lymphoma,433
68,NCT01945775,Phase III,"Active, not recruiting","[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 1685, 'therapyName': 'Vinorelbine'}, {'id': 682, 'therapyName': 'Talazoparib'}, {'id': 728, 'therapyName': 'Eribulin'}]","A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study)",433
69,NCT03191786,Phase III,Recruiting,"[{'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1685, 'therapyName': 'Vinorelbine'}]",A Study of Atezolizumab Compared With Chemotherapy in Treatment Naïve Participants With Locally Advanced or Recurrent or Metastatic Non-Small Cell Lung Cancer Who Are Deemed Unsuitable For Platinum-Containing Therapy,433
70,NCT03057106,Phase II,Recruiting,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}, {'id': 854, 'therapyName': 'Pemetrexed'}]",Durvalumab and Tremelimumab ± Platinum-Based Chemotherapy in Patients With Metastatic Squamous or Non-Squamous NSCLC,433
71,NCT02492711,Phase III,Recruiting,"[{'id': 1685, 'therapyName': 'Vinorelbine'}, {'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 808, 'therapyName': 'MGAH22'}]",Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer,433
72,NCT02620865,Phase Ib/II,Suspended,"[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1167, 'therapyName': 'Aldesleukin'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 1873, 'therapyName': 'Sargramostim'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 2278, 'therapyName': 'Fluorouracil + Leucovorin'}]",Bispecific Antibody Armed Activated T-cells With Aldesleukin and Sargramostim in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer,433
73,NCT02422381,Phase Ib/II,Recruiting,"[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",MK-3475 and Gemcitabine in Non-Small Cell Lung Cancer (NSCLC),433
74,NCT02589145,Phase Ib/II,Recruiting,"[{'id': 1164, 'therapyName': 'lenalidomide'}, {'id': 3277, 'therapyName': 'Pyridoxine'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 2558, 'therapyName': 'Busulfan + Melphalan'}, {'id': 3278, 'therapyName': 'Enoxaparin'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 2373, 'therapyName': 'Palifermin'}]",Lenalidomide Combined With Vorinostat/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Diffuse Large B-Cell Lymphoma of the ABC Subtype,433
75,NCT01959672,Phase II,Recruiting,"[{'id': 827, 'therapyName': 'Nelfinavir'}, {'id': 1189, 'therapyName': 'Oregovomab'}, {'id': 2278, 'therapyName': 'Fluorouracil + Leucovorin'}, {'id': 755, 'therapyName': 'Gemcitabine'}]",Combination Chemotherapy With or Without Oregovomab Followed by Stereotactic Body Radiation Therapy and Nelfinavir Mesylate in Treating Patients With Locally Advanced Pancreatic Cancer,433
76,NCT02265510,Phase I,Recruiting,"[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 1164, 'therapyName': 'lenalidomide'}, {'id': 619, 'therapyName': 'Abraxane'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 2747, 'therapyName': 'INCB052793'}, {'id': 688, 'therapyName': 'Bortezomib'}]","An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies",433
77,NCT00565851,Phase III,"Active, not recruiting","[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 3045, 'therapyName': 'Docetaxel + Paclitaxel'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 667, 'therapyName': 'Bevacizumab'}]","Carboplatin, Paclitaxel and Gemcitabine With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer",433
78,NCT01532687,Phase II,Recruiting,"[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1478, 'therapyName': 'Gemcitabine + Pazopanib'}]",Gemcitabine Hydrochloride With or Without Pazopanib Hydrochloride in Treating Patients With Refractory Soft Tissue Sarcoma,433
79,NCT02142738,Phase III,"Active, not recruiting","[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 854, 'therapyName': 'Pemetrexed'}]",Study of Pembrolizumab (MK-3475) Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (MK-3475-024/KEYNOTE-024),433
80,NCT01454102,Phase I,"Active, not recruiting","[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1312, 'therapyName': 'Nivolumab'}]","Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012)",433
81,NCT02788201,Phase II,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1133, 'therapyName': 'Mitomycin C'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1013, 'therapyName': 'epirubicin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1137, 'therapyName': 'Bleomycin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 781, 'therapyName': 'Ixabepilone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 2950, 'therapyName': 'Estramustine'}, {'id': 1941, 'therapyName': 'Floxuridine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 1811, 'therapyName': 'Carmustine'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 953, 'therapyName': 'Vandetanib'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 4419, 'therapyName': 'Toremifine'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 2601, 'therapyName': 'Dactinomycin'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 3035, 'therapyName': 'Chlorambucil'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 342, 'therapyName': 'Vemurafenib'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 2635, 'therapyName': 'Vinblastine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 4305, 'therapyName': 'Teniposide'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 4304, 'therapyName': 'Streptozocin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1231, 'therapyName': 'Bendamustine'}, {'id': 4303, 'therapyName': 'Mechlorethamine'}, {'id': 4302, 'therapyName': 'Mitotane'}]",Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma,433
82,NCT02574078,Phase I,Recruiting,"[{'id': 619, 'therapyName': 'Abraxane'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 2114, 'therapyName': 'Bevacizumab + Pemetrexed'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 1092, 'therapyName': 'Carboplatin'}]",A Master Protocol Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC) (CheckMate 370),433
83,NCT01497392,Phase I,Completed,"[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 721, 'therapyName': 'Dovitinib'}, {'id': 1105, 'therapyName': 'Capecitabine'}]"," Dovitinib Lactate, Gemcitabine Hydrochloride, and Capecitabine in Treating Patients With Advanced or Metastatic Solid Tumors, Pancreatic Cancer and Biliary Cancers",433
84,NCT01586611,Phase III,Unknown status,"[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}]",A Study to See if hENT1 Testing on Tumour Tissue Can Predict Response to Treatment With Gemcitabine Chemotherapy and if a Different Chemotherapy Called FOLFOX is Better Than Gemcitabine in Metastatic Pancreas Cancer,433
85,NCT01879085,Phase Ib/II,Recruiting,"[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1476, 'therapyName': 'Pegfilgrastim'}, {'id': 1077, 'therapyName': 'Vorinostat'}]",Phase 1b/2 Study of Vorinostat in Combination With Gemcitabine and Docetaxel in Advanced Sarcoma,433
86,NCT03257267,Phase III,Recruiting,"[{'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1685, 'therapyName': 'Vinorelbine'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 5656, 'therapyName': 'REGN2810'}, {'id': 942, 'therapyName': 'Topotecan'}]",Study of REGN2810 in Adults With Cervical Cancer,433
87,NCT02437370,Phase I,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 720, 'therapyName': 'Docetaxel'}]",Pembrolizumab and Docetaxel or Gemcitabine Hydrochloride in Treating Patients Urothelial Cancer,433
88,NCT02506959,Phase II,Recruiting,"[{'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 2558, 'therapyName': 'Busulfan + Melphalan'}, {'id': 3277, 'therapyName': 'Pyridoxine'}, {'id': 1080, 'therapyName': 'Panobinostat'}, {'id': 2373, 'therapyName': 'Palifermin'}, {'id': 755, 'therapyName': 'Gemcitabine'}]",Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Myeloma,433
89,NCT02079636,Phase I,Recruiting,"[{'id': 1069, 'therapyName': 'LY3023414'}, {'id': 802, 'therapyName': 'Abemaciclib'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 886, 'therapyName': 'Ramucirumab'}]",A Study of LY2835219 in Combination With Another Anti-cancer Drug in Participants With Lung Cancer (NSCLC),433
90,NCT01164228,Phase II,Recruiting,"[{'id': 930, 'therapyName': 'Sunitinib'}, {'id': 755, 'therapyName': 'Gemcitabine'}]",Sunitinib Malate With or Without Gemcitabine Hydrochloride in Treating Patients With Advanced Kidney Cancer That Cannot Be Removed By Surgery,433
91,NCT02237157,Phase I,"Active, not recruiting","[{'id': 755, 'therapyName': 'Gemcitabine'}]",A Dose Escalation Safety Study of Locally-Delivered Gemcitabine in Pancreatic Cancer,433
92,NCT02981342,Phase II,Recruiting,"[{'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 802, 'therapyName': 'Abemaciclib'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 5175, 'therapyName': 'Abemaciclib + LY3023414'}, {'id': 5176, 'therapyName': 'Abemaciclib + Galunisertib'}]",A Study of Abemaciclib (LY2835219) Alone or in Combination With Other Agents in Participants With Previously Treated Pancreatic Ductal Adenocarcinoma,433
93,NCT02275039,Phase I,"Active, not recruiting","[{'id': 1038, 'therapyName': 'MVAp53'}, {'id': 755, 'therapyName': 'Gemcitabine'}]",p53MVA Vaccine and Gemcitabine Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer,433
94,NCT03137771,Phase II,Recruiting,"[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 4, 'therapyName': 'Erlotinib'}]",Maintenance Chemotherapy With or Without Stereotactic Body Radiation Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer,433
95,NCT02551718,Phase I,Recruiting,"[{'id': 690, 'therapyName': 'Bosutinib'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 3160, 'therapyName': 'Nelarabine'}, {'id': 3159, 'therapyName': 'Bexarotene'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 998, 'therapyName': 'cabozantinib'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 877, 'therapyName': 'Ponatinib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 623, 'therapyName': 'Afatinib'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 890, 'therapyName': 'Regorafenib'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 2, 'therapyName': 'Trametinib'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 3, 'therapyName': 'Dabrafenib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 789, 'therapyName': 'Ceritinib'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1571, 'therapyName': 'Cabazitaxel'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1327, 'therapyName': 'Pralatrexate'}]",High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia,433
96,NCT02309177,Phase I,Recruiting,"[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 2489, 'therapyName': 'Abraxane + Nivolumab'}]","Safety Study of Nivolumab With Nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, Nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or Nab-Paclitaxel in Recurrent Metastatic Breast Cancer",433
97,NCT02009449,Phase I,"Active, not recruiting","[{'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 2621, 'therapyName': 'AM0010 '}, {'id': 619, 'therapyName': 'Abraxane'}]",A Phase 1 Study of AM0010 in Patients With Advanced Solid Tumors,433
98,NCT02399137,Phase II,"Active, not recruiting","[{'id': 619, 'therapyName': 'Abraxane'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1073, 'therapyName': 'MM-141'}]",A Phase 2 Study of MM-141 Plus Nab-paclitaxel and Gemcitabine in Front-line Metastatic Pancreatic Cancer,433
99,NCT02595892,Phase II,Recruiting,"[{'id': 2879, 'therapyName': 'VX-970'}, {'id': 755, 'therapyName': 'Gemcitabine'}]","Gemcitabine Hydrochloride Alone or With VX-970 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer",433
100,NCT01647828,Phase Ib/II,Completed,"[{'id': 619, 'therapyName': 'Abraxane'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 2547, 'therapyName': 'Tarextumab'}]",A Phase 1b/2 Study of OMP-59R5 in Combination With Nab-Paclitaxel and Gemcitabine in Subjects With Previously Untreated Stage IV Pancreatic Cancer,433
101,NCT02576574,Phase III,Recruiting,"[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 3144, 'therapyName': 'Avelumab'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 1092, 'therapyName': 'Carboplatin'}]",Avelumab in First-line Non-Small Cell Lung Cancer (JAVELIN Lung 100),433
102,NCT02620423,Phase I,"Active, not recruiting","[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 893, 'therapyName': 'Reolysin'}, {'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Study of Pembrolizumab With REOLYSIN and Chemotherapy in Patients With Advanced Pancreatic Adenocarcinoma,433
103,NCT02555657,Phase III,"Active, not recruiting","[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1685, 'therapyName': 'Vinorelbine'}, {'id': 1105, 'therapyName': 'Capecitabine'}]",Study of Single Agent Pembrolizumab (MK-3475) Versus Single Agent Chemotherapy for Metastatic Triple Negative Breast Cancer (MK-3475-119/KEYNOTE-119),433
104,NCT02101775,Phase II,Recruiting,"[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1279, 'therapyName': 'MK-1775 + Gemcitabine'}]","Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer",433
105,NCT02322281,Phase III,"Active, not recruiting","[{'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1003, 'therapyName': 'CO1686'}]","TIGER-3 Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet Chemotherapy",433
106,NCT02331251,Phase Ib/II,"Active, not recruiting","[{'id': 1685, 'therapyName': 'Vinorelbine'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 619, 'therapyName': 'Abraxane'}]",Study of Pembrolizumab Plus Chemotherapy in Patients With Advanced Cancer (PembroPlus),433
107,NCT02701673,Phase Ib/II,Withdrawn,"[{'id': 651, 'therapyName': 'Azacitidine'}, {'id': 3277, 'therapyName': 'Pyridoxine'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1078, 'therapyName': 'Belinostat'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1207, 'therapyName': 'Melphalan'}]",Belinostat Combined With Azacitidine/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Refractory or Relapsed Lymphoma,433
108,NCT02621151,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 755, 'therapyName': 'Gemcitabine'}]","Pembrolizumab (MK3475), Gemcitabine, and Concurrent Hypofractionated Radiation Therapy for Muscle-Invasive Urothelial Cancer of the Bladder",433
109,NCT01506973,Phase Ib/II,Recruiting,"[{'id': 1316, 'therapyName': 'Hydroxychloroquine'}, {'id': 755, 'therapyName': 'Gemcitabine'}]",A Phase I/II/Pharmacodynamic Study of Hydroxychloroquine in Combination With Gemcitabine/Abraxane to Inhibit Autophagy in Pancreatic Cancer,433
110,NCT02312245,Phase II,Recruiting,"[{'id': 942, 'therapyName': 'Topotecan'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 755, 'therapyName': 'Gemcitabine'}]","Avatar-Directed Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer",433
111,NCT02477826,Phase III,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 755, 'therapyName': 'Gemcitabine'}]","An Open-Label, Trial of Nivolumab and Nivolumab Plus Ipilimumab Versus Platinum Doublet Chemotherapy in Subjects With Stage IV Non-Small Cell Lung Cancer (NSCLC)",433
112,NCT02631876,Phase II,Recruiting,"[{'id': 3574, 'therapyName': 'Doxil + Paclitaxel'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 3232, 'therapyName': 'IMGN853'}]","PH2 Study of IMGN853 vs Investigator's Choice of Chemo in Adults With FRa+ Adv. EOC, Primary Peritoneal or Primary Fallopian Tube Cancer",433
113,NCT02117024,Phase II,"Active, not recruiting","[{'id': 2472, 'therapyName': 'HS-110 + Cyclophosphamide'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 1685, 'therapyName': 'Vinorelbine'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]",A Phase 2 Study of Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer,433
114,NCT02446600,Phase III,Recruiting,"[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 837, 'therapyName': 'Olaparib'}, {'id': 1001, 'therapyName': 'Cediranib'}]","Olaparib or Cediranib Maleate and Olaparib Compared With Standard Platinum-Based Chemotherapy in Treating Patients With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",433
115,NCT02855944,Phase III,Recruiting,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 906, 'therapyName': 'Rucaparib'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]","ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients",433
116,NCT01956812,Phase III,Terminated,"[{'id': 3000, 'therapyName': 'Y90 clivatuzumab tetraxetan'}, {'id': 755, 'therapyName': 'Gemcitabine'}]",Phase 3 Trial of 90Y-Clivatuzumab Tetraxetan & Gemcitabine vs Placebo & Gemcitabine in Metastatic Pancreatic Cancer (PANCRIT-1),433
117,NCT02157792,Phase I,Recruiting,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 2879, 'therapyName': 'VX-970'}, {'id': 755, 'therapyName': 'Gemcitabine'}]","An Open-Label, First-in-Human Study of the Safety, Tolerability, and Pharmacokinetics of VX-970 in Combination With Cytotoxic Chemotherapy",433
118,NCT02138383,Phase I,"Active, not recruiting","[{'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 619, 'therapyName': 'Abraxane'}, {'id': 755, 'therapyName': 'Gemcitabine'}]",Enzalutamide in Combination With Gemcitabine and Nab-Paclitaxel for the Treatment of Advanced Pancreatic Cancer,433
119,NCT02194829,Phase Ib/II,"Active, not recruiting","[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 822, 'therapyName': 'MK-1775'}]",Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Previously Untreated Pancreatic Cancer That Is Metastatic or Cannot Be Removed by Surgery,433
120,NCT01908478,Phase I,"Active, not recruiting","[{'id': 954, 'therapyName': 'Veliparib'}, {'id': 755, 'therapyName': 'Gemcitabine'}]","A Phase I Study of Veliparib (ABT-888) in Combination With Gemcitabine and Intensity Modulated Radiation Therapy in Patients With Locally Advanced, Unresectable Pancreatic Cancer",433
121,NCT01610206,Phase II,"Active, not recruiting","[{'id': 1478, 'therapyName': 'Gemcitabine + Pazopanib'}, {'id': 755, 'therapyName': 'Gemcitabine'}]",A Randomized Study of Safety and Efficacy of Pazopanib and Gemcitabine in Persistent or Relapsed Ovarian Cancer,433
122,NCT01858883,Phase I,Completed,"[{'id': 619, 'therapyName': 'Abraxane'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 2406, 'therapyName': 'INCB039110'}, {'id': 755, 'therapyName': 'Gemcitabine'}]",Safety Study of INCB039110 in Combination With Gemcitabine and Nab-Paclitaxel in Subjects With Advanced Solid Tumors,433
123,NCT02041533,Phase III,"Active, not recruiting","[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 755, 'therapyName': 'Gemcitabine'}]","An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026)",433
124,NCT03056599,,Recruiting,"[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1299, 'therapyName': 'Interferon alfa-2b '}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1733, 'therapyName': 'interferon gamma '}, {'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 3420, 'therapyName': 'trabectedin'}, {'id': 1167, 'therapyName': 'Aldesleukin'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 720, 'therapyName': 'Docetaxel'}]",Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO™ Device in Soft Tissue Sarcoma,433
125,NCT02565758,Phase I,Recruiting,"[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 619, 'therapyName': 'Abraxane'}, {'id': 3846, 'therapyName': 'ABBV-085'}]","ABBV-085, an Antibody Drug Conjugate, in Subjects With Advanced Solid Cancer Tumors",433
126,NCT03259503,Phase Ib/II,Not yet recruiting,"[{'id': 1206, 'therapyName': 'Busulfan'}, {'id': 837, 'therapyName': 'Olaparib'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 2373, 'therapyName': 'Palifermin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 3277, 'therapyName': 'Pyridoxine'}, {'id': 897, 'therapyName': 'Rituximab'}]",Olaparib Combined With High-Dose Chemotherapy for Refractory Lymphomas,433
127,NCT01935947,Phase II,Terminated,"[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 2645, 'therapyName': 'Azacitidine + Entinostat'}, {'id': 2646, 'therapyName': 'Docetaxel + Irinotecan + Pemetrexed '}]",Azacitidine and Entinostat Before Chemotherapy in Treating Patients With Advanced Non-small Cell Lung Cancer,433
128,NCT01248949,Phase I,Completed,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1176, 'therapyName': 'MEDI3617'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]",A Study to Evaluate the Safety and Antitumor Activity in Subjects With Advanced Solid Tumors,433
129,NCT02409355,Phase III,"Active, not recruiting","[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1201, 'therapyName': 'Atezolizumab'}]",A Study of MPDL3280A Compared With Gemcitabine + Cisplatin or Carboplatin in Patients With Stage IV Squamous Non-Small Cell Lung Cancer,433
130,NCT02365766,Phase Ib/II,Recruiting,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 755, 'therapyName': 'Gemcitabine'}]",Study of Neoadjuvant Pembrolizumab in Combination With Gemcitabine Based Therapy in Cis-eligible or -Ineligible Subjects With Urothelial Cancer,433
131,NCT01936974,Phase II,Terminated,"[{'id': 1295, 'therapyName': 'Gemcitabine + Bevacizumab + Cisplatin'}, {'id': 1296, 'therapyName': 'Gemcitabine + Bevacizumab + Oxaliplatin'}, {'id': 1294, 'therapyName': 'Gemcitabine + Bevacizumab + Carboplatin'}, {'id': 1297, 'therapyName': 'Gemcitabine + Bevacizumab'}]","(PGA) for Platinum-resistant/Refractory, Paclitaxel-Pretreated Recurrent Ovarian and Peritoneal Carcinoma",433
132,NCT00602602,Phase II,"Active, not recruiting","[{'id': 2102, 'therapyName': 'Bevacizumab + Fluorouracil + Oxaliplatin'}, {'id': 1296, 'therapyName': 'Gemcitabine + Bevacizumab + Oxaliplatin'}, {'id': 1297, 'therapyName': 'Gemcitabine + Bevacizumab'}]","Bevacizumab, Combination Chemotherapy, and Radiation Therapy in Treating Patients Undergoing Surgery For Locally Advanced Pancreatic Cancer",433
133,NCT00150657,Phase II,Unknown status,"[{'id': 1294, 'therapyName': 'Gemcitabine + Bevacizumab + Carboplatin'}]",Study of Carboplatin/Gemcitabine Plus Bevacizumab in Advanced Lung Cancer,433
134,NCT00942331,Phase III,"Active, not recruiting","[{'id': 1295, 'therapyName': 'Gemcitabine + Bevacizumab + Cisplatin'}, {'id': 1467, 'therapyName': 'Gemcitabine + Cisplatin'}]",Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer,433
135,NCT01916109,Phase II,Terminated,"[{'id': 1943, 'therapyName': 'Gemcitabine + Carboplatin + Panitumumab'}]","Study of Gemcitabine, Carboplatin, and Panitumumab (GCaP) as Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer",433
136,NCT01585805,Phase II,Recruiting,"[{'id': 954, 'therapyName': 'Veliparib'}, {'id': 1467, 'therapyName': 'Gemcitabine + Cisplatin'}]",Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Patients With Locally Advanced or Metastatic Pancreatic Cancer,433
137,NCT02177695,Phase II,Recruiting,"[{'id': 1467, 'therapyName': 'Gemcitabine + Cisplatin'}, {'id': 2564, 'therapyName': 'Aldoxorubicin + Cisplatin + Filgrastim + Methotrexate + Vinblastine'}]","S1314, Co-expression Extrapolation (COXEN) Program to Predict Chemotherapy Response in Patients With Bladder Cancer",433
138,NCT02300610,Phase I,"Active, not recruiting","[{'id': 1467, 'therapyName': 'Gemcitabine + Cisplatin'}, {'id': 1262, 'therapyName': 'Enzalutamide'}]",Enzalutamide in Combination With Gemcitabine and Cisplatin in Bladder Cancer,433
139,NCT02537561,Phase I,Withdrawn,"[{'id': 682, 'therapyName': 'Talazoparib'}, {'id': 1467, 'therapyName': 'Gemcitabine + Cisplatin'}]",Talazoparib in Combination With Gemcitabine and Cisplatin in Patients With Advanced Solid Tumors,433
140,NCT02711553,Phase II,"Active, not recruiting","[{'id': 886, 'therapyName': 'Ramucirumab'}, {'id': 1030, 'therapyName': 'LY2801653'}, {'id': 1467, 'therapyName': 'Gemcitabine + Cisplatin'}]",A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer,433
141,NCT02453282,Phase III,"Active, not recruiting","[{'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 1467, 'therapyName': 'Gemcitabine + Cisplatin'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 1652, 'therapyName': 'Tremelimumab'}]",Phase III Open Label First Line Therapy Study of MEDI 4736 With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC).,433
142,NCT02452970,Phase II,"Active, not recruiting","[{'id': 3680, 'therapyName': 'RRx-001'}, {'id': 1467, 'therapyName': 'Gemcitabine + Cisplatin'}]",RRx-001 in Second Line Treatment of Advanced Cholangiocarcinoma Prior to Readministration of First-Line Therapy (EPIC),433
143,NCT01660971,Phase I,"Active, not recruiting","[{'id': 1816, 'therapyName': 'Gemcitabine + Dasatinib + Erlotinib'}]","Gemcitabine Hydrochloride, Dasatinib, and Erlotinib Hydrochloride in Treating Patients With Metastatic Pancreatic Cancer That Cannot Be Removed By Surgery",433
144,NCT02049905,Phase III,Completed,"[{'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1440, 'therapyName': 'Aldoxorubicin'}, {'id': 1439, 'therapyName': 'Gemcitabine + Docetaxel'}]",Phase 3 Study to Treat Patients With Soft Tissue Sarcomas,433
145,NCT01593748,Phase II,"Active, not recruiting","[{'id': 1439, 'therapyName': 'Gemcitabine + Docetaxel'}, {'id': 1478, 'therapyName': 'Gemcitabine + Pazopanib'}]",A Treatment Trial Comparing Gemcitabine and Pazopanib Versus Gemcitabine and Docetaxel for Patients With Advanced Soft Tissue Sarcoma,433
146,NCT02659020,Phase Ib/II,Recruiting,"[{'id': 3269, 'therapyName': 'Olaratumab'}, {'id': 1439, 'therapyName': 'Gemcitabine + Docetaxel'}]",A Study of Olaratumab (LY3012207) in Participants With Advanced Soft Tissue Sarcoma,433
147,NCT02511132,Phase II,"Active, not recruiting","[{'id': 1157, 'therapyName': 'FANG vaccine'}, {'id': 1439, 'therapyName': 'Gemcitabine + Docetaxel'}]",Randomized Phase IIb Trial of Vigil Versus Gemcitabine + Docetaxel for Ewing's Sarcoma,433
148,NCT02045446,Phase II,"Active, not recruiting","[{'id': 1146, 'therapyName': 'Bevacizumab + Erlotinib'}, {'id': 1439, 'therapyName': 'Gemcitabine + Docetaxel'}]",Maintenance Chemotherapy Versus Consolidative Stereotactic Body Radiation Therapy (SBRT) Plus Maintenance Chemotherapy for Stage IV Non-Small Cell Lung Cancer (NSCLC),433
149,NCT01719302,Phase Ib/II,Completed,"[{'id': 1470, 'therapyName': 'Gemcitabine + Docetaxel + Pazopanib'}]","Docetaxel, Gemcitabine and Pazopanib as Treatment for Soft Tissue Sarcoma",433
150,NCT01418001,Phase Ib/II,Terminated,"[{'id': 1470, 'therapyName': 'Gemcitabine + Docetaxel + Pazopanib'}]",Gemcitabine and Docetaxel in Combination With Pazopanib (Gem/Doce/Pzb) for the Neoadjuvant Treatment of Soft Tissue Sarcoma (STS),433
151,NCT01376310,Phase II,"Active, not recruiting","[{'id': 1264, 'therapyName': 'Docetaxel + Trametinib'}, {'id': 1265, 'therapyName': 'Erlotinib + Trametinib'}, {'id': 2, 'therapyName': 'Trametinib'}, {'id': 1266, 'therapyName': 'Pemetrexed + GSK1120212'}, {'id': 1267, 'therapyName': 'Carboplatin + GSK1120212'}, {'id': 1268, 'therapyName': 'nab-paclitaxel + GSK1120212'}, {'id': 1269, 'therapyName': 'Gemcitabine + GSK1120212'}, {'id': 1271, 'therapyName': 'Everolimus + GSK1120212'}]",GSK1120212 Rollover Study,433
152,NCT02562898,Phase Ib/II,Recruiting,"[{'id': 3259, 'therapyName': 'Gemcitabine + Ibrutinib + Paclitaxel'}]",Ibrutinib Combined With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer,433
153,NCT01438112,,Terminated,"[{'id': 2524, 'therapyName': 'Gemcitabine + interferon + Mitomycin C + Valrubicin '}, {'id': 2523, 'therapyName': 'CG0070'}]",Efficacy Study of Recombinant Adenovirus for Non Muscle Invasive Bladder Cancer,433
154,NCT01473940,Phase I,"Active, not recruiting","[{'id': 2970, 'therapyName': 'Gemcitabine + Ipilimumab'}]",Ipilimumab and Gemcitabine Hydrochloride in Treating Patients With Stage III-IV or Recurrent Pancreatic Cancer That Cannot Be Removed by Surgery,433
155,NCT02583477,Phase Ib/II,Recruiting,"[{'id': 3099, 'therapyName': 'AZD5069 + MEDI4736'}, {'id': 3163, 'therapyName': 'Gemcitabine + MEDI4736 + nab-paclitaxel'}]",Phase Ib/II Study of MEDI4736 Evaluated in Different Combinations in Metastatic Pancreatic Ductal Carcinoma,433
156,NCT02105350,Phase I,Suspended,"[{'id': 2210, 'therapyName': 'Gemcitabine + MEK162 + Oxaliplatin'}]",A Study of MEK162 With Gemcitabine and Oxaliplatin in Biliary Cancer,433
157,NCT02303262,Phase II,Completed,"[{'id': 3128, 'therapyName': 'Gemcitabine + Mocetinostat'}]",A Study of Mocetinostat and Gemcitabine in Patients With Metastatic Leiomyosarcoma,433
158,NCT03193190,Phase Ib/II,Recruiting,"[{'id': 5942, 'therapyName': 'Atezolizumab + BKT140'}, {'id': 5940, 'therapyName': 'Gemcitabine + Nab-Paclitaxel + mFOLFOX-6'}, {'id': 5941, 'therapyName': 'Atezolizumab + PEGPH20'}, {'id': 1343, 'therapyName': 'Atezolizumab + Cobimetinib'}]",A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (PDAC),433
159,NCT02732938,Phase I,"Active, not recruiting","[{'id': 4340, 'therapyName': 'Gemcitabine + nab-paclitaxel + PF-04136309'}]",Ph1b/2 Study of PF-04136309 in Combination With Gem/Nab-P in First-line Metastatic Pancreatic Patients (CCR2i),433
160,NCT02178436,Phase Ib/II,Suspended,"[{'id': 2560, 'therapyName': 'Gemcitabine + nab-paclitaxel + Selinexor'}]","Selinexor, Gemcitabine Hydrochloride, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Metastatic Pancreatic Cancer",433
161,NCT01431794,Phase Ib/II,"Active, not recruiting","[{'id': 2497, 'therapyName': 'Gemcitabine + nab-paclitaxel + Sonidegib'}]",Gemcitabine + Nab-paclitaxel With LDE-225 (Hedgehog Inhibitor) as Neoadjuvant Therapy for Pancreatic Adenocarcinoma,433
162,NCT02005315,Phase I,"Active, not recruiting","[{'id': 4412, 'therapyName': 'Gemcitabine + nab-paclitaxel + Vantictumab'}]",A Study of Vantictumab (OMP-18R5) in Combination With Nab-Paclitaxel and Gemcitabine in Previously Untreated Stage IV Pancreatic Cancer,433
163,NCT02651727,Phase I,Terminated,"[{'id': 4342, 'therapyName': 'Gemcitabine + nab-paclitaxel + VS-4718'}]","Ph 1 Study of VS-4718, a FAK Inhibitor, in Combination With Nab-paclitaxel and Gemcitabine in Advanced Cancer Subjects",433
164,NCT02240238,Phase Ib/II,Recruiting,"[{'id': 5626, 'therapyName': 'Gemcitabine + NC-6004'}]","Combination Therapy With NC-6004 and Gemcitabine in Advanced Solid Tumors or Non-Small Cell Lung, Biliary and Bladder Cancer",433
165,NCT03302247,Phase II,Not yet recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 6297, 'therapyName': 'Gemcitabine + Nivolumab'}]",Depletion of Myeloid Derived Suppressor Cells to Enhance Anti PD-1 Therapy,433
166,NCT02181218,Phase I,Recruiting,"[{'id': 1476, 'therapyName': 'Pegfilgrastim'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1611, 'therapyName': 'Gemcitabine + Oxaliplatin + Dexamethasone'}]","Phase I Study of Romidepsin, Gemcitabine, Oxaliplatin, and Dexamethasone in Patients With Relapsed/Refractory Aggressive Lymphomas",433
167,NCT02951156,Phase III,Recruiting,"[{'id': 5088, 'therapyName': 'Avelumab + Azacitidine + Utomilumab'}, {'id': 5087, 'therapyName': 'Avelumab + Rituximab + Utomilumab'}, {'id': 2323, 'therapyName': 'Bendamustine + Rituximab'}, {'id': 5090, 'therapyName': 'Gemcitabine + Oxaliplatin + Rituximab'}, {'id': 5089, 'therapyName': 'Avelumab + Bendamustine + Rituximab'}]","Avelumab In Combination Regimens That Include An Immune Agonist, Epigenetic Modulator, CD20 Antagonist and/or Conventional Chemotherapy in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)",433
168,NCT01764477,Phase I,Completed,"[{'id': 2566, 'therapyName': 'Gemcitabine + Pri-724'}]",Safety and Efficacy Study of PRI-724 Plus Gemcitabine in Subjects With Advanced or Metastatic Pancreatic Adenocarcinoma,433
169,NCT02383433,Phase II,"Active, not recruiting","[{'id': 2491, 'therapyName': 'Gemcitabine + Regorafenib'}]",Regorafenib Plus Gemcitabine in Metastatic Pancreatic Cancer,433
170,NCT02414724,Phase I,Terminated,"[{'id': 2898, 'therapyName': 'Gemcitabine + Ribociclib'}]",Ribociclib and Gemcitabine Hydrochloride in Treating Patients With Advanced Solid Tumors or Lymphoma,433
171,NCT03237390,Phase I,Recruiting,"[{'id': 2898, 'therapyName': 'Gemcitabine + Ribociclib'}]",Ribociclib and Gemcitabine Hydrochloride in Treating Patients With Advanced or Metastatic Solid Tumors,433
172,NCT02954406,Phase I,Recruiting,"[{'id': 5150, 'therapyName': 'Lenalidomide + TAK-659'}, {'id': 5149, 'therapyName': 'Ibrutinib + TAK-659'}, {'id': 5148, 'therapyName': 'Gemcitabine + TAK-659'}, {'id': 5147, 'therapyName': 'Bendamustine + Rituximab + TAK-659'}, {'id': 5146, 'therapyName': 'Bendamustine + TAK-659'}]","A Study of TAK-659 in Combination With Bendamustine (+/-Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Participants With Advanced Non-Hodgkin Lymphoma",433
173,NCT02213744,Phase II,Terminated,"[{'id': 1890, 'therapyName': 'Vinorelbine + Trastuzumab'}, {'id': 1409, 'therapyName': 'Capecitabine + Trastuzumab'}, {'id': 1889, 'therapyName': 'Gemcitabine + Trastuzumab'}, {'id': 1888, 'therapyName': 'MM-302 + Trastuzumab'}]",MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in HER2-Positive Locally Advanced/Metastatic Breast Cancer Patients,433
174,NCT02139358,Phase Ib/II,"Active, not recruiting","[{'id': 1592, 'therapyName': 'Gemcitabine + Trastuzumab + Pertuzumab'}]",Phase I/IIa Trial of Gemcitabine Plus Trastuzumab and Pertuzumab in Previously Treated Metastatic HER2+ Breast Cancer,433
175,NCT02252887,Phase II,"Active, not recruiting","[{'id': 1592, 'therapyName': 'Gemcitabine + Trastuzumab + Pertuzumab'}]","Gemcitabine, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer After Prior Trastuzumab/Pertuzumab-Based Therapy, TDM-1, and TDM-1 + Pertuzumab",433
176,NCT03085914,Phase Ib/II,Recruiting,"[{'id': 5483, 'therapyName': 'INCB024360 + Nivolumab + mFOLFOX6'}, {'id': 5484, 'therapyName': 'INCB024360 + Nivolumab + Gemcitabine + nab-paclitaxel'}, {'id': 5485, 'therapyName': 'INCB024360 + Pembrolizumab + Carboplatin + Paclitaxel'}, {'id': 5486, 'therapyName': 'INCB024360 + Pembrolizumab + Carboplatin + Pemetrexed'}, {'id': 5487, 'therapyName': 'INCB024360 + Pembrolizumab + Cyclophosphamide'}]",A Study of Epacadostat in Combination With a PD-1 Inhibitor and Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors (ECHO-207),433
177,NCT01593228,Phase III,Completed,"[{'id': 1173, 'therapyName': 'Iniparib + doxorubicin + carboplatin'}, {'id': 1172, 'therapyName': 'Iniparib + Paclitaxel'}, {'id': 1171, 'therapyName': 'Iniparib + Irinotecan'}, {'id': 1170, 'therapyName': 'Iniparib + Topotecan'}, {'id': 1169, 'therapyName': 'Iniparib + Gemcitabine + Carboplatin'}, {'id': 1168, 'therapyName': 'Iniparib'}]", Treatment Extension Study for Patients Who Have Previously Participated and Have Benefited From Iniparib in a Clinical Trial,433
178,NCT00790816,Phase I,Completed,"[{'id': 1410, 'therapyName': 'Lapatinib + Paclitaxel'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 1414, 'therapyName': 'Trastuzumab + Lapatinib'}, {'id': 1399, 'therapyName': 'Lapatinib + Capecitabine'}, {'id': 1497, 'therapyName': 'Lapatinib + Letrozole'}, {'id': 1498, 'therapyName': 'Lapatinib + Oxaliplatin + Capecitabine'}, {'id': 1499, 'therapyName': 'Lapatinib + Gemcitabine'}, {'id': 1500, 'therapyName': 'Lapatinib + Docetaxel'}, {'id': 1501, 'therapyName': 'Lapatinib + Oxaliplatin + Leucovorin + Fluorouracil'}, {'id': 1502, 'therapyName': 'Lapatinib + Irinotecan + Leucovorin + Fluorouracil'}]",Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents,433
179,NCT02632448,Phase Ib/II,Recruiting,"[{'id': 4420, 'therapyName': 'LY2880070 + Gemcitabine'}, {'id': 4315, 'therapyName': 'LY2880070'}]",A Study of LY2880070 in Patients With Advanced or Metastatic Cancer,433
180,NCT02857270,Phase I,Recruiting,"[{'id': 4588, 'therapyName': 'LY3214996'}, {'id': 4590, 'therapyName': 'LY3214996 + nab-paclitaxel + Gemcitabine'}, {'id': 4589, 'therapyName': 'LY3214996 + Midazolam'}, {'id': 4591, 'therapyName': 'LY3214996 + Abemaciclib'}]",A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer,433
181,NCT01828034,Phase Ib/II,"Active, not recruiting","[{'id': 2218, 'therapyName': 'MEK162 + Gemcitabine + Cisplatin'}]","First Line Gemcitabine, Cisplatin and MEK162 in Advanced Biliary Tract Carcinoma",433
182,NCT02037230,Phase Ib/II,Recruiting,"[{'id': 1279, 'therapyName': 'MK-1775 + Gemcitabine'}]",Dose Escalation Trial of MK1775 and Gemcitabine (+Radiation) for Unresectable Adenocarcinoma of the Pancreas,433
183,NCT02272790,Phase II,Recruiting,"[{'id': 1194, 'therapyName': 'MK-1775 + Carboplatin '}, {'id': 1279, 'therapyName': 'MK-1775 + Gemcitabine'}, {'id': 1567, 'therapyName': 'MK-1775 + Paclitaxel'}]","A Phase II Study Comparing AZD1775 + Chemotherapy Versus Chemotherapy Alone in Patients to Treat Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.",433
184,NCT01733004,Phase I,Completed,"[{'id': 1248, 'therapyName': 'MM-141 + Everolimus'}, {'id': 1073, 'therapyName': 'MM-141'}, {'id': 1249, 'therapyName': 'MM-141 + Abraxane + Gemcitabine'}]",A Phase 1 Study of MM-141 in Patients With Advanced Solid Tumors,433
185,NCT02574663,Phase I,"Active, not recruiting","[{'id': 1779, 'therapyName': 'Nab-paclitaxel + Gemcitabine'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 2022, 'therapyName': 'TGR-1202'}]",TGR-1202 Alone and in Combination With Either Nab-paclitaxel + Gemcitabine or With FOLFOX in Patients With Select Relapsed or Refractory Solid Tumors,433
186,NCT02109445,Phase II,Terminated,"[{'id': 1779, 'therapyName': 'Nab-paclitaxel + Gemcitabine'}, {'id': 859, 'therapyName': 'PF-03084014'}]",Study Of PF-03084014 In Combination With Gemcitabine And Nab-Paclitaxel In Patients With Metastatic Pancreatic Adenocarcinoma Not Previously Treated With Anticancer Therapies,433
187,NCT02879318,Phase II,Recruiting,"[{'id': 1779, 'therapyName': 'Nab-paclitaxel + Gemcitabine'}, {'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}]","Gemcitabine and Nab-Paclitaxel vs Gemcitabine, Nab-Paclitaxel, Durvalumab and Tremelimumab as 1st Line Therapy in Pancreatic Adenocarcinoma",433
188,NCT01803282,Phase I,Recruiting,"[{'id': 3320, 'therapyName': 'GS-5745'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 1602, 'therapyName': 'Carboplatin + Pemetrexed'}, {'id': 1315, 'therapyName': 'FOLFIRI'}, {'id': 1779, 'therapyName': 'Nab-paclitaxel + Gemcitabine'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 667, 'therapyName': 'Bevacizumab'}]",Safety and Tolerability Study in Solid Tumors,433
189,NCT01921751,Phase II,Terminated,"[{'id': 1779, 'therapyName': 'Nab-paclitaxel + Gemcitabine'}, {'id': 1105, 'therapyName': 'Capecitabine'}]",High or Standard Intensity Radiation Therapy After Gemcitabine Hydrochloride and Nab-paclitaxel in Treating Patients With Pancreatic Cancer That Cannot Be Removed by Surgery,433
190,NCT03086369,Phase Ib/II,Recruiting,"[{'id': 5482, 'therapyName': 'Olaratumab + nab-paclitaxel + Gemcitabine'}, {'id': 1779, 'therapyName': 'Nab-paclitaxel + Gemcitabine'}]",A Study of Nab-Paclitaxel and Gemcitabine With or Without Olaratumab (LY3012207) in Participants With Metastatic Pancreatic Cancer,433
191,NCT01804530,Phase I,"Active, not recruiting","[{'id': 2651, 'therapyName': 'PLX7486'}, {'id': 1779, 'therapyName': 'Nab-paclitaxel + Gemcitabine'}]",Phase 1 Study of PLX7486 as Single Agent and With Gemcitabine Plus Nab-Paclitaxel in Patients With Advanced Solid Tumors,433
192,NCT02570711,Phase II,Terminated,"[{'id': 1605, 'therapyName': 'Acalabrutinib'}, {'id': 1779, 'therapyName': 'Nab-paclitaxel + Gemcitabine'}]",Study of Nab Paclitaxel/Gemcitabine Alone and in Combination With ACP-196 in Subjects With Previously Untreated Metastatic Pancreatic Cancer,433
193,NCT02077881,Phase Ib/II,Recruiting,"[{'id': 2976, 'therapyName': 'indoximod'}, {'id': 1779, 'therapyName': 'Nab-paclitaxel + Gemcitabine'}]",Study of IDO Inhibitor in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer,433
194,NCT02101021,Phase II,Terminated,"[{'id': 1779, 'therapyName': 'Nab-paclitaxel + Gemcitabine'}, {'id': 823, 'therapyName': 'Momelotinib'}]",Gemcitabine and Nab-paclitaxel Combined With Momelotinib in Participants With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma,433
195,NCT02340117,Phase II,Recruiting,"[{'id': 2518, 'therapyName': 'SGT-53'}, {'id': 1779, 'therapyName': 'Nab-paclitaxel + Gemcitabine'}]",Study of Combined SGT-53 Plus Gemcitabine/Nab-Paclitaxel for Metastatic Pancreatic Cancer,433
196,NCT01621243,Phase Ib/II,Terminated,"[{'id': 1779, 'therapyName': 'Nab-paclitaxel + Gemcitabine'}, {'id': 4251, 'therapyName': 'Necuparanib'}]",M402 in Combination With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer,433
197,NCT02436668,Phase II,"Active, not recruiting","[{'id': 1779, 'therapyName': 'Nab-paclitaxel + Gemcitabine'}, {'id': 768, 'therapyName': 'Ibrutinib'}]","Study of Ibrutinib vs Placebo, in Combination With Nab-paclitaxel and Gemcitabine, in the First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma",433
198,NCT01488552,Phase Ib/II,Completed,"[{'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 1315, 'therapyName': 'FOLFIRI'}, {'id': 1779, 'therapyName': 'Nab-paclitaxel + Gemcitabine'}, {'id': 1031, 'therapyName': 'Metformin'}]",Gemcitabine+Nab-paclitaxel and FOLFIRINOX and Molecular Profiling for Patients With Advanced Pancreatic Cancer,433
199,NCT02941601,Phase II,Withdrawn,"[{'id': 4973, 'therapyName': 'Necitumumab + Gemcitabine + Carboplatin'}]",A Study of Gemcitabine-Carboplatin Plus Necitumumab (LY3012211) in Chemotherapy-Naïve Participants With Locally Advanced or Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC),433
200,NCT01788566,Phase II,Completed,"[{'id': 2882, 'therapyName': 'Necitumumab + Gemcitabine + Cisplatin'}]",A Study of Gemcitabine-Cisplatin Chemotherapy Plus Necitumumab in the First-Line Treatment of Participants With Lung Cancer,433
201,NCT02902484,Phase Ib/II,Not yet recruiting,"[{'id': 4723, 'therapyName': 'Nintedanib + Gemcitabine + nab-paclitaxel'}, {'id': 831, 'therapyName': 'Nintedanib'}]",Study of Nintedanib and Chemotherapy for Advanced Pancreatic Cancer,433
202,NCT03083808,Phase II,Recruiting,"[{'id': 5497, 'therapyName': 'Pembrolizumab + Gemcitabine'}, {'id': 5496, 'therapyName': 'Docetaxel + Pembrolizumab'}, {'id': 5498, 'therapyName': 'Pemetrexed + Pembrolizumab'}, {'id': 854, 'therapyName': 'Pemetrexed'}]",Phase II Trial of Continuation Therapy in Advanced NSCLC,433
203,NCT02930902,Phase I,Recruiting,"[{'id': 4903, 'therapyName': 'Pembrolizumab + Paricalcitol'}, {'id': 4904, 'therapyName': 'Pembrolizumab + Paricalcitol + Gemcitabine + nab-paclitaxel'}]",Preoperative Pilot Study to Assess Safety and Immunological Effect of Pembrolizumab (Keytruda) in Combination With Paricalcitol With or Without Chemotherapy in Patients With Resectable Pancreatic Cancer,433
204,NCT01878617,Phase II,Recruiting,"[{'id': 956, 'therapyName': 'Vismodegib'}, {'id': 1800, 'therapyName': 'Cyclophosphamide + Cisplatin + Vincristine '}, {'id': 1801, 'therapyName': 'Pemetrexed + Gemcitabine'}]",A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma,433
205,NCT02151084,Phase II,Recruiting,"[{'id': 2222, 'therapyName': 'Selumetinib + Cisplatin + Gemcitabine'}]",A Study of Different Dosing Schedules of Selumetinib With Cisplatin/Gemcitabine (CIS/GEM) Versus CIS/GEM Alone in Biliary Cancer,433
206,NCT01088815,Phase II,Unknown status,"[{'id': 1799, 'therapyName': 'Vismodegib + Gemcitabine + Abraxane'}]",Hedgehog Inhibitors for Metastatic Adenocarcinoma of the Pancreas,433
0,NCT01409161,Phase II,Recruiting,"[{'id': 3685, 'therapyName': 'Arsenic trioxide + Gemtuzumab ozogamicin + Tretinoin'}]","Acute Promyelocytic Leukemia (APL) Treated With ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin",6915
1,NCT02339740,Phase III,Recruiting,"[{'id': 3686, 'therapyName': 'Cytarabine + Dexamethasone + Idarubicin + Mitoxantrone'}, {'id': 3685, 'therapyName': 'Arsenic trioxide + Gemtuzumab ozogamicin + Tretinoin'}]",Tretinoin and Arsenic Trioxide in Treating Patients With Untreated Acute Promyelocytic Leukemia,6915
2,NCT02221310,Phase II,Recruiting,"[{'id': 3932, 'therapyName': 'Busulfan + Cyclophosphamide + Gemtuzumab ozogamicin'}]",Immunochemotherapy and AlloSCT in Patients With High Risk CD33+ AML/MDS,6915
3,NCT01869803,Phase I,Suspended,"[{'id': 756, 'therapyName': 'Gemtuzumab ozogamicin'}]",Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Acute Promyelocytic Leukemia,6915
4,NCT02117297,Phase II,Recruiting,"[{'id': 756, 'therapyName': 'Gemtuzumab ozogamicin'}]",SCT Plus Immune Therapy in Average Risk AML/MDS,6915
0,NCT02624388,Phase II,Recruiting,"[{'id': 757, 'therapyName': 'Genistein'}]",Study of Genistein in Pediatric Oncology Patients (UVA-Gen001),1583
1,NCT01985763,Phase Ib/II,Completed,"[{'id': 757, 'therapyName': 'Genistein'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}]",Genistein in Treatment of Metastatic Colorectal Cancer,1583
2,NCT02766478,Phase II,Recruiting,"[{'id': 757, 'therapyName': 'Genistein'}]",Genistein Supplementation to Mitigate Cardiometabolic Dysfunction in Patients Undergoing Androgen Deprivation Therapy for Prostate Cancer,1583
3,NCT01489813,Phase II,Recruiting,"[{'id': 757, 'therapyName': 'Genistein'}]",Study of Genistein in Reducing Side Effects of Superficial Bladder Cancer Treatment,1583
4,NCT02499861,Phase Ib/II,Recruiting,"[{'id': 1734, 'therapyName': 'Genistein + Decitabine'}]",Phase I/II a Study of Decitabine in Combination With Genistein in Pediatric Relapsed or Refractory Malignancies,1583
5,NCT01628471,Phase Ib/II,Completed,"[{'id': 1734, 'therapyName': 'Genistein + Decitabine'}]","MTD Determination, Safety and Efficacy of the Decitabine-Genistein Drug Combination in Advanced Solid Tumors and Non-Small Cell Lung Cancer",1583
0,NCT03136406,Phase Ib/II,Recruiting,"[{'id': 1018, 'therapyName': 'GI-4000'}, {'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 3144, 'therapyName': 'Avelumab'}, {'id': 619, 'therapyName': 'Abraxane'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 6163, 'therapyName': 'ETBX-011'}, {'id': 3060, 'therapyName': 'ALT-803'}]",QUILT-3.039: NANT Pancreatic Cancer Vaccine: Combination Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy,7135
0,NCT02752035,Phase II,Recruiting,"[{'id': 2865, 'therapyName': 'Gilteritinib'}, {'id': 651, 'therapyName': 'Azacitidine'}]","A Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the Treatment of Newly Diagnosed Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation in Patients Not Eligible for Intensive Induction Chemotherapy",7799
1,NCT02236013,Phase I,Recruiting,"[{'id': 1606, 'therapyName': 'Cytarabine + Idarubicin'}, {'id': 2865, 'therapyName': 'Gilteritinib'}]",A Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia,7799
2,NCT02456883,Phase I,Completed,"[{'id': 2865, 'therapyName': 'Gilteritinib'}]","Study to Investigate the Absorption, Metabolism and Excretion of [14C] ASP2215 in Patients With Advanced Solid Tumors",7799
3,NCT02421939,Phase III,Recruiting,"[{'id': 712, 'therapyName': 'Cytarabine'}, {'id': 3193, 'therapyName': 'Cytarabine + Fludarabine + Idarubicin'}, {'id': 1752, 'therapyName': 'Mitoxantrone + Etoposide + Cytarabine'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 2865, 'therapyName': 'Gilteritinib'}, {'id': 1632, 'therapyName': 'Filgrastim'}]",A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,7799
4,NCT02561455,Phase Ib/II,"Active, not recruiting","[{'id': 2865, 'therapyName': 'Gilteritinib'}]",Rollover Study for Subjects Who Have Participated in an Astellas Sponsored ASP2215 Trial,7799
5,NCT02927262,Phase III,Recruiting,"[{'id': 2865, 'therapyName': 'Gilteritinib'}]","A Study of ASP2215 (Gilteritinib), Administered as Maintenance Therapy Following Induction/Consolidation Therapy for Subjects With FMS-like Tyrosine Kinase 3 (FLT3/ITD) Acute Myeloid Leukemia (AML) in First Complete Remission",7799
6,NCT03070093,Expanded access,Available,"[{'id': 2865, 'therapyName': 'Gilteritinib'}]",Expanded Access Study of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or FLT3-Mutated AML in Complete Remission (CR) With Minimal Residual Disease (MRD),7799
0,NCT00717587,Phase II,Unknown status,"[{'id': 930, 'therapyName': 'Sunitinib'}, {'id': 2129, 'therapyName': 'girentuximab'}, {'id': 2128, 'therapyName': 'motexafin gadolinium'}]",Sunitinib Before and After Surgery in Treating Patients With Stage IV Kidney Cancer,7429
0,NCT02180698,Phase I,Recruiting,"[{'id': 3576, 'therapyName': 'GLA-SE'}]",TLR4 Agonist GLA-SE and Radiation Therapy in Treating Patients With Soft Tissue Sarcoma That Is Metastatic or Cannot Be Removed by Surgery,8146
1,NCT02320305,Phase I,"Active, not recruiting","[{'id': 3787, 'therapyName': 'MART-1 antigen'}, {'id': 3889, 'therapyName': 'GLA-SE + MART-1 antigen'}]",MART-1 Antigen With or Without TLR4 Agonist GLA-SE in Treating Patients With Stage II-IV Melanoma That Has Been Removed by Surgery,8146
2,NCT02501473,Phase Ib/II,Recruiting,"[{'id': 3577, 'therapyName': 'GLA-SE + Pembrolizumab'}]",Study of Intratumoral G100 Therapy in Patients With Or Without Pembrolizumab With Follicular Non-Hodgkin's Lymphoma,8146
0,NCT02713828,Phase Ib/II,Recruiting,"[{'id': 3597, 'therapyName': 'Glembatumumab vedotin'}]","Study of Glembatumumab Vedotin in gpNMB-Expressing, Advanced or Metastatic SCC of the Lung",8160
1,NCT01997333,Phase II,"Active, not recruiting","[{'id': 3597, 'therapyName': 'Glembatumumab vedotin'}, {'id': 1105, 'therapyName': 'Capecitabine'}]","Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer",8160
2,NCT02487979,Phase II,"Active, not recruiting","[{'id': 3597, 'therapyName': 'Glembatumumab vedotin'}]",Glembatumumab Vedotin in Treating Patients With Recurrent or Refractory Osteosarcoma,8160
3,NCT02302339,Phase II,Recruiting,"[{'id': 3597, 'therapyName': 'Glembatumumab vedotin'}]",A Study of Glembatumumab Vedotin in Patients With Advanced Melanoma,8160
4,NCT02363283,Phase II,Recruiting,"[{'id': 3597, 'therapyName': 'Glembatumumab vedotin'}]",Glembatumumab Vedotin in Treating Patients With Metastatic or Locally Recurrent Uveal Melanoma,8160
0,NCT02306291,Phase Ib/II,Recruiting,"[{'id': 1606, 'therapyName': 'Cytarabine + Idarubicin'}, {'id': 1752, 'therapyName': 'Mitoxantrone + Etoposide + Cytarabine'}, {'id': 4402, 'therapyName': 'GMI-1271'}]","Study to Determine Safety, Pharmacokinetics and Efficacy of GMI-1271 in Combination With Chemotherapy in AML",8441
0,NCT02658396,Phase I,Withdrawn,"[{'id': 3427, 'therapyName': 'Bortezomib + GO-203-2C'}]",GO-203-2C + Bortezomib For Relapsed Or Refractory MM,8075
1,NCT02204085,Phase Ib/II,Recruiting,"[{'id': 3426, 'therapyName': 'GO-203-2C'}]","A Phase I/II Trial of the MUC1 Inhibitor, GO-203-2C in Patients With Relapsed or Refractory Acute Myeloid Leukemia",8075
0,NCT01433991,Phase Ib/II,"Active, not recruiting","[{'id': 1019, 'therapyName': 'Golvatinib'}, {'id': 792, 'therapyName': 'Lenvatinib'}]",E7050 in Combination With E7080 in Subjects With Advanced Solid Tumors (Dose Escalation) and in Subjects With Recurrent Glioblastoma or Unresectable Stage III or Stage IV Melanoma After Prior Systemic Therapy (Expansion Cohort and Phase 2),7136
0,NCT03141671,Phase II,Not yet recruiting,"[{'id': 5742, 'therapyName': 'Bicalutamide + Gonadorelin'}, {'id': 5743, 'therapyName': 'Abiraterone + ARN-509 + Gonadorelin + Prednisone'}]",Randomized Phase II Study of Salvage XRT + ADT +/- Abiraterone and Apalutamide for Rising PSA After RP (FORMULA-509),634
0,NCT03070886,Phase III,Recruiting,"[{'id': 5450, 'therapyName': 'Bicalutamide + Docetaxel + Flutamide + Goserelin + Leuprolide + Nilutamide'}, {'id': 5449, 'therapyName': 'Bicalutamide + Flutamide + Goserelin + Leuprolide + Nilutamide'}]",Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery,14
1,NCT01786265,Phase II,"Active, not recruiting","[{'id': 759, 'therapyName': 'Goserelin'}, {'id': 1814, 'therapyName': 'Degarelix'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 795, 'therapyName': 'Leuprolide'}]",Finite Androgen Ablation vs. Finite Androgen Ablation in Combination With Abiraterone Acetate and Prednisone,14
2,NCT00541047,Phase III,"Active, not recruiting","[{'id': 795, 'therapyName': 'Leuprolide'}, {'id': 759, 'therapyName': 'Goserelin'}, {'id': 1507, 'therapyName': 'Bicalutamide'}]",Radiation Therapy and Androgen Deprivation Therapy in Treating Patients Who Have Undergone Surgery for Prostate Cancer (RADICALS),14
3,NCT02476786,Phase II,Recruiting,"[{'id': 633, 'therapyName': 'Anastrozole'}, {'id': 744, 'therapyName': 'Fulvestrant'}, {'id': 759, 'therapyName': 'Goserelin'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 738, 'therapyName': 'Exemestane'}]",Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score,14
4,NCT02003209,Phase III,"Active, not recruiting","[{'id': 759, 'therapyName': 'Goserelin'}, {'id': 1879, 'therapyName': 'Pertuzumab + Trastuzumab + Carboplatin + Docetaxel'}]","Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer",14
5,NCT02346253,Phase Ib/II,Recruiting,"[{'id': 795, 'therapyName': 'Leuprolide'}, {'id': 2050, 'therapyName': 'Triptorelin'}, {'id': 1814, 'therapyName': 'Degarelix'}, {'id': 1507, 'therapyName': 'Bicalutamide'}, {'id': 759, 'therapyName': 'Goserelin'}]",High-Dose Brachytherapy in Treating Patients With Prostate Cancer,14
6,NCT02278185,Phase II,Recruiting,"[{'id': 759, 'therapyName': 'Goserelin'}, {'id': 1814, 'therapyName': 'Degarelix'}, {'id': 2047, 'therapyName': 'Histrelin acetate'}, {'id': 2050, 'therapyName': 'Triptorelin'}, {'id': 795, 'therapyName': 'Leuprolide'}, {'id': 1262, 'therapyName': 'Enzalutamide'}]",Enzalutamide Versus Standard Androgen Deprivation Therapy for the Treatment Hormone Sensitive Prostate Cancer,14
7,NCT02059213,Phase II,"Active, not recruiting","[{'id': 759, 'therapyName': 'Goserelin'}, {'id': 850, 'therapyName': 'Palbociclib'}, {'id': 1507, 'therapyName': 'Bicalutamide'}, {'id': 795, 'therapyName': 'Leuprolide'}]", A Phase II Study of Androgen Deprivation Therapy With or Without PD 0332991 in RB-Positive Metastatic Prostate Cancer,14
8,NCT03279250,Phase II,Not yet recruiting,"[{'id': 759, 'therapyName': 'Goserelin'}, {'id': 2050, 'therapyName': 'Triptorelin'}, {'id': 2649, 'therapyName': 'Abiraterone + ARN-509 + Prednisone'}, {'id': 795, 'therapyName': 'Leuprolide'}, {'id': 1947, 'therapyName': 'ARN-509'}]",Effects of Apalutamide Plus LHRH Agonist or Apalutamide Plus Abiraterone Acetate Plus LHRH Agonist for Six Months for Prostate Cancer Patients at High Risk for Recurrence,14
9,NCT02626507,Phase I,Recruiting,"[{'id': 850, 'therapyName': 'Palbociclib'}, {'id': 1040, 'therapyName': 'PF-05212384'}, {'id': 759, 'therapyName': 'Goserelin'}, {'id': 744, 'therapyName': 'Fulvestrant'}]",Phase I Study of Combination of Gedatolisib With Palbociclib and Faslodex in Patients With ER+/HER2- Breast Cancer,14
10,NCT02064036,Phase I,Recruiting,"[{'id': 1507, 'therapyName': 'Bicalutamide'}, {'id': 759, 'therapyName': 'Goserelin'}, {'id': 795, 'therapyName': 'Leuprolide'}]",Stereotactic Boost and Long-Term Androgen Deprivation for Adenocarcinoma of the Prostate,14
11,NCT02594072,Phase I,Recruiting,"[{'id': 759, 'therapyName': 'Goserelin'}]",Androgen Suppression With Stereotactic Body or External Beam Radiation Therapy (ASSERT) (ASSERT),14
12,NCT02586675,Phase I,"Active, not recruiting","[{'id': 759, 'therapyName': 'Goserelin'}, {'id': 3175, 'therapyName': 'LEE001 + Tamoxifen'}]",TEEL Study- Phase 1 Tamoxifen and Ribociclib (LEE011) in Advanced ER+ (HER2 Negative) Breast Cancer,14
13,NCT02907918,Phase II,Recruiting,"[{'id': 759, 'therapyName': 'Goserelin'}, {'id': 4756, 'therapyName': 'Letrozole + Palbociclib + Trastuzumab'}]",Neoadjuvant Study of Palbociclib in Combination With Letrozole and Trastuzumab in Stage II-III ER+ HER2+ Breast Cancer (PALTAN),14
14,NCT00936390,Phase III,"Active, not recruiting","[{'id': 742, 'therapyName': 'Flutamide'}, {'id': 759, 'therapyName': 'Goserelin'}, {'id': 795, 'therapyName': 'Leuprolide'}, {'id': 2050, 'therapyName': 'Triptorelin'}, {'id': 1507, 'therapyName': 'Bicalutamide'}]",Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer,14
15,NCT01674140,Phase III,Recruiting,"[{'id': 759, 'therapyName': 'Goserelin'}, {'id': 633, 'therapyName': 'Anastrozole'}, {'id': 794, 'therapyName': 'Letrozole'}, {'id': 795, 'therapyName': 'Leuprolide'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 738, 'therapyName': 'Exemestane'}]",S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer,14
16,NCT02366494,Phase I,Recruiting,"[{'id': 795, 'therapyName': 'Leuprolide'}, {'id': 759, 'therapyName': 'Goserelin'}, {'id': 2050, 'therapyName': 'Triptorelin'}, {'id': 1507, 'therapyName': 'Bicalutamide'}, {'id': 720, 'therapyName': 'Docetaxel'}]",Micro RNAs to Predict Response to Androgen Deprivation Therapy,14
17,NCT01717053,Phase II,"Active, not recruiting","[{'id': 795, 'therapyName': 'Leuprolide'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 759, 'therapyName': 'Goserelin'}]","Abiraterone, Radiotherapy and Short-Term Androgen Deprivation in Unfavorable Localized Prostate Cancer",14
18,NCT01723774,Phase II,Recruiting,"[{'id': 850, 'therapyName': 'Palbociclib'}, {'id': 633, 'therapyName': 'Anastrozole'}, {'id': 759, 'therapyName': 'Goserelin'}]",PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer,14
19,NCT02278120,Phase III,"Active, not recruiting","[{'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 794, 'therapyName': 'Letrozole'}, {'id': 790, 'therapyName': 'Ribociclib'}, {'id': 759, 'therapyName': 'Goserelin'}, {'id': 633, 'therapyName': 'Anastrozole'}]","Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer",14
20,NCT03007979,Phase II,Recruiting,"[{'id': 759, 'therapyName': 'Goserelin'}, {'id': 3205, 'therapyName': 'Fulvestrant + Palbociclib'}, {'id': 2922, 'therapyName': 'Palbociclib + Letrozole'}]",Alternative Dosing Schedule of Palbociclib in Metastatic Hormone Receptor Positive Breast Cancer,14
21,NCT02023463,Phase I,"Active, not recruiting","[{'id': 759, 'therapyName': 'Goserelin'}, {'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 795, 'therapyName': 'Leuprolide'}]","Enzalutamide, Radiation Therapy and Hormone Therapy in Treating Patients With Intermediate or High-Risk Prostate Cancer",14
22,NCT02058706,Phase II,Recruiting,"[{'id': 759, 'therapyName': 'Goserelin'}, {'id': 1507, 'therapyName': 'Bicalutamide'}, {'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 795, 'therapyName': 'Leuprolide'}]",LHRH Analogue Therapy With Enzalutamide or Bicalutamide in Treating Patients With Metastatic Hormone Sensitive Prostate Cancer,14
23,NCT02430480,Phase II,Recruiting,"[{'id': 759, 'therapyName': 'Goserelin'}]",Using Multiparametric MRI to Evaluate Intraprostatic Tumor Responses and Androgen Resistance Patterns in Newly Diagnosed Prostate Cancer,14
24,NCT02204098,Phase I,Recruiting,"[{'id': 794, 'therapyName': 'Letrozole'}, {'id': 633, 'therapyName': 'Anastrozole'}, {'id': 759, 'therapyName': 'Goserelin'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 1456, 'therapyName': 'Tamoxifen'}]",Safety and Immune Response to a Mammaglobin-A DNA Vaccine In Breast Cancer Patients Undergoing Neoadjuvant Endocrine Therapy,14
25,NCT02472275,Phase I,Recruiting,"[{'id': 795, 'therapyName': 'Leuprolide'}, {'id': 874, 'therapyName': 'PLX3397'}, {'id': 759, 'therapyName': 'Goserelin'}, {'id': 1814, 'therapyName': 'Degarelix'}]","PLX3397, Radiation Therapy, and Antihormone Therapy in Treating Patients With Intermediate- or High-Risk Prostate Cancer",14
26,NCT02115282,Phase III,Recruiting,"[{'id': 759, 'therapyName': 'Goserelin'}, {'id': 1541, 'therapyName': 'Entinostat'}, {'id': 738, 'therapyName': 'Exemestane'}]",Exemestane With or Without Entinostat in Treating Postmenopausal Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic,14
27,NCT02685397,Phase II,Recruiting,"[{'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 2050, 'therapyName': 'Triptorelin'}, {'id': 759, 'therapyName': 'Goserelin'}, {'id': 795, 'therapyName': 'Leuprolide'}]",Management of Castration-Resistant Prostate Cancer With Oligometastases,14
28,NCT00002651,Phase III,Completed,"[{'id': 1507, 'therapyName': 'Bicalutamide'}, {'id': 759, 'therapyName': 'Goserelin'}]",Hormone Therapy in Treating Men With Stage IV Prostate Cancer,14
29,NCT01776008,Phase II,"Active, not recruiting","[{'id': 1548, 'therapyName': 'Goserelin + MK2206'}]",Akt Inhibitor MK-2206 and Anastrozole With or Without Goserelin Acetate in Treating Patients With Stage II-III Breast Cancer,14
30,NCT02941926,Phase III,Recruiting,"[{'id': 5310, 'therapyName': 'Ribociclib + Letrozole + Goserelin'}]",Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC,14
0,NCT02267083,Phase II,Completed,"[{'id': 2041, 'therapyName': 'GPX-150'}]",Efficacy and Safety Study of GPX-150 to Treat Soft Tissue Sarcoma,7403
0,NCT02575404,Phase I,Recruiting,"[{'id': 2975, 'therapyName': 'GR-MD-02'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",GR-MD-02 Plus Pembrolizumab in Melanoma Patients,7883
1,NCT02117362,Phase I,Recruiting,"[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 2975, 'therapyName': 'GR-MD-02'}]",Galectin Inhibitor (GR-MD-02) and Ipilimumab in Patients With Metastatic Melanoma,7883
0,NCT01967810,Phase II,Completed,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 2053, 'therapyName': 'GRN1005'}]",ANG1005 in Patients With Recurrent High-Grade Glioma,7409
1,NCT02048059,Phase II,Completed,"[{'id': 2053, 'therapyName': 'GRN1005'}]",ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases,7409
0,NCT01803282,Phase I,Recruiting,"[{'id': 3320, 'therapyName': 'GS-5745'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 1602, 'therapyName': 'Carboplatin + Pemetrexed'}, {'id': 1315, 'therapyName': 'FOLFIRI'}, {'id': 1779, 'therapyName': 'Nab-paclitaxel + Gemcitabine'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 667, 'therapyName': 'Bevacizumab'}]",Safety and Tolerability Study in Solid Tumors,8031
1,NCT02545504,Phase III,"Active, not recruiting","[{'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 3320, 'therapyName': 'GS-5745'}]",GS-5745 With mFOLFOX6 as First Line Treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma,8031
2,NCT02864381,Phase II,"Active, not recruiting","[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 4736, 'therapyName': 'GS-5745 + Nivolumab'}]",GS-5745 Combined With Nivolumab Versus Nivolumab Alone in Adults With Unresectable or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma,8031
0,NCT02392611,Phase I,"Active, not recruiting","[{'id': 3561, 'therapyName': 'GS-5829 + Exemestane'}]","Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5829 in Adults With Advanced Solid Tumors and Lymphomas",8138
1,NCT02607228,Phase Ib/II,Recruiting,"[{'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 3561, 'therapyName': 'GS-5829 + Exemestane'}]","Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5829 as a Single Agent and In Combination With Enzalutamide in Participants With Metastatic Castrate-Resistant Prostate Cancer",8138
2,NCT02983604,Phase Ib/II,Recruiting,"[{'id': 738, 'therapyName': 'Exemestane'}, {'id': 5074, 'therapyName': 'GS-5829 + Fulvestrant'}, {'id': 3561, 'therapyName': 'GS-5829 + Exemestane'}, {'id': 744, 'therapyName': 'Fulvestrant'}]",GS-5829 in Combination With Exemestane or Fulvestrant Comparing With Exemestane or Fulvestrant Alone in Women With Advanced Estrogen Receptor Positive HER2- Breast Cancer,8138
0,NCT02523014,Phase II,Recruiting,"[{'id': 3078, 'therapyName': 'GSK2256098'}, {'id': 956, 'therapyName': 'Vismodegib'}]",A Study Looking at Targeted Therapy According to Tumor Markers for People With Meningiomas,7929
1,NCT02428270,Phase II,Recruiting,"[{'id': 4205, 'therapyName': 'GSK2256098 + Trametinib'}]",A Study of GSK2256098 and Trametinib in Advanced Pancreatic Cancer,7929
0,NCT01458067,Phase I,Completed,"[{'id': 765, 'therapyName': 'GSK2636771'}]"," A Phase I/IIa, First Time in Human, Study of GSK2636771 in Subjects With Advanced Solid Tumors With Phosphatase and Tensin Homolog (PTEN) Deficiency",6921
1,NCT02465060,Phase II,Recruiting,"[{'id': 660, 'therapyName': 'AZD9291'}, {'id': 3, 'therapyName': 'Dabrafenib'}, {'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 2, 'therapyName': 'Trametinib'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 623, 'therapyName': 'Afatinib'}, {'id': 654, 'therapyName': 'AZD4547'}, {'id': 958, 'therapyName': 'VS-6063'}, {'id': 765, 'therapyName': 'GSK2636771'}]",NCI-MATCH Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas,6921
2,NCT02215096,Phase I,Recruiting,"[{'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 765, 'therapyName': 'GSK2636771'}]",Dose-finding Study of GSK2636771 When Administered in Combination With Enzalutamide in Male Subjects With Metastatic Castration-Resistant Prostate Cancer,6921
3,NCT03131908,Phase Ib/II,Recruiting,"[{'id': 3518, 'therapyName': 'GSK2636771 + Pembrolizumab'}]",Study of the Selective PI3K-Beta Inhibitor GSK2636771 in Combination With Pembrolizumab in Patients With Metastatic Melanoma and PTEN Loss,6921
0,NCT02082977,Phase I,Terminated,"[{'id': 2734, 'therapyName': 'GSK2816126'}]","A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK2816126 in Subjects With Relapsed/Refractory Diffuse Large B Cell and Transformed Follicular Lymphoma",7689
0,NCT01966445,Phase I,"Active, not recruiting","[{'id': 2919, 'therapyName': 'GSK2849330'}]","Dose Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of GSK2849330 in Subjects With Advanced Her3-Positive Solid Tumors",7842
0,NCT02177812,Phase I,Recruiting,"[{'id': 3014, 'therapyName': 'GSK2879552 '}]",A Phase I Dose Escalation Study of GSK2879552 in Subjects With Acute Myeloid Leukemia (AML),7911
1,NCT02034123,Phase I,Terminated,"[{'id': 3014, 'therapyName': 'GSK2879552 '}]",Investigation of GSK2879552 in Subjects With Relapsed/Refractory Small Cell Lung Carcinoma,7911
0,NCT01868022,Phase I,"Active, not recruiting","[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1857, 'therapyName': 'Cisplatin + Pemetrexed'}, {'id': 2899, 'therapyName': 'GSK3052230'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]","Study to Evaluate GSK3052230 in Combination With Paclitaxel and Carboplatin, or Docetaxel or as Single Agent in Subjects With Solid Malignancies and Deregulated Fibroblast Growth Factor (FGF) Pathway Signaling",7822
0,NCT02528357,Phase I,Recruiting,"[{'id': 5177, 'therapyName': 'GSK3174998'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",GSK3174998 Alone or With Pembrolizumab in Subjects With Advanced Solid Tumors,8626
0,NCT02723955,Phase I,Recruiting,"[{'id': 4409, 'therapyName': 'GSK3359609'}, {'id': 4410, 'therapyName': 'GSK3359609 + Pembrolizumab'}]",Dose Escalation and Expansion Study of GSK3359609 in Subjects With Selected Advanced Solid Tumors (INDUCE-1),8444
0,NCT03150056,Phase I,Recruiting,"[{'id': 6034, 'therapyName': 'Abiraterone + GSK525762'}, {'id': 6035, 'therapyName': 'Enzalutamide + GSK525762'}, {'id': 2188, 'therapyName': 'Prednisone'}]",Dose Escalation and Dose Expansion Study of GSK525762 in Combination With Androgen Deprivation Therapy and Other Agents in Subjects With Castrate-resistant Prostate Cancer,7066
1,NCT01943851,Phase I,Recruiting,"[{'id': 784, 'therapyName': 'GSK525762'}]","A Dose Escalation Study to Investigate the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD) and Clinical Activity of GSK525762 in Subjects With Relapsed, Refractory Hematologic Malignancies",7066
2,NCT01587703,Phase I,Recruiting,"[{'id': 784, 'therapyName': 'GSK525762'}]","A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK525762 in Subjects With NUT Midline Carcinoma (NMC) and Other Cancers",7066
3,NCT02964507,Phase II,Recruiting,"[{'id': 744, 'therapyName': 'Fulvestrant'}, {'id': 5242, 'therapyName': 'GSK525762 + Fulvestrant'}]",Dose Escalation and Expansion Study of GSK525762 in Combination With Fulvestrant in Subjects With Estrogen Receptor Positive (ER+) Breast Cancer,7066
0,NCT02981524,Phase II,Recruiting,"[{'id': 5079, 'therapyName': 'Cyclophosphamide + GVAX colorectal cancer vaccine + Pembrolizumab'}]",Phase 2 Study of GVAX (With CY) and Pembrolizumab in MMR-p Advanced Colorectal Cancer,7885
1,NCT01966289,Phase I,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1949, 'therapyName': 'SGI-110'}, {'id': 2977, 'therapyName': 'GVAX colorectal cancer vaccine'}]",SGI-110 in Combination With an Allogeneic Colon Cancer Cell Vaccine (GVAX) and Cyclophosphamide (CY) in Metastatic Colorectal Cancer (mCRC),7885
0,NCT03006302,Phase II,Not yet recruiting,"[{'id': 5169, 'therapyName': 'CRS-207 + INCB024360 + Pembrolizumab'}, {'id': 5170, 'therapyName': 'CRS-207 + Cyclophosphamide + GVAX panc vaccine + INCB024360 + Pembrolizumab'}]","Epacadostat, Pembrolizumab, and CRS-207, With or Without CY/GVAX Pancreas in Patients With Metastatic Pancreas Cancer",7622
1,NCT02451982,Phase Ib/II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 3622, 'therapyName': 'Cyclophosphamide + GVAX pancreatic cancer vaccine '}]",Neoadjuvant/Adjuvant GVAX Pancreas Vaccine (With CY) With or Without Nivolumab Trial for Surgically Resectable Pancreatic Cancer,7622
2,NCT03153410,Phase I,Not yet recruiting,"[{'id': 5778, 'therapyName': 'Cyclophosphamide + GVAX pancreatic cancer vaccine + LY3022855 + Pembrolizumab'}]","Pilot Study With CY, Pembrolizumab, GVAX, and IMC-CS4 (LY3022855) in Patients With Borderline Resectable Adenocarcinoma of the Pancreas",7622
3,NCT02648282,Phase II,Recruiting,"[{'id': 4473, 'therapyName': 'Cyclophosphamide + GVAX pancreatic cancer vaccine + Pembrolizumab'}]","Study With CY, Pembrolizumab, GVAX, and SBRT in Patients With Locally Advanced Pancreatic Cancer",7622
4,NCT02243371,Phase II,"Active, not recruiting","[{'id': 2642, 'therapyName': 'GVAX pancreatic cancer vaccine  '}, {'id': 2641, 'therapyName': 'CRS-207'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}]",GVAX Pancreas Vaccine (With CY) and CRS-207 With or Without Nivolumab,7622
0,NCT02740270,Phase I,Recruiting,"[{'id': 4469, 'therapyName': 'GWN 323 + PDR001'}, {'id': 4468, 'therapyName': 'GWN 323'}]",Phase I/Ib Study of GWN323 Alone and in Combination With PDR001 in Patients With Advanced Malignancies and Lymphomas,8462
0,NCT03250676,Phase Ib/II,Recruiting,"[{'id': 6150, 'therapyName': 'H3B-6545'}]","Trial of H3B-6545, a Covalent Antagonist of Estrogen Receptor Alpha, in Women With Locally Advanced or Metastatic Estrogen Receptor-positive, HER2 Negative Breast Cancer",8929
0,NCT02780128,Phase I,Recruiting,"[{'id': 2186, 'therapyName': 'HDM201'}, {'id': 2638, 'therapyName': 'Ceritinib + LEE011'}, {'id': 2, 'therapyName': 'Trametinib'}]",Next Generation Personalized Neuroblastoma Therapy,7457
1,NCT02143635,Phase I,Recruiting,"[{'id': 2186, 'therapyName': 'HDM201'}]",Study to Determine and Evaluate a Safe and Tolerated Dose of HDM201 in Patients With Selected Advanced Tumors That Are TP53wt,7457
2,NCT02343172,Phase Ib/II,Recruiting,"[{'id': 2481, 'therapyName': 'HDM201 + LEE011'}]",Study of Safety and Efficacy of HDM201 in Combination With LEE011 in Patients With Liposarcoma,7457
0,NCT01922921,Phase Ib/II,"Active, not recruiting","[{'id': 1556, 'therapyName': 'HER-2/neu intracellular domain protein + Trastuzumab '}, {'id': 1558, 'therapyName': 'HER-2/neu intracellular domain protein + Trastuzumab + Polysaccharide-K'}]",Vaccine Therapy and Trastuzumab With or Without Polysaccharide-K in Treating Patients With Stage IV HER2 Positive Breast Cancer,7281
0,NCT02442297,Phase I,Recruiting,"[{'id': 2940, 'therapyName': 'HER2 sensitized T-cells'}]",T Cells Expressing HER2-specific Chimeric Antigen Receptors(CAR) for Patients With Glioblastoma,7856
1,NCT00902044,Phase I,Recruiting,"[{'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 2940, 'therapyName': 'HER2 sensitized T-cells'}]",Her2 Chimeric Antigen Receptor Expressing T Cells in Advanced Sarcoma,7856
0,NCT01730118,Phase I,Recruiting,"[{'id': 1404, 'therapyName': 'HER2 Vaccine'}]",Ad/HER2/Neu Dendritic Cell Cancer Vaccine Testing,7254
1,NCT01376505,Phase I,Recruiting,"[{'id': 1404, 'therapyName': 'HER2 Vaccine'}]",Vaccine Therapy in Treating Patients With Metastatic Solid Tumors,7254
0,NCT02336984,Phase Ib/II,"Active, not recruiting","[{'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 5222, 'therapyName': 'HER2-pulsed DC1 vaccine'}]",A Phase I/II Trial of HER-2/Neu Pulsed DC1 Vaccine Combined With Trastuzumab for Patients With DCIS,8639
1,NCT02063724,Phase I,"Active, not recruiting","[{'id': 5222, 'therapyName': 'HER2-pulsed DC1 vaccine'}]",HER-2 Pulsed DC Vaccine to Prevent Recurrence of Invasive Breast Cancer (Adjuvant),8639
2,NCT02061332,Phase Ib/II,"Active, not recruiting","[{'id': 5222, 'therapyName': 'HER2-pulsed DC1 vaccine'}]",DC Vaccine for Patients With Ductal Carcinoma In Situ,8639
0,NCT02272855,Phase II,"Active, not recruiting","[{'id': 2003, 'therapyName': 'HF10 + Ipilimumab'}]",A Study of Combination Treatment With HF10 and Ipilimumab in Patients With Unresectable or Metastatic Melanoma,7375
1,NCT03259425,Phase II,Not yet recruiting,"[{'id': 6149, 'therapyName': 'HF10 + Nivolumab'}]","Neoadjuvant Trial of Nivolumab in Combination With HF10 Oncolytic Viral Therapy in Resectable Stage IIIB, IIIC, IVM1a Melanoma",7375
0,NCT02278185,Phase II,Recruiting,"[{'id': 759, 'therapyName': 'Goserelin'}, {'id': 1814, 'therapyName': 'Degarelix'}, {'id': 2047, 'therapyName': 'Histrelin acetate'}, {'id': 2050, 'therapyName': 'Triptorelin'}, {'id': 795, 'therapyName': 'Leuprolide'}, {'id': 1262, 'therapyName': 'Enzalutamide'}]",Enzalutamide Versus Standard Androgen Deprivation Therapy for the Treatment Hormone Sensitive Prostate Cancer,7405
0,NCT02648490,Phase I,Recruiting,"[{'id': 3939, 'therapyName': 'Acetaminophen + Dexamethasone + Diphenhydramine + Ondansetron'}, {'id': 3938, 'therapyName': 'HLX07'}]","An Open-label, Phase 1 Study to Determine the Maximum Tolerated Dose of HLX07,in Patients With Advanced Solid Cancers",8303
0,NCT02485652,Phase II,"Active, not recruiting","[{'id': 2137, 'therapyName': 'HM61713'}]",Phase II Trial of HM61713 (BI 1482694) for the Treatment of >2nd Line T790M Mutation Positive Adenocarcinoma of the Lung (NSCLC),7434
0,NCT02981108,Phase Ib/II,Recruiting,"[{'id': 5830, 'therapyName': 'HS-10296'}]","A Study to Evaluate Safety, PK and Efficacy of HS-10296 in Patients With NSCLC",8823
0,NCT02439450,Phase I,Recruiting,"[{'id': 2457, 'therapyName': 'HS-110'}, {'id': 1312, 'therapyName': 'Nivolumab'}]",A Study of Combination Therapies With Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer,7537
1,NCT02117024,Phase II,"Active, not recruiting","[{'id': 2472, 'therapyName': 'HS-110 + Cyclophosphamide'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 1685, 'therapyName': 'Vinorelbine'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]",A Phase 2 Study of Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer,7537
0,NCT02130869,Phase I,Recruiting,"[{'id': 2378, 'therapyName': 'Bendamustine + Cytarabine + Etoposide'}, {'id': 2460, 'therapyName': 'Busulfan + Hu14.18K322A'}, {'id': 2459, 'therapyName': 'Aldesleukin + Melphalan + Sargramostim'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1791, 'therapyName': 'Carboplatin + Etoposide'}]",A Pilot Study of Immunotherapy Including Haploidentical NK Cell Infusion Following CD133+ Positively-Selected Autologous Hematopoietic Stem Cells in Children With High Risk Solid Tumors or Lymphomas,7538
1,NCT01857934,Phase II,Recruiting,"[{'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1873, 'therapyName': 'Sargramostim'}, {'id': 1167, 'therapyName': 'Aldesleukin'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 2627, 'therapyName': 'Levetiracetam'}, {'id': 2585, 'therapyName': 'Cisplatin + Etoposide'}, {'id': 2458, 'therapyName': 'Hu14.18K322A'}, {'id': 2558, 'therapyName': 'Busulfan + Melphalan'}, {'id': 2590, 'therapyName': 'Cyclophosphamide + Topotecan'}]",Therapy for Children With Advanced Stage Neuroblastoma,7538
0,NCT03248479,Phase I,Not yet recruiting,"[{'id': 6133, 'therapyName': 'Azacitidine + Hu5F9-G4'}, {'id': 4947, 'therapyName': 'Hu5F9-G4'}]",Hu5F9-G4 Monotherapy or Hu5F9-G4 in Combination With Azacitidine in Patients With Hematological Malignancies,8585
1,NCT02953782,Phase Ib/II,Recruiting,"[{'id': 4948, 'therapyName': 'Cetuximab + Hu5F9-G4'}]",Trial of Hu5F9-G4 in Combination With Cetuximab in Patients With Solid Tumors and Advanced Colorectal Cancer,8585
2,NCT02216409,Phase I,Recruiting,"[{'id': 4947, 'therapyName': 'Hu5F9-G4'}]","Phase 1 Trial of Hu5F9-G4, a CD47-targeting Antibody",8585
3,NCT02953509,Phase Ib/II,Recruiting,"[{'id': 4955, 'therapyName': 'Hu5F9-G4 + Rituximab'}]",Trial of Hu5F9-G4 in Combination With Rituximab in Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma,8585
0,NCT02988817,Phase Ib/II,Recruiting,"[{'id': 5864, 'therapyName': 'HuMax-Axl-ADC'}]",HuMax-AXL-ADC Safety Study in Patients With Solid Tumors,8837
0,NCT01649947,Phase II,Completed,"[{'id': 1487, 'therapyName': 'Bevacizumab + Carboplatin + Paclitaxel + Hydroxychloroquine'}, {'id': 1488, 'therapyName': 'Paclitaxel + Carboplatin + Hydroxychloroquine'}]",Modulation of Autophagy in Patients With Advanced/Recurrent Non-small Cell Lung Cancer - Phase II,1550
1,NCT03215264,Phase Ib/II,Not yet recruiting,"[{'id': 6052, 'therapyName': 'Entinostat + Hydroxychloroquine + Regorafenib'}]","Phase I/II Trial of Regorafenib, Hydroxychloroquine, and Entinostat in Metastatic Colorectal Cancer",1550
2,NCT03032406,Phase II,Recruiting,"[{'id': 2231, 'therapyName': 'Everolimus + Hydroxychloroquine'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 1316, 'therapyName': 'Hydroxychloroquine'}]","CLEVER Pilot Trial: A Phase II Pilot Trial of HydroxyChLoroquine, EVErolimus or the Combination for Prevention of Recurrent Breast Cancer",1550
3,NCT01510119,Phase Ib/II,"Active, not recruiting","[{'id': 2231, 'therapyName': 'Everolimus + Hydroxychloroquine'}]",Autophagy Inhibition to Augment mTOR Inhibition: A Phase I/II Trial of RAD001 and Hydroxychloroquine in Patients With Previously Treated Renal Cell Carcinoma,1550
4,NCT01006369,Phase II,Completed,"[{'id': 1316, 'therapyName': 'Hydroxychloroquine'}, {'id': 1601, 'therapyName': 'Capecitabine + Oxaliplatin + Bevacizumab'}, {'id': 1484, 'therapyName': 'Bevacizumab + Oxaliplatin + Leucovorin + Fluorouracil'}]","Hydroxychloroquine, Capecitabine, Oxaliplatin, and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer",1550
5,NCT02232243,Phase I,Recruiting,"[{'id': 1316, 'therapyName': 'Hydroxychloroquine'}]",HCQ on PAR-4 Levels in Patients With Resectable Solid Tumors,1550
6,NCT02316340,Phase II,Recruiting,"[{'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1316, 'therapyName': 'Hydroxychloroquine'}, {'id': 890, 'therapyName': 'Regorafenib'}]",Vorinostat Plus Hydroxychloroquine Versus Regorafenib in Colorectal Cancer,1550
7,NCT01828476,Phase II,Terminated,"[{'id': 1316, 'therapyName': 'Hydroxychloroquine'}, {'id': 2597, 'therapyName': 'Abiraterone + Navitoclax'}]",Navitoclax and Abiraterone Acetate With or Without Hydroxychloroquine in Treating Patients With Progressive Metastatic Castrate Refractory Prostate Cancer,1550
8,NCT01206530,Phase Ib/II,"Active, not recruiting","[{'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1316, 'therapyName': 'Hydroxychloroquine'}]",FOLFOX/Bevacizumab/Hydroxychloroquine (HCQ) in Colorectal Cancer,1550
9,NCT01506973,Phase Ib/II,Recruiting,"[{'id': 1316, 'therapyName': 'Hydroxychloroquine'}, {'id': 755, 'therapyName': 'Gemcitabine'}]",A Phase I/II/Pharmacodynamic Study of Hydroxychloroquine in Combination With Gemcitabine/Abraxane to Inhibit Autophagy in Pancreatic Cancer,1550
10,NCT03081702,Phase Ib/II,Not yet recruiting,"[{'id': 5495, 'therapyName': 'Hydroxychloroquine + Itraconazole'}]","A Study of the Safety, Tolerability and Effectiveness of Hydroxychloroquine and Itraconazole in Platinum-resistant Epithelial Ovarian Cancer",1550
11,NCT00909831,Phase I,"Active, not recruiting","[{'id': 2302, 'therapyName': 'Hydroxychloroquine + Temsirolimus '}]",Hydroxychloroquine and Temsirolimus in Treating Patients With Metastatic Solid Tumors That Have Not Responded to Treatment,1550
12,NCT01480154,Phase I,"Active, not recruiting","[{'id': 1393, 'therapyName': 'MK2206 + hydroxychloroquine'}]","Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostate or Kidney Cancer",1550
13,NCT01689987,Phase I,Completed,"[{'id': 2385, 'therapyName': 'Sirolimus + Cyclophosphamide + Dexamethasone + Hydroxychloroquine'}]","Hydroxychloroquine, Cyclophosphamide, Dexamethasone, and Sirolimus in Treating Patients With Relapsed or Refractory Multiple Myeloma",1550
14,NCT01266057,Phase I,"Active, not recruiting","[{'id': 1135, 'therapyName': 'Vorinostat + Hydroxychloroquine'}, {'id': 1177, 'therapyName': 'Sirolimus + Hydroxychloroquine'}]",Sirolimus or Vorinostat and Hydroxychloroquine in Advanced Cancer,1550
15,NCT01634893,Phase I,Completed,"[{'id': 1208, 'therapyName': 'Sorafenib + Hydroxychloroquine'}]",Oral Hydroxychloroquine Plus Oral Sorafenib to Treat Patients With Refractory or Relapsed Solid Tumors,1550
16,NCT01897116,Phase I,"Active, not recruiting","[{'id': 1281, 'therapyName': 'Vemurafenib + Hydroxychloroquine'}]", A Phase I Trial of Vemurafenib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma,1550
17,NCT01023737,Phase I,Recruiting,"[{'id': 1135, 'therapyName': 'Vorinostat + Hydroxychloroquine'}]",Hydroxychloroquine + Vorinostat in Advanced Solid Tumors,1550
0,NCT01711541,Phase Ib/II,Suspended,"[{'id': 1544, 'therapyName': 'Carboplatin + Etoposide + Veliparib'}, {'id': 1849, 'therapyName': 'Cisplatin + Fluorouracil + Hydroxyurea'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]",Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IV Head and Neck Cancer,994
1,NCT03107182,Phase II,Recruiting,"[{'id': 5581, 'therapyName': 'Dexamethasone + Diphenhydramine + Famotidine + 5FU + Hydroxyurea + Paclitaxel'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 5303, 'therapyName': 'Nivolumab + Carboplatin + Paclitaxel'}]",Oropharyngeal Tumor Induction Chemotherapy and Response-stratified Locoregional Therapy Trial in Order to Minimize Long-term Adverse Events,994
2,NCT02551718,Phase I,Recruiting,"[{'id': 690, 'therapyName': 'Bosutinib'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 3160, 'therapyName': 'Nelarabine'}, {'id': 3159, 'therapyName': 'Bexarotene'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 998, 'therapyName': 'cabozantinib'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 877, 'therapyName': 'Ponatinib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 623, 'therapyName': 'Afatinib'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 890, 'therapyName': 'Regorafenib'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 2, 'therapyName': 'Trametinib'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 3, 'therapyName': 'Dabrafenib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 789, 'therapyName': 'Ceritinib'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1571, 'therapyName': 'Cabazitaxel'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1327, 'therapyName': 'Pralatrexate'}]",High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia,994
3,NCT02788201,Phase II,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1133, 'therapyName': 'Mitomycin C'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1013, 'therapyName': 'epirubicin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1137, 'therapyName': 'Bleomycin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 781, 'therapyName': 'Ixabepilone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 2950, 'therapyName': 'Estramustine'}, {'id': 1941, 'therapyName': 'Floxuridine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 1811, 'therapyName': 'Carmustine'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 953, 'therapyName': 'Vandetanib'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 4419, 'therapyName': 'Toremifine'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 2601, 'therapyName': 'Dactinomycin'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 3035, 'therapyName': 'Chlorambucil'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 342, 'therapyName': 'Vemurafenib'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 2635, 'therapyName': 'Vinblastine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 4305, 'therapyName': 'Teniposide'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 4304, 'therapyName': 'Streptozocin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1231, 'therapyName': 'Bendamustine'}, {'id': 4303, 'therapyName': 'Mechlorethamine'}, {'id': 4302, 'therapyName': 'Mitotane'}]",Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma,994
4,NCT02088541,Phase II,"Active, not recruiting","[{'id': 712, 'therapyName': 'Cytarabine'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 1749, 'therapyName': 'Selinexor'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}]",Selinexor (KPT-330) in Older Patients With Relapsed AML,994
0,NCT03291938,Phase I,Not yet recruiting,"[{'id': 6267, 'therapyName': 'IACS-010759'}]",Study to Evaluate the Safety and Tolerability of IACS-010759 in Subjects With Advanced Solid Tumors and Lymphoma,8960
1,NCT02882321,Phase I,Recruiting,"[{'id': 6267, 'therapyName': 'IACS-010759'}]",Study of IACS-010759 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia (AML),8960
0,NCT02787369,Phase I,"Active, not recruiting","[{'id': 4273, 'therapyName': 'ACY-1215 + Idelalisib '}, {'id': 4272, 'therapyName': 'ACY-1215 + Ibrutinib'}]",ACY-1215 in Combination With BCR Pathway Inhibitors in Relapsed CLL,6923
1,NCT03128879,Phase II,"Active, not recruiting","[{'id': 5876, 'therapyName': 'Allopurinol + Ibrutinib + Venetoclax'}]",Study of Venetoclax (ABT-199) Added to Ibrutinib in Patients With High-Risk Chronic Lymphocytic Leukemia (CLL),6923
2,NCT02553941,Phase I,Recruiting,"[{'id': 3632, 'therapyName': 'Azacitidine + Ibrutinib'}]",Ibrutinib and Azacitidine for Treatment of Higher Risk Myelodysplastic Syndrome,6923
3,NCT02759016,Phase I,Recruiting,"[{'id': 4277, 'therapyName': 'BI 836826 + Ibrutinib'}]","Intravenous BI 836826 in Combination With Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) Patients Who Have Received at Least One Prior Systemic Therapy, and Who Are Eligible for Treatment With Ibrutinib",6923
4,NCT02614508,Phase I,"Active, not recruiting","[{'id': 3630, 'therapyName': 'BKM120 + Ibrutinib'}, {'id': 3629, 'therapyName': 'BKM120 + Ofatumumab'}]",Buparlisib and Ofatumumab or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia,6923
5,NCT02756247,Phase I,Recruiting,"[{'id': 3630, 'therapyName': 'BKM120 + Ibrutinib'}]",A Clinical Trial of Buparlisib and Ibrutinib in Lymphoma,6923
6,NCT02997761,Phase II,Recruiting,"[{'id': 5125, 'therapyName': 'Blinatumomab + Ibrutinib'}]",Ibrutinib and Blinatumomab in Treating Patients With Relapsed or Refractory B Acute Lymphoblastic Leukemia,6923
7,NCT02744612,Phase II,Recruiting,"[{'id': 4300, 'therapyName': 'Brentuximab vedotin + Ibrutinib'}]",Ibrutinib and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma,6923
8,NCT01962792,Phase Ib/II,Recruiting,"[{'id': 3282, 'therapyName': 'Carfilzomib + Ibrutinib'}, {'id': 1390, 'therapyName': 'Dexamethasone'}]","Study of the Bruton's Tyrosine Kinase Inhibitor in Combination With Carfilzomib (Kyprolis), in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma",6923
9,NCT02269085,Phase Ib/II,"Active, not recruiting","[{'id': 3282, 'therapyName': 'Carfilzomib + Ibrutinib'}]",A Phase I/II Trial of PCI-32765 (BTK Inhibitor) in Combination With Carfilzomib in Relapse/Refractory Mantle Cell Lymphoma,6923
10,NCT03088878,Phase Ib/II,Not yet recruiting,"[{'id': 5480, 'therapyName': 'Cirmtuzumab + Ibrutinib'}, {'id': 768, 'therapyName': 'Ibrutinib'}]",A Study of the Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies,6923
11,NCT02635074,Phase I,Recruiting,"[{'id': 3573, 'therapyName': 'Cytarabine + Idarubicin + Ibrutinib'}]","Ibrutinib, Idarubicin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia",6923
12,NCT02815059,Phase I,Recruiting,"[{'id': 4438, 'therapyName': 'Dasatinib + Ibrutinib + Prednisone'}]","Study of Pts With Philadelphia Chromosome-Pos ALL With Comb of Ibrutinib, Dasatinib, and Prednisone",6923
13,NCT02381080,Phase I,Completed,"[{'id': 3793, 'therapyName': 'Erythromycin + Ibrutinib + Voriconazole'}]",Interaction Study of Ibrutinib and Cytochrome P450 (CYP) 3A Inhibitors in Participants With B-cell Malignancy,6923
14,NCT02514083,Phase II,Recruiting,"[{'id': 3633, 'therapyName': 'Fludarabine + Ibrutinib'}]",A Phase II Study Using Ibrutinib and Short-Course Fludarabine in Previously Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL),6923
15,NCT03204188,Phase II,Recruiting,"[{'id': 6154, 'therapyName': 'Fludarabine + Ibrutinib + Pembrolizumab'}]","Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma",6923
16,NCT02910583,Phase II,"Active, not recruiting","[{'id': 768, 'therapyName': 'Ibrutinib'}, {'id': 3392, 'therapyName': 'GDC-0199 + Ibrutinib'}]",Ibrutinib Plus Venetoclax in Patients With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma,6923
17,NCT02419560,Phase I,Suspended,"[{'id': 3392, 'therapyName': 'GDC-0199 + Ibrutinib'}]",Optimal Dose Finding Study ABT-199 and Ibrutinib in MCL,6923
18,NCT03045328,Phase Ib/II,Recruiting,"[{'id': 3392, 'therapyName': 'GDC-0199 + Ibrutinib'}]",Venetoclax and Ibrutinib in Patients With Relapsed/Refractory CLL or SLL,6923
19,NCT02756897,Phase II,Recruiting,"[{'id': 3392, 'therapyName': 'GDC-0199 + Ibrutinib'}]",Venetoclax and Ibrutinib in Patients With Chronic Lymphocytic Leukemia (CLL),6923
20,NCT02956382,Phase Ib/II,Recruiting,"[{'id': 3392, 'therapyName': 'GDC-0199 + Ibrutinib'}]",Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma,6923
21,NCT03112174,Phase III,Recruiting,"[{'id': 768, 'therapyName': 'Ibrutinib'}, {'id': 3392, 'therapyName': 'GDC-0199 + Ibrutinib'}]",Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO),6923
22,NCT02427451,Phase Ib/II,"Active, not recruiting","[{'id': 3472, 'therapyName': 'GDC-0199 + Ibrutinib + Obinutuzumab'}]","Bcl-2 Inhibitor GDC-0199 in Combination With Obinutuzumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or Previously Untreated Chronic Lymphocytic Leukemia",6923
23,NCT02562898,Phase Ib/II,Recruiting,"[{'id': 3259, 'therapyName': 'Gemcitabine + Ibrutinib + Paclitaxel'}]",Ibrutinib Combined With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer,6923
24,NCT02662296,Phase II,Withdrawn,"[{'id': 1023, 'therapyName': 'Idelalisib'}, {'id': 768, 'therapyName': 'Ibrutinib'}]","Ibrutinib or Idelalisib in Treating Patients With Persistent or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma After Donor Stem Cell Transplant",6923
25,NCT02207062,Phase I,Recruiting,"[{'id': 768, 'therapyName': 'Ibrutinib'}]",Ibrutinib in Treating Patients With Relapsed or Refractory Transformed Indolent B-cell Non-Hodgkin Lymphoma,6923
26,NCT02219737,Phase I,"Active, not recruiting","[{'id': 768, 'therapyName': 'Ibrutinib'}, {'id': 3360, 'therapyName': 'Carboplatin + Etoposide + Ifosfamide + Rituximab'}]",Ibrutinib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma,6923
27,NCT03207555,Phase II,Not yet recruiting,"[{'id': 768, 'therapyName': 'Ibrutinib'}]",Ibrutinib as Early Therapy in Chronic Lymphocytic Leukemia (CLL),6923
28,NCT02436707,Phase II,Recruiting,"[{'id': 768, 'therapyName': 'Ibrutinib'}, {'id': 3391, 'therapyName': 'Cisplatin + Dexamethasone + Gemcitabine + Rituximab'}]",Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma,6923
29,NCT02315326,Phase Ib/II,Recruiting,"[{'id': 768, 'therapyName': 'Ibrutinib'}]","Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Patients With Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL)",6923
30,NCT02575300,Phase II,Recruiting,"[{'id': 768, 'therapyName': 'Ibrutinib'}]",Phase II Study of Ibrutinib in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors,6923
31,NCT02824029,Phase II,Recruiting,"[{'id': 768, 'therapyName': 'Ibrutinib'}]",Ibrutinib in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma,6923
32,NCT02943473,Phase II,Recruiting,"[{'id': 768, 'therapyName': 'Ibrutinib'}]",Study on the Effect of Ibrutinib on High Risk Smoldering Multiple Myeloma Patients,6923
33,NCT02801578,Phase I,"Active, not recruiting","[{'id': 768, 'therapyName': 'Ibrutinib'}]",A Study of Different Doses of Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL),6923
34,NCT02599324,Phase Ib/II,Recruiting,"[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 768, 'therapyName': 'Ibrutinib'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 694, 'therapyName': 'Cetuximab'}]",A Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors,6923
35,NCT01804686,Phase III,Recruiting,"[{'id': 768, 'therapyName': 'Ibrutinib'}]",A Long-term Extension Study of PCI-32765 (Ibrutinib),6923
36,NCT02007044,Phase II,Recruiting,"[{'id': 768, 'therapyName': 'Ibrutinib'}, {'id': 897, 'therapyName': 'Rituximab'}]",Ibrutinib Versus Ibrutinib + Rituximab (i vs iR) in Patients With Relapsed Chronic Lymphocytic Leukemia (CLL),6923
37,NCT02272686,Phase II,"Active, not recruiting","[{'id': 768, 'therapyName': 'Ibrutinib'}]",Ibrutinib Post Stem Cell Transplantation (SCT) in Double-Hit B-Cell Lymphoma,6923
38,NCT03219047,Phase I,Not yet recruiting,"[{'id': 768, 'therapyName': 'Ibrutinib'}]",The EXPLORE Trial: Study Evaluating Xenografts to Personalize Therapies (PDX) in Relapsed Mantle Cell Lymphoma to Optimize Response,6923
39,NCT02436668,Phase II,"Active, not recruiting","[{'id': 1779, 'therapyName': 'Nab-paclitaxel + Gemcitabine'}, {'id': 768, 'therapyName': 'Ibrutinib'}]","Study of Ibrutinib vs Placebo, in Combination With Nab-paclitaxel and Gemcitabine, in the First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma",6923
40,NCT02703272,Phase III,Recruiting,"[{'id': 768, 'therapyName': 'Ibrutinib'}, {'id': 4307, 'therapyName': 'Carboplatin + Dexamethasone + Etoposide + Ifosfamide + Rituximab'}, {'id': 4308, 'therapyName': 'Carboplatin + Dexamethasone + Idarubicin + Ifosfamide + Rituximab + Vincristine'}]",A Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Participants With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma,6923
41,NCT03267186,Phase II,Recruiting,"[{'id': 768, 'therapyName': 'Ibrutinib'}]",Ibrutinib in Preventing Acute Leukemia in Patients After Reduced-Intensity Conditioning and Stem Cell Transplant,6923
42,NCT02415608,Phase II,Recruiting,"[{'id': 768, 'therapyName': 'Ibrutinib'}]",Ibrutinib in Treating Patients With Advanced Systemic Mastocytosis,6923
43,NCT02966730,Phase I,Recruiting,"[{'id': 768, 'therapyName': 'Ibrutinib'}]",Ibrutinib for Patients With Follicular Lymphoma Without Complete Response to Initial Chemoimmunotherapy,6923
44,NCT02649387,Phase II,Recruiting,"[{'id': 768, 'therapyName': 'Ibrutinib'}]",Ibrutinib in Treating Minimal Residual Disease in Patients With Chronic Lymphocytic Leukemia After Front-Line Therapy (MERIT),6923
45,NCT02912754,Phase Ib/II,Not yet recruiting,"[{'id': 768, 'therapyName': 'Ibrutinib'}, {'id': 4768, 'therapyName': 'Ibrutinib + Ruxolitinib'}]",Ruxolitinib Combined With Ibrutinib in Chronic Lymphocytic Leukemia Patients,6923
46,NCT02643667,Phase Ib/II,Recruiting,"[{'id': 768, 'therapyName': 'Ibrutinib'}]",A Study of Ibrutinib as Neoadjuvant Therapy in Localized Prostate Cancer,6923
47,NCT02129062,Phase II,Terminated,"[{'id': 768, 'therapyName': 'Ibrutinib'}]",Ibrutinib in Treating Patients With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia,6923
48,NCT02581930,Phase II,Recruiting,"[{'id': 768, 'therapyName': 'Ibrutinib'}]",Ibrutinib in Treating Patients With Refractory Stage IV Cutaneous Melanoma,6923
49,NCT02629809,Phase II,Recruiting,"[{'id': 3628, 'therapyName': 'Allopurinol'}, {'id': 3627, 'therapyName': 'Cyclophosphamide + Fludarabine + Obinutuzumab'}, {'id': 768, 'therapyName': 'Ibrutinib'}]","First-line Therapy With Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (GA-101) (iFCG) for Patients With Chronic Lymphocytic Leukemia (CLL)",6923
50,NCT02351037,Phase II,Terminated,"[{'id': 768, 'therapyName': 'Ibrutinib'}, {'id': 712, 'therapyName': 'Cytarabine'}]",A Multicenter Open-Label Phase 2a Study of Ibrutinib With or Without Cytarabine in Subjects With Acute Myeloid Leukemia,6923
51,NCT02604511,Phase II,"Active, not recruiting","[{'id': 768, 'therapyName': 'Ibrutinib'}]","Study of Ibrutinib in Patients With Symptomatic, Previously Untreated Waldenstrom's Macroglobulinemia, and Impact on Tumor Genomic Evolution Using Whole Genome Sequencing",6923
52,NCT03229200,FDA approved,Recruiting,"[{'id': 768, 'therapyName': 'Ibrutinib'}]",Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.,6923
53,NCT02406742,Phase Ib/II,Recruiting,"[{'id': 1646, 'therapyName': 'Obinutuzumab'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 768, 'therapyName': 'Ibrutinib'}, {'id': 2358, 'therapyName': 'CC-122'}]","A Phase 1/2, Open-label, Dose Finding Study to Evaluate CC-122 in Combination With Rituximab, Ibrutinib and Obinutuzumab in Subjects With Relapsed/Refractory CLL/SLL (ENHANCE)",6923
54,NCT02947347,Phase III,Recruiting,"[{'id': 768, 'therapyName': 'Ibrutinib'}, {'id': 3280, 'therapyName': 'Ibrutinib + Rituximab'}]",Study of Ibrutinib and Rituximab in Treatment Naïve Follicular Lymphoma,6923
55,NCT02518555,Phase II,"Active, not recruiting","[{'id': 768, 'therapyName': 'Ibrutinib'}]","Ibrutinib as an Immune Modulating Agent for Patients With Asymptomatic, High-risk CLL/SLL Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma",6923
56,NCT01974440,Phase III,"Active, not recruiting","[{'id': 768, 'therapyName': 'Ibrutinib'}, {'id': 2323, 'therapyName': 'Bendamustine + Rituximab'}, {'id': 3266, 'therapyName': 'Cyclophosphamide + Doxorubicin + Prednisone + Vincristine '}]","A Study of PCI-32765 (Ibrutinib) in Combination With Either Bendamustine and Rituximab or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Participants With Previously Treated Indolent Non-Hodgkin Lymphoma",6923
57,NCT02006485,Phase I,Recruiting,"[{'id': 2319, 'therapyName': 'TGR-1202 + Ublituximab'}, {'id': 768, 'therapyName': 'Ibrutinib'}]",Ublituximab in Combination With TGR-1202 in Patients With B-cell Malignancies,6923
58,NCT01841723,Phase II,Recruiting,"[{'id': 768, 'therapyName': 'Ibrutinib'}]",Ibrutinib in Treating Patients With Relapsed Hairy Cell Leukemia,6923
59,NCT01855750,Phase III,"Active, not recruiting","[{'id': 768, 'therapyName': 'Ibrutinib'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 3266, 'therapyName': 'Cyclophosphamide + Doxorubicin + Prednisone + Vincristine '}]","A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma",6923
60,NCT03053440,Phase III,Recruiting,"[{'id': 768, 'therapyName': 'Ibrutinib'}, {'id': 2544, 'therapyName': 'BGB-3111'}]",A Study Comparing BGB-3111 and Ibrutinib in Subjects With Waldenström's Macroglobulinemia (WM),6923
61,NCT02301156,Phase III,"Active, not recruiting","[{'id': 2287, 'therapyName': 'Ublituximab'}, {'id': 768, 'therapyName': 'Ibrutinib'}]",Ublituximab in Combination With Ibrutinib Versus Ibrutinib Alone in Patients With Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL),6923
62,NCT02443077,Phase III,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 3359, 'therapyName': 'Carmustine + Cytarabine + Etoposide + Melphalan'}, {'id': 768, 'therapyName': 'Ibrutinib'}]",Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma,6923
63,NCT02869633,Phase II,Recruiting,"[{'id': 768, 'therapyName': 'Ibrutinib'}]",Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant,6923
64,NCT03282396,Phase II,Not yet recruiting,"[{'id': 768, 'therapyName': 'Ibrutinib'}]",Ibrutinib in Newly Diagnosed Mantle Cell Lymphoma With Low-Risk Disease,6923
65,NCT02309580,Phase I,Recruiting,"[{'id': 768, 'therapyName': 'Ibrutinib'}]",Study of Ibrutinib in Relapsed and Refractory T-cell Lymphoma,6923
66,NCT02321540,Phase Ib/II,"Active, not recruiting","[{'id': 768, 'therapyName': 'Ibrutinib'}]",A Phase I/II Study of Ibrutinib in Previously Treated Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer,6923
67,NCT02548962,Phase Ib/II,Recruiting,"[{'id': 768, 'therapyName': 'Ibrutinib'}, {'id': 3792, 'therapyName': 'Dexamethasone + Pomalidomide'}]",Study of Ibrutinib in Combination With Pomalidomide and Dexamethasone in Subjects With Relapsed/Refractory Multiple Myeloma,6923
68,NCT02352558,Phase I,"Active, not recruiting","[{'id': 770, 'therapyName': 'Imatinib'}, {'id': 2057, 'therapyName': 'BBI608'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 768, 'therapyName': 'Ibrutinib'}, {'id': 1390, 'therapyName': 'Dexamethasone'}]","A Study of BBI608 in Adult Patients With Advanced, Refractory Hematologic Malignancies",6923
69,NCT02477696,Phase III,Recruiting,"[{'id': 1605, 'therapyName': 'Acalabrutinib'}, {'id': 768, 'therapyName': 'Ibrutinib'}]",Elevate CLL R/R: Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects With High Risk Chronic Lymphocytic Leukemia,6923
70,NCT02242097,Phase II,Recruiting,"[{'id': 768, 'therapyName': 'Ibrutinib'}]",Ibrutinib After Intensive Induction in Treating Patients With Previously Untreated Mantle Cell Lymphoma,6923
71,NCT02760485,Phase Ib/II,Recruiting,"[{'id': 5151, 'therapyName': 'Ibrutinib + INCB039110'}]",A Study of INCB039110 in Combination With Ibrutinib in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma,6923
72,NCT02743546,Phase I,Withdrawn,"[{'id': 4167, 'therapyName': 'Ibrutinib + JNJ-64052781'}]","Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of JNJ-64052781 Plus Ibrutinib in Lymphoma",6923
73,NCT01955499,Phase I,"Active, not recruiting","[{'id': 3580, 'therapyName': 'Ibrutinib + lenalidomide'}]",Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma,6923
74,NCT01886859,Phase I,"Active, not recruiting","[{'id': 3580, 'therapyName': 'Ibrutinib + lenalidomide'}]",Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma,6923
75,NCT03015792,Phase Ib/II,Recruiting,"[{'id': 5240, 'therapyName': 'Ibrutinib + Lenalidomide + Dexamethasone'}]","Ibrutinib, Lenalidomide, and Dexamethasone in Treating Patients With Multiple Myeloma Ineligible for Transplant",6923
76,NCT03223610,Phase I,Not yet recruiting,"[{'id': 6189, 'therapyName': 'Ibrutinib + Lenalidomide + Obinutuzumab + Prednisone + Venetoclax'}]","Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma",6923
77,NCT02403271,Phase Ib/II,Completed,"[{'id': 2573, 'therapyName': 'Ibrutinib + MEDI4736'}]",A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors,6923
78,NCT02401048,Phase Ib/II,"Active, not recruiting","[{'id': 2573, 'therapyName': 'Ibrutinib + MEDI4736'}]",A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Lymphomas,6923
79,NCT02733042,Phase Ib/II,Recruiting,"[{'id': 897, 'therapyName': 'Rituximab'}, {'id': 4278, 'therapyName': 'lenalidomide + MEDI4736 + Rituximab'}, {'id': 4279, 'therapyName': 'Bendamustine + MEDI4736 + Rituximab'}, {'id': 2573, 'therapyName': 'Ibrutinib + MEDI4736'}, {'id': 1356, 'therapyName': 'Durvalumab'}]","A Study to Determine Dose, Safety, and Efficacy of Durvalumab as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocytic Leukemia (FUSION NHL 001)",6923
80,NCT02005289,Phase II,Recruiting,"[{'id': 5843, 'therapyName': 'Lenalidomide + MOR208'}, {'id': 5847, 'therapyName': 'Ibrutinib + MOR208'}]","Phase II MOR00208 in Combination With Lenalidomide for Patients With Relapsed or Refractory CLL, SLL or PLL or Older Patients With Untreated CLL, SLL or PLL",6923
81,NCT02329847,Phase Ib/II,Recruiting,"[{'id': 3198, 'therapyName': 'Ibrutinib + Nivolumab'}]",Pharmacokinetic and Pharmacodynamic Study to Evaluate Safety and Efficacy of the Combination of Ibrutinib With Nivolumab in Participants With Hematologic Malignancies,6923
82,NCT02940301,Phase II,Recruiting,"[{'id': 3198, 'therapyName': 'Ibrutinib + Nivolumab'}]",Ibrutinib and Nivolumab in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma,6923
83,NCT02420912,Phase II,Recruiting,"[{'id': 3198, 'therapyName': 'Ibrutinib + Nivolumab'}]","Nivolumab With Ibrutinib for Relapsed, Refractory or High-Risk Untreated Patients With Chronic Lymphocytic Leukemia (CLL)",6923
84,NCT02899078,Phase Ib/II,Recruiting,"[{'id': 3198, 'therapyName': 'Ibrutinib + Nivolumab'}]",Ibrutinib and Nivolumab in Treating Patients With Previously-Treated Metastatic Kidney Cancer,6923
85,NCT02950038,Phase II,Withdrawn,"[{'id': 3198, 'therapyName': 'Ibrutinib + Nivolumab'}]",Study of Ibrutinib Followed by Ibrutinib in Combination With Nivolumab in Non-Small Cell Lung Cancer (NSCLC),6923
86,NCT02315768,Phase Ib/II,Recruiting,"[{'id': 3476, 'therapyName': 'Ibrutinib + Obinutuzumab'}]",Ibrutinib in Combination With GA101 (Obinutuzumab) in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Patients.,6923
87,NCT02736617,Phase II,Recruiting,"[{'id': 3476, 'therapyName': 'Ibrutinib + Obinutuzumab'}]",Obinutuzumab in Combination With Ibrutinib in Treating Patients With Relapsed Mantle Cell Lymphoma,6923
88,NCT02611908,Phase I,Recruiting,"[{'id': 3476, 'therapyName': 'Ibrutinib + Obinutuzumab'}]",Obinutuzumab With High-dose Ibrutinib for the Treatment of Patients With Chronic Lymphocytic Leukemia With Progressive Disease on Single Agent Ibrutinib.,6923
89,NCT02537613,Phase I,Recruiting,"[{'id': 3476, 'therapyName': 'Ibrutinib + Obinutuzumab'}]",A Study of Ibrutinib + Obinutuzumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia,6923
90,NCT01644253,Phase I,Recruiting,"[{'id': 4745, 'therapyName': 'Idelalisib + Otlertuzumab + Rituximab'}, {'id': 4742, 'therapyName': 'Otlertuzumab + Rituximab'}, {'id': 4743, 'therapyName': 'Obinutuzumab + Otlertuzumab'}, {'id': 4744, 'therapyName': 'Ibrutinib + Otlertuzumab'}]","Phase 1b Safety and Efficacy Study of TRU-016 and Rituximab, Obinutuzumab, Idelalisib, or Ibrutinib in Chronic Lymphocytic Leukemia",6923
91,NCT02677948,Phase Ib/II,Withdrawn,"[{'id': 3623, 'therapyName': 'Ibrutinib + Pacritinib'}]",Multicenter Study of Pacritinib Combined With Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL),6923
92,NCT02159755,Phase I,"Active, not recruiting","[{'id': 1729, 'therapyName': 'ibrutinib + palbociclib'}]",Ibrutinib and Palbociclib Isethionate in Treating Patients With Previously Treated Mantle Cell Lymphoma,6923
93,NCT01880567,Phase II,Recruiting,"[{'id': 3280, 'therapyName': 'Ibrutinib + Rituximab'}]",Phase 2 Ibrutinib + Rituximab in Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL),6923
94,NCT02251548,Phase II,Recruiting,"[{'id': 2185, 'therapyName': 'Ibrutinib + Rituximab + Cyclophosphamide + Fludarabine'}]","A Phase II Study of Ibrutinib Plus FCR in Previously Untreated, Younger Patients With Chronic Lymphocytic Leukemia",6923
95,NCT03136497,Phase I,Recruiting,"[{'id': 5777, 'therapyName': 'Ibrutinib + Rituximab + Venetoclax'}]",A Study of ABT-199 Plus Ibrutinib and Rituximab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL),6923
96,NCT02927964,Phase Ib/II,Recruiting,"[{'id': 4828, 'therapyName': 'Ibrutinib + SD-101 + Radiotherapy'}]","TLR9 Agonist SD-101, Ibrutinib, and Radiation Therapy in Treating Patients With Relapsed or Refractory Grade 1-3A Follicular Lymphoma",6923
97,NCT02303392,Phase I,Recruiting,"[{'id': 3579, 'therapyName': 'Ibrutinib + Selinexor'}]",Selinexor and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Aggressive Non-Hodgkin Lymphoma,6923
98,NCT02973399,Phase I,Recruiting,"[{'id': 4780, 'therapyName': 'Ibrutinib + SNX-5422'}]",Efficacy and Safety of SNX-5422 Added to an Established Dose of Ibrutinib in CLL,6923
99,NCT02914327,Phase I,Recruiting,"[{'id': 4780, 'therapyName': 'Ibrutinib + SNX-5422'}]",Safety and Activity of SNX-5422 Plus Ibrutinib in CLL,6923
100,NCT02954406,Phase I,Recruiting,"[{'id': 5150, 'therapyName': 'Lenalidomide + TAK-659'}, {'id': 5149, 'therapyName': 'Ibrutinib + TAK-659'}, {'id': 5148, 'therapyName': 'Gemcitabine + TAK-659'}, {'id': 5147, 'therapyName': 'Bendamustine + Rituximab + TAK-659'}, {'id': 5146, 'therapyName': 'Bendamustine + TAK-659'}]","A Study of TAK-659 in Combination With Bendamustine (+/-Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Participants With Advanced Non-Hodgkin Lymphoma",6923
101,NCT02874404,Phase II,Recruiting,"[{'id': 2044, 'therapyName': 'Ibrutinib + TGR-1202'}]",TGR-1202 and Ibrutinib in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma,6923
102,NCT02268851,Phase I,Recruiting,"[{'id': 2044, 'therapyName': 'Ibrutinib + TGR-1202'}]",A Phase I/Ib Safety and Efficacy Study of the PI3K-delta Inhibitor TGR-1202 and Ibrutinib in Patients With CLL or MCL,6923
103,NCT02950220,Phase I,Recruiting,"[{'id': 4917, 'therapyName': 'Pembrolizumab + Ibrutinib'}]",Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma,6923
104,NCT03153202,Phase Ib/II,Recruiting,"[{'id': 4917, 'therapyName': 'Pembrolizumab + Ibrutinib'}]",Study to Evaluate the Safety and Preliminary Efficacy of Ibrutinib and Pembrolizumab in Patients With Chronic Lymphocytic Leukemia (CLL) or Mantle Cell Lymphoma (MCL),6923
105,NCT03021460,Phase II,Suspended,"[{'id': 4917, 'therapyName': 'Pembrolizumab + Ibrutinib'}]",Pembrolizumab and Ibrutinib in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery,6923
106,NCT02200848,Phase I,Terminated,"[{'id': 1610, 'therapyName': 'Rituximab + Lenalidomide + Ibrutinib'}]","Phase I Study of Lenalidomide, Rituximab and Ibrutinib in Relapsed/Refractory CLL",6923
107,NCT03232307,Phase II,Not yet recruiting,"[{'id': 1610, 'therapyName': 'Rituximab + Lenalidomide + Ibrutinib'}]",Ibrutinib Plus Rituximab and Lenalidomide in Elderly Patients With Newly Diagnosed Mantle Cell Lymphoma (MCL),6923
108,NCT02532257,Phase II,Recruiting,"[{'id': 1610, 'therapyName': 'Rituximab + Lenalidomide + Ibrutinib'}]",Study of Ibrutinib in Combination With Rituximab and Lenalidomide,6923
109,NCT02446236,Phase I,Recruiting,"[{'id': 1610, 'therapyName': 'Rituximab + Lenalidomide + Ibrutinib'}]","Dose Finding Study of Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765) Plus Lenalidomide / Rituximab in Relapsed or Refractory Mantle Cell Lymphoma (MCL)",6923
110,NCT02077166,Phase Ib/II,Recruiting,"[{'id': 1610, 'therapyName': 'Rituximab + Lenalidomide + Ibrutinib'}]",Ibrutinib in Combination With Lenalidomide and Rituximab in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma,6923
111,NCT02636322,Phase II,Recruiting,"[{'id': 2482, 'therapyName': 'Cyclophosphamide + Doxorubicin + Etoposide + Vincristine '}, {'id': 1610, 'therapyName': 'Rituximab + Lenalidomide + Ibrutinib'}, {'id': 2188, 'therapyName': 'Prednisone'}]","A Study of Rituximab, Lenalidomide, and Ibrutinib Combined With Dose Adjusted Chemotherapy For Patients With High Risk Diffuse Large B-Cell Lymphoma",6923
112,NCT02160015,Phase I,"Active, not recruiting","[{'id': 1610, 'therapyName': 'Rituximab + Lenalidomide + Ibrutinib'}]","Lenalidomide, Ibrutinib, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma",6923
113,NCT02203526,Phase I,Suspended,"[{'id': 1607, 'therapyName': 'Temozolomide + Etoposide + Doxil + Dexamethasone + Ibrutinib'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 897, 'therapyName': 'Rituximab'}]","Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Dose-Adjusted-Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (DA-TEDDI-R) in Primary CNS Lymphoma",6923
0,NCT03056339,Phase Ib/II,Recruiting,"[{'id': 6217, 'therapyName': 'Cyclophosphamide + Fludarabine phosphate + iC9/CAR.19/IL15-Transduced CB-NK'}]",Umbilical & Cord Blood (CB)- Derived CAR-Engineered NK Cells for B Lymphoid Malignancies,8939
0,NCT02033148,Phase I,Withdrawn,"[{'id': 769, 'therapyName': 'Icotinib'}]",Icotinib Hydrochloride in Treating Patients With Advanced Cancers,7064
0,NCT02609984,Phase II,"Active, not recruiting","[{'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 3273, 'therapyName': 'G305 + ID-LV305'}]",Trial of CMB305 and Atezolizumab in Patients With Sarcoma,8002
1,NCT02122861,Phase I,"Active, not recruiting","[{'id': 3271, 'therapyName': 'ID-LV305'}]","A Phase 1 Safety Study of Intradermal ID-LV305 in Patients With Locally Advanced, Relapsed or Metastatic Cancer Expressing NY-ESO-1",8002
0,NCT02703272,Phase III,Recruiting,"[{'id': 768, 'therapyName': 'Ibrutinib'}, {'id': 4307, 'therapyName': 'Carboplatin + Dexamethasone + Etoposide + Ifosfamide + Rituximab'}, {'id': 4308, 'therapyName': 'Carboplatin + Dexamethasone + Idarubicin + Ifosfamide + Rituximab + Vincristine'}]",A Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Participants With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma,1164
1,NCT02680951,Phase I,Recruiting,"[{'id': 3731, 'therapyName': 'Cytarabine + Dasatinib + Fludarabine  + Idarubicin'}]",Dasatinib in Combination With Chemotherapy for Relapsed or Refractory Core Binding Factor Acute Myeloid Leukemia,1164
2,NCT02668653,Phase III,Recruiting,"[{'id': 3543, 'therapyName': 'Cytarabine + Daunorubicin + Idarubicin'}, {'id': 882, 'therapyName': 'Quizartinib'}]",Quizartinib With Standard of Care Chemotherapy and as Maintenance Therapy in Patients With Newly Diagnosed FLT3-ITD (+) AML,1164
3,NCT02339740,Phase III,Recruiting,"[{'id': 3686, 'therapyName': 'Cytarabine + Dexamethasone + Idarubicin + Mitoxantrone'}, {'id': 3685, 'therapyName': 'Arsenic trioxide + Gemtuzumab ozogamicin + Tretinoin'}]",Tretinoin and Arsenic Trioxide in Treating Patients With Untreated Acute Promyelocytic Leukemia,1164
4,NCT02421939,Phase III,Recruiting,"[{'id': 712, 'therapyName': 'Cytarabine'}, {'id': 3193, 'therapyName': 'Cytarabine + Fludarabine + Idarubicin'}, {'id': 1752, 'therapyName': 'Mitoxantrone + Etoposide + Cytarabine'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 2865, 'therapyName': 'Gilteritinib'}, {'id': 1632, 'therapyName': 'Filgrastim'}]",A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,1164
5,NCT02039726,Phase III,"Active, not recruiting","[{'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 3193, 'therapyName': 'Cytarabine + Fludarabine + Idarubicin'}, {'id': 1752, 'therapyName': 'Mitoxantrone + Etoposide + Cytarabine'}, {'id': 882, 'therapyName': 'Quizartinib'}]",An Open-label Study of Quizartinib Monotherapy vs. Salvage Chemotherapy in Acute Myeloid Leukemia (AML) Subjects,1164
6,NCT01812252,Phase II,Recruiting,"[{'id': 1606, 'therapyName': 'Cytarabine + Idarubicin'}, {'id': 1798, 'therapyName': 'Decitabine + Azacitidine'}]",Chemotherapy in Treating Patients With Myelodysplastic Syndrome Before Donor Stem Cell Transplant,1164
7,NCT02236013,Phase I,Recruiting,"[{'id': 1606, 'therapyName': 'Cytarabine + Idarubicin'}, {'id': 2865, 'therapyName': 'Gilteritinib'}]",A Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia,1164
8,NCT02835729,Phase Ib/II,Recruiting,"[{'id': 1606, 'therapyName': 'Cytarabine + Idarubicin'}, {'id': 4499, 'therapyName': 'Cytarabine + Idarubicin + indoximod'}]",A Study of Indoximod in Combination With (7+3) Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia,1164
9,NCT02306291,Phase Ib/II,Recruiting,"[{'id': 1606, 'therapyName': 'Cytarabine + Idarubicin'}, {'id': 1752, 'therapyName': 'Mitoxantrone + Etoposide + Cytarabine'}, {'id': 4402, 'therapyName': 'GMI-1271'}]","Study to Determine Safety, Pharmacokinetics and Efficacy of GMI-1271 in Combination With Chemotherapy in AML",1164
10,NCT02665143,Phase Ib/II,Recruiting,"[{'id': 1606, 'therapyName': 'Cytarabine + Idarubicin'}, {'id': 831, 'therapyName': 'Nintedanib'}]",A Randomized Trial of a Combination of Nintedanib/Placebo in Combination With Induction Chemotherapy for Patients With Refractory or First Relapse Acute Myeloid Leukemia,1164
11,NCT02779283,Phase I,Recruiting,"[{'id': 717, 'therapyName': 'Dasatinib'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 877, 'therapyName': 'Ponatinib'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 1606, 'therapyName': 'Cytarabine + Idarubicin'}, {'id': 930, 'therapyName': 'Sunitinib'}]",Personalized Kinase Inhibitor Therapy Combined With Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,1164
12,NCT02046122,Phase I,Recruiting,"[{'id': 1606, 'therapyName': 'Cytarabine + Idarubicin'}]",Adoptive Transfer of Haplo-identical DLI for AML and MDS,1164
13,NCT02400281,Phase Ib/II,Recruiting,"[{'id': 651, 'therapyName': 'Azacitidine'}, {'id': 705, 'therapyName': 'Crenolanib'}, {'id': 1606, 'therapyName': 'Cytarabine + Idarubicin'}]",Study of Crenolanib Combined With Chemotherapy in FLT3-mutated Acute Myeloid Leukemia Patients,1164
14,NCT01876953,Phase Ib/II,"Active, not recruiting","[{'id': 1850, 'therapyName': 'Cytarabine + Idarubicin + Dasatinib'}]","Dasatinib, Cytarabine, and Idarubicin in Treating Patients With High-Risk Acute Myeloid Leukemia",1164
15,NCT02635074,Phase I,Recruiting,"[{'id': 3573, 'therapyName': 'Cytarabine + Idarubicin + Ibrutinib'}]","Ibrutinib, Idarubicin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia",1164
16,NCT02652871,Phase I,Recruiting,"[{'id': 3470, 'therapyName': 'Cytarabine + Idarubicin + LY2510924'}]","A Phase 1b, Open-label Study of LY2510924, Idarubicin and Cytarabine in Patients With Relapsed or Refractory Acute Myeloid Leukemia",1164
17,NCT02464657,Phase Ib/II,Recruiting,"[{'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 3192, 'therapyName': 'Cytarabine + Idarubicin + Nivolumab'}]",Nivolumab in Acute Myeloid Leukemia (AML),1164
18,NCT01822015,Phase I,"Active, not recruiting","[{'id': 2232, 'therapyName': 'Cytarabine + Idarubicin + Sirolimus'}]","Sirolimus, Idarubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia",1164
19,NCT02527174,Phase I,Withdrawn,"[{'id': 3213, 'therapyName': 'Cytarabine + Idarubicin + Volasertib'}]",A Study of Volasertib Plus Induction Chemotherapy for Acute Myeloid Leukemia (VIAC),1164
20,NCT02905994,Phase I,Withdrawn,"[{'id': 3213, 'therapyName': 'Cytarabine + Idarubicin + Volasertib'}]",Volasertib Combined With Induction Chemotherapy in Acute Myeloid Leukemia,1164
21,NCT03164057,Phase II,Recruiting,"[{'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 5153, 'therapyName': 'dexrazoxane'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 651, 'therapyName': 'Azacitidine'}]",A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia,1164
22,NCT01794702,Phase Ib/II,"Active, not recruiting","[{'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 650, 'therapyName': 'Decitabine'}]","Decitabine Followed by Clofarabine, Idarubicin, and Cytarabine in Acute Leukemia",1164
23,NCT03214562,,Recruiting,"[{'id': 1562, 'therapyName': 'Venetoclax'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 712, 'therapyName': 'Cytarabine'}]",Study of the BCL-2 Inhibitor Venetoclax in Combination With Standard Intensive Acute Myeloid Leukemia (AML) Induction/Consolidation Therapy With FLAG-IDA in Patients With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia (AML),1164
24,NCT02560025,Phase II,"Active, not recruiting","[{'id': 626, 'therapyName': 'Alisertib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 712, 'therapyName': 'Cytarabine'}]",Phase II Trial of Alisertib With Induction Chemotherapy in High-risk AML,1164
25,NCT03117751,Phase II,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1876, 'therapyName': 'Blinatumomab '}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1638, 'therapyName': 'Pegaspargase'}]",Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma,1164
26,NCT02096055,Phase II,Recruiting,"[{'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1949, 'therapyName': 'SGI-110'}, {'id': 1022, 'therapyName': 'Idarubicin'}]",4-Arm Phase II Study of SGI-110 in Elderly Acute Myeloid Leukemia (AML),1164
27,NCT02788201,Phase II,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1133, 'therapyName': 'Mitomycin C'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1013, 'therapyName': 'epirubicin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1137, 'therapyName': 'Bleomycin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 781, 'therapyName': 'Ixabepilone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 2950, 'therapyName': 'Estramustine'}, {'id': 1941, 'therapyName': 'Floxuridine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 1811, 'therapyName': 'Carmustine'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 953, 'therapyName': 'Vandetanib'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 4419, 'therapyName': 'Toremifine'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 2601, 'therapyName': 'Dactinomycin'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 3035, 'therapyName': 'Chlorambucil'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 342, 'therapyName': 'Vemurafenib'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 2635, 'therapyName': 'Vinblastine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 4305, 'therapyName': 'Teniposide'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 4304, 'therapyName': 'Streptozocin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1231, 'therapyName': 'Bendamustine'}, {'id': 4303, 'therapyName': 'Mechlorethamine'}, {'id': 4302, 'therapyName': 'Mitotane'}]",Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma,1164
28,NCT02049801,Phase I,"Active, not recruiting","[{'id': 2220, 'therapyName': 'MEK162 + Idarubicin + Cytarabine'}]","MEK Inhibitor MEK162, Idarubicin, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia",1164
0,NCT02545283,Phase III,Recruiting,"[{'id': 712, 'therapyName': 'Cytarabine'}, {'id': 4395, 'therapyName': 'Cytarabine + Idasanutlin'}]",A Study of Idasanutlin With Cytarabine Versus Cytarabine Plus Placebo in Patients With Relapsed or Refractory Acute Myeloid Leukemia,7389
1,NCT02633059,Phase Ib/II,Recruiting,"[{'id': 4392, 'therapyName': 'Dexamethasone + Idasanutlin + Ixazomib'}]","Idasanutlin, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma",7389
2,NCT02624986,Phase Ib/II,Recruiting,"[{'id': 4393, 'therapyName': 'Idasanutlin + Obinutuzumab'}]",A Study of Obinutuzumab With Idasanutlin in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL),7389
3,NCT03135262,Phase Ib/II,Recruiting,"[{'id': 5646, 'therapyName': 'Idasanutlin + Rituximab + Venetoclax'}, {'id': 5644, 'therapyName': 'Idasanutlin + Obinutuzumab + Venetoclax'}, {'id': 5645, 'therapyName': 'Idasanutlin + Obinutuzumab + Rituximab + Venetoclax'}]",A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large B-Cell Lymphoma (DLBCL),7389
0,NCT02787369,Phase I,"Active, not recruiting","[{'id': 4273, 'therapyName': 'ACY-1215 + Idelalisib '}, {'id': 4272, 'therapyName': 'ACY-1215 + Ibrutinib'}]",ACY-1215 in Combination With BCR Pathway Inhibitors in Relapsed CLL,7140
1,NCT01980888,Phase III,Terminated,"[{'id': 2324, 'therapyName': 'Bendamustine + Idelalisib + Rituximab'}]",Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab in Subjects With Previously Untreated Chronic Lymphocytic Leukemia,7140
2,NCT02970318,Phase III,Recruiting,"[{'id': 2324, 'therapyName': 'Bendamustine + Idelalisib + Rituximab'}, {'id': 1605, 'therapyName': 'Acalabrutinib'}]",A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL,7140
3,NCT02538614,Phase Ib/II,Terminated,"[{'id': 4396, 'therapyName': 'BI 836826 + Idelalisib '}]",Study of Idelalisib in Combination With BI 836826 in Participants With Chronic Lymphocytic Leukemia,7140
4,NCT01732913,Phase III,Terminated,"[{'id': 1023, 'therapyName': 'Idelalisib'}, {'id': 897, 'therapyName': 'Rituximab'}]",Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas,7140
5,NCT02662296,Phase II,Withdrawn,"[{'id': 1023, 'therapyName': 'Idelalisib'}, {'id': 768, 'therapyName': 'Ibrutinib'}]","Ibrutinib or Idelalisib in Treating Patients With Persistent or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma After Donor Stem Cell Transplant",7140
6,NCT03133221,Phase II,Not yet recruiting,"[{'id': 1023, 'therapyName': 'Idelalisib'}]",1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation,7140
7,NCT01732926,Phase III,Terminated,"[{'id': 1023, 'therapyName': 'Idelalisib'}, {'id': 2323, 'therapyName': 'Bendamustine + Rituximab'}]",Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas,7140
8,NCT01306643,Phase Ib/II,Completed,"[{'id': 1023, 'therapyName': 'Idelalisib'}]","Safety and Efficacy Study of Idelalisib (GS-1101, CAL-101) in Patients With Previously Treated Low-grade Lymphoma",7140
9,NCT03126019,Phase II,Recruiting,"[{'id': 3088, 'therapyName': 'INCB050465 '}, {'id': 1023, 'therapyName': 'Idelalisib'}]","An Open-Label, Randomized Study Comparing INCB050465 to Idelalisib in Relapsed or Refractory Follicular Lymphoma (CITADEL-203)",7140
10,NCT02639910,Phase II,Recruiting,"[{'id': 5785, 'therapyName': 'MOR208 + Venetoclax'}, {'id': 5784, 'therapyName': 'Idelalisib + MOR208'}]",Study to Evaluate Efficacy and Safety of MOR208 With Idelalisib or Venetoclax in R/R CLL/SLL Patients Pretreated With BTKi (COSMOS),7140
11,NCT01980875,Phase III,Terminated,"[{'id': 1647, 'therapyName': 'Idelalisib + Obinutuzumab'}, {'id': 1648, 'therapyName': 'Obinutuzumab + Chlorambucil'}]",Efficacy and Safety of Idelalisib in Combination With Obinutuzumab Compared to Chlorambucil in Combination With Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia,7140
12,NCT02135133,Phase II,Suspended,"[{'id': 2326, 'therapyName': 'Idelalisib + Ofatumumab'}]","A Study of Idelalisib (GS1101, CAL101) + Ofatumumab in Previously Untreated CLL/SLL",7140
13,NCT01644253,Phase I,Recruiting,"[{'id': 4745, 'therapyName': 'Idelalisib + Otlertuzumab + Rituximab'}, {'id': 4742, 'therapyName': 'Otlertuzumab + Rituximab'}, {'id': 4743, 'therapyName': 'Obinutuzumab + Otlertuzumab'}, {'id': 4744, 'therapyName': 'Ibrutinib + Otlertuzumab'}]","Phase 1b Safety and Efficacy Study of TRU-016 and Rituximab, Obinutuzumab, Idelalisib, or Ibrutinib in Chronic Lymphocytic Leukemia",7140
14,NCT03257722,Phase Ib/II,Recruiting,"[{'id': 6145, 'therapyName': 'Idelalisib + Pembrolizumab'}]",Pembrolizumab + Idelalisib for Lung Cancer Study,7140
15,NCT02044822,Phase II,Terminated,"[{'id': 2325, 'therapyName': 'Idelalisib + Rituximab'}]",Efficacy and Safety of Idelalisib in Combination With Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia With 17p Deletion,7140
0,NCT02381886,Phase I,Suspended,"[{'id': 2981, 'therapyName': 'IDH305'}]",A Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 Mutations,7888
1,NCT02977689,Phase II,Not yet recruiting,"[{'id': 2981, 'therapyName': 'IDH305'}]",Trial of IDH305 in IDH1 Mutant Grade II or III Glioma,7888
0,NCT02584829,Phase Ib/II,Suspended,"[{'id': 3156, 'therapyName': 'IFN-B'}, {'id': 3144, 'therapyName': 'Avelumab'}]",Localized Radiation Therapy or Recombinant Interferon Beta and MSB0010718C With or Without Cellular Adoptive Immunotherapy in Treating Patients With Metastatic Merkel Cell Carcinoma,7961
0,NCT02703272,Phase III,Recruiting,"[{'id': 768, 'therapyName': 'Ibrutinib'}, {'id': 4307, 'therapyName': 'Carboplatin + Dexamethasone + Etoposide + Ifosfamide + Rituximab'}, {'id': 4308, 'therapyName': 'Carboplatin + Dexamethasone + Idarubicin + Ifosfamide + Rituximab + Vincristine'}]",A Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Participants With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma,1168
1,NCT01453205,Phase II,Completed,"[{'id': 2354, 'therapyName': 'Cisplatin + Cytarabine + Dexamethasone'}, {'id': 2352, 'therapyName': 'Carboplatin + Etoposide + Ifosfamide '}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 2407, 'therapyName': 'MEDI-551'}]","A Phase 2, Multicenter, Randomized, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)",1168
2,NCT02408042,Phase Ib/II,Withdrawn,"[{'id': 897, 'therapyName': 'Rituximab'}, {'id': 2352, 'therapyName': 'Carboplatin + Etoposide + Ifosfamide '}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 2486, 'therapyName': 'Brentuximab vedotin'}]",Study of Pembrolizumab With Chemotherapy in Patients With Advanced Lymphoma (PembroHeme),1168
3,NCT02018861,Phase I,"Active, not recruiting","[{'id': 2406, 'therapyName': 'INCB039110'}, {'id': 3097, 'therapyName': 'INCB039110 + INCB050465'}, {'id': 1231, 'therapyName': 'Bendamustine'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 2352, 'therapyName': 'Carboplatin + Etoposide + Ifosfamide '}, {'id': 3088, 'therapyName': 'INCB050465 '}]","A Phase 1, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 Monotherapy and in Combination With INCB039110 in Subjects With Previously Treated B-Cell Malignancies",1168
4,NCT01169636,Phase Ib/II,Completed,"[{'id': 1080, 'therapyName': 'Panobinostat'}, {'id': 1476, 'therapyName': 'Pegfilgrastim'}, {'id': 2352, 'therapyName': 'Carboplatin + Etoposide + Ifosfamide '}]","Panobinostat Plus Ifosfamide, Carboplatin, and Etoposide (ICE) Compared With ICE For Relapsed Hodgkin Lymphoma",1168
5,NCT01959698,Phase Ib/II,Recruiting,"[{'id': 2351, 'therapyName': 'Carfilzomib + Rituximab'}, {'id': 2352, 'therapyName': 'Carboplatin + Etoposide + Ifosfamide '}]","Carfilzomib, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma",1168
6,NCT02471911,Phase I,Recruiting,"[{'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 3360, 'therapyName': 'Carboplatin + Etoposide + Ifosfamide + Rituximab'}, {'id': 1749, 'therapyName': 'Selinexor'}]",KPT-330 Plus RICE for Relapsed/Refractory Aggressive B-Cell Lymphoma,1168
7,NCT02219737,Phase I,"Active, not recruiting","[{'id': 768, 'therapyName': 'Ibrutinib'}, {'id': 3360, 'therapyName': 'Carboplatin + Etoposide + Ifosfamide + Rituximab'}]",Ibrutinib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma,1168
8,NCT01446809,Phase I,"Active, not recruiting","[{'id': 1472, 'therapyName': 'Doxorubicin + Ifosfamide'}, {'id': 1471, 'therapyName': 'Pazopanib + Doxorubicin + Ifosfamide'}]",Pazopanib Hydrochloride Followed By Chemotherapy and Surgery in Treating Patients With Soft Tissue Sarcoma,1168
9,NCT02180867,Phase II,Recruiting,"[{'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1472, 'therapyName': 'Doxorubicin + Ifosfamide'}]",Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Hydrochloride Before Surgery in Treating Patients With Newly Diagnosed Non-Rhabdomyosarcoma Soft Tissue Sarcomas That Can be Removed by Surgery (PAZNTIS),1168
10,NCT03283696,Phase I,Not yet recruiting,"[{'id': 6292, 'therapyName': 'Doxorubicin + Ifosfamide + Mesna + Olaratumab'}]","A Study of Olaratumab (LY3012207), Doxorubicin, and Ifosfamide in Participants With Advanced or Metastatic Soft Tissue Sarcoma",1168
11,NCT02050919,Phase II,Recruiting,"[{'id': 2365, 'therapyName': 'Epirubicin + Ifosfamide + Sorafenib'}]","Sorafenib Tosylate, Combination Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With High-Risk Stage IIB-IV Soft Tissue Sarcoma",1168
12,NCT00936936,Phase II,Recruiting,"[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 2101, 'therapyName': 'Etoposide + Ifosfamide'}, {'id': 2100, 'therapyName': 'Docetaxel + Gemcitabine + Melphalan'}, {'id': 2074, 'therapyName': 'Bevacizumab + Carboplatin'}]",High-dose Chemotherapy for Poor-prognosis Relapsed Germ-Cell Tumors,1168
13,NCT01505569,Phase I,Recruiting,"[{'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 2558, 'therapyName': 'Busulfan + Melphalan'}, {'id': 2101, 'therapyName': 'Etoposide + Ifosfamide'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 1092, 'therapyName': 'Carboplatin'}]",Auto Transplant for High Risk or Relapsed Solid or CNS Tumors,1168
14,NCT02049905,Phase III,Completed,"[{'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1440, 'therapyName': 'Aldoxorubicin'}, {'id': 1439, 'therapyName': 'Gemcitabine + Docetaxel'}]",Phase 3 Study to Treat Patients With Soft Tissue Sarcomas,1168
15,NCT02677116,Phase I,Recruiting,"[{'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 3618, 'therapyName': 'Irinotecan + Vincristine'}, {'id': 3269, 'therapyName': 'Olaratumab'}]",A Study of Olaratumab Alone and in Combination With Standard Chemotherapies in Children With Cancer,1168
16,NCT02112916,Phase III,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1009, 'therapyName': 'Doxorubicin'}]",Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma,1168
17,NCT02788201,Phase II,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1133, 'therapyName': 'Mitomycin C'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1013, 'therapyName': 'epirubicin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1137, 'therapyName': 'Bleomycin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 781, 'therapyName': 'Ixabepilone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 2950, 'therapyName': 'Estramustine'}, {'id': 1941, 'therapyName': 'Floxuridine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 1811, 'therapyName': 'Carmustine'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 953, 'therapyName': 'Vandetanib'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 4419, 'therapyName': 'Toremifine'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 2601, 'therapyName': 'Dactinomycin'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 3035, 'therapyName': 'Chlorambucil'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 342, 'therapyName': 'Vemurafenib'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 2635, 'therapyName': 'Vinblastine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 4305, 'therapyName': 'Teniposide'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 4304, 'therapyName': 'Streptozocin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1231, 'therapyName': 'Bendamustine'}, {'id': 4303, 'therapyName': 'Mechlorethamine'}, {'id': 4302, 'therapyName': 'Mitotane'}]",Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma,1168
18,NCT03007147,Phase III,Recruiting,"[{'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 5153, 'therapyName': 'dexrazoxane'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 5167, 'therapyName': 'Methylprednisolone'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 5168, 'therapyName': 'Prednisolone'}, {'id': 1009, 'therapyName': 'Doxorubicin'}]",Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia,1168
19,NCT03016871,Phase II,Recruiting,"[{'id': 5198, 'therapyName': 'Nivolumab + Etoposide + Ifosfamide + Carboplatin'}]","Nivolumab, Ifosfamide, Carboplatin, and Etoposide as Second-Line Therapy in Treating Patients With Refractory or Relapsed Hodgkin Lymphoma",1168
20,NCT00954174,Phase III,"Active, not recruiting","[{'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 1125, 'therapyName': 'Paclitaxel + Ifosfamide'}]","Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritorium Cavity Cancer",1168
21,NCT03077828,Phase II,Recruiting,"[{'id': 5435, 'therapyName': 'Pembrolizumab + Etoposide + Carboplatin + Ifosfamide'}]",Pembrolizumab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma,1168
22,NCT03064867,Phase I,Recruiting,"[{'id': 5404, 'therapyName': 'Venetoclax + Rituximab + Ifosfamide + Carboplatin + Etoposide'}]",Venetoclax Plus R-ICE Chemotherapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma,1168
23,NCT01946529,Phase II,"Active, not recruiting","[{'id': 1433, 'therapyName': 'Vincristine + Doxorubicin + Cyclophosphamide + Ifosfamide + Etoposide'}, {'id': 1434, 'therapyName': 'Vincristine + Doxorubicin + Cyclophosphamide + Ifosfamide + Etoposide + others'}]",Therapeutic Trial for Patients With Ewing Sarcoma Family of Tumor and Desmoplastic Small Round Cell Tumors,1168
24,NCT02306161,Phase II,Recruiting,"[{'id': 1433, 'therapyName': 'Vincristine + Doxorubicin + Cyclophosphamide + Ifosfamide + Etoposide'}, {'id': 746, 'therapyName': 'Ganitumab'}]",Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma,1168
25,NCT00020566,Phase III,Unknown status,"[{'id': 2558, 'therapyName': 'Busulfan + Melphalan'}, {'id': 2670, 'therapyName': 'Vincristine + Doxorubicin + Dactinomycin + Ifosfamide + Etoposide'}]","Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation, Radiation Therapy, and/or Surgery in Treating Patients With Ewing's Sarcoma",1168
0,NCT02507583,Phase I,Recruiting,"[{'id': 4325, 'therapyName': 'IGF-1R/AS ODN'}]",Antisense102: Pilot Immunotherapy for Newly Diagnosed Malignant Glioma,8415
0,NCT02493361,Phase II,"Active, not recruiting","[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 2990, 'therapyName': 'IL-12 gene'}]",Trial of pIL-12/MK-3475 in Metastatic Melanoma,7892
0,NCT02924038,Phase I,Recruiting,"[{'id': 4835, 'therapyName': 'IMA950 + poly ICLC '}, {'id': 2525, 'therapyName': 'Varlilumab'}]",A Study of Varlilumab and IMA950 Vaccine Plus Poly-ICLC in Patients With WHO Grade II Low-Grade Glioma (LGG),8557
0,NCT02540356,Phase Ib/II,Terminated,"[{'id': 2996, 'therapyName': 'Imalumab'}]",Phase 1/2a Two-Arm Dose-Escalation Study of BAX69 in Subjects With Malignant Ascites of Ovarian Cancer,7895
1,NCT02448810,Phase II,Terminated,"[{'id': 2278, 'therapyName': 'Fluorouracil + Leucovorin'}, {'id': 2996, 'therapyName': 'Imalumab'}, {'id': 845, 'therapyName': 'Panitumumab'}]",Phase 2a Study of BAX69 and 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer,7895
0,NCT02257541,Phase Ib/II,"Active, not recruiting","[{'id': 2284, 'therapyName': 'BGJ398 + Imatinib'}]",BGJ398 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST),609
1,NCT01188889,Phase Ib/II,Withdrawn,"[{'id': 2198, 'therapyName': 'Everolimus + Imatinib'}]",RAD001 in Patients With Chronic Phase Chronic Myeloid Leukemia w/ Molecular Disease,609
2,NCT03023046,Phase II,Recruiting,"[{'id': 897, 'therapyName': 'Rituximab'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 1631, 'therapyName': 'Vincristine'}]","Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma",609
3,NCT01319981,Phase II,Recruiting,"[{'id': 1476, 'therapyName': 'Pegfilgrastim'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}]",Hyper-CVAD With Liposomal Vincristine in Acute Lymphoblastic Leukemia,609
4,NCT00812240,Phase III,Unknown status,"[{'id': 804, 'therapyName': 'Masitinib'}, {'id': 770, 'therapyName': 'Imatinib'}]",A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Comparison to Imatinib in Patients With Gastro-Intestinal Stromal Tumour in First Line Medical Treatment,609
5,NCT01593254,Phase II,"Active, not recruiting","[{'id': 770, 'therapyName': 'Imatinib'}, {'id': 717, 'therapyName': 'Dasatinib'}]",Phase IIb Study of Dasatinib Versus Imatinib in Patients With CML-CP Who Have Not Achieved an Early Optimal Response to Imatinib,609
6,NCT02788201,Phase II,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1133, 'therapyName': 'Mitomycin C'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1013, 'therapyName': 'epirubicin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1137, 'therapyName': 'Bleomycin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 781, 'therapyName': 'Ixabepilone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 2950, 'therapyName': 'Estramustine'}, {'id': 1941, 'therapyName': 'Floxuridine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 1811, 'therapyName': 'Carmustine'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 953, 'therapyName': 'Vandetanib'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 4419, 'therapyName': 'Toremifine'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 2601, 'therapyName': 'Dactinomycin'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 3035, 'therapyName': 'Chlorambucil'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 342, 'therapyName': 'Vemurafenib'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 2635, 'therapyName': 'Vinblastine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 4305, 'therapyName': 'Teniposide'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 4304, 'therapyName': 'Streptozocin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1231, 'therapyName': 'Bendamustine'}, {'id': 4303, 'therapyName': 'Mechlorethamine'}, {'id': 4302, 'therapyName': 'Mitotane'}]",Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma,609
7,NCT03007147,Phase III,Recruiting,"[{'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 5153, 'therapyName': 'dexrazoxane'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 5167, 'therapyName': 'Methylprednisolone'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 5168, 'therapyName': 'Prednisolone'}, {'id': 1009, 'therapyName': 'Doxorubicin'}]",Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia,609
8,NCT02177825,Phase II,Recruiting,"[{'id': 770, 'therapyName': 'Imatinib'}]",Study of Imatinib Mesylate in Neurofibromatosis Type I Patients Aged 2 to 21 With Plexiform Neurofibromas,609
9,NCT02551718,Phase I,Recruiting,"[{'id': 690, 'therapyName': 'Bosutinib'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 3160, 'therapyName': 'Nelarabine'}, {'id': 3159, 'therapyName': 'Bexarotene'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 998, 'therapyName': 'cabozantinib'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 877, 'therapyName': 'Ponatinib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 623, 'therapyName': 'Afatinib'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 890, 'therapyName': 'Regorafenib'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 2, 'therapyName': 'Trametinib'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 3, 'therapyName': 'Dabrafenib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 789, 'therapyName': 'Ceritinib'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1571, 'therapyName': 'Cabazitaxel'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1327, 'therapyName': 'Pralatrexate'}]",High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia,609
10,NCT01244750,Phase I,"Active, not recruiting","[{'id': 770, 'therapyName': 'Imatinib'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 829, 'therapyName': 'Nilotinib'}]",Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting,609
11,NCT02130557,Phase III,"Active, not recruiting","[{'id': 690, 'therapyName': 'Bosutinib'}, {'id': 770, 'therapyName': 'Imatinib'}]","A Multicenter Phase 3, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia",609
12,NCT02352558,Phase I,"Active, not recruiting","[{'id': 770, 'therapyName': 'Imatinib'}, {'id': 2057, 'therapyName': 'BBI608'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 768, 'therapyName': 'Ibrutinib'}, {'id': 1390, 'therapyName': 'Dexamethasone'}]","A Study of BBI608 in Adult Patients With Advanced, Refractory Hematologic Malignancies",609
13,NCT00290485,Phase II,Unknown status,"[{'id': 770, 'therapyName': 'Imatinib'}]",Gleevec Administered Preoperatively to Reduce Gastrointestinal Stromal Tumor (GIST),609
14,NCT00718263,Phase III,Recruiting,"[{'id': 770, 'therapyName': 'Imatinib'}, {'id': 829, 'therapyName': 'Nilotinib'}]",Efficacy and Safety of Nilotinib Patients With Newly Diagnosed CML - CP (Chronic Myelogenous Leukemia - Chronic Phase),609
15,NCT02538926,Phase II,Not yet recruiting,"[{'id': 770, 'therapyName': 'Imatinib'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 3212, 'therapyName': 'Doxorubicin + Etoposide + Vincristine '}, {'id': 2206, 'therapyName': 'Asparaginase'}]","Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride With Asparaginase in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma",609
16,NCT02709083,Phase II,Recruiting,"[{'id': 717, 'therapyName': 'Dasatinib'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 770, 'therapyName': 'Imatinib'}]","Dasatinib or Nilotinib Followed by Imatinib in Patients With Newly Diagnosed, Chronic Phase Chronic Myeloid Leukemia",609
17,NCT00573378,Phase II,Withdrawn,"[{'id': 2467, 'therapyName': 'Imatinib + Interferon alfa-2b '}, {'id': 2468, 'therapyName': 'Interferon alfa-2b + Nilotinib '}]",Imatinib or Nilotinib With Pegylated Interferon-alpha2b in Chronic Myeloid Leukemia,609
18,NCT02812693,Phase Ib/II,Recruiting,"[{'id': 4376, 'therapyName': 'Imatinib + Pembrolizumab'}]",Pembrolizumab and Imatinib in Patients With Locally Advanced/Metastatic Melanoma With c-KIT Mutation/Amplification,609
19,NCT01738139,Phase I,Recruiting,"[{'id': 1250, 'therapyName': 'Ipilimumab + Imatinib Mesylate'}]",Ipilimumab and Imatinib Mesylate in Advanced Cancer,609
20,NCT01991379,Phase Ib/II,Recruiting,"[{'id': 1430, 'therapyName': 'MEK162 + Imatinib mesylate'}]",MEK162 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST),609
0,NCT02570308,Phase I,Recruiting,"[{'id': 3847, 'therapyName': 'IMCgp100'}]",A Study of the Intra-Patient Escalation Dosing Regimen With IMCgp100 in Patients With Advanced Uveal Melanoma,8267
1,NCT02535078,Phase Ib/II,Recruiting,"[{'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 3847, 'therapyName': 'IMCgp100'}, {'id': 1652, 'therapyName': 'Tremelimumab'}]",Phase 1b/2 Study of the Combination of IMCgp100 With Durvalumab and/or Tremelimumab in Cutaneous Melanoma,8267
2,NCT02889861,Phase Ib/II,Recruiting,"[{'id': 3847, 'therapyName': 'IMCgp100'}]",IMCgp100-401 Rollover Study,8267
3,NCT03070392,Phase II,Recruiting,"[{'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 3847, 'therapyName': 'IMCgp100'}]",Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma,8267
0,NCT02598661,Phase III,Recruiting,"[{'id': 3710, 'therapyName': 'Imetelstat'}]",Study to Evaluate Imetelstat (JNJ-63935937) in Subjects With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS),8217
0,NCT01609556,Phase I,"Active, not recruiting","[{'id': 3232, 'therapyName': 'IMGN853'}]","First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of IMGN853 in Adults With Ovarian Cancer and Other FOLR1-Positive Solid Tumors",7977
1,NCT03106077,Phase II,Recruiting,"[{'id': 3232, 'therapyName': 'IMGN853'}]",Mirvetuximab Soravtansine in Localized Triple-Negative Breast Cancer (TNBC),7977
2,NCT02606305,Phase I,Recruiting,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 3232, 'therapyName': 'IMGN853'}]","Study of IMGN853 in Comb. With Bevacizumab, Carboplatin or PLD in Adults With FRa + Adv. EOC, Primary Peritoneal, Fallopian Tube, or Endometrial Cancer",7977
3,NCT02631876,Phase II,Recruiting,"[{'id': 3574, 'therapyName': 'Doxil + Paclitaxel'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 3232, 'therapyName': 'IMGN853'}]","PH2 Study of IMGN853 vs Investigator's Choice of Chemo in Adults With FRa+ Adv. EOC, Primary Peritoneal or Primary Fallopian Tube Cancer",7977
4,NCT02996825,Phase I,Recruiting,"[{'id': 3232, 'therapyName': 'IMGN853'}]","Mirvetuximab Soravtansine and Gemcitabine Hydrochloride in Treating Patients With FRa-Positive Recurrent Ovarian, Primary Peritoneal, Fallopian Tube, Endometrial, or Triple Negative Breast Cancer",7977
0,NCT03052205,Phase I,Recruiting,"[{'id': 4243, 'therapyName': 'IMO-2125'}]",A Study of Intratumoral IMO-2125 in Patients With Refractory Solid Tumors,8386
1,NCT02644967,Phase Ib/II,Recruiting,"[{'id': 4244, 'therapyName': 'IMO-2125 + Ipilimumab'}, {'id': 4245, 'therapyName': 'IMO-2125 + Pembrolizumab'}]",A Study to Assess the Safety and Efficacy of Intratumoral IMO-2125 in Combination With Ipilimumab or Pembrolizumab in Patients With Metastatic Melanoma,8386
0,NCT02252146,Phase Ib/II,Completed,"[{'id': 2866, 'therapyName': 'IMO-8400'}]",Dose Escalation Study in Patients With Relapsed or Refractory DLBCL and MyD88L265P Mutation,7800
1,NCT02092909,Phase Ib/II,"Active, not recruiting","[{'id': 2866, 'therapyName': 'IMO-8400'}]",Phase 1/2 Dose Escalation Study in Patients With Relapsed or Refractory Waldenstrom's Macroglobulinemia (8400-401),7800
0,NCT03277352,Phase Ib/II,Not yet recruiting,"[{'id': 6277, 'therapyName': 'Epacadostat + INCAGN01876 + Pembrolizumab'}]",INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies,8412
1,NCT02697591,Phase Ib/II,Recruiting,"[{'id': 4321, 'therapyName': 'INCAGN01876'}]","An Open-Label, Dose-Escalation, Safety Study of INCAGN01876 in Subjects With Advanced or Metastatic Solid Tumors",8412
2,NCT03126110,Phase Ib/II,Recruiting,"[{'id': 5599, 'therapyName': 'INCAGN01876 + Nivolumab + Ipilimumab'}, {'id': 5598, 'therapyName': 'INCAGN01876 + Nivolumab'}, {'id': 5597, 'therapyName': 'INCAGN01876 + Ipilimumab'}]","Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies",8412
0,NCT02923349,Phase Ib/II,Recruiting,"[{'id': 5831, 'therapyName': 'INCAGN01949'}]","A Phase 1/2, Open-Label, Dose-Escalation, Safety Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors",8824
1,NCT03241173,Phase Ib/II,Not yet recruiting,"[{'id': 6120, 'therapyName': 'INCAGN01949 + Ipilimumab'}, {'id': 6119, 'therapyName': 'INCAGN01949 + Nivolumab'}, {'id': 6121, 'therapyName': 'INCAGN01949 + Ipilimumab + Nivolumab'}]",A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies,8824
0,NCT01911507,Phase I,Recruiting,"[{'id': 1284, 'therapyName': 'INCB028060 + Erlotinib'}]",INC280 and Erlotinib Hydrochloride in Treating Patients With Non-small Cell Lung Cancer,6924
0,NCT03272464,Phase I,Not yet recruiting,"[{'id': 6176, 'therapyName': 'Dabrafenib + INCB039110 + Trametinib'}]",Phase I Study of INCB039110 in Combination With Dabrafenib and Trametinib in Patients With BRAF-mutant Melanoma and Other Solid Tumors.,7512
1,NCT02760485,Phase Ib/II,Recruiting,"[{'id': 5151, 'therapyName': 'Ibrutinib + INCB039110'}]",A Study of INCB039110 in Combination With Ibrutinib in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma,7512
2,NCT02018861,Phase I,"Active, not recruiting","[{'id': 2406, 'therapyName': 'INCB039110'}, {'id': 3097, 'therapyName': 'INCB039110 + INCB050465'}, {'id': 1231, 'therapyName': 'Bendamustine'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 2352, 'therapyName': 'Carboplatin + Etoposide + Ifosfamide '}, {'id': 3088, 'therapyName': 'INCB050465 '}]","A Phase 1, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 Monotherapy and in Combination With INCB039110 in Subjects With Previously Treated B-Cell Malignancies",7512
3,NCT02355431,Phase II,Withdrawn,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 2406, 'therapyName': 'INCB039110'}]",INCB039110 in Combination With Erlotinib in Non Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor (EGFR) Activating Mutations,7512
4,NCT01858883,Phase I,Completed,"[{'id': 619, 'therapyName': 'Abraxane'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 2406, 'therapyName': 'INCB039110'}, {'id': 755, 'therapyName': 'Gemcitabine'}]",Safety Study of INCB039110 in Combination With Gemcitabine and Nab-Paclitaxel in Subjects With Advanced Solid Tumors,7512
5,NCT02646748,Phase I,Recruiting,"[{'id': 3088, 'therapyName': 'INCB050465 '}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 2406, 'therapyName': 'INCB039110'}]",Pembrolizumab Combined With INCB039110 and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors,7512
6,NCT02257619,Phase II,Terminated,"[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 2406, 'therapyName': 'INCB039110'}]",Study of INCB039110 in Combination With Docetaxel in Subjects With Non-Small Cell Lung Cancer,7512
7,NCT02559492,Phase I,"Active, not recruiting","[{'id': 3096, 'therapyName': 'INCB039110 + INCB024360'}, {'id': 3097, 'therapyName': 'INCB039110 + INCB050465'}]",INCB039110 Combined With INCB024360 and/or INCB039110 Combined With INCB050465 in Advanced Solid Tumors,7512
8,NCT01905813,Phase I,"Active, not recruiting","[{'id': 2420, 'therapyName': 'INCB039110 + INCB040093'}, {'id': 2021, 'therapyName': 'INCB040093'}]",Study of INCB040093 in Subjects With Previously Treated B-Cell Malignancies,7512
9,NCT02917993,Phase Ib/II,Recruiting,"[{'id': 4777, 'therapyName': 'INCB039110 + Osimertinib'}]",An Open-Label Phase 1/2 Study of INCB039110 in Combination With Osimertinib in Subjects With Non-Small Cell Lung Cancer,7512
0,NCT01905813,Phase I,"Active, not recruiting","[{'id': 2420, 'therapyName': 'INCB039110 + INCB040093'}, {'id': 2021, 'therapyName': 'INCB040093'}]",Study of INCB040093 in Subjects With Previously Treated B-Cell Malignancies,7387
0,NCT03039114,Phase I,Recruiting,"[{'id': 6260, 'therapyName': 'Bendamustine + INCB050465 + Obinutuzumab'}]",Study Evaluating Safety and Efficacy of INCB050465 Combined With Bendamustine and Obinutuzumab in Relapsed or Refractory Follicular Lymphoma (CITADEL-102),7933
1,NCT02018861,Phase I,"Active, not recruiting","[{'id': 2406, 'therapyName': 'INCB039110'}, {'id': 3097, 'therapyName': 'INCB039110 + INCB050465'}, {'id': 1231, 'therapyName': 'Bendamustine'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 2352, 'therapyName': 'Carboplatin + Etoposide + Ifosfamide '}, {'id': 3088, 'therapyName': 'INCB050465 '}]","A Phase 1, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 Monotherapy and in Combination With INCB039110 in Subjects With Previously Treated B-Cell Malignancies",7933
2,NCT02559492,Phase I,"Active, not recruiting","[{'id': 3096, 'therapyName': 'INCB039110 + INCB024360'}, {'id': 3097, 'therapyName': 'INCB039110 + INCB050465'}]",INCB039110 Combined With INCB024360 and/or INCB039110 Combined With INCB050465 in Advanced Solid Tumors,7933
3,NCT02646748,Phase I,Recruiting,"[{'id': 3088, 'therapyName': 'INCB050465 '}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 2406, 'therapyName': 'INCB039110'}]",Pembrolizumab Combined With INCB039110 and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors,7933
4,NCT03126019,Phase II,Recruiting,"[{'id': 3088, 'therapyName': 'INCB050465 '}, {'id': 1023, 'therapyName': 'Idelalisib'}]","An Open-Label, Randomized Study Comparing INCB050465 to Idelalisib in Relapsed or Refractory Follicular Lymphoma (CITADEL-203)",7933
5,NCT02998476,Phase II,Recruiting,"[{'id': 3088, 'therapyName': 'INCB050465 '}]",A Phase 2 Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202),7933
6,NCT03144674,Phase II,Recruiting,"[{'id': 3088, 'therapyName': 'INCB050465 '}]",A Study of INCB050465 in Subjects With Relapsed or Refractory Marginal Zone Lymphoma (CITADEL-204),7933
7,NCT02718300,Phase II,Recruiting,"[{'id': 4224, 'therapyName': 'INCB050465 + Ruxolitinib'}]",A Study of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis,7933
0,NCT02265510,Phase I,Recruiting,"[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 1164, 'therapyName': 'lenalidomide'}, {'id': 619, 'therapyName': 'Abraxane'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 2747, 'therapyName': 'INCB052793'}, {'id': 688, 'therapyName': 'Bortezomib'}]","An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies",7699
0,NCT02587598,Phase Ib/II,Recruiting,"[{'id': 3696, 'therapyName': 'INCB053914'}]",Study of INCB053914 in Subjects With Advanced Malignancies,8211
0,NCT02431260,Phase I,"Active, not recruiting","[{'id': 2812, 'therapyName': 'INCB054329'}]","An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced Malignancies",7759
0,NCT02393248,Phase Ib/II,Recruiting,"[{'id': 4176, 'therapyName': 'Cisplatin + Gemcitabine + INCB054828'}, {'id': 4174, 'therapyName': 'Docetaxel + INCB054828'}, {'id': 4088, 'therapyName': 'Epacadostat + Pembrolizumab'}]","Open-Label, Dose-Escalation Study of INCB054828 in Subjects With Advanced Malignancies",8373
1,NCT02872714,Phase II,Recruiting,"[{'id': 4173, 'therapyName': 'INCB054828'}]",A Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Urothelial Carcinoma,8373
2,NCT03011372,Phase II,Recruiting,"[{'id': 4173, 'therapyName': 'INCB054828'}]",A Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement,8373
3,NCT02924376,Phase II,Recruiting,"[{'id': 4173, 'therapyName': 'INCB054828'}]",Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Who Failed Previous Therapy,8373
0,NCT02711137,Phase Ib/II,Recruiting,"[{'id': 4319, 'therapyName': 'INCB057643 '}]","A Phase 1/2, Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies",8410
0,NCT02712905,Phase Ib/II,Recruiting,"[{'id': 5464, 'therapyName': 'INCB059872'}]","An Open-Label, Dose-Escalation/Dose-Expansion Safety Study of INCB059872 in Subjects With Advanced Malignancies",8699
0,NCT03144661,Phase I,Recruiting,"[{'id': 5832, 'therapyName': 'INCB062079'}]",An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies,8825
0,NCT02835729,Phase Ib/II,Recruiting,"[{'id': 1606, 'therapyName': 'Cytarabine + Idarubicin'}, {'id': 4499, 'therapyName': 'Cytarabine + Idarubicin + indoximod'}]",A Study of Indoximod in Combination With (7+3) Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia,7884
1,NCT02460367,Phase Ib/II,Recruiting,"[{'id': 3578, 'therapyName': 'Docetaxel + Indoximod'}]",Immunotherapy Combination Study in Advanced Previously Treated Non-Small Cell Lung Cancer,7884
2,NCT01792050,Phase II,"Active, not recruiting","[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 2976, 'therapyName': 'indoximod'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]",Study of Chemotherapy in Combination With IDO Inhibitor in Metastatic Breast Cancer,7884
3,NCT02502708,Phase I,Recruiting,"[{'id': 2976, 'therapyName': 'indoximod'}, {'id': 1141, 'therapyName': 'Temozolomide'}]","Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Primary Malignant Brain Tumors",7884
4,NCT02077881,Phase Ib/II,Recruiting,"[{'id': 2976, 'therapyName': 'indoximod'}, {'id': 1779, 'therapyName': 'Nab-paclitaxel + Gemcitabine'}]",Study of IDO Inhibitor in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer,7884
5,NCT02052648,Phase Ib/II,Recruiting,"[{'id': 1141, 'therapyName': 'Temozolomide'}, {'id': 2976, 'therapyName': 'indoximod'}]",Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors,7884
6,NCT02073123,Phase Ib/II,Recruiting,"[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 2976, 'therapyName': 'indoximod'}]",Study of IDO Inhibitor in Combination With Ipilimumab for Adult Patients With Metastatic Melanoma,7884
0,NCT01593228,Phase III,Completed,"[{'id': 1173, 'therapyName': 'Iniparib + doxorubicin + carboplatin'}, {'id': 1172, 'therapyName': 'Iniparib + Paclitaxel'}, {'id': 1171, 'therapyName': 'Iniparib + Irinotecan'}, {'id': 1170, 'therapyName': 'Iniparib + Topotecan'}, {'id': 1169, 'therapyName': 'Iniparib + Gemcitabine + Carboplatin'}, {'id': 1168, 'therapyName': 'Iniparib'}]", Treatment Extension Study for Patients Who Have Previously Participated and Have Benefited From Iniparib in a Clinical Trial,7213
0,NCT02960594,Phase I,Recruiting,"[{'id': 5844, 'therapyName': 'INO-1400 + INO-9012'}, {'id': 5807, 'therapyName': 'INO-1400'}]",hTERT Immunotherapy Alone or in Combination With IL-12 DNA Followed by Electroporation in Adults With Solid Tumors at High Risk of Relapse,8803
0,NCT02241369,Phase I,Recruiting,"[{'id': 5846, 'therapyName': 'INO-3106 + INO-9012'}]",Immunotherapy in Subjects With HPV-6 Associated Aerodigestive Precancerous Lesions and Malignancies,8829
0,NCT02960594,Phase I,Recruiting,"[{'id': 5844, 'therapyName': 'INO-1400 + INO-9012'}, {'id': 5807, 'therapyName': 'INO-1400'}]",hTERT Immunotherapy Alone or in Combination With IL-12 DNA Followed by Electroporation in Adults With Solid Tumors at High Risk of Relapse,8804
1,NCT02241369,Phase I,Recruiting,"[{'id': 5846, 'therapyName': 'INO-3106 + INO-9012'}]",Immunotherapy in Subjects With HPV-6 Associated Aerodigestive Precancerous Lesions and Malignancies,8804
0,NCT02311998,Phase Ib/II,Recruiting,"[{'id': 3200, 'therapyName': 'Bosutinib + inotuzumab ozogamicin'}]",Phase I/II Study of Bosutinib in Combination With Inotuzumab Ozogamicin in CD22-positive Philadelphia-Chromosome (PC) Positive Acute Lymphoblastic Leukemia (ALL) and Chronic Myeloid Leukemia (CML),7969
1,NCT02981628,Phase II,Recruiting,"[{'id': 3199, 'therapyName': 'inotuzumab ozogamicin'}]",Inotuzumab Ozogamicin in Treating Younger Patients With Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia,7969
2,NCT03094611,Phase II,Not yet recruiting,"[{'id': 3199, 'therapyName': 'inotuzumab ozogamicin'}]",Study of Low Dose Inotuzumab Ozogamicin in Patients With Relapsed and Refractory CD22 Positive Acute Lymphocytic Leukemia,7969
3,NCT03104491,Phase Ib/II,Recruiting,"[{'id': 3199, 'therapyName': 'inotuzumab ozogamicin'}]",Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia,7969
4,NCT01925131,Phase I,Recruiting,"[{'id': 3221, 'therapyName': 'Cyclophosphamide + Prednisone + Vincristine'}, {'id': 3199, 'therapyName': 'inotuzumab ozogamicin'}]","S1312, Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Leukemia",7969
5,NCT03150693,Phase III,Recruiting,"[{'id': 897, 'therapyName': 'Rituximab'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1783, 'therapyName': 'Cyclophosphamide + Cytarabine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 3628, 'therapyName': 'Allopurinol'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 3199, 'therapyName': 'inotuzumab ozogamicin'}]",Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia,7969
0,NCT02197169,Phase I,"Active, not recruiting","[{'id': 4407, 'therapyName': 'DNX-2401'}, {'id': 4444, 'therapyName': 'DNX-2401 + interferon gamma '}]",DNX-2401 With Interferon Gamma (IFN-gamma) for Recurrent Glioblastoma or Gliosarcoma Brain Tumors (TARGET-I),7323
1,NCT01438112,,Terminated,"[{'id': 2524, 'therapyName': 'Gemcitabine + interferon + Mitomycin C + Valrubicin '}, {'id': 2523, 'therapyName': 'CG0070'}]",Efficacy Study of Recombinant Adenovirus for Non Muscle Invasive Bladder Cancer,7323
2,NCT03056599,,Recruiting,"[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1299, 'therapyName': 'Interferon alfa-2b '}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1733, 'therapyName': 'interferon gamma '}, {'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 3420, 'therapyName': 'trabectedin'}, {'id': 1167, 'therapyName': 'Aldesleukin'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 720, 'therapyName': 'Docetaxel'}]",Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO™ Device in Soft Tissue Sarcoma,7323
3,NCT02614456,Phase I,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 1733, 'therapyName': 'interferon gamma '}]",Combination of Interferon-gamma and Nivolumab for Advanced Solid Tumors,7323
4,NCT03112590,Phase Ib/II,Recruiting,"[{'id': 5548, 'therapyName': 'Interferon gamma + Paclitaxel + Pertuzumab + Trastuzumab'}]",Phase I-II Study of Interferon-gamma in Patients With HER-2 Positive Breast Cancer,7323
5,NCT02948426,Phase I,Recruiting,"[{'id': 4975, 'therapyName': 'interferon gamma + peginterferon alfa-2b'}]","Intraperitoneal Infusion of Autologous Monocytes With Sylatron (Peginterferon Alfa-2b) and Actimmune (Interferon Gamma-1b) in Women With Recurrent or Refractory Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer",7323
6,NCT03063632,Phase II,Not yet recruiting,"[{'id': 5367, 'therapyName': 'Pembrolizumab + interferon gamma'}]",Pembrolizumab and Interferon Gamma-1b in Treating Patients With Stage IB-IVB Relapsed or Refractory Mycosis Fungoides and Sezary Syndrome,7323
0,NCT02542124,Phase II,Recruiting,"[{'id': 5262, 'therapyName': 'Interleukin-12'}]",NM-IL-12 in Cutaneous T-Cell Lymphoma (CTCL) Undergoing Total Skin Electron Beam Therapy (TSEBT),8650
1,NCT03030378,Phase I,Not yet recruiting,"[{'id': 5263, 'therapyName': 'Pembrolizumab + Interleukin-12'}]",Pembrolizumab and Recombinant Interleukin-12 in Treating Patients With Solid Tumors,8650
0,NCT02069145,Phase I,Completed,"[{'id': 2413, 'therapyName': 'Ipafricept + Sorafenib'}]",Dose Escalation Study of OMP-54F28 in Combination With Sorafenib in Patients With Hepatocellular Cancer,7503
0,NCT03072238,Phase III,Recruiting,"[{'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 5438, 'therapyName': 'Abiraterone + Ipatasertib'}]","Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer",6909
1,NCT03280563,Phase Ib/II,Not yet recruiting,"[{'id': 6269, 'therapyName': 'Atezolizumab + Ipatasertib'}, {'id': 6270, 'therapyName': 'Atezolizumab + Bevacizumab + Exemestane'}, {'id': 1343, 'therapyName': 'Atezolizumab + Cobimetinib'}, {'id': 6271, 'therapyName': 'Atezolizumab + Bevacizumab + Fulvestrant'}, {'id': 6272, 'therapyName': 'Atezolizumab + Bevacizumab + Tamoxifen'}, {'id': 6273, 'therapyName': 'Atezolizumab + Ipatasertib + Fulvestrant'}, {'id': 744, 'therapyName': 'Fulvestrant'}, {'id': 6268, 'therapyName': 'Atezolizumab + Fulvestrant'}]",A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer,6909
2,NCT01562275,Phase I,Completed,"[{'id': 1160, 'therapyName': 'Cobimetinib + GDC-0068'}]"," A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0973 in Combination With GDC-0068 When Administered in Patients With Locally Advanced or Metastatic Solid Tumors",6909
3,NCT01362374,Phase I,"Active, not recruiting","[{'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 747, 'therapyName': 'Ipatasertib'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}]","Safety and Pharmacology Of GDC-0068 in Combination With Docetaxel, Fluoropyrimidine Plus Oxaliplatin, Paclitaxel, or Enzalutamide in Patients With Advanced Solid Tumors",6909
4,NCT01896531,Phase II,"Active, not recruiting","[{'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 747, 'therapyName': 'Ipatasertib'}]",A Study of GDC-0068 in Combination With Fluoropyrimidine Plus Oxaliplatin in Patients With Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer,6909
5,NCT01485861,Phase II,"Active, not recruiting","[{'id': 750, 'therapyName': 'GDC-0980'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 747, 'therapyName': 'Ipatasertib'}]",Study of GDC-0068 Or GDC-0980 With Abiraterone Acetate Versus Abiraterone Acetate in Patients With Castration-Resistant Prostate Cancer Previously Treated With Docetaxel Chemotherapy,6909
6,NCT02301988,Phase II,"Active, not recruiting","[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 747, 'therapyName': 'Ipatasertib'}]",A Study of Ipatasertib (GDC-0068) in Combination With Paclitaxel as Neoadjuvant Treatment for Patients With Early Stage Triple Negative Breast Cancer,6909
7,NCT02162719,Phase II,"Active, not recruiting","[{'id': 1588, 'therapyName': 'Ipatasertib + Paclitaxel'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]",A Study of Ipatasertib (GDC-0068) in Combination With Paclitaxel as Front-line Treatment for Patients With Metastatic Triple-Negative Breast Cancer,6909
0,NCT02643550,Phase Ib/II,Recruiting,"[{'id': 3383, 'therapyName': 'Cetuximab + IPH2201'}]",Study of IPH2201 (Monalizumab) and Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck,8060
1,NCT02459301,Phase I,"Active, not recruiting","[{'id': 3382, 'therapyName': 'IPH2201'}]","Dose-Ranging Study of IPH2201 in Patients With High Grade Serious CA of Ovarian, Fallopian Tube or Peritoneal Origin",8060
2,NCT02557516,Phase Ib/II,Recruiting,"[{'id': 3382, 'therapyName': 'IPH2201'}]",Combination Study of IPH2201 With Ibrutinib in Patients With Relapse or Refractory Chronic Lymphocytic Leukemia,8060
0,NCT02637531,Phase I,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 3363, 'therapyName': 'IPI-549'}]","A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549",8049
0,NCT02935790,Phase I,Completed,"[{'id': 3312, 'therapyName': 'ACY-241 + Ipilimumab + Nivolumab'}]",Selective HDAC6 Inhibitor ACY-241 in Combination With Ipilimumab and Nivolumab,6926
1,NCT02635061,Phase I,Recruiting,"[{'id': 3312, 'therapyName': 'ACY-241 + Ipilimumab + Nivolumab'}]",Selective HDAC6 Inhibitor ACY 241 in Combination With Nivolumab in Patients With Unresectable Non Small Cell Lung Cancer,6926
2,NCT03068624,Phase I,Recruiting,"[{'id': 5733, 'therapyName': 'Aldesleukin + Cyclophosphamide + Ipilimumab'}]",Study of Cellular Adoptive Immunotherapy Using Autologous CD8+ Antigen-Specific T Cells and Anti-CTLA4 for Patients With Metastatic Uveal Melanoma,6926
3,NCT02203604,Phase II,"Active, not recruiting","[{'id': 1612, 'therapyName': 'Aldesleukin + Ipilimumab'}]",High-Dose Aldesleukin and Ipilimumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed By Surgery,6926
4,NCT02174172,Phase I,Recruiting,"[{'id': 6252, 'therapyName': 'Atezolizumab + Bevacizumab +Peg-interferon alfa-2a'}, {'id': 6253, 'therapyName': 'Atezolizumab + Interferon alfa-2b'}, {'id': 6250, 'therapyName': 'Atezolizumab + Peg-interferon alfa-2a'}, {'id': 6249, 'therapyName': 'Atezolizumab + Ipilimumab'}, {'id': 1975, 'therapyName': 'Atezolizumab + Obinutuzumab'}]",A Study to Assess the Safety and Tolerability of MPDL3280A in Combination With Other Immune-modulating Therapies in Patients With Locally Advanced or Metastatic Solid Tumors,6926
5,NCT02879695,Phase I,Recruiting,"[{'id': 4613, 'therapyName': 'Blinatumomab + Ipilimumab + Nivolumab'}]",Blinatumomab and Nivolumab With or Without Ipilimumab in Treating Patients With Poor-Risk Relapsed or Refractory CD19+ Precursor B-Lymphoblastic Leukemia,6926
6,NCT03251924,Phase Ib/II,Recruiting,"[{'id': 6136, 'therapyName': 'BMS-986226 + Nivolumab'}, {'id': 6135, 'therapyName': 'BMS-986226 + Ipilimumab'}, {'id': 6134, 'therapyName': 'BMS-986226'}]",A Dose Escalation and Combination Immunotherapy Study to Evaluate BMS-986226 Alone or in Combination With Nivolumab or Ipilimumab in Patients With Advanced Solid Tumors,6926
7,NCT01896999,Phase I,Recruiting,"[{'id': 2487, 'therapyName': 'Brentuximab vedotin + Ipilimumab'}]",Ipilimumab and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma,6926
8,NCT03141177,Phase III,Recruiting,"[{'id': 2068, 'therapyName': 'Cabozantinib + Ipilimumab + Nivolumab'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 2067, 'therapyName': 'Cabozantinib + Nivolumab'}]",A Study of Nivolumab Combined With Cabozantinib or Nivolumab and Ipilimumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 9ER),6926
9,NCT01860430,Phase I,"Active, not recruiting","[{'id': 1926, 'therapyName': 'Cetuximab + Ipilimumab'}]",A Phase Ib Trial of Concurrent Cetuximab (ERBITUX) and Intensity Modulated Radiotherapy (IMRT) With Ipilimumab (YERVOY) in Locally Advanced Head and Neck Cancer,6926
10,NCT01935921,Phase I,"Active, not recruiting","[{'id': 1926, 'therapyName': 'Cetuximab + Ipilimumab'}]","Ipilimumab, Cetuximab, and Intensity-Modulated Radiation Therapy in Treating Patients With Previously Untreated Stage III-IVB Head and Neck Cancer",6926
11,NCT03013491,Phase II,Recruiting,"[{'id': 5209, 'therapyName': 'CX-072 + Ipilimumab'}, {'id': 5210, 'therapyName': 'CX-072 + Vemurafenib'}, {'id': 5208, 'therapyName': 'CX-072'}]",A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas,6926
12,NCT02200562,Phase Ib/II,Terminated,"[{'id': 1257, 'therapyName': 'Dabrafenib + Ipilimumab'}]",Ipilimumab and Dabrafenib in the 1st Line Tx of Unresectable Stage III/IV Melanoma,6926
13,NCT01767454,Phase I,Completed,"[{'id': 1258, 'therapyName': 'Dabrafenib + Ipilimumab + Trametinib'}, {'id': 1257, 'therapyName': 'Dabrafenib + Ipilimumab'}]",Study of Dabrafenib +/- Trametinib in Combination With Ipilimumab for V600E/K Mutation Positive Metastatic or Unresectable Melanoma,6926
14,NCT01323517,Phase II,Recruiting,"[{'id': 5900, 'therapyName': 'Dactinomycin + Ipilimumab + Melphalan'}]",Addition of Ipilimumab (MDX-010) To Isolated Limb Infusion (ILI) With Standard Melphalan and Dactinomycin In The Treatment of Advanced Unresectable Melanoma of The Extremity,6926
15,NCT01643278,Phase I,Completed,"[{'id': 1803, 'therapyName': 'Dasatinib + Ipilimumab'}]",Dasatinib and Ipilimumab in Treating Patients With Gastrointestinal Stromal Tumors or Other Sarcomas That Cannot Be Removed by Surgery or Are Metastatic,6926
16,NCT02890329,Phase I,Recruiting,"[{'id': 5738, 'therapyName': 'Decitabine + Ipilimumab'}]",Ipilimumab and Decitabine in Treating Patients With Relapsed or Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia,6926
17,NCT03098160,Phase I,Recruiting,"[{'id': 5745, 'therapyName': 'Evofosfamide + Ipilimumab'}]",Immunotherapy Study of Evofosfamide in Combination With Ipilimumab,6926
18,NCT01473940,Phase I,"Active, not recruiting","[{'id': 2970, 'therapyName': 'Gemcitabine + Ipilimumab'}]",Ipilimumab and Gemcitabine Hydrochloride in Treating Patients With Stage III-IV or Recurrent Pancreatic Cancer That Cannot Be Removed by Surgery,6926
19,NCT02272855,Phase II,"Active, not recruiting","[{'id': 2003, 'therapyName': 'HF10 + Ipilimumab'}]",A Study of Combination Treatment With HF10 and Ipilimumab in Patients With Unresectable or Metastatic Melanoma,6926
20,NCT02644967,Phase Ib/II,Recruiting,"[{'id': 4244, 'therapyName': 'IMO-2125 + Ipilimumab'}, {'id': 4245, 'therapyName': 'IMO-2125 + Pembrolizumab'}]",A Study to Assess the Safety and Efficacy of Intratumoral IMO-2125 in Combination With Ipilimumab or Pembrolizumab in Patients With Metastatic Melanoma,6926
21,NCT03126110,Phase Ib/II,Recruiting,"[{'id': 5599, 'therapyName': 'INCAGN01876 + Nivolumab + Ipilimumab'}, {'id': 5598, 'therapyName': 'INCAGN01876 + Nivolumab'}, {'id': 5597, 'therapyName': 'INCAGN01876 + Ipilimumab'}]","Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies",6926
22,NCT03241173,Phase Ib/II,Not yet recruiting,"[{'id': 6120, 'therapyName': 'INCAGN01949 + Ipilimumab'}, {'id': 6119, 'therapyName': 'INCAGN01949 + Nivolumab'}, {'id': 6121, 'therapyName': 'INCAGN01949 + Ipilimumab + Nivolumab'}]",A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies,6926
23,NCT02117362,Phase I,Recruiting,"[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 2975, 'therapyName': 'GR-MD-02'}]",Galectin Inhibitor (GR-MD-02) and Ipilimumab in Patients With Metastatic Melanoma,6926
24,NCT01804465,Phase II,Recruiting,"[{'id': 779, 'therapyName': 'Ipilimumab'}]",A Randomized Phase 2 Trial of Combining Sipuleucel-T With Immediate vs. Delayed CTLA-4 Blockade for Prostate Cancer,6926
25,NCT01592370,Phase I,"Active, not recruiting","[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 2583, 'therapyName': 'Lirilumab '}]",Safety Study in Nivolumab Alone and in Combination With Ipilimumab or Lirilumab in Lymphoma and Multiple Myeloma,6926
26,NCT01950195,Phase I,Terminated,"[{'id': 779, 'therapyName': 'Ipilimumab'}]",SRS (Stereotactic Radiosurgery) Plus Ipilimumab,6926
27,NCT02538666,Phase III,Recruiting,"[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 1312, 'therapyName': 'Nivolumab'}]","A Randomized, Multicenter, Double-Blind, Phase 3 Study of Nivolumab, Nivolumab in Combination With Ipilimumab, or Placebo as Maintenance Therapy in Subjects With Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) After Completion of Platinum-based First Line Chemotherapy (CheckMate 451)",6926
28,NCT03110107,Phase Ib/II,Recruiting,"[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 5552, 'therapyName': 'BMS-986218 + Nivolumab'}, {'id': 5551, 'therapyName': 'BMS-986218'}]",First-In-Human Study of Monoclonal Antibody BMS-986218 by Itself and in Combination With Nivolumab in Patients With Advanced Solid Tumors,6926
29,NCT02530463,Phase II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 779, 'therapyName': 'Ipilimumab'}]",Nivolumab and Ipilimumab With 5-azacitidine in Patients With Myelodysplastic Syndromes (MDS),6926
30,NCT02115243,Phase I,"Active, not recruiting","[{'id': 779, 'therapyName': 'Ipilimumab'}]",Trial of Neoadjuvant Ipilimumab Followed by Melphalan Via Isolated Limb Infusion for Patients With Unresectable In-transit Extremity Melanoma,6926
31,NCT01176474,Phase I,"Active, not recruiting","[{'id': 2696, 'therapyName': 'NY-ESO-1 peptide vaccine'}, {'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 1312, 'therapyName': 'Nivolumab'}]",A Phase I Trial of a Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV Melanoma,6926
32,NCT01896869,Phase II,Suspended,"[{'id': 1903, 'therapyName': 'FOLFIRINOX'}, {'id': 779, 'therapyName': 'Ipilimumab'}]","A Phase 2, Multicenter Study of FOLFIRINOX Followed by Ipilimumab With Allogenic GM-CSF Transfected Pancreatic Tumor Vaccine in the Treatment of Metastatic Pancreatic Cancer",6926
33,NCT02239900,Phase Ib/II,Recruiting,"[{'id': 779, 'therapyName': 'Ipilimumab'}]",Ipilimumab and Stereotactic Body Radiation Therapy (SBRT) in Advanced Solid Tumors,6926
34,NCT02731729,Phase II,Recruiting,"[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 1312, 'therapyName': 'Nivolumab'}]",Ipilimumab vs Ipilimumab Plus Nivolumab in Patients With Stage III-IV Melanoma Who Have Progressed or Relapsed on PD-1 Inhibitor Therapy,6926
35,NCT02073123,Phase Ib/II,Recruiting,"[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 2976, 'therapyName': 'indoximod'}]",Study of IDO Inhibitor in Combination With Ipilimumab for Adult Patients With Metastatic Melanoma,6926
36,NCT02009397,Phase Ib/II,Recruiting,"[{'id': 1873, 'therapyName': 'Sargramostim'}, {'id': 779, 'therapyName': 'Ipilimumab'}]",A Phase I/II Open-Label Study of Ipilimumab and GM-CSF Administered to Unresectable Stage IIIC and Stage IV Melanoma Patients,6926
37,NCT02452281,Phase Ib/II,Withdrawn,"[{'id': 2973, 'therapyName': 'Vitespen'}, {'id': 779, 'therapyName': 'Ipilimumab'}]",Pilot Study to Evaluate the Effects of a Vaccine (HSPPC-96) Combined With Ipilimumab in Patients With Advanced Melanoma,6926
38,NCT02060188,Phase Ib/II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 779, 'therapyName': 'Ipilimumab'}]",A Study of Nivolumab and Nivolumab Plus Ipilimumab in Recurrent and Metastatic Colon Cancer (CheckMate 142),6926
39,NCT01530984,Phase II,Withdrawn,"[{'id': 1873, 'therapyName': 'Sargramostim'}, {'id': 779, 'therapyName': 'Ipilimumab'}]",Ipilimumab and GMCSF Immunotherapy for Prostate Cancer,6926
40,NCT01928394,Phase Ib/II,Recruiting,"[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 1312, 'therapyName': 'Nivolumab'}]","A Phase 1/2, Open-label Study of Nivolumab Monotherapy or Nivolumab Combined With Ipilimumab in Subjects With Advanced or Metastatic Solid Tumors",6926
41,NCT02259231,Phase Ib/II,Recruiting,"[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 3062, 'therapyName': 'RTA 408'}]",RTA 408 Capsules in Patients With Melanoma - REVEAL,6926
42,NCT01585194,Phase II,Recruiting,"[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 1312, 'therapyName': 'Nivolumab'}]",Phase II Study of Nivolumab in Combination With Ipilimumab for Uveal Melanoma,6926
43,NCT01740297,Phase Ib/II,"Active, not recruiting","[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 2695, 'therapyName': 'talimogene laherparepvec '}]",Ipilimumab With or Without Talimogene Laherparepvec in Unresected Melanoma,6926
44,NCT01450761,Phase III,Completed,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1136, 'therapyName': 'Etoposide'}]",Trial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab Plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy Alone,6926
45,NCT02307149,Phase I,Recruiting,"[{'id': 2974, 'therapyName': 'coxsackievirus A21'}, {'id': 779, 'therapyName': 'Ipilimumab'}]",Study of Intratumoral CAVATAK (Coxsackievirus A21) and Ipilimumab in Patients With Advanced Melanoma,6926
46,NCT01449279,Phase I,"Active, not recruiting","[{'id': 779, 'therapyName': 'Ipilimumab'}]",Pilot Ipilimumab in Stage IV Melanoma Receiving Palliative Radiation Therapy,6926
47,NCT01688492,Phase Ib/II,"Active, not recruiting","[{'id': 2748, 'therapyName': 'Abiraterone + Prednisone'}, {'id': 779, 'therapyName': 'Ipilimumab'}]",Combining Ipilimumab With Abiraterone Acetate Plus Prednisone in Chemotherapy and Immunotherapy-na&#239;ve Patients With Progressive Metastatic Castration-resistant Prostate Cancer,6926
48,NCT02339571,Phase II,Suspended,"[{'id': 1873, 'therapyName': 'Sargramostim'}, {'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 779, 'therapyName': 'Ipilimumab'}]",Nivolumab and Ipilimumab With or Without Sargramostim in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery,6926
49,NCT02027935,Phase II,Recruiting,"[{'id': 1167, 'therapyName': 'Aldesleukin'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 779, 'therapyName': 'Ipilimumab'}]",Cellular Adoptive Immunotherapy Using Autologous CD8+ Antigen-Specific T Cells and Anti-CTLA4,6926
50,NCT02054520,Phase II,Unknown status,"[{'id': 779, 'therapyName': 'Ipilimumab'}]",Immunotherapy Study for Patients With Stage IV Melanoma,6926
51,NCT02089685,Phase Ib/II,Recruiting,"[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 2624, 'therapyName': 'peginterferon alfa-2b'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Safety and Tolerability of Pembrolizumab (MK-3475) + Pegylated Interferon Alfa-2b and Pembrolizumab+ Ipilimumab in Participants With Advanced Melanoma or Renal Cell Carcinoma (MK-3475-029/KEYNOTE-29),6926
52,NCT01454102,Phase I,"Active, not recruiting","[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1312, 'therapyName': 'Nivolumab'}]","Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012)",6926
53,NCT01565837,Phase II,Recruiting,"[{'id': 779, 'therapyName': 'Ipilimumab'}]",Concurrent Ipilimumab and Stereotactic Ablative Radiation Therapy (SART) for Oligometastatic But Unresectable Melanoma,6926
54,NCT01970527,Phase II,Recruiting,"[{'id': 779, 'therapyName': 'Ipilimumab'}]",Phase II Trial of Stereotactic Body Radiotherapy Followed by Ipilimumab in Treating Patients With Stage IV Melanoma,6926
55,NCT02737475,Phase Ib/II,Recruiting,"[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 4030, 'therapyName': 'BMS-986178'}, {'id': 1312, 'therapyName': 'Nivolumab'}]",Study of BMS-986178 Monotherapy or in Combination With Nivolumab or Ipilimumab in Subjects With Advanced Solid Tumors,6926
56,NCT02388906,Phase III,"Active, not recruiting","[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 779, 'therapyName': 'Ipilimumab'}]",Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV Melanoma (CheckMate 238),6926
57,NCT01696045,Phase II,Terminated,"[{'id': 779, 'therapyName': 'Ipilimumab'}]","Phase 2 Study of Ipilimumab in Children and Adolescents (12 to <18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage lV Malignant Melanoma",6926
58,NCT01940809,Phase II,Recruiting,"[{'id': 3, 'therapyName': 'Dabrafenib'}, {'id': 2, 'therapyName': 'Trametinib'}, {'id': 779, 'therapyName': 'Ipilimumab'}]","Ipilimumab With or Without Dabrafenib, and/or Trametinib in Treating Patients With Melanoma That is Metastatic or Cannot Be Removed By Surgery",6926
59,NCT02107755,Phase II,"Active, not recruiting","[{'id': 779, 'therapyName': 'Ipilimumab'}]",Stereotactic Radiation Therapy and Ipilimumab in Treating Patients With Metastatic Melanoma,6926
60,NCT01621490,Phase I,"Active, not recruiting","[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 1312, 'therapyName': 'Nivolumab'}]",PH 1 Biomarker Study of Nivolumab and Ipilimumab and Nivolumab in Combination With Ipilimumab in Advanced Melanoma (PD-1),6926
61,NCT01711515,Phase I,"Active, not recruiting","[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 700, 'therapyName': 'Cisplatin'}]",Chemoradiation Therapy and Ipilimumab in Treating Patients With Locally Advanced Cervical Cancer,6926
62,NCT02519322,Phase II,"Active, not recruiting","[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 1312, 'therapyName': 'Nivolumab'}]",Neoadjuvant and Adjuvant Checkpoint Blockade in Patients With Clinical Stage III or Oligometastatic Stage IV Melanoma,6926
63,NCT02279862,Phase II,Completed,"[{'id': 779, 'therapyName': 'Ipilimumab'}]",Safety and Efficacy Study of Ipilimumab 3 mg/kg Versus Ipilimumab 10 mg/kg in Subjects With Metastatic Castration Resistant Prostate Cancer Who Are Chemotherapy Naive,6926
64,NCT01701674,Phase I,"Active, not recruiting","[{'id': 2291, 'therapyName': 'Cyclophosphamide + Fludarabine'}, {'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 1167, 'therapyName': 'Aldesleukin'}]",Ipilimumab With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 in Melanoma Mets Pts,6926
65,NCT01703507,Phase I,"Active, not recruiting","[{'id': 779, 'therapyName': 'Ipilimumab'}]",Ipilimumab and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Melanoma With Brain Metastases,6926
66,NCT03271047,,Recruiting,"[{'id': 807, 'therapyName': 'Binimetinib'}, {'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 779, 'therapyName': 'Ipilimumab'}]",Study of Binimetinib + Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Microsatellite-stable (MSS) Metastatic Colorectal Cancer With RAS Mutation,6926
67,NCT01689974,Phase II,Terminated,"[{'id': 779, 'therapyName': 'Ipilimumab'}]",Phase II Randomized Trial of Ipilimumab Versus Ipilimumab and Radiotherapy in Metastatic Melanoma,6926
68,NCT01708941,Phase II,"Active, not recruiting","[{'id': 1299, 'therapyName': 'Interferon alfa-2b '}, {'id': 779, 'therapyName': 'Ipilimumab'}]",Ipilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery,6926
69,NCT02703623,Phase II,Recruiting,"[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 2649, 'therapyName': 'Abiraterone + ARN-509 + Prednisone'}, {'id': 3844, 'therapyName': 'Cabazitaxel + Carboplatin'}]",A Dynamic Allocation Modular Sequential Trial of Approved and Promising Therapies in Men With Metastatic Castrate Resistant Prostate Cancer (DynaMO),6926
70,NCT02950766,,Not yet recruiting,"[{'id': 779, 'therapyName': 'Ipilimumab'}]","A Study Combining NeoVax, a Personalized NeoAntigen Cancer Vaccine, With Ipilimumab to Treat High-risk Renal Cell Carcinoma",6926
71,NCT02500797,Phase II,Recruiting,"[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 1312, 'therapyName': 'Nivolumab'}]",Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic or Unresectable Sarcoma,6926
72,NCT03056599,,Recruiting,"[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1299, 'therapyName': 'Interferon alfa-2b '}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1733, 'therapyName': 'interferon gamma '}, {'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 3420, 'therapyName': 'trabectedin'}, {'id': 1167, 'therapyName': 'Aldesleukin'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 720, 'therapyName': 'Docetaxel'}]",Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO™ Device in Soft Tissue Sarcoma,6926
73,NCT02097732,Phase II,"Active, not recruiting","[{'id': 779, 'therapyName': 'Ipilimumab'}]",Ipilimumab Induction in Patients With Melanoma Brain Metastases Receiving Stereotactic Radiosurgery,6926
74,NCT02678572,Phase III,Recruiting,"[{'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Percutaneous Hepatic Perfusion vs Best Alternative Care in Patients With Hepatic-dominant Ocular Melanoma,6926
75,NCT02812524,Phase I,Recruiting,"[{'id': 779, 'therapyName': 'Ipilimumab'}]",Ipilimumab for Head and Neck Cancer Patients,6926
76,NCT03070392,Phase II,Recruiting,"[{'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 3847, 'therapyName': 'IMCgp100'}]",Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma,6926
77,NCT03305445,,Not yet recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 779, 'therapyName': 'Ipilimumab'}]",Nivolumab/Ipilimumab-Primed Immunotransplant for DLBCL,6926
78,NCT02553642,Phase II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 779, 'therapyName': 'Ipilimumab'}]",Relationship Between Tumor Mutation Burden and Predicted Neo-antigen Burden in Patients With Advanced Melanoma or Bladder Cancer Treated With Nivolumab or Nivolumab Plus Ipilimumab (CA209-260),6926
79,NCT02113657,Phase II,Recruiting,"[{'id': 779, 'therapyName': 'Ipilimumab'}]",T-Cell Responses to Neoantigens Post Treatment With Ipilimumab in Men With Metastatic Castration-Resistant Prostate Cancer,6926
80,NCT01810016,Phase I,Terminated,"[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 2696, 'therapyName': 'NY-ESO-1 peptide vaccine'}]",NY-ESO-1 Vaccine in Combination With Ipilimumab in Patients With Unresectable or Metastatic Melanoma,6926
81,NCT02020070,Phase II,"Active, not recruiting","[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 1814, 'therapyName': 'Degarelix'}]","Combining Ipilimumab, Degarelix, and Radical Prostatectomy in Men With Newly Diagnosed Metastatic Castration Sensitive Prostate Cancer or Ipilimumab and Degarelix in Men With Biochemically Recurrent Castration Sensitive Prostate Cancer After Radical Prostatectomy",6926
82,NCT01409174,Phase Ib/II,Terminated,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 1167, 'therapyName': 'Aldesleukin'}, {'id': 1141, 'therapyName': 'Temozolomide'}, {'id': 1299, 'therapyName': 'Interferon alfa-2b '}]",IPI Biochemotherapy for Chemonaive Patients With Metastatic Melanoma,6926
83,NCT02846376,Phase I,Recruiting,"[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}, {'id': 1312, 'therapyName': 'Nivolumab'}]",Single Agent and Combined Inhibition After Allogeneic Stem Cell Transplant (CPIT-002),6926
84,NCT01498978,Phase II,"Active, not recruiting","[{'id': 779, 'therapyName': 'Ipilimumab'}]",Ipilimumab in Combination With Androgen Suppression Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer,6926
85,NCT01820754,Phase II,"Active, not recruiting","[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]",Evaluation of Circulating T Cells and Tumor Infiltrating Lymphocytes (TILs) During / After Pre-Surgery Chemotherapy in Non-Small Cell Lung Cancer (NSCLC),6926
86,NCT02696993,Phase Ib/II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 779, 'therapyName': 'Ipilimumab'}]",Phase I/II Trial of Nivolumab With Radiation or Nivolumab and Ipilimumab With Radiation for the Treatment of Intracranial Metastases From Non-small Cell Lung Cancer,6926
87,NCT02032810,Phase I,"Active, not recruiting","[{'id': 1080, 'therapyName': 'Panobinostat'}, {'id': 779, 'therapyName': 'Ipilimumab'}]",Phase I of Histone Deacetylase (HDAC) Inhibitor Panobinostat With Ipilimumab With Unresectable III/IV Melanoma,6926
88,NCT02221739,Phase II,Completed,"[{'id': 779, 'therapyName': 'Ipilimumab'}]",Study of Combined Ionizing Radiation and Ipilimumab in Metastatic Non-small Cell Lung Cancer (NSCLC),6926
89,NCT02210104,Phase I,Withdrawn,"[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}]",Adoptive Therapy Using Antigen-Specific CD4 T-Cells,6926
90,NCT02498600,Phase II,Recruiting,"[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 1312, 'therapyName': 'Nivolumab'}]","Nivolumab With or Without Ipilimumab in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer",6926
91,NCT02496208,Phase I,Recruiting,"[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 2067, 'therapyName': 'Cabozantinib + Nivolumab'}]",Cabozantinib Plus Nivolumab (CaboNivo) Alone or in Combination With Ipilimumab (CaboNivoIpi) in Patients With Advanced/Metastatic Urothelial Carcinoma and Other Genitourinary Tumors,6926
92,NCT01274338,Phase III,"Active, not recruiting","[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 1299, 'therapyName': 'Interferon alfa-2b '}]",Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery,6926
93,NCT02506114,Phase II,Recruiting,"[{'id': 4892, 'therapyName': 'PROSTVAC-V/F'}, {'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 4895, 'therapyName': 'PROSTVAC-V/F + Ipilimumab'}]",Neoadjuvant PROSTVAC-VF With or Without Ipilimumab for Prostate Cancer,6926
94,NCT01950390,Phase II,"Active, not recruiting","[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 1301, 'therapyName': 'Ipilimumab + Bevacizumab'}]",Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot be Removed by Surgery,6926
95,NCT02477826,Phase III,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 755, 'therapyName': 'Gemcitabine'}]","An Open-Label, Trial of Nivolumab and Nivolumab Plus Ipilimumab Versus Platinum Doublet Chemotherapy in Subjects With Stage IV Non-Small Cell Lung Cancer (NSCLC)",6926
96,NCT03033576,Phase II,Recruiting,"[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Ipilimumab With or Without Nivolumab in Treating Patients With Melanoma That is Stage IV or Stage III and Cannot Be Removed by Surgery,6926
97,NCT01497808,Phase Ib/II,"Active, not recruiting","[{'id': 779, 'therapyName': 'Ipilimumab'}]",RADVAX: A Stratified Phase I/II Dose Escalation Trial of Stereotactic Body Radiotherapy Followed by Ipilimumab in Metastatic Melanoma,6926
98,NCT02311920,Phase I,"Active, not recruiting","[{'id': 1141, 'therapyName': 'Temozolomide'}, {'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 779, 'therapyName': 'Ipilimumab'}]",Temozolomide in Combination With Ipilimumab and/or Nivolumab in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma,6926
99,NCT02158520,Phase II,"Active, not recruiting","[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 1261, 'therapyName': 'Bevacizumab + Abraxane'}]",Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery,6926
100,NCT02467361,Phase Ib/II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 2057, 'therapyName': 'BBI608'}]",A Study of BBI608 Administered in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Cancers,6926
101,NCT03068455,Phase III,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",A Study of Nivolumab in Combination With Ipilimumab Compared to Nivolumab or Ipilimumab Alone in Treatment of Patients After Complete Resection of Stage IIIb/c/d or Stage IV Melanoma (CheckMate 915),6926
102,NCT02385669,Phase Ib/II,Recruiting,"[{'id': 2620, 'therapyName': '6MHP vaccine'}, {'id': 779, 'therapyName': 'Ipilimumab'}]",A Phase I/II Trial to Evaluate a Peptide Vaccine Plus Ipilimumab in Patients With Melanoma,6926
103,NCT01998126,Phase I,"Active, not recruiting","[{'id': 1348, 'therapyName': 'Ipilimumab + Erlotinib'}, {'id': 1349, 'therapyName': 'Ipilimumab + Crizotinib'}]",Ipilimumab Plus Targeted Inhibitor (Erlotinib or Crizotinib) for EGFR or ALK Mutated Stage IV Non-small Cell Lung Cancer: Phase Ib With Expansion Cohorts,6926
104,NCT01738139,Phase I,Recruiting,"[{'id': 1250, 'therapyName': 'Ipilimumab + Imatinib Mesylate'}]",Ipilimumab and Imatinib Mesylate in Advanced Cancer,6926
105,NCT01750983,Phase I,"Active, not recruiting","[{'id': 2992, 'therapyName': 'Ipilimumab + lenalidomide'}]",Ipilimumab and Lenalidomide in Advanced Cancer,6926
106,NCT02381314,Phase I,Recruiting,"[{'id': 3058, 'therapyName': 'Ipilimumab + MGA271'}]",Safety Study of MGA271 in Combination With Ipilimumab in Refractory Cancer,6926
107,NCT01827111,Phase II,"Active, not recruiting","[{'id': 2978, 'therapyName': 'Ipilimumab + nab-paclitaxel'}]",Phase II Study of Abraxane Plus Ipilimumab in Patients With Metastatic Melanoma,6926
108,NCT02723006,Phase I,Recruiting,"[{'id': 4198, 'therapyName': 'MLN2480 + Nivolumab'}, {'id': 4200, 'therapyName': 'MLN1202 + Nivolumab'}, {'id': 4202, 'therapyName': 'Ipilimumab + Nivolumab + Vedolizumab '}]","Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Investigational Treatments in Combination With Standard of Care Immune Checkpoint Inhibitors in Participants With Advanced Melanoma",6926
109,NCT03302234,Phase III,Not yet recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 2106, 'therapyName': 'Ipilimumab + Pembrolizumab '}]",Study of Pembrolizumab Given With Ipilimumab or Placebo in Participants With Untreated Metastatic Non-small Cell Lung Cancer (MK-3475-598/KEYNOTE-598),6926
110,NCT02743819,Phase II,Recruiting,"[{'id': 2106, 'therapyName': 'Ipilimumab + Pembrolizumab '}]",Phase II Study of Pembrolizumab and Ipilimumab Following Initial Anti-PD1/L1 Antibody,6926
111,NCT02039674,Phase Ib/II,"Active, not recruiting","[{'id': 2103, 'therapyName': 'Carboplatin + Paclitaxel + Pembrolizumab'}, {'id': 2104, 'therapyName': 'Bevacizumab + Carboplatin + Paclitaxel + Pembrolizumab'}, {'id': 1602, 'therapyName': 'Carboplatin + Pemetrexed'}, {'id': 2106, 'therapyName': 'Ipilimumab + Pembrolizumab '}, {'id': 2107, 'therapyName': 'Erlotinib + Pembrolizumab '}, {'id': 2108, 'therapyName': 'Gefitinib + Pembrolizumab '}]",A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Lung Cancer (MK-3475-021/KEYNOTE-021),6926
112,NCT02254772,Phase Ib/II,Completed,"[{'id': 3848, 'therapyName': 'Ipilimumab + SD-101'}]","TLR9 Agonist SD-101, Ipilimumab, and Radiation Therapy in Treating Patients With Low-Grade Recurrent B-cell Lymphoma",6926
113,NCT02668770,Phase I,Recruiting,"[{'id': 5741, 'therapyName': 'Ipilumumab + Lefitolimod'}]",Ipilimumab (Immunotherapy) and MGN1703 (TLR Agonist) in Patients With Advanced Solid Malignancies,6926
114,NCT03146650,Phase II,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Nivolumab and Ipilimumab in Treating Patients With Metastatic Recurrent Major or Minor Salivary Gland Cancer,6926
115,NCT02231749,Phase III,"Active, not recruiting","[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}, {'id': 930, 'therapyName': 'Sunitinib'}]",Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214),6926
116,NCT02834013,Phase 0,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Nivolumab and Ipilimumab in Treating Patients With Rare Tumors,6926
117,NCT03043599,Phase Ib/II,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Ipilimumab + Nivolumab w/Thoracic Radiotherapy for Extensive-Stage Small Cell Lung Cancer,6926
118,NCT03065179,Phase II,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Trial of SBRT in Combination With Nivolumab/Ipilimumab in RCC / Kidney Cancer Patients,6926
119,NCT03143153,Phase III,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}, {'id': 1833, 'therapyName': 'Cisplatin + Fluorouracil'}, {'id': 5799, 'therapyName': 'Nivolumab + Cisplatin + Fluorouacil'}]",A Study to Evaluate Efficacy in Subjects With Esophageal Cancer Treated With Nivolumab and Ipilimumab or Nivolumab Combined With Fluorouracil Plus Cisplatin Versus Fluorouracil Plus Cisplatin (CheckMate 648),6926
120,NCT02935634,Phase II,Recruiting,"[{'id': 4197, 'therapyName': 'BMS-986016 + Nivolumab'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",A Study to Test Combination Treatments in Patients With Advanced Gastric Cancer (FRACTION-GC),6926
121,NCT02186249,Phase III,No longer available,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Expanded Access Program With Nivolumab (BMS-936558) in Combination With Ipilimumab (Yervoy®) in Anti-CTLA-4 Treatment-Naïve Subjects With Unresectable or Metastatic Melanoma (CheckMate 218),6926
122,NCT02978443,Phase II,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",A Biomarker Study in Advanced Mucosal or Acral Lentiginous Melanoma Receiving Nivolumab in Combination With Ipilimumab,6926
123,NCT02714218,Phase III,"Active, not recruiting","[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]","A Study of Two Different Dose Combinations of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated, Unresectable or Metastatic Melanoma",6926
124,NCT02681302,Phase Ib/II,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Study of Combined Check Point Inhibition After Autologous Hematopoietic Stem Cell Transplantation in Patients at High Risk for Post-transplant Recurrence (CPIT001),6926
125,NCT03203473,Phase II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Study of Optimized Management of Nivolumab Based on Response in Patients With Advanced RCC (OMNIVORE Study),6926
126,NCT02899299,Phase III,Recruiting,"[{'id': 4616, 'therapyName': 'Carboplatin + Cisplatin + Pemetrexed'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients (CheckMate743),6926
127,NCT03162731,Phase I,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]","Nivolumab, Ipilimumab, and Radiation Therapy in Treating Patients With Stage IVA-B Head and Neck Cancer",6926
128,NCT03223155,Phase I,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]","Evaluate Concurrent Or Sequential Ipilimumab, Nivolumab, and Stereotactic Body Radiotherapy in Patients With Stage IV Non-Small Cell Lung Cancer",6926
129,NCT02599402,Phase III,"Active, not recruiting","[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}, {'id': 1312, 'therapyName': 'Nivolumab'}]",Nivolumab Combined With Ipilimumab Followed by Nivolumab Monotherapy as First-Line Treatment for Patients With Advanced Melanoma,6926
130,NCT03274258,Phase II,Not yet recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Nivolumab Plus Ipilimumab in Patients With Renal Medullary Carcinoma,6926
131,NCT02880020,Phase II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Nivolumab With or Without Ipilimumab in Treating Patients With Gastrointestinal Stromal Tumor That Is Metastatic or Cannot Be Removed by Surgery,6926
132,NCT03158129,Phase II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Study Of Induction Checkpoint Blockade For Untreated Stage I-IIIA Non-Small Cell Lung Cancers Amenable For Surgical Resection,6926
133,NCT03101566,Phase II,Recruiting,"[{'id': 5511, 'therapyName': 'Cisplatin + Gemcitabine + Nivolumab'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Study of Nivolumab in Combination With Gemcitabine/Cisplatin or Ipilimumab for Patients With Advanced Unresectable Biliary Tract Cancer,6926
134,NCT02320058,Phase II,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",A Multi-Center Phase 2 Open-Label Study to Evaluate Safety and Efficacy in Subjects With Melanoma Metastatic to the Brain Treated With Nivolumab in Combination With Ipilimumab Followed by Nivolumab Monotherapy (CheckMate 204),6926
135,NCT02210117,Phase II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 2111, 'therapyName': 'Bevacizumab + Nivolumab'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Nivolumab vs Nivolumab + Bevacizumab vs Nivolumab + Ipilimumab in Metastatic Renal Cell Carcinoma (mRCC),6926
136,NCT03001882,Phase II,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",An Exploratory Study of the Effects of Nivolumab Combined With Ipilimumab in Patients With Treatment-Naive Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC),6926
137,NCT03104439,Phase II,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Nivolumab and Ipilimumab and Radiation Therapy in MSS and MSI High Colorectal and Pancreatic Cancer,6926
138,NCT03149159,Phase II,Not yet recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]","Investigator-Initiated Trial of Combined Ipilimumab, Nivolumab and Stereotactic Radiation in Patients With Metastatic Clear-Cell RCC (ccRCC) Who Have Failed Treatment With Single-Agent Nivolumab",6926
139,NCT03256136,Phase II,Not yet recruiting,"[{'id': 6159, 'therapyName': 'Carboplatin + Nivolumab + Pemetrexed'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]","A Phase II Study of Nivolumab in Combination With Carboplatin and Pemetrexed, or Nivolumab in Combination With Ipilimumab, in Patients With Advanced, EGFR-mutant or ALK-rearranged, Non-Small Cell Lung Cancer",6926
140,NCT02864251,Phase III,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}, {'id': 4616, 'therapyName': 'Carboplatin + Cisplatin + Pemetrexed'}]","A Study of Nivolumab + Chemotherapy or Nivolumab + Ipilimumab Versus Chemotherapy in Patients With EGFR Mutation, T790M Negative NSCLC Who Have Failed 1L EGFR TKI Therapy (CheckMate722)",6926
141,NCT03029780,Phase II,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",An Investigational Immuno-Therapy Safety and Efficacy Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Renal Cell Carcinoma,6926
142,NCT02823574,Phase II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Study of Nivolumab in Combination With Ipilimumab Versus Nivolumab in Combination With Ipilimumab Placebo in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck,6926
143,NCT03215706,Phase III,Recruiting,"[{'id': 6132, 'therapyName': 'Carboplatin + Cisplatin + Paclitaxel + Pemetrexed'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",A Study of Nivolumab and Ipilimumab Combined With Chemotherapy Compared to Chemotherapy by Itself as the First Treatment Given for Stage IV Non-Small Cell Lung Cancer (NSCLC) (CheckMate 9LA),6926
144,NCT02996110,Phase II,Recruiting,"[{'id': 4197, 'therapyName': 'BMS-986016 + Nivolumab'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",A Study to Test Combination Treatments in People With Advanced Renal Cell Carcinoma (FRACTION-RCC),6926
145,NCT03036098,Phase III,Recruiting,"[{'id': 1467, 'therapyName': 'Gemcitabine + Cisplatin'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}, {'id': 2667, 'therapyName': 'Carboplatin + Gemcitabine'}]",Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care Chemotherapy in Treatment of Patients With Untreated Inoperable or Metastatic Urothelial Cancer,6926
146,NCT02998528,Phase III,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}, {'id': 5241, 'therapyName': 'Cisplatin + Vinorelbine + Gemcitabine + Docetaxel + Pemetrexed + Carboplatin'}]",A Neoadjuvant Study of Nivolumab and Ipilimumab Compared to Chemotherapy Doublet in Early Stage Non-Small Cell Lung Cancer (NSCLC) (CheckMate 816),6926
147,NCT03138512,Phase III,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",A Study Comparing the Combination of Nivolumab and Ipilimumab Versus Placebo in Participants With Localized Renal Cell Carcinoma (CheckMate 914),6926
148,NCT02304458,Phase Ib/II,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas,6926
149,NCT02659540,Phase I,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",A Pilot Study to Evaluate the Safety and Efficacy of Combination Checkpoint Blockade Plus External Beam Radiotherapy in Subjects With Stage IV Melanoma,6926
150,NCT02741570,Phase III,Recruiting,"[{'id': 4168, 'therapyName': 'Carboplatin + Cetuximab + Cisplatin + Fluorouracil'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care (Extreme Study Regimen) as First Line Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck,6926
151,NCT03071406,Phase II,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Randomized Study of Nivolumab+Ipilimumab+/- SBRT for Metastatic Merkel Cell Carcinoma,6926
152,NCT02970981,Phase II,Not yet recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Study of Combination of Ipilimumab and Nivolumab in Patients With Melanoma,6926
153,NCT02982954,Phase III,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",A Study to Evaluate the Safety of Nivolumab and Ipilimumab in Subjects With Previously Untreated Advanced or Metastatic Renal Cell Cancer (CHECKMATE 920),6926
154,NCT02869789,Phase III,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",A Safety Study of Nivolumab in Combination With Ipilimumab to Treat Advanced Cancers,6926
155,NCT03126461,Phase II,Not yet recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",SAbR Plus Ipilimumab Plus Nivolumab in Metastatic Melanoma Patients,6926
156,NCT03130959,Phase II,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}, {'id': 1312, 'therapyName': 'Nivolumab'}]",An Investigational Immuno-therapy Study of Nivolumab Monotherapy and Nivolumab in Combination With Ipilimumab in Pediatric Patients With High Grade Primary CNS Malignancies (CheckMate 908),6926
157,NCT02601014,Phase II,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Biomarker-Driven Therapy With Nivolumab and Ipilimumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Expressing AR-V7,6926
158,NCT03285321,Phase II,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}, {'id': 1312, 'therapyName': 'Nivolumab'}]",Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC),6926
159,NCT02736123,Phase Ib/II,Withdrawn,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Neoadjuvant Combination Biotherapy With Ipilimumab and Nivolumab or Nivolumab Alone,6926
160,NCT02453620,Phase I,Recruiting,"[{'id': 1541, 'therapyName': 'Entinostat'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]","Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer",6926
161,NCT02659059,Phase II,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Nivolumab Plus Ipilimumab to Treat First Line Stage IV Non-Small Cell Lung Cancer (CheckMate568),6926
162,NCT02892734,Phase II,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Ipilimumab and Nivolumab in Treating Patients With Recurrent Stage IV HER2 Negative Inflammatory Breast Cancer,6926
163,NCT02939300,Phase II,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Ipilimumab and Nivolumab in Leptomeningeal Metastases From Melanoma,6926
164,NCT02985957,Phase II,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",A Study to Evaluate Preliminary Safety and Efficacy of Nivolumab Plus Ipilimumab in Men With Metastatic Castration-Resistant Prostate Cancer,6926
165,NCT03048136,Phase III,Not yet recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",A Safety Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Non-small Cell Lung Cancer (CheckMate 955),6926
166,NCT03117309,Phase II,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}, {'id': 1312, 'therapyName': 'Nivolumab'}]",Study of Front Line Therapy With Nivolumab and Salvage Nivolumab + Ipilimumab in Patients With Advanced Renal Cell Carcinoma,6926
167,NCT03222076,Phase II,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}, {'id': 1312, 'therapyName': 'Nivolumab'}]",Study Evaluating Nivolumab (Anti-PD-1 Antibody) Alone Versus Nivolumab Plus Ipilimumab (Anti-CTLA-4 Antibody) in Patients With Resectable and Potentially Resectable Hepatocellular Carcinoma (HCC) (CA209-956),6926
168,NCT02872116,Phase III,Recruiting,"[{'id': 1597, 'therapyName': 'Capecitabine + Oxaliplatin'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}]",Efficacy Study of Nivolumab Plus Ipilimumab Against Chemotherapy Standard of Care in Stomach Cancer or Stomach/Esophagus Junction Cancer (CheckMate649),6926
169,NCT02919683,Phase II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Window Study of Nivolumab With or Without Ipilimumab in Squamous Cell Carcinoma of the Oral Cavity,6926
170,NCT03203304,Phase I,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Study of Stereotactic Body Radiotherapy (SBRT) Followed by Nivolumab or Ipilimumab With Nivolumab in Unresectable Hepatocellular Carcinoma,6926
171,NCT03220009,Phase II,Not yet recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]","Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma",6926
172,NCT03172624,Phase II,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Study of Nivolumab Plus Ipilimumab in Patients With Salivary Gland Cancer,6926
173,NCT02224781,Phase III,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}, {'id': 1066, 'therapyName': 'Trametinib + Dabrafenib'}]",Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma,6926
174,NCT02408861,Phase I,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Nivolumab and Ipilimumab in Treating Patients With Advanced HIV Associated Solid Tumors,6926
175,NCT01822509,Phase I,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant,6926
176,NCT02785952,Phase III,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers,6926
177,NCT02017717,Phase III,"Active, not recruiting","[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",A Randomized Study of Nivolumab Versus Bevacizumab and a Safety Study of Nivolumab in Adult Subjects With Recurrent Glioblastoma (GBM) (CheckMate 143),6926
178,NCT02833233,Phase I,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",A Study of Pre-Operative Treatment With Cryoablation and Immune Therapy in Early Stage Breast Cancer,6926
179,NCT03262779,Phase II,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Ipilimumab and Nivolumab in Patients With Anti-PD-1-axis Therapy-resistant Advanced Non-small Cell Lung Cancer.,6926
180,NCT02656706,Phase II,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",BrUOG 324: Adjuvant Nivolumab and Low Dose Ipilimumab for Stage III and Resected Stage IV Melanoma: A Phase II Brown University Oncology Research Group Trial,6926
181,NCT03246958,Phase II,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Nivolumab Plus Ipilimumab in Thyroid Cancer,6926
182,NCT03044613,Phase I,Recruiting,"[{'id': 5304, 'therapyName': 'Nivolumab + Ipilimumab + Carboplatin + Paclitaxel'}, {'id': 5303, 'therapyName': 'Nivolumab + Carboplatin + Paclitaxel'}]",Nivolumab or Nivolumab/Ipilimumab Prior to Chemoradiation Plus Nivolumab With II/III Gastro/Esophageal Cancer,6926
183,NCT02933255,Phase Ib/II,Recruiting,"[{'id': 4895, 'therapyName': 'PROSTVAC-V/F + Ipilimumab'}, {'id': 4893, 'therapyName': 'PROSTVAC-V/F + Nivolumab + Ipilimumab'}, {'id': 4894, 'therapyName': 'PROSTVAC-V/F + Nivolumab'}]",PROSTVAC in Combination With Nivolumab and/or Ipilimumab in Men With Prostate Cancer,6926
184,NCT03026166,Phase I,Recruiting,"[{'id': 5640, 'therapyName': 'Rovalpituzumab Tesirine + Nivolumab + Ipilimumab'}, {'id': 5641, 'therapyName': 'Rovalpituzumab Tesirine + Nivolumab'}]",A Study of Rovalpituzumab Tesirine Administered in Combination With Nivolumab and With or Without Ipilimumab for Adults With Extensive-Stage Small Cell Lung Cancer,6926
185,NCT03138161,Phase Ib/II,Recruiting,"[{'id': 5800, 'therapyName': 'trabectedin + Ipilimumab + Nivolumab'}]","Trabectedin, Ipilimumab and Nivolumab as First Line Treatment for Advanced Soft Tissue Sarcoma",6926
186,NCT02913417,Phase Ib/II,Recruiting,"[{'id': 4769, 'therapyName': 'Yttrium-90 + Nivolumab + Ipilimumab'}]","Yttrium90, Ipilimumab, & Nivolumab for Uveal Melanoma With Liver Metastases",6926
0,NCT02035137,,Recruiting,"[{'id': 1425, 'therapyName': '131I-MIBG'}, {'id': 1426, 'therapyName': '131I-MIBG + Irinotecan + Vincristine'}, {'id': 1427, 'therapyName': '131I-MIBG + Vorinostat'}]",131I-MIBG Alone VS. 131I-MIBG With Vincristine and Irinotecan VS131I-MIBG With Vorinistat,752
1,NCT01571284,Phase III,Completed,"[{'id': 2095, 'therapyName': 'Aflibercept + FOLFIRI'}]",Safety and Quality of Life Study of Aflibercept in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen,752
2,NCT02045030,Phase II,Terminated,"[{'id': 2095, 'therapyName': 'Aflibercept + FOLFIRI'}]",Study to Identify Biomarkers of Clinical Response to Aflibercept in Patients With Metastatic Colorectal Cancer,752
3,NCT01601535,Phase Ib/II,"Active, not recruiting","[{'id': 2628, 'therapyName': 'Alisertib + Irinotecan + Temozolomide'}]",Study of MLN8237 in Combination With Irinotecan and Temozolomide,752
4,NCT02292758,Phase II,Recruiting,"[{'id': 1923, 'therapyName': 'Bevacizumab + Cetuximab + Irinotecan'}, {'id': 1874, 'therapyName': 'Cetuximab + Irinotecan'}]","Phase II Trial of Irinotecan, Cetuximab, and Bevacizumab Compared With Irinotecan, Cetuximab, and Placebo in KRAS-Wildtype, Irinotecan-Refractory, Metastatic Colorectal Cancer",752
5,NCT01442935,Phase II,"Active, not recruiting","[{'id': 1484, 'therapyName': 'Bevacizumab + Oxaliplatin + Leucovorin + Fluorouracil'}, {'id': 2180, 'therapyName': 'Cetuximab + FOLFIRI'}, {'id': 2181, 'therapyName': 'Bevacizumab + FOLFIRI'}, {'id': 2182, 'therapyName': 'Cetuximab + FOLFOX'}, {'id': 2183, 'therapyName': 'Bevacizumab + FOLFIRINOX'}, {'id': 2184, 'therapyName': 'Cetuximab + FOLFIRINOX'}]",Chemotherapies Associated With Targeted Therapies on the Resection Rate of Hepatic Metastases,752
6,NCT01999270,Phase I,Completed,"[{'id': 2112, 'therapyName': 'Bevacizumab + Irinotecan'}]",Evaluation of FDOPA-PET/MRI in Pediatric Patients With CNS Tumors,752
7,NCT02575508,Phase Ib/II,Withdrawn,"[{'id': 3142, 'therapyName': 'BGJ398 + Fluorouracil + Irinotecan + Oxaliplatin'}]",Pan FGFR Kinase Inhibitor BGJ398 and Combination Chemotherapy in Treating Patients With Untreated Metastatic Pancreatic Cancer,752
8,NCT02613650,Phase I,Recruiting,"[{'id': 3247, 'therapyName': 'Binimetinib + FOLFIRI'}]",A Trial of FOLFIRI With MEK162 in Patients With Advanced KRAS Positive Metastatic Colorectal Cancers,752
9,NCT03184870,Phase Ib/II,Recruiting,"[{'id': 5905, 'therapyName': 'BMS-813160 + Fluorouracil + Irinotecan + Leucovorin'}, {'id': 5903, 'therapyName': 'BMS-813160 + Nivolumab'}, {'id': 5904, 'therapyName': 'BMS-813160 + Gemcitabine + nab-paclitaxel'}, {'id': 5902, 'therapyName': 'BMS-813160'}]",A Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Patients With Advanced Solid Tumors,752
10,NCT02358863,Phase I,Terminated,"[{'id': 4311, 'therapyName': 'Docetaxel + Irinotecan'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 1835, 'therapyName': 'Docetaxel + Cisplatin'}, {'id': 1406, 'therapyName': 'Camptosar + Cisplatin'}, {'id': 4310, 'therapyName': 'Epirubicin + Docetaxel'}, {'id': 4309, 'therapyName': 'Capecitabine + Docetaxel'}]",Molecularly Tailored Therapy for Patients With Metastatic Cancer of the Esophagus and Stomach (mEGA),752
11,NCT03263429,Phase Ib/II,Recruiting,"[{'id': 6158, 'therapyName': 'CB-839 + Irinotecan + Panitumumab'}]",Novel PET/CT Imaging Biomarkers of CB-839 in Combination With Panitumumab and Irinotecan in Patients With Metastatic and Refractory RAS Wildtype Colorectal Cancer,752
12,NCT02573220,Phase I,Withdrawn,"[{'id': 2180, 'therapyName': 'Cetuximab + FOLFIRI'}]",Irinotecan Hydrochloride With FOLFIRI and Cetuximab as First-Line Therapy in Treating Patients With RAS Wild-Type Colorectal Cancer,752
13,NCT02928224,Phase III,Recruiting,"[{'id': 1916, 'therapyName': 'Cetuximab + Encorafenib'}, {'id': 4886, 'therapyName': 'Binimetinib + Cetuximab + LGX818'}, {'id': 1874, 'therapyName': 'Cetuximab + Irinotecan'}, {'id': 2180, 'therapyName': 'Cetuximab + FOLFIRI'}]",Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer (BEACON CRC),752
14,NCT01703390,Phase II,Unknown status,"[{'id': 2182, 'therapyName': 'Cetuximab + FOLFOX'}, {'id': 2180, 'therapyName': 'Cetuximab + FOLFIRI'}]",Biomarker Directed Treatment in Metastatic Colorectal Cancer,752
15,NCT02164916,Phase II,"Active, not recruiting","[{'id': 1874, 'therapyName': 'Cetuximab + Irinotecan'}, {'id': 1331, 'therapyName': 'Vemurafenib + Cetuximab + Irinotecan '}]",S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer,752
16,NCT01079780,Phase II,Unknown status,"[{'id': 1920, 'therapyName': 'Irinotecan + Cetuximab + Ramucirumab'}, {'id': 1874, 'therapyName': 'Cetuximab + Irinotecan'}]",Irinotecan Hydrochloride and Cetuximab With or Without Ramucirumab in Treating Patients With Advanced Colorectal Cancer With Progressive Disease After Treatment With Bevacizumab-Containing Chemotherapy,752
17,NCT03290937,Phase I,Not yet recruiting,"[{'id': 6288, 'therapyName': 'Cetuximab + Irinotecan + Utomilumab'}]","Clinical Trial Evaluating the Safety and Response With PF-05082566, Cetuximab and Irinotecan in Patients With Advanced Colorectal Cancer",752
18,NCT01822613,Phase Ib/II,Completed,"[{'id': 2282, 'therapyName': 'Docetaxel + Irinotecan + Paclitaxel'}, {'id': 2283, 'therapyName': 'BYL719 + LJM716'}]",Study of Safety and Efficacy of the Combination of LJM716 and BYL719 in Patients With Previously Treated Esophageal Squamous Cell Carcinoma (ESCC),752
19,NCT02564263,Phase III,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 2282, 'therapyName': 'Docetaxel + Irinotecan + Paclitaxel'}]",Study of Pembrolizumab (MK-3475) Versus Investigator's Choice Standard Therapy for Participants With Advanced Esophageal/Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181),752
20,NCT01935947,Phase II,Terminated,"[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 2645, 'therapyName': 'Azacitidine + Entinostat'}, {'id': 2646, 'therapyName': 'Docetaxel + Irinotecan + Pemetrexed '}]",Azacitidine and Entinostat Before Chemotherapy in Treating Patients With Advanced Non-small Cell Lung Cancer,752
21,NCT03069950,Phase II,Recruiting,"[{'id': 5476, 'therapyName': 'Floxiuridine + Panitumumab + Dexamethasone + FOLFIRI'}]",Study of Chemotherapy With or Without Hepatic Arterial Infusion for Patients With Unresectable Metastatic Colorectal Cancer to the Liver,752
22,NCT01765582,Phase II,Terminated,"[{'id': 1523, 'therapyName': 'Fluorouracil + Capecitabine + Irinotecan + Leucovorin + Oxaliplatin'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1484, 'therapyName': 'Bevacizumab + Oxaliplatin + Leucovorin + Fluorouracil'}]",STEAM: A Study of Sequential and Concurrent FOLFOXIRI/Avastin (Bevacizumab) Regimens Versus FOLFOX/Avastin in First-Line in Patients With Metastatic Colorectal Cancer,752
23,NCT02785068,Phase I,Withdrawn,"[{'id': 4532, 'therapyName': 'Fluorouracil + Irinotecan + Leucovorin + MM-151'}]",Evaluation of MM-151 + Nal-IRI + 5-FU + Leucovorin in RAS/RAF Wild-type Metastatic Colorectal Cancer,752
24,NCT01383538,Phase I,Completed,"[{'id': 2498, 'therapyName': 'Fluorouracil + Leucovorin + Irinotecan + Oxaliplatin + Saridegib'}]",FOLFIRINOX Plus IPI-926 for Advanced Pancreatic Adenocarcinoma,752
25,NCT01814501,Phase II,Recruiting,"[{'id': 1315, 'therapyName': 'FOLFIRI'}, {'id': 845, 'therapyName': 'Panitumumab'}]",Panitumumab and Chemotherapy in Patients With Advanced Colorectal Cancer After Prior Therapy With Bevacizumab,752
26,NCT02046538,Phase II,Withdrawn,"[{'id': 1315, 'therapyName': 'FOLFIRI'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 624, 'therapyName': 'Aflibercept'}]",Phase II Study of Zaltrap and Chemotherapy for Advanced Resectable Colorectal Cancer,752
27,NCT02482441,Phase I,Recruiting,"[{'id': 4401, 'therapyName': 'Rosmantuzumab'}, {'id': 1315, 'therapyName': 'FOLFIRI'}]","A Phase 1a/b Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of OMP-131R10",752
28,NCT01312857,Phase II,Recruiting,"[{'id': 845, 'therapyName': 'Panitumumab'}, {'id': 1315, 'therapyName': 'FOLFIRI'}, {'id': 1941, 'therapyName': 'Floxuridine'}]","Study of Hepatic Arterial Infusion With Intravenous Irinotecan, 5FU and Leucovorin With or Without Panitumumab, in Patients With Wild Type KRAS Who Have Resected Hepatic Metastases From Colorectal Cancer",752
29,NCT01488552,Phase Ib/II,Completed,"[{'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 1315, 'therapyName': 'FOLFIRI'}, {'id': 1779, 'therapyName': 'Nab-paclitaxel + Gemcitabine'}, {'id': 1031, 'therapyName': 'Metformin'}]",Gemcitabine+Nab-paclitaxel and FOLFIRINOX and Molecular Profiling for Patients With Advanced Pancreatic Cancer,752
30,NCT01274624,Phase I,"Active, not recruiting","[{'id': 1315, 'therapyName': 'FOLFIRI'}, {'id': 2099, 'therapyName': 'Bevacizumab + Reolysin'}]",Study of REOLYSIN; in Combination With FOLFIRI and Bevacizumab in FOLFIRI Naive Patients With KRAS Mutant Metastatic Colorectal Cancer,752
31,NCT02024607,Phase Ib/II,"Active, not recruiting","[{'id': 1597, 'therapyName': 'Capecitabine + Oxaliplatin'}, {'id': 2093, 'therapyName': 'BBI608 + Bevacizumab'}, {'id': 2094, 'therapyName': 'BBI608 + Regorafenib'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 2057, 'therapyName': 'BBI608'}, {'id': 1315, 'therapyName': 'FOLFIRI'}]",A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer,752
32,NCT01260415,Phase II,Completed,"[{'id': 845, 'therapyName': 'Panitumumab'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 1315, 'therapyName': 'FOLFIRI'}]",A Study of Perioperative Chemotherapy Plus Panitumumab in Patients With Colorectal Cancer Liver Metastases,752
33,NCT02605044,Phase III,Recruiting,"[{'id': 804, 'therapyName': 'Masitinib'}, {'id': 1315, 'therapyName': 'FOLFIRI'}]",Study to Compare the Efficacy and Safety of Masitinib in Combination With FOLFIRI to Placebo in Combination With FOLFIRI in Second Line Treatment of Patients With Metastatic Colorectal Cancer,752
34,NCT02753127,Phase III,Recruiting,"[{'id': 1315, 'therapyName': 'FOLFIRI'}, {'id': 2057, 'therapyName': 'BBI608'}]",A Study of Napabucasin (BBI-608) in Combination With FOLFIRI in Adult Patients With Previously Treated Metastatic Colorectal Cancer (CanStem303C),752
35,NCT02305758,Phase II,Completed,"[{'id': 1315, 'therapyName': 'FOLFIRI'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 954, 'therapyName': 'Veliparib'}]",Study Comparing Veliparib Plus FOLFIRI Versus Placebo Plus FOLFIRI With or Without Bevacizumab in Previously Untreated Metastatic Colorectal Cancer,752
36,NCT02508077,Phase II,Terminated,"[{'id': 1315, 'therapyName': 'FOLFIRI'}, {'id': 845, 'therapyName': 'Panitumumab'}]",FOLFIRI and Panitumumab in Treating Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer,752
37,NCT01803282,Phase I,Recruiting,"[{'id': 3320, 'therapyName': 'GS-5745'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 1602, 'therapyName': 'Carboplatin + Pemetrexed'}, {'id': 1315, 'therapyName': 'FOLFIRI'}, {'id': 1779, 'therapyName': 'Nab-paclitaxel + Gemcitabine'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 667, 'therapyName': 'Bevacizumab'}]",Safety and Tolerability Study in Solid Tumors,752
38,NCT01298570,Phase II,"Active, not recruiting","[{'id': 1315, 'therapyName': 'FOLFIRI'}, {'id': 890, 'therapyName': 'Regorafenib'}]",Regorafenib+FOLFIRI Versus Placebo+FOLFIRI as 2nd Line Tx in Metastatic Colorectal Cancer,752
39,NCT01653470,Phase I,"Active, not recruiting","[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1315, 'therapyName': 'FOLFIRI'}, {'id': 2545, 'therapyName': 'BMS-906024'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]","Study to Evaluate Safety & Tolerability of BMS-906024 in Combination With Chemotherapy & to Define DLTs & MTD of BMS-906024 in Combination With One of the Following Chemotherapy Regimens; Weekly Paclitaxel, 5FU+Irinotecan or Carboplatin+Paclitaxel in Subjects With Advanced / Metastatic Solid Tumors",752
40,NCT01937715,Phase II,Terminated,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1040, 'therapyName': 'PF-05212384'}, {'id': 1315, 'therapyName': 'FOLFIRI'}]",A Study Of PF-05212384 Plus FOLFIRI Versus Bevacizumab Plus FOLFIRI In Metastatic Colorectal Cancer,752
41,NCT02890355,,Recruiting,"[{'id': 954, 'therapyName': 'Veliparib'}, {'id': 1315, 'therapyName': 'FOLFIRI'}]",FOLFIRI or Modified FOLFIRI and Veliparib as Second Line Therapy in Treating Patients With Metastatic Pancreatic Cancer,752
42,NCT02563002,Phase III,Recruiting,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1315, 'therapyName': 'FOLFIRI'}, {'id': 694, 'therapyName': 'Cetuximab'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}]",Study of Pembrolizumab (MK-3475) vs Standard Therapy in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (MK-3475-177/KEYNOTE-177),752
43,NCT02213289,Phase Ib/II,Recruiting,"[{'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 1913, 'therapyName': 'FOLTAX'}, {'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 1315, 'therapyName': 'FOLFIRI'}, {'id': 629, 'therapyName': 'AMG102'}]",PANGEA-IMBBP: Personalized Antibodies for Gastro-Esophageal Adenocarcinoma - A 1st Pilot Metastatic Trial of Biologics Beyond Progression,752
44,NCT01472016,Phase I,Completed,"[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1063, 'therapyName': 'ABT-700'}, {'id': 694, 'therapyName': 'Cetuximab'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 1315, 'therapyName': 'FOLFIRI'}]",Study of ABT-700 in Subjects With Advanced Solid Tumors,752
45,NCT01652482,Phase II,Completed,"[{'id': 694, 'therapyName': 'Cetuximab'}, {'id': 806, 'therapyName': 'MEHD7945A'}, {'id': 1315, 'therapyName': 'FOLFIRI'}]",A Study of MEHD7945A + FOLFIRI Versus Cetuximab + FOLFIRI in Second Line in Patients With KRAS Wild-Type Metastatic Colorectal Cancer,752
46,NCT03035253,Phase I,Recruiting,"[{'id': 5297, 'therapyName': 'FOLFIRI + OMP-305B83'}]",A Study of OMP-305B83 in Subjects With Metastatic Colorectal Cancer,752
47,NCT02568046,Phase Ib/II,"Active, not recruiting","[{'id': 3949, 'therapyName': 'FOLFIRI + SYM004'}]",Sym004 in Combination With FOLFIRI in Metastatic Colorectal Cancer Patients,752
48,NCT01485744,Phase I,"Active, not recruiting","[{'id': 1903, 'therapyName': 'FOLFIRINOX'}, {'id': 1428, 'therapyName': 'Sonidegib'}]","LDE225 With Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan for Untreated Advanced Pancreatic Cancer",752
49,NCT01821729,Phase II,Recruiting,"[{'id': 1903, 'therapyName': 'FOLFIRINOX'}, {'id': 2998, 'therapyName': 'Losartan'}]",Proton w/FOLFIRINOX-Losartan for Pancreatic Cancer,752
50,NCT01928290,Phase II,Recruiting,"[{'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 1903, 'therapyName': 'FOLFIRINOX'}]","Combination Chemotherapy in Treating Patients With Advanced Stomach, Gastroesophageal, or Esophageal Cancer",752
51,NCT01896869,Phase II,Suspended,"[{'id': 1903, 'therapyName': 'FOLFIRINOX'}, {'id': 779, 'therapyName': 'Ipilimumab'}]","A Phase 2, Multicenter Study of FOLFIRINOX Followed by Ipilimumab With Allogenic GM-CSF Transfected Pancreatic Tumor Vaccine in the Treatment of Metastatic Pancreatic Cancer",752
52,NCT02581215,Phase II,Recruiting,"[{'id': 886, 'therapyName': 'Ramucirumab'}, {'id': 1903, 'therapyName': 'FOLFIRINOX'}]",Phase II Randomized Trial of FOLFIRINOX +/- Ramucirumab in Advanced Pancreatic Cancer,752
53,NCT01593228,Phase III,Completed,"[{'id': 1173, 'therapyName': 'Iniparib + doxorubicin + carboplatin'}, {'id': 1172, 'therapyName': 'Iniparib + Paclitaxel'}, {'id': 1171, 'therapyName': 'Iniparib + Irinotecan'}, {'id': 1170, 'therapyName': 'Iniparib + Topotecan'}, {'id': 1169, 'therapyName': 'Iniparib + Gemcitabine + Carboplatin'}, {'id': 1168, 'therapyName': 'Iniparib'}]", Treatment Extension Study for Patients Who Have Previously Participated and Have Benefited From Iniparib in a Clinical Trial,752
54,NCT00940316,Phase II,"Active, not recruiting","[{'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 1940, 'therapyName': 'Panitumumab + Erlotinib'}]",Dual Epidermal Growth Factor Receptor Inhibition With Erlotinib and Panitumumab With or Without Chemotherapy for Advanced Colorectal Cancer,752
55,NCT02551718,Phase I,Recruiting,"[{'id': 690, 'therapyName': 'Bosutinib'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 3160, 'therapyName': 'Nelarabine'}, {'id': 3159, 'therapyName': 'Bexarotene'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 998, 'therapyName': 'cabozantinib'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 877, 'therapyName': 'Ponatinib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 623, 'therapyName': 'Afatinib'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 890, 'therapyName': 'Regorafenib'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 2, 'therapyName': 'Trametinib'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 3, 'therapyName': 'Dabrafenib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 789, 'therapyName': 'Ceritinib'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1571, 'therapyName': 'Cabazitaxel'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1327, 'therapyName': 'Pralatrexate'}]",High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia,752
56,NCT03257267,Phase III,Recruiting,"[{'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1685, 'therapyName': 'Vinorelbine'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 5656, 'therapyName': 'REGN2810'}, {'id': 942, 'therapyName': 'Topotecan'}]",Study of REGN2810 in Adults With Cervical Cancer,752
57,NCT00576654,Phase I,Recruiting,"[{'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 954, 'therapyName': 'Veliparib'}]",Irinotecan Hydrochloride and Veliparib in Treating Patients With Cancer That Is Metastatic or Cannot Be Removed by Surgery,752
58,NCT00730158,Phase II,Suspended,"[{'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 1699, 'therapyName': 'KD018'}]","A Phase II Multicenter, Randomized, Placebo Controlled, Double Blinded Clinical Study of KD018 as a Modulator of Irinotecan Chemotherapy in Patients With Metastatic Colorectal Cancer",752
59,NCT02579226,Phase I,Recruiting,"[{'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 3547, 'therapyName': 'AZD2811'}]","A Phase I Study of Safety, Tolerability, and PK of AZD2811 in Patients With Advanced Solid Tumors",752
60,NCT02138617,Phase II,Recruiting,"[{'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 1715, 'therapyName': 'Fluorouracil'}]",Genotype-Directed Study Of Irinotecan Dosing In FOLFIRI + BevacizumabTreated Metastatic Colorectal Cancer,752
61,NCT01520389,Phase I,Completed,"[{'id': 821, 'therapyName': 'MM-151'}, {'id': 1074, 'therapyName': 'Irinotecan'}]",Safety Study of the Drug MM-151 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment,752
62,NCT02423954,Phase Ib/II,"Active, not recruiting","[{'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 1074, 'therapyName': 'Irinotecan'}]",Study of Nivolumab Plus Chemotherapy in Patients With Advanced Cancer (NivoPlus),752
63,NCT01916447,Phase I,Completed,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 2426, 'therapyName': 'trifluridine/tipiracil hydrochloride'}, {'id': 1074, 'therapyName': 'Irinotecan'}]",A Phase I Study of TAS-102 in Patients With Advanced Gastrointestinal Tumors.,752
64,NCT00967655,Phase II,Unknown status,"[{'id': 1960, 'therapyName': 'Capecitabine + Panitumumab'}, {'id': 1074, 'therapyName': 'Irinotecan'}]","Capecitabine, Panitumumab, and Radiation Therapy With or Without Irinotecan Hydrochloride in Treating Patients Undergoing Surgery for Localized Rectal Cancer",752
65,NCT02567435,Phase III,Suspended,"[{'id': 1435, 'therapyName': 'Vincristine + Dactinomycin + Cyclophosphamide'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1074, 'therapyName': 'Irinotecan'}]",Combination Chemotherapy and Irinotecan Hydrochloride or Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma,752
66,NCT02004262,Phase II,Completed,"[{'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 2383, 'therapyName': 'Capecitabine + Fluorouracil + Gemcitabine '}]",Safety and Efficacy of Combination Listeria/GVAX Pancreas Vaccine in the Pancreatic Cancer Setting,752
67,NCT02620423,Phase I,"Active, not recruiting","[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 893, 'therapyName': 'Reolysin'}, {'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Study of Pembrolizumab With REOLYSIN and Chemotherapy in Patients With Advanced Pancreatic Adenocarcinoma,752
68,NCT02331251,Phase Ib/II,"Active, not recruiting","[{'id': 1685, 'therapyName': 'Vinorelbine'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 619, 'therapyName': 'Abraxane'}]",Study of Pembrolizumab Plus Chemotherapy in Patients With Advanced Cancer (PembroPlus),752
69,NCT01347866,Phase I,Terminated,"[{'id': 1040, 'therapyName': 'PF-05212384'}, {'id': 849, 'therapyName': 'PD-0325901'}, {'id': 1074, 'therapyName': 'Irinotecan'}]",Clinical Study Of PI3K/mTOR Inhibitors In Combination With An Oral MEK Inhibitor Or Irinotecan In Patients With Advanced Cancer,752
70,NCT02788201,Phase II,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1133, 'therapyName': 'Mitomycin C'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1013, 'therapyName': 'epirubicin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1137, 'therapyName': 'Bleomycin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 781, 'therapyName': 'Ixabepilone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 2950, 'therapyName': 'Estramustine'}, {'id': 1941, 'therapyName': 'Floxuridine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 1811, 'therapyName': 'Carmustine'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 953, 'therapyName': 'Vandetanib'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 4419, 'therapyName': 'Toremifine'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 2601, 'therapyName': 'Dactinomycin'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 3035, 'therapyName': 'Chlorambucil'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 342, 'therapyName': 'Vemurafenib'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 2635, 'therapyName': 'Vinblastine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 4305, 'therapyName': 'Teniposide'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 4304, 'therapyName': 'Streptozocin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1231, 'therapyName': 'Bendamustine'}, {'id': 4303, 'therapyName': 'Mechlorethamine'}, {'id': 4302, 'therapyName': 'Mitotane'}]",Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma,752
71,NCT02625623,Phase III,"Active, not recruiting","[{'id': 3144, 'therapyName': 'Avelumab'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1074, 'therapyName': 'Irinotecan'}]",Avelumab in Third-Line Gastric Cancer (JAVELIN Gastric 300),752
72,NCT01923337,Phase I,"Active, not recruiting","[{'id': 1288, 'therapyName': 'Irinotecan + Alisertib'}]",Irinotecan and Alisertib in Treating Patients With Advanced Solid Tumors or Colorectal Cancer,752
73,NCT00871169,Phase II,Completed,"[{'id': 1919, 'therapyName': 'Irinotecan + Oxaliplatin + Cetuximab'}]","Combination of Irinotecan, Oxaliplatin and Cetuximab for Locally Advanced or Metastatic Pancreatic Cancer",752
74,NCT03136055,Phase II,Recruiting,"[{'id': 5643, 'therapyName': 'Irinotecan + Pembrolizumab'}, {'id': 4021, 'therapyName': 'Paclitaxel + Pembrolizumab'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab-based Therapy in Previously Treated High Grade Neuroendocrine Carcinomas,752
75,NCT03141034,Phase II,Not yet recruiting,"[{'id': 5633, 'therapyName': 'Irinotecan + Ramucirumab'}]",Ramucirumab Plus Irinotecan for Previously Treated Advanced Gastric or Gastro-esophageal Junction Adenocarcinoma,752
76,NCT02801097,Phase I,Recruiting,"[{'id': 4323, 'therapyName': 'Irinotecan + RRx-001'}]","A Phase I, Multiple Ascending Dose Study to Assess the Safety and Tolerability of RRx-001 in Combination With Irinotecan in Metastatic or Advanced Cancer  (PAYLOAD) (PAYLOAD)",752
77,NCT02283359,Phase I,Terminated,"[{'id': 2588, 'therapyName': 'Irinotecan + Selinexor'}]",Selinexor in Combination With Irinotecan in Adenocarcinoma of Stomach and Distal Esophagus,752
78,NCT02392793,Phase I,Recruiting,"[{'id': 1378, 'therapyName': 'Irinotecan + Talazoparib'}, {'id': 1141, 'therapyName': 'Temozolomide'}]",Talazoparib Plus Irinotecan With or Without Temozolomide in Children With Refractory or Recurrent Solid Malignancies,752
79,NCT02049593,Phase I,"Active, not recruiting","[{'id': 1377, 'therapyName': 'Talazoparib + Temozolomide'}, {'id': 1378, 'therapyName': 'Irinotecan + Talazoparib'}]",PARP Inhibitor BMN-673 and Temozolomide or Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic Solid Tumors,752
80,NCT00980460,Phase III,Recruiting,"[{'id': 2298, 'therapyName': 'Irinotecan + Temsirolimus + Vincristine'}, {'id': 2297, 'therapyName': 'Cisplatin + Fluorouracil + Vincristine'}, {'id': 1009, 'therapyName': 'Doxorubicin'}]",Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer,752
81,NCT02631733,Phase I,Recruiting,"[{'id': 3314, 'therapyName': 'Irinotecan + Veliparib'}]",Liposomal Irinotecan and Veliparib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery,752
82,NCT02677116,Phase I,Recruiting,"[{'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 3618, 'therapyName': 'Irinotecan + Vincristine'}, {'id': 3269, 'therapyName': 'Olaratumab'}]",A Study of Olaratumab Alone and in Combination With Standard Chemotherapies in Children With Cancer,752
83,NCT00790816,Phase I,Completed,"[{'id': 1410, 'therapyName': 'Lapatinib + Paclitaxel'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 1414, 'therapyName': 'Trastuzumab + Lapatinib'}, {'id': 1399, 'therapyName': 'Lapatinib + Capecitabine'}, {'id': 1497, 'therapyName': 'Lapatinib + Letrozole'}, {'id': 1498, 'therapyName': 'Lapatinib + Oxaliplatin + Capecitabine'}, {'id': 1499, 'therapyName': 'Lapatinib + Gemcitabine'}, {'id': 1500, 'therapyName': 'Lapatinib + Docetaxel'}, {'id': 1501, 'therapyName': 'Lapatinib + Oxaliplatin + Leucovorin + Fluorouracil'}, {'id': 1502, 'therapyName': 'Lapatinib + Irinotecan + Leucovorin + Fluorouracil'}]",Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents,752
84,NCT01837862,Phase Ib/II,Recruiting,"[{'id': 2134, 'therapyName': 'Mebendazole + Vincristine + Carboplatin + Temozolomide'}, {'id': 2133, 'therapyName': 'Mebendazole + Bevacizumab + Irinotecan'}]",A Phase I/II Study of Mebendazole for the Treatment of Pediatric Gliomas,752
85,NCT02095132,Phase Ib/II,Recruiting,"[{'id': 1361, 'therapyName': 'MK-1775 + Irinotecan'}]",WEE1 Inhibitor MK-1775 and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors,752
86,NCT02906059,Phase I,Recruiting,"[{'id': 1361, 'therapyName': 'MK-1775 + Irinotecan'}]","Study of Irinotecan and AZD1775, a Selective Wee 1 Inhibitor, in RAS or BRAF Mutated, Second-line Metastatic Colorectal Cancer",752
87,NCT02975882,Phase I,Recruiting,"[{'id': 5030, 'therapyName': 'Nab-Rapamycin + Temozolomide + Irinotecan'}]","Nanoparticle Albumin-Bound Rapamycin, Temozolomide, and Irinotecan Hydrochloride in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors",752
88,NCT03139331,Phase I,Recruiting,"[{'id': 5635, 'therapyName': 'Pazopanib + Irinotecan + Temozolomide'}]",PAZIT Study for Children and Young Adults With Relapsed or Refractory Sarcoma,752
89,NCT01896856,Phase Ib/II,Recruiting,"[{'id': 2015, 'therapyName': 'SGI-110 + Irinotecan'}, {'id': 890, 'therapyName': 'Regorafenib'}]",Phase I Study of SGI-110 With Irinotecan Followed by Randomized Phase II Study of SGI-110 With Irinotecan Versus Regorafenib in Previously Treated Metastatic Colorectal Cancer,752
90,NCT02747537,Phase II,Recruiting,"[{'id': 1323, 'therapyName': 'Sorafenib + Irinotecan'}]",Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors With Sorafenib in Combination With Irinotecan,752
91,NCT01518413,Phase I,Completed,"[{'id': 1323, 'therapyName': 'Sorafenib + Irinotecan'}]",Dose Escalation Study of Sorafenib and Irinotecan Combination Therapy in Pediatric Patients With Solid Tumors,752
92,NCT01217437,Phase II,"Active, not recruiting","[{'id': 1462, 'therapyName': 'Temozolomide + Irinotecan'}, {'id': 1463, 'therapyName': 'Temozolomide + Irinotecan + Bevacizumab'}]",Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors,752
93,NCT01767194,Phase II,Suspended,"[{'id': 2286, 'therapyName': 'Dinutuximab  '}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1462, 'therapyName': 'Temozolomide + Irinotecan'}]",Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Monoclonal Antibody Ch14.18 in Treating Younger Patients With Refractory or Relapsed Neuroblastoma,752
94,NCT01189643,Phase I,"Active, not recruiting","[{'id': 1463, 'therapyName': 'Temozolomide + Irinotecan + Bevacizumab'}]","Irinotecan, Temozolomide and Bevacizumab in Combination With Existing High Dose Alkylator Based Chemotherapy for Treatment of Newly Diagnosed Patients With Desmoplastic Small Round Cell Tumor",752
95,NCT00876993,Phase I,Completed,"[{'id': 1463, 'therapyName': 'Temozolomide + Irinotecan + Bevacizumab'}]",Study of Irinotecan and Bevacizumab With Temozolomide in Refractory/Relapsed Central Nervous System (CNS) Tumors,752
96,NCT01787500,Phase I,"Active, not recruiting","[{'id': 1331, 'therapyName': 'Vemurafenib + Cetuximab + Irinotecan '}]","Vemurafenib, Cetuximab, and Irinotecan in Advanced Solid Cancers",752
97,NCT01946529,Phase II,"Active, not recruiting","[{'id': 1433, 'therapyName': 'Vincristine + Doxorubicin + Cyclophosphamide + Ifosfamide + Etoposide'}, {'id': 1434, 'therapyName': 'Vincristine + Doxorubicin + Cyclophosphamide + Ifosfamide + Etoposide + others'}]",Therapeutic Trial for Patients With Ewing Sarcoma Family of Tumor and Desmoplastic Small Round Cell Tumors,752
98,NCT01528046,Phase I,Recruiting,"[{'id': 1031, 'therapyName': 'Metformin'}, {'id': 1826, 'therapyName': 'Vincristine + Irinotecan + Temozolomide '}]",Metformin in Children With Relapsed or Refractory Solid Tumors,752
99,NCT02595931,Phase I,Recruiting,"[{'id': 2883, 'therapyName': 'VX-970 + Irinotecan'}]",VX-970 and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery,752
0,NCT02991651,Phase I,Recruiting,"[{'id': 5135, 'therapyName': 'Erlotinib + IRX4204'}]",Study of IRX4204 With Erlotinib in Previously Treated Advanced NSCLC,8617
0,NCT03258008,Phase II,Not yet recruiting,"[{'id': 6148, 'therapyName': 'ISA101b + Utomilumab'}]",Utomilumab and ISA101b Vaccination in Patients With HPV-16-Positive Incurable Oropharyngeal Cancer,8928
0,NCT02824042,Phase I,Recruiting,"[{'id': 4594, 'therapyName': 'Anetumab ravtansine + Itraconazole'}, {'id': 4593, 'therapyName': 'Anetumab ravtansine'}]",Thorough ECG (Electrocardiogram) and Drug Interaction Study With Anetumab Ravtansine and Itraconazole,1154
1,NCT02699723,Phase I,Not yet recruiting,"[{'id': 3791, 'therapyName': 'Arsenic trioxide + Itraconazole'}]",Arsenic Trioxide and Itraconazole in Treating Patients With Advanced Basal Cell Cancer,1154
2,NCT02401295,Phase I,Completed,"[{'id': 3433, 'therapyName': 'Celecoxib + Itraconazole + Tretinoin '}]","ATRA, Celecoxib, and Itraconazole as Maintenance",1154
3,NCT00585195,Phase I,Recruiting,"[{'id': 1526, 'therapyName': 'Crizotinib + Itraconazole\t'}, {'id': 1483, 'therapyName': 'Crizotinib + Rifampin'}]","A Study Of Oral PF-02341066, A c-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer",1154
4,NCT03081702,Phase Ib/II,Not yet recruiting,"[{'id': 5495, 'therapyName': 'Hydroxychloroquine + Itraconazole'}]","A Study of the Safety, Tolerability and Effectiveness of Hydroxychloroquine and Itraconazole in Platinum-resistant Epithelial Ovarian Cancer",1154
5,NCT02735356,Phase I,"Active, not recruiting","[{'id': 1026, 'therapyName': 'Itraconazole'}]",Topical Itraconazole in Treating Patients With Basal Cell Cancer,1154
6,NCT01787331,Phase II,"Active, not recruiting","[{'id': 1026, 'therapyName': 'Itraconazole'}]",A Phase II Study of Itraconazole in Biochemical Relapse,1154
7,NCT02122770,Phase I,"Active, not recruiting","[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1026, 'therapyName': 'Itraconazole'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1688, 'therapyName': 'MLN4924'}, {'id': 1689, 'therapyName': 'Fluconazole'}]","Effects of Fluconazole and Itraconazole CYP3A-Mediated Inhibition on the Pharmacokinetics, Safety, and Tolerability of MLN4924 in Patients With Advanced Solid Tumors",1154
8,NCT02749513,Phase I,Recruiting,"[{'id': 1026, 'therapyName': 'Itraconazole'}]",Itraconazole as a Targeted Therapy for Inhibiting Hedgehog Pathway Signaling in Esophageal Cancer Patients,1154
9,NCT02120677,Phase I,Recruiting,"[{'id': 1026, 'therapyName': 'Itraconazole'}]",Topical Itraconazole in the Treatment of Basal Cell Carcinoma,1154
10,NCT02259010,Phase I,"Active, not recruiting","[{'id': 626, 'therapyName': 'Alisertib'}, {'id': 1026, 'therapyName': 'Itraconazole'}]",A Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics of Alisertib in Patients With Advanced Solid Tumors or Relapsed/Refractory Lymphoma,1154
11,NCT02157883,Phase I,"Active, not recruiting","[{'id': 1026, 'therapyName': 'Itraconazole'}, {'id': 660, 'therapyName': 'AZD9291'}]","Study to Assess the Effect of Itraconazole (a CYP3A4 Inhibitor) on the Pharmacokinetics of AZD9291, in Patients With EGFR Positive Non-small Cell Lung Cancer. Patients Will be Chosen From Those Who Have Already Been Prescribed an EGFR TKI Medicine (Such as Iressa or Tarceva)",1154
12,NCT02253420,Phase I,Recruiting,"[{'id': 995, 'therapyName': 'Copanlisib'}, {'id': 1026, 'therapyName': 'Itraconazole'}]",COPANLISIB (BAY80-6946) Drug-drug Interaction Study in Advanced Solid Tumor Patients,1154
13,NCT02457351,Phase I,Completed,"[{'id': 663, 'therapyName': 'BAY1000394'}, {'id': 1026, 'therapyName': 'Itraconazole'}]",Roniciclib (BAY 1000394) Drug-Drug Interaction (DDI) Study,1154
14,NCT02357836,Phase I,Recruiting,"[{'id': 1026, 'therapyName': 'Itraconazole'}]",Neoadjuvant Itraconazole in Non-small Cell Lung Cancer,1154
0,NCT02633059,Phase Ib/II,Recruiting,"[{'id': 4392, 'therapyName': 'Dexamethasone + Idasanutlin + Ixazomib'}]","Idasanutlin, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma",7246
1,NCT02057640,Phase Ib/II,"Active, not recruiting","[{'id': 4565, 'therapyName': 'Dexamethasone + Ixazomib + Panobinostat'}]",MLN9708 (Ixazomib) in Combination With Panobinostat and Dexamethasone in Multiple Myeloma,7246
2,NCT02831686,Phase I,Recruiting,"[{'id': 4500, 'therapyName': 'Dexamethasone + Ixazomib + Selinexor'}]","A Study to Test the Combination of Selinexor (KPT-330), Ixazomib, and Dexamethasone in Patients With Myeloma",7246
3,NCT02942095,Phase I,Recruiting,"[{'id': 4885, 'therapyName': 'Erlotinib + Ixazomib'}]",Phase I Study of Ixazomib and Erlotinib in Solid Tumors,7246
4,NCT02384746,Phase I,Recruiting,"[{'id': 2568, 'therapyName': 'Fulvestrant + Ixazomib'}]",Phase I Study of the Combination of MLN9708 and Fulvestrant,7246
5,NCT02440464,Phase II,Recruiting,"[{'id': 3321, 'therapyName': 'Tacrolimus + Methotrexate'}, {'id': 1359, 'therapyName': 'Ixazomib'}, {'id': 2237, 'therapyName': 'Fludarabine + Melphalan'}, {'id': 688, 'therapyName': 'Bortezomib'}]",Allogeneic Hematopoietic Stem Cell Transplantation With Ixazomib for High Risk Multiple Myeloma (BMT CTN 1302),7246
6,NCT02042989,Phase I,"Active, not recruiting","[{'id': 1360, 'therapyName': 'Ixazomib + Vorinostat'}]",MLN9708 and Vorinostat in Patients With Advanced p53 Mutant Malignancies,7246
0,NCT02706405,Phase I,Recruiting,"[{'id': 4365, 'therapyName': 'Cyclophosphamide + JCAR014 + MEDI4736'}]",JCAR014 and Durvalumab in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma,8434
0,NCT02631044,Phase I,Recruiting,"[{'id': 5980, 'therapyName': 'JCAR017'}]",Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (NHL),8878
0,NCT02952573,Phase II,Recruiting,"[{'id': 4950, 'therapyName': 'Dexamethasone + JNJ-42756493'}]",Testing JNJ-42756493 In Combination With Dexamethasone in Multiple Myeloma That Came Back After a Period of Improvement,7144
1,NCT02365597,Phase II,Recruiting,"[{'id': 1028, 'therapyName': 'JNJ-42756493'}]",An Efficacy and Safety Study of JNJ-42756493 in Participants With Urothelial Cancer,7144
2,NCT03210714,Phase II,Not yet recruiting,"[{'id': 1028, 'therapyName': 'JNJ-42756493'}]","Pediatric MATCH: Pan-FGFR Tyrosine Kinase Inhibitor JNJ-42756493 in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations",7144
3,NCT01703481,Phase I,"Active, not recruiting","[{'id': 1028, 'therapyName': 'JNJ-42756493'}]","A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493 in Adult Patients With Advanced or Refractory Solid Tumors or Lymphoma",7144
4,NCT03238196,Phase I,Recruiting,"[{'id': 6099, 'therapyName': 'JNJ-42756493 + Fulvestrant + Palbociclib'}]","Fulvestrant, Palbociclib and Erdafitinib in ER+/HER2-/FGFR-amplified Metastatic Breast Cancer",7144
0,NCT02671955,Phase I,Terminated,"[{'id': 3614, 'therapyName': 'JNJ-61610588 '}]","A Study of Safety, Pharmacokinetics, Pharmacodynamics of JNJ-61610588 in Participants With Advanced Cancer",8173
0,NCT03145181,Phase I,Recruiting,"[{'id': 5708, 'therapyName': 'JNJ-64007957'}]","Dose Escalation Study of JNJ-64007957, a Humanized BCMA CD3 DuoBody® Antibody, in Participants With Relapsed or Refractory Multiple Myeloma",8758
0,NCT02906605,Phase II,Withdrawn,"[{'id': 1947, 'therapyName': 'ARN-509'}, {'id': 4890, 'therapyName': 'ARN-509 + JNJ-64041809'}]","A Study of the Clinical Activity and Safety of JNJ-64041809, a Live Attenuated Listeria Monocytogenes Immunotherapy, in Combination With Apalutamide Versus Apalutamide in Subjects With Metastatic Castration-resistant Prostate Cancer",8569
1,NCT02625857,Phase I,"Active, not recruiting","[{'id': 4889, 'therapyName': 'JNJ-64041809'}]","Safety & Immunogenicity of JNJ-64041809, a Live Attenuated Double-deleted Listeria Immunotherapy, in Participants With Metastatic Castration-resistant Prostate Cancer",8569
0,NCT02743546,Phase I,Withdrawn,"[{'id': 4167, 'therapyName': 'Ibrutinib + JNJ-64052781'}]","Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of JNJ-64052781 Plus Ibrutinib in Lymphoma",8372
1,NCT02454270,Phase II,"Active, not recruiting","[{'id': 4166, 'therapyName': 'JNJ-64052781'}]",A Dose Escalation Study of JNJ-64052781 in Participants With Relapsed or Refractory B-cell Malignancies,8372
0,NCT02904226,Phase Ib/II,Recruiting,"[{'id': 4720, 'therapyName': 'JTX-2011 + Nivolumab'}, {'id': 4719, 'therapyName': 'JTX-2011'}]",Dose Escalation and Expansion of JTX-2011 Alone or in Combination With Anti-PD-1 in Subjects With Advanced Solid Tumors (ICONIC),8530
0,NCT02562755,Phase III,Recruiting,"[{'id': 3341, 'therapyName': 'JX-594'}, {'id': 920, 'therapyName': 'Sorafenib'}]",Hepatocellular Carcinoma Study Comparing Vaccinia Virus Based Immunotherapy Plus Sorafenib vs Sorafenib Alone,8047
0,NCT00730158,Phase II,Suspended,"[{'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 1699, 'therapyName': 'KD018'}]","A Phase II Multicenter, Randomized, Placebo Controlled, Double Blinded Clinical Study of KD018 as a Modulator of Irinotecan Chemotherapy in Patients With Metastatic Colorectal Cancer",7320
1,NCT02178644,Phase I,Recruiting,"[{'id': 1699, 'therapyName': 'KD018'}, {'id': 1105, 'therapyName': 'Capecitabine'}]",Pilot Trial of KD018 With Neo-Adjuvant Concurrent Chemo-Radiation Therapy in Patients With Locally Advanced Rectal Cancer,7320
2,NCT01666756,Phase I,"Active, not recruiting","[{'id': 2387, 'therapyName': 'Sorafenib + KD018'}]",Chinese Herbal Formulation PHY906 and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer,7320
0,NCT02560051,Phase II,Recruiting,"[{'id': 1814, 'therapyName': 'Degarelix'}, {'id': 3087, 'therapyName': 'Aldoxorubicin + Docetaxel + Estramustine + Ketoconazole'}]",Hormone Therapy Plus Chemotherapy as Initial Treatment for Local Failures or Advanced Prostate Cancer,1015
1,NCT02075177,Phase I,Available,"[{'id': 2858, 'therapyName': 'Ketoconazole'}, {'id': 2731, 'therapyName': 'Fenretinide'}]",Expanded Access Study of Fenretinide Lym-X-Sorb Plus Ketoconazole in Neuroblastoma,1015
2,NCT00859781,Phase II,Recruiting,"[{'id': 2188, 'therapyName': 'Prednisone'}, {'id': 2858, 'therapyName': 'Ketoconazole'}]",177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu-J591) and Ketoconazole in Patients With Prostate Cancer,1015
3,NCT01535157,Phase Ib/II,"Active, not recruiting","[{'id': 2858, 'therapyName': 'Ketoconazole'}, {'id': 2731, 'therapyName': 'Fenretinide'}]",Fenretinide/LXS Oral Powder Plus Ketoconazole in Recurrent Ovarian Cancer,1015
4,NCT02163356,Phase I,Recruiting,"[{'id': 1631, 'therapyName': 'Vincristine'}, {'id': 2731, 'therapyName': 'Fenretinide'}, {'id': 2858, 'therapyName': 'Ketoconazole'}]",Fenretinide Lym-X-Sorb + Ketoconazole + Vincristine for Recurrent or Resistant Neuroblastoma,1015
5,NCT02494713,Phase II,Recruiting,"[{'id': 1814, 'therapyName': 'Degarelix'}, {'id': 2950, 'therapyName': 'Estramustine'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 2858, 'therapyName': 'Ketoconazole'}]",Hormonal Therapy and Chemotherapy Followed by Prostatectomy in Patients With Prostate Cancer,1015
6,NCT00536991,Phase Ib/II,Terminated,"[{'id': 2188, 'therapyName': 'Prednisone'}, {'id': 2889, 'therapyName': 'calcitriol'}, {'id': 2858, 'therapyName': 'Ketoconazole'}]","Calcitriol, Ketoconazole, and Hydrocortisone in Treating Patients With Advanced or Recurrent Prostate Cancer",1015
0,NCT03139370,Phase I,Recruiting,"[{'id': 5803, 'therapyName': 'KITE-718'}]",A Study Evaluating the Safety and Efficacy of MAGE-A3/A6 T Cell Receptor Engineered T Cells (KITE-718) in HLA-DPB1*04:01 Positive Subjects With Advanced Cancers,8801
0,NCT02827968,Phase I,Recruiting,"[{'id': 6140, 'therapyName': 'KN035'}]",Phase 1 Study of Anti-PD-L1 Monoclonal Antibody KN035 to Treat Locally Advanced or Metastatic Solid Tumors,8926
0,NCT03051035,Phase I,Recruiting,"[{'id': 5747, 'therapyName': 'KO-947'}]",First-in-Human Study of KO-947 in Non-Hematological Malignancies,8768
0,NCT02649790,Phase Ib/II,Recruiting,"[{'id': 5687, 'therapyName': 'KPT-8602'}]","Study of the Safety, Tolerability and Efficacy of KPT-8602 in Patients With Relapsed/Refractory Multiple Myeloma",8743
0,NCT02702492,Phase I,Recruiting,"[{'id': 4662, 'therapyName': 'KPT-9274'}, {'id': 4688, 'therapyName': 'KPT-9274 + Niacin'}]",PAK4 and NAMPT in Patients With Solid MAlignancies or NHL (PANAMA) (PANAMA),8506
0,NCT02926833,Phase Ib/II,Recruiting,"[{'id': 4830, 'therapyName': 'Atezolizumab + KTE-C19'}]",A Study Evaluating KTE-C19 in Combination With Atezolizumab in Subjects With Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (ZUMA-6),8556
1,NCT02625480,Phase Ib/II,Recruiting,"[{'id': 4829, 'therapyName': 'KTE-C19'}]",A Multi-Center Study Evaluating KTE-C19 in Pediatric and Adolescent Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ZUMA-4),8556
2,NCT02614066,Phase Ib/II,Recruiting,"[{'id': 4829, 'therapyName': 'KTE-C19'}]",A Study Evaluating KTE-C19 in Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r ALL) (ZUMA-3) (ZUMA-3),8556
3,NCT03105336,Phase II,Recruiting,"[{'id': 4829, 'therapyName': 'KTE-C19'}]",A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (ZUMA-5),8556
4,NCT02348216,Phase Ib/II,Recruiting,"[{'id': 4829, 'therapyName': 'KTE-C19'}]",A Phase 1-2 Multi-Center Study Evaluating KTE-C19 in Subjects With Refractory Aggressive Non-Hodgkin Lymphoma (ZUMA-1),8556
5,NCT03153462,Expanded access,Available,"[{'id': 5098, 'therapyName': 'KTE-C19 + Fludarabine phosphate + Cyclophosphamide'}]",Axicabtagene Ciloleucel Expanded Access Study,8556
6,NCT02601313,Phase II,Recruiting,"[{'id': 5098, 'therapyName': 'KTE-C19 + Fludarabine phosphate + Cyclophosphamide'}]",A Phase 2 Multicenter Study Evaluating Subjects With Relapsed/Refractory Mantle Cell Lymphoma (ZUMA-2),8556
0,NCT02834403,Phase Ib/II,Recruiting,"[{'id': 1476, 'therapyName': 'Pegfilgrastim'}, {'id': 6123, 'therapyName': 'Docetaxel + L-NMMA'}, {'id': 6096, 'therapyName': 'L-NMMA'}]",L-NMMA Plus Docetaxel in Refractory Locally Advanced or Metastatic Triple Negative Breast Cancer Patients,8915
1,NCT03236935,Phase I,Not yet recruiting,"[{'id': 6097, 'therapyName': 'L-NMMA + Pembrolizumab'}]",Phase Ib of L-NMMA and Pembrolizumab,8915
0,NCT02460224,Phase Ib/II,Recruiting,"[{'id': 2887, 'therapyName': 'LAG525'}, {'id': 2659, 'therapyName': 'PDR001'}]",Safety and Efficay of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies,7815
0,NCT03289741,FDA approved,Recruiting,"[{'id': 6279, 'therapyName': 'Lanreotide Depot + Octreotide'}]",A Study to Evaluate Patient Experience in the Therapy of Neuroendocrine Tumors Treated With Octreotide Long Acting Release Versus Lanreotide,8920
1,NCT03043664,Phase Ib/II,Recruiting,"[{'id': 6129, 'therapyName': 'Lanreotide Depot + Pembrolizumab'}]",Study of Pembrolizumab With Lanreotide Depot for Gastroenteropancreatic Neuroendocrine Tumors (PLANET),8920
0,NCT01300962,Phase I,"Active, not recruiting","[{'id': 1538, 'therapyName': 'BKM120 + Capecitabine + Lapatinib'}, {'id': 1537, 'therapyName': 'BKM120 + Capecitabine + Trastuzumab'}, {'id': 1536, 'therapyName': 'BKM120 + Capecitabine'}, {'id': 1535, 'therapyName': 'BYL719 + Capecitabine'}]",Study of BKM120 or BYL719 and Capecitabine in Patients With Metastatic Breast Cancer,1246
1,NCT01934894,Phase II,Terminated,"[{'id': 1572, 'therapyName': 'Cabazitaxel + Lapatinib'}]",Cabazitaxel Plus Lapatinib as Therapy for HER2-Positive Metastatic Breast Cancer Patients With Intracranial Metastases,1246
2,NCT01873833,Phase II,Recruiting,"[{'id': 1559, 'therapyName': 'Capecitabine + Cyclophosphamide + Lapatinib + Trastuzumab'}]","Capecitabine, Cyclophosphamide, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With HER2-Positive Metastatic Breast Cancer",1246
3,NCT01947023,Phase I,Recruiting,"[{'id': 2478, 'therapyName': 'Dabrafenib + Lapatinib'}]",Dabrafenib and Lapatinib Ditosylate in Treating Patients With Refractory Thyroid Cancer That Cannot Be Removed by Surgery,1246
4,NCT01434303,Phase I,"Active, not recruiting","[{'id': 1542, 'therapyName': 'Entinostat + Lapatinib + Trastuzumab'}]","Entinostat, Lapatinib Ditosylate and Trastuzumab in Treating Patients With Locally Recurrent or Distant Relapsed Metastatic Breast Cancer Previously Treated With Trastuzumab Only",1246
5,NCT01283789,Phase II,"Active, not recruiting","[{'id': 1539, 'therapyName': 'Everolimus + Lapatinib'}]",Lapatinib and RAD-001 for HER2 Positive Metastatic Breast Cancer,1246
6,NCT01328054,,Completed,"[{'id': 787, 'therapyName': 'Lapatinib'}]",A Study in Cancer Patients to Evaluate the Effect of Lapatinib on the QTc Interval,1246
7,NCT01427322,,Terminated,"[{'id': 787, 'therapyName': 'Lapatinib'}]",Randomized RT +/- Lapatinib for Advanced Solid Tumor Cancer Patients Receiving Radiation Therapy for Metastatic Disease,1246
8,NCT01306045,Phase II,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 816, 'therapyName': 'MK2206'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 913, 'therapyName': 'Selumetinib'}]","Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies",1246
9,NCT01622868,Phase II,Recruiting,"[{'id': 787, 'therapyName': 'Lapatinib'}]",Whole-Brain Radiation Therapy With or Without Lapatinib Ditosylate in Treating Patients With Brain Metastasis From HER2-Positive Breast Cancer,1246
10,NCT02551718,Phase I,Recruiting,"[{'id': 690, 'therapyName': 'Bosutinib'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 3160, 'therapyName': 'Nelarabine'}, {'id': 3159, 'therapyName': 'Bexarotene'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 998, 'therapyName': 'cabozantinib'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 877, 'therapyName': 'Ponatinib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 623, 'therapyName': 'Afatinib'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 890, 'therapyName': 'Regorafenib'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 2, 'therapyName': 'Trametinib'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 3, 'therapyName': 'Dabrafenib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 789, 'therapyName': 'Ceritinib'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1571, 'therapyName': 'Cabazitaxel'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1327, 'therapyName': 'Pralatrexate'}]",High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia,1246
11,NCT00863122,Phase I,Unknown status,"[{'id': 787, 'therapyName': 'Lapatinib'}]",Concentration and Activity of Lapatinib in Vestibular Schwannomas,1246
12,NCT01868503,Phase II,Terminated,"[{'id': 787, 'therapyName': 'Lapatinib'}]",Lapatinib Ditosylate and Radiation Therapy in Treating Patients With Locally Advanced or Locally Recurrent Breast Cancer,1246
13,NCT00790816,Phase I,Completed,"[{'id': 1410, 'therapyName': 'Lapatinib + Paclitaxel'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 1414, 'therapyName': 'Trastuzumab + Lapatinib'}, {'id': 1399, 'therapyName': 'Lapatinib + Capecitabine'}, {'id': 1497, 'therapyName': 'Lapatinib + Letrozole'}, {'id': 1498, 'therapyName': 'Lapatinib + Oxaliplatin + Capecitabine'}, {'id': 1499, 'therapyName': 'Lapatinib + Gemcitabine'}, {'id': 1500, 'therapyName': 'Lapatinib + Docetaxel'}, {'id': 1501, 'therapyName': 'Lapatinib + Oxaliplatin + Leucovorin + Fluorouracil'}, {'id': 1502, 'therapyName': 'Lapatinib + Irinotecan + Leucovorin + Fluorouracil'}]",Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents,1246
14,NCT00759642,Phase II,"Active, not recruiting","[{'id': 787, 'therapyName': 'Lapatinib'}]",Lapatinib in Women With Metastatic Breast Cancer Who Have Failed Prior Antihormone Therapy,1246
15,NCT02559778,Phase I,Recruiting,"[{'id': 688, 'therapyName': 'Bortezomib'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 2629, 'therapyName': 'Eflornithine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 717, 'therapyName': 'Dasatinib'}]",Pediatric Precision Laboratory Advanced Neuroblastoma Therapy,1246
16,NCT02788201,Phase II,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1133, 'therapyName': 'Mitomycin C'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1013, 'therapyName': 'epirubicin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1137, 'therapyName': 'Bleomycin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 781, 'therapyName': 'Ixabepilone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 2950, 'therapyName': 'Estramustine'}, {'id': 1941, 'therapyName': 'Floxuridine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 1811, 'therapyName': 'Carmustine'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 953, 'therapyName': 'Vandetanib'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 4419, 'therapyName': 'Toremifine'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 2601, 'therapyName': 'Dactinomycin'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 3035, 'therapyName': 'Chlorambucil'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 342, 'therapyName': 'Vemurafenib'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 2635, 'therapyName': 'Vinblastine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 4305, 'therapyName': 'Teniposide'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 4304, 'therapyName': 'Streptozocin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1231, 'therapyName': 'Bendamustine'}, {'id': 4303, 'therapyName': 'Mechlorethamine'}, {'id': 4302, 'therapyName': 'Mitotane'}]",Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma,1246
17,NCT02101905,Phase I,Recruiting,"[{'id': 787, 'therapyName': 'Lapatinib'}]",Lapatinib Ditosylate Before Surgery in Treating Patients With Recurrent High-Grade Glioma,1246
18,NCT01160211,Phase III,"Active, not recruiting","[{'id': 1414, 'therapyName': 'Trastuzumab + Lapatinib'}, {'id': 794, 'therapyName': 'Letrozole'}, {'id': 633, 'therapyName': 'Anastrozole'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 738, 'therapyName': 'Exemestane'}]","A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer",1246
19,NCT00939523,Phase II,Recruiting,"[{'id': 787, 'therapyName': 'Lapatinib'}]",Targeted Therapy With Lapatinib in Patients With Recurrent Pituitary Tumors Resistant to Standard Therapy,1246
20,NCT01497626,Phase I,Terminated,"[{'id': 1394, 'therapyName': 'Lapatinib + bortezomib'}]",Lapatinib and Bortezomib in Patients With Advanced Malignancies,1246
21,NCT02650752,Phase I,Recruiting,"[{'id': 1399, 'therapyName': 'Lapatinib + Capecitabine'}]",Intermittent High-Dose Lapatinib in Tandem With Capecitabine for HER2 Overexpressed/Amplified Metastatic Breast Cancer With Central Nervous System (CNS) Metastases,1246
22,NCT01808573,Phase III,"Active, not recruiting","[{'id': 1399, 'therapyName': 'Lapatinib + Capecitabine'}, {'id': 1543, 'therapyName': 'Capecitabine + Neratinib'}]",A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic Setting,1246
23,NCT01783756,Phase Ib/II,"Active, not recruiting","[{'id': 1552, 'therapyName': 'Lapatinib + Capecitabine + Everolimus'}]","Phase 1b/2 Trial Using Lapatinib, Everolimus and Capecitabine for Treatment of HER-2 Positive Breast Cancer With CNS Metastasis",1246
24,NCT01612351,Phase II,"Active, not recruiting","[{'id': 2477, 'therapyName': 'Lapatinib + Carboplatin + Cisplatin + Paclitaxel'}, {'id': 2476, 'therapyName': 'Lapatinib + Carboplatin + Paclitaxel'}]",Multimodality Risk Adapted Tx Including Induction Chemo for SCCHN Amenable to Transoral Surgery,1246
25,NCT01711658,Phase II,"Active, not recruiting","[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 2475, 'therapyName': 'Lapatinib + Cisplatin'}]",TRYHARD: Radiation Therapy Plus Cisplatin With or Without Lapatinib in Treating Patients With Head and Neck Cancer,1246
26,NCT01087983,Phase I,Completed,"[{'id': 1139, 'therapyName': 'Lapatinib + Sirolimus'}, {'id': 1140, 'therapyName': 'Lapatinib + Metformin'}]",Lapatinib With Sirolimus or Metformin,1246
27,NCT01591577,Phase II,Recruiting,"[{'id': 2440, 'therapyName': 'Lapatinib + Temozolomide'}]",Lapatinib With Temozolomide and Regional Radiation Therapy for Patients With Newly-Diagnosed Glioblastoma Multiforme,1246
28,NCT02158507,Phase I,"Active, not recruiting","[{'id': 2543, 'therapyName': 'Lapatinib + Veliparib'}]","Pilot Study of Veliparib (ABT-888) and Lapatinib (Tykerb) in Patients With Metastatic, Triple Negative Breast Cancer",1246
29,NCT02073916,Phase I,Recruiting,"[{'id': 1907, 'therapyName': 'T-DM1 + Lapatinib + Abraxane'}]",TDM1 With Abraxane and Lapatinib for Metastatic HER2 Positive Breast Cancer,1246
30,NCT02073487,Phase II,Recruiting,"[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1583, 'therapyName': 'Trastuzumab emtansine + Lapatinib'}, {'id': 1414, 'therapyName': 'Trastuzumab + Lapatinib'}, {'id': 619, 'therapyName': 'Abraxane'}]",Neoadjuvant TDM1 With Lapatinib and Abraxane Compared With Trastuzumab With Lapatinib and Paclitaxel,1246
31,NCT01875666,Phase I,"Active, not recruiting","[{'id': 1414, 'therapyName': 'Trastuzumab + Lapatinib'}, {'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 856, 'therapyName': 'Pertuzumab'}, {'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}]","Defining the HER2 Positive (+) Breast Cancer Kinome Response to Trastuzumab, Pertuzumab, Combination Trastuzumab +Pertuzumab, or Combination Trastuzumab + Lapatinib",1246
32,NCT01273610,Phase II,"Active, not recruiting","[{'id': 1414, 'therapyName': 'Trastuzumab + Lapatinib'}]",Tolerability of the Combination of Lapatinib and Trastuzumab in Adults Age 60 or Older With HER2 Positive Metastatic Breast Cancer,1246
33,NCT02213042,Phase II,"Active, not recruiting","[{'id': 1414, 'therapyName': 'Trastuzumab + Lapatinib'}, {'id': 947, 'therapyName': 'Trastuzumab'}]",Evaluation of Biomarkers Associated With Response to Subsequent Therapies in Subjects With HER2-Positive Metastatic Breast Cancer,1246
34,NCT00968968,Phase III,"Active, not recruiting","[{'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 1414, 'therapyName': 'Trastuzumab + Lapatinib'}]",Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone,1246
0,NCT01837667,Phase I,Completed,"[{'id': 3683, 'therapyName': 'Docetaxel + LB-100'}]",Phase I Study of LB-100 With Docetaxel in Solid Tumors,8112
1,NCT03027388,Phase I,Not yet recruiting,"[{'id': 3514, 'therapyName': 'LB-100'}]","Protein Phosphatase 2A Inhibitor, in Recurrent Glioblastoma",8112
0,NCT01955434,Phase II,Recruiting,"[{'id': 4019, 'therapyName': 'Cyclophosphamide + LCL161'}]",SMAC Mimetic LCL161 Alone or With Cyclophosphamide in Treating Patients With Relapsed or Refractory Multiple Myeloma,8184
1,NCT02649673,Phase Ib/II,Recruiting,"[{'id': 3845, 'therapyName': 'LCL161 + Topotecan'}]",LCL161 Plus Topotecan for Patients With Relapsed/Refractory Small Cell Lung Cancer and Select Gynecologic Malignancies,8184
2,NCT03111992,Phase I,Recruiting,"[{'id': 5311, 'therapyName': 'PDR001 + LCL161'}, {'id': 5397, 'therapyName': 'PDR001 + CJM112'}, {'id': 2659, 'therapyName': 'PDR001'}]","Study of Single Agent CJM112, and PDR001 in Combination With LCL161 or CJM112 in Patients With Multiple Myeloma",8184
3,NCT02890069,Phase I,Recruiting,"[{'id': 5311, 'therapyName': 'PDR001 + LCL161'}, {'id': 5312, 'therapyName': 'PDR001 + Everolimus'}, {'id': 5313, 'therapyName': 'PDR001 + Panobinostat'}]","A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat",8184
0,NCT02668770,Phase I,Recruiting,"[{'id': 5741, 'therapyName': 'Ipilumumab + Lefitolimod'}]",Ipilimumab (Immunotherapy) and MGN1703 (TLR Agonist) in Patients With Advanced Solid Malignancies,8766
0,NCT02631577,Phase I,Suspended,"[{'id': 3387, 'therapyName': 'Atezolizumab + lenalidomide + Obinutuzumab'}]",A Study Evaluating the Safety and Efficacy of Atezolizumab in Combination With Obinutuzumab Plus Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma,7212
1,NCT01729338,Phase II,Terminated,"[{'id': 3358, 'therapyName': 'Bortezomib + Cyclophosphamide + lenalidomide'}]",Velcade + Cyclophosphamide in Newly Diagnosed Multiple Myeloma,7212
2,NCT03168100,Phase II,Recruiting,"[{'id': 3342, 'therapyName': 'Bortezomib + Dexamethasone + lenalidomide'}, {'id': 3353, 'therapyName': 'Elotuzumab + Dexamethasone + Lenalidomide'}]","2017-03: A Single-Arm, Open-label Study of Anti-Signaling Lymphocytic Activation Molecule F7 (Anti-SLAMF7) Monoclonal Antibody (mAb) Therapy After Autologous Stem Cell Transplant in Patients With Multiple Myeloma",7212
3,NCT01668719,Phase Ib/II,Recruiting,"[{'id': 3343, 'therapyName': 'Elotuzumab'}, {'id': 3342, 'therapyName': 'Bortezomib + Dexamethasone + lenalidomide'}]","S1211, Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma",7212
4,NCT01208662,Phase III,Recruiting,"[{'id': 3342, 'therapyName': 'Bortezomib + Dexamethasone + lenalidomide'}]","Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65  (DFCI 10-106)",7212
5,NCT02874742,Phase II,Recruiting,"[{'id': 1630, 'therapyName': 'Daratumumab'}, {'id': 3342, 'therapyName': 'Bortezomib + Dexamethasone + lenalidomide'}]","Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Subjects With Newly Diagnosed Multiple Myeloma",7212
6,NCT02720510,Phase II,Recruiting,"[{'id': 1080, 'therapyName': 'Panobinostat'}, {'id': 3342, 'therapyName': 'Bortezomib + Dexamethasone + lenalidomide'}]","A Trial Evaluating Efficacy & Safety of RVD +/- Panobinostat in Transplant Eligible, Newly Diagnosed Multiple Myeloma (NDMM)",7212
7,NCT02375555,Phase II,"Active, not recruiting","[{'id': 3343, 'therapyName': 'Elotuzumab'}, {'id': 3342, 'therapyName': 'Bortezomib + Dexamethasone + lenalidomide'}]","Study of Bortezomib,Lenalidomide,Dexamethasone & Elotuzumab in Newly Diagnosed MM",7212
8,NCT02441686,Phase II,"Active, not recruiting","[{'id': 3342, 'therapyName': 'Bortezomib + Dexamethasone + lenalidomide'}]","Phase II Study of Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone Therapy for Newly Diagnosed Multiple Myeloma",7212
9,NCT01440582,Phase I,"Active, not recruiting","[{'id': 3362, 'therapyName': 'Bortezomib + Dexamethasone + lenalidomide + Panobinostat'}]",Combination Therapy of Lenalidomide/Bortezomib/Dexamethasone and Panobinostat in Transplant Eligible New Diagnosed Multiple Myeloma (MM) Patients,7212
10,NCT01965353,Phase I,"Active, not recruiting","[{'id': 3362, 'therapyName': 'Bortezomib + Dexamethasone + lenalidomide + Panobinostat'}]",A Phase I Study Of Panobinostat/Lenalidomide/Bortezomib/Dex for Relapsed And Relapsed/Refractory Multiple Myeloma,7212
11,NCT02719613,Phase II,Recruiting,"[{'id': 4533, 'therapyName': 'Bortezomib + Elotuzumab + Dexamethasone + lenalidomide'}]",Continuing Treatment for Subjects Who Have Participated in a Prior Protocol Investigating Elotuzumab,7212
12,NCT02312102,Phase I,Recruiting,"[{'id': 3220, 'therapyName': 'Bortezomib + lenalidomide'}]",Phase I Study of Velcade and Lenalidomide in Patients With Relapsed AML and MDS After Allogeneic Stem Cell Transplantation,7212
13,NCT02802163,Phase Ib/II,Withdrawn,"[{'id': 4367, 'therapyName': 'Carfilzomib + Dexamethasone + lenalidomide + Panobinostat'}]","Induction Therapy for Multiple Myeloma With Carfilzomib, Lenalidomide,Dexamethasone,Panobinostat",7212
14,NCT02969837,Phase II,Recruiting,"[{'id': 5033, 'therapyName': 'Carfilzomib + Elotuzumab + Dexamethasone + lenalidomide'}]","Study of Initial Treatment With Elotuzumab, Carfilzomib, Lenalidomide and Dexamethasone in Multiple Myeloma",7212
15,NCT01208051,Phase Ib/II,"Active, not recruiting","[{'id': 2437, 'therapyName': 'Cediranib + Lenalidomide'}, {'id': 1001, 'therapyName': 'Cediranib'}]",Cediranib Maleate With or Without Lenalidomide in Treating Patients With Thyroid Cancer,7212
16,NCT00829647,Phase Ib/II,Withdrawn,"[{'id': 1825, 'therapyName': 'Dasatinib + lenalidomide'}]",A Study Using Two Oral Chemotherapy Agents for Chronic Lymphocytic Leukemia,7212
17,NCT02426723,Phase I,Recruiting,"[{'id': 3081, 'therapyName': 'CWP232291'}, {'id': 4036, 'therapyName': 'Dexamethasone + lenalidomide'}]",Clinical Study of CWP232291 in Relapsed or Refractory Myeloma Patients,7212
18,NCT02880228,Phase II,"Active, not recruiting","[{'id': 4612, 'therapyName': 'Dexamethasone + lenalidomide + Pembrolizumab'}]","Pembrolizumab, Lenalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma Eligible for Stem Cell Transplant",7212
19,NCT02666209,Phase I,No longer available,"[{'id': 3556, 'therapyName': 'Bortezomib + Dexamethasone + Ulocuplumab'}, {'id': 3555, 'therapyName': 'Dexamethasone + lenalidomide + Ulocuplumab'}]",Early Patient Access Single Named Patient Program for the Use of Ulocuplumab for the Treatment of Multiple Myeloma,7212
20,NCT02159365,Phase II,"Active, not recruiting","[{'id': 3353, 'therapyName': 'Elotuzumab + Dexamethasone + Lenalidomide'}]",Study of Safety of Elotuzumab Administered Over Approximately 60 Minutes in Combination With Lenalidomide and Dexamethasone for Newly Diagnosed or Relapsed/Refractory Multiple Myeloma Patients,7212
21,NCT02368301,Phase I,Approved for marketing,"[{'id': 3353, 'therapyName': 'Elotuzumab + Dexamethasone + Lenalidomide'}]",Expanded Access Treatment Protocol CA204-143,7212
22,NCT02843074,Phase II,Recruiting,"[{'id': 3353, 'therapyName': 'Elotuzumab + Dexamethasone + Lenalidomide'}]","Elotuzumab, Lenalidomide and Dexamethasone (ERd) in the Induction, Consolidation and Maintenance Treatment of Transplant-Eligible, Newly Diagnosed Multiple Myeloma Patients",7212
23,NCT02420860,Phase II,Recruiting,"[{'id': 5972, 'therapyName': 'Famotidine'}, {'id': 3430, 'therapyName': 'Elotuzumab + lenalidomide'}, {'id': 1275, 'therapyName': 'Diphenhydramine'}, {'id': 1390, 'therapyName': 'Dexamethasone'}]",Study of Elotuzumab With Lenalidomide as Maintenance After Autologous Stem Cell Transplant (ASCT),7212
24,NCT02279394,Phase II,"Active, not recruiting","[{'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 3430, 'therapyName': 'Elotuzumab + lenalidomide'}]",Trial of Combination of Elotuzumab and Lenalidomide +/- Dexamethasone in High-Risk Smoldering Multiple Myeloma,7212
25,NCT02655458,Phase I,Completed,"[{'id': 3430, 'therapyName': 'Elotuzumab + lenalidomide'}]",Elotuzumab in Autologous Stem Cell Transplantation (ASCT) and Lenalidomide Maintenance for Multiple Myeloma,7212
26,NCT01955499,Phase I,"Active, not recruiting","[{'id': 3580, 'therapyName': 'Ibrutinib + lenalidomide'}]",Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma,7212
27,NCT01886859,Phase I,"Active, not recruiting","[{'id': 3580, 'therapyName': 'Ibrutinib + lenalidomide'}]",Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma,7212
28,NCT03015792,Phase Ib/II,Recruiting,"[{'id': 5240, 'therapyName': 'Ibrutinib + Lenalidomide + Dexamethasone'}]","Ibrutinib, Lenalidomide, and Dexamethasone in Treating Patients With Multiple Myeloma Ineligible for Transplant",7212
29,NCT03223610,Phase I,Not yet recruiting,"[{'id': 6189, 'therapyName': 'Ibrutinib + Lenalidomide + Obinutuzumab + Prednisone + Venetoclax'}]","Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma",7212
30,NCT01750983,Phase I,"Active, not recruiting","[{'id': 2992, 'therapyName': 'Ipilimumab + lenalidomide'}]",Ipilimumab and Lenalidomide in Advanced Cancer,7212
31,NCT01218555,Phase I,"Active, not recruiting","[{'id': 1164, 'therapyName': 'lenalidomide'}, {'id': 735, 'therapyName': 'Everolimus'}]",Study of Everolimus (RAD001)in Combination With Lenalidomide,7212
32,NCT01604031,Phase Ib/II,Terminated,"[{'id': 1164, 'therapyName': 'lenalidomide'}]",Treatment of B-CLL With Autologous IL2 and CD40 Ligand-Expressing Tumor Cells + Lenalidomide,7212
33,NCT01954784,Phase I,Terminated,"[{'id': 3434, 'therapyName': 'Bortezomib + Cyclosporine + Mycophenolate'}, {'id': 1164, 'therapyName': 'lenalidomide'}]",Lenalidomide After Donor Stem Cell Transplant and Bortezomib in Treating Patients With High Risk Multiple Myeloma,7212
34,NCT02589145,Phase Ib/II,Recruiting,"[{'id': 1164, 'therapyName': 'lenalidomide'}, {'id': 3277, 'therapyName': 'Pyridoxine'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 2558, 'therapyName': 'Busulfan + Melphalan'}, {'id': 3278, 'therapyName': 'Enoxaparin'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 2373, 'therapyName': 'Palifermin'}]",Lenalidomide Combined With Vorinostat/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Diffuse Large B-Cell Lymphoma of the ABC Subtype,7212
35,NCT01827137,Phase I,"Active, not recruiting","[{'id': 2893, 'therapyName': 'WT1 vaccine'}, {'id': 1164, 'therapyName': 'lenalidomide'}, {'id': 1873, 'therapyName': 'Sargramostim'}]",WT1 Analog Peptide Vaccine in Patients With Multiple Myeloma Following Autologous Stem Cell Transplantation,7212
36,NCT03004287,Phase II,Recruiting,"[{'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1164, 'therapyName': 'lenalidomide'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 1630, 'therapyName': 'Daratumumab'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1475, 'therapyName': 'Thalidomide'}]",2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy,7212
37,NCT01216683,Phase II,Unknown status,"[{'id': 2323, 'therapyName': 'Bendamustine + Rituximab'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1164, 'therapyName': 'lenalidomide'}]","Bendamustine Hydrochloride and Rituximab With or Without Bortezomib Followed by Rituximab With or Without Lenalidomide in Treating Patients With High-Risk Stage II, Stage III, or Stage IV Follicular Lymphoma",7212
38,NCT02265510,Phase I,Recruiting,"[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 1164, 'therapyName': 'lenalidomide'}, {'id': 619, 'therapyName': 'Abraxane'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 2747, 'therapyName': 'INCB052793'}, {'id': 688, 'therapyName': 'Bortezomib'}]","An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies",7212
39,NCT02431208,Phase I,Suspended,"[{'id': 1164, 'therapyName': 'lenalidomide'}, {'id': 1201, 'therapyName': 'Atezolizumab'}]",A Study of Atezolizumab (Anti-Programmed Death Ligand 1 [PD-L1] Antibody) Administered With or Without Lenalidomide in Participants With Multiple Myeloma (MM),7212
40,NCT02331368,Phase II,"Active, not recruiting","[{'id': 1164, 'therapyName': 'lenalidomide'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Phase 2 Multi-center Study of Anti-PD-1 During Lymphopenic State After HDT/ASCT for Multiple Myeloma,7212
41,NCT02579863,Phase III,Suspended,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 1164, 'therapyName': 'lenalidomide'}]",Study of Lenalidomide and Dexamethasone With or Without Pembrolizumab (MK-3475) in Participants With Newly Diagnosed Treatment Naive Multiple Myeloma (MK-3475-185/KEYNOTE-185),7212
42,NCT01459211,Phase II,Completed,"[{'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 1164, 'therapyName': 'lenalidomide'}]",Pilot Study to Establish Safety and Efficacy of a Combination of Dexamethasone and Lenalidomide in Patients With Relapsed or Refractory Chronic Lymphocytic Leukaemia (CLL),7212
43,NCT01729091,Phase Ib/II,Recruiting,"[{'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 3343, 'therapyName': 'Elotuzumab'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1164, 'therapyName': 'lenalidomide'}]",Study of Umbilical Cord Blood-derived Natural Killer Cells in Conjunction With High Dose Chemotherapy and Autologous Stem Cell Transplant for Patients With Multiple Myeloma,7212
44,NCT02030483,Phase I,Terminated,"[{'id': 850, 'therapyName': 'Palbociclib'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 1164, 'therapyName': 'lenalidomide'}]",Palbociclib in Combination With Lenalidomide and Dexamethasone for Multiple Myeloma,7212
45,NCT01863550,Phase III,Recruiting,"[{'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 1164, 'therapyName': 'lenalidomide'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 688, 'therapyName': 'Bortezomib'}]",Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma,7212
46,NCT01919086,Phase II,"Active, not recruiting","[{'id': 1164, 'therapyName': 'lenalidomide'}, {'id': 2470, 'therapyName': 'Bortezomib + Dexamethasone'}]",Response Adapted Therapy With Bortezomib/Dexamethasone Followed by Addition of Lenalidomide in Non Responders as Initial Treatment for Patients With Multiple Myeloma,7212
47,NCT01415752,Phase II,Recruiting,"[{'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1231, 'therapyName': 'Bendamustine'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1164, 'therapyName': 'lenalidomide'}]","Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma",7212
48,NCT01998971,Phase I,Recruiting,"[{'id': 1622, 'therapyName': 'Pomalidomide'}, {'id': 2470, 'therapyName': 'Bortezomib + Dexamethasone'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1475, 'therapyName': 'Thalidomide'}, {'id': 1164, 'therapyName': 'lenalidomide'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 1630, 'therapyName': 'Daratumumab'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 1275, 'therapyName': 'Diphenhydramine'}, {'id': 3323, 'therapyName': 'Montelukast'}]",A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma,7212
49,NCT01556776,Phase III,Terminated,"[{'id': 1164, 'therapyName': 'lenalidomide'}]",A Study of Lenalidomide Maintenance for High-risk Patients With CLL Following First-line Therapy,7212
50,NCT02126553,Phase II,Recruiting,"[{'id': 1164, 'therapyName': 'lenalidomide'}]",Lenalidomide Maintenance With High Risk (HR) Acute Myeloid Leukemia (AML) in Remission,7212
51,NCT01619761,Phase I,Recruiting,"[{'id': 897, 'therapyName': 'Rituximab'}, {'id': 1847, 'therapyName': 'lenalidomide + Fludarabine + Melphalan'}, {'id': 1845, 'therapyName': 'Mycophenolate mofetil'}, {'id': 1843, 'therapyName': 'Tacrolimus'}]",Natural Killer (NK) Cells in Cord Blood Transplantation,7212
52,NCT03011814,Phase Ib/II,"Active, not recruiting","[{'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 3934, 'therapyName': 'lenalidomide + MEDI4736'}]",Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma,7212
53,NCT02685826,Phase I,Suspended,"[{'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 3934, 'therapyName': 'lenalidomide + MEDI4736'}]",A Study of Durvalumab in Combination With Lenalidomide With and Without Dexamethasone in Subjects With Newly Diagnosed Multiple Myeloma,7212
54,NCT02733042,Phase Ib/II,Recruiting,"[{'id': 897, 'therapyName': 'Rituximab'}, {'id': 4278, 'therapyName': 'lenalidomide + MEDI4736 + Rituximab'}, {'id': 4279, 'therapyName': 'Bendamustine + MEDI4736 + Rituximab'}, {'id': 2573, 'therapyName': 'Ibrutinib + MEDI4736'}, {'id': 1356, 'therapyName': 'Durvalumab'}]","A Study to Determine Dose, Safety, and Efficacy of Durvalumab as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocytic Leukemia (FUSION NHL 001)",7212
55,NCT02399085,Phase II,Recruiting,"[{'id': 5843, 'therapyName': 'Lenalidomide + MOR208'}]",A Study to Evaluate the Safety and Efficacy of Lenalidomide With MOR00208 in Patients With R-R DLBCL,7212
56,NCT02005289,Phase II,Recruiting,"[{'id': 5843, 'therapyName': 'Lenalidomide + MOR208'}, {'id': 5847, 'therapyName': 'Ibrutinib + MOR208'}]","Phase II MOR00208 in Combination With Lenalidomide for Patients With Relapsed or Refractory CLL, SLL or PLL or Older Patients With Untreated CLL, SLL or PLL",7212
57,NCT03015896,Phase Ib/II,Suspended,"[{'id': 5239, 'therapyName': 'Lenalidomide + Nivolumab'}]",Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma,7212
58,NCT03269669,Phase II,Recruiting,"[{'id': 6257, 'therapyName': 'Obinutuzumab + CHOP'}, {'id': 6302, 'therapyName': 'Lenalidomide + Obinutuzumab\t'}, {'id': 6301, 'therapyName': 'Obinutuzumab + TGR-1202'}, {'id': 2188, 'therapyName': 'Prednisone'}]","Obinutuzumab With or Without PI3K-delta Inhibitor TGR-1202, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma",7212
59,NCT02600897,Phase Ib/II,Recruiting,"[{'id': 4394, 'therapyName': 'lenalidomide + Obinutuzumab + Polatuzumab Vedotin'}]","A Study of Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)",7212
60,NCT02992522,Phase I,Recruiting,"[{'id': 5133, 'therapyName': 'Lenalidomide + Obinutuzumab + Venetoclax'}]","Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma",7212
61,NCT02875067,Phase Ib/II,Recruiting,"[{'id': 3322, 'therapyName': 'lenalidomide + Pembrolizumab'}]","Safety & Efficacy Study of Combination of Pembrolizumab and Lenalidomide, in Patients With Relapsed Non-Hodgkin and Hodgkin Lymphoma",7212
62,NCT02963610,Phase Ib/II,Recruiting,"[{'id': 3322, 'therapyName': 'lenalidomide + Pembrolizumab'}]",Phase I/II Study of Lenalidomide Plus Pembrolizumab in Patients With Solid Tumors With Expansion in Non-small Cell Lung Cancer,7212
63,NCT02036502,Phase I,Recruiting,"[{'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 3322, 'therapyName': 'lenalidomide + Pembrolizumab'}]",A Study of Pembrolizumab (MK-3475) in Combination With Lenalidomide and Dexamethasone in Participants With Multiple Myeloma (MK-3475-023/KEYNOTE-023),7212
64,NCT02077959,Phase Ib/II,"Active, not recruiting","[{'id': 3357, 'therapyName': 'lenalidomide + Pidilizumab'}]",Lenalidomide and Pidilizumab in Treating Patients With Relapsed or Refractory Multiple Myeloma,7212
65,NCT02281279,Phase Ib/II,Withdrawn,"[{'id': 2349, 'therapyName': 'Lenalidomide + Rituximab + Romidepsin '}]","Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma",7212
66,NCT02086552,Phase II,Recruiting,"[{'id': 4445, 'therapyName': 'lenalidomide + Sonidegib'}]",Sonidegib and Lenalidomide After Stem Cell Transplant in Treating Patients With Multiple Myeloma,7212
67,NCT02954406,Phase I,Recruiting,"[{'id': 5150, 'therapyName': 'Lenalidomide + TAK-659'}, {'id': 5149, 'therapyName': 'Ibrutinib + TAK-659'}, {'id': 5148, 'therapyName': 'Gemcitabine + TAK-659'}, {'id': 5147, 'therapyName': 'Bendamustine + Rituximab + TAK-659'}, {'id': 5146, 'therapyName': 'Bendamustine + TAK-659'}]","A Study of TAK-659 in Combination With Bendamustine (+/-Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Participants With Advanced Non-Hodgkin Lymphoma",7212
68,NCT03050450,Phase I,Recruiting,"[{'id': 5337, 'therapyName': 'Lenalidomide + Vorinostat'}]",Study of Lenalidomide With Vorinostat in Pediatric Patients With High Grade or Progressive CNS Tumors,7212
69,NCT03003520,Phase II,Recruiting,"[{'id': 5350, 'therapyName': 'MEDI4736 + R2-CHOP'}, {'id': 5349, 'therapyName': 'MEDI4736 + Rituximab + Doxorubicin + Vincristine + Cyclophosphamide + Prednisone'}]",A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma,7212
70,NCT03110822,Phase I,Recruiting,"[{'id': 5550, 'therapyName': 'Methylprednisolone + Lenalidomide + Ruxolitinib'}]","A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients",7212
71,NCT02903381,Phase II,Recruiting,"[{'id': 5128, 'therapyName': 'Nivolumab + Lenalidomide + Dexamethasone'}]",Nivolumab + Lenalidomide + Dexamethasone In SMM,7212
72,NCT02886065,Phase I,Recruiting,"[{'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 5082, 'therapyName': 'PVX-410 + MEDI4736'}, {'id': 5081, 'therapyName': 'PVX-410 + MEDI4736 + lenalidomide'}]","A Phase 1b Study of PVX-410, a Multi-Peptide Cancer Vaccine, and Durvalumab (Anti-PDL1) With and Without Lenalidomide for Patients With Smoldering Multiple Myeloma",7212
73,NCT02200848,Phase I,Terminated,"[{'id': 1610, 'therapyName': 'Rituximab + Lenalidomide + Ibrutinib'}]","Phase I Study of Lenalidomide, Rituximab and Ibrutinib in Relapsed/Refractory CLL",7212
74,NCT03232307,Phase II,Not yet recruiting,"[{'id': 1610, 'therapyName': 'Rituximab + Lenalidomide + Ibrutinib'}]",Ibrutinib Plus Rituximab and Lenalidomide in Elderly Patients With Newly Diagnosed Mantle Cell Lymphoma (MCL),7212
75,NCT02532257,Phase II,Recruiting,"[{'id': 1610, 'therapyName': 'Rituximab + Lenalidomide + Ibrutinib'}]",Study of Ibrutinib in Combination With Rituximab and Lenalidomide,7212
76,NCT02446236,Phase I,Recruiting,"[{'id': 1610, 'therapyName': 'Rituximab + Lenalidomide + Ibrutinib'}]","Dose Finding Study of Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765) Plus Lenalidomide / Rituximab in Relapsed or Refractory Mantle Cell Lymphoma (MCL)",7212
77,NCT02077166,Phase Ib/II,Recruiting,"[{'id': 1610, 'therapyName': 'Rituximab + Lenalidomide + Ibrutinib'}]",Ibrutinib in Combination With Lenalidomide and Rituximab in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma,7212
78,NCT02636322,Phase II,Recruiting,"[{'id': 2482, 'therapyName': 'Cyclophosphamide + Doxorubicin + Etoposide + Vincristine '}, {'id': 1610, 'therapyName': 'Rituximab + Lenalidomide + Ibrutinib'}, {'id': 2188, 'therapyName': 'Prednisone'}]","A Study of Rituximab, Lenalidomide, and Ibrutinib Combined With Dose Adjusted Chemotherapy For Patients With High Risk Diffuse Large B-Cell Lymphoma",7212
79,NCT02160015,Phase I,"Active, not recruiting","[{'id': 1610, 'therapyName': 'Rituximab + Lenalidomide + Ibrutinib'}]","Lenalidomide, Ibrutinib, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma",7212
80,NCT01076543,Phase Ib/II,"Active, not recruiting","[{'id': 2280, 'therapyName': 'Temsirolimus + Lenalidomide'}]",Lenalidomide and Temsirolimus in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma,7212
0,NCT02935309,Phase I,Recruiting,"[{'id': 4779, 'therapyName': 'Capecitabine + Lenvatinib'}]",Phase I Study of Capecitabine and Lenvatinib With External Radiation in Rectal Adenocarcinoma,6934
1,NCT02915172,Phase I,Withdrawn,"[{'id': 4779, 'therapyName': 'Capecitabine + Lenvatinib'}]",Lenvatinib and Capecitabine in Patients With Advanced Malignancies,6934
2,NCT02640508,Phase II,Recruiting,"[{'id': 3352, 'therapyName': 'Eribulin + Lenvatinib'}]",Eribulin and Lenvatinib in Advanced Solid Tumors,6934
3,NCT02811861,Phase III,Recruiting,"[{'id': 1713, 'therapyName': 'Everolimus + Lenvatinib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 4782, 'therapyName': 'Lenvatinib + Pembrolizumab'}]",Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma,6934
4,NCT03173560,Phase II,Recruiting,"[{'id': 1713, 'therapyName': 'Everolimus + Lenvatinib'}]",Trial to Assess Safety and Efficacy of Lenvatinib in Combination With Everolimus in Participants With Renal Cell Carcinoma,6934
5,NCT03245151,Phase Ib/II,Not yet recruiting,"[{'id': 1713, 'therapyName': 'Everolimus + Lenvatinib'}]","Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including Central Nervous System Tumors",6934
6,NCT02915783,Phase II,Recruiting,"[{'id': 1713, 'therapyName': 'Everolimus + Lenvatinib'}]",A Phase 2 Trial to Evaluate Efficacy and Safety of Lenvatinib in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Non Clear Cell Renal Cell Carcinoma (nccRCC) Who Have Not Received Any Chemotherapy for Advanced Disease,6934
7,NCT03139747,Phase II,Recruiting,"[{'id': 1713, 'therapyName': 'Everolimus + Lenvatinib'}]",UPCC 36315 A Phase II Study Of Everolimus (RAD001) And Lenvatinib (E7080) In Patients With Metastatic Differentiated Thyroid Cancer Who Have Progressed on Lenvatinib Alone,6934
8,NCT02846766,Phase II,Not yet recruiting,"[{'id': 792, 'therapyName': 'Lenvatinib'}]",Study of Lenvatinib in Patients With Advanced Cancer and Aberrations in FGF/FGFR Signaling,6934
9,NCT02780310,Phase II,"Active, not recruiting","[{'id': 792, 'therapyName': 'Lenvatinib'}]",Testing Lenvatinib in Patients With Adenoid Cystic Carcinoma,6934
10,NCT01433991,Phase Ib/II,"Active, not recruiting","[{'id': 1019, 'therapyName': 'Golvatinib'}, {'id': 792, 'therapyName': 'Lenvatinib'}]",E7050 in Combination With E7080 in Subjects With Advanced Solid Tumors (Dose Escalation) and in Subjects With Recurrent Glioblastoma or Unresectable Stage III or Stage IV Melanoma After Prior Systemic Therapy (Expansion Cohort and Phase 2),6934
11,NCT02501096,Phase Ib/II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 792, 'therapyName': 'Lenvatinib'}]",Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors,6934
12,NCT01877083,Phase II,"Active, not recruiting","[{'id': 792, 'therapyName': 'Lenvatinib'}]",Study of the Safety and Activity of Lenvatinib (E7080) in Subjects With KIF5B-RET-Positive Adenocarcinoma of the Lung,6934
13,NCT01761266,Phase III,"Active, not recruiting","[{'id': 792, 'therapyName': 'Lenvatinib'}, {'id': 920, 'therapyName': 'Sorafenib'}]","A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-Line Treatment of Subjects With Unresectable Hepatocellular Carcinoma",6934
14,NCT02211222,Phase I,Approved for marketing,"[{'id': 792, 'therapyName': 'Lenvatinib'}]",An Expanded Access Program With Lenvatinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer,6934
15,NCT02432274,Phase Ib/II,Recruiting,"[{'id': 1136, 'therapyName': 'Etoposide'}, {'id': 792, 'therapyName': 'Lenvatinib'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}]",Study of Lenvatinib in Children and Adolescents With Refractory or Relapsed Solid Malignancies,6934
16,NCT02657369,Phase II,Recruiting,"[{'id': 792, 'therapyName': 'Lenvatinib'}]",A Phase 2 Trial of Lenvatinib for the Treatment of Anaplastic Thyroid Cancer (ATC),6934
17,NCT03008369,Phase II,Recruiting,"[{'id': 792, 'therapyName': 'Lenvatinib'}]",Lenvatinib in Treating Patients With Metastatic or Advanced Pheochromocytoma or Paraganglioma That Cannot Be Removed by Surgery,6934
18,NCT02702388,Phase II,Recruiting,"[{'id': 792, 'therapyName': 'Lenvatinib'}]","Phase 2 Trial of Lenvatinib (E7080) in Subjects With Iodine-131 Refractory Differentiated Thyroid Cancer to Evaluate Whether an Oral Starting Dose of 20 mg or 14 mg Daily Will Provide Comparable Efficacy to a 24 mg Starting Dose, But Have a Better Safety Profile",6934
19,NCT02686164,Phase I,"Active, not recruiting","[{'id': 3730, 'therapyName': 'Lenvatinib + Midazolam'}]",Phase 1 Study to Determine the Effect of Lenvatinib (E7080) on the Pharmacokinetics of Midazolam in Subjects With Advanced Solid Tumors,6934
20,NCT02788708,Phase I,Recruiting,"[{'id': 4236, 'therapyName': 'Lenvatinib + Paclitaxel'}]",Lenvatinib and Weekly Paclitaxel for Patients With Recurrent Endometrial or Ovarian Cancer,6934
21,NCT02973997,Phase II,Not yet recruiting,"[{'id': 4782, 'therapyName': 'Lenvatinib + Pembrolizumab'}]",Pembrolizumab and Lenvatinib in Treating Metastatic or Recurrent Differentiated Thyroid Cancer That Cannot Be Removed by Surgery,6934
22,NCT03006926,Phase I,Recruiting,"[{'id': 4782, 'therapyName': 'Lenvatinib + Pembrolizumab'}]",A Trial of Lenvatinib Plus Pembrolizumab in Subjects With Hepatocellular Carcinoma,6934
0,NCT01655225,Phase I,Recruiting,"[{'id': 1214, 'therapyName': 'LY3023414 + Midazolam '}, {'id': 1215, 'therapyName': ' LY3023414 + Letrozole '}, {'id': 1069, 'therapyName': 'LY3023414'}]",A Study of LY3023414 in Participants With Advanced Cancer,995
1,NCT02246621,Phase III,"Active, not recruiting","[{'id': 1854, 'therapyName': 'Abemaciclib + Anastrozole + Letrozole'}, {'id': 1853, 'therapyName': 'Anastrozole + Letrozole'}]",A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast Cancer,995
2,NCT02057133,Phase I,Recruiting,"[{'id': 2254, 'therapyName': 'Abemaciclib + Letrozole'}, {'id': 2257, 'therapyName': 'Abemaciclib + Exemestane'}, {'id': 2258, 'therapyName': 'Everolimus + Exemestane + LY2835219'}, {'id': 2255, 'therapyName': 'Abemaciclib + Anastrozole'}, {'id': 2256, 'therapyName': 'Abemaciclib + Tamoxifen'}, {'id': 2259, 'therapyName': 'Abemaciclib + Trastuzumab'}]",A Study of LY2835219 in Combination With Hormone Therapies for Breast Cancer That Has Spread,995
3,NCT03099174,Phase I,Recruiting,"[{'id': 5514, 'therapyName': 'Abemaciclib + Xentuzumab'}, {'id': 5515, 'therapyName': 'Abemaciclib + Letrozole + Xentuzumab'}, {'id': 5516, 'therapyName': 'Abemaciclib + Anastrozole + Xentuzumab'}, {'id': 5517, 'therapyName': 'Abemaciclib + Fulvestrant + Xentuzumab'}]",This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast Cancer.,995
4,NCT03054363,Phase Ib/II,Not yet recruiting,"[{'id': 5334, 'therapyName': 'ARRY-380 + Palbociclib + Letrozole'}]","Tucatinib, Palbociclib and Letrozole in Metastatic Hormone Receptor Positive and HER2-positive Breast Cancer",995
5,NCT01923168,Phase II,Completed,"[{'id': 1570, 'therapyName': 'BKM120 + Letrozole'}, {'id': 794, 'therapyName': 'Letrozole'}, {'id': 1553, 'therapyName': 'Letrozole + BYL719'}]","Study of Letrozole With or Without BYL719 or Buparlisib, for the Neoadjuvant Treatment of Postmenopausal Women",995
6,NCT03128619,Phase Ib/II,Recruiting,"[{'id': 5594, 'therapyName': 'Copanlisib + Palbociclib + Letrozole'}, {'id': 5593, 'therapyName': 'Copanlisib + Letrozole'}]","Copanlisib, Letrozole, and Palbociclib in Treating Patients With Hormone Receptor Positive HER2 Negative Stage I-IV Breast Cancer",995
7,NCT02101788,Phase II,Recruiting,"[{'id': 942, 'therapyName': 'Topotecan'}, {'id': 2173, 'therapyName': 'Doxil + Letrozole + Tamoxifen + Paclitaxel'}, {'id': 2, 'therapyName': 'Trametinib'}]",Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer,995
8,NCT02228681,Phase II,"Active, not recruiting","[{'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 2401, 'therapyName': 'Medroxyprogesterone'}, {'id': 1621, 'therapyName': 'Everolimus + Letrozole'}]",Everolimus and Letrozole or Hormonal Therapy to Treat Endometrial Cancer,995
9,NCT02291913,Phase II,"Active, not recruiting","[{'id': 2267, 'therapyName': 'Everolimus + Tamoxifen'}, {'id': 2268, 'therapyName': 'Anastrozole + Everolimus'}, {'id': 1589, 'therapyName': 'Fulvestrant + Everolimus'}, {'id': 1621, 'therapyName': 'Everolimus + Letrozole'}, {'id': 2269, 'therapyName': 'Everolimus + Toremifene'}, {'id': 1966, 'therapyName': 'Exemestane + Everolimus'}]",Everolimus Combined With Anti-estrogen Therapy in Hormone-Receptor-Positive HER-2 Negative Advanced Breast Cancer,995
10,NCT02188550,Phase II,Unknown status,"[{'id': 1621, 'therapyName': 'Everolimus + Letrozole'}]",Single Arm Trial With Combination of Everolimus and Letrozole in Treatment of Platinum Resistant Relapse or Refractory or Persistent Ovarian Cancer/Endometrial Cancer,995
11,NCT02283658,Phase II,"Active, not recruiting","[{'id': 1621, 'therapyName': 'Everolimus + Letrozole'}]","Everolimus and Letrozole in Treating Patients With Recurrent Hormone Receptor Positive Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer",995
12,NCT01698918,Phase II,"Active, not recruiting","[{'id': 1966, 'therapyName': 'Exemestane + Everolimus'}, {'id': 1621, 'therapyName': 'Everolimus + Letrozole'}]","Open-label, Phase II, Study of Everolimus Plus Letrozole in Postmenopausal Women With ER+, HER2- Metastatic or Locally Advanced Breast Cancer",995
13,NCT02152943,Phase I,Recruiting,"[{'id': 1591, 'therapyName': 'Everolimus + Letrozole + Trastuzumab'}]","Everolimus, Letrozole and Trastuzumab in HR- and HER2/Neu-positive Patients",995
14,NCT03006172,Phase I,Recruiting,"[{'id': 5182, 'therapyName': 'GDC-0077 + Letrozole + Palbociclib'}, {'id': 5181, 'therapyName': 'GDC-0077'}, {'id': 5184, 'therapyName': 'GDC-0077 + Fulvestrant'}, {'id': 5183, 'therapyName': 'GDC-0077 + Letrozole'}]","To Evaluate the Safety, Tolerability, and Pharmacokinetics of GDC-0077 Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer",995
15,NCT00790816,Phase I,Completed,"[{'id': 1410, 'therapyName': 'Lapatinib + Paclitaxel'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 1414, 'therapyName': 'Trastuzumab + Lapatinib'}, {'id': 1399, 'therapyName': 'Lapatinib + Capecitabine'}, {'id': 1497, 'therapyName': 'Lapatinib + Letrozole'}, {'id': 1498, 'therapyName': 'Lapatinib + Oxaliplatin + Capecitabine'}, {'id': 1499, 'therapyName': 'Lapatinib + Gemcitabine'}, {'id': 1500, 'therapyName': 'Lapatinib + Docetaxel'}, {'id': 1501, 'therapyName': 'Lapatinib + Oxaliplatin + Leucovorin + Fluorouracil'}, {'id': 1502, 'therapyName': 'Lapatinib + Irinotecan + Leucovorin + Fluorouracil'}]",Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents,995
16,NCT02154776,Phase I,Completed,"[{'id': 1594, 'therapyName': 'LEE011 + BKM120 + Letrozole'}]","Dose Escalation Study of LEE011 in Combination With Buparlisib and Letrozole in HR+, HER2-negative Post-menopausal Women With Advanced Breast Cancer. (LeeBLet)",995
17,NCT01872260,Phase Ib/II,Recruiting,"[{'id': 1553, 'therapyName': 'Letrozole + BYL719'}, {'id': 1569, 'therapyName': 'LEE011 + BYL719 + Letrozole'}, {'id': 1568, 'therapyName': 'LEE011 + Letrozole'}]","Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer",995
18,NCT03050398,Phase III,Recruiting,"[{'id': 1568, 'therapyName': 'LEE011 + Letrozole'}]",A Companion Sample Collection Protocol to Support the Discovery of Breast Cancer Aberrations With Treatment of CDK4/6 Therapy/LEE011/Ribociclib,995
19,NCT02657928,Phase II,Recruiting,"[{'id': 1568, 'therapyName': 'LEE011 + Letrozole'}]","Ribociclib and Letrozole in Treating Patients With Relapsed ER Positive Ovarian, Fallopian Tube, Primary Peritoneal or Endometrial Cancer",995
20,NCT02712723,Phase II,Recruiting,"[{'id': 1568, 'therapyName': 'LEE011 + Letrozole'}]","Letrozole Plus Ribociclib or Placebo as Neo-adjuvant Therapy in ER-positive, HER2-negative Early Breast Cancer",995
21,NCT02450175,Phase I,Unknown status,"[{'id': 794, 'therapyName': 'Letrozole'}, {'id': 735, 'therapyName': 'Everolimus'}]","Etiology of the Platelet-Cancer Metastatic Pathway - A Study of Inflammatory Markers, Platelet Characteristics and Metastatic Surrogates in Cancer Patients and Controls",995
22,NCT01674140,Phase III,Recruiting,"[{'id': 759, 'therapyName': 'Goserelin'}, {'id': 633, 'therapyName': 'Anastrozole'}, {'id': 794, 'therapyName': 'Letrozole'}, {'id': 795, 'therapyName': 'Leuprolide'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 738, 'therapyName': 'Exemestane'}]",S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer,995
23,NCT01296555,Phase I,Recruiting,"[{'id': 744, 'therapyName': 'Fulvestrant'}, {'id': 1016, 'therapyName': 'GDC-0032'}, {'id': 794, 'therapyName': 'Letrozole'}]",A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Patients With Locally Advanced or Metastatic Solid Tumors And in Combination With Endocrine Therapy in Patients With Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer,995
24,NCT02278120,Phase III,"Active, not recruiting","[{'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 794, 'therapyName': 'Letrozole'}, {'id': 790, 'therapyName': 'Ribociclib'}, {'id': 759, 'therapyName': 'Goserelin'}, {'id': 633, 'therapyName': 'Anastrozole'}]","Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer",995
25,NCT02619669,Phase I,Recruiting,"[{'id': 1282, 'therapyName': 'Sapanisertib'}, {'id': 794, 'therapyName': 'Letrozole'}]",Neoadjuvant Run-In Study With TAK-228 (MLN0128) Followed by Letrozole/TAK-228 (MLN0128) in Women With High-Risk ER+/HER2- Breast Cancer,995
26,NCT01669343,Phase I,"Active, not recruiting","[{'id': 794, 'therapyName': 'Letrozole'}]",Aromatase Inhibitor Host Factors Study,995
27,NCT02296801,Phase II,Recruiting,"[{'id': 850, 'therapyName': 'Palbociclib'}, {'id': 794, 'therapyName': 'Letrozole'}]",A Phase II Randomized Study Evaluating the Biological and Clinical Effects of the Combination of Palbociclib With Letrozole as Neoadjuvant Therapy in Post-Menopausal Women With Estrogen-Receptor Positive Primary Breast Cancer,995
28,NCT02115048,Phase II,"Active, not recruiting","[{'id': 623, 'therapyName': 'Afatinib'}, {'id': 794, 'therapyName': 'Letrozole'}]",Clinical Study for the Treatment of Breast Cancer the Patient Will Receive Afatinib Plus Letrozole or Letrozole Alone,995
29,NCT02188745,Phase II,Recruiting,"[{'id': 738, 'therapyName': 'Exemestane'}, {'id': 1643, 'therapyName': 'Estradiol'}, {'id': 633, 'therapyName': 'Anastrozole'}, {'id': 794, 'therapyName': 'Letrozole'}]",ER Reactivation Therapy for Breast Cancer,995
30,NCT01035099,Phase I,Recruiting,"[{'id': 794, 'therapyName': 'Letrozole'}]",RCT of Fixed vs Titrated Letrozole in Breast Cancer Patient Undergoing IVF,995
31,NCT02204098,Phase I,Recruiting,"[{'id': 794, 'therapyName': 'Letrozole'}, {'id': 633, 'therapyName': 'Anastrozole'}, {'id': 759, 'therapyName': 'Goserelin'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 1456, 'therapyName': 'Tamoxifen'}]",Safety and Immune Response to a Mammaglobin-A DNA Vaccine In Breast Cancer Patients Undergoing Neoadjuvant Endocrine Therapy,995
32,NCT01491737,Phase II,"Active, not recruiting","[{'id': 633, 'therapyName': 'Anastrozole'}, {'id': 794, 'therapyName': 'Letrozole'}, {'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}]","A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Patients With Hormone Receptor-Positive, Metastatic HER2-positive Breast Cancer",995
33,NCT01272037,Phase III,Recruiting,"[{'id': 633, 'therapyName': 'Anastrozole'}, {'id': 794, 'therapyName': 'Letrozole'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 738, 'therapyName': 'Exemestane'}]","Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer",995
34,NCT02095184,Phase I,Recruiting,"[{'id': 633, 'therapyName': 'Anastrozole'}, {'id': 794, 'therapyName': 'Letrozole'}]",GCC 1366 Anti-Proliferative Response to NeoAdjuvant AIs in Overweight and Obese Patients,995
35,NCT02764541,Phase II,Recruiting,"[{'id': 850, 'therapyName': 'Palbociclib'}, {'id': 794, 'therapyName': 'Letrozole'}, {'id': 1456, 'therapyName': 'Tamoxifen'}]",Palbociclib and Endocrine Therapy for LObular Breast Cancer Preoperative Study (PELOPS),995
36,NCT01797523,Phase II,"Active, not recruiting","[{'id': 794, 'therapyName': 'Letrozole'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 1031, 'therapyName': 'Metformin'}]",RAD/Letrozole/Metformin,995
37,NCT00651976,Phase I,Suspended,"[{'id': 794, 'therapyName': 'Letrozole'}]","Letrozole in Treating Postmenopausal Women With Stage I, II or III Breast Cancer That Can Be Removed by Surgery",995
38,NCT01160211,Phase III,"Active, not recruiting","[{'id': 1414, 'therapyName': 'Trastuzumab + Lapatinib'}, {'id': 794, 'therapyName': 'Letrozole'}, {'id': 633, 'therapyName': 'Anastrozole'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 738, 'therapyName': 'Exemestane'}]","A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer",995
39,NCT02648477,Phase II,Recruiting,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 794, 'therapyName': 'Letrozole'}, {'id': 633, 'therapyName': 'Anastrozole'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 1009, 'therapyName': 'Doxorubicin'}]",Pembrolizumab and Doxorubicin Hydrochloride or Anti-Estrogen Therapy in Treating Patients With Triple-Negative or Hormone Receptor-Positive Metastatic Breast Cancer,995
40,NCT02689921,Phase II,Recruiting,"[{'id': 633, 'therapyName': 'Anastrozole'}, {'id': 794, 'therapyName': 'Letrozole'}, {'id': 795, 'therapyName': 'Leuprolide'}, {'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}, {'id': 738, 'therapyName': 'Exemestane'}]",NEOADjuvant Aromatase Inhibitor and Pertuzumab/Trastuzumab for Women With Breast Cancer (NEOADAPT),995
41,NCT00461773,Phase II,Unknown status,"[{'id': 794, 'therapyName': 'Letrozole'}, {'id': 667, 'therapyName': 'Bevacizumab'}]",Randomized Phase II Study of Preoperative Letrozole (Femara) in Combination With Avastin in Hormone Receptor Positive Breast Cancer,995
42,NCT02753686,Phase I,Recruiting,"[{'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 744, 'therapyName': 'Fulvestrant'}, {'id': 794, 'therapyName': 'Letrozole'}, {'id': 633, 'therapyName': 'Anastrozole'}, {'id': 1966, 'therapyName': 'Exemestane + Everolimus'}]",Treatment of Canadian Postmenopausal Women With ER+ Advanced Breast Cancer in the Real-World Setting With Hormone Therapy ± Targeted Therapy (Treat ER+ight),995
43,NCT02269670,Phase II,"Active, not recruiting","[{'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 1869, 'therapyName': 'Megestrol'}, {'id': 794, 'therapyName': 'Letrozole'}, {'id': 744, 'therapyName': 'Fulvestrant'}, {'id': 633, 'therapyName': 'Anastrozole'}]",Everolimus and Hormone Therapy in Treating Patients With Advanced Hormone Receptor Positive Breast Cancer That Has Progressed or Recurred on Everolimus and Exemestane Therapy,995
44,NCT03122197,Phase I,Recruiting,"[{'id': 794, 'therapyName': 'Letrozole'}]",Study of Letrozole in Recurrent Gliomas,995
45,NCT02947685,Phase III,Recruiting,"[{'id': 744, 'therapyName': 'Fulvestrant'}, {'id': 856, 'therapyName': 'Pertuzumab'}, {'id': 794, 'therapyName': 'Letrozole'}, {'id': 633, 'therapyName': 'Anastrozole'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 947, 'therapyName': 'Trastuzumab'}]","Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer (PATINA)",995
46,NCT02684032,Phase I,Recruiting,"[{'id': 794, 'therapyName': 'Letrozole'}, {'id': 744, 'therapyName': 'Fulvestrant'}, {'id': 4034, 'therapyName': 'Gedatolisib + Palbociclib'}]",A Study To Assess The Tolerability And Clinical Activity Of Gedatolisib In Combination With Palbociclib/Letrozole Or Palbociclib/Fulvestrant In Women With Metastatic Breast Cancer,995
47,NCT02040857,Phase II,"Active, not recruiting","[{'id': 738, 'therapyName': 'Exemestane'}, {'id': 850, 'therapyName': 'Palbociclib'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 794, 'therapyName': 'Letrozole'}, {'id': 633, 'therapyName': 'Anastrozole'}]",Palbociclib + Endocrine Therapy for HR + BrCa,995
48,NCT02520063,Phase Ib/II,Recruiting,"[{'id': 794, 'therapyName': 'Letrozole'}, {'id': 1242, 'therapyName': 'TRC105'}, {'id': 735, 'therapyName': 'Everolimus'}]","Preoperative Combination of Letrozole, Everolimus, and TRC105 in Postmenopausal Hormone-Receptor Positive and Her2 Negative Breast Cancer",995
49,NCT01958021,Phase III,"Active, not recruiting","[{'id': 790, 'therapyName': 'Ribociclib'}, {'id': 794, 'therapyName': 'Letrozole'}]",Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer.(MONALEESA-2),995
50,NCT03238703,FDA approved,Not yet recruiting,"[{'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 4419, 'therapyName': 'Toremifine'}, {'id': 633, 'therapyName': 'Anastrozole'}, {'id': 794, 'therapyName': 'Letrozole'}]","Endocrine Therapy in Treating Patients With HER2 Negative, Low Risk Breast Cancer",995
51,NCT02010021,Phase I,"Active, not recruiting","[{'id': 794, 'therapyName': 'Letrozole'}]",Presurgical Treatment With Letrozole in Patients With Early-stage Breast Cancer.,995
52,NCT01870505,Phase I,"Active, not recruiting","[{'id': 2318, 'therapyName': 'BYL719 + Exemestane'}, {'id': 1553, 'therapyName': 'Letrozole + BYL719'}]",BYL719 Plus Letrozole or Exemestane for Patients With Hormone-Receptor Positive Locally-Advanced Unresectable or Metastatic Breast Cancer,995
53,NCT03056755,Phase II,Recruiting,"[{'id': 5929, 'therapyName': 'Alpelisib + Fulvestrant'}, {'id': 1553, 'therapyName': 'Letrozole + BYL719'}]","Efficacy and Safety of Treatment With Alpelisib Plus Endocrine Therapy in Patients With HR+, HER2-negative aBC, With PIK3CA Mutations, Whose Disease Has Progressed on or After CDK 4/6 Treatment With an Aromatase Inhibitor (AI) or Fulvestrant",995
54,NCT01791478,Phase I,"Active, not recruiting","[{'id': 1553, 'therapyName': 'Letrozole + BYL719'}]",BYL719 and Letrozole in Post-Menopausal Patients With Hormone Receptor-Positive Metastatic Breast Cancer,995
55,NCT02778685,Phase II,Recruiting,"[{'id': 4222, 'therapyName': 'Letrozole + Palbociclib + Pembrolizumab'}]","Pembrolizumab, Letrozole, and Palbociclib in Treating Patients With Stage IV Estrogen Receptor Positive Breast Cancer With Stable Disease That Has Not Responded to Letrozole and Palbociclib",995
56,NCT02907918,Phase II,Recruiting,"[{'id': 759, 'therapyName': 'Goserelin'}, {'id': 4756, 'therapyName': 'Letrozole + Palbociclib + Trastuzumab'}]",Neoadjuvant Study of Palbociclib in Combination With Letrozole and Trastuzumab in Stage II-III ER+ HER2+ Breast Cancer (PALTAN),995
57,NCT02142868,Phase III,No longer available,"[{'id': 2922, 'therapyName': 'Palbociclib + Letrozole'}]","Expanded Access Study Of Palbociclib (PD-0332991) In Combination With Letrozole As Treatment Of Post-Menopausal Women With HR-Positive, Her2-Negative Advanced Breast Cancer For Whom Letrozole Therapy Is Deemed Appropriate",995
58,NCT02692755,Phase II,Recruiting,"[{'id': 2922, 'therapyName': 'Palbociclib + Letrozole'}]",Palbociclib / Letrozole in African American Women With HR+ HER2- Breast Cancer (PALINA),995
59,NCT03007979,Phase II,Recruiting,"[{'id': 759, 'therapyName': 'Goserelin'}, {'id': 3205, 'therapyName': 'Fulvestrant + Palbociclib'}, {'id': 2922, 'therapyName': 'Palbociclib + Letrozole'}]",Alternative Dosing Schedule of Palbociclib in Metastatic Hormone Receptor Positive Breast Cancer,995
60,NCT03008408,Phase II,Recruiting,"[{'id': 5180, 'therapyName': 'Ribociclib + Everolimus + Letrozole'}]","Phase II Ribociclib, Everolimus and Letrozole in Endometrial Cancer",995
61,NCT02941926,Phase III,Recruiting,"[{'id': 5310, 'therapyName': 'Ribociclib + Letrozole + Goserelin'}]",Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC,995
0,NCT03050814,Phase II,Suspended,"[{'id': 1524, 'therapyName': 'Fluorouracil + Bevacizumab + Capecitabine + Leucovorin + Oxaliplatin'}, {'id': 5336, 'therapyName': 'Ad-CEA + Bevacizumab + FOLFOX'}]",Standard of Care Alone or in Combination With Ad-CEA Vaccine and Avelumab in People With Previously Untreated Metastatic Colorectal Cancer,640
1,NCT01571284,Phase III,Completed,"[{'id': 2095, 'therapyName': 'Aflibercept + FOLFIRI'}]",Safety and Quality of Life Study of Aflibercept in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen,640
2,NCT02045030,Phase II,Terminated,"[{'id': 2095, 'therapyName': 'Aflibercept + FOLFIRI'}]",Study to Identify Biomarkers of Clinical Response to Aflibercept in Patients With Metastatic Colorectal Cancer,640
3,NCT02235324,Phase II,Withdrawn,"[{'id': 1841, 'therapyName': 'Aflibercept + Leucovorin + Fluorouracil'}, {'id': 624, 'therapyName': 'Aflibercept'}]","Ziv-Aflibercept Followed by Ziv-Aflibercept, Fluorouracil, and Leucovorin Calcium in Treating Patients With Stage IV Colorectal Cancer",640
4,NCT01652196,Phase II,"Active, not recruiting","[{'id': 2367, 'therapyName': 'Aflibercept + mFOLFOX-6'}]",Aflibercept and FOLFOX6 Treatment for Previously Untreated Stage IV Colorectal Cancer,640
5,NCT02923921,Phase III,Recruiting,"[{'id': 5849, 'therapyName': 'AM0010 + mFOLFOX-6'}, {'id': 5850, 'therapyName': 'mFOLFOX-6'}]",Study of AM0010 With FOLFOX Compared to FOLFOX Alone Second-line Tx in Pts With Metastatic Pancreatic Cancer,640
6,NCT02997228,Phase III,Not yet recruiting,"[{'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 1484, 'therapyName': 'Bevacizumab + Oxaliplatin + Leucovorin + Fluorouracil'}, {'id': 5126, 'therapyName': 'Bevacizumab + Atezolizumab + Fluorouracil + Leucovorin + Oxaliplatin'}]","Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Microsatellite Instability-High Metastatic Colorectal Cancer",640
7,NCT02141295,Phase II,Completed,"[{'id': 1484, 'therapyName': 'Bevacizumab + Oxaliplatin + Leucovorin + Fluorouracil'}, {'id': 1598, 'therapyName': 'RO5520985'}, {'id': 1599, 'therapyName': 'Bevacizumab + Fluorouracil + Leucovorin'}, {'id': 1600, 'therapyName': 'RO5520985 + Leucovorin + Fluorouracil'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}]",A Study Comparing the Efficacy and Safety of RO5520985 and FOLFOX With Bevacizumab and FOLFOX in Patients With Untreated Metastatic Colorectal Cancer (McCAVE),640
8,NCT01442935,Phase II,"Active, not recruiting","[{'id': 1484, 'therapyName': 'Bevacizumab + Oxaliplatin + Leucovorin + Fluorouracil'}, {'id': 2180, 'therapyName': 'Cetuximab + FOLFIRI'}, {'id': 2181, 'therapyName': 'Bevacizumab + FOLFIRI'}, {'id': 2182, 'therapyName': 'Cetuximab + FOLFOX'}, {'id': 2183, 'therapyName': 'Bevacizumab + FOLFIRINOX'}, {'id': 2184, 'therapyName': 'Cetuximab + FOLFIRINOX'}]",Chemotherapies Associated With Targeted Therapies on the Resection Rate of Hepatic Metastases,640
9,NCT02754856,Phase I,Recruiting,"[{'id': 4097, 'therapyName': 'Bevacizumab + MEDI4736 + Tremelimumab + FOLFOX'}]",Tremelimumab (Anti-CTLA-4) Plus MEDI4736 (Anti-PD-L1) in Resectable Colorectal Cancer Liver Metastases.,640
10,NCT01871571,Phase II,Recruiting,"[{'id': 1484, 'therapyName': 'Bevacizumab + Oxaliplatin + Leucovorin + Fluorouracil'}]","Bevacizumab, Fluorouracil, Leucovorin Calcium, and Oxaliplatin Before Surgery in Treating Patients With Stage II-III Rectal Cancer",640
11,NCT01212822,Phase II,"Active, not recruiting","[{'id': 1484, 'therapyName': 'Bevacizumab + Oxaliplatin + Leucovorin + Fluorouracil'}]",Bevacizumab and Combination Chemotherapy Before Surgery in Treating Patients With Locally Advanced Esophageal or Stomach Cancer,640
12,NCT01006369,Phase II,Completed,"[{'id': 1316, 'therapyName': 'Hydroxychloroquine'}, {'id': 1601, 'therapyName': 'Capecitabine + Oxaliplatin + Bevacizumab'}, {'id': 1484, 'therapyName': 'Bevacizumab + Oxaliplatin + Leucovorin + Fluorouracil'}]","Hydroxychloroquine, Capecitabine, Oxaliplatin, and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer",640
13,NCT01622543,Phase II,"Active, not recruiting","[{'id': 1484, 'therapyName': 'Bevacizumab + Oxaliplatin + Leucovorin + Fluorouracil'}, {'id': 893, 'therapyName': 'Reolysin'}]",Reolysin in Combination With FOLFOX6 and Bevacizumab or FOLFOX6 and Bevacizumab Alone in Metastatic Colorectal Cancer,640
14,NCT01765582,Phase II,Terminated,"[{'id': 1523, 'therapyName': 'Fluorouracil + Capecitabine + Irinotecan + Leucovorin + Oxaliplatin'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1484, 'therapyName': 'Bevacizumab + Oxaliplatin + Leucovorin + Fluorouracil'}]",STEAM: A Study of Sequential and Concurrent FOLFOXIRI/Avastin (Bevacizumab) Regimens Versus FOLFOX/Avastin in First-Line in Patients With Metastatic Colorectal Cancer,640
15,NCT02613650,Phase I,Recruiting,"[{'id': 3247, 'therapyName': 'Binimetinib + FOLFIRI'}]",A Trial of FOLFIRI With MEK162 in Patients With Advanced KRAS Positive Metastatic Colorectal Cancers,640
16,NCT03184870,Phase Ib/II,Recruiting,"[{'id': 5905, 'therapyName': 'BMS-813160 + Fluorouracil + Irinotecan + Leucovorin'}, {'id': 5903, 'therapyName': 'BMS-813160 + Nivolumab'}, {'id': 5904, 'therapyName': 'BMS-813160 + Gemcitabine + nab-paclitaxel'}, {'id': 5902, 'therapyName': 'BMS-813160'}]",A Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Patients With Advanced Solid Tumors,640
17,NCT02573220,Phase I,Withdrawn,"[{'id': 2180, 'therapyName': 'Cetuximab + FOLFIRI'}]",Irinotecan Hydrochloride With FOLFIRI and Cetuximab as First-Line Therapy in Treating Patients With RAS Wild-Type Colorectal Cancer,640
18,NCT02928224,Phase III,Recruiting,"[{'id': 1916, 'therapyName': 'Cetuximab + Encorafenib'}, {'id': 4886, 'therapyName': 'Binimetinib + Cetuximab + LGX818'}, {'id': 1874, 'therapyName': 'Cetuximab + Irinotecan'}, {'id': 2180, 'therapyName': 'Cetuximab + FOLFIRI'}]",Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer (BEACON CRC),640
19,NCT01703390,Phase II,Unknown status,"[{'id': 2182, 'therapyName': 'Cetuximab + FOLFOX'}, {'id': 2180, 'therapyName': 'Cetuximab + FOLFIRI'}]",Biomarker Directed Treatment in Metastatic Colorectal Cancer,640
20,NCT02676323,Phase Ib/II,Recruiting,"[{'id': 3732, 'therapyName': 'Cytarabine + Fludarabine + Leucovorin + Panobinostat'}]",Panobinostat With Fludarabine and Cytarabine for Treatment of Children With Acute Myeloid Leukemia or Myelodysplastic Syndrome,640
21,NCT03152370,Phase I,Recruiting,"[{'id': 5798, 'therapyName': 'E7046 + mFOLFOX-6'}, {'id': 5805, 'therapyName': 'Capecitabine + E7046'}]",Preoperative Radiotherapy and E7046 in Rectum Cancer (PRAER 1),640
22,NCT02620800,Phase Ib/II,Recruiting,"[{'id': 3621, 'therapyName': 'FABLOx'}]","Study of 5-fluorouracil (5-FU), Nab-paclitaxel, Bevacizumab, Leucovorin, and Oxaliplatin in Patients With Metastatic Pancreatic Cancer",640
23,NCT03069950,Phase II,Recruiting,"[{'id': 5476, 'therapyName': 'Floxiuridine + Panitumumab + Dexamethasone + FOLFIRI'}]",Study of Chemotherapy With or Without Hepatic Arterial Infusion for Patients With Unresectable Metastatic Colorectal Cancer to the Liver,640
24,NCT02785068,Phase I,Withdrawn,"[{'id': 4532, 'therapyName': 'Fluorouracil + Irinotecan + Leucovorin + MM-151'}]",Evaluation of MM-151 + Nal-IRI + 5-FU + Leucovorin in RAS/RAF Wild-type Metastatic Colorectal Cancer,640
25,NCT02448810,Phase II,Terminated,"[{'id': 2278, 'therapyName': 'Fluorouracil + Leucovorin'}, {'id': 2996, 'therapyName': 'Imalumab'}, {'id': 845, 'therapyName': 'Panitumumab'}]",Phase 2a Study of BAX69 and 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer,640
26,NCT02042443,Phase II,Completed,"[{'id': 2278, 'therapyName': 'Fluorouracil + Leucovorin'}, {'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 2, 'therapyName': 'Trametinib'}]",Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery,640
27,NCT02620865,Phase Ib/II,Suspended,"[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1167, 'therapyName': 'Aldesleukin'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 1873, 'therapyName': 'Sargramostim'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 2278, 'therapyName': 'Fluorouracil + Leucovorin'}]",Bispecific Antibody Armed Activated T-cells With Aldesleukin and Sargramostim in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer,640
28,NCT01959672,Phase II,Recruiting,"[{'id': 827, 'therapyName': 'Nelfinavir'}, {'id': 1189, 'therapyName': 'Oregovomab'}, {'id': 2278, 'therapyName': 'Fluorouracil + Leucovorin'}, {'id': 755, 'therapyName': 'Gemcitabine'}]",Combination Chemotherapy With or Without Oregovomab Followed by Stereotactic Body Radiation Therapy and Nelfinavir Mesylate in Treating Patients With Locally Advanced Pancreatic Cancer,640
29,NCT01383538,Phase I,Completed,"[{'id': 2498, 'therapyName': 'Fluorouracil + Leucovorin + Irinotecan + Oxaliplatin + Saridegib'}]",FOLFIRINOX Plus IPI-926 for Advanced Pancreatic Adenocarcinoma,640
30,NCT02124148,Phase I,Recruiting,"[{'id': 1994, 'therapyName': 'Cisplatin + Prexasertib'}, {'id': 1993, 'therapyName': 'Cetuximab + Prexasertib'}, {'id': 6248, 'therapyName': 'Pemetrexed + Prexasertib'}, {'id': 6247, 'therapyName': 'LY3023414 + Prexasertib'}, {'id': 6246, 'therapyName': 'Fluoruracil + Leucovorin + Prexasertib'}]",A Study of LY2606368 With Cisplatin or Cetuximab in Participants With Advanced Cancer,640
31,NCT01814501,Phase II,Recruiting,"[{'id': 1315, 'therapyName': 'FOLFIRI'}, {'id': 845, 'therapyName': 'Panitumumab'}]",Panitumumab and Chemotherapy in Patients With Advanced Colorectal Cancer After Prior Therapy With Bevacizumab,640
32,NCT02046538,Phase II,Withdrawn,"[{'id': 1315, 'therapyName': 'FOLFIRI'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 624, 'therapyName': 'Aflibercept'}]",Phase II Study of Zaltrap and Chemotherapy for Advanced Resectable Colorectal Cancer,640
33,NCT02482441,Phase I,Recruiting,"[{'id': 4401, 'therapyName': 'Rosmantuzumab'}, {'id': 1315, 'therapyName': 'FOLFIRI'}]","A Phase 1a/b Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of OMP-131R10",640
34,NCT01312857,Phase II,Recruiting,"[{'id': 845, 'therapyName': 'Panitumumab'}, {'id': 1315, 'therapyName': 'FOLFIRI'}, {'id': 1941, 'therapyName': 'Floxuridine'}]","Study of Hepatic Arterial Infusion With Intravenous Irinotecan, 5FU and Leucovorin With or Without Panitumumab, in Patients With Wild Type KRAS Who Have Resected Hepatic Metastases From Colorectal Cancer",640
35,NCT01488552,Phase Ib/II,Completed,"[{'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 1315, 'therapyName': 'FOLFIRI'}, {'id': 1779, 'therapyName': 'Nab-paclitaxel + Gemcitabine'}, {'id': 1031, 'therapyName': 'Metformin'}]",Gemcitabine+Nab-paclitaxel and FOLFIRINOX and Molecular Profiling for Patients With Advanced Pancreatic Cancer,640
36,NCT01274624,Phase I,"Active, not recruiting","[{'id': 1315, 'therapyName': 'FOLFIRI'}, {'id': 2099, 'therapyName': 'Bevacizumab + Reolysin'}]",Study of REOLYSIN; in Combination With FOLFIRI and Bevacizumab in FOLFIRI Naive Patients With KRAS Mutant Metastatic Colorectal Cancer,640
37,NCT02024607,Phase Ib/II,"Active, not recruiting","[{'id': 1597, 'therapyName': 'Capecitabine + Oxaliplatin'}, {'id': 2093, 'therapyName': 'BBI608 + Bevacizumab'}, {'id': 2094, 'therapyName': 'BBI608 + Regorafenib'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 2057, 'therapyName': 'BBI608'}, {'id': 1315, 'therapyName': 'FOLFIRI'}]",A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer,640
38,NCT01260415,Phase II,Completed,"[{'id': 845, 'therapyName': 'Panitumumab'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 1315, 'therapyName': 'FOLFIRI'}]",A Study of Perioperative Chemotherapy Plus Panitumumab in Patients With Colorectal Cancer Liver Metastases,640
39,NCT02605044,Phase III,Recruiting,"[{'id': 804, 'therapyName': 'Masitinib'}, {'id': 1315, 'therapyName': 'FOLFIRI'}]",Study to Compare the Efficacy and Safety of Masitinib in Combination With FOLFIRI to Placebo in Combination With FOLFIRI in Second Line Treatment of Patients With Metastatic Colorectal Cancer,640
40,NCT02753127,Phase III,Recruiting,"[{'id': 1315, 'therapyName': 'FOLFIRI'}, {'id': 2057, 'therapyName': 'BBI608'}]",A Study of Napabucasin (BBI-608) in Combination With FOLFIRI in Adult Patients With Previously Treated Metastatic Colorectal Cancer (CanStem303C),640
41,NCT02305758,Phase II,Completed,"[{'id': 1315, 'therapyName': 'FOLFIRI'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 954, 'therapyName': 'Veliparib'}]",Study Comparing Veliparib Plus FOLFIRI Versus Placebo Plus FOLFIRI With or Without Bevacizumab in Previously Untreated Metastatic Colorectal Cancer,640
42,NCT02508077,Phase II,Terminated,"[{'id': 1315, 'therapyName': 'FOLFIRI'}, {'id': 845, 'therapyName': 'Panitumumab'}]",FOLFIRI and Panitumumab in Treating Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer,640
43,NCT01803282,Phase I,Recruiting,"[{'id': 3320, 'therapyName': 'GS-5745'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 1602, 'therapyName': 'Carboplatin + Pemetrexed'}, {'id': 1315, 'therapyName': 'FOLFIRI'}, {'id': 1779, 'therapyName': 'Nab-paclitaxel + Gemcitabine'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 667, 'therapyName': 'Bevacizumab'}]",Safety and Tolerability Study in Solid Tumors,640
44,NCT01298570,Phase II,"Active, not recruiting","[{'id': 1315, 'therapyName': 'FOLFIRI'}, {'id': 890, 'therapyName': 'Regorafenib'}]",Regorafenib+FOLFIRI Versus Placebo+FOLFIRI as 2nd Line Tx in Metastatic Colorectal Cancer,640
45,NCT01653470,Phase I,"Active, not recruiting","[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1315, 'therapyName': 'FOLFIRI'}, {'id': 2545, 'therapyName': 'BMS-906024'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]","Study to Evaluate Safety & Tolerability of BMS-906024 in Combination With Chemotherapy & to Define DLTs & MTD of BMS-906024 in Combination With One of the Following Chemotherapy Regimens; Weekly Paclitaxel, 5FU+Irinotecan or Carboplatin+Paclitaxel in Subjects With Advanced / Metastatic Solid Tumors",640
46,NCT01937715,Phase II,Terminated,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1040, 'therapyName': 'PF-05212384'}, {'id': 1315, 'therapyName': 'FOLFIRI'}]",A Study Of PF-05212384 Plus FOLFIRI Versus Bevacizumab Plus FOLFIRI In Metastatic Colorectal Cancer,640
47,NCT02890355,,Recruiting,"[{'id': 954, 'therapyName': 'Veliparib'}, {'id': 1315, 'therapyName': 'FOLFIRI'}]",FOLFIRI or Modified FOLFIRI and Veliparib as Second Line Therapy in Treating Patients With Metastatic Pancreatic Cancer,640
48,NCT02563002,Phase III,Recruiting,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1315, 'therapyName': 'FOLFIRI'}, {'id': 694, 'therapyName': 'Cetuximab'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}]",Study of Pembrolizumab (MK-3475) vs Standard Therapy in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (MK-3475-177/KEYNOTE-177),640
49,NCT02213289,Phase Ib/II,Recruiting,"[{'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 1913, 'therapyName': 'FOLTAX'}, {'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 1315, 'therapyName': 'FOLFIRI'}, {'id': 629, 'therapyName': 'AMG102'}]",PANGEA-IMBBP: Personalized Antibodies for Gastro-Esophageal Adenocarcinoma - A 1st Pilot Metastatic Trial of Biologics Beyond Progression,640
50,NCT01472016,Phase I,Completed,"[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1063, 'therapyName': 'ABT-700'}, {'id': 694, 'therapyName': 'Cetuximab'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 1315, 'therapyName': 'FOLFIRI'}]",Study of ABT-700 in Subjects With Advanced Solid Tumors,640
51,NCT01652482,Phase II,Completed,"[{'id': 694, 'therapyName': 'Cetuximab'}, {'id': 806, 'therapyName': 'MEHD7945A'}, {'id': 1315, 'therapyName': 'FOLFIRI'}]",A Study of MEHD7945A + FOLFIRI Versus Cetuximab + FOLFIRI in Second Line in Patients With KRAS Wild-Type Metastatic Colorectal Cancer,640
52,NCT03035253,Phase I,Recruiting,"[{'id': 5297, 'therapyName': 'FOLFIRI + OMP-305B83'}]",A Study of OMP-305B83 in Subjects With Metastatic Colorectal Cancer,640
53,NCT02568046,Phase Ib/II,"Active, not recruiting","[{'id': 3949, 'therapyName': 'FOLFIRI + SYM004'}]",Sym004 in Combination With FOLFIRI in Metastatic Colorectal Cancer Patients,640
54,NCT01485744,Phase I,"Active, not recruiting","[{'id': 1903, 'therapyName': 'FOLFIRINOX'}, {'id': 1428, 'therapyName': 'Sonidegib'}]","LDE225 With Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan for Untreated Advanced Pancreatic Cancer",640
55,NCT01821729,Phase II,Recruiting,"[{'id': 1903, 'therapyName': 'FOLFIRINOX'}, {'id': 2998, 'therapyName': 'Losartan'}]",Proton w/FOLFIRINOX-Losartan for Pancreatic Cancer,640
56,NCT01928290,Phase II,Recruiting,"[{'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 1903, 'therapyName': 'FOLFIRINOX'}]","Combination Chemotherapy in Treating Patients With Advanced Stomach, Gastroesophageal, or Esophageal Cancer",640
57,NCT01896869,Phase II,Suspended,"[{'id': 1903, 'therapyName': 'FOLFIRINOX'}, {'id': 779, 'therapyName': 'Ipilimumab'}]","A Phase 2, Multicenter Study of FOLFIRINOX Followed by Ipilimumab With Allogenic GM-CSF Transfected Pancreatic Tumor Vaccine in the Treatment of Metastatic Pancreatic Cancer",640
58,NCT02581215,Phase II,Recruiting,"[{'id': 886, 'therapyName': 'Ramucirumab'}, {'id': 1903, 'therapyName': 'FOLFIRINOX'}]",Phase II Randomized Trial of FOLFIRINOX +/- Ramucirumab in Advanced Pancreatic Cancer,640
59,NCT03193190,Phase Ib/II,Recruiting,"[{'id': 5942, 'therapyName': 'Atezolizumab + BKT140'}, {'id': 5940, 'therapyName': 'Gemcitabine + Nab-Paclitaxel + mFOLFOX-6'}, {'id': 5941, 'therapyName': 'Atezolizumab + PEGPH20'}, {'id': 1343, 'therapyName': 'Atezolizumab + Cobimetinib'}]",A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (PDAC),640
60,NCT03085914,Phase Ib/II,Recruiting,"[{'id': 5483, 'therapyName': 'INCB024360 + Nivolumab + mFOLFOX6'}, {'id': 5484, 'therapyName': 'INCB024360 + Nivolumab + Gemcitabine + nab-paclitaxel'}, {'id': 5485, 'therapyName': 'INCB024360 + Pembrolizumab + Carboplatin + Paclitaxel'}, {'id': 5486, 'therapyName': 'INCB024360 + Pembrolizumab + Carboplatin + Pemetrexed'}, {'id': 5487, 'therapyName': 'INCB024360 + Pembrolizumab + Cyclophosphamide'}]",A Study of Epacadostat in Combination With a PD-1 Inhibitor and Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors (ECHO-207),640
61,NCT00790816,Phase I,Completed,"[{'id': 1410, 'therapyName': 'Lapatinib + Paclitaxel'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 1414, 'therapyName': 'Trastuzumab + Lapatinib'}, {'id': 1399, 'therapyName': 'Lapatinib + Capecitabine'}, {'id': 1497, 'therapyName': 'Lapatinib + Letrozole'}, {'id': 1498, 'therapyName': 'Lapatinib + Oxaliplatin + Capecitabine'}, {'id': 1499, 'therapyName': 'Lapatinib + Gemcitabine'}, {'id': 1500, 'therapyName': 'Lapatinib + Docetaxel'}, {'id': 1501, 'therapyName': 'Lapatinib + Oxaliplatin + Leucovorin + Fluorouracil'}, {'id': 1502, 'therapyName': 'Lapatinib + Irinotecan + Leucovorin + Fluorouracil'}]",Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents,640
62,NCT02138617,Phase II,Recruiting,"[{'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 1715, 'therapyName': 'Fluorouracil'}]",Genotype-Directed Study Of Irinotecan Dosing In FOLFIRI + BevacizumabTreated Metastatic Colorectal Cancer,640
63,NCT01535053,Phase III,"Active, not recruiting","[{'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 2601, 'therapyName': 'Dactinomycin'}, {'id': 1639, 'therapyName': 'Methotrexate'}]",Methotrexate or Dactinomycin in Treating Patients With Low-Risk Gestational Trophoblastic Neoplasia,640
64,NCT03136406,Phase Ib/II,Recruiting,"[{'id': 1018, 'therapyName': 'GI-4000'}, {'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 3144, 'therapyName': 'Avelumab'}, {'id': 619, 'therapyName': 'Abraxane'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 6163, 'therapyName': 'ETBX-011'}, {'id': 3060, 'therapyName': 'ALT-803'}]",QUILT-3.039: NANT Pancreatic Cancer Vaccine: Combination Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy,640
65,NCT03007147,Phase III,Recruiting,"[{'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 5153, 'therapyName': 'dexrazoxane'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 5167, 'therapyName': 'Methylprednisolone'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 5168, 'therapyName': 'Prednisolone'}, {'id': 1009, 'therapyName': 'Doxorubicin'}]",Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia,640
66,NCT02883049,Phase III,Suspended,"[{'id': 717, 'therapyName': 'Dasatinib'}, {'id': 4685, 'therapyName': 'Dexamethasone + Doxorubicin'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1746, 'therapyName': 'Clofarabine'}]",Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations,640
67,NCT01424982,Phase II,Recruiting,"[{'id': 1476, 'therapyName': 'Pegfilgrastim'}, {'id': 2048, 'therapyName': 'Cytarabine + Methotrexate + Ponatinib'}, {'id': 2049, 'therapyName': 'Ponatinib + Vincristine'}, {'id': 2046, 'therapyName': 'Cyclophosphamide + Dexamethasone + Doxorubicin + Vincristine '}, {'id': 1642, 'therapyName': 'Leucovorin'}]",Hyper-CVAD and Ponatinib in Ph-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL),640
68,NCT02723994,Phase II,Recruiting,"[{'id': 2188, 'therapyName': 'Prednisone'}, {'id': 4685, 'therapyName': 'Dexamethasone + Doxorubicin'}, {'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 2346, 'therapyName': 'Mercaptopurine + Thioguanine'}, {'id': 2394, 'therapyName': 'Asparaginase + Cytarabine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 1848, 'therapyName': 'Cyclophosphamide + Methotrexate + Vincristine + Pegaspargase '}]",A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia,640
69,NCT02620423,Phase I,"Active, not recruiting","[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 893, 'therapyName': 'Reolysin'}, {'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Study of Pembrolizumab With REOLYSIN and Chemotherapy in Patients With Advanced Pancreatic Adenocarcinoma,640
70,NCT01256398,Phase II,"Active, not recruiting","[{'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 2291, 'therapyName': 'Cyclophosphamide + Fludarabine'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1824, 'therapyName': 'Vincristine + Methotrexate + Mercaptopurine'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 2391, 'therapyName': 'Cytarabine + Daunorubicin + Etoposide'}, {'id': 1476, 'therapyName': 'Pegfilgrastim'}, {'id': 1205, 'therapyName': 'Alemtuzumab'}, {'id': 1642, 'therapyName': 'Leucovorin'}]",Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,640
71,NCT01775501,Phase II,Recruiting,"[{'id': 920, 'therapyName': 'Sorafenib'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 1642, 'therapyName': 'Leucovorin'}]",Sorafenib + mFOLFOX for Hepatocellular Carcinoma,640
72,NCT01467115,Phase II,Completed,"[{'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 1930, 'therapyName': 'Cisplatin + Docetaxel + Fluorouracil'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 694, 'therapyName': 'Cetuximab'}]",INDUCTION CHEMOTHERAPY FOLLOWED BY CETUXIMAB AND RADIATION THERAPY FOR HEAD AND NECK CANCER,640
73,NCT02112916,Phase III,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1009, 'therapyName': 'Doxorubicin'}]",Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma,640
74,NCT02043587,Phase II,Recruiting,"[{'id': 897, 'therapyName': 'Rituximab'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1136, 'therapyName': 'Etoposide'}]",Chemotherapy With Liposomal Cytarabine CNS Prophylaxis for Adult Acute Lymphoblastic Leukemia &amp; Lymphoblastic Lymphoma,640
75,NCT02427620,Phase II,Recruiting,"[{'id': 2353, 'therapyName': 'Cyclophosphamide + Doxorubicin + Vincristine '}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 3195, 'therapyName': 'Cytarabine + Methotrexate '}, {'id': 1642, 'therapyName': 'Leucovorin'}]",A Study of Ibrutinib Plus Rituximab With Hyper-CVAD Consolidation in Newly Diagnosed Young Patients With Mantle Cell Lymphoma,640
76,NCT00267865,Phase II,Recruiting,"[{'id': 897, 'therapyName': 'Rituximab'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1642, 'therapyName': 'Leucovorin'}]",Chemotherapy and HAART to Treat AIDS-related Primary Brain Lymphoma,640
77,NCT00293475,Phase Ib/II,Recruiting,"[{'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1476, 'therapyName': 'Pegfilgrastim'}, {'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 2669, 'therapyName': 'Carboplatin + Methotrexate + Rituximab'}]",Rituximab and Methotrexate Chemotherapy w/Blood-Brain Barrier Disruption (BBBD) &amp; Sodium Thiosulfate Chemoprotection for Patients With Newly Diagnosed PCNSL,640
78,NCT00550992,Phase I,Unknown status,"[{'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1752, 'therapyName': 'Mitoxantrone + Etoposide + Cytarabine'}, {'id': 1848, 'therapyName': 'Cyclophosphamide + Methotrexate + Vincristine + Pegaspargase '}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1650, 'therapyName': 'Cyclosporine'}, {'id': 1844, 'therapyName': 'anti-thymocyte globulin'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1642, 'therapyName': 'Leucovorin'}]",Different Therapies in Treating Infants With Newly Diagnosed Acute Leukemia,640
79,NCT02553460,Phase II,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1642, 'therapyName': 'Leucovorin'}]",Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) I,640
80,NCT03020030,Phase III,Recruiting,"[{'id': 3160, 'therapyName': 'Nelarabine'}, {'id': 5153, 'therapyName': 'dexrazoxane'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1642, 'therapyName': 'Leucovorin'}]",Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents,640
81,NCT02101853,Phase III,Recruiting,"[{'id': 1876, 'therapyName': 'Blinatumomab '}, {'id': 2347, 'therapyName': 'Leucovorin + Pegaspargase  + Vincristine'}, {'id': 2346, 'therapyName': 'Mercaptopurine + Thioguanine'}, {'id': 2348, 'therapyName': 'Asparaginase + Cyclophosphamide + Etoposide'}, {'id': 2345, 'therapyName': 'Cytarabine + Dexamethasone+ Methotrexate '}]",Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia,640
82,NCT02041481,Phase I,"Active, not recruiting","[{'id': 2217, 'therapyName': 'MEK162 + FOLFOX'}]","MEK Inhibitor MEK162 in Combination With Leucovorin Calcium, Fluorouracil, and Oxaliplatin in Treating Patients With Advanced Metastatic Colorectal Cancer",640
83,NCT02270788,Phase I,Completed,"[{'id': 1865, 'therapyName': 'Methotrexate + Cytarabine + Leucovorin'}, {'id': 1864, 'therapyName': 'Crenolanib + Sorafenib'}]",Crenolanib in Combination With Sorafenib in Patients With Refractory or Relapsed Hematologic Malignancies,640
84,NCT03281369,Phase Ib/II,Not yet recruiting,"[{'id': 1343, 'therapyName': 'Atezolizumab + Cobimetinib'}, {'id': 6274, 'therapyName': 'mFOLFOX-6 + Atezolizumab + Cobimetinib'}, {'id': 6275, 'therapyName': 'mFOLFOX-6 + Atezolizumab'}, {'id': 6276, 'therapyName': 'Atezolizumab + Linagliptin'}, {'id': 5941, 'therapyName': 'Atezolizumab + PEGPH20'}, {'id': 5942, 'therapyName': 'Atezolizumab + BKT140'}, {'id': 1721, 'therapyName': 'Ramucirumab + Paclitaxel'}, {'id': 5850, 'therapyName': 'mFOLFOX-6'}]",A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) (UMBRELLA),640
85,NCT01206530,Phase Ib/II,"Active, not recruiting","[{'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1316, 'therapyName': 'Hydroxychloroquine'}]",FOLFOX/Bevacizumab/Hydroxychloroquine (HCQ) in Colorectal Cancer,640
86,NCT02730546,Phase Ib/II,Suspended,"[{'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]","Pembrolizumab, Combination Chemotherapy, and Radiation Therapy Before Surgery in Treating Adult Patients With Locally Advanced Gastroesophageal Junction or Gastric Cardia Cancer That Can Be Removed by Surgery",640
87,NCT01662869,Phase III,Completed,"[{'id': 838, 'therapyName': 'Onartuzumab'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}]",A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic HER2-Negative And Met-Positive Gastroesophageal Cancer (MetGastric),640
88,NCT02625610,Phase III,Recruiting,"[{'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 3144, 'therapyName': 'Avelumab'}, {'id': 1597, 'therapyName': 'Capecitabine + Oxaliplatin'}]",Avelumab in First-Line Gastric Cancer (JAVELIN Gastric 100),640
89,NCT02912559,Phase III,Recruiting,"[{'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}]",Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair or Microsatellite Instability,640
90,NCT01586611,Phase III,Unknown status,"[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}]",A Study to See if hENT1 Testing on Tumour Tissue Can Predict Response to Treatment With Gemcitabine Chemotherapy and if a Different Chemotherapy Called FOLFOX is Better Than Gemcitabine in Metastatic Pancreas Cancer,640
91,NCT02268825,Phase Ib/II,"Active, not recruiting","[{'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Phase I/IIA Study MK-3475 With Chemotherapy in Patients With Advanced GI Cancers,640
92,NCT02413853,Phase II,Withdrawn,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1083, 'therapyName': 'Pri-724'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}]",Combination Chemotherapy and Bevacizumab With or Without PRI-724 in Treating Patients With Newly Diagnosed Metastatic Colorectal Cancer,640
93,NCT01985763,Phase Ib/II,Completed,"[{'id': 757, 'therapyName': 'Genistein'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}]",Genistein in Treatment of Metastatic Colorectal Cancer,640
94,NCT02344810,Phase Ib/II,Unknown status,"[{'id': 1064, 'therapyName': 'AMG 337'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}]","C-Met Inhibitor AMG 337, Oxaliplatin, Leucovorin Calcium, and Fluorouracil in Treating Patients With Advanced Stomach or Esophageal Cancer",640
95,NCT01327612,Phase II,"Active, not recruiting","[{'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 746, 'therapyName': 'Ganitumab'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1458, 'therapyName': 'Conatumumab'}]",Open Label Extension Study of Conatumumab and AMG 479,640
96,NCT02009449,Phase I,"Active, not recruiting","[{'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 2621, 'therapyName': 'AM0010 '}, {'id': 619, 'therapyName': 'Abraxane'}]",A Phase 1 Study of AM0010 in Patients With Advanced Solid Tumors,640
97,NCT02921256,Phase II,Recruiting,"[{'id': 954, 'therapyName': 'Veliparib'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 4838, 'therapyName': 'Capecitabine + Veliparib'}, {'id': 1105, 'therapyName': 'Capecitabine'}]",Veliparib and Combination Chemotherapy in Treating Patient With Locally Advanced Rectal Cancer,640
98,NCT01896531,Phase II,"Active, not recruiting","[{'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 747, 'therapyName': 'Ipatasertib'}]",A Study of GDC-0068 in Combination With Fluoropyrimidine Plus Oxaliplatin in Patients With Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer,640
99,NCT02574663,Phase I,"Active, not recruiting","[{'id': 1779, 'therapyName': 'Nab-paclitaxel + Gemcitabine'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 2022, 'therapyName': 'TGR-1202'}]",TGR-1202 Alone and in Combination With Either Nab-paclitaxel + Gemcitabine or With FOLFOX in Patients With Select Relapsed or Refractory Solid Tumors,640
100,NCT02943603,Phase II,Withdrawn,"[{'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}]",A Study of Perioperative mFOLFOX6 Plus Pembrolizumab in Patients With Potentially Resectable Adenocarcinoma of the Gastroesophageal Junction (GEJ) and Stomach,640
101,NCT01362374,Phase I,"Active, not recruiting","[{'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 747, 'therapyName': 'Ipatasertib'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}]","Safety and Pharmacology Of GDC-0068 in Combination With Docetaxel, Fluoropyrimidine Plus Oxaliplatin, Paclitaxel, or Enzalutamide in Patients With Advanced Solid Tumors",640
102,NCT01747551,Phase II,"Active, not recruiting","[{'id': 624, 'therapyName': 'Aflibercept'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}]",FOLFOX +/- Ziv-Aflibercept for Esophageal and Gastric Cancer,640
103,NCT00602329,Phase II,Unknown status,"[{'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 667, 'therapyName': 'Bevacizumab'}]",MRI in Predicting Response in Patients Receiving Combination Chemotherapy and Bevacizumab For Advanced or Metastatic Colorectal Cancer,640
104,NCT02358863,Phase I,Terminated,"[{'id': 4311, 'therapyName': 'Docetaxel + Irinotecan'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 1835, 'therapyName': 'Docetaxel + Cisplatin'}, {'id': 1406, 'therapyName': 'Camptosar + Cisplatin'}, {'id': 4310, 'therapyName': 'Epirubicin + Docetaxel'}, {'id': 4309, 'therapyName': 'Capecitabine + Docetaxel'}]",Molecularly Tailored Therapy for Patients With Metastatic Cancer of the Esophagus and Stomach (mEGA),640
105,NCT01516216,Phase II,"Active, not recruiting","[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}]",Study of Vitamin D in Untreated Metastatic Colorectal Cancer,640
106,NCT01489865,Phase Ib/II,Recruiting,"[{'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 954, 'therapyName': 'Veliparib'}]",ABT-888 With Modified FOLFOX6 in Patients With Metastatic Pancreatic Cancer,640
107,NCT02375672,Phase II,"Active, not recruiting","[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}]",Study of Pembrolizumab in Combination With Chemotherapy for Patients With Advanced Colorectal Cancer,640
108,NCT01571024,Phase I,Completed,"[{'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 680, 'therapyName': 'BKM120'}]", BKM120 + mFOLFOX6 in Advanced Solid Tumors With Expansion Cohort Pancreatic Cancer,640
109,NCT01420874,Phase I,"Active, not recruiting","[{'id': 1012, 'therapyName': 'EGFRBi-armed autologous activated T cells'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}]",Anti-CD3 x Anti-Erbitux Armed Activated T Cells (Phase Ib) for Gastrointestinal (GI Cancer),640
110,NCT02715531,Phase I,Recruiting,"[{'id': 3947, 'therapyName': 'Atezolizumab + Gemcitabine + nab-paclitaxel'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 1202, 'therapyName': 'Atezolizumab + Bevacizumab + Capecitabine'}]",A Study of the Safety and Tolerability of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors,640
111,NCT02872116,Phase III,Recruiting,"[{'id': 1597, 'therapyName': 'Capecitabine + Oxaliplatin'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}]",Efficacy Study of Nivolumab Plus Ipilimumab Against Chemotherapy Standard of Care in Stomach Cancer or Stomach/Esophagus Junction Cancer (CheckMate649),640
112,NCT01666730,Phase II,Recruiting,"[{'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 1031, 'therapyName': 'Metformin'}]",Metformin Plus Modified FOLFOX 6 in Metastatic Pancreatic Cancer,640
113,NCT02319018,Phase I,"Active, not recruiting","[{'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 626, 'therapyName': 'Alisertib'}]",Alisertib and Combination Chemotherapy in Treating Patients With Gastrointestinal Tumors,640
114,NCT02658214,Phase I,Recruiting,"[{'id': 2667, 'therapyName': 'Carboplatin + Gemcitabine'}, {'id': 2634, 'therapyName': 'Carboplatin + nab-paclitaxel'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 1791, 'therapyName': 'Carboplatin + Etoposide'}]",Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors,640
115,NCT01652976,Phase II,"Active, not recruiting","[{'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 717, 'therapyName': 'Dasatinib'}]","Phase II Study of 5-FU, Oxaliplatin Plus Dasatinib in Metastatic Pancreatic Adenocarcinoma",640
116,NCT02545504,Phase III,"Active, not recruiting","[{'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 3320, 'therapyName': 'GS-5745'}]",GS-5745 With mFOLFOX6 as First Line Treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma,640
117,NCT01307956,Phase II,Unknown status,"[{'id': 1986, 'therapyName': 'Panitumumab + FOLFOX'}]","Panitumumab, Combination Chemotherapy, and Radiation Therapy Before Surgery in Treating Patients With Advanced Esophageal or Gastroesophageal Junction Cancer",640
118,NCT01913639,Phase II,"Active, not recruiting","[{'id': 2014, 'therapyName': 'Regorafenib + FOLFOX'}]",FOLFOX Plus Regorafenib in Patients With Unresectable or Metastatic Esophagogastric Cancer,640
0,NCT02772588,Phase II,Recruiting,"[{'id': 4206, 'therapyName': 'Abiraterone + ARN-509 + Leuprolide'}]",AASUR in High Risk Prostate Cancer,7
1,NCT03298087,Phase II,Not yet recruiting,"[{'id': 4206, 'therapyName': 'Abiraterone + ARN-509 + Leuprolide'}]",Systemic and Tumor-Directed Therapy for Oligometastatic Prostate Cancer,7
2,NCT02903368,Phase II,Recruiting,"[{'id': 3079, 'therapyName': 'Abiraterone + Leuprolide + Prednisone'}, {'id': 4758, 'therapyName': 'Abiraterone + ARN-509 + Leuprolide + Prednisone'}]",Neoadjuvant And Adjuvant Abiraterone Acetate + Aptilutamide Prostate Cancer Undergoing Prostatectomy,7
3,NCT02543255,Phase II,Recruiting,"[{'id': 1571, 'therapyName': 'Cabazitaxel'}, {'id': 3079, 'therapyName': 'Abiraterone + Leuprolide + Prednisone'}, {'id': 1476, 'therapyName': 'Pegfilgrastim'}]",Anti-Androgens and Cabazitaxel in Defining Complete Response in Prostatectomy (ACDC Trial),7
4,NCT02770391,Phase II,Recruiting,"[{'id': 4207, 'therapyName': 'ARN-509 + Leuprolide'}]",ARN-509 and Leuprolide in Intermediate and High-risk Prostate Cancer,7
5,NCT02811809,Phase II,Not yet recruiting,"[{'id': 795, 'therapyName': 'Leuprolide'}, {'id': 4207, 'therapyName': 'ARN-509 + Leuprolide'}]",Apalutamide Plus Intermittent Hormone Therapy Versus Intermittent Hormone Therapy Alone in Prostate Cancer,7
6,NCT03070886,Phase III,Recruiting,"[{'id': 5450, 'therapyName': 'Bicalutamide + Docetaxel + Flutamide + Goserelin + Leuprolide + Nilutamide'}, {'id': 5449, 'therapyName': 'Bicalutamide + Flutamide + Goserelin + Leuprolide + Nilutamide'}]",Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery,7
7,NCT03043807,Phase II,Recruiting,"[{'id': 3945, 'therapyName': 'Bicalutamide + Docetaxel + Leuprolide'}]",A Study of Definitive Therapy to Treat Prostate Cancer After Prostatectomy,7
8,NCT02716974,Phase I,Recruiting,"[{'id': 3945, 'therapyName': 'Bicalutamide + Docetaxel + Leuprolide'}]",A Study of Definitive Therapy to Treat Prostate Cancer,7
9,NCT02508636,Phase II,Recruiting,"[{'id': 3180, 'therapyName': 'Enzalutamide + Leuprolide'}]",Trial of Radiotherapy With Leuprolide and Enzalutamide in High Risk Prostate,7
10,NCT02268175,Phase II,"Active, not recruiting","[{'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 795, 'therapyName': 'Leuprolide'}]",Enzalutamide/Leuprolide +/- Abiraterone/Pred in Prostate,7
11,NCT02366494,Phase I,Recruiting,"[{'id': 795, 'therapyName': 'Leuprolide'}, {'id': 759, 'therapyName': 'Goserelin'}, {'id': 2050, 'therapyName': 'Triptorelin'}, {'id': 1507, 'therapyName': 'Bicalutamide'}, {'id': 720, 'therapyName': 'Docetaxel'}]",Micro RNAs to Predict Response to Androgen Deprivation Therapy,7
12,NCT01717053,Phase II,"Active, not recruiting","[{'id': 795, 'therapyName': 'Leuprolide'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 759, 'therapyName': 'Goserelin'}]","Abiraterone, Radiotherapy and Short-Term Androgen Deprivation in Unfavorable Localized Prostate Cancer",7
13,NCT00936390,Phase III,"Active, not recruiting","[{'id': 742, 'therapyName': 'Flutamide'}, {'id': 759, 'therapyName': 'Goserelin'}, {'id': 795, 'therapyName': 'Leuprolide'}, {'id': 2050, 'therapyName': 'Triptorelin'}, {'id': 1507, 'therapyName': 'Bicalutamide'}]",Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer,7
14,NCT02064582,Phase II,Recruiting,"[{'id': 795, 'therapyName': 'Leuprolide'}, {'id': 1262, 'therapyName': 'Enzalutamide'}]","Enzalutamide and Hormone Therapy Before, During, and After Radiation for High Risk Localized Prostate Cancer",7
15,NCT00223665,Phase II,Unknown status,"[{'id': 795, 'therapyName': 'Leuprolide'}, {'id': 742, 'therapyName': 'Flutamide'}]",Intermittent Hormone Therapy in Men With Localized Prostate Cancer After Radiation Therapy or Radical Prostatectomy,7
16,NCT01674140,Phase III,Recruiting,"[{'id': 759, 'therapyName': 'Goserelin'}, {'id': 633, 'therapyName': 'Anastrozole'}, {'id': 794, 'therapyName': 'Letrozole'}, {'id': 795, 'therapyName': 'Leuprolide'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 738, 'therapyName': 'Exemestane'}]",S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer,7
17,NCT02064036,Phase I,Recruiting,"[{'id': 1507, 'therapyName': 'Bicalutamide'}, {'id': 759, 'therapyName': 'Goserelin'}, {'id': 795, 'therapyName': 'Leuprolide'}]",Stereotactic Boost and Long-Term Androgen Deprivation for Adenocarcinoma of the Prostate,7
18,NCT02472275,Phase I,Recruiting,"[{'id': 795, 'therapyName': 'Leuprolide'}, {'id': 874, 'therapyName': 'PLX3397'}, {'id': 759, 'therapyName': 'Goserelin'}, {'id': 1814, 'therapyName': 'Degarelix'}]","PLX3397, Radiation Therapy, and Antihormone Therapy in Treating Patients With Intermediate- or High-Risk Prostate Cancer",7
19,NCT02736435,Phase III,Not yet recruiting,"[{'id': 795, 'therapyName': 'Leuprolide'}]",Treatment of Uterine Fibroids With Magnetic Resonance Guided High Intensity Focused Ultrasound,7
20,NCT03085095,Phase III,Recruiting,"[{'id': 5492, 'therapyName': 'Relugolix'}, {'id': 795, 'therapyName': 'Leuprolide'}]",A Study to Evaluate the Safety and Efficacy of Relugolix in Men With Advanced Prostate Cancer (HERO),7
21,NCT02023463,Phase I,"Active, not recruiting","[{'id': 759, 'therapyName': 'Goserelin'}, {'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 795, 'therapyName': 'Leuprolide'}]","Enzalutamide, Radiation Therapy and Hormone Therapy in Treating Patients With Intermediate or High-Risk Prostate Cancer",7
22,NCT02058706,Phase II,Recruiting,"[{'id': 759, 'therapyName': 'Goserelin'}, {'id': 1507, 'therapyName': 'Bicalutamide'}, {'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 795, 'therapyName': 'Leuprolide'}]",LHRH Analogue Therapy With Enzalutamide or Bicalutamide in Treating Patients With Metastatic Hormone Sensitive Prostate Cancer,7
23,NCT02685397,Phase II,Recruiting,"[{'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 2050, 'therapyName': 'Triptorelin'}, {'id': 759, 'therapyName': 'Goserelin'}, {'id': 795, 'therapyName': 'Leuprolide'}]",Management of Castration-Resistant Prostate Cancer With Oligometastases,7
24,NCT02663908,Phase III,Recruiting,"[{'id': 1814, 'therapyName': 'Degarelix'}, {'id': 795, 'therapyName': 'Leuprolide'}]",A Trial Comparing Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Advanced Prostate Cancer and Cardiovascular Disease,7
25,NCT02234115,Phase III,Completed,"[{'id': 795, 'therapyName': 'Leuprolide'}]","Safety, Efficacy, and Pharmacokinetic Behavior of Leuprolide Mesylate in Subjects With Advanced Prostate Carcinoma",7
26,NCT03093272,Phase II,Recruiting,"[{'id': 795, 'therapyName': 'Leuprolide'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 5521, 'therapyName': 'ARN-509 + Docetaxel'}]",A Study of Docetaxel + ARN-509 in Castration-Resistant Prostate Cancer,7
27,NCT03261999,Phase III,Recruiting,"[{'id': 795, 'therapyName': 'Leuprolide'}]","Safety, Efficacy, and Pharmacokinetic Behavior of Leuprolide Mesylate (LMIS 25 mg) in Subjects With Prostate Cancer",7
28,NCT00541047,Phase III,"Active, not recruiting","[{'id': 795, 'therapyName': 'Leuprolide'}, {'id': 759, 'therapyName': 'Goserelin'}, {'id': 1507, 'therapyName': 'Bicalutamide'}]",Radiation Therapy and Androgen Deprivation Therapy in Treating Patients Who Have Undergone Surgery for Prostate Cancer (RADICALS),7
29,NCT02689921,Phase II,Recruiting,"[{'id': 633, 'therapyName': 'Anastrozole'}, {'id': 794, 'therapyName': 'Letrozole'}, {'id': 795, 'therapyName': 'Leuprolide'}, {'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}, {'id': 738, 'therapyName': 'Exemestane'}]",NEOADjuvant Aromatase Inhibitor and Pertuzumab/Trastuzumab for Women With Breast Cancer (NEOADAPT),7
30,NCT02278185,Phase II,Recruiting,"[{'id': 759, 'therapyName': 'Goserelin'}, {'id': 1814, 'therapyName': 'Degarelix'}, {'id': 2047, 'therapyName': 'Histrelin acetate'}, {'id': 2050, 'therapyName': 'Triptorelin'}, {'id': 795, 'therapyName': 'Leuprolide'}, {'id': 1262, 'therapyName': 'Enzalutamide'}]",Enzalutamide Versus Standard Androgen Deprivation Therapy for the Treatment Hormone Sensitive Prostate Cancer,7
31,NCT02319837,Phase III,Recruiting,"[{'id': 795, 'therapyName': 'Leuprolide'}, {'id': 1262, 'therapyName': 'Enzalutamide'}]",Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK),7
32,NCT02346253,Phase Ib/II,Recruiting,"[{'id': 795, 'therapyName': 'Leuprolide'}, {'id': 2050, 'therapyName': 'Triptorelin'}, {'id': 1814, 'therapyName': 'Degarelix'}, {'id': 1507, 'therapyName': 'Bicalutamide'}, {'id': 759, 'therapyName': 'Goserelin'}]",High-Dose Brachytherapy in Treating Patients With Prostate Cancer,7
33,NCT01746849,Phase II,Recruiting,"[{'id': 795, 'therapyName': 'Leuprolide'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 2373, 'therapyName': 'Palifermin'}]",Palifermin With Leuprolide Acetate for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation,7
34,NCT01338987,Phase II,"Active, not recruiting","[{'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 795, 'therapyName': 'Leuprolide'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}]",Pilot Study of Lupron to Improve Immune Function After Allogeneic Bone Marrow Transplantation,7
35,NCT02057939,Phase II,"Active, not recruiting","[{'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 795, 'therapyName': 'Leuprolide'}]",Salvage Therapeutic Radiation With Enzalutamide and ADT in Men With Recurrent Prostate Cancer (STREAM),7
36,NCT02059213,Phase II,"Active, not recruiting","[{'id': 759, 'therapyName': 'Goserelin'}, {'id': 850, 'therapyName': 'Palbociclib'}, {'id': 1507, 'therapyName': 'Bicalutamide'}, {'id': 795, 'therapyName': 'Leuprolide'}]", A Phase II Study of Androgen Deprivation Therapy With or Without PD 0332991 in RB-Positive Metastatic Prostate Cancer,7
37,NCT01786265,Phase II,"Active, not recruiting","[{'id': 759, 'therapyName': 'Goserelin'}, {'id': 1814, 'therapyName': 'Degarelix'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 795, 'therapyName': 'Leuprolide'}]",Finite Androgen Ablation vs. Finite Androgen Ablation in Combination With Abiraterone Acetate and Prednisone,7
38,NCT03279250,Phase II,Not yet recruiting,"[{'id': 759, 'therapyName': 'Goserelin'}, {'id': 2050, 'therapyName': 'Triptorelin'}, {'id': 2649, 'therapyName': 'Abiraterone + ARN-509 + Prednisone'}, {'id': 795, 'therapyName': 'Leuprolide'}, {'id': 1947, 'therapyName': 'ARN-509'}]",Effects of Apalutamide Plus LHRH Agonist or Apalutamide Plus Abiraterone Acetate Plus LHRH Agonist for Six Months for Prostate Cancer Patients at High Risk for Recurrence,7
0,NCT02144038,Phase Ib/II,Completed,"[{'id': 2419, 'therapyName': 'BYL719 + LGH447'}, {'id': 2402, 'therapyName': 'LGH447 '}]",Study of the Safety and Effectiveness of LGH447 and BYL719 in Patients With Relapsed and Refractory Multiple Myeloma,7508
1,NCT01456689,Phase I,"Active, not recruiting","[{'id': 2685, 'therapyName': 'Midazolam'}, {'id': 2402, 'therapyName': 'LGH447 '}]",A Study of Oral LGH447 in Patients With Relapsed and/or Refractory Multiple Myeloma,7508
2,NCT02078609,Phase I,Recruiting,"[{'id': 2402, 'therapyName': 'LGH447 '}]",A Safety and Efficacy Study of LGH447 in Patients With Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS),7508
0,NCT02649530,Phase II,Withdrawn,"[{'id': 1937, 'therapyName': 'LGK974'}]","An Open Label, Non-randomized Phase II Trial Evaluating WNT974 in Patients With Metastatic Head and Neck Squamous Cell Carcinoma",7364
1,NCT01351103,Phase I,Recruiting,"[{'id': 1937, 'therapyName': 'LGK974'}]",A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands,7364
2,NCT02278133,Phase Ib/II,Completed,"[{'id': 2008, 'therapyName': 'LGK974 + LGX818 + Cetuximab'}]",Study of WNT974 in Combination With LGX818 and Cetuximab in Patients With BRAF-mutant Metastatic Colorectal Cancer (mCRC) and Wnt Pathway Mutations,7364
0,NCT03301896,Phase I,Not yet recruiting,"[{'id': 6299, 'therapyName': 'LHC165 + PDR001'}, {'id': 6298, 'therapyName': 'LHC165'}]",Phase I/Ib Study of LHC165 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies,8966
0,NCT01672736,Phase Ib/II,"Active, not recruiting","[{'id': 1831, 'therapyName': 'Linsitinib + Bortezomib + Dexamethasone'}]",A Trial of ASP7487 (OSI-906) in Combination With Bortezomib for the Treatment of Relapsed Multiple Myeloma,6938
0,NCT01182285,Phase II,Completed,"[{'id': 2674, 'therapyName': 'liothyronine sodium  '}, {'id': 1076, 'therapyName': 'Valproic acid'}]",A Phase II Trial of Valproic Acid in Patients With Advanced Thyroid Cancers of Follicular Cell Origin,7642
0,NCT02252263,Phase I,"Active, not recruiting","[{'id': 2055, 'therapyName': 'Urelumab'}, {'id': 2583, 'therapyName': 'Lirilumab '}, {'id': 3343, 'therapyName': 'Elotuzumab'}]",A Phase I Open Label Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination With Either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects With Multiple Myeloma,7593
1,NCT01592370,Phase I,"Active, not recruiting","[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 2583, 'therapyName': 'Lirilumab '}]",Safety Study in Nivolumab Alone and in Combination With Ipilimumab or Lirilumab in Lymphoma and Multiple Myeloma,7593
2,NCT02599649,Phase II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 2583, 'therapyName': 'Lirilumab '}]",Lirilumab and Nivolumab With 5-Azacitidine in Patients With Myelodysplastic Syndromes (MDS),7593
3,NCT01714739,Phase I,Recruiting,"[{'id': 2584, 'therapyName': 'Lirilumab + Nivolumab'}]",A Phase I Study of an Anti-KIR Antibody in Combination With an Anti-PD1 Antibody in Patients With Advanced Solid Tumors,7593
0,NCT01822613,Phase Ib/II,Completed,"[{'id': 2282, 'therapyName': 'Docetaxel + Irinotecan + Paclitaxel'}, {'id': 2283, 'therapyName': 'BYL719 + LJM716'}]",Study of Safety and Efficacy of the Combination of LJM716 and BYL719 in Patients With Previously Treated Esophageal Squamous Cell Carcinoma (ESCC),7401
1,NCT02167854,Phase I,Recruiting,"[{'id': 2059, 'therapyName': 'BYL719 + LJM716 + Trastuzumab'}]","Open-Label Study Evaluating the Safety and Tolerability of LJM716, BYL719 and Trastuzumab in Patients With Metastatic HER2+ Breast Cancer",7401
2,NCT01602406,Phase I,Completed,"[{'id': 2037, 'therapyName': 'LJM716 + Trastuzumab'}]",Phase I Study LJM716 Combined With Trastuzumab in Patients With HER2 Overexpressing Metastatic Breast or Gastric Cancer,7401
0,NCT03030417,Phase I,Recruiting,"[{'id': 5749, 'therapyName': 'LMP744'}]",Indenoisoquinoline LMP744 in Adults With Relapsed Solid Tumors and Lymphomas,8770
0,NCT02126579,Phase Ib/II,Recruiting,"[{'id': 2595, 'therapyName': 'poly ICLC  '}, {'id': 3009, 'therapyName': 'Long peptide vaccine 7'}]",Phase I/II Trial of a Long Peptide Vaccine (LPV7) Plus TLR Agonists,7906
0,NCT03052608,Phase III,Recruiting,"[{'id': 869, 'therapyName': 'PF-06463922'}, {'id': 706, 'therapyName': 'Crizotinib'}]",A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC,7074
1,NCT03107988,Phase I,Recruiting,"[{'id': 5580, 'therapyName': 'PF-06463922 + Cyclophosphamide + Topotecan'}, {'id': 869, 'therapyName': 'PF-06463922'}]",Study of Lorlatinib (PF-06463922),7074
2,NCT01970865,Phase Ib/II,Recruiting,"[{'id': 869, 'therapyName': 'PF-06463922'}, {'id': 706, 'therapyName': 'Crizotinib'}]",A Study Of PF-06463922 An ALK/ROS1 Inhibitor In Patients With Advanced Non Small Cell Lung Cancer With Specific Molecular Alterations,7074
3,NCT02927340,Phase II,Recruiting,"[{'id': 869, 'therapyName': 'PF-06463922'}]",A Study of Lorlatinib in Advanced ALK and ROS1 Rearranged Lung Cancer With CNS Metastasis in the Absence of Measurable Extracranial Lesions,7074
4,NCT02584634,Phase I,Recruiting,"[{'id': 706, 'therapyName': 'Crizotinib'}, {'id': 3144, 'therapyName': 'Avelumab'}, {'id': 869, 'therapyName': 'PF-06463922'}]","Study to Evaluate Safety, Efficacy, Pharmacokinetics And Pharmacodynamics Of Avelumab In Combination With Either Crizotinib Or PF-06463922 In Patients With NSCLC. (Javelin Lung 101)",7074
0,NCT03155620,Phase II,Recruiting,"[{'id': 2683, 'therapyName': 'Tazemetostat'}, {'id': 2650, 'therapyName': 'LOXO-101'}, {'id': 1069, 'therapyName': 'LY3023414'}, {'id': 342, 'therapyName': 'Vemurafenib'}, {'id': 837, 'therapyName': 'Olaparib'}, {'id': 913, 'therapyName': 'Selumetinib'}, {'id': 961, 'therapyName': 'X-396'}]",Pediatric MATCH: Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Advanced Refractory Solid Tumors or Lymphomas,7625
1,NCT02122913,Phase I,Recruiting,"[{'id': 2650, 'therapyName': 'LOXO-101'}]",Oral TRK Inhibitor LOXO-101 for Treatment of Advanced Adult Solid Tumors,7625
2,NCT02576431,Phase II,Recruiting,"[{'id': 2650, 'therapyName': 'LOXO-101'}]",Study of LOXO-101 in Subjects With NTRK Fusion Positive Solid Tumors,7625
3,NCT02637687,Phase I,Recruiting,"[{'id': 2650, 'therapyName': 'LOXO-101'}]",Oral TRK Inhibitor LOXO-101 for Treatment of Advanced Pediatric Solid or Primary Central Nervous System Tumors,7625
4,NCT03213704,Phase II,Recruiting,"[{'id': 2650, 'therapyName': 'LOXO-101'}]","Pediatric MATCH: Trk Inhibitor LOXO-101 in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions",7625
0,NCT03215511,Phase Ib/II,Recruiting,"[{'id': 5917, 'therapyName': 'LOXO-195'}]",Phase 1/2 Study of LOXO-195 in Patients With Previously Treated NTRK Fusions or Non-fusion NTRK Cancers,8860
0,NCT03157128,Phase I,Recruiting,"[{'id': 5702, 'therapyName': 'LOXO-292'}]","Phase 1 Study of LOXO-292 in Patients With Advanced Solid Tumors, RET-Fusion Lung Cancer and Medullary Thyroid Cancer",8754
0,NCT02734615,Phase I,Recruiting,"[{'id': 4441, 'therapyName': 'Alpelisib + LSZ 102'}, {'id': 4440, 'therapyName': 'LSZ 102 + Ribociclib'}, {'id': 4439, 'therapyName': 'LSZ 102'}]",Phase I/Ib Trial of LSZ102 Single Agent or LSZ102 + LEE011 or LSZ102 + BYL719 in ER+ Breast Cancers,8455
0,NCT01283945,Phase Ib/II,Completed,"[{'id': 1029, 'therapyName': 'Lucitanib'}]","Study of Oral Lucitanib (E-3810), a Dual VEGFR-FGFR Tyrosine Kinase Inhibitor, in Patients With Solid Tumors",7145
1,NCT02202746,Phase II,"Active, not recruiting","[{'id': 1029, 'therapyName': 'Lucitanib'}]","A Study to Assess the Safety and Efficacy of the VEGFR-FGFR Inhibitor, Lucitanib, Given to Patients With FGF Aberrant Metastatic Breast Cancer",7145
2,NCT02747797,Phase II,Withdrawn,"[{'id': 1029, 'therapyName': 'Lucitanib'}]","Lucitanib (E3810) in Patients With Advanced Cancer and FGFR, VEGFR, or PDGFR Pathway Aberrations",7145
3,NCT02053636,Phase II,Completed,"[{'id': 1029, 'therapyName': 'Lucitanib'}]",A Phase II Trial Testing Oral Administration of Lucitanib in Patients With Fibroblast Growth Factor Receptor (FGFR)1-amplified or Non-amplified Estrogen Receptor Positive Metastatic Breast Cancer,7145
4,NCT02109016,Phase II,Completed,"[{'id': 1029, 'therapyName': 'Lucitanib'}]","A Study to Assess the Efficacy of the VEGFR-FGFR Inhibitor, Lucitanib, Given to Patients With FGFR1-driven Lung Cancer",7145
0,NCT01405391,Phase I,Completed,"[{'id': 1195, 'therapyName': 'Lurbinectedin'}]",Study of PM01183 in Non-Colorectal Cancer Patients as a Days 1 and 8 Intravenous Short Infusion Every 3 Weeks,7219
1,NCT01525589,Phase II,Recruiting,"[{'id': 1195, 'therapyName': 'Lurbinectedin'}]",A Phase II Clinical Trial of PM01183 in BRCA 1/2-Associated or Unselected Metastatic Breast Cancer,7219
2,NCT02454972,Phase II,Recruiting,"[{'id': 1195, 'therapyName': 'Lurbinectedin'}]",Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors,7219
3,NCT01831089,Phase I,Completed,"[{'id': 1196, 'therapyName': 'Lurbinectedin + Paclitaxel + Bevacizumab'}, {'id': 1197, 'therapyName': 'Lurbinectedin + Paclitaxel'}]","Phase I Study of Lurbinectedin (PM01183) in Combination With Paclitaxel, With or Without Bevacizumab, in Selected Advanced Solid Tumors",7219
0,NCT02607813,Phase I,Recruiting,"[{'id': 4443, 'therapyName': 'LXH 254 + PDR001'}, {'id': 4442, 'therapyName': 'LXH 254'}]",Phase I Study of LXH254 in Patients With Advanced Solid Tumors Haboring MAPK Pathway Alterations,8456
0,NCT02652871,Phase I,Recruiting,"[{'id': 3470, 'therapyName': 'Cytarabine + Idarubicin + LY2510924'}]","A Phase 1b, Open-label Study of LY2510924, Idarubicin and Cytarabine in Patients With Relapsed or Refractory Acute Myeloid Leukemia",7783
1,NCT02737072,Phase I,"Active, not recruiting","[{'id': 4210, 'therapyName': 'LY2510924 + MEDI4736'}]",A Study of LY2510924 and Durvalumab in Participants With Solid Tumors,7783
0,NCT02711553,Phase II,"Active, not recruiting","[{'id': 886, 'therapyName': 'Ramucirumab'}, {'id': 1030, 'therapyName': 'LY2801653'}, {'id': 1467, 'therapyName': 'Gemcitabine + Cisplatin'}]",A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer,7147
1,NCT01285037,Phase I,"Active, not recruiting","[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 694, 'therapyName': 'Cetuximab'}, {'id': 1030, 'therapyName': 'LY2801653'}]",A Study of LY2801653 in Advanced Cancer,7147
2,NCT02920996,Phase II,Recruiting,"[{'id': 1030, 'therapyName': 'LY2801653'}]",Merestinib In Non-Small Cell Lung Cancer And Solid Tumors,7147
3,NCT03125239,Phase I,Recruiting,"[{'id': 5744, 'therapyName': 'LY2801653 + LY2874455'}]",Combination Merestinib and LY2874455 for Patients With Relapsed or Refractory Acute Myeloid Leukemia,7147
4,NCT02745769,Phase I,Recruiting,"[{'id': 4208, 'therapyName': 'LY2801653 + Ramucirumab'}, {'id': 4209, 'therapyName': 'Abemaciclib + Ramucirumab'}]",A Study in Advanced Cancers Using Ramucirumab (LY3009806) and Other Targeted Agents,7147
0,NCT03125239,Phase I,Recruiting,"[{'id': 5744, 'therapyName': 'LY2801653 + LY2874455'}]",Combination Merestinib and LY2874455 for Patients With Relapsed or Refractory Acute Myeloid Leukemia,7398
0,NCT02632448,Phase Ib/II,Recruiting,"[{'id': 4420, 'therapyName': 'LY2880070 + Gemcitabine'}, {'id': 4315, 'therapyName': 'LY2880070'}]",A Study of LY2880070 in Patients With Advanced or Metastatic Cancer,8406
0,NCT02014116,Phase I,"Active, not recruiting","[{'id': 3268, 'therapyName': 'LY3009120'}]",A Study of LY3009120 in Participants With Advanced Cancer or Cancer That Has Spread to Other Parts of Their Body,7999
0,NCT03101254,Phase Ib/II,Recruiting,"[{'id': 5512, 'therapyName': 'Cobimetinib + LY3022855 + Vemurafenib'}]",LY3022855 With BRAF/MEK Inhibition in Patients With Melanoma,7376
1,NCT03153410,Phase I,Not yet recruiting,"[{'id': 5778, 'therapyName': 'Cyclophosphamide + GVAX pancreatic cancer vaccine + LY3022855 + Pembrolizumab'}]","Pilot Study With CY, Pembrolizumab, GVAX, and IMC-CS4 (LY3022855) in Patients With Borderline Resectable Adenocarcinoma of the Pancreas",7376
2,NCT02265536,Phase I,Recruiting,"[{'id': 2004, 'therapyName': 'LY3022855'}]",A Study of LY3022855 In Participants With Breast or Prostate Cancer,7376
3,NCT02323191,Phase I,Recruiting,"[{'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 2004, 'therapyName': 'LY3022855'}]",A Study of RO5509554 and MPDL3280A Administered in Combination in Patients With Advanced Solid Tumors,7376
4,NCT01346358,Phase I,"Active, not recruiting","[{'id': 2004, 'therapyName': 'LY3022855'}]",A Study of IMC-CS4 in Subjects With Advanced Solid Tumors,7376
5,NCT02718911,Phase I,Recruiting,"[{'id': 4216, 'therapyName': 'LY3022855 + Tremelimumab'}, {'id': 4215, 'therapyName': 'LY3022855 + MEDI4736'}]",A Study of LY3022855 in Combination With Durvalumab or Tremelimumab in Participants With Advanced Solid Tumors,7376
0,NCT01655225,Phase I,Recruiting,"[{'id': 1214, 'therapyName': 'LY3023414 + Midazolam '}, {'id': 1215, 'therapyName': ' LY3023414 + Letrozole '}, {'id': 1069, 'therapyName': 'LY3023414'}]",A Study of LY3023414 in Participants With Advanced Cancer,7186
1,NCT02981342,Phase II,Recruiting,"[{'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 802, 'therapyName': 'Abemaciclib'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 5175, 'therapyName': 'Abemaciclib + LY3023414'}, {'id': 5176, 'therapyName': 'Abemaciclib + Galunisertib'}]",A Study of Abemaciclib (LY2835219) Alone or in Combination With Other Agents in Participants With Previously Treated Pancreatic Ductal Adenocarcinoma,7186
2,NCT03155620,Phase II,Recruiting,"[{'id': 2683, 'therapyName': 'Tazemetostat'}, {'id': 2650, 'therapyName': 'LOXO-101'}, {'id': 1069, 'therapyName': 'LY3023414'}, {'id': 342, 'therapyName': 'Vemurafenib'}, {'id': 837, 'therapyName': 'Olaparib'}, {'id': 913, 'therapyName': 'Selumetinib'}, {'id': 961, 'therapyName': 'X-396'}]",Pediatric MATCH: Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Advanced Refractory Solid Tumors or Lymphomas,7186
3,NCT02549989,Phase II,Recruiting,"[{'id': 1069, 'therapyName': 'LY3023414'}]",Study of LY3023414 for the Treatment of Recurrent,7186
4,NCT03213678,Phase II,Recruiting,"[{'id': 1069, 'therapyName': 'LY3023414'}]","Pediatric MATCH: PI3K/mTOR Inhibitor LY3023414 in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations",7186
5,NCT02079636,Phase I,Recruiting,"[{'id': 1069, 'therapyName': 'LY3023414'}, {'id': 802, 'therapyName': 'Abemaciclib'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 886, 'therapyName': 'Ramucirumab'}]",A Study of LY2835219 in Combination With Another Anti-cancer Drug in Participants With Lung Cancer (NSCLC),7186
6,NCT02443337,Phase II,"Active, not recruiting","[{'id': 826, 'therapyName': 'Necitumumab'}, {'id': 1069, 'therapyName': 'LY3023414'}]",A Study of LY3023414 and Necitumumab in Squamous Lung Cancer,7186
7,NCT02784795,Phase I,Recruiting,"[{'id': 4374, 'therapyName': 'Cisplatin + Gemcitabine + LY3039478'}, {'id': 4375, 'therapyName': 'Carboplatin + Gemcitabine + LY3039478'}, {'id': 4372, 'therapyName': 'LY3039478 + LY3023414'}, {'id': 4373, 'therapyName': 'Abemaciclib + LY3039478'}, {'id': 4371, 'therapyName': 'LY3039478 + Taladegib'}, {'id': 2958, 'therapyName': 'LY3039478'}, {'id': 1069, 'therapyName': 'LY3023414'}]",A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors,7186
8,NCT02407054,Phase II,Recruiting,"[{'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 1069, 'therapyName': 'LY3023414'}]",A Study of Enzalutamide and LY3023414 in Men With Prostate Cancer,7186
9,NCT02124148,Phase I,Recruiting,"[{'id': 1994, 'therapyName': 'Cisplatin + Prexasertib'}, {'id': 1993, 'therapyName': 'Cetuximab + Prexasertib'}, {'id': 6248, 'therapyName': 'Pemetrexed + Prexasertib'}, {'id': 6247, 'therapyName': 'LY3023414 + Prexasertib'}, {'id': 6246, 'therapyName': 'Fluoruracil + Leucovorin + Prexasertib'}]",A Study of LY2606368 With Cisplatin or Cetuximab in Participants With Advanced Cancer,7186
0,NCT02784795,Phase I,Recruiting,"[{'id': 4374, 'therapyName': 'Cisplatin + Gemcitabine + LY3039478'}, {'id': 4375, 'therapyName': 'Carboplatin + Gemcitabine + LY3039478'}, {'id': 4372, 'therapyName': 'LY3039478 + LY3023414'}, {'id': 4373, 'therapyName': 'Abemaciclib + LY3039478'}, {'id': 4371, 'therapyName': 'LY3039478 + Taladegib'}, {'id': 2958, 'therapyName': 'LY3039478'}, {'id': 1069, 'therapyName': 'LY3023414'}]",A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors,7872
1,NCT02518113,Phase Ib/II,Recruiting,"[{'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 2958, 'therapyName': 'LY3039478'}]",A Study of LY3039478 in Combination With Dexamethasone in Participants With T-ALL/T-LBL,7872
2,NCT01695005,Phase I,Recruiting,"[{'id': 2958, 'therapyName': 'LY3039478'}]",A Study of LY3039478 in Participants With Advanced Cancer,7872
0,NCT02529553,Phase I,Recruiting,"[{'id': 3164, 'therapyName': 'LY3076226'}]",A Study of LY3076226 in Participants With Advanced or Metastatic Cancer,7964
0,NCT02597036,Phase I,"Active, not recruiting","[{'id': 3562, 'therapyName': 'LY3127804 '}, {'id': 886, 'therapyName': 'Ramucirumab'}]",A Study of LY3127804 With Ramucirumab in Participants With Advanced Solid Tumors,8139
0,NCT02221882,Phase I,Completed,"[{'id': 1969, 'therapyName': 'LY3164530'}]",A Study of LY3164530 in Participants With Cancer,7371
0,NCT02937272,Phase I,Recruiting,"[{'id': 5811, 'therapyName': 'LY3200882'}]",A Study of LY3200882 in Participants With Solid Tumors,8806
0,NCT02857270,Phase I,Recruiting,"[{'id': 4588, 'therapyName': 'LY3214996'}, {'id': 4590, 'therapyName': 'LY3214996 + nab-paclitaxel + Gemcitabine'}, {'id': 4589, 'therapyName': 'LY3214996 + Midazolam'}, {'id': 4591, 'therapyName': 'LY3214996 + Abemaciclib'}]",A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer,8491
0,NCT02791334,Phase I,Recruiting,"[{'id': 4370, 'therapyName': 'LY3300054 + Necitumumab'}, {'id': 4369, 'therapyName': 'LY3300054 + Ramucirumab'}, {'id': 4368, 'therapyName': 'LY3300054'}]",A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors  (PACT),8435
1,NCT03099109,Phase I,Recruiting,"[{'id': 5556, 'therapyName': 'LY3321367'}, {'id': 5557, 'therapyName': 'LY3300054 + LY3321367'}]",A Study of LY3321367 Alone or With LY3300054 in Participants With Advanced Relapsed/Refractory Solid Tumors,8435
0,NCT03099109,Phase I,Recruiting,"[{'id': 5556, 'therapyName': 'LY3321367'}, {'id': 5557, 'therapyName': 'LY3300054 + LY3321367'}]",A Study of LY3321367 Alone or With LY3300054 in Participants With Advanced Relapsed/Refractory Solid Tumors,8717
0,NCT02929862,Phase Ib/II,Recruiting,"[{'id': 5812, 'therapyName': 'LYC-55716'}]",Study of LYC-55716 in Adult Subjects With Locally Advanced or Metastatic Cancer,8807
0,NCT03286296,Phase I,Recruiting,"[{'id': 6281, 'therapyName': 'LZM009'}]",LZM009 to Treat Patients With Advanced Solid Tumors,8962
0,NCT01971515,Phase I,Recruiting,"[{'id': 1037, 'therapyName': 'MSC2363318A'}]",First-in-Human Dose Escalation Trial in Subjects With Advanced Malignancies,7156
0,NCT03225105,Phase I,Recruiting,"[{'id': 6059, 'therapyName': 'M3541'}]",M3541 in Combination With Radiotherapy in Subjects With Solid Tumors,8903
0,NCT02517398,Phase I,Recruiting,"[{'id': 5860, 'therapyName': 'M7824'}]",MSB0011359C (M7824) in Metastatic or Locally Advanced Solid Tumors,8834
0,NCT02873819,Phase II,Recruiting,"[{'id': 4614, 'therapyName': 'MAGE-A3 vaccine'}, {'id': 4615, 'therapyName': 'Cyclophosphamide + poly ICLC  + Sargramostim'}]",Safety and Efficacy Study of GL-0817 (With Cyclophosphamide) for the Prevention of Recurrence of Squamous Cell Carcinoma of the Oral Cavity,8495
0,NCT02330562,Phase I,Recruiting,"[{'id': 2166, 'therapyName': 'Bevacizumab + Marizomib'}]",Study of Marizomib With Bevacizumab in Bevacizumab-Na&#239;ve Subjects With WHO Grade IV Malignant Glioma,7440
0,NCT02320305,Phase I,"Active, not recruiting","[{'id': 3787, 'therapyName': 'MART-1 antigen'}, {'id': 3889, 'therapyName': 'GLA-SE + MART-1 antigen'}]",MART-1 Antigen With or Without TLR4 Agonist GLA-SE in Treating Patients With Stage II-IV Melanoma That Has Been Removed by Surgery,8239
0,NCT01470131,Phase III,Unknown status,"[{'id': 804, 'therapyName': 'Masitinib'}, {'id': 2470, 'therapyName': 'Bortezomib + Dexamethasone'}]",A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Patients With Relapse or Refractory Multiple Myeloma,6944
1,NCT00812240,Phase III,Unknown status,"[{'id': 804, 'therapyName': 'Masitinib'}, {'id': 770, 'therapyName': 'Imatinib'}]",A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Comparison to Imatinib in Patients With Gastro-Intestinal Stromal Tumour in First Line Medical Treatment,6944
2,NCT00814073,Phase III,Unknown status,"[{'id': 804, 'therapyName': 'Masitinib'}]","A Phase 3 Study to Compare Efficacy and Safety of Masitinib to Placebo in the Treatment of Patients With Smouldering Systemic, Indolent Systemic or Cutaneous Mastocytosis With Handicap",6944
3,NCT02605044,Phase III,Recruiting,"[{'id': 804, 'therapyName': 'Masitinib'}, {'id': 1315, 'therapyName': 'FOLFIRI'}]",Study to Compare the Efficacy and Safety of Masitinib in Combination With FOLFIRI to Placebo in Combination With FOLFIRI in Second Line Treatment of Patients With Metastatic Colorectal Cancer,6944
0,NCT02608268,Phase Ib/II,Recruiting,"[{'id': 2659, 'therapyName': 'PDR001'}, {'id': 3560, 'therapyName': 'MBG453'}]",Safety and Efficacy of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies,8137
0,NCT03285607,Phase I,Not yet recruiting,"[{'id': 6236, 'therapyName': 'Cyclophosphamide + Doxorubicin + Paclitaxel + MCS110'}]","MCS110 Combined With Neoadjuvant Doxorubicin, Cyclophosphamide, and Weekly Paclitaxel in Patients With Hormone-Receptor Positive and HER2- Breast Cancer",7775
1,NCT01643850,Phase II,Recruiting,"[{'id': 2838, 'therapyName': 'MCS110'}]",MCS110 in Patients With Pigmented Villonodular Synovitis (PVNS) or Giant Cell Tumor of the Tendon Sheath (GCTTS),7775
2,NCT02435680,Phase II,"Active, not recruiting","[{'id': 2838, 'therapyName': 'MCS110'}, {'id': 2667, 'therapyName': 'Carboplatin + Gemcitabine'}]",Efficacy Study of MCS110 Given With Carboplatin and Gemcitabine in Advanced Triple Negative Breast Cancer (TNBC),7775
3,NCT02807844,Phase Ib/II,Recruiting,"[{'id': 5072, 'therapyName': 'MCS110 + PDR001'}]",Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies,7775
0,NCT02100007,Phase Ib/II,Terminated,"[{'id': 2174, 'therapyName': 'ME-344 + Topotecan'}]",ME-344 Given in Combination With Hycamtin in Patients With Solid Tumors,7372
0,NCT01453205,Phase II,Completed,"[{'id': 2354, 'therapyName': 'Cisplatin + Cytarabine + Dexamethasone'}, {'id': 2352, 'therapyName': 'Carboplatin + Etoposide + Ifosfamide '}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 2407, 'therapyName': 'MEDI-551'}]","A Phase 2, Multicenter, Randomized, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)",7513
0,NCT02520791,Phase I,Recruiting,"[{'id': 4762, 'therapyName': 'MEDI-570'}]",Anti-ICOS Monoclonal Antibody MEDI-570 in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Follicular Variant or Angioimmunoblastic T-cell Lymphoma,8536
0,NCT03162224,Phase Ib/II,Recruiting,"[{'id': 5791, 'therapyName': 'Durvalumab + MEDI0457'}]",Safety and Efficacy of MEDI0457 and Durvalumab in Patients With HPV Associated Recurrent/Metastatic Head and Neck Cancer,8798
0,NCT02318394,Phase I,"Active, not recruiting","[{'id': 3838, 'therapyName': 'MEDI0562'}]",A Phase 1 Study of MEDI0562 in Adult Subjects With Selected Advanced Solid Tumors,8263
1,NCT02705482,Phase I,Recruiting,"[{'id': 3840, 'therapyName': 'MEDI0562 + Tremelimumab'}, {'id': 3839, 'therapyName': 'MEDI0562 + MEDI4736'}]",A Study to Evaluate MEDI0562 in Combination With Immune Therapeutic Agents in Adult Subjects With Advanced Solid Tumors,8263
2,NCT02701400,Phase II,Recruiting,"[{'id': 3840, 'therapyName': 'MEDI0562 + Tremelimumab'}]",Tremelimumab and Durvalumab With or Without Radiation Therapy in Patients With Relapsed Small Cell Lung Cancer,8263
0,NCT01577745,Phase I,Completed,"[{'id': 2546, 'therapyName': 'MEDI0639'}]","A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI0639 in Advanced Solid Tumors",7575
0,NCT02013804,Phase I,Completed,"[{'id': 3120, 'therapyName': 'MEDI0680'}]",A Phase 1 Multicenter Open-label Study to Evaluate the Safety Tolerability and PK of MEDI0680 (AMP-514) in Subjects With Advanced Malignancies,7949
1,NCT02118337,Phase I,Recruiting,"[{'id': 3121, 'therapyName': 'MEDI0680 + MEDI4736'}]","A Phase 1, Open-label Study to Evaluate the Safety and Tolerability of MEDI0680 (AMP-514) in Combination With MEDI4736 in Subjects With Advanced Malignancies",7949
0,NCT02141542,Phase I,"Active, not recruiting","[{'id': 1652, 'therapyName': 'Tremelimumab'}, {'id': 1176, 'therapyName': 'MEDI3617'}]",Phase I Clinical Trial of Tremelimumab Plus MEDI3617 in Patients With Unresectable Stage III or Stage IV Melanoma,7214
1,NCT01248949,Phase I,Completed,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1176, 'therapyName': 'MEDI3617'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]",A Study to Evaluate the Safety and Antitumor Activity in Subjects With Advanced Solid Tumors,7214
0,NCT02991911,Phase I,Recruiting,"[{'id': 5217, 'therapyName': 'Enzalutamide + MEDI3726'}, {'id': 5216, 'therapyName': 'MEDI3726'}]",A Phase 1/1b Study of MEDI3726 in Adults Subjects With Metastatic Castration Resistant Prostate Cancer,8637
0,NCT03089645,Phase I,Recruiting,"[{'id': 5588, 'therapyName': 'MEDI5083'}, {'id': 5589, 'therapyName': 'MEDI4736 + MEDI5083'}]",MEDI5083 Alone and in Combination With Durvalumab in Subjects With Select Advanced Solid Tumors,8724
0,NCT02221960,Phase I,"Active, not recruiting","[{'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 3119, 'therapyName': 'MEDI6383'}]",A Phase 1 Study to Evaluate MEDI6383 Alone and in Combination With MEDI4736 in Adult Subjects With Select Advanced Solid Tumors,7948
0,NCT02559024,Phase I,"Active, not recruiting","[{'id': 1653, 'therapyName': 'MEDI6469'}]",Anti-OX40 Antibody (MEDI6469) in Patients With Metastatic Colorectal Cancer,7308
1,NCT02205333,Phase Ib/II,Terminated,"[{'id': 897, 'therapyName': 'Rituximab'}, {'id': 1653, 'therapyName': 'MEDI6469'}, {'id': 1652, 'therapyName': 'Tremelimumab'}, {'id': 1356, 'therapyName': 'Durvalumab'}]",A Phase 1b/2 Safety and Tolerability of MEDI6469 in Combination With Therapeutic Immune Agents or Monoclonal Antibodies,7308
2,NCT01862900,Phase Ib/II,"Active, not recruiting","[{'id': 1653, 'therapyName': 'MEDI6469'}]",Stereotactic Body Radiation and Monoclonal Antibody to OX40 (MEDI6469) in Breast Cancer Patients With Metastatic Lesions,7308
0,NCT03106428,Phase I,Recruiting,"[{'id': 5762, 'therapyName': 'MEDI7247'}]",A Multiple Ascending Dose Study of MEDI7247 in Patients With Selected Relapsed/Refractory Hematological Malignancies,8783
0,NCT02900157,Phase I,"Active, not recruiting","[{'id': 4727, 'therapyName': 'MEDI4736 + MEDI9090'}]",Study to Evaluate the Safety and Pharmacokinetics of MEDI9090 in Subjects With Advanced Solid Tumors,8533
0,NCT02556463,Phase I,Recruiting,"[{'id': 5457, 'therapyName': 'MEDI9197'}, {'id': 5458, 'therapyName': 'MEDI9197 + MEDI4736'}]",A Study of MEDI9197 in Subjects With Solid Tumors or CTCL and in Combination With Durvalumab and Palliative Radiation in Subjects With Solid Tumors,8696
0,NCT02503774,Phase I,Recruiting,"[{'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 3089, 'therapyName': 'MEDI9447'}]",MEDI9447 Alone and in Combination With MEDI4736 in Adult Subjects With Select Advanced Solid Tumors,7934
0,NCT03018249,Phase II,Recruiting,"[{'id': 2401, 'therapyName': 'Medroxyprogesterone'}, {'id': 5203, 'therapyName': 'Medroxyprogesterone + Entinostat'}]",Medroxyprogesterone Acetate With or Without Entinostat Before Surgery in Treating Patients With Endometrioid Endometrial Cancer,593
1,NCT02228681,Phase II,"Active, not recruiting","[{'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 2401, 'therapyName': 'Medroxyprogesterone'}, {'id': 1621, 'therapyName': 'Everolimus + Letrozole'}]",Everolimus and Letrozole or Hormonal Therapy to Treat Endometrial Cancer,593
2,NCT02335203,Phase II,"Active, not recruiting","[{'id': 2401, 'therapyName': 'Medroxyprogesterone'}]",The Effect of Neoadjuvant DMPA on Glandular Cellularity in Women Awaiting Hysterectomy,593
0,NCT01577173,Phase II,Completed,"[{'id': 694, 'therapyName': 'Cetuximab'}, {'id': 806, 'therapyName': 'MEHD7945A'}]",A Study of MEHD7945A Versus Cetuximab in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of The Head And Neck,6946
1,NCT01652482,Phase II,Completed,"[{'id': 694, 'therapyName': 'Cetuximab'}, {'id': 806, 'therapyName': 'MEHD7945A'}, {'id': 1315, 'therapyName': 'FOLFIRI'}]",A Study of MEHD7945A + FOLFIRI Versus Cetuximab + FOLFIRI in Second Line in Patients With KRAS Wild-Type Metastatic Colorectal Cancer,6946
2,NCT01986166,Phase I,Completed,"[{'id': 1342, 'therapyName': 'MEHD7945A + Cobimetinib'}]",A Study of MEHD7945A and Cobimetinib (GDC-0973) in Patients With Locally Advanced or Metastatic Cancers With Mutant KRAS,6946
0,NCT02334735,Phase II,Recruiting,"[{'id': 2595, 'therapyName': 'poly ICLC  '}, {'id': 3012, 'therapyName': 'Melan-A/MART-1 peptide vaccine'}, {'id': 2696, 'therapyName': 'NY-ESO-1 peptide vaccine'}]",A Comparison of Matured Dendritic Cells and Montanide&#174; in Study Subjects With High Risk of Melanoma Recurrence,7909
0,NCT01961115,Phase II,"Active, not recruiting","[{'id': 2575, 'therapyName': 'Epacadostat'}, {'id': 3016, 'therapyName': 'MELITAC 12.1 Peptide Vaccine '}]",INCB024360 and Vaccine Therapy in Treating Patients With Stage III-IV Melanoma,7912
0,NCT02130869,Phase I,Recruiting,"[{'id': 2378, 'therapyName': 'Bendamustine + Cytarabine + Etoposide'}, {'id': 2460, 'therapyName': 'Busulfan + Hu14.18K322A'}, {'id': 2459, 'therapyName': 'Aldesleukin + Melphalan + Sargramostim'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1791, 'therapyName': 'Carboplatin + Etoposide'}]",A Pilot Study of Immunotherapy Including Haploidentical NK Cell Infusion Following CD133+ Positively-Selected Autologous Hematopoietic Stem Cells in Children With High Risk Solid Tumors or Lymphomas,1030
1,NCT01476839,Phase I,Recruiting,"[{'id': 6258, 'therapyName': 'Basiliximab + 90Y basiliximab + Carmustine + Cytarbine + Etoposide + Melphalan'}]",Radiolabeled Monoclonal Antibody Therapy and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Primary Refractory or Relapsed Hodgkin Lymphoma,1030
2,NCT01163357,Phase I,Recruiting,"[{'id': 917, 'therapyName': 'Sirolimus'}, {'id': 2288, 'therapyName': 'Bortezomib + Fludarabine + Melphalan'}]","Bortezomib, Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant For High-Risk Stage I or II Multiple Myeloma",1030
3,NCT02961816,Phase II,Withdrawn,"[{'id': 3277, 'therapyName': 'Pyridoxine'}, {'id': 4976, 'therapyName': 'Busulfan + Gemcitabine + Melphalan + Panobinostat'}, {'id': 4977, 'therapyName': 'Dexamethasone + Filgrastim + Palifermin + Rituximab'}]",Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Lymphoma,1030
4,NCT00020566,Phase III,Unknown status,"[{'id': 2558, 'therapyName': 'Busulfan + Melphalan'}, {'id': 2670, 'therapyName': 'Vincristine + Doxorubicin + Dactinomycin + Ifosfamide + Etoposide'}]","Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation, Radiation Therapy, and/or Surgery in Treating Patients With Ewing's Sarcoma",1030
5,NCT00084695,Phase II,Unknown status,"[{'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 2558, 'therapyName': 'Busulfan + Melphalan'}, {'id': 1844, 'therapyName': 'anti-thymocyte globulin'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 2188, 'therapyName': 'Prednisone'}]",Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases,1030
6,NCT01175356,Phase I,Completed,"[{'id': 2558, 'therapyName': 'Busulfan + Melphalan'}, {'id': 2590, 'therapyName': 'Cyclophosphamide + Topotecan'}, {'id': 1425, 'therapyName': '131I-MIBG'}, {'id': 2353, 'therapyName': 'Cyclophosphamide + Doxorubicin + Vincristine '}, {'id': 2585, 'therapyName': 'Cisplatin + Etoposide'}]","Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin",1030
7,NCT02506959,Phase II,Recruiting,"[{'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 2558, 'therapyName': 'Busulfan + Melphalan'}, {'id': 3277, 'therapyName': 'Pyridoxine'}, {'id': 1080, 'therapyName': 'Panobinostat'}, {'id': 2373, 'therapyName': 'Palifermin'}, {'id': 755, 'therapyName': 'Gemcitabine'}]",Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Myeloma,1030
8,NCT01505569,Phase I,Recruiting,"[{'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 2558, 'therapyName': 'Busulfan + Melphalan'}, {'id': 2101, 'therapyName': 'Etoposide + Ifosfamide'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 1092, 'therapyName': 'Carboplatin'}]",Auto Transplant for High Risk or Relapsed Solid or CNS Tumors,1030
9,NCT01983969,Phase Ib/II,"Active, not recruiting","[{'id': 897, 'therapyName': 'Rituximab'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 2558, 'therapyName': 'Busulfan + Melphalan'}, {'id': 2557, 'therapyName': 'Azacitidine + Gemcitabine + vorinostat'}]",Aza-SAHA-GBM With AutoSCT for Refractory Lymphoma,1030
10,NCT02589145,Phase Ib/II,Recruiting,"[{'id': 1164, 'therapyName': 'lenalidomide'}, {'id': 3277, 'therapyName': 'Pyridoxine'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 2558, 'therapyName': 'Busulfan + Melphalan'}, {'id': 3278, 'therapyName': 'Enoxaparin'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 2373, 'therapyName': 'Palifermin'}]",Lenalidomide Combined With Vorinostat/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Diffuse Large B-Cell Lymphoma of the ABC Subtype,1030
11,NCT01857934,Phase II,Recruiting,"[{'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1873, 'therapyName': 'Sargramostim'}, {'id': 1167, 'therapyName': 'Aldesleukin'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 2627, 'therapyName': 'Levetiracetam'}, {'id': 2585, 'therapyName': 'Cisplatin + Etoposide'}, {'id': 2458, 'therapyName': 'Hu14.18K322A'}, {'id': 2558, 'therapyName': 'Busulfan + Melphalan'}, {'id': 2590, 'therapyName': 'Cyclophosphamide + Topotecan'}]",Therapy for Children With Advanced Stage Neuroblastoma,1030
12,NCT02116959,Phase I,Unknown status,"[{'id': 2559, 'therapyName': 'Carboplatin + Etoposide + Melphalan + Vincristine'}]",Alternating Systemic Chemotherapy and Intra-Arterial Melphalan Chemotherapy in Children With Intra-Ocular Retinoblastoma,1030
13,NCT00983398,Phase Ib/II,Recruiting,"[{'id': 1476, 'therapyName': 'Pegfilgrastim'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 2587, 'therapyName': 'Carboplatin + Melphalan'}]","Melphalan, Carboplatin, and Sodium Thiosulfate for Patients With Central Nervous System (CNS) Embryonal or Germ Cell Tumors",1030
14,NCT02570542,Phase II,Recruiting,"[{'id': 1756, 'therapyName': 'Plerixafor'}, {'id': 3359, 'therapyName': 'Carmustine + Cytarabine + Etoposide + Melphalan'}]",Impact of CD34+ Cell Dose on Progression-free Survival Following High-Dose Therapy and Autologous Stem Cell Transplantation for Relapsed and Refractory Diffuse Large B-cell Lymphoma (DLBCL),1030
15,NCT02443077,Phase III,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 3359, 'therapyName': 'Carmustine + Cytarabine + Etoposide + Melphalan'}, {'id': 768, 'therapyName': 'Ibrutinib'}]",Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma,1030
16,NCT01885689,Phase II,Recruiting,"[{'id': 2236, 'therapyName': 'Clofarabine + Melphalan'}]",Clofarabine and Melphalan Before Donor Stem Cell Transplant in Treating Patients With Myelodysplasia or Acute Leukemia in Remission,1030
17,NCT01804634,Phase II,Recruiting,"[{'id': 1373, 'therapyName': 'Cyclophosphamide + Fludarabine + Melphalan + Sirolimus'}]",A Phase II Trial of Reduced Intensity Conditioning and Haploidentical BMT for High-risk Solid Tumors,1030
18,NCT02556931,Phase II,Recruiting,"[{'id': 4228, 'therapyName': 'Cyclophosphamide + Fludarabine + Melphalan + Tacrolimus'}]","Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies",1030
19,NCT01323517,Phase II,Recruiting,"[{'id': 5900, 'therapyName': 'Dactinomycin + Ipilimumab + Melphalan'}]",Addition of Ipilimumab (MDX-010) To Isolated Limb Infusion (ILI) With Standard Melphalan and Dactinomycin In The Treatment of Advanced Unresectable Melanoma of The Extremity,1030
20,NCT02780609,Phase Ib/II,Recruiting,"[{'id': 4221, 'therapyName': 'Dexamethasone + Melphalan + Selinexor'}]",Selinexor Plus High-Dose Melphalan (HDM) Before Autologous Hematopoietic Cell Transplantation for Multiple Myeloma,1030
21,NCT00936936,Phase II,Recruiting,"[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 2101, 'therapyName': 'Etoposide + Ifosfamide'}, {'id': 2100, 'therapyName': 'Docetaxel + Gemcitabine + Melphalan'}, {'id': 2074, 'therapyName': 'Bevacizumab + Carboplatin'}]",High-dose Chemotherapy for Poor-prognosis Relapsed Germ-Cell Tumors,1030
22,NCT00303849,Phase Ib/II,Recruiting,"[{'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 2562, 'therapyName': 'Etoposide + Melphalan'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1476, 'therapyName': 'Pegfilgrastim'}]",Combination Chemotherapy With BBBD Followed By Sodium Thiosulfate in Treating Patients With Anaplastic Oligodendroglioma or Oligoastrocytoma,1030
23,NCT01453101,Phase II,"Active, not recruiting","[{'id': 2237, 'therapyName': 'Fludarabine + Melphalan'}, {'id': 688, 'therapyName': 'Bortezomib'}]",Allogeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma,1030
24,NCT02771197,Phase II,Recruiting,"[{'id': 2237, 'therapyName': 'Fludarabine + Melphalan'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Lymphodepletion and Anti-PD-1 Blockade to Reduce Relapse in AML Patient Not Eligible for Transplant,1030
25,NCT02440464,Phase II,Recruiting,"[{'id': 3321, 'therapyName': 'Tacrolimus + Methotrexate'}, {'id': 1359, 'therapyName': 'Ixazomib'}, {'id': 2237, 'therapyName': 'Fludarabine + Melphalan'}, {'id': 688, 'therapyName': 'Bortezomib'}]",Allogeneic Hematopoietic Stem Cell Transplantation With Ixazomib for High Risk Multiple Myeloma (BMT CTN 1302),1030
26,NCT02508038,Phase I,Recruiting,"[{'id': 2971, 'therapyName': 'Zoledronic acid'}, {'id': 2237, 'therapyName': 'Fludarabine + Melphalan'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 1844, 'therapyName': 'anti-thymocyte globulin'}, {'id': 1845, 'therapyName': 'Mycophenolate mofetil'}]", Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa,1030
27,NCT02528877,Phase I,Withdrawn,"[{'id': 2237, 'therapyName': 'Fludarabine + Melphalan'}, {'id': 3181, 'therapyName': 'Ruxolitinib + Sirolimus + Tacrolimus'}]","Ruxolitinib Phosphate, Tacrolimus and Sirolimus in Preventing Acute Graft-versus-Host Disease During Reduced Intensity Donor Hematopoietic Cell Transplant in Patients With Myelofibrosis",1030
28,NCT02333162,Phase I,Recruiting,"[{'id': 1845, 'therapyName': 'Mycophenolate mofetil'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 2237, 'therapyName': 'Fludarabine + Melphalan'}]","Intensity Modulated Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients With Relapsed Hematologic Cancers Undergoing a Second Donor Stem Cell Transplant",1030
29,NCT00577278,Phase II,"Active, not recruiting","[{'id': 767, 'therapyName': 'Ibritumomab'}, {'id': 2238, 'therapyName': 'Sirolimus + Tacrolimus + Methotrexate'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 2237, 'therapyName': 'Fludarabine + Melphalan'}]","Yttrium Y 90 Ibritumomab Tiuxetan, Rituximab, Indium In-111 Ibritumomab Tiuxetan, Fludarabine, Melphalan, and Donor Stem Cell Transplant in Treating Patients With B-Cell Non-Hodgkin Lymphoma",1030
30,NCT02653196,Phase II,Terminated,"[{'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1205, 'therapyName': 'Alemtuzumab'}, {'id': 2373, 'therapyName': 'Palifermin'}, {'id': 2237, 'therapyName': 'Fludarabine + Melphalan'}, {'id': 3948, 'therapyName': 'Cyclosporine + Mycophenolate mofetil + Tacrolimus'}]",A Multi-Institutional Phase II Feasibility Study of Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Malignant Neuro-Epithelial and Other Solid Tumors,1030
31,NCT01619761,Phase I,Recruiting,"[{'id': 897, 'therapyName': 'Rituximab'}, {'id': 1847, 'therapyName': 'lenalidomide + Fludarabine + Melphalan'}, {'id': 1845, 'therapyName': 'Mycophenolate mofetil'}, {'id': 1843, 'therapyName': 'Tacrolimus'}]",Natural Killer (NK) Cells in Cord Blood Transplantation,1030
32,NCT02097134,Phase I,"Active, not recruiting","[{'id': 1207, 'therapyName': 'Melphalan'}]",Intra-arterial Melphalan in Treating Younger Patients With Unilateral Retinoblastoma,1030
33,NCT01453088,Phase II,Recruiting,"[{'id': 1207, 'therapyName': 'Melphalan'}, {'id': 688, 'therapyName': 'Bortezomib'}]",Auto Transplant High Dose Melphalan vs High Dose Melphalan+Bortezomib in Pts With Multiple Myeloma Age 65 Years or Older,1030
34,NCT01998971,Phase I,Recruiting,"[{'id': 1622, 'therapyName': 'Pomalidomide'}, {'id': 2470, 'therapyName': 'Bortezomib + Dexamethasone'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1475, 'therapyName': 'Thalidomide'}, {'id': 1164, 'therapyName': 'lenalidomide'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 1630, 'therapyName': 'Daratumumab'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 1275, 'therapyName': 'Diphenhydramine'}, {'id': 3323, 'therapyName': 'Montelukast'}]",A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma,1030
35,NCT03126916,Phase III,Not yet recruiting,"[{'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1425, 'therapyName': '131I-MIBG'}, {'id': 1873, 'therapyName': 'Sargramostim'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 5595, 'therapyName': 'Isotretinoin'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 5153, 'therapyName': 'dexrazoxane'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1167, 'therapyName': 'Aldesleukin'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 2286, 'therapyName': 'Dinutuximab  '}]",Iobenguane I-131 or Crizotinib and Standard Therapy in Treating Younger Patients With Newly-Diagnosed High-Risk Neuroblastoma or Ganglioneuroblastoma,1030
36,NCT02756572,Phase I,Recruiting,"[{'id': 917, 'therapyName': 'Sirolimus'}, {'id': 1845, 'therapyName': 'Mycophenolate mofetil'}, {'id': 1650, 'therapyName': 'Cyclosporine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 5215, 'therapyName': 'mitoxantrone hydrochloride'}, {'id': 1166, 'therapyName': 'Fludarabine'}]",Early Allogeneic Hematopoietic Cell Transplantation in Treating Patients With Relapsed or Refractory High-Grade Myelodysplastic Syndrome or Acute Myeloid Leukemia,1030
37,NCT02788201,Phase II,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1133, 'therapyName': 'Mitomycin C'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1013, 'therapyName': 'epirubicin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1137, 'therapyName': 'Bleomycin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 781, 'therapyName': 'Ixabepilone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 2950, 'therapyName': 'Estramustine'}, {'id': 1941, 'therapyName': 'Floxuridine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 1811, 'therapyName': 'Carmustine'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 953, 'therapyName': 'Vandetanib'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 4419, 'therapyName': 'Toremifine'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 2601, 'therapyName': 'Dactinomycin'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 3035, 'therapyName': 'Chlorambucil'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 342, 'therapyName': 'Vemurafenib'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 2635, 'therapyName': 'Vinblastine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 4305, 'therapyName': 'Teniposide'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 4304, 'therapyName': 'Streptozocin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1231, 'therapyName': 'Bendamustine'}, {'id': 4303, 'therapyName': 'Mechlorethamine'}, {'id': 4302, 'therapyName': 'Mitotane'}]",Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma,1030
38,NCT02551718,Phase I,Recruiting,"[{'id': 690, 'therapyName': 'Bosutinib'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 3160, 'therapyName': 'Nelarabine'}, {'id': 3159, 'therapyName': 'Bexarotene'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 998, 'therapyName': 'cabozantinib'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 877, 'therapyName': 'Ponatinib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 623, 'therapyName': 'Afatinib'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 890, 'therapyName': 'Regorafenib'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 2, 'therapyName': 'Trametinib'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 3, 'therapyName': 'Dabrafenib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 789, 'therapyName': 'Ceritinib'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1571, 'therapyName': 'Cabazitaxel'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1327, 'therapyName': 'Pralatrexate'}]",High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia,1030
39,NCT02790515,Phase II,Recruiting,"[{'id': 917, 'therapyName': 'Sirolimus'}, {'id': 1844, 'therapyName': 'anti-thymocyte globulin'}, {'id': 1876, 'therapyName': 'Blinatumomab '}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 5682, 'therapyName': 'Mesna'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1632, 'therapyName': 'Filgrastim'}]",Provision of TCR?? T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation,1030
40,NCT02472392,Phase I,Completed,"[{'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1844, 'therapyName': 'anti-thymocyte globulin'}]",Study To Examine Toxicity Of Allogeneic Stem Cell Transplantation For Relapsed Or Therapy Refractory Ewings Sarcoma,1030
41,NCT01526096,Phase I,Recruiting,"[{'id': 5985, 'therapyName': 'Basiliximab'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1756, 'therapyName': 'Plerixafor'}, {'id': 1207, 'therapyName': 'Melphalan'}]",Stem Cell Transplantation for Patients With Multiple Myeloma,1030
42,NCT02678572,Phase III,Recruiting,"[{'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Percutaneous Hepatic Perfusion vs Best Alternative Care in Patients With Hepatic-dominant Ocular Melanoma,1030
43,NCT03030261,Phase II,Not yet recruiting,"[{'id': 1207, 'therapyName': 'Melphalan'}, {'id': 3355, 'therapyName': 'Elotuzumab + Dexamethasone + Pomalidomide'}]","Elotuzumab, Pomalidomide, & Dexamethasone (Elo-Pom-Dex) With Second Autologous Stem Cell Transplantation for Relapsed Multiple Myeloma",1030
44,NCT02701673,Phase Ib/II,Withdrawn,"[{'id': 651, 'therapyName': 'Azacitidine'}, {'id': 3277, 'therapyName': 'Pyridoxine'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1078, 'therapyName': 'Belinostat'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1207, 'therapyName': 'Melphalan'}]",Belinostat Combined With Azacitidine/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Refractory or Relapsed Lymphoma,1030
45,NCT01529827,Phase II,"Active, not recruiting","[{'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 1845, 'therapyName': 'Mycophenolate mofetil'}, {'id': 1166, 'therapyName': 'Fludarabine'}]","Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies",1030
46,NCT00550992,Phase I,Unknown status,"[{'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1752, 'therapyName': 'Mitoxantrone + Etoposide + Cytarabine'}, {'id': 1848, 'therapyName': 'Cyclophosphamide + Methotrexate + Vincristine + Pegaspargase '}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1650, 'therapyName': 'Cyclosporine'}, {'id': 1844, 'therapyName': 'anti-thymocyte globulin'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1642, 'therapyName': 'Leucovorin'}]",Different Therapies in Treating Infants With Newly Diagnosed Acute Leukemia,1030
47,NCT03004287,Phase II,Recruiting,"[{'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1164, 'therapyName': 'lenalidomide'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 1630, 'therapyName': 'Daratumumab'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1475, 'therapyName': 'Thalidomide'}]",2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy,1030
48,NCT02342782,Phase I,Recruiting,"[{'id': 2485, 'therapyName': '90Y basiliximab'}, {'id': 1811, 'therapyName': 'Carmustine'}, {'id': 2392, 'therapyName': 'Cytarabine + Etoposide'}, {'id': 1207, 'therapyName': 'Melphalan'}]",Yttrium Y 90 Basiliximab and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Mature T-cell Non-Hodgkin Lymphoma,1030
49,NCT02195479,Phase III,Recruiting,"[{'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1630, 'therapyName': 'Daratumumab'}, {'id': 1207, 'therapyName': 'Melphalan'}]",A Study of Combination of Daratumumanb and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma,1030
50,NCT02251821,Phase II,Recruiting,"[{'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 1845, 'therapyName': 'Mycophenolate mofetil'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 2006, 'therapyName': 'Pacritinib'}, {'id': 823, 'therapyName': 'Momelotinib'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}]",JAK-2 Inhibitor Before Donor Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis,1030
51,NCT01625351,Phase I,"Active, not recruiting","[{'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1205, 'therapyName': 'Alemtuzumab'}]",A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas,1030
52,NCT01526603,Phase I,Recruiting,"[{'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1092, 'therapyName': 'Carboplatin'}]",High Dose Chemotherapy and Autologous Transplant for Neuroblastoma,1030
53,NCT02406508,Phase II,Recruiting,"[{'id': 1207, 'therapyName': 'Melphalan'}, {'id': 920, 'therapyName': 'Sorafenib'}]",Sequential Melphalan for Use With Hepatic Delivery System Treatment Followed by Sorafenib in Patients With Unresectable HCC,1030
54,NCT03259503,Phase Ib/II,Not yet recruiting,"[{'id': 1206, 'therapyName': 'Busulfan'}, {'id': 837, 'therapyName': 'Olaparib'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 2373, 'therapyName': 'Palifermin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 3277, 'therapyName': 'Pyridoxine'}, {'id': 897, 'therapyName': 'Rituximab'}]",Olaparib Combined With High-Dose Chemotherapy for Refractory Lymphomas,1030
55,NCT01256398,Phase II,"Active, not recruiting","[{'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 2291, 'therapyName': 'Cyclophosphamide + Fludarabine'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1824, 'therapyName': 'Vincristine + Methotrexate + Mercaptopurine'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 2391, 'therapyName': 'Cytarabine + Daunorubicin + Etoposide'}, {'id': 1476, 'therapyName': 'Pegfilgrastim'}, {'id': 1205, 'therapyName': 'Alemtuzumab'}, {'id': 1642, 'therapyName': 'Leucovorin'}]",Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,1030
56,NCT01729091,Phase Ib/II,Recruiting,"[{'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 3343, 'therapyName': 'Elotuzumab'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1164, 'therapyName': 'lenalidomide'}]",Study of Umbilical Cord Blood-derived Natural Killer Cells in Conjunction With High Dose Chemotherapy and Autologous Stem Cell Transplant for Patients With Multiple Myeloma,1030
57,NCT02331368,Phase II,"Active, not recruiting","[{'id': 1164, 'therapyName': 'lenalidomide'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Phase 2 Multi-center Study of Anti-PD-1 During Lymphopenic State After HDT/ASCT for Multiple Myeloma,1030
58,NCT00734877,Phase III,Recruiting,"[{'id': 1851, 'therapyName': 'Cisplatin + Doxorubicin + Cyclophosphamide + Etoposide'}, {'id': 1852, 'therapyName': 'Melphalan + Bortezomib + Thalidomide + Dexamethasone'}]","UARK 2008-01, Total Therapy 4 - A Phase III Trial for Low Risk Myeloma",1030
59,NCT01849783,Phase II,Recruiting,"[{'id': 1852, 'therapyName': 'Melphalan + Bortezomib + Thalidomide + Dexamethasone'}, {'id': 3435, 'therapyName': 'Aldoxorubicin + Cisplatin + Cyclophosphamide + Dexamethasone + Etoposide'}]",Autologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple Myeloma,1030
60,NCT02700841,Phase II,Recruiting,"[{'id': 5344, 'therapyName': 'Melphalan + PVX-410'}]",Enhancing Anti-Myeloma Vaccine Response After Autologous Stem Cell Transplantation,1030
0,NCT02792114,Phase I,Recruiting,"[{'id': 5992, 'therapyName': 'Rimiducid'}, {'id': 6029, 'therapyName': 'Mesothelin CAR-T cells'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}]",T-Cell Therapy for Advanced Breast Cancer,8896
0,NCT02336087,Phase I,Recruiting,"[{'id': 2204, 'therapyName': 'Abraxane + Gemcitabine + Metformin'}]","Gemcitabine Hydrochloride, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Metformin Hydrochloride, and a Standardized Dietary Supplement in Treating Patients With Metastatic Pancreatic Cancer",323
1,NCT01980823,Phase I,Recruiting,"[{'id': 1576, 'therapyName': 'Atorvastatin + Metformin'}]",Pre-Surgical Trial of the Combination of Metformin and Atorvastatin in Newly Diagnosed Operable Breast Cancer,323
2,NCT02497638,Phase II,Recruiting,"[{'id': 1576, 'therapyName': 'Atorvastatin + Metformin'}]",LIpitor and biGuanide to Androgen Delay Trial,323
3,NCT02949700,Phase Ib/II,Recruiting,"[{'id': 2205, 'therapyName': 'Cisplatin + Metformin'}]",Phase I/II Study OF Metformin in Combination With Cisplatin and Radiation in Head and Neck Squamous Cell Carcinoma,323
4,NCT02325401,Phase I,Recruiting,"[{'id': 2205, 'therapyName': 'Cisplatin + Metformin'}]",Dose-finding Study of Metformin With Chemoradiation in Locally Advanced Head and Neck Squamous Cell Carcinoma,323
5,NCT02143050,Phase Ib/II,Recruiting,"[{'id': 1443, 'therapyName': 'Dabrafenib + Trametinib + Metformin'}]","Study of Dabrafenib, Trametinib and Metformin for Melanoma Patients",323
6,NCT02339168,Phase I,Recruiting,"[{'id': 2202, 'therapyName': 'Enzalutamide + Metformin'}]",Enzalutamide and Metformin Hydrochloride in Treating Patients With Hormone-Resistant Prostate Cancer,323
7,NCT01087983,Phase I,Completed,"[{'id': 1139, 'therapyName': 'Lapatinib + Sirolimus'}, {'id': 1140, 'therapyName': 'Lapatinib + Metformin'}]",Lapatinib With Sirolimus or Metformin,323
8,NCT01996696,Phase II,Recruiting,"[{'id': 1031, 'therapyName': 'Metformin'}]","A Study With or Without Metformin to Determine if Metformin Can Prevent Weight Gain and Other Problems (i.e. Diabetes, Increased Cholesterol, Etc.) That Can Arise From the Use of Hormonal Therapy in Combination With Radiation Therapy When Treating Aggressive Localized Prostate Cancer.",323
9,NCT02402348,Phase I,Terminated,"[{'id': 1031, 'therapyName': 'Metformin'}]","Pilot Study of Metformin in HNSCC to Investigate the Effects of MF, Tumor Genotype and MF-genotype Interactions, on Tumor Metabolism and Anoikis",323
10,NCT01877564,Phase II,Recruiting,"[{'id': 1031, 'therapyName': 'Metformin'}]",A Randomized Pilot Study to Evaluate the Effects of a Short Course of Metformin Versus No Therapy in the Period Prior to Hysterectomy for Grade 1-2 Adenocarcinoma of the Endometrium in Obese Non-Diabetic Women,323
11,NCT02376166,Phase I,Completed,"[{'id': 1031, 'therapyName': 'Metformin'}]",Metformin for Rising PSA Remote Trial,323
12,NCT02531308,Phase II,Terminated,"[{'id': 1031, 'therapyName': 'Metformin'}, {'id': 3266, 'therapyName': 'Cyclophosphamide + Doxorubicin + Prednisone + Vincristine '}, {'id': 1476, 'therapyName': 'Pegfilgrastim'}, {'id': 897, 'therapyName': 'Rituximab'}]",Metformin in Combination With Standard Induction Therapy for Large B-cell Lymphoma (DLBCL),323
13,NCT01324180,Phase I,Completed,"[{'id': 1031, 'therapyName': 'Metformin'}, {'id': 1830, 'therapyName': 'Vincristine + Dexamethasone + Pegaspargase + Doxorubicin'}]","Vincristine, Dexamethasone, Doxorubicin, and PEG-asparaginase (VPLD) and Metformin for Relapsed Childhood Acute Lymphoblastic Leukemia (ALL)",323
14,NCT01528046,Phase I,Recruiting,"[{'id': 1031, 'therapyName': 'Metformin'}, {'id': 1826, 'therapyName': 'Vincristine + Irinotecan + Temozolomide '}]",Metformin in Children With Relapsed or Refractory Solid Tumors,323
15,NCT01310231,Phase II,"Active, not recruiting","[{'id': 1031, 'therapyName': 'Metformin'}]",A Trial of Standard Chemotherapy With Metformin (vs Placebo) in Women With Metastatic Breast Cancer,323
16,NCT03086733,Phase II,Recruiting,"[{'id': 1031, 'therapyName': 'Metformin'}]",Phase II Lung Metcore - Preoperative Metformin for Lung Cancer (Metcore),323
17,NCT01302379,Phase I,"Active, not recruiting","[{'id': 1031, 'therapyName': 'Metformin'}]",Reach for Health Study: Obesity-related Mechanisms and Mortality in Breast Cancer Survivors,323
18,NCT02122185,Phase II,Recruiting,"[{'id': 1031, 'therapyName': 'Metformin'}, {'id': 1827, 'therapyName': 'Paclitaxel + Carboplatin + Docetaxel'}]","Metformin Hydrochloride and Combination Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",323
19,NCT01620593,Phase II,Completed,"[{'id': 1031, 'therapyName': 'Metformin'}]",Castration Compared to Castration Plus Metformin as First Line Treatment for Patients With Advanced Prostate Cancer,323
20,NCT02040376,Phase III,"Active, not recruiting","[{'id': 1031, 'therapyName': 'Metformin'}]",Placebo Controlled Double Blind Crossover Trial of Metformin for Brain Repair in Children With Cranial-Spinal Radiation for Medulloblastoma,323
21,NCT02048384,Phase Ib/II,Recruiting,"[{'id': 1593, 'therapyName': 'Sirolimus + Metformin'}, {'id': 1031, 'therapyName': 'Metformin'}]",A Study of Metformin With or Without Rapamycin as Maintenance Therapy After Induction Chemotherapy in Subjects With Pancreatic Cancer,323
22,NCT02278965,Phase I,"Active, not recruiting","[{'id': 1031, 'therapyName': 'Metformin'}]",Metformin and Omega-3 Fatty Acids in Woman With a History of Early Stage Breast Cancer,323
23,NCT01340300,Phase II,"Active, not recruiting","[{'id': 1031, 'therapyName': 'Metformin'}]",Exercise and Metformin in Colorectal and Breast Cancer Survivors,323
24,NCT01578551,Phase II,"Active, not recruiting","[{'id': 1031, 'therapyName': 'Metformin'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 667, 'therapyName': 'Bevacizumab'}]",A Randomized Phase II Study of Metformin Plus Paclitaxel/Carboplatin/Bevacizumab in Patients With Adenocarcinoma.,323
25,NCT02019979,Phase II,Terminated,"[{'id': 1031, 'therapyName': 'Metformin'}]",Metformin and Carbohydrate Restriction With Platinum Based Chemotherapy In Stage IIIB/IV Non-Squamous Non-Small Cell Lung Cancer (NS-NSCLC) (METRO),323
26,NCT02176161,Phase II,Recruiting,"[{'id': 1031, 'therapyName': 'Metformin'}]",Metformin Prostate Cancer Adjuvant Trial,323
27,NCT01430351,Phase I,"Active, not recruiting","[{'id': 1141, 'therapyName': 'Temozolomide'}, {'id': 1784, 'therapyName': 'Memantine'}, {'id': 1031, 'therapyName': 'Metformin'}, {'id': 1785, 'therapyName': 'Mefloquine'}]","Phase I Factorial Trial of Temozolomide, Memantine, Mefloquine, and Metformin for Post-Radiation Therapy (RT) Glioblastoma Multiforme (GBM)",323
28,NCT02815397,Phase II,Recruiting,"[{'id': 1031, 'therapyName': 'Metformin'}]",DA-EPOCH-Rituximab/Metformin (RM) for Double Hit Lymphoma,323
29,NCT01717482,Phase II,"Active, not recruiting","[{'id': 1031, 'therapyName': 'Metformin'}]",Metformin as a Chemoprevention Agent in Non-small Cell Lung Cancer,323
30,NCT01666730,Phase II,Recruiting,"[{'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 1031, 'therapyName': 'Metformin'}]",Metformin Plus Modified FOLFOX 6 in Metastatic Pancreatic Cancer,323
31,NCT02978547,Phase II,Not yet recruiting,"[{'id': 1031, 'therapyName': 'Metformin'}]",The Effects of Neoadjuvant Metformin on Tumour Cell Proliferation and Tumour Progression in Pancreatic Ductal Adenocarcinoma (Metformin 001),323
32,NCT02035787,Phase I,Recruiting,"[{'id': 1031, 'therapyName': 'Metformin'}]",Metformin With the Levonorgestrel-Releasing Intrauterine Device for the Treatment of Complex Atypical Hyperplasia (CAH) and Endometrial Cancer (EC) in Non-surgical Patients,323
33,NCT02437812,Phase II,Recruiting,"[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1031, 'therapyName': 'Metformin'}]","Study of Paclitaxel, Carboplatin and Oral Metformin in the Treatment of Advanced Stage Ovarian Carcinoma",323
34,NCT01750567,Phase II,Recruiting,"[{'id': 1031, 'therapyName': 'Metformin'}]",A Pilot Study of Metformin Therapy in Patients With Relapsed Chronic Lymphocytic Leukemia (CLL) and Untreated CLL,323
35,NCT01579812,Phase II,"Active, not recruiting","[{'id': 1031, 'therapyName': 'Metformin'}]","Evaluation of Metformin, Targeting Cancer Stem Cells for Prevention of Relapse in Gynecologic Patients",323
36,NCT01697566,Phase III,"Active, not recruiting","[{'id': 1031, 'therapyName': 'Metformin'}]",An Endometrial Cancer Chemoprevention Study of Metformin,323
37,NCT02186847,Phase II,"Active, not recruiting","[{'id': 1031, 'therapyName': 'Metformin'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]",Chemotherapy and Radiation Therapy With or Without Metformin Hydrochloride in Treating Patients With Stage III Non-small Cell Lung Cancer,323
38,NCT02285855,Phase II,Recruiting,"[{'id': 1031, 'therapyName': 'Metformin'}]",Metformin in Non Small Cell Lung Cancer (NSCLC),323
39,NCT02614859,Phase II,Recruiting,"[{'id': 1507, 'therapyName': 'Bicalutamide'}, {'id': 1031, 'therapyName': 'Metformin'}]",Bicalutamide With or Without Metformin for Biochemical Recurrence in Overweight or Obese Prostate Cancer Patients,323
40,NCT01954732,Phase I,Withdrawn,"[{'id': 1031, 'therapyName': 'Metformin'}]",Metformin Hydrochloride in Treating Patients With Pancreatic Cancer That Can be Removed by Surgery,323
41,NCT02394652,Phase II,Recruiting,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1031, 'therapyName': 'Metformin'}]",The Potential for Metformin to Improve Tumor Oxygenation in Locally Advanced Cervix Cancer,323
42,NCT03076281,Phase II,Recruiting,"[{'id': 1391, 'therapyName': 'Doxycycline'}, {'id': 4610, 'therapyName': 'Metformin + Doxycycline'}, {'id': 1031, 'therapyName': 'Metformin'}]",Metformin Hydrochloride and Doxycycline in Treating Patients With Head and Neck Squamous Cell Carcinoma That Can Be Removed by Surgery,323
43,NCT01797523,Phase II,"Active, not recruiting","[{'id': 794, 'therapyName': 'Letrozole'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 1031, 'therapyName': 'Metformin'}]",RAD/Letrozole/Metformin,323
44,NCT01864096,Phase III,Recruiting,"[{'id': 1031, 'therapyName': 'Metformin'}]",The Metformin Active Surveillance Trial (MAST) Study,323
45,NCT02153450,Phase I,Recruiting,"[{'id': 1031, 'therapyName': 'Metformin'}]",Stereotactic Radiosurgery and Metformin Hydrochloride in Treating Patients With Borderline-Resectable or Locally-Advanced Pancreatic Cancer,323
46,NCT01422746,,Recruiting,"[{'id': 1031, 'therapyName': 'Metformin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}]", Effect of Metformin on Adrenal or Ovarian Androgen Production in Overweight Pubertal Girls With Androgen Excess,323
47,NCT01793948,Phase I,"Active, not recruiting","[{'id': 1031, 'therapyName': 'Metformin'}]",Metformin Hydrochloride vs. Placebo in Overweight or Obese Patients at Elevated Risk for Breast Cancer,323
48,NCT03053544,Phase II,Recruiting,"[{'id': 1031, 'therapyName': 'Metformin'}]",Metformin With Neoadjuvant Chemoradiation to Improve Pathologic Responses in Rectal Cancer,323
49,NCT02083692,,Completed,"[{'id': 1031, 'therapyName': 'Metformin'}]",Pilot Study of Metformin in Head and Neck Squamous Cell Cancer and Its Effects on Stromal-epithelial Metabolic Uncoupling,323
50,NCT02042495,Phase II,Withdrawn,"[{'id': 1031, 'therapyName': 'Metformin'}]",Endometrial Cancer Biomarker Changes Following Exposure to Metformin,323
51,NCT02420652,Phase II,Recruiting,"[{'id': 1031, 'therapyName': 'Metformin'}]",Metformin Hydrochloride and Aspirin in Treating Patients With Hormone-Dependent Prostate Cancer That Has Progressed After Surgery or Radiation Therapy,323
52,NCT02780024,Phase II,Recruiting,"[{'id': 1031, 'therapyName': 'Metformin'}]","Metformin, Neo-adjuvant Temozolomide and Hypo- Accelerated Radiotherapy Followed by Adjuvant TMZ in Patients With GBM",323
53,NCT01981525,,Completed,"[{'id': 1031, 'therapyName': 'Metformin'}]",A Pilot Study of Metformin in Patients With a Diagnosis of Li-Fraumeni Syndrome,323
54,NCT01488552,Phase Ib/II,Completed,"[{'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 1315, 'therapyName': 'FOLFIRI'}, {'id': 1779, 'therapyName': 'Nab-paclitaxel + Gemcitabine'}, {'id': 1031, 'therapyName': 'Metformin'}]",Gemcitabine+Nab-paclitaxel and FOLFIRINOX and Molecular Profiling for Patients With Advanced Pancreatic Cancer,323
55,NCT03109873,Phase I,Recruiting,"[{'id': 1031, 'therapyName': 'Metformin'}]",Metformin Hydrochloride in Affecting Cytokines and Exosomes in Patients With Head and Neck Cancer,323
56,NCT02115464,Phase II,Recruiting,"[{'id': 1031, 'therapyName': 'Metformin'}]",Advanced Lung Cancer Treatment With Metformin and Chemo-Radiotherapy,323
57,NCT01849276,Phase I,"Active, not recruiting","[{'id': 1792, 'therapyName': 'Metformin + Cytarabine'}]",Metformin+Cytarabine for the Treatment of Relapsed/Refractory AML,323
58,NCT02874430,Phase II,Recruiting,"[{'id': 4610, 'therapyName': 'Metformin + Doxycycline'}]",Metformin Hydrochloride and Doxycycline in Treating Patients With Localized Breast or Uterine Cancer,323
59,NCT01650506,Phase I,Completed,"[{'id': 1828, 'therapyName': 'Metformin + Erlotinib'}]",Study of Erlotinib and Metformin in Triple Negative Breast Cancer,323
60,NCT03048500,Phase II,Not yet recruiting,"[{'id': 5302, 'therapyName': 'Metformin + Nivolumab'}]",Nivolumab and Metformin Hydrochloride in Treating Patients With Stage III-IV Non-small Cell Lung Cancer That Cannot Be Removed by Surgery,323
61,NCT03238495,Phase II,Recruiting,"[{'id': 1879, 'therapyName': 'Pertuzumab + Trastuzumab + Carboplatin + Docetaxel'}, {'id': 6101, 'therapyName': 'Metformin + Pertuzumab + Trastuzumab + Carboplatin + Docetaxel'}]",Randomized Trial of Neo-adjuvant Chemotherapy With or Without Metformin for HER2 Positive Operable Breast Cancer,323
62,NCT02948283,Phase 0,Recruiting,"[{'id': 4919, 'therapyName': 'Metformin + Ritonavir'}]",Metformin Hydrochloride and Ritonavir in Treating Patients With Relapsed or Refractory Multiple Myeloma or Chronic Lymphocytic Leukemia,323
63,NCT02360618,Phase II,Recruiting,"[{'id': 1829, 'therapyName': 'Metformin + Simvastatin'}]",Metformin and Simvastatin Use in Bladder Cancer,323
64,NCT01561482,Phase II,Withdrawn,"[{'id': 1829, 'therapyName': 'Metformin + Simvastatin'}]",Study of Metformin With Simvastatin for Men With Prostate Carcinoma,323
65,NCT02495103,Phase Ib/II,Recruiting,"[{'id': 2959, 'therapyName': 'Metformin + Vandetanib'}]",Vandetanib in Combination With Metformin in People With HLRCC or SDH-Associated Kidney Cancer or Sporadic Papillary Renal Cell Carcinoma,323
66,NCT03017833,Phase I,Not yet recruiting,"[{'id': 5197, 'therapyName': 'MLN0128 + Metformin'}]",Study of TAK-228 (MLN0128) in Combination With Metformin in Patients With Advanced Cancers,323
67,NCT03092635,Phase I,Recruiting,"[{'id': 5908, 'therapyName': 'OPC + Metformin'}]",AGE Levels in ER+ Metastatic Breast Cancer Patients Receiving Endocrine Therapy,323
68,NCT02050009,Phase I,Withdrawn,"[{'id': 1381, 'therapyName': 'Paclitaxel + Carboplatin + Metformin'}]","Metformin Hydrochloride, Carboplatin, and Paclitaxel in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",323
69,NCT02065687,Phase III,Recruiting,"[{'id': 1381, 'therapyName': 'Paclitaxel + Carboplatin + Metformin'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]","Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer",323
70,NCT02145559,Phase I,"Active, not recruiting","[{'id': 1593, 'therapyName': 'Sirolimus + Metformin'}, {'id': 917, 'therapyName': 'Sirolimus'}]",A Pharmacodynamic Study of Sirolimus and Metformin in Patients With Advanced Solid Tumors,323
71,NCT01529593,Phase I,Recruiting,"[{'id': 1325, 'therapyName': 'Temsirolimus + Metformin'}]",Temsirolimus in Combination With Metformin in Patients With Advanced Cancers,323
72,NCT01638676,Phase Ib/II,Recruiting,"[{'id': 1210, 'therapyName': 'Vemurafenib + Metformin '}]", A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients,323
0,NCT02177695,Phase II,Recruiting,"[{'id': 1467, 'therapyName': 'Gemcitabine + Cisplatin'}, {'id': 2564, 'therapyName': 'Aldoxorubicin + Cisplatin + Filgrastim + Methotrexate + Vinblastine'}]","S1314, Co-expression Extrapolation (COXEN) Program to Predict Chemotherapy Response in Patients With Bladder Cancer",553
1,NCT02412670,Phase II,Recruiting,"[{'id': 2667, 'therapyName': 'Carboplatin + Gemcitabine'}, {'id': 2668, 'therapyName': 'Aldoxorubicin + Cisplatin + Methotrexate + Vincristine'}]",Chemotherapy Before Surgery in Treating Patients With High Grade Upper Urinary Tract Cancer,553
2,NCT03263572,Phase II,Not yet recruiting,"[{'id': 6155, 'therapyName': 'Blinatumomab + Cytarabine + Dexamethasone + Methotrexate + Ponatinib'}, {'id': 6156, 'therapyName': 'Blinatumomab + Dexamethasone + Ponatinib'}]",Blinatumomab and Ponatinib in Patients With Philadelphia Chromosome (Ph)-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL),553
3,NCT00293475,Phase Ib/II,Recruiting,"[{'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1476, 'therapyName': 'Pegfilgrastim'}, {'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 2669, 'therapyName': 'Carboplatin + Methotrexate + Rituximab'}]",Rituximab and Methotrexate Chemotherapy w/Blood-Brain Barrier Disruption (BBBD) &amp; Sodium Thiosulfate Chemoprotection for Patients With Newly Diagnosed PCNSL,553
4,NCT02017964,Phase II,Completed,"[{'id': 1791, 'therapyName': 'Carboplatin + Etoposide'}, {'id': 2673, 'therapyName': 'Cyclophosphamide + Methotrexate + Vincristine  '}]","Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed, Non-Metastatic Desmoplastic Medulloblastoma",553
5,NCT00550992,Phase I,Unknown status,"[{'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1752, 'therapyName': 'Mitoxantrone + Etoposide + Cytarabine'}, {'id': 1848, 'therapyName': 'Cyclophosphamide + Methotrexate + Vincristine + Pegaspargase '}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1650, 'therapyName': 'Cyclosporine'}, {'id': 1844, 'therapyName': 'anti-thymocyte globulin'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1642, 'therapyName': 'Leucovorin'}]",Different Therapies in Treating Infants With Newly Diagnosed Acute Leukemia,553
6,NCT02723994,Phase II,Recruiting,"[{'id': 2188, 'therapyName': 'Prednisone'}, {'id': 4685, 'therapyName': 'Dexamethasone + Doxorubicin'}, {'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 2346, 'therapyName': 'Mercaptopurine + Thioguanine'}, {'id': 2394, 'therapyName': 'Asparaginase + Cytarabine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 1848, 'therapyName': 'Cyclophosphamide + Methotrexate + Vincristine + Pegaspargase '}]",A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia,553
7,NCT02212561,Phase Ib/II,Completed,"[{'id': 1749, 'therapyName': 'Selinexor'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 2345, 'therapyName': 'Cytarabine + Dexamethasone+ Methotrexate '}, {'id': 1166, 'therapyName': 'Fludarabine'}]",Selinexor With Fludarabine and Cytarabine for Treatment of Refractory or Relapsed Leukemia or Myelodysplastic Syndrome,553
8,NCT02101853,Phase III,Recruiting,"[{'id': 1876, 'therapyName': 'Blinatumomab '}, {'id': 2347, 'therapyName': 'Leucovorin + Pegaspargase  + Vincristine'}, {'id': 2346, 'therapyName': 'Mercaptopurine + Thioguanine'}, {'id': 2348, 'therapyName': 'Asparaginase + Cyclophosphamide + Etoposide'}, {'id': 2345, 'therapyName': 'Cytarabine + Dexamethasone+ Methotrexate '}]",Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia,553
9,NCT02420717,Phase II,Recruiting,"[{'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 3195, 'therapyName': 'Cytarabine + Methotrexate '}, {'id': 2046, 'therapyName': 'Cyclophosphamide + Dexamethasone + Doxorubicin + Vincristine '}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 3194, 'therapyName': 'Mercaptopurine + Methotrexate + Prednisone + Vincristine'}]",Ruxolitinib or Dasatinib With Chemotherapy in Patients With Philadelphia Chromosome (Ph)-Like Acute Lymphoblastic Leukemia (ALL),553
10,NCT02427620,Phase II,Recruiting,"[{'id': 2353, 'therapyName': 'Cyclophosphamide + Doxorubicin + Vincristine '}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 3195, 'therapyName': 'Cytarabine + Methotrexate '}, {'id': 1642, 'therapyName': 'Leucovorin'}]",A Study of Ibrutinib Plus Rituximab With Hyper-CVAD Consolidation in Newly Diagnosed Young Patients With Mantle Cell Lymphoma,553
11,NCT01769209,Phase II,"Active, not recruiting","[{'id': 688, 'therapyName': 'Bortezomib'}, {'id': 3195, 'therapyName': 'Cytarabine + Methotrexate '}, {'id': 1830, 'therapyName': 'Vincristine + Dexamethasone + Pegaspargase + Doxorubicin'}]",Bortezomib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia,553
12,NCT01424982,Phase II,Recruiting,"[{'id': 1476, 'therapyName': 'Pegfilgrastim'}, {'id': 2048, 'therapyName': 'Cytarabine + Methotrexate + Ponatinib'}, {'id': 2049, 'therapyName': 'Ponatinib + Vincristine'}, {'id': 2046, 'therapyName': 'Cyclophosphamide + Dexamethasone + Doxorubicin + Vincristine '}, {'id': 1642, 'therapyName': 'Leucovorin'}]",Hyper-CVAD and Ponatinib in Ph-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL),553
13,NCT02518750,Phase II,Recruiting,"[{'id': 1604, 'therapyName': 'Panobinostat + Bortezomib + Dexamethasone'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 3160, 'therapyName': 'Nelarabine'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 3217, 'therapyName': 'Cyclophosphamide + Etoposide'}, {'id': 3216, 'therapyName': 'Cytarabine + Methotrexate + Prednisone'}, {'id': 1746, 'therapyName': 'Clofarabine'}]",Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoma,553
14,NCT03007147,Phase III,Recruiting,"[{'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 5153, 'therapyName': 'dexrazoxane'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 5167, 'therapyName': 'Methylprednisolone'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 5168, 'therapyName': 'Prednisolone'}, {'id': 1009, 'therapyName': 'Doxorubicin'}]",Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia,553
15,NCT00513474,Phase I,Completed,"[{'id': 2313, 'therapyName': 'Rasburicase'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 1650, 'therapyName': 'Cyclosporine'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 2314, 'therapyName': 'Busulfan + Cyclophosphamide + Etoposide'}]",Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant,553
16,NCT02105636,Phase III,"Active, not recruiting","[{'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 694, 'therapyName': 'Cetuximab'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1312, 'therapyName': 'Nivolumab'}]",Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Head and Neck Carcinoma (CheckMate 141),553
17,NCT02419755,Phase II,Terminated,"[{'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 2188, 'therapyName': 'Prednisone'}]",Bortezomib and Vorinostat in Younger Patients With Refractory or Relapsed MLL Rearranged Hematologic Malignancies,553
18,NCT01535053,Phase III,"Active, not recruiting","[{'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 2601, 'therapyName': 'Dactinomycin'}, {'id': 1639, 'therapyName': 'Methotrexate'}]",Methotrexate or Dactinomycin in Treating Patients With Low-Risk Gestational Trophoblastic Neoplasia,553
19,NCT02076997,Phase I,Recruiting,"[{'id': 1639, 'therapyName': 'Methotrexate'}]",Individualized High Dose Methotrexate to Treat Cancer in Children Who Have a Significant Risk for Side Effects to Methotrexate,553
20,NCT00030264,Phase II,Completed,"[{'id': 2635, 'therapyName': 'Vinblastine'}, {'id': 1639, 'therapyName': 'Methotrexate'}]",Combination Chemotherapy in Treating Patients With Neurofibromatosis and Progressive Plexiform Neurofibromas,553
21,NCT00549848,Phase III,"Active, not recruiting","[{'id': 1781, 'therapyName': 'Vincristine + Pegaspargase + Daunorubicin'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1782, 'therapyName': 'Clofarabine + Etoposide + Cyclophosphamide'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}]",Total Therapy Study XVI for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia,553
22,NCT03150693,Phase III,Recruiting,"[{'id': 897, 'therapyName': 'Rituximab'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1783, 'therapyName': 'Cyclophosphamide + Cytarabine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 3628, 'therapyName': 'Allopurinol'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 3199, 'therapyName': 'inotuzumab ozogamicin'}]",Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia,553
23,NCT02535806,Phase II,Terminated,"[{'id': 1631, 'therapyName': 'Vincristine'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 2188, 'therapyName': 'Prednisone'}]",Four Drug Reinduction With Bortezomib for Relapsed or Refractory ALL or LL in Children and Young Adults,553
24,NCT02458339,Phase I,Recruiting,"[{'id': 1639, 'therapyName': 'Methotrexate'}]",Methotrexate Infusion Into Fourth Ventricle in Children With Recurrent Malignant Fourth Ventricular Brain Tumors,553
25,NCT01529827,Phase II,"Active, not recruiting","[{'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 1845, 'therapyName': 'Mycophenolate mofetil'}, {'id': 1166, 'therapyName': 'Fludarabine'}]","Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies",553
26,NCT02112916,Phase III,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1009, 'therapyName': 'Doxorubicin'}]",Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma,553
27,NCT01483690,Phase Ib/II,Terminated,"[{'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}]",A Pilot Study of Decitabine and Vorinostat With Chemotherapy for Relapsed ALL,553
28,NCT00621036,Phase II,Unknown status,"[{'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 1873, 'therapyName': 'Sargramostim'}]",Vaccine Therapy and GM-CSF in Treating Patients With CNS Lymphoma,553
29,NCT02788201,Phase II,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1133, 'therapyName': 'Mitomycin C'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1013, 'therapyName': 'epirubicin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1137, 'therapyName': 'Bleomycin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 781, 'therapyName': 'Ixabepilone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 2950, 'therapyName': 'Estramustine'}, {'id': 1941, 'therapyName': 'Floxuridine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 1811, 'therapyName': 'Carmustine'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 953, 'therapyName': 'Vandetanib'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 4419, 'therapyName': 'Toremifine'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 2601, 'therapyName': 'Dactinomycin'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 3035, 'therapyName': 'Chlorambucil'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 342, 'therapyName': 'Vemurafenib'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 2635, 'therapyName': 'Vinblastine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 4305, 'therapyName': 'Teniposide'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 4304, 'therapyName': 'Streptozocin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1231, 'therapyName': 'Bendamustine'}, {'id': 4303, 'therapyName': 'Mechlorethamine'}, {'id': 4302, 'therapyName': 'Mitotane'}]",Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma,553
30,NCT01614197,Phase I,Recruiting,"[{'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1639, 'therapyName': 'Methotrexate'}]",A Trial of Temsirolimus With Etoposide and Cyclophosphamide in Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkins Lymphoma,553
31,NCT01187810,Phase I,"Active, not recruiting","[{'id': 2731, 'therapyName': 'Fenretinide'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1639, 'therapyName': 'Methotrexate'}]","Fenretinide in Children With Recurrent/Resistant ALL, AML, and NHL",553
32,NCT03117751,Phase II,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1876, 'therapyName': 'Blinatumomab '}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1638, 'therapyName': 'Pegaspargase'}]",Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma,553
33,NCT02553460,Phase II,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1642, 'therapyName': 'Leucovorin'}]",Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) I,553
34,NCT00003553,Phase II,Unknown status,"[{'id': 2291, 'therapyName': 'Cyclophosphamide + Fludarabine'}, {'id': 1650, 'therapyName': 'Cyclosporine'}, {'id': 1845, 'therapyName': 'Mycophenolate mofetil'}, {'id': 1639, 'therapyName': 'Methotrexate'}]",Peripheral Stem Cell Transplant in Treating Patients With Metastatic Kidney Cancer,553
35,NCT01823198,Phase Ib/II,Recruiting,"[{'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1846, 'therapyName': 'Busulfan + Fludarabine + anti-thymocyte globulin'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 1632, 'therapyName': 'Filgrastim'}]",Natural Killer (NK) Cells With HLA Compatible Hematopoietic Transplantation for High Risk Myeloid Malignancies,553
36,NCT00267865,Phase II,Recruiting,"[{'id': 897, 'therapyName': 'Rituximab'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1642, 'therapyName': 'Leucovorin'}]",Chemotherapy and HAART to Treat AIDS-related Primary Brain Lymphoma,553
37,NCT02043587,Phase II,Recruiting,"[{'id': 897, 'therapyName': 'Rituximab'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1136, 'therapyName': 'Etoposide'}]",Chemotherapy With Liposomal Cytarabine CNS Prophylaxis for Adult Acute Lymphoblastic Leukemia &amp; Lymphoblastic Lymphoma,553
38,NCT01338987,Phase II,"Active, not recruiting","[{'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 795, 'therapyName': 'Leuprolide'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}]",Pilot Study of Lupron to Improve Immune Function After Allogeneic Bone Marrow Transplantation,553
39,NCT01790568,Phase II,"Active, not recruiting","[{'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 1077, 'therapyName': 'Vorinostat'}]",Vorinostat Plus Tacrolimus & Methotrexate to Prevent Graft vs Host Disease Following Unrelated Stem Cell Transplant,553
40,NCT00857389,Phase II,"Active, not recruiting","[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 2469, 'therapyName': 'Busulfan + Clofarabine + Thymoglobulin'}, {'id': 1639, 'therapyName': 'Methotrexate'}]",Thiotepa-Clofarabine-Busulfan With Allogeneic Stem Cell Transplant for High Risk Malignancies,553
41,NCT03020030,Phase III,Recruiting,"[{'id': 3160, 'therapyName': 'Nelarabine'}, {'id': 5153, 'therapyName': 'dexrazoxane'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1642, 'therapyName': 'Leucovorin'}]",Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents,553
42,NCT02252042,Phase III,"Active, not recruiting","[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 694, 'therapyName': 'Cetuximab'}, {'id': 720, 'therapyName': 'Docetaxel'}]",Pembrolizumab (MK-3475) Versus Standard Treatment for Recurrent or Metastatic Head and Neck Cancer (MK-3475-040/KEYNOTE-040),553
43,NCT02551718,Phase I,Recruiting,"[{'id': 690, 'therapyName': 'Bosutinib'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 3160, 'therapyName': 'Nelarabine'}, {'id': 3159, 'therapyName': 'Bexarotene'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 998, 'therapyName': 'cabozantinib'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 877, 'therapyName': 'Ponatinib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 623, 'therapyName': 'Afatinib'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 890, 'therapyName': 'Regorafenib'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 2, 'therapyName': 'Trametinib'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 3, 'therapyName': 'Dabrafenib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 789, 'therapyName': 'Ceritinib'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1571, 'therapyName': 'Cabazitaxel'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1327, 'therapyName': 'Pralatrexate'}]",High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia,553
44,NCT02251821,Phase II,Recruiting,"[{'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 1845, 'therapyName': 'Mycophenolate mofetil'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 2006, 'therapyName': 'Pacritinib'}, {'id': 823, 'therapyName': 'Momelotinib'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}]",JAK-2 Inhibitor Before Donor Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis,553
45,NCT02883049,Phase III,Suspended,"[{'id': 717, 'therapyName': 'Dasatinib'}, {'id': 4685, 'therapyName': 'Dexamethasone + Doxorubicin'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1746, 'therapyName': 'Clofarabine'}]",Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations,553
46,NCT03147612,Phase II,Not yet recruiting,"[{'id': 5682, 'therapyName': 'Mesna'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 877, 'therapyName': 'Ponatinib'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 712, 'therapyName': 'Cytarabine'}]",Study of the Combination of Low-Intensity Chemotherapy and Ponatinib in Patients With Philadelphia Chromosome (Ph)-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL),553
47,NCT02114229,Phase II,Recruiting,"[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 2449, 'therapyName': 'Methotrexate + Cisplatin + Cyclophosphamide + Vincristine'}, {'id': 626, 'therapyName': 'Alisertib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 942, 'therapyName': 'Topotecan'}]",Phase 2 Study of Alisertib Therapy for Rhabdoid Tumors,553
48,NCT00602667,Phase I,"Active, not recruiting","[{'id': 2449, 'therapyName': 'Methotrexate + Cisplatin + Cyclophosphamide + Vincristine'}, {'id': 2450, 'therapyName': 'Cyclophosphamide + Etoposide + Topotecan'}, {'id': 2451, 'therapyName': 'Erlotinib + Cyclophosphamide + Topotecan'}]","Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma",553
49,NCT02270788,Phase I,Completed,"[{'id': 1865, 'therapyName': 'Methotrexate + Cytarabine + Leucovorin'}, {'id': 1864, 'therapyName': 'Crenolanib + Sorafenib'}]",Crenolanib in Combination With Sorafenib in Patients With Refractory or Relapsed Hematologic Malignancies,553
50,NCT03071276,Phase II,Recruiting,"[{'id': 5448, 'therapyName': 'Selinexor + Fludarabine phosphate + Cytarabine + Methotrexate + Prednisone'}]",Selinexor in Combination With Fludarabine and Cytarabine in Patients With Refractory or Relapsed Acute Myeloid Leukemia,553
51,NCT01162551,Phase II,Completed,"[{'id': 2304, 'therapyName': 'Sirolimus + Methotrexate'}]",Trial of Sirolimus and Methotrexate in Relapsed/Refractory Lymphoblastic Leukemia and Lymphoma,553
52,NCT00577278,Phase II,"Active, not recruiting","[{'id': 767, 'therapyName': 'Ibritumomab'}, {'id': 2238, 'therapyName': 'Sirolimus + Tacrolimus + Methotrexate'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 2237, 'therapyName': 'Fludarabine + Melphalan'}]","Yttrium Y 90 Ibritumomab Tiuxetan, Rituximab, Indium In-111 Ibritumomab Tiuxetan, Fludarabine, Melphalan, and Donor Stem Cell Transplant in Treating Patients With B-Cell Non-Hodgkin Lymphoma",553
53,NCT02356159,Phase Ib/II,Recruiting,"[{'id': 2294, 'therapyName': 'Cytarabine + Fludarabine'}, {'id': 2373, 'therapyName': 'Palifermin'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 2238, 'therapyName': 'Sirolimus + Tacrolimus + Methotrexate'}, {'id': 2292, 'therapyName': 'Doxorubicin + Etoposide + Fludarabine + Vincristine '}, {'id': 2291, 'therapyName': 'Cyclophosphamide + Fludarabine'}, {'id': 897, 'therapyName': 'Rituximab'}]",Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation,553
54,NCT00520130,Phase Ib/II,"Active, not recruiting","[{'id': 2294, 'therapyName': 'Cytarabine + Fludarabine'}, {'id': 2305, 'therapyName': 'Alemtuzumab + Cyclosporine'}, {'id': 2306, 'therapyName': 'Rituximab + Fludarabine + EPOCH'}, {'id': 2307, 'therapyName': 'Fludarabine + EPOCH'}, {'id': 2238, 'therapyName': 'Sirolimus + Tacrolimus + Methotrexate'}, {'id': 1632, 'therapyName': 'Filgrastim'}]",Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,553
55,NCT02440464,Phase II,Recruiting,"[{'id': 3321, 'therapyName': 'Tacrolimus + Methotrexate'}, {'id': 1359, 'therapyName': 'Ixazomib'}, {'id': 2237, 'therapyName': 'Fludarabine + Melphalan'}, {'id': 688, 'therapyName': 'Bortezomib'}]",Allogeneic Hematopoietic Stem Cell Transplantation With Ixazomib for High Risk Multiple Myeloma (BMT CTN 1302),553
56,NCT01256398,Phase II,"Active, not recruiting","[{'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 2291, 'therapyName': 'Cyclophosphamide + Fludarabine'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1824, 'therapyName': 'Vincristine + Methotrexate + Mercaptopurine'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 2391, 'therapyName': 'Cytarabine + Daunorubicin + Etoposide'}, {'id': 1476, 'therapyName': 'Pegfilgrastim'}, {'id': 1205, 'therapyName': 'Alemtuzumab'}, {'id': 1642, 'therapyName': 'Leucovorin'}]",Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,553
57,NCT02143414,Phase II,Recruiting,"[{'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1824, 'therapyName': 'Vincristine + Methotrexate + Mercaptopurine'}]","Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia",553
0,NCT01015222,Phase I,"Active, not recruiting","[{'id': 1032, 'therapyName': 'methylnaltrexone'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 667, 'therapyName': 'Bevacizumab'}]","Dasatinib, Bevacizumab, Paclitaxel in Patients With Advanced Malignancies",4809
0,NCT03059823,Phase I,Recruiting,"[{'id': 5813, 'therapyName': 'MGA012'}]",A Phase 1 Study of MGA012 in Patients With Advanced Solid Tumors,8808
0,NCT02381314,Phase I,Recruiting,"[{'id': 3058, 'therapyName': 'Ipilimumab + MGA271'}]",Safety Study of MGA271 in Combination With Ipilimumab in Refractory Cancer,7798
1,NCT02982941,Phase I,Recruiting,"[{'id': 2863, 'therapyName': 'MGA271'}]",Enoblituzumab (MGA271) in Children With B7-H3-expressing Solid Tumors,7798
2,NCT01391143,Phase I,Recruiting,"[{'id': 2863, 'therapyName': 'MGA271'}]",Safety Study of MGA271 in Refractory Cancer,7798
3,NCT02923180,Phase I,Recruiting,"[{'id': 2863, 'therapyName': 'MGA271'}]",Neoadjuvant Enoblituzumab (MGA271) in Men With Localized Intermediate and High-Risk Prostate Cancer,7798
4,NCT02475213,Phase I,Recruiting,"[{'id': 2864, 'therapyName': 'MGA271 + Pembrolizumab'}]",Safety Study of MGA271 in Combination With Pembrolizumab in Refractory Cancer,7798
0,NCT01148849,Phase I,"Active, not recruiting","[{'id': 808, 'therapyName': 'MGAH22'}]",Safety Study of MGAH22 in HER2-positive Carcinomas,6947
1,NCT01828021,Phase II,Completed,"[{'id': 808, 'therapyName': 'MGAH22'}]",Phase 2 Study of the Monoclonal Antibody MGAH22(Margetuximab)in Patients With Relapsed or Refractory Advanced Breast Cancer,6947
2,NCT02492711,Phase III,Recruiting,"[{'id': 1685, 'therapyName': 'Vinorelbine'}, {'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 808, 'therapyName': 'MGAH22'}]",Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer,6947
3,NCT02689284,Phase Ib/II,Recruiting,"[{'id': 3728, 'therapyName': 'MGAH22 + Pembrolizumab'}]","Combination Margetuximab and Pembrolizumab for Advanced, Metastatic HER2(+) Gastric or Gastroesophageal Junction Cancer",6947
0,NCT00697632,Phase I,Recruiting,"[{'id': 809, 'therapyName': 'MGCD265'}]",Safety Study of Oral MGCD265 Administered Without Interruption to Subjects With Advanced Malignancies,6948
1,NCT02544633,Phase II,Recruiting,"[{'id': 809, 'therapyName': 'MGCD265'}]",Phase 2 Study of MGCD265 in Patients With Non-Small Cell Lung Cancer With Activating Genetic Alterations in MET,6948
2,NCT00975767,Phase Ib/II,Terminated,"[{'id': 1127, 'therapyName': 'MGCD265 + Docetaxel'}, {'id': 1126, 'therapyName': 'MGCD265 + Erlotinib'}]",A Study of MGCD265 Given With Erlotinib or Docetaxel in Subjects With Advanced Malignancies or Non-Small Cell Lung Cancer,6948
3,NCT02954991,Phase II,Recruiting,"[{'id': 4943, 'therapyName': 'MGCD516 + Nivolumab'}, {'id': 4944, 'therapyName': 'Mocetinostat + Nivolumab'}, {'id': 4942, 'therapyName': 'MGCD265 + Nivolumab'}]","Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Non-Small Cell Lung Cancer",6948
0,NCT02978859,Phase II,Recruiting,"[{'id': 1655, 'therapyName': 'MGCD516'}]",MGCD516 in Advanced Liposarcoma and Other Soft Tissue Sarcomas,7309
1,NCT02219711,Phase I,Recruiting,"[{'id': 1655, 'therapyName': 'MGCD516'}]",Phase 1/1b Study of MGCD516 in Patients With Advanced Cancer,7309
2,NCT02954991,Phase II,Recruiting,"[{'id': 4943, 'therapyName': 'MGCD516 + Nivolumab'}, {'id': 4944, 'therapyName': 'Mocetinostat + Nivolumab'}, {'id': 4942, 'therapyName': 'MGCD265 + Nivolumab'}]","Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Non-Small Cell Lung Cancer",7309
3,NCT03015740,Phase Ib/II,Recruiting,"[{'id': 4943, 'therapyName': 'MGCD516 + Nivolumab'}]",MGCD516 Combined With Nivolumab in Renal Cell Cancer (RCC),7309
0,NCT02248805,Phase I,Recruiting,"[{'id': 3093, 'therapyName': 'MGD007'}]",Phase 1 Study of MGD007 in Relapsed/Refractory Metastatic Colorectal Carcinoma,7938
0,NCT03219268,Phase I,Recruiting,"[{'id': 6060, 'therapyName': 'MGD013'}]",A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms,8904
0,NCT03092674,Phase II,Not yet recruiting,"[{'id': 1736, 'therapyName': 'Decitabine + Cytarabine'}, {'id': 2471, 'therapyName': 'Azacitidine + Midostaurin'}, {'id': 3196, 'therapyName': 'Azacitidine + Nivolumab'}, {'id': 651, 'therapyName': 'Azacitidine'}]","Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome",6949
1,NCT01093573,Phase Ib/II,"Active, not recruiting","[{'id': 2471, 'therapyName': 'Azacitidine + Midostaurin'}]",Midostaurin and Azacitidine in Treating Elderly Patients With Acute Myelogenous Leukemia,6949
2,NCT03207334,Phase II,Not yet recruiting,"[{'id': 6095, 'therapyName': 'Cytarabine + Midostaurin'}]",iCare4: Genomic Signatures With Midostaurin in Acute Myeloid Leukemia (UF-BMT-AML-001),6949
3,NCT02634827,Phase II,Recruiting,"[{'id': 1769, 'therapyName': 'Decitabine + Midostaurin'}]",Midostaurin and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia and FLT3 Mutation,6949
4,NCT01846624,Phase II,"Active, not recruiting","[{'id': 1769, 'therapyName': 'Decitabine + Midostaurin'}]",Decitabine and Midostaurin in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia,6949
5,NCT00866281,Phase Ib/II,Terminated,"[{'id': 810, 'therapyName': 'Midostaurin'}]",A Study of the Safety and Preliminary Efficacy of Oral Midostaurin (PKC412) in Relapsed or Refractory Pediatric Leukemia,6949
6,NCT02756962,Phase II,Recruiting,"[{'id': 810, 'therapyName': 'Midostaurin'}, {'id': 712, 'therapyName': 'Cytarabine'}]",Improving Risk Assessment of AML With a Precision Genomic Strategy to Assess Mutation Clearance,6949
7,NCT02723435,Phase II,Not yet recruiting,"[{'id': 810, 'therapyName': 'Midostaurin'}]",Midostaurin in Treating Older Patients With Mutated Acute Myeloid Leukemia Post-Transplant,6949
8,NCT01282502,Phase I,"Active, not recruiting","[{'id': 810, 'therapyName': 'Midostaurin'}]",Midostaurin (PKC412) for Locally Advanced Rectal Cancer,6949
9,NCT01883362,Phase II,Recruiting,"[{'id': 810, 'therapyName': 'Midostaurin'}]",Standard of Care +/- Midostaurin to Prevent Relapse Post Stem Cell Transplant in Patients With FLT3-ITD Mutated AML,6949
10,NCT02624570,Phase I,Available,"[{'id': 810, 'therapyName': 'Midostaurin'}]",Midostaurin Access Program for Newly Diagnosed FLT3 (ITD or TKD) Mutated AML Adult Patients Eligible for Standard Induction and Consolidation Chemotherapy.,6949
0,NCT02014337,Phase I,"Active, not recruiting","[{'id': 3053, 'therapyName': 'Eribulin + Mifepristone'}]",Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors,824
1,NCT02012296,Phase Ib/II,Recruiting,"[{'id': 2603, 'therapyName': 'Mifepristone'}, {'id': 1262, 'therapyName': 'Enzalutamide'}]",Enzalutamide and Mifepristone in Treating Patients With Metastatic Hormone Resistant Prostate Cancer,824
2,NCT02046421,Phase I,"Active, not recruiting","[{'id': 2603, 'therapyName': 'Mifepristone'}, {'id': 2667, 'therapyName': 'Carboplatin + Gemcitabine'}]","Carboplatin, Gemcitabine Hydrochloride, and Mifepristone in Treating Patients With Advanced Breast Cancer or Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer",824
3,NCT02642939,Phase II,Recruiting,"[{'id': 2603, 'therapyName': 'Mifepristone'}]",Study of Oral Mifepristone as Salvage Therapy in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer,824
4,NCT02788981,Phase II,Recruiting,"[{'id': 4350, 'therapyName': 'Mifepristone + Nab-paclitaxel'}, {'id': 619, 'therapyName': 'Abraxane'}]","A Trial of Nanoparticle Albumin-Bound Paclitaxel (Nab-Paclitaxel, Abraxane) With or Without Mifepristone for Advanced, Glucocorticoid Receptor-Positive, Triple-Negative Breast Cancer",824
5,NCT03225547,Phase II,Not yet recruiting,"[{'id': 6030, 'therapyName': 'Mifepristone + Pembrolizumab'}]",Study of Pembrolizumab and Mifepristone in Patients With Advanced HER2-negative Breast Cancer,824
0,NCT02992483,Phase I,Recruiting,"[{'id': 5814, 'therapyName': 'MIK665'}]","Phase I Study of MIK665, a Mcl-1 Inhibitor, in Patients With Refractory or Relapsed Lymphoma or Multiple Myeloma",8809
0,NCT01301391,Phase II,"Active, not recruiting","[{'id': 2654, 'therapyName': 'PHA-848125AC'}]",Study Of Oral PHA-848125AC In Patients With Malignant Thymoma Previously Treated With Multiple Lines Of Chemotherapy,7629
1,NCT01011439,Phase II,"Active, not recruiting","[{'id': 2654, 'therapyName': 'PHA-848125AC'}]",Phase II Study Of Oral PHA-848125AC In Patients With Thymic Carcinoma,7629
0,NCT02876003,Phase II,Withdrawn,"[{'id': 4338, 'therapyName': 'mipsagargin'}]",Efficacy and Safety of G-202 in PSMA-Positive Glioblastoma,8425
1,NCT02607553,Phase II,Completed,"[{'id': 4338, 'therapyName': 'mipsagargin'}]",Safety and Activity of G-202 in Patients With Clear Cell Renal Cell Carcinoma That Expresses PSMA,8425
2,NCT02067156,Phase II,Completed,"[{'id': 4338, 'therapyName': 'mipsagargin'}]","Efficacy, Safety and CNS Exposure of G-202 (Mipsagargin) in Patients With Recurrent or Progressive Glioblastoma",8425
3,NCT02381236,Phase II,Completed,"[{'id': 4338, 'therapyName': 'mipsagargin'}]",G-202 in the Neoadjuvant Setting Followed by Radical Prostatectomy in Patients With Prostate Cancer,8425
0,NCT01438112,,Terminated,"[{'id': 2524, 'therapyName': 'Gemcitabine + interferon + Mitomycin C + Valrubicin '}, {'id': 2523, 'therapyName': 'CG0070'}]",Efficacy Study of Recombinant Adenovirus for Non Muscle Invasive Bladder Cancer,7209
1,NCT01580410,Phase II,"Active, not recruiting","[{'id': 1133, 'therapyName': 'Mitomycin C'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}]",Surgery and Oxaliplatin or Mitomycin C in Treating Patients With Tumors of the Appendix,7209
2,NCT02788201,Phase II,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1133, 'therapyName': 'Mitomycin C'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1013, 'therapyName': 'epirubicin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1137, 'therapyName': 'Bleomycin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 781, 'therapyName': 'Ixabepilone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 2950, 'therapyName': 'Estramustine'}, {'id': 1941, 'therapyName': 'Floxuridine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 1811, 'therapyName': 'Carmustine'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 953, 'therapyName': 'Vandetanib'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 4419, 'therapyName': 'Toremifine'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 2601, 'therapyName': 'Dactinomycin'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 3035, 'therapyName': 'Chlorambucil'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 342, 'therapyName': 'Vemurafenib'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 2635, 'therapyName': 'Vinblastine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 4305, 'therapyName': 'Teniposide'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 4304, 'therapyName': 'Streptozocin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1231, 'therapyName': 'Bendamustine'}, {'id': 4303, 'therapyName': 'Mechlorethamine'}, {'id': 4302, 'therapyName': 'Mitotane'}]",Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma,7209
3,NCT02349958,Phase II,Recruiting,"[{'id': 1133, 'therapyName': 'Mitomycin C'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1009, 'therapyName': 'Doxorubicin'}]",Clinical Trial of Intraperitoneal Hyperthermic Chemotherapy,7209
4,NCT01017640,Phase I,Completed,"[{'id': 954, 'therapyName': 'Veliparib'}, {'id': 1134, 'therapyName': 'Veliparib + Mitomycin C'}]"," Veliparib With or Without Mitomycin C in Treating Patients With Metastatic, Unresectable, or Recurrent Solid Tumors",7209
0,NCT02728050,Phase Ib/II,Recruiting,"[{'id': 920, 'therapyName': 'Sorafenib'}, {'id': 4363, 'therapyName': 'Cladribine + Cytarabine + Filgrastim + Mitoxantrone'}]","Filgrastim, Cladribine, Cytarabine and Mitoxantrone With or Without Sorafenib Tosylate in Treating Patients With Newly-Diagnosed, High-Risk Acute Myeloid Leukemia or Myelodysplastic Syndrome",1191
1,NCT02626338,Phase Ib/II,Recruiting,"[{'id': 4024, 'therapyName': 'Crenolanib + Cytarabine + Mitoxantrone'}]",Pilot Study of Crenolanib Combined With Cytarabine and Mitoxantrone in Subjects With R/R AML,1191
2,NCT02632708,Phase I,Recruiting,"[{'id': 1491, 'therapyName': 'AG-120'}, {'id': 2982, 'therapyName': 'Enasidenib'}, {'id': 3431, 'therapyName': 'Cytarabine + Daunorubicin + Etoposide + Mitoxantrone'}]",Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia With an IDH1 and/or IDH2 Mutation,1191
3,NCT02339740,Phase III,Recruiting,"[{'id': 3686, 'therapyName': 'Cytarabine + Dexamethasone + Idarubicin + Mitoxantrone'}, {'id': 3685, 'therapyName': 'Arsenic trioxide + Gemtuzumab ozogamicin + Tretinoin'}]",Tretinoin and Arsenic Trioxide in Treating Patients With Untreated Acute Promyelocytic Leukemia,1191
4,NCT01371981,Phase III,"Active, not recruiting","[{'id': 2391, 'therapyName': 'Cytarabine + Daunorubicin + Etoposide'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 2392, 'therapyName': 'Cytarabine + Etoposide'}, {'id': 2393, 'therapyName': 'Cytarabine + Mitoxantrone'}, {'id': 2394, 'therapyName': 'Asparaginase + Cytarabine'}, {'id': 688, 'therapyName': 'Bortezomib'}]",Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,1191
5,NCT02520011,Phase II,Recruiting,"[{'id': 628, 'therapyName': 'Alvocidib'}, {'id': 2393, 'therapyName': 'Cytarabine + Mitoxantrone'}]",Alvocidib Biomarker-driven Phase 2 AML Study,1191
6,NCT02553460,Phase II,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1642, 'therapyName': 'Leucovorin'}]",Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) I,1191
7,NCT02788201,Phase II,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1133, 'therapyName': 'Mitomycin C'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1013, 'therapyName': 'epirubicin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1137, 'therapyName': 'Bleomycin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 781, 'therapyName': 'Ixabepilone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 2950, 'therapyName': 'Estramustine'}, {'id': 1941, 'therapyName': 'Floxuridine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 1811, 'therapyName': 'Carmustine'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 953, 'therapyName': 'Vandetanib'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 4419, 'therapyName': 'Toremifine'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 2601, 'therapyName': 'Dactinomycin'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 3035, 'therapyName': 'Chlorambucil'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 342, 'therapyName': 'Vemurafenib'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 2635, 'therapyName': 'Vinblastine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 4305, 'therapyName': 'Teniposide'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 4304, 'therapyName': 'Streptozocin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1231, 'therapyName': 'Bendamustine'}, {'id': 4303, 'therapyName': 'Mechlorethamine'}, {'id': 4302, 'therapyName': 'Mitotane'}]",Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma,1191
8,NCT02573363,Phase I,Recruiting,"[{'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 1749, 'therapyName': 'Selinexor'}]",Selinexor With Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia,1191
9,NCT02518750,Phase II,Recruiting,"[{'id': 1604, 'therapyName': 'Panobinostat + Bortezomib + Dexamethasone'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 3160, 'therapyName': 'Nelarabine'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 3217, 'therapyName': 'Cyclophosphamide + Etoposide'}, {'id': 3216, 'therapyName': 'Cytarabine + Methotrexate + Prednisone'}, {'id': 1746, 'therapyName': 'Clofarabine'}]",Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoma,1191
10,NCT02551718,Phase I,Recruiting,"[{'id': 690, 'therapyName': 'Bosutinib'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 3160, 'therapyName': 'Nelarabine'}, {'id': 3159, 'therapyName': 'Bexarotene'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 998, 'therapyName': 'cabozantinib'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 877, 'therapyName': 'Ponatinib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 623, 'therapyName': 'Afatinib'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 890, 'therapyName': 'Regorafenib'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 2, 'therapyName': 'Trametinib'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 3, 'therapyName': 'Dabrafenib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 789, 'therapyName': 'Ceritinib'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1571, 'therapyName': 'Cabazitaxel'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1327, 'therapyName': 'Pralatrexate'}]",High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia,1191
11,NCT03164057,Phase II,Recruiting,"[{'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 5153, 'therapyName': 'dexrazoxane'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 651, 'therapyName': 'Azacitidine'}]",A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia,1191
12,NCT02419755,Phase II,Terminated,"[{'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 2188, 'therapyName': 'Prednisone'}]",Bortezomib and Vorinostat in Younger Patients With Refractory or Relapsed MLL Rearranged Hematologic Malignancies,1191
13,NCT01483690,Phase Ib/II,Terminated,"[{'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}]",A Pilot Study of Decitabine and Vorinostat With Chemotherapy for Relapsed ALL,1191
14,NCT02535806,Phase II,Terminated,"[{'id': 1631, 'therapyName': 'Vincristine'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 2188, 'therapyName': 'Prednisone'}]",Four Drug Reinduction With Bortezomib for Relapsed or Refractory ALL or LL in Children and Young Adults,1191
15,NCT02421939,Phase III,Recruiting,"[{'id': 712, 'therapyName': 'Cytarabine'}, {'id': 3193, 'therapyName': 'Cytarabine + Fludarabine + Idarubicin'}, {'id': 1752, 'therapyName': 'Mitoxantrone + Etoposide + Cytarabine'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 2865, 'therapyName': 'Gilteritinib'}, {'id': 1632, 'therapyName': 'Filgrastim'}]",A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,1191
16,NCT00550992,Phase I,Unknown status,"[{'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1752, 'therapyName': 'Mitoxantrone + Etoposide + Cytarabine'}, {'id': 1848, 'therapyName': 'Cyclophosphamide + Methotrexate + Vincristine + Pegaspargase '}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1650, 'therapyName': 'Cyclosporine'}, {'id': 1844, 'therapyName': 'anti-thymocyte globulin'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1642, 'therapyName': 'Leucovorin'}]",Different Therapies in Treating Infants With Newly Diagnosed Acute Leukemia,1191
17,NCT01729845,Phase Ib/II,"Active, not recruiting","[{'id': 1752, 'therapyName': 'Mitoxantrone + Etoposide + Cytarabine'}, {'id': 650, 'therapyName': 'Decitabine'}]","Decitabine Followed By Mitoxantrone Hydrochloride, Etoposide, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes",1191
18,NCT01222143,Phase Ib/II,Terminated,"[{'id': 1752, 'therapyName': 'Mitoxantrone + Etoposide + Cytarabine'}, {'id': 829, 'therapyName': 'Nilotinib'}]","Safety and Efficacy Study of Nilotinib Combined With Mitoxantrone, Etoposide, and High-dose Cytarabine Induction Chemotherapy Followed by Consolidation for Patients With C-kit Positive Acute Myeloid Leukemia",1191
19,NCT02306291,Phase Ib/II,Recruiting,"[{'id': 1606, 'therapyName': 'Cytarabine + Idarubicin'}, {'id': 1752, 'therapyName': 'Mitoxantrone + Etoposide + Cytarabine'}, {'id': 4402, 'therapyName': 'GMI-1271'}]","Study to Determine Safety, Pharmacokinetics and Efficacy of GMI-1271 in Combination With Chemotherapy in AML",1191
20,NCT02299518,Phase I,Recruiting,"[{'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1749, 'therapyName': 'Selinexor'}, {'id': 1752, 'therapyName': 'Mitoxantrone + Etoposide + Cytarabine'}]",Selinexor and Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia,1191
21,NCT02039726,Phase III,"Active, not recruiting","[{'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 3193, 'therapyName': 'Cytarabine + Fludarabine + Idarubicin'}, {'id': 1752, 'therapyName': 'Mitoxantrone + Etoposide + Cytarabine'}, {'id': 882, 'therapyName': 'Quizartinib'}]",An Open-label Study of Quizartinib Monotherapy vs. Salvage Chemotherapy in Acute Myeloid Leukemia (AML) Subjects,1191
22,NCT02583893,Phase II,Recruiting,"[{'id': 917, 'therapyName': 'Sirolimus'}, {'id': 1752, 'therapyName': 'Mitoxantrone + Etoposide + Cytarabine'}]",Biomarkers in Predicting Treatment Response to Sirolimus and Chemotherapy in Patients With High-Risk Acute Myeloid Leukemia,1191
0,NCT03172936,Phase I,Recruiting,"[{'id': 6219, 'therapyName': 'MIW815 + PDR001'}]",Study of the Safety and Efficacy of MIW815 With PDR001 to Patients With Advanced/Metastatic Solid Tumors or Lymphomas,8940
0,NCT03179436,Phase I,Recruiting,"[{'id': 6039, 'therapyName': 'MK-1308 + Pembrolizumab'}]","Safety, Pharmacokinetics (PK), and Efficacy of MK-1308 in Combination With Pembrolizumab in Advanced Solid Tumors (MK-1308-001)",8898
0,NCT03010176,Phase I,Recruiting,"[{'id': 5348, 'therapyName': 'MK-1454 + Pembrolizumab'}, {'id': 5347, 'therapyName': 'MK-1454'}]",Study of MK-1454 Alone or in Combination With Pembrolizumab in Participants With Advanced/Metastatic Solid Tumors or Lymphomas (MK-1454-001),8670
0,NCT02381548,Phase I,"Active, not recruiting","[{'id': 3197, 'therapyName': 'Belinostat + MK-1775'}]",Phase I Trial of AZD1775 and Belinostat in Treating Patients With Relapsed or Refractory Myeloid Malignancies or Untreated Acute Myeloid Leukemia,7067
1,NCT02617277,Phase I,Recruiting,"[{'id': 3414, 'therapyName': 'MEDI4736 + MK-1775'}]","Safety, Tolerability and Pharmacokinetics of AZD1775 Plus MEDI4736 in Patients With Advanced Solid Tumours",7067
2,NCT02511795,Phase I,Recruiting,"[{'id': 822, 'therapyName': 'MK-1775'}, {'id': 837, 'therapyName': 'Olaparib'}]",AZD1775 Combined With Olaparib in Patients With Refractory Solid Tumors,7067
3,NCT02659241,Phase I,Recruiting,"[{'id': 822, 'therapyName': 'MK-1775'}]",A Pilot Study of Induction Wee1 Inhibition in Ovarian Cancer,7067
4,NCT01357161,Phase II,Completed,"[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 822, 'therapyName': 'MK-1775'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]", A Study of MK-1775 in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone for Participants With Platinum-Sensitive Ovarian Tumors With the P53 Gene Mutation (MK-1775-004),7067
5,NCT02087176,Phase II,Terminated,"[{'id': 822, 'therapyName': 'MK-1775'}, {'id': 1476, 'therapyName': 'Pegfilgrastim'}]",A Placebo Controlled Study Comparing AZD1775+ Docetaxel Versus Placebo+Docetaxel to Treat Lung Cancer,7067
6,NCT02087241,Phase II,Terminated,"[{'id': 822, 'therapyName': 'MK-1775'}, {'id': 1602, 'therapyName': 'Carboplatin + Pemetrexed'}]",Ph II Trial of Carboplatin and Pemetrexed With or Without AZD1775 for Untreated Lung Cancer,7067
7,NCT02610075,Phase I,Recruiting,"[{'id': 822, 'therapyName': 'MK-1775'}]",Study to Determine MTD of AZD1775 Monotherapy in Patients With Locally Advanced or Metastatic Solid Tumours.,7067
8,NCT03253679,Phase II,Not yet recruiting,"[{'id': 822, 'therapyName': 'MK-1775'}]",WEE1 Inhibitor AZD1775 in Treating Patients With Advanced Refractory Solid Tumors With CCNE1 Amplification,7067
9,NCT02194829,Phase Ib/II,"Active, not recruiting","[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 822, 'therapyName': 'MK-1775'}]",Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Previously Untreated Pancreatic Cancer That Is Metastatic or Cannot Be Removed by Surgery,7067
10,NCT02791919,Phase I,Withdrawn,"[{'id': 822, 'therapyName': 'MK-1775'}, {'id': 4271, 'therapyName': 'Cytarabine + Filgrastim + Fludarabine'}]","Wee1 Kinase Inhibitor AZD1775 and Combination Chemotherapy in Treating Children, Adolescents and Young Adults With Relapsed or Refractory Acute Myeloid Leukemia",7067
11,NCT01748825,Phase I,Recruiting,"[{'id': 822, 'therapyName': 'MK-1775'}]",MK-1775 for Advanced Solid Tumors,7067
12,NCT02341456,Phase I,"Active, not recruiting","[{'id': 822, 'therapyName': 'MK-1775'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]",Phase Ib Study AZD1775 in Combination With Carboplatin and Paclitaxel in Adult Asian Patients With Solid Tumours,7067
13,NCT02508246,Phase I,Recruiting,"[{'id': 822, 'therapyName': 'MK-1775'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 700, 'therapyName': 'Cisplatin'}]","AZD1775, Docetaxel, and Cisplatin Before Surgery in Treating Patients With Borderline Resectable Stage III-IVB Squamous Cell Carcinoma of the Head and Neck",7067
14,NCT01922076,Phase I,Recruiting,"[{'id': 822, 'therapyName': 'MK-1775'}]",WEE1 Inhibitor MK-1775 and Local Radiation Therapy in Treating Younger Patients With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas,7067
15,NCT02196168,Phase II,Terminated,"[{'id': 822, 'therapyName': 'MK-1775'}, {'id': 700, 'therapyName': 'Cisplatin'}]",Cisplatin With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer,7067
16,NCT02513563,Phase II,Recruiting,"[{'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 822, 'therapyName': 'MK-1775'}]",AZD1775 Plus Carboplatin-Paclitaxel in Squamous Cell Lung Cancer,7067
17,NCT02666950,Phase II,Recruiting,"[{'id': 822, 'therapyName': 'MK-1775'}, {'id': 712, 'therapyName': 'Cytarabine'}]",WEE1 Inhibitor AZD1775 With or Without Cytarabine in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome,7067
18,NCT01827384,Phase II,Recruiting,"[{'id': 1194, 'therapyName': 'MK-1775 + Carboplatin '}, {'id': 1193, 'therapyName': 'Veliparib + Temozolomide'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 2, 'therapyName': 'Trametinib'}]",Molecular Profiling-Based Targeted Therapy in Treating Patients With Advanced Solid Tumors,7067
19,NCT02272790,Phase II,Recruiting,"[{'id': 1194, 'therapyName': 'MK-1775 + Carboplatin '}, {'id': 1279, 'therapyName': 'MK-1775 + Gemcitabine'}, {'id': 1567, 'therapyName': 'MK-1775 + Paclitaxel'}]","A Phase II Study Comparing AZD1775 + Chemotherapy Versus Chemotherapy Alone in Patients to Treat Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.",7067
20,NCT02585973,Phase I,Recruiting,"[{'id': 1725, 'therapyName': 'MK-1775 + Cisplatin'}]",Dose-escalating AZD1775 + Concurrent Radiation + Cisplatin for Intermediate/High Risk HNSCC,7067
21,NCT01958658,Phase I,Suspended,"[{'id': 1725, 'therapyName': 'MK-1775 + Cisplatin'}]","AZD1775, Cisplatin, and Radiation Therapy in Treating Patients With Cervical Cancer",7067
22,NCT03012477,Phase II,Recruiting,"[{'id': 1725, 'therapyName': 'MK-1775 + Cisplatin'}]",CISPLATIN + AZD-1775 In Breast Cancer,7067
23,NCT02037230,Phase Ib/II,Recruiting,"[{'id': 1279, 'therapyName': 'MK-1775 + Gemcitabine'}]",Dose Escalation Trial of MK1775 and Gemcitabine (+Radiation) for Unresectable Adenocarcinoma of the Pancreas,7067
24,NCT02101775,Phase II,Recruiting,"[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1279, 'therapyName': 'MK-1775 + Gemcitabine'}]","Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer",7067
25,NCT02095132,Phase Ib/II,Recruiting,"[{'id': 1361, 'therapyName': 'MK-1775 + Irinotecan'}]",WEE1 Inhibitor MK-1775 and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors,7067
26,NCT02906059,Phase I,Recruiting,"[{'id': 1361, 'therapyName': 'MK-1775 + Irinotecan'}]","Study of Irinotecan and AZD1775, a Selective Wee 1 Inhibitor, in RAS or BRAF Mutated, Second-line Metastatic Colorectal Cancer",7067
27,NCT02576444,Phase II,Recruiting,"[{'id': 3140, 'therapyName': 'MK-1775 + Olaparib'}, {'id': 837, 'therapyName': 'Olaparib'}, {'id': 3141, 'therapyName': 'Olaparib + Vistusertib'}, {'id': 3139, 'therapyName': 'AZD5363 + Olaparib'}]",OLAParib COmbinations,7067
28,NCT01849146,Phase I,Recruiting,"[{'id': 2713, 'therapyName': 'MK-1775 + Temozolomide'}]","WEE1 Inhibitor MK-1775, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed or Recurrent Glioblastoma Multiforme",7067
0,NCT02731742,Phase I,Recruiting,"[{'id': 4471, 'therapyName': 'MK-1966 + SD-101'}]",Dose Evaluation of MK-1966 in Combination With SD-101 in Participants With Advanced Malignancies (MK-1966-001),8463
0,NCT03249792,Phase I,Recruiting,"[{'id': 6131, 'therapyName': 'MK-2118 + Pembrolizumab'}, {'id': 6130, 'therapyName': 'MK-2118'}]",Study of MK-2118 Administered as Intratumoral Injection as Monotherapy and in Combination With Pembrolizumab (MK-3475) in the Treatment of Adults With Advance/Metastatic Solid Tumors or Lymphomas (MK-2118-001),8921
0,NCT02132754,Phase I,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 2829, 'therapyName': 'MK-4166'}]",Study of MK-4166 and MK-4166 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-4166-001),7767
0,NCT02720068,Phase I,Recruiting,"[{'id': 4213, 'therapyName': 'MK-4280 + Pembrolizumab'}, {'id': 4212, 'therapyName': 'MK-4280'}]",Study of MK-4280 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Adults With Advanced Solid Tumors (MK-4280-001),8379
0,NCT02964013,Phase I,Recruiting,"[{'id': 5218, 'therapyName': 'MK-7684'}, {'id': 5219, 'therapyName': 'MK-7684 + Pembrolizumab'}]",Study of MK-7684 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors (MK-7684-001),8638
0,NCT02972034,Phase I,Recruiting,"[{'id': 5269, 'therapyName': 'MK-8353 + Pembrolizumab'}]",Study of MK-8353 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Malignancies (MK-8353-013),8022
0,NCT01870596,Phase II,Completed,"[{'id': 712, 'therapyName': 'Cytarabine'}, {'id': 2027, 'therapyName': 'MK-8776'}]",Cytarabine With or Without SCH 900776 in Treating Adult Patients With Relapsed Acute Myeloid Leukemia,7393
0,NCT01783171,Phase I,Completed,"[{'id': 2193, 'therapyName': 'Dinaciclib + MK2206'}]",Dinaciclib and Akt Inhibitor MK2206 in Treating Patients With Pancreatic Cancer That Cannot Be Removed By Surgery,6953
1,NCT01248247,Phase I,"Active, not recruiting","[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 1098, 'therapyName': 'MK2206 + Selumetinib'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 1097, 'therapyName': 'Erlotinib + MK2206'}]",BATTLE-2 Program: A Biomarker-Integrated Targeted Therapy Study,6953
2,NCT01776008,Phase II,"Active, not recruiting","[{'id': 1548, 'therapyName': 'Goserelin + MK2206'}]",Akt Inhibitor MK-2206 and Anastrozole With or Without Goserelin Acetate in Treating Patients With Stage II-III Breast Cancer,6953
3,NCT01306045,Phase II,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 816, 'therapyName': 'MK2206'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 913, 'therapyName': 'Selumetinib'}]","Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies",6953
4,NCT01802320,Phase II,"Active, not recruiting","[{'id': 816, 'therapyName': 'MK2206'}]",Akt Inhibitor MK2206 in Treating Patients With Previously Treated Colon or Rectal Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery,6953
5,NCT01480154,Phase I,"Active, not recruiting","[{'id': 1393, 'therapyName': 'MK2206 + hydroxychloroquine'}]","Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostate or Kidney Cancer",6953
6,NCT01042379,Phase II,Recruiting,"[{'id': 1218, 'therapyName': 'Trebananib'}, {'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}, {'id': 746, 'therapyName': 'Ganitumab'}, {'id': 1495, 'therapyName': 'Paclitaxel + Doxorubicin + Cyclophosphamide'}, {'id': 1494, 'therapyName': 'MK2206 + Trastuzumab'}, {'id': 1493, 'therapyName': 'Trebananib + Trastuzumab'}, {'id': 1492, 'therapyName': 'T-DM1 + Pertuzumab'}]",I-SPY 2 TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer,6953
0,NCT01449370,Phase I,Completed,"[{'id': 1033, 'therapyName': 'MLN1117'}]",Dose Escalation Study of MLN1117 in Subjects With Advanced Cancer,7149
1,NCT02551055,Phase I,Terminated,"[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 626, 'therapyName': 'Alisertib'}, {'id': 3146, 'therapyName': 'TAK-659'}, {'id': 1033, 'therapyName': 'MLN1117'}]","MLN1117 in Combination With Docetaxel, Paclitaxel, and Other Investigational Anticancer Agents to Treat Participants With Gastric and Gastroesophageal Adenocarcinoma",7149
2,NCT02724020,Phase II,Recruiting,"[{'id': 1283, 'therapyName': 'MLN1117 + Sapanisertib'}, {'id': 1282, 'therapyName': 'Sapanisertib'}, {'id': 735, 'therapyName': 'Everolimus'}]",MLN0128 and MLN0128 + MLN1117 Compared With Everolimus in the Treatment of Adults With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma,7149
3,NCT01899053,Phase I,"Active, not recruiting","[{'id': 1283, 'therapyName': 'MLN1117 + Sapanisertib'}]",Phase 1b Study of MLN0128 in Combination With MLN1117 in Adult Patients With Advanced Nonhematologic Malignancies,7149
4,NCT02725268,Phase II,Recruiting,"[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1282, 'therapyName': 'Sapanisertib'}, {'id': 1283, 'therapyName': 'MLN1117 + Sapanisertib'}]","Phase 2 Study of MLN0128, Combination of MLN0128 With MLN1117, Paclitaxel and Combination of MLN0128 With Paclitaxel in Women With Endometrial Cancer",7149
5,NCT03193853,Phase II,Recruiting,"[{'id': 3126, 'therapyName': 'Cisplatin + nab-paclitaxel'}, {'id': 1283, 'therapyName': 'MLN1117 + Sapanisertib'}]",TAK-228 and TAK-117 Followed by Cisplatin and Nab Paclitaxel for Metastatic Triple Negative Breast Cancer,7149
6,NCT03154294,Phase I,Not yet recruiting,"[{'id': 5731, 'therapyName': 'Paclitaxel + MLN0128 + MLN1117'}]",Evaluation of the Safety and Tolerability of TAK-228 With TAK-117 and Paclitaxel in Advanced Solid Tumors,7149
0,NCT02723006,Phase I,Recruiting,"[{'id': 4198, 'therapyName': 'MLN2480 + Nivolumab'}, {'id': 4200, 'therapyName': 'MLN1202 + Nivolumab'}, {'id': 4202, 'therapyName': 'Ipilimumab + Nivolumab + Vedolizumab '}]","Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Investigational Treatments in Combination With Standard of Care Immune Checkpoint Inhibitors in Participants With Advanced Melanoma",8377
0,NCT02327169,Phase I,Recruiting,"[{'id': 2175, 'therapyName': 'MLN0128 + MLN2480'}, {'id': 2176, 'therapyName': 'MLN2480 + Alisertib'}, {'id': 2177, 'therapyName': 'MLN2480 + Paclitaxel'}]",A Phase 1B Study of MLN2480 in Combination With MLN0128 or Alisertib or Paclitaxel in Adult Patients With Advanced Nonhematologic Malignancies,7152
1,NCT01425008,Phase I,"Active, not recruiting","[{'id': 1034, 'therapyName': 'MLN2480'}]",Study of MLN2480 in Patients With Relapsed or Refractory Solid Tumors Followed by a Dose Expansion in Patients With Metastatic Melanoma,7152
2,NCT02723006,Phase I,Recruiting,"[{'id': 4198, 'therapyName': 'MLN2480 + Nivolumab'}, {'id': 4200, 'therapyName': 'MLN1202 + Nivolumab'}, {'id': 4202, 'therapyName': 'Ipilimumab + Nivolumab + Vedolizumab '}]","Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Investigational Treatments in Combination With Standard of Care Immune Checkpoint Inhibitors in Participants With Advanced Melanoma",7152
0,NCT03238248,Phase II,Recruiting,"[{'id': 6164, 'therapyName': 'Azacitidine + MLN4924'}]",Pevonedistat and Azacitidine in MDS or MDS/MPN Patients Who Fail Primary Therapy With DNA Methyl Transferase Inhibitors,7319
1,NCT03009240,Phase I,Recruiting,"[{'id': 5214, 'therapyName': 'Decitabine + MLN4924'}]",Pevonedistat and Decitabine in Treating Patients With High Risk Acute Myeloid Leukemia,7319
2,NCT03228186,Phase II,Not yet recruiting,"[{'id': 6033, 'therapyName': 'Docetaxel + MLN4924'}]",Trial of Pevonedistat Plus Docetaxel in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer,7319
3,NCT01814826,Phase I,"Active, not recruiting","[{'id': 1688, 'therapyName': 'MLN4924'}, {'id': 651, 'therapyName': 'Azacitidine'}]",Study of MLN4924 Plus Azacitidine in Treatment-Naïve Patients With Acute Myelogenous Leukemia (AML) Who Are 60 Years or Older,7319
4,NCT02122770,Phase I,"Active, not recruiting","[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1026, 'therapyName': 'Itraconazole'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1688, 'therapyName': 'MLN4924'}, {'id': 1689, 'therapyName': 'Fluconazole'}]","Effects of Fluconazole and Itraconazole CYP3A-Mediated Inhibition on the Pharmacokinetics, Safety, and Tolerability of MLN4924 in Patients With Advanced Solid Tumors",7319
5,NCT02610777,Phase II,"Active, not recruiting","[{'id': 651, 'therapyName': 'Azacitidine'}, {'id': 1688, 'therapyName': 'MLN4924'}]","An Efficacy and Safety Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine in Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML) and Low-Blast Acute Myelogenous Leukemia (AML)",7319
0,NCT01774851,Phase II,Terminated,"[{'id': 1892, 'therapyName': 'Paclitaxel + Trastuzumab + MM-111'}, {'id': 1551, 'therapyName': 'Trastuzumab + Paclitaxel'}]","A Study of MM-111 and Paclitaxel With Trastuzumab in Patients HER2 Positive Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach",6956
0,NCT01733004,Phase I,Completed,"[{'id': 1248, 'therapyName': 'MM-141 + Everolimus'}, {'id': 1073, 'therapyName': 'MM-141'}, {'id': 1249, 'therapyName': 'MM-141 + Abraxane + Gemcitabine'}]",A Phase 1 Study of MM-141 in Patients With Advanced Solid Tumors,7190
1,NCT02399137,Phase II,"Active, not recruiting","[{'id': 619, 'therapyName': 'Abraxane'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1073, 'therapyName': 'MM-141'}]",A Phase 2 Study of MM-141 Plus Nab-paclitaxel and Gemcitabine in Front-line Metastatic Pancreatic Cancer,7190
0,NCT02785068,Phase I,Withdrawn,"[{'id': 4532, 'therapyName': 'Fluorouracil + Irinotecan + Leucovorin + MM-151'}]",Evaluation of MM-151 + Nal-IRI + 5-FU + Leucovorin in RAS/RAF Wild-type Metastatic Colorectal Cancer,6958
1,NCT01520389,Phase I,Completed,"[{'id': 821, 'therapyName': 'MM-151'}, {'id': 1074, 'therapyName': 'Irinotecan'}]",Safety Study of the Drug MM-151 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment,6958
2,NCT02538627,Phase I,Terminated,"[{'id': 820, 'therapyName': 'Seribantumab'}, {'id': 821, 'therapyName': 'MM-151'}]",Phase 1 Combination Study of MM-151 and MM-121,6958
0,NCT02213744,Phase II,Terminated,"[{'id': 1890, 'therapyName': 'Vinorelbine + Trastuzumab'}, {'id': 1409, 'therapyName': 'Capecitabine + Trastuzumab'}, {'id': 1889, 'therapyName': 'Gemcitabine + Trastuzumab'}, {'id': 1888, 'therapyName': 'MM-302 + Trastuzumab'}]",MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in HER2-Positive Locally Advanced/Metastatic Breast Cancer Patients,7251
0,NCT03076372,Phase I,Recruiting,"[{'id': 5758, 'therapyName': 'MM-310'}]",A Study Evaluating MM-310 in Patients With Solid Tumors,8779
0,NCT02429375,Phase Ib/II,"Active, not recruiting","[{'id': 3264, 'therapyName': 'Brentuximab vedotin + Mocetinostat'}]",Mocetinostat (MGCD0103) Plus Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Hodgkin Lymphoma,7899
1,NCT02303262,Phase II,Completed,"[{'id': 3128, 'therapyName': 'Gemcitabine + Mocetinostat'}]",A Study of Mocetinostat and Gemcitabine in Patients With Metastatic Leiomyosarcoma,7899
2,NCT02805660,Phase Ib/II,Recruiting,"[{'id': 4378, 'therapyName': 'MEDI4736 + Mocetinostat'}]",Phase 1/2 Study of Mocetinostat and Durvalumab in Patients With Advanced Solid Tumors and NSCLC,7899
3,NCT02993991,Phase I,Not yet recruiting,"[{'id': 4378, 'therapyName': 'MEDI4736 + Mocetinostat'}]",Pre-operative Mocetinostat (MGCD0103) and Durvalumab (MEDI4736) (PRIMED) for Squamous Cell Carcinoma of the Oral Cavity,7899
4,NCT02236195,Phase II,Completed,"[{'id': 3002, 'therapyName': 'Mocetinostat'}]",Study of Mocetinostat in Patients With Urothelial Carcinoma Having Inactivating Alterations of Specific Genes,7899
5,NCT02282358,Phase Ib/II,"Active, not recruiting","[{'id': 3002, 'therapyName': 'Mocetinostat'}]",Study of Mocetinostat in Selected Patients With Mutations of Acetyltransferase Genes in Relapsed and Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma,7899
6,NCT02954991,Phase II,Recruiting,"[{'id': 4943, 'therapyName': 'MGCD516 + Nivolumab'}, {'id': 4944, 'therapyName': 'Mocetinostat + Nivolumab'}, {'id': 4942, 'therapyName': 'MGCD265 + Nivolumab'}]","Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Non-Small Cell Lung Cancer",7899
7,NCT03220477,Phase I,Recruiting,"[{'id': 6042, 'therapyName': 'Mocetinostat + Pembrolizumab + SGI-110'}]",Pembrolizumab (Immunotherapy Drug) in Combination With Guadecitabine and Mocetinostat (Epigenetic Drugs) for Patients With Advanced Lung Cancer.,7899
0,NCT02301130,Phase I,"Active, not recruiting","[{'id': 2968, 'therapyName': 'Mogamulizumab '}, {'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 1652, 'therapyName': 'Tremelimumab'}]",Study of Mogamulizumab + MEDI4736 and Mogamulizumab + Tremelimumab in Subjects w/ Advanced Solid Tumors,7880
1,NCT02705105,Phase Ib/II,Recruiting,"[{'id': 3843, 'therapyName': 'Mogamulizumab + Nivolumab'}]",Study of Mogamulizumab + Nivolumab in Subjects w/Locally Advanced or Metastatic Solid Tumors,7880
0,NCT02206763,Phase I,Terminated,"[{'id': 2380, 'therapyName': 'Erlotinib + Momelotinib'}]",Erlotinib and Momelotinib for the Treatment of Epidermal Growth Factor Receptor (EGFR) Mutated EGFR Tyrosine Kinase Inhibitor (TKI) Naive Metastatic Non-Small Cell Lung Cancer (NSCLC),6959
1,NCT02258607,Phase I,Terminated,"[{'id': 823, 'therapyName': 'Momelotinib'}, {'id': 1860, 'therapyName': 'Momelotinib + Trametinib'}]",Efficacy and Safety of Momelotinib and Momelotinib Combined With Trametinib in Adults With Metastatic KRAS-mutated Non-Small Cell Lung Cancer (NSCLC) Who Have Failed Platinum-Based Chemotherapy Preceded by a Dose-finding Lead-in Phase,6959
2,NCT02101021,Phase II,Terminated,"[{'id': 1779, 'therapyName': 'Nab-paclitaxel + Gemcitabine'}, {'id': 823, 'therapyName': 'Momelotinib'}]",Gemcitabine and Nab-paclitaxel Combined With Momelotinib in Participants With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma,6959
3,NCT02251821,Phase II,Recruiting,"[{'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 1845, 'therapyName': 'Mycophenolate mofetil'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 2006, 'therapyName': 'Pacritinib'}, {'id': 823, 'therapyName': 'Momelotinib'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}]",JAK-2 Inhibitor Before Donor Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis,6959
4,NCT02244489,Phase I,Terminated,"[{'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 823, 'therapyName': 'Momelotinib'}]",Momelotinib Combined With Capecitabine and Oxaliplatin in Adults With Relapsed/Refractory Metastatic Pancreatic Ductal Adenocarcinoma,6959
0,NCT02005289,Phase II,Recruiting,"[{'id': 5843, 'therapyName': 'Lenalidomide + MOR208'}, {'id': 5847, 'therapyName': 'Ibrutinib + MOR208'}]","Phase II MOR00208 in Combination With Lenalidomide for Patients With Relapsed or Refractory CLL, SLL or PLL or Older Patients With Untreated CLL, SLL or PLL",8796
1,NCT02639910,Phase II,Recruiting,"[{'id': 5785, 'therapyName': 'MOR208 + Venetoclax'}, {'id': 5784, 'therapyName': 'Idelalisib + MOR208'}]",Study to Evaluate Efficacy and Safety of MOR208 With Idelalisib or Venetoclax in R/R CLL/SLL Patients Pretreated With BTKi (COSMOS),8796
2,NCT02399085,Phase II,Recruiting,"[{'id': 5843, 'therapyName': 'Lenalidomide + MOR208'}]",A Study to Evaluate the Safety and Efficacy of Lenalidomide With MOR00208 in Patients With R-R DLBCL,8796
0,NCT02262910,Phase I,Recruiting,"[{'id': 4651, 'therapyName': 'MOR209/ES414'}]",Study of MOR209/ES414 in Metastatic Castration-Resistant Prostate Cancer,8503
0,NCT00717587,Phase II,Unknown status,"[{'id': 930, 'therapyName': 'Sunitinib'}, {'id': 2129, 'therapyName': 'girentuximab'}, {'id': 2128, 'therapyName': 'motexafin gadolinium'}]",Sunitinib Before and After Surgery in Treating Patients With Stage IV Kidney Cancer,7428
0,NCT02431559,Phase Ib/II,Recruiting,"[{'id': 3101, 'therapyName': 'Aldoxorubicin + MEDI4736 + Motolimod'}]","A Phase 1/2 Study of Motolimod (VTX-2337) and MEDI4736 in Subjects With Recurrent, Platinum-Resistant Ovarian Cancer for Whom Pegylated Liposomal Doxorubicin (PLD) is Indicated",7936
1,NCT02650635,Phase I,"Active, not recruiting","[{'id': 3413, 'therapyName': 'Cyclophosphamide + Pegfilgrastim + VTX-2337'}]","TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid Tumors",7936
0,NCT03029832,Phase II,"Active, not recruiting","[{'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 5451, 'therapyName': 'Atezolizumab + MOXR0916'}]",A Study of MOXR0916 in Combination With Atezolizumab Versus Atezolizumab Alone in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma Who Are Ineligible for Cisplatin-Based Therapy,7685
1,NCT02410512,Phase I,Recruiting,"[{'id': 2729, 'therapyName': 'MOXR0916'}, {'id': 1201, 'therapyName': 'Atezolizumab'}]",A Dose-Escalation Study of the Safety and Pharmacokinetics of MOXR0916 and MPDL3280A in Patients With Locally Advanced or Metastatic Solid Tumors,7685
2,NCT02219724,Phase I,"Active, not recruiting","[{'id': 2729, 'therapyName': 'MOXR0916'}]","A Phase I, Open-Label Study of MOXR0916 in Patients With Locally Advanced or Metastatic Solid Tumors",7685
0,NCT01829971,Phase I,Terminated,"[{'id': 1035, 'therapyName': 'MRX34'}]","A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection",7153
0,NCT02864992,Phase II,Recruiting,"[{'id': 1398, 'therapyName': 'MSC2156119J'}]",Tepotinib Phase II Study in Lung Adenocarcinoma Harbouring MET Exon 14 (METex14) Skipping Alterations,7249
0,NCT02516813,Phase I,Recruiting,"[{'id': 3616, 'therapyName': 'MSC2490484A '}]","Phase 1 Trial of MSC2490484A, an Inhibitor of a DNA-dependent Protein Kinase, in Combination With Radiotherapy",8175
1,NCT03116971,Phase Ib/II,Recruiting,"[{'id': 5546, 'therapyName': 'MSC2490484A  + Cisplatin + Etoposide'}, {'id': 3616, 'therapyName': 'MSC2490484A '}]",Phase Ib/II Study of M3814 With Etoposide and Cisplatin in Small Cell Lung Cancer (SCLC) Extensive Disease (ED),8175
0,NCT02794571,Phase I,Recruiting,"[{'id': 4269, 'therapyName': 'Atezolizumab + MTIG7192A '}, {'id': 4268, 'therapyName': 'MTIG7192A '}]",Safety and Pharmacokinetics (PK) of Escalating Doses of MTIG7192A as a Single Agent and in Combination With Atezolizumab in Locally Advanced or Metastatic Tumors,8394
0,NCT02192775,Phase II,Recruiting,"[{'id': 6125, 'therapyName': 'MV-NIS'}]",UARK 2014-21 A Phase II Trial of Oncolytic Virotherapy by Systemic Administration of Edmonston Strain of Measles Virus,8919
1,NCT02919449,Phase I,Recruiting,"[{'id': 6127, 'therapyName': 'MV-NIS + Atezolizumab'}]",Trial of Measles Virotherapy in Combination With Atezolizumab in Patients With Metastatic Non-Small Cell Lung Cancer,8919
0,NCT01383148,Phase Ib/II,Terminated,"[{'id': 1273, 'therapyName': 'MVA-MUC1-IL2 vaccine'}]",Phase IIB/III Of TG4010 Immunotherapy In Patients With Stage IV Non-Small Cell Lung Cancer,7231
1,NCT02823990,Phase II,Recruiting,"[{'id': 4435, 'therapyName': 'MVA-MUC1-IL2 vaccine + Nivolumab'}]",TG4010 and Nivolumab in Patients With Lung Cancer,7231
0,NCT02275039,Phase I,"Active, not recruiting","[{'id': 1038, 'therapyName': 'MVAp53'}, {'id': 755, 'therapyName': 'Gemcitabine'}]",p53MVA Vaccine and Gemcitabine Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer,7157
1,NCT02432963,Phase I,Recruiting,"[{'id': 1038, 'therapyName': 'MVAp53'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy,7157
2,NCT03113487,Phase II,Not yet recruiting,"[{'id': 5547, 'therapyName': 'MVAp53 + Pembrolizumab'}]","P53MVA and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer",7157
0,NCT03118349,Phase I,Recruiting,"[{'id': 5801, 'therapyName': 'MVT-1075 + MVT-5873'}]",Study of 177Lu Human Monoclonal Antibody 5B1 (MVT-1075) in Combination With a Blocking Dose of MVT-5873 as Radioimmunotherapy,8756
0,NCT03118349,Phase I,Recruiting,"[{'id': 5801, 'therapyName': 'MVT-1075 + MVT-5873'}]",Study of 177Lu Human Monoclonal Antibody 5B1 (MVT-1075) in Combination With a Blocking Dose of MVT-5873 as Radioimmunotherapy,8762
1,NCT02672917,Phase I,Recruiting,"[{'id': 5712, 'therapyName': 'MVT-5873'}]",Study of HuMab-5B1 (MVT-5873) in Subjects With Pancreatic Cancer or Other Cancer Antigen 19-9 (CA19-9) Positive Malignancies,8762
0,NCT01954784,Phase I,Terminated,"[{'id': 3434, 'therapyName': 'Bortezomib + Cyclosporine + Mycophenolate'}, {'id': 1164, 'therapyName': 'lenalidomide'}]",Lenalidomide After Donor Stem Cell Transplant and Bortezomib in Treating Patients With High Risk Multiple Myeloma,7348
1,NCT02722668,Phase II,Recruiting,"[{'id': 2281, 'therapyName': 'Cyclophosphamide + Fludarabine + Mycophenolate mofetil'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 1844, 'therapyName': 'anti-thymocyte globulin'}]",UCB Transplant for Hematological DIseases Using a Non Myeloablative Prep,7348
2,NCT02423915,Phase Ib/II,Recruiting,"[{'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 2281, 'therapyName': 'Cyclophosphamide + Fludarabine + Mycophenolate mofetil'}, {'id': 917, 'therapyName': 'Sirolimus'}]",Fucosylated T Cells for Graft Versus Host Disease (GVHD) Prevention,7348
3,NCT01203722,Phase Ib/II,Recruiting,"[{'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 2281, 'therapyName': 'Cyclophosphamide + Fludarabine + Mycophenolate mofetil'}]","Reduced Intensity, Partially HLA Mismatched BMT to Treat Hematologic Malignancies",7348
4,NCT03128034,Phase Ib/II,Recruiting,"[{'id': 5714, 'therapyName': 'Cyclosporine + Fludarabine phosphate + Mycophenolate mofetil + Sirolimus'}]","211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome",7348
5,NCT01252667,Phase II,Recruiting,"[{'id': 2272, 'therapyName': 'Cyclosporine + Mycophenolate mofetil'}, {'id': 1746, 'therapyName': 'Clofarabine'}]",Clofarabine and Low-Dose Total-Body Irradiation in Treating Patients With Acute Myeloid Leukemia Undergoing Donor Peripheral Blood Stem Cell Transplant,7348
6,NCT01231412,Phase III,"Active, not recruiting","[{'id': 917, 'therapyName': 'Sirolimus'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 2272, 'therapyName': 'Cyclosporine + Mycophenolate mofetil'}]",Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant,7348
7,NCT01251575,Phase II,Recruiting,"[{'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 2270, 'therapyName': 'Cyclosporine + Mycophenolate mofetil + Sirolimus'}]","Sirolimus, Cyclosporine, and Mycophenolate Mofetil In Preventing Graft-Versus-Host Disease in Treating Patients With Hematologic Malignancies Undergoing Donor Peripheral Blood Stem Cell Transplant",7348
8,NCT02653196,Phase II,Terminated,"[{'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1205, 'therapyName': 'Alemtuzumab'}, {'id': 2373, 'therapyName': 'Palifermin'}, {'id': 2237, 'therapyName': 'Fludarabine + Melphalan'}, {'id': 3948, 'therapyName': 'Cyclosporine + Mycophenolate mofetil + Tacrolimus'}]",A Multi-Institutional Phase II Feasibility Study of Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Malignant Neuro-Epithelial and Other Solid Tumors,7348
9,NCT00305682,Phase II,Recruiting,"[{'id': 917, 'therapyName': 'Sirolimus'}, {'id': 1845, 'therapyName': 'Mycophenolate mofetil'}, {'id': 1844, 'therapyName': 'anti-thymocyte globulin'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1166, 'therapyName': 'Fludarabine'}]",Non-Myeloablative Conditioning for Unrelated Donor Umbilical Cord Blood Transplant,7348
10,NCT02756572,Phase I,Recruiting,"[{'id': 917, 'therapyName': 'Sirolimus'}, {'id': 1845, 'therapyName': 'Mycophenolate mofetil'}, {'id': 1650, 'therapyName': 'Cyclosporine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 5215, 'therapyName': 'mitoxantrone hydrochloride'}, {'id': 1166, 'therapyName': 'Fludarabine'}]",Early Allogeneic Hematopoietic Cell Transplantation in Treating Patients With Relapsed or Refractory High-Grade Myelodysplastic Syndrome or Acute Myeloid Leukemia,7348
11,NCT02333162,Phase I,Recruiting,"[{'id': 1845, 'therapyName': 'Mycophenolate mofetil'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 2237, 'therapyName': 'Fludarabine + Melphalan'}]","Intensity Modulated Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients With Relapsed Hematologic Cancers Undergoing a Second Donor Stem Cell Transplant",7348
12,NCT01529827,Phase II,"Active, not recruiting","[{'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 1845, 'therapyName': 'Mycophenolate mofetil'}, {'id': 1166, 'therapyName': 'Fludarabine'}]","Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies",7348
13,NCT02251821,Phase II,Recruiting,"[{'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 1845, 'therapyName': 'Mycophenolate mofetil'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 2006, 'therapyName': 'Pacritinib'}, {'id': 823, 'therapyName': 'Momelotinib'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}]",JAK-2 Inhibitor Before Donor Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis,7348
14,NCT01621477,Phase II,Terminated,"[{'id': 1756, 'therapyName': 'Plerixafor'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 1845, 'therapyName': 'Mycophenolate mofetil'}, {'id': 2469, 'therapyName': 'Busulfan + Clofarabine + Thymoglobulin'}, {'id': 1783, 'therapyName': 'Cyclophosphamide + Cytarabine'}]",T-Cell Replete Haploidentical Donor Hematopoietic Stem Cell Plus Natural Killer (NK) Cell Transplantation in Patients With Hematologic Malignancies Relapsed or Refractory Despite Previous Allogeneic Transplant,7348
15,NCT02793544,Phase II,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 1845, 'therapyName': 'Mycophenolate mofetil'}, {'id': 5682, 'therapyName': 'Mesna'}, {'id': 1166, 'therapyName': 'Fludarabine'}]",HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide,7348
16,NCT01701986,Phase Ib/II,Recruiting,"[{'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1845, 'therapyName': 'Mycophenolate mofetil'}, {'id': 1844, 'therapyName': 'anti-thymocyte globulin'}, {'id': 3992, 'therapyName': 'Busulfan + Clofarabine + Gemcitabine'}]",Gemcitabine/Clofarabine/Busulfan and Allogeneic Transplantation for Aggressive Lymphomas,7348
17,NCT00003553,Phase II,Unknown status,"[{'id': 2291, 'therapyName': 'Cyclophosphamide + Fludarabine'}, {'id': 1650, 'therapyName': 'Cyclosporine'}, {'id': 1845, 'therapyName': 'Mycophenolate mofetil'}, {'id': 1639, 'therapyName': 'Methotrexate'}]",Peripheral Stem Cell Transplant in Treating Patients With Metastatic Kidney Cancer,7348
18,NCT01619761,Phase I,Recruiting,"[{'id': 897, 'therapyName': 'Rituximab'}, {'id': 1847, 'therapyName': 'lenalidomide + Fludarabine + Melphalan'}, {'id': 1845, 'therapyName': 'Mycophenolate mofetil'}, {'id': 1843, 'therapyName': 'Tacrolimus'}]",Natural Killer (NK) Cells in Cord Blood Transplantation,7348
19,NCT01760655,Phase II,Recruiting,"[{'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 1842, 'therapyName': 'Fludarabine + Thiotepa + Cyclophosphamide'}, {'id': 1845, 'therapyName': 'Mycophenolate mofetil'}]",Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies,7348
20,NCT02508038,Phase I,Recruiting,"[{'id': 2971, 'therapyName': 'Zoledronic acid'}, {'id': 2237, 'therapyName': 'Fludarabine + Melphalan'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 1844, 'therapyName': 'anti-thymocyte globulin'}, {'id': 1845, 'therapyName': 'Mycophenolate mofetil'}]", Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa,7348
0,NCT02399137,Phase II,"Active, not recruiting","[{'id': 619, 'therapyName': 'Abraxane'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1073, 'therapyName': 'MM-141'}]",A Phase 2 Study of MM-141 Plus Nab-paclitaxel and Gemcitabine in Front-line Metastatic Pancreatic Cancer,6828
1,NCT02265510,Phase I,Recruiting,"[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 1164, 'therapyName': 'lenalidomide'}, {'id': 619, 'therapyName': 'Abraxane'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 2747, 'therapyName': 'INCB052793'}, {'id': 688, 'therapyName': 'Bortezomib'}]","An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies",6828
2,NCT02331251,Phase Ib/II,"Active, not recruiting","[{'id': 1685, 'therapyName': 'Vinorelbine'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 619, 'therapyName': 'Abraxane'}]",Study of Pembrolizumab Plus Chemotherapy in Patients With Advanced Cancer (PembroPlus),6828
3,NCT02229149,Phase II,"Active, not recruiting","[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}, {'id': 619, 'therapyName': 'Abraxane'}, {'id': 1685, 'therapyName': 'Vinorelbine'}, {'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 1105, 'therapyName': 'Capecitabine'}]","Phase 2 Study of Standard Chemotherapy With Trastuzumab, Plus or Minus Pertuzumab, for Pre-treated Metastatic Breast Cancer",6828
4,NCT01620190,Phase II,"Active, not recruiting","[{'id': 619, 'therapyName': 'Abraxane'}]",Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Previously Treated Advanced Non-Small Cell Lung Cancer,6828
5,NCT02574078,Phase I,Recruiting,"[{'id': 619, 'therapyName': 'Abraxane'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 2114, 'therapyName': 'Bevacizumab + Pemetrexed'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 1092, 'therapyName': 'Carboplatin'}]",A Master Protocol Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC) (CheckMate 370),6828
6,NCT01572038,Phase III,"Active, not recruiting","[{'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}, {'id': 619, 'therapyName': 'Abraxane'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]",A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) and A Taxane in First-Line Treatment in Patients With HER2-Positive Advanced Breast Cancer (PERUSE),6828
7,NCT01647828,Phase Ib/II,Completed,"[{'id': 619, 'therapyName': 'Abraxane'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 2547, 'therapyName': 'Tarextumab'}]",A Phase 1b/2 Study of OMP-59R5 in Combination With Nab-Paclitaxel and Gemcitabine in Subjects With Previously Untreated Stage IV Pancreatic Cancer,6828
8,NCT02999477,Phase I,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 619, 'therapyName': 'Abraxane'}]",A Study Of Changes In PD-L1 Expression During Preoperative Treatment With Nab-Paclitaxel And Pembrolizumab In Hormone Receptor-Positive Breast Cancer,6828
9,NCT02489903,Phase II,Recruiting,"[{'id': 1136, 'therapyName': 'Etoposide'}, {'id': 3680, 'therapyName': 'RRx-001'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 619, 'therapyName': 'Abraxane'}]","RRx-001 in Small, Non-small Cell Lung Cancer, and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens",6828
10,NCT02073487,Phase II,Recruiting,"[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1583, 'therapyName': 'Trastuzumab emtansine + Lapatinib'}, {'id': 1414, 'therapyName': 'Trastuzumab + Lapatinib'}, {'id': 619, 'therapyName': 'Abraxane'}]",Neoadjuvant TDM1 With Lapatinib and Abraxane Compared With Trastuzumab With Lapatinib and Paclitaxel,6828
11,NCT02138383,Phase I,"Active, not recruiting","[{'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 619, 'therapyName': 'Abraxane'}, {'id': 755, 'therapyName': 'Gemcitabine'}]",Enzalutamide in Combination With Gemcitabine and Nab-Paclitaxel for the Treatment of Advanced Pancreatic Cancer,6828
12,NCT02367794,Phase III,"Active, not recruiting","[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 619, 'therapyName': 'Abraxane'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1201, 'therapyName': 'Atezolizumab'}]",A Phase III Study of MPDL3280A (Anti-PD-L1) in Combination With Carboplatin + Paclitaxel or Carboplatin + Nab-paclitaxel Compared With Carboplatin + Nab-paclitaxel in Patients With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC),6828
13,NCT03136406,Phase Ib/II,Recruiting,"[{'id': 1018, 'therapyName': 'GI-4000'}, {'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 3144, 'therapyName': 'Avelumab'}, {'id': 619, 'therapyName': 'Abraxane'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 6163, 'therapyName': 'ETBX-011'}, {'id': 3060, 'therapyName': 'ALT-803'}]",QUILT-3.039: NANT Pancreatic Cancer Vaccine: Combination Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy,6828
14,NCT02020707,Phase I,Suspended,"[{'id': 619, 'therapyName': 'Abraxane'}]",Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab in Treating Patients With Stage IV Melanoma That Cannot be Removed by Surgery,6828
15,NCT02227940,Phase I,Recruiting,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 619, 'therapyName': 'Abraxane'}, {'id': 2554, 'therapyName': 'Ceritinib + Gemcitabine'}]",Ceritinib and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors or Locally Advanced or Metastatic Pancreatic Cancer,6828
16,NCT02819518,Phase III,Recruiting,"[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 619, 'therapyName': 'Abraxane'}, {'id': 2667, 'therapyName': 'Carboplatin + Gemcitabine'}]",Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs. Placebo Plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (MK-3475-355/KEYNOTE-355),6828
17,NCT02250326,Phase II,"Active, not recruiting","[{'id': 1950, 'therapyName': 'Abraxane + Azacitidine'}, {'id': 619, 'therapyName': 'Abraxane'}]",Safety and Efficacy Study of Nab-Paclitaxel With CC-486 and Nab-Paclitaxel Monotherapy as Second Line Treatment for Advanced Nonsquamous Non-small Cell Lung Cancer,6828
18,NCT03181100,Phase II,Recruiting,"[{'id': 619, 'therapyName': 'Abraxane'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1343, 'therapyName': 'Atezolizumab + Cobimetinib'}, {'id': 4595, 'therapyName': 'Atezolizumab + Bevacizumab'}, {'id': 3049, 'therapyName': 'Atezolizumab + nab-paclitaxel'}, {'id': 4825, 'therapyName': 'Atezolizumab + Vemurafenib + Cobimetinib'}, {'id': 5606, 'therapyName': 'Atezolizumab + Paclitaxel'}]",Atezolizumab Combinations With Chemotherapy for Anaplastic and Poorly Differentiated Thyroid Carcinomas,6828
19,NCT02048943,Phase I,Withdrawn,"[{'id': 1372, 'therapyName': 'Dovitinib + Gemcitabine + Abraxane'}, {'id': 619, 'therapyName': 'Abraxane'}, {'id': 721, 'therapyName': 'Dovitinib'}]","Dovitinib Lactate, Gemcitabine Hydrochloride, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Solid Tumors or Pancreatic Cancer",6828
20,NCT02425891,Phase III,"Active, not recruiting","[{'id': 619, 'therapyName': 'Abraxane'}, {'id': 1201, 'therapyName': 'Atezolizumab'}]",A Study of MPDL3280A in Combination With Nab-Paclitaxel Compared With Placebo With Nab-Paclitaxel for Patients With Previously Untreated Metastatic Triple Negative Breast Cancer,6828
21,NCT01858883,Phase I,Completed,"[{'id': 619, 'therapyName': 'Abraxane'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 2406, 'therapyName': 'INCB039110'}, {'id': 755, 'therapyName': 'Gemcitabine'}]",Safety Study of INCB039110 in Combination With Gemcitabine and Nab-Paclitaxel in Subjects With Advanced Solid Tumors,6828
22,NCT02565758,Phase I,Recruiting,"[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 619, 'therapyName': 'Abraxane'}, {'id': 3846, 'therapyName': 'ABBV-085'}]","ABBV-085, an Antibody Drug Conjugate, in Subjects With Advanced Solid Cancer Tumors",6828
23,NCT02788981,Phase II,Recruiting,"[{'id': 4350, 'therapyName': 'Mifepristone + Nab-paclitaxel'}, {'id': 619, 'therapyName': 'Abraxane'}]","A Trial of Nanoparticle Albumin-Bound Paclitaxel (Nab-Paclitaxel, Abraxane) With or Without Mifepristone for Advanced, Glucocorticoid Receptor-Positive, Triple-Negative Breast Cancer",6828
24,NCT03197935,Phase III,Recruiting,"[{'id': 1476, 'therapyName': 'Pegfilgrastim'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 619, 'therapyName': 'Abraxane'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}]",A Study to Investigate Atezolizumab and Chemotherapy Compared With Placebo and Chemotherapy in the Neoadjuvant Setting in Participants With Early Stage Triple Negative Breast Cancer (IMpassion031),6828
25,NCT02503358,Phase I,Recruiting,"[{'id': 913, 'therapyName': 'Selumetinib'}, {'id': 619, 'therapyName': 'Abraxane'}]",Selumetinib and Nab-Paclitaxel (Albumin-stabilized Nanoparticle Formulation) as Second-Line Treatment in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer,6828
26,NCT02009449,Phase I,"Active, not recruiting","[{'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 2621, 'therapyName': 'AM0010 '}, {'id': 619, 'therapyName': 'Abraxane'}]",A Phase 1 Study of AM0010 in Patients With Advanced Solid Tumors,6828
27,NCT01113476,Phase I,Recruiting,"[{'id': 1144, 'therapyName': 'Abraxane + Avastin + Gemcitabine'}]","Nab-paclitaxel, Gemcitabine, and Bevacizumab in Advanced Malignancies",6828
28,NCT00733408,Phase II,"Active, not recruiting","[{'id': 1496, 'therapyName': 'Abraxane + Bevacizumab + Erlotinib'}]",Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab Followed By Bevacizumab and Erlotinib Hydrochloride in Treating Patients With Metastatic Breast Cancer,6828
29,NCT01412229,Phase II,"Active, not recruiting","[{'id': 1957, 'therapyName': 'Abraxane + Carboplatin + Cetuximab'}]",Induction Chemotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck,6828
30,NCT02270814,Phase II,Recruiting,"[{'id': 1957, 'therapyName': 'Abraxane + Carboplatin + Cetuximab'}, {'id': 1956, 'therapyName': 'Abraxane + Cisplatin + Cetuximab'}]","Cisplatin, Nab-Paclitaxel, and Cetuximab (CACTUX) in Patients With Incurable Head and Neck Squamous Cell Carcinoma",6828
31,NCT02336087,Phase I,Recruiting,"[{'id': 2204, 'therapyName': 'Abraxane + Gemcitabine + Metformin'}]","Gemcitabine Hydrochloride, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Metformin Hydrochloride, and a Standardized Dietary Supplement in Treating Patients With Metastatic Pancreatic Cancer",6828
32,NCT02349867,Phase I,Recruiting,"[{'id': 2429, 'therapyName': 'Abraxane + Gemcitabine + Sorafenib + Vorinostat'}]","Gemcitabine Hydrochloride, Nab-Paclitaxel, Radiation Therapy, Sorafenib Tosylate,Vorinostat in Treating Previously Untreated Pancreatic Cancer Patients",6828
33,NCT02379416,Phase I,Recruiting,"[{'id': 2490, 'therapyName': 'Abraxane + Nilotinib'}]",Combination Nilotinib and Paclitaxel in Adults With Relapsed Solid Tumors,6828
34,NCT02309177,Phase I,Recruiting,"[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 2489, 'therapyName': 'Abraxane + Nivolumab'}]","Safety Study of Nivolumab With Nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, Nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or Nab-Paclitaxel in Recurrent Metastatic Breast Cancer",6828
35,NCT02317991,Phase II,Recruiting,"[{'id': 2039, 'therapyName': 'Abraxane + Ramucirumab'}]",Study of Nab-Paclitaxel and Ramucirumab as Second-line Treatment for Patients With Metastatic Gastroesophageal Cancer,6828
36,NCT02730247,Phase II,Recruiting,"[{'id': 2039, 'therapyName': 'Abraxane + Ramucirumab'}]",Clinical Trial of the Safety and Efficacy of the Addition of Ramucirumab to Nab-paclitaxel in Previously Treated Patients With Advanced Non-small Cell Lung Cancer (NSCLC),6828
37,NCT02065466,Phase Ib/II,Withdrawn,"[{'id': 1380, 'therapyName': 'Abraxane + Temozolomide + Bevacizumab'}]","Combo of Abraxane, TMZ, Bevacizumab in Metastatic Melanoma With Brain Metastases",6828
38,NCT02632071,Phase I,Recruiting,"[{'id': 3313, 'therapyName': 'ACY-1215 + nab-paclitaxel'}]",Phase I of ACY-1215 + Nab-paclitaxel in Breast Cancer,6828
39,NCT01677559,Phase I,"Active, not recruiting","[{'id': 1226, 'therapyName': 'Alisertib + Abraxane'}]",Combining MLN8237 With Nab-Paclitaxel in Patients With Advanced Solid Malignancies,6828
40,NCT02559674,Phase Ib/II,Recruiting,"[{'id': 3095, 'therapyName': 'ALT-803 + Gemcitabine + nab-paclitaxel'}]",ALT-803 in Patients With Advanced Pancreatic Cancer Conjunction With Gemcitabine and Nab-Paclitaxel,6828
41,NCT03214250,Phase Ib/II,Recruiting,"[{'id': 6047, 'therapyName': 'Gemcitabine + nab-paclitaxel + Nivolumab'}, {'id': 6048, 'therapyName': 'APX005M + Gemcitabine + nab-paclitaxel'}, {'id': 6049, 'therapyName': 'APX005M + Gemcitabine + nab-paclitaxel + Nivolumab'}]",Safety and Efficacy of APX005M With Gemcitabine and Nab-Paclitaxel With or Without Nivolumab in Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma,6828
42,NCT02716038,Phase II,Recruiting,"[{'id': 3946, 'therapyName': 'Atezolizumab + Carboplatin + nab-Paclitaxel'}]","Neoadjuvant MPDL3280A, Nab-paclitaxel and Carboplatin (MAC) in NSCLC",6828
43,NCT02715531,Phase I,Recruiting,"[{'id': 3947, 'therapyName': 'Atezolizumab + Gemcitabine + nab-paclitaxel'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 1202, 'therapyName': 'Atezolizumab + Bevacizumab + Capecitabine'}]",A Study of the Safety and Tolerability of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors,6828
44,NCT02530489,Phase II,Recruiting,"[{'id': 3049, 'therapyName': 'Atezolizumab + nab-paclitaxel'}]",Neoadjuvant Trial of Nab-Paclitaxel and MPDL3280A,6828
45,NCT02231723,Phase I,"Active, not recruiting","[{'id': 2630, 'therapyName': 'BBI608 + Gemcitabine + nab-paclitaxel'}]",A Study of BBI608 in Combination With Gemcitabine and Nab-Paclitaxel in Adult Patients With Metastatic Pancreatic Adenocarcinoma,6828
46,NCT02993731,Phase III,Recruiting,"[{'id': 2630, 'therapyName': 'BBI608 + Gemcitabine + nab-paclitaxel'}, {'id': 1779, 'therapyName': 'Nab-paclitaxel + Gemcitabine'}]",A Study of Napabucasin Plus Nab-Paclitaxel With Gemcitabine in Adult Patients With Metastatic Pancreatic Adenocarcinoma (CanStem111P),6828
47,NCT02158520,Phase II,"Active, not recruiting","[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 1261, 'therapyName': 'Bevacizumab + Abraxane'}]",Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery,6828
48,NCT02117817,Phase I,Withdrawn,"[{'id': 1367, 'therapyName': 'BKM120 + Abraxane'}]","Phase I BKM120/Abraxane in Solid Tumors, Expansion Phase Recurrent Endometrial or Ovarian Cancer",6828
49,NCT03184870,Phase Ib/II,Recruiting,"[{'id': 5905, 'therapyName': 'BMS-813160 + Fluorouracil + Irinotecan + Leucovorin'}, {'id': 5903, 'therapyName': 'BMS-813160 + Nivolumab'}, {'id': 5904, 'therapyName': 'BMS-813160 + Gemcitabine + nab-paclitaxel'}, {'id': 5902, 'therapyName': 'BMS-813160'}]",A Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Patients With Advanced Solid Tumors,6828
50,NCT02608229,Phase I,Recruiting,"[{'id': 3249, 'therapyName': 'BVD-523 + Gemcitabine + nab-paclitaxel'}]",BVD-523 Plus Nab-paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Cancer,6828
51,NCT02155088,Phase I,"Active, not recruiting","[{'id': 1870, 'therapyName': 'BYL719 + Gemcitabine + Abraxane'}]",BYL719 in Combination With Gemcitabine and (Nab)-Paclitaxel in Locally Advanced and Metastatic Pancreatic Cancer,6828
52,NCT02379247,Phase Ib/II,Recruiting,"[{'id': 2503, 'therapyName': 'BYL719 + nab-paclitaxel'}]",BYL719 and Nab-Paclitaxel in Locally Recurrent or Metastatic HER-2 Negative Breast Cancer,6828
53,NCT02775435,Phase III,Recruiting,"[{'id': 2634, 'therapyName': 'Carboplatin + nab-paclitaxel'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]",A Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With First Line Metastatic Squamous Non-small Cell Lung Cancer (MK-3475-407/KEYNOTE-407),6828
54,NCT02658214,Phase I,Recruiting,"[{'id': 2667, 'therapyName': 'Carboplatin + Gemcitabine'}, {'id': 2634, 'therapyName': 'Carboplatin + nab-paclitaxel'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 1791, 'therapyName': 'Carboplatin + Etoposide'}]",Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors,6828
55,NCT02367781,Phase III,"Active, not recruiting","[{'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 2634, 'therapyName': 'Carboplatin + nab-paclitaxel'}]",A Phase III Study of MPDL3280A (Anti-PD-L1 Antibody) in Combination With Carboplatin + Nab-Paclitaxel in Patients With Non-Squamous Non-Small Cell Lung Cancer,6828
56,NCT02382406,Phase Ib/II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 2634, 'therapyName': 'Carboplatin + nab-paclitaxel'}]",Carboplatin/Nab-Paclitaxel and MK-3475 in NSCLC,6828
57,NCT03164616,Phase III,Recruiting,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}, {'id': 1857, 'therapyName': 'Cisplatin + Pemetrexed'}, {'id': 1602, 'therapyName': 'Carboplatin + Pemetrexed'}, {'id': 1467, 'therapyName': 'Gemcitabine + Cisplatin'}, {'id': 2667, 'therapyName': 'Carboplatin + Gemcitabine'}, {'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 2634, 'therapyName': 'Carboplatin + nab-paclitaxel'}]",Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON). (POSEIDON),6828
58,NCT02392507,Phase II,Recruiting,"[{'id': 2599, 'therapyName': 'Carboplatin + nab-paclitaxel + Necitumumab'}]",A Study of Nab-Paclitaxel and Carboplatin Plus Necitumumab (LY3012211) in Participants With Stage IV Squamous NSCLC,6828
59,NCT03121352,Phase I,Recruiting,"[{'id': 5591, 'therapyName': 'Carboplatin + nab-paclitaxel + Pembrolizumab'}]","Pilot Study of Carboplatin, Nab-Paclitaxel and Pembrolizumab for Metastatic Triple-Negative Breast Cancer",6828
60,NCT02573493,Phase II,Recruiting,"[{'id': 3126, 'therapyName': 'Cisplatin + nab-paclitaxel'}, {'id': 3127, 'therapyName': 'Cetuximab + nab-paclitaxel'}]",Nab-Paclitaxel and Cisplatin or Nab-paclitaxel as Induction Therapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (HNSCC),6828
61,NCT02754726,Phase II,Recruiting,"[{'id': 4087, 'therapyName': 'Cisplatin + Gemcitabine + nab-paclitaxel + Nivolumab + Paricalcitol'}]",Combination Therapy for Patients With Untreated Metastatic Pancreatic Ductal Adenocarcinoma,6828
62,NCT03193853,Phase II,Recruiting,"[{'id': 3126, 'therapyName': 'Cisplatin + nab-paclitaxel'}, {'id': 1283, 'therapyName': 'MLN1117 + Sapanisertib'}]",TAK-228 and TAK-117 Followed by Cisplatin and Nab Paclitaxel for Metastatic Triple Negative Breast Cancer,6828
63,NCT02289898,Phase II,"Active, not recruiting","[{'id': 2639, 'therapyName': 'Demcizumab + Gemcitabine + nab-paclitaxel'}]","Study of Gemcitabine, Abraxane Plus Placebo Versus Gemcitabine, Abraxane Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With 1st-Line Metastatic Pancreatic Ductal Adenocarcinoma",6828
64,NCT02620800,Phase Ib/II,Recruiting,"[{'id': 3621, 'therapyName': 'FABLOx'}]","Study of 5-fluorouracil (5-FU), Nab-paclitaxel, Bevacizumab, Leucovorin, and Oxaliplatin in Patients With Metastatic Pancreatic Cancer",6828
65,NCT02583477,Phase Ib/II,Recruiting,"[{'id': 3099, 'therapyName': 'AZD5069 + MEDI4736'}, {'id': 3163, 'therapyName': 'Gemcitabine + MEDI4736 + nab-paclitaxel'}]",Phase Ib/II Study of MEDI4736 Evaluated in Different Combinations in Metastatic Pancreatic Ductal Carcinoma,6828
66,NCT03193190,Phase Ib/II,Recruiting,"[{'id': 5942, 'therapyName': 'Atezolizumab + BKT140'}, {'id': 5940, 'therapyName': 'Gemcitabine + Nab-Paclitaxel + mFOLFOX-6'}, {'id': 5941, 'therapyName': 'Atezolizumab + PEGPH20'}, {'id': 1343, 'therapyName': 'Atezolizumab + Cobimetinib'}]",A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (PDAC),6828
67,NCT02732938,Phase I,"Active, not recruiting","[{'id': 4340, 'therapyName': 'Gemcitabine + nab-paclitaxel + PF-04136309'}]",Ph1b/2 Study of PF-04136309 in Combination With Gem/Nab-P in First-line Metastatic Pancreatic Patients (CCR2i),6828
68,NCT02178436,Phase Ib/II,Suspended,"[{'id': 2560, 'therapyName': 'Gemcitabine + nab-paclitaxel + Selinexor'}]","Selinexor, Gemcitabine Hydrochloride, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Metastatic Pancreatic Cancer",6828
69,NCT01431794,Phase Ib/II,"Active, not recruiting","[{'id': 2497, 'therapyName': 'Gemcitabine + nab-paclitaxel + Sonidegib'}]",Gemcitabine + Nab-paclitaxel With LDE-225 (Hedgehog Inhibitor) as Neoadjuvant Therapy for Pancreatic Adenocarcinoma,6828
70,NCT02005315,Phase I,"Active, not recruiting","[{'id': 4412, 'therapyName': 'Gemcitabine + nab-paclitaxel + Vantictumab'}]",A Study of Vantictumab (OMP-18R5) in Combination With Nab-Paclitaxel and Gemcitabine in Previously Untreated Stage IV Pancreatic Cancer,6828
71,NCT02651727,Phase I,Terminated,"[{'id': 4342, 'therapyName': 'Gemcitabine + nab-paclitaxel + VS-4718'}]","Ph 1 Study of VS-4718, a FAK Inhibitor, in Combination With Nab-paclitaxel and Gemcitabine in Advanced Cancer Subjects",6828
72,NCT03085914,Phase Ib/II,Recruiting,"[{'id': 5483, 'therapyName': 'INCB024360 + Nivolumab + mFOLFOX6'}, {'id': 5484, 'therapyName': 'INCB024360 + Nivolumab + Gemcitabine + nab-paclitaxel'}, {'id': 5485, 'therapyName': 'INCB024360 + Pembrolizumab + Carboplatin + Paclitaxel'}, {'id': 5486, 'therapyName': 'INCB024360 + Pembrolizumab + Carboplatin + Pemetrexed'}, {'id': 5487, 'therapyName': 'INCB024360 + Pembrolizumab + Cyclophosphamide'}]",A Study of Epacadostat in Combination With a PD-1 Inhibitor and Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors (ECHO-207),6828
73,NCT01827111,Phase II,"Active, not recruiting","[{'id': 2978, 'therapyName': 'Ipilimumab + nab-paclitaxel'}]",Phase II Study of Abraxane Plus Ipilimumab in Patients With Metastatic Melanoma,6828
74,NCT02857270,Phase I,Recruiting,"[{'id': 4588, 'therapyName': 'LY3214996'}, {'id': 4590, 'therapyName': 'LY3214996 + nab-paclitaxel + Gemcitabine'}, {'id': 4589, 'therapyName': 'LY3214996 + Midazolam'}, {'id': 4591, 'therapyName': 'LY3214996 + Abemaciclib'}]",A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer,6828
75,NCT02489448,Phase Ib/II,Recruiting,"[{'id': 3100, 'therapyName': 'MEDI4736 + nab-paclitaxel'}, {'id': 1977, 'therapyName': 'Doxorubicin + Cyclophosphamide'}]",Neoadjuvant MEDI4736 Concomitant With Weekly Nab-paclitaxel and Dose-dense AC for Stage I-III Triple Negative Breast Cancer,6828
76,NCT01733004,Phase I,Completed,"[{'id': 1248, 'therapyName': 'MM-141 + Everolimus'}, {'id': 1073, 'therapyName': 'MM-141'}, {'id': 1249, 'therapyName': 'MM-141 + Abraxane + Gemcitabine'}]",A Phase 1 Study of MM-141 in Patients With Advanced Solid Tumors,6828
77,NCT02366143,Phase III,"Active, not recruiting","[{'id': 2370, 'therapyName': 'Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel'}, {'id': 1489, 'therapyName': 'Nab-paclitaxel + Carboplatin + Bevacizumab'}, {'id': 1203, 'therapyName': 'Atezolizumab + Carboplatin + Paclitaxel'}]",TBAA Phase III Study of MPDL3280A (Anti-PD-L1 Antibody) in Combination With Carboplatin + Paclitaxel With or Without Bevacizumab in Patients With Stage IV Non-squamous Non-small Cell Lung Cancer,6828
78,NCT00618657,Phase II,"Active, not recruiting","[{'id': 1490, 'therapyName': 'Nab-paclitaxel + Carboplatin + Trastuzumab'}, {'id': 1489, 'therapyName': 'Nab-paclitaxel + Carboplatin + Bevacizumab'}]","Carboplatin+Nab-paclitaxel, Plus Trastuzumab (HER2+) or Bevacizumab (HER2-) in the Neoadjuvant Setting",6828
79,NCT02574663,Phase I,"Active, not recruiting","[{'id': 1779, 'therapyName': 'Nab-paclitaxel + Gemcitabine'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 2022, 'therapyName': 'TGR-1202'}]",TGR-1202 Alone and in Combination With Either Nab-paclitaxel + Gemcitabine or With FOLFOX in Patients With Select Relapsed or Refractory Solid Tumors,6828
80,NCT02109445,Phase II,Terminated,"[{'id': 1779, 'therapyName': 'Nab-paclitaxel + Gemcitabine'}, {'id': 859, 'therapyName': 'PF-03084014'}]",Study Of PF-03084014 In Combination With Gemcitabine And Nab-Paclitaxel In Patients With Metastatic Pancreatic Adenocarcinoma Not Previously Treated With Anticancer Therapies,6828
81,NCT02879318,Phase II,Recruiting,"[{'id': 1779, 'therapyName': 'Nab-paclitaxel + Gemcitabine'}, {'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}]","Gemcitabine and Nab-Paclitaxel vs Gemcitabine, Nab-Paclitaxel, Durvalumab and Tremelimumab as 1st Line Therapy in Pancreatic Adenocarcinoma",6828
82,NCT01803282,Phase I,Recruiting,"[{'id': 3320, 'therapyName': 'GS-5745'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 1602, 'therapyName': 'Carboplatin + Pemetrexed'}, {'id': 1315, 'therapyName': 'FOLFIRI'}, {'id': 1779, 'therapyName': 'Nab-paclitaxel + Gemcitabine'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 667, 'therapyName': 'Bevacizumab'}]",Safety and Tolerability Study in Solid Tumors,6828
83,NCT01921751,Phase II,Terminated,"[{'id': 1779, 'therapyName': 'Nab-paclitaxel + Gemcitabine'}, {'id': 1105, 'therapyName': 'Capecitabine'}]",High or Standard Intensity Radiation Therapy After Gemcitabine Hydrochloride and Nab-paclitaxel in Treating Patients With Pancreatic Cancer That Cannot Be Removed by Surgery,6828
84,NCT03086369,Phase Ib/II,Recruiting,"[{'id': 5482, 'therapyName': 'Olaratumab + nab-paclitaxel + Gemcitabine'}, {'id': 1779, 'therapyName': 'Nab-paclitaxel + Gemcitabine'}]",A Study of Nab-Paclitaxel and Gemcitabine With or Without Olaratumab (LY3012207) in Participants With Metastatic Pancreatic Cancer,6828
85,NCT01804530,Phase I,"Active, not recruiting","[{'id': 2651, 'therapyName': 'PLX7486'}, {'id': 1779, 'therapyName': 'Nab-paclitaxel + Gemcitabine'}]",Phase 1 Study of PLX7486 as Single Agent and With Gemcitabine Plus Nab-Paclitaxel in Patients With Advanced Solid Tumors,6828
86,NCT02570711,Phase II,Terminated,"[{'id': 1605, 'therapyName': 'Acalabrutinib'}, {'id': 1779, 'therapyName': 'Nab-paclitaxel + Gemcitabine'}]",Study of Nab Paclitaxel/Gemcitabine Alone and in Combination With ACP-196 in Subjects With Previously Untreated Metastatic Pancreatic Cancer,6828
87,NCT02077881,Phase Ib/II,Recruiting,"[{'id': 2976, 'therapyName': 'indoximod'}, {'id': 1779, 'therapyName': 'Nab-paclitaxel + Gemcitabine'}]",Study of IDO Inhibitor in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer,6828
88,NCT02101021,Phase II,Terminated,"[{'id': 1779, 'therapyName': 'Nab-paclitaxel + Gemcitabine'}, {'id': 823, 'therapyName': 'Momelotinib'}]",Gemcitabine and Nab-paclitaxel Combined With Momelotinib in Participants With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma,6828
89,NCT02340117,Phase II,Recruiting,"[{'id': 2518, 'therapyName': 'SGT-53'}, {'id': 1779, 'therapyName': 'Nab-paclitaxel + Gemcitabine'}]",Study of Combined SGT-53 Plus Gemcitabine/Nab-Paclitaxel for Metastatic Pancreatic Cancer,6828
90,NCT01621243,Phase Ib/II,Terminated,"[{'id': 1779, 'therapyName': 'Nab-paclitaxel + Gemcitabine'}, {'id': 4251, 'therapyName': 'Necuparanib'}]",M402 in Combination With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer,6828
91,NCT02436668,Phase II,"Active, not recruiting","[{'id': 1779, 'therapyName': 'Nab-paclitaxel + Gemcitabine'}, {'id': 768, 'therapyName': 'Ibrutinib'}]","Study of Ibrutinib vs Placebo, in Combination With Nab-paclitaxel and Gemcitabine, in the First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma",6828
92,NCT01488552,Phase Ib/II,Completed,"[{'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 1315, 'therapyName': 'FOLFIRI'}, {'id': 1779, 'therapyName': 'Nab-paclitaxel + Gemcitabine'}, {'id': 1031, 'therapyName': 'Metformin'}]",Gemcitabine+Nab-paclitaxel and FOLFIRINOX and Molecular Profiling for Patients With Advanced Pancreatic Cancer,6828
93,NCT01376310,Phase II,"Active, not recruiting","[{'id': 1264, 'therapyName': 'Docetaxel + Trametinib'}, {'id': 1265, 'therapyName': 'Erlotinib + Trametinib'}, {'id': 2, 'therapyName': 'Trametinib'}, {'id': 1266, 'therapyName': 'Pemetrexed + GSK1120212'}, {'id': 1267, 'therapyName': 'Carboplatin + GSK1120212'}, {'id': 1268, 'therapyName': 'nab-paclitaxel + GSK1120212'}, {'id': 1269, 'therapyName': 'Gemcitabine + GSK1120212'}, {'id': 1271, 'therapyName': 'Everolimus + GSK1120212'}]",GSK1120212 Rollover Study,6828
94,NCT02300935,Phase I,Withdrawn,"[{'id': 1268, 'therapyName': 'nab-paclitaxel + GSK1120212'}]",Study of Trametinib and Nab-paclitaxel in Patients With Melanoma,6828
95,NCT02501902,Phase I,Recruiting,"[{'id': 3112, 'therapyName': 'nab-paclitaxel + Palbociclib'}]",Dose-Escalation Study Of Palbociclib + Nab-Paclitaxel In mPDAC,6828
96,NCT02733250,Phase Ib/II,Recruiting,"[{'id': 4023, 'therapyName': 'nab-paclitaxel + Pembrolizumab'}]",Pembrolizumab With Nab-Paclitaxel in Non-Small Cell Lung Cancer (URCOH-PMS-001),6828
97,NCT02752685,Phase II,Recruiting,"[{'id': 4023, 'therapyName': 'nab-paclitaxel + Pembrolizumab'}]",Phase II Study of Pembrolizumab and Nab-paclitaxel in HER-2 Negative Metastatic Breast Cancer,6828
98,NCT03240016,Phase II,Not yet recruiting,"[{'id': 4023, 'therapyName': 'nab-paclitaxel + Pembrolizumab'}]",Abraxane With Anti-PD1/PDL1 in Cisplatin-ineligible Patients With Advanced Urothelial Cancer,6828
99,NCT02902484,Phase Ib/II,Not yet recruiting,"[{'id': 4723, 'therapyName': 'Nintedanib + Gemcitabine + nab-paclitaxel'}, {'id': 831, 'therapyName': 'Nintedanib'}]",Study of Nintedanib and Chemotherapy for Advanced Pancreatic Cancer,6828
100,NCT01036087,Phase II,"Active, not recruiting","[{'id': 1984, 'therapyName': 'Panitumumab + Abraxane + Carboplatin'}, {'id': 1982, 'therapyName': 'Fluorouracil + Epirubicin + Cyclophosphamide'}]","Panitumumab, Nab-paclitaxel and Carboplatin for HER2 Negative Inflammatory Breast Cancer",6828
101,NCT02930902,Phase I,Recruiting,"[{'id': 4903, 'therapyName': 'Pembrolizumab + Paricalcitol'}, {'id': 4904, 'therapyName': 'Pembrolizumab + Paricalcitol + Gemcitabine + nab-paclitaxel'}]",Preoperative Pilot Study to Assess Safety and Immunological Effect of Pembrolizumab (Keytruda) in Combination With Paricalcitol With or Without Chemotherapy in Patients With Resectable Pancreatic Cancer,6828
102,NCT03166085,Phase I,Recruiting,"[{'id': 5796, 'therapyName': 'PU-H71 + nab-paclitaxel'}]",PU-H71 With Nab-paclitaxel (Abraxane) in Metastatic Breast Cancer,6828
103,NCT02073916,Phase I,Recruiting,"[{'id': 1907, 'therapyName': 'T-DM1 + Lapatinib + Abraxane'}]",TDM1 With Abraxane and Lapatinib for Metastatic HER2 Positive Breast Cancer,6828
104,NCT01088815,Phase II,Unknown status,"[{'id': 1799, 'therapyName': 'Vismodegib + Gemcitabine + Abraxane'}]",Hedgehog Inhibitors for Metastatic Adenocarcinoma of the Pancreas,6828
0,NCT02494570,Phase II,Recruiting,"[{'id': 3380, 'therapyName': 'Nab-Rapamycin'}]",A Phase 2 Study of ABI-009 in Patients With Advanced Malignant PEComa,8059
1,NCT02646319,Phase II,"Active, not recruiting","[{'id': 3380, 'therapyName': 'Nab-Rapamycin'}]",Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR Mutations,8059
2,NCT03190174,Phase Ib/II,Recruiting,"[{'id': 5931, 'therapyName': 'Nab-Rapamycin + Nivolumab'}]",Nivolumab (Opdivo) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma,8059
3,NCT02975882,Phase I,Recruiting,"[{'id': 5030, 'therapyName': 'Nab-Rapamycin + Temozolomide + Irinotecan'}]","Nanoparticle Albumin-Bound Rapamycin, Temozolomide, and Irinotecan Hydrochloride in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors",8059
0,NCT01828476,Phase II,Terminated,"[{'id': 1316, 'therapyName': 'Hydroxychloroquine'}, {'id': 2597, 'therapyName': 'Abiraterone + Navitoclax'}]",Navitoclax and Abiraterone Acetate With or Without Hydroxychloroquine in Treating Patients With Progressive Metastatic Castrate Refractory Prostate Cancer,6961
1,NCT02520778,Phase I,Recruiting,"[{'id': 3065, 'therapyName': 'Navitoclax + Osimertinib'}]",EGFR Inhibitor AZD9291 and Navitoclax in Treating Patients With EGFR-Positive Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer,6961
2,NCT02143401,Phase I,Recruiting,"[{'id': 1872, 'therapyName': 'Navitoclax + Sorafenib'}]",Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid Tumors,6961
3,NCT03181126,Phase I,Not yet recruiting,"[{'id': 6187, 'therapyName': 'Navitoclax + Venetoclax'}]",A Study of Venetoclax in Combination With Navitoclax and Chemotherapy in Subjects With Relapsed Acute Lymphoblastic Leukemia,6961
4,NCT01989585,Phase Ib/II,Recruiting,"[{'id': 1303, 'therapyName': 'Trametinib + Dabrafenib + Navitoclax'}, {'id': 1066, 'therapyName': 'Trametinib + Dabrafenib'}]","Dabrafenib, Trametinib, and Navitoclax in Treating Patients With Solid Tumors That Are Metastatic or Cannot be Removed by Surgery",6961
5,NCT02079740,Phase Ib/II,Recruiting,"[{'id': 1386, 'therapyName': 'Trametinib + Navitoclax'}]",Trametinib and Navitoclax in Treating Patients With Advanced or Metastatic Solid Tumors,6961
0,NCT03109158,Phase Ib/II,Recruiting,"[{'id': 5578, 'therapyName': 'Cetuximab + Fluorouracil + NC-6004'}]",NC-6004 With 5-FU and Cetuximab for Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck,8721
1,NCT02240238,Phase Ib/II,Recruiting,"[{'id': 5626, 'therapyName': 'Gemcitabine + NC-6004'}]","Combination Therapy With NC-6004 and Gemcitabine in Advanced Solid Tumors or Non-Small Cell Lung, Biliary and Bladder Cancer",8721
0,NCT03054038,Phase I,Recruiting,"[{'id': 5363, 'therapyName': 'Afatinib + Necitumumab'}]",Afatinib and Necitumumab in Patients With EGFR Mutation Positive Advanced or Metastatic Non-small Cell Lung Cancer,7068
1,NCT02392507,Phase II,Recruiting,"[{'id': 2599, 'therapyName': 'Carboplatin + nab-paclitaxel + Necitumumab'}]",A Study of Nab-Paclitaxel and Carboplatin Plus Necitumumab (LY3012211) in Participants With Stage IV Squamous NSCLC,7068
2,NCT02791334,Phase I,Recruiting,"[{'id': 4370, 'therapyName': 'LY3300054 + Necitumumab'}, {'id': 4369, 'therapyName': 'LY3300054 + Ramucirumab'}, {'id': 4368, 'therapyName': 'LY3300054'}]",A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors  (PACT),7068
3,NCT02496663,Phase I,Recruiting,"[{'id': 826, 'therapyName': 'Necitumumab'}, {'id': 660, 'therapyName': 'AZD9291'}]",EGFR Inhibitor AZD9291 and Necitumumab in Treating Patients With EGFR-Positive Stage IV or Recurrent Non-small Cell Lung Cancer Who Have Progressed on a Previous EGFR Tyrosine Kinase Inhibitor,7068
4,NCT01624467,Phase II,Completed,"[{'id': 826, 'therapyName': 'Necitumumab'}]",A Study of Necitumumab Monotherapy and the QT/QTc Interval in Patient With Advanced Solid Tumors,7068
5,NCT01769391,Phase II,"Active, not recruiting","[{'id': 826, 'therapyName': 'Necitumumab'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]",A Study of Necitumumab and Chemotherapy in Participants With Stage IV Squamous Non-Small Cell Lung Cancer,7068
6,NCT02443337,Phase II,"Active, not recruiting","[{'id': 826, 'therapyName': 'Necitumumab'}, {'id': 1069, 'therapyName': 'LY3023414'}]",A Study of LY3023414 and Necitumumab in Squamous Lung Cancer,7068
7,NCT02451930,Phase I,"Active, not recruiting","[{'id': 826, 'therapyName': 'Necitumumab'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",A Study of the Combination of Necitumumab (LY3012211) and Pembrolizumab (MK3475) in Participants With NSCLC,7068
8,NCT02941601,Phase II,Withdrawn,"[{'id': 4973, 'therapyName': 'Necitumumab + Gemcitabine + Carboplatin'}]",A Study of Gemcitabine-Carboplatin Plus Necitumumab (LY3012211) in Chemotherapy-Naïve Participants With Locally Advanced or Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC),7068
9,NCT01788566,Phase II,Completed,"[{'id': 2882, 'therapyName': 'Necitumumab + Gemcitabine + Cisplatin'}]",A Study of Gemcitabine-Cisplatin Chemotherapy Plus Necitumumab in the First-Line Treatment of Participants With Lung Cancer,7068
10,NCT02789345,Phase I,Recruiting,"[{'id': 4379, 'therapyName': 'Osimertinib + Ramucirumab'}, {'id': 4380, 'therapyName': 'Necitumumab + Osimertinib'}]",A Study of Ramucirumab (LY3009806) or Necitumumab (LY3012211) Plus Osimertinib in Participants With Lung Cancer,7068
0,NCT01621243,Phase Ib/II,Terminated,"[{'id': 1779, 'therapyName': 'Nab-paclitaxel + Gemcitabine'}, {'id': 4251, 'therapyName': 'Necuparanib'}]",M402 in Combination With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer,8389
0,NCT02636582,Phase II,Recruiting,"[{'id': 1873, 'therapyName': 'Sargramostim'}, {'id': 5152, 'therapyName': 'Nelipepimut-S Plus GM-CSF'}]",Nelipepimut-S Plus GM-CSF Vaccine Therapy in Treating Patients With Breast Cancer,8620
0,NCT02897765,Phase I,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 4733, 'therapyName': 'NEO-PV-01 + poly ICLC'}]","A Personalized Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer",8534
0,NCT02129075,Phase II,"Active, not recruiting","[{'id': 3006, 'therapyName': 'NeoVax melanoma vaccine'}, {'id': 3007, 'therapyName': 'CDX-301'}, {'id': 1324, 'therapyName': 'DEC-205-NY-ESO-1 fusion protein vaccine'}]",CDX-1401 and Poly-ICLC Vaccine Therapy With or Without CDX-301in Treating Patients With Stage IIB-IV Melanoma,7903
1,NCT01970358,Phase I,Recruiting,"[{'id': 3006, 'therapyName': 'NeoVax melanoma vaccine'}]",A Phase I Study With a Personalized NeoAntigen Cancer Vaccine in Melanoma,7903
0,NCT01494662,Phase II,"Active, not recruiting","[{'id': 1543, 'therapyName': 'Capecitabine + Neratinib'}, {'id': 828, 'therapyName': 'Neratinib'}]",HKI-272 for HER2-Positive Breast Cancer and Brain Metastases,6962
1,NCT01808573,Phase III,"Active, not recruiting","[{'id': 1399, 'therapyName': 'Lapatinib + Capecitabine'}, {'id': 1543, 'therapyName': 'Capecitabine + Neratinib'}]",A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic Setting,6962
2,NCT01960023,Phase Ib/II,"Active, not recruiting","[{'id': 1118, 'therapyName': 'Cetuximab + Neratinib'}]",Safety and Efficacy Study of Neratinib and Cetuximab to Treat Patients With Quadruple Wild-Type Metastatic Colorectal Cancer,6962
3,NCT03289039,,Not yet recruiting,"[{'id': 828, 'therapyName': 'Neratinib'}, {'id': 5705, 'therapyName': 'Fulvestrant + Neratinib'}]","A Phase 2 Study of Neratinib With or Without Fulvestrant in HER2-Positive, ER-Positive Metastatic Breast Cancer",6962
4,NCT01670877,Phase II,Recruiting,"[{'id': 828, 'therapyName': 'Neratinib'}]",Neratinib in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer,6962
5,NCT03094052,Phase II,Recruiting,"[{'id': 828, 'therapyName': 'Neratinib'}, {'id': 2700, 'therapyName': 'Loperamide'}, {'id': 5906, 'therapyName': 'Crofelemer'}, {'id': 4359, 'therapyName': 'Neratinib + Trastuzumab'}]","Diarrhea Prophylaxis in Patients With HER2+ Breast Cancer Treated With Trastuzumab and Neratinib, Followed by Neratinib Monotherapy",6962
6,NCT01953926,Phase II,Recruiting,"[{'id': 828, 'therapyName': 'Neratinib'}]","An Open-label, Phase 2 Study of Neratinib in Patients With Solid Tumors With Somatic Human Epidermal Growth Factor Receptor (EGFR, HER2, HER3) Mutations or EGFR Gene Amplification",6962
7,NCT02400476,Phase II,Recruiting,"[{'id': 828, 'therapyName': 'Neratinib'}]",A Study Looking the Incidence and Severity of Diarrhea in Patients With Early-Stage HER2+ Breast Cancer Treated With Neratinib and Loperamide,6962
8,NCT02673398,Phase II,Recruiting,"[{'id': 828, 'therapyName': 'Neratinib'}]",Neratinib in Treating Older Patients With Locally Advanced or Metastatic HER2-Positive Breast Cancer,6962
9,NCT02932280,Phase Ib/II,Recruiting,"[{'id': 828, 'therapyName': 'Neratinib'}]",Safety and Dose Finding Study of Neratinib in Children and Young Adults With Cancer That Has Returned or Not Responded to Treatment,6962
10,NCT03065387,Phase I,Not yet recruiting,"[{'id': 5401, 'therapyName': 'Neratinib + Everolimus'}, {'id': 5402, 'therapyName': 'Neratinib + Palbociclib'}, {'id': 5403, 'therapyName': 'Neratinib + Trametinib'}]","Study of the Pan-ERBB Inhibitor Neratinib Given in Combination With Everolimus, Palbociclib or Trametinib in Advanced Cancer Subjects With EGFR Mutation/Amplification, HER2 Mutation/Amplification or HER3/4 Mutation",6962
11,NCT03101748,Phase Ib/II,Not yet recruiting,"[{'id': 3187, 'therapyName': 'Neratinib + Paclitaxel + Pertuzumab + Trastuzumab'}, {'id': 1505, 'therapyName': 'Paclitaxel + Neratinib + Doxorubicin + Cyclophosphamide'}]",3HT With Taxol for Metastatic Breast Cancer,6962
12,NCT02593708,Phase I,Unknown status,"[{'id': 3187, 'therapyName': 'Neratinib + Paclitaxel + Pertuzumab + Trastuzumab'}]","Phase1 of Neratinib+Trastuzumab, Pertuzumab, Paclitaxel in Patients With Advanced Solid Tumors/HER2+",6962
13,NCT02977780,Phase II,Recruiting,"[{'id': 1000, 'therapyName': 'CC-115'}, {'id': 5028, 'therapyName': 'Abemaciclib + Temozolomide'}, {'id': 1141, 'therapyName': 'Temozolomide'}, {'id': 5029, 'therapyName': 'Neratinib + Temozolomide'}]",INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT),6962
14,NCT02236000,Phase Ib/II,Recruiting,"[{'id': 1906, 'therapyName': 'Neratinib + trastuzumab emtansine'}]",A Dose-Escalation Study Evaluating the Combination of Trastuzumab Emtansine (T-DM1) With Neratinib in Women With Metastatic HER2-Positive Breast Cancer,6962
15,NCT01008150,Phase II,Unknown status,"[{'id': 1504, 'therapyName': 'Paclitaxel + Trastuzumab + Neratinib + Doxorubicin + Cyclophosphamide'}, {'id': 1503, 'therapyName': 'Paclitaxel + Trastuzumab + Doxorubicin + Cyclophosphamide'}, {'id': 1505, 'therapyName': 'Paclitaxel + Neratinib + Doxorubicin + Cyclophosphamide'}]",Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer,6962
16,NCT01111825,Phase Ib/II,Completed,"[{'id': 1527, 'therapyName': 'Temsirolimus + Neratinib'}]",Temsirolimus Plus Neratinib for Patients With Metastatic HER2-Amplified or Triple Negative Breast Cancer,6962
0,NCT02994953,Phase I,Recruiting,"[{'id': 5131, 'therapyName': 'Avelumab + NHS-IL12'}]","A Phase Ib Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Avelumab in Combination With M9241(NHS-IL12)",8615
0,NCT02807805,Phase II,Recruiting,"[{'id': 4377, 'therapyName': 'Abiraterone + Niclosamide + Prednisone'}]","Abiraterone Acetate, Niclosamide, and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer",4811
1,NCT02687009,Phase I,Recruiting,"[{'id': 3072, 'therapyName': 'Niclosamide'}]",A Study of Niclosamide in Patients With Resectable Colon Cancer,4811
2,NCT02532114,Phase I,Recruiting,"[{'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 3072, 'therapyName': 'Niclosamide'}]","Niclosamide and Enzalutamide in Treating Patients With Androgen Receptor Splice Variant-Positive, Castration-Resistant, Metastatic Prostate Cancer",4811
3,NCT03123978,Phase I,Recruiting,"[{'id': 5607, 'therapyName': 'Niclosamide + Enzalutamide'}]",Enzalutamide and Niclosamide in Treating Patients With Recurrent or Metastatic Castration-Resistant Prostate Cancer,4811
0,NCT02379416,Phase I,Recruiting,"[{'id': 2490, 'therapyName': 'Abraxane + Nilotinib'}]",Combination Nilotinib and Paclitaxel in Adults With Relapsed Solid Tumors,4655
1,NCT00573378,Phase II,Withdrawn,"[{'id': 2467, 'therapyName': 'Imatinib + Interferon alfa-2b '}, {'id': 2468, 'therapyName': 'Interferon alfa-2b + Nilotinib '}]",Imatinib or Nilotinib With Pegylated Interferon-alpha2b in Chronic Myeloid Leukemia,4655
2,NCT02225574,Phase Ib/II,Completed,"[{'id': 2219, 'therapyName': 'MEK162 + Nilotinib'}]","An Open-Label, Phase I/II Study of Nilotinib (Tasigna) and MEK-162 (ARRY-162) Used in Combination for Patients With Refractory or Advanced Chronic Myeloid Leukemia and Philadelphia Positive Acute Leukemia (Protocol CAMN107AUS41T)",4655
3,NCT02788201,Phase II,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1133, 'therapyName': 'Mitomycin C'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1013, 'therapyName': 'epirubicin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1137, 'therapyName': 'Bleomycin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 781, 'therapyName': 'Ixabepilone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 2950, 'therapyName': 'Estramustine'}, {'id': 1941, 'therapyName': 'Floxuridine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 1811, 'therapyName': 'Carmustine'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 953, 'therapyName': 'Vandetanib'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 4419, 'therapyName': 'Toremifine'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 2601, 'therapyName': 'Dactinomycin'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 3035, 'therapyName': 'Chlorambucil'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 342, 'therapyName': 'Vemurafenib'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 2635, 'therapyName': 'Vinblastine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 4305, 'therapyName': 'Teniposide'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 4304, 'therapyName': 'Streptozocin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1231, 'therapyName': 'Bendamustine'}, {'id': 4303, 'therapyName': 'Mechlorethamine'}, {'id': 4302, 'therapyName': 'Mitotane'}]",Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma,4655
4,NCT01407198,Phase I,"Active, not recruiting","[{'id': 829, 'therapyName': 'Nilotinib'}]",Nilotinib With Radiation for High Risk Chordoma,4655
5,NCT02081378,Phase I,Recruiting,"[{'id': 2484, 'therapyName': 'ABL001'}, {'id': 829, 'therapyName': 'Nilotinib'}]","A Phase I, Multicenter, Open-label Study of Oral ABL001 in Patients With Chronic Myelogenous Leukemia (CML) or Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia (Ph+ ALL)",4655
6,NCT01201538,Phase II,Terminated,"[{'id': 829, 'therapyName': 'Nilotinib'}]",A Study of Nilotinib in Growing Vestibular Schwannomas,4655
7,NCT01698905,Phase II,"Active, not recruiting","[{'id': 829, 'therapyName': 'Nilotinib'}]",Treatment-free Remission After Achieving Sustained MR4.5 on Nilotinib (ENESTop),4655
8,NCT01140568,Phase II,Recruiting,"[{'id': 829, 'therapyName': 'Nilotinib'}]",Study of Platelet Derived Growth Factor Receptor (PDGFR) in Recurrent Malignant Gliomas,4655
9,NCT01784068,Phase II,"Active, not recruiting","[{'id': 829, 'therapyName': 'Nilotinib'}]",Nilotinib Treatment-free Remission Study in CML (Chronic Myeloid Leukemia) Patients,4655
10,NCT02551718,Phase I,Recruiting,"[{'id': 690, 'therapyName': 'Bosutinib'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 3160, 'therapyName': 'Nelarabine'}, {'id': 3159, 'therapyName': 'Bexarotene'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 998, 'therapyName': 'cabozantinib'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 877, 'therapyName': 'Ponatinib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 623, 'therapyName': 'Afatinib'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 890, 'therapyName': 'Regorafenib'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 2, 'therapyName': 'Trametinib'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 3, 'therapyName': 'Dabrafenib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 789, 'therapyName': 'Ceritinib'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1571, 'therapyName': 'Cabazitaxel'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1327, 'therapyName': 'Pralatrexate'}]",High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia,4655
11,NCT01207492,Phase II,"Active, not recruiting","[{'id': 829, 'therapyName': 'Nilotinib'}]",Nilotinib in Patients With Relapsed or Metastatic Pigmented Villonodular Synovitis/Tenosynovial Giant Cell Tumor/Diffuse-Type Giant Cell Tumor,4655
12,NCT01844765,Phase II,"Active, not recruiting","[{'id': 829, 'therapyName': 'Nilotinib'}]","Open Label, Phase II Study to Evaluate Efficacy and Safety of Oral Nilotinib in Philadelphia Positive (Ph+) Chronic Myelogenous Leukemia (CML) Pediatric Patients.",4655
13,NCT02779283,Phase I,Recruiting,"[{'id': 717, 'therapyName': 'Dasatinib'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 877, 'therapyName': 'Ponatinib'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 1606, 'therapyName': 'Cytarabine + Idarubicin'}, {'id': 930, 'therapyName': 'Sunitinib'}]",Personalized Kinase Inhibitor Therapy Combined With Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,4655
14,NCT01028222,Phase II,Completed,"[{'id': 829, 'therapyName': 'Nilotinib'}]",A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation,4655
15,NCT01806571,Phase II,Recruiting,"[{'id': 1738, 'therapyName': 'Daunorubicin + Cytarabine'}, {'id': 829, 'therapyName': 'Nilotinib'}]","Daunorubicin Hydrochloride, Cytarabine, and Nilotinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia",4655
16,NCT01744665,Phase II,"Active, not recruiting","[{'id': 829, 'therapyName': 'Nilotinib'}]",Safety and Efficacy of CML Patients Who Switch to Nilotinib and Stop Treatment After Achieving and Sustaining MR4.5.,4655
17,NCT00129740,Phase II,"Active, not recruiting","[{'id': 829, 'therapyName': 'Nilotinib'}]",Phase II Nilotinib With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML),4655
18,NCT02709083,Phase II,Recruiting,"[{'id': 717, 'therapyName': 'Dasatinib'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 770, 'therapyName': 'Imatinib'}]","Dasatinib or Nilotinib Followed by Imatinib in Patients With Newly Diagnosed, Chronic Phase Chronic Myeloid Leukemia",4655
19,NCT01620216,Phase II,Recruiting,"[{'id': 930, 'therapyName': 'Sunitinib'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 877, 'therapyName': 'Ponatinib'}, {'id': 920, 'therapyName': 'Sorafenib'}]",Validation of an in Vitro Assay to Predict Targeted Therapies for Acute Leukemia Patients,4655
20,NCT02353728,Phase II,Not yet recruiting,"[{'id': 829, 'therapyName': 'Nilotinib'}]",Stem Cell Monitoring for CML Patients Undergoing Nilotinib Therapy,4655
21,NCT01244750,Phase I,"Active, not recruiting","[{'id': 770, 'therapyName': 'Imatinib'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 829, 'therapyName': 'Nilotinib'}]",Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting,4655
22,NCT00718263,Phase III,Recruiting,"[{'id': 770, 'therapyName': 'Imatinib'}, {'id': 829, 'therapyName': 'Nilotinib'}]",Efficacy and Safety of Nilotinib Patients With Newly Diagnosed CML - CP (Chronic Myelogenous Leukemia - Chronic Phase),4655
23,NCT01222143,Phase Ib/II,Terminated,"[{'id': 1752, 'therapyName': 'Mitoxantrone + Etoposide + Cytarabine'}, {'id': 829, 'therapyName': 'Nilotinib'}]","Safety and Efficacy Study of Nilotinib Combined With Mitoxantrone, Etoposide, and High-dose Cytarabine Induction Chemotherapy Followed by Consolidation for Patients With C-kit Positive Acute Myeloid Leukemia",4655
24,NCT01077544,Phase I,Completed,"[{'id': 829, 'therapyName': 'Nilotinib'}]",A Pharmacokinetic (PK) Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphoblastic Leukemia (ALL),4655
25,NCT01871311,Phase I,Recruiting,"[{'id': 1929, 'therapyName': 'Nilotinib + Cetuximab'}]",A Phase I Study of the BCR-ABL Tyrosine Kinase Inhibitor Nilontinib and Cetuximab in Patients With Solid Tumors That Can be Treated With Cetuximab,4655
26,NCT01702064,Phase I,"Active, not recruiting","[{'id': 1116, 'therapyName': 'Ruxolitinib + Nilotinib'}]",Ruxolitinib in Combination With Nilotinib in Chronic Myeloid Leukemia (CML) Patients,4655
27,NCT02973711,Phase Ib/II,Recruiting,"[{'id': 1116, 'therapyName': 'Ruxolitinib + Nilotinib'}]",A Phase I/II Study of Ruxolitinib in Combination With Nilotinib in Patients With Chronic Phase CML,4655
28,NCT01914484,Phase II,Recruiting,"[{'id': 1116, 'therapyName': 'Ruxolitinib + Nilotinib'}]",Phase I/II Study of Nilotinib/Ruxolitinb Therapy for TKI Resistant Ph-Leukemia,4655
0,NCT03070886,Phase III,Recruiting,"[{'id': 5450, 'therapyName': 'Bicalutamide + Docetaxel + Flutamide + Goserelin + Leuprolide + Nilutamide'}, {'id': 5449, 'therapyName': 'Bicalutamide + Flutamide + Goserelin + Leuprolide + Nilutamide'}]",Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery,655
0,NCT02947386,Phase Ib/II,Recruiting,"[{'id': 4920, 'therapyName': 'Nimotuzumab + Nivolumab'}]",Nimotuzumab and Nivolumab in Treating Patients With Advanced Non-small Cell Lung Cancer,6963
0,NCT02835833,Phase I,Recruiting,"[{'id': 4498, 'therapyName': 'Bevacizumab + Nintedanib'}]",Study of Nintedanib Plus Bevacizumab in Advanced Solid Tumors,6964
1,NCT02780700,Phase II,Terminated,"[{'id': 2589, 'therapyName': 'Capecitabine + Nintedanib'}, {'id': 831, 'therapyName': 'Nintedanib'}]",Nintedanib Alone or in Combination With Capecitabine in Refractory Metastatic Colorectal Cancer [LUME-Colon 2],6964
2,NCT02393755,Phase Ib/II,"Active, not recruiting","[{'id': 2589, 'therapyName': 'Capecitabine + Nintedanib'}]",Nintedanib and Capecitabine in Treating Patients With Refractory Metastatic Colorectal Cancer,6964
3,NCT02225405,Phase I,Recruiting,"[{'id': 2372, 'therapyName': 'Cisplatin + Docetaxel + Nintedanib'}]","Induction Study of Cisplatin, Docetaxel, and Nintedanib Stage IB-IIIA Non-Small Cell Lung Cancer (NCLC)",6964
4,NCT02452463,Phase II,Recruiting,"[{'id': 831, 'therapyName': 'Nintedanib'}]",Nintedanib Compared With Placebo in Treating Against Radiation-Induced Pneumonitis in Patients With Non-small Cell Lung Cancer That Cannot Be Removed by Surgery and Are Undergoing Chemoradiation Therapy,6964
5,NCT02496585,Phase II,Recruiting,"[{'id': 831, 'therapyName': 'Nintedanib'}, {'id': 2188, 'therapyName': 'Prednisone'}]",Study to Evaluate the Efficacy and Safety of Nintedanib (BIBF 1120) + Prednisone Taper in Patients With Radiation Pneumonitis,6964
6,NCT01907100,Phase III,Recruiting,"[{'id': 1857, 'therapyName': 'Cisplatin + Pemetrexed'}, {'id': 831, 'therapyName': 'Nintedanib'}]",Nintedanib (BIBF 1120) in Mesothelioma,6964
7,NCT02231164,Phase III,Terminated,"[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 831, 'therapyName': 'Nintedanib'}]",LUME-Columbus: Nintedanib Plus Docetaxel in Advanced Non-small Cell Lung Cancer With Translational Research,6964
8,NCT02568449,Phase II,Recruiting,"[{'id': 831, 'therapyName': 'Nintedanib'}]",Nintedanib in Treating Patients With Malignant Pleural Mesothelioma That Is Recurrent,6964
9,NCT02152059,Phase II,Withdrawn,"[{'id': 831, 'therapyName': 'Nintedanib'}]",A Study to Evaluate the Good and Bad Effects of BIBF1120 in Small Cell Lung Cancer Patients Who Have Previously Benefited From First-line Platinum-based Chemotherapy,6964
10,NCT01948141,Phase II,Completed,"[{'id': 831, 'therapyName': 'Nintedanib'}]",Nintedanib in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Up to Two Previous Chemotherapy Regimens,6964
11,NCT02389764,Phase II,Recruiting,"[{'id': 831, 'therapyName': 'Nintedanib'}]",Nintedanib For HER2-negative Metastatic Inflammatory Breast Cancer (MIBC),6964
12,NCT02149108,Phase III,Completed,"[{'id': 831, 'therapyName': 'Nintedanib'}]",Nintedanib (BIBF 1120) vs Placebo in Refractory Colorectal Cancer,6964
13,NCT01669798,Phase II,Recruiting,"[{'id': 831, 'therapyName': 'Nintedanib'}]","BIBF 1120 in Bevacizumab Resistant, Persistent, or Recurrent Epithelial Ovarian Cancer",6964
14,NCT02399215,Phase II,Recruiting,"[{'id': 831, 'therapyName': 'Nintedanib'}]",Nintedanib in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors,6964
15,NCT02902484,Phase Ib/II,Not yet recruiting,"[{'id': 4723, 'therapyName': 'Nintedanib + Gemcitabine + nab-paclitaxel'}, {'id': 831, 'therapyName': 'Nintedanib'}]",Study of Nintedanib and Chemotherapy for Advanced Pancreatic Cancer,6964
16,NCT02299141,Phase I,Recruiting,"[{'id': 831, 'therapyName': 'Nintedanib'}]",Nintedanib in Molecularly Selected Patients With Advanced Non-Small Cell Lung Cancer,6964
17,NCT02665143,Phase Ib/II,Recruiting,"[{'id': 1606, 'therapyName': 'Cytarabine + Idarubicin'}, {'id': 831, 'therapyName': 'Nintedanib'}]",A Randomized Trial of a Combination of Nintedanib/Placebo in Combination With Induction Chemotherapy for Patients With Refractory or First Relapse Acute Myeloid Leukemia,6964
18,NCT02234596,Phase II,"Active, not recruiting","[{'id': 831, 'therapyName': 'Nintedanib'}]",Nintedanib in Patients With Advanced Esophagogastric Cancer,6964
0,NCT02924766,Phase I,Recruiting,"[{'id': 4832, 'therapyName': 'ARN-509 + Niraparib'}]",A Safety and Pharmacokinetics Study of Niraparib Plus Apalutamide in Men With Metastatic Castration-Resistant Prostate Cancer (BEDIVERE),6965
1,NCT02354131,Phase Ib/II,Recruiting,"[{'id': 832, 'therapyName': 'Niraparib'}, {'id': 4254, 'therapyName': 'Bevacizumab + Niraparib'}]",Niraparib Versus Niraparib-bevacizumab Combination in Women With Platinum-sensitive Epithelial Ovarian Cancer (AVANOVA),6965
2,NCT03209401,Phase I,Not yet recruiting,"[{'id': 5984, 'therapyName': 'Carboplatin + Niraparib'}]",Niraparib Plus Carboplatin in Patients With Homologous Recombination Deficient Advanced Solid Tumor Malignancies,6965
3,NCT01847274,Phase III,Completed,"[{'id': 832, 'therapyName': 'Niraparib'}]",A Maintenance Study With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer,6965
4,NCT03016338,Phase II,Not yet recruiting,"[{'id': 832, 'therapyName': 'Niraparib'}]",Study of Niraparib in Recurrent Endometrial Cancer,6965
5,NCT01905592,Phase III,"Active, not recruiting","[{'id': 832, 'therapyName': 'Niraparib'}]","A Phase III Trial of Niraparib Versus Physician's Choice in Her2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients",6965
6,NCT02854436,Phase II,Suspended,"[{'id': 832, 'therapyName': 'Niraparib'}]",An Efficacy and Safety Study of Niraparib in Men With Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Anomalies,6965
7,NCT03307785,,Not yet recruiting,"[{'id': 832, 'therapyName': 'Niraparib'}]",Study of Niraparib or Carboplatin-Paclitaxel in Combination With TSR-042,6965
8,NCT02500901,Phase I,"Active, not recruiting","[{'id': 832, 'therapyName': 'Niraparib'}, {'id': 1262, 'therapyName': 'Enzalutamide'}]",Enzalutamide and Niraparib in the Treatment of Metastatic Castrate-Resistant Prostate Cancer (CRPC),6965
9,NCT03207347,Phase II,Not yet recruiting,"[{'id': 832, 'therapyName': 'Niraparib'}]",A Trial of Niraparib in BAP1 and Other DNA Double-Strand Break Repair Deficient Neoplasms (UF-STO-ETI-001),6965
10,NCT02655016,Phase III,Recruiting,"[{'id': 832, 'therapyName': 'Niraparib'}]",A Study of Niraparib Maintenance Treatment in Patients With HRD-Positive Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy,6965
11,NCT02354586,Phase II,Recruiting,"[{'id': 832, 'therapyName': 'Niraparib'}]",A Study of Niraparib in Patients With Ovarian Cancer Who Have Received at Least Three Previous Chemotherapy Regimens,6965
12,NCT03154281,Phase I,Not yet recruiting,"[{'id': 5732, 'therapyName': 'Niraparib + Everolimus'}]",Evaluation of the Safety and Tolerability of Niraparib With Everolimus in Ovarian and Breast,6965
13,NCT02657889,Phase Ib/II,Recruiting,"[{'id': 3935, 'therapyName': 'Niraparib + Pembrolizumab'}]",Study of Niraparib in Combination With Pembrolizumab (MK-3475) in Patients With Triple-negative Breast Cancer or Ovarian Cancer (KEYNOTE-162),6965
14,NCT03076203,Phase I,Recruiting,"[{'id': 5436, 'therapyName': 'Niraparib + radium Ra 223 dichloride'}]",Radium Ra 223 Dichloride and Niraparib in Treating Patients With Hormone- Resistant Prostate Cancer Metastatic to the Bone,6965
15,NCT02044120,Phase I,Recruiting,"[{'id': 1437, 'therapyName': 'Niraparib + Temozolomide'}]","ESP1/SARC025 Global Collaboration: A Phase I Study of a Combination of the PARP Inhibitor, Niraparib and Temozolomide in Patients With Previously Treated, Incurable Ewing Sarcoma",6965
0,NCT02947165,Phase I,Recruiting,"[{'id': 5632, 'therapyName': 'NIS793 + PDR001'}, {'id': 5631, 'therapyName': 'NIS793'}]",Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies.,8730
0,NCT03071757,Phase I,Recruiting,"[{'id': 5446, 'therapyName': 'ABBV-368'}, {'id': 5447, 'therapyName': 'ABBV-368 + Nivolumab'}]","A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors",7235
1,NCT02955251,Phase I,Recruiting,"[{'id': 5051, 'therapyName': 'ABBV-428 + Nivolumab'}, {'id': 5050, 'therapyName': 'ABBV-428'}]","A Study Evaluating Safety and Pharmacokinetics, and the Recommended Phase 2 Dose (RPTD) of ABBV-428 in Participants With Advanced Solid Tumors",7235
2,NCT02988960,Phase I,Recruiting,"[{'id': 5143, 'therapyName': 'ABBV-927 + Nivolumab'}, {'id': 5142, 'therapyName': 'ABBV-927'}]","A Study of ABBV-927, an Immunotherapy, in Participants With Advanced Solid Tumors",7235
3,NCT02309177,Phase I,Recruiting,"[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 2489, 'therapyName': 'Abraxane + Nivolumab'}]","Safety Study of Nivolumab With Nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, Nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or Nab-Paclitaxel in Recurrent Metastatic Breast Cancer",7235
4,NCT02935790,Phase I,Completed,"[{'id': 3312, 'therapyName': 'ACY-241 + Ipilimumab + Nivolumab'}]",Selective HDAC6 Inhibitor ACY-241 in Combination With Ipilimumab and Nivolumab,7235
5,NCT02635061,Phase I,Recruiting,"[{'id': 3312, 'therapyName': 'ACY-241 + Ipilimumab + Nivolumab'}]",Selective HDAC6 Inhibitor ACY 241 in Combination With Nivolumab in Patients With Unresectable Non Small Cell Lung Cancer,7235
6,NCT02831933,Phase II,Recruiting,"[{'id': 4462, 'therapyName': 'AdV-tk + Nivolumab'}]",Trial of Stereotactic Body Radiation and Gene Therapy Before Nivolumab for Metastatic Non-Small Cell Lung Carcinoma (ENSIGN),7235
7,NCT02989714,Phase Ib/II,Recruiting,"[{'id': 5139, 'therapyName': 'Aldesleukin + Nivolumab'}]","Phase Ib/II Trial of Interleukin-2 and PD-1 Checkpoint Inhibitor, Nivolumab In Metastatic Clear Cell Renal Cell Cancer",7235
8,NCT03228667,Phase II,Not yet recruiting,"[{'id': 3061, 'therapyName': 'ALT-803 + Nivolumab'}, {'id': 6037, 'therapyName': 'ALT-803 + Pembrolizumab'}]","QUILT-3.055: A Phase IIb, Single-Arm, Open-Label Study of ALT-803 in Combination With Pembrolizumab or Nivolumab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Disease Progression Following an Initial Response to Treatment With PD-1 Checkpoint Inhibitor Therapy",7235
9,NCT02523469,Phase Ib/II,Recruiting,"[{'id': 3061, 'therapyName': 'ALT-803 + Nivolumab'}]","ALT-803 Plus Nivolumab in Patients With Pretreated, Advanced or Metastatic Non-Small Cell Lung Cancer",7235
10,NCT03214250,Phase Ib/II,Recruiting,"[{'id': 6047, 'therapyName': 'Gemcitabine + nab-paclitaxel + Nivolumab'}, {'id': 6048, 'therapyName': 'APX005M + Gemcitabine + nab-paclitaxel'}, {'id': 6049, 'therapyName': 'APX005M + Gemcitabine + nab-paclitaxel + Nivolumab'}]",Safety and Efficacy of APX005M With Gemcitabine and Nab-Paclitaxel With or Without Nivolumab in Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma,7235
11,NCT03123783,Phase Ib/II,Recruiting,"[{'id': 5608, 'therapyName': 'APX005M + Nivolumab'}]",CD40 Agonistic Antibody APX005M in Combination With Nivolumab,7235
12,NCT03172754,Phase Ib/II,Recruiting,"[{'id': 5837, 'therapyName': 'Axitinib + Nivolumab'}]",Study of Nivolumab and Axitinib in Patients With Advanced Renal Cell Carcinoma,7235
13,NCT02397720,Phase II,Recruiting,"[{'id': 3196, 'therapyName': 'Azacitidine + Nivolumab'}]",A Study of Nivolumab (BMS-936558) in Combination With 5-azacytidine (Vidaza) for the Treatment of Patients With Refractory/ Relapsed Acute Myeloid Leukemia,7235
14,NCT03092674,Phase II,Not yet recruiting,"[{'id': 1736, 'therapyName': 'Decitabine + Cytarabine'}, {'id': 2471, 'therapyName': 'Azacitidine + Midostaurin'}, {'id': 3196, 'therapyName': 'Azacitidine + Nivolumab'}, {'id': 651, 'therapyName': 'Azacitidine'}]","Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome",7235
15,NCT02873962,Phase II,Recruiting,"[{'id': 2111, 'therapyName': 'Bevacizumab + Nivolumab'}]",A Phase II Study Of Nivolumab/ Bevacizumab,7235
16,NCT02210117,Phase II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 2111, 'therapyName': 'Bevacizumab + Nivolumab'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Nivolumab vs Nivolumab + Bevacizumab vs Nivolumab + Ipilimumab in Metastatic Renal Cell Carcinoma (mRCC),7235
17,NCT03033914,Phase I,Recruiting,"[{'id': 5296, 'therapyName': 'Dacarbazine + Doxorubicin + Vinblastine + Nivolumab'}, {'id': 5295, 'therapyName': 'Bleomycin + Dacarbazine + Doxorubicin + Vinblastine + Nivolumab'}]",A(B)VD Followed by Nivolumab as Frontline Therapy for Higher Risk Patients With Classical Hodgkin Lymphoma,7235
18,NCT02879695,Phase I,Recruiting,"[{'id': 4613, 'therapyName': 'Blinatumomab + Ipilimumab + Nivolumab'}]",Blinatumomab and Nivolumab With or Without Ipilimumab in Treating Patients With Poor-Risk Relapsed or Refractory CD19+ Precursor B-Lymphoblastic Leukemia,7235
19,NCT03184870,Phase Ib/II,Recruiting,"[{'id': 5905, 'therapyName': 'BMS-813160 + Fluorouracil + Irinotecan + Leucovorin'}, {'id': 5903, 'therapyName': 'BMS-813160 + Nivolumab'}, {'id': 5904, 'therapyName': 'BMS-813160 + Gemcitabine + nab-paclitaxel'}, {'id': 5902, 'therapyName': 'BMS-813160'}]",A Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Patients With Advanced Solid Tumors,7235
20,NCT02247349,Phase Ib/II,"Active, not recruiting","[{'id': 4534, 'therapyName': 'BMS-986012'}, {'id': 4535, 'therapyName': 'BMS-986012 + Nivolumab'}]",BMS-986012 in Relapsed/Refractory SCLC,7235
21,NCT02996110,Phase II,Recruiting,"[{'id': 4197, 'therapyName': 'BMS-986016 + Nivolumab'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",A Study to Test Combination Treatments in People With Advanced Renal Cell Carcinoma (FRACTION-RCC),7235
22,NCT02935634,Phase II,Recruiting,"[{'id': 4197, 'therapyName': 'BMS-986016 + Nivolumab'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",A Study to Test Combination Treatments in Patients With Advanced Gastric Cancer (FRACTION-GC),7235
23,NCT02750514,Phase II,Recruiting,"[{'id': 1813, 'therapyName': 'Dasatinib + Nivolumab'}, {'id': 4197, 'therapyName': 'BMS-986016 + Nivolumab'}, {'id': 1312, 'therapyName': 'Nivolumab'}]",A Study to Test Combination Treatments in People With Advanced Non-Small Cell Lung Cancer,7235
24,NCT01968109,Phase I,Recruiting,"[{'id': 4197, 'therapyName': 'BMS-986016 + Nivolumab'}, {'id': 4196, 'therapyName': 'BMS-986016'}]",Safety Study of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors,7235
25,NCT02061761,Phase Ib/II,Recruiting,"[{'id': 4197, 'therapyName': 'BMS-986016 + Nivolumab'}, {'id': 4196, 'therapyName': 'BMS-986016'}]",Safety Study of Anti-LAG-3 in Relapsed or Refractory Hematologic Malignancies,7235
26,NCT02341625,Phase Ib/II,"Active, not recruiting","[{'id': 4923, 'therapyName': 'BMS-986148'}, {'id': 4924, 'therapyName': 'BMS-986148 + Nivolumab'}]",A Study of BMS-986148 in Patients With Select Advanced Solid Tumors,7235
27,NCT02754141,Phase Ib/II,Recruiting,"[{'id': 4195, 'therapyName': 'BMS-986179 + Nivolumab'}]",A Study of BMS-986179 Administered in Combination With Nivolumab in Advanced Cancers,7235
28,NCT02828124,Phase Ib/II,"Active, not recruiting","[{'id': 5628, 'therapyName': 'BMS-986183'}, {'id': 5629, 'therapyName': 'BMS-986183 + Nivolumab'}]",A Study of the Safety and Tolerability of BMS-986183 in Patients With Liver Cancer,7235
29,NCT02658890,Phase Ib/II,Recruiting,"[{'id': 3569, 'therapyName': 'BMS-986205 + Nivolumab'}]","Safety, Tolerability, Pharmacokinetic/Pharmacodynamic and Preliminary Efficacy Study of BMS-986205 Administered in Combination With Nivolumab in Advanced Cancers",7235
30,NCT02913313,Phase Ib/II,Recruiting,"[{'id': 4888, 'therapyName': 'BMS-986207 + Nivolumab'}, {'id': 4887, 'therapyName': 'BMS-986207 '}]",A Study to Evaluate the Safety and Tolerability of Monoclonal Antibody BMS-986207 Alone and in Combination With Nivolumab in Advanced (Solid Tumor) Cancers,7235
31,NCT03110107,Phase Ib/II,Recruiting,"[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 5552, 'therapyName': 'BMS-986218 + Nivolumab'}, {'id': 5551, 'therapyName': 'BMS-986218'}]",First-In-Human Study of Monoclonal Antibody BMS-986218 by Itself and in Combination With Nivolumab in Patients With Advanced Solid Tumors,7235
32,NCT03251924,Phase Ib/II,Recruiting,"[{'id': 6136, 'therapyName': 'BMS-986226 + Nivolumab'}, {'id': 6135, 'therapyName': 'BMS-986226 + Ipilimumab'}, {'id': 6134, 'therapyName': 'BMS-986226'}]",A Dose Escalation and Combination Immunotherapy Study to Evaluate BMS-986226 Alone or in Combination With Nivolumab or Ipilimumab in Patients With Advanced Solid Tumors,7235
33,NCT02758717,Phase II,Recruiting,"[{'id': 3263, 'therapyName': 'Brentuximab vedotin + Nivolumab'}]",Nivolumab and Brentuximab Vedotin in Treating Older Patients With Untreated Hodgkin Lymphoma,7235
34,NCT01716806,Phase II,Recruiting,"[{'id': 3263, 'therapyName': 'Brentuximab vedotin + Nivolumab'}, {'id': 5055, 'therapyName': 'Brentuximab vedotin + Bendamustine'}, {'id': 5056, 'therapyName': 'Brentuximab vedotin + Dacarbazine'}, {'id': 2486, 'therapyName': 'Brentuximab vedotin'}]",A Study of Brentuximab Vedotin in Adults Age 60 and Above With Newly Diagnosed Hodgkin Lymphoma (HL),7235
35,NCT03138499,Phase III,Recruiting,"[{'id': 2486, 'therapyName': 'Brentuximab vedotin'}, {'id': 3263, 'therapyName': 'Brentuximab vedotin + Nivolumab'}]","Phase III Trial of Nivolumab Plus Brentuximab Vedotin Versus Brentuximab Vedotin Alone in Patients With Advanced Stage Classical Hodgkin Lymphoma, Who Are Relapsed/ Refractory or Who Are Not Eligible for Autologous Stem Cell Transplant,",7235
36,NCT02572167,Phase Ib/II,"Active, not recruiting","[{'id': 3263, 'therapyName': 'Brentuximab vedotin + Nivolumab'}]",A Study of Brentuximab Vedotin Combined With Nivolumab for Relapsed or Refractory Hodgkin Lymphoma,7235
37,NCT02581631,Phase Ib/II,Recruiting,"[{'id': 3263, 'therapyName': 'Brentuximab vedotin + Nivolumab'}]",A Safety and Efficacy Study of Nivolumab in Combination With Brentuximab Vedotin to Treat Non-Hodgkin Lymphomas (CheckMate 436),7235
38,NCT03057795,Phase II,Recruiting,"[{'id': 3263, 'therapyName': 'Brentuximab vedotin + Nivolumab'}]",Nivolumab and Brentuximab Vedotin After Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Classical Hodgkin Lymphoma,7235
39,NCT02927769,Phase II,Recruiting,"[{'id': 3263, 'therapyName': 'Brentuximab vedotin + Nivolumab'}, {'id': 5055, 'therapyName': 'Brentuximab vedotin + Bendamustine'}]","A Study of Nivolumab + Brentuximab Vedotin in Children, Adolescents, and Young Adults With Classic Hodgkin Lymphoma (cHL) After Failure of First Line Therapy, Followed by Brentuximab Vedotin + Bendamustine for Participants With a Suboptimal Response (CheckMate 744)",7235
40,NCT03141177,Phase III,Recruiting,"[{'id': 2068, 'therapyName': 'Cabozantinib + Ipilimumab + Nivolumab'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 2067, 'therapyName': 'Cabozantinib + Nivolumab'}]",A Study of Nivolumab Combined With Cabozantinib or Nivolumab and Ipilimumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 9ER),7235
41,NCT03299946,Phase I,Not yet recruiting,"[{'id': 2067, 'therapyName': 'Cabozantinib + Nivolumab'}]",Feasibility and Efficacy of Neoadjuvant Cabozantinib Plus Nivolumab (CaboNivo) Followed by Definitive Resection for Patients With Locally Advanced Hepatocellular Carcinoma (HCC),7235
42,NCT02496208,Phase I,Recruiting,"[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 2067, 'therapyName': 'Cabozantinib + Nivolumab'}]",Cabozantinib Plus Nivolumab (CaboNivo) Alone or in Combination With Ipilimumab (CaboNivoIpi) in Patients With Advanced/Metastatic Urothelial Carcinoma and Other Genitourinary Tumors,7235
43,NCT03256136,Phase II,Not yet recruiting,"[{'id': 6159, 'therapyName': 'Carboplatin + Nivolumab + Pemetrexed'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]","A Phase II Study of Nivolumab in Combination With Carboplatin and Pemetrexed, or Nivolumab in Combination With Ipilimumab, in Patients With Advanced, EGFR-mutant or ALK-rearranged, Non-Small Cell Lung Cancer",7235
44,NCT02944396,Phase II,Recruiting,"[{'id': 5054, 'therapyName': 'Carboplatin + Paclitaxel + Pemetrexed + Veliparib'}, {'id': 5053, 'therapyName': 'Carboplatin + Paclitaxel + Pemetrexed + Nivolumab + Veliparib'}]",Study of Veliparib in Combination With Nivolumab and Platinum Doublet Chemotherapy in Participants With Metastatic or Advanced Non-Small Cell Lung Cancer (NSCLC),7235
45,NCT02903914,Phase I,Recruiting,"[{'id': 4722, 'therapyName': 'CB-1158 + Nivolumab'}, {'id': 4721, 'therapyName': 'CB-1158'}]",Arginase Inhibitor CB-1158 in Patients With Solid Tumors,7235
46,NCT02771626,Phase Ib/II,Recruiting,"[{'id': 4274, 'therapyName': 'CB-839 + Nivolumab'}]",Study CB-839 in Combination With Nivolumab in Patients With ccRCC and Other Solid Tumors,7235
47,NCT03113188,Phase I,Recruiting,"[{'id': 6186, 'therapyName': 'CBP501 + Cisplatin + Nivolumab'}]","CBP501, Cisplatin and Nivolumab in Advanced Refractory Tumors",7235
48,NCT02859324,Phase Ib/II,Recruiting,"[{'id': 4611, 'therapyName': 'CC-122 + Nivolumab'}]",A Safety and Efficacy Study of CC-122 in Combination With Nivolumab in Subjects With Unresectable Hepatocellular Carcinoma (HCC),7235
49,NCT02393625,Phase I,Recruiting,"[{'id': 2565, 'therapyName': 'Ceritinib + Nivolumab'}]",Study of Safety and Efficacy of Ceritinib in Combination With Nivolumab in Patients With ALK-positive Non-small Cell Lung Cancer,7235
50,NCT02764593,Phase I,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 4760, 'therapyName': 'Cisplatin + Nivolumab'}, {'id': 4761, 'therapyName': 'Cetuximab + Nivolumab'}]",Chemotherapy +/- Nivolumab in Patients With Intermediate and High-Risk Local-Regionally Advanced Head and Neck Squamous Cell Carcinoma,7235
51,NCT02718066,Phase Ib/II,Recruiting,"[{'id': 4689, 'therapyName': 'Chidamide + Nivolumab'}]","Study of HBI-8000 With Nivolumab in Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancer",7235
52,NCT02955290,Phase Ib/II,Recruiting,"[{'id': 4941, 'therapyName': 'CIMAvax-EGF + Nivolumab'}]",CIMAvax Vaccine and Nivolumab in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer,7235
53,NCT02768558,Phase III,Recruiting,"[{'id': 2585, 'therapyName': 'Cisplatin + Etoposide'}, {'id': 4922, 'therapyName': 'Cisplatin + Etoposide + Nivolumab'}]",Cisplatin and Etoposide Plus Radiation Followed By Nivolumab/Placebo For Locally Advanced NSCLC,7235
54,NCT02754726,Phase II,Recruiting,"[{'id': 4087, 'therapyName': 'Cisplatin + Gemcitabine + nab-paclitaxel + Nivolumab + Paricalcitol'}]",Combination Therapy for Patients With Untreated Metastatic Pancreatic Ductal Adenocarcinoma,7235
55,NCT03101566,Phase II,Recruiting,"[{'id': 5511, 'therapyName': 'Cisplatin + Gemcitabine + Nivolumab'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Study of Nivolumab in Combination With Gemcitabine/Cisplatin or Ipilimumab for Patients With Advanced Unresectable Biliary Tract Cancer,7235
56,NCT02840994,Phase Ib/II,Recruiting,"[{'id': 5244, 'therapyName': 'CV301 + Nivolumab'}, {'id': 1312, 'therapyName': 'Nivolumab'}]",A Trial of CV301 in Combination With Nivolumab Versus Nivolumab in Subjects With Previously Treated Non-Small Cell Lung Cancer,7235
57,NCT02379520,Phase I,Recruiting,"[{'id': 5328, 'therapyName': 'Cyclophosphamide + Fludarabine phosphate + Nivolumab'}]","HPV-16/18 E6/E7-Specific T Lymphocytes, Relapsed HPV-Associated Cancers, HESTIA (HESTIA)",7235
58,NCT02464657,Phase Ib/II,Recruiting,"[{'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 3192, 'therapyName': 'Cytarabine + Idarubicin + Nivolumab'}]",Nivolumab in Acute Myeloid Leukemia (AML),7235
59,NCT02910700,Phase II,Recruiting,"[{'id': 4753, 'therapyName': 'Nivolumab + Trametinib'}, {'id': 4754, 'therapyName': 'Dabrafenib + Nivolumab + Trametinib'}]",Study of the Anti-PD-1 Antibody Nivolumab in Combination With Dabrafenib and/or Trametinib in Patients With BRAF or NRAS-mutated Metastatic Melanoma,7235
60,NCT03098550,Phase Ib/II,Recruiting,"[{'id': 5520, 'therapyName': 'Daratumumab + Nivolumab '}]",A Study to Test the Safety and Effectiveness of Nivolumab Combined With Daratumumab in Patients With Advanced Solid Tumors or Tumors That Have Spread,7235
61,NCT02819804,Phase I,Recruiting,"[{'id': 1813, 'therapyName': 'Dasatinib + Nivolumab'}]",Nivolumab and Dasatinib in Treating Patients With Relapsed or Refractory Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia,7235
62,NCT02011945,Phase I,"Active, not recruiting","[{'id': 1813, 'therapyName': 'Dasatinib + Nivolumab'}]",A Phase 1B Study to Investigate the Safety and Preliminary Efficacy for the Combination of Dasatinib Plus Nivolumab in Patients With Chronic Myeloid Leukemia,7235
63,NCT03014804,Phase II,Not yet recruiting,"[{'id': 5205, 'therapyName': 'DCVax-L'}, {'id': 5206, 'therapyName': 'DCVax-L + Nivolumab'}]",Dendritic Cell-Autologous Lung Tumor Vaccine and Nivolumab in Treating Patients With Recurrent Glioblastoma,7235
64,NCT02664181,Phase II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 5910, 'therapyName': 'Decitabine + Nivolumab + Tetrahydrouridine'}]",Pharmacologically Rational EpigenetiC Immunotherapy for SEcond Line Therapy in Patients With Non-Small Cell Lung Cancer (PRECISE),7235
65,NCT03227432,Phase II,Not yet recruiting,"[{'id': 6118, 'therapyName': 'Dexamethasone + Elotuzumab + Nivolumab + Pomalidomide'}, {'id': 6117, 'therapyName': 'Elotuzumab + Nivolumab'}]",An Exploratory Study to Evaluate the Combination of Elotuzumab and Nivolumab With and Without Pomalidomide in Relapsed Refractory Multiple Myeloma,7235
66,NCT03041181,Phase II,Recruiting,"[{'id': 5288, 'therapyName': 'Docetaxel + Nivolumab'}, {'id': 720, 'therapyName': 'Docetaxel'}]",Docetaxel Plus Nivolumab or Docetaxel Alone in Patients With Advanced Non-squamous NSCLC Previously Treated With Nivolumab,7235
67,NCT02991196,Phase I,Terminated,"[{'id': 5078, 'therapyName': 'DS-8273a + Nivolumab'}]",Antibody DS-8273a Administered in Combination With Nivolumab in Subjects With Advanced Colorectal Cancer,7235
68,NCT02983006,Phase I,Recruiting,"[{'id': 5078, 'therapyName': 'DS-8273a + Nivolumab'}]",Study of DS-8273a With Nivolumab in Unresectable Stage III or Stage IV Melanoma,7235
69,NCT02973113,Phase I,Recruiting,"[{'id': 5058, 'therapyName': 'EB-VST cells + Nivolumab'}]","Nivolumab With Epstein Barr Virus Specific T Cells (EB-VSTS), Relapsed/Refractory EBV Positive Lymphoma (PREVALE) (PREVALE)",7235
70,NCT02323126,Phase II,Recruiting,"[{'id': 2443, 'therapyName': 'EGF816 + Nivolumab'}, {'id': 2444, 'therapyName': 'INC280 + Nivolumab'}]",Study of Efficacy and Safety of Nivolumab in Combination With EGF816 and of Nivolumab in Combination With INC280 in Patients With Previously Treated Non-small Cell Lung Cancer,7235
71,NCT03250273,Phase II,Not yet recruiting,"[{'id': 6114, 'therapyName': 'Entinostat + Nivolumab'}]",A Clinical Trial of Entinostat in Combination With Nivolumab for Patients With Previously Treated Unresectable or Metastatic Cholangiocarcinoma and Pancreatic Adenocarcinoma,7235
72,NCT02639234,Phase II,Withdrawn,"[{'id': 3572, 'therapyName': 'FANG vaccine + Nivolumab'}]",Vigil + Nivolumab in Advanced Non-Small Cell Lung Cancer,7235
73,NCT03302247,Phase II,Not yet recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 6297, 'therapyName': 'Gemcitabine + Nivolumab'}]",Depletion of Myeloid Derived Suppressor Cells to Enhance Anti PD-1 Therapy,7235
74,NCT02864381,Phase II,"Active, not recruiting","[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 4736, 'therapyName': 'GS-5745 + Nivolumab'}]",GS-5745 Combined With Nivolumab Versus Nivolumab Alone in Adults With Unresectable or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma,7235
75,NCT03259425,Phase II,Not yet recruiting,"[{'id': 6149, 'therapyName': 'HF10 + Nivolumab'}]","Neoadjuvant Trial of Nivolumab in Combination With HF10 Oncolytic Viral Therapy in Resectable Stage IIIB, IIIC, IVM1a Melanoma",7235
76,NCT02329847,Phase Ib/II,Recruiting,"[{'id': 3198, 'therapyName': 'Ibrutinib + Nivolumab'}]",Pharmacokinetic and Pharmacodynamic Study to Evaluate Safety and Efficacy of the Combination of Ibrutinib With Nivolumab in Participants With Hematologic Malignancies,7235
77,NCT02940301,Phase II,Recruiting,"[{'id': 3198, 'therapyName': 'Ibrutinib + Nivolumab'}]",Ibrutinib and Nivolumab in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma,7235
78,NCT02420912,Phase II,Recruiting,"[{'id': 3198, 'therapyName': 'Ibrutinib + Nivolumab'}]","Nivolumab With Ibrutinib for Relapsed, Refractory or High-Risk Untreated Patients With Chronic Lymphocytic Leukemia (CLL)",7235
79,NCT02899078,Phase Ib/II,Recruiting,"[{'id': 3198, 'therapyName': 'Ibrutinib + Nivolumab'}]",Ibrutinib and Nivolumab in Treating Patients With Previously-Treated Metastatic Kidney Cancer,7235
80,NCT02950038,Phase II,Withdrawn,"[{'id': 3198, 'therapyName': 'Ibrutinib + Nivolumab'}]",Study of Ibrutinib Followed by Ibrutinib in Combination With Nivolumab in Non-Small Cell Lung Cancer (NSCLC),7235
81,NCT03126110,Phase Ib/II,Recruiting,"[{'id': 5599, 'therapyName': 'INCAGN01876 + Nivolumab + Ipilimumab'}, {'id': 5598, 'therapyName': 'INCAGN01876 + Nivolumab'}, {'id': 5597, 'therapyName': 'INCAGN01876 + Ipilimumab'}]","Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies",7235
82,NCT03241173,Phase Ib/II,Not yet recruiting,"[{'id': 6120, 'therapyName': 'INCAGN01949 + Ipilimumab'}, {'id': 6119, 'therapyName': 'INCAGN01949 + Nivolumab'}, {'id': 6121, 'therapyName': 'INCAGN01949 + Ipilimumab + Nivolumab'}]",A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies,7235
83,NCT02327078,Phase Ib/II,Recruiting,"[{'id': 3059, 'therapyName': 'INCB024360 + Nivolumab'}]","A Study of the Safety, Tolerability, and Efficacy of INCB24360 Administered in Combination With Nivolumab in Select Advanced Cancers",7235
84,NCT03085914,Phase Ib/II,Recruiting,"[{'id': 5483, 'therapyName': 'INCB024360 + Nivolumab + mFOLFOX6'}, {'id': 5484, 'therapyName': 'INCB024360 + Nivolumab + Gemcitabine + nab-paclitaxel'}, {'id': 5485, 'therapyName': 'INCB024360 + Pembrolizumab + Carboplatin + Paclitaxel'}, {'id': 5486, 'therapyName': 'INCB024360 + Pembrolizumab + Carboplatin + Pemetrexed'}, {'id': 5487, 'therapyName': 'INCB024360 + Pembrolizumab + Cyclophosphamide'}]",A Study of Epacadostat in Combination With a PD-1 Inhibitor and Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors (ECHO-207),7235
85,NCT02723006,Phase I,Recruiting,"[{'id': 4198, 'therapyName': 'MLN2480 + Nivolumab'}, {'id': 4200, 'therapyName': 'MLN1202 + Nivolumab'}, {'id': 4202, 'therapyName': 'Ipilimumab + Nivolumab + Vedolizumab '}]","Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Investigational Treatments in Combination With Standard of Care Immune Checkpoint Inhibitors in Participants With Advanced Melanoma",7235
86,NCT02904226,Phase Ib/II,Recruiting,"[{'id': 4720, 'therapyName': 'JTX-2011 + Nivolumab'}, {'id': 4719, 'therapyName': 'JTX-2011'}]",Dose Escalation and Expansion of JTX-2011 Alone or in Combination With Anti-PD-1 in Subjects With Advanced Solid Tumors (ICONIC),7235
87,NCT03015896,Phase Ib/II,Suspended,"[{'id': 5239, 'therapyName': 'Lenalidomide + Nivolumab'}]",Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma,7235
88,NCT01714739,Phase I,Recruiting,"[{'id': 2584, 'therapyName': 'Lirilumab + Nivolumab'}]",A Phase I Study of an Anti-KIR Antibody in Combination With an Anti-PD1 Antibody in Patients With Advanced Solid Tumors,7235
89,NCT03048500,Phase II,Not yet recruiting,"[{'id': 5302, 'therapyName': 'Metformin + Nivolumab'}]",Nivolumab and Metformin Hydrochloride in Treating Patients With Stage III-IV Non-small Cell Lung Cancer That Cannot Be Removed by Surgery,7235
90,NCT02954991,Phase II,Recruiting,"[{'id': 4943, 'therapyName': 'MGCD516 + Nivolumab'}, {'id': 4944, 'therapyName': 'Mocetinostat + Nivolumab'}, {'id': 4942, 'therapyName': 'MGCD265 + Nivolumab'}]","Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Non-Small Cell Lung Cancer",7235
91,NCT03015740,Phase Ib/II,Recruiting,"[{'id': 4943, 'therapyName': 'MGCD516 + Nivolumab'}]",MGCD516 Combined With Nivolumab in Renal Cell Cancer (RCC),7235
92,NCT02705105,Phase Ib/II,Recruiting,"[{'id': 3843, 'therapyName': 'Mogamulizumab + Nivolumab'}]",Study of Mogamulizumab + Nivolumab in Subjects w/Locally Advanced or Metastatic Solid Tumors,7235
93,NCT02823990,Phase II,Recruiting,"[{'id': 4435, 'therapyName': 'MVA-MUC1-IL2 vaccine + Nivolumab'}]",TG4010 and Nivolumab in Patients With Lung Cancer,7235
94,NCT03190174,Phase Ib/II,Recruiting,"[{'id': 5931, 'therapyName': 'Nab-Rapamycin + Nivolumab'}]",Nivolumab (Opdivo) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma,7235
95,NCT03050060,Phase II,Recruiting,"[{'id': 5301, 'therapyName': 'Nelfinavir + Nivolumab'}]","Image Guided Hypofractionated Radiation Therapy, Nelfinavir Mesylate, and Nivolumab in Treating Patients With Advanced Melanoma, Lung, or Kidney Cancer",7235
96,NCT02947386,Phase Ib/II,Recruiting,"[{'id': 4920, 'therapyName': 'Nimotuzumab + Nivolumab'}]",Nimotuzumab and Nivolumab in Treating Patients With Advanced Non-small Cell Lung Cancer,7235
97,NCT02314169,Phase II,"Active, not recruiting","[{'id': 1312, 'therapyName': 'Nivolumab'}]",Nivolumab in Treating Patients With Refractory Metastatic Squamous Cell Carcinoma of the Anal Canal,7235
98,NCT02992964,Phase Ib/II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Pilot Study of Nivolumab in Pediatric Patients With Hypermutant Cancers,7235
99,NCT02775292,Phase I,Recruiting,"[{'id': 3409, 'therapyName': 'Aldesleukin + Cyclophosphamide + Fludarabine '}, {'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 2696, 'therapyName': 'NY-ESO-1 peptide vaccine'}]","Gene-Modified T Cells, Vaccine Therapy, and Nivolumab in Treating Patients With Stage IV or Locally Advanced Solid Tumors Expressing NY-ESO-1",7235
100,NCT03259867,Phase II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Combination of TATE and PD-1 Inhibitor in Liver Cancer,7235
101,NCT02569242,Phase III,"Active, not recruiting","[{'id': 3045, 'therapyName': 'Docetaxel + Paclitaxel'}, {'id': 1312, 'therapyName': 'Nivolumab'}]",Study of Nivolumab in Unresectable Advanced or Recurrent Esophageal Cancer,7235
102,NCT02526017,Phase I,Recruiting,"[{'id': 2840, 'therapyName': 'FPA008'}, {'id': 1312, 'therapyName': 'Nivolumab'}]",Study of FPA008 in Combination With Nivolumab in Patients With Selected Advance Cancers,7235
103,NCT02857426,Phase II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",A Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) and Relapsed/Refractory Primary Testicular Lymphoma (PTL) (CheckMate 647),7235
104,NCT02731729,Phase II,Recruiting,"[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 1312, 'therapyName': 'Nivolumab'}]",Ipilimumab vs Ipilimumab Plus Nivolumab in Patients With Stage III-IV Melanoma Who Have Progressed or Relapsed on PD-1 Inhibitor Therapy,7235
105,NCT01592370,Phase I,"Active, not recruiting","[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 2583, 'therapyName': 'Lirilumab '}]",Safety Study in Nivolumab Alone and in Combination With Ipilimumab or Lirilumab in Lymphoma and Multiple Myeloma,7235
106,NCT02617589,Phase III,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 1141, 'therapyName': 'Temozolomide'}]","Study of Nivolumab Versus Temozolomide, Given With Radiation Therapy, for Newly-diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer) (CheckMate 498)",7235
107,NCT02311920,Phase I,"Active, not recruiting","[{'id': 1141, 'therapyName': 'Temozolomide'}, {'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 779, 'therapyName': 'Ipilimumab'}]",Temozolomide in Combination With Ipilimumab and/or Nivolumab in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma,7235
108,NCT03241745,Phase II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",A Study of Nivolumab in Selected Uterine Cancer Patients,7235
109,NCT02743494,Phase III,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Study of Adjuvant Nivolumab or Placebo in Subjects With Resected Esophageal or Gastroesophageal Junction Cancer (CheckMate 577),7235
110,NCT03106610,Phase I,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Trial of Anti-PD-1 (Nivolumab) in Bladder Cancer Patients Recently Treated With Intravesical BCG Immunotherapy,7235
111,NCT02596035,FDA approved,"Active, not recruiting","[{'id': 1312, 'therapyName': 'Nivolumab'}]",A Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374),7235
112,NCT03285321,Phase II,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}, {'id': 1312, 'therapyName': 'Nivolumab'}]",Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC),7235
113,NCT03080974,Phase II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Immunotherapy and Irreversible Electroporation in the Treatment of Advanced Pancreatic Adenocarcinoma,7235
114,NCT03021993,Phase II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Trial of Nivolumab as a Novel Neoadjuvant Pre-Surgical Therapy for Locally Advanced Oral Cavity Cancer,7235
115,NCT02575222,Phase I,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Study of Neoadjuvant Nivolumab in Patients With Non-metastatic Stage II-IV Clear Cell Renal Cell Carcinoma,7235
116,NCT02736123,Phase Ib/II,Withdrawn,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Neoadjuvant Combination Biotherapy With Ipilimumab and Nivolumab or Nivolumab Alone,7235
117,NCT02017717,Phase III,"Active, not recruiting","[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",A Randomized Study of Nivolumab Versus Bevacizumab and a Safety Study of Nivolumab in Adult Subjects With Recurrent Glioblastoma (GBM) (CheckMate 143),7235
118,NCT02565758,Phase I,Recruiting,"[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 619, 'therapyName': 'Abraxane'}, {'id': 3846, 'therapyName': 'ABBV-085'}]","ABBV-085, an Antibody Drug Conjugate, in Subjects With Advanced Solid Cancer Tumors",7235
119,NCT02532231,Phase II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Nivolumab in Acute Myeloid Leukemia (AML) in Remission at High Risk for Relapse,7235
120,NCT02781506,Phase II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Nivolumab and Stereotactic Ablative Radiation Therapy Versus Nivolumab Alone for Metastatic Renal Cancer,7235
121,NCT02475382,Expanded access,No longer available,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Expanded Access Program With Nivolumab Therapy for Treatment of Advanced/Metastatic SqNSCLC or Non-SqNSCLC After One Prior Systemic Regimen (CheckMate 169),7235
122,NCT03025256,Phase I,Not yet recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Study of Concurrent Intravenous and Intrathecal Nivolumab for Patients With Leptomeningeal Disease (LMD),7235
123,NCT02785952,Phase III,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers,7235
124,NCT02553642,Phase II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 779, 'therapyName': 'Ipilimumab'}]",Relationship Between Tumor Mutation Burden and Predicted Neo-antigen Burden in Patients With Advanced Melanoma or Bladder Cancer Treated With Nivolumab or Nivolumab Plus Ipilimumab (CA209-260),7235
125,NCT02919683,Phase II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Window Study of Nivolumab With or Without Ipilimumab in Squamous Cell Carcinoma of the Oral Cavity,7235
126,NCT03203304,Phase I,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Study of Stereotactic Body Radiotherapy (SBRT) Followed by Nivolumab or Ipilimumab With Nivolumab in Unresectable Hepatocellular Carcinoma,7235
127,NCT02598960,Phase Ib/II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 3559, 'therapyName': 'BMS-986156'}]",A Study of BMS-986156 Given Alone and in Combination With Nivolumab in Subjects With Advanced Solid Tumors,7235
128,NCT02483247,Phase Ib/II,Recruiting,"[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1945, 'therapyName': 'BBI503'}]",A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer,7235
129,NCT02530463,Phase II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 779, 'therapyName': 'Ipilimumab'}]",Nivolumab and Ipilimumab With 5-azacitidine in Patients With Myelodysplastic Syndromes (MDS),7235
130,NCT03121417,Phase II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Biomarker-Driven Phase 2 Study of Nivolumab in Advanced Metastatic Non-small Cell Lung Cancer,7235
131,NCT02897765,Phase I,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 4733, 'therapyName': 'NEO-PV-01 + poly ICLC'}]","A Personalized Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer",7235
132,NCT01658878,Phase I,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}]","Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab in Subjects With Advanced Liver Cancer Anti-PD-1 HCC (Anti-Programmed-Death-1 Hepatocellular Carcinoma)",7235
133,NCT02439450,Phase I,Recruiting,"[{'id': 2457, 'therapyName': 'HS-110'}, {'id': 1312, 'therapyName': 'Nivolumab'}]",A Study of Combination Therapies With Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer,7235
134,NCT01928394,Phase Ib/II,Recruiting,"[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 1312, 'therapyName': 'Nivolumab'}]","A Phase 1/2, Open-label Study of Nivolumab Monotherapy or Nivolumab Combined With Ipilimumab in Subjects With Advanced or Metastatic Solid Tumors",7235
135,NCT01454102,Phase I,"Active, not recruiting","[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1312, 'therapyName': 'Nivolumab'}]","Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012)",7235
136,NCT01928576,Phase II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 1541, 'therapyName': 'Entinostat'}, {'id': 651, 'therapyName': 'Azacitidine'}]",Phase II Anti-PD1 Epigenetic Priming Study in NSCLC.,7235
137,NCT03203473,Phase II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Study of Optimized Management of Nivolumab Based on Response in Patients With Advanced RCC (OMNIVORE Study),7235
138,NCT02631746,Phase II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Nivolumab in Treating Patients With HTLV-Associated T-Cell Leukemia/Lymphoma,7235
139,NCT02142218,Phase I,No longer available,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Expanded Access Program With Nivolumab to Treat Melanoma,7235
140,NCT02477826,Phase III,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 755, 'therapyName': 'Gemcitabine'}]","An Open-Label, Trial of Nivolumab and Nivolumab Plus Ipilimumab Versus Platinum Doublet Chemotherapy in Subjects With Stage IV Non-Small Cell Lung Cancer (NSCLC)",7235
141,NCT03075553,Phase II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma,7235
142,NCT02451982,Phase Ib/II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 3622, 'therapyName': 'Cyclophosphamide + GVAX pancreatic cancer vaccine '}]",Neoadjuvant/Adjuvant GVAX Pancreas Vaccine (With CY) With or Without Nivolumab Trial for Surgically Resectable Pancreatic Cancer,7235
143,NCT02466568,Phase Ib/II,Not yet recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Study of Nivolumab in Combination With GM.CD40L Vaccine in Adenocarcinoma of the Lung,7235
144,NCT03068455,Phase III,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",A Study of Nivolumab in Combination With Ipilimumab Compared to Nivolumab or Ipilimumab Alone in Treatment of Patients After Complete Resection of Stage IIIb/c/d or Stage IV Melanoma (CheckMate 915),7235
145,NCT02257528,Phase II,"Active, not recruiting","[{'id': 1312, 'therapyName': 'Nivolumab'}]","Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer",7235
146,NCT03158129,Phase II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Study Of Induction Checkpoint Blockade For Untreated Stage I-IIIA Non-Small Cell Lung Cancers Amenable For Surgical Resection,7235
147,NCT02837029,Phase I,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Nivolumab and Yttrium Y 90 Glass Microspheres in Treating Patients With Advanced Liver Cancer,7235
148,NCT02529072,Phase I,Terminated,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Nivolumab With DC Vaccines for Recurrent Brain Tumors,7235
149,NCT02599402,Phase III,"Active, not recruiting","[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}, {'id': 1312, 'therapyName': 'Nivolumab'}]",Nivolumab Combined With Ipilimumab Followed by Nivolumab Monotherapy as First-Line Treatment for Patients With Advanced Melanoma,7235
150,NCT02105636,Phase III,"Active, not recruiting","[{'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 694, 'therapyName': 'Cetuximab'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1312, 'therapyName': 'Nivolumab'}]",Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Head and Neck Carcinoma (CheckMate 141),7235
151,NCT03115801,Phase II,Recruiting,"[{'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 1312, 'therapyName': 'Nivolumab'}]",A Phase II Randomized Trial of Immunotherapy Plus Radiotherapy in Metastatic Genitourinary Cancers,7235
152,NCT02467361,Phase Ib/II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 2057, 'therapyName': 'BBI608'}]",A Study of BBI608 Administered in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Cancers,7235
153,NCT02472977,Phase Ib/II,Terminated,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 2847, 'therapyName': 'Ulocuplumab'}]",Safety and Efficacy Study of Ulocuplumab and Nivolumab in Subjects With Solid Tumors,7235
154,NCT02864251,Phase III,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}, {'id': 4616, 'therapyName': 'Carboplatin + Cisplatin + Pemetrexed'}]","A Study of Nivolumab + Chemotherapy or Nivolumab + Ipilimumab Versus Chemotherapy in Patients With EGFR Mutation, T790M Negative NSCLC Who Have Failed 1L EGFR TKI Therapy (CheckMate722)",7235
155,NCT02339558,Phase II,"Active, not recruiting","[{'id': 1312, 'therapyName': 'Nivolumab'}]",Nivolumab in Treating Patients With Recurrent and/or Metastatic Nasopharyngeal Cancer,7235
156,NCT02823574,Phase II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Study of Nivolumab in Combination With Ipilimumab Versus Nivolumab in Combination With Ipilimumab Placebo in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck,7235
157,NCT03215810,,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1166, 'therapyName': 'Fludarabine'}]",Nivolumab and Tumor Infiltrating Lymphocytes (TIL) in Advanced Non-Small Cell Lung Cancer,7235
158,NCT02428192,Phase II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Nivolumab in Treating Patients With Advanced Uterine Leiomyosarcoma,7235
159,NCT03055013,Phase III,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy (PROSPER),7235
160,NCT03126331,Phase II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Intermittent Nivolumab in Metastatic Renal Cell Carcinoma Patients,7235
161,NCT02041533,Phase III,"Active, not recruiting","[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 755, 'therapyName': 'Gemcitabine'}]","An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026)",7235
162,NCT02696993,Phase Ib/II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 779, 'therapyName': 'Ipilimumab'}]",Phase I/II Trial of Nivolumab With Radiation or Nivolumab and Ipilimumab With Radiation for the Treatment of Intracranial Metastases From Non-small Cell Lung Cancer,7235
163,NCT02978404,Phase II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Combining Radiosurgery and Nivolumab in the Treatment of Brain Metastases,7235
164,NCT02538666,Phase III,Recruiting,"[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 1312, 'therapyName': 'Nivolumab'}]","A Randomized, Multicenter, Double-Blind, Phase 3 Study of Nivolumab, Nivolumab in Combination With Ipilimumab, or Placebo as Maintenance Therapy in Subjects With Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) After Completion of Platinum-based First Line Chemotherapy (CheckMate 451)",7235
165,NCT02426892,Phase II,"Active, not recruiting","[{'id': 1312, 'therapyName': 'Nivolumab'}]",Nivolumab and HPV-16 Vaccination in Patients With HPV-16 Positive Incurable Solid Tumors,7235
166,NCT02469701,Phase II,"Active, not recruiting","[{'id': 1312, 'therapyName': 'Nivolumab'}]",BrUOG 317: Nivolumab and Ablation For Patients With Advanced Non-Small Cell Lung Cancer Progressing After at Least One Prior Therapy For Metastatic Disease,7235
167,NCT03224871,Phase I,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1167, 'therapyName': 'Aldesleukin'}, {'id': 1312, 'therapyName': 'Nivolumab'}]",A Pilot Study of Interlesional IL-2 and RT in Patients With NSCLC.,7235
168,NCT02387996,Phase II,"Active, not recruiting","[{'id': 1312, 'therapyName': 'Nivolumab'}]",A Study of Nivolumab in Participants With Metastatic or Unresectable Bladder Cancer,7235
169,NCT02599649,Phase II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 2583, 'therapyName': 'Lirilumab '}]",Lirilumab and Nivolumab With 5-Azacitidine in Patients With Myelodysplastic Syndromes (MDS),7235
170,NCT03149120,Phase II,Withdrawn,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 5681, 'therapyName': 'Nivolumab + Pazopanib'}]",Study of Nivolumab With or Without Pazopanib in Metastatic or Unresectable Soft Tissue Sarcomas,7235
171,NCT03238365,Phase I,Recruiting,"[{'id': 6100, 'therapyName': 'Nivolumab + Tadalafil'}, {'id': 1312, 'therapyName': 'Nivolumab'}]",Nivolumab With or Without Tadalafil in Treating Patients With Recurrent Head and Neck Squamous Cell Carcinoma That Can Be Removed by Surgery,7235
172,NCT03038672,Phase II,Not yet recruiting,"[{'id': 2526, 'therapyName': 'Nivolumab + Varlilumab'}, {'id': 1312, 'therapyName': 'Nivolumab'}]",Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas,7235
173,NCT03130959,Phase II,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}, {'id': 1312, 'therapyName': 'Nivolumab'}]",An Investigational Immuno-therapy Study of Nivolumab Monotherapy and Nivolumab in Combination With Ipilimumab in Pediatric Patients With High Grade Primary CNS Malignancies (CheckMate 908),7235
174,NCT02576509,Phase III,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 920, 'therapyName': 'Sorafenib'}]",A Study of Nivolumab Versus Sorafenib as First-Line Treatment in Patients With Advanced Hepatocellular Carcinoma,7235
175,NCT02985554,Phase I,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Phase I Study to Assess the Tolerability and Efficacy of Nivolumab in Patients With Hematologic Malignancies,7235
176,NCT02713867,Phase III,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}]","A Dose Frequency Optimization,Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects With Advanced or Metastatic Non-small Cell Lung Cancer Who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks (CheckMate 384)",7235
177,NCT03143270,Phase I,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",A Study to Test the Safety and Feasibility of Nivolumab With Drug Eluting Bead Transarterial Chemoembolization in Patients With Liver Cancer,7235
178,NCT03233347,,Not yet recruiting,"[{'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 2486, 'therapyName': 'Brentuximab vedotin'}, {'id': 2635, 'therapyName': 'Vinblastine'}, {'id': 1312, 'therapyName': 'Nivolumab'}]","Doxorubicin Hydrochloride, Vinblastine, Dacarbazine, Brentuximab Vedotin, and Nivolumab in Treating Patients With Stage I-II Hodgkin Lymphoma",7235
179,NCT02339571,Phase II,Suspended,"[{'id': 1873, 'therapyName': 'Sargramostim'}, {'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 779, 'therapyName': 'Ipilimumab'}]",Nivolumab and Ipilimumab With or Without Sargramostim in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery,7235
180,NCT03171025,Phase II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Adjuvant Nivolumab Following Chemo-Radiation in Localized Muscle-Invasive Bladder Cancer (NEXT),7235
181,NCT02684253,Phase II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}]","Screening Trial of Nivolumab With Image Guided, Stereotactic Body Radiotherapy (SBRT) Versus Nivolumab Alone in Patients With Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)",7235
182,NCT02066636,Phase III,"Active, not recruiting","[{'id': 1312, 'therapyName': 'Nivolumab'}]",A Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Systemic Regimen (CheckMate 153),7235
183,NCT02060188,Phase Ib/II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 779, 'therapyName': 'Ipilimumab'}]",A Study of Nivolumab and Nivolumab Plus Ipilimumab in Recurrent and Metastatic Colon Cancer (CheckMate 142),7235
184,NCT02962804,Phase II,Not yet recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Combination Radiation and PD-1 Inhibition in Metastatic or Recurrent Renal Cell Carcinoma (RCC),7235
185,NCT02350764,Phase II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Evaluate the Mediators of Sensitivity and Resistance to Nivolumab in Patients With Advanced NSCLCs,7235
186,NCT03090737,Phase II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Safety Study of Nivolumab to Treat Advanced or Metastatic Non-small Cell Lung Cancer (CheckMate 907),7235
187,NCT03117309,Phase II,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}, {'id': 1312, 'therapyName': 'Nivolumab'}]",Study of Front Line Therapy With Nivolumab and Salvage Nivolumab + Ipilimumab in Patients With Advanced Renal Cell Carcinoma,7235
188,NCT01176474,Phase I,"Active, not recruiting","[{'id': 2696, 'therapyName': 'NY-ESO-1 peptide vaccine'}, {'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 1312, 'therapyName': 'Nivolumab'}]",A Phase I Trial of a Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV Melanoma,7235
189,NCT02652455,Phase I,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 3409, 'therapyName': 'Aldesleukin + Cyclophosphamide + Fludarabine '}, {'id': 2055, 'therapyName': 'Urelumab'}]","Combining PD-1 Blockade, CD137 Agonism and Adoptive Cell Therapy for Metastatic Melanoma",7235
190,NCT03110978,Phase II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Clinical Trials Comparing Immunotherapy Plus Stereotactic Ablative Radiotherapy (I-SABR) Versus SABR Alone for Stage I or Isolated Lung Parenchymal Recurrent Non-small Cell Lung Cancer: I-SABR,7235
191,NCT02924233,Phase Ib/II,Withdrawn,"[{'id': 4833, 'therapyName': 'Nivolumab + SYM004'}, {'id': 1312, 'therapyName': 'Nivolumab'}]",Sym004 in Combination With Nivolumab Versus Nivolumab Monotherapy in EGFR-amplified Squamous Non-Small Cell Lung Cancer,7235
192,NCT02716948,Phase I,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Stereotactic Radiosurgery and Nivolumab in Treating Patients With Newly Diagnosed Melanoma Metastases in the Brain or Spine,7235
193,NCT02829918,Phase II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Study of Nivolumab in Patients With Advanced Refractory Biliary Tract Cancers,7235
194,NCT03173950,Phase II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Immune Checkpoint Inhibitor Nivolumab in People With Select Rare CNS Cancers,7235
195,NCT02388906,Phase III,"Active, not recruiting","[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 779, 'therapyName': 'Ipilimumab'}]",Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV Melanoma (CheckMate 238),7235
196,NCT02156804,Phase II,"Active, not recruiting","[{'id': 1312, 'therapyName': 'Nivolumab'}]","A Single-Arm, Open-Label, Multicenter Clinical Trial With Nivolumab (BMS-936558) for Subjects With Histologically Confirmed Stage III (Unresectable) or Stage IV Melanoma Progressing Post Prior Treatment Containing an Anti-CTLA4 Monoclonal Antibody (CheckMate 172)",7235
197,NCT02614456,Phase I,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 1733, 'therapyName': 'interferon gamma '}]",Combination of Interferon-gamma and Nivolumab for Advanced Solid Tumors,7235
198,NCT03222076,Phase II,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}, {'id': 1312, 'therapyName': 'Nivolumab'}]",Study Evaluating Nivolumab (Anti-PD-1 Antibody) Alone Versus Nivolumab Plus Ipilimumab (Anti-CTLA-4 Antibody) in Patients With Resectable and Potentially Resectable Hepatocellular Carcinoma (HCC) (CA209-956),7235
199,NCT02259231,Phase Ib/II,Recruiting,"[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 3062, 'therapyName': 'RTA 408'}]",RTA 408 Capsules in Patients With Melanoma - REVEAL,7235
200,NCT02275533,Phase II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Nivolumab in Eliminating Minimal Residual Disease and Preventing Relapse in Patients With Acute Myeloid Leukemia in Remission After Chemotherapy,7235
201,NCT02574078,Phase I,Recruiting,"[{'id': 619, 'therapyName': 'Abraxane'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 2114, 'therapyName': 'Bevacizumab + Pemetrexed'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 1092, 'therapyName': 'Carboplatin'}]",A Master Protocol Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC) (CheckMate 370),7235
202,NCT02720484,Phase II,"Active, not recruiting","[{'id': 1312, 'therapyName': 'Nivolumab'}]",Nivolumab in Treating Patients With Metastatic Adrenocortical Cancer,7235
203,NCT02648997,Phase II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",A Study of Nivolumab in Adult Participants With Recurrent High-Grade Meningioma,7235
204,NCT02829931,Phase I,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Hypofractionated Stereotactic Irradiation With Nivolumab in Patients With Recurrent High Grade Gliomas,7235
205,NCT02595918,Phase I,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Nivolumab in Treating Patients With HIgh-Risk Non-Metastatic Kidney Cancer,7235
206,NCT02726581,Phase III,"Active, not recruiting","[{'id': 3343, 'therapyName': 'Elotuzumab'}, {'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 3792, 'therapyName': 'Dexamethasone + Pomalidomide'}]","Study of Combinations of Nivolumab, Elotuzumab, Pomalidomide and Dexamethasone in Multiple Myeloma",7235
207,NCT02846376,Phase I,Recruiting,"[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}, {'id': 1312, 'therapyName': 'Nivolumab'}]",Single Agent and Combined Inhibition After Allogeneic Stem Cell Transplant (CPIT-002),7235
208,NCT02880020,Phase II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Nivolumab With or Without Ipilimumab in Treating Patients With Gastrointestinal Stromal Tumor That Is Metastatic or Cannot Be Removed by Surgery,7235
209,NCT01621490,Phase I,"Active, not recruiting","[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 1312, 'therapyName': 'Nivolumab'}]",PH 1 Biomarker Study of Nivolumab and Ipilimumab and Nivolumab in Combination With Ipilimumab in Advanced Melanoma (PD-1),7235
210,NCT02737475,Phase Ib/II,Recruiting,"[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 4030, 'therapyName': 'BMS-986178'}, {'id': 1312, 'therapyName': 'Nivolumab'}]",Study of BMS-986178 Monotherapy or in Combination With Nivolumab or Ipilimumab in Subjects With Advanced Solid Tumors,7235
211,NCT02989636,Phase I,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}]","Nivolumab With or Without Stereotactic Radiosurgery in Treating Patients With Recurrent, Advanced, or Metastatic Chordoma",7235
212,NCT03271047,,Recruiting,"[{'id': 807, 'therapyName': 'Binimetinib'}, {'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 779, 'therapyName': 'Ipilimumab'}]",Study of Binimetinib + Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Microsatellite-stable (MSS) Metastatic Colorectal Cancer With RAS Mutation,7235
213,NCT01585194,Phase II,Recruiting,"[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 1312, 'therapyName': 'Nivolumab'}]",Phase II Study of Nivolumab in Combination With Ipilimumab for Uveal Melanoma,7235
214,NCT02519322,Phase II,"Active, not recruiting","[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 1312, 'therapyName': 'Nivolumab'}]",Neoadjuvant and Adjuvant Checkpoint Blockade in Patients With Clinical Stage III or Oligometastatic Stage IV Melanoma,7235
215,NCT03233711,Phase II,Not yet recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer,7235
216,NCT02488759,Phase Ib/II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",A Study to Investigate the Safety and Efficacy of Nivolumab in Virus-associated Tumors (CheckMate358),7235
217,NCT02498600,Phase II,Recruiting,"[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 1312, 'therapyName': 'Nivolumab'}]","Nivolumab With or Without Ipilimumab in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer",7235
218,NCT02481830,Phase III,"Active, not recruiting","[{'id': 2951, 'therapyName': 'Amrubicin'}, {'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 942, 'therapyName': 'Topotecan'}]",Efficacy Study of Nivolumab or Chemotherapy in Subjects With Relapsed Small-cell Lung Cancer,7235
219,NCT02500797,Phase II,Recruiting,"[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 1312, 'therapyName': 'Nivolumab'}]",Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic or Unresectable Sarcoma,7235
220,NCT03305445,,Not yet recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 779, 'therapyName': 'Ipilimumab'}]",Nivolumab/Ipilimumab-Primed Immunotransplant for DLBCL,7235
221,NCT02259621,Phase II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}]","Neoadjuvant Anti-PD-1, Nivolumab in Resectable NSCLC",7235
222,NCT03168464,Phase Ib/II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Radiation and Immune Checkpoints Blockade in Metastatic NSCLC (BMS # CA209-632),7235
223,NCT02632409,Phase III,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",A Study of Adjuvant Nivolumab Versus Placebo Post-Surgical Removal of High Risk Invasive Urothelial Carcinoma,7235
224,NCT02038946,Phase II,"Active, not recruiting","[{'id': 1312, 'therapyName': 'Nivolumab'}]",Study of Nivolumab in Subjects With Relapsed or Refractory Follicular Lymphoma (FL) (CheckMate 140),7235
225,NCT02181738,Phase II,"Active, not recruiting","[{'id': 1312, 'therapyName': 'Nivolumab'}]",Study of Nivolumab in Subjects With Hodgkin's Lymphoma (Registrational) (CheckMate 205),7235
226,NCT02423954,Phase Ib/II,"Active, not recruiting","[{'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 1074, 'therapyName': 'Irinotecan'}]",Study of Nivolumab Plus Chemotherapy in Patients With Advanced Cancer (NivoPlus),7235
227,NCT03247712,Phase Ib/II,Not yet recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Neoadjuvant Immunoradiotherapy in Head & Neck Cancer,7235
228,NCT02518958,Phase I,"Active, not recruiting","[{'id': 1312, 'therapyName': 'Nivolumab'}]","A Phase I, Open-Label, Multiple Ascending Dose Study of RRx-001 and Nivolumab",7235
229,NCT02864316,Phase II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Phase 2 Study of Nivolumab in Solid Tumors Induced by Prior Radiation Exposure,7235
230,NCT02595944,Phase III,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (ANVIL),7235
231,NCT02423343,Phase Ib/II,Recruiting,"[{'id': 2409, 'therapyName': 'Galunisertib'}, {'id': 1312, 'therapyName': 'Nivolumab'}]","A Study of Galunisertib (LY2157299) in Combination With Nivolumab in Advanced Refractory Solid Tumors and in Recurrent or Refractory NSCLC, Hepatocellular Carcinoma, or Glioma",7235
232,NCT03107182,Phase II,Recruiting,"[{'id': 5581, 'therapyName': 'Dexamethasone + Diphenhydramine + Famotidine + 5FU + Hydroxyurea + Paclitaxel'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 5303, 'therapyName': 'Nivolumab + Carboplatin + Paclitaxel'}]",Oropharyngeal Tumor Induction Chemotherapy and Response-stratified Locoregional Therapy Trial in Order to Minimize Long-term Adverse Events,7235
233,NCT03245892,Phase I,Recruiting,"[{'id': 5303, 'therapyName': 'Nivolumab + Carboplatin + Paclitaxel'}]",A Study of Carboplatin and Paclitaxel Chemotherapy With Nivolumab in Patients With Ovarian Cancer,7235
234,NCT03044613,Phase I,Recruiting,"[{'id': 5304, 'therapyName': 'Nivolumab + Ipilimumab + Carboplatin + Paclitaxel'}, {'id': 5303, 'therapyName': 'Nivolumab + Carboplatin + Paclitaxel'}]",Nivolumab or Nivolumab/Ipilimumab Prior to Chemoradiation Plus Nivolumab With II/III Gastro/Esophageal Cancer,7235
235,NCT03143153,Phase III,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}, {'id': 1833, 'therapyName': 'Cisplatin + Fluorouracil'}, {'id': 5799, 'therapyName': 'Nivolumab + Cisplatin + Fluorouacil'}]",A Study to Evaluate Efficacy in Subjects With Esophageal Cancer Treated With Nivolumab and Ipilimumab or Nivolumab Combined With Fluorouracil Plus Cisplatin Versus Fluorouracil Plus Cisplatin (CheckMate 648),7235
236,NCT03016871,Phase II,Recruiting,"[{'id': 5198, 'therapyName': 'Nivolumab + Etoposide + Ifosfamide + Carboplatin'}]","Nivolumab, Ifosfamide, Carboplatin, and Etoposide as Second-Line Therapy in Treating Patients With Refractory or Relapsed Hodgkin Lymphoma",7235
237,NCT03146650,Phase II,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Nivolumab and Ipilimumab in Treating Patients With Metastatic Recurrent Major or Minor Salivary Gland Cancer,7235
238,NCT02231749,Phase III,"Active, not recruiting","[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}, {'id': 930, 'therapyName': 'Sunitinib'}]",Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214),7235
239,NCT02834013,Phase 0,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Nivolumab and Ipilimumab in Treating Patients With Rare Tumors,7235
240,NCT03043599,Phase Ib/II,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Ipilimumab + Nivolumab w/Thoracic Radiotherapy for Extensive-Stage Small Cell Lung Cancer,7235
241,NCT03065179,Phase II,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Trial of SBRT in Combination With Nivolumab/Ipilimumab in RCC / Kidney Cancer Patients,7235
242,NCT03033576,Phase II,Recruiting,"[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Ipilimumab With or Without Nivolumab in Treating Patients With Melanoma That is Stage IV or Stage III and Cannot Be Removed by Surgery,7235
243,NCT02186249,Phase III,No longer available,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Expanded Access Program With Nivolumab (BMS-936558) in Combination With Ipilimumab (Yervoy®) in Anti-CTLA-4 Treatment-Naïve Subjects With Unresectable or Metastatic Melanoma (CheckMate 218),7235
244,NCT02978443,Phase II,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",A Biomarker Study in Advanced Mucosal or Acral Lentiginous Melanoma Receiving Nivolumab in Combination With Ipilimumab,7235
245,NCT02714218,Phase III,"Active, not recruiting","[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]","A Study of Two Different Dose Combinations of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated, Unresectable or Metastatic Melanoma",7235
246,NCT02681302,Phase Ib/II,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Study of Combined Check Point Inhibition After Autologous Hematopoietic Stem Cell Transplantation in Patients at High Risk for Post-transplant Recurrence (CPIT001),7235
247,NCT02899299,Phase III,Recruiting,"[{'id': 4616, 'therapyName': 'Carboplatin + Cisplatin + Pemetrexed'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients (CheckMate743),7235
248,NCT03162731,Phase I,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]","Nivolumab, Ipilimumab, and Radiation Therapy in Treating Patients With Stage IVA-B Head and Neck Cancer",7235
249,NCT03223155,Phase I,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]","Evaluate Concurrent Or Sequential Ipilimumab, Nivolumab, and Stereotactic Body Radiotherapy in Patients With Stage IV Non-Small Cell Lung Cancer",7235
250,NCT03274258,Phase II,Not yet recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Nivolumab Plus Ipilimumab in Patients With Renal Medullary Carcinoma,7235
251,NCT02320058,Phase II,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",A Multi-Center Phase 2 Open-Label Study to Evaluate Safety and Efficacy in Subjects With Melanoma Metastatic to the Brain Treated With Nivolumab in Combination With Ipilimumab Followed by Nivolumab Monotherapy (CheckMate 204),7235
252,NCT03001882,Phase II,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",An Exploratory Study of the Effects of Nivolumab Combined With Ipilimumab in Patients With Treatment-Naive Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC),7235
253,NCT03104439,Phase II,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Nivolumab and Ipilimumab and Radiation Therapy in MSS and MSI High Colorectal and Pancreatic Cancer,7235
254,NCT03149159,Phase II,Not yet recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]","Investigator-Initiated Trial of Combined Ipilimumab, Nivolumab and Stereotactic Radiation in Patients With Metastatic Clear-Cell RCC (ccRCC) Who Have Failed Treatment With Single-Agent Nivolumab",7235
255,NCT03029780,Phase II,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",An Investigational Immuno-Therapy Safety and Efficacy Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Renal Cell Carcinoma,7235
256,NCT03215706,Phase III,Recruiting,"[{'id': 6132, 'therapyName': 'Carboplatin + Cisplatin + Paclitaxel + Pemetrexed'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",A Study of Nivolumab and Ipilimumab Combined With Chemotherapy Compared to Chemotherapy by Itself as the First Treatment Given for Stage IV Non-Small Cell Lung Cancer (NSCLC) (CheckMate 9LA),7235
257,NCT03036098,Phase III,Recruiting,"[{'id': 1467, 'therapyName': 'Gemcitabine + Cisplatin'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}, {'id': 2667, 'therapyName': 'Carboplatin + Gemcitabine'}]",Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care Chemotherapy in Treatment of Patients With Untreated Inoperable or Metastatic Urothelial Cancer,7235
258,NCT02998528,Phase III,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}, {'id': 5241, 'therapyName': 'Cisplatin + Vinorelbine + Gemcitabine + Docetaxel + Pemetrexed + Carboplatin'}]",A Neoadjuvant Study of Nivolumab and Ipilimumab Compared to Chemotherapy Doublet in Early Stage Non-Small Cell Lung Cancer (NSCLC) (CheckMate 816),7235
259,NCT03138512,Phase III,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",A Study Comparing the Combination of Nivolumab and Ipilimumab Versus Placebo in Participants With Localized Renal Cell Carcinoma (CheckMate 914),7235
260,NCT02304458,Phase Ib/II,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas,7235
261,NCT02659540,Phase I,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",A Pilot Study to Evaluate the Safety and Efficacy of Combination Checkpoint Blockade Plus External Beam Radiotherapy in Subjects With Stage IV Melanoma,7235
262,NCT02741570,Phase III,Recruiting,"[{'id': 4168, 'therapyName': 'Carboplatin + Cetuximab + Cisplatin + Fluorouracil'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care (Extreme Study Regimen) as First Line Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck,7235
263,NCT03071406,Phase II,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Randomized Study of Nivolumab+Ipilimumab+/- SBRT for Metastatic Merkel Cell Carcinoma,7235
264,NCT02970981,Phase II,Not yet recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Study of Combination of Ipilimumab and Nivolumab in Patients With Melanoma,7235
265,NCT02982954,Phase III,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",A Study to Evaluate the Safety of Nivolumab and Ipilimumab in Subjects With Previously Untreated Advanced or Metastatic Renal Cell Cancer (CHECKMATE 920),7235
266,NCT02869789,Phase III,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",A Safety Study of Nivolumab in Combination With Ipilimumab to Treat Advanced Cancers,7235
267,NCT03126461,Phase II,Not yet recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",SAbR Plus Ipilimumab Plus Nivolumab in Metastatic Melanoma Patients,7235
268,NCT02601014,Phase II,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Biomarker-Driven Therapy With Nivolumab and Ipilimumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Expressing AR-V7,7235
269,NCT02453620,Phase I,Recruiting,"[{'id': 1541, 'therapyName': 'Entinostat'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]","Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer",7235
270,NCT02659059,Phase II,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Nivolumab Plus Ipilimumab to Treat First Line Stage IV Non-Small Cell Lung Cancer (CheckMate568),7235
271,NCT02892734,Phase II,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Ipilimumab and Nivolumab in Treating Patients With Recurrent Stage IV HER2 Negative Inflammatory Breast Cancer,7235
272,NCT02939300,Phase II,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Ipilimumab and Nivolumab in Leptomeningeal Metastases From Melanoma,7235
273,NCT02985957,Phase II,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",A Study to Evaluate Preliminary Safety and Efficacy of Nivolumab Plus Ipilimumab in Men With Metastatic Castration-Resistant Prostate Cancer,7235
274,NCT03048136,Phase III,Not yet recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",A Safety Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Non-small Cell Lung Cancer (CheckMate 955),7235
275,NCT02872116,Phase III,Recruiting,"[{'id': 1597, 'therapyName': 'Capecitabine + Oxaliplatin'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}]",Efficacy Study of Nivolumab Plus Ipilimumab Against Chemotherapy Standard of Care in Stomach Cancer or Stomach/Esophagus Junction Cancer (CheckMate649),7235
276,NCT03220009,Phase II,Not yet recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]","Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma",7235
277,NCT03172624,Phase II,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Study of Nivolumab Plus Ipilimumab in Patients With Salivary Gland Cancer,7235
278,NCT02224781,Phase III,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}, {'id': 1066, 'therapyName': 'Trametinib + Dabrafenib'}]",Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma,7235
279,NCT02408861,Phase I,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Nivolumab and Ipilimumab in Treating Patients With Advanced HIV Associated Solid Tumors,7235
280,NCT01822509,Phase I,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant,7235
281,NCT02833233,Phase I,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",A Study of Pre-Operative Treatment With Cryoablation and Immune Therapy in Early Stage Breast Cancer,7235
282,NCT03262779,Phase II,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Ipilimumab and Nivolumab in Patients With Anti-PD-1-axis Therapy-resistant Advanced Non-small Cell Lung Cancer.,7235
283,NCT02656706,Phase II,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",BrUOG 324: Adjuvant Nivolumab and Low Dose Ipilimumab for Stage III and Resected Stage IV Melanoma: A Phase II Brown University Oncology Research Group Trial,7235
284,NCT03246958,Phase II,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Nivolumab Plus Ipilimumab in Thyroid Cancer,7235
285,NCT02903381,Phase II,Recruiting,"[{'id': 5128, 'therapyName': 'Nivolumab + Lenalidomide + Dexamethasone'}]",Nivolumab + Lenalidomide + Dexamethasone In SMM,7235
286,NCT02949843,Phase II,Recruiting,"[{'id': 4918, 'therapyName': 'Nivolumab + Pembrolizumab'}]",Targeted Therapy in Treating Patients With Incurable Non-Small Cell Lung Cancer With Genetic Mutations,7235
287,NCT03229278,Phase I,Not yet recruiting,"[{'id': 6055, 'therapyName': 'Nivolumab + Pembrolizumab + Trigriluzole'}]",Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma,7235
288,NCT02812667,Phase I,Recruiting,"[{'id': 4512, 'therapyName': 'Nivolumab + Plinabulin'}]",Nivolumab in Combination With Plinabulin in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC),7235
289,NCT02846792,Phase Ib/II,Recruiting,"[{'id': 4512, 'therapyName': 'Nivolumab + Plinabulin'}]","Nivolumab and Plinabulin in Treating Patients With Stage IIIB-IV, Recurrent, or Metastatic Non-small Cell Lung Cancer",7235
290,NCT03121677,Phase I,Not yet recruiting,"[{'id': 5592, 'therapyName': 'Nivolumab + poly ICLC + Rituximab'}]",Personalized Synthetic Long Peptide Vaccine Strategy and PD-1 Blockade in Patients With Follicular Lymphoma,7235
291,NCT02400385,Phase II,Withdrawn,"[{'id': 2626, 'therapyName': 'Nivolumab + Sunitinib'}]",A Phase II Trial of Sunitinib and Nivolumab for KIT-mutated Advanced Melanoma,7235
292,NCT02834247,Phase I,Recruiting,"[{'id': 4680, 'therapyName': 'Nivolumab + TAK-659'}]",A Study of TAK-659 in Combination With Nivolumab in Participants With Advanced Solid Tumors,7235
293,NCT02667587,Phase II,Recruiting,"[{'id': 1141, 'therapyName': 'Temozolomide'}, {'id': 3724, 'therapyName': 'Nivolumab + Temozolomide'}]","Study of Temozolomide Plus Radiation Therapy With Nivolumab or Placebo, for Newly Diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer).",7235
294,NCT02860546,Phase II,"Active, not recruiting","[{'id': 4560, 'therapyName': 'Nivolumab + trifluridine/tipiracil hydrochloride'}]",A Study Evaluating TAS-102 Plus Nivolumab in Patients With MSS CRC,7235
295,NCT02253992,Phase Ib/II,Recruiting,"[{'id': 2567, 'therapyName': 'Nivolumab + Urelumab'}]",Study of the Safety and Tolerability of Urelumab Administered in Combination With Nivolumab in Solid Tumors and B-cell Non-Hodgkins Lymphoma,7235
296,NCT02845323,Phase II,Recruiting,"[{'id': 2055, 'therapyName': 'Urelumab'}, {'id': 2567, 'therapyName': 'Nivolumab + Urelumab'}]",Neoadjuvant Nivolumab With and Without Urelumab in Patients With Cisplatin-Ineligible Muscle-Invasive Urothelial Carcinoma of the Bladder,7235
297,NCT02648633,Phase I,Terminated,"[{'id': 4219, 'therapyName': 'Nivolumab + Valproic acid'}]",Stereotactic Radiosurgery With Nivolumab and Valproate in Patients With Recurrent Glioblastoma,7235
298,NCT02413827,Phase Ib/II,Terminated,"[{'id': 2526, 'therapyName': 'Nivolumab + Varlilumab'}, {'id': 1324, 'therapyName': 'DEC-205-NY-ESO-1 fusion protein vaccine'}, {'id': 2595, 'therapyName': 'poly ICLC  '}]",A Study of Varlilumab (Anti-CD27) and Ipilimumab and CDX-1401 in Patients With Unresectable Stage III or IV Melanoma,7235
299,NCT02335918,Phase Ib/II,Recruiting,"[{'id': 2526, 'therapyName': 'Nivolumab + Varlilumab'}]",A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors,7235
300,NCT02737787,Phase I,Recruiting,"[{'id': 4020, 'therapyName': 'Nivolumab + WT1 vaccine'}]",A Study of WT1 Vaccine and Nivolumab For Recurrent Ovarian Cancer,7235
301,NCT02923531,Phase Ib/II,Recruiting,"[{'id': 4837, 'therapyName': 'Nivolumab + X4P-001'}]",Addition of X4P-001 to Nivolumab Treatment in Patients With Renal Cell Carcinoma,7235
302,NCT03282344,Phase II,Recruiting,"[{'id': 5076, 'therapyName': 'NKTR-214 + Nivolumab'}]",A Study of NKTR-214 in Combination With Nivolumab in Patients With Metastatic and/or Locally Advanced Sarcoma,7235
303,NCT02983045,Phase Ib/II,Recruiting,"[{'id': 5076, 'therapyName': 'NKTR-214 + Nivolumab'}]",A Dose Escalation and Cohort Expansion Study of CD122-Biased Cytokine (NKTR-214) in Combination With Anti-PD-1 Antibody (Nivolumab) in Patients With Select Advanced or Metastatic Solid Tumors (PIVOT-02),7235
304,NCT02933255,Phase Ib/II,Recruiting,"[{'id': 4895, 'therapyName': 'PROSTVAC-V/F + Ipilimumab'}, {'id': 4893, 'therapyName': 'PROSTVAC-V/F + Nivolumab + Ipilimumab'}, {'id': 4894, 'therapyName': 'PROSTVAC-V/F + Nivolumab'}]",PROSTVAC in Combination With Nivolumab and/or Ipilimumab in Men With Prostate Cancer,7235
305,NCT02293980,Phase I,"Active, not recruiting","[{'id': 4146, 'therapyName': 'PT2385'}, {'id': 4347, 'therapyName': 'PT2385 + Nivolumab'}]","A Phase 1, Dose-Escalation Trial of PT2385 Tablets In Patients With Advanced Clear Cell Renal Cell Carcinoma",7235
306,NCT03026166,Phase I,Recruiting,"[{'id': 5640, 'therapyName': 'Rovalpituzumab Tesirine + Nivolumab + Ipilimumab'}, {'id': 5641, 'therapyName': 'Rovalpituzumab Tesirine + Nivolumab'}]",A Study of Rovalpituzumab Tesirine Administered in Combination With Nivolumab and With or Without Ipilimumab for Adults With Extensive-Stage Small Cell Lung Cancer,7235
307,NCT02978625,Phase II,Recruiting,"[{'id': 5080, 'therapyName': 'Talimogene laherparepvec + Nivolumab'}]",Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers,7235
308,NCT03138161,Phase Ib/II,Recruiting,"[{'id': 5800, 'therapyName': 'trabectedin + Ipilimumab + Nivolumab'}]","Trabectedin, Ipilimumab and Nivolumab as First Line Treatment for Advanced Soft Tissue Sarcoma",7235
309,NCT03061188,Phase I,Recruiting,"[{'id': 5368, 'therapyName': 'Veliparib + Nivolumab'}]",Nivolumab and Veliparib in Treating Patients With Recurrent or Refractory Stage IV Solid Tumors That Cannot Be Removed by Surgery or Lymphoma With or Without Alterations in DNA Repair Genes,7235
310,NCT02913417,Phase Ib/II,Recruiting,"[{'id': 4769, 'therapyName': 'Yttrium-90 + Nivolumab + Ipilimumab'}]","Yttrium90, Ipilimumab, & Nivolumab for Uveal Melanoma With Liver Metastases",7235
0,NCT02452268,Phase I,Recruiting,"[{'id': 6032, 'therapyName': 'PDR001 + NIZ985'}]",A Phase I/Ib Study of NIZ985 in Combination With PDR001 in Adults With Metastatic Cancers,8897
0,NCT03018405,Phase I,Recruiting,"[{'id': 5998, 'therapyName': 'NKR-2 cells'}]",A Dose Escalation Phase I Study to Assess the Safety and Clinical Activity of Multiple Cancer Indications (THINK),8886
0,NCT02869295,Phase I,Recruiting,"[{'id': 5075, 'therapyName': 'NKTR-214'}]",A Phase 1 Dose Escalation and Expansion Study Of NKTR-214 In Subjects With Locally Advanced Or Metastatic Solid Tumors,8606
1,NCT03282344,Phase II,Recruiting,"[{'id': 5076, 'therapyName': 'NKTR-214 + Nivolumab'}]",A Study of NKTR-214 in Combination With Nivolumab in Patients With Metastatic and/or Locally Advanced Sarcoma,8606
2,NCT02983045,Phase Ib/II,Recruiting,"[{'id': 5076, 'therapyName': 'NKTR-214 + Nivolumab'}]",A Dose Escalation and Cohort Expansion Study of CD122-Biased Cytokine (NKTR-214) in Combination With Anti-PD-1 Antibody (Nivolumab) in Patients With Select Advanced or Metastatic Solid Tumors (PIVOT-02),8606
3,NCT03138889,Phase I,Recruiting,"[{'id': 5625, 'therapyName': 'NKTR-214 + Pembrolizumab'}]",A Study of a CD122-Biased Cytokine (NKTR-214) in Combination With Anti-PD-L1 (Atezolizumab) in Patients With Metastatic Urothelial Bladder Cancer or Metastatic Non-Small Cell Lung Cancer,8606
0,NCT03164603,Phase I,Recruiting,"[{'id': 5815, 'therapyName': 'NLG802'}]","NLG802 Indoleamine 2,3-Dioxygenase (IDO) Inhibitor in Advanced Solid Tumors",8810
0,NCT01176474,Phase I,"Active, not recruiting","[{'id': 2696, 'therapyName': 'NY-ESO-1 peptide vaccine'}, {'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 1312, 'therapyName': 'Nivolumab'}]",A Phase I Trial of a Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV Melanoma,7660
1,NCT02334735,Phase II,Recruiting,"[{'id': 2595, 'therapyName': 'poly ICLC  '}, {'id': 3012, 'therapyName': 'Melan-A/MART-1 peptide vaccine'}, {'id': 2696, 'therapyName': 'NY-ESO-1 peptide vaccine'}]",A Comparison of Matured Dendritic Cells and Montanide&#174; in Study Subjects With High Risk of Melanoma Recurrence,7660
2,NCT02070406,Phase I,Recruiting,"[{'id': 3409, 'therapyName': 'Aldesleukin + Cyclophosphamide + Fludarabine '}, {'id': 2696, 'therapyName': 'NY-ESO-1 peptide vaccine'}]","Gene-Modified T Cells, Vaccine Therapy, and Ipilimumab in Treating Patients With Locally Advanced or Metastatic Malignancies",7660
3,NCT02833506,Phase I,Not yet recruiting,"[{'id': 4460, 'therapyName': 'NY-ESO-1 peptide vaccine + Sirolimus'}, {'id': 2696, 'therapyName': 'NY-ESO-1 peptide vaccine'}]","Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",7660
4,NCT01810016,Phase I,Terminated,"[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 2696, 'therapyName': 'NY-ESO-1 peptide vaccine'}]",NY-ESO-1 Vaccine in Combination With Ipilimumab in Patients With Unresectable or Metastatic Melanoma,7660
5,NCT02775292,Phase I,Recruiting,"[{'id': 3409, 'therapyName': 'Aldesleukin + Cyclophosphamide + Fludarabine '}, {'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 2696, 'therapyName': 'NY-ESO-1 peptide vaccine'}]","Gene-Modified T Cells, Vaccine Therapy, and Nivolumab in Treating Patients With Stage IV or Locally Advanced Solid Tumors Expressing NY-ESO-1",7660
0,NCT01343043,Phase Ib/II,Recruiting,"[{'id': 5877, 'therapyName': 'NY-ESO-1-c259T'}]",A Pilot Study of Genetically Engineered NY-ESO-1 Specific NY-ESO-1c259T in HLA-A2+ Patients With Synovial Sarcoma  (NY-ESO-1),8842
1,NCT03168438,Phase I,Recruiting,"[{'id': 5877, 'therapyName': 'NY-ESO-1-c259T'}, {'id': 5878, 'therapyName': 'NY-ESO-1-c259T + Pembrolizumab'}]",NY-ESO-1-c259T Alone and in Combination With Pembrolizumab for Multiple Myeloma,8842
0,NCT00669669,Phase Ib/II,"Active, not recruiting","[{'id': 2556, 'therapyName': 'O6-benzylguanine'}, {'id': 2555, 'therapyName': 'Carmustine + Filgrastim + Plerixafor + Temozolomide'}]",Dose-Intensive Chemotherapy in Combination With Chemoprotected Autologous Stem Cells in Treating Patients With Malignant Gliomas,7582
1,NCT02343666,Phase I,Recruiting,"[{'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1811, 'therapyName': 'Carmustine'}, {'id': 1756, 'therapyName': 'Plerixafor'}, {'id': 2556, 'therapyName': 'O6-benzylguanine'}]",HIV-Resistant Gene Modified Stem Cells and Chemotherapy in Treating Patients With Lymphoma With HIV Infection,7582
2,NCT01269424,Phase I,Suspended,"[{'id': 2972, 'therapyName': 'O6-benzylguanine + Temozolomide'}]",O6-Benzylguanine and Temozolomide With MGMTP140K Genetically Modified Blood Stem Cells in Untreated Glioblastoma,7582
0,NCT02296918,Phase I,"Active, not recruiting","[{'id': 3477, 'therapyName': 'Acalabrutinib + Obinutuzumab'}]",ACP-196 in Combination With Obinutuzumab in Relapsed/Refractory or Untreated CLL/SLL/PLL,7305
1,NCT02631577,Phase I,Suspended,"[{'id': 3387, 'therapyName': 'Atezolizumab + lenalidomide + Obinutuzumab'}]",A Study Evaluating the Safety and Efficacy of Atezolizumab in Combination With Obinutuzumab Plus Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma,7305
2,NCT02846623,Phase II,Recruiting,"[{'id': 1975, 'therapyName': 'Atezolizumab + Obinutuzumab'}]",Atezolizumab (PD-L1 mAb) in Combination With Obinutuzumab and Ibrutinib in Patients With Relapsed Refractory or High-risk Untreated Chronic Lymphocytic Leukemia (CLL),7305
3,NCT02596971,Phase I,Recruiting,"[{'id': 1975, 'therapyName': 'Atezolizumab + Obinutuzumab'}, {'id': 3266, 'therapyName': 'Cyclophosphamide + Doxorubicin + Prednisone + Vincristine '}, {'id': 1231, 'therapyName': 'Bendamustine'}]",Safety and Efficacy of MPDL3280A in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus CHOP in Patients With Follicular Lymphoma or Diffuse Large B-Cell Lymphoma,7305
4,NCT02220842,Phase I,Recruiting,"[{'id': 1975, 'therapyName': 'Atezolizumab + Obinutuzumab'}]",A Safety and Pharmacology Study of MPDL3280A Administered With Obinutuzumab in Patients With Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma,7305
5,NCT02174172,Phase I,Recruiting,"[{'id': 6252, 'therapyName': 'Atezolizumab + Bevacizumab +Peg-interferon alfa-2a'}, {'id': 6253, 'therapyName': 'Atezolizumab + Interferon alfa-2b'}, {'id': 6250, 'therapyName': 'Atezolizumab + Peg-interferon alfa-2a'}, {'id': 6249, 'therapyName': 'Atezolizumab + Ipilimumab'}, {'id': 1975, 'therapyName': 'Atezolizumab + Obinutuzumab'}]",A Study to Assess the Safety and Tolerability of MPDL3280A in Combination With Other Immune-modulating Therapies in Patients With Locally Advanced or Metastatic Solid Tumors,7305
6,NCT02729896,Phase Ib/II,Recruiting,"[{'id': 4362, 'therapyName': 'Atezolizumab + Obinutuzumab + Polatuzumab Vedotin'}]","A Study of Obinutuzumab, Polatuzumab Vedotin, and Atezolizumab in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)",7305
7,NCT01671904,Phase I,"Active, not recruiting","[{'id': 3638, 'therapyName': 'Bendamustine + GDC-0199 + Obinutuzumab'}, {'id': 3637, 'therapyName': 'Bendamustine + GDC-0199 + Rituximab'}]","A Study of Venetoclax (GDC-0199, ABT-199) in Combination With Bendamustine And MabThera/Rituxan in Participants With Chronic Lymphocytic Leukemia",7305
8,NCT03039114,Phase I,Recruiting,"[{'id': 6260, 'therapyName': 'Bendamustine + INCB050465 + Obinutuzumab'}]",Study Evaluating Safety and Efficacy of INCB050465 Combined With Bendamustine and Obinutuzumab in Relapsed or Refractory Follicular Lymphoma (CITADEL-102),7305
9,NCT02569476,Phase I,Recruiting,"[{'id': 4682, 'therapyName': 'BGB-3111 + Obinutuzumab'}]",BGB 3111 in Combination With Obinutuzumab in Subjects With B-Cell Lymphoid Malignancies,7305
10,NCT02100852,Phase I,"Active, not recruiting","[{'id': 2342, 'therapyName': 'Chlorambucil + Obinutuzumab + TGR-1202'}]","TGR-1202, a PI3K Delta Inhibitor, in Combination With Obinutuzumab and Chlorambucil in Patients With Chronic Lymphocytic Leukemia (CLL)",7305
11,NCT02629809,Phase II,Recruiting,"[{'id': 3628, 'therapyName': 'Allopurinol'}, {'id': 3627, 'therapyName': 'Cyclophosphamide + Fludarabine + Obinutuzumab'}, {'id': 768, 'therapyName': 'Ibrutinib'}]","First-line Therapy With Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (GA-101) (iFCG) for Patients With Chronic Lymphocytic Leukemia (CLL)",7305
12,NCT02292225,Phase I,Terminated,"[{'id': 2341, 'therapyName': 'Duvelisib + Obinutuzumab'}]",IPI-145 With Obinutuzumab in Patients With CLL/SLL Previously Treated With a BTKi,7305
13,NCT02427451,Phase Ib/II,"Active, not recruiting","[{'id': 3472, 'therapyName': 'GDC-0199 + Ibrutinib + Obinutuzumab'}]","Bcl-2 Inhibitor GDC-0199 in Combination With Obinutuzumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or Previously Untreated Chronic Lymphocytic Leukemia",7305
14,NCT02242942,Phase III,"Active, not recruiting","[{'id': 1648, 'therapyName': 'Obinutuzumab + Chlorambucil'}, {'id': 3636, 'therapyName': 'GDC-0199 + Obinutuzumab'}]",A Study to Compare the Efficacy and Safety of Obinutuzumab + GDC-0199 Versus Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemia,7305
15,NCT01685892,Phase I,"Active, not recruiting","[{'id': 3636, 'therapyName': 'GDC-0199 + Obinutuzumab'}]",A Study of Venetoclax (GDC-0199; ABT-199) in Combination With Obinutuzumab in Participants With Chronic Lymphocytic Leukemia,7305
16,NCT03223610,Phase I,Not yet recruiting,"[{'id': 6189, 'therapyName': 'Ibrutinib + Lenalidomide + Obinutuzumab + Prednisone + Venetoclax'}]","Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma",7305
17,NCT02315768,Phase Ib/II,Recruiting,"[{'id': 3476, 'therapyName': 'Ibrutinib + Obinutuzumab'}]",Ibrutinib in Combination With GA101 (Obinutuzumab) in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Patients.,7305
18,NCT02736617,Phase II,Recruiting,"[{'id': 3476, 'therapyName': 'Ibrutinib + Obinutuzumab'}]",Obinutuzumab in Combination With Ibrutinib in Treating Patients With Relapsed Mantle Cell Lymphoma,7305
19,NCT02611908,Phase I,Recruiting,"[{'id': 3476, 'therapyName': 'Ibrutinib + Obinutuzumab'}]",Obinutuzumab With High-dose Ibrutinib for the Treatment of Patients With Chronic Lymphocytic Leukemia With Progressive Disease on Single Agent Ibrutinib.,7305
20,NCT02537613,Phase I,Recruiting,"[{'id': 3476, 'therapyName': 'Ibrutinib + Obinutuzumab'}]",A Study of Ibrutinib + Obinutuzumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia,7305
21,NCT02624986,Phase Ib/II,Recruiting,"[{'id': 4393, 'therapyName': 'Idasanutlin + Obinutuzumab'}]",A Study of Obinutuzumab With Idasanutlin in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL),7305
22,NCT03135262,Phase Ib/II,Recruiting,"[{'id': 5646, 'therapyName': 'Idasanutlin + Rituximab + Venetoclax'}, {'id': 5644, 'therapyName': 'Idasanutlin + Obinutuzumab + Venetoclax'}, {'id': 5645, 'therapyName': 'Idasanutlin + Obinutuzumab + Rituximab + Venetoclax'}]",A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large B-Cell Lymphoma (DLBCL),7305
23,NCT01980875,Phase III,Terminated,"[{'id': 1647, 'therapyName': 'Idelalisib + Obinutuzumab'}, {'id': 1648, 'therapyName': 'Obinutuzumab + Chlorambucil'}]",Efficacy and Safety of Idelalisib in Combination With Obinutuzumab Compared to Chlorambucil in Combination With Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia,7305
24,NCT03269669,Phase II,Recruiting,"[{'id': 6257, 'therapyName': 'Obinutuzumab + CHOP'}, {'id': 6302, 'therapyName': 'Lenalidomide + Obinutuzumab\t'}, {'id': 6301, 'therapyName': 'Obinutuzumab + TGR-1202'}, {'id': 2188, 'therapyName': 'Prednisone'}]","Obinutuzumab With or Without PI3K-delta Inhibitor TGR-1202, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma",7305
25,NCT02600897,Phase Ib/II,Recruiting,"[{'id': 4394, 'therapyName': 'lenalidomide + Obinutuzumab + Polatuzumab Vedotin'}]","A Study of Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)",7305
26,NCT02992522,Phase I,Recruiting,"[{'id': 5133, 'therapyName': 'Lenalidomide + Obinutuzumab + Venetoclax'}]","Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma",7305
27,NCT02406742,Phase Ib/II,Recruiting,"[{'id': 1646, 'therapyName': 'Obinutuzumab'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 768, 'therapyName': 'Ibrutinib'}, {'id': 2358, 'therapyName': 'CC-122'}]","A Phase 1/2, Open-label, Dose Finding Study to Evaluate CC-122 in Combination With Rituximab, Ibrutinib and Obinutuzumab in Subjects With Relapsed/Refractory CLL/SLL (ENHANCE)",7305
28,NCT01992653,Phase I,"Active, not recruiting","[{'id': 4248, 'therapyName': 'Cyclophosphamide + Doxorubicin + Prednisone'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 4226, 'therapyName': 'Polatuzumab Vedotin'}, {'id': 1646, 'therapyName': 'Obinutuzumab'}]","A Study of Polatuzumab Vedotin in Combination With Rituximab or Obinutuzumab, Cyclophosphamide, Doxorubicin, and Prednisone in Participants With B-Cell Non-Hodgkin's Lymphoma",7305
29,NCT02257567,Phase Ib/II,"Active, not recruiting","[{'id': 2323, 'therapyName': 'Bendamustine + Rituximab'}, {'id': 4226, 'therapyName': 'Polatuzumab Vedotin'}, {'id': 1646, 'therapyName': 'Obinutuzumab'}]",A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma,7305
30,NCT02055820,Phase I,"Active, not recruiting","[{'id': 1562, 'therapyName': 'Venetoclax'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 3266, 'therapyName': 'Cyclophosphamide + Doxorubicin + Prednisone + Vincristine '}, {'id': 1646, 'therapyName': 'Obinutuzumab'}]",A Safety and Pharmacokinetics Study of GDC-0199 (ABT-199) in Patients With Non-Hodgkin's Lymphoma,7305
31,NCT02475681,Phase III,"Active, not recruiting","[{'id': 1605, 'therapyName': 'Acalabrutinib'}, {'id': 3035, 'therapyName': 'Chlorambucil'}, {'id': 1646, 'therapyName': 'Obinutuzumab'}]","Elevate CLL TN: Study of Obinutuzumab + Chlorambucil, ACP-196 + Obinutuzumab, and ACP-196 in Subjects With Previously Untreated CLL",7305
32,NCT02612311,Phase III,Recruiting,"[{'id': 2287, 'therapyName': 'Ublituximab'}, {'id': 1648, 'therapyName': 'Obinutuzumab + Chlorambucil'}, {'id': 2022, 'therapyName': 'TGR-1202'}]",Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemia,7305
33,NCT01644253,Phase I,Recruiting,"[{'id': 4745, 'therapyName': 'Idelalisib + Otlertuzumab + Rituximab'}, {'id': 4742, 'therapyName': 'Otlertuzumab + Rituximab'}, {'id': 4743, 'therapyName': 'Obinutuzumab + Otlertuzumab'}, {'id': 4744, 'therapyName': 'Ibrutinib + Otlertuzumab'}]","Phase 1b Safety and Efficacy Study of TRU-016 and Rituximab, Obinutuzumab, Idelalisib, or Ibrutinib in Chronic Lymphocytic Leukemia",7305
34,NCT01691898,Phase Ib/II,"Active, not recruiting","[{'id': 4415, 'therapyName': 'Obinutuzumab + Pinatuzumab Vedotin + Rituximab'}, {'id': 4416, 'therapyName': 'Polatuzumab Vedotin + Pinatuzumab Vedotin + Rituximab'}, {'id': 4417, 'therapyName': 'Obinutuzumab + Polatuzumab Vedotin'}]",A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or Obinutuzumab in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (ROMULUS),7305
35,NCT02611323,Phase Ib/II,Recruiting,"[{'id': 4227, 'therapyName': 'Obinutuzumab + Polatuzumab Vedotin + Venetoclax'}]","A Study of Obinutuzumab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)",7305
36,NCT03075696,Phase I,Recruiting,"[{'id': 6162, 'therapyName': 'Obinutuzumab + RO7082859 + Tocilizumab'}]","A Dose Escalation Study of RO7082859, Administered After a Fixed, Single Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma",7305
37,NCT03063762,Phase I,Recruiting,"[{'id': 5365, 'therapyName': 'RO6874281 + Obinutuzumab + Atezolizumab'}, {'id': 5366, 'therapyName': 'RO6874281 + Obinutuzumab + Atezolizumab + Bevacizumab'}]","Study to Evaluate Safety, Pharmacokinetics and Therapeutic Activity of RO6874281 as a Combination Therapy in Participants With Unresectable Advanced and/or Metastatic Renal Cell Carcinoma (RCC)",7305
0,NCT02414516,Phase I,Unknown status,"[{'id': 2906, 'therapyName': 'OBP-801'}]",A Dose-Escalation Study of OBP-801 in Patients With Advanced Solid Tumors,7829
0,NCT01312376,Phase I,"Active, not recruiting","[{'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1227, 'therapyName': 'CD3/CD28 costimulated vaccine-primed autologous T-cells'}, {'id': 1222, 'therapyName': 'OC-DC vaccine'}]",Autologous T-Cells Combined With Autologous OC-DC Vaccine in Ovarian Cancer,7223
0,NCT02452775,Phase I,Recruiting,"[{'id': 3008, 'therapyName': 'OC-L'}]",Autologous OC-L Vaccine and Ovarian Cancer,7905
0,NCT02799602,Phase III,Recruiting,"[{'id': 836, 'therapyName': 'ODM-201'}, {'id': 4921, 'therapyName': 'Docetaxel + ODM-201'}]",ODM-201 in Addition to Standard ADT and Docetaxel in Metastatic Castration Sensitive Prostate Cancer (ARASENS),6970
1,NCT02200614,Phase III,Recruiting,"[{'id': 836, 'therapyName': 'ODM-201'}]",Efficacy and Safety Study of ODM-201 in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer,6970
2,NCT03004534,Phase 0,Recruiting,"[{'id': 836, 'therapyName': 'ODM-201'}]",A Study to Evaluate Changes in Human Breast Cancer Tissue Following Short-Term Use of ODM-201,6970
0,NCT01286272,Phase II,"Active, not recruiting","[{'id': 3909, 'therapyName': 'Bendamustine + Ofatumumab'}, {'id': 3910, 'therapyName': 'Bendamustine + Bortezomib + Ofatumumab'}]",Ofatumumab and Bendamustine Hydrochloride With or Without Bortezomib in Treating Patients With Untreated Follicular Non-Hodgkin Lymphoma,7203
1,NCT02614508,Phase I,"Active, not recruiting","[{'id': 3630, 'therapyName': 'BKM120 + Ibrutinib'}, {'id': 3629, 'therapyName': 'BKM120 + Ofatumumab'}]",Buparlisib and Ofatumumab or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia,7203
2,NCT02135133,Phase II,Suspended,"[{'id': 2326, 'therapyName': 'Idelalisib + Ofatumumab'}]","A Study of Idelalisib (GS1101, CAL101) + Ofatumumab in Previously Untreated CLL/SLL",7203
3,NCT02004522,Phase III,"Active, not recruiting","[{'id': 1024, 'therapyName': 'Duvelisib'}, {'id': 1090, 'therapyName': 'Ofatumumab'}]",A Phase 3 Study of IPI-145 Versus Ofatumumab in Patients With Relapsed or Refractory CLL/SLL (DUO),7203
4,NCT02049515,Phase III,Enrolling by invitation,"[{'id': 1090, 'therapyName': 'Ofatumumab'}, {'id': 1024, 'therapyName': 'Duvelisib'}]",A Phase 3 Extension Study of IPI-145 and Ofatumumab in Patients With CLL/SLL Previously Enrolled in Study IPI-145-07,7203
5,NCT03136146,Phase II,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1090, 'therapyName': 'Ofatumumab'}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 1476, 'therapyName': 'Pegfilgrastim'}]","Study of Clofarabine, Etoposide, Cyclophosphamide [CEC], Liposomal Vincristine (VCR), Dexamethasone and Bortezomib in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LL)",7203
6,NCT01532700,Phase II,"Active, not recruiting","[{'id': 1091, 'therapyName': 'Ofatumumab + GSK2110183'}]", An Open-Label Phase 2 Study of Ofatumumab (Arzerra) in Combination With Oral GSK2110183 in the Treatment of Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL),7203
0,NCT01780545,Phase II,Completed,"[{'id': 1807, 'therapyName': 'OGX-427'}, {'id': 720, 'therapyName': 'Docetaxel'}]",Phase 2 Study of Docetaxel +/- OGX-427 in Patients With Relapsed or Refractory Metastatic Bladder Cancer,7343
1,NCT01681433,Phase II,Terminated,"[{'id': 2188, 'therapyName': 'Prednisone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 1807, 'therapyName': 'OGX-427'}]",OGX-427 in Metastatic Castrate-Resistant Prostate Cancer With Prostate-Specific Antigen Progression While Receiving Abiraterone,7343
2,NCT00959868,Phase I,Unknown status,"[{'id': 1807, 'therapyName': 'OGX-427'}]",A Study for Treatment of Superficial Bladder Cancer Using OGX-427,7343
0,NCT03012321,Phase II,Recruiting,"[{'id': 5226, 'therapyName': 'Abiraterone + Prednisone + Olaparib'}, {'id': 2748, 'therapyName': 'Abiraterone + Prednisone'}, {'id': 837, 'therapyName': 'Olaparib'}]","Abiraterone Acetate, Olaparib, and Prednisone in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer With DNA Repair Defects",6971
1,NCT02576444,Phase II,Recruiting,"[{'id': 3140, 'therapyName': 'MK-1775 + Olaparib'}, {'id': 837, 'therapyName': 'Olaparib'}, {'id': 3141, 'therapyName': 'Olaparib + Vistusertib'}, {'id': 3139, 'therapyName': 'AZD5363 + Olaparib'}]",OLAParib COmbinations,6971
2,NCT02264678,Phase Ib/II,Recruiting,"[{'id': 2881, 'therapyName': 'AZD6738'}, {'id': 4737, 'therapyName': 'AZD6738 + Carboplatin'}, {'id': 4738, 'therapyName': 'AZD6738 + MEDI4736'}, {'id': 4739, 'therapyName': 'AZD6738 + Olaparib'}]",Ascending Doses of AZD6738 in Combination With Chemotherapy and/or Novel Anti Cancer Agents,6971
3,NCT01623349,Phase I,"Active, not recruiting","[{'id': 2171, 'therapyName': 'BYL719 + Olaparib'}, {'id': 2170, 'therapyName': 'BKM120 + Olaparib'}]",Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer,6971
4,NCT02345265,Phase II,"Active, not recruiting","[{'id': 1971, 'therapyName': 'Cediranib + Olaparib'}]","Olaparib and Cediranib Maleate in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer",6971
5,NCT02893917,Phase II,Recruiting,"[{'id': 1971, 'therapyName': 'Cediranib + Olaparib'}, {'id': 837, 'therapyName': 'Olaparib'}]",Olaparib With or Without Cediranib in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer,6971
6,NCT02498613,Phase II,Recruiting,"[{'id': 1971, 'therapyName': 'Cediranib + Olaparib'}]",Cediranib Maleate and Olaparib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery,6971
7,NCT02340611,Phase II,Recruiting,"[{'id': 1971, 'therapyName': 'Cediranib + Olaparib'}]",A Study of Cediranib and Olaparib at the Time Ovarian Cancer Worsens on Olaparib,6971
8,NCT02681237,Phase I,Recruiting,"[{'id': 1971, 'therapyName': 'Cediranib + Olaparib'}]",A Study of Cediranib and Olaparib at Disease Worsening in Ovarian Cancer,6971
9,NCT01116648,Phase Ib/II,"Active, not recruiting","[{'id': 837, 'therapyName': 'Olaparib'}, {'id': 1971, 'therapyName': 'Cediranib + Olaparib'}]","Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer",6971
10,NCT02899728,Phase II,Suspended,"[{'id': 4728, 'therapyName': 'Carboplatin + Cisplatin + Etoposide'}, {'id': 1971, 'therapyName': 'Cediranib + Olaparib'}]","Olaparib, Cediranib Maleate, and Standard Chemotherapy in Treating Patients With Small Cell Lung Cancer",6971
11,NCT02889900,Phase II,Recruiting,"[{'id': 1971, 'therapyName': 'Cediranib + Olaparib'}]",Efficacy and Safety Study of Cediranib in Combination With Olaparib in Patients With Recurrent Platinum-Resistant Ovarian Cancer (CONCERTO),6971
12,NCT02974621,Phase II,Recruiting,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1971, 'therapyName': 'Cediranib + Olaparib'}]",Cediranib Maleate and Olaparib Compared to Bevacizumab in Treating Patients With Recurrent Glioblastoma,6971
13,NCT02121990,Phase I,"Active, not recruiting","[{'id': 1451, 'therapyName': 'Cisplatin + Paclitaxel + Bevacizumab + Olaparib '}]","Dose-Escalation Study of Intraperitoneal (IP) Cisplatin, IV/IP Paclitaxel, IV Bevacizumab, and Oral Olaparib for Newly Diagnosed Ovarian, Primary Peritoneal, and Fallopian Tube Cancer",6971
14,NCT02769962,Phase Ib/II,Recruiting,"[{'id': 4348, 'therapyName': 'CRLX101 + Olaparib'}]","Trial of CRLX101, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer",6971
15,NCT02734004,Phase Ib/II,"Active, not recruiting","[{'id': 2894, 'therapyName': 'Durvalumab + Olaparib'}]",A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors. (MEDIOLA),6971
16,NCT02484404,Phase Ib/II,Recruiting,"[{'id': 2895, 'therapyName': 'Cediranib + Durvalumab'}, {'id': 2894, 'therapyName': 'Durvalumab + Olaparib'}]",Phase 1 and 2 Study of MEDI4736 in Combination With Olaparib or Cediranib for Advanced Solid Tumors and Recurrent Ovarian Cancer,6971
17,NCT02953457,Phase Ib/II,Recruiting,"[{'id': 4949, 'therapyName': 'MEDI4736 + Olaparib + Tremelimumab'}]","Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRAC2 Mutation",6971
18,NCT03259503,Phase Ib/II,Not yet recruiting,"[{'id': 1206, 'therapyName': 'Busulfan'}, {'id': 837, 'therapyName': 'Olaparib'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 2373, 'therapyName': 'Palifermin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 3277, 'therapyName': 'Pyridoxine'}, {'id': 897, 'therapyName': 'Rituximab'}]",Olaparib Combined With High-Dose Chemotherapy for Refractory Lymphomas,6971
19,NCT03212274,Phase II,Not yet recruiting,"[{'id': 837, 'therapyName': 'Olaparib'}]","Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations",6971
20,NCT01445418,Phase I,"Active, not recruiting","[{'id': 837, 'therapyName': 'Olaparib'}, {'id': 1092, 'therapyName': 'Carboplatin'}]",AZD2281 Plus Carboplatin to Treat Breast and Ovarian Cancer,6971
21,NCT01844986,Phase III,"Active, not recruiting","[{'id': 837, 'therapyName': 'Olaparib'}]",Olaparib Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.,6971
22,NCT03233204,Phase II,Recruiting,"[{'id': 837, 'therapyName': 'Olaparib'}]","Pediatric MATCH: Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes",6971
23,NCT02588105,Phase I,Recruiting,"[{'id': 837, 'therapyName': 'Olaparib'}, {'id': 3557, 'therapyName': 'AZD0156'}]",Study to Assess the Safety and Preliminary Efficacy of AZD0156 at Increasing Doses Alone or in Combination With Other Anti-cancer Treatment in Patients With Advanced Cancer,6971
24,NCT02032823,Phase III,Recruiting,"[{'id': 837, 'therapyName': 'Olaparib'}]",Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer,6971
25,NCT03263650,Phase II,Recruiting,"[{'id': 3844, 'therapyName': 'Cabazitaxel + Carboplatin'}, {'id': 837, 'therapyName': 'Olaparib'}]",Randomized Phase II Study of Olaparib Maintenance Following Cabazitaxel-Carbo in Men With AVPC,6971
26,NCT02392676,Phase III,Withdrawn,"[{'id': 837, 'therapyName': 'Olaparib'}]",Olaparib Maintenance Treatment Versus Placebo in Patients With PSR Ovarian Cancer Who Are in CR or PR to Platinum-based Chemotherapy and Whose Tumours Carry sBRCAm or HRR-associated Genes Mutations,6971
27,NCT02485990,Phase Ib/II,Recruiting,"[{'id': 837, 'therapyName': 'Olaparib'}, {'id': 1652, 'therapyName': 'Tremelimumab'}]","Study of Tremelimumab Alone or Combined With Olaparib for Patients With Persistent EOC (Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma)",6971
28,NCT03022409,Phase I,Not yet recruiting,"[{'id': 837, 'therapyName': 'Olaparib'}, {'id': 2881, 'therapyName': 'AZD6738'}]",A Study to Investigate Biomarker Effects of Pre-Surgical Treatment With DNA Damage Repair (DDR) Agents in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC),6971
29,NCT03047135,Phase II,Recruiting,"[{'id': 837, 'therapyName': 'Olaparib'}]","Olaparib in Men With High-Risk Biochemically-Recurrent Prostate Cancer Following Radical Prostatectomy, With Integrated Biomarker Analysis",6971
30,NCT02502266,Phase II,Suspended,"[{'id': 942, 'therapyName': 'Topotecan'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 837, 'therapyName': 'Olaparib'}, {'id': 1001, 'therapyName': 'Cediranib'}]","Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",6971
31,NCT03155620,Phase II,Recruiting,"[{'id': 2683, 'therapyName': 'Tazemetostat'}, {'id': 2650, 'therapyName': 'LOXO-101'}, {'id': 1069, 'therapyName': 'LY3023414'}, {'id': 342, 'therapyName': 'Vemurafenib'}, {'id': 837, 'therapyName': 'Olaparib'}, {'id': 913, 'therapyName': 'Selumetinib'}, {'id': 961, 'therapyName': 'X-396'}]",Pediatric MATCH: Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Advanced Refractory Solid Tumors or Lymphomas,6971
32,NCT01874353,Phase III,"Active, not recruiting","[{'id': 837, 'therapyName': 'Olaparib'}]",Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy,6971
33,NCT02282020,Phase III,Recruiting,"[{'id': 837, 'therapyName': 'Olaparib'}]",Olaparib Treatment in Relapsed Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments.,6971
34,NCT02000622,Phase III,"Active, not recruiting","[{'id': 837, 'therapyName': 'Olaparib'}, {'id': 1685, 'therapyName': 'Vinorelbine'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1105, 'therapyName': 'Capecitabine'}]",Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations.,6971
35,NCT02446704,Phase Ib/II,"Active, not recruiting","[{'id': 837, 'therapyName': 'Olaparib'}, {'id': 1141, 'therapyName': 'Temozolomide'}]",Study of Olaparib and Temozolomide in Patients With Recurrent Small Cell Lung Cancer Following Failure of Prior Chemotherapy,6971
36,NCT02489006,Phase II,Recruiting,"[{'id': 837, 'therapyName': 'Olaparib'}]","A Study of Olaparib Prior to Surgery and Chemotherapy in Ovarian, Primary Peritoneal, and Fallopian Tube Cancer",6971
37,NCT03085147,,Recruiting,"[{'id': 837, 'therapyName': 'Olaparib'}]",A Dye for the Detection of Cancer of the Tongue and Mouth,6971
38,NCT01972217,Phase II,"Active, not recruiting","[{'id': 2188, 'therapyName': 'Prednisone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 837, 'therapyName': 'Olaparib'}]",Ph II Study to Evaluate Olaparib With Abiraterone in Treating Metastatic Castration Resistant Prostate Cancer,6971
39,NCT02184195,Phase III,Recruiting,"[{'id': 837, 'therapyName': 'Olaparib'}]",Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy,6971
40,NCT02983799,Phase II,Recruiting,"[{'id': 837, 'therapyName': 'Olaparib'}]",Olaparib Tablets as a Treatment for Ovarian Cancer Subjects With Different HRD Tumor Status,6971
41,NCT02987543,Phase III,Recruiting,"[{'id': 837, 'therapyName': 'Olaparib'}, {'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 1805, 'therapyName': 'Abiraterone'}]",Study of Olaparib (Lynparza) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer (PROfound Study),6971
42,NCT02511795,Phase I,Recruiting,"[{'id': 822, 'therapyName': 'MK-1775'}, {'id': 837, 'therapyName': 'Olaparib'}]",AZD1775 Combined With Olaparib in Patients With Refractory Solid Tumors,6971
43,NCT02677038,Phase II,Recruiting,"[{'id': 837, 'therapyName': 'Olaparib'}]",Ph II Olaparib for BRCAness Phenotype in Pancreatic Cancer,6971
44,NCT03079687,Expanded access,Approved for marketing,"[{'id': 837, 'therapyName': 'Olaparib'}]","Expanded Access Program for Olaparib Tablets as Maintenance Therapy in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Cancer.",6971
45,NCT02208375,Phase Ib/II,Recruiting,"[{'id': 837, 'therapyName': 'Olaparib'}, {'id': 655, 'therapyName': 'AZD5363'}, {'id': 991, 'therapyName': 'Vistusertib'}]",mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian Cancer,6971
46,NCT02446600,Phase III,Recruiting,"[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 837, 'therapyName': 'Olaparib'}, {'id': 1001, 'therapyName': 'Cediranib'}]","Olaparib or Cediranib Maleate and Olaparib Compared With Standard Platinum-Based Chemotherapy in Treating Patients With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",6971
47,NCT02693535,Phase II,Recruiting,"[{'id': 1657, 'therapyName': 'Vemurafenib + Cobimetinib'}, {'id': 890, 'therapyName': 'Regorafenib'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 690, 'therapyName': 'Bosutinib'}, {'id': 850, 'therapyName': 'Palbociclib'}, {'id': 694, 'therapyName': 'Cetuximab'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 837, 'therapyName': 'Olaparib'}, {'id': 4, 'therapyName': 'Erlotinib'}]",TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer,6971
48,NCT02476968,FDA approved,Recruiting,"[{'id': 837, 'therapyName': 'Olaparib'}]",To Assess Efficacy of Olaparib Maintenance Monotherapy at Preventing or Delaying the Return of the Cancer,6971
49,NCT02561832,Phase I,Completed,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 837, 'therapyName': 'Olaparib'}, {'id': 1092, 'therapyName': 'Carboplatin'}]","A Study to Assess the Safety, Tolerability and Efficacy of Olaparib in Combination With Carboplatin in Patients With HER-2 Negative Breast Cancer",6971
50,NCT02571725,Phase Ib/II,Recruiting,"[{'id': 1652, 'therapyName': 'Tremelimumab'}, {'id': 837, 'therapyName': 'Olaparib'}]",PARP-inhibition and CTLA-4 Blockade in BRCA-deficient Ovarian Cancer,6971
51,NCT01758731,Phase I,"Active, not recruiting","[{'id': 1999, 'therapyName': 'Olaparib + Cetuximab'}]",Study of Olaparib With Radiation Therapy and Cetuximab in Advanced Head and Neck Cancer With Heavy Smoking History,6971
52,NCT02898207,Phase I,Recruiting,"[{'id': 4729, 'therapyName': 'Olaparib + Onalespib'}]","Olaparib and Hsp90 Inhibitor AT13387 in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer",6971
53,NCT02861573,Phase I,Recruiting,"[{'id': 5343, 'therapyName': 'Dexamethasone + Docetaxel + Pembrolizumab + Prednisone'}, {'id': 5342, 'therapyName': 'Olaparib + Pembrolizumab'}, {'id': 2666, 'therapyName': 'Enzalutamide + Pembrolizumab'}]",Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365),6971
54,NCT03057145,Phase I,Recruiting,"[{'id': 5332, 'therapyName': 'Olaparib + Prexasertib'}]",Combination Study of Prexasertib and Olaparib in Patients With Advanced Solid Tumors,6971
55,NCT03008278,Phase Ib/II,Not yet recruiting,"[{'id': 5165, 'therapyName': 'Olaparib + Ramucirumab'}]",Olaparib and Ramucirumab in Treating Patients With Metastatic or Locally Recurrent Gastric or Gastroesophageal Junction Cancer That Cannot Be Removed by Surgery,6971
56,NCT03162627,Phase I,Recruiting,"[{'id': 5793, 'therapyName': 'Olaparib + Selumetinib'}]",Selumetinib and Olaparib in Solid Tumors,6971
57,NCT01858168,Phase I,Recruiting,"[{'id': 1438, 'therapyName': 'Olaparib + Temozolomide'}]",Phase I Study of Olaprib and Temozolomide for Ewings Sarcoma,6971
0,NCT03283696,Phase I,Not yet recruiting,"[{'id': 6292, 'therapyName': 'Doxorubicin + Ifosfamide + Mesna + Olaratumab'}]","A Study of Olaratumab (LY3012207), Doxorubicin, and Ifosfamide in Participants With Advanced or Metastatic Soft Tissue Sarcoma",8000
1,NCT02584309,Phase II,Recruiting,"[{'id': 5153, 'therapyName': 'dexrazoxane'}, {'id': 4140, 'therapyName': 'Doxorubicin + Olaratumab'}]",Doxorubicin With Upfront Dexrazoxane Plus Olaratumab for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma,8000
2,NCT02783599,Phase I,Recruiting,"[{'id': 4140, 'therapyName': 'Doxorubicin + Olaratumab'}]",A Study of Olaratumab (LY3012207) in Participants With Soft Tissue Sarcoma,8000
3,NCT02659020,Phase Ib/II,Recruiting,"[{'id': 3269, 'therapyName': 'Olaratumab'}, {'id': 1439, 'therapyName': 'Gemcitabine + Docetaxel'}]",A Study of Olaratumab (LY3012207) in Participants With Advanced Soft Tissue Sarcoma,8000
4,NCT02451943,Phase III,"Active, not recruiting","[{'id': 3269, 'therapyName': 'Olaratumab'}, {'id': 1009, 'therapyName': 'Doxorubicin'}]",A Study of Doxorubicin Plus Olaratumab (LY3012207) in Participants With Advanced or Metastatic Soft Tissue Sarcoma,8000
5,NCT02677116,Phase I,Recruiting,"[{'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 3618, 'therapyName': 'Irinotecan + Vincristine'}, {'id': 3269, 'therapyName': 'Olaratumab'}]",A Study of Olaratumab Alone and in Combination With Standard Chemotherapies in Children With Cancer,8000
6,NCT03086369,Phase Ib/II,Recruiting,"[{'id': 5482, 'therapyName': 'Olaratumab + nab-paclitaxel + Gemcitabine'}, {'id': 1779, 'therapyName': 'Nab-paclitaxel + Gemcitabine'}]",A Study of Nab-Paclitaxel and Gemcitabine With or Without Olaratumab (LY3012207) in Participants With Metastatic Pancreatic Cancer,8000
7,NCT03126591,Phase I,Recruiting,"[{'id': 5715, 'therapyName': 'Olaratumab + Pembrolizumab'}]",A Study of Olaratumab (LY3012207) Plus Pembrolizumab in Participants With Advanced or Metastatic Soft Tissue Sarcoma,8000
0,NCT02029417,Phase II,Terminated,"[{'id': 1794, 'therapyName': 'Omacetaxine + Cytarabine + Decitabine'}]","Omacetaxine Mepesuccinate, Cytarabine, and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia",7334
1,NCT02141477,Phase II,Terminated,"[{'id': 1762, 'therapyName': 'Omacetaxine + Decitabine'}]",Omacetaxine and Decitabine in Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndrome (MDS),7334
0,NCT03035253,Phase I,Recruiting,"[{'id': 5297, 'therapyName': 'FOLFIRI + OMP-305B83'}]",A Study of OMP-305B83 in Subjects With Metastatic Colorectal Cancer,7687
1,NCT02298387,Phase I,"Active, not recruiting","[{'id': 2732, 'therapyName': 'OMP-305B83 '}]",A Phase 1 Study of OMP-305B83 in Subjects With Solid Tumors,7687
2,NCT03030287,Phase I,Recruiting,"[{'id': 5264, 'therapyName': 'OMP-305B83 + Paclitaxel'}]","A Phase 1b Study of OMP-305B83 Plus Paclitaxel in Subjects With Ovarian, Peritoneal or Fallopian Tube Cancer",7687
0,NCT03119428,Phase I,Recruiting,"[{'id': 5696, 'therapyName': 'OMP-313M32'}]",A Study of OMP-313M32 in Subjects With Locally Advanced or Metastatic Solid Tumors,8751
0,NCT03295942,Phase I,Recruiting,"[{'id': 6264, 'therapyName': 'OMP-336B11'}]",A Study of OMP-336B11 in Subjects With Locally Advanced or Metastatic Tumors,8959
0,NCT01712217,Phase Ib/II,"Active, not recruiting","[{'id': 706, 'therapyName': 'Crizotinib'}, {'id': 645, 'therapyName': 'AT13387'}]",A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib,6851
1,NCT02572453,Phase II,Recruiting,"[{'id': 645, 'therapyName': 'AT13387'}]","AT13387 in Treating Patients With Relapsed or Refractory Anaplastic Large Cell Lymphoma, Mantle Cell Lymphoma, or Diffuse Large B-cell Lymphoma",6851
2,NCT02381535,Phase I,"Active, not recruiting","[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 645, 'therapyName': 'AT13387'}]",Hsp90 Inhibitor AT13387 in Treating Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck Receiving Radiation Therapy and Cisplatin,6851
3,NCT02474173,Phase I,Recruiting,"[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 645, 'therapyName': 'AT13387'}]",HSP90 Inhibitor AT13387 and Paclitaxel in Treating Patients With Advanced Triple Negative Breast Cancer,6851
4,NCT02503709,Phase I,Recruiting,"[{'id': 2727, 'therapyName': 'AT7519'}, {'id': 645, 'therapyName': 'AT13387'}]",Hsp90 Inhibitor AT13387 and CDKI AT7519 in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery,6851
5,NCT02097225,Phase I,Recruiting,"[{'id': 1362, 'therapyName': 'AT13387 + Dabrafenib + Trametinib'}]","Hsp90 Inhibitor AT13387, Dabrafenib, and Trametinib in Treating Patients With Recurrent Melanoma That is Metastatic or Cannot be Removed by Surgery",6851
6,NCT02535338,Phase Ib/II,Suspended,"[{'id': 3071, 'therapyName': 'Erlotinib + Onalespib'}]",Erlotinib Hydrochloride and Hsp90 Inhibitor AT13387 in Treating Patients With Recurrent or Metastatic Non-small Cell Lung Cancer,6851
7,NCT02898207,Phase I,Recruiting,"[{'id': 4729, 'therapyName': 'Olaparib + Onalespib'}]","Olaparib and Hsp90 Inhibitor AT13387 in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer",6851
8,NCT02627430,Phase I,Withdrawn,"[{'id': 3317, 'therapyName': 'Onalespib + Talazoparib'}]","Talazoparib and HSP90 Inhibitor AT13387 in Treating Patients With Metastatic Advanced Solid Tumor or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple Negative Breast Cancer",6851
0,NCT01662869,Phase III,Completed,"[{'id': 838, 'therapyName': 'Onartuzumab'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}]",A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic HER2-Negative And Met-Positive Gastroesophageal Cancer (MetGastric),6972
1,NCT01456325,Phase III,Completed,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 838, 'therapyName': 'Onartuzumab'}]",A Study of Onartuzumab (MetMAb) in Combination With Tarceva (Erlotinib) in Patients With Met Diagnostic-Positive Non-Small Cell Lung Cancer Who Have Received Chemotherapy For Advanced or Metastatic Disease (MetLung),6972
2,NCT01974258,Phase I,Withdrawn,"[{'id': 1306, 'therapyName': 'Onartuzumab + Vemurafenib'}, {'id': 1307, 'therapyName': 'Onartuzumab + Cobimetinib'}, {'id': 1308, 'therapyName': 'Onartuzumab + Cobimetinib + Vemurafenib'}]","Safety, Tolerability, and Pharmacokinetics of Onartuzumab Combined With Vemurafenib and/or Cobimetinib in Cancer Patients",6972
3,NCT01887886,Phase III,Completed,"[{'id': 1280, 'therapyName': 'Onartuzumab + Erlotinib'}]",A Study of Onartuzumab in Combination With Erlotinib in Patients With MET-Positive Stage IIIB or IV Non-Small Cell Lung Cancer Carrying an Activating EGFR Mutation,6972
4,NCT02044601,Phase Ib/II,Withdrawn,"[{'id': 1370, 'therapyName': 'Onartuzumab + Paclitaxel + Carboplatin'}, {'id': 1371, 'therapyName': 'Onartuzumab + Erlotinib + Paclitaxel + Carboplatin'}]",Biomarker-Integrated Approach of Targeted Therapy for Lung Cancer Elimination Plus External Beam Radiation Therapy (BATTLE-XRT),6972
0,NCT02525692,Phase II,Recruiting,"[{'id': 1687, 'therapyName': 'ONC201'}]",Oral ONC201 in Adult Recurrent Glioblastoma,7318
1,NCT03295396,Phase II,Not yet recruiting,"[{'id': 1687, 'therapyName': 'ONC201'}]",ONC201 in Adults With Recurrent High-grade Glioma,7318
2,NCT02250781,Phase I,Recruiting,"[{'id': 1687, 'therapyName': 'ONC201'}]",Akt/ERK Inhibitor ONC201 in Treating Patients With Advanced Solid Tumors,7318
3,NCT02324621,Phase I,Recruiting,"[{'id': 1687, 'therapyName': 'ONC201'}]",Continuation of Oral ONC201 in Treating Patients With Advanced Solid Tumors,7318
4,NCT02863991,Phase II,Recruiting,"[{'id': 1687, 'therapyName': 'ONC201'}]",Oral ONC201 in Relapsed/Refractory Multiple Myeloma,7318
5,NCT02038699,Phase Ib/II,Withdrawn,"[{'id': 1687, 'therapyName': 'ONC201'}]",A First-in-man Phase I/II Study of Oral ONC201 in Patients With Advanced Cancer,7318
6,NCT02392572,Phase Ib/II,Recruiting,"[{'id': 1687, 'therapyName': 'ONC201'}]",ONC201 in Relapsed/Refractory Acute Leukemias and High-risk Myelodysplastic Syndromes (HR-MDS),7318
7,NCT02420795,Phase Ib/II,Recruiting,"[{'id': 1687, 'therapyName': 'ONC201'}]",Study of Oral ONC201 in Patients With Relapsed/Refractory Non-Hodgkin's Lymphoma,7318
8,NCT03034200,Phase II,Recruiting,"[{'id': 1687, 'therapyName': 'ONC201'}]",Phase 2 Study of ONC201 in Neuroendocrine Tumors,7318
9,NCT03099499,Phase II,Recruiting,"[{'id': 1687, 'therapyName': 'ONC201'}]",Single Agent ONC201 in Recurrent or Metastatic Endometrial Cancer,7318
10,NCT03134131,Expanded access,Available,"[{'id': 1687, 'therapyName': 'ONC201'}]",Expanded Access Program for ONC201 to Treat Recurrent Histone H3 Mutant Glioma,7318
0,NCT03003676,Phase I,Recruiting,"[{'id': 5173, 'therapyName': 'Cyclophosphamide + ONCOS-102 + Pembrolizumab'}]","A Pilot Study of Sequential ONCOS-102, an Engineered Oncolytic Adenovirus Expressing GMCSF, and Pembrolizumab in Patients With Advanced or Unresectable Melanoma Progressing After Programmed Cell Death Protein 1 (PD1) Blockade",8590
1,NCT02963831,Phase Ib/II,Recruiting,"[{'id': 4978, 'therapyName': 'ONCOS-102 + MEDI4736'}]","A Phase 1/2 Study to Investigate the Safety, Biologic and Anti-tumor Activity of ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies",8590
0,NCT02270372,Phase I,Completed,"[{'id': 2525, 'therapyName': 'Varlilumab'}, {'id': 3051, 'therapyName': 'ONT-10'}]",Study of ONT-10 and Varlilumab to Treat Advanced Ovarian or Breast Cancer,7920
0,NCT03063944,Phase I,"Active, not recruiting","[{'id': 5794, 'therapyName': 'Decitabine + OPB-111077'}]",STAT Inhibitor OPB-111077 and Decitabine in Treating Patients With Acute Myeloid Leukemia That Is Refractory or Newly Diagnosed and Ineligible for Intensive Chemotherapy,8765
0,NCT03258593,Phase I,Not yet recruiting,"[{'id': 6291, 'therapyName': 'Durvalumab + Oportuzumab monatox'}]",Durvalumab and Vicinium in Subjects With High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated With Bacillus Calmette-Guerin (BCG),8964
1,NCT02449239,Phase III,Recruiting,"[{'id': 6290, 'therapyName': 'Oportuzumab monatox'}]",Vicinium Treatment for Subjects With Non-muscle Invasive Bladder Cancer Previously Treated With BCG,8964
0,NCT02227914,Phase Ib/II,Withdrawn,"[{'id': 2422, 'therapyName': 'Oprozomib'}, {'id': 920, 'therapyName': 'Sorafenib'}]",Phase 1b/2 Study of Oprozomib in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma,7524
0,NCT02970539,Phase I,Recruiting,"[{'id': 5032, 'therapyName': 'Oraxol + Ramucirumab'}]","Ph1b Study of Oraxol in Comb. w. Ramucirumab in Patients w. Gastric, Gastro-esophageal, or Esophageal Cancers",8595
0,NCT01959672,Phase II,Recruiting,"[{'id': 827, 'therapyName': 'Nelfinavir'}, {'id': 1189, 'therapyName': 'Oregovomab'}, {'id': 2278, 'therapyName': 'Fluorouracil + Leucovorin'}, {'id': 755, 'therapyName': 'Gemcitabine'}]",Combination Chemotherapy With or Without Oregovomab Followed by Stereotactic Body Radiation Therapy and Nelfinavir Mesylate in Treating Patients With Locally Advanced Pancreatic Cancer,7218
1,NCT01616303,Phase II,"Active, not recruiting","[{'id': 1190, 'therapyName': 'Oregovomab + Carboplatin + Paclitaxel'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]", A Controlled Study of the Effectiveness of Oregovomab (Antibody) Plus Chemotherapy in Advanced Ovarian Cancer,7218
2,NCT03162562,Phase I,Recruiting,"[{'id': 5792, 'therapyName': 'Oregovomab + poly ICLC '}]",The Safety and Antitumor Activity of the Combination of Oregovomab and Hiltonol in Recurrent Advanced Ovarian Cancer,7218
0,NCT01809691,Phase III,"Active, not recruiting","[{'id': 2671, 'therapyName': 'Orteronel '}, {'id': 1507, 'therapyName': 'Bicalutamide'}]","S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer",7640
1,NCT01990209,Phase II,Recruiting,"[{'id': 2671, 'therapyName': 'Orteronel '}]",Orteronel as Monotherapy in Patients With Metastatic Breast Cancer (MBC) That Expresses the Androgen Receptor (AR),7640
0,NCT02654587,Phase III,"Active, not recruiting","[{'id': 4327, 'therapyName': 'OSE 2101 '}, {'id': 4328, 'therapyName': 'Docetaxel + Pemetrexed'}]",Study of OSE2101 Versus Standard Treatment as 2nd or 3rd Line in HLA-A2 Positive Patients With Advanced NSCLC (ATALANTE 1),8417
0,NCT01802632,Phase Ib/II,"Active, not recruiting","[{'id': 660, 'therapyName': 'AZD9291'}]", AZD9291 First Time In Patients Ascending Dose Study,7059
1,NCT02451852,Phase I,No longer available,"[{'id': 660, 'therapyName': 'AZD9291'}]",AZD9291 US Expanded Access Program,7059
2,NCT02161770,Phase I,Completed,"[{'id': 660, 'therapyName': 'AZD9291'}]",Study to Assess the Blood Levels and Safety of AZD9291 in Patients With Advanced Solid Tumours and Normal Liver Function or Mild or Moderate Liver Impairment,7059
3,NCT02197234,Phase I,"Active, not recruiting","[{'id': 1645, 'therapyName': 'AZD9291 + Simvastatin'}, {'id': 660, 'therapyName': 'AZD9291'}]",Study to Assess the Effect of AZD9291 on the Blood Levels of Simvastatin in Patients With EGFRm+ NSCLC,7059
4,NCT02474355,Phase III,Recruiting,"[{'id': 660, 'therapyName': 'AZD9291'}]",Real World Treatment Study of AZD9291 for Advanced/Metastatic EGFR T790M Mutation NSCLC,7059
5,NCT02151981,Phase III,"Active, not recruiting","[{'id': 660, 'therapyName': 'AZD9291'}]",AZD9291 Versus Platinum-Based Doublet-Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer,7059
6,NCT02163733,Phase I,"Active, not recruiting","[{'id': 660, 'therapyName': 'AZD9291'}]",Study to Determine the Effect of Food on the Blood Levels of AZD9291 Following Oral Dosing of a Tablet Formulation in Patients With Non-Small Cell Lung Cancer,7059
7,NCT02454933,Phase III,"Active, not recruiting","[{'id': 660, 'therapyName': 'AZD9291'}, {'id': 1356, 'therapyName': 'Durvalumab'}]",Study of AZD9291 Plus MEDI4736 Versus AZD9291 Monotherapy in NSCLC After Previous EGFR TKI Therapy in T790M Mutation Positive Tumours,7059
8,NCT02971501,Phase II,Recruiting,"[{'id': 660, 'therapyName': 'AZD9291'}, {'id': 4366, 'therapyName': 'Bevacizumab + Osimertinib'}]",Osimertinib With or Without Bevacizumab in Treating Patients With EGFR Positive Non-small Cell Lung Cancer and Brain Metastases,7059
9,NCT02465060,Phase II,Recruiting,"[{'id': 660, 'therapyName': 'AZD9291'}, {'id': 3, 'therapyName': 'Dabrafenib'}, {'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 2, 'therapyName': 'Trametinib'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 623, 'therapyName': 'Afatinib'}, {'id': 654, 'therapyName': 'AZD4547'}, {'id': 958, 'therapyName': 'VS-6063'}, {'id': 765, 'therapyName': 'GSK2636771'}]",NCI-MATCH Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas,7059
10,NCT02759835,Phase II,Recruiting,"[{'id': 660, 'therapyName': 'AZD9291'}]","Local Ablative Therapy for Treatment of Oligoprogressive, EGFR-Mutated, Non-Small Cell Lung Cancer After Treatment With Osimertinib",7059
11,NCT02511106,Phase III,Recruiting,"[{'id': 660, 'therapyName': 'AZD9291'}]","AZD9291 Versus Placebo in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy",7059
12,NCT03191149,Phase II,Not yet recruiting,"[{'id': 660, 'therapyName': 'AZD9291'}]",Osimertinib in Treating Patients With Stage IIIB-IV or Recurrent Non-small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations,7059
13,NCT02228369,Phase I,"Active, not recruiting","[{'id': 660, 'therapyName': 'AZD9291'}, {'id': 2912, 'therapyName': 'AZD3759'}]","Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors, AZD3759 or AZD9291, in Patients Who Have Advanced Non-Small Cell Lung Cancer",7059
14,NCT02296125,Phase III,"Active, not recruiting","[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 660, 'therapyName': 'AZD9291'}, {'id': 751, 'therapyName': 'Gefitinib'}]",AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer,7059
15,NCT02317016,Phase I,"Active, not recruiting","[{'id': 660, 'therapyName': 'AZD9291'}, {'id': 2928, 'therapyName': 'Rosuvastatin'}]","Study to Assess the Effect of AZD9291 on the Blood Levels of Rosuvastatin, in Patients With EGFRm+ Non-small Cell Lung Cancer",7059
16,NCT02157883,Phase I,"Active, not recruiting","[{'id': 1026, 'therapyName': 'Itraconazole'}, {'id': 660, 'therapyName': 'AZD9291'}]","Study to Assess the Effect of Itraconazole (a CYP3A4 Inhibitor) on the Pharmacokinetics of AZD9291, in Patients With EGFR Positive Non-small Cell Lung Cancer. Patients Will be Chosen From Those Who Have Already Been Prescribed an EGFR TKI Medicine (Such as Iressa or Tarceva)",7059
17,NCT02197247,Phase I,"Active, not recruiting","[{'id': 1644, 'therapyName': 'AZD9291 + Rifampin'}, {'id': 660, 'therapyName': 'AZD9291'}]","Study to Assess the Effect of Rifampicin on Blood Levels and Safety of AZD9291, in Patients With EGFRm+ NSCLC",7059
18,NCT02496663,Phase I,Recruiting,"[{'id': 826, 'therapyName': 'Necitumumab'}, {'id': 660, 'therapyName': 'AZD9291'}]",EGFR Inhibitor AZD9291 and Necitumumab in Treating Patients With EGFR-Positive Stage IV or Recurrent Non-small Cell Lung Cancer Who Have Progressed on a Previous EGFR Tyrosine Kinase Inhibitor,7059
19,NCT02179671,Phase II,Completed,"[{'id': 1117, 'therapyName': 'Selumetinib + Docetaxel'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 660, 'therapyName': 'AZD9291'}, {'id': 1652, 'therapyName': 'Tremelimumab'}]","Immune-Modulated Study of Selected Small Molecules (Gefitinib, AZD9291, or Selumetinib + Docetaxel) or a 1st Immune-Mediated Therapy (IMT; Tremelimumab) With a Sequential Switch to a 2nd IMT (MEDI4736) in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer",7059
20,NCT02143466,Phase I,Recruiting,"[{'id': 2224, 'therapyName': 'AZD9291 + Savolitinib'}, {'id': 2225, 'therapyName': 'Osimertinib + Selumetinib'}, {'id': 2223, 'therapyName': 'AZD9291 + MEDI4736'}]",AZD9291 in Combination With Ascending Doses of Novel Therapeutics,7059
21,NCT02503722,Phase I,Recruiting,"[{'id': 2994, 'therapyName': 'AZD9291 + MLN0128'}]",TORC1/2 Inhibitor INK128 and EGFR Inhibitor AZD9291 in Treating Patients With Advanced EGFR Mutation Positive Non-small Cell Lung Cancer After Progression on a Previous EGFR Tyrosine Kinase Inhibitor,7059
22,NCT02803203,Phase Ib/II,Recruiting,"[{'id': 4366, 'therapyName': 'Bevacizumab + Osimertinib'}]",Osimertinib and Bevacizumab as Treatment for EGFR-mutant Lung Cancers,7059
23,NCT02954523,Phase Ib/II,Recruiting,"[{'id': 4946, 'therapyName': 'Dasatinib + Osimertinib'}]",Dasatinib and Osimertinib (AZD9291) in Advanced Non-Small Cell Lung Cancer With EGFR Mutations,7059
24,NCT03122717,Phase I,Recruiting,"[{'id': 5616, 'therapyName': 'Gefitinib + Osimertinib'}]",Osimertinib and Gefitinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer,7059
25,NCT02917993,Phase Ib/II,Recruiting,"[{'id': 4777, 'therapyName': 'INCB039110 + Osimertinib'}]",An Open-Label Phase 1/2 Study of INCB039110 in Combination With Osimertinib in Subjects With Non-Small Cell Lung Cancer,7059
26,NCT02520778,Phase I,Recruiting,"[{'id': 3065, 'therapyName': 'Navitoclax + Osimertinib'}]",EGFR Inhibitor AZD9291 and Navitoclax in Treating Patients With EGFR-Positive Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer,7059
27,NCT02789345,Phase I,Recruiting,"[{'id': 4379, 'therapyName': 'Osimertinib + Ramucirumab'}, {'id': 4380, 'therapyName': 'Necitumumab + Osimertinib'}]",A Study of Ramucirumab (LY3009806) or Necitumumab (LY3012211) Plus Osimertinib in Participants With Lung Cancer,7059
0,NCT01644253,Phase I,Recruiting,"[{'id': 4745, 'therapyName': 'Idelalisib + Otlertuzumab + Rituximab'}, {'id': 4742, 'therapyName': 'Otlertuzumab + Rituximab'}, {'id': 4743, 'therapyName': 'Obinutuzumab + Otlertuzumab'}, {'id': 4744, 'therapyName': 'Ibrutinib + Otlertuzumab'}]","Phase 1b Safety and Efficacy Study of TRU-016 and Rituximab, Obinutuzumab, Idelalisib, or Ibrutinib in Chronic Lymphocytic Leukemia",8514
0,NCT01910545,Phase I,Completed,"[{'id': 3951, 'therapyName': 'OTS167'}]",Phase 1 Study of OTS167 in Patients With Solid Tumors,8307
0,NCT02698176,Phase I,Terminated,"[{'id': 2034, 'therapyName': 'OTX015'}]",A Dose Exploration Study With MK-8628 in Participants With Selected Advanced Solid Tumors (MK-8628-006),7400
1,NCT02259114,Phase I,Completed,"[{'id': 2034, 'therapyName': 'OTX015'}]","A Phase IB Trial With OTX015, a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Patients With Selected Advanced Solid Tumors",7400
2,NCT02698189,Phase I,"Active, not recruiting","[{'id': 2034, 'therapyName': 'OTX015'}]",A Dose Exploration Study With MK-8628 in Participants With Selected Hematologic Malignancies (MK-8628-005),7400
0,NCT03050814,Phase II,Suspended,"[{'id': 1524, 'therapyName': 'Fluorouracil + Bevacizumab + Capecitabine + Leucovorin + Oxaliplatin'}, {'id': 5336, 'therapyName': 'Ad-CEA + Bevacizumab + FOLFOX'}]",Standard of Care Alone or in Combination With Ad-CEA Vaccine and Avelumab in People With Previously Untreated Metastatic Colorectal Cancer,516
1,NCT01652196,Phase II,"Active, not recruiting","[{'id': 2367, 'therapyName': 'Aflibercept + mFOLFOX-6'}]",Aflibercept and FOLFOX6 Treatment for Previously Untreated Stage IV Colorectal Cancer,516
2,NCT02923921,Phase III,Recruiting,"[{'id': 5849, 'therapyName': 'AM0010 + mFOLFOX-6'}, {'id': 5850, 'therapyName': 'mFOLFOX-6'}]",Study of AM0010 With FOLFOX Compared to FOLFOX Alone Second-line Tx in Pts With Metastatic Pancreatic Cancer,516
3,NCT02997228,Phase III,Not yet recruiting,"[{'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 1484, 'therapyName': 'Bevacizumab + Oxaliplatin + Leucovorin + Fluorouracil'}, {'id': 5126, 'therapyName': 'Bevacizumab + Atezolizumab + Fluorouracil + Leucovorin + Oxaliplatin'}]","Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Microsatellite Instability-High Metastatic Colorectal Cancer",516
4,NCT00602602,Phase II,"Active, not recruiting","[{'id': 2102, 'therapyName': 'Bevacizumab + Fluorouracil + Oxaliplatin'}, {'id': 1296, 'therapyName': 'Gemcitabine + Bevacizumab + Oxaliplatin'}, {'id': 1297, 'therapyName': 'Gemcitabine + Bevacizumab'}]","Bevacizumab, Combination Chemotherapy, and Radiation Therapy in Treating Patients Undergoing Surgery For Locally Advanced Pancreatic Cancer",516
5,NCT01442935,Phase II,"Active, not recruiting","[{'id': 1484, 'therapyName': 'Bevacizumab + Oxaliplatin + Leucovorin + Fluorouracil'}, {'id': 2180, 'therapyName': 'Cetuximab + FOLFIRI'}, {'id': 2181, 'therapyName': 'Bevacizumab + FOLFIRI'}, {'id': 2182, 'therapyName': 'Cetuximab + FOLFOX'}, {'id': 2183, 'therapyName': 'Bevacizumab + FOLFIRINOX'}, {'id': 2184, 'therapyName': 'Cetuximab + FOLFIRINOX'}]",Chemotherapies Associated With Targeted Therapies on the Resection Rate of Hepatic Metastases,516
6,NCT02754856,Phase I,Recruiting,"[{'id': 4097, 'therapyName': 'Bevacizumab + MEDI4736 + Tremelimumab + FOLFOX'}]",Tremelimumab (Anti-CTLA-4) Plus MEDI4736 (Anti-PD-L1) in Resectable Colorectal Cancer Liver Metastases.,516
7,NCT01871571,Phase II,Recruiting,"[{'id': 1484, 'therapyName': 'Bevacizumab + Oxaliplatin + Leucovorin + Fluorouracil'}]","Bevacizumab, Fluorouracil, Leucovorin Calcium, and Oxaliplatin Before Surgery in Treating Patients With Stage II-III Rectal Cancer",516
8,NCT01212822,Phase II,"Active, not recruiting","[{'id': 1484, 'therapyName': 'Bevacizumab + Oxaliplatin + Leucovorin + Fluorouracil'}]",Bevacizumab and Combination Chemotherapy Before Surgery in Treating Patients With Locally Advanced Esophageal or Stomach Cancer,516
9,NCT02141295,Phase II,Completed,"[{'id': 1484, 'therapyName': 'Bevacizumab + Oxaliplatin + Leucovorin + Fluorouracil'}, {'id': 1598, 'therapyName': 'RO5520985'}, {'id': 1599, 'therapyName': 'Bevacizumab + Fluorouracil + Leucovorin'}, {'id': 1600, 'therapyName': 'RO5520985 + Leucovorin + Fluorouracil'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}]",A Study Comparing the Efficacy and Safety of RO5520985 and FOLFOX With Bevacizumab and FOLFOX in Patients With Untreated Metastatic Colorectal Cancer (McCAVE),516
10,NCT01006369,Phase II,Completed,"[{'id': 1316, 'therapyName': 'Hydroxychloroquine'}, {'id': 1601, 'therapyName': 'Capecitabine + Oxaliplatin + Bevacizumab'}, {'id': 1484, 'therapyName': 'Bevacizumab + Oxaliplatin + Leucovorin + Fluorouracil'}]","Hydroxychloroquine, Capecitabine, Oxaliplatin, and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer",516
11,NCT01622543,Phase II,"Active, not recruiting","[{'id': 1484, 'therapyName': 'Bevacizumab + Oxaliplatin + Leucovorin + Fluorouracil'}, {'id': 893, 'therapyName': 'Reolysin'}]",Reolysin in Combination With FOLFOX6 and Bevacizumab or FOLFOX6 and Bevacizumab Alone in Metastatic Colorectal Cancer,516
12,NCT01765582,Phase II,Terminated,"[{'id': 1523, 'therapyName': 'Fluorouracil + Capecitabine + Irinotecan + Leucovorin + Oxaliplatin'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1484, 'therapyName': 'Bevacizumab + Oxaliplatin + Leucovorin + Fluorouracil'}]",STEAM: A Study of Sequential and Concurrent FOLFOXIRI/Avastin (Bevacizumab) Regimens Versus FOLFOX/Avastin in First-Line in Patients With Metastatic Colorectal Cancer,516
13,NCT02575508,Phase Ib/II,Withdrawn,"[{'id': 3142, 'therapyName': 'BGJ398 + Fluorouracil + Irinotecan + Oxaliplatin'}]",Pan FGFR Kinase Inhibitor BGJ398 and Combination Chemotherapy in Treating Patients With Untreated Metastatic Pancreatic Cancer,516
14,NCT00996385,Phase II,Unknown status,"[{'id': 3064, 'therapyName': 'Bortezomib + Oxaliplatin'}]",Velcade and Eloxatin for Patients With Malignant Pleural or Peritoneal Mesothelioma,516
15,NCT02918162,Phase II,Recruiting,"[{'id': 4776, 'therapyName': 'Capecitabine + Epirubicin + Oxaliplatin + Pembrolizumab'}]",Perioperative Chemo and Pembrolizumab in Gastric Cancer,516
16,NCT02872116,Phase III,Recruiting,"[{'id': 1597, 'therapyName': 'Capecitabine + Oxaliplatin'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}]",Efficacy Study of Nivolumab Plus Ipilimumab Against Chemotherapy Standard of Care in Stomach Cancer or Stomach/Esophagus Junction Cancer (CheckMate649),516
17,NCT02024607,Phase Ib/II,"Active, not recruiting","[{'id': 1597, 'therapyName': 'Capecitabine + Oxaliplatin'}, {'id': 2093, 'therapyName': 'BBI608 + Bevacizumab'}, {'id': 2094, 'therapyName': 'BBI608 + Regorafenib'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 2057, 'therapyName': 'BBI608'}, {'id': 1315, 'therapyName': 'FOLFIRI'}]",A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer,516
18,NCT02625610,Phase III,Recruiting,"[{'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 3144, 'therapyName': 'Avelumab'}, {'id': 1597, 'therapyName': 'Capecitabine + Oxaliplatin'}]",Avelumab in First-Line Gastric Cancer (JAVELIN Gastric 100),516
19,NCT01191697,Phase II,"Active, not recruiting","[{'id': 1596, 'therapyName': 'Trastuzumab + Bevacizumab'}, {'id': 1597, 'therapyName': 'Capecitabine + Oxaliplatin'}]","CAPOX, Bevacizumab and Trastuzumab for Patients With HER2-Positive Metastatic Esophagogastric Cancer",516
20,NCT00408772,Phase II,Withdrawn,"[{'id': 1601, 'therapyName': 'Capecitabine + Oxaliplatin + Bevacizumab'}]","Oxaliplatin, Capecitabine, and Bevacizumab Followed By Surgery and/or Radiofrequency Ablation in Treating Patients With Colorectal Cancer That Has Spread to the Liver and Cannot Be Removed By Surgery",516
21,NCT01208103,Phase II,"Active, not recruiting","[{'id': 1601, 'therapyName': 'Capecitabine + Oxaliplatin + Bevacizumab'}]",Bevacizumab With Capecitabine and Oxaliplatin in Advanced Adenocarcinoma of the Small Bowel or Ampulla of Vater,516
22,NCT03111732,Phase II,Recruiting,"[{'id': 5549, 'therapyName': 'Capecitabine + Oxaliplatin + Pembrolizumab'}]","Pembrolizumab, a Monoclonal Antibody Against PD-1, in Combination With Capecitabine and Oxaliplatin (CAPOX) in People With Advanced Biliary Tract Carcinoma (BTC)",516
23,NCT01703390,Phase II,Unknown status,"[{'id': 2182, 'therapyName': 'Cetuximab + FOLFOX'}, {'id': 2180, 'therapyName': 'Cetuximab + FOLFIRI'}]",Biomarker Directed Treatment in Metastatic Colorectal Cancer,516
24,NCT03152370,Phase I,Recruiting,"[{'id': 5798, 'therapyName': 'E7046 + mFOLFOX-6'}, {'id': 5805, 'therapyName': 'Capecitabine + E7046'}]",Preoperative Radiotherapy and E7046 in Rectum Cancer (PRAER 1),516
25,NCT02620800,Phase Ib/II,Recruiting,"[{'id': 3621, 'therapyName': 'FABLOx'}]","Study of 5-fluorouracil (5-FU), Nab-paclitaxel, Bevacizumab, Leucovorin, and Oxaliplatin in Patients With Metastatic Pancreatic Cancer",516
26,NCT01383538,Phase I,Completed,"[{'id': 2498, 'therapyName': 'Fluorouracil + Leucovorin + Irinotecan + Oxaliplatin + Saridegib'}]",FOLFIRINOX Plus IPI-926 for Advanced Pancreatic Adenocarcinoma,516
27,NCT01485744,Phase I,"Active, not recruiting","[{'id': 1903, 'therapyName': 'FOLFIRINOX'}, {'id': 1428, 'therapyName': 'Sonidegib'}]","LDE225 With Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan for Untreated Advanced Pancreatic Cancer",516
28,NCT01821729,Phase II,Recruiting,"[{'id': 1903, 'therapyName': 'FOLFIRINOX'}, {'id': 2998, 'therapyName': 'Losartan'}]",Proton w/FOLFIRINOX-Losartan for Pancreatic Cancer,516
29,NCT01928290,Phase II,Recruiting,"[{'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 1903, 'therapyName': 'FOLFIRINOX'}]","Combination Chemotherapy in Treating Patients With Advanced Stomach, Gastroesophageal, or Esophageal Cancer",516
30,NCT01896869,Phase II,Suspended,"[{'id': 1903, 'therapyName': 'FOLFIRINOX'}, {'id': 779, 'therapyName': 'Ipilimumab'}]","A Phase 2, Multicenter Study of FOLFIRINOX Followed by Ipilimumab With Allogenic GM-CSF Transfected Pancreatic Tumor Vaccine in the Treatment of Metastatic Pancreatic Cancer",516
31,NCT02581215,Phase II,Recruiting,"[{'id': 886, 'therapyName': 'Ramucirumab'}, {'id': 1903, 'therapyName': 'FOLFIRINOX'}]",Phase II Randomized Trial of FOLFIRINOX +/- Ramucirumab in Advanced Pancreatic Cancer,516
32,NCT01936974,Phase II,Terminated,"[{'id': 1295, 'therapyName': 'Gemcitabine + Bevacizumab + Cisplatin'}, {'id': 1296, 'therapyName': 'Gemcitabine + Bevacizumab + Oxaliplatin'}, {'id': 1294, 'therapyName': 'Gemcitabine + Bevacizumab + Carboplatin'}, {'id': 1297, 'therapyName': 'Gemcitabine + Bevacizumab'}]","(PGA) for Platinum-resistant/Refractory, Paclitaxel-Pretreated Recurrent Ovarian and Peritoneal Carcinoma",516
33,NCT02105350,Phase I,Suspended,"[{'id': 2210, 'therapyName': 'Gemcitabine + MEK162 + Oxaliplatin'}]",A Study of MEK162 With Gemcitabine and Oxaliplatin in Biliary Cancer,516
34,NCT03193190,Phase Ib/II,Recruiting,"[{'id': 5942, 'therapyName': 'Atezolizumab + BKT140'}, {'id': 5940, 'therapyName': 'Gemcitabine + Nab-Paclitaxel + mFOLFOX-6'}, {'id': 5941, 'therapyName': 'Atezolizumab + PEGPH20'}, {'id': 1343, 'therapyName': 'Atezolizumab + Cobimetinib'}]",A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (PDAC),516
35,NCT02181218,Phase I,Recruiting,"[{'id': 1476, 'therapyName': 'Pegfilgrastim'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1611, 'therapyName': 'Gemcitabine + Oxaliplatin + Dexamethasone'}]","Phase I Study of Romidepsin, Gemcitabine, Oxaliplatin, and Dexamethasone in Patients With Relapsed/Refractory Aggressive Lymphomas",516
36,NCT02951156,Phase III,Recruiting,"[{'id': 5088, 'therapyName': 'Avelumab + Azacitidine + Utomilumab'}, {'id': 5087, 'therapyName': 'Avelumab + Rituximab + Utomilumab'}, {'id': 2323, 'therapyName': 'Bendamustine + Rituximab'}, {'id': 5090, 'therapyName': 'Gemcitabine + Oxaliplatin + Rituximab'}, {'id': 5089, 'therapyName': 'Avelumab + Bendamustine + Rituximab'}]","Avelumab In Combination Regimens That Include An Immune Agonist, Epigenetic Modulator, CD20 Antagonist and/or Conventional Chemotherapy in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)",516
37,NCT03085914,Phase Ib/II,Recruiting,"[{'id': 5483, 'therapyName': 'INCB024360 + Nivolumab + mFOLFOX6'}, {'id': 5484, 'therapyName': 'INCB024360 + Nivolumab + Gemcitabine + nab-paclitaxel'}, {'id': 5485, 'therapyName': 'INCB024360 + Pembrolizumab + Carboplatin + Paclitaxel'}, {'id': 5486, 'therapyName': 'INCB024360 + Pembrolizumab + Carboplatin + Pemetrexed'}, {'id': 5487, 'therapyName': 'INCB024360 + Pembrolizumab + Cyclophosphamide'}]",A Study of Epacadostat in Combination With a PD-1 Inhibitor and Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors (ECHO-207),516
38,NCT00871169,Phase II,Completed,"[{'id': 1919, 'therapyName': 'Irinotecan + Oxaliplatin + Cetuximab'}]","Combination of Irinotecan, Oxaliplatin and Cetuximab for Locally Advanced or Metastatic Pancreatic Cancer",516
39,NCT00790816,Phase I,Completed,"[{'id': 1410, 'therapyName': 'Lapatinib + Paclitaxel'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 1414, 'therapyName': 'Trastuzumab + Lapatinib'}, {'id': 1399, 'therapyName': 'Lapatinib + Capecitabine'}, {'id': 1497, 'therapyName': 'Lapatinib + Letrozole'}, {'id': 1498, 'therapyName': 'Lapatinib + Oxaliplatin + Capecitabine'}, {'id': 1499, 'therapyName': 'Lapatinib + Gemcitabine'}, {'id': 1500, 'therapyName': 'Lapatinib + Docetaxel'}, {'id': 1501, 'therapyName': 'Lapatinib + Oxaliplatin + Leucovorin + Fluorouracil'}, {'id': 1502, 'therapyName': 'Lapatinib + Irinotecan + Leucovorin + Fluorouracil'}]",Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents,516
40,NCT02041481,Phase I,"Active, not recruiting","[{'id': 2217, 'therapyName': 'MEK162 + FOLFOX'}]","MEK Inhibitor MEK162 in Combination With Leucovorin Calcium, Fluorouracil, and Oxaliplatin in Treating Patients With Advanced Metastatic Colorectal Cancer",516
41,NCT03281369,Phase Ib/II,Not yet recruiting,"[{'id': 1343, 'therapyName': 'Atezolizumab + Cobimetinib'}, {'id': 6274, 'therapyName': 'mFOLFOX-6 + Atezolizumab + Cobimetinib'}, {'id': 6275, 'therapyName': 'mFOLFOX-6 + Atezolizumab'}, {'id': 6276, 'therapyName': 'Atezolizumab + Linagliptin'}, {'id': 5941, 'therapyName': 'Atezolizumab + PEGPH20'}, {'id': 5942, 'therapyName': 'Atezolizumab + BKT140'}, {'id': 1721, 'therapyName': 'Ramucirumab + Paclitaxel'}, {'id': 5850, 'therapyName': 'mFOLFOX-6'}]",A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) (UMBRELLA),516
42,NCT01206530,Phase Ib/II,"Active, not recruiting","[{'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1316, 'therapyName': 'Hydroxychloroquine'}]",FOLFOX/Bevacizumab/Hydroxychloroquine (HCQ) in Colorectal Cancer,516
43,NCT02213289,Phase Ib/II,Recruiting,"[{'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 1913, 'therapyName': 'FOLTAX'}, {'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 1315, 'therapyName': 'FOLFIRI'}, {'id': 629, 'therapyName': 'AMG102'}]",PANGEA-IMBBP: Personalized Antibodies for Gastro-Esophageal Adenocarcinoma - A 1st Pilot Metastatic Trial of Biologics Beyond Progression,516
44,NCT02046538,Phase II,Withdrawn,"[{'id': 1315, 'therapyName': 'FOLFIRI'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 624, 'therapyName': 'Aflibercept'}]",Phase II Study of Zaltrap and Chemotherapy for Advanced Resectable Colorectal Cancer,516
45,NCT02730546,Phase Ib/II,Suspended,"[{'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]","Pembrolizumab, Combination Chemotherapy, and Radiation Therapy Before Surgery in Treating Adult Patients With Locally Advanced Gastroesophageal Junction or Gastric Cardia Cancer That Can Be Removed by Surgery",516
46,NCT01662869,Phase III,Completed,"[{'id': 838, 'therapyName': 'Onartuzumab'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}]",A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic HER2-Negative And Met-Positive Gastroesophageal Cancer (MetGastric),516
47,NCT01260415,Phase II,Completed,"[{'id': 845, 'therapyName': 'Panitumumab'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 1315, 'therapyName': 'FOLFIRI'}]",A Study of Perioperative Chemotherapy Plus Panitumumab in Patients With Colorectal Cancer Liver Metastases,516
48,NCT02912559,Phase III,Recruiting,"[{'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}]",Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair or Microsatellite Instability,516
49,NCT01586611,Phase III,Unknown status,"[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}]",A Study to See if hENT1 Testing on Tumour Tissue Can Predict Response to Treatment With Gemcitabine Chemotherapy and if a Different Chemotherapy Called FOLFOX is Better Than Gemcitabine in Metastatic Pancreas Cancer,516
50,NCT02268825,Phase Ib/II,"Active, not recruiting","[{'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Phase I/IIA Study MK-3475 With Chemotherapy in Patients With Advanced GI Cancers,516
51,NCT02413853,Phase II,Withdrawn,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1083, 'therapyName': 'Pri-724'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}]",Combination Chemotherapy and Bevacizumab With or Without PRI-724 in Treating Patients With Newly Diagnosed Metastatic Colorectal Cancer,516
52,NCT01985763,Phase Ib/II,Completed,"[{'id': 757, 'therapyName': 'Genistein'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}]",Genistein in Treatment of Metastatic Colorectal Cancer,516
53,NCT02344810,Phase Ib/II,Unknown status,"[{'id': 1064, 'therapyName': 'AMG 337'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}]","C-Met Inhibitor AMG 337, Oxaliplatin, Leucovorin Calcium, and Fluorouracil in Treating Patients With Advanced Stomach or Esophageal Cancer",516
54,NCT01327612,Phase II,"Active, not recruiting","[{'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 746, 'therapyName': 'Ganitumab'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1458, 'therapyName': 'Conatumumab'}]",Open Label Extension Study of Conatumumab and AMG 479,516
55,NCT02009449,Phase I,"Active, not recruiting","[{'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 2621, 'therapyName': 'AM0010 '}, {'id': 619, 'therapyName': 'Abraxane'}]",A Phase 1 Study of AM0010 in Patients With Advanced Solid Tumors,516
56,NCT02921256,Phase II,Recruiting,"[{'id': 954, 'therapyName': 'Veliparib'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 4838, 'therapyName': 'Capecitabine + Veliparib'}, {'id': 1105, 'therapyName': 'Capecitabine'}]",Veliparib and Combination Chemotherapy in Treating Patient With Locally Advanced Rectal Cancer,516
57,NCT01896531,Phase II,"Active, not recruiting","[{'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 747, 'therapyName': 'Ipatasertib'}]",A Study of GDC-0068 in Combination With Fluoropyrimidine Plus Oxaliplatin in Patients With Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer,516
58,NCT02574663,Phase I,"Active, not recruiting","[{'id': 1779, 'therapyName': 'Nab-paclitaxel + Gemcitabine'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 2022, 'therapyName': 'TGR-1202'}]",TGR-1202 Alone and in Combination With Either Nab-paclitaxel + Gemcitabine or With FOLFOX in Patients With Select Relapsed or Refractory Solid Tumors,516
59,NCT02943603,Phase II,Withdrawn,"[{'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}]",A Study of Perioperative mFOLFOX6 Plus Pembrolizumab in Patients With Potentially Resectable Adenocarcinoma of the Gastroesophageal Junction (GEJ) and Stomach,516
60,NCT01362374,Phase I,"Active, not recruiting","[{'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 747, 'therapyName': 'Ipatasertib'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}]","Safety and Pharmacology Of GDC-0068 in Combination With Docetaxel, Fluoropyrimidine Plus Oxaliplatin, Paclitaxel, or Enzalutamide in Patients With Advanced Solid Tumors",516
61,NCT01747551,Phase II,"Active, not recruiting","[{'id': 624, 'therapyName': 'Aflibercept'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}]",FOLFOX +/- Ziv-Aflibercept for Esophageal and Gastric Cancer,516
62,NCT00602329,Phase II,Unknown status,"[{'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 667, 'therapyName': 'Bevacizumab'}]",MRI in Predicting Response in Patients Receiving Combination Chemotherapy and Bevacizumab For Advanced or Metastatic Colorectal Cancer,516
63,NCT02358863,Phase I,Terminated,"[{'id': 4311, 'therapyName': 'Docetaxel + Irinotecan'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 1835, 'therapyName': 'Docetaxel + Cisplatin'}, {'id': 1406, 'therapyName': 'Camptosar + Cisplatin'}, {'id': 4310, 'therapyName': 'Epirubicin + Docetaxel'}, {'id': 4309, 'therapyName': 'Capecitabine + Docetaxel'}]",Molecularly Tailored Therapy for Patients With Metastatic Cancer of the Esophagus and Stomach (mEGA),516
64,NCT01516216,Phase II,"Active, not recruiting","[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}]",Study of Vitamin D in Untreated Metastatic Colorectal Cancer,516
65,NCT01489865,Phase Ib/II,Recruiting,"[{'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 954, 'therapyName': 'Veliparib'}]",ABT-888 With Modified FOLFOX6 in Patients With Metastatic Pancreatic Cancer,516
66,NCT02375672,Phase II,"Active, not recruiting","[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}]",Study of Pembrolizumab in Combination With Chemotherapy for Patients With Advanced Colorectal Cancer,516
67,NCT01571024,Phase I,Completed,"[{'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 680, 'therapyName': 'BKM120'}]", BKM120 + mFOLFOX6 in Advanced Solid Tumors With Expansion Cohort Pancreatic Cancer,516
68,NCT01420874,Phase I,"Active, not recruiting","[{'id': 1012, 'therapyName': 'EGFRBi-armed autologous activated T cells'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}]",Anti-CD3 x Anti-Erbitux Armed Activated T Cells (Phase Ib) for Gastrointestinal (GI Cancer),516
69,NCT02715531,Phase I,Recruiting,"[{'id': 3947, 'therapyName': 'Atezolizumab + Gemcitabine + nab-paclitaxel'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 1202, 'therapyName': 'Atezolizumab + Bevacizumab + Capecitabine'}]",A Study of the Safety and Tolerability of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors,516
70,NCT01666730,Phase II,Recruiting,"[{'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 1031, 'therapyName': 'Metformin'}]",Metformin Plus Modified FOLFOX 6 in Metastatic Pancreatic Cancer,516
71,NCT01803282,Phase I,Recruiting,"[{'id': 3320, 'therapyName': 'GS-5745'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 1602, 'therapyName': 'Carboplatin + Pemetrexed'}, {'id': 1315, 'therapyName': 'FOLFIRI'}, {'id': 1779, 'therapyName': 'Nab-paclitaxel + Gemcitabine'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 667, 'therapyName': 'Bevacizumab'}]",Safety and Tolerability Study in Solid Tumors,516
72,NCT02319018,Phase I,"Active, not recruiting","[{'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 626, 'therapyName': 'Alisertib'}]",Alisertib and Combination Chemotherapy in Treating Patients With Gastrointestinal Tumors,516
73,NCT02658214,Phase I,Recruiting,"[{'id': 2667, 'therapyName': 'Carboplatin + Gemcitabine'}, {'id': 2634, 'therapyName': 'Carboplatin + nab-paclitaxel'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 1791, 'therapyName': 'Carboplatin + Etoposide'}]",Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors,516
74,NCT01652976,Phase II,"Active, not recruiting","[{'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 717, 'therapyName': 'Dasatinib'}]","Phase II Study of 5-FU, Oxaliplatin Plus Dasatinib in Metastatic Pancreatic Adenocarcinoma",516
75,NCT02545504,Phase III,"Active, not recruiting","[{'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 3320, 'therapyName': 'GS-5745'}]",GS-5745 With mFOLFOX6 as First Line Treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma,516
76,NCT02563002,Phase III,Recruiting,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1315, 'therapyName': 'FOLFIRI'}, {'id': 694, 'therapyName': 'Cetuximab'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}]",Study of Pembrolizumab (MK-3475) vs Standard Therapy in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (MK-3475-177/KEYNOTE-177),516
77,NCT01213238,Phase I,"Active, not recruiting","[{'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 667, 'therapyName': 'Bevacizumab'}]","Hepatic Arterial Infusion Oxaliplatin, Capecitabine With or Without Bevacizumab",516
78,NCT02244489,Phase I,Terminated,"[{'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 823, 'therapyName': 'Momelotinib'}]",Momelotinib Combined With Capecitabine and Oxaliplatin in Adults With Relapsed/Refractory Metastatic Pancreatic Ductal Adenocarcinoma,516
79,NCT01580410,Phase II,"Active, not recruiting","[{'id': 1133, 'therapyName': 'Mitomycin C'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}]",Surgery and Oxaliplatin or Mitomycin C in Treating Patients With Tumors of the Appendix,516
80,NCT02620865,Phase Ib/II,Suspended,"[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1167, 'therapyName': 'Aldesleukin'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 1873, 'therapyName': 'Sargramostim'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 2278, 'therapyName': 'Fluorouracil + Leucovorin'}]",Bispecific Antibody Armed Activated T-cells With Aldesleukin and Sargramostim in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer,516
81,NCT01488552,Phase Ib/II,Completed,"[{'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 1315, 'therapyName': 'FOLFIRI'}, {'id': 1779, 'therapyName': 'Nab-paclitaxel + Gemcitabine'}, {'id': 1031, 'therapyName': 'Metformin'}]",Gemcitabine+Nab-paclitaxel and FOLFIRINOX and Molecular Profiling for Patients With Advanced Pancreatic Cancer,516
82,NCT01775501,Phase II,Recruiting,"[{'id': 920, 'therapyName': 'Sorafenib'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 1642, 'therapyName': 'Leucovorin'}]",Sorafenib + mFOLFOX for Hepatocellular Carcinoma,516
83,NCT03136406,Phase Ib/II,Recruiting,"[{'id': 1018, 'therapyName': 'GI-4000'}, {'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 3144, 'therapyName': 'Avelumab'}, {'id': 619, 'therapyName': 'Abraxane'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 6163, 'therapyName': 'ETBX-011'}, {'id': 3060, 'therapyName': 'ALT-803'}]",QUILT-3.039: NANT Pancreatic Cancer Vaccine: Combination Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy,516
84,NCT01061515,Phase I,Recruiting,"[{'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}]",Biweekly Intraperitoneal Oxaliplatin With Systemic Capecitabine and Bevacizumab for Patients With Peritoneal Carcinomatosis From Appendiceal or Colorectal Cancer,516
85,NCT02788201,Phase II,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1133, 'therapyName': 'Mitomycin C'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1013, 'therapyName': 'epirubicin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1137, 'therapyName': 'Bleomycin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 781, 'therapyName': 'Ixabepilone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 2950, 'therapyName': 'Estramustine'}, {'id': 1941, 'therapyName': 'Floxuridine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 1811, 'therapyName': 'Carmustine'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 953, 'therapyName': 'Vandetanib'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 4419, 'therapyName': 'Toremifine'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 2601, 'therapyName': 'Dactinomycin'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 3035, 'therapyName': 'Chlorambucil'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 342, 'therapyName': 'Vemurafenib'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 2635, 'therapyName': 'Vinblastine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 4305, 'therapyName': 'Teniposide'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 4304, 'therapyName': 'Streptozocin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1231, 'therapyName': 'Bendamustine'}, {'id': 4303, 'therapyName': 'Mechlorethamine'}, {'id': 4302, 'therapyName': 'Mitotane'}]",Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma,516
86,NCT01522989,Phase I,"Active, not recruiting","[{'id': 1703, 'therapyName': 'Palbociclib + Fluorouracil + Oxaliplatin'}]","PD-0332991, 5-FU, and Oxaliplatin for Advanced Solid Tumor Malignancies",516
87,NCT01307956,Phase II,Unknown status,"[{'id': 1986, 'therapyName': 'Panitumumab + FOLFOX'}]","Panitumumab, Combination Chemotherapy, and Radiation Therapy Before Surgery in Treating Patients With Advanced Esophageal or Gastroesophageal Junction Cancer",516
88,NCT01913639,Phase II,"Active, not recruiting","[{'id': 2014, 'therapyName': 'Regorafenib + FOLFOX'}]",FOLFOX Plus Regorafenib in Patients With Unresectable or Metastatic Esophagogastric Cancer,516
89,NCT00538005,Phase Ib/II,Unknown status,"[{'id': 2132, 'therapyName': 'Sorafenib + Bevacizumab + Oxaliplatin'}]","Sorafenib, Bevacizumab, and Oxaliplatin in Treating Patients With Metastatic Malignant Melanoma",516
0,NCT02576301,Phase Ib/II,Recruiting,"[{'id': 3524, 'therapyName': 'OXi4503'}, {'id': 3887, 'therapyName': 'Cytarabine + OXi4503'}]",Dose Escalation of OXi4503 as Single Agent and Combination With Cytarabine w/Subsequent Ph 2 Cohorts for AML and MDS,8119
0,NCT03288493,Phase I,Recruiting,"[{'id': 6280, 'therapyName': 'P-BCMA-101 CAR-T cells'}]",P-BCMA-101 Tscm CAR-T Cells in the Treatment of Patients With Multiple Myeloma (MM),8961
0,NCT02355535,Phase I,Recruiting,"[{'id': 4602, 'therapyName': 'PAC-1'}]",Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies,8493
0,NCT02661815,Phase I,"Active, not recruiting","[{'id': 3469, 'therapyName': 'ACY-1215 + Paclitaxel'}, {'id': 667, 'therapyName': 'Bevacizumab'}]","A Phase 1b Study of Weekly Paclitaxel And Oral Ricolinostat For The Treatment Of Recurrent Platinum Resistant Ovarian, Primary Peritoneal, Or Fallopian Tube Cancer",1216
1,NCT01732640,Phase Ib/II,Completed,"[{'id': 2442, 'therapyName': 'Afatinib + Carboplatin + Paclitaxel'}, {'id': 700, 'therapyName': 'Cisplatin'}]",A Phase I/II Study Afatinib/Carboplatin/Paclitaxel Induction Chemotherapy In HPV-Negative HNSCC.,1216
2,NCT02274012,Phase II,Withdrawn,"[{'id': 2441, 'therapyName': 'Afatinib + Paclitaxel'}]","Trial of Afatinib in Combination With Weekly Paclitaxel in the Second Line Treatment of HER2 Amplified Advanced Gastric, Gastroesophageal Junction and Esophageal Cancer",1216
3,NCT03165994,Phase II,Not yet recruiting,"[{'id': 5797, 'therapyName': 'APX005M + Paclitaxel + Carboplatin'}]",APX005M With Concurrent Chemoradiation for Resectable Esophageal and Gastroesophageal Junction Cancers,1216
4,NCT02366143,Phase III,"Active, not recruiting","[{'id': 2370, 'therapyName': 'Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel'}, {'id': 1489, 'therapyName': 'Nab-paclitaxel + Carboplatin + Bevacizumab'}, {'id': 1203, 'therapyName': 'Atezolizumab + Carboplatin + Paclitaxel'}]",TBAA Phase III Study of MPDL3280A (Anti-PD-L1 Antibody) in Combination With Carboplatin + Paclitaxel With or Without Bevacizumab in Patients With Stage IV Non-squamous Non-small Cell Lung Cancer,1216
5,NCT03038100,Phase III,Recruiting,"[{'id': 2370, 'therapyName': 'Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel'}, {'id': 1152, 'therapyName': 'Bevacizumab + Carboplatin + Paclitaxel'}]","A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (IMagyn050)",1216
6,NCT01633970,Phase I,"Active, not recruiting","[{'id': 1203, 'therapyName': 'Atezolizumab + Carboplatin + Paclitaxel'}, {'id': 1204, 'therapyName': 'Atezolizumab + Carboplatin + Pemetrexed'}, {'id': 1202, 'therapyName': 'Atezolizumab + Bevacizumab + Capecitabine'}]",A Phase 1b Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) in Combination With Avastin (Bevacizumab) and/or With Chemotherapy in Patients With Locally Advanced or Metastatic Solid Tumors,1216
7,NCT02883062,Phase II,Not yet recruiting,"[{'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 1203, 'therapyName': 'Atezolizumab + Carboplatin + Paclitaxel'}]","Carboplatin and Paclitaxel With or Without Atezolizumab Before Surgery in Treating Patients With Newly Diagnosed, Stage II-III Triple-Negative Breast Cancer",1216
8,NCT03125902,Phase III,Recruiting,"[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 5606, 'therapyName': 'Atezolizumab + Paclitaxel'}]",A Study of Atezolizumab and Paclitaxel Versus Placebo and Paclitaxel in Participants With Previously Untreated Locally Advanced or Metastatic Triple Negative Breast Cancer (TNBC) (IMpassion131),1216
9,NCT03181100,Phase II,Recruiting,"[{'id': 619, 'therapyName': 'Abraxane'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1343, 'therapyName': 'Atezolizumab + Cobimetinib'}, {'id': 4595, 'therapyName': 'Atezolizumab + Bevacizumab'}, {'id': 3049, 'therapyName': 'Atezolizumab + nab-paclitaxel'}, {'id': 4825, 'therapyName': 'Atezolizumab + Vemurafenib + Cobimetinib'}, {'id': 5606, 'therapyName': 'Atezolizumab + Paclitaxel'}]",Atezolizumab Combinations With Chemotherapy for Anaplastic and Poorly Differentiated Thyroid Carcinomas,1216
10,NCT03125928,Phase II,Recruiting,"[{'id': 5600, 'therapyName': 'Atezolizumab + Paclitaxel + Trastuzumab + Pertuzumab'}]","Clinical Trial of Atezolizumab With Paclitaxel, Trastuzumab, and Pertuzumab in Patients With Metastatic HER-2 Positive Breast Cancer",1216
11,NCT01625286,Phase Ib/II,"Active, not recruiting","[{'id': 2192, 'therapyName': 'AZD5363 + Paclitaxel'}]","Investigating Safety, Tolerability and Efficacy of AZD5363 When Combined With Paclitaxel in Breast Cancer Patients",1216
12,NCT02138812,Phase I,"Active, not recruiting","[{'id': 3448, 'therapyName': 'BAY1161909 + Paclitaxel'}]",Phase I Dose Escalation of Oral BAY1161909 in Combination With Intravenous Paclitaxel,1216
13,NCT02366949,Phase I,Recruiting,"[{'id': 3447, 'therapyName': 'BAY1217389 + Paclitaxel'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]",Phase I Study of Oral BAY 1217389 in Combination With Intravenous Paclitaxel,1216
14,NCT01325441,Phase Ib/II,Recruiting,"[{'id': 2586, 'therapyName': 'BBI608 + Paclitaxel'}]",A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies,1216
15,NCT02826161,Phase III,Terminated,"[{'id': 2586, 'therapyName': 'BBI608 + Paclitaxel'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]","A Study of Napabucasin (BBI-608) Plus Weekly Paclitaxel Versus Weekly Paclitaxel Alone in Patients With Advanced, Previously Treated, Non-Squamous Non-Small Cell Lung Cancer (CanStem43L)",1216
16,NCT01146795,Phase II,Terminated,"[{'id': 1152, 'therapyName': 'Bevacizumab + Carboplatin + Paclitaxel'}]",Neoadjuvant Therapy for Ovarian Cancer,1216
17,NCT02364999,Phase III,"Active, not recruiting","[{'id': 1152, 'therapyName': 'Bevacizumab + Carboplatin + Paclitaxel'}]",A Comparative Study Of PF-06439535 Plus Paclitaxel-Carboplatin And Bevacizumab Plus Paclitaxel-Carboplatin Patients With Advanced Non-Squamous NSCLC,1216
18,NCT02810457,Phase III,Recruiting,"[{'id': 1152, 'therapyName': 'Bevacizumab + Carboplatin + Paclitaxel'}]",Evaluation of FKB238 and Avastin in Patients With Advanced/Recurrent Non-squamous Non-small Cell Lung Cancer (AVANA),1216
19,NCT01239732,Phase III,Completed,"[{'id': 1152, 'therapyName': 'Bevacizumab + Carboplatin + Paclitaxel'}]",A Study of the Addition of Avastin (Bevacizumab) to Carboplatin and Paclitaxel Therapy in Patients With Ovarian Cancer,1216
20,NCT01649947,Phase II,Completed,"[{'id': 1487, 'therapyName': 'Bevacizumab + Carboplatin + Paclitaxel + Hydroxychloroquine'}, {'id': 1488, 'therapyName': 'Paclitaxel + Carboplatin + Hydroxychloroquine'}]",Modulation of Autophagy in Patients With Advanced/Recurrent Non-small Cell Lung Cancer - Phase II,1216
21,NCT02039674,Phase Ib/II,"Active, not recruiting","[{'id': 2103, 'therapyName': 'Carboplatin + Paclitaxel + Pembrolizumab'}, {'id': 2104, 'therapyName': 'Bevacizumab + Carboplatin + Paclitaxel + Pembrolizumab'}, {'id': 1602, 'therapyName': 'Carboplatin + Pemetrexed'}, {'id': 2106, 'therapyName': 'Ipilimumab + Pembrolizumab '}, {'id': 2107, 'therapyName': 'Erlotinib + Pembrolizumab '}, {'id': 2108, 'therapyName': 'Gefitinib + Pembrolizumab '}]",A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Lung Cancer (MK-3475-021/KEYNOTE-021),1216
22,NCT01959490,Phase II,Completed,"[{'id': 1486, 'therapyName': 'Bevacizumab + Doxorubicin + Cyclophosphamide + Paclitaxel '}, {'id': 1485, 'therapyName': 'Trastuzumab + Docetaxel + Carboplatin'}]",Trastuzumab or Bevacizumab With Combination Chemotherapy in Treating Patients With Stage II-III Breast Cancer,1216
23,NCT02923739,Phase II,Recruiting,"[{'id': 4836, 'therapyName': 'Bevacizumab + Emactuzumab + Paclitaxel'}, {'id': 2123, 'therapyName': 'Bevacizumab + Paclitaxel'}]","Induction Discontinuation Trial of Emactuzumab Following Paclitaxel and Bevacizumab in Patients With Platinum-Resistant, Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer - REDIRECT",1216
24,NCT02047214,Phase II,Terminated,"[{'id': 2123, 'therapyName': 'Bevacizumab + Paclitaxel'}]",Safety and Efficacy Study of TPI 287 + Avastin in Adults With Glioblastoma That Progressed Following Prior Avastin Therapy,1216
25,NCT01297452,Phase I,Completed,"[{'id': 1183, 'therapyName': 'BKM120 + Carboplatin + Paclitaxel'}]",BKM120 + Carboplatin + Paclitaxel for Patients With Advanced Solid Tumors,1216
26,NCT01572727,Phase II,Completed,"[{'id': 1545, 'therapyName': 'BKM120 + Paclitaxel'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]","A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation",1216
27,NCT01852292,Phase II,Completed,"[{'id': 1545, 'therapyName': 'BKM120 + Paclitaxel'}]",Study of Efficacy and Safety of Buparlisib (BKM120) Plus Paclitaxel Versus Placebo Plus Paclitaxel in Recurrent or Metastatic Head and Neck Cancer Previously Pre-treated With a Platinum Therapy,1216
28,NCT02051751,Phase I,Completed,"[{'id': 1379, 'therapyName': 'BYL719 + Paclitaxel'}]",A Study to Evaluate the Potential Benefit of the Addition of BYL719 to Paclitaxel in the Treatment of Breast Cancer and Head-and-neck Cancer,1216
29,NCT02124707,Phase II,Recruiting,"[{'id': 1989, 'therapyName': 'Carboplatin + Cetuximab + Paclitaxel'}]","Weekly Carboplatin, Paclitaxel and Cetuximab Treatment for Patients With Recurrent or Metastatic SCCHN",1216
30,NCT03174275,Phase II,Not yet recruiting,"[{'id': 5873, 'therapyName': 'Carboplatin + Cisplatin + Durvalumab + Paclitaxel'}, {'id': 3997, 'therapyName': 'Carboplatin + Durvalumab + Paclitaxel'}]","Carboplatin, Nab-Paclitaxel, Durvalumab Before Surgery and Adjuvant Therapy in Head and Neck Squamous Cell Carcinoma",1216
31,NCT03215706,Phase III,Recruiting,"[{'id': 6132, 'therapyName': 'Carboplatin + Cisplatin + Paclitaxel + Pemetrexed'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",A Study of Nivolumab and Ipilimumab Combined With Chemotherapy Compared to Chemotherapy by Itself as the First Treatment Given for Stage IV Non-Small Cell Lung Cancer (NSCLC) (CheckMate 9LA),1216
32,NCT02726997,Phase Ib/II,Recruiting,"[{'id': 3997, 'therapyName': 'Carboplatin + Durvalumab + Paclitaxel'}]",Matched Paired Pharmacodynamics and Feasibility Study of Durvalumab in Combination With Chemotherapy in Frontline Ovarian Cancer,1216
33,NCT02962063,Phase Ib/II,Recruiting,"[{'id': 3997, 'therapyName': 'Carboplatin + Durvalumab + Paclitaxel'}]","Durvalumab, an Anti-PD-L1 Antibody, and Chemoradiation Before Surgery for Esophageal Cancer",1216
34,NCT02684227,Phase II,Recruiting,"[{'id': 3681, 'therapyName': 'Carboplatin + Enzalutamide + Paclitaxel'}]",Enzalutamide in Combination With Carboplatin and Paclitaxel in Endometrial Cancer,1216
35,NCT01183559,Phase I,Unknown status,"[{'id': 2071, 'therapyName': 'Carboplatin + Fluorouracil + Paclitaxel + Vandetanib'}]","A Trial of ZD6474 (Zactima), Paclitaxel, Carboplatin, 5-Fluorouracil, and XRT Followed by Surgery",1216
36,NCT03206177,Phase I,Recruiting,"[{'id': 6265, 'therapyName': 'Carboplatin + Galunisertib + Paclitaxel'}]",Paclitaxel/Carboplatin + Galunisertib for Patients With Carcinosarcoma of the Uterus or Ovary,1216
37,NCT02876107,Phase II,Recruiting,"[{'id': 1977, 'therapyName': 'Doxorubicin + Cyclophosphamide'}, {'id': 3386, 'therapyName': 'Carboplatin + Paclitaxel + Panitumumab'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]",A Phase II Study of Using Panitumumab/Carboplatin/Paclitaxel (PaCT) Followed by Anthracycline-Containing Regimen (AC) for New Triple-Negative Inflammatory Breast Cancer (TN-IBC),1216
38,NCT02593175,Phase II,Recruiting,"[{'id': 3386, 'therapyName': 'Carboplatin + Paclitaxel + Panitumumab'}]","Women's Triple-Negative First-Line Study: A Phase II Trial of Panitumumab, Carboplatin and Paclitaxel (PaCT) in Patients With Localized Triple-Negative Breast Cancer (TNBC) With Tumors Predicted Insensitive to Standard Neoadjuvant Chemotherapy",1216
39,NCT03064854,Phase I,Recruiting,"[{'id': 6027, 'therapyName': 'Carboplatin + Paclitaxel + PDR001'}, {'id': 6026, 'therapyName': 'Cisplatin + Pemetrexed + PDR001'}, {'id': 6025, 'therapyName': 'Cisplatin + Gemcitabine + PDR001'}, {'id': 6024, 'therapyName': 'Pemetrexed + PDR001 + Cisplatin + Carboplatin'}]","PDR001 in Combination With Platinum-doublet Chemotherapy in PD-L1 Unselected, Metastatic NSCLC Patients (ElevatION:NSCLC-101 Trial)",1216
40,NCT02621398,Phase I,Suspended,"[{'id': 2103, 'therapyName': 'Carboplatin + Paclitaxel + Pembrolizumab'}]","Pembrolizumab, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Stage II-IIIB Non-Small Cell Lung Cancer",1216
41,NCT02549209,Phase II,Recruiting,"[{'id': 2103, 'therapyName': 'Carboplatin + Paclitaxel + Pembrolizumab'}]",Pembro/Carbo/Taxol in Endometrial Cancer,1216
42,NCT02630823,Phase I,Recruiting,"[{'id': 2103, 'therapyName': 'Carboplatin + Paclitaxel + Pembrolizumab'}]",MK-3475 Immunotherapy in Endometrial Carcinoma,1216
43,NCT02834975,Phase II,Recruiting,"[{'id': 2103, 'therapyName': 'Carboplatin + Paclitaxel + Pembrolizumab'}]","Pembrolizumab, Paclitaxel, and Carboplatin in Patients With Advanced Stage Epithelial Ovarian Cancer (EOC).",1216
44,NCT02766582,Phase II,Recruiting,"[{'id': 2103, 'therapyName': 'Carboplatin + Paclitaxel + Pembrolizumab'}]",Phase II: Pembrolizumab/Carboplatin/Taxol in Epithelial Ovary Cancer,1216
45,NCT03064490,Phase II,Recruiting,"[{'id': 2103, 'therapyName': 'Carboplatin + Paclitaxel + Pembrolizumab'}]","Pembrolizumab, Radiotherapy, and Chemotherapy in Neoadjuvant Treatment of Malignant Esophago-gastric Diseases (PROCEED)",1216
46,NCT02617849,Phase II,Recruiting,"[{'id': 2103, 'therapyName': 'Carboplatin + Paclitaxel + Pembrolizumab'}]",Pembrolizumab With Carboplatin/Paclitaxel in Patients With Metastatic Melanoma,1216
47,NCT02944396,Phase II,Recruiting,"[{'id': 5054, 'therapyName': 'Carboplatin + Paclitaxel + Pemetrexed + Veliparib'}, {'id': 5053, 'therapyName': 'Carboplatin + Paclitaxel + Pemetrexed + Nivolumab + Veliparib'}]",Study of Veliparib in Combination With Nivolumab and Platinum Doublet Chemotherapy in Participants With Metastatic or Advanced Non-Small Cell Lung Cancer (NSCLC),1216
48,NCT03206645,Phase I,Recruiting,"[{'id': 6266, 'therapyName': 'Carboplatin + Paclitaxel + PTC596'}]",PTC-596 in Women With Ovarian Cancer Receiving Neoadjuvant Chemotherapy,1216
49,NCT02269293,Phase I,Recruiting,"[{'id': 2640, 'therapyName': 'Carboplatin + Paclitaxel + Selinexor'}]","Selective Inhibitor of Nuclear Export, Selinexor (KPT-330) in Combination With Paclitaxel and Carboplatin in Patients With Advanced Ovarian or Endometrial Cancers",1216
50,NCT01912625,Phase I,Recruiting,"[{'id': 2196, 'therapyName': 'Carboplatin + Paclitaxel + Trametinib'}]","Trametinib, Combination Chemotherapy, and Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery",1216
51,NCT02789657,Phase II,Recruiting,"[{'id': 4235, 'therapyName': 'Carboplatin + Pertuzumab + Trastuzumab + Paclitaxel'}, {'id': 1977, 'therapyName': 'Doxorubicin + Cyclophosphamide'}]",BrUOG 308: Efficacy of wPCbTP and Switching to an AC in Non-responding Patients as Neoadjuvant Therapy in Clinical Stage I-III HER2-positive Breast Cancer.,1216
52,NCT01133678,Phase II,"Active, not recruiting","[{'id': 1790, 'therapyName': 'Cetuximab + Cisplatin + Paclitaxel'}, {'id': 735, 'therapyName': 'Everolimus'}]",Study in Locally Advanced Squamous Cell Carcinoma of Head and Neck,1216
53,NCT01316757,Phase II,"Active, not recruiting","[{'id': 1921, 'therapyName': 'Cetuximab + Paclitaxel + Carboplatin + Erlotinib'}]","Carboplatin, Paclitaxel, Cetuximab, and Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Head and Neck Squamous Cell Cancer",1216
54,NCT02776917,Phase I,Not yet recruiting,"[{'id': 4313, 'therapyName': 'Cirmtuzumab + Paclitaxel'}]","Study of Cirmtuzumab and Paclitaxel for Metastatic or Locally Advanced, Unresectable Breast Cancer",1216
55,NCT01822496,Phase II,Recruiting,"[{'id': 1375, 'therapyName': 'Cisplatin + Etoposide + Paclitaxel + Carboplatin + Erlotinib'}]",Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer,1216
56,NCT02124421,Phase II,Recruiting,"[{'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 1812, 'therapyName': 'Cisplatin + Paclitaxel'}]","Outcomes in CRS/HIPEC as Initial Treatment of Ovarian, Fallopian Tube and Primary Peritoneal Cancer",1216
57,NCT02121990,Phase I,"Active, not recruiting","[{'id': 1451, 'therapyName': 'Cisplatin + Paclitaxel + Bevacizumab + Olaparib '}]","Dose-Escalation Study of Intraperitoneal (IP) Cisplatin, IV/IP Paclitaxel, IV Bevacizumab, and Oral Olaparib for Newly Diagnosed Ovarian, Primary Peritoneal, and Fallopian Tube Cancer",1216
58,NCT01411410,Phase I,Completed,"[{'id': 1276, 'therapyName': 'Copanlisib + Paclitaxel'}]",Phase I Study of PI3(Phosphoinositol 3)-Kinase Inhibitor BAY80-6946 With Paclitaxel in Patients With Advanced Cancer,1216
59,NCT03193918,Phase I,Recruiting,"[{'id': 5943, 'therapyName': 'Crenolanib + Paclitaxel + Ramucirumab'}]",Study of Crenolanib With Ramucirumab and Paclitaxel for Advanced Esophagogastric Adenocarcinoma,1216
60,NCT03285607,Phase I,Not yet recruiting,"[{'id': 6236, 'therapyName': 'Cyclophosphamide + Doxorubicin + Paclitaxel + MCS110'}]","MCS110 Combined With Neoadjuvant Doxorubicin, Cyclophosphamide, and Weekly Paclitaxel in Patients With Hormone-Receptor Positive and HER2- Breast Cancer",1216
61,NCT02876302,Phase II,Recruiting,"[{'id': 4679, 'therapyName': 'Cyclophosphamide + Doxorubicin + Paclitaxel + Ruxolitinib'}]",Study Of Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative Inflammatory Breast Cancer,1216
62,NCT01106898,Phase II,Unknown status,"[{'id': 1980, 'therapyName': 'Cyclophosphamide + Paclitaxel'}, {'id': 947, 'therapyName': 'Trastuzumab'}]",Cyclophosphamide and Paclitaxel With or Without Trastuzumab in Treating Women With Stage I or Stage II Breast Cancer Who Have Undergone Surgery,1216
63,NCT01750073,Phase II,Recruiting,"[{'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 1980, 'therapyName': 'Cyclophosphamide + Paclitaxel'}]",Paclitaxel and Cyclophosphamide With or Without Trastuzumab Before Surgery in Treating Patients With Previously Untreated Stage I-III Breast Cancer,1216
64,NCT02654119,Phase II,Recruiting,"[{'id': 1898, 'therapyName': 'Cyclophosphamide + Paclitaxel + Trastuzumab '}]","Cyclophosphamide, Paclitaxel, and Trastuzumab in Treating Patients With Stage I-II HER2/Neu Positive Breast Cancer After Surgery",1216
65,NCT01440998,Phase I,"Active, not recruiting","[{'id': 1819, 'therapyName': 'Dasatinib + Paclitaxel + Carboplatin'}]","Dasatinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer",1216
66,NCT03107182,Phase II,Recruiting,"[{'id': 5581, 'therapyName': 'Dexamethasone + Diphenhydramine + Famotidine + 5FU + Hydroxyurea + Paclitaxel'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 5303, 'therapyName': 'Nivolumab + Carboplatin + Paclitaxel'}]",Oropharyngeal Tumor Induction Chemotherapy and Response-stratified Locoregional Therapy Trial in Order to Minimize Long-term Adverse Events,1216
67,NCT02013154,Phase I,Recruiting,"[{'id': 6254, 'therapyName': 'DKN-01 + Paclitaxel'}]",A Study of DKN-01 in Combination With Paclitaxel,1216
68,NCT01822613,Phase Ib/II,Completed,"[{'id': 2282, 'therapyName': 'Docetaxel + Irinotecan + Paclitaxel'}, {'id': 2283, 'therapyName': 'BYL719 + LJM716'}]",Study of Safety and Efficacy of the Combination of LJM716 and BYL719 in Patients With Previously Treated Esophageal Squamous Cell Carcinoma (ESCC),1216
69,NCT02564263,Phase III,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 2282, 'therapyName': 'Docetaxel + Irinotecan + Paclitaxel'}]",Study of Pembrolizumab (MK-3475) Versus Investigator's Choice Standard Therapy for Participants With Advanced Esophageal/Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181),1216
70,NCT02569242,Phase III,"Active, not recruiting","[{'id': 3045, 'therapyName': 'Docetaxel + Paclitaxel'}, {'id': 1312, 'therapyName': 'Nivolumab'}]",Study of Nivolumab in Unresectable Advanced or Recurrent Esophageal Cancer,1216
71,NCT00565851,Phase III,"Active, not recruiting","[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 3045, 'therapyName': 'Docetaxel + Paclitaxel'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 667, 'therapyName': 'Bevacizumab'}]","Carboplatin, Paclitaxel and Gemcitabine With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer",1216
72,NCT02101788,Phase II,Recruiting,"[{'id': 942, 'therapyName': 'Topotecan'}, {'id': 2173, 'therapyName': 'Doxil + Letrozole + Tamoxifen + Paclitaxel'}, {'id': 2, 'therapyName': 'Trametinib'}]",Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer,1216
73,NCT02631876,Phase II,Recruiting,"[{'id': 3574, 'therapyName': 'Doxil + Paclitaxel'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 3232, 'therapyName': 'IMGN853'}]","PH2 Study of IMGN853 vs Investigator's Choice of Chemo in Adults With FRa+ Adv. EOC, Primary Peritoneal or Primary Fallopian Tube Cancer",1216
74,NCT02957968,Phase II,Recruiting,"[{'id': 1495, 'therapyName': 'Paclitaxel + Doxorubicin + Cyclophosphamide'}, {'id': 5729, 'therapyName': 'Doxorubicin + Cyclophosphamide + Paclitaxel + Carboplatin'}]",Neoadj Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca,1216
75,NCT01494688,Phase I,"Active, not recruiting","[{'id': 2843, 'therapyName': 'Emactuzumab'}, {'id': 4249, 'therapyName': 'Emactuzumab + Paclitaxel'}]",A Study of RO5509554 as Monotherapy and in Combination With Paclitaxel in Patients With Advanced Solid Tumors,1216
76,NCT02689427,Phase II,Recruiting,"[{'id': 3725, 'therapyName': 'Enzalutamide + Paclitaxel'}]",Phase IIB Neoadjuvant Enzalutamide (ZT) Plus Taxol for Androgen Receptor (AR)-Positive Triple-Negative Breast Cancer (AR+ TNBC),1216
77,NCT02929576,Phase III,Withdrawn,"[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 3725, 'therapyName': 'Enzalutamide + Paclitaxel'}, {'id': 1262, 'therapyName': 'Enzalutamide'}]","Efficacy and Safety Study of Enzalutamide in Combination With Paclitaxel Chemotherapy or as Monotherapy Versus Placebo With Paclitaxel in Patients With Advanced, Diagnostic-Positive, Triple-Negative Breast Cancer (ENDEAR)",1216
78,NCT01490749,Phase I,"Active, not recruiting","[{'id': 1924, 'therapyName': 'Everolimus + Paclitaxel + Carboplatin + Cetuximab'}]",Trial of XELOX Followed by Radiation Combined With Carboplatin and RAD001 for Esophageal Cancer,1216
79,NCT02672475,Phase I,Recruiting,"[{'id': 3541, 'therapyName': 'Galunisertib + Paclitaxel'}]",Galunisertib and Paclitaxel in Treating Patients With Metastatic Androgen Receptor Negative (AR-) Triple Negative Breast Cancer,1216
80,NCT02060253,Phase I,"Active, not recruiting","[{'id': 1579, 'therapyName': 'Ganetespib + Paclitaxel + Trastuzumab'}]","Ganetespib, Paclitaxel and Trastuzumab for Advanced or Metastatic Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Breast Cancer",1216
81,NCT01862081,Phase I,Completed,"[{'id': 2321, 'therapyName': 'Docetaxel + GDC-0032 '}, {'id': 2322, 'therapyName': 'GDC-0032 + Paclitaxel'}]","A Dose-Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of GDC-0032 in Combination With Docetaxel or With Paclitaxel in Patients With HER2-negative Locally Recurrent or Metastatic Breast Cancer",1216
82,NCT02920450,Phase Ib/II,Recruiting,"[{'id': 4785, 'therapyName': 'Gedatolisib + Paclitaxel + Carboplatin'}]","Study of Paclitaxel, Carboplatin, and PF-05212384 in Advanced or Metastatic NSCLC",1216
83,NCT02562898,Phase Ib/II,Recruiting,"[{'id': 3259, 'therapyName': 'Gemcitabine + Ibrutinib + Paclitaxel'}]",Ibrutinib Combined With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer,1216
84,NCT03085914,Phase Ib/II,Recruiting,"[{'id': 5483, 'therapyName': 'INCB024360 + Nivolumab + mFOLFOX6'}, {'id': 5484, 'therapyName': 'INCB024360 + Nivolumab + Gemcitabine + nab-paclitaxel'}, {'id': 5485, 'therapyName': 'INCB024360 + Pembrolizumab + Carboplatin + Paclitaxel'}, {'id': 5486, 'therapyName': 'INCB024360 + Pembrolizumab + Carboplatin + Pemetrexed'}, {'id': 5487, 'therapyName': 'INCB024360 + Pembrolizumab + Cyclophosphamide'}]",A Study of Epacadostat in Combination With a PD-1 Inhibitor and Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors (ECHO-207),1216
85,NCT01593228,Phase III,Completed,"[{'id': 1173, 'therapyName': 'Iniparib + doxorubicin + carboplatin'}, {'id': 1172, 'therapyName': 'Iniparib + Paclitaxel'}, {'id': 1171, 'therapyName': 'Iniparib + Irinotecan'}, {'id': 1170, 'therapyName': 'Iniparib + Topotecan'}, {'id': 1169, 'therapyName': 'Iniparib + Gemcitabine + Carboplatin'}, {'id': 1168, 'therapyName': 'Iniparib'}]", Treatment Extension Study for Patients Who Have Previously Participated and Have Benefited From Iniparib in a Clinical Trial,1216
86,NCT03112590,Phase Ib/II,Recruiting,"[{'id': 5548, 'therapyName': 'Interferon gamma + Paclitaxel + Pertuzumab + Trastuzumab'}]",Phase I-II Study of Interferon-gamma in Patients With HER-2 Positive Breast Cancer,1216
87,NCT02162719,Phase II,"Active, not recruiting","[{'id': 1588, 'therapyName': 'Ipatasertib + Paclitaxel'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]",A Study of Ipatasertib (GDC-0068) in Combination With Paclitaxel as Front-line Treatment for Patients With Metastatic Triple-Negative Breast Cancer,1216
88,NCT01612351,Phase II,"Active, not recruiting","[{'id': 2477, 'therapyName': 'Lapatinib + Carboplatin + Cisplatin + Paclitaxel'}, {'id': 2476, 'therapyName': 'Lapatinib + Carboplatin + Paclitaxel'}]",Multimodality Risk Adapted Tx Including Induction Chemo for SCCHN Amenable to Transoral Surgery,1216
89,NCT00790816,Phase I,Completed,"[{'id': 1410, 'therapyName': 'Lapatinib + Paclitaxel'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 1414, 'therapyName': 'Trastuzumab + Lapatinib'}, {'id': 1399, 'therapyName': 'Lapatinib + Capecitabine'}, {'id': 1497, 'therapyName': 'Lapatinib + Letrozole'}, {'id': 1498, 'therapyName': 'Lapatinib + Oxaliplatin + Capecitabine'}, {'id': 1499, 'therapyName': 'Lapatinib + Gemcitabine'}, {'id': 1500, 'therapyName': 'Lapatinib + Docetaxel'}, {'id': 1501, 'therapyName': 'Lapatinib + Oxaliplatin + Leucovorin + Fluorouracil'}, {'id': 1502, 'therapyName': 'Lapatinib + Irinotecan + Leucovorin + Fluorouracil'}]",Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents,1216
90,NCT03056833,Phase I,Recruiting,"[{'id': 5333, 'therapyName': 'LEE011 + Carboplatin + Paclitaxel'}]",Ribociclib (Ribociclib (LEE-011)) With Platinum-based Chemotherapy in Recurrent Platinum Sensitive Ovarian Cancer,1216
91,NCT02788708,Phase I,Recruiting,"[{'id': 4236, 'therapyName': 'Lenvatinib + Paclitaxel'}]",Lenvatinib and Weekly Paclitaxel for Patients With Recurrent Endometrial or Ovarian Cancer,1216
92,NCT01831089,Phase I,Completed,"[{'id': 1196, 'therapyName': 'Lurbinectedin + Paclitaxel + Bevacizumab'}, {'id': 1197, 'therapyName': 'Lurbinectedin + Paclitaxel'}]","Phase I Study of Lurbinectedin (PM01183) in Combination With Paclitaxel, With or Without Bevacizumab, in Selected Advanced Solid Tumors",1216
93,NCT01649336,Phase I,Completed,"[{'id': 2010, 'therapyName': 'MEK162 + Paclitaxel'}]","A Study of MEK162 and Paclitaxel in Patients With Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer",1216
94,NCT02272790,Phase II,Recruiting,"[{'id': 1194, 'therapyName': 'MK-1775 + Carboplatin '}, {'id': 1279, 'therapyName': 'MK-1775 + Gemcitabine'}, {'id': 1567, 'therapyName': 'MK-1775 + Paclitaxel'}]","A Phase II Study Comparing AZD1775 + Chemotherapy Versus Chemotherapy Alone in Patients to Treat Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.",1216
95,NCT02327169,Phase I,Recruiting,"[{'id': 2175, 'therapyName': 'MLN0128 + MLN2480'}, {'id': 2176, 'therapyName': 'MLN2480 + Alisertib'}, {'id': 2177, 'therapyName': 'MLN2480 + Paclitaxel'}]",A Phase 1B Study of MLN2480 in Combination With MLN0128 or Alisertib or Paclitaxel in Adult Patients With Advanced Nonhematologic Malignancies,1216
96,NCT03101748,Phase Ib/II,Not yet recruiting,"[{'id': 3187, 'therapyName': 'Neratinib + Paclitaxel + Pertuzumab + Trastuzumab'}, {'id': 1505, 'therapyName': 'Paclitaxel + Neratinib + Doxorubicin + Cyclophosphamide'}]",3HT With Taxol for Metastatic Breast Cancer,1216
97,NCT02593708,Phase I,Unknown status,"[{'id': 3187, 'therapyName': 'Neratinib + Paclitaxel + Pertuzumab + Trastuzumab'}]","Phase1 of Neratinib+Trastuzumab, Pertuzumab, Paclitaxel in Patients With Advanced Solid Tumors/HER2+",1216
98,NCT03245892,Phase I,Recruiting,"[{'id': 5303, 'therapyName': 'Nivolumab + Carboplatin + Paclitaxel'}]",A Study of Carboplatin and Paclitaxel Chemotherapy With Nivolumab in Patients With Ovarian Cancer,1216
99,NCT03044613,Phase I,Recruiting,"[{'id': 5304, 'therapyName': 'Nivolumab + Ipilimumab + Carboplatin + Paclitaxel'}, {'id': 5303, 'therapyName': 'Nivolumab + Carboplatin + Paclitaxel'}]",Nivolumab or Nivolumab/Ipilimumab Prior to Chemoradiation Plus Nivolumab With II/III Gastro/Esophageal Cancer,1216
100,NCT03030287,Phase I,Recruiting,"[{'id': 5264, 'therapyName': 'OMP-305B83 + Paclitaxel'}]","A Phase 1b Study of OMP-305B83 Plus Paclitaxel in Subjects With Ovarian, Peritoneal or Fallopian Tube Cancer",1216
101,NCT02044601,Phase Ib/II,Withdrawn,"[{'id': 1370, 'therapyName': 'Onartuzumab + Paclitaxel + Carboplatin'}, {'id': 1371, 'therapyName': 'Onartuzumab + Erlotinib + Paclitaxel + Carboplatin'}]",Biomarker-Integrated Approach of Targeted Therapy for Lung Cancer Elimination Plus External Beam Radiation Therapy (BATTLE-XRT),1216
102,NCT01616303,Phase II,"Active, not recruiting","[{'id': 1190, 'therapyName': 'Oregovomab + Carboplatin + Paclitaxel'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]", A Controlled Study of the Effectiveness of Oregovomab (Antibody) Plus Chemotherapy in Advanced Ovarian Cancer,1216
103,NCT01501487,FDA approved,"Active, not recruiting","[{'id': 1902, 'therapyName': 'Docetaxel + Doxorubicin + Cyclophosphamide'}, {'id': 1982, 'therapyName': 'Fluorouracil + Epirubicin + Cyclophosphamide'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1476, 'therapyName': 'Pegfilgrastim'}, {'id': 1881, 'therapyName': 'Docetaxel + Cyclophosphamide'}, {'id': 1977, 'therapyName': 'Doxorubicin + Cyclophosphamide'}, {'id': 1485, 'therapyName': 'Trastuzumab + Docetaxel + Carboplatin'}, {'id': 1978, 'therapyName': 'Pertuzumab + Trastuzumab + Docetaxel'}]",MINT I Multi- Institutional Neo-adjuvant Therapy MammaPrint Project I,1216
104,NCT02073487,Phase II,Recruiting,"[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1583, 'therapyName': 'Trastuzumab emtansine + Lapatinib'}, {'id': 1414, 'therapyName': 'Trastuzumab + Lapatinib'}, {'id': 619, 'therapyName': 'Abraxane'}]",Neoadjuvant TDM1 With Lapatinib and Abraxane Compared With Trastuzumab With Lapatinib and Paclitaxel,1216
105,NCT02312804,Phase I,Withdrawn,"[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 674, 'therapyName': 'BGJ398'}]",Ph Ib/BGJ398/Cervix and Other Solid Tumors,1216
106,NCT01215136,Phase II,"Active, not recruiting","[{'id': 735, 'therapyName': 'Everolimus'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]",First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma,1216
107,NCT02389751,Phase I,"Active, not recruiting","[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 745, 'therapyName': 'Ganetespib'}]",A Study of Ganetespib in Combination With Chemoradiation,1216
108,NCT02134067,Phase I,Recruiting,"[{'id': 1400, 'therapyName': 'TAS-119'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]","Dose-escalating, Safety, Tolerability and PK Study of TAS-119 in Combination With Paclitaxel in Patients With Advanced Solid Tumors",1216
109,NCT02470585,Phase III,"Active, not recruiting","[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 954, 'therapyName': 'Veliparib'}]","Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Subjects With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",1216
110,NCT01892046,Phase I,Completed,"[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 866, 'therapyName': 'SNX-5422'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]",Safety and Pharmacology of SNX-5422 Plus Carboplatin and Paclitaxel in Subjects With Solid Tumors,1216
111,NCT02117024,Phase II,"Active, not recruiting","[{'id': 2472, 'therapyName': 'HS-110 + Cyclophosphamide'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 1685, 'therapyName': 'Vinorelbine'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]",A Phase 2 Study of Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer,1216
112,NCT02855944,Phase III,Recruiting,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 906, 'therapyName': 'Rucaparib'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]","ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients",1216
113,NCT01320592,Phase I,"Active, not recruiting","[{'id': 850, 'therapyName': 'Palbociclib'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]",PD0332991/Paclitaxel in Advanced Breast Cancer,1216
114,NCT02581943,Phase II,Suspended,"[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1092, 'therapyName': 'Carboplatin'}]",Effect of Pembrolizumab With or Without Carboplatin and Paclitaxel on Immune Response in Patients With Recurrent or Stage IIIB-IV Non-small Cell Lung Cancer,1216
115,NCT02725268,Phase II,Recruiting,"[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1282, 'therapyName': 'Sapanisertib'}, {'id': 1283, 'therapyName': 'MLN1117 + Sapanisertib'}]","Phase 2 Study of MLN0128, Combination of MLN0128 With MLN1117, Paclitaxel and Combination of MLN0128 With Paclitaxel in Women With Endometrial Cancer",1216
116,NCT01187199,Phase I,"Active, not recruiting","[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 936, 'therapyName': 'Temsirolimus'}]","Phase I Trial of Bevacizumab and Temsirolimus in Combination With 1) Carboplatin, 2) Paclitaxel, 3) Sorafenib for the Treatment of Advanced Cancer",1216
117,NCT01281176,,"Active, not recruiting","[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1092, 'therapyName': 'Carboplatin'}]",High-Dose or Low-Dose Vorinostat in Combination With Carboplatin or Paclitaxel in Treating Patients With Advanced Solid Tumors,1216
118,NCT02301988,Phase II,"Active, not recruiting","[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 747, 'therapyName': 'Ipatasertib'}]",A Study of Ipatasertib (GDC-0068) in Combination With Paclitaxel as Neoadjuvant Treatment for Patients With Early Stage Triple Negative Breast Cancer,1216
119,NCT02009449,Phase I,"Active, not recruiting","[{'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 2621, 'therapyName': 'AM0010 '}, {'id': 619, 'therapyName': 'Abraxane'}]",A Phase 1 Study of AM0010 in Patients With Advanced Solid Tumors,1216
120,NCT02419495,Phase I,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1749, 'therapyName': 'Selinexor'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 1009, 'therapyName': 'Doxorubicin'}]",Selinexor in Combination With Standard Chemotherapy,1216
121,NCT01248949,Phase I,Completed,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1176, 'therapyName': 'MEDI3617'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]",A Study to Evaluate the Safety and Antitumor Activity in Subjects With Advanced Solid Tumors,1216
122,NCT02551718,Phase I,Recruiting,"[{'id': 690, 'therapyName': 'Bosutinib'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 3160, 'therapyName': 'Nelarabine'}, {'id': 3159, 'therapyName': 'Bexarotene'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 998, 'therapyName': 'cabozantinib'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 877, 'therapyName': 'Ponatinib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 623, 'therapyName': 'Afatinib'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 890, 'therapyName': 'Regorafenib'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 2, 'therapyName': 'Trametinib'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 3, 'therapyName': 'Dabrafenib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 789, 'therapyName': 'Ceritinib'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1571, 'therapyName': 'Cabazitaxel'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1327, 'therapyName': 'Pralatrexate'}]",High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia,1216
123,NCT01641939,Phase III,Terminated,"[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1402, 'therapyName': 'trastuzumab emtansine'}]",A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer,1216
124,NCT01962948,Phase II,"Active, not recruiting","[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 745, 'therapyName': 'Ganetespib'}]","Paclitaxel and Ganetespib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",1216
125,NCT02502266,Phase II,Suspended,"[{'id': 942, 'therapyName': 'Topotecan'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 837, 'therapyName': 'Olaparib'}, {'id': 1001, 'therapyName': 'Cediranib'}]","Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",1216
126,NCT02551055,Phase I,Terminated,"[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 626, 'therapyName': 'Alisertib'}, {'id': 3146, 'therapyName': 'TAK-659'}, {'id': 1033, 'therapyName': 'MLN1117'}]","MLN1117 in Combination With Docetaxel, Paclitaxel, and Other Investigational Anticancer Agents to Treat Participants With Gastric and Gastroesophageal Adenocarcinoma",1216
127,NCT00989651,Phase I,"Active, not recruiting","[{'id': 3047, 'therapyName': 'Bevacizumab + Veliparib'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 700, 'therapyName': 'Cisplatin'}]","Carboplatin, Paclitaxel, Bevacizumab, and ABT-888 in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer",1216
128,NCT02651610,Phase II,Withdrawn,"[{'id': 3545, 'therapyName': 'Bavituximab'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]",Taxane Therapy With or Without Bavituximab for the Treatment of HER2-Negative Metastatic Breast Cancer,1216
129,NCT02264990,Phase III,"Active, not recruiting","[{'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 954, 'therapyName': 'Veliparib'}, {'id': 700, 'therapyName': 'Cisplatin'}]",Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Subjects Receiving First Cytotoxic Chemotherapy for Metastatic or Advanced Non-Squamous Non-Small Cell Lung Cancer Who Are Current or Former Smokers,1216
130,NCT00993655,Phase III,Completed,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1092, 'therapyName': 'Carboplatin'}]"," Comparing Combination Chemotherapy Regimens in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer",1216
131,NCT01042522,Phase II,Recruiting,"[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1137, 'therapyName': 'Bleomycin'}]","Paclitaxel and Carboplatin or Bleomycin Sulfate, Etoposide Phosphate, and Cisplatin in Treating Patients With Advanced or Recurrent Sex Cord-Ovarian Stromal Tumors",1216
132,NCT01572038,Phase III,"Active, not recruiting","[{'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}, {'id': 619, 'therapyName': 'Abraxane'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]",A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) and A Taxane in First-Line Treatment in Patients With HER2-Positive Advanced Breast Cancer (PERUSE),1216
133,NCT01952249,Phase Ib/II,Completed,"[{'id': 2007, 'therapyName': 'Demcizumab'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]",A Study of Demcizumab Plus Paclitaxel in Subjects With Platinum Resistant Ovarian,1216
134,NCT02412722,Phase I,"Active, not recruiting","[{'id': 1282, 'therapyName': 'Sapanisertib'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]","Safety, Tolerability, and Pharmacokinetics of MLN0128 as a Single Agent and in Combination With Paclitaxel in Adults With Advanced Nonhematologic Malignancies",1216
135,NCT02419417,Phase Ib/II,Recruiting,"[{'id': 2811, 'therapyName': 'BMS986158'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]",Study of BMS-986158 in Subjects With Select Advanced Solid Tumors,1216
136,NCT01820754,Phase II,"Active, not recruiting","[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]",Evaluation of Circulating T Cells and Tumor Infiltrating Lymphocytes (TILs) During / After Pre-Surgery Chemotherapy in Non-Small Cell Lung Cancer (NSCLC),1216
137,NCT02194829,Phase Ib/II,"Active, not recruiting","[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 822, 'therapyName': 'MK-1775'}]",Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Previously Untreated Pancreatic Cancer That Is Metastatic or Cannot Be Removed by Surgery,1216
138,NCT02229149,Phase II,"Active, not recruiting","[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}, {'id': 619, 'therapyName': 'Abraxane'}, {'id': 1685, 'therapyName': 'Vinorelbine'}, {'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 1105, 'therapyName': 'Capecitabine'}]","Phase 2 Study of Standard Chemotherapy With Trastuzumab, Plus or Minus Pertuzumab, for Pre-treated Metastatic Breast Cancer",1216
139,NCT02620865,Phase Ib/II,Suspended,"[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1167, 'therapyName': 'Aldesleukin'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 1873, 'therapyName': 'Sargramostim'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 2278, 'therapyName': 'Fluorouracil + Leucovorin'}]",Bispecific Antibody Armed Activated T-cells With Aldesleukin and Sargramostim in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer,1216
140,NCT02446600,Phase III,Recruiting,"[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 837, 'therapyName': 'Olaparib'}, {'id': 1001, 'therapyName': 'Cediranib'}]","Olaparib or Cediranib Maleate and Olaparib Compared With Standard Platinum-Based Chemotherapy in Treating Patients With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",1216
141,NCT01236547,Phase II,"Active, not recruiting","[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}]",Intensity-Modulated Radiation Therapy and Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Anaplastic Thyroid Cancer,1216
142,NCT01656538,Phase II,"Active, not recruiting","[{'id': 893, 'therapyName': 'Reolysin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]",A Study of Reolysin For Patients With Advanced/Metastatic Breast Cancer,1216
143,NCT02625623,Phase III,"Active, not recruiting","[{'id': 3144, 'therapyName': 'Avelumab'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1074, 'therapyName': 'Irinotecan'}]",Avelumab in Third-Line Gastric Cancer (JAVELIN Gastric 300),1216
144,NCT01366144,Phase I,Recruiting,"[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 954, 'therapyName': 'Veliparib'}, {'id': 1092, 'therapyName': 'Carboplatin'}]","Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction",1216
145,NCT02038647,Phase II,"Active, not recruiting","[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 626, 'therapyName': 'Alisertib'}]",Phase 2 Study of Alisertib (MLN8237) in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel as Second Line Therapy for Small Cell Lung Cancer (SCLC),1216
146,NCT02483247,Phase Ib/II,Recruiting,"[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1945, 'therapyName': 'BBI503'}]",A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer,1216
147,NCT02819518,Phase III,Recruiting,"[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 619, 'therapyName': 'Abraxane'}, {'id': 2667, 'therapyName': 'Carboplatin + Gemcitabine'}]",Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs. Placebo Plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (MK-3475-355/KEYNOTE-355),1216
148,NCT02041533,Phase III,"Active, not recruiting","[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 755, 'therapyName': 'Gemcitabine'}]","An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026)",1216
149,NCT01779050,Phase II,"Active, not recruiting","[{'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1087, 'therapyName': 'Epirubicin + Cyclophosphamide'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1982, 'therapyName': 'Fluorouracil + Epirubicin + Cyclophosphamide'}, {'id': 1834, 'therapyName': 'Docetaxel + Carboplatin'}, {'id': 1881, 'therapyName': 'Docetaxel + Cyclophosphamide'}]",Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer Patients With ERBB2 Expressing Disseminated Tumor Cells,1216
150,NCT02142738,Phase III,"Active, not recruiting","[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 854, 'therapyName': 'Pemetrexed'}]",Study of Pembrolizumab (MK-3475) Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (MK-3475-024/KEYNOTE-024),1216
151,NCT01796197,Phase II,"Active, not recruiting","[{'id': 1977, 'therapyName': 'Doxorubicin + Cyclophosphamide'}, {'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]",Paclitaxel + Trastuzumab + Pertuzumab as Pre-Op for Inflammatory BrCa,1216
152,NCT01249443,Phase I,Terminated,"[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]",Vorinostat in Combination With Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors and HIV Infection,1216
153,NCT02230319,Phase II,Unknown status,"[{'id': 1103, 'therapyName': 'Paclitaxel'}]",Prevention of Paclitaxel Neuropathy With Cryotherapy,1216
154,NCT02581982,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]",Paclitaxel and Pembrolizumab in Treating Patients With Refractory Metastatic Urothelial Cancer,1216
155,NCT01493505,Phase III,Terminated,"[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1218, 'therapyName': 'Trebananib'}]", TRINOVA-3,1216
156,NCT02474173,Phase I,Recruiting,"[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 645, 'therapyName': 'AT13387'}]",HSP90 Inhibitor AT13387 and Paclitaxel in Treating Patients With Advanced Triple Negative Breast Cancer,1216
157,NCT01653470,Phase I,"Active, not recruiting","[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1315, 'therapyName': 'FOLFIRI'}, {'id': 2545, 'therapyName': 'BMS-906024'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]","Study to Evaluate Safety & Tolerability of BMS-906024 in Combination With Chemotherapy & to Define DLTs & MTD of BMS-906024 in Combination With One of the Following Chemotherapy Regimens; Weekly Paclitaxel, 5FU+Irinotecan or Carboplatin+Paclitaxel in Subjects With Advanced / Metastatic Solid Tumors",1216
158,NCT01792050,Phase II,"Active, not recruiting","[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 2976, 'therapyName': 'indoximod'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]",Study of Chemotherapy in Combination With IDO Inhibitor in Metastatic Breast Cancer,1216
159,NCT02122770,Phase I,"Active, not recruiting","[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1026, 'therapyName': 'Itraconazole'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1688, 'therapyName': 'MLN4924'}, {'id': 1689, 'therapyName': 'Fluconazole'}]","Effects of Fluconazole and Itraconazole CYP3A-Mediated Inhibition on the Pharmacokinetics, Safety, and Tolerability of MLN4924 in Patients With Advanced Solid Tumors",1216
160,NCT01362374,Phase I,"Active, not recruiting","[{'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 747, 'therapyName': 'Ipatasertib'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}]","Safety and Pharmacology Of GDC-0068 in Combination With Docetaxel, Fluoropyrimidine Plus Oxaliplatin, Paclitaxel, or Enzalutamide in Patients With Advanced Solid Tumors",1216
161,NCT02187991,Phase II,Recruiting,"[{'id': 626, 'therapyName': 'Alisertib'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]",Study to Compare Alisertib With Paclitaxel vs. Paclitaxel Alone in Metastatic or Locally Recurrent Breast Cancer,1216
162,NCT02514551,Phase II,"Active, not recruiting","[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 886, 'therapyName': 'Ramucirumab'}]",A Study of Ramucirumab (LY3009806) in Combination With Paclitaxel in Participants With Gastric Cancer,1216
163,NCT02341456,Phase I,"Active, not recruiting","[{'id': 822, 'therapyName': 'MK-1775'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]",Phase Ib Study AZD1775 in Combination With Carboplatin and Paclitaxel in Adult Asian Patients With Solid Tumours,1216
164,NCT02367794,Phase III,"Active, not recruiting","[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 619, 'therapyName': 'Abraxane'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1201, 'therapyName': 'Atezolizumab'}]",A Phase III Study of MPDL3280A (Anti-PD-L1) in Combination With Carboplatin + Paclitaxel or Carboplatin + Nab-paclitaxel Compared With Carboplatin + Nab-paclitaxel in Patients With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC),1216
165,NCT01982448,Phase II,Recruiting,"[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 700, 'therapyName': 'Cisplatin'}]",Cisplatin vs Paclitaxel for Triple Neg,1216
166,NCT02440425,Phase II,Recruiting,"[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Dose Dense Paclitaxel With Pembrolizumab (MK-3475) in Platinum Resistant Ovarian Cancer,1216
167,NCT02390427,Phase I,Recruiting,"[{'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 856, 'therapyName': 'Pertuzumab'}, {'id': 1016, 'therapyName': 'GDC-0032'}]",Phase Ib Dose-escalation Trial of Taselisib (GDC-0032) in Combination With Anti-HER2 Therapies in Participants With Advanced HER2+ Breast Cancer,1216
168,NCT02297230,Phase Ib/II,Completed,"[{'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1551, 'therapyName': 'Trastuzumab + Paclitaxel'}]",Locally Advanced Breast Cancer: Individualized Treatment Based On Tumor Molecular Characteristics,1216
169,NCT00828009,Phase II,Unknown status,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 2142, 'therapyName': 'Emepepimut-S  '}, {'id': 1092, 'therapyName': 'Carboplatin'}]",BLP25 Liposome Vaccine and Bevacizumab After Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery,1216
170,NCT01407562,Phase I,"Active, not recruiting","[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}]","Study of Pazopanib, Paclitaxel, and Carboplatin in Patients With Advanced Solid Tumors",1216
171,NCT02322814,Phase II,Recruiting,"[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1004, 'therapyName': 'Cobimetinib'}]",A Study of Cobimetinib in Combination With Paclitaxel as First-line Treatment for Patients With Metastatic Triple-negative Breast Cancer,1216
172,NCT01015222,Phase I,"Active, not recruiting","[{'id': 1032, 'therapyName': 'methylnaltrexone'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 667, 'therapyName': 'Bevacizumab'}]","Dasatinib, Bevacizumab, Paclitaxel in Patients With Advanced Malignancies",1216
173,NCT01897441,Phase I,Recruiting,"[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1551, 'therapyName': 'Trastuzumab + Paclitaxel'}, {'id': 1977, 'therapyName': 'Doxorubicin + Cyclophosphamide'}]",Chemotherapy Before Surgery and Tissue Sample Collection in Patients With Stage IIA-IIIC Breast Cancer,1216
174,NCT02302807,Phase III,"Active, not recruiting","[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1685, 'therapyName': 'Vinorelbine'}, {'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 720, 'therapyName': 'Docetaxel'}]",A Study of MPDL3280A Compared With Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer,1216
175,NCT02437812,Phase II,Recruiting,"[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1031, 'therapyName': 'Metformin'}]","Study of Paclitaxel, Carboplatin and Oral Metformin in the Treatment of Advanced Stage Ovarian Carcinoma",1216
176,NCT01281150,Phase I,Completed,"[{'id': 954, 'therapyName': 'Veliparib'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1092, 'therapyName': 'Carboplatin'}]",Veliparib in Combination With Carboplatin and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors,1216
177,NCT02576574,Phase III,Recruiting,"[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 3144, 'therapyName': 'Avelumab'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 1092, 'therapyName': 'Carboplatin'}]",Avelumab in First-line Non-Small Cell Lung Cancer (JAVELIN Lung 100),1216
178,NCT02599324,Phase Ib/II,Recruiting,"[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 768, 'therapyName': 'Ibrutinib'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 694, 'therapyName': 'Cetuximab'}]",A Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors,1216
179,NCT02178956,Phase III,"Active, not recruiting","[{'id': 2057, 'therapyName': 'BBI608'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]",A Study of BBI608 Plus Weekly Paclitaxel to Treat Gastric and Gastro-Esophageal Junction Cancer,1216
180,NCT01803282,Phase I,Recruiting,"[{'id': 3320, 'therapyName': 'GS-5745'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 1602, 'therapyName': 'Carboplatin + Pemetrexed'}, {'id': 1315, 'therapyName': 'FOLFIRI'}, {'id': 1779, 'therapyName': 'Nab-paclitaxel + Gemcitabine'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 667, 'therapyName': 'Bevacizumab'}]",Safety and Tolerability Study in Solid Tumors,1216
181,NCT02322281,Phase III,"Active, not recruiting","[{'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1003, 'therapyName': 'CO1686'}]","TIGER-3 Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet Chemotherapy",1216
182,NCT02574078,Phase I,Recruiting,"[{'id': 619, 'therapyName': 'Abraxane'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 2114, 'therapyName': 'Bevacizumab + Pemetrexed'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 1092, 'therapyName': 'Carboplatin'}]",A Master Protocol Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC) (CheckMate 370),1216
183,NCT02312245,Phase II,Recruiting,"[{'id': 942, 'therapyName': 'Topotecan'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 755, 'therapyName': 'Gemcitabine'}]","Avatar-Directed Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer",1216
184,NCT01357161,Phase II,Completed,"[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 822, 'therapyName': 'MK-1775'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]", A Study of MK-1775 in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone for Participants With Platinum-Sensitive Ovarian Tumors With the P53 Gene Mutation (MK-1775-004),1216
185,NCT01454102,Phase I,"Active, not recruiting","[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1312, 'therapyName': 'Nivolumab'}]","Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012)",1216
186,NCT02788201,Phase II,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1133, 'therapyName': 'Mitomycin C'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1013, 'therapyName': 'epirubicin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1137, 'therapyName': 'Bleomycin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 781, 'therapyName': 'Ixabepilone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 2950, 'therapyName': 'Estramustine'}, {'id': 1941, 'therapyName': 'Floxuridine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 1811, 'therapyName': 'Carmustine'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 953, 'therapyName': 'Vandetanib'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 4419, 'therapyName': 'Toremifine'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 2601, 'therapyName': 'Dactinomycin'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 3035, 'therapyName': 'Chlorambucil'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 342, 'therapyName': 'Vemurafenib'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 2635, 'therapyName': 'Vinblastine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 4305, 'therapyName': 'Teniposide'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 4304, 'therapyName': 'Streptozocin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1231, 'therapyName': 'Bendamustine'}, {'id': 4303, 'therapyName': 'Mechlorethamine'}, {'id': 4302, 'therapyName': 'Mitotane'}]",Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma,1216
187,NCT02403895,Phase II,Completed,"[{'id': 991, 'therapyName': 'Vistusertib'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]",AZD2014 and Weekly Paclitaxel in Squamous NSCLC,1216
188,NCT02317874,Phase I,Recruiting,"[{'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 682, 'therapyName': 'Talazoparib'}]","PARP Inhibitor BMN-673, Carboplatin, and Paclitaxel in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery",1216
189,NCT02513563,Phase II,Recruiting,"[{'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 822, 'therapyName': 'MK-1775'}]",AZD1775 Plus Carboplatin-Paclitaxel in Squamous Cell Lung Cancer,1216
190,NCT00954174,Phase III,"Active, not recruiting","[{'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 1125, 'therapyName': 'Paclitaxel + Ifosfamide'}]","Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritorium Cavity Cancer",1216
191,NCT02713386,Phase Ib/II,Recruiting,"[{'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]","Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",1216
192,NCT02718417,Phase III,Recruiting,"[{'id': 3144, 'therapyName': 'Avelumab'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]",Avelumab in Previously Untreated Patients With Epithelial Ovarian Cancer (JAVELIN OVARIAN 100),1216
193,NCT02051868,Phase II,Recruiting,"[{'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 1833, 'therapyName': 'Cisplatin + Fluorouracil'}]",International Multicentre Study in Advanced Anal Cancer Comparing Cisplatin Plus 5 FU vs Carboplatin Plus Weekly Paclitaxel (InterAACT),1216
194,NCT02453282,Phase III,"Active, not recruiting","[{'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 1467, 'therapyName': 'Gemcitabine + Cisplatin'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 1652, 'therapyName': 'Tremelimumab'}]",Phase III Open Label First Line Therapy Study of MEDI 4736 With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC).,1216
195,NCT02106546,Phase III,"Active, not recruiting","[{'id': 954, 'therapyName': 'Veliparib'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]","Randomized, Double-Blind, Multicenter, Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Previously Untreated Advanced or Metastatic Squamous Non-Small Cell Lung Cancer",1216
196,NCT02530437,Phase Ib/II,Recruiting,"[{'id': 1587, 'therapyName': 'Taladegib'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]","A Phase 1B/2 Study of LY2940680 in Combination With Weekly Paclitaxel, Carboplatin, and Radiation in Localized Adenocarcinoma of the Esophagus or Gastroesophageal Junction",1216
197,NCT01769391,Phase II,"Active, not recruiting","[{'id': 826, 'therapyName': 'Necitumumab'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]",A Study of Necitumumab and Chemotherapy in Participants With Stage IV Squamous Non-Small Cell Lung Cancer,1216
198,NCT02032277,Phase III,"Active, not recruiting","[{'id': 1977, 'therapyName': 'Doxorubicin + Cyclophosphamide'}, {'id': 954, 'therapyName': 'Veliparib'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]",A Study Evaluating Safety and Efficacy of the Addition of ABT-888 Plus Carboplatin Versus the Addition of Carboplatin to Standard Chemotherapy Versus Standard Chemotherapy in Subjects With Early Stage Triple Negative Breast Cancer,1216
199,NCT01711541,Phase Ib/II,Suspended,"[{'id': 1544, 'therapyName': 'Carboplatin + Etoposide + Veliparib'}, {'id': 1849, 'therapyName': 'Cisplatin + Fluorouracil + Hydroxyurea'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]",Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IV Head and Neck Cancer,1216
200,NCT02520154,Phase II,Recruiting,"[{'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab in Combination With Chemotherapy in Frontline Ovarian Cancer,1216
201,NCT02358200,Phase I,"Active, not recruiting","[{'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 682, 'therapyName': 'Talazoparib'}]",Study of BMN-673 With Carboplatin and Paclitaxel in Patients With Advanced BRCA-mutated Solid Tumor or Triple Negative Metastatic Breast Cancer,1216
202,NCT02591615,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 1602, 'therapyName': 'Carboplatin + Pemetrexed'}]",Optimal Sequencing of Pembrolizumab (MK-3475) and Standard Platinum-based Chemotherapy in First-Line NSCLC,1216
203,NCT01578551,Phase II,"Active, not recruiting","[{'id': 1031, 'therapyName': 'Metformin'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 667, 'therapyName': 'Bevacizumab'}]",A Randomized Phase II Study of Metformin Plus Paclitaxel/Carboplatin/Bevacizumab in Patients With Adenocarcinoma.,1216
204,NCT02998268,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]",Study of Pembrolizumab in Locally Advanced Esophageal Adenocarcinoma,1216
205,NCT01196390,Phase III,"Active, not recruiting","[{'id': 1887, 'therapyName': 'Paclitaxel + Carboplatin + Trastuzumab'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]","Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer",1216
206,NCT01367002,Phase II,"Active, not recruiting","[{'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]",Evaluation of Carboplatin/Paclitaxel With and Without Trastuzumab (Herceptin) in Uterine Serous Cancer,1216
207,NCT01506609,Phase II,"Active, not recruiting","[{'id': 1193, 'therapyName': 'Veliparib + Temozolomide'}, {'id': 1544, 'therapyName': 'Carboplatin + Etoposide + Veliparib'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]",The Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide or In Combination With Carboplatin and Paclitaxel Versus Placebo in Subjects With BRCA1 and BRCA2 Mutation and Metastatic Breast Cancer,1216
208,NCT02436993,Phase II,Recruiting,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]",Breast Cancer Treatment Using Weekly Carboplatin + Paclitaxel With Pertuzumab + Trastuzumab (HER2+) or Bevacizumab (HER2-) in the Neoadjuvant Setting,1216
209,NCT02163694,Phase III,Recruiting,"[{'id': 954, 'therapyName': 'Veliparib'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]","A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Cancer",1216
210,NCT02525757,Phase II,Recruiting,"[{'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]",MPDL3280A With Chemoradiation for Lung Cancer,1216
211,NCT02730546,Phase Ib/II,Suspended,"[{'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]","Pembrolizumab, Combination Chemotherapy, and Radiation Therapy Before Surgery in Treating Adult Patients With Locally Advanced Gastroesophageal Junction or Gastric Cardia Cancer That Can Be Removed by Surgery",1216
212,NCT00980954,Phase III,Recruiting,"[{'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 700, 'therapyName': 'Cisplatin'}]",Chemotherapy and Pelvic Radiation Therapy With or Without Additional Chemotherapy in Treating Patients With High-Risk Early-Stage Cervical Cancer After Radical Hysterectomy,1216
213,NCT02272413,Phase III,"Active, not recruiting","[{'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 667, 'therapyName': 'Bevacizumab'}]",Phase III Trial BI 695502 Plus Chemotherapy vs. Avastin Plus Chemotherapy in Patients With Lung Cancer,1216
214,NCT02542293,Phase III,Recruiting,"[{'id': 1467, 'therapyName': 'Gemcitabine + Cisplatin'}, {'id': 2667, 'therapyName': 'Carboplatin + Gemcitabine'}, {'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 1857, 'therapyName': 'Cisplatin + Pemetrexed'}, {'id': 1602, 'therapyName': 'Carboplatin + Pemetrexed'}]",Study of 1st Line Therapy Study of MEDI4736 With Tremelimumab Versus SoC in Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE).,1216
215,NCT02658214,Phase I,Recruiting,"[{'id': 2667, 'therapyName': 'Carboplatin + Gemcitabine'}, {'id': 2634, 'therapyName': 'Carboplatin + nab-paclitaxel'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 1791, 'therapyName': 'Carboplatin + Etoposide'}]",Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors,1216
216,NCT01386385,Phase Ib/II,Recruiting,"[{'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 1544, 'therapyName': 'Carboplatin + Etoposide + Veliparib'}]","Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery",1216
217,NCT02220894,Phase III,Recruiting,"[{'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Study of MK-3475 (Pembrolizumab) Versus Platinum-based Chemotherapy for Participants With PD-L1-positive Advanced or Metastatic Non-small Cell Lung Cancer (MK-3475-042/KEYNOTE-042),1216
218,NCT02186847,Phase II,"Active, not recruiting","[{'id': 1031, 'therapyName': 'Metformin'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]",Chemotherapy and Radiation Therapy With or Without Metformin Hydrochloride in Treating Patients With Stage III Non-small Cell Lung Cancer,1216
219,NCT02775435,Phase III,Recruiting,"[{'id': 2634, 'therapyName': 'Carboplatin + nab-paclitaxel'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]",A Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With First Line Metastatic Squamous Non-small Cell Lung Cancer (MK-3475-407/KEYNOTE-407),1216
220,NCT03036488,Phase III,Recruiting,"[{'id': 1087, 'therapyName': 'Epirubicin + Cyclophosphamide'}, {'id': 1977, 'therapyName': 'Doxorubicin + Cyclophosphamide'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]",Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522),1216
221,NCT02065687,Phase III,Recruiting,"[{'id': 1381, 'therapyName': 'Paclitaxel + Carboplatin + Metformin'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]","Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer",1216
222,NCT02412371,Phase II,Recruiting,"[{'id': 954, 'therapyName': 'Veliparib'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]",A Study Evaluating the Efficacy and Tolerability of Veliparib in Combination With Paclitaxel/Carboplatin-Based Chemoradiotherapy Followed by Veliparib and Paclitaxel/Carboplatin Consolidation in Subjects With Stage III Non-Small Cell Lung Cancer,1216
223,NCT01966003,Phase III,Completed,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 2141, 'therapyName': 'Bevacizumab-awwb'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]",Efficacy and Safety Study of ABP 215 Compared With Bevacizumab in Subjects With Advanced Non-Small Cell Lung Cancer,1216
224,NCT02476955,Phase I,Recruiting,"[{'id': 635, 'therapyName': 'ARQ092'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]",Open-label Phase 1b Study of ARQ 092 in Combination With Carboplatin Plus Paclitaxel,1216
225,NCT02429843,Phase I,Recruiting,"[{'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1242, 'therapyName': 'TRC105'}]",A Study of TRC105 in Combination With Paclitaxel/Carboplatin and Bevacizumab in Non-Squamous Cell Lung Cancer,1216
226,NCT00979212,Phase II,"Active, not recruiting","[{'id': 845, 'therapyName': 'Panitumumab'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]",Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer (Cetuximab Closed as of 05/14/10),1216
227,NCT01868022,Phase I,"Active, not recruiting","[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1857, 'therapyName': 'Cisplatin + Pemetrexed'}, {'id': 2899, 'therapyName': 'GSK3052230'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]","Study to Evaluate GSK3052230 in Combination With Paclitaxel and Carboplatin, or Docetaxel or as Single Agent in Subjects With Solid Malignancies and Deregulated Fibroblast Growth Factor (FGF) Pathway Signaling",1216
228,NCT02122185,Phase II,Recruiting,"[{'id': 1031, 'therapyName': 'Metformin'}, {'id': 1827, 'therapyName': 'Paclitaxel + Carboplatin + Docetaxel'}]","Metformin Hydrochloride and Combination Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",1216
229,NCT02050009,Phase I,Withdrawn,"[{'id': 1381, 'therapyName': 'Paclitaxel + Carboplatin + Metformin'}]","Metformin Hydrochloride, Carboplatin, and Paclitaxel in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",1216
230,NCT00660218,Phase Ib/II,Unknown status,"[{'id': 1988, 'therapyName': 'Paclitaxel + Cetuximab'}]","A Phase I/II Study of Radiation Therapy, Paclitaxel Poliglumex and Cetuximab in Advanced Head and Neck Cancer",1216
231,NCT02379585,Phase Ib/II,Terminated,"[{'id': 1495, 'therapyName': 'Paclitaxel + Doxorubicin + Cyclophosphamide'}, {'id': 1978, 'therapyName': 'Pertuzumab + Trastuzumab + Docetaxel'}]",Study of Short-term Fasting on Neoadjuvant Chemotherapy in Patients With Newly Diagnosed Breast Cancer,1216
232,NCT01275677,Phase III,"Active, not recruiting","[{'id': 1503, 'therapyName': 'Paclitaxel + Trastuzumab + Doxorubicin + Cyclophosphamide'}, {'id': 1881, 'therapyName': 'Docetaxel + Cyclophosphamide'}, {'id': 1882, 'therapyName': 'Docetaxel + Cyclophosphamide + Trastuzumab'}, {'id': 1495, 'therapyName': 'Paclitaxel + Doxorubicin + Cyclophosphamide'}]",Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,1216
233,NCT02132949,Phase II,"Active, not recruiting","[{'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}, {'id': 1495, 'therapyName': 'Paclitaxel + Doxorubicin + Cyclophosphamide'}, {'id': 1895, 'therapyName': 'Cyclophosphamide + Fluorouracil + Docetaxel + Epirubicin  '}]","A Study Evaluating Perjeta (Pertuzumab) Combined With Herceptin (Trastuzumab) and Standard Anthracycline-based Chemotherapy in Patients With HER2-positive Locally Advanced, Inflammatory, or Early-stage Breast Cancer.",1216
234,NCT01042379,Phase II,Recruiting,"[{'id': 1218, 'therapyName': 'Trebananib'}, {'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}, {'id': 746, 'therapyName': 'Ganitumab'}, {'id': 1495, 'therapyName': 'Paclitaxel + Doxorubicin + Cyclophosphamide'}, {'id': 1494, 'therapyName': 'MK2206 + Trastuzumab'}, {'id': 1493, 'therapyName': 'Trebananib + Trastuzumab'}, {'id': 1492, 'therapyName': 'T-DM1 + Pertuzumab'}]",I-SPY 2 TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer,1216
235,NCT02637375,Phase I,Withdrawn,"[{'id': 1495, 'therapyName': 'Paclitaxel + Doxorubicin + Cyclophosphamide'}, {'id': 745, 'therapyName': 'Ganetespib'}]",A Pilot Preoperative Trial of Ganetespib With Paclitaxel for Triple-Negative Breast Cancer,1216
236,NCT03154294,Phase I,Not yet recruiting,"[{'id': 5731, 'therapyName': 'Paclitaxel + MLN0128 + MLN1117'}]",Evaluation of the Safety and Tolerability of TAK-228 With TAK-117 and Paclitaxel in Advanced Solid Tumors,1216
237,NCT01008150,Phase II,Unknown status,"[{'id': 1504, 'therapyName': 'Paclitaxel + Trastuzumab + Neratinib + Doxorubicin + Cyclophosphamide'}, {'id': 1503, 'therapyName': 'Paclitaxel + Trastuzumab + Doxorubicin + Cyclophosphamide'}, {'id': 1505, 'therapyName': 'Paclitaxel + Neratinib + Doxorubicin + Cyclophosphamide'}]",Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer,1216
238,NCT03136055,Phase II,Recruiting,"[{'id': 5643, 'therapyName': 'Irinotecan + Pembrolizumab'}, {'id': 4021, 'therapyName': 'Paclitaxel + Pembrolizumab'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab-based Therapy in Previously Treated High Grade Neuroendocrine Carcinomas,1216
239,NCT02734290,Phase Ib/II,Recruiting,"[{'id': 4022, 'therapyName': 'Capecitabine + Pembrolizumab'}, {'id': 4021, 'therapyName': 'Paclitaxel + Pembrolizumab'}]",Standard of Care Chemotherapy Plus Pembrolizumab for Breast Cancer,1216
240,NCT03018080,Phase II,Recruiting,"[{'id': 4021, 'therapyName': 'Paclitaxel + Pembrolizumab'}]",Pilot Study of Paclitaxel Plus Pembrolizumab in Metastatic HER2-Negative Breast Cancer (PePPy),1216
241,NCT03199885,Phase III,Not yet recruiting,"[{'id': 1549, 'therapyName': 'Pertuzumab + Trastuzumab + Paclitaxel'}, {'id': 5956, 'therapyName': 'Paclitaxel + Pembrolizumab + Pertuzumab + Trastuzumab'}]","Paclitaxel, Trastuzumab, and Pertuzumab With or Without Pembrolizumab in Treating Patients With Metastatic Breast Cancer",1216
242,NCT02824575,Phase I,Recruiting,"[{'id': 4433, 'therapyName': 'Paclitaxel + Rebastinib'}, {'id': 4434, 'therapyName': 'Eribulin + Rebastinib'}]",Rebastinib Plus Antitubulin Therapy With Paclitaxel or Eribulin in Metastatic Breast Cancer,1216
243,NCT02599363,Phase I,Recruiting,"[{'id': 3206, 'therapyName': 'Paclitaxel + Ribociclib'}]",A Trial of Ribocilcib (LEE011) and Weekly Paclitaxel in Patients With Rb+ Advanced Breast Cancer,1216
244,NCT02195973,Phase Ib/II,"Active, not recruiting","[{'id': 1620, 'therapyName': 'Paclitaxel + Sonidegib'}]",Phase IB/II Trial of LDE225 and Paclitaxel in Recurrent Ovarian Cancer,1216
245,NCT01774851,Phase II,Terminated,"[{'id': 1892, 'therapyName': 'Paclitaxel + Trastuzumab + MM-111'}, {'id': 1551, 'therapyName': 'Trastuzumab + Paclitaxel'}]","A Study of MM-111 and Paclitaxel With Trastuzumab in Patients HER2 Positive Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach",1216
246,NCT03179904,Phase II,Recruiting,"[{'id': 5874, 'therapyName': 'Paclitaxel + Trastuzumab + TVB-2640'}]","FASN Inhibitor TVB-2640, Paclitaxel, and Trastuzumab in Treating Patients With HER2 Positive Advanced Breast Cancer",1216
247,NCT00781612,Phase II,Recruiting,"[{'id': 5471, 'therapyName': 'Trastuzumab + trastuzumab emtansine'}, {'id': 5470, 'therapyName': 'Paclitaxel + trastuzumab emtansine'}, {'id': 1402, 'therapyName': 'trastuzumab emtansine'}, {'id': 3930, 'therapyName': 'Docetaxel + T-DM1'}, {'id': 1976, 'therapyName': 'trastuzumab emtansine + Capecitabine'}, {'id': 1492, 'therapyName': 'T-DM1 + Pertuzumab'}]",A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies,1216
248,NCT01697293,Phase Ib/II,Recruiting,"[{'id': 3054, 'therapyName': 'Paclitaxel + Triciribine'}, {'id': 1977, 'therapyName': 'Doxorubicin + Cyclophosphamide'}]","Triciribine Phosphate, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide in Treating Patients With Stage IIB-IV Breast Cancer",1216
249,NCT01107665,Phase II,"Active, not recruiting","[{'id': 1143, 'therapyName': 'Pazopanib + Paclitaxel'}]",Pazopanib and Paclitaxel as First-Line Treatment for Subjects With Unresectable Stage III and Stage IV Melanoma,1216
250,NCT01108055,Phase II,Completed,"[{'id': 1143, 'therapyName': 'Pazopanib + Paclitaxel'}]",Phase II Pazopanib in Combination With Weekly Paclitaxel in Refractory Urothelial Cancer,1216
251,NCT01179269,Phase II,Withdrawn,"[{'id': 1143, 'therapyName': 'Pazopanib + Paclitaxel'}]",Stage IIIB/IV Non-Small Cell Lung Cancer,1216
252,NCT01730833,Phase II,Recruiting,"[{'id': 1549, 'therapyName': 'Pertuzumab + Trastuzumab + Paclitaxel'}]","Pertuzumab, Trastuzumab, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With HER2-Positive Metastatic Breast Cancer",1216
253,NCT01276041,Phase II,"Active, not recruiting","[{'id': 1549, 'therapyName': 'Pertuzumab + Trastuzumab + Paclitaxel'}]","Paclitaxel, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer",1216
254,NCT01847001,Phase II,"Active, not recruiting","[{'id': 1912, 'therapyName': 'Propranolol'}, {'id': 1549, 'therapyName': 'Pertuzumab + Trastuzumab + Paclitaxel'}]",Study of Propranolol in Newly Diagnosed Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy,1216
255,NCT01966471,Phase III,"Active, not recruiting","[{'id': 1492, 'therapyName': 'T-DM1 + Pertuzumab'}, {'id': 1978, 'therapyName': 'Pertuzumab + Trastuzumab + Docetaxel'}, {'id': 1549, 'therapyName': 'Pertuzumab + Trastuzumab + Paclitaxel'}]",A Study of Kadcyla (Trastuzumab Emtansine) Plus Perjeta (Pertuzumab) Following Anthracyclines in Comparison With Herceptin (Trastuzumab) Plus Perjeta and a Taxane Following Anthracyclines as Adjuvant Therapy in Patients With Operable HER2-Positive Primary Breast Cancer,1216
256,NCT01855828,Phase II,Recruiting,"[{'id': 1549, 'therapyName': 'Pertuzumab + Trastuzumab + Paclitaxel'}, {'id': 1550, 'therapyName': 'Pertuzumab + Trastuzumab + Fluorouracil + Epirubicin + Cyclophosphamide'}]",Phase 2 Trial of Pertuzumab and Trastuzumab With Weekly Paclitaxel and Chemotherapy for HER2 Positive Breast Cancer,1216
257,NCT01525602,Phase I,"Active, not recruiting","[{'id': 1395, 'therapyName': 'PLX3397 + Paclitaxel'}]",Safety Study of PLX3397 and Paclitaxel in Patients With Advanced Solid Tumors,1216
258,NCT03281369,Phase Ib/II,Not yet recruiting,"[{'id': 1343, 'therapyName': 'Atezolizumab + Cobimetinib'}, {'id': 6274, 'therapyName': 'mFOLFOX-6 + Atezolizumab + Cobimetinib'}, {'id': 6275, 'therapyName': 'mFOLFOX-6 + Atezolizumab'}, {'id': 6276, 'therapyName': 'Atezolizumab + Linagliptin'}, {'id': 5941, 'therapyName': 'Atezolizumab + PEGPH20'}, {'id': 5942, 'therapyName': 'Atezolizumab + BKT140'}, {'id': 1721, 'therapyName': 'Ramucirumab + Paclitaxel'}, {'id': 5850, 'therapyName': 'mFOLFOX-6'}]",A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) (UMBRELLA),1216
259,NCT02383212,Phase I,"Active, not recruiting","[{'id': 5722, 'therapyName': 'REGN2810 + Carboplatin + Docetaxel'}, {'id': 5721, 'therapyName': 'REGN2810 + Carboplatin + Pemetrexed'}, {'id': 5723, 'therapyName': 'REGN2810 + GM-CSF + Cyclophosphamide'}, {'id': 5718, 'therapyName': 'REGN2810 + Cyclophosphamide'}, {'id': 5656, 'therapyName': 'REGN2810'}, {'id': 5720, 'therapyName': 'REGN2810 + Carboplatin + Paclitaxel'}, {'id': 5719, 'therapyName': 'REGN2810 + Docetaxel'}]",Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies,1216
260,NCT02041429,Phase Ib/II,"Active, not recruiting","[{'id': 1369, 'therapyName': 'Ruxolitinib + Paclitaxel'}]",Ruxolitinib W/ Preop Chemo For Triple Negative Inflammatory Brca,1216
261,NCT01194869,Phase II,Terminated,"[{'id': 1534, 'therapyName': 'Sorafenib + Cisplatin + Paclitaxel'}]","Preoperative Clinical Trial of Sorafenib in Combination With Cisplatin Followed by Paclitaxel for Triple Negative (ER-, PR-, Her2-)Early Stage Breast Cancer",1216
262,NCT03085056,Phase I,Recruiting,"[{'id': 5493, 'therapyName': 'Trametinib + Paclitaxel'}]",Trametinib in Combination With Paclitaxel in the Treatment of Anaplastic Thyroid Cancer,1216
263,NCT01901146,Phase III,Completed,"[{'id': 1087, 'therapyName': 'Epirubicin + Cyclophosphamide'}, {'id': 1551, 'therapyName': 'Trastuzumab + Paclitaxel'}]",Efficacy and Safety Study of ABP 980 Compared With Trastuzumab in Subjects With HER2 Positive Early Breast Cancer (Lilac),1216
264,NCT01989676,Phase III,"Active, not recruiting","[{'id': 1551, 'therapyName': 'Trastuzumab + Paclitaxel'}]",A Study Of PF-05280014 [Trastuzumab-Pfizer] Or Herceptin® [Trastuzumab-EU] Plus Paclitaxel In HER2 Positive First Line Metastatic Breast Cancer Treatment (REFLECTIONS B327-02),1216
265,NCT01853748,Phase II,Recruiting,"[{'id': 1551, 'therapyName': 'Trastuzumab + Paclitaxel'}, {'id': 1402, 'therapyName': 'trastuzumab emtansine'}]",T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial),1216
266,NCT01973309,Phase I,"Active, not recruiting","[{'id': 4398, 'therapyName': 'Vantictumab + Paclitaxel'}]",A Study of Vantictumab (OMP-18R5) in Combination With Paclitaxel in Locally Recurrent or Metastatic Breast Cancer,1216
267,NCT01636622,Phase I,"Active, not recruiting","[{'id': 1209, 'therapyName': 'Vemurafenib + Carboplatin + Paclitaxel '}]"," Study of Vemurafenib, Carboplatin, and Paclitaxel",1216
268,NCT00574587,Phase Ib/II,Unknown status,"[{'id': 1983, 'therapyName': 'vorinostat + Paclitaxel'}, {'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 1977, 'therapyName': 'Doxorubicin + Cyclophosphamide'}]","Trial for Locally Advanced Her2 Positive Breast Cancer Using Paclitaxel, Trastuzumab, Doxorubicin and Cyclophasmide on a Weekly Basis",1216
0,NCT02323607,Phase I,Suspended,"[{'id': 3219, 'therapyName': 'Cytarabine + Daunorubicin + Pacritinib'}, {'id': 3177, 'therapyName': 'Pacritinib + Decitabine'}]",Pacritinib and Chemotherapy in Treating Patients With Acute Myeloid Leukemia and FLT3 Mutations,7378
1,NCT02342353,Phase Ib/II,Recruiting,"[{'id': 2382, 'therapyName': 'Erlotinib + Pacritinib'}]",Pacritinib in Patients With Endothelial Growth Factor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC) After EGFR Tyrosine Kinase Inhibitor (TKI),7378
2,NCT02677948,Phase Ib/II,Withdrawn,"[{'id': 3623, 'therapyName': 'Ibrutinib + Pacritinib'}]",Multicenter Study of Pacritinib Combined With Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL),7378
3,NCT02469415,Phase II,Terminated,"[{'id': 650, 'therapyName': 'Decitabine'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 2006, 'therapyName': 'Pacritinib'}]",Pacritinib for Patients With Lower-Risk Myelodysplastic Syndromes (MDS),7378
4,NCT02277093,Phase II,Terminated,"[{'id': 2006, 'therapyName': 'Pacritinib'}]",Pacritinib to Inhibit JAK/STAT Signaling in Refractory Colorectal Cancer,7378
5,NCT02251821,Phase II,Recruiting,"[{'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 1845, 'therapyName': 'Mycophenolate mofetil'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 2006, 'therapyName': 'Pacritinib'}, {'id': 823, 'therapyName': 'Momelotinib'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}]",JAK-2 Inhibitor Before Donor Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis,7378
6,NCT02532010,Phase II,"Active, not recruiting","[{'id': 3177, 'therapyName': 'Pacritinib + Decitabine'}, {'id': 3176, 'therapyName': 'Pacritinib + Cytarabine'}]",Pacritinib Combined With Decitabine or Cytarabine in Older Patients With AML,7378
7,NCT02564536,Phase I,Withdrawn,"[{'id': 3177, 'therapyName': 'Pacritinib + Decitabine'}]",Pacritinib in Combination With Low Dose Decitabine in Intermediate-High Risk Myelofibrosis or Myeloproliferative Neoplasm (MPN)/Myelodysplastic Syndrome (MDS),7378
0,NCT02942355,Phase II,Recruiting,"[{'id': 4974, 'therapyName': 'Anastrozole + Palbociclib'}]",Trial of Anastrozole and Palbociclib in Metastatic HER2-Negative Breast Cancer,6979
1,NCT03054363,Phase Ib/II,Not yet recruiting,"[{'id': 5334, 'therapyName': 'ARRY-380 + Palbociclib + Letrozole'}]","Tucatinib, Palbociclib and Letrozole in Metastatic Hormone Receptor Positive and HER2-positive Breast Cancer",6979
2,NCT02448771,Phase Ib/II,Recruiting,"[{'id': 2738, 'therapyName': 'Bazedoxifene + Palbociclib'}]",A Study of Palbociclib in Combination With Bazedoxifene in Hormone Receptor Positive Breast Cancer,6979
3,NCT02605486,Phase Ib/II,Recruiting,"[{'id': 3252, 'therapyName': 'Bicalutamide + Palbociclib'}]",Palbociclib in Combination With Bicalutamide for the Treatment of AR(+) Metastatic Breast Cancer (MBC),6979
4,NCT03170206,Phase Ib/II,Recruiting,"[{'id': 850, 'therapyName': 'Palbociclib'}, {'id': 807, 'therapyName': 'Binimetinib'}, {'id': 5838, 'therapyName': 'Binimetinib + Palbociclib'}]",Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the MEK Inhibitor Binimetinib (MEK162) for Patients With Advanced KRAS Mutant Non-Small Cell Lung Cancer,6979
5,NCT03194373,Phase II,Recruiting,"[{'id': 4735, 'therapyName': 'Carboplatin + Palbociclib'}]",Phase II Trial Evaluating the Efficacy of Palbociclib in Combination With Carboplatin for the Treatment of Unresectable Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma,6979
6,NCT02897375,Phase I,Recruiting,"[{'id': 4734, 'therapyName': 'Cisplatin + Palbociclib'}, {'id': 4735, 'therapyName': 'Carboplatin + Palbociclib'}]",Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors,6979
7,NCT03128619,Phase Ib/II,Recruiting,"[{'id': 5594, 'therapyName': 'Copanlisib + Palbociclib + Letrozole'}, {'id': 5593, 'therapyName': 'Copanlisib + Letrozole'}]","Copanlisib, Letrozole, and Palbociclib in Treating Patients With Hormone Receptor Positive HER2 Negative Stage I-IV Breast Cancer",6979
8,NCT02871791,Phase Ib/II,Recruiting,"[{'id': 4597, 'therapyName': 'Exemestane + Everolimus + Palbociclib'}]",Palbociclib With Everolimus + Exemestane In BC,6979
9,NCT02599714,Phase Ib/II,Recruiting,"[{'id': 3205, 'therapyName': 'Fulvestrant + Palbociclib'}, {'id': 991, 'therapyName': 'Vistusertib'}]",Study of AZD2014 and Palbociclib in Patients With Estrogen Receptor Positive (ER+) Metastatic Breast Cancer (PASTOR),6979
10,NCT03007979,Phase II,Recruiting,"[{'id': 759, 'therapyName': 'Goserelin'}, {'id': 3205, 'therapyName': 'Fulvestrant + Palbociclib'}, {'id': 2922, 'therapyName': 'Palbociclib + Letrozole'}]",Alternative Dosing Schedule of Palbociclib in Metastatic Hormone Receptor Positive Breast Cancer,6979
11,NCT02760030,Phase II,Recruiting,"[{'id': 3205, 'therapyName': 'Fulvestrant + Palbociclib'}]",Fulvestrant and Palbociclib in Treating Older Patients With Hormone Responsive Breast Cancer That Cannot Be Removed by Surgery,6979
12,NCT02738866,Phase II,Recruiting,"[{'id': 3205, 'therapyName': 'Fulvestrant + Palbociclib'}]",Palbociclib With Fulvestrant for Metastatic Breast Cancer After Treatment With Palbociclib and an Aromatase Inhibitor,6979
13,NCT03147287,Phase II,Recruiting,"[{'id': 850, 'therapyName': 'Palbociclib'}, {'id': 3205, 'therapyName': 'Fulvestrant + Palbociclib'}, {'id': 5684, 'therapyName': 'Fulvestrant + Palbociclib + Avelumab'}, {'id': 744, 'therapyName': 'Fulvestrant'}]",Palbociclib After CDK and Endocrine Therapy (PACE),6979
14,NCT03006172,Phase I,Recruiting,"[{'id': 5182, 'therapyName': 'GDC-0077 + Letrozole + Palbociclib'}, {'id': 5181, 'therapyName': 'GDC-0077'}, {'id': 5184, 'therapyName': 'GDC-0077 + Fulvestrant'}, {'id': 5183, 'therapyName': 'GDC-0077 + Letrozole'}]","To Evaluate the Safety, Tolerability, and Pharmacokinetics of GDC-0077 Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer",6979
15,NCT03065062,Phase I,Recruiting,"[{'id': 4034, 'therapyName': 'Gedatolisib + Palbociclib'}]","Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors",6979
16,NCT02684032,Phase I,Recruiting,"[{'id': 794, 'therapyName': 'Letrozole'}, {'id': 744, 'therapyName': 'Fulvestrant'}, {'id': 4034, 'therapyName': 'Gedatolisib + Palbociclib'}]",A Study To Assess The Tolerability And Clinical Activity Of Gedatolisib In Combination With Palbociclib/Letrozole Or Palbociclib/Fulvestrant In Women With Metastatic Breast Cancer,6979
17,NCT02159755,Phase I,"Active, not recruiting","[{'id': 1729, 'therapyName': 'ibrutinib + palbociclib'}]",Ibrutinib and Palbociclib Isethionate in Treating Patients With Previously Treated Mantle Cell Lymphoma,6979
18,NCT03238196,Phase I,Recruiting,"[{'id': 6099, 'therapyName': 'JNJ-42756493 + Fulvestrant + Palbociclib'}]","Fulvestrant, Palbociclib and Erdafitinib in ER+/HER2-/FGFR-amplified Metastatic Breast Cancer",6979
19,NCT02778685,Phase II,Recruiting,"[{'id': 4222, 'therapyName': 'Letrozole + Palbociclib + Pembrolizumab'}]","Pembrolizumab, Letrozole, and Palbociclib in Treating Patients With Stage IV Estrogen Receptor Positive Breast Cancer With Stable Disease That Has Not Responded to Letrozole and Palbociclib",6979
20,NCT02907918,Phase II,Recruiting,"[{'id': 759, 'therapyName': 'Goserelin'}, {'id': 4756, 'therapyName': 'Letrozole + Palbociclib + Trastuzumab'}]",Neoadjuvant Study of Palbociclib in Combination With Letrozole and Trastuzumab in Stage II-III ER+ HER2+ Breast Cancer (PALTAN),6979
21,NCT02501902,Phase I,Recruiting,"[{'id': 3112, 'therapyName': 'nab-paclitaxel + Palbociclib'}]",Dose-Escalation Study Of Palbociclib + Nab-Paclitaxel In mPDAC,6979
22,NCT03065387,Phase I,Not yet recruiting,"[{'id': 5401, 'therapyName': 'Neratinib + Everolimus'}, {'id': 5402, 'therapyName': 'Neratinib + Palbociclib'}, {'id': 5403, 'therapyName': 'Neratinib + Trametinib'}]","Study of the Pan-ERBB Inhibitor Neratinib Given in Combination With Everolimus, Palbociclib or Trametinib in Advanced Cancer Subjects With EGFR Mutation/Amplification, HER2 Mutation/Amplification or HER3/4 Mutation",6979
23,NCT01037790,Phase II,Recruiting,"[{'id': 850, 'therapyName': 'Palbociclib'}]",PD 0332991 in Treating Patients With Refractory Solid Tumors,6979
24,NCT01723774,Phase II,Recruiting,"[{'id': 850, 'therapyName': 'Palbociclib'}, {'id': 633, 'therapyName': 'Anastrozole'}, {'id': 759, 'therapyName': 'Goserelin'}]",PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer,6979
25,NCT02030483,Phase I,Terminated,"[{'id': 850, 'therapyName': 'Palbociclib'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 1164, 'therapyName': 'lenalidomide'}]",Palbociclib in Combination With Lenalidomide and Dexamethasone for Multiple Myeloma,6979
26,NCT02499120,Phase II,Recruiting,"[{'id': 850, 'therapyName': 'Palbociclib'}, {'id': 694, 'therapyName': 'Cetuximab'}]",Safety And Efficacy Study Of Palbociclib Plus Cetuximab Versus Cetuximab To Treat Head And Neck Cancer,6979
27,NCT02154490,Phase II,Recruiting,"[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 850, 'therapyName': 'Palbociclib'}, {'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 654, 'therapyName': 'AZD4547'}, {'id': 1016, 'therapyName': 'GDC-0032'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 629, 'therapyName': 'AMG102'}]",Lung-MAP: S1400 Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IIIB-IV Squamous Cell Lung Cancer,6979
28,NCT02296801,Phase II,Recruiting,"[{'id': 850, 'therapyName': 'Palbociclib'}, {'id': 794, 'therapyName': 'Letrozole'}]",A Phase II Randomized Study Evaluating the Biological and Clinical Effects of the Combination of Palbociclib With Letrozole as Neoadjuvant Therapy in Post-Menopausal Women With Estrogen-Receptor Positive Primary Breast Cancer,6979
29,NCT03132454,Phase I,Recruiting,"[{'id': 5637, 'therapyName': 'Palbociclib + Decitabine'}, {'id': 5636, 'therapyName': 'Palbociclib + Dexamethasone'}, {'id': 850, 'therapyName': 'Palbociclib'}, {'id': 5638, 'therapyName': 'Palbociclib + Sorafenib'}]",Study of Palbociclib Alone and in Combination in Patients With Relapsed and Refractory (R/R) Leukemias,6979
30,NCT01356628,Phase II,"Active, not recruiting","[{'id': 850, 'therapyName': 'Palbociclib'}]",A Clinical Research Study to Determine Whether PD 0332991 May Be Effective in Treating Patients With Liver Cancer,6979
31,NCT02334527,Phase II,Recruiting,"[{'id': 850, 'therapyName': 'Palbociclib'}]",Phase II Trial of Palbociclib (PD-0332991) in Patients With Metastatic Urothelial Cancer (UC) After Failure of First-Line Chemotherapy,6979
32,NCT02255461,Phase I,Recruiting,"[{'id': 850, 'therapyName': 'Palbociclib'}]","Palbociclib Isethionate in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors",6979
33,NCT02513394,Phase III,Recruiting,"[{'id': 850, 'therapyName': 'Palbociclib'}]",PALbociclib CoLlaborative Adjuvant Study: A Randomized Phase III Trial of Palbociclib With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone for Hormone Receptor Positive (HR+) / Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Early Breast Cancer (PALLAS),6979
34,NCT02693535,Phase II,Recruiting,"[{'id': 1657, 'therapyName': 'Vemurafenib + Cobimetinib'}, {'id': 890, 'therapyName': 'Regorafenib'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 690, 'therapyName': 'Bosutinib'}, {'id': 850, 'therapyName': 'Palbociclib'}, {'id': 694, 'therapyName': 'Cetuximab'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 837, 'therapyName': 'Olaparib'}, {'id': 4, 'therapyName': 'Erlotinib'}]",TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer,6979
35,NCT01320592,Phase I,"Active, not recruiting","[{'id': 850, 'therapyName': 'Palbociclib'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]",PD0332991/Paclitaxel in Advanced Breast Cancer,6979
36,NCT01864746,Phase III,Recruiting,"[{'id': 850, 'therapyName': 'Palbociclib'}]",A Study of Palbociclib in Addition to Standard Endocrine Treatment in Hormone Receptor Positive Her2 Normal Patients With Residual Disease After Neoadjuvant Chemotherapy and Surgery,6979
37,NCT02905318,Phase II,Recruiting,"[{'id': 850, 'therapyName': 'Palbociclib'}]",Palbociclib in Patients With Metastatic Castration-Resistant Prostate Cancer,6979
38,NCT02630693,Phase II,"Active, not recruiting","[{'id': 850, 'therapyName': 'Palbociclib'}, {'id': 744, 'therapyName': 'Fulvestrant'}, {'id': 1456, 'therapyName': 'Tamoxifen'}]","Study Comparing Two Different Schedules of Palbociclib Plus Second Line Endocrine Therapy in Women With Estrogen Receptor Positive, HER2 Negative Advanced/Metastatic Breast Cancer",6979
39,NCT02764541,Phase II,Recruiting,"[{'id': 850, 'therapyName': 'Palbociclib'}, {'id': 794, 'therapyName': 'Letrozole'}, {'id': 1456, 'therapyName': 'Tamoxifen'}]",Palbociclib and Endocrine Therapy for LObular Breast Cancer Preoperative Study (PELOPS),6979
40,NCT02896335,Phase II,Recruiting,"[{'id': 850, 'therapyName': 'Palbociclib'}]",Palbociclib In Progressive Brain Metastases,6979
41,NCT02384239,Phase II,Recruiting,"[{'id': 744, 'therapyName': 'Fulvestrant'}, {'id': 850, 'therapyName': 'Palbociclib'}, {'id': 1456, 'therapyName': 'Tamoxifen'}]",A Study of Palbociclib in Combination With Fulvestrant or Tamoxifen as Treatment for Metastatic Breast Cancer,6979
42,NCT01536743,Phase II,"Active, not recruiting","[{'id': 850, 'therapyName': 'Palbociclib'}]",A Open Label Study of the Efficacy and Safety of PD0332991 a Selective Inhibitor of the Cyclin Dependent Kinases 4 and 6 in Patients With Recurrent Ovarian Cancer Demonstrating Rb-proficiency and Low p16 Expression,6979
43,NCT02040857,Phase II,"Active, not recruiting","[{'id': 738, 'therapyName': 'Exemestane'}, {'id': 850, 'therapyName': 'Palbociclib'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 794, 'therapyName': 'Letrozole'}, {'id': 633, 'therapyName': 'Anastrozole'}]",Palbociclib + Endocrine Therapy for HR + BrCa,6979
44,NCT02626507,Phase I,Recruiting,"[{'id': 850, 'therapyName': 'Palbociclib'}, {'id': 1040, 'therapyName': 'PF-05212384'}, {'id': 759, 'therapyName': 'Goserelin'}, {'id': 744, 'therapyName': 'Fulvestrant'}]",Phase I Study of Combination of Gedatolisib With Palbociclib and Faslodex in Patients With ER+/HER2- Breast Cancer,6979
45,NCT02059213,Phase II,"Active, not recruiting","[{'id': 759, 'therapyName': 'Goserelin'}, {'id': 850, 'therapyName': 'Palbociclib'}, {'id': 1507, 'therapyName': 'Bicalutamide'}, {'id': 795, 'therapyName': 'Leuprolide'}]", A Phase II Study of Androgen Deprivation Therapy With or Without PD 0332991 in RB-Positive Metastatic Prostate Cancer,6979
46,NCT03304080,,Not yet recruiting,"[{'id': 633, 'therapyName': 'Anastrozole'}, {'id': 856, 'therapyName': 'Pertuzumab'}, {'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 850, 'therapyName': 'Palbociclib'}]","Anastrozole, Palbociclib, Trastuzumab and Pertuzumab in Her-positive, Her2-positive Metastatic Breast",6979
47,NCT03123744,Phase II,Not yet recruiting,"[{'id': 850, 'therapyName': 'Palbociclib'}]",Histology-Independent Study of Palbociclib in Patients With Advanced Cancer,6979
48,NCT02785939,Phase II,"Active, not recruiting","[{'id': 850, 'therapyName': 'Palbociclib'}]",Lung-MAP: Palbociclib as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches,6979
49,NCT02101034,Phase Ib/II,Recruiting,"[{'id': 1705, 'therapyName': 'Palbociclib + Cetuximab'}]",PD 0332991 and Cetuximab in Patients With Incurable SCCHN,6979
50,NCT01522989,Phase I,"Active, not recruiting","[{'id': 1703, 'therapyName': 'Palbociclib + Fluorouracil + Oxaliplatin'}]","PD-0332991, 5-FU, and Oxaliplatin for Advanced Solid Tumor Malignancies",6979
51,NCT02142868,Phase III,No longer available,"[{'id': 2922, 'therapyName': 'Palbociclib + Letrozole'}]","Expanded Access Study Of Palbociclib (PD-0332991) In Combination With Letrozole As Treatment Of Post-Menopausal Women With HR-Positive, Her2-Negative Advanced Breast Cancer For Whom Letrozole Therapy Is Deemed Appropriate",6979
52,NCT02692755,Phase II,Recruiting,"[{'id': 2922, 'therapyName': 'Palbociclib + Letrozole'}]",Palbociclib / Letrozole in African American Women With HR+ HER2- Breast Cancer (PALINA),6979
53,NCT03284957,Phase Ib/II,Recruiting,"[{'id': 6293, 'therapyName': 'SAR439859'}, {'id': 6294, 'therapyName': 'Palbociclib + SAR439859'}]",Phase 1 / 2 Study of SAR439859 Single Agent and in Combination With Palbociclib in Postmenopausal Women With Estrogen Receptor Positive Advanced Breast Cancer,6979
54,NCT02668666,Phase II,Recruiting,"[{'id': 3542, 'therapyName': 'Palbociclib + Tamoxifen'}]",Palbociclib in Combination With Tamoxifen as First Line Therapy for Metastatic Hormone Receptor Positive Breast Cancer,6979
55,NCT02065063,Phase I,Completed,"[{'id': 1368, 'therapyName': 'Palbociclib + Trametinib'}]","A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Anti-Cancer Activity of Trametinib in Combination With Palbociclib in Subjects With Solid Tumors",6979
56,NCT02774681,Phase II,Recruiting,"[{'id': 3041, 'therapyName': 'Palbociclib + Trastuzumab'}]",Palbociclib in Treating Patients With Metastatic HER-2 Positive or Triple-Negative Breast Cancer With Brain Metastasis,6979
57,NCT01111188,,"Active, not recruiting","[{'id': 1730, 'therapyName': 'Palbociclib + Velcade'}]", Trial of PD 0332991 Plus Bortezomib in Patients With Relapsed Mantle Cell Lymphoma,6979
58,NCT02022982,Phase Ib/II,Recruiting,"[{'id': 1823, 'therapyName': 'PD-0325901 + Palbociclib'}]",PALBOCICLIB + PD-0325901 for NSCLC & Solid Tumors,6979
59,NCT01976169,Phase I,Recruiting,"[{'id': 1731, 'therapyName': 'PD-0332991 + T-DM1'}]",Phase 1b Study of PD-0332991 in Combination With T-DM1(Trastuzumab-DM1),6979
0,NCT02961816,Phase II,Withdrawn,"[{'id': 3277, 'therapyName': 'Pyridoxine'}, {'id': 4976, 'therapyName': 'Busulfan + Gemcitabine + Melphalan + Panobinostat'}, {'id': 4977, 'therapyName': 'Dexamethasone + Filgrastim + Palifermin + Rituximab'}]",Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Lymphoma,38
1,NCT03259503,Phase Ib/II,Not yet recruiting,"[{'id': 1206, 'therapyName': 'Busulfan'}, {'id': 837, 'therapyName': 'Olaparib'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 2373, 'therapyName': 'Palifermin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 3277, 'therapyName': 'Pyridoxine'}, {'id': 897, 'therapyName': 'Rituximab'}]",Olaparib Combined With High-Dose Chemotherapy for Refractory Lymphomas,38
2,NCT02356159,Phase Ib/II,Recruiting,"[{'id': 2294, 'therapyName': 'Cytarabine + Fludarabine'}, {'id': 2373, 'therapyName': 'Palifermin'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 2238, 'therapyName': 'Sirolimus + Tacrolimus + Methotrexate'}, {'id': 2292, 'therapyName': 'Doxorubicin + Etoposide + Fludarabine + Vincristine '}, {'id': 2291, 'therapyName': 'Cyclophosphamide + Fludarabine'}, {'id': 897, 'therapyName': 'Rituximab'}]",Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation,38
3,NCT02653196,Phase II,Terminated,"[{'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1205, 'therapyName': 'Alemtuzumab'}, {'id': 2373, 'therapyName': 'Palifermin'}, {'id': 2237, 'therapyName': 'Fludarabine + Melphalan'}, {'id': 3948, 'therapyName': 'Cyclosporine + Mycophenolate mofetil + Tacrolimus'}]",A Multi-Institutional Phase II Feasibility Study of Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Malignant Neuro-Epithelial and Other Solid Tumors,38
4,NCT02506959,Phase II,Recruiting,"[{'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 2558, 'therapyName': 'Busulfan + Melphalan'}, {'id': 3277, 'therapyName': 'Pyridoxine'}, {'id': 1080, 'therapyName': 'Panobinostat'}, {'id': 2373, 'therapyName': 'Palifermin'}, {'id': 755, 'therapyName': 'Gemcitabine'}]",Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Myeloma,38
5,NCT01746849,Phase II,Recruiting,"[{'id': 795, 'therapyName': 'Leuprolide'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 2373, 'therapyName': 'Palifermin'}]",Palifermin With Leuprolide Acetate for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation,38
6,NCT02589145,Phase Ib/II,Recruiting,"[{'id': 1164, 'therapyName': 'lenalidomide'}, {'id': 3277, 'therapyName': 'Pyridoxine'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 2558, 'therapyName': 'Busulfan + Melphalan'}, {'id': 3278, 'therapyName': 'Enoxaparin'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 2373, 'therapyName': 'Palifermin'}]",Lenalidomide Combined With Vorinostat/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Diffuse Large B-Cell Lymphoma of the ABC Subtype,38
0,NCT03120832,Phase I,Recruiting,"[{'id': 5704, 'therapyName': 'PAN-301-1'}]",Phase 1 Trial of PAN-301-1 in Cancer Patients,8755
0,NCT02906670,Phase Ib/II,Recruiting,"[{'id': 3885, 'therapyName': 'Pan-HER'}]",Sym013 (Pan-HER) in Patients With Advanced Epithelial Malignancies,8286
0,NCT01061788,Phase I,Recruiting,"[{'id': 1138, 'therapyName': 'AMG479 + Everolimus + Panitumumab'}]","A Trial of AMG 479, Everolimus (RAD001) and Panitumumab in Patients With Advanced Cancer",1256
1,NCT01776307,Phase II,Recruiting,"[{'id': 2090, 'therapyName': 'BBI608 + Cetuximab'}, {'id': 2091, 'therapyName': 'BBI608 + Capecitabine'}, {'id': 2092, 'therapyName': 'BBI608 + Panitumumab'}]",A Study of BBI608 in Adult Patients With Advanced Colorectal Cancer,1256
2,NCT01591421,Phase Ib/II,"Active, not recruiting","[{'id': 1990, 'therapyName': 'BKM120 + Panitumumab'}]",P13Kinase Inhibitor BKM120 in Combination With Panitumumab in Patients With Metastatic or Advanced RAS-Wild Type Colorectal Cancer.,1256
3,NCT00967655,Phase II,Unknown status,"[{'id': 1960, 'therapyName': 'Capecitabine + Panitumumab'}, {'id': 1074, 'therapyName': 'Irinotecan'}]","Capecitabine, Panitumumab, and Radiation Therapy With or Without Irinotecan Hydrochloride in Treating Patients Undergoing Surgery for Localized Rectal Cancer",1256
4,NCT02876107,Phase II,Recruiting,"[{'id': 1977, 'therapyName': 'Doxorubicin + Cyclophosphamide'}, {'id': 3386, 'therapyName': 'Carboplatin + Paclitaxel + Panitumumab'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]",A Phase II Study of Using Panitumumab/Carboplatin/Paclitaxel (PaCT) Followed by Anthracycline-Containing Regimen (AC) for New Triple-Negative Inflammatory Breast Cancer (TN-IBC),1256
5,NCT02593175,Phase II,Recruiting,"[{'id': 3386, 'therapyName': 'Carboplatin + Paclitaxel + Panitumumab'}]","Women's Triple-Negative First-Line Study: A Phase II Trial of Panitumumab, Carboplatin and Paclitaxel (PaCT) in Patients With Localized Triple-Negative Breast Cancer (TNBC) With Tumors Predicted Insensitive to Standard Neoadjuvant Chemotherapy",1256
6,NCT03263429,Phase Ib/II,Recruiting,"[{'id': 6158, 'therapyName': 'CB-839 + Irinotecan + Panitumumab'}]",Novel PET/CT Imaging Biomarkers of CB-839 in Combination With Panitumumab and Irinotecan in Patients With Metastatic and Refractory RAS Wildtype Colorectal Cancer,1256
7,NCT03069950,Phase II,Recruiting,"[{'id': 5476, 'therapyName': 'Floxiuridine + Panitumumab + Dexamethasone + FOLFIRI'}]",Study of Chemotherapy With or Without Hepatic Arterial Infusion for Patients With Unresectable Metastatic Colorectal Cancer to the Liver,1256
8,NCT01916109,Phase II,Terminated,"[{'id': 1943, 'therapyName': 'Gemcitabine + Carboplatin + Panitumumab'}]","Study of Gemcitabine, Carboplatin, and Panitumumab (GCaP) as Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer",1256
9,NCT02415881,Phase I,Recruiting,"[{'id': 845, 'therapyName': 'Panitumumab'}]",Phase I Panitumumab IRDye800 Optical Imaging Study,1256
10,NCT00842257,Phase II,Completed,"[{'id': 845, 'therapyName': 'Panitumumab'}]",Panitumumab in Cetuximab Refractory KRAS Wild-Type Colorectal Cancer,1256
11,NCT01814501,Phase II,Recruiting,"[{'id': 1315, 'therapyName': 'FOLFIRI'}, {'id': 845, 'therapyName': 'Panitumumab'}]",Panitumumab and Chemotherapy in Patients With Advanced Colorectal Cancer After Prior Therapy With Bevacizumab,1256
12,NCT00979212,Phase II,"Active, not recruiting","[{'id': 845, 'therapyName': 'Panitumumab'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]",Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer (Cetuximab Closed as of 05/14/10),1256
13,NCT01202409,Phase II,"Active, not recruiting","[{'id': 845, 'therapyName': 'Panitumumab'}]",CAPOX in KRAS Wild-Type Advanced Adenocarcinoma of the Small Bowel or Ampulla of Vater,1256
14,NCT03087071,Phase II,Not yet recruiting,"[{'id': 845, 'therapyName': 'Panitumumab'}, {'id': 2, 'therapyName': 'Trametinib'}]",Panitumumab in Combination With Trametinib in Cetuximab-Refractory Stage IV Colorectal Cancer,1256
15,NCT01312857,Phase II,Recruiting,"[{'id': 845, 'therapyName': 'Panitumumab'}, {'id': 1315, 'therapyName': 'FOLFIRI'}, {'id': 1941, 'therapyName': 'Floxuridine'}]","Study of Hepatic Arterial Infusion With Intravenous Irinotecan, 5FU and Leucovorin With or Without Panitumumab, in Patients With Wild Type KRAS Who Have Resected Hepatic Metastases From Colorectal Cancer",1256
16,NCT01260415,Phase II,Completed,"[{'id': 845, 'therapyName': 'Panitumumab'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 1315, 'therapyName': 'FOLFIRI'}]",A Study of Perioperative Chemotherapy Plus Panitumumab in Patients With Colorectal Cancer Liver Metastases,1256
17,NCT01128387,Phase Ib/II,Completed,"[{'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 845, 'therapyName': 'Panitumumab'}, {'id': 700, 'therapyName': 'Cisplatin'}]",Trial of Panitumumab/Cisplatin/Fluorouracil With XRT in Esophageal Cancer,1256
18,NCT00610948,Phase I,Completed,"[{'id': 735, 'therapyName': 'Everolimus'}, {'id': 845, 'therapyName': 'Panitumumab'}]","Everolimus, Fluorouracil, Leucovorin, Panitumumab, and Oxaliplatin in Treating Patients With Solid Tumors That Did Not Respond to Treatment",1256
19,NCT02448810,Phase II,Terminated,"[{'id': 2278, 'therapyName': 'Fluorouracil + Leucovorin'}, {'id': 2996, 'therapyName': 'Imalumab'}, {'id': 845, 'therapyName': 'Panitumumab'}]",Phase 2a Study of BAX69 and 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer,1256
20,NCT00658658,Phase I,Completed,"[{'id': 845, 'therapyName': 'Panitumumab'}]",Panitumumab Pediatric Study,1256
21,NCT01927341,Phase Ib/II,Completed,"[{'id': 807, 'therapyName': 'Binimetinib'}, {'id': 845, 'therapyName': 'Panitumumab'}]","Phase Ib/II Study of Efficacy and Safety of MEK162 and Panitumumab, in Adult mCRC Patients With Mutant or Wild-type RAS Tumors",1256
22,NCT02508077,Phase II,Terminated,"[{'id': 1315, 'therapyName': 'FOLFIRI'}, {'id': 845, 'therapyName': 'Panitumumab'}]",FOLFIRI and Panitumumab in Treating Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer,1256
23,NCT01036087,Phase II,"Active, not recruiting","[{'id': 1984, 'therapyName': 'Panitumumab + Abraxane + Carboplatin'}, {'id': 1982, 'therapyName': 'Fluorouracil + Epirubicin + Cyclophosphamide'}]","Panitumumab, Nab-paclitaxel and Carboplatin for HER2 Negative Inflammatory Breast Cancer",1256
24,NCT02008383,Phase I,Recruiting,"[{'id': 1985, 'therapyName': 'Panitumumab + cabozantinib'}]",Cabozantinib and Panitumumab to Treat KRAS Wild-Type Metastatic Colorectal Cancer,1256
25,NCT01750918,Phase II,"Active, not recruiting","[{'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1718, 'therapyName': 'Panitumumab + Dabrafenib'}, {'id': 1992, 'therapyName': 'Panitumumab + Trametinib + Dabrafenib'}, {'id': 1991, 'therapyName': 'Panitumumab + Trametinib'}]",BRAF/MEK/EGFR Inhibitor Combination Study in Colorectal Cancer (CRC),1256
26,NCT00940316,Phase II,"Active, not recruiting","[{'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 1940, 'therapyName': 'Panitumumab + Erlotinib'}]",Dual Epidermal Growth Factor Receptor Inhibition With Erlotinib and Panitumumab With or Without Chemotherapy for Advanced Colorectal Cancer,1256
27,NCT01307956,Phase II,Unknown status,"[{'id': 1986, 'therapyName': 'Panitumumab + FOLFOX'}]","Panitumumab, Combination Chemotherapy, and Radiation Therapy Before Surgery in Treating Patients With Advanced Esophageal or Gastroesophageal Junction Cancer",1256
28,NCT02399943,Phase II,Recruiting,"[{'id': 1991, 'therapyName': 'Panitumumab + Trametinib'}]",A Trial of Trametinib and Panitumumab in RAS/RAF Wild Type Advanced Colorectal Cancer,1256
29,NCT02199223,Phase I,Terminated,"[{'id': 1617, 'therapyName': 'Regorafenib + Panitumumab'}]",Regorafenib + Panitumumab,1256
0,NCT02718833,Phase II,Recruiting,"[{'id': 4031, 'therapyName': 'Bortezomib + Dexamethasone + Elotuzumab + Panobinostat'}]","A Study of Elotuzumab With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed Multiple Myeloma",7196
1,NCT01440582,Phase I,"Active, not recruiting","[{'id': 3362, 'therapyName': 'Bortezomib + Dexamethasone + lenalidomide + Panobinostat'}]",Combination Therapy of Lenalidomide/Bortezomib/Dexamethasone and Panobinostat in Transplant Eligible New Diagnosed Multiple Myeloma (MM) Patients,7196
2,NCT01965353,Phase I,"Active, not recruiting","[{'id': 3362, 'therapyName': 'Bortezomib + Dexamethasone + lenalidomide + Panobinostat'}]",A Phase I Study Of Panobinostat/Lenalidomide/Bortezomib/Dex for Relapsed And Relapsed/Refractory Multiple Myeloma,7196
3,NCT02961816,Phase II,Withdrawn,"[{'id': 3277, 'therapyName': 'Pyridoxine'}, {'id': 4976, 'therapyName': 'Busulfan + Gemcitabine + Melphalan + Panobinostat'}, {'id': 4977, 'therapyName': 'Dexamethasone + Filgrastim + Palifermin + Rituximab'}]",Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Lymphoma,7196
4,NCT02802163,Phase Ib/II,Withdrawn,"[{'id': 4367, 'therapyName': 'Carfilzomib + Dexamethasone + lenalidomide + Panobinostat'}]","Induction Therapy for Multiple Myeloma With Carfilzomib, Lenalidomide,Dexamethasone,Panobinostat",7196
5,NCT03256045,Phase II,Not yet recruiting,"[{'id': 6289, 'therapyName': 'Carfilzomib + Dexamethasone + Panobinostat'}]","Panobinostat, Carfilzomib and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma",7196
6,NCT01301807,Phase I,"Active, not recruiting","[{'id': 3438, 'therapyName': 'Carfilzomib + Panobinostat'}]",Carfilzomib Plus Panobinostat in Relapsed/Refractory Multiple Myeloma (MM),7196
7,NCT01463046,Phase I,"Active, not recruiting","[{'id': 3185, 'therapyName': 'Cytarabine + Daunorubicin + Panobinostat'}]",Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome,7196
8,NCT02676323,Phase Ib/II,Recruiting,"[{'id': 3732, 'therapyName': 'Cytarabine + Fludarabine + Leucovorin + Panobinostat'}]",Panobinostat With Fludarabine and Cytarabine for Treatment of Children With Acute Myeloid Leukemia or Myelodysplastic Syndrome,7196
9,NCT00925132,Phase Ib/II,Terminated,"[{'id': 1737, 'therapyName': 'Decitabine + Temozolomide + Panobinostat'}]","Treatment of Resistant Metastatic Melanoma Using Decitabine, Temozolomide and Panobinostat",7196
10,NCT02057640,Phase Ib/II,"Active, not recruiting","[{'id': 4565, 'therapyName': 'Dexamethasone + Ixazomib + Panobinostat'}]",MLN9708 (Ixazomib) in Combination With Panobinostat and Dexamethasone in Multiple Myeloma,7196
11,NCT02032810,Phase I,"Active, not recruiting","[{'id': 1080, 'therapyName': 'Panobinostat'}, {'id': 779, 'therapyName': 'Ipilimumab'}]",Phase I of Histone Deacetylase (HDAC) Inhibitor Panobinostat With Ipilimumab With Unresectable III/IV Melanoma,7196
12,NCT01321346,Phase I,Completed,"[{'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1080, 'therapyName': 'Panobinostat'}]",A Study Of Panobinostat In Children With Refractory Hematologic Malignancies,7196
13,NCT01169636,Phase Ib/II,Completed,"[{'id': 1080, 'therapyName': 'Panobinostat'}, {'id': 1476, 'therapyName': 'Pegfilgrastim'}, {'id': 2352, 'therapyName': 'Carboplatin + Etoposide + Ifosfamide '}]","Panobinostat Plus Ifosfamide, Carboplatin, and Etoposide (ICE) Compared With ICE For Relapsed Hodgkin Lymphoma",7196
14,NCT01336842,Phase I,Completed,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1080, 'therapyName': 'Panobinostat'}, {'id': 854, 'therapyName': 'Pemetrexed'}]",Study of Cisplatin and Pemetrexed in Combination With Panobinostat in Solid Tumors,7196
15,NCT02506959,Phase II,Recruiting,"[{'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 2558, 'therapyName': 'Busulfan + Melphalan'}, {'id': 3277, 'therapyName': 'Pyridoxine'}, {'id': 1080, 'therapyName': 'Panobinostat'}, {'id': 2373, 'therapyName': 'Palifermin'}, {'id': 755, 'therapyName': 'Gemcitabine'}]",Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Myeloma,7196
16,NCT02720510,Phase II,Recruiting,"[{'id': 1080, 'therapyName': 'Panobinostat'}, {'id': 3342, 'therapyName': 'Bortezomib + Dexamethasone + lenalidomide'}]","A Trial Evaluating Efficacy & Safety of RVD +/- Panobinostat in Transplant Eligible, Newly Diagnosed Multiple Myeloma (NDMM)",7196
17,NCT00946647,Phase II,"Active, not recruiting","[{'id': 1080, 'therapyName': 'Panobinostat'}, {'id': 651, 'therapyName': 'Azacitidine'}]","A Phase Ib/IIb, Open-label, Multi-center, Study of Oral Panobinostat Administered With 5-Azacitidine (in Adult Patients With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML).",7196
18,NCT01032148,Phase I,Terminated,"[{'id': 1080, 'therapyName': 'Panobinostat'}]","Study of LBH589, A Deacetylase Inhibitor in Patients With Recurrent or Refractory Hodgkin or Non-Hodgkin's Lymphoma",7196
19,NCT02717455,Phase I,Recruiting,"[{'id': 1080, 'therapyName': 'Panobinostat'}]",Trial of Panobinostat in Children With Diffuse Intrinsic Pontine Glioma,7196
20,NCT02722941,Phase II,Recruiting,"[{'id': 1080, 'therapyName': 'Panobinostat'}]",Panobinostat (LBH589): Multiple Myeloma - Autologous Hematopoietic Cell Transplantation (HCT),7196
21,NCT02518750,Phase II,Recruiting,"[{'id': 1604, 'therapyName': 'Panobinostat + Bortezomib + Dexamethasone'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 3160, 'therapyName': 'Nelarabine'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 3217, 'therapyName': 'Cyclophosphamide + Etoposide'}, {'id': 3216, 'therapyName': 'Cytarabine + Methotrexate + Prednisone'}, {'id': 1746, 'therapyName': 'Clofarabine'}]",Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoma,7196
22,NCT02654990,Phase II,Recruiting,"[{'id': 1604, 'therapyName': 'Panobinostat + Bortezomib + Dexamethasone'}]",Panobinostat/Bortezomib/Dexamethasone in Relapsed or Relapsed-and-refractory Multiple Myeloma,7196
23,NCT02568943,Phase I,Available,"[{'id': 1604, 'therapyName': 'Panobinostat + Bortezomib + Dexamethasone'}]","An Expanded Treatment Protocol of Panobinostat in Combination Therapy for Relapsed, and Relapsed and Refractory Multiple Myeloma",7196
24,NCT02204553,Phase I,No longer available,"[{'id': 1604, 'therapyName': 'Panobinostat + Bortezomib + Dexamethasone'}]",Expanded Treatment Prot of Panobinostat in Combo w/ Bortez and Dex in Pts w/ Relapsed and/or Refractory Multiple Myeloma,7196
25,NCT00918333,Phase Ib/II,"Active, not recruiting","[{'id': 1964, 'therapyName': 'Panobinostat + Everolimus'}]","Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma",7196
26,NCT01582009,Phase Ib/II,Terminated,"[{'id': 1964, 'therapyName': 'Panobinostat + Everolimus'}]",Panobinostat and Everolimus in Treating Patients With Metastatic or Unresectable Renal Cell Cancer That Does Not Respond to Treatment With Sunitinib Malate or Sorafenib Tosylate,7196
27,NCT00978432,Phase II,Terminated,"[{'id': 1964, 'therapyName': 'Panobinostat + Everolimus'}]",Epigenetic Modulation in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL),7196
28,NCT01543763,Phase I,"Active, not recruiting","[{'id': 3046, 'therapyName': 'Panobinostat + Pazopanib'}]","Phase I Tolerability, Efficacy, and Safety Study of Pazopanib in Combination With PCI-24781 in Patients With Metastatic Solid Tumors",7196
29,NCT01005797,Phase I,Completed,"[{'id': 1131, 'therapyName': 'Panobinostat + Sorafenib'}]","Study of Panobinostat in Combination With Sorafenib in Kidney, Soft Tissue or Lung Cancers",7196
30,NCT02890069,Phase I,Recruiting,"[{'id': 5311, 'therapyName': 'PDR001 + LCL161'}, {'id': 5312, 'therapyName': 'PDR001 + Everolimus'}, {'id': 5313, 'therapyName': 'PDR001 + Panobinostat'}]","A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat",7196
0,NCT02134015,Phase III,Terminated,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 2530, 'therapyName': 'Patritumab + Erlotinib'}]",Study of Patritumab in Combination With Erlotinib in Subjects With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC). (HER3-Lung),7536
0,NCT01639911,Phase I,Completed,"[{'id': 1212, 'therapyName': 'Alisertib + Pazopanib'}]",MLN8237 and Pazopanib in Combination for Solid Tumors,4734
1,NCT02795819,Phase I,Suspended,"[{'id': 4267, 'therapyName': 'AR-42 + Pazopanib'}]",Study of the Pan-DAC Inhibitor AR-42 and Pazopanib in Advanced Sarcoma and Kidney Cancer,4734
2,NCT01548144,Phase I,"Active, not recruiting","[{'id': 1153, 'therapyName': 'Crizotinib + Pazopanib'}, {'id': 1151, 'therapyName': 'Crizotinib + Pemetrexed'}, {'id': 1156, 'therapyName': 'Pazopanib + Pemetrexed'}, {'id': 1155, 'therapyName': 'Crizotinib + Pazopanib + Pemetrexed'}]",Pazopanib or Pemetrexed and Crizotinib in Advanced Cancer,4734
3,NCT01713972,Phase I,"Active, not recruiting","[{'id': 1233, 'therapyName': 'Dabrafenib + Pazopanib'}]", Dabrafenib and Pazopanib Hydrochloride in Treating Patients With Advanced Malignant Tumors,4734
4,NCT01385228,Phase I,Completed,"[{'id': 2042, 'therapyName': 'Docetaxel + Pazopanib + Pegfilgrastim'}]","Pazopanib, Docetaxel, Prednisone Prostate",4734
5,NCT01184326,Phase I,Completed,"[{'id': 1806, 'therapyName': 'everolimus + pazopanib'}]",An Expanded Phase I Study of Pazopanib and Everolimus in Patients With Advanced Solid Tumors and Previously Treated Advanced Urothelial Cancer,4734
6,NCT01485042,Phase I,Completed,"[{'id': 1318, 'therapyName': 'Evofosfamide + Pazopanib'}]",Dose Escalation Study of Pazopanib Plus TH-302,4734
7,NCT01719302,Phase Ib/II,Completed,"[{'id': 1470, 'therapyName': 'Gemcitabine + Docetaxel + Pazopanib'}]","Docetaxel, Gemcitabine and Pazopanib as Treatment for Soft Tissue Sarcoma",4734
8,NCT01418001,Phase Ib/II,Terminated,"[{'id': 1470, 'therapyName': 'Gemcitabine + Docetaxel + Pazopanib'}]",Gemcitabine and Docetaxel in Combination With Pazopanib (Gem/Doce/Pzb) for the Neoadjuvant Treatment of Soft Tissue Sarcoma (STS),4734
9,NCT01593748,Phase II,"Active, not recruiting","[{'id': 1439, 'therapyName': 'Gemcitabine + Docetaxel'}, {'id': 1478, 'therapyName': 'Gemcitabine + Pazopanib'}]",A Treatment Trial Comparing Gemcitabine and Pazopanib Versus Gemcitabine and Docetaxel for Patients With Advanced Soft Tissue Sarcoma,4734
10,NCT01610206,Phase II,"Active, not recruiting","[{'id': 1478, 'therapyName': 'Gemcitabine + Pazopanib'}, {'id': 755, 'therapyName': 'Gemcitabine'}]",A Randomized Study of Safety and Efficacy of Pazopanib and Gemcitabine in Persistent or Relapsed Ovarian Cancer,4734
11,NCT01532687,Phase II,Recruiting,"[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1478, 'therapyName': 'Gemcitabine + Pazopanib'}]",Gemcitabine Hydrochloride With or Without Pazopanib Hydrochloride in Treating Patients With Refractory Soft Tissue Sarcoma,4734
12,NCT03149120,Phase II,Withdrawn,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 5681, 'therapyName': 'Nivolumab + Pazopanib'}]",Study of Nivolumab With or Without Pazopanib in Metastatic or Unresectable Soft Tissue Sarcomas,4734
13,NCT01543763,Phase I,"Active, not recruiting","[{'id': 3046, 'therapyName': 'Panobinostat + Pazopanib'}]","Phase I Tolerability, Efficacy, and Safety Study of Pazopanib in Combination With PCI-24781 in Patients With Metastatic Solid Tumors",4734
14,NCT02014636,Phase I,"Active, not recruiting","[{'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Safety and Efficacy Study of Pazopanib and MK 3475 in Advanced Renal Cell Carcinoma (RCC),4734
15,NCT02406521,Phase I,"Active, not recruiting","[{'id': 848, 'therapyName': 'Pazopanib'}, {'id': 2001, 'therapyName': 'radium Ra 223 dichloride'}, {'id': 920, 'therapyName': 'Sorafenib'}]",Exploratory Study of Radium-223 and Vascular Endothelial Growth Factor-Targeted Therapy in Patients With Metastatic Renal Cell Carcinoma and Bone Metastases,4734
16,NCT01599832,Phase I,Terminated,"[{'id': 848, 'therapyName': 'Pazopanib'}]",Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Measuring Effects of Pazopanib Hydrochloride in Patients With Metastatic Kidney Cancer,4734
17,NCT02049905,Phase III,Completed,"[{'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1440, 'therapyName': 'Aldoxorubicin'}, {'id': 1439, 'therapyName': 'Gemcitabine + Docetaxel'}]",Phase 3 Study to Treat Patients With Soft Tissue Sarcomas,4734
18,NCT01217931,Phase II,"Active, not recruiting","[{'id': 735, 'therapyName': 'Everolimus'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 667, 'therapyName': 'Bevacizumab'}]",Sequential Two-agent Assessment in Renal Cell Carcinoma Therapy,4734
19,NCT01759303,Phase II,"Active, not recruiting","[{'id': 848, 'therapyName': 'Pazopanib'}]",Study of Pazopanib in the Treatment of Osteosarcoma Metastatic to the Lung,4734
20,NCT01552356,Phase I,"Active, not recruiting","[{'id': 848, 'therapyName': 'Pazopanib'}]",Pazopanib Hydrochloride in Treating Patients With Advanced or Refractory Solid Tumors,4734
21,NCT02729194,Phase I,Recruiting,"[{'id': 848, 'therapyName': 'Pazopanib'}]",Pilot Study of Pazopanib With Low Fat Meal (PALM) in Advanced Renal Cell Carcinoma,4734
22,NCT02180867,Phase II,Recruiting,"[{'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1472, 'therapyName': 'Doxorubicin + Ifosfamide'}]",Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Hydrochloride Before Surgery in Treating Patients With Newly Diagnosed Non-Rhabdomyosarcoma Soft Tissue Sarcomas That Can be Removed by Surgery (PAZNTIS),4734
23,NCT01767636,Phase II,Recruiting,"[{'id': 848, 'therapyName': 'Pazopanib'}]",Pazopanib in Treating Patients With Metastatic Non-Clear Cell Kidney Cancer,4734
24,NCT01832259,Phase II,"Active, not recruiting","[{'id': 848, 'therapyName': 'Pazopanib'}]",A Study of VEGF Tyrosine Kinase Inhibitor (Pazopanib) in Men With High-Risk Prostate Cancer Followed by Radical Prostatectomy and Pelvic Lymph Node Dissection,4734
25,NCT02300545,Phase II,Recruiting,"[{'id': 848, 'therapyName': 'Pazopanib'}]",Pazopanib as Front-Line Therapy in Patients With Non-Resectable or Metastatic Soft Tissue Sarcomas Who Are Not Candidates for Chemotherapy,4734
26,NCT02193152,Phase I,Recruiting,"[{'id': 848, 'therapyName': 'Pazopanib'}]",Pazopanib in Molecularly Selected Patients With Advanced NSCLC,4734
27,NCT01575548,Phase III,"Active, not recruiting","[{'id': 848, 'therapyName': 'Pazopanib'}]",Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery,4734
28,NCT02009449,Phase I,"Active, not recruiting","[{'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 2621, 'therapyName': 'AM0010 '}, {'id': 619, 'therapyName': 'Abraxane'}]",A Phase 1 Study of AM0010 in Patients With Advanced Solid Tumors,4734
29,NCT02307474,Phase I,Withdrawn,"[{'id': 848, 'therapyName': 'Pazopanib'}]",A Pilot Study of SBRT With Adjuvant Pazopanib for Renal Cell Cancer,4734
30,NCT02551718,Phase I,Recruiting,"[{'id': 690, 'therapyName': 'Bosutinib'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 3160, 'therapyName': 'Nelarabine'}, {'id': 3159, 'therapyName': 'Bexarotene'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 998, 'therapyName': 'cabozantinib'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 877, 'therapyName': 'Ponatinib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 623, 'therapyName': 'Afatinib'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 890, 'therapyName': 'Regorafenib'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 2, 'therapyName': 'Trametinib'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 3, 'therapyName': 'Dabrafenib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 789, 'therapyName': 'Ceritinib'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1571, 'therapyName': 'Cabazitaxel'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1327, 'therapyName': 'Pralatrexate'}]",High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia,4734
31,NCT02560012,Phase II,Terminated,"[{'id': 735, 'therapyName': 'Everolimus'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 848, 'therapyName': 'Pazopanib'}]",Personalized Targeted Inhibitors Treatment in Renal Cell Cancer,4734
32,NCT02601209,Phase Ib/II,Suspended,"[{'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1282, 'therapyName': 'Sapanisertib'}]",Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma,4734
33,NCT02979899,Phase III,Recruiting,"[{'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1431, 'therapyName': 'TRC105 + Pazopanib'}]",A RANDOMIZED PHASE 3 TRIAL OF TRC105 AND PAZOPANIB VERSUS PAZOPANIB ALONE IN PATIENTS WITH ADVANCED ANGIOSARCOMA (TAPPAS),4734
34,NCT01361113,Phase II,Completed,"[{'id': 848, 'therapyName': 'Pazopanib'}]",Neoadjuvant Pazopanib in Renal Cell Carcinoma,4734
35,NCT02956798,Phase II,Not yet recruiting,"[{'id': 848, 'therapyName': 'Pazopanib'}]",Pazopanib Vs. Local Therapy for Renal Cancer With Metastases,4734
36,NCT01841736,Phase II,"Active, not recruiting","[{'id': 848, 'therapyName': 'Pazopanib'}]",Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors,4734
37,NCT01407562,Phase I,"Active, not recruiting","[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}]","Study of Pazopanib, Paclitaxel, and Carboplatin in Patients With Advanced Solid Tumors",4734
38,NCT01466972,Phase II,"Active, not recruiting","[{'id': 848, 'therapyName': 'Pazopanib'}]",Reversing Hormone Resistance in Advanced Breast Cancer With Pazopanib,4734
39,NCT01956669,Phase II,Recruiting,"[{'id': 848, 'therapyName': 'Pazopanib'}]",Pazopanib Paediatric Phase II Trial Children's Oncology Group (COG) in Solid Tumors,4734
40,NCT01506596,,Completed,"[{'id': 848, 'therapyName': 'Pazopanib'}]",Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Liposarcoma,4734
41,NCT01330966,Phase II,"Active, not recruiting","[{'id': 848, 'therapyName': 'Pazopanib'}]",Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Chondrosarcoma,4734
42,NCT01221506,Phase I,Completed,"[{'id': 848, 'therapyName': 'Pazopanib'}]",Pazopanib/DCE-MRIs in Renal Cell Carcinoma (RCC),4734
43,NCT01236547,Phase II,"Active, not recruiting","[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}]",Intensity-Modulated Radiation Therapy and Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Anaplastic Thyroid Cancer,4734
44,NCT01462630,Phase II,Recruiting,"[{'id': 848, 'therapyName': 'Pazopanib'}]",Pazopanib Hydrochloride in Treating Patients With Advanced Angiosarcoma,4734
45,NCT01582204,Phase I,Recruiting,"[{'id': 848, 'therapyName': 'Pazopanib'}, {'id': 930, 'therapyName': 'Sunitinib'}]",Evaluate The Utility Of 124I-cG250 for The Early Detection Of Response to Therapy In Patients With Metastatic Renal Cell Carcinoma,4734
46,NCT01158521,Phase II,Completed,"[{'id': 848, 'therapyName': 'Pazopanib'}]",Pazopanib Hydrochloride Before Surgery in Treating Patients With Kidney Cancer,4734
47,NCT02788201,Phase II,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1133, 'therapyName': 'Mitomycin C'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1013, 'therapyName': 'epirubicin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1137, 'therapyName': 'Bleomycin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 781, 'therapyName': 'Ixabepilone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 2950, 'therapyName': 'Estramustine'}, {'id': 1941, 'therapyName': 'Floxuridine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 1811, 'therapyName': 'Carmustine'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 953, 'therapyName': 'Vandetanib'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 4419, 'therapyName': 'Toremifine'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 2601, 'therapyName': 'Dactinomycin'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 3035, 'therapyName': 'Chlorambucil'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 342, 'therapyName': 'Vemurafenib'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 2635, 'therapyName': 'Vinblastine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 4305, 'therapyName': 'Teniposide'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 4304, 'therapyName': 'Streptozocin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1231, 'therapyName': 'Bendamustine'}, {'id': 4303, 'therapyName': 'Mechlorethamine'}, {'id': 4302, 'therapyName': 'Mitotane'}]",Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma,4734
48,NCT01339871,Phase I,Completed,"[{'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 848, 'therapyName': 'Pazopanib'}]",Phase I Study of Pazopanib and Vorinostat,4734
49,NCT01392183,Phase II,"Active, not recruiting","[{'id': 1275, 'therapyName': 'Diphenhydramine'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 848, 'therapyName': 'Pazopanib'}]",Pazopanib Versus Temsirolimus in Poor-Risk Clear-Cell Renal Cell Carcinoma (RCC),4734
50,NCT01468922,Phase I,Completed,"[{'id': 636, 'therapyName': 'Tivantinib'}, {'id': 848, 'therapyName': 'Pazopanib'}]",Pazopanib and ARQ 197 for Advanced Solid Tumors,4734
51,NCT01684397,Phase Ib/II,Recruiting,"[{'id': 1230, 'therapyName': 'Pazopanib + Bevacizumab'}]",Pazopanib Hydrochloride and Bevacizumab in Treating Patients With Previously Untreated Metastatic Kidney Cancer,4734
52,NCT01716416,Phase I,"Active, not recruiting","[{'id': 1838, 'therapyName': 'Pazopanib + Cetuximab'}]",Pazopanib Plus Cetuximab for Incurable Head and Neck Squamous Cell Carcinoma (HNSCC),4734
53,NCT01446809,Phase I,"Active, not recruiting","[{'id': 1472, 'therapyName': 'Doxorubicin + Ifosfamide'}, {'id': 1471, 'therapyName': 'Pazopanib + Doxorubicin + Ifosfamide'}]",Pazopanib Hydrochloride Followed By Chemotherapy and Surgery in Treating Patients With Soft Tissue Sarcoma,4734
54,NCT03139331,Phase I,Recruiting,"[{'id': 5635, 'therapyName': 'Pazopanib + Irinotecan + Temozolomide'}]",PAZIT Study for Children and Young Adults With Relapsed or Refractory Sarcoma,4734
55,NCT01107665,Phase II,"Active, not recruiting","[{'id': 1143, 'therapyName': 'Pazopanib + Paclitaxel'}]",Pazopanib and Paclitaxel as First-Line Treatment for Subjects With Unresectable Stage III and Stage IV Melanoma,4734
56,NCT01108055,Phase II,Completed,"[{'id': 1143, 'therapyName': 'Pazopanib + Paclitaxel'}]",Phase II Pazopanib in Combination With Weekly Paclitaxel in Refractory Urothelial Cancer,4734
57,NCT01179269,Phase II,Withdrawn,"[{'id': 1143, 'therapyName': 'Pazopanib + Paclitaxel'}]",Stage IIIB/IV Non-Small Cell Lung Cancer,4734
58,NCT01465659,Phase Ib/II,Recruiting,"[{'id': 2040, 'therapyName': 'Pazopanib + Temozolomide'}]",Temozolomide and Pazopanib Hydrochloride in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors That Cannot Be Removed By Surgery,4734
59,NCT01438554,Phase I,"Active, not recruiting","[{'id': 1310, 'therapyName': 'Pazopanib + Trametinib'}]","Phase 1 Study of Pazopanib With GSK1120212 in Advanced Solid Tumors, Enriched With Patients With Differentiated Thyroid Cancer, Soft-tissue Sarcoma, and Cholangiocarcinoma",4734
60,NCT00800345,Phase I,Completed,"[{'id': 1469, 'therapyName': 'Topotecan + Pazopanib'}]",Phase I Trial of Oral Metronomic Topotecan and Oral Pazopanib to Treat Recurrent/Persistent Gynecologic Tumors,4734
61,NCT02303028,Phase Ib/II,Recruiting,"[{'id': 1469, 'therapyName': 'Topotecan + Pazopanib'}]",Phase I Dose Escalation Study of Topotecan and Pazopanib in Children With Recurrent/Refractory Solid and CNS Tumours,4734
62,NCT02357810,Phase II,Recruiting,"[{'id': 1469, 'therapyName': 'Topotecan + Pazopanib'}]",Pazopanib Hydrochloride and Topotecan Hydrochloride in Treating Patients With Metastatic Soft Tissue and Bone Sarcomas,4734
63,NCT02348398,Phase II,Withdrawn,"[{'id': 1469, 'therapyName': 'Topotecan + Pazopanib'}]",Phase II Study of Pazopanib and Topotecan in Cervical Cancer,4734
64,NCT01931098,Phase II,Not yet recruiting,"[{'id': 1469, 'therapyName': 'Topotecan + Pazopanib'}]",Phase II Pazopanib Plus Topotecan for Recurrent Glioblastoma Multiforme (GBM),4734
65,NCT01975519,Phase I,"Active, not recruiting","[{'id': 1431, 'therapyName': 'TRC105 + Pazopanib'}]",A Phase 1B Dose-escalation Study of TRC105 in Combination With Pazopanib in Patients With Advanced Soft Tissue Sarcoma,4734
66,NCT01664182,Phase II,"Active, not recruiting","[{'id': 1223, 'therapyName': 'Trebananib + Sunitinib'}, {'id': 1220, 'therapyName': 'Trebananib + Pazopanib'}, {'id': 1221, 'therapyName': 'Trebananib + Sorafenib'}, {'id': 1218, 'therapyName': 'Trebananib'}, {'id': 1219, 'therapyName': 'Trebananib + Bevacizumab'}]","Trebananib With or Without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Treating Patients With Advanced Kidney Cancer",4734
0,NCT02403193,Phase Ib/II,Recruiting,"[{'id': 4741, 'therapyName': 'PBF-509 + PDR001'}, {'id': 4740, 'therapyName': 'PBF-509'}]",Trial of PBF-509 and PDR001 in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) (AdenONCO),8535
0,NCT02948101,Phase II,Not yet recruiting,"[{'id': 5848, 'therapyName': 'Cyclophosphamide + PD 0360324'}]",Pre-Conditioning Effects of Anti-Macrophage Therapy Using PD 0360324 in Recurrent Platinum-Resistant Epithelial Ovarian Cancer,8811
0,NCT01347866,Phase I,Terminated,"[{'id': 1040, 'therapyName': 'PF-05212384'}, {'id': 849, 'therapyName': 'PD-0325901'}, {'id': 1074, 'therapyName': 'Irinotecan'}]",Clinical Study Of PI3K/mTOR Inhibitors In Combination With An Oral MEK Inhibitor Or Irinotecan In Patients With Advanced Cancer,6977
1,NCT02096471,Phase II,"Active, not recruiting","[{'id': 849, 'therapyName': 'PD-0325901'}]",MEK Inhibitor PD-0325901 Trial in Adolescents and Adults With NF1,6977
2,NCT02022982,Phase Ib/II,Recruiting,"[{'id': 1823, 'therapyName': 'PD-0325901 + Palbociclib'}]",PALBOCICLIB + PD-0325901 for NSCLC & Solid Tumors,6977
0,NCT02829723,Phase Ib/II,Recruiting,"[{'id': 2844, 'therapyName': 'BLZ945'}, {'id': 5071, 'therapyName': 'BLZ945 + PDR001'}]",Phase I/II Study of BLZ945 Single Agent or BLZ945 in Combination With PDR001 in Advanced Solid Tumors,7634
1,NCT03064854,Phase I,Recruiting,"[{'id': 6027, 'therapyName': 'Carboplatin + Paclitaxel + PDR001'}, {'id': 6026, 'therapyName': 'Cisplatin + Pemetrexed + PDR001'}, {'id': 6025, 'therapyName': 'Cisplatin + Gemcitabine + PDR001'}, {'id': 6024, 'therapyName': 'Pemetrexed + PDR001 + Cisplatin + Carboplatin'}]","PDR001 in Combination With Platinum-doublet Chemotherapy in PD-L1 Unselected, Metastatic NSCLC Patients (ElevatION:NSCLC-101 Trial)",7634
2,NCT02967692,Phase III,Recruiting,"[{'id': 6023, 'therapyName': 'Dabrafenib + Trametinib + PDR001'}, {'id': 1066, 'therapyName': 'Trametinib + Dabrafenib'}]","A Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced Melanoma",7634
3,NCT02936102,Phase I,Recruiting,"[{'id': 4971, 'therapyName': 'FAZ053'}, {'id': 4972, 'therapyName': 'FAZ053 + PDR001'}]",A Study of FAZ053 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.,7634
4,NCT03294694,Phase I,Not yet recruiting,"[{'id': 6285, 'therapyName': 'Fulvestrant + PDR001 + Ribociclib'}, {'id': 6284, 'therapyName': 'PDR001 + Ribociclib'}]",Ribociclib + PDR001 in Breast Cancer and Ovarian Cancer,7634
5,NCT02740270,Phase I,Recruiting,"[{'id': 4469, 'therapyName': 'GWN 323 + PDR001'}, {'id': 4468, 'therapyName': 'GWN 323'}]",Phase I/Ib Study of GWN323 Alone and in Combination With PDR001 in Patients With Advanced Malignancies and Lymphomas,7634
6,NCT02795429,Phase Ib/II,Recruiting,"[{'id': 2659, 'therapyName': 'PDR001'}, {'id': 4492, 'therapyName': 'INC280 + PDR001'}]",Phase Ib/II Study of INC280 + PDR001 or PDR001 Single Agent in Advanced HCC,7634
7,NCT03301896,Phase I,Not yet recruiting,"[{'id': 6299, 'therapyName': 'LHC165 + PDR001'}, {'id': 6298, 'therapyName': 'LHC165'}]",Phase I/Ib Study of LHC165 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies,7634
8,NCT02607813,Phase I,Recruiting,"[{'id': 4443, 'therapyName': 'LXH 254 + PDR001'}, {'id': 4442, 'therapyName': 'LXH 254'}]",Phase I Study of LXH254 in Patients With Advanced Solid Tumors Haboring MAPK Pathway Alterations,7634
9,NCT02807844,Phase Ib/II,Recruiting,"[{'id': 5072, 'therapyName': 'MCS110 + PDR001'}]",Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies,7634
10,NCT03172936,Phase I,Recruiting,"[{'id': 6219, 'therapyName': 'MIW815 + PDR001'}]",Study of the Safety and Efficacy of MIW815 With PDR001 to Patients With Advanced/Metastatic Solid Tumors or Lymphomas,7634
11,NCT02947165,Phase I,Recruiting,"[{'id': 5632, 'therapyName': 'NIS793 + PDR001'}, {'id': 5631, 'therapyName': 'NIS793'}]",Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies.,7634
12,NCT02403193,Phase Ib/II,Recruiting,"[{'id': 4741, 'therapyName': 'PBF-509 + PDR001'}, {'id': 4740, 'therapyName': 'PBF-509'}]",Trial of PBF-509 and PDR001 in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) (AdenONCO),7634
13,NCT02404441,Phase Ib/II,Recruiting,"[{'id': 2659, 'therapyName': 'PDR001'}]",Phase I/II Study of PDR001 in Patients With Advanced Malignancies,7634
14,NCT02605967,Phase II,Recruiting,"[{'id': 2659, 'therapyName': 'PDR001'}]",Safety and Efficacy Study of PDR001 in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma,7634
15,NCT02608268,Phase Ib/II,Recruiting,"[{'id': 2659, 'therapyName': 'PDR001'}, {'id': 3560, 'therapyName': 'MBG453'}]",Safety and Efficacy of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies,7634
16,NCT02460224,Phase Ib/II,Recruiting,"[{'id': 2887, 'therapyName': 'LAG525'}, {'id': 2659, 'therapyName': 'PDR001'}]",Safety and Efficay of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies,7634
17,NCT02955069,Phase II,Recruiting,"[{'id': 2659, 'therapyName': 'PDR001'}]","Study of Efficacy and Safety of PDR001 in Patients With Advanced or Metastatic Non-functional Neuroendocrine Tumors of Pancreatic, Gastrointestinal (GI), or Thoracic Origin",7634
18,NCT03111992,Phase I,Recruiting,"[{'id': 5311, 'therapyName': 'PDR001 + LCL161'}, {'id': 5397, 'therapyName': 'PDR001 + CJM112'}, {'id': 2659, 'therapyName': 'PDR001'}]","Study of Single Agent CJM112, and PDR001 in Combination With LCL161 or CJM112 in Patients With Multiple Myeloma",7634
19,NCT02900664,Phase I,Recruiting,"[{'id': 5399, 'therapyName': 'PDR001 + EGF816'}, {'id': 5397, 'therapyName': 'PDR001 + CJM112'}, {'id': 5398, 'therapyName': 'PDR001 + Trametinib'}, {'id': 5395, 'therapyName': 'PDR001 + Canakinumab'}]","A Study of PDR001 in Combination With CJM112, EGF816, Ilaris (Canakinumab) or Mekinist (Trametinib)",7634
20,NCT02890069,Phase I,Recruiting,"[{'id': 5311, 'therapyName': 'PDR001 + LCL161'}, {'id': 5312, 'therapyName': 'PDR001 + Everolimus'}, {'id': 5313, 'therapyName': 'PDR001 + Panobinostat'}]","A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat",7634
21,NCT02452268,Phase I,Recruiting,"[{'id': 6032, 'therapyName': 'PDR001 + NIZ985'}]",A Phase I/Ib Study of NIZ985 in Combination With PDR001 in Adults With Metastatic Cancers,7634
22,NCT03081494,Phase I,Recruiting,"[{'id': 5930, 'therapyName': 'PDR001 + Regorafenib'}]",Phase Ib Study of PDR001 in Combination With Regorafenib in Adult Patients With Previously Treated Metastatic Colorectal Cancer,7634
23,NCT02988440,Phase I,Recruiting,"[{'id': 5590, 'therapyName': 'PDR001 + Sorafenib'}]",Study of Safety and Tolerability of PDR001 in Combination With Sorafenib and to Identify the Maximum Tolerated Dose and/or Phase 2 Dose for This Combination in Advanced Hepatocellular Patients,7634
0,NCT02174172,Phase I,Recruiting,"[{'id': 6252, 'therapyName': 'Atezolizumab + Bevacizumab +Peg-interferon alfa-2a'}, {'id': 6253, 'therapyName': 'Atezolizumab + Interferon alfa-2b'}, {'id': 6250, 'therapyName': 'Atezolizumab + Peg-interferon alfa-2a'}, {'id': 6249, 'therapyName': 'Atezolizumab + Ipilimumab'}, {'id': 1975, 'therapyName': 'Atezolizumab + Obinutuzumab'}]",A Study to Assess the Safety and Tolerability of MPDL3280A in Combination With Other Immune-modulating Therapies in Patients With Locally Advanced or Metastatic Solid Tumors,8955
0,NCT00550992,Phase I,Unknown status,"[{'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1752, 'therapyName': 'Mitoxantrone + Etoposide + Cytarabine'}, {'id': 1848, 'therapyName': 'Cyclophosphamide + Methotrexate + Vincristine + Pegaspargase '}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1650, 'therapyName': 'Cyclosporine'}, {'id': 1844, 'therapyName': 'anti-thymocyte globulin'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1642, 'therapyName': 'Leucovorin'}]",Different Therapies in Treating Infants With Newly Diagnosed Acute Leukemia,58
1,NCT02723994,Phase II,Recruiting,"[{'id': 2188, 'therapyName': 'Prednisone'}, {'id': 4685, 'therapyName': 'Dexamethasone + Doxorubicin'}, {'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 2346, 'therapyName': 'Mercaptopurine + Thioguanine'}, {'id': 2394, 'therapyName': 'Asparaginase + Cytarabine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 1848, 'therapyName': 'Cyclophosphamide + Methotrexate + Vincristine + Pegaspargase '}]",A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia,58
2,NCT02101853,Phase III,Recruiting,"[{'id': 1876, 'therapyName': 'Blinatumomab '}, {'id': 2347, 'therapyName': 'Leucovorin + Pegaspargase  + Vincristine'}, {'id': 2346, 'therapyName': 'Mercaptopurine + Thioguanine'}, {'id': 2348, 'therapyName': 'Asparaginase + Cyclophosphamide + Etoposide'}, {'id': 2345, 'therapyName': 'Cytarabine + Dexamethasone+ Methotrexate '}]",Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia,58
3,NCT02112916,Phase III,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1009, 'therapyName': 'Doxorubicin'}]",Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma,58
4,NCT03007147,Phase III,Recruiting,"[{'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 5153, 'therapyName': 'dexrazoxane'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 5167, 'therapyName': 'Methylprednisolone'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 5168, 'therapyName': 'Prednisolone'}, {'id': 1009, 'therapyName': 'Doxorubicin'}]",Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia,58
5,NCT01483690,Phase Ib/II,Terminated,"[{'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}]",A Pilot Study of Decitabine and Vorinostat With Chemotherapy for Relapsed ALL,58
6,NCT03020030,Phase III,Recruiting,"[{'id': 3160, 'therapyName': 'Nelarabine'}, {'id': 5153, 'therapyName': 'dexrazoxane'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1642, 'therapyName': 'Leucovorin'}]",Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents,58
7,NCT02518750,Phase II,Recruiting,"[{'id': 1604, 'therapyName': 'Panobinostat + Bortezomib + Dexamethasone'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 3160, 'therapyName': 'Nelarabine'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 3217, 'therapyName': 'Cyclophosphamide + Etoposide'}, {'id': 3216, 'therapyName': 'Cytarabine + Methotrexate + Prednisone'}, {'id': 1746, 'therapyName': 'Clofarabine'}]",Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoma,58
8,NCT02419755,Phase II,Terminated,"[{'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 2188, 'therapyName': 'Prednisone'}]",Bortezomib and Vorinostat in Younger Patients With Refractory or Relapsed MLL Rearranged Hematologic Malignancies,58
9,NCT02043587,Phase II,Recruiting,"[{'id': 897, 'therapyName': 'Rituximab'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1136, 'therapyName': 'Etoposide'}]",Chemotherapy With Liposomal Cytarabine CNS Prophylaxis for Adult Acute Lymphoblastic Leukemia &amp; Lymphoblastic Lymphoma,58
10,NCT02535806,Phase II,Terminated,"[{'id': 1631, 'therapyName': 'Vincristine'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 2188, 'therapyName': 'Prednisone'}]",Four Drug Reinduction With Bortezomib for Relapsed or Refractory ALL or LL in Children and Young Adults,58
11,NCT02553460,Phase II,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1642, 'therapyName': 'Leucovorin'}]",Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) I,58
12,NCT02883049,Phase III,Suspended,"[{'id': 717, 'therapyName': 'Dasatinib'}, {'id': 4685, 'therapyName': 'Dexamethasone + Doxorubicin'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1746, 'therapyName': 'Clofarabine'}]",Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations,58
13,NCT01523977,Phase I,"Active, not recruiting","[{'id': 2188, 'therapyName': 'Prednisone'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1638, 'therapyName': 'Pegaspargase'}]",Everolimus With Multiagent Re-Induction Chemotherapy in Pediatric Patients With ALL,58
14,NCT03117751,Phase II,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1876, 'therapyName': 'Blinatumomab '}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1638, 'therapyName': 'Pegaspargase'}]",Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma,58
15,NCT01324180,Phase I,Completed,"[{'id': 1031, 'therapyName': 'Metformin'}, {'id': 1830, 'therapyName': 'Vincristine + Dexamethasone + Pegaspargase + Doxorubicin'}]","Vincristine, Dexamethasone, Doxorubicin, and PEG-asparaginase (VPLD) and Metformin for Relapsed Childhood Acute Lymphoblastic Leukemia (ALL)",58
16,NCT01769209,Phase II,"Active, not recruiting","[{'id': 688, 'therapyName': 'Bortezomib'}, {'id': 3195, 'therapyName': 'Cytarabine + Methotrexate '}, {'id': 1830, 'therapyName': 'Vincristine + Dexamethasone + Pegaspargase + Doxorubicin'}]",Bortezomib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia,58
17,NCT00549848,Phase III,"Active, not recruiting","[{'id': 1781, 'therapyName': 'Vincristine + Pegaspargase + Daunorubicin'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1782, 'therapyName': 'Clofarabine + Etoposide + Cyclophosphamide'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}]",Total Therapy Study XVI for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia,58
0,NCT02650635,Phase I,"Active, not recruiting","[{'id': 3413, 'therapyName': 'Cyclophosphamide + Pegfilgrastim + VTX-2337'}]","TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid Tumors",19
1,NCT01385228,Phase I,Completed,"[{'id': 2042, 'therapyName': 'Docetaxel + Pazopanib + Pegfilgrastim'}]","Pazopanib, Docetaxel, Prednisone Prostate",19
2,NCT02834403,Phase Ib/II,Recruiting,"[{'id': 1476, 'therapyName': 'Pegfilgrastim'}, {'id': 6123, 'therapyName': 'Docetaxel + L-NMMA'}, {'id': 6096, 'therapyName': 'L-NMMA'}]",L-NMMA Plus Docetaxel in Refractory Locally Advanced or Metastatic Triple Negative Breast Cancer Patients,19
3,NCT00983398,Phase Ib/II,Recruiting,"[{'id': 1476, 'therapyName': 'Pegfilgrastim'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 2587, 'therapyName': 'Carboplatin + Melphalan'}]","Melphalan, Carboplatin, and Sodium Thiosulfate for Patients With Central Nervous System (CNS) Embryonal or Germ Cell Tumors",19
4,NCT01256398,Phase II,"Active, not recruiting","[{'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 2291, 'therapyName': 'Cyclophosphamide + Fludarabine'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1824, 'therapyName': 'Vincristine + Methotrexate + Mercaptopurine'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 2391, 'therapyName': 'Cytarabine + Daunorubicin + Etoposide'}, {'id': 1476, 'therapyName': 'Pegfilgrastim'}, {'id': 1205, 'therapyName': 'Alemtuzumab'}, {'id': 1642, 'therapyName': 'Leucovorin'}]",Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,19
5,NCT03136146,Phase II,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1090, 'therapyName': 'Ofatumumab'}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 1476, 'therapyName': 'Pegfilgrastim'}]","Study of Clofarabine, Etoposide, Cyclophosphamide [CEC], Liposomal Vincristine (VCR), Dexamethasone and Bortezomib in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LL)",19
6,NCT00303849,Phase Ib/II,Recruiting,"[{'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 2562, 'therapyName': 'Etoposide + Melphalan'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1476, 'therapyName': 'Pegfilgrastim'}]",Combination Chemotherapy With BBBD Followed By Sodium Thiosulfate in Treating Patients With Anaplastic Oligodendroglioma or Oligoastrocytoma,19
7,NCT01424982,Phase II,Recruiting,"[{'id': 1476, 'therapyName': 'Pegfilgrastim'}, {'id': 2048, 'therapyName': 'Cytarabine + Methotrexate + Ponatinib'}, {'id': 2049, 'therapyName': 'Ponatinib + Vincristine'}, {'id': 2046, 'therapyName': 'Cyclophosphamide + Dexamethasone + Doxorubicin + Vincristine '}, {'id': 1642, 'therapyName': 'Leucovorin'}]",Hyper-CVAD and Ponatinib in Ph-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL),19
8,NCT02181218,Phase I,Recruiting,"[{'id': 1476, 'therapyName': 'Pegfilgrastim'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1611, 'therapyName': 'Gemcitabine + Oxaliplatin + Dexamethasone'}]","Phase I Study of Romidepsin, Gemcitabine, Oxaliplatin, and Dexamethasone in Patients With Relapsed/Refractory Aggressive Lymphomas",19
9,NCT01501487,FDA approved,"Active, not recruiting","[{'id': 1902, 'therapyName': 'Docetaxel + Doxorubicin + Cyclophosphamide'}, {'id': 1982, 'therapyName': 'Fluorouracil + Epirubicin + Cyclophosphamide'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1476, 'therapyName': 'Pegfilgrastim'}, {'id': 1881, 'therapyName': 'Docetaxel + Cyclophosphamide'}, {'id': 1977, 'therapyName': 'Doxorubicin + Cyclophosphamide'}, {'id': 1485, 'therapyName': 'Trastuzumab + Docetaxel + Carboplatin'}, {'id': 1978, 'therapyName': 'Pertuzumab + Trastuzumab + Docetaxel'}]",MINT I Multi- Institutional Neo-adjuvant Therapy MammaPrint Project I,19
10,NCT03197935,Phase III,Recruiting,"[{'id': 1476, 'therapyName': 'Pegfilgrastim'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 619, 'therapyName': 'Abraxane'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}]",A Study to Investigate Atezolizumab and Chemotherapy Compared With Placebo and Chemotherapy in the Neoadjuvant Setting in Participants With Early Stage Triple Negative Breast Cancer (IMpassion031),19
11,NCT00293475,Phase Ib/II,Recruiting,"[{'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1476, 'therapyName': 'Pegfilgrastim'}, {'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 2669, 'therapyName': 'Carboplatin + Methotrexate + Rituximab'}]",Rituximab and Methotrexate Chemotherapy w/Blood-Brain Barrier Disruption (BBBD) &amp; Sodium Thiosulfate Chemoprotection for Patients With Newly Diagnosed PCNSL,19
12,NCT01319981,Phase II,Recruiting,"[{'id': 1476, 'therapyName': 'Pegfilgrastim'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}]",Hyper-CVAD With Liposomal Vincristine in Acute Lymphoblastic Leukemia,19
13,NCT01879085,Phase Ib/II,Recruiting,"[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1476, 'therapyName': 'Pegfilgrastim'}, {'id': 1077, 'therapyName': 'Vorinostat'}]",Phase 1b/2 Study of Vorinostat in Combination With Gemcitabine and Docetaxel in Advanced Sarcoma,19
14,NCT02531308,Phase II,Terminated,"[{'id': 1031, 'therapyName': 'Metformin'}, {'id': 3266, 'therapyName': 'Cyclophosphamide + Doxorubicin + Prednisone + Vincristine '}, {'id': 1476, 'therapyName': 'Pegfilgrastim'}, {'id': 897, 'therapyName': 'Rituximab'}]",Metformin in Combination With Standard Induction Therapy for Large B-cell Lymphoma (DLBCL),19
15,NCT02087176,Phase II,Terminated,"[{'id': 822, 'therapyName': 'MK-1775'}, {'id': 1476, 'therapyName': 'Pegfilgrastim'}]",A Placebo Controlled Study Comparing AZD1775+ Docetaxel Versus Placebo+Docetaxel to Treat Lung Cancer,19
16,NCT01169636,Phase Ib/II,Completed,"[{'id': 1080, 'therapyName': 'Panobinostat'}, {'id': 1476, 'therapyName': 'Pegfilgrastim'}, {'id': 2352, 'therapyName': 'Carboplatin + Etoposide + Ifosfamide '}]","Panobinostat Plus Ifosfamide, Carboplatin, and Etoposide (ICE) Compared With ICE For Relapsed Hodgkin Lymphoma",19
17,NCT02543255,Phase II,Recruiting,"[{'id': 1571, 'therapyName': 'Cabazitaxel'}, {'id': 3079, 'therapyName': 'Abiraterone + Leuprolide + Prednisone'}, {'id': 1476, 'therapyName': 'Pegfilgrastim'}]",Anti-Androgens and Cabazitaxel in Defining Complete Response in Prostatectomy (ACDC Trial),19
18,NCT03102606,Phase II,Recruiting,"[{'id': 3678, 'therapyName': 'Plinabulin'}, {'id': 1476, 'therapyName': 'Pegfilgrastim'}]",Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy (Protective-1),19
19,NCT01654965,Phase I,"Active, not recruiting","[{'id': 1477, 'therapyName': 'Tivantinib + Topotecan + Pegfilgrastim'}]",Tivantinib and Topotecan Hydrochloride in Treating Patients With Advanced or Metastatic Solid Tumors,19
0,NCT02948426,Phase I,Recruiting,"[{'id': 4975, 'therapyName': 'interferon gamma + peginterferon alfa-2b'}]","Intraperitoneal Infusion of Autologous Monocytes With Sylatron (Peginterferon Alfa-2b) and Actimmune (Interferon Gamma-1b) in Women With Recurrent or Refractory Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer",7617
1,NCT01964300,Phase II,Recruiting,"[{'id': 2624, 'therapyName': 'peginterferon alfa-2b'}]",Peginterferon Alfa-2b in Treating Younger Patients With Craniopharyngioma That is Recurrent or Cannot Be Removed By Surgery,7617
2,NCT02737046,Phase II,Recruiting,"[{'id': 1299, 'therapyName': 'Interferon alfa-2b '}, {'id': 2624, 'therapyName': 'peginterferon alfa-2b'}, {'id': 4361, 'therapyName': 'Belinostat + Zidovudine'}]",Belinostat Therapy With Zidovudine for Adult T-Cell Leukemia-Lymphoma,7617
3,NCT02089685,Phase Ib/II,Recruiting,"[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 2624, 'therapyName': 'peginterferon alfa-2b'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Safety and Tolerability of Pembrolizumab (MK-3475) + Pegylated Interferon Alfa-2b and Pembrolizumab+ Ipilimumab in Participants With Advanced Melanoma or Renal Cell Carcinoma (MK-3475-029/KEYNOTE-29),7617
4,NCT02982720,Phase II,Recruiting,"[{'id': 2625, 'therapyName': 'peginterferon alfa-2b + Pembrolizumab'}]",Evaluating Combination Immunotherapy for Advanced Cholangiocarcinoma With Pembrolizumab and PEG-Intron,7617
5,NCT02112032,Phase I,"Active, not recruiting","[{'id': 2625, 'therapyName': 'peginterferon alfa-2b + Pembrolizumab'}]",Treatment of Advanced Melanoma With MK-3475 and Peginterferon,7617
0,NCT03193190,Phase Ib/II,Recruiting,"[{'id': 5942, 'therapyName': 'Atezolizumab + BKT140'}, {'id': 5940, 'therapyName': 'Gemcitabine + Nab-Paclitaxel + mFOLFOX-6'}, {'id': 5941, 'therapyName': 'Atezolizumab + PEGPH20'}, {'id': 1343, 'therapyName': 'Atezolizumab + Cobimetinib'}]",A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (PDAC),7437
1,NCT03281369,Phase Ib/II,Not yet recruiting,"[{'id': 1343, 'therapyName': 'Atezolizumab + Cobimetinib'}, {'id': 6274, 'therapyName': 'mFOLFOX-6 + Atezolizumab + Cobimetinib'}, {'id': 6275, 'therapyName': 'mFOLFOX-6 + Atezolizumab'}, {'id': 6276, 'therapyName': 'Atezolizumab + Linagliptin'}, {'id': 5941, 'therapyName': 'Atezolizumab + PEGPH20'}, {'id': 5942, 'therapyName': 'Atezolizumab + BKT140'}, {'id': 1721, 'therapyName': 'Ramucirumab + Paclitaxel'}, {'id': 5850, 'therapyName': 'mFOLFOX-6'}]",A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) (UMBRELLA),7437
2,NCT02241187,Phase I,Completed,"[{'id': 2145, 'therapyName': 'Cetuximab + PEGPH20'}]",Two Stage Study Of Single Dose PEGPH20 And Cetuximab In Patients With Pancreatic Adenocarcinoma Prior To Surgical Resection,7437
3,NCT02563548,Phase I,Recruiting,"[{'id': 5779, 'therapyName': 'PEGPH20 + Pembrolizumab'}]",Phase 1b Open-Label Study of PEGPH20 With Pembrolizumab,7437
0,NCT02839707,Phase II,Recruiting,"[{'id': 4496, 'therapyName': 'Atezolizumab + Bevacizumab + Doxil'}, {'id': 4495, 'therapyName': 'Atezolizumab + Doxil'}, {'id': 1673, 'therapyName': 'Doxil + Bevacizamub'}]","Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",7126
1,NCT01177683,Phase Ib/II,"Active, not recruiting","[{'id': 3349, 'therapyName': 'Bendamustine + Bortezomib + pegylated liposomal-doxorubicin'}, {'id': 1632, 'therapyName': 'Filgrastim'}]",Bendamustine in Combination With Bortezomib and Pegylated Liposomal Doxorubicin for Multiple Myeloma,7126
2,NCT00761644,Phase I,"Active, not recruiting","[{'id': 1121, 'therapyName': 'Bevacizumab + Temsirolimus + Doxil'}]","Doxil, Bevacizumab and Temsirolimus Trial",7126
3,NCT01736943,Phase II,Recruiting,"[{'id': 3184, 'therapyName': 'Bortezomib + pegylated liposomal-doxorubicin'}]",Bortezomib and Doxil for the Treatment of Patients With Acute Myelogenous Leukemia,7126
4,NCT01281514,Phase I,Recruiting,"[{'id': 2168, 'therapyName': 'Carboplatin + Doxil + Everolimus'}]","Carboplatin, Pegylated Liposomal Doxorubicin Hydrochloride, and Everolimus in Treating Patients With Relapsed Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer",7126
5,NCT02186834,Phase Ib/II,"Active, not recruiting","[{'id': 3356, 'therapyName': 'Dexamethasone + pegylated liposomal-doxorubicin + Selinexor'}]",Selinexor (KPT-330) and Pegylated Liposomal Doxorubicin For Relapsed and Refractory Multiple Myeloma,7126
6,NCT01815294,Phase I,Completed,"[{'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1008, 'therapyName': 'Doxil'}]", A Pivotal Bioequivalence Study of DOXIL/CAELYX (Doxorubicin HCL) in Patients With Advanced or Refractory Solid Malignancies Including Patients With Ovarian Cancer,7126
7,NCT01990352,Phase II,Suspended,"[{'id': 1008, 'therapyName': 'Doxil'}]",Correlate BRCA1 Protein Expression With Response to DNA Damaging Chemotherapy,7126
8,NCT01991210,Phase II,Terminated,"[{'id': 1345, 'therapyName': 'DNIB0600A'}, {'id': 1008, 'therapyName': 'Doxil'}]",A Randomized Study of DNIB0600A in Comparison With Pegylated Liposomal Doxorubicin in Patients With Platinum-Resistant Ovarian Cancer,7126
9,NCT00092222,Phase II,Recruiting,"[{'id': 917, 'therapyName': 'Sirolimus'}, {'id': 1187, 'therapyName': 'Alpha 2 Interferon'}, {'id': 2211, 'therapyName': 'EPOCH'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1008, 'therapyName': 'Doxil'}]",Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity,7126
10,NCT02081495,Phase I,Completed,"[{'id': 1008, 'therapyName': 'Doxil'}]",A Study of DOXIL/CAELYX in Patients With Advanced or Refractory Solid Malignancies Including Patients With Ovarian Cancer,7126
11,NCT01846611,Phase III,Recruiting,"[{'id': 1008, 'therapyName': 'Doxil'}, {'id': 1390, 'therapyName': 'Dexamethasone'}]","A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer",7126
12,NCT00923936,Phase II,"Active, not recruiting","[{'id': 1673, 'therapyName': 'Doxil + Bevacizamub'}]",Pilot Study of Liposomal Doxorubicin Combined With Bevacizumab Followed by Bevacizumab Monotherapy in Adults With Advanced Kaposi s Sarcoma,7126
13,NCT02101788,Phase II,Recruiting,"[{'id': 942, 'therapyName': 'Topotecan'}, {'id': 2173, 'therapyName': 'Doxil + Letrozole + Tamoxifen + Paclitaxel'}, {'id': 2, 'therapyName': 'Trametinib'}]",Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer,7126
14,NCT02631876,Phase II,Recruiting,"[{'id': 3574, 'therapyName': 'Doxil + Paclitaxel'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 3232, 'therapyName': 'IMGN853'}]","PH2 Study of IMGN853 vs Investigator's Choice of Chemo in Adults With FRa+ Adv. EOC, Primary Peritoneal or Primary Fallopian Tube Cancer",7126
15,NCT02865811,Phase II,"Active, not recruiting","[{'id': 4558, 'therapyName': 'Doxil + Pembrolizumab'}]","Pembrolizumab Combined With PLD For Recurrent Platinum Resistant Ovarian, Fallopian Tube Or Peritoneal Cancer",7126
16,NCT02188368,Phase II,Recruiting,"[{'id': 1625, 'therapyName': 'Bortezomib + Carfilzomib + Clarithromycin'}, {'id': 1674, 'therapyName': 'Doxil + Pomalidomide'}, {'id': 1622, 'therapyName': 'Pomalidomide'}]",Pomalidomide for Lenalidomide for Failures,7126
17,NCT01902225,Phase I,Unknown status,"[{'id': 3393, 'therapyName': 'Doxil + romidepsin '}]",Phase I Dose-finding and Preliminary Efficacy Study of the Istodax in Combination With Doxil for the Treatment of Adults With Relapsed or Refractory Cutaneous T-cell Lymphoma,7126
18,NCT01145430,Phase I,"Active, not recruiting","[{'id': 2167, 'therapyName': 'pegylated liposomal doxorubicin + Veliparib'}]","Veliparib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer or Metastatic Breast Cancer",7126
19,NCT02203526,Phase I,Suspended,"[{'id': 1607, 'therapyName': 'Temozolomide + Etoposide + Doxil + Dexamethasone + Ibrutinib'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 897, 'therapyName': 'Rituximab'}]","Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Dose-Adjusted-Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (DA-TEDDI-R) in Primary CNS Lymphoma",7126
0,NCT02990416,Phase Ib/II,Not yet recruiting,"[{'id': 5137, 'therapyName': 'A-dmDT390-bisFv(UCHT1) + Pembrolizumab'}]",A-dmDT390-bisFv(UCHT1) Fusion Protein With Ionizing Radiation and Pembrolizumab for the Treatment of Stage IV Melanoma,7262
1,NCT02779751,Phase II,Recruiting,"[{'id': 4242, 'therapyName': 'Abemaciclib + Pembrolizumab'}]",A Study of Abemaciclib (LY2835219) in Participants With Non-Small Cell Lung Cancer or Breast Cancer,7262
2,NCT02364609,Phase I,Recruiting,"[{'id': 2435, 'therapyName': 'Afatinib + Pembrolizumab'}]",Pembrolizumab and Afatinib in Patients With Non-small Cell Lung Cancer With Resistance to Erlotinib,7262
3,NCT03157089,Phase II,Not yet recruiting,"[{'id': 2435, 'therapyName': 'Afatinib + Pembrolizumab'}]",Testing Afatinib in Combination With Pembrolizumab in Patients With Squamous Cell Carcinoma of the Lung (LUX-Lung IO),7262
4,NCT02298959,Phase I,Recruiting,"[{'id': 2369, 'therapyName': 'Aflibercept + Pembrolizumab'}]",Pembrolizumab and Ziv-aflibercept in Treating Patients With Advanced Solid Tumors,7262
5,NCT02665650,Phase I,Recruiting,"[{'id': 4390, 'therapyName': 'AFM13 + Pembrolizumab'}]",Study of the Combination of AFM13 and Pembrolizumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma,7262
6,NCT02500576,Phase II,Recruiting,"[{'id': 5683, 'therapyName': 'Aldesleukin + Cyclophosphamide + Fludarabine + Mesna + Pembrolizumab'}]","MK-3475 With Lymphodepletion, TIL and High or Low Dose Interleukin-2 (IL-2)",7262
7,NCT02858310,Phase I,Recruiting,"[{'id': 4562, 'therapyName': 'Aldesleukin + Cyclophosphamide + Fludarabine + Pembrolizumab'}]",E7 TCR T Cells With or Without PD-1 Blockade for Human Papillomavirus-Associated Cancers,7262
8,NCT02757391,Phase I,Not yet recruiting,"[{'id': 4193, 'therapyName': 'Aldesleukin + Cyclophosphamide + Pembrolizumab'}]",T Cell Immunotherapy Plus Anti-PD1 Antibody in Advanced Solid Malignancies,7262
9,NCT02964078,Phase II,Recruiting,"[{'id': 4165, 'therapyName': 'Aldesleukin + Pembrolizumab'}]",Interleukin-2 and Pembrolizumab for Metastatic Kidney Cancer,7262
10,NCT03111901,Phase Ib/II,Not yet recruiting,"[{'id': 4165, 'therapyName': 'Aldesleukin + Pembrolizumab'}]",Low-dose Interleukin-2 and Pembrolizumab in Melanoma and Renal Cell Cancer,7262
11,NCT02748564,Phase II,Recruiting,"[{'id': 4165, 'therapyName': 'Aldesleukin + Pembrolizumab'}]",Aldesleukin and Pembrolizumab in Treating Patients With Stage III-IV Melanoma,7262
12,NCT03260504,Phase I,Not yet recruiting,"[{'id': 4165, 'therapyName': 'Aldesleukin + Pembrolizumab'}]",Aldesleukin and Pembrolizumab in Treating Patients With Advanced or Metastatic Kidney Cancer,7262
13,NCT03228667,Phase II,Not yet recruiting,"[{'id': 3061, 'therapyName': 'ALT-803 + Nivolumab'}, {'id': 6037, 'therapyName': 'ALT-803 + Pembrolizumab'}]","QUILT-3.055: A Phase IIb, Single-Arm, Open-Label Study of ALT-803 in Combination With Pembrolizumab or Nivolumab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Disease Progression Following an Initial Response to Treatment With PD-1 Checkpoint Inhibitor Therapy",7262
14,NCT02713529,Phase Ib/II,Recruiting,"[{'id': 4170, 'therapyName': 'AMG820 + Pembrolizumab'}]",Safety Study of AMG 820 and Pembrolizumab Combination in Select Advanced Solid Tumor Cancer,7262
15,NCT02706353,Phase Ib/II,Recruiting,"[{'id': 3836, 'therapyName': 'APX005M + Pembrolizumab'}]",APX005M in Combination With Systemic Pembrolizumab in Patients With Metastatic Melanoma,7262
16,NCT02880371,Phase Ib/II,Recruiting,"[{'id': 4608, 'therapyName': 'ARRY-382 + Pembrolizumab'}]",A Study of ARRY-382 in Combination With Pembrolizumab for the Treatment of Patients With Advanced Solid Tumors,7262
17,NCT02133742,Phase I,"Active, not recruiting","[{'id': 2494, 'therapyName': 'Axitinib + Pembrolizumab'}]","A Dose Finding Study To Evaluate Safety, Drug Interaction, Tumor Markers Of Axitinib In Combination With MK-3475 In Adult Patients With Previously Untreated Advanced Renal Cell Cancer",7262
18,NCT02636725,Phase II,Recruiting,"[{'id': 2494, 'therapyName': 'Axitinib + Pembrolizumab'}]",Axitinib and Pembrolizumab in Subjects With Advanced Alveolar Soft Part Sarcoma and Other Soft Tissue Sarcomas,7262
19,NCT02853331,Phase III,Recruiting,"[{'id': 2494, 'therapyName': 'Axitinib + Pembrolizumab'}, {'id': 930, 'therapyName': 'Sunitinib'}]",Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Axitinib Versus Sunitinib Monotherapy in Participants With Renal Cell Carcinoma (MK-3475-426/KEYNOTE-426),7262
20,NCT02959437,Phase Ib/II,Recruiting,"[{'id': 5477, 'therapyName': 'Azacitidine + INCB024360 + Pembrolizumab'}]",Azacitidine Combined With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors (ECHO-206),7262
21,NCT03094637,Phase II,Not yet recruiting,"[{'id': 2496, 'therapyName': 'Azacitidine + Pembrolizumab'}]",Azacitidine and Pembrolizumab for Patients With Myelodysplastic Syndrome (MDS),7262
22,NCT02900560,Phase II,Recruiting,"[{'id': 2496, 'therapyName': 'Azacitidine + Pembrolizumab'}]",Study of Pembrolizumab With or Without CC-486 in Patients With Platinum-resistant Ovarian Cancer,7262
23,NCT02845297,Phase II,Recruiting,"[{'id': 2496, 'therapyName': 'Azacitidine + Pembrolizumab'}]",Phase 2 Study of Azacitidine in Combination With Pembrolizumab in Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients and in Newly Diagnosed Older (?65 Years) AML Patients,7262
24,NCT03264404,Phase II,Recruiting,"[{'id': 2496, 'therapyName': 'Azacitidine + Pembrolizumab'}]",Azacitidine and Pembrolizumab in Pancreatic Cancer,7262
25,NCT02512172,Phase I,Recruiting,"[{'id': 2496, 'therapyName': 'Azacitidine + Pembrolizumab'}, {'id': 5728, 'therapyName': 'Romidepsin + Pembrolizumab'}, {'id': 5782, 'therapyName': 'Azacitidine + Pembrolizumab + Romidepsin'}]",A Study of Enhancing Response to MK-3475 in Advanced Colorectal Cancer,7262
26,NCT02260440,Phase II,"Active, not recruiting","[{'id': 2496, 'therapyName': 'Azacitidine + Pembrolizumab'}]",A Phase 2 Study of MK-3475 in Combination With Azacitidine in Subjects With Chemo-refractory Metastatic Colorectal Cancer,7262
27,NCT02816021,Phase II,Recruiting,"[{'id': 2496, 'therapyName': 'Azacitidine + Pembrolizumab'}]",Study of Oral Azacitidine (CC-486) in Combination With Pembrolizumab (MK-3475) in Patients With Metastatic Melanoma,7262
28,NCT02925533,Phase I,Terminated,"[{'id': 4831, 'therapyName': 'B-701 + Pembrolizumab'}]",Ph 1B B-701 in Combination With Pembrolizumab in Metastatic Transitional Cell Carcinoma of the Urothelial Tract,7262
29,NCT02808143,Phase I,Recruiting,"[{'id': 4457, 'therapyName': 'BCG solution + Pembrolizumab'}]",Pembrolizumab and BCG Solution in Treating Patients With Recurrent Non-Muscle-Invasive Bladder Cancer,7262
30,NCT02039674,Phase Ib/II,"Active, not recruiting","[{'id': 2103, 'therapyName': 'Carboplatin + Paclitaxel + Pembrolizumab'}, {'id': 2104, 'therapyName': 'Bevacizumab + Carboplatin + Paclitaxel + Pembrolizumab'}, {'id': 1602, 'therapyName': 'Carboplatin + Pemetrexed'}, {'id': 2106, 'therapyName': 'Ipilimumab + Pembrolizumab '}, {'id': 2107, 'therapyName': 'Erlotinib + Pembrolizumab '}, {'id': 2108, 'therapyName': 'Gefitinib + Pembrolizumab '}]",A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Lung Cancer (MK-3475-021/KEYNOTE-021),7262
31,NCT02853318,Phase II,Recruiting,"[{'id': 4528, 'therapyName': 'Bevacizumab + Cyclophosphamide + Pembrolizumab'}]","Pembrolizumab, Bevacizumab, and Cyclophosphamide in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",7262
32,NCT02681549,Phase II,Recruiting,"[{'id': 2119, 'therapyName': 'Bevacizumab + Pembrolizumab'}]",Pembrolizumab Plus Bevacizumab for Treatment of Brain Metastases in Metastatic Melanoma or Non-small Cell Lung Cancer,7262
33,NCT02337491,Phase II,"Active, not recruiting","[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 2119, 'therapyName': 'Bevacizumab + Pembrolizumab'}]",Pembrolizumab +/- Bevacizumab for Recurrent GBM,7262
34,NCT02313272,Phase I,Recruiting,"[{'id': 2119, 'therapyName': 'Bevacizumab + Pembrolizumab'}]",Phase I Trial of HFSRT With Pembrolizumab and Bevacizumab for Recurrent High Grade Gliomas,7262
35,NCT02348008,Phase Ib/II,"Active, not recruiting","[{'id': 2119, 'therapyName': 'Bevacizumab + Pembrolizumab'}]",Phase Ib and Phase II Studies of MK-3475 in Combination + for Renal Cell Carcinoma,7262
36,NCT03184571,Phase II,Recruiting,"[{'id': 5964, 'therapyName': 'BGB-324 + Pembrolizumab'}]",BGB324 in Combination With Pembrolizumab in Patients With Advanced NSCLC,7262
37,NCT03184558,Phase II,Recruiting,"[{'id': 5964, 'therapyName': 'BGB-324 + Pembrolizumab'}]",BGB324 in Combination With Pembrolizumab in Patients With TNBC,7262
38,NCT03106415,Phase Ib/II,Recruiting,"[{'id': 5568, 'therapyName': 'Binimetinib + Pembrolizumab'}]",Pembrolizumab and Binimetinib in Treating Patients With Locally Advanced or Metastatic Triple Negative Breast Cancer,7262
39,NCT02587962,Phase Ib/II,Recruiting,"[{'id': 6160, 'therapyName': 'Birinapant  + Pembrolizumab'}]",Dose-escalation Study of Birinapant and Pembrolizumab in Solid Tumors,7262
40,NCT02826486,Phase II,Recruiting,"[{'id': 4757, 'therapyName': 'BKT140 + Pembrolizumab'}, {'id': 2849, 'therapyName': 'BKT140'}]",Study Assessing Safety and Efficacy of Combination of BL-8040 and Pembrolizumab in Metastatic Pancreatic Cancer Patients (COMBAT/KEYNOTE-202) (COMBAT),7262
41,NCT02907099,Phase II,Recruiting,"[{'id': 4757, 'therapyName': 'BKT140 + Pembrolizumab'}]",Pembrolizumab and BL-8040 in Metastatic Pancreatic Cancer,7262
42,NCT03160079,Phase Ib/II,Recruiting,"[{'id': 5839, 'therapyName': 'Blinatumomab + Pembrolizumab'}]",Blinatumomab and Pembrolizumab for Adults With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia With High Marrow Lymphoblasts,7262
43,NCT03221426,Phase III,Recruiting,"[{'id': 3999, 'therapyName': 'Capecitabine + Cisplatin'}, {'id': 6050, 'therapyName': 'Capecitabine + Cisplatin + Pembrolizumab'}, {'id': 6051, 'therapyName': 'Cisplatin + Fluorouracil + Pembrolizumab'}, {'id': 1833, 'therapyName': 'Cisplatin + Fluorouracil'}]",Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585),7262
44,NCT02954536,Phase II,Recruiting,"[{'id': 4945, 'therapyName': 'Capecitabine + Cisplatin + Pembrolizumab + Trastuzumab'}]",Phase II Trial of Pembrolizumab With Trastuzumab and Chemotherapy in Advanced HER2 Positive Esophagogastric (EG) Cancer,7262
45,NCT02918162,Phase II,Recruiting,"[{'id': 4776, 'therapyName': 'Capecitabine + Epirubicin + Oxaliplatin + Pembrolizumab'}]",Perioperative Chemo and Pembrolizumab in Gastric Cancer,7262
46,NCT03111732,Phase II,Recruiting,"[{'id': 5549, 'therapyName': 'Capecitabine + Oxaliplatin + Pembrolizumab'}]","Pembrolizumab, a Monoclonal Antibody Against PD-1, in Combination With Capecitabine and Oxaliplatin (CAPOX) in People With Advanced Biliary Tract Carcinoma (BTC)",7262
47,NCT03257163,Phase II,Recruiting,"[{'id': 4022, 'therapyName': 'Capecitabine + Pembrolizumab'}]","Pembrolizumab, Capecitabine, and Radiation Therapy in Treating Patients With Mismatch-Repair Deficient and Epstein-Barr Virus Positive Gastric Cancer",7262
48,NCT02734290,Phase Ib/II,Recruiting,"[{'id': 4022, 'therapyName': 'Capecitabine + Pembrolizumab'}, {'id': 4021, 'therapyName': 'Paclitaxel + Pembrolizumab'}]",Standard of Care Chemotherapy Plus Pembrolizumab for Breast Cancer,7262
49,NCT03044730,Phase II,Recruiting,"[{'id': 4022, 'therapyName': 'Capecitabine + Pembrolizumab'}]",Pembrolizumab and Capecitabine in Treating Patients With Locally Advanced or Metastatic Triple Negative or Hormone-Refractory Breast Cancer That Cannot Be Removed by Surgery,7262
50,NCT03242915,Phase II,Not yet recruiting,"[{'id': 2105, 'therapyName': 'Carboplatin +  Pembrolizumab + Pemetrexed '}]",Pembrolizumab in Combination With Platinum-based Doublet Chemotherapy in Patients With EGFR Mutation and ALK Positive NSCLC (Non-Small Cell Lung Cancer) With Progressive Disease Following Prior Tyrosine Kinase Inhibitors (TKIs),7262
51,NCT02934503,Phase II,Recruiting,"[{'id': 6184, 'therapyName': 'Carboplatin + Cisplatin + Etoposide + Pembrolizumab'}]",Study of Pembrolizumab and Chemotherapy With or Without Radiation in Small Cell Lung Cancer (SCLC),7262
52,NCT03066778,Phase III,Recruiting,"[{'id': 2585, 'therapyName': 'Cisplatin + Etoposide'}, {'id': 5145, 'therapyName': 'Cisplatin + Etoposide + Pembrolizumab'}, {'id': 2604, 'therapyName': 'Carboplatin + Etoposide + Pembrolizumab'}, {'id': 1791, 'therapyName': 'Carboplatin + Etoposide'}]",A Study of Pembrolizumab (MK-3475) in Combination With Etoposide/Platinum (Cisplatin or Carboplatin) for Participants With Extensive Stage Small Cell Lung Cancer (MK-3475-604/KEYNOTE-604),7262
53,NCT02402920,Phase I,Recruiting,"[{'id': 2604, 'therapyName': 'Carboplatin + Etoposide + Pembrolizumab'}, {'id': 700, 'therapyName': 'Cisplatin'}]",Phase I Trial of MK-3475 and Concurrent Chemo/Radiation for the Elimination of Small Cell Lung Cancer,7262
54,NCT03121352,Phase I,Recruiting,"[{'id': 5591, 'therapyName': 'Carboplatin + nab-paclitaxel + Pembrolizumab'}]","Pilot Study of Carboplatin, Nab-Paclitaxel and Pembrolizumab for Metastatic Triple-Negative Breast Cancer",7262
55,NCT02621398,Phase I,Suspended,"[{'id': 2103, 'therapyName': 'Carboplatin + Paclitaxel + Pembrolizumab'}]","Pembrolizumab, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Stage II-IIIB Non-Small Cell Lung Cancer",7262
56,NCT02549209,Phase II,Recruiting,"[{'id': 2103, 'therapyName': 'Carboplatin + Paclitaxel + Pembrolizumab'}]",Pembro/Carbo/Taxol in Endometrial Cancer,7262
57,NCT02630823,Phase I,Recruiting,"[{'id': 2103, 'therapyName': 'Carboplatin + Paclitaxel + Pembrolizumab'}]",MK-3475 Immunotherapy in Endometrial Carcinoma,7262
58,NCT02834975,Phase II,Recruiting,"[{'id': 2103, 'therapyName': 'Carboplatin + Paclitaxel + Pembrolizumab'}]","Pembrolizumab, Paclitaxel, and Carboplatin in Patients With Advanced Stage Epithelial Ovarian Cancer (EOC).",7262
59,NCT02766582,Phase II,Recruiting,"[{'id': 2103, 'therapyName': 'Carboplatin + Paclitaxel + Pembrolizumab'}]",Phase II: Pembrolizumab/Carboplatin/Taxol in Epithelial Ovary Cancer,7262
60,NCT03064490,Phase II,Recruiting,"[{'id': 2103, 'therapyName': 'Carboplatin + Paclitaxel + Pembrolizumab'}]","Pembrolizumab, Radiotherapy, and Chemotherapy in Neoadjuvant Treatment of Malignant Esophago-gastric Diseases (PROCEED)",7262
61,NCT02617849,Phase II,Recruiting,"[{'id': 2103, 'therapyName': 'Carboplatin + Paclitaxel + Pembrolizumab'}]",Pembrolizumab With Carboplatin/Paclitaxel in Patients With Metastatic Melanoma,7262
62,NCT03029598,Phase Ib/II,Recruiting,"[{'id': 5265, 'therapyName': 'Carboplatin + Pembrolizumab'}]","Pembrolizumab and Carboplatin in Treating Patients With Relapsed or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",7262
63,NCT03095352,Phase II,Recruiting,"[{'id': 5265, 'therapyName': 'Carboplatin + Pembrolizumab'}]","A Randomized Phase II Study of Pembrolizumab, an Anti-PD (Programmed Cell Death)-1 Antibody, in Combination With Carboplatin Compared to Carboplatin Alone in Breast Cancer Patients With Chest Wall Disease",7262
64,NCT03213041,Phase II,Recruiting,"[{'id': 5265, 'therapyName': 'Carboplatin + Pembrolizumab'}]",Pembrolizumab and Carboplatin in Treating Patients With Circulating Tumor Cells Positive Metastatic Breast Cancer,7262
65,NCT02987998,Phase I,Recruiting,"[{'id': 5145, 'therapyName': 'Cisplatin + Etoposide + Pembrolizumab'}]",Neoadjuvant Chemoradiation Plus Pembrolizumab Followed By Consolidation Pembrolizumab in NSCLC,7262
66,NCT03189719,Phase III,Recruiting,"[{'id': 1833, 'therapyName': 'Cisplatin + Fluorouracil'}, {'id': 6051, 'therapyName': 'Cisplatin + Fluorouracil + Pembrolizumab'}]",First-line Esophageal Carcinoma Study With Chemo vs. Chemo Plus Pembrolizumab (MK-3475-590/KEYNOTE-590),7262
67,NCT02608684,Phase II,Recruiting,"[{'id': 3248, 'therapyName': 'Cisplatin + Gemcitabine + Pembrolizumab'}]",A Study of Pembrolizumab With Standard Treatment in Patients With Recurrent Platinum-resistant Ovarian Cancer,7262
68,NCT02690558,Phase II,Recruiting,"[{'id': 3248, 'therapyName': 'Cisplatin + Gemcitabine + Pembrolizumab'}]",Phase 2 Study of Pembrolizumab in Combination With Gemcitabine and Cisplatin as Neoadjuvant Therapy,7262
69,NCT03040999,Phase III,Recruiting,"[{'id': 3256, 'therapyName': 'Cisplatin + Pembrolizumab'}, {'id': 700, 'therapyName': 'Cisplatin'}]",Study of Pembrolizumab (MK-3475) or Placebo With Chemoradiation in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-412/KEYNOTE-412),7262
70,NCT02759575,Phase Ib/II,Recruiting,"[{'id': 3256, 'therapyName': 'Cisplatin + Pembrolizumab'}]",A Study of Chemoradiation Plus Pembrolizumab for Locally Advanced Laryngeal Squamous Cell Carcinoma,7262
71,NCT02775812,Phase I,Recruiting,"[{'id': 3256, 'therapyName': 'Cisplatin + Pembrolizumab'}]","Cisplatin, Radiation Therapy, and Pembrolizumab in Treating Patients With Stage III-IV Head and Neck Squamous Cell Carcinoma",7262
72,NCT02586207,Phase I,Recruiting,"[{'id': 3256, 'therapyName': 'Cisplatin + Pembrolizumab'}]",Pembrolizumab in Combination With CRT for LA-SCCHN,7262
73,NCT02777385,Phase II,Recruiting,"[{'id': 3256, 'therapyName': 'Cisplatin + Pembrolizumab'}]",Pembrolizumab in Combination With Cisplatin and Intensity Modulated Radiotherapy (IMRT) in Head and Neck Cancer,7262
74,NCT02346955,Phase I,Terminated,"[{'id': 4246, 'therapyName': 'CM-24'}, {'id': 4247, 'therapyName': 'CM-24 + Pembrolizumab'}]",Study of CM-24 (MK-6018) Alone and In Combination With Pembrolizumab (MK-3475) in Participants With Selected Advanced or Recurrent Malignancies (MK-6018-001),7262
75,NCT02565992,Phase I,Recruiting,"[{'id': 3136, 'therapyName': 'coxsackievirus A21 + Pembrolizumab'}]",Phase I Study of Intratumoral CAVATAK and Pembrolizumab in Subjects With Advanced Melanoma,7262
76,NCT03006302,Phase II,Not yet recruiting,"[{'id': 5169, 'therapyName': 'CRS-207 + INCB024360 + Pembrolizumab'}, {'id': 5170, 'therapyName': 'CRS-207 + Cyclophosphamide + GVAX panc vaccine + INCB024360 + Pembrolizumab'}]","Epacadostat, Pembrolizumab, and CRS-207, With or Without CY/GVAX Pancreas in Patients With Metastatic Pancreas Cancer",7262
77,NCT03122548,Phase II,Recruiting,"[{'id': 5716, 'therapyName': 'CRS-207 + Pembrolizumab'}]","Safety and Efficacy of CRS-207 With Pembrolizumab in Gastric, Gastroesophageal Junction or Esophageal Cancers",7262
78,NCT03175172,Phase II,Recruiting,"[{'id': 5716, 'therapyName': 'CRS-207 + Pembrolizumab'}]",Evaluation of CRS-207 With Pembrolizumab in Previously Treated MPM,7262
79,NCT02981524,Phase II,Recruiting,"[{'id': 5079, 'therapyName': 'Cyclophosphamide + GVAX colorectal cancer vaccine + Pembrolizumab'}]",Phase 2 Study of GVAX (With CY) and Pembrolizumab in MMR-p Advanced Colorectal Cancer,7262
80,NCT03153410,Phase I,Not yet recruiting,"[{'id': 5778, 'therapyName': 'Cyclophosphamide + GVAX pancreatic cancer vaccine + LY3022855 + Pembrolizumab'}]","Pilot Study With CY, Pembrolizumab, GVAX, and IMC-CS4 (LY3022855) in Patients With Borderline Resectable Adenocarcinoma of the Pancreas",7262
81,NCT02648282,Phase II,Recruiting,"[{'id': 4473, 'therapyName': 'Cyclophosphamide + GVAX pancreatic cancer vaccine + Pembrolizumab'}]","Study With CY, Pembrolizumab, GVAX, and SBRT in Patients With Locally Advanced Pancreatic Cancer",7262
82,NCT03003676,Phase I,Recruiting,"[{'id': 5173, 'therapyName': 'Cyclophosphamide + ONCOS-102 + Pembrolizumab'}]","A Pilot Study of Sequential ONCOS-102, an Engineered Oncolytic Adenovirus Expressing GMCSF, and Pembrolizumab in Patients With Advanced or Unresectable Melanoma Progressing After Programmed Cell Death Protein 1 (PD1) Blockade",7262
83,NCT02768701,Phase II,Recruiting,"[{'id': 4891, 'therapyName': 'Cyclophosphamide + Pembrolizumab'}]",Study Of Single-dose Cyclophosphamide +Pembrolizumab In Patients With Metastatic Triple Negative Breast Cancer,7262
84,NCT03092453,Phase I,Recruiting,"[{'id': 4891, 'therapyName': 'Cyclophosphamide + Pembrolizumab'}]",Dendritic Cell Vaccination in Patients With Advanced Melamona,7262
85,NCT03226249,Phase II,Not yet recruiting,"[{'id': 6157, 'therapyName': 'Dacarbazine + Doxorubicin + Pembrolizumab +Vinblastine'}]",PET-Directed Therapy With Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Classical Hodgkin Lymphoma,7262
86,NCT03221634,Phase II,Not yet recruiting,"[{'id': 6115, 'therapyName': 'Daratumumab + Pembrolizumab'}]",Efficacy and Safety Study of Pembrolizumab (MK-3475) in Combination With Daratumumab in Participants With Relapsed Refractory Multiple Myeloma (MK-3475-668/KEYNOTE-668),7262
87,NCT02546531,Phase I,Recruiting,"[{'id': 3083, 'therapyName': 'Defactinib + Gemcitabine + Pembrolizumab'}]",Defactinib Combined With Pembrolizumab and Gemcitabine in Patients With Advanced Cancer,7262
88,NCT02722954,Phase I,"Active, not recruiting","[{'id': 3994, 'therapyName': 'Demcizumab + Pembrolizumab'}]",A Study of Demcizumab Plus Pembrolizumab +/- Chemotherapy,7262
89,NCT02861573,Phase I,Recruiting,"[{'id': 5343, 'therapyName': 'Dexamethasone + Docetaxel + Pembrolizumab + Prednisone'}, {'id': 5342, 'therapyName': 'Olaparib + Pembrolizumab'}, {'id': 2666, 'therapyName': 'Enzalutamide + Pembrolizumab'}]",Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365),7262
90,NCT02880228,Phase II,"Active, not recruiting","[{'id': 4612, 'therapyName': 'Dexamethasone + lenalidomide + Pembrolizumab'}]","Pembrolizumab, Lenalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma Eligible for Stem Cell Transplant",7262
91,NCT02289222,Phase Ib/II,"Active, not recruiting","[{'id': 3344, 'therapyName': 'Dexamethasone + Pembrolizumab + Pomalidomide'}]",Anti-PD-1 (MK-3475) and IMiD (Pomalidomide) Combination Immunotherapy in Relapsed/Refractory Multiple Myeloma,7262
92,NCT02684617,Phase I,Recruiting,"[{'id': 4225, 'therapyName': 'Dinaciclib + Pembrolizumab'}]",Study of Pembrolizumab (MK-3475) in Combination With Dinaciclib (MK-7965) in Hematologic Malignancies  (MK-3475-155) (KEYNOTE-155),7262
93,NCT01676753,Phase Ib/II,Recruiting,"[{'id': 4225, 'therapyName': 'Dinaciclib + Pembrolizumab'}]",Phase 1b Dose De-escalation Trial of Dinaciclib With Pembrolizumab for Advanced Breast Cancer,7262
94,NCT02798406,Phase II,Recruiting,"[{'id': 4408, 'therapyName': 'DNX-2401 + Pembrolizumab'}]",Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects (CAPTIVE),7262
95,NCT03211117,Phase II,Recruiting,"[{'id': 6040, 'therapyName': 'Docetaxel + Doxorubicin + Pembrolizumab'}]","Pembrolizumab, Chemotherapy, and Radiation Therapy With or Without Surgery in Treating Patients With Anaplastic Thyroid Cancer",7262
96,NCT03083808,Phase II,Recruiting,"[{'id': 5497, 'therapyName': 'Pembrolizumab + Gemcitabine'}, {'id': 5496, 'therapyName': 'Docetaxel + Pembrolizumab'}, {'id': 5498, 'therapyName': 'Pemetrexed + Pembrolizumab'}, {'id': 854, 'therapyName': 'Pemetrexed'}]",Phase II Trial of Continuation Therapy in Advanced NSCLC,7262
97,NCT02865811,Phase II,"Active, not recruiting","[{'id': 4558, 'therapyName': 'Doxil + Pembrolizumab'}]","Pembrolizumab Combined With PLD For Recurrent Platinum Resistant Ovarian, Fallopian Tube Or Peritoneal Cancer",7262
98,NCT03056001,Phase II,Recruiting,"[{'id': 4690, 'therapyName': 'Doxorubicin + Pembrolizumab'}]","Safety, Tolerability, and Efficacy of Doxorubicin and Pembrolizumab for Sarcoma",7262
99,NCT02888665,Phase Ib/II,Recruiting,"[{'id': 4690, 'therapyName': 'Doxorubicin + Pembrolizumab'}]",Pembrolizumab and Doxorubicin Hydrochloride in Treating Patients With Sarcoma That is Metastatic or Cannot Be Removed by Surgery,7262
100,NCT02636036,Phase I,Recruiting,"[{'id': 3620, 'therapyName': 'Enadenotucirev + Pembrolizumab'}]",Study of Enadenotucirev and Pembrolizumab in Subjects With Metastatic or Advanced Epithelial Tumors,7262
101,NCT02971761,Phase II,Recruiting,"[{'id': 5027, 'therapyName': 'enobosarm + Pembrolizumab'}]",Pembrolizumab and Enobosarm in Treating Patients With Androgen Receptor Positive Metastatic Triple Negative Breast Cancer,7262
102,NCT02936752,Phase I,Recruiting,"[{'id': 3354, 'therapyName': 'Entinostat + Pembrolizumab'}]",Entinostat and Pembrolizumab in Treating Patients With Myelodysplastic Syndrome After DNMTi Therapy Failure,7262
103,NCT02909452,Phase I,Recruiting,"[{'id': 3354, 'therapyName': 'Entinostat + Pembrolizumab'}]",Continuation Study of Entinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumors,7262
104,NCT02437136,Phase Ib/II,Recruiting,"[{'id': 3354, 'therapyName': 'Entinostat + Pembrolizumab'}]",Ph1b/2 Dose-Escalation Study of Entinostat With Pembrolizumab in NSCLC With Expansion Cohorts in NSCLC and Melanoma,7262
105,NCT03179930,Phase II,Recruiting,"[{'id': 3354, 'therapyName': 'Entinostat + Pembrolizumab'}]",Combination Therapy With Entinostat and Pembrolizumab in Relapsed and Refractory Lymphomas,7262
106,NCT02312557,Phase II,Recruiting,"[{'id': 2666, 'therapyName': 'Enzalutamide + Pembrolizumab'}]",Pembrolizumab in Treating Patients With Metastatic Castration Resistant Prostate Cancer Previously Treated With Enzalutamide,7262
107,NCT03277352,Phase Ib/II,Not yet recruiting,"[{'id': 6277, 'therapyName': 'Epacadostat + INCAGN01876 + Pembrolizumab'}]",INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies,7262
108,NCT02752074,Phase III,"Active, not recruiting","[{'id': 4088, 'therapyName': 'Epacadostat + Pembrolizumab'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",A Phase 3 Study of Pembrolizumab + Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma,7262
109,NCT03196232,Phase II,Recruiting,"[{'id': 4088, 'therapyName': 'Epacadostat + Pembrolizumab'}]",Epacadostat and Pembrolizumab in Treating Patients With Metastatic or Unresectable Gastroesophageal Junction or Gastric Cancer,7262
110,NCT03291054,Phase II,Not yet recruiting,"[{'id': 4088, 'therapyName': 'Epacadostat + Pembrolizumab'}]",Epacadostat and Pembrolizumab in Patients With GIST,7262
111,NCT02393248,Phase Ib/II,Recruiting,"[{'id': 4176, 'therapyName': 'Cisplatin + Gemcitabine + INCB054828'}, {'id': 4174, 'therapyName': 'Docetaxel + INCB054828'}, {'id': 4088, 'therapyName': 'Epacadostat + Pembrolizumab'}]","Open-Label, Dose-Escalation Study of INCB054828 in Subjects With Advanced Malignancies",7262
112,NCT03238638,Phase II,Not yet recruiting,"[{'id': 4088, 'therapyName': 'Epacadostat + Pembrolizumab'}]","A Study of Epacadostat + Pembrolizumab in Head and Neck Cancer Patients, Who Failed Prior PD-1/PD-L1 Therapy",7262
113,NCT02513472,Phase Ib/II,"Active, not recruiting","[{'id': 3080, 'therapyName': 'Eribulin + Pembrolizumab'}]",Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Subjects With Metastatic Triple-Negative Breast Cancer (mTNBC),7262
114,NCT03051659,Phase II,Recruiting,"[{'id': 728, 'therapyName': 'Eribulin'}, {'id': 3080, 'therapyName': 'Eribulin + Pembrolizumab'}]",A Randomized Phase II Study Of Eribulin Mesylate With or Without Pembrolizumab For Metastatic Hormone Receptor Positive Breast Cancer,7262
115,NCT03204188,Phase II,Recruiting,"[{'id': 6154, 'therapyName': 'Fludarabine + Ibrutinib + Pembrolizumab'}]","Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma",7262
116,NCT03193190,Phase Ib/II,Recruiting,"[{'id': 5942, 'therapyName': 'Atezolizumab + BKT140'}, {'id': 5940, 'therapyName': 'Gemcitabine + Nab-Paclitaxel + mFOLFOX-6'}, {'id': 5941, 'therapyName': 'Atezolizumab + PEGPH20'}, {'id': 1343, 'therapyName': 'Atezolizumab + Cobimetinib'}]",A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (PDAC),7262
117,NCT02501473,Phase Ib/II,Recruiting,"[{'id': 3577, 'therapyName': 'GLA-SE + Pembrolizumab'}]",Study of Intratumoral G100 Therapy in Patients With Or Without Pembrolizumab With Follicular Non-Hodgkin's Lymphoma,7262
118,NCT03131908,Phase Ib/II,Recruiting,"[{'id': 3518, 'therapyName': 'GSK2636771 + Pembrolizumab'}]",Study of the Selective PI3K-Beta Inhibitor GSK2636771 in Combination With Pembrolizumab in Patients With Metastatic Melanoma and PTEN Loss,7262
119,NCT02723955,Phase I,Recruiting,"[{'id': 4409, 'therapyName': 'GSK3359609'}, {'id': 4410, 'therapyName': 'GSK3359609 + Pembrolizumab'}]",Dose Escalation and Expansion Study of GSK3359609 in Subjects With Selected Advanced Solid Tumors (INDUCE-1),7262
120,NCT03257722,Phase Ib/II,Recruiting,"[{'id': 6145, 'therapyName': 'Idelalisib + Pembrolizumab'}]",Pembrolizumab + Idelalisib for Lung Cancer Study,7262
121,NCT02812693,Phase Ib/II,Recruiting,"[{'id': 4376, 'therapyName': 'Imatinib + Pembrolizumab'}]",Pembrolizumab and Imatinib in Patients With Locally Advanced/Metastatic Melanoma With c-KIT Mutation/Amplification,7262
122,NCT03276832,Phase I,Not yet recruiting,"[{'id': 6220, 'therapyName': 'Imiquimod + Pembrolizumab'}]",Imiquimod and Pembrolizumab in Treating Patients With Stage IIIB-IV Melanoma,7262
123,NCT02644967,Phase Ib/II,Recruiting,"[{'id': 4244, 'therapyName': 'IMO-2125 + Ipilimumab'}, {'id': 4245, 'therapyName': 'IMO-2125 + Pembrolizumab'}]",A Study to Assess the Safety and Efficacy of Intratumoral IMO-2125 in Combination With Ipilimumab or Pembrolizumab in Patients With Metastatic Melanoma,7262
124,NCT02981303,Phase II,Recruiting,"[{'id': 5174, 'therapyName': 'Imprime PGG + Pembrolizumab'}]",Study of Imprime PGG and Pembrolizumab in Advanced Melanoma and Triple Negative Breast Cancer,7262
125,NCT03003468,Phase Ib/II,Recruiting,"[{'id': 5174, 'therapyName': 'Imprime PGG + Pembrolizumab'}]",Pembrolizumab + Imprime PGG for Metastatic Non-small Cell Lung Cancer After Progression on First-Line Chemotherapy: Big Ten Cancer Research Consortium BTCRC-LUN15-017,7262
126,NCT03085914,Phase Ib/II,Recruiting,"[{'id': 5483, 'therapyName': 'INCB024360 + Nivolumab + mFOLFOX6'}, {'id': 5484, 'therapyName': 'INCB024360 + Nivolumab + Gemcitabine + nab-paclitaxel'}, {'id': 5485, 'therapyName': 'INCB024360 + Pembrolizumab + Carboplatin + Paclitaxel'}, {'id': 5486, 'therapyName': 'INCB024360 + Pembrolizumab + Carboplatin + Pemetrexed'}, {'id': 5487, 'therapyName': 'INCB024360 + Pembrolizumab + Cyclophosphamide'}]",A Study of Epacadostat in Combination With a PD-1 Inhibitor and Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors (ECHO-207),7262
127,NCT03302234,Phase III,Not yet recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 2106, 'therapyName': 'Ipilimumab + Pembrolizumab '}]",Study of Pembrolizumab Given With Ipilimumab or Placebo in Participants With Untreated Metastatic Non-small Cell Lung Cancer (MK-3475-598/KEYNOTE-598),7262
128,NCT02743819,Phase II,Recruiting,"[{'id': 2106, 'therapyName': 'Ipilimumab + Pembrolizumab '}]",Phase II Study of Pembrolizumab and Ipilimumab Following Initial Anti-PD1/L1 Antibody,7262
129,NCT03136055,Phase II,Recruiting,"[{'id': 5643, 'therapyName': 'Irinotecan + Pembrolizumab'}, {'id': 4021, 'therapyName': 'Paclitaxel + Pembrolizumab'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab-based Therapy in Previously Treated High Grade Neuroendocrine Carcinomas,7262
130,NCT03236935,Phase I,Not yet recruiting,"[{'id': 6097, 'therapyName': 'L-NMMA + Pembrolizumab'}]",Phase Ib of L-NMMA and Pembrolizumab,7262
131,NCT03043664,Phase Ib/II,Recruiting,"[{'id': 6129, 'therapyName': 'Lanreotide Depot + Pembrolizumab'}]",Study of Pembrolizumab With Lanreotide Depot for Gastroenteropancreatic Neuroendocrine Tumors (PLANET),7262
132,NCT02875067,Phase Ib/II,Recruiting,"[{'id': 3322, 'therapyName': 'lenalidomide + Pembrolizumab'}]","Safety & Efficacy Study of Combination of Pembrolizumab and Lenalidomide, in Patients With Relapsed Non-Hodgkin and Hodgkin Lymphoma",7262
133,NCT02963610,Phase Ib/II,Recruiting,"[{'id': 3322, 'therapyName': 'lenalidomide + Pembrolizumab'}]",Phase I/II Study of Lenalidomide Plus Pembrolizumab in Patients With Solid Tumors With Expansion in Non-small Cell Lung Cancer,7262
134,NCT02036502,Phase I,Recruiting,"[{'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 3322, 'therapyName': 'lenalidomide + Pembrolizumab'}]",A Study of Pembrolizumab (MK-3475) in Combination With Lenalidomide and Dexamethasone in Participants With Multiple Myeloma (MK-3475-023/KEYNOTE-023),7262
135,NCT02973997,Phase II,Not yet recruiting,"[{'id': 4782, 'therapyName': 'Lenvatinib + Pembrolizumab'}]",Pembrolizumab and Lenvatinib in Treating Metastatic or Recurrent Differentiated Thyroid Cancer That Cannot Be Removed by Surgery,7262
136,NCT02811861,Phase III,Recruiting,"[{'id': 1713, 'therapyName': 'Everolimus + Lenvatinib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 4782, 'therapyName': 'Lenvatinib + Pembrolizumab'}]",Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma,7262
137,NCT03006926,Phase I,Recruiting,"[{'id': 4782, 'therapyName': 'Lenvatinib + Pembrolizumab'}]",A Trial of Lenvatinib Plus Pembrolizumab in Subjects With Hepatocellular Carcinoma,7262
138,NCT02778685,Phase II,Recruiting,"[{'id': 4222, 'therapyName': 'Letrozole + Palbociclib + Pembrolizumab'}]","Pembrolizumab, Letrozole, and Palbociclib in Treating Patients With Stage IV Estrogen Receptor Positive Breast Cancer With Stable Disease That Has Not Responded to Letrozole and Palbociclib",7262
139,NCT01206530,Phase Ib/II,"Active, not recruiting","[{'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1316, 'therapyName': 'Hydroxychloroquine'}]",FOLFOX/Bevacizumab/Hydroxychloroquine (HCQ) in Colorectal Cancer,7262
140,NCT02213289,Phase Ib/II,Recruiting,"[{'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 1913, 'therapyName': 'FOLTAX'}, {'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 1315, 'therapyName': 'FOLFIRI'}, {'id': 629, 'therapyName': 'AMG102'}]",PANGEA-IMBBP: Personalized Antibodies for Gastro-Esophageal Adenocarcinoma - A 1st Pilot Metastatic Trial of Biologics Beyond Progression,7262
141,NCT02046538,Phase II,Withdrawn,"[{'id': 1315, 'therapyName': 'FOLFIRI'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 624, 'therapyName': 'Aflibercept'}]",Phase II Study of Zaltrap and Chemotherapy for Advanced Resectable Colorectal Cancer,7262
142,NCT02730546,Phase Ib/II,Suspended,"[{'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]","Pembrolizumab, Combination Chemotherapy, and Radiation Therapy Before Surgery in Treating Adult Patients With Locally Advanced Gastroesophageal Junction or Gastric Cardia Cancer That Can Be Removed by Surgery",7262
143,NCT01662869,Phase III,Completed,"[{'id': 838, 'therapyName': 'Onartuzumab'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}]",A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic HER2-Negative And Met-Positive Gastroesophageal Cancer (MetGastric),7262
144,NCT02024607,Phase Ib/II,"Active, not recruiting","[{'id': 1597, 'therapyName': 'Capecitabine + Oxaliplatin'}, {'id': 2093, 'therapyName': 'BBI608 + Bevacizumab'}, {'id': 2094, 'therapyName': 'BBI608 + Regorafenib'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 2057, 'therapyName': 'BBI608'}, {'id': 1315, 'therapyName': 'FOLFIRI'}]",A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer,7262
145,NCT02625610,Phase III,Recruiting,"[{'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 3144, 'therapyName': 'Avelumab'}, {'id': 1597, 'therapyName': 'Capecitabine + Oxaliplatin'}]",Avelumab in First-Line Gastric Cancer (JAVELIN Gastric 100),7262
146,NCT01260415,Phase II,Completed,"[{'id': 845, 'therapyName': 'Panitumumab'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 1315, 'therapyName': 'FOLFIRI'}]",A Study of Perioperative Chemotherapy Plus Panitumumab in Patients With Colorectal Cancer Liver Metastases,7262
147,NCT02912559,Phase III,Recruiting,"[{'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}]",Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair or Microsatellite Instability,7262
148,NCT01586611,Phase III,Unknown status,"[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}]",A Study to See if hENT1 Testing on Tumour Tissue Can Predict Response to Treatment With Gemcitabine Chemotherapy and if a Different Chemotherapy Called FOLFOX is Better Than Gemcitabine in Metastatic Pancreas Cancer,7262
149,NCT02268825,Phase Ib/II,"Active, not recruiting","[{'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Phase I/IIA Study MK-3475 With Chemotherapy in Patients With Advanced GI Cancers,7262
150,NCT02413853,Phase II,Withdrawn,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1083, 'therapyName': 'Pri-724'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}]",Combination Chemotherapy and Bevacizumab With or Without PRI-724 in Treating Patients With Newly Diagnosed Metastatic Colorectal Cancer,7262
151,NCT01985763,Phase Ib/II,Completed,"[{'id': 757, 'therapyName': 'Genistein'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}]",Genistein in Treatment of Metastatic Colorectal Cancer,7262
152,NCT02344810,Phase Ib/II,Unknown status,"[{'id': 1064, 'therapyName': 'AMG 337'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}]","C-Met Inhibitor AMG 337, Oxaliplatin, Leucovorin Calcium, and Fluorouracil in Treating Patients With Advanced Stomach or Esophageal Cancer",7262
153,NCT01327612,Phase II,"Active, not recruiting","[{'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 746, 'therapyName': 'Ganitumab'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1458, 'therapyName': 'Conatumumab'}]",Open Label Extension Study of Conatumumab and AMG 479,7262
154,NCT02009449,Phase I,"Active, not recruiting","[{'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 2621, 'therapyName': 'AM0010 '}, {'id': 619, 'therapyName': 'Abraxane'}]",A Phase 1 Study of AM0010 in Patients With Advanced Solid Tumors,7262
155,NCT02921256,Phase II,Recruiting,"[{'id': 954, 'therapyName': 'Veliparib'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 4838, 'therapyName': 'Capecitabine + Veliparib'}, {'id': 1105, 'therapyName': 'Capecitabine'}]",Veliparib and Combination Chemotherapy in Treating Patient With Locally Advanced Rectal Cancer,7262
156,NCT01896531,Phase II,"Active, not recruiting","[{'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 747, 'therapyName': 'Ipatasertib'}]",A Study of GDC-0068 in Combination With Fluoropyrimidine Plus Oxaliplatin in Patients With Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer,7262
157,NCT02574663,Phase I,"Active, not recruiting","[{'id': 1779, 'therapyName': 'Nab-paclitaxel + Gemcitabine'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 2022, 'therapyName': 'TGR-1202'}]",TGR-1202 Alone and in Combination With Either Nab-paclitaxel + Gemcitabine or With FOLFOX in Patients With Select Relapsed or Refractory Solid Tumors,7262
158,NCT02943603,Phase II,Withdrawn,"[{'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}]",A Study of Perioperative mFOLFOX6 Plus Pembrolizumab in Patients With Potentially Resectable Adenocarcinoma of the Gastroesophageal Junction (GEJ) and Stomach,7262
159,NCT01362374,Phase I,"Active, not recruiting","[{'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 747, 'therapyName': 'Ipatasertib'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}]","Safety and Pharmacology Of GDC-0068 in Combination With Docetaxel, Fluoropyrimidine Plus Oxaliplatin, Paclitaxel, or Enzalutamide in Patients With Advanced Solid Tumors",7262
160,NCT01747551,Phase II,"Active, not recruiting","[{'id': 624, 'therapyName': 'Aflibercept'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}]",FOLFOX +/- Ziv-Aflibercept for Esophageal and Gastric Cancer,7262
161,NCT02141295,Phase II,Completed,"[{'id': 1484, 'therapyName': 'Bevacizumab + Oxaliplatin + Leucovorin + Fluorouracil'}, {'id': 1598, 'therapyName': 'RO5520985'}, {'id': 1599, 'therapyName': 'Bevacizumab + Fluorouracil + Leucovorin'}, {'id': 1600, 'therapyName': 'RO5520985 + Leucovorin + Fluorouracil'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}]",A Study Comparing the Efficacy and Safety of RO5520985 and FOLFOX With Bevacizumab and FOLFOX in Patients With Untreated Metastatic Colorectal Cancer (McCAVE),7262
162,NCT00602329,Phase II,Unknown status,"[{'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 667, 'therapyName': 'Bevacizumab'}]",MRI in Predicting Response in Patients Receiving Combination Chemotherapy and Bevacizumab For Advanced or Metastatic Colorectal Cancer,7262
163,NCT02358863,Phase I,Terminated,"[{'id': 4311, 'therapyName': 'Docetaxel + Irinotecan'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 1835, 'therapyName': 'Docetaxel + Cisplatin'}, {'id': 1406, 'therapyName': 'Camptosar + Cisplatin'}, {'id': 4310, 'therapyName': 'Epirubicin + Docetaxel'}, {'id': 4309, 'therapyName': 'Capecitabine + Docetaxel'}]",Molecularly Tailored Therapy for Patients With Metastatic Cancer of the Esophagus and Stomach (mEGA),7262
164,NCT01516216,Phase II,"Active, not recruiting","[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}]",Study of Vitamin D in Untreated Metastatic Colorectal Cancer,7262
165,NCT01489865,Phase Ib/II,Recruiting,"[{'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 954, 'therapyName': 'Veliparib'}]",ABT-888 With Modified FOLFOX6 in Patients With Metastatic Pancreatic Cancer,7262
166,NCT02375672,Phase II,"Active, not recruiting","[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}]",Study of Pembrolizumab in Combination With Chemotherapy for Patients With Advanced Colorectal Cancer,7262
167,NCT01571024,Phase I,Completed,"[{'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 680, 'therapyName': 'BKM120'}]", BKM120 + mFOLFOX6 in Advanced Solid Tumors With Expansion Cohort Pancreatic Cancer,7262
168,NCT01420874,Phase I,"Active, not recruiting","[{'id': 1012, 'therapyName': 'EGFRBi-armed autologous activated T cells'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}]",Anti-CD3 x Anti-Erbitux Armed Activated T Cells (Phase Ib) for Gastrointestinal (GI Cancer),7262
169,NCT02715531,Phase I,Recruiting,"[{'id': 3947, 'therapyName': 'Atezolizumab + Gemcitabine + nab-paclitaxel'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 1202, 'therapyName': 'Atezolizumab + Bevacizumab + Capecitabine'}]",A Study of the Safety and Tolerability of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors,7262
170,NCT02872116,Phase III,Recruiting,"[{'id': 1597, 'therapyName': 'Capecitabine + Oxaliplatin'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}]",Efficacy Study of Nivolumab Plus Ipilimumab Against Chemotherapy Standard of Care in Stomach Cancer or Stomach/Esophagus Junction Cancer (CheckMate649),7262
171,NCT01666730,Phase II,Recruiting,"[{'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 1031, 'therapyName': 'Metformin'}]",Metformin Plus Modified FOLFOX 6 in Metastatic Pancreatic Cancer,7262
172,NCT01803282,Phase I,Recruiting,"[{'id': 3320, 'therapyName': 'GS-5745'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 1602, 'therapyName': 'Carboplatin + Pemetrexed'}, {'id': 1315, 'therapyName': 'FOLFIRI'}, {'id': 1779, 'therapyName': 'Nab-paclitaxel + Gemcitabine'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 667, 'therapyName': 'Bevacizumab'}]",Safety and Tolerability Study in Solid Tumors,7262
173,NCT02319018,Phase I,"Active, not recruiting","[{'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 626, 'therapyName': 'Alisertib'}]",Alisertib and Combination Chemotherapy in Treating Patients With Gastrointestinal Tumors,7262
174,NCT02658214,Phase I,Recruiting,"[{'id': 2667, 'therapyName': 'Carboplatin + Gemcitabine'}, {'id': 2634, 'therapyName': 'Carboplatin + nab-paclitaxel'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 1791, 'therapyName': 'Carboplatin + Etoposide'}]",Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors,7262
175,NCT01652976,Phase II,"Active, not recruiting","[{'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 717, 'therapyName': 'Dasatinib'}]","Phase II Study of 5-FU, Oxaliplatin Plus Dasatinib in Metastatic Pancreatic Adenocarcinoma",7262
176,NCT02545504,Phase III,"Active, not recruiting","[{'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 3320, 'therapyName': 'GS-5745'}]",GS-5745 With mFOLFOX6 as First Line Treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma,7262
177,NCT02563002,Phase III,Recruiting,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1315, 'therapyName': 'FOLFIRI'}, {'id': 694, 'therapyName': 'Cetuximab'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}]",Study of Pembrolizumab (MK-3475) vs Standard Therapy in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (MK-3475-177/KEYNOTE-177),7262
178,NCT02475213,Phase I,Recruiting,"[{'id': 2864, 'therapyName': 'MGA271 + Pembrolizumab'}]",Safety Study of MGA271 in Combination With Pembrolizumab in Refractory Cancer,7262
179,NCT02689284,Phase Ib/II,Recruiting,"[{'id': 3728, 'therapyName': 'MGAH22 + Pembrolizumab'}]","Combination Margetuximab and Pembrolizumab for Advanced, Metastatic HER2(+) Gastric or Gastroesophageal Junction Cancer",7262
180,NCT03225547,Phase II,Not yet recruiting,"[{'id': 6030, 'therapyName': 'Mifepristone + Pembrolizumab'}]",Study of Pembrolizumab and Mifepristone in Patients With Advanced HER2-negative Breast Cancer,7262
181,NCT03179436,Phase I,Recruiting,"[{'id': 6039, 'therapyName': 'MK-1308 + Pembrolizumab'}]","Safety, Pharmacokinetics (PK), and Efficacy of MK-1308 in Combination With Pembrolizumab in Advanced Solid Tumors (MK-1308-001)",7262
182,NCT03010176,Phase I,Recruiting,"[{'id': 5348, 'therapyName': 'MK-1454 + Pembrolizumab'}, {'id': 5347, 'therapyName': 'MK-1454'}]",Study of MK-1454 Alone or in Combination With Pembrolizumab in Participants With Advanced/Metastatic Solid Tumors or Lymphomas (MK-1454-001),7262
183,NCT03249792,Phase I,Recruiting,"[{'id': 6131, 'therapyName': 'MK-2118 + Pembrolizumab'}, {'id': 6130, 'therapyName': 'MK-2118'}]",Study of MK-2118 Administered as Intratumoral Injection as Monotherapy and in Combination With Pembrolizumab (MK-3475) in the Treatment of Adults With Advance/Metastatic Solid Tumors or Lymphomas (MK-2118-001),7262
184,NCT02720068,Phase I,Recruiting,"[{'id': 4213, 'therapyName': 'MK-4280 + Pembrolizumab'}, {'id': 4212, 'therapyName': 'MK-4280'}]",Study of MK-4280 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Adults With Advanced Solid Tumors (MK-4280-001),7262
185,NCT02964013,Phase I,Recruiting,"[{'id': 5218, 'therapyName': 'MK-7684'}, {'id': 5219, 'therapyName': 'MK-7684 + Pembrolizumab'}]",Study of MK-7684 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors (MK-7684-001),7262
186,NCT02972034,Phase I,Recruiting,"[{'id': 5269, 'therapyName': 'MK-8353 + Pembrolizumab'}]",Study of MK-8353 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Malignancies (MK-8353-013),7262
187,NCT03220477,Phase I,Recruiting,"[{'id': 6042, 'therapyName': 'Mocetinostat + Pembrolizumab + SGI-110'}]",Pembrolizumab (Immunotherapy Drug) in Combination With Guadecitabine and Mocetinostat (Epigenetic Drugs) for Patients With Advanced Lung Cancer.,7262
188,NCT03113487,Phase II,Not yet recruiting,"[{'id': 5547, 'therapyName': 'MVAp53 + Pembrolizumab'}]","P53MVA and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer",7262
189,NCT02733250,Phase Ib/II,Recruiting,"[{'id': 4023, 'therapyName': 'nab-paclitaxel + Pembrolizumab'}]",Pembrolizumab With Nab-Paclitaxel in Non-Small Cell Lung Cancer (URCOH-PMS-001),7262
190,NCT02752685,Phase II,Recruiting,"[{'id': 4023, 'therapyName': 'nab-paclitaxel + Pembrolizumab'}]",Phase II Study of Pembrolizumab and Nab-paclitaxel in HER-2 Negative Metastatic Breast Cancer,7262
191,NCT03240016,Phase II,Not yet recruiting,"[{'id': 4023, 'therapyName': 'nab-paclitaxel + Pembrolizumab'}]",Abraxane With Anti-PD1/PDL1 in Cisplatin-ineligible Patients With Advanced Urothelial Cancer,7262
192,NCT02657889,Phase Ib/II,Recruiting,"[{'id': 3935, 'therapyName': 'Niraparib + Pembrolizumab'}]",Study of Niraparib in Combination With Pembrolizumab (MK-3475) in Patients With Triple-negative Breast Cancer or Ovarian Cancer (KEYNOTE-162),7262
193,NCT02949843,Phase II,Recruiting,"[{'id': 4918, 'therapyName': 'Nivolumab + Pembrolizumab'}]",Targeted Therapy in Treating Patients With Incurable Non-Small Cell Lung Cancer With Genetic Mutations,7262
194,NCT03229278,Phase I,Not yet recruiting,"[{'id': 6055, 'therapyName': 'Nivolumab + Pembrolizumab + Trigriluzole'}]",Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma,7262
195,NCT03138889,Phase I,Recruiting,"[{'id': 5625, 'therapyName': 'NKTR-214 + Pembrolizumab'}]",A Study of a CD122-Biased Cytokine (NKTR-214) in Combination With Anti-PD-L1 (Atezolizumab) in Patients With Metastatic Urothelial Bladder Cancer or Metastatic Non-Small Cell Lung Cancer,7262
196,NCT03168438,Phase I,Recruiting,"[{'id': 5877, 'therapyName': 'NY-ESO-1-c259T'}, {'id': 5878, 'therapyName': 'NY-ESO-1-c259T + Pembrolizumab'}]",NY-ESO-1-c259T Alone and in Combination With Pembrolizumab for Multiple Myeloma,7262
197,NCT03126591,Phase I,Recruiting,"[{'id': 5715, 'therapyName': 'Olaratumab + Pembrolizumab'}]",A Study of Olaratumab (LY3012207) Plus Pembrolizumab in Participants With Advanced or Metastatic Soft Tissue Sarcoma,7262
198,NCT03018080,Phase II,Recruiting,"[{'id': 4021, 'therapyName': 'Paclitaxel + Pembrolizumab'}]",Pilot Study of Paclitaxel Plus Pembrolizumab in Metastatic HER2-Negative Breast Cancer (PePPy),7262
199,NCT03199885,Phase III,Not yet recruiting,"[{'id': 1549, 'therapyName': 'Pertuzumab + Trastuzumab + Paclitaxel'}, {'id': 5956, 'therapyName': 'Paclitaxel + Pembrolizumab + Pertuzumab + Trastuzumab'}]","Paclitaxel, Trastuzumab, and Pertuzumab With or Without Pembrolizumab in Treating Patients With Metastatic Breast Cancer",7262
200,NCT02982720,Phase II,Recruiting,"[{'id': 2625, 'therapyName': 'peginterferon alfa-2b + Pembrolizumab'}]",Evaluating Combination Immunotherapy for Advanced Cholangiocarcinoma With Pembrolizumab and PEG-Intron,7262
201,NCT02112032,Phase I,"Active, not recruiting","[{'id': 2625, 'therapyName': 'peginterferon alfa-2b + Pembrolizumab'}]",Treatment of Advanced Melanoma With MK-3475 and Peginterferon,7262
202,NCT02563548,Phase I,Recruiting,"[{'id': 5779, 'therapyName': 'PEGPH20 + Pembrolizumab'}]",Phase 1b Open-Label Study of PEGPH20 With Pembrolizumab,7262
203,NCT03091478,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab in Patients With Leptomeningeal Disease,7262
204,NCT02437071,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Assess the Efficacy of Pembrolizumab Plus Radiotherapy or Ablation in Metastatic Colorectal Cancer Patients,7262
205,NCT03295227,Phase I,Not yet recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Feasibility Trial of Pembrolizumab in Unresectable Thymoma and Thymic Carcinoma,7262
206,NCT03224871,Phase I,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1167, 'therapyName': 'Aldesleukin'}, {'id': 1312, 'therapyName': 'Nivolumab'}]",A Pilot Study of Interlesional IL-2 and RT in Patients With NSCLC.,7262
207,NCT02621151,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 755, 'therapyName': 'Gemcitabine'}]","Pembrolizumab (MK3475), Gemcitabine, and Concurrent Hypofractionated Radiation Therapy for Muscle-Invasive Urothelial Cancer of the Bladder",7262
208,NCT02541565,Phase I,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 3266, 'therapyName': 'Cyclophosphamide + Doxorubicin + Prednisone + Vincristine '}, {'id': 897, 'therapyName': 'Rituximab'}]",Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Diffuse Large B-cell Lymphoma,7262
209,NCT02489357,Phase I,"Active, not recruiting","[{'id': 1814, 'therapyName': 'Degarelix'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]","Pembrolizumab and Cryosurgery in Treating Patients With Newly Diagnosed, Oligo-metastatic Prostate Cancer",7262
210,NCT02460198,Phase II,"Active, not recruiting","[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Study of Pembrolizumab (MK-3475) as Monotherapy in Participants With Previously-Treated Locally Advanced Unresectable or Metastatic Colorectal Cancer (MK-3475-164/KEYNOTE-164),7262
211,NCT02919969,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab in Refractory Metastatic Anal Cancer,7262
212,NCT03166254,Phase I,Not yet recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Combination of a Personalized Therapeutic Anti-tumor Vaccine With Pembrolizumab in Non-Small Cell Lung Cancer,7262
213,NCT02316002,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Phase II Study of Pembrolizumab After Curative Intent Treatment for Oligometastatic Non-Small Cell Lung Cancer,7262
214,NCT03142334,Phase III,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Safety and Efficacy Study of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (MK-3475-564/KEYNOTE-564),7262
215,NCT03237572,Phase I,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Focused Ultrasound and Pembrolizumab in Metastatic Breast Cancer (Breast-48),7262
216,NCT02858869,Phase 0,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases,7262
217,NCT03304639,,Not yet recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab With or Without Stereotactic Body Radiation Therapy in Treating Patients With Advanced or Metastatic Merkel Cell Cancer,7262
218,NCT02411656,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",MK-3475 for Metastatic Inflammatory Breast Cancer (MIBC),7262
219,NCT02132754,Phase I,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 2829, 'therapyName': 'MK-4166'}]",Study of MK-4166 and MK-4166 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-4166-001),7262
220,NCT02574533,Phase I,Completed,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1157, 'therapyName': 'FANG vaccine'}]",Pilot Study of Vigil + Pembrolizumab for Advanced Melanoma,7262
221,NCT02500121,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Testing the PD-1 Inhibitor Pembrolizumab After Initial Chemotherapy in Patients With Metastatic Bladder Cancer,7262
222,NCT02305186,Phase Ib/II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1105, 'therapyName': 'Capecitabine'}]",Safety and Immunological Effect of Pembrolizumab in Resectable or Borderline Resectable Pancreatic Cancer,7262
223,NCT03056599,,Recruiting,"[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1299, 'therapyName': 'Interferon alfa-2b '}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1733, 'therapyName': 'interferon gamma '}, {'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 3420, 'therapyName': 'trabectedin'}, {'id': 1167, 'therapyName': 'Aldesleukin'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 720, 'therapyName': 'Docetaxel'}]",Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO™ Device in Soft Tissue Sarcoma,7262
224,NCT03089606,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab TX-naive Distant Mets Melanoma and Use of AMT (PET) at Baseline as Imaging Biomarker,7262
225,NCT02365766,Phase Ib/II,Recruiting,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 755, 'therapyName': 'Gemcitabine'}]",Study of Neoadjuvant Pembrolizumab in Combination With Gemcitabine Based Therapy in Cis-eligible or -Ineligible Subjects With Urothelial Cancer,7262
226,NCT02819518,Phase III,Recruiting,"[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 619, 'therapyName': 'Abraxane'}, {'id': 2667, 'therapyName': 'Carboplatin + Gemcitabine'}]",Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs. Placebo Plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (MK-3475-355/KEYNOTE-355),7262
227,NCT02620423,Phase I,"Active, not recruiting","[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 893, 'therapyName': 'Reolysin'}, {'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Study of Pembrolizumab With REOLYSIN and Chemotherapy in Patients With Advanced Pancreatic Adenocarcinoma,7262
228,NCT02494583,Phase III,"Active, not recruiting","[{'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 1833, 'therapyName': 'Cisplatin + Fluorouracil'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Study of Pembrolizumab (MK-3475) as First-Line Monotherapy and Combination Therapy for Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-062/KEYNOTE-062),7262
229,NCT02638090,Phase Ib/II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1077, 'therapyName': 'Vorinostat'}]",Pembro and Vorinostat for Patients With Stage IV Non-small Cell Lung Cancer (NSCLC),7262
230,NCT03087019,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab With or Without Radiation in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma,7262
231,NCT02252042,Phase III,"Active, not recruiting","[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 694, 'therapyName': 'Cetuximab'}, {'id': 720, 'therapyName': 'Docetaxel'}]",Pembrolizumab (MK-3475) Versus Standard Treatment for Recurrent or Metastatic Head and Neck Cancer (MK-3475-040/KEYNOTE-040),7262
232,NCT02499952,Phase II,"Active, not recruiting","[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab in Subjects With Incurable Platinum-Refractory Germ Cell Tumors,7262
233,NCT02311582,Phase Ib/II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",MK-3475 in Combination With MRI-guided Laser Ablation in Recurrent Malignant Gliomas,7262
234,NCT02407171,Phase Ib/II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Evaluating the Combination of MK-3475 and Sterotactic Body Radiotherapy in Patients With Metastatic Melanoma or NSCLC,7262
235,NCT02255097,Phase II,"Active, not recruiting","[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Study of MK-3475 (Pembrolizumab) in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma After Treatment With Platinum-based and Cetuximab Therapy (MK-3475-055/KEYNOTE-055),7262
236,NCT02684461,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Phase II Trial of Sequential Consolidation With Pembrolizumab Followed by Nab-paclitaxel,7262
237,NCT02642809,Phase I,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab With Locally Delivered Radiation Therapy for the Initial Treatment of Metastatic Esophageal Cancers,7262
238,NCT02256436,Phase III,"Active, not recruiting","[{'id': 1447, 'therapyName': 'Pembrolizumab'}]","A Study of Pembrolizumab (MK-3475) Versus Paclitaxel, Docetaxel, or Vinflunine for Participants With Advanced Urothelial Cancer (MK-3475-045/KEYNOTE-045)",7262
239,NCT02977468,Phase I,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Effects of MK-3475 (Pembrolizumab) on the Breast Tumor Microenvironment in Triple Negative Breast Cancer (Pembro/IORT),7262
240,NCT02535247,Phase II,Suspended,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Study of MK-3475 in Relapsed or Refractory Peripheral T-cell Non-Hodgkin Lymphoma,7262
241,NCT03286114,Phase I,Not yet recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Augmentation of the Graft vs. Leukemia Effect Via Checkpoint Blockade With Pembrolizumab,7262
242,NCT02608385,Phase I,"Active, not recruiting","[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Study of PD1 Blockade by Pembrolizumab With Stereotactic Body Radiotherapy in Advanced Solid Tumors,7262
243,NCT03274661,Phase II,Not yet recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab Activity in Patients With HR Competent and Deficient Tumors,7262
244,NCT02637531,Phase I,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 3363, 'therapyName': 'IPI-549'}]","A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549",7262
245,NCT02332668,Phase Ib/II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]","A Study of Pembrolizumab (MK-3475) in Pediatric Participants With Advanced Melanoma or Advanced, Relapsed, or Refractory PD-L1-Positive Solid Tumors or Lymphoma (MK-3475-051/KEYNOTE-051)",7262
246,NCT02625961,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Study of Pembrolizumab (MK-3475) in Participants With High Risk Non-muscle Invasive Bladder Cancer (MK-3475-057/KEYNOTE-057),7262
247,NCT03225664,Phase Ib/II,Not yet recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1450, 'therapyName': 'Pembrolizumab + Trametinib'}]",BATTLE-2 Program - A Biomarker-Integrated Targeted Therapy in Non-Small Cell Lung Cancer (NSCLC),7262
248,NCT02853305,Phase III,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 4686, 'therapyName': 'Carboplatin + Cisplatin + Gemcitabine'}]",Study of Pembrolizumab With or Without Platinum-based Combination Chemotherapy Versus Chemotherapy Alone in Urothelial Carcinoma (MK-3475-361/KEYNOTE-361),7262
249,NCT02362048,Phase II,"Active, not recruiting","[{'id': 1605, 'therapyName': 'Acalabrutinib'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",ACP-196 Alone and in Combination With Pembrolizumab in Subjects With Advanced or Metastatic Pancreatic Cancer,7262
250,NCT02628067,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158),7262
251,NCT02899793,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab in Ultramutated and Hypermutated Endometrial Cancer,7262
252,NCT02906332,Phase II,"Active, not recruiting","[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1390, 'therapyName': 'Dexamethasone'}]",Pembrolizumab + Lenalidomide Post Autologous Stem Cell Transplant (ASCT) in High-risk Multiple Myeloma (MM),7262
253,NCT02611960,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 4203, 'therapyName': 'Capecitabine + Docetaxel + Gemcitabine'}]","Study of Pembrolizumab (MK-3475) in Platinum Pre-treated Recurrent/Metastatic Nasopharyngeal Cancer (MK-3475-122, KEYNOTE-122)",7262
254,NCT03287050,Phase I,Not yet recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]","Anti-PD(L)1 and SBRT in the Treatment of Advanced, Platinum-Refractory Urothelial Carcinoma",7262
255,NCT02537444,Phase II,"Active, not recruiting","[{'id': 1605, 'therapyName': 'Acalabrutinib'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",ACP-196 Alone and in Combination With Pembrolizumab in Subjects With Recurrent Ovarian Cancer (KEYNOTE191),7262
256,NCT02635360,Phase II,Recruiting,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab and Chemoradiation Treatment for Advanced Cervical Cancer,7262
257,NCT03277638,Phase Ib/II,Not yet recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Laser Interstitial Thermotherapy Combined With Checkpoint Inhibitor for Recurrent Glioblastoma,7262
258,NCT02343952,Phase II,"Active, not recruiting","[{'id': 1447, 'therapyName': 'Pembrolizumab'}]","Consolidation Pembrolizumab (MK-3475), Following Chemoradiation in Patients With Inoperable/Unresectable Stage III NSCLC",7262
259,NCT02702414,Phase II,"Active, not recruiting","[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Study of Pembrolizumab (MK-3475) as Monotherapy in Adults With Previously Systemically Treated Advanced Hepatocellular Carcinoma (MK-3475-224/KEYNOTE-224),7262
260,NCT03051672,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Phase II PEMBROLIZUMAB + PALLIATIVE RADIOTHERAPY IN BC,7262
261,NCT02673333,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Single Agent Pembrolizumab in Subjects With Advanced Adrenocortical Carcinoma,7262
262,NCT02408042,Phase Ib/II,Withdrawn,"[{'id': 897, 'therapyName': 'Rituximab'}, {'id': 2352, 'therapyName': 'Carboplatin + Etoposide + Ifosfamide '}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 2486, 'therapyName': 'Brentuximab vedotin'}]",Study of Pembrolizumab With Chemotherapy in Patients With Advanced Lymphoma (PembroHeme),7262
263,NCT03255018,Phase II,Not yet recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]","Pembrolizumab in Relapsed and Refractory Gray-Zone Lymphoma (GZL), Primary Central Nervous System Lymphoma (PCNSL), and Other Extra-Nodal Diffuse Large B-cell Lymphomas",7262
264,NCT02528357,Phase I,Recruiting,"[{'id': 5177, 'therapyName': 'GSK3174998'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",GSK3174998 Alone or With Pembrolizumab in Subjects With Advanced Solid Tumors,7262
265,NCT02530502,Phase Ib/II,"Active, not recruiting","[{'id': 1141, 'therapyName': 'Temozolomide'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Radiation Therapy With Temozolomide and Pembrolizumab in Treating Patients With Newly Diagnosed Glioblastoma,7262
266,NCT02940496,Phase Ib/II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab (MK-3475) in Hepatocellular Carcinoma,7262
267,NCT02301039,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",A Phase II Study of the Anti-PD1 Antibody Pembrolizumab (MK-3475) in Patients With Advanced Sarcomas,7262
268,NCT02335411,Phase II,"Active, not recruiting","[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1833, 'therapyName': 'Cisplatin + Fluorouracil'}]",A Study of Pembrolizumab (MK-3475) in Participants With Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-059/KEYNOTE-059),7262
269,NCT02325557,Phase Ib/II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 3050, 'therapyName': 'ADXS31-142 '}]",ADXS31-142 Alone and in Combination With Pembrolizumab (MK-3475) in Patients With Prostate Cancer - KEYNOTE-046,7262
270,NCT02506153,Phase III,"Active, not recruiting","[{'id': 1299, 'therapyName': 'Interferon alfa-2b '}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",High-Dose Recombinant Interferon Alfa-2B or Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery,7262
271,NCT03087760,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Trial of Consolidation Pembrolizumab After Concurrent Chemotherapy and Proton Reirradiation for Thoracic Recurrences of Non-Small Cell Lung Cancer,7262
272,NCT02769520,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]","Efficacy Study of Pembrolizumab in Relapsed, Locally Recurrent Squamous Cell Cancer of the Head and Neck",7262
273,NCT02688608,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab in Anaplastic/Undifferentiated Thyroid Cancer,7262
274,NCT01876511,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Phase 2 Study of MK-3475 in Patients With Microsatellite Unstable (MSI) Tumors,7262
275,NCT02014636,Phase I,"Active, not recruiting","[{'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Safety and Efficacy Study of Pazopanib and MK 3475 in Advanced Renal Cell Carcinoma (RCC),7262
276,NCT03244384,Phase III,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab in Treating Patients With Locally Advanced Bladder Cancer,7262
277,NCT02579863,Phase III,Suspended,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 1164, 'therapyName': 'lenalidomide'}]",Study of Lenalidomide and Dexamethasone With or Without Pembrolizumab (MK-3475) in Participants With Newly Diagnosed Treatment Naive Multiple Myeloma (MK-3475-185/KEYNOTE-185),7262
278,NCT02707666,Phase I,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1857, 'therapyName': 'Cisplatin + Pemetrexed'}]",A Pilot Window-Of-Opportunity Study of the Anti-PD-1 Antibody Pembrolizumab in Patients With Resectable Malignant Pleural Mesothelioma,7262
279,NCT03241927,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab Effects on NK Cell Exhaustion in Melanoma (Merck NK-IIT),7262
280,NCT02621021,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1167, 'therapyName': 'Aldesleukin'}]",A Prospective Randomized and Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab,7262
281,NCT02964559,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab in Patients With Locally Advanced or Metastatic Skin Cancer,7262
282,NCT02432963,Phase I,Recruiting,"[{'id': 1038, 'therapyName': 'MVAp53'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy,7262
283,NCT02440425,Phase II,Recruiting,"[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Dose Dense Paclitaxel With Pembrolizumab (MK-3475) in Platinum Resistant Ovarian Cancer,7262
284,NCT03092323,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",A Randomized Trial of Pembrolizumab & Radiotherapy Versus Radiotherapy in High-Risk Soft Tissue Sarcoma of the Extremity (SU2C-SARC032),7262
285,NCT02564263,Phase III,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 2282, 'therapyName': 'Docetaxel + Irinotecan + Paclitaxel'}]",Study of Pembrolizumab (MK-3475) Versus Investigator's Choice Standard Therapy for Participants With Advanced Esophageal/Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181),7262
286,NCT02678572,Phase III,Recruiting,"[{'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Percutaneous Hepatic Perfusion vs Best Alternative Care in Patients With Hepatic-dominant Ocular Melanoma,7262
287,NCT02690948,Phase II,Recruiting,"[{'id': 3727, 'therapyName': 'Pembrolizumab + Vismodegib'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab With or Without Vismodegib in Treating Metastatic or Unresectable Basal Cell Skin Cancer,7262
288,NCT03057613,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",A Study of the Addition of Pembrolizumab to Postoperative Radiotherapy in Resected High Risk Cutaneous Squamous Cell Cancer of the Head and Neck,7262
289,NCT02599779,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",A Proof of Principle Study of Pembrolizumab With SBRT in TKI mRCC Patients,7262
290,NCT02332980,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",A Phase II Study of Anti-PD-1 Antibody (MK-3475) in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) and Other Low Grade B Cell Non-Hodgkin Lymphoma,7262
291,NCT02289209,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Reirradiation With MK-3475 in Locoregional Inoperable Recurrence or Second Primary Squamous Cell CA of the Head and Neck,7262
292,NCT02841748,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]","A Randomized, Double-Blind Phase II Study of Adjuvant Pembrolizumab Versus Placebo in Head and Neck Cancers at High Risk for Recurrence- the PATHWay Study",7262
293,NCT02708641,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",A Phase II Study of Pembrolizumab as Post-Remission Treatment of Patients 60 With AML,7262
294,NCT02771197,Phase II,Recruiting,"[{'id': 2237, 'therapyName': 'Fludarabine + Melphalan'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Lymphodepletion and Anti-PD-1 Blockade to Reduce Relapse in AML Patient Not Eligible for Transplant,7262
295,NCT02963090,Phase II,Recruiting,"[{'id': 5532, 'therapyName': 'Pembrolizumab + Topotecan'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab vs Topotecan in Patients With Small Cell Lung Cancer,7262
296,NCT02358031,Phase III,"Active, not recruiting","[{'id': 694, 'therapyName': 'Cetuximab'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 700, 'therapyName': 'Cisplatin'}]",A Study of Pembrolizumab (MK-3475) for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (MK-3475-048/KEYNOTE-048),7262
297,NCT03126630,Phase Ib/II,Not yet recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 5596, 'therapyName': 'Pembrolizumab + Anetumab ravtansine'}]",Pembrolizumab With or Without Anetumab Ravtansine in Treating Patients With Mesothelin-Positive Pleural Mesothelioma,7262
298,NCT02448303,Phase II,"Active, not recruiting","[{'id': 1605, 'therapyName': 'Acalabrutinib'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab Alone and In Combination With ACP-196 in Subjects With Advanced Non-small Cell Lung Cancer,7262
299,NCT02359851,Phase II,"Active, not recruiting","[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab in Treating Patients With Advanced Uveal Melanoma,7262
300,NCT02650999,Phase Ib/II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Study of Pembrolizumab in Patients Failing to Respond to or Relapsing After Anti-CD19 Chimeric Antigen Receptor Modified T Cell Therapy for Relapsed or Refractory CD19+ Lymphomas,7262
301,NCT02658097,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]","A Randomized Two Arm Phase II Trial of Pembrolizumab Alone or Sequentially Following Single Fraction Non-ablative Radiation to One of the Target Lesions, in Previously Treated Patients With Stage IV NSCLC",7262
302,NCT02674061,Phase II,"Active, not recruiting","[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Efficacy and Safety Study of Pembrolizumab (MK-3475) in Women With Advanced Recurrent Ovarian Cancer (MK-3475-100/KEYNOTE-100),7262
303,NCT03072160,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab in Recurrent or Metastatic Medullary Thyroid Cancer,7262
304,NCT03273153,Phase III,Not yet recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1343, 'therapyName': 'Atezolizumab + Cobimetinib'}]",A Study of Cobimetinib Plus Atezolizumab Versus Pembrolizumab in Participants With Previously Untreated Advanced BRAFv600 Wild-Type Melanoma,7262
305,NCT02444741,Phase Ib/II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",MK-3475 and Hypofractionated Stereotactic Radiation Therapy in Patients With Non-Small Cell Lung Cancer (NSCLC),7262
306,NCT02267603,Phase II,"Active, not recruiting","[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab in Treating Patients With Advanced Merkel Cell Cancer,7262
307,NCT02493361,Phase II,"Active, not recruiting","[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 2990, 'therapyName': 'IL-12 gene'}]",Trial of pIL-12/MK-3475 in Metastatic Melanoma,7262
308,NCT02837042,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Trial of Pembrolizumab for Advanced Penile Squamous Cell Carcinoma,7262
309,NCT02306850,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Neoadjuvant Pembrolizumab for Unresectable Stage III and Unresectable Stage IV Melanoma,7262
310,NCT03070392,Phase II,Recruiting,"[{'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 3847, 'therapyName': 'IMCgp100'}]",Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma,7262
311,NCT03267888,Phase I,Not yet recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab and Radiation Therapy in Patients With Relapsed or Refractory Multiple Myeloma,7262
312,NCT02555657,Phase III,"Active, not recruiting","[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1685, 'therapyName': 'Vinorelbine'}, {'id': 1105, 'therapyName': 'Capecitabine'}]",Study of Single Agent Pembrolizumab (MK-3475) Versus Single Agent Chemotherapy for Metastatic Triple Negative Breast Cancer (MK-3475-119/KEYNOTE-119),7262
313,NCT03085719,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Targeting PD-1 Therapy Resistance With Focused High or High and Low Dose Radiation in SCCHN,7262
314,NCT02331251,Phase Ib/II,"Active, not recruiting","[{'id': 1685, 'therapyName': 'Vinorelbine'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 619, 'therapyName': 'Abraxane'}]",Study of Pembrolizumab Plus Chemotherapy in Patients With Advanced Cancer (PembroPlus),7262
315,NCT02359019,Phase II,"Active, not recruiting","[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab in Treating Patients With Extensive Stage Small Cell Lung Cancer After Completion of Combination Chemotherapy,7262
316,NCT02740920,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Assessment of Response to Pembrolizumab in Metastatic Melanoma: Computed Tomography (CT) Texture Analysis as a Predictive Biomarker,7262
317,NCT02954874,Phase III,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab in Treating Patients With Triple-Negative Breast Cancer,7262
318,NCT02632344,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]","Study of Anti-PD-1 Therapy for HPV-associated Recurrent Respiratory Papilloma Patients With Laryngeal, Tracheal and/or Pulmonary Involvement",7262
319,NCT02837263,Phase I,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",PI Pembro in Combination With Stereotactic Body Radiotherapy for Liver Metastatic Colorectal Cancer,7262
320,NCT03233724,Phase Ib/II,Not yet recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]","The Immune Checkpoint Inhibitor Pembrolizumab in Combination With Oral Decitabine and Tetrahydrouridine as First-Line Therapy for Inoperable, Locally Advanced or Metastatic Non-small Cell Lung Cancer",7262
321,NCT03197506,Phase II,Recruiting,"[{'id': 5221, 'therapyName': 'Pembrolizumab + Temozolomide'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab and Standard Therapy in Treating Patients With Glioblastoma,7262
322,NCT02520154,Phase II,Recruiting,"[{'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab in Combination With Chemotherapy in Frontline Ovarian Cancer,7262
323,NCT02467361,Phase Ib/II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 2057, 'therapyName': 'BBI608'}]",A Study of BBI608 Administered in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Cancers,7262
324,NCT02546986,Phase II,"Active, not recruiting","[{'id': 651, 'therapyName': 'Azacitidine'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Safety and Efficacy Study of CC-486 With MK-3475 to Treat Locally Advanced or Metastatic Non-small Cell Lung Cancer,7262
325,NCT02710396,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Genetic Predictors of Benefit to Pembrolizumab,7262
326,NCT02351739,Phase II,"Active, not recruiting","[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1605, 'therapyName': 'Acalabrutinib'}]",Study of the Combination of ACP-196 and Pembrolizumab in Subjects With Platinum-refractory Metastatic Bladder Cancer,7262
327,NCT02892201,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab in HNSCC With Residual Disease After Radiation,7262
328,NCT02559687,Phase II,"Active, not recruiting","[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Study of Pembrolizumab (MK-3475) in Previously-Treated Participants With Advanced Carcinoma of the Esophagus or Esophagogastric Junction (MK-3475-180/KEYNOTE-180),7262
329,NCT02998268,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]",Study of Pembrolizumab in Locally Advanced Esophageal Adenocarcinoma,7262
330,NCT02767934,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab in Treating Minimal Residual Disease in Patients With Acute Lymphoblastic Leukemia,7262
331,NCT03036488,Phase III,Recruiting,"[{'id': 1087, 'therapyName': 'Epirubicin + Cyclophosphamide'}, {'id': 1977, 'therapyName': 'Doxorubicin + Cyclophosphamide'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]",Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522),7262
332,NCT02959463,Phase I,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Adjuvant Pembrolizumab After Radiation Therapy for Lung-Intact Malignant Pleural Mesothelioma,7262
333,NCT03099564,Phase I,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab Plus Y90 Radioembolization in HCC Subjects,7262
334,NCT02981914,Phase 0,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pilot Study of Pembrolizumab Treatment for Disease Relapse After Allogeneic Stem Cell Transplantation,7262
335,NCT03035331,Phase Ib/II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]","Dendritic Cell Therapy, Cryosurgery, and Pembrolizumab in Treating Patients With Non-Hodgkin Lymphoma",7262
336,NCT03189186,Phase I,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Phase-I Trial of Pembrolizumab and Percutaneous Cryoablation Combination Followed by Nephron-Sparing Surgery or Cytoreductive Nephrectomy in Locally Advanced and Metastatic Renal Cell Carcinomas,7262
337,NCT02852655,Phase 0,"Active, not recruiting","[{'id': 1447, 'therapyName': 'Pembrolizumab'}]","A Pilot Surgical Trial To Evaluate Early Immunologic Pharmacodynamic Parameters For The PD-1 Checkpoint Inhibitor, Pembrolizumab (MK-3475), In Patients With Surgically Accessible Recurrent/Progressive Glioblastoma",7262
338,NCT02521870,Phase I,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 3084, 'therapyName': 'SD-101'}]",A Trial of Intratumoral Injections of SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma,7262
339,NCT02359565,Phase I,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]","Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas or Diffuse Intrinsic Pontine Gliomas",7262
340,NCT02337686,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pharmacodynamic Study of Pembrolizumab in Patients With Recurrent Glioblastoma,7262
341,NCT02451930,Phase I,"Active, not recruiting","[{'id': 826, 'therapyName': 'Necitumumab'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",A Study of the Combination of Necitumumab (LY3012211) and Pembrolizumab (MK3475) in Participants With NSCLC,7262
342,NCT03065400,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",PD-1 Inhibition in Advanced Myeloproliferative Neoplasms,7262
343,NCT02603887,Phase I,"Active, not recruiting","[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab for Smoldering Multiple Myeloma (SMM),7262
344,NCT01174121,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 2291, 'therapyName': 'Cyclophosphamide + Fludarabine'}, {'id': 1167, 'therapyName': 'Aldesleukin'}]",Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer,7262
345,NCT02557321,Phase Ib/II,Recruiting,"[{'id': 879, 'therapyName': 'PV-10'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",PV-10 in Combination With Pembrolizumab for Treatment of Metastatic Melanoma,7262
346,NCT02499835,Phase Ib/II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]","Vaccine Therapy and Pembrolizumab in Treating Patients With Hormone-Resistant, Metastatic Prostate Cancer",7262
347,NCT02422381,Phase Ib/II,Recruiting,"[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",MK-3475 and Gemcitabine in Non-Small Cell Lung Cancer (NSCLC),7262
348,NCT02434354,Phase I,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",A Tissue Collection Study of Pembrolizumab (MK-3475) in Subjects With Resectable Advanced Melanoma,7262
349,NCT01953692,Phase I,"Active, not recruiting","[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",A Trial of Pembrolizumab (MK-3475) in Participants With Blood Cancers (MK-3475-013)(KEYNOTE-013),7262
350,NCT02318771,Phase I,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]","Radiation Therapy and MK-3475 for Patients With Recurrent/Metastatic Head and Neck Cancer, Renal Cell Cancer, Urothelial Cancer, Melanoma, and Non-Small Cell Lung Cancer",7262
351,NCT03179917,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab and Involved Site Radiation Therapy for Early Stage Relapsed or Primary Refractory Hodgkin Lymphoma,7262
352,NCT02999477,Phase I,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 619, 'therapyName': 'Abraxane'}]",A Study Of Changes In PD-L1 Expression During Preoperative Treatment With Nab-Paclitaxel And Pembrolizumab In Hormone Receptor-Positive Breast Cancer,7262
353,NCT02658019,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab (Keytruda) in Advanced Hepatocellular Carcinoma,7262
354,NCT02775435,Phase III,Recruiting,"[{'id': 2634, 'therapyName': 'Carboplatin + nab-paclitaxel'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]",A Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With First Line Metastatic Squamous Non-small Cell Lung Cancer (MK-3475-407/KEYNOTE-407),7262
355,NCT02702401,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Study of Pembrolizumab (MK-3475) vs. Best Supportive Care in Participants With Previously Systemically Treated Advanced Hepatocellular Carcinoma (MK-3475-240/KEYNOTE-240),7262
356,NCT02955758,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab in Patients With Metastatic Non-squamous Non-small Cell Lung Cancer,7262
357,NCT02142738,Phase III,"Active, not recruiting","[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 854, 'therapyName': 'Pemetrexed'}]",Study of Pembrolizumab (MK-3475) Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (MK-3475-024/KEYNOTE-024),7262
358,NCT02775851,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab in Treating Patients With Desmoplastic Melanoma That Can or Cannot Be Removed by Surgery,7262
359,NCT01822652,Phase I,"Active, not recruiting","[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]","3rd Generation GD-2 Chimeric Antigen Receptor and iCaspase Suicide Safety Switch, Neuroblastoma, GRAIN",7262
360,NCT02728830,Phase I,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",A Study of Pembrolizumab on the Tumoral Immunoprofile of Gynecologic Cancers,7262
361,NCT02768792,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",High Dose Cytarabine Followed by Pembrolizumab in Relapsed/Refractory AML,7262
362,NCT02447003,Phase II,"Active, not recruiting","[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Study of Pembrolizumab (MK-3475) Monotherapy for Metastatic Triple-Negative Breast Cancer (MK-3475-086/KEYNOTE-086),7262
363,NCT02362035,Phase Ib/II,"Active, not recruiting","[{'id': 1605, 'therapyName': 'Acalabrutinib'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]","ACP-196 in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies (KEYNOTE145)",7262
364,NCT02939651,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",A Study of Pembrolizumab in Patients With Neuroendocrine Tumors,7262
365,NCT02730130,Phase II,"Active, not recruiting","[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Study to Assess the Efficacy of Pembrolizumab Plus Radiotherapy in Metastatic Triple Negative Breast Cancer Patients,7262
366,NCT02212730,Phase I,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",A Study Evaluating the Effect of Pembrolizumab (MK-3475) in Participants With Renal Cell Cancer (MK-3475-031),7262
367,NCT03007732,Phase II,Recruiting,"[{'id': 5166, 'therapyName': 'Pembrolizumab + SD-101'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab in Combination With Intratumoral SD-101 Therapy,7262
368,NCT02581943,Phase II,Suspended,"[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1092, 'therapyName': 'Carboplatin'}]",Effect of Pembrolizumab With or Without Carboplatin and Paclitaxel on Immune Response in Patients With Recurrent or Stage IIIB-IV Non-small Cell Lung Cancer,7262
369,NCT02886585,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab In Central Nervous System Metastases,7262
370,NCT02882282,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Study of Pembrolizumab (MK-3475) for High Risk Oral Intra-Epithelial Neoplasias,7262
371,NCT02576977,Phase III,Suspended,"[{'id': 1622, 'therapyName': 'Pomalidomide'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1390, 'therapyName': 'Dexamethasone'}]",Study of Pomalidomide and Low Dose Dexamethasone With or Without Pembrolizumab (MK-3475) in Refractory or Relapsed and Refractory Multiple Myeloma (rrMM) (MK-3475-183/KEYNOTE-183),7262
372,NCT02576990,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Study of Pembrolizumab (MK-3475) in Participants With Advanced Primary Mediastinal Large B-cell Lymphoma (MK-3475-170/KEYNOTE-170),7262
373,NCT02362997,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab After ASCT for Hodgkin Lymphoma and DLBCL,7262
374,NCT02646748,Phase I,Recruiting,"[{'id': 3088, 'therapyName': 'INCB050465 '}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 2406, 'therapyName': 'INCB039110'}]",Pembrolizumab Combined With INCB039110 and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors,7262
375,NCT02658279,Phase I,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab (MK-3475) in Patients With Recurrent Malignant Glioma With a Hypermutator Phenotype,7262
376,NCT03259867,Phase II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Combination of TATE and PD-1 Inhibitor in Liver Cancer,7262
377,NCT02362594,Phase III,"Active, not recruiting","[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Study of Pembrolizumab (MK-3475) Versus Placebo After Complete Resection of High-Risk Stage III Melanoma (MK-3475-054/KEYNOTE-054),7262
378,NCT03025035,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab in Advanced BRCA-mutated Breast Cancer,7262
379,NCT02591615,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 1602, 'therapyName': 'Carboplatin + Pemetrexed'}]",Optimal Sequencing of Pembrolizumab (MK-3475) and Standard Platinum-based Chemotherapy in First-Line NSCLC,7262
380,NCT02595866,Phase I,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]","Pembrolizumab in Treating Patients With HIV and Relapsed, Refractory, or Disseminated Malignant Neoplasms",7262
381,NCT02879994,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]","Pembrolizumab in Treating Patients With EGFR Mutant, Tyrosine Kinase Inhibitor Naive Advanced Non-Small Cell Lung Cancer",7262
382,NCT02453594,Phase II,"Active, not recruiting","[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-087/KEYNOTE-087),7262
383,NCT02511184,Phase I,Recruiting,"[{'id': 706, 'therapyName': 'Crizotinib'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Crizotinib Plus Pembrolizumab In Alk-positive Advanced Non Small Cell Lung Cancer Patients,7262
384,NCT02437370,Phase I,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 720, 'therapyName': 'Docetaxel'}]",Pembrolizumab and Docetaxel or Gemcitabine Hydrochloride in Treating Patients Urothelial Cancer,7262
385,NCT03210662,Phase II,Not yet recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab and Fractionated External Beam Radiotherapy (EBRT) in Patients With Non-Hodgkin Lymphoma (NHL),7262
386,NCT02303990,Phase I,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",RADVAX A Stratified Phase I Trial of Pembrolizumab With Hypofractionated Radiotherapy in Patients With Advanced and Metastatic Cancers,7262
387,NCT02263508,Phase Ib/II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 2695, 'therapyName': 'talimogene laherparepvec '}]",MK-3475 With or Without Talimogene Laherparepvec in Unresected Melanoma,7262
388,NCT02830594,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]","Pembrolizumab and Palliative Radiation Therapy in Treating Patients With Metastatic Esophagus, Stomach, or Gastroesophageal Junction Cancer",7262
389,NCT02784171,Phase II,Recruiting,"[{'id': 1857, 'therapyName': 'Cisplatin + Pemetrexed'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma,7262
390,NCT01993719,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1167, 'therapyName': 'Aldesleukin'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}]",Immunotherapy Using Tumor Infiltrating Lymphocytes Comparing 2 Different Conditioning Regimens for Patients With Metastatic Melanoma,7262
391,NCT02578680,Phase III,"Active, not recruiting","[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 700, 'therapyName': 'Cisplatin'}]",Study of Platinum+Pemetrexed Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Non-squamous Non-small Cell Lung Cancer (MK-3475-189/KEYNOTE-189),7262
392,NCT03004183,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 5172, 'therapyName': 'AdV-tk + Valacyclovir'}]",SBRT and Oncolytic Virus Therapy Before Pembrolizumab for Metastatic TNBC and NSCLC,7262
393,NCT02324582,Phase I,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",MK-3475/BCG in High Risk Superficial Bladder Cancer,7262
394,NCT02483247,Phase Ib/II,Recruiting,"[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1945, 'therapyName': 'BBI503'}]",A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer,7262
395,NCT02089685,Phase Ib/II,Recruiting,"[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 2624, 'therapyName': 'peginterferon alfa-2b'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Safety and Tolerability of Pembrolizumab (MK-3475) + Pegylated Interferon Alfa-2b and Pembrolizumab+ Ipilimumab in Participants With Advanced Melanoma or Renal Cell Carcinoma (MK-3475-029/KEYNOTE-29),7262
396,NCT02331368,Phase II,"Active, not recruiting","[{'id': 1164, 'therapyName': 'lenalidomide'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Phase 2 Multi-center Study of Anti-PD-1 During Lymphopenic State After HDT/ASCT for Multiple Myeloma,7262
397,NCT02853344,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Study of Pembrolizumab (MK-3475) Monotherapy in Locally Advanced/Metastatic Renal Cell Carcinoma (MK-3475-427/KEYNOTE-427),7262
398,NCT02581982,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]",Paclitaxel and Pembrolizumab in Treating Patients With Refractory Metastatic Urothelial Cancer,7262
399,NCT02818920,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Neoadjuvant Pembrolizumab,7262
400,NCT02335424,Phase II,"Active, not recruiting","[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Study of Pembrolizumab (MK-3475) in Participants With Advanced Urothelial Cancer (MK-3475-052/KEYNOTE-52),7262
401,NCT02296684,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 700, 'therapyName': 'Cisplatin'}]",Immunotherapy With MK-3475 in Surgically Resectable Head and Neck Squamous Cell Carcinoma,7262
402,NCT02971956,Phase II,Not yet recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",A Phase II Study of Pembrolizumab in Refractory Advanced Esophageal Cancer,7262
403,NCT02575404,Phase I,Recruiting,"[{'id': 2975, 'therapyName': 'GR-MD-02'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",GR-MD-02 Plus Pembrolizumab in Melanoma Patients,7262
404,NCT02971748,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",A Study of Anti-PD-1 (Pembrolizumab) + Hormonal Therapy in HR-positive Localized IBC Patients With Non-pCR to Neoadjuvant Chemotherapy,7262
405,NCT02644369,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Study of the Effects of Pembrolizumab in Patients With Advanced Solid Tumors,7262
406,NCT02721732,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Study for the Evaluation of Efficacy of Pembrolizumab (MK-3475) in Patients With Rare Tumors,7262
407,NCT02641093,Phase II,Recruiting,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Phase II Trial of Adjuvant Cisplatin and Radiation With Pembrolizumab in Resected Head and Neck Squamous Cell Carcinoma,7262
408,NCT02501096,Phase Ib/II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 792, 'therapyName': 'Lenvatinib'}]",Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors,7262
409,NCT02949219,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab in Treating Patients With Small Bowel Adenocarcinoma That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery,7262
410,NCT02085070,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",MK-3475 in Melanoma and NSCLC Patients With Brain Metastases,7262
411,NCT02339324,Phase I,"Active, not recruiting","[{'id': 1299, 'therapyName': 'Interferon alfa-2b '}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Neoadjuvant Combination Biotherapy With Pembrolizumab and High Dose IFN-alfa2b,7262
412,NCT03217071,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab With and Without Radiotherapy for Non-Small Cell Lung Cancer,7262
413,NCT02382406,Phase Ib/II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 2634, 'therapyName': 'Carboplatin + nab-paclitaxel'}]",Carboplatin/Nab-Paclitaxel and MK-3475 in NSCLC,7262
414,NCT02693535,Phase II,Recruiting,"[{'id': 1657, 'therapyName': 'Vemurafenib + Cobimetinib'}, {'id': 890, 'therapyName': 'Regorafenib'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 690, 'therapyName': 'Bosutinib'}, {'id': 850, 'therapyName': 'Palbociclib'}, {'id': 694, 'therapyName': 'Cetuximab'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 837, 'therapyName': 'Olaparib'}, {'id': 4, 'therapyName': 'Erlotinib'}]",TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer,7262
415,NCT02399371,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab in Treating Patients With Malignant Mesothelioma,7262
416,NCT02787005,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Study of Pembrolizumab (MK-3475) in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated With Chemotherapy (MK-3475-199/KEYNOTE-199),7262
417,NCT03279692,Phase II,Not yet recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Phase II Trial of Pembrolizumab in Recurrent or Residual High Grade Meningioma,7262
418,NCT02454179,Phase II,"Active, not recruiting","[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1605, 'therapyName': 'Acalabrutinib'}]",Study of the Combination of ACP-196 and Pembrolizumab in Subjects With Advanced Head and Neck Squamous Cell Carcinoma,7262
419,NCT02364076,Phase II,"Active, not recruiting","[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",MK-3475 in Patients With Thymic Carcinoma,7262
420,NCT03190213,Phase II,Not yet recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab for the Treatment of Recurrent High Grade Neuroendocrine Carcinoma (Pembro NEC),7262
421,NCT02591654,Phase I,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",MRI/PET Imaging to Assess Response to Pembrolizumab in Metastatic Melanoma,7262
422,NCT02684292,Phase III,Recruiting,"[{'id': 2486, 'therapyName': 'Brentuximab vedotin'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Study of Pembrolizumab (MK-3475) vs. Brentuximab Vedotin in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-204/KEYNOTE-204),7262
423,NCT02054806,Phase I,"Active, not recruiting","[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-028/KEYNOTE-28),7262
424,NCT03290079,Phase II,Not yet recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab in Advanced Poorly Differentiated and/or High Grade Neuroendocrine Tumors/Carcinomas,7262
425,NCT02609503,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab + Radiation for Locally Adv SCC of the Head and Neck (SCCHN) Not Eligible Cisplatin,7262
426,NCT02755272,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 2667, 'therapyName': 'Carboplatin + Gemcitabine'}]",A Study of Pembrolizumab With Carboplatin and Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer,7262
427,NCT02220894,Phase III,Recruiting,"[{'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Study of MK-3475 (Pembrolizumab) Versus Platinum-based Chemotherapy for Participants With PD-L1-positive Advanced or Metastatic Non-small Cell Lung Cancer (MK-3475-042/KEYNOTE-042),7262
428,NCT02178722,Phase Ib/II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 2575, 'therapyName': 'Epacadostat'}]","A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of MK-3475 in Combination With INCB024360 in Subjects With Selected Solid Tumors and Advanced NSCLC (INCB 24360-202 / MK-3475-037 / KEYNOTE-037)",7262
429,NCT02179918,Phase I,Completed,"[{'id': 5086, 'therapyName': 'Utomilumab'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",A Study Of 4-1BB Agonist PF-05082566 Plus PD-1 Inhibitor MK-3475 In Patients With Solid Tumors (B1641003/KEYNOTE-0036),7262
430,NCT02880345,Phase 0,Not yet recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",RADVAX: A Trial of Combined Pembrolizumab and Hypofractionated Radiation in Patients With Advanced Urothelial Cancer Who Have Progressed on Anti-PD-1/PD-L1 Monotherapy,7262
431,NCT02987166,Phase I,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",HDCRT Plus Pembrolizumab in Advanced Malignancies (UVA-AM-001),7262
432,NCT02879760,Phase Ib/II,Recruiting,"[{'id': 5085, 'therapyName': 'Pembrolizumab + Ad-MAGEA3 + MG1-MAGEA3'}]",Oncolytic MG1-MAGEA3 With Ad-MAGEA3 Vaccine in Combination With Pembrolizumab for Non-Small Cell Lung Cancer Patients,7262
433,NCT03149822,Phase Ib/II,Not yet recruiting,"[{'id': 5680, 'therapyName': 'Pembrolizumab + Cabozantinib'}]",Study of Pembrolizumab and Cabozantinib in Patients With Metastatic Renal Cell Carcinoma,7262
434,NCT02713373,Phase Ib/II,Recruiting,"[{'id': 1910, 'therapyName': 'Pembrolizumab + Cetuximab'}]",Cetuximab and Pembrolizumab in Treating Patients With Colorectal Cancer That is Metastatic or Cannot Be Removed by Surgery,7262
435,NCT03082534,Phase II,Recruiting,"[{'id': 1910, 'therapyName': 'Pembrolizumab + Cetuximab'}]",Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma,7262
436,NCT02318901,Phase Ib/II,"Active, not recruiting","[{'id': 1909, 'therapyName': 'Pembrolizumab + trastuzumab emtansine'}, {'id': 1908, 'therapyName': 'Pembrolizumab + Trastuzumab'}, {'id': 1910, 'therapyName': 'Pembrolizumab + Cetuximab'}]",Pembrolizumab and Monoclonal Antibody Therapy in Advanced Cancer,7262
437,NCT02130466,Phase Ib/II,Recruiting,"[{'id': 1450, 'therapyName': 'Pembrolizumab + Trametinib'}, {'id': 1448, 'therapyName': 'Pembrolizumab + Dabrafenib'}, {'id': 1449, 'therapyName': 'Pembrolizumab + Dabrafenib + Trametinib'}]",A Study of the Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With Trametinib and Dabrafenib in Participants With Advanced Melanoma (MK-3475-022),7262
438,NCT03149029,Phase II,Not yet recruiting,"[{'id': 1449, 'therapyName': 'Pembrolizumab + Dabrafenib + Trametinib'}, {'id': 1450, 'therapyName': 'Pembrolizumab + Trametinib'}]",Abbreviated MAPK Targeted Therapy Plus Pembrolizumab in Melanoma,7262
439,NCT02996474,Phase Ib/II,Recruiting,"[{'id': 5127, 'therapyName': 'Pembrolizumab + Decitabine'}]",Pembrolizumab and Decitabine for Refractory or Relapsed Acute Myeloid Leukemia,7262
440,NCT03029403,Phase II,Not yet recruiting,"[{'id': 5266, 'therapyName': 'Pembrolizumab + DPX-Survivac + Cyclophosphamide'}]","Phase 2 Study of Pembrolizumab, DPX-Survivac Vaccine and Cyclophosphamide in Advanced Ovarian, Primary Peritoneal or Fallopian Tube Cancer",7262
441,NCT03077828,Phase II,Recruiting,"[{'id': 5435, 'therapyName': 'Pembrolizumab + Etoposide + Carboplatin + Ifosfamide'}]",Pembrolizumab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma,7262
442,NCT02950220,Phase I,Recruiting,"[{'id': 4917, 'therapyName': 'Pembrolizumab + Ibrutinib'}]",Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma,7262
443,NCT03153202,Phase Ib/II,Recruiting,"[{'id': 4917, 'therapyName': 'Pembrolizumab + Ibrutinib'}]",Study to Evaluate the Safety and Preliminary Efficacy of Ibrutinib and Pembrolizumab in Patients With Chronic Lymphocytic Leukemia (CLL) or Mantle Cell Lymphoma (MCL),7262
444,NCT03021460,Phase II,Suspended,"[{'id': 4917, 'therapyName': 'Pembrolizumab + Ibrutinib'}]",Pembrolizumab and Ibrutinib in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery,7262
445,NCT03063632,Phase II,Not yet recruiting,"[{'id': 5367, 'therapyName': 'Pembrolizumab + interferon gamma'}]",Pembrolizumab and Interferon Gamma-1b in Treating Patients With Stage IB-IVB Relapsed or Refractory Mycosis Fungoides and Sezary Syndrome,7262
446,NCT03030378,Phase I,Not yet recruiting,"[{'id': 5263, 'therapyName': 'Pembrolizumab + Interleukin-12'}]",Pembrolizumab and Recombinant Interleukin-12 in Treating Patients With Solid Tumors,7262
447,NCT02930902,Phase I,Recruiting,"[{'id': 4903, 'therapyName': 'Pembrolizumab + Paricalcitol'}, {'id': 4904, 'therapyName': 'Pembrolizumab + Paricalcitol + Gemcitabine + nab-paclitaxel'}]",Preoperative Pilot Study to Assess Safety and Immunological Effect of Pembrolizumab (Keytruda) in Combination With Paricalcitol With or Without Chemotherapy in Patients With Resectable Pancreatic Cancer,7262
448,NCT02452424,Phase Ib/II,"Active, not recruiting","[{'id': 2736, 'therapyName': 'Pembrolizumab + PLX3397'}]",A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors,7262
449,NCT02834052,Phase Ib/II,Not yet recruiting,"[{'id': 4458, 'therapyName': 'Pembrolizumab + poly ICLC '}]",Pembrolizumab + Poly-ICLC in MRP Colon Cancer,7262
450,NCT03099161,Phase I,Recruiting,"[{'id': 5518, 'therapyName': 'Preladenant'}, {'id': 5519, 'therapyName': 'Pembrolizumab + Preladenant'}]",Study of Preladenant (MK-3814) Alone and With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3814A-062),7262
451,NCT02680184,Phase I,Recruiting,"[{'id': 4001, 'therapyName': 'Pembrolizumab + QbG10'}]",Clinical Study of CMP-001 in Combination With Pembrolizumab,7262
452,NCT03084640,Phase Ib/II,Recruiting,"[{'id': 4001, 'therapyName': 'Pembrolizumab + QbG10'}]",Phase 1b Study Evaluating Alternative Routes of Administration of CMP-001 in Combination With Pembrolizumab in Subjects With Advanced Melanoma,7262
453,NCT03093428,Phase II,Recruiting,"[{'id': 5542, 'therapyName': 'Pembrolizumab + Ra 223'}, {'id': 2001, 'therapyName': 'radium Ra 223 dichloride'}]",Study Evaluating the Addition of Pembrolizumab to Radium-223 in mCRPC,7262
454,NCT02719015,Phase Ib/II,Not yet recruiting,"[{'id': 3943, 'therapyName': 'Pembrolizumab + rAd.CD40L'}]",Dose Escalation and Cohort Expansion of Safety and Tolerability Study of Intratumoral rAd.CD40L (ISF35) in Combination of Systemic Pembrolizumab in Patients With Refractory Metastatic Melanoma,7262
455,NCT02443324,Phase I,"Active, not recruiting","[{'id': 2896, 'therapyName': 'Pembrolizumab + Ramucirumab'}]","A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC or Transitional Cell Carcinoma of the Urothelium",7262
456,NCT02446457,Phase II,Recruiting,"[{'id': 3279, 'therapyName': 'Pembrolizumab + Rituximab'}]",Study of Rituximab Plus Pembrolizumab (MK-3475) in Subjects With Relapsed Follicular Lymphoma,7262
457,NCT03012230,Phase I,Not yet recruiting,"[{'id': 5227, 'therapyName': 'Pembrolizumab + Ruxolitinib'}]",Pembrolizumab and Ruxolitinib Phosphate in Treating Patients With Metastatic Stage IV Triple Negative Breast Cancer,7262
458,NCT02703714,Phase II,Recruiting,"[{'id': 4217, 'therapyName': 'Pembrolizumab + Sargramostim'}]",Pembrolizumab and GM-CSF in Biliary Cancer,7262
459,NCT02376699,Phase I,Recruiting,"[{'id': 5781, 'therapyName': 'Pembrolizumab + SEA-CD40'}, {'id': 5780, 'therapyName': 'SEA-CD40'}]",Safety Study of SEA-CD40 in Cancer Patients,7262
460,NCT02901899,Phase II,Recruiting,"[{'id': 4725, 'therapyName': 'Pembrolizumab + SGI-110'}]","Guadecitabine and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer",7262
461,NCT03211416,Phase Ib/II,Recruiting,"[{'id': 6041, 'therapyName': 'Pembrolizumab + Sorafenib'}]",Sorafenib Tosylate and Pembrolizumab in Treating Patients With Advanced or Metastatic Liver Cancer,7262
462,NCT03161431,Phase I,Not yet recruiting,"[{'id': 5786, 'therapyName': 'SX-682'}, {'id': 5787, 'therapyName': 'Pembrolizumab + SX-682'}]",SX-682 Treatment in Subjects With Metastatic Melanoma Concurrently Treated With Pembrolizumab,7262
463,NCT02626000,Phase Ib/II,Recruiting,"[{'id': 4035, 'therapyName': 'Pembrolizumab + talimogene laherparepvec '}]",Talimogene Laherparepvec With Pembrolizumab for Recurrent Metastatic Squamous Cell Carcinoma of the Head and Neck,7262
464,NCT02965716,Phase II,Recruiting,"[{'id': 4035, 'therapyName': 'Pembrolizumab + talimogene laherparepvec '}]",Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV Melanoma,7262
465,NCT03069378,Phase II,Recruiting,"[{'id': 4035, 'therapyName': 'Pembrolizumab + talimogene laherparepvec '}]",A Study of Talimogene Laherparepvec (T-VEC) in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced Sarcoma,7262
466,NCT02395627,Phase II,Recruiting,"[{'id': 3114, 'therapyName': 'Pembrolizumab + Tamoxifen + vorinostat'}]",Reversing Hormone Therapy Resistance With Epigenetic-Immune Modification,7262
467,NCT03018288,Phase II,Recruiting,"[{'id': 5221, 'therapyName': 'Pembrolizumab + Temozolomide'}, {'id': 5220, 'therapyName': 'Pembrolizumab + Temozolomide + Vitespen'}]",Radiation Therapy Plus Temozolomide and Pembrolizumab With and Without HSPPC-96 in Newly Diagnosed Glioblastoma (GBM),7262
468,NCT03283137,Phase I,Not yet recruiting,"[{'id': 6237, 'therapyName': 'Pembrolizumab + TGR-1202'}]",Combination of Pembrolizumab With TGR-1202 in Patients With Relapsed/Refractory CLL and B-cell NHL,7262
469,NCT02535286,Phase Ib/II,Recruiting,"[{'id': 3475, 'therapyName': 'Pembrolizumab + TGR-1202 + Ublituximab'}]",Study of Pembrolizumab in Combination With Ublituximab and TGR-1202 in Patients With Relapsed-refractory CLL,7262
470,NCT03299088,Phase I,Not yet recruiting,"[{'id': 1450, 'therapyName': 'Pembrolizumab + Trametinib'}]",Pembrolizumab and Trametinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer and KRAS Gene Mutations,7262
471,NCT03032107,Phase I,Recruiting,"[{'id': 1909, 'therapyName': 'Pembrolizumab + trastuzumab emtansine'}]",A Study Of Pembrolizumab In Combination With Trastuzumab-DM1,7262
472,NCT03239145,Phase I,Recruiting,"[{'id': 6102, 'therapyName': 'Pembrolizumab + Trebananib'}]",Phase Ib Study to Test the Safety and Potential Synergy of Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor,7262
473,NCT03200847,Phase Ib/II,Not yet recruiting,"[{'id': 5988, 'therapyName': 'Pembrolizumab + Tretinoin'}]",Pembrolizumab and All-Trans Retinoic Acid Combination Treatment of Advanced Melanoma,7262
474,NCT02818023,Phase I,Recruiting,"[{'id': 4406, 'therapyName': 'Pembrolizumab + Vemurafenib'}]",Dose-seeking and Efficacy Study of Pembrolizumab Plus Vemurafenib Advanced Melanoma,7262
475,NCT02538510,Phase Ib/II,"Active, not recruiting","[{'id': 3077, 'therapyName': 'Pembrolizumab + Vorinostat'}]",Pembrolizumab and Vorinostat in Treating Patients With Recurrent Squamous Cell Head and Neck Cancer and Salivary Gland Cancer That Is Metastatic and/or Cannot Be Removed by Surgery,7262
476,NCT03150329,Phase I,Recruiting,"[{'id': 3077, 'therapyName': 'Pembrolizumab + Vorinostat'}]","Pembrolizumab and Vorinostat in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, or Hodgkin Lymphoma",7262
477,NCT02619253,Phase Ib/II,Recruiting,"[{'id': 3077, 'therapyName': 'Pembrolizumab + Vorinostat'}]",Phase I/Ib Study of Pembrolizumab With Vorinostat for Patients With Advanced Renal or Urothelial Cell Carcinoma,7262
478,NCT02823405,Phase I,Recruiting,"[{'id': 4436, 'therapyName': 'Pembrolizumab + X4P-001'}]",Neoadjuvant X4P-001 and Pembrolizumab in Patients With Resectable Melanoma (X4P-001-MELA),7262
479,NCT03095781,Phase I,Recruiting,"[{'id': 5533, 'therapyName': 'Pembrolizumab + XL888'}]",Pembrolizumab and XL888 in Patients With Advanced Gastrointestinal Cancer,7262
480,NCT03278782,Phase Ib/II,Not yet recruiting,"[{'id': 1075, 'therapyName': 'romidepsin'}, {'id': 5728, 'therapyName': 'Romidepsin + Pembrolizumab'}]",Study of Pembrolizumab (MK-3475) in Combination With Romidepsin,7262
481,NCT03049618,Phase II,Recruiting,"[{'id': 3944, 'therapyName': 'sEphB4-HSA + Pembrolizumab'}]","Recombinant EphB4-HSA Fusion Protein and Pembrolizumab, MK-3475",7262
482,NCT02717156,Phase II,Recruiting,"[{'id': 3944, 'therapyName': 'sEphB4-HSA + Pembrolizumab'}]",Recombinant EphB4-HSA Fusion Protein and Pembrolizumab in Treating Patients With Metastatic or Recurrent Urothelial Cancer That Is Refractory to Certain Chemotherapy Drugs,7262
0,NCT02639091,Phase I,Recruiting,"[{'id': 4617, 'therapyName': 'Anetumab ravtansine + Cisplatin + Pemetrexed'}]",Phase Ib Study of Anetumab Ravtansine in Combination With Pemetrexed and Cisplatin in Mesothelin-expressing Solid Tumors,632
1,NCT01633970,Phase I,"Active, not recruiting","[{'id': 1203, 'therapyName': 'Atezolizumab + Carboplatin + Paclitaxel'}, {'id': 1204, 'therapyName': 'Atezolizumab + Carboplatin + Pemetrexed'}, {'id': 1202, 'therapyName': 'Atezolizumab + Bevacizumab + Capecitabine'}]",A Phase 1b Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) in Combination With Avastin (Bevacizumab) and/or With Chemotherapy in Patients With Locally Advanced or Metastatic Solid Tumors,632
2,NCT03228537,Phase I,Not yet recruiting,"[{'id': 6036, 'therapyName': 'Atezolizumab + Cisplatin + Pemetrexed'}]","Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma",632
3,NCT01784640,Phase I,"Active, not recruiting","[{'id': 1270, 'therapyName': 'AUY922 + Pemetrexed'}]",Pemetrexed Disodium and Hsp90 Inhibitor AUY922 in Treating Patients With Previously Treated Stage IV Non-Small Cell Lung Cancer,632
4,NCT00254319,Phase II,Unknown status,"[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 2114, 'therapyName': 'Bevacizumab + Pemetrexed'}]",Previously Untreated Advanced Non-Small Cell Lung Cancer (NSCLC),632
5,NCT02574078,Phase I,Recruiting,"[{'id': 619, 'therapyName': 'Abraxane'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 2114, 'therapyName': 'Bevacizumab + Pemetrexed'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 1092, 'therapyName': 'Carboplatin'}]",A Master Protocol Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC) (CheckMate 370),632
6,NCT01723800,Phase I,Completed,"[{'id': 1112, 'therapyName': 'BKM120 + Pemetrexed + Carboplatin'}]"," PI3K Inhibitor BKM120, Carboplatin, and Pemetrexed Disodium in Treating Patients With Stage IV Non-Small Cell Lung Cancer",632
7,NCT03023319,Phase I,Recruiting,"[{'id': 5237, 'therapyName': 'Bosutinib + Pemetrexed'}]",Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors,632
8,NCT03242915,Phase II,Not yet recruiting,"[{'id': 2105, 'therapyName': 'Carboplatin +  Pembrolizumab + Pemetrexed '}]",Pembrolizumab in Combination With Platinum-based Doublet Chemotherapy in Patients With EGFR Mutation and ALK Positive NSCLC (Non-Small Cell Lung Cancer) With Progressive Disease Following Prior Tyrosine Kinase Inhibitors (TKIs),632
9,NCT03215706,Phase III,Recruiting,"[{'id': 6132, 'therapyName': 'Carboplatin + Cisplatin + Paclitaxel + Pemetrexed'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",A Study of Nivolumab and Ipilimumab Combined With Chemotherapy Compared to Chemotherapy by Itself as the First Treatment Given for Stage IV Non-Small Cell Lung Cancer (NSCLC) (CheckMate 9LA),632
10,NCT03178552,Phase II,Recruiting,"[{'id': 4686, 'therapyName': 'Carboplatin + Cisplatin + Gemcitabine'}, {'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 4616, 'therapyName': 'Carboplatin + Cisplatin + Pemetrexed'}, {'id': 698, 'therapyName': 'Alectinib'}]",A Study to Evaluate Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC) (B-FAST),632
11,NCT02864251,Phase III,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}, {'id': 4616, 'therapyName': 'Carboplatin + Cisplatin + Pemetrexed'}]","A Study of Nivolumab + Chemotherapy or Nivolumab + Ipilimumab Versus Chemotherapy in Patients With EGFR Mutation, T790M Negative NSCLC Who Have Failed 1L EGFR TKI Therapy (CheckMate722)",632
12,NCT02899299,Phase III,Recruiting,"[{'id': 4616, 'therapyName': 'Carboplatin + Cisplatin + Pemetrexed'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients (CheckMate743),632
13,NCT03256136,Phase II,Not yet recruiting,"[{'id': 6159, 'therapyName': 'Carboplatin + Nivolumab + Pemetrexed'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]","A Phase II Study of Nivolumab in Combination With Carboplatin and Pemetrexed, or Nivolumab in Combination With Ipilimumab, in Patients With Advanced, EGFR-mutant or ALK-rearranged, Non-Small Cell Lung Cancer",632
14,NCT02944396,Phase II,Recruiting,"[{'id': 5054, 'therapyName': 'Carboplatin + Paclitaxel + Pemetrexed + Veliparib'}, {'id': 5053, 'therapyName': 'Carboplatin + Paclitaxel + Pemetrexed + Nivolumab + Veliparib'}]",Study of Veliparib in Combination With Nivolumab and Platinum Doublet Chemotherapy in Participants With Metastatic or Advanced Non-Small Cell Lung Cancer (NSCLC),632
15,NCT02259582,Phase II,"Active, not recruiting","[{'id': 1602, 'therapyName': 'Carboplatin + Pemetrexed'}, {'id': 2007, 'therapyName': 'Demcizumab'}]","A Study of Carboplatin, Pemetrexed Plus Placebo vs Carboplatin, Pemetrexed Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With Non-Squamous Non-Small Cell Lung Cancer",632
16,NCT01803282,Phase I,Recruiting,"[{'id': 3320, 'therapyName': 'GS-5745'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 1602, 'therapyName': 'Carboplatin + Pemetrexed'}, {'id': 1315, 'therapyName': 'FOLFIRI'}, {'id': 1779, 'therapyName': 'Nab-paclitaxel + Gemcitabine'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 667, 'therapyName': 'Bevacizumab'}]",Safety and Tolerability Study in Solid Tumors,632
17,NCT02039674,Phase Ib/II,"Active, not recruiting","[{'id': 2103, 'therapyName': 'Carboplatin + Paclitaxel + Pembrolizumab'}, {'id': 2104, 'therapyName': 'Bevacizumab + Carboplatin + Paclitaxel + Pembrolizumab'}, {'id': 1602, 'therapyName': 'Carboplatin + Pemetrexed'}, {'id': 2106, 'therapyName': 'Ipilimumab + Pembrolizumab '}, {'id': 2107, 'therapyName': 'Erlotinib + Pembrolizumab '}, {'id': 2108, 'therapyName': 'Gefitinib + Pembrolizumab '}]",A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Lung Cancer (MK-3475-021/KEYNOTE-021),632
18,NCT02591615,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 1602, 'therapyName': 'Carboplatin + Pemetrexed'}]",Optimal Sequencing of Pembrolizumab (MK-3475) and Standard Platinum-based Chemotherapy in First-Line NSCLC,632
19,NCT03164616,Phase III,Recruiting,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}, {'id': 1857, 'therapyName': 'Cisplatin + Pemetrexed'}, {'id': 1602, 'therapyName': 'Carboplatin + Pemetrexed'}, {'id': 1467, 'therapyName': 'Gemcitabine + Cisplatin'}, {'id': 2667, 'therapyName': 'Carboplatin + Gemcitabine'}, {'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 2634, 'therapyName': 'Carboplatin + nab-paclitaxel'}]",Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON). (POSEIDON),632
20,NCT01263782,Phase II,Completed,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1602, 'therapyName': 'Carboplatin + Pemetrexed'}, {'id': 701, 'therapyName': 'Cixutumumab'}]",BATTLE-FL: Front-Line Biomarker-Integrated Treatment Study in Non Small Cell Lung Cancer,632
21,NCT02468661,Phase Ib/II,Recruiting,"[{'id': 1065, 'therapyName': 'Capmatinib'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 1857, 'therapyName': 'Cisplatin + Pemetrexed'}, {'id': 1602, 'therapyName': 'Carboplatin + Pemetrexed'}]","A Safety and Efficacy Study of INC280 Alone, and in Combination With Erlotinib, Compared to Chemotherapy, in Advanced/Metastatic Non-small Cell Lung Cancer Patients With EGFR Mutation and cMET Amplification",632
22,NCT02542293,Phase III,Recruiting,"[{'id': 1467, 'therapyName': 'Gemcitabine + Cisplatin'}, {'id': 2667, 'therapyName': 'Carboplatin + Gemcitabine'}, {'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 1857, 'therapyName': 'Cisplatin + Pemetrexed'}, {'id': 1602, 'therapyName': 'Carboplatin + Pemetrexed'}]",Study of 1st Line Therapy Study of MEDI4736 With Tremelimumab Versus SoC in Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE).,632
23,NCT02087241,Phase II,Terminated,"[{'id': 822, 'therapyName': 'MK-1775'}, {'id': 1602, 'therapyName': 'Carboplatin + Pemetrexed'}]",Ph II Trial of Carboplatin and Pemetrexed With or Without AZD1775 for Untreated Lung Cancer,632
24,NCT01064648,Phase Ib/II,"Active, not recruiting","[{'id': 2432, 'therapyName': 'Cediranib + Cisplatin + Pemetrexed'}]",Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma,632
25,NCT02899195,Phase II,Recruiting,"[{'id': 5630, 'therapyName': 'Cisplatin + Durvalumab + Pemetrexed'}, {'id': 1356, 'therapyName': 'Durvalumab'}]",Phase II MEDI4736 in Combination With Chemotherapy for First-Line Treatment of Unresectable Mesothelioma (PrE0505),632
26,NCT02119650,Phase II,Terminated,"[{'id': 1856, 'therapyName': 'Ruxolitinib + Cisplatin + Pemetrexed'}, {'id': 1857, 'therapyName': 'Cisplatin + Pemetrexed'}]",Ruxolitinib in Combination With Pemetrexed/Cisplatin in Non Small Cell Lung Cancer,632
27,NCT02784171,Phase II,Recruiting,"[{'id': 1857, 'therapyName': 'Cisplatin + Pemetrexed'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma,632
28,NCT01907100,Phase III,Recruiting,"[{'id': 1857, 'therapyName': 'Cisplatin + Pemetrexed'}, {'id': 831, 'therapyName': 'Nintedanib'}]",Nintedanib (BIBF 1120) in Mesothelioma,632
29,NCT02357147,Phase II,"Active, not recruiting","[{'id': 1857, 'therapyName': 'Cisplatin + Pemetrexed'}, {'id': 3513, 'therapyName': 'Amatuximab'}]",Study of the Safety and Efficacy of Amatuximab in Combination With Pemetrexed and Cisplatin in Subjects With Unresectable Malignant Pleural Mesothelioma (MPM). (ARTEMIS),632
30,NCT01868022,Phase I,"Active, not recruiting","[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1857, 'therapyName': 'Cisplatin + Pemetrexed'}, {'id': 2899, 'therapyName': 'GSK3052230'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]","Study to Evaluate GSK3052230 in Combination With Paclitaxel and Carboplatin, or Docetaxel or as Single Agent in Subjects With Solid Malignancies and Deregulated Fibroblast Growth Factor (FGF) Pathway Signaling",632
31,NCT02707666,Phase I,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1857, 'therapyName': 'Cisplatin + Pemetrexed'}]",A Pilot Window-Of-Opportunity Study of the Anti-PD-1 Antibody Pembrolizumab in Patients With Resectable Malignant Pleural Mesothelioma,632
32,NCT02337530,Phase II,"Active, not recruiting","[{'id': 913, 'therapyName': 'Selumetinib'}, {'id': 1857, 'therapyName': 'Cisplatin + Pemetrexed'}]",Selumetinib in Patients Receiving Pemetrexed and Cisplatin in Advanced or Metastatic KRAS Wildtype or Unknown Non-Squamous Non-Small Cell Lung Cancer,632
33,NCT03064854,Phase I,Recruiting,"[{'id': 6027, 'therapyName': 'Carboplatin + Paclitaxel + PDR001'}, {'id': 6026, 'therapyName': 'Cisplatin + Pemetrexed + PDR001'}, {'id': 6025, 'therapyName': 'Cisplatin + Gemcitabine + PDR001'}, {'id': 6024, 'therapyName': 'Pemetrexed + PDR001 + Cisplatin + Carboplatin'}]","PDR001 in Combination With Platinum-doublet Chemotherapy in PD-L1 Unselected, Metastatic NSCLC Patients (ElevatION:NSCLC-101 Trial)",632
34,NCT02998528,Phase III,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}, {'id': 5241, 'therapyName': 'Cisplatin + Vinorelbine + Gemcitabine + Docetaxel + Pemetrexed + Carboplatin'}]",A Neoadjuvant Study of Nivolumab and Ipilimumab Compared to Chemotherapy Doublet in Early Stage Non-Small Cell Lung Cancer (NSCLC) (CheckMate 816),632
35,NCT01548144,Phase I,"Active, not recruiting","[{'id': 1153, 'therapyName': 'Crizotinib + Pazopanib'}, {'id': 1151, 'therapyName': 'Crizotinib + Pemetrexed'}, {'id': 1156, 'therapyName': 'Pazopanib + Pemetrexed'}, {'id': 1155, 'therapyName': 'Crizotinib + Pazopanib + Pemetrexed'}]",Pazopanib or Pemetrexed and Crizotinib in Advanced Cancer,632
36,NCT02134912,Phase II,Recruiting,"[{'id': 1151, 'therapyName': 'Crizotinib + Pemetrexed'}, {'id': 854, 'therapyName': 'Pemetrexed'}]",S1300: Pemetrexed Disodium With or Without Crizotinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer That Has Progressed After Crizotinib,632
37,NCT01935947,Phase II,Terminated,"[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 2645, 'therapyName': 'Azacitidine + Entinostat'}, {'id': 2646, 'therapyName': 'Docetaxel + Irinotecan + Pemetrexed '}]",Azacitidine and Entinostat Before Chemotherapy in Treating Patients With Advanced Non-small Cell Lung Cancer,632
38,NCT02654587,Phase III,"Active, not recruiting","[{'id': 4327, 'therapyName': 'OSE 2101 '}, {'id': 4328, 'therapyName': 'Docetaxel + Pemetrexed'}]",Study of OSE2101 Versus Standard Treatment as 2nd or 3rd Line in HLA-A2 Positive Patients With Advanced NSCLC (ATALANTE 1),632
39,NCT01928160,Phase II,Withdrawn,"[{'id': 1290, 'therapyName': 'Erlotinib + Pemetrexed'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1291, 'therapyName': 'Erlotinib + Carboplatin'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1292, 'therapyName': 'Erlotinib + Cisplatin'}]",Pemetrexed Disodium and Carboplatin or Cisplatin With or Without Erlotinib Hydrochloride in Treating Patient With Stage IV Non-Small Cell Lung Cancer Resistant to First-Line Therapy With Erlotinib Hydrochloride or Gefitinib,632
40,NCT00573989,Phase Ib/II,Terminated,"[{'id': 1290, 'therapyName': 'Erlotinib + Pemetrexed'}]","Intensity-Modulated Radiation Therapy, Pemetrexed, and Erlotinib in Treating Patients With Recurrent or Second Primary Head and Neck Cancer",632
41,NCT00950365,Phase II,Unknown status,"[{'id': 1290, 'therapyName': 'Erlotinib + Pemetrexed'}, {'id': 854, 'therapyName': 'Pemetrexed'}]",Pharmacodynamic Separation of Pemetrexed and Erlotinib as Second-line Therapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC),632
42,NCT03085914,Phase Ib/II,Recruiting,"[{'id': 5483, 'therapyName': 'INCB024360 + Nivolumab + mFOLFOX6'}, {'id': 5484, 'therapyName': 'INCB024360 + Nivolumab + Gemcitabine + nab-paclitaxel'}, {'id': 5485, 'therapyName': 'INCB024360 + Pembrolizumab + Carboplatin + Paclitaxel'}, {'id': 5486, 'therapyName': 'INCB024360 + Pembrolizumab + Carboplatin + Pemetrexed'}, {'id': 5487, 'therapyName': 'INCB024360 + Pembrolizumab + Cyclophosphamide'}]",A Study of Epacadostat in Combination With a PD-1 Inhibitor and Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors (ECHO-207),632
43,NCT02185690,Phase I,Not yet recruiting,"[{'id': 2213, 'therapyName': 'MEK162 + Carboplatin + Pemetrexed'}]","A Phase I/Ib Study of MEK162, a MEK Inhibitor, in Combination With Carboplatin and Pemetrexed in Patients With Non-squamous Carcinoma of the Lung",632
44,NCT02117024,Phase II,"Active, not recruiting","[{'id': 2472, 'therapyName': 'HS-110 + Cyclophosphamide'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 1685, 'therapyName': 'Vinorelbine'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]",A Phase 2 Study of Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer,632
45,NCT02387216,Phase II,Recruiting,"[{'id': 820, 'therapyName': 'Seribantumab'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 720, 'therapyName': 'Docetaxel'}]",A Study of MM-121 in Combination With Chemotherapy Versus Chemotherapy Alone in Heregulin Positive NSCLC,632
46,NCT03257267,Phase III,Recruiting,"[{'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1685, 'therapyName': 'Vinorelbine'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 5656, 'therapyName': 'REGN2810'}, {'id': 942, 'therapyName': 'Topotecan'}]",Study of REGN2810 in Adults With Cervical Cancer,632
47,NCT01708993,Phase II,Completed,"[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 1110, 'therapyName': 'Reolysin + Pemetrexed'}, {'id': 1111, 'therapyName': 'Reolysin + Docetaxel'}]"," Reolysin in Patients With Previously Treated Advanced or Metastatic, Non Small Cell Lung Cancer Receiving Standard Salvage Therapy",632
48,NCT02041533,Phase III,"Active, not recruiting","[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 755, 'therapyName': 'Gemcitabine'}]","An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026)",632
49,NCT01553942,Phase II,Recruiting,"[{'id': 623, 'therapyName': 'Afatinib'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 854, 'therapyName': 'Pemetrexed'}]",Afatinib With CT and RT for EGFR-Mutant NSCLC,632
50,NCT01646125,,Terminated,"[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 647, 'therapyName': 'AUY922'}, {'id': 854, 'therapyName': 'Pemetrexed'}]"," An Open-label, Randomized Phase II Study to Evaluate the Efficacy of AUY922 vs Pemetrexed or Docetaxel in NSCLC Patients With EGFR Mutations",632
51,NCT02079636,Phase I,Recruiting,"[{'id': 1069, 'therapyName': 'LY3023414'}, {'id': 802, 'therapyName': 'Abemaciclib'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 886, 'therapyName': 'Ramucirumab'}]",A Study of LY2835219 in Combination With Another Anti-cancer Drug in Participants With Lung Cancer (NSCLC),632
52,NCT01700400,Phase I,Completed,"[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 854, 'therapyName': 'Pemetrexed'}]"," Study of Everolimus, Pemetrexed, Carboplatin, and Bevacizumab to Treat Stage IV Lung Cancer",632
53,NCT02264990,Phase III,"Active, not recruiting","[{'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 954, 'therapyName': 'Veliparib'}, {'id': 700, 'therapyName': 'Cisplatin'}]",Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Subjects Receiving First Cytotoxic Chemotherapy for Metastatic or Advanced Non-Squamous Non-Small Cell Lung Cancer Who Are Current or Former Smokers,632
54,NCT02419495,Phase I,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1749, 'therapyName': 'Selinexor'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 1009, 'therapyName': 'Doxorubicin'}]",Selinexor in Combination With Standard Chemotherapy,632
55,NCT02578680,Phase III,"Active, not recruiting","[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 700, 'therapyName': 'Cisplatin'}]",Study of Platinum+Pemetrexed Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Non-squamous Non-small Cell Lung Cancer (MK-3475-189/KEYNOTE-189),632
56,NCT01828112,Phase III,"Active, not recruiting","[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 789, 'therapyName': 'Ceritinib'}]",LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib,632
57,NCT02220894,Phase III,Recruiting,"[{'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Study of MK-3475 (Pembrolizumab) Versus Platinum-based Chemotherapy for Participants With PD-L1-positive Advanced or Metastatic Non-small Cell Lung Cancer (MK-3475-042/KEYNOTE-042),632
58,NCT03137771,Phase II,Recruiting,"[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 4, 'therapyName': 'Erlotinib'}]",Maintenance Chemotherapy With or Without Stereotactic Body Radiation Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer,632
59,NCT03057106,Phase II,Recruiting,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}, {'id': 854, 'therapyName': 'Pemetrexed'}]",Durvalumab and Tremelimumab ± Platinum-Based Chemotherapy in Patients With Metastatic Squamous or Non-Squamous NSCLC,632
60,NCT03083808,Phase II,Recruiting,"[{'id': 5497, 'therapyName': 'Pembrolizumab + Gemcitabine'}, {'id': 5496, 'therapyName': 'Docetaxel + Pembrolizumab'}, {'id': 5498, 'therapyName': 'Pemetrexed + Pembrolizumab'}, {'id': 854, 'therapyName': 'Pemetrexed'}]",Phase II Trial of Continuation Therapy in Advanced NSCLC,632
61,NCT01336842,Phase I,Completed,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1080, 'therapyName': 'Panobinostat'}, {'id': 854, 'therapyName': 'Pemetrexed'}]",Study of Cisplatin and Pemetrexed in Combination With Panobinostat in Solid Tumors,632
62,NCT01107626,Phase III,"Active, not recruiting","[{'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 667, 'therapyName': 'Bevacizumab'}]",Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer,632
63,NCT02322281,Phase III,"Active, not recruiting","[{'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1003, 'therapyName': 'CO1686'}]","TIGER-3 Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet Chemotherapy",632
64,NCT01664754,Phase I,"Active, not recruiting","[{'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 738, 'therapyName': 'Exemestane'}]","Exemestane, Pemetrexed Disodium, and Carboplatin in Treating Post-Menopausal Women With Stage IV Non-Small Cell Lung Cancer",632
65,NCT01454102,Phase I,"Active, not recruiting","[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1312, 'therapyName': 'Nivolumab'}]","Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012)",632
66,NCT02477826,Phase III,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 755, 'therapyName': 'Gemcitabine'}]","An Open-Label, Trial of Nivolumab and Nivolumab Plus Ipilimumab Versus Platinum Doublet Chemotherapy in Subjects With Stage IV Non-Small Cell Lung Cancer (NSCLC)",632
67,NCT02409342,Phase III,Recruiting,"[{'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 700, 'therapyName': 'Cisplatin'}]",A Comparative Study of MPDL3280A (Anti-PDL1 Antibody) With Cisplatin or Carboplatin + Pemetrexed in Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC),632
68,NCT02576574,Phase III,Recruiting,"[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 3144, 'therapyName': 'Avelumab'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 1092, 'therapyName': 'Carboplatin'}]",Avelumab in First-line Non-Small Cell Lung Cancer (JAVELIN Lung 100),632
69,NCT02657434,Phase III,Recruiting,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 854, 'therapyName': 'Pemetrexed'}]",A Study of Atezolizumab in Combination With Carboplatin or Cisplatin + Pemetrexed Compared With Carboplatin or Cisplatin + Pemetrexed in Participants Who Are Chemotherapy-Naive and Have Stage IV Non-Squamous Non-Small Cell Lung Cancer,632
70,NCT02142738,Phase III,"Active, not recruiting","[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 854, 'therapyName': 'Pemetrexed'}]",Study of Pembrolizumab (MK-3475) Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (MK-3475-024/KEYNOTE-024),632
71,NCT01344824,Phase II,Completed,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 854, 'therapyName': 'Pemetrexed'}]","Carboplatin, Pemetrexed Disodium, and Bevacizumab in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Who Are Light or Never Smokers",632
72,NCT01878617,Phase II,Recruiting,"[{'id': 956, 'therapyName': 'Vismodegib'}, {'id': 1800, 'therapyName': 'Cyclophosphamide + Cisplatin + Vincristine '}, {'id': 1801, 'therapyName': 'Pemetrexed + Gemcitabine'}]",A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma,632
73,NCT01376310,Phase II,"Active, not recruiting","[{'id': 1264, 'therapyName': 'Docetaxel + Trametinib'}, {'id': 1265, 'therapyName': 'Erlotinib + Trametinib'}, {'id': 2, 'therapyName': 'Trametinib'}, {'id': 1266, 'therapyName': 'Pemetrexed + GSK1120212'}, {'id': 1267, 'therapyName': 'Carboplatin + GSK1120212'}, {'id': 1268, 'therapyName': 'nab-paclitaxel + GSK1120212'}, {'id': 1269, 'therapyName': 'Gemcitabine + GSK1120212'}, {'id': 1271, 'therapyName': 'Everolimus + GSK1120212'}]",GSK1120212 Rollover Study,632
74,NCT02124148,Phase I,Recruiting,"[{'id': 1994, 'therapyName': 'Cisplatin + Prexasertib'}, {'id': 1993, 'therapyName': 'Cetuximab + Prexasertib'}, {'id': 6248, 'therapyName': 'Pemetrexed + Prexasertib'}, {'id': 6247, 'therapyName': 'LY3023414 + Prexasertib'}, {'id': 6246, 'therapyName': 'Fluoruracil + Leucovorin + Prexasertib'}]",A Study of LY2606368 With Cisplatin or Cetuximab in Participants With Advanced Cancer,632
75,NCT01450384,Phase I,Completed,"[{'id': 1482, 'therapyName': 'Pemetrexed + Sorafenib'}]",Pemetrexed Disodium and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors,632
76,NCT02624700,Phase II,Recruiting,"[{'id': 1482, 'therapyName': 'Pemetrexed + Sorafenib'}]",Study of Pemetrexed and Sorafenib for Recurrent or Metastatic Triple Negative Breast Cancer,632
77,NCT02383212,Phase I,"Active, not recruiting","[{'id': 5722, 'therapyName': 'REGN2810 + Carboplatin + Docetaxel'}, {'id': 5721, 'therapyName': 'REGN2810 + Carboplatin + Pemetrexed'}, {'id': 5723, 'therapyName': 'REGN2810 + GM-CSF + Cyclophosphamide'}, {'id': 5718, 'therapyName': 'REGN2810 + Cyclophosphamide'}, {'id': 5656, 'therapyName': 'REGN2810'}, {'id': 5720, 'therapyName': 'REGN2810 + Carboplatin + Paclitaxel'}, {'id': 5719, 'therapyName': 'REGN2810 + Docetaxel'}]",Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies,632
0,NCT02936323,,Recruiting,"[{'id': 5819, 'therapyName': 'PEN-221'}]",PEN-221 in Somatostatin Receptor 2 Expressing Advanced Cancers Including Neuroendocrine and Small Cell Lung Cancers,8813
0,NCT02193347,Phase I,Recruiting,"[{'id': 1635, 'therapyName': 'PEPIDH1M vaccine'}]",RESIST: Patients With IDH1 Positive Recurrent Grade II Glioma Enrolled in a Safety and Immunogenicity Study of Tumor-Specific Peptide Vaccine,7304
0,NCT00776867,Phase I,Completed,"[{'id': 855, 'therapyName': 'Perifosine'}]",Study of Single Agent Perifosine for Recurrent Pediatric Solid Tumors,6981
1,NCT02238496,Phase II,"Active, not recruiting","[{'id': 2194, 'therapyName': 'Perifosine + Temsirolimus'}]",Perifosine and Torisel (Temsirolimus) for Recurrent/Progressive Malignant Gliomas,6981
0,NCT03125928,Phase II,Recruiting,"[{'id': 5600, 'therapyName': 'Atezolizumab + Paclitaxel + Trastuzumab + Pertuzumab'}]","Clinical Trial of Atezolizumab With Paclitaxel, Trastuzumab, and Pertuzumab in Patients With Metastatic HER-2 Positive Breast Cancer",4730
1,NCT02789657,Phase II,Recruiting,"[{'id': 4235, 'therapyName': 'Carboplatin + Pertuzumab + Trastuzumab + Paclitaxel'}, {'id': 1977, 'therapyName': 'Doxorubicin + Cyclophosphamide'}]",BrUOG 308: Efficacy of wPCbTP and Switching to an AC in Non-responding Patients as Neoadjuvant Therapy in Clinical Stage I-III HER2-positive Breast Cancer.,4730
2,NCT02139358,Phase Ib/II,"Active, not recruiting","[{'id': 1592, 'therapyName': 'Gemcitabine + Trastuzumab + Pertuzumab'}]",Phase I/IIa Trial of Gemcitabine Plus Trastuzumab and Pertuzumab in Previously Treated Metastatic HER2+ Breast Cancer,4730
3,NCT02252887,Phase II,"Active, not recruiting","[{'id': 1592, 'therapyName': 'Gemcitabine + Trastuzumab + Pertuzumab'}]","Gemcitabine, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer After Prior Trastuzumab/Pertuzumab-Based Therapy, TDM-1, and TDM-1 + Pertuzumab",4730
4,NCT03112590,Phase Ib/II,Recruiting,"[{'id': 5548, 'therapyName': 'Interferon gamma + Paclitaxel + Pertuzumab + Trastuzumab'}]",Phase I-II Study of Interferon-gamma in Patients With HER-2 Positive Breast Cancer,4730
5,NCT03238495,Phase II,Recruiting,"[{'id': 1879, 'therapyName': 'Pertuzumab + Trastuzumab + Carboplatin + Docetaxel'}, {'id': 6101, 'therapyName': 'Metformin + Pertuzumab + Trastuzumab + Carboplatin + Docetaxel'}]",Randomized Trial of Neo-adjuvant Chemotherapy With or Without Metformin for HER2 Positive Operable Breast Cancer,4730
6,NCT03101748,Phase Ib/II,Not yet recruiting,"[{'id': 3187, 'therapyName': 'Neratinib + Paclitaxel + Pertuzumab + Trastuzumab'}, {'id': 1505, 'therapyName': 'Paclitaxel + Neratinib + Doxorubicin + Cyclophosphamide'}]",3HT With Taxol for Metastatic Breast Cancer,4730
7,NCT02593708,Phase I,Unknown status,"[{'id': 3187, 'therapyName': 'Neratinib + Paclitaxel + Pertuzumab + Trastuzumab'}]","Phase1 of Neratinib+Trastuzumab, Pertuzumab, Paclitaxel in Patients With Advanced Solid Tumors/HER2+",4730
8,NCT03199885,Phase III,Not yet recruiting,"[{'id': 1549, 'therapyName': 'Pertuzumab + Trastuzumab + Paclitaxel'}, {'id': 5956, 'therapyName': 'Paclitaxel + Pembrolizumab + Pertuzumab + Trastuzumab'}]","Paclitaxel, Trastuzumab, and Pertuzumab With or Without Pembrolizumab in Treating Patients With Metastatic Breast Cancer",4730
9,NCT01774786,Phase III,"Active, not recruiting","[{'id': 856, 'therapyName': 'Pertuzumab'}, {'id': 1894, 'therapyName': 'Capecitabine + Fluorouracil + Cisplatin + Trastuzumab'}]",A Study of Perjeta (Pertuzumab) in Combination With Herceptin (Trastuzumab) and Chemotherapy in Patients With HER2-Positive Metastatic Gastroesophageal Junction or Gastric Cancer,4730
10,NCT01904903,Phase II,Recruiting,"[{'id': 856, 'therapyName': 'Pertuzumab'}, {'id': 1402, 'therapyName': 'trastuzumab emtansine'}, {'id': 947, 'therapyName': 'Trastuzumab'}]",Cardiac Safety Study in Patients With HER2+ Breast Cancer (SAFE-HEaRt),4730
11,NCT02947685,Phase III,Recruiting,"[{'id': 744, 'therapyName': 'Fulvestrant'}, {'id': 856, 'therapyName': 'Pertuzumab'}, {'id': 794, 'therapyName': 'Letrozole'}, {'id': 633, 'therapyName': 'Anastrozole'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 947, 'therapyName': 'Trastuzumab'}]","Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer (PATINA)",4730
12,NCT01358877,Phase III,"Active, not recruiting","[{'id': 856, 'therapyName': 'Pertuzumab'}, {'id': 947, 'therapyName': 'Trastuzumab'}]",A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer,4730
13,NCT03304080,,Not yet recruiting,"[{'id': 633, 'therapyName': 'Anastrozole'}, {'id': 856, 'therapyName': 'Pertuzumab'}, {'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 850, 'therapyName': 'Palbociclib'}]","Anastrozole, Palbociclib, Trastuzumab and Pertuzumab in Her-positive, Her2-positive Metastatic Breast",4730
14,NCT01912963,Phase II,"Active, not recruiting","[{'id': 728, 'therapyName': 'Eribulin'}, {'id': 856, 'therapyName': 'Pertuzumab'}, {'id': 947, 'therapyName': 'Trastuzumab'}]","Phase II Study of Eribulin Mesylate, Trastuzumab, and Pertuzumab in Women With Metastatic, Unresectable Locally Advanced, or Locally Recurrent HER2-Positive Breast Cancer",4730
15,NCT02605915,Phase I,Recruiting,"[{'id': 3250, 'therapyName': 'Atezolizumab + Trastuzumab'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 856, 'therapyName': 'Pertuzumab'}]",Safety and Pharmacokinetics of Atezolizumab in Combination With Trastuzumab Emtansine or With Trastuzumab and Pertuzumab in Participants With HER2-Positive Breast Cancer,4730
16,NCT01875666,Phase I,"Active, not recruiting","[{'id': 1414, 'therapyName': 'Trastuzumab + Lapatinib'}, {'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 856, 'therapyName': 'Pertuzumab'}, {'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}]","Defining the HER2 Positive (+) Breast Cancer Kinome Response to Trastuzumab, Pertuzumab, Combination Trastuzumab +Pertuzumab, or Combination Trastuzumab + Lapatinib",4730
17,NCT02390427,Phase I,Recruiting,"[{'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 856, 'therapyName': 'Pertuzumab'}, {'id': 1016, 'therapyName': 'GDC-0032'}]",Phase Ib Dose-escalation Trial of Taselisib (GDC-0032) in Combination With Anti-HER2 Therapies in Participants With Advanced HER2+ Breast Cancer,4730
18,NCT03135171,Phase I,Recruiting,"[{'id': 5648, 'therapyName': 'Pertuzumab + Tocilizumab + Trastuzumab'}]",Trastuzumab and Pertuzumab in Combination With Tocilizumab in Subjects With Metastatic HER2 Positive Breast Cancer Resistant to Trastuzumab,4730
19,NCT02003209,Phase III,"Active, not recruiting","[{'id': 759, 'therapyName': 'Goserelin'}, {'id': 1879, 'therapyName': 'Pertuzumab + Trastuzumab + Carboplatin + Docetaxel'}]","Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer",4730
20,NCT02131064,Phase III,"Active, not recruiting","[{'id': 1492, 'therapyName': 'T-DM1 + Pertuzumab'}, {'id': 1879, 'therapyName': 'Pertuzumab + Trastuzumab + Carboplatin + Docetaxel'}]",A Study Comparing Kadcyla Plus Perjeta Treatment to Chemotherapy Combined With Herceptin Plus Perjeta in Patients With HER2-Positive Breast Cancer,4730
21,NCT01966471,Phase III,"Active, not recruiting","[{'id': 1492, 'therapyName': 'T-DM1 + Pertuzumab'}, {'id': 1978, 'therapyName': 'Pertuzumab + Trastuzumab + Docetaxel'}, {'id': 1549, 'therapyName': 'Pertuzumab + Trastuzumab + Paclitaxel'}]",A Study of Kadcyla (Trastuzumab Emtansine) Plus Perjeta (Pertuzumab) Following Anthracyclines in Comparison With Herceptin (Trastuzumab) Plus Perjeta and a Taxane Following Anthracyclines as Adjuvant Therapy in Patients With Operable HER2-Positive Primary Breast Cancer,4730
22,NCT02345772,Phase I,Terminated,"[{'id': 744, 'therapyName': 'Fulvestrant'}, {'id': 1978, 'therapyName': 'Pertuzumab + Trastuzumab + Docetaxel'}]","Neoadjuvant Hormonal Therapy Combined With Chemoimmunotherapy (Taxotere, Trastuzumab and Pertuzumab) in Patients With HER2-positive and ER-Positive Breast Cancer",4730
23,NCT02379585,Phase Ib/II,Terminated,"[{'id': 1495, 'therapyName': 'Paclitaxel + Doxorubicin + Cyclophosphamide'}, {'id': 1978, 'therapyName': 'Pertuzumab + Trastuzumab + Docetaxel'}]",Study of Short-term Fasting on Neoadjuvant Chemotherapy in Patients With Newly Diagnosed Breast Cancer,4730
24,NCT02402712,Phase III,"Active, not recruiting","[{'id': 1978, 'therapyName': 'Pertuzumab + Trastuzumab + Docetaxel'}]",Phase IIIb Study to Evaluate the Safety and Tolerability of Herceptin SC With Perjeta and Docetaxel in Patients With HER2-positive Advanced Breast Cancer,4730
25,NCT01501487,FDA approved,"Active, not recruiting","[{'id': 1902, 'therapyName': 'Docetaxel + Doxorubicin + Cyclophosphamide'}, {'id': 1982, 'therapyName': 'Fluorouracil + Epirubicin + Cyclophosphamide'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1476, 'therapyName': 'Pegfilgrastim'}, {'id': 1881, 'therapyName': 'Docetaxel + Cyclophosphamide'}, {'id': 1977, 'therapyName': 'Doxorubicin + Cyclophosphamide'}, {'id': 1485, 'therapyName': 'Trastuzumab + Docetaxel + Carboplatin'}, {'id': 1978, 'therapyName': 'Pertuzumab + Trastuzumab + Docetaxel'}]",MINT I Multi- Institutional Neo-adjuvant Therapy MammaPrint Project I,4730
26,NCT01855828,Phase II,Recruiting,"[{'id': 1549, 'therapyName': 'Pertuzumab + Trastuzumab + Paclitaxel'}, {'id': 1550, 'therapyName': 'Pertuzumab + Trastuzumab + Fluorouracil + Epirubicin + Cyclophosphamide'}]",Phase 2 Trial of Pertuzumab and Trastuzumab With Weekly Paclitaxel and Chemotherapy for HER2 Positive Breast Cancer,4730
27,NCT01730833,Phase II,Recruiting,"[{'id': 1549, 'therapyName': 'Pertuzumab + Trastuzumab + Paclitaxel'}]","Pertuzumab, Trastuzumab, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With HER2-Positive Metastatic Breast Cancer",4730
28,NCT01276041,Phase II,"Active, not recruiting","[{'id': 1549, 'therapyName': 'Pertuzumab + Trastuzumab + Paclitaxel'}]","Paclitaxel, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer",4730
29,NCT01847001,Phase II,"Active, not recruiting","[{'id': 1912, 'therapyName': 'Propranolol'}, {'id': 1549, 'therapyName': 'Pertuzumab + Trastuzumab + Paclitaxel'}]",Study of Propranolol in Newly Diagnosed Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy,4730
30,NCT01565083,Phase II,Completed,"[{'id': 1666, 'therapyName': 'Pertuzumab + Trastuzumab + Vinorelbine'}]",A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) And Vinorelbine in First Line in Patients With Metastatic or Locally Advanced HER2-Positive Breast Cancer,4730
31,NCT00781612,Phase II,Recruiting,"[{'id': 5471, 'therapyName': 'Trastuzumab + trastuzumab emtansine'}, {'id': 5470, 'therapyName': 'Paclitaxel + trastuzumab emtansine'}, {'id': 1402, 'therapyName': 'trastuzumab emtansine'}, {'id': 3930, 'therapyName': 'Docetaxel + T-DM1'}, {'id': 1976, 'therapyName': 'trastuzumab emtansine + Capecitabine'}, {'id': 1492, 'therapyName': 'T-DM1 + Pertuzumab'}]",A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies,4730
32,NCT02326974,Phase II,Recruiting,"[{'id': 1492, 'therapyName': 'T-DM1 + Pertuzumab'}]",T-DM1+Pertuzumab in Pre-OP Early-Stage HER2+ BRCA,4730
33,NCT01042379,Phase II,Recruiting,"[{'id': 1218, 'therapyName': 'Trebananib'}, {'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}, {'id': 746, 'therapyName': 'Ganitumab'}, {'id': 1495, 'therapyName': 'Paclitaxel + Doxorubicin + Cyclophosphamide'}, {'id': 1494, 'therapyName': 'MK2206 + Trastuzumab'}, {'id': 1493, 'therapyName': 'Trebananib + Trastuzumab'}, {'id': 1492, 'therapyName': 'T-DM1 + Pertuzumab'}]",I-SPY 2 TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer,4730
34,NCT02536339,Phase II,"Active, not recruiting","[{'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}]",Pertuzumab With High-Dose Trastuzumab in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (MBC) With Central Nervous System (CNS) Progression Post-Radiotherapy,4730
35,NCT01796197,Phase II,"Active, not recruiting","[{'id': 1977, 'therapyName': 'Doxorubicin + Cyclophosphamide'}, {'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]",Paclitaxel + Trastuzumab + Pertuzumab as Pre-Op for Inflammatory BrCa,4730
36,NCT02436993,Phase II,Recruiting,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]",Breast Cancer Treatment Using Weekly Carboplatin + Paclitaxel With Pertuzumab + Trastuzumab (HER2+) or Bevacizumab (HER2-) in the Neoadjuvant Setting,4730
37,NCT02689921,Phase II,Recruiting,"[{'id': 633, 'therapyName': 'Anastrozole'}, {'id': 794, 'therapyName': 'Letrozole'}, {'id': 795, 'therapyName': 'Leuprolide'}, {'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}, {'id': 738, 'therapyName': 'Exemestane'}]",NEOADjuvant Aromatase Inhibitor and Pertuzumab/Trastuzumab for Women With Breast Cancer (NEOADAPT),4730
38,NCT02091141,Phase II,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 698, 'therapyName': 'Alectinib'}, {'id': 1657, 'therapyName': 'Vemurafenib + Cobimetinib'}, {'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 1201, 'therapyName': 'Atezolizumab'}]","My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors",4730
39,NCT01937117,Phase II,"Active, not recruiting","[{'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}]",Pertuzumab and Trastuzumab as Neoadjuvant Treatment in Patients With HER2-Positive Breast Cancer,4730
40,NCT02598427,Phase I,Recruiting,"[{'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}]",Intrathecal Pertuzumab and Trastuzumab in Patients With New Untreated Asymptomatic or Low Symptomatic Brain Metastasis in HER2 Positive Breast Cancer,4730
41,NCT02132949,Phase II,"Active, not recruiting","[{'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}, {'id': 1495, 'therapyName': 'Paclitaxel + Doxorubicin + Cyclophosphamide'}, {'id': 1895, 'therapyName': 'Cyclophosphamide + Fluorouracil + Docetaxel + Epirubicin  '}]","A Study Evaluating Perjeta (Pertuzumab) Combined With Herceptin (Trastuzumab) and Standard Anthracycline-based Chemotherapy in Patients With HER2-positive Locally Advanced, Inflammatory, or Early-stage Breast Cancer.",4730
42,NCT02229149,Phase II,"Active, not recruiting","[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}, {'id': 619, 'therapyName': 'Abraxane'}, {'id': 1685, 'therapyName': 'Vinorelbine'}, {'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 1105, 'therapyName': 'Capecitabine'}]","Phase 2 Study of Standard Chemotherapy With Trastuzumab, Plus or Minus Pertuzumab, for Pre-treated Metastatic Breast Cancer",4730
43,NCT02693535,Phase II,Recruiting,"[{'id': 1657, 'therapyName': 'Vemurafenib + Cobimetinib'}, {'id': 890, 'therapyName': 'Regorafenib'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 690, 'therapyName': 'Bosutinib'}, {'id': 850, 'therapyName': 'Palbociclib'}, {'id': 694, 'therapyName': 'Cetuximab'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 837, 'therapyName': 'Olaparib'}, {'id': 4, 'therapyName': 'Erlotinib'}]",TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer,4730
44,NCT01572038,Phase III,"Active, not recruiting","[{'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}, {'id': 619, 'therapyName': 'Abraxane'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]",A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) and A Taxane in First-Line Treatment in Patients With HER2-Positive Advanced Breast Cancer (PERUSE),4730
45,NCT02000596,Phase II,Terminated,"[{'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}, {'id': 1911, 'therapyName': 'Anastrozole  + Fulvestrant'}]",Trastuzmab and Pertuzumab Alone or in Combination With Hormonal Therapy or Chemotherapy With Eribulin in Women Aged 60 and Over With HER2/Neu Overexpressed Locally Advanced or MBC,4730
46,NCT02827877,Phase I,Recruiting,"[{'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}]",Copper (Cu) 64-DOTA-Trastuzumab PET in Predicting Response to Treatment With Trastuzumab and Pertuzumab Before Surgery in Patients With HER2 Positive Breast Cancer,4730
47,NCT01491737,Phase II,"Active, not recruiting","[{'id': 633, 'therapyName': 'Anastrozole'}, {'id': 794, 'therapyName': 'Letrozole'}, {'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}]","A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Patients With Hormone Receptor-Positive, Metastatic HER2-positive Breast Cancer",4730
0,NCT02299635,Phase II,Terminated,"[{'id': 859, 'therapyName': 'PF-03084014'}]",A Study Evaluating PF-03084014 In Patients With Advanced Breast Cancer With Or Without Notch Alterations,6983
1,NCT02109445,Phase II,Terminated,"[{'id': 1779, 'therapyName': 'Nab-paclitaxel + Gemcitabine'}, {'id': 859, 'therapyName': 'PF-03084014'}]",Study Of PF-03084014 In Combination With Gemcitabine And Nab-Paclitaxel In Patients With Metastatic Pancreatic Adenocarcinoma Not Previously Treated With Anticancer Therapies,6983
2,NCT02137564,Phase II,Withdrawn,"[{'id': 859, 'therapyName': 'PF-03084014'}]",Gamma Secretase Inhibitor PF-03084014 in Treating Patients With AIDS-Associated Kaposi Sarcoma,6983
3,NCT02955446,Expanded access,No longer available,"[{'id': 859, 'therapyName': 'PF-03084014'}]",Compassionate Use Protocol for PF-03084014 in Patients With Advanced Solid Tumor Malignancies,6983
4,NCT01981551,Phase II,"Active, not recruiting","[{'id': 859, 'therapyName': 'PF-03084014'}]",Phase II Trial of the Gamma-Secretase Inhibitor PF-03084014 in Adults With Desmoid Tumors/Aggressive Fibromatosis,6983
5,NCT01876251,,Terminated,"[{'id': 1115, 'therapyName': 'PF-03084014 + Docetaxel'}]", A Study Evaluating The PF-03084014 In Combination With Docetaxel In Patients With Advanced Breast Cancer,6983
0,NCT02116894,Phase I,Completed,"[{'id': 2035, 'therapyName': 'PF-03446962 + Regorafenib'}]",Safety Study of Regorafenib With PF-03446962 to Treat Colorectal Cancer,7395
0,NCT02732938,Phase I,"Active, not recruiting","[{'id': 4340, 'therapyName': 'Gemcitabine + nab-paclitaxel + PF-04136309'}]",Ph1b/2 Study of PF-04136309 in Combination With Gem/Nab-P in First-line Metastatic Pancreatic Patients (CCR2i),8426
0,NCT02367456,Phase Ib/II,Recruiting,"[{'id': 4177, 'therapyName': 'Azacitidine + PF-04449913'}]","A Combination Study of PF-04449913 (Glasdegib) and Azacitidine In 1st Line MDS, AML and CMML Patients",7326
1,NCT01546038,Phase Ib/II,"Active, not recruiting","[{'id': 1748, 'therapyName': 'PF-04449913'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 1738, 'therapyName': 'Daunorubicin + Cytarabine'}]",A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,7326
2,NCT01841333,Phase II,Recruiting,"[{'id': 1748, 'therapyName': 'PF-04449913'}]",PF-04449913 For Patients With Acute Leukemia at High Risk of Relapse After Donor Stem Cell Transplant,7326
3,NCT01842646,Phase II,"Active, not recruiting","[{'id': 1748, 'therapyName': 'PF-04449913'}]",Phase II Hedgehog Inhibitor for Myelodysplastic Syndrome (MDS),7326
0,NCT03217747,Phase Ib/II,Recruiting,"[{'id': 5052, 'therapyName': 'Avelumab + Cisplatin'}, {'id': 6044, 'therapyName': 'Avelumab + PF-04518600 + Utomilumab'}, {'id': 6043, 'therapyName': 'Avelumab + Utomilumab'}, {'id': 6045, 'therapyName': 'Avelumab + PF-04518600'}]",Study to Evaluate the Safety and Tolerability of Avelumab in Combination With Other Anti-Cancer Therapies in Patients With Advanced Malignancies,8422
1,NCT03092856,Phase II,Recruiting,"[{'id': 649, 'therapyName': 'Axitinib'}, {'id': 5522, 'therapyName': 'Axitinib + PF-04518600'}]",Axitinib With or Without Anti-OX40 Antibody PF-04518600 in Treating Patients With Metastatic Kidney Cancer,8422
2,NCT02315066,Phase I,Recruiting,"[{'id': 4333, 'therapyName': 'PF-04518600'}, {'id': 4448, 'therapyName': 'PF-04518600 + Utomilumab'}]",Study Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566,8422
0,NCT03243331,Phase I,Not yet recruiting,"[{'id': 6110, 'therapyName': 'Gedatolisib + PF-06647020'}]",An Initial Safety Study of Gedatolisib Plus PTK7-ADC for Metastatic Triple-negative Breast Cancer,8446
1,NCT02222922,Phase I,Recruiting,"[{'id': 1689, 'therapyName': 'Fluconazole'}, {'id': 4421, 'therapyName': 'PF-06647020'}]",A Study Of PF-06647020 For Adult Patients With Advanced Solid Tumors,8446
0,NCT02078752,Phase I,Completed,"[{'id': 4324, 'therapyName': 'PF-06647263 '}]",A Study Of PF-06647263 In Patients With Advanced Solid Tumors,8414
0,NCT03159117,Phase I,Recruiting,"[{'id': 5707, 'therapyName': ' PF-06688992'}]",Pfizer PF-06688992 in Patients With Stage III or Stage IV Melanoma,8757
0,NCT02954653,Phase I,Recruiting,"[{'id': 6087, 'therapyName': 'PF-06747143'}, {'id': 6092, 'therapyName': 'Cytarabine + Daunorubicin + PF-06747143'}, {'id': 6093, 'therapyName': 'Azacitidine + Decitabine + PF-06747143'}]","A Study Of PF-06747143, As Single Agent Or In Combination With Standard Chemotherapy In Adult Patients With Acute Myeloid Leukemia",8913
0,NCT02349633,Phase I,Recruiting,"[{'id': 2527, 'therapyName': 'PF-06747775  '}]",Study For Patients With NSCLC EGFR Mutations (Del 19 or L858R +/- T790M),7558
0,NCT02616185,Phase I,Recruiting,"[{'id': 3565, 'therapyName': 'PF-06755990 + PF-06755992 + Sunitinib + Tremelimumab'}]",A Phase 1 Study To Evaluate Escalating Doses Of A Vaccine-Based Immunotherapy Regimen For Prostate Cancer (PrCa VBIR),8141
0,NCT02616185,Phase I,Recruiting,"[{'id': 3565, 'therapyName': 'PF-06755990 + PF-06755992 + Sunitinib + Tremelimumab'}]",A Phase 1 Study To Evaluate Escalating Doses Of A Vaccine-Based Immunotherapy Regimen For Prostate Cancer (PrCa VBIR),8140
0,NCT01309126,Phase III,Terminated,"[{'id': 694, 'therapyName': 'Cetuximab'}, {'id': 2065, 'therapyName': 'Cetuximab + Imprime PGG'}]",Study of Imprime PGG in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer,7412
1,NCT02981303,Phase II,Recruiting,"[{'id': 5174, 'therapyName': 'Imprime PGG + Pembrolizumab'}]",Study of Imprime PGG and Pembrolizumab in Advanced Melanoma and Triple Negative Breast Cancer,7412
2,NCT03003468,Phase Ib/II,Recruiting,"[{'id': 5174, 'therapyName': 'Imprime PGG + Pembrolizumab'}]",Pembrolizumab + Imprime PGG for Metastatic Non-small Cell Lung Cancer After Progression on First-Line Chemotherapy: Big Ten Cancer Research Consortium BTCRC-LUN15-017,7412
0,NCT01790204,Phase Ib/II,Completed,"[{'id': 1457, 'therapyName': 'phenethyl isothiocyanate'}]",A Study of the Effects of PEITC on Oral Cells With Mutant p53,7265
0,NCT03026517,Phase I,Recruiting,"[{'id': 5270, 'therapyName': 'Dabrafenib + Trametinib + Phenformin'}]",Clinical Trial of Phenformin in Combination With Dabrafenib and Trametinib for Patients With BRAF-mutated Melanoma,903
0,NCT02077959,Phase Ib/II,"Active, not recruiting","[{'id': 3357, 'therapyName': 'lenalidomide + Pidilizumab'}]",Lenalidomide and Pidilizumab in Treating Patients With Relapsed or Refractory Multiple Myeloma,8045
1,NCT02530125,Phase II,"Active, not recruiting","[{'id': 3338, 'therapyName': 'Pidilizumab'}]",Pidilizumab in Treating Patients With Stage III-IV Diffuse Large B-Cell Lymphoma Following First Remission,8045
0,NCT01992874,Phase I,Completed,"[{'id': 871, 'therapyName': 'Pimasertib'}]",Relative Bioavailability of Pimasertib in Cancer Patients,6989
1,NCT01693068,Phase II,Completed,"[{'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 871, 'therapyName': 'Pimasertib'}]",Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma,6989
0,NCT01691898,Phase Ib/II,"Active, not recruiting","[{'id': 4415, 'therapyName': 'Obinutuzumab + Pinatuzumab Vedotin + Rituximab'}, {'id': 4416, 'therapyName': 'Polatuzumab Vedotin + Pinatuzumab Vedotin + Rituximab'}, {'id': 4417, 'therapyName': 'Obinutuzumab + Polatuzumab Vedotin'}]",A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or Obinutuzumab in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (ROMULUS),8445
0,NCT02442414,Phase I,Unknown status,"[{'id': 2908, 'therapyName': 'Pirotinib'}]",A Phase 1 Study of KBP-5209 in Patients With Advanced Solid Tumors,7831
0,NCT01339039,Phase I,Terminated,"[{'id': 2120, 'therapyName': 'Bevacizumab + Plerixafor'}]",Plerixafor (AMD3100) and Bevacizumab for Recurrent High-Grade Glioma,7330
1,NCT00903968,Phase Ib/II,Completed,"[{'id': 3348, 'therapyName': 'Bortezomib + Plerixafor'}]",Combination Plerixafor (AMD3100)and Bortezomib in Relapsed or Relapsed/Refractory Multiple Myeloma,7330
2,NCT00669669,Phase Ib/II,"Active, not recruiting","[{'id': 2556, 'therapyName': 'O6-benzylguanine'}, {'id': 2555, 'therapyName': 'Carmustine + Filgrastim + Plerixafor + Temozolomide'}]",Dose-Intensive Chemotherapy in Combination With Chemoprotected Autologous Stem Cells in Treating Patients With Malignant Gliomas,7330
3,NCT02416908,Phase Ib/II,Recruiting,"[{'id': 1749, 'therapyName': 'Selinexor'}, {'id': 3178, 'therapyName': 'Cladribine + Cytarabine + Plerixafor'}]",Study of CLAG + Selinexor in Relapsed or Refractory Acute Myeloid Leukemia,7330
4,NCT01408043,Phase I,Terminated,"[{'id': 3222, 'therapyName': 'Etoposide + Filgrastim + Plerixafor'}]","Etoposide, Filgrastim, and Plerixafor in Improving Stem Cell Mobilization in Treating Patients With Non-Hodgkin Lymphoma",7330
5,NCT02703779,Phase II,Recruiting,"[{'id': 688, 'therapyName': 'Bortezomib'}, {'id': 3933, 'therapyName': 'Filgrastim + Plerixafor'}]",Exploratory Trial to Estimate Proportion of Patients With Tumor Cell Contaminated Leukapheresis Products With and Without Bortezomib With In-vivo Purging - Multiple Myeloma (MM),7330
6,NCT03240861,Phase I,Not yet recruiting,"[{'id': 6116, 'therapyName': 'Busulfan + Fludarabine'}, {'id': 3933, 'therapyName': 'Filgrastim + Plerixafor'}, {'id': 1167, 'therapyName': 'Aldesleukin'}]",Genetically Engineered PBMC and PBSC Expressing NY-ESO-1 TCR After a Myeloablative Conditioning Regimen to Treat Patients With Advanced Cancer (NYESO SCT),7330
7,NCT01621477,Phase II,Terminated,"[{'id': 1756, 'therapyName': 'Plerixafor'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 1845, 'therapyName': 'Mycophenolate mofetil'}, {'id': 2469, 'therapyName': 'Busulfan + Clofarabine + Thymoglobulin'}, {'id': 1783, 'therapyName': 'Cyclophosphamide + Cytarabine'}]",T-Cell Replete Haploidentical Donor Hematopoietic Stem Cell Plus Natural Killer (NK) Cell Transplantation in Patients With Hematologic Malignancies Relapsed or Refractory Despite Previous Allogeneic Transplant,7330
8,NCT02570542,Phase II,Recruiting,"[{'id': 1756, 'therapyName': 'Plerixafor'}, {'id': 3359, 'therapyName': 'Carmustine + Cytarabine + Etoposide + Melphalan'}]",Impact of CD34+ Cell Dose on Progression-free Survival Following High-Dose Therapy and Autologous Stem Cell Transplantation for Relapsed and Refractory Diffuse Large B-cell Lymphoma (DLBCL),7330
9,NCT02200380,Phase II,Terminated,"[{'id': 1756, 'therapyName': 'Plerixafor'}, {'id': 3007, 'therapyName': 'CDX-301'}]",A Safety and Tolerability Study of CDX-301 With or Without Plerixafor for Stem Cell Mobilization in Matched Related Allogeneic Donor/Recipient Sibling Transplant Pairs,7330
10,NCT01547806,Phase II,"Active, not recruiting","[{'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1756, 'therapyName': 'Plerixafor'}]",Collection of Transplant Stem Cells for Plasma Cell Myeloma,7330
11,NCT01526096,Phase I,Recruiting,"[{'id': 5985, 'therapyName': 'Basiliximab'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1756, 'therapyName': 'Plerixafor'}, {'id': 1207, 'therapyName': 'Melphalan'}]",Stem Cell Transplantation for Patients With Multiple Myeloma,7330
12,NCT01977677,Phase Ib/II,"Active, not recruiting","[{'id': 1141, 'therapyName': 'Temozolomide'}, {'id': 1756, 'therapyName': 'Plerixafor'}]",Plerixafor After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed High Grade Glioma,7330
13,NCT02098109,Phase II,Completed,"[{'id': 1756, 'therapyName': 'Plerixafor'}, {'id': 1632, 'therapyName': 'Filgrastim'}]",Non-inferiority Study of XM02 Filgrastim (Granix) and Filgrastim (Neupogen) in Combination With Plerixafor for Autologous Stem Cell Mobilization in Patients With Multiple Myeloma or Non-Hodgkin Lymphoma,7330
14,NCT02343666,Phase I,Recruiting,"[{'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1811, 'therapyName': 'Carmustine'}, {'id': 1756, 'therapyName': 'Plerixafor'}, {'id': 2556, 'therapyName': 'O6-benzylguanine'}]",HIV-Resistant Gene Modified Stem Cells and Chemotherapy in Treating Patients With Lymphoma With HIV Infection,7330
15,NCT03277209,Phase I,Recruiting,"[{'id': 1756, 'therapyName': 'Plerixafor'}]","To Assess the Safety of Continuous IV Administration of Plerixafor and Assess Impact on the Immune Microenvironment in Patients With Pancreatic, Ovarian and Colorectal Adenocarcinomas",7330
16,NCT01352650,Phase I,"Active, not recruiting","[{'id': 1770, 'therapyName': 'Plerixafor + Decitabine'}]",Decitabine and Plerixafor in Elderly Acute Myeloid Leukemia (AML),7330
0,NCT01610570,Phase Ib/II,Terminated,"[{'id': 1397, 'therapyName': 'Mithramycin'}]",Mithramycin for Children and Adults With Solid Tumors or Ewing Sarcoma,4814
0,NCT02504489,Phase III,Recruiting,"[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 3679, 'therapyName': 'Docetaxel + Plinabulin'}]",Plinabulin (P) + Docetaxel (D) vs D as 2nd-Line Chemo in Patients With Advanced NSCLC With at Least 1 Large Lung Lesion,8206
1,NCT02812667,Phase I,Recruiting,"[{'id': 4512, 'therapyName': 'Nivolumab + Plinabulin'}]",Nivolumab in Combination With Plinabulin in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC),8206
2,NCT02846792,Phase Ib/II,Recruiting,"[{'id': 4512, 'therapyName': 'Nivolumab + Plinabulin'}]","Nivolumab and Plinabulin in Treating Patients With Stage IIIB-IV, Recurrent, or Metastatic Non-small Cell Lung Cancer",8206
3,NCT03102606,Phase II,Recruiting,"[{'id': 3678, 'therapyName': 'Plinabulin'}, {'id': 1476, 'therapyName': 'Pegfilgrastim'}]",Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy (Protective-1),8206
0,NCT03158103,Phase I,Recruiting,"[{'id': 5730, 'therapyName': 'Binimetinib + PLX3397'}]",A Study of MEK162 (Binimetinib) in Combination With Pexidartinib in Patients With Advanced Gastrointestinal Stromal Tumor (GIST),6991
1,NCT02452424,Phase Ib/II,"Active, not recruiting","[{'id': 2736, 'therapyName': 'Pembrolizumab + PLX3397'}]",A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors,6991
2,NCT01004861,Phase I,"Active, not recruiting","[{'id': 874, 'therapyName': 'PLX3397'}]",Safety Study of PLX108-01 in Patients With Solid Tumors,6991
3,NCT01790503,Phase Ib/II,"Active, not recruiting","[{'id': 874, 'therapyName': 'PLX3397'}, {'id': 1141, 'therapyName': 'Temozolomide'}]",A Phase 1b/2 Study of PLX3397 + Radiation Therapy + Temozolomide in Patients With Newly Diagnosed Glioblastoma,6991
4,NCT02472275,Phase I,Recruiting,"[{'id': 795, 'therapyName': 'Leuprolide'}, {'id': 874, 'therapyName': 'PLX3397'}, {'id': 759, 'therapyName': 'Goserelin'}, {'id': 1814, 'therapyName': 'Degarelix'}]","PLX3397, Radiation Therapy, and Antihormone Therapy in Treating Patients With Intermediate- or High-Risk Prostate Cancer",6991
5,NCT02401815,Phase Ib/II,Recruiting,"[{'id': 874, 'therapyName': 'PLX3397'}, {'id': 2602, 'therapyName': 'PLX9486'}]",A Study of PLX9486 as a Single Agent and in Combination With PLX3397 in Patients With Advanced Solid Tumors Including GIST,6991
6,NCT02390752,Phase Ib/II,Recruiting,"[{'id': 874, 'therapyName': 'PLX3397'}]",PLX3397 in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN),6991
7,NCT01596751,Phase Ib/II,"Active, not recruiting","[{'id': 728, 'therapyName': 'Eribulin'}, {'id': 874, 'therapyName': 'PLX3397'}]",Phase Ib/II Study of PLX 3397 and Eribulin in Patients With Metastatic Breast Cancer,6991
8,NCT02371369,Phase III,"Active, not recruiting","[{'id': 874, 'therapyName': 'PLX3397'}]",PLX3397 Phase 3 Study for Pigmented Villonodular Synovitis (PVNS) or Giant Cell Tumor of the Tendon Sheath (GCT-TS),6991
9,NCT01525602,Phase I,"Active, not recruiting","[{'id': 1395, 'therapyName': 'PLX3397 + Paclitaxel'}]",Safety Study of PLX3397 and Paclitaxel in Patients With Advanced Solid Tumors,6991
10,NCT02584647,Phase Ib/II,Recruiting,"[{'id': 3155, 'therapyName': 'PLX3397 + Sirolimus'}]",Combination of PLX3397 and Sirolimus in Unresectable Sarcoma (Phase 1) and Malignant Peripheral Nerve Sheath Tumors (Phase 2),6991
11,NCT01826448,Phase I,Terminated,"[{'id': 1339, 'therapyName': 'PLX3397 + Vemurafenib'}]"," A Phase 1b Open Label, Dose Escalation Study of PLX3397 in Combination With Vemurafenib in V600-mutated BRAF Melanoma",6991
0,NCT02673736,Phase I,"Active, not recruiting","[{'id': 4332, 'therapyName': 'PLX73086'}]",A Study of PLX73086 in Advanced Solid Tumors and Locally Advanced or Refractory Tenosynovial Giant Cell Tumor,8421
0,NCT01804530,Phase I,"Active, not recruiting","[{'id': 2651, 'therapyName': 'PLX7486'}, {'id': 1779, 'therapyName': 'Nab-paclitaxel + Gemcitabine'}]",Phase 1 Study of PLX7486 as Single Agent and With Gemcitabine Plus Nab-Paclitaxel in Patients With Advanced Solid Tumors,7626
0,NCT02428712,Phase Ib/II,Recruiting,"[{'id': 1041, 'therapyName': 'PLX8394'}]","A Study of PLX8394 as a Single Agent in Patients With Advanced, Unresectable Solid Tumors",7160
1,NCT02012231,Phase Ib/II,Terminated,"[{'id': 1041, 'therapyName': 'PLX8394'}]","Phase I/IIa Study to Evaluate the Safety, PK, PD, and Preliminary Efficacy of PLX8394 in Patients With Advanced Cancers.",7160
0,NCT02401815,Phase Ib/II,Recruiting,"[{'id': 874, 'therapyName': 'PLX3397'}, {'id': 2602, 'therapyName': 'PLX9486'}]",A Study of PLX9486 as a Single Agent and in Combination With PLX3397 in Patients With Advanced Solid Tumors Including GIST,7599
0,NCT01299636,Phase I,Completed,"[{'id': 1459, 'therapyName': 'PM060184'}]",Study of PM060184 in Patients With Advanced Solid Tumors,7267
0,NCT02226965,Phase II,"Active, not recruiting","[{'id': 2581, 'therapyName': 'PNT2258'}]",Wolverine: PNT2258 for Treatment of Patients With r/r DLBCL,7592
0,NCT02729896,Phase Ib/II,Recruiting,"[{'id': 4362, 'therapyName': 'Atezolizumab + Obinutuzumab + Polatuzumab Vedotin'}]","A Study of Obinutuzumab, Polatuzumab Vedotin, and Atezolizumab in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)",8382
1,NCT02600897,Phase Ib/II,Recruiting,"[{'id': 4394, 'therapyName': 'lenalidomide + Obinutuzumab + Polatuzumab Vedotin'}]","A Study of Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)",8382
2,NCT01691898,Phase Ib/II,"Active, not recruiting","[{'id': 4415, 'therapyName': 'Obinutuzumab + Pinatuzumab Vedotin + Rituximab'}, {'id': 4416, 'therapyName': 'Polatuzumab Vedotin + Pinatuzumab Vedotin + Rituximab'}, {'id': 4417, 'therapyName': 'Obinutuzumab + Polatuzumab Vedotin'}]",A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or Obinutuzumab in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (ROMULUS),8382
3,NCT02611323,Phase Ib/II,Recruiting,"[{'id': 4227, 'therapyName': 'Obinutuzumab + Polatuzumab Vedotin + Venetoclax'}]","A Study of Obinutuzumab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)",8382
4,NCT02257567,Phase Ib/II,"Active, not recruiting","[{'id': 2323, 'therapyName': 'Bendamustine + Rituximab'}, {'id': 4226, 'therapyName': 'Polatuzumab Vedotin'}, {'id': 1646, 'therapyName': 'Obinutuzumab'}]",A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma,8382
5,NCT03274492,Phase III,Not yet recruiting,"[{'id': 4226, 'therapyName': 'Polatuzumab Vedotin'}, {'id': 6177, 'therapyName': 'R-CHP'}, {'id': 2195, 'therapyName': 'R-CHOP'}]","A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma",8382
6,NCT01992653,Phase I,"Active, not recruiting","[{'id': 4248, 'therapyName': 'Cyclophosphamide + Doxorubicin + Prednisone'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 4226, 'therapyName': 'Polatuzumab Vedotin'}, {'id': 1646, 'therapyName': 'Obinutuzumab'}]","A Study of Polatuzumab Vedotin in Combination With Rituximab or Obinutuzumab, Cyclophosphamide, Doxorubicin, and Prednisone in Participants With B-Cell Non-Hodgkin's Lymphoma",8382
0,NCT01976585,Phase Ib/II,Recruiting,"[{'id': 4337, 'therapyName': 'CDX-301 + poly ICLC '}]",In Situ Vaccine for Low-Grade Lymphoma: Combination of Intratumoral Flt3L and Poly-ICLC With Low-Dose Radiotherapy,7596
1,NCT02873819,Phase II,Recruiting,"[{'id': 4614, 'therapyName': 'MAGE-A3 vaccine'}, {'id': 4615, 'therapyName': 'Cyclophosphamide + poly ICLC  + Sargramostim'}]",Safety and Efficacy Study of GL-0817 (With Cyclophosphamide) for the Prevention of Recurrence of Squamous Cell Carcinoma of the Oral Cavity,7596
2,NCT02924038,Phase I,Recruiting,"[{'id': 4835, 'therapyName': 'IMA950 + poly ICLC '}, {'id': 2525, 'therapyName': 'Varlilumab'}]",A Study of Varlilumab and IMA950 Vaccine Plus Poly-ICLC in Patients With WHO Grade II Low-Grade Glioma (LGG),7596
3,NCT02643303,Phase Ib/II,Recruiting,"[{'id': 3385, 'therapyName': 'MEDI4736 + poly ICLC '}, {'id': 1652, 'therapyName': 'Tremelimumab'}]","A Phase 1/2 Study of In Situ Vaccination With Tremelimumab and IV Durvalumab Plus PolyICLC in Subjects With Advanced, Measurable, Biopsy-accessible Cancers",7596
4,NCT02826434,Phase I,Recruiting,"[{'id': 4466, 'therapyName': 'MEDI4736 + PVX-410 + poly ICLC '}]",Adjuvant PVX-410 Vaccine and Durvalumab in Stage II/III Triple Negative Breast Cancer,7596
5,NCT02897765,Phase I,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 4733, 'therapyName': 'NEO-PV-01 + poly ICLC'}]","A Personalized Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer",7596
6,NCT03121677,Phase I,Not yet recruiting,"[{'id': 5592, 'therapyName': 'Nivolumab + poly ICLC + Rituximab'}]",Personalized Synthetic Long Peptide Vaccine Strategy and PD-1 Blockade in Patients With Follicular Lymphoma,7596
7,NCT03162562,Phase I,Recruiting,"[{'id': 5792, 'therapyName': 'Oregovomab + poly ICLC '}]",The Safety and Antitumor Activity of the Combination of Oregovomab and Hiltonol in Recurrent Advanced Ovarian Cancer,7596
8,NCT02834052,Phase Ib/II,Not yet recruiting,"[{'id': 4458, 'therapyName': 'Pembrolizumab + poly ICLC '}]",Pembrolizumab + Poly-ICLC in MRP Colon Cancer,7596
9,NCT02166905,Phase Ib/II,Recruiting,"[{'id': 2595, 'therapyName': 'poly ICLC  '}, {'id': 1324, 'therapyName': 'DEC-205-NY-ESO-1 fusion protein vaccine'}, {'id': 2575, 'therapyName': 'Epacadostat'}]","DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, and IDO1 Inhibitor INCB024360 in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission",7596
10,NCT01188096,Phase II,Recruiting,"[{'id': 2595, 'therapyName': 'poly ICLC  '}]",A Trial of Poly-ICLC in the Management of Recurrent Pediatric Low Grade Gliomas,7596
11,NCT02078648,Phase Ib/II,"Active, not recruiting","[{'id': 3010, 'therapyName': 'SL-701'}, {'id': 2595, 'therapyName': 'poly ICLC  '}, {'id': 667, 'therapyName': 'Bevacizumab'}]","Safety and Efficacy Study of SL-701, a Glioma-Associated Antigen Vaccine To Treat Recurrent Glioblastoma Multiforme",7596
12,NCT02332889,Phase Ib/II,Terminated,"[{'id': 650, 'therapyName': 'Decitabine'}, {'id': 2595, 'therapyName': 'poly ICLC  '}]",Phase I/II Decitabine/Vaccine Therapy in Relapsed/Refractory Pediatric High Grade Gliomas/Medulloblastomas/CNS PNETs,7596
13,NCT02413827,Phase Ib/II,Terminated,"[{'id': 2526, 'therapyName': 'Nivolumab + Varlilumab'}, {'id': 1324, 'therapyName': 'DEC-205-NY-ESO-1 fusion protein vaccine'}, {'id': 2595, 'therapyName': 'poly ICLC  '}]",A Study of Varlilumab (Anti-CD27) and Ipilimumab and CDX-1401 in Patients With Unresectable Stage III or IV Melanoma,7596
14,NCT01130077,Phase I,Recruiting,"[{'id': 2595, 'therapyName': 'poly ICLC  '}]",A Pilot Study of Glioma Associated Antigen Vaccines in Conjunction With Poly-ICLC in Pediatric Gliomas,7596
15,NCT02126579,Phase Ib/II,Recruiting,"[{'id': 2595, 'therapyName': 'poly ICLC  '}, {'id': 3009, 'therapyName': 'Long peptide vaccine 7'}]",Phase I/II Trial of a Long Peptide Vaccine (LPV7) Plus TLR Agonists,7596
16,NCT02334735,Phase II,Recruiting,"[{'id': 2595, 'therapyName': 'poly ICLC  '}, {'id': 3012, 'therapyName': 'Melan-A/MART-1 peptide vaccine'}, {'id': 2696, 'therapyName': 'NY-ESO-1 peptide vaccine'}]",A Comparison of Matured Dendritic Cells and Montanide&#174; in Study Subjects With High Risk of Melanoma Recurrence,7596
17,NCT02423863,Phase II,Recruiting,"[{'id': 2595, 'therapyName': 'poly ICLC  '}]","In Situ, Autologous Therapeutic Vaccination Against Solid Cancers With Intratumoral Hiltonol",7596
18,NCT02754362,Phase II,Enrolling by invitation,"[{'id': 2595, 'therapyName': 'poly ICLC  '}, {'id': 667, 'therapyName': 'Bevacizumab'}]",A Toll-like Receptor Agonist as an Adjuvant to Tumor Associated Antigens (TAA) Mixed With Montanide ISA-51 VG With Bevacizumab for Patients With Recurrent Glioblastoma,7596
19,NCT02425306,Phase Ib/II,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 2620, 'therapyName': '6MHP vaccine'}, {'id': 2595, 'therapyName': 'poly ICLC  '}]",Safety Study of a Helper Peptide Vaccine Plus Adjuvant Combinations for the Treatment of Melanoma,7596
20,NCT01532960,Phase I,Terminated,"[{'id': 2595, 'therapyName': 'poly ICLC  '}]",Pilot Study of a Breast Cancer Vaccine Plus Poly-ICLC for Breast Cancer (Breast 41),7596
21,NCT02510950,Phase I,Recruiting,"[{'id': 1873, 'therapyName': 'Sargramostim'}, {'id': 2595, 'therapyName': 'poly ICLC  '}, {'id': 1141, 'therapyName': 'Temozolomide'}]",Neoepitope-based Personalized Vaccine Approach in Patients With Newly Diagnosed Glioblastoma,7596
22,NCT02358187,Phase II,Recruiting,"[{'id': 2595, 'therapyName': 'poly ICLC  '}]",A Vaccine Trial for Low Grade Gliomas,7596
23,NCT02427581,Phase I,Recruiting,"[{'id': 2595, 'therapyName': 'poly ICLC  '}]",Safety and Immunogenicity of a Personalized Synthetic Long Peptide Breast Cancer Vaccine Strategy in Patients With Persistent Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy,7596
0,NCT01922921,Phase Ib/II,"Active, not recruiting","[{'id': 1556, 'therapyName': 'HER-2/neu intracellular domain protein + Trastuzumab '}, {'id': 1558, 'therapyName': 'HER-2/neu intracellular domain protein + Trastuzumab + Polysaccharide-K'}]",Vaccine Therapy and Trastuzumab With or Without Polysaccharide-K in Treating Patients With Stage IV HER2 Positive Breast Cancer,7282
0,NCT02189343,Phase I,"Active, not recruiting","[{'id': 1614, 'therapyName': 'ACY-1215 + Pomalidomide + Dexamethasone'}]",Phase 1b Study Evaluating ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Dexamethasone in Relapsed-and-Refractory Multiple Myeloma,6817
1,NCT01997840,Phase Ib/II,"Active, not recruiting","[{'id': 1614, 'therapyName': 'ACY-1215 + Pomalidomide + Dexamethasone'}]",ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Low-dose Dex in Relapsed-and-Refractory Multiple Myeloma,6817
2,NCT02569320,Phase I,Suspended,"[{'id': 4299, 'therapyName': 'AR-42 + Dexamethasone + Pomalidomide'}]",HDAC Inhibitor AR-42 and Pomalidomide in Treating Patients With Relapsed Multiple Myeloma,6817
3,NCT01728259,Phase I,Suspended,"[{'id': 4501, 'therapyName': 'Bortezomib + Dexamethasone + Pomalidomide'}]","First-line Pomalidomide, Bortezomib, and Dexamethasone For AL Amyloidosis or LCDD",6817
4,NCT03104270,Phase II,Recruiting,"[{'id': 5555, 'therapyName': 'Carfilzomib + Elotuzumab + Dexamethasone + Pomalidomide'}]",Combination Study for High Risk Multiple Myeloma Patients,6817
5,NCT02807454,Phase Ib/II,"Active, not recruiting","[{'id': 4531, 'therapyName': 'Daratumumab + Dexamethasone + MEDI4736 + Pomalidomide'}, {'id': 4530, 'therapyName': 'Daratumumab + MEDI4736'}]",A Study to Determine the Safety and Efficacy for the Combination of Durvalumab and Daratumumab in Relapsed and Refractory Multiple Myeloma (FUSIONMM-003),6817
6,NCT03227432,Phase II,Not yet recruiting,"[{'id': 6118, 'therapyName': 'Dexamethasone + Elotuzumab + Nivolumab + Pomalidomide'}, {'id': 6117, 'therapyName': 'Elotuzumab + Nivolumab'}]",An Exploratory Study to Evaluate the Combination of Elotuzumab and Nivolumab With and Without Pomalidomide in Relapsed Refractory Multiple Myeloma,6817
7,NCT02289222,Phase Ib/II,"Active, not recruiting","[{'id': 3344, 'therapyName': 'Dexamethasone + Pembrolizumab + Pomalidomide'}]",Anti-PD-1 (MK-3475) and IMiD (Pomalidomide) Combination Immunotherapy in Relapsed/Refractory Multiple Myeloma,6817
8,NCT02726581,Phase III,"Active, not recruiting","[{'id': 3343, 'therapyName': 'Elotuzumab'}, {'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 3792, 'therapyName': 'Dexamethasone + Pomalidomide'}]","Study of Combinations of Nivolumab, Elotuzumab, Pomalidomide and Dexamethasone in Multiple Myeloma",6817
9,NCT02548962,Phase Ib/II,Recruiting,"[{'id': 768, 'therapyName': 'Ibrutinib'}, {'id': 3792, 'therapyName': 'Dexamethasone + Pomalidomide'}]",Study of Ibrutinib in Combination With Pomalidomide and Dexamethasone in Subjects With Relapsed/Refractory Multiple Myeloma,6817
10,NCT02654132,Phase II,"Active, not recruiting","[{'id': 3792, 'therapyName': 'Dexamethasone + Pomalidomide'}, {'id': 3343, 'therapyName': 'Elotuzumab'}]",Trial of Elotuzumab With or Without Pomalidomide and Low-dose Dexamethasone to Treat Refractory and Relapsed and Refractory Multiple Myeloma,6817
11,NCT02188368,Phase II,Recruiting,"[{'id': 1625, 'therapyName': 'Bortezomib + Carfilzomib + Clarithromycin'}, {'id': 1674, 'therapyName': 'Doxil + Pomalidomide'}, {'id': 1622, 'therapyName': 'Pomalidomide'}]",Pomalidomide for Lenalidomide for Failures,6817
12,NCT02612779,Phase II,"Active, not recruiting","[{'id': 3355, 'therapyName': 'Elotuzumab + Dexamethasone + Pomalidomide'}]",A Study of Elotuzumab in Combination With Pomalidomide and Low Dose Dexamethasone (EPd) in Patients With Multiple Myeloma Relapsed or Refractory to Prior Treatment With Lenalidomide,6817
13,NCT03030261,Phase II,Not yet recruiting,"[{'id': 1207, 'therapyName': 'Melphalan'}, {'id': 3355, 'therapyName': 'Elotuzumab + Dexamethasone + Pomalidomide'}]","Elotuzumab, Pomalidomide, & Dexamethasone (Elo-Pom-Dex) With Second Autologous Stem Cell Transplantation for Relapsed Multiple Myeloma",6817
14,NCT01734928,Phase III,"Active, not recruiting","[{'id': 1622, 'therapyName': 'Pomalidomide'}, {'id': 2470, 'therapyName': 'Bortezomib + Dexamethasone'}]","Safety and Efficacy of Pomalidomide, Bortezomib and Low-dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma",6817
15,NCT01998971,Phase I,Recruiting,"[{'id': 1622, 'therapyName': 'Pomalidomide'}, {'id': 2470, 'therapyName': 'Bortezomib + Dexamethasone'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1475, 'therapyName': 'Thalidomide'}, {'id': 1164, 'therapyName': 'lenalidomide'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 1630, 'therapyName': 'Daratumumab'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 1275, 'therapyName': 'Diphenhydramine'}, {'id': 3323, 'therapyName': 'Montelukast'}]",A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma,6817
16,NCT02576977,Phase III,Suspended,"[{'id': 1622, 'therapyName': 'Pomalidomide'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1390, 'therapyName': 'Dexamethasone'}]",Study of Pomalidomide and Low Dose Dexamethasone With or Without Pembrolizumab (MK-3475) in Refractory or Relapsed and Refractory Multiple Myeloma (rrMM) (MK-3475-183/KEYNOTE-183),6817
17,NCT02616640,Phase I,"Active, not recruiting","[{'id': 1622, 'therapyName': 'Pomalidomide'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 1356, 'therapyName': 'Durvalumab'}]",A Study to Determine Dose and Regimen of Durvalumab as Monotherapy or in Combination With Pomalidomide With or Without Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma,6817
18,NCT02400242,Phase I,"Active, not recruiting","[{'id': 3311, 'therapyName': 'Citarinostat'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 1622, 'therapyName': 'Pomalidomide'}]",Study of ACY-241 Alone and in Combination With Pomalidomide and Dexamethasone in Multiple Myeloma,6817
19,NCT02343042,Phase Ib/II,Recruiting,"[{'id': 688, 'therapyName': 'Bortezomib'}, {'id': 2479, 'therapyName': 'Dexamethasone + Selinexor'}, {'id': 1622, 'therapyName': 'Pomalidomide'}]",Phase 1b/2 Study of Selinexor (KPT-330) in Combination w/ Backbone Treatments for Resistant/Refractory Multiple Myeloma,6817
20,NCT01889420,Phase I,Terminated,"[{'id': 2312, 'therapyName': 'Pomalidomide + Everolimus + Dexamethasone'}]","Phase I Trial of Everolimus, Pomalidomide and Dexamethasone Patients With Relapsed/Refractory Multiple Myeloma",6817
21,NCT03143985,Phase I,Recruiting,"[{'id': 5875, 'therapyName': 'Pomalidomide + TEW 7197'}]",TEW-7197 in Combination w/ Pomalidomide in Relapsed or Relapsed and Refractory Multiple Myeloma,6817
0,NCT02829840,Phase Ib/II,Withdrawn,"[{'id': 4464, 'therapyName': 'Azacitidine + Ponatinib'}]","Dose-Escalation Study of Ponatinib, a FLT3 Inhibitor, With and Without Combination of 5-Azacytidine, in Patients With FLT3-Mutated Acute Myeloid Leukemia (AML)",6808
1,NCT03263572,Phase II,Not yet recruiting,"[{'id': 6155, 'therapyName': 'Blinatumomab + Cytarabine + Dexamethasone + Methotrexate + Ponatinib'}, {'id': 6156, 'therapyName': 'Blinatumomab + Dexamethasone + Ponatinib'}]",Blinatumomab and Ponatinib in Patients With Philadelphia Chromosome (Ph)-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL),6808
2,NCT01424982,Phase II,Recruiting,"[{'id': 1476, 'therapyName': 'Pegfilgrastim'}, {'id': 2048, 'therapyName': 'Cytarabine + Methotrexate + Ponatinib'}, {'id': 2049, 'therapyName': 'Ponatinib + Vincristine'}, {'id': 2046, 'therapyName': 'Cyclophosphamide + Dexamethasone + Doxorubicin + Vincristine '}, {'id': 1642, 'therapyName': 'Leucovorin'}]",Hyper-CVAD and Ponatinib in Ph-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL),6808
3,NCT02467270,Phase II,Recruiting,"[{'id': 877, 'therapyName': 'Ponatinib'}]",Ponatinib in Patients With Resistant Chronic Phase Chronic Myeloid Leukemia (CML) to Characterize the Efficacy and Safety of a Range of Doses,6808
4,NCT02779283,Phase I,Recruiting,"[{'id': 717, 'therapyName': 'Dasatinib'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 877, 'therapyName': 'Ponatinib'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 1606, 'therapyName': 'Cytarabine + Idarubicin'}, {'id': 930, 'therapyName': 'Sunitinib'}]",Personalized Kinase Inhibitor Therapy Combined With Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,6808
5,NCT01888562,Phase I,Withdrawn,"[{'id': 877, 'therapyName': 'Ponatinib'}]",Ponatinib in the Treatment of FGFR Mutation Positive Recurrent or Persistent Endometrial Carcinoma,6808
6,NCT01620216,Phase II,Recruiting,"[{'id': 930, 'therapyName': 'Sunitinib'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 877, 'therapyName': 'Ponatinib'}, {'id': 920, 'therapyName': 'Sorafenib'}]",Validation of an in Vitro Assay to Predict Targeted Therapies for Acute Leukemia Patients,6808
7,NCT01935336,Phase II,Recruiting,"[{'id': 877, 'therapyName': 'Ponatinib'}]",Study of Ponatinib in Patients With Lung Cancer Preselected Using Different Candidate Predictive Biomarkers,6808
8,NCT01813734,Phase II,Recruiting,"[{'id': 877, 'therapyName': 'Ponatinib'}]",Ponatinib in Advanced NSCLC w/ RET Translocations,6808
9,NCT01838642,Phase II,Terminated,"[{'id': 877, 'therapyName': 'Ponatinib'}]",Ponatinib for Advanced Medullary Thyroid Cancer,6808
10,NCT02272998,Phase II,Recruiting,"[{'id': 877, 'therapyName': 'Ponatinib'}]",Ponatinib Hydrochloride in Treating Patients With Refractory Metastatic Cancers and Genetic Alterations,6808
11,NCT01570868,Phase II,Terminated,"[{'id': 877, 'therapyName': 'Ponatinib'}]",Ponatinib - Frontline for Chronic Myeloid Leukemia (CML) in Accelerated Phase (AP),6808
12,NCT02265341,Phase II,"Active, not recruiting","[{'id': 877, 'therapyName': 'Ponatinib'}]",Ponatinib Hydrochloride in Treating Patients With Advanced Biliary Cancer With FGFR2 Fusions,6808
13,NCT03147612,Phase II,Not yet recruiting,"[{'id': 5682, 'therapyName': 'Mesna'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 877, 'therapyName': 'Ponatinib'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 712, 'therapyName': 'Cytarabine'}]",Study of the Combination of Low-Intensity Chemotherapy and Ponatinib in Patients With Philadelphia Chromosome (Ph)-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL),6808
14,NCT02551718,Phase I,Recruiting,"[{'id': 690, 'therapyName': 'Bosutinib'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 3160, 'therapyName': 'Nelarabine'}, {'id': 3159, 'therapyName': 'Bexarotene'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 998, 'therapyName': 'cabozantinib'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 877, 'therapyName': 'Ponatinib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 623, 'therapyName': 'Afatinib'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 890, 'therapyName': 'Regorafenib'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 2, 'therapyName': 'Trametinib'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 3, 'therapyName': 'Dabrafenib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 789, 'therapyName': 'Ceritinib'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1571, 'therapyName': 'Cabazitaxel'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1327, 'therapyName': 'Pralatrexate'}]",High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia,6808
15,NCT02478164,Phase II,"Active, not recruiting","[{'id': 877, 'therapyName': 'Ponatinib'}]",Trial of Ponatinib in Patients With Bevacizumab-Refractory Glioblastoma,6808
16,NCT01874665,Phase II,Completed,"[{'id': 877, 'therapyName': 'Ponatinib'}]",A Phase 2 Trial of Ponatinib in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor,6808
0,NCT02659514,Phase II,Recruiting,"[{'id': 1042, 'therapyName': 'poziotinib'}]",Study of Poziotinib in Patients With HER2-Positive Metastatic Breast Cancer,7161
1,NCT03066206,Phase II,Recruiting,"[{'id': 1042, 'therapyName': 'poziotinib'}]",Poziotinib in EGFR Exon 20 Mutant Advanced Non-Small Cell Lung Cancer (NSCLC),7161
0,NCT02483858,Phase I,Recruiting,"[{'id': 2019, 'therapyName': 'PQR309'}]",Study of Oral PQR309 in Patients With Advanced Solid Tumors,7385
1,NCT02249429,Phase Ib/II,Recruiting,"[{'id': 2019, 'therapyName': 'PQR309'}]","Open-Label, Non Randomized Phase 2 Study With Safety Run-In",7385
2,NCT02669511,Phase II,Recruiting,"[{'id': 2019, 'therapyName': 'PQR309'}]",PQR309 in Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma,7385
0,NCT03151304,Phase II,Recruiting,"[{'id': 5987, 'therapyName': 'Azacitidine + Pracinostat'}, {'id': 651, 'therapyName': 'Azacitidine'}]",A Safety and Efficacy Study of Pracinostat and Azacitidine in Patients With High Risk Myelodysplastic Syndromes,7332
1,NCT03151408,Phase III,Recruiting,"[{'id': 651, 'therapyName': 'Azacitidine'}, {'id': 5987, 'therapyName': 'Azacitidine + Pracinostat'}]",An Efficacy and Safety Study Of Pracinostat In Combination With Azacitidine In Adults With Acute Myeloid Leukemia,7332
2,NCT01993641,Phase II,Completed,"[{'id': 1758, 'therapyName': 'Pracinostat'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 650, 'therapyName': 'Decitabine'}]",Phase 2 Study Adding Pracinostat to a Hypomethylating Agent (HMA) in Patients With MDS Who Failed to Respond to Single Agent HMA,7332
0,NCT03161223,Phase Ib/II,Not yet recruiting,"[{'id': 5882, 'therapyName': 'Durvalumab + Romidepsin'}, {'id': 4178, 'therapyName': 'Azacitidine + MEDI4736'}, {'id': 5881, 'therapyName': 'Azacitidine + Durvalumab + Romidepsin'}, {'id': 5880, 'therapyName': 'Durvalumab + Pralatrexate + Romidepsin'}]","Durvalumab in Different Combinations With Pralatrexate, Romidepsin and Oral 5-Azacitidine for Lymphoma",7239
1,NCT01532011,Phase I,Completed,"[{'id': 1328, 'therapyName': 'Erlotinib + Pralatrexate'}]",Erlotinib in Combination With Pralatrexate in Advanced Malignancies,7239
2,NCT02551718,Phase I,Recruiting,"[{'id': 690, 'therapyName': 'Bosutinib'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 3160, 'therapyName': 'Nelarabine'}, {'id': 3159, 'therapyName': 'Bexarotene'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 998, 'therapyName': 'cabozantinib'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 877, 'therapyName': 'Ponatinib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 623, 'therapyName': 'Afatinib'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 890, 'therapyName': 'Regorafenib'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 2, 'therapyName': 'Trametinib'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 3, 'therapyName': 'Dabrafenib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 789, 'therapyName': 'Ceritinib'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1571, 'therapyName': 'Cabazitaxel'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1327, 'therapyName': 'Pralatrexate'}]",High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia,7239
0,NCT02849990,Phase II,Recruiting,"[{'id': 4510, 'therapyName': 'Abiraterone + ARN-509 + Degarelix + Indomethacin + Prednisone'}]","Androgen Receptor Antagonist ARN-509, Abiraterone Acetate, Prednisone, Degarelix, and Indomethacin in Treating Patients With Localized Prostate Cancer Before Surgery",625
1,NCT03009981,Phase III,Recruiting,"[{'id': 5523, 'therapyName': 'Abiraterone + ARN-509 + Degarelix + Prednisone'}, {'id': 5524, 'therapyName': 'ARN-509 + Degarelix'}, {'id': 1814, 'therapyName': 'Degarelix'}]",A Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer,625
2,NCT02913196,Phase I,Recruiting,"[{'id': 4767, 'therapyName': 'Abiraterone + ARN-509 + Docetaxel + Prednisone'}]","Phase I Trial of Apalutamide Plus Abiraterone Acetate, Docetaxel, and Prednisone in Patients With mCRPC",625
3,NCT03141671,Phase II,Not yet recruiting,"[{'id': 5742, 'therapyName': 'Bicalutamide + Gonadorelin'}, {'id': 5743, 'therapyName': 'Abiraterone + ARN-509 + Gonadorelin + Prednisone'}]",Randomized Phase II Study of Salvage XRT + ADT +/- Abiraterone and Apalutamide for Rising PSA After RP (FORMULA-509),625
4,NCT02903368,Phase II,Recruiting,"[{'id': 3079, 'therapyName': 'Abiraterone + Leuprolide + Prednisone'}, {'id': 4758, 'therapyName': 'Abiraterone + ARN-509 + Leuprolide + Prednisone'}]",Neoadjuvant And Adjuvant Abiraterone Acetate + Aptilutamide Prostate Cancer Undergoing Prostatectomy,625
5,NCT02703623,Phase II,Recruiting,"[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 2649, 'therapyName': 'Abiraterone + ARN-509 + Prednisone'}, {'id': 3844, 'therapyName': 'Cabazitaxel + Carboplatin'}]",A Dynamic Allocation Modular Sequential Trial of Approved and Promising Therapies in Men With Metastatic Castrate Resistant Prostate Cancer (DynaMO),625
6,NCT02123758,Phase I,"Active, not recruiting","[{'id': 2649, 'therapyName': 'Abiraterone + ARN-509 + Prednisone'}]",A Study of JNJ-56021927 (ARN-509) and Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer,625
7,NCT02531516,Phase III,Recruiting,"[{'id': 2649, 'therapyName': 'Abiraterone + ARN-509 + Prednisone'}, {'id': 1507, 'therapyName': 'Bicalutamide'}]",An Efficacy and Safety Study of JNJ-56021927 (ARN-509) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy,625
8,NCT03098836,Phase II,Recruiting,"[{'id': 2649, 'therapyName': 'Abiraterone + ARN-509 + Prednisone'}]",Apalutamide and Abiraterone Acetate in African American and Caucasian Men With Metastatic Castrate Resistant Prostate Cancer,625
9,NCT03279250,Phase II,Not yet recruiting,"[{'id': 759, 'therapyName': 'Goserelin'}, {'id': 2050, 'therapyName': 'Triptorelin'}, {'id': 2649, 'therapyName': 'Abiraterone + ARN-509 + Prednisone'}, {'id': 795, 'therapyName': 'Leuprolide'}, {'id': 1947, 'therapyName': 'ARN-509'}]",Effects of Apalutamide Plus LHRH Agonist or Apalutamide Plus Abiraterone Acetate Plus LHRH Agonist for Six Months for Prostate Cancer Patients at High Risk for Recurrence,625
10,NCT02949284,Phase II,Recruiting,"[{'id': 1947, 'therapyName': 'ARN-509'}, {'id': 2649, 'therapyName': 'Abiraterone + ARN-509 + Prednisone'}]","Androgen Receptor Antagonist ARN-509 With or Without Abiraterone Acetate, Gonadotropin-Releasing Hormone Analog, and Prednisone in Treating Patients With High-Risk Prostate Cancer Undergoing Surgery",625
11,NCT01741753,Phase I,Terminated,"[{'id': 2499, 'therapyName': 'Abiraterone + BKM120 + Prednisone'}]",BKM120+Abiraterone Acetate for Metastatic CRPC,625
12,NCT02903160,Phase II,Recruiting,"[{'id': 4759, 'therapyName': 'Abiraterone + Cabazitaxel + Carboplatin + Enzalutamide + Prednisone'}]","Prostate Cancer Intensive, Non-Cross Reactive Therapy (PRINT) for Castration Resistant Prostate Cancer (CRPC)",625
13,NCT02758132,Phase I,Terminated,"[{'id': 4182, 'therapyName': 'Abiraterone + Denosumab + Enzalutamide + Prednisone'}, {'id': 4183, 'therapyName': 'Denosumab + Enzalutamide'}]","Denosumab Plus Enzalutamide, Abiraterone and Prednisone Compared to Denosumab Plus Enzalutamide Alone for Men With Castrate Resistant Prostate Cancer (CRPC) With Bone Metastases",625
14,NCT02543255,Phase II,Recruiting,"[{'id': 1571, 'therapyName': 'Cabazitaxel'}, {'id': 3079, 'therapyName': 'Abiraterone + Leuprolide + Prednisone'}, {'id': 1476, 'therapyName': 'Pegfilgrastim'}]",Anti-Androgens and Cabazitaxel in Defining Complete Response in Prostatectomy (ACDC Trial),625
15,NCT02807805,Phase II,Recruiting,"[{'id': 4377, 'therapyName': 'Abiraterone + Niclosamide + Prednisone'}]","Abiraterone Acetate, Niclosamide, and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer",625
16,NCT03012321,Phase II,Recruiting,"[{'id': 5226, 'therapyName': 'Abiraterone + Prednisone + Olaparib'}, {'id': 2748, 'therapyName': 'Abiraterone + Prednisone'}, {'id': 837, 'therapyName': 'Olaparib'}]","Abiraterone Acetate, Olaparib, and Prednisone in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer With DNA Repair Defects",625
17,NCT01715285,Phase III,"Active, not recruiting","[{'id': 2748, 'therapyName': 'Abiraterone + Prednisone'}]","A Study of Abiraterone Acetate Plus Low-Dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Participants With High-Risk, Metastatic Hormone-Naive Prostate Cancer (mHNPC)",625
18,NCT01688492,Phase Ib/II,"Active, not recruiting","[{'id': 2748, 'therapyName': 'Abiraterone + Prednisone'}, {'id': 779, 'therapyName': 'Ipilimumab'}]",Combining Ipilimumab With Abiraterone Acetate Plus Prednisone in Chemotherapy and Immunotherapy-na&#239;ve Patients With Progressive Metastatic Castration-resistant Prostate Cancer,625
19,NCT01940276,Phase II,"Active, not recruiting","[{'id': 2748, 'therapyName': 'Abiraterone + Prednisone'}]",Abiraterone Race in Metastatic Castrate-resistant Prostate Cancer,625
20,NCT02218606,Phase II,Recruiting,"[{'id': 1571, 'therapyName': 'Cabazitaxel'}, {'id': 2748, 'therapyName': 'Abiraterone + Prednisone'}]",Multicenter Trial of Abiraterone Acetate With or Without Cabazitaxel in Treatment of Metastatic Castration Resistant Prostate Cancer,625
21,NCT02429193,Phase II,Recruiting,"[{'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 2748, 'therapyName': 'Abiraterone + Prednisone'}]",Biomarkers of Androgen Response and Resistance In Evolution During a Rising PSA (BARRIER-P),625
22,NCT03016741,FDA approved,Recruiting,"[{'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 2748, 'therapyName': 'Abiraterone + Prednisone'}]",Cognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate Cancer,625
23,NCT02626455,Phase III,Recruiting,"[{'id': 1631, 'therapyName': 'Vincristine'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 3388, 'therapyName': 'Aldoxorubicin +Cyclophosphamide + Prednisone + Rituximab + Vincristine'}, {'id': 995, 'therapyName': 'Copanlisib'}, {'id': 2323, 'therapyName': 'Bendamustine + Rituximab'}, {'id': 897, 'therapyName': 'Rituximab'}]",Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL),625
24,NCT01992653,Phase I,"Active, not recruiting","[{'id': 4248, 'therapyName': 'Cyclophosphamide + Doxorubicin + Prednisone'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 4226, 'therapyName': 'Polatuzumab Vedotin'}, {'id': 1646, 'therapyName': 'Obinutuzumab'}]","A Study of Polatuzumab Vedotin in Combination With Rituximab or Obinutuzumab, Cyclophosphamide, Doxorubicin, and Prednisone in Participants With B-Cell Non-Hodgkin's Lymphoma",625
25,NCT02531308,Phase II,Terminated,"[{'id': 1031, 'therapyName': 'Metformin'}, {'id': 3266, 'therapyName': 'Cyclophosphamide + Doxorubicin + Prednisone + Vincristine '}, {'id': 1476, 'therapyName': 'Pegfilgrastim'}, {'id': 897, 'therapyName': 'Rituximab'}]",Metformin in Combination With Standard Induction Therapy for Large B-cell Lymphoma (DLBCL),625
26,NCT01855750,Phase III,"Active, not recruiting","[{'id': 768, 'therapyName': 'Ibrutinib'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 3266, 'therapyName': 'Cyclophosphamide + Doxorubicin + Prednisone + Vincristine '}]","A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma",625
27,NCT01974440,Phase III,"Active, not recruiting","[{'id': 768, 'therapyName': 'Ibrutinib'}, {'id': 2323, 'therapyName': 'Bendamustine + Rituximab'}, {'id': 3266, 'therapyName': 'Cyclophosphamide + Doxorubicin + Prednisone + Vincristine '}]","A Study of PCI-32765 (Ibrutinib) in Combination With Either Bendamustine and Rituximab or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Participants With Previously Treated Indolent Non-Hodgkin Lymphoma",625
28,NCT02596971,Phase I,Recruiting,"[{'id': 1975, 'therapyName': 'Atezolizumab + Obinutuzumab'}, {'id': 3266, 'therapyName': 'Cyclophosphamide + Doxorubicin + Prednisone + Vincristine '}, {'id': 1231, 'therapyName': 'Bendamustine'}]",Safety and Efficacy of MPDL3280A in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus CHOP in Patients With Follicular Lymphoma or Diffuse Large B-Cell Lymphoma,625
29,NCT02055820,Phase I,"Active, not recruiting","[{'id': 1562, 'therapyName': 'Venetoclax'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 3266, 'therapyName': 'Cyclophosphamide + Doxorubicin + Prednisone + Vincristine '}, {'id': 1646, 'therapyName': 'Obinutuzumab'}]",A Safety and Pharmacokinetics Study of GDC-0199 (ABT-199) in Patients With Non-Hodgkin's Lymphoma,625
30,NCT02541565,Phase I,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 3266, 'therapyName': 'Cyclophosphamide + Doxorubicin + Prednisone + Vincristine '}, {'id': 897, 'therapyName': 'Rituximab'}]",Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Diffuse Large B-cell Lymphoma,625
31,NCT02343536,Phase I,Recruiting,"[{'id': 2488, 'therapyName': 'Cyclophosphamide + Prednisone + Rituximab + Vincristine'}, {'id': 651, 'therapyName': 'Azacitidine'}]","A Phase 1, Open-label,Trial of Oral Azacitidine (CC-486) Plus R-CHOP in Subjects With Large B-Cell Lymphoma or Follicular Lymphoma",625
32,NCT01925131,Phase I,Recruiting,"[{'id': 3221, 'therapyName': 'Cyclophosphamide + Prednisone + Vincristine'}, {'id': 3199, 'therapyName': 'inotuzumab ozogamicin'}]","S1312, Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Leukemia",625
33,NCT02518750,Phase II,Recruiting,"[{'id': 1604, 'therapyName': 'Panobinostat + Bortezomib + Dexamethasone'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 3160, 'therapyName': 'Nelarabine'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 3217, 'therapyName': 'Cyclophosphamide + Etoposide'}, {'id': 3216, 'therapyName': 'Cytarabine + Methotrexate + Prednisone'}, {'id': 1746, 'therapyName': 'Clofarabine'}]",Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoma,625
34,NCT02815059,Phase I,Recruiting,"[{'id': 4438, 'therapyName': 'Dasatinib + Ibrutinib + Prednisone'}]","Study of Pts With Philadelphia Chromosome-Pos ALL With Comb of Ibrutinib, Dasatinib, and Prednisone",625
35,NCT02861573,Phase I,Recruiting,"[{'id': 5343, 'therapyName': 'Dexamethasone + Docetaxel + Pembrolizumab + Prednisone'}, {'id': 5342, 'therapyName': 'Olaparib + Pembrolizumab'}, {'id': 2666, 'therapyName': 'Enzalutamide + Pembrolizumab'}]",Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365),625
36,NCT02685267,Phase II,"Active, not recruiting","[{'id': 4681, 'therapyName': 'Docetaxel + Enzalutamide + Prednisone'}, {'id': 2462, 'therapyName': 'Docetaxel + Prednisone'}]",Docetaxel/Prednisone Versus Docetaxel/Prednisone and Enzalutamide in Castration-Resistant Prostate Cancer (Doce/Enza),625
37,NCT02494921,Phase Ib/II,Recruiting,"[{'id': 3113, 'therapyName': 'Docetaxel + Filgrastim + Prednisone + Ribociclib'}]",LEE011 (Ribociclib) in Combination With Docetaxel Plus Prednisone in mCRPC,625
38,NCT01619813,Phase II,Completed,"[{'id': 2462, 'therapyName': 'Docetaxel + Prednisone'}, {'id': 893, 'therapyName': 'Reolysin'}]",Reolysin Combined With Docetaxel and Prednisone or Docetaxel and Prednisone Alone in Metastatic Castration Resistant Prostate Cancer,625
39,NCT02960022,Phase II,Recruiting,"[{'id': 5371, 'therapyName': 'Enzalutamide + Abiraterone + Prednisone'}, {'id': 1262, 'therapyName': 'Enzalutamide'}]",A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study,625
40,NCT00092222,Phase II,Recruiting,"[{'id': 917, 'therapyName': 'Sirolimus'}, {'id': 1187, 'therapyName': 'Alpha 2 Interferon'}, {'id': 2211, 'therapyName': 'EPOCH'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1008, 'therapyName': 'Doxil'}]",Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity,625
41,NCT00520130,Phase Ib/II,"Active, not recruiting","[{'id': 2294, 'therapyName': 'Cytarabine + Fludarabine'}, {'id': 2305, 'therapyName': 'Alemtuzumab + Cyclosporine'}, {'id': 2306, 'therapyName': 'Rituximab + Fludarabine + EPOCH'}, {'id': 2307, 'therapyName': 'Fludarabine + EPOCH'}, {'id': 2238, 'therapyName': 'Sirolimus + Tacrolimus + Methotrexate'}, {'id': 1632, 'therapyName': 'Filgrastim'}]",Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,625
42,NCT03223610,Phase I,Not yet recruiting,"[{'id': 6189, 'therapyName': 'Ibrutinib + Lenalidomide + Obinutuzumab + Prednisone + Venetoclax'}]","Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma",625
43,NCT03003520,Phase II,Recruiting,"[{'id': 5350, 'therapyName': 'MEDI4736 + R2-CHOP'}, {'id': 5349, 'therapyName': 'MEDI4736 + Rituximab + Doxorubicin + Vincristine + Cyclophosphamide + Prednisone'}]",A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma,625
44,NCT02420717,Phase II,Recruiting,"[{'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 3195, 'therapyName': 'Cytarabine + Methotrexate '}, {'id': 2046, 'therapyName': 'Cyclophosphamide + Dexamethasone + Doxorubicin + Vincristine '}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 3194, 'therapyName': 'Mercaptopurine + Methotrexate + Prednisone + Vincristine'}]",Ruxolitinib or Dasatinib With Chemotherapy in Patients With Philadelphia Chromosome (Ph)-Like Acute Lymphoblastic Leukemia (ALL),625
45,NCT03269669,Phase II,Recruiting,"[{'id': 6257, 'therapyName': 'Obinutuzumab + CHOP'}, {'id': 6302, 'therapyName': 'Lenalidomide + Obinutuzumab\t'}, {'id': 6301, 'therapyName': 'Obinutuzumab + TGR-1202'}, {'id': 2188, 'therapyName': 'Prednisone'}]","Obinutuzumab With or Without PI3K-delta Inhibitor TGR-1202, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma",625
46,NCT01614197,Phase I,Recruiting,"[{'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1639, 'therapyName': 'Methotrexate'}]",A Trial of Temsirolimus With Etoposide and Cyclophosphamide in Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkins Lymphoma,625
47,NCT01523977,Phase I,"Active, not recruiting","[{'id': 2188, 'therapyName': 'Prednisone'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1638, 'therapyName': 'Pegaspargase'}]",Everolimus With Multiagent Re-Induction Chemotherapy in Pediatric Patients With ALL,625
48,NCT02538926,Phase II,Not yet recruiting,"[{'id': 770, 'therapyName': 'Imatinib'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 3212, 'therapyName': 'Doxorubicin + Etoposide + Vincristine '}, {'id': 2206, 'therapyName': 'Asparaginase'}]","Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride With Asparaginase in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma",625
49,NCT02522715,Phase Ib/II,Recruiting,"[{'id': 3056, 'therapyName': 'Cabazitaxel + Enzalutamide'}, {'id': 2188, 'therapyName': 'Prednisone'}]","Enzalutamide and Cabazitaxel in Treating Patients With Metastatic, Hormone-Resistant Prostate Cancer",625
50,NCT00859781,Phase II,Recruiting,"[{'id': 2188, 'therapyName': 'Prednisone'}, {'id': 2858, 'therapyName': 'Ketoconazole'}]",177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu-J591) and Ketoconazole in Patients With Prostate Cancer,625
51,NCT01949337,Phase III,"Active, not recruiting","[{'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 1262, 'therapyName': 'Enzalutamide'}]",Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer,625
52,NCT02268175,Phase II,"Active, not recruiting","[{'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 795, 'therapyName': 'Leuprolide'}]",Enzalutamide/Leuprolide +/- Abiraterone/Pred in Prostate,625
53,NCT01576172,Phase II,"Active, not recruiting","[{'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 954, 'therapyName': 'Veliparib'}]",Abiraterone Acetate and Prednisone With or Without Veliparib in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer,625
54,NCT01848067,Phase Ib/II,"Active, not recruiting","[{'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 626, 'therapyName': 'Alisertib'}]","Alisertib, Abiraterone Acetate and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer",625
55,NCT01681433,Phase II,Terminated,"[{'id': 2188, 'therapyName': 'Prednisone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 1807, 'therapyName': 'OGX-427'}]",OGX-427 in Metastatic Castrate-Resistant Prostate Cancer With Prostate-Specific Antigen Progression While Receiving Abiraterone,625
56,NCT01717053,Phase II,"Active, not recruiting","[{'id': 795, 'therapyName': 'Leuprolide'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 759, 'therapyName': 'Goserelin'}]","Abiraterone, Radiotherapy and Short-Term Androgen Deprivation in Unfavorable Localized Prostate Cancer",625
57,NCT01998971,Phase I,Recruiting,"[{'id': 1622, 'therapyName': 'Pomalidomide'}, {'id': 2470, 'therapyName': 'Bortezomib + Dexamethasone'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1475, 'therapyName': 'Thalidomide'}, {'id': 1164, 'therapyName': 'lenalidomide'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 1630, 'therapyName': 'Daratumumab'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 1275, 'therapyName': 'Diphenhydramine'}, {'id': 3323, 'therapyName': 'Montelukast'}]",A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma,625
58,NCT03020030,Phase III,Recruiting,"[{'id': 3160, 'therapyName': 'Nelarabine'}, {'id': 5153, 'therapyName': 'dexrazoxane'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1642, 'therapyName': 'Leucovorin'}]",Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents,625
59,NCT03023046,Phase II,Recruiting,"[{'id': 897, 'therapyName': 'Rituximab'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 1631, 'therapyName': 'Vincristine'}]","Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma",625
60,NCT02419755,Phase II,Terminated,"[{'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 2188, 'therapyName': 'Prednisone'}]",Bortezomib and Vorinostat in Younger Patients With Refractory or Relapsed MLL Rearranged Hematologic Malignancies,625
61,NCT03150056,Phase I,Recruiting,"[{'id': 6034, 'therapyName': 'Abiraterone + GSK525762'}, {'id': 6035, 'therapyName': 'Enzalutamide + GSK525762'}, {'id': 2188, 'therapyName': 'Prednisone'}]",Dose Escalation and Dose Expansion Study of GSK525762 in Combination With Androgen Deprivation Therapy and Other Agents in Subjects With Castrate-resistant Prostate Cancer,625
62,NCT00084695,Phase II,Unknown status,"[{'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 2558, 'therapyName': 'Busulfan + Melphalan'}, {'id': 1844, 'therapyName': 'anti-thymocyte globulin'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 2188, 'therapyName': 'Prednisone'}]",Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases,625
63,NCT02636322,Phase II,Recruiting,"[{'id': 2482, 'therapyName': 'Cyclophosphamide + Doxorubicin + Etoposide + Vincristine '}, {'id': 1610, 'therapyName': 'Rituximab + Lenalidomide + Ibrutinib'}, {'id': 2188, 'therapyName': 'Prednisone'}]","A Study of Rituximab, Lenalidomide, and Ibrutinib Combined With Dose Adjusted Chemotherapy For Patients With High Risk Diffuse Large B-Cell Lymphoma",625
64,NCT01972217,Phase II,"Active, not recruiting","[{'id': 2188, 'therapyName': 'Prednisone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 837, 'therapyName': 'Olaparib'}]",Ph II Study to Evaluate Olaparib With Abiraterone in Treating Metastatic Castration Resistant Prostate Cancer,625
65,NCT02883049,Phase III,Suspended,"[{'id': 717, 'therapyName': 'Dasatinib'}, {'id': 4685, 'therapyName': 'Dexamethasone + Doxorubicin'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1746, 'therapyName': 'Clofarabine'}]",Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations,625
66,NCT02403505,Phase II,"Active, not recruiting","[{'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 1814, 'therapyName': 'Degarelix'}]",Discovery Stage Clinical Study About Oncology Drugs and Single Nucleotide Polymorphisms,625
67,NCT02723994,Phase II,Recruiting,"[{'id': 2188, 'therapyName': 'Prednisone'}, {'id': 4685, 'therapyName': 'Dexamethasone + Doxorubicin'}, {'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 2346, 'therapyName': 'Mercaptopurine + Thioguanine'}, {'id': 2394, 'therapyName': 'Asparaginase + Cytarabine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 1848, 'therapyName': 'Cyclophosphamide + Methotrexate + Vincristine + Pegaspargase '}]",A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia,625
68,NCT02496585,Phase II,Recruiting,"[{'id': 831, 'therapyName': 'Nintedanib'}, {'id': 2188, 'therapyName': 'Prednisone'}]",Study to Evaluate the Efficacy and Safety of Nintedanib (BIBF 1120) + Prednisone Taper in Patients With Radiation Pneumonitis,625
69,NCT02043678,Phase III,"Active, not recruiting","[{'id': 2188, 'therapyName': 'Prednisone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 2001, 'therapyName': 'radium Ra 223 dichloride'}]","Radium-223 Dichloride and Abiraterone Acetate Compared to Placebo and Abiraterone Acetate for Men With Cancer of the Prostate When Medical or Surgical Castration Does Not Work and When the Cancer Has Spread to the Bone, Has Not Been Treated With Chemotherapy and is Causing no or Only Mild Symptoms",625
70,NCT01786265,Phase II,"Active, not recruiting","[{'id': 759, 'therapyName': 'Goserelin'}, {'id': 1814, 'therapyName': 'Degarelix'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 795, 'therapyName': 'Leuprolide'}]",Finite Androgen Ablation vs. Finite Androgen Ablation in Combination With Abiraterone Acetate and Prednisone,625
71,NCT02535806,Phase II,Terminated,"[{'id': 1631, 'therapyName': 'Vincristine'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 2188, 'therapyName': 'Prednisone'}]",Four Drug Reinduction With Bortezomib for Relapsed or Refractory ALL or LL in Children and Young Adults,625
72,NCT01503229,Phase II,"Active, not recruiting","[{'id': 2188, 'therapyName': 'Prednisone'}, {'id': 1805, 'therapyName': 'Abiraterone'}]",Abiraterone Acetate in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer,625
73,NCT02034552,Phase II,"Active, not recruiting","[{'id': 2188, 'therapyName': 'Prednisone'}, {'id': 2001, 'therapyName': 'radium Ra 223 dichloride'}, {'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 1805, 'therapyName': 'Abiraterone'}]",A Randomized Phase IIa Efficacy and Safety Study of Radium-223 Dichloride With Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (CRPC),625
74,NCT02379390,Phase II,Terminated,"[{'id': 2188, 'therapyName': 'Prednisone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 1571, 'therapyName': 'Cabazitaxel'}]",Cabazitaxel Versus the Switch to Alternative AR Targeted Therapy Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Primary Resistant Patients to Abiraterone or Enz (PRIMCAB),625
75,NCT03117751,Phase II,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1876, 'therapyName': 'Blinatumomab '}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1638, 'therapyName': 'Pegaspargase'}]",Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma,625
76,NCT01553188,Phase II,"Active, not recruiting","[{'id': 2188, 'therapyName': 'Prednisone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 1218, 'therapyName': 'Trebananib'}]",AMG 386 and Abiraterone for Advanced Prostate Cancer,625
77,NCT03093272,Phase II,Recruiting,"[{'id': 795, 'therapyName': 'Leuprolide'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 5521, 'therapyName': 'ARN-509 + Docetaxel'}]",A Study of Docetaxel + ARN-509 in Castration-Resistant Prostate Cancer,625
78,NCT02490878,Phase II,Recruiting,"[{'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 667, 'therapyName': 'Bevacizumab'}]",Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases,625
79,NCT02356159,Phase Ib/II,Recruiting,"[{'id': 2294, 'therapyName': 'Cytarabine + Fludarabine'}, {'id': 2373, 'therapyName': 'Palifermin'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 2238, 'therapyName': 'Sirolimus + Tacrolimus + Methotrexate'}, {'id': 2292, 'therapyName': 'Doxorubicin + Etoposide + Fludarabine + Vincristine '}, {'id': 2291, 'therapyName': 'Cyclophosphamide + Fludarabine'}, {'id': 897, 'therapyName': 'Rituximab'}]",Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation,625
80,NCT01961843,Phase I,"Active, not recruiting","[{'id': 2188, 'therapyName': 'Prednisone'}, {'id': 1805, 'therapyName': 'Abiraterone'}]",Abiraterone Acetate for Castrate Resistant Prostate Cancer,625
81,NCT00536991,Phase Ib/II,Terminated,"[{'id': 2188, 'therapyName': 'Prednisone'}, {'id': 2889, 'therapyName': 'calcitriol'}, {'id': 2858, 'therapyName': 'Ketoconazole'}]","Calcitriol, Ketoconazole, and Hydrocortisone in Treating Patients With Advanced or Recurrent Prostate Cancer",625
82,NCT02337985,Phase I,Recruiting,"[{'id': 897, 'therapyName': 'Rituximab'}, {'id': 2482, 'therapyName': 'Cyclophosphamide + Doxorubicin + Etoposide + Vincristine '}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 2188, 'therapyName': 'Prednisone'}]",Gene Therapy and Combination Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin Lymphoma,625
83,NCT02605694,Phase II,Withdrawn,"[{'id': 3389, 'therapyName': 'Duvelisib + Rituximab'}, {'id': 2195, 'therapyName': 'R-CHOP'}]",Duvelisib With Rituximab vs R-CHOP in Subjects With Relapsed/Refractory Follicular Lymphoma (FRESCO),625
84,NCT01334502,Phase I,Completed,"[{'id': 735, 'therapyName': 'Everolimus'}, {'id': 2195, 'therapyName': 'R-CHOP'}]","Everolimus, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Untreated Diffuse Large B-Cell Lymphoma",625
85,NCT03263026,Phase III,Not yet recruiting,"[{'id': 2195, 'therapyName': 'R-CHOP'}, {'id': 1682, 'therapyName': 'Enzastaurin'}]",Study to Assess Enzastaurin + R-CHOP in Subjects With DLBCL With the Genomic Biomarker DGM1,625
86,NCT03274492,Phase III,Not yet recruiting,"[{'id': 4226, 'therapyName': 'Polatuzumab Vedotin'}, {'id': 6177, 'therapyName': 'R-CHP'}, {'id': 2195, 'therapyName': 'R-CHOP'}]","A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma",625
87,NCT03071276,Phase II,Recruiting,"[{'id': 5448, 'therapyName': 'Selinexor + Fludarabine phosphate + Cytarabine + Methotrexate + Prednisone'}]",Selinexor in Combination With Fludarabine and Cytarabine in Patients With Refractory or Relapsed Acute Myeloid Leukemia,625
88,NCT03036904,Phase I,Recruiting,"[{'id': 5294, 'therapyName': 'Venetoclax + DA-EPOCH-R'}]",Study of Venetoclax Plus DA-EPOCH-R for the Treatment of Aggressive B-Cell Lymphomas (V+DA-EPOCH-R),625
0,NCT03099161,Phase I,Recruiting,"[{'id': 5518, 'therapyName': 'Preladenant'}, {'id': 5519, 'therapyName': 'Pembrolizumab + Preladenant'}]",Study of Preladenant (MK-3814) Alone and With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3814A-062),8710
0,NCT02124148,Phase I,Recruiting,"[{'id': 1994, 'therapyName': 'Cisplatin + Prexasertib'}, {'id': 1993, 'therapyName': 'Cetuximab + Prexasertib'}, {'id': 6248, 'therapyName': 'Pemetrexed + Prexasertib'}, {'id': 6247, 'therapyName': 'LY3023414 + Prexasertib'}, {'id': 6246, 'therapyName': 'Fluoruracil + Leucovorin + Prexasertib'}]",A Study of LY2606368 With Cisplatin or Cetuximab in Participants With Advanced Cancer,7306
1,NCT02649764,Phase I,Recruiting,"[{'id': 3535, 'therapyName': 'Cytarabine + Fludarabine + Prexasertib'}]",LY2606368 in Combination With Cytarabine and Fludarabine in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HRMDS),7306
2,NCT03057145,Phase I,Recruiting,"[{'id': 5332, 'therapyName': 'Olaparib + Prexasertib'}]",Combination Study of Prexasertib and Olaparib in Patients With Advanced Solid Tumors,7306
3,NCT02735980,Phase II,Recruiting,"[{'id': 1651, 'therapyName': 'Prexasertib'}]",A Study of LY2606368 in Participants With Extensive Stage Disease Small Cell Lung Cancer,7306
4,NCT02873975,Phase II,Recruiting,"[{'id': 1651, 'therapyName': 'Prexasertib'}]",A Study of LY2606368 (Prexasertib) in Patients With Solid Tumors With Replicative Stress or Homologous Repair Deficiency,7306
5,NCT02203513,Phase II,Recruiting,"[{'id': 1651, 'therapyName': 'Prexasertib'}]","Chk1/2 Inhibitor (LY2606368) in Women With BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Non-High Risk Triple Negative Breast Cancer, and Grade Serous Ovarian Cancer at Low Genetic Risk",7306
6,NCT02555644,Phase I,Recruiting,"[{'id': 1651, 'therapyName': 'Prexasertib'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 694, 'therapyName': 'Cetuximab'}]",A Study of LY2606368 With Chemotherapy and Radiation in Participants With Head and Neck Cancer,7306
7,NCT02808650,Phase I,Recruiting,"[{'id': 1651, 'therapyName': 'Prexasertib'}]",Prexasertib in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors,7306
8,NCT02860780,Phase I,Completed,"[{'id': 4587, 'therapyName': 'Prexasertib + Ralimetinib'}]",A Study of Prexasertib (LY2606368) in Combination With Ralimetinib in Participants With Advanced or Metastatic Cancer,7306
0,NCT01606579,Phase Ib/II,Completed,"[{'id': 2466, 'therapyName': 'Cytarabine + Pri-724'}, {'id': 2465, 'therapyName': 'Dasatinib + Pri-724'}, {'id': 1083, 'therapyName': 'Pri-724'}]",Safety and Efficacy Study of PRI-724 in Subjects With Advanced Myeloid Malignancies,7199
1,NCT01764477,Phase I,Completed,"[{'id': 2566, 'therapyName': 'Gemcitabine + Pri-724'}]",Safety and Efficacy Study of PRI-724 Plus Gemcitabine in Subjects With Advanced or Metastatic Pancreatic Adenocarcinoma,7199
2,NCT02413853,Phase II,Withdrawn,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1083, 'therapyName': 'Pri-724'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}]",Combination Chemotherapy and Bevacizumab With or Without PRI-724 in Treating Patients With Newly Diagnosed Metastatic Colorectal Cancer,7199
3,NCT01302405,Phase I,Terminated,"[{'id': 1083, 'therapyName': 'Pri-724'}]",Safety and Efficacy Study of PRI-724 in Subjects With Advanced Solid Tumors,7199
0,NCT02608125,Phase I,Recruiting,"[{'id': 3583, 'therapyName': 'PRN1371'}]",A Dose Escalation and Dose Expansion Study of PRN1371 in Adult Patients With Advanced Solid Tumors,8148
0,NCT01875250,Phase II,"Active, not recruiting","[{'id': 4884, 'therapyName': 'Enzalutamide + PROSTVAC-F/TRICOM + PROSTVAC-V/TRICOM'}]",Enzalutamide in Combination With PSA-TRICOM in Patients With Non-Metastatic Castration Sensitive Prostate Cancer,7924
1,NCT01867333,Phase II,"Active, not recruiting","[{'id': 3069, 'therapyName': 'PROSTVAC-F/TRICOM '}, {'id': 1262, 'therapyName': 'Enzalutamide'}]",Enzalutamide With or Without Vaccine Therapy for Advanced Prostate Cancer,7924
2,NCT02506114,Phase II,Recruiting,"[{'id': 4892, 'therapyName': 'PROSTVAC-V/F'}, {'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 4895, 'therapyName': 'PROSTVAC-V/F + Ipilimumab'}]",Neoadjuvant PROSTVAC-VF With or Without Ipilimumab for Prostate Cancer,7924
3,NCT02933255,Phase Ib/II,Recruiting,"[{'id': 4895, 'therapyName': 'PROSTVAC-V/F + Ipilimumab'}, {'id': 4893, 'therapyName': 'PROSTVAC-V/F + Nivolumab + Ipilimumab'}, {'id': 4894, 'therapyName': 'PROSTVAC-V/F + Nivolumab'}]",PROSTVAC in Combination With Nivolumab and/or Ipilimumab in Men With Prostate Cancer,7924
0,NCT01875250,Phase II,"Active, not recruiting","[{'id': 4884, 'therapyName': 'Enzalutamide + PROSTVAC-F/TRICOM + PROSTVAC-V/TRICOM'}]",Enzalutamide in Combination With PSA-TRICOM in Patients With Non-Metastatic Castration Sensitive Prostate Cancer,8567
1,NCT02506114,Phase II,Recruiting,"[{'id': 4892, 'therapyName': 'PROSTVAC-V/F'}, {'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 4895, 'therapyName': 'PROSTVAC-V/F + Ipilimumab'}]",Neoadjuvant PROSTVAC-VF With or Without Ipilimumab for Prostate Cancer,8567
2,NCT02933255,Phase Ib/II,Recruiting,"[{'id': 4895, 'therapyName': 'PROSTVAC-V/F + Ipilimumab'}, {'id': 4893, 'therapyName': 'PROSTVAC-V/F + Nivolumab + Ipilimumab'}, {'id': 4894, 'therapyName': 'PROSTVAC-V/F + Nivolumab'}]",PROSTVAC in Combination With Nivolumab and/or Ipilimumab in Men With Prostate Cancer,8567
0,NCT02974738,Phase I,Recruiting,"[{'id': 5820, 'therapyName': 'PT 2977'}]",A Trial of PT2977 Tablets In Patients With Advanced Solid Tumors,8814
0,NCT02266745,Phase I,Recruiting,"[{'id': 2920, 'therapyName': 'PT-112'}]",A Phase 1 Study of PT-112 Injection in Subjects With Advanced Solid Tumors,7843
0,NCT03108066,Phase II,"Active, not recruiting","[{'id': 4146, 'therapyName': 'PT2385'}]",PT2385 for the Treatment of Von Hippel-Lindau Disease-Associated Clear Cell Renal Cell Carcinoma,8365
1,NCT02293980,Phase I,"Active, not recruiting","[{'id': 4146, 'therapyName': 'PT2385'}, {'id': 4347, 'therapyName': 'PT2385 + Nivolumab'}]","A Phase 1, Dose-Escalation Trial of PT2385 Tablets In Patients With Advanced Clear Cell Renal Cell Carcinoma",8365
2,NCT03216499,Phase II,Recruiting,"[{'id': 4146, 'therapyName': 'PT2385'}]",HIF-2 Alpha Inhibitor PT2385 in Treating Patients With Recurrent Glioblastoma,8365
0,NCT03206645,Phase I,Recruiting,"[{'id': 6266, 'therapyName': 'Carboplatin + Paclitaxel + PTC596'}]",PTC-596 in Women With Ovarian Cancer Receiving Neoadjuvant Chemotherapy,8679
1,NCT02404480,Phase I,Unknown status,"[{'id': 5407, 'therapyName': 'PTC596'}]",PTC596 in Patients With Advanced Solid Tumors,8679
0,NCT02411786,Phase I,Recruiting,"[{'id': 4297, 'therapyName': 'pTVG-AR '}, {'id': 1873, 'therapyName': 'Sargramostim'}]",A Phase I Study of a DNA Vaccine Encoding Androgen Receptor Ligand-Binding Domain (AR LBD) +/-GMCSF,8402
0,NCT01706458,Phase II,"Active, not recruiting","[{'id': 2698, 'therapyName': 'pTVG-HP plasmid DNA vaccine'}, {'id': 2648, 'therapyName': 'Sipuleucel-T'}]",Provenge With or Without pTVG-HP DNA Booster Vaccine in Prostate Cancer,7661
0,NCT01393509,Phase I,"Active, not recruiting","[{'id': 1162, 'therapyName': 'PU-H71'}]",The First-in-human Phase I Trial of PU-H71 in Patients With Advanced Malignancies,7211
1,NCT01581541,Phase I,Terminated,"[{'id': 1162, 'therapyName': 'PU-H71'}]", PU-H71 in Patients With Solid Tumors and Low-Grade Non-Hodgkin s Lymphoma That Have Not Responded to Standard Treatment,7211
2,NCT03166085,Phase I,Recruiting,"[{'id': 5796, 'therapyName': 'PU-H71 + nab-paclitaxel'}]",PU-H71 With Nab-paclitaxel (Abraxane) in Metastatic Breast Cancer,7211
0,NCT02826434,Phase I,Recruiting,"[{'id': 4466, 'therapyName': 'MEDI4736 + PVX-410 + poly ICLC '}]",Adjuvant PVX-410 Vaccine and Durvalumab in Stage II/III Triple Negative Breast Cancer,8461
1,NCT02700841,Phase II,Recruiting,"[{'id': 5344, 'therapyName': 'Melphalan + PVX-410'}]",Enhancing Anti-Myeloma Vaccine Response After Autologous Stem Cell Transplantation,8461
2,NCT02886065,Phase I,Recruiting,"[{'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 5082, 'therapyName': 'PVX-410 + MEDI4736'}, {'id': 5081, 'therapyName': 'PVX-410 + MEDI4736 + lenalidomide'}]","A Phase 1b Study of PVX-410, a Multi-Peptide Cancer Vaccine, and Durvalumab (Anti-PDL1) With and Without Lenalidomide for Patients With Smoldering Multiple Myeloma",8461
0,NCT02500199,Phase I,Recruiting,"[{'id': 3082, 'therapyName': 'Pyrotinib'}]",Open Label Oral Use of Pyrotinib in Patients With HER2 Positive Solid Tumors Who Failed Prior HER2 Targeted Therapy,7931
0,NCT02680184,Phase I,Recruiting,"[{'id': 4001, 'therapyName': 'Pembrolizumab + QbG10'}]",Clinical Study of CMP-001 in Combination With Pembrolizumab,8320
1,NCT03084640,Phase Ib/II,Recruiting,"[{'id': 4001, 'therapyName': 'Pembrolizumab + QbG10'}]",Phase 1b Study Evaluating Alternative Routes of Administration of CMP-001 in Combination With Pembrolizumab in Subjects With Advanced Melanoma,8320
0,NCT01839955,Phase Ib/II,Completed,"[{'id': 1237, 'therapyName': 'Erlotinib + Quinacrine'}]",Erlotinib Hydrochloride and Quinacrine Dihydrochloride in Stage IIIB-IV Non-Small Cell Lung Cancer,1090
0,NCT02039726,Phase III,"Active, not recruiting","[{'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 3193, 'therapyName': 'Cytarabine + Fludarabine + Idarubicin'}, {'id': 1752, 'therapyName': 'Mitoxantrone + Etoposide + Cytarabine'}, {'id': 882, 'therapyName': 'Quizartinib'}]",An Open-label Study of Quizartinib Monotherapy vs. Salvage Chemotherapy in Acute Myeloid Leukemia (AML) Subjects,6997
1,NCT01892371,Phase Ib/II,Recruiting,"[{'id': 712, 'therapyName': 'Cytarabine'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 882, 'therapyName': 'Quizartinib'}]",AC220 With 5-Aza or Low Dose Cytarabine,6997
2,NCT02668653,Phase III,Recruiting,"[{'id': 3543, 'therapyName': 'Cytarabine + Daunorubicin + Idarubicin'}, {'id': 882, 'therapyName': 'Quizartinib'}]",Quizartinib With Standard of Care Chemotherapy and as Maintenance Therapy in Patients With Newly Diagnosed FLT3-ITD (+) AML,6997
0,NCT02719015,Phase Ib/II,Not yet recruiting,"[{'id': 3943, 'therapyName': 'Pembrolizumab + rAd.CD40L'}]",Dose Escalation and Cohort Expansion of Safety and Tolerability Study of Intratumoral rAd.CD40L (ISF35) in Combination of Systemic Pembrolizumab in Patients With Refractory Metastatic Melanoma,8305
0,NCT01574729,Phase II,Unknown status,"[{'id': 1680, 'therapyName': 'rAD-p53'}]",Surgery Combined With rAd-p53 Gene in Treatment Advanced Non-small-cell Carcinoma,7314
0,NCT02814669,Phase I,Recruiting,"[{'id': 4881, 'therapyName': 'Atezolizumab + Ra 223'}]",Safety and Tolerability of Atezolizumab (ATZ) in Combination With Radium-223 Dichloride (R-223-D) in Metastatic Castrate-Resistant Prostate Cancer (CRPC) Progressed Following Treatment With an Androgen Pathway Inhibitor,7374
1,NCT03208712,Phase I,Not yet recruiting,"[{'id': 4881, 'therapyName': 'Atezolizumab + Ra 223'}]",Radium-223 and Atezolizumab in Patients With Urothelial Carcinoma With Bone Metastases Who Have Had Disease Progression After Platinum-Based Chemotherapy,7374
2,NCT02582749,Phase II,Recruiting,"[{'id': 4618, 'therapyName': 'Bicalutamide + Ra 223'}, {'id': 1507, 'therapyName': 'Bicalutamide'}]",Androgen Deprivation Therapy +/- Radium-223 Dichloride in Metastatic Prostate Cancer With Bone Metastases,7374
3,NCT02928029,Phase Ib/II,Recruiting,"[{'id': 6161, 'therapyName': 'Bortezomib + Dexamethasone + radium Ra 223 dichloride'}]",Study Testing Radium-223 Dichloride in Relapsed Multiple Myeloma,7374
4,NCT03076203,Phase I,Recruiting,"[{'id': 5436, 'therapyName': 'Niraparib + radium Ra 223 dichloride'}]",Radium Ra 223 Dichloride and Niraparib in Treating Patients With Hormone- Resistant Prostate Cancer Metastatic to the Bone,7374
5,NCT03093428,Phase II,Recruiting,"[{'id': 5542, 'therapyName': 'Pembrolizumab + Ra 223'}, {'id': 2001, 'therapyName': 'radium Ra 223 dichloride'}]",Study Evaluating the Addition of Pembrolizumab to Radium-223 in mCRPC,7374
6,NCT02366130,Phase II,Recruiting,"[{'id': 2001, 'therapyName': 'radium Ra 223 dichloride'}, {'id': 1198, 'therapyName': 'Denosumab'}]",Phase II Trial of Ra-223 Dichloride and Hormonal Treatment,7374
7,NCT02406521,Phase I,"Active, not recruiting","[{'id': 848, 'therapyName': 'Pazopanib'}, {'id': 2001, 'therapyName': 'radium Ra 223 dichloride'}, {'id': 920, 'therapyName': 'Sorafenib'}]",Exploratory Study of Radium-223 and Vascular Endothelial Growth Factor-Targeted Therapy in Patients With Metastatic Renal Cell Carcinoma and Bone Metastases,7374
8,NCT02463799,Phase II,Recruiting,"[{'id': 2001, 'therapyName': 'radium Ra 223 dichloride'}, {'id': 2648, 'therapyName': 'Sipuleucel-T'}]",Ph 2 Study of Sipuleucel-T W/ or W/O Radium-223 in Men With Asymptomatic or Minimally Symptomatic Bone-MCRPC,7374
9,NCT02396368,Phase I,Withdrawn,"[{'id': 2699, 'therapyName': 'Tasquinimod'}, {'id': 2001, 'therapyName': 'radium Ra 223 dichloride'}]",A Study of Radium-223 in Combination With Tasquinimod in Bone-only Metastatic Castration-Resistant Prostate Cancer,7374
10,NCT02605356,Phase Ib/II,Withdrawn,"[{'id': 2001, 'therapyName': 'radium Ra 223 dichloride'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1390, 'therapyName': 'Dexamethasone'}]",Phase 1b/2 Study Testing Radium-223 Dichloride/Bortezomib/Dexamethasone Combination in Relapsed Multiple Myeloma,7374
11,NCT02034552,Phase II,"Active, not recruiting","[{'id': 2188, 'therapyName': 'Prednisone'}, {'id': 2001, 'therapyName': 'radium Ra 223 dichloride'}, {'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 1805, 'therapyName': 'Abiraterone'}]",A Randomized Phase IIa Efficacy and Safety Study of Radium-223 Dichloride With Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (CRPC),7374
12,NCT02258464,Phase II,Recruiting,"[{'id': 2001, 'therapyName': 'radium Ra 223 dichloride'}]",Study of Radium-223 Dichloride Versus Placebo and Hormonal Treatment as Background Therapy in Subjects With Bone Predominant HER2 (Human Epidermal Growth Factor Receptor 2) Negative Hormone Receptor Positive Metastatic Breast Cancer,7374
13,NCT02258451,Phase II,Recruiting,"[{'id': 1966, 'therapyName': 'Exemestane + Everolimus'}, {'id': 2001, 'therapyName': 'radium Ra 223 dichloride'}]",Study of Radium-223 Dichloride Versus Placebo and Treatment With Exemestane / Everolimus in Subjects With Bone Predominant HER2 (Human Epidermal Growth Factor Receptor 2) Negative Hormone Receptor Positive Metastatic Breast Cancer,7374
14,NCT02043678,Phase III,"Active, not recruiting","[{'id': 2188, 'therapyName': 'Prednisone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 2001, 'therapyName': 'radium Ra 223 dichloride'}]","Radium-223 Dichloride and Abiraterone Acetate Compared to Placebo and Abiraterone Acetate for Men With Cancer of the Prostate When Medical or Surgical Castration Does Not Work and When the Cancer Has Spread to the Bone, Has Not Been Treated With Chemotherapy and is Causing no or Only Mild Symptoms",7374
15,NCT02507570,Phase II,"Active, not recruiting","[{'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 2001, 'therapyName': 'radium Ra 223 dichloride'}]",Open Label Phase Two Study of Enzalutamide With Concurrent Administration of Radium Ra 223 Dichloride in Castration-Resistant (Hormone-Refractory) Prostate Cancer Subjects With Symptomatic Bone Metastasis,7374
0,NCT02860780,Phase I,Completed,"[{'id': 4587, 'therapyName': 'Prexasertib + Ralimetinib'}]",A Study of Prexasertib (LY2606368) in Combination With Ralimetinib in Participants With Advanced or Metastatic Cancer,8018
1,NCT01663857,Phase Ib/II,"Active, not recruiting","[{'id': 3296, 'therapyName': 'Ralimetinib'}, {'id': 2667, 'therapyName': 'Carboplatin + Gemcitabine'}]",A Study of LY2228820 for Recurrent Ovarian Cancer,8018
0,NCT03147196,Phase II,Recruiting,"[{'id': 5686, 'therapyName': 'Raloxifene + Bicalutamide'}, {'id': 5685, 'therapyName': 'Raloxifene'}, {'id': 1507, 'therapyName': 'Bicalutamide'}]",Bicalutamide and Raloxifene Hydrochloride in Treating Patients With Prostate Cancer Undergoing Surgery,473
0,NCT02745769,Phase I,Recruiting,"[{'id': 4208, 'therapyName': 'LY2801653 + Ramucirumab'}, {'id': 4209, 'therapyName': 'Abemaciclib + Ramucirumab'}]",A Study in Advanced Cancers Using Ramucirumab (LY3009806) and Other Targeted Agents,7001
1,NCT02317991,Phase II,Recruiting,"[{'id': 2039, 'therapyName': 'Abraxane + Ramucirumab'}]",Study of Nab-Paclitaxel and Ramucirumab as Second-line Treatment for Patients With Metastatic Gastroesophageal Cancer,7001
2,NCT02730247,Phase II,Recruiting,"[{'id': 2039, 'therapyName': 'Abraxane + Ramucirumab'}]",Clinical Trial of the Safety and Efficacy of the Addition of Ramucirumab to Nab-paclitaxel in Previously Treated Patients With Advanced Non-small Cell Lung Cancer (NSCLC),7001
3,NCT03193918,Phase I,Recruiting,"[{'id': 5943, 'therapyName': 'Crenolanib + Paclitaxel + Ramucirumab'}]",Study of Crenolanib With Ramucirumab and Paclitaxel for Advanced Esophagogastric Adenocarcinoma,7001
4,NCT02082210,Phase Ib/II,"Active, not recruiting","[{'id': 1387, 'therapyName': 'Emibetuzumab + Ramucirumab'}]",A Study of LY2875358 in Combination With Ramucirumab (LY3009806) in Participants With Advanced Cancer,7001
5,NCT01079780,Phase II,Unknown status,"[{'id': 1920, 'therapyName': 'Irinotecan + Cetuximab + Ramucirumab'}, {'id': 1874, 'therapyName': 'Cetuximab + Irinotecan'}]",Irinotecan Hydrochloride and Cetuximab With or Without Ramucirumab in Treating Patients With Advanced Colorectal Cancer With Progressive Disease After Treatment With Bevacizumab-Containing Chemotherapy,7001
6,NCT03141034,Phase II,Not yet recruiting,"[{'id': 5633, 'therapyName': 'Irinotecan + Ramucirumab'}]",Ramucirumab Plus Irinotecan for Previously Treated Advanced Gastric or Gastro-esophageal Junction Adenocarcinoma,7001
7,NCT02791334,Phase I,Recruiting,"[{'id': 4370, 'therapyName': 'LY3300054 + Necitumumab'}, {'id': 4369, 'therapyName': 'LY3300054 + Ramucirumab'}, {'id': 4368, 'therapyName': 'LY3300054'}]",A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors  (PACT),7001
8,NCT02572687,Phase I,Recruiting,"[{'id': 3257, 'therapyName': 'MEDI4736 + Ramucirumab'}]",A Study of Ramucirumab (LY3009806) Plus MEDI4736 in Participants With Advanced Gastrointestinal or Thoracic Malignancies,7001
9,NCT02795858,Phase II,Recruiting,"[{'id': 4266, 'therapyName': 'Octreotide + Ramucirumab'}]","A Phase II Study of Ramucirumab With Somatostatin Analog Therapy in Patients With Advanced, Progressive Carcinoid Tumors",7001
10,NCT03008278,Phase Ib/II,Not yet recruiting,"[{'id': 5165, 'therapyName': 'Olaparib + Ramucirumab'}]",Olaparib and Ramucirumab in Treating Patients With Metastatic or Locally Recurrent Gastric or Gastroesophageal Junction Cancer That Cannot Be Removed by Surgery,7001
11,NCT02970539,Phase I,Recruiting,"[{'id': 5032, 'therapyName': 'Oraxol + Ramucirumab'}]","Ph1b Study of Oraxol in Comb. w. Ramucirumab in Patients w. Gastric, Gastro-esophageal, or Esophageal Cancers",7001
12,NCT02789345,Phase I,Recruiting,"[{'id': 4379, 'therapyName': 'Osimertinib + Ramucirumab'}, {'id': 4380, 'therapyName': 'Necitumumab + Osimertinib'}]",A Study of Ramucirumab (LY3009806) or Necitumumab (LY3012211) Plus Osimertinib in Participants With Lung Cancer,7001
13,NCT02443324,Phase I,"Active, not recruiting","[{'id': 2896, 'therapyName': 'Pembrolizumab + Ramucirumab'}]","A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC or Transitional Cell Carcinoma of the Urothelium",7001
14,NCT02426125,Phase III,"Active, not recruiting","[{'id': 886, 'therapyName': 'Ramucirumab'}, {'id': 720, 'therapyName': 'Docetaxel'}]",A Study of Ramucirumab (LY3009806) Plus Docetaxel in Participants With Urothelial Cancer,7001
15,NCT02514551,Phase II,"Active, not recruiting","[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 886, 'therapyName': 'Ramucirumab'}]",A Study of Ramucirumab (LY3009806) in Combination With Paclitaxel in Participants With Gastric Cancer,7001
16,NCT02597036,Phase I,"Active, not recruiting","[{'id': 3562, 'therapyName': 'LY3127804 '}, {'id': 886, 'therapyName': 'Ramucirumab'}]",A Study of LY3127804 With Ramucirumab in Participants With Advanced Solid Tumors,7001
17,NCT02314117,Phase III,"Active, not recruiting","[{'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 886, 'therapyName': 'Ramucirumab'}]",A Study of Ramucirumab (LY3009806) in Combination With Capecitabine and Cisplatin in Participants With Stomach Cancer,7001
18,NCT02079636,Phase I,Recruiting,"[{'id': 1069, 'therapyName': 'LY3023414'}, {'id': 802, 'therapyName': 'Abemaciclib'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 886, 'therapyName': 'Ramucirumab'}]",A Study of LY2835219 in Combination With Another Anti-cancer Drug in Participants With Lung Cancer (NSCLC),7001
19,NCT02411448,Phase III,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 886, 'therapyName': 'Ramucirumab'}]",A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Participants With EGFR Mutation-Positive Metastatic NSCLC,7001
20,NCT02564198,Phase I,Recruiting,"[{'id': 886, 'therapyName': 'Ramucirumab'}]",A Study of Ramucirumab (LY3009806) in Children With Refractory Solid Tumors,7001
21,NCT02711553,Phase II,"Active, not recruiting","[{'id': 886, 'therapyName': 'Ramucirumab'}, {'id': 1030, 'therapyName': 'LY2801653'}, {'id': 1467, 'therapyName': 'Gemcitabine + Cisplatin'}]",A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer,7001
22,NCT02443883,Phase II,"Active, not recruiting","[{'id': 886, 'therapyName': 'Ramucirumab'}]",A Phase 2 Study of Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Junction (GEJ) Cancer,7001
23,NCT02435433,Phase III,Recruiting,"[{'id': 886, 'therapyName': 'Ramucirumab'}]",A Study of Ramucirumab (LY3009806) Versus Placebo in Participants With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein (REACH-2),7001
24,NCT02581215,Phase II,Recruiting,"[{'id': 886, 'therapyName': 'Ramucirumab'}, {'id': 1903, 'therapyName': 'FOLFIRINOX'}]",Phase II Randomized Trial of FOLFIRINOX +/- Ramucirumab in Advanced Pancreatic Cancer,7001
25,NCT02065765,Phase II,No longer available,"[{'id': 886, 'therapyName': 'Ramucirumab'}]",International Expanded Access Program to Provide Ramucirumab for the Treatment of Metastatic Gastric Cancer,7001
26,NCT02520141,Phase II,Recruiting,"[{'id': 886, 'therapyName': 'Ramucirumab'}]",Ramucirumab for Advanced Pre-treated Biliary Cancers,7001
27,NCT02831491,Phase II,Withdrawn,"[{'id': 1423, 'therapyName': 'Ramucirumab + Docetaxel'}]",A Study of Ramucirumab (LY3009806) in Combination With Weekly Docetaxel in Participants With Stage IV Non-Small Cell Lung Cancer,7001
28,NCT03281369,Phase Ib/II,Not yet recruiting,"[{'id': 1343, 'therapyName': 'Atezolizumab + Cobimetinib'}, {'id': 6274, 'therapyName': 'mFOLFOX-6 + Atezolizumab + Cobimetinib'}, {'id': 6275, 'therapyName': 'mFOLFOX-6 + Atezolizumab'}, {'id': 6276, 'therapyName': 'Atezolizumab + Linagliptin'}, {'id': 5941, 'therapyName': 'Atezolizumab + PEGPH20'}, {'id': 5942, 'therapyName': 'Atezolizumab + BKT140'}, {'id': 1721, 'therapyName': 'Ramucirumab + Paclitaxel'}, {'id': 5850, 'therapyName': 'mFOLFOX-6'}]",A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) (UMBRELLA),7001
29,NCT02726399,Phase II,Recruiting,"[{'id': 3999, 'therapyName': 'Capecitabine + Cisplatin'}, {'id': 3998, 'therapyName': 'Ramucirumab + Trastuzumab'}]",Ramucirumab With Trastuzumab and Capecitabine/Cisplatin in Patients With Metastatic HER2-Positive Gastroesophageal Junction and Gastric Cancer,7001
0,NCT02824575,Phase I,Recruiting,"[{'id': 4433, 'therapyName': 'Paclitaxel + Rebastinib'}, {'id': 4434, 'therapyName': 'Eribulin + Rebastinib'}]",Rebastinib Plus Antitubulin Therapy With Paclitaxel or Eribulin in Metastatic Breast Cancer,7163
0,NCT02168777,Phase Ib/II,Terminated,"[{'id': 1424, 'therapyName': 'Regorafenib + Refametinib'}, {'id': 888, 'therapyName': 'Refametinib'}]","Refametinib (BAY86-9766) in Combination With Regorafenib (Stivarga, BAY73-4506) in Patients With Advanced or Metastatic Cancer",7003
1,NCT01915602,Phase II,Completed,"[{'id': 2221, 'therapyName': 'Refametinib + Sorafenib'}]",Refametinib in Combination With Sorafenib in RAS Mutant Hepatocellular Carcinoma (HCC),7003
0,NCT01727869,Phase I,Completed,"[{'id': 1246, 'therapyName': 'REGN1400 + Erlotinib'}, {'id': 1247, 'therapyName': 'REGN1400 + Cetuximab'}, {'id': 1072, 'therapyName': 'REGN1400'}]", Study of REGN1400 Alone and in Combination With Erlotinib or Cetuximab in Patients With Certain Types of Cancer,7189
0,NCT02651662,Phase I,Recruiting,"[{'id': 5656, 'therapyName': 'REGN2810'}, {'id': 6152, 'therapyName': 'REGN1979 + REGN2810'}]",Study of REGN2810 and REGN1979 in Patients With Lymphoma,8930
0,NCT02651662,Phase I,Recruiting,"[{'id': 5656, 'therapyName': 'REGN2810'}, {'id': 6152, 'therapyName': 'REGN1979 + REGN2810'}]",Study of REGN2810 and REGN1979 in Patients With Lymphoma,8735
1,NCT03132636,Phase II,Recruiting,"[{'id': 5656, 'therapyName': 'REGN2810'}]","PD-1 in Patients With Advanced Basal Cell Carcinoma Who Experienced Progression of Disease on Hedgehog Pathway Inhibitor Therapy, or Were Intolerant of Prior Hedgehog Pathway Inhibitor Therapy",8735
2,NCT03257267,Phase III,Recruiting,"[{'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1685, 'therapyName': 'Vinorelbine'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 5656, 'therapyName': 'REGN2810'}, {'id': 942, 'therapyName': 'Topotecan'}]",Study of REGN2810 in Adults With Cervical Cancer,8735
3,NCT02383212,Phase I,"Active, not recruiting","[{'id': 5722, 'therapyName': 'REGN2810 + Carboplatin + Docetaxel'}, {'id': 5721, 'therapyName': 'REGN2810 + Carboplatin + Pemetrexed'}, {'id': 5723, 'therapyName': 'REGN2810 + GM-CSF + Cyclophosphamide'}, {'id': 5718, 'therapyName': 'REGN2810 + Cyclophosphamide'}, {'id': 5656, 'therapyName': 'REGN2810'}, {'id': 5720, 'therapyName': 'REGN2810 + Carboplatin + Paclitaxel'}, {'id': 5719, 'therapyName': 'REGN2810 + Docetaxel'}]",Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies,8735
4,NCT02760498,Phase II,Recruiting,"[{'id': 5656, 'therapyName': 'REGN2810'}]",Study of REGN2810 in Patients With Advanced Cutaneous Squamous Cell Carcinoma,8735
5,NCT03194867,,Recruiting,"[{'id': 5656, 'therapyName': 'REGN2810'}]",Isatuximab in Combination With REGN2810 in Relapsed/Refractory Multiple Myeloma (RRMM) Patients,8735
6,NCT03005782,Phase I,Recruiting,"[{'id': 5736, 'therapyName': 'REGN3767 + REGN2810'}, {'id': 5735, 'therapyName': 'REGN3767'}]",Study of REGN3767 (Anti-LAG-3) With or Without REGN2810 (Anti-PD1) in Advanced Cancers,8735
7,NCT03192345,Phase I,Recruiting,"[{'id': 5934, 'therapyName': 'SAR439459 + REGN2810'}, {'id': 5933, 'therapyName': 'SAR439459'}]","A First-in-human Study of the Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of SAR439459 Monotherapy and Combination of SAR439459 and REGN2810 in Patients With Advanced Solid Tumors",8735
0,NCT03005782,Phase I,Recruiting,"[{'id': 5736, 'therapyName': 'REGN3767 + REGN2810'}, {'id': 5735, 'therapyName': 'REGN3767'}]",Study of REGN3767 (Anti-LAG-3) With or Without REGN2810 (Anti-PD1) in Advanced Cancers,8764
0,NCT01926587,Phase Ib/II,Recruiting,"[{'id': 2320, 'therapyName': 'Azacitidine + Regorafenib'}]",Oral Rigosertib in Combination With Azacitidine,6803
1,NCT02024607,Phase Ib/II,"Active, not recruiting","[{'id': 1597, 'therapyName': 'Capecitabine + Oxaliplatin'}, {'id': 2093, 'therapyName': 'BBI608 + Bevacizumab'}, {'id': 2094, 'therapyName': 'BBI608 + Regorafenib'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 2057, 'therapyName': 'BBI608'}, {'id': 1315, 'therapyName': 'FOLFIRI'}]",A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer,6803
2,NCT02368886,Phase II,"Active, not recruiting","[{'id': 2350, 'therapyName': 'Clobetasol + Regorafenib'}]",Lower or Standard Dose Regorafenib in Treating Patients With Refractory Metastatic Colorectal Cancer,6803
3,NCT03215264,Phase Ib/II,Not yet recruiting,"[{'id': 6052, 'therapyName': 'Entinostat + Hydroxychloroquine + Regorafenib'}]","Phase I/II Trial of Regorafenib, Hydroxychloroquine, and Entinostat in Metastatic Colorectal Cancer",6803
4,NCT02383433,Phase II,"Active, not recruiting","[{'id': 2491, 'therapyName': 'Gemcitabine + Regorafenib'}]",Regorafenib Plus Gemcitabine in Metastatic Pancreatic Cancer,6803
5,NCT03081494,Phase I,Recruiting,"[{'id': 5930, 'therapyName': 'PDR001 + Regorafenib'}]",Phase Ib Study of PDR001 in Combination With Regorafenib in Adult Patients With Previously Treated Metastatic Colorectal Cancer,6803
6,NCT02651415,Phase II,"Active, not recruiting","[{'id': 3410, 'therapyName': 'Perindopril + Regorafenib'}]",Phase II Study of Perindopril and Regorafenib in mCRC,6803
7,NCT02116894,Phase I,Completed,"[{'id': 2035, 'therapyName': 'PF-03446962 + Regorafenib'}]",Safety Study of Regorafenib With PF-03446962 to Treat Colorectal Cancer,6803
8,NCT02119676,Phase II,Terminated,"[{'id': 890, 'therapyName': 'Regorafenib'}, {'id': 907, 'therapyName': 'Ruxolitinib'}]",Study of Ruxolitinib in Colorectal Cancer Patients,6803
9,NCT02278783,Phase II,Terminated,"[{'id': 890, 'therapyName': 'Regorafenib'}]","Phase 2 Trial of Regorafenib in Patients With Recurrent Ovarian, Primary Peritoneal and Fallopian Tube Cancer",6803
10,NCT02080260,Phase II,"Active, not recruiting","[{'id': 890, 'therapyName': 'Regorafenib'}]",A Study of Regorafenib in Advanced Pancreatic Cancer Patients,6803
11,NCT02402036,Phase II,"Active, not recruiting","[{'id': 890, 'therapyName': 'Regorafenib'}]",A Biomarker Study in Patients Getting Regorafenib for Metastatic Colorectal Cancer,6803
12,NCT02023333,Phase II,Recruiting,"[{'id': 890, 'therapyName': 'Regorafenib'}]",Regorafenib in Good Performance Status Patients With Newly Diagnosed Metastatic Colorectal Adenocarcinoma,6803
13,NCT01896856,Phase Ib/II,Recruiting,"[{'id': 2015, 'therapyName': 'SGI-110 + Irinotecan'}, {'id': 890, 'therapyName': 'Regorafenib'}]",Phase I Study of SGI-110 With Irinotecan Followed by Randomized Phase II Study of SGI-110 With Irinotecan Versus Regorafenib in Previously Treated Metastatic Colorectal Cancer,6803
14,NCT02241720,Phase II,Terminated,"[{'id': 890, 'therapyName': 'Regorafenib'}]",Regorafenib Second Line Treatment of Metastatic or Advanced Upper GI Cancers,6803
15,NCT02551718,Phase I,Recruiting,"[{'id': 690, 'therapyName': 'Bosutinib'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 3160, 'therapyName': 'Nelarabine'}, {'id': 3159, 'therapyName': 'Bexarotene'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 998, 'therapyName': 'cabozantinib'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 877, 'therapyName': 'Ponatinib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 623, 'therapyName': 'Afatinib'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 890, 'therapyName': 'Regorafenib'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 2, 'therapyName': 'Trametinib'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 3, 'therapyName': 'Dabrafenib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 789, 'therapyName': 'Ceritinib'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1571, 'therapyName': 'Cabazitaxel'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1327, 'therapyName': 'Pralatrexate'}]",High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia,6803
16,NCT02664077,Phase III,Recruiting,"[{'id': 890, 'therapyName': 'Regorafenib'}]",A Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients With Colon Cancer (ARGO),6803
17,NCT02048722,Phase II,Recruiting,"[{'id': 890, 'therapyName': 'Regorafenib'}]","Daily Oral Regorafenib for Chemotherapy-Refractory, Metastatic and Locally Advanced Angiosarcoma",6803
18,NCT02459119,Phase II,Recruiting,"[{'id': 890, 'therapyName': 'Regorafenib'}]",Study of Regorafenib for Urothelial Cancer Following Chemotherapy (UAB 1477),6803
19,NCT02657551,Phase II,Recruiting,"[{'id': 890, 'therapyName': 'Regorafenib'}]",A Study Using Regorafenib as Second or Third Line Therapy in Metastatic Medullary Thyroid Cancer,6803
20,NCT02195011,Phase II,"Active, not recruiting","[{'id': 890, 'therapyName': 'Regorafenib'}]",Safety Study of Regorafenib and SIR-Spheres® Microspheres Radioembolization in Patients With Refractory Metastatic Colorectal Cancer With Liver Metastases,6803
21,NCT02425683,Phase II,"Active, not recruiting","[{'id': 890, 'therapyName': 'Regorafenib'}]",Study of Colorectal Cancer Patients (Stage IIIC) With Either Regorafenib or Standard of Care (No Treatment) After Adjuvant FOLFOX,6803
22,NCT02788279,Phase III,"Active, not recruiting","[{'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 1343, 'therapyName': 'Atezolizumab + Cobimetinib'}, {'id': 890, 'therapyName': 'Regorafenib'}]",A Study to Investigate Efficacy and Safety of Cobimetinib Plus Atezolizumab and Atezolizumab Monotherapy Versus Regorafenib in Participants With Metastatic Colorectal Adenocarcinoma,6803
23,NCT02439723,Phase I,Not yet recruiting,"[{'id': 890, 'therapyName': 'Regorafenib'}]",Effects of LBM and PPIs on Pharmacokinetics and Safety of Regorafenib (BAY 73-4506) in Cancer Patients,6803
24,NCT02098538,Phase II,"Active, not recruiting","[{'id': 890, 'therapyName': 'Regorafenib'}]","Regorafenib in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma",6803
25,NCT01538680,Phase III,No longer available,"[{'id': 890, 'therapyName': 'Regorafenib'}]",Regorafenib in Subjects With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy,6803
26,NCT01774344,Phase III,"Active, not recruiting","[{'id': 890, 'therapyName': 'Regorafenib'}]",Study of Regorafenib After Sorafenib in Patients With Hepatocellular Carcinoma (RESORCE),6803
27,NCT02466802,Phase I,Recruiting,"[{'id': 890, 'therapyName': 'Regorafenib'}, {'id': 3066, 'therapyName': 'Sildenafil'}]",Study of Regorafenib and Sildenafil for Advanced Solid Tumors,6803
28,NCT01939223,Phase III,Completed,"[{'id': 890, 'therapyName': 'Regorafenib'}]","COlorectal Cancer Treated With Adjuvant Regorafenib Versus Placebo After Curative Treatment of Liver Metastases in a Randomized, Double-blind, Placebo?Controlled Phase-III STudy (COAST)",6803
29,NCT02048371,Phase II,Recruiting,"[{'id': 890, 'therapyName': 'Regorafenib'}]","A Blanket Protocol to Study Oral Regorafenib in Patients With Refractory Liposarcoma, Osteogenic Sarcoma, and Ewing/Ewing-like Sarcomas",6803
30,NCT02581059,Phase II,Recruiting,"[{'id': 890, 'therapyName': 'Regorafenib'}]",Efficacy of Ginseng for Patients on Regorafenib,6803
31,NCT02693535,Phase II,Recruiting,"[{'id': 1657, 'therapyName': 'Vemurafenib + Cobimetinib'}, {'id': 890, 'therapyName': 'Regorafenib'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 690, 'therapyName': 'Bosutinib'}, {'id': 850, 'therapyName': 'Palbociclib'}, {'id': 694, 'therapyName': 'Cetuximab'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 837, 'therapyName': 'Olaparib'}, {'id': 4, 'therapyName': 'Erlotinib'}]",TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer,6803
32,NCT02259725,Phase II,Recruiting,"[{'id': 890, 'therapyName': 'Regorafenib'}]",Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors,6803
33,NCT03042689,Phase I,Not yet recruiting,"[{'id': 890, 'therapyName': 'Regorafenib'}]",Study of Regorafenib in Patients With Advanced Myeloid Malignancies,6803
34,NCT02234180,Phase II,Completed,"[{'id': 890, 'therapyName': 'Regorafenib'}]",Study of Adjuvant Regorafenib vs Placebo in Patients With Node Positive Esophageal Cancer That Completed Pre-operative Therapy,6803
35,NCT02287025,FDA approved,Terminated,"[{'id': 890, 'therapyName': 'Regorafenib'}]",A Phase 4 Study of Regorafenib in Metastatic Colorectal Cancer - Does Educating Physicians Change Patient Out Comes?,6803
36,NCT02287727,Phase II,Withdrawn,"[{'id': 890, 'therapyName': 'Regorafenib'}]",Regorafenib in Reducing Recurrence in Patients With Non-metastatic Rectal Cancer Who Have Completed Curative-Intent Treatment,6803
37,NCT02096354,Phase II,"Active, not recruiting","[{'id': 890, 'therapyName': 'Regorafenib'}]","A Phase 2 Randomized, Open-Label Study of RRx-001 vs Regorafenib in Subjects With Metastatic Colorectal Cancer",6803
38,NCT01949194,Phase II,Recruiting,"[{'id': 890, 'therapyName': 'Regorafenib'}]",Study to Determine the Efficacy of Regorafenib in Metastatic Colorectal Cancer Patients and to Discover Biomarkers,6803
39,NCT02053376,Phase II,"Active, not recruiting","[{'id': 890, 'therapyName': 'Regorafenib'}]",A Phase 2 Trial of Regorafenib as A Single Agent in Advanced and Metastatic Biliary Tract Carcinoma/Cholangiocarcinoma Patients Who Have Failed First-line Chemotherapy,6803
40,NCT01853046,Phase I,Completed,"[{'id': 890, 'therapyName': 'Regorafenib'}]",Pharmacokinetics and Safety of Regorafenib (BAY73-4506) in Cancer Subjects With Severe Renal Impairment,6803
41,NCT02115542,Phase II,Recruiting,"[{'id': 890, 'therapyName': 'Regorafenib'}]",Single Agent Regorafenib in Refractory Advanced Biliary Cancers,6803
42,NCT02164240,Phase I,"Active, not recruiting","[{'id': 930, 'therapyName': 'Sunitinib'}, {'id': 890, 'therapyName': 'Regorafenib'}]",Phase Ib Study of SUnitinib Alternating With REgorafenib in Patients With Metastatic and/or Unresectable GIST,6803
43,NCT02795156,Phase II,Recruiting,"[{'id': 623, 'therapyName': 'Afatinib'}, {'id': 890, 'therapyName': 'Regorafenib'}]",Study to Assess the Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations,6803
44,NCT02466009,Phase II,Recruiting,"[{'id': 890, 'therapyName': 'Regorafenib'}]",Regorafenib in Metastatic Colorectal Cancer,6803
45,NCT02316340,Phase II,Recruiting,"[{'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1316, 'therapyName': 'Hydroxychloroquine'}, {'id': 890, 'therapyName': 'Regorafenib'}]",Vorinostat Plus Hydroxychloroquine Versus Regorafenib in Colorectal Cancer,6803
46,NCT01298570,Phase II,"Active, not recruiting","[{'id': 1315, 'therapyName': 'FOLFIRI'}, {'id': 890, 'therapyName': 'Regorafenib'}]",Regorafenib+FOLFIRI Versus Placebo+FOLFIRI as 2nd Line Tx in Metastatic Colorectal Cancer,6803
47,NCT02095054,Phase I,"Active, not recruiting","[{'id': 1305, 'therapyName': 'Regorafenib + Cetuximab'}]",Regorafenib and Cetuximab in Patients With Advanced Malignancy,6803
48,NCT01973868,Phase I,"Active, not recruiting","[{'id': 1305, 'therapyName': 'Regorafenib + Cetuximab'}]",Safety and Pharmacokinetics of Regorafenib and Cetuximab in Combination,6803
49,NCT01913639,Phase II,"Active, not recruiting","[{'id': 2014, 'therapyName': 'Regorafenib + FOLFOX'}]",FOLFOX Plus Regorafenib in Patients With Unresectable or Metastatic Esophagogastric Cancer,6803
50,NCT02199223,Phase I,Terminated,"[{'id': 1617, 'therapyName': 'Regorafenib + Panitumumab'}]",Regorafenib + Panitumumab,6803
51,NCT02168777,Phase Ib/II,Terminated,"[{'id': 1424, 'therapyName': 'Regorafenib + Refametinib'}, {'id': 888, 'therapyName': 'Refametinib'}]","Refametinib (BAY86-9766) in Combination With Regorafenib (Stivarga, BAY73-4506) in Patients With Advanced or Metastatic Cancer",6803
0,NCT01274624,Phase I,"Active, not recruiting","[{'id': 1315, 'therapyName': 'FOLFIRI'}, {'id': 2099, 'therapyName': 'Bevacizumab + Reolysin'}]",Study of REOLYSIN; in Combination With FOLFIRI and Bevacizumab in FOLFIRI Naive Patients With KRAS Mutant Metastatic Colorectal Cancer,7005
1,NCT02514382,Phase I,Recruiting,"[{'id': 3432, 'therapyName': 'Bortezomib + Dexamethasone + Reolysin'}]","Wild-Type Reovirus, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma",7005
2,NCT02101944,Phase I,Recruiting,"[{'id': 2463, 'therapyName': 'Carfilzomib + Dexamethasone + Reolysin'}]","Viral Protein Production After Dexamethasone, Wild-Type Reovirus, and Carfilzomib in Treating Patients With Multiple Myeloma",7005
3,NCT01656538,Phase II,"Active, not recruiting","[{'id': 893, 'therapyName': 'Reolysin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]",A Study of Reolysin For Patients With Advanced/Metastatic Breast Cancer,7005
4,NCT02620423,Phase I,"Active, not recruiting","[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 893, 'therapyName': 'Reolysin'}, {'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Study of Pembrolizumab With REOLYSIN and Chemotherapy in Patients With Advanced Pancreatic Adenocarcinoma,7005
5,NCT01619813,Phase II,Completed,"[{'id': 2462, 'therapyName': 'Docetaxel + Prednisone'}, {'id': 893, 'therapyName': 'Reolysin'}]",Reolysin Combined With Docetaxel and Prednisone or Docetaxel and Prednisone Alone in Metastatic Castration Resistant Prostate Cancer,7005
6,NCT01622543,Phase II,"Active, not recruiting","[{'id': 1484, 'therapyName': 'Bevacizumab + Oxaliplatin + Leucovorin + Fluorouracil'}, {'id': 893, 'therapyName': 'Reolysin'}]",Reolysin in Combination With FOLFOX6 and Bevacizumab or FOLFOX6 and Bevacizumab Alone in Metastatic Colorectal Cancer,7005
7,NCT01708993,Phase II,Completed,"[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 1110, 'therapyName': 'Reolysin + Pemetrexed'}, {'id': 1111, 'therapyName': 'Reolysin + Docetaxel'}]"," Reolysin in Patients With Previously Treated Advanced or Metastatic, Non Small Cell Lung Cancer Receiving Standard Salvage Therapy",7005
0,NCT02370238,Phase II,Recruiting,"[{'id': 2930, 'therapyName': 'Reparixin'}]",A Double-blind Study of Paclitaxel in Combination With Reparixin or Placebo for Metastatic Triple-Negative Breast Cancer,7848
0,NCT02159066,Phase II,"Active, not recruiting","[{'id': 1101, 'therapyName': 'Binimetinib + Encorafenib + Ribociclib'}, {'id': 1100, 'therapyName': 'Binimetinib + Encorafenib'}, {'id': 2216, 'therapyName': 'LGX818 + MEK162 + INC280'}, {'id': 2215, 'therapyName': 'LGX818 + MEK162 + BKM120'}, {'id': 2214, 'therapyName': 'LGX818 + MEK162 + BGJ398'}]","LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma",6826
1,NCT01543698,Phase Ib/II,"Active, not recruiting","[{'id': 1100, 'therapyName': 'Binimetinib + Encorafenib'}, {'id': 1101, 'therapyName': 'Binimetinib + Encorafenib + Ribociclib'}]",A Phase Ib/II Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF Dependent Advanced Solid Tumors,6826
2,NCT01781572,Phase Ib/II,"Active, not recruiting","[{'id': 5, 'therapyName': 'Binimetinib + Ribociclib'}]",A Phase Ib/II Study of LEE011 in Combination With MEK162 in Patients With NRAS Mutant Melanoma,6826
3,NCT02088684,Phase Ib/II,"Active, not recruiting","[{'id': 2315, 'therapyName': 'BKM120 + Fulvestrant + LEE011'}, {'id': 2316, 'therapyName': 'Fulvestrant + LEE011'}, {'id': 2317, 'therapyName': 'BYL719 + Fulvestrant + LEE011'}]",Study of LEE011 With Fulvestrant and BYL719 or BKM120 in Advanced Breast Cancer,6826
4,NCT02780128,Phase I,Recruiting,"[{'id': 2186, 'therapyName': 'HDM201'}, {'id': 2638, 'therapyName': 'Ceritinib + LEE011'}, {'id': 2, 'therapyName': 'Trametinib'}]",Next Generation Personalized Neuroblastoma Therapy,6826
5,NCT02292550,Phase Ib/II,"Active, not recruiting","[{'id': 2638, 'therapyName': 'Ceritinib + LEE011'}]",Study of Safety and Efficacy of LEE011 and Ceritinib in Patients With ALK-positive Non-small Cell Lung Cancer.,6826
6,NCT02494921,Phase Ib/II,Recruiting,"[{'id': 3113, 'therapyName': 'Docetaxel + Filgrastim + Prednisone + Ribociclib'}]",LEE011 (Ribociclib) in Combination With Docetaxel Plus Prednisone in mCRPC,6826
7,NCT03009201,Phase I,Recruiting,"[{'id': 5179, 'therapyName': 'Doxorubicin + Ribociclib'}]",Ribociclib and Doxorubicin Hydrochloride in Treating Patients Metastatic or Advanced Soft Tissue Sarcomas That Cannot Be Removed by Surgery,6826
8,NCT01777776,Phase Ib/II,Terminated,"[{'id': 796, 'therapyName': 'Encorafenib'}, {'id': 1260, 'therapyName': 'Encorafenib + Ribociclib'}]",Safety and Efficacy of LEE011 and LGX818 in Patients With BRAF Mutant Melanoma.,6826
9,NCT01820364,Phase II,Terminated,"[{'id': 1100, 'therapyName': 'Binimetinib + Encorafenib'}, {'id': 1260, 'therapyName': 'Encorafenib + Ribociclib'}, {'id': 1337, 'therapyName': 'Encorafenib + BKM120'}, {'id': 1336, 'therapyName': 'BGJ398 + Encorafenib'}, {'id': 1338, 'therapyName': 'Capmatinib + Encorafenib'}]", LGX818 in Combination With Agents (MEK162; BKM120; LEE011; BGJ398; INC280) in Advanced BRAF Melanoma,6826
10,NCT03294694,Phase I,Not yet recruiting,"[{'id': 6285, 'therapyName': 'Fulvestrant + PDR001 + Ribociclib'}, {'id': 6284, 'therapyName': 'PDR001 + Ribociclib'}]",Ribociclib + PDR001 in Breast Cancer and Ovarian Cancer,6826
11,NCT02414724,Phase I,Terminated,"[{'id': 2898, 'therapyName': 'Gemcitabine + Ribociclib'}]",Ribociclib and Gemcitabine Hydrochloride in Treating Patients With Advanced Solid Tumors or Lymphoma,6826
12,NCT03237390,Phase I,Recruiting,"[{'id': 2898, 'therapyName': 'Gemcitabine + Ribociclib'}]",Ribociclib and Gemcitabine Hydrochloride in Treating Patients With Advanced or Metastatic Solid Tumors,6826
13,NCT02343172,Phase Ib/II,Recruiting,"[{'id': 2481, 'therapyName': 'HDM201 + LEE011'}]",Study of Safety and Efficacy of HDM201 in Combination With LEE011 in Patients With Liposarcoma,6826
14,NCT02586675,Phase I,"Active, not recruiting","[{'id': 759, 'therapyName': 'Goserelin'}, {'id': 3175, 'therapyName': 'LEE001 + Tamoxifen'}]",TEEL Study- Phase 1 Tamoxifen and Ribociclib (LEE011) in Advanced ER+ (HER2 Negative) Breast Cancer,6826
15,NCT02154776,Phase I,Completed,"[{'id': 1594, 'therapyName': 'LEE011 + BKM120 + Letrozole'}]","Dose Escalation Study of LEE011 in Combination With Buparlisib and Letrozole in HR+, HER2-negative Post-menopausal Women With Advanced Breast Cancer. (LeeBLet)",6826
16,NCT01872260,Phase Ib/II,Recruiting,"[{'id': 1553, 'therapyName': 'Letrozole + BYL719'}, {'id': 1569, 'therapyName': 'LEE011 + BYL719 + Letrozole'}, {'id': 1568, 'therapyName': 'LEE011 + Letrozole'}]","Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer",6826
17,NCT03056833,Phase I,Recruiting,"[{'id': 5333, 'therapyName': 'LEE011 + Carboplatin + Paclitaxel'}]",Ribociclib (Ribociclib (LEE-011)) With Platinum-based Chemotherapy in Recurrent Platinum Sensitive Ovarian Cancer,6826
18,NCT01857193,Phase Ib/II,Recruiting,"[{'id': 2265, 'therapyName': 'LEE011 + Everolimus + Exemestane'}, {'id': 1966, 'therapyName': 'Exemestane + Everolimus'}, {'id': 2266, 'therapyName': 'LEE011 + Exemestane'}]",Phase Ib/II Trial of LEE011 With Everolimus (RAD001) and Exemestane in the Treatment of ER+ Her2- Advanced Breast Cancer,6826
19,NCT02732119,Phase Ib/II,Recruiting,"[{'id': 2265, 'therapyName': 'LEE011 + Everolimus + Exemestane'}]",Study of Ribociclib With Everolimus + Exemestane in HR+ HER2- Locally Advanced/Metastatic Breast Cancer Post Progression on CDK 4/6 Inhibitor. (TRINITI-1),6826
20,NCT03050398,Phase III,Recruiting,"[{'id': 1568, 'therapyName': 'LEE011 + Letrozole'}]",A Companion Sample Collection Protocol to Support the Discovery of Breast Cancer Aberrations With Treatment of CDK4/6 Therapy/LEE011/Ribociclib,6826
21,NCT02657928,Phase II,Recruiting,"[{'id': 1568, 'therapyName': 'LEE011 + Letrozole'}]","Ribociclib and Letrozole in Treating Patients With Relapsed ER Positive Ovarian, Fallopian Tube, Primary Peritoneal or Endometrial Cancer",6826
22,NCT02712723,Phase II,Recruiting,"[{'id': 1568, 'therapyName': 'LEE011 + Letrozole'}]","Letrozole Plus Ribociclib or Placebo as Neo-adjuvant Therapy in ER-positive, HER2-negative Early Breast Cancer",6826
23,NCT02734615,Phase I,Recruiting,"[{'id': 4441, 'therapyName': 'Alpelisib + LSZ 102'}, {'id': 4440, 'therapyName': 'LSZ 102 + Ribociclib'}, {'id': 4439, 'therapyName': 'LSZ 102'}]",Phase I/Ib Trial of LSZ102 Single Agent or LSZ102 + LEE011 or LSZ102 + BYL719 in ER+ Breast Cancers,6826
24,NCT02599363,Phase I,Recruiting,"[{'id': 3206, 'therapyName': 'Paclitaxel + Ribociclib'}]",A Trial of Ribocilcib (LEE011) and Weekly Paclitaxel in Patients With Rb+ Advanced Breast Cancer,6826
25,NCT02420691,Phase II,"Active, not recruiting","[{'id': 790, 'therapyName': 'Ribociclib'}]",LEE011 in Neuroendocrine Tumors of Foregut Origin,6826
26,NCT02300987,Phase II,"Active, not recruiting","[{'id': 790, 'therapyName': 'Ribociclib'}]","A Randomized, Blinded, Placebo-controlled, Phase II Trial of LEE011 in Patients With Relapsed, Refractory, Incurable Teratoma With Recent Progression",6826
27,NCT02657343,Phase Ib/II,Recruiting,"[{'id': 790, 'therapyName': 'Ribociclib'}, {'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 1402, 'therapyName': 'trastuzumab emtansine'}]","An Open-Label, Phase Ib/II Clinical Trial Of Cdk 4/6 Inhibitor, Ribociclib (Lee011), In Combination With Trastuzumab Or T-Dm1 For Advanced/Metastatic Her2-Positive Breast Cancer.",6826
28,NCT02607124,Phase Ib/II,Recruiting,"[{'id': 790, 'therapyName': 'Ribociclib'}]",Administration of Ribociclib Following Radiation Therapy in Children With Newly Diagnosed Non-biopsied Diffuse Pontine Gliomas (DIPG) and RB+ Biopsied DIPG and High Grade Gliomas (HGG),6826
29,NCT01958021,Phase III,"Active, not recruiting","[{'id': 790, 'therapyName': 'Ribociclib'}, {'id': 794, 'therapyName': 'Letrozole'}]",Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer.(MONALEESA-2),6826
30,NCT02278120,Phase III,"Active, not recruiting","[{'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 794, 'therapyName': 'Letrozole'}, {'id': 790, 'therapyName': 'Ribociclib'}, {'id': 759, 'therapyName': 'Goserelin'}, {'id': 633, 'therapyName': 'Anastrozole'}]","Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer",6826
31,NCT03078751,Phase III,Recruiting,"[{'id': 790, 'therapyName': 'Ribociclib'}]",Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- High Risk Early Breast Cancer (EarLEE-1),6826
32,NCT01747876,Phase I,Completed,"[{'id': 790, 'therapyName': 'Ribociclib'}]",Study of Safety and Efficacy in Patients With Malignant Rhabdoid Tumors (MRT) and Neuroblastoma,6826
33,NCT02632045,Phase II,Recruiting,"[{'id': 744, 'therapyName': 'Fulvestrant'}, {'id': 790, 'therapyName': 'Ribociclib'}]",Study of Efficacy of Ribociclib After Progression on CDK4/6 Inhibition in Patients With HR+ H2N- Advanced Breast Cancer,6826
34,NCT02422615,Phase III,"Active, not recruiting","[{'id': 790, 'therapyName': 'Ribociclib'}, {'id': 744, 'therapyName': 'Fulvestrant'}]",Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer.,6826
35,NCT02555189,Phase Ib/II,Recruiting,"[{'id': 790, 'therapyName': 'Ribociclib'}, {'id': 1262, 'therapyName': 'Enzalutamide'}]","Enzalutamide With and Without Ribociclib for Metastatic, Castrate-Resistant, Chemotherapy-Naive Prostate Cancer That Retains RB Expression",6826
36,NCT02933736,Phase 0,Recruiting,"[{'id': 790, 'therapyName': 'Ribociclib'}]",Ribociclib (LEE011) in Preoperative Glioma and Meningioma Patients,6826
37,NCT02345824,Phase I,Recruiting,"[{'id': 790, 'therapyName': 'Ribociclib'}]",Early-Phase Study to Assess Inhibitor LEE011 in Patients With Recurrent Glioblastoma or Anaplastic Glioma,6826
38,NCT02934568,Phase II,Recruiting,"[{'id': 790, 'therapyName': 'Ribociclib'}]",Ribociclib (LEE011) Rollover Study for Continued Access,6826
39,NCT01237236,Phase I,Completed,"[{'id': 790, 'therapyName': 'Ribociclib'}]",A Trial of LEE011 in Patients With Advanced Solid Tumors or Lymphoma.,6826
40,NCT02524119,Phase II,Recruiting,"[{'id': 790, 'therapyName': 'Ribociclib'}]",LEE001 and Chemoembolization In Patients With Advanced Hepatocellular Carcinoma (LEE001),6826
41,NCT02187783,Phase II,"Active, not recruiting","[{'id': 790, 'therapyName': 'Ribociclib'}]",LEE011 for Patients With CDK4/6 Pathway Activated Tumors (SIGNATURE),6826
42,NCT03285412,,Not yet recruiting,"[{'id': 790, 'therapyName': 'Ribociclib'}]","CDK 4/6 Inhibitor, LEE011 (Ribociclib), in Combination With Adjuvant Endocrine Therapy at Varying Duration for ER-positive Breast Cancer",6826
43,NCT03090165,Phase Ib/II,Recruiting,"[{'id': 5479, 'therapyName': 'Ribociclib + Bicalutamide'}]",Ribociclib and Bicalutamide in AR+ TNBC,6826
44,NCT03114527,Phase II,Recruiting,"[{'id': 5073, 'therapyName': 'Ribociclib + Everolimus'}]",Phase II Trial of Ribociclib and Everolimus in Advanced Dedifferentiated Liposarcoma (DDL) and Leiomyosarcoma (LMS),6826
45,NCT03070301,Phase II,Recruiting,"[{'id': 5073, 'therapyName': 'Ribociclib + Everolimus'}]",A Study of LEE011 With Everolimus in Patients With Advanced Neuroendocrine Tumors,6826
46,NCT02985125,Phase Ib/II,Recruiting,"[{'id': 5073, 'therapyName': 'Ribociclib + Everolimus'}]",LEE011 Plus Everolimus in Patients With Metastatic Pancreatic Adenocarcinoma Refractory to Chemotherapy,6826
47,NCT03008408,Phase II,Recruiting,"[{'id': 5180, 'therapyName': 'Ribociclib + Everolimus + Letrozole'}]","Phase II Ribociclib, Everolimus and Letrozole in Endometrial Cancer",6826
48,NCT02941926,Phase III,Recruiting,"[{'id': 5310, 'therapyName': 'Ribociclib + Letrozole + Goserelin'}]",Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC,6826
49,NCT02703571,Phase Ib/II,Recruiting,"[{'id': 4472, 'therapyName': 'Ribociclib + Trametinib'}]",Study of Safety and Efficacy of Ribociclib and Trametinib in Patients With Metastatic or Advanced Solid Tumors,6826
0,NCT02091063,Phase Ib/II,Recruiting,"[{'id': 1613, 'therapyName': 'ACY-1215'}]",ACY-1215 for Relapsed/Refractory Lymphoid Malignancies,7297
1,NCT01323751,Phase Ib/II,Completed,"[{'id': 2470, 'therapyName': 'Bortezomib + Dexamethasone'}, {'id': 1613, 'therapyName': 'ACY-1215'}]",Study of ACY-1215 Alone and in Combination With Bortezomib and Dexamethasone in Multiple Myeloma,7297
2,NCT02856568,Phase I,Withdrawn,"[{'id': 4526, 'therapyName': 'ACY-1215 + Cisplatin + Gemcitabine'}]","Ricolinostat, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Unresectable or Metastatic Cholangiocarcinoma",7297
3,NCT02787369,Phase I,"Active, not recruiting","[{'id': 4273, 'therapyName': 'ACY-1215 + Idelalisib '}, {'id': 4272, 'therapyName': 'ACY-1215 + Ibrutinib'}]",ACY-1215 in Combination With BCR Pathway Inhibitors in Relapsed CLL,7297
4,NCT02632071,Phase I,Recruiting,"[{'id': 3313, 'therapyName': 'ACY-1215 + nab-paclitaxel'}]",Phase I of ACY-1215 + Nab-paclitaxel in Breast Cancer,7297
5,NCT02661815,Phase I,"Active, not recruiting","[{'id': 3469, 'therapyName': 'ACY-1215 + Paclitaxel'}, {'id': 667, 'therapyName': 'Bevacizumab'}]","A Phase 1b Study of Weekly Paclitaxel And Oral Ricolinostat For The Treatment Of Recurrent Platinum Resistant Ovarian, Primary Peritoneal, Or Fallopian Tube Cancer",7297
6,NCT02189343,Phase I,"Active, not recruiting","[{'id': 1614, 'therapyName': 'ACY-1215 + Pomalidomide + Dexamethasone'}]",Phase 1b Study Evaluating ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Dexamethasone in Relapsed-and-Refractory Multiple Myeloma,7297
7,NCT01997840,Phase Ib/II,"Active, not recruiting","[{'id': 1614, 'therapyName': 'ACY-1215 + Pomalidomide + Dexamethasone'}]",ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Low-dose Dex in Relapsed-and-Refractory Multiple Myeloma,7297
0,NCT01584531,Phase II,Completed,"[{'id': 1046, 'therapyName': 'rigosertib'}]","Efficacy and Safety of Oral Rigosertib in Transfusion-dependent, Low or Int-1 or Trisomy 8 Int-2 Myelodysplastic Syndrome",7164
1,NCT01928537,Phase III,"Active, not recruiting","[{'id': 1046, 'therapyName': 'rigosertib'}]",Efficacy and Safety of IV Rigosertib in MDS Patients With Excess Blasts Progressing After Azacitidine or Decitabine,7164
2,NCT02562443,Phase III,Recruiting,"[{'id': 1046, 'therapyName': 'rigosertib'}]",Controlled Study of Rigosertib Versus Physician's Choice of Treatment in MDS Patients After Failure of an HMA (INSPIRE),7164
3,NCT02107235,Phase I,Completed,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1046, 'therapyName': 'rigosertib'}]",Platinum-based Chemoradiotherapy and Rigosertib in Head and Neck Cancer,7164
0,NCT01233687,Phase Ib/II,Completed,"[{'id': 629, 'therapyName': 'AMG102'}, {'id': 4, 'therapyName': 'Erlotinib'}]",AMG 102 and Erlotinib for Advanced Non-Small Cell Lung Cancer,6835
1,NCT02213289,Phase Ib/II,Recruiting,"[{'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 1913, 'therapyName': 'FOLTAX'}, {'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 1315, 'therapyName': 'FOLFIRI'}, {'id': 629, 'therapyName': 'AMG102'}]",PANGEA-IMBBP: Personalized Antibodies for Gastro-Esophageal Adenocarcinoma - A 1st Pilot Metastatic Trial of Biologics Beyond Progression,6835
2,NCT02154490,Phase II,Recruiting,"[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 850, 'therapyName': 'Palbociclib'}, {'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 654, 'therapyName': 'AZD4547'}, {'id': 1016, 'therapyName': 'GDC-0032'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 629, 'therapyName': 'AMG102'}]",Lung-MAP: S1400 Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IIIB-IV Squamous Cell Lung Cancer,6835
0,NCT01303341,Phase I,"Active, not recruiting","[{'id': 1724, 'therapyName': 'Rilutek + Sorafenib'}]",Riluzole and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors or Melanoma,7165
0,NCT02792114,Phase I,Recruiting,"[{'id': 5992, 'therapyName': 'Rimiducid'}, {'id': 6029, 'therapyName': 'Mesothelin CAR-T cells'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}]",T-Cell Therapy for Advanced Breast Cancer,8882
1,NCT02487459,Phase I,Not yet recruiting,"[{'id': 6053, 'therapyName': 'BPX-501'}, {'id': 5992, 'therapyName': 'Rimiducid'}]",Safety Study of Gene Modified Donor T-Cells in Adults With Advanced Hematologic Malignancies,8882
2,NCT02786485,Phase I,Not yet recruiting,"[{'id': 5992, 'therapyName': 'Rimiducid'}, {'id': 6053, 'therapyName': 'BPX-501'}]",Study of Matched Unrelated Donor T Cell Infusion for Hematologic Malignancies After Allo-HSCT,8882
3,NCT02477878,Phase I,Recruiting,"[{'id': 5995, 'therapyName': 'BPX-601'}, {'id': 5992, 'therapyName': 'Rimiducid'}]",Study of Gene Modified Donor T Cell Infusion in Patients With Recurrent Disease After Allogeneic Transplant,8882
4,NCT02743611,Phase I,Recruiting,"[{'id': 5992, 'therapyName': 'Rimiducid'}, {'id': 5991, 'therapyName': 'BPX-701'}]",Dose Finding Study Evaluating Safety and Feasibility in Patients With Relapsed or Refractory Myeloid Neoplasms,8882
5,NCT01744223,Phase Ib/II,Recruiting,"[{'id': 5992, 'therapyName': 'Rimiducid'}, {'id': 6053, 'therapyName': 'BPX-501'}]",Safety Study of Gene Modified Donor T-cells Following Partially Mismatched Stem Cell Transplant,8882
6,NCT02065869,Phase Ib/II,Recruiting,"[{'id': 6053, 'therapyName': 'BPX-501'}, {'id': 5992, 'therapyName': 'Rimiducid'}]",Safety Study of Gene Modified Donor T-cells Following TCR Alpha Beta Depleted Stem Cell Transplant,8882
0,NCT02555878,Phase III,Recruiting,"[{'id': 4119, 'therapyName': 'Rivaroxaban'}]",A Study to Evaluate the Efficacy and Safety of Rivaroxaban Venous Thromboembolism (VTE) Prophylaxis in Ambulatory Cancer Participants,4718
0,NCT02422979,Phase I,Recruiting,"[{'id': 2918, 'therapyName': 'RM-1929'}]",Study of RM-1929 and Photoimmunotherapy in Patients With Recurrent Head and Neck Cancer,7841
0,NCT02624258,Phase I,Recruiting,"[{'id': 6000, 'therapyName': 'RNA CART19 cells'}]","Pilot Study of Non-Viral, RNA-Redirected Autologous T Cells in Patients With Refractory or Relapsed Hodgkin Lymphoma",8888
0,NCT01154452,Phase Ib/II,Completed,"[{'id': 956, 'therapyName': 'Vismodegib'}, {'id': 1096, 'therapyName': 'Vismodegib + RO4929097'}, {'id': 902, 'therapyName': 'RO4929097'}]",Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma,7009
0,NCT02670044,Phase Ib/II,Recruiting,"[{'id': 4171, 'therapyName': 'Cobimetinib + Venetoclax'}, {'id': 4172, 'therapyName': 'RO5503781 + Venetoclax'}]",A Study of Venetoclax in Combination With Cobimetinib and Venetoclax in Combination With Idasanutlin in Patients Aged >/= 60 Years With Relapsed or Refractory Acute Myeloid Leukemia Who Are Not Eligible for Cytotoxic Therapy,7446
0,NCT02141295,Phase II,Completed,"[{'id': 1484, 'therapyName': 'Bevacizumab + Oxaliplatin + Leucovorin + Fluorouracil'}, {'id': 1598, 'therapyName': 'RO5520985'}, {'id': 1599, 'therapyName': 'Bevacizumab + Fluorouracil + Leucovorin'}, {'id': 1600, 'therapyName': 'RO5520985 + Leucovorin + Fluorouracil'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}]",A Study Comparing the Efficacy and Safety of RO5520985 and FOLFOX With Bevacizumab and FOLFOX in Patients With Untreated Metastatic Colorectal Cancer (McCAVE),7294
1,NCT02665416,Phase I,Recruiting,"[{'id': 3468, 'therapyName': 'RO5520985 + RO7009789'}]","Study Evaluating the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Therapeutic Activity of RO7009789 With Vanucizumab in Metastatic Solid Tumors",7294
0,NCT02098967,Phase I,"Active, not recruiting","[{'id': 2155, 'therapyName': 'RO6839921'}]","A Study of the Safety and Pharmacokinetics of RO6839921, An MDM2 Antagonist, in Patients With Advanced Cancers, Including Acute Myeloid Leukemia.",7447
0,NCT02627274,Phase I,Recruiting,"[{'id': 5364, 'therapyName': 'RO6874281'}]","A Study Evaluating Safety, Pharmacokinetics, and Therapeutic Activity of RO6874281 in Participants With Advanced and/or Metastatic Solid Tumors",8672
1,NCT03063762,Phase I,Recruiting,"[{'id': 5365, 'therapyName': 'RO6874281 + Obinutuzumab + Atezolizumab'}, {'id': 5366, 'therapyName': 'RO6874281 + Obinutuzumab + Atezolizumab + Bevacizumab'}]","Study to Evaluate Safety, Pharmacokinetics and Therapeutic Activity of RO6874281 as a Combination Therapy in Participants With Unresectable Advanced and/or Metastatic Renal Cell Carcinoma (RCC)",8672
0,NCT02558140,Phase I,Recruiting,"[{'id': 4330, 'therapyName': 'RO6874813'}]",A Dose Escalation Study of RO6874813 in Participants With Locally Advanced or Metastatic Solid Tumors,8419
0,NCT02350673,Phase I,Recruiting,"[{'id': 2886, 'therapyName': 'RO6895882'}, {'id': 1201, 'therapyName': 'Atezolizumab'}]",A Study of Intravenous RO6895882 and MPDL3280A Combination in Patients With Locally Advanced and/or Metastatic Solid Tumors,7814
1,NCT02004106,Phase I,Completed,"[{'id': 2886, 'therapyName': 'RO6895882'}]",A Study of RO6895882 in Patients With Advanced and/or Metastatic Solid Tumors,7814
0,NCT02650713,Phase I,Recruiting,"[{'id': 3412, 'therapyName': 'Atezolizumab + RO6958688 '}]","A Study of the Safety, Pharmacokinetics, and Therapeutic Activity of RO6958688 in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen (CEA)-Positive Solid Tumors",8066
0,NCT02760797,Phase I,Recruiting,"[{'id': 4181, 'therapyName': 'Emactuzumab + RO7009789'}]",A Study of Emactuzumab and RO7009789 Administered in Combination in Participants With Advanced Solid Tumors,7641
1,NCT02665416,Phase I,Recruiting,"[{'id': 3468, 'therapyName': 'RO5520985 + RO7009789'}]","Study Evaluating the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Therapeutic Activity of RO7009789 With Vanucizumab in Metastatic Solid Tumors",7641
2,NCT02304393,Phase I,Recruiting,"[{'id': 2672, 'therapyName': 'RO7009789'}, {'id': 1201, 'therapyName': 'Atezolizumab'}]",A Study of RO7009789 in Combination With MPDL3280A in Patients With Locally Advanced and Metastatic Solid Tumors,7641
0,NCT03075696,Phase I,Recruiting,"[{'id': 6162, 'therapyName': 'Obinutuzumab + RO7082859 + Tocilizumab'}]","A Dose Escalation Study of RO7082859, Administered After a Fixed, Single Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma",8785
0,NCT03289962,Phase I,Not yet recruiting,"[{'id': 6234, 'therapyName': 'RO7198457'}, {'id': 6235, 'therapyName': 'Atezolizumab + RO7198457'}]",A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors,8948
0,NCT01976741,Phase I,Recruiting,"[{'id': 2030, 'therapyName': 'Rogaratinib'}]",Phase I Dose Escalation Pan-FGFR (Fibroblast Growth Factor Receptor) Inhibitor,7396
0,NCT03161223,Phase Ib/II,Not yet recruiting,"[{'id': 5882, 'therapyName': 'Durvalumab + Romidepsin'}, {'id': 4178, 'therapyName': 'Azacitidine + MEDI4736'}, {'id': 5881, 'therapyName': 'Azacitidine + Durvalumab + Romidepsin'}, {'id': 5880, 'therapyName': 'Durvalumab + Pralatrexate + Romidepsin'}]","Durvalumab in Different Combinations With Pralatrexate, Romidepsin and Oral 5-Azacitidine for Lymphoma",7191
1,NCT02512172,Phase I,Recruiting,"[{'id': 2496, 'therapyName': 'Azacitidine + Pembrolizumab'}, {'id': 5728, 'therapyName': 'Romidepsin + Pembrolizumab'}, {'id': 5782, 'therapyName': 'Azacitidine + Pembrolizumab + Romidepsin'}]",A Study of Enhancing Response to MK-3475 in Advanced Colorectal Cancer,7191
2,NCT01537744,Phase I,Completed,"[{'id': 1396, 'therapyName': 'Azacitidine + Romidepsin'}]","A Trial of Oral 5-azacitidine in Combination With Romidepsin in Advanced Solid Tumors, With an Expansion Cohort in Non-small Cell Lung Cancer",7191
3,NCT02393794,Phase Ib/II,"Active, not recruiting","[{'id': 2993, 'therapyName': 'Cisplatin + Romidepsin '}]",Romidepsin Plus Cisplatin in Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC),7191
4,NCT01902225,Phase I,Unknown status,"[{'id': 3393, 'therapyName': 'Doxil + romidepsin '}]",Phase I Dose-finding and Preliminary Efficacy Study of the Istodax in Combination With Doxil for the Treatment of Adults With Relapsed or Refractory Cutaneous T-cell Lymphoma,7191
5,NCT02783625,Phase I,Recruiting,"[{'id': 4240, 'therapyName': 'Bortezomib + Duvelisib'}, {'id': 4239, 'therapyName': 'Duvelisib + romidepsin '}]",Trial of Duvelisib in Combination With Either Romidepsin or Bortezomib in Relapsed/Refractory T-cell Lymphomas,7191
6,NCT02281279,Phase Ib/II,Withdrawn,"[{'id': 2349, 'therapyName': 'Lenalidomide + Rituximab + Romidepsin '}]","Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma",7191
7,NCT02181218,Phase I,Recruiting,"[{'id': 1476, 'therapyName': 'Pegfilgrastim'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1611, 'therapyName': 'Gemcitabine + Oxaliplatin + Dexamethasone'}]","Phase I Study of Romidepsin, Gemcitabine, Oxaliplatin, and Dexamethasone in Patients With Relapsed/Refractory Aggressive Lymphomas",7191
8,NCT02551718,Phase I,Recruiting,"[{'id': 690, 'therapyName': 'Bosutinib'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 3160, 'therapyName': 'Nelarabine'}, {'id': 3159, 'therapyName': 'Bexarotene'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 998, 'therapyName': 'cabozantinib'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 877, 'therapyName': 'Ponatinib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 623, 'therapyName': 'Afatinib'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 890, 'therapyName': 'Regorafenib'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 2, 'therapyName': 'Trametinib'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 3, 'therapyName': 'Dabrafenib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 789, 'therapyName': 'Ceritinib'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1571, 'therapyName': 'Cabazitaxel'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1327, 'therapyName': 'Pralatrexate'}]",High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia,7191
9,NCT01897012,Phase I,Recruiting,"[{'id': 1075, 'therapyName': 'romidepsin'}, {'id': 626, 'therapyName': 'Alisertib'}]",Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas,7191
10,NCT02788201,Phase II,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1133, 'therapyName': 'Mitomycin C'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1013, 'therapyName': 'epirubicin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1137, 'therapyName': 'Bleomycin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 781, 'therapyName': 'Ixabepilone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 2950, 'therapyName': 'Estramustine'}, {'id': 1941, 'therapyName': 'Floxuridine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 1811, 'therapyName': 'Carmustine'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 953, 'therapyName': 'Vandetanib'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 4419, 'therapyName': 'Toremifine'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 2601, 'therapyName': 'Dactinomycin'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 3035, 'therapyName': 'Chlorambucil'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 342, 'therapyName': 'Vemurafenib'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 2635, 'therapyName': 'Vinblastine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 4305, 'therapyName': 'Teniposide'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 4304, 'therapyName': 'Streptozocin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1231, 'therapyName': 'Bendamustine'}, {'id': 4303, 'therapyName': 'Mechlorethamine'}, {'id': 4302, 'therapyName': 'Mitotane'}]",Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma,7191
11,NCT03278782,Phase Ib/II,Not yet recruiting,"[{'id': 1075, 'therapyName': 'romidepsin'}, {'id': 5728, 'therapyName': 'Romidepsin + Pembrolizumab'}]",Study of Pembrolizumab (MK-3475) in Combination With Romidepsin,7191
12,NCT01638533,Phase I,Recruiting,"[{'id': 1075, 'therapyName': 'romidepsin'}]","Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction",7191
0,NCT02457351,Phase I,Completed,"[{'id': 663, 'therapyName': 'BAY1000394'}, {'id': 1026, 'therapyName': 'Itraconazole'}]",Roniciclib (BAY 1000394) Drug-Drug Interaction (DDI) Study,6865
1,NCT02656849,Phase II,Withdrawn,"[{'id': 663, 'therapyName': 'BAY1000394'}]","BAY 1000394 for MCL-1-, MYC-, and CCNE1-Amplified Tumors",6865
2,NCT02161419,Phase II,Terminated,"[{'id': 663, 'therapyName': 'BAY1000394'}]",RONICICLIB / Placebo in Combination With Chemotherapy in Small Cell Lung Cancer,6865
0,NCT02482441,Phase I,Recruiting,"[{'id': 4401, 'therapyName': 'Rosmantuzumab'}, {'id': 1315, 'therapyName': 'FOLFIRI'}]","A Phase 1a/b Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of OMP-131R10",8440
0,NCT03061812,Phase III,Recruiting,"[{'id': 3544, 'therapyName': 'Rovalpituzumab Tesirine'}, {'id': 942, 'therapyName': 'Topotecan'}]",Study Comparing Rovalpituzumab Tesirine Versus Topotecan in Subjects With Advanced or Metastatic Small Cell Lung Cancer With High Levels of Delta-like Protein 3 (DLL3) and Who Have First Disease Progression During or Following Front-line Platinum-based Chemotherapy (TAHOE) (TAHOE),8127
1,NCT02874664,Phase I,Recruiting,"[{'id': 3544, 'therapyName': 'Rovalpituzumab Tesirine'}]",A Study of Rovalpituzumab Tesirine to Study Cardiac Ventricular Repolarization in Subjects With Small Cell Lung Cancer,8127
2,NCT02674568,Phase II,"Active, not recruiting","[{'id': 3544, 'therapyName': 'Rovalpituzumab Tesirine'}]",Study of Rovalpituzumab Tesirine (SC16LD6.5) for Third-line and Later Treatment of Subjects With Relapsed or Refractory Delta-Like Protein 3-Expressing Small Cell Lung Cancer (TRINITY),8127
3,NCT02709889,Phase Ib/II,Recruiting,"[{'id': 3544, 'therapyName': 'Rovalpituzumab Tesirine'}]",Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors,8127
4,NCT02819999,Phase I,Recruiting,"[{'id': 4827, 'therapyName': 'Rovalpituzumab Tesirine + Cisplatin + Etoposide'}, {'id': 3544, 'therapyName': 'Rovalpituzumab Tesirine'}]",A Study of Rovalpituzumab Tesirine (SC16LD6.5) in the Frontline Treatment of Patients With Delta-Like Protein 3-Expressing Extensive Stage Small Cell Lung Cancer,8127
5,NCT03033511,Phase III,Recruiting,"[{'id': 5307, 'therapyName': 'Rovalpituzumab Tesirine + Dexamethasone'}]",A Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Participants With Extensive Stage Small Cell Lung Cancer (MERU) (MERU),8127
6,NCT03026166,Phase I,Recruiting,"[{'id': 5640, 'therapyName': 'Rovalpituzumab Tesirine + Nivolumab + Ipilimumab'}, {'id': 5641, 'therapyName': 'Rovalpituzumab Tesirine + Nivolumab'}]",A Study of Rovalpituzumab Tesirine Administered in Combination With Nivolumab and With or Without Ipilimumab for Adults With Extensive-Stage Small Cell Lung Cancer,8127
0,NCT03119467,Phase I,Recruiting,"[{'id': 5761, 'therapyName': 'RP4010'}]","Safety and Efficacy Study of RP4010, in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma",8782
0,NCT02567656,Phase I,Recruiting,"[{'id': 2020, 'therapyName': 'RP6530'}]",Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in T-cell Lymphoma,7386
0,NCT02801097,Phase I,Recruiting,"[{'id': 4323, 'therapyName': 'Irinotecan + RRx-001'}]","A Phase I, Multiple Ascending Dose Study to Assess the Safety and Tolerability of RRx-001 in Combination With Irinotecan in Metastatic or Advanced Cancer  (PAYLOAD) (PAYLOAD)",8207
1,NCT02489903,Phase II,Recruiting,"[{'id': 1136, 'therapyName': 'Etoposide'}, {'id': 3680, 'therapyName': 'RRx-001'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 619, 'therapyName': 'Abraxane'}]","RRx-001 in Small, Non-small Cell Lung Cancer, and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens",8207
2,NCT02452970,Phase II,"Active, not recruiting","[{'id': 3680, 'therapyName': 'RRx-001'}, {'id': 1467, 'therapyName': 'Gemcitabine + Cisplatin'}]",RRx-001 in Second Line Treatment of Advanced Cholangiocarcinoma Prior to Readministration of First-Line Therapy (EPIC),8207
3,NCT02215512,Phase I,"Active, not recruiting","[{'id': 3680, 'therapyName': 'RRx-001'}]",Dose-Escalation Study of RRx-001 in Combination With Whole Brain Radiation in Subjects With Brain Metastases,8207
4,NCT02871843,Phase I,Recruiting,"[{'id': 4596, 'therapyName': 'RRx-001 + Temozolomide'}]",Phase 1 Two Part Dose Escalation Trial of RRx-001 + Radiation + Temozolomide and RRx-001 + Temozolomide Post-RT In Newly Diagnosed Glioblastoma and Anaplastic Gliomas (G-FORCE-1),8207
0,NCT02259231,Phase Ib/II,Recruiting,"[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 3062, 'therapyName': 'RTA 408'}]",RTA 408 Capsules in Patients With Melanoma - REVEAL,7922
0,NCT01482715,,"Active, not recruiting","[{'id': 906, 'therapyName': 'Rucaparib'}]",A Study of Oral Rucaparib in Patients With a Solid Tumor (Phase I) or With gBRCA Mutation Ovarian Cancer (Phase II),7013
1,NCT02042378,Phase II,Completed,"[{'id': 906, 'therapyName': 'Rucaparib'}]",A Study of Rucaparib in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation,7013
2,NCT02855944,Phase III,Recruiting,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 906, 'therapyName': 'Rucaparib'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]","ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients",7013
3,NCT02975934,Phase III,Recruiting,"[{'id': 906, 'therapyName': 'Rucaparib'}]",A Study of Rucaparib Verses Physician's Choice of Therapy in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency,7013
4,NCT01968213,Phase III,"Active, not recruiting","[{'id': 906, 'therapyName': 'Rucaparib'}]","A Study of Rucaparib as Switch Maintenance Following Platinum-Based Chemotherapy in Patients With Platinum-Sensitive, High-Grade Serous or Endometrioid Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer",7013
5,NCT02952534,Phase II,Recruiting,"[{'id': 906, 'therapyName': 'Rucaparib'}]",A Study of Rucaparib in Patients With MetA Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency (TRITON2),7013
6,NCT03140670,Phase II,Recruiting,"[{'id': 906, 'therapyName': 'Rucaparib'}]",Rucaparib in BRCA1/2 or PALB2 Mutated Pancreatic Cancer,7013
7,NCT01891344,Phase II,"Active, not recruiting","[{'id': 906, 'therapyName': 'Rucaparib'}]","A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2)",7013
0,NCT02613598,Phase I,Recruiting,"[{'id': 3262, 'therapyName': 'Bortezomib + Ruxolitinib'}]",Dose Escalation Study to Determine the Maximum Tolerated Dose of the Combination of Ruxolitinib and Bortezomib in Patients With Relapsed or Refractory Lymphoma,6787
1,NCT02876302,Phase II,Recruiting,"[{'id': 4679, 'therapyName': 'Cyclophosphamide + Doxorubicin + Paclitaxel + Ruxolitinib'}]",Study Of Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative Inflammatory Breast Cancer,6787
2,NCT02494882,Phase I,Recruiting,"[{'id': 3218, 'therapyName': 'Dasatinib + Dexamethasone + Ruxolitinib'}]",Adding Ruxolitinib to a Combination of Dasatinib Plus Dexamethasone in Remission Induction Therapy in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Patients Aged 40 Years or Older,6787
3,NCT02912754,Phase Ib/II,Not yet recruiting,"[{'id': 768, 'therapyName': 'Ibrutinib'}, {'id': 4768, 'therapyName': 'Ibrutinib + Ruxolitinib'}]",Ruxolitinib Combined With Ibrutinib in Chronic Lymphocytic Leukemia Patients,6787
4,NCT02718300,Phase II,Recruiting,"[{'id': 4224, 'therapyName': 'INCB050465 + Ruxolitinib'}]",A Study of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis,6787
5,NCT03110822,Phase I,Recruiting,"[{'id': 5550, 'therapyName': 'Methylprednisolone + Lenalidomide + Ruxolitinib'}]","A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients",6787
6,NCT03012230,Phase I,Not yet recruiting,"[{'id': 5227, 'therapyName': 'Pembrolizumab + Ruxolitinib'}]",Pembrolizumab and Ruxolitinib Phosphate in Treating Patients With Metastatic Stage IV Triple Negative Breast Cancer,6787
7,NCT02131584,Phase II,"Active, not recruiting","[{'id': 907, 'therapyName': 'Ruxolitinib'}]",Administration of Jakafi (Ruxolitinib) for Symptom Control of Patients With Chronic Lymphocytic Leukemia (CLL),6787
8,NCT01787487,Phase III,Recruiting,"[{'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}]",Evaluation of RUX and AZA Combination as a Therapy For Patients With Myelofibrosis And Myelodysplastic Syndrome/ Myeloproliferative Neoplasm,6787
9,NCT01164163,Phase I,Completed,"[{'id': 907, 'therapyName': 'Ruxolitinib'}]","INCB18424 in Treating Young Patients With Relapsed or Refractory Solid Tumor, Leukemia, or Myeloproliferative Disease",6787
10,NCT02928978,Phase II,Not yet recruiting,"[{'id': 907, 'therapyName': 'Ruxolitinib'}]",Ruxolitinib for Premalignant Breast Disease,6787
11,NCT01822756,Phase I,Terminated,"[{'id': 907, 'therapyName': 'Ruxolitinib'}]",An Open-Label Study of Ruxolitinib Given With Chemotherapy in Patients With Advanced Solid Tumors,6787
12,NCT03153982,Phase II,Not yet recruiting,"[{'id': 907, 'therapyName': 'Ruxolitinib'}]",Ruxolitinib in Operable Head and Neck Cancer,6787
13,NCT01895842,Phase I,"Active, not recruiting","[{'id': 907, 'therapyName': 'Ruxolitinib'}]",Ruxolitinib for Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS),6787
14,NCT02092324,Phase II,Recruiting,"[{'id': 907, 'therapyName': 'Ruxolitinib'}]",Ruxolitinib Phosphate in Treating Patients With Chronic Neutrophilic Leukemia or Atypical Chronic Myeloid Leukemia,6787
15,NCT01712659,Phase II,Recruiting,"[{'id': 907, 'therapyName': 'Ruxolitinib'}]",Ruxolitinib for Adult T-Cell Leukemia,6787
16,NCT02551718,Phase I,Recruiting,"[{'id': 690, 'therapyName': 'Bosutinib'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 3160, 'therapyName': 'Nelarabine'}, {'id': 3159, 'therapyName': 'Bexarotene'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 998, 'therapyName': 'cabozantinib'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 877, 'therapyName': 'Ponatinib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 623, 'therapyName': 'Afatinib'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 890, 'therapyName': 'Regorafenib'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 2, 'therapyName': 'Trametinib'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 3, 'therapyName': 'Dabrafenib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 789, 'therapyName': 'Ceritinib'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1571, 'therapyName': 'Cabazitaxel'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1327, 'therapyName': 'Pralatrexate'}]",High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia,6787
17,NCT02251821,Phase II,Recruiting,"[{'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 1845, 'therapyName': 'Mycophenolate mofetil'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 2006, 'therapyName': 'Pacritinib'}, {'id': 823, 'therapyName': 'Momelotinib'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}]",JAK-2 Inhibitor Before Donor Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis,6787
18,NCT01431209,Phase II,Recruiting,"[{'id': 907, 'therapyName': 'Ruxolitinib'}]",Ruxolitinib Phosphate (Oral JAK Inhibitor INCB18424) in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell or Peripheral T-Cell Non-Hodgkin Lymphoma,6787
19,NCT02420717,Phase II,Recruiting,"[{'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 3195, 'therapyName': 'Cytarabine + Methotrexate '}, {'id': 2046, 'therapyName': 'Cyclophosphamide + Dexamethasone + Doxorubicin + Vincristine '}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 3194, 'therapyName': 'Mercaptopurine + Methotrexate + Prednisone + Vincristine'}]",Ruxolitinib or Dasatinib With Chemotherapy in Patients With Philadelphia Chromosome (Ph)-Like Acute Lymphoblastic Leukemia (ALL),6787
20,NCT02117479,Phase III,Terminated,"[{'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 1105, 'therapyName': 'Capecitabine'}]",Study of Ruxolitinib in Pancreatic Cancer Patients (Janus 1),6787
21,NCT03286530,Phase II,Not yet recruiting,"[{'id': 907, 'therapyName': 'Ruxolitinib'}]",Ruxolitinib + Allogeneic Stem Cell Transplantation in AML,6787
22,NCT02723994,Phase II,Recruiting,"[{'id': 2188, 'therapyName': 'Prednisone'}, {'id': 4685, 'therapyName': 'Dexamethasone + Doxorubicin'}, {'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 2346, 'therapyName': 'Mercaptopurine + Thioguanine'}, {'id': 2394, 'therapyName': 'Asparaginase + Cytarabine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 1848, 'therapyName': 'Cyclophosphamide + Methotrexate + Vincristine + Pegaspargase '}]",A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia,6787
23,NCT02713386,Phase Ib/II,Recruiting,"[{'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]","Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",6787
24,NCT03117751,Phase II,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1876, 'therapyName': 'Blinatumomab '}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1638, 'therapyName': 'Pegaspargase'}]",Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma,6787
25,NCT02119676,Phase II,Terminated,"[{'id': 890, 'therapyName': 'Regorafenib'}, {'id': 907, 'therapyName': 'Ruxolitinib'}]",Study of Ruxolitinib in Colorectal Cancer Patients,6787
26,NCT02788201,Phase II,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1133, 'therapyName': 'Mitomycin C'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1013, 'therapyName': 'epirubicin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1137, 'therapyName': 'Bleomycin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 781, 'therapyName': 'Ixabepilone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 2950, 'therapyName': 'Estramustine'}, {'id': 1941, 'therapyName': 'Floxuridine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 1811, 'therapyName': 'Carmustine'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 953, 'therapyName': 'Vandetanib'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 4419, 'therapyName': 'Toremifine'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 2601, 'therapyName': 'Dactinomycin'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 3035, 'therapyName': 'Chlorambucil'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 342, 'therapyName': 'Vemurafenib'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 2635, 'therapyName': 'Vinblastine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 4305, 'therapyName': 'Teniposide'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 4304, 'therapyName': 'Streptozocin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1231, 'therapyName': 'Bendamustine'}, {'id': 4303, 'therapyName': 'Mechlorethamine'}, {'id': 4302, 'therapyName': 'Mitotane'}]",Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma,6787
27,NCT01562873,,Terminated,"[{'id': 907, 'therapyName': 'Ruxolitinib'}]", Ruxolitinib in Patients With Breast Cancer,6787
28,NCT01776723,Phase II,"Active, not recruiting","[{'id': 907, 'therapyName': 'Ruxolitinib'}]",A Sequential Two-Stage Dose Escalation Study to Evaluate the Safety and Efficacy of Ruxolitinib,6787
29,NCT01751425,Phase II,Recruiting,"[{'id': 907, 'therapyName': 'Ruxolitinib'}]",Ruxolitinib for Chronic Myeloid Leukemia (CML) With Minimal Residual Disease (MRD),6787
30,NCT03041636,Phase II,Recruiting,"[{'id': 907, 'therapyName': 'Ruxolitinib'}]",Administration of Jakafi (Ruxolitinib) to Patients With High-Risk Chronic Lymphocytic Leukemia (CLL),6787
31,NCT02974647,Phase II,Recruiting,"[{'id': 907, 'therapyName': 'Ruxolitinib'}]",Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma,6787
32,NCT02015208,Phase Ib/II,Completed,"[{'id': 907, 'therapyName': 'Ruxolitinib'}]",Ruxolitinib in the Treatment of Chronic Lymphocytic Leukemia,6787
33,NCT02120417,Phase II,Terminated,"[{'id': 1615, 'therapyName': 'Ruxolitinib + Capecitabine'}, {'id': 1105, 'therapyName': 'Capecitabine'}]",A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer,6787
34,NCT02119663,Phase III,Terminated,"[{'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 1615, 'therapyName': 'Ruxolitinib + Capecitabine'}]",A Study of Ruxolitinib in Pancreatic Cancer Patients,6787
35,NCT02119650,Phase II,Terminated,"[{'id': 1856, 'therapyName': 'Ruxolitinib + Cisplatin + Pemetrexed'}, {'id': 1857, 'therapyName': 'Cisplatin + Pemetrexed'}]",Ruxolitinib in Combination With Pemetrexed/Cisplatin in Non Small Cell Lung Cancer,6787
36,NCT02076191,Phase Ib/II,Recruiting,"[{'id': 1735, 'therapyName': 'Ruxolitinib + Decitabine'}]",Study of Combination Ruxolitinib and Decitabine Treatment for Accelerated Phase MPN or Post-MPN AML,6787
37,NCT02257138,Phase Ib/II,Recruiting,"[{'id': 1735, 'therapyName': 'Ruxolitinib + Decitabine'}]",Study of Ruxolitinib Plus Decitabine in Patients With Acute Myeloid Leukemia (AML),6787
38,NCT02155465,Phase Ib/II,"Active, not recruiting","[{'id': 1858, 'therapyName': 'Ruxolitinib + Erlotinib'}]",Trial of Ruxolitinib and Erlotinib in Patients With EGFR-mutant Lung Adenocarcinoma With Acquired Resistance to Erlotinib,6787
39,NCT01594216,Phase II,"Active, not recruiting","[{'id': 1108, 'therapyName': 'Ruxolitinib + Exemestane'}]", Ruxolitinib in Estrogen Receptor Positive Breast Cancer,6787
40,NCT01702064,Phase I,"Active, not recruiting","[{'id': 1116, 'therapyName': 'Ruxolitinib + Nilotinib'}]",Ruxolitinib in Combination With Nilotinib in Chronic Myeloid Leukemia (CML) Patients,6787
41,NCT02973711,Phase Ib/II,Recruiting,"[{'id': 1116, 'therapyName': 'Ruxolitinib + Nilotinib'}]",A Phase I/II Study of Ruxolitinib in Combination With Nilotinib in Patients With Chronic Phase CML,6787
42,NCT01914484,Phase II,Recruiting,"[{'id': 1116, 'therapyName': 'Ruxolitinib + Nilotinib'}]",Phase I/II Study of Nilotinib/Ruxolitinb Therapy for TKI Resistant Ph-Leukemia,6787
43,NCT02041429,Phase Ib/II,"Active, not recruiting","[{'id': 1369, 'therapyName': 'Ruxolitinib + Paclitaxel'}]",Ruxolitinib W/ Preop Chemo For Triple Negative Inflammatory Brca,6787
44,NCT02528877,Phase I,Withdrawn,"[{'id': 2237, 'therapyName': 'Fludarabine + Melphalan'}, {'id': 3181, 'therapyName': 'Ruxolitinib + Sirolimus + Tacrolimus'}]","Ruxolitinib Phosphate, Tacrolimus and Sirolimus in Preventing Acute Graft-versus-Host Disease During Reduced Intensity Donor Hematopoietic Cell Transplant in Patients With Myelofibrosis",6787
45,NCT02066532,Phase Ib/II,Recruiting,"[{'id': 1578, 'therapyName': 'Ruxolitinib + Trastuzumab'}]",Phase I/II Trial of Ruxolitinib in Combination With Trastuzumab in Metastatic HER2 Positive Breast Cancer,6787
0,NCT02089334,Phase Ib/II,Recruiting,"[{'id': 2262, 'therapyName': 'Everolimus + RX-0201'}, {'id': 735, 'therapyName': 'Everolimus'}]","Dose-Finding, Safety and Efficacy Study of RX-0201 Plus Everolimus in Metastatic Renal Cell Cancer",7014
0,NCT02003092,Phase I,Recruiting,"[{'id': 6224, 'therapyName': 'RX-5902'}]",RX-5902 Treatment of Subjects With Solid Tumors,8944
0,NCT03052569,Expanded access,Temporarily not available,"[{'id': 1002, 'therapyName': 'CEP-32496'}]",Expanded Access to RXDX-105 for Cancers With RET Alterations,7121
1,NCT01877811,Phase Ib/II,"Active, not recruiting","[{'id': 1002, 'therapyName': 'CEP-32496'}]",CEP-32496 in Patients With Advanced Solid Tumors in Phase 1 and Advanced Melanoma and Metastatic Colorectal Cancer in Phase 2,7121
0,NCT02352025,Phase I,Recruiting,"[{'id': 2596, 'therapyName': 'S-equol  '}]",S-equol in Women With Triple Negative Breast Cancer,7597
0,NCT01553071,Phase I,Recruiting,"[{'id': 1049, 'therapyName': 'Safingol'}, {'id': 2731, 'therapyName': 'Fenretinide'}]",Phase I Trial of IV Fenretinide (4-HPR) Plus IV Safingol for Patients With Relapsed Malignancies,7167
0,NCT03013998,Phase Ib/II,Recruiting,"[{'id': 4003, 'therapyName': 'Azacitidine + Enasidenib'}, {'id': 5539, 'therapyName': 'Azacitidine + Entospletinib'}, {'id': 5536, 'therapyName': 'Cytarabine + Daunorubicin + Samalizumab'}, {'id': 5538, 'therapyName': 'Azacitidine + BI 836858'}]",Study of Biomarker-Based Treatment of Acute Myeloid Leukemia,8714
1,NCT02987504,Phase I,Suspended,"[{'id': 5535, 'therapyName': 'Samalizumab'}]",Study of Samalizumab in Patients With Advanced Cancer,8714
0,NCT01303796,Phase III,Unknown status,"[{'id': 1747, 'therapyName': 'Decitabine + Sapacitabine'}, {'id': 650, 'therapyName': 'Decitabine'}]",A Study of Oral Sapacitabine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (SEAMLESS),7207
1,NCT01253460,Phase II,"Active, not recruiting","[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 3215, 'therapyName': 'Rituximab + sapacitabine'}]","Sapacitabine, Cyclophosphamide, Rituximab for Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma (CLL/SLL) With Deletion (11q22-23)",7207
2,NCT00999401,Phase I,Recruiting,"[{'id': 1130, 'therapyName': 'Sapacitabine + Seliciclib'}]",A Study of Oral Sapacitabine and Oral Seliciclib in Patients With Advanced Solid Tumors,7207
0,NCT02159989,Phase I,Recruiting,"[{'id': 1595, 'therapyName': 'Aflibercept + MLN0128'}]",MLN0128 and Ziv-Aflibercept in Treating Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed By Surgery,7232
1,NCT02719691,Phase I,Recruiting,"[{'id': 4214, 'therapyName': 'Alisertib + MLN0128'}]",Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer,7232
2,NCT02812056,Phase I,Withdrawn,"[{'id': 4214, 'therapyName': 'Alisertib + MLN0128'}]",Alisertib and TAK-228 in Participants With Human Papilloma Virus (HPV) Associated Malignancies,7232
3,NCT02503722,Phase I,Recruiting,"[{'id': 2994, 'therapyName': 'AZD9291 + MLN0128'}]",TORC1/2 Inhibitor INK128 and EGFR Inhibitor AZD9291 in Treating Patients With Advanced EGFR Mutation Positive Non-small Cell Lung Cancer After Progression on a Previous EGFR Tyrosine Kinase Inhibitor,7232
4,NCT02142803,Phase I,Recruiting,"[{'id': 1444, 'therapyName': 'MLN0128 + Bevacizumab'}]",MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors,7232
5,NCT02049957,Phase Ib/II,Recruiting,"[{'id': 1581, 'therapyName': 'MLN0128 + Fulvestrant'}, {'id': 1580, 'therapyName': 'MLN0128 + Exemestane'}]",Safety and Efficacy Study of MLN0128 in Combination With Exemestane or Fulvestrant in Postmenopausal Women With ER/PR+ Metastatic Breast Cancer,7232
6,NCT02756364,Phase II,Recruiting,"[{'id': 1581, 'therapyName': 'MLN0128 + Fulvestrant'}, {'id': 744, 'therapyName': 'Fulvestrant'}]",MLN0128 in Combination With Fulvestrant in Women With Advanced or Metastatic Breast Cancer After Aromatase Inhibitor Therapy,7232
7,NCT03017833,Phase I,Not yet recruiting,"[{'id': 5197, 'therapyName': 'MLN0128 + Metformin'}]",Study of TAK-228 (MLN0128) in Combination With Metformin in Patients With Advanced Cancers,7232
8,NCT02327169,Phase I,Recruiting,"[{'id': 2175, 'therapyName': 'MLN0128 + MLN2480'}, {'id': 2176, 'therapyName': 'MLN2480 + Alisertib'}, {'id': 2177, 'therapyName': 'MLN2480 + Paclitaxel'}]",A Phase 1B Study of MLN2480 in Combination With MLN0128 or Alisertib or Paclitaxel in Adult Patients With Advanced Nonhematologic Malignancies,7232
9,NCT02988986,Phase II,Recruiting,"[{'id': 5141, 'therapyName': 'MLN0128 + Tamoxifen'}]","TAK-228 Plus Tamoxifen in Patients With ER-Positive, HER2-negative Breast Cancer",7232
10,NCT02724020,Phase II,Recruiting,"[{'id': 1283, 'therapyName': 'MLN1117 + Sapanisertib'}, {'id': 1282, 'therapyName': 'Sapanisertib'}, {'id': 735, 'therapyName': 'Everolimus'}]",MLN0128 and MLN0128 + MLN1117 Compared With Everolimus in the Treatment of Adults With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma,7232
11,NCT01899053,Phase I,"Active, not recruiting","[{'id': 1283, 'therapyName': 'MLN1117 + Sapanisertib'}]",Phase 1b Study of MLN0128 in Combination With MLN1117 in Adult Patients With Advanced Nonhematologic Malignancies,7232
12,NCT02725268,Phase II,Recruiting,"[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1282, 'therapyName': 'Sapanisertib'}, {'id': 1283, 'therapyName': 'MLN1117 + Sapanisertib'}]","Phase 2 Study of MLN0128, Combination of MLN0128 With MLN1117, Paclitaxel and Combination of MLN0128 With Paclitaxel in Women With Endometrial Cancer",7232
13,NCT03193853,Phase II,Recruiting,"[{'id': 3126, 'therapyName': 'Cisplatin + nab-paclitaxel'}, {'id': 1283, 'therapyName': 'MLN1117 + Sapanisertib'}]",TAK-228 and TAK-117 Followed by Cisplatin and Nab Paclitaxel for Metastatic Triple Negative Breast Cancer,7232
14,NCT03154294,Phase I,Not yet recruiting,"[{'id': 5731, 'therapyName': 'Paclitaxel + MLN0128 + MLN1117'}]",Evaluation of the Safety and Tolerability of TAK-228 With TAK-117 and Paclitaxel in Advanced Solid Tumors,7232
15,NCT02133183,Phase I,Recruiting,"[{'id': 1282, 'therapyName': 'Sapanisertib'}]",TORC1/2 Inhibitor INK128 Before and After Surgery in Treating Patients With Recurrent Glioblastoma,7232
16,NCT02197572,Phase I,"Active, not recruiting","[{'id': 1282, 'therapyName': 'Sapanisertib'}]",Effect of MLN0128 on the QTc Interval in Participants With Advanced Solid Tumors,7232
17,NCT03047213,Phase II,Recruiting,"[{'id': 1282, 'therapyName': 'Sapanisertib'}]",Sapanisertib in Treating Patients With Locally Advanced or Metastatic Bladder Cancer With TSC1 and/or TSC2 Mutations,7232
18,NCT02091531,Phase II,"Active, not recruiting","[{'id': 1282, 'therapyName': 'Sapanisertib'}]",Dual mTOR Inhibitor MLN0128 in Advanced Castration-Resistant Prostate Cancer (CRPC) Patients,7232
19,NCT02619669,Phase I,Recruiting,"[{'id': 1282, 'therapyName': 'Sapanisertib'}, {'id': 794, 'therapyName': 'Letrozole'}]",Neoadjuvant Run-In Study With TAK-228 (MLN0128) Followed by Letrozole/TAK-228 (MLN0128) in Women With High-Risk ER+/HER2- Breast Cancer,7232
20,NCT02412722,Phase I,"Active, not recruiting","[{'id': 1282, 'therapyName': 'Sapanisertib'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]","Safety, Tolerability, and Pharmacokinetics of MLN0128 as a Single Agent and in Combination With Paclitaxel in Adults With Advanced Nonhematologic Malignancies",7232
21,NCT03097328,Phase II,Recruiting,"[{'id': 1282, 'therapyName': 'Sapanisertib'}]",Study of TAK-228 In Patients With Previously Treated Metastatic Renal Cell Carcinoma,7232
22,NCT02514824,Phase Ib/II,Recruiting,"[{'id': 1282, 'therapyName': 'Sapanisertib'}]",MLN0128 in Recurrent/Metastatic Merkel Cell Carcinoma,7232
23,NCT02244463,Phase II,Recruiting,"[{'id': 1282, 'therapyName': 'Sapanisertib'}]",A Phase II Study of MLN0128 in Metastatic Anaplastic Thyroid Cancer,7232
24,NCT02601209,Phase Ib/II,Suspended,"[{'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1282, 'therapyName': 'Sapanisertib'}]",Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma,7232
25,NCT02893930,Phase II,Recruiting,"[{'id': 1282, 'therapyName': 'Sapanisertib'}]",Sapanisertib in Treating Patients With Metastatic or Refractory Pancreatic Neuroendocrine Tumor That Cannot Be Removed by Surgery,7232
26,NCT02987959,Phase II,Recruiting,"[{'id': 1282, 'therapyName': 'Sapanisertib'}]",Study of TAK-228 (MLN0128) in Soft Tissue Sarcomas,7232
27,NCT02417701,Phase II,Recruiting,"[{'id': 1282, 'therapyName': 'Sapanisertib'}]",TORC1/2 Inhibitor MLN0128 in Treating Patients With Stage IV or Recurrent Lung Cancer,7232
28,NCT02575339,Phase Ib/II,Recruiting,"[{'id': 920, 'therapyName': 'Sorafenib'}, {'id': 1282, 'therapyName': 'Sapanisertib'}]",MLN0128 Compared to Sorafenib in Advanced or Metastatic Hepatocellular Carcinoma,7232
29,NCT01058707,Phase I,"Active, not recruiting","[{'id': 1282, 'therapyName': 'Sapanisertib'}]",Dose Escalation Study of MLN0128 in Subjects With Advanced Malignancies,7232
30,NCT02484430,Phase II,Recruiting,"[{'id': 1282, 'therapyName': 'Sapanisertib'}]",TORC1/2 Inhibitor INK128 in Treating Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia,7232
0,NCT01391533,Phase I,Completed,"[{'id': 2159, 'therapyName': 'SAR125844'}]",Study of SAR125844 Single Agent Administered as Slow Intravenous Infusion in Adult Patients With Advanced Malignant Solid Tumors,7451
1,NCT02435121,Phase II,Completed,"[{'id': 2159, 'therapyName': 'SAR125844'}]",A Study Assessing Efficacy and Safety of SAR125844 in NSCLC Patients With MET Amplification,7451
0,NCT01596270,Phase I,Completed,"[{'id': 1051, 'therapyName': 'SAR245409'}]",A Study of the Safety and Pharmacokinetics of SAR245409 Tablets in Patients With Solid Tumors or Lymphoma,7169
1,NCT01587040,Phase Ib/II,"Active, not recruiting","[{'id': 1050, 'therapyName': 'XL147'}, {'id': 1051, 'therapyName': 'SAR245409'}]",Open Label Treatment Extension Study With SAR245408 or SAR245409 as a Monotherapy or as a Combination Regimen,7169
0,NCT01673737,Phase I,Completed,"[{'id': 1052, 'therapyName': 'SAR260301'}, {'id': 1225, 'therapyName': 'SAR260301 + Vemurafenib'}]", A Phase I/Ib Trial for the Evaluation of SAR260301 in Monotherapy or in Combination With Vemurafenib in Patients With Various Advanced Cancer,7170
0,NCT01636479,Phase I,"Active, not recruiting","[{'id': 2078, 'therapyName': 'SAR405838'}]",Phase 1 Safety Testing of SAR405838,7416
0,NCT02575781,Phase I,Recruiting,"[{'id': 4026, 'therapyName': 'SAR428926'}]",A Study of SAR428926 in Patients With Advanced Solid Tumors,8326
0,NCT03192345,Phase I,Recruiting,"[{'id': 5934, 'therapyName': 'SAR439459 + REGN2810'}, {'id': 5933, 'therapyName': 'SAR439459'}]","A First-in-human Study of the Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of SAR439459 Monotherapy and Combination of SAR439459 and REGN2810 in Patients With Advanced Solid Tumors",8865
0,NCT03284957,Phase Ib/II,Recruiting,"[{'id': 6293, 'therapyName': 'SAR439859'}, {'id': 6294, 'therapyName': 'Palbociclib + SAR439859'}]",Phase 1 / 2 Study of SAR439859 Single Agent and in Combination With Palbociclib in Postmenopausal Women With Estrogen Receptor Positive Advanced Breast Cancer,8965
0,NCT02984683,Phase II,Recruiting,"[{'id': 5825, 'therapyName': 'SAR566658'}]",Study Evaluating Efficacy and Safety of SAR566658 Treatment in Patients With CA6 Positive Metastatic Triple Negative Breast Cancer,8818
0,NCT01216176,Phase Ib/II,"Active, not recruiting","[{'id': 633, 'therapyName': 'Anastrozole'}, {'id': 912, 'therapyName': 'Saracatinib'}]",A Pharmacokinetic and Randomized Trial of Neoadjuvant Treatment With Anastrozole Plus AZDO530 in Postmenopausal Patients With Hormone Receptor Positive Breast Cancer,7018
0,NCT01383538,Phase I,Completed,"[{'id': 2498, 'therapyName': 'Fluorouracil + Leucovorin + Irinotecan + Oxaliplatin + Saridegib'}]",FOLFIRINOX Plus IPI-926 for Advanced Pancreatic Adenocarcinoma,7519
0,NCT02143466,Phase I,Recruiting,"[{'id': 2224, 'therapyName': 'AZD9291 + Savolitinib'}, {'id': 2225, 'therapyName': 'Osimertinib + Selumetinib'}, {'id': 2223, 'therapyName': 'AZD9291 + MEDI4736'}]",AZD9291 in Combination With Ascending Doses of Novel Therapeutics,7453
1,NCT02630420,Phase I,Not yet recruiting,"[{'id': 3790, 'therapyName': 'Cetuximab + Savolitinib'}]",Cetuximab and Savolitinib Treatment of Ras Wild-Type Colorectal Cancer,7453
2,NCT02761057,Phase II,Recruiting,"[{'id': 2161, 'therapyName': 'Savolitinib'}, {'id': 998, 'therapyName': 'cabozantinib'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 930, 'therapyName': 'Sunitinib'}]","Cabozantinib-S-Malate, Crizotinib, Volitinib, or Sunitinib Malate in Treating Patients With Locally Advanced or Metastatic Kidney Cancer",7453
3,NCT02127710,Phase II,"Active, not recruiting","[{'id': 2161, 'therapyName': 'Savolitinib'}]",A Phase II Trial to Evaluate the Efficacy of AZD6094 (HMPL-504) in Patients With Papillary Renal Cell Carcinoma (PRCC),7453
4,NCT03091192,Phase III,Recruiting,"[{'id': 930, 'therapyName': 'Sunitinib'}, {'id': 2161, 'therapyName': 'Savolitinib'}]",Savolitinib vs. Sunitinib in MET-driven PRCC,7453
0,NCT03035279,Phase I,Recruiting,"[{'id': 5748, 'therapyName': 'SC-006'}]",A Study of SC-006 in Subjects With Advanced Cancer,8769
0,NCT02927964,Phase Ib/II,Recruiting,"[{'id': 4828, 'therapyName': 'Ibrutinib + SD-101 + Radiotherapy'}]","TLR9 Agonist SD-101, Ibrutinib, and Radiation Therapy in Treating Patients With Relapsed or Refractory Grade 1-3A Follicular Lymphoma",7932
1,NCT02254772,Phase Ib/II,Completed,"[{'id': 3848, 'therapyName': 'Ipilimumab + SD-101'}]","TLR9 Agonist SD-101, Ipilimumab, and Radiation Therapy in Treating Patients With Low-Grade Recurrent B-cell Lymphoma",7932
2,NCT02731742,Phase I,Recruiting,"[{'id': 4471, 'therapyName': 'MK-1966 + SD-101'}]",Dose Evaluation of MK-1966 in Combination With SD-101 in Participants With Advanced Malignancies (MK-1966-001),7932
3,NCT03007732,Phase II,Recruiting,"[{'id': 5166, 'therapyName': 'Pembrolizumab + SD-101'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab in Combination With Intratumoral SD-101 Therapy,7932
4,NCT02266147,Phase Ib/II,Completed,"[{'id': 3084, 'therapyName': 'SD-101'}]",Study of SD-101 in Combination With Localized Low-dose Radiation in Patients With Untreated Low-grade B-cell Lymphoma,7932
5,NCT01745354,Phase I,Terminated,"[{'id': 3084, 'therapyName': 'SD-101'}]",Immunostimulatory CpG SD-101 + RT in Recurrent/Progressive Lymphoma After Allogeneic Hematopoietic Cell Transplantation (HCT),7932
6,NCT02521870,Phase I,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 3084, 'therapyName': 'SD-101'}]",A Trial of Intratumoral Injections of SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma,7932
0,NCT02743637,Phase I,Recruiting,"[{'id': 4326, 'therapyName': 'SDX-7320'}]",A Dose Escalation Study of SDX-7320 in Patients With Advanced Refractory or Late-Stage Solid Tumors (SDX-0101),8416
0,NCT02376699,Phase I,Recruiting,"[{'id': 5781, 'therapyName': 'Pembrolizumab + SEA-CD40'}, {'id': 5780, 'therapyName': 'SEA-CD40'}]",Safety Study of SEA-CD40 in Cancer Patients,8795
0,NCT03008187,Phase Ib/II,Suspended,"[{'id': 3693, 'therapyName': 'SEL24-B489'}]",SEL24 in Patients With AML,8209
0,NCT02535533,Phase I,Recruiting,"[{'id': 3474, 'therapyName': 'Axitinib + Selenomethionine'}]",SLM + Axitinib for Clear Cell RCC,8092
0,NCT00999401,Phase I,Recruiting,"[{'id': 1130, 'therapyName': 'Sapacitabine + Seliciclib'}]",A Study of Oral Sapacitabine and Oral Seliciclib in Patients With Advanced Solid Tumors,7208
0,NCT02269293,Phase I,Recruiting,"[{'id': 2640, 'therapyName': 'Carboplatin + Paclitaxel + Selinexor'}]","Selective Inhibitor of Nuclear Export, Selinexor (KPT-330) in Combination With Paclitaxel and Carboplatin in Patients With Advanced Ovarian or Endometrial Cancers",7327
1,NCT02199665,Phase I,"Active, not recruiting","[{'id': 2985, 'therapyName': 'Carfilzomib + Dexamethasone + Selinexor'}]","Selinexor, Carfilzomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma",7327
2,NCT02628704,Phase II,Withdrawn,"[{'id': 2985, 'therapyName': 'Carfilzomib + Dexamethasone + Selinexor'}]","Selinexor, Carfilzomib, and Dexamethasone Versus Placebo, Carfilzomib, and Dexamethasone in Multiple Myeloma",7327
3,NCT02093403,Phase I,"Active, not recruiting","[{'id': 1768, 'therapyName': 'Decitabine + Selinexor'}]",Decitabine and Selinexor in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia,7327
4,NCT02831686,Phase I,Recruiting,"[{'id': 4500, 'therapyName': 'Dexamethasone + Ixazomib + Selinexor'}]","A Study to Test the Combination of Selinexor (KPT-330), Ixazomib, and Dexamethasone in Patients With Myeloma",7327
5,NCT02780609,Phase Ib/II,Recruiting,"[{'id': 4221, 'therapyName': 'Dexamethasone + Melphalan + Selinexor'}]",Selinexor Plus High-Dose Melphalan (HDM) Before Autologous Hematopoietic Cell Transplantation for Multiple Myeloma,7327
6,NCT02186834,Phase Ib/II,"Active, not recruiting","[{'id': 3356, 'therapyName': 'Dexamethasone + pegylated liposomal-doxorubicin + Selinexor'}]",Selinexor (KPT-330) and Pegylated Liposomal Doxorubicin For Relapsed and Refractory Multiple Myeloma,7327
7,NCT02343042,Phase Ib/II,Recruiting,"[{'id': 688, 'therapyName': 'Bortezomib'}, {'id': 2479, 'therapyName': 'Dexamethasone + Selinexor'}, {'id': 1622, 'therapyName': 'Pomalidomide'}]",Phase 1b/2 Study of Selinexor (KPT-330) in Combination w/ Backbone Treatments for Resistant/Refractory Multiple Myeloma,7327
8,NCT02336815,Phase II,Recruiting,"[{'id': 2479, 'therapyName': 'Dexamethasone + Selinexor'}]",Phase 2b Open-Label Single-Arm Selinexor (KPT-330) + Low-Dose Dexamethasone in Patients w/ Multiple Myeloma Quad-refractory to Previous Therapies,7327
9,NCT03095612,Phase Ib/II,Not yet recruiting,"[{'id': 5534, 'therapyName': 'Docetaxel + Selinexor'}]",Phase 1/2 Trial of Selinexor (KPT-330) With Docetaxel for Non-small Cell Lung Cancer (NSCLC),7327
10,NCT02178436,Phase Ib/II,Suspended,"[{'id': 2560, 'therapyName': 'Gemcitabine + nab-paclitaxel + Selinexor'}]","Selinexor, Gemcitabine Hydrochloride, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Metastatic Pancreatic Cancer",7327
11,NCT02303392,Phase I,Recruiting,"[{'id': 3579, 'therapyName': 'Ibrutinib + Selinexor'}]",Selinexor and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Aggressive Non-Hodgkin Lymphoma,7327
12,NCT02283359,Phase I,Terminated,"[{'id': 2588, 'therapyName': 'Irinotecan + Selinexor'}]",Selinexor in Combination With Irinotecan in Adenocarcinoma of Stomach and Distal Esophagus,7327
13,NCT02351505,Phase II,Terminated,"[{'id': 1749, 'therapyName': 'Selinexor'}]",Selinexor in Treating Patients With Relapsed Small Cell Lung Cancer,7327
14,NCT02416908,Phase Ib/II,Recruiting,"[{'id': 1749, 'therapyName': 'Selinexor'}, {'id': 3178, 'therapyName': 'Cladribine + Cytarabine + Plerixafor'}]",Study of CLAG + Selinexor in Relapsed or Refractory Acute Myeloid Leukemia,7327
15,NCT02138786,Phase II,Terminated,"[{'id': 1749, 'therapyName': 'Selinexor'}]",Study of Selinexor (KPT-330) in Patients With Refractory and/or Relapsed Richter's Transformation (RT),7327
16,NCT03193437,Phase II,Not yet recruiting,"[{'id': 1749, 'therapyName': 'Selinexor'}]",Selinexor in Patients With Advanced Thymic Epithelial Tumor Progressing After Primary Chemotherapy,7327
17,NCT02606461,Phase II,Recruiting,"[{'id': 1749, 'therapyName': 'Selinexor'}]",KCP-330-020 SEAL (Selinexor in Advanced Liposarcoma) (SEAL),7327
18,NCT02227251,Phase II,Recruiting,"[{'id': 1749, 'therapyName': 'Selinexor'}]",Study of Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (SADAL),7327
19,NCT02471911,Phase I,Recruiting,"[{'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 3360, 'therapyName': 'Carboplatin + Etoposide + Ifosfamide + Rituximab'}, {'id': 1749, 'therapyName': 'Selinexor'}]",KPT-330 Plus RICE for Relapsed/Refractory Aggressive B-Cell Lymphoma,7327
20,NCT02088541,Phase II,"Active, not recruiting","[{'id': 712, 'therapyName': 'Cytarabine'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 1749, 'therapyName': 'Selinexor'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}]",Selinexor (KPT-330) in Older Patients With Relapsed AML,7327
21,NCT02228525,Phase II,Recruiting,"[{'id': 1749, 'therapyName': 'Selinexor'}]",Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) in Patients With Myelodysplastic Syndromes,7327
22,NCT02250885,Phase II,Completed,"[{'id': 1749, 'therapyName': 'Selinexor'}]",KPT-330 to Treat Poorly Differentiated Lung and Gastroenteropancreatic Tumors,7327
23,NCT02573363,Phase I,Recruiting,"[{'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 1749, 'therapyName': 'Selinexor'}]",Selinexor With Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia,7327
24,NCT02323880,Phase I,Recruiting,"[{'id': 1749, 'therapyName': 'Selinexor'}]",Study of Selinexor in Pediatric Solid Tumors,7327
25,NCT01607905,Phase I,Completed,"[{'id': 1749, 'therapyName': 'Selinexor'}]",Safety Study of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients With Advanced or Metastatic Solid Tumor Cancer,7327
26,NCT02299518,Phase I,Recruiting,"[{'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1749, 'therapyName': 'Selinexor'}, {'id': 1752, 'therapyName': 'Mitoxantrone + Etoposide + Cytarabine'}]",Selinexor and Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia,7327
27,NCT02419495,Phase I,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1749, 'therapyName': 'Selinexor'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 1009, 'therapyName': 'Doxorubicin'}]",Selinexor in Combination With Standard Chemotherapy,7327
28,NCT02215161,Phase II,"Active, not recruiting","[{'id': 1749, 'therapyName': 'Selinexor'}]",Selinexor (KPT-330) in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Prior Therapy With Abiraterone and/or Enzalutamide,7327
29,NCT02146833,Phase II,Terminated,"[{'id': 1749, 'therapyName': 'Selinexor'}]",Study of Selinexor (KPT-330) in Metastatic Castrate Resistant Prostate Adenocarcinoma,7327
30,NCT02403310,Phase I,"Active, not recruiting","[{'id': 1738, 'therapyName': 'Daunorubicin + Cytarabine'}, {'id': 1749, 'therapyName': 'Selinexor'}]",A Study of Selinexor in Combination With Daunorubicin and Cytarabine for Untreated AML,7327
31,NCT01986348,Phase II,"Active, not recruiting","[{'id': 1749, 'therapyName': 'Selinexor'}]",Phase 2 Study of Selinexor (KPT-330) in Patients With Recurrent Glioblastoma After Failure of Radiation and Temozolomide,7327
32,NCT02069730,Phase I,Recruiting,"[{'id': 1749, 'therapyName': 'Selinexor'}]",A Study of Drug Therapies for Salivary Gland Cancers Based on Testing of Genes,7327
33,NCT02091245,Phase I,Recruiting,"[{'id': 1749, 'therapyName': 'Selinexor'}]","Phase I Trial of the Selective Inhibitor of Nuclear Export, KPT-330, in Relapsed Childhood ALL and AML",7327
34,NCT02212561,Phase Ib/II,Completed,"[{'id': 1749, 'therapyName': 'Selinexor'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 2345, 'therapyName': 'Cytarabine + Dexamethasone+ Methotrexate '}, {'id': 1166, 'therapyName': 'Fludarabine'}]",Selinexor With Fludarabine and Cytarabine for Treatment of Refractory or Relapsed Leukemia or Myelodysplastic Syndrome,7327
35,NCT02120222,Phase I,Recruiting,"[{'id': 1749, 'therapyName': 'Selinexor'}]",Evaluating SINE KPT-330 in Treating Patients With Melanoma That Cannot Be Removed By Surgery,7327
36,NCT02536495,Phase Ib/II,Withdrawn,"[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1749, 'therapyName': 'Selinexor'}]",Selinexor and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Lung Cancer,7327
37,NCT03147885,Phase Ib/II,Recruiting,"[{'id': 1749, 'therapyName': 'Selinexor'}]",Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin Lymphoma,7327
38,NCT02485535,Phase I,Recruiting,"[{'id': 1749, 'therapyName': 'Selinexor'}]",Selinexor in Treating Patients With Intermediate- and High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome After Transplant,7327
39,NCT02402764,Phase II,"Active, not recruiting","[{'id': 1749, 'therapyName': 'Selinexor'}]",Phase 2 Trial of Selinexor (KPT-330) for Metastatic TNBC,7327
40,NCT03110562,Phase III,Recruiting,"[{'id': 5639, 'therapyName': 'Selinexor + Bortezomib + Dexamethasone'}, {'id': 2470, 'therapyName': 'Bortezomib + Dexamethasone'}]","Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple Myeloma (BOSTON)",7327
41,NCT03042819,Phase I,Recruiting,"[{'id': 5286, 'therapyName': 'Selinexor + Doxorubicin'}]",Study of Selinexor and Doxorubicin in Advanced Soft Tissue Sarcomas,7327
42,NCT03071276,Phase II,Recruiting,"[{'id': 5448, 'therapyName': 'Selinexor + Fludarabine phosphate + Cytarabine + Methotrexate + Prednisone'}]",Selinexor in Combination With Fludarabine and Cytarabine in Patients With Refractory or Relapsed Acute Myeloid Leukemia,7327
43,NCT02530476,Phase Ib/II,Recruiting,"[{'id': 3189, 'therapyName': 'Selinexor + Sorafenib'}]","Phase I/II, Study of Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) + Sorafenib in Acute Myeloid Leukemia",7327
0,NCT03004105,Phase II,Not yet recruiting,"[{'id': 3162, 'therapyName': 'MEDI4736 + Selumetinib'}]",MEDI4736 With Selumetinib for KRAS Mutant Non-Small Cell Lung Cancer (NSCLC),7019
1,NCT02586987,Phase I,Recruiting,"[{'id': 3162, 'therapyName': 'MEDI4736 + Selumetinib'}]","A Study to Assess the Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of Ascending Doses of Selumetinib in Combination With MEDI4736 in Patients With Advanced Solid Tumours",7019
2,NCT01248247,Phase I,"Active, not recruiting","[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 1098, 'therapyName': 'MK2206 + Selumetinib'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 1097, 'therapyName': 'Erlotinib + MK2206'}]",BATTLE-2 Program: A Biomarker-Integrated Targeted Therapy Study,7019
3,NCT03162627,Phase I,Recruiting,"[{'id': 5793, 'therapyName': 'Olaparib + Selumetinib'}]",Selumetinib and Olaparib in Solid Tumors,7019
4,NCT02143466,Phase I,Recruiting,"[{'id': 2224, 'therapyName': 'AZD9291 + Savolitinib'}, {'id': 2225, 'therapyName': 'Osimertinib + Selumetinib'}, {'id': 2223, 'therapyName': 'AZD9291 + MEDI4736'}]",AZD9291 in Combination With Ascending Doses of Novel Therapeutics,7019
5,NCT03259633,Expanded access,Available,"[{'id': 913, 'therapyName': 'Selumetinib'}]",An Intermediate Access Protocol for Selumetinib for Treatment of Neurofibromatosis Type 1,7019
6,NCT02503358,Phase I,Recruiting,"[{'id': 913, 'therapyName': 'Selumetinib'}, {'id': 619, 'therapyName': 'Abraxane'}]",Selumetinib and Nab-Paclitaxel (Albumin-stabilized Nanoparticle Formulation) as Second-Line Treatment in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer,7019
7,NCT03040986,Phase II,Not yet recruiting,"[{'id': 913, 'therapyName': 'Selumetinib'}]",Selumetinib Sulfate in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer With KRAS G12R Mutations,7019
8,NCT01306045,Phase II,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 816, 'therapyName': 'MK2206'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 913, 'therapyName': 'Selumetinib'}]","Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies",7019
9,NCT02407405,Phase II,Recruiting,"[{'id': 913, 'therapyName': 'Selumetinib'}]",Selumetinib in Treating Patients With Neurofibromatosis Type 1 and Plexiform Neurofibromas That Cannot Be Removed by Surgery,7019
10,NCT03095248,Phase II,Recruiting,"[{'id': 913, 'therapyName': 'Selumetinib'}]",Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors,7019
11,NCT02337530,Phase II,"Active, not recruiting","[{'id': 913, 'therapyName': 'Selumetinib'}, {'id': 1857, 'therapyName': 'Cisplatin + Pemetrexed'}]",Selumetinib in Patients Receiving Pemetrexed and Cisplatin in Advanced or Metastatic KRAS Wildtype or Unknown Non-Squamous Non-Small Cell Lung Cancer,7019
12,NCT02839720,Phase I,Recruiting,"[{'id': 913, 'therapyName': 'Selumetinib'}]",Selumetinib in Treating Patients With Neurofibromatosis Type 1 and Dermal Neurofibroma,7019
13,NCT03155620,Phase II,Recruiting,"[{'id': 2683, 'therapyName': 'Tazemetostat'}, {'id': 2650, 'therapyName': 'LOXO-101'}, {'id': 1069, 'therapyName': 'LY3023414'}, {'id': 342, 'therapyName': 'Vemurafenib'}, {'id': 837, 'therapyName': 'Olaparib'}, {'id': 913, 'therapyName': 'Selumetinib'}, {'id': 961, 'therapyName': 'X-396'}]",Pediatric MATCH: Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Advanced Refractory Solid Tumors or Lymphomas,7019
14,NCT02768766,Phase I,Recruiting,"[{'id': 913, 'therapyName': 'Selumetinib'}]",Intermittent Selumetinib for Uveal Melanoma,7019
15,NCT01089101,Phase Ib/II,Recruiting,"[{'id': 913, 'therapyName': 'Selumetinib'}]",Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma,7019
16,NCT03109301,Phase II,Recruiting,"[{'id': 913, 'therapyName': 'Selumetinib'}]",A Phase II Trial of the Mitogen Activated Protein Kinase Kinase (MEK1/2) Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Patients With Neurofibromatosis Type 1 (NF1) Mutated Gastrointestinal Stromal Tumors (GIST),7019
17,NCT01783197,Phase I,"Active, not recruiting","[{'id': 913, 'therapyName': 'Selumetinib'}]", Study of Selumetinib in Patients With Previously Treated or Untreated Advanced/Metastatic NSCLC,7019
18,NCT01362803,Phase I,Recruiting,"[{'id': 913, 'therapyName': 'Selumetinib'}]",AZD6244 Hydrogen Sulfate for Children With Nervous System Tumors,7019
19,NCT02188264,Phase I,"Active, not recruiting","[{'id': 1650, 'therapyName': 'Cyclosporine'}, {'id': 913, 'therapyName': 'Selumetinib'}]",Selumetinib and Cyclosporine in Treating Patients With Advanced Solid Tumors or Advanced or Metastatic Colorectal Cancer,7019
20,NCT01843062,Phase III,"Active, not recruiting","[{'id': 913, 'therapyName': 'Selumetinib'}]",Study Comparing Complete Remission After Treatment With Selumetinib/Placebo in Patient With Differentiated Thyroid Cancer,7019
21,NCT02393690,Phase II,Recruiting,"[{'id': 913, 'therapyName': 'Selumetinib'}]",Iodine I-131 With or Without Selumetinib in Treating Patients With Recurrent or Metastatic Thyroid Cancer,7019
22,NCT03213691,Phase II,Recruiting,"[{'id': 913, 'therapyName': 'Selumetinib'}]","Pediatric MATCH: Selumetinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations",7019
23,NCT02151084,Phase II,Recruiting,"[{'id': 2222, 'therapyName': 'Selumetinib + Cisplatin + Gemcitabine'}]",A Study of Different Dosing Schedules of Selumetinib With Cisplatin/Gemcitabine (CIS/GEM) Versus CIS/GEM Alone in Biliary Cancer,7019
24,NCT01974752,Phase III,Completed,"[{'id': 1432, 'therapyName': 'Selumetinib + Dacarbazine'}]",Selumetinib (AZD6244: ARRY-142886) (Hyd-Sulfate) in Metastatic Uveal Melanoma (SUMIT),7019
25,NCT02179671,Phase II,Completed,"[{'id': 1117, 'therapyName': 'Selumetinib + Docetaxel'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 660, 'therapyName': 'AZD9291'}, {'id': 1652, 'therapyName': 'Tremelimumab'}]","Immune-Modulated Study of Selected Small Molecules (Gefitinib, AZD9291, or Selumetinib + Docetaxel) or a 1st Immune-Mediated Therapy (IMT; Tremelimumab) With a Sequential Switch to a 2nd IMT (MEDI4736) in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer",7019
26,NCT01933932,Phase III,"Active, not recruiting","[{'id': 1117, 'therapyName': 'Selumetinib + Docetaxel'}]",Assess Efficacy and Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC,7019
27,NCT01750281,Phase II,"Active, not recruiting","[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1117, 'therapyName': 'Selumetinib + Docetaxel'}]",Assess Efficacy and Safety of AZD6244 in Combination With Docetaxel in Patients Receiving Second Line Non Small Cell Lung Cancer Treatment.,7019
0,NCT01642342,Phase I,Recruiting,"[{'id': 3013, 'therapyName': 'sEphB4-HSA'}]",Recombinant Albumin Fusion Protein sEphB4-HSA in Treating Patients With Metastatic or Recurrent Solid Tumors,7910
1,NCT03049618,Phase II,Recruiting,"[{'id': 3944, 'therapyName': 'sEphB4-HSA + Pembrolizumab'}]","Recombinant EphB4-HSA Fusion Protein and Pembrolizumab, MK-3475",7910
2,NCT02717156,Phase II,Recruiting,"[{'id': 3944, 'therapyName': 'sEphB4-HSA + Pembrolizumab'}]",Recombinant EphB4-HSA Fusion Protein and Pembrolizumab in Treating Patients With Metastatic or Recurrent Urothelial Cancer That Is Refractory to Certain Chemotherapy Drugs,7910
0,NCT02387216,Phase II,Recruiting,"[{'id': 820, 'therapyName': 'Seribantumab'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 720, 'therapyName': 'Docetaxel'}]",A Study of MM-121 in Combination With Chemotherapy Versus Chemotherapy Alone in Heregulin Positive NSCLC,6957
1,NCT02538627,Phase I,Terminated,"[{'id': 820, 'therapyName': 'Seribantumab'}, {'id': 821, 'therapyName': 'MM-151'}]",Phase 1 Combination Study of MM-151 and MM-121,6957
2,NCT03241810,,Recruiting,"[{'id': 744, 'therapyName': 'Fulvestrant'}, {'id': 820, 'therapyName': 'Seribantumab'}]",Phase 2 Trial of Seribantumab Plus Fulvestrant in Postmenopausal Women With Metastatic Breast Cancer,6957
0,NCT02337309,Phase I,Recruiting,"[{'id': 915, 'therapyName': 'SF1126'}]",SF1126 for Patients With Relapsed or Refractory Neuroblastoma,7020
1,NCT02644122,Phase II,Recruiting,"[{'id': 915, 'therapyName': 'SF1126'}]",SF1126 in Recurrent or Progressive SCCHN and Mutations in PIK3CA Gene and/or PI-3 Kinase Pathway Genes,7020
2,NCT03059147,Phase I,Recruiting,"[{'id': 915, 'therapyName': 'SF1126'}]",A Study of Single Agent SF1126 Inhibitor in Patients With Advanced Hepatocellular Carcinoma,7020
0,NCT03206047,Phase Ib/II,Recruiting,"[{'id': 4693, 'therapyName': 'Atezolizumab + SGI-110'}, {'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 5982, 'therapyName': 'Atezolizumab + SGI-110 + DEC-205-NY-ESO-1 fusion protein vaccine'}]","Atezolizumab, Guadecitabine, and CDX-1401 Vaccine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",7370
1,NCT02892318,Phase I,Recruiting,"[{'id': 4693, 'therapyName': 'Atezolizumab + SGI-110'}]",A Study Evaluating the Safety and Pharmacology of Atezolizumab Administered in Combination With Immunomodulatory Agents in Participants With Acute Myeloid Leukemia (AML),7370
2,NCT02935361,Phase Ib/II,Recruiting,"[{'id': 4693, 'therapyName': 'Atezolizumab + SGI-110'}]",Guadecitabine and Atezolizumab in Treating Patients With Advanced Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia That Is Refractory or Relapsed,7370
3,NCT03257761,Phase I,Not yet recruiting,"[{'id': 6146, 'therapyName': 'Durvalumab + SGI-110'}]","Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer",7370
4,NCT03220477,Phase I,Recruiting,"[{'id': 6042, 'therapyName': 'Mocetinostat + Pembrolizumab + SGI-110'}]",Pembrolizumab (Immunotherapy Drug) in Combination With Guadecitabine and Mocetinostat (Epigenetic Drugs) for Patients With Advanced Lung Cancer.,7370
5,NCT02901899,Phase II,Recruiting,"[{'id': 4725, 'therapyName': 'Pembrolizumab + SGI-110'}]","Guadecitabine and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer",7370
6,NCT02684162,Phase II,Recruiting,"[{'id': 1949, 'therapyName': 'SGI-110'}]",SGI-110 With Donor Lymphocyte Infusion (DLI) for Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS) Relapsing Post Allogeneic Stem Cell Transplantation (AlloSCT),7370
7,NCT02348489,Phase III,"Active, not recruiting","[{'id': 1949, 'therapyName': 'SGI-110'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 650, 'therapyName': 'Decitabine'}]","SGI-110 in Adults With Untreated Acute Myeloid Leukemia (AML), Not Considered Candidates for Intensive Remission Induction",7370
8,NCT03075826,Phase II,Recruiting,"[{'id': 1949, 'therapyName': 'SGI-110'}]",A Phase II Study of SGI-110 in Philadelphia-Negative Myeloproliferative Neoplasms,7370
9,NCT03165721,Phase II,Recruiting,"[{'id': 1949, 'therapyName': 'SGI-110'}]","A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), in Children and Adults With Wild Type GIST,Pheochromocytoma and Paraganglioma Associated With Succinate Dehydrogenase Deficiency and HLRCC-associated Kidney Cancer",7370
10,NCT01966289,Phase I,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1949, 'therapyName': 'SGI-110'}, {'id': 2977, 'therapyName': 'GVAX colorectal cancer vaccine'}]",SGI-110 in Combination With an Allogeneic Colon Cancer Cell Vaccine (GVAX) and Cyclophosphamide (CY) in Metastatic Colorectal Cancer (mCRC),7370
11,NCT02096055,Phase II,Recruiting,"[{'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1949, 'therapyName': 'SGI-110'}, {'id': 1022, 'therapyName': 'Idarubicin'}]",4-Arm Phase II Study of SGI-110 in Elderly Acute Myeloid Leukemia (AML),7370
12,NCT02907359,Phase III,Recruiting,"[{'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1949, 'therapyName': 'SGI-110'}]",Guadecitabine (SGI-110) vs Treatment Choice in Adults With MDS or CMML Previously Treated With HMAs,7370
13,NCT02920008,Phase III,Recruiting,"[{'id': 650, 'therapyName': 'Decitabine'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1949, 'therapyName': 'SGI-110'}]","Phase 3 Randomized, Open-Label Study of Guadecitabine vs Treatment Choice in Previously Treated Acute Myeloid Leukemia",7370
14,NCT02429466,Phase I,Recruiting,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1949, 'therapyName': 'SGI-110'}]",Study of the Hypomethylating Drug SGI-110 Plus Cisplatin in Relapsed Refractory Germ Cell Tumors,7370
15,NCT02131597,Phase II,Recruiting,"[{'id': 1949, 'therapyName': 'SGI-110'}]",SGI-110 in Higher Risk Myelodysplastic Syndrome (MDS),7370
16,NCT01896856,Phase Ib/II,Recruiting,"[{'id': 2015, 'therapyName': 'SGI-110 + Irinotecan'}, {'id': 890, 'therapyName': 'Regorafenib'}]",Phase I Study of SGI-110 With Irinotecan Followed by Randomized Phase II Study of SGI-110 With Irinotecan Versus Regorafenib in Previously Treated Metastatic Colorectal Cancer,7370
17,NCT03085849,Phase I,Recruiting,"[{'id': 5488, 'therapyName': 'SGI-110 + MEDI4736 + Tremelimumab'}]",SGI-110 Plus Durvalumab/Tremelimumab in SCLC,7370
0,NCT02952989,Phase I,Recruiting,"[{'id': 5896, 'therapyName': 'SGN-2FF'}]",A Safety Study of SGN-2FF for Patients With Advanced Solid Tumors,8851
0,NCT01969643,Phase I,Recruiting,"[{'id': 3615, 'therapyName': 'SGN-LIV1A '}]",A Safety Study of SGN-LIV1A in Breast Cancer Patients,8174
0,NCT02340117,Phase II,Recruiting,"[{'id': 2518, 'therapyName': 'SGT-53'}, {'id': 1779, 'therapyName': 'Nab-paclitaxel + Gemcitabine'}]",Study of Combined SGT-53 Plus Gemcitabine/Nab-Paclitaxel for Metastatic Pancreatic Cancer,7551
1,NCT02340156,Phase II,Recruiting,"[{'id': 2518, 'therapyName': 'SGT-53'}, {'id': 1141, 'therapyName': 'Temozolomide'}]",Phase II Study of Combined Temozolomide and SGT-53 for Treatment of Recurrent Glioblastoma,7551
2,NCT02354547,Phase I,Recruiting,"[{'id': 3617, 'therapyName': 'SGT-53 + Cyclophosphamide + Topotecan'}]",A Study of SGT-53 in Children With Refractory or Recurrent Solid Tumors,7551
0,NCT02128282,Phase Ib/II,Recruiting,"[{'id': 1467, 'therapyName': 'Gemcitabine + Cisplatin'}, {'id': 6091, 'therapyName': 'Cisplatin + Gemcitabine + Silmitasertib'}]",Study of CX-4945 in Combination With Gemcitabine and Cisplatin for Frontline Treatment of Cholangiocarcinoma,8911
0,NCT03024216,Phase I,Recruiting,"[{'id': 5642, 'therapyName': 'Atezolizumab + Sipuleucel-T'}]",Clinical Study of Atezolizumab (Anti-PD-L1) and Sipuleucel-T in Patients Who Have Asymptomatic or Minimally Symptomatic Metastatic Castrate Resistant Prostate Cancer,7624
1,NCT02793219,Phase II,Not yet recruiting,"[{'id': 4270, 'therapyName': 'Docetaxel + Sipuleucel-T'}]",Provenge Followed by Docetaxel in Castration-Resistant Prostate Cancer,7624
2,NCT02793765,Phase II,Not yet recruiting,"[{'id': 4270, 'therapyName': 'Docetaxel + Sipuleucel-T'}]",Docetaxel Followed by Provenge in Metastatic Prostate Cancer,7624
3,NCT02036918,Phase I,Recruiting,"[{'id': 2648, 'therapyName': 'Sipuleucel-T'}]",Dendreon Lymph Node Biopsy in Metastatic Castrate-Resistant Prostate Cancer,7624
4,NCT02353715,Phase I,Recruiting,"[{'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 2648, 'therapyName': 'Sipuleucel-T'}]","Men With Metastatic Castrate-Resistant Prostate Cancer Treated With Either Sipuleucel-T (Provenge), Abiraterone Acetate (Zytiga) or Enzalutamide (Xtandi) Undergoing Cardiopulmonary EXercise Testing",7624
5,NCT01706458,Phase II,"Active, not recruiting","[{'id': 2698, 'therapyName': 'pTVG-HP plasmid DNA vaccine'}, {'id': 2648, 'therapyName': 'Sipuleucel-T'}]",Provenge With or Without pTVG-HP DNA Booster Vaccine in Prostate Cancer,7624
6,NCT01807065,Phase II,"Active, not recruiting","[{'id': 2648, 'therapyName': 'Sipuleucel-T'}]",Sipuleucel-T With or Without Radiation Therapy in Treating Patients With Hormone-Resistant Metastatic Prostate Cancer,7624
7,NCT02159950,Phase II,Completed,"[{'id': 2648, 'therapyName': 'Sipuleucel-T'}, {'id': 2699, 'therapyName': 'Tasquinimod'}]",Sipuleucel-T With or Without Tasquinimod in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer,7624
8,NCT01560923,Phase II,"Active, not recruiting","[{'id': 2648, 'therapyName': 'Sipuleucel-T'}]",Phase II Study of Sipuleucel-T and Indoximod for Patients With Refractory Metastatic Prostate Cancer,7624
9,NCT02463799,Phase II,Recruiting,"[{'id': 2001, 'therapyName': 'radium Ra 223 dichloride'}, {'id': 2648, 'therapyName': 'Sipuleucel-T'}]",Ph 2 Study of Sipuleucel-T W/ or W/O Radium-223 in Men With Asymptomatic or Minimally Symptomatic Bone-MCRPC,7624
10,NCT01818986,Phase II,Recruiting,"[{'id': 2648, 'therapyName': 'Sipuleucel-T'}]",Sipuleucel-T and Stereotactic Ablative Body Radiation (SABR) for Metastatic Castrate-resistant Prostate Cancer (mCRPC),7624
0,NCT01737502,Phase II,Recruiting,"[{'id': 2301, 'therapyName': 'Auranofin + Sirolimus'}]",PKCi and mTOR Inhibition With Auranofin+Sirolimus for Squamous Cell Lung Cancer,867
1,NCT01869114,Phase II,Recruiting,"[{'id': 2233, 'therapyName': 'Azacitidine + Sirolimus'}]",Sirolimus and Azacitidine in Treating Patients With High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia That is Recurrent or Not Eligible for Intensive Chemotherapy,867
2,NCT02565901,Phase Ib/II,Recruiting,"[{'id': 3111, 'therapyName': 'Carboplatin + Docetaxel + Sirolimus '}]","Sirolimus, Docetaxel, and Carboplatin in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer",867
3,NCT02574728,Phase II,Recruiting,"[{'id': 3143, 'therapyName': 'Celecoxib + Cyclophosphamide + Etoposide + Sirolimus'}]",Sirolimus in Combination With Metronomic Chemotherapy in Children With Recurrent and/or Refractory Solid and CNS Tumors,867
4,NCT01938573,Phase Ib/II,Completed,"[{'id': 2289, 'therapyName': 'Cisplatin + Gemcitabine + Sirolimus '}]","Sirolimus, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Bladder Cancer",867
5,NCT01888302,Phase I,Completed,"[{'id': 2289, 'therapyName': 'Cisplatin + Gemcitabine + Sirolimus '}]","Sirolimus, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients At High Risk for Cholangiocarcinoma Recurrence After Liver Transplant or Surgery",867
6,NCT01804634,Phase II,Recruiting,"[{'id': 1373, 'therapyName': 'Cyclophosphamide + Fludarabine + Melphalan + Sirolimus'}]",A Phase II Trial of Reduced Intensity Conditioning and Haploidentical BMT for High-risk Solid Tumors,867
7,NCT03128034,Phase Ib/II,Recruiting,"[{'id': 5714, 'therapyName': 'Cyclosporine + Fludarabine phosphate + Mycophenolate mofetil + Sirolimus'}]","211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome",867
8,NCT01251575,Phase II,Recruiting,"[{'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 2270, 'therapyName': 'Cyclosporine + Mycophenolate mofetil + Sirolimus'}]","Sirolimus, Cyclosporine, and Mycophenolate Mofetil In Preventing Graft-Versus-Host Disease in Treating Patients With Hematologic Malignancies Undergoing Donor Peripheral Blood Stem Cell Transplant",867
9,NCT01822015,Phase I,"Active, not recruiting","[{'id': 2232, 'therapyName': 'Cytarabine + Idarubicin + Sirolimus'}]","Sirolimus, Idarubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia",867
10,NCT02109744,Phase Ib/II,Recruiting,"[{'id': 1796, 'therapyName': 'Decitabine + Sirolimus'}, {'id': 1797, 'therapyName': 'Decitabine + Ribavirin'}]",Study of Decitabine in Combination With Sequential Rapamycin or Ribavirin in High Risk AML Patients,867
11,NCT01962896,Phase II,Recruiting,"[{'id': 2253, 'therapyName': 'Erlotinib + Sirolimus'}]",A Phase II Study of Sirolimus and Erlotinib in Recurrent/Refractory Germ Cell Tumors,867
12,NCT02008877,Phase Ib/II,"Active, not recruiting","[{'id': 2271, 'therapyName': 'Ganetespib + Sirolimus'}]",A Trial of Ganetespib Plus Sirolimus: Phase 1 Includes Multiple Sarcoma Subtypes and Phase 2 MPNST,867
13,NCT01087983,Phase I,Completed,"[{'id': 1139, 'therapyName': 'Lapatinib + Sirolimus'}, {'id': 1140, 'therapyName': 'Lapatinib + Metformin'}]",Lapatinib With Sirolimus or Metformin,867
14,NCT02833506,Phase I,Not yet recruiting,"[{'id': 4460, 'therapyName': 'NY-ESO-1 peptide vaccine + Sirolimus'}, {'id': 2696, 'therapyName': 'NY-ESO-1 peptide vaccine'}]","Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",867
15,NCT02584647,Phase Ib/II,Recruiting,"[{'id': 3155, 'therapyName': 'PLX3397 + Sirolimus'}]",Combination of PLX3397 and Sirolimus in Unresectable Sarcoma (Phase 1) and Malignant Peripheral Nerve Sheath Tumors (Phase 2),867
16,NCT02528877,Phase I,Withdrawn,"[{'id': 2237, 'therapyName': 'Fludarabine + Melphalan'}, {'id': 3181, 'therapyName': 'Ruxolitinib + Sirolimus + Tacrolimus'}]","Ruxolitinib Phosphate, Tacrolimus and Sirolimus in Preventing Acute Graft-versus-Host Disease During Reduced Intensity Donor Hematopoietic Cell Transplant in Patients With Myelofibrosis",867
17,NCT01791088,Phase I,"Active, not recruiting","[{'id': 917, 'therapyName': 'Sirolimus'}]",Sirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed By Surgery,867
18,NCT02753309,Phase 0,Recruiting,"[{'id': 917, 'therapyName': 'Sirolimus'}]",A Study of Rapamycin Combined With Intravesical BCG in Patients With Non-muscle Invasive Bladder Cancer,867
19,NCT03298958,Phase III,Not yet recruiting,"[{'id': 917, 'therapyName': 'Sirolimus'}]",Secondary Prevention Trial of Rapamycin in Patients With Resected Non-muscle Invasive Bladder Cancer,867
20,NCT02009332,Phase Ib/II,Recruiting,"[{'id': 917, 'therapyName': 'Sirolimus'}]",Phase 1/2 Study of ABI-009 in Nonmuscle Invasive Bladder Cancer,867
21,NCT02110069,Phase II,Recruiting,"[{'id': 1631, 'therapyName': 'Vincristine'}, {'id': 917, 'therapyName': 'Sirolimus'}]",A Study to Compare Vincristine to Sirolimus for Treatment of High Risk Vascular Tumors,867
22,NCT01231412,Phase III,"Active, not recruiting","[{'id': 917, 'therapyName': 'Sirolimus'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 2272, 'therapyName': 'Cyclosporine + Mycophenolate mofetil'}]",Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant,867
23,NCT00092222,Phase II,Recruiting,"[{'id': 917, 'therapyName': 'Sirolimus'}, {'id': 1187, 'therapyName': 'Alpha 2 Interferon'}, {'id': 2211, 'therapyName': 'EPOCH'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1008, 'therapyName': 'Doxil'}]",Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity,867
24,NCT02722668,Phase II,Recruiting,"[{'id': 2281, 'therapyName': 'Cyclophosphamide + Fludarabine + Mycophenolate mofetil'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 1844, 'therapyName': 'anti-thymocyte globulin'}]",UCB Transplant for Hematological DIseases Using a Non Myeloablative Prep,867
25,NCT01843998,Phase II,Withdrawn,"[{'id': 917, 'therapyName': 'Sirolimus'}]",Therapeutic Efficacy of Topical Sirolimus in Early Stage Cutaneous T-cell Lymphoma (CTCL),867
26,NCT02756572,Phase I,Recruiting,"[{'id': 917, 'therapyName': 'Sirolimus'}, {'id': 1845, 'therapyName': 'Mycophenolate mofetil'}, {'id': 1650, 'therapyName': 'Cyclosporine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 5215, 'therapyName': 'mitoxantrone hydrochloride'}, {'id': 1166, 'therapyName': 'Fludarabine'}]",Early Allogeneic Hematopoietic Cell Transplantation in Treating Patients With Relapsed or Refractory High-Grade Myelodysplastic Syndrome or Acute Myeloid Leukemia,867
27,NCT02790515,Phase II,Recruiting,"[{'id': 917, 'therapyName': 'Sirolimus'}, {'id': 1844, 'therapyName': 'anti-thymocyte globulin'}, {'id': 1876, 'therapyName': 'Blinatumomab '}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 5682, 'therapyName': 'Mesna'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1632, 'therapyName': 'Filgrastim'}]",Provision of TCR?? T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation,867
28,NCT01658007,Phase I,Terminated,"[{'id': 917, 'therapyName': 'Sirolimus'}]",Pilot Study Of Sirolimus Plus Multiagent Chemotherapy For Relapsed/Refractory Acute Lymphoblastic Leukemia/Lymphoma,867
29,NCT02551718,Phase I,Recruiting,"[{'id': 690, 'therapyName': 'Bosutinib'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 3160, 'therapyName': 'Nelarabine'}, {'id': 3159, 'therapyName': 'Bexarotene'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 998, 'therapyName': 'cabozantinib'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 877, 'therapyName': 'Ponatinib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 623, 'therapyName': 'Afatinib'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 890, 'therapyName': 'Regorafenib'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 2, 'therapyName': 'Trametinib'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 3, 'therapyName': 'Dabrafenib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 789, 'therapyName': 'Ceritinib'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1571, 'therapyName': 'Cabazitaxel'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1327, 'therapyName': 'Pralatrexate'}]",High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia,867
30,NCT00602693,Phase I,Completed,"[{'id': 917, 'therapyName': 'Sirolimus'}, {'id': 2311, 'therapyName': 'Allopurinol + Cyclophosphamide + Fludarabine'}]",T-Regulatory Cell Infusion Post Umbilical Cord Blood Transplant in Patients With Advanced Hematologic Cancer,867
31,NCT01203722,Phase Ib/II,Recruiting,"[{'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 2281, 'therapyName': 'Cyclophosphamide + Fludarabine + Mycophenolate mofetil'}]","Reduced Intensity, Partially HLA Mismatched BMT to Treat Hematologic Malignancies",867
32,NCT02145559,Phase I,"Active, not recruiting","[{'id': 1593, 'therapyName': 'Sirolimus + Metformin'}, {'id': 917, 'therapyName': 'Sirolimus'}]",A Pharmacodynamic Study of Sirolimus and Metformin in Patients With Advanced Solid Tumors,867
33,NCT01522820,Phase I,Completed,"[{'id': 1324, 'therapyName': 'DEC-205-NY-ESO-1 fusion protein vaccine'}, {'id': 917, 'therapyName': 'Sirolimus'}]",Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors,867
34,NCT01195922,Phase Ib/II,Completed,"[{'id': 917, 'therapyName': 'Sirolimus'}]",Rapamycin Therapy in Head and Neck Squamous Cell Carcinoma,867
35,NCT02423915,Phase Ib/II,Recruiting,"[{'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 2281, 'therapyName': 'Cyclophosphamide + Fludarabine + Mycophenolate mofetil'}, {'id': 917, 'therapyName': 'Sirolimus'}]",Fucosylated T Cells for Graft Versus Host Disease (GVHD) Prevention,867
36,NCT00305682,Phase II,Recruiting,"[{'id': 917, 'therapyName': 'Sirolimus'}, {'id': 1845, 'therapyName': 'Mycophenolate mofetil'}, {'id': 1844, 'therapyName': 'anti-thymocyte globulin'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1166, 'therapyName': 'Fludarabine'}]",Non-Myeloablative Conditioning for Unrelated Donor Umbilical Cord Blood Transplant,867
37,NCT02583893,Phase II,Recruiting,"[{'id': 917, 'therapyName': 'Sirolimus'}, {'id': 1752, 'therapyName': 'Mitoxantrone + Etoposide + Cytarabine'}]",Biomarkers in Predicting Treatment Response to Sirolimus and Chemotherapy in Patients With High-Risk Acute Myeloid Leukemia,867
38,NCT00923845,Phase II,Completed,"[{'id': 917, 'therapyName': 'Sirolimus'}, {'id': 2308, 'therapyName': 'Cyclophosphamide + Pentostatin'}]",Low-Intensity Stem Cell Transplantation With Multiple Lymphocyte Infusions to Treat Advanced Kidney Cancer,867
39,NCT01265030,Phase Ib/II,Recruiting,"[{'id': 917, 'therapyName': 'Sirolimus'}]",A Pilot Study Evaluating the Use of mTor Inhibitor Sirolimus in Children and Young Adults With Desmoid-Type Fibromatosis,867
40,NCT00513474,Phase I,Completed,"[{'id': 2313, 'therapyName': 'Rasburicase'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 1650, 'therapyName': 'Cyclosporine'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 2314, 'therapyName': 'Busulfan + Cyclophosphamide + Etoposide'}]",Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant,867
41,NCT01331135,Phase I,"Active, not recruiting","[{'id': 917, 'therapyName': 'Sirolimus'}]",Aflac ST0901 CHOANOME - Sirolimus in Solid Tumors,867
42,NCT01163357,Phase I,Recruiting,"[{'id': 917, 'therapyName': 'Sirolimus'}, {'id': 2288, 'therapyName': 'Bortezomib + Fludarabine + Melphalan'}]","Bortezomib, Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant For High-Risk Stage I or II Multiple Myeloma",867
43,NCT02793544,Phase II,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 1845, 'therapyName': 'Mycophenolate mofetil'}, {'id': 5682, 'therapyName': 'Mesna'}, {'id': 1166, 'therapyName': 'Fludarabine'}]",HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide,867
44,NCT01764607,,Terminated,"[{'id': 917, 'therapyName': 'Sirolimus'}]",Sirolimus in Kidney Transplant Patients With Squamous Cell Skin Carcinoma,867
45,NCT01087554,Phase I,"Active, not recruiting","[{'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 1077, 'therapyName': 'Vorinostat'}]",Sirolimus or Everolimus or Temsirolimus and Vorinostat in Advanced Cancer,867
46,NCT01853423,Phase I,Completed,"[{'id': 917, 'therapyName': 'Sirolimus'}]",Tuberou Sclerosis Complex: Facial Angiofibroma Skin Cream,867
47,NCT03099356,Phase II,Recruiting,"[{'id': 5513, 'therapyName': 'Sirolimus + Cyclophosphamide'}]","Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer",867
48,NCT01689987,Phase I,Completed,"[{'id': 2385, 'therapyName': 'Sirolimus + Cyclophosphamide + Dexamethasone + Hydroxychloroquine'}]","Hydroxychloroquine, Cyclophosphamide, Dexamethasone, and Sirolimus in Treating Patients With Relapsed or Refractory Multiple Myeloma",867
49,NCT01670175,Phase I,Completed,"[{'id': 1224, 'therapyName': 'Sirolimus + Cyclophosphamide + Topotecan'}]",Sirolimus With Cyclophosphamide and Topotecan for Pediatric/Adolescent Relapsed and Refractory Solid Tumors,867
50,NCT01266057,Phase I,"Active, not recruiting","[{'id': 1135, 'therapyName': 'Vorinostat + Hydroxychloroquine'}, {'id': 1177, 'therapyName': 'Sirolimus + Hydroxychloroquine'}]",Sirolimus or Vorinostat and Hydroxychloroquine in Advanced Cancer,867
51,NCT02048384,Phase Ib/II,Recruiting,"[{'id': 1593, 'therapyName': 'Sirolimus + Metformin'}, {'id': 1031, 'therapyName': 'Metformin'}]",A Study of Metformin With or Without Rapamycin as Maintenance Therapy After Induction Chemotherapy in Subjects With Pancreatic Cancer,867
52,NCT01162551,Phase II,Completed,"[{'id': 2304, 'therapyName': 'Sirolimus + Methotrexate'}]",Trial of Sirolimus and Methotrexate in Relapsed/Refractory Lymphoblastic Leukemia and Lymphoma,867
53,NCT00577278,Phase II,"Active, not recruiting","[{'id': 767, 'therapyName': 'Ibritumomab'}, {'id': 2238, 'therapyName': 'Sirolimus + Tacrolimus + Methotrexate'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 2237, 'therapyName': 'Fludarabine + Melphalan'}]","Yttrium Y 90 Ibritumomab Tiuxetan, Rituximab, Indium In-111 Ibritumomab Tiuxetan, Fludarabine, Melphalan, and Donor Stem Cell Transplant in Treating Patients With B-Cell Non-Hodgkin Lymphoma",867
54,NCT02356159,Phase Ib/II,Recruiting,"[{'id': 2294, 'therapyName': 'Cytarabine + Fludarabine'}, {'id': 2373, 'therapyName': 'Palifermin'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 2238, 'therapyName': 'Sirolimus + Tacrolimus + Methotrexate'}, {'id': 2292, 'therapyName': 'Doxorubicin + Etoposide + Fludarabine + Vincristine '}, {'id': 2291, 'therapyName': 'Cyclophosphamide + Fludarabine'}, {'id': 897, 'therapyName': 'Rituximab'}]",Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation,867
55,NCT00520130,Phase Ib/II,"Active, not recruiting","[{'id': 2294, 'therapyName': 'Cytarabine + Fludarabine'}, {'id': 2305, 'therapyName': 'Alemtuzumab + Cyclosporine'}, {'id': 2306, 'therapyName': 'Rituximab + Fludarabine + EPOCH'}, {'id': 2307, 'therapyName': 'Fludarabine + EPOCH'}, {'id': 2238, 'therapyName': 'Sirolimus + Tacrolimus + Methotrexate'}, {'id': 1632, 'therapyName': 'Filgrastim'}]",Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,867
56,NCT00411788,Phase II,Completed,"[{'id': 1979, 'therapyName': 'Sirolimus + Trastuzumab'}]",A Phase II Study of Rapamycin and Trastuzumab for Patients With HER-2 Receptor Positive Metastatic Breast Cancer,867
57,NCT01537107,Phase I,Suspended,"[{'id': 1329, 'therapyName': 'Sirolimus + Vismodegib'}]",Sirolimus and Vismodegib in Treating Patients With Solid Tumors or Pancreatic Cancer That is Metastatic or Cannot Be Removed By Surgery,867
0,NCT02270463,Phase Ib/II,Recruiting,"[{'id': 2005, 'therapyName': 'SL-401'}]",SL-401 as Consolidation Therapy in Patients With Adverse Risk Acute Myeloid Leukemia in First Complete Remission,7377
0,NCT02078648,Phase Ib/II,"Active, not recruiting","[{'id': 3010, 'therapyName': 'SL-701'}, {'id': 2595, 'therapyName': 'poly ICLC  '}, {'id': 667, 'therapyName': 'Bevacizumab'}]","Safety and Efficacy Study of SL-701, a Glioma-Associated Antigen Vaccine To Treat Recurrent Glioblastoma Multiforme",7907
0,NCT02667873,Phase I,Recruiting,"[{'id': 6223, 'therapyName': 'SL-801'}]",A Phase 1 Trial of a Novel XPO1 Inhibitor in Patients With Advanced Solid Tumors,8943
0,NCT02796898,Phase Ib/II,Recruiting,"[{'id': 5866, 'therapyName': 'SM88'}]","Study of the Efficacy, Safety, and Pharmacokinetics of SM88 in Patients With Prostate Cancer",8839
0,NCT03037645,Phase Ib/II,Recruiting,"[{'id': 5281, 'therapyName': 'SNS-062'}]","Safety, PK, PD, and Antitumor Activity of SNS-062 in B Lymphoid Cancers",8655
0,NCT02973399,Phase I,Recruiting,"[{'id': 4780, 'therapyName': 'Ibrutinib + SNX-5422'}]",Efficacy and Safety of SNX-5422 Added to an Established Dose of Ibrutinib in CLL,7072
1,NCT02914327,Phase I,Recruiting,"[{'id': 4780, 'therapyName': 'Ibrutinib + SNX-5422'}]",Safety and Activity of SNX-5422 Plus Ibrutinib in CLL,7072
2,NCT01635712,Phase I,Completed,"[{'id': 866, 'therapyName': 'SNX-5422'}]",Safety and Pharmacology Study of SNX-5422 in Subjects With Refractory Hematological Malignancies,7072
3,NCT02612285,Phase II,Terminated,"[{'id': 866, 'therapyName': 'SNX-5422'}]",Study of SNX-5422 in TP53 Null Cancers,7072
4,NCT01848756,Phase Ib/II,Terminated,"[{'id': 866, 'therapyName': 'SNX-5422'}]",Safety and Efficacy of SNX-5422 in Human Epidermal Growth Factor Receptor 2 (HER2) Positive Cancers,7072
5,NCT02063958,Phase I,"Active, not recruiting","[{'id': 866, 'therapyName': 'SNX-5422'}]",Safety and Pharmacology of SNX-5422 Plus Everolimus in Subjects With Neuroendocrine Tumors,7072
6,NCT01892046,Phase I,Completed,"[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 866, 'therapyName': 'SNX-5422'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]",Safety and Pharmacology of SNX-5422 Plus Carboplatin and Paclitaxel in Subjects With Solid Tumors,7072
0,NCT02303041,Phase I,"Active, not recruiting","[{'id': 1547, 'therapyName': 'BKM120 + Sonidegib'}]",Erismodegib and Buparlisib in Treating Patients With Advanced or Metastatic Basal Cell Carcinoma,7258
1,NCT01576666,Phase Ib/II,Completed,"[{'id': 1547, 'therapyName': 'BKM120 + Sonidegib'}]","Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors",7258
2,NCT02254551,Phase II,Terminated,"[{'id': 1954, 'therapyName': 'Bortezomib + Sonidegib'}]",Safety/Efficacy Study of LDE225 (Sonidegib) Plus Bortezomib in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma,7258
3,NCT01579929,Phase I,Completed,"[{'id': 2504, 'therapyName': 'Cisplatin + Etoposide + Sonidegib'}]","Combination of the Hedgehog Inhibitor, LDE225, With Etoposide and Cisplatin in the First-Line Treatment of Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC)",7258
4,NCT02138929,Phase I,"Active, not recruiting","[{'id': 1871, 'therapyName': 'Everolimus + Sonidegib'}]",LDE225 + Everolimus in Advanced Gastroesophageal Adenocarcinoma,7258
5,NCT01431794,Phase Ib/II,"Active, not recruiting","[{'id': 2497, 'therapyName': 'Gemcitabine + nab-paclitaxel + Sonidegib'}]",Gemcitabine + Nab-paclitaxel With LDE-225 (Hedgehog Inhibitor) as Neoadjuvant Therapy for Pancreatic Adenocarcinoma,7258
6,NCT02086552,Phase II,Recruiting,"[{'id': 4445, 'therapyName': 'lenalidomide + Sonidegib'}]",Sonidegib and Lenalidomide After Stem Cell Transplant in Treating Patients With Multiple Myeloma,7258
7,NCT02195973,Phase Ib/II,"Active, not recruiting","[{'id': 1620, 'therapyName': 'Paclitaxel + Sonidegib'}]",Phase IB/II Trial of LDE225 and Paclitaxel in Recurrent Ovarian Cancer,7258
8,NCT02111187,Phase I,Completed,"[{'id': 1428, 'therapyName': 'Sonidegib'}]",A Pre-surgical Study of LDE225 in Men With High-risk Localized Prostate Cancer,7258
9,NCT01769768,Phase I,Completed,"[{'id': 1428, 'therapyName': 'Sonidegib'}, {'id': 2505, 'therapyName': 'Warfarin'}, {'id': 2506, 'therapyName': 'Bupropion'}]",Phase I Study to Evaluate the Effect of LDE225 on the Pharmacokinetics of Bupropion and Warfarin in Patients,7258
10,NCT02002689,Phase II,Terminated,"[{'id': 1428, 'therapyName': 'Sonidegib'}]",LDE225 for Patients With PTCH1 or SMO Mutated Tumors,7258
11,NCT02182622,Phase I,Unknown status,"[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1428, 'therapyName': 'Sonidegib'}]",LDE225 + Docetaxel/Prednisone for Adv/Met Castrate Resistant Prostate Cancer w/ Disease Progression After Docetaxel,7258
12,NCT02151864,Phase I,"Active, not recruiting","[{'id': 1428, 'therapyName': 'Sonidegib'}]",LDE225 in Patients With Advanced or Metastatic Hepatocellular Carcinoma and Child-Pugh A Cirrhosis,7258
13,NCT01485744,Phase I,"Active, not recruiting","[{'id': 1903, 'therapyName': 'FOLFIRINOX'}, {'id': 1428, 'therapyName': 'Sonidegib'}]","LDE225 With Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan for Untreated Advanced Pancreatic Cancer",7258
14,NCT01757327,Phase II,Withdrawn,"[{'id': 1428, 'therapyName': 'Sonidegib'}]",LDE225 in Treating Patients With Stage II-III Estrogen Receptor- and HER2-Negative Breast Cancer,7258
15,NCT02129101,Phase I,"Active, not recruiting","[{'id': 651, 'therapyName': 'Azacitidine'}, {'id': 1428, 'therapyName': 'Sonidegib'}]",Azacitidine and Sonidegib in Treating Patients With Myeloid Malignancies,7258
0,NCT02349867,Phase I,Recruiting,"[{'id': 2429, 'therapyName': 'Abraxane + Gemcitabine + Sorafenib + Vorinostat'}]","Gemcitabine Hydrochloride, Nab-Paclitaxel, Radiation Therapy, Sorafenib Tosylate,Vorinostat in Treating Previously Untreated Pancreatic Cancer Patients",390
1,NCT02989870,Phase I,Recruiting,"[{'id': 5138, 'therapyName': 'Bavituximab + Sorafenib'}]",Sorafenib and Bavituximab Plus SBRT in Unresectable Hepatocellular Carcinoma,390
2,NCT02279719,Phase Ib/II,Recruiting,"[{'id': 920, 'therapyName': 'Sorafenib'}, {'id': 2361, 'therapyName': 'BBI503 + Sorafenib'}, {'id': 2362, 'therapyName': 'BBI608 + Sorafenib'}]","A Study of BBI608 in Combination With Sorafenib, or BBI503 in Combination With Sorafenib in Adult Patients With Hepatocellular Carcinoma",390
3,NCT01861314,Phase I,"Active, not recruiting","[{'id': 1793, 'therapyName': 'Bortezomib + Sorafenib + Decitabine   '}]","Bortezomib, Sorafenib Tosylate, and Decitabine in Treating Patients With Acute Myeloid Leukemia",390
4,NCT01534260,Phase Ib/II,Recruiting,"[{'id': 2366, 'therapyName': 'Bortezomib + Sorafenib + vorinostat'}]","Phase I/II Study of Combination of Sorafenib, Vorinostat, and Bortezomib for the Treatment of Acute Myeloid Leukemia With Complex- or Poor-risk (Monosomy 5/7) Cytogenetics or FLT3-ITD Positive Genotype",390
5,NCT03247088,Phase Ib/II,Recruiting,"[{'id': 6122, 'therapyName': 'Busulfan + Sorafenib + Fludarabine'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 1632, 'therapyName': 'Filgrastim'}]",Study Of Sorafenib Added To Busulfan And Fludarabine Conditioning Regimen In Patients With Relapsed/Refractory AML Undergoing Stem Cell Transplantation,390
6,NCT00492505,Phase II,Unknown status,"[{'id': 2212, 'therapyName': 'Cisplatin + Sorafenib + Tamoxifen'}]","Sorafenib, Tamoxifen, and Cisplatin in Treating Patients With High-Risk Stage III Melanoma",390
7,NCT00908167,Phase I,Completed,"[{'id': 2374, 'therapyName': 'Clofarabine + Cytarabine + Sorafenib'}]",Sorafenib in Combination With Cytarabine and Clofarabine in Patients With Refractory or Relapsed Hematologic Malignancies,390
8,NCT02270788,Phase I,Completed,"[{'id': 1865, 'therapyName': 'Methotrexate + Cytarabine + Leucovorin'}, {'id': 1864, 'therapyName': 'Crenolanib + Sorafenib'}]",Crenolanib in Combination With Sorafenib in Patients With Refractory or Relapsed Hematologic Malignancies,390
9,NCT02298348,Phase I,Recruiting,"[{'id': 2360, 'therapyName': 'Cyclophosphamide + Sorafenib + Topotecan'}]",Sorafenib and Cyclophosphamide/Topotecan in Patients With Relapsed and Refractory Neuroblastoma,390
10,NCT02024087,Phase Ib/II,"Active, not recruiting","[{'id': 2364, 'therapyName': 'Dalantercept + Sorafenib'}]",Study of Dalantercept and Sorafenib in Patients With Advanced Hepatocellular Carcinoma,390
11,NCT00589420,Phase II,Unknown status,"[{'id': 2390, 'therapyName': 'Docetaxel + Sorafenib'}]",Sorafenib and Docetaxel in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Previous Hormone Therapy,390
12,NCT01840592,Phase II,"Active, not recruiting","[{'id': 2363, 'therapyName': 'Doxorubicin + Sorafenib'}]",Sorafenib Plus Doxorubicin in Patients With Advanced Hepatocellular Carcinoma With Disease Progression on Sorafenib,390
13,NCT02050919,Phase II,Recruiting,"[{'id': 2365, 'therapyName': 'Epirubicin + Ifosfamide + Sorafenib'}]","Sorafenib Tosylate, Combination Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With High-Risk Stage IIB-IV Soft Tissue Sarcoma",390
14,NCT01434602,Phase Ib/II,Recruiting,"[{'id': 2299, 'therapyName': 'Everolimus + Sorafenib'}]",Phase I-II Everolimus and Sorafenib in Recurrent High-Grade Gliomas,390
15,NCT01263951,Phase II,"Active, not recruiting","[{'id': 2299, 'therapyName': 'Everolimus + Sorafenib'}]",Study of Everolimus and Sorafenib in Patients With Advanced Thyroid Cancer Who Progressed on Sorafenib Alone,390
16,NCT01497444,Phase Ib/II,Suspended,"[{'id': 1320, 'therapyName': 'Evofosfamide + Sorafenib'}]",Sorafenib Tosylate and Hypoxia-Activated Prodrug TH-302 in Treating Patients With Advanced Kidney Cancer or Liver Cancer That Cannot Be Removed By Surgery,390
17,NCT01246986,Phase II,"Active, not recruiting","[{'id': 2421, 'therapyName': 'Galunisertib + Sorafenib'}, {'id': 2409, 'therapyName': 'Galunisertib'}]",A Study of LY2157299 in Participants With Hepatocellular Carcinoma,390
18,NCT02069145,Phase I,Completed,"[{'id': 2413, 'therapyName': 'Ipafricept + Sorafenib'}]",Dose Escalation Study of OMP-54F28 in Combination With Sorafenib in Patients With Hepatocellular Cancer,390
19,NCT02143401,Phase I,Recruiting,"[{'id': 1872, 'therapyName': 'Navitoclax + Sorafenib'}]",Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid Tumors,390
20,NCT03132454,Phase I,Recruiting,"[{'id': 5637, 'therapyName': 'Palbociclib + Decitabine'}, {'id': 5636, 'therapyName': 'Palbociclib + Dexamethasone'}, {'id': 850, 'therapyName': 'Palbociclib'}, {'id': 5638, 'therapyName': 'Palbociclib + Sorafenib'}]",Study of Palbociclib Alone and in Combination in Patients With Relapsed and Refractory (R/R) Leukemias,390
21,NCT01005797,Phase I,Completed,"[{'id': 1131, 'therapyName': 'Panobinostat + Sorafenib'}]","Study of Panobinostat in Combination With Sorafenib in Kidney, Soft Tissue or Lung Cancers",390
22,NCT02988440,Phase I,Recruiting,"[{'id': 5590, 'therapyName': 'PDR001 + Sorafenib'}]",Study of Safety and Tolerability of PDR001 in Combination With Sorafenib and to Identify the Maximum Tolerated Dose and/or Phase 2 Dose for This Combination in Advanced Hepatocellular Patients,390
23,NCT03211416,Phase Ib/II,Recruiting,"[{'id': 6041, 'therapyName': 'Pembrolizumab + Sorafenib'}]",Sorafenib Tosylate and Pembrolizumab in Treating Patients With Advanced or Metastatic Liver Cancer,390
24,NCT01450384,Phase I,Completed,"[{'id': 1482, 'therapyName': 'Pemetrexed + Sorafenib'}]",Pemetrexed Disodium and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors,390
25,NCT02624700,Phase II,Recruiting,"[{'id': 1482, 'therapyName': 'Pemetrexed + Sorafenib'}]",Study of Pemetrexed and Sorafenib for Recurrent or Metastatic Triple Negative Breast Cancer,390
26,NCT01915602,Phase II,Completed,"[{'id': 2221, 'therapyName': 'Refametinib + Sorafenib'}]",Refametinib in Combination With Sorafenib in RAS Mutant Hepatocellular Carcinoma (HCC),390
27,NCT01303341,Phase I,"Active, not recruiting","[{'id': 1724, 'therapyName': 'Rilutek + Sorafenib'}]",Riluzole and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors or Melanoma,390
28,NCT02530476,Phase Ib/II,Recruiting,"[{'id': 3189, 'therapyName': 'Selinexor + Sorafenib'}]","Phase I/II, Study of Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) + Sorafenib in Acute Myeloid Leukemia",390
29,NCT01624285,Phase II,Recruiting,"[{'id': 920, 'therapyName': 'Sorafenib'}]",Sorafenib Tosylate Following a Liver Transplant in Treating Patients With Liver Cancer,390
30,NCT01141478,Phase I,Recruiting,"[{'id': 920, 'therapyName': 'Sorafenib'}]",Proton Beam Radiotherapy Plus Sorafenib Versus Sorafenib for Patients With Hepatocellular Carcinoma Exceeding San Francisco Criteria,390
31,NCT02560012,Phase II,Terminated,"[{'id': 735, 'therapyName': 'Everolimus'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 848, 'therapyName': 'Pazopanib'}]",Personalized Targeted Inhibitors Treatment in Renal Cell Cancer,390
32,NCT01724606,Phase I,Recruiting,"[{'id': 920, 'therapyName': 'Sorafenib'}]",Whole Brain Radiotherapy (WBRT) With Sorafenib for Breast Cancer Brain Metastases (BCBM),390
33,NCT03164057,Phase II,Recruiting,"[{'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 5153, 'therapyName': 'dexrazoxane'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 651, 'therapyName': 'Azacitidine'}]",A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia,390
34,NCT01761266,Phase III,"Active, not recruiting","[{'id': 792, 'therapyName': 'Lenvatinib'}, {'id': 920, 'therapyName': 'Sorafenib'}]","A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-Line Treatment of Subjects With Unresectable Hepatocellular Carcinoma",390
35,NCT02406521,Phase I,"Active, not recruiting","[{'id': 848, 'therapyName': 'Pazopanib'}, {'id': 2001, 'therapyName': 'radium Ra 223 dichloride'}, {'id': 920, 'therapyName': 'Sorafenib'}]",Exploratory Study of Radium-223 and Vascular Endothelial Growth Factor-Targeted Therapy in Patients With Metastatic Renal Cell Carcinoma and Bone Metastases,390
36,NCT01817751,Phase II,Recruiting,"[{'id': 1076, 'therapyName': 'Valproic acid'}, {'id': 920, 'therapyName': 'Sorafenib'}]","Sorafenib Tosylate, Valproic Acid, and Sildenafil Citrate in Treating Patients With Recurrent High-Grade Glioma",390
37,NCT01730937,Phase III,Recruiting,"[{'id': 920, 'therapyName': 'Sorafenib'}]",Sorafenib Tosylate With or Without Stereotactic Body Radiation Therapy in Treating Patients With Liver Cancer,390
38,NCT02412475,Phase I,"Active, not recruiting","[{'id': 712, 'therapyName': 'Cytarabine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 650, 'therapyName': 'Decitabine'}]",Epigenetic Reprogramming in Relapse AML,390
39,NCT01621906,,Recruiting,"[{'id': 920, 'therapyName': 'Sorafenib'}]",18F-FLT-PET Imaging of the Brain in Patients With Metastatic Breast Cancer to the Brain Treated With Whole Brain Radiation Therapy With or Without Sorafenib,390
40,NCT02728050,Phase Ib/II,Recruiting,"[{'id': 920, 'therapyName': 'Sorafenib'}, {'id': 4363, 'therapyName': 'Cladribine + Cytarabine + Filgrastim + Mitoxantrone'}]","Filgrastim, Cladribine, Cytarabine and Mitoxantrone With or Without Sorafenib Tosylate in Treating Patients With Newly-Diagnosed, High-Risk Acute Myeloid Leukemia or Myelodysplastic Syndrome",390
41,NCT01276210,Phase I,Completed,"[{'id': 920, 'therapyName': 'Sorafenib'}]",Sorafenib Tosylate and Stereotactic Radiosurgery in Treating Patients With Brain Metastases,390
42,NCT02406508,Phase II,Recruiting,"[{'id': 1207, 'therapyName': 'Melphalan'}, {'id': 920, 'therapyName': 'Sorafenib'}]",Sequential Melphalan for Use With Hepatic Delivery System Treatment Followed by Sorafenib in Patients With Unresectable HCC,390
43,NCT01849588,FDA approved,Terminated,"[{'id': 920, 'therapyName': 'Sorafenib'}]",Sorafenib for Hepatocellular Cancer With Chronic Hepatitis C,390
44,NCT01900002,Phase II,"Active, not recruiting","[{'id': 920, 'therapyName': 'Sorafenib'}]",Sorafenib and Yttrium-90 Glass Microspheres for Advanced Hepatocellular Carcinoma (HCC),390
45,NCT02072486,Phase I,"Active, not recruiting","[{'id': 920, 'therapyName': 'Sorafenib'}]",Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery,390
46,NCT01197170,Phase I,"Active, not recruiting","[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 633, 'therapyName': 'Anastrozole'}, {'id': 667, 'therapyName': 'Bevacizumab'}]",Hormone Blockade in Combination With Targeted Agents,390
47,NCT01754987,Phase Ib/II,Completed,"[{'id': 920, 'therapyName': 'Sorafenib'}]",A Study of Vitamin C in the Treatment of Liver Cancer to Determine if it is Safe and Effective,390
48,NCT00625378,Phase III,Recruiting,"[{'id': 920, 'therapyName': 'Sorafenib'}]",Sorafenib Long Term Extension Program (STEP),390
49,NCT02562755,Phase III,Recruiting,"[{'id': 3341, 'therapyName': 'JX-594'}, {'id': 920, 'therapyName': 'Sorafenib'}]",Hepatocellular Carcinoma Study Comparing Vaccinia Virus Based Immunotherapy Plus Sorafenib vs Sorafenib Alone,390
50,NCT02576509,Phase III,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 920, 'therapyName': 'Sorafenib'}]",A Study of Nivolumab Versus Sorafenib as First-Line Treatment in Patients With Advanced Hepatocellular Carcinoma,390
51,NCT02460991,Phase I,Terminated,"[{'id': 920, 'therapyName': 'Sorafenib'}, {'id': 1009, 'therapyName': 'Doxorubicin'}]",A Study of ONCO-DOX in Locally Advanced Hepatocellular Carcinoma,390
52,NCT02066181,Phase III,"Active, not recruiting","[{'id': 920, 'therapyName': 'Sorafenib'}]",Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis,390
53,NCT02627963,Phase III,"Active, not recruiting","[{'id': 920, 'therapyName': 'Sorafenib'}, {'id': 1055, 'therapyName': 'Tivozanib'}]",A Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced RCC,390
54,NCT02642913,Phase Ib/II,Recruiting,"[{'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 920, 'therapyName': 'Sorafenib'}]",Study of Enzalutamide With and Without Sorafenib in Advanced Hepatocellular Carcinoma Patients,390
55,NCT02788201,Phase II,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1133, 'therapyName': 'Mitomycin C'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1013, 'therapyName': 'epirubicin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1137, 'therapyName': 'Bleomycin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 781, 'therapyName': 'Ixabepilone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 2950, 'therapyName': 'Estramustine'}, {'id': 1941, 'therapyName': 'Floxuridine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 1811, 'therapyName': 'Carmustine'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 953, 'therapyName': 'Vandetanib'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 4419, 'therapyName': 'Toremifine'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 2601, 'therapyName': 'Dactinomycin'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 3035, 'therapyName': 'Chlorambucil'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 342, 'therapyName': 'Vemurafenib'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 2635, 'therapyName': 'Vinblastine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 4305, 'therapyName': 'Teniposide'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 4304, 'therapyName': 'Streptozocin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1231, 'therapyName': 'Bendamustine'}, {'id': 4303, 'therapyName': 'Mechlorethamine'}, {'id': 4302, 'therapyName': 'Mitotane'}]",Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma,390
56,NCT01248247,Phase I,"Active, not recruiting","[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 1098, 'therapyName': 'MK2206 + Selumetinib'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 1097, 'therapyName': 'Erlotinib + MK2206'}]",BATTLE-2 Program: A Biomarker-Integrated Targeted Therapy Study,390
57,NCT02551718,Phase I,Recruiting,"[{'id': 690, 'therapyName': 'Bosutinib'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 3160, 'therapyName': 'Nelarabine'}, {'id': 3159, 'therapyName': 'Bexarotene'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 998, 'therapyName': 'cabozantinib'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 877, 'therapyName': 'Ponatinib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 623, 'therapyName': 'Afatinib'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 890, 'therapyName': 'Regorafenib'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 2, 'therapyName': 'Trametinib'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 3, 'therapyName': 'Dabrafenib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 789, 'therapyName': 'Ceritinib'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1571, 'therapyName': 'Cabazitaxel'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1327, 'therapyName': 'Pralatrexate'}]",High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia,390
58,NCT02559778,Phase I,Recruiting,"[{'id': 688, 'therapyName': 'Bortezomib'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 2629, 'therapyName': 'Eflornithine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 717, 'therapyName': 'Dasatinib'}]",Pediatric Precision Laboratory Advanced Neuroblastoma Therapy,390
59,NCT01187199,Phase I,"Active, not recruiting","[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 936, 'therapyName': 'Temsirolimus'}]","Phase I Trial of Bevacizumab and Temsirolimus in Combination With 1) Carboplatin, 2) Paclitaxel, 3) Sorafenib for the Treatment of Advanced Cancer",390
60,NCT01775501,Phase II,Recruiting,"[{'id': 920, 'therapyName': 'Sorafenib'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 1642, 'therapyName': 'Leucovorin'}]",Sorafenib + mFOLFOX for Hepatocellular Carcinoma,390
61,NCT02288507,Phase I,Unknown status,"[{'id': 920, 'therapyName': 'Sorafenib'}]",Sorafenib Concurrent With Yttrium-90 Transarterial Radioembolization in Patients With Advanced Hepatocellular Cancer,390
62,NCT02143726,Phase II,Recruiting,"[{'id': 920, 'therapyName': 'Sorafenib'}, {'id': 735, 'therapyName': 'Everolimus'}]","Sorafenib Tosylate With or Without Everolimus in Treating Patients With Advanced, Radioactive Iodine Refractory Thyroid Cancer",390
63,NCT02575339,Phase Ib/II,Recruiting,"[{'id': 920, 'therapyName': 'Sorafenib'}, {'id': 1282, 'therapyName': 'Sapanisertib'}]",MLN0128 Compared to Sorafenib in Advanced or Metastatic Hepatocellular Carcinoma,390
64,NCT03298451,Phase III,Not yet recruiting,"[{'id': 920, 'therapyName': 'Sorafenib'}, {'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}, {'id': 1356, 'therapyName': 'Durvalumab'}]",Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Unresectable Hepatocellular Carcinoma,390
65,NCT01371981,Phase III,"Active, not recruiting","[{'id': 2391, 'therapyName': 'Cytarabine + Daunorubicin + Etoposide'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 2392, 'therapyName': 'Cytarabine + Etoposide'}, {'id': 2393, 'therapyName': 'Cytarabine + Mitoxantrone'}, {'id': 2394, 'therapyName': 'Asparaginase + Cytarabine'}, {'id': 688, 'therapyName': 'Bortezomib'}]",Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,390
66,NCT02779283,Phase I,Recruiting,"[{'id': 717, 'therapyName': 'Dasatinib'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 877, 'therapyName': 'Ponatinib'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 1606, 'therapyName': 'Cytarabine + Idarubicin'}, {'id': 930, 'therapyName': 'Sunitinib'}]",Personalized Kinase Inhibitor Therapy Combined With Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,390
67,NCT01578109,Phase I,"Active, not recruiting","[{'id': 920, 'therapyName': 'Sorafenib'}]",Sorafenib Tosylate Before and After Donor Bone Marrow Transplant in Treating Patients With Acute Myeloid Leukemia,390
68,NCT01801163,Phase I,Withdrawn,"[{'id': 920, 'therapyName': 'Sorafenib'}]",A Phase Ib Study of Stereotactic Body Radiotherapy (SBRT) Plus Sorafenib in Patients With Unresectable Hepatocellular Carcinoma (HCC),390
69,NCT01887717,Phase III,"Active, not recruiting","[{'id': 920, 'therapyName': 'Sorafenib'}]",Efficacy Evaluation of TheraSphere to Treat Inoperable Liver Cancer With Blockage of the Portal Vein,390
70,NCT01015833,Phase III,"Active, not recruiting","[{'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 920, 'therapyName': 'Sorafenib'}]",Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,390
71,NCT02015728,Phase I,"Active, not recruiting","[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1804, 'therapyName': 'Temozolomide + Etoposide'}, {'id': 920, 'therapyName': 'Sorafenib'}]",Selecting Patient-Specific Biologically Targeted Therapy for Pediatric Patients With Refractory Or Recurrent Brain Tumors,390
72,NCT01620216,Phase II,Recruiting,"[{'id': 930, 'therapyName': 'Sunitinib'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 877, 'therapyName': 'Ponatinib'}, {'id': 920, 'therapyName': 'Sorafenib'}]",Validation of an in Vitro Assay to Predict Targeted Therapies for Acute Leukemia Patients,390
73,NCT02227914,Phase Ib/II,Withdrawn,"[{'id': 2422, 'therapyName': 'Oprozomib'}, {'id': 920, 'therapyName': 'Sorafenib'}]",Phase 1b/2 Study of Oprozomib in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma,390
74,NCT01871766,Phase II,Recruiting,"[{'id': 1119, 'therapyName': 'Sorafenib + Avastin + Cyclophosphamide'}, {'id': 1436, 'therapyName': 'Vincristine + Dactinomycin'}, {'id': 1435, 'therapyName': 'Vincristine + Dactinomycin + Cyclophosphamide'}]","Treatment of Localized Rhabdomyosarcoma With Chemotherapy, Radiotherapy, and Surgery",390
75,NCT00665990,Phase I,Completed,"[{'id': 1119, 'therapyName': 'Sorafenib + Avastin + Cyclophosphamide'}]",Phase I Study of Bevacizumab and Sorafenib Combined With Low Dose Cyclophosphamide in Patients With Refractory Solid Tumors and Leukemia,390
76,NCT02196857,Phase II,Recruiting,"[{'id': 1633, 'therapyName': 'Sorafenib + Azacitidine'}]",Sorafenib Plus 5-Azacitidine Initial Therapy of Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MS) With FLT3-ITD Mutation,390
77,NCT00538005,Phase Ib/II,Unknown status,"[{'id': 2132, 'therapyName': 'Sorafenib + Bevacizumab + Oxaliplatin'}]","Sorafenib, Bevacizumab, and Oxaliplatin in Treating Patients With Metastatic Malignant Melanoma",390
78,NCT01640665,Phase I,Completed,"[{'id': 2428, 'therapyName': 'Sorafenib + Capecitabine'}]",Pilot Study of Sorafenib and Bi-weekly Capecitabine in Patients With Advanced Breast and Gastrointestinal Tumors,390
79,NCT01471353,Phase II,"Active, not recruiting","[{'id': 2428, 'therapyName': 'Sorafenib + Capecitabine'}]",Sorafenib Plus Capecitabine (SorCape) in Previously Treated Metastatic Colorectal Cancer,390
80,NCT02323906,Phase Ib/II,Terminated,"[{'id': 2430, 'therapyName': 'Sorafenib + CC-122'}]",Safety and Efficacy Study of CC-122 Combined With Sorafenib for Primary Liver Cancer,390
81,NCT02035527,Phase Ib/II,"Active, not recruiting","[{'id': 2431, 'therapyName': 'Sorafenib + Cisplatin + Docetaxel'}]","Sorafenib Tosylate, Cisplatin, and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck",390
82,NCT01194869,Phase II,Terminated,"[{'id': 1534, 'therapyName': 'Sorafenib + Cisplatin + Paclitaxel'}]","Preoperative Clinical Trial of Sorafenib in Combination With Cisplatin Followed by Paclitaxel for Triple Negative (ER-, PR-, Her2-)Early Stage Breast Cancer",390
83,NCT01634893,Phase I,Completed,"[{'id': 1208, 'therapyName': 'Sorafenib + Hydroxychloroquine'}]",Oral Hydroxychloroquine Plus Oral Sorafenib to Treat Patients With Refractory or Relapsed Solid Tumors,390
84,NCT02747537,Phase II,Recruiting,"[{'id': 1323, 'therapyName': 'Sorafenib + Irinotecan'}]",Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors With Sorafenib in Combination With Irinotecan,390
85,NCT01518413,Phase I,Completed,"[{'id': 1323, 'therapyName': 'Sorafenib + Irinotecan'}]",Dose Escalation Study of Sorafenib and Irinotecan Combination Therapy in Pediatric Patients With Solid Tumors,390
86,NCT01666756,Phase I,"Active, not recruiting","[{'id': 2387, 'therapyName': 'Sorafenib + KD018'}]",Chinese Herbal Formulation PHY906 and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer,390
87,NCT01687673,Phase II,"Active, not recruiting","[{'id': 2388, 'therapyName': 'Sorafenib + Temsirolimus'}]",Phase II Combination of Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma,390
88,NCT02292173,Phase I,Recruiting,"[{'id': 2197, 'therapyName': 'Sorafenib + Trametinib'}]",Trametinib in Combination With Sorafenib in Patients With Advanced Hepatocellular Cancer,390
89,NCT01306058,Phase Ib/II,"Active, not recruiting","[{'id': 2389, 'therapyName': 'Sorafenib + TRC105'}]",Sorafenib and TRC105 in Hepatocellular Cancer,390
90,NCT02560779,Phase Ib/II,Recruiting,"[{'id': 2389, 'therapyName': 'Sorafenib + TRC105'}]",Trial of TRC105 and Sorafenib in Patients With HCC,390
91,NCT00764972,Phase Ib/II,Unknown status,"[{'id': 2357, 'therapyName': 'Sorafenib + Vinorelbine'}]",Phase IB/II Trial Combining Vinorelbine With Sorafenib as First-Line Treatment in Patients With Metastatic Breast Cancer,390
92,NCT01075113,Phase I,"Active, not recruiting","[{'id': 2356, 'therapyName': 'Sorafenib + Vorinostat'}]",Sorafenib and Vorinostat in Treating Patients With Advanced Liver Cancer,390
93,NCT01683149,Phase I,Completed,"[{'id': 1228, 'therapyName': 'Topotecan + Sorafenib'}]", Sorafenib and Topotecan in Refractory/Recurrent Pediatric Malignancies,390
94,NCT01664182,Phase II,"Active, not recruiting","[{'id': 1223, 'therapyName': 'Trebananib + Sunitinib'}, {'id': 1220, 'therapyName': 'Trebananib + Pazopanib'}, {'id': 1221, 'therapyName': 'Trebananib + Sorafenib'}, {'id': 1218, 'therapyName': 'Trebananib'}, {'id': 1219, 'therapyName': 'Trebananib + Bevacizumab'}]","Trebananib With or Without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Treating Patients With Advanced Kidney Cancer",390
95,NCT01531361,Phase I,Recruiting,"[{'id': 706, 'therapyName': 'Crizotinib'}, {'id': 1326, 'therapyName': 'Vemurafenib + Sorafenib'}]",Sorafenib or Crizotinib and Vemurafenib in Advanced Cancer,390
96,NCT01946529,Phase II,"Active, not recruiting","[{'id': 1433, 'therapyName': 'Vincristine + Doxorubicin + Cyclophosphamide + Ifosfamide + Etoposide'}, {'id': 1434, 'therapyName': 'Vincristine + Doxorubicin + Cyclophosphamide + Ifosfamide + Etoposide + others'}]",Therapeutic Trial for Patients With Ewing Sarcoma Family of Tumor and Desmoplastic Small Round Cell Tumors,390
0,NCT03078400,Phase I,Recruiting,"[{'id': 5763, 'therapyName': 'SPL-108'}]",Safety and Efficacy Study of Daily SPL-108 Injections In Conjunction With Paclitaxel in Women With Ovarian Cancer,8784
0,NCT03221400,Phase Ib/II,Recruiting,"[{'id': 4842, 'therapyName': 'STA-8666'}]",PEN-866 in Patients With Advanced Solid Malignancies,8558
0,NCT02549937,Phase I,Recruiting,"[{'id': 3666, 'therapyName': 'Sulfatinib'}]","A Multi-Center, Open-Label Study of Sulfatinib(HMPL-012) in Patients With Advanced Solid Tumors",8196
0,NCT01254864,Phase II,"Active, not recruiting","[{'id': 1817, 'therapyName': 'Abiraterone + Sunitinib'}, {'id': 1818, 'therapyName': 'Abiraterone + Dasatinib\t'}]",Maximum Androgen Depletion,1255
1,NCT01835158,Phase II,"Active, not recruiting","[{'id': 998, 'therapyName': 'cabozantinib'}, {'id': 1236, 'therapyName': 'Cabozantinib + Sunitinib'}]",Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer,1255
2,NCT02400385,Phase II,Withdrawn,"[{'id': 2626, 'therapyName': 'Nivolumab + Sunitinib'}]",A Phase II Trial of Sunitinib and Nivolumab for KIT-mutated Advanced Melanoma,1255
3,NCT02616185,Phase I,Recruiting,"[{'id': 3565, 'therapyName': 'PF-06755990 + PF-06755992 + Sunitinib + Tremelimumab'}]",A Phase 1 Study To Evaluate Escalating Doses Of A Vaccine-Based Immunotherapy Regimen For Prostate Cancer (PrCa VBIR),1255
4,NCT01370109,Phase I,Recruiting,"[{'id': 930, 'therapyName': 'Sunitinib'}]",Cardiovascular Effects of Sunitinib Therapy (CREST),1255
5,NCT00843037,Phase II,Completed,"[{'id': 930, 'therapyName': 'Sunitinib'}]",Study Of Sunitinib In Patients With Recurrent Paraganglioma/Pheochromocytoma,1255
6,NCT02164240,Phase I,"Active, not recruiting","[{'id': 930, 'therapyName': 'Sunitinib'}, {'id': 890, 'therapyName': 'Regorafenib'}]",Phase Ib Study of SUnitinib Alternating With REgorafenib in Patients With Metastatic and/or Unresectable GIST,1255
7,NCT00981890,Phase I,"Active, not recruiting","[{'id': 930, 'therapyName': 'Sunitinib'}]",Stereotactic Radiosurgery With Sunitinib for Brain Metastases,1255
8,NCT03141177,Phase III,Recruiting,"[{'id': 2068, 'therapyName': 'Cabozantinib + Ipilimumab + Nivolumab'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 2067, 'therapyName': 'Cabozantinib + Nivolumab'}]",A Study of Nivolumab Combined With Cabozantinib or Nivolumab and Ipilimumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 9ER),1255
9,NCT01396148,Phase II,Completed,"[{'id': 930, 'therapyName': 'Sunitinib'}]",A Study of Sunitinib In Young Patients With Advanced Gastrointestinal Stromal Tumor,1255
10,NCT01099423,Phase III,"Active, not recruiting","[{'id': 930, 'therapyName': 'Sunitinib'}]",Immediate Surgery or Surgery After Sunitinib Malate in Treating Patients With Metastatic Kidney Cancer,1255
11,NCT02420821,Phase III,"Active, not recruiting","[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1201, 'therapyName': 'Atezolizumab'}]",A Study of MPDL3280A (Anti-Programmed Death Ligand 1 [PD-L1] Antibody) in Combination With Bevacizumab Versus Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma,1255
12,NCT01164228,Phase II,Recruiting,"[{'id': 930, 'therapyName': 'Sunitinib'}, {'id': 755, 'therapyName': 'Gemcitabine'}]",Sunitinib Malate With or Without Gemcitabine Hydrochloride in Treating Patients With Advanced Kidney Cancer That Cannot Be Removed By Surgery,1255
13,NCT00717587,Phase II,Unknown status,"[{'id': 930, 'therapyName': 'Sunitinib'}, {'id': 2129, 'therapyName': 'girentuximab'}, {'id': 2128, 'therapyName': 'motexafin gadolinium'}]",Sunitinib Before and After Surgery in Treating Patients With Stage IV Kidney Cancer,1255
14,NCT02465060,Phase II,Recruiting,"[{'id': 660, 'therapyName': 'AZD9291'}, {'id': 3, 'therapyName': 'Dabrafenib'}, {'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 2, 'therapyName': 'Trametinib'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 623, 'therapyName': 'Afatinib'}, {'id': 654, 'therapyName': 'AZD4547'}, {'id': 958, 'therapyName': 'VS-6063'}, {'id': 765, 'therapyName': 'GSK2636771'}]",NCI-MATCH Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas,1255
15,NCT01984242,Phase II,"Active, not recruiting","[{'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1202, 'therapyName': 'Atezolizumab + Bevacizumab + Capecitabine'}]",A Phase 2 Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) as Monotherapy or in Combination With Avastin (Bevacizumab) Compared to Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma,1255
16,NCT03091192,Phase III,Recruiting,"[{'id': 930, 'therapyName': 'Sunitinib'}, {'id': 2161, 'therapyName': 'Savolitinib'}]",Savolitinib vs. Sunitinib in MET-driven PRCC,1255
17,NCT02788201,Phase II,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1133, 'therapyName': 'Mitomycin C'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1013, 'therapyName': 'epirubicin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1137, 'therapyName': 'Bleomycin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 781, 'therapyName': 'Ixabepilone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 2950, 'therapyName': 'Estramustine'}, {'id': 1941, 'therapyName': 'Floxuridine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 1811, 'therapyName': 'Carmustine'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 953, 'therapyName': 'Vandetanib'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 4419, 'therapyName': 'Toremifine'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 2601, 'therapyName': 'Dactinomycin'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 3035, 'therapyName': 'Chlorambucil'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 342, 'therapyName': 'Vemurafenib'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 2635, 'therapyName': 'Vinblastine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 4305, 'therapyName': 'Teniposide'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 4304, 'therapyName': 'Streptozocin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1231, 'therapyName': 'Bendamustine'}, {'id': 4303, 'therapyName': 'Mechlorethamine'}, {'id': 4302, 'therapyName': 'Mitotane'}]",Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma,1255
18,NCT02315625,Phase II,Recruiting,"[{'id': 735, 'therapyName': 'Everolimus'}, {'id': 930, 'therapyName': 'Sunitinib'}]",Study of Mutation-Targeted Therapy With Sunitinib or Everolimus in People With Advanced Low- or Intermediate-Grade Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas With or Without Cytoreductive Surgery,1255
19,NCT02432846,Phase II,Recruiting,"[{'id': 930, 'therapyName': 'Sunitinib'}]",Intratumoral Vaccination With Intuvax Pre-nephrectomy Followed by Sunitinib Post-nephrectomy vs Sunitinib Post-nephrectomy in Newly Diagnosed Metastatic Renal Cell Carcinoma (mRCC) (MERECA),1255
20,NCT01582672,Phase III,"Active, not recruiting","[{'id': 930, 'therapyName': 'Sunitinib'}]",Phase 3 Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (RCC),1255
21,NCT01620216,Phase II,Recruiting,"[{'id': 930, 'therapyName': 'Sunitinib'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 877, 'therapyName': 'Ponatinib'}, {'id': 920, 'therapyName': 'Sorafenib'}]",Validation of an in Vitro Assay to Predict Targeted Therapies for Acute Leukemia Patients,1255
22,NCT02483247,Phase Ib/II,Recruiting,"[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1945, 'therapyName': 'BBI503'}]",A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer,1255
23,NCT00463060,Phase Ib/II,Unknown status,"[{'id': 930, 'therapyName': 'Sunitinib'}]",Sutent and Radiation as Treatment for Limited Extent Metastatic Cancer,1255
24,NCT02853331,Phase III,Recruiting,"[{'id': 2494, 'therapyName': 'Axitinib + Pembrolizumab'}, {'id': 930, 'therapyName': 'Sunitinib'}]",Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Axitinib Versus Sunitinib Monotherapy in Participants With Renal Cell Carcinoma (MK-3475-426/KEYNOTE-426),1255
25,NCT03035630,Phase II,Recruiting,"[{'id': 3144, 'therapyName': 'Avelumab'}, {'id': 930, 'therapyName': 'Sunitinib'}]",Sunitinib Followed by Avelumab or the Reverse for Metastatic Renal Cell Carcinoma,1255
26,NCT01603004,Phase I,Recruiting,"[{'id': 735, 'therapyName': 'Everolimus'}, {'id': 930, 'therapyName': 'Sunitinib'}]",Potential Imaging and Molecular Predictors of Response to Novel Therapies in Metastatic Pancreatic Neuroendocrine Tumors,1255
27,NCT01829217,Phase II,"Active, not recruiting","[{'id': 930, 'therapyName': 'Sunitinib'}]",Sunitinib in Never-Smokers With Lung Adenocarcinoma,1255
28,NCT00747305,Phase I,Terminated,"[{'id': 930, 'therapyName': 'Sunitinib'}]",Sunitinib Before and After Surgery in Treating Patients With Metastatic Kidney Cancer That Can Be Removed By Surgery,1255
29,NCT02231749,Phase III,"Active, not recruiting","[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}, {'id': 930, 'therapyName': 'Sunitinib'}]",Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214),1255
30,NCT01396408,Phase II,"Active, not recruiting","[{'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 930, 'therapyName': 'Sunitinib'}]",A Phase II Study of Sunitinib or Temsirolimus in Patients With Advanced Rare Tumours,1255
31,NCT01582204,Phase I,Recruiting,"[{'id': 848, 'therapyName': 'Pazopanib'}, {'id': 930, 'therapyName': 'Sunitinib'}]",Evaluate The Utility Of 124I-cG250 for The Early Detection Of Response to Therapy In Patients With Metastatic Renal Cell Carcinoma,1255
32,NCT02560012,Phase II,Terminated,"[{'id': 735, 'therapyName': 'Everolimus'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 848, 'therapyName': 'Pazopanib'}]",Personalized Targeted Inhibitors Treatment in Renal Cell Cancer,1255
33,NCT00702884,Phase II,Completed,"[{'id': 930, 'therapyName': 'Sunitinib'}]",Sunitinib in Treating Patients With Relapsed or Refractory Esophageal or Gastroesophageal Junction Cancer,1255
34,NCT02811861,Phase III,Recruiting,"[{'id': 1713, 'therapyName': 'Everolimus + Lenvatinib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 4782, 'therapyName': 'Lenvatinib + Pembrolizumab'}]",Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma,1255
35,NCT00375674,,"Active, not recruiting","[{'id': 930, 'therapyName': 'Sunitinib'}]", A Clinical Trial Comparing Efficacy And Safety Of Sunitinib Versus Placebo For TheTreatment Of Patients At High Risk Of Recurrent Renal Cell Cancer,1255
36,NCT01306045,Phase II,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 816, 'therapyName': 'MK2206'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 913, 'therapyName': 'Selumetinib'}]","Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies",1255
37,NCT01499121,Phase II,"Active, not recruiting","[{'id': 930, 'therapyName': 'Sunitinib'}]",Study of Efficacy and Safety of Sunitinib Given on an Individualized Schedule,1255
38,NCT02693535,Phase II,Recruiting,"[{'id': 1657, 'therapyName': 'Vemurafenib + Cobimetinib'}, {'id': 890, 'therapyName': 'Regorafenib'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 690, 'therapyName': 'Bosutinib'}, {'id': 850, 'therapyName': 'Palbociclib'}, {'id': 694, 'therapyName': 'Cetuximab'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 837, 'therapyName': 'Olaparib'}, {'id': 4, 'therapyName': 'Erlotinib'}]",TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer,1255
39,NCT03109015,Phase II,Recruiting,"[{'id': 930, 'therapyName': 'Sunitinib'}]",Alternative Schedule Sunitinib in Metastatic Renal Cell Carcinoma: Cardiopulmonary Exercise Testing (ASSET),1255
40,NCT01026337,Phase I,"Active, not recruiting","[{'id': 930, 'therapyName': 'Sunitinib'}]",Magnetic Resonance Imaging (MRI) in Predicting Response to Sunitinib Malate in Patients With Locally Advanced or Metastatic Kidney Cancer,1255
41,NCT02068586,Phase II,Recruiting,"[{'id': 1076, 'therapyName': 'Valproic acid'}, {'id': 930, 'therapyName': 'Sunitinib'}]",Adjuvant Sunitinib or Valproic Acid in High-Risk Patients With Uveal Melanoma,1255
42,NCT02060370,Phase II,"Active, not recruiting","[{'id': 930, 'therapyName': 'Sunitinib'}]",Sunitinib Scheduling in Metastatic Renal Cell Carcinoma (mRCC),1255
43,NCT02761057,Phase II,Recruiting,"[{'id': 2161, 'therapyName': 'Savolitinib'}, {'id': 998, 'therapyName': 'cabozantinib'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 930, 'therapyName': 'Sunitinib'}]","Cabozantinib-S-Malate, Crizotinib, Volitinib, or Sunitinib Malate in Treating Patients With Locally Advanced or Metastatic Kidney Cancer",1255
44,NCT01525550,FDA approved,"Active, not recruiting","[{'id': 930, 'therapyName': 'Sunitinib'}]",A Study Of The Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors,1255
45,NCT00794950,Phase II,"Active, not recruiting","[{'id': 930, 'therapyName': 'Sunitinib'}]",Bacillus Calmette-Guerin Followed by Sunitinib for the Treatment of High Risk Non-muscle Invasive Lower Urinary Tract Urothelial Carcinoma,1255
46,NCT01014065,Phase II,Completed,"[{'id': 930, 'therapyName': 'Sunitinib'}]",A Prospective Study of Acute Cardiovascular Effects of First-line Sunitinib in Metastatic Renal Cell Carcinoma Patients (SUnitinib Prospective CardiovasculaR Effect),1255
47,NCT01391962,Phase II,Recruiting,"[{'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1001, 'therapyName': 'Cediranib'}]",Sunitinib or Cediranib for Alveolar Soft Part Sarcoma,1255
48,NCT02779283,Phase I,Recruiting,"[{'id': 717, 'therapyName': 'Dasatinib'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 877, 'therapyName': 'Ponatinib'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 1606, 'therapyName': 'Cytarabine + Idarubicin'}, {'id': 930, 'therapyName': 'Sunitinib'}]",Personalized Kinase Inhibitor Therapy Combined With Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,1255
49,NCT02684006,Phase III,Recruiting,"[{'id': 3145, 'therapyName': 'Avelumab + Axitinib'}, {'id': 930, 'therapyName': 'Sunitinib'}]",A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer (JAVELIN Renal 101),1255
50,NCT01517243,Phase II,Unknown status,"[{'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 930, 'therapyName': 'Sunitinib'}]",Phase II Study of Alternating Sunitinib and Temsirolimus,1255
51,NCT02551718,Phase I,Recruiting,"[{'id': 690, 'therapyName': 'Bosutinib'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 3160, 'therapyName': 'Nelarabine'}, {'id': 3159, 'therapyName': 'Bexarotene'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 998, 'therapyName': 'cabozantinib'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 877, 'therapyName': 'Ponatinib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 623, 'therapyName': 'Afatinib'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 890, 'therapyName': 'Regorafenib'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 2, 'therapyName': 'Trametinib'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 3, 'therapyName': 'Dabrafenib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 789, 'therapyName': 'Ceritinib'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1571, 'therapyName': 'Cabazitaxel'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1327, 'therapyName': 'Pralatrexate'}]",High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia,1255
52,NCT00915993,Phase I,Unknown status,"[{'id': 930, 'therapyName': 'Sunitinib'}]",MRI in Predicting Response to Sunitinib Malate in Patients With Stage IV Kidney Cancer,1255
53,NCT01621568,Phase II,"Active, not recruiting","[{'id': 930, 'therapyName': 'Sunitinib'}]",Sunitinib for Advanced Thymus Cancer Following Earlier Treatment,1255
54,NCT02074878,Phase I,Terminated,"[{'id': 1962, 'therapyName': 'Sunitinib + Crizotinib'}]",CRIZENT: Crizotinib and Sunitinib in Metastatic Breast Cancer,1255
55,NCT00489944,Phase II,Unknown status,"[{'id': 1963, 'therapyName': 'Sunitinib + Tamoxifen + Cisplatin'}]","Sunitinib, Tamoxifen, and Cisplatin in Treating Patients With High-Risk Ocular Melanoma",1255
56,NCT02928575,Phase II,Recruiting,"[{'id': 4905, 'therapyName': 'Sunitinib + Temozolomide'}]","Combining Sunitinib, Temozolomide and Radiation to Treat Patients Diagnosed With Glioblastoma",1255
57,NCT02386111,Phase Ib/II,Terminated,"[{'id': 3057, 'therapyName': 'Sunitinib + Varlilumab'}]",A Study of Varlilumab (Anti-CD27) and Sunitinib in Patients With Metastatic Clear Cell Renal Cell Carcinoma,1255
58,NCT01664182,Phase II,"Active, not recruiting","[{'id': 1223, 'therapyName': 'Trebananib + Sunitinib'}, {'id': 1220, 'therapyName': 'Trebananib + Pazopanib'}, {'id': 1221, 'therapyName': 'Trebananib + Sorafenib'}, {'id': 1218, 'therapyName': 'Trebananib'}, {'id': 1219, 'therapyName': 'Trebananib + Bevacizumab'}]","Trebananib With or Without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Treating Patients With Advanced Kidney Cancer",1255
0,NCT03161431,Phase I,Not yet recruiting,"[{'id': 5786, 'therapyName': 'SX-682'}, {'id': 5787, 'therapyName': 'Pembrolizumab + SX-682'}]",SX-682 Treatment in Subjects With Metastatic Melanoma Concurrently Treated With Pembrolizumab,8797
0,NCT03134638,Phase I,Recruiting,"[{'id': 5700, 'therapyName': 'SY-1365'}]",A Phase 1 Study of SY-1365 in Adult Patients With Advanced Solid Tumors,8753
0,NCT02568046,Phase Ib/II,"Active, not recruiting","[{'id': 3949, 'therapyName': 'FOLFIRI + SYM004'}]",Sym004 in Combination With FOLFIRI in Metastatic Colorectal Cancer Patients,7026
1,NCT02924233,Phase Ib/II,Withdrawn,"[{'id': 4833, 'therapyName': 'Nivolumab + SYM004'}, {'id': 1312, 'therapyName': 'Nivolumab'}]",Sym004 in Combination With Nivolumab Versus Nivolumab Monotherapy in EGFR-amplified Squamous Non-Small Cell Lung Cancer,7026
2,NCT02083653,Phase II,"Active, not recruiting","[{'id': 931, 'therapyName': 'SYM004'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1105, 'therapyName': 'Capecitabine'}]",Sym004 vs Standard of Care in Subjects With Metastatic Colorectal Cancer,7026
3,NCT02965417,Phase II,Withdrawn,"[{'id': 931, 'therapyName': 'SYM004'}]",Sym004 in Metastatic Colorectal Cancer and ECD-EGFR Patients,7026
4,NCT02540161,Phase II,Recruiting,"[{'id': 931, 'therapyName': 'SYM004'}]",Phase 2 Study of Sym004 for Adult Patients With Recurrent Glioblastoma,7026
0,NCT02648724,Phase Ib/II,Recruiting,"[{'id': 4322, 'therapyName': 'SYM015'}]",Sym015 (Anti-MET) in Patients With Advanced Solid Tumor Malignancies,8413
0,NCT02391727,Phase I,Recruiting,"[{'id': 5330, 'therapyName': 'SYN004'}]","Safety, Immunogenicity and Pharmacokinetics of SYN004 in Patients With Solid Tumors (SYN004_Ph_1)",8664
0,NCT02556931,Phase II,Recruiting,"[{'id': 4228, 'therapyName': 'Cyclophosphamide + Fludarabine + Melphalan + Tacrolimus'}]","Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies",854
1,NCT02653196,Phase II,Terminated,"[{'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1205, 'therapyName': 'Alemtuzumab'}, {'id': 2373, 'therapyName': 'Palifermin'}, {'id': 2237, 'therapyName': 'Fludarabine + Melphalan'}, {'id': 3948, 'therapyName': 'Cyclosporine + Mycophenolate mofetil + Tacrolimus'}]",A Multi-Institutional Phase II Feasibility Study of Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Malignant Neuro-Epithelial and Other Solid Tumors,854
2,NCT02528877,Phase I,Withdrawn,"[{'id': 2237, 'therapyName': 'Fludarabine + Melphalan'}, {'id': 3181, 'therapyName': 'Ruxolitinib + Sirolimus + Tacrolimus'}]","Ruxolitinib Phosphate, Tacrolimus and Sirolimus in Preventing Acute Graft-versus-Host Disease During Reduced Intensity Donor Hematopoietic Cell Transplant in Patients With Myelofibrosis",854
3,NCT00577278,Phase II,"Active, not recruiting","[{'id': 767, 'therapyName': 'Ibritumomab'}, {'id': 2238, 'therapyName': 'Sirolimus + Tacrolimus + Methotrexate'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 2237, 'therapyName': 'Fludarabine + Melphalan'}]","Yttrium Y 90 Ibritumomab Tiuxetan, Rituximab, Indium In-111 Ibritumomab Tiuxetan, Fludarabine, Melphalan, and Donor Stem Cell Transplant in Treating Patients With B-Cell Non-Hodgkin Lymphoma",854
4,NCT02356159,Phase Ib/II,Recruiting,"[{'id': 2294, 'therapyName': 'Cytarabine + Fludarabine'}, {'id': 2373, 'therapyName': 'Palifermin'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 2238, 'therapyName': 'Sirolimus + Tacrolimus + Methotrexate'}, {'id': 2292, 'therapyName': 'Doxorubicin + Etoposide + Fludarabine + Vincristine '}, {'id': 2291, 'therapyName': 'Cyclophosphamide + Fludarabine'}, {'id': 897, 'therapyName': 'Rituximab'}]",Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation,854
5,NCT00520130,Phase Ib/II,"Active, not recruiting","[{'id': 2294, 'therapyName': 'Cytarabine + Fludarabine'}, {'id': 2305, 'therapyName': 'Alemtuzumab + Cyclosporine'}, {'id': 2306, 'therapyName': 'Rituximab + Fludarabine + EPOCH'}, {'id': 2307, 'therapyName': 'Fludarabine + EPOCH'}, {'id': 2238, 'therapyName': 'Sirolimus + Tacrolimus + Methotrexate'}, {'id': 1632, 'therapyName': 'Filgrastim'}]",Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,854
6,NCT02790515,Phase II,Recruiting,"[{'id': 917, 'therapyName': 'Sirolimus'}, {'id': 1844, 'therapyName': 'anti-thymocyte globulin'}, {'id': 1876, 'therapyName': 'Blinatumomab '}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 5682, 'therapyName': 'Mesna'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1632, 'therapyName': 'Filgrastim'}]",Provision of TCR?? T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation,854
7,NCT01338987,Phase II,"Active, not recruiting","[{'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 795, 'therapyName': 'Leuprolide'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}]",Pilot Study of Lupron to Improve Immune Function After Allogeneic Bone Marrow Transplantation,854
8,NCT01529827,Phase II,"Active, not recruiting","[{'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 1845, 'therapyName': 'Mycophenolate mofetil'}, {'id': 1166, 'therapyName': 'Fludarabine'}]","Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies",854
9,NCT01701986,Phase Ib/II,Recruiting,"[{'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1845, 'therapyName': 'Mycophenolate mofetil'}, {'id': 1844, 'therapyName': 'anti-thymocyte globulin'}, {'id': 3992, 'therapyName': 'Busulfan + Clofarabine + Gemcitabine'}]",Gemcitabine/Clofarabine/Busulfan and Allogeneic Transplantation for Aggressive Lymphomas,854
10,NCT01203722,Phase Ib/II,Recruiting,"[{'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 2281, 'therapyName': 'Cyclophosphamide + Fludarabine + Mycophenolate mofetil'}]","Reduced Intensity, Partially HLA Mismatched BMT to Treat Hematologic Malignancies",854
11,NCT02333162,Phase I,Recruiting,"[{'id': 1845, 'therapyName': 'Mycophenolate mofetil'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 2237, 'therapyName': 'Fludarabine + Melphalan'}]","Intensity Modulated Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients With Relapsed Hematologic Cancers Undergoing a Second Donor Stem Cell Transplant",854
12,NCT01823198,Phase Ib/II,Recruiting,"[{'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1846, 'therapyName': 'Busulfan + Fludarabine + anti-thymocyte globulin'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 1632, 'therapyName': 'Filgrastim'}]",Natural Killer (NK) Cells With HLA Compatible Hematopoietic Transplantation for High Risk Myeloid Malignancies,854
13,NCT02081755,,Recruiting,"[{'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 735, 'therapyName': 'Everolimus'}]",Safety and Efficacy of Everolimus Treatment in Liver Transplantation for Liver Cancer,854
14,NCT01760655,Phase II,Recruiting,"[{'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 1842, 'therapyName': 'Fludarabine + Thiotepa + Cyclophosphamide'}, {'id': 1845, 'therapyName': 'Mycophenolate mofetil'}]",Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies,854
15,NCT01256398,Phase II,"Active, not recruiting","[{'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 2291, 'therapyName': 'Cyclophosphamide + Fludarabine'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1824, 'therapyName': 'Vincristine + Methotrexate + Mercaptopurine'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 2391, 'therapyName': 'Cytarabine + Daunorubicin + Etoposide'}, {'id': 1476, 'therapyName': 'Pegfilgrastim'}, {'id': 1205, 'therapyName': 'Alemtuzumab'}, {'id': 1642, 'therapyName': 'Leucovorin'}]",Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,854
16,NCT02251821,Phase II,Recruiting,"[{'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 1845, 'therapyName': 'Mycophenolate mofetil'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 2006, 'therapyName': 'Pacritinib'}, {'id': 823, 'therapyName': 'Momelotinib'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}]",JAK-2 Inhibitor Before Donor Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis,854
17,NCT00513474,Phase I,Completed,"[{'id': 2313, 'therapyName': 'Rasburicase'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 1650, 'therapyName': 'Cyclosporine'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 2314, 'therapyName': 'Busulfan + Cyclophosphamide + Etoposide'}]",Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant,854
18,NCT01621477,Phase II,Terminated,"[{'id': 1756, 'therapyName': 'Plerixafor'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 1845, 'therapyName': 'Mycophenolate mofetil'}, {'id': 2469, 'therapyName': 'Busulfan + Clofarabine + Thymoglobulin'}, {'id': 1783, 'therapyName': 'Cyclophosphamide + Cytarabine'}]",T-Cell Replete Haploidentical Donor Hematopoietic Stem Cell Plus Natural Killer (NK) Cell Transplantation in Patients With Hematologic Malignancies Relapsed or Refractory Despite Previous Allogeneic Transplant,854
19,NCT00857389,Phase II,"Active, not recruiting","[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 2469, 'therapyName': 'Busulfan + Clofarabine + Thymoglobulin'}, {'id': 1639, 'therapyName': 'Methotrexate'}]",Thiotepa-Clofarabine-Busulfan With Allogeneic Stem Cell Transplant for High Risk Malignancies,854
20,NCT03247088,Phase Ib/II,Recruiting,"[{'id': 6122, 'therapyName': 'Busulfan + Sorafenib + Fludarabine'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 1632, 'therapyName': 'Filgrastim'}]",Study Of Sorafenib Added To Busulfan And Fludarabine Conditioning Regimen In Patients With Relapsed/Refractory AML Undergoing Stem Cell Transplantation,854
21,NCT01790568,Phase II,"Active, not recruiting","[{'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 1077, 'therapyName': 'Vorinostat'}]",Vorinostat Plus Tacrolimus & Methotrexate to Prevent Graft vs Host Disease Following Unrelated Stem Cell Transplant,854
22,NCT02508038,Phase I,Recruiting,"[{'id': 2971, 'therapyName': 'Zoledronic acid'}, {'id': 2237, 'therapyName': 'Fludarabine + Melphalan'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 1844, 'therapyName': 'anti-thymocyte globulin'}, {'id': 1845, 'therapyName': 'Mycophenolate mofetil'}]", Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa,854
23,NCT01619761,Phase I,Recruiting,"[{'id': 897, 'therapyName': 'Rituximab'}, {'id': 1847, 'therapyName': 'lenalidomide + Fludarabine + Melphalan'}, {'id': 1845, 'therapyName': 'Mycophenolate mofetil'}, {'id': 1843, 'therapyName': 'Tacrolimus'}]",Natural Killer (NK) Cells in Cord Blood Transplantation,854
24,NCT02440464,Phase II,Recruiting,"[{'id': 3321, 'therapyName': 'Tacrolimus + Methotrexate'}, {'id': 1359, 'therapyName': 'Ixazomib'}, {'id': 2237, 'therapyName': 'Fludarabine + Melphalan'}, {'id': 688, 'therapyName': 'Bortezomib'}]",Allogeneic Hematopoietic Stem Cell Transplantation With Ixazomib for High Risk Multiple Myeloma (BMT CTN 1302),854
0,NCT02954406,Phase I,Recruiting,"[{'id': 5150, 'therapyName': 'Lenalidomide + TAK-659'}, {'id': 5149, 'therapyName': 'Ibrutinib + TAK-659'}, {'id': 5148, 'therapyName': 'Gemcitabine + TAK-659'}, {'id': 5147, 'therapyName': 'Bendamustine + Rituximab + TAK-659'}, {'id': 5146, 'therapyName': 'Bendamustine + TAK-659'}]","A Study of TAK-659 in Combination With Bendamustine (+/-Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Participants With Advanced Non-Hodgkin Lymphoma",7953
1,NCT02834247,Phase I,Recruiting,"[{'id': 4680, 'therapyName': 'Nivolumab + TAK-659'}]",A Study of TAK-659 in Combination With Nivolumab in Participants With Advanced Solid Tumors,7953
2,NCT02000934,Phase I,Recruiting,"[{'id': 3146, 'therapyName': 'TAK-659'}]",A Study of TAK-659 in Adult Patients With Advanced Solid Tumor and Lymphoma Malignancies,7953
3,NCT02551055,Phase I,Terminated,"[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 626, 'therapyName': 'Alisertib'}, {'id': 3146, 'therapyName': 'TAK-659'}, {'id': 1033, 'therapyName': 'MLN1117'}]","MLN1117 in Combination With Docetaxel, Paclitaxel, and Other Investigational Anticancer Agents to Treat Participants With Gastric and Gastroesophageal Adenocarcinoma",7953
4,NCT02323113,Phase Ib/II,Recruiting,"[{'id': 3146, 'therapyName': 'TAK-659'}]","Safety, Tolerability, and Efficacy of TAK-659 in Adults With Relapsed or Refractory Acute Myelogenous Leukemia (AML)",7953
0,NCT02472145,Phase III,"Active, not recruiting","[{'id': 650, 'therapyName': 'Decitabine'}, {'id': 5909, 'therapyName': 'Decitabine + Talacotuzumab'}]",An Efficacy and Safety Study of Decitabine (DACOGEN) Plus Talacotuzumab (JNJ-56022473; Anti CD123) Versus Decitabine (DACOGEN) Alone in Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy,8805
1,NCT03011034,Phase II,Recruiting,"[{'id': 5809, 'therapyName': 'Talacotuzumab'}, {'id': 1630, 'therapyName': 'Daratumumab'}]",Study to Separately Evaluate the Activity of Talacotuzumab (JNJ-56022473) or Daratumumab in Transfusion-Dependent Participants With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) Who Are Relapsed or Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment,8805
0,NCT02784795,Phase I,Recruiting,"[{'id': 4374, 'therapyName': 'Cisplatin + Gemcitabine + LY3039478'}, {'id': 4375, 'therapyName': 'Carboplatin + Gemcitabine + LY3039478'}, {'id': 4372, 'therapyName': 'LY3039478 + LY3023414'}, {'id': 4373, 'therapyName': 'Abemaciclib + LY3039478'}, {'id': 4371, 'therapyName': 'LY3039478 + Taladegib'}, {'id': 2958, 'therapyName': 'LY3039478'}, {'id': 1069, 'therapyName': 'LY3023414'}]",A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors,7293
1,NCT01722292,Phase Ib/II,Terminated,"[{'id': 1587, 'therapyName': 'Taladegib'}, {'id': 1791, 'therapyName': 'Carboplatin + Etoposide'}]",A Study of LY2940680 in Small Cell Lung Cancer,7293
2,NCT02530437,Phase Ib/II,Recruiting,"[{'id': 1587, 'therapyName': 'Taladegib'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]","A Phase 1B/2 Study of LY2940680 in Combination With Weekly Paclitaxel, Carboplatin, and Radiation in Localized Adenocarcinoma of the Esophagus or Gastroesophageal Junction",7293
0,NCT02878785,Phase Ib/II,Recruiting,"[{'id': 5531, 'therapyName': 'Decitabine + Talazoparib'}]",Decitabine and Talazoparib in Untreated AML and R/R AML (1565GCC) ,6876
1,NCT02392793,Phase I,Recruiting,"[{'id': 1378, 'therapyName': 'Irinotecan + Talazoparib'}, {'id': 1141, 'therapyName': 'Temozolomide'}]",Talazoparib Plus Irinotecan With or Without Temozolomide in Children With Refractory or Recurrent Solid Malignancies,6876
2,NCT02049593,Phase I,"Active, not recruiting","[{'id': 1377, 'therapyName': 'Talazoparib + Temozolomide'}, {'id': 1378, 'therapyName': 'Irinotecan + Talazoparib'}]",PARP Inhibitor BMN-673 and Temozolomide or Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic Solid Tumors,6876
3,NCT02627430,Phase I,Withdrawn,"[{'id': 3317, 'therapyName': 'Onalespib + Talazoparib'}]","Talazoparib and HSP90 Inhibitor AT13387 in Treating Patients With Metastatic Advanced Solid Tumor or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple Negative Breast Cancer",6876
4,NCT02997176,Phase I,Recruiting,"[{'id': 682, 'therapyName': 'Talazoparib'}]",An Open-Label Pharmacokinetics and Safety Study of Talazoparib (MDV3800),6876
5,NCT02282345,Phase II,Recruiting,"[{'id': 682, 'therapyName': 'Talazoparib'}]",Neoadjuvant BMN673 for Patients With a BRCA Deleterious Mutation,6876
6,NCT02034916,Phase II,"Active, not recruiting","[{'id': 682, 'therapyName': 'Talazoparib'}]","A Phase 2, 2-Stage, 2-Cohort Study of Talazoparib (BMN 673), in Locally Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (ABRAZO Study)",6876
7,NCT02358200,Phase I,"Active, not recruiting","[{'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 682, 'therapyName': 'Talazoparib'}]",Study of BMN-673 With Carboplatin and Paclitaxel in Patients With Advanced BRCA-mutated Solid Tumor or Triple Negative Metastatic Breast Cancer,6876
8,NCT01989546,Phase Ib/II,Completed,"[{'id': 682, 'therapyName': 'Talazoparib'}]","Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mutations",6876
9,NCT02326844,Phase II,Terminated,"[{'id': 682, 'therapyName': 'Talazoparib'}]","BMN 673 (Talazoparib), an Oral PARP Inhibitor, in People With Deleterious BRCA1/2 Mutation-Associated Ovarian Cancer Who Have Had Prior PARP Inhibitor Treatment",6876
10,NCT03042910,Phase I,Completed,"[{'id': 682, 'therapyName': 'Talazoparib'}]",A Study to Assess the Effects of Talazoparib on Cardiac Repolarization in Patients With Advanced Solid Tumors,6876
11,NCT02401347,Phase II,Recruiting,"[{'id': 682, 'therapyName': 'Talazoparib'}]",Talazoparib Beyond BRCA (TBB) Trial,6876
12,NCT02316834,Phase I,"Active, not recruiting","[{'id': 682, 'therapyName': 'Talazoparib'}]",POSITION: A PilOt Study of InducTion PARP InhibitiON in Ovarian Cancer,6876
13,NCT03148795,Phase II,Recruiting,"[{'id': 682, 'therapyName': 'Talazoparib'}]",A Study of Talazoparib in Men With DNA Repair Defects and Metastatic Castration-Resistant Prostate Cancer,6876
14,NCT02286687,Phase II,"Active, not recruiting","[{'id': 682, 'therapyName': 'Talazoparib'}]",Phase II Study of BMN 673,6876
15,NCT02921919,Phase II,Recruiting,"[{'id': 682, 'therapyName': 'Talazoparib'}]",Open-Label Extension and Safety Study of Talazoparib,6876
16,NCT02567396,Phase I,Withdrawn,"[{'id': 682, 'therapyName': 'Talazoparib'}]",Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be Removed by Surgery and Liver or Kidney Dysfunction,6876
17,NCT01945775,Phase III,"Active, not recruiting","[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 1685, 'therapyName': 'Vinorelbine'}, {'id': 682, 'therapyName': 'Talazoparib'}, {'id': 728, 'therapyName': 'Eribulin'}]","A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study)",6876
18,NCT01286987,Phase I,Completed,"[{'id': 682, 'therapyName': 'Talazoparib'}]","Study of BMN 673, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors",6876
19,NCT02537561,Phase I,Withdrawn,"[{'id': 682, 'therapyName': 'Talazoparib'}, {'id': 1467, 'therapyName': 'Gemcitabine + Cisplatin'}]",Talazoparib in Combination With Gemcitabine and Cisplatin in Patients With Advanced Solid Tumors,6876
20,NCT02317874,Phase I,Recruiting,"[{'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 682, 'therapyName': 'Talazoparib'}]","PARP Inhibitor BMN-673, Carboplatin, and Paclitaxel in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery",6876
21,NCT02997163,Phase I,Recruiting,"[{'id': 682, 'therapyName': 'Talazoparib'}]",An Open-Label Pharmacokinetics and Safety Study of Talazoparib,6876
22,NCT02116777,Phase Ib/II,Recruiting,"[{'id': 1377, 'therapyName': 'Talazoparib + Temozolomide'}]",BMN-673 and Temozolomide in Treating Younger Patients With Refractory or Recurrent Malignancies,6876
0,NCT02626000,Phase Ib/II,Recruiting,"[{'id': 4035, 'therapyName': 'Pembrolizumab + talimogene laherparepvec '}]",Talimogene Laherparepvec With Pembrolizumab for Recurrent Metastatic Squamous Cell Carcinoma of the Head and Neck,7659
1,NCT02965716,Phase II,Recruiting,"[{'id': 4035, 'therapyName': 'Pembrolizumab + talimogene laherparepvec '}]",Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV Melanoma,7659
2,NCT03069378,Phase II,Recruiting,"[{'id': 4035, 'therapyName': 'Pembrolizumab + talimogene laherparepvec '}]",A Study of Talimogene Laherparepvec (T-VEC) in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced Sarcoma,7659
3,NCT01740297,Phase Ib/II,"Active, not recruiting","[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 2695, 'therapyName': 'talimogene laherparepvec '}]",Ipilimumab With or Without Talimogene Laherparepvec in Unresected Melanoma,7659
4,NCT02263508,Phase Ib/II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 2695, 'therapyName': 'talimogene laherparepvec '}]",MK-3475 With or Without Talimogene Laherparepvec in Unresected Melanoma,7659
5,NCT03088176,Phase I,Recruiting,"[{'id': 5481, 'therapyName': 'talimogene laherparepvec + Dabrafenib + Trametinib'}]",Combining Talimogene Laherparepvec With BRAF and MEK Inhibitors in BRAF Mutated Advanced Melanoma,7659
6,NCT02978625,Phase II,Recruiting,"[{'id': 5080, 'therapyName': 'Talimogene laherparepvec + Nivolumab'}]",Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers,7659
0,NCT02057133,Phase I,Recruiting,"[{'id': 2254, 'therapyName': 'Abemaciclib + Letrozole'}, {'id': 2257, 'therapyName': 'Abemaciclib + Exemestane'}, {'id': 2258, 'therapyName': 'Everolimus + Exemestane + LY2835219'}, {'id': 2255, 'therapyName': 'Abemaciclib + Anastrozole'}, {'id': 2256, 'therapyName': 'Abemaciclib + Tamoxifen'}, {'id': 2259, 'therapyName': 'Abemaciclib + Trastuzumab'}]",A Study of LY2835219 in Combination With Hormone Therapies for Breast Cancer That Has Spread,665
1,NCT02747004,Phase II,Recruiting,"[{'id': 4387, 'therapyName': 'Abemaciclib + Loperamide'}, {'id': 802, 'therapyName': 'Abemaciclib'}, {'id': 2256, 'therapyName': 'Abemaciclib + Tamoxifen'}]",A Study of Abemaciclib (LY2835219) Plus Tamoxifen or Abemaciclib Alone in Women With Metastatic Breast Cancer (nextMONARCH 1),665
2,NCT03280563,Phase Ib/II,Not yet recruiting,"[{'id': 6269, 'therapyName': 'Atezolizumab + Ipatasertib'}, {'id': 6270, 'therapyName': 'Atezolizumab + Bevacizumab + Exemestane'}, {'id': 1343, 'therapyName': 'Atezolizumab + Cobimetinib'}, {'id': 6271, 'therapyName': 'Atezolizumab + Bevacizumab + Fulvestrant'}, {'id': 6272, 'therapyName': 'Atezolizumab + Bevacizumab + Tamoxifen'}, {'id': 6273, 'therapyName': 'Atezolizumab + Ipatasertib + Fulvestrant'}, {'id': 744, 'therapyName': 'Fulvestrant'}, {'id': 6268, 'therapyName': 'Atezolizumab + Fulvestrant'}]",A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer,665
3,NCT00492505,Phase II,Unknown status,"[{'id': 2212, 'therapyName': 'Cisplatin + Sorafenib + Tamoxifen'}]","Sorafenib, Tamoxifen, and Cisplatin in Treating Patients With High-Risk Stage III Melanoma",665
4,NCT02101788,Phase II,Recruiting,"[{'id': 942, 'therapyName': 'Topotecan'}, {'id': 2173, 'therapyName': 'Doxil + Letrozole + Tamoxifen + Paclitaxel'}, {'id': 2, 'therapyName': 'Trametinib'}]",Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer,665
5,NCT02291913,Phase II,"Active, not recruiting","[{'id': 2267, 'therapyName': 'Everolimus + Tamoxifen'}, {'id': 2268, 'therapyName': 'Anastrozole + Everolimus'}, {'id': 1589, 'therapyName': 'Fulvestrant + Everolimus'}, {'id': 1621, 'therapyName': 'Everolimus + Letrozole'}, {'id': 2269, 'therapyName': 'Everolimus + Toremifene'}, {'id': 1966, 'therapyName': 'Exemestane + Everolimus'}]",Everolimus Combined With Anti-estrogen Therapy in Hormone-Receptor-Positive HER-2 Negative Advanced Breast Cancer,665
6,NCT02586675,Phase I,"Active, not recruiting","[{'id': 759, 'therapyName': 'Goserelin'}, {'id': 3175, 'therapyName': 'LEE001 + Tamoxifen'}]",TEEL Study- Phase 1 Tamoxifen and Ribociclib (LEE011) in Advanced ER+ (HER2 Negative) Breast Cancer,665
7,NCT02988986,Phase II,Recruiting,"[{'id': 5141, 'therapyName': 'MLN0128 + Tamoxifen'}]","TAK-228 Plus Tamoxifen in Patients With ER-Positive, HER2-negative Breast Cancer",665
8,NCT02668666,Phase II,Recruiting,"[{'id': 3542, 'therapyName': 'Palbociclib + Tamoxifen'}]",Palbociclib in Combination With Tamoxifen as First Line Therapy for Metastatic Hormone Receptor Positive Breast Cancer,665
9,NCT02395627,Phase II,Recruiting,"[{'id': 3114, 'therapyName': 'Pembrolizumab + Tamoxifen + vorinostat'}]",Reversing Hormone Therapy Resistance With Epigenetic-Immune Modification,665
10,NCT00489944,Phase II,Unknown status,"[{'id': 1963, 'therapyName': 'Sunitinib + Tamoxifen + Cisplatin'}]","Sunitinib, Tamoxifen, and Cisplatin in Treating Patients With High-Risk Ocular Melanoma",665
11,NCT02228681,Phase II,"Active, not recruiting","[{'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 2401, 'therapyName': 'Medroxyprogesterone'}, {'id': 1621, 'therapyName': 'Everolimus + Letrozole'}]",Everolimus and Letrozole or Hormonal Therapy to Treat Endometrial Cancer,665
12,NCT02269670,Phase II,"Active, not recruiting","[{'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 1869, 'therapyName': 'Megestrol'}, {'id': 794, 'therapyName': 'Letrozole'}, {'id': 744, 'therapyName': 'Fulvestrant'}, {'id': 633, 'therapyName': 'Anastrozole'}]",Everolimus and Hormone Therapy in Treating Patients With Advanced Hormone Receptor Positive Breast Cancer That Has Progressed or Recurred on Everolimus and Exemestane Therapy,665
13,NCT02936206,Phase I,Recruiting,"[{'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 744, 'therapyName': 'Fulvestrant'}]",Examination of Breast Cancer Cells of Pre-menopausal Women Before and After Exposure to Tamoxifen or Fulvestrant.,665
14,NCT00900744,FDA approved,Completed,"[{'id': 1456, 'therapyName': 'Tamoxifen'}]",A Pilot Study of Varying Doses of Tamoxifen in the Setting of Genetic Polymorphisms of CYP2D6,665
15,NCT01272037,Phase III,Recruiting,"[{'id': 633, 'therapyName': 'Anastrozole'}, {'id': 794, 'therapyName': 'Letrozole'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 738, 'therapyName': 'Exemestane'}]","Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer",665
16,NCT02204098,Phase I,Recruiting,"[{'id': 794, 'therapyName': 'Letrozole'}, {'id': 633, 'therapyName': 'Anastrozole'}, {'id': 759, 'therapyName': 'Goserelin'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 1456, 'therapyName': 'Tamoxifen'}]",Safety and Immune Response to a Mammaglobin-A DNA Vaccine In Breast Cancer Patients Undergoing Neoadjuvant Endocrine Therapy,665
17,NCT02384239,Phase II,Recruiting,"[{'id': 744, 'therapyName': 'Fulvestrant'}, {'id': 850, 'therapyName': 'Palbociclib'}, {'id': 1456, 'therapyName': 'Tamoxifen'}]",A Study of Palbociclib in Combination With Fulvestrant or Tamoxifen as Treatment for Metastatic Breast Cancer,665
18,NCT02476786,Phase II,Recruiting,"[{'id': 633, 'therapyName': 'Anastrozole'}, {'id': 744, 'therapyName': 'Fulvestrant'}, {'id': 759, 'therapyName': 'Goserelin'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 738, 'therapyName': 'Exemestane'}]",Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score,665
19,NCT03238703,FDA approved,Not yet recruiting,"[{'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 4419, 'therapyName': 'Toremifine'}, {'id': 633, 'therapyName': 'Anastrozole'}, {'id': 794, 'therapyName': 'Letrozole'}]","Endocrine Therapy in Treating Patients With HER2 Negative, Low Risk Breast Cancer",665
20,NCT02040857,Phase II,"Active, not recruiting","[{'id': 738, 'therapyName': 'Exemestane'}, {'id': 850, 'therapyName': 'Palbociclib'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 794, 'therapyName': 'Letrozole'}, {'id': 633, 'therapyName': 'Anastrozole'}]",Palbociclib + Endocrine Therapy for HR + BrCa,665
21,NCT00492687,Phase II,Unknown status,"[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1141, 'therapyName': 'Temozolomide'}, {'id': 1456, 'therapyName': 'Tamoxifen'}]","Radiation Therapy, Temozolomide, Tamoxifen, and Carboplatin in Treating Patients With Malignant Gliomas",665
22,NCT01674140,Phase III,Recruiting,"[{'id': 759, 'therapyName': 'Goserelin'}, {'id': 633, 'therapyName': 'Anastrozole'}, {'id': 794, 'therapyName': 'Letrozole'}, {'id': 795, 'therapyName': 'Leuprolide'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 738, 'therapyName': 'Exemestane'}]",S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer,665
23,NCT01293032,Phase I,Completed,"[{'id': 1456, 'therapyName': 'Tamoxifen'}]",Hormone Therapy Or Chemotherapy Before Surgery Based on Gene Expression Analysis in Treating Patients With Breast Cancer,665
24,NCT02788201,Phase II,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1133, 'therapyName': 'Mitomycin C'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1013, 'therapyName': 'epirubicin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1137, 'therapyName': 'Bleomycin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 781, 'therapyName': 'Ixabepilone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 2950, 'therapyName': 'Estramustine'}, {'id': 1941, 'therapyName': 'Floxuridine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 1811, 'therapyName': 'Carmustine'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 953, 'therapyName': 'Vandetanib'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 4419, 'therapyName': 'Toremifine'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 2601, 'therapyName': 'Dactinomycin'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 3035, 'therapyName': 'Chlorambucil'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 342, 'therapyName': 'Vemurafenib'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 2635, 'therapyName': 'Vinblastine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 4305, 'therapyName': 'Teniposide'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 4304, 'therapyName': 'Streptozocin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1231, 'therapyName': 'Bendamustine'}, {'id': 4303, 'therapyName': 'Mechlorethamine'}, {'id': 4302, 'therapyName': 'Mitotane'}]",Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma,665
25,NCT02197897,Phase II,Recruiting,"[{'id': 1456, 'therapyName': 'Tamoxifen'}]",Evaluation the Treatment of Tamoxifen of Low/Intermediate Risk Bladder Tumors,665
26,NCT02913430,Phase II,Recruiting,"[{'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 744, 'therapyName': 'Fulvestrant'}]",Phase II Treatment of Metastatic Breast Cancer With Fulvestrant or Tamoxifen,665
27,NCT02311933,Phase II,"Active, not recruiting","[{'id': 3076, 'therapyName': 'Z-endoxifen HCl'}, {'id': 1456, 'therapyName': 'Tamoxifen'}]","Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer",665
28,NCT02764541,Phase II,Recruiting,"[{'id': 850, 'therapyName': 'Palbociclib'}, {'id': 794, 'therapyName': 'Letrozole'}, {'id': 1456, 'therapyName': 'Tamoxifen'}]",Palbociclib and Endocrine Therapy for LObular Breast Cancer Preoperative Study (PELOPS),665
29,NCT02630693,Phase II,"Active, not recruiting","[{'id': 850, 'therapyName': 'Palbociclib'}, {'id': 744, 'therapyName': 'Fulvestrant'}, {'id': 1456, 'therapyName': 'Tamoxifen'}]","Study Comparing Two Different Schedules of Palbociclib Plus Second Line Endocrine Therapy in Women With Estrogen Receptor Positive, HER2 Negative Advanced/Metastatic Breast Cancer",665
30,NCT02753686,Phase I,Recruiting,"[{'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 744, 'therapyName': 'Fulvestrant'}, {'id': 794, 'therapyName': 'Letrozole'}, {'id': 633, 'therapyName': 'Anastrozole'}, {'id': 1966, 'therapyName': 'Exemestane + Everolimus'}]",Treatment of Canadian Postmenopausal Women With ER+ Advanced Breast Cancer in the Real-World Setting With Hormone Therapy ± Targeted Therapy (Treat ER+ight),665
31,NCT02206984,Phase I,Recruiting,"[{'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 633, 'therapyName': 'Anastrozole'}, {'id': 744, 'therapyName': 'Fulvestrant'}]",Endocrine Response in Women With Invasive Lobular Breast Cancer,665
32,NCT02278120,Phase III,"Active, not recruiting","[{'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 794, 'therapyName': 'Letrozole'}, {'id': 790, 'therapyName': 'Ribociclib'}, {'id': 759, 'therapyName': 'Goserelin'}, {'id': 633, 'therapyName': 'Anastrozole'}]","Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer",665
33,NCT01124695,Phase II,Unknown status,"[{'id': 1456, 'therapyName': 'Tamoxifen'}]",Tamoxifen Citrate in Treating Patients With Metastatic or Recurrent Breast Cancer,665
34,NCT02993159,Phase II,Recruiting,"[{'id': 5132, 'therapyName': 'Afimoxifene'}, {'id': 1456, 'therapyName': 'Tamoxifen'}]",Tamoxifen Citrate or Afimoxifene in Treating Patients With Estrogen Receptor Positive Breast Cancer,665
35,NCT01027416,Phase I,Completed,"[{'id': 1456, 'therapyName': 'Tamoxifen'}]",Analyzing a New Mechanism in Response to Tamoxifen Therapy in Breast Cancer Patients,665
0,NCT01647828,Phase Ib/II,Completed,"[{'id': 619, 'therapyName': 'Abraxane'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 2547, 'therapyName': 'Tarextumab'}]",A Phase 1b/2 Study of OMP-59R5 in Combination With Nab-Paclitaxel and Gemcitabine in Subjects With Previously Untreated Stage IV Pancreatic Cancer,7576
1,NCT01859741,Phase Ib/II,"Active, not recruiting","[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 2547, 'therapyName': 'Tarextumab'}]",A Phase 1b/2 Study of OMP-59R5 in Combination With Etoposide and Platinum Therapy in Subjects With Untreated Extensive Stage Small Cell Lung Cancer (PINNACLE),7576
0,NCT02025803,Phase I,"Active, not recruiting","[{'id': 4335, 'therapyName': 'Capecitabine + TAS-114'}]","A Safety, Tolerability and Pharmacokinetic Study of TAS-114 in Combination With Capecitabine in Patients With Advanced Solid Tumors",8423
1,NCT02855125,Phase II,Recruiting,"[{'id': 1407, 'therapyName': 'TS-1'}, {'id': 4527, 'therapyName': 'TAS-114 + TS-1'}]",A Randomized Phase 2 Trial of TAS-114 in Combination With S-1 Versus S-1,8423
0,NCT02965885,Phase I,Recruiting,"[{'id': 2768, 'therapyName': 'TAS-116'}]",A Study of TAS-116 in Patients With Solid Tumors,7719
0,NCT02134067,Phase I,Recruiting,"[{'id': 1400, 'therapyName': 'TAS-119'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]","Dose-escalating, Safety, Tolerability and PK Study of TAS-119 in Combination With Paclitaxel in Patients With Advanced Solid Tumors",7250
1,NCT02448589,Phase I,Recruiting,"[{'id': 1400, 'therapyName': 'TAS-119'}]",An Investigation of TAS-119 Monotherapy and in Combination With Docetaxel,7250
0,NCT02052778,Phase Ib/II,Recruiting,"[{'id': 1053, 'therapyName': 'TAS-120'}]",A Dose Finding Study Followed by a Safety and Efficacy Study in Patients With Advanced Solid Tumors or Multiple Myeloma With FGF/FGFR-Related Abnormalities,7171
0,NCT02566772,Phase I,Recruiting,"[{'id': 4329, 'therapyName': 'TAS3681'}]",Study of TAS3681 in Metastatic Castration Resistant Prostate Cancer,8418
0,NCT02978235,Phase Ib/II,Recruiting,"[{'id': 5897, 'therapyName': 'TAS4464'}]",A Dose Finding Study Followed by a Safety and Efficacy Study for Patients With Multiple Myeloma or Lymphoma,8852
0,NCT02396368,Phase I,Withdrawn,"[{'id': 2699, 'therapyName': 'Tasquinimod'}, {'id': 2001, 'therapyName': 'radium Ra 223 dichloride'}]",A Study of Radium-223 in Combination With Tasquinimod in Bone-only Metastatic Castration-Resistant Prostate Cancer,7662
1,NCT01513733,Phase I,Completed,"[{'id': 2699, 'therapyName': 'Tasquinimod'}, {'id': 1571, 'therapyName': 'Cabazitaxel'}]",The CATCH Prostate Cancer Trial Cabazitaxel And Tasquinimod in Men With Prostate Cancer,7662
2,NCT02159950,Phase II,Completed,"[{'id': 2648, 'therapyName': 'Sipuleucel-T'}, {'id': 2699, 'therapyName': 'Tasquinimod'}]",Sipuleucel-T With or Without Tasquinimod in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer,7662
0,NCT03028103,Phase I,Recruiting,"[{'id': 5267, 'therapyName': 'Tazemetostat + Fluconazole'}, {'id': 5285, 'therapyName': 'Repaglinide + Omeprazole + Tazemetostat'}]","Open-Label, Multicenter, Two-Part, Phase 1 Study to Characterize Effects of a Moderate CYP3A Inhibitor on PK of Tazemetostat, the Effects of Tazemetostat on PK of CYP2C8 and CYP2C19 Substrates, and the Effect of Increased Gastric pH on PK of Tazemetostat in B-cell Lymphoma Subjects",7650
1,NCT03155620,Phase II,Recruiting,"[{'id': 2683, 'therapyName': 'Tazemetostat'}, {'id': 2650, 'therapyName': 'LOXO-101'}, {'id': 1069, 'therapyName': 'LY3023414'}, {'id': 342, 'therapyName': 'Vemurafenib'}, {'id': 837, 'therapyName': 'Olaparib'}, {'id': 913, 'therapyName': 'Selumetinib'}, {'id': 961, 'therapyName': 'X-396'}]",Pediatric MATCH: Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Advanced Refractory Solid Tumors or Lymphomas,7650
2,NCT02601937,Phase I,Recruiting,"[{'id': 2683, 'therapyName': 'Tazemetostat'}]",A Phase 1 Study of the EZH2 Inhibitor Tazemetostat in Pediatric Subjects With Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma,7650
3,NCT02875548,Phase II,Recruiting,"[{'id': 2683, 'therapyName': 'Tazemetostat'}]",Tazemetostat Rollover Study (TRuST): An Open-Label Rollover Study,7650
4,NCT03213665,Phase II,Recruiting,"[{'id': 2683, 'therapyName': 'Tazemetostat'}]","Pediatric MATCH: Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations",7650
5,NCT02601950,Phase II,Recruiting,"[{'id': 2683, 'therapyName': 'Tazemetostat'}]","A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects With INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma",7650
6,NCT03217253,Phase I,Not yet recruiting,"[{'id': 2683, 'therapyName': 'Tazemetostat'}]",Tazemetostat in Treating Patients With Metastatic or Unresectable Solid Tumors or B-Cell Lymphomas With Liver Dysfunction,7650
7,NCT02860286,Phase II,"Active, not recruiting","[{'id': 2683, 'therapyName': 'Tazemetostat'}]",Study of the EZH2 Inhibitor Tazemetostat in Malignant Mesothelioma,7650
0,NCT02748135,Phase Ib/II,Recruiting,"[{'id': 4704, 'therapyName': 'TB-403'}]",A Two-Part Study of TB-403 in Pediatric Subjects With Relapsed or Refractory Medulloblastoma,8524
0,NCT02423057,Phase I,Recruiting,"[{'id': 2907, 'therapyName': 'TdCyd'}]",Phase I Trial of 4'-Thio-2'-Deoxycytidine (TdCyd) in Patients With Advanced Solid Tumors,7830
0,NCT02314156,Phase II,Recruiting,"[{'id': 2820, 'therapyName': 'Telapristone'}]",Transdermal or Oral Telapristone Acetate in Treating Patients Undergoing Mastectomy,7763
0,NCT02977780,Phase II,Recruiting,"[{'id': 1000, 'therapyName': 'CC-115'}, {'id': 5028, 'therapyName': 'Abemaciclib + Temozolomide'}, {'id': 1141, 'therapyName': 'Temozolomide'}, {'id': 5029, 'therapyName': 'Neratinib + Temozolomide'}]",INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT),843
1,NCT02065466,Phase Ib/II,Withdrawn,"[{'id': 1380, 'therapyName': 'Abraxane + Temozolomide + Bevacizumab'}]","Combo of Abraxane, TMZ, Bevacizumab in Metastatic Melanoma With Brain Metastases",843
2,NCT01601535,Phase Ib/II,"Active, not recruiting","[{'id': 2628, 'therapyName': 'Alisertib + Irinotecan + Temozolomide'}]",Study of MLN8237 in Combination With Irinotecan and Temozolomide,843
3,NCT03174197,Phase Ib/II,Recruiting,"[{'id': 5872, 'therapyName': 'Atezolizumab + Temozolomide'}]",Atezolizumab (aPDL1) + Temozolomide and Radiation for Newly Diagnosed Glioblastoma (GBM),843
4,NCT03139916,Phase II,Recruiting,"[{'id': 5634, 'therapyName': 'Bavituximab + Temozolomide'}]",Phase II Clinical Trial of Bavituximab With Radiation and Temozolomide for Patients With Newly Diagnosed Glioblastoma,843
5,NCT01435395,Phase I,Completed,"[{'id': 2122, 'therapyName': 'Bevacizumab + Bortezomib + Temozolomide'}]","Trial of Temozolomide, Bevacizumab Plus Bortezomib for Recurrent Glioblastoma Multiforme",843
6,NCT01525082,Phase II,"Active, not recruiting","[{'id': 2073, 'therapyName': 'Bevacizumab + Capecitabine + Temozolomide'}]","Capecitabine, Temozolomide and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors",843
7,NCT01182350,Phase II,"Active, not recruiting","[{'id': 2115, 'therapyName': 'Bevacizumab + Temozolomide'}, {'id': 2116, 'therapyName': 'Bevacizumab + Erlotinib + Temozolomide'}, {'id': 1146, 'therapyName': 'Bevacizumab + Erlotinib'}, {'id': 667, 'therapyName': 'Bevacizumab'}]",Molecularly Determined Treatment of Diffuse Intrinsic Pontine Gliomas (DIPG),843
8,NCT01478321,Phase II,"Active, not recruiting","[{'id': 2115, 'therapyName': 'Bevacizumab + Temozolomide'}]",Efficacy of Hypofractionated XRT w/Bev. + Temozolomide for Recurrent Gliomas,843
9,NCT03128047,Phase I,Recruiting,"[{'id': 2115, 'therapyName': 'Bevacizumab + Temozolomide'}]",HUMC 1612: Optune NovoTTF-200A System,843
10,NCT01891747,Phase Ib/II,"Active, not recruiting","[{'id': 2115, 'therapyName': 'Bevacizumab + Temozolomide'}]", A Phase I/II Study of High-dose L-methylfolate in Combination With Temozolomide and Bevacizumab in Recurrent High Grade Glioma,843
11,NCT01149850,Phase II,"Active, not recruiting","[{'id': 2115, 'therapyName': 'Bevacizumab + Temozolomide'}]",Bevacizumab and Temozolomide in Treating Older Patients With Newly-Diagnosed Glioblastoma Multiforme or Gliosarcoma,843
12,NCT02343549,Phase II,Recruiting,"[{'id': 2115, 'therapyName': 'Bevacizumab + Temozolomide'}]",LCI-NEU-NOV-001 Study of a Device Worn on the Head in Combination With Chemo to Treat Brain Cancer,843
13,NCT00660621,Phase II,Unknown status,"[{'id': 2115, 'therapyName': 'Bevacizumab + Temozolomide'}]","A Phase II Study Of Gliadel, Concomitant Temozolomide And Radiation, Followed By Dose Dense Therapy With Temozolomide Plus Bevacizumab For Newly Diagnosed Malignant High Grade Glioma",843
14,NCT03150810,Phase Ib/II,Recruiting,"[{'id': 6124, 'therapyName': 'BGB-290 + Temozolomide'}]","Study to Assess Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Subjects With Locally Advanced or Metastatic Solid Tumors",843
15,NCT03150862,Phase Ib/II,Recruiting,"[{'id': 2947, 'therapyName': 'BGB-290'}, {'id': 6124, 'therapyName': 'BGB-290 + Temozolomide'}]",A Study Assessing BGB-290 With Radiation and/or Temozolomide (TMZ) in Subjects With Newly Diagnosed or Recurrent Glioblastoma,843
16,NCT01473901,Phase I,Completed,"[{'id': 4474, 'therapyName': 'BKM120 + Temozolomide'}]",A Phase I Dose Escalation Study of BKM120 With Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma,843
17,NCT02655601,Phase Ib/II,Recruiting,"[{'id': 5841, 'therapyName': 'BMX-001 + Temozolomide'}, {'id': 1141, 'therapyName': 'Temozolomide'}]","Trial of Newly Diagnosed High Grade Glioma Treated With Concurrent Radiation Therapy, Temozolomide and BMX-001",843
18,NCT00998010,Phase II,"Active, not recruiting","[{'id': 3055, 'therapyName': 'Bortezomib + Temozolomide'}]","Bortezomib, Temozolomide, and Regional Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma",843
19,NCT02831179,Phase I,Withdrawn,"[{'id': 4463, 'therapyName': 'Capecitabine + Veliparib + Temozolomide'}]","Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor",843
20,NCT00669669,Phase Ib/II,"Active, not recruiting","[{'id': 2556, 'therapyName': 'O6-benzylguanine'}, {'id': 2555, 'therapyName': 'Carmustine + Filgrastim + Plerixafor + Temozolomide'}]",Dose-Intensive Chemotherapy in Combination With Chemoprotected Autologous Stem Cells in Treating Patients With Malignant Gliomas,843
21,NCT01107522,Phase I,"Active, not recruiting","[{'id': 1142, 'therapyName': 'CTO + Temozolomide'}, {'id': 999, 'therapyName': 'Carboxyamidotriazole Orotate'}]",Safety and Tolerability of Carboxyamidotriazole Orotate (CTO) in Solid Tumors or With Temodar&#174; in Glioblastoma or Other Recurrent Malignant Gliomas or in Combination With Temodar&#174; and Radiation Therapy for Patients With Newly Diagnosed Glioblastoma and Malignant Gliomas,843
22,NCT00925132,Phase Ib/II,Terminated,"[{'id': 1737, 'therapyName': 'Decitabine + Temozolomide + Panobinostat'}]","Treatment of Resistant Metastatic Melanoma Using Decitabine, Temozolomide and Panobinostat",843
23,NCT02689336,Phase II,Recruiting,"[{'id': 3726, 'therapyName': 'Erlotinib + Temozolomide'}]",Erlotinib in Combination With Temozolomide in Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors,843
24,NCT01591577,Phase II,Recruiting,"[{'id': 2440, 'therapyName': 'Lapatinib + Temozolomide'}]",Lapatinib With Temozolomide and Regional Radiation Therapy for Patients With Newly-Diagnosed Glioblastoma Multiforme,843
25,NCT01837862,Phase Ib/II,Recruiting,"[{'id': 2134, 'therapyName': 'Mebendazole + Vincristine + Carboplatin + Temozolomide'}, {'id': 2133, 'therapyName': 'Mebendazole + Bevacizumab + Irinotecan'}]",A Phase I/II Study of Mebendazole for the Treatment of Pediatric Gliomas,843
26,NCT01849146,Phase I,Recruiting,"[{'id': 2713, 'therapyName': 'MK-1775 + Temozolomide'}]","WEE1 Inhibitor MK-1775, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed or Recurrent Glioblastoma Multiforme",843
27,NCT02975882,Phase I,Recruiting,"[{'id': 5030, 'therapyName': 'Nab-Rapamycin + Temozolomide + Irinotecan'}]","Nanoparticle Albumin-Bound Rapamycin, Temozolomide, and Irinotecan Hydrochloride in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors",843
28,NCT02044120,Phase I,Recruiting,"[{'id': 1437, 'therapyName': 'Niraparib + Temozolomide'}]","ESP1/SARC025 Global Collaboration: A Phase I Study of a Combination of the PARP Inhibitor, Niraparib and Temozolomide in Patients With Previously Treated, Incurable Ewing Sarcoma",843
29,NCT02667587,Phase II,Recruiting,"[{'id': 1141, 'therapyName': 'Temozolomide'}, {'id': 3724, 'therapyName': 'Nivolumab + Temozolomide'}]","Study of Temozolomide Plus Radiation Therapy With Nivolumab or Placebo, for Newly Diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer).",843
30,NCT01269424,Phase I,Suspended,"[{'id': 2972, 'therapyName': 'O6-benzylguanine + Temozolomide'}]",O6-Benzylguanine and Temozolomide With MGMTP140K Genetically Modified Blood Stem Cells in Untreated Glioblastoma,843
31,NCT01858168,Phase I,Recruiting,"[{'id': 1438, 'therapyName': 'Olaparib + Temozolomide'}]",Phase I Study of Olaprib and Temozolomide for Ewings Sarcoma,843
32,NCT03139331,Phase I,Recruiting,"[{'id': 5635, 'therapyName': 'Pazopanib + Irinotecan + Temozolomide'}]",PAZIT Study for Children and Young Adults With Relapsed or Refractory Sarcoma,843
33,NCT01465659,Phase Ib/II,Recruiting,"[{'id': 2040, 'therapyName': 'Pazopanib + Temozolomide'}]",Temozolomide and Pazopanib Hydrochloride in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors That Cannot Be Removed By Surgery,843
34,NCT03197506,Phase II,Recruiting,"[{'id': 5221, 'therapyName': 'Pembrolizumab + Temozolomide'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab and Standard Therapy in Treating Patients With Glioblastoma,843
35,NCT03018288,Phase II,Recruiting,"[{'id': 5221, 'therapyName': 'Pembrolizumab + Temozolomide'}, {'id': 5220, 'therapyName': 'Pembrolizumab + Temozolomide + Vitespen'}]",Radiation Therapy Plus Temozolomide and Pembrolizumab With and Without HSPPC-96 in Newly Diagnosed Glioblastoma (GBM),843
36,NCT02871843,Phase I,Recruiting,"[{'id': 4596, 'therapyName': 'RRx-001 + Temozolomide'}]",Phase 1 Two Part Dose Escalation Trial of RRx-001 + Radiation + Temozolomide and RRx-001 + Temozolomide Post-RT In Newly Diagnosed Glioblastoma and Anaplastic Gliomas (G-FORCE-1),843
37,NCT02928575,Phase II,Recruiting,"[{'id': 4905, 'therapyName': 'Sunitinib + Temozolomide'}]","Combining Sunitinib, Temozolomide and Radiation to Treat Patients Diagnosed With Glioblastoma",843
38,NCT02116777,Phase Ib/II,Recruiting,"[{'id': 1377, 'therapyName': 'Talazoparib + Temozolomide'}]",BMN-673 and Temozolomide in Treating Younger Patients With Refractory or Recurrent Malignancies,843
39,NCT02049593,Phase I,"Active, not recruiting","[{'id': 1377, 'therapyName': 'Talazoparib + Temozolomide'}, {'id': 1378, 'therapyName': 'Irinotecan + Talazoparib'}]",PARP Inhibitor BMN-673 and Temozolomide or Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic Solid Tumors,843
40,NCT02530502,Phase Ib/II,"Active, not recruiting","[{'id': 1141, 'therapyName': 'Temozolomide'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Radiation Therapy With Temozolomide and Pembrolizumab in Treating Patients With Newly Diagnosed Glioblastoma,843
41,NCT01514201,Phase Ib/II,"Active, not recruiting","[{'id': 1141, 'therapyName': 'Temozolomide'}, {'id': 954, 'therapyName': 'Veliparib'}]","Veliparib, Radiation Therapy, and Temozolomide in Treating Younger Patients With Newly Diagnosed Diffuse Pontine Gliomas",843
42,NCT02311920,Phase I,"Active, not recruiting","[{'id': 1141, 'therapyName': 'Temozolomide'}, {'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 779, 'therapyName': 'Ipilimumab'}]",Temozolomide in Combination With Ipilimumab and/or Nivolumab in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma,843
43,NCT02179086,Phase II,Recruiting,"[{'id': 1141, 'therapyName': 'Temozolomide'}]",Dose-Escalated Photon IMRT or Proton Beam Radiation Therapy Versus Standard-Dose Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma,843
44,NCT01800695,Phase I,Completed,"[{'id': 1141, 'therapyName': 'Temozolomide'}, {'id': 976, 'therapyName': 'ABT-414'}]",Evaluating the Safety and Pharmacokinetics of ABT-414 for Subjects With Glioblastoma Multiforme,843
45,NCT01835145,Phase II,"Active, not recruiting","[{'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 1141, 'therapyName': 'Temozolomide'}, {'id': 998, 'therapyName': 'cabozantinib'}]",Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Melanoma of the Eye,843
46,NCT01430351,Phase I,"Active, not recruiting","[{'id': 1141, 'therapyName': 'Temozolomide'}, {'id': 1784, 'therapyName': 'Memantine'}, {'id': 1031, 'therapyName': 'Metformin'}, {'id': 1785, 'therapyName': 'Mefloquine'}]","Phase I Factorial Trial of Temozolomide, Memantine, Mefloquine, and Metformin for Post-Radiation Therapy (RT) Glioblastoma Multiforme (GBM)",843
47,NCT02052648,Phase Ib/II,Recruiting,"[{'id': 1141, 'therapyName': 'Temozolomide'}, {'id': 2976, 'therapyName': 'indoximod'}]",Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors,843
48,NCT02137759,Phase II,Recruiting,"[{'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1141, 'therapyName': 'Temozolomide'}]",MRSI to Predict Response to RT/TMZ and Vorinostat in GBM,843
49,NCT01638546,Phase II,Completed,"[{'id': 1141, 'therapyName': 'Temozolomide'}, {'id': 954, 'therapyName': 'Veliparib'}]",Temozolomide With or Without Veliparib in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer,843
50,NCT02366728,,Recruiting,"[{'id': 5985, 'therapyName': 'Basiliximab'}, {'id': 1141, 'therapyName': 'Temozolomide'}]",DC Migration Study for Newly-Diagnosed GBM,843
51,NCT02392793,Phase I,Recruiting,"[{'id': 1378, 'therapyName': 'Irinotecan + Talazoparib'}, {'id': 1141, 'therapyName': 'Temozolomide'}]",Talazoparib Plus Irinotecan With or Without Temozolomide in Children With Refractory or Recurrent Solid Malignancies,843
52,NCT02510950,Phase I,Recruiting,"[{'id': 1873, 'therapyName': 'Sargramostim'}, {'id': 2595, 'therapyName': 'poly ICLC  '}, {'id': 1141, 'therapyName': 'Temozolomide'}]",Neoepitope-based Personalized Vaccine Approach in Patients With Newly Diagnosed Glioblastoma,843
53,NCT02023905,Phase II,Recruiting,"[{'id': 1141, 'therapyName': 'Temozolomide'}, {'id': 735, 'therapyName': 'Everolimus'}]",Everolimus With and Without Temozolomide in Adult Low Grade Glioma,843
54,NCT02446704,Phase Ib/II,"Active, not recruiting","[{'id': 837, 'therapyName': 'Olaparib'}, {'id': 1141, 'therapyName': 'Temozolomide'}]",Study of Olaparib and Temozolomide in Patients With Recurrent Small Cell Lung Cancer Following Failure of Prior Chemotherapy,843
55,NCT01409174,Phase Ib/II,Terminated,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 1167, 'therapyName': 'Aldesleukin'}, {'id': 1141, 'therapyName': 'Temozolomide'}, {'id': 1299, 'therapyName': 'Interferon alfa-2b '}]",IPI Biochemotherapy for Chemonaive Patients With Metastatic Melanoma,843
56,NCT02152982,Phase II,Suspended,"[{'id': 954, 'therapyName': 'Veliparib'}, {'id': 1141, 'therapyName': 'Temozolomide'}]",Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme,843
57,NCT02573324,Phase II,Recruiting,"[{'id': 976, 'therapyName': 'ABT-414'}, {'id': 1141, 'therapyName': 'Temozolomide'}]",A Study of ABT-414 in Subjects With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification,843
58,NCT01790503,Phase Ib/II,"Active, not recruiting","[{'id': 874, 'therapyName': 'PLX3397'}, {'id': 1141, 'therapyName': 'Temozolomide'}]",A Phase 1b/2 Study of PLX3397 + Radiation Therapy + Temozolomide in Patients With Newly Diagnosed Glioblastoma,843
59,NCT02617589,Phase III,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 1141, 'therapyName': 'Temozolomide'}]","Study of Nivolumab Versus Temozolomide, Given With Radiation Therapy, for Newly-diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer) (CheckMate 498)",843
60,NCT00492687,Phase II,Unknown status,"[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1141, 'therapyName': 'Temozolomide'}, {'id': 1456, 'therapyName': 'Tamoxifen'}]","Radiation Therapy, Temozolomide, Tamoxifen, and Carboplatin in Treating Patients With Malignant Gliomas",843
61,NCT02414165,Phase II,"Active, not recruiting","[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 3211, 'therapyName': 'Toca 511 + Toca FC'}, {'id': 1141, 'therapyName': 'Temozolomide'}]",P2/3 Randomized Study of Toca 511 & Toca FC Versus SOC in Subjects Undergoing Surgery for Recurrent GBM/AA (Toca5),843
62,NCT02502708,Phase I,Recruiting,"[{'id': 2976, 'therapyName': 'indoximod'}, {'id': 1141, 'therapyName': 'Temozolomide'}]","Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Primary Malignant Brain Tumors",843
63,NCT02315534,Phase Ib/II,Recruiting,"[{'id': 2057, 'therapyName': 'BBI608'}, {'id': 1141, 'therapyName': 'Temozolomide'}]",A Study of BBI608 in Combination With Temozolomide in Adult Patients With Recurrent or Progressed Glioblastoma,843
64,NCT02340156,Phase II,Recruiting,"[{'id': 2518, 'therapyName': 'SGT-53'}, {'id': 1141, 'therapyName': 'Temozolomide'}]",Phase II Study of Combined Temozolomide and SGT-53 for Treatment of Recurrent Glioblastoma,843
65,NCT01977677,Phase Ib/II,"Active, not recruiting","[{'id': 1141, 'therapyName': 'Temozolomide'}, {'id': 1756, 'therapyName': 'Plerixafor'}]",Plerixafor After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed High Grade Glioma,843
66,NCT01390948,Phase II,"Active, not recruiting","[{'id': 1141, 'therapyName': 'Temozolomide'}, {'id': 667, 'therapyName': 'Bevacizumab'}]",A Study of Avastin (Bevacizumab) in Combination With Temolozomide (TMZ) and Radiotherapy in Paediatric and Adolescent Patients With High-Grade Glioma,843
67,NCT02343406,Phase II,Recruiting,"[{'id': 2075, 'therapyName': 'Lomustine'}, {'id': 976, 'therapyName': 'ABT-414'}, {'id': 1141, 'therapyName': 'Temozolomide'}]",ABT-414 Alone or ABT-414 Plus Temozolomide vs. Lomustine or Temozolomide for Recurrent Glioblastoma,843
68,NCT02010606,Phase I,"Active, not recruiting","[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1141, 'therapyName': 'Temozolomide'}]",Phase I Study of a Dendritic Cell Vaccine for Patients With Either Newly Diagnosed or Recurrent Glioblastoma,843
69,NCT02015728,Phase I,"Active, not recruiting","[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1804, 'therapyName': 'Temozolomide + Etoposide'}, {'id': 920, 'therapyName': 'Sorafenib'}]",Selecting Patient-Specific Biologically Targeted Therapy for Pediatric Patients With Refractory Or Recurrent Brain Tumors,843
70,NCT02203526,Phase I,Suspended,"[{'id': 1607, 'therapyName': 'Temozolomide + Etoposide + Doxil + Dexamethasone + Ibrutinib'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 897, 'therapyName': 'Rituximab'}]","Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Dose-Adjusted-Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (DA-TEDDI-R) in Primary CNS Lymphoma",843
71,NCT01217437,Phase II,"Active, not recruiting","[{'id': 1462, 'therapyName': 'Temozolomide + Irinotecan'}, {'id': 1463, 'therapyName': 'Temozolomide + Irinotecan + Bevacizumab'}]",Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors,843
72,NCT01767194,Phase II,Suspended,"[{'id': 2286, 'therapyName': 'Dinutuximab  '}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1462, 'therapyName': 'Temozolomide + Irinotecan'}]",Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Monoclonal Antibody Ch14.18 in Treating Younger Patients With Refractory or Relapsed Neuroblastoma,843
73,NCT01189643,Phase I,"Active, not recruiting","[{'id': 1463, 'therapyName': 'Temozolomide + Irinotecan + Bevacizumab'}]","Irinotecan, Temozolomide and Bevacizumab in Combination With Existing High Dose Alkylator Based Chemotherapy for Treatment of Newly Diagnosed Patients With Desmoplastic Small Round Cell Tumor",843
74,NCT00876993,Phase I,Completed,"[{'id': 1463, 'therapyName': 'Temozolomide + Irinotecan + Bevacizumab'}]",Study of Irinotecan and Bevacizumab With Temozolomide in Refractory/Relapsed Central Nervous System (CNS) Tumors,843
75,NCT02942264,Phase Ib/II,Recruiting,"[{'id': 5836, 'therapyName': 'TG02'}, {'id': 5851, 'therapyName': 'Temozolomide + TG02'}]",TG02 Plus Dose-Dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of TG02 Plus Temozolomide Versus Temozolomide Alone in Adults With Recurrent Anaplastic Astrocytoma and Glioblastoma,843
76,NCT03190967,Phase Ib/II,Recruiting,"[{'id': 1402, 'therapyName': 'trastuzumab emtansine'}, {'id': 5932, 'therapyName': 'Temozolomide + Trastuzumab emtansine'}]",T-DM1 Alone Versus T-DM1 and Metronomic Temozolomide in Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases Following Stereotactic Radiosurgery,843
77,NCT01827384,Phase II,Recruiting,"[{'id': 1194, 'therapyName': 'MK-1775 + Carboplatin '}, {'id': 1193, 'therapyName': 'Veliparib + Temozolomide'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 2, 'therapyName': 'Trametinib'}]",Molecular Profiling-Based Targeted Therapy in Treating Patients With Advanced Solid Tumors,843
78,NCT01506609,Phase II,"Active, not recruiting","[{'id': 1193, 'therapyName': 'Veliparib + Temozolomide'}, {'id': 1544, 'therapyName': 'Carboplatin + Etoposide + Veliparib'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]",The Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide or In Combination With Carboplatin and Paclitaxel Versus Placebo in Subjects With BRCA1 and BRCA2 Mutation and Metastatic Breast Cancer,843
79,NCT01946529,Phase II,"Active, not recruiting","[{'id': 1433, 'therapyName': 'Vincristine + Doxorubicin + Cyclophosphamide + Ifosfamide + Etoposide'}, {'id': 1434, 'therapyName': 'Vincristine + Doxorubicin + Cyclophosphamide + Ifosfamide + Etoposide + others'}]",Therapeutic Trial for Patients With Ewing Sarcoma Family of Tumor and Desmoplastic Small Round Cell Tumors,843
80,NCT01528046,Phase I,Recruiting,"[{'id': 1031, 'therapyName': 'Metformin'}, {'id': 1826, 'therapyName': 'Vincristine + Irinotecan + Temozolomide '}]",Metformin in Children With Relapsed or Refractory Solid Tumors,843
0,NCT00761644,Phase I,"Active, not recruiting","[{'id': 1121, 'therapyName': 'Bevacizumab + Temsirolimus + Doxil'}]","Doxil, Bevacizumab and Temsirolimus Trial",4727
1,NCT02389309,Phase I,Recruiting,"[{'id': 2697, 'therapyName': 'Cyclophosphamide + Dasatinib + Temsirolimus'}]","A Trial of Dasatinib (PDGFR and SRC Inhibitor), Temsirolimus and Cyclophosphamide in Patients With Advanced Solid Tumors",4727
2,NCT00909831,Phase I,"Active, not recruiting","[{'id': 2302, 'therapyName': 'Hydroxychloroquine + Temsirolimus '}]",Hydroxychloroquine and Temsirolimus in Treating Patients With Metastatic Solid Tumors That Have Not Responded to Treatment,4727
3,NCT00980460,Phase III,Recruiting,"[{'id': 2298, 'therapyName': 'Irinotecan + Temsirolimus + Vincristine'}, {'id': 2297, 'therapyName': 'Cisplatin + Fluorouracil + Vincristine'}, {'id': 1009, 'therapyName': 'Doxorubicin'}]",Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer,4727
4,NCT01375829,Phase I,"Active, not recruiting","[{'id': 1263, 'therapyName': 'ixabepilone + temsirolimus'}]",Ixabepilone and Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery,4727
5,NCT02238496,Phase II,"Active, not recruiting","[{'id': 2194, 'therapyName': 'Perifosine + Temsirolimus'}]",Perifosine and Torisel (Temsirolimus) for Recurrent/Progressive Malignant Gliomas,4727
6,NCT01687673,Phase II,"Active, not recruiting","[{'id': 2388, 'therapyName': 'Sorafenib + Temsirolimus'}]",Phase II Combination of Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma,4727
7,NCT01087554,Phase I,"Active, not recruiting","[{'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 1077, 'therapyName': 'Vorinostat'}]",Sirolimus or Everolimus or Temsirolimus and Vorinostat in Advanced Cancer,4727
8,NCT01396408,Phase II,"Active, not recruiting","[{'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 930, 'therapyName': 'Sunitinib'}]",A Phase II Study of Sunitinib or Temsirolimus in Patients With Advanced Rare Tumours,4727
9,NCT02423954,Phase Ib/II,"Active, not recruiting","[{'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 1074, 'therapyName': 'Irinotecan'}]",Study of Nivolumab Plus Chemotherapy in Patients With Advanced Cancer (NivoPlus),4727
10,NCT02420613,Phase I,Recruiting,"[{'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 936, 'therapyName': 'Temsirolimus'}]",Study of Suberoylanilide Hydroxamic Acid (SAHA) With Temsirolimus in Children With Diffuse Intrinsic Pontine Glioma (DIPG),4727
11,NCT02446431,Phase I,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1076, 'therapyName': 'Valproic acid'}]",Metronomic Therapy for Pediatric Patients With Solid Tumors at High Risk of Recurrence,4727
12,NCT01517243,Phase II,Unknown status,"[{'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 930, 'therapyName': 'Sunitinib'}]",Phase II Study of Alternating Sunitinib and Temsirolimus,4727
13,NCT02693535,Phase II,Recruiting,"[{'id': 1657, 'therapyName': 'Vemurafenib + Cobimetinib'}, {'id': 890, 'therapyName': 'Regorafenib'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 690, 'therapyName': 'Bosutinib'}, {'id': 850, 'therapyName': 'Palbociclib'}, {'id': 694, 'therapyName': 'Cetuximab'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 837, 'therapyName': 'Olaparib'}, {'id': 4, 'therapyName': 'Erlotinib'}]",TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer,4727
14,NCT02788201,Phase II,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1133, 'therapyName': 'Mitomycin C'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1013, 'therapyName': 'epirubicin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1137, 'therapyName': 'Bleomycin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 781, 'therapyName': 'Ixabepilone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 2950, 'therapyName': 'Estramustine'}, {'id': 1941, 'therapyName': 'Floxuridine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 1811, 'therapyName': 'Carmustine'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 953, 'therapyName': 'Vandetanib'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 4419, 'therapyName': 'Toremifine'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 2601, 'therapyName': 'Dactinomycin'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 3035, 'therapyName': 'Chlorambucil'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 342, 'therapyName': 'Vemurafenib'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 2635, 'therapyName': 'Vinblastine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 4305, 'therapyName': 'Teniposide'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 4304, 'therapyName': 'Streptozocin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1231, 'therapyName': 'Bendamustine'}, {'id': 4303, 'therapyName': 'Mechlorethamine'}, {'id': 4302, 'therapyName': 'Mitotane'}]",Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma,4727
15,NCT01392183,Phase II,"Active, not recruiting","[{'id': 1275, 'therapyName': 'Diphenhydramine'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 848, 'therapyName': 'Pazopanib'}]",Pazopanib Versus Temsirolimus in Poor-Risk Clear-Cell Renal Cell Carcinoma (RCC),4727
16,NCT02551718,Phase I,Recruiting,"[{'id': 690, 'therapyName': 'Bosutinib'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 3160, 'therapyName': 'Nelarabine'}, {'id': 3159, 'therapyName': 'Bexarotene'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 998, 'therapyName': 'cabozantinib'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 877, 'therapyName': 'Ponatinib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 623, 'therapyName': 'Afatinib'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 890, 'therapyName': 'Regorafenib'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 2, 'therapyName': 'Trametinib'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 3, 'therapyName': 'Dabrafenib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 789, 'therapyName': 'Ceritinib'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1571, 'therapyName': 'Cabazitaxel'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1327, 'therapyName': 'Pralatrexate'}]",High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia,4727
17,NCT02560012,Phase II,Terminated,"[{'id': 735, 'therapyName': 'Everolimus'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 848, 'therapyName': 'Pazopanib'}]",Personalized Targeted Inhibitors Treatment in Renal Cell Cancer,4727
18,NCT01180049,FDA approved,"Active, not recruiting","[{'id': 936, 'therapyName': 'Temsirolimus'}]",Comparison Of 2 Doses Of Temsirolimus (Torisel) In Patients With Mantle Cell Lymphoma,4727
19,NCT01614197,Phase I,Recruiting,"[{'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1639, 'therapyName': 'Methotrexate'}]",A Trial of Temsirolimus With Etoposide and Cyclophosphamide in Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkins Lymphoma,4727
20,NCT02567435,Phase III,Suspended,"[{'id': 1435, 'therapyName': 'Vincristine + Dactinomycin + Cyclophosphamide'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1074, 'therapyName': 'Irinotecan'}]",Combination Chemotherapy and Irinotecan Hydrochloride or Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma,4727
21,NCT01767194,Phase II,Suspended,"[{'id': 2286, 'therapyName': 'Dinutuximab  '}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1462, 'therapyName': 'Temozolomide + Irinotecan'}]",Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Monoclonal Antibody Ch14.18 in Treating Younger Patients With Refractory or Relapsed Neuroblastoma,4727
22,NCT00838955,Phase II,Unknown status,"[{'id': 936, 'therapyName': 'Temsirolimus'}]",Temsirolimus for Relapsed/Refractory Hodgkin's Lymphoma,4727
23,NCT01567930,Phase II,Unknown status,"[{'id': 936, 'therapyName': 'Temsirolimus'}]",Temsirolimus as Second-line Therapy in HCC,4727
24,NCT01187199,Phase I,"Active, not recruiting","[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 936, 'therapyName': 'Temsirolimus'}]","Phase I Trial of Bevacizumab and Temsirolimus in Combination With 1) Carboplatin, 2) Paclitaxel, 3) Sorafenib for the Treatment of Advanced Cancer",4727
25,NCT02456857,Phase II,Recruiting,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 936, 'therapyName': 'Temsirolimus'}]","Liposomal Doxorubicin, Bevacizumab and Temsirolimus (DAT) in Triple-Negative Breast Cancer (TNBC) Insensitive to Standard Neoadjuvant Chemotherapy",4727
26,NCT01552434,Phase I,Recruiting,"[{'id': 1376, 'therapyName': 'Temsirolimus + Bevacizumab + Valproic Acid + Cetuximab'}]","Bevacizumab, Temsirolimus, Valproic Acid, Cetuximab",4727
27,NCT01076543,Phase Ib/II,"Active, not recruiting","[{'id': 2280, 'therapyName': 'Temsirolimus + Lenalidomide'}]",Lenalidomide and Temsirolimus in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma,4727
28,NCT01529593,Phase I,Recruiting,"[{'id': 1325, 'therapyName': 'Temsirolimus + Metformin'}]",Temsirolimus in Combination With Metformin in Patients With Advanced Cancers,4727
29,NCT01111825,Phase Ib/II,Completed,"[{'id': 1527, 'therapyName': 'Temsirolimus + Neratinib'}]",Temsirolimus Plus Neratinib for Patients With Metastatic HER2-Amplified or Triple Negative Breast Cancer,4727
30,NCT02343718,Phase I,"Active, not recruiting","[{'id': 2492, 'therapyName': 'Temsirolimus + Vinblastine'}]",Vinblastine and Temsirolimus in Pediatric Patients With Recurrent or Refractory Lymphoma or Solid Tumours Including CNS Tumours,4727
31,NCT01174199,Phase I,Terminated,"[{'id': 2263, 'therapyName': 'Temsirolimus + vorinostat'}]",Temsirolimus and Vorinostat in Treating Patients With Metastatic Prostate Cancer,4727
32,NCT01625156,Phase I,Completed,"[{'id': 1200, 'therapyName': 'Tivantinib + Temsirolimus'}]",Tivantinib and Temsirolimus in Treating Patients With Solid Tumors That is Metastatic or Cannot be Removed By Surgery,4727
33,NCT01596140,Phase I,"Active, not recruiting","[{'id': 1175, 'therapyName': 'Vemurafenib + Temsirolimus'}, {'id': 1174, 'therapyName': 'Vemurafenib + Everolimus'}]",Vemurafenib in Combination With Everolimus or Temsirolimus With Advanced Cancer,4727
34,NCT01946529,Phase II,"Active, not recruiting","[{'id': 1433, 'therapyName': 'Vincristine + Doxorubicin + Cyclophosphamide + Ifosfamide + Etoposide'}, {'id': 1434, 'therapyName': 'Vincristine + Doxorubicin + Cyclophosphamide + Ifosfamide + Etoposide + others'}]",Therapeutic Trial for Patients With Ewing Sarcoma Family of Tumor and Desmoplastic Small Round Cell Tumors,4727
0,NCT03292172,Phase I,Not yet recruiting,"[{'id': 6286, 'therapyName': 'Atezolizumab + TEN-010'}]","A Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RO6870810 and Atezolizumab (PD-L1 Antibody) in Participants With Advanced Ovarian Cancer or Triple Negative Breast Cancer",7076
1,NCT03068351,Phase I,Recruiting,"[{'id': 937, 'therapyName': 'TEN-010'}, {'id': 5957, 'therapyName': 'Daratumumab + TEN-010'}]",Study of Bromodomain and Extra-Terminal Protein (BET) Inhibitor RO6870810 as Mono- and Combination Therapy in Advanced Multiple Myeloma,7076
2,NCT03255096,Phase I,Recruiting,"[{'id': 6179, 'therapyName': 'Rituximab + TEN-010 + Venetoclax'}]","A Study to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of the Combination of RO6870810 and Venetoclax, With or Without Rituximab, in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)",7076
3,NCT01987362,Phase I,"Active, not recruiting","[{'id': 937, 'therapyName': 'TEN-010'}]","A Two Part, Multicenter, Open-label Study of TEN-010 Given Subcutaneously",7076
4,NCT02308761,Phase I,Recruiting,"[{'id': 937, 'therapyName': 'TEN-010'}]",A Dose Escalation and Cohort Expansion Study of TEN-010 in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome,7076
0,NCT02664181,Phase II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 5910, 'therapyName': 'Decitabine + Nivolumab + Tetrahydrouridine'}]",Pharmacologically Rational EpigenetiC Immunotherapy for SEcond Line Therapy in Patients With Non-Small Cell Lung Cancer (PRECISE),8142
1,NCT02839694,Phase I,Withdrawn,"[{'id': 3567, 'therapyName': 'Decitabine + Tetrahydrouridine'}, {'id': 4592, 'therapyName': 'Decitabine + Tetrahydrouridine + Celecoxib'}]",Adjuvant Oral Decitabine and Tetrahydrouridine With or Without Celecoxib in People Undergoing Pulmonary Metastasectomy,8142
2,NCT02846935,Phase 0,Recruiting,"[{'id': 3567, 'therapyName': 'Decitabine + Tetrahydrouridine'}]",p53/p16-Independent Epigenetic Therapy With Oral Decitabine/Tetrahydrouridine for Refractory/Relapsed Lymphoid Malignancies,8142
3,NCT02847000,Phase 0,Recruiting,"[{'id': 3567, 'therapyName': 'Decitabine + Tetrahydrouridine'}]",p53/p16-Independent Epigenetic Therapy With Oral Decitabine/Tetrahydrouridine for Pancreatic Cancer,8142
4,NCT01534598,Phase I,Recruiting,"[{'id': 3789, 'therapyName': 'FdCyd + THU'}]",FdCyd and THU for Advanced Solid Tumors,8142
5,NCT00978250,Phase II,Recruiting,"[{'id': 3789, 'therapyName': 'FdCyd + THU'}]",A Multi-Histology Phase II Study of 5-Fluoro-2-Deoxycytidine With Tetrahydrouridine (FdCyd + THU),8142
0,NCT01837329,Phase I,Recruiting,"[{'id': 3147, 'therapyName': 'Tetrathiomolybdate'}]",Phase I Study of Tetrathiomolybdate in Combination With Carboplatin/Pemetrexed in Metastatic Non-small Cell Lung Cancer,7954
0,NCT03143985,Phase I,Recruiting,"[{'id': 5875, 'therapyName': 'Pomalidomide + TEW 7197'}]",TEW-7197 in Combination w/ Pomalidomide in Relapsed or Relapsed and Refractory Multiple Myeloma,7908
1,NCT02160106,Phase I,Recruiting,"[{'id': 3011, 'therapyName': 'TEW 7197'}]",First in Human Dose Escalation Study of TEW-7197 in Subjects With Advanced Stage Solid Tumors,7908
2,NCT03074006,Phase Ib/II,Not yet recruiting,"[{'id': 3011, 'therapyName': 'TEW 7197'}]",Dose Escalation and Proof-of-Concept Studies of TEW-7197 Monotherapy in Patients With Myelodysplastic Syndrome (MDS),7908
0,NCT02104427,Phase II,Completed,"[{'id': 2853, 'therapyName': 'TG-0054'}, {'id': 1632, 'therapyName': 'Filgrastim'}]","PD and Safety of TG-0054 Combined With G-CSF in Multiple Myeloma, Non-Hodgkin Lymphoma and Hodgkin Disease Patients",7790
0,NCT02942264,Phase Ib/II,Recruiting,"[{'id': 5836, 'therapyName': 'TG02'}, {'id': 5851, 'therapyName': 'Temozolomide + TG02'}]",TG02 Plus Dose-Dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of TG02 Plus Temozolomide Versus Temozolomide Alone in Adults With Recurrent Anaplastic Astrocytoma and Glioblastoma,8828
0,NCT02867618,Phase Ib/II,Recruiting,"[{'id': 4598, 'therapyName': 'Carfilzomib + TGR-1202'}]",Carfilzomib and TGR-1202 in Treatment of R/R Lymphoma,7388
1,NCT02100852,Phase I,"Active, not recruiting","[{'id': 2342, 'therapyName': 'Chlorambucil + Obinutuzumab + TGR-1202'}]","TGR-1202, a PI3K Delta Inhibitor, in Combination With Obinutuzumab and Chlorambucil in Patients With Chronic Lymphocytic Leukemia (CLL)",7388
2,NCT02874404,Phase II,Recruiting,"[{'id': 2044, 'therapyName': 'Ibrutinib + TGR-1202'}]",TGR-1202 and Ibrutinib in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma,7388
3,NCT02268851,Phase I,Recruiting,"[{'id': 2044, 'therapyName': 'Ibrutinib + TGR-1202'}]",A Phase I/Ib Safety and Efficacy Study of the PI3K-delta Inhibitor TGR-1202 and Ibrutinib in Patients With CLL or MCL,7388
4,NCT03269669,Phase II,Recruiting,"[{'id': 6257, 'therapyName': 'Obinutuzumab + CHOP'}, {'id': 6302, 'therapyName': 'Lenalidomide + Obinutuzumab\t'}, {'id': 6301, 'therapyName': 'Obinutuzumab + TGR-1202'}, {'id': 2188, 'therapyName': 'Prednisone'}]","Obinutuzumab With or Without PI3K-delta Inhibitor TGR-1202, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma",7388
5,NCT03283137,Phase I,Not yet recruiting,"[{'id': 6237, 'therapyName': 'Pembrolizumab + TGR-1202'}]",Combination of Pembrolizumab With TGR-1202 in Patients With Relapsed/Refractory CLL and B-cell NHL,7388
6,NCT02535286,Phase Ib/II,Recruiting,"[{'id': 3475, 'therapyName': 'Pembrolizumab + TGR-1202 + Ublituximab'}]",Study of Pembrolizumab in Combination With Ublituximab and TGR-1202 in Patients With Relapsed-refractory CLL,7388
7,NCT02793583,Phase II,Recruiting,"[{'id': 2022, 'therapyName': 'TGR-1202'}, {'id': 2319, 'therapyName': 'TGR-1202 + Ublituximab'}]",Study to Assess the Efficacy and Safety of Ublituximab + TGR-1202 and TGR-1202 Alone in Patients With Previously Treated Diffuse Large B-Cell Lymphoma (UNITY-DLBCL),7388
8,NCT01767766,Phase I,"Active, not recruiting","[{'id': 2022, 'therapyName': 'TGR-1202'}]",Evaluate the Safety and Efficacy of TGR 1202 in Patients With Relapsed or Refractory Hematologic Malignancies,7388
9,NCT02742090,Phase II,Recruiting,"[{'id': 2022, 'therapyName': 'TGR-1202'}]",Evaluate the Efficacy and Safety of TGR-1202 in Patients With Chronic Lymphocytic Leukemia Who Are Intolerant to Prior Therapy,7388
10,NCT02164006,Phase I,"Active, not recruiting","[{'id': 2022, 'therapyName': 'TGR-1202'}]","Novel PI3K Delta Inhibitor TGR-1202, in Combination With Brentuximab Vedotin for Hodgkin's Lymphoma Patients",7388
11,NCT02612311,Phase III,Recruiting,"[{'id': 2287, 'therapyName': 'Ublituximab'}, {'id': 1648, 'therapyName': 'Obinutuzumab + Chlorambucil'}, {'id': 2022, 'therapyName': 'TGR-1202'}]",Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemia,7388
12,NCT03178201,Phase II,Recruiting,"[{'id': 2022, 'therapyName': 'TGR-1202'}]",TGR1202 in Relapsed and Refractory Follicular Lymphoma,7388
13,NCT02574663,Phase I,"Active, not recruiting","[{'id': 1779, 'therapyName': 'Nab-paclitaxel + Gemcitabine'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 2022, 'therapyName': 'TGR-1202'}]",TGR-1202 Alone and in Combination With Either Nab-paclitaxel + Gemcitabine or With FOLFOX in Patients With Select Relapsed or Refractory Solid Tumors,7388
14,NCT02006485,Phase I,Recruiting,"[{'id': 2319, 'therapyName': 'TGR-1202 + Ublituximab'}, {'id': 768, 'therapyName': 'Ibrutinib'}]",Ublituximab in Combination With TGR-1202 in Patients With B-cell Malignancies,7388
15,NCT02656303,Phase II,Recruiting,"[{'id': 2319, 'therapyName': 'TGR-1202 + Ublituximab'}]",An Open-Label Study to Evaluate the Safety and Efficacy of Ublituximab in Combination With TGR-1202 for Patients Previously Enrolled in Protocol UTX-TGR-304,7388
0,NCT02449681,Phase II,Terminated,"[{'id': 2910, 'therapyName': 'TH-4000'}]",Study for Treatment of Patients With Recurrent or Metastatic SCCHN or SCCS,7833
1,NCT02454842,Phase II,Terminated,"[{'id': 2910, 'therapyName': 'TH-4000'}]","Study for Treatment of Patients With EGFR Mutant, T790M-negative NSCLC",7833
0,NCT00826085,Phase Ib/II,Completed,"[{'id': 1054, 'therapyName': 'ThermoDox'}]",Phase 1/2 Study of ThermoDox With Approved Hyperthermia in Treatment of Breast Cancer Recurrence at the Chest Wall,7172
0,NCT01664000,Phase I,Completed,"[{'id': 2999, 'therapyName': 'thioureidobutyronitrile'}]","A Safety, Pharmacokinetic and Pharmacodynamic Study of Kevetrin in Patients With Advanced Solid Tumors",7897
1,NCT03042702,Phase II,Recruiting,"[{'id': 2999, 'therapyName': 'thioureidobutyronitrile'}]",A Phase 2 Study of Kevetrin in Subjects With Ovarian Cancer,7897
0,NCT00006199,Phase I,Unknown status,"[{'id': 938, 'therapyName': 'Tipifarnib'}, {'id': 942, 'therapyName': 'Topotecan'}]","Study of the Farnesyl Transferase Inhibitor, R115777, in Combination With Topotecan (NYU 99-32)",7032
1,NCT02807272,Phase II,Recruiting,"[{'id': 938, 'therapyName': 'Tipifarnib'}]",Tipifarnib in Subjects With Chronic Myelomonocytic Leukemia (CMML),7032
2,NCT02383927,Phase II,Recruiting,"[{'id': 938, 'therapyName': 'Tipifarnib'}]",Phase II Study of Tipifarnib in Advanced Cancers With HRAS Mutations,7032
3,NCT02464228,Phase II,Recruiting,"[{'id': 938, 'therapyName': 'Tipifarnib'}]",Study of Tipifarnib in Subjects With Relapsed or Refractory Peripheral T-Cell Lymphoma,7032
4,NCT02779777,Phase II,Recruiting,"[{'id': 938, 'therapyName': 'Tipifarnib'}]","Tipifarnib in Subjects With Transfusion-dependent, Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes",7032
0,NCT02174549,Phase I,Recruiting,"[{'id': 3028, 'therapyName': 'tirapazamine'}]",Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer,7913
1,NCT03145558,Phase II,Not yet recruiting,"[{'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 3028, 'therapyName': 'tirapazamine'}]",TATE Versus TACE in Intermediate Stage HCC (TATE),7913
0,NCT03123939,Phase II,Available,"[{'id': 5981, 'therapyName': 'Tisagenlecleucel'}]",Expanded Treatment Protocol in Acute Lymphoblastic Leukemia,8879
1,NCT02435849,Phase II,Recruiting,"[{'id': 5981, 'therapyName': 'Tisagenlecleucel'}]",Determine Efficacy and Safety of CTL019 in Pediatric Patients With Relapsed and Refractory B-cell ALL (ELIANA),8879
2,NCT02445248,Phase II,Recruiting,"[{'id': 5981, 'therapyName': 'Tisagenlecleucel'}]",Study of Efficacy and Safety of CTL019 in Adult DLBCL Patients (JULIET),8879
3,NCT02228096,Phase II,Recruiting,"[{'id': 5981, 'therapyName': 'Tisagenlecleucel'}]",Study of Efficacy and Safety of CTL019 in Pediatric ALL Patients,8879
0,NCT03245736,Phase II,Recruiting,"[{'id': 6113, 'therapyName': 'Tisotumab Vedotin'}]",Tisotumab Vedotin Continued Treatment in Patients With Solid Tumors.,8918
0,NCT01749384,Phase I,Completed,"[{'id': 1254, 'therapyName': 'Bevacizumab + Tivantinib'}]",Tivantinib and Bevacizumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed By Surgery,6842
1,NCT02150733,Phase I,Completed,"[{'id': 636, 'therapyName': 'Tivantinib'}]",Pharmacokinetics of Tivantinib in Subjects With Advanced Solid Tumors and Hepatic Impairment,6842
2,NCT01468922,Phase I,Completed,"[{'id': 636, 'therapyName': 'Tivantinib'}, {'id': 848, 'therapyName': 'Pazopanib'}]",Pazopanib and ARQ 197 for Advanced Solid Tumors,6842
3,NCT01755767,Phase III,Completed,"[{'id': 636, 'therapyName': 'Tivantinib'}]",Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma Who Have Been Treated With One Prior Therapy,6842
4,NCT01625156,Phase I,Completed,"[{'id': 1200, 'therapyName': 'Tivantinib + Temsirolimus'}]",Tivantinib and Temsirolimus in Treating Patients With Solid Tumors That is Metastatic or Cannot be Removed By Surgery,6842
5,NCT01654965,Phase I,"Active, not recruiting","[{'id': 1477, 'therapyName': 'Tivantinib + Topotecan + Pegfilgrastim'}]",Tivantinib and Topotecan Hydrochloride in Treating Patients With Advanced or Metastatic Solid Tumors,6842
0,NCT01885949,Phase II,"Active, not recruiting","[{'id': 2395, 'therapyName': 'Enzalutamide + Tivozanib'}]",Tivozanib + Enzalutamide in Adv Prostate Cancer,7173
1,NCT01835223,Phase Ib/II,"Active, not recruiting","[{'id': 1055, 'therapyName': 'Tivozanib'}]",Tivozanib in Treating Patients With Liver Cancer That is Metastatic or Cannot Be Removed by Surgery,7173
2,NCT02627963,Phase III,"Active, not recruiting","[{'id': 920, 'therapyName': 'Sorafenib'}, {'id': 1055, 'therapyName': 'Tivozanib'}]",A Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced RCC,7173
3,NCT01972516,Phase II,Terminated,"[{'id': 1055, 'therapyName': 'Tivozanib'}]",Tivozanib As Maintenance Therapy In GYN,7173
4,NCT01853644,Phase II,Recruiting,"[{'id': 1055, 'therapyName': 'Tivozanib'}]","Tivozanib in Recurrent, Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer",7173
0,NCT02657005,Phase I,Recruiting,"[{'id': 4314, 'therapyName': 'TK216'}]",TK216 in Patients With Relapsed or Refractory Ewing Sarcoma,8405
0,NCT01985256,Phase I,"Active, not recruiting","[{'id': 3209, 'therapyName': 'Toca 511'}]",Study of a Retroviral Replicating Vector Given Intravenously to Patients Undergoing Surgery for Recurrent Brain Tumor,7971
1,NCT02414165,Phase II,"Active, not recruiting","[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 3211, 'therapyName': 'Toca 511 + Toca FC'}, {'id': 1141, 'therapyName': 'Temozolomide'}]",P2/3 Randomized Study of Toca 511 & Toca FC Versus SOC in Subjects Undergoing Surgery for Recurrent GBM/AA (Toca5),7971
2,NCT02576665,Phase I,Recruiting,"[{'id': 3211, 'therapyName': 'Toca 511 + Toca FC'}]","A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Subjects With Solid Tumors (Toca6)",7971
3,NCT01156584,Phase I,"Active, not recruiting","[{'id': 3211, 'therapyName': 'Toca 511 + Toca FC'}]",A Study of a Retroviral Replicating Vector Administered to Subjects With Recurrent Malignant Glioma,7971
0,NCT02414165,Phase II,"Active, not recruiting","[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 3211, 'therapyName': 'Toca 511 + Toca FC'}, {'id': 1141, 'therapyName': 'Temozolomide'}]",P2/3 Randomized Study of Toca 511 & Toca FC Versus SOC in Subjects Undergoing Surgery for Recurrent GBM/AA (Toca5),7972
1,NCT02576665,Phase I,Recruiting,"[{'id': 3211, 'therapyName': 'Toca 511 + Toca FC'}]","A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Subjects With Solid Tumors (Toca6)",7972
2,NCT01156584,Phase I,"Active, not recruiting","[{'id': 3211, 'therapyName': 'Toca 511 + Toca FC'}]",A Study of a Retroviral Replicating Vector Administered to Subjects With Recurrent Malignant Glioma,7972
0,NCT03075696,Phase I,Recruiting,"[{'id': 6162, 'therapyName': 'Obinutuzumab + RO7082859 + Tocilizumab'}]","A Dose Escalation Study of RO7082859, Administered After a Fixed, Single Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma",4724
1,NCT03135171,Phase I,Recruiting,"[{'id': 5648, 'therapyName': 'Pertuzumab + Tocilizumab + Trastuzumab'}]",Trastuzumab and Pertuzumab in Combination With Tocilizumab in Subjects With Metastatic HER2 Positive Breast Cancer Resistant to Trastuzumab,4724
2,NCT02906371,Phase I,Recruiting,"[{'id': 5647, 'therapyName': 'Tocilizumab'}]",Study of the Tocilizumab Optimization Timing for CART19 Associated Cytokine Release Syndrome,4724
3,NCT02057770,Phase I,Recruiting,"[{'id': 5724, 'therapyName': 'Busulfan + Fludarabine phosphate + Cyclophosphamide'}, {'id': 5647, 'therapyName': 'Tocilizumab'}]",Allogeneic or Haploidentical Stem Cell Transplant Followed By High-Dose Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia,4724
0,NCT00602667,Phase I,"Active, not recruiting","[{'id': 2449, 'therapyName': 'Methotrexate + Cisplatin + Cyclophosphamide + Vincristine'}, {'id': 2450, 'therapyName': 'Cyclophosphamide + Etoposide + Topotecan'}, {'id': 2451, 'therapyName': 'Erlotinib + Cyclophosphamide + Topotecan'}]","Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma",1018
1,NCT02298348,Phase I,Recruiting,"[{'id': 2360, 'therapyName': 'Cyclophosphamide + Sorafenib + Topotecan'}]",Sorafenib and Cyclophosphamide/Topotecan in Patients With Relapsed and Refractory Neuroblastoma,1018
2,NCT02030964,Phase I,"Active, not recruiting","[{'id': 2590, 'therapyName': 'Cyclophosphamide + Topotecan'}, {'id': 2124, 'therapyName': 'Celecoxib'}]",N2012-01 Phase 1 Study of Difluoromethylornithine (DFMO) and Celecoxib With Cyclophosphamide/Topotecan,1018
3,NCT01175356,Phase I,Completed,"[{'id': 2558, 'therapyName': 'Busulfan + Melphalan'}, {'id': 2590, 'therapyName': 'Cyclophosphamide + Topotecan'}, {'id': 1425, 'therapyName': '131I-MIBG'}, {'id': 2353, 'therapyName': 'Cyclophosphamide + Doxorubicin + Vincristine '}, {'id': 2585, 'therapyName': 'Cisplatin + Etoposide'}]","Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin",1018
4,NCT01606878,Phase I,Recruiting,"[{'id': 2952, 'therapyName': 'Dexamethasone + Doxorubicin + Vincristine'}, {'id': 2590, 'therapyName': 'Cyclophosphamide + Topotecan'}, {'id': 706, 'therapyName': 'Crizotinib'}]",Crizotinib and Combination Chemotherapy in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma,1018
5,NCT01857934,Phase II,Recruiting,"[{'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1873, 'therapyName': 'Sargramostim'}, {'id': 1167, 'therapyName': 'Aldesleukin'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 2627, 'therapyName': 'Levetiracetam'}, {'id': 2585, 'therapyName': 'Cisplatin + Etoposide'}, {'id': 2458, 'therapyName': 'Hu14.18K322A'}, {'id': 2558, 'therapyName': 'Busulfan + Melphalan'}, {'id': 2590, 'therapyName': 'Cyclophosphamide + Topotecan'}]",Therapy for Children With Advanced Stage Neuroblastoma,1018
6,NCT01492673,Phase II,"Active, not recruiting","[{'id': 1479, 'therapyName': 'Cyclophosphamide + Topotecan + Bevacizumab'}]","Cyclophosphamide, Topotecan, and Bevacizumab (CTB) in Patients With Relapsed/Refractory Ewing's Sarcoma and Neuroblastoma",1018
7,NCT01593228,Phase III,Completed,"[{'id': 1173, 'therapyName': 'Iniparib + doxorubicin + carboplatin'}, {'id': 1172, 'therapyName': 'Iniparib + Paclitaxel'}, {'id': 1171, 'therapyName': 'Iniparib + Irinotecan'}, {'id': 1170, 'therapyName': 'Iniparib + Topotecan'}, {'id': 1169, 'therapyName': 'Iniparib + Gemcitabine + Carboplatin'}, {'id': 1168, 'therapyName': 'Iniparib'}]", Treatment Extension Study for Patients Who Have Previously Participated and Have Benefited From Iniparib in a Clinical Trial,1018
8,NCT02649673,Phase Ib/II,Recruiting,"[{'id': 3845, 'therapyName': 'LCL161 + Topotecan'}]",LCL161 Plus Topotecan for Patients With Relapsed/Refractory Small Cell Lung Cancer and Select Gynecologic Malignancies,1018
9,NCT02100007,Phase Ib/II,Terminated,"[{'id': 2174, 'therapyName': 'ME-344 + Topotecan'}]",ME-344 Given in Combination With Hycamtin in Patients With Solid Tumors,1018
10,NCT02963090,Phase II,Recruiting,"[{'id': 5532, 'therapyName': 'Pembrolizumab + Topotecan'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab vs Topotecan in Patients With Small Cell Lung Cancer,1018
11,NCT03107988,Phase I,Recruiting,"[{'id': 5580, 'therapyName': 'PF-06463922 + Cyclophosphamide + Topotecan'}, {'id': 869, 'therapyName': 'PF-06463922'}]",Study of Lorlatinib (PF-06463922),1018
12,NCT02354547,Phase I,Recruiting,"[{'id': 3617, 'therapyName': 'SGT-53 + Cyclophosphamide + Topotecan'}]",A Study of SGT-53 in Children With Refractory or Recurrent Solid Tumors,1018
13,NCT01670175,Phase I,Completed,"[{'id': 1224, 'therapyName': 'Sirolimus + Cyclophosphamide + Topotecan'}]",Sirolimus With Cyclophosphamide and Topotecan for Pediatric/Adolescent Relapsed and Refractory Solid Tumors,1018
14,NCT01654965,Phase I,"Active, not recruiting","[{'id': 1477, 'therapyName': 'Tivantinib + Topotecan + Pegfilgrastim'}]",Tivantinib and Topotecan Hydrochloride in Treating Patients With Advanced or Metastatic Solid Tumors,1018
15,NCT02487095,Phase Ib/II,Recruiting,"[{'id': 2879, 'therapyName': 'VX-970'}, {'id': 942, 'therapyName': 'Topotecan'}]","Trial of Topotecan With VX-970, an ATR Kinase Inhibitor, in Small Cell Lung Cancer",1018
16,NCT02502266,Phase II,Suspended,"[{'id': 942, 'therapyName': 'Topotecan'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 837, 'therapyName': 'Olaparib'}, {'id': 1001, 'therapyName': 'Cediranib'}]","Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",1018
17,NCT03061812,Phase III,Recruiting,"[{'id': 3544, 'therapyName': 'Rovalpituzumab Tesirine'}, {'id': 942, 'therapyName': 'Topotecan'}]",Study Comparing Rovalpituzumab Tesirine Versus Topotecan in Subjects With Advanced or Metastatic Small Cell Lung Cancer With High Levels of Delta-like Protein 3 (DLL3) and Who Have First Disease Progression During or Following Front-line Platinum-based Chemotherapy (TAHOE) (TAHOE),1018
18,NCT02200757,Phase II,Recruiting,"[{'id': 1440, 'therapyName': 'Aldoxorubicin'}, {'id': 942, 'therapyName': 'Topotecan'}]",Efficacy and Safety of Aldoxorubicin Compared to Topotecan in Subjects With Metastatic Small Cell Lung Cancer,1018
19,NCT02114229,Phase II,Recruiting,"[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 2449, 'therapyName': 'Methotrexate + Cisplatin + Cyclophosphamide + Vincristine'}, {'id': 626, 'therapyName': 'Alisertib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 942, 'therapyName': 'Topotecan'}]",Phase 2 Study of Alisertib Therapy for Rhabdoid Tumors,1018
20,NCT02101788,Phase II,Recruiting,"[{'id': 942, 'therapyName': 'Topotecan'}, {'id': 2173, 'therapyName': 'Doxil + Letrozole + Tamoxifen + Paclitaxel'}, {'id': 2, 'therapyName': 'Trametinib'}]",Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer,1018
21,NCT02312245,Phase II,Recruiting,"[{'id': 942, 'therapyName': 'Topotecan'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 755, 'therapyName': 'Gemcitabine'}]","Avatar-Directed Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer",1018
22,NCT02631876,Phase II,Recruiting,"[{'id': 3574, 'therapyName': 'Doxil + Paclitaxel'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 3232, 'therapyName': 'IMGN853'}]","PH2 Study of IMGN853 vs Investigator's Choice of Chemo in Adults With FRa+ Adv. EOC, Primary Peritoneal or Primary Fallopian Tube Cancer",1018
23,NCT02514447,Phase Ib/II,Recruiting,"[{'id': 3074, 'therapyName': 'Trilaciclib'}, {'id': 942, 'therapyName': 'Topotecan'}]",Study of G1T28 in Patients With Previously Treated Extensive Stage SCLC Receiving Topotecan Chemotherapy,1018
24,NCT00006199,Phase I,Unknown status,"[{'id': 938, 'therapyName': 'Tipifarnib'}, {'id': 942, 'therapyName': 'Topotecan'}]","Study of the Farnesyl Transferase Inhibitor, R115777, in Combination With Topotecan (NYU 99-32)",1018
25,NCT02551718,Phase I,Recruiting,"[{'id': 690, 'therapyName': 'Bosutinib'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 3160, 'therapyName': 'Nelarabine'}, {'id': 3159, 'therapyName': 'Bexarotene'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 998, 'therapyName': 'cabozantinib'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 877, 'therapyName': 'Ponatinib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 623, 'therapyName': 'Afatinib'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 890, 'therapyName': 'Regorafenib'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 2, 'therapyName': 'Trametinib'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 3, 'therapyName': 'Dabrafenib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 789, 'therapyName': 'Ceritinib'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1571, 'therapyName': 'Cabazitaxel'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1327, 'therapyName': 'Pralatrexate'}]",High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia,1018
26,NCT03257267,Phase III,Recruiting,"[{'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1685, 'therapyName': 'Vinorelbine'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 5656, 'therapyName': 'REGN2810'}, {'id': 942, 'therapyName': 'Topotecan'}]",Study of REGN2810 in Adults With Cervical Cancer,1018
27,NCT02419495,Phase I,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1749, 'therapyName': 'Selinexor'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 1009, 'therapyName': 'Doxorubicin'}]",Selinexor in Combination With Standard Chemotherapy,1018
28,NCT03126916,Phase III,Not yet recruiting,"[{'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1425, 'therapyName': '131I-MIBG'}, {'id': 1873, 'therapyName': 'Sargramostim'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 5595, 'therapyName': 'Isotretinoin'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 5153, 'therapyName': 'dexrazoxane'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1167, 'therapyName': 'Aldesleukin'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 2286, 'therapyName': 'Dinutuximab  '}]",Iobenguane I-131 or Crizotinib and Standard Therapy in Treating Younger Patients With Newly-Diagnosed High-Risk Neuroblastoma or Ganglioneuroblastoma,1018
29,NCT02481830,Phase III,"Active, not recruiting","[{'id': 2951, 'therapyName': 'Amrubicin'}, {'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 942, 'therapyName': 'Topotecan'}]",Efficacy Study of Nivolumab or Chemotherapy in Subjects With Relapsed Small-cell Lung Cancer,1018
30,NCT02788201,Phase II,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1133, 'therapyName': 'Mitomycin C'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1013, 'therapyName': 'epirubicin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1137, 'therapyName': 'Bleomycin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 781, 'therapyName': 'Ixabepilone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 2950, 'therapyName': 'Estramustine'}, {'id': 1941, 'therapyName': 'Floxuridine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 1811, 'therapyName': 'Carmustine'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 953, 'therapyName': 'Vandetanib'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 4419, 'therapyName': 'Toremifine'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 2601, 'therapyName': 'Dactinomycin'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 3035, 'therapyName': 'Chlorambucil'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 342, 'therapyName': 'Vemurafenib'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 2635, 'therapyName': 'Vinblastine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 4305, 'therapyName': 'Teniposide'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 4304, 'therapyName': 'Streptozocin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1231, 'therapyName': 'Bendamustine'}, {'id': 4303, 'therapyName': 'Mechlorethamine'}, {'id': 4302, 'therapyName': 'Mitotane'}]",Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma,1018
31,NCT00800345,Phase I,Completed,"[{'id': 1469, 'therapyName': 'Topotecan + Pazopanib'}]",Phase I Trial of Oral Metronomic Topotecan and Oral Pazopanib to Treat Recurrent/Persistent Gynecologic Tumors,1018
32,NCT02303028,Phase Ib/II,Recruiting,"[{'id': 1469, 'therapyName': 'Topotecan + Pazopanib'}]",Phase I Dose Escalation Study of Topotecan and Pazopanib in Children With Recurrent/Refractory Solid and CNS Tumours,1018
33,NCT02357810,Phase II,Recruiting,"[{'id': 1469, 'therapyName': 'Topotecan + Pazopanib'}]",Pazopanib Hydrochloride and Topotecan Hydrochloride in Treating Patients With Metastatic Soft Tissue and Bone Sarcomas,1018
34,NCT02348398,Phase II,Withdrawn,"[{'id': 1469, 'therapyName': 'Topotecan + Pazopanib'}]",Phase II Study of Pazopanib and Topotecan in Cervical Cancer,1018
35,NCT01931098,Phase II,Not yet recruiting,"[{'id': 1469, 'therapyName': 'Topotecan + Pazopanib'}]",Phase II Pazopanib Plus Topotecan for Recurrent Glioblastoma Multiforme (GBM),1018
36,NCT01683149,Phase I,Completed,"[{'id': 1228, 'therapyName': 'Topotecan + Sorafenib'}]", Sorafenib and Topotecan in Refractory/Recurrent Pediatric Malignancies,1018
37,NCT01012817,Phase Ib/II,Recruiting,"[{'id': 1132, 'therapyName': 'Veliparib + Topotecan'}]","Veliparib and Topotecan Hydrochloride in Treating Patients With Solid Tumors, Relapsed or Refractory Ovarian Cancer, or Primary Peritoneal Cancer",1018
0,NCT02291913,Phase II,"Active, not recruiting","[{'id': 2267, 'therapyName': 'Everolimus + Tamoxifen'}, {'id': 2268, 'therapyName': 'Anastrozole + Everolimus'}, {'id': 1589, 'therapyName': 'Fulvestrant + Everolimus'}, {'id': 1621, 'therapyName': 'Everolimus + Letrozole'}, {'id': 2269, 'therapyName': 'Everolimus + Toremifene'}, {'id': 1966, 'therapyName': 'Exemestane + Everolimus'}]",Everolimus Combined With Anti-estrogen Therapy in Hormone-Receptor-Positive HER-2 Negative Advanced Breast Cancer,529
1,NCT03238703,FDA approved,Not yet recruiting,"[{'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 4419, 'therapyName': 'Toremifine'}, {'id': 633, 'therapyName': 'Anastrozole'}, {'id': 794, 'therapyName': 'Letrozole'}]","Endocrine Therapy in Treating Patients With HER2 Negative, Low Risk Breast Cancer",529
2,NCT02788201,Phase II,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1133, 'therapyName': 'Mitomycin C'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1013, 'therapyName': 'epirubicin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1137, 'therapyName': 'Bleomycin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 781, 'therapyName': 'Ixabepilone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 2950, 'therapyName': 'Estramustine'}, {'id': 1941, 'therapyName': 'Floxuridine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 1811, 'therapyName': 'Carmustine'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 953, 'therapyName': 'Vandetanib'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 4419, 'therapyName': 'Toremifine'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 2601, 'therapyName': 'Dactinomycin'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 3035, 'therapyName': 'Chlorambucil'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 342, 'therapyName': 'Vemurafenib'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 2635, 'therapyName': 'Vinblastine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 4305, 'therapyName': 'Teniposide'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 4304, 'therapyName': 'Streptozocin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1231, 'therapyName': 'Bendamustine'}, {'id': 4303, 'therapyName': 'Mechlorethamine'}, {'id': 4302, 'therapyName': 'Mitotane'}]",Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma,529
0,NCT02729298,Phase I,Recruiting,"[{'id': 3826, 'therapyName': 'TP-0903'}]",First-in-human Study of Oral TP-0903 (a Novel Inhibitor of AXL Kinase) in Patients With Advanced Solid Tumors,8256
0,NCT01933815,Phase Ib/II,Recruiting,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 2274, 'therapyName': 'TPI 287'}]",Dose-Escalation Study of TPI 287 + Avastin Followed by Randomized Study of the Same Versus Avastin for Glioblastoma,7478
0,NCT02764333,Phase II,Recruiting,"[{'id': 4180, 'therapyName': 'MEDI4736 + TPIV 200'}]",TPIV200/huFR-1 (A Multi-Epitope Anti-Folate Receptor Vaccine) Plus Anti-PD-L1 MEDI4736 (Durvalumab) in Patients With Platinum Resistant Ovarian Cancer,8374
0,NCT03093116,Phase Ib/II,Recruiting,"[{'id': 3950, 'therapyName': 'TPX-0005'}]","A Study of TPX-0005 in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements",8306
0,NCT03074318,Phase Ib/II,Recruiting,"[{'id': 5444, 'therapyName': 'Avelumab + trabectedin'}]",Avelumab and Trabectedin in Treating Patients With Liposarcoma or Leiomyosarcoma That is Metastatic or Cannot Be Removed by Surgery,8072
1,NCT03056599,,Recruiting,"[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1299, 'therapyName': 'Interferon alfa-2b '}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1733, 'therapyName': 'interferon gamma '}, {'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 3420, 'therapyName': 'trabectedin'}, {'id': 1167, 'therapyName': 'Aldesleukin'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 720, 'therapyName': 'Docetaxel'}]",Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO™ Device in Soft Tissue Sarcoma,8072
2,NCT03138161,Phase Ib/II,Recruiting,"[{'id': 5800, 'therapyName': 'trabectedin + Ipilimumab + Nivolumab'}]","Trabectedin, Ipilimumab and Nivolumab as First Line Treatment for Advanced Soft Tissue Sarcoma",8072
0,NCT02110355,Phase Ib/II,Recruiting,"[{'id': 1454, 'therapyName': 'AMG 232 + Trametinib'}, {'id': 1453, 'therapyName': 'AMG 232 + Trametinib + Dabrafenib'}, {'id': 1066, 'therapyName': 'Trametinib + Dabrafenib'}]",A Phase 1b/2a Study Evaluating AMG 232 in Metastatic Melanoma,6818
1,NCT02097225,Phase I,Recruiting,"[{'id': 1362, 'therapyName': 'AT13387 + Dabrafenib + Trametinib'}]","Hsp90 Inhibitor AT13387, Dabrafenib, and Trametinib in Treating Patients With Recurrent Melanoma That is Metastatic or Cannot be Removed by Surgery",6818
2,NCT01376310,Phase II,"Active, not recruiting","[{'id': 1264, 'therapyName': 'Docetaxel + Trametinib'}, {'id': 1265, 'therapyName': 'Erlotinib + Trametinib'}, {'id': 2, 'therapyName': 'Trametinib'}, {'id': 1266, 'therapyName': 'Pemetrexed + GSK1120212'}, {'id': 1267, 'therapyName': 'Carboplatin + GSK1120212'}, {'id': 1268, 'therapyName': 'nab-paclitaxel + GSK1120212'}, {'id': 1269, 'therapyName': 'Gemcitabine + GSK1120212'}, {'id': 1271, 'therapyName': 'Everolimus + GSK1120212'}]",GSK1120212 Rollover Study,6818
3,NCT01912625,Phase I,Recruiting,"[{'id': 2196, 'therapyName': 'Carboplatin + Paclitaxel + Trametinib'}]","Trametinib, Combination Chemotherapy, and Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery",6818
4,NCT03087448,Phase Ib/II,Recruiting,"[{'id': 6303, 'therapyName': 'Ceritinib + Trametinib'}]",Ceritinib + Trametinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer (NSCLC),6818
5,NCT02915666,Phase I,Recruiting,"[{'id': 4778, 'therapyName': 'Dabrafenib + Digoxin + Trametinib'}]",A Clinical Trial of Patients With Melanoma,6818
6,NCT02027961,Phase Ib/II,"Active, not recruiting","[{'id': 1357, 'therapyName': 'Dabrafenib + Durvalumab + Trametinib'}, {'id': 1358, 'therapyName': 'Durvalumab + Trametinib'}]",Phase 1 Safety and Tolerability of MEDI4736 in Combination With Dabrafenib and Trametinib or With Trametinib Alone,6818
7,NCT03272464,Phase I,Not yet recruiting,"[{'id': 6176, 'therapyName': 'Dabrafenib + INCB039110 + Trametinib'}]",Phase I Study of INCB039110 in Combination With Dabrafenib and Trametinib in Patients With BRAF-mutant Melanoma and Other Solid Tumors.,6818
8,NCT01767454,Phase I,Completed,"[{'id': 1258, 'therapyName': 'Dabrafenib + Ipilimumab + Trametinib'}, {'id': 1257, 'therapyName': 'Dabrafenib + Ipilimumab'}]",Study of Dabrafenib +/- Trametinib in Combination With Ipilimumab for V600E/K Mutation Positive Metastatic or Unresectable Melanoma,6818
9,NCT02910700,Phase II,Recruiting,"[{'id': 4753, 'therapyName': 'Nivolumab + Trametinib'}, {'id': 4754, 'therapyName': 'Dabrafenib + Nivolumab + Trametinib'}]",Study of the Anti-PD-1 Antibody Nivolumab in Combination With Dabrafenib and/or Trametinib in Patients With BRAF or NRAS-mutated Metastatic Melanoma,6818
10,NCT02143050,Phase Ib/II,Recruiting,"[{'id': 1443, 'therapyName': 'Dabrafenib + Trametinib + Metformin'}]","Study of Dabrafenib, Trametinib and Metformin for Melanoma Patients",6818
11,NCT02967692,Phase III,Recruiting,"[{'id': 6023, 'therapyName': 'Dabrafenib + Trametinib + PDR001'}, {'id': 1066, 'therapyName': 'Trametinib + Dabrafenib'}]","A Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced Melanoma",6818
12,NCT03026517,Phase I,Recruiting,"[{'id': 5270, 'therapyName': 'Dabrafenib + Trametinib + Phenformin'}]",Clinical Trial of Phenformin in Combination With Dabrafenib and Trametinib for Patients With BRAF-mutated Melanoma,6818
13,NCT02642042,Phase II,Recruiting,"[{'id': 1264, 'therapyName': 'Docetaxel + Trametinib'}]",Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV Non-small Cell Lung Cancer,6818
14,NCT01287546,Phase I,Completed,"[{'id': 1179, 'therapyName': 'Emibetuzumab + Erlotinib'}, {'id': 1180, 'therapyName': 'Emibetuzumab + Trametinib'}, {'id': 803, 'therapyName': 'Emibetuzumab'}]",A Study of LY2875358 in Participants With Advanced Cancer,6818
15,NCT03076164,Phase Ib/II,Recruiting,"[{'id': 1265, 'therapyName': 'Erlotinib + Trametinib'}]",A Phase 1/2 Trial of Trametinib and Erlotinib in Patients With EGFR-Mutant Lung Adenocarcinomas and Acquired Resistance to Erlotinib,6818
16,NCT01619774,Phase II,Completed,"[{'id': 1191, 'therapyName': 'GSK1120212 + Dabrafenib'}]", An Open-Label Phase II Study of the Combination of GSK2118436 and GSK1120212 in Patients With Metastatic Melanoma Which is Refractory or Resistant to BRAF Inhibitor,6818
17,NCT01138085,Phase I,Completed,"[{'id': 1150, 'therapyName': 'GSK1120212 + GSK2141795'}]","Safety, Pharmacokinetics (PK) of AKT and MEK Combination",6818
18,NCT01958112,Phase II,Terminated,"[{'id': 1150, 'therapyName': 'GSK1120212 + GSK2141795'}]",GSK1120212+GSK2141795 for Cervical Cancer,6818
19,NCT02428270,Phase II,Recruiting,"[{'id': 4205, 'therapyName': 'GSK2256098 + Trametinib'}]",A Study of GSK2256098 and Trametinib in Advanced Pancreatic Cancer,6818
20,NCT02258607,Phase I,Terminated,"[{'id': 823, 'therapyName': 'Momelotinib'}, {'id': 1860, 'therapyName': 'Momelotinib + Trametinib'}]",Efficacy and Safety of Momelotinib and Momelotinib Combined With Trametinib in Adults With Metastatic KRAS-mutated Non-Small Cell Lung Cancer (NSCLC) Who Have Failed Platinum-Based Chemotherapy Preceded by a Dose-finding Lead-in Phase,6818
21,NCT02300935,Phase I,Withdrawn,"[{'id': 1268, 'therapyName': 'nab-paclitaxel + GSK1120212'}]",Study of Trametinib and Nab-paclitaxel in Patients With Melanoma,6818
22,NCT03065387,Phase I,Not yet recruiting,"[{'id': 5401, 'therapyName': 'Neratinib + Everolimus'}, {'id': 5402, 'therapyName': 'Neratinib + Palbociclib'}, {'id': 5403, 'therapyName': 'Neratinib + Trametinib'}]","Study of the Pan-ERBB Inhibitor Neratinib Given in Combination With Everolimus, Palbociclib or Trametinib in Advanced Cancer Subjects With EGFR Mutation/Amplification, HER2 Mutation/Amplification or HER3/4 Mutation",6818
23,NCT02065063,Phase I,Completed,"[{'id': 1368, 'therapyName': 'Palbociclib + Trametinib'}]","A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Anti-Cancer Activity of Trametinib in Combination With Palbociclib in Subjects With Solid Tumors",6818
24,NCT02399943,Phase II,Recruiting,"[{'id': 1991, 'therapyName': 'Panitumumab + Trametinib'}]",A Trial of Trametinib and Panitumumab in RAS/RAF Wild Type Advanced Colorectal Cancer,6818
25,NCT01750918,Phase II,"Active, not recruiting","[{'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1718, 'therapyName': 'Panitumumab + Dabrafenib'}, {'id': 1992, 'therapyName': 'Panitumumab + Trametinib + Dabrafenib'}, {'id': 1991, 'therapyName': 'Panitumumab + Trametinib'}]",BRAF/MEK/EGFR Inhibitor Combination Study in Colorectal Cancer (CRC),6818
26,NCT01438554,Phase I,"Active, not recruiting","[{'id': 1310, 'therapyName': 'Pazopanib + Trametinib'}]","Phase 1 Study of Pazopanib With GSK1120212 in Advanced Solid Tumors, Enriched With Patients With Differentiated Thyroid Cancer, Soft-tissue Sarcoma, and Cholangiocarcinoma",6818
27,NCT02900664,Phase I,Recruiting,"[{'id': 5399, 'therapyName': 'PDR001 + EGF816'}, {'id': 5397, 'therapyName': 'PDR001 + CJM112'}, {'id': 5398, 'therapyName': 'PDR001 + Trametinib'}, {'id': 5395, 'therapyName': 'PDR001 + Canakinumab'}]","A Study of PDR001 in Combination With CJM112, EGF816, Ilaris (Canakinumab) or Mekinist (Trametinib)",6818
28,NCT03149029,Phase II,Not yet recruiting,"[{'id': 1449, 'therapyName': 'Pembrolizumab + Dabrafenib + Trametinib'}, {'id': 1450, 'therapyName': 'Pembrolizumab + Trametinib'}]",Abbreviated MAPK Targeted Therapy Plus Pembrolizumab in Melanoma,6818
29,NCT02130466,Phase Ib/II,Recruiting,"[{'id': 1450, 'therapyName': 'Pembrolizumab + Trametinib'}, {'id': 1448, 'therapyName': 'Pembrolizumab + Dabrafenib'}, {'id': 1449, 'therapyName': 'Pembrolizumab + Dabrafenib + Trametinib'}]",A Study of the Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With Trametinib and Dabrafenib in Participants With Advanced Melanoma (MK-3475-022),6818
30,NCT03299088,Phase I,Not yet recruiting,"[{'id': 1450, 'therapyName': 'Pembrolizumab + Trametinib'}]",Pembrolizumab and Trametinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer and KRAS Gene Mutations,6818
31,NCT03225664,Phase Ib/II,Not yet recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1450, 'therapyName': 'Pembrolizumab + Trametinib'}]",BATTLE-2 Program - A Biomarker-Integrated Targeted Therapy in Non-Small Cell Lung Cancer (NSCLC),6818
32,NCT02703571,Phase Ib/II,Recruiting,"[{'id': 4472, 'therapyName': 'Ribociclib + Trametinib'}]",Study of Safety and Efficacy of Ribociclib and Trametinib in Patients With Metastatic or Advanced Solid Tumors,6818
33,NCT02292173,Phase I,Recruiting,"[{'id': 2197, 'therapyName': 'Sorafenib + Trametinib'}]",Trametinib in Combination With Sorafenib in Patients With Advanced Hepatocellular Cancer,6818
34,NCT03088176,Phase I,Recruiting,"[{'id': 5481, 'therapyName': 'talimogene laherparepvec + Dabrafenib + Trametinib'}]",Combining Talimogene Laherparepvec With BRAF and MEK Inhibitors in BRAF Mutated Advanced Melanoma,6818
35,NCT02257424,Phase Ib/II,Recruiting,"[{'id': 2, 'therapyName': 'Trametinib'}]","The BAMM Trial: BRAF, Autophagy and MEK Inhibition in Metastatic Melanoma: A Phase I/2 Trial of Dabrafenib, Trametinib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma",6818
36,NCT01902173,Phase Ib/II,Suspended,"[{'id': 2, 'therapyName': 'Trametinib'}, {'id': 2200, 'therapyName': 'Dabrafenib + GSK2141795'}]","GSK2141795, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer",6818
37,NCT02465060,Phase II,Recruiting,"[{'id': 660, 'therapyName': 'AZD9291'}, {'id': 3, 'therapyName': 'Dabrafenib'}, {'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 2, 'therapyName': 'Trametinib'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 623, 'therapyName': 'Afatinib'}, {'id': 654, 'therapyName': 'AZD4547'}, {'id': 958, 'therapyName': 'VS-6063'}, {'id': 765, 'therapyName': 'GSK2636771'}]",NCI-MATCH Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas,6818
38,NCT02580708,Phase Ib/II,Completed,"[{'id': 2, 'therapyName': 'Trametinib'}, {'id': 1003, 'therapyName': 'CO1686'}]",A Phase 1/2 Study of the Safety and Efficacy of Rociletinib When Administered in Combination With Trametinib in Patients With Activating EGFR Mutation-positive Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC),6818
39,NCT02780128,Phase I,Recruiting,"[{'id': 2186, 'therapyName': 'HDM201'}, {'id': 2638, 'therapyName': 'Ceritinib + LEE011'}, {'id': 2, 'therapyName': 'Trametinib'}]",Next Generation Personalized Neuroblastoma Therapy,6818
40,NCT03091257,Phase I,Recruiting,"[{'id': 1066, 'therapyName': 'Trametinib + Dabrafenib'}, {'id': 3, 'therapyName': 'Dabrafenib'}, {'id': 2, 'therapyName': 'Trametinib'}]",A Study of Dabrafenib and/or Trametinib in Patients With Relapsed and/or Refractory Multiple Myeloma,6818
41,NCT02101788,Phase II,Recruiting,"[{'id': 942, 'therapyName': 'Topotecan'}, {'id': 2173, 'therapyName': 'Doxil + Letrozole + Tamoxifen + Paclitaxel'}, {'id': 2, 'therapyName': 'Trametinib'}]",Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer,6818
42,NCT02881242,Phase II,Not yet recruiting,"[{'id': 2, 'therapyName': 'Trametinib'}]",Trametinib in Treating Patients With Progressive Metastatic Hormone-Resistant Prostate Cancer,6818
43,NCT02551718,Phase I,Recruiting,"[{'id': 690, 'therapyName': 'Bosutinib'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 3160, 'therapyName': 'Nelarabine'}, {'id': 3159, 'therapyName': 'Bexarotene'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 998, 'therapyName': 'cabozantinib'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 877, 'therapyName': 'Ponatinib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 623, 'therapyName': 'Afatinib'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 890, 'therapyName': 'Regorafenib'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 2, 'therapyName': 'Trametinib'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 3, 'therapyName': 'Dabrafenib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 789, 'therapyName': 'Ceritinib'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1571, 'therapyName': 'Cabazitaxel'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1327, 'therapyName': 'Pralatrexate'}]",High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia,6818
44,NCT01979523,Phase II,"Active, not recruiting","[{'id': 2, 'therapyName': 'Trametinib'}, {'id': 1298, 'therapyName': 'Trametinib + GSK2141795'}]",Trametinib With or Without GSK2141795 in Treating Patients With Metastatic Uveal Melanoma,6818
45,NCT02296112,Phase II,Recruiting,"[{'id': 2, 'therapyName': 'Trametinib'}]",Trametinib in Treating Patients With Advanced Melanoma With BRAF Non-V600 Mutations,6818
46,NCT01935973,Phase II,"Active, not recruiting","[{'id': 2, 'therapyName': 'Trametinib'}, {'id': 1298, 'therapyName': 'Trametinib + GSK2141795'}]",Trametinib With or Without GSK2141795 in Treating Patients With Recurrent or Persistent Endometrial Cancer,6818
47,NCT02015117,Phase I,"Active, not recruiting","[{'id': 2, 'therapyName': 'Trametinib'}]",Trametinib With or Without Whole Brain Radiation Therapy in Treating Patients With Brain Metastases,6818
48,NCT02070549,Phase I,Recruiting,"[{'id': 2, 'therapyName': 'Trametinib'}]",Trametinib in Treating Patients With Advanced Cancer With or Without Hepatic Dysfunction,6818
49,NCT02152995,Phase II,Recruiting,"[{'id': 2, 'therapyName': 'Trametinib'}]",Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer,6818
50,NCT01231594,Phase I,Recruiting,"[{'id': 3, 'therapyName': 'Dabrafenib'}, {'id': 2, 'therapyName': 'Trametinib'}]",A Rollover Study to Provide Continued Treatment With GSK2118436 to Subjects With BRAF Mutation-Positive Tumors,6818
51,NCT03148275,Phase II,Recruiting,"[{'id': 2, 'therapyName': 'Trametinib'}]","Trametinib in Treating Patients With Epithelioid Hemangioendothelioma That Is Metastatic, Locally Advanced, or Cannot Be Removed by Surgery",6818
52,NCT02042443,Phase II,Completed,"[{'id': 2278, 'therapyName': 'Fluorouracil + Leucovorin'}, {'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 2, 'therapyName': 'Trametinib'}]",Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery,6818
53,NCT02124772,Phase I,Recruiting,"[{'id': 2, 'therapyName': 'Trametinib'}, {'id': 1066, 'therapyName': 'Trametinib + Dabrafenib'}]","Study to Investigate Safety, Pharmacokinetic (PK), Pharmacodynamic (PD) and Clinical Activity of Trametinib in Subjects With Cancer or Plexiform Neurofibromas and Trametinib in Combination With Dabrafenib in Subjects With Cancers Harboring V600 Mutations",6818
54,NCT02016729,Phase I,Completed,"[{'id': 2, 'therapyName': 'Trametinib'}, {'id': 1452, 'therapyName': 'AMG 232'}]",A Phase 1b Study Evaluating AMG 232 Alone and in Combination With Trametinib in Acute Myeloid Leukemia,6818
55,NCT03087071,Phase II,Not yet recruiting,"[{'id': 845, 'therapyName': 'Panitumumab'}, {'id': 2, 'therapyName': 'Trametinib'}]",Panitumumab in Combination With Trametinib in Cetuximab-Refractory Stage IV Colorectal Cancer,6818
56,NCT01940809,Phase II,Recruiting,"[{'id': 3, 'therapyName': 'Dabrafenib'}, {'id': 2, 'therapyName': 'Trametinib'}, {'id': 779, 'therapyName': 'Ipilimumab'}]","Ipilimumab With or Without Dabrafenib, and/or Trametinib in Treating Patients With Melanoma That is Metastatic or Cannot Be Removed By Surgery",6818
57,NCT02140840,Phase II,Withdrawn,"[{'id': 2, 'therapyName': 'Trametinib'}]","A Phase II Open-Label, Multiple-Dose, Single Agent Study to Evaluate the Overall Response Rate of Orally Administered Trametinib",6818
58,NCT01553851,Phase II,Completed,"[{'id': 2, 'therapyName': 'Trametinib'}]",GSK1120212 in Surgically Resectable Oral Cavity Squamous Cell Cancer,6818
59,NCT01827384,Phase II,Recruiting,"[{'id': 1194, 'therapyName': 'MK-1775 + Carboplatin '}, {'id': 1193, 'therapyName': 'Veliparib + Temozolomide'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 2, 'therapyName': 'Trametinib'}]",Molecular Profiling-Based Targeted Therapy in Treating Patients With Advanced Solid Tumors,6818
60,NCT03190915,Phase II,Recruiting,"[{'id': 2, 'therapyName': 'Trametinib'}]",Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic Leukemia,6818
61,NCT02705963,Phase I,Recruiting,"[{'id': 2, 'therapyName': 'Trametinib'}]",A Drug-Drug Interaction Study to Assess the Effect of Trametinib on the Pharmacokinetics of an Oral Contraceptive in Female Patients With Solid Tumors,6818
62,NCT01990196,Phase II,Recruiting,"[{'id': 717, 'therapyName': 'Dasatinib'}, {'id': 2, 'therapyName': 'Trametinib'}, {'id': 1815, 'therapyName': 'Degarelix + Enzalutamide'}]",Neoadjuvant Phase 2 Study Comparing the Effects of AR Inhibition With/Without SRC or MEK Inhibition in Prostate Cancer,6818
63,NCT01725100,Phase I,Completed,"[{'id': 2, 'therapyName': 'Trametinib'}]","A Study to Determine the Relative Bioavailability of the MEK Inhibitor, Trametinib, in Subjects With Solid Tumor Malignancies",6818
64,NCT01467310,Phase I,Completed,"[{'id': 2, 'therapyName': 'Trametinib'}]",Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212,6818
65,NCT01658553,Phase I,Completed,"[{'id': 2, 'therapyName': 'Trametinib'}]"," A Study to Look at the Electrical Activity of the Heart in Subjects With Solid Tumor Cancers, Before and After Receiving the Study Treatment, GSK1120212",6818
66,NCT01726738,Phase II,"Active, not recruiting","[{'id': 1066, 'therapyName': 'Trametinib + Dabrafenib'}]",LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations,6818
67,NCT01989585,Phase Ib/II,Recruiting,"[{'id': 1303, 'therapyName': 'Trametinib + Dabrafenib + Navitoclax'}, {'id': 1066, 'therapyName': 'Trametinib + Dabrafenib'}]","Dabrafenib, Trametinib, and Navitoclax in Treating Patients With Solid Tumors That Are Metastatic or Cannot be Removed by Surgery",6818
68,NCT02974803,Phase II,Not yet recruiting,"[{'id': 1066, 'therapyName': 'Trametinib + Dabrafenib'}]",Concurrent Dabrafenib and Trametinib With Sterotactic Radiation in Patients With BRAF Mutation-Positive Malignant Melanoma and Brain Metastases,6818
69,NCT02224781,Phase III,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}, {'id': 1066, 'therapyName': 'Trametinib + Dabrafenib'}]",Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma,6818
70,NCT01336634,Phase II,"Active, not recruiting","[{'id': 3, 'therapyName': 'Dabrafenib'}, {'id': 1066, 'therapyName': 'Trametinib + Dabrafenib'}]",Study of Selective BRAF Kinase Inhibitor Dabrafenib Monotherapy Twice Daily and in Combination With Dabrafenib Twice Daily and Trametinib Once Daily in Combination Therapy in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer.,6818
71,NCT02196181,Phase II,Recruiting,"[{'id': 1066, 'therapyName': 'Trametinib + Dabrafenib'}]",Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by Surgery,6818
72,NCT01701037,Phase II,Terminated,"[{'id': 1066, 'therapyName': 'Trametinib + Dabrafenib'}, {'id': 3, 'therapyName': 'Dabrafenib'}]", Dabrafenib Alone and in Combination With Trametinib Before Surgery in Treating Patients With Locally or Regionally Advanced Melanoma That Can Be Removed By Surgery,6818
73,NCT02039947,Phase II,"Active, not recruiting","[{'id': 1066, 'therapyName': 'Trametinib + Dabrafenib'}]",Study to Evaluate Treatment of Dabrafenib Plus Trametinib in Subjects With BRAF Mutation-Positive Melanoma That Has Metastasized to the Brain,6818
74,NCT02231775,Phase II,Recruiting,"[{'id': 1066, 'therapyName': 'Trametinib + Dabrafenib'}]",Combi-Neo Study for Stage IV Melanoma,6818
75,NCT01978236,Phase II,Completed,"[{'id': 1066, 'therapyName': 'Trametinib + Dabrafenib'}, {'id': 3, 'therapyName': 'Dabrafenib'}]","Dabrafenib/Trametinib, BRAF or BRAF AND MEK Pre-op With BRAF and MEK Post-op, Phase IIB, Melanoma With Brain Mets,Biomarkers and Metabolites",6818
76,NCT01723202,Phase II,"Active, not recruiting","[{'id': 1066, 'therapyName': 'Trametinib + Dabrafenib'}, {'id': 3, 'therapyName': 'Dabrafenib'}]",Dabrafenib With or Without Trametinib in Treating Patients With Recurrent Thyroid Cancer,6818
77,NCT01682083,Phase III,"Active, not recruiting","[{'id': 1066, 'therapyName': 'Trametinib + Dabrafenib'}]", A Study of the BRAF Inhibitor Dabrafenib in Combination With the MEK Inhibitor Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma After Surgical Resection.,6818
78,NCT02034110,Phase II,Recruiting,"[{'id': 1066, 'therapyName': 'Trametinib + Dabrafenib'}]",Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers,6818
79,NCT02138292,Phase I,"Active, not recruiting","[{'id': 1446, 'therapyName': 'Trametinib + Digoxin'}]",A Phase 1B Clinical Trial of Trametinib Plus Digoxin in Patients With Unresectable or Metastatic BRAF Wild-type Melanoma,6818
80,NCT01740648,Phase I,"Active, not recruiting","[{'id': 1113, 'therapyName': 'Trametinib + Fluorouracil'}]","Trametinib, Fluorouracil, and Radiation Therapy Before Surgery in Treating Patients With Stage II-III Rectal Cancer",6818
81,NCT01989598,Phase II,"Active, not recruiting","[{'id': 1298, 'therapyName': 'Trametinib + GSK2141795'}]",Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Relapsed or Refractory Multiple Myeloma,6818
82,NCT01907815,Phase II,"Active, not recruiting","[{'id': 1298, 'therapyName': 'Trametinib + GSK2141795'}]",Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Acute Myeloid Leukemia,6818
83,NCT01964924,Phase II,"Active, not recruiting","[{'id': 1298, 'therapyName': 'Trametinib + GSK2141795'}]",Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Metastatic Triple-Negative Breast Cancer,6818
84,NCT01941927,Phase II,Unknown status,"[{'id': 1298, 'therapyName': 'Trametinib + GSK2141795'}]",Trametinib With GSK2141795 in BRAF Wild-type Melanoma,6818
85,NCT02079740,Phase Ib/II,Recruiting,"[{'id': 1386, 'therapyName': 'Trametinib + Navitoclax'}]",Trametinib and Navitoclax in Treating Patients With Advanced or Metastatic Solid Tumors,6818
86,NCT03085056,Phase I,Recruiting,"[{'id': 5493, 'therapyName': 'Trametinib + Paclitaxel'}]",Trametinib in Combination With Paclitaxel in the Treatment of Anaplastic Thyroid Cancer,6818
0,NCT01384253,Phase I,Completed,"[{'id': 1540, 'therapyName': '212Pb-TCMC-Trastuzumab + Trastuzumab '}]",Safety Study of ²¹²Pb-TCMC-Trastuzumab Radio Immunotherapy,71
1,NCT01386580,Phase Ib/II,Completed,"[{'id': 974, 'therapyName': '2B3-101'}, {'id': 1274, 'therapyName': '2B3-101 + Trastuzumab'}]","An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma.",71
2,NCT02057133,Phase I,Recruiting,"[{'id': 2254, 'therapyName': 'Abemaciclib + Letrozole'}, {'id': 2257, 'therapyName': 'Abemaciclib + Exemestane'}, {'id': 2258, 'therapyName': 'Everolimus + Exemestane + LY2835219'}, {'id': 2255, 'therapyName': 'Abemaciclib + Anastrozole'}, {'id': 2256, 'therapyName': 'Abemaciclib + Tamoxifen'}, {'id': 2259, 'therapyName': 'Abemaciclib + Trastuzumab'}]",A Study of LY2835219 in Combination With Hormone Therapies for Breast Cancer That Has Spread,71
3,NCT01522768,Phase II,Recruiting,"[{'id': 1106, 'therapyName': 'Afatinib + Trastuzumab'}]", Afatinib (BIBW 2992) and Trastuzumab in Patients With Advanced HER2-Positive Trastuzumab-Refractory Advanced Esophagogastric Cancer,71
4,NCT03013218,Phase I,Recruiting,"[{'id': 5211, 'therapyName': 'ALX148'}, {'id': 5212, 'therapyName': 'ALX148 + Atezolizumab'}, {'id': 5213, 'therapyName': 'ALX148 + Trastuzumab'}]",A Study of ALX148 in Patients With Advanced Solid Tumors and Lymphoma,71
5,NCT02614794,Phase II,Recruiting,"[{'id': 3340, 'therapyName': 'ARRY-380 + Capecitabine + Trastuzumab'}, {'id': 1409, 'therapyName': 'Capecitabine + Trastuzumab'}]",Study of ONT-380 vs Placebo in Combo w/ Capecitabine & Trastuzumab in Patients w/ Metastatic HER2+ Breast Cancer,71
6,NCT03043313,Phase II,Recruiting,"[{'id': 1560, 'therapyName': 'ARRY-380 + Trastuzumab'}]",Tucatinib (ONT-380) and Trastuzumab for Patients With HER2-positive Metastatic Colorectal Cancer (MOUNTAINEER)Tucatinib (ONT-380) and Trastuzumab for Patients With HER2-positive Metastatic Colorectal Cancer (MOUNTAINEER) (MOUNTAINEER),71
7,NCT01921335,Phase I,"Active, not recruiting","[{'id': 1560, 'therapyName': 'ARRY-380 + Trastuzumab'}]",Phase I Dose-escalation Trial of ARRY-380 in Combination With Trastuzumab in Participants With Brain Metastases From HER2+ Breast Cancer,71
8,NCT02025192,Phase I,"Active, not recruiting","[{'id': 1560, 'therapyName': 'ARRY-380 + Trastuzumab'}, {'id': 1577, 'therapyName': 'ARRY-380 + Capecitabine'}]",A Phase 1b Study of ONT-380 Combined With Capecitabine and/or Trastuzumab in Patients With HER2+ Metastatic Breast Cancer,71
9,NCT03125928,Phase II,Recruiting,"[{'id': 5600, 'therapyName': 'Atezolizumab + Paclitaxel + Trastuzumab + Pertuzumab'}]","Clinical Trial of Atezolizumab With Paclitaxel, Trastuzumab, and Pertuzumab in Patients With Metastatic HER-2 Positive Breast Cancer",71
10,NCT02605915,Phase I,Recruiting,"[{'id': 3250, 'therapyName': 'Atezolizumab + Trastuzumab'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 856, 'therapyName': 'Pertuzumab'}]",Safety and Pharmacokinetics of Atezolizumab in Combination With Trastuzumab Emtansine or With Trastuzumab and Pertuzumab in Participants With HER2-Positive Breast Cancer,71
11,NCT02924883,Phase II,"Active, not recruiting","[{'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 3250, 'therapyName': 'Atezolizumab + Trastuzumab'}]",A Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine in Combination With Atezolizumab or Atezolizumab-Placebo in Participants With Human Epidermal Growth Factor-2 (HER2) Positive Locally Advanced or Metastatic Breast Cancer Who Have Received Prior Trastuzumab and Taxane Based Therapy,71
12,NCT01300962,Phase I,"Active, not recruiting","[{'id': 1538, 'therapyName': 'BKM120 + Capecitabine + Lapatinib'}, {'id': 1537, 'therapyName': 'BKM120 + Capecitabine + Trastuzumab'}, {'id': 1536, 'therapyName': 'BKM120 + Capecitabine'}, {'id': 1535, 'therapyName': 'BYL719 + Capecitabine'}]",Study of BKM120 or BYL719 and Capecitabine in Patients With Metastatic Breast Cancer,71
13,NCT02167854,Phase I,Recruiting,"[{'id': 2059, 'therapyName': 'BYL719 + LJM716 + Trastuzumab'}]","Open-Label Study Evaluating the Safety and Tolerability of LJM716, BYL719 and Trastuzumab in Patients With Metastatic HER2+ Breast Cancer",71
14,NCT02954536,Phase II,Recruiting,"[{'id': 4945, 'therapyName': 'Capecitabine + Cisplatin + Pembrolizumab + Trastuzumab'}]",Phase II Trial of Pembrolizumab With Trastuzumab and Chemotherapy in Advanced HER2 Positive Esophagogastric (EG) Cancer,71
15,NCT01450696,Phase III,Terminated,"[{'id': 1899, 'therapyName': 'Capecitabine + Cisplatin + Trastuzumab'}]",HELOISE Study: A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer,71
16,NCT01873833,Phase II,Recruiting,"[{'id': 1559, 'therapyName': 'Capecitabine + Cyclophosphamide + Lapatinib + Trastuzumab'}]","Capecitabine, Cyclophosphamide, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With HER2-Positive Metastatic Breast Cancer",71
17,NCT01774786,Phase III,"Active, not recruiting","[{'id': 856, 'therapyName': 'Pertuzumab'}, {'id': 1894, 'therapyName': 'Capecitabine + Fluorouracil + Cisplatin + Trastuzumab'}]",A Study of Perjeta (Pertuzumab) in Combination With Herceptin (Trastuzumab) and Chemotherapy in Patients With HER2-Positive Metastatic Gastroesophageal Junction or Gastric Cancer,71
18,NCT02213744,Phase II,Terminated,"[{'id': 1890, 'therapyName': 'Vinorelbine + Trastuzumab'}, {'id': 1409, 'therapyName': 'Capecitabine + Trastuzumab'}, {'id': 1889, 'therapyName': 'Gemcitabine + Trastuzumab'}, {'id': 1888, 'therapyName': 'MM-302 + Trastuzumab'}]",MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in HER2-Positive Locally Advanced/Metastatic Breast Cancer Patients,71
19,NCT02789657,Phase II,Recruiting,"[{'id': 4235, 'therapyName': 'Carboplatin + Pertuzumab + Trastuzumab + Paclitaxel'}, {'id': 1977, 'therapyName': 'Doxorubicin + Cyclophosphamide'}]",BrUOG 308: Efficacy of wPCbTP and Switching to an AC in Non-responding Patients as Neoadjuvant Therapy in Clinical Stage I-III HER2-positive Breast Cancer.,71
20,NCT02014909,Phase I,Completed,"[{'id': 2054, 'therapyName': 'CDX-3379'}, {'id': 2063, 'therapyName': 'CDX-3379 + Vemurafenib'}, {'id': 2064, 'therapyName': 'CDX-3379 + Trastuzumab'}, {'id': 2061, 'therapyName': 'Cetuximab + CDX-3379'}, {'id': 2062, 'therapyName': 'CDX-3379 + Erlotinib'}]",A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of KTN3379 in Adult Subjects With Advanced Tumors,71
21,NCT02654119,Phase II,Recruiting,"[{'id': 1898, 'therapyName': 'Cyclophosphamide + Paclitaxel + Trastuzumab '}]","Cyclophosphamide, Paclitaxel, and Trastuzumab in Treating Patients With Stage I-II HER2/Neu Positive Breast Cancer After Surgery",71
22,NCT01275677,Phase III,"Active, not recruiting","[{'id': 1503, 'therapyName': 'Paclitaxel + Trastuzumab + Doxorubicin + Cyclophosphamide'}, {'id': 1881, 'therapyName': 'Docetaxel + Cyclophosphamide'}, {'id': 1882, 'therapyName': 'Docetaxel + Cyclophosphamide + Trastuzumab'}, {'id': 1495, 'therapyName': 'Paclitaxel + Doxorubicin + Cyclophosphamide'}]",Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,71
23,NCT01434303,Phase I,"Active, not recruiting","[{'id': 1542, 'therapyName': 'Entinostat + Lapatinib + Trastuzumab'}]","Entinostat, Lapatinib Ditosylate and Trastuzumab in Treating Patients With Locally Recurrent or Distant Relapsed Metastatic Breast Cancer Previously Treated With Trastuzumab Only",71
24,NCT02091960,Phase II,"Active, not recruiting","[{'id': 1878, 'therapyName': 'Enzalutamide + Trastuzumab'}]","A Study to Assess the Efficacy and Safety of Enzalutamide With Trastuzumab in Subjects With Human Epidermal Growth Factor Receptor 2 Positive (HER2+), Androgen Receptor Positive (AR+) and Estrogen Receptor Negative (ER-) Metastatic or Locally Advanced Breast Cancer",71
25,NCT01401959,Phase II,"Active, not recruiting","[{'id': 728, 'therapyName': 'Eribulin'}, {'id': 1981, 'therapyName': 'Eribulin + Trastuzumab'}]",Trial of Eribulin in Patients Who Do Not Achieve Pathologic Complete Response (pCR) Following Neoadjuvant Chemotherapy,71
26,NCT02152943,Phase I,Recruiting,"[{'id': 1591, 'therapyName': 'Everolimus + Letrozole + Trastuzumab'}]","Everolimus, Letrozole and Trastuzumab in HR- and HER2/Neu-positive Patients",71
27,NCT02060253,Phase I,"Active, not recruiting","[{'id': 1579, 'therapyName': 'Ganetespib + Paclitaxel + Trastuzumab'}]","Ganetespib, Paclitaxel and Trastuzumab for Advanced or Metastatic Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Breast Cancer",71
28,NCT02139358,Phase Ib/II,"Active, not recruiting","[{'id': 1592, 'therapyName': 'Gemcitabine + Trastuzumab + Pertuzumab'}]",Phase I/IIa Trial of Gemcitabine Plus Trastuzumab and Pertuzumab in Previously Treated Metastatic HER2+ Breast Cancer,71
29,NCT02252887,Phase II,"Active, not recruiting","[{'id': 1592, 'therapyName': 'Gemcitabine + Trastuzumab + Pertuzumab'}]","Gemcitabine, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer After Prior Trastuzumab/Pertuzumab-Based Therapy, TDM-1, and TDM-1 + Pertuzumab",71
30,NCT01922921,Phase Ib/II,"Active, not recruiting","[{'id': 1556, 'therapyName': 'HER-2/neu intracellular domain protein + Trastuzumab '}, {'id': 1558, 'therapyName': 'HER-2/neu intracellular domain protein + Trastuzumab + Polysaccharide-K'}]",Vaccine Therapy and Trastuzumab With or Without Polysaccharide-K in Treating Patients With Stage IV HER2 Positive Breast Cancer,71
31,NCT03112590,Phase Ib/II,Recruiting,"[{'id': 5548, 'therapyName': 'Interferon gamma + Paclitaxel + Pertuzumab + Trastuzumab'}]",Phase I-II Study of Interferon-gamma in Patients With HER-2 Positive Breast Cancer,71
32,NCT02907918,Phase II,Recruiting,"[{'id': 759, 'therapyName': 'Goserelin'}, {'id': 4756, 'therapyName': 'Letrozole + Palbociclib + Trastuzumab'}]",Neoadjuvant Study of Palbociclib in Combination With Letrozole and Trastuzumab in Stage II-III ER+ HER2+ Breast Cancer (PALTAN),71
33,NCT01602406,Phase I,Completed,"[{'id': 2037, 'therapyName': 'LJM716 + Trastuzumab'}]",Phase I Study LJM716 Combined With Trastuzumab in Patients With HER2 Overexpressing Metastatic Breast or Gastric Cancer,71
34,NCT02649686,Phase I,"Active, not recruiting","[{'id': 4218, 'therapyName': 'MEDI4736 + Trastuzumab'}]",Durvalumab in Patients With HER-2 Positive Metastatic Breast Cancer Receiving Trastuzumab,71
35,NCT03238495,Phase II,Recruiting,"[{'id': 1879, 'therapyName': 'Pertuzumab + Trastuzumab + Carboplatin + Docetaxel'}, {'id': 6101, 'therapyName': 'Metformin + Pertuzumab + Trastuzumab + Carboplatin + Docetaxel'}]",Randomized Trial of Neo-adjuvant Chemotherapy With or Without Metformin for HER2 Positive Operable Breast Cancer,71
36,NCT01042379,Phase II,Recruiting,"[{'id': 1218, 'therapyName': 'Trebananib'}, {'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}, {'id': 746, 'therapyName': 'Ganitumab'}, {'id': 1495, 'therapyName': 'Paclitaxel + Doxorubicin + Cyclophosphamide'}, {'id': 1494, 'therapyName': 'MK2206 + Trastuzumab'}, {'id': 1493, 'therapyName': 'Trebananib + Trastuzumab'}, {'id': 1492, 'therapyName': 'T-DM1 + Pertuzumab'}]",I-SPY 2 TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer,71
37,NCT00618657,Phase II,"Active, not recruiting","[{'id': 1490, 'therapyName': 'Nab-paclitaxel + Carboplatin + Trastuzumab'}, {'id': 1489, 'therapyName': 'Nab-paclitaxel + Carboplatin + Bevacizumab'}]","Carboplatin+Nab-paclitaxel, Plus Trastuzumab (HER2+) or Bevacizumab (HER2-) in the Neoadjuvant Setting",71
38,NCT03101748,Phase Ib/II,Not yet recruiting,"[{'id': 3187, 'therapyName': 'Neratinib + Paclitaxel + Pertuzumab + Trastuzumab'}, {'id': 1505, 'therapyName': 'Paclitaxel + Neratinib + Doxorubicin + Cyclophosphamide'}]",3HT With Taxol for Metastatic Breast Cancer,71
39,NCT02593708,Phase I,Unknown status,"[{'id': 3187, 'therapyName': 'Neratinib + Paclitaxel + Pertuzumab + Trastuzumab'}]","Phase1 of Neratinib+Trastuzumab, Pertuzumab, Paclitaxel in Patients With Advanced Solid Tumors/HER2+",71
40,NCT03094052,Phase II,Recruiting,"[{'id': 828, 'therapyName': 'Neratinib'}, {'id': 2700, 'therapyName': 'Loperamide'}, {'id': 5906, 'therapyName': 'Crofelemer'}, {'id': 4359, 'therapyName': 'Neratinib + Trastuzumab'}]","Diarrhea Prophylaxis in Patients With HER2+ Breast Cancer Treated With Trastuzumab and Neratinib, Followed by Neratinib Monotherapy",71
41,NCT01196390,Phase III,"Active, not recruiting","[{'id': 1887, 'therapyName': 'Paclitaxel + Carboplatin + Trastuzumab'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]","Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer",71
42,NCT03199885,Phase III,Not yet recruiting,"[{'id': 1549, 'therapyName': 'Pertuzumab + Trastuzumab + Paclitaxel'}, {'id': 5956, 'therapyName': 'Paclitaxel + Pembrolizumab + Pertuzumab + Trastuzumab'}]","Paclitaxel, Trastuzumab, and Pertuzumab With or Without Pembrolizumab in Treating Patients With Metastatic Breast Cancer",71
43,NCT01008150,Phase II,Unknown status,"[{'id': 1504, 'therapyName': 'Paclitaxel + Trastuzumab + Neratinib + Doxorubicin + Cyclophosphamide'}, {'id': 1503, 'therapyName': 'Paclitaxel + Trastuzumab + Doxorubicin + Cyclophosphamide'}, {'id': 1505, 'therapyName': 'Paclitaxel + Neratinib + Doxorubicin + Cyclophosphamide'}]",Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer,71
44,NCT01774851,Phase II,Terminated,"[{'id': 1892, 'therapyName': 'Paclitaxel + Trastuzumab + MM-111'}, {'id': 1551, 'therapyName': 'Trastuzumab + Paclitaxel'}]","A Study of MM-111 and Paclitaxel With Trastuzumab in Patients HER2 Positive Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach",71
45,NCT03179904,Phase II,Recruiting,"[{'id': 5874, 'therapyName': 'Paclitaxel + Trastuzumab + TVB-2640'}]","FASN Inhibitor TVB-2640, Paclitaxel, and Trastuzumab in Treating Patients With HER2 Positive Advanced Breast Cancer",71
46,NCT02774681,Phase II,Recruiting,"[{'id': 3041, 'therapyName': 'Palbociclib + Trastuzumab'}]",Palbociclib in Treating Patients With Metastatic HER-2 Positive or Triple-Negative Breast Cancer With Brain Metastasis,71
47,NCT02318901,Phase Ib/II,"Active, not recruiting","[{'id': 1909, 'therapyName': 'Pembrolizumab + trastuzumab emtansine'}, {'id': 1908, 'therapyName': 'Pembrolizumab + Trastuzumab'}, {'id': 1910, 'therapyName': 'Pembrolizumab + Cetuximab'}]",Pembrolizumab and Monoclonal Antibody Therapy in Advanced Cancer,71
48,NCT03135171,Phase I,Recruiting,"[{'id': 5648, 'therapyName': 'Pertuzumab + Tocilizumab + Trastuzumab'}]",Trastuzumab and Pertuzumab in Combination With Tocilizumab in Subjects With Metastatic HER2 Positive Breast Cancer Resistant to Trastuzumab,71
49,NCT02003209,Phase III,"Active, not recruiting","[{'id': 759, 'therapyName': 'Goserelin'}, {'id': 1879, 'therapyName': 'Pertuzumab + Trastuzumab + Carboplatin + Docetaxel'}]","Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer",71
50,NCT02131064,Phase III,"Active, not recruiting","[{'id': 1492, 'therapyName': 'T-DM1 + Pertuzumab'}, {'id': 1879, 'therapyName': 'Pertuzumab + Trastuzumab + Carboplatin + Docetaxel'}]",A Study Comparing Kadcyla Plus Perjeta Treatment to Chemotherapy Combined With Herceptin Plus Perjeta in Patients With HER2-Positive Breast Cancer,71
51,NCT01966471,Phase III,"Active, not recruiting","[{'id': 1492, 'therapyName': 'T-DM1 + Pertuzumab'}, {'id': 1978, 'therapyName': 'Pertuzumab + Trastuzumab + Docetaxel'}, {'id': 1549, 'therapyName': 'Pertuzumab + Trastuzumab + Paclitaxel'}]",A Study of Kadcyla (Trastuzumab Emtansine) Plus Perjeta (Pertuzumab) Following Anthracyclines in Comparison With Herceptin (Trastuzumab) Plus Perjeta and a Taxane Following Anthracyclines as Adjuvant Therapy in Patients With Operable HER2-Positive Primary Breast Cancer,71
52,NCT02345772,Phase I,Terminated,"[{'id': 744, 'therapyName': 'Fulvestrant'}, {'id': 1978, 'therapyName': 'Pertuzumab + Trastuzumab + Docetaxel'}]","Neoadjuvant Hormonal Therapy Combined With Chemoimmunotherapy (Taxotere, Trastuzumab and Pertuzumab) in Patients With HER2-positive and ER-Positive Breast Cancer",71
53,NCT02379585,Phase Ib/II,Terminated,"[{'id': 1495, 'therapyName': 'Paclitaxel + Doxorubicin + Cyclophosphamide'}, {'id': 1978, 'therapyName': 'Pertuzumab + Trastuzumab + Docetaxel'}]",Study of Short-term Fasting on Neoadjuvant Chemotherapy in Patients With Newly Diagnosed Breast Cancer,71
54,NCT02402712,Phase III,"Active, not recruiting","[{'id': 1978, 'therapyName': 'Pertuzumab + Trastuzumab + Docetaxel'}]",Phase IIIb Study to Evaluate the Safety and Tolerability of Herceptin SC With Perjeta and Docetaxel in Patients With HER2-positive Advanced Breast Cancer,71
55,NCT01501487,FDA approved,"Active, not recruiting","[{'id': 1902, 'therapyName': 'Docetaxel + Doxorubicin + Cyclophosphamide'}, {'id': 1982, 'therapyName': 'Fluorouracil + Epirubicin + Cyclophosphamide'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1476, 'therapyName': 'Pegfilgrastim'}, {'id': 1881, 'therapyName': 'Docetaxel + Cyclophosphamide'}, {'id': 1977, 'therapyName': 'Doxorubicin + Cyclophosphamide'}, {'id': 1485, 'therapyName': 'Trastuzumab + Docetaxel + Carboplatin'}, {'id': 1978, 'therapyName': 'Pertuzumab + Trastuzumab + Docetaxel'}]",MINT I Multi- Institutional Neo-adjuvant Therapy MammaPrint Project I,71
56,NCT01855828,Phase II,Recruiting,"[{'id': 1549, 'therapyName': 'Pertuzumab + Trastuzumab + Paclitaxel'}, {'id': 1550, 'therapyName': 'Pertuzumab + Trastuzumab + Fluorouracil + Epirubicin + Cyclophosphamide'}]",Phase 2 Trial of Pertuzumab and Trastuzumab With Weekly Paclitaxel and Chemotherapy for HER2 Positive Breast Cancer,71
57,NCT01730833,Phase II,Recruiting,"[{'id': 1549, 'therapyName': 'Pertuzumab + Trastuzumab + Paclitaxel'}]","Pertuzumab, Trastuzumab, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With HER2-Positive Metastatic Breast Cancer",71
58,NCT01276041,Phase II,"Active, not recruiting","[{'id': 1549, 'therapyName': 'Pertuzumab + Trastuzumab + Paclitaxel'}]","Paclitaxel, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer",71
59,NCT01847001,Phase II,"Active, not recruiting","[{'id': 1912, 'therapyName': 'Propranolol'}, {'id': 1549, 'therapyName': 'Pertuzumab + Trastuzumab + Paclitaxel'}]",Study of Propranolol in Newly Diagnosed Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy,71
60,NCT01565083,Phase II,Completed,"[{'id': 1666, 'therapyName': 'Pertuzumab + Trastuzumab + Vinorelbine'}]",A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) And Vinorelbine in First Line in Patients With Metastatic or Locally Advanced HER2-Positive Breast Cancer,71
61,NCT02726399,Phase II,Recruiting,"[{'id': 3999, 'therapyName': 'Capecitabine + Cisplatin'}, {'id': 3998, 'therapyName': 'Ramucirumab + Trastuzumab'}]",Ramucirumab With Trastuzumab and Capecitabine/Cisplatin in Patients With Metastatic HER2-Positive Gastroesophageal Junction and Gastric Cancer,71
62,NCT02066532,Phase Ib/II,Recruiting,"[{'id': 1578, 'therapyName': 'Ruxolitinib + Trastuzumab'}]",Phase I/II Trial of Ruxolitinib in Combination With Trastuzumab in Metastatic HER2 Positive Breast Cancer,71
63,NCT00411788,Phase II,Completed,"[{'id': 1979, 'therapyName': 'Sirolimus + Trastuzumab'}]",A Phase II Study of Rapamycin and Trastuzumab for Patients With HER-2 Receptor Positive Metastatic Breast Cancer,71
64,NCT02336984,Phase Ib/II,"Active, not recruiting","[{'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 5222, 'therapyName': 'HER2-pulsed DC1 vaccine'}]",A Phase I/II Trial of HER-2/Neu Pulsed DC1 Vaccine Combined With Trastuzumab for Patients With DCIS,71
65,NCT02390427,Phase I,Recruiting,"[{'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 856, 'therapyName': 'Pertuzumab'}, {'id': 1016, 'therapyName': 'GDC-0032'}]",Phase Ib Dose-escalation Trial of Taselisib (GDC-0032) in Combination With Anti-HER2 Therapies in Participants With Advanced HER2+ Breast Cancer,71
66,NCT02571530,Phase I,Recruiting,"[{'id': 947, 'therapyName': 'Trastuzumab'}]",Super-selective Intra-arterial Cerebral Infusion of Trastuzumab for the Treatment of Cerebral Metastases of HER2/Neu Positive Breast Cancer,71
67,NCT02657343,Phase Ib/II,Recruiting,"[{'id': 790, 'therapyName': 'Ribociclib'}, {'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 1402, 'therapyName': 'trastuzumab emtansine'}]","An Open-Label, Phase Ib/II Clinical Trial Of Cdk 4/6 Inhibitor, Ribociclib (Lee011), In Combination With Trastuzumab Or T-Dm1 For Advanced/Metastatic Her2-Positive Breast Cancer.",71
68,NCT01875666,Phase I,"Active, not recruiting","[{'id': 1414, 'therapyName': 'Trastuzumab + Lapatinib'}, {'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 856, 'therapyName': 'Pertuzumab'}, {'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}]","Defining the HER2 Positive (+) Breast Cancer Kinome Response to Trastuzumab, Pertuzumab, Combination Trastuzumab +Pertuzumab, or Combination Trastuzumab + Lapatinib",71
69,NCT02492711,Phase III,Recruiting,"[{'id': 1685, 'therapyName': 'Vinorelbine'}, {'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 808, 'therapyName': 'MGAH22'}]",Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer,71
70,NCT01358877,Phase III,"Active, not recruiting","[{'id': 856, 'therapyName': 'Pertuzumab'}, {'id': 947, 'therapyName': 'Trastuzumab'}]",A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer,71
71,NCT01367002,Phase II,"Active, not recruiting","[{'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]",Evaluation of Carboplatin/Paclitaxel With and Without Trastuzumab (Herceptin) in Uterine Serous Cancer,71
72,NCT02213042,Phase II,"Active, not recruiting","[{'id': 1414, 'therapyName': 'Trastuzumab + Lapatinib'}, {'id': 947, 'therapyName': 'Trastuzumab'}]",Evaluation of Biomarkers Associated With Response to Subsequent Therapies in Subjects With HER2-Positive Metastatic Breast Cancer,71
73,NCT02229149,Phase II,"Active, not recruiting","[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}, {'id': 619, 'therapyName': 'Abraxane'}, {'id': 1685, 'therapyName': 'Vinorelbine'}, {'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 1105, 'therapyName': 'Capecitabine'}]","Phase 2 Study of Standard Chemotherapy With Trastuzumab, Plus or Minus Pertuzumab, for Pre-treated Metastatic Breast Cancer",71
74,NCT02286843,Phase I,Recruiting,"[{'id': 947, 'therapyName': 'Trastuzumab'}]","Can HER2 Targeted 89Zr-trastuzumab PET/CT Identify Unsuspected HER2 Positive Breast Cancer Metastases, Which Are Amenable to HER2 Targeted Therapy?",71
75,NCT02414646,Phase II,Recruiting,"[{'id': 947, 'therapyName': 'Trastuzumab'}]",Trastuzumab Emtansine in Treating Older Patients With Human Epidermal Growth Factor Receptor 2-Positive Stage I-III Breast Cancer,71
76,NCT01772472,Phase III,"Active, not recruiting","[{'id': 1402, 'therapyName': 'trastuzumab emtansine'}, {'id': 947, 'therapyName': 'Trastuzumab'}]",A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE),71
77,NCT01106898,Phase II,Unknown status,"[{'id': 1980, 'therapyName': 'Cyclophosphamide + Paclitaxel'}, {'id': 947, 'therapyName': 'Trastuzumab'}]",Cyclophosphamide and Paclitaxel With or Without Trastuzumab in Treating Women With Stage I or Stage II Breast Cancer Who Have Undergone Surgery,71
78,NCT01480583,Phase II,Completed,"[{'id': 947, 'therapyName': 'Trastuzumab'}]",GRN1005 Alone or in Combination With Trastuzumab in Breast Cancer Patients With Brain Metastases,71
79,NCT01750073,Phase II,Recruiting,"[{'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 1980, 'therapyName': 'Cyclophosphamide + Paclitaxel'}]",Paclitaxel and Cyclophosphamide With or Without Trastuzumab Before Surgery in Treating Patients With Previously Untreated Stage I-III Breast Cancer,71
80,NCT01325207,Phase Ib/II,"Active, not recruiting","[{'id': 947, 'therapyName': 'Trastuzumab'}]",Intrathecal Trastuzumab for Leptomeningeal Metastases in HER2+ Breast Cancer,71
81,NCT02675231,Phase II,Recruiting,"[{'id': 802, 'therapyName': 'Abemaciclib'}, {'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 744, 'therapyName': 'Fulvestrant'}]","A Study of Abemaciclib (LY2835219) in Women With HR+, HER2+ Locally Advanced or Metastatic Breast Cancer",71
82,NCT00968968,Phase III,"Active, not recruiting","[{'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 1414, 'therapyName': 'Trastuzumab + Lapatinib'}]",Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone,71
83,NCT00574587,Phase Ib/II,Unknown status,"[{'id': 1983, 'therapyName': 'vorinostat + Paclitaxel'}, {'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 1977, 'therapyName': 'Doxorubicin + Cyclophosphamide'}]","Trial for Locally Advanced Her2 Positive Breast Cancer Using Paclitaxel, Trastuzumab, Doxorubicin and Cyclophasmide on a Weekly Basis",71
84,NCT03304080,,Not yet recruiting,"[{'id': 633, 'therapyName': 'Anastrozole'}, {'id': 856, 'therapyName': 'Pertuzumab'}, {'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 850, 'therapyName': 'Palbociclib'}]","Anastrozole, Palbociclib, Trastuzumab and Pertuzumab in Her-positive, Her2-positive Metastatic Breast",71
85,NCT01904903,Phase II,Recruiting,"[{'id': 856, 'therapyName': 'Pertuzumab'}, {'id': 1402, 'therapyName': 'trastuzumab emtansine'}, {'id': 947, 'therapyName': 'Trastuzumab'}]",Cardiac Safety Study in Patients With HER2+ Breast Cancer (SAFE-HEaRt),71
86,NCT02297698,Phase II,Recruiting,"[{'id': 1873, 'therapyName': 'Sargramostim'}, {'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 3766, 'therapyName': 'E75'}]",Phase II Trial of Combination Immunotherapy With NeuVax and Trastuzumab in High-risk HER2+ Breast Cancer Patients,71
87,NCT01912963,Phase II,"Active, not recruiting","[{'id': 728, 'therapyName': 'Eribulin'}, {'id': 856, 'therapyName': 'Pertuzumab'}, {'id': 947, 'therapyName': 'Trastuzumab'}]","Phase II Study of Eribulin Mesylate, Trastuzumab, and Pertuzumab in Women With Metastatic, Unresectable Locally Advanced, or Locally Recurrent HER2-Positive Breast Cancer",71
88,NCT02947685,Phase III,Recruiting,"[{'id': 744, 'therapyName': 'Fulvestrant'}, {'id': 856, 'therapyName': 'Pertuzumab'}, {'id': 794, 'therapyName': 'Letrozole'}, {'id': 633, 'therapyName': 'Anastrozole'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 947, 'therapyName': 'Trastuzumab'}]","Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer (PATINA)",71
89,NCT00796978,Phase II,Unknown status,"[{'id': 947, 'therapyName': 'Trastuzumab'}]",Trastuzumab in Treating Older Women With Early-Stage Breast Cancer,71
90,NCT01779050,Phase II,"Active, not recruiting","[{'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1087, 'therapyName': 'Epirubicin + Cyclophosphamide'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1982, 'therapyName': 'Fluorouracil + Epirubicin + Cyclophosphamide'}, {'id': 1834, 'therapyName': 'Docetaxel + Carboplatin'}, {'id': 1881, 'therapyName': 'Docetaxel + Cyclophosphamide'}]",Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer Patients With ERBB2 Expressing Disseminated Tumor Cells,71
91,NCT00912340,Phase II,"Active, not recruiting","[{'id': 735, 'therapyName': 'Everolimus'}, {'id': 947, 'therapyName': 'Trastuzumab'}]",Randomized Phase II Trial of Trastuzumab or EVEROLIMUS in Hormone-refractory Metastatic Breast Cancer,71
92,NCT02260531,Phase II,Recruiting,"[{'id': 998, 'therapyName': 'cabozantinib'}, {'id': 947, 'therapyName': 'Trastuzumab'}]",Cabozantinib + / - Trastuzumab In Breast Cancer Patients w/ Brain Metastases,71
93,NCT00971737,Phase II,Unknown status,"[{'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}]",Cyclophosphamide and Vaccine Therapy With or Without Trastuzumab in Treating Patients With Metastatic Breast Cancer,71
94,NCT01570036,Phase II,Recruiting,"[{'id': 3766, 'therapyName': 'E75'}, {'id': 1873, 'therapyName': 'Sargramostim'}, {'id': 947, 'therapyName': 'Trastuzumab'}]",Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax,71
95,NCT02213289,Phase Ib/II,Recruiting,"[{'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 1913, 'therapyName': 'FOLTAX'}, {'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 1315, 'therapyName': 'FOLFIRI'}, {'id': 629, 'therapyName': 'AMG102'}]",PANGEA-IMBBP: Personalized Antibodies for Gastro-Esophageal Adenocarcinoma - A 1st Pilot Metastatic Trial of Biologics Beyond Progression,71
96,NCT01928290,Phase II,Recruiting,"[{'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 1903, 'therapyName': 'FOLFIRINOX'}]","Combination Chemotherapy in Treating Patients With Advanced Stomach, Gastroesophageal, or Esophageal Cancer",71
97,NCT02465060,Phase II,Recruiting,"[{'id': 660, 'therapyName': 'AZD9291'}, {'id': 3, 'therapyName': 'Dabrafenib'}, {'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 2, 'therapyName': 'Trametinib'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 623, 'therapyName': 'Afatinib'}, {'id': 654, 'therapyName': 'AZD4547'}, {'id': 958, 'therapyName': 'VS-6063'}, {'id': 765, 'therapyName': 'GSK2636771'}]",NCI-MATCH Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas,71
98,NCT01566721,Phase III,"Active, not recruiting","[{'id': 947, 'therapyName': 'Trastuzumab'}]",A Safety and Tolerability Study of Assisted- and Self-Administered Subcutaneous Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With Early HER2-Positive Breast Cancer (SafeHer),71
99,NCT01491737,Phase II,"Active, not recruiting","[{'id': 633, 'therapyName': 'Anastrozole'}, {'id': 794, 'therapyName': 'Letrozole'}, {'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}]","A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Patients With Hormone Receptor-Positive, Metastatic HER2-positive Breast Cancer",71
100,NCT01160211,Phase III,"Active, not recruiting","[{'id': 1414, 'therapyName': 'Trastuzumab + Lapatinib'}, {'id': 794, 'therapyName': 'Letrozole'}, {'id': 633, 'therapyName': 'Anastrozole'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 738, 'therapyName': 'Exemestane'}]","A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer",71
101,NCT01191697,Phase II,"Active, not recruiting","[{'id': 1596, 'therapyName': 'Trastuzumab + Bevacizumab'}, {'id': 1597, 'therapyName': 'Capecitabine + Oxaliplatin'}]","CAPOX, Bevacizumab and Trastuzumab for Patients With HER2-Positive Metastatic Esophagogastric Cancer",71
102,NCT01959490,Phase II,Completed,"[{'id': 1486, 'therapyName': 'Bevacizumab + Doxorubicin + Cyclophosphamide + Paclitaxel '}, {'id': 1485, 'therapyName': 'Trastuzumab + Docetaxel + Carboplatin'}]",Trastuzumab or Bevacizumab With Combination Chemotherapy in Treating Patients With Stage II-III Breast Cancer,71
103,NCT02187744,Phase III,Completed,"[{'id': 1485, 'therapyName': 'Trastuzumab + Docetaxel + Carboplatin'}]",A Study Of PF-05280014 Or Trastuzumab Plus Taxotere&#174; And Carboplatin In HER2 Positive Breast Cancer In The Neoadjuvant Setting (REFLECTIONS B327-04),71
104,NCT01305941,Phase II,"Active, not recruiting","[{'id': 1411, 'therapyName': 'Trastuzumab + Everolimus + Vinorelbine'}]","A Study Of Everolimus, Trastuzumab And Vinorelbine In HER2-Positive Breast Cancer Brain Metastases",71
105,NCT02073487,Phase II,Recruiting,"[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1583, 'therapyName': 'Trastuzumab emtansine + Lapatinib'}, {'id': 1414, 'therapyName': 'Trastuzumab + Lapatinib'}, {'id': 619, 'therapyName': 'Abraxane'}]",Neoadjuvant TDM1 With Lapatinib and Abraxane Compared With Trastuzumab With Lapatinib and Paclitaxel,71
106,NCT00790816,Phase I,Completed,"[{'id': 1410, 'therapyName': 'Lapatinib + Paclitaxel'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 1414, 'therapyName': 'Trastuzumab + Lapatinib'}, {'id': 1399, 'therapyName': 'Lapatinib + Capecitabine'}, {'id': 1497, 'therapyName': 'Lapatinib + Letrozole'}, {'id': 1498, 'therapyName': 'Lapatinib + Oxaliplatin + Capecitabine'}, {'id': 1499, 'therapyName': 'Lapatinib + Gemcitabine'}, {'id': 1500, 'therapyName': 'Lapatinib + Docetaxel'}, {'id': 1501, 'therapyName': 'Lapatinib + Oxaliplatin + Leucovorin + Fluorouracil'}, {'id': 1502, 'therapyName': 'Lapatinib + Irinotecan + Leucovorin + Fluorouracil'}]",Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents,71
107,NCT01273610,Phase II,"Active, not recruiting","[{'id': 1414, 'therapyName': 'Trastuzumab + Lapatinib'}]",Tolerability of the Combination of Lapatinib and Trastuzumab in Adults Age 60 or Older With HER2 Positive Metastatic Breast Cancer,71
108,NCT01901146,Phase III,Completed,"[{'id': 1087, 'therapyName': 'Epirubicin + Cyclophosphamide'}, {'id': 1551, 'therapyName': 'Trastuzumab + Paclitaxel'}]",Efficacy and Safety Study of ABP 980 Compared With Trastuzumab in Subjects With HER2 Positive Early Breast Cancer (Lilac),71
109,NCT01897441,Phase I,Recruiting,"[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1551, 'therapyName': 'Trastuzumab + Paclitaxel'}, {'id': 1977, 'therapyName': 'Doxorubicin + Cyclophosphamide'}]",Chemotherapy Before Surgery and Tissue Sample Collection in Patients With Stage IIA-IIIC Breast Cancer,71
110,NCT01989676,Phase III,"Active, not recruiting","[{'id': 1551, 'therapyName': 'Trastuzumab + Paclitaxel'}]",A Study Of PF-05280014 [Trastuzumab-Pfizer] Or Herceptin® [Trastuzumab-EU] Plus Paclitaxel In HER2 Positive First Line Metastatic Breast Cancer Treatment (REFLECTIONS B327-02),71
111,NCT01853748,Phase II,Recruiting,"[{'id': 1551, 'therapyName': 'Trastuzumab + Paclitaxel'}, {'id': 1402, 'therapyName': 'trastuzumab emtansine'}]",T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial),71
112,NCT02297230,Phase Ib/II,Completed,"[{'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1551, 'therapyName': 'Trastuzumab + Paclitaxel'}]",Locally Advanced Breast Cancer: Individualized Treatment Based On Tumor Molecular Characteristics,71
113,NCT02536339,Phase II,"Active, not recruiting","[{'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}]",Pertuzumab With High-Dose Trastuzumab in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (MBC) With Central Nervous System (CNS) Progression Post-Radiotherapy,71
114,NCT01796197,Phase II,"Active, not recruiting","[{'id': 1977, 'therapyName': 'Doxorubicin + Cyclophosphamide'}, {'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]",Paclitaxel + Trastuzumab + Pertuzumab as Pre-Op for Inflammatory BrCa,71
115,NCT02436993,Phase II,Recruiting,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]",Breast Cancer Treatment Using Weekly Carboplatin + Paclitaxel With Pertuzumab + Trastuzumab (HER2+) or Bevacizumab (HER2-) in the Neoadjuvant Setting,71
116,NCT02689921,Phase II,Recruiting,"[{'id': 633, 'therapyName': 'Anastrozole'}, {'id': 794, 'therapyName': 'Letrozole'}, {'id': 795, 'therapyName': 'Leuprolide'}, {'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}, {'id': 738, 'therapyName': 'Exemestane'}]",NEOADjuvant Aromatase Inhibitor and Pertuzumab/Trastuzumab for Women With Breast Cancer (NEOADAPT),71
117,NCT02091141,Phase II,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 698, 'therapyName': 'Alectinib'}, {'id': 1657, 'therapyName': 'Vemurafenib + Cobimetinib'}, {'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 1201, 'therapyName': 'Atezolizumab'}]","My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors",71
118,NCT01937117,Phase II,"Active, not recruiting","[{'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}]",Pertuzumab and Trastuzumab as Neoadjuvant Treatment in Patients With HER2-Positive Breast Cancer,71
119,NCT02598427,Phase I,Recruiting,"[{'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}]",Intrathecal Pertuzumab and Trastuzumab in Patients With New Untreated Asymptomatic or Low Symptomatic Brain Metastasis in HER2 Positive Breast Cancer,71
120,NCT02132949,Phase II,"Active, not recruiting","[{'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}, {'id': 1495, 'therapyName': 'Paclitaxel + Doxorubicin + Cyclophosphamide'}, {'id': 1895, 'therapyName': 'Cyclophosphamide + Fluorouracil + Docetaxel + Epirubicin  '}]","A Study Evaluating Perjeta (Pertuzumab) Combined With Herceptin (Trastuzumab) and Standard Anthracycline-based Chemotherapy in Patients With HER2-positive Locally Advanced, Inflammatory, or Early-stage Breast Cancer.",71
121,NCT02693535,Phase II,Recruiting,"[{'id': 1657, 'therapyName': 'Vemurafenib + Cobimetinib'}, {'id': 890, 'therapyName': 'Regorafenib'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 690, 'therapyName': 'Bosutinib'}, {'id': 850, 'therapyName': 'Palbociclib'}, {'id': 694, 'therapyName': 'Cetuximab'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 837, 'therapyName': 'Olaparib'}, {'id': 4, 'therapyName': 'Erlotinib'}]",TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer,71
122,NCT01572038,Phase III,"Active, not recruiting","[{'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}, {'id': 619, 'therapyName': 'Abraxane'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]",A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) and A Taxane in First-Line Treatment in Patients With HER2-Positive Advanced Breast Cancer (PERUSE),71
123,NCT02000596,Phase II,Terminated,"[{'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}, {'id': 1911, 'therapyName': 'Anastrozole  + Fulvestrant'}]",Trastuzmab and Pertuzumab Alone or in Combination With Hormonal Therapy or Chemotherapy With Eribulin in Women Aged 60 and Over With HER2/Neu Overexpressed Locally Advanced or MBC,71
124,NCT02827877,Phase I,Recruiting,"[{'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}]",Copper (Cu) 64-DOTA-Trastuzumab PET in Predicting Response to Treatment With Trastuzumab and Pertuzumab Before Surgery in Patients With HER2 Positive Breast Cancer,71
125,NCT02774421,Phase I,Recruiting,"[{'id': 1891, 'therapyName': 'Trastuzumab + Sargramostim'}]",Pilot Study of the Effect of Trastuzumab and GM-CSF on Children With Recurrent Ependymoma,71
126,NCT00781612,Phase II,Recruiting,"[{'id': 5471, 'therapyName': 'Trastuzumab + trastuzumab emtansine'}, {'id': 5470, 'therapyName': 'Paclitaxel + trastuzumab emtansine'}, {'id': 1402, 'therapyName': 'trastuzumab emtansine'}, {'id': 3930, 'therapyName': 'Docetaxel + T-DM1'}, {'id': 1976, 'therapyName': 'trastuzumab emtansine + Capecitabine'}, {'id': 1492, 'therapyName': 'T-DM1 + Pertuzumab'}]",A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies,71
127,NCT02154529,Phase Ib/II,Terminated,"[{'id': 1880, 'therapyName': 'XL647 + Trastuzumab'}]",Study of the Combination of KD019 and Trastuzumab in Subjects With HER2-Positive Metastatic Breast Cancer,71
0,NCT01983501,Phase I,"Active, not recruiting","[{'id': 1573, 'therapyName': 'ARRY-380 + Trastuzumab emtansine'}]",A Phase 1b Study of ONT-380 Combined With Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2+ Breast Cancer,7252
1,NCT02038010,Phase I,"Active, not recruiting","[{'id': 1575, 'therapyName': 'BYL719 + Trastuzumab emtansine'}]",BYL719 + T-DM1 in HER2(+) Metastatic Breast Cancer Pts Who Progress on Prior Trastuzumab & Taxane Tx,7252
2,NCT00781612,Phase II,Recruiting,"[{'id': 5471, 'therapyName': 'Trastuzumab + trastuzumab emtansine'}, {'id': 5470, 'therapyName': 'Paclitaxel + trastuzumab emtansine'}, {'id': 1402, 'therapyName': 'trastuzumab emtansine'}, {'id': 3930, 'therapyName': 'Docetaxel + T-DM1'}, {'id': 1976, 'therapyName': 'trastuzumab emtansine + Capecitabine'}, {'id': 1492, 'therapyName': 'T-DM1 + Pertuzumab'}]",A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies,7252
3,NCT02236000,Phase Ib/II,Recruiting,"[{'id': 1906, 'therapyName': 'Neratinib + trastuzumab emtansine'}]",A Dose-Escalation Study Evaluating the Combination of Trastuzumab Emtansine (T-DM1) With Neratinib in Women With Metastatic HER2-Positive Breast Cancer,7252
4,NCT01976169,Phase I,Recruiting,"[{'id': 1731, 'therapyName': 'PD-0332991 + T-DM1'}]",Phase 1b Study of PD-0332991 in Combination With T-DM1(Trastuzumab-DM1),7252
5,NCT03032107,Phase I,Recruiting,"[{'id': 1909, 'therapyName': 'Pembrolizumab + trastuzumab emtansine'}]",A Study Of Pembrolizumab In Combination With Trastuzumab-DM1,7252
6,NCT02318901,Phase Ib/II,"Active, not recruiting","[{'id': 1909, 'therapyName': 'Pembrolizumab + trastuzumab emtansine'}, {'id': 1908, 'therapyName': 'Pembrolizumab + Trastuzumab'}, {'id': 1910, 'therapyName': 'Pembrolizumab + Cetuximab'}]",Pembrolizumab and Monoclonal Antibody Therapy in Advanced Cancer,7252
7,NCT02073916,Phase I,Recruiting,"[{'id': 1907, 'therapyName': 'T-DM1 + Lapatinib + Abraxane'}]",TDM1 With Abraxane and Lapatinib for Metastatic HER2 Positive Breast Cancer,7252
8,NCT02131064,Phase III,"Active, not recruiting","[{'id': 1492, 'therapyName': 'T-DM1 + Pertuzumab'}, {'id': 1879, 'therapyName': 'Pertuzumab + Trastuzumab + Carboplatin + Docetaxel'}]",A Study Comparing Kadcyla Plus Perjeta Treatment to Chemotherapy Combined With Herceptin Plus Perjeta in Patients With HER2-Positive Breast Cancer,7252
9,NCT01966471,Phase III,"Active, not recruiting","[{'id': 1492, 'therapyName': 'T-DM1 + Pertuzumab'}, {'id': 1978, 'therapyName': 'Pertuzumab + Trastuzumab + Docetaxel'}, {'id': 1549, 'therapyName': 'Pertuzumab + Trastuzumab + Paclitaxel'}]",A Study of Kadcyla (Trastuzumab Emtansine) Plus Perjeta (Pertuzumab) Following Anthracyclines in Comparison With Herceptin (Trastuzumab) Plus Perjeta and a Taxane Following Anthracyclines as Adjuvant Therapy in Patients With Operable HER2-Positive Primary Breast Cancer,7252
10,NCT02326974,Phase II,Recruiting,"[{'id': 1492, 'therapyName': 'T-DM1 + Pertuzumab'}]",T-DM1+Pertuzumab in Pre-OP Early-Stage HER2+ BRCA,7252
11,NCT01042379,Phase II,Recruiting,"[{'id': 1218, 'therapyName': 'Trebananib'}, {'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}, {'id': 746, 'therapyName': 'Ganitumab'}, {'id': 1495, 'therapyName': 'Paclitaxel + Doxorubicin + Cyclophosphamide'}, {'id': 1494, 'therapyName': 'MK2206 + Trastuzumab'}, {'id': 1493, 'therapyName': 'Trebananib + Trastuzumab'}, {'id': 1492, 'therapyName': 'T-DM1 + Pertuzumab'}]",I-SPY 2 TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer,7252
12,NCT03190967,Phase Ib/II,Recruiting,"[{'id': 1402, 'therapyName': 'trastuzumab emtansine'}, {'id': 5932, 'therapyName': 'Temozolomide + Trastuzumab emtansine'}]",T-DM1 Alone Versus T-DM1 and Metronomic Temozolomide in Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases Following Stereotactic Radiosurgery,7252
13,NCT01816035,Phase I,Completed,"[{'id': 1402, 'therapyName': 'trastuzumab emtansine'}]",Ado-Trastuzumab Emtansine in Treating Patients With HER2-Positive Metastatic or Locally Advanced Breast Cancer That Cannot Be Removed by Surgery,7252
14,NCT02675829,Phase II,Recruiting,"[{'id': 1402, 'therapyName': 'trastuzumab emtansine'}]",Trial of Ado-Trastuzumab Emtansine for Patients With HER2 Amplified or Mutant Cancers,7252
15,NCT01641939,Phase III,Terminated,"[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1402, 'therapyName': 'trastuzumab emtansine'}]",A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer,7252
16,NCT02657343,Phase Ib/II,Recruiting,"[{'id': 790, 'therapyName': 'Ribociclib'}, {'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 1402, 'therapyName': 'trastuzumab emtansine'}]","An Open-Label, Phase Ib/II Clinical Trial Of Cdk 4/6 Inhibitor, Ribociclib (Lee011), In Combination With Trastuzumab Or T-Dm1 For Advanced/Metastatic Her2-Positive Breast Cancer.",7252
17,NCT02725541,Phase II,Withdrawn,"[{'id': 1402, 'therapyName': 'trastuzumab emtansine'}]",Trial of Neoadjuvant Trastuzumab Emtansine in Patients With HER2-Equivocal Breast Cancer,7252
18,NCT01904903,Phase II,Recruiting,"[{'id': 856, 'therapyName': 'Pertuzumab'}, {'id': 1402, 'therapyName': 'trastuzumab emtansine'}, {'id': 947, 'therapyName': 'Trastuzumab'}]",Cardiac Safety Study in Patients With HER2+ Breast Cancer (SAFE-HEaRt),7252
19,NCT01702571,Phase III,"Active, not recruiting","[{'id': 1402, 'therapyName': 'trastuzumab emtansine'}]",A Study of Kadcyla (Trastuzumab Emtansine) in Patients With HER2 Positive Breast Cancer Who Have Received Prior Anti-HER2 And Chemotherapy-based Treatment,7252
20,NCT01513083,Phase I,Completed,"[{'id': 1402, 'therapyName': 'trastuzumab emtansine'}]",A Study of Trastuzumab Emtansine in Patients With HER2-Positive Metastatic Breast Cancer and Normal or Reduced Hepatic Function,7252
21,NCT01772472,Phase III,"Active, not recruiting","[{'id': 1402, 'therapyName': 'trastuzumab emtansine'}, {'id': 947, 'therapyName': 'Trastuzumab'}]",A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE),7252
22,NCT01853748,Phase II,Recruiting,"[{'id': 1551, 'therapyName': 'Trastuzumab + Paclitaxel'}, {'id': 1402, 'therapyName': 'trastuzumab emtansine'}]",T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial),7252
23,NCT02289833,Phase II,"Active, not recruiting","[{'id': 1402, 'therapyName': 'trastuzumab emtansine'}]","A Study of Trastuzumab Emtansine in Patients With HER2 IHC-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer",7252
24,NCT01702558,Phase II,Completed,"[{'id': 1402, 'therapyName': 'trastuzumab emtansine'}, {'id': 1976, 'therapyName': 'trastuzumab emtansine + Capecitabine'}]",A Combination Study of Kadcyla (Trastuzumab Emtansine) and Capecitabine in Patients With HER2-Positive Metastatic Breast Cancer and Patients With HER2-Positive Locally Advanced / Metastatic Gastric Cancer,7252
25,NCT02073487,Phase II,Recruiting,"[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1583, 'therapyName': 'Trastuzumab emtansine + Lapatinib'}, {'id': 1414, 'therapyName': 'Trastuzumab + Lapatinib'}, {'id': 619, 'therapyName': 'Abraxane'}]",Neoadjuvant TDM1 With Lapatinib and Abraxane Compared With Trastuzumab With Lapatinib and Paclitaxel,7252
26,NCT02658084,Phase Ib/II,Recruiting,"[{'id': 3429, 'therapyName': 'Trastuzumab emtansine + Vinorelbine'}]",Vinorelbine With Trastuzumab Emtansine in Pre-Treated HER2-Positive Metastatic Breast Cancer,7252
0,NCT01806064,Phase I,"Active, not recruiting","[{'id': 1243, 'therapyName': 'Bevacizumab + TRC105'}]", A Phase 1B Dose-escalation Study of TRC105 in Combination With Axitinib in Patients With Advanced Renal Cell Carcinoma,7227
1,NCT02664961,Phase II,Recruiting,"[{'id': 1243, 'therapyName': 'Bevacizumab + TRC105'}]",Study of TRC105 and Bevacizumab in Patients With Refractory Gestational Trophoblastic Neoplasia (GTN),7227
2,NCT01727089,Phase II,Completed,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1243, 'therapyName': 'Bevacizumab + TRC105'}]", Bevacizumab With or Without Monoclonal Antibody Therapy in Treating Patients With Metastatic Kidney Cancer,7227
3,NCT01306058,Phase Ib/II,"Active, not recruiting","[{'id': 2389, 'therapyName': 'Sorafenib + TRC105'}]",Sorafenib and TRC105 in Hepatocellular Cancer,7227
4,NCT02560779,Phase Ib/II,Recruiting,"[{'id': 2389, 'therapyName': 'Sorafenib + TRC105'}]",Trial of TRC105 and Sorafenib in Patients With HCC,7227
5,NCT02520063,Phase Ib/II,Recruiting,"[{'id': 794, 'therapyName': 'Letrozole'}, {'id': 1242, 'therapyName': 'TRC105'}, {'id': 735, 'therapyName': 'Everolimus'}]","Preoperative Combination of Letrozole, Everolimus, and TRC105 in Postmenopausal Hormone-Receptor Positive and Her2 Negative Breast Cancer",7227
6,NCT01648348,Phase Ib/II,"Active, not recruiting","[{'id': 1242, 'therapyName': 'TRC105'}, {'id': 667, 'therapyName': 'Bevacizumab'}]",Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme,7227
7,NCT02429843,Phase I,Recruiting,"[{'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1242, 'therapyName': 'TRC105'}]",A Study of TRC105 in Combination With Paclitaxel/Carboplatin and Bevacizumab in Non-Squamous Cell Lung Cancer,7227
8,NCT01975519,Phase I,"Active, not recruiting","[{'id': 1431, 'therapyName': 'TRC105 + Pazopanib'}]",A Phase 1B Dose-escalation Study of TRC105 in Combination With Pazopanib in Patients With Advanced Soft Tissue Sarcoma,7227
9,NCT02979899,Phase III,Recruiting,"[{'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1431, 'therapyName': 'TRC105 + Pazopanib'}]",A RANDOMIZED PHASE 3 TRIAL OF TRC105 AND PAZOPANIB VERSUS PAZOPANIB ALONE IN PATIENTS WITH ADVANCED ANGIOSARCOMA (TAPPAS),7227
0,NCT02987829,Phase Ib/II,Recruiting,"[{'id': 5770, 'therapyName': 'TRC253'}]","A Phase 1/2A Study of TRC253, an Androgen Receptor Antagonist, in Metastatic Castration-resistant Prostate Cancer Patients",8789
0,NCT03239145,Phase I,Recruiting,"[{'id': 6102, 'therapyName': 'Pembrolizumab + Trebananib'}]",Phase Ib Study to Test the Safety and Potential Synergy of Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor,7222
1,NCT01042379,Phase II,Recruiting,"[{'id': 1218, 'therapyName': 'Trebananib'}, {'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}, {'id': 746, 'therapyName': 'Ganitumab'}, {'id': 1495, 'therapyName': 'Paclitaxel + Doxorubicin + Cyclophosphamide'}, {'id': 1494, 'therapyName': 'MK2206 + Trastuzumab'}, {'id': 1493, 'therapyName': 'Trebananib + Trastuzumab'}, {'id': 1492, 'therapyName': 'T-DM1 + Pertuzumab'}]",I-SPY 2 TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer,7222
2,NCT01553188,Phase II,"Active, not recruiting","[{'id': 2188, 'therapyName': 'Prednisone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 1218, 'therapyName': 'Trebananib'}]",AMG 386 and Abiraterone for Advanced Prostate Cancer,7222
3,NCT01664182,Phase II,"Active, not recruiting","[{'id': 1223, 'therapyName': 'Trebananib + Sunitinib'}, {'id': 1220, 'therapyName': 'Trebananib + Pazopanib'}, {'id': 1221, 'therapyName': 'Trebananib + Sorafenib'}, {'id': 1218, 'therapyName': 'Trebananib'}, {'id': 1219, 'therapyName': 'Trebananib + Bevacizumab'}]","Trebananib With or Without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Treating Patients With Advanced Kidney Cancer",7222
4,NCT01290263,Phase Ib/II,Completed,"[{'id': 1219, 'therapyName': 'Trebananib + Bevacizumab'}, {'id': 1218, 'therapyName': 'Trebananib'}]",Amgen 386 for Recurrent Glioblastoma,7222
5,NCT01493505,Phase III,Terminated,"[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1218, 'therapyName': 'Trebananib'}]", TRINOVA-3,7222
0,NCT02754856,Phase I,Recruiting,"[{'id': 4097, 'therapyName': 'Bevacizumab + MEDI4736 + Tremelimumab + FOLFOX'}]",Tremelimumab (Anti-CTLA-4) Plus MEDI4736 (Anti-PD-L1) in Resectable Colorectal Cancer Liver Metastases.,7307
1,NCT03164772,Phase Ib/II,Not yet recruiting,"[{'id': 5818, 'therapyName': 'BI 1361849 + Durvalumab + Tremelimumab'}]",Phase 1/2 Study of Combination Immunotherapy and mRNA Vaccine in Subjects With NSCLC,7307
2,NCT03084471,Phase III,Recruiting,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}, {'id': 1356, 'therapyName': 'Durvalumab'}]","An Open-Label, Multi-Centre, Study to Assess the Safety of Fixed-Dose Durvalumab + Tremelimumab Combination Therapy or Durvalumab Monotherapy in Advanced Solid Malignancies. (STRONG)",7307
3,NCT03164616,Phase III,Recruiting,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}, {'id': 1857, 'therapyName': 'Cisplatin + Pemetrexed'}, {'id': 1602, 'therapyName': 'Carboplatin + Pemetrexed'}, {'id': 1467, 'therapyName': 'Gemcitabine + Cisplatin'}, {'id': 2667, 'therapyName': 'Carboplatin + Gemcitabine'}, {'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 2634, 'therapyName': 'Carboplatin + nab-paclitaxel'}]",Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON). (POSEIDON),7307
4,NCT03298451,Phase III,Not yet recruiting,"[{'id': 920, 'therapyName': 'Sorafenib'}, {'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}, {'id': 1356, 'therapyName': 'Durvalumab'}]",Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Unresectable Hepatocellular Carcinoma,7307
5,NCT02000947,Phase Ib/II,"Active, not recruiting","[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}]",A Phase 1b Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Non-small Cell Lung Cancer,7307
6,NCT02938793,Phase II,Recruiting,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}]",Durvalumab in Combination With Tremelimumab in Subjects With Advanced Rare Solid Tumors,7307
7,NCT02812420,Phase I,Recruiting,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}]","Pre-Surgical Study Evaluating Anti-PD-L1 Antibody (Durvalumab) Plus Anti-CTLA-4 (Tremelimumab) in Patients With Muscle-Invasive, High-Risk Urothelial Carcinoma Who Are Ineligible for Cisplatin-based Neoadjuvant Chemotherapy",7307
8,NCT03130764,Phase II,Not yet recruiting,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}]",Durvalumab and Tremelimumab for Adjuvant Therapy of Resected NSCLC,7307
9,NCT03005002,Phase I,Recruiting,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}]",Durvalumab and Tremelimumab in Treating Patients With Microsatellite Stable Metastatic Colorectal Cancer to the Liver,7307
10,NCT03150836,Phase II,Not yet recruiting,"[{'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}]","Radiation Therapy and Durvalumab, With or Without Tremelimumab, in Patients With Bladder Cancer",7307
11,NCT03158064,Phase II,Recruiting,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}]","Evaluating Immune Therapy, Duravalumab (MEDI4736) With Tremelimumab for Relapsed/Refractory Germ Cell Tumors",7307
12,NCT03277482,Phase I,Not yet recruiting,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}, {'id': 1356, 'therapyName': 'Durvalumab'}]","Durvalumab, Tremelimumab + Radiotherapy in Gynecologic Cancer",7307
13,NCT02542293,Phase III,Recruiting,"[{'id': 1467, 'therapyName': 'Gemcitabine + Cisplatin'}, {'id': 2667, 'therapyName': 'Carboplatin + Gemcitabine'}, {'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 1857, 'therapyName': 'Cisplatin + Pemetrexed'}, {'id': 1602, 'therapyName': 'Carboplatin + Pemetrexed'}]",Study of 1st Line Therapy Study of MEDI4736 With Tremelimumab Versus SoC in Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE).,7307
14,NCT02868632,Phase I,Recruiting,"[{'id': 1652, 'therapyName': 'Tremelimumab'}, {'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}, {'id': 1356, 'therapyName': 'Durvalumab'}]","Study of Immune Checkpoint Inhibition With Radiation Therapy in Unresectable, Non-metastatic Pancreatic Cancer",7307
15,NCT02879162,Phase II,Recruiting,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}]",Durvalumab and Tremelimumab in Patients With Advanced Rare Tumours,7307
16,NCT03122509,Phase II,Recruiting,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}]","A Clinical Trial of Durvalumab and Tremelimumab, Administered With Radiation Therapy or Ablation in Patients With Colorectal Cancer",7307
17,NCT02879318,Phase II,Recruiting,"[{'id': 1779, 'therapyName': 'Nab-paclitaxel + Gemcitabine'}, {'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}]","Gemcitabine and Nab-Paclitaxel vs Gemcitabine, Nab-Paclitaxel, Durvalumab and Tremelimumab as 1st Line Therapy in Pancreatic Adenocarcinoma",7307
18,NCT03122496,Phase I,Recruiting,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}]",Immunotherapy and Stereotactic Body Radiotherapy (SBRT) for Metastatic Anaplastic Thyroid Cancer,7307
19,NCT02815995,Phase II,Recruiting,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}]",Multi-Arm Study to Test the Efficacy of Immunotherapeutic Agents in Multiple Sarcoma Subtypes,7307
20,NCT02639026,Phase I,Recruiting,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}]","Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic Cancers",7307
21,NCT03026062,Phase II,Recruiting,"[{'id': 1652, 'therapyName': 'Tremelimumab'}, {'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}, {'id': 1356, 'therapyName': 'Durvalumab'}]",Durvalumab and Tremelimumab in Combo Versus Sequential,7307
22,NCT02352948,Phase III,"Active, not recruiting","[{'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 2438, 'therapyName': 'Erlotinib + Gemcitabine + Vinorelbine'}, {'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}, {'id': 1652, 'therapyName': 'Tremelimumab'}]","A Global Study to Assess the Effects of MEDI4736, Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer",7307
23,NCT03275597,Phase I,Not yet recruiting,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}]",Phase Ib Study of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Non-small Lung Cancer (NSCLC) With Dual Immune Checkpoint Inhibition,7307
24,NCT02369874,Phase III,"Active, not recruiting","[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}, {'id': 1356, 'therapyName': 'Durvalumab'}]",Study of MEDI4736 Monotherapy and in Combination With Tremelimumab Versus Standard of Care Therapy in Patients With Head and Neck Cancer,7307
25,NCT02788773,Phase II,Recruiting,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}, {'id': 1356, 'therapyName': 'Durvalumab'}]",Durvalumab With or Without Tremelimumab in Metastatic Castration Resistant Prostate Cancer,7307
26,NCT02870920,Phase II,"Active, not recruiting","[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}]",Durvalumab and Tremelimumab and Best Supportive Care vs Best Supportive Care Alone in Patients With Advanced Colorectal Adenocarcinoma Refractory to Standard Therapies,7307
27,NCT03144778,Phase I,Recruiting,"[{'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}]",Checkpoint Inhibitors Assessment in Oropharynx Carcinoma (CIAO),7307
28,NCT03015129,Phase II,Recruiting,"[{'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}]",A Study of Durvalumab With or Without Tremelimumab in Endometrial Cancer,7307
29,NCT03206073,Phase Ib/II,Recruiting,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}, {'id': 1356, 'therapyName': 'Durvalumab'}]",A Phase I/II Study of Pexa-Vec Oncolytic Virus in Combination With Immune Checkpoint Inhibition in Refractory Colorectal Cancer,7307
30,NCT03132467,Phase I,Recruiting,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}]",Evaluating Anti-PD-L1 Antibody (Durvalumab) Plus Anti-CTLA-4 Antibody (Tremelimumab) in HR+/HER2- Breast Cancer,7307
31,NCT03057106,Phase II,Recruiting,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}, {'id': 854, 'therapyName': 'Pemetrexed'}]",Durvalumab and Tremelimumab ± Platinum-Based Chemotherapy in Patients With Metastatic Squamous or Non-Squamous NSCLC,7307
32,NCT03204812,Phase II,Recruiting,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}]",Tremelimumab + Durvalumab Chemotherapy Naive CRPC,7307
33,NCT02716805,Phase I,"Active, not recruiting","[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}]","Phase 1 Study to Assess Safety & Tolerability of Tremelimumab & Durvalumab, Administered With High Dose Chemotherapy and Autologous Stem Cell Transplant",7307
34,NCT02592551,Phase II,Recruiting,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}, {'id': 1356, 'therapyName': 'Durvalumab'}]",MEDI4736 Or MEDI4736 + Tremelimumab In Surgically Resectable Malignant Pleural Mesothelioma,7307
35,NCT02516241,Phase III,Recruiting,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}, {'id': 4686, 'therapyName': 'Carboplatin + Cisplatin + Gemcitabine'}, {'id': 1356, 'therapyName': 'Durvalumab'}]",Study of MEDI4736 With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer,7307
36,NCT02549651,Phase I,Recruiting,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}, {'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 3098, 'therapyName': 'AZD9150 + MEDI4736'}]",MEDI4736 Alone and in Combination With Tremelimumab or AZD9150 in Adult Subjects With Diffuse Large B-cell Lymphoma (D4190C00023),7307
37,NCT02527434,Phase II,"Active, not recruiting","[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}, {'id': 1356, 'therapyName': 'Durvalumab'}]",Study of Tremelimumab in Patients With Advanced Solid Tumors,7307
38,NCT01975831,Phase I,"Active, not recruiting","[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}]",A Phase 1 Study to Evaluate MEDI4736 in Combination With Tremelimumab,7307
39,NCT02536794,Phase II,Suspended,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}]",MEDI4736 and Tremelimumab in Treating Patients With Metastatic HER2 Negative Breast Cancer,7307
40,NCT02658214,Phase I,Recruiting,"[{'id': 2667, 'therapyName': 'Carboplatin + Gemcitabine'}, {'id': 2634, 'therapyName': 'Carboplatin + nab-paclitaxel'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 1791, 'therapyName': 'Carboplatin + Etoposide'}]",Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors,7307
41,NCT02888743,Phase II,Recruiting,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}]",Durvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating Patients With Metastatic Colorectal or Non-small Cell Lung Cancer,7307
42,NCT02261220,Phase I,"Active, not recruiting","[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}]",A Phase 1 Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Solid Tumors,7307
43,NCT02762006,Phase I,Recruiting,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}]",Neoadjuvant MEDI 4736 +/- Tremelimumab in Locally Advanced Renal Cell Carcinoma,7307
44,NCT02794883,Phase II,Recruiting,"[{'id': 1652, 'therapyName': 'Tremelimumab'}, {'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}, {'id': 1356, 'therapyName': 'Durvalumab'}]",Tremelimumab and Durvalumab in Combination or Alone in Treating Patients With Recurrent Malignant Glioma,7307
45,NCT03075527,Phase II,Recruiting,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}]",A Phase 2 Study of Durvalumab in Combination With Tremelimumab in Malignant Pleural Mesothelioma,7307
46,NCT03283605,Phase Ib/II,Not yet recruiting,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}]",Immunotherapy and SBRT for Metastatic Head and Neck Carcinomas,7307
47,NCT02821754,Phase Ib/II,Recruiting,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}]",A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC),7307
48,NCT02718911,Phase I,Recruiting,"[{'id': 4216, 'therapyName': 'LY3022855 + Tremelimumab'}, {'id': 4215, 'therapyName': 'LY3022855 + MEDI4736'}]",A Study of LY3022855 in Combination With Durvalumab or Tremelimumab in Participants With Advanced Solid Tumors,7307
49,NCT02705482,Phase I,Recruiting,"[{'id': 3840, 'therapyName': 'MEDI0562 + Tremelimumab'}, {'id': 3839, 'therapyName': 'MEDI0562 + MEDI4736'}]",A Study to Evaluate MEDI0562 in Combination With Immune Therapeutic Agents in Adult Subjects With Advanced Solid Tumors,7307
50,NCT02701400,Phase II,Recruiting,"[{'id': 3840, 'therapyName': 'MEDI0562 + Tremelimumab'}]",Tremelimumab and Durvalumab With or Without Radiation Therapy in Patients With Relapsed Small Cell Lung Cancer,7307
51,NCT03019003,Phase Ib/II,Recruiting,"[{'id': 5199, 'therapyName': 'MEDI4736 + Azacitidine + Tremelimumab'}]","A Phase IB/II Study With Azacitidine, Durvalumab, and Tremelimumab in Recurrent and/or Metastatic Head and Neck Cancer Patients",7307
52,NCT02953457,Phase Ib/II,Recruiting,"[{'id': 4949, 'therapyName': 'MEDI4736 + Olaparib + Tremelimumab'}]","Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRAC2 Mutation",7307
53,NCT03043872,Phase III,Recruiting,"[{'id': 5305, 'therapyName': 'MEDI4736 + Tremelimumab + Carboplatin + Cisplatin + Etoposide'}, {'id': 5306, 'therapyName': 'MEDI4736 + Carboplatin + Cisplatin + Etoposide'}, {'id': 4728, 'therapyName': 'Carboplatin + Cisplatin + Etoposide'}]",Durvalumab+/- Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer (Caspian),7307
54,NCT02616185,Phase I,Recruiting,"[{'id': 3565, 'therapyName': 'PF-06755990 + PF-06755992 + Sunitinib + Tremelimumab'}]",A Phase 1 Study To Evaluate Escalating Doses Of A Vaccine-Based Immunotherapy Regimen For Prostate Cancer (PrCa VBIR),7307
55,NCT03085849,Phase I,Recruiting,"[{'id': 5488, 'therapyName': 'SGI-110 + MEDI4736 + Tremelimumab'}]",SGI-110 Plus Durvalumab/Tremelimumab in SCLC,7307
56,NCT02519348,Phase II,Recruiting,"[{'id': 1652, 'therapyName': 'Tremelimumab'}, {'id': 1356, 'therapyName': 'Durvalumab'}]","A Study of MEDI4736 With Tremelimumab, MEDI4736 or Tremelimumab Monotherapy in Unresectable Hepatocellular Carcinoma",7307
57,NCT02205333,Phase Ib/II,Terminated,"[{'id': 897, 'therapyName': 'Rituximab'}, {'id': 1653, 'therapyName': 'MEDI6469'}, {'id': 1652, 'therapyName': 'Tremelimumab'}, {'id': 1356, 'therapyName': 'Durvalumab'}]",A Phase 1b/2 Safety and Tolerability of MEDI6469 in Combination With Therapeutic Immune Agents or Monoclonal Antibodies,7307
58,NCT02551159,Phase III,"Active, not recruiting","[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 1914, 'therapyName': 'Cetuximab + Carboplatin + Fluorouracil'}, {'id': 1652, 'therapyName': 'Tremelimumab'}]",Phase III Open Label First Line Therapy Study of MEDI 4736 With or Without Tremelimumab Versus Standard of Care (SOC) in SCCHN,7307
59,NCT02340975,Phase Ib/II,Recruiting,"[{'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 1652, 'therapyName': 'Tremelimumab'}]","A Phase 1b/2 Study of MEDI4736 With Tremelimumab, MEDI4736 or Tremelimumab Monotherapy in Gastric or GEJ Adenocarcinoma",7307
60,NCT02301130,Phase I,"Active, not recruiting","[{'id': 2968, 'therapyName': 'Mogamulizumab '}, {'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 1652, 'therapyName': 'Tremelimumab'}]",Study of Mogamulizumab + MEDI4736 and Mogamulizumab + Tremelimumab in Subjects w/ Advanced Solid Tumors,7307
61,NCT02571725,Phase Ib/II,Recruiting,"[{'id': 1652, 'therapyName': 'Tremelimumab'}, {'id': 837, 'therapyName': 'Olaparib'}]",PARP-inhibition and CTLA-4 Blockade in BRCA-deficient Ovarian Cancer,7307
62,NCT03007407,Phase II,Recruiting,"[{'id': 1652, 'therapyName': 'Tremelimumab'}, {'id': 1356, 'therapyName': 'Durvalumab'}]",Study of Durvalumab and Tremelimumab After Radiation for Microsatellite Stable Metastatic Colorectal Cancer Progressing on Chemotherapy,7307
63,NCT02262741,Phase I,"Active, not recruiting","[{'id': 1652, 'therapyName': 'Tremelimumab'}, {'id': 1356, 'therapyName': 'Durvalumab'}]","A Phase I Study to Evaluate the Safety, Tolerability and Efficacy of MEDI4736 With Tremelimumab or Tremelimumab Alone in Head and Neck Cancer",7307
64,NCT02141542,Phase I,"Active, not recruiting","[{'id': 1652, 'therapyName': 'Tremelimumab'}, {'id': 1176, 'therapyName': 'MEDI3617'}]",Phase I Clinical Trial of Tremelimumab Plus MEDI3617 in Patients With Unresectable Stage III or Stage IV Melanoma,7307
65,NCT02563925,Phase I,"Active, not recruiting","[{'id': 1652, 'therapyName': 'Tremelimumab'}]",Brain Irradiation and Tremelimumab in Metastatic Breast Cancer,7307
66,NCT02311361,Phase I,Recruiting,"[{'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 1652, 'therapyName': 'Tremelimumab'}]",Immune Checkpoint Inhibition (Tremelimumab and/or MEDI4736) in Combination With Radiation Therapy in Patients With Unresectable Pancreatic Cancer,7307
67,NCT02485990,Phase Ib/II,Recruiting,"[{'id': 837, 'therapyName': 'Olaparib'}, {'id': 1652, 'therapyName': 'Tremelimumab'}]","Study of Tremelimumab Alone or Combined With Olaparib for Patients With Persistent EOC (Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma)",7307
68,NCT01853618,Phase I,"Active, not recruiting","[{'id': 1652, 'therapyName': 'Tremelimumab'}]",Tremelimumab With Chemoembolization or Ablation for Liver Cancer,7307
69,NCT02535078,Phase Ib/II,Recruiting,"[{'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 3847, 'therapyName': 'IMCgp100'}, {'id': 1652, 'therapyName': 'Tremelimumab'}]",Phase 1b/2 Study of the Combination of IMCgp100 With Durvalumab and/or Tremelimumab in Cutaneous Melanoma,7307
70,NCT02453282,Phase III,"Active, not recruiting","[{'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 1467, 'therapyName': 'Gemcitabine + Cisplatin'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 1652, 'therapyName': 'Tremelimumab'}]",Phase III Open Label First Line Therapy Study of MEDI 4736 With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC).,7307
71,NCT02319044,Phase II,"Active, not recruiting","[{'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 1652, 'therapyName': 'Tremelimumab'}]","Phase II Study of MEDI4736, Tremelimumab, and MEDI4736 in Combination w/ Tremelimumab Squamous Cell Carcinoma of the Head and Neck",7307
72,NCT02537418,Phase I,"Active, not recruiting","[{'id': 2585, 'therapyName': 'Cisplatin + Etoposide'}, {'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 1652, 'therapyName': 'Tremelimumab'}]",Durvalumab With or Without Tremelimumab in Advanced Incurable Solid Malignancies Receiving Standard Chemotherapy Regimens,7307
73,NCT02643303,Phase Ib/II,Recruiting,"[{'id': 3385, 'therapyName': 'MEDI4736 + poly ICLC '}, {'id': 1652, 'therapyName': 'Tremelimumab'}]","A Phase 1/2 Study of In Situ Vaccination With Tremelimumab and IV Durvalumab Plus PolyICLC in Subjects With Advanced, Measurable, Biopsy-accessible Cancers",7307
74,NCT02179671,Phase II,Completed,"[{'id': 1117, 'therapyName': 'Selumetinib + Docetaxel'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 660, 'therapyName': 'AZD9291'}, {'id': 1652, 'therapyName': 'Tremelimumab'}]","Immune-Modulated Study of Selected Small Molecules (Gefitinib, AZD9291, or Selumetinib + Docetaxel) or a 1st Immune-Mediated Therapy (IMT; Tremelimumab) With a Sequential Switch to a 2nd IMT (MEDI4736) in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer",7307
75,NCT02558894,Phase II,Completed,"[{'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 1652, 'therapyName': 'Tremelimumab'}]",Phase II Study of MEDI4736 Monotherapy or in Combinations With Tremelimumab in Metastatic Pancreatic Ductal Carcinoma,7307
76,NCT02626130,Phase I,Recruiting,"[{'id': 1652, 'therapyName': 'Tremelimumab'}]",Pilot Study of Presurgical Tremelimumab With or Without Cryoablation in Patients With Metastatic Renal Cell Carcinoma (RCC),7307
0,NCT01409161,Phase II,Recruiting,"[{'id': 3685, 'therapyName': 'Arsenic trioxide + Gemtuzumab ozogamicin + Tretinoin'}]","Acute Promyelocytic Leukemia (APL) Treated With ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin",7356
1,NCT02339740,Phase III,Recruiting,"[{'id': 3686, 'therapyName': 'Cytarabine + Dexamethasone + Idarubicin + Mitoxantrone'}, {'id': 3685, 'therapyName': 'Arsenic trioxide + Gemtuzumab ozogamicin + Tretinoin'}]",Tretinoin and Arsenic Trioxide in Treating Patients With Untreated Acute Promyelocytic Leukemia,7356
2,NCT02401295,Phase I,Completed,"[{'id': 3433, 'therapyName': 'Celecoxib + Itraconazole + Tretinoin '}]","ATRA, Celecoxib, and Itraconazole as Maintenance",7356
3,NCT03200847,Phase Ib/II,Not yet recruiting,"[{'id': 5988, 'therapyName': 'Pembrolizumab + Tretinoin'}]",Pembrolizumab and All-Trans Retinoic Acid Combination Treatment of Advanced Melanoma,7356
4,NCT02273102,Phase I,Recruiting,"[{'id': 6126, 'therapyName': 'Tranylcypromine + Tretinoin '}]",Phase 1 Study of TCP-ATRA for Adult Patients With AML and MDS (TCP-ATRA),7356
5,NCT01857934,Phase II,Recruiting,"[{'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1873, 'therapyName': 'Sargramostim'}, {'id': 1167, 'therapyName': 'Aldesleukin'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 2627, 'therapyName': 'Levetiracetam'}, {'id': 2585, 'therapyName': 'Cisplatin + Etoposide'}, {'id': 2458, 'therapyName': 'Hu14.18K322A'}, {'id': 2558, 'therapyName': 'Busulfan + Melphalan'}, {'id': 2590, 'therapyName': 'Cyclophosphamide + Topotecan'}]",Therapy for Children With Advanced Stage Neuroblastoma,7356
6,NCT02551718,Phase I,Recruiting,"[{'id': 690, 'therapyName': 'Bosutinib'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 3160, 'therapyName': 'Nelarabine'}, {'id': 3159, 'therapyName': 'Bexarotene'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 998, 'therapyName': 'cabozantinib'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 877, 'therapyName': 'Ponatinib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 623, 'therapyName': 'Afatinib'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 890, 'therapyName': 'Regorafenib'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 2, 'therapyName': 'Trametinib'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 3, 'therapyName': 'Dabrafenib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 789, 'therapyName': 'Ceritinib'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1571, 'therapyName': 'Cabazitaxel'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1327, 'therapyName': 'Pralatrexate'}]",High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia,7356
7,NCT02788201,Phase II,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1133, 'therapyName': 'Mitomycin C'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1013, 'therapyName': 'epirubicin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1137, 'therapyName': 'Bleomycin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 781, 'therapyName': 'Ixabepilone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 2950, 'therapyName': 'Estramustine'}, {'id': 1941, 'therapyName': 'Floxuridine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 1811, 'therapyName': 'Carmustine'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 953, 'therapyName': 'Vandetanib'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 4419, 'therapyName': 'Toremifine'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 2601, 'therapyName': 'Dactinomycin'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 3035, 'therapyName': 'Chlorambucil'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 342, 'therapyName': 'Vemurafenib'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 2635, 'therapyName': 'Vinblastine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 4305, 'therapyName': 'Teniposide'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 4304, 'therapyName': 'Streptozocin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1231, 'therapyName': 'Bendamustine'}, {'id': 4303, 'therapyName': 'Mechlorethamine'}, {'id': 4302, 'therapyName': 'Mitotane'}]",Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma,7356
8,NCT01526603,Phase I,Recruiting,"[{'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1092, 'therapyName': 'Carboplatin'}]",High Dose Chemotherapy and Autologous Transplant for Neuroblastoma,7356
0,NCT01690468,Phase Ib/II,Recruiting,"[{'id': 4566, 'therapyName': 'Carboplatin + Triciribine'}]",PTX-200 and Carboplatin in Ovarian Cancer,7037
1,NCT01697293,Phase Ib/II,Recruiting,"[{'id': 3054, 'therapyName': 'Paclitaxel + Triciribine'}, {'id': 1977, 'therapyName': 'Doxorubicin + Cyclophosphamide'}]","Triciribine Phosphate, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide in Treating Patients With Stage IIB-IV Breast Cancer",7037
0,NCT02654639,Phase II,"Active, not recruiting","[{'id': 3682, 'therapyName': 'Bevacizumab + trifluridine/tipiracil hydrochloride'}]",Ph 2 Study of TAS-102 / Bevacizumab Maintenance Therapy Post Induction Chemotherapy in Metastatic Colorectal Cancer,7528
1,NCT02860546,Phase II,"Active, not recruiting","[{'id': 4560, 'therapyName': 'Nivolumab + trifluridine/tipiracil hydrochloride'}]",A Study Evaluating TAS-102 Plus Nivolumab in Patients With MSS CRC,7528
2,NCT01916447,Phase I,Completed,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 2426, 'therapyName': 'trifluridine/tipiracil hydrochloride'}, {'id': 1074, 'therapyName': 'Irinotecan'}]",A Phase I Study of TAS-102 in Patients With Advanced Gastrointestinal Tumors.,7528
3,NCT02500043,Phase III,Recruiting,"[{'id': 2426, 'therapyName': 'trifluridine/tipiracil hydrochloride'}]",Study of TAS-102 or Placebo Plus BSC in Patients With Metastatic Gastric Cancer,7528
4,NCT02602327,Phase I,Recruiting,"[{'id': 2426, 'therapyName': 'trifluridine/tipiracil hydrochloride'}]",Tas-102 and Radioembolization With 90Y Resin Microspheres for Chemo-refractory Colorectal Liver Metastases,7528
5,NCT02301117,Phase I,Recruiting,"[{'id': 2426, 'therapyName': 'trifluridine/tipiracil hydrochloride'}]",A Phase I Study of TAS-102 in Patients With Advanced Solid Tumors With Renal Impairment,7528
0,NCT03229278,Phase I,Not yet recruiting,"[{'id': 6055, 'therapyName': 'Nivolumab + Pembrolizumab + Trigriluzole'}]",Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma,8900
0,NCT03041311,Phase II,Recruiting,"[{'id': 5541, 'therapyName': 'Atezolizumab + Carboplatin + Etoposide + Trilaciclib'}, {'id': 4164, 'therapyName': 'Atezolizumab + Carboplatin + Etoposide'}]","Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Extensive Stage Small Cell Lung Cancer (SCLC)",7926
1,NCT02978716,Phase II,Recruiting,"[{'id': 2667, 'therapyName': 'Carboplatin + Gemcitabine'}, {'id': 5737, 'therapyName': 'Carboplatin + Gemcitabine + Trilaciclib'}]","Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC)",7926
2,NCT02499770,Phase Ib/II,"Active, not recruiting","[{'id': 1791, 'therapyName': 'Carboplatin + Etoposide'}, {'id': 3074, 'therapyName': 'Trilaciclib'}]",G1T28 (CDK 4/6 Inhibitor) in Combination With Etoposide and Carboplatin in Extensive Stage Small Cell Lung Cancer (SCLC),7926
3,NCT02514447,Phase Ib/II,Recruiting,"[{'id': 3074, 'therapyName': 'Trilaciclib'}, {'id': 942, 'therapyName': 'Topotecan'}]",Study of G1T28 in Patients With Previously Treated Extensive Stage SCLC Receiving Topotecan Chemotherapy,7926
0,NCT02685397,Phase II,Recruiting,"[{'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 2050, 'therapyName': 'Triptorelin'}, {'id': 759, 'therapyName': 'Goserelin'}, {'id': 795, 'therapyName': 'Leuprolide'}]",Management of Castration-Resistant Prostate Cancer With Oligometastases,7406
1,NCT02346253,Phase Ib/II,Recruiting,"[{'id': 795, 'therapyName': 'Leuprolide'}, {'id': 2050, 'therapyName': 'Triptorelin'}, {'id': 1814, 'therapyName': 'Degarelix'}, {'id': 1507, 'therapyName': 'Bicalutamide'}, {'id': 759, 'therapyName': 'Goserelin'}]",High-Dose Brachytherapy in Treating Patients With Prostate Cancer,7406
2,NCT03279250,Phase II,Not yet recruiting,"[{'id': 759, 'therapyName': 'Goserelin'}, {'id': 2050, 'therapyName': 'Triptorelin'}, {'id': 2649, 'therapyName': 'Abiraterone + ARN-509 + Prednisone'}, {'id': 795, 'therapyName': 'Leuprolide'}, {'id': 1947, 'therapyName': 'ARN-509'}]",Effects of Apalutamide Plus LHRH Agonist or Apalutamide Plus Abiraterone Acetate Plus LHRH Agonist for Six Months for Prostate Cancer Patients at High Risk for Recurrence,7406
3,NCT02366494,Phase I,Recruiting,"[{'id': 795, 'therapyName': 'Leuprolide'}, {'id': 759, 'therapyName': 'Goserelin'}, {'id': 2050, 'therapyName': 'Triptorelin'}, {'id': 1507, 'therapyName': 'Bicalutamide'}, {'id': 720, 'therapyName': 'Docetaxel'}]",Micro RNAs to Predict Response to Androgen Deprivation Therapy,7406
4,NCT02278185,Phase II,Recruiting,"[{'id': 759, 'therapyName': 'Goserelin'}, {'id': 1814, 'therapyName': 'Degarelix'}, {'id': 2047, 'therapyName': 'Histrelin acetate'}, {'id': 2050, 'therapyName': 'Triptorelin'}, {'id': 795, 'therapyName': 'Leuprolide'}, {'id': 1262, 'therapyName': 'Enzalutamide'}]",Enzalutamide Versus Standard Androgen Deprivation Therapy for the Treatment Hormone Sensitive Prostate Cancer,7406
5,NCT00936390,Phase III,"Active, not recruiting","[{'id': 742, 'therapyName': 'Flutamide'}, {'id': 759, 'therapyName': 'Goserelin'}, {'id': 795, 'therapyName': 'Leuprolide'}, {'id': 2050, 'therapyName': 'Triptorelin'}, {'id': 1507, 'therapyName': 'Bicalutamide'}]",Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer,7406
0,NCT02990481,Phase I,Recruiting,"[{'id': 5835, 'therapyName': 'TRK-950'}]",A Study of TRK-950 in Patients With Advanced Solid Tumors,8827
0,NCT02628574,Phase I,Recruiting,"[{'id': 3613, 'therapyName': 'TRX518'}]",Dose Escalation Study of TRX518 in Adults With Advanced Solid Tumors,8172
1,NCT01239134,Phase I,Recruiting,"[{'id': 3613, 'therapyName': 'TRX518'}]",Trial of TRX518 (Anti-GITR mAb) in Stage III or IV Malignant Melanoma or Other Solid Tumors,8172
0,NCT02855125,Phase II,Recruiting,"[{'id': 1407, 'therapyName': 'TS-1'}, {'id': 4527, 'therapyName': 'TAS-114 + TS-1'}]",A Randomized Phase 2 Trial of TAS-114 in Combination With S-1 Versus S-1,7256
0,NCT03201913,Phase I,Not yet recruiting,"[{'id': 5960, 'therapyName': 'TTC-352'}]",Study of TTC-352 in Patients With Metastatic Breast Cancer Progressing on Endocrine Therapy,8870
0,NCT02890368,Phase I,Recruiting,"[{'id': 5338, 'therapyName': 'TTI-621'}]",Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides,8667
1,NCT02663518,Phase I,Recruiting,"[{'id': 5338, 'therapyName': 'TTI-621'}]",A Trial of TTI-621 for Patients With Hematologic Malignancies,8667
0,NCT02025192,Phase I,"Active, not recruiting","[{'id': 1560, 'therapyName': 'ARRY-380 + Trastuzumab'}, {'id': 1577, 'therapyName': 'ARRY-380 + Capecitabine'}]",A Phase 1b Study of ONT-380 Combined With Capecitabine and/or Trastuzumab in Patients With HER2+ Metastatic Breast Cancer,6846
1,NCT02614794,Phase II,Recruiting,"[{'id': 3340, 'therapyName': 'ARRY-380 + Capecitabine + Trastuzumab'}, {'id': 1409, 'therapyName': 'Capecitabine + Trastuzumab'}]",Study of ONT-380 vs Placebo in Combo w/ Capecitabine & Trastuzumab in Patients w/ Metastatic HER2+ Breast Cancer,6846
2,NCT03054363,Phase Ib/II,Not yet recruiting,"[{'id': 5334, 'therapyName': 'ARRY-380 + Palbociclib + Letrozole'}]","Tucatinib, Palbociclib and Letrozole in Metastatic Hormone Receptor Positive and HER2-positive Breast Cancer",6846
3,NCT03043313,Phase II,Recruiting,"[{'id': 1560, 'therapyName': 'ARRY-380 + Trastuzumab'}]",Tucatinib (ONT-380) and Trastuzumab for Patients With HER2-positive Metastatic Colorectal Cancer (MOUNTAINEER)Tucatinib (ONT-380) and Trastuzumab for Patients With HER2-positive Metastatic Colorectal Cancer (MOUNTAINEER) (MOUNTAINEER),6846
4,NCT01921335,Phase I,"Active, not recruiting","[{'id': 1560, 'therapyName': 'ARRY-380 + Trastuzumab'}]",Phase I Dose-escalation Trial of ARRY-380 in Combination With Trastuzumab in Participants With Brain Metastases From HER2+ Breast Cancer,6846
5,NCT01983501,Phase I,"Active, not recruiting","[{'id': 1573, 'therapyName': 'ARRY-380 + Trastuzumab emtansine'}]",A Phase 1b Study of ONT-380 Combined With Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2+ Breast Cancer,6846
0,NCT03032484,Phase II,Recruiting,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 5260, 'therapyName': 'Bevacizumab + TVB-2640'}]",TVB- 2640 in Combination With Bevacizumab in Patients With First Relapse of High Grade Astrocytoma,8170
1,NCT03179904,Phase II,Recruiting,"[{'id': 5874, 'therapyName': 'Paclitaxel + Trastuzumab + TVB-2640'}]","FASN Inhibitor TVB-2640, Paclitaxel, and Trastuzumab in Treating Patients With HER2 Positive Advanced Breast Cancer",8170
2,NCT02980029,Phase I,Recruiting,"[{'id': 3611, 'therapyName': 'TVB-2640'}]",Pharmacodynamic Effects of Fatty Acid Synthase (FASN) Inhibition With TVB-2640 in Resectable Colon Cancer,8170
3,NCT02223247,Phase I,Completed,"[{'id': 3611, 'therapyName': 'TVB-2640'}]","A Phase 1, First-In-Human Study of Escalating Doses of Oral TVB-2640 in Patients With Solid Tumors",8170
0,NCT02535286,Phase Ib/II,Recruiting,"[{'id': 3475, 'therapyName': 'Pembrolizumab + TGR-1202 + Ublituximab'}]",Study of Pembrolizumab in Combination With Ublituximab and TGR-1202 in Patients With Relapsed-refractory CLL,7481
1,NCT02006485,Phase I,Recruiting,"[{'id': 2319, 'therapyName': 'TGR-1202 + Ublituximab'}, {'id': 768, 'therapyName': 'Ibrutinib'}]",Ublituximab in Combination With TGR-1202 in Patients With B-cell Malignancies,7481
2,NCT02793583,Phase II,Recruiting,"[{'id': 2022, 'therapyName': 'TGR-1202'}, {'id': 2319, 'therapyName': 'TGR-1202 + Ublituximab'}]",Study to Assess the Efficacy and Safety of Ublituximab + TGR-1202 and TGR-1202 Alone in Patients With Previously Treated Diffuse Large B-Cell Lymphoma (UNITY-DLBCL),7481
3,NCT02656303,Phase II,Recruiting,"[{'id': 2319, 'therapyName': 'TGR-1202 + Ublituximab'}]",An Open-Label Study to Evaluate the Safety and Efficacy of Ublituximab in Combination With TGR-1202 for Patients Previously Enrolled in Protocol UTX-TGR-304,7481
4,NCT02612311,Phase III,Recruiting,"[{'id': 2287, 'therapyName': 'Ublituximab'}, {'id': 1648, 'therapyName': 'Obinutuzumab + Chlorambucil'}, {'id': 2022, 'therapyName': 'TGR-1202'}]",Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemia,7481
5,NCT02301156,Phase III,"Active, not recruiting","[{'id': 2287, 'therapyName': 'Ublituximab'}, {'id': 768, 'therapyName': 'Ibrutinib'}]",Ublituximab in Combination With Ibrutinib Versus Ibrutinib Alone in Patients With Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL),7481
0,NCT03190278,Phase I,Suspended,"[{'id': 5994, 'therapyName': 'UCART123'}]",Study Evaluating Safety and Efficacy of UCART123 in Patients With Acute Myeloid Leukemia,8883
1,NCT03203369,Phase I,Suspended,"[{'id': 5994, 'therapyName': 'UCART123'}]",Study to Evaluate the Safety and Clinical Activity of UCART123 in Patients With BPDCN (ABC123),8883
0,NCT02746952,Phase I,Recruiting,"[{'id': 5997, 'therapyName': 'UCART19'}]",Dose Escalation Study of UCART19 in Adult Patients With Relapsed / Refractory B-cell Acute Lymphoblastic Leukaemia (CALM),8885
0,NCT02666209,Phase I,No longer available,"[{'id': 3556, 'therapyName': 'Bortezomib + Dexamethasone + Ulocuplumab'}, {'id': 3555, 'therapyName': 'Dexamethasone + lenalidomide + Ulocuplumab'}]",Early Patient Access Single Named Patient Program for the Use of Ulocuplumab for the Treatment of Multiple Myeloma,7784
1,NCT02305563,Phase Ib/II,Recruiting,"[{'id': 6259, 'therapyName': 'Cytarabine + Ulocuplumab'}]",An Investigational Immuno-therapy Study of Ulocuplumab in Combination With Low Dose Cytarabine in Patients With Newly Diagnosed Acute Myeloid Leukemia,7784
2,NCT02472977,Phase Ib/II,Terminated,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 2847, 'therapyName': 'Ulocuplumab'}]",Safety and Efficacy Study of Ulocuplumab and Nivolumab in Subjects With Solid Tumors,7784
0,NCT01902173,Phase Ib/II,Suspended,"[{'id': 2, 'therapyName': 'Trametinib'}, {'id': 2200, 'therapyName': 'Dabrafenib + GSK2141795'}]","GSK2141795, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer",6920
1,NCT01138085,Phase I,Completed,"[{'id': 1150, 'therapyName': 'GSK1120212 + GSK2141795'}]","Safety, Pharmacokinetics (PK) of AKT and MEK Combination",6920
2,NCT01958112,Phase II,Terminated,"[{'id': 1150, 'therapyName': 'GSK1120212 + GSK2141795'}]",GSK1120212+GSK2141795 for Cervical Cancer,6920
3,NCT01979523,Phase II,"Active, not recruiting","[{'id': 2, 'therapyName': 'Trametinib'}, {'id': 1298, 'therapyName': 'Trametinib + GSK2141795'}]",Trametinib With or Without GSK2141795 in Treating Patients With Metastatic Uveal Melanoma,6920
4,NCT01935973,Phase II,"Active, not recruiting","[{'id': 2, 'therapyName': 'Trametinib'}, {'id': 1298, 'therapyName': 'Trametinib + GSK2141795'}]",Trametinib With or Without GSK2141795 in Treating Patients With Recurrent or Persistent Endometrial Cancer,6920
5,NCT01989598,Phase II,"Active, not recruiting","[{'id': 1298, 'therapyName': 'Trametinib + GSK2141795'}]",Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Relapsed or Refractory Multiple Myeloma,6920
6,NCT01907815,Phase II,"Active, not recruiting","[{'id': 1298, 'therapyName': 'Trametinib + GSK2141795'}]",Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Acute Myeloid Leukemia,6920
7,NCT01964924,Phase II,"Active, not recruiting","[{'id': 1298, 'therapyName': 'Trametinib + GSK2141795'}]",Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Metastatic Triple-Negative Breast Cancer,6920
8,NCT01941927,Phase II,Unknown status,"[{'id': 1298, 'therapyName': 'Trametinib + GSK2141795'}]",Trametinib With GSK2141795 in BRAF Wild-type Melanoma,6920
0,NCT02110082,Phase I,Completed,"[{'id': 2066, 'therapyName': 'Cetuximab + Urelumab'}]",Combination Study of Urelumab and Cetuximab in Patients With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Head and Neck Cancer,7411
1,NCT02253992,Phase Ib/II,Recruiting,"[{'id': 2567, 'therapyName': 'Nivolumab + Urelumab'}]",Study of the Safety and Tolerability of Urelumab Administered in Combination With Nivolumab in Solid Tumors and B-cell Non-Hodgkins Lymphoma,7411
2,NCT02845323,Phase II,Recruiting,"[{'id': 2055, 'therapyName': 'Urelumab'}, {'id': 2567, 'therapyName': 'Nivolumab + Urelumab'}]",Neoadjuvant Nivolumab With and Without Urelumab in Patients With Cisplatin-Ineligible Muscle-Invasive Urothelial Carcinoma of the Bladder,7411
3,NCT02252263,Phase I,"Active, not recruiting","[{'id': 2055, 'therapyName': 'Urelumab'}, {'id': 2583, 'therapyName': 'Lirilumab '}, {'id': 3343, 'therapyName': 'Elotuzumab'}]",A Phase I Open Label Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination With Either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects With Multiple Myeloma,7411
4,NCT02652455,Phase I,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 3409, 'therapyName': 'Aldesleukin + Cyclophosphamide + Fludarabine '}, {'id': 2055, 'therapyName': 'Urelumab'}]","Combining PD-1 Blockade, CD137 Agonism and Adoptive Cell Therapy for Metastatic Melanoma",7411
0,NCT02951156,Phase III,Recruiting,"[{'id': 5088, 'therapyName': 'Avelumab + Azacitidine + Utomilumab'}, {'id': 5087, 'therapyName': 'Avelumab + Rituximab + Utomilumab'}, {'id': 2323, 'therapyName': 'Bendamustine + Rituximab'}, {'id': 5090, 'therapyName': 'Gemcitabine + Oxaliplatin + Rituximab'}, {'id': 5089, 'therapyName': 'Avelumab + Bendamustine + Rituximab'}]","Avelumab In Combination Regimens That Include An Immune Agonist, Epigenetic Modulator, CD20 Antagonist and/or Conventional Chemotherapy in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)",8610
1,NCT03217747,Phase Ib/II,Recruiting,"[{'id': 5052, 'therapyName': 'Avelumab + Cisplatin'}, {'id': 6044, 'therapyName': 'Avelumab + PF-04518600 + Utomilumab'}, {'id': 6043, 'therapyName': 'Avelumab + Utomilumab'}, {'id': 6045, 'therapyName': 'Avelumab + PF-04518600'}]",Study to Evaluate the Safety and Tolerability of Avelumab in Combination With Other Anti-Cancer Therapies in Patients With Advanced Malignancies,8610
2,NCT02554812,Phase I,Recruiting,"[{'id': 6043, 'therapyName': 'Avelumab + Utomilumab'}]",A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley),8610
3,NCT03290937,Phase I,Not yet recruiting,"[{'id': 6288, 'therapyName': 'Cetuximab + Irinotecan + Utomilumab'}]","Clinical Trial Evaluating the Safety and Response With PF-05082566, Cetuximab and Irinotecan in Patients With Advanced Colorectal Cancer",8610
4,NCT03258008,Phase II,Not yet recruiting,"[{'id': 6148, 'therapyName': 'ISA101b + Utomilumab'}]",Utomilumab and ISA101b Vaccination in Patients With HPV-16-Positive Incurable Oropharyngeal Cancer,8610
5,NCT02315066,Phase I,Recruiting,"[{'id': 4333, 'therapyName': 'PF-04518600'}, {'id': 4448, 'therapyName': 'PF-04518600 + Utomilumab'}]",Study Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566,8610
6,NCT01307267,Phase I,Recruiting,"[{'id': 6111, 'therapyName': 'Utomilumab + Rituximab'}, {'id': 5086, 'therapyName': 'Utomilumab'}]",A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab,8610
7,NCT02179918,Phase I,Completed,"[{'id': 5086, 'therapyName': 'Utomilumab'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",A Study Of 4-1BB Agonist PF-05082566 Plus PD-1 Inhibitor MK-3475 In Patients With Solid Tumors (B1641003/KEYNOTE-0036),8610
0,NCT01478178,Phase Ib/II,Completed,"[{'id': 2921, 'therapyName': 'VAL-083'}]",Safety Study of VAL-083 in Patients With Recurrent Malignant Glioma or Progressive Secondary Brain Tumor,7844
0,NCT02768363,Phase II,Recruiting,"[{'id': 5172, 'therapyName': 'AdV-tk + Valacyclovir'}, {'id': 5171, 'therapyName': 'Valacyclovir'}]",Randomized Controlled Trial of ProstAtak Immunotherapy During Active Surveillance for Prostate Cancer (ULYSSES),8625
1,NCT03131037,Phase I,Recruiting,"[{'id': 5172, 'therapyName': 'AdV-tk + Valacyclovir'}]",Intratumoral Gene Mediated Cytotoxic Immunotherapy in Patients With Resectable Non-Small Cell Lung Cancer,8625
2,NCT03004183,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 5172, 'therapyName': 'AdV-tk + Valacyclovir'}]",SBRT and Oncolytic Virus Therapy Before Pembrolizumab for Metastatic TNBC and NSCLC,8625
3,NCT01436968,Phase III,Recruiting,"[{'id': 5171, 'therapyName': 'Valacyclovir'}, {'id': 5172, 'therapyName': 'AdV-tk + Valacyclovir'}]",Phase 3 Study of ProstAtak Immunotherapy With Standard Radiation Therapy for Localized Prostate Cancer,8625
0,NCT01106872,Phase Ib/II,Completed,"[{'id': 1466, 'therapyName': 'Bevacizumab + Gemcitabine + Docetaxel + Valproic Acid '}]","Bevacizumab, Chemotherapy and Valproic Acid in Advanced Sarcomas",7192
1,NCT02648633,Phase I,Terminated,"[{'id': 4219, 'therapyName': 'Nivolumab + Valproic acid'}]",Stereotactic Radiosurgery With Nivolumab and Valproate in Patients With Recurrent Glioblastoma,7192
2,NCT01552434,Phase I,Recruiting,"[{'id': 1376, 'therapyName': 'Temsirolimus + Bevacizumab + Valproic Acid + Cetuximab'}]","Bevacizumab, Temsirolimus, Valproic Acid, Cetuximab",7192
3,NCT00670046,Phase II,Unknown status,"[{'id': 1076, 'therapyName': 'Valproic acid'}]","Valproic Acid in Treating Patients With Progressive, Non-Metastatic Prostate Cancer",7192
4,NCT01817751,Phase II,Recruiting,"[{'id': 1076, 'therapyName': 'Valproic acid'}, {'id': 920, 'therapyName': 'Sorafenib'}]","Sorafenib Tosylate, Valproic Acid, and Sildenafil Citrate in Treating Patients With Recurrent High-Grade Glioma",7192
5,NCT02068586,Phase II,Recruiting,"[{'id': 1076, 'therapyName': 'Valproic acid'}, {'id': 930, 'therapyName': 'Sunitinib'}]",Adjuvant Sunitinib or Valproic Acid in High-Risk Patients With Uveal Melanoma,7192
6,NCT01182285,Phase II,Completed,"[{'id': 2674, 'therapyName': 'liothyronine sodium  '}, {'id': 1076, 'therapyName': 'Valproic acid'}]",A Phase II Trial of Valproic Acid in Patients With Advanced Thyroid Cancers of Follicular Cell Origin,7192
7,NCT01738815,Phase I,Unknown status,"[{'id': 1076, 'therapyName': 'Valproic acid'}]",Impact of Valproate on Angiogenesis and Histone Deacetylation in Bladder Cancer,7192
8,NCT02446431,Phase I,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1076, 'therapyName': 'Valproic acid'}]",Metronomic Therapy for Pediatric Patients With Solid Tumors at High Risk of Recurrence,7192
9,NCT00879437,Phase II,"Active, not recruiting","[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1076, 'therapyName': 'Valproic acid'}]",Valproic Acid and Radiation Followed by Maintenance Valproic Acid and Bevacizumab in Children With High Grade Gliomas,7192
10,NCT01007695,Phase I,Terminated,"[{'id': 1076, 'therapyName': 'Valproic acid'}]",Molecular Signature of Valproic Acid in Breast Cancer With Functional Imaging Assessment - a Pilot,7192
11,NCT01010958,Phase I,Terminated,"[{'id': 1076, 'therapyName': 'Valproic acid'}]",Adjuvant Valproate for High Grade Sarcomas,7192
12,NCT02520115,Phase I,Recruiting,"[{'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 1076, 'therapyName': 'Valproic acid'}]",Folate Receptor in Diagnosing Ovarian Cancer Using Serum Samples From Patients With Newly Diagnosed Pelvic Mass or Previously Diagnosed Ovarian Cancer,7192
0,NCT01438112,,Terminated,"[{'id': 2524, 'therapyName': 'Gemcitabine + interferon + Mitomycin C + Valrubicin '}, {'id': 2523, 'therapyName': 'CG0070'}]",Efficacy Study of Recombinant Adenovirus for Non Muscle Invasive Bladder Cancer,7174
0,NCT01183559,Phase I,Unknown status,"[{'id': 2071, 'therapyName': 'Carboplatin + Fluorouracil + Paclitaxel + Vandetanib'}]","A Trial of ZD6474 (Zactima), Paclitaxel, Carboplatin, 5-Fluorouracil, and XRT Followed by Surgery",4691
1,NCT02495103,Phase Ib/II,Recruiting,"[{'id': 2959, 'therapyName': 'Metformin + Vandetanib'}]",Vandetanib in Combination With Metformin in People With HLRCC or SDH-Associated Kidney Cancer or Sporadic Papillary Renal Cell Carcinoma,4691
2,NCT02015065,Phase II,"Active, not recruiting","[{'id': 953, 'therapyName': 'Vandetanib'}]",Phase II Trial of Vandetanib in Children and Adults With Wild-Type Gastrointestinal Stromal Tumors,4691
3,NCT02788201,Phase II,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1133, 'therapyName': 'Mitomycin C'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1013, 'therapyName': 'epirubicin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1137, 'therapyName': 'Bleomycin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 781, 'therapyName': 'Ixabepilone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 2950, 'therapyName': 'Estramustine'}, {'id': 1941, 'therapyName': 'Floxuridine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 1811, 'therapyName': 'Carmustine'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 953, 'therapyName': 'Vandetanib'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 4419, 'therapyName': 'Toremifine'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 2601, 'therapyName': 'Dactinomycin'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 3035, 'therapyName': 'Chlorambucil'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 342, 'therapyName': 'Vemurafenib'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 2635, 'therapyName': 'Vinblastine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 4305, 'therapyName': 'Teniposide'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 4304, 'therapyName': 'Streptozocin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1231, 'therapyName': 'Bendamustine'}, {'id': 4303, 'therapyName': 'Mechlorethamine'}, {'id': 4302, 'therapyName': 'Mitotane'}]",Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma,4691
4,NCT01414426,Phase II,Recruiting,"[{'id': 953, 'therapyName': 'Vandetanib'}]",Vandetanib in Preventing Head and Neck Cancer in Patients With Precancerous Head and Neck Lesions,4691
5,NCT01876784,Phase III,Completed,"[{'id': 953, 'therapyName': 'Vandetanib'}]","Evaluation of Efficacy, Safety of Vandetanib in Patients With Differentiated Thyroid Cancer",4691
6,NCT01585415,Phase I,Terminated,"[{'id': 953, 'therapyName': 'Vandetanib'}]", Vemurafenib and White Blood Cell Therapy for Advanced Melanoma,4691
7,NCT01934335,Phase I,Recruiting,"[{'id': 953, 'therapyName': 'Vandetanib'}]",Effect of Vandetanib on Cellular Markers in Invasive Breast Cancer,4691
8,NCT01582191,Phase I,Recruiting,"[{'id': 1163, 'therapyName': 'Vandetanib + Everolimus'}]",Vandetanib With Everolimus,4691
0,NCT01957007,Phase I,Completed,"[{'id': 4413, 'therapyName': 'Docetaxel + Vantictumab'}]",A Study of Vantictumab (OMP-18R5) in Combination With Docetaxel in Patients With Previously Treated NSCLC,8439
1,NCT02005315,Phase I,"Active, not recruiting","[{'id': 4412, 'therapyName': 'Gemcitabine + nab-paclitaxel + Vantictumab'}]",A Study of Vantictumab (OMP-18R5) in Combination With Nab-Paclitaxel and Gemcitabine in Previously Untreated Stage IV Pancreatic Cancer,8439
2,NCT01973309,Phase I,"Active, not recruiting","[{'id': 4398, 'therapyName': 'Vantictumab + Paclitaxel'}]",A Study of Vantictumab (OMP-18R5) in Combination With Paclitaxel in Locally Recurrent or Metastatic Breast Cancer,8439
0,NCT02543645,Phase Ib/II,Terminated,"[{'id': 3086, 'therapyName': 'Atezolizumab + Varlilumab'}]",A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer,7557
1,NCT03038672,Phase II,Not yet recruiting,"[{'id': 2526, 'therapyName': 'Nivolumab + Varlilumab'}, {'id': 1312, 'therapyName': 'Nivolumab'}]",Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas,7557
2,NCT02413827,Phase Ib/II,Terminated,"[{'id': 2526, 'therapyName': 'Nivolumab + Varlilumab'}, {'id': 1324, 'therapyName': 'DEC-205-NY-ESO-1 fusion protein vaccine'}, {'id': 2595, 'therapyName': 'poly ICLC  '}]",A Study of Varlilumab (Anti-CD27) and Ipilimumab and CDX-1401 in Patients With Unresectable Stage III or IV Melanoma,7557
3,NCT02335918,Phase Ib/II,Recruiting,"[{'id': 2526, 'therapyName': 'Nivolumab + Varlilumab'}]",A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors,7557
4,NCT02386111,Phase Ib/II,Terminated,"[{'id': 3057, 'therapyName': 'Sunitinib + Varlilumab'}]",A Study of Varlilumab (Anti-CD27) and Sunitinib in Patients With Metastatic Clear Cell Renal Cell Carcinoma,7557
5,NCT02284971,Phase I,Terminated,"[{'id': 2525, 'therapyName': 'Varlilumab'}]",Pilot Study of SBRT and CDX-1127 in Prostate Cancer (Prostate-04),7557
6,NCT02924038,Phase I,Recruiting,"[{'id': 4835, 'therapyName': 'IMA950 + poly ICLC '}, {'id': 2525, 'therapyName': 'Varlilumab'}]",A Study of Varlilumab and IMA950 Vaccine Plus Poly-ICLC in Patients With WHO Grade II Low-Grade Glioma (LGG),7557
7,NCT02270372,Phase I,Completed,"[{'id': 2525, 'therapyName': 'Varlilumab'}, {'id': 3051, 'therapyName': 'ONT-10'}]",Study of ONT-10 and Varlilumab to Treat Advanced Ovarian or Breast Cancer,7557
0,NCT03093870,Phase II,Not yet recruiting,"[{'id': 5543, 'therapyName': 'Capecitabine + Varlitinib'}, {'id': 1105, 'therapyName': 'Capecitabine'}]",Varlitinib in Combination With Capecitabine for Advanced or Metastatic Biliary Tract Cancer,7175
0,NCT01260506,Phase Ib/II,Unknown status,"[{'id': 2277, 'therapyName': 'Bevacizumab + VB-111'}]",Single-Arm Open-Label Multicenter Study of VB-111 in Patients With Recurrent Glioblastoma Multiforme,7479
1,NCT02511405,Phase III,"Active, not recruiting","[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 2276, 'therapyName': 'VB-111'}]","A Phase 3, Pivotal Trial of VB-111 Plus Bevacizumab vs. Bevacizumab in Patients With Recurrent Glioblastoma (GLOBE)",7479
0,NCT02723006,Phase I,Recruiting,"[{'id': 4198, 'therapyName': 'MLN2480 + Nivolumab'}, {'id': 4200, 'therapyName': 'MLN1202 + Nivolumab'}, {'id': 4202, 'therapyName': 'Ipilimumab + Nivolumab + Vedolizumab '}]","Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Investigational Treatments in Combination With Standard of Care Immune Checkpoint Inhibitors in Participants With Advanced Melanoma",8378
0,NCT00740805,Phase I,"Active, not recruiting","[{'id': 2989, 'therapyName': 'Aldoxorubicin + Cyclophosphamide + Veliparib'}]","Veliparib, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Non-Hodgkin Lymphoma",7042
1,NCT02849496,Phase II,Recruiting,"[{'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 4511, 'therapyName': 'Atezolizumab + Veliparib'}, {'id': 954, 'therapyName': 'Veliparib'}]",Veliparib and Atezolizumab Either Alone or in Combination in Treating Patients With Stage III-IV Triple Negative Breast Cancer,7042
2,NCT00989651,Phase I,"Active, not recruiting","[{'id': 3047, 'therapyName': 'Bevacizumab + Veliparib'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 700, 'therapyName': 'Cisplatin'}]","Carboplatin, Paclitaxel, Bevacizumab, and ABT-888 in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer",7042
3,NCT02921256,Phase II,Recruiting,"[{'id': 954, 'therapyName': 'Veliparib'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 4838, 'therapyName': 'Capecitabine + Veliparib'}, {'id': 1105, 'therapyName': 'Capecitabine'}]",Veliparib and Combination Chemotherapy in Treating Patient With Locally Advanced Rectal Cancer,7042
4,NCT02831179,Phase I,Withdrawn,"[{'id': 4463, 'therapyName': 'Capecitabine + Veliparib + Temozolomide'}]","Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor",7042
5,NCT02289690,Phase I,Recruiting,"[{'id': 1544, 'therapyName': 'Carboplatin + Etoposide + Veliparib'}]",Dose Escalation and Double-blind Study of Veliparib in Combination With Carboplatin and Etoposide in Treatment-naive Extensive Stage Disease Small Cell Lung Cancer,7042
6,NCT01711541,Phase Ib/II,Suspended,"[{'id': 1544, 'therapyName': 'Carboplatin + Etoposide + Veliparib'}, {'id': 1849, 'therapyName': 'Cisplatin + Fluorouracil + Hydroxyurea'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]",Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IV Head and Neck Cancer,7042
7,NCT01506609,Phase II,"Active, not recruiting","[{'id': 1193, 'therapyName': 'Veliparib + Temozolomide'}, {'id': 1544, 'therapyName': 'Carboplatin + Etoposide + Veliparib'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]",The Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide or In Combination With Carboplatin and Paclitaxel Versus Placebo in Subjects With BRCA1 and BRCA2 Mutation and Metastatic Breast Cancer,7042
8,NCT01386385,Phase Ib/II,Recruiting,"[{'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 1544, 'therapyName': 'Carboplatin + Etoposide + Veliparib'}]","Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery",7042
9,NCT02944396,Phase II,Recruiting,"[{'id': 5054, 'therapyName': 'Carboplatin + Paclitaxel + Pemetrexed + Veliparib'}, {'id': 5053, 'therapyName': 'Carboplatin + Paclitaxel + Pemetrexed + Nivolumab + Veliparib'}]",Study of Veliparib in Combination With Nivolumab and Platinum Doublet Chemotherapy in Participants With Metastatic or Advanced Non-Small Cell Lung Cancer (NSCLC),7042
10,NCT02723864,Phase I,Recruiting,"[{'id': 3993, 'therapyName': 'Cisplatin + Veliparib + VX-970'}]","Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors",7042
11,NCT01749397,Phase I,Recruiting,"[{'id': 2009, 'therapyName': 'Floxuridine + Veliparib'}]","Veliparib and Floxuridine in Treating Patients With Metastatic Epithelial Ovarian, Primary Peritoneal Cavity, or Fallopian Tube Cancer",7042
12,NCT02631733,Phase I,Recruiting,"[{'id': 3314, 'therapyName': 'Irinotecan + Veliparib'}]",Liposomal Irinotecan and Veliparib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery,7042
13,NCT02158507,Phase I,"Active, not recruiting","[{'id': 2543, 'therapyName': 'Lapatinib + Veliparib'}]","Pilot Study of Veliparib (ABT-888) and Lapatinib (Tykerb) in Patients With Metastatic, Triple Negative Breast Cancer",7042
14,NCT01145430,Phase I,"Active, not recruiting","[{'id': 2167, 'therapyName': 'pegylated liposomal doxorubicin + Veliparib'}]","Veliparib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer or Metastatic Breast Cancer",7042
15,NCT02890355,,Recruiting,"[{'id': 954, 'therapyName': 'Veliparib'}, {'id': 1315, 'therapyName': 'FOLFIRI'}]",FOLFIRI or Modified FOLFIRI and Veliparib as Second Line Therapy in Treating Patients With Metastatic Pancreatic Cancer,7042
16,NCT02595905,Phase I,Recruiting,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 954, 'therapyName': 'Veliparib'}]",Cisplatin With or Without Veliparib in Treating Patients With Stage IV Triple-Negative and/or BRCA Mutation-Associated Breast Cancer,7042
17,NCT01642251,Phase Ib/II,"Active, not recruiting","[{'id': 2585, 'therapyName': 'Cisplatin + Etoposide'}, {'id': 954, 'therapyName': 'Veliparib'}]",Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer or Metastatic Large Cell Neuroendocrine Non-small Cell Lung Cancer,7042
18,NCT02412371,Phase II,Recruiting,"[{'id': 954, 'therapyName': 'Veliparib'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]",A Study Evaluating the Efficacy and Tolerability of Veliparib in Combination With Paclitaxel/Carboplatin-Based Chemoradiotherapy Followed by Veliparib and Paclitaxel/Carboplatin Consolidation in Subjects With Stage III Non-Small Cell Lung Cancer,7042
19,NCT02163694,Phase III,Recruiting,"[{'id': 954, 'therapyName': 'Veliparib'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]","A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Cancer",7042
20,NCT01514201,Phase Ib/II,"Active, not recruiting","[{'id': 1141, 'therapyName': 'Temozolomide'}, {'id': 954, 'therapyName': 'Veliparib'}]","Veliparib, Radiation Therapy, and Temozolomide in Treating Younger Patients With Newly Diagnosed Diffuse Pontine Gliomas",7042
21,NCT01638546,Phase II,Completed,"[{'id': 1141, 'therapyName': 'Temozolomide'}, {'id': 954, 'therapyName': 'Veliparib'}]",Temozolomide With or Without Veliparib in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer,7042
22,NCT01351909,Phase Ib/II,"Active, not recruiting","[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 954, 'therapyName': 'Veliparib'}]",Cyclophosphamide With or Without Veliparib in Treating Patients With Locally Advanced or Metastatic Breast Cancer,7042
23,NCT02032277,Phase III,"Active, not recruiting","[{'id': 1977, 'therapyName': 'Doxorubicin + Cyclophosphamide'}, {'id': 954, 'therapyName': 'Veliparib'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]",A Study Evaluating Safety and Efficacy of the Addition of ABT-888 Plus Carboplatin Versus the Addition of Carboplatin to Standard Chemotherapy Versus Standard Chemotherapy in Subjects With Early Stage Triple Negative Breast Cancer,7042
24,NCT02470585,Phase III,"Active, not recruiting","[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 954, 'therapyName': 'Veliparib'}]","Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Subjects With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",7042
25,NCT01585805,Phase II,Recruiting,"[{'id': 954, 'therapyName': 'Veliparib'}, {'id': 1467, 'therapyName': 'Gemcitabine + Cisplatin'}]",Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Patients With Locally Advanced or Metastatic Pancreatic Cancer,7042
26,NCT01281150,Phase I,Completed,"[{'id': 954, 'therapyName': 'Veliparib'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1092, 'therapyName': 'Carboplatin'}]",Veliparib in Combination With Carboplatin and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors,7042
27,NCT01326702,Phase Ib/II,Completed,"[{'id': 954, 'therapyName': 'Veliparib'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1231, 'therapyName': 'Bendamustine'}]"," Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors",7042
28,NCT01576172,Phase II,"Active, not recruiting","[{'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 954, 'therapyName': 'Veliparib'}]",Abiraterone Acetate and Prednisone With or Without Veliparib in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer,7042
29,NCT01017640,Phase I,Completed,"[{'id': 954, 'therapyName': 'Veliparib'}, {'id': 1134, 'therapyName': 'Veliparib + Mitomycin C'}]"," Veliparib With or Without Mitomycin C in Treating Patients With Metastatic, Unresectable, or Recurrent Solid Tumors",7042
30,NCT02152982,Phase II,Suspended,"[{'id': 954, 'therapyName': 'Veliparib'}, {'id': 1141, 'therapyName': 'Temozolomide'}]",Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme,7042
31,NCT02009631,Phase I,Completed,"[{'id': 954, 'therapyName': 'Veliparib'}]",A Study to Evaluate the Effects of Veliparib on Heart Rhythms in Patients With Solid Tumors,7042
32,NCT01908478,Phase I,"Active, not recruiting","[{'id': 954, 'therapyName': 'Veliparib'}, {'id': 755, 'therapyName': 'Gemcitabine'}]","A Phase I Study of Veliparib (ABT-888) in Combination With Gemcitabine and Intensity Modulated Radiation Therapy in Patients With Locally Advanced, Unresectable Pancreatic Cancer",7042
33,NCT02106546,Phase III,"Active, not recruiting","[{'id': 954, 'therapyName': 'Veliparib'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]","Randomized, Double-Blind, Multicenter, Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Previously Untreated Advanced or Metastatic Squamous Non-Small Cell Lung Cancer",7042
34,NCT01853306,Phase I,Completed,"[{'id': 954, 'therapyName': 'Veliparib'}]","A Study to Evaluate the Safety, Pharmacokinetics and Oral Bio Availability of Veliparib in Subjects With Solid Tumors",7042
35,NCT01366144,Phase I,Recruiting,"[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 954, 'therapyName': 'Veliparib'}, {'id': 1092, 'therapyName': 'Carboplatin'}]","Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction",7042
36,NCT01489865,Phase Ib/II,Recruiting,"[{'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 954, 'therapyName': 'Veliparib'}]",ABT-888 With Modified FOLFOX6 in Patients With Metastatic Pancreatic Cancer,7042
37,NCT00576654,Phase I,Recruiting,"[{'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 954, 'therapyName': 'Veliparib'}]",Irinotecan Hydrochloride and Veliparib in Treating Patients With Cancer That Is Metastatic or Cannot Be Removed by Surgery,7042
38,NCT01264432,Phase I,"Active, not recruiting","[{'id': 954, 'therapyName': 'Veliparib'}]","Veliparib and Radiation Therapy in Treating Patients With Advanced Solid Malignancies With Peritoneal Carcinomatosis, Epithelial Ovarian, Fallopian, or Primary Peritoneal Cancer",7042
39,NCT02985658,Phase I,Available,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 954, 'therapyName': 'Veliparib'}, {'id': 1685, 'therapyName': 'Vinorelbine'}]",Expanded Access With ABT-888 (Veliparib) to Treat Metastatic Breast Cancer,7042
40,NCT02264990,Phase III,"Active, not recruiting","[{'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 954, 'therapyName': 'Veliparib'}, {'id': 700, 'therapyName': 'Cisplatin'}]",Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Subjects Receiving First Cytotoxic Chemotherapy for Metastatic or Advanced Non-Squamous Non-Small Cell Lung Cancer Who Are Current or Former Smokers,7042
41,NCT02305758,Phase II,Completed,"[{'id': 1315, 'therapyName': 'FOLFIRI'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 954, 'therapyName': 'Veliparib'}]",Study Comparing Veliparib Plus FOLFIRI Versus Placebo Plus FOLFIRI With or Without Bevacizumab in Previously Untreated Metastatic Colorectal Cancer,7042
42,NCT01459380,Phase I,Completed,"[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 954, 'therapyName': 'Veliparib'}, {'id': 667, 'therapyName': 'Bevacizumab'}]","Veliparib, Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer",7042
43,NCT00892736,Phase I,"Active, not recruiting","[{'id': 954, 'therapyName': 'Veliparib'}]",Veliparib in Treating Patients With Malignant Solid Tumors That Did Not Respond to Previous Therapy,7042
44,NCT01434316,Phase I,Recruiting,"[{'id': 1277, 'therapyName': 'Veliparib + Dinaciclib'}, {'id': 1278, 'therapyName': 'Veliparib + Dinaciclib + carboplatin'}]",Veliparib and Dinaciclib With or Without Carboplatin in Treating Patients With Advanced Solid Tumors,7042
45,NCT03061188,Phase I,Recruiting,"[{'id': 5368, 'therapyName': 'Veliparib + Nivolumab'}]",Nivolumab and Veliparib in Treating Patients With Recurrent or Refractory Stage IV Solid Tumors That Cannot Be Removed by Surgery or Lymphoma With or Without Alterations in DNA Repair Genes,7042
46,NCT01827384,Phase II,Recruiting,"[{'id': 1194, 'therapyName': 'MK-1775 + Carboplatin '}, {'id': 1193, 'therapyName': 'Veliparib + Temozolomide'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 2, 'therapyName': 'Trametinib'}]",Molecular Profiling-Based Targeted Therapy in Treating Patients With Advanced Solid Tumors,7042
47,NCT01012817,Phase Ib/II,Recruiting,"[{'id': 1132, 'therapyName': 'Veliparib + Topotecan'}]","Veliparib and Topotecan Hydrochloride in Treating Patients With Solid Tumors, Relapsed or Refractory Ovarian Cancer, or Primary Peritoneal Cancer",7042
0,NCT01754376,Phase II,Terminated,"[{'id': 1229, 'therapyName': 'Aldesleukin + Vemurafenib'}]",Combined BRAF-Targeted Therapy and Immunotherapy for Melanoma,6791
1,NCT01683188,Phase III,Terminated,"[{'id': 1229, 'therapyName': 'Aldesleukin + Vemurafenib'}]", HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma,6791
2,NCT01603212,Phase Ib/II,Completed,"[{'id': 1188, 'therapyName': 'Aldesleukin + Vemurafenib + IFN A2b'}]"," Systemic Therapy With Interferon, Interleukin-2 and BRAF Inhibitor",6791
3,NCT01656642,Phase I,"Active, not recruiting","[{'id': 1216, 'therapyName': 'Atezolizumab + vemurafenib'}]", A Phase 1b Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) in Combination With Vemurafinib (Zelboraf&#174;) in Patients With Previously Untreated BRAFV600-Mutation Positive Metastatic Melanoma,6791
4,NCT02908672,Phase III,Recruiting,"[{'id': 1657, 'therapyName': 'Vemurafenib + Cobimetinib'}, {'id': 4825, 'therapyName': 'Atezolizumab + Vemurafenib + Cobimetinib'}]",A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Participants With Metastatic or Unresectable Locally Advanced Melanoma,6791
5,NCT03181100,Phase II,Recruiting,"[{'id': 619, 'therapyName': 'Abraxane'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1343, 'therapyName': 'Atezolizumab + Cobimetinib'}, {'id': 4595, 'therapyName': 'Atezolizumab + Bevacizumab'}, {'id': 3049, 'therapyName': 'Atezolizumab + nab-paclitaxel'}, {'id': 4825, 'therapyName': 'Atezolizumab + Vemurafenib + Cobimetinib'}, {'id': 5606, 'therapyName': 'Atezolizumab + Paclitaxel'}]",Atezolizumab Combinations With Chemotherapy for Anaplastic and Poorly Differentiated Thyroid Carcinomas,6791
6,NCT01512251,Phase Ib/II,Completed,"[{'id': 1322, 'therapyName': 'BKM120 + Vemurafenib'}]",BKM120 Combined With Vemurafenib (PLX4032) in BRAFV600E/K Mutant Advanced Melanoma,6791
7,NCT01835184,Phase I,Terminated,"[{'id': 1235, 'therapyName': 'Cabozantinib + Vemurafenib'}]",Cabozantinib-S-Malate and Vemurafenib in Treating Patients With Solid Tumors or Melanoma That is Metastatic or That Cannot Be Removed By Surgery,6791
8,NCT02014909,Phase I,Completed,"[{'id': 2054, 'therapyName': 'CDX-3379'}, {'id': 2063, 'therapyName': 'CDX-3379 + Vemurafenib'}, {'id': 2064, 'therapyName': 'CDX-3379 + Trastuzumab'}, {'id': 2061, 'therapyName': 'Cetuximab + CDX-3379'}, {'id': 2062, 'therapyName': 'CDX-3379 + Erlotinib'}]",A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of KTN3379 in Adult Subjects With Advanced Tumors,6791
9,NCT02456701,Phase I,Completed,"[{'id': 2063, 'therapyName': 'CDX-3379 + Vemurafenib'}]",Enhancing Radioiodine Incorporation Into BRAF Mutant Thyroid Cancers With the Combination of Vemurafenib and KTN3379,6791
10,NCT03101254,Phase Ib/II,Recruiting,"[{'id': 5512, 'therapyName': 'Cobimetinib + LY3022855 + Vemurafenib'}]",LY3022855 With BRAF/MEK Inhibition in Patients With Melanoma,6791
11,NCT02721459,Phase I,Recruiting,"[{'id': 3995, 'therapyName': 'Cobimetinib + XL888 + Vemurafenib'}]",XL888 + Vemurafenib + Cobimetinib for Unresectable B Rapidly Accelerated Fibrosarcoma (BRAF) Mutated Stage III/IV Melanoma,6791
12,NCT03013491,Phase II,Recruiting,"[{'id': 5209, 'therapyName': 'CX-072 + Ipilimumab'}, {'id': 5210, 'therapyName': 'CX-072 + Vemurafenib'}, {'id': 5208, 'therapyName': 'CX-072'}]",A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas,6791
13,NCT01974258,Phase I,Withdrawn,"[{'id': 1306, 'therapyName': 'Onartuzumab + Vemurafenib'}, {'id': 1307, 'therapyName': 'Onartuzumab + Cobimetinib'}, {'id': 1308, 'therapyName': 'Onartuzumab + Cobimetinib + Vemurafenib'}]","Safety, Tolerability, and Pharmacokinetics of Onartuzumab Combined With Vemurafenib and/or Cobimetinib in Cancer Patients",6791
14,NCT02818023,Phase I,Recruiting,"[{'id': 4406, 'therapyName': 'Pembrolizumab + Vemurafenib'}]",Dose-seeking and Efficacy Study of Pembrolizumab Plus Vemurafenib Advanced Melanoma,6791
15,NCT01826448,Phase I,Terminated,"[{'id': 1339, 'therapyName': 'PLX3397 + Vemurafenib'}]"," A Phase 1b Open Label, Dose Escalation Study of PLX3397 in Combination With Vemurafenib in V600-mutated BRAF Melanoma",6791
16,NCT01765543,Phase I,Completed,"[{'id': 1256, 'therapyName': 'Rifampin + Vemurafenib'}]",A Pharmacokinetics Study to Investigate the Effect of Rifampin on Vemurafenib in Patients With BRAFV600 Mutation-Positive Metastatic Malignancy,6791
17,NCT01673737,Phase I,Completed,"[{'id': 1052, 'therapyName': 'SAR260301'}, {'id': 1225, 'therapyName': 'SAR260301 + Vemurafenib'}]", A Phase I/Ib Trial for the Evaluation of SAR260301 in Monotherapy or in Combination With Vemurafenib in Patients With Various Advanced Cancer,6791
18,NCT01709292,Phase II,"Active, not recruiting","[{'id': 342, 'therapyName': 'Vemurafenib'}]",Vemurafenib Neoadjuvant Trial in Locally Advanced Thyroid Cancer,6791
19,NCT01739764,Phase III,Recruiting,"[{'id': 342, 'therapyName': 'Vemurafenib'}]", An Extension (Rollover) Study of Vemurafenib in Patients With BRAF V600 Mutation-Positive Malignancies Previously Enrolled in an Antecedent Vemurafenib Protocol,6791
20,NCT02382549,Phase Ib/II,Recruiting,"[{'id': 342, 'therapyName': 'Vemurafenib'}, {'id': 2620, 'therapyName': '6MHP vaccine'}]",A Clinical Trial to Evaluate a Helper Peptide Vaccine Plus Vemurafenib in Melanoma,6791
21,NCT01843738,Phase I,Withdrawn,"[{'id': 342, 'therapyName': 'Vemurafenib'}]",Radiation Use During Vemurafenib Treatment,6791
22,NCT03155620,Phase II,Recruiting,"[{'id': 2683, 'therapyName': 'Tazemetostat'}, {'id': 2650, 'therapyName': 'LOXO-101'}, {'id': 1069, 'therapyName': 'LY3023414'}, {'id': 342, 'therapyName': 'Vemurafenib'}, {'id': 837, 'therapyName': 'Olaparib'}, {'id': 913, 'therapyName': 'Selumetinib'}, {'id': 961, 'therapyName': 'X-396'}]",Pediatric MATCH: Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Advanced Refractory Solid Tumors or Lymphomas,6791
23,NCT01586195,Phase II,Terminated,"[{'id': 342, 'therapyName': 'Vemurafenib'}]"," Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E",6791
24,NCT02427893,Phase III,Withdrawn,"[{'id': 1004, 'therapyName': 'Cobimetinib'}, {'id': 342, 'therapyName': 'Vemurafenib'}]",Trial of Vemurafenib and Cobimetinib in Patients With Advanced BRAFV600 Mutant Melanoma,6791
25,NCT02788201,Phase II,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1133, 'therapyName': 'Mitomycin C'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1013, 'therapyName': 'epirubicin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1137, 'therapyName': 'Bleomycin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 781, 'therapyName': 'Ixabepilone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 2950, 'therapyName': 'Estramustine'}, {'id': 1941, 'therapyName': 'Floxuridine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 1811, 'therapyName': 'Carmustine'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 953, 'therapyName': 'Vandetanib'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 4419, 'therapyName': 'Toremifine'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 2601, 'therapyName': 'Dactinomycin'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 3035, 'therapyName': 'Chlorambucil'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 342, 'therapyName': 'Vemurafenib'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 2635, 'therapyName': 'Vinblastine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 4305, 'therapyName': 'Teniposide'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 4304, 'therapyName': 'Streptozocin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1231, 'therapyName': 'Bendamustine'}, {'id': 4303, 'therapyName': 'Mechlorethamine'}, {'id': 4302, 'therapyName': 'Mitotane'}]",Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma,6791
26,NCT01781026,Phase II,Completed,"[{'id': 342, 'therapyName': 'Vemurafenib'}]",Phase 2 Study of Neoadjuvant Vemurafenib in Melanoma Patients With Untreated Brain Metastases,6791
27,NCT01519323,Phase I,Terminated,"[{'id': 342, 'therapyName': 'Vemurafenib'}]", BRIM-P,6791
28,NCT01748149,Phase I,Recruiting,"[{'id': 342, 'therapyName': 'Vemurafenib'}]",Vemurafenib in Children With Recurrent/Refractory BRAFV600E-mutant Gliomas,6791
29,NCT01495988,Phase II,Terminated,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 342, 'therapyName': 'Vemurafenib'}]",Trial of Vemurafenib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma,6791
30,NCT02145910,Phase I,Withdrawn,"[{'id': 342, 'therapyName': 'Vemurafenib'}]",Vemurafenib Combined With Whole Brain Radiation Therapy or Radiosurgery in Patients With BRAF Mutation-Positive Melanoma and Brain Metastases,6791
31,NCT01711632,Phase II,"Active, not recruiting","[{'id': 342, 'therapyName': 'Vemurafenib'}]","BRAF Inhibitor, Vemurafenib, in Patients With Relapsed or Refractory Hairy Cell Leukemia",6791
32,NCT02145143,Phase I,"Active, not recruiting","[{'id': 342, 'therapyName': 'Vemurafenib'}]","Enhancing Radioiodine (RAI) Incorporation Into BRAF Mutant, RAI-Refractory Thyroid Cancers With the BRAF Inhibitor Vemurafenib",6791
33,NCT01909453,Phase III,"Active, not recruiting","[{'id': 342, 'therapyName': 'Vemurafenib'}, {'id': 796, 'therapyName': 'Encorafenib'}, {'id': 1100, 'therapyName': 'Binimetinib + Encorafenib'}]",Study Comparing Combination of LGX818 Plus MEK162 and LGX818 Monotherapy Versus Vemurafenib in BRAF Mutant Melanoma,6791
34,NCT01667419,Phase III,"Active, not recruiting","[{'id': 342, 'therapyName': 'Vemurafenib'}]",BRIM8: A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma,6791
35,NCT01767623,Phase I,"Active, not recruiting","[{'id': 342, 'therapyName': 'Vemurafenib'}]", A Study of The Impact of Severe Hepatic Impairment on the Pharmacokinetics and Safety of Vemurafenib in BRAF V600 Mutation-Positive Cancer Patients,6791
36,NCT01813214,Phase II,Terminated,"[{'id': 342, 'therapyName': 'Vemurafenib'}]", The Effects of Vemurafenib on Immunity in Patients With Melanoma,6791
37,NCT01942993,Phase II,Terminated,"[{'id': 342, 'therapyName': 'Vemurafenib'}]",The Effects of Treatment With Vemurafenib on the Immune System in Advanced Melanoma,6791
38,NCT01524978,Phase II,"Active, not recruiting","[{'id': 342, 'therapyName': 'Vemurafenib'}, {'id': 694, 'therapyName': 'Cetuximab'}]",A Study of Zelboraf (Vemurafenib) in Patients With BRAF V600 Mutation-Positive Cancers,6791
39,NCT03220035,Phase II,Recruiting,"[{'id': 342, 'therapyName': 'Vemurafenib'}]","Pediatric MATCH: Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations",6791
40,NCT01659151,Phase II,"Active, not recruiting","[{'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 342, 'therapyName': 'Vemurafenib'}]", Vemurafenib With Lymphodepletion Plus Adoptive Cell Transfer &amp; High Dose IL-2 Metastatic Melanoma,6791
41,NCT02050321,Phase II,Terminated,"[{'id': 1936, 'therapyName': 'Vemurafenib + Acitretin'}]",A Phase II Study of Vemurafenib Combined With Acitretin in Patients With Advanced Melanoma,6791
42,NCT01636622,Phase I,"Active, not recruiting","[{'id': 1209, 'therapyName': 'Vemurafenib + Carboplatin + Paclitaxel '}]"," Study of Vemurafenib, Carboplatin, and Paclitaxel",6791
43,NCT01787500,Phase I,"Active, not recruiting","[{'id': 1331, 'therapyName': 'Vemurafenib + Cetuximab + Irinotecan '}]","Vemurafenib, Cetuximab, and Irinotecan in Advanced Solid Cancers",6791
44,NCT02164916,Phase II,"Active, not recruiting","[{'id': 1874, 'therapyName': 'Cetuximab + Irinotecan'}, {'id': 1331, 'therapyName': 'Vemurafenib + Cetuximab + Irinotecan '}]",S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer,6791
45,NCT02036086,Phase II,Recruiting,"[{'id': 1657, 'therapyName': 'Vemurafenib + Cobimetinib'}]",Study of Neo-adjuvant Use of Vemurafenib Plus Cobimetinib for BRAF Mutant Melanoma With Palpable Lymph Node Metastases,6791
46,NCT02693535,Phase II,Recruiting,"[{'id': 1657, 'therapyName': 'Vemurafenib + Cobimetinib'}, {'id': 890, 'therapyName': 'Regorafenib'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 690, 'therapyName': 'Bosutinib'}, {'id': 850, 'therapyName': 'Palbociclib'}, {'id': 694, 'therapyName': 'Cetuximab'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 837, 'therapyName': 'Olaparib'}, {'id': 4, 'therapyName': 'Erlotinib'}]",TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer,6791
47,NCT03005639,Phase II,Recruiting,"[{'id': 1657, 'therapyName': 'Vemurafenib + Cobimetinib'}]",ML29255 Neoadjuvant Vemurafenib and Cobimetinib Melanoma,6791
48,NCT03224767,Phase II,Recruiting,"[{'id': 1657, 'therapyName': 'Vemurafenib + Cobimetinib'}]",Vemurafenib and Cobimetinib in Treating Patients With BRAF V600E Mutation Positive Craniopharyngioma,6791
49,NCT02091141,Phase II,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 698, 'therapyName': 'Alectinib'}, {'id': 1657, 'therapyName': 'Vemurafenib + Cobimetinib'}, {'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 1201, 'therapyName': 'Atezolizumab'}]","My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors",6791
50,NCT02230306,Phase II,Terminated,"[{'id': 1657, 'therapyName': 'Vemurafenib + Cobimetinib'}]",Phase II Study of Cobimetinib in Combination With Vemurafenib in Active Melanoma Brain Metastases,6791
51,NCT01876641,Phase Ib/II,Recruiting,"[{'id': 1259, 'therapyName': 'Vemurafenib + Decitabine'}]",Treatment of a Resistant Disease Using Decitabine Combined With Vemurafenib,6791
52,NCT01596140,Phase I,"Active, not recruiting","[{'id': 1175, 'therapyName': 'Vemurafenib + Temsirolimus'}, {'id': 1174, 'therapyName': 'Vemurafenib + Everolimus'}]",Vemurafenib in Combination With Everolimus or Temsirolimus With Advanced Cancer,6791
53,NCT01897116,Phase I,"Active, not recruiting","[{'id': 1281, 'therapyName': 'Vemurafenib + Hydroxychloroquine'}]", A Phase I Trial of Vemurafenib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma,6791
54,NCT01943422,Phase Ib/II,"Active, not recruiting","[{'id': 1300, 'therapyName': 'Vemurafenib + Interferon alfa-2b'}]",Safety and Efficacy Study of Vemurafenib and High-dose Interferon Alfa-2b in Melanoma,6791
55,NCT01638676,Phase Ib/II,Recruiting,"[{'id': 1210, 'therapyName': 'Vemurafenib + Metformin '}]", A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients,6791
56,NCT01531361,Phase I,Recruiting,"[{'id': 706, 'therapyName': 'Crizotinib'}, {'id': 1326, 'therapyName': 'Vemurafenib + Sorafenib'}]",Sorafenib or Crizotinib and Vemurafenib in Advanced Cancer,6791
57,NCT01844674,Phase I,Completed,"[{'id': 1241, 'therapyName': 'Vemurafenib + Tizanidine'}]",A Study on the Effect of Vemurafenib on the Pharmacokinetics of a Single Dose of Tizanidine in Patients With BRAFV600 Mutation-Positive Metastatic Malignancies,6791
58,NCT02068079,Phase I,Withdrawn,"[{'id': 1383, 'therapyName': 'Vemurafenib + Trientine'}]",A Pilot Study of Trientine With Vemurafenib for the Treatment BRAF Mutated Metastatic Melanoma,6791
59,NCT01841463,Phase Ib/II,Suspended,"[{'id': 1238, 'therapyName': 'Vemurafenib + Voruciclib'}]",Study of an Oral Cdk Inhibitor Administered With an Oral BRAF Inhibitor in Patients With Advanced or Inoperable Malignant Melanoma With BRAF Mutation,6791
60,NCT01657591,Phase I,"Active, not recruiting","[{'id': 1217, 'therapyName': 'XL888 + Vemurafenib'}]", Study of XL888 With Vemurafenib for Patients With Unresectable BRAF Mutated Stage III/IV Melanoma,6791
0,NCT03128879,Phase II,"Active, not recruiting","[{'id': 5876, 'therapyName': 'Allopurinol + Ibrutinib + Venetoclax'}]",Study of Venetoclax (ABT-199) Added to Ibrutinib in Patients With High-Risk Chronic Lymphocytic Leukemia (CLL),7284
1,NCT01671904,Phase I,"Active, not recruiting","[{'id': 3638, 'therapyName': 'Bendamustine + GDC-0199 + Obinutuzumab'}, {'id': 3637, 'therapyName': 'Bendamustine + GDC-0199 + Rituximab'}]","A Study of Venetoclax (GDC-0199, ABT-199) in Combination With Bendamustine And MabThera/Rituxan in Participants With Chronic Lymphocytic Leukemia",7284
2,NCT02187861,Phase II,"Active, not recruiting","[{'id': 2323, 'therapyName': 'Bendamustine + Rituximab'}, {'id': 3637, 'therapyName': 'Bendamustine + GDC-0199 + Rituximab'}, {'id': 3937, 'therapyName': 'GDC-0199 + Rituximab'}]",A Study Evaluating the Safety and Efficacy of GDC-0199 (ABT-199) Plus Bendamustine + Rituximab (BR) in Comparison With BR or GDC-0199 Plus Rituximab in Patients With Relapsed and Refractory Follicular Non-Hodgkin's Lymphoma,7284
3,NCT02755597,Phase III,Recruiting,"[{'id': 2470, 'therapyName': 'Bortezomib + Dexamethasone'}, {'id': 3436, 'therapyName': 'Bortezomib + Dexamethasone + GDC-0199\t'}]",A Study Evaluating Venetoclax (ABT-199) in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy,7284
4,NCT01794507,Phase I,"Active, not recruiting","[{'id': 3436, 'therapyName': 'Bortezomib + Dexamethasone + GDC-0199\t'}]",A Study Evaluating ABT-199 in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy,7284
5,NCT02899052,Phase II,Recruiting,"[{'id': 5268, 'therapyName': 'Carfilzomib + Dexamethasone + Venetoclax'}]",Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma (MM),7284
6,NCT02670044,Phase Ib/II,Recruiting,"[{'id': 4171, 'therapyName': 'Cobimetinib + Venetoclax'}, {'id': 4172, 'therapyName': 'RO5503781 + Venetoclax'}]",A Study of Venetoclax in Combination With Cobimetinib and Venetoclax in Combination With Idasanutlin in Patients Aged >/= 60 Years With Relapsed or Refractory Acute Myeloid Leukemia Who Are Not Eligible for Cytotoxic Therapy,7284
7,NCT02287233,Phase I,"Active, not recruiting","[{'id': 3182, 'therapyName': 'Cytarabine + GDC-0199'}]",A Study Evaluating ABT-199 in Combination With Low-Dose Cytarabine in Treatment-Naïve Subjects With Acute Myelogenous Leukemia (AML),7284
8,NCT03069352,Phase III,Recruiting,"[{'id': 3182, 'therapyName': 'Cytarabine + GDC-0199'}, {'id': 712, 'therapyName': 'Cytarabine'}]",A Study of Venetoclax in Combination With Low Dose Cytarabine Versus Low Dose Cytarabine Alone in Treatment Naïve Patients With Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy,7284
9,NCT02203773,Phase I,"Active, not recruiting","[{'id': 1636, 'therapyName': 'GDC-0199 + Decitabine'}, {'id': 1637, 'therapyName': 'GDC-0199 + Azacitidine'}]",Phase 1b Acute Myelogenous Leukemia (AML) Study With ABT-199 + Decitabine or Azacitidine (Chemo Combo),7284
10,NCT02993523,Phase III,Recruiting,"[{'id': 1637, 'therapyName': 'GDC-0199 + Azacitidine'}, {'id': 651, 'therapyName': 'Azacitidine'}]",A Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Treatment Naïve Elderly Subjects With Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy,7284
11,NCT02966782,Phase I,Recruiting,"[{'id': 1637, 'therapyName': 'GDC-0199 + Azacitidine'}, {'id': 1562, 'therapyName': 'Venetoclax'}]",A Study Evaluating Venetoclax Alone and in Combination With Azacitidine in Subjects With Higher-Risk Myelodysplastic Syndromes (MDS) After Hypomethylating Agent-Failure,7284
12,NCT02942290,Phase II,Recruiting,"[{'id': 651, 'therapyName': 'Azacitidine'}, {'id': 1637, 'therapyName': 'GDC-0199 + Azacitidine'}]",A Study Evaluating Venetoclax in Combination With Azacitidine Compared With Azacitidine Alone in Participants With Previously Untreated Higher-Risk Myelodysplastic Syndromes (MDS),7284
13,NCT02640833,Phase I,Withdrawn,"[{'id': 3624, 'therapyName': 'GDC-0199 + Duvelisib'}]","A Study of Duvelisib and Venetoclax in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Indolent or Aggressive Non-Hodgkin Lymphoma, Who Have Not Previously Received a Bcl-2 or PI3K Inhibitor",7284
14,NCT02910583,Phase II,"Active, not recruiting","[{'id': 768, 'therapyName': 'Ibrutinib'}, {'id': 3392, 'therapyName': 'GDC-0199 + Ibrutinib'}]",Ibrutinib Plus Venetoclax in Patients With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma,7284
15,NCT02419560,Phase I,Suspended,"[{'id': 3392, 'therapyName': 'GDC-0199 + Ibrutinib'}]",Optimal Dose Finding Study ABT-199 and Ibrutinib in MCL,7284
16,NCT03045328,Phase Ib/II,Recruiting,"[{'id': 3392, 'therapyName': 'GDC-0199 + Ibrutinib'}]",Venetoclax and Ibrutinib in Patients With Relapsed/Refractory CLL or SLL,7284
17,NCT02756897,Phase II,Recruiting,"[{'id': 3392, 'therapyName': 'GDC-0199 + Ibrutinib'}]",Venetoclax and Ibrutinib in Patients With Chronic Lymphocytic Leukemia (CLL),7284
18,NCT02956382,Phase Ib/II,Recruiting,"[{'id': 3392, 'therapyName': 'GDC-0199 + Ibrutinib'}]",Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma,7284
19,NCT03112174,Phase III,Recruiting,"[{'id': 768, 'therapyName': 'Ibrutinib'}, {'id': 3392, 'therapyName': 'GDC-0199 + Ibrutinib'}]",Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO),7284
20,NCT02427451,Phase Ib/II,"Active, not recruiting","[{'id': 3472, 'therapyName': 'GDC-0199 + Ibrutinib + Obinutuzumab'}]","Bcl-2 Inhibitor GDC-0199 in Combination With Obinutuzumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or Previously Untreated Chronic Lymphocytic Leukemia",7284
21,NCT02242942,Phase III,"Active, not recruiting","[{'id': 1648, 'therapyName': 'Obinutuzumab + Chlorambucil'}, {'id': 3636, 'therapyName': 'GDC-0199 + Obinutuzumab'}]",A Study to Compare the Efficacy and Safety of Obinutuzumab + GDC-0199 Versus Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemia,7284
22,NCT01685892,Phase I,"Active, not recruiting","[{'id': 3636, 'therapyName': 'GDC-0199 + Obinutuzumab'}]",A Study of Venetoclax (GDC-0199; ABT-199) in Combination With Obinutuzumab in Participants With Chronic Lymphocytic Leukemia,7284
23,NCT03223610,Phase I,Not yet recruiting,"[{'id': 6189, 'therapyName': 'Ibrutinib + Lenalidomide + Obinutuzumab + Prednisone + Venetoclax'}]","Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma",7284
24,NCT03136497,Phase I,Recruiting,"[{'id': 5777, 'therapyName': 'Ibrutinib + Rituximab + Venetoclax'}]",A Study of ABT-199 Plus Ibrutinib and Rituximab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL),7284
25,NCT03135262,Phase Ib/II,Recruiting,"[{'id': 5646, 'therapyName': 'Idasanutlin + Rituximab + Venetoclax'}, {'id': 5644, 'therapyName': 'Idasanutlin + Obinutuzumab + Venetoclax'}, {'id': 5645, 'therapyName': 'Idasanutlin + Obinutuzumab + Rituximab + Venetoclax'}]",A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large B-Cell Lymphoma (DLBCL),7284
26,NCT02992522,Phase I,Recruiting,"[{'id': 5133, 'therapyName': 'Lenalidomide + Obinutuzumab + Venetoclax'}]","Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma",7284
27,NCT02639910,Phase II,Recruiting,"[{'id': 5785, 'therapyName': 'MOR208 + Venetoclax'}, {'id': 5784, 'therapyName': 'Idelalisib + MOR208'}]",Study to Evaluate Efficacy and Safety of MOR208 With Idelalisib or Venetoclax in R/R CLL/SLL Patients Pretreated With BTKi (COSMOS),7284
28,NCT03181126,Phase I,Not yet recruiting,"[{'id': 6187, 'therapyName': 'Navitoclax + Venetoclax'}]",A Study of Venetoclax in Combination With Navitoclax and Chemotherapy in Subjects With Relapsed Acute Lymphoblastic Leukemia,7284
29,NCT02611323,Phase Ib/II,Recruiting,"[{'id': 4227, 'therapyName': 'Obinutuzumab + Polatuzumab Vedotin + Venetoclax'}]","A Study of Obinutuzumab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)",7284
30,NCT03255096,Phase I,Recruiting,"[{'id': 6179, 'therapyName': 'Rituximab + TEN-010 + Venetoclax'}]","A Study to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of the Combination of RO6870810 and Venetoclax, With or Without Rituximab, in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)",7284
31,NCT01794520,Phase I,"Active, not recruiting","[{'id': 1562, 'therapyName': 'Venetoclax'}]",Study Evaluating ABT-199 in Subjects With Relapsed or Refractory Multiple Myeloma,7284
32,NCT03214562,,Recruiting,"[{'id': 1562, 'therapyName': 'Venetoclax'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 712, 'therapyName': 'Cytarabine'}]",Study of the BCL-2 Inhibitor Venetoclax in Combination With Standard Intensive Acute Myeloid Leukemia (AML) Induction/Consolidation Therapy With FLAG-IDA in Patients With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia (AML),7284
33,NCT02055820,Phase I,"Active, not recruiting","[{'id': 1562, 'therapyName': 'Venetoclax'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 3266, 'therapyName': 'Cyclophosphamide + Doxorubicin + Prednisone + Vincristine '}, {'id': 1646, 'therapyName': 'Obinutuzumab'}]",A Safety and Pharmacokinetics Study of GDC-0199 (ABT-199) in Patients With Non-Hodgkin's Lymphoma,7284
34,NCT01889186,Phase II,"Active, not recruiting","[{'id': 1562, 'therapyName': 'Venetoclax'}]",A Study of the Efficacy of ABT-199 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia With the 17p Deletion,7284
35,NCT02756611,Phase III,Recruiting,"[{'id': 1562, 'therapyName': 'Venetoclax'}]",A Study to Evaluate the Efficacy of Venetoclax in Relapsed/Refractory Participants With Chronic Lymphocytic Leukemia (CLL) Including Those With 17p Deletion or TP53 Mutation or Those Who Are Refractory or Intolerant to B-cell Receptor Inhibitors,7284
36,NCT02005471,Phase III,"Active, not recruiting","[{'id': 1562, 'therapyName': 'Venetoclax'}, {'id': 1231, 'therapyName': 'Bendamustine'}, {'id': 897, 'therapyName': 'Rituximab'}]",A Study of GDC-0199 (ABT-199) Plus MabThera/Rituxan (Rituximab) Compared With Bendamustine Plus MabThera/Rituxan (Rituximab) in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia,7284
37,NCT02141282,Phase II,"Active, not recruiting","[{'id': 1562, 'therapyName': 'Venetoclax'}]",A Phase 2 Open-Label Study of the Efficacy and Safety of ABT-199 (GDC-0199) in Chronic Lymphocytic Leukemia (CLL) Subjects With Relapse or Refractory to B-Cell Receptor Signaling Pathway Inhibitor Therapy,7284
38,NCT03236857,Phase I,Not yet recruiting,"[{'id': 1562, 'therapyName': 'Venetoclax'}]",A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies,7284
39,NCT03036904,Phase I,Recruiting,"[{'id': 5294, 'therapyName': 'Venetoclax + DA-EPOCH-R'}]",Study of Venetoclax Plus DA-EPOCH-R for the Treatment of Aggressive B-Cell Lymphomas (V+DA-EPOCH-R),7284
40,NCT03064867,Phase I,Recruiting,"[{'id': 5404, 'therapyName': 'Venetoclax + Rituximab + Ifosfamide + Carboplatin + Etoposide'}]",Venetoclax Plus R-ICE Chemotherapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma,7284
0,NCT03033225,Phase II,Recruiting,"[{'id': 3319, 'therapyName': 'Verteporfin'}]",EUS-guided PDT in Pancreatic Tumors,452
1,NCT03067051,Phase I,Recruiting,"[{'id': 3319, 'therapyName': 'Verteporfin'}]",Clinical Study to Assess the Safety and Adequacy of Effectiveness of the SpectraCure P18 System,452
2,NCT02939274,Phase II,Recruiting,"[{'id': 3319, 'therapyName': 'Verteporfin'}]","An Open Label, Phase II Trial of Continuous Low-Irradiance Photodynamic Therapy (CLIPT) Using Verteporfin (Visudyne) for the Treatment of Cutaneous Metastases of Breast Cancer",452
3,NCT02464761,Phase I,Recruiting,"[{'id': 3319, 'therapyName': 'Verteporfin'}]",Photodynamic Therapy for the Treatment of Vertebral Metastases,452
0,NCT02035137,,Recruiting,"[{'id': 1425, 'therapyName': '131I-MIBG'}, {'id': 1426, 'therapyName': '131I-MIBG + Irinotecan + Vincristine'}, {'id': 1427, 'therapyName': '131I-MIBG + Vorinostat'}]",131I-MIBG Alone VS. 131I-MIBG With Vincristine and Irinotecan VS131I-MIBG With Vorinistat,531
1,NCT02412670,Phase II,Recruiting,"[{'id': 2667, 'therapyName': 'Carboplatin + Gemcitabine'}, {'id': 2668, 'therapyName': 'Aldoxorubicin + Cisplatin + Methotrexate + Vincristine'}]",Chemotherapy Before Surgery in Treating Patients With High Grade Upper Urinary Tract Cancer,531
2,NCT02626455,Phase III,Recruiting,"[{'id': 1631, 'therapyName': 'Vincristine'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 3388, 'therapyName': 'Aldoxorubicin +Cyclophosphamide + Prednisone + Rituximab + Vincristine'}, {'id': 995, 'therapyName': 'Copanlisib'}, {'id': 2323, 'therapyName': 'Bendamustine + Rituximab'}, {'id': 897, 'therapyName': 'Rituximab'}]",Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL),531
3,NCT02703272,Phase III,Recruiting,"[{'id': 768, 'therapyName': 'Ibrutinib'}, {'id': 4307, 'therapyName': 'Carboplatin + Dexamethasone + Etoposide + Ifosfamide + Rituximab'}, {'id': 4308, 'therapyName': 'Carboplatin + Dexamethasone + Idarubicin + Ifosfamide + Rituximab + Vincristine'}]",A Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Participants With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma,531
4,NCT02116959,Phase I,Unknown status,"[{'id': 2559, 'therapyName': 'Carboplatin + Etoposide + Melphalan + Vincristine'}]",Alternating Systemic Chemotherapy and Intra-Arterial Melphalan Chemotherapy in Children With Intra-Ocular Retinoblastoma,531
5,NCT00980460,Phase III,Recruiting,"[{'id': 2298, 'therapyName': 'Irinotecan + Temsirolimus + Vincristine'}, {'id': 2297, 'therapyName': 'Cisplatin + Fluorouracil + Vincristine'}, {'id': 1009, 'therapyName': 'Doxorubicin'}]",Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer,531
6,NCT01878617,Phase II,Recruiting,"[{'id': 956, 'therapyName': 'Vismodegib'}, {'id': 1800, 'therapyName': 'Cyclophosphamide + Cisplatin + Vincristine '}, {'id': 1801, 'therapyName': 'Pemetrexed + Gemcitabine'}]",A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma,531
7,NCT02420717,Phase II,Recruiting,"[{'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 3195, 'therapyName': 'Cytarabine + Methotrexate '}, {'id': 2046, 'therapyName': 'Cyclophosphamide + Dexamethasone + Doxorubicin + Vincristine '}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 3194, 'therapyName': 'Mercaptopurine + Methotrexate + Prednisone + Vincristine'}]",Ruxolitinib or Dasatinib With Chemotherapy in Patients With Philadelphia Chromosome (Ph)-Like Acute Lymphoblastic Leukemia (ALL),531
8,NCT01424982,Phase II,Recruiting,"[{'id': 1476, 'therapyName': 'Pegfilgrastim'}, {'id': 2048, 'therapyName': 'Cytarabine + Methotrexate + Ponatinib'}, {'id': 2049, 'therapyName': 'Ponatinib + Vincristine'}, {'id': 2046, 'therapyName': 'Cyclophosphamide + Dexamethasone + Doxorubicin + Vincristine '}, {'id': 1642, 'therapyName': 'Leucovorin'}]",Hyper-CVAD and Ponatinib in Ph-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL),531
9,NCT02636322,Phase II,Recruiting,"[{'id': 2482, 'therapyName': 'Cyclophosphamide + Doxorubicin + Etoposide + Vincristine '}, {'id': 1610, 'therapyName': 'Rituximab + Lenalidomide + Ibrutinib'}, {'id': 2188, 'therapyName': 'Prednisone'}]","A Study of Rituximab, Lenalidomide, and Ibrutinib Combined With Dose Adjusted Chemotherapy For Patients With High Risk Diffuse Large B-Cell Lymphoma",531
10,NCT02337985,Phase I,Recruiting,"[{'id': 897, 'therapyName': 'Rituximab'}, {'id': 2482, 'therapyName': 'Cyclophosphamide + Doxorubicin + Etoposide + Vincristine '}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 2188, 'therapyName': 'Prednisone'}]",Gene Therapy and Combination Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin Lymphoma,531
11,NCT02531308,Phase II,Terminated,"[{'id': 1031, 'therapyName': 'Metformin'}, {'id': 3266, 'therapyName': 'Cyclophosphamide + Doxorubicin + Prednisone + Vincristine '}, {'id': 1476, 'therapyName': 'Pegfilgrastim'}, {'id': 897, 'therapyName': 'Rituximab'}]",Metformin in Combination With Standard Induction Therapy for Large B-cell Lymphoma (DLBCL),531
12,NCT01855750,Phase III,"Active, not recruiting","[{'id': 768, 'therapyName': 'Ibrutinib'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 3266, 'therapyName': 'Cyclophosphamide + Doxorubicin + Prednisone + Vincristine '}]","A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma",531
13,NCT01974440,Phase III,"Active, not recruiting","[{'id': 768, 'therapyName': 'Ibrutinib'}, {'id': 2323, 'therapyName': 'Bendamustine + Rituximab'}, {'id': 3266, 'therapyName': 'Cyclophosphamide + Doxorubicin + Prednisone + Vincristine '}]","A Study of PCI-32765 (Ibrutinib) in Combination With Either Bendamustine and Rituximab or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Participants With Previously Treated Indolent Non-Hodgkin Lymphoma",531
14,NCT02596971,Phase I,Recruiting,"[{'id': 1975, 'therapyName': 'Atezolizumab + Obinutuzumab'}, {'id': 3266, 'therapyName': 'Cyclophosphamide + Doxorubicin + Prednisone + Vincristine '}, {'id': 1231, 'therapyName': 'Bendamustine'}]",Safety and Efficacy of MPDL3280A in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus CHOP in Patients With Follicular Lymphoma or Diffuse Large B-Cell Lymphoma,531
15,NCT02055820,Phase I,"Active, not recruiting","[{'id': 1562, 'therapyName': 'Venetoclax'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 3266, 'therapyName': 'Cyclophosphamide + Doxorubicin + Prednisone + Vincristine '}, {'id': 1646, 'therapyName': 'Obinutuzumab'}]",A Safety and Pharmacokinetics Study of GDC-0199 (ABT-199) in Patients With Non-Hodgkin's Lymphoma,531
16,NCT02541565,Phase I,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 3266, 'therapyName': 'Cyclophosphamide + Doxorubicin + Prednisone + Vincristine '}, {'id': 897, 'therapyName': 'Rituximab'}]",Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Diffuse Large B-cell Lymphoma,531
17,NCT02427620,Phase II,Recruiting,"[{'id': 2353, 'therapyName': 'Cyclophosphamide + Doxorubicin + Vincristine '}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 3195, 'therapyName': 'Cytarabine + Methotrexate '}, {'id': 1642, 'therapyName': 'Leucovorin'}]",A Study of Ibrutinib Plus Rituximab With Hyper-CVAD Consolidation in Newly Diagnosed Young Patients With Mantle Cell Lymphoma,531
18,NCT01175356,Phase I,Completed,"[{'id': 2558, 'therapyName': 'Busulfan + Melphalan'}, {'id': 2590, 'therapyName': 'Cyclophosphamide + Topotecan'}, {'id': 1425, 'therapyName': '131I-MIBG'}, {'id': 2353, 'therapyName': 'Cyclophosphamide + Doxorubicin + Vincristine '}, {'id': 2585, 'therapyName': 'Cisplatin + Etoposide'}]","Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin",531
19,NCT02073097,Phase Ib/II,Recruiting,"[{'id': 2351, 'therapyName': 'Carfilzomib + Rituximab'}, {'id': 2353, 'therapyName': 'Cyclophosphamide + Doxorubicin + Vincristine '}]","Carfilzomib, Rituximab, and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Lymphoma",531
20,NCT02017964,Phase II,Completed,"[{'id': 1791, 'therapyName': 'Carboplatin + Etoposide'}, {'id': 2673, 'therapyName': 'Cyclophosphamide + Methotrexate + Vincristine  '}]","Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed, Non-Metastatic Desmoplastic Medulloblastoma",531
21,NCT00550992,Phase I,Unknown status,"[{'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1752, 'therapyName': 'Mitoxantrone + Etoposide + Cytarabine'}, {'id': 1848, 'therapyName': 'Cyclophosphamide + Methotrexate + Vincristine + Pegaspargase '}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1650, 'therapyName': 'Cyclosporine'}, {'id': 1844, 'therapyName': 'anti-thymocyte globulin'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1642, 'therapyName': 'Leucovorin'}]",Different Therapies in Treating Infants With Newly Diagnosed Acute Leukemia,531
22,NCT02723994,Phase II,Recruiting,"[{'id': 2188, 'therapyName': 'Prednisone'}, {'id': 4685, 'therapyName': 'Dexamethasone + Doxorubicin'}, {'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 2346, 'therapyName': 'Mercaptopurine + Thioguanine'}, {'id': 2394, 'therapyName': 'Asparaginase + Cytarabine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 1848, 'therapyName': 'Cyclophosphamide + Methotrexate + Vincristine + Pegaspargase '}]",A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia,531
23,NCT02343536,Phase I,Recruiting,"[{'id': 2488, 'therapyName': 'Cyclophosphamide + Prednisone + Rituximab + Vincristine'}, {'id': 651, 'therapyName': 'Azacitidine'}]","A Phase 1, Open-label,Trial of Oral Azacitidine (CC-486) Plus R-CHOP in Subjects With Large B-Cell Lymphoma or Follicular Lymphoma",531
24,NCT01925131,Phase I,Recruiting,"[{'id': 3221, 'therapyName': 'Cyclophosphamide + Prednisone + Vincristine'}, {'id': 3199, 'therapyName': 'inotuzumab ozogamicin'}]","S1312, Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Leukemia",531
25,NCT01606878,Phase I,Recruiting,"[{'id': 2952, 'therapyName': 'Dexamethasone + Doxorubicin + Vincristine'}, {'id': 2590, 'therapyName': 'Cyclophosphamide + Topotecan'}, {'id': 706, 'therapyName': 'Crizotinib'}]",Crizotinib and Combination Chemotherapy in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma,531
26,NCT02356159,Phase Ib/II,Recruiting,"[{'id': 2294, 'therapyName': 'Cytarabine + Fludarabine'}, {'id': 2373, 'therapyName': 'Palifermin'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 2238, 'therapyName': 'Sirolimus + Tacrolimus + Methotrexate'}, {'id': 2292, 'therapyName': 'Doxorubicin + Etoposide + Fludarabine + Vincristine '}, {'id': 2291, 'therapyName': 'Cyclophosphamide + Fludarabine'}, {'id': 897, 'therapyName': 'Rituximab'}]",Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation,531
27,NCT02538926,Phase II,Not yet recruiting,"[{'id': 770, 'therapyName': 'Imatinib'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 3212, 'therapyName': 'Doxorubicin + Etoposide + Vincristine '}, {'id': 2206, 'therapyName': 'Asparaginase'}]","Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride With Asparaginase in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma",531
28,NCT00092222,Phase II,Recruiting,"[{'id': 917, 'therapyName': 'Sirolimus'}, {'id': 1187, 'therapyName': 'Alpha 2 Interferon'}, {'id': 2211, 'therapyName': 'EPOCH'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1008, 'therapyName': 'Doxil'}]",Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity,531
29,NCT00520130,Phase Ib/II,"Active, not recruiting","[{'id': 2294, 'therapyName': 'Cytarabine + Fludarabine'}, {'id': 2305, 'therapyName': 'Alemtuzumab + Cyclosporine'}, {'id': 2306, 'therapyName': 'Rituximab + Fludarabine + EPOCH'}, {'id': 2307, 'therapyName': 'Fludarabine + EPOCH'}, {'id': 2238, 'therapyName': 'Sirolimus + Tacrolimus + Methotrexate'}, {'id': 1632, 'therapyName': 'Filgrastim'}]",Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,531
30,NCT02677116,Phase I,Recruiting,"[{'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 3618, 'therapyName': 'Irinotecan + Vincristine'}, {'id': 3269, 'therapyName': 'Olaratumab'}]",A Study of Olaratumab Alone and in Combination With Standard Chemotherapies in Children With Cancer,531
31,NCT02101853,Phase III,Recruiting,"[{'id': 1876, 'therapyName': 'Blinatumomab '}, {'id': 2347, 'therapyName': 'Leucovorin + Pegaspargase  + Vincristine'}, {'id': 2346, 'therapyName': 'Mercaptopurine + Thioguanine'}, {'id': 2348, 'therapyName': 'Asparaginase + Cyclophosphamide + Etoposide'}, {'id': 2345, 'therapyName': 'Cytarabine + Dexamethasone+ Methotrexate '}]",Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia,531
32,NCT01837862,Phase Ib/II,Recruiting,"[{'id': 2134, 'therapyName': 'Mebendazole + Vincristine + Carboplatin + Temozolomide'}, {'id': 2133, 'therapyName': 'Mebendazole + Bevacizumab + Irinotecan'}]",A Phase I/II Study of Mebendazole for the Treatment of Pediatric Gliomas,531
33,NCT03003520,Phase II,Recruiting,"[{'id': 5350, 'therapyName': 'MEDI4736 + R2-CHOP'}, {'id': 5349, 'therapyName': 'MEDI4736 + Rituximab + Doxorubicin + Vincristine + Cyclophosphamide + Prednisone'}]",A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma,531
34,NCT02114229,Phase II,Recruiting,"[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 2449, 'therapyName': 'Methotrexate + Cisplatin + Cyclophosphamide + Vincristine'}, {'id': 626, 'therapyName': 'Alisertib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 942, 'therapyName': 'Topotecan'}]",Phase 2 Study of Alisertib Therapy for Rhabdoid Tumors,531
35,NCT00602667,Phase I,"Active, not recruiting","[{'id': 2449, 'therapyName': 'Methotrexate + Cisplatin + Cyclophosphamide + Vincristine'}, {'id': 2450, 'therapyName': 'Cyclophosphamide + Etoposide + Topotecan'}, {'id': 2451, 'therapyName': 'Erlotinib + Cyclophosphamide + Topotecan'}]","Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma",531
36,NCT03269669,Phase II,Recruiting,"[{'id': 6257, 'therapyName': 'Obinutuzumab + CHOP'}, {'id': 6302, 'therapyName': 'Lenalidomide + Obinutuzumab\t'}, {'id': 6301, 'therapyName': 'Obinutuzumab + TGR-1202'}, {'id': 2188, 'therapyName': 'Prednisone'}]","Obinutuzumab With or Without PI3K-delta Inhibitor TGR-1202, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma",531
37,NCT02605694,Phase II,Withdrawn,"[{'id': 3389, 'therapyName': 'Duvelisib + Rituximab'}, {'id': 2195, 'therapyName': 'R-CHOP'}]",Duvelisib With Rituximab vs R-CHOP in Subjects With Relapsed/Refractory Follicular Lymphoma (FRESCO),531
38,NCT01334502,Phase I,Completed,"[{'id': 735, 'therapyName': 'Everolimus'}, {'id': 2195, 'therapyName': 'R-CHOP'}]","Everolimus, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Untreated Diffuse Large B-Cell Lymphoma",531
39,NCT03263026,Phase III,Not yet recruiting,"[{'id': 2195, 'therapyName': 'R-CHOP'}, {'id': 1682, 'therapyName': 'Enzastaurin'}]",Study to Assess Enzastaurin + R-CHOP in Subjects With DLBCL With the Genomic Biomarker DGM1,531
40,NCT03274492,Phase III,Not yet recruiting,"[{'id': 4226, 'therapyName': 'Polatuzumab Vedotin'}, {'id': 6177, 'therapyName': 'R-CHP'}, {'id': 2195, 'therapyName': 'R-CHOP'}]","A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma",531
41,NCT01193842,Phase Ib/II,"Active, not recruiting","[{'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 3395, 'therapyName': 'R-EPOCH'}]",Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas,531
42,NCT02700022,Phase I,"Active, not recruiting","[{'id': 626, 'therapyName': 'Alisertib'}, {'id': 3395, 'therapyName': 'R-EPOCH'}]",A Phase I Study of Alisertib + R-EPOCH for Treatment of Myc-Positive Aggressive B-cell Lymphomas,531
43,NCT00114738,Phase II,"Active, not recruiting","[{'id': 3395, 'therapyName': 'R-EPOCH'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 688, 'therapyName': 'Bortezomib'}]",EPOCH-R Chemotherapy Plus Bortezomib to Treat Mantle Cell Lymphoma,531
44,NCT03036904,Phase I,Recruiting,"[{'id': 5294, 'therapyName': 'Venetoclax + DA-EPOCH-R'}]",Study of Venetoclax Plus DA-EPOCH-R for the Treatment of Aggressive B-Cell Lymphomas (V+DA-EPOCH-R),531
45,NCT01857934,Phase II,Recruiting,"[{'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1873, 'therapyName': 'Sargramostim'}, {'id': 1167, 'therapyName': 'Aldesleukin'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 2627, 'therapyName': 'Levetiracetam'}, {'id': 2585, 'therapyName': 'Cisplatin + Etoposide'}, {'id': 2458, 'therapyName': 'Hu14.18K322A'}, {'id': 2558, 'therapyName': 'Busulfan + Melphalan'}, {'id': 2590, 'therapyName': 'Cyclophosphamide + Topotecan'}]",Therapy for Children With Advanced Stage Neuroblastoma,531
46,NCT02535806,Phase II,Terminated,"[{'id': 1631, 'therapyName': 'Vincristine'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 2188, 'therapyName': 'Prednisone'}]",Four Drug Reinduction With Bortezomib for Relapsed or Refractory ALL or LL in Children and Young Adults,531
47,NCT03117751,Phase II,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1876, 'therapyName': 'Blinatumomab '}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1638, 'therapyName': 'Pegaspargase'}]",Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma,531
48,NCT02110069,Phase II,Recruiting,"[{'id': 1631, 'therapyName': 'Vincristine'}, {'id': 917, 'therapyName': 'Sirolimus'}]",A Study to Compare Vincristine to Sirolimus for Treatment of High Risk Vascular Tumors,531
49,NCT02112916,Phase III,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1009, 'therapyName': 'Doxorubicin'}]",Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma,531
50,NCT03007147,Phase III,Recruiting,"[{'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 5153, 'therapyName': 'dexrazoxane'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 5167, 'therapyName': 'Methylprednisolone'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 5168, 'therapyName': 'Prednisolone'}, {'id': 1009, 'therapyName': 'Doxorubicin'}]",Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia,531
51,NCT01483690,Phase Ib/II,Terminated,"[{'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}]",A Pilot Study of Decitabine and Vorinostat With Chemotherapy for Relapsed ALL,531
52,NCT02518750,Phase II,Recruiting,"[{'id': 1604, 'therapyName': 'Panobinostat + Bortezomib + Dexamethasone'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 3160, 'therapyName': 'Nelarabine'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 3217, 'therapyName': 'Cyclophosphamide + Etoposide'}, {'id': 3216, 'therapyName': 'Cytarabine + Methotrexate + Prednisone'}, {'id': 1746, 'therapyName': 'Clofarabine'}]",Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoma,531
53,NCT03020030,Phase III,Recruiting,"[{'id': 3160, 'therapyName': 'Nelarabine'}, {'id': 5153, 'therapyName': 'dexrazoxane'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1642, 'therapyName': 'Leucovorin'}]",Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents,531
54,NCT03126916,Phase III,Not yet recruiting,"[{'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1425, 'therapyName': '131I-MIBG'}, {'id': 1873, 'therapyName': 'Sargramostim'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 5595, 'therapyName': 'Isotretinoin'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 5153, 'therapyName': 'dexrazoxane'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1167, 'therapyName': 'Aldesleukin'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 2286, 'therapyName': 'Dinutuximab  '}]",Iobenguane I-131 or Crizotinib and Standard Therapy in Treating Younger Patients With Newly-Diagnosed High-Risk Neuroblastoma or Ganglioneuroblastoma,531
55,NCT01319981,Phase II,Recruiting,"[{'id': 1476, 'therapyName': 'Pegfilgrastim'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}]",Hyper-CVAD With Liposomal Vincristine in Acute Lymphoblastic Leukemia,531
56,NCT02043587,Phase II,Recruiting,"[{'id': 897, 'therapyName': 'Rituximab'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1136, 'therapyName': 'Etoposide'}]",Chemotherapy With Liposomal Cytarabine CNS Prophylaxis for Adult Acute Lymphoblastic Leukemia &amp; Lymphoblastic Lymphoma,531
57,NCT02788201,Phase II,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1133, 'therapyName': 'Mitomycin C'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1013, 'therapyName': 'epirubicin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1137, 'therapyName': 'Bleomycin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 781, 'therapyName': 'Ixabepilone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 2950, 'therapyName': 'Estramustine'}, {'id': 1941, 'therapyName': 'Floxuridine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 1811, 'therapyName': 'Carmustine'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 953, 'therapyName': 'Vandetanib'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 4419, 'therapyName': 'Toremifine'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 2601, 'therapyName': 'Dactinomycin'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 3035, 'therapyName': 'Chlorambucil'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 342, 'therapyName': 'Vemurafenib'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 2635, 'therapyName': 'Vinblastine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 4305, 'therapyName': 'Teniposide'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 4304, 'therapyName': 'Streptozocin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1231, 'therapyName': 'Bendamustine'}, {'id': 4303, 'therapyName': 'Mechlorethamine'}, {'id': 4302, 'therapyName': 'Mitotane'}]",Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma,531
58,NCT03023046,Phase II,Recruiting,"[{'id': 897, 'therapyName': 'Rituximab'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 1631, 'therapyName': 'Vincristine'}]","Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma",531
59,NCT03150693,Phase III,Recruiting,"[{'id': 897, 'therapyName': 'Rituximab'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1783, 'therapyName': 'Cyclophosphamide + Cytarabine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 3628, 'therapyName': 'Allopurinol'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 3199, 'therapyName': 'inotuzumab ozogamicin'}]",Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia,531
60,NCT02883049,Phase III,Suspended,"[{'id': 717, 'therapyName': 'Dasatinib'}, {'id': 4685, 'therapyName': 'Dexamethasone + Doxorubicin'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1746, 'therapyName': 'Clofarabine'}]",Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations,531
61,NCT03147612,Phase II,Not yet recruiting,"[{'id': 5682, 'therapyName': 'Mesna'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 877, 'therapyName': 'Ponatinib'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 712, 'therapyName': 'Cytarabine'}]",Study of the Combination of Low-Intensity Chemotherapy and Ponatinib in Patients With Philadelphia Chromosome (Ph)-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL),531
62,NCT02553460,Phase II,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1642, 'therapyName': 'Leucovorin'}]",Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) I,531
63,NCT01523977,Phase I,"Active, not recruiting","[{'id': 2188, 'therapyName': 'Prednisone'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1638, 'therapyName': 'Pegaspargase'}]",Everolimus With Multiagent Re-Induction Chemotherapy in Pediatric Patients With ALL,531
64,NCT02163356,Phase I,Recruiting,"[{'id': 1631, 'therapyName': 'Vincristine'}, {'id': 2731, 'therapyName': 'Fenretinide'}, {'id': 2858, 'therapyName': 'Ketoconazole'}]",Fenretinide Lym-X-Sorb + Ketoconazole + Vincristine for Recurrent or Resistant Neuroblastoma,531
65,NCT00074490,Phase II,Completed,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1650, 'therapyName': 'Cyclosporine'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1166, 'therapyName': 'Fludarabine'}]",Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,531
66,NCT01871766,Phase II,Recruiting,"[{'id': 1119, 'therapyName': 'Sorafenib + Avastin + Cyclophosphamide'}, {'id': 1436, 'therapyName': 'Vincristine + Dactinomycin'}, {'id': 1435, 'therapyName': 'Vincristine + Dactinomycin + Cyclophosphamide'}]","Treatment of Localized Rhabdomyosarcoma With Chemotherapy, Radiotherapy, and Surgery",531
67,NCT02567435,Phase III,Suspended,"[{'id': 1435, 'therapyName': 'Vincristine + Dactinomycin + Cyclophosphamide'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1074, 'therapyName': 'Irinotecan'}]",Combination Chemotherapy and Irinotecan Hydrochloride or Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma,531
68,NCT01324180,Phase I,Completed,"[{'id': 1031, 'therapyName': 'Metformin'}, {'id': 1830, 'therapyName': 'Vincristine + Dexamethasone + Pegaspargase + Doxorubicin'}]","Vincristine, Dexamethasone, Doxorubicin, and PEG-asparaginase (VPLD) and Metformin for Relapsed Childhood Acute Lymphoblastic Leukemia (ALL)",531
69,NCT01769209,Phase II,"Active, not recruiting","[{'id': 688, 'therapyName': 'Bortezomib'}, {'id': 3195, 'therapyName': 'Cytarabine + Methotrexate '}, {'id': 1830, 'therapyName': 'Vincristine + Dexamethasone + Pegaspargase + Doxorubicin'}]",Bortezomib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia,531
70,NCT01946529,Phase II,"Active, not recruiting","[{'id': 1433, 'therapyName': 'Vincristine + Doxorubicin + Cyclophosphamide + Ifosfamide + Etoposide'}, {'id': 1434, 'therapyName': 'Vincristine + Doxorubicin + Cyclophosphamide + Ifosfamide + Etoposide + others'}]",Therapeutic Trial for Patients With Ewing Sarcoma Family of Tumor and Desmoplastic Small Round Cell Tumors,531
71,NCT02306161,Phase II,Recruiting,"[{'id': 1433, 'therapyName': 'Vincristine + Doxorubicin + Cyclophosphamide + Ifosfamide + Etoposide'}, {'id': 746, 'therapyName': 'Ganitumab'}]",Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma,531
72,NCT00020566,Phase III,Unknown status,"[{'id': 2558, 'therapyName': 'Busulfan + Melphalan'}, {'id': 2670, 'therapyName': 'Vincristine + Doxorubicin + Dactinomycin + Ifosfamide + Etoposide'}]","Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation, Radiation Therapy, and/or Surgery in Treating Patients With Ewing's Sarcoma",531
73,NCT01528046,Phase I,Recruiting,"[{'id': 1031, 'therapyName': 'Metformin'}, {'id': 1826, 'therapyName': 'Vincristine + Irinotecan + Temozolomide '}]",Metformin in Children With Relapsed or Refractory Solid Tumors,531
74,NCT01256398,Phase II,"Active, not recruiting","[{'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 2291, 'therapyName': 'Cyclophosphamide + Fludarabine'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1824, 'therapyName': 'Vincristine + Methotrexate + Mercaptopurine'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 2391, 'therapyName': 'Cytarabine + Daunorubicin + Etoposide'}, {'id': 1476, 'therapyName': 'Pegfilgrastim'}, {'id': 1205, 'therapyName': 'Alemtuzumab'}, {'id': 1642, 'therapyName': 'Leucovorin'}]",Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,531
75,NCT02143414,Phase II,Recruiting,"[{'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1824, 'therapyName': 'Vincristine + Methotrexate + Mercaptopurine'}]","Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia",531
76,NCT00549848,Phase III,"Active, not recruiting","[{'id': 1781, 'therapyName': 'Vincristine + Pegaspargase + Daunorubicin'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1782, 'therapyName': 'Clofarabine + Etoposide + Cyclophosphamide'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}]",Total Therapy Study XVI for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia,531
77,NCT02861040,Phase I,Withdrawn,"[{'id': 4781, 'therapyName': 'Vincristine + Volasertib'}]",Volasertib and Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia,531
0,NCT02998528,Phase III,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}, {'id': 5241, 'therapyName': 'Cisplatin + Vinorelbine + Gemcitabine + Docetaxel + Pemetrexed + Carboplatin'}]",A Neoadjuvant Study of Nivolumab and Ipilimumab Compared to Chemotherapy Doublet in Early Stage Non-Small Cell Lung Cancer (NSCLC) (CheckMate 816),353
1,NCT02352948,Phase III,"Active, not recruiting","[{'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 2438, 'therapyName': 'Erlotinib + Gemcitabine + Vinorelbine'}, {'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}, {'id': 1652, 'therapyName': 'Tremelimumab'}]","A Global Study to Assess the Effects of MEDI4736, Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer",353
2,NCT01565083,Phase II,Completed,"[{'id': 1666, 'therapyName': 'Pertuzumab + Trastuzumab + Vinorelbine'}]",A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) And Vinorelbine in First Line in Patients With Metastatic or Locally Advanced HER2-Positive Breast Cancer,353
3,NCT00764972,Phase Ib/II,Unknown status,"[{'id': 2357, 'therapyName': 'Sorafenib + Vinorelbine'}]",Phase IB/II Trial Combining Vinorelbine With Sorafenib as First-Line Treatment in Patients With Metastatic Breast Cancer,353
4,NCT01305941,Phase II,"Active, not recruiting","[{'id': 1411, 'therapyName': 'Trastuzumab + Everolimus + Vinorelbine'}]","A Study Of Everolimus, Trastuzumab And Vinorelbine In HER2-Positive Breast Cancer Brain Metastases",353
5,NCT02658084,Phase Ib/II,Recruiting,"[{'id': 3429, 'therapyName': 'Trastuzumab emtansine + Vinorelbine'}]",Vinorelbine With Trastuzumab Emtansine in Pre-Treated HER2-Positive Metastatic Breast Cancer,353
6,NCT02000622,Phase III,"Active, not recruiting","[{'id': 837, 'therapyName': 'Olaparib'}, {'id': 1685, 'therapyName': 'Vinorelbine'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1105, 'therapyName': 'Capecitabine'}]",Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations.,353
7,NCT02331251,Phase Ib/II,"Active, not recruiting","[{'id': 1685, 'therapyName': 'Vinorelbine'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 619, 'therapyName': 'Abraxane'}]",Study of Pembrolizumab Plus Chemotherapy in Patients With Advanced Cancer (PembroPlus),353
8,NCT02492711,Phase III,Recruiting,"[{'id': 1685, 'therapyName': 'Vinorelbine'}, {'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 808, 'therapyName': 'MGAH22'}]",Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer,353
9,NCT03257267,Phase III,Recruiting,"[{'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1685, 'therapyName': 'Vinorelbine'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 5656, 'therapyName': 'REGN2810'}, {'id': 942, 'therapyName': 'Topotecan'}]",Study of REGN2810 in Adults With Cervical Cancer,353
10,NCT03191786,Phase III,Recruiting,"[{'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1685, 'therapyName': 'Vinorelbine'}]",A Study of Atezolizumab Compared With Chemotherapy in Treatment Naïve Participants With Locally Advanced or Recurrent or Metastatic Non-Small Cell Lung Cancer Who Are Deemed Unsuitable For Platinum-Containing Therapy,353
11,NCT02117024,Phase II,"Active, not recruiting","[{'id': 2472, 'therapyName': 'HS-110 + Cyclophosphamide'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 1685, 'therapyName': 'Vinorelbine'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]",A Phase 2 Study of Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer,353
12,NCT02555657,Phase III,"Active, not recruiting","[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1685, 'therapyName': 'Vinorelbine'}, {'id': 1105, 'therapyName': 'Capecitabine'}]",Study of Single Agent Pembrolizumab (MK-3475) Versus Single Agent Chemotherapy for Metastatic Triple Negative Breast Cancer (MK-3475-119/KEYNOTE-119),353
13,NCT01945775,Phase III,"Active, not recruiting","[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 1685, 'therapyName': 'Vinorelbine'}, {'id': 682, 'therapyName': 'Talazoparib'}, {'id': 728, 'therapyName': 'Eribulin'}]","A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study)",353
14,NCT02302807,Phase III,"Active, not recruiting","[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1685, 'therapyName': 'Vinorelbine'}, {'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 720, 'therapyName': 'Docetaxel'}]",A Study of MPDL3280A Compared With Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer,353
15,NCT02229149,Phase II,"Active, not recruiting","[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}, {'id': 619, 'therapyName': 'Abraxane'}, {'id': 1685, 'therapyName': 'Vinorelbine'}, {'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 1105, 'therapyName': 'Capecitabine'}]","Phase 2 Study of Standard Chemotherapy With Trastuzumab, Plus or Minus Pertuzumab, for Pre-treated Metastatic Breast Cancer",353
16,NCT02985658,Phase I,Available,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 954, 'therapyName': 'Veliparib'}, {'id': 1685, 'therapyName': 'Vinorelbine'}]",Expanded Access With ABT-888 (Veliparib) to Treat Metastatic Breast Cancer,353
17,NCT02213744,Phase II,Terminated,"[{'id': 1890, 'therapyName': 'Vinorelbine + Trastuzumab'}, {'id': 1409, 'therapyName': 'Capecitabine + Trastuzumab'}, {'id': 1889, 'therapyName': 'Gemcitabine + Trastuzumab'}, {'id': 1888, 'therapyName': 'MM-302 + Trastuzumab'}]",MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in HER2-Positive Locally Advanced/Metastatic Breast Cancer Patients,353
0,NCT01880437,Phase II,Terminated,"[{'id': 1802, 'therapyName': 'Cytarabine + Vismodegib'}]",A Study of Vismodegib in Patients With Relapsed/Refractory Acute Myelogenous Leukemia and Relapsed Refractory High-Risk Myleodysplastic Syndrome,6764
1,NCT02690948,Phase II,Recruiting,"[{'id': 3727, 'therapyName': 'Pembrolizumab + Vismodegib'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab With or Without Vismodegib in Treating Metastatic or Unresectable Basal Cell Skin Cancer,6764
2,NCT01537107,Phase I,Suspended,"[{'id': 1329, 'therapyName': 'Sirolimus + Vismodegib'}]",Sirolimus and Vismodegib in Treating Patients With Solid Tumors or Pancreatic Cancer That is Metastatic or Cannot Be Removed By Surgery,6764
3,NCT02788201,Phase II,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1133, 'therapyName': 'Mitomycin C'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1013, 'therapyName': 'epirubicin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1137, 'therapyName': 'Bleomycin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 781, 'therapyName': 'Ixabepilone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 2950, 'therapyName': 'Estramustine'}, {'id': 1941, 'therapyName': 'Floxuridine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 1811, 'therapyName': 'Carmustine'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 953, 'therapyName': 'Vandetanib'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 4419, 'therapyName': 'Toremifine'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 2601, 'therapyName': 'Dactinomycin'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 3035, 'therapyName': 'Chlorambucil'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 342, 'therapyName': 'Vemurafenib'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 2635, 'therapyName': 'Vinblastine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 4305, 'therapyName': 'Teniposide'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 4304, 'therapyName': 'Streptozocin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1231, 'therapyName': 'Bendamustine'}, {'id': 4303, 'therapyName': 'Mechlorethamine'}, {'id': 4302, 'therapyName': 'Mitotane'}]",Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma,6764
4,NCT02639117,Phase I,Recruiting,"[{'id': 956, 'therapyName': 'Vismodegib'}]",Photodynamic Therapy and Vismodegib for Multiple Basal Cell Carcinomas,6764
5,NCT02067104,Phase II,Completed,"[{'id': 956, 'therapyName': 'Vismodegib'}]",Vismodegib in Basal Cell Carcinomas (BCC) Chemoprevention,6764
6,NCT02115828,Phase I,"Active, not recruiting","[{'id': 956, 'therapyName': 'Vismodegib'}]",A Study of Vismodegib in Men With Metastatic CRPC With Accessible Metastatic Lesions for Tumor Biopsy,6764
7,NCT01700049,Phase II,"Active, not recruiting","[{'id': 956, 'therapyName': 'Vismodegib'}]",Study Evaluating the Efficacy of Oral Vismodegib in Various Histologic Subtypes,6764
8,NCT02693535,Phase II,Recruiting,"[{'id': 1657, 'therapyName': 'Vemurafenib + Cobimetinib'}, {'id': 890, 'therapyName': 'Regorafenib'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 690, 'therapyName': 'Bosutinib'}, {'id': 850, 'therapyName': 'Palbociclib'}, {'id': 694, 'therapyName': 'Cetuximab'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 837, 'therapyName': 'Olaparib'}, {'id': 4, 'therapyName': 'Erlotinib'}]",TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer,6764
9,NCT01367665,Phase II,Completed,"[{'id': 956, 'therapyName': 'Vismodegib'}]",STEVIE: A Study of Vismodegib in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma,6764
10,NCT01898598,Phase II,Terminated,"[{'id': 956, 'therapyName': 'Vismodegib'}]",A Study of Vismodegib With Surgery in Patients With Previously Untreated Basal Cell Carcinoma,6764
11,NCT01835626,Phase II,Recruiting,"[{'id': 956, 'therapyName': 'Vismodegib'}]",Phase II Study of Radiation Therapy and Vismodegib for Advanced Head/Neck Basal Cell Carcinoma,6764
12,NCT01154452,Phase Ib/II,Completed,"[{'id': 956, 'therapyName': 'Vismodegib'}, {'id': 1096, 'therapyName': 'Vismodegib + RO4929097'}, {'id': 902, 'therapyName': 'RO4929097'}]",Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma,6764
13,NCT01543581,,Completed,"[{'id': 956, 'therapyName': 'Vismodegib'}]",Vismodegib for Treatment of Basal Cell Carcinoma,6764
14,NCT01774253,Phase II,Terminated,"[{'id': 956, 'therapyName': 'Vismodegib'}]",Erivedge (Vismodegib) in the Treatment of Pediatric Patients With Refractory Pontine Glioma,6764
15,NCT01878617,Phase II,Recruiting,"[{'id': 956, 'therapyName': 'Vismodegib'}, {'id': 1800, 'therapyName': 'Cyclophosphamide + Cisplatin + Vincristine '}, {'id': 1801, 'therapyName': 'Pemetrexed + Gemcitabine'}]",A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma,6764
16,NCT02523014,Phase II,Recruiting,"[{'id': 3078, 'therapyName': 'GSK2256098'}, {'id': 956, 'therapyName': 'Vismodegib'}]",A Study Looking at Targeted Therapy According to Tumor Markers for People With Meningiomas,6764
17,NCT02366312,Phase II,"Active, not recruiting","[{'id': 956, 'therapyName': 'Vismodegib'}]","A Phase 2, Single-center, Single-arm, Open Label Trial of Vismodegib in Patients With Keratocystic Odontogenic Tumors",6764
18,NCT02091141,Phase II,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 698, 'therapyName': 'Alectinib'}, {'id': 1657, 'therapyName': 'Vemurafenib + Cobimetinib'}, {'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 1201, 'therapyName': 'Atezolizumab'}]","My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors",6764
19,NCT01815840,Phase II,Completed,"[{'id': 956, 'therapyName': 'Vismodegib'}]",A Study of Two Vismodegib Regimens in Patients With Multiple Basal Cell Carcinomas,6764
20,NCT02436408,FDA approved,Recruiting,"[{'id': 956, 'therapyName': 'Vismodegib'}]",VISmodegib for ORbital and Periocular Basal Cell Carcinoma,6764
21,NCT01088815,Phase II,Unknown status,"[{'id': 1799, 'therapyName': 'Vismodegib + Gemcitabine + Abraxane'}]",Hedgehog Inhibitors for Metastatic Adenocarcinoma of the Pancreas,6764
22,NCT02073838,Phase II,Recruiting,"[{'id': 650, 'therapyName': 'Decitabine'}, {'id': 3179, 'therapyName': 'Vismodegib + Ribavirin'}]",Ribavirin and Hedgehog Inhibitor With or Without Decitabine in AML,6764
0,NCT03205046,Phase Ib/II,Recruiting,"[{'id': 6188, 'therapyName': 'Acalabrutinib + Vistusertib'}]",A Study of Acalabrutinib and Vistusertib in Subjects With Relapsed/Refractory B-cell Malignancies,7107
1,NCT02576444,Phase II,Recruiting,"[{'id': 3140, 'therapyName': 'MK-1775 + Olaparib'}, {'id': 837, 'therapyName': 'Olaparib'}, {'id': 3141, 'therapyName': 'Olaparib + Vistusertib'}, {'id': 3139, 'therapyName': 'AZD5363 + Olaparib'}]",OLAParib COmbinations,7107
2,NCT02619864,Phase Ib/II,Recruiting,"[{'id': 991, 'therapyName': 'Vistusertib'}]",mTORC1/mTORC2 Kinase Inhibitor AZD2014 in Previously Treated Glioblastoma Multiforme,7107
3,NCT03071874,Phase II,Recruiting,"[{'id': 991, 'therapyName': 'Vistusertib'}]",Phase II Study Of Vistusertib (AZD2014) For Recurrent Grade II-III Meningiomas,7107
4,NCT02831257,Phase II,"Active, not recruiting","[{'id': 991, 'therapyName': 'Vistusertib'}]",AZD2014 In NF2 Patients With Progressive or Symptomatic Meningiomas,7107
5,NCT02599714,Phase Ib/II,Recruiting,"[{'id': 3205, 'therapyName': 'Fulvestrant + Palbociclib'}, {'id': 991, 'therapyName': 'Vistusertib'}]",Study of AZD2014 and Palbociclib in Patients With Estrogen Receptor Positive (ER+) Metastatic Breast Cancer (PASTOR),7107
6,NCT02208375,Phase Ib/II,Recruiting,"[{'id': 837, 'therapyName': 'Olaparib'}, {'id': 655, 'therapyName': 'AZD5363'}, {'id': 991, 'therapyName': 'Vistusertib'}]",mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian Cancer,7107
7,NCT02403895,Phase II,Completed,"[{'id': 991, 'therapyName': 'Vistusertib'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]",AZD2014 and Weekly Paclitaxel in Squamous NSCLC,7107
8,NCT01597388,Phase I,"Active, not recruiting","[{'id': 2199, 'therapyName': 'Vistusertib + Fulvestrant'}]",AZD2014 and Fulvestrant in Patients With ER+ Advanced Metastatic Breast Cancer,7107
0,NCT03018288,Phase II,Recruiting,"[{'id': 5221, 'therapyName': 'Pembrolizumab + Temozolomide'}, {'id': 5220, 'therapyName': 'Pembrolizumab + Temozolomide + Vitespen'}]",Radiation Therapy Plus Temozolomide and Pembrolizumab With and Without HSPPC-96 in Newly Diagnosed Glioblastoma (GBM),7881
1,NCT02452281,Phase Ib/II,Withdrawn,"[{'id': 2973, 'therapyName': 'Vitespen'}, {'id': 779, 'therapyName': 'Ipilimumab'}]",Pilot Study to Evaluate the Effects of a Vaccine (HSPPC-96) Combined With Ipilimumab in Patients With Advanced Melanoma,7881
0,NCT02372240,Phase Ib/II,Suspended,"[{'id': 5099, 'therapyName': 'VLX1570 + Dexamethasone'}]",A Study of VLX1570 and Dexamethasone in Myeloma Patients,8597
0,NCT02875002,Phase I,Not yet recruiting,"[{'id': 4826, 'therapyName': 'Belinostat + Volasertib'}]",Study of Volasertib and Belinostat in Patients With Relapsed and Refractory Aggressive B-cell and T-cell Lymphomas,7043
1,NCT02527174,Phase I,Withdrawn,"[{'id': 3213, 'therapyName': 'Cytarabine + Idarubicin + Volasertib'}]",A Study of Volasertib Plus Induction Chemotherapy for Acute Myeloid Leukemia (VIAC),7043
2,NCT02905994,Phase I,Withdrawn,"[{'id': 3213, 'therapyName': 'Cytarabine + Idarubicin + Volasertib'}]",Volasertib Combined With Induction Chemotherapy in Acute Myeloid Leukemia,7043
3,NCT02861040,Phase I,Withdrawn,"[{'id': 4781, 'therapyName': 'Vincristine + Volasertib'}]",Volasertib and Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia,7043
4,NCT02721875,Phase I,Terminated,"[{'id': 651, 'therapyName': 'Azacitidine'}, {'id': 957, 'therapyName': 'Volasertib'}]",Trial of Volasertib With or Without Azacitidine in Patients With Myelodysplastic Syndromes,7043
5,NCT02003573,Phase I,Terminated,"[{'id': 1745, 'therapyName': 'Volasertib + Decitabine'}]",Volasertib + Decitabine in Patients With Acute Myeloid Leukemia (AML),7043
0,NCT02035137,,Recruiting,"[{'id': 1425, 'therapyName': '131I-MIBG'}, {'id': 1426, 'therapyName': '131I-MIBG + Irinotecan + Vincristine'}, {'id': 1427, 'therapyName': '131I-MIBG + Vorinostat'}]",131I-MIBG Alone VS. 131I-MIBG With Vincristine and Irinotecan VS131I-MIBG With Vorinistat,7193
1,NCT02349867,Phase I,Recruiting,"[{'id': 2429, 'therapyName': 'Abraxane + Gemcitabine + Sorafenib + Vorinostat'}]","Gemcitabine Hydrochloride, Nab-Paclitaxel, Radiation Therapy, Sorafenib Tosylate,Vorinostat in Treating Previously Untreated Pancreatic Cancer Patients",7193
2,NCT01983969,Phase Ib/II,"Active, not recruiting","[{'id': 897, 'therapyName': 'Rituximab'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 2558, 'therapyName': 'Busulfan + Melphalan'}, {'id': 2557, 'therapyName': 'Azacitidine + Gemcitabine + vorinostat'}]",Aza-SAHA-GBM With AutoSCT for Refractory Lymphoma,7193
3,NCT01266031,Phase Ib/II,Completed,"[{'id': 2110, 'therapyName': 'Bevacizumab + Vorinostat'}, {'id': 667, 'therapyName': 'Bevacizumab'}]",Bevacizumab Versus Bevacizumab Plus Vorinostat in Adults With Recurrent Glioblastoma,7193
4,NCT01534260,Phase Ib/II,Recruiting,"[{'id': 2366, 'therapyName': 'Bortezomib + Sorafenib + vorinostat'}]","Phase I/II Study of Combination of Sorafenib, Vorinostat, and Bortezomib for the Treatment of Acute Myeloid Leukemia With Complex- or Poor-risk (Monosomy 5/7) Cytogenetics or FLT3-ITD Positive Genotype",7193
5,NCT02042989,Phase I,"Active, not recruiting","[{'id': 1360, 'therapyName': 'Ixazomib + Vorinostat'}]",MLN9708 and Vorinostat in Patients With Advanced p53 Mutant Malignancies,7193
6,NCT03050450,Phase I,Recruiting,"[{'id': 5337, 'therapyName': 'Lenalidomide + Vorinostat'}]",Study of Lenalidomide With Vorinostat in Pediatric Patients With High Grade or Progressive CNS Tumors,7193
7,NCT02395627,Phase II,Recruiting,"[{'id': 3114, 'therapyName': 'Pembrolizumab + Tamoxifen + vorinostat'}]",Reversing Hormone Therapy Resistance With Epigenetic-Immune Modification,7193
8,NCT02538510,Phase Ib/II,"Active, not recruiting","[{'id': 3077, 'therapyName': 'Pembrolizumab + Vorinostat'}]",Pembrolizumab and Vorinostat in Treating Patients With Recurrent Squamous Cell Head and Neck Cancer and Salivary Gland Cancer That Is Metastatic and/or Cannot Be Removed by Surgery,7193
9,NCT03150329,Phase I,Recruiting,"[{'id': 3077, 'therapyName': 'Pembrolizumab + Vorinostat'}]","Pembrolizumab and Vorinostat in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, or Hodgkin Lymphoma",7193
10,NCT02619253,Phase Ib/II,Recruiting,"[{'id': 3077, 'therapyName': 'Pembrolizumab + Vorinostat'}]",Phase I/Ib Study of Pembrolizumab With Vorinostat for Patients With Advanced Renal or Urothelial Cell Carcinoma,7193
11,NCT01075113,Phase I,"Active, not recruiting","[{'id': 2356, 'therapyName': 'Sorafenib + Vorinostat'}]",Sorafenib and Vorinostat in Treating Patients With Advanced Liver Cancer,7193
12,NCT01174199,Phase I,Terminated,"[{'id': 2263, 'therapyName': 'Temsirolimus + vorinostat'}]",Temsirolimus and Vorinostat in Treating Patients With Metastatic Prostate Cancer,7193
13,NCT01193842,Phase Ib/II,"Active, not recruiting","[{'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 3395, 'therapyName': 'R-EPOCH'}]",Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas,7193
14,NCT02083250,Phase I,Recruiting,"[{'id': 1844, 'therapyName': 'anti-thymocyte globulin'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 3201, 'therapyName': 'Busulfan + Clofarabine + Fludarabine'}]",Fludarabine/Clofarabine/Busulfan Combined With SAHA in Acute Leukemia,7193
15,NCT03263936,Phase I,Recruiting,"[{'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1632, 'therapyName': 'Filgrastim'}]",Epigenetic Reprogramming in Relapse/Refractory AML,7193
16,NCT02137759,Phase II,Recruiting,"[{'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1141, 'therapyName': 'Temozolomide'}]",MRSI to Predict Response to RT/TMZ and Vorinostat in GBM,7193
17,NCT03117751,Phase II,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1876, 'therapyName': 'Blinatumomab '}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1638, 'therapyName': 'Pegaspargase'}]",Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma,7193
18,NCT02589145,Phase Ib/II,Recruiting,"[{'id': 1164, 'therapyName': 'lenalidomide'}, {'id': 3277, 'therapyName': 'Pyridoxine'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 2558, 'therapyName': 'Busulfan + Melphalan'}, {'id': 3278, 'therapyName': 'Enoxaparin'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 2373, 'therapyName': 'Palifermin'}]",Lenalidomide Combined With Vorinostat/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Diffuse Large B-Cell Lymphoma of the ABC Subtype,7193
19,NCT00719875,Phase Ib/II,Completed,"[{'id': 1077, 'therapyName': 'Vorinostat'}]",HDAC Inhibitor Vorinostat (SAHA) With Capecitabine (Xeloda) Using a New Weekly Dose Regimen for Advanced Breast Cancer,7193
20,NCT01339871,Phase I,Completed,"[{'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 848, 'therapyName': 'Pazopanib'}]",Phase I Study of Pazopanib and Vorinostat,7193
21,NCT01587352,Phase II,Suspended,"[{'id': 1077, 'therapyName': 'Vorinostat'}]",Vorinostat in Treating Patients With Metastatic Melanoma of the Eye,7193
22,NCT01064921,Phase I,"Active, not recruiting","[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1077, 'therapyName': 'Vorinostat'}]",Ph I Vorinostat in the Treatment of Advanced Staged Oropharyngeal Squamous Cell Carcinoma,7193
23,NCT02788201,Phase II,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1133, 'therapyName': 'Mitomycin C'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1013, 'therapyName': 'epirubicin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1137, 'therapyName': 'Bleomycin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 781, 'therapyName': 'Ixabepilone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 2950, 'therapyName': 'Estramustine'}, {'id': 1941, 'therapyName': 'Floxuridine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 1811, 'therapyName': 'Carmustine'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 953, 'therapyName': 'Vandetanib'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 4419, 'therapyName': 'Toremifine'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 2601, 'therapyName': 'Dactinomycin'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 3035, 'therapyName': 'Chlorambucil'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 342, 'therapyName': 'Vemurafenib'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 2635, 'therapyName': 'Vinblastine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 4305, 'therapyName': 'Teniposide'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 4304, 'therapyName': 'Streptozocin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1231, 'therapyName': 'Bendamustine'}, {'id': 4303, 'therapyName': 'Mechlorethamine'}, {'id': 4302, 'therapyName': 'Mitotane'}]",Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma,7193
24,NCT01059552,Phase I,"Active, not recruiting","[{'id': 1077, 'therapyName': 'Vorinostat'}]",Treatment of Locally Advanced Non-Small Cell Lung Cancer (NSCLC),7193
25,NCT01087554,Phase I,"Active, not recruiting","[{'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 1077, 'therapyName': 'Vorinostat'}]",Sirolimus or Everolimus or Temsirolimus and Vorinostat in Advanced Cancer,7193
26,NCT01790568,Phase II,"Active, not recruiting","[{'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 1077, 'therapyName': 'Vorinostat'}]",Vorinostat Plus Tacrolimus & Methotrexate to Prevent Graft vs Host Disease Following Unrelated Stem Cell Transplant,7193
27,NCT01249443,Phase I,Terminated,"[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]",Vorinostat in Combination With Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors and HIV Infection,7193
28,NCT01879085,Phase Ib/II,Recruiting,"[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1476, 'therapyName': 'Pegfilgrastim'}, {'id': 1077, 'therapyName': 'Vorinostat'}]",Phase 1b/2 Study of Vorinostat in Combination With Gemcitabine and Docetaxel in Advanced Sarcoma,7193
29,NCT02553460,Phase II,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1642, 'therapyName': 'Leucovorin'}]",Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) I,7193
30,NCT02316340,Phase II,Recruiting,"[{'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1316, 'therapyName': 'Hydroxychloroquine'}, {'id': 890, 'therapyName': 'Regorafenib'}]",Vorinostat Plus Hydroxychloroquine Versus Regorafenib in Colorectal Cancer,7193
31,NCT02420613,Phase I,Recruiting,"[{'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 936, 'therapyName': 'Temsirolimus'}]",Study of Suberoylanilide Hydroxamic Acid (SAHA) With Temsirolimus in Children With Diffuse Intrinsic Pontine Glioma (DIPG),7193
32,NCT03259503,Phase Ib/II,Not yet recruiting,"[{'id': 1206, 'therapyName': 'Busulfan'}, {'id': 837, 'therapyName': 'Olaparib'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 2373, 'therapyName': 'Palifermin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 3277, 'therapyName': 'Pyridoxine'}, {'id': 897, 'therapyName': 'Rituximab'}]",Olaparib Combined With High-Dose Chemotherapy for Refractory Lymphomas,7193
33,NCT02412475,Phase I,"Active, not recruiting","[{'id': 712, 'therapyName': 'Cytarabine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 650, 'therapyName': 'Decitabine'}]",Epigenetic Reprogramming in Relapse AML,7193
34,NCT02419755,Phase II,Terminated,"[{'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 2188, 'therapyName': 'Prednisone'}]",Bortezomib and Vorinostat in Younger Patients With Refractory or Relapsed MLL Rearranged Hematologic Malignancies,7193
35,NCT02559778,Phase I,Recruiting,"[{'id': 688, 'therapyName': 'Bortezomib'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 2629, 'therapyName': 'Eflornithine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 717, 'therapyName': 'Dasatinib'}]",Pediatric Precision Laboratory Advanced Neuroblastoma Therapy,7193
36,NCT03022565,Phase I,Not yet recruiting,"[{'id': 1077, 'therapyName': 'Vorinostat'}]",Vorinostat in Patients With Class 2 High Risk Uveal Melanoma,7193
37,NCT02638090,Phase Ib/II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1077, 'therapyName': 'Vorinostat'}]",Pembro and Vorinostat for Patients With Stage IV Non-small Cell Lung Cancer (NSCLC),7193
38,NCT01281176,,"Active, not recruiting","[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1092, 'therapyName': 'Carboplatin'}]",High-Dose or Low-Dose Vorinostat in Combination With Carboplatin or Paclitaxel in Treating Patients With Advanced Solid Tumors,7193
39,NCT01593670,Phase II,Terminated,"[{'id': 650, 'therapyName': 'Decitabine'}, {'id': 1167, 'therapyName': 'Aldesleukin'}, {'id': 1077, 'therapyName': 'Vorinostat'}]",Decitabine and Vorinostat Conditioning Followed by CD3-/CD19- NK Cells Infusion for High Risk Myelodysplastic Syndromes,7193
40,NCT01294670,Phase Ib/II,"Active, not recruiting","[{'id': 1182, 'therapyName': 'Vorinostat + Etoposide'}]",Clinical Study of Vorinostat in Combination With Etoposide in Pediatric Patients &lt; 21 Years at Diagnosis With Refractory Solid Tumors,7193
41,NCT01266057,Phase I,"Active, not recruiting","[{'id': 1135, 'therapyName': 'Vorinostat + Hydroxychloroquine'}, {'id': 1177, 'therapyName': 'Sirolimus + Hydroxychloroquine'}]",Sirolimus or Vorinostat and Hydroxychloroquine in Advanced Cancer,7193
42,NCT01023737,Phase I,Recruiting,"[{'id': 1135, 'therapyName': 'Vorinostat + Hydroxychloroquine'}]",Hydroxychloroquine + Vorinostat in Advanced Solid Tumors,7193
43,NCT00574587,Phase Ib/II,Unknown status,"[{'id': 1983, 'therapyName': 'vorinostat + Paclitaxel'}, {'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 1977, 'therapyName': 'Doxorubicin + Cyclophosphamide'}]","Trial for Locally Advanced Her2 Positive Breast Cancer Using Paclitaxel, Trastuzumab, Doxorubicin and Cyclophasmide on a Weekly Basis",7193
0,NCT01841463,Phase Ib/II,Suspended,"[{'id': 1238, 'therapyName': 'Vemurafenib + Voruciclib'}]",Study of an Oral Cdk Inhibitor Administered With an Oral BRAF Inhibitor in Patients With Advanced or Inoperable Malignant Melanoma With BRAF Mutation,6975
0,NCT01893320,Phase Ib/II,"Active, not recruiting","[{'id': 1766, 'therapyName': 'Decitabine + Vosaroxin'}]",Study of Vosaroxin and Decitabine in Older Patients With Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome,7335
0,NCT02651727,Phase I,Terminated,"[{'id': 4342, 'therapyName': 'Gemcitabine + nab-paclitaxel + VS-4718'}]","Ph 1 Study of VS-4718, a FAK Inhibitor, in Combination With Nab-paclitaxel and Gemcitabine in Advanced Cancer Subjects",7361
1,NCT01849744,Phase I,Terminated,"[{'id': 1933, 'therapyName': 'VS-4718'}]",Phase I Dose Escalation Study of VS-4718 in Subjects With Metastatic Non-Hematologic Malignancies,7361
0,NCT01991938,Phase I,Terminated,"[{'id': 960, 'therapyName': 'VS-5584'}]",Phase I Dose Escalation Study of VS-5584 in Subjects With Advanced Non-Hematologic Malignancies or Lymphoma,7079
1,NCT02372227,Phase I,Terminated,"[{'id': 2464, 'therapyName': 'VS-5584 + VS-6063'}]","A Phase 1 Dose Escalation Study of VS-5584 Administered in Combination With VS-6063, in Subjects With Relapsed Malignant Mesothelioma",7079
0,NCT02546531,Phase I,Recruiting,"[{'id': 3083, 'therapyName': 'Defactinib + Gemcitabine + Pembrolizumab'}]",Defactinib Combined With Pembrolizumab and Gemcitabine in Patients With Advanced Cancer,7077
1,NCT02372227,Phase I,Terminated,"[{'id': 2464, 'therapyName': 'VS-5584 + VS-6063'}]","A Phase 1 Dose Escalation Study of VS-5584 Administered in Combination With VS-6063, in Subjects With Relapsed Malignant Mesothelioma",7077
2,NCT02943317,Phase I,Recruiting,"[{'id': 958, 'therapyName': 'VS-6063'}, {'id': 3144, 'therapyName': 'Avelumab'}]","Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of Defactinib in Combination With Avelumab in Epithelial Ovarian Cancer",7077
3,NCT02004028,Phase II,Completed,"[{'id': 958, 'therapyName': 'VS-6063'}]",Window of Opportunity Study of VS-6063 (Defactinib) in Participants With Surgical Resectable Malignant Pleural Mesothelioma.,7077
4,NCT01951690,Phase II,Completed,"[{'id': 958, 'therapyName': 'VS-6063'}]",Phase II Study of VS-6063 in Patients With KRAS Mutant Non-Small Cell Lung Cancer,7077
5,NCT02465060,Phase II,Recruiting,"[{'id': 660, 'therapyName': 'AZD9291'}, {'id': 3, 'therapyName': 'Dabrafenib'}, {'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 2, 'therapyName': 'Trametinib'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 623, 'therapyName': 'Afatinib'}, {'id': 654, 'therapyName': 'AZD4547'}, {'id': 958, 'therapyName': 'VS-6063'}, {'id': 765, 'therapyName': 'GSK2636771'}]",NCI-MATCH Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas,7077
6,NCT01870609,Phase II,Terminated,"[{'id': 958, 'therapyName': 'VS-6063'}]",Placebo Controlled Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma,7077
0,NCT01628640,Phase I,Recruiting,"[{'id': 2423, 'therapyName': 'VSV-IFN-beta'}]",Viral Therapy in Treating Patient With Liver Cancer,7525
0,NCT02580448,Phase Ib/II,Recruiting,"[{'id': 2822, 'therapyName': 'VT-464'}]","A Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of VT-464 in Patients With Advanced Breast Cancer",7764
0,NCT02567409,Phase II,Recruiting,"[{'id': 1467, 'therapyName': 'Gemcitabine + Cisplatin'}, {'id': 3110, 'therapyName': 'Cisplatin + Gemcitabine + VX-970'}]",Cisplatin and Gemcitabine Hydrochloride With or Without ATR Kinase Inhibitor VX-970 in Treating Patients With Metastatic Urothelial Cancer,7811
1,NCT02723864,Phase I,Recruiting,"[{'id': 3993, 'therapyName': 'Cisplatin + Veliparib + VX-970'}]","Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors",7811
2,NCT02567422,Phase I,Recruiting,"[{'id': 3109, 'therapyName': 'Cisplatin + VX-970'}]","VX-970, Cisplatin, and Radiation Therapy in Treating Patients With Locally Advanced HPV-Negative Head and Neck Squamous Cell Carcinoma",7811
3,NCT02487095,Phase Ib/II,Recruiting,"[{'id': 2879, 'therapyName': 'VX-970'}, {'id': 942, 'therapyName': 'Topotecan'}]","Trial of Topotecan With VX-970, an ATR Kinase Inhibitor, in Small Cell Lung Cancer",7811
4,NCT02157792,Phase I,Recruiting,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 2879, 'therapyName': 'VX-970'}, {'id': 755, 'therapyName': 'Gemcitabine'}]","An Open-Label, First-in-Human Study of the Safety, Tolerability, and Pharmacokinetics of VX-970 in Combination With Cytotoxic Chemotherapy",7811
5,NCT02595892,Phase II,Recruiting,"[{'id': 2879, 'therapyName': 'VX-970'}, {'id': 755, 'therapyName': 'Gemcitabine'}]","Gemcitabine Hydrochloride Alone or With VX-970 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer",7811
6,NCT02589522,Phase I,Recruiting,"[{'id': 2879, 'therapyName': 'VX-970'}]",VX-970 and Whole Brain Radiation Therapy in Treating Patients With Brain Metastases From Non-Small Cell Lung Cancer,7811
7,NCT02627443,Phase II,Recruiting,"[{'id': 2667, 'therapyName': 'Carboplatin + Gemcitabine'}, {'id': 2879, 'therapyName': 'VX-970'}]","Carboplatin and Gemcitabine Hydrochloride With or Without ATR Kinase Inhibitor VX-970 in Treating Patients With Recurrent and Metastatic Ovarian, Primary Peritoneal, or Fallopian Tube Cancer",7811
8,NCT02595931,Phase I,Recruiting,"[{'id': 2883, 'therapyName': 'VX-970 + Irinotecan'}]",VX-970 and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery,7811
0,NCT03268057,Phase Ib/II,Recruiting,"[{'id': 6153, 'therapyName': 'Avelumab + VX15/2503'}]",VX15/2503 in Combination With Avelumab in Advanced Non-small Cell Lung Cancer,8221
0,NCT01904123,Phase I,Not yet recruiting,"[{'id': 2784, 'therapyName': 'WP1066'}]",A Phase I Trial of WP1066,7735
0,NCT01995708,Phase I,Recruiting,"[{'id': 2901, 'therapyName': 'WT1 senstized T cells'}]","CT7, MAGE-A3, and WT1 mRNA-electroporated Autologous Langerhans-type Dendritic Cells as Consolidation for Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation",7824
1,NCT00620633,Phase I,"Active, not recruiting","[{'id': 2901, 'therapyName': 'WT1 senstized T cells'}]",Dose Escalation Trial of WT1-Sensitized T Cells for Residual or Relapsed Leukemia After Allogeneic Hematopoietic Progenitor Cell Transplantation,7824
2,NCT01640301,Phase Ib/II,Suspended,"[{'id': 1167, 'therapyName': 'Aldesleukin'}, {'id': 2901, 'therapyName': 'WT1 senstized T cells'}]","Laboratory-Treated T Cells in Treating Patients With High-Risk Relapsed Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia Previously Treated With Donor Stem Cell Transplant",7824
0,NCT02737787,Phase I,Recruiting,"[{'id': 4020, 'therapyName': 'Nivolumab + WT1 vaccine'}]",A Study of WT1 Vaccine and Nivolumab For Recurrent Ovarian Cancer,7820
1,NCT01827137,Phase I,"Active, not recruiting","[{'id': 2893, 'therapyName': 'WT1 vaccine'}, {'id': 1164, 'therapyName': 'lenalidomide'}, {'id': 1873, 'therapyName': 'Sargramostim'}]",WT1 Analog Peptide Vaccine in Patients With Multiple Myeloma Following Autologous Stem Cell Transplantation,7820
2,NCT01266083,Phase II,"Active, not recruiting","[{'id': 2893, 'therapyName': 'WT1 vaccine'}]",Trial of a WT-1 Analog Peptide Vaccine in Patients With Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL),7820
3,NCT01890980,Phase II,"Active, not recruiting","[{'id': 2893, 'therapyName': 'WT1 vaccine'}, {'id': 1873, 'therapyName': 'Sargramostim'}]",Phase II Study of Adjuvant WT-1 Analog Peptide Vaccine in MPM Patients After MSK10-134,7820
4,NCT01621542,Phase I,Completed,"[{'id': 2893, 'therapyName': 'WT1 vaccine'}]",Clinical Study of WT2725 in Patients With Advanced Malignancies,7820
5,NCT01265433,Phase II,Completed,"[{'id': 1873, 'therapyName': 'Sargramostim'}, {'id': 2893, 'therapyName': 'WT1 vaccine'}]",Randomized Study of Adjuvant WT-1 Analog Peptide Vaccine in Patients With Malignant Pleural Mesothelioma (MPM) After Completion of Combined Modality Therapy,7820
0,NCT01296581,Phase I,"Active, not recruiting","[{'id': 962, 'therapyName': 'X-82'}]", Safety Study of X-82 in Patients With Advanced Solid Tumors,7045
1,NCT02146222,Phase I,"Active, not recruiting","[{'id': 1442, 'therapyName': 'X-82 + Docetaxel'}]",VEGFR/PDGFR Dual Kinase Inhibitor X-82 and Docetaxel in Treating Patients With Solid Tumors,7045
2,NCT01784861,Phase Ib/II,"Active, not recruiting","[{'id': 1272, 'therapyName': 'X-82 + Everolimus'}]",VEGFR/PDGFR Dual Kinase Inhibitor X-82 and Everolimus for Treating Patients With Pancreatic Neuroendocrine Tumors,7045
0,NCT02923531,Phase Ib/II,Recruiting,"[{'id': 4837, 'therapyName': 'Nivolumab + X4P-001'}]",Addition of X4P-001 to Nivolumab Treatment in Patients With Renal Cell Carcinoma,8144
1,NCT02823405,Phase I,Recruiting,"[{'id': 4436, 'therapyName': 'Pembrolizumab + X4P-001'}]",Neoadjuvant X4P-001 and Pembrolizumab in Patients With Resectable Melanoma (X4P-001-MELA),8144
2,NCT02667886,Phase Ib/II,Recruiting,"[{'id': 649, 'therapyName': 'Axitinib'}, {'id': 3570, 'therapyName': 'X4P-001'}]",Trial of X4P-001 in Patients With Advanced Renal Cell Carcinoma,8144
0,NCT03099174,Phase I,Recruiting,"[{'id': 5514, 'therapyName': 'Abemaciclib + Xentuzumab'}, {'id': 5515, 'therapyName': 'Abemaciclib + Letrozole + Xentuzumab'}, {'id': 5516, 'therapyName': 'Abemaciclib + Anastrozole + Xentuzumab'}, {'id': 5517, 'therapyName': 'Abemaciclib + Fulvestrant + Xentuzumab'}]",This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast Cancer.,7839
1,NCT02204072,Phase I,Recruiting,"[{'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 2916, 'therapyName': 'Xentuzumab'}]",BI836845 Plus Enzalutamide in Castrate Resistant Prostate Cancer (CRPC),7839
0,NCT01587040,Phase Ib/II,"Active, not recruiting","[{'id': 1050, 'therapyName': 'XL147'}, {'id': 1051, 'therapyName': 'SAR245409'}]",Open Label Treatment Extension Study With SAR245408 or SAR245409 as a Monotherapy or as a Combination Regimen,7168
0,NCT02844439,Phase II,"Active, not recruiting","[{'id': 967, 'therapyName': 'XL647'}]",Study of Tesevatinib Monotherapy in Patients With Recurrent Glioblastoma,7049
1,NCT02616393,Phase II,Recruiting,"[{'id': 967, 'therapyName': 'XL647'}]","Study of Tesevatinib in Subjects With Non-Small Cell Lung Cancer, EGFR Activating Mutation, Prior Treatment With a Tyrosine Kinase Inhibitor, and Brain Metastases or Leptomeningeal Metastases",7049
2,NCT02154529,Phase Ib/II,Terminated,"[{'id': 1880, 'therapyName': 'XL647 + Trastuzumab'}]",Study of the Combination of KD019 and Trastuzumab in Subjects With HER2-Positive Metastatic Breast Cancer,7049
0,NCT02721459,Phase I,Recruiting,"[{'id': 3995, 'therapyName': 'Cobimetinib + XL888 + Vemurafenib'}]",XL888 + Vemurafenib + Cobimetinib for Unresectable B Rapidly Accelerated Fibrosarcoma (BRAF) Mutated Stage III/IV Melanoma,7052
1,NCT03095781,Phase I,Recruiting,"[{'id': 5533, 'therapyName': 'Pembrolizumab + XL888'}]",Pembrolizumab and XL888 in Patients With Advanced Gastrointestinal Cancer,7052
2,NCT01657591,Phase I,"Active, not recruiting","[{'id': 1217, 'therapyName': 'XL888 + Vemurafenib'}]", Study of XL888 With Vemurafenib for Patients With Unresectable BRAF Mutated Stage III/IV Melanoma,7052
0,NCT02952729,Phase I,Recruiting,"[{'id': 5834, 'therapyName': 'XMT-1522'}]",Study of Antibody Drug Conjugate in Patients With Advanced Breast Cancer Expressing HER2,8826
0,NCT01956812,Phase III,Terminated,"[{'id': 3000, 'therapyName': 'Y90 clivatuzumab tetraxetan'}, {'id': 755, 'therapyName': 'Gemcitabine'}]",Phase 3 Trial of 90Y-Clivatuzumab Tetraxetan & Gemcitabine vs Placebo & Gemcitabine in Metastatic Pancreatic Cancer (PANCRIT-1),7898
0,NCT02311933,Phase II,"Active, not recruiting","[{'id': 3076, 'therapyName': 'Z-endoxifen HCl'}, {'id': 1456, 'therapyName': 'Tamoxifen'}]","Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer",7928
0,NCT02711956,Phase I,Recruiting,"[{'id': 4033, 'therapyName': 'Enzalutamide + ZEN003694'}]",A Study of ZEN003694 in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer,8331
1,NCT02705469,Phase I,"Active, not recruiting","[{'id': 4032, 'therapyName': 'ZEN003694'}]",A Study of ZEN003694 in Patients With Metastatic Castration-Resistant Prostate Cancer,8331
0,NCT02892123,Phase I,Recruiting,"[{'id': 6240, 'therapyName': 'ZW25'}]",Trial of ZW25 in Patients With Advanced HER2-expressing Cancers,8949
